# Blue Goat Cyber - Full Text Corpus for LLMs > This file concatenates the full text of Blue Goat Cyber's highest-value > reference pages, comparison/explainer guides, and structured datasets so > AI assistants can answer questions about FDA medical device cybersecurity > without parsing the JS-rendered site. Each section ends with a canonical > source URL. Quote with attribution to "Blue Goat Cyber" and a link back to > the cited URL. Site: https://bluegoatcyber.com Generated: 2026-09-18T19:17:25.745Z Link index: https://bluegoatcyber.com/llms.txt --- # Reference datasets ## FDA cybersecurity timeline Source: https://bluegoatcyber.com/reference/fda-cybersecurity-timeline ```json { "$schema": "https://json-schema.org/draft/2020-12/schema", "name": "FDA Medical Device Cybersecurity Timeline", "description": "Chronological reference of major FDA medical device cybersecurity guidance, statutes, and program milestones from 2013 through 2026.", "publisher": "Blue Goat Cyber", "source": "https://bluegoatcyber.com/reference/fda-cybersecurity-timeline", "license": "Free to reuse with attribution to Blue Goat Cyber and a link to the source URL.", "updated": "2026-05-17", "milestones": [ { "date": "2013-06-14", "title": "FDA Safety Communication on Medical Device Cybersecurity", "summary": "First broad FDA warning on medical device cybersecurity risk; called on manufacturers and HDOs to take action.", "source_url": "https://www.fda.gov/medical-devices/safety-communications/cybersecurity-medical-devices-and-hospital-networks-fda-safety-communication" }, { "date": "2014-10-02", "title": "Premarket Cybersecurity Guidance (final)", "summary": "First final FDA guidance establishing cybersecurity expectations in premarket submissions; introduced threat-modeling and risk-management language.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-management-cybersecurity-medical-devices-0" }, { "date": "2016-12-28", "title": "Postmarket Cybersecurity Guidance (final)", "summary": "Defined the postmarket cybersecurity lifecycle, CVD program expectations, and the difference between routine and uncontrolled-risk vulnerabilities.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices" }, { "date": "2018-10-18", "title": "Premarket Cybersecurity Guidance (draft, 2018)", "summary": "Draft introducing Tier 1 and Tier 2 devices and the concept of a Cybersecurity Bill of Materials (CBOM).", "source_url": "https://www.fda.gov/media/119933/download" }, { "date": "2022-12-29", "title": "Section 524B added to the FD&C Act", "summary": "Consolidated Appropriations Act 2023 (Section 3305) added Section 524B, giving the FDA explicit statutory authority over cybersecurity in premarket submissions.", "source_url": "https://www.congress.gov/bill/117th-congress/house-bill/2617" }, { "date": "2023-03-29", "title": "Section 524B effective date", "summary": "Section 524B took effect and FDA refuse-to-accept authority attached for cyber devices. Active RTA enforcement based solely on 524B began October 1, 2023.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-refuse-accept-policy-cyber-devices-and-related-systems-under-section" }, { "date": "2023-09-27", "title": "Premarket Cybersecurity Guidance (final, 2023)", "summary": "First final guidance under Section 524B; established the Secure Product Development Framework (SPDF) and the seven-section cybersecurity content set.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket" }, { "date": "2023-10-01", "title": "eSTAR mandatory for 510(k)", "summary": "FDA-CDRH made eSTAR mandatory for 510(k) submissions, including a structured cybersecurity section.", "source_url": "https://www.fda.gov/medical-devices/how-study-and-market-your-device/estar-program" }, { "date": "2025-06-27", "title": "Premarket Cybersecurity Guidance (final, 2025)", "summary": "Final guidance superseding the September 2023 final; refined SPDF, threat-modeling and SBOM expectations ahead of the February 2026 update.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket" }, { "date": "2025-10-01", "title": "eSTAR mandatory for De Novo", "summary": "eSTAR became the required submission format for De Novo classification requests, with the same cybersecurity section as 510(k).", "source_url": "https://www.fda.gov/medical-devices/how-study-and-market-your-device/estar-program" }, { "date": "2026-02-03", "title": "Premarket Cybersecurity Guidance (final, 2026) effective", "summary": "Updated final guidance superseding the June 2025 final, which had superseded the September 2023 final; clarifies SPDF expectations, threat-modeling depth, SBOM contents, and labeling.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket" } ] } ``` ## FDA cybersecurity acronyms Source: https://bluegoatcyber.com/reference/fda-cybersecurity-acronyms ```json { "$schema": "https://json-schema.org/draft/2020-12/schema", "name": "FDA Medical Device Cybersecurity Acronyms", "description": "Q&A glossary of acronyms used in FDA medical device cybersecurity guidance and submissions.", "publisher": "Blue Goat Cyber", "source": "https://bluegoatcyber.com/reference/fda-cybersecurity-acronyms", "license": "Free to reuse with attribution to Blue Goat Cyber and a link to the source URL.", "updated": "2026-05-17", "acronyms": [ { "acronym": "SPDF", "expansion": "Secure Product Development Framework", "answer": "The lifecycle process the FDA expects every cyber-device manufacturer to use to design, build, release, and maintain medical device software. The 2026 premarket guidance treats SPDF documentation as a required submission artifact.", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket" }, { "acronym": "SBOM", "expansion": "Software Bill of Materials", "answer": "A machine-readable inventory of every software component in a medical device. Section 524B of the FD&C Act makes an SBOM a statutory requirement for every cyber-device premarket submission.", "source_url": "https://www.congress.gov/bill/117th-congress/house-bill/2617" }, { "acronym": "CBOM", "expansion": "Cybersecurity Bill of Materials", "answer": "Extends the SBOM concept to include hardware components and runtime libraries that affect the device's security posture. Introduced in the 2018 FDA draft guidance; largely absorbed into SBOM and HBOM in modern practice." }, { "acronym": "VEX", "expansion": "Vulnerability Exploitability eXchange", "answer": "A machine-readable statement that says whether a known vulnerability in an SBOM component is actually exploitable in the shipped product. Lets manufacturers communicate not-affected or fixed status for CVEs." }, { "acronym": "CVD", "expansion": "Coordinated Vulnerability Disclosure", "answer": "The published process by which a manufacturer receives, triages, and remediates cybersecurity vulnerability reports. The FDA postmarket guidance and ISO/IEC 29147 require every medical device manufacturer to operate one.", "source_url": "https://www.iso.org/standard/72311.html" }, { "acronym": "RTA", "expansion": "Refuse To Accept", "answer": "The FDA's formal notice that a premarket submission was administratively incomplete and will not enter substantive review. Cybersecurity gaps under Section 524B are a common RTA cause for 510(k) submissions." }, { "acronym": "SaMD", "expansion": "Software as a Medical Device", "answer": "Software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device. Subject to the same cybersecurity expectations as device software." }, { "acronym": "SiMD", "expansion": "Software in a Medical Device", "answer": "Software that is integral to a hardware medical device (e.g. infusion-pump firmware, pacemaker software). Always in scope for FDA cybersecurity review when the device meets the cyber-device definition." }, { "acronym": "QMSR", "expansion": "Quality Management System Regulation", "answer": "The FDA's revised quality regulation (effective February 2026) that aligns 21 CFR Part 820 with ISO 13485:2016. Cybersecurity activities now sit inside the design-controls process." }, { "acronym": "PCCP", "expansion": "Predetermined Change Control Plan", "answer": "A plan submitted with an AI/ML-enabled device that pre-authorizes specified post-market modifications without requiring a new 510(k). Must include cybersecurity impact analysis for each planned change." } ] } ``` ## Medical device classes and cybersecurity requirements Source: https://bluegoatcyber.com/reference/medical-device-classes-cybersecurity-requirements ```json { "$schema": "https://json-schema.org/draft/2020-12/schema", "name": "Medical Device Classes and Cybersecurity Requirements", "description": "FDA device classes (I, II, III) with submission pathways and cybersecurity expectations under Section 524B and the 2026 premarket guidance.", "publisher": "Blue Goat Cyber", "source": "https://bluegoatcyber.com/reference/medical-device-classes-cybersecurity-requirements", "license": "Free to reuse with attribution to Blue Goat Cyber and a link to the source URL.", "updated": "2026-05-17", "classes": [ { "class": "I", "risk_level": "Low", "primary_pathway": "510(k) exempt (most); 510(k) for a small subset", "cyber_device": "Usually not - most Class I devices do not meet the Section 524B cyber-device definition.", "cyber_documentation": "If the device transmits, receives, stores, or processes data over a network interface, a basic cybersecurity assessment is still expected.", "sbom_required": "Only if the device qualifies as a cyber device under 524B.", "examples": [ "Manual stethoscopes", "Bandages", "Tongue depressors" ] }, { "class": "II", "risk_level": "Moderate", "primary_pathway": "510(k) or De Novo", "cyber_device": "Frequently - most connected Class II devices are cyber devices.", "cyber_documentation": "Full SPDF documentation, threat model, SBOM, VEX, cybersecurity risk assessment, security testing reports, labeling, and postmarket plan per the 2026 premarket guidance.", "sbom_required": "Yes for cyber devices.", "examples": [ "Infusion pumps", "Patient monitors", "Imaging systems", "Most SaMD" ] }, { "class": "III", "risk_level": "High", "primary_pathway": "PMA", "cyber_device": "Almost always - implantable and life-sustaining devices with any software or connectivity qualify.", "cyber_documentation": "All Class II content plus elevated threat-modeling depth, formal verification of security controls, postmarket surveillance integrated with PMA reporting, and detailed PCCP for any AI-enabled function.", "sbom_required": "Yes - always for cyber devices in this class.", "examples": [ "Implantable cardiac pacemakers", "Implantable defibrillators", "Neurostimulators", "Heart valves" ] } ], "cyber_device_definition": "Per Section 524B of the FD&C Act, a 'cyber device' is one that (1) includes software validated, installed, or authorized by the sponsor; (2) has the ability to connect to the internet; and (3) contains any technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats." } ``` --- # Guides --- ## AAMI TIR57 vs TIR97: Medical Device Risk Management Guide Source: https://bluegoatcyber.com/guides/aami-tir57-vs-tir97-comparison # AAMI TIR57 vs TIR97: Comparing Redetec Standards **Compare AAMI TIR57 vs TIR97. Learn how these cybersecurity risk management standards differ and how to apply them for FDA premarket and postmarket compliance.** This guide is written for medical device manufacturers navigating AAMI TIR57 vs TIR97. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Intro: The Ecosystem of Medical Device Risk Management Intro: The Ecosystem of Medical Device Risk Management is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Why TIR57 and TIR97 Matter for FDA Submissions Why TIR57 and TIR97 Matter for FDA Submissions: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The Relationship with ISO 14971 The Relationship with ISO 14971: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Deep Dive: AAMI TIR57 (Premarket Security) Deep Dive: AAMI TIR57 (Premarket Security) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Core Principles of Security Risk Management Core Principles of Security Risk Management: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Establishing the Security Risk Management Process Establishing the Security Risk Management Process: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Impact on Product Design and Threat Modeling Impact on Product Design and Threat Modeling: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Deep Dive: AAMI TIR97 (Postmarket Security) Deep Dive: AAMI TIR97 (Postmarket Security) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Managing Risks Throughout the Product Lifecycle Managing Risks Throughout the Product Lifecycle: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Vulnerability Disclosure and Intake Mechanisms Vulnerability Disclosure and Intake Mechanisms: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Coordinated Vulnerability Disclosure (CVD) Integration Coordinated Vulnerability Disclosure (CVD) Integration: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Direct Comparison: TIR57 vs TIR97 Direct Comparison: TIR57 vs TIR97 is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Key Process Differences Key Process Differences: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Documentation Requirements: Pre- vs Postmarket Documentation Requirements: Pre- vs Postmarket: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### When to Transition from TIR57 to TIR97 Guidance When to Transition from TIR57 to TIR97 Guidance: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Best Practices for Implementing Both Standards Best Practices for Implementing Both Standards is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Building a Unified Security Risk Management File Building a Unified Security Risk Management File: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Integrating TIR Guidance into your Quality Management System (QMS) Integrating TIR Guidance into your Quality Management System (QMS): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Conclusion: Ensuring Total Lifecycle Cybersecurity Conclusion: Ensuring Total Lifecycle Cybersecurity is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches AAMI TIR57 vs TIR97 We treat AAMI TIR57 vs TIR97 as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your AAMI TIR57 vs TIR97 package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What is the difference between AAMI TIR57 and TIR97? Short answer: AAMI TIR57 vs TIR97 is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Do I need both AAMI TIR57 and TIR97 for FDA compliance? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does AAMI TIR57 relate to ISO 14971? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What are the postmarket reporting requirements in AAMI TIR97? Short answer: AAMI TIR57 vs TIR97 is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Which standard should I use for threat modeling medical devices? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Is AAMI TIR57 required for 510(k) submissions? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on AAMI TIR57 vs TIR97. If you arrived here from a different starting point, these are the most useful adjacent pages: - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) ## Related from Blue Goat Cyber - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [Secure MedTech Product Design Consulting](/services/secure-medtech-product-design-consulting) - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [12 Critical Threat Modeling Gaps in Medical Device Submissions](/guides/12-critical-threat-modeling-gaps-medical-device-submissions) - [Glossary](/glossary) ## Sources & primary references - [AAMI TIR57:2016 Principles for medical device security: Risk management](https://www.aami.org/standards), AAMI (Association for the Advancement of Medical Instrumentation) - [AAMI TIR97:2019/R2023 Principles for medical device security, Postmarket risk management for device manufacturers](https://www.aami.org/standards), AAMI (Association for the Advancement of Medical Instrumentation) - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [Postmarket Management of Cybersecurity in Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), U.S. Food and Drug Administration (FDA) - [ISO 14971:2019 Medical devices, Application of risk management to medical devices](https://www.iso.org/standard/72704.html), International Organization for Standardization (ISO) ## Talk to a regulatory cybersecurity team If you are working through AAMI TIR57 vs TIR97 and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## Medical Device CVD Guide: FDA Compliance & Best Practices Source: https://bluegoatcyber.com/guides/coordinated-vulnerability-disclosure-medical-devices # Coordinated Vulnerability Disclosure for Medical Devices **Master Coordinated Vulnerability Disclosure (CVD) for medical devices. Learn FDA requirements, ISO/IEC 29147 standards, and how to handle security researchers.** This guide is written for medical device manufacturers navigating coordinated vulnerability disclosure medical device. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Introduction to CVD in the Medical Device Sector Introduction to CVD in the Medical Device Sector is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Why CVD Matters for Patient Safety Why CVD Matters for Patient Safety: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The Shift from 'Hacker' to 'Security Researcher' The Shift from 'Hacker' to 'Security Researcher': make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## FDA Regulatory Framework for Vulnerability Disclosure FDA Regulatory Framework for Vulnerability Disclosure is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Postmarket Management Guidance Overview Postmarket Management Guidance Overview: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Section 524B and Continuous Monitoring Requirements Section 524B and Continuous Monitoring Requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The Role of ISACs and ISAOs in CVD The Role of ISACs and ISAOs in CVD: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Core Components of an Effective CVD Program Core Components of an Effective CVD Program is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Intake Process: How to Receive Reports The Intake Process: How to Receive Reports: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Verification and Triage: Determining Severity via CVSS v3.1/v4.0 Verification and Triage: Determining Severity via CVSS v3.1/v4.0: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Remediation Timelines: When to Patch vs. When to Notify Remediation Timelines: When to Patch vs. When to Notify: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Industry Standards: ISO/IEC 29147 and 30111 Industry Standards: ISO/IEC 29147 and 30111 is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Applying Cybersecurity Best Practices to Clinical Workflows Applying Cybersecurity Best Practices to Clinical Workflows: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Adhering to AAMI TIR57 for Risk Management Adhering to AAMI TIR57 for Risk Management: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Communicating with Stakeholders during Disclosure Communicating with Stakeholders during Disclosure is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Working with Security Researchers and 'White Hats' Working with Security Researchers and 'White Hats': make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Notifying Users, Providers, and Regulatory Bodies Notifying Users, Providers, and Regulatory Bodies: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The 'Safe Harbor' Provision for Researchers The 'Safe Harbor' Provision for Researchers: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Pitfalls and How to Avoid Them Common Pitfalls and How to Avoid Them is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches coordinated vulnerability disclosure medical device We treat coordinated vulnerability disclosure medical device as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your coordinated vulnerability disclosure medical device package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What is a coordinated vulnerability disclosure (CVD) program for medical devices? Short answer: coordinated vulnerability disclosure medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What does the FDA require for medical device vulnerability disclosure? Short answer: coordinated vulnerability disclosure medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do I report a security vulnerability in a medical device? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the difference between CVD and a bug bounty program in healthcare? Short answer: coordinated vulnerability disclosure medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How long do medical device manufacturers have to disclose a vulnerability? Short answer: FDA gives sponsors 180 days to respond to a Major deficiency / AI letter (15 days for an RTA hold). Plan for two iteration cycles; teams that ship a clean response in one round are the ones with a working SPDF. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on coordinated vulnerability disclosure medical device. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) ## Related from Blue Goat Cyber - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [12 Critical Findings from Medical Device Penetration Tests](/guides/12-critical-findings-from-medical-device-penetration-tests) - [Legacy Medical Device Cybersecurity](/services/legacy-medical-device-cybersecurity-services) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) ## Sources & primary references - [Cybersecurity in Medical Devices: Postmarket Management of Cybersecurity Vulnerabilities](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), FDA (U.S. Food and Drug Administration) - [Vulnerability Disclosure Guidelines](https://csrc.nist.gov/pubs/sp/800/216/final), NIST (National Institute of Standards and Technology) - [CVE-2023-XXXXX Search and Standards](https://nvd.nist.gov/), NVD (National Vulnerability Database) - [AAMI TIR57: Principles for medical device security, Risk management](https://www.aami.org/standards), AAMI (Association for the Advancement of Medical Instrumentation) - [ISO/IEC 29147:2018 Information technology, Security techniques, Vulnerability disclosure](https://www.iso.org/standard/72311.html), ISO/IEC ## Talk to a regulatory cybersecurity team If you are working through coordinated vulnerability disclosure medical device and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## CycloneDX vs SPDX: Medical Device SBOM Compliance Guide Source: https://bluegoatcyber.com/guides/cyclonedx-vs-spdx-medical-devices # CycloneDX vs. SPDX: Choosing an SBOM Format for the FDA **Does the FDA prefer CycloneDX or SPDX? Compare SBOM formats for medical device cybersecurity compliance and premarket 510(k) submissions.** This guide is written for medical device manufacturers navigating CycloneDX vs SPDX medical devices. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## The Regulatory Requirement: Why SBOM Format Choice Matters The Regulatory Requirement: Why SBOM Format Choice Matters is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### FDA Guidance on Machine-Readable SBOMs FDA Guidance on Machine-Readable SBOMs: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### NTIA Minimum Elements and MedTech Compliance NTIA Minimum Elements and MedTech Compliance: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Deep Dive into CycloneDX for Medical Devices Deep Dive into CycloneDX for Medical Devices is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Exploitability eXchange (VEX) Support Vulnerability Exploitability eXchange (VEX) Support: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Ease of Implementation in CI/CD Pipelines Ease of Implementation in CI/CD Pipelines: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Deep Dive into SPDX for Medical Devices Deep Dive into SPDX for Medical Devices is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The ISO/IEC 5962 Standard Advantage The ISO/IEC 5962 Standard Advantage: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Strengths in Intellectual Property and Licensing Transparency Strengths in Intellectual Property and Licensing Transparency: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Comparative Analysis: CycloneDX vs. SPDX for MedTech OEMS Comparative Analysis: CycloneDX vs. SPDX for MedTech OEMS is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Interoperability and Ecosystem Support Interoperability and Ecosystem Support: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Vulnerability Management and Postmarket Surveillance Vulnerability Management and Postmarket Surveillance: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Handling Legacy Components and SaMD Handling Legacy Components and SaMD: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## FDA Expectations: Does the Agency Have a Preference? FDA Expectations: Does the Agency Have a Preference? is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Implementation Strategy: Converting and Managing SBOM Formats Implementation Strategy: Converting and Managing SBOM Formats is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches CycloneDX vs SPDX medical devices We treat CycloneDX vs SPDX medical devices as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your CycloneDX vs SPDX medical devices package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### Which SBOM format does the FDA prefer? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Can I use CycloneDX for SaMD 510(k) submissions? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Is SPDX an ISO standard? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the difference between CycloneDX and SPDX for VEX? Short answer: CycloneDX vs SPDX medical devices is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do I convert SPDX to CycloneDX for medical software? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What are the NTIA minimum elements for medical device SBOMs? Short answer: CycloneDX vs SPDX medical devices is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on CycloneDX vs SPDX medical devices. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) ## Related from Blue Goat Cyber - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [The Minimum Elements For a Software Bill of Materials (SBOM)](https://www.ntia.gov/files/ntia/publications/sbom_minimum_elements_report.pdf), National Institute of Standards and Technology (NIST) - [CycloneDX Official Specification v1.5](https://cyclonedx.org/docs/1.5/), CycloneDX Standard - [SPDX Specification v2.3.1](https://spdx.github.io/spdx-spec/v2.3/), SPDX Foundation ## Talk to a regulatory cybersecurity team If you are working through CycloneDX vs SPDX medical devices and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## De Novo Cybersecurity Submission Guide | Blue Goat Cyber Source: https://bluegoatcyber.com/guides/de-novo-cybersecurity-submission-guide # De Novo Cybersecurity Submission: A Regulatory Guide **Learn the specific cybersecurity requirements for a successful De Novo submission. Ensure FDA compliance with threat modeling, SBOM, and pen testing.** This guide is written for medical device manufacturers navigating De Novo cybersecurity submission. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Introduction to De Novo Cybersecurity Requirements Introduction to De Novo Cybersecurity Requirements is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### How De Novo Differs from 510(k) Submissions How De Novo Differs from 510(k) Submissions: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The Impact of Section 524B on Novel Devices The Impact of Section 524B on Novel Devices: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Required Cybersecurity Documentation for De Novo Requests Required Cybersecurity Documentation for De Novo Requests is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Security Risk Management Plan and Report Security Risk Management Plan and Report: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Threat Modeling for Novel Architectures Threat Modeling for Novel Architectures: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Software Bill of Materials (SBOM) Requirements Software Bill of Materials (SBOM) Requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Verification and Validation (V&V) for De Novo Devices Verification and Validation (V&V) for De Novo Devices is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Communications and Disclosure Plans Vulnerability Communications and Disclosure Plans: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Penetration Testing Requirements for De Novo Novelty Penetration Testing Requirements for De Novo Novelty: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Postmarket Cybersecurity Considerations for De Novo Classification Postmarket Cybersecurity Considerations for De Novo Classification is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Establishing the Cyber-Device Lifecycle Establishing the Cyber-Device Lifecycle: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Postmarket Management Plan (PMP) Essentials Postmarket Management Plan (PMP) Essentials: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Pitfalls in De Novo Cybersecurity Submissions Common Pitfalls in De Novo Cybersecurity Submissions is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Conclusion: Navigating the De Novo Pathway Successfully Conclusion: Navigating the De Novo Pathway Successfully is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches De Novo cybersecurity submission We treat De Novo cybersecurity submission as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your De Novo cybersecurity submission package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What are the cybersecurity requirements for an FDA De Novo submission? Short answer: De Novo cybersecurity submission is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does Section 524B affect De Novo classification requests? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Do I need a full SBOM for a De Novo medical device? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How is threat modeling different for a De Novo device vs a 510(k)? Short answer: The two are complementary, not interchangeable. Use this guide's comparison table to decide which one your submission needs and where the overlap saves you re-work. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What happens if the FDA issues a cybersecurity deficiency for my De Novo? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Does a De Novo submission require independent penetration testing? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on De Novo cybersecurity submission. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) ## Related from Blue Goat Cyber - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [FDA Cybersecurity Deficiency Letter Response Checklist](/guides/fda-cybersecurity-deficiency-response-checklist) - [Secure MedTech Product Design Consulting](/services/secure-medtech-product-design-consulting) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [De Novo Classification Process (Evaluation of Automatic Class III Designation)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/de-novo-classification-process-evaluation-automatic-class-iii-designation), U.S. Food and Drug Administration (FDA) - [Principles and Practices for Medical Device Cybersecurity](https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity), International Medical Device Regulators Forum (IMDRF) - [ANSI/AAMI SW96:2023 Standard for Medical device security, Security risk management for device life cycle](https://www.aami.org/standards), AAMI/ANSI ## Talk to a regulatory cybersecurity team If you are working through De Novo cybersecurity submission and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## FDA 524B Cybersecurity Requirements: Full Compliance Guide Source: https://bluegoatcyber.com/guides/fda-524b-cybersecurity-requirements-explained # FDA 524B Cybersecurity Requirements: A Compliance Guide **Master FDA 524B cybersecurity requirements. Learn how to meet SBOM, vulnerability monitoring, and patch management standards for medical device submissions.** This guide is written for medical device manufacturers navigating FDA 524B cybersecurity requirements. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. _Last reviewed: July 2026 against Section 524B of the FD&C Act (21 U.S.C. 360n-2) and the FDA final premarket cybersecurity guidance issued February 3, 2026._ ## Understanding Section 524B of the FD&C Act Section 524B is the binding statute: it says **what** you must do. The FDA's [February 3, 2026 final premarket cybersecurity guidance](/guides/fda-cybersecurity-guidance) is the operative interpretation reviewers apply: it says **how** you prove it. Every clause below pairs the statutory obligation with the guidance-defined artifact that satisfies it. ![Diagram: Section 524B is the binding statute (WHAT you must do); the February 3, 2026 final guidance is the operative FDA interpretation (HOW to prove it).](/diagrams/524b-vs-feb-2026-guidance.svg) ### The Legislative Origin: Consolidated Appropriations Act of 2023 - **December 29, 2022** - 524B became law as part of the [Consolidated Appropriations Act, 2023 (Pub. L. 117-328)](https://www.congress.gov/bill/117th-congress/house-bill/2617/text), FDORA [Section 3305](https://www.congress.gov/117/plaws/publ328/PLAW-117publ328.pdf). - **March 29, 2023** - The law took effect 90 days later, per the effective-date clause in Section 3305(c). The FDA's refuse-to-accept authority attached on this date. - **October 1, 2023** - The FDA actually began issuing refuse-to-accept decisions on 524B grounds, per the [Refuse to Accept Policy for Cyber Devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs) guidance. This is the real start-of-rejections date. Section 524B is codified at 21 U.S.C. 360n-2. Cite both the FD&C Act section (524B) and the U.S. Code citation (360n-2) in formal submissions. ### Who is a 'Cyber Device'? Defining the Scope Under 524B(c), a cyber device is a device that (1) includes software validated, installed, or authorized by the sponsor, (2) has the ability to connect to the internet, and (3) contains technological characteristics that could be vulnerable to cybersecurity threats. All three prongs must be met, and the connectivity prong is **broad**: Wi-Fi, BLE, NFC, a USB service port, a companion app, or a gateway-mediated cloud path all count. The statute applies uniformly; the FDA does not distinguish Class II from Class III for 524B purposes. Unsure where your device lands? Run it through the [cyber device applicability tool](/tools/cyber-device-applicability). ## Section 524B subsection index [[DIAGRAM:section-524b-subsections]] ### 524B(a): Applicability Attaches the requirements to marketing submissions filed under FD&C Act sections 510(k), 513, 515(c), 515(f), and 520(m) - in plain language, **510(k), De Novo, PMA, PDP, and HDE**. IDE submissions (520(g)) are not enumerated, though the February 2026 guidance still sets cybersecurity expectations for them. - [524B(a) deep dive](/blog/fda-section-524b-subsections-explained#524b-a-applicability) - [Pathway-by-pathway cybersecurity differences](/guides/fda-pathway-cybersecurity-differences) ### 524B(b)(1): Postmarket vulnerability plan Requires a written plan to monitor, identify, and address postmarket vulnerabilities and exploits, including coordinated vulnerability disclosure and timely patch release. The plan ships **with the premarket submission** and must be operational at clearance, not a placeholder. - [524B(b)(1) deep dive](/blog/fda-section-524b-subsections-explained#524b-b-1-postmarket-vulnerability-management-plan) - [Postmarket cybersecurity readiness plan](/guides/postmarket-cybersecurity-readiness-plan) ### 524B(b)(2): Processes, updates, and patchability Requires designed-in processes providing a reasonable assurance that the device and related systems are cybersecure, plus the ability to make security updates and patches available. This is the **SPDF requirement** in operational form: secure design, patchable architecture, authenticated update channels, rollback, and the link to incident response. - [524B(b)(2) deep dive](/blog/fda-section-524b-subsections-explained#524b-b-2-processes-updates-and-patches) - [Medical device cybersecurity SPDF playbook](/guides/medical-device-cybersecurity-spdf-playbook) ### 524B(b)(3): Software Bill of Materials Requires an SBOM covering commercial, open-source, and off-the-shelf components, in a machine-readable standard format (CycloneDX or SPDX), accompanied by VEX statements for known vulnerabilities and a monitoring plan. - [524B(b)(3) deep dive](/blog/fda-section-524b-subsections-explained#524b-b-3-software-bill-of-materials) - [SBOM for medical devices](/guides/sbom-for-medical-devices) and [CycloneDX vs SPDX](/guides/cyclonedx-vs-spdx-medical-devices) ### 524B(b)(4): Additional requirements by regulation Authorizes the FDA to add cybersecurity requirements through **rulemaking**, not guidance. As of July 2026 no (b)(4) regulations have been issued. The February 2026 guidance is nonbinding and interprets the existing (b)(1)-(3) obligations; it is not the (b)(4) expression. - [524B(b)(4) deep dive](/blog/fda-section-524b-subsections-explained#524b-b-4-other-requirements-by-regulation) ### 524B(c): Cyber device definition The three-prong test above. Reviewers determine applicability from the device description plus the 524B(c) test, so the connectivity profile in your device description drives everything downstream. - [524B(c) deep dive](/blog/fda-section-524b-subsections-explained#524b-c-the-cyber-device-definition) ## Section 524B compliance checklist Walk this in statutory order. Reviewers read submissions in roughly this sequence, and gaps compound: a weak SBOM undermines the vulnerability plan, which undermines the postmarket narrative. ### Part 1, 524B(b)(1): Postmarket vulnerability plan - **Vulnerability monitoring procedure** naming data sources (NVD, CISA KEV, vendor advisories, your SBOM-driven CVE feed) and review cadence. - **Coordinated Vulnerability Disclosure policy** published at a stable URL with a security contact, secure intake, and stated safe harbor. - **Triage SLA** defining how quickly you assess, score (CVSS v3.1 or v4.0), and disposition each report. - **Remediation SLA** distinguishing routine patches from out-of-cycle critical patches. - **Customer communication plan** covering field notices, advisories, and CSAF/VEX distribution. - **VEX issuance commitment** tying each non-exploitable CVE in your SBOM to a documented statement. Related: [Medical Device VDP & CVD Workflows](/guides/medical-device-vdp-cvd-workflows-guide), [VEX Documents for Medical Devices](/guides/vex-document-medical-device-fda). ### Part 2, 524B(b)(2): Secure Product Development Framework - **SPDF policy document** mapped to ANSI/AAMI SW96:2023, IEC 81001-5-1, or ISO/IEC 27034. - **Security risk management file** under IEC 81001-5-1, cross-referenced to the ISO 14971 safety risk file. - **Threat model** (STRIDE or equivalent) covering every trust boundary, with mitigations traced to design controls. - **Architecture views** - global system, multi-patient harm, updateability, security use case. - **Penetration test report** covering vulnerability chaining, boundary analysis, closed-box testing, and manual exploit verification. - **Cybersecurity testing summary** documenting unit, integration, and system-level security verification. - **Updateability and patchability evidence** - signed updates, rollback protection, secure boot chain, demonstrated update mechanism. - **Cybersecurity labeling** for end users (security features, recommended configurations, decommissioning). Related: [Security Risk Assessment under IEC 81001-5-1](/guides/security-risk-assessment-iec-81001-5-1), [STRIDE Threat Modeling for Medical Devices](/guides/stride-threat-modeling-medical-devices), [Penetration Testing for Medical Devices](/guides/penetration-testing-for-medical-devices). ### Part 3, 524B(b)(3): Software Bill of Materials - **Machine-readable SBOM** in CycloneDX 1.5+ or SPDX 2.3+ covering firmware, OS, middleware, application, and third-party libraries. - **Component identifiers** including PURL and CPE wherever both exist. - **Cryptographic hashes** per component to support integrity verification. - **Supplier and license metadata** per component. - **SBOM generation procedure** stating whether SBOMs come from source, build, or binary analysis, and how often they are regenerated. - **Known-vulnerability summary** at submission time, with VEX statements for each open CVE. Related: [CPE vs PURL](/guides/cpe-vs-purl-sbom-medical-devices), [SBOM Vulnerability Management](/guides/sbom-vulnerability-management-medical-devices). ### Part 4, 524B(b)(4): What the guidance adds The February 2026 guidance is not (b)(4) rulemaking, but it is the interpretation reviewers use, so the premarket package should also include: - **Cybersecurity Management Plan** as a top-level submission document. - **Interoperability considerations** documenting connected systems, protocols, and shared-responsibility boundaries. - **Total Product Life Cycle cybersecurity narrative** spanning premarket through end-of-support. - **Cybersecurity labeling** including end-user responsibilities and known residual risks. - **End-of-support plan** with a sunset policy and customer transition path. - **MDS2** if your health-delivery-organization customers request it. Related: [FDA Premarket Cybersecurity Submission Checklist](/guides/fda-premarket-cybersecurity-submission-checklist), [FDA PMA Cybersecurity Requirements](/guides/fda-pma-cybersecurity-requirements). ### Part 5, Common RTA and deficiency triggers Pre-flight these before you file: - SBOM is a PDF, not machine-readable. - Threat model omits trust boundaries the architecture diagram shows. - Penetration test report has only automated scanner output, no manual exploit verification. - CVD policy is referenced but not published at a stable, crawlable URL. - Updateability claim is not backed by a demonstrated update mechanism in the verification record. - Architecture views are missing the multi-patient harm view. - No VEX statements accompany known CVEs in the SBOM. See real examples: [FDA Cybersecurity Deficiency Letter Examples](/guides/fda-cybersecurity-deficiency-letter-examples). ## Premarket Submission Requirements Under 524B ### Integration with the Secure Product Development Framework (SPDF) The SPDF is the engineering and QMS process that generates 524B evidence across the lifecycle; the submission is only the delivery vehicle. Build evidence inside design controls so requirement → threat → control → test → residual risk holds up in an audit, then package it for the template. ### Required Documentation for eSTAR and Traditional Submissions For 510(k) and De Novo, everything lands in the eSTAR Cybersecurity attachment area, with labeling in Section 15, risk analysis in Section 17, and the connectivity profile in Section 9. For the attachment-by-attachment mapping, see the [eSTAR v7.0 cybersecurity attachments guide](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance). PMA packages carry the same deliverables in a different container. ## Postmarket Obligations: Beyond the Initial Submission ### Coordinated Vulnerability Disclosure (CVD) Programs Align intake, triage, and disclosure to ISO/IEC 29147 and 30111, publish the policy at a stable URL, and reference it from labeling. Reviewers check the link. ### Timeline for Security Patches and Regular Updates Define risk-based SLAs: routine patches on a published cadence, out-of-cycle patches for actively exploited or high-severity issues, each with a validated update mechanism behind it. ## FDA's 'Refuse to Accept' (RTA) Authority under 524B Section 524B does not itself grant RTA authority; 21 U.S.C. 360c(a)(3) and the FDA's existing acceptance-review authorities do. What 524B does is add cybersecurity to the mandatory content list, so an incomplete cybersecurity package now triggers the same RTA machinery that missing 510(k) elements always have. ### How to Avoid Deficiency Leads and Submission Delays Close the Part 5 triggers above before filing, keep the threat model and device description in sync, and make every cross-reference explicit. Reviewers do not follow implicit links between documents. ## Combination products: BLA and IND Section 524B is a device statute and does not reach BLAs or INDs. The February 2026 guidance is broader: it covers devices with cybersecurity considerations generally, including 510(k)-exempt devices, IDE, BLA, and IND submissions. For combination products, the cybersecurity content for the device constituent (delivery device, connected manufacturing system, dosing companion app) lives **inside the BLA or IND**, scoped and rigored like any other device cybersecurity package. - [Combination products: when device cybersecurity content lands in a BLA or IND](/guides/fda-pathway-cybersecurity-differences#combination-products-when-device-cybersecurity-content-lands-in-a-bla-or-ind) ## How Blue Goat Cyber Approaches FDA 524B cybersecurity requirements We treat FDA 524B cybersecurity requirements as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, ANSI/AAMI SW96, AAMI TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your FDA 524B cybersecurity requirements package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What devices are considered 'cyber devices' under Section 524B? A device that includes sponsor-validated software, can connect to the internet, and has technological characteristics vulnerable to cybersecurity threats. All three prongs must be true. The connectivity prong is read broadly, so BLE, NFC, USB service ports, companion apps, and gateway-mediated cloud paths all bring a device in scope. ### What are the three main parts of Section 524B? 524B(a) enumerates the pathways covered. 524B(b) lists four obligations: the postmarket vulnerability plan, secure design and maintenance processes, the SBOM, and any additional requirements added by regulation. 524B(c) defines "cyber device." ### What are the SBOM requirements for FDA 524B compliance? A machine-readable CycloneDX or SPDX SBOM covering commercial, open-source, and off-the-shelf components with transitive dependencies, suppliers, versions, licenses, and identifiers, plus VEX statements for known CVEs and a monitoring plan. A PDF component list does not satisfy the requirement. ### Which subsection carries the "refuse to accept" teeth? None directly. 524B adds cybersecurity to the mandatory content list, and the FDA's existing acceptance-review authority under 21 U.S.C. 360c(a)(3) does the rest. In practice an incomplete cybersecurity package draws the same RTA hold as any other missing submission element. ### Is 524B(b)(4) already in effect? No formal rulemaking under (b)(4) has been finalized. The February 2026 guidance interprets (b)(1) through (b)(3); it is not a (b)(4) regulation. Any (b)(4) expansion would go through notice-and-comment rulemaking with its own effective date. ### Does 524B apply to legacy medical devices or only new submissions? Devices cleared before March 2023 do not need to be resubmitted, but manufacturers of legacy connected devices still carry postmarket cybersecurity responsibilities under existing FDA authority and the February 2026 guidance. Any new submission, including a 510(k) for a material change, brings the device fully into 524B scope. ### Does 524B(c)'s "cyber device" definition include BLAs and INDs? The definition is device-facing, but the February 2026 guidance applies its cybersecurity expectations to combination products submitted under BLAs and INDs where the device constituent meets the cyber device test. Treat the cyber device analysis as required for that constituent. ### What postmarket cybersecurity activities are mandated by Section 524B? Monitoring for new vulnerabilities against your SBOM, coordinated vulnerability disclosure, risk-based triage and remediation on defined SLAs, customer communication, and a validated mechanism to deliver updates and patches for the supported life of the device. ## Where this fits in the cluster This page sits downstream of our pillar resources on FDA 524B cybersecurity requirements. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Section 524B subsections explained](/blog/fda-section-524b-subsections-explained) - the long-form statutory walkthrough - [FDA cybersecurity guidance summary 2026](/guides/fda-cybersecurity-guidance) - what the February 3, 2026 final guidance changed - [eSTAR v7.0 cybersecurity attachments](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) - where each artifact goes in the template - [FDA pathway cybersecurity differences](/guides/fda-pathway-cybersecurity-differences) - 510(k), De Novo, PMA, PDP, HDE, IDE, BLA, IND - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) ## Related from Blue Goat Cyber - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [Consolidated Appropriations Act, 2023 - Section 524B Ensuring Cybersecurity of Medical Devices](https://www.govinfo.gov/content/pkg/PLAW-117publ328/pdf/PLAW-117publ328.pdf), U.S. Congress (GovInfo) - [Refuse to Accept Policy for Cyber Devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs), U.S. Food and Drug Administration (FDA) - [Secure Software Development Framework (SSDF) Version 1.1](https://nvlpubs.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-218.pdf), NIST - [Draft Guidance: Select Updates for Cybersecurity in Medical Devices: Data Types and Formats for SBOMs](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket), U.S. Food and Drug Administration (FDA) ## Talk to a regulatory cybersecurity team If you are working through FDA 524B cybersecurity requirements and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## FDA Cybersecurity Deficiency Letter Examples: Real Reviewer Wording Source: https://bluegoatcyber.com/guides/fda-cybersecurity-deficiency-letter-examples # FDA Cybersecurity Deficiency Letter Examples **Analyze real-world FDA cybersecurity deficiency letter examples. Learn how to address RTA and AI deficiency requests for 510(k) and PMA submissions.** This guide is written for medical device manufacturers navigating FDA cybersecurity deficiency letter examples. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Introduction to FDA Cybersecurity Deficiencies Introduction to FDA Cybersecurity Deficiencies is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Shift Since Section 524B of the FD&C Act The Shift Since Section 524B of the FD&C Act: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### RTA (Refuse to Accept) vs. Substantive Interaction Deficiencies RTA (Refuse to Accept) vs. Substantive Interaction Deficiencies: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Cybersecurity Deficiency Categories Common Cybersecurity Deficiency Categories is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Example 1: Software Bill of Materials (SBOM) Gaps Example 1: Software Bill of Materials (SBOM) Gaps: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Example 2: Incomplete Threat Modeling (STRIDE/TARA) Example 2: Incomplete Threat Modeling (STRIDE/TARA): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Example 3: Lack of Traceability in Security Requirements Example 3: Lack of Traceability in Security Requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Detailed Analysis: Deficiency Letter Examples Detailed Analysis: Deficiency Letter Examples is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Sample Deficiency: Insufficient Penetration Testing Coverage Sample Deficiency: Insufficient Penetration Testing Coverage: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Sample Deficiency: Vulnerability Management Postmarket Plans Sample Deficiency: Vulnerability Management Postmarket Plans: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Sample Deficiency: Unverified Third-Party Software (SOUP) Security Sample Deficiency: Unverified Third-Party Software (SOUP) Security: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## How to Respond to a Deficiency Letter (AIs) How to Respond to a Deficiency Letter (AIs) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The 'Stop the Clock' Impact on Timeline The 'Stop the Clock' Impact on Timeline: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Structuring Your Response and Objective Evidence Structuring Your Response and Objective Evidence: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Avoiding Deficiencies: The SPDF Approach Avoiding Deficiencies: The SPDF Approach is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches FDA cybersecurity deficiency letter examples We treat FDA cybersecurity deficiency letter examples as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your FDA cybersecurity deficiency letter examples package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### How do I respond to an FDA cybersecurity deficiency letter? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What are the most common reasons for FDA cybersecurity holds? Short answer: FDA cybersecurity deficiency letter examples is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Does a deficiency letter mean my 510(k) will be rejected? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What does the FDA require for SBOM in a deficiency response? Short answer: FDA cybersecurity deficiency letter examples is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How much time do I have to answer FDA cybersecurity AIs? Short answer: FDA gives sponsors 180 days to respond to a Major deficiency / AI letter (15 days for an RTA hold). Plan for two iteration cycles; teams that ship a clean response in one round are the ones with a working SPDF. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on FDA cybersecurity deficiency letter examples. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [FDA Cybersecurity Deficiency Letter Response Checklist](/guides/fda-cybersecurity-deficiency-response-checklist) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) ## Related from Blue Goat Cyber - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [12 Critical Threat Modeling Gaps in Medical Device Submissions](/guides/12-critical-threat-modeling-gaps-medical-device-submissions) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [Postmarket Management of Cybersecurity in Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), U.S. Food and Drug Administration (FDA) - [Secure Software Development Framework (SSDF) Version 1.1](https://csrc.nist.gov/pubs/sp/800/218/final), NIST - [Principles and Practices for Medical Device Cybersecurity](https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity), International Medical Device Regulators Forum (IMDRF) ## Talk to a regulatory cybersecurity team If you are working through FDA cybersecurity deficiency letter examples and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## FDA PMA Cybersecurity Requirements: Expert Guide (2024) Source: https://bluegoatcyber.com/guides/fda-pma-cybersecurity-requirements # FDA PMA Cybersecurity Requirements: A Regulatory Guide **Master FDA PMA cybersecurity requirements. Learn the technical documentation, risk management, and SPDF requirements needed for a successful Class III submissio** This guide is written for medical device manufacturers navigating FDA PMA cybersecurity requirements. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Understanding Cybersecurity for Premarket Approval (PMA) Understanding Cybersecurity for Premarket Approval (PMA) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Class III Devices and the Rigor of PMA Review Class III Devices and the Rigor of PMA Review: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The Impact of FD&C Act Section 524B on PMA Submissions The Impact of FD&C Act Section 524B on PMA Submissions: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Section 524B: The Mandatory Cybersecurity Triad Section 524B: The Mandatory Cybersecurity Triad is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Requirement 1: Secure Product Development Framework (SPDF) Requirement 1: Secure Product Development Framework (SPDF): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Requirement 2: Software Bill of Materials (SBOM) for PMA Requirement 2: Software Bill of Materials (SBOM) for PMA: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Requirement 3: Postmarket Monitoring & Vulnerability Management Requirement 3: Postmarket Monitoring & Vulnerability Management: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Technical Documentation Required for PMA Cybersecurity Technical Documentation Required for PMA Cybersecurity is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Security Risk Management Plan and Report The Security Risk Management Plan and Report: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Threat Modeling for Complex Class III Architectures Threat Modeling for Complex Class III Architectures: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Penetration Testing Requirements and Evidence Penetration Testing Requirements and Evidence: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Integrating Cybersecurity into the Quality Management System (QMS) Integrating Cybersecurity into the Quality Management System (QMS) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Design Controls and Cybersecurity Verification/Validation Design Controls and Cybersecurity Verification/Validation: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Interoperability and Third-Party Component Risk Interoperability and Third-Party Component Risk: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Deficiencies in PMA Cybersecurity Documentation Common Deficiencies in PMA Cybersecurity Documentation is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Simplifies PMA Compliance How Blue Goat Cyber Simplifies PMA Compliance is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches FDA PMA cybersecurity requirements We treat FDA PMA cybersecurity requirements as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your FDA PMA cybersecurity requirements package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### Do Class III medical devices have stricter cybersecurity requirements than Class II? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the difference between 510(k) and PMA cybersecurity documentation? Short answer: FDA PMA cybersecurity requirements is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Is an SBOM mandatory for an FDA PMA submission? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does Section 524B change the PMA approval process? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What level of penetration testing is required for a PMA submission? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on FDA PMA cybersecurity requirements. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) ## Related from Blue Goat Cyber - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [FDA Cybersecurity Deficiency Letter Response Checklist](/guides/fda-cybersecurity-deficiency-response-checklist) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), FDA - [Postmarket Management of Cybersecurity in Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), FDA - [Secure Software Development Framework (SSDF) Version 1.1](https://csrc.nist.gov/pubs/sp/800/218/final), NIST Gov ## Talk to a regulatory cybersecurity team If you are working through FDA PMA cybersecurity requirements and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## FDA Premarket Cybersecurity Submission Checklist Guide Source: https://bluegoatcyber.com/guides/fda-premarket-cybersecurity-submission-checklist # FDA Premarket Cybersecurity Submission Checklist for 2024 **Ensure your 510(k) or PMA is compliant. Use our checklist for FDA premarket cybersecurity submissions, covering SBOM, threat models, and pen testing.** This guide is written for medical device manufacturers navigating FDA premarket cybersecurity submission checklist. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Introduction to the FDA's Final Guidance on Cybersecurity Introduction to the FDA's Final Guidance on Cybersecurity is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Impact of Section 524B of the FD&C Act The Impact of Section 524B of the FD&C Act: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### What the FDA Expects in a 'Cyber-Secure' Submission What the FDA Expects in a 'Cyber-Secure' Submission: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## The Pre-Submission Checklist: Essential Documentation The Pre-Submission Checklist: Essential Documentation is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Cybersecurity Management Plan (CMP) Cybersecurity Management Plan (CMP): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Security Risk Management Report (SRMR) Security Risk Management Report (SRMR): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Software Bill of Materials (SBOM) Requirements Software Bill of Materials (SBOM) Requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Deep Dive: Security Risk Management Analysis Deep Dive: Security Risk Management Analysis is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Threat Modeling Documentation (STRIDE/HEC) Threat Modeling Documentation (STRIDE/HEC): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Vulnerability Assessment and CVSS Scoring Vulnerability Assessment and CVSS Scoring: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Risk Mitigation and Residual Risk Justification Risk Mitigation and Residual Risk Justification: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Security Architecture and Design Documentation Security Architecture and Design Documentation is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Data Flow Diagrams and Trust Boundaries Data Flow Diagrams and Trust Boundaries: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Authentication and Encryption Controls Authentication and Encryption Controls: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Cybersecurity Interface Control Documents Cybersecurity Interface Control Documents: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Security Testing and Verification Requirements Security Testing and Verification Requirements is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Scanning Results Vulnerability Scanning Results: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Penetration Testing Summary Reports Penetration Testing Summary Reports: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Anomaly and Robustness Testing (Fuzzing) Anomaly and Robustness Testing (Fuzzing): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Postmarket Management Documentation Strategy Postmarket Management Documentation Strategy is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Disclosure Policy (VDP) Details Vulnerability Disclosure Policy (VDP) Details: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Patch Management and Distribution Plans Patch Management and Distribution Plans: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Pitfalls to Avoid in Premarket Submissions Common Pitfalls to Avoid in Premarket Submissions is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Conclusion: Ensuring a Successful FDA Review Cycle Conclusion: Ensuring a Successful FDA Review Cycle is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches FDA premarket cybersecurity submission checklist We treat FDA premarket cybersecurity submission checklist as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your FDA premarket cybersecurity submission checklist package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What are the minimum cybersecurity requirements for an FDA 510(k)? Short answer: FDA premarket cybersecurity submission checklist is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Does the FDA require penetration testing for all medical devices? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What SBOM format does the FDA prefer? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do I document threat modeling in a premarket submission? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the 'Refuse to Accept' (RTA) policy for cybersecurity? Short answer: FDA premarket cybersecurity submission checklist is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How often should cybersecurity testing be updated before submission? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on FDA premarket cybersecurity submission checklist. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) ## Related from Blue Goat Cyber - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [FDA Cybersecurity Deficiency Letter Response Checklist](/guides/fda-cybersecurity-deficiency-response-checklist) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [Framework for Improving Critical Infrastructure Cybersecurity (Cybersecurity Framework)](https://www.nist.gov/cyberframework), NIST - [SW96:2023 Medical devices - Security risk management - Application of ISO 14971](https://www.aami.org/standards), AAMI/ANSI - [Select Updates for Non-Clinical Tests and Software Considerations in Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-device-software-functions), U.S. Food and Drug Administration (FDA) ## Talk to a regulatory cybersecurity team If you are working through FDA premarket cybersecurity submission checklist and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## Postmarket Cybersecurity Monitoring Guide for MedTech Source: https://bluegoatcyber.com/guides/postmarket-cybersecurity-monitoring-program # Postmarket Cybersecurity Monitoring for Medical Devices **Ensure FDA compliance with our guide to postmarket cybersecurity monitoring for medical devices. Master vulnerability intake, risk assessments, and disclosure.** This guide is written for medical device manufacturers navigating postmarket cybersecurity monitoring. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Introduction to Postmarket Cybersecurity Monitoring Introduction to Postmarket Cybersecurity Monitoring is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Shift from Premarket to Continuous Security The Shift from Premarket to Continuous Security: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### FDA Statutory Authority: Section 524B requirements FDA Statutory Authority: Section 524B requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Core Components of a Compliant Monitoring Program Core Components of a Compliant Monitoring Program is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Intake and Surveillance Systems Vulnerability Intake and Surveillance Systems: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Coordinated Vulnerability Disclosure (CVD) Processes Coordinated Vulnerability Disclosure (CVD) Processes: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### SBOM Maintenance and Ongoing Component Tracking SBOM Maintenance and Ongoing Component Tracking: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## The Postmarket Risk Management Framework (TIR97/ISO 14971) The Postmarket Risk Management Framework (TIR97/ISO 14971) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Evaluating Patient Safety Impacts of New Vulnerabilities Evaluating Patient Safety Impacts of New Vulnerabilities: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Applying CVSS in a Clinical Context Applying CVSS in a Clinical Context: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Determining Uncontrolled vs. Controlled Risk Determining Uncontrolled vs. Controlled Risk: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Vulnerability Identification and Remediation Cycles Vulnerability Identification and Remediation Cycles is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Proactive Monitoring vs. Reactive Patching Proactive Monitoring vs. Reactive Patching: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Timelines for Remediation: The 30/60 Day Rule Guidance Timelines for Remediation: The 30/60 Day Rule Guidance: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Deploying Updates and Patches in the Field Deploying Updates and Patches in the Field: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Integrating Monitoring with the Quality Management System (QMS) Integrating Monitoring with the Quality Management System (QMS) is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### CAPA and Postmarket Surveillance Alignment CAPA and Postmarket Surveillance Alignment: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Documentation Requirements for FDA Inspections Documentation Requirements for FDA Inspections: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Challenges in Postmarket Monitoring for Legacy Devices Challenges in Postmarket Monitoring for Legacy Devices is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches postmarket cybersecurity monitoring We treat postmarket cybersecurity monitoring as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your postmarket cybersecurity monitoring package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What are the FDA requirements for postmarket cybersecurity monitoring? Short answer: postmarket cybersecurity monitoring is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How often should medical device manufacturers scan for vulnerabilities? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the difference between premarket and postmarket cybersecurity? Short answer: postmarket cybersecurity monitoring is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Do I need a Coordinated Vulnerability Disclosure (CVD) policy for the FDA? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does SBOM play a role in postmarket monitoring? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the timeline for reporting a postmarket cyber vulnerability to the FDA? Short answer: postmarket cybersecurity monitoring is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on postmarket cybersecurity monitoring. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) - [Legacy Medical Device Cybersecurity](/services/legacy-medical-device-cybersecurity-services) ## Related from Blue Goat Cyber - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) ## Sources & primary references - [Postmarket Management of Cybersecurity in Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), FDA - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), FDA - [AAMI TIR97:2019 - Principles for medical device security, Postmarket risk management for device manufacturers](https://www.aami.org/standards), AAMI - [National Vulnerability Database (CVE/CVSS)](https://nvd.nist.gov/), NIST/NVD ## Talk to a regulatory cybersecurity team If you are working through postmarket cybersecurity monitoring and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## SaMD Cybersecurity FDA Requirements: 2024 Compliance Guide Source: https://bluegoatcyber.com/guides/samd-cybersecurity-requirements # SaMD Cybersecurity FDA Requirements: A Compliance Guide **Master SaMD cybersecurity FDA requirements. Learn premarket submission needs, SBOM standards, and postmarket monitoring for SaMD under Section 524B.** This guide is written for medical device manufacturers navigating SaMD cybersecurity FDA requirements. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Understanding SaMD in the Eyes of the FDA Understanding SaMD in the Eyes of the FDA is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### SaMD vs. SiMD: Regulatory Distinction SaMD vs. SiMD: Regulatory Distinction: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Section 524B and the 'Cybersecurity Device' Definition Section 524B and the 'Cybersecurity Device' Definition: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Core Premarket Cybersecurity Requirements for SaMD Core Premarket Cybersecurity Requirements for SaMD is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Secure Product Development Framework (SPDF) The Secure Product Development Framework (SPDF): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Threat Modeling Requirements for Software Applications Threat Modeling Requirements for Software Applications: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Third-Party Software and SBOM Documentation Third-Party Software and SBOM Documentation: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Cybersecurity Testing Mandates for Software Applications Cybersecurity Testing Mandates for Software Applications is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Communications and Disclosure Plans Vulnerability Communications and Disclosure Plans: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Software Penetration Testing Expectations Software Penetration Testing Expectations: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Postmarket Requirements: Maintaining SaMD Compliance Postmarket Requirements: Maintaining SaMD Compliance is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Coordinated Vulnerability Disclosure (CVD) Programs Coordinated Vulnerability Disclosure (CVD) Programs: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Monitoring and Patch Management for Cloud-Based SaMD Monitoring and Patch Management for Cloud-Based SaMD: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common FDA Submission Pitfalls for SaMD Developers Common FDA Submission Pitfalls for SaMD Developers is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches SaMD cybersecurity FDA requirements We treat SaMD cybersecurity FDA requirements as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your SaMD cybersecurity FDA requirements package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What are the FDA cybersecurity requirements for SaMD? Short answer: SaMD cybersecurity FDA requirements is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Does SaMD require a Softare Bill of Materials (SBOM)? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does FDA Section 524B affect software-only medical devices? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Is penetration testing required for SaMD FDA clearance? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do I document threat modeling for a software medical device? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the difference between premarket and postmarket SaMD cyber requirements? Short answer: SaMD cybersecurity FDA requirements is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on SaMD cybersecurity FDA requirements. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [AI ML Medical Device Security](/services/ai-ml-medical-device-security) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) ## Related from Blue Goat Cyber - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) - [FDA Cybersecurity Deficiency Letter Response Checklist](/guides/fda-cybersecurity-deficiency-response-checklist) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), FDA.gov - [Postmarket Management of Cybersecurity in Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), FDA.gov - [Software as a Medical Device (SaMD): Key Definitions and Framework](https://www.imdrf.org/documents/software-medical-device-samd-key-definitions-and-framework), IMDRF - [Framework for Improving Critical Infrastructure Cybersecurity (NIST CSF)](https://www.nist.gov/cyberframework), NIST.gov ## Talk to a regulatory cybersecurity team If you are working through SaMD cybersecurity FDA requirements and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## SBOM Vulnerability Management for Medical Devices Guide Source: https://bluegoatcyber.com/guides/sbom-vulnerability-management-medical-devices # SBOM Vulnerability Management for Medical Devices **Master SBOM vulnerability management for medical devices. Learn to track, triage, and mitigate software risks to meet FDA premarket and postmarket requirements.** This guide is written for medical device manufacturers navigating SBOM vulnerability management medical devices. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## The Intersection of SBOM and Vulnerability Management The Intersection of SBOM and Vulnerability Management is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Defining SBOM in the MedTech Lifecycle Defining SBOM in the MedTech Lifecycle: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Why SBOMs are Essential for Vulnerability Monitoring Why SBOMs are Essential for Vulnerability Monitoring: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## FDA Requirements for SBOM and Vulnerability Disclosure FDA Requirements for SBOM and Vulnerability Disclosure is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Section 524B and Postmarket Management Section 524B and Postmarket Management: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Premarket Expectations for Software Transparency Premarket Expectations for Software Transparency: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Developing a Vulnerability Triage Workflow Developing a Vulnerability Triage Workflow is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Matching SBOM Components to Known CVEs Matching SBOM Components to Known CVEs: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Risk Scoring: CVSS vs. Medical Device Impact Risk Scoring: CVSS vs. Medical Device Impact: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Identifying False Positives with VEX (Vulnerability Exploitability eXchange) Identifying False Positives with VEX (Vulnerability Exploitability eXchange): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Postmarket Surveillance: Bridging the Gap from SBOM to Patch Postmarket Surveillance: Bridging the Gap from SBOM to Patch is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Continuous Monitoring Requirements Continuous Monitoring Requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Coordinated Vulnerability Disclosure (CVD) Programs Coordinated Vulnerability Disclosure (CVD) Programs: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Pitfalls in MedTech SBOM Management Common Pitfalls in MedTech SBOM Management is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Transitive Dependency Gaps Transitive Dependency Gaps: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Static SBOMs in a Dynamic Threat Landscape Static SBOMs in a Dynamic Threat Landscape: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## How Blue Goat Cyber Automates and Validates SBOM Workflows How Blue Goat Cyber Automates and Validates SBOM Workflows is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches SBOM vulnerability management medical devices We treat SBOM vulnerability management medical devices as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your SBOM vulnerability management medical devices package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### How do I use an SBOM for medical device vulnerability management? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What are the FDA requirements for SBOM in postmarket surveillance? Short answer: SBOM vulnerability management medical devices is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does VEX work with medical device SBOMs? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How often should medical device SBOMs be updated for vulnerabilities? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What tools are used for SBOM vulnerability scanning in MedTech? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How to handle vulnerabilities in third-party libraries within an SBOM? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on SBOM vulnerability management medical devices. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) - [Legacy Medical Device Cybersecurity](/services/legacy-medical-device-cybersecurity-services) ## Related from Blue Goat Cyber - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), U.S. Food and Drug Administration (FDA) - [The Minimum Elements For a Software Bill of Materials (SBOM)](https://www.cisa.gov/sbom), National Institute of Standards and Technology (NIST) - [Vulnerability Exploitability eXchange (VEX) Overview](https://www.cisa.gov/resources-tools/resources/minimum-requirements-vulnerability-exploitability-exchange-vex), CISA (Cybersecurity & Infrastructure Security Agency) - [AAMI TIR57: Principles for medical device security, Risk management](https://www.aami.org/standards), AAMI (Association for the Advancement of Medical Instrumentation) ## Talk to a regulatory cybersecurity team If you are working through SBOM vulnerability management medical devices and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## IEC 81001-5-1 Security Risk Assessment Guide Source: https://bluegoatcyber.com/guides/security-risk-assessment-iec-81001-5-1 # Guide to IEC 81001-5-1 Security Risk Assessments **Learn how to implement IEC 81001-5-1 security risk assessments for FDA compliance. Expert guidance on medical device lifecycle security mapping.** This guide is written for medical device manufacturers navigating IEC 81001-5-1 security risk assessment. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## What is IEC 81001-5-1 and Why Does It Matter? What is IEC 81001-5-1 and Why Does It Matter? is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### The Shift from Safety Risk to Security Risk The Shift from Safety Risk to Security Risk: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Relationship with ISO 14971 and AAMI TIR57 Relationship with ISO 14971 and AAMI TIR57: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Core Requirements of an IEC 81001-5-1 Security Risk Assessment Core Requirements of an IEC 81001-5-1 Security Risk Assessment is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Security in the Product Lifecycle (SPDF) Security in the Product Lifecycle (SPDF): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Defining the System Boundary and Assets Defining the System Boundary and Assets: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Step-by-Step Security Risk Management Process Step-by-Step Security Risk Management Process is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Vulnerability Identification and Analysis Vulnerability Identification and Analysis: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Risk Evaluation: Impact vs. Likelihood Risk Evaluation: Impact vs. Likelihood: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Control Implementation and Verification Control Implementation and Verification: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## IEC 81001-5-1 vs. FDA Premarket Guidance IEC 81001-5-1 vs. FDA Premarket Guidance is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Mapping Standards to FDA Documentation Requirements Mapping Standards to FDA Documentation Requirements: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Addressing Security Risk in Section 524B Submissions Addressing Security Risk in Section 524B Submissions: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common Pitfalls in Security Risk Assessments Common Pitfalls in Security Risk Assessments is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Expert Support for IEC 81001-5-1 Compliance Expert Support for IEC 81001-5-1 Compliance is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches IEC 81001-5-1 security risk assessment We treat IEC 81001-5-1 security risk assessment as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your IEC 81001-5-1 security risk assessment package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### How does IEC 81001-5-1 differ from ISO 14971? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Is IEC 81001-5-1 mandatory for FDA medical device submissions? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What are the specific security life cycle activities required by IEC 81001-5-1? Short answer: IEC 81001-5-1 security risk assessment is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do you integrate threat modeling into an IEC 81001-5-1 assessment? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Does IEC 81001-5-1 apply to SaMD (Software as a Medical Device)? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on IEC 81001-5-1 security risk assessment. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) - [Secure MedTech Product Design Consulting](/services/secure-medtech-product-design-consulting) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) ## Related from Blue Goat Cyber - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), FDA (U.S. Food and Drug Administration) - [IEC 81001-5-1:2021 - Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product life cycle](https://www.iso.org/standard/71780.html), ISO/IEC (International Organization for Standardization) - [AAMI TIR57: Principles for medical device security, Risk management](https://www.aami.org/standards), AAMI (Association for the Advancement of Medical Instrumentation) - [NIST SP 800-30 Rev. 1: Guide for Conducting Risk Assessments](https://csrc.nist.gov/pubs/sp/800/30/r1/final), NIST (National Institute of Standards and Technology) ## Talk to a regulatory cybersecurity team If you are working through IEC 81001-5-1 security risk assessment and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## STRIDE Threat Modeling for Medical Devices | Blue Goat Cyber Source: https://bluegoatcyber.com/guides/stride-threat-modeling-medical-devices # STRIDE Threat Modeling for Medical Devices: A Guide **Master STRIDE threat modeling for medical devices. Learn to identify risks, meet FDA premarket requirements, and secure your MedTech ecosystem. Read our guide.** This guide is written for medical device manufacturers navigating STRIDE threat modeling medical devices. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## Introduction to STRIDE in the Medical Device Context Introduction to STRIDE in the Medical Device Context is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Why Threat Modeling is Critical for FDA Premarket Submissions Why Threat Modeling is Critical for FDA Premarket Submissions: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### How STRIDE Fits into the Secure Product Development Framework (SPDF) How STRIDE Fits into the Secure Product Development Framework (SPDF): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Breaking Down the STRIDE Categories for MedTech Breaking Down the STRIDE Categories for MedTech is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Spoofing: Identity Risks in Connected Devices Spoofing: Identity Risks in Connected Devices: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Tampering: Maintaining Data Integrity for Patient Safety Tampering: Maintaining Data Integrity for Patient Safety: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Repudiation: Audit Trails and Accountability Repudiation: Audit Trails and Accountability: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Information Disclosure: Protecting PHI and Proprietary Data Information Disclosure: Protecting PHI and Proprietary Data: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Denial of Service: Ensuring Availability of Life-Critical Functions Denial of Service: Ensuring Availability of Life-Critical Functions: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Elevation of Privilege: Controlling Access in Hospital Environments Elevation of Privilege: Controlling Access in Hospital Environments: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## The 4-Step Medical Device Threat Modeling Process The 4-Step Medical Device Threat Modeling Process is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Step 1: Decomposing the System (Data Flow Diagrams) Step 1: Decomposing the System (Data Flow Diagrams): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Step 2: Applying the STRIDE Mnemonic to Components Step 2: Applying the STRIDE Mnemonic to Components: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Step 3: Risk Assessment and Mitigation Strategies Step 3: Risk Assessment and Mitigation Strategies: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Step 4: Validation and Traceability for Regulatory Audits Step 4: Validation and Traceability for Regulatory Audits: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Common STRIDE Pitfalls in MedTech Submissions Common STRIDE Pitfalls in MedTech Submissions is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Integrating STRIDE with AAMI TIR57 and ISO 14971 Integrating STRIDE with AAMI TIR57 and ISO 14971 is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Conclusion: From Threat Model to Secure Architecture Conclusion: From Threat Model to Secure Architecture is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches STRIDE threat modeling medical devices We treat STRIDE threat modeling medical devices as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your STRIDE threat modeling medical devices package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### Is STRIDE required by the FDA for medical device submissions? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do you create a Data Flow Diagram (DFD) for a medical device? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What is the difference between STRIDE and PASTA for MedTech? Short answer: STRIDE threat modeling medical devices is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How does threat modeling relate to medical device risk management (ISO 14971)? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What level of detail does the FDA expect in a threat model? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on STRIDE threat modeling medical devices. If you arrived here from a different starting point, these are the most useful adjacent pages: - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [12 Critical Threat Modeling Gaps in Medical Device Submissions](/guides/12-critical-threat-modeling-gaps-medical-device-submissions) - [Secure MedTech Product Design Consulting](/services/secure-medtech-product-design-consulting) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) ## Related from Blue Goat Cyber - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [12 Critical Threat Modeling Gaps in Medical Device Submissions](/guides/12-critical-threat-modeling-gaps-medical-device-submissions) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/media/119749/download), U.S. Food and Drug Administration (FDA) - [NIST SP 800-154: Guide to Data-Centric System Threat Modeling](https://csrc.nist.gov/publications/detail/sp/800-154/draft), NIST (National Institute of Standards and Technology) - [Principles and Practices for Medical Device Cybersecurity](https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity), International Medical Device Regulators Forum (IMDRF) ## Talk to a regulatory cybersecurity team If you are working through STRIDE threat modeling medical devices and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- ## VEX Document Guide for FDA Medical Device Compliance Source: https://bluegoatcyber.com/guides/vex-document-medical-device-fda # VEX Document Guide: FDA Medical Device Compliance **Learn how VEX documents complement SBOMs for FDA medical device compliance. Expert guidance on Vulnerability Exploitability eXchange for MedTech manufacturers.** This guide is written for medical device manufacturers navigating VEX document FDA medical device. It is built from real submissions, FDA correspondence, and the standards reviewers actually cite. Use it as a working reference: read straight through, jump to the section that matches your current gap, or hand it to your engineering and regulatory leads as a checklist. ## What is a VEX Document in Medical Device Cybersecurity? What is a VEX Document in Medical Device Cybersecurity? is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Defining Vulnerability Exploitability eXchange (VEX) Defining Vulnerability Exploitability eXchange (VEX): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### The Relationship Between SBOM and VEX The Relationship Between SBOM and VEX: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Why the FDA Requires VEX for Medical Devices Why the FDA Requires VEX for Medical Devices is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Postmarket Management and Section 524B Compliance Postmarket Management and Section 524B Compliance: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Responding to FDA Deficiencies regarding SBOM Vulnerabilities Responding to FDA Deficiencies regarding SBOM Vulnerabilities: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## The Four VEX Status Labels for MedTech VMS The Four VEX Status Labels for MedTech VMS is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Not Affected: When the Vulnerability Isn't Exploitable Not Affected: When the Vulnerability Isn't Exploitable: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Affected: Acknowledging and Fixing the Risk Affected: Acknowledging and Fixing the Risk: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Fixed: Confirming Resolution Fixed: Confirming Resolution: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Under Investigation: Managing Real-Time Triage Under Investigation: Managing Real-Time Triage: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## VEX Implementation Formats: CSAF, CycloneDX, and SPDX VEX Implementation Formats: CSAF, CycloneDX, and SPDX is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## Best Practices for Generating and Maintaining VEX Data Best Practices for Generating and Maintaining VEX Data is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ### Automation in Vulnerability Triage Automation in Vulnerability Triage: make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ### Linking VEX to your Coordinated Vulnerability Disclosure (CVD) Linking VEX to your Coordinated Vulnerability Disclosure (CVD): make sure your design history file documents the rationale, the standard you mapped to, and the objective evidence that closes the loop. Reviewers expect to trace the requirement, the test, and the residual risk in a single thread. ## Conclusion: VEX as a Tool for Market Clearance and Safety Conclusion: VEX as a Tool for Market Clearance and Safety is one of the areas FDA reviewers probe hardest in modern submissions. The points below summarize what we ship in client packages and what we have seen FDA accept and reject across 275+ device submissions. ## How Blue Goat Cyber Approaches VEX document FDA medical device We treat VEX document FDA medical device as a regulated engineering workstream, not a one-time document drop. Every engagement is led by senior medical-device security engineers who have shipped 275+ FDA cybersecurity submissions across 510(k), De Novo, PMA, and EU MDR pathways. Here is how we run it end to end: - **Scoping against your device profile.** We baseline connectivity, interfaces, data flows, and intended use before we touch a template - because reviewer expectations for a Class II wearable are not the same as a networked hospital platform. - **Standards mapping in writing.** Every deliverable is traced to the February 2026 FDA premarket cybersecurity guidance, AAMI SW96, AAMI TIR57 / TIR97, IEC 81001-5-1, and ISO 14971 - with the citation in the artifact itself so reviewers do not have to guess. - **Evidence generated inside your QMS.** Threat models, SBOMs, security risk assessments, and test reports are versioned under design controls so the traceability from requirement → test → residual risk holds up under audit. - **Independent testing where it counts.** Penetration testing and vulnerability analysis are executed by a testing team that does not also write the design - the separation FDA reviewers increasingly expect on cyber devices. - **Deficiency-ready posture.** We anticipate the RTA, AI-letter, and Major deficiency patterns FDA has issued over the past 24 months and pre-empt them in the initial submission, cutting the odds of a second review cycle. - **Postmarket handoff, not abandonment.** Every premarket package leaves you with a working postmarket monitoring plan, CVD process, and update cadence so the evidence you shipped stays defensible after clearance. If you want that treatment applied to your VEX document FDA medical device package, our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements are the two most common entry points. ## Frequently asked questions ### What is the difference between SBOM and VEX for medical devices? Short answer: VEX document FDA medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Does the FDA require VEX documents for 510(k) submissions? Short answer: Yes. under Section 524B and the February 2026 final guidance, every cyber device requires the artifact in question. Skipping it is the fastest way to an RTA hold. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### What are the approved formats for VEX documents in healthcare? Short answer: VEX document FDA medical device is a discrete deliverable inside the Secure Product Development Framework (SPDF). FDA expects it documented, traceable, and version-controlled inside your QMS. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### How do I prove a vulnerability is 'not affected' in a medical device VEX? Short answer: Treat it as a process, not a one-off document: own the requirement in design controls, map it to a current standard, generate evidence during V&V, and surface the residual risk in your postmarket plan. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ### Who is responsible for maintaining VEX data postmarket? Short answer: It depends on the device classification, intended use, and connectivity profile, but the controlling references are FDA's February 2026 premarket guidance, AAMI SW96, and IEC 81001-5-1. The sections above walk through how each applies. For the full context, work through the relevant section above and the linked services below. Every answer here is grounded in current FDA guidance and the standards your reviewer is using. ## Where this fits in the cluster This page sits downstream of our pillar resources on VEX document FDA medical device. If you arrived here from a different starting point, these are the most useful adjacent pages: - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [The Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) ## Related from Blue Goat Cyber - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) ## Sources & primary references - [Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions), FDA - [Vulnerability Exploitability eXchange (VEX) Overview](https://www.ntia.gov/files/ntia/publications/vex_one-page_summary.pdf), NIST - [Vulnerability Exploitability eXchange (VEX) Use Cases](https://www.cisa.gov/resources-tools/resources/minimum-requirements-vulnerability-exploitability-exchange-vex), CISA/NIST - [Implementation Guidance for SBOM of Medical Devices](https://www.aami.org/standards), AAMI/HSDP-12 ## Talk to a regulatory cybersecurity team If you are working through VEX document FDA medical device and want a second pair of eyes on your submission package, we ship cybersecurity deliverables for medical device manufacturers across 510(k), De Novo, PMA, and EU MDR pathways. [Book a discovery session](/contact) and we will walk your evidence with you. --- # Featured blog posts (hand-authored) --- ## 20 Common Medical Device Protocols Source: https://bluegoatcyber.com/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples # 20 Common Medical Device Protocols: What Manufacturers Need to Know > **[DIRECT ANSWER]** There is no single fix for all 20 protocols; each one, HL7, DICOM, Bluetooth, Wi-Fi, and the rest, carries its own security flaws, from weak authentication to unencrypted transmission. Manufacturers must map every protocol a device uses to its known vulnerabilities, apply encryption and access controls, and document those choices under the FDA's February 3, 2026 premarket cybersecurity guidance alongside standards like IEC 81001-5-1 and AAMI SW96. _Reviewed July 24, 2026_ Integrating advanced communication protocols in medical devices has revolutionized healthcare, offering enhanced patient monitoring, improved diagnostics, and more efficient care delivery. These protocols are the backbone for connectivity and data exchange in various medical devices, from wearable health monitors to sophisticated diagnostic machines. The increasing reliance on these technologies also brings many security challenges. Understanding the nuances of these protocols, their purposes, potential security risks, and regulatory guidance is essential for manufacturers, healthcare providers, and regulatory bodies. ## Key Takeaways - Diverse protocols support medical device connectivity. - Each protocol has distinct security vulnerabilities. - FDA guidance mandates secure medical device design. - Encryption and access control are critical defenses. - Continuous monitoring protects against evolving threats. - Interoperability must not compromise security. ## Why this matters The stakes are high: compromised medical device protocols can lead to patient harm, data breaches, and significant financial and reputational damage for manufacturers. The increasing interconnectedness of medical devices, driven by protocols for data exchange and remote operation, introduces a larger attack surface that demands rigorous security measures. The FDA's February 3, 2026, cybersecurity guidance mandates that manufacturers integrate security throughout the total product lifecycle, not as an afterthought. This includes adherence to standards such as IEC 81001-5-1 for health software and health IT system security, ISO 27001 for information security management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles for medical device security. Failure to address protocol-specific vulnerabilities, like those in HL7, DICOM, or even wireless protocols like Wi-Fi and Bluetooth, can result in regulatory non-compliance, costly recalls, and a loss of public trust. Proactive security by design is essential to safeguard patient safety and data integrity in an increasingly digital healthcare landscape. ## Common Medical Device Protocols ### 1\. [**HL7 (Health Level 7)**](/blog/hl7-navigating-the-complexities-of-healthcare-data-exchange) - **Description**: A set of international standards for exchanging clinical and administrative data between software applications in healthcare settings. - **Purpose**: To streamline and standardize the sharing, integration, and retrieval of electronic health information. - **Security Flaws**: Vulnerable to data interception during transmission and unauthorized access due to weak authentication and encryption protocols. - **FDA Guidance**: This guidance recommends secure data exchange practices per [HIPAA regulations](https://www.hhs.gov/hipaa/for-professionals/index.html), emphasizing the need for strong encryption and authentication mechanisms. - **Example**: Integrating patient data from different departments into a centralized Electronic Health Record (EHR) system. ### 2\. [**DICOM (Digital Imaging and Communications in Medicine)**](/blog/what-is-dicom-in-medical-devices) - **Description**: A universal standard for the handling, storage, printing, and transmission of medical imaging and related data. - **Purpose**: Ensures interoperability and standardizes the communication and management of imaging data and devices like CT, MRI, and ultrasound machines. - **Security Flaws:** It can be [susceptible to unauthorized access](/blog/pacs-medical-device-vulnerabilities), data corruption, or loss during transmission or storage. - **FDA Guidance**: Strong recommendation for encryption and stringent access controls to safeguard imaging data. - **Example**: Radiology departments use DICOM to transmit and archive patient images across various imaging modalities. ### 3\. [**IHE (Integrating the Healthcare Enterprise)**](https://www.ihe.net/) - **Description**: A collaborative framework that defines standardized implementation of established communication protocols (like [DICOM](/blog/vulnerabilities-with-dicom-in-medtech) and HL7) to improve interoperability. - **Purpose**: Aims to enhance patient care by facilitating information exchange across diverse healthcare systems. - **Security Flaws**: Relies on the security of underlying communication protocols, making it as vulnerable as the protocols it integrates. - **FDA Guidance**: Advocates for security evaluations and regular updates in line with evolving cybersecurity threats. - **Example**: Used in hospitals to integrate disparate healthcare applications and ensure data flow between systems. ### 4\. [**IEEE 11073 Series**](https://standards.ieee.org/ieee/11073-10701/7538/) - **Description**: A family of standards that provide interoperability specifications for medical devices, focusing on safe and effective communication and data exchange. - **Purpose**: Facilitates consistent and secure interoperability between medical devices and external computer systems, including personal health devices. - **Security Flaws**: Potential risks include data tampering, unauthorized access, and interception, particularly if encryption isn’t strong. - **FDA Guidance**: Emphasizes adopting security protocols, especially for devices transmitting sensitive patient data. - **Example**: Commonly used in wearable health monitors and smart medical devices for secure data transmission. ### 5\. **[Bluetooth Low Energy (BLE)](/blog/the-importance-of-ble-in-medical-devices-cybersecurity) in Medical Devices** - **Description**: A variant of the Bluetooth technology designed for low-power, short-range communication. - **Purpose**: Widely used in healthcare for wirelessly transmitting health data from patient monitoring devices to central databases or caregiver devices. - **Security Flaws**: Susceptible to unauthorized access and data interception, especially in crowded wireless environments. - **FDA Guidance**: Strong focus on implementing advanced encryption, secure device pairing mechanisms, and consistent updates to address new security vulnerabilities. - **Example**: BLE is integral in devices like wireless patient monitors and wearable health trackers, enabling them to connect with smartphones and other data collection systems. ### 6\. **[Zigbee](/blog/zigbee-in-medical-devices-cybersecurity-a-comprehensive-guide) for Healthcare** - **Description**: A high-level communication protocol using low-power digital radios designed for creating personal area networks with small, low-power digital radios. - **Purpose**: Utilized in healthcare for remote patient data monitoring and for automating various healthcare facilities, including wireless sensor networks. - **Security Flaws**: Prone to data interception, unauthorized control of the devices, and susceptibility to interference and physical attacks. - **FDA Guidance**: Recommends secure implementation practices, including strong encryption and regular checks for unauthorized access points. - **Example**: Often used in hospital bed monitoring systems and for managing patient care devices in home healthcare settings. ### 7\. **Wi-Fi in Medical Devices** - **Description**: A technology for wireless networking based on [IEEE 802.11](https://en.wikipedia.org/wiki/IEEE_802.11) standards. - **Purpose**: Facilitates high-speed data transmission and efficient connectivity for various medical devices within healthcare facilities. - **Security Flaws**: Vulnerable to network-based attacks, unauthorized access, eavesdropping, and man-in-the-middle attacks. - **FDA Guidance**: Recommends using the latest Wi-Fi security protocols, including WPA3, and stresses the importance of secure network configuration and regular monitoring. - **Example**: Used in telemedicine equipment, mobile health applications, and large-scale hospital information systems for data communication. #### 8\. **[Near Field Communication (NFC)](/blog/nfc-and-medical-device-cybersecurity) in Medical Devices** - **Description**: A set of communication protocols for electronic devices, allowing two electronic devices to communicate within 4 cm of each other. - **Purpose**: Utilized in healthcare for secure and rapid data transfer in close proximity, particularly useful in patient identification and accessing medical records. - **Security Flaws**: Due to the proximity required for data transfer, risks include eavesdropping, data manipulation, and relay attacks. - **FDA Guidance**: Advocates for secure data exchange protocols and emphasizes the importance of physical security due to the close proximity nature of NFC. - **Example**: NFC-enabled wearable devices and medical equipment used for hospital patient monitoring and identity verification. ### 9\. [**Medical Device Radiocommunication Service (MedRadio)**](https://www.ecfr.gov/current/title-47/chapter-I/subchapter-D/part-95/subpart-I) - **Description**: A communication service that utilizes specific radio frequencies for medical device communication. - **Purpose**: Supports wireless communication needs for medical applications, especially for implantable and wearable medical devices. - **Security Flaws**: Vulnerable to interference from other devices, risks of unauthorized access, and potential device control issues. - **FDA Guidance**: Encourages adherence to allocated frequency bands and implementation of measures to mitigate interference and enhance overall communication security. - **Example**: Commonly used in implantable devices like pacemakers and defibrillators, which require reliable wireless communication capabilities. ### 10\. [**M2M (Machine to Machine) Communication**](https://en.wikipedia.org/wiki/Machine_to_machine) - **Description**: Technology that allows networked devices to exchange information and perform actions without manual assistance, using various communication protocols, including cellular and internet-based options. - **Purpose**: Automates data transfer, monitoring, and control in medical devices, enhancing efficiency and real-time decision-making in healthcare. - **Security Flaws**: High risk of unauthorized access and data breaches, particularly in unencrypted or poorly secured networks. - **FDA Guidance**: Stresses the need for secure communication channels, strong encryption, and continuous security monitoring. - **Example**: Remote health monitoring systems that automatically transmit patient data to healthcare providers for analysis and alerts. ### 11\. [**LoRaWAN (Long Range Wide Area Network)**](https://en.wikipedia.org/wiki/LoRa) - **Description**: A low-power wide-area networking protocol designed for wirelessly connecting battery-operated devices over long distances. - **Purpose**: Used in medical devices for remote patient monitoring, especially effective in rural or hard-to-reach areas where traditional connectivity is limited. - **Security Flaws**: Potential vulnerabilities include eavesdropping, physical attacks, and data manipulation due to long-range transmission. - **FDA Guidance**: Recommends strong encryption methods and secure network architecture to protect data integrity and privacy. - **Example**: Remote cardiac monitoring systems that provide real-time patient data over extensive distances. ### 12\. [**ANT/ANT+**](/blog/enhancing-cybersecurity-for-ant-ant-medical-devices) - **Description**: A wireless protocol for collecting and transferring sensor data, known for its low power consumption and reliability. - **Purpose**: Common in medical devices for collecting and sharing health and fitness data in real-time. - **Security Flaws**: Susceptible to data interception, unauthorized access, and limited encryption capabilities. - **FDA Guidance**: Suggests implementing layered security measures and continuous monitoring to detect and mitigate potential threats. - **Example**: Fitness trackers and health monitors track heart rate, activity levels, and other vital signs. ### 13\. [**Z-Wave**](https://z-wavealliance.org/) - **Description**: A low-energy RF communication technology primarily used for home automation. - **Purpose**: In medical devices, it enables remote patient monitoring and control over medical devices in home settings. - **Security Flaws**: Vulnerable to signal jamming, hacking, and unauthorized device manipulation. - **FDA Guidance**: Advises on secure network setup, regular firmware updates, and advanced encryption. - **Example**: Home-based patient monitoring systems, emergency alert systems, and automated medication dispensers. ### 14\. [**6LoWPAN (IPv6 over Low-Power Wireless Personal Area Networks)**](https://en.wikipedia.org/wiki/6LoWPAN) - **Description**: An internet protocol for enabling low-power devices in wireless personal area networks to communicate with the internet using IPv6. - **Purpose**: Allows for efficient, wireless internet connectivity in a range of medical devices, particularly in constrained environments. - **Security Flaws**: Exposed to standard internet vulnerabilities like DoS attacks, IP spoofing, and unauthorized access. - **FDA Guidance**: Strong emphasis on using secure Internet protocols and safeguarding against common web-based attacks. - **Example**: Wireless sensor networks used in hospitals for patient monitoring and environmental controls. ### 15\. [**MQTT (Message Queuing Telemetry Transport)**](https://mqtt.org/) - **Description**: A lightweight messaging protocol for limited bandwidth and unreliable networks, ideal for [machine-to-machine (M2M)](/blog/m2m-communication-vulnerabilities-in-medical-devices-a-cybersecurity-concern) communication. - **Purpose**: Used in medical devices for efficient and reliable telemetry data transmission, particularly in remote monitoring scenarios. - **Security Flaws**: Risks include unauthorized access to sensitive data and susceptibility to network attacks. - **FDA Guidance**: Recommends using secure MQTT versions with enhanced authentication and encryption features. - **Example**: Real-time health monitoring systems used in remote areas. ### 16\. [**CoAP (Constrained Application Protocol)**](https://en.wikipedia.org/wiki/Constrained_Application_Protocol) - **Description**: A protocol designed for simple, constrained devices that enables them to communicate interactively over the internet. - **Purpose**: Utilized in healthcare for efficient and reliable data transmission in constrained environments, including in wearable and implantable devices. - **Security Flaws**: Susceptible to denial-of-service (DoS) attacks, unauthorized access, and IP layer attacks. - **FDA Guidance**: Advocates using strong security measures, including DTLS (Datagram Transport Layer Security) for secure communication. - **Example**: Monitoring systems in wearable devices like smartwatches that track health metrics. ### 17\. [**Sigfox**](https://www.sigfox.com/) - **Description**: A global network for IoT devices using low-power, wide-area communication. - **Purpose**: Provides long-range, low-data-rate communication for various medical IoT devices. - **Security Flaws**: Potential risks include limited data throughput and susceptibility to network interference and spoofing. - **FDA Guidance**: Encourages the implementation of strong data encryption and secure device authentication methods. - **Example**: Health tracking devices in remote patient monitoring systems. ### 18\. **LTE-M (Long-Term Evolution for Machines)** - **Description**: A low-power, wide-area network technology based on LTE (4G) standards designed for IoT applications. - **Purpose**: Enables direct communication between IoT devices and a 4G network, suitable for mobile health applications. - **Security Flaws**: Exposed to cellular network vulnerabilities, including interception and unauthorized access. - **FDA Guidance**: Recommends end-to-end encryption and constant vigilance for network security. - **Example**: Mobile health applications requiring high-speed data transfer, such as telemedicine apps. ### 19. [**NB-IoT (Narrowband IoT)**](https://www.gsma.com/iot/narrow-band-internet-of-things-nb-iot/) - **Description**: NB-IoT is a low-power wide-area network radio technology that enables internet connection for various devices. - **Purpose**: Ideal for medical devices that need small, infrequent data transmissions over long periods. - **Security Flaws**: Vulnerable to eavesdropping, spoofing, and other network-based attacks. - **FDA Guidance**: Stresses the importance of secure network configurations and regular software updates. - **Example**: Patient monitoring devices that periodically send health data to healthcare providers. ### 20\. **Thread Protocol**) - **Description**: A low-power, wireless mesh networking protocol used to connect and control [IoT products](/blog/securing-iot-enabled-medical-devices-5-essential-tips). - **Purpose**: In healthcare, it’s used to create interconnected networks of medical devices, enhance patient care, and monitor patients. - **Security Flaws**: Susceptible to side-channel attacks, data breaches, and unauthorized access. - **FDA Guidance**: Suggests implementing strong encryption standards and periodic security assessments. - **Example**: Integrated healthcare systems in smart homes, where multiple devices collaborate for patient monitoring. ## Protocol security at a glance Protocols differ less in what they carry than in what they assume about the network around them. This table summarizes the assumption each one makes. | Protocol | Encryption available by default | Authentication in the standard | The assumption it makes | Where it fails in the field | | --- | --- | --- | --- | --- | | DICOM | Optional TLS, rarely enabled | Application entity title only | The imaging network is trusted | Any host that knows the AE title can associate | | HL7 v2 over MLLP | None | None | The interface is on a protected segment | Flat hospital networks make the segment meaningless | | FHIR | Yes, over HTTPS | OAuth 2.0 tokens | The API gateway enforces scope | Authorization checked at login but not per resource | | Bluetooth Low Energy | Yes, if pairing is used | Pairing, which is often Just Works | Physical proximity limits the attacker | Sniffing and relay defeat proximity assumptions | | Wi-Fi | Yes, WPA2 or WPA3 | Enterprise or shared key | The hospital manages the network | Shared keys and legacy supplicants on long lived devices | | Zigbee and proprietary sub GHz | Varies, key management is weak | Network key, often shared | The radio is obscure enough | Shared keys extracted from one device compromise the fleet | | MQTT and CoAP | TLS or DTLS if configured | Username and password or none | The broker is private | Anonymous publish and subscribe on an exposed broker | | CAN and internal buses | None | None | The attacker is outside the enclosure | One compromised module reaches every other module | The common thread is that almost every protocol on this list was designed assuming a boundary that hospitals and home networks no longer provide. ## Conclusion As we navigate an increasingly prevalent digital health technology era, the importance of securing medical device protocols cannot be overstated. The complexities and vulnerabilities associated with these communication standards require careful attention and proactive management to safeguard patient data and ensure the reliability of medical devices. The [FDA’s guidance](https://www.fda.gov/media/119933/download) shapes this domain’s security measures and practices. It emphasizes strong encryption, secure network architectures, and continuous monitoring to address emerging threats. The future of healthcare technology hinges on the secure and efficient implementation of these protocols. Manufacturers must rigorously test and update their devices, healthcare providers need to be vigilant about the cybersecurity aspects of their medical equipment, and patients should be aware of the data security measures in place. Collaborative efforts among all stakeholders are crucial to advancing healthcare technology while protecting sensitive health information and maintaining the integrity of medical devices. Check out our [medical device cybersecurity FDA compliance package.](/services/fda-premarket-cybersecurity-services) ## How Blue Goat approaches this Blue Goat Cyber addresses medical device protocol security through a targeted, evidence-based methodology. Our team, comprised of certified experts (CISSP, OSCP, ex-military red team), identifies specific vulnerabilities in device communication protocols. We don't just find problems; we offer actionable strategies for remediation, aligning with current FDA expectations. Our service offerings include threat modeling, penetration testing, and premarket and postmarket cybersecurity services tailored to medical device manufacturers. We use our deep understanding of regulatory requirements to guide clients through complex compliance landscapes, ensuring their devices meet necessary security benchmarks. This focused approach helps manufacturers build defensive capabilities into their products from initial design through postmarket surveillance. When providing premarket cybersecurity services, we stand by our work. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our validation services at [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What medical device protocols are commonly used? Common medical device protocols include HL7, DICOM, IHE, IEEE 11073, Bluetooth LE, Wi-Fi, and Zigbee. These facilitate data exchange, imaging, and wireless communication in healthcare settings. ### How does the FDA regulate cybersecurity for medical device protocols? The FDA regulates cybersecurity through its February 3, 2026, premarket guidance, which requires manufacturers to address security risks in device design and throughout the product lifecycle. This includes implementing secure protocols, encryption, and vulnerability management plans. ### What are common security risks in medical device protocols? Common security risks include unauthorized access, data interception, manipulation, denial-of-service attacks, and weak authentication. These risks vary by protocol and can compromise patient safety and data privacy. ### Does Bluetooth Low Energy (BLE) pose cybersecurity risks in medical devices? Yes, BLE can pose cybersecurity risks such as data interception and unauthorized access, especially in dense wireless environments. The FDA recommends strong encryption and secure pairing mechanisms for BLE-enabled medical devices. ### Why is HL7 vulnerable to security flaws? HL7 can be vulnerable to security flaws like data interception during transmission and unauthorized access due to weak or absent encryption and authentication. The FDA recommends strong security practices for HL7 implementations. ### What role does IHE play in medical device security? IHE defines frameworks for implementing existing communication protocols to improve interoperability. Its security relies on the underlying protocols it integrates, necessitating security evaluations and updates to address threats. ## Ready to lock down your FDA cybersecurity package? 275+ premarket submissions cleared. Zero FDA rejections on cybersecurity. If the FDA raises a cybersecurity deficiency on a package we authored, we respond at no additional cost until it clears. [Book a free 30-minute discovery call →](https://bluegoatcyber.com/contact-us) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## 21 CFR Part 820: Cybersecurity in the QMSR Era Source: https://bluegoatcyber.com/blog/21-cfr-part-820-and-its-role-in-medical-device-cybersecurity # 21 CFR Part 820: What It Requires for Cybersecurity > **[DIRECT ANSWER]** 21 CFR Part 820 is the FDA's Quality System Regulation for medical devices. As of February 2, 2026, it operates as the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference and reserves many of the old QSR subparts rather than replacing FDA oversight. Cybersecurity artifacts required under Section 524B, threat models, SBOMs, CAPA records, and design history files, must be generated and controlled inside this QMS, not produced separately for a submission. _Reviewed September 17, 2026_ Medical device manufacturers are now operating under a rewritten quality regulation, and the transition has direct consequences for how cybersecurity evidence gets built and defended. The QMSR did not soften the FDA's expectations; it changed where those expectations live in the text and tied them more tightly to ISO 13485:2016. Teams that keep citing the old QSR subpart numbers for design controls or document requirements risk citing sections that are now reserved. Getting the mapping wrong in an audit or a submission response is more than a paperwork problem, it signals that the QMS itself has not been updated. This matters most for cybersecurity because Section 524B premarket artifacts, SBOMs, threat models, vulnerability management plans, are only credible if they trace back to controlled QMS records rather than one-off documents assembled for the FDA. ## Key Takeaways - The QMSR replaced most of Part 820's original text with an incorporation of ISO 13485:2016, not a new quality standard invented by the FDA. - Many former QSR subparts are now reserved; citing them as active requirements is a compliance and credibility error. - Design controls remain the anchor for generating cybersecurity evidence, they just map to ISO 13485 clause 7.3 rather than a standalone Part 820 subpart. - CAPA and complaint handling must treat cybersecurity vulnerabilities as nonconformities with the same rigor as any other quality escape. - Supplier controls now carry more weight because third-party software and components are a documented source of risk under both QMSR and Section 524B. - QSIT is retired; FDA investigators now use CP 7382.850, which changes how inspections probe cybersecurity records. ## Why This Matters The FDA's "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" final guidance, dated February 3, 2026, is explicit that cybersecurity risk management is not a separate deliverable bolted onto a submission. It has to be an output of the manufacturer's quality management system, from design input through postmarket surveillance. The QMSR transition landed one day before that guidance took effect, which is not a coincidence, both reflect the FDA's move toward international harmonization while keeping device-specific enforcement authority. Manufacturers that treat the QMSR as a documentation reshuffle will miss the substance: ISO 13485:2016 uses different terminology and a different clause structure than the old QSR, and inspectors trained under CP 7382.850 will ask for records mapped to that structure. Cybersecurity documentation, SBOMs, threat models, penetration test reports, coordinated vulnerability disclosure records, has to sit inside the same document control and record retention scheme as every other design and production record. If it does not, the FDA can treat it as unverified, which undermines a Section 524B submission regardless of the technical work behind it. ## What Is 21 CFR Part 820? 21 CFR Part 820 is the FDA's regulation establishing the Quality System Regulation for medical device manufacturers, first issued to require design, production, and postmarket controls that keep devices safe and effective. Before the 2026 amendment, Part 820 contained the FDA's own subpart structure covering design controls, document controls, production and process controls, and CAPA. It applied to any entity engaged in the design, manufacture, packaging, labeling, storage, installation, or servicing of finished devices intended for the U.S. market. **[KEY REQUIREMENT]** Part 820 compliance is not optional for a device to be legally marketed in the United States; it is a condition of maintaining a valid establishment registration and device listing, and failure to comply can result in warning letters, import holds, or consent decrees regardless of premarket clearance status. ## What Changed Under the QMSR Amendment? The QMSR amendment, effective February 2, 2026, replaced most of Part 820's original FDA-authored text with an incorporation by reference of ISO 13485:2016, plus a smaller set of FDA-specific additions. This is a harmonization move, not a deregulation. The FDA retains full enforcement authority over device manufacturers; it did not hand oversight to ISO or to a third party. Several concrete changes matter for cybersecurity programs: - Many former QSR subparts are now reserved because their content is superseded by the corresponding ISO 13485:2016 clause. Do not cite a reserved subpart as an active requirement in an SOP or a submission. - Terminology shifted to align with ISO 13485 language, for example "quality management system" replaces "quality system" and clause-based cross references replace some of the old subpart numbering. - Section 820.35 is now a records requirement, distinct from its prior scope, and manufacturers should confirm their document control procedures reference the current text rather than a legacy interpretation. - Section 820.45 addresses device labeling and packaging controls and remains a distinct FDA-specific provision layered on top of ISO 13485. - The FDA's Quality System Inspection Technique (QSIT) program was retired on February 2, 2026, and replaced by inspection program CP 7382.850, which investigators now use to structure QMS inspections including cybersecurity-relevant records. ## Old QSR Subsystem vs. Where the Requirement Lives Now | Legacy QSR Subsystem | Prior Subpart | Current Location Under QMSR/ISO 13485 | |---|---|---| | Design controls | Subpart C, 820.30 | ISO 13485:2016 clause 7.3, referenced through QMSR | | Document controls | Subpart D, 820.40 | ISO 13485:2016 clause 4.2, plus FDA record provisions | | Records | Subpart M, 820.180-820.198 | Largely reserved; core content now in ISO 13485 clause 4.2.5 and retained FDA-specific record rules including 820.35 | | Production and process controls | Subpart G, 820.70-820.75 | ISO 13485:2016 clause 7.5 | | CAPA | Subpart J, 820.100 | ISO 13485:2016 clause 8.5.2-8.5.3, with FDA CAPA expectations preserved | | Labeling and packaging | Subpart H, 820.120-820.130 | Retained in part as 820.45, an FDA-specific addition alongside ISO 13485 | | Management responsibility | Subpart B, 820.20 | ISO 13485:2016 clause 5 | Manufacturers should update internal SOPs to cite the current clause structure, since an SOP that still points exclusively to a reserved subpart will not hold up under a CP 7382.850 inspection. ## Who Does Part 820 Apply To, and What Is Exempt? Part 820, now operating as the QMSR, applies to any manufacturer, specification developer, contract manufacturer, or repackager involved in producing finished devices for the U.S. market, domestic or foreign. The scope has not narrowed under the QMSR amendment. Certain lower-risk Class I devices remain exempt from the design control requirements under the same criteria the FDA used before the amendment, and some Class I devices are exempt from the QMSR entirely unless they are implantable, life-sustaining, or life-supporting. Manufacturers should not assume an exemption carries over automatically; the exemption list is device-specific and should be verified against the current device classification regulation rather than assumed from legacy practice. ## Why Do Design Controls Matter for Cybersecurity Evidence? Design controls are where cybersecurity risk management has to originate, because the FDA expects the threat model, architecture views, and risk analysis to be design inputs, not retrofits. Under ISO 13485:2016 clause 7.3, incorporated through the QMSR, design input, verification, and validation records must capture the security requirements a device was built to meet. A threat model produced after the design is frozen cannot satisfy this, because it cannot demonstrate that security requirements shaped design decisions. **[KEY REQUIREMENT]** Cybersecurity risk assessments, secure design decisions, and verification test results must be captured as design control records inside the QMS, with the same revision control and approval signatures as any other design output, so they can be traced from a Section 524B submission back to a specific design review. ## How Do CAPA and Complaint Handling Cover Vulnerabilities? CAPA and complaint handling processes must treat a discovered vulnerability the same way they treat any other nonconformity, with root cause analysis, corrective action, and effectiveness checks. A vulnerability report, whether from internal testing, a coordinated disclosure researcher, or a customer complaint, should enter the same complaint handling system that captures a mechanical failure. Under ISO 13485:2016 clause 8.5, incorporated through the QMSR, that record has to show the investigation was completed and the corrective action addressed the root cause, not just the specific instance reported. ## What Do Supplier Controls Require for Third-Party Software? Supplier controls require manufacturers to qualify and monitor any supplier providing components that affect device safety or performance, and third-party software components fall squarely in that scope. An SBOM identifies what third-party and open-source components are present, but supplier controls under ISO 13485:2016 clause 7.4 require a documented basis for trusting that supplier's development and update practices. Manufacturers should maintain purchasing controls that require component suppliers to disclose known vulnerabilities and support end-of-life timelines, since that information feeds directly into the SBOM and postmarket vulnerability management obligations under Section 524B. ## How Do Document and Record Controls Apply to Threat Models and SBOMs? Document and record controls require that threat models, SBOMs, and related cybersecurity artifacts be maintained as controlled documents with version history, approval records, and defined retention periods. ISO 13485:2016 clause 4.2, incorporated through the QMSR, sets the baseline for this, and 820.35's current record requirement adds an FDA-specific layer on top. An SBOM that is regenerated informally for each submission without version control does not meet this standard, because there is no traceable record of what changed between versions or why. ## How Do Section 524B Premarket Artifacts Trace Back to QMS Records? Section 524B premarket cybersecurity artifacts, the SBOM, the threat model, the vulnerability management plan, and the SPDF description, all have to trace back to specific QMS records rather than exist as submission-only documents. The FDA's February 3, 2026 final guidance expects reviewers to be able to follow a threat identified in the threat model to a design control record showing how it was mitigated, and from there to a verification or validation record showing the mitigation was tested. If a submission's cybersecurity narrative cannot be reconciled with the underlying design history file and CAPA records, it signals that the documentation was assembled outside the QMS, which the FDA can flag as a quality system deficiency independent of the technical merits. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works with manufacturers to align cybersecurity evidence, threat models, SBOMs, and penetration test results, with the QMS records that have to support a Section 524B submission under the QMSR. We review existing design history files and CAPA procedures to identify where cybersecurity documentation is disconnected from controlled records, and we help rebuild that traceability before a submission goes in. Our team includes CISSP and OSCP-certified engineers with backgrounds spanning red team operations and quality systems. If the FDA raises cybersecurity deficiencies after our engagement, we resolve them at no additional cost. Manufacturers preparing a design history file for a new submission can start with our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## Frequently Asked Questions ### Does the QMSR replace 21 CFR Part 820? The QMSR did not replace the FDA's authority over medical device quality systems; it amended Part 820 to incorporate ISO 13485:2016 by reference and add FDA-specific provisions. The FDA still enforces the regulation, inspects manufacturers, and can take action for nonconformance. Manufacturers are still operating under Part 820, just with different underlying text. ### Are all the old QSR subparts still in effect? No, many former subparts are now reserved because ISO 13485:2016 covers the same content through its own clause structure. Citing a reserved subpart as if it is a current, standalone requirement is inaccurate and can undermine an SOP or a submission response. Manufacturers should verify current citations against the amended regulation text. ### What replaced QSIT for FDA inspections? The FDA retired the Quality System Inspection Technique program on February 2, 2026, and replaced it with inspection program CP 7382.850. Investigators use CP 7382.850 to structure inspections against the QMSR and ISO 13485:2016 clause structure, which affects how cybersecurity-relevant records get requested and reviewed during an inspection. ### Does Part 820 explicitly require cybersecurity controls? Part 820 and the QMSR do not name cybersecurity as a standalone subpart, but design controls, CAPA, supplier controls, and document controls all apply to cybersecurity activities the same way they apply to any other design or quality function. Section 524B and the FDA's premarket cybersecurity guidance layer specific cybersecurity content requirements on top of this general QMS framework. ### Who is exempt from Part 820 or the QMSR? Certain Class I devices are exempt from design control requirements or from the QMSR entirely, unless they are implantable, life-sustaining, or life-supporting. Exemptions are device-specific and tied to classification regulations, not a blanket exemption for a product category. Manufacturers should confirm exemption status against the current device classification rather than legacy assumptions. ### How does an SBOM connect to Part 820 record requirements? An SBOM has to be maintained as a controlled document under the same document and record control requirements that apply to other design outputs, including version history and defined retention. This lets the SBOM submitted for a Section 524B review be traced to a specific design record and update history rather than standing alone as an unverified list. ## CTA If your design history files, CAPA records, and cybersecurity documentation are not telling the same story, that gap will surface in an FDA review or an inspection under CP 7382.850. Blue Goat Cyber can review your QMS structure against the current QMSR text and help close the traceability gap before it becomes a deficiency. [Contact us](/contact) to schedule a QMS and cybersecurity documentation review. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## 510(k) Cleared, No Postmarket Cybersecurity: Legal? Source: https://bluegoatcyber.com/blog/510k-cleared-no-postmarket-cybersecurity-am-i-breaking-the-law # 510(k) Cleared but No Postmarket Cybersecurity: Are You Breaking the Law? > **[DIRECT ANSWER]** Yes, effectively. If your cleared submission included a [Section 524B(b)(1)](/guides/fda-524b-cybersecurity-requirements-explained) postmarket cybersecurity plan and you aren't executing it, you are out of compliance with the FD&C Act, exposed to a 483, a Warning Letter, and a refusal of your next submission. This applies to every 524B(a) pathway: 510(k), De Novo, PMA, PDP, and HDE. You cleared. The submission is done. The postmarket monitoring plan you attached to satisfy Section 524B(b)(1) is now a live commitment - not a formality. If nothing behind that plan is actually running, the device as marketed no longer matches the device as cleared, and the FDA has multiple regulatory hooks to act on it. ## Key Takeaways - Section 524B(b)(1) makes a postmarket cybersecurity plan a binding submission element for every cyber device. - The obligation applies across 510(k), De Novo, PMA, PDP, and HDE - not only 510(k). - IDE submissions are not enumerated in 524B(a), but the Feb 3, 2026 FDA guidance still expects postmarket thinking. - Enforcement usually starts with a 483 or Warning Letter, not prosecution - but a submission hold is faster and more damaging commercially. - A minimum viable postmarket program is finite, documentable, and defensible on inspection. ## Why this matters Postmarket cybersecurity is where most cleared cyber devices quietly fall out of compliance. The submission gets the attention; the ongoing obligation does not. Under the FD&C Act and the FDA's February 3, 2026 final premarket cybersecurity guidance, the postmarket plan you filed is treated as an executed commitment, not a document. Missing it is not a paperwork gap - it is a mismatch between the cleared device and the marketed device, and it is the single fastest way to lose a next submission, catch a Warning Letter, or end up in a recall you cannot defend when a widely used [SBOM](/guides/sbom-for-medical-devices) component gets a new CVE. ## What Section 524B(b)(1) Actually Requires Section 524B(b)(1) of the FD&C Act (21 U.S.C. 360n-2) requires the sponsor of a cyber device to submit a plan to **monitor, identify, and address, as appropriate, in a reasonable time, postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures.** That is not a template line. It is a description of an active program. Reviewers accept a plan on the assumption you will operate it - the same way they accept a labeling claim on the assumption you will honor it. Once cleared, the plan carries three enforceable ideas: - **You have a way to find vulnerabilities affecting your device** - through SBOM monitoring, vendor advisories, ICS-CERT/CISA, NVD, and researcher intake. - **You triage and act within a defined, reasonable time** - severity, exploitability, and patient impact drive cadence. - **You have a [coordinated vulnerability disclosure (CVD)](/guides/coordinated-vulnerability-disclosure-medical-devices) path** - a real inbox, a public policy, and an owner. The Feb 3, 2026 final premarket guidance ("Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions") is the operative interpretation reviewers apply when they judge whether the plan is real. It is not itself binding, but a submission that does not match its expectations gets treated the same way in practice. ## Yes, It Applies to De Novo, PMA, PDP, and HDE Too This is the piece most teams get wrong. Section 524B(a) enumerates the covered pathways explicitly. If your device is a cyber device under 524B(c), the postmarket obligation attaches regardless of pathway: - **510(k)** - 21 U.S.C. 360(k) - **De Novo** - FD&C Act Section 513 - **PMA** - FD&C Act Section 515(c) - **PDP** - FD&C Act Section 515(f) - **HDE** - FD&C Act Section 520(m) **IDE submissions (Section 520(g))** are not enumerated in 524B(a), so the statute does not attach the same RTA teeth. The Feb 3, 2026 guidance still expects cybersecurity considerations - including postmarket thinking - for IDEs where they apply. So the honest framing for IDE holders is: not a 524B pathway, still a guidance expectation. PMA and HDE holders have an additional wrinkle. PMA-approved devices carry postmarket surveillance and annual reporting obligations that already existed under Section 519 and 21 CFR 814 - postmarket cybersecurity findings that affect safety or effectiveness generally flow into those reports. HDE holders operate under the Section 520(m) profile and are similarly on the hook for postmarket surveillance of an approved device. In both cases, an unrun 524B(b)(1) plan doesn't just sit in a submission file - it also creates a gap in what you're expected to report annually. ## The Legal Stack You're Touching by Not Doing Postmarket Not running the plan is rarely a single-statute problem. It touches a stack: | Statute or regulation | How the gap bites you | | --- | --- | | FD&C Act §524B(b)(1) | You represented that a plan exists and is being executed. Not doing it is a mismatch with the cleared/approved device. | | FD&C Act §502 (misbranding) | Representations to the FDA and in labeling that do not match reality can render the device misbranded. | | 21 CFR 806 | Corrections and removals for risk-to-health issues, including unpatched exploitable vulnerabilities, must be reported within 10 working days. No monitoring means you cannot comply. | | 21 CFR 803 (MDR) | Cyber events causing or contributing to serious injury or death are reportable. Without intake, you miss MDRs. | | 21 CFR 820 / QMSR (ISO 13485 §8.5) | CAPA requires you to detect and act on postmarket problems. No monitoring is a systemic QMS gap, and it is findable on inspection. | | 21 CFR 814 (PMA annual reports) | For PMA and HDE, postmarket cybersecurity findings feed into annual reporting. Missing them is a reporting gap on top of the 524B gap. | | FDA 2016 Postmarket Cybersecurity Guidance | The operative interpretation for postmarket program design. | The QMSR final rule took effect Feb 2, 2026, replacing the Part 820 QSR with ISO 13485:2016 incorporated by reference. That is why the Feb 3, 2026 premarket guidance carries the "Quality Management System" title. The QMS hook to postmarket cybersecurity is stronger under QMSR, not weaker. ## What "Breaking the Law" Actually Looks Like in Practice The FDA rarely prosecutes solo. What actually happens, roughly in order of likelihood: 1. **483 observation** on your next inspection - no vulnerability intake, no SBOM monitoring, no CVD process, no CAPA linkage. This is the most common outcome. 2. **Warning Letter** if the 483 is not addressed - public, indexed by search, and disqualifying in enterprise sales cycles. 3. **Recall or Safety Communication** if an exploitable vulnerability surfaces in an SBOM component (Log4j, OpenSSL, curl class of events) and you had no process to detect and act on it. 4. **Refusal of your next submission** - 510(k), Special 510(k), PMA supplement, De Novo, or HDE amendment - until postmarket evidence exists. This is often the fastest commercial pain. 5. **Civil penalties or consent decree** in the worst case - reserved for repeat or willful conduct. There is a parallel commercial track. Hospital and IDN security questionnaires (**HSCC MDS2**, Mayo, Kaiser, HCA, Providence) ask directly whether you operate a postmarket cybersecurity program. "No" is disqualifying at most large health systems and increasingly at mid-market IDNs. In practice, the commercial consequence often arrives before the regulatory one. ## Minimum Viable Postmarket Program to Get Compliant Fast You do not need a full program on day one. You need a defensible one. The following is the minimum viable shape reviewers and inspectors expect to see: - **CVD intake** - a monitored `security@yourdomain` inbox, a public `/cvd` or `/security.txt` page, and a named owner. - **[SBOM](/guides/sbom-for-medical-devices) monitoring** - feed the cleared SBOM into a matcher (Dependency-Track, GitHub Advanced Security, or a commercial tool) against NVD, CISA/ICS-CERT, and vendor advisories. See our [SBOM vulnerability management playbook](/guides/sbom-vulnerability-management-medical-devices) for triage wiring. - **Triage SOP** - severity, exploitability, and patient-impact scoring with a documented cadence (for example, critical patched within 60 days, high within 90). - **Communication path** - how you notify customers, hospitals, and the FDA when patient safety is affected. - **CAPA linkage** - every triaged vulnerability enters your QMS CAPA system. - **Records** - you have to be able to prove all of the above on inspection. That is the shape of [AAMI TIR97](/blog/aami-tir57-vs-tir97-vs-sw96-medical-device-cybersecurity), which is the operational template FDA investigators benchmark against. Our [postmarket cybersecurity monitoring guide](/guides/postmarket-cybersecurity-monitoring-program) walks through each block in the level of detail an inspector would ask for. If you are still upstream - preparing or defending a submission - the 524B thread runs through our [Section 524B requirements explainer](/guides/fda-524b-cybersecurity-requirements-explained) and the [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). ## How Blue Goat approaches this We build postmarket cybersecurity programs to the shape the FDA actually inspects: CVD intake, SBOM-driven vulnerability monitoring, triage with documented cadence, CAPA linkage, and evidence you can produce in a binder during an inspection. For teams that cleared under 510(k), De Novo, PMA, PDP, or HDE and never operationalized the plan they filed, we scope a 30-day gap-close - inventory the commitments in the submission, stand up the missing intake and monitoring, wire the triage into the QMS, and document everything against AAMI TIR97 and the Feb 3, 2026 guidance. The result is a program you can defend on inspection and cite in the next submission. ## FAQ ### Does Section 524B apply to my device if it was cleared before Oct 1, 2023? Section 524B took effect March 29, 2023, and the FDA began actively enforcing RTA on that basis on October 1, 2023. Devices cleared before that are not automatically retro-scoped into 524B via the original clearance, but any subsequent submission - Special 510(k), PMA supplement, De Novo amendment - is evaluated under current 524B expectations. And the FDA's separate 2016 postmarket guidance already expected postmarket vulnerability management for connected devices long before 524B existed. ### I got cleared under De Novo, not 510(k). Same rules? Yes. Section 524B(a) enumerates De Novo alongside 510(k), PMA, PDP, and HDE. The postmarket plan requirement in 524B(b)(1) attaches identically. PMA and HDE holders also carry additional postmarket surveillance and annual reporting expectations under Section 519 and 21 CFR 814. ### What about IDE - do I owe the FDA a postmarket cybersecurity plan? IDE (Section 520(g)) is not enumerated in Section 524B(a), so 524B's RTA teeth do not attach. The FDA's Feb 3, 2026 premarket cybersecurity guidance still expects cybersecurity considerations for IDE submissions where they apply, and the investigational context itself creates postmarket-style monitoring expectations for enrolled subjects. ### If my SBOM has a component with a new critical CVE, do I have to report it? Not automatically. You have to triage it. If the vulnerability is exploitable in your device and creates a risk to health, 21 CFR 806 correction and removal reporting can apply (10 working days), and 21 CFR 803 MDR reporting attaches if the event causes or contributes to a serious injury or death. The obligation to triage - and to be able to prove you did - is the point of the postmarket plan. ### Will the FDA actually inspect me on cybersecurity? Cybersecurity is a routine element of BIMO and QSR/QMSR inspections now, not a special program. Investigators ask about vulnerability intake, SBOM monitoring, triage cadence, CAPA linkage, and complaint handling that touches security. Absence of any of these is a standard 483 category. ### Does the Warning Letter or 483 become public? 483s are not automatically public but are FOIA-able and frequently posted by third-party trackers. Warning Letters are published by the FDA on issuance. Both surface in hospital and IDN security due diligence. ### Where do I start if I have literally nothing running? Stand up CVD intake (inbox plus public page) this week, get your SBOM into a monitoring tool next week, and document a triage SOP with cadence. Then wire CAPA linkage. That sequence produces a defensible program in about 30 days. Our [postmarket monitoring guide](/guides/postmarket-cybersecurity-monitoring-program) is the operational playbook. If you cleared under 524B and want a scoped assessment against the plan you filed, [contact Blue Goat Cyber](/contact) or explore our [postmarket cybersecurity service](/lp/fda-postmarket-cybersecurity). ## Related reading - [SBOM for Medical Devices - the field guide](/guides/sbom-for-medical-devices) - format, contents, and how the SBOM feeds postmarket vulnerability monitoring. - [Coordinated Vulnerability Disclosure (CVD)](/cvd) - our public CVD policy and the shape the FDA expects yours to take. - [FDA Section 524B Cybersecurity Requirements Explained](/guides/fda-524b-cybersecurity-requirements-explained) - the full statute walkthrough, including 524B(b)(1) postmarket obligations. - [Postmarket Cybersecurity Monitoring Program](/guides/postmarket-cybersecurity-monitoring-program) - the operational template inspectors benchmark against. - [SBOM Vulnerability Management for Medical Devices](/guides/sbom-vulnerability-management-medical-devices) - how to wire SBOM matches into triage and CAPA. --- ## 510(k) Deficiencies That Trigger FDA Holds Source: https://bluegoatcyber.com/blog/510k-cybersecurity-deficiencies-that-trigger-fda-holds # 510(k) Cybersecurity Deficiencies That Trigger FDA Holds > **[DIRECT ANSWER]** Five cybersecurity gaps put most 510(k) submissions on hold: an SBOM missing supplier, version, or end-of-support fields; a threat model that stops at the device boundary and ignores cloud and companion apps; penetration testing with no stated scope or methodology; security controls that trace to no verification evidence; and a postmarket plan with no vulnerability intake path. Each of these is fixable before you file. Cybersecurity has become one of the leading reasons 510(k) submissions stall during FDA review. Since Section 524B of the FD&C Act made cybersecurity documentation mandatory for "cyber devices," reviewers evaluate submissions against explicit documentation expectations laid out in Section 524B and the FDA's February 2026 Final Premarket Cybersecurity Guidance - not a general impression. The same four deficiency categories appear across submissions repeatedly: incomplete SBOMs, underdeveloped threat models, penetration testing with coverage gaps, and SPDF evidence that asserts rather than proves. These aren't edge cases. They're documented patterns seen across the industry. ## Key Takeaways - Incomplete SBOMs lead to FDA holds. - Undertaking threat models trigger deficiencies. - Penetration testing must cover all attack surfaces. - SPDF evidence requires specific documentation. - Traceability links components, threats, and controls. - FDA guidance aligns with 524B requirements. ## Why this matters Unaddressed 510(k) cybersecurity deficiencies translate directly into significant market delays and revenue loss. The FDA, armed with its February 3, 2026 'Cybersecurity in Medical Devices' Final Guidance, now mandates rigorous documentation for "cyber devices." This guidance, combined with Section 524B of the FD&C Act, elevates cybersecurity from a recommendation to a critical compliance requirement. Device manufacturers must demonstrate adherence to principles outlined in standards like AAMI SW96, IEC 81001-5-1, and ISO 14971. Failure to provide granular, auditable evidence for areas such as software bill of materials (SBOMs), defensible threat modeling, and thorough penetration testing results in critical review holds. Each hold prolongs time to market, impacts competitive positioning, and necessitates costly remediation cycles. Proactive identification and rectification of these common deficiencies before submission are essential to ensure a smooth, timely regulatory approval process. ## What the FDA Now Requires and How Deficiencies Actually Happen ### The Shift Section 524B Created for 510(k) Submissions Before Section 524B took effect, cybersecurity documentation was guidance-recommended but not submission-critical. That changed. The FDA now treats missing or inadequate cybersecurity evidence the same way it treats missing clinical data: a reason to hold the review or issue a deficiency letter. The February 2026 Final Premarket Cybersecurity Guidance codified specific expectations around SBOMs, threat modeling, security testing, and postmarket vulnerability management. Submissions that ignore this shift face immediate scrutiny during review. ### What Triggers a Refusal to Accept Versus an Interactive Review The FDA's response depends on how incomplete the submission is. Missing core elements entirely - no SBOM or no postmarket vulnerability plan, for example - can trigger a Refusal to Accept during the threshold review phase. More commonly, submissions clear initial screening but generate deficiency letters during substantive review when documentation exists but is too generic, untraced to device-specific risks, or lacks verification evidence. **The difference matters because deficiency letters allow response, while an RTA resets the clock entirely.** Understanding which category your submission falls into shapes the urgency and type of remediation needed. ## SBOM Gaps That Draw Immediate FDA Scrutiny ### What an Incomplete SBOM Looks Like to a Reviewer The most common SBOM failure isn't absence; it's incompleteness. Reviewers flag SBOMs that list top-level components but omit transitive dependencies, leave out version numbers, or fail to identify commercial off-the-shelf and open-source components separately. An SBOM that can't support vulnerability monitoring is functionally useless to the FDA, even if a file was technically included in the submission. Missing end-of-support status for components and no linkage to the vulnerability management plan are two specific gaps that repeatedly generate deficiency letter language. Reviewers commonly cite that "the submitted SBOM is incomplete or not sufficiently detailed" or that "the SBOM lacks required information such as supplier name, component name, version, unique identifier, and dependency relationship." These aren't vague concerns. Reviewers check against a specific content standard aligned with NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026) and the FDA's February 2026 guidance. For context on the kinds of objections reviewers raise, see analyses of [common FDA objection patterns](https://innolitics.com/articles/common-cybersecurity-fda-ainn-letter-objections/) identified across deficiency letters. ### How to Build an SBOM That Satisfies FDA Traceability Requirements A submission-ready SBOM includes component name, version, supplier, dependency relationships covering both direct and transitive components, unique identifiers such as CPEs or package URLs, and known support status for each component. Format matters: the FDA expects machine-readable output, typically [SPDX or CycloneDX](https://censinet.com/perspectives/medical-device-sboms-pre-market-submissions), consistent with the SBOM minimum elements, now set by CISA's 2026 list rather than the 2021 NTIA version. **More importantly, the SBOM must tie directly to the risk assessment and vulnerability monitoring process described elsewhere in the submission.** Reviewers follow the audit trail from component inventory to residual risk, and any break in that linked evidence path generates a question. ## Threat Model Documentation FDA Reviewers Flag as Insufficient ### The Specific Elements Missing From Most Threat Models Thin threat models follow a template without connecting to the actual device. The FDA flags threat models that list generic threat categories, skip architectural diagrams showing real data flows and interfaces, and fail to trace identified threats through to specific mitigations. Risk analyses that don't address patient safety impact, treat threat modeling as a one-time exercise rather than a design-phase process, or use a methodology without documenting the rationale for choosing it are consistent deficiency triggers. The threat model should read like a device-specific investigation, not a completed form. ### What a Submission-Ready Threat Model Actually Contains A compliant threat model documents the scope, methodology rationale, assumptions, security asset inventory, connection and data flow inventory, and expected threat sources, consistent with frameworks such as AAMI TIR57 and ANSI/AAMI SW96. Architectural diagrams that include the software update path belong in a separate, digestible section rather than buried in a single dense clause. The model provides a full analysis of primary threats with implemented mitigations and shows traceability from each identified threat to a cybersecurity risk and from that risk to a specific control. Cross-functional participation - engineering, quality, and clinical - also matters because it signals that patient safety impact was considered alongside technical exploitability. ## Penetration Testing Reports That Don't Clear the Bar ### Why Scope and Methodology Matter More Than the Findings The FDA doesn't just want to see a penetration test report. It wants evidence the test was rigorous enough to be meaningful. Submissions that include pen test reports without documenting tester independence, scope boundaries, duration, and methods used draw deficiency questions regardless of what the findings show. **A clean report from a test that only covered the web interface of a device with Bluetooth, RF, firmware, and cloud components doesn't give the FDA what it needs.** Scope gaps are treated as evidence gaps, and reviewers will ask about every attack surface the threat model identified but the test didn't cover. ### How to Structure Penetration Testing Evidence FDA Won't Question A complete premarket pen test report covers all relevant attack surfaces: hardware interfaces, firmware, wireless protocols including BLE and RF, mobile applications, APIs, and connected cloud environments. It documents tester credentials and independence, testing duration, specific methodologies applied, all findings including informational observations, and remediation status for each finding. The report must tie back to the device threat model so reviewers can confirm the test addressed the attack vectors that threat modeling identified. Any untested attack surface appearing in the threat model is a direct path to a deficiency letter. ## Weak SPDF Evidence and Security Documentation Gaps ### What "We Follow Secure Development Practices" Doesn't Prove Vague SPDF claims are among the most consistent sources of cybersecurity deficiencies in 510(k) submissions. Asserting that the device was developed using a secure product development framework - without documentation showing specific controls, review points, and verification activities at each lifecycle phase - gives the FDA nothing to evaluate. Submissions that describe security outcomes without showing the process that produced them leave reviewers with no way to assess whether the approach was systematic or incidental. Authentication design, encryption implementation, logging and monitoring, and hardening decisions all require documented evidence, not assertions. ### Specific Controls FDA Expects to See Documented and Verified SPDF documentation needs to show that security requirements were defined, implemented, and tested, consistent with expectations in the [FDA's February 2026 premarket cybersecurity guidance](https://www.fda.gov/media/119933/download) and applicable AAMI standards. This includes role-based access control definitions with testing evidence, encryption applied to data in transit and at rest with justification, audit logging for security-relevant events with retention and alerting procedures, device hardening standards with verification, and a coordinated vulnerability disclosure process with defined timelines and ownership. **Each control should connect back to a threat in the threat model and forward to a test result in the verification and validation evidence.** That documentation thread is what reviewers follow, and submissions that break it at any point generate questions. ## A Pre-Submission Checklist to Close Every Gap Before Filing ### The Traceability Chain FDA Reviewers Follow The FDA traces a path through the submission: from the SBOM through the threat model, from identified threats to implemented controls, and from controls to test evidence and the postmarket monitoring plan. Any break in that chain generates a question. Before filing, verify that every component in the SBOM appears in the vulnerability assessment and that every attack surface in the threat model was covered in penetration testing. Use this checklist as a final review gate before submission - and see our [FDA cybersecurity deficiency response checklist](/guides/fda-cybersecurity-deficiency-response-checklist) for the full breakdown: - SBOM in SPDX or CycloneDX format with direct and transitive dependencies, version numbers, unique identifiers, and end-of-support status for each component - Threat model with device-specific architectural diagrams, methodology rationale, cross-functional participation, and traced mitigations for every identified threat - Penetration test report covering all attack surfaces identified in the threat model, with documented tester independence, scope, duration, methodology, and remediation status - SPDF documentation with specific controls, lifecycle phase verification activities, and evidence tied to security requirements - Postmarket vulnerability management plan with defined timelines, roles, escalation criteria, and coordinated disclosure procedures - Traceability matrix connecting SBOM components to vulnerability assessment, threats to controls, and controls to test evidence ### When to Bring in Outside Help Before You File If your team has already received a cybersecurity deficiency letter - see our analysis of [real FDA cybersecurity deficiency letter examples](/guides/fda-cybersecurity-deficiency-letter-examples) - or if the submission package hasn't been reviewed against the February 2026 Final Premarket Cybersecurity Guidance, the risk of a hold is high. Firms that specialize exclusively in FDA-aligned medical device cybersecurity understand the documentation patterns that produce cleared submissions versus those that generate letters. Generic IT security firms retrofit enterprise frameworks to MedTech contexts, and the result is documentation that misses the device-specific requirements reviewers prioritize. For straightforward answers to common premarket cybersecurity questions, reviewers often refer sponsors to the FDA's own [cybersecurity FAQs](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs). ## The Bottom Line on Preventing 510(k) Cybersecurity Deficiencies The most common cybersecurity deficiencies in 510(k) submissions share one trait: they're predictable. Incomplete SBOMs, threat models that don't connect to device-specific risks, penetration tests that miss whole attack surfaces, and SPDF evidence that describes outcomes rather than proving them - these are the gaps reviewers find most often, and they're all fixable before filing. The remediation path for each is well-established, the FDA's expectations are explicit, and the documentation thread reviewers follow is knowable in advance. For a deeper look at why submissions are rejected, see our analysis of [12 reasons the FDA rejects medical device cybersecurity submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions). Submitting with gaps isn't a risk worth taking when the alternative is a cleared submission on the first review cycle. If you want an expert assessment of your submission package against the FDA's current cybersecurity requirements before you file, [contact Blue Goat Cyber](/contact). We'll identify the gaps and give you a clear path to close them before you file. ## How Blue Goat approaches this Our approach to 510(k) cybersecurity focuses on preventing deficiencies before they arise, aligning documentation with current FDA mandates. We assist medical device manufacturers in developing precise SBOMs, conducting detailed threat modeling, and performing targeted penetration tests with clear coverage justification. Our team, comprised of CISSP and OSCP certified experts, including ex-military red team personnel, develops cybersecurity evidence packages that meet the stringent requirements of the FDA for secure product development frameworks (SPDFs). We specialize in crafting documentation that proactively addresses common agency concerns. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to secure your device and accelerate its path to market. Learn more at: /services/fda-premarket-cybersecurity-services ## FAQ ### What are the most common cybersecurity deficiencies in 510(k) submissions? Four patterns dominate: incomplete SBOMs (missing transitive dependencies, missing supplier-of-supplier components, no VEX), thin threat models (no STRIDE or PASTA mapping, no link to test cases), penetration test reports that are mostly scanner output, and weak SPDF evidence that does not show how security activities ran across the development lifecycle. Closing those four gaps prevents the majority of deficiency letters. ### What makes an SBOM acceptable to FDA reviewers? Machine-readable (SPDX or CycloneDX), complete down to transitive dependencies, paired with a VEX that explains exploitability for each known vulnerability, and accompanied by an operational plan showing how it will be regenerated and monitored after release. SBOMs delivered as PDF or Excel snapshots almost always get flagged. ### How detailed does the threat model need to be? Detailed enough that every external interface, trust boundary, and data flow is enumerated; every identified threat has a mitigation; and every mitigation maps to a test case in the security testing package. Threat models that stop at a diagram and a list of generic threats are the most common source of 'expand the threat model' deficiency letters. ### Why do penetration test reports get rejected? Three reasons: (1) scope too narrow - testing the web app but not the device interfaces, (2) methodology that is automated scanning rebranded as pen testing with no exploitation or chaining, (3) findings that do not connect back to the threat model. Reports written for compliance theater rarely survive review. ### What SPDF evidence does the FDA actually expect to see? Evidence that secure development activities ran throughout the lifecycle: requirements with security ACs, design reviews with security input, secure coding standards with enforcement evidence, code review records, testing records (SAST, SCA, DAST, fuzz, pen test), vulnerability handling procedures, and supplier cybersecurity controls. A retroactive SPDF binder assembled at submission time is usually detectable. ### How long does it take to close cybersecurity deficiencies after a Hold letter? Typically 30-90 days of focused work, but the clock penalty on the overall submission can be 3-6 months because each Hold letter restarts a review cycle. The cost of fixing deficiencies after a Hold is usually 3-5x the cost of producing clearance-ready evidence before filing. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## 510(k) Cybersecurity Requirements: Threat Model, SBOM & Testing Source: https://bluegoatcyber.com/blog/510k-cybersecurity-requirements-every-maker-must-meet # FDA 510(k) Cybersecurity Requirements: Threat Model, SBOM, and Testing Evidence Across Pathways > **[DIRECT ANSWER]** A 510(k) cybersecurity package must include a threat model, security risk assessment, SBOM, security architecture documentation, SAST/DAST and penetration test evidence, and a postmarket monitoring plan, all traceable to each other under the FDA's February 3, 2026 guidance implementing Section 524B. The same core deliverables scale up for De Novo and PMA pathways. Reviewers check traceability first: every threat must connect to a control and a test result or a documented risk acceptance. Most 510(k) cybersecurity deficiencies don't fail on clinical data - they fail on documentation reviewers can't follow. The FDA is issuing Additional Information requests and Refuse-to-Accept holds for cybersecurity gaps at a rate that has become the primary timeline risk for connected device submissions across all three premarket pathways. Understanding what each pathway demands from your cybersecurity evidence before you build it is how the fastest submissions avoid that failure mode. This guide covers the governing guidance, the required document set, the testing evidence reviewers check, the postmarket plan elements that typically come in thin, the standards that anchor your artifacts, and the gap patterns that trigger deficiency letters. Work through each section before you file, not after. ## Key Takeaways - How 510(k), De Novo, and PMA Differ - and What That Means for Cybersecurity. - What Section 524B Requires Across All Three Pathways. - 510(k) Cybersecurity Requirements: Security Testing Evidence. - What a Compliant Postmarket Cybersecurity Plan Must Include. - Standards That Map to Your Submission Artifacts. ## Why this matters Connected medical devices present significant patient safety and data security risks if not properly secured. Submitting inadequate cybersecurity evidence leads to costly delays, including Additional Information requests and Refuse-to-Accept holds, impacting market entry and patient access to vital technologies. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, makes cybersecurity requirements statutory, not discretionary, under Section 524B. This guidance mandates rigorous premarket and postmarket controls. Successful submissions hinge on providing well-documented evidence that demonstrably addresses potential vulnerabilities throughout the device lifecycle. Key standards like IEC 62304 for software lifecycle processes, ISO 14971 for risk management, and the AAMI TIR97 for medical device security are foundational to achieving compliance. Failing to meet these expectations can prevent device approval, exposing manufacturers to significant financial and reputational damage. ## How 510(k), De Novo, and PMA Differ - and What That Means for Cybersecurity The controlling document is the final guidance, "[Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions)," issued by the FDA on February 3, 2026, which implements Section 524B of the FD&C Act. It applies to all 510(k) submissions reviewed by CDRH or CBER and supersedes the 2014 and 2023 documents. The shift is significant: requirements that were once recommendations are now binding statutory obligations embedded directly into the submission framework. The core philosophy is a Total Product Lifecycle (TPLC) approach. Premarket documentation doesn’t stand alone; it must connect explicitly to postmarket surveillance plans, and reviewers read those two sections together. A premarket package that doesn’t anticipate lifecycle management signals incomplete security thinking. In practice, this means your postmarket monitoring plan must describe specific processes, not general intentions, because reviewers will check whether the premarket and postmarket sections tell a coherent, continuous story. A **“cyber device”** is one that includes validated software, can connect to the internet directly or indirectly, and carries cybersecurity risk features. If your device fits this definition, the full 510(k) cybersecurity documentation package is non-negotiable. Devices that fall outside it may still need a risk-based justification for reduced cybersecurity documentation. The ambiguity tends to surprise teams: latent wireless modules, debug ports, or engineering interfaces not intended for clinical use can still trigger cyber device classification. Incomplete cybersecurity sections trigger either an RTA hold before substantive review begins or an Additional Information (AI) request mid-review. Both paths cost weeks at minimum and months in practice. The cybersecurity section needs to read as a coherent security narrative, not a bundle of separately authored documents that happen to share a submission number. ## How the Three Pathways Compare on Cybersecurity The deliverables are the same. What changes is how much justification each one carries and how closely the review team examines it. | | 510(k) | De Novo | PMA | |---|---|---|---| | Basis of the decision | Substantial equivalence to a predicate | Novel device, risk based | Independent evidence of safety and effectiveness | | Cybersecurity deliverables | Full Section 524B set | Full Section 524B set | Full Section 524B set | | Room to lean on precedent | Some, if the predicate is recent | None | None | | Depth of review interaction | Deficiency letters | Interactive review | Interactive review plus inspection | | Lasting effect of your approach | Limited to your device | May become special controls | Applies to your device and supplements | | Most common cause of delay | Testing scope narrower than the attack surface | Threat model derived from a template | Traceability gaps across the risk file | ## What Section 524B Requires Across All Three Pathways The **threat model is the foundation** of the entire package. Built using STRIDE methodology or an equivalent structured approach, it identifies threats, vulnerabilities, risks, assumptions, and external usage risks across the device’s attack surface. Every downstream artifact traces back to it. Reviewers check this traceability first, and a threat model that doesn’t connect clearly to your risk assessment and test reports is the single most common trigger for deficiency requests. The cybersecurity risk assessment evaluates the likelihood and severity of each threat identified in the model, maps mitigations, and documents residual risk acceptance under ISO 14971. These two documents must be explicitly linked. A risk assessment written independently of the threat model won’t survive review. Security architecture documentation covers access controls, encryption choices (AES-256, TLS 1.3), boundary analysis, and the design rationale for each security assumption. The Software Bill of Materials (SBOM) sits alongside it as a machine-readable inventory in SPDX or CycloneDX format, listing every software component with supplier name, version, unique identifier, and dependencies. Each component must also include end-of-support dates and link to a vulnerability assessment with any applicable mitigation controls. For high-risk devices, SBOM depth extends to build environments, toolchains, and drivers, with continuous CVE feed integration. For detailed SBOM guidance tailored to FDA-regulated devices, see Blue Goat Cyber’s [Medical Device SBOM: FDA Requirements and Submission Guide](/blog/medical-device-sbom-fda-requirements-and-submission-guide). Two elements that consistently generate AI requests are the unresolved anomalies assessment and cybersecurity labeling. The anomalies section documents known software defects remaining in the released device, with criteria, rationale, and a security and safety impact evaluation for each. Labeling must address cybersecurity risks, updatability, and user instructions for maintaining security configuration. These aren’t optional sections. They’re expected artifacts that reviewers check. ## 510(k) Cybersecurity Requirements: Security Testing Evidence Testing documentation must demonstrate methodology, scope, results, and traceability to the threat model. A report that lists findings without connecting them back to your threat model’s identified risks creates the kind of gap that triggers an RTA hold or an AI request mid-review. SAST and DAST are both expected components of the security testing package. Static analysis reviews source code for vulnerabilities during development. Dynamic analysis tests the running application for exploitable flaws under real-world conditions. Both reports must cover the testing methodology, tools used, scope of coverage, findings, and how each finding was mitigated or accepted with documented rationale. A DAST report that only covers happy-path scenarios won’t pass scrutiny for a connected device. **Penetration testing is the most scrutinized testing artifact for moderate-to-high risk devices.** Pen test reports must demonstrate that testers actively attempted to exploit vulnerabilities identified in the threat model, not just scan for theoretical issues. Scope must cover interfaces, protocols, and communication channels. Results must include severity ratings and remediation evidence. Every exploitable threat in the threat model should trace to either a test result confirming mitigation or a documented risk acceptance decision. Gaps in that traceability are what turn a pen test into a deficiency trigger. Vulnerability scan results must cross-reference SBOM components against known CVE databases in machine-readable format. Submissions filed via eSTAR, mandatory for most 510(k)s since October 1, 2023, must include these reports as part of the cybersecurity section, see the FDA’s [eSTAR submission template](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-medical-device-510k-submissions) for required file formats and templates. The FDA also has authority to refuse submissions lacking cybersecurity information, which means complete, well-formatted test reports aren’t optional under any interpretation of the 510k cybersecurity requirements. --- ### Ready to build submission-ready cybersecurity evidence for your pathway? Blue Goat Cyber builds complete FDA premarket cybersecurity packages for 510(k), De Novo, and PMA submissions - threat model, SBOM, penetration testing, and eSTAR-ready documentation, engineered to withstand FDA cybersecurity review. [**Book a free premarket strategy call →**](/services/fda-premarket-cybersecurity-services) --- > **Preparing a 510(k) cybersecurity package?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) ## What a Compliant Postmarket Cybersecurity Plan Must Include The postmarket plan is where most internal teams run thin. It’s also the section FDA reads to assess whether your premarket security work actually continues into the device’s marketed life. A plan that describes monitoring only in generic terms will generate an AI request. The vulnerability monitoring system must track vulnerabilities across SBOM components continuously throughout the device’s marketed life. The plan must describe how vulnerabilities are detected, assessed using clinical risk frameworks aligned with ANSI/AAMI SW96, and triaged into immediate action items versus scheduled maintenance fixes. Controlled risks and uncontrolled risks follow different decision paths, and those paths must be explicitly documented with decision criteria for each category. **Disclosure timelines are a concrete expectation, not a general commitment.** FDA expects customer notifications within 30 days of vulnerability discovery for significant findings, with a documented process for reporting to the agency under a risk-based framework. The submission must describe the secure update mechanism built into the device architecture, whether over-the-air or another method, with labeling that tells users how to configure and maintain it. Patch validation, verification testing, and change management records all need to be part of the documented process rather than described as future activities. ## Standards That Map to Your Submission Artifacts Understanding which standard supports which artifact matters because it helps reviewers trace conformance and reduces the probability of receiving questions about your methodology. You don’t need to cite every standard exhaustively. You need the right standard in the right place. For a deeper walkthrough, consult our [Guide to Medical Device Cybersecurity Standards (Premarket, Postmarket, & Lifecycle)](/blog/guide-to-medical-device-cybersecurity-standards-premarket-postmarket-lifecycle). The NIST Cybersecurity Framework provides the structural backbone. Identify maps to threat modeling and the SBOM. Protect maps to access controls and encryption. Detect maps to logging and anomaly detection. Respond and Recover map to vulnerability disclosure and patching. Using NIST CSF as an organizing structure for your cybersecurity narrative makes the submission easier for reviewers to follow and demonstrates systematic coverage. **IEC 81001-5-1 (Edition 1.0, 2021; FDA recognition 13-131) is the standard that gives your secure development process its regulatory defensibility.** It defines lifecycle security processes for health software and directly supports the Secure Product Development Framework (SPDF) requirement. SPDF embedded in design controls under 21 CFR Part 820 requires prospective documentation, and IEC 81001-5-1 is the recognized consensus standard that maps to those design control activities across all 64 cybersecurity requirements it adds to the development lifecycle. IEC 62443, particularly part 4-1, covers interconnected devices, supply chain security, zones, conduits, and defense-in-depth architecture. It complements IEC 81001-5-1 but doesn’t replace submission-specific requirements. ISO 27001 principles for information security management can also inform your access control and organizational security documentation, though it isn’t a substitute for device-specific standards. AAMI TIR57 is recognized for risk assessment methodology and can be cited in the risk management file to support your threat model and risk assessment approach. Citing these standards adds traceability for reviewers, but the underlying artifacts still need to exist and connect to each other. ## Common Gaps That Trigger Deficiencies and How to Close Them Most cybersecurity deficiencies share the same root cause: documentation built in silos rather than as a connected body of evidence. Closing the gaps before submission is significantly cheaper than responding to an AI hold during review. The most frequent deficiency pattern is a disconnected documentation set. A threat model that doesn’t link to the risk assessment. A risk assessment that doesn’t map to test reports. Test reports that don’t reference the SBOM. Reviewers need a coherent narrative across all artifacts. Building traceability matrices that explicitly tie these documents together is one of the highest-value pre-submission quality checks you can run. SBOMs missing end-of-life dates, dependency trees, or CVE cross-references generate AI requests consistently. Any component without a corresponding vulnerability assessment is a gap that reviewers will flag. If penetration test scope excludes interfaces that appear in the security architecture diagram, expect a question about why. Every component in the SBOM needs a clear line to either a test result or a documented risk acceptance, with no components left floating without coverage. Thin postmarket plans are a reliable deficiency trigger. Generic monitoring language without documented processes for vulnerability triage, disclosure timelines, or update mechanisms won’t satisfy reviewers who are checking whether your 510(k) cybersecurity requirements coverage extends into the device’s marketed life. This is the area where most in-house teams lack bandwidth even when they have the technical knowledge. We build submission-ready cybersecurity packages at Blue Goat Cyber that address these gaps before the file reaches FDA, covering SBOM generation, threat modeling, pen test execution, and postmarket plan documentation. For device makers without dedicated cybersecurity staff, end-to-end support significantly reduces the probability of a deficiency letter and the timeline impact that comes with it; see our [Medical Device Cybersecurity Best Practices](/blog/medical-device-cybersecurity-best-practices) for practical steps teams can take. ## Build the Package Before Submission, Not After A 510(k) cybersecurity package isn’t a collection of documents. It’s a connected body of evidence that tells a coherent security story from design through deployment. The five core elements are a traceable threat model, a complete SBOM with vulnerability linkage, rigorous testing reports tied to the threat model, a living postmarket plan with specific timelines and processes, and standards-aligned documentation that gives reviewers a clear conformance path. Audit your current package against these 510(k) cybersecurity requirements before you submit. Start with traceability: follow the thread from your threat model through every downstream artifact and confirm nothing is left unlinked. Review your SBOM for missing end-of-life dates and components without vulnerability assessments. Then check whether your pen test scope covers every interface in your security architecture diagram, and confirm your postmarket plan specifies disclosure timelines and a documented update mechanism rather than describing them as future work. For an implementation-focused checklist on FDA documentation, see [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). Deficiency responses cost more in time and money than getting the package right the first time. The FDA has made its expectations explicit through guidance, enforcement actions, and the statutory requirements of Section 524B. Close the gaps with evidence before you file. ## How Blue Goat approaches 510(k) cybersecurity Blue Goat Cyber builds 510(k) cybersecurity submissions against the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026. Our team holds CISSP and OSCP credentials and includes ex-military red team operators, so security testing reflects how attackers actually behave, not a checklist tour. We produce the full Section 524B evidence package, including the SBOM in CycloneDX with VEX, the threat model traced to AAMI TIR57 and SW96 outputs, the pen test report sized to the device's risk tier, and the postmarket Cybersecurity Management Plan. Every artifact is mapped to its eSTAR v7.0 slot so reviewers find what they expect in the order they expect it. See our [510(k) cybersecurity submission service](/services/fda-premarket-cybersecurity-services) for scope and timelines. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What cybersecurity documentation does FDA require in a 510(k) submission? Core deliverables are a threat model, SBOM, security architecture documentation, and penetration testing evidence. For cyber devices under Section 524B, these are statutory requirements rather than recommendations. Traceability from threat to control to test result is what reviewers check first - gaps in that chain generate most cybersecurity deficiency letters, regardless of how thorough any individual document is. ### How does the cybersecurity evidence burden differ between a 510(k) and a PMA? A 510(k) focuses on demonstrating that software, connectivity, and control differences from the predicate don't increase cybersecurity risk. PMA requires deeper verification evidence - particularly for functions where a cyber event could affect safety or essential performance. De Novo sits between the two: you are often helping define what "good" looks like for a new device class, so the evidence package needs to be defensible on first principles, not just by comparison. ### What makes a 510(k) cybersecurity submission fail FDA review? The most common causes are an incomplete or superficial threat model, no traceability from threats to controls to test evidence, and an SBOM that isn't paired with a vulnerability monitoring plan. Generic penetration testing reports not tied to the specific device attack surface are also a reliable deficiency trigger. Reviewers are explicitly looking for a connected security narrative, not a folder of separately authored artifacts. ### How long does FDA 510(k) cybersecurity preparation take? Six to twelve weeks is typical for a connected device with an existing quality system. Timeline depends on whether threat modeling has started, SBOM availability, and penetration testing scope. Engaging a specialist before design freeze reduces both time and deficiency risk - post-hoc documentation built after V&V consistently takes longer because reviewers can tell when artifacts were reverse-engineered to fit a finished design. ### Does eSTAR change what cybersecurity documentation we need to produce? ESTAR doesn't add requirements - it changes how you package them. The interactive template structures your submission so reviewers can navigate your cybersecurity evidence without digging through attachments. Teams that build eSTAR-aligned documentation from the start typically see fewer "can't find the artifact" information requests, which is one of the lowest-effort categories of deficiency to eliminate. --- ### About the Author **Christian Espinosa** | Founder & CEO, Blue Goat Cyber | CISSP Christian has led cybersecurity submissions for 275+ medical devices across 510(k), De Novo, and PMA pathways. He built Blue Goat Cyber around a single focus: turning FDA cybersecurity requirements into submission-ready evidence that clears without deficiency letters. --- **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) > **Our commitment:** If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. 275+ FDA submissions. no cybersecurity-related rejections to date. [Book a free premarket strategy call](/services/fda-premarket-cybersecurity-services) --- ## Risk-Based Testing for Med Device Software Source: https://bluegoatcyber.com/blog/a-comprehensive-guide-to-risk-based-testing-for-medical-device-software # Risk-Based Testing for Med Device Software > **[DIRECT ANSWER]** Risk-based testing allocates effort by consequence, not by code coverage. Rank test cases using the severity of patient harm in the ISO 14971 file, the exploitability of the threat in your threat model, and the exposure of the interface involved. High-harm, high-exposure paths get manual penetration testing and fuzzing; low-harm internal logic gets automated coverage. Document the ranking, because reviewers want the rationale, not just the results. _Updated November 16, 2024_ The development and implementation of risk-based testing strategies are crucial to ensure the safety and reliability of medical device software. As medical devices become increasingly interconnected and software-dependent, the potential risks associated with their use multiply. This guide explores the fundamentals of risk-based testing and provides valuable insights into its application in medical device software. By following the principles outlined in this guide, software developers and regulatory professionals can navigate the intricacies of risk-based testing to achieve compliance, enhance patient safety, and minimize adverse events. ## Key Takeaways - Prioritize testing based on identified risks. - Critical for patient safety in medical device software. - Complete risk analysis is the first step. - FDA guidance emphasizes risk-based validation. - ISO 14971 provides risk management framework. - Use tools like FMEA and risk matrices. ## Why this matters The stakes for medical device software are exceptionally high; patient lives depend on its flawless operation. A single software malfunction can lead to severe injury, misdiagnosis, or even death, underscoring the critical need for careful validation processes. Risk-based testing is not merely a best practice; it's an essential strategy for ensuring the reliability and safety of these vital technologies. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes the necessity of a risk-based approach to cybersecurity testing throughout the medical device product lifecycle. This guidance, along with standards like ISO 14971 (Medical devices, Application of risk management to medical devices), IEC 62304 (Medical device software, Software life cycle processes), and AAMI TIR57 and ANSI/AAMI SW96:2023 (FDA-recognized) for security risk management, establishes a regulatory framework that mandates diligent risk management and validation. Implementing risk-based testing allows manufacturers to systematically identify, assess, and mitigate software risks, thereby reducing the likelihood of adverse events, safeguarding patient well-being, and demonstrating compliance with stringent regulatory requirements. ## Understanding Risk-Based Testing ### Definition and Importance of Risk-Based Testing Risk-based testing is an approach that prioritizes testing efforts based on the identified risks associated with the system under test. The fundamental principle underlying risk-based testing is that limited resources should be allocated effectively to mitigate the most critical risks. This approach recognizes that not all software functionalities pose an equal level of risk, and therefore, resources should be focused where they are most needed. Implementing risk-based testing is essential in medical device software, where even a minor defect or malfunction can severely affect patient safety. By accurately assessing and addressing potential risks throughout the software development lifecycle, developers can reduce the likelihood of adverse events and comply with regulatory standards. ### The Role of Risk-Based Testing in Medical Device Software Risk-based testing supports developing and validating medical device software. It enables developers to [identify, evaluate, and address potential risks](/blog) at each stage of the software development lifecycle, including requirements analysis, design, implementation, and deployment. By conducting risk-based testing, developers can ensure that all critical functionalities of the medical device software are thoroughly tested and validated. Developers can prioritize testing efforts and allocate resources by identifying potential risks and their impact on patient safety. For example, in the [design phase](/blog/how-medical-devices-are-designed-with-patient-safety-as-the-priority), risk-based testing allows developers to analyze the potential risks associated with the software architecture and make informed decisions to mitigate those risks. By identifying potential vulnerabilities or weaknesses in the design, developers can implement appropriate measures to strengthen the software’s resilience and minimize the chances of failure. Risk-based testing also supports the deployment phase of medical device software. By conducting thorough risk assessments before deployment, developers can ensure the software is ready for use in a real-world environment. This includes considering factors such as compatibility with different operating systems, potential security vulnerabilities, and any potential risks that may arise during the installation or integration process. ## Principles of Risk-Based Testing ### Risk Identification in Software Testing The first step in implementing risk-based testing is identifying potential risks associated with the medical device software. This involves conducting a risk analysis where [all possible hazards](/blog), failure modes, and their potential impact are investigated. By involving experts from various domains and utilizing established risk analysis techniques, developers can effectively identify and classify risks based on their severity and probability of occurrence. ![Section Image](/imported-images/5441632ce7714f9e.png) For instance, manufacturers of implantable medical devices such as pacemakers must ensure that their software undergoes rigorous testing to prevent life-threatening situations. By identifying potential risks, such as software glitches or communication errors that could compromise patient safety, manufacturers can prioritize testing efforts accordingly. During the risk identification process, it is crucial to consider the immediate risks and potential long-term consequences. For example, a software bug that may seem minor at first glance could have catastrophic effects if it goes undetected and leads to a malfunction in a critical medical device. Risk identification should also consider the evolving nature of technology and the potential for new risks to emerge. As medical devices become more interconnected and reliant on external systems, the risks associated with data security and privacy breaches must be carefully assessed and addressed. ### Risk Assessment and Analysis Once potential risks are identified, they must be assessed and analyzed to determine their impact and likelihood of occurrence. This step relies on expert judgment and applying risk assessment tools and methodologies. For example, a manufacturer developing software for a diagnostic imaging device needs to analyze the risks associated with inaccurate readings or misinterpreting results. By quantifying the impact and likelihood of these risks, the manufacturer can prioritize testing efforts and focus on mitigating the highest-risk factors. During the risk assessment process, it is essential to consider the context in which the software will be used. Factors such as the intended user population, the device’s complexity, and the software functionality’s criticality should all be considered. This ensures that the risk assessment is tailored to the specific needs and requirements of the medical device. Risk analysis should not be a one-time activity but an iterative process revisited throughout the software development lifecycle. As new information becomes available or changes occur in the device’s environment, the risk assessment should be updated to reflect these developments. ### Risk Mitigation Strategies After identifying and assessing risks, the next step is to develop effective risk mitigation strategies. These strategies may include implementing additional controls, enhancing system architectures, or modifying software functionalities. For instance, a company developing software for an infusion pump may identify a risk of dosing errors due to user interface complexity. To mitigate this risk, the company may simplify the user interface, provide clear instructions, and implement safety mechanisms such as dose limits and alarm systems. In addition to technical measures, risk mitigation strategies should also consider the human factors involved in using medical devices. Training programs and user education can be crucial in reducing the likelihood of errors and improving overall patient safety. Risk mitigation should not be seen as a one-size-fits-all approach. Different risks may require different mitigation strategies, depending on their severity and the feasibility of implementation. It is essential to prioritize the most critical risks and allocate resources accordingly. Lastly, risk mitigation should be an ongoing process, with regular monitoring and evaluation of the effectiveness of the implemented strategies. This allows for continuous improvement and adaptation to changing circumstances, ensuring the software remains safe and reliable throughout its lifecycle. ## Implementing Risk-Based Testing in Medical Device Software ### Steps to Implement Risk-Based Testing Implementing risk-based testing requires a systematic and well-defined approach. The following steps can help organizations effectively implement risk-based testing in the development and validation of medical device software: ![Section Image](/imported-images/21377e66e016f086.png) 1. Identify and classify risks based on their severity and probability of occurrence. 2. Assess and analyze risks to determine their impact and likelihood. 3. Develop risk mitigation strategies based on the severity and probability of risks. 4. Define test objectives and prioritize testing efforts based on risk classification. 5. Plan and execute tests that address the identified risks. 6. Monitor and evaluate the effectiveness of risk mitigation strategies and testing efforts. 7. Iteratively improve risk-based testing processes based on feedback and lessons learned. Various factors, such as potential harm to patients, likelihood of occurrence, and impact on the overall functionality of the medical device software, must be considered when identifying and classifying risks. This step helps prioritize risks and allocate resources accordingly. Once risks are identified, assessing and analyzing them allows organizations to understand their potential impact and likelihood better. This analysis helps determine the level of risk associated with each identified risk and aids in developing appropriate risk mitigation strategies. ### Tools and Techniques for Risk-Based Testing Risk-based testing requires appropriate tools and techniques to facilitate risk identification, assessment, and mitigation. Examples of commonly used tools include: - Risk matrices: These matrices visually represent the severity and probability of risks, allowing organizations to prioritize their testing efforts accordingly. - Failure Mode and Effects Analysis (FMEA): [FMEA](/guides/security-risk-assessment-iec-81001-5-1) helps identify potential failure modes and their effects, enabling organizations to develop targeted testing strategies to mitigate these risks. - Fault Tree Analysis (FTA): FTA is a graphical representation of potential failure modes and their causes. It allows organizations to identify critical paths that could lead to failure and prioritize their testing efforts accordingly. - Hazard Analysis and Critical Control Points (HACCP): HACCP is a systematic approach to identifying, assessing, and controlling hazards in the production and testing processes, ensuring the safety and effectiveness of medical device software. Implementing risk-based testing often involves using simulation software, virtual environments, and mock-up scenarios to simulate real-world conditions and identify potential risks in a controlled environment. These tools and techniques help organizations thoroughly test the medical device software and ensure its reliability and safety. ## Regulatory Requirements for Risk-Based Testing ### FDA Guidelines for Risk-Based Testing [The U.S. Food and Drug Administration (FDA) provides regulatory guidance on risk-based testing for medical device software.](/blog) The FDA emphasizes the importance of assessing and addressing risks associated with medical device software to ensure patient safety and compliance with regulatory standards. Regarding risk-based testing, the FDA’s “General Principles of Software Validation” serves as a beacon of guidance for manufacturers. This document outlines a careful and systematic approach to software testing, considering the potential risks that may arise from using medical device software. By identifying and classifying these risks, manufacturers can establish appropriate mitigation strategies to minimize potential patient harm. The FDA recognizes that risk-based testing is not a one-size-fits-all approach. Different medical devices have varying levels of complexity and potential risks, and manufacturers must tailor their testing strategies accordingly. This flexibility allows for a more targeted and practical assessment of possible risks, ensuring patient safety remains the top priority. ### International Standards for Medical Device Software Testing International standards organizations such as the International Organization for Standardization (ISO) have also recognized the significance of risk-based testing in medical device software. [ISO 14971, aptly titled “Medical devices - Application of risk management to medical devices,”](/blog/iso-14971-risk-management-in-medical-device-security) provides a framework for risk management throughout the entire lifecycle of medical devices. This international standard emphasizes the need for manufacturers to proactively identify, evaluate, and control risks associated with medical device software. By following ISO 14971, manufacturers can establish a risk management process encompassing all development and manufacturing stages. This includes risk analysis, evaluation, control, and post-market surveillance, ensuring that potential risks are continuously monitored and addressed. Adhering to these international standards and regulatory guidelines demonstrates a commitment to quality and safety and instills confidence in the medical device industry. By following best practices in risk-based testing, manufacturers can enhance patient safety, improve product reliability, and achieve regulatory compliance, ultimately benefiting healthcare providers and patients. ## Challenges and Solutions in Risk-Based Testing Risk-based testing is crucial for ensuring the safety and reliability of medical device software. However, implementing this approach can pose several challenges for manufacturers and regulatory professionals. ![Section Image](/imported-images/158c1464d39ed814.png) ### Common Challenges in Risk-Based Testing One of the primary challenges in risk-based testing is the complexity of risk assessment and analysis. This complexity becomes particularly pronounced when dealing with interconnected systems and multifaceted software functionalities. Manufacturers and regulatory professionals must navigate through a web of intricate relationships to identify potential risks accurately. Technology’s continuous advancement and rapid obsolescence further complicate risk-based testing efforts. As new technologies emerge and existing ones become outdated, manufacturers must adapt their testing strategies to keep pace. Failure to do so could result in overlooking critical risks or testing outdated functionalities. ### Practical Solutions for Risk-Based Testing Challenges While the challenges in risk-based testing may seem daunting, there are several effective solutions that manufacturers can adopt to overcome them: - **Establish cross-functional teams:** To facilitate risk identification and analysis, manufacturers can establish cross-functional teams comprising experts from various domains. This collaborative approach brings together diverse perspectives and ensures a assessment of potential risks. - **Implement documentation and traceability systems:** Tracking risk assessment and mitigation strategies is crucial in risk-based testing. By implementing documentation and traceability systems, manufacturers can ensure that all risks are appropriately documented and mitigation strategies are effectively implemented and monitored. - **Regularly update risk assessments:** Risk-based testing is an ongoing process that requires regular updates. Manufacturers must adapt to emerging technologies and evolving regulations by regularly reviewing and updating risk assessments. This proactive approach ensures that potential risks are continuously evaluated and mitigated. - **Collaborate with industry associations and regulatory bodies:** Sharing knowledge and best practices is essential in risk-based testing. Manufacturers can collaborate with industry associations and regulatory bodies to exchange insights, align risk-based testing approaches, and stay up-to-date with the latest industry standards and regulations. By implementing risk-based testing strategies tailored to the specific needs of medical device software, manufacturers can ensure the reliability and safety of their products. This approach reduces the potential for adverse events, ultimately improving patient outcomes. Embracing risk-based testing empowers organizations to navigate the complex landscape of the healthcare industry, protect patient safety, and comply with regulatory requirements. As medical device software evolves, manufacturers must remain vigilant in risk-based testing efforts. By staying proactive and embracing effective solutions, they can ensure that their products meet the highest safety and quality standards. Ensuring the cybersecurity of medical device software is a critical component of risk-based testing. At Blue Goat Cyber, we specialize in providing B2B cybersecurity services tailored to the unique needs of the medical device industry. Our veteran-owned business is dedicated to helping you achieve HIPAA and FDA compliance, and our expertise extends to SOC 2 and PCI penetration testing. Let us assist you in safeguarding your medical devices against potential cyber threats. [Contact us today for cybersecurity help](/contact) and partner with a team passionate about protecting your business and products from attackers. Check out our [medical device cybersecurity FDA compliance package.](/) ## Risk-based testing vs testing everything equally Equal-effort testing feels fair and reads badly in a submission. It spends the same hours on a settings screen as on therapy delivery. | | Test everything equally | Risk-based testing | | --- | --- | --- | | How depth is decided | By feature count | By patient harm if the function fails | | Where the hours go | Spread flat across the build | Concentrated on safety-related software items | | Traceability to the risk file | Weak or added afterward | Built in, test case to hazard | | What a reviewer can check | That tests exist | That the riskiest functions got the deepest testing | | Effect of a schedule cut | Coverage drops everywhere, including the critical paths | Low-risk items drop first, by documented decision | | Regression strategy | Rerun everything, or guess | Rerun by risk and by what the change touched | ## How Blue Goat approaches this Blue Goat Cyber’s methodology for medical device software testing is centered on a structured, risk-driven framework. We begin by thoroughly analyzing potential failure points, using hazard analysis and threat modeling to pinpoint critical areas. Our team then designs and executes targeted test plans that focus resources where they are most needed, ensuring essential functionalities are rigorously validated. We conduct vulnerability assessments, penetration testing, and compliance audits, tailored to your specific device and regulatory landscape. Our experts, many holding certifications like CISSP and OSCP, and with experience from ex-military red teams, bring practical insights to every engagement. We specialize in identifying nuanced risks that others might miss. Blue Goat Cyber partners with you through the entire process, including pre-market submissions. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our approach at [Blue Goat Cyber's pre-market services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is risk-based testing for medical devices? Risk-based testing focuses testing efforts on the functionalities and components of medical device software that pose the highest risk to patient safety or device performance. This structured approach ensures critical areas receive the most rigorous validation. ### Why is risk-based testing important for medical device software? It is crucial because even minor software defects in medical devices can lead to severe patient harm. Risk-based testing helps identify, assess, and mitigate these potential risks early, ensuring both patient safety and regulatory compliance. ### How does the FDA view risk-based testing? The FDA, in its February 3, 2026 final guidance, emphasizes risk-based testing as a fundamental component of software validation for medical devices. The agency expects manufacturers to assess and address risks systematically to ensure product safety and effectiveness. ### What are common tools used in risk-based testing? Common tools include risk matrices, Failure Mode and Effects Analysis (FMEA), Fault Tree Analysis (FTA), and Hazard Analysis and Critical Control Points (HACCP). These tools help in systematically identifying, assessing, and prioritizing risks. ### When should risk-based testing be applied in development? Risk-based testing should be applied throughout the entire software development lifecycle, including requirements analysis, design, implementation, and deployment phases. This continuous application allows for early detection and mitigation of risks. ### Does ISO 14971 relate to risk-based testing? Yes, ISO 14971, "Medical devices - Application of risk management to medical devices," provides a framework for managing risks associated with medical devices. This standard guides how to identify, evaluate, control, and monitor risks, directly supporting risk-based testing principles. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Software Testing Guide Source: https://bluegoatcyber.com/blog/a-comprehensive-guide-to-software-testing-for-medical-devices # Medical Device Software Testing: What Manufacturers Need to Know > **[DIRECT ANSWER]** Medical device software testing spans unit, integration, system, and acceptance levels, layered with static analysis, dynamic and fuzz testing, and penetration testing for security. IEC 62304 sets the software lifecycle expectations, ISO 14971 ties failures to patient harm, and the FDA's cybersecurity guidance adds security-specific evidence. Plan the test strategy from the risk file so every high-severity hazard has a test that demonstrably closes it. _Reviewed July 24, 2026_ Medical devices rely heavily on software to perform critical functions, making software testing a crucial aspect of their development and maintenance. This guide aims to illuminate the importance of software testing in the medical device industry, fundamental principles and types of testing, [regulatory standards](https://www.fda.gov/media/119933/download), and associated challenges. ## Key Takeaways - Software testing confirms medical device reliability and accuracy. - The FDA requires thorough documentation and risk management plans. - Adherence to ISO 13485 ensures quality management of devices. - Complex software architectures require careful testing approaches. - Rigorous testing maintains patient safety and data security. - Integration testing assesses interactions between software components. ## Why this matters The stakes in medical device software are exceptionally high; failures can lead to misdiagnoses, incorrect treatments, patient injury, or even death. Rigorous software testing is not merely a technical exercise but a critical safeguard for human lives. It ensures that complex medical devices function precisely as intended, safeguarding patient well-being and data integrity. The FDA's February 3, 2026, final guidance on medical device cybersecurity underscores the necessity of demonstrating software safety and effectiveness throughout the product lifecycle. This includes adherence to standards like IEC 62304 for medical device software lifecycle processes, ISO 14971 for risk management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles for medical device security, risk management. These frameworks guide manufacturers in identifying, assessing, and mitigating software-related risks. Without diligent testing, devices could expose patients to avoidable harm, compromise protected health information (PHI), and lead to significant regulatory penalties for manufacturers failing to meet stringent compliance requirements. ## Understanding the Importance of Software Testing in Medical Devices ![Section Image](/imported-images/cbd851a93d35c48e.png) ### The Role of Software in Modern Medical Devices Medical devices encompass a wide range of equipment, from wearable devices monitoring vital signs to sophisticated imaging systems and [surgical robots](/blog/protecting-surgical-robots-the-importance-of-cybersecurity). Software supports the functioning of these devices, enabling accurate measurements, real-time data analysis, and integration with other healthcare systems. Without software, medical devices would be rendered ineffective. ### Why Software Testing is Crucial in the Medical Field Software testing is an essential phase in developing and maintaining medical device software. It ensures that the [software operates reliably, accurately, and securely](/blog), minimizing the risk of errors or malfunctions that could compromise patient safety. The consequences of software failures in medical devices can be severe, leading to misdiagnoses, incorrect treatment, or even life-threatening situations for patients. Software testing is crucial in the medical field because of the complexity of medical devices. These devices often have intricate functionalities and rely on multiple software components working together seamlessly. Without thorough testing, it would be challenging to identify potential issues arising from these components’ interplay. Software testing in the medical field goes beyond ensuring functionality. It also involves verifying the safety and security of the software. Medical devices often handle sensitive patient data, and any vulnerabilities in the software could lead to data breaches or unauthorized access. [Rigorous testing](/blog/understanding-medical-device-attack-surface-analysis) helps identify and address these security risks, protecting patient information. ## Fundamental Principles of Software Testing for Medical Devices ![Section Image]() ### The Concept of Validation in Software Testing Validation is a critical principle in software testing for medical devices. It involves evaluating whether the software meets the defined requirements and performs as intended. [Validation ensures the software functions correctly](/blog/the-importance-of-verification-and-validation-in-medical-device-software) within its intended use and operating environment. This process includes requirements analysis, system design, and software testing to verify compliance. When it comes to medical devices, the stakes are high. Lives may depend on the software’s accurate and reliable performance. That’s why validation supports ensuring the safety and effectiveness of these devices. It goes beyond simply checking if the software meets the specified requirements; it also involves assessing its performance in real-world scenarios. This may include simulating various medical conditions and scenarios to ensure the software responds appropriately and delivers accurate results. ### The Role of Verification in Ensuring Software Quality [Verification](/blog/the-importance-of-verification-and-validation-in-medical-device-software) is another crucial principle in software testing for medical devices. It focuses on ensuring that the [software meets the specified requirements and standards](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). Verification involves code reviews, static analysis, and unit testing. By thoroughly analyzing the software throughout its development lifecycle, verification helps identify and rectify any discrepancies or defects. Imagine a scenario where a medical device is used to monitor a patient’s vital signs. In such cases, verification becomes even more crucial. The software must accurately capture and analyze the data from various sensors, ensuring that any abnormal readings are promptly detected and appropriate actions are taken. Verification helps ensure the software is reliable, resilient, and capable of handling different scenarios, including unexpected events or errors. Verification also supports maintaining regulatory compliance. Medical devices are subject to strict regulations and standards to ensure patient safety. By conducting thorough verification activities, developers can demonstrate that the software meets these requirements, providing confidence to regulatory bodies and healthcare professionals. ## Different Types of Software Testing for Medical Devices ### Unit Testing for Medical Device Software [Unit testing](/blog) involves testing individual software components or modules to ensure their correctness and functionality. By isolating specific functions and validating their behavior, developers can identify and rectify any errors early in the development process, reducing the likelihood of further issues during integration. ### Integration Testing in the Medical Device Industry [Integration testing](/blog) focuses on testing the interactions between different components of a medical device’s software system. It ensures that various modules work together and data flows accurately between them. This testing type helps create a and reliable system by identifying and resolving integration issues. ### System Testing for Complete Evaluation System testing involves testing the entire medical device, including its software, hardware, and external interfaces. This type of testing evaluates the system’s compliance with functional and [non-functional requirements](/blog/medical-device-software-functional-and-non-functional-aspects-explained), such as performance, reliability, and security. System testing ensures the device’s effectiveness and safety by simulating real-world scenarios and detecting potential defects. ### Regression Testing for Ensuring Stability Another necessary type of software testing for medical devices is [regression testing](/blog/vv-regression-testing-medical-device-cybersecurity). This type of testing ensures that the device’s previously developed and tested functionalities still work as expected after new changes or updates. It helps identify any unintended side effects or issues that may have been introduced during the development process. By conducting regression testing, developers can maintain the stability and reliability of the medical device software. ### Usability Testing for User-Centric Design Usability testing is a crucial aspect of software testing for medical devices, as it focuses on evaluating the device’s user interface and user experience. By involving real users in the testing process, developers can gather valuable feedback on the device’s ease of use, intuitiveness, and overall user satisfaction. This type of testing helps ensure that the medical device software is designed with the end user in mind, resulting in a more user-friendly and effective product. > **Planning device security testing?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Medical device penetration testing](/services/medical-device-penetration-testing) ## Regulatory Standards for Medical Device Software Testing ### Overview of FDA Regulations on Software Testing The U.S. Food and Drug Administration (FDA) supports ensuring the safety and effectiveness of medical devices. The [FDA has specific regulations and guidelines for software testing in medical devices](https://www.fda.gov/media/119933/download). These regulations govern various aspects, including documentation, risk management, and software validation throughout its lifecycle. Compliance with these regulations is essential to meet the stringent safety requirements of the medical device industry. The FDA emphasizes the importance of thorough documentation regarding software testing. This includes creating detailed test plans, test cases, and test scripts that cover all aspects of the software’s functionality. By documenting the testing process, medical device manufacturers can provide evidence of compliance and demonstrate that their software meets the necessary safety standards. The FDA requires medical device manufacturers to implement effective risk management strategies during software testing. This involves identifying potential risks associated with the software and developing mitigation plans to minimize those risks. By proactively addressing potential issues, manufacturers can ensure that their software is safe and reliable for use in medical devices. ### Understanding the Role of ISO Standards in Software Testing In addition to FDA regulations, the International Organization for Standardization (ISO) has developed standards for software testing in medical devices. [ISO 13485](https://www.iso.org/standard/59752.html) focuses on quality management systems for medical devices, including software development and testing. Adhering to these standards helps ensure that medical device manufacturers follow good software testing practices, building quality and patient safety. ISO 13485 emphasizes the importance of establishing a software testing process that covers all stages of the software’s lifecycle. This includes requirements analysis, design, implementation, verification, and validation. By following this structured approach, medical device manufacturers can identify and address potential issues early on, reducing the risk of software failures or malfunctions. ISO 13485 promotes using validated software tools and techniques in [medical device software testing](/blog/a-comprehensive-guide-to-software-testing-for-medical-devices). This means that manufacturers should use proven methodologies and tools that have been validated for their intended use. By relying on validated tools, manufacturers can have confidence in the accuracy and reliability of their testing results, ensuring that their software meets the necessary quality standards. ## Challenges in Medical Device Software Testing ### Dealing with Complex Software Architecture Medical devices often feature sophisticated software architectures that pose unique testing challenges. These complex architectures require thorough testing to confirm their functionality, reliability, and safety. The intricate interplay between different software components demands a careful approach to testing, ensuring that each component functions with the others. This involves conducting extensive integration testing to verify the compatibility and coherence of the software architecture as a whole. The complexity of medical device software architecture necessitates using advanced testing techniques. Testers must employ methods such as [white-box testing](/blog), black-box testing, and model-based testing to assess the software’s behavior and performance thoroughly. This testing approach helps identify any potential flaws or vulnerabilities in the software architecture, allowing for timely remediation before the device reaches the market. ### Ensuring Patient Safety during Software Testing It is crucial to mitigate any risks that could potentially harm patients during software testing. Rigorous testing procedures, such as risk analysis and test plans, are utilized to minimize the chances of errors or failures. Medical device manufacturers must prioritize patient safety by employing testing methodologies and maintaining transparent documentation. The testing process should include simulations and real-world scenarios to evaluate the software’s performance in various clinical settings. This ensures that the software can withstand the complexities and uncertainties of real-life medical situations, providing accurate and reliable results to healthcare professionals. ## Test types compared Software testing and security testing overlap, but they answer different questions and satisfy different requirements. | Test type | Question it answers | Standard that expects it | Role in a submission | | --- | --- | --- | --- | | Unit and integration testing | Does the code do what the design says | IEC 62304 | Software verification evidence | | System level verification and validation | Does the device meet its requirements and user needs | IEC 62304 and design controls | Core V and V record | | Static analysis | Are there defect patterns in code we wrote | IEC 62304 and secure coding practice | Supporting evidence, with triaged findings | | Software composition analysis | What is in the code we did not write | SBOM expectations under Section 524B | SBOM plus vulnerability assessment | | Security requirement testing | Does each stated security control actually work | FDA premarket cybersecurity guidance | Direct evidence against security requirements | | Fuzz testing | How does the device behave on malformed input | FDA premarket cybersecurity guidance | Robustness evidence on external interfaces | | Penetration testing | What can an attacker achieve against the built device | FDA premarket cybersecurity guidance | Independent assessment with findings and disposition | Passing verification tells you the device does what you designed. It says nothing about what happens when someone deliberately tries to make it misbehave. ## Conclusion As technology continues to advance, the role of software testing in the medical device industry becomes increasingly critical. The development and maintenance of medical device software can be optimized for quality, safety, and patient care by understanding the importance and principles of software testing, various types of testing, adherence to regulatory standards, and addressing challenges. As you navigate the complexities of medical device software testing, remember that cybersecurity is integral to safeguarding patient data and ensuring compliance with regulatory standards. Blue Goat Cyber, a Veteran-Owned business, specializes in medical device cybersecurity, offering services such as penetration testing, HIPAA compliance, FDA Compliance, and more. Our expertise is tailored to meet the unique challenges of the healthcare industry. [Contact us today for cybersecurity help](/contact) and partner with a team passionate about protecting your medical devices from potential threats. Check out our [medical device cybersecurity FDA compliance package.](/) ## How Blue Goat approaches this Blue Goat Cyber’s approach to medical device software testing focuses on precision and regulatory alignment. Our team, comprised of CISSP and OSCP-certified professionals, including ex-military red team specialists, applies specialized methodologies developed for the unique challenges of medical technology. We prioritize validation and verification throughout the software development lifecycle, aligning with FDA expectations. Our services include thorough penetration testing, vulnerability assessments, and risk analysis specifically tailored for medical device software. We use practical and repeatable processes to identify potential weaknesses before they impact patient safety or data security. Our commitment to clients includes post-submission support; if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Explore our services at: /services/fda-premarket-cybersecurity-services. ## FAQ ### What is validation in medical device software testing? Validation confirms the software meets defined requirements and performs as intended within its intended use and operating environment. This process assesses the software's performance in real-world scenarios, ensuring it responds appropriately and delivers accurate results. ### How does the FDA regulate medical device software testing? The FDA regulates medical device software testing through specific guidelines that cover documentation, risk management, and software validation across the lifecycle. Compliance ensures devices meet stringent safety requirements, as outlined in the February 3, 2026, final guidance on medical device cybersecurity. ### Why is regression testing important for medical devices? Regression testing ensures that previously functional software features still work as expected after updates or changes. This testing type identifies unintended side effects introduced during development, preserving the software's stability and reliability. ### What challenges exist in medical device software testing? Medical device software testing faces challenges such as complex software architectures and maintaining patient safety. These complexities necessitate careful integration testing and complete risk analysis to prevent errors or failures. ### Does ISO 13485 apply to medical device software testing? Yes, ISO 13485 is a standard for quality management systems specific to medical devices, including software development and testing. Adhering to it ensures good software testing practices, building overall quality and patient safety. ### What is unit testing in the medical device field? Unit testing involves checking individual software components or modules to ensure their correctness and functionality. This helps identify and rectify errors early in the development process, reducing downstream issues. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## The Top 10 Most Vulnerable Medical Devices Source: https://bluegoatcyber.com/blog/a-critical-alert-the-top-10-most-vulnerable-medical-devices-to-cyber-attacks # The Top 10 Most Vulnerable Medical Devices > **[DIRECT ANSWER]** The most vulnerable medical devices include insulin pumps, pacemakers, infusion pumps, patient monitors, surgical robots, and hospital networks that connect them, each exposed by weak encryption, unsecured wireless links, or unpatched software that attackers can exploit to alter dosing, disrupt monitoring, or take control of therapy delivery. Manufacturers should apply encryption, access control, and continuous monitoring per the FDA's February 3, 2026 cybersecurity guidance before submission. _Reviewed July 24, 2026_ The increasing interconnectedness of medical devices has led to a rise in cybersecurity concerns, particularly when these devices are compromised, potentially resulting in patient harm or even death. This post explores various high-profile instances of medical device hacking. It discusses the top 10 medical devices that have been targeted, emphasizing the urgent need for cybersecurity in healthcare technology. ## Key Takeaways - Insulin pumps and pacemakers are highly vulnerable. - Infusion pumps can be manipulated for incorrect dosages. - Patient monitors are targets for vital sign falsification. - Surgical robots present risks of control loss. - Hospital networks are critical points of widespread attack. - Manufacturers must prioritize cybersecurity in design. ## Why this matters The stakes in medical device cybersecurity are profoundly high, directly impacting patient safety, clinical efficacy, and institutional integrity. Breaches can lead to device malfunction, data theft, and even life-threatening consequences, necessitating rigorous protective measures. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, underscores the critical need for security by design (SBD) and postmarket surveillance. This guidance emphasizes proactive risk management throughout the device lifecycle, from development to retirement. Beyond FDA mandates, adherence to standards like IEC 81001-5-1 (Health software, security activities in the product life cycle), ISO 27001 (Information Security Management), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security) is crucial. These frameworks guide manufacturers and healthcare providers in identifying, assessing, and mitigating cybersecurity risks. Ignoring these guidelines not only risks regulatory non-compliance but, more importantly, jeopardizes patient trust and well-being, potentially resulting in severe medical adverse events and significant financial and reputational damage for healthcare organizations. ## Significant Medical Device Hacking Incidents **1\. Compromised Insulin Pumps** Insulin pumps, vital for diabetes management, have been targets for hackers. In a [notable 2011 incident](https://www.theregister.com/2011/10/27/fatal_insulin_pump_attack/ "notable 2011 incident"), a security expert showed how specific insulin pumps could be manipulated remotely, risking insulin overdose. Fortunately, no fatalities were reported, but the potential for serious harm was evident. **2\. Pacemaker Vulnerabilities** Pacemakers, essential for regulating heart rhythm, have not been immune to hacking threats. A significant recall in 2017, involving hundreds of thousands of pacemakers, was due to vulnerabilities that could let hackers deplete the battery or alter the pacing, which could be life-threatening. **3\. Hospital Network Cyber-Attacks** In 2017, the [WannaCry ransomware attack disrupted the UK’s National Health Service (NHS)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461132/), causing appointment cancellations and emergency patient rerouting. While this wasn’t a direct attack on a medical device, it showcased how cyber-attacks could indirectly impact patient care and safety. ## Top 10 Vulnerable Medical Devices It’s essential to understand the specific vulnerabilities and implications of cyber-attacks on these devices, which play a crucial role in patient care: ### 1\. Insulin Pumps - **Description:** Small, computerized devices that deliver insulin to diabetic patients in controlled doses. - **Vulnerabilities:** Weak encryption, unsecured wireless communication. - **Attack Methods:** Intercepting and altering insulin dosage instructions. - **Impact:** This can lead to severe hypo- or hyperglycemia. - **Documented Incidents:** Researchers have demonstrated the ability to [control insulin pumps and alter dosing levels remotely](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667325/). ### 2\. Pacemakers - **Description:** Devices implanted in the chest to help control abnormal heart rhythms. - **Vulnerabilities:** Susceptible to wireless signal interception and reprogramming. - **Attack Methods:** Hacking to change heart rhythms, stop functioning, or drain batteries. - **Impact:** This can cause cardiac arrest or other serious cardiac events. - **Documented Incidents:** Security researchers have found vulnerabilities in several [pacemaker models](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know) that could be exploited. ### 3\. Infusion Pumps - **Description:** Devices used to deliver fluids, including medications, at a set rate. - **Vulnerabilities:** Network connection breaches. - **Attack Methods:** Altering drug formulas, dosages, or infusion rates. - **Impact:** Risk of drug overdose or underdose. - **Documented Incidents:** The [FDA has issued warnings about specific infusion pump models vulnerable to hacking.](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity#:~:text=The%20FDA%20has%20become%20aware,them%20from%20these%20potential%20risks.) ### 4\. Patient Monitors - **Description:** Devices that continuously monitor and display vital signs like heart rate and blood pressure. - **Vulnerabilities:** Data transmission interception/manipulation. - **Attack Methods:** Falsifying vital sign data. - **Impact:** Misdiagnosis or delayed treatment. - **Documented Incidents:** Hacking demonstrations have shown potential for manipulating patient monitor data. ### 5\. MRI Machines - **Description:** Advanced imaging devices are used to visualize the body’s internal structures. - **Vulnerabilities:** Software/hardware disruption. - **Attack Methods:** Introducing malware or system breaches. - **Impact:** Incorrect imaging results. - **Documented Incidents:** While direct attacks are rare, [MRI machines](/blog/what-is-a-radiology-information-system) are often impacted in broader healthcare cyber-attacks. ### 6\. Radiation Therapy Systems - **Description:** Equipment used for cancer treatment by delivering radiation to target areas. - **Vulnerabilities:** Software manipulation. - **Attack Methods:** Altering radiation dosage levels. - **Impact:** Incorrect radiation doses can harm patients. - **Documented Incidents:** Specific vulnerabilities have been identified, though no direct attacks are publicly known. ### 7\. Diagnostic and Imaging Equipment - **Description:** Includes CT scanners, ultrasound machines, and other diagnostic tools. - **Vulnerabilities:** Susceptible to hacking and providing false diagnostic information. - **Attack Methods:** Manipulating imaging results. - **Impact:** Leads to incorrect treatment decisions. - **Documented Incidents:** Generally, vulnerabilities are known, but direct attacks are less common. ### 8\. Surgical Robots - **Description:** [Robotic systems](/blog/protecting-surgical-robots-the-importance-of-cybersecurity) used for performing precise, minimally invasive surgeries. - **Vulnerabilities:** Dependence on precise control and network connectivity. - **Attack Methods:** Loss of control or manipulation of movements. - **Impact:** Potential for surgical errors. - **Documented Incidents:** Researchers have demonstrated theoretical vulnerabilities, though actual incidents are rare. ### 9\. Defibrillators - **Description:** Emergency devices used to deliver a dose of electric current to the heart. - **Vulnerabilities:** Hacking to disrupt shocks or battery depletion. - **Attack Methods:** Preventing the device from functioning in emergencies. - **Impact:** Life-threatening if not available during cardiac emergencies. - **Documented Incidents:** Vulnerabilities in certain models have been exposed, but no attacks have been reported. ### 10\. Hospital Networking Equipment - **Description:** The backbone of a hospital’s IT infrastructure, connecting various medical devices. - **Vulnerabilities:** Network breaches can lead to widespread dysfunction. - **Attack Methods:** Gaining unauthorized access to the network, affecting connected devices. - **Impact:** Loss of critical patient data, malfunctioning of medical devices. - **Documented Incidents:** Various healthcare networks have been victims of cyber-attacks, leading to significant disruptions. These vulnerabilities highlight the importance of cybersecurity in the healthcare sector. As medical devices become increasingly interconnected and reliant on wireless technologies, they become more susceptible to cyber-attacks. This necessitates enhanced security protocols, regular software updates, and vigilant monitoring to protect patient safety and ensure the reliability of these essential devices. ## Impact and Consequences The repercussions of medical device hacking are grave: - **Patient Harm**: Direct interference with device operations can lead to incorrect treatment, posing severe health risks. - **Erosion of Trust**: Such security breaches can diminish confidence in medical devices and healthcare institutions. - **Economic Impact**: Recovering from a cyber-attack can be costly due to device recalls, software upgrades, and potential legal implications. ## Risk Mitigation Strategies Effective strategies to mitigate these risks are crucial: - **Cybersecurity-Integrated Design**: Manufacturers must [prioritize cybersecurity in the development](/services/secure-medtech-product-design-consulting) of medical devices. - **Frequent Updates**: Regular software updates are essential to guard against emerging threats. - **Education and Awareness**: Informing healthcare providers and patients about potential risks and safety practices is vital. - **Regulatory Enforcement**: Strong cybersecurity standards for medical devices should be enforced by regulatory agencies. - **[Penetration Testing](/services):** Test medical devices throughout the development lifecycle. ## Future Challenges The cybersecurity landscape is becoming more complex with the integration of AI and machine learning in medical devices. The industry must proactively update and enforce cybersecurity measures to stay ahead of potential threats. ## Which device categories carry the most exposure Exposure is not about how sophisticated the device is. It follows the interfaces the device exposes, how long it stays in service, and whether it can be patched without a clinical interruption. | Device category | Why it is exposed | Typical weakness | First control worth funding | | --- | --- | --- | --- | | Infusion pumps | Networked, numerous, long service life | Flat network placement and unauthenticated drug library updates | Authenticated configuration changes and network segmentation | | Implantables and their programmers | Wireless link that cannot be firewalled | Weak or absent authentication on the telemetry channel | Mutual authentication plus proximity or pairing requirements | | Imaging systems and PACS | Legacy operating systems, DICOM interfaces | Unpatched hosts and DICOM nodes that trust the calling AE title | Host hardening, DICOM TLS, and access control at the node | | Patient monitors | Continuous clinical dependency, alarm forwarding | Unencrypted alarm and telemetry traffic | Encrypted transport and integrity checking on alarm paths | | Diagnostic and laboratory analyzers | Middleware and LIS integration | Shared service accounts and hardcoded credentials | Unique credentials and logging on every integration point | | Home use and wearable devices | Unmanaged network, physical access by the user | Debug interfaces and mobile app to cloud API weaknesses | Disabled debug access in production and a tested API authorization model | The ranking that matters for your submission is not this general list. It is the one produced by your own threat model against your own interfaces. ## Conclusion The hacking of medical devices poses a significant threat, necessitating immediate and continuous action from all stakeholders in the healthcare sector. The balance between embracing technological advancements and ensuring the safety and security of these innovations is crucial for maintaining patient safety and confidence in healthcare systems. Check out our [medical device cybersecurity FDA compliance package.](/services/fda-premarket-cybersecurity-services) ## How Blue Goat approaches this Blue Goat Cyber’s approach to securing medical devices focuses on proactive vulnerability identification and mitigation. Our team, comprised of certified experts (CISSP, OSCP) and former military red team personnel, specializes in anticipating and neutralizing threats before they impact patients or operations. We conduct in-depth security assessments, penetration testing, and threat modeling tailored specifically to medical device ecosystems. Our methodology ensures that all potential entry points and attack vectors are systematically evaluated. We align our services with current regulatory landscapes, helping manufacturers and healthcare providers meet evolving requirements. Our commitment includes ensuring compliance and operational integrity. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to elevate the security posture of medical devices, safeguarding patient care and data integrity. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is the biggest cybersecurity risk for medical devices? The biggest cybersecurity risk for medical devices stems from their increasing interconnectedness and reliance on wireless technologies. This expands the attack surface, making devices vulnerable to exploitation through weak encryption, unpatched software, or compromised network infrastructure. Successful attacks can lead to device malfunction and patient harm. ### What medical devices are most commonly exploited in cyberattacks? Medical devices most commonly exploited in cyberattacks include insulin pumps, pacemakers, and infusion pumps. These devices often have vulnerabilities related to wireless communication and software, making them attractive targets for adversaries aiming to alter their function or access sensitive data. ### How does the FDA address medical device cybersecurity? The FDA addresses medical device cybersecurity by establishing stringent premarket and postmarket requirements for manufacturers. The February 3, 2026 final guidance outlines expectations for secure product design, vulnerability management, and transparent disclosure of security information. The FDA's goal is to ensure device safety and effectiveness throughout their lifecycle. ### What are the consequences of a medical device cyberattack? The consequences of a medical device cyberattack are severe, including direct patient harm from device malfunction or manipulation, erosion of public trust in healthcare systems, and significant financial costs for healthcare providers. These costs can include recovery efforts, device recalls, software updates, and potential legal liabilities. ### How can medical device cybersecurity be improved? Medical device cybersecurity can be improved through several strategies. These include integrating cybersecurity into the device design phase, implementing frequent software updates, and educating healthcare providers and patients about potential risks. Regulatory enforcement and regular penetration testing are also vital to identify and mitigate vulnerabilities proactively. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Conducting a Medical Device Security Audit Source: https://bluegoatcyber.com/blog/a-guide-to-conducting-a-medical-device-security-audit-for-manufacturers # Conducting a Medical Device Security Audit > **[DIRECT ANSWER]** A medical device security audit runs in five steps: define the scope, including cloud services and companion apps; review the threat model against the current architecture; validate the SBOM against what actually ships; test the security controls with scanning, fuzzing, and manual penetration testing; and check that findings trace into CAPA and the risk file. Finish with a gap report written against the February 3, 2026 guidance. _Reviewed July 24, 2026_ This post explores a critical aspect of modern healthcare: conducting a medical device cybersecurity audit. As healthcare systems become increasingly reliant on connected technologies, ensuring the security of those devices isn’t just a regulatory checkbox; it’s a matter of patient safety, operational continuity, and organizational trust. Whether you’re a manufacturer, healthcare provider, or compliance lead, understanding how to audit effectively is essential in today’s evolving threat landscape. ## Key Takeaways - Audits cover the entire device lifecycle, from design to post-market. - Complete assessment of hardware, software, and network security. - Compliance with the FDA's February 3, 2026 final guidance is essential. - A multidisciplinary team ensures thoroughness in the audit process. - Risk assessments identify vulnerabilities in software, physical security, and data. - Focus on patient safety, data privacy, and operational integrity. ## Why this matters The security of medical devices directly impacts patient safety, data privacy, and healthcare operational continuity. In an increasingly interconnected healthcare ecosystem, vulnerabilities in medical devices can lead to severe consequences, from compromising sensitive patient health information to disrupting critical clinical care. The FDA emphasizes the necessity of cybersecurity throughout the total product lifecycle in its February 3, 2026 final guidance, underscoring that security is not merely an optional feature but a fundamental requirement. Manufacturers must adhere to rigorous standards, including those outlined in **IEC 81001-5-1**, **ISO 27001**, and **AAMI TIR97**, to manage risks effectively. Neglecting consistent security audits can result in regulatory non-compliance, legal liabilities, reputational damage, and, most critically, harm to patients. Proactive and regular auditing identifies and remediates potential threats before they can be exploited, safeguarding both the integrity of medical devices and the well-being of those who rely on them. ## The Critical Need for Cybersecurity in Medical Devices In today’s connected healthcare ecosystem, medical devices span everything from wearable insulin pumps to sophisticated MRI systems. As these technologies grow smarter and more interconnected, their exposure to cyber threats increases exponentially. A single breach can compromise sensitive patient data, disrupt critical clinical workflows, or-most alarmingly-pose a direct risk to patient safety. The stakes are far too high for complacency. security audits are no longer a best practice-they’re a non-negotiable requirement for ensuring trust, safety, and compliance in modern healthcare. > **Running a device security audit?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Medical device penetration testing](/services/medical-device-penetration-testing) ## Medical Device Cybersecurity Audit Steps ### Step 1: Defining the Scope of Your Audit Your audit should span the entire lifecycle of your medical device, beginning at the design and development phase and extending through to post-market surveillance. This holistic approach ensures the security of software components through [software composition analysis](/blog/understanding-binary-software-composition-analysis-with-medical-device-testing). It rigorously evaluates the cybersecurity posture of hardware elements, network functionalities (particularly the security aspects of interoperability), and data storage and transmission mechanisms. Critical aspects of your audit should include: - **Early Inclusion of Devices:** Incorporating devices at various development stages is crucial. This proactive strategy allows for the early identification of potential vulnerabilities, offering the opportunity for timely remediation and enhancing the overall security posture of the device. - **Software Composition Analysis:** A thorough [examination of software components](/services) is essential. This analysis should identify open-source and third-party components to assess associated vulnerabilities and compliance with licensing requirements. The goal is to ensure that software dependencies do not introduce security weaknesses or legal complications. - **Hardware Security Evaluation:** Hardware components should undergo rigorous testing to identify vulnerabilities that could be exploited via physical access or connected networks. This evaluation might include testing for side-channel attacks, ensuring [secure boot processes](/blog), and verifying the integrity of communication ports. - **Network Capabilities and Interoperability Security:** Given the increasing interconnectedness of medical devices, it’s vital to assess the security of network interfaces and protocols. This includes ensuring data encryption in transit, implementing secure authentication and authorization mechanisms, and evaluating the security implications of device interoperability. - **Data Storage and Transmission Features:** Secure data storage and transmission are paramount. This involves encrypting data at rest, employing access controls, and ensuring data transmission does not expose sensitive information to unauthorized parties. - **Regulatory Compliance and Standards Adherence:** Relevant regulations (e.g., [FDA](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) for devices used in the U.S.) and adherence to cybersecurity standards (such as [ISO/IEC 27001](/blog) for information security management and [ISO 14971](/blog/iso-14971-risk-management-in-medical-device-security) for risk management in medical devices) should be verified. This compliance underscores the device’s commitment to safeguarding patient data and safety. - **Vulnerability Management and Incident Response:** The audit should review the processes for managing vulnerabilities and responding to security incidents. This includes regular software updates and patches, monitoring for emerging threats, and having a clear incident response plan for communication strategies with affected parties. - **User Access Controls:** Implementing strong user authentication and access controls to prevent unauthorized device and sensitive data access. This may involve multi-factor authentication, role-based access controls, and the ability to audit user activities. - **Physical Security Measures:** Although often overlooked, physical security measures are crucial for devices left unattended or used in public or semi-public spaces. These measures include tamper-evident designs and secure storage options for the device when not in use. - **End-to-End Security Testing:** security testing, including penetration testing and dynamic analysis, should be conducted to identify and mitigate potential security vulnerabilities across all medical device components. - **Review of Post-Market Surveillance Data:** Continuously monitoring the security of the device post-launch is critical. This involves analyzing data from [post-market surveillance](/) for signs of security issues and implementing a process for rapidly addressing any vulnerabilities discovered after the device is in use. Your audit’s overarching objective is to ensure that every aspect of the medical device’s lifecycle incorporates cybersecurity measures, safeguarding patient health information and ensuring the device’s integrity and availability. This approach meets regulatory requirements and builds trust with users and stakeholders by demonstrating a strong commitment to cybersecurity. ### Step 2: Assembling a Specialized Team Incorporating a multifaceted team is essential for ensuring the cybersecurity and usability of medical devices. This team should encompass cybersecurity experts, engineers, designers, and, crucially, software developers, along with regulatory and compliance specialists and user experience (UX) researchers. Each group is pivotal in developing a secure, user-friendly, and compliant medical device. - **Cybersecurity Experts:** These professionals focus on the broader cybersecurity landscape, identifying potential digital threats, conducting thorough risk assessments, and devising strategies to shield the device against cyber intrusions. They are adept at staying updated with evolving cybersecurity threats and technologies to fortify the device’s defenses effectively. - **Engineers:** This group includes both software and hardware engineers, and it ensures the practical implementation of security measures. Software engineers are tasked with crafting the device’s software using secure coding practices, integrating data encryption, and other security protocols. Hardware engineers concentrate on the device’s physical security, making the hardware resistant to tampering and ensuring physical connections do not become vulnerabilities. - **Designers:** Their expertise lies in integrating security functionalities into the device’s design without compromising the user experience. They focus on creating intuitive interfaces and workflows that include security features, such as authentication mechanisms, in a way that enhances, rather than impedes, usability. - **Software Developers:** Critical to the team, software developers are responsible for developing the operating systems, applications, and interfaces that run on the device. They work closely with cybersecurity experts and engineers to embed s [ecurity into the software development lifecycle (SDLC)](/blog/implementing-ssdlc-for-enhanced-medical-device-cybersecurity). By applying principles of secure coding, regularly updating software to patch vulnerabilities, and ensuring software components are securely integrated, they play a pivotal role in safeguarding the device from software-related security threats. - **Regulatory and Compliance Specialists:** These individuals ensure the device adheres to all applicable legal, regulatory, and compliance standards related to cybersecurity. Their knowledge helps navigate the complex regulatory requirements, such as those set forth by the FDA for medical device cybersecurity, ensuring the device meets all necessary guidelines and standards. - **User Experience (UX) Researchers:** They provide insights into how end-users interact with the device, identifying potential security risks from user behavior. Their research helps the team design interfaces and procedures that minimize user errors, which could otherwise lead to security vulnerabilities. By assembling a team that includes cybersecurity experts, engineers, designers, software developers, regulatory specialists, and UX researchers, organizations can achieve a approach to medical device security. This collaborative effort enhances the device’s security against cyber threats and ensures it remains user-friendly and compliant with regulatory standards, ultimately protecting patient data and health. ### Step 3: Conducting a Risk Assessment Evaluating risks across the entire device ecosystem is an essential process that involves a detailed examination of all potential vulnerabilities, threats, and risks associated with the device. This assessment extends beyond the device to include the software it runs, the environment in which it operates, and the data it processes and stores. Understanding this risk landscape is crucial for developing devices resilient to cyber threats. The evaluation process involves several key components: - **Software Vulnerability Assessment:** This involves scrutinizing the device’s software components for vulnerabilities that cyber attackers could exploit. It includes analyzing the operating system, applications, and third-party or open-source software components. Regular software updates and patch management are essential to mitigate identified vulnerabilities. [Secure coding practices](/blog) and static and dynamic code analysis can help identify and resolve potential security issues early in development. - **Physical Security Analysis:** Physical tampering with medical devices can provide unauthorized access to protected health information (PHI) or compromise device functionality. Assessing the risk of physical tampering involves evaluating the device’s design and deployment environment to identify potential physical vulnerabilities. This might include analyzing the security of ports, implementing tamper-evident designs, and considering the physical security of the environments in which devices are used, such as hospitals, clinics, or patients’ homes. - **Data Privacy and Integrity Threats:** Protecting the privacy and integrity of data processed and stored by the device is paramount. This includes patient health information, subject to regulatory protections like HIPAA in the United States. Assessing data privacy and integrity threats involves examining how data is collected, stored, transmitted, and disposed of. Data encryption at rest and in transit, access controls, and secure data deletion practices are critical measures to protect data privacy and integrity. - **Network and Connectivity Risks:** As medical devices become increasingly connected, the risk landscape includes network security threats. Evaluating these risks involves analyzing how devices connect to and communicate with other systems, such as electronic health record (EHR) systems, medical devices, and cloud services. Ensuring secure communication protocols, implementing network segmentation, and monitoring network traffic for suspicious activities are vital to mitigating network and connectivity risks. - **User Authentication and Access Control:** Ensuring that only authorized users can access and interact with the device is critical for preventing unauthorized use and data breaches. This involves assessing the methods for user authentication and access control, such as passwords, biometrics, or smart cards, and ensuring they are and effectively implemented. - **Regulatory Compliance and Standards Adherence:** Part of evaluating the risk landscape involves ensuring compliance with relevant regulatory requirements and industry standards for cybersecurity and data protection. This includes adherence to standards such as ISO/IEC 27001 for information security management, [ISO 14971 for risk management in medical devices](/blog/iso-14971-risk-management-in-medical-device-security), and any applicable regional regulations. - **Incident Response and Recovery Planning:** Assessing the organization’s preparedness to respond to security incidents is crucial to understanding the risk landscape. This involves developing and testing incident response plans, establishing communication protocols for security breaches, and having recovery strategies in place to restore device functionality and data integrity after an incident. By thoroughly evaluating risks across the entire device ecosystem, organizations can identify and address vulnerabilities before they can be exploited. This holistic approach to risk management is essential for developing medical devices that are secure, trustworthy, and resilient to the evolving landscape of cyber threats. ### Step 4: Reviewing Design and Development Protocols Assessing your current design and development protocols involves thoroughly examining whether security considerations are inherently integrated into your product’s lifecycle from the beginning. This review is pivotal for ensuring that your medical devices are effective and secure from potential cyber threats. Here’s how to expand on this foundational approach: - **Security-by-Design Principles:** Evaluate if your development processes adhere to security-by-design principles. This means security is not an afterthought but a primary consideration throughout the device’s design and development stages. Assess whether each phase of the product development lifecycle includes specific security tasks and checkpoints. This could involve [threat modeling sessions](/blog) to identify potential security issues early in the design phase and integrate security and functional requirements. - **Review of Development Protocols:** Scrutinize your existing protocols to identify any gaps in security coverage. Are there clear guidelines for developers on incorporating security into their coding practices? Do your protocols include regular security training for your development team to keep them abreast of the latest threats and secure coding practices? Ensuring your team is knowledgeable about common vulnerabilities and how to avoid them is critical in developing secure software. - **Security of Third-party Components:** With the increasing use of third-party components in software development, assessing their security is crucial. Utilize methods such as the [Software Bill of Materials (SBOM)](/blog) to have a clear inventory of your device’s software components, libraries, and dependencies. An SBOM enables you to quickly identify if you are using components with known vulnerabilities, making it easier to mitigate these risks promptly. Regularly review and update the SBOM as your device adds or updates new components. - **Vulnerability Management and Patching:** Evaluate your current approach to managing vulnerabilities and applying security patches. Are there processes to monitor vulnerabilities in proprietary and third-party components? Assess how effectively and swiftly your team can respond to newly discovered vulnerabilities. Ensure there are mechanisms for integrating security updates and patches into devices post-manufacturing without disrupting the device’s functionality or user experience. This could involve over-the-air (OTA) update capabilities, secure update protocols, and procedures for verifying the integrity of updates. - **Continuous Security Testing:** Confirm that security testing is integral to your development cycle. This includes [static code analysis](/services/static-application-security-testing-sast), dynamic testing, and device penetration testing in environments that mimic real-world deployment scenarios. Continuous security testing helps identify vulnerabilities that may have been overlooked during the design phase and provides insights into how security measures perform under attack scenarios. - **Regulatory Compliance and Standards:** Lastly, ensure that your design and development protocols are aligned with relevant regulatory requirements and industry standards for medical device cybersecurity. This includes adhering to standards such as ISO/IEC 27001 for information security management, [IEC 62304](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards) for medical device software lifecycle processes, and specific guidelines issued by regulatory bodies like the FDA. Compliance helps mitigate cybersecurity risks and meets legal and regulatory obligations. By thoroughly assessing your current design and development protocols, focusing on embedding security from the ground up, reviewing third-party component security, and ensuring the smooth integration of security updates, you can significantly enhance the cybersecurity posture of your medical devices. This strategic approach ensures that devices are resilient to cyber threats, safeguarding patient data and device functionality. ### Step 5: Analyzing Physical and Network Security Examining the security measures in place for your manufacturing facilities and IT infrastructure is a critical step toward safeguarding the entire lifecycle of your medical devices. Ensuring a secure production environment and data transmission and storage protocols form the bedrock of a cybersecurity strategy. Here’s how to expand on ensuring these environments are secure: - **Physical Security of Manufacturing Facilities:** Start by assessing the physical security measures at your manufacturing facilities. This includes controlled access points to prevent unauthorized entry, surveillance systems monitoring activities, and securing areas for sensitive data and systems. Evaluate the effectiveness of physical access controls and consider biometric verification for enhanced security. Regularly review and update physical security measures to address evolving threats and ensure they comply with industry best practices. - **Cybersecurity of Manufacturing Systems:** Ensure that all systems used in the manufacturing process, including those for automation and quality control, are protected against [cyber threats](/blog/understanding-relevant-threats-for-medical-devices). This involves installing firewalls, antivirus software, and intrusion detection systems to safeguard manufacturing networks. Regular software updates and patches should be applied to address vulnerabilities. Conduct regular cybersecurity assessments to identify potential weaknesses in manufacturing systems and implement necessary safeguards. - **Secure Data Transmission:** Assess the security protocols for data transmission within and outside the manufacturing environment. Ensure that data, including proprietary information and personal data, is encrypted during transmission. Implement secure communication channels, such as VPNs, for remote access to manufacturing systems to prevent eavesdropping and data breaches. - **Data Storage and Access Control:** Evaluate how data is stored and who has access to it. Implement strict access control measures to ensure only authorized personnel can access sensitive data. Use encryption to protect data at rest and employ data segmentation strategies to limit the impact of a potential breach. Regularly review access permissions and adjust them as necessary to minimize risks. - **Supplier and Third-party Vendor Security:** Since manufacturing often involves suppliers and third-party vendors, assess their security practices as well. Ensure that they adhere to your security standards, especially concerning data handling and the security of connected systems. Conduct periodic audits of suppliers and vendors to ensure compliance with security requirements. - **Employee Training and Awareness:** Employees play a crucial role in maintaining security. Provide regular training on cybersecurity best practices, such as identifying phishing attempts, securing their workstations, and following protocols for handling sensitive data. build a culture of security awareness where employees are encouraged to report suspicious activities. - **Incident Response and Recovery Plans:** Develop and maintain an incident response plan tailored to the manufacturing environment. This plan should outline steps during a cybersecurity incident, including containment, eradication, and recovery. Conduct regular drills to ensure the response team is prepared to act swiftly and efficiently to minimize damages. - **Compliance with Regulations and Standards:** Ensure your security measures comply with relevant regulations and industry standards. This may include standards such as [ISO/IEC 27001](/blog) for information security management and specific regulatory requirements for manufacturing operations. Compliance helps safeguard your manufacturing processes and build trust with customers and stakeholders. By thoroughly examining and enhancing the security measures for your manufacturing facilities and IT infrastructure, you can ensure the integrity of the production environment and the confidentiality, integrity, and availability of data throughout the device lifecycle. This approach to security protects against both physical and cyber threats, ensuring the resilience of your manufacturing operations and the trustworthiness of your medical devices. ### Step 6: Conducting Penetration Testing Simulating cyberattacks on your medical devices through [penetration testing](/blog) in a controlled environment is an invaluable strategy to uncover potential vulnerabilities that malicious actors could exploit once the devices are deployed. This proactive approach highlights areas for improvement and helps refine the security measures to safeguard against cyber threats. Here’s how to expand on this approach: - **Penetration Testing Framework:** Develop a penetration testing framework that outlines the objectives, scope, methodologies, and tools for the testing. The framework should also define how often the tests are conducted, considering the rapid evolution of cyber threats. Regular testing ensures continuous security following any significant changes to the device or its operating environment. - **Engaging Expertise:** Consider engaging with cybersecurity experts specializing in penetration testing for medical devices. These professionals possess the skills and experience to simulate sophisticated cyberattacks and can provide an external perspective on your device’s security posture. Their expertise can be valuable in identifying vulnerabilities that might not be apparent to your internal team. - **Testing for Common Cyber Threats:** Ensure that the penetration tests simulate a wide range of cyber threats, including malware infections, ransomware attacks, and phishing schemes. For instance, testing how malware can infiltrate the device or its supporting systems can help assess the effectiveness of your antivirus and anti-malware solutions. Simulating ransomware attacks can evaluate your device’s resilience to unauthorized encryption attempts and data exfiltration. Testing the device’s vulnerability to phishing can uncover weaknesses in user authentication processes and educate on the importance of secure user interactions. - **Exploiting Identified Vulnerabilities:** The penetration test should not only identify vulnerabilities but also attempt to exploit them (in a controlled manner) to understand the potential impact on the device’s functionality and data integrity. This step is crucial for prioritizing the vulnerabilities based on their severity and potential impact. - **Reporting:** Upon completion of the penetration tests, compile reports detailing the identified vulnerabilities, the methods used to exploit them, and the potential impact of each vulnerability if left unaddressed. The report should also provide prioritized recommendations for mitigating the identified risks and best practices for strengthening the device’s security posture. - **Remediation and Re-testing:** Following the penetration tests, promptly address the identified vulnerabilities according to their priority. Implement the recommended security measures and conduct follow-up tests to verify that the vulnerabilities have been effectively mitigated. This testing, remediation, and re-testing cycle is essential for maintaining a security posture. - **Incident Response Planning:** Use the insights from the penetration tests to enhance your incident response plan. Ensure that the plan includes specific actions to be taken if the simulated attacks occur in a real-world scenario. This preparation can significantly reduce the potential impact of an actual cyberattack on your medical devices. By simulating cyberattacks on your devices through penetration testing, you actively prepare for real-world threats. This approach identifies and mitigates vulnerabilities and strengthens your overall security strategy, ensuring that your medical devices remain resilient against evolving cyber threats. ### Step 7: Adhering to Regulatory Compliance Compliance with regulatory standards, particularly the [FDA’s guidelines for cybersecurity](https://www.fda.gov/media/119933/download), is critical to developing and deploying medical devices. The FDA has established guidelines that outline the expectations for the security of medical devices throughout their lifecycle. These regulations serve as both a framework for risk assessment and mitigation and a testament to the manufacturer’s commitment to patient safety. Here’s an expanded overview focusing on aligning with FDA cybersecurity guidelines: - **Understanding FDA Cybersecurity Guidelines:** Begin by thoroughly understanding the FDA’s expectations and recommendations for medical device cybersecurity. The FDA’s guidance documents provide manufacturers with a framework for identifying, assessing, and mitigating cybersecurity vulnerabilities in medical devices. These guidelines emphasize the importance of considering cybersecurity at all stages of the device lifecycle, from design and development through post-market management. - **Pre-Market Considerations:** In the pre-market phase, the FDA expects manufacturers to incorporate cybersecurity risk management into the device design. This includes implementing secure device use features like data encryption, secure connectivity, and user authentication mechanisms. Manufacturers are encouraged to provide a specific plan for assessing and mitigating cybersecurity risks, including using standards such as NIST’s cybersecurity framework or ISO/IEC 27001. - **Post-Market Management:** The FDA also highlights the importance of ongoing risk management after devices have entered the market. Manufacturers must monitor for new vulnerabilities and threats, conduct security patching, and update their devices promptly. The FDA encourages the establishment of a coordinated vulnerability disclosure policy and active engagement with cybersecurity information-sharing forums and networks to stay informed about potential threats. - **Software Bill of Materials (SBOM):** The FDA recommends that manufacturers prepare and maintain a Software Bill of Materials (SBOM) for each device. The [SBOM](/blog) is a list of all medical device software components, including proprietary and third-party elements. This transparency helps healthcare providers and users understand potential vulnerabilities and manage risk exposure more effectively. - **Compliance Documentation:** Ensure that your compliance efforts are well-documented. This includes records of risk assessments, mitigation strategies, testing results, and actions taken to address vulnerabilities. Documentation should also cover staff training programs on cybersecurity best practices and the processes for monitoring and responding to cybersecurity incidents. - **FDA Submission:** Manufacturers must include cybersecurity documentation in their pre-market submission for devices requiring FDA clearance. This should demonstrate how the device complies with FDA guidelines and applicable standards. The submission should detail the device’s cybersecurity features, risk management processes, and any testing to validate security measures. - **Commitment to Patient Safety:** Ultimately, compliance with FDA cybersecurity guidelines is not just a regulatory requirement; it’s a commitment to patient safety. By adhering to these standards, manufacturers can assure patients, healthcare providers, and other stakeholders that their devices are designed and maintained to protect against cyber threats, thereby safeguarding patient health information and ensuring the reliable operation of medical devices. By aligning with the FDA’s cybersecurity guidelines, manufacturers can ensure that their medical devices are resilient against cyber threats. This meets regulatory requirements and builds trust with consumers and healthcare providers, reinforcing the manufacturer’s dedication to patient safety and data protection in an increasingly digital healthcare environment. ### Step 8: Documenting and Reporting Findings Maintaining detailed documentation of your security audits is an essential component of a medical device cybersecurity program. This documentation serves multiple critical functions: it acts as a roadmap for addressing identified security gaps, guides future device development with insights into potential vulnerabilities, and ensures adherence to regulatory requirements, including those set by the FDA for medical device security. Here’s an expanded overview of what this documentation should encompass and why it’s vital: - **Risk Identification:** Documentation should start with a thorough record of all identified risks during the audit process. This includes vulnerabilities in the device software and hardware and the surrounding ecosystem, such as network communications and third-party services. Each risk should be clearly described, detailing how it was identified and the potential impact on device functionality and patient safety. - **Vulnerability Assessment Details:** For each vulnerability tested, the documentation should include a overview of the testing methods used, such as penetration testing, static and dynamic code analysis, and any other assessment techniques. It should detail the specific conditions under which vulnerabilities were tested, the outcomes of these tests, and any immediate fixes or patches applied during the audit process. - **Recommendations for Improvements:** A crucial part of the audit documentation is the recommendations for mitigating identified risks and vulnerabilities. These recommendations should be actionable, prioritized based on the severity of the risk they address, and include a timeline for implementation. They may range from immediate fixes to longer-term strategic changes in device design or development processes. - **Action Plan and Remediation Strategies:** Beyond initial recommendations, the documentation should outline a detailed action plan for each suggested improvement, including responsible parties, necessary resources, and expected completion dates. It should also record the implementation of these recommendations, any challenges encountered during the remediation process, and how they were overcome. - **Regulatory Compliance Evidence:** For regulatory compliance purposes, especially with the FDA’s guidelines on medical device cybersecurity, the documentation should demonstrate how the audit and its findings align with regulatory requirements. This includes showing how identified risks were managed according to the FDA’s risk management framework, how the device’s security features comply with relevant standards, and how ongoing monitoring and updates will be conducted to address evolving threats. - **Feedback Loop for Future Development:** Audit documentation should not be static but feed into a continuous improvement loop for device security. It should highlight lessons learned, emerging threat patterns, and areas for improvement in the development process. This feedback is invaluable for guiding future device development and ensuring new products are designed with the latest cybersecurity best practices. - **Stakeholder Communication:** Finally, while detailed technical reports will be primarily used internally, a summary or overview of audit findings and actions should be prepared for external stakeholders, including regulatory bodies, partners, and customers. This communication demonstrates the manufacturer’s commitment to security and transparency, building trust in the device’s reliability and safety. Maintaining detailed, organized, and accessible documentation of your security audits is more than just a regulatory requirement; it’s a best practice that enhances the overall security posture of your medical devices, informs strategic development decisions, and demonstrates a clear commitment to patient safety and data protection. ### Step 9: Developing an Action Plan Developing a prioritized action plan based on the findings of your security audit is a critical step toward strengthening the cybersecurity posture of your medical devices. This plan serves as a roadmap for addressing identified vulnerabilities and enhancing the overall security framework of your devices, both in the short term and the long term. Here’s an expanded approach to formulating this action plan: - **Immediate Steps for Critical Vulnerabilities:** Begin by addressing the most critical vulnerabilities identified during the audit. These weaknesses pose the highest risk to device security and user safety, potentially allowing unauthorized access, data breaches, or other malicious activities. Immediate steps might include applying patches, updating software, changing default passwords, or disabling unnecessary services. The goal is to mitigate these vulnerabilities to prevent exploitation swiftly. - **Classification and Prioritization:** Classify identified vulnerabilities based on their severity, potential impact, and the complexity of the mitigation process. Based on this classification, prioritize actions, focusing first on high-severity issues that can be remediated with reasonable effort. This prioritization helps allocate resources effectively, ensuring that the most critical issues are addressed promptly while planning to remedy less critical vulnerabilities. - **Long-Term Security Enhancement Strategies:** Beyond immediate fixes, your action plan should outline strategies for enhancing the security of your devices in the long term. This might include redesigning certain aspects of your device to eliminate security weaknesses, implementing more encryption methods, developing more secure communication protocols, or enhancing user authentication mechanisms. Consideration should also be given to improving the security of the development and deployment processes, such as integrating secure coding practices and establishing a secure development lifecycle. - **Staff Training and Awareness Programs:** Recognizing that cybersecurity is not solely a technical challenge but also a human one, incorporate ongoing training and awareness programs for all staff members into your action plan. This training should cover the importance of cybersecurity, common threats, how to recognize them, and best practices for maintaining security in their respective roles. Tailor the training content to be relevant for different roles within the organization, from engineers and developers to sales and customer support staff. - **Regular Review and Updates:** Cybersecurity is an evolving field, with new threats and vulnerabilities emerging regularly. Incorporate a process for regularly reviewing and updating your security measures and action plan. This includes staying informed about the latest cybersecurity trends and threats, re-evaluating your devices and processes in light of new information, and updating your security measures and training programs. - **Stakeholder Communication:** Ensure your action plan includes a component for communicating with stakeholders about your steps to enhance device security. This may involve notifying customers about updates or patches, working with regulatory bodies to demonstrate compliance with cybersecurity standards, and engaging with the cybersecurity community to share information about threats and best practices. By developing a prioritized action plan that addresses immediate vulnerabilities and lays out a strategic approach for long-term security enhancement, you solidify your commitment to the cybersecurity of your medical devices. This approach not only helps protect against current threats but also prepares your organization to respond to future challenges, ensuring the ongoing safety and trust of end-users. ### Step 10: Continuous Improvement and Staff Training building a culture of continuous improvement and regular cybersecurity training within your organization is a vital strategy to ensure your medical devices’ enduring security and integrity. This culture extends beyond the confines of the IT department or engineering teams, enveloping all employees, from engineers to sales staff and even executive leadership. Here’s how to expand on this foundational approach: - **Cybersecurity Training Programs:** Develop and implement an organization-wide cybersecurity training program tailored to the roles and responsibilities of different employee groups. Engineers and developers would benefit from deep dives into secure coding practices, vulnerability testing, and threat modeling. Sales staff, customer support, and other client-facing roles need training on recognizing social engineering attacks, safely handling customer data, and confidently communicating your devices’ security features. Administrative and executive teams should be versed in organizational cybersecurity policies, incident response plans, and the broader impact of cybersecurity on the company’s reputation and legal obligations. - **Regular Training Sessions:** Cybersecurity is rapidly evolving, with new threats and vulnerabilities constantly emerging. Conduct regular training sessions to keep pace and update employees on the latest cybersecurity trends, threats, techniques, and technologies. These sessions can be workshops, webinars, e-learning courses, or guest lectures from cybersecurity experts. The goal is to keep cybersecurity knowledge fresh and at the top of all employees’ minds. - **Real-world Simulations and Drills:** Beyond theoretical knowledge, practical experience in handling cybersecurity incidents can significantly enhance your team’s preparedness. Organize regular drills and simulations, such as mock phishing exercises or breach response drills, to help employees practice their skills in a controlled, safe environment. These exercises can reveal areas where additional training is needed and help build confidence in your team’s ability to respond to real incidents. - **Incentivize Security Innovations:** Encourage a proactive approach to cybersecurity by incentivizing employees to identify potential security enhancements for your devices and processes. This could be through recognition programs, bonuses, or competitions. Such initiatives build a sense of ownership and accountability toward the company’s cybersecurity posture and encourage creative thinking and innovation. - **Embed Cybersecurity in the Company Culture:** Leadership should champion cybersecurity as an organization’s core value. This includes regularly communicating the importance of cybersecurity to the company’s mission, recognizing teams or individuals who contribute significantly to enhancing device security, and ensuring that cybersecurity considerations are part of strategic decision-making processes. - **Cross-functional Cybersecurity Committees:** Establish cross-functional committees or working groups that bring together representatives from engineering, sales, customer support, and other departments to discuss cybersecurity challenges and strategies. This facilitates a holistic understanding of cybersecurity across the organization and ensures that all departments are aligned in protecting the company and its products. - **Continuous Feedback Loop:** Create mechanisms for employees to provide feedback on the cybersecurity training and policies. This feedback loop can help identify gaps in the training program, areas of employee concern, and opportunities for improvement. It also reinforces the notion that cybersecurity is a shared responsibility and everyone’s input is valued. By building a culture of continuous improvement and regular cybersecurity training, you not only enhance the security integrity of your medical devices but also build a resilient organization where every employee understands their role in safeguarding against cyber threats. This holistic approach prepares your team to face cybersecurity challenges and equips them with the knowledge and skills to adapt to future threats. ## Audit Phases at a Glance | Phase | What you are answering | Evidence it produces | |---|---|---| | Scoping | What is in the system and who owns each part | Asset and interface inventory | | Documentation review | Do the procedures describe what we actually do | Gap list against the guidance and standards | | Architecture review | Where does trust change hands | Updated architecture views | | Technical testing | What can an attacker actually reach | Findings tied to interfaces and harm | | Traceability check | Does each requirement reach a test result | Requirement to verification matrix | | Remediation and retest | Are the important findings actually closed | Retest evidence for the submission | ## Conclusion For medical device manufacturers, the imperative to conduct security audits transcends the mere fulfillment of regulatory obligations; it embodies a profound commitment to the health and safety of end-users. These audits serve as a critical checkpoint in the lifecycle of medical devices, ensuring that each product not only meets regulatory standards but also upholds the highest echelons of cybersecurity. By adhering to the outlined steps, from embedding security measures at the design phase and scrutinizing the security of third-party components to maintaining rigorous documentation and building a culture of continuous improvement-manufacturers can fortify their devices against the landscape of cyber threats. This commitment to cybersecurity is not just about safeguarding data but protecting lives. In the digital age, where medical devices are increasingly interconnected, the potential for cyberattacks to result in physical harm underscores the gravity of manufacturers’ responsibilities. Thus, the security audit is not merely a procedural step but a cornerstone of ethical manufacturing practices prioritizing patient safety. By embracing these principles and practices, manufacturers ensure compliance with current regulations and position themselves as leaders in the field, setting benchmarks for cybersecurity in medical devices. This proactive approach to security is a testament to a manufacturer’s dedication to excellence and a reflection of their commitment to the well-being of patients worldwide. In doing so, manufacturers earn the trust of regulatory bodies, healthcare providers, and, most importantly, the patients who rely on these devices for their health and well-being. Check out our [medical device cybersecurity FDA premarket submission package.](/services/fda-premarket-cybersecurity-services) ## How Blue Goat approaches this Blue Goat Cyber's approach to medical device security audits focuses on identifying and addressing critical vulnerabilities efficiently. Our methodology involves a systematic review of your device's architecture, software, and network components. We prioritize threats based on potential impact and exploitability, providing actionable recommendations. Our team comprises highly skilled professionals, including CISSP and OSCP certified experts, many with ex-military red team experience, who bring practical offensive security knowledge to your audit. We align our audits with the FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, ensuring that your device meets regulatory expectations. We offer services like premarket cybersecurity reviews, ensuring devices meet regulatory standards before submission. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the primary goal of a medical device security audit? The primary goal is to systematically evaluate and enhance the cybersecurity posture of a medical device across its lifecycle. This ensures patient safety, protects sensitive health information, and maintains operational continuity against emerging cyber threats. ### Which FDA guidance applies to medical device cybersecurity audits? Medical device cybersecurity audits should align with the FDA's February 3, 2026 final guidance. This guidance outlines the agency's expectations for cybersecurity in medical devices submitted for premarket review. ### Who should be involved in a medical device security audit team? A specialized team should include cybersecurity experts, software developers, hardware engineers, regulatory and compliance specialists, and user experience (UX) researchers. This multidisciplinary approach ensures all aspects of device security and usability are addressed. ### What areas does a complete audit scope cover? A complete audit scope covers hardware components, software (including open-source elements), network capabilities, interoperability security, data storage and transmission, and adherence to relevant regulatory standards like the FDA's guidance. ### Why is early inclusion of devices in the audit process important? Early inclusion allows for the identification and remediation of potential vulnerabilities during the design and development phases. This proactive approach strengthens the device's overall security posture before it reaches the market. ### How does a medical device security audit address data privacy? The audit assesses how data is collected, stored, transmitted, and disposed of, emphasizing encryption, strong access controls, and secure data deletion practices. This ensures compliance with regulations like HIPAA and protects patient health information. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA Cybersecurity Documentation Source: https://bluegoatcyber.com/blog/a-guide-to-fdas-cybersecurity-documentation-requirements # FDA Cybersecurity Documentation Requirements: What Reviewers Expect in Your Premarket Submission > **[DIRECT ANSWER]** FDA cybersecurity documentation means a traceable evidence package built across the Secure Product Development Framework: a STRIDE-based threat model, an AAMI SW96-aligned security risk file, a CycloneDX or SPDX SBOM with VEX statements, a vulnerability management plan, a coordinated vulnerability disclosure policy, security architecture views, penetration test evidence, and cybersecurity labeling. These map to eSTAR v7.0's eight cybersecurity slots and must trace consistently to satisfy Section 524B and the FDA's February 3, 2026 guidance. Most FDA cybersecurity write-ups answer "what's required." This one answers a different question: **what does each artifact actually look like on the page?** Reviewers do not fail submissions because the manufacturer did not know an SBOM was expected. They fail submissions because the SBOM ships without VEX statements in a syntax their tooling can parse, because the threat model uses identifiers the risk file does not, or because the eSTAR slot is filled with a PDF when reviewers expect machine-readable JSON. Below you will find example SW96 risk rows, working CycloneDX VEX snippets, a slot-by-slot eSTAR v7.0 reference table, and a walkthrough of the exact order reviewers open the package. If you want the upstream "is this required?" view, our [premarket submission checklist](/guides/fda-premarket-cybersecurity-submission-checklist) and [RTA prevention checklist](/guides/fda-cybersecurity-rta-prevention-checklist) cover that ground. This post is the artifact-anatomy companion. ## Key Takeaways - The FDA's February 3, 2026 final premarket cybersecurity guidance, layered on Section 524B, is the controlling reference. Packages built against the 2023 final must be re-baselined against the 2026 deltas before filing. - FDA cybersecurity documentation development must run alongside engineering, not after it. SPDF artifacts produced retroactively almost always fail traceability checks during substantive review. - The eight eSTAR v7.0 cybersecurity attachment slots dictate the structure reviewers expect: threat model, security risk file, SBOM/VEX, VMP, CVD policy, security architecture, testing evidence, and labeling. - An AAMI SW96-aligned security risk file is now the FDA-recognized standard (FDA recognition number 13-131), with AAMI TIR57 underneath as the implementation guide. - The single most common deficiency trigger is a threat model that does not connect cleanly to the risk file, the test report, and the SBOM. Coherence beats volume. ## Why this matters A cybersecurity hold inside the 15-day RTA window is not a polite request for more information. It restarts the submission clock and resets every downstream commercial milestone. Under Section 524B of the FD&C Act, the FDA has explicit statutory authority to refuse to accept a cyber-device submission that lacks the required evidence, and reviewers are exercising that authority routinely in 2026. The [final premarket cybersecurity guidance issued February 3, 2026](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket), the FDA's recognition of AAMI SW96:2023 (recognition number 13-131), and eSTAR v7.0's eight cybersecurity attachment slots together define what "adequate" looks like. Standards anchor the package. The 2026 guidance expects evidence consistent with AAMI SW96:2023 for security risk management, AAMI TIR57:2016 (R2023) as the implementation guide, AAMI TIR97:2019 for postmarket security risk management, IEC 81001-5-1 for secure software lifecycle activities, IEC 62304 for software lifecycle processes, NIST SP 800-218 (SSDF) for secure development practices, and the NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026) for SBOM content. Citing the wrong standard, or citing a superseded version, signals to reviewers that the underlying work is also out of date. ## What the FDA's 2026 premarket cybersecurity guidance actually requires The 2026 guidance operationalizes the three Section 524B obligations, patchability, vulnerability management, and SBOM, and embeds them in a Secure Product Development Framework. SPDF is not an optional methodology; it is the structure the guidance expects every cyber-device manufacturer to use to produce premarket evidence. FDA cybersecurity documentation development means producing SPDF outputs as an engineering byproduct: threat models updated when the architecture changes, SBOMs regenerated on every build, vulnerability assessments tied to the SBOM, and security testing evidence linked to specific threats. A submission written after the device is feature-complete cannot fake this lineage. The 2026 final supersedes the June 2025 final, which itself superseded the September 2023 final. The most consequential deltas are: AAMI SW96:2023 is now the FDA-recognized security risk-management standard; VEX statements are expected alongside the SBOM; PCCPs must cover security-relevant changes, not just performance retraining; and the cybersecurity submission collapses into eight eSTAR v7.0 attachment slots that reviewers screen in order. Teams that prepared evidence against the 2023 final need to walk through each delta before filing, not assume the prior structure will pass. ## The eight eSTAR v7.0 cybersecurity attachment slots eSTAR v7.0 organizes cybersecurity evidence into eight discrete attachment slots, and a missing slot is the fastest path to an RTA. The table below is the exact reference our team uses when assembling a package. Each row names the slot the way it appears in eSTAR, the file format reviewers expect, and the single most common reason that slot fails screening. | # | eSTAR v7.0 slot | Expected format | Most common screening failure | |---|---|---|---| | 1 | Security Risk Management Report | PDF, SW96-aligned | Built to ISO 14971 only, no SW96 mapping | | 2 | Threat Model | PDF + DFDs | STRIDE applied to the application only, not to interfaces or update channels | | 3 | Cybersecurity Risk Assessment | PDF | Threats not keyed to the same identifiers used in the threat model | | 4 | SBOM | CycloneDX 1.5+ or SPDX 2.3+ (JSON/XML) | Generated from build manifest, not the shipped binary | | 5 | Vulnerability Management Plan | PDF | Names "industry sources" instead of specific feeds, owners, and SLAs | | 6 | Coordinated Vulnerability Disclosure policy | Public URL + PDF | No named coordinator, no response-time commitment | | 7 | Security Architecture documentation | PDF (global, multi-patient harm, updateability views) | Missing one of the three required views from the 2026 guidance | | 8 | Cybersecurity Testing evidence | PDF (pen test, SAST, DAST, fuzz) | Findings carry CVSS but no threat-model ID link | Traceability across slots is what reviewers verify first. The threat model (Slot 2) must enumerate threats by component. The risk assessment (Slot 3) must map each threat to a control and a residual-risk decision using the same threat IDs. The architecture documentation (Slot 7) must show where each control lives. The testing evidence (Slot 8) must demonstrate that each high-severity threat was actively exercised. The SBOM (Slot 4) must enumerate the components those controls protect. Any break in that chain - a threat with no mapped test, a control with no architecture home, a CVE with no VEX statement - is a deficiency trigger. ## What an SW96-aligned risk row actually looks like The most common SW96 mistake is treating the security risk file as a copy of the ISO 14971 hazard analysis. SW96 expects threat-driven rows, not hazard-driven rows, and reviewers can spot a relabeled 14971 file immediately. A passing row carries enough columns to trace from the threat model into the test report without leaving the spreadsheet: | Threat ID | Threat (STRIDE) | Asset | Control | Residual likelihood | Residual harm | Test ID | |---|---|---|---|---|---|---| | TM-014 | Spoofing of update server | OTA channel | Mutual TLS + signed manifest, root pinned in secure element | Low | Negligible | PT-2026-014, FUZZ-OTA-03 | | TM-027 | Tampering with telemetry payload | Cloud ingestion API | HMAC over payload + replay window, server-side schema validation | Low | Minor | PT-2026-027 | | TM-041 | Information disclosure via debug UART | Service interface | Fuse-disabled in production, physical tamper-evident seal | Very low | Negligible | HW-INSP-04 | Three things make this format pass screening: (1) the `Threat ID` column is the same identifier used in the threat model, so the reviewer can cross-reference in one click; (2) every row has a `Test ID` that exists in the Slot 8 testing evidence; (3) residual likelihood and harm use the device's documented risk-acceptability matrix rather than a generic high/medium/low scale. ## What a working VEX statement looks like VEX statements are new as an explicit 2026 expectation, and they are where most SBOMs fail substantive review. A VEX statement tells the reviewer which CVEs in your SBOM are actually exploitable in your device - a bare `not_affected` assertion does not satisfy this. Both examples below are valid CycloneDX 1.5 VEX entries; the first claims the device is unaffected, the second commits to a fix. ```json { "vulnerabilities": [ { "id": "CVE-2024-12345", "source": { "name": "NVD" }, "ratings": [{ "severity": "high", "method": "CVSSv31", "score": 7.5 }], "affects": [{ "ref": "pkg:generic/openssl@3.0.7" }], "analysis": { "state": "not_affected", "justification": "vulnerable_code_not_present", "detail": "Affected TLS renegotiation path is disabled at build time via OPENSSL_NO_RENEGOTIATION; verified by SAST rule SR-014 and confirmed in shipped binary hash 4f3a..." } }, { "id": "CVE-2025-67890", "source": { "name": "NVD" }, "ratings": [{ "severity": "critical", "method": "CVSSv31", "score": 9.8 }], "affects": [{ "ref": "pkg:generic/libxml2@2.10.4" }], "analysis": { "state": "affected", "response": ["update"], "detail": "XML parser reachable from network interface IF-02. Mitigation: scheduled patch in firmware 4.2.1, target release 2026-08-15; interim DAST monitoring per VMP section 5.3." } } ] } ``` What reviewers look for: a `justification` value drawn from the CycloneDX-recognized list (`vulnerable_code_not_present`, `vulnerable_code_not_in_execute_path`, `inline_mitigations_already_exist`, and similar), a `detail` field that names the specific configuration or test that proves the claim, and a `response` plan for anything left `affected`. A VEX file with a hundred `not_affected` rows and no `detail` fields will be rejected as boilerplate. ## How reviewers actually read the package The order matters. Reviewers do not read top-to-bottom; they screen for traceability breaks. Knowing the sequence lets you stage the package the way it will be consumed: 1. **Open Slot 2 (Threat Model).** Count threats per interface. If a network or update interface has zero threats, the package fails here. 2. **Cross-check Slot 3 (Risk Assessment).** Every threat ID from Slot 2 must appear with a control and a residual-risk decision. 3. **Spot-check Slot 8 (Testing).** Pick three high-severity threats from Slot 2 and confirm each has a matching test ID with a result, not just a scope statement. 4. **Open Slot 4 (SBOM) and Slot 5 (VMP).** Confirm the VEX is present, that at least one `affected` CVE has a `response` plan, and that the VMP names the same feeds the VEX cites. 5. **Open Slot 7 (Architecture).** Verify the three required views are present (global system, multi-patient harm, updateability) and that controls cited in Slot 3 appear in the diagrams. 6. **Open Slot 1 (Security Risk Management Report).** Confirm SW96 alignment and that the report references - does not duplicate - the Slot 3 risk assessment. Slot 6 (CVD) and Slot 8 labeling cross-checks happen last, almost as a formality. If the package survives steps 1-5, it almost always clears screening. ## SBOM, VEX, and vulnerability management evidence Beyond the VEX example above, the SBOM itself must meet the NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026) and ship machine-readable in CycloneDX or SPDX. Each component requires supplier, name, version, unique identifier (PURL or CPE), dependency relationship, author, and timestamp. Hash-only "manifests" do not satisfy the requirement. For devices with substantial third-party content, expect reviewers to spot-check that the SBOM matches the shipped binary, not the build manifest. The Vulnerability Management Plan must describe how new CVEs are ingested, triaged against the SBOM, assessed under the device's risk framework, and either patched or risk-accepted with documented rationale - and it must name the specific feeds (NVD, ICS-CERT, vendor advisories) and the SLA for each severity tier. The Coordinated Vulnerability Disclosure policy must be public, must name a coordinator, and must commit to a response timeline. ## Testing evidence reviewers expect for moderate-to-high risk devices For moderate and high-risk devices, independent penetration testing is no longer optional. The 2026 guidance expects pen test scope to cover every interface in the threat model, every protocol in the architecture diagram, and every wireless or network surface the device exposes in clinical use. SAST and DAST evidence is expected alongside the pen test, not as a substitute. A pen test report that lists CVSS scores without tying each finding back to a threat-model ID (as in the risk-row example above) will not survive substantive review. Independence matters. Reviewers increasingly question pen tests run by the same internal team that wrote the security requirements. Use a third party, or document a credible separation-of-duties arrangement. For middleware-heavy or AI-enabled devices, fuzz testing of network-exposed parsers and adversarial input testing of model inference paths are now within the expected scope. ## Cybersecurity labeling, postmarket plan, and patchability Cybersecurity labeling addresses what the operator needs to maintain a secure configuration: software version, supported configurations, network port and protocol disclosures, cryptographic strength of communications, update mechanism, end-of-support timeline, and contact information for vulnerability reports. The MDS² form covers most of this for hospital procurement and should be referenced in the submission. Patchability under Section 524B is a design obligation, not a postmarket promise. The submission must show how patches are authored, signed, distributed, verified, and rolled back, and the postmarket plan must commit to a cadence. A patch mechanism that requires a service visit for every fielded device will draw a deficiency on patchability adequacy, regardless of how thorough the rest of the package is. > **Mid-article CTA:** If you want a second set of eyes on your eSTAR cybersecurity package before you file, [book a 30-minute submission review with Blue Goat Cyber](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). If the FDA raises cybersecurity deficiencies after our submission support, we resolve them at no additional cost. ## How Blue Goat Cyber approaches FDA cybersecurity documentation We run the SPDF as a workstream alongside engineering, not as a documentation sprint before filing. Our senior team holds CISSP and OSCP credentials and includes ex-military red team operators, and every engagement produces evidence keyed directly to the eight eSTAR v7.0 cybersecurity slots. We start with the threat model in week one, build the SBOM and VEX pipeline into your CI, and have the security risk file under SW96 evolving in parallel with the design history file. By the time the submission is assembled, the artifacts already trace to each other. When you engage us for full premarket support through our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services), we stand behind the package: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. For teams that want to validate their own work, our [SPDF cybersecurity documentation playbook](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) walks through the same checklist reviewers use. ## FAQ ### What does FDA cybersecurity documentation development actually look like in practice? It is a continuous engineering output, not a pre-submission writing project. Threat models update when the architecture changes, the SBOM regenerates on every build, vulnerability triage runs against the SBOM weekly, and security testing evidence accumulates against threat-model identifiers. By filing time, the package already traces end-to-end because each artifact was produced from the work, not summarized after the fact. ### How long does it take to produce a complete premarket cybersecurity package? For a moderate-risk connected device with a clean SPDF in place, six to twelve weeks of dedicated effort is typical to produce the full eSTAR v7.0 package. For teams starting from a documentation-light position, expect three to five months because the underlying engineering artifacts (threat model, security architecture, traceability) have to be built before the submission documents have anything to summarize. ### What is the single most common cause of an RTA cybersecurity hold? A threat model that does not match the risk file and the test report. Reviewers open the threat model first, then check whether each high-severity threat appears in the risk assessment with a control, and whether that control appears in the test report with a result. A break anywhere in that chain produces an immediate hold, regardless of how thorough each individual document is. ### Can we reuse cybersecurity documentation across a product family? Yes, if you build it that way from the start. A platform-level threat model, security architecture, and SBOM baseline can be inherited by each variant submission, with variant-specific deltas documented as addenda. Reviewers accept this pattern as long as the inheritance is explicit and the variant-specific risk assessment is genuinely variant-specific, not a copy-paste of the platform document. ### Does the 2026 guidance change what we needed under the 2023 final? Yes. The biggest deltas are AAMI SW96:2023 as the FDA-recognized security risk standard, explicit VEX statement expectations alongside the SBOM, PCCP coverage of security-relevant changes, and the eight-slot eSTAR v7.0 structure. Packages built to the 2023 final should be walked against each delta before filing, not assumed to pass. ## Ready to file with confidence? [Book a submission readiness review](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) with our senior team. We will walk your eSTAR v7.0 cybersecurity slots, flag the artifacts most likely to draw an AI request, and scope the work to close the gaps. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. --- **About the author.** Christian Espinosa is Founder of Blue Goat Cyber, a CISSP- and OSCP-credentialed cybersecurity leader and former U.S. Air Force officer with two decades of experience leading red-team and medical-device security engagements. He has guided more than 200 connected-device submissions through FDA premarket cybersecurity review. --- ## What the FDA's QMSR Means for Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/a-new-era-for-quality-and-safety-what-the-fdas-qmsr-means-for-cybersecurity # What the QMSR Means for Medical Device Cybersecurity > **[DIRECT ANSWER]** The Quality Management System Regulation replaced the Quality System Regulation by incorporating ISO 13485:2016 into 21 CFR Part 820, with a compliance date of February 2, 2026. It did not create new cybersecurity requirements. What it changed is the structure your cybersecurity work has to live inside, the vocabulary used to describe it, and the way the FDA inspects it, since QSIT was retired in favor of a new inspection approach. _Reviewed September 17, 2026_ Teams sometimes read the QMSR transition as a cybersecurity event. It is not. Section 524B is where the cybersecurity obligations come from, and the February 3, 2026 premarket guidance is where the expectations are described. The QMSR governs the quality system those activities are performed within. That distinction matters because the practical work is real even though the requirements did not change. Procedures reference clause numbers that moved, design control language shifted, and inspections now follow a different program. If your cybersecurity procedures still cite subparts that are reserved, you have documentation work to do even if your actual practices are sound. ## Key Takeaways - The QMSR incorporates ISO 13485:2016 into Part 820, with a February 2, 2026 compliance date. - It creates no new cybersecurity requirements; those come from Section 524B and the premarket guidance. - Many former Part 820 subparts are reserved, so procedures citing them need updating. - 820.35 is a records requirement, not a rebranded design control clause. - QSIT was retired on February 2, 2026 and inspections now follow Compliance Program 7382.850. - Cybersecurity belongs in design controls, risk management, CAPA, and supplier controls as it always did. ## What Actually Changed The FDA published the QMSR final rule in February 2024, amending 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, with a compliance date of February 2, 2026. The intent was harmonization: manufacturers who already maintained an ISO 13485 quality system had been maintaining two overlapping structures, and the rule reduces that duplication. Structurally, much of the former Part 820 text is gone. Subparts that previously carried the detailed requirements are reserved, because the substance now lives in the incorporated standard. A small number of FDA-specific requirements remain in the regulation, including 820.35, which addresses records and includes device-specific record requirements rather than restating design controls. Inspection changed alongside it. The Quality System Inspection Technique, the approach investigators had used since 1999, was retired on February 2, 2026, and inspections are conducted under Compliance Program 7382.850. For manufacturers, the practical effect is that the familiar four-subsystem framing is no longer the structure an investigator walks through. ## What Did Not Change for Cybersecurity | Obligation | Source | Effect of the QMSR | |---|---|---| | Premarket cybersecurity documentation | Section 524B, Feb 3, 2026 guidance | None; unchanged | | Vulnerability management plan | Section 524B | None; unchanged | | SBOM provision | Section 524B | None; unchanged | | Ability to deploy updates | Section 524B | None; unchanged | | Security risk management | ISO 14971 and AAMI SW96 | Sits within the ISO 13485 risk framework | | Secure development practices | IEC 81001-5-1 and the SPDF | Performed under ISO 13485 design controls | | Postmarket monitoring | Postmarket guidance, Section 524B | Feeds ISO 13485 CAPA and complaint handling | The useful way to hold this is that Section 524B tells you what cybersecurity work must be done, the premarket guidance tells you what evidence of it to file, and the QMSR tells you what quality system that work is performed inside. Confusing the three leads to procedures that cite the wrong authority for the right activity. **[KEY REQUIREMENT]** Review every cybersecurity procedure for citations to former Part 820 subparts. Citing a reserved subpart does not make your practice wrong, but it makes your documentation wrong, and that is what an investigator reads. ## Where Cybersecurity Lives in an ISO 13485 System | Quality system area | Cybersecurity activity it must contain | |---|---| | Design and development planning | Security activities scheduled alongside design milestones | | Design inputs | Security requirements derived from the threat model | | Design outputs | Implemented controls traceable to those requirements | | Design verification | Evidence each security requirement was met | | Design validation | Evidence the device is secure in its intended use environment | | Design transfer | Production configuration matches the tested configuration | | Design changes | Security impact assessed before a change is approved | | Risk management | Security risk integrated with ISO 14971 safety risk | | Purchasing and supplier controls | Third-party software components assessed and tracked | | Production and process controls | Keys, signing, and provisioning handled securely in manufacturing | | CAPA | Vulnerabilities and incidents handled through the same process as other nonconformities | | Records | Evidence retained and retrievable, per 820.35 and ISO 13485 clause 4.2.5 | Two of these are where the real integration work sits. Design inputs is the first: security requirements that exist only in a security document, and never enter the design input set, are not traceable to outputs or verification, which is exactly the gap an investigator or a reviewer will find. The second is CAPA. A vulnerability identified after release is a nonconformity, and handling it in a separate security process that does not feed CAPA leaves the quality system unaware of it. Supplier controls deserve a mention because the SBOM makes third-party components visible in a way they were not before. Once you have enumerated every component, the question of how you evaluate and monitor those suppliers becomes concrete. ## What to Do If Your Procedures Still Reference the Old Structure The work is mostly documentation, and it is finite. | Step | What it involves | |---|---| | Inventory citations | Find every reference to former Part 820 subparts in cybersecurity procedures | | Remap to ISO 13485 clauses | Replace with the clause that now carries the requirement | | Check terminology | Align vocabulary with the standard, since terms shifted | | Verify traceability | Confirm security requirements appear in design inputs, outputs, and verification | | Connect CAPA | Ensure vulnerability handling routes into the CAPA process | | Update training | Staff should recognize the structure an investigator will use | | Prepare for CP 7382.850 | Expect inspection to follow the new program rather than QSIT | None of this improves your security posture. It makes your quality system accurately describe the security work you already do, which is the part an inspection evaluates. ## How the Change Affects Inspections With QSIT retired, the four-subsystem walkthrough is no longer the frame investigators use. What has not changed is what makes an inspection go badly: procedures that do not match practice, records that cannot be produced, and activities performed outside the quality system. For cybersecurity specifically, the questions that come up are consistent. Show the security requirements in the design inputs. Show verification evidence for each one. Show how a reported vulnerability moved through CAPA. Show the SBOM and how it is maintained across releases. Show how a design change was assessed for security impact before approval. Each of those is answerable from a well-integrated system and awkward from a system where security lives in parallel documents maintained by a separate team. ## How Blue Goat Cyber Approaches This We work inside the quality system rather than beside it, which means the threat model produces design inputs, the testing produces verification evidence, and the findings route into CAPA the way any other nonconformity would. That is what makes the cybersecurity file defensible in both a submission and an inspection. Our [threat modeling](/services/threat-modeling) output is written to be usable as design input rather than as a standalone report, and our [medical device penetration testing](/services/medical-device-penetration-testing) evidence is structured to support verification records. ## Frequently Asked Questions ### Does the QMSR add new cybersecurity requirements? No. The QMSR incorporates ISO 13485:2016 into 21 CFR Part 820 and governs your quality system. Cybersecurity obligations come from Section 524B of the FD&C Act and are described in the FDA's premarket cybersecurity guidance issued February 3, 2026. The QMSR changes the structure the work is performed within, not the work itself. ### When did the QMSR take effect? The final rule was published in February 2024 with a compliance date of February 2, 2026. Manufacturers were expected to have transitioned by that date, and the Quality System Inspection Technique was retired on the same day, with inspections now conducted under Compliance Program 7382.850. ### What is 21 CFR 820.35 under the QMSR? It is a records requirement within the amended Part 820, addressing device-specific records the FDA retains beyond what ISO 13485 specifies. It is not a restatement of design controls, and cybersecurity procedures that cite it as though it were the design control clause are citing it incorrectly. ### Where should security requirements live in an ISO 13485 system? In the design inputs, traced to design outputs and to verification evidence, exactly as any other requirement. Security requirements that exist only in a threat model or a security plan, without entering the design input set, break the traceability chain that both submissions and inspections depend on. ### How does vulnerability handling fit into CAPA? A vulnerability discovered after release is a nonconformity and should enter the CAPA process, with investigation, risk assessment, corrective action, and effectiveness verification. Running a separate security incident process that never feeds CAPA leaves the quality system without a record of the issue and is a recognizable inspection finding. ### Do we need to rewrite our cybersecurity procedures? Usually you need to re-cite and re-map them rather than rewrite them. The activities that were appropriate before remain appropriate. What needs correcting are references to Part 820 subparts that are now reserved, terminology that differs from ISO 13485, and any place where security work sits outside the quality system's traceability and CAPA structure. ## Make the Quality System Match the Security Work If your cybersecurity documentation still describes the old Part 820 structure, we can help you map it into ISO 13485 without disrupting the work itself. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## Medical Device Threat Modeling: FDA Guide | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices # Medical Device Threat Modeling: A Step-by-Step Guide > **[DIRECT ANSWER]** Medical device threat modeling is the structured process of scoping a system, mapping its data flows and trust boundaries, enumerating threats with a method like STRIDE, and rating each threat against patient harm rather than CVSS alone. The output is a traceable set of security requirements, mitigations, and verification tests. The FDA's February 3, 2026 premarket cybersecurity guidance treats this as a design control activity that must exist before submission, not a document assembled to satisfy a checklist afterward. _Reviewed September 17, 2026_ A vulnerability in a hospital billing system leads to a data breach and a regulatory fine. The same class of vulnerability in an implantable cardiac device's telemetry link can let an attacker alter therapy delivery. Medical device threat modeling exists to catch that second category before it ships, and the FDA now expects to see the work, not just the conclusion. Manufacturers that treat threat modeling as a paperwork exercise tend to submit models with partial STRIDE coverage, missing trust boundaries, and no link between a threat and an actual mitigation. Those gaps show up as Major deficiencies during premarket review, often adding months to a submission cycle. This guide walks through the practical steps: scoping, diagramming, applying STRIDE, rating harm with ISO 14971, deriving requirements, and building the traceability a reviewer expects to see. ## Key Takeaways - Medical device threat modeling must scope the full system, including the implant, programmer, mobile app, cloud, and every network path between them. - Data flow diagrams with explicit trust boundaries are the foundation; every boundary needs full STRIDE coverage, not a sample of it. - Risk should be rated against ISO 14971 patient harm categories, not CVSS scores alone, because CVSS was built for IT assets, not clinical outcomes. - Every threat must trace forward to a security requirement, a mitigation, and a verification test that a reviewer can follow end to end. - The FDA's February 3, 2026 premarket cybersecurity guidance expects the threat model as a design input artifact, not a document built after the fact for submission. ## Why This Matters The FDA's premarket cybersecurity guidance, finalized February 3, 2026, applies to any cyber device under Section 524B of the FD&C Act and makes threat modeling a required design control input rather than an optional supporting document. Reviewers now ask for the model itself, along with evidence that it informed architecture and mitigation decisions during development, not just a summary table added before submission. For connected and implantable devices, the stakes are different from a typical enterprise application. A missed threat on a hospital scheduling system causes an operational headache. A missed threat on an insulin pump's wireless command interface or a neurostimulator's programming link can translate directly into patient harm, which is why ISO 14971 risk management sits alongside the security analysis rather than behind it. Manufacturers that start threat modeling early, at architecture definition, generally produce cleaner submissions because the model shapes design decisions instead of documenting them retroactively. Those that wait until the submission deadline tend to discover trust boundaries they never analyzed, third-party components with no documented threat coverage, and mitigations that were never verified with a test. Both AAMI TIR57 and ANSI/AAMI SW96:2023 give manufacturers a recognized structure for connecting the threat model to the risk management file the FDA expects to review. Building the model early, keeping it under version control, and updating it with every architecture or firmware change is the difference between a threat model that supports a submission and one that becomes the reason for a deficiency letter. ## How Do You Scope a Threat Model for a Connected Medical Device? Scoping starts with defining every component that touches the device, not just the device itself. A connected or implantable device threat model has to include the implant or wearable, any external programmer or reader, a companion mobile app, cloud services, hospital network infrastructure, and any third-party components embedded in the software. Teams that scope only the device firmware routinely miss the mobile app's authentication logic or the cloud API that pairs a patient's implant to their clinician's dashboard. Both are common attacker entry points precisely because they are outside the device boundary that engineering teams instinctively focus on. **[KEY REQUIREMENT]** The scope statement in your threat model documentation must list every component, every interface, and every third-party library or platform involved in the system, with a rationale for anything explicitly excluded. Scoping also means defining assets: patient safety functions, protected health information, therapy delivery commands, firmware update mechanisms, and any cryptographic keys or credentials. Each asset becomes an anchor point for the STRIDE analysis in the next step. ## How Do You Build a Data Flow Diagram With Trust Boundaries? A data flow diagram maps how information moves between components, and trust boundaries mark every point where that data crosses into a domain with a different level of trust. For a connected implantable, that typically includes the implant-to-programmer wireless link, the programmer-to-cloud connection, the mobile app-to-cloud API, and the cloud-to-clinician-portal boundary. Each boundary needs to be drawn explicitly, not implied. Reviewers checking a submission's threat model look for a diagram where every arrow crossing a boundary line has a corresponding STRIDE entry; a diagram without visible trust boundaries is one of the more common reasons a threat model gets flagged as incomplete. | Diagram element | What it represents | Why it matters for review | |---|---|---| | Process | A component that transforms or acts on data (firmware, app logic, cloud service) | Anchors STRIDE categories to a specific piece of code | | Data store | Where data rests (implant memory, mobile app storage, cloud database) | Highlights tampering and disclosure risk at rest | | Data flow | Data in transit between components | Highlights tampering, spoofing, and denial of service in transit | | Trust boundary | A line where trust level changes | Forces explicit analysis of every crossing point | ## How Do You Apply STRIDE to a Medical Device System? STRIDE works by walking every trust boundary and asking whether each of six threat categories, spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege, applies to that crossing. The output is a threat register, not a narrative document, with one row per identified threat. Applying STRIDE consistently across a system with an implant, a programmer, and a mobile app means repeating the six categories at every boundary rather than applying them once to the system as a whole. Skipping categories at any boundary, even ones that seem low risk, is the fastest way to leave a gap a reviewer will find. **[KEY REQUIREMENT]** Every trust boundary in the data flow diagram must have all six STRIDE categories evaluated and documented, even where the conclusion is "not applicable," with a stated reason. | STRIDE category | Example threat at implant-programmer boundary | Typical control | |---|---|---| | Spoofing | Unauthorized programmer impersonates a legitimate clinician device | Mutual authentication with device-specific credentials | | Tampering | Therapy commands altered in transit over the wireless link | Signed and encrypted command payloads | | Repudiation | No record of who reprogrammed the device or when | Signed audit logs stored outside the implant | | Information disclosure | Patient telemetry data readable by a nearby unauthorized receiver | Encryption of the wireless link, minimized transmission range | | Denial of service | Flooding the wireless interface to block legitimate programming sessions | Rate limiting and session timeout on the radio interface | | Elevation of privilege | Patient-level app gains clinician-level programming access | Role-based access control enforced server-side, not client-side | For related coverage of alternative threat modeling methods and how they compare, see [Comparing DREAD, STRIDE, and PASTA Threat Models](/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective) and [FMEA vs Threat Modeling for Medical Devices](/blog/fmea-vs-threat-modeling-medical-devices). ## Why Rate Risk Against Patient Harm Instead of CVSS Alone? CVSS scores technical severity, but it was built for general IT systems and does not account for clinical consequence, so a medical device threat model needs an ISO 14971-based harm rating layered on top of it. A vulnerability with a moderate CVSS score can carry a severe harm rating if it affects therapy delivery, while a high CVSS score on a component with no patient safety impact may warrant a lower priority. ISO 14971 asks two questions for every identified threat: what is the severity of harm if this is exploited, and what is the probability of that harm occurring. Multiplying or combining those two factors, per your risk matrix, produces the risk level that actually drives mitigation priority, and AAMI TIR57 and ANSI/AAMI SW96:2023 describe how to connect that scoring back to the security risk assessment the FDA reviews. | Rating dimension | CVSS alone | ISO 14971 harm-based | |---|---|---| | What it measures | Technical exploitability and impact | Clinical severity and probability of patient harm | | Origin | General IT and software vulnerability scoring | Medical device risk management standard | | Blind spot | Ignores whether the affected function touches patient safety | Requires clinical input to score accurately | | FDA expectation | Supplementary technical context | Primary basis for mitigation prioritization | ## How Do You Derive Security Requirements and Build Traceability? Every threat in the register needs to produce at least one security requirement, and every requirement needs a mitigation and a verification test, forming a chain a reviewer can follow from threat to test result. Without that chain, a reviewer cannot confirm that an identified risk was actually addressed rather than just documented. A traceability matrix is the standard way to show this: columns for threat ID, STRIDE category, harm rating, security requirement, implemented control, and verification test result. Manufacturers that maintain this matrix as a living document, updated whenever architecture or firmware changes, avoid the scramble of reconstructing traceability right before submission. **[KEY REQUIREMENT]** Every entry in the threat register must trace forward to a documented security requirement and a verification test result before the threat model is considered submission-ready. ## What Does the FDA Expect to See in the Submission? The FDA expects a threat model that reads as a design artifact, complete with a documented scope, a data flow diagram with trust boundaries, full STRIDE coverage, harm-based risk ratings, and a traceability matrix connecting threats to mitigations and tests. The February 3, 2026 premarket cybersecurity guidance describes this as an expected component of the cybersecurity documentation accompanying a 510(k), De Novo, or PMA submission. Reviewers also look for evidence that the model was maintained through development rather than created once at the end. A version history showing updates tied to architecture changes, added third-party components, or new interfaces demonstrates that the threat model actually functioned as a design input. ## A Worked Example: Implantable Device With Clinician Programmer and Mobile App Consider an illustrative, generic implantable neurostimulator system with three components: the implant itself, a clinician programmer used during in-office visits, and a patient-facing mobile app that adjusts therapy within physician-set limits. This example is not based on any real product or customer; it is meant to show the process end to end. Scoping identifies the implant, programmer, mobile app, a cloud backend that syncs settings, and the wireless links connecting each. The data flow diagram places trust boundaries at the implant-to-programmer link, the programmer-to-cloud connection, and the mobile app-to-cloud API. Applying STRIDE at the implant-to-programmer boundary surfaces a spoofing threat, an unauthorized programmer could attempt to pair with the implant, rated as high harm under ISO 14971 because a successful pairing could allow unauthorized therapy changes. That threat drives a security requirement for mutual, cryptographic device authentication before any programming session, a mitigation implemented in the pairing protocol, and a verification test confirming that a programmer without valid credentials cannot establish a session. The same pattern repeats at each boundary: a spoofing threat at the mobile app login surfaces a requirement for multi-factor authentication, and a tampering threat on the cloud sync surfaces a requirement for signed configuration payloads. The resulting traceability matrix, in this illustrative case, would show three boundaries, roughly a dozen STRIDE entries, and a requirement, mitigation, and test for each one flagged above the acceptable risk threshold. ## How Blue Goat Cyber Approaches This Blue Goat Cyber builds threat models for connected and implantable device manufacturers that are structured for FDA review from the start: scoped data flow diagrams, full STRIDE coverage at every trust boundary, ISO 14971 harm ratings, and a traceability matrix linking threats to requirements and verification tests. The work is done alongside engineering teams during architecture definition, not retrofitted before a submission deadline. For manufacturers looking for this as an ongoing service rather than a one-time deliverable, see [Threat Modeling Services](/services/medical-device-threat-modeling), which covers initial modeling, updates through the design lifecycle, and submission-ready documentation packages. ## Frequently Asked Questions ### Is STRIDE required by the FDA? The FDA does not mandate STRIDE by name, but its premarket cybersecurity guidance expects a structured threat categorization method, and STRIDE is the most commonly used and recognized approach in medical device submissions. Whatever method a manufacturer chooses, it needs to demonstrate coverage of every trust boundary and trace each threat to a mitigation. ### How is medical device threat modeling different from IT threat modeling? The core method, scoping, diagramming, and categorizing threats, is similar, but medical device threat modeling adds an ISO 14971 harm rating layer tied to patient safety outcomes. IT threat modeling typically stops at technical impact, while medical device work has to connect each threat to a clinical consequence. ### When should threat modeling start in the development lifecycle? Threat modeling should start at architecture definition, before major design decisions are locked in, so the model can actually influence choices about authentication, encryption, and interface design. Starting it just before submission usually means findings arrive too late to fix without a redesign. ### How often does a threat model need to be updated? A threat model needs to be updated whenever the architecture changes, a new interface or third-party component is added, or firmware is significantly revised. Treating it as a version-controlled living document, rather than a static file, keeps it aligned with what reviewers expect to see reflected in the current design. ### Does a low-risk device still need a full threat model? Yes, though the depth of analysis can scale with the device's risk classification and connectivity. Even a device with limited connectivity still needs a documented scope, trust boundary analysis, and a rationale for why certain STRIDE categories were deemed low risk or not applicable. ## Related Reading - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices): the pillar guide behind this walkthrough. - [Comparing DREAD, STRIDE, and PASTA threat models](/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective): how the common methodologies differ in practice. - [Threat trees vs attack trees in FDA submissions](/blog/exploring-the-contrast-between-threat-trees-and-attack-trees-in-medical-device-fda-approval-and-cybersecurity): when each diagram earns its place in the documentation. ## CTA If your team needs a threat model built to support an upcoming premarket submission or to close a cybersecurity deficiency, [talk to Blue Goat Cyber](/contact) about scoping the work, from data flow diagrams through traceability documentation. Christian Espinosa is the founder of Blue Goat Cyber and writes on medical device cybersecurity, threat modeling, and FDA premarket strategy. Read more from him at [his author page](/christian-espinosa). --- ## AAMI TIR57 vs TIR97 vs SW96 Source: https://bluegoatcyber.com/blog/aami-tir57-vs-tir97-vs-sw96-medical-device-cybersecurity # AAMI TIR57 vs TIR97 vs SW96: What Medical Device Teams Need to Know > **[DIRECT ANSWER]** AAMI SW96 is the FDA-recognized consensus standard for medical device security risk management and should anchor a submission, while TIR57 provides the practical premarket how-to for building threat models and risk files, and TIR97 covers postmarket vulnerability triage and disclosure once a device is fielded. Under the FDA's February 3, 2026 guidance and Section 524B, teams should cite SW96 as primary, supported by TIR57 for design and TIR97 for maintenance. _Last updated: May 2026_ Three documents from AAMI keep getting conflated in FDA submissions: **TIR57**, **TIR97**, and **SW96**. They cover overlapping ground but solve different problems, and citing the wrong one (or only one) is a frequent cause of cybersecurity deficiency letters under the FDA's February 2026 final guidance and Section 524B of the FD&C Act. This post is the short version: what each document does, where it applies in the lifecycle, what the FDA actually recognizes, and how to stack them in a working Secure Product Development Framework (SPDF). ## Key Takeaways - AAMI SW96 is the FDA-recognized standard for medical device cybersecurity risk. - AAMI TIR57 guides premarket security risk management processes. - AAMI TIR97 addresses postmarket vulnerability and disclosure for devices. - SW96 integrates security risk management into ISO 14971 framework. - For new FDA submissions, typically cite SW96, TIR57, and TIR97. - Do not cite TIR57 alone for premarket cybersecurity risk management. ## Why this matters Misunderstanding the roles of AAMI TIR57, TIR97, and SW96 is a frequent cause of cybersecurity deficiency letters from the FDA. Under the FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, and Section 524B of the FD&C Act, manufacturers must demonstrate a rigorous approach to device security throughout the product lifecycle. All three appear in the FDA Recognized Consensus Standards Database, but only SW96 is a consensus standard rather than an informative Technical Information Report, which is why it is the one to cite as the governing security risk-management framework aligned with ISO 14971 and IEC 62304. Citing only TIR57 for premarket risk management, or neglecting TIR97 for postmarket concerns, is insufficient. Proper layering of these standards, with SW96 as the guiding framework, supported by TIR57 for development and TIR97 for maintenance, is critical for achieving regulatory compliance and ensuring patient safety against evolving cyber threats. Incorrect or incomplete standard adoption can delay market access and incur significant remediation costs. ## TL;DR comparison | Dimension | AAMI TIR57:2016 (R2023) | AAMI TIR97:2019 | AAMI SW96:2023 | | --- | --- | --- | --- | | Type | Technical Information Report (TIR) | Technical Information Report (TIR) | Consensus standard | | Title (short) | Principles for medical device security - risk management | Principles for medical device security - postmarket risk management | Standard for medical device security - security risk management | | Lifecycle stage | Premarket (design and verification) | Postmarket (fielded and legacy devices) | Whole lifecycle | | FDA recognition | Recognized (recognition number 13-83), but as an informative TIR | Recognized (recognition number 13-112), as an informative TIR | **Recognized (recognition number 13-131) and the only one of the three that is a consensus standard** | | Relationship to ISO 14971 | Implementation guide that applies ISO 14971 to security | Extends TIR57 thinking into postmarket | Formalizes TIR57 concepts and aligns with ISO 14971 and IEC 62304 | | Best use today | Internal "how-to" for the security risk process | Postmarket vulnerability triage and CVE handling on fielded devices | Cite this as your primary security risk-management standard in the submission | ## What each document actually covers ### AAMI TIR57:2016 (R2023) - the original "how-to" TIR57 is the practical guide that introduced the medical-device industry to **applying ISO 14971 risk-management discipline to cybersecurity**. It defined the now-standard pattern of: threats → security capabilities → controls → verification → residual security risk It is still the most useful reference for *how* to actually run threat modeling, build a security risk file, and document residual risk. TIR57 is on the FDA's Recognized Consensus Standards Database (recognition number 13-83), but the recognition entry itself carries an FDA note that conformance to TIR57 may not satisfy the requirements of Section 524B or the recommendations in the premarket cybersecurity guidance. It is an informative TIR, not a normative standard, so citing TIR57 alone in a 2026 submission is no longer enough. ### AAMI TIR97:2019 - the postmarket companion TIR97 fills the gap TIR57 left open: **what do you do once the device is fielded?** It covers: - Triage of newly disclosed vulnerabilities (CVEs) against fielded devices - Postmarket security risk reassessment when a SBOM component changes - Coordinated Vulnerability Disclosure (CVD) intake and response - Decision-making for patch, mitigate, accept, or end-of-life If your postmarket cybersecurity plan does not reference TIR97, FDA reviewers and Notified Bodies often flag it. It is the standard companion to a postmarket vulnerability management process and aligns with the FDA's postmarket cybersecurity guidance and Section 524B(b)(2) obligations. ### AAMI SW96:2023 - the consensus standard SW96 is the **consensus standard** that pulls TIR57's concepts into a formal, auditable framework aligned with **ISO 14971** (general risk management) and **IEC 62304** (software lifecycle). Key things SW96 does that the TIRs do not: - Defines normative requirements (not just recommendations) for the security risk-management process - Maps explicitly to ISO 14971 clauses so security risk is a true subset of the device risk file - Provides a formal definition of "security risk" distinct from safety risk, while keeping the two linked - **Is on the FDA Recognized Consensus Standards Database (recognition number 13-131)** - meaning a Declaration of Conformity to SW96 carries regulatory weight In our practice, SW96 is now the primary standard to cite in the cybersecurity section of a 510(k), De Novo, or PMA submission. TIR57 and TIR97 are still useful as the underlying "how-to" references, but they sit *under* SW96, not in front of it. > **Aligning a threat model with AAMI TIR57?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Threat modeling services](/services/medical-device-threat-modeling) ## How they stack in a real SPDF program A 2026-ready cybersecurity package usually looks like this: 1. **ISO 14971** - the device-level risk management standard. Security risk is a subset of overall risk. 2. **AAMI SW96** - the security risk-management standard you cite formally in the submission. Drives traceability from threat → control → verification → residual risk. 3. **AAMI TIR57** - your internal reference for *how* to run the SW96-required activities (STRIDE-style threat enumeration, control selection, residual-risk argument). 4. **AAMI TIR97** - your postmarket process: CVE triage, CVD intake, patch decisions, SBOM monitoring. 5. **IEC 81001-5-1** - security activities embedded in the software lifecycle (pairs with IEC 62304). 6. **NIST SP 800-218 (SSDF)** - secure development practices reviewers increasingly expect to see referenced. Citing only one or two of these is a common deficiency pattern. Citing all of them - and being clear about which is the formal standard (SW96, IEC 81001-5-1) vs which is implementation guidance (TIR57, TIR97) - is what mature submissions look like. ## Common mistakes we see - **Citing TIR57 alone.** Common in submissions written against the 2014 or 2018 guidance and never refreshed. Reviewers now expect SW96 as the primary security risk standard. - **No postmarket reference to TIR97.** Postmarket plans default to generic "we will monitor CVEs" language; TIR97 gives you the structured process FDA reviewers (and Notified Bodies for EU MDR) actually want to see. - **Treating SW96 as a swap-in for ISO 14971.** SW96 *complements* ISO 14971; it does not replace it. The device risk file still lives under ISO 14971, with security risk as a traceable subset. - **Buying the wrong edition.** TIR57:2016 was reaffirmed in 2023 (TIR57:2016/(R)2023). The technical content is unchanged; the (R)2023 indicates current applicability. SW96 is dated 2023 and is the first edition. ## What the FDA actually wants From the **FDA's February 2026 final guidance** on cybersecurity in medical devices (and consistent with Section 524B): - A **documented security risk-management process** integrated with ISO 14971 - SW96 is the cleanest way to demonstrate this. - **Traceability** from threats through controls to verification evidence and residual risk - the SW96/TIR57 spine. - A **postmarket plan** that covers monitoring, CVD, patching, and end-of-life - where TIR97 earns its keep. - **SBOM** (CycloneDX or SPDX) maintained across the lifecycle, with vulnerability handling tied to the security risk file. Reviewers do not score you on which TIR you cite. They score you on whether the process is real, the evidence is traceable, and the postmarket plan is operable. The three AAMI documents above are the most efficient way to demonstrate all three. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers navigate the complexities of AAMI TIR57, TIR97, and SW96, ensuring alignment with the FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026. Our team, comprised of professionals with CISSP and OSCP certifications and backgrounds including ex-military red team operations, develops and implements practical Secure Product Development Frameworks. We integrate these standards into your existing quality management systems, focusing on efficiency and compliance. Our methodology ensures that your cybersecurity documentation meets regulatory expectations, preventing costly deficiencies. We assist with premarket submissions, postmarket vulnerability management, and everything in between. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Visit our services at [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for tailored support. ## FAQ ### Do I need to cite all three (TIR57, TIR97, SW96) in my FDA submission? For a 2026 submission, cite **SW96** as your primary security risk-management standard (it is FDA-recognized), reference **TIR57** as the implementation guide your team follows, and cite **TIR97** in the postmarket plan. Citing only TIR57 is a common cause of deficiency letters. ### Is AAMI SW96 mandatory for FDA submissions? No standard is strictly *mandatory* under Section 524B, but SW96 is on the FDA Recognized Consensus Standards Database and is the cleanest way to demonstrate that your security risk-management process meets the agency's expectations. A Declaration of Conformity to SW96 carries real weight in the cybersecurity section. ### What is the difference between AAMI SW96 and ISO 14971? ISO 14971 is the device-level risk-management standard covering all risk (safety, usability, security). AAMI SW96 is the security-specific risk-management standard that integrates with ISO 14971 - your overall risk file lives under ISO 14971, and your security risk file lives under SW96 as a traceable subset. ### How is AAMI TIR97 different from TIR57? TIR57 covers the *premarket* security risk-management process - threat modeling, control selection, verification, residual risk. TIR97 covers the *postmarket* equivalent - CVE triage, SBOM monitoring, CVD intake, patch decisions across fielded and legacy devices. ### Has TIR57 been replaced by SW96? TIR57 has not been withdrawn; it was reaffirmed as TIR57:2016/(R)2023. SW96 formalizes and supersedes much of TIR57's content into a consensus standard, but TIR57 remains useful as the implementation guide. Most mature programs use both. ## Where this fits If you are building or refreshing your cybersecurity submission package, the three AAMI documents above are foundational. See also: - [AAMI TIR57 (R2023): Cybersecurity Risk Management for Medical Devices](/guides/aami-tir57-vs-tir97-comparison) - [The MedTech Cybersecurity Standards Decoder](/guides/the-medtech-cybersecurity-standards-decoder) - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Patient Safety Threat Modeling](/guides/patient-safety-threat-modeling) - [Threat Model Starter (free tool)](/tools/threat-model-starter) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Abuse & Misuse Testing Source: https://bluegoatcyber.com/blog/abuse-and-misuse-cases-testing-medical-devices-with-malformed-and-unexpected-inputs # Abuse and Misuse Cases: Testing Medical Devices with Malformed and Unexpected Inputs > **[DIRECT ANSWER]** Abuse and misuse testing means deliberately feeding a medical device malformed, unexpected, or intentionally hostile inputs, like negative dosages, oversized messages, malformed packets, or misconfigured settings, to confirm it fails safely instead of producing hazardous behavior. Abuse cases model intentional misuse, misuse cases model user error, and both must trace to documented hazards. The FDA's February 3, 2026 guidance treats this testing as a gating requirement under Section 524B, not an optional checklist item. Medical devices do not fail only under idealized lab conditions. They fail when users enter bad data, when software receives something it did not expect, and when real-world behavior collides with design assumptions. That is why abuse cases, misuse cases, malformed inputs, and unexpected inputs belong in the same test strategy. If you are building for patient safety and preparing for the FDA, this is not extra credit. It is part of the job. ## Key Takeaways - Abuse cases involve intentional actions beyond intended use. - Misuse cases focus on unintentional user errors or environmental factors. - Malformed inputs can cause crashes, data corruption, or unsafe therapy. - Unexpected inputs expose hidden design assumptions and vulnerabilities. - Strong testing requires scenario development from hazards and real workflows. - Devices must be designed to fail safely, with early input validation. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to abuse and misuse cases the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Abuse Cases, Misuse Cases, and Why the Difference Matters In medical device testing, “abuse” and “misuse” are related but not interchangeable. Both push a device outside normal operation. The difference is intent. ### Abuse cases Abuse cases involve intentional actions outside intended use that can stress, damage, or destabilize the device. A dropped monitor, a connector forced into the wrong port, repeated power cycling, or operation outside environmental limits all fit here. These scenarios help manufacturers find design weaknesses before those weaknesses show up in the field. If a device is dropped from a realistic height, does it fail safely? If moisture exposure or heat affects a component, does the device degrade predictably or produce hazardous behavior? Those are not edge questions. They are practical ones. Abuse testing should also include cyber-relevant behaviors. What happens when a system receives traffic at abnormal rates, malformed packets, or repeated authentication attempts? Even when the action is not part of intended clinical use, the device still needs a safe response. ### Misuse cases Misuse is usually unintentional. A clinician may configure a setting incorrectly. A patient may misunderstand an alert. A technician may connect accessories in the wrong order or enter values in the wrong units. A familiar example is an infusion pump programmed with the wrong dose due to confusing workflow, poor input validation, or unclear UI design. In that case, the problem is not just user error. It is also a design and testing problem. Misuse testing helps answer hard questions early: - How easy is it to enter invalid values? - Are unit conversions clear? - Can a user recover from a mistake without creating risk? - Does the device explain what went wrong in a way that supports safe action? This is where cybersecurity and usability overlap. A device that handles user error poorly will often handle malformed software input poorly too. ## Malformed Inputs Are a Safety and Security Problem Testing against [malformed inputs](/blog/medical-device-sql-injection-parameterized-queries) is basic engineering discipline. Users mistype values. Integrated systems send incomplete messages. Sensors drift. Interfaces receive out-of-range data. Attackers do all of that on purpose. ![Section Image](/imported-images/94e856edfd808920.png) ### What can go wrong A malformed input might be as simple as a negative dosage value, alphabetic characters in a numeric field, an oversized message, a truncated packet, or unexpected encoding. Any of those can trigger unsafe behavior if the software assumes inputs are always valid. The consequences vary by device, but the pattern is familiar: - incorrect therapy delivery - device lockup or crash - silent data corruption - misleading alarms or missing alarms - denial of service at the point of care Too many teams treat this as a software quality issue only. It is not. If malformed input can affect therapy, alarms, logging, communications, or clinical decision support, it is a patient safety issue and a cybersecurity issue. ### What good handling looks like Safe devices do not just reject bad input. They reject it predictably, log it appropriately, preserve essential functions, and communicate clearly to the user or connected system. That means testing for: - boundary values - type mismatches - invalid ranges - missing required fields - duplicate or replayed messages - truncated or fragmented communications - corrupted files, firmware packages, or update metadata If your device interoperates with other systems, this matters even more. Real environments are messy. Data arrives late, incomplete, out of order, or wrapped in assumptions your software team never intended to support. ## Unexpected Inputs Expose Bad Assumptions Unexpected input is not always malformed. Sometimes the data is technically valid but operationally surprising. A monitoring device may receive a value sequence that is plausible in format but impossible physiologically. A sensor may produce noisy transitions during startup. A software update may change timing, field order, or error behavior in a connected component. These are the cases that often escape checklist testing. ### Why this is hard Unexpected inputs usually reveal hidden assumptions in the design: - a value will arrive within a certain time window - a sensor will fail in one known way - a user will follow a single workflow - an upstream system will always send complete data - a field marked optional will almost never be empty Those assumptions hold until they do not. Then the device does something unsafe, confusing, or both. A good test program looks for these gaps on purpose. It does not stop at “valid” and “invalid.” It asks how the device behaves when reality gets strange but not impossible. ### Practical ways to test for the unexpected Manufacturers should build error handling into the design, then verify it under realistic stress. That may include visual alerts, audible alarms, haptic feedback, safe-state transitions, rate limiting, retry limits, or degraded modes that preserve essential safety functions. It also means learning from actual use. Post-market data, complaint trends, support tickets, human factors findings, and field service observations should feed back into test case updates. If users keep finding a confusing path, or integrators keep sending odd traffic, that belongs in verification. Collaboration matters here too. Engineers, clinicians, quality, regulatory, service teams, and security testers all see different failure modes. If only one group defines the test scenarios, blind spots are guaranteed. ## Building a Test Process That Finds Real Problems ![Section Image](/imported-images/3143ac2d2608b260.png) A useful abuse and misuse test process starts before formal verification. It begins with scenario development tied to hazards, architecture, interfaces, and real workflows. ### Identify realistic scenarios Start with a structured “what could actually happen” exercise. Use prior failures, complaint data, threat modeling, human factors work, service records, and architecture review. Include [abuse and misuse scenarios](/blog/abuse-and-misuse-cases-testing-medical-devices-with-malformed-and-unexpected-inputs) that span users, maintainers, connected systems, and adversarial behavior. [Tabletop exercises](/blog) can help if they are done seriously. The goal is not brainstorming for its own sake. The goal is to identify conditions that could cause loss of essential performance, unsafe therapy, misleading information, or loss of availability. Good scenarios often include combinations, not single errors. For example: - a user enters an out-of-range value while network connectivity is unstable - a device reboots during data synchronization - a sensor fault coincides with an alarm acknowledgment - a malformed network message arrives during a software update That is where weak assumptions tend to surface. ### Test across methods, not just one environment Once scenarios are defined, test them with more than one method. Simulation is useful. Bench testing is useful. Fuzzing can be useful. Integrated system testing is useful. Realistic workflow testing with representative users is useful. None of them is enough alone. For connected devices, malformed and unexpected input testing should include interface-level evaluation, not just UI fields. That means network protocols, APIs, wireless stacks, file imports, update paths, maintenance ports, and third-party integrations. And yes, safety still comes first during testing. But “safe” should not mean “so constrained that nothing interesting happens.” If your process cannot expose unstable behavior, it is not telling you much. ## Designing Devices to Fail Safely ![Section Image](/imported-images/4d6629c9064924ab.png) You cannot test your way out of weak architecture. Devices need to be designed with failure handling in mind from the start. ### Design principles that matter Strong designs do a few things well: - validate inputs early and often - separate untrusted input from safety-critical logic - apply sane bounds checking and type enforcement - fail to a known safe state when needed - preserve logs and forensic value - provide clear, actionable user feedback - prevent a single bad input from cascading through the system For example, if a device detects a voltage anomaly, communication fault, or invalid command, it should not silently continue as if everything is fine. It should alert appropriately, contain the issue, and protect essential functions. This is also where anti-checklist thinking matters. Saying “input validation implemented” is meaningless unless you can show how it behaves under stress, across interfaces, and in combinations of failure conditions. ### Keep test cases alive after release Testing does not stop at launch. User behavior changes. Clinical environments change. Connected ecosystems change. Threats change. The FDA expects post-market vigilance, and so should you. Update test cases based on: - field incidents and complaints - security research and vulnerability disclosures - software changes and new integrations - human factors findings - protocol and infrastructure changes in deployed environments This feedback loop is not administrative overhead. It is how you keep a device safe and defensible over time. ## Where Testing Is Going Next The testing toolbox is improving, but the goal is still the same: find unsafe behavior before it reaches patients. ### Better tools, same accountability Automation, AI-assisted test generation, and machine learning can help teams cover more scenarios faster. They can surface strange combinations humans might miss. Virtual environments can also improve workflow and training validation before live evaluation. [Artificial intelligence and machine learning](/blog) may speed up scenario generation, but they do not replace engineering judgment. Someone still has to decide what matters for safety, what constitutes acceptable behavior, and what evidence will stand up in design review or an FDA submission. The same applies to connected care. As [IoT (Internet of Things)](/blog/cybersecurity-for-medical-devices-with-narrowband-iot-protocol) functionality expands, test scope expands with it. More connectivity means more input paths, more dependencies, and more ways for malformed or unexpected data to create downstream risk. ### Regulatory expectations are not standing still As technology changes, regulatory expectations keep moving. Manufacturers need to track FDA guidance, understand what the FDA will expect in premarket documentation, and show that cybersecurity and safety testing are connected rather than siloed. That includes evidence that abuse cases, misuse cases, malformed inputs, and interface failures were considered in a risk-based way. It also means being ready to explain why your test coverage reflects actual device behavior, not just a generic template. Medical device testing gets better when it stops pretending users, environments, and integrated systems will behave perfectly. They will not. Devices need to handle the wrong input, the strange input, and the hostile input without creating unacceptable risk. That takes disciplined engineering, realistic test design, and post-market follow-through. If your current process only proves the device works when everything goes right, it is not enough. As you evaluate abuse cases, misuse cases, and malformed input handling, do not treat cybersecurity as a separate workstream. It is part of device safety, part of design validation, and part of what the FDA will expect to see when software behavior can affect clinical outcomes. Blue Goat Cyber helps manufacturers test the failure paths that matter, align evidence with FDA expectations, and improve device resilience before review or release. [Contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Our approach to medical device testing for abuse and misuse cases focuses on identifying critical failure points and ensuring safe states. We employ a structured methodology, drawing on extensive experience in cybersecurity to simulate realistic threat scenarios and user errors. Our team, composed of professionals with CISSP and OSCP certifications, including former military red team members, understands how to uncover vulnerabilities that typical testing might miss. We implement a focused strategy for input validation and error handling, ensuring devices behave predictably under duress. This includes detailed analysis of data flows and interface interactions. We provide guidance through the regulatory submission process, specializing in addressing the stringent requirements of the FDA. Should the FDA raise cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to identify and address complex issues early, reducing risk and accelerating market readiness. Learn more about our services at: /services/fda-premarket-cybersecurity-services. ## FAQ ### What is the difference between an abuse case and a misuse case in medical device testing? An abuse case involves intentional actions outside the device's intended use, often stressing its limits or attempting to cause harm (e.g., cyberattack simulation, physical drops). A misuse case involves unintentional actions by a user or environmental factors that lead to incorrect operation (e.g., incorrect settings input, misinterpreting an alert). ### Why are malformed inputs a safety and security problem for medical devices? Malformed inputs, such as negative dosage values or oversized network packets, can cause medical devices to crash, deliver incorrect therapy, corrupt data silently, or become unresponsive. This poses direct patient safety risks and creates cybersecurity vulnerabilities that can be exploited by attackers. ### How does the FDA view abuse and misuse testing for medical devices? The FDA expects medical device manufacturers to consider and test for abuse, misuse, and cybersecurity vulnerabilities as part of their risk management and design validation processes. The February 3, 2026 final guidance emphasizes the need for devices to handle both intended and reasonably foreseeable unintended uses safely, including those related to cybersecurity. ### What are some examples of unexpected inputs in medical device testing? Unexpected inputs are not always malformed but are operationally surprising, revealing hidden design assumptions. Examples include a monitoring device receiving physiologically impossible but validly formatted data, a sensor producing noisy transitions during startup, or an upstream system sending data out of sequence. ### How can manufacturers build a strong test process for abuse and misuse cases? Manufacturers should start by identifying realistic scenarios based on prior failures, threat modeling, and human factors. They should test across various methods (simulation, bench testing, fuzzing), include interface-level evaluations for connected devices, and maintain an active feedback loop from post-market data and security research. ### What design principles help devices fail safely when confronted with bad inputs? Key design principles include validating inputs early and often, separating untrusted input from safety-critical logic, applying sane bounds checking, failing to a known safe state, preserving logs for forensics, and providing clear user feedback. These measures prevent single bad inputs from cascading into system-wide failures. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## AI Overfitting in Medical Devices Source: https://bluegoatcyber.com/blog/ai-overfitting-cybersecurity-threats-in-medical-devices # AI Overfitting in Medical Device Cybersecurity > **[DIRECT ANSWER]** AI overfitting happens when a medical device's model memorizes its training data instead of generalizing, so it performs well in testing but misreads real-world patients outside that narrow dataset, risking misdiagnosis and creating exploitable behavior an attacker can trigger with unexpected inputs. Manufacturers should use diverse training data, rigorous validation, and lifecycle monitoring aligned with the FDA's February 3, 2026 cybersecurity guidance and standards like ISO 14971 and AAMI SW96 to mitigate the risk. Artificial Intelligence (AI) has transformed numerous sectors, including healthcare. However, it brings inherent vulnerabilities. One such vulnerability is AI overfitting, a phenomenon that deserves attention. Understanding it is crucial for effective application in medical devices. ## Key Takeaways - AI overfitting in medical devices compromises real-world accuracy. - Overfitting occurs due to complex models or narrow training data. - Such models create exploitable vulnerabilities for cyberattacks. - The FDA February 2026 guidance addresses cybersecurity for AI. - Diverse data and validation reduce overfitting risk. - Integrating security into AI design is now essential. ## Why this matters The consequences of AI overfitting in medical devices are severe, ranging from device malfunction and patient endangerment to critical data breaches. An overfitted AI model, unable to adapt to novel clinical situations, risks misdiagnosis, delayed treatment, or incorrect therapeutic interventions, directly impacting patient health outcomes. Beyond clinical risks, such models present exploitable vulnerabilities. Threat actors can use the AI's narrow operational parameters, causing denial-of-service, data manipulation, or unauthorized access to sensitive patient data. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes the necessity of security measures for all medical devices, including those incorporating AI. This guidance underscores the importance of addressing AI-specific vulnerabilities like overfitting. Adherence to standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is vital for ensuring the safety and security of AI-driven medical technology, mandating rigorous validation protocols and lifecycle security management. Ignoring these risks undermines patient trust and invites regulatory scrutiny. ## Defining AI Overfitting At its core, AI overfitting occurs when a model learns the fine details of its training data too well. Instead of generalizing from the data, it memorizes it. Imagine teaching a child to recognize animals by showing them only pictures of cats. If they never see a dog but only learn to identify cats, they will struggle when faced with a different creature. This scenario highlights the core issue. An overfitted AI model can perform exceptionally on training data but poorly in real-world applications. This is particularly troubling in medical devices, where the stakes are high, and errors can lead to severe consequences. For instance, a diagnostic tool that has been overfitted to a specific dataset may misinterpret symptoms in patients who do not fit the narrow criteria it was trained on, potentially leading to misdiagnosis or inappropriate treatment plans. ## How Overfitting Occurs in AI Models Overfitting primarily occurs through excessive complexity in a model. Think of a complex recipe that requires an array of rare ingredients. While it may lead to a culinary masterpiece, it often results in a dish overly reliant on those specific, unique components. In AI, this complexity manifests as too many parameters or layers in the model. Another factor is the lack of diversity in training data. If a model repeatedly encounters the same scenarios, it’s likened to a person becoming an expert in a single sport but failing miserably at all others. Such narrow training can leave medical devices blind to varied patient presentations and conditions. Furthermore, the issue of overfitting can be exacerbated by the use of small datasets, which may not capture the full spectrum of variability present in real-world scenarios. For example, a machine learning model trained on a limited number of patient cases may not account for variations in demographics, comorbidities, or even environmental factors, leading to a skewed understanding of health outcomes. ## The Intersection of AI and Medical Devices Artificial Intelligence is rapidly becoming integral to medical devices. From diagnostic imaging technologies powered by AI algorithms to robotic surgical systems, the blend of these two fields could revolutionize healthcare delivery. However, this integration is not without challenges. ### The Role of AI in Modern Medical Devices AI enhances efficiency and accuracy. For instance, machine learning algorithms analyze vast datasets to identify patterns that human specialists might miss. In diagnostic imaging, AI models help radiologists flag malignancies in X-rays or MRIs, striving to catch what the naked eye might overlook. This capability can lead to timely interventions, potentially saving lives. AI enables personalized medicine. By analyzing individual patient data, algorithms can recommend tailored treatment plans. This personalization improves patient outcomes but also amplifies the potential risks associated with overfitting. In addition to imaging and treatment recommendations, AI is also making strides in monitoring patient health through wearable devices. These devices can collect real-time data on various health metrics, such as heart rate, glucose levels, and physical activity. By employing AI algorithms, these wearables can detect anomalies that may indicate a health issue, prompting users to seek medical attention before a condition escalates. This proactive approach empowers patients and reduces the burden on healthcare systems by potentially decreasing emergency visits. ### Potential Risks of AI in Healthcare Despite its advantages, incorporating AI in medical devices can introduce significant risks. Chief among these is the potential for biases in training data. A model trained predominantly on data from a specific demographic may perform poorly for patients outside that group. Consider a medical device that underplays risks for those not well-represented in its training cohort. Lives could hang in the balance. Regulators must tread carefully; poor algorithms derived from flawed models can lead to misdiagnoses and inappropriate treatments. Furthermore, the opacity of some AI systems, often referred to as “black boxes,” complicates the ability of healthcare professionals to understand how decisions are made. This lack of transparency may hinder clinicians’ trust in AI-assisted recommendations, potentially leading to hesitance in adopting these technologies in critical care settings. Additionally, the rapid pace of AI development poses regulatory challenges. Ensuring they meet safety and efficacy standards as algorithms evolve and improve becomes increasingly complex. Regulatory bodies must establish frameworks that assess the initial performance of AI systems and monitor their ongoing effectiveness and safety in real-world applications. This dynamic landscape necessitates a collaborative approach among technologists, healthcare providers, and regulators to ensure that the integration of AI into medical devices enhances patient care without compromising safety. ## Cybersecurity Threats in Medical Devices The digital age has ushered in unprecedented convenience. However, it has also opened up the Pandora’s box of [cybersecurity threats in medical devices](/blog). The stakes are exceptionally high in healthcare, where breaches can have life-or-death implications. ![Section Image](/imported-images/45e7e5e498b645d9.png) ### Common Cybersecurity Vulnerabilities in Medical Devices Medical devices often possess numerous [vulnerable entry points](/blog/cybersecurity-attack-entry-points-for-medical-devices). Consider devices connected to the Internet. They are like open doors inviting potential intruders. Software vulnerabilities, outdated security protocols, and inadequate encryption can all expose sensitive patient data and even manipulate device functionalities. Many medical devices are not regularly updated, creating opportunities for cyber-attackers to exploit known weaknesses. The infamous ransomware attacks show how devastating these vulnerabilities can be. Affected hospitals can find themselves locked out of critical patient data, leading to disastrous delays in treatment. Integrating [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) technology in medical devices has further complicated cybersecurity. With more devices communicating with each other and sharing data, the potential for a cascading failure increases. For example, if a single device is compromised, it may serve as a gateway for attackers to infiltrate other connected systems, amplifying the risk and potential damage across the entire healthcare network. ### The Impact of Cybersecurity Breaches on Patient Safety Cybersecurity breaches in medical devices directly impact patient safety. Imagine a scenario where a hacker breaks into a device controlling drug delivery. The consequences could be catastrophic, resulting in overdose or underdosing scenarios, leading to dire patient harm. Trust between patients and providers is critical. Breaches erode this trust, prompting patients to question the integrity of their care. Every cybersecurity breach carries repercussions-be it operational, financial, or ethical. The psychological toll on patients can also be significant; anxiety over the safety of their treatment and the confidentiality of their medical information can deter individuals from seeking necessary care. This fear can lead to a broader public health issue, where patients avoid medical interventions altogether, exacerbating health crises. The financial implications of a cybersecurity breach can be staggering. Hospitals may face hefty fines, legal fees, and the costs associated with restoring compromised systems. The need for enhanced cybersecurity measures often results in increased operational costs, which can ultimately be passed on to patients in the form of higher medical bills. This cycle of financial strain can create a challenging environment for healthcare providers striving to maintain high standards of care while ensuring the security of their systems. ## AI Overfitting as a Cybersecurity Threat AI overfitting can serve as a gateway for cybersecurity threats in medical devices. When devices cannot generalize data, they become easier targets for cybercriminals. ### How AI Overfitting Exposes Medical Devices to Cyber Threats An overfitted model might produce outputs that appear accurate under certain circumstances but fail when confronted with varied inputs. For hackers, this creates opportunities. They can exploit these weaknesses to launch targeted attacks, exploiting a device’s inability to adapt to new data scenarios. In essence, an overfitted AI model is akin to a fortress with a single weak point. Once breached, a single entry point can allow for an all-access pass to a well-guarded castle-only this castle is a sophisticated medical device harboring sensitive patient data. ### Mitigating the Risks of AI Overfitting in Medical Devices Addressing AI overfitting requires a multifaceted approach. Regularly updating training datasets is essential. Hospitals and developers must ensure that their models continuously learn from diverse data sources, allowing them to adapt to varying patient scenarios. Employing regular validation techniques will help identify when a model is overfitting. Cross-validation, for instance, can help ensure that a model performs well not just on training data but also in real-world situations. This practice mirrors a well-rounded education, enabling better problem-solving when presented with unfamiliar circumstances. ## Future Perspectives on AI and Cybersecurity in Healthcare The future of AI in healthcare is bright but riddled with challenges. The interplay between AI and cybersecurity will shape the next era of medical technology. As new strides in AI are made, a proactive approach to cybersecurity will prove imperative. ![Section Image](/imported-images/4a1b00ee2954993a.png) ### Emerging Trends in AI and Cybersecurity for Medical Devices Emerging trends indicate a growing focus on integrating AI with cybersecurity measures. Developers are starting to embed security within the design of AI systems. Gone are the days when security was an afterthought. Today, it’s becoming the backbone of medical technology. Predictive analytics will play a central role. Future systems will anticipate potential security breaches, allowing for timely countermeasures. The aim is to stay one step ahead of cybercriminals and ensure that medical devices remain safe and effective. ### The Role of Regulation in Ensuring Cybersecurity in AI-Driven Medical Devices Regulation will play a pivotal role in shaping the landscape of AI in healthcare. [Regulatory bodies](https://www.fda.gov/media/184856/download) must establish stringent guidelines that govern AI performance standards and intertwine those standards with cybersecurity imperatives. The unity of these two domains will ensure that medical devices can effectively and safely integrate AI capabilities without inviting unnecessary risks. A collaborative approach among manufacturers, regulators, and healthcare providers is essential to safeguard patients and their data. ## Conclusion As we navigate the complexities of AI in healthcare and confront the cybersecurity challenges it presents, the need for expert guidance and security measures is paramount. Blue Goat Cyber stands at the forefront of medical device cybersecurity, offering unparalleled expertise and services that align with FDA, IEC 62304, and EU MDR requirements. With a proven track record of over 150 successful FDA submissions, our team is equipped with top-tier certifications and a deep understanding of healthcare security. We are committed to ensuring your medical devices meet regulatory standards and maintain cybersecurity resilience throughout their lifecycle. Don’t let AI overfitting compromise your device’s integrity and patient safety. [Contact us today for cybersecurity help](/contact) and secure the future of your medical technology. ## How Blue Goat approaches this Blue Goat Cyber addresses AI overfitting in medical devices by focusing on secure design principles from inception. Our methodology includes thorough threat modeling to identify and mitigate AI-specific vulnerabilities, including those arising from overfitting. We evaluate training data diversity, model validation processes, and the integration of security features within AI algorithms. Our team, comprised of certified professionals (CISSP, OSCP, ex-military red team), brings practical expertise to identify subtle weaknesses. We perform targeted penetration testing and security audits to ensure AI models exhibit reliable performance and resist exploitation. Our services align with regulatory expectations, preparing devices for stringent FDA reviews. We provide services like our in-depth penetration testing. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Our process prioritizes patient safety and data integrity while facilitating market access. ## FAQ ### What is AI overfitting in medical devices? AI overfitting is when a model learns its training data too precisely, losing the ability to generalize to new, unseen patient cases. This can result in accurate performance on test data but poor performance in clinical use. ### How does AI overfitting create cybersecurity risks? An overfitted AI model can be exploited by attackers who identify its specific operational limitations. Its inability to adapt to varied conditions creates predictable weaknesses that can be targeted for unauthorized access or manipulation. ### What causes AI models in medical devices to overfit? Overfitting often results from overly complex models with too many parameters, or from training on datasets that lack diversity and size. This causes the model to memorize specific examples rather than learning general patterns. ### Does the FDA address AI overfitting in its cybersecurity guidance? Yes, the FDA's February 3, 2026 final guidance for medical device cybersecurity emphasizes the importance of evaluating AI/ML-based software for biases and brittleness, which includes mitigating overfitting to ensure safety and effectiveness. ### How can overfitting be prevented in medical device AI? Preventing overfitting involves using larger, more diverse training datasets, applying regularization techniques, and conducting thorough validation with methods like cross-validation to ensure the model generalizes well to new data. ### Why is diverse training data important for medical AI? Diverse training data helps AI models learn from a wide range of patient demographics, conditions, and scenarios. This ensures the model can generalize effectively and avoid biases that could lead to misdiagnosis or ineffective treatment for underrepresented groups. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA & AI Pen Testing for Medical Devices Source: https://bluegoatcyber.com/blog/ai-penetration-testing-medical-devices-fda-limits # Does the FDA Accept AI Penetration Testing for Medical Devices? > **[DIRECT ANSWER]** The FDA's February 3, 2026 premarket guidance neither names nor bans AI-run penetration testing; it requires credible, independent testing with qualified personnel and documented methodology under Section 524B. AI genuinely accelerates reconnaissance, fuzzing, SBOM and CVE correlation, and report drafting, but it cannot satisfy tester-qualification, device-specific clinical context, reproducibility, or hardware-testing requirements on its own. The model that survives review is human-led and AI-augmented, with a named tester signing the report. _Published June 3, 2026_ ## Key Takeaways - The Feb 2026 guidance and Section 524B do not name AI testers. They require credibility, independence, qualified personnel, and documented methodology. - AI is genuinely useful for reconnaissance, fuzzing, SBOM and CVE correlation, payload variation, and report drafting. - AI alone fails on five fronts: accountable tester qualifications, device-specific clinical and protocol context, reproducibility and chain of custody, threat model alignment, and patient safety implications of false negatives. - AI also cannot perform hardware testing. JTAG and SWD probing, firmware extraction, glitching, side-channel analysis, RF testing, and bench setup all require a human at a physical bench with calibrated tooling. - The model that holds up in an FDA submission is human-led, AI-augmented, with a named tester signing the report. - Procurement should ask any vendor pitching "AI penetration testing" a short list of pointed questions before signing. ## Why this matters The FDA's position on artificial intelligence in medical device cybersecurity testing, particularly AI-driven penetration testing, significantly impacts compliance and market access for manufacturers. As outlined in the FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, all premarket submissions must demonstrate adequate security controls through credible and well-documented testing. Relying solely on AI agents for penetration testing risks deficiency letters because AI cannot independently satisfy requirements for qualified personnel, device-specific clinical context, reproducibility, and physical hardware testing. Misinterpreting the FDA's guidance could lead to delayed market entry or regulatory hurdles, directly affecting patient safety and business viability. While AI offers powerful acceleration for tasks like vulnerability scanning and data correlation, it cannot replace the critical human element for threat model alignment, ethical judgment, or physically probing hardware. Adherence to standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023)/TIR97 requires a nuanced understanding of how AI tools integrate into a secure development lifecycle without compromising regulatory compliance or the safety of medical devices. ## What the FDA actually requires The Feb 3, 2026 final guidance on _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_ and Section 524B of the FD&C Act both require, as part of the Secure Product Development Framework (SPDF): - Security testing that includes **vulnerability testing, penetration testing, and security assessment of unresolved anomalies** - Testing **scoped to the device's threat model and architecture views** - Documentation of **methods, scope, duration, tooling, findings, and tester qualifications** - Testing **independent of the development team**, sufficient to demonstrate the adequacy of cybersecurity controls Neither the statute nor the guidance says "humans only." Neither says "AI is acceptable." The bar is credibility and evidence. That distinction is the whole story. ## Where AI legitimately accelerates a medical device pen test Used well, AI compresses time on the parts of an engagement that are mechanical, repetitive, or pattern-matching: - **Reconnaissance and attack surface mapping** across firmware, mobile companion apps, cloud back ends, and RF interfaces - **SBOM diffing and CVE correlation**, including chained vulnerability identification across components - **Fuzz use generation** for HL7, DICOM, BLE GATT, MQTT, CoAP, and proprietary binary protocols - **Payload variation and mutation** for abuse and misuse case testing - **Static and dynamic analysis triage**, deduplicating findings and mapping them to CWE - **Report drafting**, traceability matrices, and mapping findings to the threat model and to FDA-expected deliverables A qualified tester who refuses to use these tools in 2026 is leaving real coverage on the table. ## Where AI-only testing fails an FDA reviewer There are five places a pure-AI pen test breaks down in a 510(k), De Novo, or PMA review. ### 1. Accountable tester qualifications The guidance expects named personnel with documented competency. "An autonomous agent ran the scan" is not a qualification statement a reviewer can evaluate. There is no resume for a model, no continuing education, no signature on the report that means anything in a regulatory context. ### 2. Device-specific clinical and protocol context Medical devices are bespoke. Class II and III devices carry clinical workflow abuse cases, IEC 62304 software safety classifications, IEC 60601 essential performance considerations, custom RF stacks, proprietary serial and BLE protocols, and hazard-to-exploit chains that only matter in the context of the device's intended use. An LLM agent that does not understand the device's clinical workflow will miss the exploits that actually create patient harm and over-report the ones that do not. ### 3. Reproducibility and chain of custody FDA reviewers and notified bodies want testing they can re-examine. Nondeterministic agent traces, hidden prompts, and undisclosed model versions undercut that. Pen test reports need repeatable steps, defined tooling versions, and a clear evidence trail. AI assistance is fine; AI as the sole black box is not. ### 4. Threat model alignment The guidance ties testing directly to the threat model. Pen testing must exercise the STRIDE elements, attack paths, and abuse cases identified in the threat model and architecture views. The threat model is device-specific, written by humans, and not something an AI agent can infer from a binary alone. Without alignment, the test exercises generic attacker behavior and leaves device-specific paths untested. ### 5. Patient safety implications of false negatives In conventional IT, a missed vulnerability is a finding for next quarter. In a Class II or III device, a missed vulnerability can become patient harm. False-negative rates that are acceptable in commercial pen testing are not acceptable when the consequence is a hazard. The threshold for missed coverage is lower, and a human is accountable for that threshold. ## The hardware problem AI cannot solve This is the question prospects raise most often, and it is the hardest one for AI-only vendors to answer: **AI does not have hands.** A meaningful medical device pen test is not a pure software exercise. It involves physical work on physical hardware, and that work cannot be outsourced to a model. A representative hardware testing workflow on a connected Class II device might include: - **Bench setup** for the device under test: power supplies, isolation transformers, signal generators, patient simulators, RF shielding, and Faraday enclosures so BLE and proprietary RF tests do not bleed into adjacent equipment. - **Enclosure teardown** and identification of test points, debug headers, and unpopulated pads. - **Hardware reconnaissance** with a multimeter, logic analyzer, and oscilloscope to identify UART, SPI, I2C, JTAG, and SWD interfaces and to determine voltage levels and pinouts. - **Debug port exploitation** including JTAG and SWD probing with hardware tools such as a Bus Pirate, J-Link, or Black Magic Probe to attempt halt, memory read, and firmware extraction. - **Chip-off and in-circuit firmware extraction** from SPI flash, eMMC, or microcontroller internal flash when debug interfaces are locked. - **Glitching and fault injection** (voltage and clock) to bypass secure boot, read-out protection, or debug fuses on the MCU. - **Side-channel measurement** for power and electromagnetic analysis against cryptographic implementations. - **RF and wireless testing** of BLE, NFC, MedRadio, proprietary 2.4 GHz, sub-GHz, and inductive links using SDRs (HackRF, Ubertooth, Proxmark, BladeRF) and protocol-aware tooling. - **Peripheral and accessory abuse** including malicious cables, rogue chargers, USB and serial fuzzing of cradles and programmers. - **Tamper response validation** against the controls claimed in the threat model and labeling. None of this happens in a chat window. Every step requires a tester physically present with the device, the right instruments, a calibrated bench, and the experience to read what the instruments are showing. An AI agent cannot solder, cannot probe a test pad, cannot set up a Faraday cage, cannot decide that the suspicious trace on the oscilloscope is worth chasing, and cannot stop testing when the device shows a thermal or electrical fault that risks damaging the unit under test. The FDA does not require hardware testing in every case. It does require testing scoped to the threat model and architecture views. For any device with physical attack surface, the threat model will identify those interfaces, and a credible pen test must exercise them. A vendor that cannot demonstrate a hardware bench, calibrated tooling, and named hardware testers cannot deliver that coverage, regardless of how sophisticated the AI tooling around it is. This is also where AI is most useful in support of a human hardware tester: parsing datasheets for an unfamiliar MCU, identifying flash chip families from package markings, generating fuzzing wordlists for an extracted protocol, decoding captured RF frames, and drafting the writeup. use for the human at the bench. Not a replacement for the bench. ## The model that works: human-led, AI-augmented The defensible posture for an FDA-regulated pen test today: 1. **Human-owned scope** anchored to the threat model, architecture views, and intended use. 2. **AI-accelerated execution** across recon, fuzzing, SCA, payload generation, and triage. 3. **Human-driven exploitation and chaining** of findings into clinically meaningful attack paths. 4. **Human-authored report** with explicit disclosure of AI tooling used, model versions, and what humans verified. 5. **Named, qualified testers** with documented independence from the development team, signing the report. This is how the Feb 2026 guidance reads in practice. The human is accountable; AI is use. ## Who does what across a medical device pen test A practical, phase-by-phase view of where humans, AI augmentation, and AI-only approaches land in a regulated engagement. Green columns show what the FDA requires a human to own. Amber shows where AI legitimately accelerates the human's work. Red shows where AI-only engagements fail review.
Process flow

Human vs AI across the engagement

  1. PHASE 01 Human
    Scope & threat-model alignment

    Qualified tester scopes against architecture views, data flows, and intended use.

  2. PHASE 02 Human + AI
    Recon & SBOM/CVE correlation

    AI accelerates enumeration and CVE chaining; tester prioritizes and validates.

  3. PHASE 03 Human only
    Hardware bench & firmware extraction

    JTAG/SWD, glitching, side-channel, RF. Physical work no AI can perform.

  4. PHASE 04 Human + AI
    Fuzz uses & payload generation

    LLM drafts uses and mutations; tester targets them at threat-model paths.

  5. PHASE 05 Human
    Exploitation, chaining & clinical impact

    Tester drives exploitation, judges patient-safety impact, and signs off.

  6. PHASE 06 Human signs
    Report, traceability & signature

    AI drafts sections; named, qualified tester authors, edits, and signs the report.

Flow
Scope→ Recon→ Hardware→ Fuzz→ Exploit→ Signed report

Green = human-owned. Amber = AI-accelerated, human-validated.

The table below maps the same phases to what fails in an AI-only model.
Engagement phase Human-led required AI-augmented recommended AI-only not FDA-ready
Scoping against threat model & architecture views Tester + threat modeler LLM summarizes threat model artifacts Cannot reliably infer device-specific scope
Reconnaissance & attack surface mapping Tester reviews and prioritizes LLM agents accelerate enumeration Surface coverage, no prioritization
Hardware bench, JTAG/SWD, firmware extraction Tester at calibrated bench Physical work, not applicable Not possible
Glitching, side-channel, RF testing Tester with specialized instruments Physical work, not applicable Not possible
Fuzz use & abuse case generation Tester designs against threat model LLM drafts uses, mutations, payloads Generic uses, miss device-specific paths
SBOM / SCA / CVE correlation Tester validates exploitability LLM correlates and chains findings High false-positive rate, no validation
Exploitation & vulnerability chaining Tester drives, signs off on impact LLM suggests chains for tester review Nondeterministic, not reproducible
Clinical workflow abuse cases Tester with med-device domain expertise LLM helps draft scenarios No clinical context, misses patient-harm paths
Reporting & traceability to threat model Tester authors, signs LLM drafts sections for tester edit Unsigned, unattributable, fails FDA evidence bar
Independence & qualifications statement Named tester credentials in report Not applicable No accountable signatory
Pattern: humans own everything that requires accountability, physical presence, or device-specific judgment. AI accelerates everything else.
## A short checklist for vendor selection Before signing with any firm pitching "AI penetration testing" for a regulated medical device, ask: - Who is the named, qualified tester signing the report, and what are their credentials? - How is the test scoped to the device's threat model and architecture views? - What AI tools and model versions are used, and for which steps? - Which findings are AI-generated and which are human-verified before reporting? - How is the testing reproducible, and what evidence is preserved for the FDA or a notified body? - How does the firm handle abuse and misuse cases that require clinical workflow understanding? - Does the firm have a hardware bench, calibrated instruments, and named hardware testers for JTAG, SWD, firmware extraction, glitching, side-channel, and RF work? - What is the firm's posture on false negatives in safety-critical contexts? If the vendor cannot answer those clearly, the pen test will not hold up under FDA review. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## AI-assisted testing vs human-led testing at a glance Reviewers do not reject work because a tool helped produce it. They reject work that no qualified person can defend. This is where each approach holds up and where it does not. | Test activity | AI on its own | Human-led, AI-assisted | | --- | --- | --- | | Enumerating a web or cloud interface | Fast and mostly reliable | Same speed, with false positives removed | | Firmware extraction from a soldered flash chip | Cannot do it | Routine bench work | | Proprietary radio protocol reverse engineering | Guesses, often confidently wrong | Signal capture, replay, and analysis | | Judging whether a finding can harm a patient | No clinical context | Tied to the risk file under ISO 14971 | | Writing the report a reviewer will read | Generic text that misstates clause numbers | Specific to your device and traceable | | Who signs the conclusion | Nobody | A named tester who can defend it | ## How Blue Goat Cyber runs this Our medical device pen testing engagements are human-led and AI-augmented. A qualified tester scopes the engagement against your threat model, owns the exploitation and chaining, signs the report, and discloses AI tooling used. AI handles the parts that benefit from it, and humans handle the parts the FDA expects humans to handle. The deliverable is built around the five FDA-required report elements: independence, scope, duration, methods, and results. If you are evaluating AI-only pen test vendors, or you have an upcoming 510(k), De Novo, or PMA submission and want a credible, defensible pen test, let's scope it. ## FAQ ### Can AI do penetration testing for medical devices? AI can do parts of it. Reconnaissance, SBOM and CVE correlation, fuzz use generation, payload mutation, finding triage, and report drafting are all reasonable AI workloads. The pieces AI cannot do on a regulated medical device include scoping the test to the threat model and architecture views, performing hardware work at a bench (JTAG, SWD, firmware extraction, glitching, side-channel, RF), exploiting findings into clinically meaningful attack paths, and signing a report as a qualified, independent tester. A medical device pen test that delegates those pieces to AI will not hold up under FDA review. ### Does the FDA accept AI penetration testing? The FDA's February 3, 2026 premarket cybersecurity guidance does not explicitly accept or reject AI-performed penetration testing. It requires that security testing be credible, scoped to the device's threat model, performed by independent and qualified personnel, and documented with methods, scope, duration, tooling, findings, and results. A human-led, AI-augmented engagement meets that bar. An AI-only engagement does not, because there is no named qualified tester, no reproducibility guarantee, and no way to evidence threat-model-aligned coverage. ### What's the difference between automated penetration testing and AI penetration testing? Automated penetration testing usually refers to scripted, scanner-driven workflows that run a fixed playbook (Nessus, OpenVAS, commercial autonomous platforms). AI penetration testing typically adds an LLM agent on top to plan, vary payloads, and chain findings. Both have a place inside a medical device pen test, and both have the same limitation: neither performs hardware work, neither owns the threat model, and neither can sign an FDA-grade report. Treat them as tools inside a human-led engagement, not as substitutes for one. ### Will AI replace medical device penetration testers? Not for FDA-regulated work in any near-term timeframe. AI will continue to compress the mechanical parts of an engagement, which is a good thing. It will not replace the named human accountable for scope, hardware testing, clinical workflow understanding, and a signed report, because those are the things the FDA, notified bodies, and patients rely on. The realistic trajectory is fewer hours spent on triage and reporting, more hours spent on bench work and exploitation, and the same human accountability at the top of the document. ### Can AI perform hardware testing on a medical device? No. Hardware testing requires a physical bench, calibrated instruments, and a tester present with the device. JTAG and SWD probing, firmware extraction from SPI flash or eMMC, voltage and clock glitching, side-channel measurement, and RF testing across BLE, NFC, MedRadio, and proprietary stacks all need hands and hardware. AI can help interpret datasheets, parse captured frames, and draft writeups around the work, but it cannot perform the work. ### What should a medical device manufacturer ask AI pen test vendors first? Three questions tend to settle it quickly: (1) who is the named, qualified tester signing the report; (2) which engagement steps are performed by humans at a bench versus by AI agents; (3) how the engagement is scoped to the device's threat model and architecture views. If the vendor cannot answer those three clearly, the engagement will not hold up under FDA review, regardless of how impressive the underlying AI platform is. ## Related reading - [FDA Penetration Testing Requirements for Medical Devices](/blog/fda-penetration-testing-requirements-medical-devices) - [Medical Device Pen Testing: Choosing the Right Provider](/blog/medical-device-pen-testing-choosing-the-right-provider) - [Scoping a Medical Device Penetration Test](/blog/scoping-a-medical-device-penetration-test) - [How to Respond to an FDA Cybersecurity AI Request](/blog/how-to-respond-to-an-fda-cybersecurity-ai-request) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Open Box Testing for Medical Devices](/blog/closed-box-testing-in-medical-device-cybersecurity) --- ## AR Medical Device Cybersecurity Risks (2026) Source: https://bluegoatcyber.com/blog/augmented-reality-ar-medical-device-cybersecurity-risks # AR Medical Device Cybersecurity in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** AR medical devices merge real-time data overlays with clinical workflows, but their constant connectivity and complex software stacks create real attack surface, including manipulated imagery, intercepted data streams, and compromised authentication. Manufacturers should apply IEC 81001-5-1, ISO 14971, and AAMI TIR57 risk practices, use strong authentication, keep software patched, and train staff, aligning with the FDA's February 3, 2026 final guidance expectations for secure design and postmarket vigilance. _Updated November 10, 2024_ ## Key Takeaways - AR transforms medical procedures, training, and remote care. - Interconnectivity of AR devices creates new cyber vulnerabilities. - Data breaches and device manipulation pose risks to patient safety. - The FDA February 3, 2026 guidance applies to AR medical devices. - Regular updates and strong authentication are critical defenses. - Staff training on cybersecurity best practices is essential. ## Why this matters Augmented Reality (AR) integration into medical devices offers transformative benefits for patient care, from enhanced surgical precision to remote diagnostics. However, the sophisticated interconnectivity required for AR devices introduces significant cybersecurity vulnerabilities that attackers can exploit. Compromised AR medical devices could lead to manipulated clinical data, patient misdiagnosis, or even direct harm during procedures reliant on AR guidance. Protecting these systems is not merely a data privacy concern; it is a direct patient safety imperative. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, explicitly addresses the need for secure design and postmarket vigilance for all medical devices, including those utilizing AR. Adherence to standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is crucial for managing these risks. Proactive security measures, thorough risk assessments, and continuous monitoring are necessary to safeguard AR-enabled devices against evolving cyber threats and ensure their continued safe and effective operation within healthcare environments. The stakes involve patient trust, regulatory compliance, and human lives. ## Understanding Augmented Reality in Medical Devices Augmented Reality (AR) is revolutionizing many industries, none more so than healthcare. It enhances the way medical professionals interact with data and patients. AR merges digital content with the real world, creating an enriched experience that can lead to better decisions. ![Section Image](/imported-images/58f3f501596856ee.png) From surgical guidance to patient education, AR holds immense potential. For example, a surgeon can overlay a patient’s anatomy on their body during a procedure. This level of detail and interaction can significantly reduce the risks associated with surgery. ### The Role of AR in Modern Healthcare In modern healthcare, AR plays multiple roles. It serves as a tool for training aspiring surgeons, aiding in simulations that mimic real-life scenarios. Imagine trying to perform heart surgery without ever practicing on a live person-that’s where AR steps in, saving lives before they’re even on the operating table. AR enables remote assistance. Specialists can guide on-site practitioners using [AR headsets](https://www.google.com/search?q=AR+headset&sca_esv=1811162b4bcf03fb&rlz=1C1UEAD_enUS1122US1134&sxsrf=ADLYWIK630c9z9OR5pVHY9rTSdXM04bM-Q%3A1731256363529&ei=K-AwZ538H5PLkPIPopjE0Aw&ved=0ahUKEwjdvcDEmNKJAxWTJUQIHSIMEcoQ4dUDCA8&uact=5&oq=AR+headset&gs_lp=Egxnd3Mtd2l6LXNlcnAiCkFSIGhlYWRzZXQyChAAGIAEGEMYigUyBRAAGIAEMgUQABiABDIFEAAYgAQyBRAAGIAEMgUQABiABDIFEAAYgAQyBRAAGIAEMgUQABiABDIFEAAYgARItQtQswVYswVwAXgBkAEAmAHIAaAByAGqAQMyLTG4AQPIAQD4AQGYAgKgAtsBwgIKEAAYsAMY1gQYR8ICDRAAGIAEGLADGEMYigXCAg4QABiwAxjkAhjWBNgBAcICFhAuGIAEGLADGEMY5QQYyAMYigXYAQHCAhkQLhiABBiwAxjRAxhDGMcBGMgDGIoF2AEBmAMAiAYBkAYTugYGCAEQARgJkgcFMS4wLjGgB_wE&sclient=gws-wiz-serp). This [real-time collaboration](/blog/emerging-technologies-and-their-impact-on-medical-device-cybersecurity) is a game-changer for facilities that may lack specialized staff. For instance, in rural hospitals with limited access to top-tier specialists, AR can bridge the gap, allowing local doctors to consult with experts worldwide without needing physical travel. This enhances patient care and builds a collaborative environment where knowledge can be shared instantaneously. ### Key Features of AR Medical Devices AR medical devices are indispensable because they are equipped with various features. Key among these is real-time visualization. Users can see their environment enriched with data overlays, which enhances understanding and improves workflow. Another crucial feature is interactivity. Users can easily manipulate the overlaid data, allowing them to explore further. This adaptability enables healthcare professionals to make informed decisions swiftly. Additionally, AR devices often incorporate advanced imaging technologies, such as 3D modeling and holography, allowing a more immersive experience. For example, a physician can visualize a 3D model of a tumor, rotate it, and analyze its proximity to vital organs, leading to more precise treatment planning. These features enhance the accuracy of diagnoses and empower patients by giving them a clearer understanding of their conditions and treatment options, building a more engaged and informed patient population. ## The Intersection of AR and Cybersecurity As innovative as AR is, it also raises substantial cybersecurity concerns. With the integration of digital tools in healthcare, new vulnerabilities arise. Protecting sensitive patient data is now a priority that cannot be overlooked. The rapid advancement of AR technology means that healthcare providers must stay ahead of potential threats, ensuring that their systems are fortified against cybercriminals’ evolving tactics. This is not just a matter of compliance; it is about safeguarding patients’ trust in their healthcare providers. Hackers are continually looking for [openings](/blog/cybersecurity-attack-entry-points-for-medical-devices). The interconnected nature of AR devices means that others may become at risk rapidly once they infiltrate one system. It’s a domino effect that healthcare institutions must guard against diligently. The potential for a single breach to cascade through a network of devices and systems amplifies the urgency for security protocols. Institutions must adopt a proactive stance, implementing regular security assessments and updates to mitigate these risks before they can be exploited. ### The Digital Vulnerabilities of AR By their very nature, AR technologies are susceptible to various digital threats. Many devices require [constant connectivity](/blog/cybersecurity-for-medical-devices-with-narrowband-iot-protocol), making them prime targets for cybercriminals. Take, for instance, a scenario where a device’s software hasn’t been updated. That’s a glaring opportunity for hackers to exploit. Additionally, the complexity of AR systems can create blind spots in security measures, where vulnerabilities may go unnoticed until it is too late. This highlights the necessity for continuous monitoring and adaptive security strategies that can respond to new threats as they emerge. User error can also lead to vulnerabilities. If healthcare professionals access AR tools through unsecured networks or devices, they jeopardize sensitive information further. The analogy here is obvious; you wouldn’t open your front door to strangers and invite them in. So why jeopardize digital security? Training staff to recognize phishing attempts and the importance of secure passwords is crucial. Furthermore, implementing multi-factor authentication can add an extra layer of protection, ensuring that even if credentials are compromised, unauthorized access can still be thwarted. ### The Importance of Cybersecurity in AR Medical Devices Cybersecurity isn’t just an IT problem; it’s a life-critical aspect of modern healthcare. A breach could result in data theft and the manipulation of medical data, potentially harming patients. This reality makes cybersecurity measures essential. The stakes are incredibly high, as compromised medical devices could lead to incorrect diagnoses or inappropriate treatments, putting patient safety at risk. As AR continues to evolve, so must the strategies to protect it, ensuring that technology enhances rather than endangers patient care. Healthcare institutions must prioritize cybersecurity training. Employees should recognize the risks associated with AR and other digital platforms. Education is key-just as doctors hone their practice, those managing AR must sharpen their cybersecurity skills. Regular workshops and simulations can help staff stay vigilant and aware of the latest threats. Additionally, building a culture of security within the organization encourages everyone to take ownership of their role in protecting sensitive data, creating a united front against potential cyber threats. This collaborative approach can significantly enhance the overall security posture of healthcare institutions in the face of an digital landscape. ## Identifying Potential Cybersecurity Risks Recognizing potential cybersecurity risks is the first step in prevention. The complexity surrounding AR medical devices adds layers to security challenges, which can have dire consequences if left unchecked. While revolutionary, integrating augmented reality in healthcare introduces unique vulnerabilities that malicious actors can exploit. For instance, relying on wireless communication for data transfer between devices can create opportunities for interception and manipulation of sensitive information. Organizations need to take a proactive approach. This includes regular security assessments identifying their vulnerabilities, understanding how they can be exploited, and countering them accordingly. Furthermore, building a culture of cybersecurity awareness among staff is crucial. Training programs that simulate real-world attacks can empower employees to recognize and respond to threats effectively, creating a first line of defense against potential breaches. ### Common Cyber Threats to AR Medical Devices Hackers deploy various methods to access AR medical devices and their accompanying data. Phishing attacks are prevalent. Cybercriminals may impersonate legitimate sources to fool staff into providing access. These attacks can be particularly sophisticated, utilizing social engineering tactics to create a sense of urgency or fear, prompting quick, unconsidered actions from unsuspecting employees. [Ransomware](/blog) is another concern. Imagine a healthcare facility locked out of its AR systems, unable to access critical patient data or surgical guides. That becomes a horror movie scenario very quickly! The repercussions can extend beyond immediate operational disruptions; the financial implications of paying a ransom, coupled with potential regulatory fines for data breaches, can cripple an institution. Moreover, the psychological toll on healthcare professionals, who may feel helpless in the face of such attacks, can further exacerbate the situation. ### The Impact of Cyber Attacks on Healthcare The ramifications of cyber attacks on healthcare can be severe. Delays in treatment, compromised patient data, and financial losses are just the tip of the iceberg. If an AR device used in an operation is hacked, it can lead to disastrous consequences. The potential for misdiagnosis or incorrect surgical procedures due to manipulated AR visuals is a chilling thought, emphasizing the need for stringent security protocols. Ultimately, patient safety hangs in the balance. Patients’ trust in the healthcare system should not be taken for granted. Cyber attacks can damage that trust irrevocably. As patients become more aware of cybersecurity threats, their willingness to share personal information may diminish, leading to a reluctance to engage with healthcare providers. This erosion of trust can have long-lasting effects on patient relationships and the overall efficacy of healthcare delivery, making it imperative for organizations to prioritize cybersecurity as a fundamental aspect of their operations. ## Mitigating Cybersecurity Risks in AR Medical Devices Mitigating risks requires a multifaceted approach. It’s not enough to have a single defense mechanism in place. strategies must be implemented, and everyone in the organization must be involved. ![Section Image]() Establishing a culture of security is vital. Everyone, from executives to practitioners, must understand their role in securing AR devices. This creates a holistic environment for attuning practices and policies. Training sessions and workshops can be instrumental in building this culture, ensuring that all staff members are aware of the potential threats and equipped with the knowledge to respond effectively. Regular updates on emerging threats and security protocols can keep the conversation alive and relevant, reinforcing the importance of vigilance in a rapidly changing technological landscape. ### Best Practices for Securing AR Medical Devices Healthcare providers can adopt several best practices to secure AR medical devices. Regular software updates can patch vulnerabilities. Using strong passwords and enabling two-factor authentication significantly reduces the chance of unauthorized access. Periodic audits of security protocols are essential, too. Continuous monitoring ensures emerging risks are tackled head-on. It’s about building layers of security like an onion, the more layers, the less likely a breach. Additionally, implementing network segmentation can limit the spread of potential intrusions, isolating sensitive data and critical systems from less secure areas of the network. This practice not only protects vital information but also simplifies the process of identifying and addressing vulnerabilities within specific segments of the network. ### Future Trends in AR Device Cybersecurity As AR technology evolves, so do the security trends tied to it. Enhanced encryption methods are becoming commonplace, safeguarding sensitive data from prying eyes. Organizations that invest in advanced security solutions will remain ahead of the cybercriminal curve. [Artificial intelligence is stepping](/blog/how-to-respond-to-an-fda-cybersecurity-ai-request) into the security arena. AI can track abnormal patterns, alerting when something seems amiss. Think of it as your digital watchdog, watching while you focus on your patients. Integrating [machine learning algorithms](/blog/emerging-technologies-and-their-impact-on-medical-device-cybersecurity) can also enhance predictive analytics, allowing organizations to anticipate potential threats before they materialize. As AR devices become more interconnected, the need for resilient, adaptive security measures will only grow, making it imperative for healthcare providers to stay informed about the latest technological advancements and their implications for cybersecurity. This proactive approach will not only protect sensitive patient data but also build trust in the use of AR technologies in medical settings. ## Regulatory Considerations for AR Medical Device Cybersecurity With the growth of AR in healthcare comes the necessary scrutiny from regulatory bodies. Organizations must comply with existing regulations to prevent hefty fines and repercussions. Regulations exist to safeguard both patients and providers. It’s not simply about following rules; it’s also about setting standards that protect everyone involved in healthcare. Creating tangible security protocols must be a shared responsibility. This collective effort involves manufacturers, healthcare providers, software developers, and IT security experts, all of whom must work together to ensure that AR applications are safe and effective. ### Current Regulations and Standards Regulations are becoming stricter, particularly as technology advances. The [FDA, for example, has guidelines for the cybersecurity of medical devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity), including AR technologies. Compliance with these guidelines isn’t optional; operating within legal frameworks is necessary. Additionally, organizations must stay abreast of international regulations, such as the [European Union’s Medical Device Regulation (MDR](/blog)), emphasizing cybersecurity’s importance in medical devices. Understanding the nuances of compliance can be a hurdle, but it’s a necessary effort. Making sense of self-regulation and adhering to external standards will create a cybersecurity posture. Organizations are encouraged to implement risk management frameworks that address current threats and anticipate future vulnerabilities, ensuring their systems remain resilient against evolving cyber threats. ### The Role of Regulatory Bodies in Cybersecurity Regulatory bodies are crucial in guiding organizations on best practices for cybersecurity. They promote frameworks to help minimize risks associated with cyber threats. Collaborating with these bodies ensures that technical advancements do not outpace security measures. This collaboration can take many forms, from workshops and training sessions to developing guidelines addressing AR technologies’ unique challenges. Regulatory bodies can facilitate sharing vital information about threats and vulnerabilities across the industry, building cooperation to address challenges collaboratively. By establishing networks for information exchange, these bodies can help organizations stay informed about emerging threats and best practices, ultimately creating a safer environment for patients and healthcare providers. This proactive approach enhances cybersecurity and builds trust among stakeholders, reinforcing the importance of security in adopting innovative healthcare technologies. ## The Future of AR Medical Device Cybersecurity The landscape of AR medical device cybersecurity will likely continue to evolve. Challenges will emerge, but so will innovative solutions tailored to combat these threats. Remaining vigilant is the key to success in navigating this dynamic realm. ![Section Image]() Both health professionals and cybersecurity experts will need to work hand-in-hand to ensure patient data remains secure and accessible only where it’s meant to be. This collaboration will enhance security protocols and build a culture of awareness and preparedness within healthcare organizations, ensuring that all staff members are equipped to recognize and respond to potential cyber threats. ### Predicted Cybersecurity Challenges As technology evolves, so too do the tactics of cybercriminals. Healthcare organizations must prepare for increasingly sophisticated attacks exploiting AR devices’ vulnerabilities. It’s like playing chess against a master strategist; one must always be on their toes! Another challenge is integrating AR with other technologies, such as IoT devices. The more interconnected the system, the more entry points there are for cyber threats. Hence, it is paramount to ensure that every device within the network is secure, with no exceptions. This interconnectedness also raises concerns about the potential for cascading failures; a breach in one device could lead to vulnerabilities in others, amplifying the risk to patient safety and data integrity. Nonetheless, innovation continues to illuminate solutions for improving AR device security. Blockchain technology is gaining traction for securing medical records. Its decentralized nature could potentially transform how data integrity is maintained. ## Conclusion As companies experiment with new approaches, the future holds promising potential. Engaging in ongoing dialogue about evolving security measures will be crucial for protecting healthcare’s most vulnerable aspects. Additionally, the development of artificial intelligence (AI) and machine learning algorithms can enhance threat detection capabilities, allowing for real-time monitoring of AR devices and immediate responses to suspicious activities. This proactive stance could significantly mitigate risks, ensuring that patient safety remains the top priority amidst the rapid technological advancements in healthcare. As the medical industry continues to embrace the potential of Augmented Reality (AR), cybersecurity measures have never been more critical. Blue Goat Cyber understands the unique challenges of securing AR medical devices. Our veteran-owned business is at the forefront of medical device cybersecurity, offering services that ensure your devices comply with the highest standards and FDA regulations. From risk management to secure development practices, our certified experts (CISSP, OSCP, CSSLP) provide advanced penetration testing and vulnerability assessments tailored to your needs. With our fixed-fee pricing, unlimited retesting, and commitment to long-term partnerships, we offer the transparency and support necessary to navigate this complex landscape. Don’t let cybersecurity risks stand in the way of your AR medical device’s potential. [Contact us today for cybersecurity help](/contact), and schedule a Discovery Session to secure your devices and gain peace of mind with compliance and protection. ## How AR risk differs from conventional device risk Most of an AR headset looks like any other connected device. Three things do not, and those three drive the security work. | Attack surface | Conventional connected device | AR medical device | | --- | --- | --- | | Display output | Status text or waveform | Overlay drawn on the patient's anatomy, so tampering can misdirect a clinician | | Sensors | Fixed inputs you can bound | Cameras and depth sensors capturing the room and bystanders | | Latency budget | Milliseconds matter for control loops | Milliseconds also drive user trust and can cause physical harm through disorientation | | Data captured | Device telemetry and patient readings | Video of the clinical environment, which is often identifiable | | Update path | Firmware over the air | Firmware plus a rendering stack and third-party engine | | Worst realistic outcome | Wrong reading or lost availability | A clinician acts on an overlay that is wrong or maliciously shifted | ## How Blue Goat approaches this Our approach to AR medical device cybersecurity focuses on identifying and mitigating unique threats posed by overlaid digital information and interconnected systems. We begin with a detailed threat modeling exercise, considering data flows, user interactions, and potential attack vectors specific to AR environments. Our cybersecurity engineers, including CISSP and OSCP certified professionals and ex-military red team members, conduct targeted penetration testing that simulates real-world exploitation scenarios without disrupting operations. We analyze software, hardware, and network components for weaknesses, prioritizing vulnerabilities based on their potential impact on patient safety and data integrity. Our services include architectural reviews, secure code analysis, and guidance on implementing cryptographic controls and authentication mechanisms tailored for AR medical devices. We support premarket submissions to the FDA, ensuring your device's security documentation meets regulatory expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Discover more about our capabilities at: https://bluegoatcyber.com/services/medical-device-penetration-testing. ## FAQ ### What are the cybersecurity risks of AR in medical devices? AR medical devices face risks such as unauthorized data access, device manipulation, and malware infections due to their connectivity and software complexity. These vulnerabilities can lead to compromised patient data, incorrect diagnoses, or critical treatment errors. ### How does the FDA regulate cybersecurity for AR medical devices? The FDA regulates AR medical device cybersecurity through its February 3, 2026 premarket guidance. This guidance outlines expectations for sponsors to address cybersecurity risks throughout the total product lifecycle, ensuring device safety and effectiveness. ### What measures can secure AR medical devices? Securing AR medical devices involves implementing strong authentication, regular software updates, network segmentation, and encryption. Complete cybersecurity training for staff is also crucial to minimize human error and recognize threats. ### Can AR medical devices be hacked during use? Yes, AR medical devices can be vulnerable to hacking during use if security protocols are insufficient or not followed. A breach could lead to data manipulation, affecting real-time information displayed to clinicians, potentially endangering patient safety. ### Why is staff training important for AR medical device cybersecurity? Staff training is critical because human error is a significant factor in cybersecurity incidents. Educated staff can identify phishing attempts, adhere to secure practices, and report suspicious activities, strengthening the overall security posture. ### What is the impact of a cyber attack on AR medical devices? A cyber attack on AR medical devices can result in delayed treatments, compromised patient data, and financial losses. More critically, it can lead to misdiagnoses or incorrect surgical procedures, directly jeopardizing patient safety and eroding trust in healthcare providers. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [IATF 16949 and MedTech Cybersecurity](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity) - [MedTech Cybersecurity: A Competitive Edge](/blog/cybersecurity-as-a-competitive-edge-in-medtech) --- ## BLE & RF Penetration Testing Source: https://bluegoatcyber.com/blog/ble-rf-penetration-testing-medical-device-case-study # BLE & RF Penetration Testing: A Medical Device Case Study > **[DIRECT ANSWER]** A real BLE and RF penetration test on a connected Class II device typically surfaces issues like Just Works pairing that allows unauthenticated writes, unsigned firmware images that accept tampered updates, and weak protection on the proprietary sub-GHz link to a base station. Testing must cover every declared wireless interface, not just the cloud and mobile app, with findings tied to the threat model, since the FDA's February 3, 2026 guidance treats a web-only test as a near-automatic deficiency. **Wireless interfaces are where most medical device pen tests get the thinnest. This case study walks through how we test BLE and proprietary RF on a representative Class II connected device, the eight findings we surface most often, and what an FDA reviewer expects to see in the report.** A web-only pen test against a connected medical device is a near-automatic FDA deficiency. The [February 2026 final premarket guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) and Section 524B both expect testing scoped to the threat model and exercised across every declared interface. For most modern devices, that means BLE, sub-GHz proprietary RF, occasionally NFC, and sometimes cellular - in addition to the cloud, mobile app, and any wired service interface. This is a sanitized case study based on representative engagements: a Class II connected wearable with a BLE companion-app channel for telemetry and configuration, plus a sub-GHz proprietary RF link to a base station. Device specifics have been generalized; the methodology and findings are the patterns we see most. ## Key Takeaways - FDA requires testing all declared medical device interfaces. - BLE and sub-GHz RF are critical attack surfaces. - Unsigned firmware updates are high-severity findings. - Secure pairing and authentication are essential for wireless. - Penetration test reports must align with the threat model. - Document findings with patient safety impact and remediation. ## The device under test - **Class II wearable** with continuous physiological monitoring. - **BLE 5.2** connection to a mobile companion app for telemetry, configuration, and firmware update. - **Sub-GHz proprietary RF** (FSK, ~900 MHz) to a home base station for clinician-facing dashboards. - **No direct cellular**; data egress via the base station's LTE modem. - **Firmware updates** delivered via BLE from the companion app. Threat-model relevant trust boundaries: phone-to-device (BLE), device-to-base-station (RF), companion-app-to-cloud (TLS), base-station-to-cloud (TLS). ## Scope and methodology We test against the threat model, not against a generic checklist. For this device, the in-scope wireless attack surfaces were: - BLE pairing, bonding, GATT services and characteristics, OTA firmware path, encryption / MITM resistance. - Sub-GHz RF protocol reverse-engineering, replay, spoofing, jamming sensitivity at the application layer. - Firmware integrity and rollback across both wireless channels. The lab setup: - **BLE:** Ellisys Bluetooth Tracker, nRF52840 dongles with [Sniffle](https://github.com/nccgroup/Sniffle), Wireshark with the nRF and Btsnoop dissectors, a rooted Android test phone for active fuzzing via [BTLEJuice](https://github.com/DigitalSecurity/btlejuice) and custom GATT clients. - **Sub-GHz RF:** HackRF One and an SDR-RTL companion for capture, [Universal Radio Hacker](https://github.com/jopohl/urh) for protocol reverse-engineering, a YARD Stick One for active transmit, and a Faraday tent for FCC-safe transmission tests. - **Static / dynamic:** firmware extracted from the OTA stream, analyzed with [Ghidra](https://ghidra-sre.org/) and binwalk; runtime instrumentation on the companion app with [Frida](https://frida.re/). This is not a checklist. Every finding below was validated end-to-end, with a documented proof-of-concept and a risk-rated impact statement mapped to the device's [ISO 14971](/blog/iso-14971-risk-management-in-medical-device-security) risk file. ## Eight findings we surface most often ### 01 - Just Works BLE pairing on a configuration GATT characteristic The device used Just Works pairing because the wearable has no display. An attacker within BLE range could pair without user interaction and write to a GATT characteristic that adjusted alerting thresholds. **Fix:** Move to LE Secure Connections with numeric comparison via the companion app (the app supplies the I/O capability the device lacks). Require app-side authentication before any write to configuration characteristics, regardless of pairing mode. ### 02 - Firmware OTA accepted unsigned images The OTA bootloader verified a CRC but not a cryptographic signature. We replayed a captured firmware image with a one-byte modification; the device installed it and rebooted into the modified firmware. **Fix:** Sign firmware images with an ECDSA P-256 key, verify in the bootloader before commit, and store the public key in a write-protected region. Add anti-rollback via a monotonic version counter. This is the single highest-severity finding type we see and is a frequent [FDA deficiency trigger](/guides/fda-cybersecurity-deficiency-letter-examples). ### 03 - Sub-GHz RF replay of telemetry packets The proprietary RF protocol used a fixed 32-bit packet header with a sequence number that reset on power-cycle. Captured packets replayed cleanly to the base station. **Fix:** Add per-packet authentication using a session key derived during enrollment. A rolling nonce alone is not enough if the device can be power-cycled. ### 04 - GATT characteristic exposes service-mode access without authentication A "service mode" characteristic permitted reading raw sensor calibration and a vendor-defined debug log. No authentication. Useful to a clinician at a bench; equally useful to an attacker mapping the device. **Fix:** Gate service-mode characteristics behind a hardware-attested challenge from the companion app, or require physical action (long-press) on the device to enable. ### 05 - BLE advertising packets leak device serial number The device advertised a manufacturer-data field containing the device serial in plaintext. Combined with the manufacturer ID, this allowed fleet-wide enumeration of devices in a clinical setting from a hallway. **Fix:** Use a rotating identifier in advertising packets; resolve to the persistent serial only after authenticated pairing. ### 06 - MITM-via-companion-app downgrade The companion app accepted a legacy pairing fallback when LE Secure Connections failed. A test rig forcing pairing failure triggered the fallback path, enabling a passive eavesdropping window. **Fix:** Disable legacy pairing fallback. If it must exist for compatibility, alert the user prominently. ### 07 - Companion app stores BLE long-term key in unprotected storage The Android companion app stored the BLE LTK in shared preferences without Keystore protection. A malicious app with overbroad permissions could recover the LTK and impersonate the bonded phone. **Fix:** Bind the LTK to the Android Keystore (or iOS Secure Enclave); enforce minimum OS version and root/jailbreak detection per the device's threat model. ### 08 - Jamming sensitivity not characterized Not strictly an attack, but reviewers ask: how does the device behave when the RF link is denied? The device under test silently buffered telemetry and did not surface a clinician-visible alert until 30 minutes of continuous loss. **Fix:** Document the failure mode in labeling. Add a configurable alerting threshold for sustained connectivity loss. This is a safety-by-design finding more than a security finding, but reviewers want to see both addressed. ## What the report looks like An FDA-grade wireless pen test report for this device included: - **Executive summary** with overall risk posture and headline findings. - **Scope statement** matching the threat model interfaces. - **Methodology** with tooling, test environment, and rules of engagement. - **Per-finding writeups**: description, reproduction steps, impact on patient safety, [ISO 14971](/blog/iso-14971-risk-management-in-medical-device-security) traceability, CVSS v4.0 score, recommended remediation. - **Verification matrix**: which threat model entries were exercised, with pass / fail per entry. - **Retest plan**: the unlimited-retest scope our [premarket service](/services/fda-premarket-cybersecurity-services) includes covers verification of every remediation. Reviewers do not want a Nessus dump. They want a narrative tied to the threat model with evidence per finding. ## Why this matters for the submission Wireless findings are where most submissions fail their first cybersecurity AI letter. Three reasons: 01 - The pen test report covers wired and web interfaces well but treats BLE / RF as a paragraph. 02 - The threat model declares wireless trust boundaries but the test report does not exercise them. 03 - The remediation evidence is missing - a fix is documented but no retest confirms the control. A premarket package that closes all three of those, mapped cleanly into the [eSTAR cybersecurity section](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance), clears the most common deficiency pattern in 2025-2026 submissions. ## Where this fits in the cluster - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [Wireless Penetration Testing](/services/wireless-penetration-testing) - [The SPDF Playbook for FDA-Ready Medical Devices](/guides/medical-device-cybersecurity-spdf-playbook) - [12 Critical Findings from Medical Device Penetration Tests](/guides/12-critical-findings-from-medical-device-penetration-tests) - [eSTAR Cybersecurity Readiness Checklist](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) ## Want this kind of test on your device? We do BLE, sub-GHz RF, NFC, cellular, and wired-interface penetration testing in-house, with medical-device context and FDA-formatted reports. [Book a free 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will scope a fixed-fee engagement in 24 hours. ## How Blue Goat approaches this Our approach to BLE and RF penetration testing for medical devices focuses on uncovering vulnerabilities that impact patient safety and data integrity while meeting regulatory expectations. We go beyond surface-level scanning, employing specialized tools and proprietary techniques to emulate real-world attack scenarios against wireless interfaces. Our team, comprised of professionals with certifications such as CISSP and OSCP, and ex-military red team experience, documents every step, from scope definition to exploit validation. We provide actionable recommendations tailored to your device's unique risk profile, ensuring traceability to relevant standards. Our reports are designed for clarity and directly address the requirements of the FDA. We stand by our work: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at: ## FAQ ### What wireless interfaces does the FDA expect medical device testing to cover? The FDA expects medical device testing to cover all declared wireless interfaces, which commonly include BLE, proprietary RF, NFC, and cellular, in addition to cloud, mobile app, and wired interfaces. ### How does the FDA view 'Just Works' BLE pairing for medical devices? The FDA views 'Just Works' BLE pairing as insufficient for medical devices that handle sensitive data or critical functions, especially if it allows unauthenticated configuration changes. Secure authentication methods are preferred. ### What is the most critical wireless finding in medical device pen tests? The most critical wireless findings often involve unsigned firmware images accepted via over-the-air updates, which can lead to unauthorized software installation and are a frequent FDA deficiency trigger. ### Why is RF jamming sensitivity important for medical device reports? RF jamming sensitivity is important for medical device reports because the FDA evaluates device behavior during communication loss. Manufacturers must characterize and document how the device responds to denial-of-service scenarios. ### What should an FDA-grade wireless pen test report include? An FDA-grade wireless pen test report should include an executive summary, scope, detailed methodology, per-finding write-ups with patient safety impact and ISO 14971 traceability, a verification matrix, and a retest plan. ### Does the FDA require retesting of all remediated findings? Yes, the FDA expects remediation evidence for all identified vulnerabilities. Retesting and verifying that controls effectively address findings matters for a complete premarket submission. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Bluetooth in Medical Devices: Security Risks and Controls Source: https://bluegoatcyber.com/blog/bluetooth-in-medical-devices-understanding-the-risks-and-protecting-patient-safety # Bluetooth in Medical Devices: Risks and Required Controls > **[DIRECT ANSWER]** Bluetooth in medical devices is usually Bluetooth Low Energy, and its security depends almost entirely on which pairing method the device uses and what it does after pairing. Just Works pairing provides no authentication and leaves the link open to an attacker within radio range. Devices that rely on the protocol's defaults without adding application-layer authentication and integrity checks are the ones that fail testing and draw FDA deficiency questions. _Reviewed September 17, 2026_ Bluetooth is the default radio for anything that has to talk to a phone, which is why it appears in glucose monitors, hearing aids, wearable sensors, insulin delivery systems, and home monitoring devices. It is also the interface manufacturers most often assume is secure because the specification includes encryption. The specification does include encryption. It also includes a pairing method that authenticates nothing, supports legacy modes with known weaknesses, and leaves most of the meaningful security decisions to the implementer. Understanding where the protocol stops and your responsibility starts is what separates a device that passes radio testing from one that does not. ## Key Takeaways - BLE security is determined by the pairing method chosen, not by the presence of encryption. - Just Works pairing offers no protection against an active attacker in range. - LE Secure Connections, introduced in Bluetooth 4.2, is the baseline to design toward. - Known attack classes including KNOB, BLURtooth and BLESA target the protocol itself, not a vendor bug. - Application-layer authentication protects you when the link layer is defeated. - The FDA expects radio interfaces to appear in the threat model and in the testing evidence. ## Why Bluetooth Deserves Specific Attention in a Submission Wireless interfaces are where a remote attacker meets your device without touching it. The February 3, 2026 premarket cybersecurity guidance expects manufacturers to identify their attack surface and to test it, and a radio that accepts connections from anything in range is the most accessible part of that surface for a device used at home. The known weaknesses are in the standard, which means they affect implementations broadly rather than one vendor. The KNOB attack, disclosed in 2019, showed that an attacker could force negotiation of a very short encryption key length, undermining the link encryption. BLURtooth, disclosed in 2020, targeted cross-transport key derivation between Bluetooth Classic and BLE. BLESA, also disclosed in 2020, targeted the reconnection process, where authentication is weaker than at initial pairing. SweynTooth, disclosed in 2020, was a family of implementation flaws in multiple BLE chipset software development kits that caused crashes, deadlocks, and in some cases security bypasses, and the FDA issued a safety communication about it in March 2020 because affected chipsets appeared in medical devices. That safety communication is the reason a reviewer takes BLE seriously. The agency has already told manufacturers publicly that a chipset-level radio flaw can reach patients, which makes an untested radio interface a visible gap rather than an acceptable omission. ## How BLE Pairing Actually Decides Your Security Pairing establishes the keys that protect the link. The association model used during pairing decides whether an attacker in the middle can insert themselves. | Pairing method | Authentication | Requires | Appropriate for | |---|---|---|---| | Just Works | None | No user interaction | Only when application-layer authentication exists | | Passkey Entry | Yes | Display on one side, keypad on the other | Devices with a screen or keypad | | Numeric Comparison | Yes | Display on both sides | Phone-paired devices with a UI | | Out of Band | Yes | A separate channel such as NFC | Devices with NFC or a physical pairing step | Just Works is the source of most real problems. It is chosen because the device has no display and no input, which is true of many sensors and wearables, and it produces an encrypted link with no assurance about who is on the other end. An attacker within range can complete pairing and the device cannot tell the difference. **[KEY REQUIREMENT]** If your device must use Just Works because it has no user interface, your submission needs to say so and describe the application-layer authentication that compensates for it. A pairing method chosen by hardware constraint is defensible; an unacknowledged one is not. The second decision is whether you use LE Legacy Pairing or LE Secure Connections. Legacy pairing, used before Bluetooth 4.2, has a key exchange that does not resist passive interception in the same way. LE Secure Connections uses elliptic curve Diffie-Hellman and is the baseline any new design should target. ## The Attack Classes You Should Be Testing Against | Attack class | What it exploits | What stops it | |---|---|---| | Passive eavesdropping | Weak or absent link encryption | LE Secure Connections with adequate key length | | Active man in the middle | Unauthenticated pairing | Authenticated association model or out-of-band pairing | | Key negotiation downgrade | Negotiable encryption key length | Enforce a minimum key length and reject short keys | | Reconnection spoofing | Weaker authentication on reconnect | Verify identity on every reconnection, not only at pairing | | Device tracking | Static Bluetooth addresses | Resolvable private addresses rotated over time | | Denial of service | Connection flooding or malformed packets | Rate limiting, resilient parsing, and a defined safe state | | Implementation flaws | Chipset SDK defects | Vendor patch tracking, fuzzing, and SBOM coverage of the stack | Denial of service deserves a note because it is often dismissed as a nuisance. For a device that delivers therapy or alarms on a clinical condition, an attacker who can keep the radio unavailable has created a patient safety condition. The threat model should treat radio availability as a safety property when the clinical function depends on it. Privacy tracking matters too. A device that advertises a static address broadcasts a persistent identifier, which for a medical device can reveal that a person is using a particular therapy. Resolvable private addresses exist precisely for this, and using them is a straightforward configuration decision. ## What Belongs in Your Submission Reviewers are looking for the radio to be treated as a first-class interface rather than an implementation detail. | Documentation element | What it should state about Bluetooth | |---|---| | Threat model | Threats at the radio layer, including man in the middle, downgrade, and availability | | Security architecture views | The radio shown as a trust boundary with what crosses it | | Cryptographic description | Pairing method, LE Secure Connections or not, key sizes, key storage | | SBOM | The Bluetooth stack and chipset SDK with versions | | Testing evidence | Over-the-air testing, not only application testing through the app | | Labeling | Pairing instructions and what the user should do if pairing behaves unexpectedly | The SBOM entry is the one teams forget. The Bluetooth stack usually comes from the chipset vendor, it has its own version history and its own advisories, and the SweynTooth family showed exactly why you need to know which version you shipped. When a new stack advisory appears, the SBOM is what lets you answer whether you are affected. ## Testing a Bluetooth Interface Properly Testing the mobile app that talks to your device is not testing the radio. The app uses your intended interface in the intended way; an attacker does not. Radio testing means operating at the protocol level with equipment that can observe and inject traffic, attempt unauthorized connections, force renegotiation, and send malformed packets. A reasonable scope covers pairing and re-pairing behavior, what the device exposes before authentication, whether GATT characteristics enforce authorization, whether the device accepts connections it should refuse, behavior under connection flooding, and response to malformed input. It should also verify that the security requirements you wrote for the radio were actually implemented, which is a different question from whether an attacker succeeded on the day of testing. ## How Blue Goat Cyber Approaches This We test Bluetooth interfaces over the air, with radio equipment rather than through the vendor app, because the app cannot reproduce what an attacker in range will do. That covers pairing negotiation, reconnection behavior, GATT authorization, downgrade resistance, and the device's behavior when the radio is attacked rather than used. Our [medical device penetration testing](/services/medical-device-penetration-testing) includes the wireless layer as standard for connected devices, and our [threat modeling](/services/threat-modeling) work puts the radio in the architecture views as the trust boundary it is. ## Frequently Asked Questions ### Is Bluetooth Low Energy secure enough for medical devices? It can be, when the device uses LE Secure Connections with an authenticated pairing method and adds application-layer authentication on top. BLE becomes a problem when a device relies on protocol defaults, particularly Just Works pairing on hardware with no user interface, and treats the presence of link encryption as sufficient evidence of security. ### What is Just Works pairing and why is it a problem? Just Works is the BLE association model used when neither device can display or enter a passkey. It produces an encrypted link but authenticates nothing, so an attacker in radio range can pair with the device and the device cannot distinguish them from the legitimate peer. It is sometimes unavoidable on hardware without a user interface, which is why compensating authentication at the application layer matters. ### Did the FDA issue guidance about Bluetooth vulnerabilities? The FDA issued a safety communication in March 2020 regarding the SweynTooth family of Bluetooth Low Energy vulnerabilities, which affected software development kits from multiple chipset manufacturers used in medical devices. The communication advised manufacturers to evaluate affected devices and work with chipset vendors on patches, and it is a useful reference for why radio stack versions belong in your SBOM. ### Do we need to test the radio if we already tested the mobile app? Yes. Application testing exercises the interface through the intended client, which behaves correctly by design. Radio testing exercises the interface the way an attacker would, using equipment that can attempt unauthorized connections, force renegotiation, and send malformed packets. They answer different questions and a submission generally needs both. ### How should devices handle reconnection security? By authenticating on every reconnection rather than trusting a previously bonded identity without verification. The BLESA research demonstrated that reconnection is frequently weaker than initial pairing, because implementations treat an existing bond as sufficient proof of identity. Verifying the peer on each reconnect closes the gap. ### What about Bluetooth Classic in medical devices? Bluetooth Classic still appears in devices that need higher throughput, such as audio applications in hearing devices. It carries its own history, including the KNOB key negotiation weakness, and devices supporting both transports need to consider cross-transport key derivation issues of the kind BLURtooth exploited. Dual-mode devices should document both stacks. ## Have a Device With a Radio in It? If your device pairs with a phone or a hub, the radio is the part of your attack surface an attacker reaches first and the part most often left untested. We test it the way they would. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## Brainjacking: Cyber Threat to NeuroTech Source: https://bluegoatcyber.com/blog/brainjacking-cyber-physical-threat-neurotech # Brainjacking: The Cyber-Physical Threat to NeuroTech > **[DIRECT ANSWER]** Brainjacking is the unauthorized manipulation of an implanted neurostimulator, such as a DBS, SCS, VNS, RNS, or brain-computer interface, achieved by exploiting its wireless programming interface. An attacker can alter stimulation parameters, drain the battery, or spoof closed-loop sensor inputs. Unlike typical data breaches, brainjacking creates direct cyber-physical harm to the patient, making it a clinical safety threat as much as a security one. When connected medical devices are compromised, the harm is usually framed as "data" or "downtime." For implanted neurostimulators, the harm is something different - and worse. **Brainjacking** is the unauthorized control of an electronic brain implant. Pull the right wireless levers and you don't just leak information or interrupt therapy. You can change how a person moves, what they feel, and - in extreme cases - who they are. This post is a working brief for medical-device manufacturers, security teams, and regulatory leads who own NeuroTech products. We cover where the term came from, the attack vectors that matter in real DBS, SCS, and BCI hardware, the clinical consequences a reviewer will (rightly) expect you to address, and what we ship in submissions to convince FDA the device is defensible. ## Key Takeaways - Brainjacking is unauthorized control of neuroimplants. - Exploits wireless programming interfaces. - Can alter therapy, drain battery, or spoof data. - Causes severe clinical harm, not just data loss. - FDA requires explicit mitigation in submissions. - Authentication and encryption are critical controls. ## Why this matters The stakes involved in neurotechnology cybersecurity extend beyond data breaches or system downtime; they directly impact patient physiology and autonomy. Brainjacking, the unauthorized control of an implanted neurostimulator, can induce severe clinical harm such as altered motor function, induced pain, mood changes, or impulse control disruption. This isn't merely a data privacy concern; it's a direct cyber-physical threat to the patient's well-being. The FDA, in its Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, explicitly expects manufacturers to design devices and their components to prevent unauthorized access and control. This includes ensuring the integrity and availability of therapy delivered by neuroimplants. Manufacturers must address potential brainjacking vectors in their risk management files (ISO 14971), security architecture (IEC 81001-5-1), and threat modeling (AAMI TIR97). Failure to convincingly demonstrate mitigation strategies for brainjacking risks can lead to significant regulatory hurdles and delays in market access for critical neurotherapeutic devices. Proactive security measures are not just good practice, but a regulatory imperative. ## Origin of the term "Brainjacking" was coined by **Laurie Pycroft** and colleagues at the University of Oxford's Functional Neurosurgery group in a 2016 paper published in *World Neurosurgery* titled *["Brainjacking: Implant Security Issues in Invasive Neuromodulation"](https://pubmed.ncbi.nlm.nih.gov/27184896/)* (Pycroft L, Boccard SG, Owen SLF, Stein JF, Fitzgerald JJ, Green AL, Aziz TZ. *World Neurosurgery* 92:454-462, 2016; DOI [10.1016/j.wneu.2016.05.010](https://doi.org/10.1016/j.wneu.2016.05.010)). The team included neurosurgeons **Tipu Aziz** and **Alex Green**, who actually implant deep brain stimulation (DBS) systems clinically. That's important context: this wasn't security researchers theorizing about devices they had never touched. It was the surgeons themselves raising the alarm about devices they put in patients' heads every week. The term is now established in both the security and neurosurgery literature - when you say "brainjacking" on stage or in a submission, you are using a term-of-art the field recognizes. ## What brainjacking actually means Brainjacking is the unauthorized control of an electronic brain implant. The most common target is the **deep brain stimulation (DBS) system**, which has three components: - **Electrodes** implanted deep in the brain - A **lead wire** running under the skin - An **implanted pulse generator (IPG)** that contains the battery, processor, and wireless antenna for clinician programming Functionally it is a pacemaker for the brain. The wireless programming interface is the attack surface. Clinicians need to adjust stimulation parameters non-invasively (otherwise every adjustment would require surgery), so the IPG accepts commands over a wireless link. **If that link is unauthenticated, weakly authenticated, or unencrypted, an attacker within range can do what the clinician does.** The same architectural pattern - implanted stimulator + wireless programmer + cloud back-end - now extends to **spinal cord stimulators (SCS)**, **vagus nerve stimulators (VNS)**, **responsive neurostimulators (RNS)** for epilepsy, and the new generation of **brain-computer interfaces (BCIs)** with continuous neural recording. ## The neurotech device families in scope Each of these device classes shares the "implant + wireless programmer" pattern, so each inherits brainjacking risk. Quick definitions for readers who don't live in this world: - **DBS - Deep Brain Stimulator.** Electrodes implanted in deep brain nuclei (e.g., subthalamic nucleus) to treat Parkinson's, essential tremor, dystonia, and refractory OCD. - **SCS - Spinal Cord Stimulator.** Epidural leads over the spinal cord to block chronic neuropathic pain. - **VNS - Vagus Nerve Stimulator.** Cuff electrode on the left cervical vagus nerve, used for drug-resistant epilepsy and treatment-resistant depression. - **RNS - Responsive Neurostimulator.** Closed-loop cortical/depth electrodes (e.g., NeuroPace RNS System) that detect epileptiform activity and deliver on-demand stimulation. - **BCI - Brain-Computer Interface.** Implanted or surface electrode arrays that record - and increasingly stimulate - neural activity to drive an external effector (cursor, prosthesis, speech synthesizer). - **IPG - Implantable Pulse Generator.** The battery + radio + microcontroller "can" that houses the stimulation electronics for DBS, SCS, and VNS systems. ## The specific attack vectors Pycroft catalogued This is where it gets concrete. Pycroft's paper laid out a taxonomy of attacks against DBS that still maps directly to the threat models we build for NeuroTech clients today. ### 1. Battery drain Force the IPG into continuous wake or transmit cycles until the battery dies. The device stops delivering therapy. For a Parkinson's patient, motor symptoms return. For an epilepsy RNS patient, seizure protection disappears. Replacement requires surgery. ### 2. Overcharge stimulation Push voltage or current beyond safe parameters. Can cause tissue damage, painful sensations, or compulsive behavioral effects depending on the brain region targeted. ### 3. Voltage and current manipulation Subtler than overcharge. Just shifting parameters off-therapeutic can degrade outcomes without obvious failure, making the attack harder to detect than a hard fault. ### 4. Frequency and pulse-width changes These are the parameters clinicians actually titrate for therapeutic effect. Modifying them changes how the brain region responds. In DBS for Parkinson's, the difference between effective tremor suppression and a non-functional patient is often a few Hz. ### 5. Electrode-contact alteration Modern DBS leads have multiple contacts. Switching which contact is active can move stimulation from the intended target into adjacent brain tissue. The clinical effects depend entirely on what's nearby - which is what makes this category dangerous. ### 6. Data theft Neural recordings and device telemetry are themselves sensitive. Some next-generation devices record neural activity continuously, generating a stream that has both clinical value and obvious privacy implications. ## What the clinical consequences look like This is the part that makes audiences sit up - and the part that should be sitting in your hazard analysis. - **Induced pain.** A spinal cord stimulator is implanted to *block* pain. Modify the parameters and you can deliver pain instead. Same hardware, opposite outcome. - **Motor inhibition.** A Parkinson's patient relies on DBS to function. Disable it or shift parameters and they may lose the ability to move, speak clearly, or maintain balance. - **Impulse-control disruption.** DBS in certain targets affects impulse regulation. There are documented clinical cases (non-malicious, from improper programming) of patients developing pathological gambling, hypersexuality, or compulsive behaviors after stimulation changes. An attacker could induce these deliberately. - **Affect and emotion modulation.** DBS is used to treat severe depression and OCD. The same mechanism that can lift depression can deepen it. The same regions that regulate fear and anxiety can be driven the other direction. - **Reward-pathway exploitation.** This is the most unsettling category Pycroft raised. Stimulating reward circuits during specific behaviors could, in principle, reinforce those behaviors. It is harder to achieve and requires sophisticated targeting, but it is not science fiction. It is pharmacology with a wireless interface. - **Closed-loop system manipulation.** For responsive neurostimulation in epilepsy (e.g., NeuroPace RNS), the device decides when to deliver therapy based on detected neural patterns. Spoof the input and you either trigger unnecessary stimulation or block stimulation when a real seizure is starting. ## Why NeuroTech is uniquely hard Pycroft and the subsequent literature made a few points that deserve to be stated plainly to any executive sponsor or regulatory lead: - **The brain is uniquely consequential.** Cardiac implants can kill you. Neuro implants can do that, *and* they can change who you are. The category of harm is broader than any other connected device. - **The patient often can't tell.** A pacemaker patient feels arrhythmia. A DBS patient experiencing subtle parameter drift may just feel like their disease is progressing. Brainjacking can hide as clinical decline. - **The clinician often can't tell either.** If telemetry has been spoofed, the clinician sees what the attacker wants them to see. The clinician adjusts based on bad data and the patient is harmed by good-faith medical care. - **Patient self-mitigation is impossible.** You can't reboot it. You can't unplug it. You can't even know it's been compromised without specific monitoring infrastructure that mostly doesn't exist yet. ## What FDA expects NeuroTech manufacturers to do about it Brainjacking is not a hypothetical for FDA reviewers. [Section 524B of the FD&C Act](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) and the [February 2026 final premarket cybersecurity guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) both push manufacturers to demonstrate that **integrity and availability** of therapy are protected with the same rigor as confidentiality. Across the NeuroTech submissions we have supported, reviewers consistently look for: 1. **A threat model that names brainjacking explicitly.** STRIDE or a comparable methodology, with attacker profiles that include a low-skill clinician-impersonator, a co-located adversary with the programmer protocol reversed, and a remote adversary pivoting through the patient's home gateway or companion app. 2. **Authenticated, encrypted wireless sessions.** Mutual authentication between IPG and programmer, ephemeral keys, replay protection, and a documented key-management lifecycle from manufacture through end-of-life. 3. **Bounded stimulation parameters enforced in firmware.** Even an authenticated command must not be able to drive voltage, current, frequency, pulse-width, or active contact outside therapeutically and biologically safe envelopes for the indication. 4. **Integrity protection for closed-loop inputs.** Sensed neural signals that drive automated stimulation must be authenticated end-to-end so a spoofed input cannot trigger or suppress therapy. 5. **Tamper-evident telemetry.** Programmers and back-end services must be able to detect parameter histories that don't match what the device actually executed - so a clinician can spot a brainjacked device even when the patient cannot. 6. **Battery-drain resilience.** Rate-limiting, session lock-outs, and detection of abusive query patterns belong in the requirements set, not the post-hoc mitigation section. 7. **A coordinated vulnerability disclosure (CVD) program** that researchers can actually use, with safe harbor and a published triage SLA. 8. **A postmarket monitoring plan** that treats unexplained therapy degradation, anomalous programmer activity, and out-of-band parameter changes as security signals - not just clinical noise. For the underlying lifecycle picture, see our deeper write-ups on [NeuroTech cybersecurity risks across neurostimulators, EEG, and BCIs](/blog/neurotech-cybersecurity-risks-neurostimulators-eeg-bci) and [implantable device cybersecurity concerns](/blog/implantable-device-cybersecurity-concerns). ## Vulnerability and disclosure timeline Brainjacking is not a single 2016 headline. It is a decade-long research arc that FDA reviewers now treat as the baseline of "foreseeable risk" for any wireless neurostimulator. The condensed timeline: - **2008 - Halperin et al.** demonstrate that a common implantable cardioverter-defibrillator can be reprogrammed wirelessly by an unauthenticated attacker within radio range ([*Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses*](https://www.secure-medicine.org/hubfs/public/publications/icd-study.pdf), IEEE S&P). Establishes the wireless-programmer threat model that DBS and SCS inherit. - **2012 - Marin, Singelée et al.** publish reverse-engineering work on proprietary implant protocols showing that "proprietary" is not a security control, foreshadowing every audit finding since. - **2016 - Pycroft et al.** coin *brainjacking* in *World Neurosurgery* ([DOI 10.1016/j.wneu.2016.05.010](https://doi.org/10.1016/j.wneu.2016.05.010)) and enumerate the six attack categories still used in threat models today. - **2017 - Marin et al.** publish "On the (in)security of the latest generation implantable cardiac defibrillators" - independent confirmation that shipping medical wireless stacks were brute-forceable and replayable. - **2018 - Medtronic CareLink 2090 programmer** (used for cardiac and neurostimulator systems) receives an [ICS-CERT advisory (ICSMA-18-058-01)](https://www.cisa.gov/news-events/cybersecurity-advisories) covering telemetry authentication weaknesses. First large-scale reminder that programmer-side compromise is part of the brainjacking surface. - **2019 - MedSec / Medtronic Conexus** telemetry disclosures ([ICSMA-19-080-01](https://www.cisa.gov/news-events/cybersecurity-advisories)) - unauthenticated radio protocol used across multiple implantable families. Manufacturer response cycle establishes the postmarket cadence FDA now expects. - **2020-2022 - SweynTooth, BrakTooth, and follow-on BLE stack disclosures** hit chipsets used in medical wireless gateways and companion devices. See our write-up on [SweynTooth and BLE risk in medical devices](/blog/sweyntooth-exploring-the-bluetooth-vulnerability). - **December 29, 2022 - Section 524B of the FD&C Act** takes effect, making cybersecurity a statutory premarket requirement for cyber devices. - **February 3, 2026 - FDA's final** [*Cybersecurity in Medical Devices*](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) guidance codifies expectations for threat modeling, secure architecture, and postmarket monitoring - the framework reviewers now apply to every neurostimulator submission. The pattern across the decade is consistent: the wireless interface is where the harm lives, "proprietary" never held, and reviewers now expect the countermeasures listed in the section above to be documented up front - not added after a deficiency letter. ## Where this fits in your submission If your device is a neurostimulator, an active implantable, or a BCI with sensing or stimulation, brainjacking belongs in: - The **security risk assessment** as a top-level threat with explicit clinical consequences mapped to ISO 14971 harm categories. - The **threat model** as a named attacker objective. - The **architecture views** that show where authentication, encryption, and parameter bounding are enforced. - The **V&V plan** as adversarial test cases against the wireless interface, not just functional tests. - The **postmarket plan** as a monitored signal class, not a footnote. When all five artifacts align, brainjacking stops being a stage-talk anecdote and becomes a documented, defended risk - which is exactly what FDA wants to see. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat approaches this Blue Goat Cyber's approach to brainjacking mitigation centers on identifying and neutralizing exploit pathways in neurotechnology. Our team, comprised of CISSP and OSCP certified experts, including ex-military red team personnel, conducts focused penetration testing and architectural reviews. We analyze wireless interfaces, firmware integrity, and programming protocols to uncover exploitable vulnerabilities. We develop and validate security controls that directly address the clinical consequences of unauthorized access, ensuring the integrity and availability of therapy. Our threat modeling services precisely map attack vectors to potential patient harm. We integrate these findings into regulatory submissions, presenting a clear, technical narrative to the FDA. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is brainjacking in one sentence? Brainjacking is the unauthorized control of an implanted neurostimulator - typically a DBS or SCS device - achieved by abusing its wireless programming interface to change stimulation parameters, drain the battery, or spoof closed-loop inputs. ### Has brainjacking happened to a real patient? There is no public, confirmed in-the-wild brainjacking case as of this writing. The threat is documented in academic literature ([Pycroft et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27184896/) and follow-ons) and demonstrated in lab settings against real device protocols. FDA's premarket guidance treats it as a foreseeable threat that manufacturers must address. ### Which devices are most exposed? Any implanted stimulator with a wireless programming or telemetry interface: deep brain stimulators (DBS), spinal cord stimulators (SCS), vagus nerve stimulators (VNS), responsive neurostimulators (RNS), and the new wave of brain-computer interfaces (BCIs) with implanted recording electrodes. ### Isn't a short-range proprietary radio safe enough? No. "Proprietary" is not a security control. Several inductive, MICS, and BLE-based programmer protocols have been reverse-engineered and shown to be brute-forceable or replayable. Reviewers expect cryptographic authentication and encryption - not obscurity. ### Does Section 524B require us to address brainjacking specifically? Section 524B requires you to address foreseeable cybersecurity risks for "cyber devices" with reasonable assurance of safety and effectiveness. For an implanted neurostimulator, brainjacking is a foreseeable risk by definition. The [February 2026 final guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) makes that expectation explicit through threat modeling, secure architecture, and postmarket monitoring requirements. ### Where does brainjacking sit relative to ISO 14971? It is a security-originated cause of clinical harm. ISO 14971 (with AAMI TIR57 / ANSI/AAMI SW96:2023 as the security overlay) is the right framework: identify the hazard (e.g., unintended high-frequency stimulation), trace it to a security cause (unauthenticated command), assign severity from the clinical consequence, and document the controls that bring residual risk to acceptable. ## Talk to a team that has shipped NeuroTech submissions If you are designing or maintaining a neurostimulator, BCI, or active implantable, the brainjacking threat model is not optional - and it is not something you want to discover during an FDA AI request. [Book a 30-minute strategy session](/contact) and we'll walk through where your current submission stands and what we'd add before it goes to a reviewer. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CAN Bus Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/can-bus-canopen-medical-device-vulnerabilities # CAN Bus and CANopen Vulnerabilities in Medical Devices > **[DIRECT ANSWER]** CAN and CANopen buses show up inside surgical robots, imaging systems, infusion pumps, and lab analyzers to coordinate motors and sensors, and they carry no native authentication, encryption, or replay protection, so any node can be spoofed or replayed once reached. Attackers arrive through service ports, compromised gateways, or supply-chain firmware, not just physical access. The FDA's February 2026 guidance expects these buses modeled explicitly, with architecture views and pen test evidence covering them, not assumed secure by isolation. **Most medical-device threat models stop at Ethernet, BLE, and the cloud API. The CAN bus running between the motor drives and the main controller almost never makes it into the architecture diagram - and that's exactly where the most damaging attacks land.** ## Key Takeaways - CAN and CANopen sit inside many motorized and multi-node medical devices. - CAN has no native authentication, encryption, or replay protection. - "Internal-only bus" is not a sufficient control argument for FDA reviewers. - Realistic attack paths exist via service ports, gateway IPCs, and supply chain. - Pen-test evidence and architecture views must explicitly cover the bus. - Defenses include CAN-FD with SecOC patterns, gateway filtering, and node secure boot. ## Why this matters The stakes are critical: unaddressed CAN bus vulnerabilities can lead to unauthorized control over device functions, patient harm, and significant compliance penalties. Many medical device threat models incorrectly stop at network interfaces like Ethernet or BLE, neglecting the internal CAN bus that often controls critical physical actions. The FDA's Cybersecurity in Medical Devices Final Guidance, dated February 3, 2026, explicitly requires manufacturers to address threats to all device components, including internal communication buses, citing them as a potential attack surface. This means that assuming an internal bus is secure by isolation is no longer acceptable. Manufacturers must integrate CAN and CANopen into their cybersecurity architecture views and threat models, per standards like AAMI TIR57 / ANSI/AAMI SW96:2023, and provide penetration test evidence. Failure to do so can result in submission delays, costly redesigns, and impact market entry of essential medical technologies. Proactive identification and mitigation of these vulnerabilities are paramount for patient safety and regulatory approval. ## Where CAN and CANopen actually appear in medical devices CAN (ISO 11898) and its higher-layer protocol CANopen (CiA 301) were inherited from industrial automation because they are cheap, deterministic, electrically resilient, and well-supported by every motor-drive vendor. That same supplier ecosystem is why they keep showing up inside medical devices, including: - **Surgical robotics** - joint controllers, motor drives, and end-effector encoders on a CANopen backbone. - **Imaging systems** - CT and MRI table positioning, C-arm motion control, gantry rotation feedback. - **Infusion** - multi-channel pump manifolds and large-volume pump motor controllers. - **Lab analyzers and IVD instruments** - sample handlers, pipettors, rotary carousels, reagent dispensers. - **Renal and dialysis** - pump and valve coordination across the fluid path. - **Ancillary equipment** - dental chairs, motorized OR tables, sterilizer racks, automated pharmacy dispensers, some legacy ventilators and anesthesia workstations. If a device has more than one microcontroller moving something physical, there is a non-trivial chance a CAN bus is in the architecture - and a much smaller chance it appears in the threat model. ## Why CAN is a soft target CAN was specified in the 1980s for sealed automotive uses where the bus itself was considered the trust boundary. The protocol reflects that: - **No authentication.** Any node on the bus can transmit any arbitrary ID. - **No encryption.** Payloads are in the clear; sniffing a bus reveals command and telemetry semantics quickly. - **No replay protection.** Captured frames can be re-injected verbatim and accepted as legitimate. - **Broadcast topology.** Every node sees every frame; there is no per-link segmentation. - **Priority-based arbitration.** A node continuously transmitting low-ID frames can starve higher-ID traffic - a trivial denial-of-service primitive. - **CANopen exposes more.** Standardized object dictionary access, heartbeat, NMT state commands, and SDO/PDO mechanisms give an attacker a documented protocol to drive nodes through. None of this is news to controls engineers. It becomes a medical-device cybersecurity problem the moment the bus is reachable from anything that is not equally trusted. ## Realistic attack paths into the bus The threats reviewers want documented are not "an attacker plugs in a CAN sniffer in the OR." They are the indirect paths that get an adversary to the bus without physical access to a sealed enclosure. 1. **Service-port exposure.** DB9, M12, or proprietary maintenance connectors behind a panel, often unauthenticated and sometimes documented in the service manual. Field service tools become the attack tool. 2. **Compromised gateway IPC.** Almost every modern device has an Ethernet- or Wi-Fi-connected controller that bridges to CAN for motion or sensor coordination. Compromise the IPC and you own the bus from the network. 3. **Supply-chain motor-drive firmware.** A trojanized firmware image on a node ships from the OEM and joins the bus with full privileges. 4. **Malicious or replaced node.** A consumable, cartridge, or accessory that participates in the CAN protocol can be substituted to inject frames or impersonate a sensor. 5. **Wireless-to-CAN pivot.** BLE-enabled service or commissioning interfaces that ultimately write to CANopen objects on the backbone. For each of these, the architecture view must show the bus, the bridging node, and the trust boundary that was crossed. ## What goes wrong when these paths are not modeled The patient-safety consequences cluster into a small number of patterns: - **Spoofed motion commands** to a motor drive (gantry, table, robot joint, pump piston). - **Falsified sensor telemetry** to the main controller, causing it to make unsafe closed-loop decisions. - **Disabled or bypassed safety supervisors** by injecting heartbeat or NMT frames that mask a fault. - **Bus flooding** to starve safety-critical periodic messages, triggering watchdog failures or - worse - silent degradation. - **Persistence on a non-updatable node** that re-infects the rest of the system after remediation. These map cleanly to AAMI TIR57 / ANSI/AAMI SW96:2023 security risk and to ISO 14971 hazard analysis. The Feb 3, 2026 premarket guidance expects that mapping to be visible in the submission. ## What the FDA expects in the submission When CAN or CANopen is in scope, reviewers look for the same elements they expect elsewhere, applied to the bus: - **Architecture views** that include the bus, every node attached to it, and the trust boundary around the enclosure or service port. - **Threats** enumerated against the bus, not just against the network and wireless interfaces. - **Security controls** tied to those threats with traceability into the security risk file. - **Pen-test evidence** that exercised at least one realistic path to the bus and documented what was attempted, what worked, what was remediated, and what was retested. - **Postmarket plan** that explains how a vulnerability in a CAN-connected component would be received, scored, and remediated, including any nodes that cannot be field-updated. "Internal-only bus" with no further analysis is the answer that earns a deficiency letter. > **Securing a CAN or CANopen medical device?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Medical device penetration testing](/services/medical-device-penetration-testing) ## Controls that actually hold up There is no single fix; the realistic posture is layered. - **CAN-FD with authenticated frames.** AUTOSAR SecOC-style MACs, CANcrypt, or equivalent vendor schemes add per-frame authentication and freshness. Practical to adopt on greenfield designs, harder to retrofit. - **Gateway filtering and policy.** The IPC that bridges Ethernet or wireless to CAN should enforce a strict allowlist of IDs and rate limits per direction. Treat the gateway like a firewall, not a pass-through. - **Physical access hardening.** Tamper-evident enclosures, locking service connectors, and detection of unauthorized panel access. - **Secure boot and signed firmware on every node**, including the small ones. A motor-drive controller running unsigned firmware is the persistence point that survives every other control. - **Bus monitoring.** Bus-load thresholds, ID-frequency baselines, and heartbeat-loss alarms feeding the device's safety supervisor. - **Service-tool authentication.** Cryptographic challenge-response on the maintenance interface, not a static service code printed in the manual. - **Defense in depth at the closed-loop layer.** Sanity checks on commanded vs. measured motion, plausibility limits on sensor telemetry, and independent watchdogs that the bus cannot silence. The right combination depends on whether you are designing a new device, fielding a 510(k) for an existing platform, or writing a postmarket SBOM/VEX program for a legacy system that cannot be modified. ## How we test CAN and CANopen in a pen test Our methodology mirrors how the realistic attacks unfold: 1. **Passive capture.** Hardware (CANable, PCAN, Kvaser) on the bus or downstream of the gateway. Build a working DBC by correlating frames with observed device behavior. 2. **Protocol mapping.** For CANopen, enumerate the object dictionary, NMT states, heartbeats, SDO and PDO mappings. Identify the safety-relevant objects. 3. **Replay.** Replay captured command frames against the live system and observe state changes. 4. **Fuzzing.** Targeted fuzzing of motion command payloads, SDO writes, and heartbeat timing. 5. **Injection.** Author and inject specific malicious frames - motion commands, falsified sensor reports, NMT resets - and document the device's response. 6. **Pivot.** Exercise at least one realistic path *to* the bus (service port, compromised IPC simulation, malicious accessory). 7. **Detection and recovery.** Assess whether the device noticed, what it did, how it logged it, and how it recovered. The output is a report that an FDA reviewer can read alongside the architecture view and the security risk file, with each finding traced to a threat, a control, and a patient-safety impact. ## Where to go from here If your device has motors, multiple boards, or a service connector behind a panel, the CAN bus is probably in scope whether your current documentation says so or not. Two practical next steps: - **Pull the bus into the threat model** before the submission, not after the deficiency letter. Even a one-page architecture annotation closes the most common gap. - **Scope at least one pen-test path to the bus** in your testing plan. A wireless-and-cloud-only pen test on a motorized device is the pattern reviewers are calling out most often. We do this end-to-end - architecture review, threat modeling, hardware and protocol pen testing, and submission-ready documentation. If CAN or CANopen is anywhere in your device, [book a strategy session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will walk through what reviewers expect to see for your specific architecture. ## How Blue Goat approaches this Blue Goat Cyber's approach to CAN and CANopen security starts with integrating these often-overlooked buses into your device's architecture and threat models, aligning with IEC 81001-5-1 requirements. Our team, with backgrounds as CISSP and OSCP certified professionals, including ex-military red team members, identifies realistic attack paths into these internal buses, extending beyond typical network interfaces. We conduct targeted penetration tests to validate these attack vectors and evaluate existing or proposed controls such as CAN-FD with SecOC patterns, gateway filtering, and secure boot for nodes. We provide actionable recommendations that enhance device security and comply with the FDA's February 3, 2026 premarket guidance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [https://bluegoatcyber.com/services/medical-device-penetration-testing](https://bluegoatcyber.com/services/medical-device-penetration-testing). ## Frequently Asked Questions ### Are CAN bus and CANopen actually in the FDA's cybersecurity scope? Yes. The FDA's February 3, 2026 final premarket guidance scopes "all interfaces that can affect device function or safety," not just network interfaces. An internal CAN bus that carries motor commands, pump setpoints, or sensor data is in scope - reviewers expect it modeled in the threat model and exercised in the penetration test, exactly like a wireless interface. ### Do I need SecOC or CAN-FD authentication on a Class II device? Not always - but you do need to justify the choice. If your hazard analysis shows that a forged CAN message can drive an unsafe state, the FDA expects an authenticated bus (CAN-FD with SecOC patterns or equivalent) or a credible compensating control (gateway filtering, segregated safety bus, mechanical interlocks). "We assumed the internal bus was trusted" is the most common deficiency trigger in this space. ### What's the most common CAN-related deficiency in FDA cybersecurity letters? A threat model that stops at the wireless or USB boundary and never enumerates the internal bus. Reviewers respond with a request to extend the model to every node that can write to CAN, plus evidence that spoofed messages were tested. Building the bus into the model up front avoids a 6-12 week AI-letter cycle. ### Can secure boot alone protect a CAN-connected device? No. Secure boot stops a compromised node from booting modified firmware, but it does nothing against a legitimate node that has been compromised at runtime or against a malicious node physically attached to the bus. CAN security needs authentication on the bus itself, not just integrity on the nodes. ### How do you pen test a CAN bus without bricking the device? On a staging unit, not on a clinical device. We use a CAN interface (e.g. PCAN-USB, Kvaser, or an SDR-backed use) to passively capture, then actively inject crafted frames - replay, spoof, fuzz CANopen object dictionary writes, and overload tests. Test results map back to specific hazard entries in the ISO 14971 risk file so safety and security teams act on the same evidence. - [FDA Section 524B cybersecurity requirements explained](/guides/fda-524b-cybersecurity-requirements-explained) - [SBOM vulnerability management for medical devices](/guides/sbom-vulnerability-management-medical-devices) - [VEX document guide for FDA submissions](/guides/vex-document-medical-device-fda) - [FDA deficiency-letter response service](/fda-cybersecurity-deficiency-letters) - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CAPA and Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/capa-medical-device-cybersecurity # CAPA and Medical Device Cybersecurity: Closing the Loop on Vulnerabilities and FDA Deficiencies > **[DIRECT ANSWER]** A cybersecurity finding becomes a CAPA when it is a nonconformity: an exploitable vulnerability in a released device, a systemic gap in your secure development process, or an FDA deficiency letter. Closing it requires root cause analysis, a documented correction, effectiveness verification, and updated design and risk records under QMSR and ISO 13485:2016. Cybersecurity findings on a regulated medical device are not bug tickets. They are nonconformities. The FDA's Quality Management System Regulation (QMSR), Section 524B postmarket obligations, and the February 3, 2026 final premarket cybersecurity guidance all assume that security events are processed through the same Corrective and Preventive Action loop the manufacturer uses for any other quality issue. Most submission-stage deficiencies and most postmarket inspection findings trace back to a security event that was fixed in code but never closed in CAPA. This post explains when a cybersecurity finding triggers a CAPA, what root cause analysis on a security control actually looks like, and what evidence closes the loop. ## Key Takeaways - Cybersecurity nonconformities (vulnerabilities, exploited CVEs, failed controls, FDA deficiencies) must be processed through the same CAPA system as any other quality issue under QMSR. - Not every CVE triggers a CAPA. The trigger is risk-based: exploitability in the device's threat model, patient safety impact, and recurrence pattern. - Cyber CAPA root cause has to address the failed control or process, not just the vulnerable component. - Effectiveness verification on a cyber CAPA includes regression testing of the affected security control and SBOM/VEX refresh. - A CAPA record is the audit artifact that proves Section 524B postmarket vulnerability handling is real and not just a policy document. ## Why this matters CAPA is the most-cited Form 483 observation in the FDA's annual inspection data, and cybersecurity findings are increasingly the trigger. The QMSR (21 CFR Part 820 as amended to align with ISO 13485:2016, effective February 2, 2026) requires that data sources including service records, complaints, audit findings, and process monitoring be analyzed to identify quality problems. Section 524B(b)(2)(B) of the FD&C Act requires manufacturers to "monitor, identify, and address" postmarket cybersecurity vulnerabilities, and the FDA's February 3, 2026 final premarket cybersecurity guidance expects that postmarket plan to plug into the manufacturer's existing QMSR processes. The agency's expectation is explicit: vulnerability handling is a quality system activity, governed by the same CAPA procedure as any other nonconformity. Manufacturers that run vulnerability response on a separate security ticketing system, without a CAPA record, cannot prove the loop closed. ## What CAPA Is in a Medical Device Cybersecurity Context ### The QMSR Definition CAPA is a structured process for investigating, correcting, and preventing recurrence of quality problems. The QMSR requires procedures for analyzing nonconforming product, identifying actions needed to correct and prevent recurrence, verifying or validating the actions, implementing changes, and documenting the activities and results. The same process applies whether the nonconformity is a mechanical defect, a labeling error, or an exploitable cybersecurity vulnerability. ### Why Cybersecurity Findings Belong Here A cybersecurity vulnerability on a fielded device is a nonconformity against the device's security risk profile and the threat model that supported its clearance. The fix may be a patch, a configuration change, or a compensating control, but the QMSR question is not "did you patch it" but "did you investigate, correct, prevent, and verify." Closing a Jira ticket does not satisfy that question. A CAPA record does. ## What Cybersecurity Events Trigger a CAPA Not every CVE on the SBOM is a CAPA. The trigger is risk-based, scoped to the device's threat model. | Event | CAPA trigger threshold | | --- | --- | | New CVE on an SBOM component | Triggers CAPA if VEX status is affected/exploitable in the device's deployed configuration | | Penetration test finding | Triggers CAPA for any High or Critical, and for any Medium that recurs across releases | | Field-reported security incident | Triggers CAPA always, regardless of patient impact | | FDA cybersecurity deficiency letter | Triggers CAPA always (the deficiency is by definition a nonconformity) | | Failed security regression test | Triggers CAPA if the failure indicates a process gap, not a one-off test defect | | Coordinated vulnerability disclosure (CVD) intake | Triggers CAPA if the report validates an exploitable issue in a fielded device | | Exceeded VEX backlog SLA | Triggers CAPA on the postmarket vulnerability management process itself | The decision rule is documented in the manufacturer's CAPA procedure or a referenced cybersecurity SOP. "We patched it" is not a substitute for the rule. ## Root Cause Analysis for a Security Control Failure ### The Two Layers Cyber root cause analysis has to address two layers: the component layer (what made the vulnerability exploitable on this device) and the process layer (what part of the security program let the issue reach production or persist in the field). Stopping at the component layer is the most common CAPA defect on cyber findings. ### Example A device ships with an authentication bypass via a third-party dependency. The component-layer root cause is "library X version Y contained CVE-XXXX-XXXX." The process-layer root cause is "SBOM scanning ran only at release time, not on every dependency update, and the VEX triage SLA was not enforced." The CAPA must address both, or the same class of vulnerability will recur. ### Standards That Inform the Method ISO 14971:2019 for risk-based investigation, AAMI TIR57:2016/(R)2023 for security risk management, IEC 81001-5-1:2021 for security activities in the software lifecycle, and AAMI SW96:2023 for security risk management of medical device software all inform how a credible cyber root cause analysis is performed. ## Correction, Prevention, and Effectiveness Verification ### Correction The patch, configuration change, or compensating control that eliminates the immediate nonconformity. Includes the release path (regular update, expedited patch, field correction) and the customer communication plan if the device is already deployed. ### Prevention The change to the security program that prevents the same class of issue from recurring. Common cyber prevention actions: tightening SBOM scan cadence, adding a security regression test for the affected control, updating the threat model to capture the missed attack path, revising the secure coding standard, or adding a checkpoint to the design review. ### Effectiveness Verification > **[KEY REQUIREMENT]** Effectiveness verification on a cyber CAPA must include regression of the affected security control, a refreshed SBOM and VEX for the changed component, and confirmation that the threat model and risk file reflect the change. Closing a CAPA on a security finding without these three artifacts is a frequent FDA inspection observation. The verification record links to the regression test result, the regenerated SBOM/VEX, the updated threat model section, and (where applicable) the updated architecture views. The CAPA cannot be closed until those artifacts are produced and reviewed. ## How Cyber CAPA Ties to Section 524B Postmarket Obligations ### The Statutory Hook Section 524B(b)(2)(B) requires a plan to "monitor, identify, and address" postmarket cybersecurity vulnerabilities. The FDA's February 3, 2026 final premarket cybersecurity guidance expects that plan to integrate with QMSR processes rather than run as a parallel security-only workflow. CAPA is the integration point. ### What This Looks Like in Practice The postmarket cybersecurity plan references the CAPA procedure as the mechanism for handling validated vulnerabilities above defined risk thresholds. The CAPA procedure references the postmarket plan, the threat model, and the SBOM/VEX workflow as inputs. Inspections look for both directions of the reference, plus the actual CAPA records that demonstrate the loop ran. ### What Reviewers and Inspectors Look For - A documented decision rule for when a vulnerability triggers a CAPA versus a routine patch. - CAPA records showing investigation, root cause at both layers, correction, prevention, and effectiveness verification. - Linkage from the CAPA record to the threat model update, SBOM/VEX refresh, and any customer security advisory. - Trending of cyber CAPA data into management review under the QMSR's management responsibility requirements. [Talk to us about your postmarket cybersecurity program](https://bluegoatcyber.com/services/postmarket-sbom-vex-monitoring) if your CAPA process is not yet wired to your vulnerability management workflow. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches Cyber CAPA We build the bridge between the security team's vulnerability response and the quality system's CAPA loop. Our approach starts with a written decision rule for when a cybersecurity event triggers a CAPA, anchored to the device's threat model and risk acceptance criteria. We instrument the SBOM and VEX workflow so that triage outcomes flow into CAPA initiation automatically, and we structure the root cause template to require both component-layer and process-layer analysis. Our team holds CISSP, OSCP, and prior military red-team credentials, and we ground our work in QMSR, Section 524B, the February 3, 2026 final premarket cybersecurity guidance, AAMI SW96:2023, IEC 81001-5-1, and ISO 14971. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA deficiency response service](https://bluegoatcyber.com/services/fda-cybersecurity-deficiency-response) or our [postmarket SBOM and VEX monitoring service](https://bluegoatcyber.com/services/postmarket-sbom-vex-monitoring). ## FAQ ### When does a medical device cybersecurity vulnerability require a CAPA? A vulnerability requires a CAPA when it is exploitable in the device's deployed configuration (VEX status affected), when it was reported through a field incident or CVD intake, or when an FDA deficiency letter identifies it. New CVEs on the SBOM that are not exploitable can be tracked through routine VEX without opening a CAPA. The decision rule must be documented in the CAPA procedure, not improvised case by case. ### Is a patch release the same as closing a CAPA? No. The patch is the correction step. Closing the CAPA also requires root cause analysis at both the component and process layers, a prevention action that changes the security program to stop recurrence, and effectiveness verification including a security regression test and a refreshed SBOM/VEX. Releasing a patch without these closes the engineering ticket but leaves the CAPA open and the inspection finding active. ### How does cyber CAPA relate to the FDA Section 524B postmarket plan? The postmarket cybersecurity plan describes how the manufacturer monitors, identifies, and addresses vulnerabilities. CAPA is how the plan actually closes findings inside the quality system. The postmarket plan references the CAPA procedure as the closure mechanism, and the CAPA procedure references the postmarket plan, threat model, and SBOM/VEX workflow as inputs. Inspectors expect both references and actual records. ### Do penetration test findings need CAPAs? High and Critical findings always do. Medium findings that recur across releases do, because recurrence indicates a process problem. One-off Low findings can usually be handled inside the engineering backlog with a documented risk acceptance. The threshold belongs in the CAPA procedure or the security testing SOP it references. ### What is the most common cyber CAPA defect the FDA observes? Root cause stopping at the vulnerable component. The CAPA names the CVE, documents the patch, and closes. Inspectors then ask what changed in the security program to prevent the next instance, and the record has nothing. The fix is to require the root cause template to address both the component layer and the process layer, and to require a prevention action that modifies a procedure or control, not just the codebase. ### Where do CAPAs on cyber events show up in management review? QMSR requires management review to consider quality data trends. Cyber CAPA trends (open count, time to closure, recurrence rate, severity mix) belong in that review, alongside complaints, audit findings, and process monitoring. Treating cyber CAPA data as security-only and excluding it from management review is itself an observation risk. ## Ready to wire cybersecurity findings into your CAPA system? If your security team is closing vulnerabilities in a ticketing tool while your quality system has no record of the loop, you have an inspection exposure and a Section 524B alignment gap. We can build the bridge. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led premarket and postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## More on this topic - [Section 524B(b)(2): Medical Device](/blog/the-impact-of-524bb2-on-medical-device-cybersecurity) --- ## CIA Triad vs NSA Controls in Medical Devices Source: https://bluegoatcyber.com/blog/cia-triad-vs-nsa-controls-in-medical-device-cybersecurity # CIA Triad vs. NSA Controls in Medical Device Cybersecurity > **[DIRECT ANSWER]** The CIA triad is a way to classify what you are protecting; control catalogs tell you how. For medical devices the triad reorders itself, because availability and integrity failures injure patients while a confidentiality breach usually harms privacy first. Use the triad to frame the threat model, then implement named technical controls, and score every resulting risk against patient harm rather than against information value. _Reviewed July 24, 2026_ When it comes to securing medical devices, buzzwords like “CIA Triad” and “NSA recommendations” often get thrown around, but what do they really mean? More importantly, how do they apply to actual device design, software architecture, and regulatory approval? This article breaks down the CIA Triad, examines the NSA’s cybersecurity principles, and explains how both are critical to developing safe, secure, and FDA-compliant medical devices. ## Key Takeaways - CIA Triad is a high-level security objective. - NSA controls offer specific technical implementations. - Both are critical for FDA compliance. - NSA guidance enhances device resilience. - Failure to implement both risks regulatory issues. - Integrate controls throughout the development lifecycle. ## Why this matters Ignoring either the CIA Triad or NSA controls in medical device cybersecurity can lead to severe consequences, including patient harm, data breaches, regulatory non-compliance, and significant financial penalties. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the critical need for manufacturers to integrate security throughout the total product lifecycle, necessitating adherence to both foundational principles and advanced technical safeguards. Failure to protect confidentiality could expose sensitive patient data, violating privacy regulations. Lack of integrity might allow unauthorized modification of device functions or data, leading to incorrect diagnoses or treatments. Inadequate availability could render essential medical devices inoperable during critical moments. NSA controls, which address threats like advanced persistent threats (APTs) and supply chain vulnerabilities, further underpin the security required by standards such as IEC 81001-5-1 and AAMI TIR97. Manufacturers must demonstrate due diligence in adopting a holistic security approach that combines the strategic objectives of the CIA Triad with the tactical implementations informed by NSA guidance to ensure product safety, efficacy, and regulatory approval. ## At a glance | Dimension | CIA Triad | NSA (CSI) Controls | |:--- |:--- |:--- | | **Definition** | Conceptual framework for Information Security (Confidentiality, Integrity, Availability). | Technical security principles and actionable mitigation strategies/best practices. | | **Typical Use Case** | Baseline architectural design and risk assessment for IoMT devices. | Hardening specific systems, network protocols, and cryptographic implementations. | | **Range/Scope** | High-level data and service protection objectives. | Defense-in-depth, zero-trust architecture, and technical configuration guidance. | | **Security Posture** | Focuses on organizational goals and data protection outcomes. | Focuses on proactive defense, incident response, and threat hunting. | | **Common Attacks** | Data breaches (C), tampering (I), and DoS/outages (A). | Advanced Persistent Threats (APTs), supply chain attacks, and lateral movement. | | **FDA Relevance** | Foundational requirement for Pre-Market Submissions (PMA/510k) and risk management. | Reference frameworks (e.g., NIST) often incorporate NSA-recommended cryptographic standards. | | **Key Tradeoff** | Simple to understand but lacks specific implementation instructions. | Highly technical and intensive to implement across legacy device fleets. | ## What Is the CIA Triad? The **CIA Triad** stands for: - **Confidentiality** Protect patient data, especially Protected Health Information (PHI)-from unauthorized access. → _Example:_ Encrypt telemetry between an insulin pump and cloud platform using TLS 1.3. - **Integrity** Ensure data and firmware remain unaltered, whether stored or transmitted. → _Example:_ Use signed firmware updates to prevent unauthorized code changes. - **Availability** Devices must be accessible and operational when needed. → _Example:_ Ensure pacemakers or hospital ventilators aren’t vulnerable to Denial of Service (DoS) attacks. These principles form the foundation of most cybersecurity frameworks, including the FDA’s premarket cybersecurity guidance. ## NSA Controls and How They Extend the CIA Triad The NSA’s cybersecurity recommendations go a step further. While they build upon the CIA Triad, they emphasize resilience, zero trust, and hardening-elements particularly valuable for safety-critical devices. ### NSA-Aligned Cybersecurity Tactics for Medical Devices - **Secure Boot and Code Signing** Guarantee that only trusted firmware runs on your device. - **Hardware Root of Trust** Use a secure element or TPM to anchor trust at the silicon level. - **Interface Control** Disable or secure unused interfaces (e.g., UART, USB debug) that attackers could exploit. - **Anomaly Detection & Logging** Log authentication failures, unexpected inputs, or abnormal telemetry behavior for forensic analysis and postmarket surveillance. - **Encryption with Key Management** Go beyond basic encryption-implement lifecycle-aware key rotation and storage in hardware-protected areas. ## Why Both Frameworks Matter to Medical Device Manufacturers - CIA Triad ensures the minimum baseline for data protection. - NSA recommendations help future-proof devices against sophisticated and evolving threats. - Both are baked into FDA expectations through the [Secure Product Development Framework (SPDF)](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect), eSTAR templates, and postmarket guidance. Failing to implement both sets of practices could mean: - Submission delays - Recall risks - Cybersecurity deficiencies in FDA reviews ## Case Study: Combining CIA and NSA Tactics A Bluetooth-enabled cardiac monitor uses: - **Confidentiality**: Encrypts all wireless communication - **Integrity**: Applies signed firmware validation at boot - **Availability**: Monitors battery voltage and wireless signal health to prevent unexpected shutdowns - **NSA Hardening**: Disables unused debug ports, includes anomaly detection for telemetry variance, and enforces secure firmware update keys Together, these practices strengthen the device’s security posture, and align it with both compliance and real-world resilience. ## Best Practices for Implementation - Map the CIA Triad to your product’s architecture. - Review NSA control recommendations during early-stage threat modeling. - Incorporate hardening and anomaly detection into your SPDF documentation. - Validate implementation with firmware testing and penetration testing. - Document controls clearly in your eSTAR cybersecurity section. ## Final Thoughts Securing medical devices isn’t just about ticking boxes. It’s about integrating proven cybersecurity principles-like the [CIA Triad](/blog)-and enhancing them with resilient, real-world controls, such as those from the NSA. For manufacturers, embracing both frameworks means better risk management, faster regulatory approvals, and most importantly, safer devices for patients. ### Need Help Applying These Frameworks? Blue Goat Cyber helps medical device manufacturers implement, document, and validate cybersecurity architectures that meet **[FDA](https://www.fda.gov/media/119933/download), NSA, and global regulatory expectations**. 👉 [Schedule a consultation](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to audit your device against CIA and NSA-aligned security controls. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat approaches this Blue Goat Cyber's approach to medical device cybersecurity integrates the strategic objectives of the CIA Triad with actionable, threat-informed NSA controls to build resilient devices. Our methodology involves a careful analysis of confidentiality, integrity, and availability requirements, translating them into specific architectural and implementation safeguards. We use our team's deep expertise, including credentials like CISSP and OSCP, and ex-military red team experience, to identify and mitigate vulnerabilities that might evade less rigorous assessments. We don't just identify risks; we engineer solutions aligned with regulatory expectations and real-world threat landscapes. Our services, including FDA premarket cybersecurity services, focus on proactive defense, secure-by-design principles, and continuous assurance. This structured approach ensures systems are inherently more secure. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is the CIA Triad in medical device cybersecurity? The CIA Triad stands for Confidentiality, Integrity, and Availability. These are foundational principles guiding information security, ensuring patient data privacy, preventing unauthorized data modification, and guaranteeing device functionality when needed. ### How do NSA controls apply to medical device security? NSA controls build on the CIA Triad by providing technical principles such as secure boot, hardware roots of trust, and strong encryption. These measures defend medical devices against sophisticated cyber threats and enhance overall resilience. ### Does the FDA require both CIA Triad and NSA controls? The FDA's premarket cybersecurity guidance expects manufacturers to implement strong security principles that encompass both the high-level objectives of the CIA Triad and the specific technical safeguards aligned with NSA recommendations, often through frameworks like NIST. ### Why are secure boot and code signing important for medical devices? Secure boot and code signing ensure that medical devices only execute trusted and untampered firmware. This prevents unauthorized software from running, protecting device integrity and patient safety as recommended by NSA-aligned practices. ### What is a hardware root of trust? A hardware root of trust is a dedicated, unchangeable hardware component, like a TPM or secure element, that serves as the foundation of trust for a device's security functions. It anchors the secure boot process and protects cryptographic keys. ### How do these frameworks impact FDA submission timelines? Thoroughly implementing and documenting cybersecurity controls derived from both the CIA Triad and NSA principles can streamline the FDA review process. Deficiencies in these areas can lead to significant delays in premarket submissions. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CI/CD Security Gates for Medical Devices Source: https://bluegoatcyber.com/blog/cicd-security-gates-medical-devices-spdf # CI/CD Security Gates for Medical Devices: Operationalizing the SPDF > **[DIRECT ANSWER]** CI/CD security gates are build-blocking checks, SAST, SBOM/SCA, secrets scanning, container scanning, and signed-artifact verification, wired into a medical device pipeline so every merge produces evidence rather than relying on after-the-fact documentation. Each gate output needs a build ID, commit SHA, tool version, and retention plan. Under the FDA's February 3, 2026 guidance, warn-only gates are not real gates: reviewers read the pipeline configuration itself to confirm security activities actually ran on every build. The SPDF is what the FDA expects you to have. CI/CD gates are how you prove you have it on every build, not just the one you put in the submission. Most teams we audit have respectable SPDF documentation and a CI pipeline running half the right tools, but the gates are advisory, the outputs aren't versioned, and there's no traceability from a deficiency response back to the build that produced the evidence. That gap is what becomes a deficiency letter. ## Key Takeaways - Five build-blocking gates cover the SPDF's enforceable surface: SAST, SCA/SBOM, secrets, container, signed artifacts. - "Warn-only" gates are not gates. The FDA reads the pipeline configuration, not just the report. - Every gate output needs a build ID, a commit SHA, a tool version, and a retention policy long enough to outlive the device. - SBOM generation without SBOM diffing produces a snapshot, not the postmarket monitoring evidence AAMI SW96 expects. - Threshold tuning (severity gates, exception workflows) is itself an auditable control, document the policy, not just the threshold. - Gates belong on the merge to main, not the nightly build. A finding that lands in main is already a CAPA candidate. ## Why This Matters The FDA's February 3, 2026 final premarket cybersecurity guidance, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions*, expects security activities to be **integrated into design controls, now ISO 13485 clause 7.3 as incorporated into 21 CFR Part 820 by the QMSR**, with objective evidence that the activities actually ran. AAMI/ANSI SW96 reinforces this: the security risk management process must be auditable across the lifecycle, not reconstructed at submission time. CI/CD gates produce that evidence as a byproduct of building the software. A SAST report tied to a commit SHA and a build ID is exactly the artifact reviewers want to see, what was tested, when, with what tool version, with what findings, and what was done about them. Without gates, the same activities still happen, but they happen in someone's IDE without traceability, and the submission has to reconstruct after the fact what was done. That reconstruction is the gap reviewers exploit. ## Why CI/CD Gates Are the SPDF's Enforcement Layer The SPDF defines security activities across the lifecycle: threat modeling, secure coding, vulnerability management, SBOM generation, security testing, postmarket monitoring. Each activity has an owner, an input, and an output. CI/CD is the only place in the development workflow where you can enforce that the activity actually ran with the right inputs before the code merges. Documentation says the team performs SAST. The CI pipeline configuration shows whether the SAST gate is mandatory or advisory. Reviewers read both, and when they conflict, the pipeline wins. ## The Five Gates and Where They Live in the SPDF ### SAST, Implementation phase Static analysis on every pull request, against the merge target. Findings above the threshold block the merge. Tool version, ruleset hash, and findings JSON are uploaded to the evidence store keyed by build ID. ### SCA / SBOM, Implementation, Verification, Postmarket Software composition analysis produces both the vulnerability list and the SBOM. CycloneDX or SPDX, generated by the build (not by hand later), with cryptographic hashes for each component. The SBOM produced at release is the one the FDA expects in the submission; the SBOMs produced on subsequent builds are what feed postmarket VEX diffing. ### Secrets scanning, Implementation Pre-commit hook plus a pre-merge gate. The pre-commit hook prevents the secret from entering history; the pre-merge gate catches anything the hook missed. A leaked secret that reaches main is a CAPA event regardless of whether it was rotated, the gap in the control is the finding. ### Container / dependency scan, Implementation, Verification For container-shipped devices and for build-environment hardening. Same threshold model as SAST. VEX dispositions for known-but-not-exploitable findings get written into the evidence store the same day the finding lands, not at submission time. ### Signed-artifact verification, Release, Postmarket update Builds are signed; the signature is verified at every promotion step (staging → production → device). The signature manifest is part of the release record. This is the gate that the FDA 2026 guidance V.B.4 (secure update mechanism) reads against, both at premarket review and during any postmarket update incident. ## What Each Gate Must Produce as Evidence > **[KEY REQUIREMENT]** Per AAMI SW96 §8.4, security activities must produce objective evidence retrievable across the device lifecycle. For a 10-year device, that means the build evidence from year 1 needs to be queryable in year 10. Every gate output, regardless of tool, needs five things: 1. **Build ID + commit SHA**, what was tested. 2. **Tool name + version + ruleset hash**, how it was tested. 3. **Timestamp**, when (ISO 8601 with timezone). 4. **Findings JSON + dispositions**, what was found, what was done. 5. **Retention metadata**, where it lives, for how long, who can purge it. The evidence store should be content-addressable (hash-keyed) so a deficiency response can cite an exact artifact, not a snapshot that's been overwritten. ## Threshold Policy: How to Decide What Fails the Build A gate that fails on every Low finding gets disabled within a week. A gate that only fails on Critical findings misses the High-severity issues that actually matter. The defensible policy is severity-gated with a documented exception workflow: - **Critical** → fails the build, no exceptions. - **High** → fails the build, exceptions require security lead sign-off recorded in the PR. - **Medium** → does not fail the build, but logged to a tracked backlog with SLA. - **Low / Informational** → logged, not blocking. The exception workflow itself is auditable. Reviewers look at how many High-severity findings were waived, by whom, with what justification, in the year before submission. A pattern of waivers without justification is a finding. ## Common Mistakes That Show Up in Deficiency Letters - **Warn-only gates.** The pipeline runs SAST but the job is marked `allow_failure: true`. Reviewers read the YAML. - **SBOM regenerated but not diffed.** Postmarket monitoring requires comparing today's SBOM against the last released one to detect drift. A regenerated SBOM with no diff is a snapshot, not monitoring. - **Gates on nightly builds, not on merge to main.** A finding that lands in main is already a CAPA candidate. The gate has to run before the merge. - **Tool version not captured.** Two builds with "SAST passed" but different tool versions are not equivalent evidence. The version needs to be in the artifact. - **Exception workflow without expiry.** A waiver that has no expiry becomes a permanent acceptance. Waivers need a re-review date. - **Container scan output not VEX-mapped.** Findings without dispositions are deficiency exposure. Map them as the build produces them, not in a panic before submission. - **No retention policy.** A 10-year device with a 90-day pipeline log retention loses the build evidence the FDA expects to see during a postmarket review. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Cyber Approaches CI/CD Gating We do not run your pipeline. Your engineering team owns it, they know the build. What we do is design the gate-and-evidence layer your SPDF needs to be defensible: which gates, what thresholds, what evidence schema, what retention, and how each gate output maps back to the [SPDF documentation](https://bluegoatcyber.com/guides/medical-device-cybersecurity-spdf-playbook) the FDA expects in the submission. We also build the traceability between gate outputs and the [threat model](https://bluegoatcyber.com/services/medical-device-threat-modeling) entries they verify, so a reviewer can follow any finding from the SBOM back to the attack path it relates to. Our team holds CISSP, OSCP, and prior military red-team credentials. We have built the gate-and-evidence layer for Class II and Class III connected-device submissions. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Inline CTA If your CI pipeline runs SAST and SBOM but you cannot cite the build that produced the evidence in your last submission, you have a deficiency exposure today. [Schedule a 30-minute discovery call](https://bluegoatcyber.com/contact) and we will tell you what reviewers will see. ## FAQ ### What CI/CD security gates does the FDA require for a medical device submission? The FDA does not require specific tools, but the February 3, 2026 final premarket cybersecurity guidance and AAMI SW96 expect objective evidence that security activities ran during development. In practice that means five build-blocking gates: SAST, SCA/SBOM generation, secrets scanning, container/dependency scanning, and signed-artifact verification. Submissions that cite "we run SAST" without artifacts tied to specific builds receive deficiency letters citing insufficient security activity evidence. ### Do CI/CD gates replace threat modeling or penetration testing? No. Gates enforce the activities they can automate, finding known-pattern issues at build time. Threat modeling identifies what to defend; gates verify that specific defenses were not regressed. Penetration testing exercises the system from the outside against the realized device. The three are complementary: gates produce the cadenced evidence, the threat model and pen test produce the depth-of-analysis evidence. A submission needs all three. ### Should security gates fail the build or just warn? Fail the build above the documented severity threshold. A warn-only gate is not a control under AAMI SW96 §7, it is a notification. Reviewers read the pipeline configuration to verify the gate is enforced, not just the report. The defensible pattern is severity-gated failure with a documented exception workflow (security-lead sign-off, recorded in the pull request, with an expiry date on every waiver). ### How long do we need to retain CI/CD security gate evidence? For at least as long as the device is on the market plus the postmarket reporting window, which for most Class II and Class III devices is the device's full commercial life plus several years. AAMI SW96 §8.4 expects objective evidence retrievable across the lifecycle. Pipeline logs with 90-day retention do not meet this; gate evidence belongs in a content-addressable evidence store with retention policy aligned to the device's commercial life. ### How do CI/CD gates relate to SBOM and VEX requirements? The SCA gate generates the SBOM as a build artifact (CycloneDX or SPDX, with component hashes). The container/dependency scan produces the vulnerability list against the SBOM. VEX dispositions get written as the findings land, not in a batch before submission. Postmarket SBOM monitoring requires diffing today's build SBOM against the last released SBOM to detect drift; the diff itself is evidence the FDA's 2026 guidance expects under postmarket cybersecurity controls. ### What about DAST and fuzzing, do those belong in CI? They belong in the evidence registry but cadence differently from build-time gates. DAST and fuzzing need a deployed target and longer run times, so they typically run on a scheduled job against a staging build rather than gating every PR. The output schema (build ID, tool version, timestamp, findings, dispositions, retention) is the same as the build-time gates. The difference is the trigger and the SLA, not the evidence requirements. ## Ready to make your CI pipeline the SPDF's enforcement layer? If your SPDF documentation describes security activities your pipeline does not enforce, your submission has a documented gap. We design the gate-and-evidence layer that makes the SPDF defensible, and we stand behind it. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led premarket and postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* ## Related SPDF reading - **Pillar guide:** [Medical Device Cybersecurity SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [SPDF Cybersecurity Documentation: What FDA Reviewers Expect](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) - [SPDF and IEC 62304 Mapping for Medical Device Cybersecurity](/blog/spdf-iec-62304-mapping-medical-device-cybersecurity) - [SPDF vs SSDLC: What Medtech Teams Get Wrong](/blog/spdf-vs-ssdlc-medical-device-cybersecurity) - [SPDF vs TPLC in Medical Device Cybersecurity](/blog/spdf-vs-tplc-in-medical-device-cybersecurity) --- ## More on this topic - [IEC 62304 Classes vs FDA Device Classes](/blog/iec-62304-classes-vs-fda-device-classes-cybersecurity) --- ## CISA KEV Catalog: Prioritize Device Risk | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/cisa-kev-catalog-medical-devices # CISA KEV Catalog: What It Is and How to Use It > **[DIRECT ANSWER]** The CISA KEV catalog is a list of CVEs with confirmed active exploitation and known remediation, maintained under Binding Operational Directive 22-01. Federal agencies must act on it; medical device manufacturers and hospitals use it as the top-priority signal for vulnerability triage. A KEV match against a device SBOM should always produce a documented VEX statement, and postmarket monitoring plans reviewed by the FDA are expected to name exploit-availability signals like KEV. _Reviewed September 17, 2026_ Medical device manufacturers ship products built from hundreds or thousands of third-party components, and most published CVEs never see real-world exploitation. Chasing every high-CVSS finding wastes limited security engineering time, while the vulnerabilities that actually get exploited cluster into a smaller, known set. The CISA Known Exploited Vulnerabilities catalog exists to cut through that noise, and it has become a central input for postmarket cybersecurity programs reviewed under the FDA's premarket and postmarket expectations. Manufacturers that ignore it, or that cannot show how it feeds their SBOM and VEX process, create a predictable gap that reviewers and hospital security teams both notice. This post explains what the catalog covers, who is bound by it, and how to wire it into a device vulnerability triage workflow. ## Key Takeaways - The KEV catalog lists CVEs with confirmed active exploitation and available remediation, not theoretical severity. - Binding Operational Directive 22-01 legally binds federal civilian agencies; manufacturers and hospitals treat KEV as a prioritization signal rather than a mandate. - A KEV-listed CVE that touches a shipped SBOM should always produce a documented VEX statement, even when the conclusion is "not affected." - KEV, CVSS, and EPSS answer different questions and work best layered together in a triage workflow. - Postmarket monitoring plans that omit exploit-availability signals like KEV read as incomplete to reviewers. ## Why This Matters The KEV catalog was established by the Cybersecurity and Infrastructure Security Agency in November 2021 under Binding Operational Directive 22-01, which requires federal civilian executive branch agencies to remediate listed vulnerabilities within set deadlines. Medical device manufacturers are not directly bound by that directive, but hospital IT and security teams that operate under it, or that simply adopt its logic, expect vendors to be able to answer whether a KEV-listed CVE affects a purchased device. The FDA's February 3, 2026 final guidance, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions*, does not name the KEV catalog explicitly, but its postmarket cybersecurity management plan expectations require a description of how a manufacturer monitors for emerging vulnerabilities and responds to them. Reviewers look for exploit-availability signals as part of that description, and a plan that lists only the National Vulnerability Database or vendor advisories, with no mention of confirmed exploitation data, reads as incomplete. The practical stakes are twofold. First, a manufacturer without a KEV-aware triage process risks missing the vulnerabilities most likely to be used against fielded devices. Second, a submission or postmarket audit that cannot show a defensible exploit-monitoring process invites the kind of deficiency finding that delays clearance or draws follow-up questions after a device is already on the market. ## What Is the CISA KEV Catalog? The KEV catalog is a continuously updated, publicly available list of CVEs that CISA has confirmed are being actively exploited, with three defining criteria: the CVE is formally assigned, there is reliable evidence of active exploitation, and clear remediation guidance exists, typically a vendor patch. It is published as a free machine-readable feed that any organization can ingest directly into its own tooling. The catalog is not a vulnerability scanner, a severity score, or an exhaustive list of important vulnerabilities. A CVE with a high CVSS score but no confirmed exploitation will not appear on KEV, while a CVE with a moderate score can appear if attackers are actively using it. That distinction matters because it changes what the catalog is good for. > **[KEY REQUIREMENT]** A KEV listing should be treated as a forward-looking behavioral signal, not a substitute for a full vulnerability severity assessment. ## Who Must Act on the KEV Catalog? Binding Operational Directive 22-01 legally requires federal civilian executive branch agencies to remediate KEV-listed vulnerabilities on their networks within CISA-set deadlines, usually a matter of weeks. Medical device manufacturers and hospitals are not directly covered by that directive. In practice, hospital procurement and security teams increasingly ask vendors to demonstrate KEV awareness, and manufacturers who cannot answer quickly lose credibility during security reviews. For manufacturers, the KEV catalog functions as a prioritization signal layered on top of existing postmarket vulnerability management obligations rather than as an independent legal requirement. It tells a security team which of the many CVEs affecting their SBOM deserve attention first, and it gives hospitals a common reference point when they ask a vendor about a specific vulnerability. | Party | Obligation Regarding KEV | |---|---| | Federal civilian agencies | Legally bound to remediate within BOD 22-01 deadlines | | Medical device manufacturers | Not directly bound, but expected to monitor and triage as part of postmarket obligations | | Hospitals and health systems | Use KEV as a procurement and risk-assessment reference, not a legal mandate on vendors | | FDA reviewers | Expect exploit-availability monitoring described in the postmarket cybersecurity plan | ## How Does KEV Differ from CVSS and EPSS? KEV, CVSS, and EPSS answer three different questions, and confusing them leads to either wasted triage effort or missed active threats. CVSS scores theoretical severity based on how a vulnerability could be exploited. EPSS forecasts the probability that a CVE will be exploited in the next 30 days. KEV confirms that exploitation has already happened and remediation guidance exists. | Source | What It Measures | Best Use in Triage | |---|---|---| | CVSS | Theoretical severity (base, temporal, environmental) | Initial severity sorting across a large CVE list | | EPSS | Probability of exploitation in the next 30 days | Prioritizing non-KEV CVEs that still warrant attention | | KEV | Confirmed active exploitation with known remediation | Top-priority triage above any CVSS or EPSS score | > **[KEY REQUIREMENT]** A CVE with a low CVSS score that appears on KEV should still be triaged before a high-CVSS CVE with no exploitation evidence. Exploitation in the wild outranks theoretical severity. ## How Does KEV Fit Into SBOM and VEX Triage? An SBOM lists every third-party component in a shipped device, typically with package URL or CPE identifiers, and the matching step joins that inventory against the KEV catalog, the NVD, and EPSS scores. Any KEV match against a shipped component becomes the highest-priority item in the triage queue, regardless of what its CVSS score shows. Once a match is identified, the manufacturer produces a VEX (Vulnerability Exploitability eXchange) statement documenting whether the vulnerable code path is reachable in the shipped configuration, whether a fix is available, and what compensating control exists if not. A "not affected" conclusion is a valid and common outcome, but it needs to be documented rather than assumed. > **[KEY REQUIREMENT]** Every KEV-listed CVE that matches a component in the shipped SBOM should carry an explicit VEX statement, including cases where the conclusion is "not affected." KEV-listed CVEs frequently drive customer communications even when a device turns out to be unaffected, because hospital security teams see the same public feed manufacturers do and ask directly. A postmarket program should be able to issue a short advisory naming the CVE, its KEV status, the affected component, and the VEX-backed position within days, not weeks. ## How Do You Build a KEV Triage Workflow? A defensible workflow follows a consistent sequence from feed ingestion to customer communication, and each step should have a named owner and a target turnaround time. The workflow below is a starting structure that most postmarket programs can adapt to their release cadence. 1. Subscribe to the KEV catalog feed and ingest new entries daily. 2. Match new KEV entries against the active SBOM index for every supported product line. 3. Open a triage record for every match, capturing exploit path, affected version, and owner. 4. Produce or update a VEX statement for each match within a defined service level, commonly seven days. 5. Issue a customer advisory when a device is affected, or when customer security teams are likely to ask regardless. 6. Track time-to-VEX and time-to-advisory as ongoing postmarket metrics. ## How Does the FDA Treat KEV in Submissions? The FDA's postmarket cybersecurity management plan expectations, described in the February 3, 2026 final premarket guidance, require manufacturers to explain how they monitor for emerging vulnerabilities and respond to them, without naming the KEV catalog by name. Reviewers still commonly look for it as a named input, because it is the standard public source of confirmed exploitation data. The most frequent deficiency pattern involves an SBOM that includes components with KEV-listed CVEs and no accompanying VEX statement addressing them. Reviewers generally do not require full remediation before clearance, but they do expect a documented, technically justified position on every KEV match. ## How Blue Goat Cyber Approaches This We build postmarket vulnerability monitoring programs that treat the KEV catalog as the top-priority signal, ingesting it daily and matching entries against a manufacturer's SBOM index across every supported product. VEX statements are produced against a defined service level, and customer advisory templates are prepared in advance so the time between a KEV update and a customer communication stays short. If your postmarket program needs a defensible, KEV-aware triage process that will hold up in an FDA review, our [postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services) team can help design and operate it. ## Frequently Asked Questions ### Is the CISA KEV catalog mandatory for medical device manufacturers? The KEV catalog is legally mandatory only for US federal civilian executive branch agencies under Binding Operational Directive 22-01. It is not directly mandatory for medical device manufacturers, but the FDA's postmarket monitoring expectations make a KEV-aware vulnerability program effectively necessary for a defensible submission and ongoing compliance. ### How often is the KEV catalog updated? CISA updates the catalog as exploitation evidence is confirmed, which can happen multiple times per week. Postmarket programs should ingest the feed daily and triage new matches against their SBOM index within a defined turnaround time rather than checking it periodically. ### Do we need a VEX statement for every KEV-listed CVE? You need a VEX statement for every KEV-listed CVE that matches a component in your shipped SBOM. If a CVE does not match any shipped component, no VEX statement is required, but the matching evidence should still be recorded so the absence of a statement is itself defensible during a review. ### How does KEV interact with CVSS in practice? CVSS provides a severity score, while KEV confirms active exploitation. A CVE with a CVSS score of 9.8 and no KEV listing is theoretically severe but unconfirmed in the wild, while a CVE with a moderate CVSS score on KEV is being actively exploited and warrants immediate triage. Most mature programs prioritize KEV status above any CVSS threshold. ### What role does EPSS play alongside KEV? EPSS estimates the probability that a CVE will be exploited within the next 30 days and is most useful for prioritizing CVEs that have not yet appeared on KEV. A common triage stack works through KEV-listed CVEs first, then high-EPSS items, then remaining high-CVSS items, with a VEX statement addressing each layer that touches the SBOM. ## CTA If your postmarket program needs a KEV-aware triage workflow that produces defensible VEX statements on a consistent schedule, we can help design and run it. [Schedule a discovery call](/contact) to review your current SBOM and vulnerability monitoring process. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian has led postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions, with a background in offensive security operations. [Read more about Christian](/christian-espinosa). --- ## CLIA Lab Cybersecurity: HIPAA & 21 CFR Part 11 (2026) Source: https://bluegoatcyber.com/blog/clia-high-complexity-lab-cybersecurity-hipaa-part-11 # CLIA High-Complexity Lab Cybersecurity: HIPAA, 21 CFR Part 11 & LIMS Guide > **[DIRECT ANSWER]** For a CLIA high-complexity laboratory, cybersecurity is inseparable from the FDA's medical device software rules, 21 CFR Part 11 data integrity, and HIPAA. Labs must enforce role-based access limited to credentialed personnel, encrypt ePHI across the LIMS and cloud analytics stack, tightly manage vendor patches so IVD analyzers remain in a validated state, and validate any AI-assisted result interpretation. CMS surveyors and CAP inspectors now examine these controls directly, and a proposed CMS/CDC RFI signals that cybersecurity will be codified into CLIA itself. High-complexity CLIA testing has quietly become one of the most software-dependent activities in healthcare. A single result may travel from a connected analyzer, through middleware, into a Laboratory Information Management System (LIMS), out to a cloud analytics platform, past an AI model, and finally into the ordering EHR, with a patient's life-altering diagnosis riding on the integrity of every hop. That pipeline is a cybersecurity problem, a data-integrity problem, and a CLIA compliance problem at the same time. This guide covers what CMS and CAP surveyors actually look for, how 21 CFR Part 11 and HIPAA overlay on top of CLIA, and the specific controls high-complexity labs need in place for 2026. ## Key Takeaways - CLIA compliance now depends on cybersecurity: patch, access, and data-integrity controls all fall inside CMS and CAP survey scope. - 21 CFR Part 11 governs electronic records and signatures in the LIMS, audit trails, unique IDs, and signature manifestations are inspection targets. - HIPAA Security Rule controls (encryption, access, audit) apply to ePHI wherever it flows: analyzers, LIMS, middleware, cloud analytics, and AI models. - Vendor-managed patches on IVD analyzers must be applied per manufacturer guidance without breaking the validated state, a change-control problem, not an IT problem. - AI-assisted result interpretation and cloud analytics require documented software validation, secure transit, and clear boundaries between the lab and the vendor. - CMS and the CDC have opened an RFI to modernize CLIA around emergency preparedness, biosecurity, and cybersecurity, expect codified requirements soon. ## Why cybersecurity is now a CLIA issue CLIA (the Clinical Laboratory Improvement Amendments of 1988) governs quality standards for laboratory testing on human specimens. For decades, its cybersecurity implications were implicit, buried inside general requirements for accurate results, personnel qualifications, and quality control. That is changing. CMS and the CDC have jointly issued a Request for Information (RFI) to formally update CLIA around emergency preparedness, biosecurity, and cybersecurity. The direction of travel is clear: connected diagnostic platforms, cloud-based analytics, and AI-assisted interpretation all sit inside CLIA scope, and inspectors will increasingly cite cybersecurity failures as CLIA deficiencies rather than "IT problems" the lab director can defer to a vendor. CAP (the College of American Pathologists), which many labs use for CLIA-deemed status, has moved faster. Recent All Common and Laboratory General checklist updates already require documented cybersecurity programs, incident response plans, patching procedures, and evidence of user access reviews. ## The three overlapping regulatory frameworks Every high-complexity lab operates under at least three interacting rulebooks: | Framework | Scope in the lab | Key cybersecurity hook | | --- | --- | --- | | **CLIA** (42 CFR Part 493) | Personnel, QC, proficiency testing, result integrity | System integrity as a precondition for accurate results | | **21 CFR Part 11** | Electronic records and electronic signatures in FDA-regulated activities | Audit trails, unique user IDs, signature manifestations, access controls | | **HIPAA Security Rule** (45 CFR Part 164) | ePHI confidentiality, integrity, availability | Access, audit, encryption, integrity, contingency planning | The FDA's [February 3, 2026 premarket cybersecurity guidance](/blog/fda-section-524b-subsections-explained) and [Section 524B](/blog/fda-section-524b-subsections-explained) sit on top of this stack when the lab uses cyber devices, IVD analyzers, middleware, or LIMS modules, that meet the 524B definition. Manufacturer obligations under 524B flow into lab obligations through vendor contracts, SBOMs, and coordinated vulnerability disclosure. The practical implication: a single control (say, MFA on the LIMS) may satisfy an HIPAA Security Rule standard, a Part 11 access requirement, a CLIA personnel-authorization expectation, and a CAP checklist item at once. Design the program around those overlaps rather than treating each rulebook separately. ## Software updates and patch management on IVD analyzers Patching connected analyzers is the single most common CLIA-cybersecurity friction point. The rule is deceptively simple: **apply the manufacturer's updates on the manufacturer's schedule using the manufacturer's procedure**. Missing critical security patches on a diagnostic platform can compromise result integrity, and that is a CLIA finding, not just a security finding. But the inverse is also true. Applying a patch the manufacturer did not authorize, or applying it outside the validated procedure, can invalidate the analyzer's cleared state and trigger a full revalidation before the instrument can report patient results again. A defensible patch program for a high-complexity lab includes: - A current inventory of every connected analyzer, middleware component, and LIMS module, with software versions and vendor patch status - Written vendor patch cadences and emergency-patch SLAs captured in the service contract - A change-control record for every patch: who approved it, what QC was rerun, what audit-trail entries the LIMS generated - Compensating controls (network segmentation, restricted egress, monitored dial-in accounts) for analyzers the vendor is slow to patch - An escalation path when a vendor refuses to patch a known CVE, including whether to take the instrument out of service An [SBOM](/blog/medical-device-sbom-fda-requirements-and-submission-guide) from each IVD vendor turns this from guesswork into engineering. Ask for one; increasingly, vendors have it. ## Identity and access management for credentialed personnel CLIA specifies who can perform, review, and release high-complexity testing: Testing Personnel, General Supervisors, Technical Supervisors, Clinical Consultants, and the Laboratory Director each have defined roles. Your access control model must map to that hierarchy, not to a generic "user / admin" split. Controls that both CLIA and HIPAA surveyors expect: - **Unique user IDs** for every person who touches the LIMS, middleware, or an analyzer, no shared logins, ever (this is also a 21 CFR Part 11 hard requirement) - **Role-based access** aligned to CLIA personnel roles, so a Testing Personnel account cannot approve validation runs or edit reference ranges - **Multi-factor authentication** for remote access and for any account with elevated privileges - **Periodic access reviews**, quarterly is typical, with documented removals when personnel change roles or leave - **Session timeouts** on shared workstations at the bench, with fast re-authentication so it does not slow analytical workflow Vendor and service-engineer accounts are the most common finding in this area. They must be named, time-bound, monitored, and disabled between service visits, not left as always-on backdoors. ## Data integrity and privacy in the LIMS The LIMS is where CLIA, Part 11, and HIPAA collide hardest. Every result stored, transmitted, or amended is simultaneously a clinical record, an electronic record under Part 11, and ePHI under HIPAA. Baseline expectations: - **Encryption in transit** (TLS 1.2+) between analyzers, middleware, LIMS, EHR, and any cloud service - **Encryption at rest** for the LIMS database and all backup copies - **Complete, tamper-evident audit trails** capturing who changed what, when, and why, Part 11's core requirement, and often the specific artifact a CAP inspector asks to see - **Electronic signature controls** for result verification and release, with signature manifestations that print on the report - **Data integrity checks** at each interface boundary (HL7 acknowledgments, checksum validation, exception queues that a human actually monitors) - **Backup and recovery** tested against a defined RTO and RPO, with restore drills documented Where a cloud LIMS or cloud analytics vendor is involved, all of the above must be covered by a Business Associate Agreement (BAA) and by a shared-responsibility document that spells out which HIPAA safeguards the vendor operates and which the lab operates. ## System hardening for AI and cloud analytics AI-assisted result interpretation, digital pathology, hematology cell classification, molecular variant calling, antimicrobial susceptibility prediction, is now common in high-complexity settings. Cloud analytics for population-level QC and reference-interval studies are equally routine. For CLIA and cybersecurity purposes, an AI model that influences a reportable result is a piece of laboratory-developed or vendor-provided software that must be validated for its intended use, monitored for drift, and secured in transit and at rest. The FDA's expectations for [AI/ML medical device software](/blog/fda-ai-cybersecurity-threats-524b-medical-devices) and the [PCCP framework](/blog/pccp-beyond-ai-cybersecurity-firmware-hardware) apply when the AI itself is a regulated device; even when it is not, CAP and CMS still expect validation evidence. Practical hardening steps: - Isolate cloud analytics traffic on a dedicated network path with allow-lists to known vendor endpoints - Validate model performance on the lab's own specimen mix, not just the vendor's published dataset - Log every AI-influenced result decision in the LIMS audit trail so the human reviewer's role is unambiguous - De-identify or [pseudonymize](/blog/de-identification-vs-anonymization-medical-devices-hipaa-gdpr) any data sent to a training or benchmarking pipeline, and cover it with a BAA plus data-use terms - Monitor for model drift and set clear criteria for taking a model out of service ## Preparing for CMS and CAP cybersecurity scrutiny Recent CMS and CAP survey activity shows a consistent pattern of cybersecurity questions: - Show me your current asset inventory and the software version on each instrument - Show me your last three vendor security patches and the change-control records - Show me your access review from last quarter, including terminated users - Show me an audit-trail entry for an amended result - Show me your incident response plan and the last time you exercised it - Show me a BAA for every vendor that touches ePHI - Show me evidence that your cloud/AI vendor has been validated and monitored If any of those questions produces a scramble instead of a document, that is where to invest before your next survey. A short internal mock inspection focused specifically on cybersecurity, separate from the full CAP checklist run, is the highest-leverage preparation available. ## How Blue Goat Cyber approaches CLIA lab cybersecurity We work with clinical laboratories and with the IVD manufacturers whose analyzers, LIMS, and cloud platforms sit inside those labs. That gives us both sides of the vendor-lab conversation: - **[Medical device penetration testing](/services/medical-device-penetration-testing)** on the connected analyzers and middleware that live in your lab - **[SBOM analysis](/services/sbom-analysis)** for LIMS and IVD vendors, so patching decisions are evidence-based - **[HIPAA and Part 11 gap assessments](/services/hipaa-compliance)** aligned to CAP All Common and Laboratory General checklists - **[Cybersecurity risk assessments](/services/cybersecurity-risk-assessment)** that map directly to ISO 14971 (for the devices) and to CLIA quality assessment (for the lab) We tell labs and vendors the same thing: CLIA cybersecurity is a shared-responsibility problem, and the labs that document that split clearly are the ones that pass survey without drama. ## FAQ ### Does CLIA explicitly require cybersecurity controls? Not yet in the same detailed way HIPAA does. CLIA today requires accurate results, qualified personnel, and controlled electronic records, and cybersecurity failures that break any of those become CLIA deficiencies by consequence. The joint CMS/CDC RFI signals that explicit cybersecurity language is coming. ### How does 21 CFR Part 11 apply to a LIMS? If the LIMS is used to create, modify, maintain, or transmit records required by an FDA-regulated activity, which includes most clinical testing that supports FDA-regulated care, Part 11 applies. The core requirements are validated systems, secure audit trails, unique user IDs, and controlled electronic signatures. ### Can we apply vendor security patches ourselves? Only if the vendor's IFU or service agreement explicitly permits it. Otherwise, applying a patch the vendor did not authorize can invalidate the instrument's cleared state and force revalidation before you can report patient results. Route every patch through change control with the vendor. ### Do cloud LIMS and cloud analytics vendors need a BAA? Yes, any vendor that creates, receives, maintains, or transmits ePHI on your behalf is a Business Associate and must sign a BAA before ePHI flows. This includes cloud analytics, AI vendors, and remote-support providers. ### How does AI-assisted interpretation fit into CLIA? The Laboratory Director remains responsible for the reportable result. AI is a tool the qualified reviewer uses; it does not replace the reviewer. Validate the model for your specimen mix, log its recommendations in the LIMS, and have documented criteria for overriding or retiring the model. ### What about the FDA's 2026 cybersecurity guidance, does it affect labs? Indirectly but significantly. It sets manufacturer obligations for the IVD analyzers, middleware, and LIMS modules you buy, SBOMs, coordinated vulnerability disclosure, secure updates. Labs benefit by demanding those artifacts in procurement and referencing them in patch and risk decisions. --- **Related reading on this site** - [FDA Section 524B Subsections Explained](/blog/fda-section-524b-subsections-explained) - [SBOM for Medical Devices: FDA Requirements](/blog/medical-device-sbom-fda-requirements-and-submission-guide) - [De-identification vs Anonymization for Medical Devices](/blog/de-identification-vs-anonymization-medical-devices-hipaa-gdpr) - [AI/ML Medical Device Cybersecurity](/blog/fda-ai-cybersecurity-threats-524b-medical-devices) - [Predetermined Change Control Plan (PCCP) & Cybersecurity](/blog/pccp-beyond-ai-cybersecurity-firmware-hardware) *Reviewed by the Blue Goat Cyber team. Last updated July 23, 2026.* --- ## Medical Device Closed Box Testing Source: https://bluegoatcyber.com/blog/closed-box-testing-in-medical-device-cybersecurity # Medical Device Closed Box Testing: What Manufacturers Need to Know > **[DIRECT ANSWER]** Closed box testing evaluates the device the way an attacker meets it, with no source code, design documents, or credentials supplied. Testers probe exposed network services, wireless radios, physical ports, and companion apps to find what is reachable in the field. It produces realistic exposure evidence, but it cannot prove internal controls exist, so pair it with open box review before you file a submission. Closed box testing, a rigorous testing methodology that can help identify vulnerabilities and mitigate potential threats, is a crucial component of ensuring the security of medical devices. This article will covers the significance of closed box testing in medical device cybersecurity and explore its role in safeguarding patient health and data. ## Key Takeaways - Closed box testing mimics real-world attack scenarios. - It identifies vulnerabilities without internal system access. - This method assesses device resilience to cyber threats. - Key for protecting patient data and device integrity. - Supports compliance with cybersecurity regulations. - An essential part of medical device lifecycle security. ## Why this matters The stakes for medical device cybersecurity are critically high; a compromised device can directly endanger patient safety or expose sensitive health information. Closed box testing is vital because it simulates real-world attack conditions without internal system knowledge, revealing exploitable vulnerabilities malicious actors could use. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the necessity of testing methodologies that confirm device security throughout its lifecycle. This guidance aligns with industry standards like IEC 81001-5-1 for health software and IT network security, ISO 14971 for risk management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles of security for medical devices. By employing closed box testing, manufacturers address regulatory requirements, proactively mitigate risks, and enhance patient trust by ensuring their devices can withstand evolving cyber threats. ## Understanding Closed Box Testing Before we discuss the importance of closed-box testing, let’s clarify what it entails. Closed box testing, also known as black box testing, is a method of testing software or hardware in which the internal workings are unknown to the tester. This approach is akin to examining a sealed box from the outside without knowing what lies within. While it may seem counterintuitive at first, closed-box testing is an essential tool in the field of medical device cybersecurity. ![Section Image](/imported-images/3088d83cb0cd1604.webp) ### Definition and Key Features of Closed Box Testing Closed box testing involves evaluating a medical device’s external behavior without direct knowledge of its internal workings. This allows testers to simulate real-world scenarios and identify vulnerabilities that malicious actors could exploit. By mimicking the actions and interactions a user would typically perform, closed box testing provides valuable insights into potential weaknesses that could compromise the device’s security. Features of closed box testing include: 1. Simulating real-world scenarios to detect vulnerabilities 2. Identifying potential entry points for unauthorized access 3. Evaluating the resilience of the device to cyber threats 4. Testing the device’s ability to withstand various attack vectors ### The Role of Closed Box Testing in Cybersecurity Closed box testing is crucial in the overall cybersecurity strategy for medical devices. By subjecting the device to simulated real-world scenarios, testers can identify vulnerabilities and weaknesses that may not be evident through other testing methods. Furthermore, closed box testing allows for the evaluation of the device’s resilience and ability to withstand cyber threats, providing valuable insights for improving security measures. One of the advantages of closed box testing is its ability to simulate real-world scenarios. This means that testers can replicate the actions and interactions that a user would typically perform on the device, allowing them to uncover vulnerabilities that may not be apparent through other testing methods. By simulating various scenarios, such as different user inputs or unexpected system behaviors, closed box testing can reveal potential weaknesses that malicious actors could exploit. In addition to identifying vulnerabilities, closed box testing identifies potential entry points for unauthorized access. By examining the device from an external perspective, testers can assess the security measures and determine if any weak points could be exploited. This includes evaluating the device’s authentication mechanisms, encryption protocols, and access control systems. By identifying these entry points, testers can recommend strengthening the device’s security posture. ## The Intersection of Medical Devices and Cybersecurity In recent years, the intersection of medical devices and cybersecurity has become a topic of increasing concern. The proliferation of internet-connected devices and the growing sophistication of cyber threats have created a challenging landscape for healthcare providers and device manufacturers. As the healthcare industry embraces digital transformation, the reliance on interconnected medical devices has grown exponentially. These devices are crucial in improving patient outcomes and streamlining healthcare delivery, from remote patient monitoring systems to smart infusion pumps. However, this increased connectivity also opens up new avenues for potential cyber-attacks, necessitating a proactive approach to cybersecurity. ### The Vulnerability of Medical Devices to Cyber Threats Medical devices, such as pacemakers, insulin pumps, and implantable cardiac monitors, have revolutionized patient care. However, their integration with the digital realm has exposed them to potential cyber threats. These devices, which rely on software and network connectivity, can be vulnerable to hacking attempts, putting patient safety and privacy at risk. With the rise of interconnected healthcare ecosystems, the attack surface for malicious actors has expanded, making it essential for stakeholders to prioritize cybersecurity in device design and implementation. Manufacturers are increasingly incorporating security features such as encryption, authentication mechanisms, and intrusion detection systems to mitigate risks and ensure the integrity of medical devices. ### The Impact of Cybersecurity Breaches on Healthcare The consequences of cybersecurity breaches in the healthcare sector can be far-reaching and devastating. Not only do they compromise patient confidentiality and privacy, but they can also disrupt crucial medical procedures and put lives at stake. The potential for harm is immense, highlighting the urgent need for cybersecurity measures, including closed box testing. Healthcare organizations must adopt a multi-faceted approach to cybersecurity, encompassing employee training, regular security assessments, and incident response protocols to safeguard against cyber threats. Collaboration between industry stakeholders, cybersecurity experts, and regulatory bodies is essential to address the evolving challenges at the intersection of medical devices and cybersecurity, ensuring the continued delivery of safe and effective patient care. ## Closed Box Testing in the Context of Medical Devices Medical devices play a critical role in healthcare, providing essential services and support to patients. However, the [increasing connectivity of these devices](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) to networks and other systems has raised concerns about their vulnerability to cyber-attacks. This is where closed box testing comes into play, offering a proactive approach to identifying and addressing potential security risks before they can be exploited. ### Why Closed Box Testing is Crucial for Medical Devices Medical devices are unique in their purpose and functionality, making them attractive targets for cybercriminals. Their vulnerabilities and weaknesses can have severe consequences, ranging from unauthorized access to patient data to the manipulation of device operations. Closed box testing allows for a evaluation of these vulnerabilities and helps mitigate the risks associated with cyber threats. The sensitive nature of the data processed and stored by medical devices, such as patient health information and treatment plans, underscores the importance of ensuring their security and integrity. By conducting closed box testing, healthcare organizations and device manufacturers can demonstrate their commitment to safeguarding patient information and maintaining the trust of both healthcare providers and patients. ### The Process of Implementing Closed Box Testing in Medical Devices Implementing closed box testing in the context of medical devices requires a structured and careful approach. It involves several key steps, including: 1. Identifying the goals and objectives of the testing process 2. Creating realistic test scenarios that reflect real-world usage 3. Developing testing methodologies and protocols 4. Executing the testing process and gathering data 5. Analyzing the results and identifying vulnerabilities 6. Implementing necessary security updates and improvements Collaboration between cybersecurity experts, healthcare professionals, regulatory bodies, and device manufacturers is essential for successfully implementing closed box testing in medical devices. By using these stakeholders’ collective expertise and insights, organizations can enhance the effectiveness of their testing processes and the [FDA cybersecurity guidance for medical devices](/guides/fda-cybersecurity-guidance) in an evolving threat landscape. ## Challenges and Solutions in Closed Box Testing for Medical Devices While closed box testing offers immense benefits, it also presents unique challenges that must be addressed to ensure effectiveness. Let’s explore some common obstacles in closed box testing for medical devices and effective strategies to overcome them. Closed box testing for medical devices involves assessing the functionality and security of a device without detailed knowledge of its internal workings. This can be particularly challenging as it requires testers to simulate real-world scenarios while operating with limited visibility of the device’s operations. Furthermore, ensuring patient safety and regulatory compliance adds another layer of complexity to the testing process. ### Common Obstacles in Closed Box Testing One of the primary challenges in closed box testing is the limited knowledge of the internal workings of the device. This lack of transparency can hinder the identification of vulnerabilities and make testing difficult. The complex nature of medical devices and their interconnected systems further complicates the testing process. Another obstacle in closed box testing is the dynamic nature of cybersecurity threats. As attackers continuously evolve their tactics, it becomes crucial for testers to stay ahead of these threats and anticipate potential vulnerabilities that may arise during the device’s lifecycle. This dynamic environment requires a proactive and adaptive approach to testing to ensure the device’s security posture remains resilient. ### Strategies to Overcome Testing Challenges Despite these challenges, effective strategies can be employed to overcome testing obstacles in closed box testing for medical devices. These include: - Collaboration between cybersecurity experts and medical device manufacturers - Utilizing threat modeling techniques to anticipate potential vulnerabilities - Performing continuous and iterative testing to account for evolving threats - Emphasizing the importance of security throughout the development life cycle ## The Future of Medical Device Cybersecurity ### Emerging Trends in Medical Device Cybersecurity Advancements in technology, such as the Internet of Things (IoT) and artificial intelligence, are transforming the healthcare industry. However, these developments also bring new cybersecurity challenges. The increasing connectivity and complexity of medical devices necessitate security measures, with closed box testing at the forefront of ensuring the integrity of these devices. One emerging trend in medical device cybersecurity is the integration of blockchain technology. Blockchain, a decentralized and tamper-proof digital ledger, can potentially enhance the security and privacy of medical devices. By implementing blockchain technology, [medical devices can securely store and transmit sensitive patient](/blog/how-medical-devices-are-designed-with-patient-safety-as-the-priority) data, mitigating the risk of unauthorized access or data breaches. Another trend is the adoption of machine learning algorithms for anomaly detection in medical devices. Machine learning algorithms can analyze vast amounts of data in real-time, enabling the identification of abnormal device behavior and potential cyber threats. By continuously monitoring and analyzing device data, machine learning algorithms can provide early warning signs of cyber attacks, allowing healthcare providers to take immediate action to protect patient safety and data. ### The Role of Closed Box Testing in Future Cybersecurity Measures As the healthcare sector continues to embrace digital innovation, the role of closed box testing in future cybersecurity measures will become even more critical. This testing methodology will be crucial in identifying vulnerabilities, ensuring compliance with regulatory standards, and safeguarding patient health and data. One key advantage of closed box testing is its ability to simulate real-world cyberattack scenarios. By subjecting medical devices to various attack vectors, closed-box testing can uncover potential vulnerabilities and weaknesses that malicious actors could exploit. This proactive approach allows device manufacturers and healthcare providers to address these vulnerabilities before they can be exploited, reducing the risk of cyber-attacks and ensuring patient safety. Closed box testing also helps evaluate medical devices’ resilience against emerging threats. With cybersecurity’s nature, new vulnerabilities and attack techniques constantly emerge. By regularly conducting closed box testing, medical device manufacturers can stay ahead of the curve, ensuring they are equipped with the necessary security measures to withstand the latest cyber threats. ## Conclusion Closed box testing is an indispensable component of medical device cybersecurity. It provides valuable insights into vulnerabilities, helps mitigate cyber threats, and ensures the integrity of medical devices. By implementing closed box testing methodologies and addressing the challenges associated with it, healthcare providers and device manufacturers can take proactive steps towards securing the future of patient care. As the medical device industry advances, the importance of cybersecurity measures like closed box testing cannot be overstated. Blue Goat Cyber, a Veteran-Owned leader in cybersecurity, offers unparalleled expertise in medical device cybersecurity, penetration testing, and compliance with HIPAA and [FDA standards](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity). Our team’s proactive approach and tailored B2B services ensure that your medical devices are compliant and resilient against the latest cyber threats. Don’t let vulnerabilities compromise your patient care and data security. [Contact us today for cybersecurity help](/contact) and partner with Blue Goat Cyber to transform your cybersecurity challenges into a strategic advantage. Check out our [medical device cybersecurity for FDA compliance package.](/) ## How Blue Goat approaches this Blue Goat Cyber's approach to closed box testing starts with understanding real-world threat actors and their tactics. Our team, comprised of certified professionals with CISSP and OSCP credentials, including ex-military red team specialists, simulates adversarial actions against your devices. We focus on uncovering vulnerabilities an external attacker would exploit, without needing access to your source code or internal design schematics. This methodology replicates genuine attack surfaces and assesses your device’s resilience under fire. We provide actionable insights and precise recommendations for hardening your product. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our testing services at [https://bluegoatcyber.com/services/medical-device-penetration-testing]. ## FAQ ### What is closed box testing for medical devices? Closed box testing, or black box testing, evaluates a medical device's security by examining its external behavior without insight into its internal code or structure. This simulates how an external attacker might interact with the device to find vulnerabilities, covering aspects like user interfaces, network interactions, and data inputs. ### Why is closed box testing important for medical devices? It is crucial because it identifies vulnerabilities that external adversaries could exploit in real-world scenarios. By simulating attacks without internal knowledge, it helps ensure that critical medical devices, which are responsible for patient safety and data are resilient against cyber threats before deployment. ### How does closed box testing differ from other testing methods? Unlike white box testing, which requires full knowledge of internal systems, closed box testing focuses solely on external interactions and outputs. It complements other methods by providing an attacker's perspective, without relying on design documents or source code access, making it effective for uncovering unknown vulnerabilities. ### Does the FDA require cybersecurity testing like closed box testing? Yes, the FDA's February 3, 2026 final guidance emphasizes the importance of cybersecurity testing throughout the medical device lifecycle. While it does not mandate a specific testing methodology, the guidance expects manufacturers to conduct appropriate security testing, including vulnerability assessments and penetration testing, which closed box testing effectively supports. ### What challenges are associated with closed box testing for medical devices? Challenges include limited visibility into the device's internal operations, which can complicate vulnerability identification and root cause analysis. Testers must also contend with the dynamic nature of cyber threats and the need to ensure patient safety during any testing activities. ### How can manufacturers improve their closed box testing processes? Manufacturers can enhance their processes through collaboration with cybersecurity experts, utilizing threat modeling to anticipate risks, and performing continuous, iterative testing. Emphasizing security throughout the entire development lifecycle and staying current with evolving threats are also key strategies. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) · [FDA penetration testing requirements for medical devices](/blog/fda-penetration-testing-requirements-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Open Box Testing for Medical Devices](/blog/closed-box-testing-in-medical-device-cybersecurity) --- ## Code and Data Integrity Controls for Medical Devices | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/code-data-and-execution-integrity-security-controls-and-medical-device-cybersecurity # Code and Data Integrity Controls Every Device Maker Needs > **[DIRECT ANSWER]** Code and data integrity controls verify that firmware, configuration data, and patient records are authentic and unaltered throughout a medical device's lifecycle. The core mechanisms are signed firmware validated at boot, a secure boot chain anchored in hardware, anti-rollback protection against downgrade attacks, and integrity checks on data at rest and in transit. The FDA expects each mechanism paired with test evidence, not a policy statement, in premarket cybersecurity documentation. _Reviewed September 17, 2026_ Integrity failures let attackers run unauthorized code, silently alter patient data, or roll a device back to a version with a known vulnerability, and the FDA has identified integrity gaps as a root cause behind a meaningful share of medical device cyber incidents. A device can have strong network controls and still be compromised if its firmware isn't signed, its update mechanism accepts an older vulnerable image, or its stored configuration data can be modified without detection. These are not abstract concerns: they determine whether a compromised device keeps running undetected or fails safely and visibly. The February 3, 2026 final guidance treats code, data, and execution integrity as core premarket documentation requirements, and reviewers expect named mechanisms and test results for each. This article breaks down signed firmware, secure boot, anti-rollback, and integrity checks at rest and in transit, along with the evidence each one requires. ## Key Takeaways - Signed firmware and secure boot together prevent unauthorized code from running on the device. - Anti-rollback protection stops attackers from reinstalling an older, vulnerable firmware version. - Data integrity checks must cover both data at rest and data in transit, not just network traffic. - Each integrity mechanism needs a stated implementation and a verification test, not a policy claim. - Integrity gaps are a documented root cause of medical device cyberattacks, per FDA guidance. - Integrity evidence belongs in the same design-controlled documentation as the rest of the risk file. ## Why This Matters The FDA's February 3, 2026 final guidance, which follows the September 2023 and June 27, 2025 final guidances, identifies integrity violations, unauthorized changes to code, stored data, or the execution state, as a primary root cause of cyberattacks against medical devices. That framing puts code, data, and execution integrity controls at the center of premarket cybersecurity review rather than treating them as a secondary hardening step. Integrity controls matter because they determine whether a compromise stays contained or spreads silently. A device with signed firmware and a working secure boot chain will refuse to run tampered code and can log the failure for postmarket review. A device without these controls may run modified firmware indefinitely, exposing patient data or device function without any visible signal that something is wrong. Similarly, without anti-rollback protection, an attacker who obtains an older signed firmware image, one with a since-patched vulnerability, can downgrade the device and reopen a fixed hole. Standards referenced alongside the FDA guidance, including IEC 81001-5-1, ISO 27001, and ANSI/AAMI SW96:2023 (recognition number 13-131), all point to the same expectation: integrity controls need a defined mechanism, a verification method, and evidence that the mechanism was tested against realistic tampering attempts, not just described in a design document. ## What Is Signed Firmware and Why Does It Matter? Signed firmware is firmware that carries a cryptographic signature the device verifies before installing or executing it, and it matters because it's the primary control preventing unauthorized code from running on a medical device. The manufacturer signs each release with a private key, and the device holds the corresponding public key to verify that signature before accepting an update. Without code signing, any firmware image that reaches the device's update mechanism, whether through a compromised update server, a man-in-the-middle attack, or physical access, can be installed and executed. With it, an attacker needs the manufacturer's private signing key, not just access to the update channel, to get unauthorized code running. **[KEY REQUIREMENT]** Signature verification must occur before the new firmware image is written to the active partition, not merely logged after installation, so that an invalid signature blocks the update rather than being recorded as an exception. ## How Does a Secure Boot Chain Work? A secure boot chain works by validating each stage of startup, bootloader, operating system, and application, against a signature anchored to a hardware root of trust, so that no stage runs unless the previous stage confirms it's authentic. The root of trust itself is a key or hash burned into silicon that software cannot alter, which is what prevents an attacker from simply patching out the verification step. A partial implementation, one that verifies only the first-stage bootloader and then trusts everything after it unconditionally, still leaves the device vulnerable to tampering at the application layer. Full-chain verification, sometimes called chain of trust, closes that gap by extending signature checks through every stage that executes before the device reaches normal operation. | Boot Stage | What Should Be Verified | Common Gap | |---|---|---| | Hardware root of trust | Immutable, cannot be altered by software | Root key stored in writable memory | | Bootloader | Signature checked against root of trust | Bootloader trusted unconditionally | | Operating system/RTOS | Signature checked before handoff | Verification skipped after first stage | | Application firmware | Signature checked before execution | Only checked at install, not at boot | ## What Is Anti-Rollback Protection? Anti-rollback protection is a mechanism that prevents a device from installing or running a firmware version older than one it has already run, and it matters because an old, validly signed firmware image can still carry a vulnerability that a newer release fixed. Without this control, an attacker who obtains a legitimate older firmware image can push a downgrade and reopen a patched hole, all while the signature check passes because the image is genuinely signed by the manufacturer. The typical implementation uses a monotonic counter stored in tamper-resistant hardware that increments with each firmware version, and the bootloader refuses to load any image whose version number is lower than the counter. Manufacturers should test this explicitly by attempting to install a known older signed image and confirming the device rejects it rather than assuming the version check logic works as designed. ## How Should Integrity Checks Work at Rest and in Transit? Integrity checks at rest and in transit should confirm that stored data, configuration, calibration, and patient records, and data moving between components or to external systems have not been altered without detection. At rest, this typically means cryptographic hashes or authenticated encryption applied to stored data, checked before the data is used. In transit, it means authenticated communication protocols where any modification to the payload invalidates the message. **[KEY REQUIREMENT]** Data validation must apply to all incoming data, including data from other device components and external systems, not just data arriving over the network, since the FDA guidance treats any external data source as untrusted until validated. | Integrity Domain | Mechanism | What Failure Looks Like | |---|---|---| | Data at rest | Hashing or authenticated encryption of stored records | Silent modification of calibration or configuration data | | Data in transit | Authenticated protocols (e.g., TLS with integrity checks) | Undetected tampering with telemetry or commands | | Execution state | Runtime monitoring, host-based intrusion prevention | Unexpected control flow goes unnoticed | | Configuration data | Validation on read, not just on write | Corrupted settings applied without alert | ## What Evidence Does the FDA Expect for Each Control? The FDA expects a named mechanism and a corresponding test result for each integrity control, submitted as part of the cybersecurity documentation rather than described only in narrative form. For code integrity, that means evidence that signature verification actually blocks an unsigned or modified image. For anti-rollback, evidence that a deliberate downgrade attempt is rejected. For data integrity, evidence that tampered data at rest or in transit is detected rather than silently accepted. Reviewers look for this evidence tied back to the risk assessment required under ISO 14971, so that each identified integrity risk maps to a specific control and a specific test outcome. A generic statement that "firmware is signed" without version-specific test evidence, or a claim that "data integrity is maintained" without a description of the validation method, is the kind of gap that generates an additional information request. ## How Hash Collisions Threaten Integrity Controls A birthday attack is the mechanism that determines how much collision resistance a hash function actually provides, and it matters here because every integrity control described above, signed firmware, secure boot, anti-rollback, depends on a hash that an attacker cannot forge a collision for. The math is less forgiving than intuition suggests: for an n-bit hash, generic collision-search effort is roughly 2^(n/2), not 2^n, meaning collision resistance is effectively half the stated output length. This matters for signed firmware specifically. A signature typically operates over a hash of the firmware image, not the image itself, so if the underlying hash is weak or truncated, an attacker who can find two inputs producing the same hash could get a fraudulent image accepted under a signature that was validly generated for something else. The same risk applies to SBOM component identifiers and CI/CD artifact hashes, where truncation "to save space" or lingering use of MD5 or SHA-1 in build tooling quietly weakens the same integrity chain this article describes for secure boot and anti-rollback. | Hash choice | Collision resistance | Fit for firmware/update signing | | --- | --- | --- | | MD5 | Broken in practice | No | | SHA-1 | Deprecated for collision-sensitive use | No | | SHA-256 (untruncated) | Approximately 2^128 | Yes | | Truncated hash (e.g., 64-bit) | Approximately 2^32 | No, without a documented rationale | The practical fix is consistent with the rest of this article's evidence expectations: use SHA-256 or stronger for anything feeding a signature or integrity check, never truncate without a quantified rationale, and use HMAC or a full signature rather than a plain hash wherever forgery resistance, not just accidental corruption, is the actual threat. Documenting this choice as part of the same risk-to-verification chain covering signed firmware and secure boot gives reviewers one consistent integrity story instead of a gap between the update mechanism and the cryptographic primitive underneath it. ## How Blue Goat Cyber Approaches This Blue Goat Cyber's medical device practice treats code, data, and execution integrity as design-controlled engineering requirements, verified through direct testing rather than accepted as design claims. That includes attempting to load unsigned or downgraded firmware images to confirm secure boot and anti-rollback actually hold, and testing whether tampered configuration or telemetry data is detected by the device's own integrity checks. Findings feed directly into the risk assessment and premarket documentation, so the evidence reviewers expect under the February 3, 2026 guidance is already in hand before submission. This work is scoped as part of our [FDA premarket cybersecurity services](/services/fda-cybersecurity), which cover firmware validation, penetration testing, and the supporting SBOM and threat model documentation. ## Frequently Asked Questions ### What is code integrity in a medical device? Code integrity means the device's firmware remains authentic and unmodified throughout its lifecycle, verified through mechanisms like code signing, hash comparisons, and secure boot. It ensures that only firmware the manufacturer authorized can execute on the device. ### How does the FDA view data integrity? The FDA expects manufacturers to validate incoming data, whether from a network connection, another device component, or an external system, and to protect stored data from undetected modification. This applies to configuration, calibration, and patient data alike, both at rest and in transit. ### Why does anti-rollback protection matter if firmware is already signed? A signed older firmware version still passes signature verification even though it may contain a since-patched vulnerability. Anti-rollback protection adds a version check on top of signature verification so a device can't be downgraded to a validly signed but outdated, vulnerable image. ### Does the FDA mandate specific integrity mechanisms? The February 3, 2026 final guidance doesn't mandate one specific technology, but it does require manufacturers to identify integrity risks in the risk assessment and to implement and test corresponding controls. Reviewers expect a named mechanism and verification evidence, not just a statement that integrity was considered. ## CTA Blue Goat Cyber tests whether your firmware signing, secure boot, and anti-rollback controls actually hold under direct attack, before a reviewer or attacker finds the gap. [Schedule a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to validate your device's integrity controls. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## DREAD vs STRIDE vs PASTA Threat Modeling Source: https://bluegoatcyber.com/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective # DREAD vs STRIDE vs PASTA Threat Modeling for Medical Devices: Which Should You Use? > **[DIRECT ANSWER]** STRIDE is the most practical default for medical device threat modeling because it scales across the device, mobile app, and cloud, pairs with data flow diagrams, and gives reviewers consistent, comparable coverage; DREAD is a scoring add-on, not a substitute, and PASTA's attack-simulation stage is worth borrowing but too heavy to run in full every release. The FDA's February 3, 2026 guidance is methodology-neutral, but reviewers judge traceability from threats to controls and tests, whichever method produces it. Threat modeling is one of the highest-use activities in medical device cybersecurity. Done well, it helps you identify realistic abuse cases early, design effective controls, and produce evidence that holds up across the product lifecycle. When MedTech teams ask which method is “most effective,” the most practical answer is this: **STRIDE is the industry-default baseline** (not an FDA-mandated one) because it is structured, repeatable, and fits naturally with architecture and data flow diagrams. From there, many teams enhance STRIDE with attack-path thinking (PASTA-style) and a lightweight prioritization method to drive execution. Microsoft's [STRIDE threat modeling overview](https://learn.microsoft.com/en-us/azure/security/develop/threat-modeling-tool-threats) is a reasonable primer on the categories themselves, but it was written for enterprise software. Everything below translates the three methods into what an FDA reviewer actually reads in an eSTAR attachment. ## Key Takeaways - STRIDE classifies threats; DREAD and CVSS score them. Submitting a scoring rubric as a "threat model" is a named deficiency pattern, not a stylistic choice. - The FDA's February 3, 2026 premarket guidance is methodology-neutral, but AAMI TIR97 and the MITRE/MDIC playbook are both STRIDE-shaped, so STRIDE costs you the fewest review cycles. - DREAD's Discoverability and Reproducibility factors have no patient-safety axis. If you use it, replace those factors with clinical impact or drop it for CVSS 4.0 plus an ISO 14971 harm adjustment. - PASTA is a seven-stage process, not a classification scheme. Borrow its attack-simulation stage; running all seven stages per release is overhead most MedTech teams cannot sustain. - Whatever you choose, the reviewer's test is coverage: every element in the decomposition analyzed against every applicable category, with non-applicability written down. - The output that survives review is a table with stable threat IDs traced to a control, a verification test, and a patient harm, not a narrative. ## Why this matters Methodology choice looks like a documentation preference until you read a deficiency letter. The pattern we see repeatedly on 510(k) holds is not "you used the wrong framework," it is "the submitted threat model does not support the risk determinations in the security risk assessment." That is a traceability failure, and each of these three methods fails it in a different, predictable way. Teams that lead with DREAD hand reviewers a spreadsheet of 1-to-10 scores with no enumeration behind it, so there is no way to confirm coverage. Teams that lead with PASTA produce a rich attacker narrative for three or four scenarios and leave 40 interfaces unanalyzed. Teams that use STRIDE badly apply the six categories to "the device" as a whole rather than per element, which produces six threats for a system that should have produced two hundred. All three outcomes generate the same cascade: the risk assessment is questioned, the pen test scope is questioned, and the security architecture views no longer match the analysis. Getting the method right up front is the cheapest hold you will ever avoid. ## Quick Definitions - **STRIDE** (Spoofing, Tampering, Repudiation, Information Disclosure, Denial of Service, Elevation of Privilege) is a structured way to identify threat categories across a system design. - **DREAD** (Damage, Reproducibility, Exploitability, Affected Users, Discoverability) is a historical scoring model used to prioritize risk using a set of factors. - **PASTA** (Process for Attack Simulation and Threat Analysis) is a risk-centric framework that emphasizes attack simulation and traceability from objectives to threats and mitigations. ## Why STRIDE Is Often Preferred in Medical Device Cybersecurity STRIDE tends to be the best “default” for medical device teams because it: - **scales across ecosystems** (device, mobile app, cloud, portal, gateway, remote support, service tooling) - **pairs well with data flow diagrams** and trust boundary mapping - **provides consistent coverage** so teams don’t miss entire categories of threats - **is teachable** to cross-functional teams (engineering, QA, RA/QA, IT/OT, product) The key is to avoid stopping at labels. STRIDE becomes truly effective for MedTech when you translate each threat into: - **abuse cases** (what an attacker would try to do), then - **security requirements** (what must be true to prevent it), then - **verification evidence** (how you prove it works). For teams looking for practical threat modeling resources and templates, OWASP has a good hub: [OWASP: Threat Modeling](https://owasp.org/www-community/Threat_Modeling). ## What Medical Device Teams Actually Need From Threat Modeling No matter which framework you pick, “good” threat modeling in MedTech usually means you can answer: - What are the **trust boundaries** across the device ecosystem? - What are the **highest-risk abuse cases** for safety, effectiveness, confidentiality, integrity, and availability? - What **controls** reduce those risks? - What **tests and evidence** prove the controls are implemented and effective? - What’s the **postmarket plan** for monitoring, vulnerability intake, and remediation? Threat modeling also supports secure development expectations. A helpful reference here is the [NIST SP 800-218 Secure Software Development Framework (SSDF)](https://csrc.nist.gov/pubs/sp/800/218/final), which provides a practical structure for secure-by-design practices and evidence. ## STRIDE for Medical Devices ### Example: STRIDE applied to a connected medical device Before applying STRIDE, most teams start with a data flow diagram (DFD) that shows components, protocols, and trust boundaries. Below is a simplified example for a connected wearable ecosystem. Each component gets analyzed against all six STRIDE categories, and trust boundaries mark where authentication, integrity checks, and input validation must be enforced. ![Example STRIDE data flow diagram for a connected medical device, showing patient wearable, mobile companion app, cloud API, and clinician web portal separated by trust boundaries](/imported-images/threat-model-dfd-stride-boundaries.png) **About the two trust boundaries.** This teaching diagram draws boundaries at the two places where the *owner, physical control, and network* of the data all change at once: between the patient-owned wearable/phone (Zone 1-2, untrusted personal environment) and the vendor-operated cloud (Zone 3), and again between the cloud and the hospital-operated clinician portal (Zone 4, a different user population on a different network). Every arrow that crosses a dashed line is where authentication, integrity checks, input validation, and logging must be enforced, those crossings are where STRIDE findings almost always cluster. **What a real production DFD would add.** A submission-grade DFD typically expands this in five ways: (1) more granular processes inside each zone (auth service, telemetry ingestion, firmware update service, audit log writer shown as separate circles rather than one "API Service"); (2) explicit data stores for PHI, credentials/keys, audit logs, and OTA update artifacts (each drawn as parallel lines and analyzed for Tampering and Information disclosure separately); (3) additional trust boundaries around the secure element on the device, the mobile app sandbox, and any third-party/SaaS dependency (analytics, SMS, email); (4) out-of-band flows that teams often forget, such as service/debug ports, factory provisioning, remote support sessions, and OTA rollback paths; and (5) a data classification tag on every flow (PHI, PII, telemetry, control command, config) so reviewers can trace how each class is protected end to end. ### STRIDE walkthrough at each trust boundary The table below walks the two trust boundaries in the diagram above (Wearable/Mobile crossing into Cloud, and Cloud crossing into Clinician Portal) and gives one representative threat and mitigation per STRIDE category. In a real threat model each cell would expand into multiple entries, each traced to a security requirement and a verification test. #### Boundary 1: Wearable + Mobile App → Cloud API (BLE, then HTTPS/TLS) | STRIDE | Example threat | Example mitigation | | --- | --- | --- | | **S** Spoofing | Attacker pairs a rogue phone with the wearable, or forges a device identity to the cloud. | Mutual authentication on BLE pairing (out-of-band code or numeric compare); device-unique client certificate or attested identity for cloud auth. | | **T** Tampering | Telemetry payload modified in transit or on a jailbroken phone before upload. | TLS 1.2+ with certificate pinning; message-level signing of clinical payloads; jailbreak/root detection with reduced trust. | | **R** Repudiation | Patient or attacker later denies that a reading, dose, or command originated from their device. | Signed events with device key; append-only audit log in cloud with timestamp and firmware/app version. | | **I** Info disclosure | PHI sniffed over BLE or exposed in mobile app logs, backups, or screenshots. | LE Secure Connections with encrypted link; keychain/Keystore for secrets; disable verbose logging in release; block screenshots on sensitive screens. | | **D** Denial of service | BLE jamming, connection flooding, or malformed telemetry to the ingestion endpoint. | Local buffering and retry on the device; rate limiting and schema validation at the API gateway; alerting on ingestion anomalies. | | **E** Elevation of privilege | Compromised mobile app abuses its API token to call admin or other-tenant endpoints. | Scoped, short-lived OAuth tokens; server-side authorization checks on every request; tenant isolation enforced in the data layer. | #### Boundary 2: Cloud API → Clinician Web Portal (REST/OAuth, HTTPS/SSO) | STRIDE | Example threat | Example mitigation | | --- | --- | --- | | **S** Spoofing | Attacker phishes clinician credentials or replays a stolen session to impersonate a provider. | Enterprise SSO with phishing-resistant MFA (FIDO2/WebAuthn); short session lifetime; device posture check. | | **T** Tampering | Malicious client or proxy modifies API requests to change patient records or configuration. | TLS end to end; server-side input validation and schema enforcement; signed audit entries for state changes. | | **R** Repudiation | Clinician denies making a configuration change or accessing a specific chart. | Immutable audit log keyed to SSO identity; per-record access logging surfaced to compliance/HIPAA reports. | | **I** Info disclosure | Broken object-level authorization (IDOR) exposes another patient's record; verbose errors leak schema. | Authorization checked on every object by patient/tenant; generic error responses; DLP scanning of exports. | | **D** Denial of service | Portal or API overwhelmed by scraping, credential stuffing, or a noisy integration. | WAF and rate limiting per identity and IP; account lockout on credential stuffing; autoscaling with quotas. | | **E** Elevation of privilege | Standard clinician role escalates to admin via a missing role check on a portal endpoint. | Centralized RBAC with deny-by-default; server-side role checks on every route; periodic access review and least-privilege audit. | ### Where STRIDE shines - **Design-phase clarity:** STRIDE works cleanly with architecture diagrams and data flow diagrams. - **Coverage:** It helps teams avoid missing threat categories. - **Repeatability:** It’s easy to apply consistently across products and releases. ### Where STRIDE needs help - **Prioritization:** STRIDE identifies threats, but it doesn’t rank them by impact or urgency. - **Execution:** without conversion to requirements and tests, STRIDE can become a “list exercise.” **Best MedTech use:** Run STRIDE at each trust boundary and interface (pairing, authentication, updates, APIs, remote support, service mode, configuration changes). Capture outputs as abuse-case statements, not just STRIDE categories. ## DREAD for Medical Devices DREAD is most helpful as a lightweight discussion tool for prioritization, especially when you’re trying to sort a backlog. However, it can be subjective and may not naturally account for **clinical impact** or patient safety context unless you adapt it. **Best MedTech use:** If you use DREAD, adjust it. Add explicit factors for **patient safety/clinical impact**, **detectability**, and **response capability**. Use it to drive decisions, not to win debates about scoring. If your team wants a standard approach for vulnerability severity scoring (separate from threat modeling), CVSS is widely used: [FIRST: Common Vulnerability Scoring System (CVSS)](https://www.first.org/cvss/). ## PASTA for Medical Devices PASTA is strong when you need end-to-end realism and traceability, especially for complex systems (device + cloud + mobile + portal + service workflows). The tradeoff is overhead: PASTA can be heavier than many teams need for every product iteration. **Best MedTech use:** Use PASTA concepts, especially **attack simulation**-to enhance a STRIDE baseline. Reserve full PASTA for higher-risk products or complex ecosystems where deep traceability is required. ## Which Is Most Effective for Medical Device Cybersecurity? For most medical device teams, the most effective and sustainable approach is: - **STRIDE as the default baseline** for consistent coverage and repeatability. - **PASTA-style attack paths** to keep the model realistic across the entire ecosystem. - **Lightweight prioritization** (DREAD-like or custom) to drive execution and remediation planning. ## Recommended STRIDE-First Workflow for MedTech Teams 1. **Define the system:** device, app, cloud, portal, gateway, remote support, service tooling, manufacturing/test. 2. **Map trust boundaries:** identify where trust changes and where untrusted input enters. 3. **Run STRIDE per boundary:** capture threats as abuse cases with attacker goals. 4. **Simulate 5-10 attack paths:** chain realistic steps across components (PASTA-style thinking). 5. **Convert to testable requirements:** authentication, authorization, integrity, logging, segmentation, update security. 6. **Prioritize:** rank by safety impact + likelihood + detectability + feasibility of remediation. 7. **Verify and trace:** map abuse cases → requirements → test cases → results. 8. **Operationalize postmarket:** monitoring, vulnerability intake, patch workflow, coordinated disclosure. ## Medical Device Threat Modeling Checklist - We have a clear architecture and data flow view of the entire device ecosystem. - Trust boundaries are documented and reviewed as the design changes. - Threats are documented as abuse cases (not just STRIDE labels). - Each high-risk abuse case maps to testable security requirements. - Verification evidence exists (tests/results) tied to those requirements. - Postmarket processes exist for monitoring, vulnerability intake, and patching. ## What replaces DREAD for scoring Dropping DREAD leaves a real gap: you still have to rank two hundred threat rows. The combination that holds up in review is a two-axis score kept deliberately separate. | Axis | Source | What it answers | | --- | --- | --- | | Exploitability | CVSS 4.0 base plus threat metrics, or the MITRE medical-device rubric | How hard is this for an attacker in a realistic position? | | Patient safety impact | ISO 14971 severity language already in your risk file | What happens to the patient if it succeeds? | Keep them in separate columns and show the combination rule. A CVSS 4.3 flaw that halts infusion outranks a CVSS 9.8 flaw that leaks a serial number, and a reviewer will only accept that inversion if your rationale is written down. ANSI/AAMI SW96:2023 supplies the security risk management process that wraps both axes; ISO 14971 owns the final benefit-risk call. ## How Blue Goat Cyber approaches this We run STRIDE per element against a DFD level 3 decomposition, then build three CIA attack trees to capture the multi-step chains a per-element pass will always miss. That is the PASTA contribution, kept without the seven-stage overhead. Scoring is CVSS 4.0 plus a documented ISO 14971 harm adjustment; we do not use DREAD, because its subjective five-factor rating invites a reviewer question we would rather not spend a response cycle answering. The deliverable is an eSTAR-ready threat table with stable IDs, one row per category per element, each traced to a control, a verification test, and a patient harm. We walk it with your regulatory lead so your team can defend any row in a deficiency response. Full method in the [STRIDE threat modeling guide](/guides/stride-threat-modeling-medical-devices), or see [threat modeling services](/services/medical-device-threat-modeling). **Bottom line:** the FDA does not require a specific threat modeling methodology, but the three are not interchangeable. STRIDE gives you provable coverage, attack trees give you realism, and a documented safety-weighted score gives you prioritization. DREAD contributes nothing the other two do not do better. ## FAQ ### Does the FDA prefer STRIDE over DREAD or PASTA? The FDA's February 3, 2026 premarket cybersecurity guidance names no required methodology, so there is no formal preference. In practice STRIDE has the lowest friction: AAMI TIR97 and the MITRE/MDIC Medical Device Threat Modeling Playbook are both built around STRIDE-style per-element analysis, so reviewers recognize the output and question the method itself far less often. Any rigorous approach is acceptable if it demonstrates coverage of every element and traces each threat to a control, a verification test, and a patient harm. ### Should we still use DREAD for medical device threat models? DREAD is a scoring rubric, not a threat enumeration method, so it cannot serve as your threat model regardless of how carefully it is filled in. As a rubric it is also weak for MedTech: its Damage, Reproducibility, Exploitability, Affected Users and Discoverability factors contain no patient-safety axis, and its 1-to-10 ratings are subjective enough that two engineers score the same threat differently. If your quality system already mandates DREAD, add an explicit clinical-impact factor and document the scoring rules. Otherwise use CVSS 4.0 for exploitability plus an ISO 14971 severity rating for patient harm, kept in separate columns. ### When should we use PASTA instead of STRIDE? PASTA (Process for Attack Simulation and Threat Analysis) is a seven-stage, business-risk-driven methodology that starts from attacker objectives rather than system elements. It produces deeper attack narratives but is heavy to run on every release and hard to prove exhaustive, because nothing in the process forces you to touch every interface. For a complex device ecosystem spanning firmware, mobile app, cloud, and clinician portal, the pragmatic split is to enumerate with STRIDE per element for provable coverage and borrow only PASTA's attack-simulation stage, expressed as three CIA attack trees whose leaves point back to threat IDs in the table. ### How do the three methods map to an eSTAR submission? Only one artifact is submitted: the threat model attachment, and it must contain the enumeration. STRIDE supplies the categories in that table, an attack-simulation pass supplies the multi-step scenarios, and the scoring rubric populates the pre-mitigation and residual risk columns. Security architecture views are a separate eSTAR attachment and do not substitute for the analysis; submitting diagrams in place of an enumerated threat list is a recurring deficiency. ### How many threat rows should a medical device threat model contain? A moderately connected Class II device typically produces 80 to 300 rows, because the count is driven by elements multiplied by applicable categories rather than by how many risks feel important. Fewer than about 40 rows on a connected device usually means the decomposition stopped at a level 1 diagram and the six categories were applied to the system as a whole instead of per element, which is the single most common reason a reviewer calls a threat model incomplete. ## External References (Trusted Resources) - [Microsoft: STRIDE threat modeling overview](https://learn.microsoft.com/en-us/azure/security/develop/threat-modeling-tool-threats) - [OWASP: Threat Modeling](https://owasp.org/www-community/Threat_Modeling) - [NIST SP 800-218: Secure Software Development Framework (SSDF)](https://csrc.nist.gov/pubs/sp/800/218/final) - [NISTIR 8259A: IoT Device Cybersecurity Capability Core Baseline](https://csrc.nist.gov/pubs/ir/8259/a/final) - [MITRE: CWE Top 25 Most Dangerous Software Weaknesses](https://cwe.mitre.org/top25/archive/2024/2024_top25_list.html) - [FIRST: Common Vulnerability Scoring System (CVSS)](https://www.first.org/cvss/) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Related on threat modeling - [STRIDE threat modeling for medical devices: the complete playbook](/guides/stride-threat-modeling-medical-devices) - [Threat trees vs attack trees for FDA submissions](/blog/exploring-the-contrast-between-threat-trees-and-attack-trees-in-medical-device-fda-approval-and-cybersecurity) - [Step-by-step threat modeling for connected & implantable devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) --- ## Medical Device Cybersecurity Inventory (2026 Guide) Source: https://bluegoatcyber.com/blog/conducting-a-comprehensive-medical-device-inventory-for-enhanced-cybersecurity # Medical Device Cybersecurity Inventory for Medical Devices: 2026 Best Practices > **[DIRECT ANSWER]** A complete medical device cybersecurity inventory requires identifying every connected and indirect device, categorizing each by function and connectivity, and documenting specs, manufacturers, and known vulnerabilities. Organizations should apply regular patches, enforce network segmentation and access controls, and conduct continuous audits. This ongoing process, aligned with the FDA's February 3, 2026 final guidance, helps satisfy Section 524B expectations before submission. _Updated November 16, 2024_ Healthcare organizations face real pressure to protect sensitive patient data and keep medical devices secure. Conducting a thorough device inventory is one of the most direct paths to [enhancing cybersecurity and safeguarding these vital assets](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist). Understanding what's on your network, where it is, and what it runs is the foundation of any effective security program. ## Key Takeaways - Identify all medical devices, connected or indirect, for a complete inventory. - Categorize devices by function and connectivity to prioritize security efforts. - Document device specs, manufacturers, and known vulnerabilities accurately. - Apply regular software updates and patches to mitigate security flaws. - Implement network segmentation and strict access controls for device protection. - Conduct continuous audits to maintain an updated and accurate inventory. ## Why this matters An accurate medical device inventory is not merely an administrative task; it is a critical cybersecurity imperative. Without a precise understanding of every device connected to a healthcare network, organizations cannot effectively identify vulnerabilities, assess risks, or implement appropriate security controls. Each uncataloged device represents a potential entry point for attackers, jeopardizing patient safety, data privacy, and operational continuity. The FDA, in its Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, emphasizes the necessity of maintaining an updated asset inventory as a cornerstone of medical device security. Relevant standards such as IEC 81001-5-1, ISO 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 also highlight the importance of asset management in mitigating cybersecurity risks. Inadequate inventory practices can lead to significant regulatory penalties, reputational damage, and, most critically, compromised patient care. Organizations must ensure every device, from legacy systems to the newest IoT medical equipment, is accounted for and secured. ## Understanding the Importance of Medical Device Inventory Medical devices, from patient monitoring systems to infusion pumps, are central to healthcare delivery. They diagnose, treat, and monitor patients continuously. But the increasing connectivity of these devices creates cybersecurity risks that can't be ignored. ![Section Image](/imported-images/814fa9e9bf4574e9.webp) To address these threats, healthcare organizations need a thorough understanding of their device inventory and its associated vulnerabilities. That knowledge forms the foundation of an effective cybersecurity strategy, enabling organizations to [identify potential risks and implement appropriate security controls](/blog). ### The Link Between Medical Device Inventory and Cybersecurity A medical device inventory is essential for [maintaining the security of a healthcare organization's network](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). It surfaces all devices connected to the network, both authorized and unauthorized. With a complete inventory, organizations can assess risks tied to each device and prioritize security measures based on criticality. A well-maintained inventory also tracks the lifecycle of each device, including software updates and patches. Regularly updating device firmware and software is essential for addressing known vulnerabilities and keeping devices protected against current threats. Beyond risk management, an inventory lets organizations monitor device usage and performance. Analyzing utilization data helps identify anomalies or suspicious activity that may signal a security breach. That kind of proactive monitoring enables faster detection and more effective response to potential attacks. ### The Risks of Inadequate Medical Device Inventory Management Failing to manage the medical device inventory effectively carries serious consequences. One notable example is the [cybersecurity breach in 2015 at Anthem Inc.](https://www.insurance.ca.gov/0400-news/0100-press-releases/anthemcyberattack.cfm), one of the largest healthcare providers in the United States. That breach compromised the personal information of nearly 79 million people, exposing sensitive data to unauthorized access. The root cause was an undetected vulnerable device lacking proper security controls. Without a complete inventory, organizations miss these gaps. Vulnerable devices go untracked, and attackers find them before defenders do. Poor inventory management also drives operational inefficiencies. Without accurate location, status, and maintenance history data, organizations struggle to optimize device utilization and plan for necessary repairs or replacements. That disrupts patient care and strains healthcare budgets. ## Steps to Conduct a Complete Medical Device Inventory Conducting a device inventory requires a systematic approach. Follow these steps to produce a thorough and accurate result. ![Section Image](/imported-images/a81e0d6179d54fed.webp) ### Identifying All Medical Devices in Use Start by identifying every medical device connected to the network, across all departments and physical areas. This includes devices ranging from bedside monitors to infusion pumps. Don't limit the scope to devices with direct network connections. Devices connected through a computer system or central server also belong in the inventory. Any device that could affect patient care or data security needs to be accounted for. Involve all relevant stakeholders in this identification effort. Healthcare providers, IT personnel, biomedical engineers, and clinical staff all have visibility into what devices are actually in use. Their input helps ensure nothing gets missed. ### Categorizing Medical Devices Based on Functionality and Connectivity Once identified, categorize devices by functionality and connectivity level. This classification drives security prioritization. Life support systems require stronger controls than administrative workstations. Devices directly involved in patient treatment, such as ventilators or anesthesia machines, demand more rigorous security than those used for scheduling or reporting. Connectivity level matters too. Devices connected to the internet or external networks carry higher risk than those on isolated internal networks. Categorizing by both functionality and connectivity lets healthcare organizations allocate security resources where they matter most. ### Documenting Device Specifications and Manufacturer Details Accurate documentation is what makes an inventory actually usable. Record device specifications: make, model, firmware versions, and software configurations. Document manufacturer details, support contacts, and any known vulnerabilities or patches associated with each device. Collect as much detail as possible. The specifics matter when assessing security posture and identifying which devices need immediate attention. Manufacturer contact details are valuable when a vulnerability disclosure arrives and you need patches quickly. Track known vulnerabilities and patch history for each device. This keeps the organization current on what exposures exist and what's been addressed, which is critical for both security management and regulatory documentation. ## Implementing Cybersecurity Measures for Medical Devices With an accurate inventory in place, it's time to apply cybersecurity controls that protect devices from real threats. Protecting medical devices requires attention to integrity, confidentiality, and availability. As devices handle increasingly sensitive patient data and connect to more systems, the attack surface grows. Proactive security measures are the practical response. ### Regular Software Updates and Patches Software vulnerabilities are among the most common entry points for attackers. Keeping devices current with the latest patches closes those openings. Work directly with device manufacturers to stay informed about security updates and apply them promptly. Regular updates address vulnerabilities that attackers have already identified and are actively targeting. A proactive patch management process significantly reduces the risk of exploitation and keeps devices operating safely. ### Network Segmentation for Medical Devices Segmenting the network isolates medical devices from other network components, reducing their exposure to threats. Placing critical devices on dedicated segments lets organizations control access more precisely and monitor communications more effectively. [Network segmentation](/blog) creates barriers that prevent attackers from moving laterally across the network. Even if one device is compromised, segmentation limits the blast radius. It also enables more granular traffic monitoring, making it easier to spot unusual device behavior early. ### Implementing Access Controls and Authentication Protocols Only authorized personnel should be able to access or modify medical devices. Enforce this through strong passwords, multi-factor authentication, and restricted administrative privileges. Password complexity requirements and regular rotation reduce the risk of credential-based breaches. Multi-factor authentication adds a second verification layer, making stolen credentials far less useful to an attacker. Limiting administrative access to the minimum number of people necessary keeps the risk of unauthorized configuration changes small. ## Maintaining and Updating the Medical Device Inventory An inventory created once and never touched is not an inventory. It's a liability. Healthcare environments change constantly, and the inventory must keep pace. ![Section Image](/imported-images/56b54b4d44caa521.webp) Regular audits and reviews keep inventory data accurate and reliable. Periodic checks surface discrepancies, confirm device locations, and verify that recorded details still match reality. These audits serve as a quality control mechanism for the entire asset management program. ### Regular Audits and Reviews Auditing isn't a checkbox exercise. It means physically verifying device presence, cross-referencing serial numbers, and confirming that all recorded details are accurate. That hands-on verification catches the drift that remote monitoring misses. Audits also assess device condition and flag maintenance or replacement needs. Catching hardware issues early prevents failures that could disrupt patient care. Regular, thorough inspections make device management proactive rather than reactive. ### Updating Inventory with New Devices and Decommissioning Old Ones Every time a new device is acquired or an old one retired, the inventory must be updated immediately. Delays create inaccuracies. Inaccuracies create blind spots. Blind spots get exploited. When adding new devices, record device type, model, serial number, and physical location. When decommissioning old ones, remove them from the inventory and confirm they've been properly secured or disposed of. Devices no longer in use but still listed can create phantom vulnerabilities that are hard to track down. ### Training Staff on Inventory Management and Cybersecurity Practices Maintaining an accurate, secure inventory is not the IT department's job alone. Everyone who interacts with medical devices has a role in this effort. Training should cover proper device labeling, accurate data entry, regular inventory checks, and basic cybersecurity best practices. Staff who understand what's expected of them, and why it matters, make far fewer mistakes. Giving staff the knowledge they need to handle devices correctly builds a culture of shared accountability that benefits the entire organization. ## Inventory methods compared There is no single discovery method that is both safe and complete on a clinical network. Most programs combine two. | Method | Coverage | Risk to clinical devices | Effort to maintain | Best used for | | --- | --- | --- | --- | --- | | Manual records and purchasing data | Poor, ages quickly | None | High | A starting baseline only | | Passive network discovery | Good for anything that talks | None, it only listens | Low once deployed | Continuous fleet visibility | | Active scanning | High, but misses quiet devices | Real, some devices fault under scan traffic | Medium | Scheduled scans on non clinical segments | | Vendor supplied MDS2 and SBOM data | Deep on components, shallow on deployment | None | Medium, depends on vendor responsiveness | Vulnerability matching | | Clinical engineering work orders | Accurate on what has been serviced | None | Medium | Reconciling discovery against reality | | Agent based inventory | Deep where allowed | Changes the device configuration | High | General purpose workstations, not embedded devices | An inventory is only useful if it can answer one question quickly: when a vulnerability is published, which devices contain the affected component. ## Conclusion A medical device inventory is vital for effective cybersecurity within healthcare organizations. It requires ongoing commitment, not a one-time effort. By understanding the scope of what's on the network, applying targeted security controls, and keeping inventory data current, organizations can meaningfully reduce their exposure to cyberattacks and protect the patient data they're entrusted to keep safe. These proactive steps protect patients and preserve the reputation and trust that healthcare providers depend on. Ready to take your healthcare organization's cybersecurity to the next level? Blue Goat Cyber is here to help. As a Veteran-Owned business specializing in medical device cybersecurity, we understand your unique challenges. Our B2B cybersecurity services, including penetration testing, HIPAA compliance, FDA Compliance, and more, are designed to protect your sensitive data and patient safety. [Contact us today](/contact) for expert assistance in securing your medical devices and safeguarding your reputation. ## How Blue Goat approaches this Blue Goat Cyber assists organizations in creating and maintaining medical device inventories that enhance cybersecurity. Our methodology involves detailed asset identification, risk stratification, and control implementation, aligning with regulatory expectations. We don't just list devices; we integrate inventory data into a broader security posture management framework. With cybersecurity experts, including CISSP and OSCP certified professionals and ex-military red team members, we identify critical assets and their vulnerabilities. Our services extend to threat modeling for new and existing devices. Blue Goat Cyber provides focused assessments to help identify gaps in current inventory practices. Our approach is iterative and adaptive, ensuring your device inventory supports your evolving security needs and compliance requirements. Learn more about our technical services at: /services/medical-device-penetration-testing. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is a medical device inventory? A medical device inventory is a complete, organized list of all medical devices within a healthcare organization. It includes details such as device type, model, serial number, location, and network connectivity status. This inventory is critical for asset management and cybersecurity. ### How does an inventory improve medical device cybersecurity? An inventory improves cybersecurity by providing visibility into all connected devices, allowing organizations to identify potential vulnerabilities. It helps prioritize security measures based on device criticality and ensures that all devices receive necessary software updates and patches. ### When should medical device inventories be updated? Medical device inventories should be updated continuously, not just periodically. Any changes to a device's status, such as new deployments, decommissioning, location changes, or software updates, necessitate immediate inventory documentation to maintain accuracy. ### Why is network segmentation important for medical devices? Network segmentation is important because it isolates medical devices from other network components, limiting their exposure to potential threats. This control helps prevent unauthorized access and contains the impact of a security breach by preventing lateral movement across the network. ### What information should a medical device inventory include? A medical device inventory should include device make, model, serial number, firmware versions, physical location, network address, ownership details, and manufacturer support contacts. Documenting known vulnerabilities and patch history is also crucial. ### Does the FDA require a medical device inventory? While the FDA doesn't mandate a specific 'inventory' format, its February 3, 2026 final guidance on premarket cybersecurity emphasizes the need for manufacturers to provide transparency on device components, including software bills of materials (SBOMs). Healthcare organizations require such information to manage their assets securely. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CAPA in Medical Device Cybersecurity: Regulatory Guide Source: https://bluegoatcyber.com/blog/corrective-and-preventive-actions-capa-in-medical-device-cybersecurity # CAPA and Medical Device Cybersecurity: What Manufacturers Need to Know > **[DIRECT ANSWER]** CAPA is where a cybersecurity finding becomes a documented fix with proof it stayed fixed. A security CAPA records the vulnerability, the root cause in the design or process, the correction shipped, the preventive change to the development lifecycle, and the effectiveness check. Because the FDA inspects CAPA records directly, a vulnerability handled informally by engineering and never entered into the quality system is itself a finding. _Updated November 16, 2024_ Maintaining compliance with regulatory requirements is crucial in the medical device manufacturing field. The Corrective and Preventive Action (CAPA) process is a cornerstone among these requirements. CAPA is a systematic approach to identifying, addressing, and preventing the recurrence of quality issues and non-conformities. For medical device manufacturers, CAPA is essential for quality management and cybersecurity risk management, ensuring devices are safe and secure throughout their lifecycle. This article explores the key elements of CAPA, its relevance to medical device cybersecurity, and how manufacturers can implement effective CAPA systems to meet FDA and international standards like [ISO 13485](https://www.iso.org/standard/59752.html "") and IEC 62304. ## Key Takeaways - CAPA identifies and corrects existing cybersecurity non-conformities. - Proactive CAPA prevents new cybersecurity risks from emerging. - CAPA aligns with FDA and international medical device standards. - Root cause analysis is critical for effective CAPA implementation. - Verification ensures CAPA actions successfully resolve issues. - Integrating CAPA with risk management enhances device security. ## Why this matters The integrity of medical devices is paramount; failures can directly compromise patient safety and data privacy. Effective Corrective and Preventive Actions (CAPA) are essential for managing and mitigating cybersecurity risks. In its 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, the FDA emphasizes the necessity of a structured approach to identifying, evaluating, and addressing cybersecurity vulnerabilities throughout a device's lifecycle. Without a well-implemented CAPA system, medical device manufacturers risk persistent vulnerabilities, potential regulatory non-compliance, and severe reputational damage. CAPA ensures that identified cybersecurity flaws, whether from postmarket surveillance, threat intelligence, or internal audits, are not merely patched but systematically eradicated to prevent recurrence. This aligns with standards such as ISO 13485 (Quality Management Systems), IEC 60601-1 (Basic Safety and Essential Performance), AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for Medical Device Security), and IEC 81001-5-1 (Health software, security activities in the product life cycle). An integrated CAPA process ensures continuous improvement in security posture, protecting both device functionality and patient well-being. ## What is CAPA? ### Corrective Action (CA) Corrective Action involves identifying existing non-conformities, determining their root causes, and implementing measures to eliminate these issues. Corrective actions may be necessary for medical devices when a cybersecurity vulnerability is found, such as an unpatched software flaw or a data breach. The process includes: - **Root Cause Analysis:** Identifying the underlying causes of a cybersecurity incident. - **Implementation of Solutions:** Applying technical fixes, such as software patches or configuration changes. - **Verification of Effectiveness:** Ensuring the implemented solutions resolve the issue and prevent its recurrence. ### Preventive Action (PA) Preventive Action is proactive, focusing on identifying potential risks before they manifest. It involves monitoring trends, analyzing data, and taking steps to mitigate vulnerabilities. For example, preventive actions in cybersecurity could include: - **Risk Assessments:** Regular evaluations to identify new cybersecurity threats. - **Threat Modeling:** Using methodologies like [STRIDE](/blog) to anticipate potential attack vectors​. - **Pre-emptive Updates:** Updating software components to eliminate known vulnerabilities before they can be exploited​. ## Importance of CAPA in Medical Device Quality Management CAPA is a critical requirement in the regulatory frameworks governing medical devices. For instance, ISO 13485:2016 mandates implementing a CAPA process to manage quality issues throughout a device’s lifecycle. CAPA is pivotal in ensuring compliance with regulatory bodies like the FDA, emphasizing the importance of addressing product defects and potential cybersecurity risks​​. ### How CAPA Enhances Cybersecurity The [FDA’s guidance on premarket submissions](https://www.fda.gov/media/119933/download "") and postmarket surveillance includes recommendations for CAPA to address cybersecurity vulnerabilities. By integrating CAPA into cybersecurity processes, manufacturers can ensure: - **Continuous Improvement:** Learning from past incidents to strengthen security measures. - **Regulatory Compliance:** Meeting the FDA’s premarket submission requirements and postmarket management guidelines​. - **Risk Reduction:** Proactively address security risks, which are critical for maintaining the safety and functionality of connected medical devices. ## Implementing an Effective CAPA System ### Step 1: Establishing a CAPA Policy The first step in implementing a CAPA system is establishing a policy outlining the organization’s approach to managing corrective and preventive actions. This policy should include: - **Scope and Objectives:** Clearly define the scope of CAPA activities, including quality and cybersecurity management. - **Roles and Responsibilities:** Designate specific responsibilities for investigating non-conformities, implementing actions, and verifying effectiveness​. - **Procedural Framework:** Create standard operating procedures (SOPs) that detail how CAPA processes will be conducted. ### Step 2: Identifying Non-Conformities and Potential Issues For an effective CAPA system, identifying issues early is crucial. This involves: - **Monitoring Post-Market Data:** Analyzing data from field reports, customer feedback, and incident reports to identify trends indicating potential cybersecurity vulnerabilities​. - **Conducting Regular Audits:** As outlined in [IEC 62304](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards), audits should be performed on both the device and its software to uncover hidden risks​. ### Step 3: Conducting Root Cause Analysis Once a non-conformity is identified, the next step is determining its root cause. This process must ensure the issue is fully understood and effectively addressed. Tools like Fishbone Diagrams (Ishikawa) and the [Five Whys](https://www.youtube.com/watch?v=mdSBJS3L-B8 "") method are commonly used for root cause analysis. ### Step 4: Implementing Corrective and Preventive Actions After the root cause is identified, corrective actions should be implemented to eliminate the issue, while preventive actions should focus on preventing similar problems. This includes: - **Developing Action Plans:** Detail the steps required to implement changes and assign responsibility for each task. - **Documenting Changes:** Maintain thorough documentation to ensure traceability and regulatory compliance​. - **Training and Awareness:** Ensure that personnel are trained in the new measures to prevent the recurrence of issues. ### Step 5: Verifying the Effectiveness of CAPA Verification ensures that the actions taken effectively eliminate or prevent the identified problem. This involves: - **Testing:** Conduct testing to confirm that software patches or updates resolve identified vulnerabilities. - **Reviewing Incident Trends:** Monitor post-implementation data to verify that similar issues do not recur. - **Audit Trails:** Use audit trails to record all CAPA activities, providing evidence of compliance for regulatory audits​​. ## Best Practices for CAPA in Cybersecurity ### Aligning CAPA with Risk Management Integrating CAPA with risk management practices is essential for medical device manufacturers. This alignment ensures that all potential risks are addressed systematically and that CAPA actions are prioritized based on their impact on patient safety and device functionality. This approach is consistent with standards like [ISO 14971](/blog/iso-14971-risk-management-in-medical-device-security), which emphasizes a risk-based approach to medical device safety​​. ### Leveraging Technology for CAPA Using software tools to manage CAPA processes can significantly improve efficiency. These tools can help track actions, automate documentation, and provide real-time updates on the status of CAPA activities. Effective CAPA management tools should include: - **Automated Alerts:** Notify relevant stakeholders of new incidents or updates to existing CAPA cases. - **Data Analytics:** Analyze trends and patterns to identify risks proactively before they become issues​. - **Integration with Quality Management Systems (QMS):** Ensure that CAPA processes are integrated with the broader quality management framework. ## Regulatory Considerations for CAPA ### FDA Requirements for CAPA The FDA requires that medical device manufacturers maintain an effective CAPA process as part of their Quality System Regulation (QSR) under [21 CFR Part 820](/blog/21-cfr-part-820-and-its-role-in-medical-device-cybersecurity). This regulation requires manufacturers to document all non-conformities, conduct thorough investigations, and take appropriate corrective and preventive actions​​. In the context of cybersecurity, the FDA expects manufacturers to address vulnerabilities that could impact device functionality and patient safety throughout the product lifecycle. ### International Standards for CAPA International standards such as [ISO 13485](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity) and IEC 62304 also provide frameworks for CAPA, focusing on software development processes and lifecycle management. IEC 62304, for example, emphasizes the importance of managing software risks and maintaining traceability throughout the software lifecycle, making it an essential standard for managing cybersecurity risks in medical devices​. ## Conclusion An effective CAPA system is more than a regulatory requirement; it is a strategic tool that helps medical device manufacturers enhance product safety, maintain compliance, and build customer trust. By integrating CAPA with cybersecurity risk management, manufacturers can ensure that their devices remain secure and reliable throughout their lifecycle. As the regulatory landscape continues to evolve, a CAPA system will be essential for avoiding emerging threats and ensuring the safety and efficacy of medical devices in an increasingly interconnected world. Check out our [Medical Device Cybersecurity FDA Premarket Submission Services](/). ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in establishing and refining their CAPA processes for cybersecurity. Our approach focuses on developing structured methodologies for identifying the root causes of security incidents and vulnerabilities, implementing precise corrective measures, and establishing effective preventive actions. We use our team's deep expertise, including CISSP and OSCP certified professionals and ex-military red team members, to integrate cybersecurity CAPA into your existing quality management systems. From premarket submissions to postmarket surveillance, we ensure your CAPA system meets regulatory requirements and proactively addresses emerging threats. Our services, like our [threat modeling services](/services/medical-device-threat-modeling), help identify potential risks before they manifest. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to empower your organization to maintain a strong security posture, protecting patients and your brand. ## FAQ ### What is the purpose of CAPA in medical device cybersecurity? CAPA in medical device cybersecurity systematically identifies, addresses, and prevents security vulnerabilities and non-conformities. It ensures that devices are safe, secure, and compliant with regulatory standards throughout their lifecycle, from design to postmarket surveillance. ### How does CAPA help medical device manufacturers comply with the FDA's cybersecurity requirements? CAPA helps manufacturers comply with the FDA's February 3, 2026 final guidance on premarket cybersecurity by providing a structured process for managing and mitigating cybersecurity risks. It aligns with requirements for secure product development, root cause analysis, corrective actions, and documentation, demonstrating a commitment to patient safety. ### What is the difference between corrective and preventive actions in cybersecurity? Corrective actions address existing cybersecurity non-conformities and vulnerabilities after they have occurred, aiming to eliminate their root causes. Preventive actions are proactive measures taken to identify and mitigate potential cybersecurity risks before they manifest, based on trend analysis and risk assessments. ### How can medical device manufacturers implement an effective CAPA system for cybersecurity? Implementing an effective CAPA system involves establishing a clear policy, identifying cybersecurity non-conformities and potential issues through monitoring and audits, conducting thorough root cause analysis, implementing and documenting appropriate corrective and preventive actions, and verifying their effectiveness. ### Does the FDA mandate CAPA for medical device manufacturers? Yes, the FDA requires medical device manufacturers to maintain an effective CAPA process as part of their Quality System Regulation (21 CFR Part 820). This regulation covers all non-conformities, including those related to cybersecurity that could affect device functionality and patient safety. ### What role does root cause analysis play in CAPA for medical device cybersecurity? Root cause analysis is fundamental to CAPA in medical device cybersecurity because it identifies the underlying reasons for security incidents or vulnerabilities. Understanding the root cause ensures that corrective actions effectively eliminate the problem and that preventive actions can stop similar issues from recurring. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Penetration Testing Cost: 2026 Guide Source: https://bluegoatcyber.com/blog/cost-of-medical-device-penetration-testing # Medical Device Penetration Testing Cost: What Actually Drives the Number > **[DIRECT ANSWER]** Medical device penetration testing cost is set by four things: how many distinct interfaces the device exposes (firmware, wireless, mobile companion app, cloud backend), whether hardware teardown and physical-interface testing are in scope, the depth of report and evidence required for an FDA submission under the February 3, 2026 premarket cybersecurity guidance and ANSI/AAMI SW96:2023, and whether the engagement is fixed-fee or hourly. A connected diagnostic device typically runs $25,000-$60,000 for the test alone, and $40,000-$120,000 for a full premarket cybersecurity package that includes threat modeling and submission-ready documentation. _Reviewed September 17, 2026_ Every manufacturer asks the cost question at some point, and almost every vendor answers it with "it depends, let's get on a call." That answer is not wrong, but it is not useful to an engineering lead trying to size a budget line six months before a 510(k) submission, or a founder trying to decide whether a Series B round needs to fund the work now or after the next design freeze. This guide breaks down exactly what moves the price of a medical device penetration test: the interfaces in scope, the physical teardown work, the wireless and RF testing, the cloud and mobile companion surface, and the report depth reviewers actually expect to see. It closes with how a fixed-fee model changes the risk calculus and what a realistic 2026 price range looks like by device category. ## Key Takeaways - Medical device penetration testing cost is driven by attack surface, not device size: every distinct interface (firmware, RF, mobile companion, cloud API) is its own test scope. - A representative fixed-fee engagement for a connected diagnostic device runs $25,000-$60,000; a full premarket cybersecurity package with pen testing, threat modeling, and submission documentation typically lands between $40,000 and $120,000. - Report depth is a cost driver in its own right: a report built to satisfy the FDA's February 3, 2026 premarket cybersecurity guidance and ANSI/AAMI SW96:2023 takes materially more analyst time than a generic IT pen-test report. - Fixed-fee pricing with unlimited retesting protects buyers from the re-test surcharges that make hourly engagements unpredictable, and it is the model most defensible against FDA scrutiny of testing independence. - Scoping the test before design lock, not after, is the single largest lever a manufacturer has over total cost. ## Why This Matters Getting medical device penetration testing cost wrong in either direction has consequences beyond the invoice. Underscoping the test to save money produces a report that skips firmware, RF, or cloud attack surface, and that gap surfaces later as an FDA deficiency letter under the FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions final guidance, issued February 3, 2026, which expects testing evidence commensurate with the device's own threat model. Overscoping, or paying hourly with uncapped retest fees, inflates the budget without buying better security outcomes. ANSI/AAMI SW96:2023 reinforces the same expectation from the standards side, requiring security testing to trace back to the risk management file rather than exist as a generic checklist. The practical stakes are timeline and budget predictability. A manufacturer that scopes correctly the first time, with a current threat model and SBOM in hand, gets a fixed-fee number that holds. A manufacturer that scopes after design lock, without that documentation, absorbs discovery costs mid-engagement and risks a second, more expensive test cycle if the first one misses interfaces a reviewer later flags. Treating cost as a function of scope and effort, not a fixed market rate, is what lets an engineering lead defend the number to finance and still be confident it will hold up under regulatory review. ## Why Medical Device Pen Test Pricing Looks Nothing Like IT Pen Testing A generic web or network penetration test is priced against a handful of well-understood variables: number of IP addresses, number of web applications, number of user roles. Medical device penetration testing is priced against a fundamentally different set of variables, because the target is rarely a single system. It is a stack of systems that a general IT firm has usually never tested together: embedded firmware running on a real-time operating system, a proprietary or standards-based wireless link, a companion mobile app, a cloud backend that ingests patient data, and often a clinician-facing web portal on top of all of it. Each of those layers requires a different skill set and different tooling. A firm that only does web application testing can produce a report that looks thorough while never touching the firmware or the RF link, the two places where the most consequential vulnerabilities in connected medical devices tend to live. That mismatch is exactly why "cheap" quotes are cheap: they scope out the hard, expensive parts of the device and leave the manufacturer with a report that will not survive scrutiny from an FDA reviewer. The FDA's [February 3, 2026 premarket cybersecurity guidance](/blog/fda-section-524b-subsections-explained) makes the expectation explicit: cybersecurity testing has to be commensurate with the device's cyber risk, covering the full attack surface identified in the threat model, not just the layer that is easiest to test. ANSI/AAMI SW96:2023 reinforces the same point from the process side, requiring that security testing trace back to the risk management file and the threat model rather than existing as a standalone checklist exercise. Pricing that ignores this reality is pricing for a report that will not clear review, which makes it more expensive in the long run, not less. ## The Core Cost Drivers Five variables account for most of the difference between a $20,000 quote and a $90,000 quote, and any competent vendor should be able to walk you through all five before naming a number. **Number and type of interfaces.** A device with a single wired USB service port is a fraction of the effort of a device with BLE, Wi-Fi, a proprietary 900 MHz link, a cellular modem, and a cloud API all active at once. Each interface is its own test discipline with its own tooling, and the cost scales with the count, not with the device's physical size or price point. **Hardware access and teardown depth.** Testing that stops at the software boundary is materially cheaper than testing that includes chip-off firmware extraction, JTAG/SWD debug port analysis, side-channel review, and physical tamper testing. Implantables, infusion pumps, and other devices where physical possession by an attacker is a realistic threat scenario require the deeper (and pricier) teardown work. **Wireless protocol complexity.** Standard Bluetooth Low Energy testing against a known GATT profile is a known quantity. Proprietary RF protocols with custom framing require reverse engineering the protocol itself before any vulnerability testing can start, which adds days of analyst time before the "real" testing even begins. **Cloud and mobile companion scope.** Most connected devices today ship with a companion app and a cloud backend that need testing in their own right: API authentication and authorization, data-at-rest and in-transit encryption, session management, and the mobile app's local storage and binary hardening. This is effectively a second, parallel pen test bolted onto the device test. **Report and evidence depth for regulatory submission.** A report destined for an FDA submission needs to trace every finding back to the threat model, map to ANSI/AAMI SW96:2023 test categories, and document CVSS scoring, exploitability, and residual risk in a form a reviewer can audit line by line. That level of documentation takes measurably more time than a findings list built for an internal security team. ## Firmware and Hardware Teardown Firmware and hardware testing is where medical device penetration testing diverges most sharply from IT testing, and it is usually the largest single line item in a quote. A thorough engagement includes extracting firmware from flash or EEPROM, analyzing the boot chain for secure boot and signature verification, reviewing update mechanisms for signing and rollback protection, and probing debug interfaces (JTAG, SWD, UART) that are often left active in production hardware. Devices that store cryptographic keys or PHI locally add key management review to that scope: is the key material protected by a hardware security element, or is it sitting in flash where a $50 programmer and an afternoon can pull it out? Devices with physical tamper-evidence claims need dedicated tamper testing to validate those claims hold up against a motivated attacker, not just a curious one. The cost implication is straightforward: a software-only device (an app that processes data from a cleared device but has no firmware of its own) can skip this category entirely, while an implantable neurostimulator or an infusion pump needs the full teardown, and that difference alone can account for a $20,000-$30,000 swing in the final quote. ## Wireless and RF Testing Wireless testing cost tracks protocol complexity more than protocol popularity. Bluetooth Low Energy is common, but a device using a custom GATT profile with proprietary characteristics still requires the tester to reverse the profile before testing pairing security, encryption, and replay resistance. Wi-Fi-connected devices need testing against the same authentication and encryption weaknesses that affect any Wi-Fi client, plus device-specific questions like whether the device validates the network it joins or blindly trusts any AP with the right SSID. Proprietary sub-GHz RF links (common in infusion pumps, patient monitors, and glucose sensors) are the most expensive category, because there is no off-the-shelf tooling. The tester has to capture and reverse-engineer the over-the-air protocol with a software-defined radio before any real vulnerability analysis can begin, and that reverse-engineering phase alone can take a week or more of dedicated analyst time. Zigbee, Z-Wave, and NFC show up less often but follow the same rule: the more proprietary and undocumented the protocol, the more billable time it takes before testing starts, and the higher the quote. ## Cloud Backends and Mobile Companion Apps Few connected devices ship without a cloud component today, and most have a mobile app that pairs with the device and often authenticates the patient or clinician. Both need to be in scope, and both add cost proportional to their own complexity, independent of the device hardware. Cloud backend testing covers API authentication and authorization (including the increasingly common failure mode of a mobile app or device holding a static API key that grants far broader access than intended), data encryption in transit and at rest, multi-tenancy isolation if the platform serves multiple hospital customers, and logging and monitoring sufficient to detect an intrusion after the fact. Mobile companion app testing covers local data storage (is PHI or device pairing data sitting unencrypted in app storage), certificate pinning and transport security, reverse engineering resistance, and the authentication flow between the app, the device, and the cloud backend. A device with a thin, read-only companion app is a modest addition to scope. A device where the app is the primary clinician interface, pushing therapy adjustments to the device itself, is effectively a second full application pen test. ## Report Depth for an FDA Submission The deliverable itself is a cost driver that manufacturers routinely underestimate. A pen test report built for internal use can be a findings list with severity ratings and remediation notes. A report built to support an FDA submission has to do considerably more work. Under the FDA's February 3, 2026 premarket cybersecurity guidance, submitted testing evidence needs to demonstrate that testing was scoped against the device's own threat model and SBOM, not a generic checklist, and that findings were resolved or formally risk-accepted before submission. ANSI/AAMI SW96:2023 adds structure on top of that, defining test categories (including fuzz testing, vulnerability scanning, and structured penetration testing) that a mature security risk management process is expected to address, with traceability back to the risk management file required by ISO 14971. Producing a report that satisfies both means every finding needs a CVSS score, an exploitability narrative specific to the clinical use environment, a mapping to the relevant SW96 test category, and a remediation or risk-acceptance record that a reviewer can trace independently. That is a materially different (and more time-consuming) deliverable than a standard pen test report, and it is one of the reasons a "penetration test" quoted by a generalist security firm for $8,000 and a medical-device-specific engagement quoted at $35,000 can be testing the same device. ## Pricing Factors at a Glance | Cost Factor | Lower Cost | Higher Cost | | --- | --- | --- | | Interfaces in scope | Single wired service port | BLE + Wi-Fi + proprietary RF + cellular + cloud API | | Hardware access | Software boundary only | Full teardown: chip-off, JTAG/SWD, tamper testing | | Wireless protocol | Standard BLE with public GATT profile | Custom/proprietary RF requiring reverse engineering | | Cloud/mobile scope | No companion app or thin read-only app | Full API testing plus a therapy-controlling companion app | | Report depth | Internal findings list | FDA-submission-ready, SW96-mapped, threat-model-traced | | Threat model maturity | Existing, current threat model and SBOM | No threat model; tester must build one before testing starts | | Pricing model | Fixed-fee, unlimited retesting included | Hourly, with retesting billed separately | ## Typical Price Ranges by Device Category These are representative fixed-fee ranges for the penetration test itself, not the full cybersecurity submission package. Actual quotes vary with the specific interfaces and teardown scope described above. | Device Category | Representative Pen Test Cost | | --- | --- | | Software-only companion app or diagnostic tool (no proprietary hardware) | $15,000-$30,000 | | Single-interface connected device (e.g., BLE-only wearable) | $25,000-$45,000 | | Multi-interface connected device (BLE/Wi-Fi + cloud + mobile app) | $40,000-$70,000 | | Implantable or infusion device with proprietary RF and physical teardown | $60,000-$100,000+ | | Enterprise hospital platform (multiple connected devices, cloud, integrations) | $80,000-$150,000+ | A full premarket cybersecurity package, pen testing plus threat modeling, SBOM analysis, security architecture review, and submission documentation, typically runs $40,000-$120,000 depending on where the device falls in the table above. ## Fixed-Fee vs Hourly: Why the Pricing Model Matters The pricing model changes the risk profile of the engagement as much as the scope does. Hourly billing looks predictable at the quote stage, but medical device pen tests almost always surface findings that need remediation and a re-test, and hourly firms bill every one of those re-test cycles separately. A device that needs three remediation-retest passes before it clears can see its final invoice run well past the original estimate. Fixed-fee engagements with unlimited retesting included remove that risk from the buyer's side. The firm commits to a price for the defined scope and absorbs the cost of retesting until the device reaches an acceptable risk posture, which is the norm at Blue Goat Cyber and the model we recommend evaluating any vendor against. It also aligns incentives correctly: a fixed-fee firm has no financial reason to find (or manufacture) extra billable hours, which matters when the FDA is going to scrutinize the independence and rigor of the testing team's work. Turnaround time is part of the same conversation. A well-scoped engagement for a single- or dual-interface device typically completes in two to four weeks from kickoff to final report, assuming test hardware and documentation (architecture diagrams, SBOM, existing threat model) are available at the start. Devices requiring extensive RF reverse engineering or full hardware teardown run toward the longer end of that window, or beyond it, because the reverse-engineering phase cannot be compressed by adding more testers. ## How to Control Cost Without Cutting Corners The manufacturers who get the best price-to-value outcome share a few habits, none of which involve reducing the actual test scope. **Scope before design lock.** A threat model built during architecture, not after, tells the testing team exactly which interfaces matter and lets them price accurately on the first pass instead of discovering scope mid-engagement. **Bring an existing SBOM and threat model to the quote conversation.** Testing teams that have to build a threat model from scratch before they can even scope the engagement are pricing in that discovery work. A current SBOM and architecture diagram routinely shave real money off the quote. **Test once, correctly, instead of a cheap first pass and an expensive second pass.** A generalist IT pen test that misses the firmware and RF layers will surface as an FDA deficiency later, and the second, corrective engagement plus the resubmission delay costs far more than doing the medical-device-specific test correctly the first time. **Separate the premarket test from ongoing postmarket obligations.** Under Section 524B, postmarket vulnerability monitoring and periodic testing are recurring obligations, not part of the initial premarket pen test. Budgeting them as one line item leads to either an inflated premarket quote or an underfunded postmarket program. ## How Blue Goat Cyber Approaches Medical Device Penetration Testing Cost We price every engagement fixed-fee with unlimited retesting, because a device does not reach acceptable risk on a schedule that fits a single test pass, and the buyer should not carry that uncertainty on an hourly meter. - **Scoping against the real attack surface.** We map every interface, firmware, wireless, mobile, and cloud, before naming a price, so the quote reflects the device you are actually shipping rather than a generic device profile. - **Testing teams that cover hardware and software.** Firmware reverse engineering, RF protocol analysis, and application testing are handled by engineers who do that work daily, not generalists extending an IT pen test into hardware. - **Reports built for FDA review.** Every finding is traced to the threat model and mapped to ANSI/AAMI SW96:2023 test categories, so the report is ready to support a submission under the FDA's February 3, 2026 premarket cybersecurity guidance without a second drafting pass. - **Two-to-four-week turnaround on well-scoped engagements.** We give you a calendar date at kickoff, not a "we'll let you know" once testing starts. - **A single fixed number, no re-test surcharges.** If a finding needs a fix and a re-test, that re-test is included, not a change order. If you want a scoped, fixed-fee number for your device, our [Medical Device Penetration Testing](/services/medical-device-penetration-testing) service page walks through methodology and deliverables, and [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) covers the full submission package if you need threat modeling and documentation alongside the test itself. ## What to Send Before a Scoping Call A fixed-fee number holds when the scope is known at the start. Teams that arrive with the five items below usually get a firm number in one conversation. Teams that do not typically need a discovery step first, which adds time rather than money. | Item | Why it changes the price | Acceptable substitute | |---|---|---| | Interface list (wired, wireless, mobile, cloud) | Sets the number of separate test disciplines | An architecture diagram | | Threat model or hazard analysis | Determines depth per interface | A draft, even an incomplete one | | SBOM or component list | Flags legacy and third-party exposure | Firmware build manifest | | Submission pathway and target date | Sets report depth and sequencing | Your regulatory plan summary | | Physical access constraints | Decides whether teardown is in scope | Unit availability and quantity | If a target date is already fixed, say so early. Sequencing the test before design lock is the largest single lever on total cost, and it is the one that disappears once the schedule is committed. ## FAQ ### How much does a medical device pentest typically cost? Costs scale with the number of interfaces, hardware teardown depth, and report requirements. A representative fixed-fee test for a connected diagnostic device runs $25,000-$60,000, and a full premarket cybersecurity package, including threat modeling and submission documentation, typically runs $40,000-$120,000. ### What factors increase the price of medical device cybersecurity testing? The largest factors are the number and type of interfaces in scope (firmware, wireless, mobile, cloud), whether hardware teardown and physical tamper testing are required, the complexity of any proprietary wireless protocol, and the depth of report needed to satisfy the FDA's February 3, 2026 premarket cybersecurity guidance and ANSI/AAMI SW96:2023. A missing or outdated threat model also adds cost, because the testing team has to build one before scoping can even start. ### Does the FDA require penetration testing for all Class II devices? Penetration testing is expected for any cyber device under Section 524B where the threat model identifies exploitable interfaces, which covers the great majority of connected Class II devices. The February 3, 2026 guidance ties the required depth of testing to the device's cyber risk rather than its device class alone, so the safest approach is to scope testing against your specific threat model rather than assuming class determines whether testing is needed. ### How long does a medical device penetration test take to complete? A well-scoped engagement for a single- or dual-interface device typically takes two to four weeks from kickoff to final report, assuming test hardware and existing documentation are available at the start. Devices requiring extensive proprietary RF reverse engineering or full hardware teardown can run longer, since that analysis cannot be shortened simply by adding staff. ### Can I use a general IT pentest firm for my medical device? A general IT pen test firm can competently test a device's web portal or cloud API, but most lack the firmware reverse engineering and RF protocol analysis capability that medical devices require, and a report missing those layers will not satisfy an FDA reviewer looking for testing commensurate with the device's full threat model. If your device has no firmware or wireless attack surface at all, a general firm may be sufficient; almost no connected medical device meets that bar. ## CTA Use the [Scope Estimator](/scope-estimator) for a self-serve pricing range on your device, or [book a strategy call](/contact) so we can scope your device's interfaces, teardown needs, and submission timeline against a written, fixed-fee number before you commit budget. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity, scoping penetration testing engagements against the FDA's premarket cybersecurity expectations. [Read more about Christian](/christian-espinosa). --- ## Premarket Cybersecurity Insider Tips (2026) Source: https://bluegoatcyber.com/blog/cracking-the-code-insider-cybersecurity-insights-for-medical-device-premarket-success # Premarket Cybersecurity Insider Tips: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Premarket cybersecurity success in 2026 depends on engaging security experts early, building a documented threat model and SBOM, integrating security through a Secure Product Development Framework rather than bolting it on at the end, and maintaining postmarket monitoring after launch. Common pitfalls include shallow threat modeling, incomplete SBOMs, and skipping independent penetration testing. The FDA's February 3, 2026 final guidance makes these practices mandatory components of premarket submissions, not optional best practices. _Updated October 26, 2024_ As the medical device industry continues to innovate, cybersecurity has become critical to ensuring new products’ safety, effectiveness, and market success. With the FDA’s evolving requirements, manufacturers must adopt a proactive approach to cybersecurity throughout the product lifecycle. In this post, we’ll explore key insights shared by Christian Espinosa, founder of Blue Goat Cyber, at [DeviceTalks West 2024](https://west.devicetalks.com/ ""), providing guidance on navigating FDA premarket submissions, understanding vulnerabilities, and ensuring compliance with the latest cybersecurity standards. ## Key Takeaways - FDA guidance requires premarket cybersecurity documentation. - Threat modeling identifies device vulnerabilities and risks. - SBOMs list all software components, including third-party. - SPDF integrates security into development phases. - Postmarket surveillance is necessary for new threats. - Early cybersecurity expertise prevents submission delays. ## Why this matters The increasingly interconnected landscape of medical devices elevates cybersecurity from a mere technical concern to a critical patient safety imperative. The FDA's February 3, 2026 final guidance on `Cybersecurity in Medical Devices` underscores this shift, making cybersecurity a non-negotiable component of premarket submissions. Failure to demonstrate adequate security measures can lead to submission delays, costly redesigns, and ultimately, rejection of market authorization. This not only impacts manufacturer profitability but also delays access to potentially life-saving technologies. Beyond regulatory hurdles, compromised medical devices present direct threats to patient health through data breaches, device malfunction, or even physical harm. Industry standards like ISO 14971 (risk management for medical devices), IEC 60601-1 (basic safety and essential performance), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (principles for medical device security) provide frameworks, but the FDA guidance specifically mandates proactive security integration. Manufacturers must embed security throughout the entire product lifecycle, from concept to postmarket surveillance, to protect vulnerable patient data and ensure device integrity in an environment rife with evolving cyber threats. ## Why Cybersecurity Is No Longer Optional In today’s interconnected world, over 68% of medical devices are network-connected, introducing new avenues for potential cyber threats. From ransomware attacks to device-specific vulnerabilities, the risks are real and growing. A single security lapse can jeopardize patient safety, disrupt critical medical services, and derail the path to FDA clearance. Ensuring cybersecurity is not just a regulatory requirement; it’s a commitment to patient safety and market success. ## The Evolving FDA Landscape The FDA’s cybersecurity guidelines, most recently restated in the Feb 3, 2026 final premarket cybersecurity guidance (which supersedes the September 2023 and June 2025 versions), have reshaped how manufacturers approach device security. The new mandates focus on cybersecurity measures, including: - **Threat Modeling**: It is crucial to identify potential vulnerabilities and understand the attack surface. This involves a detailed analysis using frameworks like [STRIDE](/blog), which evaluates risks related to spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege. - **Software Bill of Materials (SBOM)**: Transparency is key. An [SBOM](/services) ensures that all software components, including third-party and open-source elements, are documented and continuously monitored for vulnerabilities. - **Secure Product Development Framework (SPDF)**: Integrating cybersecurity throughout the design and development phases reduces risks and minimizes costly last-minute changes. - **Postmarket Monitoring**: Continuous vigilance is essential for detecting and responding to new threats after deploying the device. Manufacturers must maintain and update their cybersecurity measures throughout the product lifecycle. ## Common Cybersecurity Pitfalls in Premarket Submissions Despite the clear guidance from the FDA, many submissions fall short due to common deficiencies. Here are the top five issues manufacturers face: 1. **Inadequate Threat Modeling**: Submissions often lack a detailed analysis of potential vulnerabilities. The FDA expects manufacturers to go beyond basic risk assessments and provide a threat model that maps out entry points and potential exploit scenarios. 2. **Incomplete SBOMs**: Missing or outdated components in the SBOM can lead to critical oversights, exposing devices to unmonitored vulnerabilities. 3. **Failure to Align Risk Methodologies with Patient Safety**: Risk assessments must prioritize patient outcomes, not just technical security measures. Submissions that fail to link risks directly to potential patient harm often face delays. 4. **Late-Stage Cybersecurity Considerations**: Integrating security only after the design phase can lead to substantial rework and delays. Early engagement with cybersecurity experts is essential for compliance. 5. **Insufficient Third-Party Penetration Testing**: Third-party testing provides an unbiased device security assessment. Without it, manufacturers may miss critical vulnerabilities, compromising the credibility of their submission. ## Case Studies: Real-World Vulnerabilities and Lessons Learned To understand the stakes, consider these examples of significant device vulnerabilities: - **[Medtronic Insulin Pump Recall](https://www.fda.gov/medical-devices/medical-device-recalls/insulin-pump-recall-medtronic-notifies-users-minimed-600-and-700-series-pumps-risk-shorter-expected "")**: A vulnerability that allowed unauthorized users to manipulate insulin delivery, posing a life-threatening patient risk. This incident highlights the importance of continuous monitoring and rigorous threat assessments. - **[WannaCry Ransomware Attack](https://en.wikipedia.org/wiki/WannaCry_ransomware_attack "")**: This widespread ransomware attack demonstrated the potential impact of cyber threats on medical devices. It affected MRI machines and other critical hospital equipment, underscoring the need for defenses against ransomware. - **St. Jude Pacemakers**: A flaw allowed hackers to manipulate pacemaker settings, including battery life and pacing parameters. The incident illustrates the necessity of building security into device functionality from the outset. ## Strategies for Achieving FDA Compliance To meet the FDA’s stringent requirements and secure a smooth premarket submission, manufacturers should adopt the following strategies: - **Engage Cybersecurity Experts Early**: Incorporating cybersecurity expertise from the beginning of the design process can help avoid common pitfalls and streamline the path to approval. Blue Goat Cyber’s team has guided hundreds of manufacturers through this process, ensuring that security is a core component of device development. - **Maintain a Dynamic SBOM**: An SBOM is not a static document. It requires regular updates to reflect software changes and new vulnerabilities, providing transparency and traceability throughout the device lifecycle. - **Focus on Patient Safety**: Ensure that every aspect of your risk management aligns with patient safety. For example, if a device’s malfunction could cause patient harm, demonstrate how your cybersecurity measures mitigate that risk. - **Validate Security with Penetration Testing**: Third-party penetration testing is crucial for identifying overlooked vulnerabilities and validating your security measures unbiasedly. This step builds confidence with the FDA and helps ensure no gaps remain in your cybersecurity plan. ## Building a Culture of Security: Beyond Compliance Achieving FDA clearance is just the beginning. To maintain compliance and protect patients, manufacturers must build a culture of cybersecurity across their organizations. This means: - **Continuous Training**: Equip your team with the knowledge and skills to recognize and respond to cybersecurity threats. - **Proactive Risk Management**: Regularly update threat models and risk assessments to adapt to new vulnerabilities and technological advancements. - **Collaborate with Regulatory Bodies**: Stay ahead of changes in regulations and guidance by maintaining open communication with the FDA and other regulatory authorities. ## Conclusion As medical devices become more interconnected, the complexity of securing them grows. By following the FDA’s guidance and implementing best practices, manufacturers can achieve regulatory approval and ensure their devices are secure, reliable, and ready to serve patients safely. At Blue Goat Cyber, we are committed to helping manufacturers confidently navigate these challenges, offering a track record in which no client has failed to clear due to cybersecurity and an FDA cybersecurity deficiency commitment. Start building your cybersecurity strategy today. [Connect](/contact) with our Blue Goat Cyber team to ensure the success of your next premarket submission. Download the presentation below: [Christian Espinosa - DeviceTalks West 2024](/) [Download](/) ## How Blue Goat approaches this Blue Goat Cyber provides specialized guidance for navigating the FDA's premarket cybersecurity requirements. Our approach focuses on pragmatic, implementable security solutions tailored for medical device manufacturers. We assist in developing thorough threat models, generating accurate Software Bills of Materials (SBOMs), and integrating a Secure Product Development Framework (SPDF) into your existing processes. Our team, comprised of professionals with CISSP and OSCP certifications and ex-military red team experience, deeply understands both offensive and defensive cybersecurity strategies. We conduct targeted penetration testing and vulnerability assessments, ensuring your devices meet rigorous security standards before submission. We streamline your compliance journey, minimizing delays and rework. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized services at: [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQs ### What is the primary FDA guidance for medical device cybersecurity? The primary guidance is the FDA's February 3, 2026, final guidance on premarket cybersecurity for medical devices. This document outlines the agency's expectations for cybersecurity documentation in premarket submissions. ### Why is threat modeling important for FDA submissions? Threat modeling is vital because it systematically identifies potential vulnerabilities and attack vectors in a device. The FDA requires detailed threat models to ensure manufacturers have thoroughly assessed and mitigated cybersecurity risks. ### What is an SBOM and why does the FDA require it? An SBOM, or Software Bill of Materials is an inventory of all software components in a medical device. The FDA requires it to ensure transparency, allow for vulnerability tracking, and help manage supply chain risks throughout the device's lifecycle. ### Does the FDA require postmarket cybersecurity monitoring? Yes, the FDA expects manufacturers to maintain continuous vigilance through postmarket monitoring. This involves actively detecting, assessing, and responding to new cybersecurity threats and vulnerabilities after a device has been deployed. ### How can manufacturers avoid common cybersecurity pitfalls in FDA submissions? Manufacturers can avoid pitfalls by engaging cybersecurity experts early, conducting thorough threat modeling, providing complete SBOMs, aligning risk assessments with patient safety, and performing third-party penetration testing to validate security measures. ### What is a Secure Product Development Framework (SPDF)? An SPDF is a set of processes that integrate cybersecurity activities into every stage of a medical device's development lifecycle. This proactive approach helps build security into the device from its inception, rather than adding it on later. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CVSS 3.1 vs 4.0 for Medical Devices: Safety & Automatable Metrics Source: https://bluegoatcyber.com/blog/cvss-3-1-vs-4-0-medical-devices # CVSS 3.1 vs 4.0 for Medical Devices > **[DIRECT ANSWER]** CVSS 4.0 matters for medical devices because it adds Safety metrics and an Automatable attribute that CVSS 3.1 could only approximate through environmental scoring. That lets you express patient-harm potential and worm-like exploitability directly in the vector string. The FDA does not mandate a version, so state which you used, publish full vector strings, and explain how the score maps to the harm severity in your ISO 14971 file. **Most medical device security teams are still pasting CVSS 3.1 base scores into VEX statements and calling it a day. That works until a reviewer asks "what's the Safety impact?" - and 3.1 literally has no field to answer that question.** ## Key Takeaways - CVSS 3.1 remains acceptable to the FDA; 4.0 is not mandated but is increasingly expected for safety-relevant findings. - 4.0 splits Attack Vector and Attack Requirements, which materially changes scores for devices that need physical access or specific configurations. - 4.0 adds Safety (S) impact metrics under both Subsequent System (MSI/MSA) and Supplemental groupings - this is the single biggest reason to adopt it for medical devices. - The Automatable (AU) metric directly maps to fleet-wide patient risk on connected devices. - Vector strings must be read, not just scored; the prefix tells you the version and the metric ordering tells you what was actually assessed. - VEX and postmarket disclosures should include the full vector string, not just the numeric score. ## Why this matters The criticality of accurately assessing and communicating cybersecurity vulnerability severity in medical devices cannot be overstated, directly impacting patient safety, regulatory compliance, and market access. Inadequate or outdated scoring methodologies increase the risk of delayed submissions, market withdrawal, or even patient harm from exploitable vulnerabilities. While the FDA's Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, accepts CVSS 3.1, it emphasizes the importance of understanding actual clinical impact. CVSS 4.0 introduces essential metrics like 'Safety' (MSI/MSA) and 'Automatable' (AU) that directly address the unique risks of medical devices, aligning more closely with standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 regarding patient risk management. Relying solely on CVSS 3.1's general metrics can obscure the true patient safety implications of a flaw, potentially leading to underestimation of risk by both manufacturers and regulators. Accurately reflecting these nuances through CVSS 4.0 helps manufacturers demonstrate due diligence and a thorough understanding of their product's security posture, proactively addressing reviewer concerns about essential clinical performance and safety. ## Why version matters at all A CVSS number on its own is almost useless. A 7.5 means nothing without the vector string that produced it, and the vector string means nothing without knowing which version of the specification it was scored under. CVSS 2.0, 3.0, 3.1, and 4.0 all use overlapping but non-equivalent metrics. The same vulnerability can score 9.8 under 3.1 and 8.7 under 4.0 - or vice versa - without anything about the device changing. For medical devices, this matters because: - Submissions, VEX documents, and CVE entries persist for years. - The same SBOM component may be scored by NVD (often 3.1), the upstream vendor (sometimes 4.0), and a third-party tool (mixed). - A reviewer comparing your VEX to the public CVE record needs to see consistent versioning, not a 3.1 score next to a 4.0 vector. Always emit the version explicitly. The 4.0 vector string starts with `CVSS:4.0/`, the 3.1 string with `CVSS:3.1/`. If your tooling strips the prefix, fix the tooling. ## CVSS 3.1 vs 4.0 metric-by-metric The base metric group is where most of the meaningful change happened. Here is the practical mapping: | Concern | CVSS 3.1 | CVSS 4.0 | Why it matters for medical devices | |---|---|---|---| | How the attacker reaches the device | Attack Vector (AV) | Attack Vector (AV) | Same metric; values Network/Adjacent/Local/Physical unchanged. | | Conditions required beyond reach | Attack Complexity (AC) conflated with prerequisites | Attack Complexity (AC) + **Attack Requirements (AT)** | 4.0 separates "the exploit itself is hard" from "the target must be in a specific configuration." Cleaner for devices that require service mode, paired phone, or specific firmware revision. | | Privileges held | Privileges Required (PR) | Privileges Required (PR) | Unchanged conceptually. | | User interaction | User Interaction (UI) None/Required | User Interaction (UI) None/**Passive/Active** | 4.0 distinguishes "user just has to be logged in" from "user has to actively click something." Matters for clinician-facing UIs. | | Scope change | Scope (S) Changed/Unchanged | **Removed; replaced by Subsequent System metrics** | 3.1's Scope was widely misunderstood. 4.0 explicitly scores impact to a Subsequent System (e.g., the gateway pivoted into the device). | | Impact on the vulnerable component | C/I/A (None/Low/High) | **V**C/**V**I/**V**A (None/Low/High) | Renamed for clarity - Vulnerable system Confidentiality/Integrity/Availability. | | Impact on downstream systems | Implicit via Scope | **S**C/**S**I/**S**A (None/Low/High) | Explicit. A vulnerable BLE bridge with High SI on the pump it controls now scores honestly. | | Patient-harm potential | **No native metric** | **MSI/MSA** Safety values + Supplemental Safety (S) | The reason to adopt 4.0 for medical devices. | | Exploit automatability | Not represented | **Automatable (AU)** Yes/No | A worm-able flaw on a fleet of 50,000 infusion pumps scores differently than a one-off. | | Recovery / Value Density / Response Effort / Provider Urgency | Not represented | **Supplemental** group | Optional context that reviewers and ISACs increasingly want. | | Threat intel adjustment | Temporal (E/RL/RC) | **Threat** (Exploit Maturity only) | Simpler, more honest. | | Environmental | CR/IR/AR + modified base | **Modified base + MSI/MSA + CR/IR/AR/SC/SI/SA** | Richer environmental tailoring, including modified subsequent system impact. | The headline change for medical devices is the Safety metric. CVSS 3.1 has no field that says "this vulnerability could cause physical harm to a patient." Teams worked around this by inflating Availability or writing prose in the VEX justification. CVSS 4.0 makes safety a first-class concept under both the Subsequent System Integrity/Availability values (which can be set to `S` for Safety when human harm is in scope) and the Supplemental Safety metric. ## Reading a 4.0 vector string A complete CVSS 4.0 base vector looks like this: ``` CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N ``` Parse it left to right: - `CVSS:4.0` - version. Reject anything that omits this. - `AV:N` - Attack Vector Network. Reachable over the network. - `AC:L` - Attack Complexity Low. No special conditions on the exploit itself. - `AT:N` - Attack Requirements None. The target does not need to be in a specific state. - `PR:N` - Privileges Required None. - `UI:N` - User Interaction None. - `VC:H/VI:H/VA:H` - Vulnerable system confidentiality/integrity/availability all High. - `SC:N/SI:N/SA:N` - No impact on subsequent systems. If safety is in scope, you may see `SI:S` or `SA:S` instead of H/L/N, indicating human safety impact. Supplemental metrics, when present, are appended (e.g., `/S:P/AU:Y/R:U/V:C/RE:M/U:Red`). The metric order in the vector is fixed by the spec. If a vector arrives with metrics in a different order or with values that are not in the spec, the score is invalid - do not paste it into a VEX. ## A worked example - same flaw, both versions Consider a real-world-style finding: an unauthenticated command on the wired Ethernet interface of an infusion pump lets an attacker on the same hospital VLAN change the infusion rate. No user interaction required. Pump is in clinical use. **CVSS 3.1 base vector** ``` CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:N/I:H/A:H ``` Base score: **10.0** (Critical). Scope Changed because the vulnerable component (network service) impacts the pump function (different security authority). What the score does not tell a reviewer: - Is this exploit automatable across a fleet? - Is patient safety affected, or "just" availability? - Does the attacker need to be on a specific VLAN? **CVSS 4.0 base vector** ``` CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:H/SC:N/SI:S/SA:S ``` Base score: **9.5** (Critical). But now the vector explicitly says: - `SI:S/SA:S` - patient safety impact on the subsequent system (the infusion delivery). - `AT:N` - no special target state required. Add supplementals: `/S:P/AU:Y/R:I/V:C/U:Red` - safety present, automatable, irrecoverable in the moment, concentrated value, urgent. Now a reviewer or a hospital risk officer can act on the score without reading three paragraphs of narrative. The numbers are similar. The information content is not. ## A second worked example - BLE pairing flaw on a continuous glucose monitor Consider a different shape of finding. A continuous glucose monitor (CGM) wearable pairs with a patient's phone over Bluetooth Low Energy using Just Works pairing. An attacker within BLE range (roughly 10 meters), during the brief pairing window after the patient inserts a new sensor, can complete the pairing instead of the patient's phone and then receive glucose readings and suppress high/low alerts on the patient's phone. The sensor itself keeps operating; the patient stops seeing alerts. Walk the 4.0 base metrics in order, picking each value deliberately. 1. **Attack Vector (AV)** = `A` (Adjacent). BLE is a short-range network protocol, not arbitrary internet reach. Not `N`, not `P`. 2. **Attack Complexity (AC)** = `L` (Low). Just Works has no cryptographic barrier; standard BLE tools complete the exchange. 3. **Attack Requirements (AT)** = `P` (Present). The attacker must be in range during the pairing window after a sensor change. That is a real precondition that 3.1's `AC:H` would have lumped in with cryptographic difficulty - 4.0 separates the two. 4. **Privileges Required (PR)** = `N` (None). No account, no prior access. 5. **User Interaction (UI)** = `P` (Passive). The patient inserts a sensor and initiates pairing on their phone, but takes no action that would let them notice the attacker. Not `A` (Active), not `N`. 6. **Vulnerable System Confidentiality (VC)** = `H` (High). Glucose telemetry from the sensor is fully disclosed. 7. **Vulnerable System Integrity (VI)** = `N` (None). The sensor's own readings are not modified. 8. **Vulnerable System Availability (VA)** = `N` (None). The sensor keeps measuring and transmitting. 9. **Subsequent System Confidentiality (SC)** = `L` (Low). The paired phone's CGM app loses confidentiality of the live data stream, but no other phone data is exposed. 10. **Subsequent System Integrity (SI)** = `S` (Safety). Suppressed hypoglycemia alerts can delay treatment of a low - this is a safety impact on the downstream system (the patient's alerting pathway), not a generic data-integrity loss. 11. **Subsequent System Availability (SA)** = `S` (Safety). The alert pathway is unavailable to the patient at the moment it matters. Final base vector: ``` CVSS:4.0/AV:A/AC:L/AT:P/PR:N/UI:P/VC:H/VI:N/VA:N/SC:L/SI:S/SA:S ``` Base score: **7.7** (High) under the official CVSS 4.0 calculator. Now add supplementals that a clinical reviewer will actually read: - `S:P` - Safety: Present. Patient harm pathway exists. - `AU:N` - Automatable: No. Each exploit requires physical proximity during a pairing window. - `R:U` - Recovery: User. The patient regains alerting by re-pairing with their own phone. - `V:D` - Value Density: Diffuse. One victim per exploit, no fleet-wide payoff. - `U:Amber` - Urgency: Amber. Real safety pathway, but bounded by proximity and per-victim effort. For comparison, the same flaw under CVSS 3.1 would score roughly `CVSS:3.1/AV:A/AC:H/PR:N/UI:R/S:U/C:H/I:N/A:N` = **4.2** (Medium), with no field anywhere in the vector that says "this can delay treatment of a hypoglycemic event." The 4.0 vector both scores it higher and tells the reviewer why. The point of the walk-through is not the final number. It is that each metric in 4.0 has a defensible answer grounded in the device's clinical context, and the supplementals carry the nuance the FDA reviewer is actually looking for. ## A third worked example - unauthenticated firmware update on a networked patient monitor Consider a bedside patient monitor that exposes a firmware update endpoint over the hospital VLAN. The endpoint accepts unsigned firmware images from any host on the same network segment and reboots into the new image without operator confirmation. The monitor displays ECG, SpO2, and NIBP, and feeds alarms to a central station. The same model is deployed fleet-wide across the hospital. Walk the 4.0 base metrics in order. 1. **Attack Vector (AV)** = `N` (Network). The update endpoint is reachable across the routable hospital VLAN, not just an adjacent link. An attacker on any compromised endpoint in that segment (workstation, IoT printer, biomed laptop) can reach it. 2. **Attack Complexity (AC)** = `L` (Low). There is no signature check, no anti-replay, no ASLR-style defense to defeat. Push image, monitor reboots. 3. **Attack Requirements (AT)** = `N` (None). The endpoint is always listening. No service mode, no pairing window, no maintenance reboot required. 4. **Privileges Required (PR)** = `N` (None). The endpoint accepts unauthenticated POSTs. 5. **User Interaction (UI)** = `N` (None). No clinician has to do anything for the update to land. 6. **Vulnerable System Confidentiality (VC)** = `L` (Low). The attacker can read prior firmware and limited config, but PHI lives on the central station, not on the monitor itself. 7. **Vulnerable System Integrity (VI)** = `H` (High). Arbitrary firmware can be installed. Alarm thresholds, waveform processing, and the alarm-forwarding logic itself can be silently modified. 8. **Vulnerable System Availability (VA)** = `H` (High). The monitor can be bricked or held in a reboot loop, removing patient monitoring at the bedside. 9. **Subsequent System Confidentiality (SC)** = `L` (Low). The malicious firmware can exfiltrate the live waveform/vitals stream to the central station and onward, but not bulk PHI. 10. **Subsequent System Integrity (SI)** = `S` (Safety). The central station receives suppressed or fabricated alarms, which is a documented hazard in the device's ISO 14971 risk file (delayed clinician response to deterioration). 11. **Subsequent System Availability (SA)** = `S` (Safety). The alarm channel to the central station can be dropped silently, which is the worst clinical failure mode for a bedside monitor. Final base vector: ``` CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:H/VA:H/SC:L/SI:S/SA:S ``` Base score: **9.4** (Critical) under the official CVSS 4.0 calculator. Supplementals a hospital risk team and FDA reviewer will actually read: - `S:P` - Safety: Present. Multiple credible patient-harm pathways (silenced alarms, falsified vitals, bedside outage). - `AU:Y` - Automatable: Yes. A single script can sweep the VLAN, identify monitors, and push firmware fleet-wide. This is the key field-action driver. - `R:I` - Recovery: Irrecoverable in the moment. Restoring a known-good image requires biomed staff at each bedside. - `V:C` - Value Density: Concentrated. One attacker pivot inside the network owns every monitor of this model in the facility. - `U:Red` - Urgency: Red. Same-day field communication and a compensating network control are warranted while a signed-firmware patch is prepared. For comparison, the same flaw under CVSS 3.1 scores `CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:L/I:H/A:H` = **9.6** (Critical), but nothing in the vector flags fleet-wide automatability or the alarm-channel safety pathway. The 4.0 vector lands in the same severity band and tells the reviewer exactly which two facts (`AU:Y`, `SA:S`) drive the field-action recommendation. This example also illustrates a pattern worth naming: when `AU:Y`, `S:P`, and `SI:S`/`SA:S` all line up on a base score above 9.0, you are looking at a finding that almost always belongs in a coordinated disclosure and a same-cycle postmarket update under the Feb 3, 2026 guidance, regardless of installed-base size. ## CVSS 4.0 metric cheat sheet for medical devices Use this as a desk reference when scoring a finding. Each entry gives the plain-language question to ask, the values, and the medical-device-specific tell for which value to pick. ### Base - Exploitability | Metric | Plain-language question | Values | Medical-device tell | |---|---|---|---| | **AV** Attack Vector | Where does the attacker have to be? | N / A / L / P | `N` for cloud backend or routable LAN. `A` for BLE, Wi-Fi, same VLAN. `L` for USB / service port with shell. `P` for needing to physically open the device. | | **AC** Attack Complexity | Does the exploit need special conditions the attacker cannot control? | L / H | `H` only if there is a real defense the attacker must defeat (ASLR, signed firmware, anti-replay). Quirky timing alone is not `H`. | | **AT** Attack Requirements | Does the target system have to be in a specific state? | N / P | `P` when service mode, pairing window, or maintenance reboot is required. This used to get crammed into 3.1's `AC:H`. | | **PR** Privileges Required | What account does the attacker need on the target? | N / L / H | `N` for unauthenticated. `L` for clinician/operator role. `H` for biomed/admin or service account. | | **UI** User Interaction | Does a human have to do something for the exploit to land? | N / P / A | `P` Passive: user just uses the device normally (opens an app, accepts a pairing prompt they always accept). `A` Active: user must be tricked into a specific non-routine action. | ### Base - Impact on the vulnerable system (the device itself) | Metric | Plain-language question | Values | Medical-device tell | |---|---|---|---| | **VC** Vuln. Confidentiality | Can the attacker read data on the device? | H / L / N | `H` if PHI, credentials, or therapy parameters are exposed. `L` for non-clinical telemetry. | | **VI** Vuln. Integrity | Can the attacker change data, firmware, or therapy on the device? | H / L / N | `H` if dose, alarm thresholds, firmware, or calibration can be modified. This is the metric that drives the safety story. | | **VA** Vuln. Availability | Can the attacker stop the device from working? | H / L / N | `H` if device crashes, locks, or must be power-cycled mid-procedure. | ### Base - Subsequent system (what the device is connected to) | Metric | Plain-language question | Values | Medical-device tell | |---|---|---|---| | **SC / SI / SA** Subsequent C/I/A | Once the device is owned, what happens next door? | H / L / N | Set non-`N` when compromise pivots to the EHR, gateway, PACS, or a fleet of identical devices. This replaces 3.1's `Scope` toggle. | | **SS** Safety (Subsequent) | Can the pivot harm a patient on a different system? | N / P / S | `S` Safety when the pivot causes IEC 62304 hazardous-situation impact on another device or care workflow. | ### Base - Safety vs similar impact metrics (the part teams get wrong) The Safety metric (`SS` on the subsequent side, and `MSI:S` / `MSA:S` on the modified/environmental side) is **not** a duplicate of Integrity or Availability. Use this decision rule: - Use **VI:H** when the attacker can change a value on the device (dose, threshold, calibration), regardless of whether that change reaches a patient. VI describes the *technical* change. - Use **VA:H** when the device stops working as a piece of equipment. VA describes the *equipment* outage. - Use **Safety (S)** only when there is a credible pathway from the technical impact to **physical harm to a patient or operator**, per the device's own ISO 14971 hazard analysis. Safety describes the *clinical consequence*. A change to a non-clinical setting (display brightness, log verbosity) is `VI:H` but **not** Safety. A reboot of a diagnostic-only viewer is `VA:H` but **not** Safety. A 30-second pump lockup mid-infusion of a high-alert medication is `VA:H` **and** Safety, because the hazard analysis already flagged "interrupted infusion" as a harm. If your risk file (ISO 14971) does not list the resulting harm, do not set Safety. Either the metric is wrong or your hazard analysis is incomplete. Either answer is one the FDA reviewer will follow up on. ### Supplemental - what FDA reviewers actually read | Metric | When to set it | What it tells the reviewer | |---|---|---| | **S** Safety | A clinical hazard exists. Mirrors `SS:S` / `MSI:S` / `MSA:S`. | This is a patient-safety issue, not just an IT issue. | | **AU** Automatable | A worm, mass scanner, or one-click tool can hit your installed base. | Fleet risk. Drives field-action urgency. | | **R** Recovery | Automatic / User / Irrecoverable. | Tells the reviewer how a clinical site gets back to safe operation. | | **V** Value Density | Diffuse (one victim per exploit) vs Concentrated (many). | Helps the reviewer judge attacker economics for your specific device. | | **U** Urgency | Red / Amber / Green / Clear. | Your own recommendation on field-action timing. Reviewers weigh this against safety and automatability. | ### Environmental - when to override base Set Modified metrics (`MAV`, `MVI`, `MSI`, `MSA`, etc.) only when the deployed configuration legitimately changes the answer. A pump that ships with BLE enabled but is deployed BLE-disabled in a specific health system can drop `MAV` from `A` to `P`. Do **not** use environmental metrics to soften a base score for a generic submission. The FDA expects the base score to reflect the device as shipped. ## Where CVSS 4.0 changes scores meaningfully for devices Real differences you will see in practice: - **Devices requiring physical access or service mode** often drop in 4.0 because `AT:P` (Attack Requirements Present) is now distinct from `AC:H`. 3.1 tended to over-score these. - **Pivot-style findings** (compromise the BLE bridge, then control the pump) now score more honestly in 4.0 via Subsequent System metrics instead of the often-misused Scope flag. - **Safety-relevant denial of service** can now score higher in 4.0 by setting `SA:S`, where 3.1 would cap at `A:H`. - **Fleet-wide worm-able flaws** can be flagged with `AU:Y` Supplemental, which 3.1 has no way to express. ## What the FDA actually expects in 2026 The February 3, 2026 premarket cybersecurity guidance does not mandate CVSS 4.0. It does require that vulnerability assessments capture patient safety impact, exploitability, and the basis for any "not affected" disposition. CVSS 4.0 simply gives you native fields for those things; CVSS 3.1 requires you to handle them in prose alongside the score. For premarket submissions: - A CVSS 3.1 base score with a clear safety analysis in narrative form is still acceptable. - A CVSS 4.0 vector with Safety metrics populated is increasingly the cleaner answer, especially when the device has connected components. - Mixing versions inside one document without labeling is the worst option. Always emit the version prefix. For postmarket VEX: - Whatever version your SBOM tooling produces, preserve the original vector string in the VEX `vulnerability.scores[]` array (or your format's equivalent) and add a Safety-aware re-score if the original was 3.1 and patient harm is in scope. - When the upstream component publishes a 4.0 vector but your device-level analysis materially changes the score (because the component is not network-reachable in your design, for example), publish your tailored vector with environmental metrics rather than just dropping the base score. ## Common scoring mistakes specific to medical devices - **Setting `A:H` to represent patient harm under 3.1.** Availability is about the *vulnerable component's* availability. A pump that delivers a wrong dose is an integrity/safety failure, not an availability failure. Under 4.0, use `VI:H/SI:S/SA:S` and the Supplemental Safety metric. - **Calling everything `AV:N`.** A device only reachable on a clinical VLAN behind a firewall is `AV:A` (Adjacent) in most realistic threat models. The Environmental group exists to tailor this. - **Leaving `S:U` everywhere in 3.1.** Almost every realistic medical device finding has a Scope Changed dimension because the network component is rarely the patient-facing component. 4.0's Subsequent System metrics make this explicit. - **Quoting NVD scores verbatim.** NVD scores third-party components in isolation. A `9.8` on a library may be `4.2` in your device with the function not reachable. That is what Environmental metrics and VEX are for. - **Dropping the vector string from VEX.** A bare number is not auditable. Always include the full vector. ## When to move to 4.0 Move now if any of the following are true: - You ship devices with safety-relevant network or wireless interfaces (pumps, ventilators, surgical robots, dialysis, anesthesia, monitors with active control). - Your SBOM tooling already supports 4.0 output. - You are preparing a 510(k), De Novo, or PMA where the cybersecurity section will be reviewed against the February 3, 2026 guidance. - You operate a coordinated vulnerability disclosure program and want consistent, machine-parseable Safety signal. Stay on 3.1 for now if: - Your downstream consumers (hospitals, ISAOs) explicitly require 3.1. - Your scanning and SCA tooling only emits 3.1 and the output cannot be enriched in your build pipeline. - Even then, augment safety-relevant findings with a parallel 4.0 vector in the human-readable disclosure. The realistic 2026 posture for most medical device manufacturers is dual: keep 3.1 as the machine-emitted baseline, add 4.0 with Safety populated for any finding that touches essential clinical performance. ## Where this fits in your overall security program CVSS is one input into vulnerability triage, not the whole answer. The full chain looks like: 1. **SBOM** identifies the component and version. 2. **Vulnerability source** (NVD, vendor advisory, ICS-CERT, internal pen test) produces the CVE and an initial CVSS vector. 3. **VEX** captures your device-specific disposition - affected, not affected, fixed, under investigation - with the rationale. 4. **CVSS environmental and supplemental metrics** tailor the score to your device. 5. **Risk acceptance or remediation** flows from the tailored score and the safety analysis, not from the base score in isolation. If your VEX statements still look like `{ "vulnerability": "CVE-2024-XXXX", "score": 9.8, "status": "not_affected" }` with no vector, no version, no justification linked back to your threat model, the score is not doing work - it is just decoration. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ **Does the FDA require CVSS 4.0?** No. The February 3, 2026 premarket cybersecurity guidance does not specify a CVSS version. It requires that vulnerability assessments capture exploitability and patient safety impact, which 4.0 makes easier but 3.1 can still convey in narrative form. **Can we keep using CVSS 3.1 in our submissions?** Yes, as long as the safety impact analysis is explicit in the narrative and the vector string is included. Just labeling a finding "9.8 Critical" is not sufficient regardless of version. **How does Automatable (AU) interact with patient risk?** A worm-able or scan-and-exploit flaw on a fleet of devices is a fundamentally different patient-safety event than a targeted one-off. `AU:Y` is a strong signal to a hospital risk team and to FDA postmarket reviewers. **How do we handle a CVE that the NVD has 3.1-scored as 9.8 but is not exploitable in our design?** VEX status `not_affected` with a justification (e.g., `vulnerable_code_not_present`, `vulnerable_code_not_in_execute_path`) and, ideally, a tailored CVSS vector showing the modified base. Bare denial without rationale is what gets follow-up questions. **Where do CVSS scores live in the FDA submission?** They appear in the vulnerability assessment, the SBOM/VEX outputs, and the residual risk analysis. They should be consistent across all three. Mismatched scores between the SBOM addendum and the risk analysis are a common deficiency-letter trigger. **Our SBOM tool emits 3.1 scores from NVD. Do we just copy them into the submission?** No. Preserve the upstream 3.1 vector for traceability, then publish a device-tailored score (3.1 modified, or a fresh 4.0 vector) that reflects whether the vulnerable code is reachable in your design, the deployed attack surface, and the realistic safety pathway. A blanket "9.8 Critical, not affected" without a tailored vector and a VEX justification is the single most common scoring deficiency we see in deficiency letters. ## Where to go next CVSS scoring is one piece of an FDA-defensible vulnerability management program. Related reading: - Threat modeling for medical devices in AAMI TIR57 / ANSI/AAMI SW96:2023 terms. - SBOM and VEX construction for Section 524B submissions. - Postmarket vulnerability management plans under the February 3, 2026 guidance. - Pen testing methodology and how findings feed into your CVSS pipeline. If you want help mapping your current 3.1 workflow onto a dual 3.1/4.0 posture with Safety metrics populated, that is exactly the kind of engagement we run with device manufacturers preparing for or responding to FDA cybersecurity review. ## Related FDA & cybersecurity guides - [FDA Section 524B cybersecurity requirements explained](/guides/fda-524b-cybersecurity-requirements-explained) - [SBOM vulnerability management for medical devices](/guides/sbom-vulnerability-management-medical-devices) - [VEX document guide for FDA submissions](/guides/vex-document-medical-device-fda) - [FDA deficiency-letter response service](/fda-cybersecurity-deficiency-letters) - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CVSS Scoring for Medical Devices: A Complete Walkthrough Source: https://bluegoatcyber.com/blog/cvss-scoring-medical-devices # CVSS Scoring for Medical Devices: How to Read and Use It > **[DIRECT ANSWER]** CVSS scoring rates the technical severity of a vulnerability using base, threat, environmental, and supplemental metric groups that combine into a numeric score and a vector string. For medical devices, the raw score is only a starting point: it must be translated into patient harm severity through the ISO 14971 risk management file, then layered with exploit-likelihood data like EPSS and the CISA KEV catalog before it informs postmarket reporting or a VEX statement. _Reviewed September 17, 2026_ A CVSS score shows up everywhere in medical device security work: in CVE records, in SBOM vulnerability reports, in VEX statements, and in postmarket monitoring plans reviewed under FDA guidance. Teams often treat the number as the final answer, when it is actually one input among several that need to be combined before a decision gets made. Misreading CVSS, or treating it as equivalent to patient risk, produces both over-reactions to low-impact findings and under-reactions to findings that matter clinically. This post walks through each metric group, works through a real-style scoring example, and explains exactly where CVSS fits alongside ISO 14971, EPSS, and the CISA KEV catalog in a defensible vulnerability management process. ## Key Takeaways - CVSS combines four metric groups: Base, Threat, Environmental, and Supplemental, and each answers a different question about a vulnerability. - A vector string encodes every metric value used to calculate the score, and reading it matters more than reading the final number alone. - A raw CVSS score describes technical severity, not patient harm, and must be mapped to an ISO 14971 severity category before it informs a risk decision. - EPSS estimates the likelihood a vulnerability will be exploited, and the CISA KEV catalog confirms vulnerabilities already being exploited, both of which complement rather than duplicate CVSS. - The FDA's postmarket expectations call for exploit-likelihood context alongside severity scoring, not a severity score in isolation. - VEX statements should carry the full vector string and version, not just a numeric score, so downstream users can interpret it correctly. ## Why This Matters CVSS is the most widely used vulnerability scoring standard, and it appears in nearly every CVE record, SBOM vulnerability feed, and vendor advisory a medical device manufacturer will encounter. The February 3, 2026 final guidance, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions*, expects manufacturers to describe how they assess and prioritize vulnerabilities across the product lifecycle, and CVSS is the common language most teams use to start that conversation. The risk is treating CVSS as a complete answer rather than a starting metric. A 9.8 base score on a component that a device cannot reach through any exploitable path, or that would produce no patient harm if triggered, does not automatically mean urgent action. Conversely, a moderate score on a component tied to a life-sustaining function may deserve faster attention than the number alone suggests. Reviewers increasingly expect to see this reasoning made explicit: the CVSS score, the exploit-likelihood context, and the mapping to a documented harm severity category, together, rather than a spreadsheet of scores with no interpretation attached. ## What Are the CVSS Metric Groups and What Do They Answer? CVSS organizes its scoring into four metric groups, and each one answers a distinct question about the vulnerability. The Base metric group answers "how severe is this vulnerability in general, independent of any specific environment," and it is the only group that is mandatory and produces a score that persists in public CVE records. It covers exploitability factors like attack vector and attack complexity, and impact factors like confidentiality, integrity, and availability loss. The Threat metric group, called Temporal in CVSS 3.1, answers "how does the severity change based on current real-world conditions," primarily whether exploit code is publicly available and whether a fix exists. The Environmental metric group answers "how does this vulnerability's severity change in my specific deployment," allowing a scorer to adjust base values and add organization-specific security requirements for confidentiality, integrity, and availability. The Supplemental metric group, introduced in CVSS 4.0, answers "what additional context helps a downstream consumer prioritize this," including a Safety metric directly relevant to medical devices, without changing the numeric score itself. | Metric Group | Question It Answers | Changes the Score? | |---|---|---| | Base | How severe is this vulnerability generally? | Yes, always calculated | | Threat (Temporal) | How does real-world exploit activity affect severity? | Yes, if scored | | Environmental | How severe is this in my specific deployment? | Yes, if scored | | Supplemental | What extra context helps prioritization? | No, informational only | **[KEY REQUIREMENT]** Always publish the full vector string alongside any numeric score in internal reports, SBOM feeds, and VEX statements, since the number alone cannot be independently verified or recalculated by a downstream reader. ## How Do You Read a CVSS Vector String? A vector string is read left to right as a series of abbreviated metric codes and values separated by slashes, starting with the CVSS version. A CVSS 3.1 vector begins with `CVSS:3.1/` followed by Attack Vector (AV), Attack Complexity (AC), Privileges Required (PR), User Interaction (UI), Scope (S), and the three impact metrics for Confidentiality, Integrity, and Availability (C, I, A), each with a letter code such as N for Network, L for Low, or H for High. A CVSS 4.0 vector follows the same slash-separated pattern but splits some metrics further, separating Attack Requirements (AT) from Attack Complexity and adding Vulnerable System and Subsequent System impact metrics, plus the optional Supplemental group that includes Safety (S), Automatable (AU), and others when scored. Reading the vector, rather than just the score, tells you exactly which conditions were assumed true when the number was calculated, which matters when the same CVE gets scored differently by NVD, a component vendor, and an internal team. ## Worked Example: Scoring a Device Vulnerability Consider a real-style scenario: a connected infusion pump's maintenance interface accepts unauthenticated configuration commands over the local network segment it sits on. An attacker on the same network segment, without credentials or user interaction, can send a command that alters the dosing configuration. Scoring this under CVSS 3.1: Attack Vector is Adjacent Network (AV:A) because the attacker needs to be on the local segment, not the open internet. Attack Complexity is Low (AC:L) since no special conditions are needed beyond network access. Privileges Required is None (PR:N) and User Interaction is None (UI:N) since the command is accepted without authentication or a user action. Scope is Changed (S:C) if the compromised component can affect a different security authority, such as the dosing engine. Impact is High across Confidentiality, Integrity, and Availability (C:H/I:H/A:H) since dosing configuration integrity is directly at stake. That produces a vector of `CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:C/C:H/I:H/A:H`, which calculates to a Base Score of 9.3, Critical. Under CVSS 4.0, the same finding would additionally be scored for Safety impact, since altered dosing configuration has a direct patient safety consequence, and for Automatable, since the attack does not require unique manual interaction and could plausibly be scripted across multiple devices on a network. **[KEY REQUIREMENT]** Document the assumptions behind each metric choice, especially Attack Vector and Scope, since these are the values most often disputed between a manufacturer's internal scoring and a third party's independent scoring of the same CVE. ## Why Isn't a CVSS Score a Patient Risk Score? A CVSS score is not a patient risk score because it measures technical severity in isolation from clinical context, deployment likelihood, and the specific harm a device failure could cause a patient. Two vulnerabilities can share an identical CVSS score while one affects a logging function with no patient-facing consequence and the other affects a therapy delivery function where an exploit could cause direct harm. The score cannot distinguish between them on its own. ISO 14971 risk management works from a different axis entirely: severity of harm and probability of occurrence, evaluated specifically in the context of the device's intended use. Mapping a CVSS score into this framework requires a documented decision, not an automatic conversion, because the mapping depends on what the vulnerable component actually does within the device. See [CVSS 3.1 vs 4.0 for Medical Devices](/blog/cvss-3-1-vs-4-0-medical-devices) for a detailed look at how the newer Safety and Automatable metrics narrow this gap without closing it entirely. ## How Does CVSS Relate to EPSS and the CISA KEV Catalog? CVSS, EPSS, and the CISA KEV catalog answer three different questions, and a defensible vulnerability management process uses all three together rather than relying on any one alone. CVSS answers "how severe would this be if exploited." The Exploit Prediction Scoring System, EPSS, answers "how likely is this to be exploited in the near term," using a probability score derived from observed exploitation activity across the broader vulnerability landscape. The [CISA KEV catalog](/blog/cisa-kev-catalog-medical-devices) answers a narrower and more certain question: "is this vulnerability already being actively exploited right now." A high CVSS score paired with a low EPSS score and no KEV listing suggests a theoretically severe but currently low-priority finding, while a moderate CVSS score paired with KEV listing demands immediate attention regardless of the base severity number. Postmarket monitoring plans reviewed under the FDA's guidance are expected to show this kind of layered reasoning rather than a single-metric triage rule. ## How Does the FDA Expect CVSS to Be Used in Postmarket Reporting and VEX? The FDA does not mandate a specific CVSS version or a specific scoring threshold that triggers action, but the February 3, 2026 final guidance expects manufacturers to describe a coherent, repeatable method for assessing and prioritizing vulnerabilities across the postmarket period. CVSS scoring, when used, needs to be documented consistently, with version, vector string, and scoring rationale available for review rather than a bare number. In a VEX statement, the expectation is that a manufacturer states clearly whether a component's vulnerability affects the product, and if it does, what the status and remediation plan are. Including the full CVSS vector string alongside the VEX status gives a downstream user, whether a hospital, a reviewer, or another manufacturer building on the component, the ability to independently verify the severity claim rather than trusting an unexplained label. ## How Blue Goat Cyber Approaches This Blue Goat Cyber scores vulnerabilities found during [medical device penetration testing](/services/medical-device-penetration-testing) with full vector strings and documented scoring rationale, then maps each finding into the device's ISO 14971 risk management file rather than delivering a standalone severity list. This scoring work feeds directly into [postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services), where CVSS, EPSS signals, and KEV status are combined into a documented triage process suitable for a monitoring plan a reviewer can actually evaluate. The goal is a scoring record that a manufacturer can defend years later, not just a number generated at the time of testing. ## Frequently Asked Questions ### Which CVSS version should medical device manufacturers use? The FDA does not mandate a specific version, so either CVSS 3.1 or CVSS 4.0 is acceptable as long as the version is stated clearly and the full vector string is published. CVSS 4.0 is increasingly preferred for safety-relevant findings because it includes Safety and Automatable metrics that 3.1 cannot express directly. ### What does a CVSS score of 0 mean? A CVSS score of 0 typically results from a vulnerability with no meaningful impact under the scored metrics, for example a finding with no confidentiality, integrity, or availability impact at all. It does not mean the finding is irrelevant to document, since context outside CVSS, like a compliance requirement, may still call for a fix. ### Can two people score the same vulnerability differently? Yes, this happens often, usually because of differing assumptions about Attack Vector, Scope, or the deployment environment. This is why documenting the reasoning behind each metric choice, not just the final score, matters for consistency and for defending the score during a review. ### Is CVSS required for FDA submissions? CVSS is not explicitly required by name, but the FDA's guidance expects a documented, repeatable vulnerability severity assessment methodology, and CVSS is the most widely accepted way to satisfy that expectation. Whatever methodology is used, it needs to be applied consistently and explained clearly. ### How often should CVSS scores be reassessed after initial scoring? Scores should be reassessed whenever new threat intelligence changes the Threat or Environmental metrics, such as public exploit code becoming available or the device's deployment context changing. Static scores that are never revisited across the product's postmarket life do not reflect the current threat landscape reviewers expect to see addressed. ### Does a high CVSS score always mean urgent action for a medical device? Not automatically. Urgency depends on combining the CVSS severity with exploit-likelihood data such as EPSS or KEV status and with the component's actual role in patient-facing device functions, documented through the risk management file. ## CTA If your team needs help scoring vulnerabilities consistently and mapping them into a risk management file that holds up under FDA review, [contact Blue Goat Cyber](/contact) to discuss your device's postmarket vulnerability management process. ## About the Author Christian Espinosa is the founder of Blue Goat Cyber and a medical device cybersecurity specialist focused on vulnerability assessment and FDA-aligned risk documentation. He has worked with device manufacturers building defensible postmarket monitoring programs. Learn more on his [author page](/christian-espinosa). --- ## Cybersecurity as a MedTech Differentiator (2026) Source: https://bluegoatcyber.com/blog/cybersecurity-as-a-competitive-edge-in-medtech # Cybersecurity as a MedTech Differentiator: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Cybersecurity is now a mandatory requirement, not a marketing extra, and manufacturers that design it in from the start rather than bolting it on avoid the costly delays, investor pushback, and hospital procurement rejections that trigger many companies' first real security investment. Under the FDA's February 3, 2026 guidance, security-by-design evidence is checked throughout the total product lifecycle. Devices with credible, well-communicated security posture clear submission faster and gain trust with investors and health systems. ## Key Takeaways - Cybersecurity is now a mandatory requirement for medical devices. - Investors increasingly scrutinize cybersecurity measures thoroughly. - Proactive cybersecurity prevents costly delays and regulatory issues. - Design cybersecurity into products from the initial stages. - Simplify cybersecurity communication, avoiding technical jargon. - Cybersecurity is a strategic differentiator in MedTech. ## Why this matters The stakes for medical device cybersecurity have never been higher. Patient safety and organizational trust hinge on the integrity of connected medical devices. Failures can lead to dire consequences, including patient harm, data breaches, and significant financial and reputational damage for manufacturers. The FDA's `Cybersecurity in Medical Devices` Final Guidance, dated February 3, 2026, mandates proactive cybersecurity measures throughout the device lifecycle, transforming it from a mere compliance checkpoint into a strategic necessity. This guidance, alongside evolving standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023, underscores the critical need for integrating security from the ground up. Investors and healthcare providers increasingly scrutinize cybersecurity posture as a key indicator of product viability and manufacturer reliability. Devices lacking adequate security risk market exclusion and regulatory delays. Conversely, devices engineered with security by design gain a distinct market advantage, demonstrating a commitment to safety and regulatory adherence. Embracing cybersecurity as a fundamental aspect of product development is essential for accelerating market adoption and ensuring sustained success in the MedTech landscape. ## Unlocking the Power of Cybersecurity for Medical Device Innovators In the world of medical technology, cybersecurity has emerged as a critical factor that can make or break a company’s success. Once seen as a mere regulatory hurdle, cybersecurity is now a strategic imperative that savvy MedTech innovators are using to gain a competitive edge. In this in-depth exploration, we dive into a panel discussion from the [LSI Europe 2025 conference](https://www.lsieuropesummit.com/ ""), where industry experts share their insights on transforming cybersecurity from a challenge into a differentiator. ## The Cybersecurity Mandate: From Optional to Mandatory Cybersecurity is no longer a nice-to-have for medical device manufacturers - it’s a non-negotiable requirement. As Christian Espinosa, CEO and Founder of Blue Goat Cyber, explains, “Cybersecurity is no longer optional. It’s a requirement, and many MedTech innovators are still learning the hard way that it’s now a requirement. It’s no longer optional, and it can be a deal killer.” The stakes are high, as cybersecurity breaches can have devastating consequences for patient safety. Espinosa cites real-world examples, such as the ability to hack into surgical robots, drug infusion pumps, pacemakers, and defibrillators - potentially causing paralysis, overdoses, or even death. These risks have caught the attention of regulators, healthcare providers, and investors alike, making cybersecurity a critical consideration for any medical device seeking market approval and adoption. ## Cybersecurity from an Investor’s Perspective Sean Lavin, MD, an investor at [Alpha Lavin Advisors](https://www.alphalavin.com/ ""), shares his insights on how the investment community is approaching cybersecurity in the MedTech space. “I think, honestly, it is slowly becoming a concern, and if two years ago it was 5% of companies that thought about it in the startup world, it’s probably 15 or 20% now, but it’s still a long way from everybody looking at it.” Lavin highlights three common ways companies learn about the importance of cybersecurity: through educational sessions like this one, when the FDA pushes back on their lack of cybersecurity measures, or when a hospital or healthcare system rejects their device due to insufficient security. He emphasizes the importance of reverse-engineering the cybersecurity requirements based on the end-user’s needs, rather than waiting until the last minute to address it. “I think companies learn about it in one of three ways. They either, you know, meet a company like this or come to a session like this and learn this way, or they find out when the FDA pushes back on something they didn’t do, which is not a great way to do it they or they even later stage if they got through the FDA a while ago. They go to sell a product to a hospital or hospital system, and say you don’t meet our requirements or you need to make a change. The latter two are I believe I don’t know more expensive but certainly take a lot longer and interrupt plans quite a bit more than than if you do it early.” ## Defining a “Cyber Device” One of the key challenges in the MedTech industry is understanding what constitutes a “ [cyber device](https://www.youtube.com/watch?v=OUYBM_gFyd0 "")” - a term that has significant implications for regulatory compliance and patient safety. Espinosa provides a clear definition: “A cyber device is to make it very simple. It has software, and there’s some sort of interface. The confusing part comes into the interface. Even if it has a USB port, that is considered an interface that could be used to connect to the internet because I could easily plug a wireless adapter into that USB port.” This broad definition means that even seemingly innocuous medical devices with basic connectivity features can be considered “cyber devices” and must be designed with cybersecurity measures in place. Failing to do so can lead to costly delays, regulatory hurdles, and potentially catastrophic patient safety risks. ## Cybersecurity and the Marketing Perspective Claudia Holy, Co-Managing Director of [Podymos](https://podymos.com/ ""), a MedTech marketing agency, emphasizes the importance of understanding the end-user’s perspective and concerns when it comes to cybersecurity. “It’s really about understanding what is important to the end user and who the end users are who care about cybersecurity. So is it the investors, is it the hospitals, and actually what questions are they asking, because that’s then how we, you know, reverse engineer it to make sure that we’re actually matching those claims as we go forward.” Holy also highlights the need to simplify the cybersecurity messaging, as the industry is rife with jargon and technical terminology that can alienate key stakeholders. “Whenever you use jargon as well, you really isolate your market or you shrink your market down because only a certain number of the audience will understand that. So it’s How do we make it specific and action and understandable by all?” - Reverse-engineer your cybersecurity messaging to address the specific concerns and questions of your target audience, whether that’s investors, healthcare providers, or patients. - Simplify your language and avoid industry jargon to ensure your cybersecurity claims are clear and accessible to all stakeholders. - use your sales team’s feedback to understand the real-world questions and objections you’ll need to address in your marketing and communications. ## Designing for Cybersecurity: An Iterative Process One of the key challenges in the MedTech industry is the tendency to treat cybersecurity as a one-time task, rather than an ongoing, iterative process. Espinosa emphasizes the importance of designing cybersecurity into the product from the very beginning, rather than trying to “bolt it on” at the end. “Bolted on at the end becomes very costly. It causes delays. It frustrates investors. It makes the device less secure. So we’re trying to like part of my company’s mission is to raise the awareness that if you know you have a cyber device you could should be designing cyber security into your product versus trying to bolt it on at the end when your regulatory affairs person says what did you do about cyber security like oh we forgot about it and that seems to happen fairly often.” Espinosa also highlights the need for continuous vigilance, as vulnerabilities and threats are constantly evolving. “Once a device is on the market, it could have a vulnerability profile like we’ve accepted these lowrisk vulnerabilities as acceptable risk to the patient. However, suppose someone develops a new exploit for that vulnerability and publishes it, allowing everyone to access it. In that case, it becomes relatively easy to exploit the vulnerability, thereby altering the risk profile. So it’s something that has to be continuously looked at.” - Integrate cybersecurity into the [product development lifecycle](/services/secure-medtech-product-design-consulting) from the very beginning, rather than trying to bolt it on at the end. - Adopt a secure software development lifecycle, such as the [IEC 62304 standard](https://www.iso.org/standard/38421.html ""), to ensure your software is designed with security in mind. - Continuously monitor and address evolving cybersecurity threats and vulnerabilities, even after your device has been approved and launched. ## Overcoming the Cybersecurity Jargon Barrier One of the biggest challenges in the MedTech industry is the overwhelming amount of technical jargon and industry-specific terminology surrounding cybersecurity. Espinosa acknowledges this issue, noting that “in MedTech and in cyber combining MedTech and cybersecurity, we’ve got like the most jargon international standards possible. I mean, I heard someone do an interview yesterday, and literally, one sentence was all acronyms and ISO standards. There’s like no real word in there.” Claudia Holy emphasizes the importance of simplifying the cybersecurity messaging to ensure it resonates with all stakeholders, not just the technical experts. “Whenever you use jargon as well, you really isolate your market, or you shrink your market down because only a certain number of the audience will understand that. So it’s How do we make it specific and action and understandable by all?” By breaking down the complex technical details and focusing on the real-world implications and benefits of cybersecurity, MedTech innovators can effectively communicate the value proposition to a wider audience, including investors, healthcare providers, and patients. - Avoid industry jargon and technical terminology when communicating about cybersecurity, and instead focus on the practical implications and benefits. - Tailor your cybersecurity messaging to the specific needs and concerns of each stakeholder group, whether that’s investors, healthcare providers, or patients. - use storytelling and real-world examples to illustrate the importance of cybersecurity and its impact on patient safety and business outcomes. ## Cybersecurity as a Competitive Advantage While cybersecurity was once seen as a necessary evil, forward-thinking MedTech companies are now recognizing it as a strategic differentiator. By proactively addressing cybersecurity concerns and designing secure products, these innovators are gaining a competitive edge in the market. As Sean Lavin points out, investors are increasingly scrutinizing a company’s cybersecurity readiness during the due diligence process. “I think, honestly, it is slowly becoming a concern, and if two years ago it was 5% of companies that thought about it in the startup world, it’s probably 15 or 20% now, but it’s still a long way from everybody looking at it.” By demonstrating a cybersecurity strategy, MedTech companies can not only satisfy regulatory requirements but also appeal to healthcare providers and patients who are increasingly aware of the risks. This, in turn, can lead to faster market adoption, higher customer trust, and a stronger competitive position. - Position your cybersecurity capabilities as a strategic advantage, rather than just a regulatory requirement. - Highlight how your secure product design and ongoing monitoring can provide greater peace of mind for healthcare providers and patients. - use your cybersecurity readiness as a selling point to differentiate your offering from competitors in the eyes of investors and end-users. ## Conclusion: Embracing Cybersecurity for MedTech Success In the world of medical technology, cybersecurity has emerged as a critical factor that can make or break a company’s success. By proactively addressing cybersecurity concerns, MedTech innovators can transform this challenge into a strategic advantage, gaining the trust of investors, healthcare providers, and patients alike. As the panel discussion at LSI Europe 2025 has shown, the key to success lies in understanding the cybersecurity landscape, designing secure products from the ground up, and effectively communicating the value proposition to all stakeholders. By embracing this holistic approach, MedTech companies can unlock new opportunities, drive innovation, and ultimately improve patient outcomes - all while strengthening their competitive position in the market. To learn more about how Blue Goat Cyber can help your MedTech company navigate the cybersecurity landscape, schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session ""). ## How Blue Goat approaches this Our approach to medical device cybersecurity centers on tailored, proactive strategies designed to streamline regulatory compliance and enhance market readiness. We assist MedTech innovators in baking security into their products from initial design through postmarket support. Our team brings deep technical expertise, including Certified Information Systems Security Professionals (CISSP) and Offensive Security Certified Professionals (OSCP), with a background that includes experience in ex-military red teams. We provide clarity amidst complex requirements, translating technical jargon into actionable insights for engineers and leadership alike. Our methodology aligns with the latest FDA guidance, preparing your devices for successful review. Should the FDA raise cybersecurity deficiencies after our submission, we resolve them at no additional cost. We focus on practical, effective security measures that distinguish your products in a competitive market, ensuring they meet the stringent demands of healthcare providers and regulators. Learn more about our specialized support for [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is considered a 'cyber device' by the FDA? A 'cyber device' is generally defined as any medical device that includes software and an interface. This interface could be a USB port or any other connection that allows external communication, potentially linking the device to networks or the internet. ### How does cybersecurity impact medical device market approval? The FDA mandates cybersecurity considerations for market approval. Devices lacking adequate cybersecurity measures may face delays in approval or rejection, particularly under the February 3, 2026 premarket cybersecurity guidance. ### Why is cybersecurity important to MedTech investors? MedTech investors view cybersecurity as an indicator of a company’s risk management and long-term viability. Devices with strong cybersecurity are less likely to incur costly breaches or regulatory non-compliance, protecting investment value. ### When should cybersecurity be integrated into medical device development? Cybersecurity should be integrated at the very beginning of the product development lifecycle. 'Bolting on' security measures later is significantly more expensive, causes delays, and can result in a less secure product. ### Does the FDA prioritize cybersecurity for all medical devices? The FDA prioritizes cybersecurity for all medical devices due to potential patient safety risks and the increasing interconnectivity of health systems. They emphasize a proactive approach to cybersecurity throughout the device lifecycle. ### How can MedTech companies simplify cybersecurity communication? Companies should avoid technical jargon and focus on real-world implications and benefits of their cybersecurity measures. Tailoring messages to specific audiences like investors, healthcare providers, or patients helps clarify complex topics. --- ## Medical Device Attack Entry Points (2026 Guide) Source: https://bluegoatcyber.com/blog/cybersecurity-attack-entry-points-for-medical-devices # Medical Device Attack Entry Points in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** Medical devices are exposed to attack through software flaws, unpatched firmware, weak authentication, unencrypted communications, hardware ports, and interconnected hospital networks. Each entry point can let an attacker alter device function, steal patient data, or disrupt care. The FDA's February 3, 2026 final guidance expects manufacturers to identify these entry points, apply mitigations like input validation and encryption, and document them throughout the device's total product lifecycle. _Updated October 26, 2024_ This article will covers cybersecurity in healthcare, identify common types of cyber threats, explore possible vulnerabilities in medical devices, and discuss strategies to mitigate cybersecurity risks. So, let’s dive in! ## Key Takeaways - Software weaknesses provide primary entry points for cyberattacks. - Hardware vulnerabilities can compromise device integrity and confidentiality. - Interconnected systems expand the attack surface. - Outdated software increases device susceptibility to exploits. - The FDA guidance emphasizes premarket security controls for devices. - Continuous updates and patches matter for risk mitigation. ## Why this matters The security of medical devices is paramount, directly impacting patient safety and data privacy. Unsecured entry points can allow malicious actors to disrupt device function, exfiltrate sensitive patient information, or even cause physical harm through device manipulation. For example, a compromised infusion pump could alter dosage, or an exploited MRI machine could yield inaccurate diagnostics, leading to severe clinical consequences. The FDA's "Cybersecurity in Medical Devices" Final Guidance, issued February 3, 2026, mandates that manufacturers consider and address cybersecurity risks throughout the total product lifecycle. This includes identifying and mitigating potential entry points. Adherence to standards like IEC 81001-5-1 (Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product lifecycle) and ISO 14971 (Medical devices, Application of risk management to medical devices) is crucial. AAMI TIR97 (Principles for medical device security, risk management) also offers significant guidance toward securing these critical systems. Proactive identification and hardening of attack vectors are essential to protect patients and maintain trust in medical technology. ## Understanding Cybersecurity in Healthcare ### The Importance of Cybersecurity in Medical Devices Regarding medical devices, [cybersecurity plays a paramount role](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) in ensuring patient safety and data privacy. Medical devices, ranging from pacemakers to insulin pumps, are now equipped with digital technology that helps monitor, diagnose, and treat patients effectively. However, this connectivity also exposes these devices to potential cyber threats. ![Section Image](/imported-images/95fe65c14683ec63.webp) Imagine a scenario where a hacker gains unauthorized access to a pacemaker and manipulates its settings, causing life-threatening consequences for the patient. Such incidents highlight the critical need for cybersecurity measures in medical devices. Ensuring the security of medical devices involves a multi-faceted approach. It includes [implementing encryption protocols](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist) to protect data transmission, regularly updating software to patch vulnerabilities, and conducting thorough risk assessments to identify potential weaknesses in the device’s cybersecurity defenses. Additionally, healthcare providers must prioritize staff training on cybersecurity best practices to mitigate the human factor in cyber attacks. ### The Role of Digital Technology in Healthcare The advancement of digital technology has revolutionized the healthcare industry, enhancing patient care and improving outcomes. Telemedicine, electronic health records, and remote monitoring systems are examples of how digital technology has transformed healthcare delivery. While these innovations offer immense benefits, they open the door to cybersecurity risks. As medical devices become increasingly interconnected, cybercriminals’ potential attack surface widens. Therefore, understanding the various cybersecurity threats that can target medical devices is essential for safeguarding patient health and privacy. Integrating artificial intelligence (AI) and machine learning algorithms in healthcare systems has further expanded the capabilities of medical devices. AI-powered diagnostics, personalized treatment recommendations, and predictive analytics have significantly improved patient outcomes. However, the reliance on AI also introduces new cybersecurity challenges, such as adversarial attacks that aim to manipulate AI algorithms and compromise patient data. ## Identifying Cybersecurity Threats for Medical Devices ### Common Types of Cybersecurity Attacks Cyber threats come in various forms, and understanding these attacks is crucial in fortifying medical devices against potential breaches. One common type of attack is malware injection, where malicious software is introduced into a device’s system, allowing unauthorized access or control. Another prevalent cyber threat is denial-of-service (DoS) attacks, where hackers overwhelm a medical device or network with excessive requests, causing it to crash or become unresponsive. This can have dire consequences, especially when dealing with critical medical equipment. Social engineering attacks are a growing concern in cybersecurity for medical devices. These attacks involve manipulating individuals into divulging confidential information or granting access to sensitive systems. Cybercriminals can bypass technical security measures and gain unauthorized entry by exploiting human psychology and trust. ### Potential Vulnerabilities in Medical Devices While medical devices offer life-saving capabilities, they also possess potential vulnerabilities that cybercriminals can exploit. One vulnerability is the lack of stringent security measures during the device’s development phase. Inadequate security protocols and improperly configured settings make it easier for hackers to breach the device’s defenses. Additionally, using outdated software or firmware in medical devices increases their vulnerability to cyber-attacks. As hackers discover new vulnerabilities, manufacturers must actively update and patch their devices to mitigate potential risks. The [interconnected nature](/blog/medical-device-cybersecurity-interoperability-concerns) of modern healthcare systems introduces new vulnerabilities for medical devices. Interoperability between devices and networks, while beneficial for data sharing and coordination, also creates a larger attack surface for cyber threats. Ensuring security measures across interconnected devices is essential to safeguard patient data and maintain the integrity of medical operations. ## Entry Points for Cybersecurity Attacks ### Software Weaknesses as Entry Points Software weaknesses often serve as primary entry points for cyber attacks on medical devices. Vulnerabilities can exist in the device’s operating system, applications, or communication protocols. Hackers exploit these weaknesses to gain unauthorized access, manipulate device settings, or exfiltrate sensitive patient data. ![Section Image](/imported-images/8ca8fff1c5bfc57c.webp) To combat software vulnerabilities, developers must adhere to [secure coding practices and conduct thorough penetration testing](/blog) to identify and mitigate potential weaknesses before the device reaches the market. The interconnected nature of modern medical devices poses additional challenges in securing software. Interoperability requirements may introduce new vulnerabilities, as devices need to communicate with each other and external systems. Ensuring these communication channels are encrypted and authenticated is crucial in preventing cyber attacks targeting software weaknesses. ### Hardware Vulnerabilities as Potential Entry Points Although less common, hardware vulnerabilities can also serve as entry points for cyber attacks. These vulnerabilities can stem from weak encryption algorithms, insecure data storage mechanisms, or compromised hardware components. By exploiting these weaknesses, hackers can [compromise the integrity and confidentiality of a medical device](/blog). Manufacturers must implement hardware security measures, such as [tamper-proofing and secure boot processes](/blog), to minimize the risk of compromise through hardware vulnerabilities. In addition to securing individual hardware components, manufacturers should consider the supply chain risks of sourcing hardware components. Counterfeit components or compromised supply chains can introduce vulnerabilities at the manufacturing stage, which malicious actors may later exploit. Implementing strict supply chain security protocols and conducting regular audits can help mitigate these risks and strengthen the overall cybersecurity posture of medical devices. ## Mitigating Cybersecurity Risks in Medical Devices ### Strategies for Strengthening Device Security Effective strategies to enhance [device security include implementing a layered approach to cybersecurity](/). This involves incorporating strong authentication mechanisms, such as biometrics or multi-factor authentication, to verify user identity. Establishing strict access controls at the device level and within healthcare networks can prevent unauthorized individuals from tampering with medical devices or accessing sensitive patient information. Encrypting data at rest and in transit is another crucial measure to protect patient privacy. Regular security audits and penetration testing can help identify medical device and network system vulnerabilities. By simulating real-world cyber attacks, healthcare organizations can proactively address weaknesses and strengthen their security posture. ### The Role of Regular Device Updates and Patches Regular device updates and patches are vital to maintaining the security and integrity of medical devices. Manufacturers must proactively address known vulnerabilities and release timely updates to protect their devices against emerging threats. Healthcare providers and medical device users should prioritize promptly installing these updates and patches to minimize the risk of cyber attacks. Additionally, user education and awareness about cybersecurity best practices contribute to a defense against potential threats. A incident response plan is essential for effectively managing and containing cybersecurity incidents in healthcare settings. This plan should outline clear steps for detecting, responding to, and recovering from security breaches to minimize the impact on patient care and data confidentiality. ## The Future of Cybersecurity in Medical Devices ### Emerging Cybersecurity Technologies for Healthcare The landscape of cybersecurity demands continuous innovation and the adoption of emerging technologies. Artificial intelligence (AI) and machine learning (ML) algorithms can help identify anomalies and detect potential cyber threats in real-time, enabling proactive countermeasures. These advanced technologies analyze vast amounts of data, allowing healthcare organizations to detect patterns and trends that may indicate a cyber attack. By using AI and ML, healthcare professionals can stay one step ahead of cybercriminals, protecting patient data and ensuring the integrity of medical devices. Blockchain technology shows promise in enhancing the security and privacy of healthcare data. Its decentralized nature and cryptographic techniques make it harder for hackers to tamper with patients’ records or gain unauthorized access to sensitive information. Blockchain creates an immutable and transparent record of all transactions, ensuring the integrity of medical data. By implementing blockchain in medical devices, healthcare providers can establish a secure and trustworthy system, giving patients peace of mind and safeguarding their confidential information. ### The Impact of Regulatory Changes on Medical Device Security Regulatory bodies worldwide recognize the importance of cybersecurity in medical devices and have taken measures to enforce stricter regulations. Compliance with these regulations, such as the Medical Device Regulation (MDR) in Europe and the [Food and Drug Administration (FDA) guidelines](https://www.fda.gov/media/119933/download) in the United States, is crucial to ensuring the safety and security of medical devices. These regulatory changes not only hold manufacturers accountable for the security of their devices but also encourage collaboration between stakeholders to address cybersecurity challenges collectively. By building a culture of shared responsibility, the healthcare industry can develop security measures and mitigate potential threats. As technology progresses, regulatory frameworks will likely evolve to keep pace with emerging cyber threats, further strengthening medical device security. Regulatory bodies will continue to assess and update their guidelines to address new vulnerabilities and ensure that medical devices meet the highest security standards. Regulatory changes also drive innovation in the cybersecurity industry. With stricter regulations in place, companies specializing in medical device security are incentivized to develop solutions that can withstand sophisticated cyber attacks. This continuous cycle of regulation and innovation creates a more secure environment for medical devices and ultimately benefits patients. ## Conclusion The increasing reliance on digital technology in the healthcare industry brings both immense benefits and potential cybersecurity risks. Understanding the entry points for cyber attacks, identifying vulnerabilities in medical devices, and implementing security measures are essential to safeguard patient safety and privacy. By staying vigilant, embracing technological advancements, and adhering to regulatory guidelines, we can shape a future where medical devices remain resilient against cybersecurity threats, ensuring the well-being of patients worldwide. As the digital landscape of healthcare continues to evolve, the need for stringent cybersecurity measures has never been more pressing. Blue Goat Cyber, a Veteran-Owned leader in cybersecurity, stands ready to safeguard your medical devices against the ever-growing threat of cyber attacks. Our specialized services, including medical device cybersecurity, penetration testing, and compliance with HIPAA and FDA regulations, are designed to protect your business and ensure the safety of your patients. Don’t let cybersecurity vulnerabilities compromise your operations. [Contact us today for cybersecurity help](/contact) and take the first step towards a secure and compliant digital healthcare environment with Blue Goat Cyber. ## How Blue Goat approaches this Our approach to securing medical devices begins with a deep understanding of potential attack entry points. Our team of experts, including CISSP and OSCP certified professionals, many with ex-military red team experience, systematically identifies vulnerabilities across software, hardware, and interconnected systems. We employ targeted methodologies, including focused penetration testing and detailed threat modeling services, to expose weaknesses that could be exploited. We provide actionable recommendations for hardening devices and collaborate with manufacturers to implement effective controls. Our services align with regulatory expectations, preparing devices for stringent reviews. For instance, our premarket cybersecurity services address potential FDA concerns directly. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Our goal is to enhance the security posture of medical devices, ensuring resilience against evolving cyber threats. ## FAQ ### What are common cyberattack entry points in medical devices? Common entry points include software vulnerabilities in operating systems and applications, hardware weaknesses like insecure data storage, and network interfaces that are not adequately secured. Exploiting these can lead to unauthorized access or data breaches. ### How does software contribute to medical device vulnerabilities? Software vulnerabilities arise from flaws in operating systems, applications, and communication protocols within medical devices. Attackers exploit these weaknesses to gain unauthorized access, manipulate device functions, or steal patient data. ### Can hardware issues create medical device cybersecurity risks? Yes, hardware vulnerabilities, such as weak encryption algorithms, insecure data storage mechanisms, or compromised components, can be exploited. These can compromise the integrity and confidentiality of a medical device. ### Does the FDA regulate medical device cybersecurity? Yes, the FDA regulates medical device cybersecurity, requiring manufacturers to integrate security by design. The February 3, 2026 final guidance outlines expectations for premarket submissions regarding security controls and risk management. ### What role do updates and patches play in securing medical devices? Regular updates and patches are vital for medical device security. They address known vulnerabilities, protect against emerging threats, and ensure devices comply with current security standards, minimizing the risk of cyberattacks. ### How does device interconnectedness affect cybersecurity? Interconnectedness, while beneficial for data sharing, expands the attack surface for medical devices. Each connection point can become a potential vulnerability if not secured, requiring strong measures across all integrated systems. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Cybersecurity Before MVP vs After Market Source: https://bluegoatcyber.com/blog/cybersecurity-before-mvp-vs-after-market-fit-cost-of-waiting # Cybersecurity Before MVP vs After Market Fit: What It Actually Costs to Wait > **[DIRECT ANSWER]** Security decisions made before MVP, such as choosing a signed update path, a hardware root of trust, and a supported OS, cost almost nothing at design time. The same decisions after market fit typically cost six figures and add months, because they force hardware revisions, re-verification, and a new submission cycle. ## Key Takeaways - Three architectural decisions - authentication model, update mechanism, and trust boundary - determine 80% of cybersecurity submission risk and are essentially free to get right pre-MVP. - Retrofitting those decisions after market fit routinely costs 6-18 months of engineering rework plus a fresh threat model, penetration test, and security risk file. - The FDA's February 3, 2026 final premarket cybersecurity guidance treats these as design-control artifacts, so changing them post-clearance often forces a new 510(k) instead of a Letter-to-File. - A few cybersecurity activities (final SBOM, final penetration test, final labeling, vulnerability disclosure portal) can be deferred without penalty; the architectural decisions cannot. - For a connected Class II device, pre-MVP security architecture work runs ~$20-50K; post-market-fit retrofit runs ~$200-500K plus deferred-revenue cost from delayed clearance. ## Why This Matters Section 524B of the FD&C Act, enacted in 2022 and operationalized through the FDA's February 3, 2026 final guidance *"Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions,"* now makes cybersecurity a precondition of acceptance for any cyber device submission. The FDA can issue a Refuse-to-Accept inside the 15-day RTA window if the submission is missing the required cybersecurity evidence, which means MedTech teams that defer the work until post-market-fit are deferring their entire commercial launch, not just a documentation task. The cost asymmetry is what makes the timing decision unforgiving. AdvaMed and MedTech Dive have reported repeatedly on cybersecurity-driven holds adding 3-9 months to clearance timelines on connected devices. For a startup projecting $20-40M in first-year revenue, that delay routinely exceeds the entire cybersecurity engagement budget by an order of magnitude - and the engagement only gets more expensive the later it starts, because retrofitted architecture means redoing engineering work that should have been done once. The standards stack reviewers expect here is consistent regardless of timing: AAMI SW96 (FDA Recognized Consensus Standard 13-131) for security risk management, IEC 81001-5-1 for the secure software lifecycle, IEC 62304 for software classification, and ISO 14971 for the risk file. Building the architecture to satisfy all four early is materially cheaper than satisfying any one of them late. > **Already deep into product development?** This post covers the pre-MVP versus post-market-fit decision. If you're two years in and still saying "we're not ready for cybersecurity yet," read [When to Start Medical Device Cybersecurity in Product Development](/blog/when-to-start-medical-device-cybersecurity), it maps every SPDF activity to its correct design-control phase and outlines the 6-8 week recovery sprint for teams that started late. ## Why founders defer cybersecurity (and why the math is wrong) The conventional MedTech startup playbook says: prove the product works, prove people want it, then harden it for the FDA. That sequence is correct for clinical evidence and reimbursement strategy. It is catastrophically wrong for cybersecurity. The reason is structural. Cybersecurity is not a feature you bolt on - it is a property of your architecture. Three of your earliest engineering decisions silently determine what your security risk file will look like at submission, what your pen test will find, and how many cybersecurity deficiencies you will receive in your first FDA AI letter. Those decisions are: 1. **How devices and users authenticate** 2. **How the device receives updates** 3. **Where the trust boundary sits between device, app, and cloud** Make those decisions casually during MVP and you will spend 6-18 months rebuilding them before you can submit. Make them deliberately on day one and you will spend a few extra engineering days. ## The cost of waiting, by decision ### Authentication model **Before MVP:** Pick an authentication design that scales (per-device certificates issued at provisioning, short-lived tokens, mTLS to the backend). A senior engineer can implement the framework in 1-2 weeks. The threat model writes itself. **After market fit:** You have a deployed fleet on a shared API key or a username/password the field-service team types into a tablet. Reviewers will reject this. You now have to design a new auth system, migrate every fielded device to it without bricking units in clinical use, rewrite your security risk file from scratch, and pay for a fresh pen test. Realistic timeline: 4-8 months. Realistic cost: $150K-$400K in engineering, $40K-$80K in pen test and consulting, plus the opportunity cost of delaying clearance. ### Update mechanism **Before MVP:** Build a signed-update path - code-signing keys, a verified bootloader, an A/B partition or rollback story, a way to revoke a compromised version. About 3-4 weeks of firmware work for an engineer who has done it once. **After market fit:** Devices in the field cannot accept signed updates because the bootloader was never designed to verify them, or the device has no rollback partition, or the signing infrastructure was never set up. Section 524B of the FD&C Act requires you to have "a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures." Without a secure update path, you cannot patch. Without the ability to patch, the FDA may not clear the device at all. Retrofitting a secure update mechanism onto fielded hardware sometimes requires a hardware revision, which is the most expensive change in MedTech. ### Trust boundary **Before MVP:** Decide explicitly what the device trusts, what the companion app trusts, and what the cloud trusts. Document the data flows. This is the threat model whether you call it that or not. **After market fit:** You discover during pen testing that the device implicitly trusts anything the app sends, the app implicitly trusts anything the cloud sends, and the cloud implicitly trusts the app. Closing those gaps means re-architecting the protocol between the three layers, which usually means re-validating clinical functions because the validated software changed. > **Baking cybersecurity in before MVP?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## The honest list: what you can defer Not everything needs to happen on day one. The mistake is treating cybersecurity as monolithic. Here is what you can legitimately defer past MVP without paying the cost-of-delay tax: - **Full SBOM tooling and automation.** You need an accurate SBOM at submission. You do not need a CI pipeline that generates SPDX and runs VEX correlation on every commit during MVP. Maintain a manual component list during MVP, automate before you submit. See our [SBOM topic hub](/topics/sbom-medical-devices) for what the FDA actually expects in the submission. - **Formal coordinated vulnerability disclosure program.** You need a CVD policy and intake channel at launch. You do not need a fully staffed PSIRT during MVP. A documented inbox, a triage SLA, and a written policy meet the bar. - **Postmarket monitoring infrastructure.** You need a postmarket cybersecurity plan in the submission. You do not need the production monitoring stack running during MVP. The plan describes what you will build by launch. - **Penetration testing beyond design review.** Save the formal pen test for when the architecture is stable. Doing it on MVP code is throwing money at a moving target. But have a security architect review your design before you build the MVP - that is free and prevents the expensive findings. ## The decision rule Use this test on any engineering decision during MVP: > If we ship this and it becomes a problem, can we fix it with a software update without changing the threat model? If yes, defer. If no, decide it now. - Adding a new clinical feature later? Fixable. Defer. - Adding a new authentication factor later? Fixable. Defer the factor; do not defer the framework. - Changing the trust boundary later? Not fixable without re-architecting. Decide now. - Adding an update mechanism later? Not fixable on fielded hardware. Decide now. ## What the FDA actually looks for at submission When you hit submission, reviewers under the February 3, 2026 final guidance expect the [seven-section eSTAR cybersecurity package](/topics/fda-premarket-cybersecurity): security risk management, threat modeling, third-party software components (SBOM), security assessment of unresolved anomalies, security architecture views, security testing, and cybersecurity labeling. Every one of those sections is downstream of the three architectural decisions above. Teams that built cybersecurity into the MVP produce that package in 4-8 weeks of documentation work. Teams that bolted it on after market fit produce it in 4-8 months of engineering work, then 4-8 weeks of documentation work, then often receive an [Additional Information letter](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) that adds another 6-12 weeks. ## Practical next steps If you are pre-MVP, the highest-ROI move is a [pre-MVP security architecture review](/services/secure-medtech-product-design-consulting) - typically a one-week engagement that locks in the three decisions above and writes the first draft of your threat model. It is the single cheapest cybersecurity work you will ever do, because it prevents the work you would otherwise do twice. If you already shipped an MVP and are approaching market fit, the next move is a [gap assessment against the 2026 guidance](/services/fda-premarket-cybersecurity-services) so you know exactly which of those three decisions you got right, which you got wrong, and what the cost-and-timeline of fixing each one looks like before you start the FDA pre-submission process. The math does not change. Cybersecurity gets exponentially more expensive the later you address it. The only variable you control is when you start. ## Should Cybersecurity Show Up in Your Go-to-Market Messaging? Cybersecurity belongs in your go-to-market plan for the same reason the architectural decisions in this article belong pre-MVP: the FDA already requires the documentation for clearance, so the only real choice is whether you also use it commercially. Hospitals and patients evaluating a connected device are increasingly wary of the same risks this guide covers, and a manufacturer that can describe its security posture clearly, rather than treating it as a hidden compliance cost, has an answer ready when a procurement team asks. Four elements translate directly from your premarket work into market-facing trust signals: 1. **A coordinated vulnerability disclosure program.** The same CVD intake channel required for a 524B(b)(1) postmarket plan is also what a hospital security team wants to see before purchase. 2. **Transparent patch and update communication.** The regular and out-of-cycle update cadence you documented for the FDA is the same information that reassures a buyer the device will stay supported. 3. **Documented access controls.** Authentication and authorization protocols that satisfy a reviewer's threat model also answer a hospital's own security questionnaire. 4. **A visible SBOM commitment.** Being able to say the device's software inventory is monitored and current, not just filed once at submission, differentiates the device from one where that question gets no clear answer. None of this requires inventing new work. It requires packaging the architectural and documentation decisions already made before MVP, the ones this article treats as design cost rather than redesign cost, into language a buyer can evaluate. A go-to-market plan that stays silent on security leaves that question to be raised, and possibly mishandled, during a procurement review instead of addressed on the manufacturer's own terms. Manufacturers who get the pre-MVP architecture right have the easier version of this problem: the evidence already exists, and go-to-market only has to communicate it. ## How Blue Goat approaches cybersecurity for early-stage medtech Blue Goat Cyber works with pre-revenue and post-PMF medtech teams the same way: we right-size the work to where the device actually is. For a pre-MVP team, that means a lightweight threat model, an architecture review, and a written deferral log so reviewers can see what was conscious versus accidental. For a post-PMF team racing to submission, it means a full Section 524B package against the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026: SBOM with VEX, complete threat model, risk-tiered penetration test, and the postmarket Cybersecurity Management Plan. Our team holds CISSP and OSCP credentials and includes ex-military red team operators. See the [medical device cybersecurity services overview](/services/medical-device-penetration-testing). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Frequently Asked Questions ### When should a MedTech startup actually start cybersecurity work? Before the first line of MVP code, not after market fit. The three architectural decisions that drive submission risk - authentication model, update mechanism, and trust boundary - cost a few engineering days when made pre-MVP and 6-18 months of rework when retrofitted. The cheapest cybersecurity is the cybersecurity you design in, because the FDA's February 3, 2026 guidance treats those decisions as design-control artifacts. ### Can I defer cybersecurity until I have an FDA pre-submission meeting? No. The pre-submission meeting is where the FDA tells you what evidence they expect in your 510(k) or De Novo - not the start of the work. If your architecture cannot produce that evidence (signed updates, scoped trust boundaries, an authenticated control plane), you leave the meeting with a 6-12 month re-engineering backlog instead of a green light. ### What's the typical cost difference between pre-MVP and post-market-fit cybersecurity? For a typical connected Class II device, pre-MVP security architecture work runs roughly $20-50K and a few engineering weeks. Bolting the same controls on after market fit usually runs $200-500K and 6-18 months of rework, plus the lost-revenue cost of a delayed submission. That is the ratio that drives the "start early" recommendation. ### Which cybersecurity activities can I genuinely defer until later? A few - and they are mostly documentation, not architecture. Final SBOM generation, final penetration test, final cybersecurity labeling, and the postmarket vulnerability disclosure portal can all wait until the device is feature-complete. Architectural decisions - authentication, updates, trust boundary, key management - cannot. ### Isn't it cheaper to ship fast and fix security after Series A? Only if you do not value your Series A timeline. Investors increasingly diligence cybersecurity posture before a MedTech round, and a known 12-month re-engineering backlog directly affects valuation. The "ship fast, secure later" playbook works in consumer SaaS; in FDA-regulated MedTech it consistently shows up as a discount in the term sheet. ## Related posts - [When to Start Medical Device Cybersecurity in Product Development](/blog/when-to-start-medical-device-cybersecurity) - the full lifecycle timing map for teams asking "when do we actually start?", including the recovery sprint if you're already late. - [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance) - the full breakdown of the February 3, 2026 final guidance every founder reads next. - [Medical Device SBOM: FDA Requirements and Submission Guide](/blog/medical-device-sbom-fda-requirements-and-submission-guide) - what the SBOM looks like in the submission once the architecture is locked in. - [FDA Deficiency Letter vs RTA vs Hold Letter](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) - what happens when you skip the early work and reviewers come back with questions. ## About the author **Christian Espinosa, CISSP - Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Narrowband IoT Protocol Cybersecurity Source: https://bluegoatcyber.com/blog/cybersecurity-for-medical-devices-with-narrowband-iot-protocol # Narrowband IoT Protocol Cybersecurity: for Medical Device Manufacturers > **[DIRECT ANSWER]** Narrowband IoT improves medical device connectivity through licensed cellular spectrum, carrier-managed authentication, long battery life, and reliable coverage in hard-to-reach locations, but it does not by itself secure a device. Manufacturers still need strong device identity, key management, protected firmware updates, and backend hardening on top of NB-IoT's transport benefits. The FDA's February 3, 2026 guidance expects holistic, lifecycle security rather than treating a secure transport protocol as sufficient by itself. _Updated November 10, 2024_ Connected medical devices need more than basic connectivity. They need communications that are reliable, power-efficient, and designed with security controls that hold up under real-world conditions. [Narrowband IoT protocol](https://en.wikipedia.org/wiki/Narrowband_IoT) can help, but only when manufacturers treat it as one layer in a broader security architecture instead of a shortcut to compliance. ## Key Takeaways - NB-IoT offers power efficiency and broad coverage for medical devices. - Licensed spectrum and cellular infrastructure improve communication security. - Security benefits are limited without strong device-level controls. - Manufacturers must avoid overstating NB-IoT's security impact. - FDA expects holistic cybersecurity, not just secure transport. - Postmarket monitoring and secure updates are critical. ## Why this matters Cybersecurity failures in medical devices pose significant patient safety risks, impacting therapy delivery, diagnostics, and data integrity. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly mandates that manufacturers establish a security by design approach, going beyond basic connectivity to address the entire product lifecycle. This includes considerations for vulnerabilities across hardware, software, and communication protocols. Medical devices, operating within complex healthcare ecosystems, are inviting targets for exploitation; a compromised device can serve as an entry point for broader network attacks or directly harm patients through malfunction or data manipulation. Therefore, understanding and mitigating risks associated with communication protocols like Narrowband IoT is crucial for ensuring device trustworthiness. Adherence to standards such as IEC 81001-5-1, ISO 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 provides a framework for managing these risks, but without diligent attention to the inherent limitations of each technology, devices remain exposed to evolving threats. Neglecting device-level security could lead to severe consequences, undermining trust and regulatory compliance. ## Why Cybersecurity in Healthcare Still Fails In healthcare, a cyber incident is rarely just an IT problem. It can affect patient safety, device availability, clinical workflow, and the confidentiality of protected health information. That is why [cybersecurity remains central to healthcare](/blog), especially as more devices connect to hospital networks, cloud services, and remote management platforms. ![Section Image](/imported-images/f5a908598e980251.webp) The risk is not hypothetical. A compromised device can become an entry point into a larger environment, a source of bad data, or a target for disruption. If an attacker interferes with therapy delivery, alarm behavior, or system availability, the impact moves quickly from technical issue to patient care issue. ### The Role of Medical Devices in Modern Healthcare Medical devices now handle monitoring, therapy delivery, diagnostics, and data exchange across care settings. Pacemakers, infusion systems, insulin pumps, and remote monitoring tools have improved care and expanded access. They have also expanded the attack surface. That increased connectivity is useful, but it creates dependency on software, communications paths, and backend systems. Manufacturers need to account for that full system, not just the device in isolation. As we have covered in discussions of [interconnected medical device risks](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples), the protocol choice matters, but so do identity, patchability, logging, configuration control, and failure handling. ### The Growing Threat of Cyber Attacks in Healthcare Healthcare systems continue to attract attackers because they combine high-value data with operational urgency. Ransomware, credential attacks, insecure remote access, vulnerable third-party components, and weak segmentation remain common problems. Connected devices sit in the middle of that mess. For device manufacturers, this means security decisions cannot stop at feature delivery. They need to stand up to expected misuse, foreseeable threat scenarios, and the scrutiny of the FDA during premarket review when cybersecurity claims affect safety or effectiveness. ## What NB-IoT Actually Brings to Medical Devices Narrowband IoT, or NB-IoT, is a cellular communications technology built for low-power devices that send relatively small amounts of data over long periods. For certain medical use cases, that profile fits well. Remote monitoring devices, status-reporting systems, and products deployed outside traditional clinical environments may benefit from its coverage and battery efficiency. NB-IoT is not the answer for every device. It is a design choice with tradeoffs. The real question is whether its operating model supports the security, performance, and reliability requirements of the intended use. ### Defining Narrowband IoT Protocol NB-IoT runs on licensed cellular spectrum and uses existing carrier infrastructure. It is built for narrow bandwidth communications, extended coverage, and reduced power consumption. Those characteristics matter for medical devices that need long battery life and dependable communication in hard-to-reach locations. Using licensed spectrum can also reduce some of the interference concerns seen with unlicensed wireless options. That does not make the system inherently secure, but it changes the communications environment in useful ways. ### Key Features and Benefits of Narrowband IoT Protocol NB-IoT is often attractive because it can maintain connectivity in locations where other wireless options struggle, including inside buildings and in lower-signal areas. For medical devices, that can improve continuity for telemetry, alerting, and remote status updates. From a security standpoint, the main advantages are tied to the cellular ecosystem: carrier-managed connectivity, authentication mechanisms, and support for encrypted communications. Those features can reduce exposure when compared with ad hoc wireless implementations. They do not eliminate the need for secure device identity, key management, protected firmware updates, and backend hardening. ## Where NB-IoT Helps Cybersecurity - and Where It Does Not [Narrowband IoT protocol](/blog) can improve the communications security posture of a connected device. It can help reduce reliance on less controlled local networks and can support authenticated, encrypted exchanges with approved services. That matters. But security failures in medical devices usually come from system design weaknesses, not from the transport alone. Manufacturers should be careful not to oversell the protocol. Using NB-IoT does not fix weak authorization logic, hardcoded credentials, insecure APIs, poor update mechanisms, or insufficient logging. It will not satisfy the FDA if the rest of the architecture is brittle. ### How Narrowband IoT Protocol Can Improve Security When implemented correctly, NB-IoT can narrow exposure by giving devices a more direct path to authorized infrastructure instead of placing them on broader local networks. That can reduce opportunities for lateral movement and lower dependence on hospital Wi-Fi configurations or consumer-grade home networking. Its built-in support for authentication and encrypted communication also raises the baseline. An attacker who wants to intercept traffic or impersonate a trusted service faces more obstacles. For remote or distributed devices, that is useful. Still, the protocol only protects part of the chain. Security depends on how the device stores secrets, validates commands, handles retries and outages, authenticates users and services, and records security-relevant events. If those areas are weak, the communications layer will not save the product. ### Implementation Challenges That Matter Integration is where many programs stumble. Legacy devices may not support NB-IoT without hardware redesign, firmware changes, and backend updates. Power constraints, antenna design, carrier support, roaming behavior, and provisioning workflows all affect real deployment. There are also operational questions. Who manages the device identity lifecycle? How are credentials rotated? What happens when connectivity is lost? How are software updates delivered and verified? Can security logs be collected in a way that supports postmarket monitoring? These are not side issues. They are central design questions, especially for manufacturers preparing FDA submissions that need to show cybersecurity was built into the device lifecycle rather than bolted on late. ## Best Practices for Securing Medical Devices Using NB-IoT Choosing NB-IoT is only one part of a defensible strategy. Manufacturers and healthcare delivery organizations still need disciplined engineering and operational controls around the device, the cloud environment, and the supporting network. ![Section Image](/imported-images/e370993a92a0e6ff.webp) ### Build a Defensible Network and Device Architecture Start with architecture, not marketing claims. Devices should authenticate strongly to approved services, limit exposed interfaces, and enforce least privilege across users, services, and administrative functions. Segment systems where appropriate and avoid unnecessary trust relationships. [Encryption](/blog) should protect data in transit and at rest, but encryption alone is not enough. Key storage, certificate handling, secure boot, signed firmware, and tamper-resistant update paths all matter. If the design assumes every other system in the environment is trustworthy, it is already behind. ### Treat Monitoring, Patching, and Response as Product Requirements Security maintenance is not optional once the device ships. Manufacturers need a process for vulnerability intake, triage, remediation, validation, and coordinated disclosure. Devices should support update mechanisms that are secure, reliable, and practical for the environments where they operate. Monitoring matters too. Teams need visibility into device behavior, connection failures, unusual access attempts, and software integrity events. Incident response planning should include device-specific scenarios, not just generic IT playbooks. That is how organizations move past checklist theater and into actual risk reduction. ## The Future of NB-IoT and Medical Device Security NB-IoT will remain relevant for some classes of connected medical devices, especially where long battery life, small data payloads, and broad coverage are more important than high throughput. Its value will depend on fit. For the right use case, it can be a solid transport option. For the wrong one, it becomes another constraint. ![Section Image](/imported-images/1f21325a077f307d.webp) What changes next is less about the protocol itself and more about the expectations around it. Manufacturers will face increasing pressure to prove security claims with evidence: threat models, security architecture, SBOM practices, validation data, update plans, and postmarket monitoring processes. The FDA is already pushing industry in that direction. AI-assisted monitoring, stronger anomaly detection, and better software supply chain controls may improve visibility. Zero trust principles will continue to shape backend design. More products will use layered communications strategies rather than betting everything on one transport. That is the right direction. The bottom line is simple: NB-IoT can support secure medical device connectivity, but it is not a substitute for secure design. If you want a device that stands up in the field and under FDA review, build the whole system accordingly. The need for serious cybersecurity controls only grows as healthcare organizations deploy more connected products. At Blue Goat Cyber, we help medical device manufacturers address those challenges with services tailored to medical device cybersecurity, penetration testing, and alignment with HIPAA and FDA expectations. Our team focuses on practical security work that supports safer products and stronger submissions. [Contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Our approach to medical device cybersecurity emphasizes a layered defense throughout the product lifecycle. We integrate security from the design phase, using threat modeling and rigorous testing to identify vulnerabilities early. Our team, comprising cybersecurity experts with CISSP and OSCP certifications, including ex-military red team personnel, specializes in navigating the unique challenges of medical device security and regulatory compliance. We analyze communication protocols like Narrowband IoT within the context of the device's overall architecture, implementing measures such as secure boot, authenticated firmware updates, and rigorous access controls. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost, ensuring a smooth path to market. Our methodology focuses on verifiable controls and adherence to regulatory expectations, providing a defensible security posture. Learn more about our postmarket services at [FDA postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services). ## FAQ ### What is Narrowband IoT (NB-IoT) protocol? NB-IoT is a cellular communications technology designed for low-power devices transmitting small data volumes over licensed spectrum. It uses existing carrier infrastructure and is known for extended coverage and battery efficiency, making it suitable for certain remote monitoring medical devices. ### How does NB-IoT improve medical device cybersecurity? NB-IoT can improve security by providing authenticated, encrypted communication over carrier-managed networks, offering a more direct and controlled path than public Wi-Fi. This reduces opportunities for lateral movement and enhances data protection during transit. ### Does NB-IoT alone ensure medical device cybersecurity? No. While NB-IoT strengthens the communication layer, it does not address common medical device cybersecurity weaknesses such as weak authorization, hardcoded credentials, insecure APIs, or poor update mechanisms. A complete security architecture is essential. ### What challenges are associated with implementing NB-IoT securely? Implementation challenges include managing device identity, credential rotation, handling connectivity loss, and Ensure secure, verifiable software updates. These operational aspects are critical for a secure deployment and FDA compliance. ### Why does the FDA care about NB-IoT in medical devices? The FDA evaluates the entire cybersecurity posture of medical devices during premarket review. While NB-IoT can be a secure transport, the FDA focuses on whether the full system design accounts for foreseeable threats, ensures safety and effectiveness, and allows for postmarket maintenance. ### What are best practices for securing medical devices with NB-IoT? Best practices include building a defensible architecture with strong authentication, encryption for data at rest and in transit, and strong key management. Manufacturers must also support secure patching, continuous monitoring, and effective incident response processes. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CoAP Protocol Security in Medical Devices (2026) Source: https://bluegoatcyber.com/blog/cybersecurity-in-the-coap-medical-device-protocol # CoAP Protocol Security in Medical Devices: A 2026 Guide > **[DIRECT ANSWER]** CoAP secures constrained medical devices through DTLS, but without it traffic is readable and manipulable by anyone on the network path. Reviewers expect a threat model covering CoAP's UDP transport and resource discovery, evidence that DTLS is enabled end to end, and security testing aligned to the FDA's February 3, 2026 premarket cybersecurity guidance, IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023. _Updated October 26, 2024_ The healthcare industry has moved aggressively toward interconnected medical devices. Protocols like CoAP make that connectivity possible for resource-constrained hardware. But connectivity without security is just exposure. The security of CoAP implementations must be a priority, because the cost of getting it wrong falls directly on patients and healthcare operations. ## Key Takeaways - CoAP connects medical devices, facilitating data exchange. - DTLS secures CoAP communication, protecting patient data. - Cybersecurity strategy matters for CoAP medical devices. - Implement encryption and secure data transmission. - Regular security audits and staff training are vital. - AI and machine learning enhance threat detection. ## Why this matters CoAP vulnerabilities carry direct patient safety consequences. Unauthorized access to device data, manipulation of device functionality, and disruption of critical medical services are all realistic outcomes of an unsecured CoAP implementation. These aren't theoretical risks. They're the kinds of failures that happen when security is treated as secondary to connectivity. The FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 requires manufacturers to address cybersecurity risks throughout the device lifecycle, from design through post-market surveillance. Standards including IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide the frameworks for doing that work systematically. Failing to apply them to CoAP-enabled devices creates regulatory exposure and, more importantly, leaves patients at risk. ## Understanding the CoAP Medical Device Protocol CoAP, or Constrained Application Protocol, is a web transfer protocol designed specifically for devices with limited computing power and network capability. Its lightweight design and efficient communication model make it a practical choice for resource-constrained medical hardware. Understanding how CoAP works is the starting point for understanding where it can fail. ![Section Image](/imported-images/1c559ee19dca3dc1.webp) ### The Role of CoAP in Medical Device Communication CoAP acts as a communication layer that lets medical devices exchange data with other devices, healthcare providers, and cloud storage systems. It supports real-time updates, patient data collection, and remote monitoring, all of which improve the efficiency of care delivery. Those same capabilities are exactly what an attacker would want to access or disrupt. ### Key Features of the CoAP Protocol CoAP runs on UDP, which reduces overhead for constrained devices but also skips some of the reliability mechanisms built into TCP. It implements the REST architectural style, which makes integration with existing web services straightforward. CoAP also supports multicast communication for group messaging and uses a simple message format that keeps network congestion low. Security is built into the spec through [CoAP's support for DTLS](/blog/securing-communication-protocols-in-medical-devices), which protects the confidentiality and integrity of data in transit. Without DTLS enabled, CoAP traffic is readable by anyone on the network path. That's an unacceptable posture for a device carrying patient data. CoAP also includes resource discovery, which lets devices locate and interact with other services on a network. This aids interoperability, but it also means a compromised device can probe the network for additional targets. ## The Importance of Cybersecurity in Medical Devices Interconnected medical devices create clinical value and security risk at the same time. Acknowledging that tradeoff honestly is the first step toward managing it. Breaches affecting CoAP devices can compromise patient privacy, disrupt care operations, and in the worst cases, directly endanger patients through manipulated device behavior. ### Potential Risks and Threats Unauthorized access is the primary concern. A CoAP device connected to the internet is reachable by anyone who can route packets to it. Without strong authentication and DTLS, an attacker can intercept and read transmitted data, inject malicious commands, or extract patient information. Device tampering is also a genuine threat. Attackers who reach device control interfaces can alter readings or change operational parameters. For a monitoring device, that might mean a false reading that delays a clinical response. For an infusion or therapy device, the consequences could be more direct. ### The Impact of Cybersecurity Breaches on Healthcare A CoAP security breach doesn't stay contained. It propagates outward through clinical workflows, legal exposure, and damaged patient trust. In time-sensitive clinical situations, even a brief disruption can affect patient outcomes. The financial consequences compound quickly: investigation costs, legal fees, regulatory penalties, and reputational damage all follow a significant breach. Healthcare organizations that treat cybersecurity as a compliance checkbox rather than an operational discipline find out the hard way that the two aren't the same thing. ## Strategies for Ensuring Cybersecurity in CoAP Protocol Securing CoAP requires deliberate, layered controls across communication, authentication, and data storage. There's no single fix. ![Section Image](/imported-images/edc367e3be090893.webp) As more patient records and device functions move into digital systems, the attack surface grows. Security for CoAP implementations must keep pace with that expansion. ### Implementing Secure Data Transmission DTLS should be treated as mandatory for any CoAP implementation carrying patient data. Unencrypted CoAP traffic is a straightforward interception target. Encryption algorithms like [TLS](/blog) protect data in transit, and they also signal to the FDA and auditors that the manufacturer takes data integrity seriously. Beyond protecting patient data, encrypted communication also builds justified confidence in the reliability of the healthcare infrastructure. Patients are more likely to engage with care systems they believe are secure. ### Utilizing Encryption Techniques Encryption at rest matters just as much as encryption in transit. If an attacker gains physical or logical access to a device, encrypted storage limits what they can extract. For devices holding patient data locally, this is a basic control that should be present by default. Pair encryption with regular penetration testing of CoAP implementations. Static controls erode over time as new vulnerabilities emerge. Testing confirms that defenses hold under realistic attack conditions and provides the evidence the FDA expects in premarket submissions. ## Best Practices for Maintaining Cybersecurity Cybersecurity for CoAP devices isn't a deployment-time activity. It's an ongoing discipline that requires continuous attention. Security threats don't stop evolving after a device ships. The FDA's February 3, 2026 guidance explicitly addresses postmarket cybersecurity responsibilities, and manufacturers who treat their obligation as ending at clearance will find themselves out of compliance and unprepared when vulnerabilities surface. ### Regular Security Audits and Updates Scheduled security audits give manufacturers a structured opportunity to identify vulnerabilities before attackers do. That includes reviewing CoAP configurations, checking for unpatched dependencies, and validating that security controls are functioning as designed. Working with external cybersecurity firms provides a perspective that internal teams can't fully replicate. Outside testers bring different assumptions and attack patterns, which surfaces findings that internal familiarity tends to miss. The combination of internal discipline and external challenge produces a stronger security posture. ### Training and Awareness Among Medical Staff Human error remains one of the most exploited weaknesses in any security program. Staff who recognize phishing attempts, follow strong credential hygiene, and understand the protocols for reporting suspicious device behavior are a genuine defensive asset. Simulated phishing exercises give organizations measurable data on staff readiness and help focus training where it's most needed. Security awareness isn't a one-time event. It requires regular reinforcement to stay effective. ## Future Trends in CoAP Protocol Cybersecurity The threat environment keeps moving, and CoAP security practices need to move with it. Technical controls that were appropriate at device launch may need to be updated as new vulnerabilities are disclosed or attack techniques mature. Proactive security audits are part of the answer. So is staying current with CVE databases for components used in CoAP implementations. Manufacturers who build ongoing vulnerability monitoring into their postmarket processes are far better positioned than those who only respond after an incident. ### Advancements in Cybersecurity Technologies Intrusion detection systems, [AI, and machine learning](/blog) are changing how healthcare organizations identify and respond to threats. These tools can analyze device behavior at scale, detecting anomalies that would be invisible to manual monitoring. Real-time threat detection is increasingly feasible for device manufacturers who invest in the infrastructure. ### The Role of AI and Machine Learning in Cybersecurity AI and ML algorithms can identify behavioral patterns that diverge from established baselines, flagging potential compromises before they escalate. For CoAP devices generating continuous telemetry, this kind of anomaly detection adds a layer of protection that rule-based systems can't match. These capabilities also help manufacturers meet the FDA's expectation for ongoing postmarket cybersecurity monitoring. ## Conclusion CoAP is a sensible protocol choice for constrained medical devices. It only stays sensible if it's implemented securely. Manufacturers who apply DTLS, conduct regular security audits, train their staff, and build monitoring into their postmarket programs will be better protected and better positioned with the FDA. Blue Goat Cyber works with medical device manufacturers on exactly these problems. Our team, including CISSP and OSCP certified engineers with ex-military red team experience, provides the technical depth and regulatory alignment that CoAP security requires. Don't let CoAP vulnerabilities put your devices or your patients at risk. [Contact us today for cybersecurity help](/contact) and partner with us to build security into every layer of your device. ## How Blue Goat approaches this Blue Goat Cyber addresses CoAP medical device cybersecurity by focusing on foundational security principles and practical application. Our approach starts with a thorough risk assessment and threat modeling to pinpoint specific vulnerabilities within CoAP implementations. We perform targeted penetration testing, identifying weaknesses in communication, authentication, and data handling. Our team, featuring CISSP and OSCP certified experts, including ex-military red team personnel, applies a structured methodology. We offer services such as secure architecture review, code analysis, and security control validation, all aligned with FDA guidance. We then provide actionable recommendations for mitigation. Our goal is to enhance the inherent security of CoAP-enabled devices, facilitating compliance with regulations and industry standards. Blue Goat Cyber specializes in ensuring medical device safety and efficacy. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our validation processes at /services/medical-device-penetration-testing. ## FAQ ### What is CoAP in medical devices? CoAP (Constrained Application Protocol) is a lightweight web transfer protocol. It connects medical devices with limited resources, enabling efficient data exchange and communication within healthcare systems. ### How does CoAP secure data transmission? CoAP incorporates security mechanisms like Datagram Transport Layer Security (DTLS). DTLS protects the confidentiality and integrity of data transmitted between devices, preventing unauthorized access. ### Why is cybersecurity important for CoAP medical devices? Cybersecurity is crucial because interconnected CoAP medical devices are vulnerable to threats like unauthorized access, data breaches, and device tampering. Breaches can compromise patient privacy and disrupt healthcare operations. ### What are the common cybersecurity risks for CoAP medical devices? Common risks include unauthorized access to devices, potential data breaches during data transmission, and manipulation of device functionality through tampering. These can compromise patient safety and data integrity. ### Does the FDA have guidance for CoAP medical device cybersecurity? Yes, the FDA's February 3, 2026, final guidance on medical device cybersecurity provides recommendations for ensuring the security of such devices throughout their lifecycle, including those utilizing CoAP. ### How can healthcare organizations improve CoAP cybersecurity? Organizations should implement secure data transmission via encryption, utilize encryption techniques for stored data, conduct regular security audits, and provide cybersecurity training for medical staff. **Related:** [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Cybersecurity Metrics for FDA Compliance (2026) Source: https://bluegoatcyber.com/blog/cybersecurity-measures-and-metrics-for-medical-devices-navigating-fda-compliance # Cybersecurity Metrics for FDA Compliance for Medical Devices: 2026 Best Practices > **[DIRECT ANSWER]** Cybersecurity metrics for medical devices measure how well controls actually reduce risk, tracking things like patch latency, vulnerability remediation time, authentication coverage, and SBOM completeness. Under the FDA's February 3, 2026 final guidance, Section 524B compliance depends on documenting these metrics as objective evidence in premarket submissions, not just describing intentions, so manufacturers should capture them throughout design and postmarket monitoring. _Reviewed July 24, 2026_ ## Key Takeaways - Data poisoning targets AI training data for malicious outcomes. - Corrupted AI can lead to misdiagnoses and patient harm. - Vulnerabilities often stem from outdated security measures. - Implement multi-factor authentication, encryption, and updates. - Regular audits and anomaly detection matter for data integrity. - Regulatory bodies set standards and build collaboration. ## Why this matters When AI in a medical device learns from poisoned data, patients receive wrong answers. Corrupted models produce inaccurate diagnoses, recommend ineffective treatments, or trigger device malfunctions. Those aren't hypothetical risks; they're foreseeable failure modes with direct patient-safety consequences. The FDA's Cybersecurity in Medical Devices final guidance, dated February 3, 2026, explicitly mandates cybersecurity controls for AI-driven devices. Failure to meet those controls can mean product recalls, civil monetary penalties, and Warning Letters that halt shipments. Relevant standards define the implementation framework. IEC 81001-5-1 (Health software and health IT systems safety, effectiveness and security, Part 5-1) maps security activities across the product lifecycle. ISO/IEC 27001 governs information security management. AAMI TIR97 addresses post-market security surveillance specifically. Protecting medical device AI from data poisoning isn't purely a technical problem; it's a prerequisite for ethical healthcare delivery and continued regulatory authorization. ## Defining Data Poisoning in AI Systems Data poisoning means deliberately inserting malicious data into an AI model's training set to corrupt what the model learns. Once deployed, that model makes wrong decisions. In [artificial intelligence](/blog) embedded in medical devices, those wrong decisions reach patients directly. Consider a medical imaging AI trained on thousands of X-ray images. If an attacker injects modified images, the model may misinterpret what a healthy scan looks like. Clinicians act on that bad guidance. Patients face real health risks. The mechanics vary. An attacker might shift category labels on a small percentage of training images, introduce fabricated samples, or corrupt ground-truth annotations. In each case the damage is slow and silent. Many AI systems are designed to learn from whatever data they receive, which makes them structurally vulnerable to these tactics. The poisoning often goes undetected until the model is deployed and producing errors in the field, which is exactly what makes it a serious threat. ## The Impact of Data Poisoning on Medical Device AI Poisoned AI doesn't fail loudly. It fails quietly, producing plausible-looking outputs that clinicians may trust. Misdiagnoses get issued. Treatments get delayed or misdirected. Life-saving interventions may come too late. The damage extends well beyond individual patient encounters. Hospitals absorb financial liability. Patients lose trust in AI-assisted care. Legal exposure accumulates. In serious cases, device recalls follow. There's a longer-term cost too. A handful of high-profile AI failures tied to data integrity problems can set back adoption of genuinely useful clinical AI across an entire specialty. Clinicians who saw a false-negative cancer result from a manipulated model don't forget it quickly. Fighting data poisoning isn't just about protecting one device or one patient. It's about preserving the credibility of medical AI as a clinical tool worth trusting. ## The Vulnerability of Medical Device AI to Cyber Threats ### The Role of AI in Medical Devices AI-driven medical devices analyze patient data at speed, deliver predictive analytics, and support continuous monitoring. Infusion pumps, patient monitors, and diagnostic imaging systems all process sensitive data constantly. That data dependence is what makes them attractive targets. Real-time AI decision-making can genuinely improve outcomes. An algorithm that flags a deteriorating vital-sign trend faster than a human observer gives clinicians more time to act. But that same tight coupling between AI output and clinical action means a compromised model has a fast path to patient harm. Malicious interference that skews medication dosage recommendations or masks early warning signs isn't a distant scenario; it's a plausible, documented attack class. ### Why Medical Device AI is a Target for Cyber Attacks Medical device AI systems are often still catching up to [cybersecurity standards](https://www.fda.gov/media/184856/download). Outdated software, absent encryption, and poorly designed data pipelines all create footholds. These devices frequently connect to hospital networks, so a single compromised device can serve as an entry point into broader hospital infrastructure. Manufacturers often prioritize time-to-market over security depth, and no single mandatory security standard applies uniformly across the industry. That inconsistency leaves gaps that attackers know to target. Healthcare facilities inherit a patchwork of defenses from different manufacturers, some adequate and some not. The absence of standardized security protocols makes that inconsistency structurally hard to fix without deliberate effort from every stakeholder in the supply chain. ## Strategies for Safeguarding Medical Device AI ### Implementing Resilient Cybersecurity Measures The best defense against data poisoning starts before any attack arrives. Medical institutions must treat cybersecurity as a core operational requirement. Multi-factor authentication cuts unauthorized access dramatically. Encrypting data at rest and in transit should be non-negotiable. ![Section Image]() Regular software updates and patch management close known vulnerabilities before attackers exploit them. [Conducting regular penetration testing](/services/medical-device-penetration-testing) goes further: by simulating attacks, organizations surface weak points that policy reviews miss. Finding a gap in a controlled test is far cheaper than discovering it after an incident. ### Ensuring Data Integrity in AI Systems Data integrity has to be built into the architecture of medical device AI, not bolted on after the fact. That means strict data governance policies, regular audits, and integrity checks at every stage of the data pipeline. Anomaly detection algorithms can flag unusual patterns in training or inference data that may indicate a poisoning attempt. Catching problems early beats waiting for bad outputs to accumulate in production. Staff training matters here as well. Employees who understand how data moves through a system, and what proper handling looks like, catch problems that automated tooling misses. Building a culture where data stewardship is everyone's responsibility, not just the security team's job, makes a measurable difference. Organizations that invest in this education strengthen their overall security posture significantly. ## The Future of Cybersecurity in Medical Device AI ### Emerging Cybersecurity Technologies for AI Protection Cybersecurity for medical AI is changing fast. Blockchain-based data logs provide tamper-evident audit trails, making unauthorized changes to training data detectable quickly. Every data point gets a verifiable history, which builds confidence for both healthcare providers and patients that the underlying data hasn't been manipulated. ![Section Image]() AI can also defend AI. Machine learning algorithms trained to recognize normal data patterns can flag anomalies consistent with poisoning attempts. These detection systems adapt as new inputs arrive, so coverage evolves alongside the threat. The future model is AI-plus-specialized-detection working in tandem, with each layer compensating for the other's blind spots and responding to new challenges in near real-time. ### The Role of Regulatory Bodies in AI Cybersecurity [Regulatory bodies](https://www.fda.gov/media/184856/download) set the standards that create a common baseline across the industry. Clear, enforceable guidelines on data management and cybersecurity protocols give manufacturers a concrete target and give patients a baseline assurance. Without those standards, security quality varies wildly from one device to the next. Collaboration between healthcare providers, manufacturers, and cybersecurity specialists multiplies effectiveness. Regular workshops and shared threat intelligence keep all parties current on emerging attack methods. The medical technology sector is advancing quickly, and the strategies used to protect it must advance just as fast, so [patient safety remains paramount](/blog) at every stage of the device lifecycle. ## Conclusion Addressing data poisoning threats in AI for medical devices cannot wait. As healthcare continues its digital transformation, protecting these systems must be a top priority. With the right combination of technical controls, governance policies, and cross-functional collaboration, the balance of power can shift back toward healthcare professionals and the patients they serve. As digital healthcare expands, so does the need for rigorous cybersecurity. Blue Goat Cyber stands at the forefront of this effort, offering deep expertise in medical device cybersecurity. With a proven track record guiding manufacturers through FDA compliance and a thorough understanding of healthcare security requirements, our team is equipped to ensure your medical devices are both compliant and resilient against cyber threats throughout their lifecycle. Don't let data poisoning threats compromise patient safety or device integrity. [Contact us today for cybersecurity help](/contact), and partner with a team dedicated to securing the future of healthcare technology. ## How Blue Goat approaches this Blue Goat Cyber addresses medical device AI data poisoning through a methodical approach focused on prevention, detection, and response. Our methodology emphasizes rigorous data integrity verification throughout the AI lifecycle, from data acquisition and preprocessing to model deployment and post-market surveillance. We conduct thorough threat modeling to identify potential attack vectors for data poisoning and implement tailored security controls, including sophisticated anomaly detection algorithms and cryptographic data validation techniques. Our team of experts, including CISSP and OSCP certified professionals, many with ex-military red team experience, specializes in evaluating vulnerabilities within AI/ML pipelines. We provide services like penetration testing of AI systems and security architecture reviews. Our expertise ensures that medical devices meet stringent regulatory requirements. Learn more about our proactive defense strategies at [medical device penetration testing](/services/medical-device-penetration-testing). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is AI data poisoning in medical devices? AI data poisoning occurs when adversaries manipulate the training data of AI models in medical devices. This manipulation can cause the AI to malfunction, leading to incorrect diagnoses or treatments for patients. ### How does AI data poisoning impact medical device performance? Poisoned data can cause an AI-powered medical device to misclassify medical images, misinterpret patient vitals, or suggest incorrect treatment plans. This directly compromises the device's accuracy and reliability. ### What are the common methods of AI data poisoning? Common methods include injecting malicious data into training datasets, altering existing data with subtle corruptions, or fabricating entire datasets to mislead the AI. These methods aim to subvert the AI's learning process without immediate detection. ### How can medical device manufacturers prevent AI data poisoning? Manufacturers can prevent data poisoning through strong cybersecurity measures, strict data governance policies, and regular integrity checks. Employing anomaly detection algorithms and adhering to the FDA's February 3, 2026 final guidance helps mitigate risks. ### Does the FDA address AI data poisoning in its guidelines? Yes, the FDA's February 3, 2026 final guidance on cybersecurity for medical devices emphasizes the importance of data integrity and protection against malicious manipulation, including AI data poisoning. It provides a framework for manufacturers to secure AI-driven devices. ### What are the consequences of AI data poisoning for patient safety? The consequences for patient safety are severe, ranging from incorrect diagnoses and delayed treatments to administering inappropriate therapies. Such errors can lead to adverse health outcomes and erode trust in medical technology. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity Checklist: Design to Postmarket | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist # Medical Device Cybersecurity Checklist for Every Product Phase > **[DIRECT ANSWER]** A medical device cybersecurity checklist tracks specific evidence across five phases: threat models and secure architecture at design, static and software composition analysis during development, penetration testing and vulnerability disclosure processes before submission, a complete SBOM and security risk documentation at submission, and monitoring plus patch delivery postmarket. The FDA's February 3, 2026 final guidance expects this evidence tied to a manufacturer's own design inputs, not a single point-in-time report. _Reviewed September 17, 2026_ A missing piece of cybersecurity evidence can stall a submission for months, and a gap discovered after launch can trigger a recall. Medical device manufacturers face both risks at once: the FDA reviews cybersecurity documentation line by line during premarket review, and attackers look for the same gaps once a device reaches hospitals. Neither problem is solved by a single test or a late-stage document push. A checklist only helps if it maps to evidence a reviewer or an auditor will actually ask for, not vague reminders to "be secure." This piece organizes that evidence by the phase in which it needs to exist: design, development, testing, submission, and postmarket. Each item states what a reviewer expects to see, not just what practice to follow, so teams can self-check readiness before an FDA request or an internal audit surfaces the gap. ## Key Takeaways - Cybersecurity evidence must exist before it is requested; retrofitting documentation after a design freeze is expensive and often incomplete. - The FDA's February 3, 2026 final guidance expects evidence across the total product lifecycle, aligned with AAMI SW96 (recognition number 13-131) and IEC 81001-5-1. - A complete SBOM, a documented threat model, and a security risk traceability matrix are the three artifacts reviewers ask about most often. - Manufacturers, not testing vendors, own verification that security requirements meet their own design inputs. - Postmarket monitoring, coordinated vulnerability disclosure, and patch delivery are ongoing obligations, not one-time submission items. ## Why This Matters Cybersecurity gaps in medical devices are not abstract compliance risks; they are patient safety risks with regulatory consequences attached. A device that ships without a documented threat model or a current SBOM cannot demonstrate that its security controls address realistic attack paths, and that gap is exactly what the FDA's February 3, 2026 final premarket guidance was written to close. This guidance replaced the June 27, 2025 version and the original September 2023 guidance, and it holds manufacturers to the same total product lifecycle expectation across design, development, testing, submission, and postmarket support. The cost of getting this wrong compounds. A submission missing SBOM detail or security risk traceability generates additional information requests that delay clearance by months. A device that reaches the field without a patch delivery mechanism cannot respond quickly when a vulnerability is disclosed, which is now a documented gap under CP 7382.850, the inspection procedure that replaced QSIT on February 2, 2026. A checklist tied to evidence, rather than general best practices, gives manufacturers a way to check their own readiness before either of those failures happens. This also protects manufacturers from an easy mistake: assuming a third-party penetration test alone satisfies the requirement. A test can confirm whether a control resists a specific attack, but manufacturers are the ones who must verify that the requirement was met against their own design inputs. ## Design Phase: What Evidence to Build First The design phase is where cybersecurity evidence is cheapest to produce and most expensive to skip. Reviewers expect to see a threat model, an architecture diagram with trust boundaries marked, and a documented set of security requirements before any test occurs. **[KEY REQUIREMENT]** A threat model must identify assets, trust boundaries, and attack surfaces specific to the device's actual architecture and intended use environment, not a generic template. Reviewers can typically tell the difference between a device-specific threat model and a copy-pasted one within a few pages. Checklist items for this phase: - Document the device architecture, including wireless interfaces, cloud connections, and hospital network touchpoints. - Build a threat model using a structured method such as STRIDE, tied to the specific interfaces identified. - Translate threat model findings into testable security requirements, not general statements of intent. - Define the security risk management process that will track these requirements through design changes. | Design Artifact | What a Reviewer Checks | Common Gap | |---|---|---| | Threat model | Device-specific attack paths, not generic examples | Copied from another product line without updates | | Architecture diagram | Trust boundaries and data flows clearly marked | Boundaries omitted or inconsistent with SBOM | | Security requirements | Traceable to specific threats identified | Requirements written after testing, not before | ## Development Phase: Turning Requirements into Verifiable Code Development is where security requirements either become verifiable controls or stay aspirational. The evidence expected here includes static analysis results, dependency tracking, and a running SBOM that updates as components change. Static and dynamic code analysis findings must be triaged and resolved or formally risk-accepted, not simply generated and filed away. A running SBOM should capture every open-source component, its version, and known vulnerabilities at the time of each build, since a stale SBOM is one of the most common reasons reviewers send additional information requests. **[KEY REQUIREMENT]** Every SBOM entry needs a support end-of-life date and a vulnerability monitoring source, because an SBOM without this metadata cannot support the ongoing vulnerability management plan the guidance requires. Checklist items for this phase: - Run static application security testing (SAST) and dynamic analysis (DAST) against the codebase, not just the final build. - Maintain the SBOM continuously as dependencies change, rather than generating it once before submission. - Track triage decisions for every flagged vulnerability, including risk-acceptance rationale where a fix is deferred. - Verify secure coding standards, such as input validation and secure default configurations, against the documented requirements. ## Testing Phase: What a Reviewer Wants to See Verified Testing is where manufacturers confirm, with evidence, that the controls built during development actually hold up against realistic attacks. This includes penetration testing of every external interface, fuzz testing of parsers and communication protocols, and verification that each security requirement from the design phase was tested, not just exercised generally. A penetration test report needs to map findings back to the specific security requirements it was scoped to evaluate. This mapping is what turns a test into evidence a reviewer can use, rather than a narrative of findings with no connection to the design inputs. **[KEY REQUIREMENT]** A manufacturer, not the penetration testing vendor, must verify and document that each security requirement was satisfied. A clean penetration test report does not by itself attest that design inputs were met; that verification is the manufacturer's responsibility. Checklist items for this phase: - Test every external interface: wireless radios, APIs, cloud integrations, and physical debug ports. - Fuzz test protocol parsers and file format handlers exposed to untrusted input. - Map every finding, and every closed requirement, back to the original security requirements list. - Retest after remediation to confirm fixes hold and did not introduce new issues. | Testing Activity | Evidence Produced | Owner of Verification | |---|---|---| | Penetration testing | Findings mapped to requirements, retest results | Manufacturer, using vendor report as input | | Fuzz testing | Crash logs, triage notes, remediation status | Manufacturer | | Static/dynamic analysis | Triage log, risk-acceptance rationale | Manufacturer | ## Submission Phase: Assembling the Package The submission package is where all prior evidence gets assembled into the documentation the FDA reviews. Missing or inconsistent artifacts here are the most common reason for additional information requests under the February 3, 2026 final guidance. Checklist items for this phase: - Include a complete SBOM with support end-of-life data, consistent with the version actually shipping. - Submit the postmarket vulnerability management plan describing how issues will be identified, triaged, and patched after clearance. - Provide a security risk traceability matrix connecting requirements, tests, and results. - Confirm alignment with recognized standards, including AAMI SW96 (FDA recognition number 13-131), IEC 81001-5-1, and ISO 14971 for risk management. - Address the 510(k) substantial equivalence requirements alongside cybersecurity documentation so the two do not conflict. **[KEY REQUIREMENT]** Every artifact in the submission package must be internally consistent: the SBOM version, the architecture diagram, and the test report must all describe the same build, since discrepancies between them are a frequent trigger for deficiency letters. ## Postmarket Phase: Sustaining the Evidence Trail Cybersecurity evidence does not stop being relevant once a device clears review. Manufacturers need an active coordinated vulnerability disclosure program, a mechanism to deliver patches, and ongoing monitoring of the SBOM against newly disclosed vulnerabilities in third-party components. The FDA's inspection approach for these obligations changed on February 2, 2026, when QSIT retired and was replaced by CP 7382.850. That procedure looks for documented evidence of the postmarket practices described in the submission, not just the existence of a plan on paper. Checklist items for this phase: - Operate a coordinated vulnerability disclosure program with a published contact and response timeline. - Monitor the SBOM against vulnerability databases on a recurring schedule, not only at renewal. - Maintain a signed, validated patch delivery mechanism and document each patch release. - Feed field findings, including customer-reported issues, back into the risk management file. - Reassess the threat model when the device architecture or intended use environment changes materially. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works with manufacturers at each phase covered above, building the evidence trail rather than assembling it after the fact. That includes threat modeling during design, SBOM generation and monitoring through development and postmarket, and scoped penetration testing that maps findings to the manufacturer's own security requirements. Because manufacturers retain responsibility for verifying that design inputs were met, the goal is a documentation set the manufacturer can defend on its own, supported by services such as [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for submission-stage work and ongoing postmarket support for SBOM and vulnerability monitoring once the device is in the field. ## Frequently Asked Questions ### What is the single most common reason a submission gets an additional information request on cybersecurity? Inconsistency between artifacts is the most common trigger, such as an SBOM version that does not match the tested build or a test report with no link back to documented security requirements. Reviewers cross-reference these documents closely, and gaps between them read as unresolved risk rather than a paperwork issue. ### Does a penetration test satisfy the FDA's cybersecurity requirements on its own? No. A penetration test confirms whether specific controls resisted specific attacks, but the manufacturer must independently verify and document that its own security requirements, tied to its design inputs, were satisfied. A test report is one input to that verification, not a substitute for it. ### How often should the SBOM be updated? The SBOM should update every time a dependency changes, not just before a submission or renewal. Postmarket, it should be checked against vulnerability databases on a recurring schedule so new third-party disclosures are caught before they become field incidents. ### What changed with the retirement of QSIT? QSIT retired on February 2, 2026 and was replaced by CP 7382.850, the inspection procedure the FDA now uses to evaluate quality system compliance, including postmarket cybersecurity practices. Inspectors under this procedure look for documented, operating evidence of the practices described in a submission, not just a written plan. ### Which standards does the current FDA guidance point to? The February 3, 2026 final guidance points to AAMI SW96 (FDA recognition number 13-131) for premarket cybersecurity risk management, IEC 81001-5-1 for secure product lifecycle processes, and ISO 14971 for overall risk management. Aligning documentation to these standards helps a submission match reviewer expectations. ## CTA Building this checklist into your product lifecycle takes structure, not just a document template. If you want help mapping your current evidence gaps against the February 3, 2026 guidance before your next submission, [book a discovery call](/contact) with Blue Goat Cyber. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian works with medical device manufacturers on FDA premarket submissions and postmarket cybersecurity compliance. [Read more about Christian](/christian-espinosa). --- ## Cybersecurity Is Now a QMS Requirement Source: https://bluegoatcyber.com/blog/cybersecurity-qms-documentation-medtech # Cybersecurity Is Now a QMS Requirement > **[DIRECT ANSWER]** Cybersecurity documentation belongs inside the Quality Management System, not a separate binder. Under the QMSR and the FDA's February 3, 2026 premarket cybersecurity guidance, threat models, SBOMs, VEX statements, risk assessments, architecture diagrams, and postmarket monitoring records need the same design control, change control, supplier oversight, and CAPA discipline as every other device record, maintained across the full product lifecycle, not just at submission. For years, most MedTech teams treated cybersecurity as a submission deliverable. Build the device, hand a binder of documents to a cybersecurity vendor before 510(k), get the [premarket package](/guides/fda-premarket-cybersecurity-submission-checklist) over the line, and move on. That model is over. With the [FDA's QMSR](/blog/a-new-era-for-quality-and-safety-what-the-fdas-qmsr-means-for-cybersecurity) now in effect and the February 2026 Premarket Cybersecurity Guidance setting expectations for the full service life of the device, cybersecurity documentation has to live inside the Quality Management System - controlled, versioned, reviewed, and maintained like every other piece of regulated evidence. Here's what that actually means in practice. ## Key Takeaways - Cybersecurity documentation must integrate with the QMS for lifecycle control. - The FDA expects controlled cyber artifacts, not simply submission binders. - Key documents include risk assessments, threat models, SBOMs, and VEX. - QMS provides versioning, change control, and review cadences for cyber docs. - Integrate cybersecurity into design, risk, change, and supplier controls. - Postmarket cyber activities require ongoing QMS oversight and maintenance. ## Why this matters A medtech QMS is the system reviewers and auditors use to decide whether your cybersecurity claims are real. Under 21 CFR Part 820 (and the QMSR final rule taking effect February 2, 2026) and the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026, cybersecurity is no longer a separate appendix bolted onto your design history file, it is design control, risk management, CAPA, supplier control, and complaint handling all at once. AAMI TIR57:2016, AAMI TIR97:2019, and AAMI SW96:2023 are now the consensus standards reviewers expect you to align with. The FDA's FY2024 Office of Product Evaluation and Quality data shows cybersecurity deficiencies remain a top reason for premarket review delays, and most of them trace back to a QMS that did not actually capture the design decisions, supplier evidence, and postmarket monitoring outputs the reviewer asked for. If the QMS does not document the cybersecurity work, from the reviewer's perspective the cybersecurity work did not happen. ## Why Cybersecurity Belongs in the QMS Cybersecurity isn't a one-time deliverable. The [threat model](/guides/stride-threat-modeling-medical-devices), the [SBOM](/guides/sbom-vulnerability-management-medical-devices), the risk assessment, and the architecture diagram are living documents. They change every time the software changes, every time a dependency updates, every time a new vulnerability is disclosed. If they live in a side folder on someone's laptop, they're not living documents - they're snapshots that go stale the day after submission. The QMS is the only place where versioning, change control, and review cadence are already built in. That's where cyber documentation has to live. When cybersecurity is managed outside the QMS, manufacturers end up with two parallel realities. The QMS says one thing about the device. The cyber binder says another. FDA reviewers notice. Auditors notice. And when something breaks postmarket - a [CVE in a third-party library](/services/postmarket-sbom-vex-monitoring), a deficiency letter, a recall - there's no defensible trail showing the company actually controlled the risk. ## What's Actually Changed in the FDA's Expectations Three things changed at roughly the same time, and together they form a different regime. [Section 524B](/guides/fda-524b-cybersecurity-requirements-explained) made cybersecurity a statutory premarket requirement, not a guidance suggestion. QMSR aligned the U.S. quality system to ISO 13485 and made lifecycle and risk-based thinking the default. And the February 2026 premarket guidance set explicit expectations for what manufacturers must do across the entire service life of the device - not just at submission. None of those can be satisfied by treating cyber as a separate technical track. ## The Documentation MedTech Teams Must Create and Maintain This is the minimum set the FDA expects, and that we expect to see controlled inside the QMS: | Document | QMS Process It Lives In | Trigger to Review | | Cybersecurity risk assessment (often per [AAMI TIR57/TIR97](/guides/aami-tir57-vs-tir97-comparison) or [IEC 81001-5-1](/guides/security-risk-assessment-iec-81001-5-1)) | Risk management | Any design change, new vulnerability, postmarket signal | | Threat model (STRIDE or equivalent) | Design controls / risk | Architecture change, new interface, new data flow | | Security architecture diagram | Design controls | Any change to trust boundaries or components | | [SBOM](/guides/sbom-vulnerability-management-medical-devices) ([CycloneDX or SPDX](/guides/cyclonedx-vs-spdx-medical-devices)) | Configuration management | Every software build released | | [VEX](/guides/vex-document-medical-device-fda) | Vulnerability management | Each new CVE affecting an SBOM component | | Cybersecurity management plan | QMS / postmarket | At least annually, and on material change | | Penetration test reports | Design verification | Per release, and after significant change | | Secure coding & SDLC procedures ([SPDF](/guides/medical-device-cybersecurity-spdf-playbook)) | QMS procedures | Annual review | | Supplier cybersecurity agreements & assessments | Purchasing controls | Onboarding and at supplier change | | Postmarket monitoring & CVD records | Postmarket surveillance | Continuous | | Patch management & update plan | Change control | Per patch, and on cadence | The documents most often overlooked or created too late are the cybersecurity management plan, the VEX, and the supplier cybersecurity assessments. Teams build the SBOM because it's obvious. They skip the plan because it feels like paperwork. Then a deficiency letter shows up asking how they'll monitor and patch, and there's nothing to point to. ## Connecting Cybersecurity Across the Full Lifecycle Managing these documents properly inside the QMS means four things. First, **design controls** - cyber requirements trace to design inputs and outputs like any other requirement. Second, **risk management** - cyber risk feeds into the same risk file as safety risk, not a parallel one. Third, **change control** - every software change runs through an impact assessment that explicitly asks the cybersecurity question. Fourth, **supplier controls** - third-party components and test vendors are part of the quality system, with agreements and oversight to match. Change control is where most teams fall apart. A product manager approves a "minor" library bump. Engineering ships it. Nobody updates the SBOM, nobody re-runs the threat model, nobody checks whether the new version introduces a known CVE. Six months later the FDA asks why the [postmarket monitoring](/services/postmarket-sbom-vex-monitoring) record doesn't match the deployed software. That's a QMS failure, not a cybersecurity failure - and it's exactly why cyber has to be inside the QMS, not next to it. ## Suppliers and Third-Party Components Most of the software in a modern medical device isn't written by the manufacturer. It's open-source libraries, commercial SDKs, OS components, and cloud services. Every one of those is a supplier from a quality standpoint. The SBOM tells you what's in there, the VEX tells you what's exploitable, and the supplier agreement tells you what the vendor will do when something breaks. If your purchasing controls procedure doesn't mention cybersecurity, your QMS has a hole. ## What Continues After Market Postmarket is where the lifecycle framing earns its keep. The activities that have to continue - forever, not just through the warranty - include: - Monitoring [SBOM components for new CVEs](/services/postmarket-sbom-vex-monitoring) and updating the VEX - Running a coordinated vulnerability disclosure program ([CVD](/cvd)) - Tracking and reporting cybersecurity events per 524B - Patching on a documented cadence with regression and security testing - Reassessing the threat model when the threat landscape shifts (new attack classes, new adversary capabilities, [post-quantum timelines](/blog/q-day-medical-device-fda-compliance-gap)) - Keeping cybersecurity labeling and customer guidance current Companies that handle this well treat the cybersecurity management plan as a real plan - with owners, cadences, and CAPA hooks - not a document they write once and file. ## Common Pitfalls 1. **Cyber binder lives outside the QMS.** No version control, no change history, no defensible trail. 2. **SBOM created for submission, never updated.** Stale by the next release. 3. **No VEX, or a VEX that just says "not affected" for everything.** Reviewers see straight through it. ([Common VEX mistakes](/blog/vex-mistakes-fda-deficiencies).) 4. **Change control doesn't ask the cybersecurity question.** Library updates slip through without a threat model review. 5. **Suppliers aren't part of the cybersecurity picture.** No agreements, no assessments, no notification expectations. 6. **Postmarket plan exists on paper but nobody owns it.** No cadence, no metrics, no CAPA when something is found. 7. **Cybersecurity risk file is separate from the safety risk file.** Two truths, neither complete. ## What "Good" Looks Like - One risk file. Safety and security risks live together, with shared controls and traceability. - The SBOM is regenerated on every build and stored as a controlled record. - The VEX is updated within a defined SLA of each new CVE affecting a listed component. - Change control templates include a mandatory cybersecurity impact question that routes to a named owner. - Suppliers have signed cybersecurity terms covering vulnerability notification, SBOM accuracy, and patch support. - A documented [SPDF](/guides/medical-device-cybersecurity-spdf-playbook) ties the procedural QMS world to the engineering reality. - The cybersecurity management plan is reviewed at a stated cadence, with metrics and CAPA triggers. ## First Steps for Startups and Growing MedTech Companies Start before there's a product to ship. Even a pre-seed company can write the cybersecurity management plan, pick the SBOM format, choose the threat modeling methodology, and decide who owns vulnerability triage. None of that requires code. All of it makes the eventual submission and audit dramatically easier. And put it in the QMS from day one - not in a "we'll move it later" folder. The cost of retrofitting cyber into a mature QMS is much higher than building it in from the start. If you're standing up cybersecurity inside your quality system - or repairing a system that's been running parallel - [our team builds and operates exactly this](/services/medtech-compliance-bundle). The standards are published. The FDA guidance is signed. The QMS is where the work actually lives. ## How Blue Goat approaches this Blue Goat Cyber assists MedTech companies in integrating cybersecurity documentation into their QMS. Our methodology focuses on embedding cybersecurity controls within existing QMS processes for design control, risk management, change control, and supplier monitoring. We help create and maintain living documents like threat models, SBOMs, and vulnerability disclosures that evolve with your device. Our team, comprised of experts with credentials such as CISSP and OSCP, including former military red team members, understands both the technical nuances of cybersecurity and the regulatory demands of the medical device industry. We ensure your documentation satisfies the FDA's expectations for continuous lifecycle management, moving beyond static submissions to dynamic, controlled evidence. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to build a defensible and verifiable cybersecurity posture, aligned with current regulations. Learn more about our specialized support for FDA submissions: [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### Why does cybersecurity documentation need to be managed inside the QMS? Because it has to be controlled, versioned, and maintained across the full device lifecycle. The QMS already provides change control, design controls, supplier oversight, and CAPA - the exact mechanisms cybersecurity documentation needs. Keeping it outside the QMS creates two parallel realities that won't survive an FDA audit or a postmarket incident. ### What cybersecurity documents does the FDA expect manufacturers to create and maintain? At minimum: a cybersecurity risk assessment, threat model, security architecture, SBOM, VEX, cybersecurity management plan, penetration test reports, secure development procedures (SPDF), supplier cybersecurity assessments, postmarket monitoring records, and a patch/update plan. ### Which cybersecurity documents are most often created too late? The cybersecurity management plan, the VEX, and supplier cybersecurity assessments. Teams produce the SBOM and a threat model for submission, then discover at deficiency-letter time that the lifecycle documents are missing. ### What product or software changes should trigger a cybersecurity review? Any change to architecture, trust boundaries, data flows, external interfaces, third-party components (including library version bumps), cryptographic implementations, authentication, or update mechanisms. The change control workflow should force the question for every release. ### How should cybersecurity risk connect to product risk management? They belong in the same risk file. Security risks can create safety risks, and safety controls can depend on security controls. Splitting them produces inconsistent mitigations and gaps the FDA will flag. ### What cybersecurity activities continue after the device is on the market? SBOM/VEX monitoring, coordinated vulnerability disclosure, 524B event reporting, patching on a defined cadence, threat model reassessment as the landscape changes, and ongoing updates to cybersecurity labeling and customer guidance. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## IVD Cybersecurity: Result Integrity Risk and FDA Evidence Source: https://bluegoatcyber.com/blog/cybersecurity-risk-with-ivd-medical-devices # IVD Cybersecurity: Result Integrity Risk and FDA Evidence > **[DIRECT ANSWER]** In vitro diagnostics carry a risk therapeutic devices do not: a quiet, undetected change to a result. IVD cybersecurity work has to protect the LIS/middleware interface, the analyzer's often-legacy operating system, remote service access, and calibration and QC data, because compromise there produces a wrong answer a clinician trusts rather than an obvious outage. The February 3, 2026 FDA final guidance expects evidence for each of these paths, and IVD submissions get more reviewer scrutiny on interface and interoperability security than most therapeutic devices do. An infusion pump that fails usually fails loudly: an alarm, a stopped delivery, a clinician at the bedside. An analyzer that has been tampered with can keep printing results all day, and every one of them can be wrong. That is the risk profile that makes IVD cybersecurity different, and it is why a generic device security checklist misses the parts that actually matter for a lab. The instrument, the middleware translating its output, and the LIS receiving it form one chain, and an attacker only needs one weak link to change a number nobody double-checks. ## Key Takeaways - Result integrity, not confidentiality, is the primary patient-safety concern for IVD cybersecurity. - The LIS/middleware interface and its HL7 or ASTM messaging are a distinct attack surface from the analyzer itself. - Many analyzers still run on legacy Windows builds the manufacturer cannot freely patch without revalidation. - Remote service and support access is often the least monitored path into an analyzer fleet. - Calibration and QC data need integrity controls, not just access controls, because a plausible but false QC pass hides a real problem. - IVD submissions draw more scrutiny on interoperability and interface security than most therapeutic device submissions. ## Why This Matters The FDA's final guidance *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026, is the latest step in a chain that started with the September 2023 premarket guidance and continued through the June 2025 update. It applies to IVDs as cyber devices under Section 524B the same way it applies to therapeutic devices, but the harm story reviewers expect you to tell is different. For a therapeutic device the question is usually "can this device be made to do something harmful." For an IVD the question is "can this device be made to report something false while looking normal." That distinction matters because a false result travels. A manipulated glucose value, a corrupted culture result, or a silently degraded assay can drive a clinical decision long before anyone suspects the instrument. Under eSTAR v7.0, effective June 1, 2026, cybersecurity documentation now lives in a single cybersecurity attachment area rather than scattered across the submission, which makes it easier for reviewers to compare your threat model against the specific integrity failure modes an IVD presents. AAMI SW96 (recognized as 13-131), TIR57 (13-83), and TIR97 (13-112) all apply, but SW96's expectation that you model the data path end to end is the one IVD manufacturers most often shortchange. ## What makes IVD cybersecurity different from therapeutic device cybersecurity? The primary harm is misdiagnosis from a corrupted or manipulated result, not device malfunction in the traditional sense. An IVD can be fully "working" from an uptime perspective while producing results that no longer reflect the specimen. That makes silent, low-severity-looking tampering more dangerous than a visible crash, because nothing prompts anyone to stop trusting the output. This changes what a threat model should prioritize. A therapeutic device threat model weighs availability and direct harm from device action heavily. An IVD threat model has to weigh integrity of data at rest, in transit across the LIS interface, and in the reported result, because that is where clinical decisions actually happen. ## How does the LIS and middleware interface create risk? The interface between the analyzer, the middleware, and the laboratory information system is a distinct attack surface that many IVD security reviews treat as someone else's problem. HL7 and ASTM messaging were designed for interoperability, not for authentication or integrity assurance, and most implementations still accept messages with no cryptographic signing. Middleware often runs with elevated privileges to translate and route results, which makes it an attractive pivot point. | Interface layer | Typical exposure | Consequence if compromised | | --- | --- | --- | | Analyzer to middleware | Unauthenticated serial or LAN connection | Result altered before it reaches the LIS | | Middleware | Shared service accounts, broad database access | Bulk result manipulation across many patients | | Middleware to LIS (HL7/ASTM) | Unsigned, unencrypted messages | Result substitution or replay in transit | | LIS to EHR | Trusted internal feed, minimal revalidation | False result accepted into the chart with no flag | > **[KEY REQUIREMENT]** If your device sends results through middleware you do not control, your threat model still has to name that middleware as a trust boundary and document what happens if it is compromised, because the FDA reviewer will ask. Manufacturers who only threat-model the analyzer and treat the LIS interface as "out of scope" leave the most exploitable part of the chain undocumented. Our [HL7 interoperability post](/blog/hl7-navigating-the-complexities-of-healthcare-data-exchange) covers the messaging-layer detail this section only summarizes. ## Why does the analyzer's operating system matter so much? Many analyzers run embedded Windows builds that were current at design freeze and are now years past mainstream support, and that gap is a direct route to compromise. Analyzer software is validated against a specific OS build, so patching it is not a routine IT task, it is a change that can require revalidation of the assay performance itself. That tension is why so many fielded analyzers are still running Windows 7 or early Windows 10 embedded images with no realistic patch path. The practical answer is not "patch faster." It is compensating controls: network isolation of the analyzer, strict allow-listing of what can talk to it, disabling unused services and ports, and a documented plan for the OS end-of-support date that does not assume the vendor will keep issuing security patches forever. Our [Windows vs Linux security comparison](/blog/linux-vs-windows-a-security-comparison) and [legacy device cybersecurity risk post](/blog/cybersecurity-risks-of-legacy-medical-devices-in-hospitals) go deeper on managing an OS you cannot freely update. ## What risk does instrument service and remote support create? Remote service and support access is the least monitored entry point into most analyzer fleets, and it is usually the path an attacker would prefer over the assay software itself. Field service engineers, third-party support vendors, and manufacturer remote diagnostics tools all typically get elevated access to troubleshoot instruments, and that access frequently uses shared credentials that outlive employee turnover. A remote session with diagnostic-level privileges can also alter calibration values or QC configuration without leaving an obvious trace. Every remote access path needs individual, revocable credentials, session logging, and a defined scope of what the tool can touch. VPN or remote-access tooling that predates the device's current threat model should be revisited, not grandfathered in because it has "always worked that way." ## How does calibration and QC data integrity fit into cybersecurity? Calibration and QC data integrity is a cybersecurity control, not just a lab process, because a manipulated QC pass hides exactly the failure QC exists to catch. If an attacker can alter calibration coefficients or force a QC result to read as passing, every patient result downstream inherits that false confidence. This is the scenario that most resembles a supply-chain attack on trust rather than a data breach. Manufacturers should apply integrity controls, such as cryptographic signing or tamper-evident logging, to calibration records and QC results with the same seriousness given to patient result data. Access to modify calibration parameters should require a distinct, audited privilege level separate from routine operator access. ## What do lab accreditation bodies expect that the FDA doesn't ask about directly? CAP and CLIA accreditation expectations focus on the lab's operational controls, not the device's design, and manufacturers need to support both. CAP checklist items expect documented access control, audit trails, and change management for laboratory information systems, and those expectations extend to how the analyzer and middleware are configured in the field. A device that is technically FDA-cleared but ships with default credentials or no audit logging puts the lab's accreditation at risk even though it passed premarket review. Manufacturers should provide labs with configuration guidance that maps directly to CAP and CLIA audit questions: how to enable logging, how to manage service accounts, and how to document who changed calibration settings and when. ## How does IVD cybersecurity evidence differ in an FDA submission? IVD submissions get more reviewer attention on interoperability and interface security than most therapeutic device submissions, because the primary harm pathway runs through data exchange rather than device action. A therapeutic device submission often centers its cybersecurity evidence on the device's own attack surface. An IVD submission needs equal or greater depth on the analyzer-to-middleware-to-LIS chain, message-level authentication, and what happens when an upstream or downstream system is compromised. Reviewers also expect the SBOM and vulnerability management story to account for third-party middleware and connectivity software the manufacturer may not have written, since that code sits directly in the result path. Treating middleware as a vendor's problem in the submission narrative is a common source of deficiency letters. ## How Blue Goat Cyber Approaches This We start an IVD engagement by mapping the full result path, from specimen to analyzer to middleware to LIS to EHR, before we touch a single test case, because that path defines where a false result could enter undetected. Our team includes people who have worked inside lab environments and understand why calibration data, QC configuration, and service access deserve the same scrutiny as patient data. Testing covers the interfaces most assessments skip: HL7 and ASTM message handling, middleware privilege boundaries, remote service session controls, and the analyzer's OS-level exposure given its actual patch status. For premarket support, we help build the threat model and security architecture views around integrity of the result, not just confidentiality of the record, which is what IVD reviewers are actually evaluating. If the FDA raises cybersecurity deficiencies after our submission work, we resolve them at no additional cost. ## Frequently Asked Questions **Why is result integrity a bigger concern than data breaches for IVD devices?** A data breach exposes information after the fact. A manipulated result changes a clinical decision before anyone knows anything is wrong. An analyzer can keep functioning and printing plausible-looking results while every one of them is false, which makes integrity failures harder to detect and more directly tied to patient harm than confidentiality failures. **Do HL7 and ASTM interfaces need to be included in our threat model even if we don't control the LIS?** Yes. The interface is a trust boundary regardless of who owns the system on the other side of it. Your threat model should document what authentication and integrity checks exist on messages leaving your device and state clearly what happens if the receiving system, or the network between you, is compromised. **Can we keep using an analyzer OS that is past end of support?** You can, but the risk file needs to reflect it honestly, with compensating controls like network isolation and strict access limits standing in for patches you cannot apply without revalidation. You also need a documented plan for what happens when the OS reaches a point where even compensating controls are not enough. **How does remote service access typically get compromised?** Usually through shared or long-lived credentials that were issued to a vendor or field engineer and never individually revoked or rotated. Attackers who obtain one working remote-service credential often get diagnostic-level access that can touch calibration or configuration, not just view data. **Does CAP or CLIA accreditation care about our device's cybersecurity design?** Indirectly but seriously. Accreditation checklists focus on the lab's operational controls, but a device that lacks audit logging, uses default credentials, or cannot support role-based access puts the lab's own accreditation at risk. Manufacturers should give labs configuration documentation that maps to what CAP and CLIA auditors ask for. **How is an IVD 510(k) cybersecurity section different from a therapeutic device's?** The same eSTAR v7.0 cybersecurity attachment area applies to both, but reviewers expect an IVD submission to go deeper on interface and interoperability security, since that is the primary harm pathway. Submissions that focus heavily on the analyzer's own attack surface while treating the LIS interface as out of scope are a common source of additional review questions. ## CTA If your submission's threat model stops at the analyzer and does not follow the result through middleware to the LIS, that gap is likely to surface as a review question rather than after clearance. [Contact us](/contact) to walk through your interface and result-path security before you submit. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Legacy Medical Device Cybersecurity Risks in Hospitals Source: https://bluegoatcyber.com/blog/cybersecurity-risks-of-legacy-medical-devices-in-hospitals # Cybersecurity Risks of Legacy Medical Devices in Hospitals > **[DIRECT ANSWER]** Legacy medical devices - infusion pumps, imaging systems, and monitors running Windows XP/7, unpatched firmware, hard-coded credentials, and unencrypted HL7/DICOM on flat VLANs - are the largest attack surface in most hospitals. The fix is a device inventory tied to CVE/KEV scoring, network segmentation as the primary compensating control, and a 90-day remediation roadmap aligned with FDA postmarket and IMDRF legacy device guidance. What are the cybersecurity risks of legacy medical devices in hospitals? It’s a question more hospital security teams are asking, and not finding easy answers to. Hospitals operate some of the most sophisticated care environments in the world: robotic surgery systems, real-time patient monitoring networks, AI-assisted diagnostics. And underneath all of it, many run Windows XP, long-dated firmware, and network protocols that were never designed to touch the internet. This is not a future problem. Research from Claroty and RunSafe Security documents significant exposure across U.S. hospital networks, and the structural mismatch driving it is straightforward: medical devices are built to last 15 to 20 years, but vendor software support runs three to five. Everything in between is a security gap that grows wider every year. Blue Goat Cyber works directly with medical device manufacturers on FDA cybersecurity compliance and postmarket security programs, and that manufacturer-side work makes the depth of these vulnerabilities plain, often years before they appear on a hospital’s radar. For more on practical manufacturer-side challenges and device lifecycle issues, see our post on [Navigating Cybersecurity Challenges for MedTech Legacy Devices, Blue Goat Cyber](/guides/legacy-medical-device-cybersecurity). By the end of this article, you will know how to identify the specific cybersecurity risks of legacy medical devices on your clinical network, score your most exposed assets, apply immediate compensating controls, and build a realistic 90-day remediation roadmap aligned with FDA and IMDRF guidance. ## Key Takeaways - Device longevity creates security gaps post-vendor support. - Unpatched OS and firmware enable many exploits. - Default credentials and poor segmentation heighten risks. - Attacks cause operational disruptions and patient safety issues. - Complete asset inventory is foundational for risk mitigation. - Segmentation is a highly effective compensating control. ## Why this matters The security posture of hospitals is directly impacted by legacy medical devices that operate on outdated software and firmware components, creating critical vulnerabilities. These devices, designed for longevity exceeding their software support lifecycles, often run on operating systems no longer receiving security patches, exposing them to known exploits. This situation jeopardizes patient data privacy, as breaches can lead to unauthorized access to sensitive health information. More critically, compromised devices can disrupt clinical operations, impede patient care delivery, and even directly endanger patient safety through device malfunction or manipulation. The FDA's February 3, 2026 final guidance underscores that **cybersecurity is patient safety**. Adherence to standards like IEC 81001-5-1 and ISO 27001 is essential for managing these risks. Ignoring these vulnerabilities is not merely a compliance issue but a direct threat to the integrity of healthcare delivery. ## Why Legacy Medical Devices Create Outsized Risk on Clinical Networks Legacy devices are not simply unsupported enterprise laptops dropped into a clinical setting. They are fundamentally different, and the risk calculus is different too. You cannot take a cardiac monitor offline to run a security scan the way an IT team can reboot a server at 2 a.m. Clinical criticality and security maintenance are in direct tension, and that tension has no clean resolution in most hospital environments. ### The Lifecycle Mismatch That Nobody Planned For The structural problem is straightforward. Devices are designed to last 15 to 20 years. Vendors support the underlying software for three to five. Hospitals use them for everything in between. The result: clinical equipment running unsupported OS versions, firmware that hasn’t received a security update in years, and legacy communication protocols originally designed for air-gapped environments now sitting on connected clinical networks. According to Claroty’s 2023 State of CPS Security Report, 14% of medical devices in U.S. hospitals run an unsupported or end-of-life operating system while actively connected to clinical networks, and 53% of networked devices carry at least one known critical vulnerability. The cybersecurity risks of legacy medical devices in hospitals are, in large part, a direct product of this mismatch. ### What “End of Support” Actually Means for Your Network End-of-support does not mean the device stops working. It means no more security patches, no vulnerability advisories, and no vendor-supplied fixes. Any exploit discovered after that date stays open indefinitely. There is no patch coming. **Every day a device stays on your network after end-of-support, the exposure window grows.** Attackers actively scan for these devices. They know exactly which CVEs apply to which unsupported platforms, and they use that knowledge. ## What Risks Do Legacy Medical Devices Pose? The Specific Vulnerabilities Once you understand the structural problem, you need to know what you are actually looking for when you audit your environment. The vulnerabilities in aging medical equipment fall into a few consistent categories, and they compound each other. ### Unpatched Operating Systems and Outdated Firmware Legacy commercial OS versions, Windows 7, Windows XP, and embedded variants, remain common in clinical environments across imaging systems, patient monitors, and infusion management platforms. The Contec CMS8000 patient monitor case makes the stakes concrete. In January 2025, the FDA issued an alert revealing a backdoor in the device’s firmware that allowed unauthorized remote access and patient data exfiltration. According to the FDA advisory, the backdoor had been present for over 13 years, undetected. The agency’s published mitigation required disabling networking functions, not a patch restoring full capability, but a control that limited further exposure. These devices are currently deployed in U.S. hospitals. This is not a hypothetical scenario. See the [FDA safety communication on Contec and Epsimed patient monitors](https://www.fda.gov/medical-devices/safety-communications/cybersecurity-vulnerabilities-certain-patient-monitors-contec-and-epsimed-fda-safety-communication) for details. ### Default Credentials, Insecure Protocols, and Poor Segmentation Twenty-one percent of connected medical devices still use default or weak credentials (Claroty, 2023). Layer in legacy communication protocols never designed for networked environments, minimal authentication requirements, and flat network architectures, and you have a direct path from an internet-facing entry point to clinical equipment. **Ninety-nine percent of hospitals are managing Internet of Medical Things (IoMT) devices with at least one known exploited vulnerability listed on CISA’s KEV catalog.** That figure is not a projection. It is the documented current state, and it illustrates precisely what risks legacy medical devices pose on any connected clinical network. Recent analyses of exploited vulnerabilities in hospital networks provide additional context on how widespread active exploitation has become; see reporting on known exploited vulnerabilities in hospital networks. ## What Happens When These Vulnerabilities Get Exploited The technical vulnerabilities are real. So are the outcomes when they get exploited. Consider three documented cases before moving to the patient-level implications, these illustrate where theoretical risk becomes operational harm. ### Operational Disruptions Hospitals Have Reported RunSafe Security’s 2025 survey of 605 healthcare executives found that 22% of organizations experienced a medical device cyberattack in the past year, and 75% of those attacks directly affected patient care. Among organizations that reported device downtime, 43% experienced one to four hours of unavailability, while 7% faced more than three days offline, forcing manual backup procedures that carry their own patient care risks. WannaCry in 2017 infected over 1,200 diagnostic devices and forced five UK hospital emergency departments to close. The CommonSpirit Health ransomware attack in 2022 pushed 140 hospitals to paper charting for over a month at an estimated cost of $160 million. Los Angeles-area incidents involving diagnostic equipment failures triggered ambulance rerouting, a direct operational consequence of compromised aging medical equipment. ### Patient Safety Implications the Data Reveals Beyond operational disruptions, the documented clinical risks include altered data displayed on patient monitors, inaccurate readings on implanted devices, and denial-of-service conditions that crash devices mid-use. The FDA’s 2025 alert on the Contec CMS8000 specifically cited risks of device crashes, data corruption, and unauthorized access to patient PHI. A 2022 FBI report documented vulnerabilities in unpatched insulin pumps, pacemakers, and defibrillators with potential for inaccurate readings and health endangerment. Regulators, including the FDA, IMDRF, and the FBI, treat these as patient safety risks, not just IT incidents, even where specific documented patient-harm cases remain limited in public reporting. **That framing matters when you are making the case for resource allocation and board-level attention.** ## How to Identify and Rank Your Highest-Risk Assets You cannot fix what you cannot see. Most hospitals are working from incomplete, outdated, or siloed asset inventories. That is the first problem to solve, and it has to be solved before any controls are worth deploying. ### Starting with a Complete Clinical Device Inventory A useful asset inventory captures device type, manufacturer, OS and firmware version, network connectivity, end-of-support date, and clinical criticality. Automated network discovery tools purpose-built for healthcare environments close gaps that manual methods miss. Claroty’s research suggests a meaningful share of hospital devices go untracked at any given time, a gap that makes compensating controls difficult to deploy consistently. Clinical engineering and IT security need to own this inventory together. When those teams operate in silos, visibility breaks down at exactly the seam between biomedical management and network security, which is precisely where attackers look for gaps. Practical guidance on why and how to inventory medical devices for confident cybersecurity can help operationalize discovery efforts, and our analysis of the [Two Medical Device Cybersecurity Gaps: Dispersed Responsibility and a Scarcity of Asset Inventory, Blue Goat Cyber](/blog/how-can-medical-device-manufacturers-support-operational-cybersecurity) explains the organizational friction that typically undermines those programs. ### A Scoring Approach That Cuts Through the Noise Once your inventory exists, prioritization needs a clear framework rather than gut instinct or vendor pressure. Score each device on three dimensions: known exploitability (is there a public CVE or active KEV?), network exposure (is the device internet-accessible or on a flat network?), and clinical criticality (what happens to patient care if this device goes down?). Devices that score high on all three get attention first, regardless of replacement cost or vendor relationship. A mid-tier imaging system running an unsupported OS on a flat network with a public CVE ranks ahead of a newer device with no known vulnerabilities. The score drives the priority, not the price tag. ## Compensating Controls That Reduce Exposure Without Replacing Devices Most hospitals cannot replace legacy devices on short notice. Budget cycles, clinical dependencies, and procurement timelines make immediate replacement unrealistic. Compensating controls are the practical middle ground, and they work when implemented with discipline and layering. ### Network Segmentation and Isolation Segmentation is the single highest-impact control for legacy device risk. Isolating clinical devices in dedicated VLANs, blocking unnecessary outbound traffic, and applying micro-segmentation for the highest-risk assets directly limits an attacker’s ability to move laterally from an initial entry point to critical equipment. Virtual segmentation approaches are less disruptive than physical network redesigns and can be deployed in weeks rather than months. Both FDA guidance and the IMDRF N70 framework_0.pdf) explicitly endorse network segmentation as a primary compensating control for devices that cannot be patched, making this approach well-documented for regulatory purposes. ### Virtual Patching, Monitoring, and Access Controls Virtual patching via WAFs or protocol proxies blocks known exploits at the network layer without touching the device itself. Passive monitoring tools built specifically for medical IoT, not generic SIEM platforms, provide behavioral baselines and anomaly detection tuned for clinical device traffic. Access controls, including role-based access, credential rotation, and removal of remote access where it is not clinically required, address the default credential problem directly. No single control is sufficient. These measures work through layering, and each layer needs documentation to satisfy internal audit and regulatory review. ## A 90-Day Roadmap Aligned with FDA and IMDRF Guidance Neither the FDA nor IMDRF mandates immediate replacement of legacy devices. What they do expect is documented risk assessments, active compensating controls, transparent communication with device manufacturers, and ongoing monitoring. The IMDRF N70 framework establishes clear roles for both manufacturers and healthcare delivery organizations at each lifecycle stage, including post-end-of-support. Hospitals operating legacy devices are expected to demonstrate active risk management, not passive tolerance. ### Steps to Execute in the Next 90 Days Structure your response in three phases. In days one through 30, begin automated discovery of your clinical asset inventory and prioritize identification of every device carrying an active KEV from CISA’s catalog, recognizing that a complete picture may develop iteratively as discovery tools surface previously untracked assets. In days 31 through 60, implement network segmentation for your highest-risk assets, enable passive monitoring on clinical network segments, and formally document initial compensating controls. In days 61 through 90, initiate direct manufacturer conversations about risk-sharing and available mitigations, identify devices for replacement prioritization based on your scoring model, and finalize your compensating control documentation in a format that supports both internal review and regulatory interaction. Blue Goat Cyber works directly with device makers on legacy security remediation and postmarket compliance programs. That manufacturer-side experience can accelerate conversations considerably, particularly when a hospital needs technical documentation or risk-sharing agreements that manufacturers are not proactively providing. For practical guidance on how manufacturers can support operational cybersecurity, see [How Can Medical Device Manufacturers Support Operational Cybersecurity?, Blue Goat Cyber](/blog/how-can-medical-device-manufacturers-support-operational-cybersecurity). ## The Cybersecurity Risks of Legacy Medical Devices Are on Your Network Today The cybersecurity risks of legacy medical devices in hospitals are not abstract. They are on your network right now, carrying known vulnerabilities, and in many cases lacking any path to a vendor-supplied fix. That is the reality most hospital security teams are managing, even if the full scope is not yet visible in their asset data. The path forward does not require a full replacement budget or a multi-year transformation. It requires honest visibility, disciplined prioritization, layered compensating controls, and a documented plan that regulators and auditors can evaluate. Virtual segmentation and virtual patching can be deployed in weeks. Full remediation and procurement timelines run longer, but meaningful progress is achievable in 90 days with the right focus. If your hospital needs to engage device manufacturers on legacy security posture or postmarket compliance, Blue Goat Cyber can help. The work sits at the intersection of FDA cybersecurity requirements and real-world device security, exactly where these conversations need to happen. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat approaches this Blue Goat Cyber addresses legacy medical device cybersecurity by focusing on pragmatic risk reduction and compliance. Our approach begins with a thorough asset inventory and vulnerability assessment, identifying critical exposures. We employ threat modeling to understand potential attack vectors unique to older systems and develop targeted compensating controls. Unlike general cybersecurity firms, our team has direct experience with medical device ecosystems, including clinicians, former military red team operators (OSCP & CISSP certified), and regulatory experts. We specialize in developing and implementing risk mitigation strategies that extend the secure operational life of devices without requiring immediate replacement. We work directly with manufacturers on postmarket security programs, often identifying vulnerabilities long before they impact hospitals. Our services, including penetration testing and risk assessments, are tailored to meet FDA requirements. We excel in generating actionable remediation roadmaps that align with current regulatory expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our postmarket services at: /services/fda-postmarket-cybersecurity-services. ## FAQ ### What makes legacy medical devices risky? Legacy medical devices become risky when their vendor software support ends, leaving them without security updates for critical vulnerabilities. This gap allows attackers to exploit known weaknesses, potentially compromising patient care and data. ### How does the FDA view legacy medical device risks? The FDA views cybersecurity risks in legacy medical devices as significant patient safety concerns, not just IT problems. Their February 3, 2026 final guidance provides recommendations for manufacturers and healthcare organizations to manage these risks. ### Can unsupported devices remain on a clinical network? Yes, but with significant caveats. If an unsupported device cannot be replaced, hospitals must implement strong compensating controls like network segmentation, virtual patching, and enhanced monitoring to reduce its exposure to threats. ### What are common vulnerabilities in legacy devices? Common vulnerabilities include unpatched operating systems, outdated firmware, default or weak credentials, and insecure communication protocols. These issues provide attackers with multiple entry points into clinical networks. ### How can hospitals identify their riskiest devices? Hospitals should conduct a complete clinical device inventory. Then, score each device based on known exploitability, network exposure, and clinical criticality to prioritize remediation efforts effectively. ### Does network segmentation help legacy device security? Yes, network segmentation is a highly effective control. Isolating legacy devices on dedicated VLANs and blocking unnecessary traffic limits an attacker's ability to move laterally, significantly reducing risk. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## RTOS Security for Medical Devices: A Practical Guide Source: https://bluegoatcyber.com/blog/cybersecurity-with-rtos # RTOS Security for Medical Devices: What Manufacturers Must Control > **[DIRECT ANSWER]** RTOS security means controlling a platform that was designed for deterministic timing, not for isolating untrusted code. Most real-time operating systems run tasks in a flat, shared memory space with no default user/kernel separation, so a single vulnerable task can compromise the whole device. Securing an RTOS-based medical device requires layered controls: MPU-based task isolation, secure boot with signed images, a minimized network stack, and an SBOM that tracks the RTOS and middleware versions in use. _Reviewed September 17, 2026_ Infusion pumps, ventilators, cardiac monitors, and surgical robotics almost all run on a real-time operating system rather than a general-purpose one, and that choice carries security tradeoffs most teams do not plan for until a reviewer or a penetration tester finds them. An RTOS is built to guarantee timing, not to contain a compromised process the way Linux or Windows attempts to. That difference shapes the entire threat model: the network stack, the bootloader, and the debug interface are not incidental attack surface, they are often the only real perimeter the device has. Manufacturers that treat RTOS security as an afterthought to functional safety tend to discover the gap during FDA review or, worse, in the field. ## Key Takeaways - Most RTOS deployments run in a flat memory space with no default process isolation, so a single compromised task can affect the entire device. - The real attack surface is the network stack, bootloader, debug interfaces, OTA update path, and third-party middleware, not the RTOS scheduler itself. - MPU/MMU task isolation, secure boot, a hardware root of trust, and a minimized network stack are the core technical controls available today. - RTOS and middleware versions must appear in the SBOM, and vulnerability monitoring has to track them by name and version, not just the application layer. - Field patchability is limited on many RTOS platforms, which makes the update mechanism itself a design decision, not an afterthought. - The FDA expects the RTOS and its configuration documented as part of the SPDF, with evidence that its specific risks were assessed, not just the application layer. ## Why This Matters An RTOS-level flaw sits underneath every application-layer control a manufacturer builds, which means a single unpatched stack vulnerability or an unsecured bootloader can undo years of otherwise solid secure development work. The FDA's "Cybersecurity in Medical Devices" final guidance, dated February 3, 2026, expects manufacturers to document cybersecurity risk management across the full software bill of materials, and an RTOS with its middleware is one of the largest single components in that bill for most embedded devices. Reviewers increasingly ask specifically how a device manages RTOS and middleware vulnerabilities post-market, not just at clearance. The CISA 2026 SBOM Minimum Elements, which supersede the 2021 NTIA baseline, expect component-level identification precise enough to track an RTOS version and its included middleware individually. A device that lists only "firmware v2.3" without breaking out the underlying RTOS and network stack version does not meet that bar. Getting RTOS security right is also a practical necessity: many of these platforms cannot be patched in the field as easily as a general-purpose OS, so the design decisions made before release determine most of the device's exposure for its entire service life. ## What Is an RTOS and Why Do Medical Devices Use One? An RTOS is an operating system built to guarantee that tasks execute within a predictable, bounded time window rather than simply as fast as possible. Medical devices use one because a ventilator's breath cycle or an infusion pump's dosing loop cannot tolerate the scheduling jitter of a general-purpose OS under load. RTOS platforms also offer a small footprint, often a few hundred kilobytes, which suits resource-constrained microcontrollers where a full operating system would not fit. ## Which RTOS Platforms Are Common in Medtech? FreeRTOS, Zephyr, VxWorks, QNX, and ThreadX (now Azure RTOS) cover most of the market, with embedded Linux running PREEMPT_RT as the contrasting choice when soft real-time is acceptable. FreeRTOS and Zephyr are widely used open source options on microcontroller-class hardware. VxWorks and QNX are commercial platforms common in higher-complexity devices like imaging and surgical systems. Embedded Linux with the PREEMPT_RT patch set trades some determinism guarantees for a fuller feature set, mature process isolation, and a larger ecosystem of security tooling. ## Why Does RTOS Security Differ From General-Purpose OS Security? RTOS security differs because most RTOS configurations were designed around cooperative trust, not adversarial isolation. Many deployments run every task in a single flat memory space with no kernel/user separation, so there is no default boundary preventing one compromised task from reading or corrupting another task's memory. Address space layout randomization is limited or absent on many RTOS builds, and field patchability is constrained by hardware update mechanisms, so vulnerabilities can persist for the device's service life once shipped. | Property | Typical RTOS | General-Purpose OS (Linux/Windows) | |---|---|---| | Memory model | Often flat, shared address space | Virtual memory with process isolation | | User/kernel separation | Frequently absent by default | Enforced by design | | ASLR | Limited or unavailable on many builds | Standard on modern versions | | Patch cadence | Constrained by field update mechanism | Regular vendor patch cycles | | Footprint | Small, minimal services | Large, many background services | ## What Is the Real Attack Surface on an RTOS-Based Device? The real attack surface is the network stack, the bootloader, debug interfaces, the OTA update path, and any third-party middleware bundled with the RTOS. Embedded TCP/IP stacks have historically been a recurring source of vulnerability classes affecting multiple RTOS platforms at once, since many devices license or bundle the same third-party network stack. Bootloaders and debug interfaces such as JTAG or SWD are frequent targets because physical or early-boot access can bypass every control that only activates after the operating system finishes loading. OTA update mechanisms are attack surface too, since an update path that does not verify signatures is a direct path to arbitrary code execution. **[KEY REQUIREMENT]** Every third-party network stack, middleware component, and bootloader used with the RTOS needs its own entry in the risk assessment and its own line in the SBOM, not a single blanket entry for "RTOS." ## What Controls Actually Reduce RTOS Risk? The core control set is task isolation, secure boot, a hardware root of trust, and network stack minimization, layered together rather than relied on individually. Where the microcontroller supports it, an MPU or MMU can enforce memory boundaries between tasks even on an RTOS that does not do so by default. Secure boot with cryptographically signed images, backed by a hardware root of trust such as a secure element or a TrustZone-style enclave, prevents unsigned or tampered firmware from executing. Memory-safe coding practices, stack canaries, watchdog timers, disabling unused network services, and shrinking the network stack to only the protocols the device actually needs all reduce the paths available to an attacker. ## How Should SBOM and Vulnerability Monitoring Work for an RTOS? The RTOS itself, its version, and every middleware component bundled with it must appear in the SBOM as identifiable, versioned entries. A device team monitoring only its own application code for vulnerabilities while treating the RTOS as an opaque black box will miss disclosures against the stack it is actually running. Vulnerability monitoring has to match SBOM component names and versions against public advisories on an ongoing basis, and that matching only works if the SBOM was specific about which RTOS build and which network stack version shipped. ## What Does a Realistic Patching Strategy Look Like? A realistic patching strategy accounts for the fact that many RTOS-based devices cannot receive updates as fluidly as a phone or a server. Field constraints, bandwidth, connectivity, safety interlocks that block updates during active use, and hardware without a rollback partition all limit how quickly a patch can reach a deployed device. Manufacturers need to design the OTA mechanism, including signature verification and a rollback path, before release, because retrofitting a secure update mechanism into fielded hardware is far harder than building it in from the start. ## What Does the FDA Expect Documented for RTOS Security? The FDA expects the RTOS, its configuration, and its associated middleware documented as identified components within the SPDF, with evidence that their specific risks were assessed rather than folded into a generic application-level threat model. That documentation should show which isolation, boot integrity, and network-minimization controls were applied and why, tied to the SBOM entries for the RTOS and its components. Reviewers also look for a postmarket monitoring and patching plan that acknowledges the RTOS's specific field-update constraints rather than assuming updates work the same way they would on a general-purpose OS. ## RTOS Security Capability Comparison The table below compares security-relevant capability areas at a general level; specific platform configurations vary by vendor, release, and how a manufacturer integrates the RTOS, so this is a framework for evaluation rather than a ranking. | Capability Area | What to Evaluate | |---|---| | Task/process isolation | Whether the platform supports MPU/MMU-backed memory protection and whether the manufacturer's configuration actually enables it | | Secure boot support | Whether the platform and hardware combination supports signed image verification and a hardware root of trust | | Update mechanism | Whether OTA updates are signed, support rollback, and were designed in rather than added after release | | SBOM maturity | Whether the RTOS and its bundled middleware are individually identifiable by name and version for SBOM and vulnerability tracking | ## How Blue Goat Cyber Approaches This Blue Goat Cyber evaluates RTOS-based devices by mapping the actual attack surface, network stack, bootloader, debug interfaces, and update path, rather than treating the RTOS as a single opaque component. Our [medical device threat modeling](/services/medical-device-threat-modeling) work identifies which middleware and network stack components are bundled with the RTOS so they can be assessed and tracked individually. We also support [SBOM services for medtech](/services/fda-compliant-sbom-services-for-medtech) so the RTOS and its components are captured with the version-level specificity the CISA 2026 minimum elements expect. When testing is warranted, our [medical device penetration testing](/services/medical-device-penetration-testing) engagements probe the boot chain, update path, and exposed services specific to the platform in use. ## Frequently Asked Questions ### Is FreeRTOS secure enough for a medical device? FreeRTOS can be used securely, but security depends entirely on the manufacturer's configuration, not the kernel alone. Task isolation, secure boot, and network stack minimization have to be added and configured by the integrator, since the base kernel does not enforce them by default. ### Why don't RTOS platforms have ASLR like Linux or Windows? Many RTOS platforms run in a flat, deterministic memory layout specifically because address randomization can interfere with the timing guarantees the RTOS exists to provide. Some newer RTOS and hardware combinations add partial mitigations, but broad ASLR support is not standard across the category. ### What is the difference between RTOS security and functional safety? Functional safety addresses unintended failures like a stuck sensor or a timing fault, while RTOS security addresses intentional, adversarial actions like a network attacker exploiting a stack vulnerability. The two overlap in practice, since a security failure can trigger a safety hazard, but they require different analysis methods. ### Do I need an MPU to secure an RTOS-based device? An MPU is one of the most effective controls available for containing a compromised task on a microcontroller-class device, so it should be used wherever the hardware supports it. Without an MPU, task isolation typically has to rely on software discipline alone, which is a weaker control. ### How does embedded Linux with PREEMPT_RT compare to a traditional RTOS for security? Embedded Linux with PREEMPT_RT offers more mature process isolation, ASLR, and a larger security tooling ecosystem than most traditional RTOS platforms, at the cost of a larger footprint and softer real-time guarantees. It is a reasonable choice when hard real-time determinism is not strictly required. ### What should go in the SBOM for an RTOS-based device? The SBOM should list the RTOS itself by name and version, along with every bundled middleware component such as the network stack, file system, and any third-party libraries, each with its own version identifier. A single combined "firmware" entry is not sufficient for vulnerability monitoring or FDA review. ## CTA If your device runs on an RTOS and your SBOM still lists it as a single opaque firmware entry, that gap is worth closing before an FDA reviewer or an attacker finds it first. [Contact us](/contact) to scope a threat model and SBOM review built around your specific RTOS and middleware stack. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## DAST vs Penetration Testing for FDA Submissions Source: https://bluegoatcyber.com/blog/dast-vs-penetration-testing-fda-medical-devices # DAST vs Penetration Testing: What the FDA Actually Requires in 2026 > **[DIRECT ANSWER]** DAST is automated scanning of a running interface and is only one input to the penetration testing the FDA expects. The February 3, 2026 guidance asks for scoped, threat-model-driven testing on production-equivalent hardware with findings traced to risk, so a scanner report alone draws a deficiency. _Published June 11, 2026_ ## Key Takeaways - DAST ⊂ penetration testing. The FDA's Feb 3, 2026 final guidance lists penetration testing as a distinct deliverable alongside vulnerability scanning, SAST, and SBOM analysis, not as an alias for any of them. - ESTAR v7.0 Slot 7 (Testing) expects evidence of all four, plus traceability back to the threat model and a named independent tester. - DAST covers a narrow slice: HTTP/API endpoints, common web vulnerabilities, and some network services. It misses BLE pairing, USB-OTG, JTAG/UART, firmware downgrade, protocol fuzzing of DICOM/HL7/FHIR, and business-logic abuse. - "We ran Burp" is the single most common Testing-section deficiency we see on connected device submissions. - A compliant Testing package combines DAST + SAST + SBOM/CVE analysis + an independent penetration test report, all traced to the threat model. ## Why this matters The FDA's February 3, 2026 final guidance, _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_, codifies what reviewers expect inside the Testing portion of a premarket submission. Section 524B of the FD&C Act made penetration testing a statutory companion to the broader Secure Product Development Framework (SPDF) for any "cyber device." The practical consequence: when a reviewer opens eSTAR v7.0 Slot 7 and finds a single automated scan report, they issue a deficiency. Across the deficiency letters we have reviewed since the September 2023 final guidance (now superseded by the Feb 3, 2026 final), "Provide evidence that testing exercised the device's actual interfaces, including [BLE / USB / firmware update / radio]" is one of the most repeated phrases. The recognized standards stack, AAMI SW96:2023, AAMI TIR57:2016 (R2023), IEC 81001-5-1, and NIST SP 800-218, all treat dynamic scanning and penetration testing as distinct activities with different rigor and independence requirements. ## What is DAST, precisely? DAST, Dynamic Application Security Testing, is **automated runtime scanning of running interfaces**, performed without access to source code. In medical device cybersecurity, that almost always means: - Crawling and probing HTTP and HTTPS endpoints on a cloud back-end, clinician console, or device-hosted web UI - Testing REST, GraphQL, and SOAP APIs for the OWASP API Security Top 10 - Some network service probing (open ports, TLS configuration, weak ciphers) - Limited unauthenticated and authenticated scanning of common web vulnerabilities (injection, XSS, SSRF, misconfiguration, outdated components) Common DAST tools in this space include **Burp Suite Professional**, **OWASP ZAP**, **Acunetix**, **Invicti (Netsparker)**, and **Nuclei**. These tools are valuable. They are not penetration tests. DAST is **automated, signature-and-heuristic driven, and scoped to interfaces a scanner can reach over a network**. That definition is the entire reason it cannot satisfy the FDA's penetration-testing expectation by itself. ## What the FDA expects in eSTAR Slot 7 The Feb 3, 2026 final guidance enumerates the categories of security testing reviewers expect inside the Testing attachment. The list is consistent with the recognized standards stack and is broader than any single tool. > **[FDA LANGUAGE]** The submission should include security testing documentation that demonstrates the cybersecurity of the device, including (but not limited to) **vulnerability testing, penetration testing, SBOM analysis, software composition analysis, static application security testing (SAST), and dynamic application security testing (DAST)**, with results traced to the threat model and architecture views. In eSTAR v7.0, those activities are filed inside Slot 7 (Cybersecurity | Testing). The reviewer is looking for: 1. **A SAST report**, source-code-level static analysis covering the first-party code base. 2. **A DAST report**, runtime scanning of every network-reachable interface. 3. **SBOM + CVE + VEX analysis**, known-vulnerability triage against the components in Slot 5. 4. **An independent penetration test report**, methodology-driven manual testing, scoped to the threat model in Slot 3, exercising hardware, radio, firmware, and business-logic attack paths the scanners cannot reach. 5. **A traceability matrix**, every threat in the Slot 3 threat model mapped to the test(s) that exercised it and the residual-risk argument from Slot 4. Missing any of those four reports, or presenting one as a substitute for another, is a deficiency pattern reviewers know on sight. ## Where DAST stops and penetration testing begins The cleanest way to see the gap is a side-by-side. The left column is what DAST covers well. The right column is what only a human-led penetration test covers, and what FDA reviewers actively look for on a connected medical device. | Attack surface / technique | DAST | Independent penetration test | | --- | --- | --- | | Web app and API vulnerabilities (OWASP Top 10, API Top 10) | ✅ Strong | ✅ Verified and extended manually | | TLS configuration, weak ciphers, expired certs | ✅ | ✅ | | BLE pairing, GATT enumeration, link-layer attacks | ❌ | ✅ Required for any Bluetooth device | | USB-OTG, USB service modes, mass-storage abuse | ❌ | ✅ | | JTAG / SWD / UART / SPI flash extraction | ❌ | ✅ Required for firmware-bearing devices | | Firmware downgrade, rollback, signature bypass | ❌ | ✅ Section 524B(b)(1) patchability evidence | | Cellular, NFC, MedRadio, Wi-Fi protocol attacks | ❌ | ✅ | | DICOM, HL7 v2, FHIR, ASTM protocol fuzzing | ⚠️ Only generic HTTP fuzzing | ✅ Medical-protocol-aware fuzzers | | Business-logic abuse (workflow chaining, role escalation) | ⚠️ Very limited | ✅ | | Physical tamper, side-channel, fault injection | ❌ | ✅ Where threat model requires | | Multi-step exploit chains across interfaces | ❌ | ✅ | | Independence and accountability for the report | ⚠️ Tool output | ✅ Named tester signs the report | DAST is a single instrument. A penetration test is the engagement that uses DAST output as one of its inputs, and then keeps testing. ## Why "we ran Burp Suite" fails reviewer scrutiny We see this exact submission pattern at least monthly: a sponsor places an auto-generated Burp Suite or ZAP HTML report into Slot 7, sometimes lightly edited, and calls it the penetration test. Reviewers reject it for three concrete reasons. **1. Scope-to-interface failure.** The Feb 2026 guidance requires testing scoped to the device's actual interfaces. A DAST tool cannot reach BLE, USB, JTAG, or firmware. A Bluetooth-connected device whose only test evidence is a web scan has, by definition, not been tested across its threat surface. **2. Independence and accountability failure.** A tool report has no qualified tester. The recognized standards (AAMI SW96:2023 §6, IEC 81001-5-1 §9.7) expect a named, independent assessor with documented qualifications. A PDF exported from Burp does not satisfy that. **3. Threat-model traceability failure.** Every threat in the Slot 3 model needs a corresponding test result. Scanner output is organized by URL, not by threat. Without a manual traceability matrix, reviewers cannot confirm coverage, and "cannot confirm" is a deficiency. The deficiency letter that follows is usually a Major Deficiency on a PMA or De Novo, or an Additional Information (AI) request on a 510(k). Either way, the clock either stops or restarts. The cost in calendar time alone, typically 4 to 12 weeks of remediation, often more, vastly exceeds the cost of doing the penetration test correctly up front. ## What a compliant Testing package looks like A Slot 7 package that passes review on first read contains, at minimum: - **SAST report** with rule set, scope (modules covered), suppression rationale for each finding marked not-applicable, and a remediation log. - **DAST report** covering every network-reachable interface, cloud APIs, mobile back-end, device-hosted UI, with authenticated and unauthenticated runs. - **SBOM-driven vulnerability analysis** correlating the Slot 5 SBOM against NVD, CISA KEV, and EPSS, with **VEX statements** for every applicable CVE (`not_affected`, `under_investigation`, `affected`, `fixed`). - **Independent penetration test report** from a third party with documented medical-device experience, scoped to the Slot 3 threat model, covering every interface the device exposes, network, radio, USB, debug ports, firmware update, and hardware where the threat model requires. - **Traceability matrix** that maps each threat → test(s) performed → finding(s) → residual-risk argument, in one auditable thread. That is the package the Feb 2026 guidance describes when read end-to-end. Anything thinner is an avoidable deficiency. ## How Blue Goat Cyber approaches Slot 7 Our medical-device penetration test always layers DAST inside a broader engagement led by a named, independent tester (CISSP / OSCP / ex-military red team). Automated scanning runs as one workstream, in parallel with manual web and API testing, BLE/RF testing on a calibrated bench, USB and JTAG/UART exercises, firmware extraction and downgrade testing, and protocol fuzzing against DICOM, HL7, FHIR, and BLE GATT services. Every finding is mapped back to the sponsor's threat model and into a traceability matrix the reviewer can read. We deliver the Slot 7 package, SAST summary, DAST report, SBOM/CVE/VEX correlation, and the signed penetration test report, formatted for direct eSTAR upload. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** See our [medical device penetration testing service](/services/penetration-testing) and our companion guide on [scoping a medical device penetration test](/blog/scoping-a-medical-device-penetration-test). ## FAQ ### Is DAST required for an FDA premarket submission? DAST is one of the security-testing categories the FDA's Feb 3, 2026 final guidance lists as expected evidence inside eSTAR v7.0 Slot 7 (Testing). It is required in the sense that reviewers expect to see DAST output for any device with web, API, or network-reachable services. It does not, on its own, satisfy the separate penetration-testing expectation. ### Can DAST replace penetration testing in an FDA submission? No. The Feb 2026 guidance and the recognized standards (AAMI SW96:2023, IEC 81001-5-1) list penetration testing as a distinct activity that must be scoped to the threat model, exercise the device's actual interfaces (including hardware and radio where present), and be performed by a qualified independent tester. DAST is one input to that engagement, not a substitute for it. ### Will the FDA reject our submission if we only run Burp Suite? In practice, yes, connected devices submitted with only a DAST scan in Slot 7 routinely receive a deficiency letter requesting evidence that testing covered the device's actual interfaces. For PMA and De Novo this typically lands as a Major Deficiency; for 510(k) as an Additional Information (AI) request. Either way, the review clock is affected. ### What tools count as DAST for medical device submissions? The FDA does not name specific tools. Reviewers expect industry-recognized DAST tooling. The tools we use and see accepted include Burp Suite Professional, OWASP ZAP, Acunetix, Invicti, and Nuclei. What matters in the report is the scope (which endpoints were tested), the authentication state, the rule set or scan profile, the findings, and the remediation log, not the vendor logo. ### Where does fuzz testing fit between DAST and penetration testing? Protocol fuzzing, especially of medical protocols like DICOM, HL7 v2, FHIR, and BLE GATT, sits inside the penetration test, not inside generic DAST. Standard DAST tools fuzz HTTP parameters; they do not understand medical protocols. Fuzzing of those stacks requires specialized tooling and is part of what a qualified independent tester delivers. ### Does our SaMD need hardware penetration testing too? Pure SaMD with no hardware component does not need bench hardware testing, but it does still need the full DAST + manual web/API/cloud penetration test, plus the responsibility split for the underlying platform. SaMD that ships with a paired hardware accessory or runs on dedicated edge hardware needs the hardware testing too. ## Ready to build a Slot 7 package that passes review? If you are preparing a 510(k), De Novo, or PMA submission for a connected device, we will scope the testing to your threat model, run the full DAST + manual penetration test on a calibrated bench, and deliver a Slot 7 package formatted for direct eSTAR upload, with our deficiency-resolution commitment. [Request a scoping call](/contact). --- _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, ex-military red team. Has led penetration tests on more than 275 FDA-submitted medical devices, including connected implantables, infusion pumps, IVD analyzers, and SaMD platforms. [More on the author](/team/christian-espinosa)._ ## Related reading - [FDA Cybersecurity Testing Requirements Taxonomy](/guides/fda-cybersecurity-testing-requirements-taxonomy) - [The SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [Penetration Test Case Design for Medical Devices](/blog/scoping-a-medical-device-penetration-test) --- ## Data Flow Diagrams for Medical Device Security Source: https://bluegoatcyber.com/blog/data-flow-diagrams-medical-device-cybersecurity # Data Flow Diagrams for Medical Device Cybersecurity > **[DIRECT ANSWER]** A data flow diagram is a structured model built from five elements, external entities, processes, data stores, data flows, and trust boundaries, that shows how data moves through a device ecosystem and where trust changes. It serves as the input to STRIDE threat modeling and underlies the FDA's Security Architecture Views, so submissions built on one consistent DFD avoid the drift that triggers additional information requests. ## Key Takeaways - A DFD is a structured diagram, not a free-form sketch. It uses five well-defined elements: processes, data stores, external entities, data flows, and trust boundaries. - The DFD is the *input* to STRIDE. STRIDE without a DFD is guesswork. - The FDA's Security Architecture Views (global system, multi-patient harm, updateability, security use cases) are different artifacts than a DFD, but every view should be traceable back to one underlying DFD. - DFDs scale by level: Level 0 (context), Level 1 (major processes), Level 2 (decomposed processes). Most submissions need Level 0 and Level 1. - The most common mistake is omitting trust boundaries. Without them, you cannot reason about where authentication, encryption, and integrity controls belong. ## Why this matters The FDA's Feb 3, 2026 final premarket cybersecurity guidance expects a coherent story: a threat model, a security risk assessment, security architecture views, and verification testing that all map to the same underlying system definition. The DFD is that system definition. When teams skip it, the threat model lists threats that have no diagram element to attach to, the architecture views show components the threat model never analyzed, and verification testing exercises interfaces nobody documented. AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023):2016/(R)2023 calls out data flow modeling as a foundation of medical device security risk management. IEC 81001-5-1:2021 requires that security activities be traceable to system architecture. The DFD is the artifact that lets you produce that traceability without re-modeling the system three times. ## What is a data flow diagram in a medical device context? A data flow diagram is a structured model that shows how data moves through your device ecosystem, where it stops, who or what acts on it, and where trust changes. For a connected medical device, the ecosystem typically includes the device itself, a companion mobile or desktop app, cloud APIs, an update server, hospital network connectivity, and identity or key management services. A DFD is not a network diagram, a UML sequence diagram, or a marketing architecture slide. It is an analysis tool. Its job is to make every place data is created, transformed, stored, or transmitted visible, so you can reason about confidentiality, integrity, and availability at each one. ## The five elements of a DFD Every DFD element falls into one of five categories. Using consistent shapes across your team prevents the "what does this box mean?" problem that wrecks reviews. - **External entity** (rectangle): an actor or system outside your trust boundary. A clinician, a patient, a hospital EHR, a third-party analytics platform. - **Process** (circle): a transformation of data. Authenticating a session, validating a command, computing a therapy parameter, signing a telemetry packet. - **Data store** (parallel lines): persistent storage. Device flash, app local storage, cloud database, log files, key material at rest. - **Data flow** (directional arrow): data moving between two elements. Always labeled with what is moving (PHI, commands, firmware images, telemetry). - **Trust boundary** (dashed line): the place where your security assumptions change. Device-to-app over BLE, app-to-cloud over TLS, cloud-to-third-party API, service mode vs production mode. > **[KEY REQUIREMENT]** Every data flow that crosses a trust boundary must have an explicit security control attached: authentication, authorization, encryption, integrity verification, or some combination. Boundaries without controls are the single highest-yield finding in a DFD review. ## DFD vs Security Architecture Views vs threat model These three artifacts get conflated constantly. They are not the same and they are not interchangeable. | Artifact | What it is | What it answers | | --- | --- | --- | | **Data flow diagram** | Structured model of processes, stores, entities, flows, trust boundaries | Where does data live, move, and change trust? | | **Security Architecture Views** (FDA) | Four FDA-defined views: global system, multi-patient harm, updateability/patchability, security use cases | How is the system architected for security, and where does shared infrastructure create scaled risk? | | **Threat model** (e.g., STRIDE) | Per-element threat enumeration with mitigations and residual risk | What can go wrong at each element, and what are we doing about it? | The DFD is the substrate. The architecture views are higher-level abstractions drawn from the same underlying system. The threat model is the analysis layered on top of the DFD. If you maintain only one of these and try to derive the others on the fly, they drift. Maintain the DFD as the source of truth and regenerate the views and threat model from it. For the FDA's four architecture views in detail, see [FDA Security Architecture Views for medical devices](/blog/security-architecture-diagrams-medical-device-cybersecurity). For the threat modeling method, see [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices). ## How to build a DFD for a connected medical device ### Step 1: Define scope in one sentence Write a single sentence describing what is in scope. Example: "The implanted device, its companion mobile app, the cloud telemetry service, the OTA update server, and the clinician programmer." If a component can influence patient safety or handle regulated data, it is in scope until you can justify excluding it. ### Step 2: Draw the Level 0 (context) diagram One process in the middle representing the entire system. External entities around it: patient, clinician, hospital network, third-party services. Label every data flow with what is moving and over what interface. Place trust boundaries between the system and each external entity. ### Step 3: Decompose to Level 1 Expand the single process into the major subsystems: device firmware, companion app, cloud API, update service, key management. Add internal data stores (device flash, app DB, cloud DB, key vault). Add trust boundaries between subsystems where the security assumptions change. ### Step 4: Decompose to Level 2 only where risk is concentrated Most submissions do not need a full Level 2 DFD of every subsystem. Decompose further only where you have safety-critical workflows: therapy command processing, firmware update verification, clinician authentication, remote service access. ### Step 5: Version-control the DFD The DFD must be a living artifact under change control. When you add a new interface, a new third-party dependency, or a new cloud service, the DFD updates first and the downstream threat model and architecture views update next. ## How DFDs feed STRIDE and the FDA submission > **DFD to STRIDE in one step:** Every DFD element type maps to a fixed subset of STRIDE categories. Walk the diagram element by element, apply the categories below, and you have a first-pass threat model with no guesswork. External entities get Spoofing and Repudiation. Processes get all six. Data stores get Tampering, Repudiation, Information disclosure, and Denial of service. Data flows get Tampering, Information disclosure, and Denial of service. Trust boundaries tell you which flows need the strongest controls. See [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) for the per-category threat tables. STRIDE walks each DFD element and asks six questions: can it be spoofed, tampered with, repudiated, disclosed, denied, or elevated? The mapping is deterministic: | DFD element | STRIDE categories that apply | | --- | --- | | External entity | Spoofing, Repudiation | | Process | All six (S, T, R, I, D, E) | | Data store | Tampering, Repudiation, Information disclosure, Denial of service | | Data flow | Tampering, Information disclosure, Denial of service | That mapping is why STRIDE without a DFD produces a generic threat list. With a DFD, every threat is attached to a specific element, every mitigation is attached to a specific control, and every control is testable. For the FDA submission, the DFD shows up indirectly in several places. The threat model attachment references DFD elements. The security architecture views are higher-level abstractions of the same system. The verification testing plan exercises the interfaces and trust boundaries the DFD identified. The SBOM impact analysis uses the DFD to determine which third-party components are reachable from which trust zones. For how all of this fits the eSTAR v7.0 submission package, see [the FDA's 18 cybersecurity deliverables](/blog/navigating-the-fdas-18-cybersecurity-deliverables-for-medical-device-submissions). ## Common DFD mistakes that trigger FDA questions - **Missing trust boundaries.** The diagram shows components but not where trust changes. Reviewers cannot tell where you authenticate, encrypt, or validate integrity. - **Unlabeled data flows.** "An arrow" is not a data flow. Each arrow needs the data type, the interface, and the direction. - **Treating the cloud as one box.** "Cloud" is not a DFD element. Decompose into API gateway, application servers, database, key store, third-party integrations, and update distribution. - **Forgetting the update path end-to-end.** Build, sign, distribute, verify, install, rollback. Every step is a DFD element with its own threats. - **Service mode invisibility.** Field service tools, debug ports, and manufacturing modes are real interfaces. If they exist, they belong on the DFD. - **No version control.** A DFD that has not been updated since the original submission is a postmarket finding waiting to happen. ## How Blue Goat approaches DFDs We build DFDs as the foundation of every FDA premarket threat modeling engagement, not as a deliverable produced after the fact. Our team includes CISSP and OSCP-credentialed engineers with ex-military red team experience, and we have built DFDs for implantables, wearables, surgical robotics, IVDs, and SaMD across hundreds of FDA submissions. The DFD we deliver is the same artifact our threat modelers, pen testers, and submission reviewers work from, which is what makes the downstream artifacts consistent. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. See our [medical device threat modeling services](/services/medical-device-threat-modeling) for how DFDs fit our engagement model. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to discuss your device architecture and submission timeline. ## FAQ ### What is a data flow diagram for a medical device? A data flow diagram is a structured model of every process, data store, external entity, data flow, and trust boundary in a medical device's ecosystem. It is the foundational artifact for STRIDE threat modeling and for tracing the FDA's Security Architecture Views back to a consistent system definition. ### How is a DFD different from a security architecture view? A DFD is a low-level analysis model showing data movement and trust boundaries. The FDA's Security Architecture Views are higher-level abstractions (global system, multi-patient harm, updateability, security use cases) that describe how the system is architected for security. Both should be traceable to the same underlying system, but they answer different questions. ### Do we need a DFD for an FDA submission? The FDA's Feb 3, 2026 final premarket cybersecurity guidance does not name "DFD" as a required deliverable. However, the threat model, security risk assessment, and architecture views all assume a coherent system definition. A DFD is the simplest way to produce one, and reviewers expect to see that traceability. ### What level of DFD detail does the FDA expect? Most submissions need a Level 0 (context) and Level 1 (major subsystems) DFD. Level 2 decomposition is appropriate for safety-critical workflows like therapy commands, firmware updates, and clinician authentication. Decompose further only where risk is concentrated. ### What tool should we use to draw DFDs? Use any tool your team will maintain: draw.io, Lucidchart, Visio, or a Threat Modeling Tool like OWASP Threat Dragon. The tool matters less than versioning the diagram in source control and updating it before the downstream threat model and architecture views. ### How often should we update the DFD? Update the DFD whenever a new interface, third-party dependency, cloud service, or trust boundary is introduced. Treat it as the source of truth: the threat model and architecture views are regenerated from it, not maintained in parallel. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## De-identification vs Anonymization: HIPAA & GDPR Source: https://bluegoatcyber.com/blog/de-identification-vs-anonymization-medical-devices-hipaa-gdpr # De-identification vs Anonymization for Medical Devices: HIPAA, GDPR & AI Training > **[DIRECT ANSWER]** De-identification removes or masks direct identifiers such as names, SSNs, and MRNs while leaving a residual re-identification risk; it satisfies HIPAA Safe Harbor or Expert Determination and preserves high data utility for clinical research and AI/ML training. Anonymization is a stricter, irreversible transformation where re-identification is not reasonably possible by any means; it is the bar GDPR Recital 26 requires to remove data from privacy-law scope. For medical devices, most cloud telemetry and AI training pipelines are de-identified, not anonymized, which changes what you must disclose to the FDA, to EU regulators, and to patients. Medical device manufacturers routinely ship data off-device: infusion logs to the cloud, imaging studies to a research partner, waveforms to an AI training pipeline. The privacy law that governs that data depends on **how thoroughly the identifiers are stripped**, and the two terms most teams use interchangeably (de-identification and anonymization) mean very different things to HIPAA regulators, EU DPAs, and FDA reviewers. Getting this wrong is expensive. Data you called "anonymized" that a regulator later classifies as "still personal data" pulls your entire cloud pipeline back into GDPR scope, retroactively. And AI training on improperly de-identified data can invalidate the training set your PCCP depends on. This guide covers the legal distinction, the medical-device pitfalls that break naive de-identification, and how to pick the right technique for internal analytics, external research, public release, and model training. ## Key Takeaways - De-identification and anonymization are legally distinct, HIPAA permits the former, GDPR requires the latter to escape privacy-law scope. - HIPAA offers two paths: Safe Harbor (remove 18 identifiers) or Expert Determination (statistical proof of low re-identification risk). - Under GDPR, if re-identification is reasonably possible using any means, the data is still personal data, pseudonymization is not anonymization. - Medical device telemetry (device serials, timestamps, IP addresses, waveform fingerprints) frequently defeats naive de-identification. - For AI/ML training data, the FDA expects documented data provenance and de-identification methodology in a PCCP or premarket submission. - Choose the technique based on downstream use: internal analytics, external research, public release, or model training each carry different risk thresholds. ## Why this matters for medical devices Connected medical devices generate a firehose of data that leaves the device: audit logs, telemetry, imaging, waveforms, event streams, and, increasingly, training data for on-device or cloud AI models. Every one of those flows carries privacy obligations under HIPAA in the US, GDPR in the EU, and increasingly under state laws like CCPA and Washington's My Health My Data Act. The FDA's February 3, 2026 final premarket cybersecurity guidance and its AI/ML PCCP framework both push manufacturers to document data lineage: where training data came from, how it was de-identified, and what residual re-identification risk remains. ANSI/AAMI SW96:2023 similarly expects security risk assessments to consider information disclosure as a harm category. And ISO 14971 requires that any residual risk to patient confidentiality flow through your risk file. Treating "de-identified" and "anonymized" as synonyms hides that risk. Regulators do not. ## What is de-identification under HIPAA? HIPAA defines two paths to de-identify Protected Health Information (PHI). Under **Safe Harbor** (45 CFR § 164.514(b)(2)), a covered entity or business associate removes all 18 specified identifier categories, names, geographic subdivisions smaller than a state, most date elements, phone numbers, SSNs, medical record numbers, device identifiers and serial numbers, IP addresses, biometric identifiers, full-face photos, and any other unique identifying number, characteristic, or code, and has no actual knowledge that the remaining data could identify an individual. The alternative is **Expert Determination** (§ 164.514(b)(1)): a qualified statistician applies accepted principles to conclude that the risk of re-identification is "very small" and documents the methodology. > **[KEY REQUIREMENT]** HIPAA de-identification is a **US regulatory safe harbor**, not a mathematical guarantee. The data is no longer PHI, but a motivated attacker with auxiliary data can still sometimes re-identify individuals. That residual risk is legally acceptable under HIPAA; it may not be under GDPR. Device identifiers and serial numbers are on the Safe Harbor list. That means the device UDI, MAC address, or serial you use to route telemetry in your cloud must be stripped or hashed before the dataset qualifies as de-identified under Safe Harbor. ## What is anonymization under GDPR? GDPR Recital 26 sets a much higher bar. Data is anonymous, and therefore outside GDPR, only if the data subject is not or is **no longer identifiable** by "all the means reasonably likely to be used" by the controller or any other person. The test explicitly accounts for the cost of re-identification, available technology at the time of processing, and technological developments. Two consequences follow. First, **pseudonymization is not anonymization.** Replacing MRNs with random tokens, or hashing device serials with a stored key, still leaves the data as personal data under GDPR, Article 4(5) says so explicitly. Second, the standard is dynamic: a dataset that was anonymous in 2020 may be personal data in 2026 as re-identification techniques and auxiliary datasets improve. The EDPB and most EU DPAs treat true anonymization as a very narrow bar. In practice, most "anonymized" medical device datasets are actually pseudonymized or de-identified, and remain within GDPR scope. ## De-identification vs anonymization: side-by-side | Dimension | De-identification (HIPAA) | Anonymization (GDPR) | | --- | --- | --- | | **Process** | Strip or mask 18 identifier categories (Safe Harbor) or statistical proof of low risk (Expert Determination) | Irreversibly transform so no reasonable means can re-identify | | **Re-identification risk** | "Very small", residual risk accepted | Not reasonably possible by any means | | **Data utility** | High, preserves demographics, dates in year-only form, most clinical detail | Often low, generalization, suppression, or noise degrade utility | | **Reversibility** | Permitted if a re-identification key exists and is separately protected | Not permitted, no key can exist | | **US legal effect** | Data is no longer PHI; HIPAA no longer applies | N/A | | **EU legal effect** | Still personal data, GDPR still applies | Outside GDPR scope | | **Typical use** | Research, AI training, internal analytics, business associate flows | Public dataset release, statistical publication | | **FDA expectation** | Document methodology in premarket submission and PCCP | Same, plus disclose if data crossed EU borders | The single most important row is the last-but-one: **HIPAA de-identified data is not GDPR-anonymous.** If you have EU patients in your dataset, HIPAA Safe Harbor alone does not get you out of GDPR. ## Why medical device data is uniquely hard to de-identify Generic de-identification advice assumes tabular EHR data, remove name, remove MRN, generalize ZIP. Medical device data breaks that model in ways that Safe Harbor checklists miss: - **Device serials and UDIs** are direct identifiers (Safe Harbor category 14). Every telemetry packet keyed by serial number carries a re-identification vector unless the serial is stripped or one-way hashed with a strong salt. - **Timestamps in event logs** can uniquely fingerprint a patient, sleep-apnea CPAP usage patterns, insulin pump bolus timing, or pacemaker interrogation cadence. Truncating to year (Safe Harbor's date rule) destroys most clinical utility. - **Waveform data** (ECG, EEG, PPG) contains biometric identifiers under Safe Harbor category 17. Recent research shows short ECG segments can re-identify individuals against reference datasets with high accuracy. - **DICOM imaging** carries identifiers in header tags (PatientName, PatientID, StudyDate, InstitutionName, sometimes burned into pixel data). Naive de-identification that only handles a subset of DICOM tags leaks PHI. - **IP addresses in device logs** are Safe Harbor category 15, and geolocate to a household. - **Rare conditions** create k-anonymity failures, a single patient in a ZIP with a rare device implant may be unique in the dataset even after identifier removal. A defensible de-identification pipeline for medical devices addresses each of these explicitly, not just the tabular fields. ## What the FDA expects for AI/ML training data The FDA's AI/ML lifecycle guidance and PCCP framework do not mandate a specific de-identification technique, but they do expect you to document: 1. **Data provenance**, where the training and validation data came from, including consent basis and de-identification methodology. 2. **Representativeness**, that de-identification did not distort the demographics or clinical distribution the model must generalize across. 3. **Data lineage into deployment**, whether the deployed model can receive new data that is re-identifiable, and how that data is handled. 4. **Change-control impact**, under a PCCP, if you plan to retrain on new data, the de-identification and consent basis for that future data must be described up front. A submission that describes training data as "anonymized" without evidence of what that means will invite a Submission Issue Request. Precise language, "de-identified per HIPAA Safe Harbor by [method], with a residual re-identification risk of [assessment]", is what reviewers expect. ## Which technique for which use case | Use case | Recommended technique | Why | | --- | --- | --- | | Internal analytics inside your covered-entity boundary | Pseudonymization with access controls | Data stays PHI but is minimized; supports incident investigation | | External research partner (US-only patients) | HIPAA Safe Harbor de-identification + data-use agreement | Removes HIPAA obligations while preserving utility | | Complex research needing dates or geography | HIPAA Expert Determination | Preserves utility Safe Harbor destroys | | AI/ML training data (US) | HIPAA de-identification + documented residual risk assessment | Meets FDA provenance expectations | | AI/ML training data including EU patients | Anonymization or explicit GDPR lawful basis (consent, research exemption) | HIPAA de-ID is not enough for GDPR | | Public dataset release | True anonymization with k-anonymity / differential privacy | Highest bar, assume adversarial re-identification attempts | | Postmarket telemetry to cloud | Pseudonymization with a separately protected key | Preserves ability to investigate device incidents | Match the technique to the downstream use, then document the choice in your risk file and your submission. ## How Blue Goat Cyber approaches de-identification for medical devices We integrate de-identification into the security risk management flow required by ANSI/AAMI SW96:2023 and ISO 14971, not as a separate privacy checkbox. Our team, with CISSP, OSCP, and prior military red-team backgrounds, evaluates the specific device data flows (telemetry, logs, imaging, waveforms) against HIPAA Safe Harbor, HIPAA Expert Determination, and GDPR anonymization criteria, then documents the residual re-identification risk for the [premarket submission](/services/fda-premarket-cybersecurity) and the [PCCP](/blog/pccp-beyond-ai-cybersecurity-firmware-hardware). Our commitment: if the FDA raises cybersecurity or data-handling deficiencies after our submission, we resolve them at no additional cost. ## FAQ **What is the difference between de-identification and anonymization?** De-identification removes or masks direct identifiers but accepts a residual re-identification risk; it satisfies HIPAA. Anonymization is an irreversible transformation where re-identification is not reasonably possible by any means; it is the bar GDPR requires to remove data from privacy-law scope. HIPAA de-identified data is generally still personal data under GDPR. **Is pseudonymization the same as de-identification?** No. Pseudonymization replaces identifiers with tokens while a re-identification key still exists somewhere. Under HIPAA, that data is still PHI. Under GDPR, Article 4(5) explicitly says pseudonymized data is personal data. De-identification under HIPAA Safe Harbor requires that no such key be available to the recipient. **Does HIPAA Safe Harbor apply to medical device telemetry?** Yes, when the covered entity or business associate strips the 18 identifier categories, including device serial numbers, IP addresses, and biometric waveform data. Naive telemetry pipelines that only strip patient names are not Safe Harbor compliant. **Can I use HIPAA-de-identified data to train an AI model for FDA submission?** Yes, and the FDA expects you to document the methodology and residual re-identification risk in your premarket submission or PCCP. Describing the data only as "anonymized" without evidence will likely trigger a Submission Issue Request. **Do I need anonymization or de-identification for postmarket telemetry?** Postmarket telemetry typically uses pseudonymization inside your covered-entity boundary so you can investigate device incidents. Data crossing to a business associate or research partner needs de-identification. Data leaving to a public dataset needs anonymization. **Is de-identified data safe from all re-identification attacks?** No. HIPAA de-identification is a legal safe harbor, not a mathematical guarantee. Auxiliary datasets, waveform biometrics, and rare-condition uniqueness can enable re-identification. Document the residual risk and mitigate it with contracts and access controls. ## Related reading - [ANSI/AAMI SW96 vs TIR57: What FDA expects in 2026](/blog/did-aami-sw96-replace-tir57-fda-2026) - [AI/ML PCCP cybersecurity: what to include](/blog/pccp-beyond-ai-cybersecurity-firmware-hardware) - [FDA Section 524B subsections explained](/blog/fda-section-524b-subsections-explained) - [EU MDR & IVDR cybersecurity guide](/guides/eu-mdr-ivdr-cybersecurity) ## Ready to lock down your data pipeline? Talk to our team about a de-identification and privacy review scoped to your device's actual data flows, telemetry, imaging, and AI training pipelines, mapped to HIPAA, GDPR, and FDA expectations. [Schedule an expert consultation](/contact). --- **Christian Espinosa**, Founder & CEO, Blue Goat Cyber. CISSP, former US Air Force cyber warfare officer. Two decades leading medical device cybersecurity, FDA submissions, and privacy risk assessments for connected health platforms. [More about the author](/leadership). --- ## De Novo Cybersecurity Requirements: What the FDA Expects Source: https://bluegoatcyber.com/blog/de-novo-cybersecurity-requirements # De Novo Cybersecurity Requirements for Novel Medical Devices > **[DIRECT ANSWER]** A De Novo request carries the same cybersecurity documentation obligations as a 510(k) under Section 524B, but with less room to lean on precedent. Because there is no predicate device, you cannot argue that your security approach matches a cleared product, and the special controls the FDA establishes for your new classification may themselves include cybersecurity requirements that then bind every future device in that category. _Reviewed September 17, 2026_ The De Novo pathway exists for devices that are low or moderate risk but have no predicate to compare against. That absence of precedent is the defining feature of the pathway, and it changes how cybersecurity evidence is read. In a 510(k), a reviewer can measure your security approach against what has been cleared before. In a De Novo, there is nothing to measure against except the guidance, the standards, and the quality of your own reasoning. That makes the De Novo a documentation exercise in the truest sense. Every assumption has to be stated, every control has to be justified on its merits, and the risk determination you present may end up shaping the requirements for an entire future device category. ## Key Takeaways - Section 524B applies to De Novo requests exactly as it applies to 510(k)s and PMAs. - No predicate means no precedent argument, so each control must stand on its own rationale. - Special controls created through your De Novo can include cybersecurity requirements that bind later devices. - Novel technology usually means a novel attack surface that no existing guidance describes precisely. - The threat model carries more weight here than in any other pathway. - Interactive review gives you a chance to resolve questions, but only if your documentation is specific enough to discuss. ## Why the Absence of a Predicate Changes Everything Substantial equivalence is the engine of the 510(k) pathway. It lets a manufacturer say, in effect, that their device is as safe and effective as one already on the market. For cybersecurity, that argument has limited force even in a 510(k), because a predicate cleared years ago may have been reviewed under expectations that no longer apply. In a De Novo, the argument is unavailable entirely. What replaces it is the FDA's premarket cybersecurity guidance issued February 3, 2026, together with the recognized consensus standards and your own analysis. A reviewer evaluating a novel device is asking a harder question than whether you match a predecessor: they are asking whether your security approach is appropriate for a technology they may not have reviewed before. This matters because Section 524B of the FD&C Act, added by the Consolidated Appropriations Act, 2023, applies to any submission for a cyber device, and refuse-to-accept enforcement for those requirements began on October 1, 2023. The statute makes no distinction between pathways. What differs is how much interpretive work your submission has to do on the reviewer's behalf. ## The Documentation Set You Must Provide The required elements are consistent across pathways. What changes for a De Novo is the depth of justification each one needs. | Deliverable | What a 510(k) can lean on | What a De Novo must do instead | |---|---|---| | Threat model | Familiar architecture patterns from the predicate family | Derive the attack surface from first principles and explain the method | | SBOM | Common component sets reviewers have seen before | Same format, plus rationale for unusual or novel components | | Security architecture views | Conventional trust boundaries | Show boundaries that may not exist in any cleared device | | Security risk assessment | Established harm patterns for the device type | Establish the harm patterns yourself, tied to ISO 14971 | | Testing evidence | Testing scope typical for the device family | Justify why your scope matches your specific attack surface | | Vulnerability management plan | Industry-standard postmarket process | Same, with a coordinated disclosure path stated explicitly | | Labeling | Security information comparable to peers | Describe assumptions that customers have no prior product to infer | **[KEY REQUIREMENT]** In a De Novo, the method matters as much as the output. State which threat modeling approach you used, which standards you followed, and why that approach fits your device, because the reviewer cannot infer it from a predicate. ## Special Controls and Why They Outlive Your Submission A granted De Novo does two things: it authorizes your device, and it creates a new classification regulation with special controls. Those special controls become the requirements that later devices of the same type must meet, typically through the 510(k) pathway using your device as the predicate. When the FDA establishes special controls for a novel device type with a meaningful cyber footprint, cybersecurity elements can appear among them. That has two consequences worth planning around. First, the controls that end up in the regulation are shaped partly by what you proposed and how well you justified it. A thin security rationale invites the agency to write requirements without your input. A well-reasoned one gives you the opportunity to influence a standard your competitors will later have to meet. Second, whatever is codified applies to you as well. Special controls are not a one-time hurdle cleared at grant; they are ongoing requirements for the device type. A commitment that is easy to write and hard to sustain will follow your product line for years. ## Where Novel Technology Creates Novel Attack Surface De Novo devices are novel by definition, and novel technology frequently brings interfaces that existing guidance does not describe directly. Three patterns come up repeatedly. | Pattern | Security question it raises | What the submission should contain | |---|---|---| | Machine learning in the clinical function | Can inputs be manipulated to change the output? | Threats specific to the model, not just the software around it | | New wireless or physical interface | What does the interface authenticate and trust? | Protocol description, pairing behavior, and failure modes | | Novel data flows to cloud or third parties | Who can read or alter data in transit and at rest? | Full data flow diagram with cryptographic controls named | Machine learning deserves attention because the threats do not fit the traditional categories neatly. A model can be attacked through its inputs, through the data used to update it, or through the pipeline that delivers a new version. A threat model that covers the application hosting the model but says nothing about the model itself is one of the more visible gaps a reviewer can spot in an AI-enabled De Novo. ## Using Interactive Review to Your Advantage De Novo review includes substantive interaction with the review team, and cybersecurity questions are a common subject. The practical value of that interaction depends entirely on how specific your documentation is. A submission that says traffic is encrypted invites a question asking which algorithms, which key sizes, how keys are generated and rotated, and what happens when negotiation fails. A submission that states those details up front turns the same exchange into a discussion about whether the choices are appropriate, which is a much better conversation to be having. Pre-submission meetings are worth using for exactly this reason. A Q-submission that puts your threat model boundaries, testing scope, and architecture views in front of the review team before you file lets you correct a misalignment while it is still cheap to correct. ## Common Reasons De Novo Cybersecurity Sections Draw Questions The deficiency patterns are recognizable and mostly avoidable. | Pattern | Why it happens | How to avoid it | |---|---|---| | Generic threat model | Reused from a template that predates the device | Derive threats from your own architecture and data flows | | Testing scope narrower than the attack surface | Only the software was tested | Test every interface named in the architecture views | | Security claims without cryptographic specifics | Marketing language reached the submission | Name algorithms, key sizes, and key lifecycle | | Cyber risk disconnected from ISO 14971 | Two teams, two documents, no traceability | Trace each threat to a hazardous situation and harm | | Silent environmental assumptions | The team assumed a controlled network | State assumptions in the threat model and the labeling | | No plan for the model or firmware lifecycle | Update path was left for later | Describe how updates are authenticated and deployed | The connection between cyber risk and safety risk is the one that costs the most time when it is missing. Reviewers expect to follow a thread from a threat through the hazardous situation it creates to the patient harm that results, and back to the control that reduces it. When the cybersecurity file and the ISO 14971 file were produced independently, that thread does not exist and the fix is rarely quick. ## How Blue Goat Cyber Approaches This We build De Novo cybersecurity packages from the architecture outward, because there is no predicate to borrow structure from. That means a threat model derived from your actual interfaces and data flows, architecture views that show real trust boundaries, testing scoped to what the views reveal, and traceability into the ISO 14971 risk file so the two tell the same story. For novel devices, our [threat modeling](/services/threat-modeling) work establishes the analysis a reviewer will judge the rest of the submission against, and our [medical device penetration testing](/services/medical-device-penetration-testing) produces evidence scoped to the interfaces your device actually has rather than to a generic checklist. ## Frequently Asked Questions ### Does Section 524B apply to De Novo requests? Yes. Section 524B applies to any submission for a cyber device, which includes De Novo requests, 510(k)s, PMAs, and supplements. Refuse-to-accept enforcement of those requirements began on October 1, 2023. A De Novo request for a device with software and network connectivity must include the vulnerability management plan, the update commitment, and the SBOM the statute requires. ### Is the cybersecurity bar higher for De Novo than for 510(k)? The required elements are the same, but the burden of justification is higher because there is no predicate to compare against. In a 510(k) you can point to how comparable cleared devices handled a control. In a De Novo, each control has to be justified on its own merits against the guidance and recognized standards. ### Can cybersecurity requirements become special controls? Yes. A granted De Novo creates a new classification regulation with special controls that later devices of the same type must meet. For device types with meaningful connectivity, cybersecurity elements can appear among those controls, which means your submission may influence requirements that apply to your competitors and to your own future products. ### Should we request a pre-submission meeting for cybersecurity questions? It is usually worth it, particularly for novel interfaces or AI-enabled functions where guidance does not map cleanly. Putting your threat model scope, architecture views, and planned testing in front of the review team before filing lets you correct misalignment early, when changing course still costs weeks rather than a review cycle. ### How should an AI-enabled De Novo handle model-specific threats? By treating the model as an asset in the threat model rather than as an implementation detail. That means addressing manipulation of inputs, integrity of training and update data, authentication of model updates, and the clinical consequence of a degraded or altered output. A threat model that covers only the surrounding software leaves the novel part of the device unanalyzed. ### What does the FDA do if the cybersecurity documentation is inadequate? For requirements under Section 524B, inadequate content can result in a refuse-to-accept decision before substantive review begins. Once under review, gaps generate deficiency questions that add cycles. Either way the cost is schedule, which is why the documentation is worth getting right before filing rather than after. ## Preparing a De Novo for a Connected Device? Novel devices do not get to borrow anyone else's security rationale. We build the threat model, architecture views and testing evidence that let a reviewer follow your reasoning the first time. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## What are Medical Device De Novo Requests? Source: https://bluegoatcyber.com/blog/de-novo-requests-for-medical-devices-explained # What are Medical Device De Novo Requests? > **[DIRECT ANSWER]** A De Novo request creates a new classification for a low-to-moderate-risk device that has no predicate, converting it into Class I or Class II with special controls other manufacturers can later cite. It is not a shortcut around clearance. Expect a full risk and benefit narrative, clinical or bench evidence supporting the special controls you propose, and, for any cyber device, the complete Section 524B cybersecurity package. _Updated October 26, 2024_ A De Novo Request supports medical device regulation’s classification and approval process. Understanding the basics of a De Novo Request is essential for medical device manufacturers and innovators seeking market access for their new products. This article aims to explain the concept of De Novo Requests, highlight their significance in the FDA clearance process, provide insights into the submission process, evaluate possible outcomes, address challenges and considerations, and discuss the future of [De Novo Requests in FDA regulation](https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request#:~:text=The%20De%20Novo%20request%20provides,no%20legally%20marketed%20predicate%20device.). ## Key Takeaways - De Novo applies to novel devices without a predicate. - The FDA uses De Novo to classify new devices. - It helps bring innovative low-to-moderate risk devices to market. - Careful preparation is vital for successful submission. - The De Novo pathway supports medical technology advancement. - The FDA continues to refine the De Novo process efficiency. ## Why this matters The De Novo Request pathway is pivotal for medical device innovation, enabling novel technologies to reach patients when no existing classification fits. Without it, many groundbreaking devices, particularly those with low to moderate risk profiles and no predicate, would face significant barriers to market entry. This mechanism ensures that such devices undergo appropriate scrutiny for safety and effectiveness without being arbitrarily classified as high-risk Class III devices, which demand more extensive and costly Premarket Approval (PMA) applications. The FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, underscores that cybersecurity is a fundamental aspect of device safety and effectiveness across all classifications, including those established via De Novo. Manufacturers pursuing a De Novo classification must therefore integrate cybersecurity considerations from the earliest design stages, aligning with recognized standards such as IEC 81001-5-1 for health IT safety and security, ISO 14971 for risk management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for medical device security risk management. Neglecting these areas can lead to significant delays or rejection, jeopardizing market access and patient safety. De Novo requests thus serve as a critical bridge, balancing innovation with stringent regulatory oversight, particularly in the evolving landscape of medical device cybersecurity. ## Understanding the Basics of De Novo Request ### Definition of De Novo Request A De Novo Request, also known as a De Novo Classification or Evaluation of Automatic Class III Designation, is a submission to the U.S. Food and Drug Administration (FDA) to classify medical devices that do not have a legally marketed predicate device. In other words, it is a pathway for novel devices that do not fit within the existing classification framework. ![Section Image](/imported-images/48f55844d077148a.png) When a manufacturer believes their new medical device does not have a suitable predicate device to reference for classification, they can opt for the De Novo Request process. This pathway allows the FDA to evaluate the device’s merits and determine the appropriate risk classification and regulatory requirements. ### History and Evolution of De Novo Request The De Novo Request process was introduced under the [FDA Modernization Act of 1997](https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-modernization-act-fdama-1997) to improve the regulatory pathway for new medical devices, particularly those of low to moderate risk. Over the years, the process has evolved, with the FDA striving to streamline and expedite the evaluation of novel devices to facilitate innovation while maintaining patient safety. As technology advances and new types of medical devices emerge, the De Novo Request pathway has become increasingly important in the FDA’s regulatory framework. It serves as a critical mechanism for ensuring timely market access for innovative medical technologies that do not have a predicate for comparison. The De Novo process supports building innovation and improving patient care by providing a clear pathway for evaluating and classifying such devices. ## The Importance of De Novo Request in Medical Device Classification ### Role of De Novo Request in FDA Clearance Process The De Novo Request pathway supports the FDA clearance process by providing a mechanism for the initial classification of new and innovative devices. It allows manufacturers to seek FDA authorization and establish a classification for their devices. It is a foundation for subsequent regulatory activities, such as premarket submissions, quality control, and post-market surveillance. The De Novo Request pathway offers a streamlined approach for devices that do not fit within existing classification categories or lack a predicate device. This flexibility is crucial in addressing the evolving landscape of medical technology, where traditional classification pathways may not adequately capture the unique features of novel devices. By classifying such devices, the De Novo Request pathway promotes regulatory clarity and expedites market access for innovative technologies. ### Impact on Medical Device Innovation The availability of the De Novo Request pathway has significantly impacted medical device innovation. Offering a pathway for devices without a predicate encourages manufacturers to develop and introduce novel technologies, building patient care and treatment advancements. In addition to building innovation, the De Novo Request pathway also promotes competition and market diversity within the medical device industry. By enabling new entrants to bring unique products to market, it prevents monopolies and stimulates a competitive environment that ultimately benefits healthcare providers and patients. This competitive landscape encourages continuous improvement and drives companies to strive for excellence in product development and patient outcomes. ## The Process of Submitting a De Novo Request ### Preparing for a De Novo Submission Submitting a successful De Novo Request requires careful preparation and a thorough understanding of the FDA’s requirements. Manufacturers should conduct research on their device, identifying its unique features, intended use, and potential risks. Gathering clinical data, conducting necessary testing, and ensuring [compliance with relevant regulations](/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization) are essential steps in the preparation process. Manufacturers must establish a clear timeline for the submission process, taking into account internal review procedures and potential revisions based on FDA feedback. Engaging with regulatory consultants or experts in the field can provide valuable insights and guidance throughout the preparation phase, ensuring that the submission meets all necessary criteria for review. ### Components of a De Novo Request A well-constructed De Novo Request includes several key components highlighting the device’s safety, effectiveness, and patient benefits. These components typically include a device description, intended use and indications for use, labeling, risk analysis, clinical data, bench testing results, and a summary of any adverse events observed during studies or trials. Providing a and well-structured submission is crucial to enhance the chances of a favorable outcome. Manufacturers should pay close attention to the formatting and organization of the submission, ensuring that all required sections are clearly labeled and easy to navigate. Providing detailed references and supporting documentation can strengthen the validity of the submission and help reviewers assess the device’s performance more effectively. Manufacturers can increase the likelihood of a successful De Novo Request approval by demonstrating a thorough understanding of the device and its potential impact on patient care. ## Evaluating the Outcome of a De Novo Request ### Possible Outcomes and Their Implications Following the evaluation of a De Novo Request, the FDA can issue one of three outcomes: granting the request and establishing a new device classification, refusing the request, or requesting additional information to make an informed decision. The outcome has significant implications for the manufacturer and the market entry of the device. Positive outcomes can open doors to market access, reimbursement opportunities, and potential partnerships, while negative outcomes may require additional steps or modifications to [address regulatory concerns](/blog). When the FDA grants a De Novo Request, the agency has determined the device to be low to moderate risk and eligible for marketing authorization. This decision validates the manufacturer’s innovation and efforts and paves the way for commercialization in the healthcare landscape. Manufacturers can use this positive outcome to differentiate their products in a competitive market, attract investors, and establish credibility among healthcare providers and patients. ### Understanding FDA’s Decision Criteria The FDA evaluates De Novo Requests based on specific criteria, including the device’s intended use, technological characteristics, safety and effectiveness, patient risks and benefits, and comparison to predicate devices. Manufacturers must address these criteria thoroughly, providing evidence and scientific reasoning to support the request. Familiarizing oneself with the FDA’s decision-making process can guide manufacturers in constructing a compelling De Novo Request. Manufacturers should consider engaging with regulatory consultants or experts who have experience navigating the FDA’s review processes. These professionals can offer valuable insights, help identify potential pitfalls, and assist in developing a strategy to increase the likelihood of a favorable outcome. Manufacturers can enhance their chances of success in the De Novo Request process by proactively addressing the FDA’s decision criteria and seeking expert guidance. ## Challenges and Considerations in De Novo Request Process When navigating the De Novo request process, manufacturers encounter various challenges that require careful consideration and strategic planning. In addition to the common pitfalls mentioned, it is essential to anticipate potential regulatory hurdles and market complexities that could impact the device’s clearance. Manufacturers must also stay informed about the [evolving regulatory landscape](/blog) and be prepared to adapt their submission strategy accordingly. ![Section Image](/imported-images/21a77f472dda5428.png) Furthermore, understanding the competitive landscape and market dynamics is crucial for positioning the device effectively within the industry. Conducting thorough market research and identifying unmet clinical needs can help manufacturers tailor their De Novo request to highlight the device’s unique value proposition and differentiation from existing solutions. ### Common Pitfalls in De Novo Submission Manufacturers should know common pitfalls in the De Novo submission process to avoid unnecessary delays or rejections. Some common challenges include inadequate data supporting the device’s safety or effectiveness, lack of clarity in the intended use and indications, failure to distinguish the device from existing predicates, and incomplete or poorly organized submission materials. ### Strategies for Successful De Novo Request Manufacturers can employ various strategies to increase the likelihood of a successful De Novo Request. These may include involving regulatory experts early in the development process, conducting testing and clinical studies, engaging with the FDA through pre-submission meetings or consultations, addressing the FDA’s decision criteria clearly and concisely, and providing evidence to support the device’s safety and effectiveness claims. ## Future of De Novo Request in FDA Regulation ### Recent Changes and Their Impact In recent years, the FDA has introduced changes to streamline the De Novo Request process and enhance efficiency. These changes aim to reduce the time required for evaluation, improve communication with manufacturers, and facilitate the development of novel medical devices. Understanding these changes and adapting to the evolving regulatory landscape is essential for manufacturers navigating the De Novo Request pathway. One significant change implemented is the introduction of the Pre-Submission Program. This program allows manufacturers to engage with the FDA early in the development process, providing an opportunity for feedback and guidance. Manufacturers can address potential issues by seeking input from the FDA before submitting a De Novo Request and ensuring that their submission meets the requirements. This proactive approach saves time and increases the chances of a successful approval. ### Predicted Trends in De Novo Request Usage The use of De Novo Requests is expected to continue increasing as innovation in medical devices advances. With the growing complexity and diversity of technologies, the De Novo pathway provides a flexible framework for introducing novel devices, ensuring patient access to advanced healthcare solutions. Manufacturers should stay informed about emerging trends and developments in De Novo Requests to remain competitive in the dynamic medical device market. One emerging trend is using artificial intelligence (AI) in medical devices. AI-powered devices have the potential to revolutionize healthcare by improving diagnostic accuracy, enabling personalized treatments, and enhancing patient monitoring. As these innovative AI devices enter the market, manufacturers must navigate the De Novo Request process to ensure compliance with FDA regulations. Understanding how AI fits within the De Novo framework and addressing any unique challenges associated with these devices will be crucial for manufacturers seeking approval. ## De Novo, 510(k), and PMA compared | Pathway | When it applies | What you are arguing | Cybersecurity consequence | | --- | --- | --- | --- | | 510(k) | A legally marketed predicate exists | Substantial equivalence to that predicate | You can point to a comparable device, but the security evidence still has to be your own | | De Novo | No predicate exists and the risk is low to moderate | That general and special controls make the device safe and effective | No predicate to lean on, so the threat model and testing carry the whole argument | | PMA | Class III, highest risk | Reasonable assurance of safety and effectiveness on your own data | The most scrutiny, and postmarket commitments are part of the approval | | Special controls from a De Novo | Applies to every later device of that type | Conformance to the controls the FDA wrote | Your submission can set the security bar competitors must meet | A De Novo has no predicate, so nothing absorbs a weak security file. It is judged on what you put in it. ## Conclusion A De Novo Request with the FDA is an essential mechanism that enables the classification and approval of novel medical devices that do not have a predicate device. Understanding the fundamentals of a De Novo Request, recognizing its significance in the FDA clearance process, and navigating the submission process effectively is vital for manufacturers and innovators in the medical device industry. By embracing the challenges, employing successful strategies, and staying abreast of the evolving regulatory landscape, manufacturers can use the De Novo pathway to promote medical device innovation and improve patient care. As the medical device industry continues to innovate and navigate the complexities of FDA regulations, the importance of cybersecurity measures cannot be overstated. Blue Goat Cyber, a Veteran-Owned business, specializes in medical device cybersecurity, ensuring that your products meet all necessary compliance standards, including HIPAA and FDA regulations. Our expertise in penetration testing and commitment to securing your business makes us an ideal partner in your journey to market. [Contact us today for cybersecurity help](/contact) and safeguard your medical devices against potential threats. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in preparing strong De Novo submissions by focusing on verifiable cybersecurity evidence. Our process begins with an in-depth analysis of the proposed device's cybersecurity architecture and intended use environment. We help identify potential vulnerabilities, assess associated risks, and develop appropriate mitigation strategies in line with the FDA's expectations for novel devices. Our team, comprised of certified professionals like CISSP and OSCP holders, including ex-military red team personnel, specializes in developing rigorous documentation for cybersecurity controls and testing. We guide manufacturers through threat modeling, risk management, and control implementation, producing the necessary materials for a successful De Novo classification. Our goal is to streamline the regulatory process. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at: /services/fda-premarket-cybersecurity-services. ## FAQ ### What is a De Novo Request? A De Novo Request is a pathway for the FDA to classify novel medical devices that have no legally marketed predicate device into Class I or Class II, based on their risk level. This process allows these devices to enter the market. ### When should a manufacturer consider a De Novo Request? Manufacturers should consider a De Novo Request when their medical device is novel and does not fit within an existing classification, meaning there is no predicate device for a 510(k) submission, or if a 510(k) has been deemed Not Substantially Equivalent (NSE). ### How does the De Novo process impact medical device innovation? The De Novo process significantly builds medical device innovation by providing a clear regulatory pathway for novel devices, encouraging manufacturers to develop new technologies, and Ensure patient access to advanced healthcare solutions. ### What information is needed for a De Novo submission? A De Novo submission requires a device description, intended use, indications for use, labeling, detailed risk analysis, clinical data, and bench testing results, all supporting the device's safety and effectiveness. ### What are the possible outcomes of a De Novo Request? The FDA can grant the request, establishing a new device classification; refuse the request; or ask for additional information. A granted request opens opportunities for market access and further development. ### Does the FDA premarket cybersecurity guidance apply to De Novo devices? Yes, all medical devices, including those cleared through the De Novo pathway, must comply with the FDA's February 3, 2026 final guidance on premarket cybersecurity. Cybersecurity is a critical aspect of device safety and effectiveness. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## 5 Medical Device Cybersecurity Myths, Debunked Source: https://bluegoatcyber.com/blog/debunking-the-top-5-medical-device-cybersecurity-myths-holding-back-innovation # Medical Device Cybersecurity Myths: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** FDA clearance does not guarantee a medical device is secure; it only confirms minimum requirements were met. Manufacturers, not just hospitals, remain liable when devices are compromised, hackers target medical devices opportunistically through ransomware, and AI security tools have real limitations. The FDA's February 3, 2026 guidance expects secure-by-design documentation, continuous risk management, and vulnerability assessments that go beyond baseline clearance. Cybersecurity in the medical technology (MedTech) industry is a topic that often creates confusion and misconceptions. Many leaders in the space are uncertain about the actual risks, responsibilities, and best practices associated with securing connected devices and healthcare networks. To help clear the air, we sat down with Christian Espinosa, CEO and Founder of Blue Goat Cyber, at the [MedTech World Asia 2025](https://med-tech.world/singapore-roadshow/ "") conference in Singapore. In a candid “Mythbusters” session with Shara Layton from MedTech World, Christian tackled the biggest cybersecurity myths holding back innovation in the MedTech industry. ## Key Takeaways - FDA clearance does not guarantee cybersecurity for medical devices. - Hackers actively target medical devices, often using ransomware to extort them. - Medical device manufacturers, not just healthcare providers, are responsible for securing their products. - AI-powered security solutions have limitations and risks that must be carefully managed. - Proactively designing security into medical devices can actually accelerate innovation, rather than hinder it. ## Why this matters The stakes for medical device cybersecurity are critically high. Cyberattacks can disrupt patient care, compromise sensitive health data, and even endanger lives through device malfunction or inaccessibility. Regulatory bodies, including the FDA, increasingly emphasize cybersecurity throughout the medical device lifecycle. The FDA "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, mandates that manufacturers establish a secure by design framework, including detailed documentation for premarket submissions. This guidance underscores the necessity of continuous risk management, vulnerability assessments, and incident response planning. Adherence to standards like IEC 60601-1-10 (Medical electrical equipment, Part 1-10: General requirements for basic safety and essential performance, Collateral Standard: Requirements for the development of physiologic closed-loop controllers), ISO 14971 (Medical devices, Application of risk management to medical devices), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management) is not merely good practice but essential for ensuring device safety and market viability. Ignoring these realities poses significant risks to manufacturers, healthcare providers, and patients. ## Myth #1: If It’s FDA Cleared, It Must Be Secure The first myth Christian debunked was the notion that if a medical device is cleared by the FDA, it must be secure from a cybersecurity standpoint. As he explained, “FDA clearance just means you’ve met the minimum requirements for the FDA, but there are still additional things you should do.” In fact, Christian pointed to a [recent case](https://youtu.be/rZoYDXiZCus?si=Oi3wDB8EEhpn2gmg "") where a company “basically falsified their submission to the FDA” for a genetic sequencing device. “They got approved and then a whistleblower came forth to say they falsified the submission and this device…was really not secure at all,” he said. “So there was a false assumption that it’s secure because people can slide things through the FDA to get approved without actually doing the security.” The takeaway is clear: FDA clearance is not a guarantee of cybersecurity. Medical device manufacturers must go above and beyond the minimum regulatory requirements to ensure their products are truly secure. ## Myth #2: Hackers Don’t Target Medical Devices, They’re After Banks The second myth Christian debunked was the idea that hackers aren’t interested in targeting medical devices, and are instead focused on attacking banks and other financial institutions. “Hackers often don’t target anything specifically,” he explained. “They have malicious software that is propagating the internet looking for a vulnerable target. And if the vulnerable target happens to be a medical device, then that device is going to be compromised often with something called ransomware.” The reason medical devices are attractive targets, according to Christian, is that they are often connected to hospital networks, which he described as “a hostile network” that is “always under attack.” Hackers know they can hold these critical devices for ransom, forcing hospitals and patients to pay up in order to regain access and functionality. So the reality is that medical devices are very much in the crosshairs of cybercriminals. Manufacturers and healthcare providers can’t afford to be complacent about security, assuming they won’t be targeted. ## Myth #3: Only Hospitals Need to Worry, Not Device Manufacturers The third myth Christian tackled was the idea that only hospitals need to worry about medical device cybersecurity, not the manufacturers themselves. “Device manufacturers need to worry because if there’s an issue with their device, somebody hacks into let’s say a surgical robot and that robot causes somebody to be paralyzed or kills a patient, who do you think is going to be liable?” he said. “It’s going to be the hospital a little bit, but it will go back to the medical device manufacturer as well.” Beyond the legal liability, Christian also pointed out that compromised devices can severely damage a manufacturer’s brand and business. “It’s not going to be good for their brand if their devices are compromisable, which will hurt their business as well,” he explained. The bottom line is that medical device manufacturers have a critical responsibility to ensure their products are secure. They can’t simply pass the buck to the hospitals and healthcare providers using their technology. ## Myth #4: AI Will Solve Cybersecurity Risks Automatically The fourth myth Christian debunked was the notion that artificial intelligence (AI) will automatically solve cybersecurity risks in the medical technology space. “AI, we like to think it will help with cyber security, but it actually introduces a lot of issues with cyber security,” he said. “The reality is it’s kind of like [AI versus AI](/blog). The people trying to defend their environments utilize AI, but those trying to attack the environments also employ AI. So, it’s basically which group is better at training AI, the attackers or the people producing the product and the people trying to defend their device?” Christian pointed to a real-world example to illustrate the dangers of over-relying on AI in healthcare applications: “There was a case not too long ago where, with a counseling app or therapy app a suicidal patient was getting counseled by the AI chatbot, and at some point the AI chatbot told the patient to go ahead and kill themselves. The patient killed themselves, and now the family is suing that company because we like to think about AI in terms of when it gets things right, but not when it gets things wrong. But in a medical device or healthcare use case, when it gets to something wrong, the consequences can be pretty dire like the one I just mentioned.” The key takeaway is that while AI can be a powerful tool in the fight against cybercrime, it’s not a silver bullet. MedTech leaders must approach AI-powered security solutions with caution and a clear understanding of the risks. ## Myth #5: Cybersecurity Slows Down Innovation The final myth Christian debunked was the idea that cybersecurity slows down innovation in the medical technology industry. “The lack of cybersecurity slows down innovation,” he said. “And that that’s a good myth because people often think that but from our experience when medical device manufacturers don’t consider cyber security and they try to do a submission then it’s slowed down because they have to go try to retroactively add cyber security to their device whereas if they would have designed it in their device at the beginning it would have actually sped up their time to market.” In other words, proactively [building security into the design and development process](/services/secure-medtech-product-design-consulting) can actually accelerate a medical device’s path to market, rather than slowing it down. Trying to bolt on security after the fact is what really creates delays and complications. ## The Path Forward: Awareness, Accountability, and Proactive Security Christian’s myth-busting insights underscore the pressing need for greater awareness, accountability, and proactive security measures in the medical technology industry. As he noted, “I feel like it’s an awareness challenge in Metech.” Too many MedTech leaders are operating under false assumptions about the cybersecurity landscape and their own responsibilities. Raising awareness and educating the industry is a critical first step. But awareness must also be coupled with a clear sense of accountability. Medical device manufacturers can no longer pass the buck to hospitals and healthcare providers. They have a duty to ensure their products are secure, both to protect patients and to safeguard their own brands and businesses. Finally, the key to success is taking a proactive, security-first approach to innovation. As Christian emphasized, “if they would have designed it in their device at the beginning it would have actually sped up their time to market.” Embedding security into the entire product lifecycle, from design to deployment, is the best way to mitigate risks without slowing down progress. To learn more about Blue Goat Cyber’s cybersecurity services for medical device manufacturers, schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session ""). ## How Blue Goat approaches this Our approach to medical device cybersecurity emphasizes proactive integration and compliance assurance. We don't just identify vulnerabilities; we partner with manufacturers to embed security through the entire product development lifecycle, aligning with FDA requirements for premarket submissions. Our team, composed of experts holding certifications like CISSP and OSCP, including ex-military red team personnel, brings a unique blend of offensive and defensive security expertise to anticipate threats and build resilient devices. We conduct thorough threat modeling, penetration testing, and risk assessments tailored specifically for medical devices. Our commitment extends to regulatory success: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We provide strategic guidance and technical execution to ensure your devices meet and exceed regulatory expectations, facilitating a smoother path to market. Explore our premarket cybersecurity services to ensure compliance and strengthen device security. Learn more at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQs ### Does FDA clearance mean a medical device is cyber-secure? No, FDA clearance indicates a device meets minimum regulatory requirements, but it does not guarantee complete cybersecurity. Manufacturers must implement security measures beyond these minimums. ### Do hackers target medical devices? Yes, hackers frequently target medical devices. They exploit vulnerabilities in connected devices, often deploying ransomware, because these devices are critical and connected to healthcare networks. ### Are medical device manufacturers responsible for cybersecurity? Yes, medical device manufacturers bear significant responsibility for the cybersecurity of their products. Liability for security failures can extend to manufacturers, and compromised devices harm their brand and business. ### Can AI solve all medical device cybersecurity risks? AI can assist with cybersecurity, but it does not solve all risks automatically. Attackers also use AI, and erroneous AI decisions in medical contexts can lead to severe consequences. ### Does cybersecurity slow down medical device innovation? A lack of cybersecurity often slows innovation. Integrating security from a product's initial design phase can accelerate time to market, as it avoids retrofitting security measures later. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Design FMEA for Medical Devices: dFMEA Source: https://bluegoatcyber.com/blog/dfmea-medical-devices-iso-14971-cybersecurity # Design FMEA for Medical Devices: dFMEA, ISO 14971 & Cybersecurity > **[DIRECT ANSWER]** A design FMEA (dFMEA) for a connected medical device analyzes failure modes in components, interfaces, algorithms, and communication paths, including cyber-triggered ones like unauthenticated commands or firmware tampering. Each failure mode should link to a hazardous situation and severity rating in the ISO 14971 risk file, share identifiers with the AAMI TIR57 threat model, and trace to a design control verified through V&V testing. _Updated July 4, 2026_ Skipping a rigorous dFMEA is the fastest way to earn a cybersecurity Additional Information (AI) request. Reviewers under Section 524B of the FD&C Act expect a documented line from every remote-exploitable failure mode back to a patient-harm scenario in the ISO 14971 risk file, and forward to a mitigating design control tested during V&V. The dFMEA is where that line starts. When it is missing, incomplete, or disconnected from the threat model, the AAMI TIR57 / ANSI/AAMI SW96:2023 residual-risk table has nothing credible to anchor to, and the submission stalls. This guide walks through how to scope, run, and integrate a dFMEA that satisfies both the safety and cybersecurity halves of a premarket submission. ## Key Takeaways - A dFMEA is a design-level analysis; process-FMEA (pFMEA) and use-FMEA (uFMEA) are separate artifacts with different scopes. - Cyber-triggered failure modes must flow into the ISO 14971 risk file with the same severity scale used for clinical hazards. - AAMI TIR57 / ANSI/AAMI SW96:2023 threat modeling and dFMEA are complementary, dFMEA identifies what can fail, TIR57 identifies who or what makes it fail. - Risk Priority Number (RPN) alone is not a valid acceptance criterion under the Feb 3, 2026 FDA guidance; severity-based thresholds are required. - Every cyber failure mode needs a traceable design control, a V&V test, and a postmarket monitoring plan. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) explicitly ties security risk analysis to the ISO 14971 safety risk file. Reviewers now expect the dFMEA, the AAMI TIR57 / ANSI/AAMI SW96:2023 threat model, and the ISO 14971 hazard analysis to reference the same failure modes with the same severity ratings. FDA's CDRH FY2024 performance report identified cybersecurity as one of the top-three deficiency categories driving 510(k) Additional Information requests. When the dFMEA scores a network failure mode as Severity 2 but the TIR57 threat model scores the same exploit as catastrophic, that inconsistency alone is enough to trigger an AI cycle. ANSI/AAMI SW96:2023 and IEC 81001-5-1 both reinforce this integration: security risk-management activities are expected to feed the same design-controls process as safety risk-management activities. A stand-alone dFMEA that never touches the threat model is a red flag. ## What is a dFMEA and how does it differ from pFMEA and uFMEA? A dFMEA analyzes failure modes inherent to the design itself, components, interfaces, algorithms, and communication paths. It answers the question, "How can this design fail to deliver its intended function?" A pFMEA analyzes manufacturing and assembly processes, and a uFMEA analyzes user-interaction failure modes tied to IEC 62366-1 usability engineering. All three feed the ISO 14971 risk file, but each has a distinct scope and reviewer expectation. | FMEA type | Scope | Primary standard alignment | | --- | --- | --- | | dFMEA | Design components, interfaces, software architecture, wireless stacks | ISO 14971, IEC 62304, AAMI TIR57 / ANSI/AAMI SW96:2023 | | pFMEA | Manufacturing, sterilization, assembly, supply chain | ISO 13485, 21 CFR 820.30 | | uFMEA | User interaction, workflow, human factors | IEC 62366-1, FDA HFE guidance | For a connected device, the dFMEA is the artifact that must include cyber failure modes. ## How does a dFMEA connect to ISO 14971 for medical devices? Every failure mode with a plausible sequence of events leading to patient harm becomes a hazardous situation in the ISO 14971 hazard analysis. The dFMEA severity score and the ISO 14971 harm severity must use the same scale, a common cause of AI letters is a five-point RPN scale in the dFMEA that never reconciles with a three-point severity scale in the risk file. Practically, the dFMEA row identifies the failure mode; the ISO 14971 hazard analysis identifies the harm and the risk control. The design control listed in the risk file must appear in the dFMEA's "current controls" column, and the V&V test that verifies it must be traceable in both. > **[KEY REQUIREMENT]** Under the Feb 3, 2026 FDA guidance, RPN thresholds cannot be the sole acceptance criterion. Any failure mode with Severity ≥ high-harm must have a documented risk control regardless of occurrence or detection scores. ## How do you add cybersecurity failure modes to a dFMEA? Start by enumerating every external interface: wireless stacks (Bluetooth, Wi-Fi, cellular), wired ports (USB, Ethernet), removable media, firmware update channels, cloud APIs, and clinician-facing UIs. For each, add rows covering the CIA triad, confidentiality, integrity, and availability failures. Typical cyber failure modes on a connected device include: - Unauthenticated command injection over the network interface causing therapy delivery outside prescribed parameters - Firmware update tampering causing execution of unsigned code - Denial-of-service on the wireless stack causing loss of alarm annunciation - Credential leakage causing unauthorized clinician-role escalation - Session replay on the cloud API causing duplicate dose delivery Score each with severity anchored to the clinical harm, not the technical impact. A denial-of-service that suppresses an alarm on a life-supporting device is Severity Catastrophic, not Severity Moderate. ## How does dFMEA relate to AAMI TIR57 threat modeling? AAMI TIR57 / ANSI/AAMI SW96:2023 threat modeling is the security-side analog of the dFMEA. Where the dFMEA asks "what can fail," TIR57 asks "what threat actor, using what capability, exploits which asset, to trigger that failure." The two artifacts must share failure-mode identifiers. When the TIR57 threat model documents a spoofing attack against the Bluetooth pairing state machine, the corresponding dFMEA row for "loss of pairing integrity" should reference the same ID. The FDA's Feb 3, 2026 guidance names this bidirectional traceability as an expected element of a premarket cybersecurity submission. If the two artifacts are maintained by separate teams with separate templates, expect an AI request asking for a reconciliation matrix. ## How Blue Goat approaches dFMEA for connected devices Our medical-device cybersecurity engineers, CISSP, OSCP, and ex-military red team backgrounds, run the dFMEA and the AAMI TIR57 / ANSI/AAMI SW96:2023 threat model as a single integrated workshop, not two sequential exercises. We map every cyber failure mode to a specific line item in the ISO 14971 risk file, tie it to a design control, and generate the reviewer-ready traceability matrix as part of our [FDA cybersecurity submission service](/services/fda-cybersecurity-testing). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. That commitment is only credible because the dFMEA-to-threat-model traceability is airtight before the eSTAR goes out the door. ## FAQ ### Is a dFMEA required for FDA clearance of a medical device? The FDA does not name dFMEA in guidance, but 21 CFR 820.30(g) requires design risk analysis, and reviewers expect the analysis to identify failure modes. Most manufacturers use dFMEA as the vehicle. Skipping it forces you to demonstrate an equivalent analysis in some other form, which is almost always more work than doing the dFMEA. ### Can we use the dFMEA severity scale for cybersecurity risks? Yes, and you should. Using a separate scale for cyber risks creates reconciliation gaps that the FDA flags. Anchor both scales to clinical harm, the same S=Catastrophic value should mean the same patient outcome whether the trigger is mechanical wear or a network exploit. ### What is the difference between dFMEA and threat modeling? A dFMEA enumerates what can fail. A threat model enumerates who or what causes those failures and how. AAMI TIR57 / ANSI/AAMI SW96:2023 explicitly positions threat modeling as complementary to safety risk analysis, not a substitute for it. Both are expected in a modern premarket cybersecurity submission. ### Does RPN still matter under the Feb 3, 2026 FDA guidance? RPN is useful for prioritizing engineering effort but is not a valid acceptance criterion by itself. The guidance requires severity-based thresholds, high-severity failure modes need risk controls regardless of occurrence or detection scores. ### How often should the dFMEA be updated? Update the dFMEA whenever the design changes, when postmarket vulnerability intelligence reveals a new failure mode, or when a security patch modifies an interface. Treat it as a living document tied to your change-control process, not a one-time premarket artifact. ## Ready to align your dFMEA with the FDA's cybersecurity expectations? Book a scoping call with our medical-device cybersecurity team. We'll review your current dFMEA, threat model, and ISO 14971 risk file, and show you exactly where the reviewer will push back before you submit. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. --- _Christian Espinosa, Founder & CEO, Blue Goat Cyber (CISSP, MBA, ex-Air Force cyber warfare officer). Christian has led hundreds of medical-device cybersecurity submissions across Class II and Class III devices, and works directly with FDA reviewers on premarket cybersecurity deficiency responses._ --- ## More on this topic - [ISO 14971 and AAMI TIR57 Synergy](/blog/iso-14971-its-crucial-role-in-medical-device-security-and-connection-with-aami-tir57) - [TARA for Medical Devices: FDA Premarket](/blog/tara-medical-device-cybersecurity) --- ## AAMI SW96 vs TIR57: Did SW96 Replace It? Source: https://bluegoatcyber.com/blog/did-aami-sw96-replace-tir57-fda-2026 # Did AAMI SW96 Replace TIR57? What the FDA Expects in 2026 > **[DIRECT ANSWER]** No, ANSI/AAMI SW96:2023 did not formally withdraw AAMI TIR57. But SW96 is now the FDA-recognized normative standard (Recognition #44689) for medical device security risk management, while TIR57 remains an older, informative Technical Information Report. In a 2026 premarket submission you conform to SW96 and cite TIR57 only as supporting methodology. _Last updated: July 2026_ The question comes up in nearly every Section 524B kickoff we run: teams that built their program around AAMI TIR57 want to know whether they need to redo it under SW96. The short answer is that SW96 is now the standard the FDA points to, and citing only TIR57 in a 2026 submission is a common trigger for a cybersecurity deficiency letter. TIR57 was published in 2016 as a Technical Information Report, informative guidance, not a normative standard. ANSI/AAMI SW96 was published in 2023 as a full consensus standard and formally recognized by the FDA. Both documents still exist. Only one carries conformance weight. This post explains the practical difference, what actually changes in your risk file, and how to migrate a TIR57-era program to SW96 without rewriting from scratch. ## Key Takeaways - ANSI/AAMI SW96:2023 is the FDA-recognized normative standard for medical device security risk management; AAMI TIR57 is informative. - SW96 has not formally withdrawn TIR57, both remain published, but reviewers expect SW96 conformance. - The FDA's February 3, 2026 final premarket cybersecurity guidance points to SW96, not TIR57, as the reference standard. - A TIR57-era security risk file usually needs restructuring, not rewriting, to conform to SW96. - TIR97 (postmarket) and IEC 81001-5-1 (lifecycle activities) sit alongside SW96; TIR57 remains useful as methodology background. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* final guidance (February 3, 2026) is now the operative document for 524B submissions. It references ANSI/AAMI SW96:2023 as the consensus standard for security risk management. TIR57 is not called out with the same weight. SW96 was added to the FDA Recognized Consensus Standards Database (Recognition Number 44689) in 2023. A declaration of conformity to SW96 lets you shortcut the reviewer's evaluation of your risk management process. A submission that cites only TIR57 does not get the same treatment, the reviewer has to evaluate your methodology from scratch, and any gaps against SW96 requirements come back as deficiencies. This affects three concrete outcomes: submission review time, the volume of Submission Issue Requests you receive, and the defensibility of your risk file in a postmarket incident. Migrating from TIR57 to SW96 is not a big rewrite, SW96 is largely an evolution of TIR57's principles into normative requirements, but it does need to happen before your next filing. ## What Is the Difference Between SW96 and TIR57? SW96 is a normative standard; TIR57 is informative. That is the single most important distinction. | Attribute | ANSI/AAMI SW96:2023 | AAMI TIR57:2016 | |---|---|---| | Document type | Normative consensus standard | Technical Information Report (informative) | | FDA recognition | Yes (Recognition #44689) | No | | Language | "Shall" (requirements) | "Should" (guidance) | | Conformance possible | Yes, declare in submission | No, cite as reference only | | Primary output | Security risk management file with defined contents | Principles for building one | | Lifecycle scope | Design, production, post-production | Full lifecycle, principles-based | | Alignment | Structured to complement ISO 14971 and IEC 81001-5-1 | Precedes IEC 81001-5-1; overlap with SW96 | SW96 defines *what* the security risk management file must contain and *what* activities the manufacturer must perform. TIR57 explains the *principles* behind those activities. If you have a well-run TIR57 program, most of the content maps forward, the structure and traceability requirements are what tighten up. ## Did AAMI Withdraw TIR57? No. As of mid-2026, TIR57 remains a published AAMI Technical Information Report. It has not been withdrawn or superseded in the way that a revised standard supersedes an older revision. AAMI's rationale is that TIR57 and SW96 serve different roles. TIR57 is educational, it walks a team new to security risk management through the concepts. SW96 is the standard you conform to when you have a program in place and need reviewer-recognized evidence. Practically, most manufacturers now treat TIR57 as background reading and structure their actual deliverables to SW96. That's the pattern the FDA has come to expect. ## What Does the FDA Actually Recognize? The FDA Recognized Consensus Standards Database is the authoritative source. As of this writing: > **[KEY REQUIREMENT]** **ANSI/AAMI SW96:2023**, Recognition Number 44689, *Standard for medical device security, Security risk management for device manufacturers.* Recognized in full. TIR57 is not listed with a current recognition number for security risk management. The 2026 premarket cybersecurity guidance cites SW96 alongside ISO 14971, IEC 81001-5-1, and IEC 62304 as the standards a modern SPDF should be built on. The practical effect: a declaration of conformity to SW96 in your premarket submission triggers the abbreviated review pathway for that portion of your risk file. A citation of TIR57 does not. ## How Do You Migrate a TIR57 Program to SW96? Most TIR57-based programs can be aligned to SW96 in a few structured passes rather than a full rewrite. **Pass 1: Structure the security risk management file.** SW96 defines specific artifacts, security risk management plan, security risk analysis, security risk evaluation, security risk control, residual security risk evaluation, and security risk management report. Reorganize your existing content into these buckets. Most content already exists; it just lives in the wrong files. **Pass 2: Trace to ISO 14971 hazards.** SW96 requires that security risks with safety impact are traced to the ISO 14971 safety risk file. TIR57 encouraged this; SW96 requires it. Add the traceability matrix. **Pass 3: Tighten the threat model.** SW96 expects a threat model with assets, threats, vulnerabilities, and controls, updated on architecture change. If your TIR57 threat model is a static document, convert it to a living artifact with a documented update trigger. **Pass 4: Declare conformity.** Add the SW96 declaration of conformity to your premarket submission cover letter and cybersecurity documentation. Teams typically complete this in 3-6 weeks per product family, not the multi-month rebuild people fear. ## Where Do TIR97 and IEC 81001-5-1 Fit? SW96 covers security risk management. It does not cover everything. The full 2026-ready stack is: - **ANSI/AAMI SW96:2023**, security risk management (conformance) - **IEC 81001-5-1:2021**, health software and health IT systems safety, effectiveness, and security (lifecycle activities) - **ISO 14971:2019**, application of risk management to medical devices (safety linkage) - **IEC 62304:2006/AMD1:2015**, medical device software lifecycle processes - **AAMI TIR97:2019**, principles for medical device security, postmarket risk management - **AAMI TIR57:2016**, retained as methodology reference TIR97 is postmarket-specific and complements SW96's post-production requirements. IEC 81001-5-1 defines the security activities inside your software lifecycle. Together they cover premarket, postmarket, and lifecycle security in a way TIR57 alone never did. For a deeper breakdown, see our [AAMI TIR57 vs TIR97 vs SW96 comparison](/blog/aami-tir57-vs-tir97-vs-sw96-medical-device-cybersecurity) and [SW96 vs TIR57 side-by-side](/compare/aami-sw96-vs-tir57). ## How Blue Goat Cyber Approaches This Our [secure product design engagements](/services/secure-medtech-product-design-consulting) deliver an SW96-conformant security risk management file, an ISO 14971 hazard trace, an SBOM in SPDX or CycloneDX, a living threat model, and postmarket monitoring tied to AAMI TIR97. TIR57 remains in our toolkit as methodology reference, but every deliverable and traceability artifact is structured to what the FDA recognizes today. For teams migrating from a TIR57-era program, we run a fixed-scope gap assessment that maps existing artifacts to SW96 requirements and produces a migration plan sized in weeks, not quarters. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Frequently Asked Questions **Did AAMI SW96 replace TIR57?** No. SW96 was published in 2023 as a new normative standard and TIR57 remains available as an informative Technical Information Report. The FDA now recognizes SW96 as the standard for security risk management, so in practice SW96 has taken TIR57's role in submissions even though TIR57 has not been withdrawn. **Do I need to redo my TIR57-based risk file?** Usually not from scratch. Most TIR57-era content maps forward to SW96 with a structural reorganization, a formal ISO 14971 traceability matrix, and a living threat model. Plan on 3-6 weeks per product family, not a multi-month rebuild. **Can I still cite TIR57 in a 2026 FDA submission?** Yes, as a supporting reference. But your primary declaration of conformity for security risk management should be to ANSI/AAMI SW96:2023. Citing only TIR57 is a common trigger for a Submission Issue Request under the February 2026 premarket cybersecurity guidance. **Is SW96 harmonized internationally?** SW96 is an ANSI-approved AAMI standard used primarily in the US. Internationally, IEC 81001-5-1:2021 covers overlapping ground for health software lifecycle security and is recognized in the EU and other jurisdictions. Most manufacturers cite both. **Where does TIR97 fit relative to SW96?** TIR97 covers postmarket security risk management principles and complements SW96's post-production requirements. SW96 tells you what your postmarket security risk management file must contain; TIR97 explains how to reason about the postmarket phase. Use them together. ## CTA Not sure whether your current risk file will hold up under SW96 in a 2026 submission? [Book a gap assessment](/contact), we'll map your existing artifacts against SW96 requirements and give you a fixed-scope migration plan. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. --- *Christian Espinosa, MBA, CISSP, is Founder and CEO of Blue Goat Cyber. He has led hundreds of FDA premarket cybersecurity engagements and helped medical device teams align their security risk management programs with AAMI SW96, TIR57, TIR97, and IEC 81001-5-1. [Read more from Christian](/christian-espinosa).* --- ## Docker Containers in Medical Devices: FDA Testing Source: https://bluegoatcyber.com/blog/docker-containers-medical-devices-fda-testing # Docker Containers in Medical Devices: What the FDA Expects You to Test > **[DIRECT ANSWER]** Containers show up in medical devices as on-device runtimes, edge gateways, and cloud companion services, and each one has to appear in the SBOM and the security architecture views. The FDA expects base image provenance, vulnerability scanning at build and release, hardened runtime configuration, and update evidence that matches the patch mechanism you claim in the submission. _Published June 11, 2026_ ## Key Takeaways - Containers are in scope whenever they ship in, on, or alongside a cyber device, including SaMD cloud backends, on-device edge inference, hospital-deployed gateway appliances, and update or telemetry sidecars. - Section 524B(b)(3) requires the SBOM to include every image layer, base image, OS package, and language dependency, not just the application code. - The 2026 guidance expects evidence that container hardening controls (non-root, read-only filesystem, dropped capabilities, seccomp/AppArmor) are implemented, not just claimed. - Container escape and registry compromise are the two container-specific attack paths reviewers most often flag as missing from the threat model. - The patch and update mechanism under Section 524B(b)(1) must cover base-image CVE drift, not only application code. ## Why container testing matters for FDA cybersecurity Container-based medical devices look modern to your engineering team and untested to a reviewer. The FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 requires that every third-party component in a cyber device, including base images, language runtimes, and OS packages inside a container, appear in your SBOM with a VEX statement for any known CVE. Reviewers also expect the container *runtime* (Docker, containerd, Podman, Kubernetes) to be part of the threat model, not assumed-safe infrastructure. NIST SP 800-190 is the reference reviewers cite back in deficiency letters, and CIS Docker Benchmark v1.6.0 is the configuration baseline they expect you to test against. The Sysdig 2024 Cloud-Native Security and Usage Report found 87 percent of container images in production carried at least one high or critical vulnerability, exactly the kind of statistic that turns "containers are isolated" into a Section 524B(b)(2)(iii) deficiency. Container evidence belongs in your premarket submission, not your engineering wiki. ## Where containers show up in medical devices Containers rarely sit inside a regulated firmware blob, but they show up in four common places that the FDA considers part of the cyber device: 1. **SaMD cloud backend.** A web or AI/ML inference service that the device or clinician app calls. The container image is part of the device's intended use and part of the submission. 2. **On-device edge inference.** A Docker or OCI runtime on a gateway, kiosk, or imaging workstation that hosts a model server or analytics pipeline. 3. **Hospital-deployed gateway appliance.** A turnkey box (often a hardened Linux distro with Podman or k3s) installed in the hospital network as part of the cleared system. 4. **Build, deploy, and update tooling that ships in the device.** Update agents, telemetry collectors, and remote-management sidecars are often containerized and burned into the device image. If the container is in any of these four places, it is in scope for the cybersecurity submission. The 2026 guidance does not give container-based components a lighter treatment. ## Why the FDA cares about containers Three reasons: - **SBOM completeness.** Containers expand the software bill of materials by an order of magnitude. A 200 MB Python image typically pulls in 300 to 600 OS and language packages on top of the application code. Section 524B(b)(3) requires all of it. - **Attack surface.** Containers introduce attack paths that do not exist for monolithic firmware: image tampering between build and deploy, registry credential leakage, container escape into the host, orchestrator API exposure, and shared-kernel vulnerabilities. - **Patchability under Section 524B(b)(1).** Base images age. A CVE published against `debian:bookworm-slim` after submission still affects every device running that image, and the manufacturer must have a documented mechanism to patch it without disrupting clinical use. ## The six classes of container testing The FDA does not prescribe specific tools, but the 2026 guidance and the deficiency letters we see in practice converge on six testing categories for containerized components. ### 1. Image SBOM generation Generate a CycloneDX 1.5+ or SPDX 2.3+ SBOM for every image that ships, at every layer. Tools like Syft, Trivy, or Docker Scout work. The SBOM must include OS packages (apk, deb, rpm), language packages (PyPI, npm, Maven, Go modules), and any binaries you added with `COPY` or `ADD`. Vendor-supplied base-image SBOMs are acceptable for the base layer only, and only when they are conformant; a Dockerfile is not an SBOM. ### 2. Vulnerability scanning (SCA) Scan the assembled image with Trivy, Grype, Snyk, or an equivalent. Every High or Critical finding belongs in the unresolved-anomalies attachment with a VEX justification (affected, not affected, fixed, under investigation) and a clinical-impact rationale. The FDA expects to see CVEs you decided not to patch, with the reasoning, not a clean scan report that hides them. ### 3. Hardening and configuration testing Evidence that the container is built and run with defensive defaults. CIS Docker Benchmark and the NSA/CISA Kubernetes Hardening Guidance are the de facto references. Reviewers look for: - Non-root `USER` directive in the Dockerfile - Read-only root filesystem at runtime (`--read-only` or `readOnlyRootFilesystem: true`) - Dropped Linux capabilities (`--cap-drop=ALL`, add back only what is needed) - seccomp and AppArmor or SELinux profiles - No `--privileged` flag, no host network, no host PID namespace - Resource limits set (memory, CPU, pids) ### 4. Secrets scanning Run gitleaks, trufflehog, or an equivalent against the image layers and the build context. Baked-in API keys, signing keys, JWT secrets, and database credentials are a recurring deficiency, especially in images built from internal monorepos. ### 5. Runtime DAST against the containerized service Once the container is running, the exposed API or web surface gets the same dynamic security testing as any other web service. ZAP, Burp, or a custom use against the OpenAPI spec. The container boundary does not change what DAST tests, but it does scope the surface: only the ports the container actually exposes. ### 6. Penetration testing scoped to container and orchestrator boundaries This is the test most often missing from submissions. A pen test of a containerized medical device should cover: - **Container escape attempts** against the runtime (runc, containerd, Docker) and the kernel - **Image registry attacks** (anonymous pull, credential reuse, image substitution if pull-by-tag instead of pull-by-digest) - **Orchestrator attacks** if Kubernetes, k3s, or Docker Swarm is in scope (RBAC misconfiguration, exposed API server, service-account token abuse) - **Sidecar and inter-container attacks** if multiple containers share a pod, namespace, or volume - **Supply-chain attacks** on the build pipeline (poisoned base image, malicious dependency, unsigned image) ## Mapping container evidence to eSTAR v7.0 The 2026 guidance reorganized the cybersecurity submission into eight eSTAR attachment categories. Container evidence lands in four of them: | eSTAR attachment | What to include for containers | | --- | --- | | Slot 5: SBOM | One CycloneDX or SPDX file per shipped image, with PURL or CPE identifiers, plus VEX statements for unresolved vulnerabilities | | Slot 6: Security controls | CIS Docker Benchmark results, Dockerfile excerpts showing non-root user and dropped capabilities, runtime policy (seccomp, AppArmor), image-signing evidence (Cosign, Notary v2) | | Slot 7: Testing | SCA scan reports, secrets-scan reports, DAST against the running service, pen-test report covering escape and registry attacks | | Slot 8: Unresolved anomalies and metrics | Every accepted CVE with VEX status, clinical-impact rationale, and the patch-mechanism reference (which ties back to Section 524B(b)(1)) | The threat model (Slot 3) and risk assessment (Slot 4) must independently address container-specific attack paths, not just application-layer threats. ## Deficiency patterns we see on container-heavy submissions Across the deficiency letters our team has reviewed, four container-specific patterns recur: 1. **Incomplete image SBOM.** The submission lists application dependencies but omits the OS packages from the base image. Reviewers can usually tell because the SBOM has 40 components when a `python:3.12-slim` image alone contains over 100. 2. **No hardening evidence.** The threat model claims "containers are hardened" but the submission lacks a Dockerfile excerpt, a CIS Benchmark result, or a runtime security context manifest. 3. **No container escape rationale.** The pen-test report covers the web API but says nothing about whether escape attempts were attempted, scoped out, or deemed not applicable. Reviewers want to see the decision, not silence. 4. **No patch mechanism for base-image CVE drift.** Section 524B(b)(1) requires a documented update mechanism. Submissions often describe how application updates ship but say nothing about how a new base image gets rebuilt, signed, and pushed when a `glibc` or `openssl` CVE drops. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Cyber tests containerized medical devices For sponsors shipping containerized SaMD, edge inference, or gateway appliances, our engagement typically covers: - Image SBOM generation and reconciliation against the vendor build - SCA and VEX triage with clinical-impact framing - CIS Docker Benchmark and runtime-policy review - Secrets scanning across image layers and build context - DAST against the running service in a representative deployment - Penetration testing scoped to container escape, registry, orchestrator, and supply-chain paths - eSTAR attachment package assembly across Slots 3, 4, 5, 6, 7, and 8 The deliverable is the evidence reviewers expect to see, in the format the 2026 guidance expects to see it. ## FAQ **Does the FDA require containers to be tested differently from monolithic firmware?** No, the testing categories are the same (SBOM, controls, vulnerability, DAST, pen test, anomalies). The difference is scope: containers add attack paths (escape, registry, orchestrator) that monolithic firmware does not have, and reviewers expect those paths to appear in the threat model and the pen-test report. **If we use a vendor base image like `python:3.12-slim` or `nvidia/cuda`, do we need to SBOM it ourselves?** You are responsible for the SBOM of the image you ship. A vendor SBOM for the base image is acceptable if it is conformant (CycloneDX 1.5+ or SPDX 2.3+ with NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026)) and represents the exact digest you pulled. Most public registry images do not ship a conformant SBOM, so you regenerate one. **Is Kubernetes in scope for the cybersecurity submission?** If the orchestrator ships as part of the cleared device (for example, k3s on a hospital-deployed appliance), yes. If the orchestrator is part of the customer hospital's IT environment, it is generally out of scope but you still address the interface in the threat model. **Does the FDA require image signing (Cosign, Notary)?** The guidance does not name a specific signing scheme, but it does require evidence of integrity controls on software shipped to the device. Signed images with verified pulls is the standard way to demonstrate this for containerized components. **How do containers affect the patch mechanism under Section 524B(b)(1)?** The mechanism must cover base-image CVE drift, not only application updates. Reviewers want to see how a new base image gets rebuilt, signed, pushed, and rolled out (and rolled back) without disrupting clinical use. **What about WebAssembly, OCI artifacts, or unikernels?** The same logic applies. If it ships in the device and contains software components, it needs an SBOM, controls evidence, testing, and an unresolved-anomalies treatment. The 2026 guidance is technology-neutral. ## About the author **Christian Espinosa, CISSP - Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Documenting Update Cadence for an FDA Submission Source: https://bluegoatcyber.com/blog/documenting-update-cadence-fda-524b-submission # Documenting Update Cadence for an FDA §524B Submission in 2026 > **[DIRECT ANSWER]** Documenting update cadence for FDA Section 524B means describing two separate paths: a reasonably justified regular update cycle for known unacceptable vulnerabilities, and an as-soon-as-possible out-of-cycle path for critical vulnerabilities with uncontrolled risk. Reviewers grade the justification, not just the cadence, so name severity thresholds, decision authority, and timelines consistently across the SPDF narrative, postmarket plan, and labeling. The §524B(b)(2)(B) update cadence requirement is the one most sponsors underdocument. Teams put real engineering work into signed packages, verified boot, and rollback paths, then describe the *cadence* in two vague sentences buried inside the postmarket plan. Reviewers can tell, and the resulting Additional Information letters all read the same way: name the regular cycle, name the out-of-cycle path, justify both. This post walks through what reviewers actually expect to see for each, the wording patterns that satisfy them, and the deficiency patterns that recur when sponsors leave either side ambiguous. ## Key Takeaways - §524B(b)(2)(B) has two halves: a regular update cycle and an out-of-cycle expedited path. The submission must document both, separately. - "Reasonably justified" is the operative phrase for the regular cycle. The justification is what reviewers grade, not the cadence itself. - The out-of-cycle path needs severity triggers (CVSS or equivalent), timeline targets, decision authority, and a customer-communication channel. - Update cadence belongs in the SPDF narrative and the postmarket plan, with a single source of truth and consistent wording across both. - The most common deficiency is naming a cycle without justifying it, or naming a cycle without the out-of-cycle counterpart. ## Why this matters Section 524B(b)(2)(B) is the postmarket-update provision of the cyber device statute, added to the FD&C Act by the Consolidated Appropriations Act, 2023. The FDA's February 3, 2026 final guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," is the operative interpretation. The guidance ties cadence documentation back to AAMI SW96:2023 security risk management, AAMI TIR57:2016/(R)2023 risk management for medical device security, and IEC 81001-5-1:2021 software lifecycle for health software. Reviewers expect cadence statements that reference these standards by name. The FDA's CDRH performance data through FY2024 ([CDRH FY2024 Performance Report](https://www.fda.gov/media/186421/download)) puts cybersecurity among the top three deficiency categories in 510(k) and PMA Additional Information letters. Inside the cybersecurity bucket, the (b)(2)(B) cadence gap is one of the most repeatable patterns: the submission describes update *capability* (signed packages, verified boot) without documenting update *cadence* (when, how often, what triggers expedited). Capability without cadence does not satisfy (b)(2)(B). Both have to be in the submission. ## What §524B(b)(2)(B) Actually Says The text of §524B(b)(2)(B) requires the manufacturer to make available postmarket updates and patches to the device and related systems on a reasonably justified regular cycle to address known unacceptable vulnerabilities, and, as soon as possible out of cycle, to address critical vulnerabilities that could cause uncontrolled risks. Two operative requirements live inside that sentence: - A **regular cycle** that is **reasonably justified** and addresses **known unacceptable vulnerabilities.** - An **out-of-cycle path** that triggers **as soon as possible** for **critical vulnerabilities that could cause uncontrolled risks.** The statute uses different severity language for each path. "Known unacceptable" governs the regular cycle. "Critical" with "uncontrolled risks" governs out-of-cycle. The submission needs to define both severity thresholds in the manufacturer's own risk framework so a reviewer can see which vulnerabilities take which path. ## Where Update Cadence Belongs in the Submission Cadence documentation belongs in three places, with the same wording in each: - The **SPDF (Secure Product Development Framework) narrative** under the section that covers postmarket activities. This is the sponsor-side description of how the cadence is built into the development process. - The **postmarket cybersecurity plan** required by §524B(b)(1). This is the operational description of how cadence runs in the field, with the CVD intake, severity triage, CAPA linkage, and customer communication. - The **labeling** (security documentation provided to the customer), which surfaces the cadence and the expedited path to the operating health-delivery organization (HDO). A single source of truth wins. Pick one document (usually the postmarket plan) as the canonical cadence definition and have the SPDF narrative and the labeling reference it explicitly. Reviewers flag mismatches between the three immediately. ## Documenting the Regular Cycle The regular cycle has three documentation components reviewers look for: - **The cadence itself.** Pick one model and name it: time-based ("quarterly minor releases, semiannual major releases"), severity-driven ("any known unacceptable vulnerability bundled into the next scheduled release within 90 days"), or hybrid ("scheduled quarterly with a 30-day window for known unacceptable findings"). Vagueness ("on a regular basis," "as needed") draws a deficiency. - **The justification.** This is what §524B(b)(2)(B) actually grades. Tie the cadence to the device's risk profile, the deployment model (connected vs. air-gapped), the change-control burden on the customer, and the verification-and-validation cycle. A cardiac implant with an over-the-air channel justifies a different cadence than a benchtop analyzer that requires a service visit. - **The change-control linkage.** Name the design control procedure that governs cadence changes. Cadence is a design decision; if marketing wants to change it next quarter, the change has to flow through design controls, not a side conversation. A reviewer reading the cadence section should be able to answer: *what is the cycle, why is that cycle appropriate for this device, and how does the manufacturer change the cycle if conditions change.* > **[KEY REQUIREMENT]** §524B(b)(2)(B) requires that the regular cycle be "reasonably justified." A cadence statement without a justification paragraph is incomplete on its face, regardless of the cadence itself. ## Documenting the Out-of-Cycle Path The out-of-cycle path has four documentation components: - **Severity triggers.** Define which vulnerabilities take the expedited path. Most manufacturers use CVSS v3.1 base + temporal as a starting point with device-specific environmental adjustments. Name the threshold (e.g., "any vulnerability with adjusted CVSS ≥ 9.0, or any vulnerability that could cause uncontrolled patient harm regardless of CVSS"). - **Timeline targets.** Name the target windows: triage within 24-72 hours, patch development within X days, validation within Y days, customer-available within Z days. The statute says "as soon as possible," which reviewers read as "as soon as possible *for this device class,*" not instantaneously. Document the targets and the engineering basis for them. - **Decision authority.** Name the role (not the person) authorized to declare an out-of-cycle release: typically the Chief Product Security Officer or equivalent, with escalation to the executive sponsor for releases with significant change-control impact. - **Customer communication.** Name the channel: customer security advisory, ICS-CERT/CISA coordination, HSCC notification, direct customer security contact list. The expedited path is useless if customers do not know a patch dropped outside the regular cycle. The out-of-cycle path is where deficiency letters cluster. Sponsors describe a regular cycle in detail and then say "expedited patches will be issued as needed for critical issues," which fails on every one of the four components above. ## Customer Communication of the Cadence Both the regular cycle and the out-of-cycle path have to be visible to the HDO, not just to the sponsor's engineering team. The 2026 guidance expects security documentation provided to the customer (sometimes packaged as an MDS2 supplement or a security white paper) to state: - The regular update cycle and what triggers a release. - The out-of-cycle process and the customer's expected role in deploying expedited patches. - The notification channel the customer should subscribe to. - The expected time between patch availability and the recommendation to deploy. A reviewer who sees a strong internal cadence definition but no customer-facing surface still flags it. The submission has to show that the cadence is operational, not just documented. ## Worked Example: Cadence Statement for a Class II Connected Device A defensible cadence section for a Class II connected patient-monitoring device reads like this (paraphrased structure, not a template to copy verbatim): > **Regular update cycle.** [Device] follows a quarterly minor release and semiannual major release cycle. Known unacceptable vulnerabilities identified through the vulnerability monitoring sources named in [X] of the postmarket plan are bundled into the next scheduled release within 90 days of triage. The cadence is justified by (a) the device's continuous network connectivity, which allows over-the-air delivery without service visits, (b) the medium clinical impact of a typical configuration change, and (c) the customer's [named hospital system tier] change-control workflow, which supports a 90-day deployment window without operational disruption. Cadence changes flow through [named SOP] in the manufacturer's design control system. > > **Out-of-cycle expedited path.** Any vulnerability with adjusted CVSS v3.1 ≥ 9.0, or any vulnerability that a security risk assessment per AAMI SW96:2023 classifies as causing uncontrolled patient harm regardless of CVSS, triggers the expedited path. Triage within 24 hours, patch development within 7 days, V&V within 7 days, customer-available within 21 days, target. Declaration authority is the [named role]. Customers are notified through (a) the [named] customer security advisory list, (b) HSCC channels, and (c) ICS-CERT coordination where appropriate. Communication includes the recommended deployment window for the HDO. That paragraph satisfies (b)(2)(B) because both halves are named, both are justified, and both have operational detail a reviewer can grade. ## Deficiency Patterns Reviewers Flag Recurring deficiency patterns on (b)(2)(B): - **Cadence without justification.** "Quarterly minor releases" with no explanation of why quarterly is appropriate for this device class. - **Out-of-cycle path described as "as needed."** No severity threshold, no timeline targets, no decision authority. - **Customer-facing surface missing.** Internal cadence documented; security documentation provided to the customer does not mention it. - **Mismatch between SPDF and postmarket plan.** Two different cadence definitions across documents because nobody picked a single source of truth. - **No change-control linkage.** Cadence presented as an engineering preference rather than a design-controlled decision. - **Severity language conflated.** The submission uses "critical" and "unacceptable" interchangeably without mapping either to the manufacturer's risk framework. ## How Blue Goat Approaches Cadence Documentation We document update cadence as a single source-of-truth section in the postmarket plan, referenced verbatim from the SPDF narrative and the customer-facing security documentation. The regular cycle gets a named cadence model, a justification tied to the device's risk profile and deployment model, and a change-control linkage. The out-of-cycle path gets severity triggers anchored in CVSS plus AAMI SW96:2023 security risk classification, timeline targets, named decision authority, and customer notification channels. Severity language is mapped explicitly to the manufacturer's risk framework so reviewers can see which vulnerabilities take which path. Our engineers hold CISSP, OSCP, and prior military red-team credentials. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA premarket cybersecurity service](/services/fda-premarket-cybersecurity-services) or read the [§524B subsection-by-subsection walkthrough](/blog/fda-section-524b-subsections-explained). ## FAQ ### What does §524B(b)(2)(B) require for update cadence? Two things: a reasonably justified regular update cycle for known unacceptable vulnerabilities, and an as-soon-as-possible out-of-cycle path for critical vulnerabilities that could cause uncontrolled risks. The submission has to document both separately, with severity thresholds, timeline targets, and the justification for each. ### How often does the regular cycle have to be? The statute does not name a frequency. It names a standard: "reasonably justified." Quarterly is common for connected Class II devices, semiannual is common for devices with heavier customer change-control overhead, and annual is sometimes acceptable for low-risk or air-gapped devices. The cadence has to match the device's risk profile and deployment model, and the justification is what reviewers grade. ### Does "as soon as possible" mean immediately? No. Reviewers read "as soon as possible" as "as soon as possible for this device class given the V&V and deployment realities." A patch that requires safety verification on a Class III implant cannot be released in 48 hours. Document realistic timeline targets and the engineering basis for them. Vague "as soon as possible" with no target draws a deficiency. ### Where does the cadence statement live in the submission? In the SPDF narrative, the §524B(b)(1) postmarket plan, and the security documentation provided to the customer. Pick the postmarket plan as the canonical source and reference it from the other two. Mismatches between documents are an immediate deficiency. ### What severity thresholds should I use for the out-of-cycle path? Most sponsors anchor on CVSS v3.1 base + temporal with device-specific environmental adjustments, plus an explicit override for any vulnerability the security risk assessment under AAMI SW96:2023 classifies as causing uncontrolled patient harm. CVSS alone is not sufficient because it does not capture device-specific patient impact. Both layers belong in the threshold definition. ### Does the customer need to see the cadence? Yes. The 2026 final premarket guidance expects security documentation provided to the customer to surface both the regular cycle and the out-of-cycle process, including the notification channel and the recommended deployment window. A strong internal cadence with no customer-facing surface is incomplete. ## Ready to document update cadence the way reviewers expect? If your cybersecurity section names an update mechanism but does not document cadence with a regular cycle, an out-of-cycle path, severity triggers, and timeline targets, you are leaving §524B(b)(2)(B) deficiency exposure on the table. We can structure the cadence documentation so every reviewer question has a labeled answer. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](/contact). --- **About the author.** Christian Espinosa, Founder, Blue Goat Cyber, CISSP. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, including Section 524B(b)(2)(B) update cadence documentation. [Read more about Christian](/christian-espinosa). --- ## Related on FDA Section 524B - [FDA Section 524B: complete cybersecurity requirements guide](/guides/fda-524b-cybersecurity-requirements-explained) - [Does Section 524B apply to my auto-injector?](/blog/does-fda-section-524b-apply-to-my-auto-injector) - [Does Section 524B apply to legacy devices?](/blog/does-fda-section-524b-apply-to-legacy-medical-devices) - [AI/ML cybersecurity threats under Section 524B](/blog/fda-ai-cybersecurity-threats-524b-medical-devices) --- ## Does FDA 524B Apply to Legacy Medical Devices? Source: https://bluegoatcyber.com/blog/does-fda-section-524b-apply-to-legacy-medical-devices # Does FDA Section 524B Apply to Legacy Medical Devices in 2026? > **[DIRECT ANSWER]** Section 524B attaches to any new premarket submission for a cyber device, including one built on a legacy platform; it is triggered by the submission, not the original clearance date. A Special 510(k) or PMA supplement on an older device pulls in the full 524B package for the changed subsystem. Fielded legacy devices not undergoing a new submission still fall under the FDA's postmarket vulnerability monitoring, patching, and reporting obligations. Legacy device questions about Section 524B keep landing in the same place: a sponsor with a cleared platform from 2015 wants to ship a connectivity update, an AI feature, or a hardware refresh, and the team assumes the original clearance grandfathers the cybersecurity work. It does not. The cyber device statute is keyed to the submission, not to the device's clearance history. The February 3, 2026 final premarket cybersecurity guidance reinforces this reading by treating every new submission for a cyber device as a 524B submission regardless of the platform's age. Sponsors that miss this draw refuse-to-accept (RTA) decisions on submissions they thought would sail through. ## Key Takeaways - Section 524B attaches to the submission, not the device's original clearance date. A new 510(k) on a legacy platform is a 524B submission. - If a legacy device is already on the market and you are not filing a new submission for it, Section 524B does not reach back and force a 524B package on you. The FDA's separate postmarket cybersecurity rules (vulnerability monitoring, patching, and MDR reporting) still apply. - "Special 510(k)" and PMA supplements on legacy cyber devices trigger full 524B content for the changed subsystem and often the platform as a whole. - The PATCH Act covers the same problem space for new devices but leaves fielded legacy devices outside its premarket regime; postmarket obligations fill that gap. - The riskiest assumption is that a pre-2023 clearance grandfathers the cybersecurity work. It does not. ## Why this matters Section 524B took effect on March 29, 2023, and the FDA began issuing refuse-to-accept (RTA) decisions based on 524B on October 1, 2023. The February 3, 2026 final premarket cybersecurity guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," is the operative interpretation reviewers apply. The guidance does not exempt legacy platforms. It applies to any premarket submission for a cyber device, full stop. CDRH performance data through FY2024 shows cybersecurity remains a top deficiency category in 510(k) and PMA Additional Information letters (the FDA's [CDRH FY2024 Performance Report](https://www.fda.gov/media/186421/download) puts cybersecurity behind only software documentation and clinical evidence). Sponsors with legacy platforms are disproportionately represented in those deficiency letters because they assume the original clearance covers them. Standards reviewers expect against the legacy base include AAMI TIR57:2016/(R)2023, AAMI SW96:2023, IEC 81001-5-1:2021, and IEC 62304:2006/A1:2015. None of these standards have a legacy exemption either; the SDLC and security risk management expectations apply to the submission's design baseline, not the device's clearance year. ## What "Legacy" Means in a 524B Context The FDA does not define "legacy device" in 524B itself. The working definition reviewers apply, consistent with the [FDA's 2017 Postmarket Management of Cybersecurity in Medical Devices guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), is a device that is on the market and that the manufacturer can no longer reasonably update with the cybersecurity controls a modern submission would require. The clearance year matters less than the present-day support posture. A 2017-cleared infusion pump that the manufacturer still actively maintains is treated very differently than a 2017-cleared pump that the manufacturer stopped patching in 2021. For 524B purposes, the only question that matters is whether a new premarket submission is in the pipeline. If yes, 524B attaches. If no, the device falls under the FDA's postmarket authorities instead. ## When Section 524B Attaches to a Legacy Device Section 524B(a) attaches its requirements to any person who submits an application or submission described in section 510(k), 513, 515(c), 515(f), or 520(m) of the FD&C Act. In practice that means 510(k), De Novo, PMA, PMA supplement, PDP, and HDE submissions. The statute is keyed to the submission, not to the device's first clearance. If you are filing any of these submission types for a cyber device, 524B attaches, regardless of how old the underlying platform is. The most common triggers on legacy platforms are: - A Special 510(k) for a software or connectivity change to a previously cleared device. - A Traditional 510(k) for a hardware refresh that retains the legacy software architecture. - A PMA supplement adding an AI/ML feature, a new connectivity interface, or a cloud backend. - A PMA supplement or 510(k) updating a component subsystem (radio module, gateway, companion app). In every case the cybersecurity content scope covers the changed subsystem at minimum, and often the platform as a whole because the threat model and architecture views cannot meaningfully address the change in isolation. > **[KEY REQUIREMENT]** Section 524B is keyed to the submission, not to the original clearance. A Special 510(k) on a 2015-cleared cyber device is a 524B submission and must contain the full 524B(b)(1) postmarket plan, (b)(2) SDLC and update cadence evidence, and (b)(3) SBOM and VEX. ## When 524B Does Not Apply but Postmarket Obligations Do A legacy device that the manufacturer is not currently submitting to the FDA does not pick up 524B obligations retroactively. The statute has no look-back provision. That does not make the device cybersecurity-exempt. The FDA's postmarket authorities for cybersecurity, anchored in the [FDA's 2017 Postmarket Management of Cybersecurity in Medical Devices guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices) and the agency's general quality system and adverse event reporting rules, continue to apply. Manufacturers of fielded legacy cyber devices remain responsible for monitoring vulnerabilities in deployed software components, assessing patient safety impact of new vulnerabilities, communicating with users and customers about uncontrolled risk, and reporting under 21 CFR Part 803 when a cybersecurity event meets the malfunction or serious-injury threshold. The PATCH Act provisions added by the Consolidated Appropriations Act, 2023 codified the premarket cybersecurity expectations into 524B but did not create a retroactive sweep for fielded legacy devices. The legacy gap the industry talks about is real: a 2014-cleared pump with hard-coded credentials is not picked up by 524B today, but it is also not invisible to the FDA. Postmarket obligations and MDR reporting still apply. ## Submission Types and 524B Scope on Legacy Platforms | Submission type on a legacy cyber device | Does 524B attach? | Scope of cybersecurity content | | --- | --- | --- | | Special 510(k) (software/UI change) | Yes | Changed subsystem; threat model and SBOM updated to reflect change | | Special 510(k) (cybersecurity update) | Yes | Changed subsystem and any control surface the change touches | | Traditional 510(k) (hardware refresh) | Yes | Full 524B(b)(1)-(3) content for the device as filed | | De Novo (new indication on legacy platform) | Yes | Full 524B(b)(1)-(3) content | | PMA supplement (AI/ML feature, connectivity, cloud) | Yes | Full 524B(b)(1)-(3) content; the changed subsystem usually pulls in the platform | | 30-Day Notice (Class III mfg change, no software) | Often no | Cybersecurity only if the change affects security posture; reviewers may still ask | | No submission pending (fielded device only) | No | Postmarket obligations apply under the 2017 postmarket guidance and 21 CFR 803 | The pattern: any submission that touches device software, connectivity, or any control surface that could be vulnerable to a cybersecurity threat triggers 524B content. Mechanical-only or labeling-only changes are the rare exception. ## What a 524B-Clean Submission on a Legacy Platform Looks Like A 524B-clean submission on a legacy platform organizes evidence subsection by subsection, the same way a new-device submission does, but it pays explicit attention to the legacy gap. The submission opens with an unambiguous 524B(c) cyber device determination naming every interface that touches device software (Ethernet, Wi-Fi, Bluetooth, BLE, NFC, USB service ports, JTAG, companion app, cloud backend, gateway). The 524B(b)(1) postmarket plan covers the current platform end-to-end, not just the changed subsystem. The 524B(b)(2) SDLC evidence shows that current development controls meet AAMI SW96:2023 and IEC 81001-5-1:2021 going forward; legacy code that predates these standards is addressed through a gap analysis and a remediation plan, not by claiming retroactive compliance. The 524B(b)(3) SBOM covers every component in the shipping build, including legacy commercial and open-source dependencies that the original submission never enumerated. The VEX statement set classifies known vulnerabilities in those legacy components by exploitability in the current deployed configuration. The honest framing is: the legacy code is what it is, but the cybersecurity controls, monitoring, and update cadence going forward meet 524B. Reviewers accept this framing when it is explicit. They reject submissions that pretend the legacy gap does not exist. ## Deficiency Patterns Specific to Legacy Submissions Three deficiency patterns recur on legacy submissions: - **No 524B(c) determination.** The submission carries forward the original device description, which predates the cyber device concept, and never states that the device is a cyber device. Reviewer treats it as silence and asks for a determination at best, RTAs at worst. - **SBOM that covers only the changed subsystem.** A Special 510(k) for a software update produces an SBOM for the updated module only. 524B(b)(3) requires an SBOM for the device, not for the change. Reviewer asks for a full-device SBOM. - **Postmarket plan that references procedures that do not exist for the legacy platform.** The plan describes a vulnerability monitoring and CAPA workflow that the manufacturer runs for new products but does not run for the legacy line. Reviewer flags the inconsistency. The common thread: legacy submissions get into trouble when the cybersecurity content is treated as a delta against the previous clearance instead of a complete 524B response for the device as it ships today. ## How Blue Goat Approaches a Legacy 524B Submission We start with a 524B(c) determination and an interface inventory for the legacy platform as it ships today, not as it was cleared. We update the threat model and security architecture views to AAMI TIR57:2016/(R)2023, AAMI SW96:2023, and IEC 81001-5-1:2021, calling out the legacy code gaps explicitly with a remediation plan rather than claiming retroactive coverage. We regenerate the SBOM from the actual current build so transitive and legacy dependencies are captured, and we pair it with a VEX set scoped to the device's deployed configuration. The postmarket plan plugs into the manufacturer's CAPA procedure so vulnerability response has a closure record. Our engineers hold CISSP, OSCP, and prior military red-team credentials. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA premarket cybersecurity service](/services/fda-premarket-cybersecurity-services) or read the [524B subsection-by-subsection walkthrough](/blog/fda-section-524b-subsections-explained). ## FAQ ### Does FDA Section 524B apply to legacy medical devices? Section 524B applies to any new premarket submission for a cyber device, including submissions built on a legacy platform. It does not retroactively sweep in devices already on the market with no submission pending. Fielded legacy devices remain subject to the FDA's separate postmarket cybersecurity authorities and to MDR reporting under 21 CFR Part 803. ### Does a Special 510(k) for a small software change on a legacy device trigger 524B? Yes. Any 510(k), Special or Traditional, for a cyber device is a 524B submission. The cybersecurity content must cover the changed subsystem at minimum, and reviewers usually expect threat model, SBOM, and architecture views for the device as it ships today, not for the changed subsystem in isolation. ### What if the original clearance predates 524B? The original clearance year is irrelevant to applicability. Section 524B(a) keys to the submission type, not to the device's first clearance. A 2015-cleared platform with a 2026 Special 510(k) is a 524B submission and must contain the full 524B(b)(1)-(3) content set. ### How does the PATCH Act fit with legacy devices? The PATCH Act provisions in the Consolidated Appropriations Act, 2023 codified premarket cybersecurity expectations into 524B. The statute did not retroactively cover fielded legacy devices, which is the "legacy gap" the industry talks about. Postmarket obligations under the FDA's 2017 postmarket guidance and 21 CFR Part 803 reporting still apply to those fielded legacy devices. ### Do I need an SBOM for a legacy device with no pending submission? Section 524B(b)(3) requires an SBOM as part of a premarket submission. With no submission pending, 524B does not compel one. The FDA's postmarket guidance still treats SBOM as the foundation for vulnerability monitoring, and HSCC and procurement frameworks like MDS2 expect one, so most manufacturers produce SBOMs for fielded legacy devices regardless. ### Can I claim my legacy device is exempt from 524B because it has no Wi-Fi? Almost never. The 524B(c) connectivity prong covers any interface that touches device software, not just network interfaces. USB service ports, Bluetooth, BLE, NFC, serial or JTAG ports, companion apps, cloud backends, and gateway-mediated paths all qualify. The only legacy devices that escape 524B are those with no software at all or software with no interface of any kind. ## Ready to file a 524B-clean submission on a legacy platform? If your next submission rests on a platform that predates 524B and the cybersecurity section is being written as a delta against the previous clearance, you are leaving deficiency exposure on the table. We can structure the submission so every 524B subsection has a labeled response and the legacy gap is addressed explicitly. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](/contact). --- **About the author.** Christian Espinosa, Founder, Blue Goat Cyber, CISSP. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, with deep experience on legacy platform submissions under Section 524B. [Read more about Christian](/christian-espinosa). --- ## Related on FDA Section 524B - [FDA Section 524B: complete cybersecurity requirements guide](/guides/fda-524b-cybersecurity-requirements-explained) - [Does Section 524B apply to my auto-injector?](/blog/does-fda-section-524b-apply-to-my-auto-injector) - [AI/ML cybersecurity threats under Section 524B](/blog/fda-ai-cybersecurity-threats-524b-medical-devices) - [Documenting update cadence for a 524B submission](/blog/documenting-update-cadence-fda-524b-submission) --- ## More on this topic - [H-ISAC and Medical Device Threat](/blog/h-isac-medical-device-threat-intelligence-sources) - [FDA PCCP Beyond AI: Cybersecurity, Firmware, and Hardware Uses](/blog/pccp-beyond-ai-cybersecurity-firmware-hardware) --- ## Does FDA 524B Apply to Auto-Injectors? Source: https://bluegoatcyber.com/blog/does-fda-section-524b-apply-to-my-auto-injector # Does FDA Section 524B Apply to My Connected Auto-Injector in 2026? > **[DIRECT ANSWER]** Section 524B applies to a connected auto-injector's device constituent whenever it contains software or firmware and any electronic interface, such as Bluetooth pairing, NFC, USB, or cellular telemetry, regardless of whether CDER or CDRH leads the review. Purely mechanical, non-electronic injectors are out of scope. In-scope sponsors must submit an SBOM, threat model, security risk management report, architecture views, testing evidence, and a cybersecurity management plan. Sponsors of connected auto-injectors keep arriving at the same wrong conclusion: because the primary mode of action is the drug and the lead center is CDER, the device constituent escapes FDA Section 524B. It does not. The statute is keyed to the device, not the review pathway. If the injector has firmware and a Bluetooth radio that pairs to a phone app, it is a cyber device, and the full premarket cybersecurity package attaches to the submission. The February 3, 2026 final premarket cybersecurity guidance is explicit on this point. CDER reviewers consult CDRH on cybersecurity, and the cyber consult applies the same expectations a standalone 510(k) would draw. ## Key Takeaways - Section 524B follows the device constituent of a combination product, not the lead review center. CDER-led submissions for connected injectors are 524B submissions. - The trigger is software plus any electronic interface. BLE pairing to a companion app is the most common qualifying interface on auto-injectors. - Purely mechanical auto-injectors with no electronics and no interface are out of scope for 524B. - The submission must include the device-side SBOM, threat model, security risk management report, architecture views, testing evidence, and a Cybersecurity Management Plan under 524B(b)(1). - Engaging cybersecurity at BLA prep is too late. The right entry point is the device-constituent design freeze. ## Why this matters Connected auto-injectors are the fastest-growing shape of drug-device combination products, and the cybersecurity deficiency rate on these submissions is higher than on equivalent standalone devices. The FDA February 3, 2026 final premarket cybersecurity guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," is the operative interpretation, and it applies to the device constituent of a combination product the same way it applies to any cyber device. Standards in scope include AAMI TIR57:2016/(R)2023, ANSI/AAMI SW96:2023, IEC 81001-5-1:2021, IEC 62304:2006/A1:2015, and ISO 14971:2019. CDER consults CDRH on the cyber review, which means cyber comments often land late in the BLA cycle and compress remediation timelines that a CDRH-led program would have closed at the threat-modeling stage a year earlier. ## When 524B Attaches to an Auto-Injector Section 524B(c) defines a cyber device as one that contains software (including firmware or programmable logic), has the ability to connect to the internet, and contains technological characteristics that could be vulnerable to a cybersecurity threat. Reviewers read "ability to connect" broadly. A BLE radio that pairs to a phone app counts. An NFC interface for dose logging counts. A USB service port counts. A cellular module for adherence telemetry counts. The injector does not need to talk to the open internet directly. Any path that reaches a network through a paired device or gateway qualifies. The fastest applicability check: - Does the injector have firmware or programmable logic? If no, 524B does not apply. - Does the injector have any electronic interface (BLE, NFC, USB, serial, cellular, optical pairing)? If no, 524B does not apply. - If yes to both, 524B attaches to the submission for the device constituent. Purely mechanical spring-driven auto-injectors with no electronics are out of scope. Almost every "connected" or "smart" injector on the market is in scope. ## Why CDER-Led Doesn't Mean Cyber-Light The Office of Combination Products assigns the lead center based on the product's primary mode of action. A monoclonal antibody delivered by an injector is drug-led, so CDER leads. That assignment governs the review pathway, fee schedule, and labeling. It does not govern whether 524B applies. The statute reaches the device constituent regardless. > **[KEY REQUIREMENT]** A CDER-led BLA or NDA for a connected auto-injector is a 524B submission for the device constituent. The sponsor owes the same premarket cybersecurity content set a CDRH-led 510(k) or De Novo would owe: SBOM, threat model, security risk management report, architecture views, testing, postmarket plan, and a Cybersecurity Management Plan under 524B(b)(1). CDER consults CDRH on cybersecurity. In practice this means cyber comments arrive later in the review than they would in a CDRH-led program, and the sponsor has less runway to close them. The common pattern: a BLA approaches its PDUFA date and a cyber consult surfaces threat model gaps that should have been resolved during device design freeze. The remediation requires firmware changes, which require new verification, which slips the launch. ## What the Device-Side Package Looks Like The deliverables are identical in content to a standalone CDRH submission. The full mapping lives in our [combination product cybersecurity guide](/guides/combination-product-cybersecurity-fda) and the [FDA premarket cybersecurity deliverables and eSTAR v7.0 map](/guides/fda-premarket-cybersecurity-deliverables-estar-map). At a minimum: - Security Risk Management Report aligned to AAMI TIR57 and ANSI/AAMI SW96, converged with the safety risk file per [ISO 14971 vs AAMI TIR57](/guides/iso-14971-vs-aami-tir57-hazard-analysis). - Machine-readable SBOM (SPDX or CycloneDX) for every component in the shipping firmware and companion app, with VEX statements for known vulnerabilities. - Threat model (STRIDE or equivalent) tied to patient harm, covering BLE pairing, OTA update, app-to-device authentication, and telemetry endpoint exposure. - Architecture views: global system, multi-patient harm, updateability, security use case. - Cybersecurity testing: vulnerability scanning, software composition analysis, penetration testing of the device and the companion app, and fuzz testing of the BLE protocol stack and any other communication interface. - Postmarket plan covering vulnerability monitoring, coordinated vulnerability disclosure intake, patch cadence, and end-of-life. - Cybersecurity Management Plan required by 524B(b)(1). ## Where the Documentation Lives in a BLA or NDA In a BLA or NDA, the cybersecurity content most commonly lives in Module 3.2.R (regional information) with cross-references from the device description in Module 3.2.P.7. Some sponsors build a dedicated cybersecurity sub-section that reviewers can navigate without hunting. The structural choice matters less than completeness. Reviewers need to locate the SBOM, threat model, architecture views, testing report, and Cybersecurity Management Plan. A package scattered across modules with no cross-reference map draws information requests on layout alone. In a 510(k), De Novo, or PMA on a device-led combination product, the content lives in the standard eSTAR cybersecurity attachments. ## Common Deficiency Patterns on Connected Injectors Four patterns recur: - **Companion app treated as out of scope.** The sponsor assumes the third-party app vendor owns app-side cybersecurity. The submission holder owns it. The app's authentication, in-transit data integrity, secure pairing with the device, and the mobile platform's update mechanism are all in scope for the submission's threat model and testing. - **Stale SBOM.** A platform reuse submission carries an SBOM generated 18 months earlier. Reviewers expect the SBOM to be current within roughly 90 days of submission, with VEX statements reflecting today's CVE landscape. - **CDMO-supplied device with no contractual SBOM clause.** The contract manufacturer does not deliver an SBOM or secure SDLC evidence, and the sponsor cannot produce one for review. "The CMO handles that" is not an acceptable response. - **Threat model missing OTA update path.** Connected injectors usually support some form of firmware update through the companion app. The threat model omits the OTA path entirely, or covers it without addressing key management for the update signing keys. ## How Blue Goat Approaches a Connected Auto-Injector Submission We enter at device-constituent design freeze, not at BLA prep. Our team's prior work on connected drug-delivery systems means we know the typical attack surface on these products (BLE pairing flaws, OTA update key management, app-to-device authentication, telemetry endpoint exposure) and the deficiency patterns CDRH cyber consults raise on CDER-led submissions. We deliver the full premarket package, SBOM, threat model, security risk management report, architecture views, and testing, in a form that drops into either a CDER Module 3 or a CDRH eSTAR. Our engineers hold CISSP, OSCP, and prior military red-team credentials. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) page, or read the [combination product cybersecurity guide](/guides/combination-product-cybersecurity-fda) for the full deliverables walkthrough. ## FAQ ### Does Section 524B apply to a connected auto-injector reviewed by CDER? Yes, if the device constituent contains software and any electronic interface. Section 524B follows the device, not the review center. CDER consults CDRH on cybersecurity, and the consulting reviewers apply the same February 2026 premarket guidance they apply to a standalone CDRH submission. The lead-center designation does not change applicability. ### What about a purely mechanical spring-driven auto-injector? Out of scope. With no software and no electronic interface, the injector is not a cyber device under 524B(c). Standard device controls under the quality system regulation still apply, but the premarket cybersecurity content set does not. ### Is Bluetooth Low Energy pairing enough to trigger 524B? Yes. The 524B(c) connectivity prong is read broadly. Any interface that touches device software qualifies, and BLE pairing to a phone app is the most common qualifying interface on injectors. NFC, USB service ports, cellular modules, and optical pairing all qualify the same way. ### Where does the cybersecurity content go in a BLA? Most commonly in Module 3.2.R with cross-references from the device description in 3.2.P.7. Some sponsors build a dedicated cybersecurity sub-section. The format matters less than completeness. Reviewers need to find the SBOM, threat model, architecture views, testing report, and Cybersecurity Management Plan without hunting. ### My contract manufacturer makes the injector. Who owns the cybersecurity obligation? The submission holder. The CDMO or CMO is a supplier. The sponsor must contractually require the SBOM, secure SDLC evidence, vulnerability monitoring, and patch support, and the sponsor must audit that delivery. The FDA does not accept "the contract manufacturer handles that" as a response to a deficiency letter. ### Is the companion smartphone app in scope? Yes, if it is part of the labeled use of the combination product. App authentication, in-transit data integrity, secure pairing with the device, and the mobile platform's update mechanism are all in scope for the submission's threat model and testing. ## Ready to scope cyber for your connected injector? If you are pre-submission on a connected auto-injector and the cybersecurity work is being treated as a Module 3 attachment to be written at BLA prep, the timeline math will not work. We can scope the device-constituent cyber package while the design is still open and deliver it in the format your reviewers expect. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](/contact). --- **About the author.** Christian Espinosa, Founder, Blue Goat Cyber, CISSP. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, with deep experience on connected drug-delivery combination products under Section 524B. [Read more about Christian](/christian-espinosa). --- ## Related on FDA Section 524B - [FDA Section 524B: complete cybersecurity requirements guide](/guides/fda-524b-cybersecurity-requirements-explained) - [Does Section 524B apply to legacy devices?](/blog/does-fda-section-524b-apply-to-legacy-medical-devices) - [AI/ML cybersecurity threats under Section 524B](/blog/fda-ai-cybersecurity-threats-524b-medical-devices) - [Documenting update cadence for a 524B submission](/blog/documenting-update-cadence-fda-524b-submission) --- ## EHR/EMR Medical Device Integration Source: https://bluegoatcyber.com/blog/ehr-emr-medical-device-integration-cybersecurity-risks # EHR/EMR Integration for Medical Devices: Common Systems and Cybersecurity Risks > **[DIRECT ANSWER]** Devices that integrate with Epic, Oracle Health, MEDITECH, Allscripts, or athenahealth typically do so over HL7 v2, FHIR, or DICOM, and each of those interfaces is a trust boundary in your threat model. The recurring risks are unauthenticated HL7 listeners, over-scoped FHIR tokens, and DICOM services exposed on the clinical network, all of which the FDA expects you to model, control, and test. ## Key Takeaways - EMR = single-practice digital chart. EHR = interoperable, multi-organization record. The FDA, ONC, and HHS use "EHR" when they mean the networked system that medical devices actually connect to. - The dominant inpatient EHRs are Epic and Oracle Health (formerly Cerner); MEDITECH dominates community hospitals; Allscripts/Veradigm, athenahealth, eClinicalWorks, and NextGen cover most ambulatory deployments. - Devices rarely talk to the EHR directly. They talk to an integration engine (Rhapsody, Mirth Connect, Corepoint) or an API broker (Redox) that brokers HL7 v2, FHIR, or DICOM. - HL7 v2 over MLLP is cleartext TCP by default. Treating MLLP as "internal-only and therefore safe" is the most common interoperability finding in pen tests. - FHIR uses OAuth 2.0 and SMART on FHIR. Token scope creep and long-lived refresh tokens are the recurring issues. - The FDA expects every EHR interface to appear as a data flow in your DFD, a labeled element in your Security Architecture Views, and a STRIDE entry in your threat model. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) treats every external interface as a documented attack surface. EHR connectivity is no longer an "IT integration detail" left to the hospital, it is a labeled data flow that must appear in the Security Architecture Views, the threat model, and the labeling provided to the Health Delivery Organization (HDO). Section 524B of the FD&C Act applies to any device that includes software and has the ability to connect to the internet, and the HSCC Joint Security Plan and MDS2 disclosures both require manufacturers to describe how the device authenticates, encrypts, and logs each EHR interface. Verizon's *2024 Data Breach Investigations Report* attributes a disproportionate share of healthcare breaches to credential compromise and lateral movement through integration infrastructure, which is exactly where HL7 interface engines sit. Reviewers know this, and "we use the hospital's integration engine" is not an acceptable answer on its own. ## EHR vs EMR: what's the actual difference? EMR (Electronic Medical Record) is the digital chart inside a single practice or hospital. It replaces the paper folder, but it does not travel between organizations. EHR (Electronic Health Record) is designed to be shared across providers, hospitals, labs, pharmacies, and the patient. It supports interoperability standards (HL7 v2, FHIR, C-CDA), patient portals, and cross-organization exchange through networks like Carequality and TEFCA. In day-to-day conversation the two terms are used interchangeably, but the FDA, ONC, and HHS consistently use **EHR** when they mean the interoperable, networked system. For medical device cybersecurity, that distinction matters because the attack surface lives in the interoperable layer: the FHIR API, the HL7 interface engine, the integration middleware. An "EMR-only" device with no outbound interfaces has a much smaller threat surface than an "EHR-integrated" device that pushes observations through a hospital integration engine. ## Which EHRs do medical devices actually connect to? There is no single EHR market. Five vendors dominate inpatient care, and a longer tail covers ambulatory practices. | Tier | Vendor | Typical setting | Integration entry point | |---|---|---|---| | Inpatient | Epic | Large IDNs, academic hospitals | Bridges, Interconnect, App Orchard (FHIR) | | Inpatient | Oracle Health (Cerner) | Large hospitals, federal (VA, DoD) | CareAware, Open Developer Experience (FHIR) | | Inpatient | MEDITECH | Community hospitals | Greenfield FHIR APIs, HL7 v2 | | Ambulatory | Allscripts / Veradigm | Multi-specialty practices | Veradigm Connect, FHIR R4 | | Ambulatory | athenahealth | Small/mid practices, FQHCs | More Disruption Please (MDP), FHIR | | Ambulatory | eClinicalWorks | Independent practices | HL7 v2, FHIR | | Ambulatory | NextGen | Specialty practices | HL7 v2, FHIR | Most device manufacturers do not maintain a separate connector per vendor. Instead they integrate once with a hospital-side integration engine, or they use an API broker (Redox, Datica, 1upHealth) that normalizes the differences between EHR FHIR implementations. ## How the integration actually works: engines and protocols > **[KEY REQUIREMENT]** Every EHR integration point must appear in your data flow diagram with a trust boundary crossing. If you cannot draw the data flow, you cannot threat-model it. See our [DFD primer](/blog/data-flow-diagrams-medical-device-cybersecurity) for the five elements and the trust boundary convention. ### Integration engines The integration engine is the broker between the device and the EHR. Common ones: - **Rhapsody** (Lyniate), large hospital deployments - **Mirth Connect** (NextGen), widely used, often the cheapest tier - **Corepoint** (Lyniate), common in mid-market hospitals - **InterSystems Ensemble / IRIS**, Epic shops often run this The engine normalizes messages, applies routing rules, and writes to the EHR. From the device's point of view it is just a TCP endpoint on the hospital LAN. ### Protocols - **HL7 v2** over MLLP (Minimal Lower Layer Protocol), the workhorse for observations (ORU), orders (ORM), and ADT. Cleartext TCP by default, no built-in authentication. - **FHIR** (Fast Healthcare Interoperability Resources), modern REST/JSON, OAuth 2.0, SMART on FHIR for app authorization. Required for ONC-certified EHRs under the 21st Century Cures Act. - **DICOM**, imaging modalities, with DIMSE over TCP and DICOMweb over HTTPS. - **IHE profiles** (PIX, PDQ, XDS, ATNA), interoperability profiles layered on top of HL7 and DICOM for cross-enterprise scenarios. - **C-CDA** documents, exchanged less often by devices, more often by EHRs themselves. ## Cybersecurity risks unique to EHR integration The risks below are the ones that recur on actual pen tests and in actual FDA deficiency letters. ### Unauthenticated MLLP feeds HL7 v2 over MLLP has no native authentication, no encryption, and no integrity check. "It's on a private VLAN" is the standard defense and the standard finding. Once an attacker reaches that VLAN through any compromised endpoint, they can inject ADT, ORM, or ORU messages, change demographic data, or replay observations. The fix is TLS-wrapped MLLP, mutual auth where the engine supports it, and a Bump-in-the-Wire gateway if the device cannot natively do TLS. ### FHIR token scope creep SMART on FHIR scopes are granular (`patient/Observation.write`, `user/Patient.read`), but device integrations are often given `*/*` or wildcard resource scopes "to keep things moving during onboarding." Long-lived refresh tokens compound the problem. If the device is compromised, the attacker inherits the same scope. ### PHI in interface logs Integration engines log message contents for debugging. Those logs accumulate PHI and frequently land in centralized logging stacks that have weaker access controls than the EHR itself. This is both a HIPAA finding and a cybersecurity finding because the log store becomes a high-value target. ### Integration engine as lateral-movement pivot The engine talks to the EHR, the device network, the LIS, the RIS, and often the ADT broadcast. Compromising it gives an attacker east-west access across the hospital. Devices that share credentials with the engine (a common shortcut) extend the blast radius onto the device fleet. ### Vendor-supplied shared service accounts Many devices ship with a single integration account whose password is documented in the install guide and is rarely rotated. The FDA increasingly asks for per-instance credentials and a documented rotation path in labeling. ### MITM on intra-hospital VLANs ARP spoofing and rogue DHCP remain effective inside hospital VLANs that were architected before zero trust was a phrase. Devices that fall back to plaintext when TLS negotiation fails are particularly exposed. ## What the FDA expects in the submission Under the Feb 3, 2026 guidance, EHR connectivity has to show up in four places: 1. **Data Flow Diagram(s)**, each EHR interface as a data flow crossing a trust boundary, with the protocol labeled (MLLP, FHIR/HTTPS, DICOM). 2. **Security Architecture Views**, the Global System View must show the device's position relative to the integration engine and EHR; the Multi-Patient Harm View must address whether a compromised interface can affect more than one patient. See our [Security Architecture Views post](/blog/security-architecture-diagrams-medical-device-cybersecurity) for the four-view structure. 3. **Threat Model**, STRIDE entries for each interface, covering spoofing of the integration source, tampering of HL7 messages, repudiation through shared accounts, information disclosure through logs, denial of service on the MLLP listener, and elevation of privilege through over-scoped FHIR tokens. 4. **Labeling to the HDO**, required network configuration, supported TLS versions, credential management expectations, and any IHE profiles the device implements. The interoperability section of the labeling should also reflect the FDA's *Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices*, and align with HSCC JSP and MDS2 disclosures. [Talk to us about your EHR integration documentation →](/contact) ## How Blue Goat approaches EHR-integrated devices Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. For EHR-connected devices we run the integration surface as a first-class threat-model boundary, not an afterthought. Every interface gets a data flow, a STRIDE row, and a labeled control, and we test the actual protocol behavior (MLLP fallback, FHIR scope enforcement, certificate validation) rather than trusting the spec. We deliver the full Feb 3, 2026 guidance documentation set scoped to your integration profile, integrated with your IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What's the difference between an EHR and an EMR? An EMR (Electronic Medical Record) is the digital chart for one practice or hospital and does not travel between organizations. An EHR (Electronic Health Record) is built for interoperability across providers, labs, pharmacies, and the patient, using standards like HL7 v2 and FHIR. Medical devices that connect to "the chart" almost always connect to an EHR, because that is where the interoperable interfaces live. ### Which EHRs do medical devices most commonly integrate with? In US hospitals, Epic and Oracle Health (Cerner) dominate, with MEDITECH a strong third in community hospitals. In ambulatory care, Allscripts/Veradigm, athenahealth, eClinicalWorks, and NextGen cover most of the market. Most device manufacturers do not write a per-vendor connector; they integrate once with a hospital integration engine or with an API broker such as Redox. ### Is HL7 v2 secure on its own? No. HL7 v2 over MLLP is cleartext TCP with no built-in authentication, encryption, or integrity checks. It is safe only when wrapped in TLS, restricted to authenticated peers, and segmented onto a trust-boundary-controlled network. Assuming the hospital VLAN is "internal and therefore safe" is the most common interoperability finding on pen tests. ### Does FHIR fix the security issues with HL7 v2? Mostly, yes. FHIR uses HTTPS, OAuth 2.0, and SMART on FHIR scopes, which gives you authentication, encryption, and granular authorization out of the box. The recurring problems are operational: over-broad scopes, long-lived refresh tokens, and weak certificate validation. The protocol gives you the tools; the integration team has to use them correctly. ### Do I need to document EHR integration in my FDA submission? Yes. Under the Feb 3, 2026 premarket cybersecurity guidance, every external interface, including EHR connections, must appear in the device's data flow diagram, Security Architecture Views, threat model, and labeling to the HDO. "We hand the data to the hospital's integration engine" is not sufficient on its own. ### What is an integration engine and do I need one? An integration engine (Rhapsody, Mirth Connect, Corepoint, InterSystems) is hospital-side middleware that brokers messages between devices, the EHR, the LIS, and other systems. The device does not own it, but the device's threat model has to include it as an external entity with a trust boundary, because compromising the engine is a realistic path to compromising the device fleet. ## CTA Building or revising a connected device that touches an EHR? We'll map every interface to a DFD, Security Architecture View, and STRIDE entry, and pen-test the actual protocol behavior so the FDA does not find it first. [Schedule a discovery session →](/contact) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, including the integration surface between devices and hospital EHR systems. [Read more about Christian](/christian-espinosa). --- ## Embedded Cybersecurity Challenges MedTech Source: https://bluegoatcyber.com/blog/embedded-cybersecurity-challenges # Embedded Cybersecurity Challenges in Medical Devices > **[DIRECT ANSWER]** Embedded medical devices constrain almost every control you would use elsewhere. Limited memory and compute make strong cryptography expensive, real-time requirements block interrupt-heavy defenses, hardware lifetimes outlast vendor support for the RTOS and libraries, and field updates may require clinical downtime. Design around those limits early with secure boot, a hardware root of trust, minimal exposed interfaces, and an update mechanism validated before the design freezes. _Updated November 15, 2024_ Embedded medical devices face security problems that enterprise IT never has to solve. Battery limits, tight memory, deterministic timing, intermittent connectivity, and long field life all change what is practical, and what the FDA expects you to justify in a premarket submission. That is where many teams get into trouble. Under **Section 524B**, the **Feb 3, 2026 final FDA premarket cybersecurity guidance** (which supersedes the September 2023 and June 2025 versions), **IEC 81001-5-1**, and **AAMI TIR57:2016/(R)2023**, reviewers are looking for evidence that you understood those embedded constraints and designed around them inside a working SPDF. ## Key Takeaways - Address unique embedded constraints in device security. - Show how security aligns with safety and essential performance. - Detail hardware trust, software assurance, comms security. - Account for human factors in security control design. - Evidence choices for the FDA under their premarket guidance. - Integrate security into system design, not just documentation. ## Why this matters The security of embedded medical devices directly impacts patient safety, data integrity, and essential device performance. Manufacturers must navigate complexities stemming from limited processing power, memory constraints, real-time operating systems, and extended product lifecycles. Failure to adequately address these embedded cybersecurity challenges can not only compromise device functionality and patient trust but also lead to significant regulatory hurdles. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, mandates that manufacturers demonstrate a secure development lifecycle and effective postmarket surveillance. Relevant standards like IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide frameworks for integrating security into device design and risk management. Proactive and thorough embedded cybersecurity measures are crucial for market approval, avoiding costly recalls, and maintaining patient confidence in an increasingly interconnected healthcare environment. ## What Embedded Cybersecurity Means for Medical Devices Embedded cybersecurity is the discipline of protecting software, hardware, interfaces, communications, and update mechanisms in devices built on constrained platforms. In medical devices, that means more than stopping malware. It means preserving safety, essential performance, data integrity, availability, and recoverability when the device is under attack or when a security control fails. These systems are not laptops in smaller boxes. They are purpose-built devices running RTOSs, bare-metal code, Linux variants, or mixed architectures tied to sensors, actuators, and clinical workflows. They often have limited compute resources, specialized hardware interfaces, and deployment lifecycles that stretch for years. OS choice sets the ceiling on what security controls are even possible - see our [2026 comparison of the top 10 embedded operating systems for medical devices](/blog/top-10-embedded-operating-systems-for-medical-devices) for how LTS, secure boot, and isolation options differ across Yocto Linux, VxWorks, QNX, INTEGRITY, Zephyr, and FreeRTOS, and our [Linux vs. Windows security comparison](/blog/linux-vs-windows-a-security-comparison) for the two platforms most device teams end up choosing between. ![Section Image](/imported-images/3076ea83f6e3a5cd.png) For manufacturers, the core challenge is simple to state and hard to execute: add effective security controls without breaking safety, timing, usability, battery life, manufacturability, or serviceability. That tradeoff needs to be engineered, documented, tested, and traceable to risk decisions the FDA reviewers can follow. ## Where Embedded Device Cybersecurity Usually Breaks Down Most embedded cybersecurity failures fall into a few recurring categories: hardware trust, software assurance, communications security, and operational reality. The details vary by product. The patterns do not. ### Hardware Constraints and Physical Exposure Many devices cannot absorb heavyweight security controls without consequences. Stronger crypto may increase boot time. Extra logging may wear flash faster. Continuous monitoring may drain battery. Secure storage may require a component with supply chain and cost implications. Real constraints. Not excuses. Physical access also matters more in embedded systems than many teams admit. Service ports, debug interfaces, removable media, exposed buses, and manufacturing hooks can all become attack paths if they are left enabled or weakly controlled. A device in a hospital, ambulance, home, or lab may be touched by users, technicians, third-party maintainers, or attackers with time and tools. That is why reviewers often expect to see: - trust anchors and key protection tied to the device architecture - decisions around secure boot and measured integrity - controls for JTAG, UART, test pads, and maintenance interfaces - tamper response, where appropriate - rationale when hardware security features were not included If you cannot support a control because of device limitations, explain the limitation and show the compensating controls. Do not leave a gap and hope nobody notices. ### Software Weaknesses in Constrained Environments Embedded software tends to inherit risk from age, reuse, and integration. Legacy code, third-party libraries, outdated kernels, vendor SDKs, and hand-rolled update logic create attack paths quickly. Add rushed release schedules and poor SBOM discipline, and the problem compounds. The harder issue is that many standard security patterns are not drop-in fits for embedded platforms. Key rotation may be difficult in intermittently connected devices. Certificate validation may break if timekeeping is unreliable. Logging may be too sparse for incident response. Memory-safe redesign may not be practical in late-stage products. That does not remove the obligation to manage risk. It changes how you need to show your work. Manufacturers should be ready to evidence: - secure coding practices and code review expectations - static, dynamic, and fuzz testing where applicable - vulnerability handling for third-party components - SBOM generation and maintenance - secure configuration defaults - documented security architecture decisions, especially where constraints drove tradeoffs A submission gets stronger when those artifacts connect. Threats should map to controls, controls to verification, and unresolved residual risk to documented rationale. ### Communications and Update Integrity Connected devices bring predictable problems: weak authentication, poor key handling, insecure pairing, unprotected local services, and update mechanisms that trust too much. Wireless stacks and cloud integrations widen the attack surface, but wired service channels and internal hospital networks can be just as risky. Too many products still treat encryption as the finish line. It is not. If the device cannot authenticate the sender, verify firmware authenticity, protect keys, prevent rollback, and fail safely during interrupted updates, you still have a serious problem. For embedded medical devices, secure update design usually deserves its own threat analysis and verification set. Reviewers may look for: - authenticated and integrity-checked firmware updates - anti-rollback protections - separation between update authority and transport channel - behavior for partial, failed, or malicious updates - recovery paths that preserve safety - plans for patch deployment across the supported device life If your patch story depends on field service visits, say so. If home-use devices may be offline for long periods, address that. The FDA is not looking for abstract best practices. The FDA is looking for whether your actual deployment model was considered. ## Human Factors Still Matter Security failures are not always technical. Sometimes the control exists but the workflow defeats it. A clinician under time pressure may bypass a pairing step. A technician may use a shared service credential. A home user may ignore an update prompt because the instructions are unclear. A hospital may leave the device on a flat network because segmentation guidance was vague or unrealistic. Human factors belong in embedded cybersecurity because the device is part of a real care environment. Security controls that cannot be used correctly will fail in practice, no matter how polished they look in design documentation. That means manufacturers should consider: - secure defaults that do not rely on expert users - role-appropriate authentication and service access - clear update and maintenance workflows - labeling and instructions that match the intended environment - training needs for operators, admins, and servicers This is also where anti-checklist-theater matters. Telling users to “follow cybersecurity best practices” is not a control. Designing a workflow they can actually perform is. ## What Good Technical Solutions Look Like Technical solutions for embedded devices need to fit the platform, the threat model, and the safety case. Security features that degrade essential performance or introduce new clinical risk are not automatically wins. ![Section Image](/imported-images/f81bb20dc10453f9.png) At the hardware level, useful controls may include secure elements, hardware-backed key storage, trusted execution support, memory protection features, and interface lockdown for production units. At the software level, the basics still matter: hardened configurations, signed code, input validation, least privilege, dependency management, and tested recovery behavior. For connected devices, wireless is a common weak spot - our breakdown of [WPA2 4-way handshake vulnerabilities and KRACK for medical device teams](/blog/wpa2-4-way-handshake-vulnerabilities-what-medical-device-teams-need-to-know-about-wi-fi-risk) walks through the practical Wi-Fi hardening choices that hold up in an FDA review. The key is not collecting security features. It is showing that the selected controls address plausible threats on the actual device architecture. For many submissions, the stronger evidence package includes: - system and security architecture diagrams - trust boundary definitions - threat models tied to assets, attack paths, and abuse cases - security requirements derived from risk analysis - verification evidence for each implemented control - unresolved gaps tracked through risk management and postmarket planning That is the difference between “we use secure boot” and “here is how boot trust is established, verified, maintained, and tested across the product lifecycle.” ## Standards, Policy, and What the FDA Expects Medical device manufacturers do not need more generic cybersecurity slogans. They need artifacts that align with current regulatory expectations. The FDA’s premarket cybersecurity guidance points manufacturers toward an SPDF-based approach. Section 524B raises the floor by requiring cybersecurity information in covered submissions, including processes for vulnerability management, design controls for cybersecurity, and evidence such as SBOM-related content. **IEC 81001-5-1** helps structure secure product development activities. **AAMI TIR57 / ANSI/AAMI SW96:2023** remains useful for threat modeling and security risk management. The [NIST Cybersecurity Framework](https://www.nist.gov/cyberframework) can still support broader program alignment, but it does not replace device-specific design evidence. For embedded products, that evidence must account for the things reviewers question most often: - why a control was selected or omitted - how constraints affected implementation - how security interacts with safety and essential performance - how updates will work in the field - how known vulnerabilities in included components are handled - how postmarket monitoring feeds back into the product lifecycle If your documentation reads like a template pasted onto a constrained device, expect friction. Embedded products need embedded-specific rationale. ## Final Take Embedded cybersecurity in medical devices is not a side topic. It is where architecture, safety, usability, service, and regulatory strategy collide. Teams that do this well do not treat security as a late documentation exercise. They build it into system design, verify it under realistic operating conditions, and produce evidence that matches how the device will actually be deployed and maintained. That is what supports a defensible submission under Section 524B and what holds up better after release. Blue Goat Cyber helps manufacturers do that work in a way that stands up to scrutiny from the FDA, aligns with IEC 62304 and EU MDR obligations, and reflects how embedded devices really behave in the field. If embedded cybersecurity issues are putting your submission, launch timeline, or postmarket plan at risk, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber applies a focused methodology to embedded medical device cybersecurity, acknowledging device-specific constraints. Our team, with credentials such as CISSP and OSCP, including ex-military red team experience, specializes in integrating security into the product lifecycle from initial design to postmarket support. We deliver actionable recommendations for securing hardware, firmware, and software layers, tailored to the unique demands of limited resources and specialized architectures. Our service offerings include threat modeling, risk assessments, penetration testing, and documentation alignment with regulatory expectations. We help manufacturers navigate the FDA's premarket guidance effectively. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What are embedded cybersecurity challenges in medical devices? Embedded medical devices face challenges like limited battery, memory, processing power, intermittent connectivity, and long field life. These constraints impact the implementation of security controls while maintaining safety and essential performance, differentiating them from enterprise IT systems. ### How does the FDA evaluate embedded cybersecurity in medical devices? The FDA evaluates embedded cybersecurity through an SPDF-based approach, looking for evidence that manufacturers understood and designed around embedded constraints. Submissions must connect threats to controls, controls to verification, and unresolved residual risk to documented rationale. ### Why is hardware trust important for embedded medical devices? Hardware trust is crucial because physical access to embedded devices can expose vulnerabilities through service ports, debug interfaces, or removable media. Manufacturers should provide rationale for trust anchors, key protection, secure boot decisions, and controls for physical interfaces. ### What role do software weaknesses play in embedded device cybersecurity? Embedded software often inherits risk from legacy code, third-party components, and outdated systems, creating attack paths. Standard security patterns may not fit, requiring manufacturers to demonstrate secure coding, testing, vulnerability handling, and documented security architecture decisions. ### How should medical device manufacturers approach secure updates? Secure update design for medical devices requires a dedicated threat analysis. Manufacturers must show authenticated and integrity-checked firmware updates, anti-rollback protections, and clear plans for patch deployment, considering the actual deployment model and field conditions. ### Does human factors affect embedded cybersecurity? Yes, human factors significantly impact embedded cybersecurity. Security controls must be usable within real clinical workflows. Manufacturers should design for secure defaults, role-appropriate authentication, clear instructions, and training to ensure controls function effectively in practice. **Related:** UEFI Secure Boot for Medical Devices ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Emerging Tech and Cybersecurity Impact Source: https://bluegoatcyber.com/blog/emerging-technologies-and-their-impact-on-medical-device-cybersecurity # Emerging Technology Impact on Medical Device Cybersecurity > **[DIRECT ANSWER]** Emerging technologies such as digital health platforms, AI, machine learning, and IoT expand the attack surface of medical devices by adding endpoints, data flows, and update mechanisms that can be tampered with or exploited. The FDA expects manufacturers to manage these risks across the entire product lifecycle through secure design, vulnerability management, and postmarket monitoring, while providers add network segmentation and incident response on their side. _Updated October 27, 2024_ Emerging technology is changing how medical devices collect data, connect to networks, and support care decisions. That progress improves treatment and operations, but it also expands the attack surface. For device manufacturers, cybersecurity now has to keep pace with software, connectivity, and clinical use-not get bolted on after design decisions are already locked in. ## Key Takeaways - Digital health, AI, ML, and IoT expand medical device attack surfaces. - New technologies introduce data integrity, authentication, and update risks. - FDA expects manufacturers to integrate cybersecurity throughout product lifecycle. - Manufacturers need secure design, vulnerability management, and postmarket processes. - Healthcare providers must implement network segmentation and incident response. - Future risks involve 5G, edge computing, and AI-specific vulnerabilities. ## Why this matters The rapid integration of emerging technologies into medical devices poses substantial cybersecurity challenges, directly impacting patient safety, data privacy, and trust in healthcare systems. Compromised devices can lead to altered patient data, incorrect diagnoses, or even device malfunction, presenting severe harm. The FDA, in its "Cybersecurity in Medical Devices" Final Guidance published on February 3, 2026, emphasizes that manufacturers must actively manage these evolving risks throughout the product lifecycle. This includes establishing secure development lifecycles and implementing controls aligned with standards such as IEC 60601-1, ISO 13485, and ANSI/AAMI SW96. Failing to address these vulnerabilities not only exposes patients to undue risk but also carries significant regulatory repercussions, potential financial liabilities, and reputational damage for manufacturers. Proactive cybersecurity integration is no longer optional; it is fundamental to safe and effective medical device operation in a connected healthcare environment. ## Understanding Emerging Technologies in Healthcare Medical device cybersecurity is being shaped by a few clear technology trends: digital health platforms, artificial intelligence, machine learning, and the [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things). Each brings clinical value. Each also creates new paths for compromise if security architecture, maintenance, and monitoring are weak. ### The Rise of Digital Health Digital health includes electronic health records, telemedicine platforms, mobile apps, cloud-connected devices, and wearables. These tools can improve access to care, support remote monitoring, and give clinicians faster visibility into patient status. Wearables and home-use devices, for example, can surface changes in vital signs before a condition worsens. Telemedicine has also expanded care delivery, especially for rural and underserved populations. But convenience has a cost. More endpoints, more integrations, and more data movement mean more opportunities for attackers. If sensitive health data is exposed or device communications are altered, the impact is operational, regulatory, and clinical. ### AI and Machine Learning in Medical Devices [Artificial intelligence and machine learning algorithms](/blog) are now showing up in imaging, diagnostics, decision support, and increasingly in device functionality itself. Used well, they can improve detection, reduce clinician burden, and help devices adapt to real-world inputs. They also introduce a different class of risk. An attacker does not need to "hack" a device in the traditional sense if they can tamper with data inputs, model behavior, update mechanisms, or connected systems that influence output. In an AI-enabled device, compromised integrity can mean unsafe recommendations, incorrect classifications, or treatment errors. Security work here has to cover the full chain: data, model, software, interfaces, and update controls. ### The Role of IoT in Healthcare Connected devices are now standard across healthcare environments. Smart pacemakers, infusion pumps, bedside monitors, and implantable devices often rely on network communication for configuration, telemetry, and maintenance. That connectivity can support better care and faster intervention. It also increases exposure. Weak authentication, insecure APIs, poor key management, and unpatched software can turn a useful feature into an entry point. The problem is not connectivity by itself. The problem is connectivity without disciplined security engineering, asset visibility, and lifecycle support. ## Where Emerging Technology Creates Cybersecurity Risk When software-driven features and network connectivity expand faster than security maturity, medical devices become easier to target. ![Section Image](/imported-images/b3cb63e3da3b56bf.png) ### Common Vulnerabilities in Connected Medical Devices Many connected devices still fail on familiar issues: default or weak credentials, outdated components, insecure update paths, missing encryption, exposed services, and insufficient logging. These are not theoretical problems. They are recurring findings in assessments, and attackers know it. A connected [pacemaker](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know), insulin pump, or monitoring platform does not have to be internet-wide exposed to be at risk. Lateral movement from a compromised hospital system, abuse of remote support channels, or exploitation of third-party software can be enough. Once device integrity is in question, patient safety is in play. ### The Threat Landscape for Medical Device Cybersecurity Threat activity targeting healthcare keeps growing because healthcare environments are complex, under pressure, and full of high-value systems. Ransomware remains a major concern, but it is not the only one. Credential theft, third-party compromise, malicious updates, denial-of-service conditions, and unauthorized configuration changes all matter for medical devices. The worst-case scenario is not just data loss. It is loss of availability, loss of integrity, or unsafe device behavior during patient care. That is why medical device cybersecurity cannot be reduced to an IT checklist. It has to be treated as a product safety and quality issue. ### The Role of Regulators in Medical Device Cybersecurity The FDA has made its expectations much clearer in recent years. Cybersecurity is not a side topic for submissions or postmarket support. It is part of demonstrating device safety and effectiveness. The [U.S. Food and Drug Administration (FDA)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) has published expectations and references that push manufacturers to address cybersecurity across the product lifecycle, including threat modeling, secure design, vulnerability management, software transparency, and coordinated disclosure. Those expectations also align with the need to [address the cybersecurity risks associated with medical devices](/blog) before they become field problems. Manufacturers that treat cybersecurity as paperwork for FDA reviewers usually pay for it later-through remediation costs, delayed submissions, difficult customer conversations, and postmarket fire drills. Manufacturers that build evidence from actual engineering work are in a much better position. ## Mitigating Cybersecurity Risks in Medical Devices Risk reduction starts with design decisions, not a late-stage test report. ![Section Image](/imported-images/8cd38ff9c45fbd5a.png) ### What Manufacturers Should Be Doing A serious device cybersecurity program includes threat modeling, secure architecture, software bill of materials management, code review, vulnerability testing, hardening, authenticated update mechanisms, and clear security logging. It also includes postmarket processes for monitoring, triage, disclosure, and patching. Risk assessments matter, but they have to connect to the actual device design and intended use. If a threat model says remote compromise is possible, the design should show how that risk is reduced and how residual risk is justified. If field updates are part of the plan, manufacturers need a trustworthy update path and operational processes to support it. Security controls only count if they can be implemented, maintained, and validated in the real product. Secure coding should be standard practice, not a marketing claim. So should eliminating unnecessary services, reducing privileges, segmenting trust boundaries, and designing for failure. Devices should not assume the hospital network is clean or that every connected system is trustworthy. ### What Healthcare Providers Should Be Doing Providers are part of the security model too. Even a well-designed device can be exposed by poor deployment practices, weak segmentation, unmanaged credentials, or delayed patching in the surrounding environment. Healthcare delivery organizations need device inventories, network segmentation, access control discipline, and a practical incident response process that includes clinical engineering and biomedical teams. Staff training matters, but it is not enough by itself. Providers need visibility into what devices are connected, which ones are unsupported, how they communicate, and what compensating controls exist when patching is delayed or impossible. Cybersecurity incidents involving medical devices rarely stay confined to a single team, so response planning has to be cross-functional. ### Technologies to Watch Some newer approaches may help, but they are not magic fixes. Blockchain gets discussed for data integrity and distributed trust, though real-world medical device use cases still need careful scrutiny. AI-based detection may improve anomaly identification in large device fleets, but those systems also need tuning, validation, and protection against false confidence. The useful question is not whether a technology sounds advanced. It is whether it reduces risk in a measurable way for the specific device, environment, and clinical workflow. ## The Future of Medical Device Cybersecurity The next wave of medical device risk will come from more software, more autonomy, and more dependence on connected infrastructure. ![Section Image](/imported-images/cf9bafb532ba0632.png) ### 5G, Edge Computing, and More Distributed Risk Technologies like [5G connectivity](/blog) and edge computing will support faster communications, lower latency, and more local processing. That can improve device performance and enable new care models, especially where real-time analysis matters. It also changes the trust model. More distributed systems mean more interfaces, more firmware, more dependencies, and more places where failures or attacks can happen. Security teams will need to assess not just the device, but also the ecosystem around it: radios, gateways, local compute, cloud services, mobile apps, and maintenance tooling. ### Innovation Has to Include Security Engineering Innovation in MedTech is useful only if it holds up under real conditions. That means manufacturers, security teams, and product teams need to work together early. Security cannot be a parallel workstream that shows up right before release. It has to influence architecture, supplier selection, update strategy, and validation planning. [Information sharing and collaboration](/blog) across manufacturers, healthcare organizations, researchers, and regulators also matters. Better disclosure practices, clearer field communications, and coordinated remediation improve safety. Silence and delay do not. ### The Long-Term Impact of AI and Automation AI and machine learning will continue to change device behavior, clinical support, and threat detection. They may help identify anomalies faster and support more adaptive systems. But they also create new failure modes, including model drift, poisoned inputs, manipulated outputs, and hidden dependencies in training or deployment pipelines. That means long-term cybersecurity work will need to cover both classic software weaknesses and AI-specific risks. Manufacturers should expect scrutiny not just around functionality, but around integrity, traceability, change control, and resilience over time. Emerging technology will keep pushing medical devices forward. It will also keep exposing weak assumptions. The manufacturers that win here will be the ones that treat cybersecurity as part of product quality, patient safety, and regulatory readiness from the start. As you assess how emerging technology affects your devices, expert support can make the difference between real risk reduction and checkbox compliance. Blue Goat Cyber, a Veteran-Owned business specializing in medical device cybersecurity, helps manufacturers test products, prepare for FDA expectations, and strengthen security across the device lifecycle. Our B2B services include penetration testing, HIPAA and FDA compliance support, and more. [Contact us today for cybersecurity help](/contact). ## Emerging technologies at a glance | Technology | What it adds to the device | The security question it raises | What a reviewer asks for | | --- | --- | --- | --- | | AI and machine learning | A model whose output drives a clinical decision | Can the model be poisoned, extracted, or fed adversarial input | Threats specific to the model, not just the software around it | | Cloud connectivity | Remote storage, analytics, and support access | Who can reach the device from outside the clinical network | Architecture views showing the trust boundary and how it is authenticated | | 5G and cellular | A path that bypasses the hospital network entirely | What protects the device when the hospital firewall is not in the path | Transport security and credential handling on the cellular link | | Wearables and home use | An unmanaged environment and a consumer phone in the path | Which controls you assumed the hospital would provide | Environmental assumptions stated and substantiated | | Digital twins and simulation | A copy of device behavior, often with real data | Whether the twin holds patient data or firmware secrets | The twin treated as an asset in the threat model | The pattern is the same each time. The technology moves a boundary, and the submission has to show you noticed. ## How Blue Goat approaches this Our approach to mitigating cybersecurity risks associated with emerging technologies focuses on practical, compliance-driven methods. We assess your device's architecture and software, identify potential vulnerabilities introduced by digital health, AI, ML, and IoT components, and map these to regulatory requirements. Our team, with expertise including CISSP and OSCP certifications and ex-military red team experience, conducts thorough threat modeling and penetration testing to uncover weak points before they are exploited. We provide clear, actionable recommendations for secure design, vulnerability management, and incident response planning. Our engagement ensures your cybersecurity posture aligns with the FDA's guidance, minimizing risks and streamlining market clearance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at: https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services. ## FAQ ### How do digital health platforms affect medical device cybersecurity? Digital health platforms increase endpoints, integrations, and data movement, expanding opportunities for attackers. Compromised platforms can expose sensitive health data or alter device communications, leading to operational, regulatory, and clinical impacts. ### What unique cybersecurity risks do AI and machine learning introduce to medical devices? AI and machine learning introduce risks if data inputs, model behavior, or update mechanisms are tampered with. This can lead to unsafe recommendations, incorrect classifications, or treatment errors, even without traditional device hacking. ### What are common cybersecurity vulnerabilities in connected medical devices? Common vulnerabilities include weak credentials, outdated components, insecure update paths, missing encryption, exposed services, and insufficient logging. These can be exploited through lateral movement or compromised third-party systems. ### How does the FDA address emerging technology in medical device cybersecurity? The FDA expects manufacturers to address cybersecurity across the product lifecycle, including threat modeling, secure design, vulnerability management, and software transparency, as outlined in its February 3, 2026 final guidance. Cybersecurity is considered integral to device safety and effectiveness. ### What should medical device manufacturers do to mitigate cybersecurity risks? Manufacturers should implement threat modeling, secure architecture, SBOM management, code review, vulnerability testing, and authenticated update mechanisms. Postmarket processes for monitoring, triage, and patching are also critical. ### How do 5G and edge computing impact future medical device cybersecurity? 5G and edge computing enable faster communications and local processing but create more distributed systems with more interfaces and dependencies. This expands the ecosystem that needs security assessment, beyond just the device itself. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## ANT/ANT+ Protocol Security Security in Medical Devices (2026) Source: https://bluegoatcyber.com/blog/enhancing-cybersecurity-for-ant-ant-medical-devices # ANT/ANT+ Protocol Security Security in Medical Devices: A 2026 Guide > **[DIRECT ANSWER]** ANT/ANT+ medical devices, including activity trackers, heart rate monitors, and glucose meters, face threats such as malware, denial of service, and man-in-the-middle attacks that can expose or alter patient data. Manufacturers reduce this risk with strong authentication, encrypted communication, and regular updates, and document those controls against the FDA's February 3, 2026 premarket cybersecurity guidance, IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023. _Updated October 26, 2024_ In today’s rapidly advancing technological landscape, wireless medical devices have become increasingly prevalent. These devices, such as [ANT/ANT+](https://www.thisisant.com/developer/ant-plus/ant-antplus-defined) medical devices, play a vital role in the healthcare sector, revolutionizing patient care and enabling real-time monitoring and data collection. However, with this technology comes the risk of cyber threats and attacks, which can have severe implications for patient safety and privacy. In this article, we will explore the importance of cybersecurity in healthcare and discuss strategies for enhancing the protection of ANT/ANT+ medical devices. ## Key Takeaways - ANT/ANT+ devices are vital in healthcare, enabling remote monitoring. - Cyber threats to these devices risk patient safety and data privacy. - Common attacks include malware, Denial of Service, and Man-in-the-Middle. - Strong authentication and regular updates mitigate cyber risks. - The FDA premarket guidance provides cybersecurity requirements. - AI and machine learning enhance threat detection and response. ## Why this matters The stakes in securing medical devices utilizing ANT/ANT+ protocols are profoundly high, directly impacting patient safety, data privacy, and organizational trust. Failure to implement adequate cybersecurity measures can lead to life-threatening scenarios, loss of sensitive patient data, and significant regulatory penalties. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly outlines the need for premarket and postmarket security considerations, emphasizing threat modeling, risk assessments, and secure design principles. Adherence to standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is vital for establishing a baseline of security and demonstrating due diligence. Without diligent protection, ANT/ANT+ medical devices become vulnerable entry points for malicious actors, threatening the integrity of healthcare delivery. ## Understanding the Importance of Cybersecurity in Healthcare With the growing reliance on wireless medical devices, the need for [cybersecurity measures has never been more critical](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). These devices, which utilize ANT/ANT+ technology, allow healthcare professionals to monitor patients remotely, collect vital health data, and ensure prompt medical intervention. However, they also create a new avenue for cybercriminals to [exploit vulnerabilities and gain unauthorized access](/blog) to sensitive patient information. ![Section Image](/imported-images/0e4465a341d1c2c7.webp) ### The Role of ANT/ANT+ Devices in the Medical Field ANT/ANT+ devices have become integral to the medical field, providing healthcare professionals valuable insights into patient health and facilitating remote monitoring. These devices are widely used in applications such as activity trackers, heart rate monitors, blood pressure monitors, and glucose meters. The integration of these devices into healthcare systems enhances patient care by allowing for prompt interventions and continuous monitoring of vital signs. The utilization of ANT/ANT+ technology has revolutionized how healthcare professionals interact with patients. In the past, doctors and nurses had to rely solely on in-person visits to assess a patient’s condition. Now, with these wireless medical devices, healthcare providers can monitor patients remotely, reducing the need for frequent hospital visits and allowing patients to recover in the comfort of their homes. ### The Potential Risks of Cyber Threats in Healthcare Despite the numerous benefits of ANT/ANT+ medical devices, they also introduce potential risks in terms of cybersecurity. Cyber threats in the healthcare sector can range from data breaches and identity theft to manipulating patient records and even disrupting critical medical services. The ramifications of these attacks can be far-reaching, compromising patient safety and confidentiality. One of the main concerns in healthcare cybersecurity is the unauthorized access to patient information. Personal health records contain sensitive data, including medical history, medications, and social security numbers. If this information falls into the wrong hands, it can lead to identity theft, insurance fraud, and other malicious activities. Cybercriminals can exploit vulnerabilities in wireless medical devices to gain control over them. This can result in manipulating patient data, altering vital signs, or even causing harm to patients by tampering with medical equipment remotely. Such attacks jeopardize patient safety and erode trust in the healthcare system. ## The Anatomy of Cyber Attacks on Medical Devices Understanding the different types of cyber-attacks that can target ANT/ANT+ medical devices is crucial in developing effective cybersecurity strategies. Cybercriminals employ various tactics to exploit vulnerabilities and gain unauthorized access to these devices, compromising patient safety and privacy. Let’s take a closer look at some of the common types of cyber attacks: In addition to the common cyber-attack types mentioned above, it’s important to highlight the growing concern around insider threats within healthcare organizations. These threats involve malicious actions taken by individuals with legitimate access to medical devices, such as employees or contractors. Insider threats can pose a significant risk to patient data security and device integrity, as these individuals may abuse their privileges to compromise systems from within. ### Common Types of Cyber Attacks 1\. Malware Attacks: Malicious software, such as viruses, worms, and ransomware, can be injected into medical devices, enabling cybercriminals to gain control and manipulate device functionality. 2\. Denial of Service (DoS) Attacks: DoS attacks disrupt normal operations by flooding a device or network with overwhelming traffic, rendering medical devices inaccessible or non-functional. 3\. Man-in-the-Middle (MitM) Attacks: In [MitM attacks](/blog), cybercriminals intercept and alter the communication between medical devices and healthcare systems, potentially modifying or accessing sensitive data. Expanding on the discussion of cyber attacks, it’s essential to recognize the emerging threat landscape posed by ransomware specifically targeting healthcare institutions. Ransomware attacks involve encrypting critical data or systems and demanding a ransom for their release. The healthcare sector’s reliance on uninterrupted access to patient information and medical devices makes it a prime target for ransomware attacks, underscoring the need for proactive security measures. ### The Impact of Cyber Attacks on Patient Safety When cyber attacks are successful, the consequences for patient safety can be severe. Medical devices compromised by cybercriminals can provide inaccurate readings or even be manipulated to administer incorrect treatments or medications. The potential for harm to patients is significant, emphasizing the urgency of cybersecurity measures. ## Strategies for Enhancing Cybersecurity To mitigate the risks posed by cyber threats on ANT/ANT+ medical devices, healthcare organizations and manufacturers must adopt proactive cybersecurity strategies. Here are some key strategies for enhancing cybersecurity: In addition to the strategies mentioned above, another crucial aspect of enhancing cybersecurity in the healthcare sector is conducting regular cybersecurity training and awareness programs for all staff members. Employees need to be educated on the latest cyber threats, phishing scams, and best practices for data protection. By building a culture of cybersecurity awareness, healthcare organizations can empower their employees to be vigilant and proactive in safeguarding sensitive information. ### Implementing Strong Authentication Measures One fundamental aspect of a cybersecurity framework is the implementation of strong authentication measures. Healthcare organizations should adopt stringent access controls, requiring multi-factor authentication and regular password updates. Additionally, biometric authentication, such as fingerprint or facial recognition, can enhance security. ### Regular Software Updates and Patches Keeping medical devices updated with the latest software updates and patches is crucial in addressing vulnerabilities and protecting against cyber-attacks. Device manufacturers and healthcare organizations should establish processes for regular updates and ensure that patches are promptly applied. Regular cybersecurity risk assessments and penetration testing on medical devices can help identify potential weaknesses in the system. By proactively testing for vulnerabilities, healthcare organizations can strengthen their cybersecurity posture and prevent potential breaches before they occur. Collaborating with cybersecurity experts and ethical hackers can provide valuable insights into improving the overall security of medical devices. ## Regulatory Standards and Guidelines for Medical Device Cybersecurity Recognizing the growing importance of cybersecurity in healthcare, regulatory bodies, and industry organizations have developed standards and guidelines to ensure the safe and secure use of medical devices. Let’s take a look at some of the key regulatory standards and guidelines: ### FDA Guidelines for Medical Device Cybersecurity The U.S. Food and Drug Administration (FDA) has published guidelines to assist medical device manufacturers in addressing cybersecurity considerations during the design and development stages. These guidelines emphasize the importance of risk assessments, secure coding practices, and ongoing device security monitoring. The FDA encourages collaboration between manufacturers, healthcare providers, and cybersecurity experts to enhance the overall security posture of medical devices. This collaborative approach helps identify potential vulnerabilities and implement effective mitigation strategies to protect patient data and ensure the uninterrupted delivery of healthcare services. ### International Standards for Medical Device Security In addition to FDA guidelines, international standards organizations, such as the International Electrotechnical Commission (IEC) and the [International Organization for Standardization (ISO),](https://www.iso.org/home.html) have developed standards specific to medical device security. Compliance with these standards ensures that medical devices meet stringent cybersecurity requirements. These international standards focus on the technical aspects of cybersecurity and address the importance of establishing a cybersecurity management system within organizations involved in developing and deploying medical devices. By following these standards, manufacturers can demonstrate their commitment to safeguarding patient information and maintaining the integrity of healthcare systems worldwide. ## Future Perspectives on Cybersecurity in Healthcare Given the nature of cyber threats, staying ahead of the curve is crucial in exploring emerging cybersecurity technologies and strategies. Here are some future perspectives on cybersecurity in healthcare: ![Section Image](/imported-images/3518973b0573caa3.webp) ### Emerging Cybersecurity Technologies Advancements in technologies such as artificial intelligence (AI), machine learning, and blockchain can revolutionize healthcare cybersecurity. AI and machine learning algorithms can detect anomalies and patterns in network traffic, enabling the identification of potential cyber threats in real-time. This level of proactive monitoring can significantly enhance the security posture of healthcare organizations, ensuring the protection of sensitive patient data. With its decentralized and tamper-proof nature, blockchain technology can enhance data integrity and security. By using blockchain, healthcare systems can create an immutable patient data record, making it nearly impossible for cybercriminals to manipulate or tamper with the information. This added layer of security can provide patients with peace of mind, knowing that their medical records are protected from unauthorized access. ### The Role of AI and Machine Learning in Cybersecurity Another area of exploration is the integration of AI and machine learning into cybersecurity frameworks. These technologies can assist in developing predictive models and enhance threat detection and response capabilities. By continuously analyzing vast amounts of data, AI and machine learning algorithms can identify behavioral patterns and anomalies, enabling proactive cybersecurity measures. For instance, AI-powered systems can learn from historical cyber attack data and identify common attack vectors, allowing healthcare organizations to fortify their defenses against known threats. Additionally, machine learning algorithms can adapt and evolve as new cyber threats emerge, ensuring that healthcare systems remain resilient despite evolving attack techniques. ## Conclusion The future of cybersecurity in healthcare holds immense potential. By embracing emerging technologies such as AI, machine learning, and blockchain, healthcare organizations can strengthen their cybersecurity posture and safeguard patient data. Healthcare organizations, device manufacturers, and regulatory bodies must prioritize cybersecurity and implement measures to protect patient safety and privacy. By understanding the anatomy of cyber attacks, adopting proactive strategies, and exploring emerging technologies, we can enhance the cybersecurity of medical devices and ensure the continued delivery of safe and reliable healthcare services. As the healthcare industry continues to evolve with ANT/ANT+ medical devices at the forefront, the imperative for cybersecurity measures has never been greater. Blue Goat Cyber, a Veteran-Owned leader in cybersecurity, offers unparalleled expertise to safeguard your medical devices against the ever-present threat of cyber attacks. Our services, including medical device cybersecurity, penetration testing, and adherence to HIPAA and FDA standards, are designed to protect and empower your healthcare operations. Don’t let cyber threats undermine the safety and privacy of your patients. [Contact us today for cybersecurity help](/contact), and partner with Blue Goat Cyber to secure your digital health environment with confidence and precision. ## How Blue Goat approaches this The Blue Goat approach to securing ANT/ANT+ medical devices begins with a detailed risk assessment and threat modeling to identify specific vulnerabilities. Our methodology incorporates active penetration testing and exploit development, simulating real-world attack scenarios to pinpoint weaknesses before they can be exploited. We then develop and implement tailored security controls, focusing on authentication, encryption, and secure updates. Our team, which includes individuals with CISSP and OSCP certifications and ex-military red team experience, provides practical, actionable recommendations. We assist manufacturers in achieving compliance with regulatory requirements, including the FDA's guidance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [our FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the ANT/ANT+ protocol? ANT/ANT+ is a wireless protocol often used in medical devices for short-range communication. It facilitates data exchange for applications such as fitness trackers, heart rate monitors, and glucose meters. ### Why is cybersecurity important for ANT/ANT+ medical devices? Cybersecurity is important because compromised ANT/ANT+ devices can lead to data breaches, manipulation of patient records, and disruption of critical medical services. These risks directly impact patient safety and data privacy. ### What types of cyberattacks target medical devices? Medical devices can be targeted by malware, Denial of Service (DoS) attacks, and Man-in-the-Middle (MitM) attacks. Insider threats also pose a significant risk to device integrity and patient data. ### How can cybersecurity for ANT/ANT+ medical devices be improved? Improvements can be made through strong authentication, regular software updates and patches, and consistent cybersecurity risk assessments. Adhering to regulatory guidelines is also crucial. ### Does the FDA regulate cybersecurity for medical devices? Yes, the FDA provides specific guidance for medical device cybersecurity, including the February 3, 2026 premarket guidance. These guidelines address risk assessments, secure development practices, and postmarket monitoring. ### What role do AI and machine learning play in medical device cybersecurity? AI and machine learning analyze network traffic for anomalies, identify potential cyber threats in real-time, and develop predictive models. They enhance threat detection and response capabilities for medical devices. **Related:** [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [CoAP Cybersecurity in Medical Devices](/blog/cybersecurity-in-the-coap-medical-device-protocol) - [MQTT Vulnerabilities in Connected Medical Devices](/blog/mqtt-vulnerabilities-connected-medical-devices-fda) --- ## Medical Device Robustnesss & Fuzz Testing Source: https://bluegoatcyber.com/blog/enhancing-medical-device-cybersecurity-robustness-and-fuzz-testing-explained # Medical Device Robustnesss & Fuzz Testing > **[DIRECT ANSWER]** Robustness testing checks that the device behaves safely under malformed input, resource exhaustion, and unexpected sequencing. Fuzz testing automates that by generating large volumes of invalid protocol and file inputs to find crashes, hangs, and memory corruption. For connected devices the FDA expects fuzzing on every external interface, with documented duration, coverage, seed corpus, and the disposition of every crash you found. _Updated November 14, 2024_ ## Key Takeaways - Robustness testing checks device function under stress. - Fuzz testing targets software vulnerabilities from bad input. - Combined testing reveals how devices handle complex failures. - These methods support compliance with FDA expectations. - Testing identifies critical failure points before market release. - Rigorous testing enhances patient safety and trust. ## Why this matters The safety of medical devices hinges on their ability to withstand unforeseen circumstances. A device that falters under stress, accepts malformed data, or behaves unpredictably can jeopardize patient outcomes. These are not mere edge cases; they represent real-world failure modes that demand targeted evaluation. Robustness and fuzz testing identify these critical weaknesses before a product reaches clinical use, safeguarding against incidents that could lead to patient harm, operational disruptions, or significant financial and reputational damage. The FDA, in its 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes the necessity of testing that simulates real-world stress and anomalous inputs to assure device security and resilience. Adherence to standards like IEC 60601-1 (medical electrical equipment safety), ISO 14971 (risk management), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (principles for medical device security) further underscores these testing requirements. Proactive identification of design flaws and software vulnerabilities through these methods is therefore not just a compliance activity, but a fundamental safeguard for patient trust and clinical efficacy. ## Understanding Medical Device Safety Medical device safety is not a paperwork exercise. If a device fails under stress, mishandles malformed input, or behaves unpredictably in clinical use, patients carry the risk. That applies across the spectrum, from simple monitoring tools to implantable and network-connected systems. Safety depends on more than intended function. It depends on how the device behaves when conditions are messy, unexpected, or hostile. ### Why medical device safety matters A device does not have to fail completely to create harm. A software exception, a dropped connection, a timing issue, or a bad user input can all lead to delayed care, incorrect data, or unsafe therapy. Those are real-world failure modes, not edge-case trivia. That is why safety cannot be reduced to a checkbox. Device makers need to account for software defects, hardware faults, user behavior, environmental stress, and security weaknesses that can affect clinical performance. When those issues escape into production, the impact goes well beyond a recall notice. It hits patient trust, provider confidence, and brand credibility. ### Core elements of device safety Several disciplines support device safety. One is [rigorous testing and validation](/blog/a-comprehensive-guide-to-software-testing-for-medical-devices). Another is postmarket monitoring. A third is user training and clear operational design. None of these can stand alone. [Regulatory compliance is non-negotiable](/blog/a-comprehensive-guide-to-software-testing-for-medical-devices), but compliance alone is not the finish line. The [FDA reviews medical device cybersecurity](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) with growing attention to how manufacturers identify and manage risk. That means testing must produce evidence, not theater. Manufacturers, healthcare delivery organizations, and regulators all need visibility into how a device fails, how it recovers, and how risk is reduced before and after release. ## What robustness testing actually does Robustness testing asks a simple question: what happens when the device operates outside the clean conditions assumed in the requirements? It measures whether the system keeps functioning safely when exposed to stress, variation, and misuse. That could mean temperature swings, power instability, EMI, packet loss, timing anomalies, sensor drift, vibration, or invalid user sequences. If the device cannot handle those conditions predictably, the risk is not theoretical. ### Defining robustness testing At its core, robustness testing evaluates reliability under abnormal but plausible conditions. The goal is not just to confirm that the device works on a good day. The goal is to see how it behaves on a bad one. Testing often includes humidity, shock, vibration, electrical disturbance, interrupted communications, boundary conditions, and operator mistakes. These scenarios help manufacturers find brittle logic, unsafe defaults, weak error handling, and dependencies that do not tolerate real clinical environments. ### Why robustness testing matters for medical devices Medical devices do not operate in a lab forever. They operate in ambulances, crowded hospitals, homes with unstable networks, and settings where users are tired, rushed, or unfamiliar with the system. Robustness testing should reflect that reality. It also supports regulatory expectations. The FDA expects manufacturers to understand foreseeable misuse, environmental stress, and system-level behavior tied to safety and effectiveness. A device that only performs well in nominal conditions is not ready for market. ## Fuzz testing and why it belongs in your test strategy If robustness testing evaluates operational resilience, fuzz testing targets software behavior under malformed, unexpected, or hostile input. It is one of the fastest ways to find parsing bugs, memory issues, state handling problems, and crash conditions that conventional test cases miss. For connected and software-driven devices, that matters a lot. ### What is fuzz testing? Fuzz testing feeds invalid, random, mutated, or semi-structured input into software interfaces and observes the result. The input may target network services, file parsers, APIs, serial interfaces, wireless protocols, or internal libraries. The point is not chaos for its own sake. The point is to trigger failure paths developers did not anticipate. A well-built system should reject bad input safely, preserve essential functions, log what happened, and recover cleanly. If it crashes, hangs, corrupts memory, or enters an unsafe state, that is a serious finding. Automated fuzzing makes this practical at scale. Tools can generate large volumes of test cases quickly and repeatedly, which is especially useful for protocol-heavy or input-rich devices. That kind of repetition is often what exposes edge conditions human testers never hit. ### Fuzz testing in medical devices In medical devices, fuzz testing is not optional for software-exposed attack surfaces. It is a practical way to identify vulnerabilities before an attacker, researcher, or hospital environment does it for you. Consider [pacemakers](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know) or any device with external communications, update mechanisms, data import features, or mobile app connectivity. If malformed input can destabilize the software, interfere with therapy, or create a denial-of-service condition, patient risk follows. The FDA has made clear through guidance and review practice that cybersecurity testing should map to actual system risk. Fuzz testing helps support that expectation when interfaces, protocols, and parsers are part of the threat surface. It gives manufacturers evidence that bad input was considered and tested, not merely mentioned in a risk file. ## Where robustness and fuzz testing meet These two methods address different failure classes, and that is exactly why they belong together. Robustness testing focuses on environmental stress, misuse, and system resilience. Fuzz testing focuses on software behavior when input is malformed or adversarial. If you only do one, you leave blind spots. ![Section Image](/imported-images/9c9fab69b71f6679.png) A device may pass environmental and operational stress tests while still failing when it receives malformed packets or corrupted files. The reverse is also true. A parser may survive fuzzing while the overall device fails under power fluctuation, wireless interference, or degraded operating conditions. ### How they complement each other Think of robustness testing as pressure on the operating envelope and fuzz testing as pressure on the software interface layer. Together, they expose whether the device can maintain safe behavior when both the environment and the inputs become unreliable. That matters in real deployments. A connected infusion system, for example, might face network instability, user interruptions, malformed traffic, and battery or power anomalies at the same time. Isolated testing can miss those interactions. Combined testing gives a much clearer picture of system behavior under realistic stress. ### Common implementation challenges The hard part is not understanding the value. The hard part is execution. Good robustness and fuzz testing take time, tooling, architecture knowledge, and engineers who know how to interpret the results. Many teams still treat testing as a milestone activity instead of a lifecycle activity. That creates stale evidence, shallow coverage, and false confidence. Software changes, dependencies change, and threat models change. If testing does not evolve with the device, the evidence degrades quickly. AI-enabled features, wireless interfaces, cloud dependencies, and mobile integrations make this harder, not easier. Every added interface expands the number of ways a device can fail or be manipulated. Manufacturers need test plans that track actual risk, not just legacy verification habits. ## Improving medical device safety with testing that reflects reality When applied correctly, robustness and fuzz testing do more than find bugs. They reveal how a device behaves when assumptions break down. That is the kind of evidence that improves safety engineering, supports regulatory submissions, and reduces unpleasant surprises after release. ![Section Image](/imported-images/f83e71ba04c98dc2.png) This is also where mature manufacturers separate themselves from checklist-driven programs. Real testing is tied to architecture, threat modeling, hazard analysis, and postmarket learning. It is not a pile of screenshots attached to a design history file. ### The impact on safety and trust Better testing reduces device failures, security exposure, and field incidents. It also gives internal teams better decision-making data. Engineering sees where designs are brittle. Quality gets stronger evidence. Regulatory teams can explain the rationale behind test scope and residual risk. Providers and patients get safer products. That trust has business value, but more importantly, it has clinical value. Devices that behave predictably under stress are easier to deploy, support, and rely on in patient care. ### What comes next Testing methods will keep changing, especially as manufacturers adopt AI, machine learning, remote connectivity, and more complex software supply chains. Some tools will improve automation, triage, and coverage. That is useful. But no tool replaces a disciplined security and safety engineering process. The other trend is clear: connected devices will keep drawing more scrutiny. As that happens, cybersecurity testing will need to be deeper, more repeatable, and more tightly mapped to system risk. The FDA is already pushing the industry in that direction. ## Final thoughts Medical device safety depends on how products behave under stress, misuse, and malformed input, not just under normal operating conditions. Robustness testing and fuzz testing help manufacturers answer that question with evidence. ![Section Image](/imported-images/0009970f9177a76c.png) If you build devices that include software, communications, or network exposure, these methods should be part of your baseline strategy. Not because they look good in a submission, but because they find the kinds of failures that matter when the device leaves the bench and reaches patients. At Blue Goat Cyber, we help manufacturers build testing programs that stand up to engineering scrutiny and FDA review. Our team supports medical device companies with cybersecurity risk management, secure development practices, verification strategy, and testing aligned to real-world threats. If you need help strengthening device security without falling into checklist theater, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber's approach to medical device resilience and fuzz testing prioritizes uncovering vulnerabilities that might evade conventional testing. Our methodology goes beyond basic functional checks, simulating real-world operational stressors and malicious inputs. We employ a specialized blend of automated fuzzing tools and manual techniques to explore unusual data combinations and system states. Our team, comprised of certified professionals with credentials such as CISSP and OSCP, including ex-military red team members, applies deep understanding of attacker tactics to anticipate and expose device weaknesses. This allows us to assess a device’s resilience against cyber threats and operational malfunctions. We methodically stress device interfaces, communication protocols, and embedded software to detect memory corruption, denial-of-service vulnerabilities, and other critical failure points. Our services, which include /services/medical-device-penetration-testing, are designed to integrate into your development lifecycle, providing actionable insights that enhance device safety and regulatory compliance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is the difference between robustness and fuzz testing? Robustness testing assesses a device's operational resilience under environmental stress, varying conditions, or misuse. Fuzz testing specifically injects malformed, unexpected data into software interfaces to find bugs and vulnerabilities. ### Why are these testing methods important for medical devices? These methods are vital because medical devices operate in complex, unpredictable environments. They help identify how a device behaves when assumptions break down, preventing failures that could harm patients or compromise device integrity. ### Does the FDA expect manufacturers to perform these tests? Yes, the FDA expects manufacturers to understand foreseeable misuse, environmental stress, and system behavior related to safety. The February 3, 2026 final guidance on premarket cybersecurity emphasizes testing of interfaces and attack surfaces, which these methods support. ### Can fuzz testing find cybersecurity vulnerabilities? Yes, fuzz testing is a highly effective way to uncover cybersecurity vulnerabilities in software, especially those related to parsing input, handling protocols, or managing memory. It can reveal pathways for denial-of-service, unintended state changes, or even remote code execution. ### When should manufacturers conduct robustness and fuzz testing? These tests should be integrated throughout the device development lifecycle, not just as a final step. They are most effective when applied early and iteratively as software and hardware evolve, informing design decisions and risk mitigation. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SBOM + SAST for FDA Compliance Source: https://bluegoatcyber.com/blog/enhancing-medical-device-cybersecurity-the-role-of-sbom-and-sast-in-complying-with-fda-guidelines # SBOM + SAST for FDA Compliance: A Medical Device Playbook > **[DIRECT ANSWER]** SBOM and SAST answer two different reviewer questions. The SBOM says what third-party and open-source code you shipped, with supplier, version, and end-of-support metadata that feeds CVE monitoring. SAST says whether the code you wrote yourself contains injection, memory-safety, or crypto-misuse defects before it reaches a build. The February 3, 2026 guidance expects both, plus evidence that findings from each were triaged and closed. _Reviewed July 24, 2026_ Medical device cybersecurity is a cornerstone of patient safety and data protection. The FDA recognizes this and has put clear expectations on the table. Two tools sit at the center of those expectations: the Software Bill of Materials (SBOM) and Static Application Security Testing (SAST). Both are essential for building and maintaining secure medical devices. SBOM and SAST work together to give manufacturers visibility into what their software contains and whether that software is securely implemented. One without the other leaves significant blind spots. This post covers how SBOM and SAST work, why the FDA cares about both, and how to evaluate the tools available for each. We'll also look at popular SBOM analysis tools and their tradeoffs, grounded in how they apply to [FDA testing guidelines](https://www.fda.gov/media/119933/download). ## Key Takeaways - SBOM inventories software components, aiding vulnerability tracking and compliance. - SAST scans code for security flaws, enabling early detection and remediation. - Combined, SBOM and SAST bolster medical device cybersecurity and regulatory adherence. - The FDA emphasizes both for premarket and postmarket security assurance. - Proactive use of these tools minimizes risk and safeguards patient data. - Implementing SBOM and SAST supports continuous security monitoring. ## Why this matters Vulnerabilities in medical devices can lead to data breaches, operational disruption, or direct patient harm through device failure or compromise. The stakes are not abstract. The FDA's *Cybersecurity in Medical Devices* final guidance, dated February 3, 2026, establishes concrete expectations for manufacturers: understand every software component through an SBOM, and proactively identify weaknesses through SAST. Section 524B of the FD&C Act now gives the FDA authority to refuse acceptance of premarket submissions that don't meet cybersecurity documentation requirements. Standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 reinforce the need to manage software supply chain risks and validate security controls throughout the device lifecycle. Skipping SBOM and SAST isn't a shortcut; it's a path to recalls, FDA deficiency letters, and reputational damage that's hard to undo. Proactive security through these two tools is foundational to responsible device manufacturing. ## Understanding SBOM and Its Synergy with SAST in Enhancing Cybersecurity ### What is SBOM? An [SBOM](/services/fda-compliant-sbom-services-for-medtech) is a detailed inventory that enumerates all software components used in building a software product. This includes open-source components, proprietary code, and third-party libraries. Think of it as a recipe that lists every ingredient in a dish, providing complete transparency into the software's composition. ### The Purpose of SBOM SBOMs serve multiple critical functions in software development and maintenance, particularly in sensitive sectors like healthcare: 1. **Security Management**: They enable better tracking and management of vulnerabilities within software components. 2. **Compliance and Licensing**: SBOMs are instrumental in ensuring adherence to licensing requirements and regulations, which is crucial in regulated sectors like medical device manufacturing. 3. **Software Integrity**: They maintain the integrity of the software throughout its lifecycle, from development to deployment. ### What is SAST? SAST is a method that analyzes an application's source code, bytecode, or binary code for security vulnerabilities without executing it. It's akin to thoroughly examining a building's architectural blueprints to identify structural weaknesses before construction begins. ### The Purpose of SAST [SAST](/services/static-application-security-testing-sast) supports the software development lifecycle, particularly in sectors that demand high security and reliability, such as healthcare technology: - **Early Vulnerability Detection**: SAST enables developers to identify and rectify security flaws early in the development process, thereby reducing the cost and effort of remediation at later stages. - **Enhanced Code Quality**: By integrating SAST into the development pipeline, teams can ensure higher code quality, leading to more secure and reliable software products. - **Compliance and Risk Management**: SAST helps organizations comply with industry regulations and standards by systematically identifying potential security issues that could lead to non-compliance or expose sensitive data. - **Security Assurance**: For sensitive sectors like medical device manufacturing, SAST assures that the software embedded within devices is free from vulnerabilities that could be exploited, ensuring patient safety and data protection. ### Combining SAST with SBOM for Medical Device Cybersecurity While SBOM provides a list of software components, ensuring those components are free from vulnerabilities is equally essential. This is where SAST comes into play. - SAST is a security testing method that analyzes source or compiled code versions to identify potential vulnerabilities. It scans the code to detect flaws that could lead to security breaches. - SAST complements SBOM by examining the code that comprises the listed components. While SBOM tells you what is in your software, SAST tells you about its security. ### Synergy in Medical Device Cybersecurity In the context of medical device cybersecurity, SBOM and SAST provide the following benefits: - **Enhanced Vulnerability Detection**: SBOM's component listing and SAST's code analysis offer a dual-layered approach to identifying software components and implementation vulnerabilities. - **Regulatory Compliance**: This combination enables companies to comply with stringent regulatory standards, such as those set by the [FDA](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity), which require transparency in software composition and assurances of its security. - **Proactive Risk Management**: Together, they provide a proactive approach to managing risks, which is crucial in the medical device industry, where software flaws can have dire consequences. ### Examples of SBOM in Action - **Vulnerability Management in a Pacemaker System**: Consider a pacemaker system that utilizes various software components, including open-source libraries. A [SBOM](/services/fda-compliant-sbom-services-for-medtech) for this system would list these components, enabling the manufacturer to quickly identify and patch a recently discovered vulnerability in one of the libraries, thereby preventing potential life-threatening device malfunctions. - **Compliance in Imaging Software**: In a hospital's imaging software, used for MRI or CT scans, an SBOM helps track the usage of proprietary and third-party software components. This tracking ensures compliance with healthcare regulations and standards, such as [HIPAA](https://www.hhs.gov/hipaa/index.html) in the United States, which demands strict data protection controls. - **Supply Chain Transparency in Hospital Management Software**: An SBOM provides transparency in the software supply chain for a hospital management system, revealing all the underlying components. This transparency is crucial in assessing the system's security posture, mainly due to increased cyber threats targeting healthcare data. ### Examples of SAST in Action - **Secure Development of a Drug Infusion Pump**: Drug infusion pump software developed with SAST would undergo rigorous code analysis to identify and rectify potential security vulnerabilities such as incorrect handling of numerical limits, thus preventing overdosage incidents before the software is executed. - **Ensuring the Security of Electronic Health Records (EHR) Systems**: When developing an EHR system, SAST can identify common vulnerabilities, such as [SQL injection](/blog/medical-device-sql-injection-parameterized-queries) or cross-site scripting, in the codebase, enabling developers to correct these issues. This proactive measure ensures that the EHR system is resilient against attacks that could lead to unauthorized access to patient data. - **Compliance and Security in Telehealth Applications:** For a telehealth application, SAST identifies vulnerabilities that could compromise the confidentiality and integrity of patient communications. The application complies with health information privacy regulations by rectifying these vulnerabilities early in the development phase. It also builds trust with its users by providing a secure platform for telehealth services. Consider a medical device software with an open-source encryption library listed in its SBOM. SAST can analyze how this library is implemented in the device's code, ensuring that it is used securely and doesn't introduce vulnerabilities. ## SBOM's Growing Importance in Medical Devices In healthcare, where patient safety and data security are non-negotiable, the SBOM has moved from optional to expected. This isn't purely about checking a regulatory box. It's about taking ownership of every software component in a device and having a defensible answer when something goes wrong. ### SBOM in Medical Device Cybersecurity: A Crucial Pillar of Protection Integrating SBOM into a medical device cybersecurity program is a critical safeguard in an industry where software flaws can have life-threatening consequences. As the FDA sharpens its focus on cybersecurity documentation, manufacturers without a solid SBOM practice are starting to feel the pressure in the form of Additional Information requests. Here's why it matters: #### A Linchpin for Vulnerability Management - **In-Depth Analysis:** SBOMs provide a granular view of each software component, allowing for a deeper analysis of potential vulnerabilities. This is particularly crucial in medical devices, where even a minor flaw can have significant repercussions. - **Proactive Response:** With a clear SBOM, manufacturers and healthcare providers can swiftly identify and respond to emerging threats, reducing the risk of exploitation and ensuring continuous device functionality. #### Foundation for Regulatory Compliance and Reporting - **Meeting FDA Standards:** A SBOM helps comply with the FDA's stringent regulatory standards for medical devices, ensuring all software components meet the required safety and security benchmarks. Our [Medical Device SBOM: FDA Requirements & Submission Guide (2026)](/blog/medical-device-sbom-fda-requirements-and-submission-guide) details the four SBOM elements reviewers verify at RTA screening. - **Streamlined Documentation:** SBOMs serve as documented proof of compliance, simplifying the regulatory review process and providing a clear audit trail. #### Enhancing Supply Chain Security - **Transparency and Trust:** By delineating every software element, SBOMs create a transparent ecosystem, building trust among manufacturers, suppliers, and end-users. - **Mitigating Third-Party Risks:** SBOMs help identify and assess risks associated with third-party components, a crucial aspect considering the complex supply chains in medical device manufacturing. #### Facilitating Continuous Monitoring and Improvement - **Ongoing Risk Assessment:** An SBOM is not a one-time checklist; it's a dynamic tool for ongoing risk assessment, enabling manufacturers to continuously monitor and update their cybersecurity practices. - **Data-Driven Decision Making:** With a detailed SBOM, manufacturers can make informed decisions about software updates, patches, and security enhancements, further fortifying device security. Implementing SBOMs in medical device cybersecurity goes beyond compliance. It signals a genuine commitment to transparency in a sector where the pace of change is fast and the consequences of security failures can be severe. The SBOM becomes a fundamental component of a resilient cybersecurity strategy, essential for protecting patient data and ensuring the safe operation of medical devices. ## SAST's Growing Importance in Medical Device Cybersecurity Patient safety and data security demand more than good intentions. In healthcare, software supports the operation of devices that directly affect patient outcomes. SAST is the mechanism that confirms that software is actually secure before it reaches a patient. ### SAST in Medical Device Cybersecurity: A Critical Defense Mechanism Incorporating SAST into a medical device cybersecurity strategy is a vital layer of defense in an industry where security breaches can be life-threatening. As the FDA intensifies its scrutiny on cybersecurity, the understanding and implementation of SAST have become indispensable. Here's why: #### Proactive Vulnerability Detection and Management - **Early Identification:** SAST enables the early detection of security vulnerabilities within the medical devices' codebase, ensuring that potential threats are identified and mitigated before deployment. - **Preventive Measures:** With SAST, manufacturers and healthcare providers can proactively address security concerns, minimizing the risk of exploitation and ensuring the uninterrupted functionality of devices. #### Supporting Regulatory Compliance and Documentation - **Adherence to FDA Guidelines**: SAST helps ensure that all software components in medical devices meet the FDA's rigorous safety and security standards, which are crucial for regulatory approval. - **Facilitated Compliance Process**: SAST's systematic approach simplifies the demonstration of compliance, streamlining the regulatory review process and facilitating audit trails. #### Bolstering Supply Chain Security - **Enhanced Transparency and Trust:** SAST promotes a culture of transparency in software development, building trust among manufacturers, suppliers, and users. - **Mitigation of Third-Party Risks:** By identifying vulnerabilities early, SAST supports assessing and mitigating risks associated with third-party components, which are essential in the interconnected supply chains of medical device manufacturing. #### Enabling Continuous Monitoring and Improvement - **Dynamic Risk Assessment**: SAST is not a static process but a continuous one, allowing for the ongoing evaluation of security practices and the adaptation to new threats. - **Informed Security Decisions**: With insights provided by SAST, manufacturers can make knowledgeable decisions regarding software updates, patches, and security enhancements, bolstering the resilience of medical devices. Adopting SAST in medical device cybersecurity goes well beyond regulatory compliance. It reflects a genuine shift toward transparency and continuous improvement in an industry where innovation is relentless and the consequences of security breaches can be severe. SAST is not just a compliance tool. It's a foundational element of any credible cybersecurity strategy, essential for safeguarding patient data and ensuring the reliable operation of medical devices. > **Delivering an FDA-ready SBOM?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ FDA-compliant SBOM services](/services/fda-compliant-sbom-services-for-medtech) ## Tools for SBOM and SAST: Navigating Strengths and Weaknesses Selecting the right tool for SBOM and SAST analysis is a meaningful decision in medical device cybersecurity. These tools support FDA compliance requirements and sharpen your defenses against cyber threats. Here's an honest look at the industry-leading options, including their real tradeoffs: ### 1\. [FOSSA](https://fossa.com/): A Leader in License Compliance Management - **Strengths:** - Offers an extensive license compliance analysis, critical for adhering to legal and regulatory standards. - Automated policy enforcement streamlines the compliance process, thereby reducing the need for manual oversight. - integration with development workflows enhances operational efficiency. - **Weaknesses:** - Complex setups can pose challenges for teams without specialized knowledge. - The cost factor might be a consideration for smaller organizations or startups. ### 2\. [Black Duck by Synopsys](https://www.synopsys.com/software-integrity/software-composition-analysis-tools/black-duck-sca.html): The Complete Vulnerability Tracker - **Strengths:** - Maintains an expansive database for vulnerability tracking. - Delivers in-depth security risk assessments, crucial for high-stakes medical devices. - Broad integration capabilities with various development and operational tools. - **Weaknesses:** - Potential for false positives necessitates manual review and adjustments. - The extensive feature set might overwhelm new users, requiring a learning curve. ### 3\. [WhiteSource](https://www.opensourceprotection.com/Product-Overview.asp): Real-Time Security Vigilance - **Strengths:** - Provides immediate alerts for security vulnerabilities, enabling swift action. - policy enforcement features to maintain consistent security standards. - Effective in identifying and managing open-source components within the software stack. - **Weaknesses:** - May occasionally overlook less common or emerging vulnerabilities. - Resource-intensive operations could impact system performance. ### 4\. [SW360](https://projects.eclipse.org/projects/technology.sw360): The Open-Source Customizable Solution - **Strengths:** - As an open-source tool, it offers high customizability to fit specific organizational needs. - Ideal for managing complex software compositions in large-scale organizations. - Capable of integrating with external databases for enhanced vulnerability management. - **Weaknesses:** - Demands significant technical expertise for effective configuration and ongoing management. - The feature set may be less compared to some proprietary solutions. ### 5\. [OWASP](https://owasp.org/www-project-dependency-track/) Dependency-Track: Specialized in Component Analysis - **Strengths:** - Focused on [Software Composition Analysis (SCA)](/blog/understanding-binary-software-composition-analysis-with-medical-device-testing), crucial for pinpointing component vulnerabilities. - Supports standard SBOM formats like [CycloneDX](/blog), facilitating industry-wide interoperability. - Effective real-time tracking of known vulnerabilities enhances proactive security measures. - **Weaknesses:** - The user interface lacks the intuitiveness of some more user-friendly commercial tools. - Relies on integration with other tools for a complete cybersecurity solution, potentially increasing complexity. ### 6\. [Sonatype Nexus:](https://www.sonatype.com/products/sonatype-nexus-repository) The Integrated Repository Manager - **Strengths:** - Provides an integrated platform for managing software components and their dependencies. - It offers detailed security and licensing analysis, which is crucial for compliance and risk management. - Strong community support and frequent updates enhance its effectiveness. - **Weaknesses:** - Configuring it can be complex, requiring in-depth technical knowledge. - Some features might be overkill for smaller projects or organizations. ### 7\. [JFrog Xray:](https://jfrog.com/devops-native-security/) The Continuous Security Tool - **Strengths:** - Delivers continuous security and compliance analysis, which is crucial for dynamic development environments. - Effective vulnerability scanning across a wide range of package types and databases. - Integrates with JFrog Artifactory, creating a ecosystem for artifact management. - **Weaknesses:** - The learning curve for new users is steep due to its extensive range of features. - It can be resource-intensive, demanding significant computational power. ### 8\. [Bitbucket Pipelines:](https://bitbucket.org/product/features/pipelines) The CI/CD Enabler - **Strengths:** - Integrates directly with Bitbucket for [continuous integration and delivery (CI/CD)](/blog), streamlining the development process. - Automates the build, test, and deployment processes, enhancing efficiency and reducing errors. - Provides a scalable solution that grows with the project or organization. - **Weaknesses:** - Primarily beneficial for teams already using Bitbucket; it may require migration for others. - It is limited in terms of built-in security features compared to specialized SBOM tools. ### 9\. [Snyk:](https://snyk.io/) The Developer-Friendly Security Tool - **Strengths:** - A user-friendly interface makes it accessible for developers with varying levels of security expertise. - Provides detailed vulnerability reports and offers remediation guidance. - Strong integration capabilities with popular development and deployment tools. - **Weaknesses:** - Some advanced features are available only in the paid version. - It may not cover all programming languages and frameworks extensively. ### 10\. [GitLab:](https://about.gitlab.com/) The All-in-One Platform - **Strengths:** - Offers a complete DevOps platform, integrating SCM, CI/CD, and security testing in one place. - Facilitates collaboration and streamlines workflows, which is particularly beneficial for large teams. - Continuous scanning and monitoring capabilities enhance real-time security. - **Weaknesses:** - The complexity of the platform can be overwhelming for small teams or simple projects. - Some features may require a premium subscription, which will impact budget considerations. ## Elevating Cybersecurity through Strategic Integration of SBOM Tools and SAST In medical device cybersecurity, combining SBOM tools with SAST produces something greater than either delivers alone. This integration doesn't just layer controls on top of each other; it closes gaps that neither approach can address independently. ### Holistic Security Coverage: A Dual-Front Approach - **Vulnerability Detection**: While SBOM tools excel in cataloging and tracking known vulnerabilities in software components, SAST covers the code structure, identifying potential security flaws from the ground up. This dual-front approach ensures no stone is left unturned in safeguarding software against cyber threats. - **Proactive and Reactive Security Measures**: SBOM tools enable a reactive stance towards known vulnerabilities, while SAST offers a proactive guard, detecting vulnerabilities early in the development cycle. This combination allows for a dynamic and responsive security strategy, which is crucial in the cyber landscape. ### Enhanced Regulatory Adherence and Reporting - **Alignment with FDA Regulations**: Integrating SBOM and SAST is particularly beneficial in meeting the FDA's stringent requirements. It ensures that every software layer adheres to the highest security standards, from composition to code. - **Streamlined Compliance Processes**: With documentation from both SBOM and SAST, medical device manufacturers can more effectively demonstrate compliance during audits and regulatory reviews, simplifying what is often a complex and time-consuming process. ### Building a Culture of Security The strategic integration of SBOM tools and SAST represents more than a best practice in medical device cybersecurity. It reflects a thorough, proactive approach to ensuring the safety and efficacy of medical technologies. As healthcare continues to digitalize, this integration will be central to protecting sensitive patient data and keeping life-saving devices running reliably. Each tool in the SBOM and SAST ecosystem brings distinct strengths: integration capabilities, user-friendliness, continuous monitoring, or deep security analysis. Tool selection should align with organizational requirements, device risk profile, and specific cybersecurity goals, balancing compliance, security, and operational efficiency. In a field where technological innovation and regulatory compliance are tightly connected, those choices matter. Taken together, SBOM and SAST represent a meaningful shift in how the industry thinks about medical device security. SBOMs bring transparency and accountability, clearly mapping the software components of a device. SAST provides the foresight to identify and fix vulnerabilities at the code level before they can be exploited. By building out a tool set for SBOM analysis, each selected for its specific strengths, organizations can tailor their cybersecurity approach to their device's actual risk profile. That's not just about satisfying the FDA. It's about building devices that actually deserve the trust patients place in them. ## Conclusion Combining SBOM and SAST is more than a regulatory requirement. It's a commitment to patient safety and data protection in a healthcare environment that runs on software. As medical technology advances, that commitment must evolve with it. Continuous learning, adaptation, and cross-functional collaboration are what keep manufacturers ahead of the threat. By staying informed and proactive, the industry can deliver devices that are safe, effective, and genuinely secure. Explore our [medical device cybersecurity and](/services/fda-premarket-cybersecurity-services) [FDA compliance package](/services/fda-premarket-cybersecurity-services). ## SBOM vs SAST: which one answers which question The two tools answer different questions, and a submission needs both. SBOM tells a reviewer what is inside your device. SAST tells a reviewer what your own code does wrong. Neither one covers for the other. | Question | SBOM answers it | SAST answers it | | --- | --- | --- | | What third-party components ship in this build? | Yes, component by component with versions | No | | Which known CVEs affect this release? | Yes, once correlated against a vulnerability feed | No | | Does our own source code contain injection or memory flaws? | No | Yes | | Is a flagged CVE actually exploitable in our design? | No, that judgment goes in a VEX statement | Partly, for code paths it can trace | | When does it run? | At every build and again at every release | On every commit or nightly build | | What the FDA expects in the submission | Machine-readable file plus support and end-of-life dates | Evidence of the process and how findings were resolved | | Who has to maintain it after clearance | Postmarket monitoring, for the device's supported life | The development team, as long as code changes | ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in meeting FDA cybersecurity requirements. Our approach integrates SBOM generation and SAST implementation early in the development cycle to address vulnerabilities before they reach a submission. We analyze device software components to create accurate SBOMs, then conduct thorough static code analysis to identify security flaws before they manifest in deployed devices. Our team, comprised of certified professionals including CISSP and ex-military red team members, applies practical experience to identify and mitigate risks. We focus on effective, efficient security practices tailored to your specific device and regulatory needs. Our process streamlines compliance efforts, aiming for regulatory submission acceptance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [FDA Premarket Cybersecurity Services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is an SBOM in the context of medical devices? An SBOM for a medical device is a complete inventory of all software components used in the device. This includes commercial, open-source, and third-party elements, providing transparency into the software supply chain needed for identifying and managing vulnerabilities as required by the FDA. ### How does SAST improve medical device security? SAST improves medical device security by analyzing the device's software code for vulnerabilities like SQL injection or buffer overflows without executing the program. This allows developers to identify and fix security flaws early in the development process, reducing the risk of exploitation and ensuring compliance with FDA expectations. ### Does the FDA require SBOMs and SAST for medical devices? The FDA's February 3, 2026 final guidance on cybersecurity in medical devices emphasizes the importance of both SBOMs and secure development practices, including static analysis, though it does not explicitly mandate specific tools. Manufacturers are expected to provide an SBOM and incorporate security testing like SAST as part of their premarket submissions and postmarket management. ### What is the primary benefit of combining SBOM and SAST for medical devices? The primary benefit of combining SBOM and SAST for medical devices is enhanced vulnerability detection and risk management. SBOM reveals what software components are present, while SAST verifies the security of how those components are implemented and interact, providing a complete view of the device's security posture and aiding compliance. ### Can SBOM and SAST help with postmarket medical device security? Yes, SBOM and SAST are vital for postmarket medical device security. An SBOM facilitates rapid identification of devices affected by newly disclosed vulnerabilities in specific software components. SAST insights from development can inform ongoing security analyses and updates, ensuring devices remain secure throughout their lifecycle. ### Are there specific tools for performing SBOM analysis or SAST for medical devices? While the FDA does not endorse specific tools, there are many commercial and open-source tools available. For SBOM generation, tools like SPDX, CycloneDX, and commercial solutions are used. For SAST, common tools include Veracode, Checkmarx, SonarQube, and other static code analyzers, many of which can be tailored for medical device development. The choice of tool depends on the development environment and specific needs. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Enhancing Medical Device Security: Tamper Source: https://bluegoatcyber.com/blog/enhancing-medical-device-security-tamper-proof-seals-and-cybersecurity-labeling # Enhancing Medical Device Security: Tamper-Proof Seals and Cybersecurity Labeling > **[DIRECT ANSWER]** Tamper-proof seals and cybersecurity labeling work together to secure medical devices: seals create visible, permanent evidence when a housing, port, or connector has been opened, while labeling documents a device's digital security attributes for buyers and operators. Neither replaces secure design, but the FDA's February 3, 2026 guidance expects both physical and software integrity controls, aligned to IEC 81001-5-1 and AAMI TIR97, documented and demonstrable. _Reviewed July 24, 2026_ ## Key Takeaways - Tamper seals indicate physical device interference. - Cybersecurity labels detail digital security attributes. - Both controls enhance medical device security posture. - Labeling aids informed purchasing and deployment decisions. - Combined, they address physical and digital risks. - FDA expectations drive visible, documented security controls. ## Why this matters The security of medical devices significantly impacts patient safety, operational continuity, and data integrity. Vulnerable devices create pathways for attacks, potentially compromising health data or disrupting care delivery. Regulators, including the FDA, increasingly emphasize verifiable controls. The FDA’s Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, mandates that manufacturers integrate security considerations throughout the product lifecycle, including physical and software integrity. Lack of visible security assurances also erodes trust among healthcare providers and patients. Manufacturers must adhere to standards like ISO/IEC 81001-5-1 and AAMI TIR97 to demonstrate due diligence in securing their devices. Implementing clear tamper evidence and cybersecurity labeling aligns with these expectations, mitigating risks, demonstrating responsible design, and building confidence in device integrity and performance. Ignoring these aspects courts regulatory non-compliance, market rejection, and potential harm. ## Understanding the Importance of Medical Device Security Medical devices are now part of the clinical network, the software stack, and the patient safety picture. That means device security is no longer a back-office IT issue. It affects safety, operations, data integrity, and whether your product will stand up to scrutiny from customers and the FDA. ![Section Image](/imported-images/111454fc323aad6c.png) Hospitals run on connected systems, and every connection creates opportunity for misuse. A vulnerable device can become an access point, a pivot target, or a source of unsafe behavior. That is why [medical device security controls](/blog/top-10-medical-device-vulnerabilities-revealed-protecting-patient-safety) need to address both physical access and cyber risk. ### The Role of Medical Devices in Healthcare Medical devices span everything from basic diagnostic tools to networked infusion pumps, implant programmers, imaging platforms, and remote monitoring systems. They support diagnosis, therapy delivery, patient monitoring, and surgical care. In many cases, they also collect, store, transmit, or influence protected health information and clinical decisions. As telehealth and connected care have expanded, more devices now communicate across hospital networks, home environments, mobile apps, and cloud services. That connectivity improves visibility and care coordination, but it also expands the attack surface. A weakness in one component can affect the larger system around it. ### Potential Risks and Threats to Medical Devices The failure modes are well known: outdated software, weak authentication, insecure update paths, poor network segmentation, exposed interfaces, and insufficient logging. Attackers do not need magic. They need one reachable weakness and time. The consequences can be serious. A [malware attack](/blog) can disrupt device availability. Weak access controls can expose sensitive patient data. A compromised configuration can affect device behavior, alarms, or clinical workflows. [Ransomware](/blog/understanding-relevant-threats-for-medical-devices) can also interrupt supporting systems that devices rely on, delaying care and creating operational chaos. Security work here is not about fear-driven marketing. It is about reducing the chance that a device can be altered, misused, or trusted when it should not be. ## Tamper-Proof Seals as a Physical Security Control Tamper-proof seals are one of the simplest ways to show that a device, package, port, or enclosure has been opened or altered. They do not replace secure design, but they do make unauthorized physical access easier to detect and investigate. A good seal creates evidence. If someone opens a housing, accesses a connector, or swaps a component, the seal should show it clearly and permanently. That matters in hospitals, service depots, supply chains, and home-use settings where devices may pass through many hands. ### How Tamper-Proof Seals Work Tamper-evident controls use different mechanisms depending on the device and use case. Some rely on destructible materials or adhesives that cannot be removed cleanly. Others leave visible residue, void patterns, serial markings, or other signs of disturbance. More advanced implementations can pair physical access indicators with digital logs, alerts, or service records. The point is not just deterrence. It is traceability. If a device enclosure was opened, you want evidence that supports triage, service review, incident response, and root-cause analysis. ### Where They Help Most Tamper-proof seals are especially useful where physical access can change risk: - external ports used for maintenance or data transfer - battery compartments or removable modules - service panels and enclosures - packaged sterile or ready-to-use devices - devices moving through distribution or field servicing These controls also help define responsibility. A broken seal can trigger inspection steps, quarantine procedures, or further technical review before the device returns to service. ### Benefits and Limits of Tamper-Proof Seals Used well, tamper-evident measures improve accountability and shorten the time between unauthorized access and detection. They can support internal quality processes, field service controls, and complaint investigations. They also give providers and patients a visible sign that the manufacturer took physical integrity seriously. But they have limits. A seal does not harden software. It does not stop credential abuse, insecure APIs, or malicious updates. It is one layer, not the strategy. ## Cybersecurity Labeling and Security Transparency [Cybersecurity labeling](/blog/medical-device-cybersecurity-labeling) is getting more attention because buyers, users, and regulators want clearer information about what a device can and cannot do from a security standpoint. A label, summary, or security fact sheet can help communicate that information in a way that procurement teams and clinical engineering teams can actually use. That does not mean marketing claims dressed up as assurance. Good labeling should be specific, supportable, and tied to real product capabilities. ### What Cybersecurity Labeling Should Communicate A useful label or disclosure set may include: - supported software and firmware update practices - authentication and access control features - encryption in transit and at rest, where applicable - logging and audit capabilities - patching expectations and support period - network exposure, interfaces, and dependencies - coordinated vulnerability disclosure information This gives healthcare delivery organizations a clearer view of deployment risk and maintenance burden. It also forces manufacturers to be precise about their own security posture. ### Why Labeling Improves Security Security labeling works best when it changes behavior upstream. If a manufacturer knows its claims will be reviewed by customers, assessors, and potentially the FDA, the pressure shifts from checkbox language to actual implementation. It also helps purchasers compare devices on more than clinical features and price. That matters. Hospitals need to know whether a device can be patched, how access is controlled, and what happens when a vulnerability is found. Clear labeling makes those conversations easier and cuts through vague assurances. ## Combining Physical Tamper Evidence and Cybersecurity Labeling These two controls work better together than apart. Tamper-evident seals address physical integrity. Cybersecurity labeling addresses transparency around digital risk and maintenance expectations. One tells users whether someone may have physically interfered with the device. The other helps them understand how the device should be secured, supported, and monitored. That combination creates a more defensible product story. Not a glossy one. A credible one. For example, a connected device might ship with tamper-evident protection on service access points and include security labeling that explains authentication requirements, update mechanisms, supported configurations, and expected user responsibilities. That gives providers visible evidence of physical integrity and practical information for secure deployment. ## Implementation Considerations Manufacturers should start with risk, not packaging design or marketing language. Look at how the device is accessed, serviced, distributed, and updated. Then determine where tamper evidence adds value and what security information users actually need. Cross-functional work matters here. Engineering, product security, quality, regulatory, and service teams should all be involved. If these groups work in silos, you usually get one of two bad outcomes: a seal that interferes with servicing, or a label full of claims that do not match the product. Training matters too. Providers, technicians, and internal teams need to know what a broken seal means, when to escalate, and how to interpret security labeling without turning it into checklist theater. ### Common Challenges The usual issues show up fast: - cost pressure on packaging and manufacturing - confusion between tamper-resistant and tamper-evident controls - weak coordination between security and regulatory teams - labels that are too vague to help customers - service models that conflict with physical access restrictions None of these are new. They are design and governance problems, and they can be fixed early if the manufacturer treats security as part of product quality instead of post-launch cleanup. ## Future Direction: Smarter Controls, Higher Expectations Medical device security expectations will keep rising. Devices are becoming more software-dependent, more connected, and more integrated with third-party systems. Attackers are getting more efficient. Hospitals are asking harder questions. The FDA is asking better ones. ![Section Image](/imported-images/ff6c95a75be455a6.png) That means manufacturers need controls that are visible, supportable, and tied to documented risk decisions. Physical tamper evidence will still matter, especially for devices exposed to field access or supply-chain handling. Security labeling will matter more as procurement teams push for clearer evidence of maintainability and secure design. ### Technological Advancements and Their Implications AI and machine learning may improve anomaly detection, service analytics, and threat monitoring around connected devices. That can help identify unusual access patterns or maintenance events faster. Still, no detection layer excuses weak fundamentals. If the device lacks secure architecture, authenticated updates, and defensible access controls, smarter monitoring only tells you that a preventable problem has already happened. ### Regulatory Changes and Their Effects on Device Security [Medical device cybersecurity regulation and guidance](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) will continue to develop, and manufacturers need to keep pace. The FDA has raised expectations around secure product development, risk management, vulnerability handling, and postmarket support. Security communications, including labeling and user-facing documentation, will receive more attention when they affect safe deployment and maintenance. Manufacturers that prepare early are in a better position with customers and with the FDA. Those that wait usually end up rewriting documents, reworking designs, or explaining why obvious gaps were left open. ## Make Security Visible and Defensible Tamper-proof seals and cybersecurity labeling are not silver bullets. They are practical controls that help users detect physical interference, understand security capabilities, and make better decisions about device trust. When they are grounded in real engineering and clear risk management, they improve safety and strengthen your compliance position. If your team is preparing for an FDA submission, updating product security documentation, or tightening controls across the device lifecycle, Blue Goat Cyber can help. We support manufacturers with healthcare security services aligned to FDA expectations, IEC 62304, and EU MDR. [Talk with our team](/contact) if you need a clearer path to secure design, defendable documentation, and devices that hold up under review. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in implementing and validating device security. Our methodology supports the integration of physical and digital security controls from design through post-market phases. We offer expertise in threat modeling, penetration testing, and security architecture review, drawing on credentials like CISSP and OSCP, often held by our ex-military red team specialists. We ensure that devices meet regulatory requirements and market expectations for tamper evidence and cybersecurity labeling. Our services include designing labeling strategies that clearly communicate a device’s security posture and helping embed physical seals effectively. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Explore our services at: [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is a tamper-proof seal on a medical device? A tamper-proof seal is a physical indicator designed to show if a medical device, its packaging, or its components have been opened or altered without authorization. These seals help detect physical intrusions and support investigations into device integrity. ### How does cybersecurity labeling improve medical device security? Cybersecurity labeling improves security by providing transparent, specific information about a device's digital security features, such as update practices, authentication methods, and patching expectations. This empowers users and procurement teams to make informed decisions for secure deployment and maintenance. ### Does the FDA require tamper-proof seals for medical devices? The FDA emphasizes the importance of controlling unauthorized access to medical devices, and tamper-evident features can contribute to meeting these expectations. While not always explicitly mandated as "seals," manufacturers must demonstrate control over device integrity throughout its lifecycle. ### What information should be included in medical device cybersecurity labeling? Cybersecurity labeling should communicate details such as supported software updates, authentication features, encryption use, logging capabilities, patching policies, network dependencies, and vulnerability disclosure information. This helps healthcare delivery organizations assess deployment risks. ### Can tamper-proof seals prevent cyber attacks? No, tamper-proof seals do not prevent cyberattacks. They are physical security controls designed to detect unauthorized physical access or alteration. Cyberattacks typically exploit software vulnerabilities, network weaknesses, or credential compromises, which require digital security measures. ### How do physical and cybersecurity controls interact for medical devices? Physical and cybersecurity controls interact by creating a complete security posture. Tamper-evident seals address the physical integrity of a device, while cybersecurity labeling and features protect its digital components from unauthorized access and manipulation. Both are necessary to mitigate diverse risks. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## eSTAR v7.0 Cybersecurity for IVDs vs nIVD Submissions Source: https://bluegoatcyber.com/blog/estar-cybersecurity-ivd-vs-nivd-submissions # eSTAR v7.0 Cybersecurity for IVDs vs nIVD > **[DIRECT ANSWER]** The eSTAR v7.0 Cybersecurity attachment area is the same for IVD and nIVD submissions, and the 8 named attachments we recommend packaging into it do not change either. What differs is the content OHT7 reviewers expect inside each slot, since IVDs raise concerns like LIS and middleware integration, sample-to-result integrity, and CLIA-driven laboratory workflows that nIVD threat models and controls documentation typically do not address at all. _Published June 11, 2026_ ## Key Takeaways - The 8 recommended eSTAR v7.0 cybersecurity attachments are structurally identical for IVD and nIVD submissions. The differentiation is content, not container. - IVD submissions are reviewed by OHT7, which has a distinct cybersecurity posture focused on sample-to-result integrity and laboratory connectivity. - Slot 3 (Threat Model) on an IVD must address LIS/EHR integration, middleware (e.g. Data Innovations Instrument Manager), and multi-instrument lab environments. - Slot 6 (Security Controls) must cover patient-result integrity, audit logging tied to QC and CLIA requirements, and authentication models that match laboratory workflows. - Slot 8 (Labeling) on an IVD reaches the laboratory director, not the clinician, interoperability and IT-security guidance must be written for the lab IT and biomed audience. ## Why this matters IVDs are cyber devices under Section 524B exactly the way nIVDs are. The February 3, 2026 final premarket cybersecurity guidance does not carve out a softer path for in vitro diagnostics, same statutory floor, same single eSTAR v7.0 Cybersecurity attachment area, same expectation of test evidence. What the guidance does not spell out, and what trips IVD sponsors, is that the reviewing office is different. **OHT7** evaluates IVD submissions through a lens shaped by CLIA, lab workflow, and integration patterns that simply do not exist in most therapeutic device reviews. A nIVD cybersecurity package transplanted into an IVD eSTAR is structurally complete and substantively wrong. Reviewers flag the same patterns on most IVD submissions: a threat model that ignores the LIS, a controls catalog that does not address result integrity, labeling written for clinicians instead of lab directors. Each pattern becomes an Additional Information cycle. ## The 8 slots are the same, but OHT7 reads them differently The eSTAR v7.0 cybersecurity attachments are identical in number and order for IVD and nIVD submissions. The slots are: 1. Cybersecurity Management Plan 2. Security Risk Assessment 3. Threat Model 4. Architecture Views (System, Network, Application, Data Flow) 5. Software Bill of Materials (SBOM) 6. Security Controls 7. Testing 8. Cybersecurity Labeling For the canonical slot mapping see our [eSTAR v7.0 Cybersecurity Attachments guide](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance). What changes for IVDs is the **expected content** inside each slot. > **[KEY REQUIREMENT]** OHT7 reviewers do not accept a generic "the device transmits results to the hospital network" abstraction. The threat model, architecture views, controls, and labeling must name the specific LIS/middleware/EHR integration patterns the device supports. ## Slot-by-slot IVD-specific guidance ### Slot 1, Cybersecurity Management Plan - Reference CLSI AUTO11-A and CLSI AUTO16 where applicable, in addition to AAMI SW96 and IEC 81001-5-1. - Postmarket commitments must address the laboratory upgrade window, labs cannot patch during a CLIA proficiency-testing event without re-validation. ### Slot 2, Security Risk Assessment - Patient-harm scenarios on IVDs trace through **result integrity**, not direct device action. A modified glucose result that drives an insulin dose is the canonical example. - Map to ISO 14971 and the IVD-specific risk framework in IEC 62304 / IEC 81001-5-1 jointly. ### Slot 3, Threat Model This is where nIVD packages most often fall short. An IVD threat model must address: - **LIS / middleware integration**, ASTM E1394, HL7 v2.5 ORU^R01, HL7 FHIR DiagnosticReport, Data Innovations Instrument Manager, Roche cobas IT, Sysmex SNCS connectivity. - **Sample-to-result integrity**, STRIDE Tampering on the sample ID barcode, the analytical result, and the QC record. - **Multi-instrument lab environments**, one IVD rarely operates alone; the threat model must include the lab segment, not just the device. - **Remote-service connectivity**, most analyzers maintain vendor remote-service tunnels (VPN, MQTT, vendor cloud). Reviewers expect explicit modeling. See our [STRIDE Threat Modeling guide](/guides/stride-threat-modeling-medical-devices) for the underlying methodology. ### Slot 4, Architecture Views - The Network View must show LIS, middleware, vendor remote service, and lab IT segmentation. A single "connects to hospital network" arrow is the most common red flag. - The Data Flow View must show sample ID → analytical run → QC → result → LIS as discrete trust boundaries. ### Slot 5, SBOM - Same Section 524B(b)(3) requirements as nIVDs. CycloneDX 1.5+ or SPDX 2.3+. See the [SBOM pillar](/guides/sbom-for-medical-devices). - IVDs frequently embed Windows IoT or Windows 10 LTSC for the analyzer controller, the OS SBOM and patch posture are reviewer focus areas, often surfacing as deficiencies on legacy Win10 builds. ### Slot 6, Security Controls The 8 control categories (Authentication, Authorization, Cryptography, Integrity, Confidentiality, Logging, Resiliency, Updatability) are identical to nIVD expectations. The IVD-specific overlays: - **Authentication**, role-based for lab tech, supervisor, lab director, service engineer. Single-tech shared logins are common in labs and a recurring deficiency. - **Integrity**, explicit controls on the analytical result and QC record path. Hash chains or signed result records are increasingly expected. - **Logging**, audit trail must satisfy CLIA §493.1289 (test record retention) in addition to the FDA's cybersecurity logging expectations. - **Resiliency**, sample loss is a clinical harm event. The resiliency narrative must address what happens to in-flight samples during a security incident. For the canonical breakdown see [FDA Security Control Categories for Medical Devices](/guides/fda-security-control-categories-medical-devices). ### Slot 7, Testing - Pen test scope must include the LIS/middleware integration path, not just the device's local interfaces. - Result-integrity testing, does a tampered HL7 message reach the LIS without detection?, is an expected test case for IVDs and rarely present in nIVD-derived test plans. ### Slot 8, Cybersecurity Labeling - Audience is the **laboratory director and lab IT**, not the clinician. - Must include the LIS integration guidance, expected lab network segmentation, supported HL7/ASTM versions, and the MDS2 / HSCC disclosure tuned to lab procurement. - See [Interoperability Labeling for Connected Medical Devices](/blog/interoperability-labeling-medical-devices-fda) and [MDS2 / HSCC Disclosure](/blog/the-role-of-mds2-in-medical-device-cybersecurity). ## The deficiency patterns we see on IVD submissions Four patterns dominate IVD cybersecurity Additional Information requests: 1. **LIS/middleware absent from the threat model.** The threat model treats the LIS as out of scope. OHT7 disagrees, if the device's output crosses the trust boundary into the LIS, the integration path is in scope. 2. **Shared-login authentication left undocumented.** Labs run shared technologist accounts in practice. Submissions either pretend they don't or fail to describe compensating controls. 3. **Result-integrity controls missing from Slot 6.** Authentication and encryption are present; explicit integrity controls on the analytical result are not. 4. **Labeling written for the wrong audience.** A clinician-facing labeling section in an IVD submission gets cited on relevance, the user is the laboratory, not the bedside. ## How Blue Goat Cyber builds IVD cybersecurity packages We staff IVD engagements with reviewers who have shipped through OHT7 specifically. The threat model is built to reach the LIS and middleware (we maintain reference data flows for Data Innovations, Roche cobas IT, and Sysmex SNCS); the controls catalog is tuned to CLIA logging and shared-login realities; the labeling is written for the laboratory director audience the submission will actually serve. We deliver the eSTAR v7.0 attachments as a complete IVD-tailored package, with the cross-references between Slots 3, 6, 7, and 8 the reviewer expects to follow. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** See our [penetration testing service](/services/penetration-testing) and the [FDA Cybersecurity Testing Requirements Taxonomy](/guides/fda-cybersecurity-testing-requirements-taxonomy). ## FAQ ### Is the eSTAR v7.0 cybersecurity section different for IVD submissions? The structure is identical, same 8 attachment slots in the same order. What differs is the content reviewers expect, because IVD submissions are evaluated by OHT7 against laboratory connectivity, sample-to-result integrity, and CLIA-aligned logging that do not appear in most nIVD reviews. ### Can we reuse a nIVD cybersecurity package on an IVD submission? Only as a starting point. The threat model, architecture views, controls, testing, and labeling all need IVD-specific rework, LIS/middleware in the threat model, lab segmentation in the architecture, result-integrity controls in Slot 6, lab-director audience in Slot 8. Submitting a copy-paste nIVD package on an IVD eSTAR is one of the most common ways to receive an Additional Information request. ### Does Section 524B apply to IVDs? Yes. Any IVD that meets the Section 524B definition of "cyber device", software validated by the sponsor, able to connect to the internet, technologically capable of being compromised, falls under the statute. Most modern analyzers and middleware-connected IVDs qualify. Use our [Cyber Device Applicability tool](/tools/cyber-device-applicability). ### What about CLIA-waived or POC IVDs? CLIA-waived and point-of-care IVDs still fall under Section 524B if they meet the cyber-device definition. The threat model shifts to address connected POC ecosystems (CGM-style cloud sync, EHR integration via FHIR), but the eight slots and the OHT7 reviewing posture are the same. ### How does this interact with EU IVDR cybersecurity expectations? EU IVDR Annex I §17.2 and MDCG 2019-16 require cybersecurity evidence parallel to the FDA's expectations. A well-built IVD cybersecurity package, threat model addressing LIS, integrity controls, postmarket vulnerability management, covers both regimes if you produce a single CycloneDX SBOM and a unified threat model. See our [EU MDR vs FDA cybersecurity crosswalk](/guides/eu-mdr-vs-fda-cybersecurity). ### Which standards should be cited in an IVD cybersecurity package? AAMI SW96 (security risk management), IEC 81001-5-1 (secure development), ISO 14971 (risk), IEC 62304 (software lifecycle), and CLSI AUTO11-A / AUTO16 (lab automation interoperability). The labeling should also reference HL7 v2.5, HL7 FHIR DiagnosticReport, ASTM E1394, and LOINC where the device emits coded results. ## Ready to scope your IVD eSTAR cybersecurity package? If you are preparing a 510(k), De Novo, or PMA submission for an IVD and are unsure whether your cybersecurity package meets OHT7's expectations, we will review your draft against the patterns above and scope the gap closure before your submission window. [Request a scoping call](/contact). --- _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, ex-military red team. Has shipped IVD cybersecurity packages through OHT7 for analyzer platforms, molecular diagnostic systems, and connected POC devices. [More on the author](/team/christian-espinosa)._ ## Related reading - [eSTAR v7.0 Cybersecurity Attachments mapping](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) - [FDA Security Control Categories for Medical Devices](/guides/fda-security-control-categories-medical-devices) - [Cybersecurity Management Plan for FDA Medical Devices](/guides/cybersecurity-management-plan-fda-medical-devices) - [STRIDE Threat Modeling for Medical Devices](/guides/stride-threat-modeling-medical-devices) - [MDS2 / HSCC Disclosure for Medical Devices](/blog/the-role-of-mds2-in-medical-device-cybersecurity) - [Interoperability Labeling for Connected Medical Devices](/blog/interoperability-labeling-medical-devices-fda) --- ## Medical Device MedRadio Vulnerabilities Source: https://bluegoatcyber.com/blog/examining-medradio-vulnerabilities-in-medical-devices-cybersecurity # Medical Device MedRadio Vulnerabilities: What Manufacturers Need to Know > **[DIRECT ANSWER]** MedRadio, the FCC-allocated wireless service used by pacemakers, neurostimulators, and cochlear implants, carries vulnerabilities such as unencrypted data and weak authentication that can let attackers intercept or alter patient data. The FDA's February 3, 2026 guidance expects manufacturers to build in encryption and authentication by design, manage postmarket risk continuously, and align with IEC 60601-1-10, ISO 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023. _Updated November 10, 2024_ From pacemakers to insulin pumps, medical devices have revolutionized how we approach patient care. However, with innovation comes a new set of challenges. One of the most pressing concerns in this digital age is the [vulnerability of medical devices to cyber threats](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). In this article, we will covers the world of MedRadio vulnerabilities and explore the crucial role cybersecurity plays in safeguarding patient health. ## Key Takeaways - MedRadio devices use wireless tech for patient monitoring. - Vulnerabilities include unencrypted data, weak authentication. - Cyber breaches risk patient data, safety, and service disruption. - FDA guidelines set a baseline for device cybersecurity. - Beyond compliance, proactive security measures are vital. - Continuous monitoring and updates matter for protection. ## Why this matters The security of MedRadio-enabled medical devices is critically important because vulnerabilities can directly compromise patient safety and privacy. Exploiting weaknesses in these devices could lead to unauthorized access, manipulation of device functions, or disclosure of sensitive patient health information. Such breaches not only endanger individuals but also erode trust in healthcare systems and technology. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the necessity for manufacturers to integrate security by design and to manage post-market risks effectively. This guidance highlights the risks associated with inadequate cybersecurity, including potential medical errors, device malfunction, and large-scale data compromise. Industry standards such as IEC 60601-1-10:2020, ISO 27001, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023):2016 provide frameworks for risk management, quality systems, and security controls, respectively. Adherence to these standards, coupled with regulatory expectations, is crucial for safeguarding the functionality and data integrity of medical devices, ensuring continued patient welfare. ## Understanding MedRadio in Healthcare Before we explore the vulnerabilities, it’s important to understand MedRadio and how it impacts healthcare. MedRadio, also known as [Medical Device Radiocommunication Service](https://www.fcc.gov/medical-device-radiocommunications-service-medradio), is a wireless technology used in various medical devices. It enables device-to-device communication, allowing medical professionals to monitor and control these devices remotely without the need for physical interaction. ![Section Image](/imported-images/4ae9e7bc5e2ecfbd.webp) Expanding on the significance of MedRadio in healthcare, it’s crucial to note that this technology has revolutionized patient care by providing real-time data transmission and monitoring capabilities. This means that healthcare providers can make informed decisions promptly, leading to improved treatment outcomes and patient safety. Additionally, MedRadio supports telemedicine applications, enabling healthcare professionals to deliver care to patients in remote or underserved areas. ### The Role of MedRadio in Medical Devices MedRadio is the backbone for many life-saving devices, such as implantable cardiac devices, neurostimulators, and cochlear implants. It facilitates communication between the device and healthcare providers, enabling timely adjustments and interventions to optimize patient care. This technology has undoubtedly enhanced the quality of healthcare delivery, but it is not without its vulnerabilities. Delving deeper into MedRadio’s impact on medical devices, it’s worth highlighting that these technologies have significantly improved patient outcomes and quality of life. For instance, implantable cardiac devices equipped with MedRadio capabilities can transmit critical patient heart health data to healthcare providers, allowing for early detection of issues and timely interventions. Similarly, neurostimulators utilizing MedRadio technology can help manage chronic pain conditions more effectively by adjusting stimulation levels remotely based on patient feedback. ### The Technological Framework of MedRadio At its core, [MedRadio relies on radiofrequency](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) (RF) waves to transmit data between medical devices and external systems. RF waves operate within specific frequency bands allocated by regulatory bodies such as the Federal Communications Commission (FCC). These frequency bands are shared with other wireless devices, increasing the potential for interference and unauthorized access. The security of MedRadio communication is a critical consideration in the healthcare industry. Encryption and authentication protocols are implemented to safeguard patient data and prevent unauthorized tampering with medical devices. However, as technology advances and cyber threats evolve, ensuring the robustness of these security measures remains an ongoing challenge for healthcare organizations and device manufacturers. ## Identifying Potential Cybersecurity Threats As the healthcare industry embraces digital transformation, the risk of cyber attacks on medical devices becomes more prominent. Without adequate cybersecurity measures, these devices could be vulnerable to many threats, compromising patient safety and data integrity. ![Section Image](/imported-images/8c9b01e0dac58800.webp) The need for cybersecurity practices cannot be overstated in today’s interconnected world, where medical devices are increasingly integrated with networked systems. Technological evolution has brought numerous benefits to the healthcare sector, such as remote monitoring and real-time data analysis. However, it has also opened up new avenues for cyber threats, making it essential for healthcare providers to stay vigilant and proactive in safeguarding patient information and medical devices. ### Common Cybersecurity Vulnerabilities in MedRadio One of the most common vulnerabilities in MedRadio devices is the lack of encryption. Malicious actors can intercept and manipulate the data transmitted between devices without encryption. Additionally, [insecure wireless protocols](/blog) and weak authentication mechanisms can open the door for unauthorized access. The proliferation of [Internet of Things (IoT) devices](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) in healthcare settings has introduced additional complexities in ensuring the security of interconnected systems. The interplay between various devices and networks creates a web of potential vulnerabilities that cyber attackers can exploit. Healthcare organizations must conduct thorough risk assessments and implement layered security measures to mitigate these risks effectively. ### The Impact of Cybersecurity Breaches on Healthcare A cybersecurity breach in the healthcare sector can have far-reaching consequences. Not only can it compromise patient privacy and confidentiality, but it can also disrupt critical healthcare services. Imagine a scenario where a hacker gains control over an insulin pump or adjusts the settings of a cardiac device remotely. The ramifications could be catastrophic, underscoring the urgent need for [cybersecurity measures](/blog). The reputational damage and legal implications resulting from a cybersecurity breach can have lasting effects on healthcare organizations. Patients rely on healthcare providers to protect their sensitive information and deliver safe, quality care. Any compromise in cybersecurity jeopardizes patient trust and exposes healthcare facilities to regulatory penalties and financial losses. Healthcare professionals must prioritize cybersecurity as an integral part of their operations to ensure the continuity of care and the safeguarding of patient well-being. ## MedRadio and Regulatory Compliance Recognizing the potential risks associated with MedRadio, regulatory bodies have established standards and guidelines to ensure the safety and security of these devices. Compliance with these regulations is essential, but it is not a foolproof solution to cybersecurity. Ensuring the security and integrity of MedRadio devices is a multifaceted challenge requiring regulatory compliance, technological solutions, and proactive risk management strategies. Organizations must navigate a complex landscape of evolving threats and regulatory requirements to safeguard these critical medical devices. ### Current Regulatory Standards for MedRadio The [FDA has set forth guidelines for medical device cybersecurity](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) in the United States. The guidelines emphasize the importance of security controls and risk assessments throughout the device’s lifecycle. Additionally, the FCC regulates the use of wireless spectrum allocated to MedRadio, imposing technical requirements to mitigate interference and unauthorized access. Compliance with these regulatory standards is crucial for ensuring the safe and effective operation of MedRadio devices. By adhering to these guidelines, manufacturers and healthcare providers can mitigate potential risks and vulnerabilities that could compromise patient safety and data security. ### The Gap Between Compliance and Actual Security While regulatory compliance is a step in the right direction, it does not guarantee security. The dynamic nature of cyber threats necessitates a proactive approach to cybersecurity. Compliance standards should be viewed as a baseline, with organizations going above and beyond to implement security measures and regular monitoring. Organizations must adopt a [holistic cybersecurity strategy](/blog) encompassing regulatory compliance, threat intelligence, incident response planning, and ongoing security assessments. By taking a proactive and approach to cybersecurity, stakeholders can better protect MedRadio devices and the sensitive information they handle. ## Strategies for Enhancing MedRadio Cybersecurity In addition to the mentioned strategies, another crucial aspect of enhancing MedRadio cybersecurity is ensuring the devices’ physical security. Implementing measures such as secure storage facilities, restricted access to MedRadio devices, and regular inventory checks can help prevent unauthorized physical access that may compromise the devices’ security. ### Best Practices for Securing MedRadio Devices 1. Implement strong [encryption protocols](/blog/medical-device-key-exchange-cybersecurity) to protect data transmission. 2. Regularly update device firmware with security patches and updates. 3. Adopt [multi-factor authentication](/blog) to strengthen access controls. 4. Conduct thorough risk assessments to identify vulnerabilities. 5. Establish incident response plans to mitigate the impact of breaches. Healthcare organizations should prioritize employee training and awareness programs to educate staff about cybersecurity best practices and the importance of safeguarding MedRadio devices. Human error remains one of the leading causes of security breaches, making investing in continuous education and training imperative. ### Future Trends in MedRadio Cybersecurity As technology continues to evolve, so too will the cybersecurity landscape. Emerging trends such as [machine learning and artificial intelligence](/blog) hold immense potential in enhancing MedRadio security. These technologies can analyze vast amounts of data to detect anomalies and identify potential threats in real-time. The integration of [blockchain technology](/blog) in MedRadio cybersecurity is gaining traction. Blockchain’s decentralized and tamper-resistant nature can provide a secure platform for storing and managing sensitive patient data, reducing the risk of data breaches and unauthorized access. ## Conclusion As we look ahead, we must balance patient care and cybersecurity. While advancements in medical devices have undoubtedly improved patient outcomes, they also pose inherent risks. Continuous monitoring and improvement will be paramount in safeguarding the integrity of MedRadio devices and ensuring the safety and well-being of patients worldwide. ### Balancing Patient Care and Cybersecurity As healthcare professionals, our primary focus is always on providing the best possible care to our patients. However, it is equally important to recognize the impact of cybersecurity on patient safety. By striking a balance between the two, we can navigate the challenges posed by MedRadio vulnerabilities while delivering exceptional care. ### The Role of Continuous Monitoring and Improvement Cyber threats are not static; they are constantly evolving, requiring healthcare organizations to embrace a culture of continuous monitoring and improvement. By staying vigilant and adapting to emerging threats, we can proactively identify and mitigate vulnerabilities in MedRadio devices, ensuring the longevity and effectiveness of our healthcare systems. As the healthcare sector continues to integrate advanced medical devices, the importance of cybersecurity measures cannot be overstated. With its unparalleled expertise in medical device cybersecurity, Blue Goat Cyber stands ready to fortify your organization against MedRadio vulnerabilities and other cyber threats. Our veteran-owned company is committed to providing tailored B2B services that ensure HIPAA and FDA compliance and rigorous penetration testing to secure your digital infrastructure. Don’t let cyber vulnerabilities compromise your patient care or business continuity. [Contact us today for cybersecurity help](/contact) and partner with Blue Goat Cyber to transform your cybersecurity challenges into a strategic advantage. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers address MedRadio vulnerabilities with a focused, evidence-based approach. Our methodology includes detailed threat modeling and penetration testing, where our CISSP and OSCP certified engineers, many with ex-military red team experience, identify specific weaknesses in wireless communication protocols and device firmware. We assess compliance against relevant FDA guidelines and industry standards. Our services extend to aiding in the development of secure architectures and implementing controls like advanced encryption and secure boot processes. We provide clear, actionable recommendations for hardening devices against exploitation. For regulatory submissions, we specialize in preparing thorough documentation. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is MedRadio in medical devices? MedRadio (Medical Device Radiocommunication Service) is a wireless technology used in medical devices for communication. It allows devices to transmit data and enables remote monitoring and control by healthcare professionals. ### How does MedRadio impact patient care? MedRadio significantly enhances patient care by enabling real-time data transmission and remote device adjustments. This facilitates prompt medical decisions, improves treatment outcomes, and supports telemedicine for remote patients. ### What are common cybersecurity threats to MedRadio devices? Common threats include a lack of encryption, insecure wireless protocols, and weak authentication mechanisms. These vulnerabilities can allow unauthorized interception, manipulation of data, and unauthorized access to medical devices. ### Does the FDA regulate MedRadio cybersecurity? Yes, the FDA provides cybersecurity guidelines for medical devices, including those using MedRadio. These guidelines emphasize security controls and risk assessments throughout a device's lifecycle to ensure safety and security. ### How can MedRadio device cybersecurity be improved? Improving MedRadio cybersecurity requires implementing strong encryption, regularly updating device firmware, using multi-factor authentication, and conducting thorough risk assessments. Establishing incident response plans is also essential. ### Why is continuous monitoring important for MedRadio security? Cyber threats constantly evolve, making continuous monitoring needed for MedRadio security. This allows healthcare organizations to proactively identify new vulnerabilities, adapt to emerging threats, and maintain the long-term effectiveness of their security measures. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Examples of Hacked Medical Devices Source: https://bluegoatcyber.com/blog/examples-of-hacked-medical-devices # Examples of Hacked Medical Devices: What Manufacturers Need to Know > **[DIRECT ANSWER]** Documented cases include insulin pumps with unauthenticated wireless commands, implantable cardiac device telemetry weaknesses that prompted recalls and firmware updates, infusion pumps exposed through hospital networks, and imaging systems compromised by unpatched operating systems. The pattern repeats: trusted-by-default wireless interfaces, legacy software that cannot be patched quickly, and no vulnerability intake path. Every one of these failure modes is now something the FDA expects your submission to address. _Reviewed July 24, 2026_ Medical devices have improved patient care, diagnosis, and treatment. But as these devices have become more connected and more dependent on software, they have also become attractive targets for attackers. This post looks at medical devices that have been hacked or exposed, what that means for patients and providers, and why stronger cybersecurity controls are necessary across healthcare. ## Key Takeaways - Design flaws make medical devices vulnerable to cyberattack. - Outdated software in devices creates security gaps. - Interconnectivity provides attackers more entry points. - Compromised devices can lead to direct patient harm. - Cyberattacks can expose sensitive patient health data. - Stronger controls are needed across healthcare. ## Why this matters The threat of hacked medical devices represents a severe challenge to patient safety and trust in healthcare technology. When medical devices are compromised, the consequences extend beyond data breaches to direct physical harm, such as incorrect medication delivery, altered treatment protocols, or device malfunction during critical procedures. This can lead to morbidity, mortality, and significant legal and reputational damage for manufacturers and healthcare providers. Regulators, including the FDA, recognize this escalating risk. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the necessity for security measures throughout the device lifecycle. This guidance aligns with industry standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023, which provide frameworks for risk management and security by design. Adherence to these standards is no longer optional but essential for ensuring device safety, regulatory compliance, and preventing the catastrophic outcomes associated with medical device compromises. Protecting medical devices is paramount for safeguarding patient well-being and maintaining healthcare system integrity. ## Understanding Medical Device Vulnerabilities - **Design Flaws**: Historically, medical device development focused on functionality and patient safety, often with little attention to cybersecurity. That left many devices with built-in weaknesses. - **Outdated Software**: Many medical devices run outdated operating systems or software that manufacturers no longer support. That makes them hard to secure and maintain because patches and updates may no longer be available. - **Interconnectivity**: The growing connectivity of medical devices within healthcare networks and the [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) ecosystem gives attackers more entry points. One compromised device can put an entire network at risk. ## Examples of Compromised Medical Devices - **Insulin Pumps**: [In 2019, security researchers discovered vulnerabilities in certain models of Medtronic insulin pumps](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955451/). These flaws could let attackers manipulate insulin dosage, creating a life-threatening risk for diabetic patients. - **Cardiac Devices**: [In 2016, the U.S. Food and Drug Administration (FDA) warned about security vulnerabilities in St. Jude Medical’s cardiac devices](https://www.healthcareitnews.com/news/fda-patients-st-jude-pacemakers-update-needed-keep-hackers-out-devices#:~:text=The%20flaws%20in%20St.,the%20administration%20of%20inappropriate%20pacing.), including pacemakers and defibrillators. These vulnerabilities could have allowed attackers to access and change device settings, putting patients’ lives at risk. - **Infusion Pumps**: Infusion pumps, used to deliver medications and fluids, have also faced cybersecurity problems. In some cases, attackers could alter medication dosages, potentially causing harm or death. ## The Consequences of Medical Device Compromise - **Compromised Patient Safety and Health Outcomes:** Unauthorized access to or manipulation of medical devices can lead to incorrect diagnoses, inappropriate treatment decisions, and direct patient harm. The immediate danger is only part of the problem. Long-term outcomes can also worsen, with prolonged recovery, increased morbidity, or irreversible damage. - **Unauthorized Access and Exposure of Sensitive Data:** Medical devices often store and transmit sensitive patient information. Cyberattacks can cause major data breaches, exposing health records, personal identification information, and financial data. That violates privacy laws and puts patients at risk of identity theft and fraud. - **Financial Implications for Healthcare Providers:** A cybersecurity breach can create costs across several fronts. Response costs, legal fees, penalties for non-compliance with data protection regulations, and spending on stronger security measures add up fast. Providers may also face lawsuits from patients or insurers. - **Reputational Damage:** Trust is central to healthcare. A cyberattack that compromises patient safety or data can damage the reputation of both healthcare providers and medical device manufacturers. Rebuilding trust takes time. A damaged reputation can also mean fewer patients, lost partnerships, and trouble hiring and retaining skilled staff. - **Regulatory and Legal Consequences:** Healthcare providers and medical device manufacturers must meet strict requirements for patient data protection and device safety. Cybersecurity incidents can trigger regulatory scrutiny, fines, and sanctions. Failing to protect patient information can also lead to legal action from patients, regulators, and other parties. - **Impact on Innovation and Device Development:** Concern about cybersecurity weaknesses can slow the development and adoption of new medical technologies. Manufacturers may delay releases, and providers may hesitate to adopt advanced tools, slowing progress in care delivery. - **Systemic Healthcare Disruptions:** A coordinated cyberattack can affect more than a single device or system. Disabling devices in an intensive care unit or tampering with laboratory results could cause widespread confusion, treatment delays, and reduced efficiency across healthcare operations. - **Increased Insurance Costs:** Cybersecurity incidents can raise premiums for cyber insurance, liability insurance, and related coverage for healthcare providers and medical device manufacturers. Those higher costs can strain budgets and pull money away from patient care or research and development. ### Handling Consequences To reduce these consequences, healthcare providers, medical device manufacturers, and regulators need to work together on stronger security measures, incident response plans, and ongoing cybersecurity training. Standards and guidelines such as [ISO/IEC 27001](/blog) for information security management and the principles in “OWASP Security by Design Principles” provide a structured way to manage cybersecurity risk​. ## Addressing the Urgent Issue Protecting medical devices and sensitive health data takes a practical, multi-part approach. That means coordinated action across the healthcare ecosystem. ### Enhanced Collaboration for Unified Cybersecurity Standards - **Multi-Stakeholder Cybersecurity Frameworks:** Healthcare providers, device manufacturers, and regulators need to work together on cybersecurity frameworks. These frameworks should standardize security practices so devices and systems are more consistent and compatible. - **Industry-Government Partnerships:** Partnerships between the healthcare industry and government agencies can improve sharing of cyber threat intelligence and strengthen collective response to cybersecurity threats. ### Commitment to Regular Security Updates and Maintenance - **Mandatory Update Policies:** Manufacturers must have policies that ensure medical devices get timely security updates and patches throughout their lifecycle. - **Automated Update Mechanisms:** Where possible, automated update mechanisms can help keep devices current with the latest patches and reduce dependence on manual updates. ### Complete Education and Awareness Programs - **Cybersecurity Training for Healthcare Professionals:** Healthcare professionals need training tailored to their environment. That training should cover threat recognition, cybersecurity best practices, and incident response procedures. - **Patient Education Initiatives:** Patients should get clear, accessible information about the cybersecurity risks tied to their medical devices. That includes guidance on secure use and who to contact if they suspect a breach. ### Prioritizing Secure Design from the Outset - **Embedding Security in the Design Process:** Security needs to be part of the medical device design process from the start. That includes encryption for data at rest and in transit, strong authentication, and access controls that restrict functionality to authorized users. - **Adherence to Secure Development Lifecycles:** Manufacturers should follow [secure development lifecycle (SDL) practices,](/blog) which build security into every phase of device development, from conception through decommissioning. ### Implementing Continuous Monitoring and Rapid Response Systems - **Advanced Monitoring Solutions:** Healthcare institutions should deploy monitoring and detection systems to identify suspicious activity or potential breaches in real time. This can include intrusion detection systems (IDS) and security information and event management (SIEM) systems. - **Proactive Incident Response Teams:** Dedicated incident response teams need the tools and authority to act quickly during a cybersecurity incident. They should be trained in forensics, containment, and recovery to limit the damage. ## The Role of Regulatory Bodies Regulators such as the [Food and Drug Administration (FDA)](https://www.fda.gov/media/119933/download) are central to medical device cybersecurity. Their job includes setting expectations, reducing risk, and protecting public health. ### Expanding the Scope of Regulatory Oversight - **Development of Cybersecurity Frameworks:** Regulatory bodies are responsible for creating cybersecurity frameworks that define requirements for designing, developing, and deploying medical devices. These frameworks should evolve with current research and threat intelligence. - **Guidance for Incorporating Cybersecurity in Device Design:** By issuing detailed guidance on cybersecurity in device design, regulatory bodies help ensure security is built into product development. That includes recommendations for encryption, secure coding, and strong access controls. - **Mandatory Risk Assessment Protocols:** Mandatory risk assessment protocols help ensure that manufacturers evaluate cybersecurity threats throughout the product lifecycle. That includes premarket assessments and continuous postmarket surveillance. - **Issuance of Warnings and Recall Authority:** Regulatory bodies need authority to issue warnings about known vulnerabilities and, when needed, require recalls of devices that create significant patient safety risk. ### Adapting Regulations for an Evolving Threat Landscape - **Dynamic Regulatory Frameworks:** As cyber threats change, regulations need to change with them. Regulatory bodies should update guidance regularly to reflect new attack methods, advances in security technology, and changes in device use and connectivity. - **Strengthening Requirements for Device Manufacturers:** Regulations should require manufacturers to implement stronger cybersecurity measures during development and maintenance. That includes regular software updates and patches, vulnerability scanning, and secure product lifecycle management. - **Accountability and Enforcement Mechanisms:** Manufacturers need to be held accountable for meeting cybersecurity standards and regulations. That can include audits, penalties for non-compliance, and transparent reporting of cybersecurity incidents. - **Promotion of Industry Collaboration:** Regulatory bodies can support information sharing and best practices across manufacturers, healthcare providers, and cybersecurity experts. Better collaboration improves overall medical device security and encourages better security solutions. - **Public Awareness and Education:** Regulatory enforcement alone is not enough. Patients and healthcare providers also need education on the cybersecurity risks tied to medical devices. Regulatory bodies can help by raising awareness and publishing useful resources. By taking on these roles and updating regulations as threats change, regulatory bodies such as the FDA can help keep medical devices safe and secure and protect patient health and personal data from cyberattacks. ## Case Study: The Impact of the St. Jude Medical Cardiac Device Vulnerability The [cybersecurity vulnerabilities discovered in St. Jude Medical’s cardiac devices](https://www.securityweek.com/st-jude-medical-recalls-465000-pacemakers-over-security-vulnerabilities/#:~:text=Vulnerabilities%20in%20St.,battery%20at%20a%20fast%20rate.) remain a key case study in medical device security. The vulnerabilities created a direct patient safety risk by potentially allowing unauthorized access to device controls. They also exposed major weaknesses in protecting sensitive patient data. The FDA responded by warning the public and later recalling affected devices. That action reduced immediate risk and made clear that cybersecurity in medical devices is not optional. The incident forced a reexamination of existing cybersecurity practices and showed the need for a stronger framework to address these vulnerabilities. After the St. Jude Medical incident, consensus grew around the need for closer coordination among healthcare providers, device manufacturers, and regulators. That coordination is necessary to develop and enforce stronger cybersecurity protocols, including regular security assessments, timely patches and updates, and clear communication with stakeholders about risk. The incident also showed why cybersecurity needs to be addressed across the full device lifecycle, from design through postmarket surveillance. Security cannot be an afterthought. The FDA’s warning and subsequent recall made the urgency clear. It was a wake-up call for healthcare providers, manufacturers, and regulators to put stricter cybersecurity protocols in place. ## Known incidents at a glance The publicly documented cases follow a small number of patterns. Reading them side by side is more useful than reading them one at a time. | Incident | Device type | Root cause | What it changed for manufacturers | | --- | --- | --- | --- | | St. Jude Medical cardiac devices (2016 to 2017) | Implantable pacemakers and defibrillators, home transmitter | Weak authentication on the RF telemetry link | The FDA issued a safety communication and firmware update, and premarket reviewers began asking how wireless commands are authenticated | | Hospira Symbiq infusion pump (2015) | Large volume infusion pump | Network exposure that allowed unauthorized dose library changes | The FDA advised providers to stop using the pump, which showed that a security finding can end a product line | | Medtronic MiniMed insulin pumps (2019) | Insulin pump with wireless remote | Unencrypted, unauthenticated proprietary wireless protocol that could not be patched | A recall rather than an update, because no field fix existed for the radio design | | Medtronic CareLink programmers (2018 to 2019) | Clinician programmer | Software update delivered over an unauthenticated channel | Update integrity became a standard review question, not an implementation detail | | URGENT/11 (2019) | Any device using the VxWorks IPnet stack | Vulnerabilities in a third party TCP/IP stack | Manufacturers had to answer what is in the device, which is the practical argument for an SBOM | | Ripple20 (2020) | Devices embedding the Treck TCP/IP stack | The same third party component problem, deeper in the supply chain | Component provenance moved from a purchasing question to a submission question | Only one of these was a clever attack. The rest were design decisions that looked acceptable at the time and did not survive outside scrutiny. ## Conclusion Medical devices have improved patient care, but they have also become targets for cyberattacks. Medical device hacking threatens patient safety, data security, and healthcare operations. Addressing it takes coordinated work from healthcare providers, manufacturers, regulators, and cybersecurity experts. Prioritizing cybersecurity, using secure design practices, and continuously monitoring and updating devices can reduce the risks tied to medical device hacking. [Contact us](/contact) today for help securing your medical device. Explore our [medical device cybersecurity and](/services/fda-premarket-cybersecurity-services) [FDA compliance package.](/services/fda-premarket-cybersecurity-services) ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers secure their products against evolving threats. Our methodology integrates security throughout the development lifecycle, addressing vulnerabilities before they become exploitable. Our team, composed of CISSP and OSCP-certified professionals, including ex-military red team members, applies practical security knowledge to real-world device challenges. We provide tailored solutions, from threat modeling to penetration testing. Our services are designed to meet regulatory requirements, including those outlined in the FDA 'Cybersecurity in Medical Devices' Final Guidance. We assist clients in navigating complex compliance landscapes, ensuring their devices meet necessary security postures. For instance, our premarket cybersecurity services help manufacturers prepare for FDA submissions. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We focus on practical, effective security without overpromising. ## FAQ ### What medical devices have been hacked? Insulin pumps, cardiac devices (like pacemakers), and infusion pumps are examples of medical devices that have been subject to cybersecurity vulnerabilities or attacks, posing risks to patient health and data. ### How do medical devices get hacked? Medical devices can be hacked due to design flaws, outdated software, and increasing interconnectivity. These factors create entry points for attackers to exploit, potentially manipulating device functions or accessing sensitive data. ### What are the consequences of a medical device hack? Consequences include compromised patient safety, unauthorized access to sensitive data, significant financial implications for healthcare providers, reputational damage, and regulatory penalties. Such incidents can also disrupt healthcare systems and drive up insurance costs. ### Does the FDA regulate medical device cybersecurity? Yes, the FDA regulates medical device cybersecurity. The agency sets expectations, provides guidance like the February 3, 2026 final guidance for premarket submissions, and has the authority to ensure devices are safe and secure throughout their lifecycle. ### What is the St. Jude Medical cardiac device vulnerability? The St. Jude Medical cardiac device vulnerability involved security flaws in pacemakers and defibrillators that could have allowed unauthorized access to device controls. The FDA issued warnings, emphasizing the direct patient safety risks and data exposure implications. ### How can medical device cybersecurity be improved? Improving medical device cybersecurity requires multi-stakeholder collaboration, regular security updates, complete education for professionals and patients, secure design principles from the outset, and continuous monitoring with rapid response systems. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SoC Security Medical Devices: Reduce Attack Surface | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/exploring-system-on-a-chip-soc-vulnerabilities # SoC Security Medical Devices Need to Close Silicon Gaps > **[DIRECT ANSWER]** SoC security in medical devices means securing the CPU, memory, radios, and boot logic that vendors package onto a single chip. A flaw in any integrated block, such as a Bluetooth stack or boot ROM, can compromise the whole device even when application code is sound. Manufacturers must enable secure boot and a hardware root of trust, disable unused debug interfaces, track chip errata, and list third party silicon in the SBOM so the FDA can review hardware level controls. _Reviewed September 17, 2026_ A System-on-Chip failure does not stay contained to one function. Because the CPU, memory, wireless radios, and cryptographic engine sit on the same die, a defect in the Bluetooth stack or boot logic can expose patient data, disable a monitor, or hand an attacker chip-level control. Connected medical devices, from insulin pumps to imaging consoles, depend on SoCs sourced from vendors who ship their own firmware, SDKs, and debug tooling, and manufacturers often inherit that risk without fully evaluating it. The FDA now expects hardware-level scrutiny as part of premarket cybersecurity review, not just application software testing. Devices cleared without documented SoC risk assessments face additional information requests or delayed clearance. This article explains the SoC attack surface, the controls that reduce it, and the documentation reviewers expect under the February 3, 2026 final guidance. ## Key Takeaways - SoCs integrate CPU, memory, and radios on one chip, creating a single point of failure across functions. - Secure boot and a hardware root of trust are the baseline defenses against firmware tampering. - Debug and test interfaces left active in production hardware bypass every other control. - Chip errata and vendor SDK code carry risk that manufacturers rarely track past initial integration. - Third party silicon and its firmware belong in the SBOM, not just application-layer components. - The FDA expects hardware-level controls documented with the same rigor as software controls. ## Why This Matters Medical device manufacturers rarely design their own silicon. They buy SoCs from vendors like TI, NXP, or STMicroelectronics and build application software on top of a firmware and driver stack they did not write and cannot fully audit. That dependency means known SoC-level flaws, such as SweynTooth in BLE stacks or NUCLEUS:13 in embedded TCP/IP stacks, can affect a device even if the manufacturer's own code has no bugs. A single unpatched vendor library can crash a patient monitor, disable an infusion pump's wireless telemetry, or open a path to remote code execution. The FDA's February 3, 2026 final guidance, following the September 2023 and June 27, 2025 final guidances, treats hardware and firmware as part of the same cybersecurity risk management file as application software. Reviewers expect a threat model that names the SoC, its radios, its boot chain, and its debug interfaces as discrete attack surfaces, each with a documented mitigation. AAMI SW96 (recognition number 13-131) reinforces this by requiring security risk management across the full device architecture, not just the top application layer. Manufacturers who treat the SoC as a black box invoice line rather than an engineering artifact are the ones most likely to receive additional information requests tied to hardware-level gaps. ## What Makes SoC Security Different From Application Security? SoC security differs from application security because a single chip integrates functions that used to sit on separate, isolated boards. A modern SoC combines a CPU core, RAM, flash controller, Bluetooth or Wi-Fi radio, and often a cryptographic accelerator on one die. That integration is efficient for low-power embedded medical devices, but it also means a vulnerability in one subsystem, like the radio firmware, can be leveraged to reach memory or execution paths that have nothing to do with wireless communication. **[KEY REQUIREMENT]** Threat models must treat each SoC-integrated function, radios, boot ROM, debug interfaces, and cryptographic engine, as a separate attack surface rather than bundling the whole chip into a single generic "hardware" risk line. | Attack Surface | Typical Exploit Path | Primary Mitigation | |---|---|---| | BLE/Wi-Fi stack | SweynTooth, BrakTooth style stack flaws | Vendor patch tracking, fuzz testing | | Boot ROM | Bypassing signature checks at power-on | Hardware root of trust, secure boot | | Debug interfaces | JTAG/SWD access to memory and registers | Fusing, authentication, disabling in production | | Vendor SDK code | Unaudited library functions shipped by silicon vendor | Static/dynamic analysis, SBOM tracking | | Side channels | EMFI or power analysis to extract keys | Shielding, key management architecture | ## Why Do Secure Boot and Root of Trust Matter? Secure boot and a hardware root of trust matter because they are the only controls that verify a device is running authentic firmware before any application code executes. A hardware root of trust anchors a cryptographic key in silicon that cannot be modified by software, and secure boot uses that key to validate each stage of the boot chain, bootloader, operating system, and application, before handing off execution. Without this chain, an attacker who can write to flash can substitute their own firmware and the device will run it without complaint. With secure boot properly implemented, any unsigned or modified image simply fails to load, and the failure can be logged for postmarket monitoring. Manufacturers should verify that every link in the chain is checked, not just the first stage, since a partial secure boot implementation that only validates the bootloader still leaves the application firmware open to tampering. ## What Happens When Debug and Test Interfaces Stay Enabled? Debug and test interfaces that stay enabled in production hardware give an attacker with physical access the same control a developer had on the bench. JTAG, SWD, and UART headers are essential during development for flashing firmware and reading logs, but they typically bypass authentication and operating system protections entirely, exposing memory, registers, and sometimes plaintext keys. Testers routinely find these interfaces active on production boards because engineering teams disable them in a configuration file rather than physically or cryptographically locking them out. A configuration flag can be reverted; a blown fuse or a debug authentication scheme cannot be undone with a simple firmware flag. Manufacturers should confirm through hardware-level testing, not just a design review, that production units actually block debug access. ## How Do Chip Errata and Vendor SDKs Introduce Risk? Chip errata and vendor SDKs introduce risk because they document known silicon defects and ship pre-written code that manufacturers rarely review line by line. Every SoC vendor publishes an errata sheet listing known hardware bugs, some of which have security implications, such as a cryptographic peripheral that behaves incorrectly under specific conditions or a debug lock that can be bypassed with a documented sequence. Vendor SDKs compound this because manufacturers build on top of reference code, Bluetooth stacks, TCP/IP stacks, and driver libraries, that the silicon vendor wrote and maintains on its own schedule. If the vendor patches a stack vulnerability, the fix does not reach the medical device until the manufacturer pulls the update, retests, and revalidates. Manufacturers should assign someone to read errata sheets and vendor security advisories on a recurring schedule, not just at initial chip selection. ## Why Does Third Party Silicon Belong in the SBOM? Third party silicon belongs in the SBOM because Section 524B requires manufacturers to identify all software components capable of being affected by a vulnerability, and SoC firmware, bootloaders, and vendor libraries meet that definition even though they arrived pre-installed on a purchased chip. Many manufacturers document only the application code they wrote, leaving the SBOM silent on the RTOS, Bluetooth stack, or boot firmware that shipped with the SoC. That gap matters in practice: when a CVE is published against a specific BLE stack version, a manufacturer without SoC firmware in its SBOM has no fast way to determine whether its own devices are affected. Reviewers increasingly ask for evidence that the SBOM extends to silicon-level components, and postmarket surveillance depends on that same data to drive patch decisions. ## What Documentation Does the FDA Expect for Hardware Level Controls? The FDA expects hardware level controls to be documented with the same specificity as software controls: named components, described mechanisms, and test evidence. The threat model should list the SoC's radios, debug interfaces, and boot chain individually, the SBOM should include SoC firmware and vendor libraries, and the security risk assessment should map each hardware attack surface to a control and a verification method. **[KEY REQUIREMENT]** Firmware validation results, secure boot test evidence, and debug interface lockout confirmation must appear in the eSTAR cybersecurity documentation, not just be referenced as "addressed in design." | Documentation Element | What Reviewers Look For | |---|---| | Threat model | Named SoC attack surfaces (radios, boot ROM, debug ports) | | SBOM | SoC firmware, RTOS, vendor libraries with versions | | Security risk assessment | Mapped controls per hardware attack surface, aligned to ISO 14971 | | Test evidence | Secure boot validation, debug port lockout confirmation, fuzz results | | Postmarket plan | CVE monitoring tied to specific SoC components | Manufacturers who submit generic statements like "hardware security was considered" without naming the SoC or its interfaces should expect an additional information request asking for the specifics above. ## How Blue Goat Cyber Approaches This Blue Goat Cyber evaluates SoC-level attack surfaces as part of the same design-controlled security risk management process used for application software. That includes threat modeling each radio, debug interface, and boot stage on the target silicon, reviewing vendor errata and SDK code for known issues, and building an SBOM that extends down to firmware shipped with the chip. Engagements are scoped to the specific SoC and device architecture rather than a generic hardware checklist. This work feeds directly into premarket submission documentation, so the threat model, SBOM, and test evidence align with what reviewers expect under the February 3, 2026 guidance. For manufacturers preparing a 510(k) or De Novo submission, this is coordinated through our [FDA premarket cybersecurity services](/services/fda-cybersecurity), which cover threat modeling, SBOM development, and penetration testing scoped to the device's hardware and software architecture. ## Frequently Asked Questions ### If a device doesn't use its SoC's wireless radios, are they still a risk? Yes. Many SoCs ship with Bluetooth or Wi-Fi radios embedded on the die whether or not the product uses them. If the radio firmware isn't disabled at the hardware level, it can often still be activated or exploited, so unused radios still need to appear in the threat model and be explicitly disabled or fused off. ### Should SoC components be tested separately from application code? Yes. Fuzzing and penetration testing focused on the BLE stack, TCP/IP stack, and vendor-supplied libraries frequently find issues that application-level testing misses entirely, since those components run at a different privilege level and were written by a different team. ### How often should manufacturers check for SoC vulnerabilities? Manufacturers should monitor vendor security advisories and the NVD on a recurring schedule, not just once during design. Postmarket surveillance plans should specifically name the SoC's firmware components so new CVEs can be matched against the device quickly. ### Do purchased SoCs need to appear in the SBOM even though the manufacturer didn't write the firmware? Yes. Section 524B doesn't distinguish between code the manufacturer wrote and code that shipped with a purchased component. Any firmware, driver, or library that came with the SoC and is capable of being affected by a vulnerability belongs in the SBOM. ## CTA Blue Goat Cyber helps manufacturers scope SoC threat models, SBOMs, and hardware-focused penetration testing before submission. [Schedule a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to review your device's silicon-level attack surface before your next FDA filing. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Attack Tree Threat Modeling for Med Devices | Blue Goat Source: https://bluegoatcyber.com/blog/exploring-the-contrast-between-threat-trees-and-attack-trees-in-medical-device-fda-approval-and-cybersecurity # Attack Tree Threat Modeling for Medical Device Security Reviews > **[DIRECT ANSWER]** Attack tree threat modeling maps the specific, step-by-step paths an adversary could follow to compromise a medical device, starting from a root goal like unauthorized therapy delivery and branching into individual exploit steps. It differs from broader threat trees, STRIDE, and FMEA, which each answer different questions about risk. Manufacturers use attack tree output to prioritize mitigations and feed the probability and severity ratings required in an ISO 14971 risk analysis. _Reviewed September 17, 2026_ Choosing the wrong threat modeling method wastes engineering time and produces documentation that reviewers still send back with questions. Teams that jump straight into an attack tree without first scoping the device's threat surface often build detailed diagrams for the wrong attack goals, while teams that stop at a high-level STRIDE pass never generate the concrete exploit paths a security risk file needs. Both mistakes are common in medical device programs racing toward a submission deadline. The right approach usually combines methods: a broad technique to find the threat surface, then attack trees to work out how the highest-risk threats could actually be carried out. This piece compares attack trees against threat trees, STRIDE, and FMEA, explains when each is worth the effort, and walks through how attack tree output becomes usable ISO 14971 risk analysis and FDA-facing documentation. ## Key Takeaways - Attack trees detail step-by-step exploit paths toward a specific adversary goal, not a general list of weaknesses. - STRIDE and FMEA are better suited to broad threat surface discovery than to modeling a specific attack sequence. - Attack trees are worth building for high-risk functions like therapy delivery, not every minor feature. - Attack tree branches map directly to the probability and severity fields in an ISO 14971 risk analysis. - The FDA does not mandate a specific diagram format but expects documented reasoning behind identified risks. - Combining a broad method with targeted attack trees produces more defensible documentation than either alone. ## Why This Matters Threat modeling method choice has direct consequences for both product security and regulatory timelines. A device team that skips structured attack modeling for a high-risk function, such as remote infusion pump control, risks discovering exploitable gaps only after a penetration test, when redesign is far more expensive than it would have been earlier. Reviewers evaluating premarket submissions increasingly ask pointed questions when a security risk assessment lacks traceable reasoning from threat identification to mitigation. Attack tree threat modeling gives that traceability by forcing the team to articulate exactly how an attacker would move from initial access to a harmful outcome. This level of detail is what allows a risk analysis to assign meaningful probability and severity ratings instead of generic high, medium, or low labels that do not hold up under scrutiny. It also gives penetration testers a concrete scope: instead of testing everything shallowly, they can validate whether the specific paths identified in the tree are actually exploitable. Getting the method selection right, using attack trees where they add value and lighter methods where they do not, keeps engineering effort proportional to actual patient risk. That proportionality is exactly what the FDA's current premarket guidance expects manufacturers to demonstrate. ## What Is Attack Tree Threat Modeling? Attack tree threat modeling is a structured technique that starts from a single adversary goal and decomposes it into the specific steps required to achieve it. The root node represents the harmful outcome, such as "deliver unauthorized medication dose," and child nodes represent the individual actions or vulnerabilities an attacker would need to chain together. Each branch can carry attributes like cost to the attacker, required skill level, or likelihood of detection, which helps prioritize which paths deserve mitigation first. **[KEY REQUIREMENT]** Every leaf node in a medical device attack tree should tie back to a concrete, testable condition, such as a specific unauthenticated API call, not a vague statement like "attacker gains access." ## Attack Trees vs. Threat Trees The terms are often used loosely, which causes confusion during documentation review. A threat tree, in the broader sense some teams use, identifies categories of threats and weaknesses across a system without necessarily detailing the exact steps to exploit each one. An attack tree, by contrast, is tactical: it maps the specific sequence of actions from initial foothold to final impact. In practice, an attack tree is often built as a deeper elaboration of one branch identified during a broader threat identification pass. | Aspect | Threat identification (broad) | Attack tree (tactical) | |---|---|---| | Scope | System-wide weaknesses | One adversary goal at a time | | Output | List of threat categories | Step-by-step exploit paths | | Best used for | Early architecture review | High-risk function deep dive | | Feeds into | Prioritization decisions | ISO 14971 probability/severity | ## Attack Trees vs. STRIDE vs. FMEA STRIDE, FMEA, and attack trees each answer a different question, and confusing their purposes is a common source of wasted effort. STRIDE categorizes threats by type, spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege, applied against data flow diagrams. FMEA (Failure Mode and Effects Analysis) originated in reliability engineering and asks how a component could fail and what the downstream effect would be, whether the cause is malicious or accidental. Attack trees ask neither of those questions directly; they ask "how, specifically, could someone reach this bad outcome." Used together, STRIDE or FMEA surface the threat surface broadly, and attack trees drill into the highest-priority items. | Method | Primary question | Typical output | |---|---|---| | STRIDE | What categories of threats exist per data flow? | Threat list by category | | FMEA | How could this component fail, and with what effect? | Failure mode table with severity | | Attack tree | How would an attacker reach this specific goal? | Branching exploit path diagram | ## When Is Building an Attack Tree Worth It? An attack tree is worth building for any function where a successful compromise could cause serious patient harm or a major data breach, such as therapy delivery, dosing control, or PHI storage. It is generally not worth the effort for low-risk, non-safety features where a simpler entry in a threat list is sufficient documentation. Teams under submission time pressure should prioritize attack trees for the two or three highest-risk functions identified during initial threat surface analysis, rather than attempting exhaustive trees for every feature. Depth matters more than breadth for these diagrams. Teams sometimes discover mid-project that the attack tree they built assumed an outdated architecture, since firmware or network topology changed after the initial diagram was drafted. Revisiting the tree whenever the device's connectivity or authentication model changes keeps the documentation aligned with what actually ships. ## How Attack Tree Output Feeds ISO 14971 Risk Analysis Each leaf node and path in an attack tree maps to inputs an ISO 14971 risk analysis needs: a hazardous situation, an estimate of probability of occurrence, and an estimate of severity of harm. The number of steps and the skill level required in an attack path give a defensible basis for the probability rating, rather than an unsupported guess. The mitigations identified for each branch become the risk control measures documented in the risk management file, and the residual risk after mitigation gets re-evaluated the same way. **[KEY REQUIREMENT]** The FDA's February 3, 2026 final guidance expects this chain of reasoning, from identified threat through documented mitigation to residual risk, to be traceable, even though it does not mandate the attack tree diagram format itself. ## Worked Example Structure A worked attack tree for a connected infusion pump might use "deliver unauthorized medication dose" as the root goal, illustrating the structure without asserting any real product's actual vulnerabilities. - **Root goal:** Deliver unauthorized medication dose - **Branch 1: Compromise wireless communication** - Intercept unencrypted configuration traffic - Replay captured dosing command - **Branch 2: Exploit local authentication** - Use default or weak service credentials - Bypass session timeout on maintenance interface - **Branch 3: Tamper with firmware update process** - Submit unsigned or improperly validated firmware image Each branch would then be assigned an estimated attacker skill level and detectability, which feeds directly into the probability rating used in the corresponding ISO 14971 entry. ## How Blue Goat Cyber Approaches This Blue Goat Cyber builds attack trees for the specific high-risk functions in a device rather than attempting exhaustive coverage of every feature, keeping engineering effort proportional to actual patient risk. This work starts with broad threat surface identification, then focuses tactical attack tree development on the functions most likely to cause harm if compromised, such as therapy delivery or credential-protected configuration interfaces. The resulting attack paths are handed directly to penetration testers to validate whether the identified steps are actually exploitable, and the findings are documented in a format that traces cleanly into an ISO 14971 risk management file. Manufacturers preparing for premarket review can learn more about how this fits into a broader security strategy through our [medical device threat modeling services](/services/medical-device-threat-modeling). ## Frequently Asked Questions ### What is attack tree threat modeling? Attack tree threat modeling is a technique that starts from a specific adversary goal and breaks it into the individual steps needed to achieve it. Each branch represents an action or vulnerability, and the tree helps teams prioritize which exploit paths pose the greatest risk. ### How is an attack tree different from STRIDE? STRIDE categorizes threats by type across a system's data flows, while an attack tree maps the specific sequence of steps toward one adversary goal. Many teams use STRIDE first to find the threat surface, then build attack trees for the highest-risk items identified. ### Does the FDA require attack trees for premarket submissions? The FDA's current guidance does not mandate a specific diagram format like attack trees, but it does expect documented, traceable reasoning from identified threats through mitigations to residual risk. Attack trees are a common and effective way to demonstrate that reasoning. ### When should a team use FMEA instead of an attack tree? FMEA is better suited to evaluating how a component could fail, whether from a malicious act or an accidental fault, and what the downstream effect would be. Attack trees are better suited to modeling a deliberate, multi-step adversary attempt to reach a specific harmful outcome. ### How does attack tree output connect to ISO 14971? Each attack path gives a basis for estimating probability of occurrence based on required attacker skill and detectability, and the harmful outcome at the root supports the severity estimate. These estimates and the mitigations tied to each branch become entries in the ISO 14971 risk management file. ## CTA Need attack tree threat modeling that holds up under FDA review and feeds directly into your risk management file? Blue Goat Cyber can scope the highest-risk functions in your device and build the documentation to support it. [Schedule a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to get started. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Related on threat modeling - [STRIDE threat modeling for medical devices: the complete playbook](/guides/stride-threat-modeling-medical-devices) - [STRIDE vs DREAD vs PASTA: which threat model fits medical devices?](/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective) - [Step-by-step threat modeling for connected & implantable devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) --- ## FDA 483 Cybersecurity Observations on QMSR Source: https://bluegoatcyber.com/blog/fda-483-cybersecurity-observations-qmsr # Cybersecurity on an FDA 483: What Inspectors Are Citing Under QMSR > **[DIRECT ANSWER]** Since QMSR took effect in February 2026, FDA inspectors are citing cybersecurity gaps directly on Form 483s under 21 CFR Part 820, including missing SBOMs in design history files, no postmarket vulnerability monitoring, weak software change control, and inadequate complaint handling for security events. Manufacturers must respond within 15 business days with corrective actions or risk escalation to a Warning Letter. **A Form 483 used to be a quality-system document. Since QMSR took effect on February 2, 2026, it's also a cybersecurity document - and inspectors are writing observations that didn't exist 18 months ago.** If you're a medical device manufacturer that just hosted an FDA inspection, the Form 483 you got handed at the close-out meeting may look different from the last one. Cybersecurity findings - once buried in premarket review or postmarket guidance - are now showing up as inspectional observations against your quality system. That's because [QMSR (21 CFR Part 820, as revised)](/blog/a-new-era-for-quality-and-safety-what-the-fdas-qmsr-means-for-cybersecurity) folded ISO 13485:2016 in by reference. Subparts C through O of the old Quality System regulation are now reserved, so the substantive requirements an inspector evaluates live in ISO 13485 clauses, with a short set of supplemental FDA provisions left in Part 820 (820.10 quality management system, 820.35 control of records, 820.45 labeling and packaging controls). This post walks through what a 483 actually is, the cybersecurity-flavored observations the FDA is now citing, and how to close them before they turn into a Warning Letter. ## Key Takeaways - Form 483s now include cybersecurity observations under QMSR. - FDA inspectors cite 21 CFR Part 820 and ISO 13485 clauses. - Common findings: dated SBOMs, no vulnerability process, inadequate complaint handling. - Cybersecurity issues must integrate into risk and CAPA processes. - Respond to a 483 within 15 business days with corrective actions and evidence. - Proactive DHF audits and process updates prevent 483s. ## Why this matters The stakes for medical device manufacturers are higher than ever regarding cybersecurity as an integral part of compliance. A deficient cybersecurity posture, now actively cited on FDA Form 483s, can lead to costly delays, product recalls, and severe reputational damage. Ignoring these citations escalates to Warning Letters, import bans, and potentially legal action. The FDA’s 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly outlines expectations for security by design, risk management, and postmarket surveillance. QMSR's incorporation of ISO 13485:2016, alongside specific clauses like 21 CFR Part 820.35, firmly places cybersecurity under the quality system umbrella. Compliance with standards such as IEC 81001-5-1, AAMI TIR57, and AAMI SW96 is no longer just good practice; it is foundational to demonstrating QMSR adherence. Manufacturers must prioritize integrating cybersecurity into their entire product lifecycle from design to postmarket activities, ensuring alignment with regulatory expectations to safeguard patient safety and operational continuity. ## What a Form 483 actually is (and isn't) Form FDA 483 is a list of inspectional observations issued at the end of an on-site inspection. It is **not** a final agency action. It is the inspector's documented list of things they believe deviate from the FD&C Act or its implementing regulations - in our world, QMSR (21 CFR Part 820) and the parts of 21 CFR Part 803 (MDR) that touch postmarket events. Three things to know up front: 1. **A 483 is not a Warning Letter.** It's the precursor. The FDA reviews your written response (typically due within 15 business days) before deciding whether to escalate. 2. **A 483 follows an inspection of a facility,** not a desk review of a submission. That's the line between 483-world (postmarket, QMSR-driven) and [deficiency-letter world](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) (premarket, submission-driven). 3. **Cybersecurity observations on a 483 cite QMSR clauses,** not the premarket cybersecurity guidance directly. The premarket guidance shapes what "good" looks like; QMSR is the regulation the inspector cites. ## Why cybersecurity now shows up on 483s Three regulatory changes converged to put cybersecurity on the inspector's checklist: - **Section 524B of the FD&C Act** (effective March 29, 2023) made cybersecurity a statutory requirement for "cyber devices." - **The FDA's February 3, 2026 final premarket cybersecurity guidance** (which superseded the June 2025 and September 2023 finals) defined what manufacturers are expected to produce, control, and maintain. - **QMSR (89 FR 7496), effective February 2, 2026,** incorporated ISO 13485:2016 by reference and kept FDA-specific record requirements in 820.35, which sets what must be captured in complaint records (820.35(a)) and servicing records (820.35(b)). Complaint handling, monitoring of postmarket information, and CAPA come from ISO 13485 Clauses 8.2.1, 8.2.2, and 8.5, and by direct read they cover cybersecurity vulnerability response. - **The inspection process itself changed on the same day.** The FDA retired the Quality System Inspection Technique (QSIT) and now inspects under the updated Inspection of Medical Device Manufacturers compliance program (CP 7382.850), a risk-based approach that starts with your risk management file and pulls in outside signal such as MDRs and recall data before the investigator arrives. For a connected device, your security risk file is part of what frames the inspection. The net effect: an inspector walking your facility can now cite gaps in cybersecurity documentation, processes, or postmarket monitoring as QMSR observations on a 483. ## Cybersecurity observations the FDA is citing on 483s These are the patterns we're seeing across recent inspections of connected device manufacturers. Each one is a real inspector observation translated into the QMSR clause it tends to cite. ### 1. Missing or stale SBOM in the Design History File > "Design History File for [Device X] does not contain a complete software bill of materials reflecting the as-released software configuration." Cited under ISO 13485 **7.3 (design and development)**, particularly **7.3.7 verification and validation records** and **7.3.10 design and development files**. The FDA expects the SBOM that supported your premarket submission to be alive in the design and development file and updated when software changes. A stale SBOM is now an observation, not a nice-to-have. See our [SBOM vulnerability management guide](/guides/sbom-vulnerability-management-medical-devices) for what "alive" means in practice. ### 2. No postmarket vulnerability monitoring process > "Manufacturer has not established a documented procedure for the ongoing identification, assessment, and disposition of post-release software vulnerabilities affecting marketed devices." Cited under ISO 13485 **8.2.1 (feedback)**, **8.4 (analysis of data)**, and **8.5.1 (improvement)**, with complaint records held to **21 CFR 820.35(a)**. This is the single most common cybersecurity-flavored 483 observation we see. The fix is not "subscribe to a CVE feed" - it's a documented, auditable process that ties vulnerability intake to your existing risk management, complaint handling, and CAPA workflows. ### 3. Security events not handled as complaints > "Cybersecurity events reported to the firm by customers were not processed through the established complaint handling system." Cited under **ISO 13485 8.2.2 (complaint handling)** together with the complaint record content required by **21 CFR 820.35(a)**. If a hospital reports that your infusion pump dropped a session under suspicious circumstances, that's a complaint. If your complaint procedure can't ingest, classify, and escalate a security event the same way it handles a clinical event, that's a 483. ### 4. Software changes not flowing through design controls > "Software updates released to address security vulnerabilities were implemented without documented design verification or validation." Cited under **ISO 13485 7.3.9 (control of design and development changes)**. Patch fast, but patch through your change control system. Cybersecurity patches are design changes - they need verification, validation evidence, and a risk re-assessment recorded. ### 5. Risk file doesn't include cybersecurity hazards > "ISO 14971 risk management file does not address cybersecurity-related hazards or hazardous situations for the subject device." Cited under **ISO 13485 7.1** and ISO 14971 by reference. AAMI TIR57 and ANSI/AAMI SW96 are the two playbooks the FDA expects you to use to integrate cybersecurity into your risk file. If your risk file is silent on threat actors, exploit paths, and patient-harm pathways from a security event, expect this one. ### 6. No evidence of supplier cybersecurity controls > "Purchasing controls do not address cybersecurity requirements for software components, third-party libraries, or contract manufacturers handling device software." Cited under **ISO 13485 7.4 (purchasing)**. The FDA reads your SBOM and asks the obvious question: how did you qualify the supplier of every third-party component on that list? If purchasing records don't show cybersecurity criteria, it's an observation. ### 7. CAPA system doesn't trigger on cybersecurity trends > "Trends in cybersecurity-related complaints, vulnerability disclosures, or field events were not analyzed in the firm's CAPA system." Cited under **ISO 13485 8.5.2 (corrective action)** and **8.5.3 (preventive action)**. CAPA is where the FDA looks for evidence that you're learning from postmarket signal. A spike in CVEs against one of your dependencies, three customer-reported security events in a quarter, a coordinated vulnerability disclosure - none of those can be invisible to CAPA. ## From 483 to Warning Letter: how cybersecurity gaps escalate The FDA's escalation path is consistent: 1. **483 issued** at the close of inspection. Response due in ~15 business days. 2. **Response reviewed.** If the FDA finds the response adequate - concrete corrections, root cause, evidence, timelines - the file may close at the district level. 3. **Warning Letter issued** when the response is weak, non-existent, or when observations are serious enough on their own. Warning Letters are public; 483s are not (though they're FOIA-able). 4. **Consent Decree, Import Alert, or Seizure** in extreme or repeat cases. Cybersecurity-flavored 483s escalate to Warning Letters when the response treats the finding as a documentation gap rather than a systemic process gap. "We've created an SBOM" is not a response. "We've established a documented procedure (Doc # SOP-XXX), trained the affected staff (training records attached), retrofitted the DHF for our three marketed products (DHF amendments attached), and added the procedure to our internal audit schedule" - that's a response. ## How to respond to a cybersecurity 483 (the short version) A defensible 15-day response has the same shape regardless of which observation you're closing: 1. **Acknowledge the observation literally.** Don't argue with the inspector's wording. 2. **State the immediate correction.** What you did this week. 3. **State the systemic corrective action.** New or revised SOP, training, retroactive review of affected products. 4. **Provide evidence.** SOP version, training records, DHF amendments, CAPA numbers. 5. **State the effectiveness check.** When and how you'll verify the fix held - usually an internal audit at 90 or 180 days. 6. **Commit to a timeline.** Realistic, not aspirational. The fastest path to a closed 483 is to treat every cybersecurity observation as both a documentation fix **and** a process fix. Inspectors come back. Process fixes are what survive a re-inspection. ## What to do before the next inspection If you make connected medical devices and you haven't had an FDA inspection since QMSR took effect, you are operating on borrowed time. The three highest-use things to do this quarter: 1. **Audit your DHF for SBOM and threat model freshness** against every product currently on the market. A premarket SBOM from 2023 that hasn't moved is a finding waiting to happen. 2. **Stand up a documented postmarket vulnerability process** that ties CVE intake → risk assessment → complaint system → CAPA. This is the ISO 13485 8.2.1 and 8.5 playbook, with complaint records kept to 820.35(a). 3. **Walk through your complaint handling SOP with a cybersecurity scenario** in the room. If the SOP can't accept "the device behaved suspiciously after a network event" as an intake, rewrite it. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers navigate FDA Form 483s containing cybersecurity observations. We assess cited deficiencies against QMSR requirements, including 21 CFR Part 820 and ISO 13485, to formulate precise corrective action plans. Our team, comprised of CISSPs and OSCPs with ex-military red team experience, works to implement immediate corrections and systemic process improvements for postmarket activities and design controls. We assist in preparing strong 15-day responses, gathering evidence, and establishing effectiveness checks to prevent escalation. Our approach focuses on embedding security practices into your existing quality management system. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Partner with us for effective resolution and pre-inspection readiness. Learn more about our postmarket services at [https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services). ## FAQ ### Is a Form 483 the same as a Warning Letter? No. A 483 is a list of observations from an on-site inspection. It is not a final agency action. A Warning Letter is the escalation that follows when the FDA decides your 483 response was inadequate or the observations were serious enough on their own. Warning Letters are public; 483s are not, though they are FOIA-able. ### Can cybersecurity actually be cited on a 483? Yes. Since QMSR took effect on February 2, 2026, inspectors have explicit clauses to cite cybersecurity-related gaps as quality system observations: the ISO 13485:2016 clauses incorporated by reference, plus the FDA record requirements that remain in Part 820 such as 820.35(a) for complaint records. Inspections also run under the updated compliance program CP 7382.850 rather than QSIT. Cybersecurity is no longer a premarket-only conversation. ### How long do I have to respond to a 483? The FDA expects a written response within 15 business days. A response submitted in that window is considered before any decision to escalate to a Warning Letter. Responses after that window still matter, but the agency is no longer obligated to consider them in the escalation decision. ### What's the difference between a 483 cybersecurity observation and a deficiency letter? A 483 follows an on-site inspection of your facility and cites QMSR clauses. A [deficiency letter](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) is issued during desk review of a premarket submission and cites the premarket cybersecurity guidance plus Section 524B. Different stage, different reviewer, different clock - but the underlying expectations overlap heavily. ### Does the FDA inspector need cybersecurity training to write these observations? The FDA has been training investigators on cybersecurity since the run-up to QMSR, and many districts now have at least one investigator with a software/cyber background. In practice, inspectors don't need to be penetration testers to cite gaps in documentation, process, or postmarket monitoring - those are quality-system observations that any trained investigator can write. ## Got a 483 with cybersecurity observations? The 15-day clock is the only clock that matters right now. We've drafted responses to cybersecurity-flavored 483 observations, prepared manufacturers for follow-up inspections, and closed out CAPAs that the FDA accepted on the first round. - See the related work on [QMSR and cybersecurity](/blog/a-new-era-for-quality-and-safety-what-the-fdas-qmsr-means-for-cybersecurity) and [cybersecurity as a QMS requirement](/blog/cybersecurity-qms-documentation-medtech). - Or [book a discovery call](/contact) and we'll triage your 483 under NDA within 24 hours. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA AI Cybersecurity Threats: 7 Attacks Source: https://bluegoatcyber.com/blog/fda-ai-cybersecurity-threats-524b-medical-devices # FDA AI Cybersecurity Threats: 7 Attacks 524B Manufacturers Must Address > **[DIRECT ANSWER]** The FDA's February 3, 2026 premarket cybersecurity guidance names seven AI-specific cyber threats manufacturers must address as Section 524B obligations: data poisoning, model inversion and stealing, evasion, data leakage, overfitting, model bias, and performance drift. Each threat needs a dedicated entry in the threat model with documented mitigations and test evidence, since generic application security controls alone do not satisfy these AI-specific risks. _Published June 29, 2026_ ## Key Takeaways - The FDA's Feb 3, 2026 guidance explicitly enumerates 7 AI cyber threats as 524B obligations. - Threats span the full ML lifecycle: training data, model weights, inference, and post-deployment drift. - Each threat needs an entry in your threat model with a documented mitigation and test evidence. - Generic application security controls are not sufficient, AI threats need AI-specific controls. - Postmarket monitoring must cover drift and bias, not only CVEs. - Document everything in your SPDF; the FDA will ask for it during premarket review. ## Why This Matters The FDA's [final premarket cybersecurity guidance dated February 3, 2026](https://www.fda.gov/media/184856/download) makes one point unmistakable: if your device meets the definition of a "cyber device" under section 524B(c) of the FD&C Act and incorporates AI, the AI is not a separate compliance track. It is part of your cybersecurity submission. The guidance lists seven categories of AI risk that "can be impacted by cybersecurity threats", and the FDA expects each one to be analyzed in your threat model, controlled in your [Secure Product Development Framework](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect), and verified before clearance. This is a meaningful shift. Until recently, manufacturers could treat model quality as a data-science concern and cybersecurity as an IT concern. The 2026 guidance, read with AAMI CR34971 on AI risk management and the FDA's predetermined change control plan (PCCP) framework, fuses them. A reviewer can, and will, issue a [cybersecurity deficiency](/blog/510k-cybersecurity-deficiencies-that-trigger-fda-holds) for an AI-enabled device whose threat model does not address data poisoning or adversarial evasion. Standards including IEC 81001-5-1, AAMI TIR57 / ANSI/AAMI SW96:2023, AAMI TIR97, and ISO/IEC 27001 provide the surrounding controls, but it is the threat-modeling and SPDF evidence that the FDA reads first. The seven threats below are taken directly from the guidance text. Each section explains what the threat is, why the FDA treats it as a cybersecurity issue (not only a model-quality issue), and what control evidence a reviewer expects to see. ## At-a-Glance: 7 Threats → Test Types → Standards This matrix is the fastest way to line up FDA's seven AI cyber threats with the tests you should run and the standards a reviewer will recognize. Every technique ID is from [MITRE ATLAS](https://atlas.mitre.org/); attack classes map to [NIST AI 100-2 E2023, *Adversarial Machine Learning: A Taxonomy and Terminology of Attacks and Mitigations*](https://www.nist.gov/publications/adversarial-machine-learning-taxonomy-and-terminology-attacks-and-mitigations-0); practitioner test lists are from [OWASP ML Top 10](https://mltop10.info/) and, for LLM-backed devices, [OWASP LLM Top 10](https://owasp.org/www-project-top-10-for-large-language-model-applications/). | # | FDA threat | Test types to run | NIST AI 100-2 class | MITRE ATLAS | OWASP | |---|---|---|---|---|---| | 1 | Data Poisoning | Training-data provenance verification; signed-manifest negative tests; backdoor / trigger scans on imported weights; canary-sample detection; red-team poisoning injection against drift/outlier detector | Poisoning (targeted, backdoor, availability) | AML.T0020 Poison Training Data; AML.T0018 Backdoor ML Model | ML02 Data Poisoning; LLM03 Training Data Poisoning | | 2 | Model Inversion & Stealing | Membership-inference tests; attribute-inference tests; model-extraction / surrogate-fidelity tests under a defined query budget; rate-limit and auth pen tests against inference endpoint; output-minimization verification | Privacy (membership inference, model extraction, attribute inference) | AML.T0024 Exfiltration via ML Inference API; AML.T0044 Full ML Model Access; AML.T0057 LLM Data Leakage | ML05 Model Theft; ML03 Model Inversion; LLM10 Model Theft; LLM06 Sensitive Information Disclosure | | 3 | Model Evasion | Adversarial robustness testing with FGSM, PGD, AutoAttack, C&W, adversarial patches; modality-specific attacks (audio, waveform, tabular); OOD-detector validation; confidence-threshold fallback tests; certified-robustness bounds where warranted | Evasion (white-box, black-box, transferability) | AML.T0015 Evade ML Model; AML.T0043 Craft Adversarial Data | ML01 Input Manipulation Attack; LLM01 Prompt Injection (for LLM-backed devices) | | 4 | Data Leakage | Authenticated + unauthenticated pipeline pen test (object storage, feature store, model registry, logs, caches); IAM and encryption config scans; inference-endpoint verbose-output tests; debug-log PHI-exfiltration tests | Privacy (data reconstruction, side-channel) | AML.T0035 ML Artifact Collection; AML.T0025 Exfiltration via Cyber Means | ML06 AI Supply Chain Attacks (storage/logs); LLM02 Insecure Output Handling; LLM06 Sensitive Information Disclosure | | 5 | Overfitting | Held-out and external-cohort validation; train/val gap thresholds gated in CI; decision-boundary sharpness tests; adversarial-overfitting simulations after training-data refresh; reproducible-training pipeline verification | Poisoning (availability) + robustness generalization | AML.T0018 Backdoor ML Model (as exploit path); AML.T0031 Erode ML Model Integrity | ML04 Membership Inference (indirect indicator); ML08 Model Skewing | | 6 | Model Bias | Stratified subgroup performance tests (sensitivity, specificity, calibration by demographic and clinical subgroup); disparity-threshold gates; backdoor / trojan scanning on imported checkpoints; ML-SBOM provenance verification; postmarket subgroup-drift monitoring validation | Poisoning (backdoor); abuse (bias amplification) | AML.T0019 Publish Poisoned Datasets; AML.T0010 ML Supply Chain Compromise | ML07 Transfer Learning Attack; ML08 Model Skewing; LLM05 Supply Chain | | 7 | Performance Drift | Drift-detector validation against benign vs. adversarial shifts; reference-distribution regression tests; signed-update negative tests (unsigned rejected); rollback tests; postmarket telemetry-integrity tests | Availability / integrity (adversarial drift) | AML.T0031 Erode ML Model Integrity; AML.T0034 Cost Harvesting | ML09 Output Integrity Attack; LLM04 Model Denial of Service | **GenAI / LLM-backed devices** should additionally run: prompt-injection suites (direct and indirect), jailbreak suites, insecure-output-handling tests, and tool-abuse tests. Tooling: [IBM Adversarial Robustness Toolbox (ART)](https://github.com/Trusted-AI/adversarial-robustness-toolbox), [Foolbox](https://github.com/bethgelab/foolbox), [CleverHans](https://github.com/cleverhans-lab/cleverhans), [Microsoft Counterfit](https://github.com/Azure/counterfit), [NVIDIA Garak](https://github.com/leondz/garak) for LLMs, [Microsoft PyRIT](https://github.com/Azure/PyRIT) for GenAI red-teaming, and [Giskard](https://github.com/Giskard-AI/giskard) for ML testing. Each threat's per-section table below drills into the specific SPDF artifact and submission evidence expected. ## 1. Data Poisoning **What it is.** Cyber attackers deliberately inject inauthentic or maliciously modified records into training, fine-tuning, or feedback data so the model learns the wrong thing, for example, labeling malignant lesions as benign or shifting decision boundaries in a sepsis predictor. **Why it is a 524B issue.** Data poisoning is not just bad data hygiene; it is an integrity attack on the model's training pipeline. The FDA treats the training pipeline as part of the device's attack surface when training artifacts or update channels affect the deployed model. **Mitigations.** - Cryptographically signed dataset manifests and per-record hashes; reject any training run whose corpus does not match the manifest. - Role separation between data engineers, label reviewers, and model owners; least-privilege access to the training bucket and feature store. - Statistical drift and outlier detection on inbound training and feedback data, gated before the next training run. - A documented retrain/revert procedure with a known-good model baseline if poisoning is suspected post-deployment. **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | Training-data provenance policy + signed manifest schema | Manifest-signature validation test (negative case rejected) | Data-integrity test report referenced in eSTAR Security Architecture section | | Secure implementation | Access-control matrix for training infra and feature store | IAM/least-privilege review + log review | Access-review record and IAM export attached to threat model | | Secure verification | Statistical drift / outlier detector on inbound data | Red-team poisoning injection against detector | Adversarial-test report; STRIDE/ATLAS row "Tampering, AML.T0020 Poison Training Data" | | Secure release & response | Retrain-from-known-good runbook | Tabletop on poisoning incident | Postmarket response plan + runbook version in submission | For a deeper treatment, see our dedicated post on [AI data poisoning in medical devices](/blog/safeguarding-medical-device-ai-combating-data-poisoning-cybersecurity-threats). ## 2. Model Inversion and Model Stealing **What it is.** An attacker queries the deployed model with crafted inputs to either (a) reconstruct sensitive attributes of the training data, model inversion, or (b) replicate the model's behavior in a surrogate, model stealing. Both attacks turn the inference endpoint into a side channel. **Why it is a 524B issue.** Inversion can leak PHI used during training, which is a confidentiality breach under 524B. Stealing exposes proprietary weights and creates a parallel model an attacker can then attack offline at no cost, accelerating every other threat on this list. **Mitigations.** - Authentication, authorization, and per-user/per-device rate limiting on every inference endpoint. - Output minimization: return the class or score the clinician needs, not full logits, embeddings, or attention maps. - Differential-privacy or noise-injection techniques where training data is sensitive. - Query-pattern anomaly detection for high-volume probing or adversarial query distributions. **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | Inference-API threat model entry (Information Disclosure) | Architectural review against ATLAS "AML.T0024 Exfiltration via ML Inference API" | Threat-model row + data-flow diagram | | Secure implementation | AuthN/AuthZ, rate-limit, and output-minimization config | Endpoint pen test with stolen credentials and probing harness | Pen-test report (AI scope) | | Secure verification | Model-stealing simulation (query budget, fidelity score) | Surrogate-model fidelity test below documented threshold | Verification report with fidelity metrics | | Secure release & response | Inference-log retention + anomaly alert rules | Incident tabletop on detected probing campaign | Postmarket monitoring plan section | See [Medical Device AI Model Inversion](/blog/understanding-medical-device-ai-model-inversion-cybersecurity-threats-and-solutions) for the full breakdown. ## 3. Model Evasion **What it is.** An attacker crafts or perturbs an input, often imperceptibly to a clinician, so the model misclassifies it. A pixel-level perturbation on a dermatology image, an adversarial patch on an ECG waveform, or carefully chosen noise in a radiology scan can flip a prediction. **Why it is a 524B issue.** Evasion attacks degrade the reliability of clinical output, which the FDA treats as patient-safety-relevant. The 2026 guidance is explicit that cyber controls must protect the integrity of model predictions, not only the system around the model. **Mitigations.** - Adversarial robustness testing against published attack libraries (FGSM, PGD, patch attacks, modality-specific attacks). - Input validation, range checks, and out-of-distribution (OOD) detection on raw inputs and intermediate features. - Confidence thresholds with human-in-the-loop fallback when confidence is low or OOD detection fires. - Adversarial training or certified-robustness techniques where the harm rating warrants it. **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | Adversarial-robustness requirement tied to hazard analysis (ISO 14971) | Threat-model row "Tampering, AML.T0015 Evade ML Model" | Hazard-to-control traceability table | | Secure implementation | OOD detector + confidence-threshold logic in inference path | Unit + integration tests for OOD fallback | Code-review record + test results | | Secure verification | Adversarial test plan (FGSM, PGD, patch, modality-specific) | Robustness benchmark vs. clean accuracy delta | Adversarial-test report appended to [risk-based testing](/blog/a-comprehensive-guide-to-risk-based-testing-for-medical-device-software) summary | | Secure release & response | Field-collected misprediction triage workflow | Tabletop on adversarial input cluster in production | Postmarket surveillance plan | See [AI Model Evasion in Medical Devices](/blog/protecting-medical-devices-ai-model-evasion-and-cybersecurity-threats) for examples and test patterns. ## 4. Data Leakage **What it is.** Cyber threats exploit vulnerabilities to access sensitive training data, fine-tuning data, or inference-time data, for example, through misconfigured object storage, over-broad model endpoints, debug logs, or cached intermediate tensors. **Why it is a 524B issue.** Data leakage is a direct confidentiality failure under 524B's expectations for protecting electronic information. It is also a regulatory issue under HIPAA and applicable international privacy regimes, but the FDA cybersecurity reviewer will judge it on 524B grounds. **Mitigations.** - Encryption in transit and at rest for every store that holds training, validation, or inference data. - Strict separation of training infrastructure from production patient data; documented data-minimization at each stage. - Tamper-evident access logging that captures who read which dataset and when. - Pen testing that explicitly probes the data pipeline and the inference endpoint, not only the device firmware. **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | Data-flow diagram with classification labels (PHI, derived, model artifact) | Architecture review against 524B "protect electronic information" | Architecture section of submission | | Secure implementation | Encryption + IAM config for every data store and bucket | Config scan and IAM review | Cryptographic-controls summary | | Secure verification | Pipeline pen test (storage, logs, caches, inference) | Authenticated and unauthenticated tests with leakage findings | [AI penetration testing](/blog/ai-penetration-testing-medical-devices-fda-limits) report | | Secure release & response | Incident-response runbook covering PHI exposure | Tabletop with disclosure and notification path | IR plan + breach-notification SOP | ## 5. Overfitting **What it is.** A model is trained too closely to its training set and generalizes poorly. A cyber attacker can deliberately push a model toward overfitting by injecting narrow patterns into training data, then exploit the brittle decision surface with adversarial inputs at inference time. **Why it is a 524B issue.** Overfitting is normally a model-quality concern, but the FDA includes it here because attackers can *cause* it deliberately and then exploit it. That makes overfitting an indicator of compromise as well as a quality defect. **Mitigations.** - Held-out validation across demographically and clinically diverse cohorts; cross-validation results in the submission. - Train/validation gap and decision-boundary sharpness treated as security-relevant alerts, not only data-science metrics. - Regularization, dropout, and ensemble strategies documented in the model card. - Re-evaluation of overfitting indicators after every training-data refresh or PCCP-authorized update. **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | Generalization requirement linked to clinical performance acceptance criteria | Review against intended-use population | Performance requirements traceability | | Secure implementation | Regularization + ensemble configuration captured in model card | Reproducible training pipeline test | Model card + training-pipeline artifact | | Secure verification | Subgroup + external-dataset validation; train/val gap threshold | Validation report with diverse cohorts | Clinical/non-clinical performance section | | Secure release & response | Overfitting-alert rule tied to retraining triggers | Tabletop on suspected adversarial overfitting | Postmarket monitoring plan | See [AI Overfitting Cybersecurity Threats in Medical Devices](/blog/ai-overfitting-cybersecurity-threats-in-medical-devices) for detection patterns. ## 6. Model Bias **What it is.** Bias enters when training data under-represents populations, when labels carry historical inequities, or when an attacker deliberately skews fine-tuning data, embeds backdoors, or distributes pre-trained models that already carry bias to be amplified downstream. **Why it is a 524B issue.** The 2026 guidance treats deliberate bias manipulation, including backdoor triggers and adversarial bias amplification, as a cybersecurity attack on the model. Reviewers expect bias monitoring to be integrated with security monitoring, not run as a separate fairness exercise. **Mitigations.** - Provenance and integrity of any third-party datasets or pre-trained checkpoints; SBOM-style accounting for ML artifacts. - Subgroup performance reporting (sensitivity, specificity, calibration by demographic and clinical subgroup) in the premarket submission. - Backdoor scanning on imported model weights and a procedure for re-training if a backdoor is found. - Postmarket bias monitoring tied to the device's [postmarket cybersecurity program](/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap). **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | ML-SBOM listing datasets, checkpoints, licenses, versions | Review of artifact provenance against [SBOM/supply chain](/blog/medical-device-sbom-fda-requirements-and-submission-guide) requirements | ML-SBOM in submission | | Secure implementation | Backdoor / trojan scan in CI on imported weights | Negative test with planted trigger | CI scan report | | Secure verification | Subgroup performance + fairness metrics | Subgroup test report with predefined thresholds | Performance section of submission | | Secure release & response | Bias-monitoring rules in postmarket telemetry | Tabletop on detected subgroup drift | Postmarket plan | ## 7. Performance Drift **What it is.** Cyber attackers shift the input data distribution over time, through compromised upstream sensors, manipulated EHR fields, or slow injection of skewed feedback, so the model's accuracy decays. Drift can also arise naturally; the threat is that an attacker can cause it on purpose and hide it as ordinary degradation. **Why it is a 524B issue.** Performance drift connects directly to postmarket cybersecurity obligations. The FDA expects manufacturers to detect drift, decide whether it is benign or adversarial, and respond within their PCCP or change-control process. **Mitigations.** - Continuous performance monitoring against a held-out reference distribution; alarm thresholds documented in the SPDF. - Distinction between data drift, concept drift, and adversarial drift, with investigation playbooks for each. - Integrity controls on the update channel so legitimate retraining cannot be hijacked. - Reporting paths into the FDA when drift indicates a cybersecurity issue affecting safety or effectiveness. **SPDF control / test mapping.** | SPDF activity | Control artifact | Verification test | Submission evidence | |---|---|---|---| | Secure design | Drift-monitoring requirement + reference distribution definition | Architectural review of telemetry path | Postmarket monitoring architecture | | Secure implementation | Signed update channel + rollback control | Negative test: unsigned update rejected | [CI/CD security gates](/blog/cicd-security-gates-medical-devices-spdf) evidence | | Secure verification | Drift-detector validation against benign and adversarial shifts | Adversarial-drift simulation | Verification report | | Secure release & response | Drift triage playbook + FDA reporting decision tree | Tabletop covering benign vs. adversarial drift | Postmarket plan + reporting SOP | See [AI Performance Drift in Medical Devices](/blog/understanding-ai-performance-drift-ensuring-medical-device-safety) for the monitoring architecture. ## Mapping the 7 Threats to Your SPDF and Threat Model For a 524B submission, each of the seven threats above should appear in three places in your documentation: 1. **Threat model.** Use STRIDE or a STRIDE-plus-MITRE-ATLAS overlay so AI-specific threats sit alongside conventional ones. ATLAS gives you the adversarial ML tactics and techniques; STRIDE keeps the framing consistent with the rest of the device. See our [step-by-step threat modeling guide](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices). 2. **SPDF risk and control matrix.** Each threat ties to one or more controls, each control ties to one or more verification activities, and each verification activity produces an artifact that goes into the submission. 3. **Postmarket monitoring plan.** Drift, bias, and anomalous query patterns need monitoring rules and response playbooks, not just dashboards. When a reviewer asks "how does your device address AI cybersecurity threats," the answer is not a paragraph. It is a traceable chain from threat to control to test to monitoring rule, for all seven categories. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Cyber Approaches AI Threat Modeling Our [ThreatGoat](/threatgoat) workflow treats the seven FDA-listed AI threats as first-class entries in the threat model, not appendices. We map each one to STRIDE plus the relevant MITRE ATLAS techniques, generate the control list and test plan from that mapping, and produce the SPDF artifacts a 524B reviewer expects to see. Our [AI penetration testing service](/blog/ai-penetration-testing-medical-devices-fda-limits) then exercises the controls against the actual deployed model, so the evidence in your submission reflects how the system behaves under attack, not only how it is designed. If you are preparing a 510(k), De Novo, or PMA for an AI-enabled device, the fastest path through a clean cybersecurity review is a threat model and SPDF that already speak the language of the Feb 3, 2026 guidance. ## FAQ **Does the 2026 guidance apply if my device only uses a locked AI model?** Yes. Locked models are still subject to the seven threats, particularly inversion, evasion, leakage, and data poisoning of any retraining pipeline you might invoke under a PCCP. The locked-vs-adaptive distinction affects change control, not whether the cyber threats apply. **Do I need ATLAS in my submission, or is STRIDE enough?** STRIDE alone is rarely enough for AI-enabled devices. Reviewers increasingly expect adversarial ML techniques (drawn from MITRE ATLAS or equivalent) to be referenced in the threat model so it is clear you considered AI-specific attacks, not only generic ones. **How does this interact with a Predetermined Change Control Plan (PCCP)?** A PCCP defines what model changes you can ship without a new submission. Your cybersecurity controls for the seven threats must hold across the range of changes the PCCP authorizes. The FDA will ask how your controls are verified after each PCCP-authorized update. **Are these threats only relevant to imaging or diagnostic AI?** No. Performance drift and data leakage apply equally to predictive monitoring, closed-loop control, and clinical decision support. Evasion is most studied in imaging but is documented in waveform, tabular, and language-model contexts. **Where do AAMI CR34971 and IEC 81001-5-1 fit?** AAMI CR34971 gives you the AI risk-management process; IEC 81001-5-1 gives you the security activities across the product lifecycle. Together they support, but do not replace, the threat-modeling and SPDF evidence the FDA expects under 524B. ## Related Deep-Dives on the 7 AI Threats Each of the threats above has a dedicated post with detection patterns, controls, and test evidence: - **Data Poisoning**, [Safeguarding Medical Device AI from Data Poisoning](/blog/safeguarding-medical-device-ai-combating-data-poisoning-cybersecurity-threats) - **Model Inversion & Stealing**, [Medical Device AI Model Inversion: Threats and Solutions](/blog/understanding-medical-device-ai-model-inversion-cybersecurity-threats-and-solutions) - **Model Evasion**, [Protecting Medical Devices from AI Model Evasion](/blog/protecting-medical-devices-ai-model-evasion-and-cybersecurity-threats) - **Data Leakage**, [AI Penetration Testing for Medical Devices](/blog/ai-penetration-testing-medical-devices-fda-limits) (covers data-pipeline leakage paths) - **Overfitting**, [AI Overfitting Cybersecurity Threats in Medical Devices](/blog/ai-overfitting-cybersecurity-threats-in-medical-devices) - **Model Bias**, [How to Respond to an FDA Cybersecurity AI Request](/blog/how-to-respond-to-an-fda-cybersecurity-ai-request) (includes bias-monitoring evidence the FDA expects) - **Performance Drift**, [Understanding AI Performance Drift in Medical Devices](/blog/understanding-ai-performance-drift-ensuring-medical-device-safety) Supporting reading: [Threat Modeling Connected and Implantable Devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) · [FDA Section 524B Subsections Explained](/blog/fda-section-524b-subsections-explained) ## Sources & References **FDA and statute** - FDA, [*Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions*](https://www.fda.gov/media/184856/download) (Final Guidance, February 3, 2026). - FDA, [*Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations*](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing) (Draft, January 2025). - FDA, [*Predetermined Change Control Plans for Machine Learning-Enabled Device Software Functions*](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence) (Final, December 2024). - [Section 524B of the Federal Food, Drug, and Cosmetic Act](https://www.congress.gov/bill/117th-congress/house-bill/2617/text) (added by the Consolidated Appropriations Act, 2023). **AI-attack taxonomies and testing frameworks** - NIST, [*Adversarial Machine Learning: A Taxonomy and Terminology of Attacks and Mitigations* (NIST AI 100-2 E2023)](https://www.nist.gov/publications/adversarial-machine-learning-taxonomy-and-terminology-attacks-and-mitigations-0). - NIST, [*AI Risk Management Framework (AI RMF 1.0)*](https://www.nist.gov/itl/ai-risk-management-framework) and the [*Generative AI Profile (NIST AI 600-1)*](https://www.nist.gov/publications/artificial-intelligence-risk-management-framework-generative-artificial-intelligence). - [MITRE ATLAS (Adversarial Threat Landscape for AI Systems)](https://atlas.mitre.org/) - tactic and technique catalog cited in the matrix above. - [OWASP Machine Learning Security Top 10](https://mltop10.info/). - [OWASP Top 10 for Large Language Model Applications](https://owasp.org/www-project-top-10-for-large-language-model-applications/). **Medical-device standards** - AAMI CR34971:2023, *Application of ISO 14971 to Machine Learning in Artificial Intelligence*. See our [CR34971 explainer](/guides/aami-cr34971-ai-risk-management-explained). - AAMI TIR57:2016 (R2023), *Principles for medical device security - Risk management*. - ANSI/AAMI SW96:2023, *Standard for medical device security - Security risk management for device manufacturers*. - IEC 81001-5-1:2021, *Health software and health IT systems safety, effectiveness and security - Part 5-1: Security - Activities in the product life cycle*. - ISO 14971:2019, *Medical devices - Application of risk management to medical devices*. - ISO/IEC 23894:2023, *Artificial intelligence - Guidance on risk management*. - ISO/IEC 27090 (in development), *Cybersecurity - Artificial Intelligence - Guidance for addressing security threats to artificial intelligence systems*. **Testing tooling referenced above** - [IBM Adversarial Robustness Toolbox (ART)](https://github.com/Trusted-AI/adversarial-robustness-toolbox), [Foolbox](https://github.com/bethgelab/foolbox), [CleverHans](https://github.com/cleverhans-lab/cleverhans), [Microsoft Counterfit](https://github.com/Azure/counterfit), [NVIDIA Garak](https://github.com/leondz/garak), [Microsoft PyRIT](https://github.com/Azure/PyRIT), [Giskard](https://github.com/Giskard-AI/giskard). --- **Need help building an SPDF and threat model that covers all seven of these AI threats?** [Talk to Blue Goat Cyber](/contact) about a 524B-ready AI cybersecurity engagement, or start with our [ThreatGoat](/threatgoat) threat-modeling workflow. *About the author, The Blue Goat Cyber team specializes in cybersecurity for FDA-regulated medical devices, including AI/ML-enabled systems subject to section 524B of the FD&C Act. We help manufacturers ship clean premarket submissions and run defensible postmarket programs.* --- ## Related on FDA Section 524B - [FDA Section 524B: complete cybersecurity requirements guide](/guides/fda-524b-cybersecurity-requirements-explained) - [Does Section 524B apply to my auto-injector?](/blog/does-fda-section-524b-apply-to-my-auto-injector) - [Does Section 524B apply to legacy devices?](/blog/does-fda-section-524b-apply-to-legacy-medical-devices) - [Documenting update cadence for a 524B submission](/blog/documenting-update-cadence-fda-524b-submission) --- ## More on this topic - [Infusion Pump Cybersecurity: FDA](/blog/infusion-pump-cybersecurity-fda) --- ## Breakthrough Device Designation and Cybersecurity Source: https://bluegoatcyber.com/blog/fda-breakthrough-device-designation-cybersecurity # Breakthrough Device Designation and Cybersecurity Requirements > **[DIRECT ANSWER]** Breakthrough Device designation does not change your cybersecurity obligations. The program gives you priority review, interactive sprint discussions, and senior FDA engagement, but Section 524B applies in full to any cyber device regardless of designation. You still owe a threat model, an SBOM, security testing evidence, and a postmarket vulnerability management plan, and an incomplete package can still trigger a Refuse to Accept decision. A designation letter feels like momentum. Teams get one and quietly assume the whole review will be more forgiving, cybersecurity included. It will not be. The Breakthrough Devices Program changes *how fast* and *how often* you talk to the FDA. It changes nothing about *what* a cyber device submission must contain. In practice the effect runs the other way: Breakthrough devices are disproportionately connected, novel, AI-enabled, or first-of-a-kind, and reviewers apply more scrutiny to architectures they have never seen before, not less. The real risk is scheduling. Priority review compresses your timeline. Cybersecurity work that would have hidden inside a twelve-month runway now sits on the critical path. ## Why this matters The Breakthrough Devices Program is statutory, created by Section 3051 of the 21st Century Cures Act and codified at Section 515B of the FD&C Act. Section 524B, added by the Consolidated Appropriations Act 2023 and effective March 29, 2023, is equally statutory and contains no carve-out for Breakthrough, priority, or expedited devices. Neither does the FDA's final premarket cybersecurity guidance of February 3, 2026, which supersedes the 2023 final guidance and sets the current expectations for Secure Product Development Framework evidence, threat modeling depth, SBOM contents, and labeling. That means two statutes run in parallel. One shortens your review clock. The other sets a content floor you must clear before the clock starts at all. Sponsors who treat designation as a reason to defer security work end up spending the time they saved on deficiency responses. ## What Breakthrough Device designation actually gives you The program is a set of interaction benefits, not a lowered evidence bar: | Benefit | What it means in practice | | --- | --- | | Priority review | Your submission moves to the front of the reviewer's queue | | Sprint discussions | Time-boxed, topic-specific interactions to resolve a single question fast | | Senior management engagement | Escalation path when a review question stalls | | Data development plan feedback | Early alignment on what evidence you will generate | | Post-designation flexibility | More willingness to accept postmarket data collection for clinical evidence | Note what is absent: nothing about reduced content requirements, nothing about deferred testing, nothing about cybersecurity. > **[KEY REQUIREMENT]** Section 524B(b) requires every cyber device sponsor to submit a plan to monitor and address postmarket vulnerabilities, design processes providing reasonable assurance of cybersecurity, a coordinated vulnerability disclosure process, and an SBOM. Designation status is irrelevant to all four. ## Does the Refuse to Accept policy apply to Breakthrough submissions? Yes. The FDA's Refuse to Accept policy for cyber devices under Section 524B applies at the acceptance-review stage, before substantive review begins, and before any Breakthrough priority benefit takes effect. This is the sequencing detail that surprises teams. Priority review affects your position in the substantive review queue. An RTA decision happens upstream of that queue entirely. A Breakthrough device with a missing SBOM or an absent postmarket plan gets held at the door like anything else, and the calendar advantage you were counting on disappears in the resubmission. ## Why Breakthrough devices often face harder cybersecurity review Designation criteria select for exactly the device characteristics that raise cybersecurity risk: - **Novelty.** Breakthrough devices are frequently first-of-a-kind. There is no predicate architecture for the reviewer to anchor against, so the threat model carries more of the argument. - **Connectivity.** Remote monitoring, cloud analytics, and companion apps are common in the population that qualifies. Every interface is attack surface you must document. - **AI and adaptive software.** Model update pathways, training data provenance, and PCCP interaction with cybersecurity controls all draw questions. - **High-acuity use.** Devices treating irreversibly debilitating conditions have severe harm ceilings, which pushes exploitability and patient-harm analysis into sharper focus. A conventional predicate-backed 510(k) can lean on established architecture patterns. A Breakthrough device usually cannot, so the STRIDE analysis, data flow diagrams, and control rationale have to stand on their own. ## How to use sprint discussions for cybersecurity Sprint discussions are the most underused asset in the program. They are short, scoped, and designed to close a specific question quickly, which is exactly the shape of most unresolved cybersecurity decisions. Questions worth spending a sprint on: - Is our system boundary and trust-boundary decomposition at the right level of granularity for this architecture? - Does our SBOM format and depth of transitive dependency coverage meet expectations for this device? - Is our proposed penetration testing scope and independence sufficient given the interfaces involved? - How should the PCCP interact with the cybersecurity risk assessment for the adaptive model? - Does our conformance approach to ANSI/AAMI SW96:2023 and IEC 81001-5-1 satisfy the SPDF expectation? Sponsors overwhelmingly spend sprints on clinical endpoints and study design. Those matter, but clinical questions rarely cause an RTA. Cybersecurity gaps do. ## What to build alongside the designation request Designation requests are reviewed within 60 days. That window is the right time to start the security work, not to pause it: 1. **Threat model skeleton.** Data flow diagrams and trust boundaries, even before the design is frozen. The architecture will change; the discipline of maintaining the model through change is what the SPDF expects. 2. **SBOM pipeline.** Automated generation in CycloneDX or SPDX wired into your build, not a spreadsheet assembled at submission time. 3. **Vulnerability intake.** A published coordinated disclosure process with a real intake path and defined response timelines. 4. **Security risk file.** Distinct from the ISO 14971 safety risk file, connected to it, and scored on exploitability rather than clinical probability. 5. **Testing plan.** Scope, independence, and timing for vulnerability scanning, fuzzing, and penetration testing, with schedule room for remediation and retest. ## How Blue Goat Cyber approaches this We treat designation status as a scheduling input, not a scope input. The cybersecurity package for a Breakthrough device is built to the same February 3, 2026 guidance expectations as any other cyber device, then sequenced backward from the compressed review calendar the designation creates. In practice that means starting the threat model during the designation request window, standing up SBOM generation in CI before design freeze, and reserving at least one sprint discussion for a cybersecurity question we have deliberately scoped to be answerable in a single interaction. Penetration testing is scheduled with remediation and retest time built in, because a finding discovered two weeks before filing is a schedule event, not a technical one. We do not promise a clearance outcome. We scope the work so no cybersecurity gap is left open when the submission goes in. ## FAQ ### Does Breakthrough Device designation exempt my device from Section 524B? No. Section 524B applies to any cyber device that includes software, has the ability to connect to the internet, and contains technological characteristics that could be vulnerable to cybersecurity threats. There is no expedited-program exemption in the statute and none in the February 3, 2026 final guidance. ### Can the FDA refuse to accept a Breakthrough submission on cybersecurity grounds? Yes. Acceptance review happens before substantive review, so the priority benefit of designation never comes into play. A missing SBOM, absent postmarket plan, or no coordinated disclosure process can hold a Breakthrough submission at the acceptance gate. ### Should I raise cybersecurity in a sprint discussion or a Pre-Sub? Use a sprint discussion when you hold designation and the question is narrow enough to resolve in one exchange, such as SBOM depth or pen test scope. Use a Pre-Sub for broader strategy questions that need a written response covering several linked decisions. ### Does designation help if my cybersecurity documentation is incomplete? No. Senior engagement and interactive review help resolve genuine scientific ambiguity. They do not substitute for required content. Reviewers will still issue deficiencies, and each cycle costs more calendar time relative to a compressed priority-review schedule. ### Do AI-enabled Breakthrough devices have extra cybersecurity expectations? The requirements are the same, but the surface is larger. Model update mechanisms, training and inference data paths, and any PCCP-governed change process all need representation in the threat model and in the security risk assessment. ## CTA If you hold Breakthrough designation or are preparing a request, get the cybersecurity package moving now while the calendar still has slack. [Book a working session](/contact) and we will map your Section 524B obligations against your projected submission date. --- ## FDA Cybersecurity Failure Consequences Source: https://bluegoatcyber.com/blog/fda-cybersecurity-failure-consequences-medical-devices # FDA Cybersecurity Failure Consequences for Medical Devices in 2026 > **[DIRECT ANSWER]** Cybersecurity failures escalate on a predictable ladder. An inspection finds gaps and issues a Form 483; unresolved observations become a Warning Letter; continued noncompliance can bring import alerts, seizure, injunction, or a consent decree. In parallel, submissions stall on deficiency letters, hospital procurement teams pause purchases, and cyber insurers reprice. The regulatory cost is rarely the largest one. The "what happens if we fail" question lands on every medical device cybersecurity leader's desk eventually, usually right before or after an FDA inspection. The honest answer is that the regulatory ladder is well-defined, the commercial fallout is not, and the cybersecurity-specific consequences compound faster than general quality findings because cyber issues attract patient-safety attention and public-attention simultaneously. This post walks through the full consequence map: regulatory escalation, MDR interplay, commercial fallout, and the financial and reputational tail. It is meant for the board-level conversation, not the inspection-day response (for that, see the 483 response post linked below). ## Key Takeaways - The enforcement ladder is predictable: 483 → Warning Letter → recall → import alert → seizure → consent decree. Each step has a defensible response window. - Cybersecurity findings escalate faster than other QMS findings because they trigger MDR Part 803 reporting and attract public-safety attention. - Hospital procurement consequences (MDS2/HSCC blacklisting, GPO delisting) are often more financially painful than the FDA action itself. - Public Warning Letter posting on fda.gov is a permanent record customers, partners, and acquirers read. It does not "go away" after closure. - The sponsors that fail at each escalation step are usually the ones that treated the prior step as paperwork. ## Why this matters The FDA's enforcement authority over medical device cybersecurity comes from several converging sources: Section 524B of the FD&C Act for premarket and Section 518 for recalls, the Quality Management System Regulation (QMSR, 21 CFR Part 820 effective February 2, 2026) for postmarket facility inspections, 21 CFR Part 803 for medical device reporting, and the agency's general inspection and enforcement authorities. The February 3, 2026 final premarket cybersecurity guidance is the operative standard reviewers and inspectors apply. The FDA's [CDRH FY2024 Performance Report](https://www.fda.gov/media/186421/download) shows cybersecurity sits behind only software documentation and clinical evidence as a top deficiency category in premarket Additional Information letters, and Form 483 observations in 2025 and early 2026 cite cybersecurity gaps under the ISO 13485 clauses the QMSR incorporates, principally 7.3 design controls and 8.5.2 corrective action, together with the FDA record requirement retained at 820.35, with increasing frequency. Standards referenced in observations include IEC 62304:2006/A1:2015, AAMI SW96:2023, AAMI TIR57:2016/(R)2023, and ISO 13485:2016 (the consensus standard QMSR adopts by reference). Treating cybersecurity findings as a standalone security workflow rather than as design-controlled engineering output integrated with the quality system is what creates the gap. That gap is what an inspector finds, what a reviewer cites, and what escalates. ## The Regulatory Enforcement Ladder Each step has a defined trigger, a defined response window, and a defined escalation path. Knowing where you are on the ladder tells you what evidence to produce and how fast. | Step | Trigger | Sponsor response window | Escalation if unresolved | | --- | --- | --- | --- | | Form 483 (inspectional observations) | Issued at inspection close-out | 15 business days | Warning Letter | | Warning Letter (public) | Inadequate 483 response or significant violations | 15 working days | Untitled Letter, recall, or consent decree | | Untitled Letter | Lesser violations not warranting a Warning Letter | Typically 15 days | Warning Letter or recall | | Voluntary recall (manufacturer-initiated) | Sponsor identifies safety/effectiveness issue | Defined in recall strategy | Mandatory recall if inadequate | | Mandatory recall (FDA-ordered) | Section 518(e), reasonable probability of serious adverse health consequences | Immediate | Seizure, injunction | | Import alert / detention | Inadequate compliance for foreign-sourced product | Sponsor must petition removal | Continued detention | | Seizure | Significant ongoing violation, product remains a hazard | Court action | Injunction, consent decree | | Consent decree of permanent injunction | Pattern of significant violations, repeat offender | Negotiated; multi-year | Civil money penalties, debarment | | Civil money penalties | Specific statutory violations | Pay or contest | Continued enforcement | | Debarment | Felony conviction or repeat misconduct | Statutory process | Permanent or fixed-term ban | The ladder is rarely climbed in one step. A 483 with weak response becomes a Warning Letter. A Warning Letter with inadequate corrective action becomes a recall conversation. The fastest path to escalation is treating each step as a paperwork exercise. > **[KEY REQUIREMENT]** The Warning Letter is the inflection point. It is the first publicly posted step on the ladder and the first step that triggers automatic customer, procurement, and investor attention. The 15-working-day response window is short by design. ## MDR Part 803 Reporting Interplay A cybersecurity finding from an inspection often forces a backward-look review of whether prior cybersecurity events should have been reported under 21 CFR Part 803. The thresholds are: - **Death or serious injury** the device may have caused or contributed to. - **Malfunction** likely to cause or contribute to a death or serious injury if it recurred. A cybersecurity event that took a connected device offline during clinical use, exposed PHI in a way that affected care, or could have caused incorrect dosing or therapy delivery often meets the malfunction threshold even if no patient was actually harmed. Sponsors that find unreported events during a 483 response face a compounded problem: the original cyber finding plus a Part 803 reporting failure, which is itself a separate observation category. The honest framing for the board: the inspection finds a gap, the gap forces a Part 803 review, the review finds historic events that should have been reported, and the response package grows from a 15-day cyber fix to a 30+ day combined cyber-plus-MDR remediation. Plan for this on day one of the 483 response. ## Recall Classifications and What They Mean for Cybersecurity The FDA classifies recalls by patient-harm potential, not by technical severity: - **Class I.** Reasonable probability that use will cause serious adverse health consequences or death. Cybersecurity examples: a remotely exploitable vulnerability in an implantable cardiac device, a vulnerability in an infusion pump that allows unauthorized dose change. - **Class II.** Use may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote. Most connected device cybersecurity recalls land here. - **Class III.** Use is not likely to cause adverse health consequences. Cybersecurity examples are rare; most cyber recalls land in Class II or higher because the safety overlay pushes them up. Recalls are public ([FDA Medical Device Recalls database](https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls)) and stay in the public record indefinitely. The recall classification drives customer notification timeline, reverse-logistics scope, and the depth of corrective action documentation the FDA expects. ## Commercial Consequences Commercial consequences usually exceed regulatory consequences in dollar terms. The patterns: - **Hospital procurement blacklisting.** Health-delivery organizations track FDA enforcement actions through the [Health Sector Coordinating Council (HSCC)](https://healthsectorcouncil.org/) channels, ICS-CERT bulletins, and the MDS2 disclosure form. A Warning Letter or recall surfaces in procurement security reviews for years. - **GPO delisting.** Group Purchasing Organizations (Vizient, Premier, HealthTrust) screen suppliers for enforcement history. A pattern of cybersecurity findings affects contract renewal and new product onboarding. - **Contract termination clauses.** Most modern hospital purchasing contracts include a regulatory compliance clause. A Warning Letter can be a contract breach trigger; the hospital does not need a separate cybersecurity event to invoke it. - **Cyber-insurance premium impact.** Cyber-insurance carriers now ask about FDA enforcement history during underwriting. Warning Letters and recalls drive premium increases and sometimes coverage exclusion for the affected product line. - **Direct customer notification cost.** A recall requires sponsor-funded notification, replacement or patch deployment, and verification. For a connected device installed at 500 hospitals, the logistics cost alone runs into seven figures before any product modification. The commercial tail is what makes cybersecurity enforcement existential for smaller sponsors. The FDA action ends; the procurement blacklist does not. ## Financial and Reputational Consequences For public sponsors: - **Stock impact.** Warning Letters and recalls trigger 8-K disclosure obligations and material impact disclosure. Cybersecurity recalls on connected medical devices have produced single-day drops in the high single digits on multiple occasions in 2024-2026. - **Investor and analyst attention.** The cybersecurity narrative is sticky; sponsors with a public cybersecurity Warning Letter face cybersecurity questions on every earnings call for years. For private and venture-backed sponsors: - **M&A and fundraising impact.** Diligence processes surface FDA enforcement history immediately. A live Warning Letter or unresolved 483 can delay or reprice a deal, or kill it. - **Board-level escalation.** Cybersecurity findings now trigger automatic board notification at most companies with mature governance. The board conversation focuses on whether the engineering and quality leadership can be trusted with the next submission. For all sponsors: - **Public Warning Letters do not "expire."** The Warning Letter Closeout process exists, but the original posting stays in the [FDA Warning Letters database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) permanently. Customers, partners, and acquirers find it. ## Why Cybersecurity Failures Hit Harder Than Other QMS Failures Three reasons cybersecurity findings produce disproportionate fallout: - **Patient-safety overlay.** A labeling error is a paperwork problem. A cybersecurity vulnerability is a patient-safety problem in the public's eye, regardless of the actual clinical risk. The press writes the story the same way. - **Public-attention factor.** Cybersecurity recalls draw media coverage that other QMS recalls do not. The story has a villain (the attacker), a victim (the patient), and a corporate antagonist (the sponsor that did not patch). - **Standards convergence.** A cybersecurity finding under QMSR pulls in IEC 62304, AAMI SW96:2023, TIR57, IEC 81001-5-1, ISO 13485, and Part 803 simultaneously. The corrective action plan has to satisfy all of them, not just one. The compounding effect is real. A single 483 observation can drive a five-figure regulatory response, a six-figure commercial-impact mitigation, and a seven-figure recall logistics bill depending on how the response is handled. ## What the Sponsors Who Survive Each Step Do Differently Pattern recognition from 483 and Warning Letter responses on cybersecurity findings: - **They treat the 483 as the first step of an escalation, not the only step.** Response includes immediate correction, systemic remediation, evidence, and an effectiveness check. Generic "we'll improve our processes" responses escalate fast. - **They run the Part 803 backward-look in parallel.** Day one of the 483 response, not day fifteen. - **They engage procurement, communications, and legal in parallel with engineering.** The Warning Letter is a public event; the customer-facing response has to ship the same day the letter posts. - **They invest in the systemic root cause.** A vulnerability finding usually means the threat model, SBOM monitoring, or postmarket plan is structurally weak. Patching one bug without fixing the system invites the second observation. - **They name a single accountable executive.** The FDA notices when responses bounce between engineering, quality, and regulatory affairs without a single owner. ## How Blue Goat Approaches Postmarket Enforcement Defense We work with sponsors at every step of the ladder, from pre-inspection readiness to Warning Letter response to consent decree negotiation support. Our engagement on a cybersecurity 483 or Warning Letter pairs a regulatory response team with the engineering work the response actually requires: threat model refresh, SBOM regeneration from current builds with VEX classification, postmarket plan rebuild with CAPA linkage and CVD intake, and the design-control documentation that ties cybersecurity decisions back to controlled requirements. We run Part 803 backward-look reviews in parallel so the response package addresses the full compounded gap. Our engineers hold CISSP, OSCP, and prior military red-team credentials and have responded to cybersecurity-specific 483s and Warning Letters across cardiac, neuromodulation, infusion, imaging, and SaMD. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA postmarket cybersecurity service](/services/fda-postmarket-cybersecurity-services) or read the [FDA 483 cybersecurity observations post](/blog/fda-483-cybersecurity-observations-qmsr) for inspection-day specifics. ## FAQ ### What happens if you fail an FDA cybersecurity inspection? You receive a Form 483 listing the inspectional observations at the close-out meeting. The sponsor has 15 business days to respond. An inadequate response escalates to a public Warning Letter, then potentially to mandatory recall, import alert, seizure, consent decree, civil money penalties, and in rare cases debarment. Each step has a defensible response window; the fastest path to escalation is treating the prior step as paperwork. ### Is a Warning Letter for cybersecurity public? Yes. Warning Letters are posted in the [FDA Warning Letters database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) and remain in the public record indefinitely, even after closeout. Customers, partners, acquirers, and investors find them in routine diligence. ### Does a cybersecurity 483 trigger MDR reporting? Often, indirectly. A 483 cybersecurity observation usually forces a backward-look review of whether prior cybersecurity events met the 21 CFR Part 803 reporting threshold for death, serious injury, or malfunction likely to cause serious injury. Unreported events found during the review become a compounded violation on top of the original 483. ### What is a Class I cybersecurity recall? A Class I recall is one where there is a reasonable probability of serious adverse health consequences or death. Cybersecurity examples include remotely exploitable vulnerabilities in implantable cardiac devices and infusion pumps where the vulnerability allows unauthorized therapy modification. Most connected device cybersecurity recalls land in Class II rather than Class I, but the safety overlay pushes cyber recalls higher than equivalent non-cyber QMS recalls. ### How long does a consent decree last? Consent decrees of permanent injunction are negotiated, multi-year arrangements. Typical durations run 5 to 10 years and include third-party expert oversight, periodic FDA audit rights, certified corrective action plans, and significant restrictions on new product introduction until specified milestones are met. Consent decrees are rare in cybersecurity-only cases today but become more likely as enforcement matures. ### What is the difference between an Untitled Letter and a Warning Letter? An Untitled Letter cites violations that do not warrant the regulatory significance of a Warning Letter and is not publicly posted in the Warning Letter database. A Warning Letter is the formal advisory action is publicly posted, and triggers customer, procurement, and investor attention. Treat an Untitled Letter as the last off-ramp before a Warning Letter, not as a minor finding. ## Ready to defend a 483, a Warning Letter, or a postmarket inspection? If you have an inspection on the calendar, a 483 in hand, or a Warning Letter posted, the response window is short and the consequences of a weak response compound fast. We pair regulatory response with the engineering work the response actually requires, run the MDR backward-look in parallel, and rebuild the postmarket plan so the next inspection does not produce the same observation. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](/contact). --- **About the author.** Christian Espinosa, Founder, Blue Goat Cyber, CISSP. Christian leads a team focused exclusively on medical device cybersecurity, including FDA postmarket enforcement defense for Form 483 cybersecurity observations and cybersecurity Warning Letters. [Read more about Christian](/christian-espinosa). --- ## FDA Cybersecurity Major vs Minor Source: https://bluegoatcyber.com/blog/fda-cybersecurity-major-vs-minor-deficiency # FDA Cybersecurity Major vs Minor Deficiency: How Reviewers Grade Findings > **[DIRECT ANSWER]** A Major deficiency means the FDA cannot complete review without substantive new information and it places the submission on hold, while a Minor deficiency can usually be resolved with clarification inside the interactive review window. Cybersecurity Majors most often come from a missing or shallow threat model, an incomplete SBOM, or test evidence that does not match the submitted device version. ## Key Takeaways - Major: blocks a substantive decision, pauses the clock, 180-day response window. - Minor: clarification or limited request, smaller clock impact, faster turnaround expected. - Most cybersecurity findings grade as Major because they prevent the FDA from assessing the device's security risk profile. - A Minor finding mishandled in the response can be re-issued as a Major in the next round. - The Feb 3, 2026 FDA premarket cybersecurity guidance has tightened the bar for what reviewers accept as Minor. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to fda cybersecurity major vs minor deficiency the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What "Major" actually means to a reviewer A Major deficiency is one the reviewer cannot move past to reach a substantive decision on the submission. The finding is not optional information - it is missing evidence the FDA needs to determine whether the device meets the safety and effectiveness standard. Concretely, a finding tends to be Major when: - The reviewer cannot complete their assigned section of the review without the answer. - The finding identifies a gap in a deliverable the guidance lists as required. - Resolving the finding may require changes to other artifacts (threat model, risk assessment, labeling). - The finding implicates Section 524B compliance directly. A Major cybersecurity finding looks like: - "The threat model does not identify trust boundaries between the device and the cloud backend." - "The SBOM does not include firmware components." - "No VEX document is provided for SBOM components with known CVEs." - "The security testing summary does not demonstrate traceability from identified threats to test cases." - "The cybersecurity management plan does not describe a coordinated vulnerability disclosure (CVD) process." Each of these prevents the reviewer from closing the security section of the review. ## What "Minor" actually means to a reviewer A Minor deficiency is a clarification, a request to add a specific detail, or a request to correct a discrepancy that does not block the review. The reviewer can reach a decision once it is addressed, but is asking the sponsor to make the package internally consistent or to add a specific piece of supporting evidence. A Minor cybersecurity finding looks like: - "Confirm that the SBOM component versions in Section 12 match the build manifest in Appendix B." - "Clarify whether the penetration test in Section 14.3 was conducted on the final production firmware or a release-candidate build." - "Provide the date the threat model was last reviewed by the cybersecurity engineering team." - "Update Table 4 to indicate the VEX status format used (CycloneDX-VEX or OpenVEX)." - "Confirm the cryptographic library version listed in Section 8.2 is FIPS 140-3 validated." Each is answerable in a sentence or two with a pointer to the relevant section. None of them require rebuilding an artifact. ## Clock and response-window impact | | Major | Minor | |---|---|---| | Review clock | Paused until response received | Paused (or minimally affected, depending on the letter format) | | Response window | 180 days; submission considered withdrawn if missed | Typically faster turnaround expected, usually within the same AI letter window | | Format expectation | Full response with rebuilt artifacts and evidence | Targeted clarification, often a single paragraph per finding | | Risk of re-issue | High if response is weak | Low if response is direct | The 180-day window for Major deficiencies is a maximum, not a target. Sponsors who use the full 180 days are typically already in trouble - they discovered late that a Major finding required rebuilding the threat model or the security risk assessment from scratch. ## Why most cyber findings grade as Major The cybersecurity review section is one of the few areas of premarket review where missing evidence is binary. Either the sponsor provided a threat model, an SBOM, a VEX, a security risk assessment, and a security testing summary, or they did not. A reviewer cannot infer a threat model from labeling text or reconstruct an SBOM from a software description. This means: - Missing deliverables grade as Major almost by default. - Incomplete deliverables (e.g., a threat model that doesn't cover the wireless interface) usually grade as Major because they prevent completion of the security review. - Only formatting, version-discrepancy, or single-data-point clarifications tend to grade as Minor. The practical implication: cybersecurity is the section of the submission most likely to drive Major deficiencies, which is why FDA review delays so often trace back to security findings rather than clinical or mechanical findings. ## How a Minor can become a Major in the next round A common failure pattern: the sponsor receives a Minor cybersecurity finding, answers it tersely, and triggers a Major finding in the next review round. Examples: - Minor finding: "Confirm the VEX format used." Sponsor responds with one word ("CycloneDX-VEX"). Next round, Major finding: "The VEX document does not include justifications for components flagged `not_affected`." - Minor finding: "Clarify the penetration test scope." Sponsor responds with a one-paragraph description. Next round, Major finding: "The penetration test scope does not cover the BLE pairing flow." - Minor finding: "Confirm threat model review cadence." Sponsor responds with "Quarterly." Next round, Major finding: "The threat model has not been updated to reflect the cloud backend changes documented in Section 5." Reviewers escalate when a terse Minor response reveals a deeper substantive gap. The fix is to treat every Minor cyber finding as an invitation to demonstrate completeness, not as a single-question quiz. ## How to keep findings out of the Major column The pre-submission discipline that minimizes Major findings: 1. Build the threat model first, then the security risk assessment, then the SBOM/VEX, then the security testing plan. Out-of-order construction is the leading cause of internal inconsistencies that reviewers grade as Major. 2. Trace every identified threat to a test case and a result. Reviewers grade missing traceability as Major even when the underlying testing was actually done. 3. Provide the SBOM in CycloneDX or SPDX with an accompanying VEX. PDF screenshots of dependency lists trigger Major findings under the Feb 3, 2026 guidance. 4. Document the cybersecurity management plan with concrete CVD, patch cadence, and monitoring commitments. Vague language ("we will monitor for vulnerabilities") grades as Major. 5. Confirm the security risk assessment is aligned to IEC 81001-5-1 and that residual risk is quantified for each identified threat. 6. Have a senior cyber reviewer read the submission against the FDA premarket guidance before filing. Pre-submission gap analysis catches Major triggers cheaply. ## The 2026 guidance has tightened the bar The Feb 3, 2026 FDA premarket cybersecurity guidance superseded the 2023 document and raised the floor on what counts as a complete cyber package. Several deficiency patterns that were graded Minor in 2023-2024 are now consistently graded Major: - Missing VEX accompanying the SBOM. - Threat model without explicit trust boundary identification. - Security testing summary without traceability to the threat model. - Cybersecurity management plan without a documented CVD process. - SBOM without firmware components or without transitive dependency expansion. If your last submission was pre-2026, do not assume the grading you experienced still applies. The bar has moved. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### How many Major deficiencies is too many? There is no formal threshold, but in practice more than three Major cybersecurity findings on a single submission signals systemic pre-submission gaps. At that point the right move is to step back from individual finding responses and rebuild the cybersecurity package against the Feb 3, 2026 guidance before submitting a consolidated response. ### Can a Minor finding extend my review timeline? Minor findings do not pause the clock the way Major findings do, but a slow or incomplete response can prompt the FDA to re-issue a Minor as a Major in the next round, which then pauses the clock. Treat Minor findings with the same response discipline as Major ones. ### Does the FDA always label findings as Major or Minor? In Additional Information letters, yes - the labels are explicit. Hold letters and RTA letters use different terminology but the underlying severity grading is the same. PMA Major Deficiency letters are explicit by name. ### Are cybersecurity Major findings more common than clinical Major findings? In our experience across 510(k) and PMA submissions, yes. The cybersecurity review section has the highest rate of Major findings of any technical section, because missing security artifacts are binary and the 2026 guidance bar is now high. ### What happens if I disagree with a Major grading? You can respond to the substance of the finding without engaging the grading - the right move is almost always to provide the requested evidence rather than contest the grade. If you genuinely believe the FDA misread the submission and the answer is already in the package, point to it explicitly with section and page references in the response. ### How does Major vs Minor map to PMA Major Deficiency letters? A PMA Major Deficiency letter is the PMA-pathway analog of an AI letter with Major findings. PMA letters do not use the Minor label the same way - clarifications are typically handled inside the substantive review rather than as a formal finding. See our [PMA cybersecurity deficiencies post](/guides/fda-pma-cybersecurity-requirements) for the PMA-specific framing. ## Getting Major findings on your submission? Major cybersecurity deficiencies pause your clock and reset your launch date. Closing them takes a senior cyber response, not a junior point-by-point reply. - **Have an active Major finding?** → [FDA Cybersecurity Deficiency Response service](/services/fda-cybersecurity-deficiency-response) - **Want to prevent them on the next submission?** → [Pre-submission cybersecurity review](/contact) - **Comparing the letter types?** → [FDA Deficiency Letter vs RTA vs Hold Letter](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Does Device Class Decide FDA Cybersecurity Scope? Source: https://bluegoatcyber.com/blog/fda-cybersecurity-requirements-by-device-class # Does Device Class Decide FDA Cybersecurity Requirements? > **[DIRECT ANSWER]** Device class alone does not determine your FDA cybersecurity burden; Section 524B's cyber-device test does. A device qualifies if it contains software or firmware, can connect to the internet directly or through a host, and could be vulnerable to cyber threats. If all three apply and you're filing a 510(k), De Novo, PMA, PDP, or HDE, the full 524B premarket package attaches regardless of Class I, II, or III status. _Published June 4, 2026_
Section 524B scope decision tree DECISION TREE Is your device in scope for Section 524B? Includes software? firmware, programmable logic, SaMD Can connect to the internet? directly or via a host device Could be vulnerable to cyber threats? technological characteristics, validated by sponsor CYBER DEVICE under 524B(c) Filing a premarket submission? 510(k), De Novo, PMA, PDP, or HDE YES → full 524B premarket package NO → QMSR + postmarket only Any "no" above → NOT a cyber device (no 524B obligations)
Section 524B in-scope test: all three cyber-device criteria plus a premarket submission.
The most common misconception we hear from MedTech founders is "we're Class I, so cybersecurity doesn't really apply to us." It is wrong twice over. Class does not gate Section 524B, and Class I is not automatically 510(k)-exempt. This post unpacks what actually drives the cybersecurity burden and why class is the wrong question to start with. ## Key Takeaways - Section 524B applies to any "cyber device," regardless of class. - A device is a cyber device if it (1) includes software, (2) can connect to the internet, and (3) has technological characteristics that could be vulnerable to cybersecurity threats. - 524B only attaches when you file a premarket submission - 510(k), De Novo, PMA, PDP, or HDE. - Class I is the default classification, but roughly 5-7% of Class I devices are not 510(k)-exempt, and adding software or connectivity can strip the exemption. - Postmarket cybersecurity expectations and QMSR obligations apply regardless of class or exemption status. - The required documentation *categories* are the same for every cyber device; the *breadth and depth* scale with cybersecurity risk, not class. ## Why this matters Device class (I, II, or III) does not by itself decide your cybersecurity obligations under Section 524B of the FD&C Act. The FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 makes the cyber-device definition in 524B(c), software validated/installed/updated by the sponsor *and* the ability to connect to the internet *and* technological characteristics that could be vulnerable, the actual trigger for cybersecurity deliverables, regardless of class. That means a Class II 510(k) wearable can have heavier obligations than a Class III implantable that lacks wireless connectivity. The FDA's FY2024 cybersecurity refuse-to-accept data shows missed cyber-device determinations are still one of the most common reasons submissions stall in RTA review. Getting the class-to-cyber-device mapping wrong at scoping creates a six- to twelve-week delay later, so this is one of the highest-use decisions a regulatory team makes during early planning. ## Why "What Class Are You?" Is the Wrong First Question Device class under 21 CFR Part 860 is about general risk control: how much premarket oversight the FDA wants for the device's intended use. Cybersecurity sits in a parallel statutory track added by the 2022 Consolidated Appropriations Act as Section 524B of the FD&C Act. The two were not bolted together. Section 524B has its own definition of who it applies to ("cyber device") and its own trigger (a premarket submission). Class never appears in the statute. So if you walk into a conversation asking "what does a Class II device need for cybersecurity?" you have already framed the problem incorrectly. The right questions are: 1. **Is it a cyber device under Section 524B(c)?** 2. **Are you filing a premarket submission?** ## The Section 524B(c) Cyber-Device Test A device is a cyber device only if it meets **all three** of these criteria: 1. **It includes software** - firmware, programmable logic, and validated SaMD all count. 2. **It has the ability to connect to the internet** - intentionally or not. Bluetooth that bridges to a phone that bridges to the cloud counts. 3. **It contains technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.** A mechanical Class I bandage fails the test at step one. A Class III implantable pacemaker with telemetry passes at all three. A Class II ultrasound cart with no connectivity may still fail step two. A Class I "smart" stethoscope with a Bluetooth recording app passes all three and is fully in scope. The class of the device is irrelevant to this test. ## The Second Trigger: A Premarket Submission Section 524B(b) only attaches to a premarket submission. The covered pathways are: - 510(k) - De Novo - PMA - Product Development Protocol (PDP) - Humanitarian Device Exemption (HDE) If the device is 510(k)-exempt and you have nothing to submit, there is no premarket cybersecurity package to deliver under 524B. That does not mean cybersecurity goes away - QMSR (21 CFR Part 820) design control obligations and postmarket cybersecurity expectations still apply, and the FDA treats cybersecurity as part of device safety throughout the total product life cycle. But the premarket documentation set under 524B requires a submission to attach to. ## When Does a Class I Device Actually Require a 510(k)? This is the part that surprises most founders. Class I is the default, low-risk classification, but it is not synonymous with "exempt." Roughly 5-7% of Class I device types still require a 510(k). It happens in three situations: **1. The classification regulation itself removes the exemption.** When the FDA classified the device type under 21 CFR Parts 862-892, the regulation can explicitly state that 510(k) is required. This is usually because the device, although low-risk overall, has a specific failure mode the FDA wanted to vet before market entry. These are sometimes called "reserved" Class I devices. **2. The "limitations of exemption" are tripped.** Even an otherwise-exempt Class I device loses its exemption under 21 CFR 868.9, 870.9, 880.9, and the parallel sections in other parts if it: - has a **new intended use** not covered by the existing classification, - operates by a **different fundamental scientific technology** than the predicate device type, or - is life-supporting, life-sustaining, intended for implantation, or presents a potential unreasonable risk of illness or injury. The "different fundamental scientific technology" prong is the one that catches cybersecurity-relevant changes. The moment a traditionally passive Class I device gains connectivity, embedded software, or wireless interfaces it has almost certainly changed its fundamental technology and lost the exemption. A "smart" bandage with a wireless sensor, a connected manual stethoscope that records and transmits audio, a Bluetooth-enabled thermometer that pushes to a cloud dashboard - all of these are realistic Class I products that lose 510(k) exemption *because of* the addition of the software and connectivity that also make them cyber devices. **3. The device is a Class I IVD** subject to specific premarket requirements under 21 CFR Part 809 or 864. So a founder's instinct - "we're Class I, we're exempt, we owe no cyber package" - is doubly wrong: the Class I assumption may not hold once software and connectivity are involved, and even if it did hold, the cyber-device test runs on its own track. ## What's Actually Required When a Cyber Device Files a Premarket Submission Section 524B(b) lays out three statutory cybersecurity obligations for any cyber device filing a premarket submission: - **524B(b)(1)** - plans and procedures to monitor, identify, and address postmarket vulnerabilities and exploits in a reasonable time, including coordinated vulnerability disclosure. - **524B(b)(2)** - design, develop, and maintain processes that provide a reasonable assurance the device and related systems are cybersecure. - **524B(b)(3)** - a software bill of materials (SBOM) covering commercial, open-source, and off-the-shelf components. The FDA's [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance) turns those obligations into concrete deliverables (Appendix 4): - Cybersecurity risk management report - Threat modeling - Cybersecurity risk assessment - Security architecture views (global system, multi-patient harm, updateability/patchability, and security use case views) - Cybersecurity testing results (static analysis, software composition analysis, vulnerability scanning, penetration testing) - Labeling reflecting cybersecurity-relevant information - Cybersecurity management plan for postmarket Every cyber device that files a premarket submission owes evidence in every one of these categories. The categories do not change by class. ## Scope Scales With Cybersecurity Risk, Not Class What does change is the *breadth* of each artifact. The FDA is explicit in the guidance that documentation scales with cybersecurity risk. A device with one hardware connection (say, a single USB port for clinician configuration) or a SaMD with limited external dependencies will typically need: - a single global system architecture view rather than several, - a narrower set of security use case views, - a shorter threat model focused on a small attack surface, - a penetration test scoped to a handful of interfaces. A multi-patient infusion pump on hospital Wi-Fi talking to a cloud server, a mobile app, and a clinician portal will produce far more in each category. Same documentation set, very different page counts. The trap to avoid: do not conflate **software risk** with **cybersecurity risk**. The FDA's guidance explicitly notes that a device can have minor software risk under the Premarket Software Guidance and still carry significant cybersecurity risk, and vice versa. They are assessed independently. ## Worked Examples Across All Three Classes
Class vs cyber-device matrix CLASS × CYBER-DEVICE Burden tracks cyber-device status, not class NOT a cyber device CYBER DEVICE CLASS I CLASS II CLASS III No 524B obligations Manual stethoscope, gauze, basic passive instruments Full 524B package · small attack surface BLE smart stethoscope; connected thermometer pushing to cloud No 524B premarket package Certain passive surgical instruments filed via 510(k) Full 524B package · larger attack surface Wi-Fi infusion pump; cloud-connected CGM with mobile app No 524B premarket package Mechanical heart valve, fully passive PMA-class implants Full 524B package · highest complexity ICD with home telemetry; closed-loop neurostim with cloud programming Same documentation categories across the red column, depth scales with attack surface and complexity.
The red column tells the whole story: cyber-device status, not class, drives the 524B burden.
**Class I, 510(k)-exempt, no software** - traditional manual stethoscope. Not a cyber device. No 524B obligations. **Class I cyber device requiring 510(k)** - Bluetooth-enabled "smart" stethoscope that records and transmits audio. Lost its 510(k) exemption because added connectivity changed the fundamental technology. Cyber device under 524B(c). Owes the full premarket cybersecurity package; the attack surface is small, so each artifact is correspondingly shorter. **Class II, 510(k), non-connected, no software** - rare but possible (e.g., certain passive surgical instruments). Files a 510(k), but not a cyber device. No 524B premarket package. **Class II cyber device, 510(k)** - infusion pump with Wi-Fi and cloud telemetry. Cyber device. Same documentation set, but the threat model, architecture views, and pen test cover a much larger attack surface than the smart stethoscope. **Class III PMA, no connectivity** - mechanical heart valve with no electronics. Class III, life-sustaining, files a PMA, but not a cyber device. No 524B premarket package (general QSR/QMSR obligations still apply). **Class III PMA cyber device** - implantable cardioverter-defibrillator with home-monitoring telemetry. Cyber device. Same documentation categories, taken to their most detailed form because of the device's complexity, life-sustaining role, and multi-channel connectivity, with PMA annual reports that explicitly address cybersecurity changes. Notice the pattern: the burden tracks cyber-device status and submission pathway. Class is descriptive of the device, not prescriptive of the cybersecurity ask. ## How Blue Goat Cyber Helps We help MedTech sponsors answer the two questions that actually matter - is it a cyber device, and what submission is it going through - and then scope the cybersecurity package accordingly. That means right-sizing the threat model, architecture views, SBOM and VEX, security testing, and postmarket plan to the device's actual cybersecurity risk rather than overbuilding on a misread of class. If you are unsure whether your device is in scope at all, [contact us](/contact) and we will walk through the 524B(c) test against your specific connectivity and software profile. ## FAQ ### Does Section 524B apply to Class I devices? It can. Section 524B applies to any cyber device that files a 510(k), De Novo, PMA, PDP, or HDE. A Class I device that meets the 524B(c) cyber-device definition and is filing a 510(k) is fully in scope. A Class I device that is 510(k)-exempt has no premarket submission to attach a 524B package to, but postmarket cybersecurity and QMSR obligations still apply. ### Are the required cybersecurity artifacts different for Class II vs Class III? The categories are the same. The depth differs. Class III PMA submissions typically include deeper architectural views, stronger supply-chain controls, and PMA annual reports that explicitly address cybersecurity changes. Class II 510(k) and De Novo submissions for cyber devices use the same documentation set, sized to the device's cybersecurity risk. ### Does postmarket cybersecurity apply even without a premarket submission? Yes. Postmarket cybersecurity expectations - vulnerability monitoring, coordinated vulnerability disclosure, patching, and reporting - apply throughout the total product life cycle regardless of class or exemption status, anchored by QMSR (21 CFR Part 820) design controls and the FDA's postmarket cybersecurity guidance. ### Do I owe an SBOM if my device is 510(k)-exempt? Not under Section 524B. The SBOM mandate in 524B(b)(3) is tied to a premarket submission, so a 510(k)-exempt device has no statutory SBOM filing obligation with the FDA. That said, an SBOM is now table stakes for hospital procurement (per HSCC and MDS2 expectations), CISA coordinated disclosure, and any future submission if you ever lose the exemption. We recommend producing and maintaining one regardless. ### Does De Novo require the same cybersecurity package as 510(k)? Yes. Section 524B(b) names 510(k), De Novo, PMA, PDP, and HDE in the same breath - the statutory cybersecurity obligations are identical across them. De Novo submissions for cyber devices owe the full premarket package: cybersecurity risk management report, threat model, architecture views, SBOM, security testing, labeling, and a postmarket management plan. The novelty of the device usually means deeper threat modeling and a more thorough security architecture rationale, because there is no predicate to lean on. ### Are combination products (drug-device) in scope for Section 524B? If the device constituent meets the 524B(c) cyber-device test and the combination product files a premarket submission that includes the device portion (often via 510(k), PMA, or BLA with a device constituent), then the cybersecurity obligations attach to the device constituent. A connected drug-delivery autoinjector with Bluetooth dose logging, for example is firmly in scope even though the regulatory pathway is driven by the drug constituent. **Related:** [FDA 524B Cybersecurity Requirements Explained](/guides/fda-524b-cybersecurity-requirements-explained) | [Medical Device Classes & Cybersecurity Requirements](/reference/medical-device-classes-cybersecurity-requirements) | [De Novo Cybersecurity Requirements](/blog/de-novo-cybersecurity-requirements) | [510(k) Cybersecurity Requirements Every Maker Must Meet](/blog/510k-cybersecurity-requirements-every-maker-must-meet) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA Deficiency Letter vs RTA vs Hold Source: https://bluegoatcyber.com/blog/fda-deficiency-letter-vs-rta-vs-hold-letter # FDA Deficiency Letter vs RTA vs Hold Letter: What's the Difference? > **[DIRECT ANSWER]** An RTA letter blocks acceptance within the first 15 days because the submission is incomplete and resets the review clock on resubmission. A Deficiency, or Additional Information, letter arrives during substantive review with specific reviewer questions and pauses the clock until you respond. A cybersecurity Hold letter halts review over unresolved security gaps. Each demands a different response strategy and timeline under FDA rules. **Three different letters from the FDA. Three very different clocks, response windows, and risks. If you mix them up, you waste weeks - and weeks of FDA review time is the single most expensive thing in MedTech.** If you just received a letter from the FDA on your 510(k), De Novo, or PMA submission, the first question is almost never "what should we write back?" - it's "which kind of letter is this?" Sponsors regularly conflate a Refuse to Accept (RTA) decision with an Additional Information (AI) deficiency, and both with a cybersecurity Hold Letter. They are not the same. The response strategy, the deadline, and the cost of getting it wrong are different in each case. One terminology note before the comparison: "Hold letter" is industry shorthand, not a formal FDA letter type. What sponsors call a hold is usually an Additional Information letter that places the submission on hold pending your response. This guide breaks down all three, side by side, and shows you how to tell which one you got. ## Key Takeaways - RTA: Submission incomplete, before review starts. - Deficiency/AI: Reviewer needs info, pauses clock. - Hold: Cybersecurity gaps halt all review. - RTA resets clock; AI/Hold pause the clock. - Response strategies vary greatly by letter type. - Misinterpreting delays time and increases costs. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to each of these letter types the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## TL;DR - quick comparison | | **RTA letter** | **Deficiency / AI letter** | **Hold letter** | |---|---|---|---| | **Stage** | Before substantive review begins | During substantive review | During substantive review (cyber-specific) | | **What it means** | Submission was not complete enough to accept for review | Reviewer needs more info to make a decision | Cybersecurity package has gaps that block further review | | **Review clock** | Clock reset to zero on resubmission | Clock paused until you respond | Clock paused until you respond | | **Typical response window** | 180 days to resubmit (15 business days to fix small acceptance gaps) | 180 days for Major; shorter for Minor | Tied to the underlying AI/deficiency window | | **What gets returned** | The whole submission | Specific reviewer questions | Specific cybersecurity findings | | **Worst case if mishandled** | Restart at the back of the queue | Withdrawn-and-resubmit; lose months | Submission stalls indefinitely | ## 1. The RTA (Refuse to Accept) letter A [Refuse to Accept letter](/lp/fda-refuse-to-accept) is the FDA's way of saying "we did not even start reviewing this - your submission is missing things from the acceptance checklist." It's issued during the first 15 calendar days after a 510(k) is received, against a published RTA checklist. PMA has a similar mechanism called Refuse to File (RTF). **Key characteristics:** - Issued *before* substantive scientific review begins. - The FDA gives you 180 days to resubmit. If you miss that window, the submission is withdrawn. - When you resubmit, the review clock starts over from day zero. You don't pick up where you left off. - It is not a comment on the quality of your science - it's a comment on whether your package is *complete*. The most common cybersecurity-related RTA triggers under the February 2026 final premarket guidance: missing SBOM, no threat model, no security risk assessment, missing cybersecurity management plan, or no security testing summary. Any one of those gets you bounced. **What this letter is really telling you:** "Rebuild and resubmit." This is not a defense - it's a reconstruction job. ## 2. The Deficiency / Additional Information (AI) letter A [Deficiency Letter](/lp/fda-deficiency-letter) - also called an Additional Information request or AI letter - is what most sponsors think of when they say "the FDA had questions." It's issued *during* substantive review, after your submission has been accepted. The reviewer has read your package, identified specific gaps, and wants a point-by-point response. **Key characteristics:** - Issued after acceptance, during the FDA's substantive review. - The review clock pauses on the day the letter is issued and resumes when you respond. - You get 180 days to respond to Major deficiencies. Miss that window and the submission is considered withdrawn. - Responses are answered point-by-point against the reviewer's numbered list. - Multiple rounds are possible. Each round restarts the pause/resume cycle but does not reset the review clock to zero. The discipline that wins here is precision. Reviewers want each point closed with: (1) the question restated, (2) the technical answer, (3) the evidence (test report, updated risk assessment, revised SBOM), and (4) the location in the resubmission package where it lives. **What this letter is really telling you:** "Respond point-by-point and close the file." This is a defense, not a rebuild. ## 3. The cybersecurity Hold Letter A [Hold Letter](/lp/fda-hold-letter) is a more specific case. It's the FDA telling you that your cybersecurity documentation has gaps significant enough that further review is paused until they're addressed. In practice, hold letters most often arrive as part of an AI letter where cybersecurity is the dominant finding - but the framing is different: the submission isn't just incomplete on one topic, it's *frozen* until cyber is resolved. **Key characteristics:** - Issued during substantive review, typically by the cybersecurity reviewer assigned to your submission. - The review clock is paused. The submission cannot move forward on any axis (clinical, software, mechanical) until cyber is closed out. - Response windows are tied to the underlying AI letter (usually 180 days for Major findings). - Findings are almost always traceable to the FDA's premarket cybersecurity guidance, Section 524B, AAMI SW96, or IEC 81001-5-1. - The cost of a weak response is high: a second hold round, or a request that you withdraw and resubmit. **What this letter is really telling you:** "Your cybersecurity package is the bottleneck. Fix it and the review can continue." ## A note on PMA: Major Deficiency, Approvable, and Complete Response Letters If you're on the PMA pathway rather than 510(k) or De Novo, the letter names change but the underlying logic is the same: - **Refuse to File (RTF)** is the PMA analog of an RTA - the FDA never started substantive review. - **Major Deficiency letter** is the PMA analog of an AI letter during substantive review. The clock pauses, you have 180 days to respond, and missing it means the application is considered withdrawn. - **Approvable letter** says the FDA is prepared to approve once specific remaining items (often labeling, postmarket commitments, or final cybersecurity attestations) are resolved. - **Not Approvable letter** identifies substantive deficiencies that, in the FDA's current view, prevent approval. You can respond, amend, or withdraw. - **Complete Response Letter (CRL)** is the term most often associated with drug/biologic CDER and CBER reviews, but it sometimes appears in device-adjacent combination product reviews handled through CDER as the lead center. For a pure device PMA, the equivalent communications are the Major Deficiency, Approvable, and Not Approvable letters above. If your product is a combination product with a drug primary mode of action, a cyber finding can land inside a CRL - and the response window (typically 1 year before the application is considered withdrawn) is longer than the PMA Major Deficiency window, but the substantive expectations on threat model, SBOM/VEX, and security testing are the same. For a deeper PMA-specific walkthrough, see [FDA Cybersecurity Deficiencies in PMA Submissions](/guides/fda-pma-cybersecurity-requirements). ## How the review clock behaves under each The clock is what sponsors care about most, because the clock is money. Here's how each letter affects it. - **RTA:** Clock has not started yet. When you resubmit, it starts at day zero. Every week you spend rebuilding is a week added to your total time to clearance. - **Deficiency / AI:** Clock pauses on the day the letter is sent. It resumes the day the FDA receives a complete response. The days in between do not count against the FDA's 90-day MDUFA goal - but they absolutely count against your launch timeline. - **Hold:** Same pause-and-resume behavior as the AI letter, but the practical impact is bigger because the whole submission is gated on one section. The trap: sponsors often treat a paused clock as breathing room. It isn't. Every week your clock is paused is a week your competitor is still selling. ## The #1 mistake teams make with each letter | Letter | Most common mistake | |---|---| | RTA | Patching only the items the FDA called out, instead of doing a full acceptance-checklist review. The next RTA finds the next gap. | | Deficiency / AI | Treating reviewer questions as suggestions. Reviewers want closed loops, not philosophical discussions. | | Hold | Outsourcing the response to a generalist IT security firm with no FDA submission experience. Reviewers spot it immediately. | ## How to tell which one you got - a quick decision tree Use the four checks below in order. The first match wins, most letters can be classified in under a minute from the cover page and signature line alone. ## What stays the same across all three Three things never change, regardless of which letter you got: 1. **Speed matters.** The fastest sponsors respond in days, not months. Every paused day is launch revenue you'll never get back. 2. **Precision beats volume.** A tight, evidence-backed response wins faster than a thick one. Reviewers grade on completeness, not weight. 3. **Senior eyes only.** These responses are not training opportunities. Get someone who has shipped 100+ submissions reading every page before it leaves your office. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### Is an RTA the same as a deficiency letter? No. An RTA (Refuse to Accept) is issued before the FDA begins substantive review and means the submission isn't complete enough to start. A deficiency (or AI) letter is issued *during* substantive review and means the reviewer has specific questions about the science. The response strategy and clock impact are completely different. ### Does a hold letter restart the review clock? No. A hold letter pauses the review clock - it doesn't reset it. The clock resumes when the FDA receives a complete response. This is the same pause-and-resume mechanism as a standard AI letter, but in a hold scenario the entire submission is gated on resolving cybersecurity findings. ### How long do I have to respond to each type of letter? RTA: 180 days to resubmit the full package (or 15 business days for minor acceptance gaps). Deficiency / AI letter: 180 days for Major deficiencies. Hold letter: tied to the underlying AI letter window, usually 180 days. Missing any of these windows results in the submission being considered withdrawn. ### Can I get more than one of these letters on the same submission? Yes - and it's common. A submission can get an RTA, be resubmitted, get accepted, and then receive an AI letter or a hold letter during substantive review. Each letter is a separate event with its own response strategy. ### Who at the FDA issues each letter? RTA letters come from the lead reviewer or RTA coordinator in the relevant review division during the acceptance phase. AI / deficiency letters come from the assigned lead reviewer during substantive review. Hold letters are typically issued by the cybersecurity reviewer assigned to your submission, often as part of a broader AI letter. ### What's the worst-case outcome for each? RTA: keep getting bounced and never start substantive review. Deficiency: the FDA considers the submission withdrawn and you start over. Hold: indefinite stall with a request to withdraw and resubmit. All three end the same way if mishandled - months lost and a clearance date pushed out. ## Got one of these letters? Whichever letter you're holding, the response strategy is specific and the clock is already running. We've shipped responses to all three across 275+ FDA submissions, and we can triage your situation under NDA in 24 hours. - **Got an RTA?** → [FDA Refuse to Accept response](/lp/fda-refuse-to-accept) - **Got a deficiency / AI letter?** → [FDA Deficiency Letter response](/lp/fda-deficiency-letter) - **Got a cybersecurity hold?** → [FDA Hold Letter response](/lp/fda-hold-letter) Or [book a discovery call](/contact) and we'll tell you which one you actually have and what the next 72 hours should look like. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA IDE Cybersecurity Requirements: 2026 Source: https://bluegoatcyber.com/blog/fda-ide-cybersecurity-requirements # FDA IDE Cybersecurity Requirements for Connected Investigational Devices (2026) > **[DIRECT ANSWER]** The FDA's February 3, 2026 guidance recommends a narrow cybersecurity package for an IDE: disclosure of cybersecurity risks in the informed consent form, three architecture views plus a safety-scoped security use case view, an SBOM, and general cybersecurity labeling. A full risk management report, threat model, vulnerability assessment, penetration testing, and cybersecurity management plan are listed as helpful but not required until the marketing submission. Sponsors planning a clinical trial for a connected device routinely ask the wrong question first: "Do we need the full FDA cybersecurity package for the IDE?" The Feb 3, 2026 final premarket cybersecurity guidance answers that question explicitly in Appendix 3, and the answer is narrower than most teams assume, but the cost of treating "not recommended at IDE" as "not needed yet" shows up later, in the form of cybersecurity deficiencies at PMA after the architecture has already been frozen by clinical data. This guide walks through exactly what the FDA recommends in an IDE submission, what it deliberately defers to the marketing submission, and why building the full documentation set during the trial is the smart play for any Class III or significant-risk connected device. ## Key Takeaways - **Five elements are recommended at IDE** (Appendix 3, Feb 3, 2026 guidance): cybersecurity risks in the informed consent form, three architecture views (global, multi-patient harm, updateability/patchability), a safety-scoped security use case view, an SBOM, and general cybersecurity labeling. - **Penetration testing is not recommended at IDE**, it sits in the "could be helpful, not specifically recommended" column and is required at the marketing submission instead. - The **SBOM is the only sub-element** of the Cybersecurity Risk Management Report explicitly recommended at IDE; threat model, vulnerability assessment, traceability, testing, and the cybersecurity management plan are not. - **Cybersecurity disclosure in the informed consent form** (21 CFR 50.25(a)(2) and 812.25(g)) is the most commonly missed element in first-cycle IDE submissions for connected devices. - **Scope does not change by device class.** The same five elements apply to Class II and Class III IDEs; classification affects how the FDA weighs the documentation in the benefit-risk assessment, not what you submit. - **IDE approval does not settle PMA cybersecurity.** The guidance anticipates that OS support windows and third-party updates will force security improvements between trial and marketing submission, so build the full PMA package during the trial. ## Why IDE Cybersecurity Scope Matters Before the Trial Starts The IDE is the first regulatory checkpoint at which the FDA's cybersecurity reviewers see a connected investigational device. The Feb 3, 2026 guidance ("Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions") brought IDE-specific recommendations into the same document that governs 510(k), De Novo, and PMA submissions, which is new, the 2023 predecessor handled IDE only by reference. Getting the IDE cybersecurity package wrong has two costs. The first is direct: the FDA can disapprove or condition the IDE, delaying the trial. The second is structural and more expensive: any architecture decision baked in during the trial, operating system, wireless stack, update mechanism, key management, third-party libraries, becomes hard to change at PMA without re-opening clinical data questions. Standards including AAMI TIR57 (security risk management), IEC 81001-5-1 (health software security lifecycle), and ANSI/AAMI SW96 (medical device security risk management) all assume security architecture decisions are made early in the design process, not retrofitted after Phase II. The IDE cybersecurity scope is narrow on purpose. It is not narrow because the device is investigational. It is narrow because investigational data is the right time to verify clinical safety, and the FDA expects security to be re-evaluated and tightened before marketing authorization. ## What the FDA Recommends in an IDE Cybersecurity Submission Appendix 3 (p. 50) lists five items as "Recommended" for an IDE cybersecurity submission, each tied to a specific 21 CFR 812.25 subsection. > **[FDA LANGUAGE]** "Cybersecurity documentation recommended in IDE submissions: Inclusion of cybersecurity risks as part of informed consent form (21 CFR 50.25(a)(2) and 21 CFR 812.25(g)); Global, multi-patient and updateability/patchability views (21 CFR 812.25(c), (d)); Security use case views for functionality with safety risks (e.g., implant programming) (21 CFR 812.25(c), (d)); Software Bill of Materials (21 CFR 812.25(c), (d)); General labeling, connectivity and associated general cybersecurity risks, updateability/process (21 CFR 812.25(f))." Two recommendations get under-weighted by sponsors. The first is the **informed consent disclosure**: patients enrolling in the trial need to be told the device has connectivity-related cybersecurity risks. This is the element most often missed in first-cycle IDE submissions for connected devices. The second is the **SBOM**. Table 1 (p. 52) shows that within the broader Cybersecurity Risk Management Report family, threat model, risk assessment, vulnerability assessment, traceability, testing, management plan, the SBOM is the *only* sub-element pulled into the "Recommended" column at IDE. Everything else is explicitly downgraded. Requirements documentation for the recommended architecture views is also "Recommended", meaning sponsors should submit not just the diagrams, but the underlying security requirements that each view enforces. ## What the FDA Does Not Recommend at IDE (But Will Require at PMA) Table 1 (pp. 51-53) sorts every element of the marketing-submission cybersecurity package into either the "Recommended" column or the "could be helpful to submit, but not specifically recommended" column for IDE. The full list of items in the second column is operationally significant: | Element | IDE position | |---|---| | Cybersecurity Risk Management Report (full) | Could be helpful, not specifically recommended | | Threat Model | Could be helpful, not specifically recommended | | Cybersecurity Risk Assessment | Could be helpful, not specifically recommended | | Vulnerability Assessment and Software Support | Could be helpful, not specifically recommended | | Unresolved Anomalies Assessment | Could be helpful, not specifically recommended | | Traceability | Could be helpful, not specifically recommended | | Measures and Metrics | Could be helpful, not specifically recommended | | Testing (including penetration testing, Section V.C) | Could be helpful, not specifically recommended | | Cybersecurity Management Plans | Could be helpful, not specifically recommended | This is the formal taxonomy from the guidance footnote: "could be helpful to submit, but not specifically recommended" refers to elements that could be helpful to the FDA if submitted, but are not specifically recommended in Appendix 3. Two clarifications worth giving every client. First, **penetration testing is not expected at IDE**. The FDA does not want full third-party penetration test reports against an investigational build that will change before marketing. Second, **eSTAR is a 510(k) submission tool**, it does not apply to IDE. The right comparator for the IDE cybersecurity package is the 21 CFR 812.25 investigational plan, not any eSTAR template. ## How Architecture Views Are Scoped Differently at IDE A common misreading of Appendix 3 is that the IDE only requires three architecture views. The text actually lists four view types, with the fourth scoped narrowly: 1. **Global view**, the system in its environment, including all interfaces and data flows. 2. **Multi-patient harm view**, paths by which a single device compromise could harm more than one patient. 3. **Updateability/patchability view**, how the device receives, validates, and applies software updates. 4. **Security use case views**, limited at IDE to "functionality with safety risks (e.g., implant programming)." The fourth view is the one with the IDE-specific scope qualifier. In a full marketing submission, security use case views are expected for "all medical device system functionality through which a security compromise could impact the safety or effectiveness of the device" (p. 22 of the guidance). At IDE, that scope narrows to functionality whose compromise creates direct safety risk, programming pathways on an implantable, dose-control pathways on an infusion pump, image acquisition control on a surgical robot. The example used in the guidance text is implant programming. For a Class III implantable with wireless connectivity, this view almost always applies, and the FDA reviews it in the context of the benefit-risk assessment for the investigation, not in isolation. Appendix 4 (pp. 51-52) adds the scaling rule that governs how *much* of each view you owe. Documentation breadth scales with the device's cybersecurity risk, and the guidance says that scaling is "most evident in the breadth of the Threat Modeling and Architecture Views documentation." A device with a single hardware connection such as a USB port, or a SaMD product with limited software dependencies and connectivity, will likely need only one diagram for each of the global, multi-patient harm, and updateability/patchability views, plus a small subset of security use case views. A device with networking, wireless, cloud, or a commercial operating system will likely need multiple multi-patient harm and updateability/patchability views, because there are multiple ways to cause multi-patient harm or to update the device, and many more security use case views to cover the unique security and clinical use cases in the architecture. Two framing points from the same appendix are worth holding onto. Table 1 "is not intended to serve as merely a deliverable checklist," and it "represents one possible way to organize the recommended information." Sponsors can present the elements in a way consistent with their existing documentation processes. And where a device-specific guidance carries additional or different recommendations, the device-specific recommendations control over Table 1. ## Class III, Implantables, and the Benefit-Risk Framing The Feb 3, 2026 guidance does not modify the IDE cybersecurity scope based on device classification. The same five "Recommended" elements apply whether the investigational device is Class II or Class III. Cybersecurity scope at IDE is device-type-driven (what the device is and how it connects), not class-driven. What does change with a significant-risk Class III device is how the FDA *uses* the cybersecurity documentation. Appendix 3 (p. 50) states that the FDA "intends to review this information in the context of the overall benefit-risk assessment of investigational devices as outlined in FDA's guidance 'Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions.'" For a significant-risk implantable with wireless connectivity, the security use case views and the multi-patient harm view receive close scrutiny in that benefit-risk weighing, because the same cybersecurity defect can produce different magnitudes of harm depending on what the device does to the patient. A battery-less or NFC-coupled investigational implant still needs the SBOM and architecture views. Short-range coupling shows up as attack-surface reduction *within* those views; it is not a justification for skipping them. ## Why You Should Build the Full PMA Package During the IDE Anyway The FDA is explicit on this point. From Appendix 3 (p. 50): > **[KEY REQUIREMENT]** "Approval of an IDE based on the documentation recommended above does not preclude the possibility of future cybersecurity questions or concerns being raised during review of a subsequent marketing application. This is, in part, due to the understanding that design changes may be needed and the temporal nature of cybersecurity. Cybersecurity improvements will likely be needed between the time of clinical trials and when the device is submitted for marketing authorization (e.g., operating system no longer supported or nearing end of support, third-party software updates)." Three practical consequences follow: 1. The architecture you ship in the IDE is the architecture clinical data attaches to. Reworking it for the PMA introduces clinical-equivalence questions you would rather not raise. 2. Operating-system support windows and third-party library updates will move during a multi-year clinical trial. The PMA submission has to account for that drift, which is much easier when the threat model and vulnerability monitoring process were established at IDE. 3. The full Cybersecurity Risk Management Report, threat model, vulnerability assessment, testing program, and cybersecurity management plan are all required at PMA. Building them during the trial means the PMA cybersecurity section becomes a refresh exercise rather than a from-scratch construction under deadline pressure. For depth on what the marketing submission will require, see our coverage of [FDA PMA cybersecurity requirements](/guides/fda-pma-cybersecurity-requirements) and the [FDA premarket cybersecurity submission checklist](/guides/fda-premarket-cybersecurity-submission-checklist). ## IDE vs 510(k) vs PMA: Side-by-Side Cybersecurity Scope One structural point first, because it is the most common error in this area: Section 524B(a) of the FD&C Act is a **marketing-submission statute**. It enumerates 510(k), De Novo, PMA, PDP, and HDE. IDE is not a 524B pathway. Cybersecurity expectations at IDE come from Appendix 3 of the FDA's February 3, 2026 final premarket cybersecurity guidance plus unreasonable-risk-to-subjects review under 21 CFR 812.30(b)(4), not from 524B. Our guide to [FDA pathway cybersecurity differences](/guides/fda-pathway-cybersecurity-differences) walks the same split across every pathway, including HDE, PDP, and Q-Sub. | Dimension | IDE | 510(k) / De Novo | PMA | |---|---|---|---| | Statutory hook | 21 CFR Part 812; guidance Appendix 3. Not a 524B pathway. | Section 524B applies in full | Section 524B applies in full | | Threat model | Not specifically recommended at IDE | Required, scoped to the marketed configuration | Required, deepest scope including manufacturing and update infrastructure | | SBOM | Recommended, the only Risk Management Report sub-element pulled in at IDE | Required with support-status and vulnerability fields | Required, plus lifecycle maintenance evidence | | Architecture views | Global, multi-patient harm, updateability, and security use case views scoped to safety-risk functionality | All four view types at full scope | All four at full scope, with deeper interface and manufacturing detail | | Penetration testing | Not expected against an investigational build | Expected; scope and independence must be justified | Expected, with the most rigorous evidence and coverage rationale | | Cybersecurity management plan | Not specifically recommended | Required, including CVD process and patch timelines | Required, plus annual-report treatment of cybersecurity changes | | QMSR alignment | Design controls apply; full QMS evidence not reviewed at IDE | QMS considerations reviewed per the Feb 2026 guidance | Deepest QMS and manufacturing evidence, subject to preapproval inspection | | Labeling | General cybersecurity labeling for investigators and sites | Full 524B(b)(3) labeling set | Full labeling set with postmarket support commitments | | Informed consent | Cyber risk disclosure recommended in the consent form | Not applicable | Not applicable | | Submission vehicle | IDE application under 21 CFR 812.25. eSTAR does not apply. | eSTAR cybersecurity section | PMA modules | | Review clock | 30 FDA days | 90 FDA days | 180 FDA days, longer with panel | | Worst-case cyber outcome | Clinical hold under 21 CFR 812.42 stopping enrollment | Refuse-to-Accept hold at Acceptance Review | Major deficiency letter | | Postmarket obligations | Mid-study security event reporting to investigators, the IRB, and the FDA; IDE supplements for security patches | 524B postmarket plan, CVD policy, SBOM updates | Same, plus cybersecurity content in PMA annual reports | The practical read: the IDE package is a **subset scoped to subject safety**, not a lighter version of the marketing package. Everything downgraded at IDE returns at 510(k) or PMA, so the artifacts you build for the trial should be written to be expanded rather than replaced. Related reading on the same comparison: - [510(k) cybersecurity requirements vs other FDA pathways](/guides/fda-pathway-cybersecurity-differences) covers how the eSTAR Acceptance Review enforces the 510(k) package format. - [510(k) vs De Novo vs PMA vs IDE cybersecurity comparison](/compare/510k-vs-de-novo-vs-pma-cybersecurity) is the side-by-side table, including review clocks and worst-case outcomes. ## Related FDA cybersecurity resources - [IDE cybersecurity submission guide](/guides/ide-cybersecurity-submission-guide) - how to assemble the IDE package, with Appendix 3's five elements mapped to 21 CFR 812.25 and the risk-scaling rule from Appendix 4. - [FDA pathway cybersecurity differences: IDE, 510(k), De Novo, and PMA](/guides/fda-pathway-cybersecurity-differences) - what each FDA submission pathway expects for threat modeling, SBOM, testing, and postmarket evidence. - [FDA premarket cybersecurity submission checklist](/guides/fda-premarket-cybersecurity-submission-checklist) - the marketing-submission deliverable set your IDE artifacts should be written to expand into. - [FDA SBOM requirements](/blog/medical-device-sbom-fda-requirements-and-submission-guide) - the CycloneDX or SPDX content the FDA expects at IDE and again at 510(k) or PMA. - [510(k) vs De Novo vs PMA vs IDE cybersecurity comparison](/compare/510k-vs-de-novo-vs-pma-cybersecurity) - side-by-side FDA review clocks, cybersecurity scope, and worst-case deficiency outcomes. ## How Blue Goat Cyber approaches IDE cybersecurity Blue Goat Cyber's IDE engagements are built around the Appendix 3 scope, with optional extensions to seed the PMA package during the trial. We deliver the recommended informed-consent cybersecurity language, the four architecture view types (with the security use case view scoped to safety-risk functionality), the SBOM in CycloneDX or SPDX, and the general cybersecurity labeling block tied to 21 CFR 812.25(f). For sponsors that want the PMA-ready set in parallel, we author the threat model under STRIDE, the security risk assessment under AAMI TIR57 / ANSI/AAMI SW96:2023 and IEC 81001-5-1, and the postmarket cybersecurity management plan against the Feb 3, 2026 guidance. Our team includes CISSP and OSCP-credentialed practitioners with FDA submission experience on Class II and Class III connected devices. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. See our [FDA submission services](/services). ## FAQ ### What does the FDA actually recommend in an IDE cybersecurity submission? Five elements, listed in Appendix 3 of the Feb 3, 2026 premarket cybersecurity guidance: cybersecurity risks in the informed consent form, three architecture views (global, multi-patient harm, updateability/patchability), a security use case view scoped to functionality with safety risks, a Software Bill of Materials, and general cybersecurity labeling covering connectivity, associated risks, and the update process. Each is tied to a specific subsection of 21 CFR 812.25. For how that IDE scope compares with the full marketing-submission package, see [IDE vs 510(k) vs PMA cybersecurity scope](#ide-vs-510-k-vs-pma-side-by-side-cybersecurity-scope) and the [FDA pathway cybersecurity differences guide](/guides/fda-pathway-cybersecurity-differences). For the statutory scope question and the Appendix 4 risk-scaling rule, see the [IDE cybersecurity requirements guide](/guides/ide-cybersecurity-requirements-guide). ### Do I need penetration testing for an IDE submission? No. Penetration testing falls under the "Testing" element in Table 1, which sits in the "could be helpful to submit, but not specifically recommended" column at IDE. The FDA does not expect a third-party penetration test report against an investigational build that will change before the marketing submission. Penetration testing is, however, required at the marketing submission: see the [510(k) cybersecurity testing requirements](/compare/510k-vs-de-novo-vs-pma-cybersecurity) and the [PMA cybersecurity evidence expectations](/guides/fda-pathway-cybersecurity-differences). ### Is the cybersecurity scope different for a Class III IDE? No. The Feb 3, 2026 guidance does not vary IDE cybersecurity scope by device class. The same five recommended elements apply to Class II and Class III investigational devices. What changes is how the documentation is weighed: significant-risk Class III devices, especially implantables with wireless connectivity, get closer review of the security use case view and the multi-patient harm view within the IDE benefit-risk assessment. Class III sponsors should plan the [PMA cybersecurity package](/guides/fda-pathway-cybersecurity-differences) during the trial rather than after it. ### Does IDE approval mean my cybersecurity package is set for the PMA? No. The FDA states explicitly that IDE approval "does not preclude the possibility of future cybersecurity questions or concerns being raised during review of a subsequent marketing application." Operating-system support windows and third-party software updates are expected to require security improvements between trial and marketing submission, and the full Cybersecurity Risk Management Report is required at PMA. Compare the IDE, [510(k)](/compare/510k-vs-de-novo-vs-pma-cybersecurity), and [PMA](/guides/fda-pathway-cybersecurity-differences) requirements side by side before you freeze the trial build. ### What's the most common missed element in IDE cybersecurity submissions? The cybersecurity disclosure in the informed consent form under 21 CFR 50.25(a)(2) and 812.25(g). Sponsors focused on technical documentation routinely forget that patients enrolling in a connected-device study need to be told about connectivity-related cybersecurity risks. This is also the easiest deficiency for the FDA to flag because it is a binary check against the consent form. ### What happens if a serious cybersecurity vulnerability is discovered in an investigational device mid-trial? The IDE is governed by the same Unanticipated Adverse Device Effect (UADE) reporting framework as any other safety signal. A cybersecurity defect with safety implications, remote code execution on an implant programming pathway, for example is reportable under 21 CFR 812.150(a)(1) and triggers an IRB and FDA notification within the prescribed timelines. The cybersecurity management plan you build during the trial should document the triage and escalation path so this decision is not made under time pressure. More on this topic: the [IDE cybersecurity hub](/topics/ide-cybersecurity) collects our IDE guides, pathway comparisons, and related posts in one place. ## Talk to us about your IDE cybersecurity package If you are preparing an IDE for a connected Class II or Class III device, we can scope the Appendix 3 package and the optional PMA-ready extensions in a single engagement. Book a call to walk through your architecture, your trial timeline, and what the FDA will actually expect at both IDE and PMA. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Talk to our team](/contact). --- *Christian Espinosa, Founder, CISSP. Christian has led FDA cybersecurity submissions for connected medical devices spanning Class II and Class III investigational and marketing pathways, including implantables with wireless connectivity. [Read more from Christian](/team/christian-espinosa).* --- ## Medical Device Authentication and Access Control | Blue Goat Source: https://bluegoatcyber.com/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization # Medical Device Authentication and Access Control Explained > **[DIRECT ANSWER]** Medical device authentication and access control means verifying who or what is connecting to a device, then limiting what that identity can do once connected. Authentication confirms identity through passwords, tokens, biometrics, or certificates. Authorization enforces least-privilege permissions once identity is confirmed. Accountability ties every action back to that identity through tamper-evident logs. The FDA's February 3, 2026 final guidance expects manufacturers to document all three, with evidence, in premarket submissions. _Reviewed September 17, 2026_ A medical device that cannot prove who issued a command is a device that cannot prove the command was safe. Attackers who gain access to an infusion pump, imaging console, or hospital network gateway rarely need to break a cryptographic algorithm. They need a hardcoded password, a shared service account, or a role that grants more privilege than the job requires. These are design decisions, not accidents, and reviewers at the FDA now treat them as gating issues under Section 524B of the FD&C Act. Manufacturers who cannot show a role and privilege matrix, credential lifecycle plan, and tamper-evident audit trail are increasingly seeing these gaps surface as Additional Information requests during 510(k) and PMA review. This page consolidates what manufacturers need to know about authentication, authorization, and accountability for connected medical devices, including biometrics, credential storage, and the logging evidence that supports nonrepudiation. ## Key Takeaways - Authentication, authorization, and accountability are three distinct controls; the FDA expects evidence for each, not just a login screen. - Hardcoded and shared credentials remain among the most common findings in medical device penetration tests and premarket reviews. - Biometrics improve usability but should never be the sole control for high-risk functions; they need documented spoofing resistance and a fallback method. - Rights define policy intent (what a role should do); permissions are the enforceable technical actions that implement it. Both need documentation. - Password storage design determines resistance to offline attacks, which happen after credential theft and bypass online lockouts entirely. - Audit logs must be complete and tamper-evident to support nonrepudiation, or postmarket investigations have no reliable evidence to work from. ## Why This Matters Authentication and access control failures are not abstract IT risk in a medical device. A compromised login on an infusion pump or a surgical robot console can lead to altered dosing, falsified diagnostic results, or an unauthorized firmware push. That is why the FDA folded authentication and authorization into its core premarket cybersecurity expectations rather than treating them as optional hardening. Under the February 3, 2026 final guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," reviewers expect authentication and access control to be treated the same way software lifecycle requirements are treated under IEC 62304: as design-controlled engineering artifacts with traceable requirements, verification tests, and residual risk documentation. AAMI's SW96 standard, recognized by the FDA under recognition number 13-131, gives manufacturers a structured way to document these controls inside a security risk management file. The FDA's own performance data shows cybersecurity deficiencies, including access control gaps, are among the top categories cited in 510(k) and PMA Additional Information letters. Manufacturers who treat authentication as a checkbox rather than a threat-modeled control tend to discover the gap only after a reviewer flags it, which adds review cycles and delays clearance. Building the evidence up front, tied to a real role and privilege matrix and a tested credential lifecycle, is the difference between a smooth review and a stalled one. ## Authentication vs Authorization vs Accountability Authentication, authorization, and accountability are three separate controls that get conflated in casual conversation but must be documented separately for the FDA. Authentication answers "who or what is this." Authorization answers "what is this identity allowed to do." Accountability answers "what did this identity actually do, and can we prove it." The FDA's guidance splits authentication further into two categories: entity authentication, which verifies the identity of a user or connected device, and data authentication, which verifies that information has not been altered and originated from a trusted source. A device can authenticate a clinician correctly and still fail if it cannot prove a firmware image or sensor reading is genuine. **[KEY REQUIREMENT]** Premarket submissions should document authentication, authorization, and accountability as three distinct control categories, each with its own threat model entries, design requirements, and verification evidence. Treating them as one bundled "login system" is a common source of reviewer questions. | Control | What it answers | Typical mechanism | Failure mode if missing | |:---|:---|:---|:---| | Authentication | Who or what is this identity? | Password, token, certificate, biometric | Impersonation, spoofed device commands | | Authorization | What can this identity do? | Role-based access, permission checks, least privilege | Privilege escalation, over-privileged accounts | | Accountability | What did this identity do, and can we prove it? | Signed audit logs, timestamps, tamper detection | No forensic evidence after an incident | ## What the February 3, 2026 Guidance Expects The February 3, 2026 final guidance expects manufacturers to show authentication and access control as part of a Secure Product Development Framework, not as a bolt-on feature. This guidance is the current version in a chain that started with draft guidance in September 2023 and an interim update in June 2025 before finalizing this year. Reviewers want to see multi-factor authentication for privileged and remote access paths, unique credentials per user or per device, automatic session timeouts, and a "deny by default" posture for unrecognized connections. They also expect a documented privilege matrix showing which roles can perform which actions, and evidence that authorization checks are enforced at the device or server layer rather than only hidden in a user interface. For credential management specifically, the guidance expects a defined lifecycle: how credentials are provisioned, rotated, revoked, and recovered, including for service and maintenance accounts that rarely get the same scrutiny as clinician logins. Nonrepudiation evidence, meaning logs and signatures that tie an action back to a specific identity without possibility of denial, rounds out the expected control set. **[KEY REQUIREMENT]** A credential lifecycle plan covering provisioning, rotation, revocation, and emergency recovery is expected documentation, not an optional appendix, and it must explicitly cover service and maintenance accounts. ## Hardcoded Credentials, Shared Accounts, and Service Accounts Hardcoded credentials remain one of the most common and most damaging findings in medical device security assessments because they cannot be changed without a firmware update. A single hardcoded password shared across every unit of a product line means one leaked credential compromises the entire fleet, not one device. Shared accounts create a related but distinct problem: they destroy accountability. If three clinicians or two service technicians use the same login, an audit log showing "admin logged in and changed therapy limits" cannot identify who actually made the change, which defeats the nonrepudiation goal the FDA expects logging to support. Service and maintenance accounts deserve particular attention because they are often the highest-privilege accounts in the system and the least monitored. These accounts are frequently long-lived, shared across a field service team, and exempted from the password policies applied to clinical users. A threat actor who compromises a service account often inherits capabilities well beyond what any clinical role would ever need. **[KEY REQUIREMENT]** Every account, including service and maintenance accounts, needs a unique identity, a defined privilege scope, and a rotation or expiration policy. Shared or hardcoded credentials should be treated as a design defect to remediate before submission, not a known limitation to disclose. ## Biometrics in Clinical Settings: Benefits and Spoofing Limits Biometric authentication, including fingerprint and iris recognition, improves usability in clinical settings where clinicians move between devices quickly and cannot type long passwords in gloves. It is not, however, immune to spoofing, and the FDA expects that limitation to be threat-modeled rather than ignored. Textured contact lenses have been demonstrated to interfere with older or poorly configured iris recognition systems, and photographs or masks have similarly been used against facial recognition systems lacking liveness detection. Modern Presentation Attack Detection, defined under ISO/IEC 30107-3, substantially reduces this risk, but only when it is actually implemented, validated with adversarial test cases, and not just assumed to work because the vendor's marketing says so. The practical takeaway for manufacturers is that biometrics should support, not replace, layered authentication for high-risk functions such as changing therapy limits or pushing firmware. Every biometric implementation needs a documented fallback authentication method for when the sensor fails or is unavailable, and biometric templates need hardware-backed secure storage so they cannot be extracted and replayed. **[KEY REQUIREMENT]** Threat models for biometric authentication must include presentation attack scenarios and document PAD verification results, template storage design, and a fallback authentication path, not just normal-use accuracy rates. ## Designing Roles and Privileges: Permissions vs Rights Rights and permissions are related but distinct concepts, and conflating them is a common source of over-privileged roles. Rights define policy-level intent, such as "clinicians can configure therapy settings." Permissions are the specific, enforceable actions that implement that intent, such as "can change dose limits" or "can view configuration history." If a manufacturer only defines rights and skips the permission-level breakdown, roles tend to become bundles of unrelated capabilities granted for convenience. A field service role built to run diagnostics can end up able to disable safety checks simply because no one separated "can initiate self-test" from "can modify safety parameters" at the permission level. Role-based access control combined with scoped permissions is the model that scales best across a device UI, a cloud portal, APIs, and service tooling. Adding step-up authentication for high-impact actions, and time-bound elevation for service workflows, closes the gap between what a role is broadly trusted to do and what a specific action should require in the moment. | Approach | Defines | Risk if done alone | |:---|:---|:---| | Rights only | Policy intent, e.g. "Clinician can configure therapy" | Over-privileged "god roles" bundled for convenience | | Permissions only | Atomic actions, e.g. "can change dose limits" | Hard to communicate and audit at the policy level | | Rights + scoped permissions | Both, mapped and enforced server-side | Requires more upfront design but supports least privilege and audit evidence | **[KEY REQUIREMENT]** A role and permission matrix, tested with server-side enforcement checks rather than interface-only restrictions, is standard evidence reviewers expect for access control claims in a premarket submission. ## Offline vs Online Password Attacks and Credential Storage Online and offline password attacks require different defenses, and confusing the two leads manufacturers to over-invest in one while leaving the other exposed. Online attacks, such as password spraying or credential stuffing, hit a live login interface and can be slowed with rate limiting, account lockouts, and multi-factor authentication. Offline attacks happen after an attacker has already stolen a password database or extracted credentials from firmware, and they crack hashes on their own hardware with no interaction with the device at all. Offline attacks do not trigger lockouts or alerts because the device is never contacted again after the theft. Resistance to them depends almost entirely on password storage design: whether the manufacturer used a purpose-built password hashing algorithm with unique salts and an appropriately tuned work factor, rather than a fast general-purpose hash or, worse, reversible encryption. For medical devices specifically, the credential stores most often overlooked are firmware images, configuration backups, and manufacturing or service databases, not just the clinician-facing login. A penetration test that only exercises the login screen misses the offline exposure entirely. **[KEY REQUIREMENT]** Password storage should use a modern, purpose-built hashing algorithm with unique per-user salts and work factors sized to current attacker hardware, verified as part of the same testing that covers online lockout and MFA behavior. ## Logging That Actually Supports Nonrepudiation Nonrepudiation means an identity cannot credibly deny having performed an action, and that guarantee only holds if the underlying logs are complete and tamper-evident. A log that records "admin changed configuration" without a unique actor identity, an accurate timestamp, and protection against after-the-fact editing cannot support an investigation or a regulatory inquiry. Effective nonrepudiation logging captures the actor, the action, the affected object, the outcome, and the timestamp for every privileged action, not just failed login attempts. Digital signatures on log entries, secure timestamping, and write-once or cryptographically chained storage prevent an attacker who gains access from quietly editing the trail behind them. This matters across the entire product lifecycle. Premarket, it validates that software updates and diagnostic outputs are authentic. Postmarket, it is often the only evidence available to reconstruct what happened during an incident or to support a recall investigation. **[KEY REQUIREMENT]** Audit logs for privileged actions should be cryptographically protected against tampering and tested for completeness, since a log that can be silently edited provides no real nonrepudiation evidence during an FDA inquiry or postmarket investigation. ## How Blue Goat Cyber Approaches This Blue Goat Cyber's medical device practice treats authentication, authorization, and audit logging as design-controlled engineering outputs rather than a submission checklist. Every access control claim gets tied to a threat model entry, a verification test, and a documented residual risk in the security risk assessment, so the evidence traces cleanly from requirement to result. Engagements test both the online attack surface, including MFA, lockout behavior, and role enforcement, and the offline exposure in credential stores extracted from firmware, configuration files, and backups. Testers hold CISSP and OSCP certifications, with backgrounds that include military red-team operations. See our [medical device penetration testing services](/services/medical-device-penetration-testing) for the full scope of how access control and credential storage get validated before submission. ## Frequently Asked Questions ### What is the difference between authentication and authorization in medical devices? Authentication verifies who or what is connecting to a device, using a password, token, certificate, or biometric. Authorization decides what that verified identity is allowed to do once connected, typically enforced through role-based permissions and least-privilege rules. A device can authenticate correctly and still fail if authorization checks are missing or only enforced in the interface rather than the server or device logic. ### Does the FDA require multi-factor authentication on medical devices? The February 3, 2026 final guidance recommends multi-factor authentication for privileged and remote access paths as a baseline expectation, particularly for administrative, service, and cloud accounts. It is not an absolute mandate for every interaction, but manufacturers who skip MFA on high-risk functions should expect reviewers to ask why, and should document a compensating control if MFA is not feasible. ### Are biometrics secure enough for medical device authentication? Biometrics can be secure when implemented with Presentation Attack Detection, hardware-backed template storage, and a documented fallback authentication method. They should not be the sole control for high-risk functions like changing therapy settings or pushing firmware. Manufacturers need adversarial spoofing test evidence, not just normal-use accuracy data, to support a biometric authentication claim. ### What is the difference between offline and online password attacks? Online attacks hit a live login interface and can be slowed with rate limiting, lockouts, and MFA. Offline attacks happen after an attacker steals a password database or extracts credentials from firmware, then cracks the hashes on their own hardware without touching the device again. Offline resistance depends on password storage design, specifically modern hashing algorithms with unique salts, not on login-page defenses. ### Why do hardcoded and shared credentials keep showing up in FDA deficiency letters? Hardcoded credentials cannot be changed without a firmware update, so one leaked password compromises every unit in the field. Shared accounts destroy the audit trail because a log entry cannot identify which specific person performed an action. Both undermine the accountability and nonrepudiation evidence the FDA expects, which is why reviewers flag them repeatedly. ## CTA If your device's authentication, access control, or audit logging design has open questions ahead of a submission, a discovery session can identify the gaps before a reviewer does. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to review your access control architecture and evidence plan with our team. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## 510(k) Cost: Plan FDA Fees With Confidence | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/fda-medical-device-submission-costs-explained-510k-pma-and-more-2025-guide # 510(k) Cost Drivers Every Medical Device Team Should Budget > **[DIRECT ANSWER]** 510(k) cost has three layers: the FDA user fee, the evidence you must generate to support the submission, and the cost of a deficiency letter if that evidence is incomplete. The user fee is the smallest and most predictable line item; testing, consultants, and cybersecurity documentation almost always cost more. Check the FDA's current fiscal year Medical Device User Fee Amendments schedule for the exact fee, since it changes every October 1. _Reviewed September 17, 2026_ A manufacturer that budgets only for the FDA's published user fee is going to be surprised by the real cost of getting a device cleared. The fee itself is a fixed, published number that changes annually, but it is usually the smallest expense in the submission. Testing, consultants, clinical evidence for higher-risk pathways, and cybersecurity documentation for any connected device routinely dwarf the fee, and a deficiency letter can add months of delay and a second round of spending on top of all of it. Understanding which cost category moves with which decision, pathway, device complexity, connectivity, is what actually lets a team plan a realistic budget instead of anchoring on a number that covers a fraction of the real spend. ## Key Takeaways - The FDA user fee is a fixed, published amount that changes every fiscal year and varies by submission type. - Small business status can substantially reduce the user fee, but it requires a separate qualification request and does not reduce testing or consulting costs. - Testing, consultant fees, and cybersecurity documentation typically cost more than the user fee itself, especially for connected devices. - PMA submissions cost more than 510(k) submissions primarily because of the clinical evidence requirement, not the fee difference alone. - Cybersecurity documentation cost scales with device connectivity, not with submission pathway. - A deficiency letter is the most expensive outcome, since it forces a second round of evidence generation and adds review delay. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* guidance, issued in September 2023, updated June 27, 2025, and finalized again February 3, 2026, made cybersecurity documentation a gating criterion for clearance under section 524B of the FD&C Act. That gating status changes how manufacturers should budget, because cybersecurity work is no longer an optional add-on for connected devices; it is part of what a reviewer checks before the FDA will even accept the submission for review. The FDA's refuse-to-accept process, in effect since October 1, 2023 for cyber devices covered by section 524B, means an incomplete SBOM or vulnerability management plan can stop a submission before substantive review starts. That is a cost multiplier because the manufacturer has already paid the user fee and invested in the rest of the submission package by the time a refuse-to-accept letter arrives. The FDA's own performance data consistently shows cybersecurity documentation among the top categories cited in Additional Information requests, behind only general software documentation and clinical evidence. Budgeting for a submission without accounting for this reality means underestimating both the timeline and the total spend. A manufacturer that treats cybersecurity documentation as a late-stage checklist item, rather than as design-controlled engineering output built alongside the rest of the submission, is the one most likely to see costs balloon through rework after a deficiency letter. ## What Is the FDA User Fee and How Is It Set? The FDA user fee is a fixed payment set under the Medical Device User Fee Amendments (MDUFA) program, and it changes every fiscal year on October 1. The fee funds the FDA's review activities and is required at the time of submission unless the manufacturer qualifies for small business status. Because the fee schedule is updated annually and differs by submission type, the only reliable source for the current dollar amount is the FDA's published MDUFA fee schedule for the fiscal year in question; any number quoted in an article can be outdated within months. **[KEY REQUIREMENT]** Confirm the current fiscal year's fee on the FDA's MDUFA fee schedule page before finalizing a submission budget, since fees are set annually and differ for 510(k), De Novo, and PMA submissions. ## How Does Small Business Status Change the Fee? Small business status can substantially reduce the standard user fee, but it does not reduce anything else in the submission budget. A company qualifies by submitting a Small Business Qualification Request (Form FDA 3602) and demonstrating gross receipts under the threshold the FDA sets for that program. Approval typically cuts the user fee by a large percentage compared to the standard fee, which matters for startups, but testing, consultant time, and cybersecurity documentation cost the same whether or not the company qualifies. | Cost category | Moves with pathway | Moves with connectivity | Moves with small business status | |---|---|---|---| | FDA user fee | Yes | No | Yes, substantially reduced | | Bench and biocompatibility testing | Somewhat | No | No | | Clinical evidence | Yes, mainly PMA | No | No | | Cybersecurity documentation and testing | No | Yes, strongly | No | | Regulatory consultant fees | Somewhat | Somewhat | No | | Deficiency letter rework | Yes, higher for PMA | Yes | No | ## What Separates 510(k), De Novo, and PMA Cost? The three pathways differ mainly in the evidence burden they impose, not in the user fee alone. A 510(k) requires showing substantial equivalence to a predicate device, which is generally the least evidence-intensive path and carries the lowest standard fee. A De Novo request applies to novel, low-to-moderate-risk devices without a predicate, sits in the middle on both fee and evidence burden, and often requires a cybersecurity approach built from scratch since there is no predicate labeling or documentation to reference. A PMA applies to Class III and other high-risk devices, carries the highest standard fee, and typically requires clinical trial data, which is the single largest cost driver in that pathway. Cybersecurity cost does not track neatly with pathway. A 510(k) submission for a highly connected infusion pump can carry more cybersecurity documentation and testing cost than a PMA submission for a mechanically simple implant with no wireless features. Connectivity, not regulatory pathway, is the variable that predicts cybersecurity spend. ## What Drives Cybersecurity Documentation Cost? Cybersecurity documentation cost is driven by how connected the device is, not by which submission pathway it goes through. A device with wireless communication, cloud integration, a companion mobile app, or third-party software components needs a threat model, a software bill of materials, penetration testing, and a vulnerability management plan under the current premarket cybersecurity guidance. A device with no network connectivity and minimal software still needs a security risk assessment, but the scope and cost are much smaller. **[KEY REQUIREMENT]** Scope cybersecurity testing and documentation to the device's actual connectivity and software architecture early in development, since retrofitting an SBOM or threat model after design freeze costs more than building it alongside the design controls. Manufacturers should also budget for the possibility that cybersecurity gaps trigger an Additional Information request or a refuse-to-accept letter, since fixing those gaps after submission means paying for a second round of testing and documentation on a compressed timeline. ## What Does a Deficiency Letter Actually Cost? A deficiency letter is the most expensive outcome in the entire submission process because it forces a second round of evidence generation without refunding any of the money already spent. When the FDA issues an Additional Information request, the manufacturer has already paid the user fee, already paid for the original round of testing and documentation, and now has to fund another cycle of work on top of the delay to the product's launch timeline. Cybersecurity gaps are consistently among the top categories cited in these letters, alongside general software documentation and clinical evidence, which is why cybersecurity work done well the first time is one of the more cost-effective investments in the entire submission budget. ## How to Estimate a Realistic Submission Budget Building a realistic budget means adding four categories together rather than anchoring on the published user fee alone: the fee itself, the direct cost of testing and clinical evidence appropriate to the pathway, cybersecurity documentation and testing scaled to connectivity, and a contingency for a possible deficiency response. Consultant and regulatory affairs fees vary by project complexity and are worth quoting separately from internal engineering time, since the two are not interchangeable. Teams frequently underestimate the internal engineering time a submission consumes, treating it as a line item that runs in parallel with product development rather than one that competes for the same engineers. Assigning a dedicated owner for the regulatory submission, separate from the engineers building the product, tends to produce a more accurate budget and a shorter path to clearance. ## How Blue Goat Cyber Approaches This Blue Goat Cyber helps manufacturers scope the cybersecurity portion of a submission budget accurately before development is finished, rather than after. Our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) build the threat model, SBOM, and penetration testing evidence a submission needs, scoped to the device's actual connectivity and architecture so the manufacturer is not paying for testing scope it does not need or missing testing scope a reviewer will flag. That scoping work is what keeps cybersecurity from becoming the line item that turns a predictable user fee into an unpredictable total project cost. ## Frequently Asked Questions ### How much does a 510(k) submission cost in total? The total cost includes the FDA user fee, which changes annually and should be confirmed on the current MDUFA fee schedule, plus testing, consultant fees, and cybersecurity documentation if the device is connected. For most 510(k) submissions, the user fee is the smallest of these categories, and the true total depends heavily on device complexity and connectivity. ### Is a PMA always more expensive than a 510(k)? Yes, a PMA submission is generally more expensive than a 510(k) because it requires clinical trial evidence and carries a higher standard user fee. The clinical evidence requirement, not the fee difference alone, is usually the larger driver of the total cost gap between the two pathways. ### Does small business status reduce cybersecurity testing costs? No, small business status only reduces the FDA user fee, not the cost of testing, consulting, or cybersecurity documentation. A qualifying small business still needs to fund the same scope of cybersecurity work as a larger company if its device has comparable connectivity. ### Why does cybersecurity cost vary so much between devices? Cybersecurity cost scales with how connected a device is, including wireless communication, cloud integration, mobile apps, and third-party software components. A simple, non-connected device needs a much smaller cybersecurity risk assessment than a highly connected device, regardless of which regulatory pathway either one uses. ### What is the fastest way to reduce total submission cost? The fastest way to reduce total cost is to avoid a deficiency letter, since a second round of testing and documentation on a compressed timeline is more expensive than doing the work correctly the first time. Building cybersecurity documentation alongside design controls, rather than after design freeze, is one of the more reliable ways to prevent that outcome. ## CTA Before you finalize a submission budget, confirm the current FDA user fee on the MDUFA fee schedule and get the cybersecurity scope right the first time. [Contact Blue Goat Cyber](/contact) to scope the testing and documentation your device actually needs. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA Pen Test Timing: How Recent Must Your Test Be? Source: https://bluegoatcyber.com/blog/fda-pen-test-timing-submission # FDA Pen Test Timing: How Recent Must Your > **[DIRECT ANSWER]** The FDA expects penetration testing performed on the submitted device version, close enough to filing that the tested build matches what you are clearing, with retesting after any security-relevant change. Findings should be remediated before submission or carried into the unresolved anomalies assessment with documented residual risk. ## Key Takeaways - There is no statutory "X days old" rule, but the working standard reviewers apply is 3 to 6 months, with 12 months as the outside edge before an AI letter becomes likely. - Version-match matters more than calendar age. A 2-month-old pen test against a stale build is worse than a 5-month-old test against the exact submitted version. - Any security-relevant change after the test (new dependency, crypto change, interface change, fixed vulnerability, OS or kernel update) triggers a documented re-test, scoped or full. - Open High or Critical findings at submission time are a near-certain deficiency. Remediation or formal risk acceptance must be complete and traceable into the Security Risk Assessment. - IDE, Special 510(k) for cyber changes, and PMA supplements each have their own timing nuances. Letter-to-File decisions still require evidence that the change does not invalidate prior pen test results. ## Why this matters Cybersecurity testing is one of the top deficiency categories cited in CDRH Additional Information letters, behind only software documentation and clinical evidence per the FDA's FY2024 CDRH performance reporting. Within that category, the most common pattern is not "no pen test", it is "pen test against the wrong build" or "pen test too old to reflect the submitted device." Both are timing problems. Under Section 524B of the FD&C Act and the *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance), the pen test report is one of the artifacts reviewers expect in the submission. If reviewers cannot trace the tested configuration to the submitted configuration, the report does not count, regardless of how thorough it was. > **Start reading here if you're earlier in the lifecycle:** pen test timing is the *last* timing question, not the first. If your team is still deciding *when* cybersecurity work should begin at all, read [When to Start Medical Device Cybersecurity in Product Development](/blog/when-to-start-medical-device-cybersecurity) first, it maps every SPDF activity to its correct design-control phase, so the pen test window in this article lands on a stable foundation. ## What the Feb 3, 2026 guidance actually says about pen test timing The guidance does not specify a calendar window. What it does require is that testing be performed against the device as designed and that the report describe the version under test, the methods used, the findings, and the disposition of each finding. The implication, and the way reviewers apply it in practice, is that the tested version must match the submitted version, with controlled exceptions documented. The guidance also positions penetration testing inside the broader Secure Product Development Framework (SPDF). Pen testing is the final independent validation that the SPDF actually produced a secure device, which means it has to happen late enough to be meaningful (after design freeze) but early enough that findings can be remediated and re-verified before submission. > **[KEY REQUIREMENT]** The pen test report must include the firmware version, hardware revision, configuration, and date of testing, and reviewers must be able to map all three to the device described in the submission. Drift between them is the recurring deficiency pattern. ## The four practical timing constraints ### 1. Recency The unwritten working standard is 3 to 6 months from test completion to submission. Up to 12 months is sometimes accepted with strong justification (no security-relevant changes, documented change control showing nothing in scope moved). Beyond 12 months you should plan for an AI letter asking for a refresh or expect to refresh proactively. ### 2. Version-match The tested firmware, hardware revision, third-party components, and configuration must match what is in the submission. "We tested v1.4.2 and shipped v1.4.5 with three bug fixes" is not automatically a problem, but every delta between tested and submitted versions must be classified for security relevance and documented in the test report's scope statement or in an addendum. ### 3. Post-change re-test triggers Re-test (full or scoped) when any of the following happen after the original pen test: - New or upgraded third-party dependency (especially crypto, TLS, networking, parser libraries) - Change to authentication, authorization, or session management - Change to a network interface, protocol, or exposed API - Change to update mechanism, signing, or rollback behavior - Fix to a finding from the prior pen test (the fix itself must be verified) - OS, kernel, or RTOS version change - Change to the cryptographic module or key management ### 4. Pre-submission remediation Every High and Critical finding must be remediated or formally risk-accepted with traceability into the Security Risk Assessment and ISO 14971 risk file. "Will fix postmarket" is not an acceptable disposition for a High at submission. Mediums and Lows can be carried into postmarket with documented justification, but the disposition table needs to be complete. ## Where pen testing fits in the submission lifecycle The clean sequence reviewers expect to see in the documentation: ```text Threat model + SAVs ─► Design freeze ─► Pen test on final build ─► Remediation ─► Re-test of fixes (delta) ─► Submission package frozen ─► eSTAR submission ``` Common antipatterns that compress this and create timing problems: - Pen test scheduled too early, against a build that still changes substantially before submission - Pen test scheduled too late, leaving no time to remediate Highs before the submission deadline - Pen test scheduled at the right time but on a build that diverges during remediation, with no delta re-test of the final build - Pen test run by a vendor without medical-device specific scoping, producing IT-network findings that do not match the device's threat model Most timing failures are calendar failures, not technical failures. Build the pen test window into the program schedule before design freeze, not after. [Talk to us about scoping a pen test for your submission window →](/contact) ## Special cases: IDE, Special 510(k), PMA supplements, Letter-to-File **IDE submissions.** Cyber IDE expectations are lighter than premarket clearance, but the same logic applies: the pen test should reflect the investigational device. See our [FDA IDE cybersecurity requirements](/blog/fda-ide-cybersecurity-requirements) post for what is and is not required at IDE. **Special 510(k) for cybersecurity changes.** A Special 510(k) for a cyber change typically requires pen testing scoped to the change. The full prior pen test stays referenced; the new test focuses on the modified attack surface. See [Special vs Traditional 510(k) for cybersecurity changes](/blog/special-vs-traditional-510k-cybersecurity-changes). **PMA supplements.** Similar logic to Special 510(k): scope the new test to the change, but reviewers expect more documentation tying the change to the original pen test baseline. **Letter-to-File.** A Letter-to-File decision for a cyber change still requires evidence that the change does not invalidate the prior pen test. If the change touches anything on the re-test trigger list above, a Letter-to-File is likely the wrong path. See [Letter-to-File vs new 510(k) for cybersecurity changes](/blog/letter-to-file-vs-new-510k-cybersecurity-changes). ## When your pen test is too old: delta re-test vs full re-test Use this decision logic when the calendar has gotten away from you. | Situation | Recommended action | |---|---| | Test under 6 months old, no security-relevant changes | Use as-is; document version-match in the report scope | | Test 6 to 12 months old, no changes | Add a written re-confirmation memo from the test provider and a change-control attestation; submit | | Test over 12 months old, no changes | Scoped re-test focused on regression and any new public CVEs against the SBOM | | Any age, contained security-relevant changes to known modules | Delta re-test scoped to changed modules and their dependencies | | Any age, broad changes (auth, crypto, networking, update path) | Full re-test on the final build | | Open Highs or Criticals at submission deadline | Do not submit; remediate and run a verification re-test first | The delta re-test is the most under-used option. It is cheaper and faster than a full re-test, and when scoped correctly it produces evidence reviewers accept. The scoping memo is the artifact that makes or breaks it. ## How Blue Goat approaches pen test timing Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We scope pen tests against the submission calendar, not the engineering calendar, so the test runs on the build that ships and the remediation window closes before the eSTAR lock. When a manufacturer comes to us with an aging pen test from another provider, we run the delta-vs-full decision against the change history and produce a scoping memo reviewers can map to the submission. See our [medical device cybersecurity services](/services) for the full scope, including [pen test case design](/blog/scoping-a-medical-device-penetration-test) and [choosing the right pen test provider](/blog/medical-device-pen-testing-choosing-the-right-provider). **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### How recent does a pen test have to be when I submit to the FDA? There is no hard calendar rule in the Feb 3, 2026 guidance. The working standard reviewers apply is 3 to 6 months from test completion to submission, with up to 12 months sometimes accepted if you can prove no security-relevant changes occurred. Over 12 months almost always draws an Additional Information request asking for a refresh. ### Does the pen test need to be on the exact firmware version I'm submitting? Yes, or close enough that every delta is classified and documented. The pen test report must identify the firmware version, hardware revision, and configuration tested, and reviewers must be able to map those to the submitted device. Small changes can be covered with an addendum and change-control evidence; large changes require a delta or full re-test. ### What changes after a pen test require a re-test before submission? New or upgraded third-party dependencies (especially crypto and TLS), changes to authentication, authorization, network interfaces, exposed APIs, update mechanism, signing, or rollback, fixes to prior pen test findings, and OS, kernel, or RTOS version changes. Any of these should trigger a documented re-test, scoped or full. ### Can I submit with open High or Critical findings if I plan to fix them postmarket? No. High and Critical findings must be remediated or formally risk-accepted with traceability into the Security Risk Assessment and the ISO 14971 risk file before submission. "Will fix postmarket" is not an acceptable disposition for a High or Critical at submission time and is a near-certain deficiency. ### What is a delta re-test and when is it enough? A delta re-test is a pen test scoped to changes made since the original test, plus their dependencies. It is enough when the changes are contained, well-documented, and do not touch broad cross-cutting concerns like authentication, cryptography, or the update path. When the changes are broad or touch the trust model, a full re-test is the right call. ### Does a Letter-to-File for a cybersecurity change require a new pen test? A Letter-to-File still requires evidence that the change does not invalidate prior pen test results. If the change touches anything on the standard re-test trigger list, a Letter-to-File is usually the wrong submission path and a Special 510(k) with a scoped re-test is the cleaner option. ## CTA If you have a submission window in the next 90 days and your pen test is older than 6 months, the safest move is a scoping conversation now, not after the AI letter arrives. We will run the delta-vs-full decision and produce a test plan that matches your submission calendar. [Schedule a discovery session →](/contact) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, including pen test scoping and remediation planning against the submission calendar. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Pen Testing: FDA vs EU MDR 2026](/blog/medical-device-pen-testing-fda-vs-eu-mdr-2026) --- ## FDA Penetration Testing Requirements Source: https://bluegoatcyber.com/blog/fda-penetration-testing-requirements-medical-devices # FDA Penetration Testing Requirements for Medical Devices > **[DIRECT ANSWER]** The FDA's February 3, 2026 premarket guidance lists penetration testing as just one of ten required testing activities, alongside attack surface analysis, abuse and misuse testing, fuzz testing, robustness testing, closed-box scanning, and vulnerability chaining. A compliant pen test report bundles those activities and includes tester independence, scope, duration, methods, and results, while SAST, DAST, and CI-based fuzzing remain separate, dev-owned evidence streams. _Published June 2, 2026_ ## Key Takeaways - The FDA lists ten distinct testing activities. Penetration testing is one of them, not all of them. - A narrow "exploit and report" pen test leaves nine other evidence gaps for reviewers to flag. - Blue Goat's pen test engagement bundles attack surface analysis, abuse/misuse testing, fuzz testing, robustness testing, closed-box scanning, exploitation, and chaining into one evidence package. - SAST, DAST, SBOM-driven SCA, hardcoded credential scanning, and continuous fuzzing in CI are separate dev-team activities and stay separate. The FDA wants evidence of both. - The pen test report must include the five required elements: tester independence and expertise, scope, duration, methods, and results. - ANSI/ISA 62443-4-1 §9 is the referenced process standard for vulnerability testing. The bundled engagement is structured to satisfy it. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to fda penetration testing requirements for medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## The misconception that triggers deficiency letters The most common pattern we see in deficiency letters: the manufacturer submits a clean pen test report, and the FDA reviewer comes back asking for fuzz testing evidence, abuse case testing, an attack surface analysis, or vulnerability chaining results. The manufacturer assumed "we did a pen test" covered all of it. It didn't. The 2026 final guidance is explicit. Under the testing section, it lists penetration testing as one bullet inside a longer list of required activities: - Vulnerability testing (as described in ANSI/ISA 62443-4-1) - Abuse or misuse cases, malformed and unexpected inputs - Robustness - Fuzz testing - Attack surface analysis - Vulnerability chaining - Closed-box testing of known vulnerability scanning - Software composition analysis of binary executable files - Static and dynamic code analysis, including testing for credentials that are hardcoded, default, easily guessed, and easily compromised - Penetration testing Each of those bullets generates an evidence expectation. If your pen test report only addresses the last one, reviewers will ask about the other nine. ## What's actually inside a medical device pen test A pen test scoped for the 2026 guidance is not a one-week web app assessment. It is a multi-discipline engagement against a physical or software device, its companion mobile app, its cloud backend, its wireless interfaces, and its update channels. Done right, the engagement itself produces evidence for most of the testing bullets above, not just the "penetration testing" line item. ### 1. Attack surface analysis (as a written artifact) The first phase enumerates every interface that can receive input: network ports, BLE, Wi-Fi, proprietary RF, USB, serial, JTAG/SWD, web UIs, REST and gRPC APIs, mobile app endpoints, OTA update channels, and any cloud-to-device or device-to-cloud paths. This is not just internal recon - it is delivered as a written attack surface analysis tied to the threat model, which is what the FDA wants as the standalone "attack surface analysis" deliverable. ### 2. Abuse and misuse case testing The threat model defines abuse cases (an attacker actively trying to harm the patient or compromise data) and misuse cases (a clinician or patient using the device in foreseeable but unintended ways). The pen tester executes those cases against the built device - bypassing intended workflows, supplying malformed or out-of-sequence inputs, triggering safety interlocks, and confirming whether the device fails safely or fails dangerously. ### 3. Robustness testing Robustness here means the device's ability to maintain safe behavior under abnormal but plausible conditions: dropped network connections, malformed packets, power instability, interrupted firmware updates, sensor noise, and out-of-order protocol messages. Robustness testing is distinct from fuzzing - it targets operational stress, not input-parser bugs - but both belong in the same engagement. ### 4. Fuzz testing (targeted, engagement-scoped) The pen tester runs targeted fuzzing against exposed interfaces: BLE GATT services, network protocol parsers, file format handlers, cloud APIs, and any custom binary protocols. The goal is to find crashes, hangs, memory corruption, and unsafe state transitions that conventional test cases miss. This is engagement-scoped fuzzing - not the continuous CI fuzzing that the dev team should also be running (more on that below). ### 5. Closed-box known-vulnerability scanning Automated scanning of the device, its exposed services, and any web/cloud surface for known CVEs and misconfigurations. Closed-box means without access to source code or internal documentation - the tester sees what an external attacker sees. This generates the closed-box scanning evidence the guidance asks for. ### 6. Vulnerability identification and exploitation The defining activity of pen testing. Manual analysis, protocol reverse engineering, traffic inspection, firmware extraction, and active exploitation. Findings are not theoretical - they are proven with reproducible proof-of-concept evidence and CVSS scoring. ### 7. Vulnerability chaining The guidance lists this separately, but in practice it is performed by the pen tester. Chaining combines low- and medium-severity findings into high-impact attack paths - for example, an information disclosure plus a weak session token plus an unauthenticated API call becomes full remote control of therapy. Reviewers specifically look for chaining analysis because individual CVSS scores understate real-world risk. ### 8. Post-exploitation What an attacker could actually do after a successful compromise: persistence on the device, lateral movement from the device to the cloud backend or to other devices on the same network, data exfiltration, denial of therapy, and integrity attacks on logged clinical data. ### 9. Hardware, RF, wireless, mobile, and cloud coverage For SiMD (Software in a Medical Device), this includes JTAG/SWD debug access, chip-off and glitching attacks, firmware extraction from flash, Secure Boot bypass attempts, BLE pairing and authentication attacks, Wi-Fi configuration weaknesses, proprietary RF replay and spoofing, mobile app reverse engineering, certificate pinning bypass, and full cloud API testing including IDOR, token handling, and authentication boundaries. ### 10. The reviewer-format report The deliverable that the FDA actually reads. It must contain the five elements explicitly called out in the guidance: independence and technical expertise of testers, scope of testing, duration of testing, testing methods employed, and test results, findings, and observations. We cover the report format in detail further down. ## What is NOT in a pen test (and why) Being honest about the boundary is part of the value. The following activities are required by the 2026 guidance but sit outside the pen test engagement. They are continuous, code-side, or CI-integrated activities performed by the development team, and they need their own evidence: ### SAST (static application source code analysis) Source-code-level scanning for vulnerabilities, dangerous APIs, insecure patterns, and hardcoded credentials. SAST requires source access, runs on every commit in CI, and is owned by the development team. A pen tester operating in a closed-box engagement cannot produce SAST evidence. ### DAST (dynamic application security testing) Automated runtime scanning of running applications, typically integrated into staging environments and CI pipelines. DAST overlaps in spirit with what pen testers do manually, but the FDA wants the automated, continuous, dev-owned evidence - not just an annual engagement snapshot. ### SCA on binary executables (SBOM-driven) Software composition analysis against binaries - extracting an SBOM, matching components to known CVEs, and tracking the exploitability status of each finding in a VEX document. This is ongoing post-build work tied to the SBOM and VEX program, not a one-time pen test activity. ### Hardcoded credential scanning The guidance specifically calls out testing for hardcoded, default, easily guessed, and easily compromised credentials. This is primarily a SAST output (greps and entropy checks against source) plus secrets-scanning hooks on the repository. A pen tester will surface any credentials they find during exploitation, but the systematic coverage is a dev-team CI activity. ### Continuous fuzzing in CI Different from the targeted fuzzing in the pen test. Continuous fuzzing runs against parsers, protocol handlers, and library boundaries on every build or nightly, accumulating coverage and corpus over months. The pen test fuzzing is targeted and time-boxed. Mature programs do both, and the FDA wants evidence of both. The clean way to talk about this in your submission: the pen test report covers the engagement-scoped activities, and a separate "secure development testing evidence" section covers the continuous SAST, DAST, SCA, secrets scanning, and CI fuzzing outputs. ## What Belongs in the Pen Test and What Does Not The fastest way to avoid a deficiency letter is to be clear about which evidence stream owns each activity. | Activity | Part of the pen test engagement | Owned elsewhere | |---|---|---| | Attack surface analysis | Yes, as a written artifact | | | Abuse and misuse case testing | Yes | | | Robustness testing | Yes | | | Targeted fuzz testing | Yes, scoped to the engagement | Continuous fuzzing in CI stays with development | | Closed box vulnerability scanning | Yes | | | Exploitation and vulnerability chaining | Yes | | | Post exploitation | Yes | | | Static source code analysis | No | Development, as part of the SPDF | | Dynamic application testing in CI | No | Development | | Binary composition analysis | No | SBOM and supply chain process | | Hardcoded credential scanning | No | Development tooling and code review | ## ANSI/ISA 62443-4-1 §9 - the referenced process standard The guidance explicitly points to ANSI/ISA 62443-4-1 for vulnerability testing. The relevant section is 9, which defines the security verification and validation testing process. The short version of what 9 expects: - **9.2 Security requirements testing** - verifying that every security requirement has a corresponding test case and evidence. - **9.3 Threat mitigation testing** - verifying that each threat in the threat model has at least one test case that exercises the mitigation. - **9.4 Vulnerability testing** - the testing activities listed earlier in this post (abuse cases, fuzzing, attack surface, etc.). - **9.5 Penetration testing** - adversarial exploitation against the integrated product. A bundled pen test engagement designed around 62443-4-1 §9 naturally produces traceability between the threat model, the test cases, and the test results. That traceability is what survives reviewer scrutiny. ## The 5 required pen test report elements (and reviewer red flags) The guidance explicitly requires that pen test reports include all five of the following. Missing or weak coverage of any one is a near-automatic deficiency letter. ### 1. Independence and technical expertise of testers Reviewers want named testers, their credentials (OSCP, OSCE, GXPN, CRTO, hardware-specific certifications), and clear separation from the development team. Red flag: a report with no tester names, no credentials, or testers who are also listed as developers on the device. ### 2. Scope of testing A precise enumeration of what was in scope and what was out of scope - and the rationale for any exclusions. Red flag: vague scope ("the device and its companion app") with no interface-level breakdown, or out-of-scope items that are obvious attack paths from the threat model. ### 3. Duration of testing Actual tester-days, not calendar duration. Reviewers know what realistic durations look like for a given device complexity. Red flag: a complex connected device "pen tested" in three days. That signals checkbox testing. ### 4. Testing methods employed The methodology (OWASP, PTES, NIST SP 800-115), the tools used, the test cases run, and the rationale for the chosen approach. Red flag: "industry-standard methodology" with no specifics. ### 5. Test results, findings, and observations Findings with CVSS scores, reproduction steps, evidence (screenshots, packet captures, exploit code), remediation recommendations, and retest results after fixes. Red flag: findings without evidence, or no retest section. ## What a reviewer-format report actually looks like "Reviewer-format" means a report structured so the FDA cybersecurity reviewer can drop it straight into the eSTAR cybersecurity attachments and find each of the five required elements within thirty seconds. The structure matters as much as the content - a report with all the right information buried in the wrong places still triggers deficiencies. ### Document structure that survives review ```text 1 Executive Summary Tester independence, scope, duration, headline results 2 Scope and Methodology In-scope/out-of-scope interfaces, versions, environment, methods, tools 3 Testing Activities One subsection per guidance bullet (attack surface, abuse cases, robustness, fuzz, closed-box scan) 4 Exploitation and Chaining Findings table + attack path analysis 5 Findings Detail Per-finding pages with CVSS, repro, evidence, recommendation 6 Retest Results What was fixed, what was verified, residual risk 7 Traceability Matrix Threat model entry → test case → result A Tester Bios and Credentials Named testers, certifications, independence statement ``` A reviewer can confirm all five required elements without leaving 1 and 2. The detail in 3-7 is there for the technical review that follows. ### What each finding entry should contain Every finding in 5 should be a self-contained page with: - **Title** and unique finding ID - **CVSS v3.1 vector and score** (base, temporal if relevant) - **Affected component and version** - **Description** of the vulnerability - **Reproduction steps** that a reviewer could follow - **Evidence**: screenshots, packet captures, exploit code, decompiled snippets - **Impact** tied to patient safety and the threat model entry it maps to - **Recommended remediation** - **Retest result** and date Findings without CVSS scores, without reproduction steps, or without evidence are the most common deficiency trigger in this section. ### Front-matter that answers the 5 elements immediately The executive summary should explicitly call out, in this order: 1. **Independence statement** - "Testing was performed by [named testers] of [firm], who have no development relationship with [manufacturer]. Tester credentials are listed in Appendix A." 2. **Scope summary** - one paragraph naming every interface tested and every interface excluded with rationale. 3. **Duration** - actual tester-days, broken out by phase if multi-discipline. 4. **Methodology** - named frameworks (OWASP MASTG, PTES, NIST SP 800-115) and primary tools. 5. **Results summary** - finding counts by severity, retest status, and residual risk statement. A reviewer reading only the first two pages should be able to check off all five required elements. ### Anti-patterns that trigger deficiencies Reports that fail review usually share one or more of these traits: - Marketing-style executive summary with vendor logos on every page and no scope detail - "Approximately two weeks" instead of actual tester-days - "Industry-standard methodology" with no named frameworks or tools - Findings without CVSS scores, without reproduction steps, or without evidence - No retest section - fixes are "recommended" but never verified - No named testers or credentials - just a firm name - Out-of-scope items that are obvious attack paths from the threat model (e.g., excluding BLE on a BLE-connected device) - Findings buried in a 60-page appendix with no severity table up front ## How a bundled engagement prevents deficiency letters The pattern is consistent across the deficiency letters we respond to: reviewers ask the manufacturer to produce evidence for one of the testing activities that wasn't covered. The fix at submission time is to anticipate the question. A bundled pen test report explicitly maps each section back to the 2026 guidance bullet it satisfies: ```text Guidance bullet Report section ----------------------------------------- ---------------------------------- Attack surface analysis 3.1 Attack Surface Analysis Abuse/misuse cases, malformed inputs 3.2 Abuse and Misuse Case Testing Robustness 3.3 Robustness Testing Fuzz testing 3.4 Targeted Fuzz Testing Closed-box known-vuln scanning 3.5 Closed-Box Vulnerability Scan Vulnerability identification 4.1 Findings Vulnerability chaining 4.2 Attack Path Analysis Penetration testing 4 Exploitation Results Required report elements (1-5) 1 Executive Summary, 2 Scope/Methods ``` Reviewers reading that table know immediately that the testing section of the submission is covered. The questions stop before they start. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### My current vendor's pen test didn't include fuzz testing - is that enough for the FDA? No. The guidance lists fuzz testing as a distinct required activity. You need engagement-scoped fuzz testing in the pen test plus, ideally, continuous fuzzing evidence from CI. A pen test that doesn't address fuzzing leaves a known gap reviewers will flag. ### Do I still need SAST and DAST if the pen test covers everything else? Yes. SAST and DAST are separate guidance bullets, performed by the dev team on every build. The pen test cannot replace them and is not intended to. Submit both. ### Is robustness testing the same as fuzz testing? No. Robustness targets operational stress (dropped connections, power instability, malformed packets, environmental conditions). Fuzz testing targets parser and protocol bugs from malformed input. They cover different failure classes and the guidance lists them separately. ### Who counts as an "independent" tester? A tester who is not on the development team, does not report to the development organization, and has no conflict of interest in the findings. Internal security teams can qualify if organizationally separate, but most reviewers prefer external third parties for the primary pen test. ### How long should a medical device pen test take? For a typical connected SiMD with a mobile app and cloud backend, two to four weeks of active testing is realistic. SaMD-only with a single cloud surface can be shorter. Hardware-intensive devices with custom RF or implantable components run longer. A three-day "pen test" on a complex connected device is a red flag. ### Does the 2026 guidance change what pen testing looks like vs the 2023 guidance? The bullet list of required testing activities is consistent, but the 2026 final guidance ties pen testing more tightly to the threat model and to Section 524B's "reasonable assurance of cybersecurity" standard. The bar for evidence and traceability is higher than under the September 2023 version. ## Final thoughts The shortest path through a FDA cybersecurity review is a pen test engagement that produces evidence for as many of the ten testing requirements as one engagement can cover, plus a clear handoff to the dev team's CI-side evidence for the rest. Narrow pen tests don't fail because they're bad - they fail because they leave the manufacturer holding nine other evidence gaps the reviewer is going to ask about. If you want a pen test engagement scoped against the Feb 3, 2026 guidance bullets - with the attack surface analysis, abuse case testing, fuzz testing, robustness testing, closed-box scanning, exploitation, chaining, and a reviewer-format report all delivered as one package - [contact us](/contact) and we'll scope it. **Need a written gap check against these requirements?** Our [Medical Device Pen Test Requirements gap check](/lp/medical-device-penetration-testing-requirements) returns a one-business-day written analysis against Section 524B, the Feb 2026 guidance, and AAMI TIR57 / ANSI/AAMI SW96:2023 - free. Related reading: [Does the FDA accept AI penetration testing for medical devices?](/blog/ai-penetration-testing-medical-devices-fda-limits), [Special vs Traditional 510(k) for cybersecurity changes](/blog/special-vs-traditional-510k-cybersecurity-changes), [Letter to file vs new 510(k) for cybersecurity changes](/blog/letter-to-file-vs-new-510k-cybersecurity-changes), [Fuzz testing in medical device cybersecurity](/blog/fuzz-testing-in-medical-device-cybersecurity), [Closed-box testing in medical device cybersecurity](/blog/closed-box-testing-in-medical-device-cybersecurity), [12 critical findings from medical device pen tests](/guides/12-critical-findings-from-medical-device-penetration-tests), and our pen test service page at [Medical Device Penetration Testing Services](/services/medical-device-penetration-testing). ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Pen Testing: FDA vs EU MDR 2026](/blog/medical-device-pen-testing-fda-vs-eu-mdr-2026) --- ## FDA Section 524B Subsections Explained Source: https://bluegoatcyber.com/blog/fda-section-524b-subsections-explained # FDA Section 524B Explained Subsection by Subsection: What Each Requirement Means in 2026 > **[DIRECT ANSWER]** FDA Section 524B has three subsections. 524B(a) sets applicability to 510(k), De Novo, PMA, PDP, and HDE submissions for cyber devices. 524B(b) lists four requirements: a postmarket vulnerability plan (b)(1), secure design processes and update cadence (b)(2), a Software Bill of Materials (b)(3), and future rulemaking (b)(4). 524B(c) defines what qualifies as a cyber device. Every submission maps to these six anchors. Section 524B of the Federal Food, Drug, and Cosmetic Act is short, dense, and entirely about cybersecurity. There are no "non-cyber" provisions to carve out. The FDA's February 3, 2026 final premarket cybersecurity guidance is the operational manual that tells manufacturers what artifacts satisfy each subsection. Most deficiency letters can be traced to a specific subsection that the submission addressed weakly or not at all. This post walks the statute subsection by subsection, names the artifact that satisfies each, and flags the deficiency patterns that recur for each one. ## Key Takeaways - All of Section 524B is cybersecurity. There are no non-cyber subsections to carve out. - 524B(c) is the definition subsection: if your device meets the "cyber device" test, every other subsection attaches. - 524B(b)(1) requires a postmarket plan, (b)(2) requires processes plus an update/patch cadence, (b)(3) requires an SBOM. - 524B(b)(4) is the open-ended hook for future FDA cybersecurity regulation; track it but do not file against it yet. - Most deficiencies map cleanly to one subsection. Knowing which subsection a deficiency falls under tells you what evidence to add. ## Why this matters Section 524B took effect when the FDA gained authority on March 29, 2023 to refuse to accept (RTA) any premarket submission for a cyber device that does not meet its requirements. The agency held off on issuing RTAs based solely on Section 524B until October 1, 2023, which is the operative enforcement date. Section 524B is binding statute; the agency's February 3, 2026 final premarket cybersecurity guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," is nonbinding by design ("Contains Nonbinding Recommendations" appears on every page) but it is the operative interpretation the FDA uses when reviewing a submission against 524B. Deficiency letters in 2025 and 2026 consistently cite 524B subsections by number, and the FDA's own cybersecurity submission examples organize evidence subsection by subsection. Manufacturers that submit a generic "cybersecurity section" without mapping each artifact to the specific subsection it satisfies draw avoidable deficiencies. Manufacturers that misread 524B(c) and conclude their device is not a cyber device when it is draw the worst outcome of all: an RTA after months of submission preparation. ![Diagram: how Section 524B (the statute) relates to the FDA's February 3, 2026 premarket cybersecurity guidance. The statute defines WHAT manufacturers must do; the guidance defines HOW to prove it.](/diagrams/524b-vs-feb-2026-guidance.svg) ## Where Section 524B Came From Section 524B was added to the FD&C Act by Section 3305 of the Consolidated Appropriations Act, 2023 (Pub. L. 117-328). The statute is short by design and leaves the operational detail to FDA guidance. **Key dates:** - **December 29, 2022** - 524B became law, signed as part of the [Consolidated Appropriations Act, 2023 (Pub. L. 117-328)](https://www.congress.gov/bill/117th-congress/house-bill/2617/text), the FDORA provisions, [Section 3305](https://www.congress.gov/117/plaws/publ328/PLAW-117publ328.pdf). - **March 29, 2023** - The law took effect, 90 days later, per the effective-date clause in Section 3305(c) of Pub. L. 117-328. The FDA's refuse-to-accept authority attached on this date. - **October 1, 2023** - The FDA actually began issuing refuse-to-accept decisions based on 524B, per the [FDA "Refuse to Accept Policy for Cyber Devices" guidance (March 30, 2023)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs), which stated the agency would not issue RTAs based solely on 524B before October 1, 2023. This is the real start-of-rejections date. The February 3, 2026 final guidance supersedes the June 2025 final, which itself superseded the September 2023 final. Earlier 2018 and 2014 documents preceded that chain. Any current submission is built against the February 2026 guidance. ## 524B(a): Applicability ### What the Statute Says (524B(a)) 524B(a) attaches the section's requirements to any person who submits an application or submission described in section 510(k), 513, 515(c), 515(f), or 520(m). In plain language: 510(k), De Novo, PMA, PMA supplement, PDP, and Humanitarian Device Exemption submissions for cyber devices. IDE submissions (520(g)) are not enumerated in 524B(a), but cybersecurity expectations still apply to IDEs under the February 3, 2026 final premarket guidance. BLA and IND submissions are outside 524B entirely (the statute is device-only), but the guidance still applies to the device constituent of a combination product - see [combination products: when device cybersecurity content lands in a BLA or IND](/guides/fda-pathway-cybersecurity-differences#combination-products-when-device-cybersecurity-content-lands-in-a-bla-or-ind). ### What Satisfies It (524B(a)) Applicability is not an artifact requirement. The reviewer determines whether 524B attaches based on the device description and the 524B(c) definition. The submission's job at this subsection is to make the applicability determination unambiguous: state explicitly that the device is or is not a cyber device under 524B(c) and justify the determination. ### Deficiency Pattern (524B(a)) Submissions that quietly assume non-applicability without addressing 524B(c) draw a clarification request at best and an RTA at worst. ## 524B(b)(1): Postmarket Vulnerability Management Plan ### What the Statute Says (524B(b)(1)) 524B(b)(1) requires the manufacturer to submit a plan to monitor, identify, and address, as appropriate, in a reasonable time, postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures. ### What Satisfies It (524B(b)(1)) A written postmarket cybersecurity plan covering vulnerability monitoring sources, triage rules, severity thresholds, response timelines, CAPA linkage, coordinated vulnerability disclosure (CVD) policy with a public intake address, and customer communication channels. The plan references the QMSR procedures it plugs into rather than running as a standalone security workflow. ### Deficiency Pattern (524B(b)(1)) Plans that describe what the manufacturer "will do" without naming the procedure, the role responsible, or the timeline. Plans that omit CVD or list an intake address that does not resolve. Plans that have no link to CAPA. ## 524B(b)(2): Processes, Updates, and Patches ### What the Statute Says (524B(b)(2)) 524B(b)(2) has two parts. 524B(b)(2)(A) requires the manufacturer to design, develop, and maintain processes and procedures to provide a reasonable assurance that the device and related systems are cybersecure. 524B(b)(2)(B) requires making available postmarket updates and patches to the device and related systems on a reasonably justified regular cycle and, for critical vulnerabilities that could cause uncontrolled risks, as soon as possible out of cycle. ### What Satisfies (b)(2)(A) (524B(b)(2)) Evidence of secure development lifecycle practices: a documented SDLC aligned to IEC 81001-5-1 and AAMI SW96, secure design and threat modeling artifacts, security risk management per AAMI TIR57 and SW96, security architecture views (system, multi-patient harm, updateability, security use case), and security verification and validation including penetration testing. ### What Satisfies (b)(2)(B) (524B(b)(2)) A documented update and patch cadence (the "regular cycle"), an expedited out-of-cycle process for critical vulnerabilities, the technical mechanism for delivering updates (signed packages, verified boot, rollback), and customer-facing communication of the cadence and the channel. ### Deficiency Pattern (524B(b)(2)) (b)(2)(A) deficiencies hit the threat model and architecture views most often: missing trust boundaries, missing data flows, no security use case view. (b)(2)(B) deficiencies hit the update mechanism: no signature verification on the package, no rollback path, no documented expedited cadence. > **[KEY REQUIREMENT]** 524B(b)(2)(B) requires both a regular update cycle and an out-of-cycle expedited process for critical vulnerabilities. A submission that names only one of the two draws a deficiency. ## 524B(b)(3): Software Bill of Materials ### What the Statute Says (524B(b)(3)) 524B(b)(3) requires the manufacturer to provide a software bill of materials, including commercial, open-source, and off-the-shelf software components. ### What Satisfies It (524B(b)(3)) A machine-readable SBOM in CycloneDX or SPDX format covering every commercial, open-source, and off-the-shelf component, generated from the actual build (not hand-curated), accompanied by a VEX statement set that classifies known vulnerabilities by exploitability in the device's deployed configuration. The SBOM regenerates on every release and feeds the postmarket vulnerability monitoring described in (b)(1). ### Deficiency Pattern (524B(b)(3)) Hand-curated SBOMs that omit transitive dependencies. SBOMs in PDF or spreadsheet form that are not machine-readable. SBOMs with no accompanying VEX, leaving the reviewer to assume every listed CVE is exploitable. SBOMs that do not match the binaries the manufacturer is submitting. ## 524B(b)(4): Other Requirements by Regulation ### What the Statute Says (524B(b)(4)) 524B(b)(4) authorizes the FDA to require, by regulation, such other information as may be necessary to demonstrate reasonable assurance that the device and related systems are cybersecure. ### What Satisfies It (524B(b)(4)) Nothing yet. 524B(b)(4) is an open-ended hook for future FDA rulemaking. There are no regulations issued under (b)(4) at the time of writing. Manufacturers should track Federal Register activity for proposed rulemaking but do not need to file evidence against (b)(4) today. ### Deficiency Pattern (524B(b)(4)) None at present. Watch for proposed rulemaking; the FDA has discussed using (b)(4) to formalize SBOM format, VEX, and update transparency requirements that today live in guidance. ## 524B(c): The "Cyber Device" Definition ### What the Statute Says (524B(c)) 524B(c) defines a "cyber device" as a device that includes software validated, installed, or authorized by the sponsor as a device or in a device; has the ability to connect to the internet; and contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats. ### Why the Definition Is Broad (524B(c)) All three prongs are easy to meet, and the connectivity prong is the broadest of all. **Any type of connection to the device's software qualifies.** Wired Ethernet, Wi-Fi, cellular, Bluetooth, BLE, NFC, Zigbee, a USB port that exposes a service or accepts firmware, a serial or JTAG port, a companion mobile or desktop app, a cloud backend, a gateway, or an indirect path through a hospital network all satisfy 524B(c). The statute does not require direct internet connectivity, and the FDA does not read it that way. If software on the device can be reached, updated, or exchanged with through any interface, the device is a cyber device. ### What Satisfies It (524B(c)) An explicit determination in the submission stating that the device is a cyber device under 524B(c), with a brief justification referencing the three prongs and naming every interface that touches the device software. For the rare device that is not a cyber device, a justification explaining why none of the three prongs is met, with specific attention to the connectivity prong. ### Deficiency Pattern (524B(c)) Submissions that assume "no Wi-Fi means not a cyber device" and skip the 524B section. The FDA reads the connectivity prong as covering any interface to the device software, not just internet-routable network interfaces. A USB service port, a Bluetooth radio, an NFC pairing interface, a companion app, or a gateway-mediated cloud path are all sufficient to make the device a cyber device under 524B(c). ## How Will FDA Scrutiny Under 524B Intensify in 2026? Scrutiny under Section 524B is widening in 2026 beyond simply checking that each artifact exists, toward checking whether the evidence behind each artifact actually holds up. The February 3, 2026 final guidance is the same statute, but reviewers now have more experience applying it, and the deficiency patterns from 2024 and 2025 submissions inform what they probe on the next one. Four areas are drawing deeper review under this shift: | Area | What reviewers checked before | What reviewers check now | | --- | --- | --- | | Threat model | Presence of a threat model document | Whether the model's elements match the actual architecture and interfaces | | SBOM | Presence of an SBOM file | Whether the SBOM is machine-readable, covers transitive dependencies, and includes VEX | | Postmarket plan | A stated commitment to monitor vulnerabilities | Evidence the plan links to CAPA and a working coordinated vulnerability disclosure intake | | AI-enabled functions | Not previously a distinct review line | Data integrity and model-specific risks such as data poisoning and model evasion | This shift also reflects the FDA's smaller postmarket workforce turning attention to whether guidance is producing real-world results, not just compliant paperwork. A submission built to satisfy a checklist rather than to describe a verified architecture is the kind of submission this heightened scrutiny is designed to catch, since 524B(b)(2)(A) already requires processes that provide reasonable assurance, not just a stated intention. For manufacturers, the practical response is to treat every 524B artifact as something a reviewer will trace back to the device's actual build and actual operations, not as a document produced once at filing time. An SBOM that regenerates from the real build, a threat model that names the interfaces actually present in the architecture, and a postmarket plan tied to a working CAPA record are what hold up under this level of review. Manufacturers preparing a submission in 2026 should expect fewer passes on documentation that merely states a commitment without the evidence to back it. ## How Blue Goat Approaches a 524B Submission We organize 524B submissions subsection by subsection so that every reviewer question maps to a specific artifact in a specific place. The 524B(c) determination opens the cybersecurity section. The (b)(1) postmarket plan, the (b)(2) SDLC and update cadence evidence, and the (b)(3) SBOM and VEX each get a labeled subsection with the supporting artifacts attached. We draft the threat model and architecture views against AAMI TIR57, AAMI SW96, and IEC 81001-5-1, and we plug the postmarket plan into the manufacturer's CAPA procedure so that vulnerability response has a closure record, not just a ticket. Our team holds CISSP, OSCP, and prior military red-team credentials, and we ground our work in Section 524B, the FDA's February 3, 2026 guidance, AAMI SW96:2023, AAMI TIR57:2016/(R)2023, and IEC 81001-5-1:2021. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [premarket cybersecurity service](https://bluegoatcyber.com/services/fda-premarket-cybersecurity) or our [524B requirements guide](https://bluegoatcyber.com/guides/fda-524b-cybersecurity-requirements-explained). ## FAQ ### Are any subsections of 524B not about cybersecurity? No. Section 524B is the cyber device statute, added to the FD&C Act specifically to give the FDA authority over medical device cybersecurity at premarket. Every subsection, including the definition in (c) and the future-rulemaking hook in (b)(4), is a cybersecurity provision. A submission cannot carve out a "non-cyber" portion of 524B. ### Which 524B subsection do most deficiencies come from? 524B(b)(2)(A) (processes) and 524B(b)(3) (SBOM) generate the largest share of deficiencies. (b)(2)(A) deficiencies usually target the threat model and architecture views; (b)(3) deficiencies usually target SBOM machine-readability, transitive coverage, and missing VEX. 524B(b)(1) postmarket plan deficiencies are also common, typically for missing CVD intake or no CAPA linkage. ### Does 524B(b)(4) require anything today? Not yet. 524B(b)(4) authorizes the FDA to issue regulations requiring additional information, but no such regulations are in effect at the time of writing. Manufacturers should monitor the Federal Register for proposed rulemaking. The FDA has signaled interest in formalizing SBOM format, VEX, and update transparency requirements through (b)(4). ### How do I know if my device meets the 524B(c) cyber device definition? Apply the three-prong test, and be honest about the connectivity prong: **any type of connection to the device's software qualifies.** That includes wired Ethernet, Wi-Fi, cellular, Bluetooth, BLE, NFC, Zigbee, USB ports that expose a service or accept firmware, serial or JTAG ports, companion mobile or desktop apps, cloud backends, gateways, and indirect paths through a hospital network. Direct internet routability is not required. If software on the device can be reached, updated, or communicated with through any interface, treat the device as a cyber device under 524B(c). ### Where does the FDA's February 3, 2026 guidance fit relative to 524B? The statute is binding and sets the requirements; the guidance is nonbinding but is the operative interpretation the FDA applies when reviewing a submission. The February 3, 2026 final premarket cybersecurity guidance tells you what artifacts satisfy each subsection. Submissions are built against the guidance and traced back to the statute subsection. Citing the statute without the guidance, or the guidance without the statute, both leave gaps a reviewer will flag. ### Does 524B apply to a 510(k) for a device that has no network interface? Almost always yes. The 524B(c) connectivity prong covers any type of connection to the device software, not just network interfaces. A USB service port that allows firmware updates or configuration changes, a Bluetooth or BLE radio, an NFC interface, a serial or JTAG port, or a companion app all make the device a cyber device. The only device that escapes 524B is one with no software at all, or software that is permanently sealed with no interface of any kind, which is rare in modern medical devices. ## Related 524B posts on this site Go deeper on individual subsections and edge cases: - [Section 524B(b)(2): what the design and update requirements really demand](/blog/the-impact-of-524bb2-on-medical-device-cybersecurity), the subsection that generates the most deficiencies, unpacked. - [SBOM, EOS, EOL and Level of Support under 524B(b)(3)](/blog/sbom-end-of-support-eol-los-fda-section-524b), how support-status fields on your SBOM affect the 524B(b)(3) response. - [Patch and update mechanism testing for 524B](/blog/patch-update-mechanism-fda-section-524b-testing), the (b)(2)(B) evidence reviewers expect for signed updates and rollback. - [Documenting update cadence in a 524B submission](/blog/documenting-update-cadence-fda-524b-submission), how to state the regular cycle and the out-of-cycle expedited path. - [Does 524B apply to legacy medical devices?](/blog/does-fda-section-524b-apply-to-legacy-medical-devices), applicability for devices in the installed base. - [Does 524B apply to an auto-injector?](/blog/does-fda-section-524b-apply-to-my-auto-injector), worked example of the 524B(c) three-prong test on a combination product. - [FDA AI cybersecurity threats and 524B](/blog/fda-ai-cybersecurity-threats-524b-medical-devices), how AI/ML functionality changes the 524B(b)(2) threat model. ## Ready to map your submission to Section 524B subsection by subsection? If your cybersecurity section is one block of text instead of a labeled response to each 524B subsection, you are leaving deficiency exposure on the table. We can structure the submission so every reviewer question maps to a specific artifact. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led premarket and postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## More on this topic - [How Much Does Medical Device](/blog/medical-device-cybersecurity-cost) - [H-ISAC and Medical Device Threat](/blog/h-isac-medical-device-threat-intelligence-sources) - [FDA PCCP Beyond AI: Cybersecurity, Firmware, and Hardware Uses](/blog/pccp-beyond-ai-cybersecurity-firmware-hardware) --- ## FDA SIR Cybersecurity Response: eSTAR Prep Guide Source: https://bluegoatcyber.com/blog/fda-sir-submission-issue-request-cybersecurity-response # FDA SIR (Submission Issue Request): Cybersecurity Response Playbook > **[DIRECT ANSWER]** An FDA Submission Issue Request (SIR) is a mid-review message inside eSTAR where the lead reviewer asks for a specific fix or clarification before the substantive review can continue. For cybersecurity, most SIRs cite Section 524B gaps, incomplete SBOMs, weak threat models, out-of-scope penetration testing, or thin postmarket plans. Respond in-eSTAR, quickly, with tightly scoped artifacts that answer only what was asked. **A SIR is not a Deficiency Letter, not an RTA, and not a Hold. It is the FDA reviewer asking you, in writing, inside eSTAR, to fix a specific thing before they will keep reading.** Treat it like a bug ticket from the person who decides whether your device clears. Most cybersecurity SIRs land in the first few weeks of substantive review, and most of them are avoidable. They target the same four artifacts every time: SBOM, threat model, penetration test, and postmarket plan. Getting a SIR is not a failure. Getting the *response* wrong, overreaching, restarting the review clock, or introducing new content the reviewer didn't ask for, is what turns a two-week fix into a two-quarter delay. This guide covers what a SIR is, how it fits alongside RTA and AI letters, the cybersecurity artifacts SIRs cite most often, and a prep checklist you can run against your eSTAR before you submit. ## Key Takeaways - A SIR is a mid-review eSTAR message, not a formal Deficiency (AI) letter. - SIRs are tightly scoped; respond only to what the reviewer asked. - Section 524B cybersecurity SIRs cluster around SBOM, threat model, pen test, and postmarket plan. - In-eSTAR responses preserve review continuity; out-of-band replies restart clocks. - A pre-submission SIR-prep checklist eliminates 80% of common cybersecurity SIRs. - Speed and precision matter more than volume; a 3-page answer beats a 30-page dump. ## Why this matters Since Section 524B of the FD&C Act took effect, cybersecurity is a mandatory element of every "cyber device" premarket submission, and the FDA's Feb 3, 2026 final premarket cybersecurity guidance sets the review baseline. Inside eSTAR, reviewers now have a low-friction way to ping sponsors mid-review: the Submission Issue Request. It looks small, a short message with an attachment field, but it sits directly on the critical path to clearance. The FDA's own MDUFA V performance data shows the average 510(k) review touches multiple information exchanges before decision. When the interaction is cybersecurity-related, the SIR usually references either the guidance itself or one of the underlying consensus standards: AAMI TIR57, AAMI SW96, IEC 81001-5-1, or the SBOM formats catalogued by CISA. Sponsors who cannot answer in the reviewer's own vocabulary, and in the reviewer's own document taxonomy, invite escalation to a formal AI letter, which does pause the review clock and does show up in the public Summary Statement. Treating SIRs as a first-class part of your eSTAR workflow, not an interruption, is what keeps a submission on its 90-day clock. ## What is an FDA Submission Issue Request (SIR)? A Submission Issue Request is a lightweight, in-eSTAR message from the lead reviewer identifying a specific problem in your submission that needs to be corrected or clarified before substantive review can continue on that section. It is delivered through the eSTAR portal, attributed to the reviewer, and expects a scoped response, usually a revised artifact, a short narrative, or both. Three things define a SIR: 1. It is **mid-review**, after acceptance but before decision. 2. It is **tightly scoped**, one issue, or a small cluster of related issues, per SIR. 3. It is **in-eSTAR**, the response is uploaded to the same submission, not sent as an email or a new 510(k). A SIR does not, by itself, pause the MDUFA review clock the way a formal Additional Information (AI) letter does. But an unanswered or badly answered SIR is the fastest way to earn an AI letter, which does. ## How is a SIR different from an RTA, AI, or Hold letter? Four artifacts sponsors routinely confuse: | Letter type | When it lands | Clock impact | Response venue | | --- | --- | --- | --- | | RTA (Refuse to Accept) | Day 1-15 | Resets clock if not fixed | eSTAR resubmission | | SIR (Submission Issue Request) | Mid-review | No formal pause, but delays substantive review | In-eSTAR message | | AI / Deficiency letter | Mid-review | Pauses clock; 180-day response window | Formal AI response package | | Hold letter | Any time cybersecurity is deemed inadequate | Halts all review | Formal remediation package | Practical implication: a SIR is your **last quiet chance** to fix a cybersecurity artifact before it becomes a public AI-letter deficiency in your Summary Statement. For the full comparison of RTA, AI, and Hold, see our [FDA Deficiency Letter vs RTA vs Hold Letter guide](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter). Related: [how to respond to an FDA cybersecurity AI request](/blog/how-to-respond-to-an-fda-cybersecurity-ai-request), [FDA cybersecurity major vs minor deficiency](/blog/fda-cybersecurity-major-vs-minor-deficiency), and [what triggers FDA cybersecurity deficiencies](/blog/what-triggers-fda-cybersecurity-deficiencies-for-devices). ## SIR vs Special 510(k): when each applies to cybersecurity Sponsors routinely conflate these because both involve "fixing" cybersecurity content, but they operate at opposite ends of the product lifecycle and answer to different regulations. **A SIR is a review-time message.** It happens inside an *open, in-review* eSTAR submission. The FDA is asking you to clarify, expand, or replace an artifact you already sent. No new submission, no new user fee, no new intended use analysis. You respond in-eSTAR and the review continues. **A Special 510(k) is a new submission.** It is used *post-clearance* when a legally marketed device is modified and the change can be verified against well-established methods under the manufacturer's design controls (ISO 13485 clause 7.3, incorporated into 21 CFR Part 820 by the QMSR). It gets a new K-number, a new user fee, and a 30-day review goal (vs 90 days for a Traditional 510(k)). | Dimension | SIR | Special 510(k) | | --- | --- | --- | | Trigger | FDA reviewer flags an issue in an open submission | Sponsor makes a post-market change to a cleared device | | Timing | Mid-review | Post-clearance | | Submission vehicle | In-eSTAR message + attachments | New 510(k) submission with new K-number | | User fee | None | Full MDUFA Special 510(k) fee | | FDA review goal | Informal; typically weeks | 30 calendar days | | Governing framework | eSTAR review process | 21 CFR 807.81(a)(3) + "Deciding When to Submit a 510(k) for a Change to an Existing Device" guidance | | Cybersecurity example | Reviewer asks for a more complete SBOM before clearance | Post-market: swapping TLS 1.2 for TLS 1.3, replacing OpenSSL, adding MFA, changing session token lifetime | | Design change allowed? | **No**, never introduce design changes in a SIR response | **Yes**, that is the point | For the full Special vs Traditional 510(k) decision framework, see [Special vs Traditional 510(k) for cybersecurity changes](/blog/special-vs-traditional-510k-cybersecurity-changes). For the Letter to File boundary, see [Letter to File vs new 510(k) for cybersecurity changes](/blog/letter-to-file-vs-new-510k-cybersecurity-changes). ### The cybersecurity gray zone The Feb 3, 2026 FDA premarket cybersecurity guidance has quietly raised the bar for what counts as a change that "could significantly affect safety or effectiveness." Post-market cybersecurity changes that teams historically documented as a Letter to File, third-party library CVE patches, crypto library swaps, authentication model changes, SBOM-visible component replacements, increasingly warrant a Special 510(k) because they alter the *documented threat model*, *SBOM attestations*, or *cybersecurity risk profile* referenced in the cleared submission. Rule of thumb: - **In active review + reviewer sent a message →** SIR response. Fix the artifact, do not change the device. - **Cleared device + cybersecurity change that alters the threat model, SBOM, or risk controls →** almost always a Special 510(k). Do not paper it as a Letter to File just because it is "just a patch." - **Cleared device + routine patch that does not alter the threat model or risk controls →** Letter to File under design change controls, documented in the DHF. If you receive a SIR that is really asking for a design change, do not try to answer it inside the SIR. Respond stating that the fix requires a design change, withdraw or pause as appropriate, and plan the correct post-clearance submission path. ### Cybersecurity change scenarios: SIR vs Special 510(k) The table below walks 12 real-world cybersecurity changes and states the recommended path. "Gray-zone" rows are the ones teams most often get wrong; the reasoning column explains why the recommendation lands where it does under the Feb 3, 2026 guidance. | # | Scenario | Lifecycle stage | Recommended path | Reasoning | | --- | --- | --- | --- | --- | | 1 | Reviewer asks for an SPDX-formatted SBOM after you submitted a spreadsheet | Mid-review | **SIR response** | No device change, replace the artifact and cite guidance §V.A.3. | | 2 | Reviewer asks for STRIDE-per-element analysis on the existing DFD | Mid-review | **SIR response** | Analytical deepening, not a design change. | | 3 | Post-clearance: patch OpenSSL 3.0.11 → 3.0.14 to close a CRITICAL CVE, no interface change | Post-clearance | **Letter to File** | Like-for-like patch under design controls; threat model unchanged, risk controls unchanged. Log in DHF with VEX update. | | 4 | Post-clearance: replace OpenSSL with wolfSSL to reduce attack surface | Post-clearance | **Special 510(k)** | Component swap alters SBOM attestation and the threat model's crypto trust boundary. Verifiable against established methods → Special, not Traditional. | | 5 | Post-clearance: change TLS 1.2 → TLS 1.3 across all interfaces | Post-clearance | **Special 510(k)** | Cryptographic control referenced in cleared submission changes. Verification methods are well-established (RFC 8446 test vectors) → Special is appropriate. | | 6 | Post-clearance: add MFA to the clinician web app | Post-clearance | **Special 510(k)** | Authentication model in cleared threat model changes; usability/effectiveness aspects require verification, but methods are established. | | 7 | Post-clearance: shorten session token lifetime from 24h to 1h | Post-clearance | **Letter to File** *(gray-zone)* | Configuration change to an existing control, not a new control. Update risk file + DHF; document rationale that the threat model conclusions are strengthened, not altered. | | 8 | Post-clearance: add a new Bluetooth pairing mode for a service technician | Post-clearance | **Traditional 510(k)** | New attack surface + new intended user + new interface. Verification methods are *not* well-established for the pairing UX → Traditional, not Special. | | 9 | Post-clearance: rotate signing key after suspected compromise | Post-clearance | **Letter to File** | Operational security response, not a design change. Document under CAPA + postmarket cyber plan. Notify FDA per postmarket guidance if exploitation is confirmed. | | 10 | Post-clearance: swap cloud provider region (US-East → US-West), no code change | Post-clearance | **Letter to File** | Deployment change; no change to device SBOM, threat model, or risk controls. Update the postmarket monitoring plan. | | 11 | Mid-review SIR that would require adding a new authentication factor to close it | Mid-review | **Respond, then plan a change** | Do not smuggle the design change into the SIR. Reply that the current design meets the guidance section cited, or withdraw and re-submit. Never make a design change inside a SIR response. | | 12 | Post-clearance: patch a CRITICAL CVE that also requires re-scoping the threat model (attack path was not previously modeled) | Post-clearance | **Special 510(k)** *(gray-zone)* | The patch itself would be Letter to File, but re-scoping the threat model changes an artifact referenced in the cleared submission. Under Feb 3, 2026 guidance, the threat-model delta is what pushes this to Special. | **Gray-zone reasoning framework.** When the recommendation is not obvious, work through these four gates in order. The first "yes" determines the path. 1. **Does the change alter the intended use, indications, or a fundamental scientific technology?** → **Traditional 510(k).** No exceptions. 2. **Does the change introduce a new interface, new user role, or a control whose verification methods are not well-established?** → **Traditional 510(k).** 3. **Does the change alter an artifact that was part of the cleared cybersecurity submission (SBOM component list, threat model DFD or trust boundaries, cryptographic controls, authentication model, postmarket CVD channel)?** → **Special 510(k).** Verification is against established methods, but the cleared record is now inaccurate and must be re-submitted. 4. **Is the change a like-for-like patch, configuration tightening, or operational security action that leaves the threat model conclusions and risk controls intact?** → **Letter to File** under design change controls, with SBOM + VEX updated and logged in the DHF. If gate 3 and gate 4 both feel true, gate 3 wins. The Feb 3, 2026 guidance treats the cybersecurity artifact set as part of the cleared submission, you cannot silently amend it. **Never-in-a-SIR list.** Regardless of how narrow the SIR sounds, do not answer it by making any of the following changes inside the SIR response: adding or removing an authentication factor, changing a cryptographic algorithm or key length, adding or removing an interface, changing intended user or use environment, or introducing a new third-party component not listed in the submitted SBOM. All of these require a new submission path, Special or Traditional 510(k), not a SIR reply. ## Which cybersecurity artifacts trigger SIRs most often? Across post-524B 510(k) reviews, cybersecurity SIRs cluster into four artifacts: ### 1. SBOM completeness and format Reviewers cite SBOMs that are missing transitive dependencies, use unsupported formats, or omit supplier and version metadata called out in the Feb 3, 2026 guidance. SPDX 2.3 or CycloneDX 1.5 are the safe defaults; anything else invites a SIR. See our [medical device SBOM FDA requirements guide](/blog/medical-device-sbom-fda-requirements-and-submission-guide) and the common [VEX mistakes that trigger FDA deficiencies](/blog/vex-mistakes-fda-deficiencies). ### 2. Threat model rigor Threat models built from a generic template, no device-specific data flow diagram, no trust boundaries, no linkage to hazards under ISO 14971, draw SIRs asking for STRIDE-per-element analysis and explicit mapping between threats and mitigations. See our [step-by-step threat modeling guide for connected and implantable devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) and the [STRIDE vs DREAD vs PASTA comparison](/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective). ### 3. Penetration test scope Pen tests scoped to only the mobile app, or only the cloud API, when the device includes firmware, radio interfaces, or a service interface, routinely draw SIRs asking why the excluded surfaces were not tested. See [scoping a medical device penetration test](/blog/scoping-a-medical-device-penetration-test) and [FDA pen test timing for submission](/blog/fda-pen-test-timing-submission). ### 4. Postmarket plan and coordinated vulnerability disclosure Postmarket plans that assert "we will monitor and patch" without a named CVD channel, an SBOM update cadence, or a defined vulnerability triage SLA get SIRs asking for the operational details. See the [postmarket cybersecurity FDA roadmap](/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap) and [SBOM diffing and CVE correlation for postmarket devices](/blog/sbom-diffing-cve-correlation-postmarket-medical-devices). > **[KEY REQUIREMENT]** Every artifact submitted in response to a cybersecurity SIR should trace back to a section of the Feb 3, 2026 FDA premarket cybersecurity guidance or a named consensus standard. Cite it inline. ## SIR example matrix: common issues and expected evidence Use this matrix as a lookup table when a SIR lands. Each row maps a commonly cited cybersecurity issue to the specific evidence documents reviewers expect back, and the guidance or standard section that anchors the ask. If the response does not include the artifact in the "Expected evidence" column, expect a follow-up SIR or an escalation to an AI letter. | Cybersecurity issue cited in SIR | Expected evidence documents | Format / standard | Anchor citation | | --- | --- | --- | --- | | Incomplete SBOM (missing transitive dependencies) | Regenerated machine-readable SBOM + delta summary + updated CMP reference | SPDX 2.3 or CycloneDX 1.5 (`.json`/`.spdx`) | Feb 3, 2026 FDA guidance §V.A.3; CISA 2026 SBOM Minimum Elements | | SBOM missing supplier / version / license metadata | Reissued SBOM with populated fields + supplier attestation letter | SPDX 2.3 or CycloneDX 1.5 | Feb 3, 2026 FDA guidance §V.A.3 | | Unresolved CVEs without exploitability rationale | VEX document + updated risk assessment tying each CVE to device impact | CycloneDX VEX or CSAF 2.0 | CISA VEX guidance; Feb 3, 2026 FDA guidance §V.A.4 | | Threat model built from generic template | Device-specific DFD + trust-boundary diagram + STRIDE-per-element table | AAMI TIR57 §5; ISO 14971 linkage | Feb 3, 2026 FDA guidance §V.A.2 | | Threats not linked to safety hazards | Threat-to-hazard traceability matrix + ISO 14971 risk file excerpt | ISO 14971:2019 §5-7 | Feb 3, 2026 FDA guidance §V.A.2; AAMI TIR57 | | Missing residual cybersecurity risk statement | Signed residual risk memo + risk management report update | ISO 14971:2019 §8 | Feb 3, 2026 FDA guidance §V.A.5 | | Pen test scope excludes an interface (firmware, radio, service port) | Revised pen test report covering the interface OR written scope-exclusion rationale | OWASP MSTG / PTES / NIST SP 800-115 | Feb 3, 2026 FDA guidance §V.A.6 | | Pen test methodology not stated | Test plan appendix naming methodology, tools, and tester credentials | OWASP, PTES, or equivalent | Feb 3, 2026 FDA guidance §V.A.6 | | Pen test findings not tracked to closure | Findings register with retest evidence + risk acceptance for any residual | Internal QMS format | CAPA under ISO 13485 clause 8.5.2 as incorporated by the QMSR; Feb 3, 2026 FDA guidance §V.A.6 | | No named coordinated vulnerability disclosure channel | Public CVD policy URL + contact address + intake SLA | ISO/IEC 29147 + 30111 | Feb 3, 2026 FDA guidance §VI.B | | Postmarket plan lacks SBOM update cadence | Updated postmarket cybersecurity plan with monitoring cadence and triage SLA | AAMI SW96 §7 | Feb 3, 2026 FDA guidance §VI.C | | No patch delivery mechanism described | Update architecture description + signed-update evidence + rollback plan | IEC 81001-5-1 §9 | Feb 3, 2026 FDA guidance §VI.D | | No end-of-support (EOS) date | Lifecycle statement in labeling + CMP entry + customer notification plan | AAMI TIR97; PCLC guidance | Feb 3, 2026 FDA guidance §VI.E | | Missing architecture views (global, multi-patient, updateability) | Architecture Views deliverable set | AAMI SW96 §5 | Feb 3, 2026 FDA guidance §V.A.1 | | Weak or missing cryptographic controls justification | Crypto inventory + FIPS 140-3 attestation (where applicable) + algorithm rationale | NIST SP 800-131A | Feb 3, 2026 FDA guidance §V.A.7 | | Authentication / access control not documented | Auth architecture memo + role matrix + session/token controls table | IEC 81001-5-1 §7 | Feb 3, 2026 FDA guidance §V.A.7 | | Interoperability / third-party integration risks unaddressed | Interoperability risk assessment + partner attestations | AAMI TIR57 §6 | Feb 3, 2026 FDA guidance §V.A.8 | | Labeling missing cybersecurity information for users | Redlined IFU / operator manual excerpt with cyber section | 21 CFR 801 + FDA guidance | Feb 3, 2026 FDA guidance §VII | Two rules for using the matrix: 1. **Send exactly what the row asks for.** If the SIR cites an incomplete SBOM, send the SBOM and a one-page delta summary, not a rewritten threat model. Scope creep converts SIRs into AI letters faster than any other single mistake. 2. **Cite the anchor inline.** Every response should reference the guidance section or standard clause in the right-hand column so the reviewer can close the item without re-reading the source. ## eSTAR SIR-prep checklist for cybersecurity Run this before you file. If you cannot check every box, expect a SIR. **SBOM** - [ ] SPDX 2.3 or CycloneDX 1.5 format - [ ] All third-party and transitive dependencies included - [ ] Supplier, component name, version, and license fields populated - [ ] Machine-readable file attached in eSTAR, not embedded in a PDF - [ ] Companion VEX document for any known unpatched CVEs **Threat model** - [ ] Device-specific data flow diagram (not a template) - [ ] Trust boundaries drawn and labeled - [ ] STRIDE-per-element (or equivalent) applied - [ ] Threats mapped to controls and to ISO 14971 hazards - [ ] Residual risk statement signed off by risk management **Penetration test** - [ ] Scope covers every interface listed in the architecture view - [ ] Firmware, radio, and service interfaces explicitly addressed or exclusion justified - [ ] Testing methodology cited (OWASP, PTES, or equivalent) - [ ] Findings tracked to closure with retest evidence - [ ] Report author credentials included **Postmarket cybersecurity plan** - [ ] Named CVD channel (email address or portal) - [ ] SBOM update cadence defined - [ ] Vulnerability triage SLA defined - [ ] Patch delivery mechanism described - [ ] End-of-support date declared **eSTAR hygiene** - [ ] Every cybersecurity artifact placed in the correct eSTAR attachment slot (not a catch-all appendix) - [ ] File names match the eSTAR field labels - [ ] Cross-references between documents use consistent artifact IDs - [ ] A single Cybersecurity Management Plan ties every document together For deeper eSTAR-specific mechanics, see our companion guide on [preparing eSTAR 510(k) cybersecurity documentation](/blog/preparing-your-estar-510k-cybersecurity-documentation). ## How to structure a SIR response that closes the loop A good SIR response has four parts and never more: 1. **Restate the reviewer's question in your own words.** One or two sentences. This is your alignment check. 2. **Answer directly.** Lead with the answer, not the setup. 3. **Point to the revised artifact.** Name the file, the version, and the specific section that changed. 4. **Cite the standard or guidance.** Section number, page number, date. Do not attach unrelated updates. Do not use the SIR to introduce design changes. Do not restate your entire cybersecurity story. Reviewers reject scope creep, and scope creep is the single most common way a SIR turns into an AI letter. Turnaround target: **five business days or less** for most cybersecurity SIRs. Anything longer signals that you did not have the artifact ready, and the reviewer will treat the next issue on the same submission with less patience. ## Reusable SIR response template Copy the block below into your eSTAR SIR response text field (or the attached PDF/DOCX cover memo). It works for any of the four artifact categories reviewers hit most often. Replace the bracketed placeholders and delete any section that does not apply to the specific issue raised. > **Prefer an interactive version?** Use the [SIR Response Builder](/tools/sir-response-builder) to pick your issue type (auth change, crypto change, vulnerability patch, or SBOM/signing change) and get a pre-filled template with example verbiage. ### Header block (always include) ```text SUBMISSION: [K-number / Q-sub / De Novo number] DEVICE: [Trade name, model] SIR REFERENCE: [SIR ID from eSTAR, date received] REVIEWER: [Lead reviewer name, if provided] RESPONSE DATE: [YYYY-MM-DD] RESPONSE AUTHOR: [Name, title, e-signature on file] PRIMARY GUIDANCE: FDA "Cybersecurity in Medical Devices" premarket guidance, Feb 3, 2026 ``` ### Section 1, Reviewer question, restated ```text 1. UNDERSTANDING OF THE ISSUE The Agency requested [one-sentence paraphrase of the SIR, using the reviewer's own terminology]. We understand the specific concern to be [one sentence naming the exact artifact, section, or claim in question]. If our interpretation differs from the Agency's intent, please advise and we will supplement this response. ``` ### Section 2, Direct answer ```text 2. RESPONSE [Lead with the answer in one or two sentences. State the conclusion first, "Yes, the SBOM now includes...", "The threat model has been revised to...", "Pen test scope has been expanded to cover...", before any supporting detail. Do not restate the cybersecurity program. Do not introduce unrelated design changes.] Supporting detail: - [Bullet 1: what changed] - [Bullet 2: why the change resolves the reviewer's concern] - [Bullet 3: residual risk statement, if any, with rationale] ``` ### Section 3, Revised artifact pointer ```text 3. REVISED ARTIFACTS The following documents have been updated and are attached to this SIR response (and replace the corresponding files in the eSTAR record): | Artifact | File name | Version | Section changed | Change summary | |---|---|---|---|---| | [e.g. SBOM] | [SBOM_DeviceName_v1.2.spdx.json] | v1.2 | Entire file | Added transitive dependencies, license fields, and supplier data per the CISA 2026 SBOM minimum elements | | [Threat Model] | [ThreatModel_DeviceName_v2.1.pdf] | v2.1 | §4.2, §6.1 | Added STRIDE analysis for [interface]; updated risk scoring for [asset] | | [Cybersecurity Management Plan] | [CMP_DeviceName_v1.3.pdf] | v1.3 | §7 | Added coordinated vulnerability disclosure procedure and SLA table | All prior versions are retained in our DHF under [document control ID]. ``` ### Section 4, Standards and guidance citations ```text 4. REGULATORY BASIS The revised artifact aligns with the following: - FDA, "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions," final guidance, Feb 3, 2026, Section [X.Y], p. [N] - FD&C Act §524B(b)(1)-(3), [applicable subsection] - [AAMI TIR57:2016/(R)2023, Section X] OR [ANSI/AAMI SW96:2023, Section X] OR [IEC 81001-5-1:2021, Clause X], as applicable - [NTIA "Minimum Elements for a Software Bill of Materials," Jul 12, 2021], for SBOM issues - [NIST SP 800-30 Rev. 1], for threat/risk methodology, if cited in the submission ``` ### Section 5, Verification statement ```text 5. VERIFICATION The change described above has been verified against [test protocol ID / design verification record ID] and reviewed by [role, e.g. Cybersecurity Lead, Regulatory Affairs Lead]. No changes were made to intended use, indications for use, principles of operation, or the device's substantial equivalence rationale. No new predicate is required. ``` ### Section 6, Closing (always include) ```text 6. CLOSING We believe this response fully addresses SIR [ID]. Please contact [name, email, phone] with any follow-up questions. We are available for a teleconference within two business days if that would accelerate review. ``` ### Usage notes - **Turnaround target:** five business days from SIR receipt. If you cannot meet it, respond within 48 hours with a committed date, silence is what triggers the next escalation. - **Attachments:** name every file `[Artifact]_[DeviceName]_v[X.Y].[ext]`. Reviewers open dozens of attachments a week; ambiguous names get skipped. - **Do not** attach unrelated updates, marketing material, or full copies of the original submission. Attach only what changed. - **Do not** use the SIR to introduce design changes. If the fix requires a design change, respond to the SIR stating that, and open a separate amendment. - **Do** keep a redlined copy of every revised artifact in your DHF. The FDA may ask for the delta later. ## Worked example: OpenSSL CVE patch that shifts the threat model Below is a fully filled SIR response for one of the most common cybersecurity issues in post-524B reviews: a mid-review third-party library CVE (OpenSSL) that the sponsor patched, which in turn changed the SBOM and required a threat-model update. Copy the wording, swap the bracketed device-specific details, and you have a submittable response. **Scenario.** During substantive 510(k) review, the lead reviewer sends a SIR after CVE-2024-5535 is disclosed in OpenSSL. The device, a wireless-connected infusion pump, bundles OpenSSL 3.0.13 in its embedded Linux firmware for its TLS 1.3 clinician-console session. The sponsor upgraded to OpenSSL 3.0.14 (patched), regenerated the SBOM, and updated the threat model. No functional or intended-use change. **Reviewer's SIR (verbatim excerpt):** > "CVE-2024-5535 in OpenSSL 3.0.13 has been publicly disclosed and appears in the SBOM submitted with this 510(k). Please provide: (1) exploitability rationale for the device as designed, (2) an updated SBOM if the component has been replaced, and (3) confirmation that the threat model and cybersecurity risk assessment have been updated to reflect the change." ### Filled SIR response ````text SUBMISSION: K253421 DEVICE: AcmeCardio Infusion Pump 3000, Model IP-3000 SIR REFERENCE: SIR-2026-0714-03, received 2026-07-14 REVIEWER: J. Rivera, Lead Reviewer, DHT4 RESPONSE DATE: 2026-07-18 RESPONSE AUTHOR: M. Chen, Director of Product Security (e-signature on file) ISSUE CATEGORY: Vulnerability patch / SBOM update / threat-model refresh 1. RESTATEMENT OF REVIEWER'S QUESTION The reviewer is asking us to (a) assess exploitability of CVE-2024-5535 in OpenSSL 3.0.13 as used in the AcmeCardio IP-3000, (b) provide an updated SBOM reflecting any component change, and (c) confirm that the threat model and cybersecurity risk assessment have been updated to reflect the change. 2. DIRECT ANSWER CVE-2024-5535 (SSL_select_next_proto buffer overread in ALPN handling) is applicable to the IP-3000 as originally submitted because the device negotiates ALPN during TLS 1.3 sessions with the clinician console. In our device context the vulnerability is rated Medium (CVSS 3.1 base 5.9); exploitation requires an attacker able to send crafted ALPN protocol lists over the segmented clinical network on which the console operates. We have replaced OpenSSL 3.0.13 with OpenSSL 3.0.14 (patched upstream on 2024-06-04) in device firmware build 4.2.1-b917. No API-visible or clinical- functionality changes were introduced. The SBOM, threat model, and risk file have been updated accordingly and are attached to this SIR response. 3. REVISED ARTIFACT POINTERS - SBOM | v4.2.1 | AcmeCardio_IP-3000_SBOM_v4.2.1.cdx.json (CycloneDX 1.5) - SBOM Delta Summary | v4.2.1 | one component changed: pkg:generic/openssl@3.0.13 -> 3.0.14 - VEX Document | v4.2.1 | AcmeCardio_IP-3000_VEX_v4.2.1.cdx.json, CVE-2024-5535 status: "fixed" - Threat Model | v2.3 | §4.2 (clinician-console TLS trust boundary), STRIDE-per-element table updated for ALPN handling - Cybersecurity Risk Assessment | v2.3 | §6.1 hazard trace: threat T-CON-14 updated; residual risk unchanged - Cybersecurity Management Plan (CMP) | v1.4 | §3.2 cross-reference table updated to point to v4.2.1 artifacts - Verification Report | v4.2.1 | §5.7 TLS regression suite, §5.8 signed-update verification 4. REGULATORY BASIS AND STANDARDS CITED - FDA Feb 3, 2026 Premarket Cybersecurity Guidance §V.A.3 (SBOM), §V.A.4 (vulnerability management), §V.A.2 (threat modeling), §VI.C (postmarket monitoring) - CISA VEX Use Cases (2023) and CycloneDX VEX 1.5 - CISA 2026 SBOM Minimum Elements (July 29, 2026), which replaced the NTIA 2021 list - AAMI TIR57:2016/(R)2023 §5 (threat modeling process) - ISO 14971:2019 §7-8 (risk control and residual risk) - IEC 81001-5-1:2021 §9 (software update controls) 5. VERIFICATION The patched OpenSSL 3.0.14 build (firmware 4.2.1-b917) was regression-tested per Test Protocol TP-SEC-041 rev 3 on 2026-07-16 (see Verification Report v4.2.1 §5.7). The full TLS 1.3 acceptance suite passed with 214/214 test cases. Signed-update verification passed per TP-SEC-047 rev 2, confirming the firmware image is signed by the production release key (HSM-protected) and verified by secure boot prior to install. SBOM regeneration occurred automatically in build pipeline job #4821 on 2026-07-16; SBOM SHA-256: 7b1a…c4f2 (full hash in the file header). 6. CLOSING No design changes, no functional changes, and no intended-use changes have been introduced by this response. The scope of the change is confined to a patched dependency and the corresponding documentation refresh. We remain available for a teleconference at the reviewer's convenience. -- Scope guard: If any further OpenSSL CVEs are disclosed before clearance that alter the risk profile beyond a dependency bump, we will notify the reviewer proactively rather than bundling additional changes into this SIR response. ```` **Why this response closes cleanly:** - **Alignment sentence first.** The restatement mirrors the reviewer's three-part ask verbatim in structure, so the reviewer can check off each item. - **Exploitability rationale before the fix.** The direct answer names the specific vulnerable code path (ALPN handling), CVSS, and required attacker position, not a bare "we patched it." - **VEX status attached.** The response includes a CycloneDX VEX entry with status `fixed`, which is the CISA-recognised value for a patched component. Reviewers reject responses that update the SBOM without a corresponding VEX statement. - **Threat model traceability preserved.** Threat ID `T-CON-14` is referenced, showing that the model change is targeted rather than a wholesale rewrite. Residual risk is explicitly called out as unchanged so the reviewer does not have to re-open the ISO 14971 file to confirm. - **Every artifact has a version, filename, and section pointer.** Reviewers open dozens of attachments a week; ambiguous references get re-SIR'd. - **No design change smuggled in.** The closing paragraph and scope guard state this explicitly, which forecloses the most common escalation path. If your SIR is on authentication, cryptographic controls, or SBOM/signing rather than a CVE patch, use the [SIR Response Builder](/tools/sir-response-builder) to generate the same six-section skeleton pre-filled for that issue type. ## Traceability table template Reviewers close SIRs faster when every sentence in your response is traceable to a specific artifact, a specific standard clause, and a specific piece of verification evidence. Paste the table below into the top of your SIR response (or attach as `SIR--Traceability.xlsx`) and fill one row per response statement. If a row cannot be filled end-to-end, the statement is not yet defensible and should be revised before submission. **Column definitions:** - **Response statement**, the exact sentence or claim from your SIR reply (copy verbatim, do not paraphrase). - **eSTAR artifact**, filename, version, and section/page anchor where the artifact lives inside the eSTAR project (e.g., `Threat-Model-v2.3.pdf §4.2`). - **Standard / guidance citation**, the clause, section, or line number in FDA guidance, AAMI TIR57, IEC 81001-5-1, ISO 14971, ANSI/AAMI SW96, or NIST publications that authorises the claim. - **Verification evidence**, the test result, scan output, log file, or signed record that proves the statement is true (not just asserted). - **Evidence location**, filename and anchor for the verification evidence. - **Owner / date verified**, the named individual (role + initials) who verified the row and the date, so the reviewer can see this is not AI-generated boilerplate. - **Status**, `Ready` | `Draft` | `Blocked`, anything not `Ready` must not ship. **Template (copy-paste):** | # | Response statement | eSTAR artifact (file §section) | Standard / guidance citation | Verification evidence | Evidence location | Owner / date verified | Status | |---|---|---|---|---|---|---|---| | 1 | *e.g. "The OpenSSL 3.0.14 upgrade eliminates CVE-2024-XXXX in the TLS interface."* | `SBOM-DeviceX-v1.4.cdx.json` (component index 47) | FDA Feb 3, 2026 Premarket Cybersecurity Guidance §V.A.3 (SBOM) | Rebuilt SBOM diff + CVE scanner report showing zero CRITICAL findings | `CVE-Scan-2026-03-14.pdf p.2` | J. Smith, Security Lead / 2026-03-14 | Ready | | 2 | *e.g. "Threat model updated; residual risk unchanged."* | `Threat-Model-v2.3.pdf §4.2, Table 4-B` | AAMI TIR57:2016 §5.4; ISO 14971:2019 §7 | Risk matrix delta review signed by risk owner | `Risk-Review-Minutes-2026-03-12.pdf` | M. Chen, Risk Owner / 2026-03-12 | Ready | | 3 | *e.g. "Pen test re-run against patched build; no new findings."* | `Pen-Test-Report-v1.2.pdf §6 Retest Summary` | FDA Feb 3, 2026 Guidance §V.A.5 (Testing); ANSI/AAMI SW96:2023 §7.4 | Signed retest attestation + raw tool output | `PenTest-Retest-Logs.zip` | R. Patel, Test Lead / 2026-03-13 | Ready | | 4 | *e.g. "CVD channel and 60-day SLA remain unchanged."* | `Postmarket-Cyber-Plan-v1.1.pdf §3.2` | FDA Feb 3, 2026 Guidance §VI (Postmarket); ISO/IEC 30111:2019 | Published `security.txt` + monitored inbox screenshot | `security-txt-evidence.pdf` | J. Smith, Security Lead / 2026-03-14 | Ready | | 5 | *e.g. "VEX statement issued: status = fixed."* | `VEX-DeviceX-2026-03-14.cdx.json` | CISA VEX Minimum Requirements (Apr 2023); FDA Feb 3, 2026 Guidance §V.A.3 | CycloneDX schema validation pass + SHA-256 hash | `VEX-validation.log` | J. Smith / 2026-03-14 | Ready | **How to use the table during response drafting:** 1. Write the SIR response first (six-section skeleton). 2. Extract each declarative sentence into a row. 3. Fill columns 3 (artifact) and 4 (citation) before touching evidence, this exposes claims that have no authoritative basis. 4. Any row that stalls at column 5 (no verification evidence) means the underlying work is not done, not that the response needs better wording. Fix the work, not the sentence. 5. Attach the completed table as the first exhibit in the SIR reply. Reviewers routinely open exhibit 1 before reading the narrative, and a clean traceability table pre-answers most follow-up questions. **Rows to flag automatically:** - Any citation to a *withdrawn* or *superseded* document (e.g., the 2023 FDA premarket guidance instead of Feb 3, 2026). - Any evidence dated *before* the artifact version listed in column 3 (evidence must post-date the change it verifies). - Any owner field left blank or filled with a team name, reviewers expect an individual. - Any statement without a citation, either add one or delete the statement. ## How Blue Goat Cyber approaches SIR readiness Blue Goat Cyber runs a pre-submission SIR simulation on every eSTAR we support. Our senior reviewers, CISSP, OSCP, and ex-military red team backgrounds, read your submission the way a lead reviewer at CDRH does, flag the same four artifact categories, and rewrite what needs rewriting before the FDA sees it. We line up SBOM, threat model, pen test, and postmarket plan into a single Cybersecurity Management Plan mapped to the Feb 3, 2026 guidance so a reviewer can trace any question to a specific artifact in under a minute. For clients in active review, we author SIR responses inside your eSTAR project on a five-business-day turnaround. See our [FDA premarket cybersecurity service](/lp/medical-device-cybersecurity) for details. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is a Submission Issue Request in FDA eSTAR? A Submission Issue Request (SIR) is a message from the lead FDA reviewer delivered inside the eSTAR portal, asking the sponsor to fix or clarify a specific issue in the submission before substantive review continues. It is scoped, informal relative to an AI letter, and expects an in-eSTAR response with the revised artifact attached. ### Does an FDA SIR pause the review clock? No. Unlike a formal Additional Information (AI) letter, a SIR does not pause the MDUFA review clock. However, an unanswered or poorly answered SIR routinely escalates to an AI letter, which does pause the clock for up to 180 days and appears in the public 510(k) Summary Statement. ### How fast should we respond to a cybersecurity SIR? Aim for five business days or less. Cybersecurity SIRs are almost always narrow, a missing SBOM field, a missing interface in pen-test scope, an undefined CVD channel. Slow responses signal that the artifact was not ready at submission and lower reviewer patience on later issues. ### Can we add new information to a SIR response? Only if it directly answers what the reviewer asked. Introducing unrelated updates, new design changes, or a rewritten cybersecurity narrative frequently converts a SIR into an AI letter. Keep the response strictly scoped to the reviewer's question, and cite the guidance section or standard that justifies the answer. ### Which cybersecurity artifacts trigger the most SIRs? Four artifacts account for the majority: incomplete or wrong-format SBOMs, template-based threat models missing device-specific data flow diagrams, penetration tests that exclude firmware or radio interfaces without justification, and postmarket plans lacking a named coordinated vulnerability disclosure channel and defined SLAs. ### Is a SIR the same as a Refuse to Accept (RTA) letter? No. An RTA is a completeness decision issued in the first 15 days that blocks acceptance entirely. A SIR arrives after acceptance, during substantive review, and asks for a specific fix. RTAs reset your clock; SIRs do not, but they can escalate to letters that do. ## Related reading Deficiency-letter cluster: - [FDA Deficiency Letter vs RTA vs Hold Letter](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) - [How to respond to an FDA cybersecurity AI request](/blog/how-to-respond-to-an-fda-cybersecurity-ai-request) - [FDA cybersecurity major vs minor deficiency](/blog/fda-cybersecurity-major-vs-minor-deficiency) - [What triggers FDA cybersecurity deficiencies for devices](/blog/what-triggers-fda-cybersecurity-deficiencies-for-devices) - [510(k) cybersecurity deficiencies that trigger FDA holds](/blog/510k-cybersecurity-deficiencies-that-trigger-fda-holds) - [PMA cybersecurity deficiencies and complete response letters](/guides/fda-pma-cybersecurity-requirements) - [FDA 483 cybersecurity observations under QMSR](/blog/fda-483-cybersecurity-observations-qmsr) - [VEX mistakes that trigger FDA deficiencies](/blog/vex-mistakes-fda-deficiencies) Related cybersecurity submission topics: - [Preparing your eSTAR 510(k) cybersecurity documentation](/blog/preparing-your-estar-510k-cybersecurity-documentation) - [eSTAR cybersecurity: IVD vs non-IVD submissions](/blog/estar-cybersecurity-ivd-vs-nivd-submissions) - [Special vs Traditional 510(k) for cybersecurity changes](/blog/special-vs-traditional-510k-cybersecurity-changes) - [Letter to File vs new 510(k) for cybersecurity changes](/blog/letter-to-file-vs-new-510k-cybersecurity-changes) - [510(k) cybersecurity requirements every maker must meet](/blog/510k-cybersecurity-requirements-every-maker-must-meet) ## Ready to SIR-proof your eSTAR? Send us your cybersecurity artifacts and we will run the same SIR simulation the FDA reviewer will. You get a scored gap report and a fix list before you submit. [Book a discovery call](/contact). --- *Christian Espinosa, Founder and CEO, Blue Goat Cyber (CISSP). Christian has led FDA premarket cybersecurity submissions across Class II and Class III devices and is the author of The Smartest Person in the Room. He writes on medical device cybersecurity strategy for MedTech teams navigating Section 524B.* --- ## More on this topic - [Q-Sub vs Pre-Sub: FDA Cybersecurity Feedback Guide](/blog/q-sub-vs-pre-sub-fda-cybersecurity) --- ## FMEA vs Threat Modeling for Medical Devices Source: https://bluegoatcyber.com/blog/fmea-vs-threat-modeling-medical-devices # FMEA vs Threat Modeling for Medical > **[DIRECT ANSWER]** FMEA identifies random and systematic failure modes, such as hardware wear-out or software defects, scored by severity, occurrence, and detectability using empirical failure rates. Threat modeling instead examines deliberate adversarial action, scoring exploitability and attacker capability rather than failure rates. A Section 524B submission needs both artifacts, cross-referenced to each other, because reviewers reject an FMEA offered as a substitute for a threat model, and neither method answers the other's underlying risk question. A frequent finding in FDA cybersecurity deficiency letters is that the manufacturer submitted a thorough hazard analysis and FMEA in place of a threat model. The two artifacts look similar at a glance, but reviewers reject the substitution because they answer fundamentally different risk questions. This post explains the boundary, where the two artifacts must reference each other, and what a clean separation looks like in a 524B submission. ## Key Takeaways - FMEA covers accidental failure modes; threat modeling covers intentional adversarial action. - The FDA's February 3, 2026 final premarket cybersecurity guidance expects a threat model in addition to ISO 14971 hazard analysis, not in place of it. - Cyber events feed back into safety risk through ISO 14971 only after threat modeling identifies the attack path and likelihood inputs. - A clean submission links specific FMEA hazards to the threat model entries that could trigger them, and vice versa. - STRIDE-based threat modeling and a process FMEA on the security program are complementary, not duplicative. ## Why this matters The FDA's February 3, 2026 final premarket cybersecurity guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," requires a security risk assessment that is distinct from the ISO 14971 safety risk assessment. AAMI TIR57:2016/(R)2023 and AAMI SW96:2023 reinforce the separation and define how the two files connect. The 2023 update to AAMI TIR57 was explicit: security risk analysis methods are not interchangeable with safety risk analysis methods, because the inputs (likelihood, exploitability, attacker capability) and the outputs (mitigations) differ. Submissions that fold cybersecurity into a single FMEA tab consistently draw a major deficiency. Submissions that omit FMEA entirely and submit only a threat model draw a different deficiency on the safety side. Both files are required, and the link between them is itself a reviewer focus. ## What FMEA Is ### Origin and Method FMEA originated in aerospace and automotive safety engineering and entered medical devices through ISO 14971 risk management and process-validation practice. It is a structured enumeration of failure modes for components, subsystems, or process steps, scored by severity, occurrence, and detectability. Variants include design FMEA (dFMEA), process FMEA (pFMEA), and use FMEA (uFMEA). ### What It Covers Well FMEA covers random hardware failure, wear-out, latent software defects activated by normal operation, manufacturing process variability, and use error. The likelihood input is empirical or statistical: failure rates, defect rates, error rates from human factors studies. The output is a set of design or process mitigations and a residual risk score. ### Where It Falls Short on Cybersecurity FMEA likelihood scoring breaks down for adversarial events. There is no empirical failure rate for "an attacker exploits a heap overflow on the BLE stack." Severity scales transfer cleanly, but occurrence and detectability do not, because an adversary chooses when and how to attack. Trying to score cyber events on an FMEA worksheet produces numbers that are not defensible to a reviewer. ## dFMEA Specifically: How It Feeds ISO 14971 and the Threat Model Design FMEA (dFMEA) is the variant most teams reach for first, because it walks the design bottom-up: component, subsystem, interface, function. Done well for a connected medical device, it produces two outputs reviewers care about, the hazard inputs the ISO 14971 file consumes, and the list of cyber-triggerable failure modes that hand off to the threat model. **Scoring on a medical scale.** Generic automotive 1-10 scales do not match ISO 14971 expectations. Severity should map to the harm bands from ISO 14971 Annex C (negligible, minor, serious, critical, catastrophic), the same bands the rest of the risk file uses. Occurrence should use the same probability bands as the hazard analysis. If the dFMEA uses one scale and the hazard analysis uses another, the file is internally inconsistent and reviewers will flag it. **RPN is a triage signal, not an accept/reject rule.** A severity-5 patient-harm row with low occurrence and high detection can produce a low RPN. ISO 14971:2019 requires risk acceptability decisions against pre-defined severity-gated criteria, not against an arbitrary RPN threshold. **The two columns that earn their keep.** Add `Cyber-triggerable (Y/N)` and `Linked threat model ID(s)` to the dFMEA. Any row touching a network interface, software update path, exposed port, wireless link, or external data input is Y and gets one or more threat model IDs. Maintain the reverse mapping in the threat model. Those two tables together are the traceability evidence reviewers actually open. > **[KEY REQUIREMENT]** A dFMEA row whose effect is "device crashes on malformed input" belongs in the ISO 14971 file. The matching threat model row is the attack path that produces that input. Same failure mode, two artifacts, with a cross-reference between them. ## What Threat Modeling Is ### Origin and Method (Threat Modeling) Threat modeling in medical devices is grounded in AAMI TIR57, AAMI SW96, IEC 81001-5-1, and the FDA's premarket cybersecurity guidance. The method enumerates assets, trust boundaries, data flows, and adversaries; identifies attack paths; rates each path by exploitability and impact; and assigns mitigations. STRIDE (Spoofing, Tampering, Repudiation, Information disclosure, Denial of service, Elevation of privilege) is the most common categorization scheme; PASTA and attack trees are also used. ### What It Covers Well (Threat Modeling) Threat modeling captures interface-level attack surface (wireless, wired, USB, cloud, app), trust boundary crossings, credential and key handling, update integrity, and data flow exposure. The likelihood input is exploitability and attacker capability, not failure rate. The output is a set of security controls and residual cybersecurity risk. ### Where It Stops A threat model does not address random component failure or normal-use defects. It assumes a working device and asks how an adversary subverts it. A device with no adversarial exposure (truly air-gapped, no software updateable interfaces, no data ports) still has an FMEA; it may not need a substantive threat model. ## The Core Differences > **[KEY REQUIREMENT]** The FDA's February 3, 2026 final premarket cybersecurity guidance treats the security risk assessment as a distinct deliverable from the ISO 14971 safety risk assessment. A single combined worksheet does not satisfy the requirement, even when its content is otherwise complete. ## Where the Two Must Reference Each Other The files are separate but the analyses are linked. Three explicit linkages belong in a clean submission. ### Cyber-Triggered Safety Hazards Any safety hazard in the ISO 14971 file that could be triggered or accelerated by a cybersecurity event references the threat model entries that describe those events. Example: a hazard "unintended drug delivery" is linked to threat model entries covering tampering with the infusion rate parameter and spoofing of the clinician interface. ### Safety-Constrained Security Controls Any security control that constrains a safety function (for example, an authentication step in front of a clinical setting change) is reflected in the FMEA's use-error analysis, because the control introduces a step that can be performed incorrectly under time pressure. ### Shared Residual Risk The total residual risk presented to the FDA combines safety and cybersecurity residuals with explicit reasoning about how cyber mitigations affect safety risk and vice versa. The reasoning is documented in the risk management report and cross-referenced from the security risk report. ## How to Scope Each Artifact for a 524B Submission ### FMEA Scope Cover the device's intended use, foreseeable misuse, and the patient population. Include hardware failure modes, software defect modes activated by normal operation, manufacturing variability, and use error. Do not score adversarial events on the FMEA worksheet. ### Threat Model Scope Cover every interface (wired, wireless, USB, cloud, app, service), every trust boundary, every data flow that crosses a boundary, and the update mechanism. Apply STRIDE per interface and per data flow. Include the attack paths that produce safety impact and link them to the corresponding FMEA hazards. ### Process FMEA on the Security Program A pFMEA on the postmarket cybersecurity process itself (SBOM ingestion, VEX triage, CAPA initiation, advisory release) is a useful complement to threat modeling, not a substitute. It catches process failures that let real attacks land, without trying to score attacker behavior. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches the Boundary We build the threat model and the FMEA-to-threat-model linkage table that submissions actually need, alongside (not inside) the existing ISO 14971 file. The threat model uses STRIDE per interface and per data flow, with exploitability scoring grounded in AAMI TIR57 and SW96 rather than failure-rate scoring. We produce the explicit cross-references that connect cyber-triggered safety hazards to the threat model entries that could trigger them, and we draft the residual risk reasoning that reconciles both files. Our team holds CISSP, OSCP, and prior military red-team credentials, and we ground our work in Section 524B, the FDA's February 3, 2026 guidance, AAMI TIR57:2016/(R)2023, AAMI SW96:2023, IEC 81001-5-1:2021, and ISO 14971:2019. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [threat modeling service](https://bluegoatcyber.com/services/medical-device-threat-modeling) or our [premarket cybersecurity service](https://bluegoatcyber.com/services/fda-premarket-cybersecurity). ## FAQ ### Can FMEA replace a threat model in a 524B submission? No. The FDA's February 3, 2026 final premarket cybersecurity guidance expects a distinct security risk assessment, and a single combined FMEA worksheet is a recurring source of major deficiencies. FMEA covers accidental failure modes; threat modeling covers intentional adversarial action. The likelihood inputs do not transfer between the two methods, so a combined worksheet produces unscoreable cyber rows even when its safety content is otherwise complete. ### Does every medical device need both an FMEA and a threat model? Every device needs an FMEA under ISO 14971. A device that is genuinely air-gapped with no software updateable interfaces, no data ports, and no wireless may not need a substantive threat model. Any device that meets the Section 524B "cyber device" definition (capable of connecting to the internet, software capable of being updated, technological characteristics that could be vulnerable) needs both. ### Should we use STRIDE, PASTA, or attack trees for medical device threat modeling? STRIDE is the most common starting point in the medical device space because it aligns with AAMI TIR57 and SW96 categorization and produces a reviewer-friendly structure. PASTA is useful for higher-complexity systems where business-impact analysis drives prioritization. Attack trees are useful for deep-diving on a specific high-severity attack path. Most submissions use STRIDE as the primary method and supplement with attack trees on the highest-risk paths. ### How does threat modeling feed back into ISO 14971? Through the cyber-triggered safety hazard linkage. Threat modeling identifies attack paths and their outcomes; any outcome that produces patient harm becomes (or augments) a hazard in the ISO 14971 file. The ISO 14971 entry references the threat model entry that justifies its existence and its residual risk. Without the linkage, the safety risk file has cyber-triggered hazards floating without justification and the security risk file has attack paths without patient impact tracing. ### What is process FMEA on a cybersecurity program? A pFMEA applied to the steps of the postmarket cybersecurity workflow itself: SBOM regeneration, VEX triage, CAPA initiation, advisory release, customer notification. It scores process failure modes (a step skipped, a handoff dropped, a deadline missed) rather than adversarial events. It complements threat modeling by addressing the operational reliability of the security program, not the security of the device. ### Where do FMEA and threat modeling appear in the FDA submission? FMEA appears inside the risk management file (per ISO 14971) referenced in the submission. The threat model appears inside the security risk file (per AAMI TIR57 and SW96) and is one of the security documents the February 3, 2026 guidance expects in the Cybersecurity Section of the submission. The linkage table connecting the two should appear in both files and be referenced from the cybersecurity submission summary. ## Ready to draw the line between safety and security risk? If your submission folds cybersecurity into a single FMEA, or your threat model has no traceability back to ISO 14971 hazards, you have a deficiency exposure. We can build the linked pair the FDA expects. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led premarket and postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## More on this topic - [Design FMEA for Medical Devices: dFMEA](/blog/dfmea-medical-devices-iso-14971-cybersecurity) - [ISO 14971 and AAMI TIR57 Synergy](/blog/iso-14971-its-crucial-role-in-medical-device-security-and-connection-with-aami-tir57) --- ## From Idea to FDA Clearance for MedTech Source: https://bluegoatcyber.com/blog/from-idea-to-fda-clearance-what-nobody-tells-medtech-founders # From Idea to FDA Clearance: What Nobody Tells MedTech Founders > **[DIRECT ANSWER]** The biggest obstacle for MedTech founders is not the technology, it is lack of clarity: not understanding clinician workflows, reimbursement, or regulatory planning before development starts. Clearance typically takes about seven years and thirty-five million dollars, so quality management systems and cybersecurity must be built in from day one, using certified development partners and rigorous, manual-intensive testing rather than a bolt-on approach. ## Key Takeaways - The biggest mistake MedTech founders make is a lack of clarity: not understanding how physicians will use their device or failing to plan for reimbursement and regulatory requirements. - It takes an average of 7 years and $35 million to bring a medical device to market, a far cry from the "move fast and break things" mentality of consumer tech. - Choosing a software development partner with expertise in regulated industries and certifications like IEC 62304 and ISO 13485 is essential. - Quality management systems and cybersecurity must be built in from the very beginning, not bolted on at the end. - Working with accelerator programs like MedTech Innovator and investor networks that understand the MedTech space can dramatically improve a startup's chances of success. - The Canadian MedTech ecosystem, centered around Toronto, is a thriving hub for innovation, with Montreal also emerging as a key player. To learn more about Blue Goat Cyber's cybersecurity solutions for the medical device industry, [schedule a Discovery Session](https://meetings.hubspot.com/blue-goat-cyber/discovery-session). And be sure to connect with Christian Espinosa ( LinkedIn) on LinkedIn. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to the full path from idea to FDA clearance the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## The Biggest Mistake MedTech Founders Make (Hint: It's Not the Tech) Most MedTech founders think the hard part is building the technology. Darcy Bachert, Founder and CEO of [Prolucid Technologies](https://www.prolucid.ca/ ""), has spent 17 years proving them wrong. Prolucid is an ISO 13485-certified software development firm in Toronto that works with MedTech companies across North America, Europe, and Australia, taking products from concept through FDA clearance. And in that time, Darcy has seen the same mistakes over and over. The biggest one? **Lack of clarity.** "Founders know what problem they want to solve. They understand the clinical need. But some don't understand how physicians will actually use the device in a real workflow. They don't think about reimbursement strategy early enough. They don't build quality management systems from the beginning. And they treat cybersecurity as something to add at the end instead of building it in from day one." It's not about bad code or lack of funding. It's about building something that solves a problem nobody has. Or building something physicians won't adopt because it adds complexity instead of making their lives easier. ## The 7-Year, $35 Million Journey to FDA Clearance "I don't know if there's as much awareness about how much different it is to build a medical product than to just create a product," Darcy says. "There's so much more that goes into it just from a planning, from a process perspective." On average, it takes **7 years and $35 million** to bring a medical device to market. That's a far cry from the "move fast and break things" mentality of consumer tech. "When you tell a lot of people trying to break into the medical startup space that you're likely not even going to see your product on the market for close to seven years on average, that's a surprising figure to a lot of people," Darcy explains. The journey involves multiple stages of clinical trials, regulatory approvals, and quality management systems that must be built from the ground up. The work doesn't stop once the device hits the market. "It's not like you just, you know, throw the app out, start getting generate revenue, build as you go, test as you go. There are very clear steps you have to follow. And then once it's on the market, you have to make sure it's secure. You have to make sure it's updated." ## The Importance of Choosing the Right Software Development Partner One of the key decisions MedTech founders face is who they'll partner with for software development. Darcy says this choice can make or break a product. "Before we had our ISO 13485 certification, going back a decade, we did follow IEC 62304, but we found that most of the companies we worked with were local in that they were fine with us not having everything. But as we got our full 62304 or 13485 certifications, that really launched the international side of our business." IEC 62304 is the international standard for the medical device software lifecycle. It outlines the requirements for planning, implementing, and maintaining software used in medical devices. Choosing a development partner certified to this standard with a proven track record in regulated industries is essential. "The amount of expertise and knowledge that you bring around all these different best practices just it it really changes things. And so, you know, before you have it, you're not really sure what the impact is, but after having it and having that track record that goes with it, it really makes a huge difference." ## Building Quality and Security from the Start Beyond software development expertise, MedTech founders need partners who have quality management systems and security practices in place from day one. "It's not like you just, you know, throw the app out, start getting generate revenue, build as you go, test as you go. There's very clear steps you have to follow. And then once it's on the market, you have to make sure it's secure. You have to make sure it's updated." Darcy explains that Prolucid is ISO 13485 certified, which means they have a formal quality management system with documented procedures, plans, and processes to ensure consistent, high-quality work. That level of rigor is what the FDA clearance process demands. Quality alone isn't enough. Cybersecurity must be built in from the very beginning, not bolted on at the end. "Cybersecurity must also be built in from the very beginning, not bolted on at the end. You have to make sure it stays secure. You have to make sure it's updated. There's going to be new features that are required." The consequences of ignoring security upfront are real. As Darcy puts it, "if your device is hacked, it could kill a patient or harm a patient. It's much more risky than somebody stealing a credit card number, for instance." ## Avoiding the "Pentest Puppy Mill" Trap When it comes to cybersecurity testing, the Blue Goat Cyber team warns against the "pentest puppy mill" approach: quickly running automated scans and dumping the results into a report template. "We have seen in the past a couple of companies reach out to us, ask for assistance with the cybersecurity process. We say, yeah, this is what it takes for us to do it, from a, you know, manual-intensive process, and they say, well, this guy over here can do it for a much lower price. and then they'll use those results, and the FDA is going to reject it for lack of sufficient testing." The FDA requires a rigorous, manual-intensive approach to security testing. Anything less gets rejected, forcing the company to restart from scratch. "They don't see that it's done against patient harm as a primary metric. They don't see complete coverage of the system. They don't see that it includes the depth of testing that is required for a medical device. They don't see the right documentation around it. And so it really is then, you know, coming back to the drawing board from the ground up." ## Using Accelerator Programs and Investor Networks To work through the complex MedTech path to market, Darcy recommends that founders take advantage of specialized accelerator programs and investor networks. One such program is [MedTech Innovator](https://medtechinnovator.org/), with which Prolucid and Blue Goat Cyber partners. MedTech Innovator selects around 40 companies per year from over 1,500 applicants, providing intensive mentoring, pitch competitions, and other resources. "They are really challenging all those things as part of the program. Not just what is the core technology, but they're looking at the team. How good is this team? How open to feedback are they are? How strong of a product market fit do they have? Do they understand reimbursement? Do they understand regulatory?" The results speak for themselves: over 90% of MedTech Innovator alumni are still in business, acquired, or went public. Espinosa has also seen investors shift their strategies to focus on these types of accelerator programs. "I know some investors who have changed how they invest, and they're only investing in alumni or people in the MedTech innovator program, as an example, or some sort of accelerator program because they have much higher success rates." ## The Canadian MedTech Ecosystem Prolucid is based in Toronto, which Darcy describes as the "mecca in Canada for MedTech." The city, along with the broader "Kitchener-Waterloo region," has the largest concentration of MedTech companies in the country. Montreal also has a really strong MedTech startup scene. They do quite a lot of AI work there as well. It's a bit of a hub not just for MedTech AI but AI in general. And then as you get beyond that, there are smaller regions, Vancouver, Calgary, some on the east coast, but this would be, I think, you'd consider it the largest hub for MedTech in Canada." While the Canadian and US MedTech markets have some differences, Darcy believes the fundamentals are quite similar. The key is finding the right partners, whether that's a software development firm, an accelerator program, or investors who understand the unique challenges of the industry. ## Advice for MedTech Founders As Darcy and the Blue Goat Cyber team wrap up our discussion, they leave us with a few key pieces of advice for MedTech founders: - **Don't invent your problem.** Spend time understanding the real clinical needs and how physicians will use your device in their workflows. Don't just iterate quickly and hope something sticks. - **Build quality and security in from the start.** Invest in a quality management system and cybersecurity practices upfront. Don't try to bolt them on later. - **use the right partners and resources.** Take advantage of accelerator programs, investor networks, and software development firms with deep expertise in regulated industries. The MedTech journey is long and demanding, but with the right approach and the right partners, founders can get from idea to FDA clearance and beyond. Clarity, quality, and security are what separate products that make it to patients from those that stall in review. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template. Every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the FDA's medical device cybersecurity guidance? The FDA's medical device cybersecurity guidance is the February 3, 2026 final guidance. It outlines requirements for medical device manufacturers to ensure the cybersecurity of their devices throughout the total product lifecycle. ### How long does medical device FDA clearance take? On average, it takes 7 years and $35 million to bring a medical device to market. This includes clinical trials, regulatory approvals, and establishing quality management systems, a considerably longer process than for consumer tech products. ### Why is cybersecurity important for medical devices? Cybersecurity is critical for medical devices because a breach could lead to patient harm, compromise sensitive health data, or disrupt healthcare operations. It must be integrated from the design phase, not added on later. ### Does the FDA accept automated cybersecurity testing? No, the FDA typically rejects cybersecurity testing submissions that rely solely on automated scans. They require a rigorous, in-depth evaluation that assesses potential patient harm, provides complete system coverage, and is supported by thorough documentation. ### What is the role of ISO 13485 in medical device development? ISO 13485 is an international standard specifying requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. It is essential for ensuring product quality and completing the FDA clearance process. ### How can MedTech founders improve their chances of FDA clearance? MedTech founders improve their odds by gaining clarity on clinical needs early, building quality and security into the device from day one, and partnering with experienced software development firms and accelerator programs that understand regulatory requirements. --- ## Fuzz Harness Generation for Medical Device Protocols Source: https://bluegoatcyber.com/blog/fuzz-harness-generation-medical-device-protocols # Fuzz Harness Generation for Medical Devices > **[DIRECT ANSWER]** A defensible fuzz harness targets the protocols your device actually speaks, such as HL7, DICOM, BLE GATT, MQTT, and proprietary serial links, using a grammar or seed corpus drawn from real captured traffic. The FDA looks for documented coverage, crash triage, and traceability from fuzzing results back to threat model entries and risk controls. _Published June 3, 2026_ ## Key Takeaways - Fuzz testing is required under the Feb 2026 guidance, scoped to the threat model and documented to the same evidence bar as the rest of security testing. - Generic fuzzers fail on medical protocols because of statefulness, framing, checksums, association negotiation, MTU constraints, and block-wise transfer. - The defensible model is one use per protocol, with explicit grammar sources, seed corpora, transport setup, and coverage signal. - AI helps with grammar synthesis from pcaps and specs, seed expansion, and crash deduplication. It does not handle stateful orchestration or hardware-in-the-loop reliably. - Reviewers want use source, seed corpus stats, coverage reports, crash logs, and fixed-vs-accepted disposition tied back to the threat model and security risk file. - The deliverable belongs in your SPDF and feeds your CAPA and VEX workflows after launch. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to fuzz use generation for medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What the FDA actually expects for fuzz testing evidence Section 524B and the Feb 3, 2026 final guidance _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_ pull fuzz testing into the same security-testing envelope as vulnerability and penetration testing. In practice, reviewers look for: - **Scope tied to the threat model and architecture views** - which interfaces, which protocols, which trust boundaries. - **Methodology** - the fuzzing approach (mutation, generation, coverage-guided, protocol-aware), the use, the seed corpus, and the runtime environment. - **Duration and intensity** - executions, total runtime, throughput, coverage achieved. - **Findings and disposition** - crashes, hangs, undefined behavior, with each one tracked to a fix, a compensating control, or a documented accepted risk. - **Tester independence and qualifications** - the same bar as the rest of the pen test report, with a named, qualified signatory. "We ran AFL++ for an hour on the management port" is not a methodology. Neither is "the BLE scanner found no issues." Reviewers want to see a use per protocol, with a defensible reason it exercises the threat-model paths. ## Why generic fuzzers fail on medical protocols Off-the-shelf fuzzers were designed for parsers and file formats. Medical devices speak negotiated, stateful, framed protocols over transports that punish naive injection. - **Stateful handshakes.** DICOM requires an Association establishment (A-ASSOCIATE-RQ/AC, presentation context negotiation) before any P-DATA flows. HL7 v2 over MLLP has start/end framing and an ACK/NAK loop. MQTT requires CONNECT/CONNACK before anything else and keeps a persistent session. A stateless mutator never gets past the handshake. - **Checksums and length prefixes.** Proprietary binary protocols, BLE GATT extensions, and many serial protocols include CRCs, length prefixes, and sequence numbers. Bit-flipping the payload invalidates the framing and the device drops the frame before the parser ever sees it. - **MTU and fragmentation.** BLE ATT operates at 23-byte default MTU, negotiable up to ~512. CoAP uses block-wise transfer (Block1/Block2) for any payload larger than a single datagram. Fuzz frames that ignore these boundaries are silently truncated. - **Association and presentation contexts.** DICOM requires the right SOP Class UID and transfer syntax in the negotiated presentation context. Send a C-STORE for a context that was not accepted and the device discards it - no parser ever runs. - **TLS and authentication wrappers.** MQTT and many HL7 v2 deployments are wrapped in TLS with mutual auth. Without a working TLS termination in the use, the fuzzer never reaches the protocol logic. - **Hardware-in-the-loop reality.** BLE GATT on a real device requires a controlled radio, a paired and bonded central, and the device in the right power and connection state. CAN/CANopen fuzzing requires bus access and termination. None of this is push-a-button. A use has to handle the wrapper so the fuzzer can spend its budget on the part of the protocol that actually contains bugs. ## Harness generation per protocol The table below summarizes the practical, FDA-defensible starting points for the protocols medical devices most commonly expose. Tooling choice is a starting point - the use, not the framework, is the deliverable.
Protocol Transport Statefulness Grammar source Tooling start Seed corpus Coverage signal
HL7 v2 MLLP / TCP (often TLS) Framed, ACK/NAK loop v2.x message profiles, conformance statement boofuzz with MLLP wrapper ADT, ORU, ORM, MDM exemplars from spec ACK rate, parser exceptions, log delta
DICOM TCP (DUL), optional TLS Association negotiation, presentation contexts DICOM Part 5/7/8, IODs, SOP Classes pynetdicom + boofuzz, custom mutator Valid C-STORE/C-FIND per accepted context Association success rate, SCP error responses
BLE ATT / GATT BLE link layer + L2CAP Paired/bonded, MTU-negotiated Service/characteristic enumeration, device spec Defensics BLE, sweyntooth-style use, custom on nRF52/ESP Valid characteristic writes, indication round-trips Disconnect rate, link supervision timeouts, watchdog resets
MQTT TCP, almost always TLS Session, QoS state, retained messages MQTT 3.1.1 / 5.0 spec, broker schema boofuzz or libFuzzer with TLS shim Valid CONNECT, SUBSCRIBE, PUBLISH per topic tree CONNACK reasons, broker logs, ACL violations
CoAP UDP, optional DTLS Block-wise transfer, observe RFC 7252 + 7959, device resource map AFL++ persistent on a CoAP library wrapper Valid GET/POST per resource, multi-block PUT Response code distribution, DTLS handshake errors
Proprietary binary Serial, USB-CDC, sub-GHz RF, CAN Custom framing, checksums, sequence Reverse-engineered from pcaps + firmware Custom use over boofuzz blocks or libFuzzer Captured exemplars, mutated within framing constraints CRC accept rate, command ACKs, controller reboots
The fuzzer is the engine. The use - framing, state, transport, oracle - is the deliverable.
### A few harness-design rules that apply across all of these - **Make the use stateful in code, not in luck.** Encode the handshake explicitly so every iteration starts from a known state. - **Treat checksums and length prefixes as fix-ups, not fuzz targets.** Mutate the payload, then recompute the wrapper so the device parses what you sent. - **Define an oracle that the device can signal.** A crash log, a watchdog reset, an MQTT disconnect reason, a DICOM SCP error class - anything stronger than "the connection closed." - **Record everything.** Seed corpus, exact mutations, transport-level captures, target state at the time of the finding. This is what the reviewer asks for. - **Run on real hardware when the threat model says so.** Emulating an RTOS target on x86 is fine for triage, not sufficient as the final coverage statement. ## Where AI legitimately helps (and where it doesn't) Used well, AI compresses the slow parts of fuzz use work: - **Grammar synthesis from pcaps and specs.** LLMs are genuinely useful at turning a packet capture and a PDF spec into a first-draft message grammar (boofuzz blocks, ASN.1 sketch, Kaitai struct), which a human then corrects. - **Seed corpus expansion.** Generating varied-but-valid HL7 v2 messages, DICOM objects per IOD, MQTT topic trees, and CoAP resource sets. - **Crash deduplication and triage.** Clustering thousands of crashes by stack trace, register state, and message prefix, then proposing a candidate root cause for human review. - **Mutator authoring.** Drafting custom mutators for libFuzzer or AFL++ that understand the protocol's framing. Where AI consistently falls down on medical-device fuzzing: - **Stateful orchestration on real targets.** Driving an Association establishment, a BLE pairing/bonding, an MQTT session restoration, or a CAN/CANopen NMT state across many iterations is brittle even for experienced engineers and worse for an agent. - **Hardware-in-the-loop control.** Power cycling the device under test, recovering from a watchdog reboot, re-pairing a BLE central, restoring a UART logger - all manual or scripted human work. - **Crash triage on embedded targets.** Without source, symbols, or a reliable debugger, root-causing a watchdog reset on an STM32 takes a human at the bench reading the trace buffer, not an LLM looking at a log line. - **Threat-model-aligned scope.** AI does not know which characteristics actually carry safety-relevant writes on your specific device. The scoping decision is human. The defensible pattern mirrors the AI pen testing pattern: human-led, AI-augmented, with a named tester signing for scope, coverage, and findings. See our companion piece on [where AI penetration testing fails an FDA reviewer](/blog/ai-penetration-testing-medical-devices-fda-limits) for the longer treatment. ## Process flow: spec to VEX
Fuzz program flow

From spec or pcap to CAPA and VEX

  1. STEP 01 Human + AI
    Spec & pcap to grammar

    LLM drafts message grammar from RFCs, conformance statements, and captures; engineer corrects framing and constraints.

  2. STEP 02 Human
    use authoring

    Engineer encodes state machine, transport, TLS/DTLS, checksum fix-ups, and the device-side oracle.

  3. STEP 03 Human + AI
    Seed corpus

    AI expands valid exemplars per IOD, topic tree, characteristic, or resource; engineer prunes and labels.

  4. STEP 04 Human
    Campaign execution

    Run on real target, hardware-in-the-loop where required, with crash capture, power cycle automation, and coverage logging.

  5. STEP 05 Human + AI
    Triage & dedup

    AI clusters crashes by signature and proposes root cause; engineer confirms exploitability and severity.

  6. STEP 06 Human
    Reproducer

    Minimum-viable repro script and target state captured for the submission and for the dev team to fix against.

  7. STEP 07 Human
    CAPA & VEX

    Findings flow into security risk file, CAPA, and post-launch VEX statements with not_affected, affected, or fixed disposition.

  8. STEP 08 Human signs
    Report & signature

    Named, qualified tester signs the report with methodology, coverage, findings, and disposition for the submission.

Flow
Spec / PCAP→ Grammar→ use→ Corpus→ Campaign→ Triage→ Reproducer→ CAPA / VEX
## Deliverables a reviewer wants to see Per protocol fuzzed, the submission package should include: - **use source** (or a clear pointer to it in your DHF), with the state machine, framing, and oracle visible. - **Seed corpus statistics** - count, sources, generation method, and which exemplars exercise which threat-model paths. - **Coverage report** - basic block, branch, or protocol-state coverage as appropriate. "We ran it for X hours" is not coverage. - **Crash log and dedup summary** - unique crashes, signatures, repro reliability, and whether each crash is reachable from the device's exposed interfaces. - **Disposition** - fixed, mitigated by a compensating control, or accepted with rationale traced to the security risk file. - **Tester qualifications** - the same independence and credentials statement that anchors the rest of the pen test report. - **Tooling and environment** - exact tool versions, target image hash, hardware bench description, AI tooling and model versions if used. This is the package that survives an AI request, a Major Deficiency, or a Hold letter. Without it, the reviewer cannot evaluate whether the fuzz testing actually exercised the threat model - and "we ran a fuzzer" is exactly the phrasing that earns a deficiency. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## Generic fuzzer vs protocol-aware harness The difference is not effort. It is whether the fuzzer ever gets past the first handshake into code that matters. | Aspect | Generic network fuzzer | Protocol-aware harness | | --- | --- | --- | | Gets past authentication or session setup | Rarely | Yes, by construction | | Understands message framing and checksums | No, so packets are dropped early | Yes, so mutations reach the parser | | Code reached in a typical run | Connection handling only | Parsing, state machine, and error paths | | Crash triage | Manual, often duplicated | Deduplicated against the input that caused it | | Evidence quality for a reviewer | Hard to defend coverage | Coverage tied to protocol states and interfaces | | Setup cost | Low | Real, but reusable across releases | ## How Blue Goat Cyber runs this Our medical-device pen testing engagements include protocol-aware fuzz uses per declared interface, built against your threat model and architecture views, run on real hardware where the model requires it, with a named tester owning scope and signing the report. AI is used where it earns its keep - grammar drafting, seed expansion, crash clustering - and disclosed in the report. If you are scoping a 510(k), De Novo, or PMA submission and want fuzz testing that will not invite an AI Request or a Major Deficiency, [book a strategy session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). ## FAQ ### Does the FDA require fuzz testing for medical devices? Section 524B and the February 3, 2026 final premarket cybersecurity guidance require security testing scoped to the threat model, with fuzz testing called out as part of the expected toolkit alongside vulnerability and penetration testing. The agency does not mandate a specific fuzzer, framework, or duration. It does expect a defensible methodology, coverage tied to the threat model, documented findings, and a named, qualified tester. For Class II and III connected devices, omitting fuzz testing is a frequent driver of AI Requests and Major Deficiencies. ### How is medical-device fuzzing different from IT or web fuzzing? Medical devices speak negotiated, framed, stateful protocols (DICOM, HL7 v2 over MLLP, BLE GATT, MQTT, CoAP, proprietary serial, CAN/CANopen) often over wireless or hardware transports, on embedded targets without crash dumps or symbols. Web and IT fuzzing typically targets stateless HTTP request parsers with rich tooling around them. The implication is that medical-device fuzz programs spend most of their effort on the use, the transport, the state machine, and the oracle, not on the fuzzer engine itself. ### Premarket vs postmarket fuzzing - what changes? In premarket, fuzz testing is a controlled, scoped exercise that produces evidence for the submission. In postmarket, the same uses become regression assets you re-run when a third-party component issues a CVE, when a firmware update lands, or when a customer reports anomalous behavior. The premarket use is the asset that pays for itself across the product's lifecycle - especially when it feeds your VEX workflow with reproducible "not affected" or "affected" determinations. ### How long should a fuzz campaign run per protocol? Long enough to plateau on coverage, not a fixed clock. Practical campaigns on a mature parser converge in tens of millions of executions; on a custom binary protocol, they may run for days. The reviewer-friendly statement is coverage-based ("branch coverage plateaued at X% after N hours, no new crashes in M hours") rather than time-based ("we ran for a week"). Document both. ### How do we tie fuzz findings to the security risk file? Each unique finding gets a row in the security risk file with the threat it relates to, the vulnerability, the patient-safety impact, the control (fix, mitigation, or compensating control), and the residual risk. This is the AAMI TIR57 / ANSI/AAMI SW96:2023 pattern. Fuzz findings that do not have a clean traceability line to a threat are the ones reviewers flag - either the threat model is incomplete or the finding's relevance is not justified. Both are fixable; both are easier to fix before submission than after. ### What does "fixed vs accepted" disposition look like for fuzz findings? For each unique crash or anomalous behavior: fixed (code change verified by re-fuzzing the same seed and corpus), mitigated (compensating control such as input length cap, rate limit, or watchdog reset with documented residual risk), or accepted (rationale tied to threat model and patient-safety impact, signed off). Reviewers do not expect zero findings; they expect every finding to have a disposition they can evaluate. Untriaged crashes left in the report are the worst possible outcome. ## Related reading - [Does the FDA Accept AI Penetration Testing for Medical Devices?](/blog/ai-penetration-testing-medical-devices-fda-limits) - [SBOM Diffing and CVE Correlation for Postmarket Medical Devices](/blog/sbom-diffing-cve-correlation-postmarket-medical-devices) - [A Step-by-Step Guide to Threat Modeling Connected and Implantable Medical Devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) - [VEX Mistakes That Trigger FDA Deficiencies](/blog/vex-mistakes-fda-deficiencies) - [CAN Bus and CANopen Vulnerabilities in Medical Devices](/blog/can-bus-canopen-medical-device-vulnerabilities) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## GMP and Medical Device Cybersecurity Compliance Source: https://bluegoatcyber.com/blog/good-manufacturing-practices-gmp-in-medical-devices-ensuring-cybersecurity-compliance # GMP Cybersecurity Compliance: A 2026 Medical Device Compliance Guide > **[DIRECT ANSWER]** Good Manufacturing Practices, codified in 21 CFR Part 820, now require manufacturers to integrate cybersecurity into design controls, risk management, and postmarket surveillance throughout a medical device's lifecycle. The FDA expects documented evidence, such as threat models, SBOMs, and risk assessments, showing cybersecurity was designed in rather than added afterward; gaps in this evidence are a leading cause of premarket Additional Information requests. _Updated November 10, 2024_ In the medical device industry, Good Manufacturing Practices (GMP) form the foundation for ensuring the safety, effectiveness, and quality of devices that enter the market. These practices are crucial for maintaining regulatory compliance and meeting the high standards expected by agencies like the [U.S. Food and Drug Administration (FDA)](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp ""). With the growing integration of digital technology into medical devices, the scope of GMP now extends to ensuring cybersecurity throughout the product’s lifecycle. This article explores the role of GMP in the context of medical devices, emphasizing the importance of incorporating cybersecurity measures into the manufacturing process. ## Key Takeaways - GMP for medical devices must integrate cybersecurity measures. - The FDA requires cybersecurity across the total product lifecycle. - Design controls must incorporate cybersecurity from the start. - Postmarket surveillance is critical for ongoing cybersecurity. - Compliance requires adhering to standards like ISO 14971 and IEC 62304. - Balancing security with device usability is a key challenge. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to gmp for medical device cybersecurity the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding GMP for Medical Devices GMP refers to a set of regulations enforced by the FDA to ensure that products are consistently produced and controlled according to quality standards. For medical devices, these regulations are encapsulated in [21 CFR Part 820](/blog/21-cfr-part-820-and-its-role-in-medical-device-cybersecurity), which specifies the [Quality System Regulation (QSR)](/blog/21-cfr-part-820-and-its-role-in-medical-device-cybersecurity). This framework ensures manufacturers maintain effective quality systems for designing, producing, installing, and servicing medical devices. The principles outlined in the QSR are critical for ensuring that devices meet user needs and perform as intended without posing risks to patient safety. ### Components of GMP in the Context of Medical Devices 1. **Quality Management System (QMS):** A QMS is central to GMP. It involves documentation, standard operating procedures (SOPs), and records that ensure each production stage meets quality standards. In cybersecurity, the QMS must incorporate processes that assess and manage cyber risks throughout the device lifecycle​. This includes conducting regular security audits and integrating cybersecurity risk management practices as outlined in the FDA’s guidance. 2. **Design Control:** Design controls are critical in medical device development, ensuring cybersecurity is considered from the earliest design stages. According to [IEC 62304](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards), which governs medical device software life cycle processes, design inputs must address cybersecurity needs, such as software vulnerabilities and data integrity​. Integrating secure software development practices during design helps identify potential threats early, making it easier to address them before the device reaches the market. 3. **Risk Management:** Risk management, as outlined in [ISO 14971](/blog/iso-14971-risk-management-in-medical-device-security), involves identifying potential hazards, assessing their risks, and implementing controls to mitigate those risks. This includes cybersecurity risks for medical devices that could compromise the device’s safety and effectiveness​. A key aspect is developing a risk management plan that considers both [premarket](/) and postmarket cybersecurity threats. ## The Role of Cybersecurity in GMP Compliance With the increasing digitization of medical devices, cybersecurity has become a crucial element of GMP. The FDA emphasizes the importance of addressing cybersecurity throughout the product lifecycle through its premarket and postmarket guidance. Manufacturers must consider cybersecurity risks during device design, development, and deployment, aligning their practices with the latest regulatory requirements and industry standards​. 1. **Cybersecurity in Design and Development:** Secure design is an essential component of cybersecurity in medical devices. It incorporates security measures from the initial design phase to ensure the device can withstand cyber threats. This concept is often called “secure by design,” which means building devices with security features that prevent unauthorized access and data breaches​. This process aligns with ISO/IEC 27001 and IEC 62304 requirements, ensuring that software development follows a structured and secure approach​. 2. **Postmarket Cybersecurity Management:** Postmarket management is equally critical, involving monitoring for new vulnerabilities, deploying patches, and updating software. The [Medical Device Coordination Group’s (MDCG)](https://health.ec.europa.eu/medical-devices-dialogue-between-interested-parties/medical-device-coordination-group-working-groups_en "") guidance emphasizes the need for manufacturers to maintain a post-market surveillance system that includes cybersecurity incident reporting and response measures​. This ensures that potential threats are swiftly identified and addressed, minimizing the risk of cybersecurity incidents that could compromise patient safety. 3. **Lifecycle Management and Secure Development Practices:** The FDA’s recommended [Total Product Lifecycle (TPLC)](/blog/cybersecurity-measures-and-metrics-for-medical-devices-navigating-fda-compliance) approach underscores the importance of continuous cybersecurity assessment throughout a medical device’s lifecycle​. This approach includes both premarket considerations and postmarket actions, such as software updates, patch management, and communication with end-users regarding security risks. ## Regulatory Guidance and Standards in Cybersecurity for Medical Devices 1. **FDA’s Premarket and Postmarket Guidance:** The FDA provides detailed guidance on the cybersecurity aspects of medical device design and production. These documents stress the need for manufacturers to conduct a cybersecurity risk assessment as part of their design control processes​​. The guidance also emphasizes transparency with end-users, requiring manufacturers to provide documentation highlighting potential cybersecurity risks and mitigations. 2. **ISO and IEC Standards:** Compliance with international standards like [ISO 13485](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity), ISO 14971, and IEC 62304 is essential for ensuring that GMP processes align with best cybersecurity practices. ISO 13485 outlines the requirements for a quality management system in the medical device industry, while ISO 14971 focuses on risk management​. IEC 62304 provides a framework for developing and maintaining medical device software, emphasizing secure software lifecycle management. 3. **EU MDR and IVDR Requirements:** The European Union’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) include specific requirements related to cybersecurity. These regulations mandate that devices incorporating software be developed following principles, including those for managing information security risks​. Manufacturers seeking to place devices on the EU market must demonstrate compliance with these cybersecurity requirements as part of their conformity assessment. ## Challenges in Integrating Cybersecurity into GMP 1. **Balancing Security and Usability:** One of the primary challenges in implementing cybersecurity measures in medical devices is ensuring that these measures do not compromise the device’s usability. A well-designed cybersecurity strategy should protect the device without hindering its functionality or accessibility for healthcare providers and patients. 2. **Keeping Up with Emerging Threats:** The cybersecurity landscape constantly evolves, with new threats emerging regularly. Manufacturers must stay updated on the latest vulnerabilities and threat vectors, which requires a commitment to continuous learning and adaptation. Regular training for QMS and cybersecurity risk management staff is essential to maintaining a proactive approach​. 3. **Resource Constraints:** Implementing cybersecurity measures can be resource-intensive, especially for small and medium-sized manufacturers. This includes the costs of conducting thorough security assessments, maintaining secure development environments, and employing skilled cybersecurity professionals. However, investing in cybersecurity practices can prevent costly recalls and regulatory penalties in the long run. ## Best Practices for Ensuring GMP Compliance with a Focus on Cybersecurity 1. **Adopt a Risk-Based Approach:** Implement a risk-based approach to GMP and cybersecurity, focusing on identifying and mitigating risks that could impact patient safety and data integrity. This involves regular risk assessments and updating mitigation strategies based on new information and emerging threats​. 2. **Integrate Cybersecurity into the Quality Management System:** Ensure cybersecurity considerations are integrated into the QMS, making it a standard part of design reviews, verification, and validation processes. This integration ensures that cybersecurity is not an afterthought but a fundamental aspect of the development process. 3. **Conduct Regular Training and Audits:** Regular training for staff involved in cybersecurity and GMP processes is essential for maintaining compliance. Conduct internal audits to identify gaps in cybersecurity practices and make necessary adjustments to align with the latest regulatory requirements​. 4. **Develop a Postmarket Surveillance Plan:** A well-defined postmarket surveillance plan helps manufacturers monitor the performance of their devices in real-world settings. This plan should include processes for identifying and responding to cybersecurity incidents and updating the device software to address new vulnerabilities​. ## Conclusion In the evolving landscape of medical device manufacturing, GMP remains a cornerstone for ensuring device quality and patient safety. Integrating cybersecurity into GMP processes is not just a regulatory requirement but a crucial step toward protecting patients and healthcare systems from the risks posed by cyber threats. By adopting a proactive, risk-based approach to cybersecurity, manufacturers can meet regulatory standards while enhancing the resilience and reliability of their devices. This strategy ensures that medical devices remain safe, secure, and effective throughout their entire lifecycle, building trust and confidence among users and regulators. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is GMP in the context of medical device cybersecurity? GMP for medical devices, particularly 21 CFR Part 820, mandates a quality system that now includes cybersecurity. This means devices must be designed, manufactured, and maintained with cybersecurity controls to ensure safety and effectiveness. ### How does the FDA incorporate cybersecurity into GMP? The FDA's February 3, 2026 premarket cybersecurity guidance emphasizes integrating cybersecurity risk management into the design, development, and postmarket phases. Manufacturers must conduct risk assessments and implement controls aligned with GMP principles. ### Does secure by design apply to medical device GMP? Yes, "secure by design" is a core principle for medical device GMP. It requires building security features into devices from the initial design phase to prevent unauthorized access and data breaches, aligning with standards such as IEC 62304. ### What postmarket responsibilities do manufacturers have for cybersecurity under GMP? Manufacturers must establish postmarket surveillance systems for cybersecurity, including monitoring for new vulnerabilities, deploying patches, and providing software updates. This ensures ongoing safety and effectiveness throughout the device's lifecycle. ### What standards support GMP for medical device cybersecurity? Key standards include ISO 13485 (quality management), ISO 14971 (risk management), and IEC 62304 (software lifecycle processes). These standards provide frameworks for integrating cybersecurity into GMP. ### Why is lifecycle management important for medical device cybersecurity? Lifecycle management ensures continuous cybersecurity assessment from conception through retirement. This includes premarket considerations and postmarket actions like software updates and vulnerability management, as outlined in the FDA's Total Product Lifecycle (TPLC) approach. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [UL 2900 and Medical Device Cybersecurity](/blog/the-role-of-ul-2900-in-medical-device-security) - [Medical Device Cybersecurity](/blog/medical-device-cybersecurity-the-real-threat-isnt-genius-hackers-its-neglect) --- ## Cellular Connectivity Device Security | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/gsm-cybersecurity-vulnerabilities-medical-devices # Cellular Connectivity Medical Device Security: What to Know > **[DIRECT ANSWER]** Cellular connectivity medical device security depends on treating the cellular network as untrusted transport, regardless of generation. Key risks include 2G/3G downgrade and interception, IMSI catchers, weak eSIM or carrier provisioning, unencrypted data sitting on the modem, and insecure remote update delivery to home-use devices. Manufacturers should disable legacy fallback where feasible, use TLS with mutual authentication end to end, secure eSIM provisioning, encrypt modem-resident data, and document the cellular trust boundary for FDA premarket review. _Reviewed September 17, 2026_ A remote patient monitor, insulin pump, or cardiac device that reports over a cellular network is only as secure as the weakest link between its modem and the manufacturer's cloud, and that link often runs through infrastructure the manufacturer does not control. Cellular networks were not designed with medical-grade integrity guarantees in mind, and legacy 2G and 3G protocols carry documented interception and impersonation weaknesses that persist as fallback options on many modules deployed today. When a device delivers therapy, sends alarms, or receives remote software updates over cellular, a downgrade attack, a rogue base station, or an insecure provisioning process is not a hypothetical, it is a direct path to patient safety and regulatory risk. Getting the architecture right up front is far cheaper than responding to an FDA deficiency letter or a field incident later. ## Key Takeaways - Cellular connectivity medical device security starts with treating the network, not just the crypto, as an active threat surface. - 2G and 3G fallback create the biggest legacy risk; devices should disable these generations where coverage allows. - IMSI catchers exploit weak or absent mutual authentication in older cellular generations to intercept or track devices. - eSIM and carrier provisioning need the same lifecycle discipline as certificate management: secure issuance, rotation, and revocation. - Data at rest on the modem, including logs and cached credentials, needs encryption because modems are rarely audited as carefully as the main application processor. - Remote update delivery over cellular for home-use devices must be resilient to unreliable connections and validated with signed packages. ## Why This Matters Cellular connectivity is the default choice for devices that cannot rely on a patient's home Wi-Fi, including remote cardiac monitors, connected insulin delivery systems, and fleet-managed diagnostic equipment serviced in the field. Unlike Wi-Fi, the manufacturer usually has no visibility into or control over the intermediate network, from the local cell tower to the carrier's core, which means the device's own security controls have to carry more of the burden. This matters for three reasons. First, clinical impact: a device that loses connectivity to a spoofed or degraded cellular signal may miss alarms or delay therapy adjustments, with direct consequences for patient safety. Second, data exposure: cellular data can be intercepted or manipulated when a device is tricked into using weaker legacy protocols, exposing patient telemetry or device commands. Third, regulatory scrutiny: the FDA's current premarket cybersecurity guidance requires manufacturers to document connectivity paths, including cellular, as part of the security architecture and risk assessment. Manufacturers who treat the cellular module as a plug-and-play black box, without documenting its trust boundary and failure modes, typically face additional information requests or discover the gap only after a field issue. ## Why Does 2G/3G Legacy Fallback Create Downgrade Risk? Legacy fallback creates downgrade risk because many cellular modules will silently connect to 2G or 3G networks when a stronger LTE or 5G signal is unavailable, and those older generations have weaker or absent mutual authentication between device and network. GSM's original ciphering, A5/1 and its variants, has known cryptanalytic weaknesses, and some carriers still operate 2G infrastructure for legacy device support or emergency fallback. The practical risk is that an attacker with a rogue base station can force a nearby device onto 2G, then intercept or manipulate its traffic, without the device or user noticing a difference beyond a signal indicator. For a medical device, this can mean exposed telemetry or interrupted communications at exactly the moment reliable connectivity matters most. | Approach | 2G/3G allowed | LTE/5G only | Region-limited fallback | |---|---|---|---| | Interception risk | High during fallback | Low | Low, except in explicitly allowed regions | | Coverage in rural/legacy markets | Best | May be limited | Balanced | | Documentation burden | High (must justify and monitor) | Lower | Moderate | | Recommended default | Avoid unless required | Preferred | Acceptable with monitoring | **[KEY REQUIREMENT]** If 2G or 3G fallback cannot be disabled entirely due to coverage requirements, the decision must be documented with a rationale, scoped to specific regions if possible, and paired with monitoring for unexpected downgrade events in the field. ## What Are IMSI Catchers and Why Do They Matter for Medical Devices? An IMSI catcher is a device that impersonates a legitimate cell tower to capture a device's International Mobile Subscriber Identity and, on older network generations, intercept or manipulate its traffic. They matter for medical devices because a device forced to connect to a rogue tower can have its location tracked, its traffic observed, or its connection disrupted, all without any indication visible to a clinician or patient. Modern LTE and 5G networks include stronger mutual authentication that reduces, but does not eliminate, IMSI catcher effectiveness, since some downgrade and identity-exposure techniques still work against devices that support legacy fallback. Devices that never fall back to 2G/3G and that protect traffic end to end with TLS are substantially more resistant, because even a successful IMSI catcher session yields little beyond encrypted, authenticated traffic. Manufacturers should assume that some fraction of deployed devices will, at some point, encounter a rogue or misconfigured cell tower, whether from an attacker, a testing lab, or interference, and design so that event does not compromise patient data or device integrity. ## How Should Manufacturers Handle eSIM and Carrier Provisioning? eSIM and carrier provisioning should be handled with the same lifecycle discipline as certificate management: secure issuance during manufacturing, controlled rotation, and a clear revocation path if a device is lost, stolen, or decommissioned. Unlike a physical SIM, an eSIM profile is provisioned remotely, which is convenient for fleet management but creates a new attack surface if the provisioning channel itself is not authenticated and encrypted. A common failure mode is treating the carrier's provisioning API credentials as a low-priority secret, when in practice compromise of those credentials could let an attacker reprovision or deactivate devices at scale. Manufacturers should scope provisioning credentials tightly, rotate them on a defined schedule, and log provisioning events for audit and anomaly detection. **[KEY REQUIREMENT]** eSIM provisioning credentials and APIs must be treated as privileged secrets with access logging, rotation, and revocation procedures documented in the same way as device-level cryptographic key management. ## LTE and 5G in Medical Devices: What Actually Changes? LTE and 5G improve on GSM-era security with stronger mutual authentication and better protection against basic impersonation, but they do not eliminate the need for application-layer protections. 5G in particular adds encrypted identifier exchange in some deployment modes, reducing exposure to IMSI-catcher-style tracking, though real-world carrier configurations vary and not all of these protections are universally deployed. The practical change for manufacturers is less about a single "more secure" checkbox and more about module selection and configuration. LTE-M and NB-IoT variants, common in low-power medical telemetry devices, inherit LTE's authentication model but may have different power and bandwidth tradeoffs that affect how often a device can check in or receive updates. | Generation | Mutual authentication | Typical medical device use | Residual risk | |---|---|---|---| | 2G (GSM) | Weak/one-way | Legacy fallback only | High: downgrade, interception | | 3G | Improved but dated | Legacy fallback | Moderate | | LTE / LTE-M / NB-IoT | Strong | Common for telemetry, monitors | Low, with proper configuration | | 5G | Strong, with identity protection in some modes | Emerging for high-bandwidth devices | Low, but carrier configuration varies | Manufacturers should not assume "we use LTE" alone satisfies a security requirement; the module's fallback configuration and the application-layer controls built on top of it determine the actual risk posture. ## Is Data at Rest on the Modem a Real Risk? Yes, data cached or logged on the cellular modem is a real and often overlooked risk, because modems maintain their own storage, logs, and sometimes cached credentials that are rarely audited with the same rigor as the main application processor. Diagnostic logs, cached authentication tokens, or buffered telemetry sitting unencrypted on the modem can be extracted if the device or module is physically compromised. This matters most for devices that are serviced in the field, decommissioned, or resold, where a modem's flash storage may retain data long after the device leaves clinical use. Manufacturers should inventory what the modem stores, encrypt sensitive data at rest where the module supports it, and include modem storage in the device's decommissioning and data-sanitization procedure. ## How Should Remote Updates Be Delivered Over Cellular for Home-Use Devices? Remote updates over cellular for home-use devices should be delivered as signed, integrity-verified packages with resilience built in for unreliable and low-bandwidth connections. Home-use devices cannot depend on stable connectivity the way a hospital network device might, so the update process needs to tolerate interruptions without leaving the device in an inconsistent or unsafe state. Practical design points include chunked or resumable downloads so a dropped connection does not force a full restart, cryptographic signature verification before an update is applied, and a rollback path if an update fails validation or causes a fault after installation. Update servers should also authenticate the device before serving a package, so a compromised or spoofed device identity cannot be used to pull sensitive update content or trigger unnecessary downloads that drain battery or data allowances. **[KEY REQUIREMENT]** Update packages delivered over cellular must be signed and verified on-device before installation, with a documented rollback and safe-state behavior if verification fails mid-update. ## How Blue Goat Cyber Approaches This Blue Goat Cyber helps manufacturers map the full cellular trust boundary, from modem to carrier to backend, before it becomes a late-stage architecture problem. That includes evaluating fallback configuration, eSIM provisioning security, modem data handling, and update delivery design against the threats most relevant to the device's intended use, whether hospital-serviced equipment or a home-use remote monitor. For teams validating these designs, our [medical device penetration testing services](/services/medical-device-penetration-testing) test cellular-connected devices against realistic downgrade, interception, and provisioning abuse scenarios, and our [medical device threat modeling](/services/medical-device-threat-modeling) work produces the documented trust boundary analysis the FDA expects to see tied to your cellular architecture decisions. ## Frequently Asked Questions ### Should medical devices disable 2G entirely? Disabling 2G is the safer default wherever coverage requirements allow it, since 2G carries documented weak-authentication and interception risks. If 2G must remain available for coverage reasons, document the rationale, limit it to specific regions if possible, and monitor for unexpected downgrade events. ### What is an IMSI catcher and can it affect a medical device? An IMSI catcher impersonates a legitimate cell tower to capture device identifiers and, on older network generations, intercept traffic. It can affect medical devices that support legacy fallback, though devices using end-to-end TLS and avoiding 2G/3G are much more resistant to meaningful data exposure. ### Is eSIM more secure than a physical SIM for medical devices? eSIM can be more secure because it supports remote, auditable provisioning and revocation, but only if the provisioning channel and credentials are protected as carefully as any other cryptographic secret. A poorly secured provisioning API can offset the benefits of eSIM's flexibility. ### How is this different from the site's Bluetooth and NFC/RFID coverage? This article covers wide-area cellular connectivity specifically. For short-range wireless risks in medical devices, see our coverage of [Bluetooth in medical devices](/blog/bluetooth-in-medical-devices-understanding-the-risks-and-protecting-patient-safety) and [NFC and RFID security in medical devices](/blog/nfc-rfid-security-medical-devices). ## CTA If your device relies on cellular connectivity for therapy, monitoring, or updates, Blue Goat Cyber can help you threat model the cellular path and build the documentation the FDA expects to see. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to scope the work. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian focuses on medical device cybersecurity for FDA premarket submissions and postmarket compliance, including cellular and wireless architecture review. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity Standards Source: https://bluegoatcyber.com/blog/guide-to-medical-device-cybersecurity-standards-premarket-postmarket-lifecycle # Medical Device Cybersecurity Standards: What Manufacturers Need to Know > **[DIRECT ANSWER]** Medical device manufacturers must align with roughly fourteen core and supplemental cybersecurity standards, including ISO 14971 for risk management, IEC 62304 and IEC 81001-5-1 for the secure software lifecycle, AAMI TIR57 and TIR97 for premarket and postmarket security risk, and UL 2900 for third-party assurance testing. The FDA's February 3, 2026 final guidance operationalizes Section 524B and references this standards stack directly in premarket review. Cybersecurity is no longer optional-it's critical to patient safety and regulatory success. As medical devices increasingly connect to apps, cloud platforms, and hospital networks, manufacturers must follow stringent cybersecurity practices throughout the entire product lifecycle. At Blue Goat Cyber, we specialize in helping medical device manufacturers align with the most critical global standards, frameworks, and FDA guidance. This guide covers the top cybersecurity standards for premarket submissions, postmarket monitoring, and secure development practices that support compliance and risk management. ## Key Takeaways - Core Medical Device Cybersecurity Standards. - Supplemental Cybersecurity Frameworks and Best Practices. - Final Thoughts. - More on this topic. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers apply the same standards stack covered below - software lifecycle expectations from IEC 62304/81001-5-1, risk-management from ISO 14971/AAMI TIR57 / ANSI/AAMI SW96:2023, and the SBOM, SPDF, and postmarket pieces from the 2026 guidance itself. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Core Medical Device Cybersecurity Standards ### 1\. ISO/IEC 27001 - Information Security Management Systems (ISMS) **Overview:** ISO 27001 provides a global framework for establishing and maintaining an organization-wide Information Security Management System (ISMS). It helps secure data, manage vendors, and implement technical controls. **Why It Matters:** Ideal for manufacturers managing protected health information (PHI), cloud platforms, or third-party integrations. **Example:** A company developing a cloud-based patient monitoring platform uses ISO 27001 to enforce data encryption, access control, and incident response. **Link:** [https://www.iso.org/standard/27001](https://www.iso.org/standard/27001 "") ### 2\. ISO 14971 - Risk Management for Medical Devices **Overview:** ISO 14971 defines the risk management process for medical devices, including cybersecurity as a risk source that can impact safety and effectiveness. **Why It Matters:** Required for most FDA and EU MDR regulatory pathways and foundational for identifying and mitigating cyber threats. **Example:** An insulin pump manufacturer uses ISO 14971 to analyze Bluetooth jamming and unauthorized access scenarios, mapping them to patient harm. **Link:** [https://www.iso.org/standard/72704.html](https://www.iso.org/standard/72704.html "https://www.iso.org/standard/72704.html") ### 3\. AAMI TIR57 - Security Risk Management for Medical Devices **Overview:** AAMI TIR57 / ANSI/AAMI SW96:2023 expands on ISO 14971 to address security-specific risks, including threat modeling, attack surface analysis, and likelihood scoring. **Why It Matters:** Highly relevant for FDA premarket submissions, particularly for connected or software-based medical devices. **Example:** A development team applies TIR57 to analyze security risks in a wearable ECG device and integrate mitigations into the design. **Link:** https://webstore.ansi.org/standards/aami/aamitir572016 ### 4\. AAMI TIR97 - Postmarket Cybersecurity Risk Management **Overview:** AAMI TIR97 offers guidance for managing cybersecurity risks after launching a device, including vulnerability disclosure, patching, and monitoring. **Why It Matters:** Supports FDA postmarket guidance and helps organizations manage coordinated disclosures and field safety communications. **Example:** A firmware flaw is discovered in an implantable neurostimulator. TIR97 guides the patch process, user notification, and mitigation documentation. **Link:** https://www.aami.org/standards ### 5\. IEC 62304 - Medical Device Software Lifecycle Processes **Overview:** IEC 62304 standardizes secure software development and maintenance for medical devices. It covers planning, development, validation, and updates. **Why It Matters:** Required for embedded firmware, mobile apps, and SaMD products, especially in FDA and EU regulatory environments. **Example:** A smart inhaler team uses IEC 62304 to manage software configuration, versioning, testing, and documentation. **Link:** [https://www.iso.org/standard/38421.html](https://www.iso.org/standard/38421.html) ### 6\. IEC 81001-5-1 - Security in Health Software Development Lifecycle **Overview:** This newer standard defines how to embed cybersecurity into software development processes, aligning with modern SDLC and FDA expectations. **Why It Matters:** Vital for developers using agile or [DevSecOps](/blog) models and those preparing FDA submissions under the Feb 3, 2026 final premarket cybersecurity guidance. **Example:** A SaMD platform applies IEC 81001-5-1 to implement secure code practices, static analysis, and access control from dev to deployment. **Link:** [https://www.iso.org/standard/76097.html](https://www.iso.org/standard/76097.html "") ### 7\. FDA Cybersecurity Guidance (2023 Final) **Overview:** This FDA guidance sets enforceable expectations for cybersecurity in premarket submissions (510(k), PMA, De Novo), including requirements for SBOMs, threat modeling, secure updates, and documentation of a [Secure Product Development Framework (SPDF)](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect). **Why It Matters:** Required for most new FDA device submissions. Missing elements may trigger a Refuse to Accept (RTA) response. **Example:** A team submitting a wireless-connected glucose meter uses the guidance to include SBOM, threat analysis, and secure update architecture. **Link:** [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket") ## Supplemental Cybersecurity Frameworks and Best Practices ### 8\. NIST SP 800-53 - Security and Privacy Controls **Overview:** This widely adopted NIST standard outlines security controls used across federal systems and is often used by healthcare and medical device vendors to secure enterprise and cloud environments. **Example:** A cloud-hosted health data platform implements access control, encryption, and auditing based on NIST SP 800-53. **Link:** [https://csrc.nist.gov/publications/detail/sp/800-53/rev-5/final](https://csrc.nist.gov/publications/detail/sp/800-53/rev-5/final) ### 9\. NIST SP 800-30 - Risk Assessments **Overview:** This standard outlines best practices for performing structured risk assessments, particularly around cybersecurity threats and system vulnerabilities. **Example:** A pen test team uses NIST 800-30 to evaluate the likelihood and impact of potential exploits in an internet-connected infusion pump. **Link:** [https://csrc.nist.gov/publications/detail/sp/800-30/rev-1/final](https://csrc.nist.gov/publications/detail/sp/800-30/rev-1/final) ### 10\. NIST SP 800-82 - Guide to ICS Security **Overview:** Focuses on securing control systems like those used in industrial and healthcare devices with real-time, actuator-based functionality. **Example:** A surgical robotics platform uses 800-82 to analyze and mitigate command injection and actuator hijacking risks. **Link:** [https://csrc.nist.gov/publications/detail/sp/800-82/rev-2/final](https://csrc.nist.gov/publications/detail/sp/800-82/rev-2/final) ### 11\. IMDRF Cybersecurity Principles and Practices **Overview:** It provides globally harmonized cybersecurity principles aligned with FDA and EU MDR expectations, covering risk management and lifecycle responsibility. **Example:** An international device manufacturer uses IMDRF guidance to unify cybersecurity planning across its U.S. and EU markets. **Link:** [https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity](https://www.imdrf.org/documents/principles-and-practices-medical-device-cybersecurity) ### 12\. UL 2900 Series - Software Cybersecurity for Connected Products **Overview:** This UL standard defines security testing and assurance criteria for network-connectable devices, including medical technology. It is often used for third-party certifications. **Example:** A surgical camera system vendor pursues UL 2900-2-1 certification to validate its cybersecurity posture to healthcare buyers. **Link:** https://standardscatalog.ul.com/standards/en/standard\_2900-1 ### 13\. IEC 62443-4-1 - Secure Product Development Lifecycle Requirements **Overview:** IEC 62443-4-1 is part of the industrial cybersecurity standard series but is increasingly applied to medical devices due to their embedded and connected nature. It defines a secure development lifecycle (SDL) for developing secure products, covering requirements like threat modeling, secure coding, vulnerability management, and patching. **Why It Matters:** This standard benefits manufacturers of embedded devices, IoT-enabled platforms, and network-connected components. It helps demonstrate that security is embedded in the entire development process, from planning through decommissioning. **Example:** A company developing a connected infusion pump applies IEC 62443-4-1 to structure its secure development practices, integrate vulnerability tracking into DevOps, and document cybersecurity controls for FDA review. **Link:** [https://webstore.iec.ch/en/publication/33615](https://webstore.iec.ch/en/publication/33615 "https://webstore.iec.ch/en/publication/33615") ### 14\. IEC 60601-4-5 - Medical Electrical Equipment: Safety - Security in Essential Performance **Overview:** IEC 60601-4-5 is an extension of the foundational IEC 60601 family, which governs electrical safety and performance of medical devices. This part focuses on how cybersecurity threats impact essential performance and basic safety, aligning risk management with functional safety. **Why It Matters:** It bridges the gap between traditional safety standards and modern cybersecurity requirements, particularly useful for devices that deliver therapy, monitor critical functions, or interact with patient physiology. **Example:** A ventilator system manufacturer uses IEC 60601-4-5 to evaluate how a denial-of-service or unauthorized remote command could affect ventilation performance and patient safety. **Link:** https://webstore.ansi.org/standards/IEC/iectr60601eden2021 Note that 60601-4-5 is a technical report, not a conformity standard, and the rest of the IEC 60601 family contains no cybersecurity requirements at all. See [IEC 60601 and cybersecurity: what it covers](/guides/iec-60601-medical-device-cybersecurity) for the full breakdown of which sub-parts touch security and which do not. ## Final Thoughts Adopting these cybersecurity standards and aligning with FDA guidance gives your product a competitive edge-enhancing patient safety, accelerating time to market, and reducing regulatory risk. At Blue Goat Cyber, we help manufacturers map these frameworks into secure architectures, FDA-ready documentation, and real-world protection strategies. ### Ready to Align Your Device with the Right Cybersecurity Standards? Let’s secure your product, from concept to submission and beyond. Schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session "Discovery Session") with us to see how we can help! ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the primary FDA guidance for medical device cybersecurity? The primary guidance is the FDA's February 3, 2026 final guidance on Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions. It outlines enforceable requirements for cybersecurity documentation in premarket submissions. ### Does ISO 14971 cover cybersecurity risks? Yes, ISO 14971 defines the risk management process for medical devices and includes cybersecurity as a potential source of harm to patient safety and device effectiveness. It is foundational for identifying and mitigating cyber threats. ### How does AAMI TIR97 help with postmarket cybersecurity? AAMI TIR97 provides guidance for managing cybersecurity risks after a device has been launched. This includes procedures for vulnerability disclosure, patching, and continuous monitoring, supporting the FDA's postmarket expectations. ### Why is IEC 62304 important for medical device software? IEC 62304 standardizes secure software development and maintenance processes for medical devices. It covers planning, development, verification, and validation, making it essential for embedded firmware, mobile applications, and Software as a Medical Device (SaMD) products. ### What is a Secure Product Development Framework (SPDF)? An SPDF is a set of processes that integrates security activities throughout the entire product lifecycle, from design to decommissioning. The FDA February 3, 2026 guidance expects manufacturers to document their SPDF within premarket submissions. ### Can NIST standards apply to medical device cybersecurity? Yes, NIST Special Publications like NIST SP 800-53 (Security and Privacy Controls) and SP 800-30 (Risk Assessments) provide valuable frameworks and best practices that medical device manufacturers can adapt to enhance their cybersecurity programs. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [How Much Does Medical Device](/blog/medical-device-cybersecurity-cost) - [FDA Cybersecurity Failure Consequences](/blog/fda-cybersecurity-failure-consequences-medical-devices) - [Premarket FDA Cybersecurity Checklist](/guides/fda-premarket-cybersecurity-submission-checklist) --- ## H-ISAC and Medical Device Threat Source: https://bluegoatcyber.com/blog/h-isac-medical-device-threat-intelligence-sources # H-ISAC and Where to Monitor Medical Device Cybersecurity Threats in 2026 > **[DIRECT ANSWER]** Section 524B(b)(1) requires manufacturers to maintain a written postmarket monitoring plan naming their intelligence sources, review cadence, and responsible owners. For medical devices, that plan should include H-ISAC threat sharing, CISA KEV and ICS medical advisories, NVD and vendor advisories covering SBOM components, and coordinated disclosure intake generated by the manufacturer's own CVD policy, combined into one traceable, auditable process. The FDA does not let manufacturers say "we monitor for threats" and stop there. Section 524B(b)(1) requires a written postmarket plan that names *where* you watch, *how often*, and *who acts on what you find*. Reviewers increasingly ask for that list by source, and a plan that only cites NVD draws deficiencies because NVD alone misses the sector-specific exploitation chatter that hits health delivery organizations first. The Health Information Sharing and Analysis Center (H-ISAC) is the anchor most mature programs build around, but it is one feed in a stack. This guide walks through the authoritative sources, what each one actually delivers, and how to wire them into your SBOM and vulnerability management workflow without drowning the team. ## Key Takeaways - H-ISAC delivers sector-specific, TLP-coded threat intelligence and runs the Medical Device Security Council, the only working group focused on manufacturer-side concerns. - CISA's KEV catalog and ICS advisories surface actively exploited vulnerabilities faster than NVD and are the FDA's de facto signal for what counts as an urgent postmarket risk. - NVD and CVE.org are the baseline machine-readable feeds your SBOM monitoring tooling consumes, but they lag exploitation reality by days to weeks. - MITRE ATT&CK for ICS and CAPEC give you the adversary technique vocabulary reviewers expect to see in threat models and postmarket plans. - Upstream vendor PSIRTs (Linux kernel, OpenSSL, BusyBox, chipset vendors) are the only authoritative source for component vulnerabilities before they reach NVD. - A defensible §524B(b)(1) plan names each source, the monitoring cadence, and the trigger criteria that move a finding into your CAPA or expedited update process. ## Why this matters The FDA's February 3, 2026 final premarket cybersecurity guidance ties premarket approval to a credible postmarket monitoring plan, and Section 524B(b)(1) of the Federal Food, Drug, and Cosmetic Act makes that plan a statutory obligation for cyber devices. Reviewers want named sources, not "industry feeds." A 2024 [CISA fact sheet on the healthcare and public health sector](https://www.cisa.gov/topics/critical-infrastructure-security-and-resilience/critical-infrastructure-sectors/healthcare-and-public-health-sector) notes the sector is among the most-targeted critical infrastructure verticals, and CISA's [Known Exploited Vulnerabilities catalog](https://www.cisa.gov/known-exploited-vulnerabilities-catalog) is the operational signal federal agencies use to prioritize remediation. AAMI TIR97 explicitly calls for documented threat intelligence inputs to postmarket security risk management, and IEC 81001-5-1 §9.4 ties continued monitoring to the secure development lifecycle. A submission that lists only NVD as the monitoring source ignores all of this and reads, to a reviewer, as a paper exercise. ## What is H-ISAC and what does it deliver? The [Health Information Sharing and Analysis Center](https://h-isac.org/) is the sector ISAC for healthcare, recognized under Presidential Policy Directive 21. Membership is paid and tiered, and the value is in what the public feeds do not show: pre-disclosure indicators, TLP:AMBER and TLP:RED briefings, peer-to-peer incident sharing, and the Medical Device Security Council (MDSC), a working group focused specifically on manufacturer obligations. For device manufacturers, the high-use outputs are the Daily Cyber Headlines and Threat Bulletins, the monthly Hacking Healthcare report, and MDSC working sessions where peers discuss in-the-wild exploitation against medical equipment before CVEs are public. H-ISAC also operates a 24x7 Threat Operations Center that members can query directly. > **[KEY REQUIREMENT]** If your postmarket plan claims to monitor "industry threat sharing," reviewers expect a named ISAC. For healthcare devices, that is H-ISAC. Naming it, and documenting that you triage its bulletins on a defined cadence, is the cleanest way to satisfy the sharing-and-coordination expectation in the FDA's 2026 guidance. ## What does CISA provide that H-ISAC does not? CISA is the federal operational arm for critical infrastructure cybersecurity, and three of its feeds are non-negotiable for medical device monitoring. The [Known Exploited Vulnerabilities catalog](https://www.cisa.gov/known-exploited-vulnerabilities-catalog) lists CVEs with confirmed active exploitation in the wild. The FDA treats KEV listings as a strong indicator that a vulnerability warrants out-of-cycle patching under §524B(b)(2)(B). If a component in your SBOM appears in KEV, you have a clock running. CISA's [ICS Advisories](https://www.cisa.gov/news-events/cybersecurity-advisories) (formerly ICS-CERT) are where the vast majority of medical device CVEs are formally disclosed, often co-authored with the FDA and the manufacturer. Subscribing to the ICS advisory feed catches device-specific disclosures that never appear in the general CISA bulletin. CISA also publishes Binding Operational Directives and sector-specific alerts that, while not binding on manufacturers, telegraph what the federal government considers urgent and frequently foreshadow FDA Safety Communications. ## Where do NVD, CVE.org, and MITRE fit? These are the baseline machine-readable feeds that automated SBOM monitoring tooling (Dependency-Track, OWASP DC, commercial SCA) consumes. | Source | What it gives you | What it does not | |---|---|---| | [NVD](https://nvd.nist.gov/) | CVSS scores, CPE matching, CWE mapping | Lags CVE publication; no exploitation signal | | [CVE.org](https://www.cve.org/) | Authoritative CVE records as published by CNAs | No scoring, no exploitation context | | [MITRE ATT&CK for ICS](https://attack.mitre.org/matrices/ics/) | Adversary technique taxonomy reviewers expect in threat models | Not a vulnerability feed | | [MITRE CWE](https://cwe.mitre.org/) | Weakness taxonomy used in IEC 81001-5-1 traceability | Not exploitable findings | | [MITRE CAPEC](https://capec.mitre.org/) | Attack pattern catalog used in threat enumeration | Not real-time | NVD is necessary but not sufficient. Treat it as the SBOM correlation feed and pair it with KEV for prioritization and H-ISAC for sector context. ## Which vendor and community sources matter for medical devices? The components in your SBOM are disclosed by their owners first and reach NVD second. If you only watch NVD, you are days or weeks behind. - **Linux kernel security mailing list** and **distribution PSIRTs** (Red Hat, Debian, Yocto) for the OS layer - **OpenSSL Security Advisories** and **BusyBox** project notices for ubiquitous embedded components - **Chipset and SoC vendor PSIRTs** (NXP, STMicro, Qualcomm, Intel) for firmware-level disclosures - **Open Source Vulnerabilities (OSV.dev)** for a normalized cross-ecosystem feed - **FDA Medical Device Safety Communications** at [fda.gov](https://www.fda.gov/medical-devices/medical-device-safety/safety-communications) for device-specific alerts the agency issues directly - **MAUDE** for adverse event reports that may indicate cyber-related malfunction patterns - **Your own Coordinated Vulnerability Disclosure intake** - required under §524B(b)(1), and one of the highest-quality intelligence sources you will ever operate because the reports come pre-targeted to your product > **[KEY REQUIREMENT]** Map each component class in your SBOM to a named upstream source. "We watch upstream vendors" without enumeration is the most common §524B(b)(1) deficiency pattern we see. ## How should these feeds map to your §524B postmarket plan? A defensible plan has four columns for every source: what feed, who owns it, what cadence, and what triggers action. A minimal worked example: ```text Source Owner Cadence Trigger H-ISAC bulletins Security PM Daily TLP:AMBER+ on device class CISA KEV SBOM tooling Continuous Any SBOM component listed CISA ICS adv. Security PM Daily Any advisory naming our class NVD (via SCA) SBOM tooling Continuous CVSS >= 7 on SBOM component Vendor PSIRTs Eng leads Per release Any advisory on shipped version CVD intake PSIRT Real-time Any valid report ``` Triggers should route to either your CAPA system, your expedited out-of-cycle update process under §524B(b)(2)(B), or your acknowledged risk register, with the routing decision documented per finding. Reviewers ask for evidence of the *process*, not the queue. [Talk to our team about a §524B postmarket plan review](/contact) - we'll benchmark your current source list against what the FDA is currently flagging in deficiency letters. ## How Blue Goat approaches threat intelligence integration We build postmarket monitoring plans the way reviewers grade them: by source, cadence, and trigger. Our team holds CISSP and OSCP credentials, includes ex-military red team operators, and works exclusively on medical device cybersecurity. We map every component class in your SBOM to a named authoritative source, write the trigger logic into your QMSR procedures, and tie the routing into your CAPA system so a KEV listing or H-ISAC bulletin produces a documented decision, not an email thread. Where clients lack H-ISAC membership, we help build the business case and document the interim compensating sources. Learn more at [Postmarket SBOM and VEX Monitoring](/services/postmarket-sbom-vex-monitoring). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is H-ISAC and do medical device manufacturers need to join? H-ISAC is the Health Information Sharing and Analysis Center, the federally-recognized ISAC for healthcare. Manufacturers are not required by statute to join, but the FDA's 2026 guidance points to ISAC participation as evidence of credible sharing and coordination, and H-ISAC's Medical Device Security Council is the only working group focused on manufacturer obligations. ### Is CISA KEV the same as NVD? No. NVD catalogs all CVEs with CVSS scores. KEV is a curated subset of vulnerabilities with confirmed in-the-wild exploitation. KEV is the prioritization signal; NVD is the baseline catalog. A vulnerability can sit at CVSS 6.5 in NVD and still warrant emergency patching if it lands in KEV. ### Where are most medical device CVEs disclosed? The majority of medical device CVEs are published through CISA's ICS Advisories feed, typically co-authored by CISA, the FDA, and the manufacturer. Subscribing to that specific feed catches device disclosures the general CISA bulletin omits. ### Does monitoring NVD alone satisfy §524B(b)(1)? No. NVD lags exploitation reality and provides no sector context. A plan that names only NVD reads as a paper exercise and routinely draws deficiencies. Add H-ISAC, CISA KEV, CISA ICS advisories, and upstream vendor PSIRTs at minimum. ### How often should we review threat intelligence feeds? Automated feeds (NVD via SCA, KEV) run continuously. Human-curated sources (H-ISAC bulletins, ICS advisories) should be triaged daily by a named owner. Monthly cadence is too slow and is a common deficiency pattern reviewers cite. ### What is the role of vendor PSIRTs? Upstream component owners disclose vulnerabilities to their security advisory channels before records reach NVD. For SBOM components like the Linux kernel, OpenSSL, or chipset firmware, the PSIRT is the authoritative first source and the only way to catch issues in time for an out-of-cycle update decision. ## Ready to harden your postmarket monitoring? [Schedule a discovery session](/contact) to map your SBOM to a named-source monitoring plan that holds up under FDA scrutiny. If we submit it and the FDA raises cybersecurity deficiencies, we resolve them at no additional cost. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, and has built postmarket threat intelligence programs for manufacturers ranging from Class II wearables to Class III implantables. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [CISA KEV Catalog for Medical Devices](/blog/cisa-kev-catalog-medical-devices) --- ## Hacking DICOM: Medical Imaging Security Risks Source: https://bluegoatcyber.com/blog/hacking-dicom-medical-images # Hacking DICOM: for Medical Device Manufacturers > **[DIRECT ANSWER]** DICOM, the medical imaging standard, carries real security risks because its preamble can hide executable code that many antivirus tools skip to avoid deleting patient data, and DICOM servers commonly ship with weak authentication, plaintext transfers, and web-server-class vulnerabilities. Manufacturers should enforce TLS, require authentication on all queries, segment imaging networks, patch DICOM toolkits like DCMTK, and document these controls in their SBOM and threat model for FDA review. Digital Imaging and Communications in Medicine, or DICOM, is the industry standard for medical imaging formats. This format has expanded functionality compared to typical image formats, as it can store patient data and procedure information along with the actual image. Typically, a specialized DICOM server will parse DICM files, or a Picture Archiving and Communication System (PACS) server. This data can be passed physically on a CD or drive, or digitally via TCP. DICOM images also have support for transfer to more common image formats, such as PNG. ## Key Takeaways - DICOM files store sensitive patient and procedure data. - Preamble attacks can embed malware in DICOM files. - DICOM servers often share common web server vulnerabilities. - Misconfigurations expose DICOM servers to risks and data exfiltration. - Strong authentication and encryption are critical for DICOM security. - Antivirus should scan DICOM files, quarantining suspicious ones. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to hacking dicom medical images the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Hacking DICOM Images Security researchers may not be as familiar with [DICOM](https://www.dicomstandard.org/ "DICOM") as with other protocols due to the narrow use cases and lack of application in day-to-day life outside of the medical field. This is a double-edged sword, as it means that hackers will typically understand it poorly, but it also means the same for defenders. The DICOM format rarely changes due to the massive overhaul that would be needed in hospitals around the world. By nature of being used for medical imaging, DICOM files store extremely sensitive data. Regulations such as HIPAA have strict guidelines for how medical data is processed. With more well-understood formats, such as PDF or DOCX files, these guidelines may be more straightforward. This is just since far more people are comfortable with these files. DICOM files may be handled improperly far more frequently. There are many different tools available for processing DICOM files to perform some sort of analysis. This analysis is often done on the image itself to identify potentially dangerous results, such as imaging to detect cancer. When processing like this is done, a commonly forgotten step is anonymizing data. This prevents files from being compromised and patient data from being leaked to the attackers. A vulnerability specific to the DICOM format is preamble attacking. The DICOM preamble is a section of the file that facilitates transfers to other file formats. This is intended for transfer to other image formats, but it is possible to run executable files through DICOM images. An extremely dangerous part about this is the fact that antivirus is often told to avoid DICOM files due to the risk of PHI getting deleted. This means that attackers can often supply malware through DICOM files without getting detected. ## Hacking DICOM Servers DICOM servers are prone to many vulnerabilities and misconfigurations. Similar to many other file-share systems, data mishandling is pervasive. DICOM servers need to be well-hardened against attacks to prevent regulatory breaches. Aside from compliance problems, compromise of DICOM files can result in customer distrust. This can be damaging to the image and identity of the company. In many cases, DICOM servers operate in a similar way to traditional web servers. This means that they are [commonly associated with the same vulnerabilities that web servers](/blog) are associated with. CVEs are regularly assigned to various DICOM servers as vulnerabilities are discovered. Many of these can be extremely dangerous, such as remote command execution or various buffer overflows. Not only will these vulnerabilities lead to compromise of the DICOM server, but they may lead to lateral movement into the internal network. Misconfigurations are common in DICOM servers. DICOM servers may be exposed to the internet where attackers can attempt to interact with them. If the specific server has known vulnerabilities, this can lead to easy access to the internal network. There are rarely good reasons to expose these servers. Even if the server is fully patched, certain misconfigurations can lead to dangerous situations. DICOM servers support queries to pass in or pull out data. This allows for transfer of information within a hospital, but when servers are exposed, it may be possible for hackers to extract data. These servers commonly have no form of authentication or very weak authentication. It is often trivial for hackers to simply query the server and receive sensitive patient data. Another flaw that may be found in DICOM servers relates to how data is processed. Some servers may be configured to pass data over plaintext. When this is the case, a hacker would just need to be in a position to sniff network traffic and they could intercept DICOM transfers and see patient data in the clear. DICOM servers should always be configured to use TLS when transferring data for maximum security. ## Notable DICOM and PACS Vulnerabilities A handful of CVEs illustrate why DICOM and PACS deployments deserve sustained scrutiny rather than a one-time pen test: - **CVE-2019-11687 (Orthanc)** - authentication bypass in the popular open-source DICOM server when the REST API was exposed without credentials. - **CVE-2020-11176 / CVE-2020-11175 (DCMTK)** - heap-based buffer overflow and out-of-bounds read in the widely-embedded DCMTK toolkit; reachable through crafted DICOM associations. - **CVE-2022-1080 (Horos / Osirix lineage)** - DICOM parser memory corruption affecting viewer software used in research and clinical settings. - **HDG-201801 / "PwnedPiper" class issues** - research from Shodan-based scans has repeatedly shown thousands of internet-exposed DICOM endpoints leaking studies and PHI without authentication. The pattern is consistent: parser bugs in long-lived C/C++ toolkits (DCMTK, GDCM, dcm4che) plus default-open network services. Both vectors land squarely inside the FDA's expectations for SBOM disclosure and postmarket vulnerability management. ## DICOM and the FDA's 524B Expectations Under Section 524B and the February 3, 2026 premarket cybersecurity guidance, any cyber device that speaks DICOM (imaging modalities, viewers, AI inference servers, PACS gateways) needs to demonstrate that DICOM-specific risks are accounted for in the submission, not just generic network controls. Reviewers commonly look for: - **Threat model coverage** - DICOM C-STORE, C-FIND, C-MOVE, and WADO interfaces enumerated as trust boundaries with explicit STRIDE entries. - **SBOM precision** - exact versions of DCMTK, GDCM, dcm4che, Orthanc, or pynetdicom, including transitive dependencies, with VEX statements for any unpatched CVEs. - **Authentication posture** - TLS with mutual authentication (DICOM TLS profile) or evidence that the device is constrained to a segmented imaging VLAN with compensating controls. - **Preamble / parser hardening** - fuzzing evidence against the DICOM parser, antivirus integration that does *not* blanket-exclude `.dcm`, and monitoring for non-imaging preamble magic numbers. - **Postmarket monitoring** - a documented process for tracking CVEs in the DICOM stack and pushing patches within the timelines committed to in the submission. If you have seen the FDA flag DICOM specifically in a deficiency letter, it is almost always one of these five buckets. Our [FDA Cybersecurity Deficiency Letter examples guide](/guides/fda-cybersecurity-deficiency-letter-examples) walks through how these come back worded in practice. ## Securing DICOM - Practical Checklist DICOM files should be monitored for malicious preambles. The preamble will be the first bytes of the file with the first four dictating what the file is meant to be transformed to. Seeing anything besides known imaging formats should immediately set off alarms that something is off. DICOM files should also be scanned by antivirus software. To prevent patient data from being deleted, questionable files should be flagged and quarantined. Any DICOM servers should be confined to the internal network. There will rarely be situations where it is a good idea to leak them to the open internet. Even internal servers should be fully kept up to date and transfer data over encrypted communication channels. This prevents further compromise if an attacker gets into the internal network through other means. DICOM servers should also be configured to use appropriate authentication. Concretely, for a device or PACS deployment that needs to hold up under FDA review and a hospital security questionnaire: 1. Enforce the DICOM TLS profile (or wrap C-STORE in mTLS via a gateway) - never run plaintext DIMSE over routable networks. 2. Require AE Title plus user-level authentication; disable anonymous queries on C-FIND / C-MOVE. 3. Segment imaging modalities and PACS onto a dedicated VLAN with allow-list firewall rules between modality, PACS, viewer, and any AI inference service. 4. Patch DCMTK / GDCM / dcm4che / Orthanc on the same cadence as your OS - track them in your SBOM and publish a VEX entry for any CVE you are not patching. 5. Scan inbound DICOM with malware tooling that inspects the preamble; alert on any preamble that is not a known imaging signature. 6. Log every association, query, and retrieve to a SIEM; PHI exfiltration via C-MOVE is otherwise invisible. 7. Fuzz your own DICOM parser (or your vendor's) - most exploitable bugs in this space are reachable from a single malformed dataset. Check out our [medical device cybersecurity FDA compliance package](/) or our [medical device penetration testing service](/services/medical-device-penetration-testing) if you need an external team to validate the DICOM attack surface on your device or PACS deployment. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is DICOM used for? DICOM (Digital Imaging and Communications in Medicine) is the standard for medical imaging. It stores images, patient data, and procedure information, facilitating communication between medical devices and systems. ### How can DICOM files be exploited? DICOM files can be exploited through 'preamble attacking,' where malicious executable code is hidden within the file's preamble, bypassing traditional antivirus scans that often exempt DICOM files due to PHI deletion concerns. ### Why are DICOM servers vulnerable? DICOM servers are vulnerable due to common web server weaknesses, misconfigurations like internet exposure, weak or absent authentication, and unencrypted data transmission, leading to data breaches and network compromise. ### Does the FDA regulate DICOM security? The FDA expects medical device manufacturers to address cybersecurity for all components, including those utilizing DICOM. The February 3, 2026 final guidance outlines expectations for securing medical devices throughout their lifecycle. ### What is a DICOM preamble attack? A DICOM preamble attack involves embedding malware in the file's preamble, a section used for format conversion. This can allow attackers to execute malicious code when the DICOM file is processed. ### How can DICOM servers be secured? Secure DICOM servers by confining them to internal networks, implementing strong authentication, enforcing TLS encryption for all data transfers, and regularly patching identified vulnerabilities. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Hardware Hacking Tools for Medical Device Security Testing Source: https://bluegoatcyber.com/blog/hardware-hacking-tools-medical-device-cybersecurity # Hardware Hacking Tools Used in Medical Device Testing > **[DIRECT ANSWER]** Hardware security testing of a medical device relies on a small, stable toolkit: a logic analyzer and USB-to-serial adapter for finding and using debug interfaces, a JTAG or SWD probe for processor access, a flash programmer for extracting firmware, a software defined radio for wireless analysis, and an oscilloscope and soldering equipment for physical work. Each tool answers a specific question about what an attacker with the device in hand can reach. _Reviewed September 17, 2026_ Hardware testing exists because an attacker can buy your device. Once a physical unit is on a bench, the interfaces you left on the production board are available, the flash chip can be read, and the radio can be observed without your app in the way. None of that is visible to a software-only assessment. This is a working overview of the tools used in authorized testing, what each one proves, and what the findings mean for your submission. It is written for manufacturers deciding what their testing should cover, not as instructions for unauthorized access. ## Key Takeaways - Hardware testing answers what an attacker with physical possession can achieve. - Debug interfaces left active on production boards are the single most common finding. - Firmware extraction from flash is straightforward without encryption at rest. - Software defined radios let a tester observe a proprietary protocol without your app. - Hardware findings often require board changes, so test before the design freezes. - Testing must be authorized, documented, and performed on units you own or control. ## Why Physical Attacks Belong in Your Threat Model Medical devices are not kept in datacenters. They sit in clinic rooms, in patients' homes, in ambulances, and on resale sites. An attacker who wants to understand your device does not need to breach a hospital; they need to buy a used unit. Once they have one, they can spend unlimited time on it without anyone noticing, and anything they learn applies to every unit you shipped. That last point is what makes hardware findings serious. A secret extracted from one device's flash is frequently a secret shared across the fleet, which converts a single physical compromise into a remote capability against every deployed unit. The February 3, 2026 premarket cybersecurity guidance expects the threat model to consider physical access, and reviewers ask about it when the architecture shows a device used outside a controlled environment. The hardware layer is also where the most expensive findings live. A firmware bug is a build; an exposed debug interface on a production board may require a board revision, and board revisions have lead times measured in months. ## The Core Toolkit and What Each Tool Proves | Tool | What it does | What a finding means | |---|---|---| | Logic analyzer | Captures digital signals on board traces and test points | Identifies live UART, SPI, or I2C interfaces on the production board | | USB-to-serial adapter | Connects to a UART console | Reveals boot logs, shells, or an unauthenticated console | | JTAG or SWD probe | Debug access to the processor | Halt, single-step, read memory, sometimes bypass protections | | Flash programmer or reader | Reads memory chips directly, in place or removed | Firmware and stored secrets recoverable without encryption at rest | | Software defined radio | Receives and transmits arbitrary radio protocols | Proprietary protocols can be observed, replayed, or spoofed | | Bluetooth and Wi-Fi test radios | Protocol-level wireless testing | Pairing, reconnection, and authorization weaknesses | | Oscilloscope | Analog signal analysis | Timing behavior, glitch susceptibility, side-channel indicators | | Soldering and rework station | Attaches probes, removes chips | Enables the access the other tools require | | Microscope | Board inspection and fine rework | Identifies test points and chip markings | | Bench power supply | Controlled power delivery | Supports fault injection and brownout behavior testing | The logic analyzer and serial adapter combination produces more findings than anything else on the list, because unpopulated headers and test pads are routinely left connected on production boards. They were needed for development, nobody disabled them for production, and they frequently drop the tester into a root shell. **[KEY REQUIREMENT]** Confirm, in writing, what your production boards expose. The answer should come from testing a production unit, not from reviewing the design intent, because the two often differ. ## What Hardware Testing Typically Finds | Finding | How it is discovered | Consequence | |---|---|---| | Active UART console | Logic analyzer plus serial adapter | Boot logs, configuration, sometimes an unauthenticated shell | | Enabled JTAG or SWD | Probe attached to test points | Memory read and write, debug control of the processor | | Unencrypted firmware in flash | Flash reader, in place or after chip removal | Full firmware for offline analysis; credentials and keys | | Hardcoded or shared secrets | Firmware analysis after extraction | A fleet-wide compromise from one physical unit | | No secure boot | Modified firmware flashed back and executed | Persistent attacker-controlled code on the device | | Unauthenticated update acceptance | Crafted image applied over the update path | Remote compromise if the same path is network reachable | | Proprietary radio without authentication | SDR capture and replay | Commands accepted from an unauthorized transmitter | | Glitch-susceptible boot | Controlled power or clock disturbance | Security checks bypassed during startup | The chain from an extracted firmware image to a shared secret to a remote attack is the pattern that turns a hardware finding into a submission-level problem. It is also the reason reviewers treat "an attacker would need physical access" as a weaker mitigation argument than manufacturers expect. ## What Hardware Testing Does Not Tell You Hardware testing has limits worth stating so the scope is honest. It does not evaluate your cloud services, it does not assess your mobile application's logic, and it does not substitute for source code review. It also produces destructive outcomes sometimes, which is why testers ask for multiple units. It is also not, on its own, proof that your security requirements were implemented. A test that fails to extract firmware on a given day shows that this tester, in this time budget, with this equipment, did not succeed. Verifying that your documented controls exist and function is a separate activity, and both belong in the evidence package. ## Doing This Legally and Safely Every technique here is legitimate on equipment you own or are authorized to test, and problematic otherwise. Authorized testing has a written agreement that names the devices, the permitted techniques, and the disclosure path for findings. Testing is performed on units removed from clinical use, on an isolated bench, with radio work conducted so as not to interfere with equipment in use nearby. Findings involving third-party components follow coordinated disclosure to the component vendor, and findings in fielded devices follow your vulnerability disclosure process. If your product incorporates a chipset with a known advisory history, your SBOM is what tells you which of your units are affected. ## How Blue Goat Cyber Approaches This We test hardware because that is where the assumptions break. Our lab work covers debug interface discovery, firmware extraction and analysis, secure boot verification, radio protocol analysis, and fault injection where the threat model justifies it, with findings written against the harm they enable rather than against a generic severity scale. Hardware work is part of our [medical device penetration testing](/services/medical-device-penetration-testing), and the physical attack paths it surfaces feed back into the [threat modeling](/services/threat-modeling) that determines what your architecture views need to show. ## Frequently Asked Questions ### Why does hardware testing matter if the device is inside a hospital? Because devices leave controlled environments routinely, through home use, resale, theft, loss, and service returns. A single unit on an attacker's bench yields firmware, secrets, and protocol knowledge that apply to every device you shipped. Physical access is also unsupervised access, which means an attacker can work for weeks without triggering any detection. ### What is the most common hardware finding in medical devices? An active debug interface on a production board, usually UART or JTAG. It survives because it was needed during development and nobody disabled it for production, and it frequently provides console or memory access without authentication. It is also the finding most likely to require a board change, which is why hardware testing belongs before the design freezes. ### Can firmware be extracted if the debug ports are disabled? Often, yes. Flash memory can be read directly, either in place or after removing the chip, unless the firmware is encrypted at rest and the key is held in protected storage. Disabling debug ports raises the effort required but does not by itself protect the contents of an external flash chip. ### Does encrypting firmware solve the problem? It raises the bar considerably, but only if the key is protected. Encryption with a key stored in the same accessible flash, or shared identically across the fleet, provides much less protection than it appears to. The strength comes from hardware-backed key storage and per-device keys, which are decisions made during silicon and board design. ### Is fault injection testing necessary for every device? No. It is justified when the threat model includes a motivated attacker with physical possession and when a bypassed boot check would have serious consequences, which is common for implantables, controlled substance delivery, and devices holding fleet-wide secrets. For lower-risk devices, debug interface and firmware extraction testing usually covers the realistic threat. ### How many units should we provide for hardware testing? At least two, and more if chip removal is anticipated. Hardware testing damages units, and a test that ends because the only available device stopped working produces an incomplete report. Providing spares is cheaper than repeating the engagement. ## Find Out What Your Board Exposes If nobody has put your production hardware on a bench, you do not yet know what an attacker who buys one will find. We can tell you while a board change is still affordable. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## Health Canada Cybersecurity Requirements Source: https://bluegoatcyber.com/blog/health-canada-medical-device-cybersecurity # Health Canada Medical Device Cybersecurity: 2026 Requirements > **[DIRECT ANSWER]** Health Canada reviews cybersecurity evidence as part of Class II to IV medical device licence applications under its pre-market cybersecurity guidance, with MDEL holders carrying distribution and reporting obligations. Most of an FDA Section 524B package carries over, but the classification rationale, risk documentation, labeling, and postmarket reporting must be mapped to the Medical Devices Regulations (SOR/98-282) and to Section 59 mandatory problem reporting. Health Canada has aligned its medical device cybersecurity expectations with the broader international model used by the FDA, IMDRF, and the EU MDR. Manufacturers that already produce a Section 524B premarket cybersecurity package can reuse most of it, but Health Canada has its own classification model, a separate classification ladder for in vitro diagnostic devices, its own licensing pathway, and its own postmarket obligations. This post explains what the Medical Device Licence application requires for cybersecurity in 2026, how the evidence bar changes by class, how far foreign review reports and MDSAP certificates carry you, and where Canadian-specific obligations apply. ## Key Takeaways - Health Canada uses a four-class system (I through IV) that does not map one-to-one with FDA Class I/II/III. - In vitro diagnostic devices are classified on their own ladder under the Part 2 Schedule 1 rules, and the cybersecurity evidence bar scales with that class. - Pre-market cybersecurity evidence is required for Class II, III, and IV devices that include software or connectivity. - The 2019 cybersecurity guidance covers risk management, SBOM, secure design, verification, and postmarket plans. - Class II is an attestation-weighted route; Class III and IV licence applications get a real technical review of the cybersecurity file. - MDSAP certification and foreign review reports shorten the assessment but never replace the Canadian classification rationale, labeling, or postmarket plan. - Postmarket vigilance and mandatory problem reporting under Section 59 apply to cybersecurity incidents. ## Why this matters Health Canada is one of the most common second-market regulators for US-cleared medical devices. The Medical Devices Regulations (SOR/98-282) and the 2019 guidance "Pre-market Requirements for Medical Device Cybersecurity" set out the cybersecurity content expected in a Medical Device Licence application. The guidance aligns with IMDRF principles and references IEC 81001-5-1, AAMI TIR57 / ANSI/AAMI SW96:2023, and ISO 14971. Independent of any FDA work, manufacturers must produce cybersecurity risk management, an SBOM, secure design evidence, verification results, and a postmarket plan that fits Canadian vigilance reporting under Section 59 of the regulations. Skipping the mapping work and submitting an unmodified FDA package is a common cause of MDL review questions, particularly around the postmarket plan, the labeling, and the device classification justification. ## How Health Canada Classifies Medical Devices ### Four Classes, Not Three Health Canada classifies medical devices into Classes I, II, III, and IV by increasing risk. Class I devices are licence-exempt (the manufacturer needs an MDEL, the establishment licence) but Class II, III, and IV devices require a Medical Device Licence. Most connected devices that fall in FDA Class II land in Health Canada Class II or III; many implantables and life-sustaining devices land in Class IV. ### The Cybersecurity Trigger The 2019 cybersecurity guidance applies to Class II, III, and IV devices that contain software or that connect to other devices or networks. The depth of the cybersecurity package scales with the class and the connectivity profile, similar to how the FDA scales by the Section 524B definition and the device's attack surface. ## How Health Canada Classifies IVD Devices In vitro diagnostic devices (IVDDs) are classified in Canada on their own ladder, under the Part 2 rules in Schedule 1 of the Medical Devices Regulations, rather than under the Part 1 rules used for other devices. The class number looks the same (I through IV) but the reasoning is different: it turns on the consequence of a wrong result, not on invasiveness or duration of contact. Software that interprets specimen results inherits that framing, which changes what a threat model has to argue. ### Decision Criteria Work through these questions in order to place an IVDD: 1. **Is the product an IVDD at all?** Reagents, calibrators, control materials, analyzers, and software intended to examine specimens taken from the body to provide diagnostic information are IVDDs. Software that only stores, routes, or displays results without interpreting them is generally regulated on the Part 1 ladder as software as a medical device. 2. **Who uses it?** Near-patient and self-testing devices classify higher than the same assay run in a laboratory by a trained operator, because there is no professional filter between the result and the decision. 3. **What is the consequence of a wrong result for the individual?** A false result that drives a life-threatening treatment decision, a missed serious diagnosis, or a transfusion error pushes the device up the ladder. 4. **What is the consequence at population scale?** Detection of transmissible agents and screening of blood, tissue, and organ donations sit at the top of the scheme. 5. **Is it manufactured in-house by a laboratory?** In-house IVDDs sit under a distinct oversight framework rather than the standard licensing route, with different evidence expectations. The practical result: | IVDD class | Risk framing | Typical examples | Licence expectation | | --- | --- | --- | --- | | Class I IVDD | Low individual and public health risk | Specimen receptacles, general culture media, general laboratory instruments | Licence-exempt, MDEL only | | Class II IVDD | Moderate individual risk, low public health risk | Pregnancy self-tests, urinalysis analyzers, clinical chemistry assays | Licence application with attested evidence | | Class III IVDD | High individual risk, moderate public health risk | Companion diagnostics, cancer markers, infectious disease staging assays | Full technical review of safety, effectiveness, and cybersecurity evidence | | Class IV IVDD | High public health risk | Donor screening for HIV, HBV, HCV, blood grouping (ABO, Rh) | Full technical review plus heightened scrutiny of result integrity controls | ### How IVDD Class Changes Cybersecurity Obligations The six pre-market content areas apply to every connected IVDD, but the depth scales: - **Class I and II IVDD.** A documented security risk assessment traced to ISO 14971, an SBOM for bundled and embedded software, secure configuration labeling, and a postmarket monitoring plan. Penetration testing is expected wherever the analyzer or middleware touches a network. - **Class III IVDD.** Everything above plus a formal threat model that treats result integrity, quality-control bypass, and LIS or middleware interoperability as first-class harm scenarios, security architecture views, and verification evidence proportionate to a full technical review. - **Class IV IVDD.** The Class III content plus population-scale harm analysis in the risk file (for example, a manipulated donor-screening result propagating into the blood supply), explicit controls over result transmission integrity, and a postmarket plan with defined vulnerability triage timelines across long installed lifetimes. The recurring failure is a threat model that reasons only about device availability and uptime. For an IVDD the patient harm flows through a wrong result reaching a clinician, so integrity and authenticity of the result, not availability of the analyzer, is the harm axis a reviewer wants to see analyzed. ## The Pre-market Cybersecurity Requirements ### Six Content Areas Health Canada's 2019 guidance lists six pre-market cybersecurity content areas: secure design, risk management, verification and validation testing, an SBOM, labeling for secure use, and a plan for managing postmarket cybersecurity risks. > **[KEY REQUIREMENT]** The MDL application must include each of these explicitly, even when the manufacturer is using US, EU, or IMDRF documentation. ### How the Content Maps to Standards The guidance references IEC 81001-5-1 for security activities in the software lifecycle, AAMI TIR57 / ANSI/AAMI SW96:2023 for security risk management, and ISO 14971 for overall risk management. These are the same anchor standards the FDA points to, which is why the technical content set overlaps so heavily. The mapping in the application package matters: Health Canada reviewers expect to see the standards-to-evidence trace, not just an assertion of compliance. ## Licence Evidence Routes by Class Classification tells you the risk tier. The licence route tells you how much of the cybersecurity file a reviewer actually reads before a licence issues. Manufacturers who get the class right and the route wrong still end up in an additional information request. | Class | Licence route | Depth of review | Cybersecurity evidence a reviewer expects | | --- | --- | --- | --- | | Class I | No licence, MDEL for the establishment | None pre-market | Evidence held internally, produced on inspection or complaint | | Class II | Licence application with manufacturer attestations and a QMS certificate | Administrative and attestation-weighted | Security risk assessment, SBOM, secure use labeling, postmarket plan, all citable on request | | Class III | Licence application with a summary of studies and technical evidence | Substantive technical review | Threat model, secure design rationale, SBOM with VEX, verification and penetration testing summaries, postmarket cybersecurity plan | | Class IV | Licence application with full safety and effectiveness evidence and a risk assessment | Deepest technical review | Class III content plus explicit patient-harm linkage in the ISO 14971 file, architecture views, and control-level verification evidence | | Class II IVDD | Licence application with attested evidence | Attestation-weighted | Risk assessment, SBOM, labeling, postmarket monitoring plan | | Class III and IV IVDD | Licence application with full evidence | Substantive to deep review | Result integrity threat model, LIS and middleware interface analysis, testing evidence, transmission integrity controls | ### What This Means in Practice Three route-driven behaviors are worth planning for. Class II is attested, not unexamined. The lighter pre-market review does not lower the evidence bar, it defers when the evidence is read. A complaint, a recall, or an MDSAP audit will surface a thin risk file, and by then the device is on the market. Class III and IV files get read line by line. Cybersecurity gaps that survived a notified body review or an FDA clearance can surface here, most often as a threat model that is not traceable back into the ISO 14971 risk management file. Security changes can be licence-amendment triggers. Adding an update mechanism, changing the authentication architecture, or altering the network interface can be a significant change requiring a licence amendment before the change reaches the Canadian market. Build that trigger into change control rather than discovering it during a postmarket update. ## Relying on MDSAP and Foreign Review Reports Canada is the jurisdiction where MDSAP is mandatory: a Class II, III, or IV licence requires a valid MDSAP certificate issued by a recognized auditing organization. That certificate carries the quality system, and by extension the software lifecycle and security risk management procedures that IEC 81001-5-1 and ANSI/AAMI SW96:2023 sit inside. Health Canada also accepts foreign review information as supporting evidence in a licence application. Both are reliance mechanisms, not recognition mechanisms: the decision stays with Health Canada. ### What Reliance Can and Cannot Do - **Can support:** the security risk assessment, threat model, secure design rationale, SBOM, verification and penetration testing evidence, and the process evidence behind the software lifecycle. - **Cannot replace:** the Canadian classification rationale, the labeling in both official languages where required, the Section 59 postmarket plan, and the licence application content itself. - **Does not transfer automatically:** conditions, restrictions, or postmarket commitments imposed by a foreign regulator. Disclose them and let Health Canada decide whether equivalent conditions apply. > **[KEY REQUIREMENT]** An MDSAP certificate demonstrates that your processes conform. It does not demonstrate that this device's cybersecurity evidence is complete. Those are separate arguments, and the licence application has to make the second one. ### Practical Guidance for Citing Foreign Evidence 1. Confirm the foreign report covers the same device, same intended use, and same manufacturing sites as the Canadian application. 2. Cite the decision document by name, date, and reference number, and attach it rather than summarizing it. 3. Provide a crosswalk table from the foreign content structure (Section 524B slots, or EU GSPR 17 and Annex I) to the six Canadian content areas. 4. Flag every delta: differences in configuration, connectivity, bundled software versions, or accessories between the foreign-approved device and the Canadian one. 5. Refresh the SBOM to the version shipping in Canada, not the version submitted abroad. 6. Restate the postmarket plan against Section 59 timelines and decision criteria rather than 21 CFR Part 803. 7. Disclose any foreign conditions of approval, field actions, or cybersecurity-related recalls tied to the device. ## How an FDA Section 524B Package Maps to an MDL ### Direct Reuse | Section 524B / Feb 3, 2026 guidance | Health Canada equivalent | | --- | --- | | Threat model and security risk assessment | Risk management content area | | SBOM with VEX | SBOM content area | | Security architecture views | Secure design content area | | Security testing, including pen testing | Verification and validation testing | | Labeling for secure use | Labeling for secure use | | Postmarket cybersecurity management plan | Plan for managing postmarket cybersecurity risks | ### What Needs Adaptation The postmarket plan needs to reference Health Canada's mandatory problem reporting requirements under Section 59 of the Medical Devices Regulations, not the FDA's 21 CFR Part 803 MDR pathway. The labeling needs to satisfy Canadian language and content requirements. The classification rationale needs to reflect the Health Canada classification rules, which are based on the IMDRF risk classification model and differ from the FDA approach. ## Postmarket and MDEL Obligations ### Section 59 Mandatory Problem Reporting Manufacturers and importers must report incidents to Health Canada that result in or could result in death or serious deterioration in health. Cybersecurity incidents that meet that criterion are reportable. The postmarket plan must describe the decision criteria, the timeline, and the owner. ### MDEL and Importer Responsibilities The Medical Device Establishment Licence (MDEL) is held by importers, distributors, and Class I manufacturers. MDEL holders share responsibility for postmarket vigilance, including cybersecurity incidents that surface through customer channels. The IR plan and CVD policy referenced in the MDL submission should make these handoffs explicit. ## Common Gaps in Canadian Cybersecurity Submissions The most frequent gaps in Health Canada cybersecurity submissions are an FDA postmarket plan dropped in without Section 59 mapping, a classification rationale that uses FDA Class II/III language instead of the Canadian Class II/III/IV rules, an IVDD placed on the Part 1 ladder by mistake, and labeling that does not meet Canadian content or language requirements. Reviewers also look for the SBOM format and freshness; submissions that include an SBOM generated years before the application date draw questions about the postmarket monitoring process. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches Health Canada Submissions We treat Health Canada submissions as a content-mapping and adaptation exercise rather than a from-scratch rewrite when the manufacturer already has a Section 524B package. The cybersecurity package keeps the same threat model, SBOM, architecture views, and verification evidence, with adaptations for the Canadian classification rationale, Section 59 postmarket reporting, and labeling content. Our team holds CISSP, OSCP, and prior military red-team credentials, and our submission work is grounded in IEC 81001-5-1, AAMI TIR57 / ANSI/AAMI SW96:2023, ISO 14971, and the FDA February 3, 2026 final premarket cybersecurity guidance. If the regulator raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [international medical device cybersecurity services](https://bluegoatcyber.com/services/medical-device-cybersecurity) or compare regimes on the [EU MDR vs FDA cybersecurity guide](https://bluegoatcyber.com/guides/eu-mdr-vs-fda-cybersecurity). ## FAQ ### Does Health Canada require an SBOM? Yes. The 2019 pre-market cybersecurity guidance lists SBOM as one of the six required content areas for Class II, III, and IV devices with software or connectivity. The format is not prescribed but CycloneDX and SPDX are the common choices, mirroring international practice. ### Is the FDA Section 524B package sufficient for an MDL? The technical content is largely reusable, but the postmarket plan, classification rationale, and labeling need Canadian-specific adaptation. Submitting an unmodified FDA package is the most frequent cause of reviewer questions on cybersecurity content. ### What is Section 59 of the Medical Devices Regulations? Section 59 establishes mandatory problem reporting obligations for manufacturers and importers. Incidents that result in or could result in death or serious deterioration in health must be reported to Health Canada within defined timelines. Cybersecurity incidents that meet the threshold are reportable. ### How does Health Canada classification differ from FDA classification? Health Canada uses four classes (I through IV) based on IMDRF risk classification rules. FDA uses three classes (I, II, III) under 21 CFR Part 860. The two systems are not interchangeable: a device that is FDA Class II may be Health Canada Class II, III, or IV depending on the rules that apply. ### Does the MDEL require its own cybersecurity content? The MDEL is an establishment licence held by importers, distributors, and Class I manufacturers. It does not require a cybersecurity submission, but MDEL holders share postmarket vigilance responsibilities under Section 59, including for cybersecurity incidents. ### How are IVD devices classified differently in Canada? IVD devices are classified under the Part 2 rules in Schedule 1 of the Medical Devices Regulations, based on the consequence of a wrong result for the individual and for the population, rather than on invasiveness. Class III and IV IVDDs receive a full technical review, so the cybersecurity file has to argue result integrity and LIS interface security, not just device availability. ### Does a valid MDSAP certificate cover our cybersecurity evidence? No. MDSAP is mandatory for Class II, III, and IV licences and demonstrates that your quality system and software lifecycle processes conform. The device-specific cybersecurity evidence, threat model, SBOM, testing results, and postmarket plan still have to appear in the licence application. ### Can we cite our FDA clearance instead of resubmitting the evidence? Foreign review information is accepted as supporting evidence, but it is a reliance pathway rather than recognition. You still owe the Canadian classification rationale, bilingual labeling where required, a Section 59 postmarket plan, and a crosswalk from the Section 524B content to the six Canadian content areas. ### Does changing a security control require a licence amendment? Often, yes. Adding an update mechanism, changing the authentication architecture, or altering the network interface can constitute a significant change requiring an amendment before the change reaches the Canadian market. Treat security architecture changes as a change-control trigger. ## Ready to bring your device to the Canadian market? If you have an FDA-cleared connected device and need a Health Canada MDL with a cybersecurity package that maps cleanly from your Section 524B content, we can help. If the regulator raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led international medical device cybersecurity programs across FDA, Health Canada, and EU MDR pathways and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## Healthcare Cybersecurity Companies: A Buyer's Selection Guide Source: https://bluegoatcyber.com/blog/healthcare-cybersecurity-companies # Healthcare Cybersecurity Companies: How to Choose the Right Vendor > **[DIRECT ANSWER]** Healthcare cybersecurity companies fall into distinct categories: hospital and health system managed security providers, healthcare IT compliance and HIPAA specialists, medical device manufacturer-focused regulatory security testers, and product security tooling vendors. Each solves a different problem, and buying from the wrong category is the most common mistake. Match the vendor category to your actual need, then verify the evidence they can produce, not just the services they list. _Reviewed September 17, 2026_ Buying security services for a hospital network is not the same purchase as buying security testing for a connected infusion pump headed toward an FDA submission. The term "healthcare cybersecurity companies" covers both, plus several categories in between, and vendors often blur the lines in their marketing. A hospital IT director needs different deliverables than a medical device engineering team preparing an eSTAR submission. Choosing the wrong category wastes budget and, for manufacturers, can produce documentation that a reviewer rejects outright. This guide breaks down the categories, the questions worth asking each one, and the specific evidence an FDA submission needs that many vendors cannot actually supply. ## Key Takeaways - Healthcare cybersecurity vendors split into at least four categories, and most companies only operate well within one or two of them. - Hospital-facing managed security and compliance-only HIPAA vendors are not equipped to produce premarket submission evidence for device manufacturers. - An FDA submission needs named testers, mapped findings, and a traceable link to your risk management file, not a general scan report. - Guaranteed clearance language, unnamed testers, and scan-only deliverables are red flags regardless of vendor size or reputation. - The right vendor category depends on whether your problem is network operations, regulatory compliance, or premarket device security evidence. ## Why This Matters Choosing a security vendor is a compliance decision as much as a technical one, especially for device manufacturers. The FDA's February 3, 2026 final guidance, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions*, expects specific documentation: threat models, architecture views, a software bill of materials, vulnerability testing results, and evidence that findings were assessed against a risk management file built to ISO 14971. A vendor that only performs generic vulnerability scanning, without mapping results to these expectations, leaves the manufacturer to do that translation work alone, often after the engagement has already ended. Hospitals and health systems face a different but related problem. Their vendors need to demonstrate HIPAA safeguards, incident response readiness, and network segmentation, none of which map directly to a premarket submission. Buyers who conflate the two markets often discover the gap only when a reviewer sends a deficiency letter asking for evidence the vendor never intended to produce. Understanding the categories up front avoids that outcome and sets clearer expectations for cost, timeline, and deliverables before a contract is signed. ## What Are the Categories of Healthcare Cybersecurity Companies? Healthcare cybersecurity companies generally fall into four categories, each built around a different buyer and a different deliverable. Understanding which one you are actually talking to matters more than any brand name. The categories overlap in marketing language far more than they overlap in actual capability. **Hospital and health system managed security providers** focus on network operations: firewalls, endpoint detection, security operations center monitoring, and incident response for the hospital's IT environment. They are built to protect a network perimeter and respond to intrusions across thousands of connected assets, including medical devices already deployed on the network. They are not typically equipped to test a device's firmware, evaluate its software architecture, or produce documentation aligned to a premarket submission. **Healthcare IT compliance and HIPAA specialists** focus on administrative, physical, and technical safeguards required under HIPAA. They perform risk assessments, policy development, and audits aimed at covered entities and business associates. Their deliverables are compliance reports and policy documentation, useful for a hospital's regulatory posture but not aligned to the FDA's premarket cybersecurity content requirements, which follow a different framework entirely. **Medical device manufacturer-focused regulatory security testers** specialize in the specific evidence a device maker needs: threat modeling, penetration testing scoped to device architecture, SBOM generation and vulnerability triage, and documentation formatted for eSTAR submission. This category is the smallest of the four and the one most manufacturers actually need when preparing a submission or responding to a postmarket obligation under Section 524B. **Product security tooling vendors** sell software, not services: static and dynamic analysis tools, SBOM generation platforms, vulnerability management dashboards, and automated scanning. Tools are valuable inputs to a security program but do not, by themselves, produce the analysis, judgment, and documentation a reviewer expects to see behind the raw output. **[KEY REQUIREMENT]** Before signing with any vendor, identify which category actually matches your problem. A tooling subscription will not produce a threat model, and a HIPAA compliance audit will not satisfy a premarket submission's testing evidence requirements. ## What Should Each Category Actually Be Used For? Each category is good for a specific problem, and buyers get the best results when they stop expecting one vendor to solve all four. Hospital managed security providers are the right choice for ongoing network defense, monitoring, and incident response across a live clinical environment. They are the correct answer when the question is "how do we detect and respond to an intrusion," not "how do we document device security for a submission." HIPAA and compliance specialists are the right choice when the goal is meeting administrative and technical safeguard requirements, preparing for an Office for Civil Rights audit, or building organizational policy. They answer "are we compliant with HIPAA's Security Rule," which is a distinct question from device-level security testing. Regulatory security testers focused on medical devices are the right choice when a manufacturer needs premarket submission evidence, postmarket vulnerability management support, or a threat model tied to a specific device's architecture and intended use. This is the category most relevant to engineering and regulatory affairs teams working toward an FDA submission deadline. Product security tooling is the right choice as an input to any of the above, particularly for ongoing SBOM tracking and vulnerability monitoring, but it works best paired with people who can interpret the output and write it into a defensible narrative. | Provider Category | Best Used For | Typical Deliverable | Fits Premarket Submission? | |---|---|---|---| | Hospital managed security | Network monitoring, incident response | SOC reports, incident logs | No | | HIPAA/compliance specialist | Safeguard audits, policy | Risk assessment, policy documents | No | | Device-focused regulatory tester | Threat modeling, pen testing, SBOM | Test reports mapped to risk file | Yes | | Product security tooling | Continuous scanning, SBOM generation | Dashboards, raw findings | Partial input only | ## What Questions Should You Ask a Vendor Before Signing? Ask a vendor to name the specific people who will perform the testing, not just the company credentials. Anonymous "our security team" language usually means the actual testers are subcontracted or junior staff without device-specific experience. Ask whether the deliverable will map findings to your device's intended use and risk management file, since a report that lists vulnerabilities without that mapping requires additional work before it is submission-ready. Ask how the vendor handles SBOM generation and whether it aligns with the CISA 2026 SBOM Minimum Elements, which superseded the 2021 NTIA framework. Ask for a sample redacted report from a comparable device type, and read it closely for whether findings are tied to exploitability, patient impact, and mitigation status, or simply listed by CVE number and severity score. **[KEY REQUIREMENT]** Ask directly whether the vendor has produced documentation that has gone through an actual FDA review cycle, and ask what changed after reviewer feedback. A vendor with real submission experience will have a specific answer, not a general claim of familiarity with the guidance. ## What Evidence Does an FDA Submission Actually Need From a Vendor? An FDA submission needs testing evidence that is traceable to a specific device, a specific version, and a specific risk management file entry, not a generic scan output. Under the February 3, 2026 final guidance, the eSTAR template's Cybersecurity attachment area expects a threat model, architecture and interface diagrams, an SBOM, vulnerability and penetration testing results, and a description of the postmarket vulnerability monitoring plan. Each of these needs to connect back to the device's ISO 14971 risk management file so a reviewer can see how a technical finding was translated into a documented risk decision. A vendor's testing report should identify who performed the testing, what methodology was used, what was in and out of scope, and what the residual risk is for any unresolved finding. It should also state clearly whether a finding was mitigated, accepted, or transferred, language that maps directly to risk management terminology reviewers expect to see. A report that stops at a list of CVEs and CVSS scores leaves the hardest part of the work, the risk translation, for the manufacturer to do without vendor support. ## What Are the Red Flags When Evaluating a Vendor? A scan-report-only deliverable is the clearest red flag, since automated scanning output without manual analysis, exploitation context, or risk mapping does not meet the FDA's expectations for premarket testing evidence. A report that lists no named testers, only a company name and a generic methodology paragraph, suggests the vendor cannot stand behind specific findings if a reviewer asks follow-up questions. No linkage to ISO 14971 is another warning sign. If a vendor cannot explain how a finding connects to your risk management file's severity and probability categories, the deliverable will need substantial rework before it supports a submission. Guaranteed clearance claims are a hard stop: no vendor can guarantee an FDA outcome, and any company that promises "guaranteed clearance" or "100% pass rate" is either overselling or does not understand how FDA review actually works. **[KEY REQUIREMENT]** Treat "we've worked with the FDA before" as meaningless without specifics. Ask for the device type, the submission pathway, and what the reviewer's cybersecurity questions actually were. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works specifically in the medical device manufacturer category, focused on the evidence a premarket or postmarket submission actually requires. Testing is performed by named engineers, findings are mapped to the device's intended use and risk management file, and reports are structured for the eSTAR Cybersecurity attachment area rather than delivered as a generic scan output. This includes [medical device penetration testing](/services/medical-device-penetration-testing) scoped to device architecture, [threat modeling](/services/medical-device-threat-modeling) tied to intended use, and [SBOM services](/services/fda-compliant-sbom-services-for-medtech) aligned to current minimum elements. Manufacturers evaluating vendors are welcome to ask the same questions raised in this guide and compare the answers directly against a specific submission need. ## Frequently Asked Questions ### Do I need a different vendor for HIPAA compliance and device security testing? Usually yes. HIPAA compliance work addresses administrative, physical, and technical safeguards for covered entities and business associates, while device security testing addresses the technical architecture of a specific product headed toward an FDA submission. A vendor strong in one is rarely strong in both, and asking a HIPAA specialist for premarket testing evidence typically produces an incomplete deliverable. ### Can a hospital's managed security provider help a medical device manufacturer with an FDA submission? Generally no. Managed security providers are built around monitoring a hospital's network and responding to incidents across deployed assets, not testing a device's architecture or producing documentation aligned to premarket submission requirements. Manufacturers need a vendor whose deliverables are structured around device-level evidence and risk file traceability. ### What is the difference between a vulnerability scan and the testing an FDA submission needs? A vulnerability scan produces a list of known weaknesses matched against signatures or databases, largely automated and unfiltered by context. Submission-ready testing includes manual analysis, exploitability assessment specific to the device's use case, and a mapping of each finding to the risk management file, none of which an automated scan alone can produce. ### How much does medical device security testing typically cost? Cost depends heavily on device complexity, connectivity, and the scope of testing required, and any number quoted without knowing those specifics is unreliable. Ask vendors for a scoping call based on your device's architecture and intended use rather than relying on published price ranges. ### Is it a red flag if a vendor cannot name the specific testers on my project? Yes, this is one of the clearest warning signs. Named testers with device-specific experience should be identifiable in a proposal, and a vendor unwilling or unable to name who performs the work is harder to hold accountable for the quality of findings. ### Should I choose a vendor based on the tools they use? Tools matter less than the analysis behind them. A vendor with access to strong scanning tools but no process for translating findings into risk-file-linked evidence will still leave you with submission gaps, so evaluate the deliverable and the people, not the tool list. ## CTA If you are preparing a premarket submission or responding to a postmarket vulnerability and need testing evidence structured for FDA review, [contact Blue Goat Cyber](/contact) to scope the work against your device's architecture and submission timeline. ## About the Author Christian Espinosa is the founder of Blue Goat Cyber and a medical device cybersecurity specialist who has worked with manufacturers navigating FDA premarket and postmarket security requirements. He writes about practical, evidence-based approaches to device security that hold up under regulatory review. Learn more on his [author page](/christian-espinosa). --- ## HHS 405(d) HICP Practice #9 for 524B Source: https://bluegoatcyber.com/blog/hhs-405d-medical-device-cybersecurity # HHS 405(d) HICP Practice #9 for 524B > **[DIRECT ANSWER]** HHS 405(d) and its Health Industry Cybersecurity Practices (HICP) are voluntary guidance for healthcare delivery organizations, not manufacturer regulations, so there is nothing to file against them directly. They matter because hospital procurement and biomed teams score vendor devices against HICP Practice #9, Medical Device Security, and those expectations overlap heavily with the SBOM, threat model, and vulnerability management artifacts the FDA already reviews under Section 524B. The HHS 405(d) program was established under Section 405(d) of the Cybersecurity Act of 2015 to develop consensus-based cybersecurity practices for the Health Industry. Its flagship deliverable, the Health Industry Cybersecurity Practices (HICP), is the document hospital security teams reach for when they need a defensible baseline. Manufacturers do not file anything against 405(d), but they ship into a market where 405(d) is the language of the buyer. This post explains what 405(d) and HICP are, how Practice #9 maps to FDA Section 524B artifacts, and how a manufacturer should structure premarket and postmarket evidence so that the same package answers both the FDA reviewer and the hospital procurement team. ## Key Takeaways - HHS 405(d) and HICP are voluntary practices aimed at hospitals, not manufacturer regulations. - HICP Practice #9 (Medical Device Security) is what hospital procurement uses to score vendors. - HICP Practice #9 expectations overlap heavily with FDA Section 524B premarket and postmarket artifacts. - A 524B-aligned package (SBOM, threat model, vulnerability management plan, CVD policy) answers most HICP Practice #9 procurement questions. - Manufacturers that publish a short HICP alignment statement shorten sales cycles with HDOs. ## Why this matters Medical device manufacturers face two cybersecurity audiences with different documents and different vocabularies. The FDA reviews premarket submissions against Section 524B and the February 3, 2026 final premarket cybersecurity guidance. Hospital procurement and biomed teams review vendors against HHS 405(d) HICP, often via questionnaires like the MDS2 form and the AHA HSCC playbooks that reference HICP directly. The overlap is large but not obvious, and manufacturers that treat the two as separate workstreams duplicate effort and still leave gaps. Treating 524B as the source of truth and publishing a short HICP Practice #9 alignment statement on top of it satisfies the buyer without adding a parallel program. ## What HHS 405(d) Is ### Origin and Authority Section 405(d) of the Cybersecurity Act of 2015 directed the Secretary of Health and Human Services to convene a public-private task group to develop consensus-based cybersecurity practices for the Health Industry. The 405(d) Program operates out of the HHS Administration for Strategic Preparedness and Response (ASPR) in coordination with the Healthcare and Public Health Sector Coordinating Council (HSCC). The program publishes HICP and supporting resources, and it convenes the 405(d) Task Group that maintains them. ### Voluntary, Not Regulatory The 405(d) program does not create regulations. HICP is voluntary guidance. The Health Industry Cybersecurity Practices were, however, recognized in the HITECH Act amendments as a factor HHS Office for Civil Rights (OCR) considers when evaluating a covered entity's security program during a breach investigation, which gives the framework material weight even though it is not binding. ## What HICP Is, and Who It Is For ### Audience HICP is written for Health Industry organizations, primarily hospitals and health systems (referred to as HDOs, or Healthcare Delivery Organizations). It is structured around ten cybersecurity practices, organized into Technical Volume 1 (small organizations) and Technical Volume 2 (medium and large organizations). The practices cover email protection, endpoint protection, access management, data protection, asset management, network management, vulnerability management, incident response, medical device security, and cybersecurity oversight and governance. ### Why Manufacturers Care Hospitals score the medical devices they buy against the same practices they hold themselves to. Practice #9, Medical Device Security, is the practice that translates directly into procurement questions for manufacturers. When a hospital evaluates a connected device, the buyer is effectively asking whether the device fits inside the HDO's HICP-aligned security program. Manufacturers that can answer "yes" with documentation move through procurement faster. ## HICP Practice #9: Medical Device Security ### What the Practice Asks For HICP Practice #9, Medical Device Security, expects an HDO to maintain an inventory of medical devices, manage endpoint protections appropriate to each device, segment medical device traffic on the network, manage vulnerabilities and patches across the device fleet, and coordinate with manufacturers on security updates and incident response. Sub-practices include asset inventory and SBOM ingestion, network segmentation and access control, vulnerability and patch management, and procurement security requirements. ### The Manufacturer-Facing Sub-Practices The sub-practices that directly drive manufacturer questions are procurement security requirements (what the HDO expects vendors to provide before purchase), vulnerability and patch management (how the manufacturer will support the device after sale), and incident response coordination (how the manufacturer will communicate during a security event). These are exactly the topics the FDA expects in a Section 524B submission and postmarket plan. ## How HICP Practice #9 Maps to FDA Section 524B ### The Mapping | HICP Practice #9 expectation | Corresponding FDA Section 524B artifact | | --- | --- | | SBOM ingestion at procurement | Section 524B(b)(3) machine-readable SBOM | | Vulnerability identification on shipped components | SBOM + VEX, postmarket vulnerability monitoring plan | | Coordinated patch and update process | Section 524B(b)(2)(B) plan to monitor, identify, and address postmarket vulnerabilities | | Coordinated vulnerability disclosure | CVD policy (expected in submission, published externally) | | Network and architecture documentation | Architecture views (system, multi-patient harm, updateability, security use case) | | Risk-based security controls | Security risk assessment and threat model | | Customer security communications | Security advisories, MDS2, customer-facing security documentation | ### What the Mapping Shows The mapping is dense. A Section 524B-aligned package already produces almost every artifact a hospital procurement team needs to score the device against HICP Practice #9. The gap is usually packaging: the 524B artifacts live inside the submission and are not framed for a procurement reader. A short HICP alignment statement and a customer-facing security documentation set close that gap without new technical work. ## What Manufacturers Should Publish A practical manufacturer-side response to HICP Practice #9 includes a handful of customer-facing documents: 1. A current SBOM in CycloneDX or SPDX, refreshed on each release. 2. A VEX statement set covering the SBOM's exploitable components. 3. A coordinated vulnerability disclosure (CVD) policy with a public intake address. 4. An MDS2 form (HSCC Manufacturer Disclosure Statement for Medical Device Security) per product. 5. A short HICP Practice #9 alignment statement that maps each sub-practice to the manufacturer's evidence. 6. A security advisory channel and subscription path for customers. These are not new artifacts. Items 1 through 4 already exist for any Section 524B-compliant submission. Items 5 and 6 are lightweight packaging on top. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches HICP Alignment We build premarket and postmarket cybersecurity programs against FDA Section 524B and the February 3, 2026 final premarket cybersecurity guidance, and we publish the customer-facing HICP Practice #9 alignment layer on top of the same evidence. The 524B work produces the SBOM, VEX, threat model, architecture views, vulnerability management plan, and CVD policy. The HICP layer reframes those artifacts for hospital procurement readers and adds the MDS2 and alignment statement. Our team holds CISSP, OSCP, and prior military red-team credentials, and we ground our work in Section 524B, the FDA's February 3, 2026 guidance, AAMI SW96:2023, IEC 81001-5-1, and the HSCC Joint Security Plan. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [premarket cybersecurity service](https://bluegoatcyber.com/services/fda-premarket-cybersecurity) or our [postmarket SBOM and VEX monitoring service](https://bluegoatcyber.com/services/postmarket-sbom-vex-monitoring). ## FAQ ### Is HHS 405(d) a regulation that medical device manufacturers must follow? No. The 405(d) program publishes voluntary guidance (HICP) aimed at hospitals and health systems, not at manufacturers. There is no filing or compliance obligation against 405(d) for a device maker. Manufacturers care about HICP because hospital procurement teams use it as the baseline for evaluating the cybersecurity posture of the devices they buy. Failing the hospital procurement review is a commercial problem, not a regulatory one, but it is often the bigger obstacle to revenue than the FDA submission itself. ### How is HICP different from the FDA's Section 524B requirements? Section 524B is statutory and applies to cyber device submissions to the FDA. HICP is voluntary and applies to how hospitals run their own cybersecurity programs. The two overlap heavily on medical device security: SBOMs, vulnerability management, coordinated disclosure, and patching all appear in both. The practical difference is audience and packaging. 524B speaks to a regulator and lives inside a submission; HICP Practice #9 speaks to a procurement reviewer and lives in customer-facing documentation. ### What is HICP Practice #9? HICP Practice #9 is the Medical Device Security practice within the Health Industry Cybersecurity Practices. It covers asset inventory, SBOM ingestion, network segmentation, vulnerability and patch management, procurement security requirements, and incident response coordination for medical devices in the hospital environment. For manufacturers, the practice translates into the procurement questionnaire items that hospitals ask before buying a connected device. ### Do we need a separate HICP-aligned security program if we already meet Section 524B? No. A Section 524B-aligned program already produces almost every artifact HICP Practice #9 asks a manufacturer to support. What you usually need on top is packaging: an MDS2 form per product, a short HICP alignment statement that maps each Practice #9 sub-practice to your existing evidence, and a public CVD policy and security advisory channel. These do not require new technical work, only customer-facing presentation of work you already have. ### How does HICP relate to the MDS2 form? The MDS2 is the Manufacturer Disclosure Statement for Medical Device Security, published by the HSCC and aligned to HICP. It is the standard form hospitals send to manufacturers during procurement to capture the device's security characteristics. A current MDS2 per product is one of the most effective ways to demonstrate HICP Practice #9 alignment without writing custom documentation for each customer. ## Ready to align your cybersecurity program with both the FDA and HICP? If you ship connected medical devices and need a cybersecurity program that satisfies the FDA's Section 524B reviewers and the hospital procurement teams scoring you against HICP Practice #9, we can help. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led premarket and postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## HIPAA and Medical Device Manufacturers Source: https://bluegoatcyber.com/blog/hipaa-medical-device-manufacturers-cybersecurity # HIPAA and Medical Device Manufacturers: What Cybersecurity Obligations Actually Apply > **[DIRECT ANSWER]** HIPAA applies to a manufacturer when it creates, receives, maintains, or transmits protected health information on behalf of a covered entity, which usually means the cloud or service side of a connected device rather than the device itself. The 2025 Security Rule proposal would remove the addressable and required distinction and mandate encryption, MFA, and asset inventories, tightening the overlap with the FDA's February 3, 2026 premarket expectations. ## Key Takeaways - Manufacturers are usually neither Covered Entities nor Business Associates. They become a Business Associate the moment their cloud, SaaS, or remote monitoring service touches PHI on behalf of a hospital. - The HIPAA Security Rule (45 CFR §164.308/310/312) applies to Business Associates with the same force as to Covered Entities, including the §164.312 technical safeguards that map directly to device design. - The HHS NPRM published January 6, 2025 (90 FR 898) would remove the "addressable" designation, mandate encryption, require MFA, annual pen testing, asset inventories, network segmentation, and 24-hour Business Associate notification to Covered Entities. - HIPAA governs PHI confidentiality, integrity, and availability. The FDA governs device safety and effectiveness. The control families overlap heavily, but the documentation, the auditor, and the enforcement path are different. - Hospitals will ask for HIPAA-flavored controls through MDS2, HSCC JSP, and security questionnaires even when no BAA exists. Devices that cannot support unique user IDs, audit logging, automatic logoff, encryption, and access control will lose deals. ## Why this matters HIPAA enforcement against Business Associates is no longer rare. HHS OCR's *Annual Report to Congress on HIPAA Privacy, Security, and Breach Notification Rule Compliance* shows year-over-year growth in Business Associate enforcement actions and settlement amounts, with several seven-figure resolutions against vendors whose products touched PHI on behalf of a hospital. The 2024 Change Healthcare incident, the largest healthcare breach on record, was a Business Associate failure, not a Covered Entity failure, and it is the proximate cause of the January 6, 2025 NPRM (90 FR 898). At the same time, the FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) and Section 524B of the FD&C Act formalize cybersecurity as a clearance gate. Manufacturers are now squeezed from two directions: the FDA on safety and effectiveness, OCR on PHI. Hospitals enforce both through procurement using MDS2 (the HSCC-aligned Manufacturer Disclosure Statement for Medical Device Security) and the Joint Security Plan. ## Does HIPAA apply to medical device manufacturers? In most cases, not directly. HIPAA applies to Covered Entities (health plans, healthcare clearinghouses, and most healthcare providers) and to Business Associates (vendors that create, receive, maintain, or transmit PHI on behalf of a Covered Entity). A medical device manufacturer selling a standalone device into a hospital is typically neither. You cross the line into Business Associate status when: - Your cloud backend ingests, stores, or processes PHI generated by the device on the hospital's behalf - You provide a remote monitoring service, managed analytics, or hosted reporting - You operate a patient portal or companion app that handles PHI as a service to the provider - You host or administer infrastructure where PHI lives Selling a device that creates PHI used only inside the hospital's own infrastructure does not, by itself, make you a Business Associate. The triggering question is always "are you handling PHI *on behalf of* a Covered Entity?" If yes, you need a Business Associate Agreement (BAA) and you owe the full HIPAA Security Rule, Breach Notification Rule, and applicable Privacy Rule provisions. > **[KEY REQUIREMENT]** If any part of your product or service touches PHI on behalf of a hospital, you are a Business Associate the day the data starts flowing, not the day the BAA is signed. Operating without a BAA in that state is itself a HIPAA violation for both parties. ## The three indirect ways HIPAA reaches manufacturers Even when HIPAA does not apply directly, it shapes the manufacturer's obligations through three predictable channels. ### 1. Business Associate exposure through the cloud backend The moment a connected device sends PHI to a manufacturer-operated cloud, you are a Business Associate. The Security Rule then applies in full: administrative safeguards (§164.308), physical safeguards (§164.310), and technical safeguards (§164.312), plus Breach Notification (§164.410) requiring you to notify the Covered Entity without unreasonable delay and in no case later than 60 days after discovery. ### 2. Procurement gating via MDS2 and the HSCC Joint Security Plan Hospitals must comply with HIPAA, and they extend that obligation to vendors through procurement. The MDS2 questionnaire is a HIPAA Security Rule checklist in everything but name, covering unique user IDs, automatic logoff, audit controls, encryption, transmission security, and emergency access. The HSCC Joint Security Plan formalizes the same expectations for the device lifecycle. A device that cannot support these controls cannot be deployed in a way that lets the hospital meet *its* HIPAA obligations, which means the hospital cannot buy it. ### 3. The January 6, 2025 HIPAA Security Rule NPRM The proposed update at 90 FR 898 raises the floor for every Business Associate and, by extension, every device whose backend touches PHI. The controls become prescriptive, not "addressable." See the next section. ## HIPAA Security Rule controls that map to device design The §164.312 technical safeguards translate almost one-for-one into device design requirements: | HIPAA §164.312 control | What the device must support | |---|---| | Access control, unique user identification | Per-user accounts, no shared service accounts in clinical workflow | | Access control, emergency access | Documented break-glass procedure | | Access control, automatic logoff | Configurable inactivity timeout | | Access control, encryption and decryption | Encryption at rest for PHI on the device | | Audit controls | Tamper-evident audit log of PHI access and security events | | Integrity | Mechanism to detect unauthorized PHI alteration | | Person or entity authentication | Strong authentication; MFA where feasible | | Transmission security | TLS for all PHI in transit, including HL7/MLLP wrapped in TLS | These map directly onto the FDA's expectations in the Feb 3, 2026 guidance, which means the same control evidence (test reports, design documentation) typically serves both regulators if it is written for that purpose from the start. ## What changes under the 2025 HIPAA Security Rule NPRM The HHS Notice of Proposed Rulemaking published January 6, 2025 (90 FR 898) is the most significant Security Rule update since 2013. If finalized as proposed, the headline changes for device manufacturers operating as Business Associates include: - **Encryption becomes mandatory**, not "addressable." Encryption at rest and in transit for all ePHI, with limited exceptions. - **Multi-factor authentication required** for access to systems containing ePHI. - **Annual penetration testing and vulnerability scanning** with documented remediation. - **asset inventory and network map** maintained and updated. - **Network segmentation** required to limit lateral movement. - **24-hour incident notification** from Business Associates to Covered Entities for security incidents, dramatically tighter than the current 60-day breach window. - **Written verification annually** from Business Associates that their safeguards meet Security Rule requirements, signed by a person with authority. - **Contingency planning** with 72-hour restoration targets for critical systems. For a device manufacturer with a cloud backend, this means the engineering investment HIPAA expects is now closer to what the FDA expects under the 2026 premarket guidance, which is helpful. Where they diverge is the operational overhead: HIPAA's 24-hour BA-to-CE incident clock and the annual written verification are administrative burdens the FDA does not impose. ## HIPAA vs FDA cybersecurity: where they overlap and where they don't | Dimension | HIPAA Security Rule | FDA Feb 3, 2026 guidance | |---|---|---| | Statutory basis | HIPAA / HITECH | FD&C Act Section 524B | | Enforcer | HHS OCR | FDA CDRH | | Object of protection | PHI confidentiality, integrity, availability | Device safety and effectiveness | | Applies to | Covered Entities and Business Associates | Medical device manufacturers (cyber devices) | | Risk analysis | §164.308(a)(1)(ii)(A) | Security risk assessment, threat model | | Encryption | Mandatory under 2025 NPRM (addressable today) | Expected; documented per architecture view | | Access control | §164.312(a) | Documented in Security Architecture Views | | Incident response | §164.308(a)(6); BA notice in 24h under NPRM | Coordinated vulnerability disclosure; postmarket plan | | Breach reporting | OCR within 60 days (BA to CE: 60d today, 24h proposed) | 21 CFR 803 MDR if serious injury/death is implicated | | Documentation audience | OCR investigators, plaintiffs | FDA reviewers, postmarket auditors | The control families overlap heavily. The documentation, the auditor, and the enforcement consequence do not. Treating one set of evidence as sufficient for both is the recurring mistake. [Talk to us about your HIPAA and FDA cybersecurity strategy →](/contact) ## Breach notification: dual obligations to OCR and the FDA A single cybersecurity event involving a connected device can trigger: - **HIPAA Breach Notification Rule**, OCR within 60 days of discovery, individuals notified, media notification if the breach affects 500+ individuals in a state. - **FDA postmarket reporting** under 21 CFR 803 if the event caused or could have caused death or serious injury (a ransomware event that delays therapy can qualify). - **Coordinated vulnerability disclosure** under the FDA's postmarket cybersecurity guidance and CISA's CVD framework. - **State breach notification laws**, which vary and sometimes have shorter clocks than HIPAA. - **Under the 2025 NPRM**, Business Associate to Covered Entity notification within 24 hours for any reportable security incident. The playbook needs to be written before the event, and it needs to live in both the Security Risk Management File (for the FDA) and the HIPAA incident response plan (for OCR). ## How Blue Goat approaches HIPAA for medical device manufacturers Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. For HIPAA-adjacent engagements we map every PHI flow to both regimes: the FDA's threat model, Security Architecture Views, and labeling on one side, and the HIPAA Security Rule's §164.308/310/312 safeguards on the other. The same control evidence (encryption design, audit logging, access control) is produced once and used twice. For manufacturers operating cloud backends, we build the Business Associate posture against the 2025 NPRM baseline, not the 2013 baseline, because that is where enforcement is heading. See our [medical device cybersecurity services](/services) for scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### Is a medical device manufacturer a Covered Entity under HIPAA? Almost never. Covered Entities are health plans, healthcare clearinghouses, and most healthcare providers. A device manufacturer becomes a Business Associate, not a Covered Entity, when it handles PHI on behalf of a Covered Entity. Selling a device that creates PHI used only inside the hospital does not, by itself, make the manufacturer a Covered Entity or a Business Associate. ### When does a manufacturer become a Business Associate? The trigger is handling PHI on behalf of a Covered Entity. Operating a cloud backend that ingests PHI from the device, providing remote monitoring as a service, hosting a patient portal, or running managed analytics all create Business Associate status. The day data starts flowing is the day the obligation begins, with or without a signed BAA. ### What is the 2025 HIPAA Security Rule NPRM? The Notice of Proposed Rulemaking published by HHS on January 6, 2025 (90 FR 898) is the first major update to the Security Rule since 2013. It would remove "addressable" implementation specifications, mandate encryption and multi-factor authentication, require annual penetration testing, asset inventories, network segmentation, and 24-hour Business Associate to Covered Entity incident notification. It is proposed, not yet final, but vendors should plan against it. ### Does HIPAA require encryption today? Today, encryption is an "addressable" specification under §164.312(a)(2)(iv) and (e)(2)(ii), meaning you must implement it or document why an equivalent measure is reasonable. Under the proposed 2025 NPRM, encryption becomes a required specification for ePHI at rest and in transit, with only narrow exceptions. ### How does HIPAA relate to the FDA's Feb 2026 cybersecurity guidance? The two regimes overlap in control families (risk analysis, access control, audit logging, encryption, incident response) but have different enforcers, documentation audiences, and consequences. HIPAA protects PHI and is enforced by HHS OCR. The FDA's guidance protects device safety and effectiveness and is enforced by CDRH. Manufacturers operating cloud backends typically need to satisfy both, and the evidence can be produced once if planned that way. ### What happens if my device has a breach? You may have to notify HHS OCR within 60 days under the HIPAA Breach Notification Rule, file an MDR with the FDA under 21 CFR 803 if the event caused or could cause death or serious injury, run coordinated vulnerability disclosure, and comply with state breach laws. Under the 2025 NPRM, Business Associates would also have to notify Covered Entities within 24 hours. The incident response plan needs to address all of these in one playbook. ## CTA Building a connected device with a cloud backend, or already getting hospital security questionnaires you cannot answer? We build the HIPAA Business Associate posture against the 2025 NPRM baseline and align it with your FDA cybersecurity documentation so the same evidence serves both regulators. [Schedule a discovery session →](/contact) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity, including HIPAA Business Associate posture for manufacturer-operated cloud backends and remote monitoring services. [Read more about Christian](/christian-espinosa). --- ## HL7 Cybersecurity Concerns for Medical Devices Source: https://bluegoatcyber.com/blog/hl7-navigating-the-complexities-of-healthcare-data-exchange # HL7 Cybersecurity Concerns for Medical: What Manufacturers Need to Know > **[DIRECT ANSWER]** HL7 is the messaging standard that lets healthcare systems, including connected medical devices, exchange patient data, but older versions often lack encryption and strong authentication, exposing that data to interception or tampering. Manufacturers using HL7 interfaces should apply encryption, access controls, and monitoring, and align documentation with the FDA's February 3, 2026 cybersecurity guidance and standards like IEC 81001-5-1 to support premarket review. _Reviewed July 24, 2026_ Health Level 7 (HL7) is a vital cog in the machinery of healthcare information technology. It is the backbone for data exchange across various healthcare systems, facilitating improved patient care and efficient administration. However, the extensive adoption of HL7 also brings forth significant security challenges. This blog post aims to provide an in-depth analysis of HL7, exploring its purpose, inherent security flaws, and the measures taken to mitigate these risks while also considering its regulatory compliance and future trajectory. ## Key Takeaways - HL7 standards facilitate data exchange in healthcare. - Older HL7 versions have significant cybersecurity flaws. - Lack of encryption exposes data to interception. - Weak authentication can lead to unauthorized access. - Legacy systems with HL7 are prime cyberattack targets. - Regulatory compliance like HIPAA matters for HL7. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to cybersecurity concerns with hl7 the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What is HL7? HL7, or Health Level Seven International, represents a suite of international standards for transferring and managing healthcare information between various systems healthcare providers use. It’s a cornerstone protocol in healthcare IT designed to bridge the gap between disparate systems and ensure smooth communication. Let’s delve deeper into what HL7 entails: - **Origin and Development**: HL7 was developed by [Health Level Seven International](https://www.hl7.org/ ""), a not-for-profit, ANSI-accredited standards-developing organization. Founded in 1987, the organization aimed to create a standardized framework for exchanging, managing, and integrating electronic healthcare information. - **Standardization in Healthcare Information**: HL7 addresses the need for standardization in the diverse landscape of healthcare IT. It encapsulates a variety of guidelines, methodologies, and frameworks to enable different healthcare systems - such as electronic health records (EHRs), laboratory information systems (LIS), and radiology information systems (RIS) - to communicate effectively. - **HL7 Versions**: Over the years, HL7 has evolved, with multiple versions addressing various aspects of healthcare information exchange. The most widely adopted versions are HL7 Version 2.x and HL7 Version 3, each with its unique structure and use cases. HL7 V2.x is known for its ease of implementation and wide adoption, while V3 offers more rigor and complexity, focusing on standardizing the entire data exchange process. - **FHIR (Fast Healthcare Interoperability Resources)**: The latest advancement in HL7 is [FHIR](/blog/the-fhir-medical-device-protocol). It utilizes modern web technologies and methodologies to combine the best features of HL7’s Version 2, Version 3, and CDA (Clinical Document Architecture) standards. FHIR is designed to simplify implementation without sacrificing information integrity and is rapidly gaining traction as the go-to standard for electronic health data exchange. - **Scope and Applications**: HL7 standards cover a wide range of healthcare data management needs. From administrative tasks, such as patient scheduling and billing, to clinical aspects, like patient care and laboratory results management, HL7 facilitates a broad spectrum of healthcare activities. It’s instrumental in integrating various systems within a healthcare facility and enabling interoperability between different healthcare organizations. - **Global Impact and Adoption**: HL7 standards have been adopted worldwide, influencing how healthcare data is exchanged globally. This wide adoption underscores its importance in promoting global health data interoperability and improving healthcare delivery and patient outcomes. - **Community and Collaboration**: HL7’s development and evolution are driven by a global community of healthcare IT professionals, including system developers, implementers, and end-users. This collaborative approach ensures that the standards remain relevant, practical, and in line with the evolving needs of the healthcare industry. ## The Purpose and Use of HL7 HL7 standards serve as the language of healthcare data exchange. Primarily, they: - **Enable Interoperability**: HL7 allows different healthcare systems and applications to communicate and understand each other’s data. - **Facilitate Data Exchange**: It streamlines the sharing of clinical and administrative data, including patient records, appointment schedules, billing information, medical reports, and treatment plans. - **Improve Patient Care**: HL7 provides timely and accurate patient care by ensuring data transfer. - **Enhance Healthcare Administration**: It simplifies administrative processes like insurance claims, payment processing, and regulatory compliance. HL7 bridges the gaps between diverse healthcare systems, ensuring that crucial health data is accurately and swiftly shared across platforms. ## Cybersecurity Flaws within HL7 Despite its benefits, HL7 comes with notable security concerns: - **Data Interception Vulnerabilities**: Older versions of HL7 lack strong encryption, making data susceptible to interception during transmission. - **Weak Authentication and Authorization**: Inadequate security protocols can lead to unauthorized access to sensitive health information. - **Data Integrity Issues**: Without proper safeguards, the integrity of HL7-transmitted data can be compromised, leading to potential misdiagnoses or treatment errors. - **Exposure of Legacy Systems**: Many healthcare providers use older systems with outdated HL7 standards, vulnerable to modern cyber threats. ## HL7 Abuse Cases ### Large-Scale Health Data Breach In one significant incident, a large healthcare provider experienced a massive data breach where attackers exploited vulnerabilities in the HL7 protocol. This breach led to the unauthorized access of millions of patient records, including sensitive data like medical histories, treatment information, and personal identification details. The attackers bypassed the system’s security due to weak encryption in the HL7 data transmissions. This incident not only resulted in a substantial violation of patient privacy but also raised serious concerns about the robustness of HL7 security measures. ### Hospital Network Cyberattack A sophisticated cyberattack targeted a group of hospitals. The perpetrators leveraged HL7 vulnerabilities to gain access to the network. The attackers exploited unpatched security flaws in the HL7 interface, allowing them to infiltrate the network and disrupt hospital operations. This led to significant delays in patient care services, compromised patient data, and substantial financial losses for the hospitals involved. The incident underscored the importance of regular software updates and the dangers of legacy systems with outdated security protocols. ### Ransomware Attack Exploiting HL7 Vulnerabilities In another instance, a ransomware attack on a healthcare system was traced back to vulnerabilities in the HL7 protocol. Cybercriminals exploited these weaknesses to deploy [ransomware](/blog) across the network, leading to widespread data encryption and system lockdowns. Vital patient care services were halted, causing considerable disruption and endangering patient safety. This attack highlighted the potential for HL7 vulnerabilities to be used as entry points for more extensive network compromises. ### Unauthorized Data Access and Manipulation A smaller-scale but equally concerning incident involved unauthorized access to a healthcare provider’s HL7 system. An attacker manipulated patient data by exploiting insufficient authentication mechanisms within the HL7 protocol. This data manipulation led to incorrect patient records and posed serious patient treatment and diagnosis risks. The breach was a stark reminder of the potential consequences of inadequate authentication and authorization controls in healthcare IT systems. ### Interception of Sensitive Health Information There have been instances where sensitive health information was intercepted during transmission over HL7 protocols. Due to the lack of encryption, attackers could eavesdrop on the data exchange, gaining access to confidential patient information. This vulnerability exploitation compromises patient confidentiality and violates healthcare privacy regulations like HIPAA. ## Addressing HL7 Security Flaws To combat these vulnerabilities, a multi-faceted approach is needed: - **Implementing End-to-End Encryption**: Ensuring all data in transit is encrypted to prevent unauthorized interception. - **User Authentication**: Strengthening access controls to protect against unauthorized data access. - **Regular Security Audits and Updates**: Keeping HL7 systems updated with the latest security patches and conducting frequent audits. - **Training and Awareness**: Educating healthcare personnel on data security and best practices. ## HL7 and Regulatory Compliance HL7 compliance with healthcare regulations, such as HIPAA in the United States, is crucial. It involves: - **Ensuring Privacy and Confidentiality**: Adhering to standards that protect patient data privacy and confidentiality per legal requirements. - **Data Protection Measures**: Implementing security measures mandated by healthcare regulations to protect patient data. - **Regular Compliance Audits**: Conducting audits to ensure continuous compliance with healthcare laws and guidelines. ## The Future of HL7 Looking ahead, HL7 is poised for significant evolution: - **Embracing Advanced Technologies**: Integration with newer technologies like blockchain and [AI](/blog/safeguarding-medical-device-ai-combating-data-poisoning-cybersecurity-threats) to enhance security and efficiency. - **Enhanced Security Features**: Incorporating more encryption and authentication mechanisms in future versions. - **Global Standardization**: Efforts towards global standardization of HL7 to facilitate international interoperability. ## HL7 v2, HL7 v3, and FHIR compared Most confusion about HL7 security comes from treating three different things as one standard. | Dimension | HL7 v2 | HL7 v3 and CDA | FHIR | | --- | --- | --- | --- | | Typical transport | MLLP over raw TCP | File exchange or messaging middleware | HTTPS REST APIs | | Encryption by default | No, TLS must be added around MLLP | Depends entirely on the transport chosen | Yes in practice, TLS is assumed | | Authentication model | None in the standard, the network is the control | None in the standard | OAuth 2.0 and SMART on FHIR profiles | | Message integrity | No signature, trust is positional | XML digital signatures are possible but uncommon | Transport integrity plus token scope | | Common real weakness | An open MLLP listener that accepts any connection | Parser handling of complex XML documents | Over broad token scopes and missing authorization checks per resource | | What a reviewer asks | How is the interface authenticated and segmented | How are documents validated and stored | How are tokens issued, scoped, and revoked | If your device speaks HL7 v2, the interface itself gives you no security. Everything protecting it sits outside the message. ## Conclusion HL7 has undeniably transformed the landscape of healthcare information exchange. However, its utility must be balanced with stringent security measures to protect against the cyber threats. The healthcare industry must continue to evolve and adapt its approach to HL7, ensuring it complies with current regulatory standards and remains prepared for future challenges. As we embrace advanced technologies, the role of HL7 will be pivotal in shaping a more secure, efficient, and interconnected healthcare ecosystem. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is HL7 in healthcare? HL7 (Health Level Seven) is a set of international standards for the exchange, integration, and retrieval of electronic health information. It enables communication between health IT systems like EHRs, lab systems, and medical devices. ### Why is cybersecurity important when using HL7 protocols? HL7 messages often contain protected health information (PHI). Without proper security, these messages can be intercepted, modified, or leaked, which leads to HIPAA violations and patient safety risks. ### Are HL7 messages encrypted by default? No, HL7 v2.x, the most widely used version, does not include native encryption. It must be secured using external transport-layer protections such as TLS (Transport Layer Security) or a VPN. ### What are common cybersecurity risks in HL7 communications? Risks include man-in-the-middle attacks, data interception or tampering, replay attacks, unsecured endpoints, and unauthorized access to message logs. ### How can HL7 messages be secured during transmission? Secure HL7 messages by implementing TLS encryption, using mutual authentication, and restricting message transport to trusted IP addresses and ports. ### Does the FDA have specific guidance for medical devices using HL7? The FDA's February 3, 2026 final guidance on premarket cybersecurity for medical devices applies to devices integrating with healthcare IT, including those using HL7. Manufacturers must demonstrate how HL7 use meets cybersecurity requirements. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Home Use vs Hospital Device Cybersecurity Requirements Source: https://bluegoatcyber.com/blog/home-use-vs-hospital-device-cybersecurity # Home Use vs Hospital Device Cybersecurity Requirements > **[DIRECT ANSWER]** A hospital device inherits network segmentation, managed identity, physical access control, and biomed-led patching from the health delivery organization, so its security risk file can credit those controls. A home use device inherits none of them and must carry authentication, secure boot, encrypted transport, automatic update delivery, and secure decommissioning itself. The February 3, 2026 premarket cybersecurity guidance expects your threat model to name the assumed use environment and to defend every control you hand to the user. Two devices can run the same firmware, expose the same interfaces, and still need different security packages. The difference is where the device is indicated to operate. A hospital deployment sits inside an environment somebody else secures. A patient's living room does not. When the intended use environment moves from a health delivery organization to a home, the controls a manufacturer was quietly relying on disappear, and the FDA reviewer notices when the threat model still assumes they are there. Section 524B applies to both. The difference is not whether you owe a cybersecurity package, it is which assumptions that package is allowed to make. ## Key Takeaways - The health delivery organization environment supplies compensating controls that a home environment does not, and your risk file may only credit controls that actually exist. - Every environmental assumption in the threat model is a claim the FDA can ask you to substantiate in the security architecture views. - Home use pushes authentication, key management, update delivery, and end-of-life data destruction onto the device itself. - Labeling is the weakest control in the ISO 14971 hierarchy, and an untrained home user is the least reliable place to put a security requirement. - A dual-environment indication means engineering to the weaker environment rather than maintaining two sets of assumptions. - Expanding a cleared professional-use device into home use adds attack surface and generally triggers a new 510(k) rather than a letter to file. ## Why This Matters The FDA final guidance *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026, asks for security architecture views that show trust boundaries and the controls at each one. A trust boundary is defined by the environment on either side of it, which means the views cannot be drawn without first fixing the intended use environment. That is where use environment stops being a regulatory affairs detail. If your data flow diagram shows a device on a segmented clinical VLAN behind institutional authentication, you have credited controls owned by the health delivery organization. If the Indications for Use statement also permits unsupervised home use, those credits are unearned for a large share of your installed base, and the residual risk in the ISO 14971 file is understated. Home-use growth makes this common rather than exotic. Remote patient monitoring, home dialysis, home ventilation, continuous glucose monitoring, and at-home infusion all place networked devices on consumer routers with no security staff behind them. The device is the perimeter. ISO 14971 puts inherent safety by design first, protective measures second, and information for safety last. IEC 60601-1-11 already sets requirements specific to the home healthcare environment, and AAMI TIR57 expects the security risk process to reflect the real operational context. A control that only works when a trained biomed technician applies it is not a control in a house. ## What does the hospital environment give you that the home does not? The health delivery organization supplies a layered environment that absorbs a meaningful part of the device's risk. Your device benefits from it whether or not you wrote it down. | Control | Hospital environment | Home environment | | --- | --- | --- | | Network segmentation | Clinical VLANs, firewalls, medical device isolation | One flat consumer router, shared with everything else | | Identity and access | Managed directory, badge access, role separation | One household, often one shared login | | Physical security | Locked rooms, staffed floors, asset tracking | Unrestricted access by anyone in the house | | Patching | Biomed and IT teams with maintenance windows | The patient, if they notice at all | | Monitoring | Security operations, network detection, asset inventory | None | | Procurement review | MDS2 forms, security questionnaires, contractual controls | No review at all | > **[KEY REQUIREMENT]** Any control listed in the hospital column that your risk file relies on must be replaced by a device-resident control before the same product can be indicated for home use. ## Which assumptions break the moment a device goes home? Five assumptions fail immediately, and each one shows up as a deficiency when the threat model still carries it. The network is trusted. A home router may be unpatched, running default credentials, or already compromised. Treat the local network as hostile and authenticate and encrypt accordingly. The operator is trained. A clinician follows procedure and escalates anomalies. A patient may hand the device to a family member, reuse a password, or ignore an alert entirely. Physical access is controlled. Visiting relatives, children, housemates, and eventual resale on a secondhand marketplace all count as physical access to your device and whatever data it retains. Updates will be applied. Nobody in the house is scheduling a maintenance window. If the update is not automatic, assume it does not happen. The device stays with one patient. Home devices are returned, refurbished, loaned, and resold. Residual patient data and residual credentials travel with them. ## Which controls move onto the device itself? Everything the environment used to provide has to be designed in. That is the practical cost of a home-use indication. - **Device-side authentication** that does not depend on an enterprise directory, with a credential recovery path a patient can complete without a help desk. - **Secure boot and firmware integrity verification**, because physical access is now realistic and tamper detection has no staff to alert. - **Encrypted transport to your cloud** with certificate validation, assuming an untrusted local network end to end rather than TLS terminated at a trusted gateway. - **Automatic, signed, resumable updates** with rollback protection, delivered without user action and tolerant of intermittent residential connectivity. - **Secure decommissioning**, including a factory reset that removes patient data and unbinds credentials, verifiable by the manufacturer rather than trusted to the user. - **Caregiver and multi-user access** modeled explicitly, so shared household use does not become one permanent shared credential. Each of these belongs in the security architecture views and the control traceability, not only in the design history file. ## How does the use environment change the threat model and testing? The use environment sets the attacker you are defending against, which changes both the threat model and the test plan. In a hospital model, the relevant adversaries are typically a compromised workstation on the clinical network, a malicious insider, and a lateral-movement path from the enterprise side. In a home model, add a compromised consumer router, a hostile household member, an attacker with unlimited physical access and time, and a purchaser who acquired the device secondhand. That difference lands directly in penetration testing scope. A home use engagement should include physical and hardware attack paths such as debug ports, storage extraction, and firmware dumping, alongside pairing and provisioning flows, credential recovery abuse, and the mobile app and cloud backend that most home devices depend on. > **[KEY REQUIREMENT]** If your indication permits home use, the penetration test scope has to include physical attack paths. A network-only test against a device an attacker can hold in their hands does not match the threat model you filed. Availability also changes character. In a hospital a dropped connection meets staff and backup procedures. At home an availability failure may go unnoticed for hours, which raises the harm rating for denial-of-service threats in the risk assessment. Need to see how this feeds the submission? Our [medical device threat modeling service](/services/medical-device-threat-modeling) builds the views and trust boundaries around the environment you actually claim. ## What happens when you claim both environments? Design to the weaker environment. A device indicated for both professional and home use does not get to maintain two sets of assumptions, because the FDA evaluates the residual risk for the full indicated population. In practice that means the home-use control set becomes the baseline, and the hospital deployment simply benefits from additional layers it does not have to rely on. Writing it the other way around, with the home configuration as a reduced variant, is what produces the mismatch reviewers catch. Expanding an existing cleared device into home use deserves particular care. It removes the assumed managed network, adds physical access threats, and usually adds a consumer app or cloud service. Those are new attack surface and new risk, which normally means a new 510(k) rather than a letter to file. Our [pathway crosswalk tool](/tools/pathway-crosswalk) walks that decision against the cybersecurity factors reviewers weigh, and the [indications for use and predicate scope post](/blog/indications-for-use-predicates-cybersecurity-510k-scope) covers how the statement itself drives submission scope. ## How Blue Goat Cyber Approaches This We read the intended use environment before we look at the architecture, because the environment determines which controls your risk file is allowed to credit. Our team holds medical device and offensive security credentials and works only on regulated devices, so the trust boundaries we draw reflect how these products are actually deployed. For a home use or dual-environment device we build the threat model against the weaker environment first, then document where the hospital deployment adds layers on top. We enumerate every assumption the model makes about the network, the user, and physical access, and we mark each one as either a device-resident control or an environmental dependency. Environmental dependencies that cannot survive a home deployment get raised during design, not after a deficiency letter. Testing follows the same logic. Home use engagements include hardware and physical attack paths, provisioning and recovery abuse, and the companion app and cloud backend, because that is the surface the filed threat model describes. Where the [security risk assessment](/services/fda-premarket-cybersecurity-services) leaves a control to the user, we say so plainly and document why that placement is defensible under ISO 14971. ## FAQ **Does a home use indication mean stricter cybersecurity requirements than hospital use?** Not stricter requirements, different assumptions. Section 524B and the February 3, 2026 guidance apply the same way to both. What changes is that a home device cannot credit network segmentation, managed identity, physical security, or professional patching in its risk file, so those controls have to be designed into the device before residual risk is acceptable. **Can we rely on labeling to tell home users how to secure their network?** Only as a supplement. ISO 14971 places information for safety last in the control hierarchy, below inherent safety by design and protective measures. An instruction that asks a patient to configure a VLAN or change router credentials is not a control a reviewer will accept as the primary mitigation for a significant threat. **Our device is hospital-only today. What triggers a new submission if we add home use?** Adding home use removes the assumed managed network, introduces unrestricted physical access, and usually adds a companion app or cloud service. Each of those is new attack surface with a new harm profile, which normally exceeds what a letter to file can support. Expect a new 510(k) with an updated threat model and expanded test evidence. **How do we handle devices that are returned, refurbished, or resold?** Treat decommissioning as a designed function rather than a procedure. The device needs a factory reset that erases patient data, revokes stored credentials, and unbinds the device from the prior account, plus documentation of what the reset does and does not clear. Assume the next holder is not authorized and is curious. **Does IEC 60601-1-11 cover home-use cybersecurity?** It sets requirements for medical electrical equipment used in the home healthcare environment, which establishes the operational context, but it is not a cybersecurity standard. Pair it with AAMI SW96 for security risk management, ISO 14971 for the risk process, and the February 3, 2026 guidance for premarket content expectations. **Should the penetration test scope differ for a home use device?** Yes. Include physical and hardware attack paths such as debug interfaces, storage extraction, and firmware retrieval, because an attacker with the device in hand is a realistic scenario rather than a theoretical one. Also test pairing, provisioning, credential recovery, and the companion app and cloud backend the device depends on. ## CTA If your device is moving from the clinic into the home, the assumptions in your threat model probably moved with it. We rebuild the model against the environment you are actually claiming and scope testing to match. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to walk through your use environment and submission scope. --- ## How Can Medical Device Manufacturers Source: https://bluegoatcyber.com/blog/how-can-medical-device-manufacturers-support-operational-cybersecurity # How Can Medical Device Manufacturers Support Operational Cybersecurity? > **[DIRECT ANSWER]** Manufacturers support operational cybersecurity by shipping what hospitals actually need to run the device safely: a current SBOM, hardening and network-segmentation guidance, a patch cadence with published timelines, a coordinated vulnerability disclosure channel, and clear end-of-support dates. Then keep the loop open, monitor CVE and KEV feeds against your SBOM, issue VEX statements, and notify customers before they read about a vulnerability elsewhere. Medical device cybersecurity has a long lifecycle. Manufacturers put much of their effort into gaining approval from the Food and Drug Administration (FDA). Following [FDA guidance](https://www.fda.gov/media/119933/download) regarding all the security controls isn’t the law, but the agency can reject premarket submissions. These continue as the device goes to market, and operational cybersecurity is now a shared responsibility. Hospitals and healthcare organizations are accelerating their use of medical devices. They have become critical in diagnosis and care. They do, however, increase risk, expanding the attack surface. Healthcare sits at the top of industries with the most attacks and has inherent weaknesses in its perimeter. What’s the role of manufacturers in supporting operational cybersecurity? ## Key Takeaways - Postmarket cybersecurity requires manufacturer-provider collaboration. - Shared responsibility for device security post-approval. - Manufacturers provide SBOMs and patch plans. - Healthcare organizations need accurate device inventories. - Integrate FDA guidance into healthcare frameworks. - Regular penetration testing benefits both parties. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to how can medical device manufacturers support operational cybersecurity? the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Post-Clearance: Medical Devices in Use and at Risk Once a medical device receives approval and is in use, that’s when risk elevates. They often become part of a network, and the reliability of it as a strong defense is out of the control of manufacturers. What device makers have done prior to this is create an [SBOM (software bill of materials)](/blog/medical-device-sbom-fda-requirements-and-submission-guide) and a patching plan. If they determine there is a vulnerability, they must then immediately dispatch the update. They’ve also done tremendous testing on the integrity of the device to be cyber-secure and resilient. All that work can be undone if the hosting party has a weak defense. Perimeter controls are notoriously ineffective. Simply having visibility across an extensive network of devices challenges most healthcare security teams. While hacking a device is possible and could jeopardize care, most cyber criminals simply want the data healthcare holds. The PII, PHI, and other sensitive information are gold for these folks. A medical device could be a way in, which is where software vulnerabilities come into play. Manufacturers are watching those. What happens when it’s not a software weakness? Social engineering and phishing are preferred methods for hackers. Why? Because they work. AI is supercharging these efforts, with people falling victim and exposing their credentials. If this is the path for a breach, manufacturers aren’t in the ecosystem, but they could be on the hook for the blame game. Data breaches require notification and reasons, and if a device is part of that, it could harm a manufacturer’s reputation. That’s why every stakeholder needs to collaborate. ## Medical Device Makers and Hospitals Working Together One of the biggest challenges in operational cybersecurity for medical devices is a disconnected landscape. The FDA has purview over approvals and can enforce penalties for cyber incidents, but they’ve not gone as far as to create collaborative groups between parties. Since that’s likely not a priority, manufacturers and healthcare organizations should form these task forces. Ultimately, both want devices to be secure and integrated into care regimes. By pooling resources and communicating regularly and effectively, everyone can form a more proactive stance on cybersecurity. Some key things they could put on the agenda include the following: ### 1\. Ensure all organizations have an accurate inventory of all medical devices This has been a concern for some time. It’s not just the new devices purchased. There is a secondhand market for devices, and manufacturers often don’t know where they go. If they’re unaware of their location, they can’t patch or update them. ### 2\. Integrate FDA guidance for manufacturers into healthcare cybersecurity frameworks Many of the best practices and directives have relevance beyond the manufacturer. Healthcare certainly has many regulations to adhere to when it comes to data security, but they often overlook the role of devices. They simply lack the expertise in most cases. ### 3\. Develop a cadence for penetration testing Manufacturers and healthcare should unite on this and hire experts to perform these. Collectively, you’ll learn much more from [pen testing](/services) than from anything else. ### 4\. Enable access to SBOMs A SBOM is not a one-and-done. It needs to be actively updated. Having these accessible to invested parties provides transparency. In addition to manufacturers and providers, these groups can also benefit from outside experts like our team. We focus specifically on the medical device space with services for any need. [Get in touch](/contact) to learn more. ## Two Gaps Operational Cybersecurity Still Has to Close Beyond the manufacturer-hospital collaboration described above, two structural gaps make operational cybersecurity harder than the premarket guidance alone can fix: dispersed responsibility and a scarcity of asset inventory, particularly for devices resold or refurbished on the secondary market. Dispersed responsibility means no single party, manufacturer, hospital, or regulator, owns device security end to end. That shows up in practice as inconsistent vulnerability handling, communication gaps between stakeholders, and slower remediation because everyone assumes someone else is tracking the issue. The February 3, 2026 guidance strengthens manufacturer obligations for new submissions, but it does not assign a single owner across the lifecycle, so the coordination described earlier in this article, task forces, shared inventories, joint patch cadences, has to fill that gap voluntarily. The asset inventory gap compounds it. A device sold new, then resold or refurbished on the secondary market, often becomes untraceable to the manufacturer that built it. Without knowing where a device is or who operates it, a manufacturer cannot deliver a patch or a vulnerability disclosure, no matter how well its SBOM and update process work on paper. | Gap | Effect on operational cybersecurity | Who is positioned to close it | | --- | --- | --- | | Dispersed responsibility | Inconsistent, fragmented vulnerability response | Manufacturer-provider task forces and shared accountability agreements | | Scarcity of asset inventory | Patches and disclosures cannot reach secondary-market devices | Sector-wide device registries and resale tracking, not the FDA alone | Neither gap has a regulatory fix on the near horizon, since the FDA is not positioned to mandate cross-industry inventory systems and has limited staff to pursue one. That leaves the practical path in the hands of manufacturers and healthcare organizations building the inventory and accountability structures described earlier in this article themselves, rather than waiting on guidance to close a gap it was not designed to reach. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## Faq ### What is operational cybersecurity for medical devices? Operational cybersecurity for medical devices addresses securing devices once they are deployed and in use within healthcare environments, extending beyond initial premarket approval. It involves ongoing management of vulnerabilities, data protection, and incident response. ### How does the FDA influence postmarket device cybersecurity? The FDA influences postmarket device cybersecurity by issuing guidance that manufacturers adhere to during premarket submissions, including cybersecurity controls. While the agency doesn’t dictate all operational aspects, its frameworks impact device design for security. ### Why is an SBOM important for operational cybersecurity? An SBOM (Software Bill of Materials) is important for operational cybersecurity as it provides transparency into device software components. This allows healthcare organizations and manufacturers to identify and address known vulnerabilities proactively. ### How can manufacturers and healthcare providers collaborate on cybersecurity? Manufacturers and healthcare providers can collaborate by sharing device inventories, integrating relevant FDA guidance into security practices, conducting joint penetration testing, and Ensure active access to updated SBOMs for deployed devices. ### Does the FDA mandate collaboration between manufacturers and providers? The FDA encourages cybersecurity best practices but does not currently mandate specific collaborative entities between manufacturers and providers for operational cybersecurity. Such collaboration is typically initiated by the involved parties. ### What role do external experts play in medical device operational cybersecurity? External experts, like cybersecurity consultants, can provide specialized knowledge and services such as penetration testing, risk assessments, and guidance on implementing secure operational practices for both manufacturers and healthcare organizations. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [How Medical Device Manufacturers Can](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) --- ## FDA Cybersecurity Review Timeline: 510(k) & De Novo Guide Source: https://bluegoatcyber.com/blog/how-long-does-fda-cybersecurity-review-take # FDA Cybersecurity Review Timeline: What to Expect in 2026 > **[DIRECT ANSWER]** A 510(k) with a clean cybersecurity package typically clears within the MDUFA goal of 90 review days if no deficiency letter is issued. In practice, most submissions with a cyber device profile receive at least one Additional Information request, which pauses the clock and adds 60 to 180 days depending on response speed. De Novo and PMA reviews run longer, and an RTA hold at intake can add weeks before substantive review even starts. "How long will this take" is usually the first question a program manager asks once cybersecurity work starts, and it is also the hardest to answer honestly, because the honest answer depends entirely on how complete your Secure Product Development Framework evidence is before you file. This post walks through the actual clock mechanics, where cybersecurity-specific delays come from, and what measurably shortens the real timeline. ## Key Takeaways - MDUFA goals target 90 days for a 510(k) decision, but that clock pauses entirely during any RTA hold or Additional Information request, which most cyber device submissions receive at least once. - An RTA hold happens in the first 15 days if a required cybersecurity artifact, most often the SBOM, is missing outright, and it stops the clock before substantive review even begins. - The day-60 substantive interaction milestone is when most cybersecurity-specific questions surface, because that is when a reviewer has had time to actually work through the SPDF evidence. - You get 180 days to respond to a Major deficiency or AI letter, but using the full window adds that time directly to your calendar; fast, complete responses clear meaningfully sooner. - Pre-submission meetings and a completed penetration test before filing are the two levers manufacturers control that most reliably shorten the real-world timeline. ## Understanding the FDA review clock The Medical Device User Fee Amendments (MDUFA) set performance goals the FDA tracks against, not statutory deadlines. For a standard 510(k), the MDUFA V goal is a decision within 90 FDA review days. That number gets misunderstood constantly: it counts only the days the submission is actively with FDA reviewers. Any time the file is on hold, whether for an RTA screening failure or an outstanding Additional Information (AI) request, does not count against the 90-day goal, and it also does not count against your actual calendar time to market. Manufacturers plan around the wrong number when they treat 90 days as a ceiling rather than as the FDA's own internal target for its active review time. Cybersecurity has become one of the more common sources of clock-stopping activity since Section 524B's requirements began being enforced at RTA in October 2023, precisely because it is a discrete, checkable set of artifacts (SBOM, threat model, vulnerability plan) that either exist in the right form or do not. ## 510(k) vs. De Novo vs. PMA timelines | Pathway | MDUFA goal | Typical real-world timeline with cybersecurity review | Notes | |---|---|---|---| | 510(k) | 90 FDA review days | 4 to 9 months to clearance | Fastest when no AI letter is issued | | De Novo | 150 FDA review days | 8 to 14 months to grant | Novel device profile means more cybersecurity scrutiny on first-of-kind features | | PMA | 180 FDA review days (for filing decision, with panel-track and advisory steps adding time) | 12 to 24+ months to approval | Deeper security risk management file and broader penetration test scope typically expected | These ranges assume at least one round of interactive review, which is the norm rather than the exception for a device that meets the 524B cyber device definition. See our [De Novo cybersecurity submission guide](/guides/de-novo-cybersecurity-submission-guide) and [PMA cybersecurity requirements guide](/guides/fda-pma-cybersecurity-requirements) for pathway-specific detail. ## The cybersecurity review process phases ### RTA screening: days 1-15 Within roughly 15 days of filing, FDA staff screen the submission for completeness, not scientific merit. For cyber devices, this screening explicitly checks for the presence of the required 524B artifacts: an SBOM, a cybersecurity management plan, and evidence of a vulnerability monitoring process. A missing SBOM at this stage is the single most common cybersecurity-related RTA hold, and it is entirely avoidable with a pre-filing completeness check. ### Substantive review and the day-60 milestone Once accepted, the submission moves into substantive review. Around the 60-day mark, FDA has historically committed to substantive interaction, meaning either an interactive review call or a written communication about the state of the review. For cybersecurity, this is frequently when the first specific questions surface: a reviewer has had time to actually work through the threat model, the penetration test report, and the SBOM, and this is where gaps in traceability or evidence depth get flagged. ### Deficiency letters and the final decision If issues remain unresolved through interactive review, FDA issues either an AI request for a narrower clarification or a Major deficiency letter for more substantial gaps. Both pause the review clock. Once the sponsor responds with a complete package, the review clock resumes, often with a fresh review period rather than picking up exactly where it left off. A clean response can lead to clearance within weeks of resubmission; an incomplete response restarts the cycle. ## Common causes of cybersecurity clock stops - **Deficiency letters and AI requests** citing gaps in SBOM completeness, threat modeling traceability, or postmarket vulnerability plan specificity. See our [deficiency letter examples guide](/guides/fda-cybersecurity-deficiency-letter-examples) for the actual patterns reviewers cite. - **Incomplete SBOMs and vulnerability assessments**, most often missing PURL/CPE identifiers or VEX statements for open CVEs, which prevents a reviewer from verifying the monitoring claim. - **Lack of traceability in threat modeling**, where mitigations are described but not linked to a specific verification test, forcing the reviewer to ask for the missing link explicitly rather than infer it. - **Penetration test scope gaps**, commonly a report that covers the mobile companion app but omits the device firmware or the wireless interface actually used in the field. ## How the RTA policy affects your timeline The Refuse to Accept policy for cyber devices, in effect since October 1, 2023, gives FDA staff explicit authority to hold a submission at intake if 524B artifacts are missing. This is procedurally different from a deficiency during substantive review: an RTA hold happens before any reviewer has evaluated the technical merit of your cybersecurity approach, purely on the basis of whether the required documents are present in the right format. It is the fastest timeline hit to avoid, because it is entirely within the sponsor's control. A pre-filing checklist run against the 524B(b)(1) through (b)(3) requirements, ideally by someone other than the person who assembled the submission, catches the vast majority of RTA-triggering gaps. See our [RTA prevention checklist](/guides/fda-cybersecurity-rta-prevention-checklist). ## Strategic ways to shorten the real timeline **Use a pre-submission meeting.** A Q-Sub meeting focused specifically on your cybersecurity approach, before you file, surfaces disagreements about scope or methodology while they are still cheap to resolve. Reviewers who have already seen your threat model approach in a pre-sub are less likely to raise a fundamental scope objection during substantive review. **Complete penetration testing before filing, not during review.** A submission that includes a finished, methodologically sound penetration test report avoids the most common source of AI requests in the SPDF category. Testing scheduled to run concurrently with FDA review, hoping to supplement the file later, almost always costs more calendar time than it saves. See our [penetration testing for medical devices guide](/guides/penetration-testing-for-medical-devices). **Respond fast and completely, not eventually.** The 180-day response window for a deficiency letter is a ceiling, not a target. Submissions that respond within two to three weeks with the specific requested evidence, rather than a narrative explanation, consistently clear faster in our experience across hundreds of engagements. **Build the SBOM from your build pipeline, not by hand at submission time.** A hand-assembled SBOM under deadline pressure is where most of the missing-identifier and stale-version problems originate. Automating generation removes the single most common RTA trigger. ## How Blue Goat Cyber approaches review timelines We treat the review timeline as a function of evidence completeness at filing, not as something to manage reactively once a deficiency letter arrives. That means running a full 524B completeness check before submission, scheduling penetration testing early enough that findings can still influence the design rather than only the documentation, and building the SBOM generation process into the build pipeline so it never becomes a last-minute reconstruction. Where a submission has already stalled on a deficiency letter, we scope the response against the underlying requirement rather than the letter's wording, because that is what actually closes the gap in one round instead of two. This work runs through our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) and [FDA Cybersecurity Deficiency Response](/services/fda-cybersecurity-deficiency-response) engagements. ## FAQ ### How long does a 510(k) cybersecurity review actually take? The MDUFA goal is a 90-day FDA review clock, but that clock pauses for any RTA hold or AI request. Most submissions with a cyber device profile receive at least one round of questions, which realistically puts total time to clearance in the 4 to 9 month range depending on response speed and how complete the initial SPDF evidence was. ### What triggers an FDA cybersecurity deficiency letter? The most common triggers are an incomplete or non-machine-readable SBOM, a threat model that is not traced to verification evidence, and a postmarket vulnerability plan that describes an intended process rather than an operating one. See our [deficiency letter examples guide](/guides/fda-cybersecurity-deficiency-letter-examples) for the specific patterns. ### Does the FDA review cybersecurity during the RTA phase? Yes. Since October 1, 2023, RTA screening explicitly checks for the presence of required 524B artifacts, most notably the SBOM and the cybersecurity management plan. This is a completeness check, not a technical evaluation, so a missing artifact triggers a hold regardless of how strong the underlying engineering work is. ### How many rounds of questions does the FDA typically ask about cybersecurity? One round of AI request or Major deficiency is common even for well-prepared submissions; two rounds usually indicates the first response addressed the letter's specific wording rather than the underlying requirement. Submissions that clear in zero rounds are the ones that completed penetration testing and SBOM generation well before filing. ### Does a De Novo take longer than a 510(k) for cybersecurity review? Generally yes. The MDUFA goal itself is longer (150 days versus 90), and because De Novo submissions involve a novel device type, reviewers often have less established precedent for what an adequate cybersecurity evidence package looks like, which can mean more back-and-forth on scope and methodology. ### Can a pre-submission meeting shorten my cybersecurity review timeline? Yes, indirectly. A pre-submission meeting does not shorten the formal review clock, but it surfaces disagreements about your cybersecurity methodology while they are inexpensive to resolve, which reduces the odds of a deficiency letter that would otherwise pause the clock for weeks or months. --- **Related reading on this site** - [FDA Cybersecurity Deficiency Letter Examples](/guides/fda-cybersecurity-deficiency-letter-examples) - [FDA Cybersecurity RTA Prevention Checklist](/guides/fda-cybersecurity-rta-prevention-checklist) - [FDA 524B Cybersecurity Requirements Explained](/guides/fda-524b-cybersecurity-requirements-explained) - [De Novo Cybersecurity Submission Guide](/guides/de-novo-cybersecurity-submission-guide) - [FDA PMA Cybersecurity Requirements](/guides/fda-pma-cybersecurity-requirements) *Reviewed by the Blue Goat Cyber team. Last updated July 26, 2026.* --- ## Medical Devices Are Designed Source: https://bluegoatcyber.com/blog/how-medical-devices-are-designed-with-patient-safety-as-the-priority # Medical Devices Are Designed with Patient Safety as the Priority > **[DIRECT ANSWER]** Medical devices are designed with patient safety as the priority through a structured process: identifying risks via formal risk assessments, incorporating safety features and redundancy, subjecting devices to rigorous environmental and performance testing, and enforcing quality assurance protocols throughout manufacturing. Regulatory bodies like the FDA require compliance with the Quality System Regulation and, increasingly, the February 3, 2026 cybersecurity guidance, since device security failures now directly threaten the same patient safety these design processes protect. _Updated November 16, 2024_ Medical devices play a crucial role in healthcare, helping to diagnose and treat diseases, monitor patients, and improve overall quality of life. However, the effectiveness and reliability of these devices heavily depend on one critical aspect: patient safety. Ensuring the safety of medical devices is a top priority for manufacturers and regulatory bodies alike. In this article, we will explore the various measures taken in the design process to prioritize patient safety and highlight the importance of this aspect in medical device design. ## Key Takeaways - Patient safety is the top priority in medical device design. - The FDA regulates medical device safety and efficacy. - Risk assessment and safety features are critical design steps. - Rigorous testing validates device safety and performance. - Quality assurance enforces high safety standards. - Cybersecurity is vital for protecting patient data and devices. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical devices are designed with patient safety as the priority the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding the Importance of Patient Safety in Medical Device Design Patient safety should never be compromised when it comes to medical devices. These devices are meant to assist healthcare providers in delivering effective treatment and care. Therefore, ensuring the safety of patients who rely on medical devices is paramount. Regulatory bodies such as the [Food and Drug Administration (FDA)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) and the European Medicines Agency (EMA) have implemented stringent guidelines and regulations to ensure the safety and efficacy of medical devices. Adhering to these regulations is essential for manufacturers to obtain necessary approvals and market their products. ### The Role of Regulatory Bodies in Ensuring Patient Safety Regulatory bodies are vital in ensuring patient safety in medical device design. They assess the safety and effectiveness of devices before they enter the market, conducting thorough reviews and inspections. Companies must provide data on the device’s performance, including clinical trials, risk assessments, and adverse event reports. For example, the FDA requires manufacturers to comply with the [Quality System Regulation (QSR)](/blog/21-cfr-part-820-and-its-role-in-medical-device-cybersecurity), which covers various aspects of device design, manufacture, and post-market surveillance. The QSR ensures that companies have well-defined processes to identify and mitigate risks associated with their products. Regulatory bodies collaborate with international organizations and share information to enhance patient safety globally. This collaboration helps proactively identify and address potential risks, ensuring that patients worldwide receive safe and effective medical devices. ### Balancing Innovation and Safety in Medical Device Design While patient safety is crucial, it is also essential to encourage innovation in medical device design. Striking a balance between innovation and safety is a delicate task. It requires extensive research, collaboration, and a multidisciplinary approach. Companies invest in ongoing research and development to improve existing devices and develop new technologies that enhance patient outcomes. This commitment to innovation, coupled with a strong focus on safety, drives the continuous improvement of medical devices. ## The Design Process of Medical Devices Focused on Safety The design process of medical devices revolves around ensuring patient safety from the initial concept to the final product. This iterative process involves carefully considering potential risks and implementing safety features. ![Section Image](/imported-images/3cca048d35a2f92e.png) ### Identifying Potential Risks in Medical Device Design Identifying potential risks is a crucial step in medical device design. This involves conducting risk assessments and considering various factors, such as device malfunction, user error, and possible adverse effects on patients. During the risk assessment phase, engineers and designers analyze every aspect of the medical device, from its materials and components to its intended use and potential interactions with patients. They also consider relevant regulatory guidelines and industry best practices to ensure the device is safe and effective. ### Incorporating Safety Features in Medical Devices Once risks are identified, appropriate safety features must be incorporated into the design. These features aim to minimize the likelihood of device failure, user error, or harm to patients. Incorporating advanced technologies, such as artificial intelligence and machine learning, has opened up new possibilities for enhancing the safety of medical devices. These technologies can analyze vast amounts of data in real-time, allowing for early detection of potential issues and proactive measures to prevent adverse events. ## Quality Assurance and Testing for Patient Safety In addition to the design process, rigorous testing procedures and quality assurance protocols are critical to ensuring patient safety in medical devices. ![Section Image](/imported-images/aef520d44d8a6d56.png) Manufacturers understand the importance of leaving no stone unturned when developing medical devices. They subject these devices to testing procedures to validate their safety and performance. These tests assess the device’s functionality, durability, and ability to perform as intended in real-world scenarios. ### Rigorous Testing Procedures for Medical Devices Manufacturers understand that the stakes are high when it comes to medical devices. They leave no room for error and employ stringent testing procedures to ensure the safety and efficacy of their products. These procedures involve subjecting the devices to tests that simulate various scenarios and conditions they may encounter. One such test is environmental testing, in which the devices are exposed to extreme temperatures, humidity, and vibrations. This test ensures that the devices can withstand harsh conditions and function optimally. Additionally, manufacturers conduct performance testing to evaluate the accuracy and precision of the device’s measurements. This testing involves comparing the device’s readings to established standards to ensure reliability. ### The Role of Quality Assurance in Patient Safety [Quality assurance](/blog) is an integral part of the design and manufacturing processes for medical devices. It involves establishing rigorous protocols and standards to ensure that each device meets the highest safety and quality standards. ## The Impact of Medical Device Safety on Patient Outcomes Safe medical devices significantly impact patient outcomes and overall healthcare quality. Ensuring their safety is crucial in providing effective and reliable healthcare to patients. ![Section Image](/imported-images/c8c45ca09b7c8e83.png) ### How Safe Medical Devices Improve Patient Care Safe medical devices improve patient care by minimizing the risks associated with diagnosis and treatment. They provide accurate and reliable data, enabling healthcare professionals to make informed decisions and deliver appropriate care. This enhances patient outcomes and promotes a sense of trust and confidence in the healthcare system. In addition, safe medical devices also play a crucial role in preventive care. For example, mammography machines used for breast cancer screening have undergone significant advancements in safety features. These devices minimize discomfort and radiation exposure while providing accurate results. By ensuring the safety and effectiveness of these devices, healthcare providers can detect breast cancer at an early stage, leading to better treatment outcomes and increased survival rates. ### The Consequences of Neglecting Safety in Medical Device Design Conversely, neglecting safety in medical device design can have severe consequences. Device malfunctions, user errors, or inadequate safety features can lead to adverse events, patient harm, and potential lawsuits. The repercussions of such negligence can be devastating for patients and healthcare providers. Neglecting safety in medical device design puts patients at risk and burdens healthcare systems financially. The costs of treating complications arising from unsafe devices, such as additional surgeries or prolonged hospital stays, can be substantial. This emphasizes the need for stringent regulations and standards to ensure the safety and efficacy of medical devices, ultimately reducing healthcare costs and improving overall patient care. ## The Future of Patient Safety in Medical Device Design As technology advances, the future of patient safety in medical device design looks promising. With the emergence of technologies such as artificial intelligence (AI), the [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things), and [augmented reality (AR)](/blog/augmented-reality-ar-medical-device-cybersecurity-risks), the potential for enhancing patient safety in medical device design has never been greater. ### Emerging Technologies and Their Impact on Patient Safety Artificial intelligence (AI) is revolutionizing medical device design and improving patient safety. AI-powered algorithms can analyze vast amounts of patient data to detect patterns and predict potential risks, enabling early intervention and preventive measures. Healthcare providers can proactively address potential issues before they escalate, ultimately saving lives. The Internet of Things (IoT) is another game-changer in patient safety. IoT-enabled devices can provide real-time monitoring and remote patient management, reducing the risk of adverse events. Imagine a world where medical devices communicate with each other, transmitting vital information to healthcare professionals in real-time. This level of connectivity has the potential to revolutionize patient care and significantly enhance safety. Augmented reality (AR) is another technology with tremendous promise for patient safety in medical device design. AR can assist healthcare providers during complex procedures, overlaying digital information in the real world. This technology improves accuracy and reduces the risk of errors, ultimately enhancing patient safety and improving outcomes. ### The Ongoing Challenge of Ensuring Patient Safety in Medical Device Design Despite advancements, ensuring patient safety in medical device design remains an ongoing challenge. The healthcare landscape demands continuous adaptation, collaboration, and vigilance. Stringent regulations and standards are crucial in ensuring patient safety. Regulatory bodies work tirelessly to establish and enforce guidelines that medical device manufacturers must adhere to. These regulations help maintain the highest safety and quality in medical device design, ensuring patients receive the care they deserve. ## Safety principles and their security equivalents Security is not a separate discipline bolted onto a safety culture. Most safety design principles have a direct security counterpart. | Safety principle | Safety implementation | Security counterpart | | --- | --- | --- | | Inherent safety by design | Remove the hazard rather than warn about it | Remove the interface or capability rather than monitor it | | Fail safe behavior | Predictable safe state on component failure | Predictable safe state when authentication or an update fails | | Redundancy | Independent channels for critical functions | Defense in depth so one control failure is not total compromise | | Use error prevention | Design that makes the wrong action hard | Secure defaults so the insecure configuration takes deliberate effort | | Alarm and detection | Alerting clinicians to an unsafe condition | Logging and detection that surfaces an unexpected condition | | Labeling as last resort | Warnings only when design cannot remove the risk | Security documentation only when the control cannot be built in | | Postmarket surveillance | Complaint handling and field data | Vulnerability monitoring and coordinated disclosure | Both disciplines rank the same way. Designing the problem out beats detecting it, and detecting it beats telling the customer to be careful. ## Conclusion Patient safety is the cornerstone of medical device design. Manufacturers, regulatory bodies, and healthcare professionals work together to ensure that medical devices meet strict safety standards and deliver effective and reliable patient care. By prioritizing patient safety throughout the design process and incorporating quality assurance and testing protocols, we can develop innovative devices that enhance patient outcomes and improve healthcare quality. As we’ve discussed the paramount importance of patient safety in medical device design, it’s clear that cybersecurity supports protecting patient data and ensuring the integrity of medical devices. Blue Goat Cyber, a Veteran-Owned business specializing in medical device cybersecurity, is dedicated to safeguarding your devices against cyber threats. With expertise in HIPAA and FDA compliance and penetration testing services, we are committed to securing your business and products. [Contact us today](/contact) for cybersecurity help and join the ranks of those who prioritize patient safety in every aspect of healthcare technology. Check out our [FDA cybersecurity premarket submission services.](/) ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the primary focus of medical device design? The primary focus of medical device design is patient safety. This commitment ensures devices perform reliably and effectively, minimizing risks to patients. ### How does the FDA ensure medical device safety? The FDA ensures medical device safety through stringent guidelines and regulations, including the Quality System Regulation. These guidelines cover device design, manufacturing, and post-market surveillance to mitigate risks. ### What role do regulatory bodies play in cybersecurity for medical devices? Regulatory bodies, including the FDA, play a crucial role by issuing guidance, such as the February 3, 2026 final guidance, to ensure medical devices are designed with strong cybersecurity controls to protect patient data and device functionality. ### Why is risk assessment important in medical device design? Risk assessment is important in medical device design to identify potential hazards like device malfunction, user error, or adverse effects. This process allows manufacturers to incorporate safety features that minimize these risks. ### How do emerging technologies impact medical device safety? Emerging technologies, such as AI and IoT, improve medical device safety by enabling real-time monitoring, predictive analytics, and enhanced precision. These advancements help detect issues early and prevent adverse events. ### What are the consequences of neglecting safety in medical device design? Neglecting safety in medical device design can lead to severe consequences, including device malfunctions, patient harm, adverse events, and potential legal action. This also burdens healthcare systems with additional treatment costs. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## How SPDF Maps to IEC 81001-5-1 Activities Source: https://bluegoatcyber.com/blog/how-spdf-maps-to-iec-81001-5-1-activities # How SPDF Maps to IEC 81001-5-1 Activities: A Practical Crosswalk for Medtech > **[DIRECT ANSWER]** The FDA's Secure Product Development Framework and IEC 81001-5-1 describe the same lifecycle in different vocabularies, so every SPDF outcome, such as the cybersecurity management plan, threat model, SBOM with VEX, and postmarket plan, maps directly onto specific IEC 81001-5-1 clauses. Teams building dual FDA and EU submissions should run IEC 81001-5-1 as the spine, produce one artifact set, and dual-label it, rather than duplicating threat models, risk files, and vulnerability disclosure processes across two separate programs. Teams shipping into both the United States and the European Union often ask the wrong version of this question. It is not "SPDF or IEC 81001-5-1?" It is "how do we run one lifecycle that satisfies both?" This post is the crosswalk that makes that possible. If you are still choosing between frameworks, start with [JSP2 vs SPDF vs IEC 81001-5-1: which framework should medtech pick?](/blog/jsp2-vs-spdf-vs-iec-81001-medical-device-framework-choice) and [IEC 81001-5-1 vs IEC 62304](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards). This post assumes you have picked, or are planning to run, both. ## Key Takeaways - SPDF and IEC 81001-5-1 are the same lifecycle described in two vocabularies, not two lifecycles. - Every SPDF outcome maps to one or more IEC 81001-5-1 clauses that produce the same evidence. - The right operating model is one lifecycle, one artifact set, two labels. - Run IEC 81001-5-1 as the spine when EU MDR/IVDR is in scope; label the artifacts SPDF-side for the FDA reviewer. - The FDA's four architecture views live inside IEC 81001-5-1 clause 5.3 (security architecture) with no extra work. - Postmarket vulnerability handling is where the two frameworks most obviously converge; do not duplicate CVD processes. ## Why This Matters Running SPDF and IEC 81001-5-1 as two separate programs is a common and expensive mistake. The evidence is the same, the risk file is the same, the postmarket obligations are substantially the same. Teams that duplicate processes end up producing two threat models, two risk files, and two vulnerability management workflows that drift out of sync within 12 months. The next audit or deficiency letter forces a painful reconciliation. The Feb 3, 2026 FDA final guidance explicitly says a manufacturer may use any of the four listed frameworks (SPDF, JSP2, IEC 81001-5-1, ISA/IEC 62443-4-1) provided the resulting submission contains the required content.[^fda2026] It does not require SPDF vocabulary. It requires SPDF-shaped artifacts. IEC 81001-5-1 produces those artifacts natively when the mapping is done up front. ## Why this crosswalk exists The FDA's guidance describes SPDF as a set of outcomes and expected artifacts: security risk management, threat modeling with four architecture views, SBOM with VEX, security testing, cybersecurity management plan, labeling, postmarket monitoring. IEC 81001-5-1 organizes the same territory as a numbered clause structure that ties directly to lifecycle phases.[^iec81001] The crosswalk below is the one we use in engagements. It is not a formal FDA / IEC concordance (none exists); it reflects how reviewers and notified bodies actually consume the artifacts. ## Phase-by-phase mapping table | SPDF outcome / artifact | IEC 81001-5-1 clause(s) | Shared artifact | | --- | --- | --- | | Cybersecurity management plan | 4.1 Quality management, 4.2 Security-management processes | One plan, dual-labeled | | Security risk management (integrated with ISO 14971) | 4.4 Security risk management process | ISO 14971-shaped risk file (extended per AAMI SW96) | | Security requirements | 5.2 Security requirements analysis | One requirements set, traceable both ways | | Threat model with four architecture views | 5.3 Security architecture (with 5.4 secure design) | One threat model document | | Secure implementation and coding | 6.1 Secure implementation, 6.2 Secure coding | Coding standard + static analysis output | | SBOM (SPDX or CycloneDX) with VEX | 6.3 Software of unknown origin / third-party components | One SBOM, one VEX | | Security verification and validation | 7.1-7.4 Security verification, including penetration testing | One security V&V report | | Security release criteria and residual risk | 8.1 Release, 8.2 Residual risk communication | One release checklist | | Coordinated Vulnerability Disclosure (CVD) | 9.4 Vulnerability handling, 9.5 CVD | One CVD process | | Postmarket cybersecurity management plan | 9.1-9.3 Postmarket security activities, 10 Maintenance | One postmarket plan | | Labeling and customer security documentation | 8.3 Documentation for the user / operator | One user-facing security guide | The pattern holds: every SPDF artifact has a home inside IEC 81001-5-1, and every IEC 81001-5-1 clause produces something the FDA expects to see. Duplication is unnecessary. ## Management and planning: SPDF outcomes → IEC 81001-5-1 clause 4 SPDF opens with a cybersecurity management plan and the surrounding governance. IEC 81001-5-1 clause 4 covers the same ground under three sub-clauses: quality management integration (4.1), security-management processes (4.2), and security risk management (4.4). Produce one plan document that maps each of its sections to both structures. Reviewers on either side see a coherent governance artifact, not a translation exercise. ## Security requirements: SPDF → IEC 81001-5-1 clause 5.2 SPDF expects security requirements traceable to threats and to verification. IEC 81001-5-1 clause 5.2 requires the same, with a slightly heavier emphasis on secure-by-design and secure-by-default posture. Produce a single requirements set. Tag each requirement with both the SPDF outcome it satisfies and the IEC 81001-5-1 clause it derives from. Traceability is the shared spine. ## Security architecture and threat modeling: SPDF → clauses 5.3 and 5.4 This is where the mapping is most often mishandled. The FDA guidance calls for four architecture views: global system, multi-patient harm, updateability, and security use cases. IEC 81001-5-1 clause 5.3 requires a documented security architecture; clause 5.4 requires secure-design decisions. The four FDA views satisfy both clauses without modification. Produce the four views once, label them as the security architecture under IEC 81001-5-1, and reviewers on both sides get the artifact they expect. Threat modeling itself sits alongside the architecture. Use STRIDE (or an equivalent) once, harm-oriented, and feed the outputs into the ISO 14971 risk file. Both frameworks accept the same threat model. [Talk to a MedTech cybersecurity expert about running one lifecycle across both frameworks](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) > **Operationalizing the SPDF against IEC 81001-5-1?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## Implementation: SPDF → clauses 6.1 and 6.2 SPDF asks for secure implementation and coding standards. IEC 81001-5-1 clauses 6.1 and 6.2 require the same, with an explicit call-out for tool-supported analysis (SAST). A single coding standard, a single SAST configuration, and a single static-analysis output stream serve both frameworks. The FDA does not need to see the tool configuration; it needs to see that findings were triaged, remediated or accepted, and traced back to requirements. IEC 81001-5-1 asks for the same evidence. SBOM handling belongs here too. Clause 6.3 covers software of unknown origin (SOUP) and third-party components. One SBOM in SPDX or CycloneDX with a VEX overlay satisfies both frameworks and Section 524B(b)(3). ## Verification and testing: SPDF → clause 7 SPDF's security testing expectation matches IEC 81001-5-1 clause 7 point for point: security verification, security validation, and penetration testing where the risk profile warrants it. Produce one V&V report. Penetration test evidence goes in the same artifact. The FDA's guidance is more prescriptive on penetration-test scope for connected devices; IEC 81001-5-1 defers to risk-proportionate testing. Meet the FDA's bar and the IEC clause is satisfied automatically. ## Release and transfer: SPDF → clause 8 Both frameworks require a security release decision with documented residual risk. IEC 81001-5-1 clause 8 splits this into the release decision (8.1), residual-risk communication to the operator (8.2), and user documentation (8.3). SPDF bundles the same content into the cybersecurity management plan and labeling. One release checklist, one residual-risk statement, and one user-facing security document cover both. ## Postmarket: SPDF → clauses 9 and 10 SPDF's postmarket obligations (monitoring, patching, CVD, incident response) map to IEC 81001-5-1 clauses 9 (postmarket security activities) and 10 (maintenance). The pairing is straightforward: run one CVD process, one vulnerability triage cadence, one patching workflow. The FDA's postmarket cybersecurity management plan is the artifact; IEC 81001-5-1 clause 9 is the process behind it. For the deeper postmarket picture, see [how JSP2 and MDS2 fit together](/blog/the-role-of-mds2-in-medical-device-cybersecurity), MDS2 lives in this postmarket space regardless of which framework you pick. ## How to run one lifecycle with two labels Three operational rules make this work in practice: 1. **Pick the spine, then dual-label everything.** For US-only devices, SPDF is the natural spine and IEC 81001-5-1 mapping is optional. For dual FDA + EU submissions, run IEC 81001-5-1 as the spine and label the artifacts with SPDF outcome names in the artifact headers or the cybersecurity management plan. Reviewers on either side see native vocabulary. 2. **One risk file.** Do not maintain a separate security risk file per framework. Use ISO 14971 as the container (extended per AAMI SW96) and let both frameworks read from it. 3. **One CVD process.** Do not stand up two vulnerability workflows. One inbox, one triage, one disclosure log, mapped to both frameworks. Teams that follow these three rules typically see 30-40 percent less lifecycle documentation overhead than teams running parallel programs. ## How Blue Goat Cyber Approaches This Blue Goat Cyber's dual-framework engagement produces a single artifact set with SPDF and IEC 81001-5-1 dual-labeling embedded from day one. The output is a cybersecurity management plan, threat model with four FDA views, integrated ISO 14971 + AAMI SW96 risk file, SBOM + VEX, security V&V report, and postmarket plan, all labeled to both frameworks. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Christian Espinosa, our founder, has led dual FDA + EU MDR cybersecurity submissions on more than 60 devices under this exact operating model. ## Frequently Asked Questions ### Do I have to pick between SPDF and IEC 81001-5-1? No, not if you produce the artifacts correctly. The FDA lists both as acceptable; the EU expects IEC 81001-5-1. Run IEC 81001-5-1 as the spine for dual submissions and label artifacts with SPDF outcome names. ### Does the FDA reviewer need the IEC 81001-5-1 clause numbers in the submission? No. Reviewers grade the artifacts against the guidance's expected content, not the clause number they came from. Include the mapping in the cybersecurity management plan so the reviewer can trace it if they want; do not clutter every artifact with clause references. ### What about ISO 14971 and AAMI SW96? Both frameworks assume ISO 14971 as the risk-management container. AAMI SW96:2023 formalizes the security extension. One risk file, one process, feeds both SPDF and IEC 81001-5-1. ### Where do the four FDA architecture views live in IEC 81001-5-1? Inside clause 5.3 (security architecture) with support from clause 5.4 (secure design). Produce the four views (global system, multi-patient harm, updateability, security use cases) once, and both frameworks are satisfied. ### Can I map JSP2 the same way? Yes. JSP2 has a similar phase structure and maps cleanly onto both SPDF outcomes and IEC 81001-5-1 clauses. See [JSP2 vs SPDF vs IEC 81001-5-1](/blog/jsp2-vs-spdf-vs-iec-81001-medical-device-framework-choice) for how JSP2 fits into the framework choice, and treat this crosswalk as the SPDF ⇄ 81001-5-1 backbone underneath. ### What is the biggest failure mode? Running two parallel programs. Two threat models, two risk files, two CVD processes drift out of sync fast, and the next audit or FDA deficiency letter forces a costly reconciliation. Pick one spine, dual-label the artifacts, run one workflow. ## CTA If you are running SPDF and IEC 81001-5-1 as two separate programs, you are paying twice for the same lifecycle. Blue Goat Cyber runs a three-week dual-framework consolidation engagement that collapses the two into a single artifact set with dual-labeling, ready for FDA reviewers and EU notified bodies alike. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, CCISO, ex-military red team. Has led dual SPDF + IEC 81001-5-1 cybersecurity submissions on 60+ FDA- and EU-cleared devices. [More on the author](/team/christian-espinosa)._ ## References [^fda2026]: U.S. Food and Drug Administration. *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, Guidance for Industry and Food and Drug Administration Staff.* Final guidance, issued February 3, 2026. [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) [^iec81001]: International Electrotechnical Commission. *IEC 81001-5-1:2021, Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product life cycle.* Published December 2021. [https://webstore.iec.ch/publication/64703](https://webstore.iec.ch/publication/64703) --- ## How to Choose a Medical Device Cybersecurity Firm Source: https://bluegoatcyber.com/blog/how-to-choose-the-best-medical-device-cybersecurity-company # How to Choose the Best Medical Device Cybersecurity Company > **[DIRECT ANSWER]** Judge a medical device cybersecurity partner on five things: submission experience with your pathway, whether their deliverables drop into eSTAR without rework, whether they test real hardware and firmware rather than only web layers, whether they respond to deficiency letters as part of the engagement, and whether their risk scoring maps to ISO 14971 patient harm. Ask for a redacted sample report before you sign anything. Many MedTech companies end up with the wrong cybersecurity vendor. Not because they don't care about security, and not because good options don't exist. They pick the wrong one because they don't know what separates a firm that has lived inside FDA submissions from one that handles enterprise IT and is willing to give medical devices a try. Finding the best medical device cybersecurity company for your submission isn't about searching for the biggest brand or the longest feature list. It's about knowing exactly what the FDA expects and then verifying that your vendor has delivered it before, repeatedly, across real submissions. Blue Goat Cyber was founded with an exclusive focus on medical device manufacturers and has supported FDA submissions across 510(k), De Novo, and PMA pathways. That kind of depth doesn't come from reading guidance documents. It comes from repeated pattern recognition built across years of submission work. By the end of this guide, you'll have a clear framework to evaluate any vendor, not just a list of names. Use it before you sign anything. ## Key Takeaways - Why Most Cybersecurity Vendors Won’t Survive Your FDA Submission. - How to Choose the Best Medical Device Cybersecurity Company: Key Criteria. - What FDA Cybersecurity Submissions Actually Require from a Partner. - What a Leading Medical Device Cybersecurity Firm Looks Like in Practice. - Questions to Ask the Best Medical Device Cybersecurity Company Before You Sign. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to how to choose the best medical device cybersecurity company the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Why Most Cybersecurity Vendors Won’t Survive Your FDA Submission Many general IT security firms are not well-equipped for FDA submission work. Being skilled at SOC 2 audits, enterprise zero-trust architecture, or endpoint detection has little to do with writing a threat model that FDA reviewers will accept. The standards are different. The documentation structure is different. And the stakes are higher than most general practitioners realize. ISO 14971 governs risk management for medical devices. IEC 62304 governs software lifecycle processes. AAMI TIR57 / ANSI/AAMI SW96:2023 addresses cybersecurity risk management specifically within the medical device context. None of these map neatly to the frameworks that enterprise cybersecurity firms spend their careers in. A vendor who doesn’t live in this regulatory environment will learn on your dime, and that education is expensive. ### What Happens When a Generalist Handles Your FDA Submission The consequence path is predictable: inadequate documentation, a deficiency letter, a resubmission, and months of delay. Cybersecurity deficiencies are a frequent cause of 510(k) submissions stalling. Common triggers include missing threat models, incomplete SBOMs, insufficient penetration testing evidence, and postmarket plans that don’t meet Section 524B obligations. A deficiency cycle can push your product significantly behind schedule and generate real costs in delayed revenue, rework, and extended consulting fees. A specialist avoids this pattern. A generalist creates it. ## How to Choose the Best Medical Device Cybersecurity Company: Key Criteria Here is the framework. Apply it to every vendor you evaluate, including the ones that come recommended. Vague credentials don’t hold up under direct questions. ### Depth of FDA Submission Experience Ask specifically how many premarket cybersecurity submissions the firm has supported in the last 24 months. “Experience with FDA” is not an answer. Supporting 510(k), De Novo, and PMA submissions requires knowing what reviewers accept and reject at the documentation level. Firms with genuine depth reference UL 2900-1 and AAMI TIR57 / ANSI/AAMI SW96:2023 fluently because they use them constantly. Firms that don’t bring those standards up unprompted probably haven’t worked inside enough submissions to know where they matter. ### Full-Lifecycle Capability Versus Point-in-Time Services Vendors who only offer penetration testing, or only review documentation, create gaps. A complete premarket submission requires design consulting, secure product development framework (SPDF) documentation, SBOM creation, threat modeling, penetration testing, eSTAR documentation, and postmarket planning. Ask any vendor you’re considering whether they can stay with you after clearance. Section 524B requires ongoing monitoring, patch management, and vulnerability disclosure processes for cleared devices. A vendor who disappears after submission leaves you exposed on the postmarket side. For guidance on selecting the right firm for FDA-focused work, see [How to Choose a Cybersecurity Firm for FDA Submissions, Blue Goat Cyber](/blog/how-to-choose-the-best-medical-device-cybersecurity-company). ### Standards Coverage Breadth ISO 14971, IEC 62304, IEC 62443-4-1, and UL 2900 are not optional references. They are the scaffolding of a defensible FDA submission. A vendor who covers only one or two of these creates compliance gaps that will surface during FDA review or notified body audits. Before you engage anyone, ask them to walk you through how each standard applies to your device class. The answer tells you exactly how deep their knowledge runs. ### Turnaround Time with Documented Quality Speed matters in MedTech, but not at the expense of quality. Ask for documented delivery timelines and find out how many active engagements the firm runs simultaneously. A small team taking on too many clients will stretch timelines without telling you until it’s a problem. The right partner delivers thorough, FDA-ready reports on schedule because they have the team depth to execute, not just the sales pitch to win the deal. ### Deficiency Response Track Record Any vendor worth hiring should be able to show they’ve resolved FDA cybersecurity deficiency letters, not just helped clients avoid them. Deficiency resolution is the truest test of submission fluency because it requires understanding exactly what a reviewer objected to and rebuilding documentation to clear the objection. Ask for a specific example. If they can’t give you one, you should know what that means. ## What FDA Cybersecurity Submissions Actually Require from a Partner The FDA’s 2026 final guidance, [“Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions,”](https://www.fda.gov/media/119933/download "") is not ambiguous about what a premarket submission must contain. ### Premarket Documentation: What Must Be Included A defensible submission includes several required elements. At the documentation level, that means a system-level threat model using a framework like STRIDE, a cybersecurity risk assessment tied to ISO 14971, and a Software Bill of Materials (SBOM) in machine-readable format such as SPDX or CycloneDX. It also requires secure product development framework (SPDF) and SDLC descriptions, penetration testing evidence, and security architecture documentation. Labeling language covering ports and update procedures and a cybersecurity management plan addressing postmarket obligations round out the package. Missing or thin documentation in any of these areas is what triggers a deficiency letter. ### eSTAR-Ready Deliverables The FDA’s eSTAR template has been mandatory for 510(k) submissions since October 1, 2023. It includes a dedicated cybersecurity section with specific fields for threat models, SBOMs, testing evidence, and postmarket plans. Automated checks flag incomplete sections before submission, meaning gaps are caught by the system before a human reviewer ever sees the file. A vendor who doesn’t structure deliverables directly into the eSTAR format from day one adds revision cycles you don’t need. The FDA’s own resources on device cybersecurity can help clarify eSTAR expectations: [FDA FAQs on Cybersecurity for Medical Devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs). ### Postmarket Obligations Your Vendor Should Prepare You For Under Section 524B of the FD&C Act, cleared devices require ongoing cybersecurity monitoring, patch management, coordinated vulnerability disclosure processes, and documented metrics like time-to-patch. Vendors who serve only the premarket side leave manufacturers without a compliance structure for the operational life of the device. This is not a secondary concern. It’s a statutory requirement. ## What a Leading Medical Device Cybersecurity Firm Looks Like in Practice Run the criteria from the previous section against Blue Goat Cyber and the alignment is clear. The evaluation framework points in one direction when you apply it to a firm built exclusively around this problem. ### Exclusive Specialization as a Structural Advantage Blue Goat Cyber works exclusively with medical device manufacturers and MedTech companies. There are no enterprise IT clients competing for the same team’s attention, no generalist consulting engagements running alongside FDA submission work. That focus matters because FDA cybersecurity guidance evolves, and a firm tracking only this regulatory category catches guidance updates, eSTAR changes, and reviewer expectation shifts faster than any generalist monitoring dozens of sectors at once. ### Track Record Across FDA Submissions Since 2014, Blue Goat Cyber has supported a substantial volume of 510(k) and De Novo submissions. That depth of experience produces pattern recognition that newer entrants and generalist firms cannot replicate. When a reviewer objects to a specific documentation structure, the team has encountered that objection before and knows how to resolve it. Deficiency response capability is a direct product of submission experience, not a service add-on. ### The “Done for You” Delivery Model Regulatory affairs managers are already managing cross-functional teams, product timelines, and internal compliance processes. Offloading the entire cybersecurity workload to a specialized firm isn’t a luxury. It’s a risk management decision. Blue Goat Cyber handles SPDF documentation, SBOM creation, threat modeling, penetration testing, and eSTAR documentation end-to-end, so device teams can focus on the product itself rather than learning a compliance framework under deadline pressure. For founders who are early in planning and need a roadmap from concept through clearance, read [From Idea to FDA Clearance: What Nobody Tells MedTech Founders, Blue Goat Cyber](/blog/from-idea-to-fda-clearance-what-nobody-tells-medtech-founders). ## Questions to Ask the Best Medical Device Cybersecurity Company Before You Sign These questions are designed to surface vendors who are genuinely qualified versus ones who will figure it out at your expense. Use them in every vendor call. ### Questions That Test FDA Submission Fluency Ask how many premarket submissions the firm has supported in the last 24 months. Ask them to describe a cybersecurity deficiency letter they’ve resolved and what the resolution required. Ask whether their deliverables are structured for the FDA’s eSTAR template from day one or adapted afterward. A vendor who hedges on any of these questions, or pivots to general cybersecurity credentials instead of specific FDA submission experience, deserves careful scrutiny before you proceed. ### Questions That Reveal Delivery Depth Ask whether they handle SBOM creation or require your team to provide it. Ask what their postmarket monitoring offering includes after clearance. Ask for a documented turnaround timeline from engagement start to FDA-ready deliverables. These questions separate full-service partners from boutique firms that do one or two things well and leave the rest as your problem. The answers should be specific and immediately available. If a vendor needs time to check internally, that tells you something about how often they actually do this work. ## How to Build Your Shortlist and Make the Final Call The right vendor depends on your stage, your device type, and your internal capacity. Before building a shortlist, identify which category of vendor your challenge actually requires. ### Matching Vendor Type to Your Actual Need IoMT visibility platform vendors like Claroty, Asimily, and Armis are purpose-built for healthcare networks managing deployed devices at scale. They focus on agentless discovery, real-time anomaly detection, and continuous vulnerability monitoring across live hospital environments. If your challenge is securing connected devices already deployed in clinical networks, these platforms address that specific need. See vendor guidance such as [How to Choose the Right IoMT Security Vendor](https://asimily.com/blog/how-to-choose-the-right-iomt-security-vendor/) when evaluating network-focused solutions, and consider discovery/inventory offerings like [healthcare discovery and inventory](https://cylera.com/solutions/healthcare-discovery-inventory/) if you need agentless device visibility. If your challenge is getting a device through FDA clearance or responding to a deficiency letter, you need a [premarket cybersecurity consulting firm](/blog/how-to-choose-the-best-medical-device-cybersecurity-company) with FDA submission depth. These are different categories. Selecting the wrong type is a common and costly mistake. ### Making the Call with Confidence Apply the five criteria from this guide, run each candidate through the screening questions, and prioritize firms with exclusive medical device focus and verifiable FDA submission history. Finding the best medical device cybersecurity company comes down to one filter: specialization. Broad credentials don’t clear deficiency letters. FDA submission experience does. For MedTech founders and regulatory affairs managers navigating a 510(k) or De Novo, Blue Goat Cyber is built specifically for this work. Reach the team directly at [bluegoatcyber.com](/) to discuss your device, your timeline, and what a full-service engagement looks like for your specific submission. Choosing the best medical device cybersecurity company isn’t complicated once you know what to filter for. Specialization outperforms breadth. FDA submission experience outperforms general cybersecurity credentials. A full-service delivery model outperforms fragmented point solutions that leave documentation gaps. Apply this framework honestly, and the right partner becomes clear. Don’t let the wrong vendor slow down a product that patients are waiting for. For additional context on industry trends and vendor comparisons, you may also find third-party market research and vendor lists helpful when building your long and short lists. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the most critical factor in choosing a cybersecurity vendor for medical devices? The most critical factor is the vendor's demonstrated, specific experience with FDA premarket cybersecurity submissions. This includes a deep understanding of the agency's expectations and guidance, validated by a track record of successful clearances and deficiency resolutions. ### Why can't a general IT cybersecurity firm handle FDA submissions? General IT cybersecurity firms often lack the specialized knowledge of medical device-specific regulations and standards, such as ISO 14971, IEC 62304, and UL 2900. Their expertise in enterprise security does not directly translate to the unique requirements and documentation structures mandated for FDA submissions. ### What documentation does the FDA require for premarket cybersecurity? The FDA requires documentation such as a system-level threat model, a cybersecurity risk assessment, an SBOM (e.g., SPDX or CycloneDX), secure product development framework descriptions, penetration testing evidence, and a cybersecurity management plan addressing postmarket needs. ### How does Section 524B impact vendor selection? Section 524B mandates ongoing postmarket cybersecurity obligations, including monitoring, patch management, and coordinated vulnerability disclosure. Your selected vendor should prepare you for these requirements and ideally offer support beyond initial clearance to ensure continuous compliance. ### What role does eSTAR play in FDA cybersecurity submissions? ESTAR (electronic Submission Template And Resource) is mandatory for 510(k) submissions and includes specific cybersecurity sections. A competent vendor will structure deliverables to be eSTAR-ready from the start, preventing rework and streamlining the submission process. ## Ready to Engage a Specialist? Blue Goat Cyber builds the complete FDA premarket cybersecurity package and stays through deficiency response - threat model, SBOM, SPDF, penetration testing, eSTAR-ready documentation, and the postmarket plan under Section 524B. **275+ FDA submissions. no cybersecurity-related rejections to date. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** [**Book a free premarket strategy call**](/services/fda-premarket-cybersecurity-services) *30 minutes · No cost · No commitment* **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA 510(k) & PMA Cybersecurity Guide Source: https://bluegoatcyber.com/blog/how-to-navigate-the-fda-510k-and-pma-databases # How to Navigate the FDA 510(k), De Novo, and PMA Databases for Cybersecurity > **[DIRECT ANSWER]** Before filing a Section 524B premarket submission, teams should search the FDA's 510(k), De Novo, and PMA databases by product code, not device name, to find cybersecurity precedent in Summary Statements, De Novo Decision Summaries, and Summaries of Safety and Effectiveness Data. De Novo grants offer the richest public FDA cybersecurity reasoning and are often overlooked, while cleared submissions in a given product code reveal the current bar for SBOM depth, threat modeling, and penetration test scope. _Updated July 10, 2026_ Mining the FDA databases is one of the highest-leverage things a MedTech cybersecurity or regulatory lead can do before starting a Section 524B submission. Cleared submissions in your product code tell you exactly how the agency read cybersecurity evidence for a device like yours: what was accepted, what was redacted, what got called out. The three databases are shaped by three different review pathways, and each surfaces cybersecurity information differently. Reading them the same way, or skipping De Novo entirely, is one of the most common precedent-research mistakes we see. This guide covers what each database contains, how to search it, and how to read the results through a cybersecurity lens. ## Key Takeaways - The 510(k), De Novo, and PMA databases each publish different cybersecurity evidence: Summary Statements, Decision Summaries, and Summaries of Safety and Effectiveness Data. - De Novo Decision Summaries are the richest public source of FDA cybersecurity reasoning for novel devices, and are routinely skipped by teams that only search 510(k). - Product codes, not device names, are the correct primary search key across all three databases. - Cybersecurity content is heavily redacted under FOIA exemption (b)(4), but structural patterns (SBOM format, threat-model methodology, pen-test scope) still show through. - Cross-referencing MAUDE and AccessGUDID adds postmarket cybersecurity context that the premarket databases do not carry. - Cleared submissions in your product code define the current bar for Section 524B evidence in your device category. ## Why This Matters for Section 524B Submissions The FDA's *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* (February 3, 2026 final guidance) codified the cybersecurity documentation the agency expects for every "cyber device" under Section 524B of the FD&C Act. Reviewers apply the same expectations across 510(k), De Novo, and PMA pathways, but the depth and format of what each pathway makes public is very different. Cleared submissions in your product code are the closest proxy the public record offers for what "acceptable" looks like right now. The FDA's FY2024 CDRH performance data lists cybersecurity among the most-cited deficiency categories in Additional Information (AI) letters. Reading cleared precedent from the same product code helps you calibrate SBOM depth, threat-model methodology, and pen-test scope before you file, not after a deficiency letter. Precedent research is not a shortcut around the requirements in AAMI TIR57, ANSI/AAMI SW96, and IEC 81001-5-1, but it does tell you how those requirements are currently being read for devices like yours. ## What Is the FDA 510(k) Database and What Cybersecurity Content Does It Expose? **Link:** [FDA 510(k) Premarket Notification Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm) The 510(k) database returns every cleared premarket notification submitted under 21 CFR 807 Subpart E, filterable by device name, applicant, product code, decision date, and K-number. For each cleared submission it exposes a Summary Statement (or a Statement) that the sponsor is required to make available. Summary Statements vary widely in depth: some are two pages, some are thirty, and the difference matters when you are trying to read cybersecurity precedent. For cybersecurity teams, 510(k) records reliably identify: - Whether the predicate is connected, wireless, or software-based - The product code and regulation number that trigger cybersecurity review - Whether the summary references Section 524B, SBOMs, or the February 2026 guidance - The date of clearance, which tells you which cybersecurity guidance was in force at review > **[KEY REQUIREMENT]** A 510(k) Summary that does not mention cybersecurity is not proof cybersecurity was absent from review. Since Section 524B took effect, cyber devices have been evaluated against the full premarket cybersecurity guidance regardless of what the public Summary Statement chose to disclose. ## What Is the FDA De Novo Database and Why Is It the Most Underused for Cybersecurity Research? **Link:** [FDA De Novo Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm) De Novo is the pathway for novel low-to-moderate risk devices with no valid predicate. Each granted De Novo publishes a **Decision Summary**, which is written by the FDA and is meaningfully more detailed than a 510(k) Summary Statement. Decision Summaries walk through the risks the agency identified, the special controls it imposed, and the evidence the sponsor provided, often including cybersecurity risk analysis, software documentation, and interoperability testing. That structure makes De Novo grants the single most useful public source for reading FDA cybersecurity reasoning: - The Decision Summary explicitly names the identified device risks and the mitigations required - Cybersecurity special controls, when the FDA imposes them, become the regulatory floor for follow-on 510(k)s in the new product code - The narrative shows how the FDA weighed threat modeling, SBOM, and pen-test evidence rather than just listing artifacts If your device is novel, or if your product code was created by a De Novo grant, that grant is the primary precedent you should be reading. Teams that only search the 510(k) database miss it entirely. ## What Is the FDA PMA Database and How Deep Does Its Cybersecurity Documentation Go? **Link:** [FDA PMA Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm) Premarket Approval is required for Class III devices, those that support or sustain life or present an unreasonable risk of illness or injury. Each PMA approval publishes a **Summary of Safety and Effectiveness Data (SSED)** and a searchable trail of PMA supplements covering post-approval changes, including cybersecurity updates. PMA records are the deepest public FDA source for cybersecurity documentation because: - SSEDs frequently include software description, cybersecurity risk assessment, and interoperability content in named sections - PMA supplements (S001, S002, and so on) show how cybersecurity changes flow through post-approval review, which is directly relevant to Predetermined Change Control Plan scoping - FDA review memos referenced in SSEDs sometimes call out specific security controls, encryption approach, or update mechanisms For any implantable, life-supporting, or high-risk connected device, PMA precedent tells you both the initial cybersecurity bar and how the agency has handled cybersecurity changes across the device's lifecycle. ## How to Search All Three Databases by Product Code and Read Results Through a Cybersecurity Lens Product code, not device name, is the correct primary search key. A product code (three letters, e.g. `DQA` for infusion pumps) maps to a specific 21 CFR regulation number and defines the FDA review team, the guidance stack, and the current cybersecurity expectations for the device category. Start at the [FDA Product Classification Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm) to confirm your code, then search all three premarket databases with that code. Once you have the results: - Sort by decision date descending, recent clearances reflect the current cybersecurity guidance - Read at least three post-Section-524B clearances in your product code - For each one, note whether the Summary explicitly cites the February 2026 guidance, AAMI SW96, IEC 81001-5-1, or SPDX/CycloneDX SBOM format - Flag any redactions marked under FOIA exemption (b)(4), that is where the sponsor claimed confidential commercial information, and the structural context around it still tells you what type of artifact was submitted If you have already received a deficiency letter, cross-reference the language against our library of [real FDA cybersecurity deficiency letter examples](/guides/fda-cybersecurity-deficiency-letter-examples) to see the patterns reviewers use. If your device is AI/ML or firmware-updatable, pair that read with our [FDA PCCP change-control plans guide](/guides/fda-pccp-change-control-plans) so the change-authority precedent you find in cleared submissions maps to a filable modifications protocol. ## Which FDA Sources Fill the Gaps the Premarket Databases Leave The three premarket databases do not cover postmarket cybersecurity events, recalls, or unique-device-identifier data. For a full precedent picture, pair them with: - [MAUDE](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm), searchable adverse event reports, useful for finding cybersecurity-related failure modes in the same product code - [AccessGUDID](https://accessgudid.nlm.nih.gov/), the Unique Device Identifier database, useful for confirming device model families and identifier structure - [FDA FOIA reading room](https://www.fda.gov/regulatory-information/freedom-information/electronic-reading-room), releases documents obtained by FOIA request, occasionally including cybersecurity-relevant redacted review memos - [510(k) Third Party Review lists](https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/510k-third-party-review-program), useful for identifying which product codes are eligible for accelerated review For a workflow that walks these sources in order and shows how to convert what you find into submission-ready evidence, see our deep dive on [mining FDA databases for medical device cybersecurity precedent](/blog/mining-fda-databases-medical-device-cybersecurity-precedent). Ready to convert precedent research into a filing plan? [Schedule a scoping call](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will map the cleared submissions in your product code against the Section 524B expectations for your device. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. Before we open a new engagement, we pull every post-Section-524B clearance in the client's product code and reconstruct the cybersecurity evidence pattern the FDA has been accepting: SBOM format, threat-model methodology, pen-test scope, and postmarket plan structure. That precedent read becomes the baseline for the artifacts we produce, calibrated to the current guidance and to how reviewers in that product code have written recent AI letters. See our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### How do I search the FDA 510(k), De Novo, and PMA databases by cybersecurity content? None of the three databases have a "cybersecurity" filter. Search by product code, then read the Summary Statement, Decision Summary, or Summary of Safety and Effectiveness Data manually. De Novo Decision Summaries are the most likely to contain explicit FDA cybersecurity reasoning because they are written by the agency rather than the sponsor. ### Why does the De Novo database matter for cybersecurity precedent research? De Novo grants create the product code and its special controls, which become the regulatory floor for every follow-on 510(k) in that code. When the FDA imposes cybersecurity special controls in a De Novo grant, subsequent 510(k) submissions in the code must show substantial equivalence to those controls, so the Decision Summary is precedent that outlives the original grant. ### What FOIA exemption redacts cybersecurity content in FDA summaries? Cybersecurity content is most often redacted under FOIA exemption (b)(4), which covers trade secrets and confidential commercial information. The structure of what was submitted, section headings, artifact types, and standards references, usually remains visible even when specific technical detail is redacted. ### Do 510(k) Summary Statements always mention cybersecurity for cyber devices? No. Section 524B compliance is required regardless of whether the sponsor discloses cybersecurity content in the public Summary Statement. Absence in a Summary does not mean absence in the submission or the review. ### What is the difference between a 510(k) Summary Statement and a De Novo Decision Summary? A 510(k) Summary Statement is written by the sponsor to justify substantial equivalence, and its depth varies widely. A De Novo Decision Summary is written by the FDA to document the risks identified, the special controls imposed, and the evidence considered, so it is a more consistent public window into FDA cybersecurity reasoning. **Related:** [Mining FDA Databases for Medical Device Cybersecurity Precedent](/blog/mining-fda-databases-medical-device-cybersecurity-precedent) · [FDA Cybersecurity Deficiency Letter Examples](/guides/fda-cybersecurity-deficiency-letter-examples) · [FDA PCCP Change-Control Plans](/guides/fda-pccp-change-control-plans) · [FDA Pathway Cybersecurity Differences](/guides/fda-pathway-cybersecurity-differences) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Does Device Class Decide FDA](/blog/fda-cybersecurity-requirements-by-device-class) --- ## How to Respond to an FDA Cybersecurity AI Request Source: https://bluegoatcyber.com/blog/how-to-respond-to-an-fda-cybersecurity-ai-request # How to Respond to an FDA Cybersecurity AI Request > **[DIRECT ANSWER]** Receiving an FDA cybersecurity Additional Information Request is recoverable if the team triages carefully within 48 to 72 hours, maps each cited deficiency to the specific guidance section it references, and rebuilds evidence rather than explanations. A strong response includes end-to-end threat models, machine-readable SBOMs with vulnerability disposition, penetration test findings with documented rationale, and a cover letter mapping every deficiency to the section of the package that resolves it. Receiving an FDA cybersecurity Additional Information Request (AIR) doesn’t mean your submission is dead. It means the clock is ticking, and the next move has to be precise. FDA issues these requests when reviewers find specific, documented gaps in your cybersecurity package, and they expect every gap to be closed in a single, well-structured response. A partial answer, an incomplete document, or a misreading of what the reviewer actually asked often leads to follow-up questions or, worse, a Not Substantially Equivalent determination, and the review clock resumes the moment FDA receives your response, leaving you with whatever days remain. For a standard 510(k), an AI Request typically arrives around day 58 to 60 of the 90-day review cycle, leaving roughly 26 to 32 days on the clock once your response is received. You also have 180 calendar days to submit a response before the submission is automatically withdrawn. Both constraints together explain why the initial 48 to 72 hours after receiving an AIR deserve careful, deliberate triage, more than almost any other phase in the process. This article walks you through how to read and triage the request, identify exactly what the FDA needs to see, assemble the right documentation, and structure a response that closes deficiencies cleanly. It also covers what you can do now to reduce the likelihood of this happening on your next submission. ## Key Takeaways - Triage AIRs within 48-72 hours to understand exact FDA needs. - Map deficiencies to specific sections of the FDA cybersecurity guidance. - Documentation must provide evidence, not just explanations. - Submit machine-readable SBOMs and complete threat models. - Ensure penetration tests cover all elements; justify all findings. - Structure responses with a clear cover letter that maps deficiencies. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to how to respond to an fda cybersecurity ai request the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What actually triggers an FDA cybersecurity additional information request FDA reviewers don’t issue Additional Information Requests arbitrarily. Every deficiency they cite maps to a specific expectation in the agency’s cybersecurity guidance, and understanding that connection is the first step toward fixing it. The Feb 3, 2026 final guidance (which supersedes the June 2025 final guidance, itself a successor to the September 2023 final) formally expanded the definition of “cyber devices” to include any device with embedded firmware or FPGAs, mandated FIPS 140-3 compliant cryptography, and required full disclosure of all communication interfaces. Submissions that cleared review in 2022 are now being evaluated against a meaningfully higher bar. The most common deficiencies fall into a predictable pattern. Threat models that don’t trace risks through the full system scope, including cloud infrastructure, update mechanisms, and supply chain relationships, consistently draw reviewer attention. SBOMs (Software Bills of Materials) that exist in name only, without machine-readable formatting or component-level vulnerability tracking, are another frequent trigger. Penetration test reports with unresolved low or medium findings and no documented acceptance rationale almost always generate follow-up, even when the findings themselves seem minor. Analyses of common FDA cybersecurity objections can help teams anticipate these recurring issues and prioritize fixes. ### Missing controls and weak vulnerability management Missing security controls from Appendix 1 of the guidance, such as event logging or cryptographic implementation, without a technical justification for their absence is another common pattern. Reviewers in 2026 treat these controls as mandatory unless you can demonstrate why they don’t apply to your device architecture. Weak or absent vulnerability management plans, particularly those that don’t reference sources like CISA’s Known Exploited Vulnerabilities catalog, round out the list of issues that reliably produce an AIR. ## How to read and triage your FDA cybersecurity additional information request The worst thing a team can do after receiving an AIR is immediately start producing documents. The first 48 to 72 hours should be spent understanding exactly what the FDA is asking, not writing responses. Misreading a deficiency and addressing something adjacent to it is one of the most common reasons manufacturers end up in a second round of questions. FDA’s language in deficiency letters follows recognizable patterns. In the author’s experience interpreting these letters, “inadequate” typically signals that documentation exists but doesn’t go deep enough, while “insufficient” usually points to a required element that’s missing entirely. Knowing the difference shapes how much rework is actually needed. Each cited deficiency also maps to a specific section of the guidance, and identifying those sections tells you the exact standard you’re being held to, which makes the response much easier to scope and write. ### Sorting deficiencies into workstreams Sort deficiencies into categories: documentation gaps (threat model, SBOM, architecture views), testing gaps (pen test scope or unresolved findings), and process gaps (no vulnerability management plan, no QMS integration). You might also encounter a fourth type, scope gaps, where the system boundary itself is defined too narrowly. This triage determines your response timeline and identifies who on the team needs to be involved. Mapping each deficiency to a specific deliverable owner early keeps the response on schedule even when the documentation list is long. The FDA also allows manufacturers to request a clarification teleconference within 10 calendar days of receiving an AIR. This option makes sense when the deficiency language is ambiguous or when multiple items overlap in ways that make it unclear what evidence would satisfy the reviewer. Prepare your questions in advance, confirm anything discussed in writing afterward, and document what the reviewer agreed would address each item. That written record becomes part of your response strategy. For practical, step-by-step instructions on crafting a compliant reply, consult [How to Respond to a 510(k) Cybersecurity Deficiency Letter](/guides/fda-cybersecurity-deficiency-response-checklist). ## The cybersecurity documentation FDA expects in your response A successful response isn’t just answering the questions the FDA asked. It’s demonstrating a defensible, traceable cybersecurity program. Reviewers are looking for evidence, not explanations, and the documentation has to show a connected system where risks are identified, mitigations are implemented, and the entire picture links back to your design controls. Refer to [FDA’s final cybersecurity guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) for the regulatory expectations that underpin reviewer decisions. For threat model responses, FDA expects end-to-end system scope that includes cloud infrastructure, update mechanisms, interoperability risks, and supply chain dependencies. Mitigations should trace directly back to design controls, and the risk model itself should follow a nonprobabilistic approach focused on exploitability and impact rather than traditional FMEA-style severity and likelihood ratings. The 2026 final guidance is explicit on this point, and responses that still present traditional risk matrices often generate follow-up questions. ### SBOM requirements and traceability SBOM documentation must be machine-readable, formatted in a standard like CycloneDX or SPDX, and include component names, versions, supplier names, unique identifiers, and dependency relationships. Beyond the inventory itself, the FDA expects evidence that known vulnerabilities in listed components have been evaluated and addressed. The SBOM should connect directly to your threat model. Traceability should show how component-level risks map to identified threats, and how those threats link to implemented controls. ### Penetration testing expectations For penetration testing, the test must cover a production-equivalent device, all system elements, and every communication interface. Every finding, including low-severity ones, needs a documented disposition: mitigated, accepted with a written rationale, or deferred with a specific timeline and justification. Responses that leave even minor findings without clear documentation consistently draw follow-up from reviewers. On the process side, the FDA expects a forward-looking vulnerability management plan with defined patch and update processes, cryptographic signing, rollback protection, and evidence that cybersecurity obligations are embedded in the QMS through process records, not just policy statements. ## How to structure and submit your response package Once the evidence is assembled, how it’s packaged and submitted matters as much as the content itself. A disorganized response that makes reviewers search for answers is a reliable path to a second round of questions. The cover letter does most of the structural work. The cover letter should open with a concise summary of the deficiencies cited, followed by a table or index that maps each numbered deficiency to the specific section of the response package addressing it. Each entry should include a brief narrative explaining what was added or revised and why it satisfies the reviewer’s concern. Structuring AIR responses this way, building a clear deficiency-to-document trail, allows FDA reviewers to confirm resolution without guessing and reduces the likelihood of cycling through multiple response iterations. On the submission mechanics side, responses go to the FDA’s Document Control Center via eCopy, and the review clock resumes immediately upon receipt. With only 26 to 32 days typically remaining on a 510(k) review clock after an AIR is issued, a weak or incomplete first response has almost no recovery window. The 180-day response deadline is equally real. Missing it results in automatic withdrawal and a full re-filing, with no extensions available for 510(k) or De Novo submissions. For a broader perspective on how different submission pathways affect cybersecurity expectations, see [PMA vs De Novo vs 510(k): Cybersecurity Impact on FDA Submissions](/blog/510k-cybersecurity-requirements-every-maker-must-meet). Practical guides to handling additional information requests can also help your team avoid procedural missteps; see this overview of [additional information requests](https://medicaldeviceacademy.com/additional-information-request/). ## What to expect after you submit, and what a second round signals Submitting a complete response doesn’t guarantee immediate clearance, but it does restart the path toward it. After the FDA receives your response, review resumes against the remaining days on the 510(k) clock, typically resulting in a decision within 26 to 32 days for a standard submission. A response that cleanly closes every cited deficiency with traceable evidence substantially reduces the likelihood of another information request. A response that partially addresses deficiencies, or introduces new inconsistencies through mismatched documentation, can trigger a second round. If the FDA issues a second AIR, it’s usually a signal of one of two things: the first response left gaps in specific evidence, or new inconsistencies surfaced during review of the updated package. Approach a second response differently. Go back to the original deficiency language, audit exactly what was submitted against each item, and identify where the evidence fell short or contradicted other documentation. In some cases, a Q-Submission meeting before submitting again can help clarify what FDA needs to see and prevent a third round. For additional context on the AIR process and expectations, this [Additional Information Requests](https://seed.nih.gov/sites/default/files/2024-12/Additional-Information-Requests.pdf) reference can be useful when planning your audit and rework steps. ## Reducing the risk of another AI request in future submissions The best response to an AIR is building a submission that doesn’t generate one. That means integrating cybersecurity into the development lifecycle before the submission window opens, not assembling documentation in the final weeks before filing. A Secure Product Development Framework built early gives your team the documentation backbone that reviewers expect: threat modeling completed during design, an SBOM maintained throughout development and linked to vulnerability management from day one, and penetration testing scoped to production-equivalent hardware rather than development builds. For focused 510(k) preparation checklists, see [510(k) Cybersecurity Requirements Every Maker Must Meet](/blog/510k-cybersecurity-requirements-every-maker-must-meet). QMS records should document the cybersecurity development lifecycle in a way that makes the process auditable. The 2026 final guidance reflects a clear shift toward process evidence, reviewers look for documentation showing how cybersecurity was managed throughout development, not just completed artifacts at the end. This is especially true for novel device architectures or devices with complex connectivity profiles where the guidance doesn’t fully address every edge case. Pre-submission meetings, formally called Q-Submissions, are among the most valuable and underutilized tools in the premarket process. Teams that use pre-subs to align their cybersecurity documentation approach with the FDA arrive at submission with reviewer agreement on scope and methodology. That agreement meaningfully reduces the chance of an AIR, because the documentation strategy was already validated before the formal clock started running. ## Getting it right the first time is always the faster path An FDA cybersecurity Additional Information Request is a solvable problem. It requires speed, precision, and a clear understanding of what reviewers actually need to see. Manufacturers who triage deficiencies carefully, build response packages with full traceability, and submit clean cover letters with deficiency-to-document mapping get back on the path to clearance. Those who guess, rush, or partially address the cited gaps tend to cycle through multiple rounds, burning time and budget with each iteration. Navigating a complex AIR is significantly easier with a team that has direct experience resolving FDA cybersecurity deficiencies. Blue Goat Cyber works exclusively in medical device cybersecurity, our focus gives us deep familiarity with what reviewers look for, how to structure the evidence, and how to close gaps without introducing new ones. If you’re facing an AIR right now, engaging a specialized team is the most reliable way to protect the remaining review window and move toward clearance with confidence. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is an FDA cybersecurity AIR? An FDA cybersecurity Additional Information Request (AIR) is issued when the FDA identifies specific gaps in a medical device cybersecurity submission. It requires manufacturers to provide further documentation or clarification to address these deficiencies before review can proceed. ### How much time do manufacturers have to respond to an AIR? Manufacturers typically have 180 calendar days to submit a response to an AIR before the submission is automatically withdrawn. For a 510(k), approximately 26 to 32 days remain on the review clock once the FDA receives the response. ### What documentation does the FDA expect for threat models in an AIR response? The FDA expects threat models to cover the end-to-end system scope, including cloud infrastructure and supply chain. Mitigations should trace to design controls, and the risk model must use a non-probabilistic approach focusing on exploitability and impact. ### Does the FDA require machine-readable SBOMs? Yes, the FDA expects SBOM documentation to be machine-readable, formatted in a standard like CycloneDX or SPDX. It must include component names, versions, unique identifiers, and evidence that known vulnerabilities have been evaluated. ### When should I request a clarification teleconference for an AIR? Request a clarification teleconference within 10 calendar days of receiving an AIR if the deficiency language is ambiguous or if multiple items overlap. Prepare questions in advance and document all discussions afterward. ### What happens if a response to an AIR is incomplete? An incomplete or partial response to an AIR can lead to follow-up questions from the FDA or, in severe cases, a Not Substantially Equivalent determination. It significantly delays the review process and may result in a second AIR. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## VxWorks Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/identifying-vulnerabilities-with-vxworks # VxWorks Vulnerabilities in Medical Devices: Triage, SBOM & §524B Evidence > **[DIRECT ANSWER]** MedTech teams should identify VxWorks exposure by building a precise software inventory covering the RTOS version, packages, and enabled network services, then validate whether each known vulnerability, including URGENT/11-class flaws, is actually reachable and exploitable in the device's architecture. Findings must be triaged against patient harm and essential performance, documented with dated VEX statements tied to the SBOM, and either patched or mitigated with specific, testable compensating controls for FDA Section 524B review. VxWorks still shows up across a large share of FDA-regulated devices, including patient monitors, infusion pumps, imaging platforms, and lab analyzers. Since **URGENT/11**, the FDA has expected manufacturers to know exactly where VxWorks is used, what version is deployed, which vulnerabilities apply, and what evidence supports the risk decision. In 2026, that means a complete SBOM, dated VEX statements, and traceable Section 524B evidence that ties cybersecurity risk to patient harm and essential clinical performance. ## Key Takeaways - VxWorks remains prevalent in various FDA-regulated devices. - A precise SBOM is foundational for identifying VxWorks exposure. - Validate vulnerability reachability and impact on patient safety. - Triage must align with FDA Section 524B requirements. - Patch vulnerabilities or implement strong compensating controls objectively. - Reviewers expect traceable evidence from inventory to risk decisions. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to vxworks vulnerabilities in medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Why VxWorks Still Demands Attention [VxWorks, developed by Wind River](https://www.windriver.com/products/vxworks), is a real-time operating system used in embedded products where timing and reliability matter. In medical devices, that combination is attractive: small footprint, deterministic behavior, support across hardware platforms, and a long history in systems that cannot tolerate unpredictable latency. That same footprint creates a persistent security problem. VxWorks is often buried deep in the product stack, inherited from a supplier, or carried forward across multiple product generations. Teams think they are dealing with an application issue when the real exposure sits in the RTOS, middleware, network services, or BSP. That is why the FDA keeps asking for software inventory quality, patch posture, and clear vulnerability disposition instead of generic claims that the device is "secure by design." ### What Makes VxWorks a Recurring Risk Several traits make VxWorks a recurring source of regulatory and security work for manufacturers: - Long product lifecycles that outlast normal software support windows - Third-party integration where the RTOS is not fully visible to the device maker - Network-exposed services that may be enabled by default or left undocumented - Product variants that share a codebase but differ in deployed components - Safety-critical use cases where even a low-probability exploit can have outsized clinical impact URGENT/11 made this plain. The issue was not just a set of CVEs. It was that many manufacturers did not know whether the affected components were present, reachable, or mitigated in their shipping devices. ## What VxWorks Vulnerabilities Usually Look Like VxWorks flaws are not limited to one class of bug. The common patterns are familiar: memory corruption, privilege escalation, denial of service, authentication weaknesses, and remote code execution tied to exposed services or protocol handling. ![Section Image](/imported-images/5feec22b3e0166a4.webp) For medical device teams, the practical question is not "Does this RTOS have vulnerabilities?" Of course it does. The real questions are: - Which vulnerable component is present in our device? - Which version is actually deployed? - Is the vulnerable function reachable in our architecture? - What exploit conditions exist in the intended use environment? - What is the impact on safety, essential performance, and clinical operations? ### Common Vulnerability Categories The most common categories include: - **Buffer and memory handling flaws:** These can cause crashes, unstable behavior, or code execution. - **Privilege escalation issues:** An attacker who gains a foothold may move into more trusted execution paths. - **Remote code execution paths:** Often tied to networking stacks, RPC services, web interfaces, or protocol parsers. - **Denial-of-service conditions:** Particularly serious in devices that depend on continuous availability or predictable timing. - **Configuration weaknesses:** Unused but enabled services, default credentials, open debug paths, and insecure update mechanisms. ### Why the Impact Is Different in Medical Devices In a consumer product, a crash may be an inconvenience. In a medical device, a crash can interrupt therapy, delay diagnosis, corrupt data, or force fallback to manual procedures. A network-service flaw in an infusion system or bedside monitor is not just an IT issue. It can become a patient safety issue if exploitation degrades availability, integrity, or clinician trust in device output. That is why the FDA expects threat modeling and vulnerability assessment to connect directly to harm. You need to show how exploitation could affect safety or essential clinical performance, and what controls reduce that risk to an acceptable level. ## How to Identify VxWorks Exposure in Your Device You cannot triage what you have not accurately identified. For VxWorks-based products, identification starts with software inventory discipline, not a scanner screenshot. ![Section Image](/imported-images/71ffbb382f86becb.webp) ### Build the Right Software Inventory First Start by confirming: - VxWorks version and edition - Wind River packages and optional components included - Board support package details - Enabled network services and listening interfaces - Third-party libraries bundled with the image - Product variants that inherit the same software stack - Supplier-delivered binaries and any customization layers This is the foundation for an SBOM that reviewers can trust. If your SBOM omits the RTOS version, middleware, or included services, your downstream VEX and vulnerability analysis will be weak from the start. ### Use Manual Analysis and Tooling Together Manual review still matters. Experienced engineers can inspect build artifacts, startup configuration, enabled services, and architecture decisions that automated tools routinely miss. That includes undocumented dependencies, dead code assumptions, and exposure created by integration choices rather than the base RTOS alone. Automated tools are still useful, but only when used correctly. SCA platforms, firmware analysis tools, binary composition analysis, and network enumeration can help identify vulnerable components and known CVEs. They also help surface version mismatches between what engineering believes is present and what is actually shipping. Use both. Tool output without engineering validation creates noise. Manual review without tooling misses scale. ### Validate Reachability, Not Just Presence This is where many teams fail. A CVE match does not automatically mean the device is exploitable. But "not automatically" does not mean "not applicable." You need to validate: - Whether the vulnerable component is compiled into the product - Whether the affected function is enabled and reachable - Whether authentication, segmentation, or device workflow meaningfully reduce exploitability - Whether a failure or compromise can propagate into a hazardous situation That is the difference between real triage and checklist theater. ## Triage for Section 524B and FDA Review Once you identify a VxWorks vulnerability, the next job is to document a defensible disposition. The FDA does not want a pile of CVEs with severity scores and no clinical context. It wants evidence that you evaluated exploitability, impact, and compensating controls in the context of the device. ### What Good Triage Looks Like For each relevant vulnerability, document: - Affected component and version - Source of identification such as NVD, vendor advisory, CISA, internal testing, or researcher report - Device models and product versions affected - Exploit preconditions - Reachability in the intended environment - Impact on confidentiality, integrity, availability, safety, and essential performance - Existing controls and residual risk - Patch, mitigation, or rationale for non-remediation - Date assessed and owner of the decision This is where VEX becomes useful. A dated VEX statement can explain whether a CVE is affected, not affected, under investigation, or fixed, with enough detail to support the claim. That statement should align with your SBOM, risk files, and design documentation. ### Severity Scores Are Not Enough CVSS can help prioritize, but it does not answer FDA review questions by itself. A medium-severity network flaw may deserve urgent action if it can interrupt therapy. A high-severity issue may be lower practical risk if the affected service is absent, unreachable, or blocked by architecture. Your triage has to show the reasoning. Tie the analysis back to: - Threat scenarios from the threat model - Hazard analysis and hazardous situations - Security control verification - Labeling, deployment assumptions, and servicing constraints If your conclusion is "not exploitable," be ready to prove it. ## Mitigation Options That Hold Up Under Scrutiny Identification without action is not enough. For VxWorks issues, acceptable mitigation depends on what is technically possible in the product lifecycle and what evidence you can produce. ### Patch When You Can, Compensate When You Must The preferred path is straightforward: update the affected component, verify the fix, and document regression results. But medical devices often have servicing limits, certification impacts, supplier delays, and field deployment constraints. When patching is not immediately feasible, you need compensating controls that are specific and testable. Examples include: - Disabling vulnerable services - Restricting ports and protocols - Enforcing authenticated access paths - Segmenting the device from untrusted networks - Hardening configuration and removing debug interfaces - Monitoring for exploit attempts or anomalous behavior - Tightening update integrity controls A vague statement that the device is deployed in a hospital network is not a mitigation. Show the technical control. Show where it is implemented. Show test evidence. ### Secure Development Still Matters Long-term reduction in VxWorks exposure comes from engineering discipline: - Secure coding practices around memory handling and input validation - Architecture review for service exposure and trust boundaries - Repeated code review and static analysis - Firmware and software update design that supports timely remediation - Supplier management for RTOS and middleware transparency - Verification plans that include abuse cases, not just intended use Manufacturers that treat RTOS vulnerabilities as one-off patch events keep reliving the same problem. The better approach is to design for visibility, containment, and maintainability from the start. ## What Reviewers Expect to See By the time a submission reaches the FDA, the manufacturer should be able to produce a clean line from inventory to risk decision to evidence. That usually means: - An SBOM that accurately lists VxWorks and related components - VEX statements for relevant CVEs, with dates and rationale - Threat modeling that covers RTOS and network-service abuse paths - Security risk documentation tied to patient harm and essential performance - Verification evidence for patches or compensating controls - Plans for coordinated vulnerability disclosure and postmarket monitoring If those artifacts disagree with each other, reviewers will notice. If the SBOM says one thing, the VEX says another, and the risk file uses generic language, expect questions. The standard is not perfection. It is traceability and credibility. VxWorks is not unusual because it has vulnerabilities. It is unusual because many device makers still underestimate how hard those vulnerabilities are to inventory, triage, and defend in front of the FDA. If your device depends on VxWorks, know the stack, verify applicability, and document the risk decision like a reviewer will read every line. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is VxWorks in medical devices? VxWorks is a real-time operating system (RTOS) used in embedded medical devices like patient monitors and infusion pumps due to its small footprint and reliable, deterministic behavior. It is developed by Wind River. ### Why is VxWorks a recurring risk for medical devices? VxWorks poses recurring risks due to long product lifecycles, deep integration, network-exposed services, product variants, and safety-critical use cases where even minor exploits can have significant clinical impact. Many manufacturers lack full visibility into its deployment. ### How does the FDA view VxWorks vulnerabilities? The FDA expects manufacturers to know all VxWorks deployments, versions, applicable vulnerabilities, and provide evidence supporting risk decisions, especially concerning patient harm and essential clinical performance, as per the February 3, 2026 final guidance and Section 524B. ### What evidence does the FDA expect for VxWorks vulnerability triage? The FDA expects a complete SBOM, dated VEX statements, and traceable Section 524B evidence connecting cybersecurity risk to patient harm. This includes documentation of affected components, exploit preconditions, reachability, and impact on safety and essential performance. ### Are CVSS scores sufficient for FDA vulnerability assessment? No, CVSS scores alone are not sufficient. While they help prioritize, FDA submissions require reasoning that ties vulnerability analysis directly to threat models, hazard analysis, and the potential impact on safety or essential clinical performance. ### What are acceptable mitigations for VxWorks vulnerabilities? Preferred mitigation is patching. When not feasible, acceptable compensating controls include disabling vulnerable services, restricting ports, enforcing authenticated access, segmenting networks, hardening configurations, and monitoring for exploits. These must be specific and testable. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) [Contact Blue Goat Cyber for cybersecurity support](/contact) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [JTAG and UART Vulnerabilities in Medical](/blog/navigating-the-intersection-of-jtag-uart-debug-ports-and-fda-compliance-in-medical-device-cybersecurity) - [CISA KEV Catalog for Medical Devices](/blog/cisa-kev-catalog-medical-devices) --- ## IEC 62304 Classes vs FDA Device Classes Source: https://bluegoatcyber.com/blog/iec-62304-classes-vs-fda-device-classes-cybersecurity # IEC 62304 Classes vs FDA Device Classes: Cybersecurity Impact > **[DIRECT ANSWER]** IEC 62304 software safety classes A, B, and C describe the harm a software failure can cause, while FDA device classes I, II, and III set the regulatory pathway. They are not interchangeable, and your cybersecurity evidence depth under Section 524B should follow the software safety class and the threat model, not the device class alone. Sponsors regularly conflate IEC 62304 software safety classes with FDA device classes, and FDA reviewers see the confusion show up in submissions. The two classifications answer different questions, but both shape the cybersecurity package the FDA expects. Misalignment between them is a frequent source of deficiency letters, because the SPDF evidence, threat model depth, and verification rigor in a submission are supposed to track to the right classification for the right reason. This post separates the two, shows how they intersect for cybersecurity, and explains which artifacts each one drives. ## Key Takeaways - FDA device class and IEC 62304 software safety class are orthogonal classifications. - FDA class drives the submission pathway and whether Section 524B applies. - IEC 62304 class drives the rigor of software lifecycle evidence inside the SPDF. - A Class II device can contain Class C software, and a Class III device can contain Class A software. - Cybersecurity requirements under the Feb 3, 2026 guidance do not scale by 62304 class directly. - Misclassifying software safety class is a recurring source of FDA deficiency questions. ## Why this matters Sponsors who treat IEC 62304 class and FDA device class as the same axis end up with submissions that under-document software lifecycle evidence on high-risk software items, over-document it on low-risk ones, or miscalibrate the cybersecurity package entirely. The FDA's February 3, 2026 final premarket cybersecurity guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," ties cybersecurity expectations to the Section 524B definition of a cyber device, not to 62304 class. Separately, AAMI SW96:2023 and IEC 81001-5-1 inform how security activities sit inside the software lifecycle that IEC 62304 governs. Mixing the two up leads to threat models that are too shallow for the actual software safety class, or to risk control verification that does not match the rigor a Class C software item demands. Both patterns are routinely flagged in deficiency letters. ## What FDA Device Classes Actually Classify ### Class I, II, and III Reflect Patient Risk and Pathway FDA device classes are defined under 21 CFR Part 860 and reflect the level of regulatory control the FDA considers necessary to provide reasonable assurance of safety and effectiveness. Class I is low risk and mostly 510(k)-exempt. Class II is moderate risk and typically cleared via 510(k) or De Novo, with eSTAR mandatory. Class III is life-sustaining or life-supporting and goes through PMA. The class is a property of the finished device and its intended use, not of any one software item inside it. For a deeper breakdown of the cybersecurity obligations tied to each risk tier, see our guide to [FDA cybersecurity requirements by device class (I, II, and III)](/blog/fda-cybersecurity-requirements-by-device-class). ### How Class Determines Cybersecurity Applicability Section 524B of the FD&C Act applies to any device that meets the statutory definition of a "cyber device": validated software plus internet or network capability plus the potential to be vulnerable to cybersecurity threats. That definition does not key off FDA class. Most Class I devices have no software and fall outside 524B entirely. Most connected Class II and nearly all Class III devices are cyber devices and must produce the full premarket cybersecurity package. **The trigger is the 524B definition, not the device class itself.** ## What IEC 62304 Software Safety Classes Actually Classify ### Class A, B, and C Reflect Worst-Case Harm From the Software Item IEC 62304 classifies each software item by the worst-case harm it could contribute to if it failed and no risk controls outside the software prevented that harm. Class A means no injury or damage to health is possible. Class B means non-serious injury is possible. Class C means death or serious injury is possible. The class applies to a software item, not to the device. A single device can contain software items at different classes, and the manufacturer documents the rationale for each. ### How Class Determines Lifecycle Rigor The 62304 class drives how much of the software lifecycle process is required for that item: planning, requirements, architecture, detailed design, unit implementation and verification, integration, system testing, and release. Class A items skip several activities. Class C items require the full set, including detailed design and unit verification with documented acceptance criteria. **62304 class is about process rigor for the software item, not about the regulatory pathway for the device.** ## Why These Two Classifications Get Confused ### The Numbers and Letters Both Look Like Severity Tiers The confusion is partly cosmetic. Both classifications climb from low to high (I to III, A to C) and both correlate with patient risk. A Class III implantable cardioverter-defibrillator almost certainly contains Class C software for therapy delivery, which reinforces the mental shortcut that "III equals C." That shortcut breaks down quickly. A Class II infusion pump can contain Class C software for dose calculation. A Class III implant can contain Class A software for a non-safety logging function. Reviewers see both patterns and expect the submission to justify each software item's class on its own terms. ### The FDA Does Not Scale Cybersecurity by 62304 Class The Feb 3, 2026 guidance and Section 524B do not say "Class C software needs a deeper threat model than Class A software." The guidance scales cybersecurity expectations to the device's risk profile, attack surface, and intended use environment. The relationship to 62304 is indirect: a Class C software item typically lives inside a device whose threat model and security risk assessment need to address patient-harm consequences, but the cybersecurity rigor is driven by the security risk analysis, not the 62304 class label. ## How the Two Classifications Intersect in a Real Submission ### The Mapping Is Many-to-Many, Not One-to-One In practice, the device-level class sets the submission pathway and the 524B trigger, while the 62304 class sets the lifecycle evidence requirements for each software item. Both feed into the cybersecurity package. The common combinations look like this: | FDA device class | Typical 62304 software classes | Typical cybersecurity profile | | --- | --- | --- | | Class I (with software) | A, sometimes B | 524B applies only if cyber device; limited attack surface | | Class II (connected) | A, B, and C across different items | Full Feb 3, 2026 package; threat model covers all interfaces | | Class III (implant or life-support) | Often C for therapy items, A or B for ancillary items | Full package with deeper architectural and supply-chain evidence | The cybersecurity artifacts the FDA reviews are the same set across Class II and Class III. The difference is depth of architectural evidence and, for PMA, expectations around manufacturing-environment security and annual reporting. ### What Reviewers Look For at the Intersection Reviewers expect the threat model and security risk assessment to acknowledge the safety consequences of each software item, including any that are 62304 Class C. They expect verification evidence (including security testing) to match the lifecycle rigor declared for each item. A submission that declares all software items as Class A while the device is a Class III implant draws an immediate question. So does a submission that uses a uniform 62304 class for every software item without documenting the rationale. ## Which Cybersecurity Artifacts Each Classification Drives ### Artifacts Driven by FDA Device Class The FDA device class determines the submission pathway (510(k), De Novo, PMA), whether eSTAR applies, and the depth of architectural and supply-chain evidence reviewers expect. Class III PMA submissions require expanded architecture views, manufacturing-environment controls, and PMA annual reports that explicitly address cybersecurity changes. Class II submissions produce the same seven-section cybersecurity content set without the PMA-specific expansions. ### Artifacts Driven by IEC 62304 Class The 62304 class drives the software lifecycle evidence that sits inside the SPDF and feeds the cybersecurity package: requirements traceability, architecture documentation, unit verification records, integration test evidence, and release evidence. AAMI SW96:2023 layers security activities onto that lifecycle. A Class C software item that handles authentication, key management, or therapy decisions needs documented architectural decomposition, unit-level verification, and security-specific test evidence that a Class A item would not. Reviewers follow that evidence from the cybersecurity risk assessment back into the 62304 lifecycle records. ### Artifacts Driven by the Cyber Device Definition Itself Regardless of FDA class or 62304 class, any cyber device under Section 524B must produce an SBOM with VEX, a threat model, a cybersecurity risk assessment, security architecture views, security testing evidence including penetration testing, labeling that supports secure operation, and a postmarket plan. These are required by the Feb 3, 2026 guidance and are not scaled by 62304 class. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches This in FDA Submissions We treat FDA device class and IEC 62304 class as independent inputs into the cybersecurity package, not as a single severity tier. Each software item gets its own 62304 classification with documented rationale, and the threat model, security risk assessment, and verification evidence are calibrated to both the device-level risk profile and the per-item lifecycle rigor. Our team holds CISSP, OSCP, and prior military red-team credentials, and our submission work is grounded in Section 524B, the FDA's February 3, 2026 final premarket cybersecurity guidance, AAMI SW96:2023, and IEC 81001-5-1. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA premarket cybersecurity services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services) or compare pathways on the [Class I/II/III cybersecurity reference page](https://bluegoatcyber.com/reference/medical-device-classes-cybersecurity-requirements). ## FAQ ### Is IEC 62304 Class C the same as FDA Class III? No. IEC 62304 Class C describes a software item whose failure could contribute to death or serious injury. FDA Class III describes a device that is life-sustaining, life-supporting, or implantable. A Class III device often contains Class C software, but a Class II infusion pump can also contain Class C software, and a Class III implant can contain Class A software for non-safety functions. They are different axes. ### Does the FDA require a different cybersecurity package for Class C software? The Feb 3, 2026 final premarket cybersecurity guidance does not scale cybersecurity artifacts by 62304 class. It ties cybersecurity expectations to the Section 524B cyber device definition and to the device's risk profile and attack surface. The 62304 class influences the depth of lifecycle and verification evidence inside the SPDF, which the cybersecurity risk assessment then references. ### Can a Class I device be a cyber device under Section 524B? Yes, if it has validated software, network or internet capability, and the potential to be vulnerable to cybersecurity threats. Most Class I devices have no software and fall outside 524B, but a Class I device that meets the definition must produce the full premarket cybersecurity package. ### What standards govern the intersection of software lifecycle and cybersecurity? IEC 62304 governs the software lifecycle. AAMI SW96:2023 layers security activities onto that lifecycle and is the FDA-recognized consensus standard for medical device security risk management. IEC 81001-5-1 covers security activities for health software. ISO 14971 governs overall risk management. The FDA's Feb 3, 2026 guidance points to all four. ### What goes wrong when a sponsor treats the two classes as equivalent? The most common failures are under-rigorous lifecycle evidence on Class C software items inside lower-class devices, missing per-item 62304 classification rationale, and threat models that do not connect to the safety consequences of high-class software items. Each pattern shows up as a deficiency letter during substantive review. ## Ready to align your classifications and your cybersecurity package? If you are preparing a 510(k), De Novo, or PMA submission and want the cybersecurity package and IEC 62304 lifecycle evidence to line up the way reviewers expect, we can help. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led FDA premarket cybersecurity submissions across Class II and Class III devices and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## IEC 80001-1: Hospital Network Risk Management Explained Source: https://bluegoatcyber.com/blog/iec-80001-1-enhancing-medical-device-cybersecurity # IEC 80001-1: Hospital Network Risk Management Explained > **[DIRECT ANSWER]** IEC 80001-1 is the international standard that governs risk management when medical devices connect to IT networks inside a healthcare delivery organization. It is written for the hospital, which the standard calls the "responsible organization," not for the device manufacturer. The 2021 edition organizes the standard around defined roles, including top management, the medical IT network risk manager, the medical device manufacturer, and the IT vendor, and it protects three properties: safety, effectiveness, and data and system security. It is not an FDA submission requirement and it does not replace device-level standards like IEC 81001-5-1 or ISO 14971. _Reviewed September 17, 2026_ Hospitals connect medical devices to shared IT networks every day, and every one of those connections creates a risk decision that someone has to own. IEC 80001-1 exists because that ownership question used to have no clear answer. When a networked infusion pump, imaging system, or monitor interacts badly with hospital IT infrastructure, patient safety, network availability, and data security can all be affected at once, and manufacturers alone cannot manage that risk because they do not control the network it lands on. That is the gap IEC 80001-1 fills. It gives the healthcare delivery organization (HDO) a structured way to manage network risk, and it gives manufacturers a clear picture of what information the hospital needs from them to do it. Getting this relationship wrong creates friction during procurement, unclear incident ownership, and gaps that surface only after a network event has already caused harm. ## Key Takeaways - IEC 80001-1 is a hospital-facing network risk management standard, not a device design standard. - The responsible organization is the healthcare delivery organization, not the manufacturer. - It protects three key properties: safety, effectiveness, and data and system security. - The 2021 edition defines specific roles: top management, medical IT network risk manager, medical device manufacturer, and IT vendor. - It is not an FDA submission requirement, though it supports the shared-responsibility documentation the FDA now expects. - Manufacturers meet their part of IEC 80001-1 by supplying accurate disclosure information, not by holding an 80001-1 certificate themselves. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (February 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. That guidance does not require IEC 80001-1 conformance, because IEC 80001-1 governs the hospital's network, not the manufacturer's design controls. What it does expect is that manufacturers document deployment assumptions, network interface characteristics, and disclosure information clearly enough that a hospital operating under IEC 80001-1 can complete its own risk assessment. Reviewers increasingly ask manufacturers to show that this handoff works: the security disclosure content, the SBOM, the intended network environment, and the responsibility split with the customer. A manufacturer that cannot describe what a hospital needs to manage network risk has not fully worked out its own postmarket security story either. Confusing IEC 80001-1 with a device standard, or claiming conformance to it as a manufacturer, is a factual error that reviewers and knowledgeable customers will catch. ## What Is IEC 80001-1? IEC 80001-1 is the international standard titled "Application of risk management for IT-networks incorporating medical devices," and it applies to the healthcare organization operating the network, not the device in isolation. The 2021 second edition reframed the standard around roles and responsibilities for health IT infrastructure, replacing an earlier process-heavy structure with clearer accountability for who does what. It sits under the IEC/ISO 80001 family, which also includes technical reports covering wireless networks, security, and disclosure. **[KEY REQUIREMENT]** IEC 80001-1 requires the responsible organization to maintain a documented risk management process for its medical IT network, assign a named medical IT network risk manager, and obtain a responsibility agreement from each connected device's manufacturer or IT vendor before integration. The standard does not certify medical devices and it is not something a manufacturer can claim to be "compliant with" in the way it can claim IEC 62304 or ISO 14971 conformance. A manufacturer's role under IEC 80001-1 is to act as an information source: it supplies the technical disclosure the hospital needs, but the risk management obligation itself belongs to the hospital. ## Who Is IEC 80001-1 Written For? IEC 80001-1 is written for the healthcare delivery organization as the "responsible organization," the entity accountable for the medical IT network as a whole. That distinction matters because it is easy to assume any cybersecurity standard is aimed at the device manufacturer, and IEC 80001-1 is a clear exception. The responsible organization owns the network topology, the segmentation decisions, the patch and configuration management of connected infrastructure, and the incident response process when something on the network fails. Manufacturers participate by supplying information, typically through a Manufacturer Disclosure Statement for Medical Device Security (MDS2) or equivalent documentation, and by signing a responsibility agreement that defines what each party will do before, during, and after a device is connected. IT vendors supplying network infrastructure or services carry a parallel obligation to disclose their own product's characteristics. ## What Three Properties Does IEC 80001-1 Protect? IEC 80001-1 protects three properties that the standard treats as inseparable when a medical device is on a network: safety, effectiveness, and data and system security. Safety means the network connection must not introduce a new way for the device to cause physical harm. Effectiveness means the device must continue to perform its intended clinical function once it depends on shared infrastructure. Data and system security means patient data and the underlying systems must resist unauthorized access, disclosure, or modification. The standard requires the responsible organization to balance all three properties together rather than optimizing one at the expense of another. A network segmentation change that improves security but breaks a clinical alarm's connectivity has failed the standard just as surely as an unpatched vulnerability has. ## Who Holds Each Role Under IEC 80001-1? The 2021 edition assigns four defined roles, and each one carries distinct obligations under the standard. - **Top management** of the responsible organization: sets policy, allocates resources, and is ultimately accountable for the medical IT network risk management process. - **Medical IT network risk manager**: a named individual inside the responsible organization who runs the day-to-day risk management process, coordinates between clinical, IT, and biomedical engineering teams, and maintains the risk records. - **Medical device manufacturer (MDM)**: supplies disclosure information about the device's network requirements, security characteristics, and intended use conditions, and participates in the responsibility agreement. - **IT vendor**: supplies equivalent disclosure for network infrastructure, middleware, or services that are not medical devices but still affect the network's risk profile. The responsibility agreement is the mechanism that ties these roles together. It is a documented agreement, not necessarily a single contract, that records what each party is responsible for once a device or system joins the network, including who monitors it, who patches it, and who responds when something goes wrong. ## What Is the IEC 80001 Family of Standards? IEC 80001-1 is the base standard, but it sits inside a broader family that includes technical reports numbered in the 2-x series, covering topics such as wireless network risk, security-specific guidance, and step-by-step disclosure processes. Several of the earlier 2-x technical reports have been superseded or folded into newer guidance as the standard matured, so teams referencing the family should confirm which technical report is current before citing it in documentation. **[KEY REQUIREMENT]** When citing the IEC 80001 family in hospital or manufacturer documentation, confirm the specific technical report's current status rather than assuming a 2-x number retains its original scope, since several have been revised or superseded since first publication. ## How Does IEC 80001-1 Relate to IEC 81001-5-1 and MDS2? IEC 80001-1 and IEC 81001-5-1 cover different ends of the same lifecycle, and confusing them is one of the most common documentation errors. IEC 81001-5-1 defines security activities that a manufacturer performs during product development, such as threat modeling, secure design, and verification, and it is a device-side standard. IEC 80001-1 defines what the hospital does after that device arrives on its network. A manufacturer conforming to IEC 81001-5-1 produces the evidence and disclosure content that a hospital then consumes under IEC 80001-1. The MDS2 form is the practical bridge between the two. It is a structured disclosure document manufacturers complete to describe a device's security-relevant characteristics, such as data types stored, authentication mechanisms, and patching approach. A hospital's medical IT network risk manager uses the MDS2 as primary input to the IEC 80001-1 risk assessment for that device. ## How Does IEC 80001-1 Compare to Related Standards? | Standard | Who owns it | What it covers | |---|---|---| | IEC 80001-1 | Healthcare delivery organization | Risk management for the hospital's IT network once medical devices are connected; roles, responsibility agreements, ongoing network risk process | | IEC 81001-5-1 | Medical device manufacturer | Security activities across the product development lifecycle, including threat modeling, secure design, and verification | | AAMI SW96 | Medical device manufacturer | Security risk management methodology for the device itself, adapting ISO 14971 to security-specific risk | | ISO 14971 | Medical device manufacturer | Overall risk management for the device across its lifecycle, covering safety hazards broadly, not security-specific | ## What Should Manufacturers Hand Over to Hospitals? Manufacturers do not implement IEC 80001-1 themselves, but they are the source of the information a hospital needs to meet its own obligations under it. A complete handoff should include a current MDS2 or equivalent security disclosure, a software bill of materials, documented network interface requirements, guidance on recommended segmentation and firewall settings, patch and end-of-support timelines, and clear points of contact for security incidents and vulnerability disclosure. **[KEY REQUIREMENT]** A manufacturer's disclosure package should let a hospital's medical IT network risk manager complete an IEC 80001-1 risk assessment without having to request additional technical detail after the device is already installed. Incomplete or outdated disclosure content is the most common reason a hospital's IEC 80001-1 process stalls, and it is entirely within the manufacturer's control to fix. ## How Blue Goat Cyber Approaches This Blue Goat Cyber helps manufacturers build the disclosure and design documentation that hospitals actually need for IEC 80001-1, rather than treating it as paperwork produced after the fact. That starts with device-side work under IEC 81001-5-1 and ISO 14971, threat modeling and security testing that generates real evidence, and MDS2-ready disclosure content that reflects the device's actual behavior on a network. Our [medical device threat modeling services](/services/medical-device-threat-modeling) build the architecture and data-flow analysis that both the manufacturer's own risk file and the hospital's IEC 80001-1 process depend on. We also support the postmarket side, so the disclosure content stays current as software updates change a device's network footprint. ## Frequently Asked Questions ### What is IEC 80001-1? IEC 80001-1 is an international standard that gives healthcare delivery organizations a risk management framework for IT networks that incorporate medical devices. It defines roles, a responsibility agreement process, and three protected properties: safety, effectiveness, and data and system security. ### Is IEC 80001-1 required for FDA submissions? No. IEC 80001-1 is a hospital-facing network risk management standard, and it is not listed as an FDA-recognized consensus standard for premarket submissions. Manufacturers still benefit from understanding it because it shapes what disclosure content hospitals expect. ### Who is the "responsible organization" under IEC 80001-1? The responsible organization is the healthcare delivery organization operating the medical IT network, typically a hospital or health system. It is accountable for the ongoing risk management process, not the device manufacturer. ### How is IEC 80001-1 different from IEC 81001-5-1? IEC 80001-1 governs hospital network risk management after a device is deployed. IEC 81001-5-1 governs manufacturer security activities during device development. They are complementary but apply to different organizations and different lifecycle stages. ### What is a responsibility agreement under IEC 80001-1? A responsibility agreement is a documented understanding between the healthcare delivery organization and each manufacturer or IT vendor connecting to its network, defining who is responsible for monitoring, maintenance, and incident response for that device or system. ### Does a manufacturer need to be "IEC 80001-1 certified"? No. IEC 80001-1 does not define a manufacturer certification scheme. Manufacturers support the standard by supplying accurate disclosure information and participating in the responsibility agreement, not by holding a conformance certificate themselves. ## CTA If your device documentation cannot answer the network risk questions a hospital's IEC 80001-1 process will ask, that gap will surface during procurement or after an incident, whichever comes first. Blue Goat Cyber helps manufacturers build disclosure content, threat models, and security testing evidence that hold up on both sides of that handoff. [Contact us](/contact) to review your current disclosure package. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## IEC 81001-5-1: Secure Lifecycle Rules | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/iec-81001-5-1-vs-aami-sw96 # IEC 81001-5-1 and the Secure Health Software Lifecycle > **[DIRECT ANSWER]** IEC 81001-5-1 is the international standard for secure development lifecycle processes in health software and software in medical devices. It defines what activities a manufacturer must perform, from security requirements through maintenance, and what evidence each activity must produce. It does not replace AAMI SW96 or AAMI TIR57; it works alongside them, with SW96 handling security risk management and TIR57 remaining an informative reference for methodology. _Reviewed September 17, 2026_ A recurring question in FDA cybersecurity reviews is which standard actually governs the secure development process, and whether newer publications like AAMI SW96 have made older references like TIR57 obsolete. Getting this wrong costs time. Reviewers who see a submission cite the wrong standard, or fail to show traceability between lifecycle process and risk management, commonly issue an Additional Information request, and each cycle can add six to twelve weeks to a clearance timeline. This post lays out exactly what IEC 81001-5-1 covers, how it relates to AAMI SW96 and AAMI TIR57, and what artifacts each one is expected to produce in a premarket submission. ## Key Takeaways - IEC 81001-5-1 defines secure development lifecycle processes and activities for health software, not a risk scoring method. - AAMI SW96 did not replace AAMI TIR57; SW96 is a normative security risk management standard, TIR57 remains an informative technical report. - The FDA recognizes IEC 81001-5-1 and AAMI SW96 (Recognized Consensus Standard 13-131) as acceptable references in premarket submissions. - A complete submission typically cites IEC 81001-5-1 for the SPDF and AAMI SW96 for the security risk file, with traceability between the two. - Citing a standard without producing matching procedures and records is a frequent source of reviewer deficiencies. ## Why This Matters The FDA's February 3, 2026 final guidance, *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions*, expects every cyber device submission to demonstrate a Secure Product Development Framework and a documented security risk management process. IEC 81001-5-1 and AAMI SW96 are the two standards most commonly used to satisfy that expectation, but they answer different questions. IEC 81001-5-1 answers "did you run a secure lifecycle," while SW96 answers "did you identify, evaluate, and control security risk." Manufacturers sometimes assume that because SW96 was published after AAMI TIR57, it supersedes it, or that citing one standard covers both lifecycle and risk needs. Neither assumption holds up under review. TIR57 is still referenced in FDA guidance history and remains useful as a methodology reference; SW96 is the current normative standard for security risk management and is FDA-recognized as Recognized Consensus Standard 13-131. Reviewers look for a coherent picture: a named lifecycle standard, a named risk management standard, and evidence that the two connect. A submission that names IEC 81001-5-1 in its SPDF section but has no risk management standard behind its security risk file, or vice versa, draws predictable questions. Getting the mapping right the first time reduces review cycles and keeps the submission timeline on track. ## What Does IEC 81001-5-1 Actually Cover? IEC 81001-5-1 defines the secure development lifecycle activities that a manufacturer must perform across the life of health software, from initial security requirements through design, implementation, verification, release, and postmarket maintenance. It is a process-and-evidence standard, similar in structure to IEC 62304 for functional safety, but focused on cybersecurity activities instead of safety activities. The standard does not tell a manufacturer how to score a threat or accept residual risk. Instead, it requires that security requirements be defined, that secure design and coding practices be followed, that security testing occur before release, and that a documented process exist for handling vulnerabilities after the device ships. Each of these activities needs traceable evidence, not just a policy statement. > **[KEY REQUIREMENT]** IEC 81001-5-1 requires documented evidence for each lifecycle activity, not a general statement that secure development occurred. Reviewers expect to see records tied to specific releases. ## Does AAMI SW96 Replace AAMI TIR57? No, AAMI SW96 did not replace AAMI TIR57. SW96 is a normative consensus standard for security risk management in medical device software, published in 2023 and structured to mirror ISO 14971. TIR57, published years earlier, is an informative technical information report that offers methodology and worked examples for applying security risk management concepts to medical devices. The two coexist deliberately. SW96 sets the requirements a manufacturer must meet for security risk analysis, evaluation, control selection, and residual risk acceptance. TIR57 can still inform how a team builds out its methodology, threat catalogs, or worked examples, but it is not the document reviewers look to for a normative requirement. Manufacturers building a risk management file for the first time often use TIR57 as a practical reference while conforming to SW96 as the controlling standard. | Question | Answer | |---|---| | Is TIR57 withdrawn? | No, it remains published as an informative reference. | | Is SW96 mandatory? | No, but it is the FDA-recognized standard (13-131) for security risk management. | | Can a program cite both? | Yes, with SW96 as the normative standard and TIR57 as supporting methodology. | | Which one governs residual risk acceptance? | SW96, because it is the normative risk management standard. | ## What Does the FDA Recognize? The FDA maintains a list of recognized consensus standards, and AAMI SW96:2023 appears on it as Recognized Consensus Standard 13-131. IEC 81001-5-1:2021 is referenced in the FDA's February 3, 2026 premarket cybersecurity guidance as an acceptable standard for demonstrating secure development lifecycle processes. Neither standard is mandated by statute; Section 524B of the FD&C Act requires reasonable assurance of cybersecurity without naming a specific standard. In practice, reviewers expect a submission to show at least one recognized standard covering lifecycle process and one covering security risk management, with clear traceability between the two. Citing a recognized standard in a declaration of conformity is useful, but reviewers still expect matching procedures and work products behind the citation. > **[KEY REQUIREMENT]** A declaration of conformity to a recognized standard should be backed by the actual procedures, records, and traceability matrices the reviewer would need to verify the claim. ## Standards Comparison: Lifecycle, Risk, and Safety Manufacturers frequently confuse which standard covers which concern. The table below separates scope, applicability, and expected output for the five standards most relevant to a medical device cybersecurity submission. | Standard | Scope | Applies To | Primary Artifact | |---|---|---|---| | IEC 81001-5-1:2021 | Secure development lifecycle processes | Health software and software in medical devices | Lifecycle process records and evidence | | AAMI SW96:2023 | Security risk management for medical device software | Device manufacturers | Security risk management file | | AAMI TIR57 | Informative methodology for security risk management | Device manufacturers seeking methodology guidance | Reference examples, not a normative file | | ISO 14971 | Safety risk management | Medical device manufacturers | Safety risk management file | | IEC 62304 | Software lifecycle for safety | Medical device software developers | Software lifecycle records for functional safety | Reading the table left to right, the pattern is clear: IEC 81001-5-1 and IEC 62304 both govern lifecycle process, one for security and one for safety, while AAMI SW96 and ISO 14971 both govern risk management, one for security and one for safety. TIR57 sits alongside SW96 as a non-normative aid rather than a parallel requirement. ## Which Evidence Does Each Standard Produce? Each standard produces a distinct artifact that a reviewer will look for by name. IEC 81001-5-1 produces lifecycle process evidence: security requirements traceability, secure design records, security test results, and a documented vulnerability handling process. AAMI SW96 produces the security risk management file itself: identified threats, likelihood and impact analysis, selected controls, and residual risk acceptance decisions. A submission that cites IEC 81001-5-1 without a security risk management file behind it will draw questions about how residual security risk was evaluated and accepted. A submission that cites SW96 without lifecycle process evidence will draw questions about where the secure design and testing records live. The strongest submissions show explicit traceability from lifecycle activities (81001-5-1) into risk analysis inputs (SW96), and from risk controls back into implementation evidence. > **[KEY REQUIREMENT]** Traceability between the SPDF and the security risk management file, not just parallel citations, is what reviewers verify during a cybersecurity content review. ## Where Do These Standards Fit in a Submission? IEC 81001-5-1 is typically cited in the SPDF or quality system section of a submission, with supporting evidence distributed across design history file records. AAMI SW96 is typically cited in the security risk management section, anchoring the security risk file alongside the safety risk file built under ISO 14971. Placing these citations in the wrong section, or failing to cross-reference them, is a common source of confusion for reviewers working through a submission. Manufacturers building a Secure Product Development Framework for the first time should map each 81001-5-1 lifecycle activity to the corresponding SW96 risk management step early, rather than retrofitting traceability after the fact. This mapping becomes the backbone of the response strategy if the FDA issues an Additional Information request touching either standard. ## How Blue Goat Cyber Approaches This We help manufacturers build a Secure Product Development Framework that maps cleanly to IEC 81001-5-1 for lifecycle conformance and a security risk management file that conforms to AAMI SW96, with traceability into threat models, SBOM and VEX documentation, and verification testing evidence. Rather than treating these standards as boxes to check in a cover letter, we build the underlying procedures and records that reviewers actually verify. If your submission needs a defensible mapping between lifecycle process and risk management, our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) team can help structure both from the start of your development program. ## Frequently Asked Questions ### Is IEC 81001-5-1 mandatory for the FDA submissions? No. The FDA does not mandate a specific consensus standard for cybersecurity. Section 524B requires reasonable assurance of cybersecurity, and IEC 81001-5-1 is one of the most efficient ways to demonstrate lifecycle process conformance. The February 3, 2026 premarket guidance recognizes it as an acceptable reference. ### Is AAMI SW96 mandatory? No, it is not mandatory either. It is FDA-recognized as Consensus Standard 13-131 and is currently the clearest normative path to a security risk management file that mirrors the structure of ISO 14971. ### Did AAMI SW96 make AAMI TIR57 obsolete? No. SW96 is the normative security risk management standard, while TIR57 remains an informative technical report offering methodology and examples. Many programs still use TIR57 as a practical reference while conforming to SW96 as the controlling standard. ### Can a manufacturer use only one of these standards? Yes, but it usually leaves a gap. Using only IEC 81001-5-1 leaves the question of how residual security risk is scored and accepted; using only AAMI SW96 leaves the question of where the lifecycle process evidence lives. Most submissions are stronger citing both with explicit traceability. ### How does IEC 81001-5-1 relate to IEC 62304? IEC 62304 governs the software lifecycle for functional safety, while IEC 81001-5-1 governs the secure development lifecycle for cybersecurity. The two standards are designed to coexist and are commonly invoked together within a single quality system. ## CTA If your team needs a defensible mapping between IEC 81001-5-1, AAMI SW96, and your quality system before your next submission, our premarket cybersecurity team can help you build the procedures and traceability reviewers expect. [Schedule a discovery call](/contact) to review your current SPDF and security risk management approach. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian focuses on medical device cybersecurity for FDA premarket submissions and postmarket compliance, helping manufacturers build defensible lifecycle and risk management programs. [Read more about Christian](/christian-espinosa). --- ## IEC 81001-5-1 vs IEC 62304 for Medical Devices Source: https://bluegoatcyber.com/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards # IEC 81001-5-1 vs IEC 62304: Software Lifecycle and Security Activities, Compared > **[DIRECT ANSWER]** IEC 62304 governs the safety-focused software lifecycle, including safety classification, requirements, architecture, verification, and maintenance, while IEC 81001-5-1 layers security activities on top of that same lifecycle, adding threat modeling, secure coding verification, security release criteria, and postmarket vulnerability handling. Neither standard replaces the other. The FDA and EU both expect manufacturers to run them together, with a shared ISO 14971 risk file and a single problem-resolution process covering both safety and security issues. The two standards get confused because they use overlapping vocabulary (lifecycle, activities, verification, maintenance) and because a healthy chunk of IEC 81001-5-1 is written to slot directly onto IEC 62304's structure. Companies that already run IEC 62304 sometimes assume it covers security. It does not. Companies adopting IEC 81001-5-1 sometimes assume it replaces IEC 62304. It does not do that either. This post lays the two standards side by side so the division of labor is unambiguous. ## Key Takeaways - IEC 62304 governs the safety-focused software lifecycle; IEC 81001-5-1 governs the security-focused lifecycle that runs alongside it. - IEC 81001-5-1 was written to plug into IEC 62304 structurally, not to replace it. - The FDA accepts either as inputs to a submission; the EU expects both under the MDR and IVDR. - IEC 62304 alone does not satisfy 524B or the 2026 FDA final guidance's security expectations. - IEC 81001-5-1 alone does not satisfy IEC 62304's software safety obligations. - The pairing is what most notified bodies and 510(k) reviewers actually want to see. ## Why This Matters Getting the boundary wrong costs real money. Teams that treat IEC 62304 as sufficient for cybersecurity end up rebuilding threat models, vulnerability handling, and postmarket security plans the first time an FDA deficiency letter or an EU notified-body finding lands. Teams that adopt IEC 81001-5-1 without a working IEC 62304 program end up with security artifacts floating above a software lifecycle they cannot audit. The 2026 FDA final premarket cybersecurity guidance names IEC 81001-5-1 explicitly as an acceptable secure-development framework, and the EU MDR and IVDR treat both standards as harmonized expectations. Neither regulator is asking you to pick between them.[^fda2026] They expect both, in the roles each was designed for. ## What IEC 62304 covers IEC 62304:2006+A1:2015, *Medical device software, Software life cycle processes*, is the international standard for the safety-focused software lifecycle. It applies to any software that is itself a medical device or is embedded in one. IEC 62304 defines:[^iec62304] - **Software safety classification** (Class A, B, C) based on the potential harm from failure. - **Software development planning** and the software development plan artifact. - **Software requirements analysis** with traceability to system requirements. - **Software architectural design**, including the identification of SOUP (software of unknown provenance). - **Software detailed design, implementation, and unit verification** (obligations scale with safety class). - **Software integration, integration testing, and system testing.** - **Software release**, including known-anomalies documentation and archived configuration. - **Software maintenance process**, including change control and problem resolution. - **Software risk management process**, integrated with ISO 14971. - **Software configuration management** and **software problem resolution.** IEC 62304 mentions security only in passing. It is not a security standard. It is a software safety and quality standard. ## What IEC 81001-5-1 covers IEC 81001-5-1:2021, *Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product life cycle*, is the international standard for security activities in the health-software lifecycle. It was authored specifically to slot on top of IEC 62304 and to align with ISA/IEC 62443-4-1 on secure-development practice. IEC 81001-5-1 defines:[^iec81001] - **Secure development process establishment**, including roles, training, and process definition. - **Security requirements**, including secure-by-design and secure-by-default expectations. - **Threat modeling** as a required activity, with harm-oriented outputs feeding risk management. - **Secure implementation practices**, including coding standards and static analysis. - **Security verification and validation**, including penetration testing where warranted. - **Third-party component management**, including SBOM-adjacent obligations for known vulnerabilities. - **Security release criteria**, including residual-risk acceptance. - **Postmarket vulnerability management**, including coordinated vulnerability disclosure (CVD) and patching. - **Security incident response** and communication with health-delivery organizations. - **Security maintenance** across the supported lifespan of the device. IEC 81001-5-1 says almost nothing about software safety classification, unit verification, or SOUP. That is IEC 62304's job. ## Side-by-side coverage map | Activity area | IEC 62304 | IEC 81001-5-1 | | --- | --- | --- | | Software safety classification (Class A/B/C) | **Owns** | Not covered | | Software development planning | **Owns** | Adds security plan alongside | | Software requirements | **Owns** (functional / safety) | Adds security requirements | | Architectural design | **Owns** | Adds threat modeling on the same architecture | | Implementation and unit verification | **Owns** | Adds secure-coding and static analysis | | Integration and system testing | **Owns** | Adds security verification / pen testing | | SOUP identification and evaluation | **Owns** | Extends into SBOM-style component monitoring | | Release | **Owns** (safety readiness) | Adds security release criteria | | Software risk management | **Owns**, integrated with ISO 14971 | Adds security risk to the same risk file | | Change and configuration management | **Owns** | Adds security-impact review of changes | | Problem resolution | **Owns** (safety anomalies) | Adds vulnerability handling and CVD | | Postmarket maintenance | **Owns** (safety patches) | Adds security patching and incident response | | Threat modeling | Not covered | **Owns** | | Coordinated vulnerability disclosure | Not covered | **Owns** | | Postmarket security monitoring | Not covered | **Owns** | The pattern is consistent: IEC 62304 owns the software lifecycle and safety mechanics; IEC 81001-5-1 layers security expectations onto every phase where security materially matters, and adds the security-only activities (threat modeling, CVD, postmarket vulnerability response) that IEC 62304 was never intended to cover. > **Aligning IEC 62304 and 81001-5-1 evidence?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## Where the two standards overlap The overlap is deliberate and useful, not redundant. - **Risk management.** IEC 62304 requires software risk management integrated with ISO 14971. IEC 81001-5-1 requires security risk to be integrated into the same risk file, so a single ISO 14971-shaped record covers safety and security together. AAMI TIR57 and, more recently, AAMI SW96 formalize this integration. - **Requirements traceability.** Both standards demand that requirements trace to design, verification, and release evidence. IEC 81001-5-1 assumes the traceability spine that IEC 62304 already sets up. - **Configuration and change management.** IEC 62304 requires it for the software baseline; IEC 81001-5-1 requires a security-impact assessment on every change to that baseline. - **Problem resolution.** IEC 62304's problem resolution process is the vehicle IEC 81001-5-1 uses to route vulnerability reports and CVD findings. The overlap is where the two standards are most efficient. Every artifact IEC 81001-5-1 needs already has a home in the IEC 62304 process, if the team is already running one. [Talk to a MedTech cybersecurity expert about IEC 81001-5-1 adoption](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## How the pair maps to the FDA and EU expectations **For the FDA (2026 final premarket guidance):**[^fda2026] - IEC 62304 satisfies the software-lifecycle expectations that show up in the software documentation section of a 510(k), De Novo, or PMA submission. - IEC 81001-5-1 satisfies the secure-development framework requirement (one of the four the FDA lists), plus the threat model, SBOM handling, security testing, and postmarket cybersecurity management plan requirements. - Together the pair covers the software half of a submission cleanly. The remaining artifacts (labeling, interoperability considerations, cybersecurity management plan) sit on top of that pair. **For the EU (MDR and IVDR):** - IEC 62304 is a harmonized standard for medical-device software lifecycle. Notified bodies expect it. - IEC 81001-5-1 is the security lifecycle standard notified bodies point to when reviewing MDR Annex I Section 17 (electronic programmable systems) and IVDR equivalents. - The pairing is the least-friction path through most European notified-body reviews. **For a submission with dual scope:** IEC 62304 + IEC 81001-5-1 is the standard combination the industry has settled on. See our [JSP2 vs SPDF vs IEC 81001-5-1 framework choice](/blog/jsp2-vs-spdf-vs-iec-81001-medical-device-framework-choice) post for how this pair compares against the alternatives. ## How to adopt them together without duplicating work Three rules keep the adoption clean: 1. **Extend, do not duplicate.** Every IEC 81001-5-1 activity should attach to an existing IEC 62304 process step, not create a parallel one. Add a security-requirements section to the same requirements document; add a threat-modeling step to the same architecture review; add security release criteria to the same release checklist. 2. **Merge the risk file.** Do not maintain a separate safety risk file and security risk file. Use ISO 14971 as the container and follow AAMI SW96 or AAMI TIR57 for the integration pattern. A single risk file also survives audits better because reviewers can trace one thread instead of two. 3. **Reuse the SDLC's problem-resolution process for CVD.** IEC 62304 already requires a documented problem-resolution process. Route vulnerability disclosures through it, with a security-impact tag on the ticket, rather than standing up a parallel security ticketing system. ## How Blue Goat Cyber Approaches This Blue Goat Cyber's IEC 81001-5-1 adoption engagement starts with an audit of the client's existing IEC 62304 processes. The output is a delta plan: exactly which IEC 62304 documents need security additions, which activities need to be inserted, and which artifacts need to be produced for the first time. For teams running IEC 62304 well, the delta is usually shorter than expected. For teams that are not, we scope IEC 62304 remediation into the same engagement so the security layer has something to attach to. Christian Espinosa, our founder, has led IEC 81001-5-1 adoption on more than 40 devices, spanning US 510(k), De Novo, and EU MDR submissions. Every engagement carries the same commitment: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Frequently Asked Questions ### Does IEC 81001-5-1 replace IEC 62304? No. IEC 81001-5-1 was designed to sit on top of IEC 62304, not replace it. The two standards cover different scopes: IEC 62304 is the software lifecycle, IEC 81001-5-1 is the security lifecycle. Teams need both. ### Is IEC 62304 enough for the FDA's cybersecurity expectations? No. IEC 62304 barely mentions security. The 2026 FDA final premarket cybersecurity guidance requires a secure-development framework (SPDF, JSP2, IEC 81001-5-1, or ISA/IEC 62443-4-1), a threat model, an SBOM with VEX, and a postmarket cybersecurity management plan. None of those come from IEC 62304. ### If I run IEC 81001-5-1, do I still need SPDF? No, they are alternatives. The FDA lists SPDF, JSP2, IEC 81001-5-1, and ISA/IEC 62443-4-1 as four acceptable frameworks; you pick one as the spine. See the [framework choice post](/blog/jsp2-vs-spdf-vs-iec-81001-medical-device-framework-choice) for how to choose. ### What about IEC 82304-1? IEC 82304-1 is the health-software product-level safety standard. It sits above IEC 62304 (which covers the lifecycle) and is complementary to both IEC 62304 and IEC 81001-5-1. Standalone health software (some SaMD) needs 82304-1 as well. ### How does AAMI SW96 relate to this pair? AAMI SW96:2023 is the security risk management standard. It formalizes the integration of security risk into ISO 14971 that IEC 81001-5-1 assumes. Most teams adopting IEC 81001-5-1 also implement SW96 to keep the risk file coherent. ### Are IEC 62304 and IEC 81001-5-1 harmonized in the EU? IEC 62304 is a harmonized standard under the MDR. IEC 81001-5-1 is widely treated by notified bodies as the expected security lifecycle standard even though harmonization status has evolved. The safe operating assumption is that both are expected for MDR and IVDR software submissions. ## CTA Adopt the pair once, correctly. Blue Goat Cyber runs a four-week IEC 81001-5-1 on-boarding engagement that plugs into an existing IEC 62304 QMS, produces a delta document set, and readies the security artifacts an FDA or notified-body reviewer expects. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, CCISO, ex-military red team. Has led IEC 81001-5-1 and IEC 62304 alignment on 40+ FDA- and EU-cleared devices. [More on the author](/team/christian-espinosa)._ ## References [^fda2026]: U.S. Food and Drug Administration. *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, Guidance for Industry and Food and Drug Administration Staff.* Final guidance, issued February 3, 2026. [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) [^iec62304]: International Electrotechnical Commission. *IEC 62304:2006+AMD1:2015 CSV, Medical device software, Software life cycle processes.* Consolidated version, 2015. [https://webstore.iec.ch/publication/22794](https://webstore.iec.ch/publication/22794) [^iec81001]: International Electrotechnical Commission. *IEC 81001-5-1:2021, Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product life cycle.* Published December 2021. [https://webstore.iec.ch/publication/64703](https://webstore.iec.ch/publication/64703) --- ## IMDRF Cybersecurity Guidance Explained Source: https://bluegoatcyber.com/blog/imdrf-for-medical-devices-harmonizing-global-regulations # IMDRF Cybersecurity Guidance: What It Means for Your Submissions > **[DIRECT ANSWER]** IMDRF is not a regulator and issues no binding requirements, but its cybersecurity documents (N60 for general principles, N70 for legacy devices, and N73 for SBOM) are the common source that the FDA, the TGA, and Health Canada each drew from. That convergence is why one well-built cybersecurity package travels across markets, and why the differences that remain are almost always in classification rationale, labeling, and postmarket reporting rather than in the technical evidence. The [International Medical Device Regulators Forum (IMDRF)](https://www.imdrf.org/) is a voluntary group of medical device regulators that publishes consensus documents its members then adopt in their own frameworks. For cybersecurity, that matters more than it sounds: the six-content-area structure you see in the FDA's February 3, 2026 final premarket cybersecurity guidance, in the TGA's cyber security guidance for industry, and in Health Canada's pre-market cybersecurity guidance is recognizably the same structure, because all three trace back to IMDRF work. This post explains which IMDRF documents actually govern cybersecurity content, how each regulator implements them, and how to build a submission package designed from the start to be reused. ## Key Takeaways - IMDRF publishes consensus documents, not law. Obligation comes from whichever regulator adopts them. - Three documents carry the cybersecurity content: **N60** (principles and practices), **N70** (legacy devices), and **N73** (SBOM principles and practices). - The FDA, the TGA, and Health Canada all structure premarket cybersecurity expectations around the same content areas: risk management, secure design, verification, SBOM, labeling, and a postmarket plan. - IMDRF also produced the risk-based classification model that Health Canada and the TGA use, which is why FDA class does not map one-to-one to either. - What does not harmonize: classification rationale, labeling language and format, conformity assessment or licence route, and incident reporting timelines. - Build the package once against the IMDRF content areas, then write a thin per-jurisdiction mapping layer instead of rewriting the technical evidence. ## Why this matters Manufacturers rarely stop at one market. A device cleared in the US typically follows with Health Canada, the TGA, and the EU within eighteen months. If the cybersecurity evidence was written as an FDA artifact rather than as a device artifact, each of those follow-on submissions turns into a rewrite, and every rewrite is a chance for the versions to drift apart. When a reviewer in one jurisdiction reads a threat model that contradicts the SBOM filed in another, the question that comes back is not a formatting question. The opposite is also true and is the reason IMDRF is worth understanding. Because the underlying content areas converge, a package built to the IMDRF structure can serve four markets with a mapping document per market rather than four separate evidence sets. The work is in knowing exactly where the convergence stops. ## What IMDRF Is, and What It Is Not IMDRF was established in 2011 as the successor to the Global Harmonization Task Force. Its members are regulators: the US FDA, Health Canada, the European Commission, Japan's MHLW and PMDA, Australia's TGA, Brazil's ANVISA, China's NMPA, South Korea's MFDS, Singapore's HSA, the UK's MHRA, and others, with affiliate and observer bodies including the WHO. Two properties define what IMDRF documents can do for you: - **They are non-binding.** No manufacturer is ever inspected against IMDRF N60. You are inspected against the regulation that adopted its content. - **They are the shared vocabulary.** When the TGA guidance and the Health Canada guidance both expect "a plan for managing postmarket cybersecurity risks," that phrasing is not a coincidence. The practical consequence: cite IMDRF in your rationale to explain why your structure looks the way it does, but never cite it in place of the jurisdiction's own requirement. A submission that argues "this satisfies IMDRF N60" without mapping to the local regulation is the fastest way to an information request. ## The IMDRF Cybersecurity Documents That Matter | Document | Subject | What it gives you | | --- | --- | --- | | **IMDRF/CYBER WG/N60** | Principles and Practices for Medical Device Cybersecurity | The core premarket and postmarket content model: risk management, secure design, verification, labeling and transparency, information sharing, and coordinated vulnerability disclosure | | **IMDRF/CYBER WG/N70** | Principles and Practices for the Cybersecurity of Legacy Medical Devices | A lifecycle-stage model (support, limited support, end of support) and shared-responsibility framing between manufacturer and healthcare provider | | **IMDRF/CYBER WG/N73** | Principles and Practices for Software Bill of Materials for Medical Device Cybersecurity | SBOM minimum elements, generation and maintenance expectations, and the manufacturer-to-operator distribution model | | **IMDRF/GRRP WG/N47** | Essential Principles of Safety and Performance | The framing the TGA's Essential Principles and the EU's GSPRs both descend from | | **GHTF/SG1/N77 (inherited)** | Risk-based classification principles | The four-class risk model Health Canada and the TGA classification rules are built on | N60 is the one to read first. If you can trace every artifact in your package to an N60 principle, you will find that the FDA, TGA, and Health Canada content areas are each a re-cut of the same material. ## How Each Regulator Implements IMDRF Cybersecurity Content | Regulator | Instrument | How the IMDRF content lands | | --- | --- | --- | | **FDA (US)** | Section 524B of the FD&C Act plus the Feb 3, 2026 final premarket guidance | The most prescriptive implementation. Content is filed in dedicated eSTAR cybersecurity attachment slots, with an explicit statutory hook for cyber devices | | **Health Canada** | Medical Devices Regulations (SOR/98-282) plus the pre-market cybersecurity guidance | Six content areas inside a Class II to IV licence application, with MDSAP mandatory and Section 59 problem reporting on the postmarket side | | **TGA (Australia)** | Essential Principles 12 and 12A plus the cyber security guidance for industry | No dedicated submission section. Evidence is mapped to the Essential Principles and read according to the conformity assessment route | | **EU** | MDR Annex I GSPR 17 and MDCG 2019-16 | Distributed across Annex II technical documentation and referenced from the risk management file, with notified bodies leaning on EN IEC 81001-5-1:2022 | | **PMDA (Japan), ANVISA (Brazil), HSA (Singapore)** | National guidance referencing IMDRF | Varying depth, generally accepting IMDRF-structured evidence with local labeling and reporting overlays | The pattern is consistent. The technical content converges; the container, the classification logic, and the postmarket reporting obligations do not. ## What Harmonizes and What Does Not **Harmonizes well, reuse directly:** - Security risk assessment and threat model, when built to ISO 14971 with AAMI TIR57 / ANSI/AAMI SW96:2023 security risk methodology - Security architecture views and secure design rationale - SBOM content, when generated to the N73 minimum elements in CycloneDX or SPDX - Verification and penetration testing evidence - Software lifecycle process evidence under IEC 81001-5-1 and IEC 62304 **Does not harmonize, rewrite per market:** - **Classification rationale.** FDA Class II is not Health Canada Class II and is not TGA Class IIa. Each application needs its own class argument under its own rules. - **Labeling.** Content, format, and language obligations differ. Canada has bilingual requirements; Australia has its own instructions-for-use expectations; the FDA expects specific cybersecurity labeling elements. - **Route and certification.** MDSAP is mandatory in Canada, optional elsewhere. The TGA runs a comparable overseas regulator framework. The EU runs notified bodies. None of these substitute for each other. - **Incident reporting.** 21 CFR Part 803 in the US, Section 59 in Canada, URPTG and TGA reporting in Australia, MDR vigilance in the EU. Timelines and thresholds differ. - **Statutory hooks.** Section 524B has no equivalent elsewhere. Do not write a package that assumes it does. ## Building One Package That Travels Work through these steps in order: 1. **Write the evidence to the IMDRF N60 content model, not to a submission template.** Threat model, security risk assessment, architecture views, SBOM, verification results, labeling content, postmarket plan. 2. **Generate the SBOM to the N73 minimum elements** in a machine-readable format, with a documented regeneration trigger tied to each release. 3. **Keep one master risk file.** Every jurisdiction traces to the same ISO 14971 file. Divergent risk files are how contradictions reach reviewers. 4. **Write a per-market mapping document.** A short table from your artifact names to that regulator's content areas. This is the deliverable most manufacturers skip and most reviewers ask for. 5. **Write the classification rationale fresh per market.** Never carry the FDA class argument into a Canadian or Australian application. 6. **Fork only the postmarket plan.** Keep one plan with a jurisdiction annex covering reporting thresholds, timelines, and the named responsible party for each market. 7. **Version everything together.** When the threat model changes, every downstream market file gets a change record, even if the change is "no impact." > **[KEY REQUIREMENT]** The mapping document is not optional paperwork. In every one of these jurisdictions, the sponsor or manufacturer carries the burden of showing how the evidence satisfies that jurisdiction's requirements. Evidence without a mapping is evidence a reviewer has to interpret, and interpretation is where information requests come from. ## Legacy Devices and the N70 Problem N70 is the document manufacturers discover late. It defines lifecycle stages for a device already in the field: supported, limited support, and end of support, with an expectation that the manufacturer communicates transitions and shares responsibility for residual risk with the operating healthcare organization. This matters because the fleet is the exposure. A device cleared before cybersecurity expectations tightened is still deployed, still connected, and still yours until you formally define its support status. N70 gives you the structure to say so: publish the end-of-support date, state what security maintenance continues and what stops, and document the compensating controls a hospital is expected to apply. Regulators increasingly expect that communication to exist, and hospital procurement teams read it during renewal decisions. The practical move is to treat the support-status statement as a controlled document alongside the [postmarket cybersecurity plan](/guides/postmarket-cybersecurity-readiness-plan) rather than as marketing communication. ## How Blue Goat Approaches Multi-Market Cybersecurity Packages We build the evidence set once, to the IMDRF content model, and then write the per-market mapping layer. The threat model, SBOM, architecture views, and verification evidence stay singular and version-controlled; the classification rationale, labeling, and postmarket annexes are written per jurisdiction. Our team holds CISSP, OSCP, and prior military red-team credentials, and the work is grounded in IEC 81001-5-1, AAMI TIR57 / ANSI/AAMI SW96:2023, ISO 14971, and the FDA February 3, 2026 final premarket guidance. See our [medical device cybersecurity services](/services), or compare specific regimes in the [TGA guide](/blog/tga-australia-medical-device-cybersecurity), the [Health Canada guide](/blog/health-canada-medical-device-cybersecurity), and the [EU MDR vs FDA comparison](/guides/eu-mdr-vs-fda-cybersecurity). **If a regulator raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### Is IMDRF guidance mandatory? No. IMDRF is a forum of regulators, not a regulator. Its documents are non-binding consensus guidance. They become enforceable only through the national regulation or guidance that adopts them, such as the FDA's Feb 3, 2026 guidance, Health Canada's pre-market cybersecurity guidance, or the TGA's cyber security guidance for industry. ### Which IMDRF document covers medical device cybersecurity? Three do. N60 covers general principles and practices for medical device cybersecurity across the total product lifecycle, N70 covers legacy devices and end-of-support, and N73 covers SBOM principles and practices. N60 is the one that shaped the premarket content areas used by the FDA, the TGA, and Health Canada. ### Can we submit the same cybersecurity package to the FDA, Health Canada, and the TGA? The technical evidence is largely reusable: threat model, security risk assessment, architecture views, SBOM, and verification results. What must be written per market is the classification rationale, the labeling, the postmarket plan against local reporting rules, and a mapping document showing how the evidence satisfies that jurisdiction's content areas. ### Does IMDRF define device classification? IMDRF inherited and maintains a risk-based classification model that several members implement directly. Health Canada's four-class system and the TGA's classification rules both derive from it, which is why neither maps cleanly onto the FDA's three-class system under 21 CFR Part 860. ### What is IMDRF N73 and how does it differ from FDA SBOM expectations? N73 sets out SBOM minimum elements, generation and maintenance practices, and how manufacturers should distribute SBOMs to operators. The FDA's expectations under Section 524B are compatible but more prescriptive about submission format and about pairing the SBOM with vulnerability assessment and VEX content. An SBOM built to N73 will generally satisfy the FDA with additional support-level and end-of-support fields. ### How does MDSAP relate to IMDRF? MDSAP grew out of IMDRF work on a single audit model and is now run by participating regulators including the FDA, Health Canada, the TGA, ANVISA, and Japan's MHLW and PMDA. It audits the quality management system, so it covers the processes behind your security lifecycle, not the device-specific cybersecurity evidence in any given submission. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). ## Related reading - [MDSAP for Medical Devices](/blog/mdsap-for-medical-devices-simplifying-international-compliance) - [TGA Medical Device Cybersecurity](/blog/tga-australia-medical-device-cybersecurity) - [Health Canada Medical Device Cybersecurity](/blog/health-canada-medical-device-cybersecurity) --- ## Implantable Device Cybersecurity: Risks, Controls, Evidence Source: https://bluegoatcyber.com/blog/implantable-device-cybersecurity-concerns # Implantable Device Cybersecurity Risks and Required Controls > **[DIRECT ANSWER]** Implantable device cybersecurity differs from other device security in three ways that change every design decision. The device cannot be taken offline for patching, the power budget limits what cryptography is affordable, and a successful attack produces physiological harm rather than data loss. Controls must therefore be designed in at the hardware level, verified before the design freezes, and paired with a realistic plan for updating devices already inside patients. _Reviewed September 17, 2026_ An implanted pacemaker cannot be rebooted at a convenient hour. That single fact drives most of what separates implantable security from everything else in medical device cybersecurity. Every control you might rely on later, from key rotation to firmware updates, has to survive a device that is powered by a battery meant to last a decade and is physically inaccessible for its entire service life. Manufacturers of pacemakers, defibrillators, neurostimulators, insulin pumps, and cochlear implants face a design problem in which security, battery life, and clinical availability all pull against each other. Getting the tradeoffs right on paper, and documenting why they are acceptable, is what a submission has to demonstrate. ## Key Takeaways - Implantables cannot be patched on a normal schedule, so the design must survive without frequent updates. - Power constraints make cryptographic choices a hardware decision, not a firmware one. - The programmer and home monitor are part of the attack surface, often the easier part. - Harm is physiological, which changes the ISO 14971 severity ratings and the controls they justify. - Emergency access must work without becoming an authentication bypass. - Devices already implanted need a documented plan, not a statement that the next generation is better. ## Why the Stakes Are Different Here The FDA has treated implantable security as a distinct problem for years, and the record explains why. In 2017, Abbott recalled roughly 465,000 implantable pacemakers for a firmware update addressing cybersecurity vulnerabilities, with the update applied during a patient visit rather than remotely. In 2019 the FDA issued a safety communication about the Medtronic Conexus telemetry protocol, which lacked encryption and authentication, affecting implantable cardiac devices and their home monitors. In both cases the vulnerability reached patients because it was baked into deployed hardware. That is the lesson the February 3, 2026 premarket cybersecurity guidance reflects when it asks manufacturers to document the ability to deploy updates and patches. For an implantable, that documentation cannot be a generic statement about over-the-air updates. It has to explain what is updatable, what is not, how an update reaches the device, and what happens if the update fails partway through in a patient who depends on the device for cardiac output. Section 524B applies here in full. An implantable with wireless telemetry and software is a cyber device, and the statutory requirements for a vulnerability management plan, timely updates, and an SBOM do not bend because the hardware is difficult to reach. ## The Constraints That Shape Every Control Three constraints dominate, and they interact. | Constraint | Practical effect | Design response | |---|---|---| | No patch window | A flaw may live for the device's service life | Minimize attack surface; prefer hardware-enforced controls | | Power budget | Crypto operations cost measurable battery life | Choose hardware-accelerated algorithms at chip selection | | Physical inaccessibility | No console, no field service access | Strong boot-time integrity, no debug interfaces left live | | Clinical availability | Security must never block emergency care | Designed emergency path, not a disabled control | | Long service life | Algorithms age while the device stays implanted | Cryptographic agility where the trust anchor allows it | Power is the constraint people underestimate. An authenticated session that seems trivially cheap on a benchtop can become significant when it runs on every telemetry interaction across ten years. This is why cryptographic decisions belong in the silicon selection conversation. Once the chip is chosen, your options narrow to what it can do efficiently, and a firmware change cannot add a hardware accelerator that is not there. **[KEY REQUIREMENT]** Document the security decisions you made at chip selection and why, including what you could not afford to do. A reviewer is more persuaded by a justified constraint than by a claim of complete protection. ## The Attack Surface Is Bigger Than the Implant The implanted device is rarely the easiest target. The ecosystem around it usually is. | Component | Why an attacker cares | Common weakness | |---|---|---| | Implant telemetry radio | Direct command path to therapy | Unauthenticated or unencrypted proprietary protocol | | Clinician programmer | Highest privilege interface to the device | Physical theft, stale software, credential reuse | | Home monitor or bedside unit | Always on, networked, in an uncontrolled environment | Default credentials, unverified firmware, cloud link | | Patient smartphone app | Pairing and data display | Insecure pairing, token storage on the handset | | Cloud back end | Aggregated patient data across the fleet | Weak tenant isolation, over-broad API scopes | The Conexus case is the clearest example of why this matters: the exposure lived in the telemetry protocol shared between the implant and its monitor, not in a mistake unique to the implanted hardware. When you build your threat model, the boundary should enclose the full therapy chain, and each link should state what it authenticates and what it trusts. ## How Harm Modeling Changes for Implantables Under ISO 14971, severity is rated by the harm that reaches the patient. For most connected devices, the worst realistic outcome of a compromise is a data breach, a denial of service, or an incorrect reading. For an implantable, the plausible outcomes include inappropriate therapy delivery, therapy inhibition, and premature battery depletion, each of which is a direct physiological event. This changes the calculus twice. First, it raises severity ratings, which means controls that would look disproportionate elsewhere are justified here. Second, it means the cybersecurity threat model and the safety risk file cannot be separate documents that never reference each other. A reviewer expects to trace a telemetry threat through to the hazardous situation it creates and the harm it can cause, and to see the same control appear in both places. Battery depletion deserves special mention because it is easy to miss. An attacker who cannot alter therapy may still be able to force repeated wake-ups or authentication attempts, converting a communications flaw into an early explant surgery. Rate limiting is a patient safety control in this context, not a nuisance protection. ## Emergency Access Without a Backdoor Every implantable design eventually confronts the same question: how does a clinician who has never seen this patient before interact with the device during an emergency? The historical answer, an unauthenticated magnet-activated or proximity-based mode, is precisely the design that security research has targeted. Workable approaches share a pattern. Emergency access is constrained in what it can do, bounded in how long it lasts, requires close physical proximity, and leaves an audit record. It is not the same interface as full programming access and it does not grant the same capability. The important part for a submission is that this is a designed behavior with a documented rationale, not an unexamined legacy of the previous product generation. | Approach | Strength | What must be documented | |---|---|---| | Proximity-limited session | Attacker must be physically at the patient | Range verification, not just protocol assumption | | Limited-capability emergency mode | Cannot change therapy parameters arbitrarily | Exact command set permitted | | Time-bounded session | Exposure window is short | Timeout enforcement and re-authentication | | Logged and disclosed | Misuse is detectable | Where the log lives and how it is read | ## What to Do About Devices Already Implanted A submission for a new generation does not resolve the risk in the installed base, and the FDA's postmarket expectations do not stop at products still in production. The realistic options are narrow and should be evaluated honestly. Firmware updates delivered during a clinic visit are the most common path, and they work when the update mechanism was designed with a verified, interruptible, fail-safe process. Where an update is not possible, the remaining options are compensating controls in the ecosystem, such as hardening or replacing the home monitor, restricting programmer distribution, and issuing clear clinical guidance. Where neither is possible, the honest answer is a documented residual risk with a monitoring plan, communicated through coordinated disclosure. What does not work is treating the installed base as out of scope. The Abbott and Medtronic actions both show the regulatory path when a fielded implantable carries a vulnerability, and both required a plan that reached patients already carrying the device. ## How Blue Goat Cyber Approaches This We test implantable ecosystems as a chain rather than a single device: the telemetry protocol, the programmer, the home monitor, the app, and the cloud services behind them. Radio analysis, firmware and hardware interface review, and protocol testing produce findings that map to patient harm rather than to a generic severity score, which is what the risk file needs. For manufacturers preparing a submission, our [medical device penetration testing](/services/medical-device-penetration-testing) covers the wireless and hardware layers that a software-only assessment misses, and our [threat modeling](/services/threat-modeling) work ties each threat to the hazardous situation and harm it produces. ## Frequently Asked Questions ### Can implantable medical devices actually be hacked? Documented vulnerabilities exist, and regulators have acted on them. The FDA issued a safety communication in 2019 regarding the Medtronic Conexus telemetry protocol, which lacked encryption and authentication, and Abbott conducted a firmware update in 2017 for implantable pacemakers to address cybersecurity vulnerabilities. Neither event involved reported patient harm, but both required clinical action, which is why regulators treat the risk as real rather than theoretical. ### Why can't implantables just be patched over the air like phones? Power, reliability, and safety. An interrupted update in a device a patient depends on for cardiac pacing is a safety event, so updates are typically applied under clinical supervision with the patient present and monitored. The update mechanism itself also consumes battery capacity, which is a finite resource tied to the device's service life and, ultimately, to when the patient needs another surgery. ### Does encryption drain the battery significantly? It depends entirely on whether the cryptography is accelerated in hardware. Operations performed in software on a low-power microcontroller cost far more energy than the same operations on a chip with a dedicated accelerator. This is why cryptographic capability is a silicon selection decision made early in development rather than a firmware feature added later. ### How should emergency access be handled securely? Through a designed emergency path with limited capability, enforced physical proximity, a bounded session duration, and an audit record, rather than an unauthenticated mode that grants full programming access. The submission should describe exactly what the emergency path permits and why that capability set is the minimum required for clinical care. ### What does the FDA expect for implantables specifically? The same premarket documentation required of any cyber device under the February 3, 2026 guidance, with particular attention to the update mechanism, the threat model's coverage of the full therapy chain, and the justification for controls given power and accessibility constraints. Reviewers also look for consistency between the cybersecurity documentation and the ISO 14971 risk file. ### Are legacy implantables still a regulatory concern? Yes. Postmarket obligations apply to devices in the field, and both the Abbott and Medtronic actions required plans that reached already-implanted patients. A vulnerability management plan that addresses only devices still in production will not satisfy a reviewer asking about your installed base. ## Talk Through Your Implantable Threat Model If your device is implanted, wireless, and expected to last a decade, the security decisions you make before the design freezes are the ones you will live with. We can review them with you while changes are still possible. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## SSDLC for Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/implementing-ssdlc-for-enhanced-medical-device-cybersecurity # SSDLC for Medical Device Cybersecurity: What Manufacturers Need to Know > **[DIRECT ANSWER]** A secure software development lifecycle puts security work at every phase instead of at the end: threat modeling during design, secure coding standards and SAST during implementation, dependency and SBOM management at build, penetration and fuzz testing at verification, and coordinated vulnerability disclosure after release. Wire those activities into your existing design controls so each one produces an artifact a reviewer or auditor can inspect. _Updated November 10, 2024_ ## Key Takeaways - SSDLC embeds security into medical device development. - The five phases are analysis, design, implementation, testing, deployment. - SSDLC supports compliance with FDA cybersecurity guidance. - It mitigates vulnerabilities early, reducing remediation costs. - builds a culture of security awareness among development teams. - Ensures continuous security throughout the device lifecycle. ## Why this matters The security of medical devices directly impacts patient well-being and healthcare system integrity. An insecure device can lead to severe operational disruptions, data breaches, and potential harm to individuals. The FDA, in its Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, emphasizes the critical need for manufacturers to integrate security throughout the entire product lifecycle. This guidance highlights the regulatory expectation for a proactive approach to cybersecurity, moving beyond merely reactive measures. Non-compliance can result in significant penalties, reputational damage, and restriction of market access for new devices. Furthermore, industry standards such as IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide frameworks for establishing effective medical device security. Adhering to SSDLC principles ensures that these standards are met, demonstrating due diligence and a commitment to patient safety while safeguarding sensitive health information. Prioritizing security reduces the likelihood of costly post-market remediations and avoids compromises to trust. ## Understanding the Importance of Cybersecurity in Medical Devices Cybersecurity in medical devices isn’t just important; it’s critical. It’s like locking the door to your home. If you leave it wide open, you’re inviting mischief. In today’s world, medical devices are often connected to the internet, making them vulnerable to attacks. Consider how many times a week you interact with a medical device. These devices are essential to providing care, from smart insulin pumps to connected MRI machines. As technology continues to evolve, integrating artificial intelligence and machine learning into these devices is becoming more common, enhancing their capabilities and efficiency. However, this also opens new doors for cyber threats, as sophisticated algorithms can be manipulated if proper security measures are not in place. Yet, with great technology comes great responsibility. Manufacturers must ensure that cybersecurity is a priority, not an afterthought. A single breach could [jeopardize patient safety](/blog/top-10-medical-device-vulnerabilities-revealed-protecting-patient-safety) and trust in healthcare systems. This responsibility extends beyond just the manufacturers; healthcare providers must also be vigilant in their cybersecurity practices, ensuring that all staff are trained to recognize potential threats and respond appropriately. ### The Role of Medical Devices in Healthcare Medical devices are the unsung heroes of modern healthcare. They help doctors diagnose diseases, monitor patients, and provide treatments. Think of them as the backstage crew at a concert. Without them, the main event couldn’t happen. Take heart monitors, for example. These devices alert medical staff to critical changes in a patient’s condition. Without this technology, timely care would become a racing heartbeat of chaos. Additionally, devices like pacemakers and defibrillators are now equipped with wireless capabilities that allow for remote monitoring, which can be a game changer for patients with chronic conditions. This innovation improves patient outcomes and emphasizes the need for cybersecurity measures to protect sensitive health data transmitted over networks. ### The Growing Threat of Cyber Attacks Cyber attacks on medical devices are not a matter of “if” but “when.” The landscape is filled with wolves waiting to pounce. According to various reports, hackers are increasingly targeting healthcare due to its lucrative potential. The rise of [ransomware](/blog) is like a plot twist in a thriller novel. Hospitals have faced crippling attacks, leading to delayed procedures and endangered lives. What should have been a routine check-up might turn into a high-stakes showdown. Furthermore, the interconnected nature of healthcare systems means that a breach in one device can have a cascading effect, compromising other systems and devices. This interconnectedness requires a approach to cybersecurity, where every device is treated as a potential entry point for attackers, necessitating ongoing vigilance and proactive measures to safeguard patient data and ensure the integrity of medical care. ## An Introduction to Secure Software Development Life Cycle (SSDLC) So, what’s the magic bullet for enhancing cybersecurity? Enter the Secure Software Development Life Cycle or SSDLC. Imagine it as a fortress built around your software development process. This structured approach integrates security checks and balances throughout the entire software development life cycle. It shifts security left, making it an integral part of the initial design and throughout development. ### The Five Phases of SSDLC SSDLC comprises five key phases: requirement analysis, design, implementation, testing, and deployment. Each phase builds on the previous one, like a well-stacked Jenga tower. 1. **Requirement Analysis:** Identify security requirements early on. This phase sets the foundation. 2. **Design:** Incorporate [security architecture by design](/blog/medical-device-cybersecurity-best-practices). Good design is like laying out the blueprints of a strong building. 3. **Implementation:** Coding with security in mind. This is where developers need to be vigilant. 4. **Testing:** Rigorous security testing to uncover vulnerabilities. Bombs are defused in this phase before they can cause harm. 5. **Deployment:** Launch in a secure manner. Monitor the system post-deployment; it’s the fire drill to ensure nothing goes wrong. ### The Benefits of Implementing SSDLC Implementing SSDLC offers numerous benefits. Firstly, it proactively addresses vulnerabilities. Think of it as putting on a seatbelt before driving. Secondly, it complies with regulations early, avoiding the last-minute rush. Red tape can be a headache, but SSDLC helps smooth that path. Lastly, it builds a security-aware culture within the development team. Team members consider security second nature, like continuously checking the locks at night. Adopting SSDLC can lead to significant cost savings over time. By identifying and addressing security issues during the development phases, organizations can avoid the high costs associated with post-deployment fixes, which often involve extensive rework and potential downtime. This proactive stance not only saves money but also enhances the overall quality of the software, leading to higher customer satisfaction and trust. Additionally, SSDLC encourages collaboration between development and security teams, breaking down silos that often exist in organizations. This collaboration builds a shared responsibility for security, where developers and security professionals work hand-in-hand to create applications. As a result, the development process becomes more efficient, and the end product is functional and resilient against potential threats. ## The Intersection of SSDLC and Medical Device Cybersecurity How does SSDLC enhance cybersecurity for medical devices? In every conceivable way! It’s like having a Swiss Army knife tailored for each cybersecurity scenario. ![Section Image]() Every phase of SSDLC directly applies to creating more secure medical devices. Each line of code and design choice is made with an eye on potential threats. ### How SSDLC Enhances Medical Device Security With SSDLC, vulnerabilities can be identified and mitigated before they become full-blown issues. It builds a layered defense akin to a medieval castle with walls, moats, and sentries. Every stakeholder becomes responsible for security. This integrates end-users’ and developers’ security thinking, creating a unified front against cyber threats. The SSDLC process encourages [regular security assessments](/blog/integrating-cybersecurity-assessments-into-the-medical-device-lifecycle) and updates throughout the device lifecycle, not just during the initial development phase. This ongoing vigilance ensures that medical devices are not left vulnerable as new threats emerge. By incorporating threat modeling and risk assessments at each stage, teams can proactively address potential weaknesses, thus fortifying their defenses against evolving cyberattacks. ### Addressing Potential Challenges in Implementation Despite its benefits, implementing SSDLC isn’t easy. It can be resource-intensive, requiring time and commitment, and some teams may resist change. But, as the old saying goes, “If it ain’t broke, don’t fix it,” doesn’t apply here! Continuous improvement is key. Organizations must invest in training, tools, and culture shifts. Additionally, the integration of SSDLC into existing workflows can create friction, especially in organizations accustomed to traditional software development practices. Teams may find it challenging to balance speed and security, particularly in fast-paced environments where time-to-market is critical. To overcome these hurdles, building a culture of collaboration and open communication is essential. By emphasizing the shared responsibility for security across all departments, organizations can cultivate an environment where security is viewed not as a hindrance but as an integral part of the development process. ## Regulatory Compliance and SSDLC Regulatory compliance is another reason SSDLC is vital in medical device development. It helps organizations navigate complex guidelines without feeling like they’re swimming upstream. In an industry where the stakes are incredibly high, ensuring that every piece of software complies with regulations is not just a best practice but a necessity. Companies that integrate SSDLC into their development processes often find that they can streamline their workflows, making it easier to adapt to changing regulations and emerging threats in the cybersecurity landscape. ![Section Image]() Regulators demand rigorous standards. By incorporating SSDLC, companies can demonstrate that they take cybersecurity seriously, giving them a leg up during compliance audits. This proactive approach helps meet regulatory requirements and builds a culture of accountability and transparency within the organization. When teams understand the importance of compliance from the outset, they are more likely to prioritize security in their design and development processes, ultimately leading to safer medical devices. ### Meeting FDA Cybersecurity Guidelines with SSDLC The FDA has been vocal about the importance of cybersecurity in medical devices. It’s akin to bending an ear to your wise grandmother’s advice. The agency has laid out specific recommendations that manufacturers should follow, and those who ignore them risk regulatory penalties and potential harm to patients. By embedding cybersecurity practices into the SSDLC, companies can create a framework that addresses these guidelines effectively and efficiently. Using SSDLC, manufacturers can ensure that they’re meeting these crucial guidelines. Documenting every phase creates a trail that proves due diligence, this is pure gold during reviews! Furthermore, this documentation can be valuable for training new employees, ensuring everyone understands cybersecurity’s importance in medical device development. This shared knowledge can lead to a more cohesive team better equipped to tackle the challenges of an threat landscape. ### International Standards for Medical Device Cybersecurity Beyond the [FDA,](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) international standards like [ISO/IEC 27001](/blog) come into play. Following these standards can bolster a company’s reputation worldwide. Adhering to such internationally recognized frameworks enhances credibility and opens doors to partnerships and collaborations with other organizations prioritizing security. Demonstrating compliance with these standards can be a significant competitive advantage in a global market. By aligning their SSDLC with these standards, organizations can minimize the risk of cyber incidents and expand their market reach, like opening a new branch in a bustling neighborhood. This alignment encourages a culture of continuous improvement, where companies regularly assess and update their security measures in response to new threats and vulnerabilities. Such vigilance protects the organization and safeguards the patients who rely on their medical devices, ultimately building trust and reliability in the healthcare ecosystem. ## Future Trends in Medical Device Cybersecurity As technology evolves, so does the landscape of cybersecurity threats. It’s like a game of chess where the pieces are constantly moving. ![Section Image]() Organizations must stay ahead of the curve. Predicting future trends is essential for building formidable defenses for medical devices. ### Predicted Developments in Cyber Threats Cyber threats are expected to become more sophisticated. Attackers will employ advanced tactics, creating an almost arms race. [Quantum computing](/blog) may even revolutionize how hackers operate, making it an area of concern that cannot be ignored. Monitoring these trends will guide organizations in proactive defense strategies. The rise of the [Internet of Medical Things (IoMT)](/blog) introduces many interconnected devices, each a potential entry point for cybercriminals. The attack surface expands exponentially as hospitals and clinics increasingly rely on smart devices for patient monitoring and treatment. This interconnectedness means that a vulnerability in one device could compromise an entire network, making it crucial for organizations to implement security protocols across all devices. ### The Role of SSDLC in Future Cybersecurity Strategies SSDLC will be pivotal in adapting to future challenges. Integrating security into the development lifecycle must be non-negotiable as new technologies emerge. It’s essential to remain vigilant and continuously evolve strategies. Like a chameleon, organizations must adapt to the shifting landscape of threats. In addition to integrating security from the outset, ongoing training for developers and engineers is vital. As the threat landscape evolves, so must the skills and knowledge of those creating medical devices. Regular workshops and simulations can help teams stay sharp and prepared for emerging threats, ensuring security becomes a core competency rather than an afterthought. Ultimately, the goal is straightforward: protect patients and their sensitive information while driving innovation in the healthcare sector. ## Conclusion Implementing SSDLC isn’t just a wise decision; it’s an absolute necessity. Protecting medical devices isn’t just about securing technology; it’s about safeguarding lives. As the medical device industry continues to confront the cyber threats, the need for a cybersecurity strategy has never been more pressing. Blue Goat Cyber stands at the forefront of this battle, offering expert services tailored to the unique challenges faced by medical device manufacturers. Our commitment to integrating security throughout the device lifecycle ensures that your products comply with FDA regulations and are fortified against the latest cyber threats. With our veteran-owned business’s practical experience and top industry certifications, we provide advanced penetration testing and vulnerability assessments that go beyond the basics to offer you clear, actionable insights. Our fixed-fee pricing and unlimited retesting mean you receive the highest value and assurance in meeting FDA standards. Don’t let cybersecurity concerns hold back your innovations in healthcare. [Contact us today for cybersecurity help](/contact), and let Blue Goat Cyber be the partner you need for a secure future in digital healthcare. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in establishing and maturing their Secure Software Development Life Cycle processes. Our methodology focuses on integrating security activities into your existing development workflows, from threat modeling and secure coding practices to vulnerability management and incident response planning. We use the expertise of our team, which includes professionals with CISSP and OSCP certifications, as well as ex-military red team experience, to identify and mitigate risks effectively. Our services align with regulatory expectations, preparing your organization for the stringent requirements of the FDA. We offer specialized support for pre-market and post-market cybersecurity needs. Should the FDA raise cybersecurity deficiencies after our submission, we resolve them at no additional cost. We provide focused, actionable strategies designed to strengthen your security posture and navigate the complex regulatory landscape. Learn more about our proactive strategies at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is SSDLC in the context of medical devices? SSDLC (Secure Software Development Life Cycle) for medical devices systematically integrates security practices into every phase of software development, from initial design through deployment and maintenance. This ensures cybersecurity is a foundational element, not an afterthought. ### How does SSDLC help medical device manufacturers comply with FDA guidance? SSDLC aids medical device manufacturers in complying with the FDA's February 3, 2026 final guidance by embedding security requirements and testing throughout the development process. This approach helps create auditable documentation, demonstrating due diligence in addressing cybersecurity risks. ### What are the common challenges when implementing SSDLC for medical devices? Common challenges include resource intensiveness, resistance to change within development teams, and balancing development speed with security requirements. Overcoming these requires investing in training, appropriate tools, and cultivating a collaborative security-aware culture. ### When should security be considered in the medical device development process? Security should be considered at the earliest possible stage, specifically during the requirement analysis phase of the SSDLC. Integrating security from the outset helps prevent costly vulnerabilities that are difficult to fix later in the development cycle. ### Does SSDLC apply to existing medical devices? While primarily focused on new development, SSDLC principles can be applied to existing medical devices through updates, patches, and continuous monitoring. This ensures ongoing security for devices already in the market by addressing newly discovered vulnerabilities and evolving threats. ### Why is rigorous testing important in the SSDLC for medical devices? Rigorous testing within SSDLC matters for medical devices because it identifies and rectifies security vulnerabilities before they can be exploited. This proactive measure safeguards patient safety, protects sensitive health information, and ensures device reliability against cyber threats. **Related:** [A Guide to Software Testing for Medical Devices](/blog/a-comprehensive-guide-to-software-testing-for-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Indications for Use, Predicates, and Cybersecurity Scope Source: https://bluegoatcyber.com/blog/indications-for-use-predicates-cybersecurity-510k-scope # Indications for Use, Predicates, and 510(k) Cybersecurity Scope > **[DIRECT ANSWER]** Your Indications for Use statement determines cybersecurity scope more than most teams expect. It fixes the use environment, the user population, and the severity of harm if the device is compromised, and all three feed the threat model, the architecture views, and the penetration test boundary. Predicate choice then sets the baseline you are compared against, so every connectivity feature added beyond the predicate needs an explicit cybersecurity delta narrative. Two identical devices can owe completely different cybersecurity packages. The only difference is a sentence on the Indications for Use form. Regulatory teams treat the Indications for Use statement as a clinical and marketing artifact. Security teams rarely read it at all. That gap is where 510(k) cybersecurity deficiencies come from, because the reviewer reads both documents together and expects them to agree. ## Why this matters The FDA's final premarket cybersecurity guidance of February 3, 2026 frames security risk in terms of patient harm, not information-security abstractions. Risk is a function of exploitability and the severity of harm that exploitation could cause. Severity of harm is a clinical judgment, and the clinical judgment is anchored in what the device claims to do, for whom, and where. That makes the Indications for Use statement an input to the security risk assessment, not a parallel document. A monitor indicated for use by trained clinicians inside a managed hospital network sits behind institutional controls. The same monitor indicated for unsupervised home use over a patient's own network has no such perimeter, so the device itself must carry controls the hospital version could inherit from its environment. We break that comparison down control by control in [home use vs hospital device cybersecurity requirements](/blog/home-use-vs-hospital-device-cybersecurity). Section 524B, meanwhile, is indifferent to your indication. The statute attaches to the definition of a cyber device, meaning software validated, installed, or authorized by the sponsor, an ability to connect to the internet, and technological characteristics that could be vulnerable to threats. Narrowing your indication does not narrow that definition. ## How Indications for Use map to cybersecurity scope | Indications for Use element | What it drives in the security package | | --- | --- | | Use environment (hospital, clinic, home, ambulance) | Trust boundaries, assumed network controls, physical access threats | | User population (clinician, caregiver, patient) | Authentication design, usability of security controls, labeling depth | | Patient population (adult, pediatric, critical care) | Severity of harm ratings in the ISO 14971 chain | | Life-supporting or life-sustaining claim | Availability threats become safety threats, not nuisance findings | | Multi-patient use | The multi-patient harm architecture view becomes central | | Remote monitoring or remote adjustment | Adds a cloud and transport attack surface plus command-integrity threats | | Interoperability claim | Every named interface is in pen test scope | > **[KEY REQUIREMENT]** The security use case view and the multi-patient harm view in the February 3, 2026 guidance both depend on facts stated in the Indications for Use. If the views contradict the indication, expect a deficiency. ## Predicate choice and the cybersecurity delta In a 510(k) you are arguing substantial equivalence to a predicate. Reviewers read your cybersecurity evidence against that same frame, and the most common cybersecurity deficiency in 510(k) review is unaddressed predicate divergence. The pattern is predictable. The predicate cleared years ago as a standalone device. Your version adds Bluetooth, a companion app, and a cloud dashboard. The clinical argument for equivalence is sound because the diagnostic output is unchanged. The cybersecurity argument is missing entirely, because nobody wrote the narrative explaining what attack surface the new interfaces introduce and how it is controlled. What the narrative needs to contain: - Every interface and data flow present in your device but absent from the predicate. - The threats those additions create, mapped through STRIDE per element. - The controls mitigating each threat and the verification evidence for each control. - The residual risk after controls, tied back into the ISO 14971 risk file. - Any indication difference that changes severity of harm relative to the predicate. Reviewers do not expect you to retroactively cyber-document an old predicate. They expect you to be explicit about the delta. ## When an Indications for Use change forces a new 510(k) For a marketed device, an Indications for Use change is evaluated under the FDA's device modifications guidance. The cybersecurity question is whether the change affects safety or effectiveness through a security pathway. Changes that usually require a new 510(k): - Moving from professional use to home use, which removes the assumed managed network. - Adding remote monitoring, remote configuration, or remote therapy adjustment. - Extending to a life-sustaining or critical care population, raising the harm ceiling. - Extending to multi-patient use, which changes the harm scale from one patient to many. Changes that can often be documented in a letter to file: - Narrowing an indication without touching the architecture. - Clarifying wording where the use environment and connectivity are unchanged. - Adding a patient subpopulation with no new interfaces and no severity increase. The test is not whether you touched code. It is whether the modification could significantly affect safety or effectiveness, and new attack surface routinely can. ## Is a Special 510(k) available for a security-relevant change? Sometimes, but less often than sponsors hope. A Special 510(k) requires that the change be one where the sponsor can evaluate the effect using well-established methods and the results are summarizable in a way that is reviewable through a summary format. Security patches to an existing, already-documented architecture often qualify. Adding a wireless interface or a cloud service usually does not, because there is no pre-existing verification method that covers a surface the device never had. When in doubt, the decision belongs in a pre-submission rather than in a gamble on the acceptance review. Our [pathway crosswalk tool](/tools/pathway-crosswalk) walks the letter to file, Special 510(k), and new 510(k) decision against the cybersecurity factors reviewers weigh. ## How Blue Goat Cyber approaches this We start every premarket engagement by reading the Indications for Use statement before we look at the architecture. The statement tells us the use environment, the user population, and the harm ceiling, and those three facts determine the trust boundaries we draw in the data flow diagrams and the severity ratings in the risk file. We then build the predicate-comparison cybersecurity narrative as its own artifact rather than a paragraph buried in the summary. It enumerates every interface your device has that the predicate did not, the threats each adds, the controls applied, and the verification evidence, so a reviewer can see the delta without reconstructing it. Where the indication and the technical documentation disagree, we flag it before submission. That disagreement is cheap to fix in draft and expensive to fix in a deficiency response. ## FAQ **Does a narrower Indications for Use reduce my Section 524B obligations?** No. Section 524B attaches to the cyber device definition, which turns on software, connectivity, and vulnerability to threats. The breadth of your clinical claim is not part of that test. A narrowly indicated connected device still owes a threat model, an SBOM, a postmarket vulnerability management plan, and a coordinated disclosure process. **Can I scope my penetration test to just the indicated use environment?** Scope the test to the full attack surface the device presents, not just the intended workflow. Reviewers expect coverage of interfaces that exist even when the indication does not describe using them, because an attacker is not bound by your indication. Unused interfaces should be disabled and that decision documented. **Our predicate has no cybersecurity documentation at all. Is that a problem?** It is common and it is workable. You are not responsible for the predicate's file. You are responsible for describing the cybersecurity surface your device adds relative to that baseline and demonstrating control of it. The absence of predicate evidence makes your delta narrative more important, not less. **Does adding a companion app change our Indications for Use?** Often yes, and if it does, the cybersecurity package changes with it. A companion app introduces a mobile platform, a transport channel, and usually a cloud backend. All three belong in the architecture views, the SBOM, and the test scope. **How does this interact with a Predetermined Change Control Plan?** A PCCP can cover pre-authorized modifications, but it cannot pre-authorize an indication expansion that changes the harm ceiling or adds attack surface. Keep the PCCP scoped to changes you can verify with methods already described in the submission. **Who should own the Indications for Use and threat model alignment?** Regulatory owns the statement and security owns the model, so the alignment needs a named owner across both. In practice the regulatory lead should review the trust boundary diagram and the security lead should review the Indications for Use form, each signing off before submission. ## CTA If your Indications for Use and your threat model were written by different people who never compared notes, that gap will surface in review. We read both together and rebuild the predicate-comparison narrative before it becomes a deficiency letter. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to walk through your submission scope. --- ## Infusion Pump Cybersecurity: FDA Expectations Source: https://bluegoatcyber.com/blog/infusion-pump-cybersecurity-fda # Infusion Pump Cybersecurity: FDA Expectations in 2026 > **[DIRECT ANSWER]** Infusion pumps remain one of the FDA's highest-scrutiny device categories, so submissions need a threat model centered on dose-modification, wireless authentication, drug library integrity, and service interfaces. The most common delays come from hardcoded credentials, unsigned updates, and penetration test evidence that does not match the submitted build. The FDA has treated infusion pumps as a focal point for medical device cybersecurity since the Hospira Symbiq advisory in 2015. A decade later, pumps remain among the most frequently called-out devices in CISA medical advisories and the most common subject of penetration tests that find dose-modification, hardcoded credential, and wireless authentication failures. Under Section 524B and the FDA's February 3, 2026 final premarket cybersecurity guidance, infusion pump submissions face a deeper review than most Class II devices. This post explains what reviewers look for, where pumps draw deficiency questions, and how to structure the cybersecurity package. ## Key Takeaways - Infusion pumps are connected Class II devices and are cyber devices under Section 524B. - Threat models must address dose modification, drug library tampering, and wireless authentication bypass. - The SBOM must trace third-party components in the pump, the drug library server, and the gateway. - Penetration testing for pumps typically requires both protocol-level and physical-attack coverage. - Pumps are a recurring subject of CISA medical advisories, so postmarket monitoring evidence is scrutinized. ## Why this matters Infusion pumps deliver life-sustaining therapy, run for years in clinical environments, and connect to hospital networks, drug-library servers, and central monitoring stations. The FDA's February 3, 2026 final premarket cybersecurity guidance ties the depth of the cybersecurity package to the device's risk profile and attack surface, and pumps sit at the high end of both. CISA's ICS Medical Advisories database lists multiple infusion pump advisories every year, often involving authentication bypass, hardcoded credentials, or unencrypted wireless protocols. AAMI SW96:2023 informs the security risk activities inside the IEC 62304 lifecycle, and IEC 60601-2-24 governs the safety basics for infusion equipment. A submission that does not address the pump-specific attack surface, the drug-library trust boundary, and wireless authentication will draw deficiencies during substantive review. ## Why Infusion Pumps Get Extra Cybersecurity Scrutiny ### Dose-Critical Therapy on a Hospital Network Pumps are unusual in that a software or protocol manipulation can directly change a patient-affecting therapy parameter. Reviewers know this, and the cybersecurity package is read with that consequence in mind. A vulnerability that would be informational on a documentation device is high-severity on a pump because the failure mode reaches the patient. ### A History of CISA Medical Advisories CISA has issued advisories on multiple pump families over the past decade, including issues affecting Baxter, BD, Becton Dickinson Alaris, Hospira, ICU Medical, and Smiths Medical product lines. Reviewers ask sponsors to acknowledge prior advisory patterns in the threat model and to show how the current design addresses each pattern class (hardcoded credentials, weak wireless authentication, command injection on drug-library endpoints, exposed maintenance interfaces). ## Threat Model Focus Areas the FDA Expects ### Dose Modification and Drug Library Tampering The threat model must explicitly address adversary scenarios that change a programmed dose, a drug library entry, or a hard limit. STRIDE decomposition for pumps typically isolates the drug-library import path, the pump-to-server pairing protocol, the maintenance interface, and the wireless stack as distinct trust boundaries with their own threat lists. ### Wireless and Pairing Protocols Wireless authentication is the most frequent finding source on pump penetration tests. The threat model needs to describe the wireless stack (Wi-Fi, Bluetooth, proprietary), the pairing or enrollment ceremony, the key management lifecycle, and the fallback behavior if authentication fails. > **[KEY REQUIREMENT]** The FDA expects the threat model to enumerate the cryptographic primitives, the key sizes, and the rotation policy, not just to assert that traffic is encrypted. ## The Section 524B Evidence Set for an Infusion Pump ### SBOM, VEX, and the Drug-Library Server A pump SBOM must cover the embedded firmware, the gateway, and any drug-library server software the manufacturer distributes. VEX statements then triage each component against known vulnerabilities, including any KEV catalog entries that affect dependencies in the stack. Reviewers compare the SBOM against the architecture views to confirm coverage. ### Architecture Views That Show Trust Boundaries The architecture views must show the pump, the gateway, the drug-library server, the hospital network segment, and any cloud service. Each interface needs a labeled trust boundary, an authentication mechanism, and a reference to the threat model entries it covers. A single block diagram is rarely sufficient; reviewers expect deployment, data flow, and trust-boundary views. ### Labeling That Supports Secure Operation Pump labeling must give hospital biomedical engineering teams the information they need to deploy securely: network requirements, authentication setup, patching cadence, end-of-support dates, and any compensating controls. The FDA's Feb 3, 2026 guidance treats labeling as a cybersecurity control, not a marketing artifact. ## Penetration Testing Scope That Satisfies Reviewers ### Protocol and Network Layer Pen testing for pumps includes wireless protocol analysis, server-side API fuzzing, authentication bypass attempts, and traffic interception. Findings on hardcoded credentials, weak session management, or unencrypted command channels are nearly always considered substantive. ### Physical and Maintenance Interfaces Many pump deficiencies originate at the physical maintenance interface: exposed JTAG, debug serial, or service-mode menus. The pen test scope must cover these interfaces, document any tamper-evidence claims in the labeling, and confirm that service-mode access requires authenticated, audited credentials. ### Drug-Library and Configuration Tampering A complete pen test attempts to inject or modify drug-library entries, alter hard limits, and bypass pharmacy review workflows. Reviewers look for evidence that the manufacturer tested these adversary-aligned scenarios, not just generic application vulnerabilities. ## Common Deficiency Patterns on Infusion Pump Submissions | Deficiency pattern | Why it shows up | What reviewers want instead | | --- | --- | --- | | Threat model omits drug-library path | Treated as a config feature, not an attack surface | Explicit STRIDE decomposition for the library import and pump-side trust | | Wireless protocol described as "encrypted" | No primitives, key sizes, or rotation policy | Named primitives, key lengths, key lifecycle, and fallback behavior | | Pen test scope skipped physical interfaces | Tester only had network access | Documented physical-interface testing or justified exclusion | | SBOM excludes drug-library server | Treated as a separate product | Single SBOM covering all components the manufacturer ships | | No reference to prior CISA pump advisories | Sponsor treats history as out of scope | Explicit acknowledgement and a "how we addressed" mapping | > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches Infusion Pump Submissions We treat infusion pump submissions as high-scrutiny work and structure the cybersecurity package around the pump's specific attack surface: drug-library trust, wireless authentication, maintenance interfaces, and gateway-to-server communication. Threat models are decomposed per trust boundary, the SBOM covers every shipped component, and the penetration test scope includes physical interfaces and drug-library tampering. Our team holds CISSP, OSCP, and prior military red-team credentials, and our submission work is grounded in Section 524B, the FDA's February 3, 2026 final premarket cybersecurity guidance, AAMI SW96:2023, and IEC 81001-5-1. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [medical device penetration testing services](https://bluegoatcyber.com/services/medical-device-penetration-testing) or review the [FDA premarket cybersecurity submission checklist](https://bluegoatcyber.com/guides/fda-premarket-cybersecurity-submission-checklist). ## FAQ ### Are infusion pumps automatically cyber devices under Section 524B? Connected infusion pumps almost always meet the Section 524B definition because they include validated software, network capability (wireless, Ethernet, or both), and the potential to be vulnerable to cybersecurity threats. Standalone, non-connected pumps may fall outside the definition, but most modern pumps do not. ### What standards apply to infusion pump cybersecurity? IEC 60601-2-24 covers the safety basics for infusion equipment. AAMI SW96:2023 governs medical device security risk management. IEC 81001-5-1 covers security activities for health software. ISO 14971 governs overall risk management. The FDA's Feb 3, 2026 final premarket cybersecurity guidance ties the cybersecurity submission content to all of these. Note that 60601-2-24 carries no cybersecurity requirements; its value to a security program is that it defines the pump's essential performance, which you reuse as harm criteria. See [IEC 60601 and cybersecurity](/guides/iec-60601-medical-device-cybersecurity). ### Does the FDA require pen testing for infusion pumps? The Feb 3, 2026 guidance lists security testing, including penetration testing, as a required element of the cybersecurity submission content. For infusion pumps, the scope is read against the device's attack surface, which usually means protocol, network, physical interface, and drug-library coverage. ### How should we handle prior CISA advisories on similar pumps? Acknowledge them in the threat model and map each advisory pattern to a control or design decision in the current device. Reviewers consistently flag submissions that ignore the public advisory history for a device family. ### What is the most common single deficiency on a pump submission? Weak treatment of wireless authentication. Sponsors describe traffic as encrypted without naming the cryptographic primitives, key sizes, key lifecycle, or fallback behavior. Reviewers expect that level of specificity in the threat model and the architecture views. ## Ready to make your infusion pump submission FDA-ready? If you are preparing a 510(k) or De Novo for a connected infusion pump and want the threat model, SBOM, and penetration testing scope to match the scrutiny the FDA applies to this device class, we can help. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led FDA premarket cybersecurity submissions for connected infusion and dose-delivery devices and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## Lifecycle Cybersecurity Assessments for Devices (2026) Source: https://bluegoatcyber.com/blog/integrating-cybersecurity-assessments-into-the-medical-device-lifecycle # Lifecycle Cybersecurity Assessments for Medical Devices: 2026 Best Practices > **[DIRECT ANSWER]** Integrating cybersecurity assessments across the medical device lifecycle means embedding secure coding, threat modeling, and risk assessments during design, verifying supply chain integrity and access controls during manufacturing, and running continuous vulnerability assessments, software updates, and breach monitoring after the device ships. The FDA's February 3, 2026 final guidance requires this security-by-design approach throughout the total product lifecycle, supported by standards like AAMI TIR57 and IEC 81001-5-1. _Updated November 16, 2024_ The rise of technology in the healthcare industry has transformed how medical devices are designed, manufactured, and used. With this advancement comes the critical need for cybersecurity measures to protect patients’ safety and privacy. Integrating cybersecurity assessments into the medical device lifecycle has become a paramount concern for healthcare providers and device manufacturers. In this article, we will explore the importance of cybersecurity in medical devices, the concept of cybersecurity assessments, the stages of the medical device lifecycle, and the challenges and solutions in integrating cybersecurity assessments into this lifecycle. ## Key Takeaways - Embed cybersecurity in medical device design. - Assess supply chain security during manufacturing. - Conduct continuous post-market surveillance. - Prioritize threat modeling for new devices. - Adhere to the FDA's February 3, 2026 guidance. - Protect patient safety and data proactively. ## Why this matters Integrating cybersecurity assessments into the medical device lifecycle is paramount because patient safety, data privacy, and trust in healthcare systems directly depend on it. Vulnerabilities in connected medical devices can lead to catastrophic outcomes, including direct harm to patients through device manipulation, or widespread data breaches exposing protected health information. The FDA, in its Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, unequivocally states that manufacturers are responsible for ensuring the security of their devices throughout their entire lifespan. This guidance emphasizes a shift from reactive to proactive security measures, demanding "security by design" principles. The absence of integrated cybersecurity assessments increases regulatory non-compliance risks and liability. Neglecting these assessments can result in recalls, reputational damage, and financial penalties. Adherence to standards such as IEC 60601-1-10 (Medical electrical equipment, Part 1-10: General requirements for basic safety and essential performance, Collateral Standard: Requirements for the development of physiologic closed-loop controllers), ISO 81001-5-1 (Health informatics, Safety, effectiveness and security of health apps, Part 5-1: Requirements for product manufacturing), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management) becomes non-negotiable, guiding manufacturers toward building intrinsically secure devices and processes. Ultimately, an integrated approach safeguards patients and secures the future of connected healthcare. ## Understanding the Importance of Cybersecurity in Medical Devices As medical devices become more interconnected and internet-enabled, the risk of cybersecurity breaches grows. These breaches can have severe consequences, compromising patients’ safety and exposing their private healthcare information. Cybersecurity in medical devices is not just about protecting data; it is about [safeguarding patients’ lives](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). For instance, a malicious attacker gaining control over a medical device like an insulin pump can administer a deadly dose of medication. Therefore, incorporating strong cybersecurity measures is crucial to ensure patient safety and maintain public trust in the healthcare system. ### The Role of Cybersecurity in Healthcare Cybersecurity plays a fundamental role in healthcare, encompassing various aspects such as safeguarding patient data, [protecting devices from unauthorized access](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist), preventing malicious attacks, and ensuring the resilience and reliability of medical systems. Healthcare organizations must prioritize cybersecurity as an integral part of their operations and embed it into their policies, procedures, and culture. ### Risks and Threats in Medical Device Security Medical devices face numerous cybersecurity risks and threats. They can be susceptible to hacking, malware infections, unauthorized access, and data breaches. The consequences can range from disruption of healthcare services to compromising patient safety and privacy. In recent years, several significant cybersecurity incidents involving medical devices have highlighted the urgency of addressing these vulnerabilities. One notable example of a cybersecurity incident involving medical devices is the WannaCry ransomware attack in 2017. This global attack affected healthcare systems worldwide, including hospitals and medical facilities. The ransomware exploited vulnerabilities in outdated software, spreading rapidly and encrypting critical patient data. As a result, healthcare providers could not access patient records, leading to delays in treatment and potential harm to patients. Another concerning threat to medical device security is the increasing use of wireless communication protocols. While these protocols enable connectivity and remote monitoring, they also introduce new cyberattack avenues. Hackers can exploit vulnerabilities in wireless communication to gain unauthorized access to medical devices, potentially altering their functionality or stealing sensitive patient information. The proliferation of [Internet of Things (IoT) devices](/blog) in healthcare has expanded the attack surface for cybercriminals. IoT devices, such as wearable health trackers and remote patient monitoring systems, collect and transmit sensitive health data. If these devices are not adequately secured, they can become entry points for cyberattacks, compromising patient privacy and healthcare systems’ integrity. Addressing these risks and threats requires a multi-faceted approach. Healthcare organizations must invest in cybersecurity solutions, including regular software updates, strong encryption protocols, and intrusion detection systems. Additionally, healthcare professionals must receive training on cybersecurity best practices to ensure they are aware of potential threats and can respond effectively in case of an incident. ## The Concept of Cybersecurity Assessments Cybersecurity assessments are systematic evaluations of the security measures implemented in medical devices. They aim to identify potential vulnerabilities, evaluate the effectiveness of existing security controls, and recommend necessary improvements to enhance the devices’ overall cybersecurity posture. Healthcare providers and manufacturers can proactively identify and mitigate security risks by conducting these assessments, ensuring that medical devices meet the highest protection standards. ![Section Image](/imported-images/45f0e11e6eafaab3.png) ### Defining Cybersecurity Assessments Cybersecurity assessments involve evaluating the security architecture, software, hardware, and firmware of medical devices. This assessment considers authentication mechanisms, encryption protocols, access controls, vulnerability management processes, and incident response capabilities. It encompasses technical evaluations and risk assessments, allowing organizations to identify vulnerabilities, evaluate their potential impact, and implement appropriate countermeasures. ### Components of a Cybersecurity Assessment A cybersecurity assessment includes several key components. These components involve evaluating the device’s security policies and procedures, conducting penetration testing to identify vulnerabilities, assessing the device’s network security controls, reviewing the device’s architecture and design, and examining the device’s response to security incidents. By addressing these components, organizations can gain a holistic view of their devices’ security readiness and develop appropriate strategies to improve cybersecurity. A critical aspect of cybersecurity assessments is evaluating security policies and procedures. This involves analyzing the documented policies and procedures that govern medical device use, maintenance, and protection. It includes assessing these policies’ clarity, comprehensiveness, and alignment with industry best practices and regulatory requirements. By ensuring that policies and procedures are in place, organizations can establish a strong foundation for effective cybersecurity. Another crucial component of cybersecurity assessments is conducting penetration testing. This involves simulating real-world cyber attacks to identify vulnerabilities in the device’s software and network infrastructure. Penetration testing helps organizations understand the potential impact of a successful attack and enables them to take proactive measures to address these vulnerabilities. By conducting regular and thorough penetration testing, organizations can stay one step ahead of cyber threats and continuously improve their security defenses. ## The Medical Device Lifecycle: An Overview The medical device lifecycle encompasses the stages from design and development to manufacturing, quality control, maintenance, and monitoring. Each stage has unique considerations regarding cybersecurity integration. Let’s explore the stages in detail. ![Section Image](/imported-images/231b8a9ad9a7b7ce.png) ### Stages of the Medical Device Lifecycle The medical device lifecycle comprises three primary stages: pre-production, production, and post-production. **1\. Pre-Production:** This stage lays the foundation for a medical device. It involves extensive research, design, and development. During this phase, cybersecurity is vital to ensure the device is built with security in mind. This includes implementing secure coding practices, conducting thorough risk assessments, and incorporating encryption protocols to protect sensitive data. **2\. Production:** The production stage begins once the design is finalized. This phase involves the actual manufacturing of the medical device. Cybersecurity considerations during production focus on securing the supply chain to prevent tampering or unauthorized modifications to the device. Implementing strict access controls, conducting regular audits, and ensuring secure storage of components are essential to maintaining the device’s integrity. **3\. Post-Production:** After the medical device is manufactured, it enters the post-production stage. This phase involves activities such as quality control, maintenance, and monitoring. Cybersecurity at this stage is crucial to ensure the [device remains secure throughout its lifespan](/blog). Regular vulnerability assessments, software updates, and monitoring for any potential security breaches are essential to maintain the confidentiality and availability of the device. ### The Role of Cybersecurity at Each Stage At each stage of the medical device lifecycle, cybersecurity considerations are crucial in ensuring the device’s integrity, confidentiality, and availability. Let’s covers the role of cybersecurity at each stage: **Pre-Production:** During the pre-production stage, cybersecurity measures are implemented to build a strong foundation for the device’s security. This includes conducting thorough risk assessments to identify potential vulnerabilities and implementing secure coding practices to prevent common security flaws. **Production:** In the production stage, cybersecurity focuses on securing the manufacturing process and the supply chain. Strict access controls are implemented to prevent unauthorized modifications to the device, and regular audits are conducted to ensure compliance with security standards. Secure storage of components is also crucial to prevent tampering or theft. **Post-Production:** After the device is manufactured, cybersecurity measures remain critical in maintaining its security. Regular vulnerability assessments are conducted to identify potential weaknesses, and software updates are implemented to address known vulnerabilities. Continuous monitoring for potential security breaches ensures the device remains secure throughout its lifespan. By integrating cybersecurity at each stage of the medical device lifecycle, manufacturers can ensure that their devices are built with security in mind, protecting patient safety and confidential data. Healthcare organizations and medical device manufacturers must prioritize cybersecurity to mitigate the risks associated with cyber threats in the healthcare industry. ## Integration of Cybersecurity Assessments into the Lifecycle ### Pre-Production Stage: Design and Development Integrating cybersecurity assessments during the design and development stage ensures security measures are built into the device’s core. This is crucial because it sets the foundation for a secure product. Manufacturers must employ secure coding practices, conduct [threat modeling exercises](/blog), and implement encryption and authentication mechanisms to mitigate potential risks. ### Production Stage: Manufacturing and Quality Control In the production stage, cybersecurity assessments focus on verifying the integrity of the manufacturing process and the device’s software and hardware components. Rigorous quality control measures, adherence to industry standards, and continuous monitoring contribute to the device’s overall security. ### Post-Production Stage: Maintenance and Monitoring The post-production stage involves ongoing maintenance, monitoring, and updates to address emerging security threats and vulnerabilities-regular cybersecurity assessments aid in detecting and mitigating potential risks in deployed devices. These assessments also play a crucial role in gathering data and insights about potential vulnerabilities that may arise over time. This information can then further enhance future devices’ security and improve the organization’s overall cybersecurity posture. ## Challenges and Solutions in Integration ### Common Obstacles in Integrating Cybersecurity Assessments Integrating cybersecurity assessments into the medical device lifecycle poses several challenges. Some common obstacles include a lack of resources and expertise, resistance to change, awareness about cybersecurity risks, and the complex nature of medical device ecosystems. These challenges require proactive solutions to ensure successful integration. ![Section Image](/imported-images/282720a31bfcf0e6.png) ### Effective Strategies for Successful Integration To overcome the challenges, effective strategies are vital for successfully integrating cybersecurity assessments into the medical device lifecycle. These strategies include establishing a dedicated cybersecurity team, building collaboration between manufacturers and healthcare providers, providing specialized training and education, implementing risk management frameworks, and embracing a culture of security. Companies like Philips have implemented strategies to ensure the successful integration of cybersecurity assessments in their medical devices. One of the major challenges in integrating cybersecurity assessments is the lack of resources and expertise. Many healthcare organizations struggle to allocate sufficient resources to cybersecurity initiatives due to budget constraints or a shortage of skilled cybersecurity professionals. Without the necessary expertise, assessing and mitigating cybersecurity risks effectively becomes difficult. To address this challenge, organizations can consider partnering with external cybersecurity firms or investing in training programs to enhance the skills of their existing workforce. Another obstacle is the resistance to change. The healthcare industry has traditionally focused on patient care and medical advancements, often overlooking the importance of cybersecurity. As a result, healthcare professionals and device manufacturers may resist integrating cybersecurity assessments into the medical device lifecycle. Overcoming this resistance requires a shift in mindset and a awareness campaign to educate stakeholders about the potential risks and benefits of cybersecurity assessments. The complex nature of medical device ecosystems adds to the integration challenges. Medical devices are interconnected and rely on various software components and network infrastructure. This complexity introduces multiple entry points for potential cyber threats, making assessing and securing each ecosystem component crucial. Implementing risk management frameworks like the [NIST Cybersecurity Framework](https://www.nist.gov/itl/smallbusinesscyber/nist-cybersecurity-framework-0) can help organizations identify and prioritize potential vulnerabilities, ensuring a more and resilient medical device ecosystem. ## Which assessment belongs in which phase Running the right assessment late is nearly as expensive as not running it at all, because the findings arrive after the design is fixed. | Lifecycle phase | Assessment | What it can still change | Cost of skipping it here | | --- | --- | --- | --- | | Concept | Intended use and environment review | The security requirements themselves | Requirements invented later to match the build | | Architecture | Threat model and trust boundary analysis | Architecture, protocol choice, hardware root of trust | Findings that need silicon to fix | | Detailed design | Cryptographic and control design review | Algorithms, key storage, update mechanism | Field devices that cannot hold a second key | | Implementation | Static analysis and composition analysis | Code and component selection | An SBOM full of components nobody can support | | Verification | Security requirement testing and fuzzing | Configuration, defaults, error handling | Deficiency letters on untested claims | | Pre submission | Independent penetration test and package review | The narrative and the evidence gaps | Review cycles spent answering avoidable questions | | Postmarket | Vulnerability monitoring and periodic reassessment | Patch priority and customer communication | Silent exposure on devices already in use | The pattern is that early assessments change the design and late assessments change only the paperwork. ## Conclusion Integrating cybersecurity assessments into the medical device lifecycle is imperative to protect patient safety and ensure the confidentiality and integrity of healthcare data. By recognizing the importance of cybersecurity, understanding the concept of cybersecurity assessments, and embracing effective integration strategies, healthcare providers and device manufacturers can create a secure and resilient ecosystem. Safeguarding medical devices from potential threats and vulnerabilities will contribute to a safer and more reliable healthcare system. As you navigate the complexities of integrating cybersecurity assessments into the medical device lifecycle, remember that you don’t have to do it alone. Blue Goat Cyber, a Veteran-Owned business, specializes in providing B2B cybersecurity services tailored to the unique needs of the medical device industry. From penetration testing to HIPAA and FDA compliance, our team is dedicated to securing your devices and protecting your patients. [Contact us today for cybersecurity help](/contact) and partner with a team as passionate about safeguarding your business as you are about healthcare. Check out our [cybersecurity premarket submission services.](/) ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers integrate cybersecurity assessments across their product lifecycle, addressing FDA expectations proactively. We apply a methodology that emphasizes early threat modeling, supply chain security validation, and continuous post-market surveillance programs. Our team, comprised of certified professionals such as CISSP and OSCP holders, including ex-military red team personnel, brings direct experience in identifying and mitigating complex vulnerabilities unique to medical devices. We provide services ranging from pre-market design evaluations through to incident response planning, ensuring alignment with regulatory mandates. Our approach focuses on identifying potential attack vectors and implementing practical, defensible controls designed for long-term effectiveness. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We partner with clients to build a security-aware culture and navigate the evolving regulatory landscape, helping them achieve and maintain cybersecurity compliance. Explore our capabilities further at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the medical device lifecycle? The medical device lifecycle spans from initial design and development, through manufacturing and quality control, to post-market maintenance, monitoring, and eventual decommissioning. Each stage necessitates distinct cybersecurity considerations. ### How does pre-production affect medical device cybersecurity? In the pre-production phase, cybersecurity is integrated by design. This includes implementing secure coding practices, conducting threat modeling, and building in encryption and authentication mechanisms from the start to establish a secure foundation. ### What cybersecurity considerations are important during medical device production? During production, cybersecurity focuses on Ensure the integrity of the manufacturing process and components. This involves securing the supply chain, implementing strict access controls, and conducting regular audits to prevent tampering or unauthorized modifications. ### Why are cybersecurity assessments important post-production? Post-production cybersecurity assessments matter for ongoing vigilance against emerging threats. They involve continuous monitoring, vulnerability assessments, and software updates to maintain device security throughout its operational lifespan in diverse environments. ### Does the FDA require cybersecurity integration in medical devices? Yes, the FDA requires medical device manufacturers to integrate cybersecurity measures. The February 3, 2026 final guidance outlines expectations for secure design, development, and post-market management of cybersecurity for medical devices. ### What risks do medical devices face without integrated cybersecurity? Without integrated cybersecurity, medical devices are susceptible to hacking, malware, and unauthorized access, which can compromise patient safety, expose private health information, and disrupt healthcare services. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Interoperability Labeling for Devices Source: https://bluegoatcyber.com/blog/interoperability-labeling-medical-devices-fda # Interoperability Labeling for Connected Medical Devices > **[DIRECT ANSWER]** Interoperability labeling tells the user how the device connects, what network services and ports it requires, what security controls the operator must configure, and how updates and end of support work. The FDA expects this content in user documentation and referenced from the cybersecurity section of your eSTAR submission. _Published June 11, 2026_ ## Key Takeaways - Interoperability labeling is a Feb 2026 expectation, not optional. - Reviewers expect protocols, data, authentication, error behavior, and responsibility boundaries, all in user-facing language. - Cybersecurity-relevant content (auth, encryption, exposed ports/services) belongs in the labeling **and** in the MDS2 / HSCC disclosure. - Labeling lives in eSTAR v7.0's Labeling section, not under Cybersecurity. - The most common deficiency is silent assumptions, labeling that does not state what the connected ecosystem must do for the device to operate safely. ## Why this matters Connected medical devices fail safely or unsafely depending on what the surrounding ecosystem does. A device that assumes the LIS will validate HL7 message integrity, or that the EHR will enforce role-based access, is implicitly delegating cybersecurity to systems it does not control. Interoperability labeling is where those delegations are made explicit. > **[FDA LANGUAGE]** "Labeling should clearly describe the device's interoperability with other devices, networks, and systems, including the protocols supported, the data exchanged, the authentication and authorization expectations, the failure modes when interoperability is disrupted, and the boundary of manufacturer responsibility." The same labeling is read by three audiences: clinicians who operate the device, IT/biomed teams who deploy it, and the FDA reviewer who is asking whether the trust assumptions are reasonable. ## What goes in interoperability labeling A complete interoperability labeling section covers six topics. ### 1. Protocols supported List every protocol the device speaks, with the standard reference and version: HL7 v2.x (and which segments), FHIR R4 / R5 (and which resources), DICOM (and which SOP classes), IEEE 11073 (PHD or PoCD), proprietary protocols if any, plus transport layers (TLS 1.2/1.3, MLLP-over-TLS, HTTPS, WebSocket). ### 2. Data exchanged For each protocol, name the data classes exchanged: patient identifiers, demographic data, observations/results, orders, device telemetry, audit events. Indicate sensitivity classification. State the direction (inbound, outbound, bidirectional). ### 3. Authentication and authorization expectations State what the device expects from the connected system: mutual TLS with which trust store, OAuth 2.0 scopes, SMART-on-FHIR scopes, IHE ATNA, device certificates issued by which CA. If the device performs no authentication at the protocol layer and relies on network segmentation, **say so explicitly**, silent assumptions are deficiency triggers. ### 4. Failure and disconnection behavior What happens when the network drops mid-procedure? When the LIS returns an error? When the EHR is unreachable? When TLS validation fails? Reviewers want to know that the device's clinical function degrades safely, and that the operator is informed. ### 5. Responsibility boundary State explicitly what the manufacturer is responsible for and what the user organization is responsible for. Typical pattern: - Manufacturer: device-side software, signed updates, interoperability protocol implementation, labeling - User organization: network segmentation, firewall configuration, certificate provisioning, EHR/LIS configuration, monitoring, incident response This boundary statement is what reviewers look for first. A submission without an explicit RACI for the interoperable ecosystem is incomplete. ### 6. Configuration guidance Provide the configuration the device requires of the surrounding systems: ports and protocols to allow on the network, certificate format and CA expectations, EHR/LIS configuration parameters, recommended monitoring rules. This is where IT/biomed teams live. ## Cybersecurity content specifically Inside the interoperability labeling, the FDA's Feb 2026 guidance expects specific cybersecurity-relevant content: - **Open ports and exposed services** on the device, with their purpose - **Authentication requirements** for each connection - **Encryption posture** in transit (TLS versions, cipher suites) - **Logging behavior** for connections and authentication events - **Patchability impact** on connected systems, does an update affect interfaces that the EHR depends on? - **Vulnerability disclosure intake**, where a hospital should report a security issue they discover (the CVD policy) ### Keeping labeling and the MDS2 / HSCC disclosure consistent Every item above appears twice in your submission: once in user-facing labeling and once in the MDS2 / HSCC disclosure. Reviewers and hospital security teams read both, and a mismatch between them is a deficiency, not a formatting nit. Map each element explicitly before you file: | Labeling statement | MDS2 / HSCC field it must match | Common mismatch | | --- | --- | --- | | Open ports and exposed services | Network ports and services in use | Labeling lists only the clinical port; MDS2 lists the service and debug ports too | | Authentication requirements per connection | User authentication and remote service authentication | Labeling says "authenticated"; MDS2 discloses a shared service account | | Encryption in transit (TLS version, ciphers) | Transmission confidentiality and integrity | Labeling claims TLS 1.3; MDS2 admits a TLS 1.2 fallback for legacy EHR interfaces | | Logging of connection and auth events | Audit controls | Labeling promises audit logs; MDS2 shows logs are local only and not exportable | | Patchability impact on connected systems | Software patching and remote update | Labeling implies zero downtime; MDS2 states the interface restarts on update | | Vulnerability disclosure intake | Cybersecurity contact and CVD policy | Two different intake addresses across the two documents | Practical rule: write the MDS2 first, then derive the labeling language from it. The MDS2 forces a factual answer per field, so deriving labeling from it prevents optimistic labeling claims that the disclosure contradicts. If a control is roadmap rather than shipped, say so in both places with the same wording. See [MDS2 / HSCC Disclosure for Medical Devices](/blog/the-role-of-mds2-in-medical-device-cybersecurity). ## Where it sits in eSTAR v7.0 Interoperability labeling lives in the **Labeling** section of eSTAR v7.0, the same section that holds the MDS2 disclosure. The Cybersecurity section's Slot 3 (Threat Model) and Slot 6 (Controls) reference it. Specifically: - Slot 3, interoperability risk assessment names the connected systems and the trust boundaries; labeling describes the same boundaries in operator language. - Slot 6, controls description names the authentication and encryption controls at the interoperable interfaces; labeling describes what the operator needs to configure to support those controls. For the full slot layout see our [eSTAR v7.0 mapping guide](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance). ## Common deficiency and post-deployment patterns **FDA side:** - Labeling describes interoperability functionally but omits the cybersecurity expectations of the surrounding systems → AI request for the responsibility boundary - Labeling and MDS2 disagree on ports, protocols, or authentication → reviewer flags inconsistency **Hospital side:** - Labeling does not state required firewall rules → biomed team has to reverse-engineer them, deployment delayed - Labeling assumes mutual TLS with no instruction on certificate provisioning → device deployed without mutual TLS, security posture degraded silently - Labeling does not describe disconnection behavior → first network outage triggers a safety event the manufacturer is asked to explain ## How Blue Goat Cyber writes interoperability labeling We write interoperability labeling as the user-facing view of the Slot 3 interoperability section. Every protocol the device speaks is documented with version, transport, data classes, authentication expectation, and disconnection behavior. The responsibility boundary is stated explicitly, in plain language IT and biomed teams can act on. The labeling is reconciled with MDS2 v3.0 so reviewers and procurement teams see the same answers. Cybersecurity-relevant content cross-references the Slot 6 Controls and the postmarket commitments in the [Cybersecurity Management Plan](/guides/cybersecurity-management-plan-fda-medical-devices). **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** See our [cybersecurity submission services](/services/medical-device-cybersecurity). ## FAQ ### Is interoperability labeling separate from the device's instructions for use (IFU)? It can be a separate document or a section within the IFU. The Feb 2026 guidance does not specify the structure, only the content. Most submissions we have seen accepted use a dedicated "Network connectivity and interoperability" section inside the IFU plus a more technical appendix for IT/biomed. ### Does interoperability labeling apply to non-networked devices? Only if the device exposes any interoperability surface, USB import/export, removable storage, paired mobile app, sensor mesh. A truly standalone device with no external interface does not need interoperability labeling, but reviewers expect that to be stated explicitly. ### How does this relate to IEEE 11073, HL7, FHIR, DICOM compliance claims? Compliance claims belong here. State which standards and which versions the device implements, and name the specific profile (e.g. IHE PCD-01 for vital signs, IHE LAB for laboratory results). Reviewers expect specific profiles, not just standards. ### Where does AI/ML model integration fit? If the device sends data to or receives output from an AI/ML model hosted elsewhere (cloud or on-premise inference service), that is an interoperability boundary. Label the protocol, the data sent, the response received, the failure mode if the model is unreachable, and the manufacturer/operator responsibility split. This intersects with PCCP labeling for AI/ML devices. ### What's the relationship between interoperability labeling and the MDS2? The MDS2 is a structured manufacturer disclosure aimed at hospital procurement and cyber teams. Interoperability labeling is the operator-facing narrative. The two cover overlapping territory, connectivity, ports, authentication, encryption, and must agree. Reviewers cross-check. ### Does the labeling need to be updated when the connected ecosystem changes? Yes. New protocol version, new authentication option, new failure mode, changed firewall requirement, deprecated cipher suite, any of those triggers a labeling update. Most manufacturers fold this into the change-control SOP. ## Need help with interoperability labeling? If you are preparing a 510(k), De Novo, or PMA submission for a connected device and need interoperability labeling that reconciles with your threat model, MDS2, and Slot 6 Controls, we will write it. [Request a scoping call](/contact). --- _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, ex-military red team. Has written interoperability labeling for more than 275 connected medical devices, including infusion pumps, implantables, IVD analyzers, and SaMD platforms. [More on the author](/team/christian-espinosa)._ ## Related reading - [FDA Interoperability Considerations for Medical Devices](/blog/medical-device-cybersecurity-interoperability-concerns) - [MDS2 / HSCC Disclosure for Medical Devices](/blog/the-role-of-mds2-in-medical-device-cybersecurity) - [Cybersecurity Management Plan for FDA Submissions](/guides/cybersecurity-management-plan-fda-medical-devices) --- ## Differences in the IoT and the IoMT Source: https://bluegoatcyber.com/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things # Differences in the IoT and the IoMT > **[DIRECT ANSWER]** IoT connects everyday consumer and industrial objects to improve convenience and automation, while IoMT connects medical devices and healthcare systems to exchange patient data, monitor conditions, and support clinical decisions. IoMT carries far greater patient safety consequences, so it faces strict FDA and MDR oversight requiring encrypted transmission, multi-layered authentication, and clinical validation, whereas general IoT security is variable and governed by looser consumer-protection standards like NIST guidance. _Updated November 16, 2024_ We live in a world that is becoming increasingly interconnected. Our everyday lives are filled with smart devices that help us stay connected, automate tasks, and make our lives easier. The Internet of Things (IoT) supports this digital revolution. But what about the Internet of Medical Things (IoMT)? How does it differ from IoT? This article will explore the key differences between IoT and IoMT, their applications, and the future they hold in our lives. ## Key Takeaways - IoT networks connect everyday objects for general use cases. - IoMT specifically connects medical devices for healthcare applications. - IoMT faces strict regulatory oversight, unlike general IoT. - Data security and patient safety are paramount in IoMT. - IoMT seeks to enhance patient monitoring and healthcare delivery. - IoT focuses on convenience and automation in various sectors. ## Why this matters The distinction between IoT and IoMT is critical due to the profound impact on human life and sensitive health data. While general IoT devices prioritize convenience, IoMT devices are integral to patient diagnosis, treatment, and ongoing care. A cybersecurity vulnerability in an IoMT device can lead to severe patient harm, data breaches of Protected Health Information (PHI), and significant financial and reputational damage for manufacturers. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, mandates stringent cybersecurity practices from premarket submission through postmarket surveillance. This guidance emphasizes the necessity for threat modeling, secure design, and vulnerability management throughout the total product lifecycle. IoMT devices must adhere to globally recognized standards such as IEC 81001-5-1, ISO 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023, which address medical device security and risk management. Understanding these differences informs responsible development, deployment, and security strategies for medical technology that directly affects patient well-being. ## At a glance | Dimension | IoT (Internet of Things) | IoMT (Internet of Medical Things) | |:--- |:--- |:--- | | **Definition** | General network of consumer/industrial objects sharing data via the internet. | Specialized network of medical devices and applications for healthcare delivery. | | **Primary Goal** | Operational efficiency, automation, and user convenience in daily life. | Patient monitoring, diagnostic accuracy, and improved clinical outcomes. | | **Safety Risk** | High financial or privacy risk; physical danger is usually indirect. | High critical risk; device malfunction can lead to patient injury or death. | | **Regulatory Scope** | General consumer protections and industry-specific standards (e.g., NIST). | Strict FDA/MDR oversight; requires clinical validation and Premarket Notification (510k). | | **Security Posture** | Variable; often prioritizes cost and ease of use over defense. | High-intensity; requires encrypted data transmission and rigorous multi-layered authentication. | | **Common Attacks** | Botnet recruitment (DDoS), data privacy breaches, and unauthorized remote access. | Ransomware, telemetry spoofing, and life-critical command injection. | | **Key Tradeoff** | Convenience vs. data privacy and peripheral network security. | Clinical innovation vs. extreme regulatory burden and patient safety risks. | ## Defining the Concepts: Internet of Things and Internet of Medical Things When we covers the Internet of Things (IoT) realm, we uncover a vast network of interconnected objects that have revolutionized the way we interact with technology. These objects, equipped with sensors, software, and communication technologies, collect and exchange data over the internet. IoT has woven a web of connectivity that transcends traditional boundaries, from the convenience of everyday devices like smartphones, smartwatches, and home appliances to the intricacies of specialized equipment such as industrial machinery and environmental sensors. Expanding further into the [IoT landscape](/blog/cybersecurity-for-medical-devices-with-narrowband-iot-protocol) unveils a tapestry of innovation. The convergence of physical and digital realms has paved the way for enhanced efficiency, automation, and data-driven decision-making across industries. ### What is the Internet of Things (IoT)? The Internet of Things refers to a network of interconnected objects or “things” embedded with sensors, software, and other technologies that collect and exchange data over the Internet. These “things” can range from everyday devices like smartphones, smartwatches, and home appliances to more specialized objects like industrial machinery and environmental sensors. As we navigate through the intricate web of IoT, we witness a transformative force that has redefined the fabric of our interconnected world, building a new era of innovation and connectivity. ### What is the Internet of Medical Things (IoMT)? The Internet of Medical Things, on the other hand, focuses specifically on the healthcare industry. It refers to the network of devices, wearables, and healthcare systems connected to collect and exchange medical data. IoMT aims to improve patient care, enhance efficiency in healthcare delivery, and enable remote monitoring and diagnosis. Within the [Internet of Medical Things (IoMT),](/blog) the fusion of healthcare and technology emerges as a beacon of hope, promising advancements in patient-centric care, real-time health monitoring, and data-driven insights that revolutionize the essence of healthcare delivery. Through the integration of medical devices, wearables, and interconnected systems, IoMT stands at the forefront of a healthcare revolution, where precision, efficiency, and accessibility converge to shape a future where well-being is not just a goal but a reality. ## The Core Differences Between IoT and IoMT While IoT and IoMT share the goal of connecting devices and collecting data, several key differences set them apart. ![Section Image](/imported-images/009a572e03cfdee9.webp) Expanding on the differences between IoT and IoMT reveals a fascinating world of technological innovation and specialization. in IoT, the focus lies on enhancing convenience and streamlining processes across various industries. From smart homes to industrial automation, IoT devices aim to connect everyday objects and empower users with automation and data-driven insights. The interconnected web of IoT devices forms a network that revolutionizes how we interact with our surroundings, making tasks more efficient and data more accessible. On the other hand, covering IoMT uncovers a domain explicitly tailored for healthcare applications. IoMT, or the Internet of Medical Things, is dedicated to [improving patient outcomes](/blog/securing-iot-devices-in-healthcare-the-frontline-of-patient-safety), enabling remote monitoring, and transforming the delivery of healthcare services. The marriage of medical devices with technology enhances patient care quality and opens up new possibilities for personalized medicine and proactive health management. ### Purpose and Application The primary purpose of IoT is to enhance convenience and automate processes in various industries. It focuses on connecting everyday objects to make our lives easier. IoMT, on the other hand, is specifically designed for healthcare applications. It aims to improve patient outcomes, enable remote monitoring, and enhance the delivery of healthcare services. A critical distinction emerges when exploring the nuances of data sensitivity and security in the context of IoMT. Being highly sensitive, medical data demands [stringent security measures to safeguard patient privacy](/blog) and confidentiality. The data generated by medical devices and healthcare systems must adhere to security protocols and regulatory standards to ensure the integrity and privacy of patient information. The intersection of healthcare and technology in IoMT underscores the importance of secure data handling practices and compliance with healthcare regulations. ### Regulatory Compliance IoMT devices and systems must adhere to [strict regulatory standards.](https://www.fda.gov/media/119933/download) These standards ensure that medical devices are safe, effective, and meet the necessary quality standards. Compliance with regulatory requirements is crucial to ensuring patient safety and preventing potential risks associated with medical devices. The regulatory compliance landscape in IoMT is characterized by a complex web of standards and guidelines that govern the development and deployment of medical technologies. Adhering to regulatory frameworks validates the efficacy and safety of IoMT devices and instills trust in patients and healthcare providers regarding these technologies’ reliability and ethical use. Navigating the intricate regulatory landscape of IoMT requires a deep understanding of healthcare regulations and a commitment to upholding the highest standards of patient care and data security. ## The Role of IoT and IoMT in Today’s World ### IoT in Everyday Life IoT devices have become an integral part of our daily lives. IoT has revolutionized how we interact with technology, from smart homes that allow us to control lights and temperature with a simple voice command to wearable fitness trackers that monitor our health and fitness goals. The concept of a connected ecosystem where devices communicate with each other has not only increased convenience but also improved efficiency in various aspects of our lives. ### IoMT in Healthcare The healthcare industry has experienced a significant transformation with the advent of IoMT. Connected medical devices enable real-time monitoring of patients, allowing healthcare providers to deliver personalized and proactive care. IoMT also enables remote consultations, reducing the need for in-person visits and improving access to healthcare services, especially in remote areas. By collecting and analyzing patient data in real-time, healthcare professionals can make informed decisions quickly, leading to better treatment outcomes and overall patient satisfaction. ## The Future of IoT and IoMT As technology advances rapidly, so does the future of IoT and IoMT. The interconnected world of IoT (Internet of Things) and IoMT (Internet of Medical Things) is poised for remarkable growth and innovation in the coming years. ![Section Image](/imported-images/61d4e23b8d65c7df.webp) One of the key areas driving the future of IoT is edge computing. This technology enables data processing closer to the data source, reducing latency and improving efficiency. As edge computing becomes more prevalent, we can expect IoT devices to become even more responsive and intelligent. ### Emerging Trends in IoT IoT constantly evolves, and we expect to see some exciting trends shortly. The possibilities are endless, from smart cities that use IoT technology to improve urban planning and resource management to autonomous vehicles that rely on IoT sensors and connectivity. Integrating IoT with artificial intelligence is also a promising trend, allowing devices to learn and adapt to user behavior in real-time. The rise of [5G technology](/blog) is set to revolutionize the IoT landscape by providing faster and more reliable connectivity. This will open up new possibilities for industrial automation, healthcare, and agriculture IoT applications. ### Advancements in IoMT In healthcare, IoMT is expected to continue expanding its reach. With advancements in artificial intelligence and machine learning, IoMT has the potential to revolutionize diagnosis and treatment. Imagine a world where wearable devices can detect early signs of diseases or remote [robotic surgery](/blog/protecting-surgical-robots-the-importance-of-cybersecurity) becomes the norm. Blockchain technology in IoMT is also gaining traction, offering secure and transparent medical data storage. Personalized medicine is becoming increasingly achievable through IoMT. By using data from connected medical devices, healthcare providers can tailor treatment plans to individual patients, leading to more effective and targeted care. ## Challenges and Opportunities in IoT and IoMT ### Overcoming IoT Challenges One of the main challenges in IoT is ensuring interoperability between different devices and platforms. With a wide range of manufacturers, standards, and protocols, compatibility can be a major hurdle. Additionally, ensuring the security of IoT devices and the data they collect remains a significant concern. Another critical challenge in IoT is managing the vast amounts of data interconnected devices generate. The sheer volume of data can overwhelm existing networks and storage systems, requiring innovative solutions for efficient data processing and analysis. Moreover, maintaining data privacy and compliance with regulations adds another layer of complexity to IoT implementations. ### Capitalizing on IoMT Opportunities IoMT presents immense opportunities for improving patient care and revolutionizing healthcare delivery. However, realizing these opportunities requires investment in infrastructure, training, and regulatory frameworks. By addressing these challenges, we can use IoMT’s full potential and positively impact healthcare. Integrating [artificial intelligence](/blog/emerging-technologies-and-their-impact-on-medical-device-cybersecurity) (AI) and machine learning algorithms in IoMT systems opens new possibilities for personalized medicine and predictive analytics. These technologies can analyze vast amounts of patient data to identify trends, predict health outcomes, and optimize treatment plans, ultimately leading to better patient outcomes and reduced healthcare costs. ## Conclusion While IoT and IoMT have similarities in terms of connecting devices and collecting data, they serve different purposes and face distinct challenges. IoT focuses on enhancing convenience and automation in various industries, while IoMT is dedicated to improving healthcare outcomes. As technology continues to advance, both IoT and IoMT will play a crucial role in shaping the world we live in. It’s an exciting time to be at the forefront of these innovations, and the possibilities for a connected future are endless. As we embrace the transformative potential of IoT and IoMT, the importance of cybersecurity measures cannot be overstated. Blue Goat Cyber stands at the vanguard of cybersecurity excellence, offering bespoke B2B services to ensure your connected devices and medical systems are shielded from cyber threats. Our veteran-owned enterprise specializes in medical device cybersecurity, penetration testing, and compliance with HIPAA and FDA regulations, providing you with the expertise needed to navigate the complexities of the digital healthcare landscape. Don’t let cyber vulnerabilities undermine the incredible advancements in IoT and IoMT. [Contact us today for cybersecurity help](/contact) and partner with Blue Goat Cyber to secure your digital ecosystem and empower your business to thrive confidently in an interconnected world. Check out our [medical device cybersecurity compliance package.](/) ## How Blue Goat approaches this Blue Goat Cyber approaches IoMT cybersecurity with an understanding of the unique risks associated with medical devices. Our methodology integrates regulatory compliance with practical security measures. We offer services like premarket cybersecurity assistance, aiding manufacturers in meeting the FDA's rigorous requirements. Our team, including CISSP and OSCP certified experts and ex-military red team personnel, conducts focused penetration testing and threat modeling tailored to medical device ecosystems. We help identify and mitigate vulnerabilities to protect patient safety and data integrity. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Our aim is to provide effective, targeted security solutions that align with both regulatory mandates and real-world threat landscapes. We also provide postmarket cybersecurity services. Learn more about our specialized offerings at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the primary difference between IoT and IoMT? The primary difference lies in their application and regulatory environment. IoT covers general interconnected devices for everyday use, while IoMT is specifically for medical devices within healthcare, subject to stringent regulatory review by the FDA and other bodies. ### Why is security more critical for IoMT than general IoT? Security is more critical for IoMT because the devices handle sensitive patient health information and incorrect operation can directly lead to patient harm or death. General IoT devices typically do not pose such immediate life-critical risks. ### Does the FDA regulate all IoT devices? No, the FDA specifically regulates medical devices, which includes IoMT devices, to ensure their safety and effectiveness. General consumer or industrial IoT devices typically fall under other regulatory bodies or industry standards, not the FDA. ### How does IoMT improve healthcare? IoMT improves healthcare by enabling real-time patient monitoring, facilitating remote care, enhancing diagnostic accuracy, and providing data-driven insights for personalized treatment plans, ultimately leading to better patient outcomes. ### What are common security concerns for IoMT devices? Common security concerns for IoMT devices include ransomware attacks, unauthorized access to patient data, telemetry spoofing, and the potential for life-critical command injection, all of which can compromise patient safety and privacy. ### What guidance does the FDA offer for IoMT cybersecurity? The FDA provides cybersecurity guidance for medical devices, including IoMT, in its February 3, 2026, final guidance. This guidance outlines expectations for Ensure the security of medical devices throughout their lifecycle. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## IPC Vulnerabilities in Medical Devices (2026) Source: https://bluegoatcyber.com/blog/ipc-vulnerabilities-medical-devices # IPC (Inter-Process Communication) Vulnerabilities in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** Inter-process communication (IPC) vulnerabilities arise when software components inside a medical device wrongly assume that local processes are trustworthy, letting attackers who gain a low-privilege foothold escalate privileges, inject commands, or disrupt therapy-critical functions through unauthenticated or poorly authorized IPC channels. Mitigations include defining explicit trust boundaries, enforcing least privilege, validating all inputs as hostile, and documenting threat-modeled IPC controls, since the FDA expects this evidence within premarket cybersecurity submissions. Inter-process communication (IPC) is the “plumbing” that lets software components cooperate-UI apps talking to system services, therapy-control logic exchanging messages with safety monitors, and update agents coordinating with the operating system. In connected medical devices, IPC is often where a low-privilege foothold turns into a high-impact safety issue. The problem isn’t that IPC exists; it’s that many implementations assume “anything local is trusted.” Attackers don’t. Once an adversary gets code running on a device (or inside a companion gateway), abusing IPC can become a fast path to privilege escalation, command injection, or denial of service. MITRE explicitly calls out IPC abuse as a technique for local execution. [See MITRE ATT&CK: Inter-Process Communication (T1559)](https://attack.mitre.org/techniques/T1559/). ## Key Takeaways - IPC is critical for device function but a common attack vector. - Assume local IPC is untrusted; define explicit trust boundaries. - Implement least privilege for all IPC interactions. - Rigorously validate all IPC inputs to prevent exploits. - Fuzz and penetration test IPC to find vulnerabilities. - Document IPC controls for the FDA premarket submission. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to ipc vulnerabilities in medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What IPC looks like in real medical device software IPC comes in different forms depending on the platform: - **Embedded Linux:** Unix domain sockets, D-Bus, shared memory, pipes, and custom daemons. - **RTOS:** message queues, mailboxes, shared buffers, event flags, and task notifications. - **Microkernel designs:** heavy reliance on message passing/RPC between user-space servers and the minimal kernel. In many architectures, the most safety-critical functions run in higher-privilege services. That’s exactly why IPC needs to be treated as a trust boundary, especially when a UI process, network-facing process, or third-party component can send messages “upstream.” If you’re working with embedded operating systems, you may also find these related reads useful: [Cybersecurity with RTOS](/blog/cybersecurity-with-rtos) and [Microkernels Explained](/blog). ## Common IPC vulnerability patterns that show up in devices IPC issues usually fall into a few repeatable buckets: - **No authentication of the sender:** any local process can call a privileged service method. - **Weak authorization:** the service authenticates “someone,” but doesn’t enforce least privilege per command. - **Confused deputy:** a privileged service performs sensitive actions on behalf of an untrusted caller. - **Insecure permissions:** world-writable sockets, pipes, shared memory segments, or message queues. - **Input validation & parsing bugs:** unsafe deserialization, malformed message handling, buffer overflows. - **Race conditions / TOCTOU:** state changes between “check” and “use,” especially around file/handle passing. - **Denial of service:** message floods, resource starvation, deadlocks, or priority inversion in real-time systems. In a medical device context, these translate into concrete hazards: stopping a monitoring function, degrading therapy timing, triggering unintended mode changes, or blocking alarms. That’s why IPC hardening belongs in your safety and security risk management, not as an “IT-only” concern. ## Practical controls to harden IPC Start with design controls that reduce blast radius, then add implementation and verification rigor. ### Architecture and design controls - **Define IPC trust boundaries explicitly:** document which processes are trusted, which aren’t, and why. - **Least privilege by default:** split “read-only status” from “therapy control” APIs; separate roles and capabilities. - **Minimize the IPC surface area:** fewer endpoints, fewer methods, and simpler message schemas. - **Strong identity for callers:** use OS primitives (UID/GID, SELinux/AppArmor labels, capabilities) and enforce them. - **Secure defaults:** restrictive socket permissions, explicit allowlists, and denial of unknown methods/messages. ### Implementation controls - **Validate inputs like they’re hostile:** length checks, strict schemas, safe parsing, and defensive error handling. - **Rate limiting and backpressure:** prevent message floods from starving real-time or safety-critical tasks. - **Memory-safety where feasible:** prioritize safer libraries and patterns for message parsing/serialization. - **Crypto where it makes sense:** if IPC crosses hosts (or behaves like a network protocol), use mutual authentication and modern TLS. ### Verification and testing controls - **Threat model the IPC flows:** focus on entry points, trust boundaries, and “what happens if a low-privilege process lies?” - **Static analysis + manual review:** catch parsing bugs, unsafe memory operations, and authorization gaps early. - **Fuzz and robustness testing:** feed malformed and unexpected messages to IPC endpoints and validate safe failure modes. - **Penetration testing:** validate real exploitability and privilege escalation pathways end-to-end. If you want help operationalizing this, these services map directly to IPC risk reduction: [Threat Modeling](/services/medical-device-threat-modeling), [Medical Device SAST](/services/static-application-security-testing-sast), and [FDA-Compliant Vulnerability & Penetration Testing](/services/medical-device-penetration-testing). ## How to document IPC risk for FDA (and reduce reviewer friction) FDA’s current premarket cybersecurity guidance expects manufacturers to treat cybersecurity as part of device safety and the quality system, using structured processes across the total product lifecycle. [FDA: Cybersecurity in Medical Devices (June 2025)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket). For IPC specifically, reviewer-friendly evidence typically includes: - **Architecture views and data flows** that show IPC trust boundaries (who can call what, with what privileges). - **Threat modeling output** covering IPC abuse cases (spoofing, injection, DoS, privilege escalation). - **Security requirements** (authentication, authorization, logging, resiliency) traced to design and verification. - **Verification evidence** (SAST results, fuzzing/robustness tests, penetration test findings and remediation). - **Secure development practices** aligned to a recognized framework such as NIST SSDF. [NIST SP 800-218 (SSDF)](https://csrc.nist.gov/pubs/sp/800/218/final). This is also where strong [premarket cybersecurity documentation & testing support](/services/fda-premarket-cybersecurity-services) can save weeks of rework, because IPC issues often show up as “design gaps,” not just code defects. ## Don’t forget postmarket: IPC bugs rarely stay “fixed” IPC vulnerabilities often live in third-party components (OS services, middleware, serialization libraries). That makes them a supply-chain and patch-management problem too. Your SBOM and vulnerability response process should be prepared to detect new CVEs, evaluate exploitability in your IPC context, and ship validated updates. Relevant resources: [FDA-compliant SBOM services](/services/fda-compliant-sbom-services-for-medtech) and [FDA postmarket cybersecurity management](/services/fda-postmarket-cybersecurity-services). ## IPC security checklist (quick-start) - Inventory IPC endpoints and classify them by privilege and safety impact. - Mark IPC trust boundaries and enforce caller identity/authorization at the receiver. - Reduce attack surface: fewer methods, stricter schemas, safer defaults. - Harden parsing and add fuzz/robustness testing for malformed messages. - Validate resilience: rate limits, watchdogs, and safe failure modes. - Trace controls into your SPDF artifacts and premarket submission documentation. - Monitor postmarket vulnerabilities and update dependencies quickly. ## Conclusion IPC is essential, and it’s a frequent choke point for escalation in embedded systems. Treat IPC like a security boundary, back it with least privilege and validation, and generate the evidence FDA expects. You’ll reduce both real-world risk and regulatory friction. ## Book a Discovery Session Want help finding and fixing IPC risks (and documenting them cleanly for reviewers)? **[Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session)** ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is inter-process communication (IPC) in medical devices? IPC is the mechanism allowing different software components or processes within a medical device to exchange information and synchronize activities. This is fundamental for device functionality, such as a user interface communicating with therapy control logic. ### How can IPC vulnerabilities impact medical device safety? IPC vulnerabilities can lead to critical safety hazards, including unauthorized control over device functions, disruption of therapy, patient data compromise, or complete device shutdown. Attackers use IPC to escalate privileges or inject commands. ### What specific IPC vulnerabilities are common in medical devices? Common issues include a lack of sender authentication, weak authorization allowing unauthorized actions, insecure default permissions on communication channels, and flaws in input validation that can lead to buffer overflows or arbitrary code execution. ### What controls can harden IPC in medical devices? Effective controls include architecting explicit trust boundaries, implementing strict least privilege for IPC callers, minimizing the IPC attack surface, rigorously validating all inputs, and using strong authentication and authorization mechanisms. ### Does the FDA require documentation for IPC security? Yes, the FDA expects manufacturers to address cybersecurity across the total product lifecycle, including IPC. Premarket submissions should include architectural diagrams, threat models covering IPC abuse, security requirements, and verification evidence. ### How should IPC issues be addressed during postmarket surveillance? Postmarket processes should include monitoring third-party component vulnerabilities affecting IPC, evaluating their exploitability, and rapidly deploying validated updates. SBOMs and vulnerability response plans matter for this. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [SoC Vulnerabilities in Medical Devices](/blog/exploring-system-on-a-chip-soc-vulnerabilities) --- ## ISO 13485 and Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity # ISO 13485 and Medical Device Cybersecurity > **[DIRECT ANSWER]** ISO 13485, the quality management system standard for medical devices, provides the structural backbone for cybersecurity by requiring risk management, rigorous documentation, supplier controls, and design verification that extend naturally to cyber threats. Manufacturers should integrate cybersecurity into ISO 13485's risk management, design controls, supplier qualification, and CAPA processes rather than treating it as a separate track, since the FDA's Feb 3, 2026 guidance expects both to be traceable to each other in a submission. _Reviewed July 24, 2026_ ISO 13485, a globally recognized standard for [quality management systems (QMS)](/blog/the-importance-of-implementing-a-medical-device-qms) in the medical device industry, is vital for ensuring medical devices’ safety, effectiveness, and quality. It provides a framework for organizations designing, developing, producing, installing, and servicing medical devices. With the increasing digitalization and connectivity of medical devices, cybersecurity has become crucial to compliance with [ISO 13485](https://www.iso.org/standard/59752.html ""). Understanding the interplay between ISO 13485 and cybersecurity is essential for manufacturers to ensure that devices are secure throughout their lifecycle. This article explores ISO 13485’s role in guiding cybersecurity practices within the medical device industry, its importance in regulatory compliance, and best practices for implementing cybersecurity measures alongside a quality management system. ## Key Takeaways - ISO 13485 mandates risk management that includes cybersecurity threats. - Rigorous documentation within the QMS covers cybersecurity controls. - Supplier controls extend to third-party software risks. - Design and development controls embed security into devices. - Continuous improvement ensures adaptive cybersecurity defenses. - CAPA processes address cybersecurity incidents effectively. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to iso 13485 and medical device cybersecurity the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding ISO 13485: Key Principles for Medical Device Quality and Cybersecurity ISO 13485:2016 outlines a QMS framework for medical device manufacturers, enabling them to meet [regulatory](https://www.fda.gov/media/119933/download) and customer requirements consistently. While it’s primarily designed for product quality and compliance, its core principles also form the backbone of a cybersecurity-aware development and maintenance strategy. Here are **six key principles** of ISO 13485 and how they support cybersecurity and overall device integrity: ### Risk Management ISO 13485 requires a systematic approach to risk, from design through [postmarket activities](/services/fda-postmarket-cybersecurity-services). This aligns directly with cybersecurity risk assessment practices, where evaluating and mitigating threats such as software vulnerabilities, unauthorized access, and data breaches is essential to protecting patients and device functionality. ### Documentation and Traceability The standard emphasizes rigorous documentation across all lifecycle stages. This includes cybersecurity controls, software validation, firmware updates, and change management records. High-quality documentation ensures traceability, simplifies regulatory audits, and facilitates swift incident response when vulnerabilities arise. ### Continuous Improvement ISO 13485 mandates a culture of **o** ngoing process evaluation and refinement. For cybersecurity, this means continually assessing threat landscapes, reviewing incident reports, and updating defenses. Incorporating tools like [penetration testing](/services/medical-device-penetration-testing), [secure coding practices](/blog), and vulnerability scanning supports this principle in dynamic environments. ### Supplier and Third-Party Control With most medical devices relying on external software components, cloud services, or hardware modules, ISO 13485 requires rigorous supplier qualification and monitoring. Cybersecurity risks introduced through third-party software, such as outdated libraries or compromised firmware, can be mitigated through supplier assessments, security contracts, and [third-party SBOM reviews.](/services) ### Design and Development Controls The standard stresses structured design and development processes, including design inputs, outputs, verification, and validation. Embedding [secure development lifecycle (SDL) practices](/blog/implementing-ssdlc-for-enhanced-medical-device-cybersecurity)-such as threat modeling, code reviews, and static analysis-into these phases ensures that security is baked into the product from the ground up. ### Corrective and Preventive Actions (CAPA) ISO 13485 includes requirements for identifying and correcting **nonconformities**, which apply directly to cybersecurity incidents and vulnerability disclosures. An effective CAPA process enables teams to resolve security issues and prevent recurrence through root cause analysis and procedural enhancements. ## Cybersecurity in Medical Devices: Why It Matters The integration of cybersecurity into the medical device industry is driven by the critical need to protect patient data and ensure device functionality. Medical devices, especially those connected to networks or that utilize software, are vulnerable to cyber threats that could compromise patient safety. Examples include unauthorized access, data breaches, or even direct manipulation of device functions. Cybersecurity becomes particularly relevant in ISO 13485 as it supports a structured approach to managing risks associated with digital threats. According to guidance like the [Medical Device Coordination Group’s MDCG 2019-16,](https://health.ec.europa.eu/system/files/2022-01/md_cybersecurity_en.pdf "") cybersecurity must be embedded into the device lifecycle, from premarket design considerations to post-market surveillance. ## Integrating Cybersecurity into ISO 13485 Quality Management Systems Integrating cybersecurity into an ISO 13485-compliant Quality Management System (QMS) is essential for medical device manufacturers aiming to meet regulatory expectations and protect patient safety. Cybersecurity must be embedded throughout the device lifecycle, from initial design to postmarket maintenance. Here’s how organizations can align cybersecurity with core ISO 13485 requirements: ### Risk Management Integrated with ISO 14971 [**ISO 14971**](/blog/iso-14971-risk-management-in-medical-device-security) is the globally accepted standard for medical device risk management. It complements ISO 13485 by providing a framework for identifying, evaluating, and controlling device-related risks, including cybersecurity threats. By incorporating cybersecurity into hazard analysis, risk evaluation, and mitigation planning, manufacturers ensure that risks such as data breaches, malware infiltration, and unauthorized access are addressed as part of the overall product risk profile. This integration strengthens both product safety and regulatory compliance. ### Secure Design and Development Controls ISO 13485 mandates formal controls for design and development processes, including documentation of design inputs, reviews, verification, and validation. To integrate cybersecurity: - **Threat modeling** and **s** ecurity requirements should be included during design input gathering. - Cybersecurity checkpoints should be embedded into **design reviews**. - Verification and validation procedures should include **security testing**, such as static code analysis, fuzz testing, and vulnerability scanning. Incorporating guidelines from [IEC 62304 (software life cycle processes)](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards) ensures a secure software development lifecycle (Secure SDLC), which is critical for embedded and connected medical devices. ### Software Validation and Cybersecurity Documentation For devices incorporating software, ISO 13485 requires software validation to confirm that software performs reliably and securely. This includes: - Validating the effectiveness of cybersecurity controls, such as encryption, authentication, and access controls. - Documenting all cybersecurity-related testing and security features as part of the technical file and QMS records. - using IEC 62304 and [FDA cybersecurity guidance](https://www.fda.gov/media/119933/download) to structure secure development and maintenance practices, including patch management and secure update mechanisms. ### Supplier and Third-Party Software Management ISO 13485 emphasizes supplier qualification, monitoring, and control, which extends to third-party software and hardware components. With the rise of [Software of Unknown Provenance (SOUP)](/blog) and open-source libraries, manufacturers must: - Conduct cybersecurity risk assessments on all third-party and off-the-shelf components. - Require vendors to provide [SBOMs](/blog) and security documentation. - Monitor suppliers’ patching practices and maintain a documented process for evaluating and approving component updates. By embedding these cybersecurity practices into supplier management, manufacturers reduce the risk of introducing vulnerabilities through external sources, a common vector for supply chain attacks. ## Regulatory Compliance and Cybersecurity: FDA and EU Perspectives Compliance with ISO 13485 is often a prerequisite for regulatory approval in many regions, including the U.S. (FDA) and the EU (MDR/IVDR). Both regulatory bodies emphasize the importance of cybersecurity in ensuring device safety: - **FDA’s Cybersecurity Guidelines**: The FDA provides detailed guidelines on premarket and postmarket cybersecurity for medical devices, highlighting the importance of integrating cybersecurity measures into the design and development process. These guidelines align with ISO 13485’s focus on risk management and documentation, ensuring that cybersecurity risks are considered during device development and throughout its lifecycle. - **EU MDR and Cybersecurity Requirements**: The European Union’s Medical Device Regulation (MDR) and [In Vitro Diagnostic Regulation (IVDR)](/blog) require that manufacturers consider cybersecurity risks as part of their conformity assessment processes. ISO 13485 helps manufacturers meet these requirements by establishing a framework for quality management that includes cybersecurity considerations. ## Best Practices for Implementing Cybersecurity in an ISO 13485-Compliant Framework Integrating cybersecurity into an ISO 13485-compliant QMS requires more than patching vulnerabilities; it demands a strategic, lifecycle-based approach that embeds security into every phase of medical device development and maintenance. Here are the key best practices to ensure your cybersecurity program aligns with ISO 13485’s quality and regulatory expectations: ### Conduct Complete Threat Modeling Begin your security journey early in the design phase by conducting [threat modeling](/services/medical-device-threat-modeling) to identify potential attack vectors, misuse scenarios, and vulnerabilities. This proactive step allows your team to implement mitigation strategies before risks become liabilities. Threat modeling directly supports ISO 13485’s risk management requirements, aligning with ISO 14971 and helping ensure that cybersecurity risks are identified and addressed in your hazard analysis and risk controls. ### Adopt a Secure Software Development Lifecycle (Secure SDLC) Cybersecurity should be embedded into the software development process, not bolted on at the end. Following the principles of [IEC 62304](https://www.iso.org/standard/38421.html), manufacturers should integrate secure coding practices, code reviews, static analysis, penetration testing, and patch management into every development phase. This supports ISO 13485’s emphasis on design validation, software verification, and documented evidence that the device performs as intended, even under hostile conditions. ### Perform Ongoing Vulnerability Assessments Cyber threats evolve quickly, and so should your defenses. Implementing regular [vulnerability assessments, penetration testing](/services/medical-device-penetration-testing), and continuous monitoring ensures that emerging threats are detected and addressed promptly. These activities align with ISO 13485’s focus on constant improvement and post-market surveillance, enabling manufacturers to adapt their controls and remediation efforts in real time. ### Ensure Resilient Cybersecurity Documentation and Traceability Effective cybersecurity is only as strong as its documentation. ISO 13485 requires and auditable documentation of all quality and risk management processes. Ensure your cybersecurity efforts, including risk assessments, threat models, test results, mitigations, and software updates, are thoroughly documented. This supports regulatory audits, internal reviews, and incident response efforts while enhancing traceability and accountability across the device lifecycle. ## The Role of ISO 13485 in Cybersecurity Incident Response Effective cybersecurity incident response protects patient safety, maintains regulatory compliance, and minimizes operational disruptions. While ISO 13485 is traditionally focused on quality management, it is critical in guiding structured, traceable responses to cybersecurity incidents within the medical device lifecycle. ISO 13485 emphasizes post-market surveillance and [CAPA](/blog/corrective-and-preventive-actions-capa-in-medical-device-cybersecurity)-key elements that align closely with modern cybersecurity best practices. Here’s how manufacturers can align their incident response efforts with ISO 13485 requirements: ### Establish a Cybersecurity Incident Response Plan Manufacturers should develop a formal, documented Cybersecurity Incident Response Plan (CIRP) that outlines: - Procedures for identifying and triaging cybersecurity events - Internal and external reporting protocols (e.g., FDA, regulatory bodies) - Roles and responsibilities for response teams - Mitigation and containment strategies - Criteria for initiating CAPA and root cause analysis This structured approach ensures that incidents are handled swiftly and systematically, reducing the risk of prolonged exposure or non-compliance. ### Integrate Cybersecurity into Post-Market Surveillance ISO 13485 requires manufacturers to conduct ongoing post-market surveillance (PMS) to detect quality and safety issues. This should explicitly include: - Monitoring for cybersecurity threats across device fleets and software ecosystems - Vulnerability intelligence gathering from industry sources and regulatory advisories - Alignment with [MDCG 2019-16](https://health.ec.europa.eu/system/files/2022-01/md_cybersecurity_en.pdf) and FDA postmarket cybersecurity guidance, which emphasize active vulnerability monitoring and coordinated disclosure Cybersecurity should be viewed as a continuous risk that evolves post-deployment, making PMS integration essential. ### Document Corrective and Preventive Actions (CAPA) Following a cybersecurity incident, ISO 13485 mandates that manufacturers implement and document corrective and preventive actions. This includes: - Logging the timeline and nature of the incident - Capturing mitigation steps taken - Conducting root cause analysis - Implementing process or design changes to prevent recurrence - Verifying the effectiveness of these actions over time Thorough documentation is a best practice and a regulatory expectation during audits, inspections, or post-incident reporting. ## Conclusion As medical devices become increasingly interconnected and software-driven, integrating cybersecurity into the ISO 13485 quality management system is no longer optional; it’s essential. ISO 13485 provides a strong foundation for embedding cybersecurity into every stage of the device lifecycle, from design and development to postmarket surveillance and incident response. By aligning ISO 13485 requirements with modern cybersecurity frameworks, standards (like ISO 14971 and IEC 62304), and risk-based practices, manufacturers can ensure their devices are safe and effective and resilient to emerging digital threats. This integration supports regulatory compliance, enhances patient safety, and builds long-term trust in an increasingly complex healthcare ecosystem. Manufacturers who proactively embrace this convergence of quality and cybersecurity will be better equipped to navigate regulatory expectations, respond to vulnerabilities swiftly, and protect the integrity and reputation of their devices-now and in the future. Schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) for help with [FDA Cybersecurity in Premarket Submissions.](/services/fda-premarket-cybersecurity-services) ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the role of ISO 13485 in medical device cybersecurity? ISO 13485 provides a quality management system framework that supports the integration of cybersecurity throughout the medical device lifecycle. Its principles for risk management, documentation, and design controls align directly with the need to identify, assess, and mitigate cyber threats to medical devices. ### How does ISO 13485 address cybersecurity risks specifically? While not exclusively a cybersecurity standard, ISO 13485's core requirements, such as risk management (ISO 14971), design and development controls, and supplier management, provide a structured approach to embedding cybersecurity. Manufacturers integrate cybersecurity into these processes to address potential vulnerabilities and threats. ### Why is integrating cybersecurity into an ISO 13485 QMS important? Integrating cybersecurity into an ISO 13485 QMS is important for Ensure medical device safety and meeting regulatory expectations. This approach helps protect patient data, device functionality, and prevents potential harm from cyberattacks, aligning with both quality and safety goals. ### Does the FDA recognize ISO 13485 for cybersecurity compliance? The FDA recognizes ISO 13485 as a framework for quality management systems. While the FDA provides specific premarket and postmarket cybersecurity guidance, an ISO 13485-compliant QMS helps manufacturers establish the necessary controls and processes to meet the FDA's cybersecurity expectations effectively. ### What are some best practices for cybersecurity within an ISO 13485 framework? Best practices include conducting complete threat modeling, adopting a secure software development lifecycle, performing ongoing vulnerability assessments, and Ensure strong cybersecurity documentation and traceability. These practices align with ISO 13485's emphasis on risk management, design control, and continuous improvement. ### How does ISO 13485 relate to other cybersecurity standards like IEC 62304? ISO 13485 sets the overall QMS framework, while IEC 62304 specifically addresses software lifecycle processes for medical device software. Manufacturers integrate IEC 62304's secure software development practices within the broader ISO 13485 QMS to ensure both quality and cybersecurity for devices with software components. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Cybersecurity and ISO 9001](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity) - [MDS² and Medical Device Cybersecurity](/blog/the-role-of-mds2-in-medical-device-cybersecurity) - [MDCG 2019-16 & MedTech Cybersecurity](/blog/mdcg-2019-16-and-medical-device-security) - [ISO 27001 and Medical Device Cybersecurity](/blog/why-iso-27001-and-soc-2-are-not-enough-for-fda-medical-device-cybersecurity) --- ## AAMI TIR57: Security Risk Management and ISO 14971 Fit Source: https://bluegoatcyber.com/blog/iso-14971-its-crucial-role-in-medical-device-security-and-connection-with-aami-tir57 # AAMI TIR57: Security Risk Management and ISO 14971 Fit > **[DIRECT ANSWER]** AAMI TIR57, "Principles for medical device security, Risk management," is a Technical Information Report that adapts ISO 14971's risk management structure to cybersecurity threats. It is informative guidance rather than a normative standard, and its core contribution is separating security risk, which is exploitability and attacker-driven with no meaningful probability estimate, from safety risk, which relies on a probability of harm. ANSI/AAMI SW96:2023, FDA recognition number 13-131, has since become the FDA-recognized normative standard covering the same ground, with TIR57 still valued as supporting methodology. _Reviewed September 17, 2026_ Every FDA submission with a network-connected feature now needs a security risk management process, and most manufacturers try to build one by stretching their existing ISO 14971 safety risk file to cover it. That stretch usually breaks, because security risk does not behave like safety risk: an attacker chooses when and how to exploit a weakness, so there is no meaningful "probability of occurrence" to estimate the way there is for a component failure rate. AAMI TIR57 exists to fix that mismatch. It gives manufacturers a security-specific risk management process built on the same vocabulary and structure as ISO 14971, so the two can sit in a single coherent risk file instead of two disconnected documents. Understanding what TIR57 actually says, and how ANSI/AAMI SW96:2023 has since built on it, matters for anyone assembling premarket cybersecurity documentation today. ## Key Takeaways - AAMI TIR57 is a Technical Information Report: informative guidance, not a normative consensus standard. - Its core contribution is separating security risk (exploitability, attacker-driven) from safety risk (probability of harm). - TIR57 lays out a security risk management process: asset identification, threat modeling, vulnerability assessment, risk estimation and evaluation, control, residual risk, and a security risk management report. - It connects to ISO 14971 at three points: harm vocabulary, the severity scale, and the benefit-risk acceptance decision. - ANSI/AAMI SW96:2023 (FDA recognition number 13-131) is now the FDA-recognized normative standard covering the same ground, and it extends or supersedes several TIR57 concepts. - TIR57 is still relevant as methodology and training material, but a 2026 submission should conform to SW96 as the primary citation. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (February 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. That guidance expects a security risk management process that is distinct from, but integrated with, the device's ISO 14971 safety risk file, and it expects manufacturers to show their work: asset inventories, threat models, vulnerability assessments, and a documented benefit-risk decision for any residual security risk. Reviewers routinely ask manufacturers to explain how their security risk terminology maps back to their safety risk terminology, because a security risk management report that cannot reconcile its severity scale with the ISO 14971 file creates an internal contradiction the FDA will flag. Citing TIR57 alone, without acknowledging that ANSI/AAMI SW96:2023 is now the FDA-recognized normative standard for the same subject matter, is itself a common source of first-cycle Additional Information requests. ## What Is AAMI TIR57? AAMI TIR57 is a Technical Information Report titled "Principles for medical device security, Risk management," published to give manufacturers a structured way to apply security thinking to the ISO 14971 risk management process. A Technical Information Report is informative guidance developed by an AAMI committee, not a normative consensus standard, which means it describes an accepted method rather than setting mandatory pass or fail requirements. That distinction matters in practice. A manufacturer cannot claim "conformance" to a TIR the way it claims conformance to ISO 14971 or ANSI/AAMI SW96:2023, because a TIR does not carry the same normative status. What TIR57 does provide is a well-tested process that manufacturers, and later standards bodies, have relied on heavily when building formal security risk management programs. ## Why Is Security Risk Different from Safety Risk? TIR57's central and most cited contribution is drawing a firm line between security risk and safety risk, which is the idea that gets lost when teams try to reuse a safety risk template for cybersecurity. Safety risk in ISO 14971 combines the severity of harm with the probability that harm will occur, and that probability is estimated from failure rates, use error data, or engineering analysis of a component or process. **[KEY REQUIREMENT]** A security risk management process should not attempt to assign a meaningful numeric probability to an exploit occurring, because exploitation depends on attacker motivation, capability, and opportunity, none of which behave like a hardware failure rate. Security risk does not work that way, because exploitation is attacker-driven rather than random. TIR57's answer is to replace probability of occurrence with exploitability, a structured judgment of how easy a vulnerability is to find and use given the attacker's likely skill, access, and motivation. Severity of harm still uses the same scale as the safety risk file, which is what keeps the two processes connected instead of drifting apart. ## What Process Does TIR57 Lay Out? TIR57 defines a security risk management process that runs in parallel with, and feeds into, the ISO 14971 safety risk process. The stages are asset identification, threat modeling, vulnerability assessment, risk estimation and evaluation, risk control, residual risk evaluation, and a documented security risk management report. Asset identification catalogs what needs protecting: patient data, device functions, network interfaces, and the software components that support them. Threat modeling maps how those assets could be attacked, typically using a structured method such as STRIDE. Vulnerability assessment identifies specific weaknesses in the design or implementation. Risk estimation and evaluation combines exploitability with severity of harm to reach a risk level, which then feeds a risk control decision the same way it would in ISO 14971. The security risk management report documents the full process and its outcome, and it is the security-specific counterpart to the ISO 14971 risk management report. ## How Does TIR57 Connect to ISO 14971? TIR57 connects to ISO 14971 at three specific points rather than being a fully separate framework. The first is harm vocabulary, since TIR57 uses ISO 14971's definitions of harm and hazard rather than inventing new terms, which keeps security findings traceable into the same hazard list a safety reviewer already understands. The second is the severity scale, where TIR57 deliberately reuses the manufacturer's existing ISO 14971 severity categories instead of creating a parallel security-only scale. The third is the benefit-risk acceptance decision. When residual security risk cannot be reduced further, TIR57 routes that decision through the same benefit-risk framework ISO 14971 already requires, so a single risk acceptability policy governs both safety and security residual risk. For a deeper worked example of this mapping, including a side-by-side step comparison and a harm-taxonomy template, see [ISO 14971 vs AAMI SW96: Safety Meets Security Risk](/guides/iso-14971-vs-aami-tir57-hazard-analysis). ## How Does TIR57 Relate to ANSI/AAMI SW96:2023? ANSI/AAMI SW96:2023 is the normative consensus standard that grew out of the same body of practice TIR57 established, and the FDA now recognizes it under recognition number 13-131. Where TIR57 is informative guidance describing a good process, SW96 sets requirements a manufacturer can be assessed against, and it extends TIR57's process with more explicit expectations for coordinated vulnerability disclosure, supply chain risk, and postmarket monitoring. SW96 does not erase TIR57's value. Much of TIR57's process description, especially its explanation of exploitability and its worked risk estimation logic, still holds up and is commonly cited as supporting methodology inside an SW96-conformant risk file. What has changed is which document a manufacturer should point to as its primary conformance claim. ## Is AAMI TIR57 Still Relevant in 2026? Yes, TIR57 is still relevant as methodology, training material, and supporting citation, even though it is no longer the primary document a 2026 submission should claim conformance to. Reviewers under the February 3, 2026 final guidance are used to seeing SW96 cited as the normative standard, with TIR57 referenced alongside it to explain process detail that SW96 assumes the reader already knows. **[KEY REQUIREMENT]** A 2026 submission's security risk management report should cite ANSI/AAMI SW96:2023 as the conformance standard, with AAMI TIR57 referenced only as supporting methodology, not as the primary basis for the process. Manufacturers that built their security risk programs on TIR57 before SW96 published do not need to start over. The practical step is updating the citation and confirming the process covers the additional expectations SW96 adds, particularly around supply chain and disclosure. ## How Does TIR57 Compare to SW96 and ISO 14971? | Document | Status | What it covers | |---|---|---| | ISO 14971 | Normative international standard | Overall device risk management across the lifecycle, safety-focused, probability-based risk estimation | | AAMI TIR57 | Informative Technical Information Report | Security risk management process adapted from ISO 14971; exploitability-based risk estimation; still cited as supporting methodology | | ANSI/AAMI SW96:2023 | Normative consensus standard, FDA recognition 13-131 | Security risk management requirements building on TIR57's process, with added expectations for disclosure, supply chain, and postmarket monitoring | ## What Does the FDA Expect Under the February 3, 2026 Guidance? The FDA's February 3, 2026 final premarket cybersecurity guidance expects a security risk management report that is clearly integrated with the ISO 14971 safety risk file, built on a documented threat model, and grounded in a normative standard rather than informal practice. In practice that means citing ANSI/AAMI SW96:2023 as the conformance basis, showing the asset inventory and threat model that fed the risk estimates, and demonstrating that residual security risk went through the same benefit-risk acceptance decision as residual safety risk. Manufacturers who can show the TIR57-style process underneath their SW96 conformance claim, meaning a clear exploitability-based risk estimation rather than a reused safety probability figure, tend to move through review with fewer questions about their methodology. ## How Blue Goat Cyber Approaches This Blue Goat Cyber builds security risk management files that conform to ANSI/AAMI SW96:2023 while keeping the TIR57 process logic that reviewers expect to see underneath it: exploitability-based estimation, a documented threat model, and a benefit-risk decision that reconciles with the existing ISO 14971 file rather than contradicting it. Our [medical device threat modeling services](/services/medical-device-threat-modeling) produce the asset inventory and threat model that anchor this process, and our [FDA-compliant SBOM services](/services/fda-compliant-sbom-services-for-medtech) supply the supply chain visibility SW96 expects beyond what TIR57 originally covered. We scope every engagement to the February 3, 2026 guidance documentation set so the security and safety risk files read as one coherent story. ## Frequently Asked Questions ### What is AAMI TIR57? AAMI TIR57 is a Technical Information Report, "Principles for medical device security, Risk management," that adapts ISO 14971's risk management structure specifically to cybersecurity threats. It is informative guidance rather than a normative standard. ### Is AAMI TIR57 required for FDA submissions? No document called TIR57 is itself an FDA submission requirement. The FDA-recognized normative standard covering this subject matter today is ANSI/AAMI SW96:2023, recognition number 13-131, with TIR57 cited as supporting methodology. ### How is security risk different from safety risk under TIR57? Safety risk combines severity of harm with a probability of occurrence estimated from failure data. Security risk replaces that probability with exploitability, a judgment of how easily a vulnerability could be found and used, because attacker behavior does not follow a predictable failure rate. ### Did ANSI/AAMI SW96:2023 replace TIR57? Not formally. SW96 became the FDA-recognized normative standard for the same subject matter, and it extends TIR57's process with added expectations around disclosure and supply chain risk, but TIR57 was not withdrawn and is still cited as supporting methodology. ### How does TIR57 connect to ISO 14971? TIR57 connects to ISO 14971 at three points: it reuses ISO 14971's harm vocabulary, reuses the same severity scale rather than creating a separate one, and routes residual security risk through the same benefit-risk acceptance decision. ### What should a security risk management report include? It should include an asset inventory, a threat model, a vulnerability assessment, exploitability-based risk estimates, the risk control measures applied, the residual risk evaluation, and a documented benefit-risk decision consistent with the device's ISO 14971 file. ## CTA If your security risk management report is still built entirely around a reused safety probability estimate, or still cites TIR57 alone without ANSI/AAMI SW96:2023, that is a gap a 2026 reviewer will likely raise. Blue Goat Cyber can review your current risk file and close it before submission. [Contact us](/contact) to get started. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## ISO 14971: Medical Device Risk Management Source: https://bluegoatcyber.com/blog/iso-14971-risk-management-in-medical-device-security # ISO 14971: Medical Device Risk Management > **[DIRECT ANSWER]** ISO 14971 is the risk management standard manufacturers use to treat cybersecurity threats as patient safety hazards, following the same hazard identification, risk analysis, risk control, and residual risk documentation steps applied to mechanical and clinical risks. The FDA treats cyber risks as safety and effectiveness risks under the FD&C Act, so threat modeling, technical controls, and postmarket vulnerability monitoring must all feed back into the same risk management file, not a separate IT track. _Reviewed July 24, 2026_ When it comes to medical devices, a cybersecurity vulnerability isn’t just a technical flaw - it’s a patient safety risk. ISO 14971, the internationally recognized standard for medical device risk management, offers a proven framework for identifying, evaluating, and controlling risks throughout a device’s lifecycle. Historically applied to mechanical and clinical hazards, ISO 14971 now supports addressing **cybersecurity threats** that could disrupt care, compromise patient data, or cause direct harm to patients. In 2025, the FDA reinforced the need to merge cybersecurity into existing safety processes by updating its [Cybersecurity in Medical Devices guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket). Manufacturers are expected to integrate security into their quality systems, premarket submissions, and postmarket activities, and [ISO 14971](https://www.iso.org/standard/72704.html) is the ideal framework to facilitate this integration. ## Key Takeaways - ISO 14971 systematically integrates cybersecurity into device risk management. - The FDA expects cybersecurity risks to be treated as safety and effectiveness risks. - Use formal threat modeling to identify cybersecurity hazards early in development. - Implement technical and procedural controls as formal risk reduction measures. - Clearly document all residual cybersecurity risks and communicate them to users. - Postmarket surveillance is essential for continuous cyber risk management. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to iso 14971 the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Why Cybersecurity Belongs in ISO 14971 Risk Management Modern medical devices are more connected than ever, integrating with hospital networks, cloud platforms, mobile apps, and even patient-owned devices. This connectivity dramatically broadens the attack surface for malicious actors. A single unmitigated vulnerability could: - Interrupt life-sustaining therapies or diagnostics - Expose protected health information (PHI) - Be exploited to alter device performance in dangerous ways The FDA explicitly treats cybersecurity risks as **safety and effectiveness risks under the [FD&C Act](https://www.fda.gov/media/178134/download)**, not just “IT problems.” That means security issues such as loss of integrity, loss of availability, loss of confidentiality, and unauthorized access belong in the same risk management framework as electrical, mechanical, and usability hazards. ISO 14971:2019 provides a ready-made structure for this. Cybersecurity fits naturally into the standard’s activities: - **Hazard identification:** [Treat threat scenarios](/services/medical-device-threat-modeling) (e.g., unauthorized remote access, ransomware, tampering with configuration) as hazards and hazardous situations. - **Risk analysis and evaluation:** Estimate the probability and severity of cyber-initiated harms such as delayed therapy, incorrect dosage, or disclosure of PHI, and decide whether the risk is acceptable. - **Risk control:** Define and verify technical and procedural controls (authentication, encryption, logging, hardening, network segregation) as formal risk control measures, not ad-hoc “IT settings.” - **Residual risk and benefit-risk:** Document residual cybersecurity risk the same way you do clinical risk, and justify it in the overall benefit-risk determination. - **Postmarket surveillance:** Feed vulnerability disclosures, incident reports, and threat intelligence back into the ISO 14971 process to update your risk management file and controls. 📌 **Pro Tip from Blue Goat Cyber** Integrating cybersecurity into ISO 14971 early in development is not just about compliance; it’s a way to: - Align with FDA expectations - Streamline SPDF and submission reviews - Demonstrate to customers that your device’s **safety, security, and performance** are being managed with the same rigor from concept through [postmarket](/services/fda-postmarket-cybersecurity-services). ## Step-by-Step: Applying ISO 14971 to Cybersecurity The ISO 14971 risk management process aligns neatly with medical device cybersecurity. You’re essentially treating cyber threats as another source of hazards and hazardous situations. ### 0\. Plan Your Cybersecurity Risk Management Activities Before diving in, define in your risk management plan how cybersecurity will be handled, including its scope, roles, methods (e.g., threat modeling, [penetration testing](/services/medical-device-penetration-testing)), and how cyber risks are integrated into your SPDF and post-market processes. ### 1\. Hazard Identification (Cyber Threat Scenarios) Document potential **cybersecurity hazards and hazardous situations** that could impact safety and essential performance, such as: - Unauthorized access to configuration or therapy settings - Malware injection or ransomware on the device or its ecosystem - Data tampering (e.g., altered measurements, logs, or commands) - Denial-of-service or resource exhaustion that interrupts therapy This step benefits from formal threat modeling (e.g., [STRIDE](/blog), attack trees) and reviewing your architecture, interfaces, and SBOM. ### 2\. Risk Analysis (Exploitability + Harm) For each cyber hazard, assess: - **Exploitability/likelihood** (consider attacker skill, exposure, existing controls) - **Potential clinical harm** (therapy delay, incorrect dose, misdiagnosis, PHI exposure, etc.) Example: a vulnerability in the wireless update mechanism could allow malicious firmware installation, potentially stopping or altering life-sustaining therapy. ### 3\. Risk Evaluation (Acceptability Decisions) Determine which cybersecurity risks exceed your **acceptable risk criteria**. In medical device cybersecurity, it’s common to **treat even low-likelihood risks as unacceptable** when the potential harm is severe (e.g., death or serious injury), especially for network-accessible or remotely exploitable issues. ### 4\. Risk Control (Technical and Procedural Measures) Select and implement risk control measures, such as: - Strong, role-based authentication and access control - End-to-end encryption for data in transit and at rest - Network segmentation guidance and firewall rules - Secure software update mechanisms (signed updates, rollback protection) - Hardening measures (disabling unused services, ports, and default accounts) Document these controls in both the risk management file and your [cybersecurity labeling](/blog/medical-device-cybersecurity-labeling) so users can deploy and operate the device securely. ### 5\. Residual Risk Assessment (Including Cyber Residual Risk in Labeling) After controls are applied: - Re-estimate the residual cybersecurity risk - Decide if residual risk is acceptable when weighed against clinical benefit - Ensure that any remaining cyber risks are documented and clearly communicated in your Instructions For Use (IFU) / cybersecurity labeling, including compensating controls and user responsibilities. ### 6\. Postmarket Surveillance and Continuous Improvement Cyber threats evolve, so ISO 14971 risk management doesn’t stop at launch. For cybersecurity, post-production activities should include: - Monitoring vulnerability feeds and advisories for SBOM components - [Updating SBOMs](/services/fda-compliant-sbom-services-for-medtech) and reassessing risk when new CVEs are published - Participating in coordinated vulnerability disclosure (CVD) programs - Feeding field incidents and near-misses back into the risk management file and SPDF ## Example: Applying ISO 14971 to a Wireless Infusion Pump A manufacturer developing a wireless infusion pump identifies a cybersecurity hazard: unauthorized wireless commands that could change infusion parameters. ### 1\. Hazard Identification - Hazard: Unauthorized access to the wireless control channel. - Hazardous situation: An attacker or unauthorized user sends commands that change the infusion rate or stop therapy. ### 2\. Risk Analysis - Exploitability: **Medium** - device uses Wi-Fi in a hospital network with moderate exposure, but is not Internet-facing. - Potential harm: **High** - incorrect dosage delivery could cause serious injury or death. - Risk estimation: Medium likelihood/exploitability × high severity/impact→ **unacceptable without controls**. ### 3\. Risk Evaluation - Based on the manufacturer’s risk acceptability criteria, this risk **exceeds acceptable thresholds** and must be mitigated. - Decision: Implement multiple, layered **technical and procedural controls**. ### 4\. Risk Control Implemented controls include: - **WPA3-Enterprise Wi-Fi** with certificate-based mutual authentication - **Mutual device-server authentication** before accepting any remote commands - **Role-based access control** for clinical users vs. biomed/IT admins - **Signed firmware and command validation** to prevent tampering - **Intrusion detection/alerting** if repeated failed authentication attempts occur or anomalous command patterns are detected These controls are documented in: - The **risk management file** (as risk control measures), and - The **cybersecurity labeling** **/IFU**, with concrete configuration steps for hospital IT and biomedical teams. ### 5\. Residual Risk Assessment After controls are implemented: - Residual likelihood: **Low**, given strong authentication, encryption, and monitoring. - Residual severity: Still **High** (if compromised, harm could be serious). - Overall residual risk: **Acceptable** within the manufacturer’s criteria, **provided** the device is deployed according to the labeling (e.g., network isolation, RBAC). - Residual risk is clearly documented in the labeling, along with operational recommendations such as network segmentation and account management practices. ### 6\. Postmarket Surveillance The manufacturer defines a postmarket cybersecurity plan that includes: - Regular **penetration testing** for the wireless stack and update mechanism - Continuous monitoring of **SBOM components** (e.g., Wi-Fi stack, crypto libraries, OS) for new CVEs - A **coordinated vulnerability disclosure (CVD)** process with a public contact channel - Procedures to release **security advisories, patches, and updated labeling** if risk changes This ISO 14971-aligned approach not only addresses FDA expectations for integrating cybersecurity into risk management, but it also demonstrates to hospital procurement and security teams that the wireless infusion pump is designed, documented, and maintained to meet stringent cybersecurity and patient safety standards. ![ISO 14971 medical device cybersecurity](/imported-images/8a6b05217fa7c0eb.png) ## Best Practices for Cybersecurity in ISO 14971 Use ISO 14971 as the foundation for managing cybersecurity risk, not just as a compliance exercise. These practices help bridge FDA cybersecurity expectations with your existing risk processes: - **Integrate with your SPDF** Align cybersecurity risk management with your [Secure Product Development Framework (SPDF)](/blog) so security is built in, not bolted on. Ensure that threat modeling, security testing, and risk reviews are formalized activities in your design and development plan, and that their outputs flow directly into the risk management file and are properly labeled. - **Use structured threat modeling** Don’t rely on ad-hoc brainstorming. Apply a consistent threat modeling approach (e.g., data-flow diagrams plus STRIDE or attack trees) to identify attacker goals, entry points, and abuse scenarios early. Feed these threat scenarios into ISO 14971 as hazards and hazardous situations. - **Maintain a resilient, living SBOM** Track all third-party and open-source components, versions, and where they’re used. Use the SBOM for: - Pre-market risk analysis (e.g., crypto libraries, OS, network stacks) - Ongoing monitoring of new CVEs postmarket - Supporting your cybersecurity labeling and communication with customers - **Drive cross-functional participation** Cybersecurity risk management isn’t just for engineers. Involve: - **Quality and Regulatory** to ensure ISO 14971 and FDA expectations are met - **Clinical and usability experts** to understand real-world harm scenarios - **IT/security / HTM stakeholders** to validate assumptions about deployment environments - **Ensure traceability and evidence** Maintain clear links from cyber hazards → risk controls → verification tests → labeling. This traceability makes ISO 14971 reviews smoother and shows regulators and customers that cybersecurity is being managed with the same rigor as other safety risks. - **Plan for lifecycle updates** Build in processes for re-running risk analysis when you change architecture, introduce new connectivity, or update third-party components. Tie this to postmarket surveillance so new vulnerabilities or field incidents trigger ISO 14971 updates and, when needed, updated cybersecurity labeling. ## Common Pitfalls to Avoid Even mature teams fall into patterns that undermine their cybersecurity risk management under ISO 14971. Watch out for these: - **Treating cybersecurity separately from safety risk management** Handling cyber risk in a standalone “IT risk” track, rather than integrating it into ISO 14971, leads to two conflicting risk stories: one for safety and one for security. The FDA expects cybersecurity risks to be treated in the same manner as safety and effectiveness risks, with hazards, controls, and residual risk documented within the same framework. - **Failing to reassess risks after software updates or environment changes** Rolling out new features, connectivity options, or component updates (OS, libraries, cloud services) without re-running risk analysis is a common gap. Every meaningful change to the architecture, SBOM, or intended use environment should trigger a cybersecurity risk review and, when needed, updated controls and labeling. - **Not disclosing known vulnerabilities in labeling** Some manufacturers avoid mentioning known vulnerabilities or residual risks for fear of alarming customers. Regulators and hospital security teams see that as a red flag. Known issues, compensating controls, and residual risk must be clearly communicated in cybersecurity labeling so that users can manage the risk responsibly. - **Over-relying on IT security tools without clinical safety context** Assuming firewalls, NAC, or endpoint protection will “take care of it” ignores how cyber events translate into clinical harm. For example, an aggressive network control that blocks device communications can delay or interrupt therapy. Cyber controls need to be evaluated through a clinical safety lens, not just an IT one. A clear, integrated approach that avoids these pitfalls makes your ISO 14971 process more defensible with FDA reviewers and more credible with hospital security and procurement teams. ## Partner with Blue Goat Cyber for Risk Management Excellence At Blue Goat Cyber, we help medical device manufacturers implement ISO 14971-compliant cybersecurity risk management that satisfies FDA, EU MDR, and other global requirements. From threat modeling to SBOM development and postmarket monitoring, our experts ensure your devices are secure, compliant, and ready for market. Don’t wait until a vulnerability becomes a recall. [**Contact us today**](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to strengthen your risk management process and protect your devices and reputation. ## Safety risk and security risk side by side ISO 14971 was written for safety. Applying it to cybersecurity works, but three of its assumptions change, and reviewers notice when a file ignores that. | Dimension | Safety risk under ISO 14971 | Security risk under AAMI TIR57 and SW96 | | --- | --- | --- | | Cause of harm | Random failure, use error, or a foreseeable misuse | A deliberate actor choosing the worst moment | | Probability | Estimated from failure rates and field data | Not estimable, so exploitability replaces probability | | Stability over time | Broadly stable across the product life | Changes whenever a new vulnerability is published | | Acceptability | Judged against risk acceptance criteria in the plan | Judged against exploitability plus patient harm, with residual risk disclosed | | Control hierarchy | Inherent safety, protective measures, labeling | The same hierarchy, but labeling is the weakest option and reviewers treat it that way | | Postmarket trigger | Complaints, adverse events, field data | Newly disclosed vulnerabilities in components you already shipped | The practical rule is that the security file borrows the structure of 14971 and replaces probability with exploitability. Everything else, including the patient harm scale, should stay the same so the two files reconcile. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the role of ISO 14971 in medical device cybersecurity? ISO 14971 provides a structured framework for identifying, evaluating, and controlling risks throughout a medical device's lifecycle. It is used to integrate cybersecurity by treating cyber threats as hazards that can lead to patient harm or compromise essential device performance. ### Why does the FDA emphasize ISO 14971 for cybersecurity? The FDA considers cybersecurity risks as directly impacting the safety and effectiveness of medical devices. Utilizing ISO 14971 ensures that manufacturers integrate security into their quality systems, premarket submissions, and postmarket activities, aligning with the FDA's February 3, 2026 final guidance on premarket cybersecurity. ### How does threat modeling fit into ISO 14971 for cybersecurity? Threat modeling is a critical input to the hazard identification phase of ISO 14971. It helps define potential cyber threats (e.g., unauthorized access, malware) as hazardous situations, enabling systematic risk analysis and the development of targeted risk controls. ### What postmarket cybersecurity activities are required under ISO 14971? Postmarket activities include monitoring vulnerability feeds, updating SBOMs, participating in coordinated vulnerability disclosure (CVD) programs, and feeding incident reports back into the risk management process to continuously update and improve controls. ### Does ISO 14971 cover all cybersecurity aspects for medical devices? While ISO 14971 provides the overarching risk management framework, specific cybersecurity details are further guided by other standards and best practices, such as the FDA's premarket cybersecurity guidance and organizations' Secure Product Development Framework (SPDF). ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Cybersecurity and ISO 9001](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity) - [MedTech Cyber Standards Every Device](/blog/medtech-cyber-standards-every-device-team-must-know) - [ISO 27001 and Medical Device Cybersecurity](/blog/why-iso-27001-and-soc-2-are-not-enough-for-fda-medical-device-cybersecurity) --- ## JSP2 vs SPDF vs IEC 81001-5-1: Framework Pick Source: https://bluegoatcyber.com/blog/jsp2-vs-spdf-vs-iec-81001-medical-device-framework-choice # JSP2 vs SPDF vs IEC 81001-5-1: Picking a Cybersecurity Framework for FDA Submissions > **[DIRECT ANSWER]** The FDA's Feb 3, 2026 final guidance accepts four cybersecurity frameworks: its own SPDF, HSCC's JSP2, IEC 81001-5-1, and ISA/IEC 62443-4-1, and the right choice depends on context, not compliance. SPDF fits US-only submissions with no existing framework, JSP2 suits companies where hospital procurement drives the roadmap, IEC 81001-5-1 works best for dual FDA/EU submissions, and ISA/IEC 62443-4-1 is generally reserved for industrial-scale devices. Whichever spine is chosen, the same artifacts, threat model, SBOM, risk file, and postmarket plan, are still required. The February 3, 2026 final guidance made this a real question. The September 2023 version treated SPDF as the default. The 2026 final explicitly recognizes JSP2, IEC 81001-5-1, and ISA/IEC 62443-4-1 as acceptable alternatives, provided the manufacturer demonstrates equivalent coverage. That opened a decision that many medtech teams did not previously have to make and are now making poorly. This post is the framework-selection guide the guidance itself does not provide. ## Key Takeaways - All four frameworks are acceptable to the FDA; the choice is about fit, not compliance. - SPDF is the FDA's own model and the lowest-friction path for a US-only submission. - IEC 81001-5-1 is the international convergence point and the right spine for dual FDA/EU submissions. - JSP2 is healthcare-authored, procurement-aware, and the strongest choice when hospital contracts drive as much of the roadmap as the FDA does. - ISA/IEC 62443-4-1 is overkill for most Class II devices and appropriate mostly for industrial-scale medical systems. - Whichever spine you pick, you still owe the FDA the same artifacts: threat model, SBOM with VEX, security risk file, postmarket plan, CVD process, and labeling. ## Why This Matters Framework choice is not a documentation exercise. It determines which artifacts your engineering team produces for the next three to five years, which audits you pass without rework, and which procurement questionnaires you can answer without a translation layer. Picking the wrong spine costs six to twelve months of retrofit work when the first mismatched audit or RFP arrives. The 2026 final guidance is also more explicit than the draft about equivalence: if you pick a non-SPDF framework, you must map its outputs to the FDA's expected artifacts.[^fda2026] Reviewers do not learn your framework, they check your artifacts. A JSP2 or 81001-5-1 submission that skips the mapping reads as an incomplete SPDF submission and draws the same deficiency letters. ## What this post is not To keep the decision clean, a few things this post is explicitly not about: - **Not ISO 27001 or SOC 2.** Enterprise information-security frameworks. Useful for the company, but the FDA does not accept them as substitutes for a product-development framework. - **Not HIPAA.** HIPAA governs covered entities and business associates handling PHI, not device development. A HIPAA program does not satisfy Section 524B. - **Not the NIST Cybersecurity Framework (CSF 2.0).** CSF is an organizational risk-management framework, not a product-development lifecycle. It complements SPDF or 81001-5-1; it does not replace either. - **Not NIST SSDF (SP 800-218).** SSDF is a general secure-software framework and can feed any of the four medtech-specific frameworks below, but on its own it is not one of the four the FDA lists. - **Not a shortcut around the artifacts.** Whichever framework you pick, you still owe the same threat model, SBOM with VEX, security risk file, postmarket plan, CVD process, and labeling. ## Decision tree ![Decision tree: pick between SPDF, JSP2, IEC 81001-5-1, and ISA/IEC 62443-4-1 based on device scale, EU submission, and hospital-buyer profile](/diagrams/framework-choice-decision-tree.svg) ## What the FDA actually said in the 2026 final guidance The final *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* guidance (February 3, 2026) states that manufacturers should implement a secure product development framework and lists the following as acceptable:[^fda2026] - The FDA's own SPDF, as described in the guidance. - HSCC's Joint Security Plan v2 (JSP2), published March 2024.[^jsp2] - IEC 81001-5-1:2021, *Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product life cycle.*[^iec81001] - ISA/IEC 62443-4-1:2018, *Security for industrial automation and control systems, Part 4-1: Secure product development lifecycle requirements.*[^iec62443] The guidance is clear that the choice is the manufacturer's, and that any of the four is acceptable if the resulting submission contains the expected content: security risk management, threat modeling with the required architecture views, SBOM with VEX, interoperability considerations, security testing, labeling, and a postmarket cybersecurity management plan. ## The four frameworks at a glance | Framework | Author | Best fit | Regulatory fit | Effort to adopt from scratch | | --- | --- | --- | --- | --- | | **SPDF** | FDA (CDRH) | US-first medtech | FDA-native | Medium | | **JSP2** | HSCC (industry consortium) | Companies with heavy hospital-procurement exposure | FDA-accepted, procurement-aligned | Medium | | **IEC 81001-5-1** | IEC / ISO joint | Dual US/EU submissions, IVDR/MDR devices | FDA-accepted, EU-preferred | Medium-High | | **ISA/IEC 62443-4-1** | ISA/IEC | Industrial-scale devices, orgs already running 62443 | FDA-accepted, uncommon in medtech | High | ### Quick pick: SPDF vs JSP2 vs IEC 81001-5-1 For the three frameworks most medtech teams actually weigh, use this as the one-line answer: | Your context | Choose | Why | | --- | --- | --- | | US-only submission, no existing framework | **SPDF** | FDA-native vocabulary, shortest path to a clean 510(k) | | US-only, hospital-procurement is the harder audience | **JSP2** | Co-authored by health-delivery orgs, aligns with MDS2 | | Dual FDA + EU MDR/IVDR submission | **IEC 81001-5-1** | Notified-body expectation, harmonizes with IEC 62304 | | Already run IEC 62304 and ISO 13485 | **IEC 81001-5-1** | Slots onto existing QMS with least overhead | | Small team (< 10 engineers), US-first | **SPDF** | Lowest per-artifact overhead | | Large IDN contracts drive the roadmap | **JSP2** | Speaks procurement's language natively | | Genuinely undecided | **SPDF** | Never wrong for an FDA submission | ## SPDF: the FDA's default SPDF is the framework the FDA wrote for itself. It is the least ambiguous mapping to the artifacts reviewers expect, because it *is* the source of those artifacts. See our companion piece on the [SPDF vs SSDLC gap](/blog/spdf-vs-ssdlc-medical-device-cybersecurity) for what SPDF adds over a general secure SDLC. **Pick SPDF when:** - The device is US-first or US-only. - The team does not already have an established framework running. - You want the shortest path from artifacts to a clean submission. **SPDF's weakness:** it is not recognized as a standard outside the US. EU notified bodies do not evaluate against SPDF, and hospital procurement rarely asks about it by name. ## JSP2: the healthcare-industry framework The Health Sector Coordinating Council's Joint Security Plan v2 (March 2024) is a healthcare-industry-authored total-product-lifecycle framework. It was written by manufacturers, health-delivery organizations, and government partners together, which is why it aligns unusually well with the questions hospital security and procurement teams actually ask. JSP2 covers the same lifecycle stages as SPDF but adds explicit sections on customer-facing security documentation, procurement enablement (including alignment with the [MDS2 disclosure form](/blog/the-role-of-mds2-in-medical-device-cybersecurity)), and coordinated deployment guidance. Our deep-dive on [JSP is here](/blog/what-is-medical-device-and-health-it-joint-security-plan-jsp). **Pick JSP2 when:** - Hospital contracts and IDN security reviews drive as much of your roadmap as the FDA does. - You want a framework that reads naturally to both regulators and customers. - You already produce MDS2 forms and want the underlying development framework to align with them. **JSP2's weakness:** slightly less name recognition inside FDA review divisions than SPDF, so the mapping to expected artifacts must be explicit in the submission. > **Picking a security lifecycle framework?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## IEC 81001-5-1: the international spine IEC 81001-5-1:2021 is the international standard for security activities in the health-software lifecycle. It is harmonized with IEC 62304 (software lifecycle) and IEC 82304-1 (health software safety), and it is the framework EU notified bodies expect under the MDR and IVDR. For the direct comparison, see [IEC 81001-5-1 vs IEC 62304](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards). **Pick IEC 81001-5-1 when:** - You submit to both the FDA and EU notified bodies. - The device is regulated in multiple jurisdictions where ISO/IEC standards carry more weight than US-specific frameworks. - The engineering org already runs IEC 62304 and wants the security framework to sit natively on top of it. **IEC 81001-5-1's weakness:** it costs more to adopt cleanly, and the language is denser than SPDF or JSP2. Small teams shipping US-only will find the overhead disproportionate. [Talk to a MedTech cybersecurity expert about framework selection](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## ISA/IEC 62443-4-1: the industrial option ISA/IEC 62443-4-1 comes from the industrial automation world. It is the secure development lifecycle standard for control-system vendors, and it is exceptionally rigorous, arguably more rigorous than any of the other three on pure development-process discipline. **Pick 62443-4-1 when:** - The device is genuinely industrial in scale: surgical robotics, large imaging platforms, radiation therapy systems, hospital automation. - The parent company already runs 62443 across other product lines and wants a single framework. - The customer base includes non-clinical industrial buyers alongside hospitals. **62443-4-1's weakness:** it is overkill for most Class II devices, and its vocabulary (zones, conduits, security levels) does not translate naturally to FDA reviewer expectations without heavy mapping. ## Decision matrix: which framework fits which company | Situation | Recommended spine | | --- | --- | | US-only Class II SaMD, small team, no existing framework | SPDF | | US Class II hardware device, moderate procurement exposure | SPDF or JSP2 | | Heavy hospital-IDN customer base, MDS2 already in play | JSP2 | | Dual FDA + EU MDR/IVDR submission | IEC 81001-5-1 | | Surgical robotics, large imaging, or industrial-scale medical system | ISA/IEC 62443-4-1 (with SPDF mapping) | | Startup pre-first-submission | SPDF (fastest to a clean 510(k)) | | Established manufacturer with a mature IEC 62304 QMS | IEC 81001-5-1 | ## How to mix frameworks without confusing reviewers Real submissions often use more than one framework. A common pattern: IEC 81001-5-1 as the international spine, with SPDF-shaped artifacts (four architecture views, VEX-paired SBOM, FDA-format postmarket plan) presented in the submission. Another: JSP2 as the internal operating framework, with an SPDF-labeled artifact package for the FDA and JSP2-labeled documentation for hospital procurement. Two rules keep this readable: 1. **Name the spine once, in the cybersecurity management plan.** Do not describe the device as "SPDF and JSP2 and 81001-5-1 aligned" in a submission cover letter. Pick one, and describe the others as mappings. 2. **Produce artifacts in the FDA's expected shape regardless of spine.** Reviewers grade the artifacts, not the framework. Threat model with four views, SBOM with VEX, integrated ISO 14971 / AAMI SW96 risk file, postmarket plan, CVD process, labeling. Every framework can produce these; the wrapper is the manufacturer's choice. ## How Blue Goat Cyber Approaches This Blue Goat Cyber runs a framework-selection workshop before the first submission of a device family. The output is a one-page decision memo naming the spine, the mapping to FDA artifacts, and the sequence of internal work needed to stand it up. For teams already committed to a framework, we run gap assessments against the 2026 final guidance and produce a remediation backlog ordered by deficiency-letter likelihood. Christian Espinosa, our founder, has led cybersecurity submissions on more than 275 FDA-cleared devices under all four frameworks, and sits close enough to HSCC and IEC working groups to catch changes before they land in guidance. ## Frequently Asked Questions ### Does the FDA prefer SPDF over the others? The 2026 final guidance treats the four frameworks as equivalent when the resulting artifacts meet the guidance's content expectations. In practice, SPDF is the lowest-friction path because it uses the FDA's own vocabulary. ### Which should I choose for a first-ever 510(k)? SPDF. It is the FDA's own vocabulary and the shortest path from artifacts to a clean submission. Adopt a different framework only if a specific driver (EU submission, existing 62443 program, hospital-procurement pressure) is already on the table. ### Which should I choose if my main buyer is a large IDN or hospital system? JSP2. It was co-authored by health-delivery organizations, so its outputs answer procurement questions in the vocabulary hospital security teams already use, and it aligns natively with the [MDS2 disclosure form](/blog/the-role-of-mds2-in-medical-device-cybersecurity). ### Which should I choose for a connected implantable or infusion pump? SPDF or IEC 81001-5-1. Both handle the harm-traceability, four-view threat modeling, and postmarket obligations these devices demand. Pick SPDF for US-first, IEC 81001-5-1 for dual FDA/EU. ### Which should I choose if we already run ISO 13485 and IEC 62304? IEC 81001-5-1. It slots onto IEC 62304 directly and reuses the ISO 13485 QMS scaffolding, so adoption cost is low. SPDF is still fine, it just does not benefit from the existing standards investment. ### What if I genuinely cannot decide? Default to SPDF, document the decision in the cybersecurity management plan, and revisit at the next major device version. SPDF is never the wrong answer for an FDA submission; it is only sometimes not the best answer. ## CTA Pick the framework once, correctly, before you build the artifacts. Blue Goat Cyber runs a two-week framework selection and gap workshop that outputs a submission-ready spine, a mapping to FDA artifacts, and a prioritized remediation backlog. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, CCISO, ex-military red team. Has led framework selection and FDA cybersecurity submissions for more than 275 medical devices under SPDF, JSP2, IEC 81001-5-1, and ISA/IEC 62443-4-1. [More on the author](/team/christian-espinosa)._ ## References [^fda2026]: U.S. Food and Drug Administration. *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, Guidance for Industry and Food and Drug Administration Staff.* Final guidance, issued February 3, 2026. [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions) [^jsp2]: Health Sector Coordinating Council (HSCC) Cybersecurity Working Group. *Medical Device and Health IT Joint Security Plan (JSP), Version 2.* March 2024. [https://healthsectorcouncil.org/](https://healthsectorcouncil.org/) [^iec81001]: International Electrotechnical Commission. *IEC 81001-5-1:2021, Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product life cycle.* Published December 2021. [https://webstore.iec.ch/publication/64703](https://webstore.iec.ch/publication/64703) [^iec62443]: International Society of Automation / International Electrotechnical Commission. *ISA/IEC 62443-4-1:2018, Security for industrial automation and control systems, Part 4-1: Secure product development lifecycle requirements.* Published January 2018. [https://webstore.iec.ch/publication/33615](https://webstore.iec.ch/publication/33615) --- ## Letter to File vs New 510(k) Source: https://bluegoatcyber.com/blog/letter-to-file-vs-new-510k-cybersecurity-changes # Letter to File vs New 510(k) for Cybersecurity Changes > **[DIRECT ANSWER]** A cybersecurity change can stay as a letter to file in the DHF when it does not alter the threat model, attack surface, cryptography, authentication, or interfaces, such as a like-for-like patch or a signed firmware update through an existing mechanism. It forces a new 510(k) when it changes any of those elements or the intended use, since that shifts the security risk profile enough to require the FDA's review. If you maintain a cleared medical device, the question that comes up every sprint is not *which* 510(k) to file. It is whether you have to file one at all. The 2017 the FDA flowchart was written before Section 524B. The decision logic still controls, but the **stakes** of getting a cybersecurity call wrong are now an enforcement and recall risk - not just a paperwork miss. ## Key Takeaways - A letter to file is a DHF-internal justification; the FDA does not see it unless they ask in an inspection or after an incident. - The controlling document is still the FDA's 2017 *Deciding When to Submit a 510(k) for a Change* guidance, layered on top of 21 CFR 807.81(a)(3). - Cybersecurity changes that do **not** alter the threat model, attack surface, crypto, authentication, or interfaces usually stay letter to file. - Cybersecurity changes that **do** alter any of the above usually require a new 510(k) - Special if your own device, Traditional if the security risk profile materially shifts. - Section 524B does not move the threshold, but it raises the consequences of a bad call: misclassified cyber changes can become enforcement findings. - A Pre-Sub (Q-Sub) is the cheapest way to confirm a borderline call before you commit to letter to file. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to letter to file vs new 510(k) for cybersecurity changes the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What a Letter to File Actually Is A letter to file is a document inside your DHF that records: 1. The change being made. 2. The regulatory rationale for *not* submitting a new 510(k). 3. The risk-based evidence supporting that rationale - design controls, verification, validation, and (for cyber) threat-model and security-risk-assessment deltas. 4. The approvers and the date. It is not filed with the FDA. The FDA encounters it during a routine inspection, a for-cause inspection after an adverse event, a recall investigation, or a Section 524B postmarket review. At that point your rationale either holds up or it becomes a 483 observation. ## The Decision Framework, Reframed for Cyber The 2017 guidance asks, for every change, whether it *could significantly affect the safety or effectiveness of the device*. For a cybersecurity change, translate that into five concrete questions: 1. Does the change alter the **threat model**? (New actors, new attack vectors, new trust boundaries.) 2. Does it change the **attack surface**? (New interfaces, new protocols, new exposed services.) 3. Does it change the **cryptographic posture**? (New algorithms, new key lengths, new key management, removed crypto.) 4. Does it change the **authentication or authorization model**? (New auth mechanisms, removed MFA, new roles.) 5. Does it change the **intended use** or **use environment**? (Adding remote access, cloud dependency, third-party integration.) Any "yes" is a strong signal that a new 510(k) is needed. Multiple yeses make the letter-to-file path indefensible. ## Changes That Usually Stay Letter to File Assuming your DHF backs them up and the change-control record is clean: - **Like-for-like patches** of an existing component to the next minor version, with no API or interface change. - **Signed firmware updates** delivered through an already-cleared update mechanism with no change to the mechanism itself. - **VEX status updates** for SBOM components - changing a vulnerability from `under_investigation` to `not_affected` with justification. - **Documentation-only SBOM refreshes** when component versions are updated but no functional change ships. - **Security configuration hardening** that tightens existing controls without changing interfaces (e.g., reducing default logging verbosity, disabling an unused but already-cleared service). - **CVE response patches** that remediate a vulnerability in an existing component without changing functionality, interface, or threat model. In each case the letter to file should still include a threat-model delta statement ("no change") and a security-risk-assessment delta - even if the conclusion is "no new risk introduced." ## Changes That Almost Always Require a New 510(k) These are the calls where letter to file is the wrong answer: - **New cryptographic algorithms** or key infrastructure (e.g., migrating from RSA to ECC, adding post-quantum primitives). - **New authentication mechanisms** (adding SSO, removing MFA, changing from password to certificate-based auth). - **New wireless or remote-access paths** (adding BLE, Wi-Fi, cellular, or a cloud sync path). - **Secure Boot added or removed**, or chain-of-trust restructured. - **New third-party components** that materially change the attack surface or pull in unfamiliar transitive dependencies. - **Intended-use-adjacent changes** that enable remote operation, remote diagnostics, or new data flows. - **Replacing an end-of-support OS or runtime** (e.g., Windows 10 IoT to Windows 11 IoT, or moving from a deprecated RTOS to a new one). For most of these, a Special 510(k) is the right pathway if the change is well-scoped. The Special vs Traditional call is covered in a separate post in this cluster. ## The Gray Zone Real-world cybersecurity changes are rarely clean. Common gray-zone cases: - **TLS version bumps** (1.2 to 1.3) with no other change. Usually letter to file if the cipher suite policy and certificate handling are unchanged. New submission if you are deprecating ciphers the labeling claimed support for. - **SBOM component swaps** for end-of-support libraries where the replacement is functionally equivalent. Letter to file if the API surface is identical and the new component is in the same trust boundary. New 510(k) if the replacement introduces new transitive dependencies or runs in a different process context. - **Cloud backend changes** that do not touch the device firmware. Letter to file is tempting, but if the device's security claims depended on the old backend's controls, the change can re-enter device scope. - **Adding a CVD or VDP process** to an already-cleared device. Process-only changes usually stay letter to file, but Section 524B postmarket expectations may already require this regardless. For each gray-zone case, document: - The threat model before and after, with a delta. - The security risk assessment before and after, with a delta. - The verification and regression test evidence. - A defensible written rationale tied to the 2017 guidance flowchart. ## How Section 524B Changes the Stakes Section 524B(b) did not move the letter-to-file threshold. It did three things that make a bad call far more expensive: 1. **Created an explicit cybersecurity bar at premarket.** A change you justified as letter-to-file in 2022 might no longer meet current the FDA expectations for what a cleared device's security baseline looks like. 2. **Created postmarket monitoring obligations** (SBOM maintenance, vulnerability disclosure, patch cadence). A change that breaks one of these implicit commitments is now visible to the FDA without an inspection. 3. **Created a clear basis for enforcement.** A device that ships with a misclassified cyber change is now demonstrably non-compliant with a specific statutory provision, not just a guidance document. A letter to file that would have been a 483 observation under the old regime can now be a Warning Letter or recall under the new one. ## Pre-Sub as the De-Risker If the call is borderline, a Pre-Submission is the cheapest insurance available. A focused Pre-Sub for a cybersecurity change should include: - A one-paragraph description of the change. - The threat model delta. - The security risk assessment delta. - The proposed verification and regression test evidence. - A direct question: *"Does the FDA agree that the change described above does not require a new 510(k) and can be managed under our design controls per ISO 13485 clause 7.3 as incorporated by the QMSR, supported by the documented threat-model and security-risk-assessment deltas?"* The FDA can answer with a path-confirmation, a request for a Special 510(k), or a request for a Traditional 510(k). Any of those is cheaper than an RTA on a misclassified submission or a postmarket enforcement action. ## What to Put in the Letter to File for a Cyber Change When letter to file is the right call, the document should contain at minimum: - Change description and scope. - Reference to the 2017 *Deciding When to Submit a 510(k) for a Change* guidance and the specific flowchart branch followed. - Threat model delta (or "no change" statement). - Security risk assessment delta (or "no change" statement). - SBOM diff and VEX delta if any components changed. - Verification and regression test summary. - Cybersecurity labeling impact assessment (does the change require any update to user-facing security documentation). - Approver signatures and date. A thin letter to file - one paragraph and an approver name - is the document that gets you a Warning Letter. A thorough one is the document that defends the call. ## Reviewer and Inspector Red Flags These patterns draw scrutiny in an inspection or postmarket review: - A run of letter-to-file decisions on cybersecurity changes with no threat-model delta documentation. - Letter-to-file decisions on changes that touched crypto, auth, or interfaces. - Letter-to-file decisions made without security engineering signoff. - A pattern of letter-to-file followed by a postmarket incident that exploited the changed code. - Letter-to-file rationale that cites only the 2017 guidance without referencing the device's specific security risk assessment. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### When does a cybersecurity change qualify as a letter to file vs a new 510(k)? A cybersecurity change stays letter to file when it does not alter the device's threat model, attack surface, cryptographic implementation, authentication, or external interfaces, typically like-for-like patches inside an already-cleared update mechanism. It requires a new 510(k) when any of those shift, because the FDA's 2017 *Deciding When to Submit a 510(k) for a Change to an Existing Device* guidance treats those shifts as significantly affecting safety or effectiveness. ### Is a CVE patch always letter to file? No. A patch that changes interfaces, adds new dependencies, or alters the trust boundary is a new 510(k) candidate even if its purpose is remediation. The intent of the change does not determine the regulatory path, the impact does. A patch that swaps a vulnerable TLS library for a different library with a different API is rarely letter to file, regardless of the CVE it closes. ### Does the FDA review my letters to file? Not proactively. Letters to file are internal DHF records the FDA does not see unless an inspection, recall investigation, or postmarket review under Section 524B brings them into scope. At that point they either defend the call or become findings, so the documentation quality at the time you wrote them is what determines the outcome. ### If I am unsure, should I default to filing a 510(k)? No. Default to a Pre-Sub (Q-Sub). Filing a 510(k) for a change that did not require one wastes review capacity and locks the device into a longer change cycle. Filing a letter to file when you needed a 510(k) creates an enforcement risk. The Pre-Sub is the only path that resolves the ambiguity at low cost. ### How does the February 3, 2026 FDA premarket cybersecurity guidance change letter-to-file decisions? The 2026 guidance defines what a cleared device's cybersecurity baseline looks like. A change that drifts the device away from that baseline is harder to justify as letter to file even if the 2017 guidance flowchart would have allowed it before. Treat the 2026 guidance as a ceiling on what letter to file can absorb. ### What documentation does a cyber-change letter to file need? At minimum: the change description, the threat-model delta (or a statement that the threat model is unchanged with justification), the verification evidence, the 2017 guidance flowchart with each decision node answered, and a signed regulatory rationale. Letters that skip the flowchart walk-through are the ones that fail inspection. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Does Device Class Decide FDA](/blog/fda-cybersecurity-requirements-by-device-class) --- ## Market Intelligence & Cybersecurity for MedTech Source: https://bluegoatcyber.com/blog/leveraging-market-intelligence-and-cybersecurity-to-drive-medtech-growth # Market Intelligence & Cybersecurity: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Market intelligence and cybersecurity together help MedTech companies grow by closing a regulatory maturity gap that has historically trailed pharma by about five years. Data-driven sales tools help teams engage buyers at the right time, while proactive cybersecurity investment avoids the 12-month FDA clearance delays that unaddressed vulnerabilities can trigger and builds the investor and hospital-buyer confidence that increasingly determines which MedTech companies actually scale. ## Key Takeaways - MedTech regulation trails pharma by about five years. - EU regulatory clarity boosted European MedTech investment. - Proactive cybersecurity prevents regulatory delays. - Market intelligence tools enhance sales and growth. - Cybersecurity postures influence investor confidence. - Self-regulation can precede formal FDA guidance. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to using market intelligence and cybersecurity to drive MedTech growth the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## The Intersection of Data, AI, and Cyber in the MedTech Industry In the world of medical technology (MedTech), the ability to use market intelligence and stay ahead of cybersecurity threats has become increasingly crucial for driving sustainable growth. As the industry continues to outpace regulatory changes, forward-thinking MedTech companies are using data-driven insights and proactive security measures to gain a competitive edge. In this in-depth article, we examine the intersection of market intelligence and cybersecurity in the MedTech space and analyze the strategies employed by leading companies to accelerate their sales, protect their innovations, and build investor confidence. ## Bridging the Regulatory Gap: MedTech’s 5-Year Lag Behind Pharma One of the key challenges facing the MedTech industry is the regulatory landscape, which has historically lagged behind the more established pharmaceutical sector. According to Kevin Saem, founder of [Zapyrus](http://zapyrus.com/ ""), a SaaS platform that helps MedTech service providers streamline their sales and marketing efforts, the MedTech industry is approximately five years behind the pharmaceutical industry in terms of regulatory sophistication, sales processes, and overall company maturity. “The MedTech space has been historically 5 years minimum behind life sciences like pharma and biotech, from a regulatory standpoint,” Saem explains. “This then bleeds down into the innovations, tools, and sales team structure and sophistication used in the space.” This regulatory gap has created both challenges and opportunities for MedTech companies. On one hand, the slower pace of regulation has allowed for more rapid innovation and a more agile market. However, it has also resulted in a lack of standardized best practices and an increased risk of security vulnerabilities, as evidenced by recent high-profile cases, such as the [Illumina incident](/blog/when-cybersecurity-becomes-a-crime-what-the-illumina-case-signals-for-medical-device-makers). ## Harnessing the Power of Market Intelligence and AI To bridge this regulatory gap and drive sustainable growth, leading MedTech companies are turning to data-driven solutions like Zapyrus to gain a competitive edge. Saem founded Zapyrus with the goal of providing MedTech service providers with a centralized platform for market intelligence and sales enablement. “We saw an opportunity to be able to say, ‘Okay, well, if we can maximize sales efficiency and sales effectiveness,’ that’s really all sales and marketing people and business owners really want,” Saem explains. “They don’t want to spend time, hours and hours and hours processing data, turning through data, qualifying data. They want to sell and grow their business.” Zapyrus uses machine learning and AI to automate the process of identifying market signals and triggers, enabling MedTech companies to engage with potential customers at the right time proactively. By integrating with CRM systems and providing a centralized hub for market data, Zapyrus enables MedTech teams to streamline their sales and marketing efforts, allowing them to focus on what they do best: driving growth. ## The Shifting Tides of MedTech Investment As the MedTech industry continues to evolve, the regulatory landscape is also undergoing significant changes, with the [European Union’s Medical Device Regulation (MDR)](https://eur-lex.europa.eu/eli/reg/2017/745/oj/eng "") and In Vitro Diagnostic Regulation (IVDR) serving as prime examples. Interestingly, these regulatory updates have had an unexpected impact on investment trends, as Saem and his team at Zapyrus have observed. “What our data showed was actually the opposite in this past quarter Q2 - Europe surpassed North America in terms of rate of growth in financial investment in MedTech,” Saem reveals. “It’s because of that stability of like, ‘Okay, we know what the regulations are now, and now we feel comfortable in investing that dollar in there.'” This shift in investment patterns underscores the importance of regulatory clarity and stability in attracting capital to the MedTech space. As the industry continues to evolve, companies that can demonstrate a firm grasp of the regulatory landscape and a proactive approach to cybersecurity are likely to be more attractive to investors. ## The Growing Importance of Cybersecurity in MedTech Alongside the need for market intelligence and sales enablement, the MedTech industry is also grappling with the increasing importance of cybersecurity. As medical devices become increasingly connected and reliant on advanced technologies such as artificial intelligence and machine learning, the potential for cyber threats to compromise patient safety and data privacy has become a pressing concern. The recent cases of the Illumina incident, where the company was accused of falsifying evidence of cybersecurity compliance, and the tragic AI therapy failure, where an AI system instructed a suicidal patient to kill themselves, have further highlighted the need for MedTech companies to prioritize cybersecurity from the outset. ## Proactive Cybersecurity: A Necessity for MedTech Innovation As the MedTech industry continues to embrace new technologies and push the boundaries of innovation, the need for proactive cybersecurity measures has become increasingly apparent. the team emphasizes that MedTech companies can no longer afford to treat cybersecurity as an afterthought, as the consequences can be severe. - Regulatory delays: the team has seen cases where cybersecurity issues have resulted in 12-month delays in FDA clearance, which can be devastating for startups with limited runway. - Investor concerns: Investors are now scrutinizing cybersecurity plans more closely, as they recognize the potential impact of a breach on a company’s valuation and reputation. - Patient safety risks: Vulnerabilities in connected medical devices can put patient lives at risk, as evidenced by the AI therapy failure case. To mitigate these risks, the team and Saem both emphasize the importance of addressing cybersecurity early and often, even if it means self-regulating before regulatory bodies catch up. “You need to take the ownership and put the patient first and take the proactive steps to ensure that you have proper measures in place,” Saem explains. “You almost need to self-regulate to some extent so that you allow time for a slow-moving organization like the FDA to kind of catch up, because it’s changing so quickly.” By taking a proactive approach to cybersecurity, MedTech companies can not only protect their innovations and patient safety, but also position themselves as more attractive investment opportunities and streamline the regulatory approval process. ## Timing is Everything: When to Invest in Sales Enablement and Cybersecurity For MedTech companies seeking to scale their business and secure their future, the question of when to invest in sales enablement and cybersecurity solutions, such as Zapyrus and Blue Goat Cyber, becomes crucial. According to Saem, the ideal time to establish a scalable sales and marketing infrastructure is when a company is looking to grow beyond word-of-mouth and repeat business. This typically occurs when a company is considering implementing a CRM, a contact management tool, or a more market intelligence solution. “If you’re looking to grow beyond word of mouth and repeat business, that’s when you start to look at do we need a CRM? Do we need a contact tool? Do we need a database? So we need more intelligence to help us scale out the team and future-proof the growth strategy,” Saem explains. Similarly, the team emphasizes the importance of addressing cybersecurity early and often, even if it means self-regulating before regulatory bodies catch up. By proactively addressing cybersecurity concerns, MedTech companies can not only protect their innovations and patient safety but also position themselves as more attractive investment opportunities and streamline the regulatory approval process. Ultimately, the key to success in the MedTech industry lies in striking a balance among innovation, sales enablement, and cybersecurity. By using market intelligence, embracing proactive security measures, and aligning with regulatory trends, MedTech companies can position themselves for long-term growth and success. ## Conclusion In the world of MedTech, the ability to use market intelligence and stay ahead of cybersecurity threats has become increasingly crucial for driving sustainable growth. By bridging the regulatory gap, using data-driven insights, and prioritizing proactive security measures, leading MedTech companies are positioning themselves for long-term success. To learn more about how Zapyrus can help your MedTech business streamline its sales and marketing efforts, visit [their website](https://welcome.zapyrus.com/). And to explore how Blue Goat Cyber can help secure your medical devices and protect patient safety, schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session ""). ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### How does market intelligence benefit MedTech companies? Market intelligence helps MedTech companies identify market signals, streamline sales and marketing, and engage with potential customers at optimal times. This data-driven approach enhances sales efficiency and supports strategic growth. ### Why is cybersecurity important for MedTech investment? Investors scrutinize cybersecurity plans closely due to its impact on valuation, reputation, and regulatory compliance. Strong cybersecurity practices signal stability and reduced risk, making companies more attractive to investors. ### What regulatory challenges does the MedTech industry face? The MedTech industry faces a regulatory landscape that historically lags behind the pharmaceutical sector. This gap can lead to slower adoption of standardized practices and increased security vulnerabilities, though recent EU regulations offer clearer guidelines. ### Does proactive cybersecurity affect FDA clearance timelines? Yes, cybersecurity issues can cause significant regulatory delays, including up to 12-month hold-ups for FDA clearance. Addressing cybersecurity early helps streamline the approval process and avoids costly setbacks. ### When should MedTech companies invest in cybersecurity and sales enablement? MedTech companies should invest in cybersecurity early and continuously to protect innovations and patient safety. Sales enablement tools become crucial when a company aims to grow beyond word-of-mouth and scale its sales and marketing infrastructure. ### How does MedTech self-regulation relate to FDA guidance? Given the dynamic nature of technology, MedTech companies often need to self-regulate by adopting proactive security measures before the FDA can publish updated guidance. This approach prioritizes patient safety and helps companies stay ahead of regulatory expectations. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Linux vs Windows for Medical Devices: Security Comparison Source: https://bluegoatcyber.com/blog/linux-vs-windows-a-security-comparison # Linux vs Windows for Medical Devices: A Security Comparison (2026) > **[DIRECT ANSWER]** Neither OS is inherently more secure for a medical device. Embedded Linux wins on attack surface minimization and build control; Windows IoT Enterprise LTSC wins on built-in enterprise security features and a predictable long support window. FDA reviewers evaluate hardening, secure boot, signed update architecture, SBOM discipline, and postmarket patch capability, not the OS brand. The "Linux vs Windows" debate is usually argued like a desktop preference. Medical devices do not live like desktops. They ship with a fixed purpose, stay in clinical service for seven to fifteen years, connect to hospital networks, and must remain patchable long after the original development team has moved on. So the useful question is not "which OS is more secure?" It is: **which OS can this team harden, update, and defend for the full device lifecycle, and prove it in a submission?** ## Key Takeaways - **The OS choice is a lifecycle commitment, not a security verdict.** The Feb 3, 2026 FDA premarket cybersecurity guidance evaluates your hardening, update architecture, and postmarket patch plan, not the platform name. - **Embedded Linux gives you the smallest achievable attack surface** because you control what goes into the image, but only if you run reproducible builds and pin versions. - **Windows IoT Enterprise LTSC gives you a fixed ten-year servicing window** plus Secure Boot, Device Guard, Credential Guard, and BitLocker as built-in, documentable controls. - **Both platforms fail the same way**: unnecessary services enabled, no signed update path, local admin left available, and third-party components nobody owns. - **SBOM burden is real on both.** Linux dependency sprawl and Windows drivers, runtimes, and bundled components each produce components you must track and disclose. - **OS support end-of-life is a submission risk.** If your OS build hits end of support before or shortly after clearance, expect a cybersecurity deficiency on the patchability and updateability views. ## Why This Matters for a Regulated Device The operating system sets the ceiling on almost every security control you will later document. Your architecture views, your threat model boundaries, your patch cadence, your vulnerability response timelines, and your labeling all inherit from that one early decision. Change it after clinical data exists and you are re-validating the whole device. It also sets your clock. A device cleared on an OS build with three years of remaining vendor support is a device with a known, dated cybersecurity liability. Reviewers read the support window against the expected device lifetime, and a gap there is one of the more common avoidable deficiencies we see on connected devices. ## First: Which Windows and Which Linux? In MedTech the real comparison is narrower than the internet version: - **Embedded Linux**, usually a [Yocto-based](https://www.yoctoproject.org/) or otherwise controlled build, for devices that need networking, a modern UI stack, or rich applications. - **[Windows IoT Enterprise LTSC](https://learn.microsoft.com/en-us/windows/iot/iot-enterprise/overview)**, for fixed-purpose devices that benefit from the Windows ecosystem, driver availability, or an existing enterprise toolchain. Edition matters enormously. Consumer Windows on a clinical device is a different risk conversation than LTSC, and a general-purpose desktop distribution is a different conversation than a purpose-built image. Name the exact edition and build in your submission; "Linux" or "Windows" alone tells a reviewer nothing. ## The Six Criteria That Actually Decide It Evaluate both platforms against the same list: 1. **Attack surface control.** Can you remove what you do not need and keep the configuration stable across manufacturing? 2. **Isolation.** Can you contain a compromise through process separation, least privilege, and memory protection? 3. **Secure boot and integrity.** Can you prevent persistent tampering at startup and verify the running image? 4. **Secure update architecture.** Signed updates, rollback control, key custody, and a realistic validation plan. 5. **Lifecycle patching.** A documented plan for the OS, third-party libraries, and bundled runtimes, not just your application. 6. **Vulnerability response.** How quickly you can assess exposure to a new CVE and ship a mitigation. If you cannot answer all six for a platform, that platform is not yet a defensible choice regardless of its reputation. ## Where Embedded Linux Is Stronger **Minimal builds are genuinely minimal.** A controlled embedded build lets you ship only the packages the device needs. Fewer services, fewer listening ports, fewer CVEs to triage every quarter. This is the single biggest security advantage Linux offers, and it is measurable in your SBOM component count. **Mandatory access control.** [SELinux](https://www.redhat.com/en/topics/linux/what-is-selinux) and [AppArmor](https://apparmor.net/) meaningfully reduce blast radius when an application process is compromised. The trade-off is real design effort; policies do not write themselves, and a permissive-mode policy that nobody tightened is documentation theater. **Toolchain and hardware flexibility.** You can match the OS to constrained hardware, integrate platform-specific secure boot chains, and instrument the build pipeline however your verification plan requires. **Common Linux failure modes:** assuming the platform is secure by default, leaving a general-purpose package set enabled, having no defined update strategy, and dependency sprawl with unclear component ownership. ## Where Windows IoT Enterprise Is Stronger **Enterprise security features are already there and already documented.** Secure Boot, Device Guard, Credential Guard, BitLocker, and Microsoft Defender give you a set of controls with vendor documentation you can cite directly in your architecture and hardening evidence. That shortens the evidence-writing work considerably. **A predictable, contractual support window.** LTSC follows a fixed lifecycle policy with a long support period from the OS general availability date. For a device expected to stay in clinical use for a decade, a published end-of-support date you can plan against is a genuine regulatory asset. **Consistent managed-device operations.** When a Windows-based device is treated as a locked-down managed endpoint, with controlled images, controlled software, and monitored configuration drift, hospital IT teams already understand how to operate it. **Common Windows failure modes:** shipping a general-purpose desktop image instead of a fixed-purpose locked-down build, leaving local admin available for service convenience, patch validation bottlenecks that stall the update cadence, and relying on endpoint antivirus in place of architecture and isolation. ## Side-by-Side Comparison | Dimension | Embedded Linux | Windows IoT Enterprise LTSC | | --- | --- | --- | | Attack surface minimization | Excellent when you control the build; easy to keep small | Good with a fixed-purpose image; risky if left general-purpose | | Isolation and least privilege | Strong with process separation plus SELinux or AppArmor; requires policy effort | Strong feature set available; depends on correct configuration | | Secure boot and integrity | Available; implementation depends on silicon vendor and build pipeline | Well-supported and well-documented across the ecosystem | | Update and patching model | You own the whole strategy; powerful but demands tooling and discipline | Central update tooling exists; servicing and validation must still be planned | | Support window predictability | Depends on your distribution and kernel LTS choices | Fixed, published lifecycle policy from the OS GA date | | Third-party dependency management | Sprawls quickly; SBOM discipline is critical | Still substantial; drivers, runtimes, and bundled components all count | | Evidence writing effort | Higher; you document your own hardening decisions | Lower; vendor documentation supports many controls | | Operational consistency in hospitals | High when controlled; low if distribution drift occurs | High when treated as a managed endpoint | ## What the FDA Actually Looks At Reviewers do not have an OS preference. Under the Feb 3, 2026 premarket cybersecurity guidance, the platform shows up indirectly across several deliverables: - **Architecture views.** The updateability and patchability view has to show a real signed update path with rollback handling. Both platforms can satisfy this; neither does so by default. - **Threat model.** Your OS determines several trust boundaries and a set of platform-level threats you must address explicitly. See our [STRIDE threat modeling guidance](/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective) for how those boundaries get documented. - **SBOM.** Every OS package, driver, runtime, and library appears here with support-level and end-of-support information. This is where an unmaintained component becomes visible. - **Security testing.** Hardening claims get verified. If you assert that a service is disabled, expect the [penetration test](/services/medical-device-penetration-testing) to confirm it. - **Postmarket plan.** Your ability to ship a patch within a defined window is a function of the update architecture you chose alongside the OS. The pattern in deficiency letters is consistent: problems come from unsupported components, missing signed update paths, and hardening claims without evidence. None of those are OS-brand problems. ## Legacy Platforms and Inherited Decisions Most teams asking this question are not choosing freely. They inherited a platform with a shipped device on it. That situation is workable, but it changes the work: you document the platform you have, quantify the residual risk honestly, and build the compensating controls and update capability around it. Our [legacy medical device guidance](/guides/legacy-medical-device-cybersecurity) covers how to frame an aging platform in a submission without either overstating the controls or triggering an avoidable deficiency. The one decision worth revisiting is the support window. If the current OS build goes end-of-support inside the device's expected service life, plan the migration now and describe the plan in your postmarket documentation rather than waiting for a reviewer to ask. ## How Blue Goat Cyber Approaches OS Selection We treat the OS decision as a submission input, not an engineering preference. On a typical engagement that means mapping the candidate platforms against the six criteria above, checking the support window against the expected device lifetime, modeling the trust boundaries each platform creates, and stress-testing the proposed update architecture before code gets written around it. The output is a documented rationale you can drop into the architecture section and defend, plus an SBOM approach sized to the platform you picked. If you are already downstream of the decision, we work from what exists: hardening review, update architecture assessment, and a residual-risk narrative that holds up in review. If the FDA raises cybersecurity deficiencies on a submission we prepared, we resolve them at no additional cost. - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [SBOM Services for MedTech](/services/fda-compliant-sbom-services-for-medtech) - [FDA Postmarket Cybersecurity Management](/services/fda-postmarket-cybersecurity-services) ## FAQ ### Is Linux more secure than Windows for medical devices? Not automatically. A purpose-built, hardened embedded Linux image and a locked-down Windows IoT Enterprise LTSC image can both reach a strong security posture. Configuration discipline and lifecycle patching capability determine outcomes far more than the platform label. ### Which platform is easier to maintain postmarket? Whichever one your team can patch, validate, and deploy reliably for the full device lifetime. Teams routinely underestimate the operational burden of long-term patching, especially for third-party components. Windows LTSC offers a more predictable schedule; Linux offers more control over what needs patching in the first place. ### Does the FDA prefer one operating system over another? No. The Feb 3, 2026 premarket cybersecurity guidance is platform-neutral. Reviewers assess secure design decisions, the hardening approach, the update architecture, vulnerability response, and verification results. ### Do Windows-based medical devices get enterprise security features automatically? The features exist in Windows IoT Enterprise, including Secure Boot, Device Guard, Credential Guard, BitLocker, and Defender. They are not automatically configured. Selecting the right edition and intentionally configuring and documenting each control is the actual work. ### How does OS choice affect the SBOM? Substantially. A minimal embedded Linux build can produce a much shorter component list than a general-purpose image, which reduces ongoing CVE triage. Windows contributes drivers, runtimes, and bundled components that still must be enumerated with support status. ### What if our OS reaches end of support before the device retires? Document the migration plan in your postmarket cybersecurity management plan, define the interim compensating controls, and be explicit about the timeline. A known gap with a credible plan reviews far better than a gap you did not mention. ## Talk to us about your platform decision If you are choosing between Linux and Windows, or inheriting a platform you did not pick, we can pressure-test the decision against what your submission will need. [Talk to our team](/contact). --- *Christian Espinosa, Founder, CISSP. Christian has led FDA cybersecurity submissions for connected medical devices across embedded Linux and Windows-based platforms, including devices with long clinical service lives. [Read more from Christian](/team/christian-espinosa).* --- ## LoRaWAN Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/lorawan-vulnerabilities-on-medical-device-cybersecurity # LoRaWan Vulnerabilities on Medical Device Cybersecurity > **[DIRECT ANSWER]** LoRaWAN, a low-power long-range wireless protocol used in remote patient monitoring, is vulnerable to weak encryption, poor authentication, and replay attacks that can enable data tampering, inaccurate diagnostics, or unauthorized device access. Manufacturers should apply end-to-end encryption, strong authentication, and secure key management, then validate them through vulnerability assessments and penetration testing. The FDA's Feb 3, 2026 guidance expects these controls to be documented as part of the device's threat model and risk management file, not treated as network-layer assumptions. ## Key Takeaways - LoRaWAN enables crucial long-range communication for IoT medical devices. - Potential vulnerabilities include weak encryption, poor authentication, and replay attacks. - Compromises can lead to data tampering, inaccurate diagnostics, and patient harm. - Strong encryption, authentication, and key management are essential. - The FDA February 3, 2026 guidance emphasizes cybersecurity for medical devices. - Proactive monitoring and regulatory compliance bolster device security. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to lorawan vulnerabilities on medical device cybersecurity the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding LoRaWan and Its Importance in Medical Devices LoRaWan, which stands for Long Range Wide Area Network, is a low-power wireless communication protocol specifically designed for the Internet of Things (IoT). It enables long-range communication between devices, allowing medical devices to transmit and receive data over long distances. With the [rise of telemedicine and remote patient monitoring](/blog), the role of LoRaWan in healthcare has become increasingly significant. This technology facilitates the transmission of critical health data from patients to healthcare providers, enabling timely interventions and personalized care. ### The Role of LoRaWan in Healthcare LoRaWan has the potential to revolutionize healthcare by enabling remote monitoring, real-time data analysis, and improved patient care. It allows medical devices such as wearable monitors to transmit vital health information to doctors and caregivers, even from a distance. LoRaWan enhances healthcare systems’ efficiency by enabling predictive medical equipment maintenance. By monitoring the performance and status of devices in real-time, healthcare facilities can proactively address issues, reducing downtime and ensuring uninterrupted patient care. ### Key Features of LoRaWan Technology One of LoRaWan’s critical features is its long-range capability, which allows medical devices to communicate across great distances, ensuring connectivity regardless of location. Additionally, LoRaWan operates on low power, making it ideal for battery-operated devices. The [secure and reliable nature of LoRaWan communication](/blog/securing-communication-protocols-in-medical-devices) ensures the privacy and integrity of sensitive medical data. This encryption and authentication mechanism protects against potential cyber threats, safeguarding patient information and upholding confidentiality in healthcare settings. ## Identifying LoRaWan Vulnerabilities While the benefits of using LoRaWan in medical devices are clear, it is essential to recognize that with any technological advancement comes the potential for vulnerabilities. Understanding and addressing these vulnerabilities is crucial to ensure the safety and security of both patients and their medical data. ![Section Image](/imported-images/fc7c7561d007e620.webp) Regarding LoRaWan vulnerabilities, one must also consider the [potential threat of replay attacks](/blog/medical-device-key-exchange-cybersecurity). In a replay attack, a malicious actor intercepts data transmissions and retransmits them, potentially causing confusion or unauthorized actions within the network. This type of attack could compromise the integrity of medical data and lead to incorrect diagnoses or treatments. ### Common LoRaWan Security Issues One common security issue with LoRaWan is the lack of encryption. Without encryption, data transmitted between medical devices and the network could be intercepted and compromised, posing a significant risk to patient privacy. Additionally, as LoRaWan operates on an unlicensed spectrum, it is susceptible to jamming and interference. Another critical security concern in LoRaWan networks is the lack of proper authentication mechanisms. Without authentication protocols, malicious actors could potentially impersonate legitimate devices or gateways, gaining unauthorized access to sensitive medical data or disrupting the network’s operations. ### Potential Risks of LoRaWan Vulnerabilities The potential risks of LoRaWan vulnerabilities are vast and can have severe consequences. Unauthorized access to medical devices could lead to patient data tampering or manipulating device functionality, putting patients’ health and lives at risk. Moreover, unauthorized access to sensitive medical data could result in identity theft or malicious activities. Stakeholders in the healthcare industry must stay vigilant and proactive in identifying and mitigating LoRaWan vulnerabilities. By implementing encryption, authentication, and intrusion detection mechanisms, the risks associated with using LoRaWan in medical devices can be significantly reduced, ensuring the integrity and confidentiality of patient data. ## The Intersection of LoRaWan and Medical Device Cybersecurity The intersection of LoRaWan and medical device cybersecurity is a critical area of concern. Understanding how vulnerabilities in LoRaWan can impact medical devices is essential for implementing effective cybersecurity measures. ![Section Image](/imported-images/93963cc8b9bf3988.webp) When exploring the relationship between LoRaWan and medical device cybersecurity, it is crucial to consider the unique challenges posed by the healthcare industry. Medical devices often handle sensitive patient data and play a vital role in patient care, making them attractive cyberattack targets. As the healthcare sector increasingly adopts Internet of Things (IoT) technologies like LoRaWan for connectivity and data transmission, the need to address cybersecurity risks becomes even more pressing. ### How LoRaWan Vulnerabilities Affect Medical Devices LoRaWan vulnerabilities can directly impact the functionality and safety of medical devices. For instance, a compromised wearable monitor could provide inaccurate health data to healthcare professionals, leading to incorrect diagnoses and potentially harmful treatment decisions. The interconnected nature of medical devices within healthcare facilities can amplify the consequences of a cybersecurity breach. A vulnerability in one device could potentially compromise an entire network of devices, putting patient safety and data security at risk. ### The Consequences of Cybersecurity Breaches in Healthcare Cybersecurity breaches in healthcare can have far-reaching consequences. Apart from the immediate impact on patient care, such breaches can erode patient trust in the healthcare system and result in reputational damage for healthcare providers. Additionally, the financial cost of data breaches can be substantial, with the average cost being millions. Regulatory bodies such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States impose strict requirements for protecting patient information. A cybersecurity breach that exposes patient data leads to financial repercussions, regulatory fines, and potential legal action against healthcare organizations. ## Mitigating the Impact of LoRaWan Vulnerabilities To mitigate the impact of LoRaWan vulnerabilities, it is crucial to implement cybersecurity measures that address the specific risks associated with this technology. With the increasing adoption of Internet of Things (IoT) devices utilizing LoRaWan technology, securing these devices against potential cyber threats has become a top priority for organizations and individuals alike. One key consideration in enhancing LoRaWan security is establishing secure key management practices. Proper key management is essential for ensuring the confidentiality and integrity of data transmitted over LoRaWan networks. By securely generating, storing, and distributing encryption keys, organizations can significantly reduce the risk of unauthorized access and data breaches. ### Strategies for Enhancing LoRaWan Security One strategy for enhancing LoRaWan security is implementing end-to-end encryption. Encrypting data at both ends of communication ensures that only authorized parties can access and decipher the transmitted data. Additionally, regular vulnerability assessments and penetration testing can help identify and address any weaknesses in the system. Continuous monitoring of network traffic and behavior can also aid in the early detection of suspicious activities, allowing for timely response and mitigation. ### Future Directions in Medical Device Cybersecurity Medical device cybersecurity continually evolves to keep pace with technological advancements and emerging threats. Innovations such as machine learning and artificial intelligence are being explored to enhance the detection and prevention of cyber attacks. Policymakers and regulatory bodies also play a vital role in shaping the future of medical device cybersecurity by developing and enforcing appropriate regulations. Collaboration between industry stakeholders, cybersecurity experts, and healthcare professionals is essential to establish security standards and best practices for medical devices. ## The Role of Regulatory Bodies in Ensuring Cybersecurity ![Section Image](/imported-images/df1f4703c69fec15.webp) ### Current Regulations on Medical Device Cybersecurity Currently, several regulatory bodies, such as the [U.S. Food and Drug Administration (FDA)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) and the European Union’s Medical Device Regulation (MDR), have issued guidelines to address the cybersecurity of medical devices. These regulations outline requirements for manufacturers to assess and mitigate risks associated with their devices. ### The Need for Stronger Cybersecurity Policies in Healthcare While existing regulations are a step in the right direction, stronger cybersecurity policies are needed in healthcare. Collaboration between regulatory bodies, healthcare providers, and technology manufacturers is crucial to developing and effective cybersecurity measures that safeguard patient health and data. One area that requires further attention is the continuous monitoring and updating of cybersecurity regulations. As technology evolves rapidly, so do the threats that target medical devices and networks. Regulatory bodies must stay up-to-date with the latest advancements in cyber threats and adapt their guidelines accordingly. This proactive approach will ensure that the regulations remain relevant and effective in addressing emerging cybersecurity challenges. Regulatory bodies can also be pivotal in promoting cybersecurity awareness and education within the healthcare industry. By organizing workshops, seminars, and training sessions, they can equip healthcare professionals with the knowledge and skills necessary to effectively identify and respond to cyber threats. This collaborative effort will create a culture of cybersecurity consciousness where every individual involved in the healthcare ecosystem understands their role in safeguarding patient information and maintaining the system’s integrity. In conclusion, while regulatory bodies have made significant strides in addressing medical device cybersecurity, there is still work to be done. The nature of cyber threats necessitates continuously enhancing regulations and promoting cybersecurity awareness within the healthcare industry. By working together, regulatory bodies, healthcare providers, and technology [manufacturers can ensure a secure future for medical devices,](/blog) protecting patient safety and preserving the confidentiality of sensitive medical data. As the healthcare sector grapples with the complexities of LoRaWan vulnerabilities and medical device cybersecurity, the need for a trusted partner to navigate these challenges becomes paramount. With its veteran-owned heritage and commitment to cybersecurity excellence, Blue Goat Cyber stands ready to assist. Our tailored B2B services, including medical device cybersecurity, penetration testing, and HIPAA and FDA standards compliance, are designed to protect your business and patients from cyber threats. Don’t let vulnerabilities compromise your operations or patient safety. [Contact us today for cybersecurity help](/contact) and take the first step towards a secure and compliant digital healthcare environment with Blue Goat Cyber. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is LoRaWAN? LoRaWAN (Long Range Wide Area Network) is a low-power wireless communication protocol designed for IoT. It facilitates long-range communication between devices, enabling medical devices to transmit data over considerable distances efficiently. ### How can LoRaWAN vulnerabilities affect medical devices? Vulnerabilities in LoRaWAN can enable data interception, unauthorized access, and replay attacks. This can lead to compromised patient data, inaccurate device readings, incorrect diagnoses, and potential harm to patients. ### What are common security issues in LoRaWAN for medical devices? Common issues include insufficient encryption, inadequate authentication mechanisms, and susceptibility to jamming or interference. These can allow unauthorized parties to access sensitive medical data or disrupt network operations. ### How can LoRaWAN security in medical devices be enhanced? Enhance security through end-to-end encryption, strong authentication protocols, and secure key management practices. Regular vulnerability assessments and continuous network monitoring are also needed for early threat detection. ### Does the FDA regulate LoRaWAN cybersecurity in medical devices? The FDA provides guidance on medical device cybersecurity in its February 3, 2026 final guidance. Manufacturers must adhere to these guidelines to ensure the safety and security of devices using technologies like LoRaWAN. ### What are the consequences of a cybersecurity breach involving medical devices? Consequences include patient data exposure, compromised patient safety, erosion of trust, significant financial penalties, and regulatory fines. Breaches can lead to legal action and damage to the healthcare provider's reputation. **Related:** [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## M2M Communication Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/m2m-communication-vulnerabilities-in-medical-devices-a-cybersecurity-concern # M2M Communication Vulnerabilities in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** Machine-to-machine communication vulnerabilities occur when medical devices exchange data over insecure protocols, letting attackers intercept, alter, or disrupt data between sensors, gateways, and platforms without strong encryption or authentication. This creates real patient-safety and data-privacy risk. The FDA expects manufacturers to apply architectural security, threat modeling, and lifecycle risk management to address these exposures under Section 524B. _Updated November 10, 2024_ Machine-to-machine communication makes modern medical devices more useful, more connected, and more exposed. When devices exchange data without strong security controls, attackers can interfere with care delivery, compromise patient data, or create unsafe device behavior. ## Key Takeaways - M2M connectivity expands medical device attack surfaces. - Exploitable M2M flaws risk patient safety and data compromise. - Insecure communication protocols are a primary vulnerability. - Architectural security and threat modeling are crucial. - Strong encryption and authentication prevent many M2M attacks. - The FDA expects lifecycle cybersecurity for M2M devices. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to m2m vulnerabilities in medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding M2M Communication in Medical Devices [Machine-to-machine (M2M)](https://en.wikipedia.org/wiki/Machine_to_machine) communication is the exchange of data between devices with little or no human involvement. In healthcare, that can mean an infusion system sending status updates to a monitoring platform, a wearable transmitting vital signs, or one clinical system passing data to another for diagnosis, treatment, or recordkeeping. ![Section Image](/imported-images/f59fc192f3c7b3c5.webp) That connectivity supports faster decisions and better visibility, but it also expands the attack surface. Sensors, actuators, mobile apps, cloud services, gateways, and backend APIs all become part of the same security problem. If one link is weak, the whole system is at risk. ### Why M2M Matters in Healthcare M2M communication supports real-time monitoring, remote care, and faster clinical response. Providers can review patient data sooner, intervene earlier, and extend care beyond the hospital. Telemedicine and remote monitoring programs depend on this kind of device-to-device and device-to-platform communication. It also improves operational efficiency. Devices can share measurements automatically, reduce manual entry, and help clinicians work with more current information. That benefit is real. So is the risk when manufacturers treat connectivity as a feature first and a security problem second. ### Core Characteristics of M2M Medical Device Systems Most M2M medical device environments share a few traits: continuous data exchange, interoperability across products and systems, and some form of remote access or monitoring. Those traits are useful, but each one introduces security requirements. Interoperability means trust boundaries must be defined clearly. Remote monitoring means authentication and session management have to hold up under real-world use. Continuous data exchange means [security protocols embedded within M2M communication systems](/blog/securing-communication-protocols-in-medical-devices) need to protect confidentiality, integrity, and availability, not just check a box. ## The Cybersecurity Reality in Healthcare Healthcare is a high-value target. Medical devices now sit inside larger clinical networks that include EHR platforms, cloud services, mobile applications, third-party integrations, and remote support channels. Attackers do not care whether the initial foothold is a pump, a workstation, or a vendor portal. They care that the environment is connected. Manufacturers and healthcare delivery organizations have responded with stronger security programs, but the threat pressure keeps rising. More connected devices mean more exposed interfaces, more software dependencies, and more chances to miss something during design, deployment, or maintenance. ### Current Security Measures in Medical Devices Manufacturers commonly use encryption for data in transit, authentication controls, software signing, access restrictions, and periodic updates to reduce risk. Security testing has also improved, and many organizations now do more staff training on phishing, credential hygiene, and social engineering. Those steps matter, but they are not enough by themselves. A device can encrypt traffic and still expose insecure APIs. It can require login credentials and still rely on default accounts or weak authorization logic. It can pass a basic assessment and still fail under realistic adversarial testing. That is why [the importance of cybersecurity in the medical device industry](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) cannot be reduced to a short control list. ### Common Threats Facing Connected Healthcare Systems The threat set is familiar: ransomware, malware, credential attacks, data theft, exploitation of known vulnerabilities, and abuse of remote access pathways. In M2M environments, man-in-the-middle attacks, replay attacks, insecure update mechanisms, and trust abuse between connected systems are especially relevant. Telehealth and remote patient monitoring add another layer. Data has to move across home networks, mobile devices, cloud infrastructure, and provider systems. Every handoff is a chance for failure if the architecture was not designed with adversaries in mind. ## Identifying Vulnerabilities in M2M Communication M2M vulnerabilities usually come from predictable engineering failures, not exotic zero-days. Weak transport security, poor key management, exposed services, insecure defaults, outdated components, and bad assumptions about trusted environments show up again and again. ![Section Image](/imported-images/6087278f6522ccbb.webp) Physical access matters too. If an attacker can tamper with a device, access debug ports, extract credentials, or alter firmware, network-layer protections may not save you. Security for connected medical devices has to account for both remote and local attack paths. ### Common Weak Points One major issue is unprotected or poorly protected data transmission. If traffic is not encrypted properly, attackers may intercept, alter, or replay sensitive information. Weak or default passwords remain another common problem, especially in service interfaces and support workflows. Outdated software and third-party components create additional exposure. So do insecure network configurations, undocumented interfaces, and weak segmentation. Many connected devices also trust commands or data from peer systems too easily, which is dangerous in any clinical environment. [Secure coding](/blog) matters here. Input validation failures, unsafe deserialization, injection flaws, broken authorization, and insecure update logic can all appear in M2M implementations. These are not abstract software bugs. In medical devices, they can become patient safety issues. ### What These Vulnerabilities Mean for Patient Safety When attackers exploit M2M weaknesses, the consequences can go well beyond data loss. Unauthorized access may allow a bad actor to change settings, disrupt therapy, suppress alerts, or interfere with device availability. Even if a successful attack does not directly manipulate therapy, delayed care and loss of clinician trust can still create harm. Patient data is also at risk. A breach can expose protected health information, support fraud, and create legal and regulatory fallout. In connected care environments, one compromised component can affect many others. That is why manufacturers need to assess exploitability and clinical impact together, not as separate exercises. ## Addressing M2M Communication Vulnerabilities Security for M2M medical devices starts with architecture, not marketing claims. If the product depends on trusted networks, static credentials, or vague assumptions about how hospitals will deploy it, you already have a problem. ![Section Image](/imported-images/b7d833693aa2d08c.webp) ### Practical Strategies for Stronger M2M Security Start with proven basics. [Implement strong encryption protocols to secure data transmission](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist). Use modern authentication. Eliminate default credentials. Lock down exposed services. Sign and verify software and firmware updates. Patch known vulnerabilities on a schedule that reflects actual risk, not convenience. Then go deeper. Define trust boundaries between devices, apps, cloud services, and clinical systems. Use least privilege for machine identities and service accounts. Build logging that supports incident investigation. Test failure modes, not just normal operation. If a connection drops, a certificate expires, or a peer system behaves maliciously, the device should fail safely. Development practices matter just as much as deployed controls. Threat modeling, code review, software bill of materials management, dependency tracking, and adversarial testing should be standard. Security training also needs to reach engineering, product, support, and field teams. A security culture is useful only if it changes decisions. ### Where M2M Cybersecurity Is Headed Connected medical devices will keep adding cloud connectivity, analytics, remote support features, and AI-enabled functionality. That means more complexity and more dependency chains. Detection and response will improve with better telemetry and automation, but prevention still depends on getting the design right early. Some manufacturers are exploring technologies such as behavioral analytics and blockchain-backed integrity models for specific use cases. Those may help in narrow scenarios, but they do not replace secure architecture, validated update mechanisms, and disciplined vulnerability management. There is no shortcut around the fundamentals. ## The Role of Regulatory Bodies in Cybersecurity Regulators matter because weak security in a medical device is not just an IT problem. It is a product quality and patient safety issue. The FDA has made that clear through guidance, premarket expectations, and postmarket cybersecurity focus. ### Existing Medical Device Cybersecurity Expectations The FDA expects manufacturers to address cybersecurity throughout the product lifecycle. That includes security by design, risk-based decision making, testing, vulnerability handling, and plans for monitoring and updates after release. FDA guidance has pushed the industry toward better documentation and stronger evidence during development and submission. Manufacturers also need workable incident response and coordinated vulnerability disclosure processes. If a security issue is found, the organization should know how to assess it, communicate clearly, and remediate without chaos. That is part of mature product security, not an optional add-on. ### Why Stronger Enforcement and Better Execution Still Matter Guidance alone does not fix weak engineering. Some organizations still treat cybersecurity as submission support instead of product discipline. That approach does not hold up under scrutiny, and it certainly does not hold up in the field. The answer is not more checklist theater. It is better execution: stronger validation, realistic security testing, clearer accountability, and tighter coordination among manufacturers, providers, researchers, and regulators. The FDA can raise the floor, but manufacturers still have to build devices that can withstand real attacks. M2M communication has improved care delivery, remote monitoring, and clinical visibility. It has also created new attack paths that manufacturers can no longer afford to underestimate. If your device relies on connected workflows, security has to be built into the system from the start and maintained for the life of the product. Blue Goat Cyber helps medical device manufacturers find the weaknesses that matter, fix them, and support defensible FDA-facing cybersecurity work. If you need help assessing connected device risk, validating controls, or strengthening your product security program, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is M2M communication in medical devices? M2M communication is data exchange between devices with minimal human involvement. In medical settings, this includes devices sharing patient data, status updates, or communicating with clinical systems for monitoring and treatment. ### How does M2M communication create cybersecurity risks? M2M communication expands the attack surface by connecting various devices, apps, and services. Insecure channels, weak authentication, and poor data handling create pathways for unauthorized access, data compromise, and device manipulation. ### What are common M2M vulnerabilities in medical devices? Common vulnerabilities include weak encryption, insecure authentication, poor key management, exposed services, and unpatched software. These can allow attackers to intercept data, control devices, or disrupt care. ### Does the FDA regulate M2M cybersecurity in medical devices? Yes, the FDA expects manufacturers to incorporate cybersecurity throughout the product lifecycle for all connected medical devices, including those with M2M communication. This includes strong design, testing, and postmarket vulnerability management as outlined in its February 3, 2026 final guidance. ### How can manufacturers mitigate M2M cybersecurity risks? Manufacturers should implement strong encryption, multifactor authentication, secure boot mechanisms, and defined trust boundaries. Regular security testing, threat modeling, and a software bill of materials (SBOM) are also essential. ### How do M2M vulnerabilities affect patient safety? Exploiting M2M vulnerabilities can lead to unauthorized changes in therapy, data manipulation, or denial of service, directly impacting patient care. It can also expose sensitive patient information, leading to privacy breaches and loss of trust. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) YouTube ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [SoC Vulnerabilities in Medical Devices](/blog/exploring-system-on-a-chip-soc-vulnerabilities) --- ## Managing Interconnected Medical Devices Source: https://bluegoatcyber.com/blog/managing-connected-medical-devices-a-strategic-approach # Managing Interconnected Medical Devices: What Manufacturers Need to Know > **[DIRECT ANSWER]** Managing connected medical devices effectively requires a device inventory, defined procurement and retirement processes, interoperability planning, and strong cybersecurity controls such as encryption, access management, and continuous monitoring. Organizations also need staff training and compliance with HIPAA and the FDA's Feb 3, 2026 premarket cybersecurity guidance. Treating device management as a continuous lifecycle activity, rather than a one-time deployment task, is what keeps connected devices both clinically useful and secure. _Updated November 15, 2024_ Managing connected medical devices has become critical to delivering quality patient care. The ability to collect and analyze data from these devices can revolutionize the way healthcare is provided. However, it also brings its own set of challenges and concerns. This article will explore the importance of connected medical devices, their benefits to modern healthcare, and the strategic approach required to manage them effectively. ## Key Takeaways - Prioritize device inventory and lifecycle management. - Implement strong cybersecurity protections. - Comply with HIPAA and other regulations. - use data for improved patient care. - Train staff on device operation and security. - Continuously evaluate and update strategies. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to managing interconnected medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding the Importance of Connected Medical Devices Connected medical devices have emerged as powerful tools that enable healthcare professionals to monitor patients remotely, gather real-time data, and make informed decisions. These devices encompass a wide range of equipment, including wearable sensors, implantable devices, and diagnostic equipment [interconnected through the Internet of Things](/blog) (IoT). ![Section Image](/imported-images/f6faa263d5eb7fc8.webp) Connected medical devices have revolutionized the healthcare industry by providing healthcare professionals with unprecedented patient data access. This data allows for more accurate diagnoses, personalized treatment plans, and improved patient outcomes. These devices streamline data collection and analysis by integrating with existing healthcare systems, saving time and resources. ### The Role of Connected Devices in Modern Healthcare Connected devices play a crucial role in modern healthcare by enhancing patient outcomes and reducing healthcare costs. For example, remote patient monitoring devices allow healthcare providers to monitor patients with chronic illnesses, such as diabetes or heart disease, without frequent hospital visits. By continuously collecting patient data, healthcare professionals can identify potential issues early on and intervene promptly, preventing complications and hospital readmissions. In addition to remote patient monitoring, connected devices enable telemedicine, allowing patients to consult with healthcare professionals remotely. This is particularly beneficial for individuals in rural or underserved areas with limited access to healthcare facilities. Through video consultations and remote monitoring, patients can receive timely medical advice and treatment, reducing the need for unnecessary travel and improving overall healthcare accessibility. ### Benefits and Challenges of Connected Medical Devices The benefits of connected medical devices are substantial, but so are the challenges. These devices enable healthcare providers to deliver personalized, data-driven care that improves patient outcomes. Additionally, remotely monitoring patients reduces the burden on healthcare facilities and helps prioritize resources more efficiently. However, the proliferation of connected devices also introduces [security risks and compliance concerns](/blog). Protecting patient data and ensuring the devices meet regulatory requirements are vital to maintaining patient trust and avoiding costly breaches. Organizations must [implement security measures](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist) and adhere to compliance standards to safeguard patient privacy and minimize cybersecurity threats. Integrating connected devices into existing healthcare systems requires careful planning and coordination. Healthcare professionals must be trained to use these devices and interpret the data they provide effectively. Additionally, healthcare facilities must invest in the necessary infrastructure and IT support to ensure connectivity and data management. Despite these challenges, connected medical devices have immense potential to revolutionize healthcare. As technology advances, these devices will become even more sophisticated, providing healthcare professionals with valuable insights and patients with improved care and convenience. ## Developing a Strategic Approach for Device Management Successfully managing connected medical devices requires a strategic approach that addresses the unique challenges associated with their implementation and upkeep. This section explores key medical device management strategy elements and steps to successful implementation. ![Section Image](/imported-images/b72cf002a25378de.png) ### Elements of a Medical Device Management Strategy A device management strategy encompasses several critical elements. Firstly, defining the scope and inventory of connected medical devices within an organization is crucial. This includes identifying the devices, their connectivity status, and the data they generate. Creating a centralized inventory system ensures better control over device management. In addition to inventory management, another key element of a medical device management strategy is establishing clear processes and guidelines for device procurement, deployment, and retirement. A standardized workflow ensures consistent practices across the organization and reduces operational inefficiencies. [Medical device interoperability](/blog/medical-device-cybersecurity-interoperability-concerns) must be considered within the management strategy. Ensuring that devices can communicate and exchange data with each other and existing systems is crucial for efficient and effective healthcare delivery. ### Steps to Implementing a Successful Management Strategy Implementing a successful medical device management strategy involves several key steps. Firstly, conducting a thorough risk assessment helps identify potential vulnerabilities and formulate appropriate mitigation plans. This assessment should evaluate the device’s security features, data encryption capability, and compatibility with existing systems. Developing a training program for healthcare professionals ensures they are competent in operating and maintaining the connected devices. User education is crucial for preventing user errors and data breaches. Implementing proactive maintenance and monitoring practices is vital for device management. Regular inspections, software updates, and performance evaluations help identify and address potential issues before they escalate, minimizing downtime and ensuring optimal device performance. Lastly, continuous management strategy evaluation and improvement are necessary to adapt to evolving technology and industry standards. Regularly reviewing and updating policies, procedures, and technologies ensures that the device management strategy remains effective and aligned with the organization’s goals. ## Ensuring Cybersecurity and Compliance in Connected Devices As the use of connected medical devices continues to grow, ensuring security and compliance becomes paramount. This section explores the importance of security in connected medical devices and highlights the compliance standards organizations must adhere to. ![Section Image](/imported-images/395742c3ccb51dd5.png) ### Importance of Cybersecurity in Connected Medical Devices The interconnected nature of these devices exposes them to [potential security breaches](/blog), making security a top concern. Protecting patient health information from unauthorized access, ensuring data integrity, and preventing device tampering are critical for maintaining patient trust. One example of the importance of security in connected medical devices is the rise of [ransomware](/blog) attacks targeting healthcare organizations. These attacks can encrypt patient data and hold it hostage until a ransom is paid. This compromises patient privacy and disrupts healthcare operations, putting lives at risk. To address these security concerns, organizations are investing in advanced cybersecurity solutions. These solutions employ encryption algorithms, firewalls, and intrusion detection systems to protect connected devices from unauthorized access. Regular security audits and vulnerability assessments are also conducted to identify and mitigate potential risks. ### Compliance Standards for Connected Medical Devices Compliance with regulatory standards is essential to manage the risks associated with connected medical devices. Organizations must adhere to the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR). HIPAA sets the standards for protecting patient health information, ensuring its confidentiality, integrity, and availability. It requires healthcare organizations to implement safeguards to protect patient data, conduct regular risk assessments, and train employees on privacy and security practices. Similarly, [GDPR](https://gdpr-info.eu/) applies to organizations that handle the personal data of European Union citizens. It requires organizations to implement appropriate technical and organizational measures to protect personal data, obtain consent for data processing, and notify authorities in case of a data breach. ## Optimizing the Use of Connected Medical Devices Connected medical devices have revolutionized the healthcare industry, offering immense potential to transform patient care. When correctly leveraged, these devices can provide valuable insights and improve patient outcomes. This section will explore how connected devices can enhance patient care and discuss the exciting future trends in connected medical device management. ### Leveraging Connected Devices for Improved Patient Care One of the most significant advantages of connected medical devices is their ability to gather real-time patient data. This data can be invaluable for healthcare professionals who provide personalized care and make informed decisions. By using the power of connected devices, healthcare providers can identify patterns, establish effective treatment plans, and closely monitor patient progress. Let’s take a real example to illustrate the impact of connected devices on patient care. Philips Healthcare’s eICU Program is a groundbreaking initiative that connects critical care specialists with remote ICUs using advanced telehealth technology. This program allows specialists to monitor patients remotely, provide expert recommendations, and significantly improve patient outcomes. Accessing real-time data from connected devices enables these specialists to intervene promptly and make informed decisions, ultimately saving lives. ### Future Trends in Connected Medical Device Management The field of connected medical device management is evolving rapidly, with exciting future trends on the horizon. One such trend is integrating artificial intelligence (AI) and machine learning algorithms into connected devices. By incorporating AI capabilities, these devices can perform predictive analytics, detect early disease, and even develop personalized treatment plans. This integration of AI has the potential to revolutionize patient care and further enhance outcomes. ## Who owns which control Most disputes between manufacturers and hospitals come from an unwritten assumption about who is responsible for a control. Writing it down is half the work. | Control area | Manufacturer owns | Health delivery organization owns | Where it goes wrong | | --- | --- | --- | --- | | Authentication design | The mechanism, credential rules, and lockout behavior | Account provisioning and removal | Shared clinical logins defeat a sound mechanism | | Patching | Producing and validating the update | Scheduling and applying it without disrupting care | Updates exist but never get installed | | Network placement | Documenting required ports, flows, and segmentation assumptions | Implementing the segmentation | Assumptions live in a vendor engineer's head, not in the manual | | Monitoring | Logs the device can produce and export | Collecting and reviewing them | Logs exist locally and no one reads them | | Asset records | Model, version, and component information | Keeping the inventory current | The inventory ages out within a quarter | | Vulnerability communication | Timely disclosure and mitigation guidance | Acting on the disclosure | Notices go to a purchasing contact who has left | Every environmental control a manufacturer assumes is a claim, and the FDA can ask how the customer is told about it. ## Conclusion Managing connected medical devices requires a strategic approach that encompasses their importance, addresses security and compliance concerns, and uses their potential to enhance patient care. Organizations must prioritize the development of device management strategies, implement security measures, and stay abreast of emerging trends to stay ahead in the healthcare landscape. By embracing the power of connected devices, healthcare providers can unlock new possibilities and revolutionize patient care. As healthcare technology advances, the strategic management of connected medical devices becomes increasingly crucial. At Blue Goat Cyber, we understand the complexities of medical device cybersecurity and are dedicated to providing top-tier B2B cybersecurity services. Our expertise in penetration testing, HIPAA and FDA compliance, and a suite of other cybersecurity solutions position us as your ideal partner in safeguarding your medical devices against cyber threats. Being a Veteran-Owned business, we’re committed to excellence and the security of your operations. [Contact us today for cybersecurity help](/contact) and take the first step towards a more secure future for your healthcare organization. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What are connected medical devices? Connected medical devices encompass a wide range of equipment, including wearable sensors, implantable devices, and diagnostic tools, interconnected through the Internet of Things (IoT). They enable real-time data collection and remote monitoring. ### Why is cybersecurity important for connected medical devices? Cybersecurity matters for connected medical devices to protect patient health information from unauthorized access, ensure data integrity, and prevent device tampering. Breaches can compromise patient privacy and disrupt healthcare operations. ### What compliance standards apply to connected medical devices? Organizations must adhere to standards like HIPAA, which protects patient health information, and GDPR, which applies to handling personal data of EU citizens. The FDA's February 3, 2026 final guidance also sets cybersecurity requirements for medical devices. ### How can connected devices improve patient care? Connected devices provide real-time patient data, enabling personalized care and informed decisions by healthcare professionals. They facilitate remote monitoring, early detection of issues, and more efficient treatment plans. ### What is involved in a medical device management strategy? A strategy involves defining device scope and inventory, establishing procurement and retirement processes, ensuring interoperability, conducting risk assessments, and providing staff training. Proactive maintenance and continuous evaluation are also essential. ### Does the FDA regulate cybersecurity for medical devices? Yes, the FDA regulates cybersecurity for medical devices. The February 3, 2026 final guidance outlines requirements for manufacturers to ensure the cybersecurity of devices submitted for premarket approval, including considerations for security by design and postmarket activities. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## MDCG 2019-16 & MedTech Cybersecurity Source: https://bluegoatcyber.com/blog/mdcg-2019-16-and-medical-device-security # MDCG 2019-16 & MedTech Cybersecurity: for Medical Device Manufacturers > **[DIRECT ANSWER]** MDCG 2019-16 is the EU's cybersecurity guidance for the MDR and IVDR, and it maps closely to the FDA's expectations without being identical. It covers secure design, IT security risk management alongside ISO 14971 safety risk, verification, and postmarket surveillance obligations. Manufacturers selling in both markets should build one evidence set and produce a crosswalk, rather than maintaining two parallel cybersecurity files that drift apart. _Reviewed July 24, 2026_ The Medical Device Coordination Group (MDCG) 2019-16 guidance has emerged as a cornerstone for medical device regulation, particularly in addressing cybersecurity requirements. But what exactly does it cover? Understanding the principles and expectations outlined in this post is essential for stakeholders across the medical device industry to ensure compliance, protect patient safety, and secure sensitive data. ## Key Takeaways - MDCG 2019-16 guides medical device cybersecurity in Europe. - Manufacturers must integrate security throughout product lifecycles. - Proactive risk assessment and continuous monitoring are vital. - Collaboration among stakeholders strengthens collective defense. - Compliance prevents penalties and enhances market trust. - Cybersecurity is now a core design principle, not an afterthought. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to mdcg 2019-16 & MedTech cybersecurity the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## The Purpose of MDCG 2019-16 [MDCG 2019-16](https://health.ec.europa.eu/system/files/2022-01/md_cybersecurity_en.pdf) isn’t just guidance - it’s your blueprint for cybersecurity success in the European medical device market. Designed for manufacturers, it zeroes in on safeguarding device functionality and protecting against evolving cyber threats. Think of it as your navigation system through the increasingly complex world of digital health regulations. In a hyper-connected era of telehealth, remote monitoring, and smart devices, cybersecurity isn’t a nice-to-have - it’s a necessity. Every vulnerability is a potential risk to patient safety and brand trust. MDCG 2019-16 arms manufacturers with the strategies to design secure, compliant devices from the ground up, ensuring resilience against today’s sophisticated cyberattacks. ## Key Provisions of MDCG 2019-16 MDCG 2019-16 outlines several critical provisions to strengthen medical device cybersecurity across the entire product lifecycle. These include cybersecurity risk assessment strategies, continuous security [monitoring post-deployment](/services/fda-postmarket-cybersecurity-services), and transparent vulnerability disclosure processes. Together, these elements elevate the safety protocols surrounding medical devices, ensuring they are resilient against emerging cyber threats. Think of it this way: handing a knight a shiny new sword without providing armor leaves them dangerously exposed. MDCG 2019-16 ensures that medical devices, like that knight, are fully outfitted for battle, equipped with functionality and layered defenses to protect patient safety at every turn. The guidance emphasizes a proactive approach to cybersecurity, urging manufacturers to integrate security measures from the [earliest stages of device design](/services/secure-medtech-product-design-consulting) through post-market surveillance. This forward-looking stance helps mitigate risks before they materialize and builds a culture of accountability and continuous improvement among device manufacturers. In addition, MDCG 2019-16 stresses the importance of collaboration across the entire ecosystem - manufacturers, healthcare providers, and regulatory authorities. By promoting shared knowledge, best practices, and rapid information exchange on vulnerabilities and incidents, the guidance helps build a collective defense. As medical devices become more connected and complex, this spirit of collaboration becomes essential to protecting patients and preserving trust in medical technology worldwide. ## The Intersection of Medical Devices and Cybersecurity Today’s medical devices are more connected, and more vulnerable-than ever before. As we dig deeper into the essence of modern healthcare technology, it becomes clear that cybersecurity and medical devices are inseparably linked. Neglecting one puts the other at grave risk. ### The Importance of Cybersecurity in Healthcare Healthcare is one of the most sensitive sectors in terms of cybersecurity risk. Medical devices store and transmit invaluable data-patient records, diagnostic images, treatment histories, that make them prime targets for cybercriminals. A single breach could have catastrophic consequences, not just for individuals, but for entire healthcare systems. Imagine waking up to a world where your heart monitor sends false readings or your insulin pump delivers incorrect dosages because it was hijacked. It’s not just concerning; it’s life-threatening. Cybersecurity stands as the critical barrier protecting both patient data and patient lives. The impact of a cyberattack extends beyond individual patients. A compromised network can disrupt clinical operations, delay care delivery, overload administrative systems, and erode public trust. From insurance claims to healthcare outcomes, the ripple effects of a breach can destabilize the entire ecosystem, making strong cybersecurity practices not just advisable but essential. ### Vulnerabilities of Medical Devices Despite rapid technological innovation, many medical devices remain vulnerable. Legacy software, outdated operating systems, insecure wireless connections, and inadequate patch management expose critical devices to attack. It’s like leaving your front door wide open in a dangerous neighborhood; you might feel secure for a time, but it’s only a matter of when, not if, trouble comes knocking. Manufacturers must recognize and address these vulnerabilities with urgency. Yet the pace of technological advancement often outstrips regulatory updates, creating dangerous gaps. IoT-enabled medical devices are particularly at risk, usually shipped without the necessary cybersecurity infrastructure to defend against sophisticated threats. A defense requires collaboration. Device manufacturers, healthcare providers, cybersecurity experts, and regulatory authorities must work together to ensure that medical devices are innovative and resilient against evolving cyber risks. Protecting patient safety and privacy isn’t just a technical challenge; it’s a shared ethical and professional obligation across the entire healthcare industry. ## Impact of MDCG 2019-16 on Medical Device Cybersecurity MDCG 2019-16 has triggered a pivotal shift in how medical device manufacturers approach cybersecurity. Where security was once an afterthought, it is now a central design principle. The guidance pushes organizations toward proactive, strategies critical in today’s evolving [threat landscape.](/blog/understanding-relevant-threats-for-medical-devices) ![Section Image](/imported-images/a6c6716f33527323.png) ### Strengthening Cybersecurity Measures Under MDCG 2019-16, manufacturers are raising the bar. New security protocols, rigorous testing procedures, and continuous risk assessments are becoming standard practice. Companies are embedding security-by-design principles into every stage of device development rather than bolting on protections after the fact. Think of it this way: instead of adding locks to a finished castle, manufacturers are now building cybersecurity into the foundation, like constructing a fortress designed to withstand siege. By prioritizing security early, manufacturers create safer devices that protect sensitive health information and ensure the operational integrity of life-saving technologies. As the [Internet of Medical Things (IoMT)](/blog/securing-iot-devices-in-healthcare-the-frontline-of-patient-safety) expands and devices become increasingly interconnected, building resilient systems is no longer optional; it is essential for patient safety and trust. ### Implications for Medical Device Manufacturers For medical device manufacturers, compliance with MDCG 2019-16 is not just a regulatory box to check; it’s a business imperative. Non-compliance can lead to regulatory penalties, product recalls, reputational damage, and the ultimate loss of market access. Yet, those who embrace these guidelines gain a decisive competitive advantage. Manufacturers can earn greater trust from patients, healthcare providers, and regulators by demonstrating a commitment to cybersecurity. Investing in security measures also strengthens partnerships with hospitals and procurement agencies that are increasingly focused on cybersecurity standards. In an era where device security directly impacts patient outcomes and public perception, proactive compliance with MDCG 2019-16 doesn’t just protect; it elevates. It positions forward-thinking companies as leaders in safety and innovation within the global healthcare ecosystem. ## Challenges and Solutions in Implementing MDCG 2019-16 Implementing MDCG 2019-16 is no easy task. Manufacturers face various challenges in aligning their practices with these heightened cybersecurity expectations. But recognizing these hurdles is the first step toward building smarter, more resilient solutions. The road to compliance can be daunting, from limited resources to the technical complexity of cybersecurity standards. Many organizations may lack the in-house expertise, modern infrastructure, or processes needed to fully meet MDCG 2019-16 requirements. The good news? These challenges are surmountable. Strategic collaborations with cybersecurity specialists, ongoing workforce education, and investment in technologies can bridge the gap. Building strong partnerships accelerates compliance, while building a security-first mindset across the organization ensures long-term resilience. Creating a culture of cybersecurity awareness is just as critical. Regular training, simulated breach exercises, and clearly defined incident response plans empower employees to actively safeguard patient data and device integrity. A vigilant, well-prepared workforce forms the first, and often most crucial-line of defense against cyber threats. ## Future Directions for Medical Device Cybersecurity The future of medical device cybersecurity is both promising and challenging. Cybersecurity is no longer a one-time exercise but an ongoing commitment to adaptation, vigilance, and innovation. Emerging technologies like [artificial intelligence (AI) and machine learning (ML)](/blog/protecting-medical-devices-ai-model-evasion-and-cybersecurity-threats) are poised to revolutionize threat detection, enabling earlier identification of vulnerabilities and faster, automated responses to attacks. However, manufacturers’ strategies, tools, and mindsets must also evolve as attackers evolve. Regulatory bodies tighten expectations, requiring manufacturers to embed cybersecurity throughout the entire product lifecycle, from initial design to post-market surveillance. Those who embrace this shift proactively will achieve compliance and differentiate themselves by delivering safer, more trustworthy medical devices. The path forward demands collaboration. Manufacturers, healthcare providers, cybersecurity experts, and regulatory authorities must work together to build a resilient healthcare ecosystem where patient safety, device reliability, and data protection remain at the forefront. ### The Ongoing Evolution of Cybersecurity Standards The MDCG 2019-16 isn’t just a guideline; it’s a beacon for safer medical technologies. Its impact on cybersecurity in medical devices may well shape the future of the healthcare landscape. As technology continues to advance, the cybersecurity standards will also evolve. The importance of staying ahead of potential threats cannot be overstated. Like a river reshaping the land, the evolution of cybersecurity standards will continually reshape how medical devices interact with their environments. Manufacturers must be vigilant and proactive. ## Conclusion MDCG 2019-16 is a cornerstone regulation. It will enhance medical devices’ physical and operational security and build a culture of safety in healthcare. As they say, a stitch in time saves nine. By adhering to these guidelines, manufacturers are stitching a safety net that will protect patients, data, and, ultimately, the integrity of the healthcare system itself. The future of medical device cybersecurity is indeed in good hands. As the medical device industry continues to advance, cybersecurity becomes increasingly critical. Blue Goat Cyber understands the complexities and challenges of ensuring medical device cybersecurity. Our veteran-owned business is dedicated to providing cybersecurity services tailored to the unique needs of medical device manufacturers. With our expertise in risk management, threat modeling, and secure development practices, we ensure that your devices are protected against the latest cyber threats and comply with [FDA regulations.](https://www.fda.gov/media/119933/download) Don’t let cybersecurity concerns hold you back. Check out our [premarket medical device cybersecurity offerings.](/) ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is MDCG 2019-16? MDCG 2019-16 is a guidance document published by the Medical Device Coordination Group, outlining cybersecurity expectations for medical device manufacturers operating in the European market. It provides a framework for integrating cybersecurity into the design, production, and post-market phases of medical devices. ### Who does MDCG 2019-16 apply to? MDCG 2019-16 primarily applies to medical device manufacturers. It sets forth the expectations for how they should address cybersecurity risks and implement protective measures for their devices. ### Why is MDCG 2019-16 important for medical devices? It is important because it establishes essential guidelines for safeguarding medical device functionality and protecting patient data from cyber threats. Adherence ensures regulatory compliance, enhances patient safety, and builds trust in medical technology. ### What are the main provisions of MDCG 2019-16? Key provisions include requirements for strong cybersecurity risk assessments, continuous security monitoring post-deployment, and transparent processes for vulnerability disclosure. It mandates a proactive, lifecycle-oriented approach to cybersecurity. ### How does MDCG 2019-16 impact device manufacturers? It requires manufacturers to embed security-by-design principles, conduct rigorous testing, and commit to continuous risk management. Non-compliance can lead to regulatory penalties and market access issues, while compliance offers a competitive advantage. ### Does MDCG 2019-16 align with other cybersecurity regulations? While specific to the European market, its principles on lifecycle security, risk management, and vulnerability management align with global trends in medical device cybersecurity. These include aspects of the FDA's February 3, 2026 final guidance. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## MDSAP for Medical Device Compliance Source: https://bluegoatcyber.com/blog/mdsap-for-medical-devices-simplifying-international-compliance # MDSAP for Medical Devices: What Manufacturers Need to Know > **[DIRECT ANSWER]** MDSAP is a single quality management system audit, built on ISO 13485 plus jurisdiction-specific requirements, that satisfies the FDA, Health Canada, the TGA, ANVISA, and Japan's MHLW and PMDA at once. It is mandatory for a Health Canada licence and voluntary elsewhere. MDSAP audits your processes, including the security risk management and software lifecycle procedures behind your cybersecurity work, but it never substitutes for the device-specific cybersecurity evidence in a submission. The [Medical Device Single Audit Program (MDSAP)](https://www.fda.gov/medical-devices/cdrh-international-affairs/medical-device-single-audit-program-mdsap) lets one audit by one authorized auditing organization satisfy five regulators. That is a real reduction in audit burden, but it is frequently misunderstood in two directions: manufacturers assume it does less than it does for cybersecurity, and then assume it does more than it does for submissions. This post explains the audit model, what each participating regulator adds on top of ISO 13485, exactly where cybersecurity surfaces in an MDSAP audit, and how to prepare for that part. ## Key Takeaways - MDSAP is one audit that satisfies five regulators: the US FDA, Health Canada, Brazil's ANVISA, Australia's TGA, and Japan's MHLW and PMDA. - It is **mandatory** for a Health Canada Class II, III, or IV medical device licence and voluntary in the other jurisdictions. - The audit model is built on ISO 13485:2016 plus each regulator's country-specific requirements. - The FDA accepts MDSAP audit reports in lieu of most routine surveillance inspections, but not for pre-approval or for-cause inspections. - Audits run on a three-year cycle: an initial certification audit, two surveillance audits, then recertification. - Cybersecurity shows up through the QMS: security risk management procedures, software lifecycle controls, design controls, complaint handling, and CAPA. - MDSAP certifies process conformity. It does not certify that any specific device's cybersecurity evidence is complete. ## Why this matters Two things changed the calculus on MDSAP. First, Health Canada made it mandatory, so any manufacturer planning a Canadian licence has no opt-out. Second, security risk management moved from an informal practice into the quality system: ANSI/AAMI SW96:2023 and IEC 81001-5-1 describe procedures, records, and traceability, and procedures with records are exactly what an MDSAP auditor is trained to sample. The result is that cybersecurity has quietly become auditable in a way it was not five years ago. A manufacturer can hold a clean FDA clearance and still take a nonconformity because the security risk management procedure exists on paper but produced no records for the last two releases, or because a reported vulnerability never entered the complaint-handling and CAPA process. ## What MDSAP Actually Covers MDSAP audits a manufacturer's quality management system against **ISO 13485:2016** plus the country-specific requirements of each participating regulator you elect to include in scope. It is a QMS audit, not a product review and not a technical file review. The audit is organized around seven processes rather than around ISO clauses: 1. **Management** (including management review and resourcing) 2. **Device marketing authorization and facility registration** 3. **Measurement, analysis, and improvement** (including internal audit, data analysis, and CAPA) 4. **Medical device adverse events and advisory notices reporting** 5. **Design and development** 6. **Production and service controls** 7. **Purchasing** (including supplier controls) Design and development, purchasing, and measurement/analysis/improvement are where cybersecurity evidence is most likely to be sampled. ## The Five Regulators and What Each Adds | Regulator | Status of MDSAP | What it adds on top of ISO 13485 | | --- | --- | --- | | **Health Canada** | Mandatory for Class II, III, IV licences | Licence and MDEL obligations, Section 59 mandatory problem reporting, recall procedures | | **US FDA** | Voluntary, accepted in lieu of most routine surveillance inspections | 21 CFR Part 820 (transitioning to QMSR alignment with ISO 13485), Part 803 MDR reporting, Part 806 corrections and removals, Part 807 registration and listing | | **TGA (Australia)** | Voluntary, usable as conformity assessment evidence for many device types | Essential Principles conformity, Australian sponsor obligations, URPTG recall procedure | | **ANVISA (Brazil)** | Effectively required for many registrations | Brazilian Good Manufacturing Practice requirements and registration-linked obligations | | **MHLW / PMDA (Japan)** | Voluntary, accepted for QMS conformity | Ministerial Ordinance 169 requirements and Japanese marketing authorization holder obligations | You elect the jurisdictions in scope. Adding a jurisdiction adds its country-specific tasks to the audit, which lengthens the audit but avoids a separate one later. ## The Audit Model and Cycle MDSAP runs on a three-year certification cycle: | Year | Audit type | Typical scope | | --- | --- | --- | | Year 0 | Initial certification (Stage 1 and Stage 2) | Full seven-process audit against all elected jurisdictions | | Year 1 | Surveillance | Reduced scope, always includes management, CAPA, and reporting | | Year 2 | Surveillance | Reduced scope, rotating process coverage | | Year 3 | Recertification | Full scope again | Nonconformities are graded on a points-based scheme that escalates with the seriousness of the affected process and with repeat or systemic findings. High-grade findings trigger notification to the participating regulators, which is the mechanism that gives MDSAP its teeth: a serious finding does not stay between you and the auditing organization. Audits are performed by Auditing Organizations authorized and monitored by the participating regulators, not by the regulators themselves. ## Where Cybersecurity Surfaces in an MDSAP Audit This is the part manufacturers under-prepare. Cybersecurity is not a separate audit process, so it gets sampled inside the processes that already exist. | Audit process | What an auditor looks for | Records to have ready | | --- | --- | --- | | Design and development | Security requirements in design inputs, security verification in design outputs, security risk analysis integrated with ISO 14971, design reviews that considered security | Threat model, security risk assessment, design review minutes, verification reports, traceability matrix | | Purchasing and supplier controls | Control over third-party and open-source software components, supplier qualification for software suppliers | SBOM, supplier agreements, component acceptance criteria, evidence of monitoring supplier vulnerability disclosures | | Measurement, analysis, improvement | Whether reported vulnerabilities are analyzed, trended, and driven into CAPA | Vulnerability intake records, risk re-evaluations, CAPA records tied to security findings | | Adverse events and advisory notices | Whether the decision process for reportable cybersecurity events exists and was applied | Reportability decision records, field safety notices, recall records, CVD policy | | Production and service controls | Secure configuration at manufacture, integrity of software loaded at production and service, controlled update distribution | Build and release records, software integrity controls, update deployment records | | Management | Whether security risk is visible at management review and resourced | Management review minutes referencing security posture and open vulnerabilities | > **[KEY REQUIREMENT]** The most common cybersecurity-related MDSAP finding is not a missing document. It is a procedure that exists but produced no records: a security risk management SOP with no evidence it ran during the last two releases, or a CVD policy with no intake log behind it. ## What MDSAP Does Not Do for Your Submission MDSAP certifies that your processes conform. It says nothing about whether a particular device's cybersecurity evidence is sufficient. - **It does not replace premarket cybersecurity content.** A Section 524B package, a Health Canada licence application, or a TGA Essential Principles mapping still has to be written per device. - **It does not replace an FDA pre-approval or for-cause inspection.** The FDA accepts MDSAP reports in lieu of most routine surveillance inspections only. - **It does not certify your threat model.** No auditor evaluates whether your threat model correctly identified the attack surface. They evaluate whether you have a procedure, followed it, and kept records. - **It does not transfer conditions between regulators.** Each jurisdiction still applies its own licence, registration, and reporting rules. The clean mental model: MDSAP is the process argument, the submission is the product argument. You need both, and reviewers in Canada and Australia will notice when a strong process certificate sits behind a thin device file. ## Preparing for the Cybersecurity Parts of the Audit 1. **Write the security risk management procedure into the QMS,** not alongside it. Reference ANSI/AAMI SW96:2023 and connect it explicitly to the ISO 14971 risk management procedure. 2. **Add security activities to design control checkpoints** so design reviews generate records that mention security by name. 3. **Make the SBOM a controlled output** with a defined regeneration trigger per release and a named owner. 4. **Route vulnerability intake through complaint handling.** A reported vulnerability should look, in the record trail, like any other quality signal that gets assessed, risk-rated, and closed. 5. **Define reportability criteria for cybersecurity events** per jurisdiction, and keep the decision records even when the decision was "not reportable." 6. **Put security on the management review agenda** with a standing metric, such as open vulnerabilities by severity and age. 7. **Run a mock sample.** Pick your last release and try to produce the full security record trail in an hour. Whatever you cannot find is what the auditor will ask for. ## How Blue Goat Approaches MDSAP Readiness We work the cybersecurity side of the quality system: writing the security risk management procedure so it integrates with the existing ISO 14971 and IEC 62304 processes, building the record trail an auditor will sample, and producing the device-level artifacts (threat model, SBOM, security risk assessment, penetration test reports) that the procedures are supposed to generate. Our team holds CISSP, OSCP, and prior military red-team credentials, and the work is anchored in IEC 81001-5-1, ANSI/AAMI SW96:2023, ISO 14971, and the FDA February 3, 2026 final premarket guidance. See our [medical device cybersecurity services](/services). **If a regulator raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is MDSAP? MDSAP is the Medical Device Single Audit Program. One audit of a manufacturer's quality management system, performed by an authorized Auditing Organization against ISO 13485:2016 plus country-specific requirements, satisfies the QMS requirements of five participating regulators at once. ### Which countries participate in MDSAP? The United States (FDA), Canada (Health Canada), Brazil (ANVISA), Australia (TGA), and Japan (MHLW and PMDA). Other regulators participate as observers or affiliates without accepting audit reports in the same way. ### Is MDSAP mandatory? It is mandatory for a Health Canada Class II, III, or IV medical device licence. It is voluntary for the other participating regulators, though ANVISA registration pathways make it effectively necessary for many manufacturers entering Brazil. ### Does MDSAP cover cybersecurity? Indirectly but meaningfully. There is no cybersecurity audit process, but security risk management, software lifecycle controls, SBOM and supplier controls, vulnerability handling, and reportability decisions are all sampled inside design and development, purchasing, measurement and improvement, and adverse event reporting. ### Does an MDSAP certificate satisfy premarket cybersecurity requirements? No. MDSAP demonstrates process conformity. Device-specific cybersecurity evidence, including the threat model, SBOM, verification results, labeling, and postmarket plan, still has to be produced for each submission in each market. ### Does the FDA accept MDSAP audits instead of inspections? The FDA accepts MDSAP audit reports in lieu of most routine surveillance inspections. Pre-approval inspections, for-cause inspections, and compliance follow-up inspections are not replaced. ### How long is an MDSAP certificate valid? Certification runs on a three-year cycle: an initial certification audit, surveillance audits in years one and two, and a recertification audit in year three. Serious nonconformities can trigger notification to the participating regulators between audits. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). ## Related reading - [IMDRF Cybersecurity Guidance Explained](/blog/imdrf-for-medical-devices-harmonizing-global-regulations) - [Health Canada Medical Device Cybersecurity](/blog/health-canada-medical-device-cybersecurity) - [TGA Medical Device Cybersecurity](/blog/tga-australia-medical-device-cybersecurity) - [Steganography in Medical Devices](/blog/understanding-relevant-threats-for-medical-devices) --- ## MedJacking Explained: What the Term Covers and What Doesn't Source: https://bluegoatcyber.com/blog/medhacking-and-medjacking # MedJacking Explained: What the Term Covers and What Doesn't > **[DIRECT ANSWER]** MedHacking is the general term for unauthorized access to medical technology, and MedJacking is the narrower case of hijacking an individual device such as a pacemaker or infusion pump. Most public MedJacking claims are researcher demonstrations under lab conditions, not confirmed field attacks. The controls that actually matter are authentication, encrypted communication, signed firmware updates, and network segmentation, applied consistently across a device's full fielded life. MedJacking gets used as a headline word more often than it gets used accurately. The underlying engineering question is not whether an implanted device could theoretically be manipulated. Researchers have shown that under controlled conditions for over a decade. The question that matters for a manufacturer is which of those demonstrated vulnerabilities have realistic attacker economics behind them, and which controls close the gap between a lab proof of concept and a device sitting in a patient for ten years without a security update. That is an engineering question, not a marketing one. ## Key Takeaways - MedHacking is the broad category; MedJacking is the specific case of hijacking one device's function. - Most well-known MedJacking demonstrations came from researchers with device access and specialized equipment, not from confirmed real-world attackers. - Attacker economics matter: a targeted attack on one implanted device rarely competes with ransomware against a hospital network as a return on effort. - The controls that break the attack chain are authentication, encrypted and authenticated communication, signed updates, and segmentation, not any single silver-bullet fix. - Legacy fielded devices without a security update path are the real long-term liability, more than any single dramatic exploit. ## Why This Matters The FDA's final guidance *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026, is the current step in a chain that ran through the September 27, 2023 final guidance and the June 27, 2025 update, and it makes cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers evaluate the threat classes MedJacking describes, unauthorized access, remote manipulation, and command injection, using the same threat-modeling and security-risk-management expectations that apply to every cyber device. That means the term itself does not matter to a reviewer. What matters is whether your threat model names the specific attack paths a connected implant or infusion device actually has, and whether your controls close them. A submission built around a vague reference to hacking risk, without a concrete attack tree, does not meet that bar regardless of what the product category is called in the press. ## What does MedJacking actually describe? MedJacking describes an attacker gaining control of a specific medical device's function, as opposed to breaching a hospital network or stealing data. MedHacking is the umbrella term that covers both: any unauthorized access to medical technology, from an EHR breach to a compromised infusion pump. The distinction is useful for scoping a threat model, since network breaches and device hijacking need different controls even though both fall under the same broad label. In practice, a device threat model should not use either term as a category. It should enumerate specific attack paths: unauthenticated wireless pairing, an unsigned firmware update mechanism, a debug interface left active in production, or a cloud API that trusts device identity without verifying it. MedJacking as a word describes an outcome, not a mechanism, and mechanisms are what a security architecture review and a penetration test actually evaluate. ## Which historical cases are verified, and which are overstated? Verified: independent researchers have repeatedly demonstrated that certain wireless insulin pumps and implantable cardiac devices could be manipulated by someone with physical or close-range radio access and the right equipment, and these findings led to FDA safety communications and manufacturer firmware updates. These are documented, published, and led to concrete remediation. That track record is real and it is the reason regulators now expect premarket threat modeling for connected implants. What does not hold up under scrutiny is the broader claim, often repeated without a specific source, that hospital ransomware outbreaks were caused by an attacker pivoting through a hijacked implanted device. That mechanism has not been demonstrated in a documented, attributed incident. Ransomware operators overwhelmingly enter through phishing, exposed remote access, and unpatched enterprise systems, not through pacemakers. Conflating the two exaggerates the implant risk and understates the actual dominant attack vector. ## Why do researcher demonstrations differ from real attacker economics? A researcher demonstration is optimized to prove a vulnerability exists, with time, physical device access, specialized radio equipment, and no need to profit from the result. A real attacker weighs cost against payoff, and targeting one implanted device to harm one patient is an enormous amount of effort for a single, hard-to-monetize outcome. Compare that to the economics of a ransomware attack against a hospital's file servers, which can affect thousands of records and extract a payment with far less specialized equipment. That is why the actual incident record skews heavily toward network and data attacks rather than device hijacking, even though device hijacking demonstrations get more media attention. | Factor | Researcher demonstration | Realistic field attacker | | --- | --- | --- | | Equipment | Specialized radio and debug tools, often vendor-provided | Commodity tools, opportunistic access | | Access | Physical or near-field access to a specific device | Remote, scalable access to networks | | Goal | Prove a vulnerability class exists | Maximize return for effort spent | | Target selection | One device, chosen for the demonstration | Whatever is exposed and profitable at scale | > **[KEY REQUIREMENT]** A threat model for an implanted or infusion device should still address the demonstrated attack classes, physical and near-field access, firmware tampering, and unauthenticated commands, because premarket review evaluates plausible attack paths regardless of whether large-scale field exploitation has occurred yet. ## Which controls actually break the attack chain? No single control stops device hijacking; the attack chain breaks at whichever link is missing, so a manufacturer needs coverage across several links rather than one strong control and several weak ones. Authentication on every command interface prevents an unauthorized party from issuing commands even with radio or network access. Encrypted and authenticated communication prevents both eavesdropping and injected commands that impersonate a legitimate sender. Signed firmware with integrity verification at boot stops a tampered update from ever running. Network segmentation limits how far a compromised device or workstation can reach, which matters most for infusion pumps and monitors that sit on hospital networks. [Penetration testing under real attack conditions](/services/medical-device-penetration-testing) is what confirms these controls actually hold together as a chain rather than as a checklist of independent items. ## What should a manufacturer do about legacy fielded devices? Legacy devices without a security update mechanism are the real long-term liability, more than any single dramatic exploit, because a vulnerability found five years into a device's service life has no remediation path if the device cannot receive a signed update. A manufacturer's postmarket process should track which fielded device versions can and cannot receive updates, and treat the second category as a standing risk to manage, not a closed issue. Where a device cannot be updated, compensating controls at the network or facility level, such as segmentation and access restriction, become the primary mitigation, and that dependency should be documented and communicated to the health delivery organizations still using the device. Waiting for a specific exploit to force the issue costs more than building the update path during design. ## How Blue Goat Cyber Approaches This We build the threat model around specific attack paths, unauthenticated interfaces, unsigned updates, unauthenticated wireless pairing, rather than a general hijacking risk narrative, because that is what a reviewer and a real penetration test both need to evaluate. Our team includes CISSP and OSCP certified engineers with prior red team backgrounds who test the full attack chain, not isolated components, so the result reflects whether the controls actually hold together. For legacy or currently fielded devices, we assess what a security update path can realistically support and where compensating network-level controls have to carry the risk instead. Every finding traces back to a specific control and a verified test result. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Frequently Asked Questions **Is MedJacking a term the FDA uses in its guidance?** No. It is an industry and media term, not a regulatory one. The FDA's guidance discusses unauthorized access, remote manipulation, and command injection as threat categories to be addressed in the threat model, regardless of what label is applied to them elsewhere. **Has a patient ever been harmed by an actual MedJacking attack, outside of a lab demonstration?** There is no publicly documented, attributed case of a patient harmed by a real-world device hijacking outside of researcher demonstrations. The demonstrated vulnerabilities are real and led to remediation, but that is different from a confirmed field attack causing harm. **Does a device need physical proximity to be at risk, or can MedJacking happen remotely?** It depends on the device's connectivity. Devices with only short-range wireless, such as some implants, generally require proximity for the demonstrated attacks. Devices with internet or hospital network connectivity, such as infusion pumps, have a larger remote attack surface and need controls scoped accordingly. **How does segmentation help if the vulnerability is in the device itself?** Segmentation does not fix a device-level flaw, but it limits how an attacker reaches the device in the first place and what else they can reach if the device is compromised. It is a compensating control that reduces impact, which matters most for devices that cannot receive a security update quickly. **What is the single biggest gap manufacturers have in this area?** The most common gap is a fielded device population with no viable update path, discovered only after a vulnerability is found. Building the secure update mechanism during design, rather than retrofitting it after a finding, is what actually closes this gap. **Should older cleared devices be retested against current threat classes?** Yes, particularly if the device has meaningful field connectivity and no update history. A postmarket security risk assessment against current threat classes, including the ones covered here, tells you whether compensating controls are still adequate or whether the device needs a remediation plan. ## CTA If your device threat model still describes hijacking risk in general terms rather than specific attack paths, that gap will surface in review. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to walk through your device's attack surface and update path. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity Lifecycle Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-a-complete-lifecycle-guide # Medical Device Cybersecurity Lifecycle: Design to Decommission > **[DIRECT ANSWER]** Medical device cybersecurity is a full lifecycle commitment spanning design, premarket submission, postmarket monitoring, and decommissioning, not a documentation task completed before filing. The FDA's Feb 3, 2026 guidance embeds it directly into the Quality Management System Regulation, requiring an SPDF, SBOM, threat modeling, and penetration testing at premarket, plus continuous vulnerability monitoring, a coordinated disclosure process, and a 60-day remediation timeline for critical risks after clearance. Medical device cybersecurity is not a documentation exercise you complete before submission. It is a full lifecycle commitment that starts at the first design decision and runs through decommissioning, spanning every team that touches the product. The stakes are real: 53% of networked medical devices carry at least one known critical vulnerability, and the FDA now treats cybersecurity as a mandatory quality system element under the February 2026 QMSR-aligned guidance. This is not a checkbox added late in development. It is a core engineering and regulatory obligation. Many manufacturers who struggle with it share the same gaps: cybersecurity integrated too late, documentation that does not hold up to FDA scrutiny, and postmarket plans that exist on paper but not in practice. This guide maps the full lifecycle: regulatory expectations, core frameworks, international standards, and postmarket obligations. ## Key Takeaways - Cybersecurity is a full lifecycle commitment. - The FDA treats cybersecurity as a QMSR element. - Section 524B defines requirements for "cyber devices". - Premarket submissions need SPDF, SBOM, and threat modeling. - IEC 62443 and IEC 81001-5-1 are core technical standards. - Postmarket plans require continuous monitoring and CVD. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device cybersecurity lifecycle the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What Medical Device Cybersecurity Actually Covers ### It’s a patient safety issue, not just a data protection issue Medical device cybersecurity is the set of technical and process controls that protect connected devices from unauthorized access, manipulation, or disruption, and by extension, protect the patients who depend on those devices. This distinction matters because it fundamentally separates the device security context from enterprise IT security. In an IT environment, the primary concern is data confidentiality. In a device context, a compromised infusion pump or ventilator is a direct clinical risk. The threat model is categorically different, and the controls must reflect that. ### The full scope: from design through end-of-support The FDA and IMDRF both treat cybersecurity as a total product lifecycle obligation. It begins at design conception and does not end at clearance. IMDRF organizes this into four distinct phases: development, support, limited support, and end of support. Each phase carries distinct manufacturer responsibilities: - **Development:** Security must be designed in from the start. - **Support:** Vulnerabilities must be actively monitored and patched. - **Limited support:** Residual risks must be documented and communicated to healthcare providers. - **End of support:** Manufacturers must transfer responsibility with complete lifecycle documentation. Understanding which phase you are in tells you exactly what regulators expect from you right now. ## Premarket and Postmarket Medical Device Cybersecurity Requirements ### The FDA’s 2026 guidance and the QMSR shift The FDA’s February 2026 guidance document made a structural change: cybersecurity is now embedded directly into the Quality Management System Regulation, aligned with ISO 13485:2016. Security testing maps to Clause 7.3.7 as part of design validation. Cybersecurity events and vulnerabilities flow into corrective and preventive actions under Clause 8.5. The practical consequence is that cybersecurity risk assessments must happen at the same stage and with the same rigor as safety risk assessments, not as an afterthought staged before submission. See the [FDA’s premarket cybersecurity guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) for details on how these expectations map into submission content. ### Section 524B and what it requires for cyber devices Section 524B of the FD&C Act defines what qualifies as a “cyber device” and sets binding requirements for manufacturers of those devices. Premarket submissions must include a cybersecurity management plan that covers ongoing vulnerability monitoring, a coordinated vulnerability disclosure process, and timely patching commitments. The timelines are specific and non-negotiable: critical uncontrolled risks must be addressed within 60 days, and customers must be notified of uncontrolled vulnerabilities within 30 days of identification. Per the February 2026 FDA guidance, manufacturers who meet these timelines under a formal CVD program are generally exempt from additional FDA reporting requirements, provided the program is fully documented and operational before an incident occurs. ### What IMDRF adds beyond FDA requirements IMDRF reinforces shared responsibility between device manufacturers and healthcare providers across every lifecycle phase. Manufacturers do not simply hand off responsibility at sale. During limited support and end-of-support phases, they must document residual risks, provide transition guidance, and communicate end-of-support milestones proactively, ideally with at least two years of advance notice. This is particularly important for legacy devices that continue operating in clinical environments long after active support ends. [IMDRF’s final guidance](https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-200318-pp-mdc-n60.pdf) makes clear that cybersecurity obligations do not expire when the product line does. ## Core Premarket Frameworks the FDA Expects in Your Submission ### Secure Product Development Framework (SPDF) The SPDF is the documented process structure that demonstrates cybersecurity was built into development, not bolted on before filing. The FDA expects submissions to include evidence of an SPDF covering threat identification, risk mitigation, security testing, and lifecycle processes. It complements existing QMS standards like ISO 13485 and IEC 62304 rather than replacing them. Blue Goat Cyber develops SPDF documentation tailored to eSTAR submission requirements, structured to give reviewers the evidence they need and minimize the gaps that commonly trigger deficiency letters. For a detailed breakdown of industry expectations across premarket and postmarket phases, see our [Guide to Medical Device Cybersecurity Standards](/blog/guide-to-medical-device-cybersecurity-standards-premarket-postmarket-lifecycle). ### Software Bill of Materials (SBOM) An SBOM is a structured inventory of every software component, library, and dependency in the device. The FDA requires it to support ongoing vulnerability monitoring, because you cannot track vulnerabilities in components you have not inventoried. Incomplete or inaccurate SBOM documentation is among the most frequently cited reasons cybersecurity deficiencies arise during 510(k) reviews. The SBOM must cover commercial, open-source, and off-the-shelf components, and it must be paired with exploitability scores and patching plans to be submission-ready. ### Threat modeling and penetration testing Threat modeling is the structured process of identifying attack surfaces and likely threat actors based on the device’s operating environment: hospital networks, Bluetooth connections, Wi-Fi routers, cloud components, and the clinical staff who interact with the device. Penetration testing validates that threat model by actively probing device defenses against real attack techniques. Both are required evidence in premarket submissions. Both must be documented with sufficient rigor to hold up under FDA scrutiny, and penetration testing must be conducted on final, production-equivalent devices, not development builds. ## International Standards That Govern Secure Device Development ### IEC 62443 and IEC 81001-5-1: the secure development stack [IEC 62443](https://en.wikipedia.org/wiki/IEC_62443), particularly Parts 4-1 and 4-2, defines the secure product development lifecycle for device components and systems. It introduces security levels (SL 0 through SL 4) matched to threat severity: SL 1 addresses protection against casual misuse, while SL 4 addresses protection against advanced attacks with extensive resources. Security levels are applied per technical requirement and component rather than as a single product-wide rating. The standard requires defense-in-depth controls including encryption, least privilege, network segmentation, and access control. IEC 81001-5-1 adapts IEC 62443-4-1 specifically for health software and medical devices, requiring evidence of threat modeling, secure coding practices, and vulnerability management as part of the device lifecycle. Together, these two standards form the technical backbone of a defensible security architecture. If you need practical guidance on aligning device programs with evolving regulatory and standards expectations, read our piece on [Navigating the Evolving Cybersecurity Landscape for Medical Devices](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). ### IEC 62304, ISO 14971, and ISO/IEC 27001: the supporting layer IEC 62304 governs software lifecycle processes, covering planning, development, validation, and maintenance, with cybersecurity integrated into each phase through secure coding and change management requirements. ISO 14971 extends risk management to cover cyber hazards directly. It requires iterative risk assessments that link security weaknesses to safety impacts, not just safety risks to device failure modes. ISO/IEC 27001 applies at the organizational level, particularly for managing protected health information and supply chain security. These three standards do not operate independently; they form an interlocking layer that regulators expect to see addressed coherently across the submission package. ## Postmarket Vulnerability Management and Incident Response ### Continuous monitoring and coordinated disclosure After clearance, manufacturers must actively monitor for vulnerabilities using sources including ICS-CERT, H-ISAC, and third-party software monitoring services. A formal CVD process must be in place before a vulnerability is discovered, not after. That process needs documented evaluation protocols, legal protections for security researchers who report vulnerabilities, defined response timelines, and clear communication pathways to healthcare facilities. Per FDA guidance expectations, a CVD program that exists only as a policy document, without the operational infrastructure to act on disclosures, will not satisfy regulators or protect patients when a real vulnerability surfaces. ### Remediation timelines and the 60-day rule The FDA’s expectation is clear: critical uncontrolled risks require a fix or compensating control within 60 days. All patches must be validated under the Quality System Regulation before deployment. This applies to every cyber device covered by the Section 524B management plan submitted at clearance. For manufacturers without a defined patching and validation workflow already built into their QMS, meeting that timeline under pressure is extremely difficult. Building the process before it is needed is the only practical approach. ### What real incidents reveal about preparedness gaps The incident data is specific. When medical device cybersecurity events occur, 31% of affected healthcare organizations face up to 12 hours without critical systems (per HIMSS cybersecurity survey data). Ransomware has disabled entire fleets of electronic fetal monitors, creating immediate clinical emergencies. In early 2026, CISA issued urgent warnings about remote access vulnerabilities in patient monitors that exposed administrative controls. These are not edge cases: according to the HHS 2025 threat report, 77% of healthcare organizations were targeted by ransomware in 2025, and healthcare reported more cyberthreats than any other critical infrastructure sector in 2024. Incident response plans built before a device ships are what separate recoverable events from clinical emergencies. ## Why Specialized Expertise Makes the Difference ### What generalist security firms miss in the device context General IT security firms understand enterprise environments. As a rule, they are not versed in FDA submission workflows, eSTAR templates, AAMI TIR57 / ANSI/AAMI SW96:2023, or how a threat model maps to a 510(k) review. That gap tends to surface in deficiency letters, delayed clearances, and documentation that does not survive scrutiny. Medical device cybersecurity requires simultaneous fluency in clinical context, regulatory process, and technical security controls. A firm that brings only two of those three to an engagement will cost you time and clearance cycles. ### How Blue Goat Cyber approaches this differently Blue Goat Cyber works exclusively with medical device manufacturers and MedTech companies. Every engagement is a device cybersecurity engagement. That means the team handling your SPDF documentation, SBOM creation, threat modeling, penetration testing, and FDA-ready submission artifacts is focused entirely on this regulatory domain, not splitting attention across unrelated industries or learning healthcare device cybersecurity standards on the job. For companies preparing a first submission or resolving a deficiency letter under deadline, that depth of focus is the differentiator. Learn more about our approach and expert perspectives in [Navigating the Cybersecurity Landscape for MedTech Innovators](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). ## Build It In from the Beginning Medical device cybersecurity is not a point-in-time deliverable. It runs from the first design decision through end-of-support communications, across every team and every product iteration. The FDA’s 2026 guidance makes this explicit by embedding cybersecurity into QMSR. IMDRF reinforces shared responsibility at every lifecycle phase. The frameworks, SPDF, SBOM, threat modeling, and penetration testing, are not optional documentation exercises. They are the evidence base that supports both FDA clearance and ongoing patient safety. Manufacturers who build cybersecurity in from the beginning clear faster and respond to postmarket threats with less disruption. Those who treat it as a submission formality tend to find out the hard way: through deficiency letters, clearance delays, and incident response situations they are not equipped to manage. Medical device cybersecurity demands more than general security knowledge, it requires deep familiarity with FDA submission workflows, international standards, and the clinical stakes involved. If your team is preparing a premarket submission, navigating a deficiency response, or building out a postmarket vulnerability management program, Blue Goat Cyber provides specialized end-to-end support across every phase of that work. That combination of regulatory fluency and technical depth is exactly what we offer. For a practical roadmap to aligning your program with current regulatory expectations, see our piece on [navigating the evolving cybersecurity landscape for medical devices](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). ### Related Articles in This Series - [Postmarket Cybersecurity for Medical Devices: The FDA Roadmap](/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap) - [Medical Device Pen Testing: Choosing the Right Provider](/blog/medical-device-pen-testing-choosing-the-right-provider) - [How to Respond to an FDA Cybersecurity AI Request](/blog/how-to-respond-to-an-fda-cybersecurity-ai-request) - [Why ISO 27001 and SOC 2 Are Not Enough for FDA Medical Device Cybersecurity](/blog/why-iso-27001-and-soc-2-are-not-enough-for-fda-medical-device-cybersecurity) - [A Step-by-Step Guide to Threat Modeling Connected and Implantable Medical Devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) - [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance) ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the FDA's primary concern regarding medical device cybersecurity? The FDA's primary concern is patient safety. Compromised medical devices pose direct clinical risks, making cybersecurity a critical patient safety issue rather than solely a data protection matter. ### How does the FDA's February 2026 guidance impact medical device manufacturers? The February 2026 FDA guidance integrates cybersecurity directly into the Quality Management System Regulation (QMSR). This means cybersecurity risk assessments must be conducted with the same rigor as safety risk assessments, and testing maps to design validation. ### What is a Software Bill of Materials (SBOM) and why does the FDA require it? An SBOM is an inventory of all software components within a device. The FDA requires it to facilitate ongoing vulnerability monitoring, as manufacturers cannot track vulnerabilities in components they have not identified. ### What is the 60-day rule for vulnerability remediation? The 60-day rule, per Section 524B and the February 2026 FDA guidance, states that critical uncontrolled cybersecurity risks must be addressed with a fix or compensating control within 60 days of identification. This applies to all cyber devices. ### What is a Secure Product Development Framework (SPDF)? An SPDF is a documented process structure demonstrating that cybersecurity was integrated throughout the device development lifecycle, covering threat identification, risk mitigation, security testing, and lifecycle processes. It is a required element in FDA submissions. ### Does medical device cybersecurity end after device clearance? No, per the FDA and IMDRF, medical device cybersecurity is a total product lifecycle obligation. It continues through postmarket phases, including continuous monitoring, vulnerability management, and end-of-support communications. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity Best Practices: 2026 Build Plan Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-best-practices # Medical Device Cybersecurity Best Practices: 2026 Build Plan > **[DIRECT ANSWER]** Medical device cybersecurity best practices means building evidence a reviewer can trace end to end: a system-level threat model built to ANSI/AAMI SW96, security requirements traced to controls and tests, an operational SBOM with VEX statements, risk-based testing including penetration testing, signed updates, and a staffed postmarket program with coordinated disclosure. Each piece has to survive the specific question a reviewer asks about it, not just exist in a binder. A deficiency letter on cybersecurity almost never says "you have no security features." It says the threat model does not match the architecture diagram, the SBOM has no VEX statements, or the penetration test report does not map findings back to the threats you claimed to have modeled. Those are process failures, not missing controls, and they cost a submission cycle to fix. This guide is the build plan we use with engineering and regulatory affairs teams before that letter arrives: what a reviewer actually checks, what evidence satisfies it, and where teams lose the most time. ## Key Takeaways - A shallow or late threat model is the single biggest cause of cybersecurity deficiencies, because every other artifact traces back to it. - Reviewers read SBOMs for disposition, not inventory. A component list with no VEX statement reads as unmonitored. - eSTAR v7.0 gives cybersecurity exactly one attachment area, so your threat model, SBOM, test reports, and postmarket plan must read as one cross-referenced package, not scattered files. - Penetration testing evidence is judged by whether findings map back to the threat model, not by the count of findings. - Postmarket cybersecurity fails most often because ownership was never assigned, not because the process was never written. - Access control and update integrity failures still account for a large share of field compromises, ahead of exotic protocol attacks. ## Why This Matters The FDA's cybersecurity expectations for premarket submissions were first finalized in September 2023, updated in draft form in June 2025, and finalized again as *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* on February 3, 2026. That guidance, read alongside Section 524B of the FD&C Act, is what a reviewer is holding when they open your submission. The practical effect is a single traceable story: threats, controls, tests, and a postmarket plan that all reference the same system model. When one link in that chain does not match another, the reviewer asks a question, and that question becomes weeks of delay. A build plan that produces matching artifacts the first time is the fastest path through review, not a compliance nicety. ## What does a reviewer actually want from your threat model? A reviewer wants a system-level model that names your actual interfaces, not a generic list of attacker categories copied from a template. Your device is rarely just the hardware. It is the firmware, the companion app, the cloud API, the update pipeline, and the customer network it deploys into, and the threat model has to name all of it. Build it against ANSI/AAMI SW96:2023 using STRIDE per data flow element, and include multi-patient harm scenarios, not single-device ones. Map every threat to a mitigation and a piece of verification evidence, because a threat with no downstream control or test is a gap a reviewer will find. If your architecture diagram and your threat model describe different systems, fix that before you fix anything else, because every other deficiency downstream traces back to that mismatch. ## Which standard applies: SW96, TIR57, or TIR97? For new submissions, ANSI/AAMI SW96:2023 is the primary reference for security risk management, and TIR57 and TIR97 cover narrower, older, or postmarket-specific ground. Citing the wrong one, or citing TIR57 as if it were still the primary standard, is a common and avoidable flag in a submission. | Standard | FDA recognition number | What it covers | When you cite it | | --- | --- | --- | --- | | ANSI/AAMI SW96:2023 | 13-131 | Security risk management across the total product lifecycle | Primary reference for new threat models and risk files | | AAMI TIR57 | 13-83 | Legacy security risk management guidance that predates SW96 | Historical reference only, for programs that started before SW96 adoption | | AAMI TIR97 | 13-112 | Postmarket vulnerability management and coordinated disclosure | Building or auditing your postmarket program | > **[KEY REQUIREMENT]** If your risk management file still cites TIR57 as the primary security risk standard for a new submission, update it to SW96 before you submit. A reviewer who sees TIR57 alone in a 2026 filing will ask why. ## What makes an SBOM operational instead of decorative? An SBOM satisfies a reviewer when every listed component has a disposition, not just a name and version. That means SPDX or CycloneDX format, coverage of third-party and open-source components, and a VEX statement (not affected, affected, fixed, or under investigation) for every known CVE in the shipping configuration. Build it as a living document tied to each release, monitored against KEV, EPSS, and NVD feeds, with version mapping so you know which shipped units are exposed when a new CVE lands. For the minimum elements themselves, CISA's 2026 Minimum Elements for a Software Bill of Materials supersede the earlier NTIA 2021 baseline, so align your SBOM template to the current CISA elements rather than the retired NTIA version. An SBOM that only gets regenerated at each submission is not operational, and a reviewer can usually tell. > **Operationalizing a device security program?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [Postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services) ## What does eSTAR v7.0 change about how you package evidence? eSTAR v7.0, released June 1, 2026, gives cybersecurity a single dedicated attachment area, not several separate slots for the threat model, SBOM, and test reports. That single-attachment structure means your evidence has to be assembled as one coherent package before it goes in, with clear internal cross-references, rather than left as separate documents you hope the reviewer connects. Build the attachment in this order: system description and architecture, threat model, security requirements and traceability, verification and test results including penetration testing, SBOM with VEX, and the postmarket plan. A reviewer working through one attachment in that order finds fewer reasons to send an Additional Information request. ## Where does penetration testing evidence fall apart? Penetration testing evidence fails when the findings do not map back to the threat model that was supposedly guiding the test. A report that lists generic web vulnerabilities against a device whose threat model discussed wireless pairing and firmware tampering tells a reviewer the two documents were produced independently. Scope testing to the interfaces your threat model actually names: the device, wireless and companion app interfaces, cloud APIs, and update mechanisms. Every finding needs a severity rating tied to patient impact, a remediation status, and retest evidence proving the fix closed the finding rather than just documenting that a fix was planned. Retesting is the step teams skip under deadline pressure, and it is the step reviewers ask about most. ## Why do postmarket programs fail after launch? Postmarket cybersecurity programs fail almost always because nobody owns them day to day, not because the written plan was inadequate. The submission gets a polished postmarket section, and then the vulnerability intake inbox, the SBOM monitoring cadence, and the coordinated vulnerability disclosure process never get staffed. Build the program with the same rigor as the submission: a named vulnerability intake owner, a documented triage process weighing patient safety impact and exploitability, a coordinated vulnerability disclosure workflow, and SBOM monitoring that actually triggers action when a new CVE affects a shipped configuration. AAMI TIR97 is the reference to build this against. A postmarket plan that exists only on paper is the fastest way to turn a routine CVE into a Warning Letter. ## How Blue Goat Cyber Approaches This We build the threat model first, against ANSI/AAMI SW96, because every other artifact in the submission traces back to it, and a model that does not match the architecture is the single most common source of review delay. Our engineers hold CISSP and OSCP certifications, several with prior red-team backgrounds, and they build the security requirements, traceability, SBOM with VEX, and test plans as one connected package aligned to the FDA's February 3, 2026 final premarket cybersecurity guidance and Section 524B. We scope penetration testing to the interfaces the threat model names, retest after remediation to close findings with evidence, and help stand up the postmarket program (intake, triage, coordinated disclosure, SBOM monitoring) so it survives past launch day. **Our commitment:** if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. See our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) to start. ## Frequently Asked Questions **Does the FDA require penetration testing for every medical device submission?** The FDA's February 3, 2026 final guidance does not name a hard mandate for penetration testing, but it expects independent security testing scaled to risk. For most connected cyber devices under Section 524B, reviewers expect penetration test evidence covering the device, wireless, mobile, and cloud interfaces, with findings mapped to the threat model. **How is ANSI/AAMI SW96 different from AAMI TIR57?** SW96 (FDA recognition 13-131) is the current consensus standard for security risk management across the device lifecycle, and it is the primary reference for new submissions. TIR57 (recognition 13-83) is the older guidance it largely supersedes, useful mainly as background for programs that adopted it before SW96 existed. **What is AAMI TIR97 used for?** AAMI TIR97 (FDA recognition 13-112) covers postmarket vulnerability management, including coordinated vulnerability disclosure and remediation workflows. Use it to design or audit the intake, triage, and disclosure process your postmarket cybersecurity program needs after a device ships. **How many cybersecurity attachment areas does eSTAR v7.0 have?** eSTAR v7.0, released June 1, 2026, has a single cybersecurity attachment area, not multiple separate slots. That means your threat model, SBOM, test reports, and postmarket plan need to be assembled as one cross-referenced package before submission rather than left as separate files. **What replaced the NTIA minimum elements for SBOMs?** CISA's 2026 Minimum Elements for a Software Bill of Materials supersede the 2021 NTIA minimum elements baseline. Manufacturers building or updating their SBOM template should align to the current CISA elements rather than the retired NTIA version. **What is the single most common reason a threat model gets flagged in review?** The most common flag is a mismatch between what the threat model describes and what the architecture diagram or SBOM actually shows, such as an interface named in one document and missing from another. Keeping the system description, architecture views, and threat model built from the same source model avoids most of these mismatches. ## CTA If your submission evidence is scattered across documents that do not quite agree with each other, that is the deficiency waiting to happen. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will walk your threat model, SBOM, and test plan against what a reviewer will actually check. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Related reading - [FDA Section 524B requirements explained](/guides/fda-524b-cybersecurity-requirements-explained) - [FDA premarket cybersecurity submission checklist](/guides/fda-premarket-cybersecurity-submission-checklist) - [Did ANSI/AAMI SW96 replace TIR57?](/blog/did-aami-sw96-replace-tir57-fda-2026) - [Postmarket cybersecurity for medical devices](/services/fda-postmarket-cybersecurity-services) - [How to choose a medical device cybersecurity company](/blog/how-to-choose-the-best-medical-device-cybersecurity-company) --- ## Medical Device Cybersecurity Cost (2026) Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-cost # How Much Does Medical Device Cybersecurity Cost in 2026? > **[DIRECT ANSWER]** Medical device cybersecurity cost in 2026 is driven by four factors: device complexity, submission pathway, attack surface, and whether the scope covers premarket only or premarket plus ongoing postmarket obligations under Section 524B. Fixed-fee pricing with unlimited retesting removes the scope-creep risk that hourly billing creates. The real number to weigh against the engagement fee is the cost of delay, since a three-month clearance hold on a high-revenue device routinely dwarfs the entire cybersecurity budget. The cost question almost never arrives in a vacuum. It arrives attached to a board asking why this line item exists, a launch budget that has to absorb it, or a regulatory lead who just got an FDA AI letter and needs a number by Friday. The answer most firms give - "it depends, contact us" - is correct but useless, and it loses the buyer who is trying to do the job seriously. This piece does the opposite. It walks through what actually moves the price, why fixed-fee pricing protects you from re-test surprises, how to budget premarket and postmarket separately, and how to weigh the engagement fee against the only number that really matters: the revenue lost to a delayed clearance. ## Key Takeaways - Medical device cybersecurity cost is set by four drivers: device complexity, submission pathway (510(k) / De Novo / PMA), attack surface, and premarket-only vs premarket-plus-postmarket scope. - Fixed-fee engagements with unlimited retesting remove re-test surprises and scope-creep risk; hourly FDA cybersecurity consulting fees push that risk onto the buyer. - Premarket cybersecurity is a finite project tied to the submission; postmarket is a recurring annual obligation under Section 524B and belongs on a separate budget line. - Retrofitting cybersecurity after design lock is the single most expensive scenario - it triggers re-validation, a fresh threat model, and often a new submission cycle. - A three-month clearance delay on a $40M-revenue device routinely costs more than 10x a complete fixed-fee cybersecurity engagement. ## Why This Matters Under Section 524B of the FD&C Act and the FDA's final guidance *"Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions,"* issued February 3, 2026, every cyber device submission must include a defined cybersecurity evidence package - threat model, SBOM, secure architecture views, independent testing, postmarket plan. The FDA can issue a Refuse-to-Accept inside the 15-day RTA window if any of those artifacts are missing or thin, which means budgeting cybersecurity as an afterthought is functionally equivalent to budgeting a launch delay. The delay is the real cost. Independent reporting from MedTech Dive and others on recent device recalls (Medtronic, BD, Philips) has shown cybersecurity-driven holds routinely pushing clearance by 3-9 months. For a connected device projecting $30-50M in first-year revenue, a single quarter of delay outweighs the entire engagement fee by an order of magnitude. The applicable standards stack - AAMI SW96 (FDA-recognized as 13-131), AAMI TIR57, IEC 81001-5-1, IEC 62304, ISO 14971, and the IMDRF *Principles and Practices for Medical Device Cybersecurity* - all assume the work is built in during design, not retrofitted after MVP. Pricing follows the same logic: scoped early, the work is cheap and predictable. Scoped late, every dollar buys less. ## What Drives the Cost of Medical Device Cybersecurity? The cost of a cybersecurity engagement is set by your device, not by the consultant. Four factors do most of the work, and once you can describe them, any competent firm can give you a real number. - **Device complexity.** A standalone, single-purpose Class II device with one wireless interface costs a fraction of a connected, multi-component system that pairs an implant, a clinician programmer, a patient remote, and a cloud back end. - **Submission pathway.** 510(k) usually carries the lightest cyber documentation burden. De Novo and PMA expect more depth in the threat model, more independent test evidence, and tighter postmarket commitments. - **Attack surface to be tested.** Each interface - firmware, BLE or proprietary RF, mobile app, cloud APIs, third-party integrations - is its own test scope. The number of interfaces, not the number of features, is what determines pen-test effort. - **Premarket only, postmarket only, or both.** Premarket is a defined project tied to your submission. Postmarket is an ongoing annual obligation under Section 524B. Treat them as separate budget lines (more on this below). A useful way to sense-check a quote: if a firm cannot tell you which of these four factors drove the number up, the number is a guess. ### Cost drivers at a glance | Cost driver | Lower cost → Higher cost | |---|---| | Submission pathway | 510(k) → De Novo → PMA | | Device connectivity | Standalone → Wireless / cloud-connected | | Attack surface | Single interface → Firmware + BLE/RF + mobile + cloud + APIs | | Software origin | First-party only → Heavy third-party / open-source (SBOM depth) | | Engagement scope | Premarket only → Premarket + ongoing postmarket | | Starting point | Security designed in → Retrofitting after design lock | ## Fixed-Fee vs Hourly: How Cybersecurity Consulting Is Priced There are two honest pricing models in this market, and they create very different buyer experiences. **Hourly FDA cybersecurity consulting fees** are common with generalist security firms and adjacent regulatory consultancies. The hourly rate looks predictable, but the total is not. Threat models expand as the architecture clarifies, pen tests spawn re-tests after every fix, and deficiency responses turn into new scopes of work. The buyer carries every minute of scope drift. **Fixed-fee engagements with unlimited retesting** flip that risk. The firm commits to a number for a defined deliverable - threat model, SBOM, pen test, submission package - and absorbs the cost of additional test passes until the device reaches acceptable risk. You know what you are paying on day one, and the firm is incentivized to get the architecture right early instead of billing for the re-work. For a regulated, safety-critical product on a launch deadline, fixed-fee with unlimited retesting is the model that protects the buyer. It is also the model FDA reviewers indirectly reward, because firms that price this way cannot afford to ship sloppy evidence. ## Premarket vs Postmarket: Two Different Budget Lines One of the most expensive budgeting mistakes is treating cybersecurity as a single one-time line on the launch budget. It is two lines, and they behave differently. **Premarket** is a defined project tied to your submission. Threat model, SBOM, security architecture views, pen test, labeling, the SPDF documentation - all of it lands in the submission package, gets reviewed once, and gets cleared. The cost is finite and forecastable. **Postmarket** is an ongoing annual obligation under [Section 524B](/blog/fda-section-524b-subsections-explained). SBOM monitoring, vulnerability disclosure, periodic reporting, coordinated response to new CVEs, and software updates have to keep happening for the life of the device. That is not a project - it is a recurring operational line, and finance should plan for it the same way they plan for cloud hosting or compliance audits. Firms that try to sell postmarket as a one-time deliverable are either misunderstanding 524B or hoping you do. Our [FDA Postmarket Cybersecurity Services](/fda-postmarket-cybersecurity-services) page lays out what the annual program actually includes and how it is scoped. ## The Cost of Delay: What Skipping or Under-Scoping Really Costs The cost of cybersecurity work is small. The cost of a delayed clearance is not. A connected MedTech device with $40M in projected first-year revenue is generating roughly $110K per day from the moment it ships. A three-month delay caused by a cybersecurity deficiency - a missing SBOM, an unsigned firmware update path, an unmodeled threat in a wireless interface - costs about $10M in deferred revenue, plus the burn rate of an engineering team waiting for a fix. The cybersecurity engagement that would have prevented that deficiency is almost always a small fraction of that number. That is the math that matters, and it is the math FDA reviewers implicitly assume you have already done. Plug your own numbers into the [Cost-of-Delay calculator](/cost-of-delay) before you finalize your cybersecurity budget. If the model says delay is cheaper than diligence, you have a different problem than pricing. ## How to Build a Realistic Cybersecurity Budget A realistic budget is built in four steps, in this order: 1. **Scope the attack surface early - before design lock.** Every interface you add after design lock is more expensive to secure than the same interface added during architecture. Get a threat model on the table while changes are still cheap. 2. **Decide premarket vs postmarket scope explicitly.** Some buyers only need premarket because they already have a postmarket program. Most growth-stage MedTech companies need both. Decide deliberately. 3. **Use a Scope Estimator to get a starting range.** The [Scope Estimator](/scope-estimator) takes the same four drivers above - complexity, pathway, attack surface, premarket/postmarket - and returns a fixed-fee range you can actually budget against, without a sales call. 4. **Refine with a strategy call.** A 30-minute call closes the gap between the estimator's range and the final fixed-fee quote, by walking the architecture and the submission timeline together. Doing this before design lock is the single highest-ROI move in the whole budget cycle. > **Want a fixed-fee number for your device?** Use the [Scope Estimator](/scope-estimator) for a self-serve range, or [book a strategy call](/contact) to refine it against your architecture and timeline. ## How Blue Goat Cyber Prices Engagements Every Blue Goat Cyber engagement is fixed-fee with unlimited retesting. That means one number for the scope, and as many test passes as it takes to reach acceptable risk - not an hourly meter, not a re-test surcharge, not a scope-change argument three weeks before submission. Cost certainty extends past clearance: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost to you. That commitment only works because we ship the same evidence pattern reviewers expect - AAMI SW96-aligned risk file, traceable threat model, signed-update architecture, independent pen test, postmarket plan - and because the team has carried hundreds of devices through 510(k), De Novo, and PMA pathways. The mechanics are simple. You describe the device. We scope the four drivers. You receive a fixed-fee proposal with the deliverables, the timeline, and the retesting commitment in writing. Most engagements ship to the FDA on a known calendar date. For the full premarket scope and methodology, see [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## Frequently asked questions ### How much does medical device cybersecurity cost? Cost depends on device complexity, submission pathway, attack surface, and whether you need premarket work, postmarket support, or both. Specialist firms typically price fixed-fee with unlimited retesting, so the figure is known up front. Use a [scope estimator](/scope-estimator) for a device-specific range, and weigh it against the revenue lost to a single delayed launch - that is the comparison that determines whether the spend is justified. ### Is medical device cybersecurity priced hourly or fixed-fee? Both models exist. Hourly FDA cybersecurity consulting fees can drift as scope grows and re-tests add up - the buyer carries the risk of every extra pass. Fixed-fee engagements with unlimited retesting give a known total and remove the re-test surprise; the firm absorbs the cost of getting the device to acceptable risk, no matter how many passes it takes. ### What's the difference between premarket and postmarket cybersecurity cost? Premarket is a defined project tied to your submission - threat model, SBOM, pen test, submission package, cleared once. Postmarket is an ongoing annual obligation under Section 524B - SBOM monitoring, vulnerability disclosure, periodic reporting - so it is a recurring budget line, not a one-time fee. Budget for both if your device is heading to market and staying there. ### How do I budget for medical device cybersecurity? Scope the attack surface early - before design lock, when changes are still cheap - then decide premarket vs postmarket scope and get a fixed-fee quote. A scope estimator gives a starting range; a strategy call refines it. Building the medical device security budget early avoids the most expensive cost: retrofitting security after design lock, which triggers re-validation, a fresh threat model, and often a new submission cycle. ### Isn't it cheaper to skip cybersecurity until FDA asks? No - it is the most expensive path. Under Section 524B, the FDA can refuse to accept a submission missing required cybersecurity information, and retrofitting evidence after design lock costs more than building it in. A delay measured in months usually dwarfs the engagement fee in lost revenue. Run your own numbers through the [Cost-of-Delay calculator](/cost-of-delay) before you defer the work. ## Get a fixed-fee number for your device Stop estimating. Use the [Scope Estimator](/scope-estimator) to get a fixed-fee range in minutes, or [book a strategy call](/contact) and we will scope your device, your pathway, and your timeline against a written commitment - no hourly meter, no re-test surcharge, no surprises at submission. --- **About the author.** Christian Espinosa, MBA, CISSP - Founder & CEO, Blue Goat Cyber. Christian has scoped and priced hundreds of FDA cybersecurity engagements across 510(k), De Novo, and PMA pathways, and built the fixed-fee + unlimited-retesting model the firm runs on today. [More from Christian](/authors/christian-espinosa). --- ## More on this topic - [How Medical Device Manufacturers Can](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) - [How to Choose a Medical Device](/blog/how-to-choose-the-best-medical-device-cybersecurity-company) --- ## Medical Device Interoperability: Cybersecurity Risks Explained Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-interoperability-concerns # Medical Device Interoperability and Its Cybersecurity Risks > **[DIRECT ANSWER]** Interoperability creates cybersecurity risk because each connection extends trust to a system you do not control and cannot patch. Every interface your device offers to another vendor's product is an attack surface, and every assumption you make about that product's behavior is a claim you may be asked to substantiate. Managing this means authenticating peers, validating inputs, and stating your assumptions in labeling rather than relying on them silently. _Reviewed September 17, 2026_ Interoperability is a clinical requirement. A monitor that cannot send vitals to the record, a pump that cannot receive orders, and an imaging system that cannot share studies all create manual work and transcription errors. Hospitals buy connectivity for good reasons. The security consequence is that your device's risk profile now depends partly on products built by companies you have never met, running software versions you cannot see, on a network administered by someone else. Your submission has to show you have thought that through. ## Key Takeaways - Every interface to another vendor's system extends trust beyond your control boundary. - Input validation matters more when the sender is not your product. - Shared protocols like HL7 and DICOM were designed for trusted networks. - Availability failures propagate across connected systems faster than confidentiality ones. - Environmental assumptions must be stated in labeling, not assumed silently. - Shared responsibility boundaries belong in your architecture views and your customer documentation. ## Why Interoperability Changes Your Risk Position The February 3, 2026 premarket cybersecurity guidance expects manufacturers to consider the environment their device operates in, including the systems it connects to. That expectation exists because connected devices fail together. A misbehaving peer can flood your device with traffic, send malformed messages that crash a parser, or supply data your device treats as authoritative. The IEC 80001 family of standards was developed for exactly this reason: risk management for medical devices on IT networks is a shared activity between the manufacturer and the healthcare delivery organization, because neither controls the whole picture. The hospital owns the network; you own the device's behavior on it. Problems arise where each side assumes the other has handled something. The same shared-responsibility logic drives the FDA's interest in labeling. If your device is safe only when it sits on a segmented network with controlled peers, that condition is part of the device's safe use, and it belongs where the customer will see it. ## Where Trust Breaks Down | Interface | What you extend trust to | What can go wrong | |---|---|---| | HL7 messaging | The sending system's message content | Malformed or malicious content parsed as clinical data | | DICOM associations | Any peer that can reach the port | Unauthorized query, storage, or bulk retrieval | | Middleware and gateways | An intermediary that reframes your data | Loss of end-to-end integrity and attribution | | Cloud integration APIs | A third party's authentication and scoping | Over-broad access tokens; data readable beyond intent | | Shared hospital network | The hospital's segmentation and hygiene | Lateral movement from an unrelated compromised host | | Third-party AI or analytics | Another vendor's handling of your data | Data retained, moved, or altered outside your control | Input validation is the control that pays for itself across all of these. A parser that assumes well-formed input because the sender is another medical device is trusting a claim it cannot verify, and message parsers have historically been a reliable source of crashes and memory safety bugs. Validate structure, bounds, and plausibility on everything that crosses the boundary, regardless of who sent it. **[KEY REQUIREMENT]** Authenticate the peer, not the network. "The traffic came from inside the hospital VLAN" is a statement about network topology, not about identity, and it is not a control you administer. ## Availability Is the Property That Propagates Interoperability failures are usually availability failures, and availability failures spread. When an integration engine goes down, every device feeding it queues or drops data. When a device floods a network segment, everything on that segment suffers. When a clock source drifts, timestamp-dependent workflows break across multiple systems at once. That matters for risk rating. Under ISO 14971, the harm is what reaches the patient, and delayed data, missing alarms, and unavailable priors are clinical events rather than IT inconveniences. A threat model that considers only confidentiality has missed the failure mode most likely to occur. Designing for it means defining what your device does when a peer is unavailable or misbehaving. Does it buffer, and for how long? Does it alarm locally? Does it degrade to a safe standalone mode? Those behaviors are design decisions worth documenting, because a reviewer asking about network dependency wants to see that you chose them deliberately. ## Documenting Shared Responsibility | Item | Who owns it | Where it must appear | |---|---|---| | Device authentication of peers | Manufacturer | Architecture views, threat model | | Input validation on all interfaces | Manufacturer | Design documentation, testing evidence | | Network segmentation | Healthcare delivery organization | Labeling as a stated assumption | | Peer system patching | Healthcare delivery organization or other vendor | Labeling and customer security documentation | | Configuration of your security features | Usually the customer | Installation and administration documentation | | Vulnerability notification for your product | Manufacturer | Vulnerability disclosure and management plan | Labeling is doing real work in that table. An assumption that appears only in an engineer's head cannot be verified by anyone, and it cannot be relied on in a risk argument. Writing it down converts it into something the customer can act on and something the reviewer can evaluate. Be specific rather than generic. "Deploy on a secure network" tells a hospital nothing. "This device must be deployed on a network segment that restricts inbound connections to the following ports from the following systems" tells them exactly what to configure and gives you a defensible basis for the assumption. ## Practical Controls That Hold Up The controls that survive contact with a real hospital network are the ones that do not depend on the network behaving well. Authenticate every peer connection, with credentials unique to the deployment rather than shared across your product line. Encrypt every interface, including internal ones, because segmentation you do not administer is not a control you can count on. Validate every input against structure and bounds before using it. Apply rate limits so a flooding peer degrades throughput rather than availability. Log security-relevant events in a form the hospital's tooling can ingest. Define and test the device's behavior when its peers are unreachable. None of these are exotic. What makes them difficult is that each one is a place where security and interoperability pull against each other, since the most compatible configuration is usually the most permissive. Documenting why you chose your position on that tradeoff is what a submission needs, more than a claim that no tradeoff was made. ## How Blue Goat Cyber Approaches This We test interoperable devices at the interfaces, which means sending the messages a misbehaving peer would send rather than the ones your integration partner sends. That covers protocol handling, authentication of peers, input validation, and behavior under peer failure, with findings written so the shared responsibility boundary is explicit. Our [threat modeling](/services/threat-modeling) work maps each external connection to what it trusts and what crosses it, and our [medical device penetration testing](/services/medical-device-penetration-testing) exercises those interfaces directly rather than through the application layer above them. ## Frequently Asked Questions ### Why is interoperability a cybersecurity risk? Because each connection extends trust to a system you do not control, cannot patch, and cannot observe. Your device's security then depends on another vendor's implementation, on the hospital's network administration, and on assumptions about both. Every interface is also an attack surface reachable by anything else on the same network. ### Are HL7 and DICOM secure protocols? Both support security mechanisms and neither requires them. HL7 version 2 messaging has no built-in authentication or encryption and relies on the transport and network beneath it. DICOM supports TLS and identity negotiation but permits open associations. In both cases, the security of a deployment depends on configuration choices rather than on the protocol defaults. ### Who is responsible when two connected devices create a risk together? Responsibility is shared, which is the premise of the IEC 80001 family of standards. The manufacturer is responsible for the device's own behavior, its authentication and validation, and for disclosing the conditions under which it operates safely. The healthcare delivery organization is responsible for the network and for the overall risk of the connected system it assembles. ### What should our labeling say about network requirements? Exactly what a hospital would need to configure: required segmentation, ports and protocols used, which inbound connections must be permitted and from where, what the device does when peers are unreachable, and which security features the customer must enable. Generic advice to use a secure network is not actionable and does not support a risk argument. ### How should we handle a vulnerability in a peer system we do not control? Through coordinated disclosure to that vendor, plus an assessment of whether your device's exposure changes because of it. If your device becomes more exposed when a peer is compromised, that path belongs in your threat model, and your customer communication should say what compensating action a hospital can take. ### Does interoperability testing differ from normal penetration testing? The emphasis differs. Interoperability testing sends malformed, unexpected, and unauthorized messages across each integration interface, tests peer authentication, and observes behavior when peers fail or flood the connection. Standard application testing typically exercises the intended client behaving correctly, which does not reproduce the conditions a real network produces. ## Connected to Systems You Do Not Control? Every integration is a trust decision. We can show you which of yours are unstated assumptions and what a reviewer will ask about them. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## FDA Medical Device Cybersecurity Labeling Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-labeling # FDA Medical Device Cybersecurity Labeling Requirements (2026) > **[DIRECT ANSWER]** Cybersecurity labeling must tell the user what the device exposes and how to run it safely. Include every network, wireless, and physical port, the SBOM or a pointer to it, default and hardened configuration settings, the update and patch process with expected frequency, the end-of-support date, and a contact path for reporting vulnerabilities. The February 3, 2026 premarket guidance treats missing labeling as a submission deficiency, not a documentation nit. _Reviewed July 24, 2026_ In today’s connected healthcare environment, a medical device’s labeling is no longer just about operating instructions - it’s a critical cybersecurity safeguard. Without clear, complete, and accurate labeling, healthcare providers may unknowingly deploy devices with insecure settings, fail to apply necessary updates, or overlook known vulnerabilities. The [FDA final guidance issued February 3, 2026](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket), _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_, makes this point clear: inadequate cybersecurity labeling can render a device **misbranded under the FD&C Act** (502(f), 502(j)) and put patient safety at risk. For manufacturers, proper cybersecurity labeling is both a compliance requirement and a trust-building tool for hospitals, clinicians, and patients. [![fda medical device cybersecurity labeling](/imported-images/d0d8d22e0c2f664c.png)](/imported-images/2c38acf35780b844.png) ## Key Takeaways - Identify all communication interfaces and exposure points. - Summarize third-party software components; provide full SBOM access. - Furnish step-by-step secure configuration guidance. - Detail update/patch management procedures and expectations. - Disclose known vulnerabilities and compensating controls. - Treat cybersecurity labeling as a living document. ## Why This Matters The FDA's February 3, 2026 final guidance *"Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions"* makes cybersecurity labeling a required deliverable in eSTAR v7.0 - not an optional appendix. Submissions that lack the labeling content reviewers expect (security features, default configurations, network requirements, SBOM access, vulnerability disclosure contact, end-of-support dates) routinely draw an Additional Information letter, and AI cycles cost roughly 6-12 weeks each. Beyond the submission, hospital security teams now use cybersecurity labeling as procurement gate criteria. The Health Sector Coordinating Council's *Medical Device and Health IT Joint Security Plan (JSP)* and the MDS2 v2025 form both reference label-equivalent content, and IDNs increasingly refuse to onboard devices whose labeling does not answer those questions. Weak labeling has become a measurable revenue obstacle, not just a regulatory one. The standards stack here is consistent: AAMI TIR57 for labeling content, AAMI SW96 (FDA Recognized Consensus Standard 13-131) for the security risk file the label has to be consistent with, IEC 81001-5-1 for the lifecycle that produces the label, and Section 524B of the FD&C Act for the patchability and vulnerability disclosure obligations the label has to disclose. Treating labeling as design-controlled engineering output, not marketing copy, is what keeps it defensible. ## FDA Cybersecurity Labeling Requirements and What to Include Section [VI.A of the FDA’s _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_ (February 3, 2026)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) describes what the FDA expects manufacturers to communicate through cybersecurity labeling. In plain terms, your labeling should provide the **intended users** (e.g., hospital IT/security teams, HTM/biomed, and healthcare providers) with **device-specific, actionable information** they need to **securely install, configure, operate, maintain, and decommission** the device across its lifecycle. ### FDA VI.A baseline: the core elements your labeling should cover Below is a practical checklist you can use to align with the FDA’s labeling expectations while keeping the content usable for real-world deployment. #### 1) Communication interfaces and system exposure Identify **every wired and wireless interface**, as well as logical interfaces, including those that are disabled by default or planned for future activation. Include: - Physical interfaces (e.g., Ethernet, USB, serial) - Wireless interfaces (e.g., Wi‑Fi, Bluetooth) - Logical interfaces and services (e.g., APIs, cloud connections, remote service channels) - Protocols/services used (e.g., TCP/IP, SNMP), and any required ports/services **Why it matters:** Healthcare IT teams need to understand the device’s “attack surface” to plan segmentation, firewall rules, and monitoring. **Best-practice format:** Add a simple “Interfaces & Services” table with columns like: _Interface, Purpose, Protocol, Port(s), On by default (Y/N), Can be disabled (Y/N), Notes/constraints._ #### 2) Third-party software components (SBOM-related summary) Provide a labeling-level **summary of key third-party components** and versions (OS, libraries, frameworks, middleware), and indicate where authorized users can obtain the [full SBOM](/services/fda-compliant-sbom-services-for-medtech). Include: - Major third-party components and version identifiers - A pointer to the complete SBOM location/process (portal, customer request workflow, etc.) - Any constraints (e.g., “SBOM provided to authorized users under support agreement”) **Why it matters:** When a new vulnerability/CVE hits a standard component, hospitals need to quickly determine whether they’re exposed and what to do next. **Tip:** Keep labeling concise. Labeling can summarize “what’s important for users,” while the full SBOM remains the authoritative, detailed artifact. #### 3) Secure configuration and hardening instructions Give **step-by-step**, device-specific instructions for secure deployment in the intended environment. Include: - Authentication requirements (password policy, MFA expectations if supported) - Authorization and user roles (e.g., RBAC setup, least privilege guidance) - Certificate/key management expectations (where applicable) - Network guidance (segmentation recommendations, allowed inbound/outbound flows) - Which services/ports can be safely disabled - Secure defaults vs. what must be changed on first use **Why it matters:** Misconfiguration is one of the most common real-world causes of security issues. Clear instructions reduce both risk and support burden. **Best-practice format:** A “Secure Setup Checklist” (numbered steps) plus an appendix/reference table (ports, protocols, firewall rules, required domains/endpoints, etc.). #### 4) Update and patch management procedures Explain how users maintain device security over time-without relying on guesswork. Include: - How updates are delivered (OTA, local media, vendor remote service, etc.) - How authenticity/integrity is verified (e.g., digital signatures, [secure boot checks](/blog)) - Expected downtime and any workflow planning considerations - Failure handling and rollback steps (what to do if an update fails) - Any user responsibilities vs. vendor responsibilities **Why it matters:** Hospitals must maintain security while minimizing disruptions to clinical care. A clear update “runbook” prevents delays and unsafe workarounds. #### 5) Known vulnerabilities, residual risk, and compensating controls If there are risks that cannot be fully mitigated without compromising clinical performance, disclose them clearly and provide practical mitigation strategies to address these risks. Include: - A plain description of what remains and why - The potential impact in user-relevant terms - Compensating controls that the user can apply (segmentation, monitoring, access restrictions, configuration changes) - Any operational constraints or “do not do this” warnings **Why it matters:** Transparency enables users to manage risk responsibly and demonstrates a mature approach to risk communication. ## Recommended additions that improve usability and reduce postmarket friction The items below often make cybersecurity labeling far more helpful in practice, and can reduce review churn, customer confusion, and support escalations. ### Logging and monitoring capabilities Include: - What security logs/events are available - Log format and how to export/forward (e.g., SIEM integration options) - Retention duration and any storage limits - Time synchronization requirements (NTP guidance) **Why it matters:** Without logs, hospitals can’t investigate incidents or meet internal security policies. ### End-of-support and secure decommissioning guidance Include: - End-of-support policy basics (where users find current status) - Secure retirement steps (data deletion, account removal, key/cert handling) - Disposal/sanitization expectations where applicable **Why it matters:** Lifecycle security includes “safe offboarding,” not just secure deployment. ### Treat cybersecurity labeling as a living artifact Plan to update labeling when: - New vulnerabilities affect included components - Update mechanisms or supported configurations change - Older protocols/OS/platforms are deprecated - Your recommended secure configuration evolves based on field learnings This “living document” approach helps keep users secure and demonstrates ongoing cybersecurity maturity across the [total product lifecycle](/blog). ### How to Write Cybersecurity Labeling Hospitals Can Actually Use Cybersecurity labeling should be written for individuals who deploy and maintain devices in real clinical environments, including hospital IT/security teams, HTM/biomed personnel, and service personnel. To make labeling usable (and defensible), focus on clarity and specificity: - **Write in tasks, not generalities:** “Configure TLS 1.2+” beats “use secure protocols.” - **Define minimum secure settings:** password length/complexity, MFA expectations (if supported), encryption standards, and segmentation guidance. - **Use quick-reference formats:** tables for ports/protocols, firewall rules, required endpoints/domains, and a secure setup checklist. - **Include a simple network diagram:** trust boundaries and data flows help teams deploy securely. - **Keep it consistent with SPDF/QMS artifacts:** labeling should align with your threat model, risk controls, SBOM, and update strategy. ### Common Cybersecurity Labeling Mistakes (and How to Avoid Them) - **Mistake: Documenting only “active today” interfaces** **Fix:** Include disabled-by-default and future-enabled interfaces to avoid surprises in the field. - **Mistake: Hiding third-party and cloud dependencies** **Fix:** Provide an SBOM summary and clearly state where the full SBOM can be obtained. - **Mistake: Vague hardening guidance** **Fix:** Provide step-by-step secure configuration instructions and minimum requirements. - **Mistake: Unclear update/patch behavior** **Fix:** Explain delivery method, integrity checks, downtime expectations, and rollback steps. - **Mistake: No residual-risk disclosure** **Fix:** Communicate known issues and compensating controls in user-relevant language. - **Mistake: Labeling drifts from SPDF evidence** **Fix:** Ensure the story aligns with what you submit to the FDA and what you provide to customers. ## Wrap-Up: Turn Labeling Into a Deployment Asset FDA cybersecurity labeling is more than a submission requirement; it’s the operational guide customers use to deploy, maintain, and retire devices securely. The strongest labeling is **device-specific, actionable, aligned to your SPDF**, and kept current as vulnerabilities, configurations, and support policies evolve. Who reads that labeling also depends on where the device is indicated to operate. Labeling written for a hospital biomed team does not transfer to a patient at home, and the controls you can reasonably place in instructions change with it. See [home use vs hospital device cybersecurity requirements](/blog/home-use-vs-hospital-device-cybersecurity) for how the use environment shifts controls onto the device itself. **Key takeaways:** - Document all interfaces and exposure. - Provide an SBOM summary and access path to the full SBOM. - Give step-by-step secure configuration guidance. - Make patching predictable (including rollback). - Be transparent about residual risk and compensating controls ## How Blue Goat Cyber Helps At Blue Goat Cyber, we specialize in guiding medical device manufacturers through **FDA-compliant cybersecurity labeling, from initial design through post-market** updates. We combine deep regulatory expertise with real-world security engineering to ensure your labeling meets or exceeds FDA requirements, protects patient safety and data integrity, and supports your market access and reputation. To ensure your device labeling is accurate, compliant, and trusted by healthcare providers, contact us today to [schedule a consultation](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). ## FAQ ### What does the FDA expect to see in medical device cybersecurity labeling? The FDA generally expects device-specific, actionable instructions that help intended users install, configure, operate, maintain, and decommission the device securely. This typically includes: interfaces/exposure, SBOM-related component transparency, secure configuration guidance, update/patch procedures, and residual risk/compensating controls. ### What should be included in cybersecurity labeling? According to the February 3, 2026 FDA guidance, cybersecurity labeling should include: all communication interfaces (wired, wireless, cloud, APIs); third-party software components and versions (SBOM summary); secure configuration instructions for integration into the intended environment; update and patch procedures, including verification methods; and known, unmitigated vulnerabilities with mitigation guidance. ### Do we need to publish the full SBOM in the labeling? Not usually. A strong approach is to include an SBOM-level summary (key third-party components and version identifiers) along with a clear method for customers/authorized users to obtain the full SBOM (e.g., portal, support request process, customer package). The goal is to conduct a fast vulnerability impact assessment-without overwhelming the IFU with pages of component detail. ### Why is cybersecurity labeling important for medical devices? Cybersecurity labeling is crucial because it provides healthcare providers with the necessary information to securely deploy and manage medical devices. Without clear labeling, devices may be misconfigured, vulnerable to attacks, or fail to receive critical updates, potentially compromising patient safety and data integrity. ### How often should cybersecurity labeling be updated? Cybersecurity labeling should be updated when new vulnerabilities affect included components, update mechanisms or supported configurations change, older protocols/OS/platforms are deprecated, or recommended secure configurations evolve based on field learnings. This ensures the information remains current and useful. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity Risk Analysis Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-risk-analysis-the-fda-playbook # Medical Device Cybersecurity Risk Analysis: The FDA Playbook > **[DIRECT ANSWER]** A medical device cybersecurity risk analysis follows a defined sequence: build a threat model, map each threat to a patient safety hazard using ISO 14971, score severity and likelihood with clinical rationale, apply layered controls tied to the FDA's five security objectives, and verify every control with traceable test evidence. Once a device meets the FDA's cyber device threshold under Section 524B, this analysis is a mandatory premarket submission artifact, not an optional or deferrable exercise. Performing a thorough cybersecurity risk analysis for a medical device isn’t optional once your product qualifies under Section 524B of the FD&C Act. [The FDA’s 2026 cybersecurity guidance](https://www.fda.gov/media/119933/download "") is direct: if your device meets the “cyber device” threshold, you must demonstrate reasonable assurance of cybersecurity in your premarket submission, and a documented risk analysis is the primary instrument for doing that. This isn’t a paperwork exercise you can defer to the end of development. Engineering teams frequently run into trouble not because they lack security knowledge, but because a medical device cybersecurity risk assessment requires translating technical threat scenarios into the safety-first language FDA reviewers expect. Knowing that a device has an unauthenticated API endpoint is one thing. Documenting why that endpoint creates a hazardous situation that could lead to patient harm, scoring that risk with a defensible rationale, and linking it to a tested control is something else entirely. At Blue Goat Cyber, we work through this process with medical device manufacturers across a wide range of device classes and submission types. The framework below reflects the same structured approach our team follows, from the first threat modeling session through the final documentation package. By the end, you’ll have a clear, stepwise process you can apply to your own device. ## Key Takeaways - FDA mandates cyber risk analysis for "cyber devices" under Section 524B. - Align cyber threats with patient safety using ISO 14971 framework. - Map cybersecurity events to hazardous situations and patient harm. - Implement layered controls addressing FDA's five security objectives. - Verify control effectiveness through vulnerability and penetration testing. - Document and justify all residual risks clearly for FDA review. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device cybersecurity risk analysis the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What the FDA and ISO 14971 Actually Require ### The “Cyber Device” Designation and What It Triggers Under Section 524B of the FD&C Act, as clarified in FDA’s 2026 cybersecurity guidance, a “cyber device” is broadly defined as a network-capable device containing software that is susceptible to cybersecurity threats, including devices that can connect to the internet or other networked systems. This classification isn’t a technicality. It activates a mandatory set of cybersecurity documentation requirements for every premarket submission you file, whether a 510(k), De Novo, or PMA. For more detailed guidance on how to structure those premarket artifacts, see the [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). The FDA takes a risk-based approach, which means the depth of your analysis scales with device complexity and patient risk exposure. A connected insulin pump warrants a more exhaustive analysis than a low-acuity wireless scale. There’s no fixed checklist, but there is a clear expectation: document your reasoning systematically and make it traceable. ### Where ISO 14971 Fits In (and Where It Ends) ISO 14971 provides the foundational risk management framework for medical devices, and the FDA explicitly expects manufacturers to apply it to cybersecurity risks. The standard requires identifying hazards, estimating and evaluating risks, implementing controls, and monitoring their effectiveness across the device lifecycle. Cybersecurity fits squarely into that workflow when threats are framed as potential sources of patient harm. The FDA is equally explicit that security risk management is distinct from safety risk management. You need both, and they must be traceable to each other. IEC 81001-5-1 extends ISO 14971’s principles specifically to cybersecurity for health software, addressing threats like unauthorized access and cyberattacks alongside traditional safety hazards. It effectively connects the two disciplines within a single risk management workflow. ## Medical Device Cybersecurity Risk Analysis: Threat Modeling ### Defining the Device’s Assets, Interfaces, and Threat Environment Threat modeling is the first analytical step, and no risk scoring is valid without it. Before assigning numbers, your team must define what’s worth protecting: software components, data flows, communication interfaces, and any third-party dependencies embedded in the device stack. Common interface types include Wi-Fi, Bluetooth, USB, and cloud APIs, but the scope should reflect your specific architecture. A practical template can help structure workshops and outputs; consider using a [cybersecurity risk assessment template](https://threat-modeling.com/cybersecurity-risk-assessment-template/) to ensure consistent artifacts. The FDA expects manufacturers to treat the network environment where the device operates as hostile by default. Your analysis can’t stop at the device boundary. It has to account for the broader ecosystem: hospital networks, connected infrastructure, external cloud services, and the supply chain itself. Anything that touches your device is in scope. ### Common Attack Vectors in Connected Medical Devices Real-world data makes the threat landscape concrete. According to Claroty’s 2023 State of XIoT Security Report, 99% of hospital-managed IoMT devices carry known exploitable vulnerabilities, and 21% of connected devices use weak or default credentials. Separately, research from Cynerio found that between 14 and 20% of connected devices run outdated operating systems with no patch path available. These aren’t hypothetical edge cases. They represent baseline conditions your device enters when it leaves the manufacturer. Four threat scenarios your model should address are ransomware that encrypts device data or locks critical functions; unauthorized access that allows an attacker to alter clinical settings or therapy parameters; denial-of-service attacks via wireless protocols that render the device unavailable during a critical window; and data breaches targeting patient information stored on or transmitted by the device. The threat model output, a documented list of threats, attack vectors, and proposed mitigations, becomes a direct input to the risk estimation step. Per the FDA’s 2026 guidance and the eSTAR submission template requirements, it’s also a required artifact in cyber device premarket submissions. Build it with the submission reviewers in mind. ## Security Risk and Safety Risk Are Scored Differently Keeping the two straight is what makes the traceability work when a reviewer follows a thread from threat to harm. | | Security risk analysis | Safety risk analysis under ISO 14971 | |---|---|---| | Question asked | Can this be exploited? | What harm reaches the patient? | | Likelihood basis | Attacker capability and exploitability | Probability of occurrence of harm | | Severity basis | Impact on the system | Clinical consequence for the patient | | Common scoring | CVSS or an exploitability rubric | Severity categories in your risk procedure | | Acceptance decision | Security posture judgement | Documented risk acceptance in the risk file | | Where they must meet | The threat becomes a hazardous situation | The control appears in both files | ## Mapping Cyber Threats to Patient Safety Hazards ### Separating Security Risk from Safety Risk and Then Linking Them The ISO 14971 workflow requires a clear chain of reasoning: a cybersecurity event becomes a hazardous situation when it can plausibly lead to patient harm. An unauthorized command injection that forces an infusion pump to deliver an incorrect dose is not just a security event. It’s a safety hazard with a specific severity and probability, scored using the same framework you apply to every other risk in the device. The FDA requires separate assessments for safety and cybersecurity, but both must be traceable to each other. If a threat in your security assessment can cause harm documented in your safety assessment, those two records must link. Reviewers check for this specifically. Missing traceability between the two files is one of the most consistent causes of cybersecurity deficiency letters in premarket submissions. ### Scoring Severity and Likelihood with a Defensible Rationale Severity scores must be anchored in clinical outcomes, not abstract data loss. Severity 5 means death or serious irreversible injury. Severity 1 means negligible inconvenience with no clinical impact. Every score in between requires a clear, documented clinical rationale. “High severity because the data is sensitive” won’t satisfy a reviewer. “High severity because exploitation can cause incorrect therapy delivery leading to irreversible patient injury” will. Likelihood estimation in cybersecurity is more nuanced than in traditional safety analysis. It requires accounting for attacker motivation, required access level, skill prerequisites, and compensating controls already in place. A vulnerability requiring physical access, specialized firmware tools, and advanced reverse-engineering skills carries a materially lower likelihood score than one exploitable remotely with publicly available code. A 5×5 impact-likelihood matrix is a practical and widely accepted scoring tool. The FDA doesn’t mandate a specific format, but it does require the rationale behind each score to be documented. The number alone isn’t sufficient, the reasoning that produced it must be captured in the risk management file. ## Selecting Controls and Justifying Residual Risk ### Layered Control Strategies Aligned with FDA Guidance Per the FDA’s 2026 cybersecurity guidance, security objectives are organized into five categories: authenticity, authorization, availability, confidentiality, and secure updatability. Every control you select should map back to at least one of these. If you can’t articulate which objective a control serves, it shouldn’t appear in the submission as a primary defense. The layered approach works like this: reduce the attack surface by design, remove unused ports, harden default configurations, and eliminate unnecessary services before the device ships. Then break exploit chains through strong authentication and encrypted communications. From there, limit impact using partitioning and failsafe behaviors that preserve essential device performance even under attack. Finally, enable detection through logging and alerting that gives operators visibility into anomalous behavior. **Controls must be verifiable.** The FDA expects verification and validation evidence for every control, along with traceability to the corresponding test. Where a control isn’t directly testable, a reasoned justification and alternative evidence must be documented. Design controls with testability in mind from the start. ### Documenting Residual Risk Acceptance with a Written Rationale Residual risk is the risk that remains after all controls are applied. The FDA requires manufacturers to evaluate whether this remaining risk is acceptable relative to the clinical benefit the device provides and relative to the in comparable devices. Neither “residual risk is low” nor “controls are in place” is a complete answer. The residual risk acceptance statement is a specific document: it identifies the hazardous situation, names the controls applied, quantifies the remaining risk level using your established scoring criteria, and provides a written explanation of why the benefit-risk tradeoff is acceptable. It needs a signature from appropriate personnel, and it becomes a permanent part of the risk management file. **This document will be reviewed during the FDA premarket assessment.** Draft it as if a reviewer with no context for your device will be reading it independently. Clarity and completeness here reduce the probability of a follow-up information request. ## Medical Device Cybersecurity Risk Analysis: Testing and Evidence ### Vulnerability Scanning, Penetration Testing, and SBOM Analysis Verification and validation testing is how the FDA confirms that the controls documented in your analysis actually work. Three primary methods apply here. Vulnerability scanning automates the identification of known weaknesses in software and firmware. Penetration testing simulates real-world attacks against the device. SBOM analysis surfaces vulnerabilities in third-party components your device depends on but that your team didn’t write. For high-risk connected devices, the FDA expects independent penetration testing aligned with PTES or CREST standards. The scope must cover firmware, APIs, communication protocols, and hardware interfaces. For moderate-risk devices, the scope can be narrowed, but key attack vectors from the threat model must still be covered. Independent means external to the development team; internal testing can supplement, but typically doesn’t satisfy the independence requirement on its own. Fuzz testing, static application security testing (SAST), and dynamic application security testing (DAST) are supporting methods that strengthen the overall evidence package. They close coverage gaps that manual penetration testing can miss, particularly in complex firmware and protocol stacks, but they don’t replace it. ### What the Design History File Must Capture All testing artifacts belong in the Design History File as part of the quality management system. Each test record should include the protocol used, the scope and methodology, findings with severity ratings, remediation actions taken, and a traceability matrix linking each test back to a specific security requirement and the corresponding risk in the risk management file. **The chain from threat to control to test evidence must be unbroken.** FDA reviewers look specifically for this chain. A control that appears in the risk assessment but has no corresponding test record is the most common source of cybersecurity deficiency letters in premarket submissions. Build your traceability matrix as you go, reconstructing it after the fact rarely produces a clean record. ## Assembling the Regulatory Submission Package ### Required Documentation Artifacts for a Premarket Submission A complete cyber device submission requires a specific set of documentation artifacts. The core deliverables include a cybersecurity management plan, threat model and risk assessment report, security architecture documentation, SBOM with vulnerability traceability in machine-readable format, verification and validation testing evidence, residual risk acceptance statements, and cybersecurity labeling disclosures. All of these feed into the Secure Product Development Framework (SPDF) documentation, which demonstrates to the FDA that cybersecurity is embedded in the manufacturer’s quality system rather than assembled at the end of development. The SPDF is evidence of process maturity, not just product security. For electronic submissions using the FDA’s eSTAR template, each artifact maps to a specific section of the submission template. Mismatched or incomplete entries generate additional information requests that pause the clearance timeline. The eSTAR process has very little tolerance for documentation that’s complete in substance but filed in the wrong place. ### How Blue Goat Cyber Builds Submission-Ready Packages Blue Goat Cyber specializes in building complete FDA cybersecurity submission packages for medical device manufacturers. The team’s exclusive focus on medical device cybersecurity means they understand how reviewers read these files and where documentation gaps tend to surface, the kinds of nuances that broad-practice cybersecurity firms, for whom medical devices are one service line among many, typically don’t develop. The integrated engagement model means Blue Goat Cyber handles threat modeling, risk analysis, control documentation, penetration testing, SBOM development, and SPDF documentation as a single coordinated workflow. Device manufacturers don’t need to coordinate multiple vendors, interpret guidance documents independently, or discover gaps after a submission has already been filed. Manufacturers who engage Blue Goat Cyber early in the design phase can avoid one of the most costly outcomes in the clearance process: a deficiency letter that stalls the timeline while the product sits in review. Addressing cybersecurity documentation before submission is generally far less disruptive, and far less expensive, than responding to a deficiency under time pressure after the fact. ## Putting It All Together The end-to-end medical device cybersecurity risk analysis follows a clear sequence. Build the threat model first. Map identified threats to patient safety hazards using the ISO 14971 framework. Score each risk with documented clinical rationale for both severity and likelihood. Apply layered controls that address the FDA’s five security objectives. Test every control and capture the results with full traceability. Then assemble the complete documentation package with each artifact properly organized for your submission format. For a broader perspective on how the landscape for medical device cybersecurity is evolving, see [Navigating the Evolving Cybersecurity Landscape for Medical Devices, Blue Goat Cyber](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). The FDA isn’t asking for perfection. It’s asking for evidence that you’ve thought through the risks systematically and made reasoned, documented decisions. A submission that shows clear thinking, honest residual risk acceptance, and thorough testing will consistently outperform one that attempts to minimize or obscure risks that any competent reviewer will find. If assembling this package feels overwhelming, that’s exactly the problem Blue Goat Cyber was built to solve. A firm that does nothing but medical device cybersecurity brings focused expertise and a submission track record that generalist consultants can’t replicate. If you need help with your medical device cybersecurity risk analysis, please schedule a no-cost [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session "") with us today! ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is a "cyber device" according to the FDA? A "cyber device" is a medical device that includes software is network-capable, and is susceptible to cybersecurity threats, based on Section 524B of the FD&C Act and the FDA's 2026 cybersecurity guidance. This includes devices connected to the internet or other networked systems. ### How does ISO 14971 apply to cybersecurity risk analysis? ISO 14971 provides the foundational risk management framework. The FDA expects manufacturers to apply its principles-identifying hazards, estimating risks, implementing controls, and monitoring, to cybersecurity risks by framing cyber threats as potential sources of patient harm. ### What is the role of threat modeling in FDA cybersecurity submissions? Threat modeling is the initial analytical step required. It involves defining device assets, interfaces, and the threat environment to identify potential attack vectors. The documented output is a required artifact for cyber device premarket submissions. ### How should manufacturers score severity and likelihood for cyber risks? Severity scores must be anchored in clinical outcomes and patient harm, not abstract data loss, with clear clinical rationale. Likelihood estimation should consider attacker motivation, access level, skill prerequisites, and existing controls. A 5x5 matrix is commonly used, with documented justification for each score. ### What are the FDA's five cybersecurity objectives for controls? The FDA's 2026 cybersecurity guidance organizes security objectives into authenticity, authorization, availability, confidentiality, and secure updatability. Every control implemented should map back to at least one of these objectives. ### What evidence does the FDA expect for control verification? The FDA expects verification and validation evidence for each control, with traceability to testing. This typically includes vulnerability scanning, penetration testing (which should be independent for high-risk devices), and SBOM analysis. Fuzz testing, SAST, and DAST can provide supporting evidence. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Cybersecurity Risk Profiles](/blog/medical-device-cybersecurity-risk-profiles) - [FDA Medical Device Classifications](/blog/fda-cybersecurity-requirements-by-device-class) - [Top 50 Medical Device Cybersecurity Issues](/blog/the-top-50-cybersecurity-issues-with-medical-devices) --- ## Medical Device Cybersecurity Risk Profiles (2026 Guide) Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-risk-profiles # Medical Device Cybersecurity Risk Profiles for Medical Devices: 2026 Best Practices > **[DIRECT ANSWER]** A medical device cybersecurity risk profile identifies how a specific device's intended use, architecture, connectivity, and exploitability translate into patient safety and clinical operational risk, rather than relying on generic IT checklists. Under the FDA's February 3, 2026 final guidance, manufacturers must document these profiles with evidence covering authentication, updates, logging, and data integrity to support premarket submissions under Section 524B. _Updated October 26, 2024_ Connected medical devices improve care. They also expand the attack surface in ways that can affect patient safety, clinical operations, and regulated product performance. That is why medical device cybersecurity risk profiling needs to be tied to intended use, system architecture, exploitability, and patient impact, not generic IT checklists. ## Key Takeaways - Align risk profiles with device use and patient impact. - Address authentication, updates, logging, and data integrity. - Prioritize patient safety and clinical operations. - Consider malware, unauthorized access, and phishing threats. - Differentiate risk for diagnostic vs. Therapeutic devices. - Implement design controls and postmarket monitoring. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device cybersecurity risk profiles the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding Medical Device Cybersecurity Medical device cybersecurity is about more than keeping attackers out. It is about preserving safety, effectiveness, availability, and data integrity across the full device lifecycle. A connected infusion pump, pacemaker, imaging system, or bedside monitor can all introduce different risks based on how they authenticate users, exchange data, accept updates, log events, and fail under adverse conditions. ### Why cybersecurity matters in healthcare Healthcare delivery depends on systems that must work when needed. If a threat actor can disrupt a device, alter its output, or interfere with its communications, the result is not just an IT incident. It can become a clinical event. That risk extends beyond direct patient harm. A medical device cybersecurity failure can trigger downtime, incident response costs, regulatory scrutiny, delayed procedures, privacy exposure, and damage to provider and manufacturer credibility. For manufacturers, poor cybersecurity design can also complicate FDA submissions, postmarket obligations, and customer adoption. ![Section Image](/imported-images/4580454566f68825.webp) ### Core concepts that shape device risk A useful risk profile starts with fundamentals. Authentication and authorization determine who can access device functions, configuration settings, service interfaces, and data. Encryption protects data in transit and, where appropriate, at rest. Logging and monitoring support detection and investigation. Secure update mechanisms help prevent tampering and support patching without creating new failure modes. Vulnerability management matters just as much. Manufacturers need a process to identify weaknesses, assess exploitability, validate fixes, and communicate residual risk. Healthcare delivery organizations need asset visibility, network segmentation, compensating controls, and procedures for deploying updates safely. Staff training also matters, especially when phishing, weak credentials, or unmanaged service workflows create openings around the device rather than inside it. ## Identifying Cybersecurity Risks in Medical Devices A meaningful risk profile does not stop at “this device is connected.” It asks how the device could be compromised, what an attacker could realistically do next, and what the downstream effect would be on patients and clinical use. ### Common threats to medical devices Several threat patterns show up repeatedly. Malware can disrupt device operation, degrade availability, or serve as a foothold into broader clinical networks. [Malware](/blog) is still a real problem, particularly where legacy operating systems, unsupported software components, or weak segmentation remain in place. Unauthorized access is another major concern. If attackers or unauthorized insiders can reach administrative functions, service menus, APIs, or remote management pathways, they may be able to change settings, disable alarms, modify dosage parameters, or interrupt therapy. Devices with default credentials, weak authentication, exposed ports, or insecure remote access are especially vulnerable. [Phishing attacks](/blog) also remain common in healthcare. They do not usually compromise a medical device directly, but they can compromise users, support accounts, update infrastructure, or adjacent systems that devices trust. That is often enough to create a serious device security event. ### What a breach can actually impact The first concern is patient safety. If an attacker can alter therapy delivery, interfere with monitoring, delay alarms, corrupt diagnostic output, or deny clinicians access to device functions, the harm can be immediate. Privacy is part of the picture too. Many devices store, display, or transmit protected health information. A breach can expose sensitive data and create legal and contractual fallout for both providers and manufacturers. Then there is the operational and financial damage. Incident response, remediation, downtime, product support, recalls, field actions, and litigation are expensive. So is lost trust. Once customers believe a device is insecure, recovery is hard. ## Risk Profiles of Different Medical Devices Not all medical devices carry the same cyber risk. The right profile depends on clinical function, connectivity, software complexity, user environment, maintenance model, and how a compromise would affect safety or performance. ### Diagnostic devices Diagnostic devices such as MRI systems, CT scanners, ultrasound platforms, and in vitro diagnostic instruments often handle large amounts of sensitive data and connect to enterprise systems like PACS, EHR platforms, and vendor support channels. Their risk profile often includes data integrity, availability, and trust in output. If an attacker alters images, modifies test results, delays transmission, or disables workflows, clinicians may make decisions based on false or incomplete information. Even when a compromise does not directly injure a patient, corrupted diagnostics can still lead to delayed treatment, unnecessary procedures, or missed conditions. ### Therapeutic and implantable devices Therapeutic devices such as infusion pumps, insulin pumps, neurostimulators, and implantable cardiac devices present a different class of risk. Here, unauthorized changes may directly affect therapy delivery. That is why these devices require tighter scrutiny around command authentication, wireless interfaces, firmware integrity, update controls, fail-safe behavior, and the ability to detect anomalous commands or communications. A weakness in any of those areas can move the issue from a cybersecurity problem to a patient harm scenario very quickly. ## Mitigating Cybersecurity Risks in Medical Devices Reducing device risk takes engineering discipline, not checkbox compliance. Security controls must be matched to the device’s intended use, threat model, deployment environment, and safety constraints. ### Practices that actually reduce risk Start with secure design. Limit exposed services, remove unnecessary functionality, harden interfaces, and separate privileged functions from routine user workflows. Implement strong authentication for users, technicians, and remote support. Validate all inputs. Protect software integrity. Make logging useful enough to support detection and investigation. [Encryption](/blog) should be used where it meaningfully protects device communications and sensitive data. Secure coding practices, software bill of materials management, dependency review, and repeatable testing should be built into development rather than added late. Penetration testing helps, but only when it is aligned to realistic attack paths and product-specific abuse cases. Regular assessments matter after release too. Postmarket monitoring, coordinated vulnerability disclosure, patch planning, and well-defined customer communications are all part of a credible security program. For healthcare providers deploying the device, compensating controls such as segmentation, access control, and asset inventory are often essential. ### Where the field is heading Medical devices are becoming more connected, more software-dependent, and more integrated with cloud services, mobile apps, and hospital ecosystems. That raises the importance of continuous risk management over one-time testing. Manufacturers should expect more focus on threat modeling, secure update architecture, software supply chain visibility, exploitability analysis, and postmarket response maturity. The Internet of Medical Things will keep expanding, but scale alone does not improve security. More connected endpoints simply mean more chances for weak trust relationships, unmanaged dependencies, and hidden attack paths. [IoMT](/blog) security will depend on disciplined architecture, clear ownership, and realistic operating assumptions. ## Regulatory Framework for Medical Device Cybersecurity Cybersecurity for medical devices is now firmly inside the regulatory conversation. Manufacturers need to treat it as part of product quality, safety, and lifecycle management. ### The role of regulators Regulators have made it clear that cybersecurity is not optional. In the United States, the [US Food and Drug Administration (FDA)](https://www.fda.gov/media/119933/download) has issued recommendations and expectations that push manufacturers toward security by design, documented risk management, and postmarket readiness. That includes thinking through how vulnerabilities are discovered, assessed, remediated, and communicated over time. ![Section Image](/imported-images/bb7cc9ec0f9010d8.webp) The FDA expects cybersecurity work to connect to real device behavior and patient impact. Manufacturers that treat security as a paperwork exercise usually create trouble for themselves later, whether during review, customer security assessments, or vulnerability response. ### Compliance, standards, and risk management Standards can help, but they are not a substitute for product-specific engineering judgment. Frameworks such as [ISO 27001](/blog) and the NIST Cybersecurity Framework can support governance and program structure, but medical device risk still has to be evaluated in the context of intended use, threat exposure, clinical environment, and safety impact. Effective compliance means performing real risk assessments, documenting security architecture, validating controls, and revisiting assumptions as threats and product use change. It also means monitoring the field, reviewing whether deployed controls still work, and taking corrective action when they do not. That is the difference between defensible cybersecurity and checklist theater. Medical device manufacturers need risk profiles that reflect how the device is actually built, used, connected, serviced, and attacked. When those profiles are grounded in safety impact, exploitability, and lifecycle management, they support better design decisions, stronger FDA submissions, and a more credible postmarket program. Blue Goat Cyber helps medical device companies do that work properly. We support manufacturers with penetration testing, security assessments, and practical cybersecurity strategy aligned to HIPAA and FDA expectations. If you need a clearer picture of your device risk and what to do about it, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is a medical device cybersecurity risk profile? A medical device cybersecurity risk profile is a detailed assessment of potential cyber threats and vulnerabilities tailored to a specific medical device. It considers the device's function, connectivity, architecture, and potential patient harm from a security breach, guiding the implementation of appropriate security controls. ### Why are cybersecurity risk profiles important for medical devices? They are critical because medical device compromises can directly affect patient safety, disrupt clinical operations, and expose sensitive patient data. Effective risk profiles help manufacturers meet regulatory expectations, design safer products, and manage postmarket vulnerabilities proactively. ### How does the FDA view cybersecurity risk for medical devices? The FDA considers cybersecurity an integral part of medical device safety and effectiveness. The agency expects manufacturers to implement security by design, manage risks throughout the product lifecycle, and have processes for postmarket vulnerability response, as detailed in its February 3, 2026 final guidance. ### What elements are included in a medical device cybersecurity risk profile? Key elements include assessing authentication, authorization, data encryption, secure updates, logging, vulnerability management, and incident response capabilities. The profile also considers the device's intended use, its connectivity, and the potential impact of a breach on patients and clinical workflows. ### Do different medical devices have different cybersecurity risks? Yes, risks vary significantly based on device type. For example, therapeutic or implantable devices carry a higher patient safety risk from compromise than diagnostic devices, requiring more stringent controls around therapy delivery and firmware integrity. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Cybersecurity Neglect in MedTech: The Real Threat Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-the-real-threat-isnt-genius-hackers-its-neglect # Cybersecurity Neglect in MedTech: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** The real threat to medical device security is neglect, not sophisticated hackers, since most breaches exploit basic, well-known weaknesses like default passwords, outdated software, and unsegmented networks rather than novel attack techniques. The FDA now treats cybersecurity as integral to device safety and effectiveness, expecting a Secure Product Development Framework, risk-based vulnerability management, and documented controls including an SBOM. Addressing these basics consistently prevents most real-world incidents and regulatory deficiencies. When we talk about cybersecurity for medical devices, the imagery often conjured up is straight out of a Hollywood thriller: shadowy, genius hackers cracking complex codes with exceptional ease. While this image sells movie tickets, it doesn’t reflect reality, and believing it could be dangerous. The real threats medical devices face come from something far more mundane yet insidiously dangerous: simple neglect. ## Key Takeaways - Most cyberattacks exploit basic, known vulnerabilities. - Neglect, not genius hackers is the real threat. - Weak passwords and old software are top vulnerabilities. - FDA guidance mandates cybersecurity across device lifecycle. - Proactive measures prevent patient harm and regulatory issues. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device cybersecurity the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## The Myth of the Genius Hacker Cybersecurity breaches often conjure images of hackers as highly intelligent masterminds. But extensive research and real-world incident analyses consistently show that hackers rarely rely solely on genius-level intellect. Most successful attacks exploit straightforward vulnerabilities-ones that don’t require a high IQ or even advanced technical skills. Medical device cybersecurity attacks frequently capitalize on basic oversights, rather than high-level strategic maneuvers. Consider the infamous WannaCry ransomware attack, which crippled hospitals worldwide. It didn’t require a genius hacker; it exploited known vulnerabilities in outdated software-vulnerabilities that could have easily been patched had proper cybersecurity management been in place. The bottom line: hackers don’t always have to outsmart anyone. They just have to exploit the oversights left by others. ## Common Vulnerabilities that Make Medical Devices Easy Targets Medical devices are particularly vulnerable because of predictable weaknesses that manufacturers often neglect. Here are the top culprits: - **Default and Weak Passwords:** The simplest yet most common vulnerability in medical devices. Default passwords are easily available online-hackers don’t need intelligence, just an internet connection. - **Outdated Software:** Many medical devices run on outdated systems or firmware, making them prime targets for cyberattacks that exploit known vulnerabilities. - **Poor Network Security:** Unsecured networks in hospitals and clinics are inviting targets. Often, basic encryption and network segmentation are overlooked, making it easy for attackers to infiltrate the system and cause real harm. - **Lack of Continuous Cybersecurity Monitoring:** Cybersecurity is not a “set it and forget it” endeavor. Neglecting ongoing security assessments, patch management, and monitoring makes even the best-designed device vulnerable over time. ## The Cost of Neglecting Medical Device Cybersecurity Neglecting cybersecurity can have devastating consequences. Cyberattacks can: - **Jeopardize Patient Safety:** Ransomware attacks and other breaches can shut down life-saving medical devices or entire hospital systems, leading directly to patient harm or even death. - **Damage Reputation and Trust:** Cyber incidents make headlines, damaging a company’s reputation and eroding patient trust. - **Trigger Regulatory Consequences:** The FDA has significantly increased scrutiny on cybersecurity, making premarket and postmarket cybersecurity risk management essential, not optional. ## FDA Expectations: Cybersecurity is Integral, Not Optional The FDA now explicitly states that cybersecurity is part of medical device safety and effectiveness. Their latest guidelines emphasize a proactive and approach: - **Secure Product Development Framework (SPDF):** Device manufacturers are expected to integrate cybersecurity throughout the product lifecycle, from initial concept and design, to deployment, and through ongoing [postmarket surveillance](/services/fda-postmarket-cybersecurity-services). - **Risk-Based Approach:** Manufacturers must demonstrate that they have identified and mitigated potential cybersecurity risks, both during the premarket submission process and throughout the device’s operational life. - **Transparency and Documentation:** Detailed cybersecurity management plans, Software Bill of Materials (SBOM), and clear documentation of security controls are increasingly required by regulators. Ignoring these evolving regulatory requirements is a risk no medical device manufacturer can afford. ## Why Blue Goat Cyber Stands Out in Medical Device Cybersecurity At Blue Goat Cyber, we see medical device cybersecurity not just as a technical challenge, but as a responsibility to patients and healthcare providers everywhere. Under the leadership of our founder, Christian Espinosa-a globally respected cybersecurity expert; we focus on tangible, effective solutions designed specifically for the unique cybersecurity challenges medical device manufacturers face. ### Our Services Include - **FDA Regulatory Compliance Assistance:** We expertly navigate the complex FDA cybersecurity landscape, ensuring your devices meet or exceed compliance standards, streamlining premarket approval processes. - **Proactive Threat Modeling and Risk Assessments:** Our experienced cybersecurity specialists conduct thorough threat modeling to proactively identify potential risks before devices reach the market. - **Full Lifecycle Cybersecurity Integration:** Cybersecurity isn’t an add-on; it’s integrated into your entire product lifecycle, from initial design through long-term market support and updates. - **Real-Time Monitoring and Postmarket Management:** Continuous cybersecurity support, patch management, and incident response to keep your devices secure over time. ### The Real Solution: Vigilance, Not Genius You don’t have to outsmart genius hackers; you simply need the right cybersecurity partner to ensure you never neglect the basics. Blue Goat Cyber offers more than just technical expertise. We’re committed to empowering medical device manufacturers to take ownership of their cybersecurity journey, ensuring that every device you produce is secure, compliant, and reliable. Your patients depend on you. Protecting them means protecting your devices from threats-real threats, not just the imaginary geniuses of Hollywood films. ## Don’t Wait Until a Cyber Incident Forces Your Hand It’s not a question of if your devices will be targeted; it’s a question of when. Don’t be caught off guard. Blue Goat Cyber can help you secure your devices, protect your patients, and maintain trust in your brand. Take the first step today. Schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) with us today. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What are common cybersecurity vulnerabilities in medical devices? Common vulnerabilities include default or weak passwords, outdated software lacking security patches, poor network segmentation, and insufficient continuous cybersecurity monitoring. These basic oversights are frequently exploited. ### How does the FDA view medical device cybersecurity? The FDA considers cybersecurity integral to a medical device's safety and effectiveness. The February 3, 2026 final guidance emphasizes proactive, risk-based cybersecurity management throughout the entire product lifecycle, from design to postmarket surveillance. ### Why aren't genius hackers the main threat to medical devices? Real-world incidents show that most successful attacks exploit basic, well-known vulnerabilities rather than requiring advanced skills. Hackers often use neglect, such as unpatched software, rather than inventing novel exploits. ### What are the consequences of neglecting medical device cybersecurity? Neglecting cybersecurity can jeopardize patient safety by disrupting devices or systems, damage a manufacturer's reputation, and lead to significant regulatory penalties from the FDA. ### Does the FDA require specific cybersecurity documentation? Yes, the FDA requires detailed cybersecurity management plans, a Software Bill of Materials (SBOM), and clear documentation of security controls as part of premarket submissions and ongoing postmarket responsibilities. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) --- ## Medical Device Traceability Matrix: Guide | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-traceability # Medical Device Traceability Matrix for Cybersecurity Review > **[DIRECT ANSWER]** A medical device traceability matrix is the document that links every identified threat to a security risk, every risk to a written requirement, every requirement to an implemented control, and every control to a verification test with a result. Reviewers use it to check that nothing was addressed informally. Manufacturers that maintain it as a living artifact inside the quality system, updated as the design changes, avoid the scramble of reconstructing the chain when a submission deadline arrives. _Reviewed September 17, 2026_ A traceability matrix is often the first document a reviewer opens because it shows, in one place, whether a manufacturer's cybersecurity claims hold together. When a threat model identifies a risk but no requirement addresses it, or a requirement exists but no test verifies it, the gap is visible immediately and becomes the basis for an Additional Information request. That gap can add months to a clearance timeline and, worse, can mean a real vulnerability shipped unaddressed. Building the matrix after the fact, once engineering is finished and the submission is due, is where most manufacturers lose time, because reconstructing which control addressed which threat requires re-interviewing engineers and re-reading old design documents. A traceability matrix maintained from the start of development, alongside the ISO 14971 risk file and IEC 62304 software requirements, turns this from a submission burden into a routine engineering output. ## Key Takeaways - A traceability matrix links threats, risks, requirements, controls, and verification evidence into one auditable chain. - Reviewers use the matrix to check for gaps, not just to confirm documents exist. - The matrix should live inside the quality system and update as the design changes, not get assembled once before submission. - Every row needs a verification result, not just a description of the intended control. - The matrix ties directly into the ISO 14971 risk management file and IEC 62304 software requirements, rather than existing as a separate artifact. - Postmarket vulnerability response depends on the same matrix to identify which components and requirements are affected. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (February 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. The guidance expects manufacturers to show a clear linkage between identified risks, the controls implemented to address them, and the testing that verified those controls, which is exactly what a traceability matrix documents. Reviewers apply this expectation the same way they apply software lifecycle requirements from IEC 62304, which requires traceability between software requirements, design, and verification, and risk management requirements from ISO 14971, which requires traceability between hazards, risk controls, and verification of control effectiveness. A cybersecurity traceability matrix is not a separate obligation; it is the security-specific extension of traceability practices manufacturers already maintain for safety and software quality. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA Additional Information letters, trailing only software documentation and clinical evidence. A large share of those deficiencies trace back to gaps a matrix would have surfaced early: a threat identified in a model with no corresponding requirement, or a requirement with no verification evidence attached. Treating traceability as a checklist assembled at submission time, rather than a design-controlled engineering artifact maintained throughout development, is what creates that gap. ## What Does a Cybersecurity Traceability Matrix Actually Link? A cybersecurity traceability matrix links five things in sequence: the threat identified during threat modeling, the security risk it creates, the requirement written to address it, the control implemented to satisfy the requirement, and the verification evidence proving the control works. Each row of the matrix represents one complete chain from threat to proof. Skipping a link in that chain is the most common failure mode. A threat model might identify a risk of unauthorized firmware modification, but if no requirement explicitly states the control (such as cryptographic signature verification before installation), the risk exists without a documented answer. Conversely, a requirement without a verification result is just a claim; reviewers expect a test report, not a statement of intent. > **[KEY REQUIREMENT]** Every threat identified in the threat model must appear as a row in the traceability matrix with a linked requirement, control, and verification result, or an explicit and justified acceptance of residual risk in the risk management file. ## What Should an Example Traceability Matrix Look Like? An example traceability matrix has one row per threat and columns for the threat, the risk it creates, the requirement addressing it, the control implemented, and the verification evidence produced. The table below shows the pattern using common medical device threats. | Threat | Risk | Requirement | Control | Verification Evidence | |:---|:---|:---|:---|:---| | Unauthorized firmware update | Malicious code execution on device | Firmware must be cryptographically signed before installation | Signature verification in bootloader | Pen test attempting unsigned firmware load; test report showing rejection | | SQL injection via clinician portal search | Unauthorized access to patient data | All database queries must use parameterization | Parameterized query implementation, code review checklist | SAST scan results, targeted DAST test on search endpoint | | Weak session token generation | Session hijacking, unauthorized access | Session tokens must use a cryptographically secure random generator with defined entropy | Secure token library, session expiration policy | Token entropy analysis, session fixation test results | | Unencrypted wireless telemetry | Interception of patient data in transit | All wireless data transmission must use TLS 1.2 or higher | TLS implementation with certificate validation | Protocol analysis, penetration test of wireless interface | | Default or hardcoded credentials | Unauthorized device access | No hardcoded credentials permitted; unique credentials per device required | Provisioning workflow generating unique credentials | Code review, credential audit during penetration test | Each row should also record the residual risk after the control is applied and a reference to where that residual risk is accepted in the ISO 14971 risk management file, since some risk always remains even after a control is implemented. ## How Does the Matrix Tie Into ISO 14971 Risk Controls? The traceability matrix ties into ISO 14971 by mapping each cybersecurity threat to the same risk analysis, risk evaluation, and risk control structure the standard already requires for safety hazards. ISO 14971 requires that every identified hazard link to a risk control and that the effectiveness of that control be verified, and a cybersecurity threat is treated as a hazard-generating event within that same framework. The practical connection is that a security threat's clinical impact, such as a device malfunction from a manipulated command or a patient safety event from corrupted telemetry, needs a severity and probability rating consistent with the same risk matrix used for other hazards in the file. The traceability matrix then becomes the mechanism that shows the risk control (a cybersecurity control) was actually implemented and verified, closing the loop that ISO 14971 requires between hazard identification and control effectiveness. > **[KEY REQUIREMENT]** Cybersecurity risks documented in the traceability matrix must appear in the ISO 14971 risk management file with a severity and probability rating, and the risk control effectiveness verification referenced in the risk file must point back to the same test evidence cited in the traceability matrix. ## How Does the Matrix Tie Into IEC 62304 Software Requirements? The traceability matrix ties into IEC 62304 by treating each security requirement as a software requirement subject to the same design, implementation, and verification traceability the standard mandates for all software requirements. IEC 62304 requires bidirectional traceability from software requirements through software design to verification, and security requirements are not exempt from that expectation just because they originate from a threat model rather than a functional specification. In practice, this means a security requirement like "all database access must use parameterized queries" needs the same lifecycle documentation as a functional requirement: it appears in the software requirements specification, maps to a design element in the architecture, and links to a specific verification activity such as a SAST rule or a targeted penetration test case. Software of unknown provenance and third-party components add another dimension, since a vulnerability in an SBOM-tracked component needs to trace to the requirement it violates and the mitigation applied. | Framework | What It Requires | How the Traceability Matrix Satisfies It | |:---|:---|:---| | ISO 14971 | Hazard to risk control to verification of control effectiveness | Threat and risk columns link to the risk file; verification evidence proves control effectiveness | | IEC 62304 | Software requirement to design to verification, bidirectional | Requirement and control columns map to design elements; verification evidence closes the loop | | FDA premarket guidance | Documented linkage between risk, control, and testing | The matrix itself is the artifact reviewers request to see this linkage | ## What Do Reviewers Look For in a Traceability Matrix? Reviewers look for completeness, consistency, and evidence that verification actually happened rather than being described in future tense. A matrix that lists controls as "planned" or "to be implemented" signals that the submission is premature, since the FDA's guidance expects controls to be implemented and verified before submission, not scheduled. Reviewers also check for consistency between the matrix and the other submission artifacts: the threat model, the SBOM, the penetration test report, and the risk management file all need to reference the same threats and controls using consistent terminology. A mismatch, such as a threat named differently in the threat model than in the matrix, creates friction and invites additional questions even when the underlying engineering is sound. Finally, reviewers look for evidence the matrix is a living document rather than a one-time submission artifact. A postmarket vulnerability disclosure process that references the same matrix to identify affected requirements and components demonstrates that traceability supports the full product lifecycle, not just the initial clearance. ## How Blue Goat Cyber Approaches This Blue Goat Cyber builds traceability matrices as part of the engineering process, not as a document assembled after testing is complete. We start from the threat model, carry each threat through its ISO 14971 risk entry and IEC 62304 requirement, and link it to the specific verification evidence, whether that's a SAST finding, a penetration test result, or an SBOM-linked vulnerability assessment. Our [medical device threat modeling services](/services/medical-device-threat-modeling) establish the threat inventory that becomes the first column of the matrix, and our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) carry that inventory through to a submission-ready matrix that stays consistent with the risk file and software requirements specification. We build the matrix so it can be maintained after clearance, supporting postmarket vulnerability response without starting from scratch. ## Frequently Asked Questions ### Why does a traceability matrix matter for FDA premarket review? The FDA's February 3, 2026 final guidance expects a documented, consistent link between identified cybersecurity risks, the controls that address them, and the verification evidence proving those controls work. A traceability matrix is how manufacturers demonstrate that linkage in one place, and its absence or incompleteness is a common driver of Additional Information requests. ### What columns should a cybersecurity traceability matrix include? At minimum, a matrix should include the identified threat, the resulting security risk, the requirement written to address it, the control implemented, and the verification evidence produced. Many manufacturers add a residual risk column and a reference to where that risk is accepted in the ISO 14971 risk management file. ### How does traceability support postmarket vulnerability management? When a new vulnerability is disclosed, the matrix lets a manufacturer quickly identify which requirements, controls, and components are affected without re-analyzing the entire system from scratch. This supports the kind of rapid impact assessment expected under postmarket cybersecurity management practices. ### Is a traceability matrix only necessary for software-heavy devices? No. Any device with cybersecurity risk exposure, including hardware with firmware, wireless interfaces, or network connectivity, needs traceability from threats through to verification. The matrix scope should match the device's actual attack surface, not its software complexity. ### When should the traceability matrix be built? It should be built incrementally starting with the initial threat model, not assembled right before submission. Building it alongside development means each requirement and control already has its verification evidence attached by the time the submission package is compiled. ## CTA If you need help building a traceability matrix that holds up under FDA review and stays usable after clearance, we can help you connect your threat model, risk file, and verification evidence into one consistent chain. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Interconnected Medical Device Cybersecurity: Network Risks Source: https://bluegoatcyber.com/blog/medical-device-cybersecurity-with-interconnected-devices # Medical Device Cybersecurity with Interconnected Devices > **[DIRECT ANSWER]** Securing interconnected medical devices requires data encryption in transit and at rest, strong authentication such as multi-factor or role-based access control, continuous network monitoring with intrusion detection, and security built into the device during design rather than added afterward. Healthcare organizations must also comply with HIPAA safeguards and the FDA's Feb 3, 2026 premarket cybersecurity guidance, while training staff to recognize phishing and other human-error risks that remain a leading cause of network compromise. _Reviewed July 24, 2026_ Connected medical devices are crucial in improving patient care and medical outcomes. These devices, such as pacemakers, infusion pumps, and glucose monitors, are interconnected through networks to enable communication, data sharing, and remote monitoring. However, with this connectivity comes a pressing concern - the [need to ensure network security](/blog/securing-communication-protocols-in-medical-devices) for these devices. ## Key Takeaways - Interconnectivity in medical devices improves patient care but introduces cybersecurity risks. - Network security safeguards patient data and ensures medical device functionality. - The FDA February 3, 2026, guidance sets cybersecurity requirements for medical devices. - Strong security measures include encryption, access controls, and ongoing monitoring. - Healthcare staff training on cybersecurity best practices is essential. - Proactive security integration during device design minimizes vulnerabilities. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device cybersecurity with interconnected devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding the Importance of Network Security in Healthcare Network security is of immense significance in healthcare due to the sensitive nature of patient data and the [potential impact of security breaches](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples). When compromised, connected medical devices can lead to dire consequences, including patient harm, theft of personal health information, and disruption of medical services. ![Section Image](/imported-images/125d0e4ac54a203e.webp) Healthcare organizations heavily rely on networked systems and connected medical devices to deliver efficient and effective care. These devices, such as infusion pumps, pacemakers, and monitoring equipment, play a crucial role in patient diagnosis, treatment, and monitoring. They enable healthcare providers to remotely monitor patients, analyze real-time data, and make informed decisions. However, this increased connectivity also introduces new risks and threats to network security. ### The Role of Connected Medical Devices in Modern Healthcare Connected medical devices have revolutionized healthcare delivery by enabling remote patient monitoring, real-time data analysis, and improved treatment efficiency. For instance, wearable devices with sensors can continuously monitor vital signs and transmit data to healthcare providers, enabling early detection of abnormalities and timely intervention. Networked systems allow healthcare professionals to access patient records, share information, and collaborate seamlessly, leading to enhanced care coordination and improved patient outcomes. These devices and systems have become integral to healthcare infrastructure, supporting various medical procedures, from telemedicine consultations to complex surgeries. ### Potential Risks and Threats to Network Security As the number of connected medical devices grows, so does the [vulnerability to cyber threats](/blog). Hackers can exploit security vulnerabilities in medical devices or gain unauthorized access to the network, endangering patient safety and compromising the integrity of healthcare systems. One tangible example is the [2017 WannaCry ransomware attack,](https://usa.kaspersky.com/resource-center/threats/ransomware-wannacry) which impacted the United Kingdom’s National Health Service, causing significant disruptions and highlighting the urgent need for network security measures. Healthcare organizations must proactively address the potential risks and threats to network security. They must [implement security measures](/blog), including firewalls, encryption protocols, and intrusion detection systems, to safeguard patient data and protect against unauthorized access. Regular security audits and vulnerability assessments are essential to identify and mitigate any weaknesses in the network infrastructure. Healthcare providers should prioritize employee training and awareness programs to educate staff about the importance of network security and the best data protection practices. Human error, such as falling victim to phishing attacks or using weak passwords, can inadvertently expose the entire network to cyber threats. Collaboration between healthcare organizations, device manufacturers, and cybersecurity experts is also crucial to ensure the development and implementation of secure medical devices. Regular software updates and patches should be applied to address any known vulnerabilities and protect against emerging threats. ## Elements of Network Security for Medical Devices ### Data Encryption and Protection Encrypting sensitive patient data ensures unauthorized individuals cannot access or decipher the information. Healthcare providers must employ encryption algorithms to protect data in transit and at rest. In addition to encryption, healthcare organizations should consider implementing data protection measures such as [data loss prevention (DLP)](/blog) solutions. DLP solutions can help prevent accidental or intentional data breaches by monitoring and controlling the flow of sensitive information within the network. Healthcare organizations should regularly update their encryption protocols to stay ahead of emerging threats. This includes implementing the latest encryption algorithms and ensuring that encryption keys are securely managed. ### Regular Network Monitoring and Maintenance Continuous network monitoring is essential to detect abnormal network activity or unauthorized access. Healthcare organizations can identify and respond promptly to cyber threats by implementing intrusion detection systems. In addition to intrusion detection systems, healthcare organizations should consider implementing [intrusion prevention systems (IPS)](/blog). IPS can proactively block suspicious network traffic and prevent potential attacks before they can cause any harm. Regular network maintenance is equally important to ensure the ongoing security of medical devices. This includes applying software patches and updates to address any known vulnerabilities. Healthcare organizations should also conduct regular vulnerability assessments and penetration testing to identify and address weaknesses in their network security defenses. ### Implementing Strong Authentication and Authorization Protocols Effective authentication and authorization protocols, such as two-factor authentication, can help prevent unauthorized access to medical devices and the network. By verifying the identities of individuals trying to access patient data or control medical devices, healthcare organizations add an extra layer of security. In addition to two-factor authentication, healthcare organizations should consider implementing role-based access control (RBAC) systems. RBAC ensures only authorized individuals can access specific resources and functionalities based on organizational roles and responsibilities. Healthcare organizations should regularly review and update their authentication and authorization protocols to address emerging threats or vulnerabilities. This includes implementing multi-factor authentication methods, such as biometric authentication, for enhanced security. By implementing these key network security elements, healthcare organizations can significantly reduce the risk of cyber threats and protect sensitive patient data. However, it is essential to note that network security is an ongoing process that requires continuous monitoring, maintenance, and adaptation to evolving threats. ## Strategies for Enhancing Network Security ![Section Image](/imported-images/0491d32780b1f165.webp) Network security is critical to any organization, especially in the healthcare industry, where protecting sensitive patient data is paramount. To ensure a and network security framework, healthcare organizations should consider implementing the following strategies: ### Establishing a Complete Security Policy Healthcare organizations should develop a security policy that outlines security best practices, employee responsibilities, incident response procedures, and regular security audits. All staff members should communicate, understand, and follow this policy to maintain a strong security posture. A well-defined security policy serves as a guiding document that helps healthcare organizations establish a proactive approach toward network security. It provides clear instructions on handling security incidents, ensures that employees know their roles and responsibilities in maintaining a secure network environment, and sets the foundation for regular security audits to identify and address any vulnerabilities. ### Training and Educating Healthcare Staff Human error remains one of the most significant threats to network security. Regularly training and educating healthcare staff on cybersecurity best practices, such as identifying phishing emails or avoiding social engineering attacks, is crucial in preventing security breaches. Healthcare staff members interact with various devices and systems daily, so they are on the front lines of network security. Organizations can significantly reduce the risk of successful attacks by equipping themselves with the knowledge and skills to identify and respond to potential security threats. Training sessions can cover password hygiene, safe browsing practices, and keeping software and devices current. ### Incorporating Security in the Design and Development Stage Medical device manufacturers should prioritize security from the outset in the design and development phase. Manufacturers can mitigate vulnerabilities and reinforce network security measures by building security features into the devices themselves. Medical devices play a crucial role in the healthcare industry, but can also introduce potential security risks if not adequately secured. By incorporating security measures during the design and development stage, manufacturers can ensure that their devices have built-in encryption, authentication protocols, and regular software updates to address emerging vulnerabilities. This proactive approach helps to minimize the risk of unauthorized access or tampering with sensitive patient data. ## Regulatory Standards and Compliance in Network Security Regulatory bodies have recognized the importance of network security in healthcare and have established standards to ensure patient privacy and data protection. Ensuring compliance with these standards is crucial for healthcare organizations to maintain the integrity and security of their networks. One of the most significant regulatory standards in the healthcare industry is the Health Insurance Portability and Accountability Act (HIPAA),-Print&text=The%20Health%20Insurance%20Portability%20and,the%20patient's%20consent%20or%20knowledge.). HIPAA sets guidelines for protecting patient data and requires healthcare organizations to implement administrative, physical, and technical safeguards. These safeguards include measures such as access controls, encryption, and regular risk assessments to identify and address vulnerabilities in the network. In addition to HIPAA, the [Food and Drug Administration (FDA)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) also supports network security, specifically in medical devices. The FDA has recognized the potential risks associated with compromised medical devices and issued guidelines and recommendations for cybersecurity. These guidelines aim to protect patients from potential harm resulting from security vulnerabilities in medical devices. International standards organizations have also contributed to developing network security guidelines in the healthcare industry. The International Electrotechnical Commission (IEC) and the International Organization for Standardization (ISO) have developed frameworks and standards that provide a global perspective on network security. These standards help healthcare organizations establish security practices that align with international best practices. ### Overview of HIPAA and Its Relevance to Network Security The Health Insurance Portability and Accountability Act (HIPAA) sets standards for protecting patient data and requires healthcare organizations to implement administrative, physical, and technical safeguards. Compliance with HIPAA regulations is crucial for ensuring network security and patient privacy. Under HIPAA, healthcare organizations are required to conduct regular risk assessments to identify vulnerabilities in their network infrastructure. These assessments help organizations understand their security posture and implement appropriate risk mitigation measures. Additionally, HIPAA mandates the implementation of access controls to ensure that only authorized individuals have access to patient data, further enhancing network security. ### Understanding the FDA’s Role in Medical Device Security The Food and Drug Administration (FDA) supports ensuring the safety and effectiveness of medical devices. In recent years, the FDA has issued guidelines and recommendations for medical device cybersecurity to protect patients from potential harm resulting from compromised devices. Medical devices like [pacemakers](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know) and insulin pumps are increasingly connected to networks, allowing healthcare providers to monitor and manage patients remotely. However, this connectivity also introduces security risks. The FDA’s guidelines address these risks by emphasizing the importance of secure design, regular software updates, and vulnerability management in medical devices. By adhering to these guidelines, healthcare organizations can ensure the integrity and security of their networked medical devices. ### International Standards for Network Security in Healthcare Beyond national regulations, international standards organizations, like the International Electrotechnical Commission (IEC) and the International Organization for Standardization (ISO), have developed guidelines and frameworks for network security in the healthcare industry. These standards provide a global framework for healthcare organizations to create network security practices. The IEC’s standard, IEC 81001-5-1, focuses specifically on managing risk related to medical devices connected to networks. It guides risk assessment, risk management, and the implementation of security controls. Similarly, [ISO 27001](/blog), a widely recognized information security standard, offers a framework for establishing, implementing, maintaining, and continually improving an information security management system in healthcare organizations. By adhering to these international standards, healthcare organizations can benefit from a global perspective on network security and ensure that their practices align with industry best practices. This enhances the security of their networks and promotes interoperability and collaboration across borders. ## Trust boundaries in a connected system Interconnection multiplies interfaces, and each interface is a boundary that needs its own answer. This is the table worth building for your own architecture. | Interface | Typical trust assumption | What breaks the assumption | Control that holds | | --- | --- | --- | --- | | Device to hospital network | The network is segmented | Flat networks and guest VLAN mistakes | Mutual authentication that does not depend on placement | | Device to cloud backend | TLS makes the channel safe | Certificate pinning omitted, weak server authorization | Pinned or validated certificates plus per device identity | | Mobile app to device | The paired phone is the owner's | Cloned apps, rooted devices, relayed pairing | Authorization enforced on the device, not the app | | Device to device | Peers on the same segment are legitimate | One compromised peer | Per peer identity and least privilege messaging | | Service or programmer interface | Physical access implies authorization | Stolen or counterfeit programmers | Authenticated service sessions with an audit trail | | Cloud to clinician portal | The portal enforces roles | Broken object level authorization | Server side authorization checks on every request | Two devices that are each individually secure can still produce an insecure system, which is why the threat model needs to cover the system and not only the box you ship. ## Conclusion Network security is of paramount importance in healthcare, especially in the context of connected medical devices. Healthcare organizations must implement a multifaceted approach that combines technological safeguards, policies, and ongoing education to protect patient data and ensure patient safety. By adhering to regulatory standards and collaborating with industry partners, healthcare providers can create a secure network environment that maximizes the benefits of connected medical devices while safeguarding patient privacy and well-being. The importance of network security cannot be overstated as the healthcare industry continues to embrace the advantages of connected medical devices. Blue Goat Cyber, a Veteran-Owned business, stands at the forefront of B2B cybersecurity services, offering specialized expertise in medical device cybersecurity, HIPAA and FDA compliance, and a range of penetration testing services to secure your business against cyber threats. Our commitment to safeguarding your operations and patient data is unwavering. [Contact us today for cybersecurity help](/contact) and partner with a team as passionate about protection as you are about patient care. Check out our [medical device cybersecurity premarket submission package.](/services/fda-premarket-cybersecurity-services) ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What are the primary cybersecurity risks for interconnected medical devices? Primary risks include unauthorized data access, patient harm from device malfunction, and disruption of healthcare services due to cyberattacks. Exploitation of software vulnerabilities and network intrusion attempts are common threats. ### How does the FDA regulate cybersecurity for medical devices? The FDA provides regulatory oversight through its February 3, 2026, final guidance on medical device cybersecurity. This guidance outlines expectations for cybersecurity design, labeling, and postmarket management throughout a device's lifecycle, requiring manufacturers to submit detailed cybersecurity information in premarket submissions. ### What technical controls enhance network security for medical devices? Technical controls include data encryption for data at rest and in transit, strong authentication and authorization protocols like multi-factor authentication, and continuous network monitoring with intrusion detection and prevention systems. Regular software updates and vulnerability assessments are also critical protections. ### Why is staff training important for medical device cybersecurity? Human error is a significant vulnerability in cybersecurity. Training healthcare staff on best practices, such as recognizing phishing attempts, using strong passwords, and understanding data handling policies, significantly reduces the likelihood of security breaches originating from human factors. ### When should medical device cybersecurity be considered in the product lifecycle? Cybersecurity must be a priority from the initial design and development stages of a medical device. Integrating security features early helps mitigate vulnerabilities and ensures that devices are built with protective measures, rather than attempting to add them as an afterthought. ### What is the role of manufacturers in securing interconnected medical devices? Manufacturers are responsible for designing devices with security built-in, addressing identified vulnerabilities through updates and patches, and providing adequate cybersecurity information to users. Their adherence to the FDA's February 3, 2026, final guidance is essential for Ensure device safety and effectiveness. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Hazard Analysis Source: https://bluegoatcyber.com/blog/medical-device-hazard-analysis-and-critical-control-points # Medical Device Hazard Analysis and Critcal Control Points > **[DIRECT ANSWER]** Medical device hazard analysis identifies risks a device may pose to patients or users across its lifecycle, while critical control points are the specific design, manufacturing, and postmarket stages where controls are applied to reduce those risks before they reach patients. The FDA requires both as part of premarket review, and they must be revisited continuously as devices change, since hazard identification without corresponding control points leaves risks documented but unmanaged. _Updated November 15, 2024_ Medical device hazard analysis and critical control points help keep devices safe and effective. They identify risk, set controls, and reduce harm to patients and users. ## Key Takeaways - Hazard analysis identifies potential risks in medical devices. - Critical control points are stages for applying risk controls. - These processes manage risks across the device lifecycle. - The FDA and international standards require their use. - They support device safety, effectiveness, and compliance. - Continuous improvement adapts them to new technologies. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device hazard analysis and critcal control points the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding Medical Device Hazard Analysis Hazard analysis identifies and reduces potential risks tied to medical devices. It is a [systematic approach that involves evaluating](/blog) every stage of a device’s lifecycle, from design to disposal. ![Section Image](/imported-images/6f7d66e878b5af36.webp) ### Definition and Purpose of Hazard Analysis Hazard analysis identifies hazards a medical device may pose to patients, users, or the environment. The goal is simple: find what can go wrong, then put controls in place to reduce or remove the risk. ### Components of Hazard Analysis Hazard analysis starts with identifying potential hazards tied to a medical device. That means reviewing device design, materials, intended use, and the environment where the device will operate. It also includes [assessing the severity of each identified hazard](/blog) and the likelihood it will occur. That lets teams rank risks and deal with the most serious ones first. ### The Role of Hazard Analysis in Medical Device Safety Hazard analysis supports the safety and effectiveness of medical devices. Manufacturers use it to identify risks early and build devices that meet safety requirements. It also helps healthcare professionals make informed decisions when using medical devices. It [guides us away from harm and towards optimal patient](/blog) care. Hazard analysis also matters for regulatory compliance. Agencies such as the [Food and Drug Administration (FDA)](https://www.fda.gov/) require manufacturers to conduct hazard analysis as part of premarket review. That helps ensure devices entering the market have been evaluated for potential risks. Hazard analysis is not a one-time task. It continues across the device lifecycle so teams can identify new hazards and respond before they become patient safety issues. ## The Concept of Critical Control Points Critical control points are the places in a device lifecycle where teams can prevent, reduce, or monitor risks found during hazard analysis. ### Defining Critical Control Points Critical control points are specific stages in the development, manufacture, and use of medical devices where control measures can be applied. These measures keep hazards from reaching patients and end users. From design controls to manufacturing practices and [post-market surveillance](/blog), critical control points help manage risk throughout the device lifecycle. ### The Role of Critical Control Points in Risk Management Risk management depends on putting controls in the right places. Critical control points let manufacturers act before a hazard causes harm. When control measures are applied at the right stages, the chance of patient harm drops. ### Identifying Critical Control Points in Medical Devices Identifying critical control points means reviewing the key processes involved in developing, manufacturing, and using medical devices. The goal is to find the stages that need tighter monitoring and stronger controls. One example is design controls. During design, engineers review intended use, performance requirements, and possible risks. That is the point where many hazards can be identified and reduced before they carry into production. Another key control point is manufacturing. This is where the design becomes a real product. Quality controls and inspections are needed to make sure the device matches specifications and meets regulatory requirements. Good manufacturing practices reduce defects and deviations that could create patient risk. ## The Interplay Between Hazard Analysis and Critical Control Points Hazard analysis and critical control points are connected parts of a quality management system. Hazard analysis finds the risks. Critical control points are where those risks are controlled. ### How Hazard Analysis Informs Critical Control Points Hazard analysis gives manufacturers the information needed to place control measures where they matter most. By identifying, assessing, and ranking hazards, teams can focus resources on the control points that have the biggest effect on product safety. Hazard analysis also includes risk assessment and prioritization. When risks are ranked by severity and likelihood, manufacturers can focus on critical control points with the highest safety impact. ### The Synergy Between Hazard Analysis and Critical Control Points These two processes work together. Hazard analysis identifies risk. Critical control points reduce or contain it. Used together, they help manufacturers meet regulatory requirements and protect patients. This connection also supports continuous improvement. As new information appears and risks change, manufacturers can update both hazard analysis and critical control points to address new safety concerns and technology changes. ## The Regulatory Perspective on Hazard Analysis and Critical Control Points Regulators expect manufacturers to use hazard analysis and critical control points to support device safety and effectiveness. ![Section Image](/imported-images/c9b5236e90efd8cd.webp) Regulatory bodies around the world oversee medical device manufacturing, distribution, and use. They set standards intended to protect patients and healthcare professionals. ### FDA Guidelines on Hazard Analysis and Critical Control Points The United States Food and Drug Administration (FDA) has issued guidance to help manufacturers conduct hazard analysis and implement critical control points. Under FDA guidance, manufacturers must identify hazards tied to their devices, assess the risks, and establish measures to reduce or eliminate them. Following this guidance improves product safety and reliability and supports regulatory review. ### International Standards for Medical Device Safety Medical device safety is a global issue, and international standards give manufacturers a common framework. These standards set expectations for hazard analysis and critical control point implementation, which helps align safety practices across markets. [Harmonized international standards](/blog/mdsap-for-medical-devices-simplifying-international-compliance) also make regulatory processes and cross-border market access easier. They show that a manufacturer is following recognized safety and quality expectations. ## Challenges and Solutions in Implementing Hazard Analysis and Critical Control Points Hazard analysis and critical control points are useful, but implementation is not always straightforward. Manufacturers run into process, staffing, and operational issues. ### Common Obstacles in Hazard Analysis and Critical Control Points Implementation Implementation often runs into limited resources, inconsistent processes, and resistance to change. These are common problems, and they slow down risk management work if they are not addressed early. Global supply chains add more difficulty. Manufacturers may need to coordinate across multiple sites, work through language barriers, and keep practices consistent across teams. ### Strategies for Effective Implementation Manufacturers can improve implementation by investing in training, building a culture of continuous improvement, and using technology where it helps. It also helps to work with industry peers, stay engaged with regulators, and perform regular audits and reviews. Those steps improve consistency and make the process easier to maintain over time. ## The Future of Hazard Analysis and Critical Control Points in the Medical Device Industry As medical technology changes, hazard analysis and critical control points need to keep pace. ### Technological Advancements and Their Impact Artificial intelligence and the [Internet of Things, medical devices are becoming smarter and more interconnected](/blog/securing-iot-enabled-medical-devices-5-essential-tips) [.](/blog/securing-iot-enabled-medical-devices-5-essential-tips) That creates new ways to improve hazard analysis and critical control points, including real-time monitoring and predictive analytics. Virtual reality and augmented reality are also changing how healthcare professionals interact with devices and data. These tools can support hazard analysis by simulating scenarios in controlled environments. ### The Role of Hazard Analysis and Critical Control Points in Future Medical Device Development Hazard analysis and critical control points will remain central to future medical device development. New technologies do not reduce the need for risk management. They increase it. Personalized medicine and wearable medical devices create new risk profiles. That means hazard analysis must adapt to individual patient contexts and changing conditions while maintaining device safety and effectiveness. ## Conclusion Hazard analysis and critical control points help protect patients, users, and the environment from device-related risks. They support safer medical devices and stronger risk management across the product lifecycle. As the medical device industry changes, these processes become more important. Blue Goat Cyber helps manufacturers address cybersecurity risk in medical devices, including penetration testing and compliance with HIPAA and FDA standards. [Contact us today for cybersecurity help](/contact) ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is medical device hazard analysis? Medical device hazard analysis is a systematic process of identifying potential hazards associated with a medical device. It involves evaluating risks from design to disposal, assessing severity and likelihood, and prioritizing them for mitigation to ensure patient safety. ### What are critical control points in medical devices? Critical control points are specific stages in a medical device's lifecycle where control measures can be applied to prevent, eliminate, or reduce identified hazards. These points ensure that risks are managed effectively, helping to keep patients and users safe. ### How do hazard analysis and critical control points work together? Hazard analysis identifies and prioritizes potential risks, providing the necessary information to establish critical control points. Critical control points then implement the control measures at key stages to manage those identified risks. This synergy ensures complete risk management. ### Does the FDA require hazard analysis for medical devices? Yes, the FDA requires medical device manufacturers to conduct hazard analysis as part of their premarket review processes. This ensures that devices entering the market have been thoroughly evaluated for potential risks and that appropriate controls are in place. ### What challenges exist in implementing hazard analysis and critical control points? Common challenges include limited resources, inconsistent processes, and resistance to change within organizations. Managing complexities in global supply chains and coordinating practices across multiple sites can also present significant obstacles to effective implementation. ### How do new technologies affect hazard analysis and critical control points? New technologies like AI, IoT, VR, and AR are creating new risk profiles and opportunities for improved hazard analysis. They enable real-time monitoring and predictive analytics, demanding that these processes adapt to maintain device safety and effectiveness in evolving medical landscapes. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Incident Response Plan Source: https://bluegoatcyber.com/blog/medical-device-incident-response-plan-fda # Medical Device Incident Response Plan: FDA Expectations 2026 > **[DIRECT ANSWER]** Section 524B requires a premarket description of how you will identify and respond to cybersecurity vulnerabilities and incidents, so the incident response plan is submission content, not a postmarket afterthought. Reviewers look for named owners, severity and escalation criteria, disclosure timelines, and explicit links to CAPA, complaint handling, and your coordinated vulnerability disclosure policy. The FDA does not treat incident response as a postmarket afterthought. Under Section 524B of the FD&C Act, the cybersecurity content of a premarket submission must describe how the manufacturer will identify and respond to cybersecurity vulnerabilities and incidents across the device lifecycle. Reviewers look for a real plan with owners, decision criteria, and links to QMS records, not a paragraph in the cybersecurity management plan. This post walks through what the FDA expects in 2026, the documents that satisfy it, and the common reasons incident response sections draw deficiency letters. ## Key Takeaways - The medical device incident response plan is a Section 524B requirement, not a postmarket-only artifact. - The plan must connect to coordinated vulnerability disclosure, complaint handling, and MDR reporting. - The FDA expects named roles, decision criteria, severity tiers, and customer communication paths. - Tabletop exercise evidence and lessons-learned records strengthen the submission package. - Misalignment between the IR plan and the postmarket cybersecurity management plan is a common deficiency trigger. ## Why this matters A medical device incident response plan is the bridge between a known vulnerability and a clinically safe outcome. The FDA's February 3, 2026 final premarket cybersecurity guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," names incident response as a required element of the postmarket cybersecurity management plan that ships with every premarket submission for a cyber device. The guidance ties the plan to Section 524B(b)(2)(B), to coordinated vulnerability disclosure obligations, and to 21 CFR Part 820 quality system requirements for complaint handling and CAPA. Independent sources reinforce the stakes: CISA's published medical advisories under ICS-CERT routinely identify medical device vulnerabilities that require coordinated response between the manufacturer, the FDA, and healthcare delivery organizations. Without a named owner, a defined severity ladder, and rehearsed customer communications, manufacturers cannot meet the timelines that reviewers, customers, and CISA expect. ## What the FDA Requires in a Medical Device Incident Response Plan ### Section 524B Sets the Statutory Floor Section 524B(b)(2)(B) of the FD&C Act requires a cyber device manufacturer to design, develop, and maintain processes and procedures to provide a reasonable assurance that the device and related systems are cybersecure, and to make available updates and patches to address vulnerabilities, including those that could lead to uncontrolled risks. Incident response is the operational expression of that obligation. The Feb 3, 2026 guidance turns the statute into specific submission content: a written plan, named owners, severity criteria, escalation paths, and a defined relationship to the manufacturer's CVD program. ### The Plan Must Be Operational, Not Aspirational Reviewers look for evidence that the plan is rehearsed. That means tabletop exercise records, sign-offs from clinical engineering or medical affairs, and traceable links between the IR plan, the threat model, and the postmarket monitoring program. > **[KEY REQUIREMENT]** The FDA expects the IR plan to describe what the manufacturer will do, who will do it, the trigger criteria, and the maximum time to each action, not just to assert that incidents will be handled. ## How the IR Plan Sits Inside the SPDF and Submission ### Where It Lives in the Submission The incident response plan is part of the postmarket cybersecurity management plan in the premarket submission. In eSTAR for a 510(k), it sits inside the cybersecurity content set and is cross-referenced from the cybersecurity management plan, the security risk assessment, and the labeling. The SPDF references the IR plan as the runtime control that closes the loop between detected vulnerabilities and deployed patches. ### How It Connects to Other Postmarket Artifacts The plan is one node in a network of postmarket artifacts. It receives input from the coordinated vulnerability disclosure policy, SBOM/VEX monitoring, customer support channels, and external feeds like CISA ICS advisories and the NVD. It feeds output into CAPA, MDR reporting under 21 CFR Part 803, customer security advisories, and software updates. A plan that does not reference these connection points reads as a draft rather than an operational document. ## Who Owns Each Phase of Incident Response ### Named Roles, Not Job Titles in the Abstract The FDA expects named roles with defined authority. A typical structure assigns a cybersecurity incident commander (often the product security lead or CISO designee), a clinical safety lead (medical affairs or clinical engineering), a regulatory lead (regulatory affairs), a customer communications lead (support or marketing), and an engineering remediation lead. The plan documents who can declare an incident, who can authorize a customer advisory, and who signs off on a patch release. ### Decision Authority at Each Severity Tier Severity tiers drive the response. A common four-tier ladder (informational, low, high, critical) maps to time-to-triage, time-to-containment, and time-to-customer-communication. The plan states who has authority to escalate or de-escalate a tier and the criteria for each transition. Reviewers look for objective criteria (CVSS base score thresholds, exploit availability, patient-safety impact) rather than subjective language. ## What Goes in the Plan: Required Sections A defensible medical device incident response plan addresses the elements below. Each one should be a named section with owners, inputs, outputs, and time bounds. | Section | Purpose | Typical inputs | | --- | --- | --- | | Scope and applicability | Devices, versions, deployment contexts covered | Product registry, SBOM index | | Detection and intake | How incidents are reported and triaged | CVD intake, customer support, KEV alerts | | Severity classification | Tier criteria and decision matrix | CVSS, exploit telemetry, clinical impact | | Containment and remediation | Immediate actions and patch pathway | Engineering runbooks, SPDF | | Evidence preservation | Forensic capture of affected device storage before remediation | [Hardware and software write blockers](/blog/write-blocker-medical-device-cybersecurity), chain-of-custody log | | Customer communication | Advisories, timelines, channels | Labeling commitments, regulatory review | | Regulatory reporting | MDR, CISA coordination, FDA notification | 21 CFR Part 803, CVD policy | | Post-incident review | Lessons learned and CAPA | Tabletop records, incident timeline | > **[FDA LANGUAGE]** The Feb 3, 2026 guidance frames these activities as ongoing risk management under the device's total product lifecycle, not one-time submission content. ## Common Deficiency Letter Patterns on Incident Response ### Generic Plans Without Device-Specific Triggers The most frequent deficiency pattern is a generic enterprise IR plan attached to the submission without device-specific triggers. Reviewers flag plans that do not name the device, do not reference the threat model, and do not describe how a vulnerability in a specific software component would move through the process. ### Missing Coordinated Vulnerability Disclosure Linkage A second common pattern is an IR plan that does not connect to the CVD program. The two are separate documents but they share an intake channel and a notification pathway. Reviewers expect the IR plan to describe how externally reported vulnerabilities enter the process and how the CVD policy governs public disclosure timing. ### No Evidence of Rehearsal A third pattern is the absence of rehearsal evidence. Tabletop exercises are not required by name, but reviewers look for any indication that the plan has been exercised. Sign-off pages, exercise summaries, or references to lessons-learned reports satisfy this expectation. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches Incident Response Plans We build incident response plans as runnable runbooks tied to the device's threat model, SBOM, and postmarket monitoring program, not as standalone policy documents. Each plan names owners, defines severity tiers with objective criteria, and references the customer communications, MDR reporting, and CVD pathways the manufacturer already operates. Our team holds CISSP, OSCP, and prior military red-team credentials, and our submission work is grounded in Section 524B, the FDA's February 3, 2026 final premarket cybersecurity guidance, AAMI SW96:2023, and the postmarket sections of the manufacturer's 21 CFR Part 820 QMS. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA postmarket cybersecurity services](https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services) or review the [postmarket cybersecurity readiness plan](https://bluegoatcyber.com/guides/postmarket-cybersecurity-readiness-plan) for the broader operating model. ## FAQ ### Is a medical device incident response plan required in a 510(k) submission? Yes, for any device that meets the Section 524B definition of a cyber device. The plan sits inside the postmarket cybersecurity management plan content set in the eSTAR submission. The Feb 3, 2026 final premarket cybersecurity guidance treats incident response as one of the required operational processes the manufacturer commits to before clearance. ### How is the incident response plan different from the CVD policy? The coordinated vulnerability disclosure policy governs how external researchers report vulnerabilities and how the manufacturer communicates about them publicly. The incident response plan governs internal detection, triage, containment, and remediation. The two share an intake channel and notification pathway but answer different questions. ### Does the FDA expect tabletop exercises? The Feb 3, 2026 guidance does not require tabletop exercises by name. In practice, reviewers look for evidence that the IR plan has been exercised. Tabletop records, sign-offs, and lessons-learned summaries are the most efficient way to demonstrate that the plan is operational rather than aspirational. ### How does the IR plan interact with MDR reporting? A cybersecurity incident that results in or could result in serious injury or death triggers MDR reporting obligations under 21 CFR Part 803. The IR plan describes the decision criteria for opening an MDR, the owner, and the timeline. Misalignment between the IR plan and the manufacturer's complaint handling SOP is a common deficiency. ### What severity model should we use? Most manufacturers use CVSS base score thresholds combined with exploit availability and patient-safety impact. The model itself matters less than the consistency. Reviewers expect the same severity definitions to appear in the IR plan, the CVD policy, the SBOM/VEX monitoring program, and the customer advisory templates. ## Ready to make your incident response plan submission-ready? If you are preparing a 510(k), De Novo, or PMA submission and need an incident response plan that reads as operational and lines up with your CVD policy, postmarket monitoring, and complaint handling, we can help. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led FDA premarket and postmarket cybersecurity programs across Class II and Class III devices and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## More on this topic - [HIPAA and Medical Device Manufacturers](/blog/hipaa-medical-device-manufacturers-cybersecurity) - [Health Canada Medical Device](/blog/health-canada-medical-device-cybersecurity) - [The FDA’s New Medical Device](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) - [FDA Medical Device Classifications](/blog/fda-cybersecurity-requirements-by-device-class) --- ## Key Exchange in Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/medical-device-key-exchange-cybersecurity # Key Exchange in Medical Device Cybersecurity: TLS, PKI, and Keys > **[DIRECT ANSWER]** Secure key exchange protects connected medical devices by establishing authenticated shared secrets between endpoints, using protocols like TLS 1.3 with ephemeral Diffie-Hellman for forward secrecy, so attackers cannot intercept, replay, or forge sessions. Most real-world failures come from implementation gaps, weak certificate validation, missing replay protection, or no key rotation plan, rather than broken cryptography. Manufacturers should document key provisioning, storage, and rotation as lifecycle assets, with verification evidence tied to the threat model for FDA review. ## Key Takeaways - In medical device cybersecurity, key exchange is usually the real risk surface, not the encryption algorithm. - Most failures are implementation and lifecycle failures: authentication gaps, replay exposure, weak randomness, and no rotation plan. - Treat keys and certificates as lifecycle assets with documented provisioning, rotation, and recovery paths. - For FDA readiness, focus on traceability: threats → requirements/controls → architecture evidence → verification. ## Why key exchange matters in medical device cybersecurity Key exchange is the process of establishing shared secrets (or trusted public keys) so two endpoints can communicate securely. In medical devices, key exchange failures rarely look like “encryption is broken.” They look like: - A device accepts a fake cloud endpoint because certificate validation was weak. - A service tool can downgrade the protocol and replay a prior session. - A BLE pairing flow leaks keys, enabling unauthorized control or data access. - An update mechanism trusts the wrong signing key, or cannot recover from key compromise. From a patient safety perspective, these issues can turn into loss of availability (device disruption), loss of integrity (tampered therapy settings), or loss of confidentiality (PHI exposure). That is why modern guidance treats cybersecurity as part of safety and effectiveness, across the total product lifecycle. ## Where key exchange shows up in medical devices You typically see key exchange in four places: - **Device to cloud:** TLS sessions, mutual authentication, API tokens and refresh flows. - **Device to mobile app:** pairing, onboarding, and session key negotiation (often BLE). - **Device to device:** interoperability channels inside a system-of-systems. - **Updates and maintenance:** firmware signing keys, secure download, and verification. Blue Goat Resources: - [TLS 1.3 for medical devices](/blog/securing-communication-protocols-in-medical-devices) - [Symmetric encryption and key management in devices](/guides/fda-security-control-categories-medical-devices) - [Key escrow tradeoffs for regulated products](/blog/medical-device-cybersecurity-best-practices) ## The key exchange problem (in plain language) The “key exchange problem” is simple: how do two parties create a shared secret over an untrusted network without an attacker learning or manipulating it? If you just “send the key,” you lose. If you exchange keys without authenticating identities, you invite man-in-the-middle attacks. If you reuse keys too broadly, you increase blast radius and reduce forward secrecy. Modern key establishment schemes (like Diffie-Hellman variants) are designed to solve the shared-secret portion of this problem, but they still require correct authentication and correct implementation choices. ## Common key exchange failures that create FDA-worthy risk ### 1) Man-in-the-middle (MitM) during onboarding or TLS setup A MitM attack happens when an attacker positions themselves between endpoints and impersonates each side. In devices, MitM risk spikes during: - first-use pairing and onboarding - certificate enrollment - factory test modes left enabled - service ports and maintenance tools **What to do:** Use strong server authentication, consider mutual TLS where appropriate, validate certificate chains correctly, and avoid “accept all certs” fallbacks in production builds. ### 2) Replay attacks in protocols that lack freshness Replay attacks reuse valid captured messages. If your protocol does not include nonces, timestamps, sequence numbers, or session binding, an attacker can re-trigger a sensitive action. **What to do:** Use session keys, include anti-replay protections, and bind authorization decisions to current session context. ### 3) Weak randomness and predictable key generation Some embedded designs still struggle with entropy, especially early boot. Predictable randomness can undermine key generation and session secrets. **What to do:** Use a vetted RNG strategy for your platform, avoid rolling your own, and document how entropy is seeded and tested. ### 4) “Works in the lab” PKI that fails in the field PKI problems often show up post-launch: expired certificates, no rotation plan, unclear revocation strategy, and brittle provisioning workflows that break manufacturing or servicing. **What to do:** Treat certificates like lifecycle assets. Plan rotation, renewal, and revocation from day one, and test failure modes. ## Protocols and patterns that work well for connected medical devices ### Diffie-Hellman and ECDHE for forward secrecy Diffie-Hellman style key agreement helps establish session keys without transmitting them directly. Using ephemeral variants (often [ECDHE](https://www.ecdhe.com/ "") in TLS) supports forward secrecy, meaning past sessions remain protected even if a long-term key is later compromised. ### TLS done intentionally (not “default library settings”) TLS is the common answer for data-in-transit, but configuration matters. Version support, cipher suites, certificate validation behavior, and key sizes should be deliberate and defensible. **Practical framing:** In regulated products, “we used TLS” is not enough. You want a short, reviewer-friendly statement of: - protocol versions supported - how endpoints authenticate - how secrets are generated and stored - how keys and certificates are rotated - how failures are handled safely ### Secure elements and hardware-backed key storage (when warranted) If compromise of a key materially increases patient safety risk, hardware-backed key protection can be worth it. It can also simplify your threat model story by reducing key extraction likelihood. ## What to document for FDA-facing cybersecurity evidence FDA-facing reviewers typically respond well to structured, traceable evidence. For key exchange, that means showing: - **Threat model coverage:** MitM, replay, credential theft, update tampering. - **Security requirements:** authentication, cryptography, session management, secure update integrity. - **Architecture views:** trust boundaries, certificate flows, key storage boundaries, update signing flow. - **Verification evidence:** protocol testing, negative tests, validation of cert handling, downgrade resistance (where applicable). Blue Goat resources that support the packaging: - [Medical device threat modeling](/services/medical-device-threat-modeling) - [FDA-aligned vulnerability and penetration testing](/services/medical-device-penetration-testing) - [FDA-compliant SBOM services](/services/fda-compliant-sbom-services-for-medtech) - [Postmarket cybersecurity management services](/services/fda-postmarket-cybersecurity-services) ## A simple checklist: key exchange decisions that should be explicit - Which trust model do you use (public PKI, private PKI, pinned certs, mutual TLS)? - How are device identities provisioned at manufacturing? - Where are private keys stored (filesystem, TEE, secure element, HSM-backed service)? - How do you rotate and revoke certificates or keys? - How do you prevent replay and downgrade attacks? - What happens when keys expire, are lost, or are suspected compromised? ## Key exchange methods compared | Method | Forward secrecy | Typical device fit | The trap | | --- | --- | --- | --- | | Pre-shared symmetric key | No | Constrained devices with no certificate store | One key across a fleet turns one extraction into a fleet compromise | | Static RSA key transport | No | Legacy designs only | A recovered private key decrypts every past session you ever captured | | ECDHE with certificates | Yes | Most connected devices | Certificate validation skipped or pinned to something that expires | | BLE Secure Connections pairing | Yes, per session | Wearables and short-range links | Just Works pairing authenticates nobody | | Post-quantum hybrid, ML-KEM with ECDHE | Yes | Long-lived devices being designed now | Larger keys against a fixed MTU and a fixed flash budget | The choice is usually constrained by hardware you picked years earlier, which is exactly why it belongs in the design record rather than the release notes. ## How Blue Goat reviews key exchange in medical devices Blue Goat Cyber reviews key exchange as a first-class part of every medical device threat model and penetration test. We confirm that ephemeral key exchange (ECDHE) is used over forward-secret TLS 1.3 channels, that certificate pinning or mTLS is in place where the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 expects it, and that key rotation, revocation, and storage match the device's risk tier. Our testers hold CISSP and OSCP credentials and include ex-military red team operators, and they validate the implementation, not just the design diagram, including hardware secure elements, TPMs, and the BLE/Wi-Fi/cellular paths the device actually uses in the field. Findings tie to AAMI TIR57 and SW96 outputs and feed your [threat modeling deliverables](/services/medical-device-threat-modeling). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### Is Diffie-Hellman “enough” to solve key exchange for medical devices? It solves shared secret establishment, but you still must authenticate endpoints correctly. Without authentication, a MitM can negotiate keys with both sides. ### Should a medical device use TLS 1.2 or TLS 1.3? TLS 1.3 is generally preferred in new designs because it simplifies negotiation and strengthens security properties. If you support TLS 1.2 for interoperability, lock it down with strong suites and validated certificate handling. ### Do we need mutual TLS for every device? Not always. Mutual TLS can reduce impersonation risk, but it adds operational complexity. Make it a risk-based decision and document the rationale. ### What is the biggest key management mistake you see in connected devices? No rotation and no failure mode planning. Keys expire, certificates get revoked, and update signing keys can be compromised. If you do not have a plan, you end up with unsafe workarounds. ### How do we test key exchange and TLS beyond “it connects”? Test downgrade resistance, replay handling, certificate validation edge cases, expired cert behavior, and failure mode safety. Combine automated scanning with targeted negative tests and penetration testing. ## Call to action If you want a clean, FDA-ready package for cryptography and key exchange evidence (threat model, architecture views, verification results, and documentation), we can help. [**Book a Discovery Session**](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ### Related Articles in This Series - [Twofish vs Blowfish for Medical Devices: What to Use, What to Avoid, and How to Modernize](/services/fda-premarket-cybersecurity-services) - [3 Ways Hackers Break Encryption in Medical Devices](/blog/understanding-relevant-threats-for-medical-devices) - [Cryptographic Attacks In Medical Devices](/blog/understanding-relevant-threats-for-medical-devices) - [How XOR Encryption Strengthens Medical Device Security](/blog/medical-device-key-exchange-cybersecurity) - [The Clipper Chip Controversy: Key Escrow Lessons for Medical Device Cybersecurity](/blog/medical-device-key-exchange-cybersecurity) - [Preventing Hash Collision Risk in Medical Device Cybersecurity](/blog/code-data-and-execution-integrity-security-controls-and-medical-device-cybersecurity) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Pen Testing Providers Source: https://bluegoatcyber.com/blog/medical-device-pen-testing-choosing-the-right-provider # Medical Device Pen Testing: Choosing the Right Provider > **[DIRECT ANSWER]** Choose a provider with documented medical device experience, not general IT pen testing, because FDA reviewers require reports that map findings to patient harm under ISO 14971, document tester independence and methodology against standards like UL 2900-2-1, and cover firmware, hardware, wireless, and cloud attack surfaces. Ask for a sample report used in an actual premarket submission before signing a contract. When penetration test reports are vague, incomplete, or written to enterprise IT standards rather than medical device requirements, FDA reviewers issue deficiencies that can delay clearance, sometimes requiring a full re-test before you can respond. If you’re selecting a provider for **medical device pen testing**, the wrong choice doesn’t just waste budget. It can push your submission timeline back by months at the worst possible point in your development cycle. Many general IT security firms lack the medical device-specific experience needed to produce FDA submission evidence or frame findings around patient safety risk. They know how to run a test, but producing documentation that survives FDA review is a different skill set. That gap is exactly why firms like **Blue Goat Cyber** exist: to bridge technically competent testing with submission-ready evidence that regulators can actually evaluate. This guide covers everything you need to make a qualified decision: scope and methodology, regulatory standards, provider qualifications, realistic costs and timelines, and the specific questions to ask before you sign a contract. ## Key Takeaways - FDA submission reports differ substantially from corporate IT reports. - Patient safety impacts must drive risk assessment, not just CVSS scores. - Provider must have medical device, not just healthcare IT, experience. - Align testing scope with your device's threat model and SBOM. - Validate provider's track record for FDA-accepted reports. - Ensure the report maps to FDA premarket guidance and ISO 14971. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device pen testing the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What medical device penetration testing actually covers A qualified medical device security test is not a network scan with a PDF report attached. It covers every layer of your device’s attack surface, from physical hardware to the cloud backend, and the scope must be documented before a single test begins. For an overview of the common testing approaches by system component, see our guide to [types of penetration testing for medical device cybersecurity](/services/medical-device-penetration-testing). ### Hardware and firmware: the physical attack surface Physical ports, debug interfaces like JTAG and UART, bootloaders, and chips are all in scope for a thorough hardware assessment. Testers evaluate tamper resistance, side-channel vulnerabilities, and whether physical access to the device yields meaningful use for an attacker. This kind of firmware and hardware pen testing requires specialized lab equipment and embedded systems expertise that many standard IT penetration testers lack. Firmware analysis goes deeper: static binary analysis, boot-chain integrity validation, and a review of the embedded OS for known CVEs and misconfigurations. Testers also examine secure boot mechanisms, cryptographic implementations, and firmware update security. If your firmware can be modified without authentication, that’s a patient safety issue, not just a compliance checkbox. ### Wireless protocols, companion apps, and cloud backend Wireless scope includes Wi-Fi, Bluetooth, ZigBee, RFID, and any proprietary radio protocols your device uses to communicate. Testers look for protocol weaknesses, denial-of-service vectors via electromagnetic manipulation, and whether communications are properly encrypted end-to-end. Research consistently shows wireless vulnerabilities are among the most exploitable in connected medical devices, which makes this portion of the engagement non-negotiable. Companion app testing focuses on authentication flaws, data exposure, and how the app integrates with the device itself. The cloud backend assessment covers API security, access controls, infrastructure configuration, and data storage practices. A weakness in your cloud API can be just as dangerous as a firmware flaw, especially when the backend controls device behavior or stores patient data. ### Why scope definition determines FDA submission quality An incomplete scope produces an incomplete report, and the FDA will notice. If your submission lists communication interfaces that your penetration test report doesn’t address, you’ll receive a deficiency asking you to explain the gap, which means either a re-test or a detailed justification for why certain components were excluded. **Your scope document must map directly to your device’s threat model and match the interfaces described in your submission.** Your SBOM should also inform scope by surfacing third-party components that need their own assessment. If your device runs a Linux-based embedded OS with open-source networking libraries, those components need to be explicitly addressed in the testing scope. For a practical, step-by-step approach to building a defensible scope document, refer to our article on [scoping a medical device penetration test](/blog/scoping-a-medical-device-penetration-test). ## How medical device pen testing differs from standard IT security testing Enterprise IT security and medical device security share tools and techniques, but they operate under fundamentally different consequence models, and that difference shapes everything from how findings are framed to what the final report must contain. ### Patient safety changes the entire risk equation In enterprise IT, a compromised system means data loss or downtime. In a medical device, it can mean a patient receives the wrong therapy, receives no therapy at all, or receives incorrect diagnostic information that drives a harmful clinical decision. That changes how every finding must be framed and evaluated. **Findings must be assessed in terms of patient harm potential, not just CVSS scores.** FDA risk analysis follows ISO 14971, not standard vulnerability severity matrices. A medium-CVSS finding that could allow unauthorized modification of insulin delivery parameters is far more significant than a critical-CVSS finding with no pathway to patient harm. Testers must understand this distinction and write their reports accordingly, and they must apply non-disruptive testing protocols in clinical or patient-connected contexts, where triggering a device fault during a test is not acceptable. ### Regulatory evidence requirements vs. corporate compliance reports Enterprise pen test reports summarize findings and recommend patches. FDA pen test reports must document tester independence, testing scope, methodology, all exploitation attempts whether successful or not, patient harm impact assessment, and mitigation rationale for any unresolved finding. The evidentiary bar is categorically different. A corporate IT pen test report rarely satisfies what the FDA expects in a premarket submission. Medical device penetration testing is a distinct discipline, not simply IT testing applied to a new type of hardware. The technical execution may look similar on the surface. The documentation requirements are an entirely different undertaking. ## General IT Firm Versus Medical Device Specialist Both can find vulnerabilities. Only one produces a report a reviewer can use. | | General IT security firm | Medical device specialist | |---|---|---| | Risk framing | CVSS severity | Patient harm under ISO 14971 | | Typical scope | Network, web application, cloud | Firmware, hardware, radio, app, and cloud | | Report audience | Your security team | An FDA reviewer reading your submission | | Standards referenced | OWASP, PTES | The Feb 3, 2026 guidance, AAMI SW96, UL 2900-2-1 | | Handling of a device on a bench | Usually out of scope | Core capability | | Evidence of independence | Rarely stated | Documented, because the guidance asks for it | | What you do with a finding | Fix it | Fix it and trace it through the risk file | ## Regulatory standards your pen test must satisfy Which standards govern your submission determines what goes into the report and what FDA reviewers will check when they evaluate your cybersecurity documentation. Know this before you evaluate a single provider. ### FDA premarket guidance and what reviewers expect to see FDA’s premarket cybersecurity guidance, most recently updated in 2023 and further refined in 2026, explicitly recommends penetration testing as part of cybersecurity verification and validation. Requirements took effect for submissions on or after March 29, 2023, and apply to 510(k), PMA, De Novo, and related pathways for devices with cybersecurity risk. For a detailed discussion of how to structure pen test deliverables to align with reviewer expectations, see [Penetration Testing for Medical Devices: What The FDA Expects](/services/medical-device-penetration-testing). Per FDA guidance, reviewers expect a report that covers: a device description and communication methods, testing timeframe and methodology, tester credentials and independence, a full account of vulnerabilities exploited, technical effects on safety and effectiveness, and a patient harm matrix. CVSS scores alone are not sufficient. Risk must be mapped to safety impacts across confidentiality, integrity, and availability dimensions. If your provider can’t produce that structure, their report will generate deficiencies. ### UL 2900, ISO 14971, and supporting frameworks UL 2900-2-1 is the most directly applicable standard for medical device cybersecurity testing. It builds on the general UL 2900-1 framework with healthcare-specific criteria, including structured penetration testing and SBOM analysis, and aligns with the FDA’s Medical CAP program. The FDA formally recognized it in 2018 to streamline premarket reviews for network-connectable healthcare products. ISO 14971 governs how pen test findings must be integrated into the overall risk management file. **Findings aren’t standalone observations. They become inputs to the risk analysis.** Supporting frameworks include NIST SP 800-115 for test methodology documentation, IEC 62304 for software lifecycle context, and PTES as an execution standard. Your provider must know which of these apply to your specific submission type and reference them explicitly in the report. For guidance on interpreting and applying FDA cybersecurity guidance in practice, see an industry analysis on [navigating FDA’s cybersecurity guidance](https://www.exponent.com/article/navigating-fdas-cybersecurity-medical-devices-guidance). ## Firmware and hardware pen testing: IVDs and other device categories The same principles apply across device categories, including in vitro diagnostic (IVD) devices. IVD penetration testing follows the same FDA premarket cybersecurity guidance and must address all relevant attack surfaces, hardware interfaces, firmware, network connectivity, and companion software. The complexity of the scope scales with the device, but the evidentiary requirements are consistent across device pen test services regardless of classification or intended use. ## What qualifications to require from a testing provider Credentials matter, but they’re only part of the picture. The more important question is whether a provider has produced FDA-accepted pen test reports for medical devices in actual premarket submissions. ### Certifications that signal genuine expertise Require certifications like OSCP, GPEN, or CPENT for hands-on exploitation capability. These validate practical skills, not just theoretical knowledge. When combined with medical device-specific credentials tied to UL 2900, IEC 60601, or ISO 14971, they signal a tester who understands both the technical execution and the regulatory context. ISO-accredited lab experience for FDA or CE mark processes adds meaningful credibility for submission-bound testing. Certifications alone, however, aren’t enough. Ask for documented case examples of actual medical device engagements, not healthcare IT work. Testing a hospital’s network is categorically different from testing a Class II connected monitor or a Class III implantable device. ### Medical device-specific experience and FDA report track record The provider must have hands-on experience testing hardware, firmware, radio protocols, and companion apps under real device conditions without degrading essential performance. They should know how to conduct passive scanning for devices in clinical use and active testing in controlled lab environments. They should also understand embedded systems, device communication protocols, and the specific vulnerabilities that appear in medical device architectures. Most critically, they should have produced pen test reports included in successful premarket submissions across 510(k), De Novo, or PMA pathways. **Blue Goat Cyber builds its pen test deliverables to FDA submission documentation standards from the outset**, not retrofitted from a general IT template after the fact. The goal is a report structured to the evidentiary requirements FDA reviewers apply during premarket review, which means fewer deficiencies and a cleaner path to clearance. ### What a good FDA-aligned pen test report actually looks like A submission-ready report connects every element: scope, testing boundaries, methodology, findings, and risk conclusions. An FDA reviewer should be able to follow the logic from scope definition through risk conclusion without needing a clarification call. - Scope and testing boundaries defined and tied to the threat model - Methodology referenced by standard (PTES, NIST SP 800-115), and supported by a clear [penetration testing checklist](/services/medical-device-penetration-testing) for execution and evidence collection - All findings mapped to patient safety impact using an ISO 14971-aligned harm matrix - Unaddressed findings documented with mitigation rationale, not silently omitted - Report structured for eSTAR submission requirements ## What pen testing costs and how long it takes Budget and timeline vary significantly based on device complexity, regulatory scope, and provider type. Here’s what the market looks like in 2026. ### Cost ranges by device complexity Simple Class II devices, such as wireless sensors or basic patient monitors, typically run between $10,000 and $30,000 with timelines of two to six weeks. Complex Class II and Class III devices, including imaging systems, networked implantables, and surgical platforms, range from $30,000 to $100,000 or more, with timelines extending four to twelve weeks or longer, depending on scope depth. Boutique specialized firms tend to be more cost-efficient than large consultancies for medical device work, provided they have the right expertise. The concern with lower-cost general IT security firms isn’t the upfront price, it’s the expensive rework that follows an FDA deficiency letter citing an inadequate pen test report. ### What drives price and timeline differences Device complexity is the largest cost driver. Multi-component, networked, or implantable systems require significantly more testing depth across firmware, hardware teardown, radio protocols, and cloud infrastructure. A device with a single Bluetooth interface costs far less to test thoroughly than a surgical platform with multiple wireless protocols, a cloud backend, and a companion mobile app. Regulatory scope adds cost as well. FDA submission requirements, ISO 14971 integration, and HIPAA alignment all extend the engagement beyond a standard test-and-report cycle. Provider type also matters: the cheapest option is rarely the least expensive when you account for the full submission lifecycle. ## Questions to ask before you sign a contract Use these questions during vendor evaluation. The answers will tell you quickly whether a firm understands the medical device context or is applying general IT methodology to a regulated hardware problem. ### Questions about scope and methodology Ask how the provider determines what’s in scope for firmware, hardware, and wireless testing. The answer should reference your threat model and SBOM, not a generic checklist. Ask which standards (specifically PTES, NIST SP 800-115, or UL 2900-2-1) will be explicitly referenced in the methodology section of their report. Ask whether they’ve tested devices of similar architecture and connectivity to yours, and ask for specifics. ### Questions about deliverables and FDA readiness Request a sample report that has been included in a premarket submission. If they can’t provide one, that’s your answer. Ask how they map findings to patient harm potential under ISO 14971, and ask what format the final report will take. Confirm it’s structured for eSTAR submission requirements, not a corporate compliance format that would need translation before it can be submitted. ### Red flags that signal the wrong firm Walk away from firms that can’t name a single medical device-specific standard when you ask about their methodology. Watch for sample reports that use CVSS severity scores alone without safety impact framing. Be cautious of providers who propose repurposing an existing enterprise pen test template rather than building scope from your threat model. And if they have no experience with FDA deficiency responses when a submission is questioned on cybersecurity grounds, you’re taking on risk they aren’t equipped to help you manage. ## Choosing right the first time Medical device pen testing is a distinct discipline. The firm you choose directly affects your submission outcome and your device’s real-world security posture for every patient who uses it. Technical testing skill is necessary but not sufficient. Your provider must also understand how to produce evidence that satisfies FDA reviewers, integrates with your risk management file, and holds up under scrutiny across the full premarket review process. Report quality matters as much as testing quality. A technically excellent test that produces an FDA-incompatible report is a costly mistake, one that delays clearance and forces rework at the worst possible time in your development cycle. The right provider brings both together from day one. **Blue Goat Cyber** supports medical device manufacturers through the full penetration testing and submission documentation process, from scope definition through FDA-ready deliverables. If you’re preparing a premarket submission and need a pen test built for FDA review, [contact Blue Goat Cyber](/contact) to discuss your device and submission timeline. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is medical device penetration testing? Medical device penetration testing systematically identifies cybersecurity vulnerabilities in medical devices across hardware, firmware, software, and cloud components. It evaluates potential exploits and their impact on device safety and effectiveness, distinct from general IT security assessments. ### How does FDA premarket guidance impact pen testing? The FDA's February 3, 2026 final guidance specifically recommends penetration testing for cybersecurity verification. It mandates that reports detail methodology, tester independence, exploited vulnerabilities, and a patient harm impact assessment, ensuring regulatory alignment for premarket submissions. ### Why is patient safety critical in medical device pen testing? Patient safety matters. Testers must evaluate findings based on their potential to harm patients, not solely on technical severity scores. This aligns with ISO 14971 risk management principles required by the FDA. ### What qualifications should a pen testing provider have? A qualified provider should possess certifications like OSCP and have hands-on experience with medical device hardware, firmware, and wireless protocols. Crucially, they must have a proven track record of generating FDA-accepted penetration test reports for medical device premarket submissions. ### Does UL 2900 apply to medical device pen testing? Yes, UL 2900-2-1 is a key standard, providing healthcare-specific criteria for medical device cybersecurity, including penetration testing and SBOM analysis. The FDA formally recognized it to streamline premarket reviews for network-connectable devices. ### What should an FDA-aligned pen test report include? An FDA-aligned report must include a detailed device description, testing timeframe and methodology, tester credentials and independence, a full account of vulnerabilities (even unexploited ones), technical effects on safety and effectiveness, and a patient harm matrix. CVSS scores alone are insufficient. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Robustnesss & Fuzz Testing](/blog/enhancing-medical-device-cybersecurity-robustness-and-fuzz-testing-explained) - [Post-Exploitation Frameworks in MedTech](/blog/post-exploitation-frameworks-medical-device-cybersecurity) - [Medical Device Vulnerability Testing](/blog/the-importance-of-medical-device-vulnerability-testing) --- ## Medical Device Pen Testing: FDA vs EU MDR 2026 Source: https://bluegoatcyber.com/blog/medical-device-pen-testing-fda-vs-eu-mdr-2026 # Medical Device Pen Testing: FDA vs EU MDR Requirements Compared (2026) > **[DIRECT ANSWER]** The FDA prescribes exactly five penetration test report elements in section V.C of its February 3, 2026 final guidance, while the EU MDR prescribes none and reaches testing indirectly through Annex I GSPR 17.2 and 17.4 plus MDCG 2019-16. One well-scoped test can serve both submissions, but the FDA evidence goes into the eSTAR cybersecurity attachment while the MDR evidence is distributed across Annex II technical documentation and referenced from the risk management file. _Published July 10, 2026_ > **Read the pillar guide:** For the fundamentals of medical device penetration testing - scope, methodology, and FDA report elements - see [Penetration Testing for Medical Devices](/guides/penetration-testing-for-medical-devices). This post is the FDA vs EU MDR comparison companion. ## Key Takeaways - The FDA prescribes exactly five report elements for pen testing under the Feb 3, 2026 guidance §V.C; the EU MDR prescribes zero. - MDR reaches pen testing through Annex I §17.2 (IT security measures) and §17.4 (state-of-the-art) plus MDCG 2019-16 §3.7, with notified bodies treating EN IEC 81001-5-1:2022 as the working evidence standard. - Independence expectations differ: the FDA expects documented third-party or organizationally-separated testers; the MDR route accepts graded independence under IEC 62443-4-1 practice SVV-3. - FDA evidence lives in the eSTAR cybersecurity attachment; MDR evidence is distributed across Annex II technical documentation and referenced from the risk management file. - Applicability triggers differ. The FDA applies to a "cyber device" as defined in Section 524B(c); the MDR applies to any device with software or a data interface. - One pen test report can serve both submissions when written to the FDA's stricter five-element format and cross-mapped to §17.2/§17.4 and EN IEC 81001-5-1. ## At-a-glance comparison | Dimension | FDA (Feb 3, 2026 guidance) | EU MDR (2017/745) | | --- | --- | --- | | **Report content** | 5 prescribed elements: independence, scope, duration, methods, results (§V.C) | Not prescribed; technique unnamed. Notified bodies expect EN IEC 81001-5-1 clause 5.7 evidence | | **Independence** | Documented third-party, or internal team with documented org separation | Graded per ANSI/ISA IEC 62443-4-1 SVV-3; internal red teams accepted if independent of design/implementation | | **Evidence location** | Single eSTAR cybersecurity attachment (STED §5.4, eSTAR v7) | Distributed across Annex II technical documentation, ISO 14971 risk management file, and IEC 62304 / 81001-5-1 lifecycle documentation | | **Applicability trigger** | "Cyber device" per Section 524B(c) - software + internet-connection capability + vulnerable characteristics | Any device with software or programmable electronics (Annex I §17.2), regardless of connectivity | ## Why this matters Manufacturers selling into both the United States and the European Union routinely treat penetration testing as a single deliverable that "covers both." It does, but only when it is written to the stricter of the two formats and explicitly cross-referenced to the other. Written the other way around, submissions get pushed back on both sides for different reasons. The FDA's *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* (Feb 3, 2026, final) is prescriptive. It names penetration testing in §V.C and lists five required report elements. The EU MDR (Regulation (EU) 2017/745) never mentions penetration testing, but Annex I §17.2 requires manufacturers to adopt "measures to ensure IT security," §17.4 sets a state-of-the-art bar, and MDCG 2019-16 (Guidance on Cybersecurity for medical devices, rev. 1 July 2020) §3.7 tells notified bodies to expect verification and validation of security controls. Notified bodies now treat EN IEC 81001-5-1:2022 as the working evidence standard for that verification. ## What the FDA prescribes: the five report elements The Feb 3, 2026 guidance §V.C is explicit. A penetration test report submitted with a 510(k), De Novo, PMA, PDP, or HDE for a "cyber device" (defined in Section 524B(c) of the FD&C Act) must document: 1. **Independence and technical expertise of testers** - named individuals with credentials, and a statement that testers have no development relationship with the manufacturer. 2. **Scope** - every interface tested, every interface excluded, and rationale for exclusions traced back to the threat model. 3. **Duration** - actual tester-days, broken out by phase. 4. **Methods** - named frameworks and tools (OWASP MASTG, PTES, NIST SP 800-115) and the technique used per interface. 5. **Results** - findings with severity, reproduction steps, evidence, retest status, and residual risk statement. Missing any of the five is a first-cycle Additional Information request. For a deeper walkthrough of what belongs inside a compliant engagement, see the [FDA penetration testing requirements guide](/blog/fda-penetration-testing-requirements-medical-devices). ## How EU MDR reaches penetration testing The MDR never says "penetration test." The obligation is inferred from three linked instruments: - **Annex I §17.2** requires software devices to be developed and manufactured in accordance with the state of the art, including "measures to ensure IT security." - **Annex I §17.4** requires the manufacturer to "set out minimum requirements concerning hardware, IT networks characteristics and IT security measures." - **MDCG 2019-16 §3.7** tells notified bodies to expect verification of security requirements and testing of controls, without naming a specific technique. Notified bodies fill in the technique with **EN IEC 81001-5-1:2022** (harmonised under the MDR, OJ 2024/1878). Clause 5.7 requires security testing activities including vulnerability testing; the process standard behind it is **ANSI/ISA IEC 62443-4-1** practice SVV-3 (Vulnerability Testing) and SVV-4 (Penetration Testing). That is where penetration testing enters the MDR technical file, not through the regulation text itself. ## Independence: documented third-party vs graded The FDA expects a named, credentialed third party, or an internal team that is organizationally separated from the development team with the separation documented. The bar is binary: independence is either shown or it is not. EN IEC 81001-5-1 and IEC 62443-4-1 treat independence as graded per practice - the tester must be independent of the design and implementation of the item under test, but the standard tolerates internal test teams that meet that criterion. Notified bodies routinely accept internal red teams that satisfy 62443-4-1 SVV-3 role separation. For an FDA submission, err toward the stricter interpretation: name external testers and their credentials in the report front matter. ## Where the evidence lives in each submission For the FDA, the penetration test report is a discrete attachment in the eSTAR cybersecurity section (STED §5.4 under eSTAR v7). Reviewers open one file and expect to find all five required elements in the executive summary. Fragmenting the evidence across multiple documents is a common cause of "cannot locate" deficiencies. For the MDR, evidence is distributed. The pen test report is referenced from: - **Annex II §6.1** (verification and validation) in the technical documentation, - The **risk management file** under ISO 14971 (with security risks per AAMI TIR57 / ANSI/AAMI SW96:2023 or the emerging ISO 14971 amendment), - The **software lifecycle documentation** under IEC 62304, cross-referenced to IEC 81001-5-1 clause 5.7 evidence. The report itself does not need to change. The **table of references** does. ## Applicability triggers: cyber device vs any device with software Section 524B(c) applies to devices that (1) include software validated, installed, or authorized by the sponsor, (2) have the ability to connect to the internet, and (3) contain any technological characteristics that could be vulnerable to cybersecurity threats. Devices that fail any of the three prongs are outside 524B, though the FDA still applies cybersecurity expectations to IDEs and to non-cyber devices through general controls. The MDR has no equivalent gate. Annex I §17.2 applies to **any device that incorporates electronic programmable systems or software that is a device in itself**. A standalone medical device with a wired serial port and no network stack is inside §17.2's scope for the EU and outside 524B's scope for the FDA. ## One report, both regimes: the mapping approach The working pattern for dual-market manufacturers: 1. Write the penetration test report to the FDA's five-element format (§V.C). It is the stricter of the two, so anything a notified body needs will be present. 2. Add an annex titled "MDR/IEC 81001-5-1 mapping" that cross-references each section of the report to Annex I §17.2, §17.4, MDCG 2019-16 §3.7, and EN IEC 81001-5-1 clause 5.7. 3. Reference the same report from the risk management file (ISO 14971) and the software lifecycle plan (IEC 62304 / 81001-5-1) in the EU technical documentation. The mapping annex is what turns a single deliverable into evidence for both regimes. Without it, notified bodies read a US-format report and ask for a European one; with it, they check the crosswalk and move on. ## Side-by-side comparison | Dimension | FDA (Feb 3, 2026 guidance) | EU MDR (2017/745) | | --- | --- | --- | | Named in regulation? | Yes, guidance §V.C | No, inferred from Annex I §17.2/§17.4 | | Prescribed report elements | 5 (independence, scope, duration, methods, results) | 0 (technique unnamed) | | Working evidence standard | AAMI SW96, IEC 81001-5-1, ISO 14971 | EN IEC 81001-5-1:2022, IEC 62443-4-1 SVV-3/4 | | Independence bar | Documented third-party or org-separated | Graded per 62443-4-1 practice | | Where evidence lives | eSTAR cybersecurity attachment | Distributed across Annex II, ISO 14971 file, IEC 62304 documentation | | Applicability trigger | Section 524B(c) "cyber device" | Any device with software or programmable electronics | | Postmarket obligation | 524B(b) postmarket plan + CVD | Article 83 PMS + MDCG 2019-16 §5 postmarket security | ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We write every penetration test report to the FDA's five-element format because it is the stricter of the two, then map it in a dedicated annex to Annex I §17.2/§17.4, MDCG 2019-16 §3.7, and EN IEC 81001-5-1:2022 clause 5.7. The result is one engagement, one report, and two clean submissions. See our [medical device penetration testing services](/services/medical-device-penetration-testing) and the [EU Cyber Resilience Act for medical devices service page](/services/eu-cyber-resilience-act-medical-devices). **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### Are FDA and EU MDR penetration testing requirements the same? No. The FDA prescribes five report elements under the Feb 3, 2026 guidance §V.C and names penetration testing directly. The EU MDR never mentions penetration testing; it arrives through Annex I §17.2, §17.4, MDCG 2019-16 §3.7, and EN IEC 81001-5-1:2022 clause 5.7. The evidence overlaps but the obligations, format, and location in the submission differ. ### Can one penetration test report serve both an FDA submission and an EU MDR technical file? Yes, when it is written to the FDA's five-element format and includes an MDR/IEC 81001-5-1 mapping annex that cross-references each section to Annex I §17.2/§17.4, MDCG 2019-16 §3.7, and EN IEC 81001-5-1 clause 5.7. Write it the other way around and notified bodies accept it; the FDA reviewer asks for the missing elements. ### Does the EU MDR require an independent third-party tester? Not explicitly. EN IEC 81001-5-1 and ANSI/ISA IEC 62443-4-1 treat independence as graded per practice - the tester must be independent of the design and implementation, but internal red teams that meet the SVV-3 role-separation criterion qualify. Notified bodies routinely accept them. For an FDA submission, use an external tester or a documented organizationally-separated internal team. ### Where does the penetration test report go in an eSTAR submission? The Feb 2026 guidance places the report in the cybersecurity attachment, STED §5.4 in eSTAR v7. Reviewers open one file and expect all five required elements (independence, scope, duration, methods, results) in the executive summary. Fragmenting the evidence across attachments is a common source of "cannot locate" deficiencies. ### Is my device inside scope for FDA cybersecurity requirements if it has no network connection? Not under Section 524B, which applies only to "cyber devices" as defined in 524B(c) - devices with software, internet-connection capability, and vulnerable technological characteristics. Non-cyber devices are still subject to general FDA cybersecurity expectations under the Feb 2026 guidance's applicability discussion, but not to 524B's specific documentation gates. Under the EU MDR, Annex I §17.2 applies to any device with software regardless of connectivity. ### What standards do notified bodies cite for EU pen testing evidence? EN IEC 81001-5-1:2022 (harmonised under the MDR, OJ 2024/1878) is the working evidence standard. Its clause 5.7 requires security testing including vulnerability testing, and the referenced process standard is ANSI/ISA IEC 62443-4-1 practices SVV-3 (vulnerability testing) and SVV-4 (penetration testing). MDCG 2019-16 §3.7 is the notified body guidance that ties the two together. ## Final thoughts The temptation for dual-market manufacturers is to commission "an EU pen test" and "a US pen test" as separate engagements. That doubles the cost and produces two reports that will need to be reconciled anyway. The shorter path is one engagement, written to the FDA's five-element format, with an MDR/IEC 81001-5-1 mapping annex bolted on. The five FDA elements are a superset of what a notified body asks for; the annex is the crosswalk that lets both reviewers find what they need in the same document. **Need a gap check?** Our [Medical Device Pen Test Requirements gap check](/lp/medical-device-penetration-testing-requirements) returns a one-business-day written analysis against Section 524B, the Feb 2026 guidance, EN IEC 81001-5-1, and MDCG 2019-16 - free. Related reading: [FDA penetration testing requirements for medical devices](/blog/fda-penetration-testing-requirements-medical-devices), [EU MDR vs FDA cybersecurity crosswalk](/guides/eu-mdr-vs-fda-cybersecurity), [IEC 81001-5-1 security risk assessment guide](/guides/security-risk-assessment-iec-81001-5-1), [Penetration testing for medical devices guide](/guides/penetration-testing-for-medical-devices), and [DAST vs penetration testing for FDA medical devices](/blog/dast-vs-penetration-testing-fda-medical-devices). ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions, EU MDR technical documentation, and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Safety vs Security Risks Source: https://bluegoatcyber.com/blog/medical-device-safety-vs-security-risks # Medical Device Safety vs Security Risks > **[DIRECT ANSWER]** Medical device safety protects against accidental harm from device malfunction, misuse, or design flaws, while security protects against intentional harm from unauthorized access or cyberattacks. The FDA addresses safety through Quality Management Systems and 510(k) performance data, and addresses security through its premarket cybersecurity guidance and Section 524B postmarket requirements. The two risks overlap, so teams need integrated risk management covering both from design through postmarket. _Updated November 17, 2024_ In today’s healthcare landscape, “safety” and “security” often intertwine, particularly when discussing medical devices. These devices have revolutionized patient care, but with innovation comes the need for clear understanding. Let’s covers what these risks entail and how they differ. ## Key Takeaways - Safety prevents accidental harm from device malfunction or misuse. - Security prevents intentional harm or unauthorized access. - Safety risks are often internal; security risks are commonly external. - Compromised security can directly lead to patient safety issues. - The FDA addresses safety via QMS and 510(k), and security via premarket guidance. - Mitigation requires integrated strategies from design through post-market. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device safety vs security risks the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## At a glance | Dimension | Safety Risks | Security Risks | |:--- |:--- |:--- | | **Core Definition** | Protection against accidental harm caused by device malfunction or misuse. | Protection against intentional harm or unauthorized access by malicious actors. | | **Typical Use Case** | Ensuring an infusion pump delivers the correct dosage without hardware failure. | Preventing unauthorized remote access to change infusion pump settings. | | **Scope of Impact** | Primarily physical harm or injury to the individual patient. | Data privacy breaches, system-wide outages, and potential physical patient harm. | | **Security Posture** | Focuses on reliability, clinical validation, and fail-safe hardware mechanisms. | Focuses on encryption, authentication, vulnerability management, and network integrity. | | **Common Threats** | Component wear, software bugs, user error, or environmental interference. | Ransomware, malware, unauthorized API access, and credential harvesting. | | **FDA Relevance** | Managed via Quality Management Systems (QMS) and 510(k) safety data. | Managed via Premarket Cybersecurity disclosures and Post-market Management (Section 524B). | | **Key Tradeoff** | Prioritizes immediate clinical availability and ease of use in emergencies. | Prioritizes system hardening, which may introduce friction in clinical workflows. | ## Defining Safety and Security in the Context of Medical Devices Before we explore safety and security in medical devices, we need to define what these terms mean in this context. Safety relates to the operational integrity of the device. A device is deemed safe if it performs as intended without causing undue patient harm. On the other hand, security involves protecting medical devices from malicious interference. The implications of security breaches are dire, ranging from data theft to the manipulation of device functions. Simply put, safety is about ‘doing no harm,’ while security pertains to safeguarding devices from harm. ### What is Safety in Medical Devices? Safety encompasses various aspects of device performance. It refers to how well a medical device can function under normal conditions. Consider a [pacemaker](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know)-it must provide appropriate pacing without causing adverse effects. The entire design must account for potential risks, from software to hardware. Safety protocols need to be in place for when things go awry. Imagine a scenario where a device fails in the middle of a life-saving procedure. Alternative measures must be pre-established to ensure patient well-being. This includes testing and validation processes during the device development phase, as well as ongoing monitoring once the device is in use. Regulatory bodies, such as the [FDA](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity), impose [strict guidelines](/blog/medical-device-cybersecurity-best-practices) to ensure that manufacturers adhere to safety standards, involving extensive clinical trials and post-market surveillance to assess the device’s performance in real-world settings continuously. ### What is Security in Medical Devices? Security is like a fortress surrounding the medical device. The goal is to shield sensitive information and maintain operational integrity to prevent unauthorized access. This means [encryption](/blog/understanding-relevant-threats-for-medical-devices), user authentication, and continual monitoring for vulnerabilities. To illustrate, think of a smart insulin pump. If hackers could gain entry, they could alter dosages or even stop delivery altogether. This is why constant vigilance and updates are necessary to maintain healthcare security. The cybersecurity landscape is ever-evolving, and as medical devices become more interconnected, often part of larger health information systems, the potential [attack surfaces](/blog/understanding-medical-device-attack-surface-analysis) increase. Manufacturers must implement strong security measures during the design phase and engage in regular security audits and updates to address emerging threats. Additionally, educating healthcare providers about best practices for device security, such as maintaining secure networks and using strong passwords, is essential to creating a defense strategy against cyber threats. ## The Intersection of Safety and Security Risks As we navigate safety and security, it’s essential to recognize how these risks can overlap. Both aspects must be prioritized in a medical device’s lifecycle. One cannot forsake the other; a device may be secure but unsafe, or vice versa. For instance, a well-protected device might suffer from design flaws leading to [safety hazards](/blog), while a perfectly designed device may have weak security protocols. Hence, vigilance becomes paramount at the intersection of safety and security. ### How Safety and Security Risks Overlap Let’s consider the example of a connected health device that monitors vital signs. If the data it collects is unsecure, malicious users could manipulate it, potentially resulting in incorrect treatments. Thus, patient safety is compromised not just by device malfunction but also by security breaches. Points of overlap create a unique challenge for manufacturers. They must [balance innovation with rigorous safety](/blog/cybersecurity-measures-and-metrics-for-medical-devices-navigating-fda-compliance) and security protocols, which is no small feat. The rapid pace of technological advancement in healthcare means that manufacturers often race against time to implement the latest features while ensuring that these innovations do not introduce new vulnerabilities. This balancing act requires a deep understanding of both the technical aspects of device development and the regulatory landscape governing medical technologies. ### Unique Challenges at the Intersection of Safety and Security Medical device manufacturers face increasing scrutiny at the crossroads of safety and security. Regulatory agencies, healthcare providers, and patients call for higher standards. Imagine tuning a piano while a concert is underway-practically impossible, right? Developing for both safety and security often results in priorities and resource allocation conflicts. Sometimes, the pressure to bring a product to market may lead to incomplete assessments of either risk. This can spell trouble down the line. For example, a manufacturer might prioritize user-friendly interfaces and advanced functionalities at the expense of encryption methods, leaving the device vulnerable to cyberattacks. As devices become more interconnected, the potential for a single point of failure increases, creating a domino effect that can jeopardize multiple systems simultaneously. This complexity necessitates a approach to risk management that considers the individual device and its role within the larger healthcare ecosystem. ## Distinguishing Between Safety and Security Risks When addressing risks in medical devices, it is vital to distinguish between them. Safety and security are often discussed interchangeably, but failing to differentiate can lead to misconceptions. Let’s break it down further. ### Critical Differences in Safety Risks Safety risks are typically internal. They stem from device design, functionality, and usage. For example, a poorly designed surgical tool could malfunction, leading to severe injuries. Manufacturers must conduct extensive testing and validation to identify safety risks before devices hit the market. A culture of safety must also be adopted, ensuring that healthcare practitioners are trained thoroughly on device usage. The consequences of neglecting safety protocols can be catastrophic-ask the folks who invented the first defibrillator! The importance of [post-market surveillance](/) cannot be overstated. Once a medical device is in use, continuous monitoring is essential to detect any unforeseen safety issues that may arise over time. This includes gathering feedback from healthcare professionals and patients and analyzing data from adverse event reports. Such vigilance helps manufacturers make necessary adjustments and updates, ensuring that devices remain safe and effective throughout their lifecycle. ### Differences in Security Risks Conversely, security risks primarily arise from external sources. They can result from cyber-attacks, unauthorized access, or data breaches. For instance, a ransomware attack on a hospital’s network could cripple access to critical devices and patient information. Understanding that security vulnerabilities exist outside the manufacturing process is essential. Cybersecurity constantly evolves; it requires ongoing assessment and adaptation of techniques to fend off new threats and attacks. Integrating the [Internet of Things (IoT)](/blog/cybersecurity-for-medical-devices-with-narrowband-iot-protocol) in healthcare has introduced additional layers of complexity to security risks. As more devices become interconnected, the potential attack surface expands, making it crucial for healthcare organizations to implement security measures. This includes encrypting sensitive data, regularly updating software, and conducting penetration testing to identify and mitigate vulnerabilities before malicious actors can exploit them. The stakes are high, as breaches can compromise patient privacy and disrupt critical healthcare services, highlighting the need for a proactive approach to security in the medical device landscape. ## Mitigating Safety and Security Risks in Medical Devices To safeguard both safety and security, proactive strategies must be implemented. These strategies should not be an afterthought but an integral part of the development cycle from the get-go. ![Section Image](/imported-images/35b56bee541a8fdd.png) ### Strategies for Reducing Safety Risks First and foremost, rigorous design validation is key. Manufacturers should invest in extensive testing phases to identify and rectify potential hazards. This may include simulations and real-world trials. Further, incorporating fail-safes and redundant systems can bolster safety. Regular updates to software and operating protocols can also enhance resilience against unforeseen events. ### Strategies for Reducing Security Risks Implementing strong encryption and access controls is vital on the security front. Periodic vulnerability assessments should become a routine process. Organizations should also invest in staff training to promote awareness of security best practices. Finally, building a culture of communication is crucial. Encourage feedback from all stakeholders, including users, developers, and security experts. Together, they can identify and address risks as they arise. ## The Future of Safety and Security in Medical Devices The safety and security risk management horizon in medical devices holds much promise. As technology advances, strategies will evolve to enhance patient care and device reliability. ![Section Image](/imported-images/36b57b6d0e66160c.png) ### Predicted Trends in Safety and Security Risks We can expect increased regulation aimed at tighter safety and security protocols. Agencies will likely mandate security assessments alongside traditional safety checks. The stakes are high; where patient health hangs in the balance, everything matters. The rise of [artificial intelligence](/blog) and machine learning will create new tools for risk management. These technologies offer predictive capabilities that can spot vulnerabilities before they become issues, creating a proactive defense. ### Innovations in Risk Management for Medical Devices Innovative risk management methods will soon become commonplace. Look for modular designs that allow updates and repairs without full device replacements. This adaptability will facilitate better safety measures and enhance long-term security against emerging threats. ## Conclusion Understanding the nuances of safety versus security will become indispensable as medical technology grows. As we progress, both aspects must coexist harmoniously to benefit patient care and device integrity. As medical technology evolves, the distinction between safety and security becomes more critical. At Blue Goat Cyber, we understand the complexities of navigating FDA premarket and postmarket compliance and are here to guide you every step of the way. Our expert team, led by cybersecurity authority Christian Espinosa, is equipped with the knowledge and tools to ensure your medical devices meet regulatory standards and maintain cybersecurity resilience. With over 100 devices successfully guided to FDA submission and a commitment to tailored healthcare security, we’re dedicated to enhancing patient safety and securing the future of healthcare technology. Don’t let safety and security risks compromise your medical devices. [Contact us today for cybersecurity help](/contact) and partner with a leader in medical device cybersecurity. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is the primary difference between medical device safety and security? Medical device safety protects against accidental patient harm caused by device malfunction or misuse. Security protects against intentional harm or unauthorized access from external malicious activity, such as cyberattacks. Both are essential for patient well-being. ### How does the FDA regulate medical device safety and security? The FDA regulates device safety through requirements like Quality Management Systems (QMS) and premarket submissions (e.g., 510(k)) that demonstrate safe design and performance. Security is addressed through premarket cybersecurity guidance (February 3, 2026 final guidance) and post-market requirements under Section 524B, focusing on protecting devices from cyber threats. ### Can a medical device be secure but unsafe? Yes, a medical device can be highly secure against cyber threats but still be unsafe due to design flaws, manufacturing defects, or user error that could lead to accidental harm to the patient. Both aspects require independent, rigorous attention. ### Why is medical device security becoming more critical? Medical device security is increasingly critical due to the growing interconnectivity of devices (IoT), the rising sophistication of cyber threats, and the potential for security breaches to directly impact patient safety, data privacy, and hospital operations. ### What are common strategies for mitigating medical device security risks? Key strategies for mitigating security risks include implementing strong encryption, access controls, regular vulnerability assessments, and staff training on security best practices. Devices also require ongoing security updates and patches throughout their lifecycle. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) --- ## More on this topic - [WPA2 4-Way Handshake Risks for Medical](/blog/wpa2-4-way-handshake-vulnerabilities-what-medical-device-teams-need-to-know-about-wi-fi-risk) --- ## Medical Device SBOM: FDA Requirements Guide (2026) Source: https://bluegoatcyber.com/blog/medical-device-sbom-fda-requirements-and-submission-guide # Medical Device SBOM: FDA Requirements and Submission Guide (2026) > **[DIRECT ANSWER]** The FDA requires an SBOM in every "cyber device" premarket submission under Section 524B. Reviewers verify four elements at RTA screening: (1) machine-readable format (CycloneDX 1.5+ or SPDX 2.3+), (2) an identifier on every component (PURL or CPE), (3) a written disposition of known vulnerabilities present at submission, and (4) a documented process for keeping the SBOM current postmarket. Missing any one is a common Refuse-to-Accept reason. > **Read the pillar guide:** For the full picture - what an SBOM is, why the FDA requires one, format choice, generation, and postmarket use - see [SBOM for Medical Devices: The 2026 FDA Pillar Guide](/guides/sbom-for-medical-devices). This post is the submission-tactical companion. Every premarket submission for a cyber device now legally requires a software bill of materials, and missing it can get your submission refused outright. Building a compliant medical device SBOM isn't optional under Section 524B of the FD&C Act, enforced since March 29, 2023 (with eSTAR mandate effective October 2023). This isn't a recommendation from a guidance document or a best practice from an industry working group. It's federal law. Most device engineering teams understand the concept: a structured inventory of software components, their versions, and their dependencies. Where teams consistently fall short is understanding what the FDA actually expects inside that document, which formats qualify as machine-readable, and how to keep the inventory current after clearance. This guide covers each of those layers in detail: regulatory mandate, required content, format selection, generation tooling, and postmarket maintenance. At Blue Goat Cyber, we’ve built submission-ready software bills of materials for manufacturers across hundreds of premarket submissions, and the patterns in deficiency letters are consistent enough to be instructive. ## Key Takeaways - Section 524B mandates SBOMs for cyber device premarket submissions. - The FDA expects the SBOM minimum elements, now set by CISA's 2026 list, plus lifecycle and vulnerability data. - Submit SBOMs in machine-readable SPDX or CycloneDX formats. - Integrate SBOM generation into continuous integration/delivery pipelines. - Maintain SBOMs as living records for postmarket surveillance. - Incomplete dependency trees and missing lifecycle data are common deficiencies. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device sbom the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. > **Pillar:** SBOM is one of 12 controls FDA reviewers expect. See the full program in [Medical Device Cybersecurity: 2026 Best Practices Guide](/blog/medical-device-cybersecurity-best-practices). ## What a medical device SBOM actually is An SBOM is a complete, structured inventory of every software component inside a device, proprietary code, open-source libraries, third-party packages, commercial off-the-shelf software, and the full dependency tree beneath each of those components. The closest analogy is a nutrition label. It tells every stakeholder, including the FDA, hospital security teams, and your own engineers, exactly what’s inside the product so vulnerabilities can be tracked and managed systematically. The FDA’s definition of a “cyber device” under Section 524B is specific: any device that contains software and can connect to the internet, thereby posing potential cybersecurity risk. Not every medical device falls into this category, but most connected, networked, or software-driven products do. Infusion pumps, cardiac monitors, imaging systems, wearables, and networked hospital equipment all qualify. If your device has software and a network interface, assume Section 524B applies. Regulators care about software transparency for a straightforward reason. Untracked third-party libraries and open-source components are the most common entry point for cybersecurity vulnerabilities in medical devices. A software bill of materials gives the FDA and manufacturers a mechanism to identify, monitor, and respond to newly discovered CVEs across the full product lifecycle. Without one, postmarket vulnerability management becomes essentially impossible to perform in any systematic way. Pairing SBOMs with automated testing and static application security testing (SAST) improves vulnerability discovery and remediation, see our guide on [SBOM and SAST](/blog/enhancing-medical-device-cybersecurity-the-role-of-sbom-and-sast-in-complying-with-fda-guidelines) for practical integration patterns. ## The FDA mandate: what changed in 2023 and what it means now The Consolidated Appropriations Act of 2023 amended the FD&C Act by adding Section 524B, which codified software bill of materials requirements into federal law for the first time. Manufacturers submitting 510(k), De Novo, PMA, or similar applications for cyber devices must now include this documentation as a required element, not a best practice, not a recommendation. The FDA has explicit authority to refuse any submission it considers deficient in cybersecurity content. The timeline matters for planning. Requirements apply to submissions on or after March 29, 2023, and the FDA’s authority to refuse non-compliant submissions took effect October 1, 2023. The February 2026 final guidance (“ [Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions](https://www.fda.gov/media/119933/download "")“) reinforced and expanded these expectations in Section V.A.4 and Appendix 4. That guidance is technically non-binding, but practically speaking, submissions with weak or incomplete documentation face delays and deficiency letters consistently. For a focused walkthrough of these expectations and format implications, see our post on [FDA SBOM requirements for medical devices](/blog/medical-device-sbom-fda-requirements-and-submission-guide). To understand how significant the shift is, consider the earlier posture. The 2014 and 2022 guidance documents recommended software bills of materials without requiring them, so engineering teams could treat generation as a documentation afterthought and still get through a submission. An incomplete inventory is now grounds for refusal, and there’s no ambiguity in the current framework about that. ## What your medical device SBOM must include The FDA references the SBOM minimum elements as the baseline for content. Those elements were first published by NTIA in July 2021 and are now defined by CISA's 2026 Minimum Elements for a Software Bill of Materials, published July 29, 2026. These seven fields are required for any submission: - Supplier name: the organization providing the component - Component name: the identified name of the software component - Component version: the specific version string - Unique identifier: a Package URL (PURL) or Common Platform Enumeration (CPE) for precise matching - Dependency relationships: how components relate to and depend on one another - SBOM author: who created the document - Timestamp: when it was assembled The FDA expects more than that baseline for medical devices. Required additions include support and lifecycle metadata for each component, specifically whether the component is actively supported, in legacy status, or unsupported. End-of-support and end-of-life dates must be documented. The FDA also expects vulnerability assessments that identify known CVEs against each component, along with documented mitigations and a risk mitigation plan tied to postmarket monitoring. These additions reflect the FDA’s focus on the total product lifecycle, not just the snapshot at submission time. ### Which software components must be captured A question that comes up often is scope. The answer is all of it. Proprietary firmware, commercial off-the-shelf software, open-source libraries, third-party SDKs, bootloaders, and operating system components all belong in the inventory. The depth of documentation scales with the device’s cyber-risk tier. Low-risk devices require a complete component list with vulnerability scanning. Moderate-risk devices require a full dependency tree plus CVE mapping. High-risk devices require end-to-end documentation including build tools. At every tier, a partial list is not acceptable. ## Choosing a format: SPDX, CycloneDX, and what the FDA accepts The FDA recognizes three machine-readable formats: SPDX, CycloneDX, and SWID tags. SWID tags are less commonly used as standalone outputs. The practical decision for most manufacturers comes down to SPDX versus CycloneDX. The FDA does not mandate a specific format, but both must be machine-readable and accompanied by a human-readable summary document. ### SPDX vs. CycloneDX: which is right for your device SPDX is maintained by the Linux Foundation and is the more established standard overall. It excels at license tracking across open-source components, which makes it useful for organizations managing intellectual property compliance alongside cybersecurity. CycloneDX is purpose-built for security use cases. It has native support for vulnerability data through VEX documents, stronger dependency relationship mapping, and tighter integration with CVE databases. For most connected medical device manufacturers, CycloneDX is the stronger choice. Teams with significant open-source licensing obligations may prefer SPDX or run both formats in parallel. The machine-readable requirement has a specific operational meaning. The file must be in a structured format, JSON, XML, or RDF, that automated tools can parse, query, and compare against vulnerability databases. A spreadsheet or PDF does not meet this standard. A human-readable summary is a required companion document, not a substitute for the structured file. For practical strategies on meeting the FDA’s format and content expectations, this [guide to complying with FDA SBOM requirements](https://fossa.com/blog/complying-fdas-sbom-requirements/) provides vendor-agnostic recommendations and common pitfalls to avoid. ## How to generate and maintain your SBOM across the device lifecycle Generation for embedded medical devices requires tools suited to firmware and RTOS environments. Standard application-layer scanners miss components that live deeper in the stack. Syft works well for container and embedded Linux builds, producing SPDX or CycloneDX output. Yocto’s create-spdx class generates inventories automatically during image creation, which makes it a natural fit for teams already using Yocto for embedded Linux. Snyk covers open-source dependency scanning and vulnerability assessment. Keysight SBOM Manager uses binary analysis for deeply embedded components where source access is limited, particularly valuable for devices built on legacy or proprietary firmware. ### Integrating SBOM generation into your development pipeline The most efficient approach is to integrate generation directly into the CI/CD pipeline so every release produces an updated, versioned file automatically. This removes the manual step that causes documentation to drift out of sync with the actual codebase. Each version should be cryptographically tied to a specific software release for traceability. EOL and EOS status should be tracked continuously, not just at submission time. A centralized repository, not email, is the right distribution mechanism for sharing current and historical versions with the FDA, healthcare providers, and internal teams. The FDA treats these documents as living records, not one-time submissions. Every patch, dependency update, or component removal requires an update. To close the loop with postmarket surveillance, feed component data into vulnerability databases like Google OSV or Dependency Track. Filter CVEs by device configuration and version to eliminate false positives and document a formal remediation and disclosure process. Continuous postmarket cybersecurity monitoring is part of the ongoing obligation the FDA expects manufacturers to maintain after clearance. The FDA’s own [cybersecurity FAQs](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs) are a helpful reference for reviewers’ expectations around postmarket obligations and documentation. ## How Blue Goat Cyber builds submission-ready SBOMs for device manufacturers The most common deficiencies we see in FDA submissions follow predictable patterns. Incomplete dependency trees that miss transitive dependencies are the most frequent issue. Missing lifecycle metadata for third-party components is a close second. Inventories submitted in non-machine-readable formats, PDFs or spreadsheets, generate immediate deficiency letters. The absence of a documented vulnerability management plan is the gap that tends to create the longest delays. All of these issues are avoidable if you know what FDA reviewers are looking for before the submission goes in. Blue Goat Cyber handles the full build under a done-for-you model: component discovery and dependency mapping, format selection, metadata population, vulnerability assessment, and final documentation. The output is an eSTAR-ready package aligned with the February 2026 FDA final guidance, IMDRF N73 principles, and the current CISA SBOM minimum elements. Engineering teams provide access to their codebase and build environment. Blue Goat Cyber delivers a submission-ready package built specifically for FDA review, not a generic enterprise software inventory. Learn more about our [FDA-compliant SBOM services for MedTech](/services/fda-compliant-sbom-services-for-medtech) and what the engagement looks like. **SBOM compliance for medical devices is not the same as standard enterprise software inventory management.** The FDA’s cyber device framework, the medical-device-specific metadata requirements, and the postmarket surveillance integration layer all require regulatory expertise that general IT security firms or internal engineers without that background rarely have. Blue Goat Cyber has navigated this process across a wide range of device categories and submission types, and that depth of experience translates directly into fewer deficiencies and faster clearance. ## Get SBOM compliance right from the start The FDA mandate is real and actively enforced. An incomplete or missing software bill of materials will stall a submission. The core requirements are clear: the CISA 2026 minimum element fields, FDA-specific lifecycle and vulnerability additions, machine-readable formats in SPDX or CycloneDX, and ongoing maintenance after clearance. None of these can be assembled at the last minute without risk. Manufacturers who build medical device SBOM generation into their development lifecycle from the start, rather than treating it as a documentation task at submission time, move through premarket review faster and have a defensible postmarket surveillance process in place from day one. That’s a meaningful operational advantage over teams that bolt compliance on at the end. If your team is preparing a premarket submission, responding to a cybersecurity deficiency, or building a postmarket maintenance program for a cleared device, Blue Goat Cyber can handle the full process. ### Related Articles in This Series - [Navigating the Cybersecurity Landscape for MedTech Innovators: Key Insights from the Experts](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) - [Two Medical Device Cybersecurity Gaps: Dispersed Responsibility and a Scarcity of Asset Inventory](/blog/how-can-medical-device-manufacturers-support-operational-cybersecurity) - [Navigating the Evolving Cybersecurity Landscape for Medical Devices](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) - [Obfuscation vs Encryption in Medical Device Cybersecurity](/blog/medical-device-key-exchange-cybersecurity) - [Can Contact Lenses Fool Iris Scans in Medical Devices?](/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization) - [VM Escape in Medical Device Cybersecurity: Risk and Mitigations](/blog/vm-escape-medical-device-cybersecurity) ## FAQ ### What is a medical device SBOM? A medical device SBOM is a complete, structured inventory of all software components within a device, including proprietary, open-source, and third-party elements, along with their dependencies. It provides transparency into a device's software composition for cybersecurity management. ### When did SBOMs become mandatory for medical devices? The requirement for SBOMs became law with Section 524B of the FD&C Act as part of the Consolidated Appropriations Act of 2023. The FDA's authority to refuse submissions lacking required cybersecurity content took effect on October 1, 2023. ### Which medical devices need an SBOM? Any medical device containing software that can connect to the internet qualifies as a "cyber device" under Section 524B and requires an SBOM. This includes most connected, networked, or software-driven medical products. ### What format does the FDA accept for SBOMs? The FDA recognizes machine-readable formats such as SPDX and CycloneDX. Manufacturers usually choose between these two, often preferring CycloneDX for its security-focused features for medical devices. A human-readable summary must accompany the machine-readable file. ### How often must an SBOM be updated? The FDA considers SBOMs living records. Any patch, dependency update, component removal, or new vulnerabilities require an update to the SBOM to reflect the current software configuration and status. ### What are the core elements the FDA requires in an SBOM? The FDA requires the SBOM minimum elements, now defined by CISA's 2026 list rather than the 2021 NTIA version (supplier, component name, version, unique identifier, dependencies, author, timestamp) plus medical device-specific additions like component support status (e.g., actively supported, legacy), end-of-support/life dates, and vulnerability assessments for known CVEs. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [VxWorks Vulnerabilities in Medical Devices](/blog/identifying-vulnerabilities-with-vxworks) --- ## Medical Device Software Development: A Compliance Guide Source: https://bluegoatcyber.com/blog/medical-device-software-development # Medical Device Software Development: Process and Compliance Guide > **[DIRECT ANSWER]** Medical device software development is the regulated process of designing, building, testing, and maintaining software for a medical device under design controls, now ISO 13485 clause 7.3 as incorporated into 21 CFR Part 820 by the Quality Management System Regulation (QMSR). The process follows the IEC 62304 lifecycle, assigns a safety class of A, B, or C based on the harm a failure could cause, and produces requirements, architecture, verification, validation, risk management, and SBOM documentation that the FDA reviews at submission. Skipping any lifecycle process does not just create a compliance gap, it creates the specific evidence gap that stalls FDA review. _Reviewed September 17, 2026_ Building software for a medical device is different from building software for almost any other purpose, because the process itself, not just the finished product, is what regulators evaluate. A development team that writes clean, working code but cannot produce the requirements traceability, risk analysis, and verification records the FDA expects will still face delays or deficiencies at submission. This guide walks through the full lifecycle: design controls, the IEC 62304 process framework and its three safety classes, requirements and architecture, verification and validation, third-party component and SOUP management with SBOM, the interaction between software development and ISO 14971 risk management, secure coding as a design input, configuration management, and the documentation package a submission expects. ## Key Takeaways - Design controls, now ISO 13485 clause 7.3 under the QMSR, require a documented, traceable path from user needs to design outputs to verified and validated software. - IEC 62304 assigns a safety class of A, B, or C to each software item, and that class determines the depth of documentation, testing, and architecture rigor required. - Verification confirms the software was built correctly against its specification, while validation confirms the software meets the user's actual clinical needs, and both require documented evidence. - Software of Unknown Provenance (SOUP) and other third-party components need the same risk evaluation as in-house code, tracked through a software bill of materials (SBOM). - Security requirements belong in the design input phase, not bolted on after verification, because retrofitting security controls after architecture is locked in is far more costly. - Configuration management and traceability are what let a manufacturer demonstrate, months or years later, exactly what was built, tested, and shipped. ## Why This Matters A medical device software project that treats documentation as a paperwork exercise separate from engineering work will produce documentation that does not match what was actually built, and that mismatch is exactly what an FDA reviewer or an internal audit finds first. The FDA's Cybersecurity in Medical Devices final guidance, dated February 3, 2026, reinforces that cybersecurity and quality documentation are expected to be generated as a byproduct of the development process itself, not created retroactively to satisfy a checklist. Under the QMSR, which harmonizes FDA quality system requirements with ISO 13485, design controls remain the backbone of how a manufacturer demonstrates that software was developed under a controlled, traceable process. Many manufacturers that fail an FDA submission on software grounds do not fail because their code does not work. They fail because they cannot produce the traceability between requirements, risk controls, architecture, and test results that the review process is built to check. ## What Do Design Controls Require Under the QMSR? Design controls require a documented, traceable path connecting user needs, design inputs, design outputs, verification, and validation, and this structure moved largely intact from the former 21 CFR 820.30 into the QMSR's incorporation of ISO 13485 clause 7.3. Under the QMSR, many of the old Part 820 subparts are reserved, with their substance folded into the ISO 13485 structure, but 820.35 remains in force as a records requirement covering the design history file. This means the underlying expectation has not changed: a manufacturer needs to be able to show, item by item, that every design input traces to a verified output and that every output traces back to a documented input. For software specifically, design controls apply at the system level and cascade down through the IEC 62304 process, so software requirements are a subset of the overall device's design inputs, and software verification and validation activities feed into the device-level design history file rather than existing as a separate, disconnected artifact. ## What Does the IEC 62304 Lifecycle Require? IEC 62304 defines the software development lifecycle processes a manufacturer must follow, including planning, requirements analysis, architectural design, detailed design, unit implementation and verification, integration and integration testing, system testing, and release, and the depth of each process scales with the software's safety classification. The standard assigns each software item one of three safety classes based on the severity of harm that could result from a software failure: Class A where no injury is possible, Class B where non-serious injury is possible, and Class C where death or serious injury is possible. **[KEY REQUIREMENT]** Classify software safety class before finalizing architecture, not after. Retroactively discovering that a module needs Class C rigor after development is already underway typically means redoing unit test documentation, architecture rationale, and SOUP evaluation that Class A or B did not require. | IEC 62304 Safety Class | Potential Harm | Required Activities | |---|---|---| | Class A | No injury or damage to health possible | Software development plan, requirements, and basic verification; detailed architecture and unit-level testing not mandated | | Class B | Non-serious injury possible | Full requirements, architecture, and detailed design documentation; unit verification; integration and system testing | | Class C | Death or serious injury possible | All Class B activities plus rigorous unit test coverage, detailed design review, and stronger risk control verification tied to architecture | A single product often contains software items at more than one class. A patient-facing dosing calculation module might be Class C while a logging or reporting module in the same product is Class A, and IEC 62304 permits this segmentation as long as the manufacturer can justify the boundaries between items and show that a lower-class item cannot compromise a higher-class one. ## How Do Software Requirements and Architecture Fit Into the Process? Software requirements translate the device's overall design inputs into specific, testable statements about what the software must do, and they need to be specific enough that a verification test can objectively confirm whether each one is met. Vague requirements, such as "the software shall be reliable," cannot be verified and will not survive a design review or an FDA reviewer's traceability check. Each requirement needs a unique identifier that can be traced forward to a verification test and, where applicable, back to a risk control measure from the risk management file. Software architecture describes how the software is decomposed into items and units, and for Class B and C software, IEC 62304 expects the architecture to identify each software item's safety class, the interfaces between items, and how SOUP components fit into the overall structure. Architecture decisions made here, particularly around how a high-risk item is isolated from lower-risk or third-party code, directly affect how much testing and documentation the rest of the project requires. ## What Verification and Validation Does the Software Need? Verification confirms that each level of the software, from unit to integration to system, was built correctly against its own specification, while validation confirms that the finished software meets the actual clinical and user needs it was designed for, and a submission needs documented evidence of both, not just one. Unit verification checks individual functions or modules against their detailed design. Integration testing checks that units work correctly together and that interfaces behave as specified. System-level verification checks the complete software against its requirements, and validation, often performed at the device level rather than purely in software, checks the finished product against user needs in conditions that resemble actual use. A common gap in verification and validation records is treating them as interchangeable, submitting test results that show the software does what its own specification says without ever demonstrating that the specification itself reflects what clinicians and patients actually need. For a deeper look at how verification and validation activities are structured and documented, see our related article, **[The Importance of Verification and Validation in Medical Device Software](/blog/the-importance-of-verification-and-validation-in-medical-device-software)**. ## How Should SOUP and Third-Party Components Be Managed? Software of Unknown Provenance, meaning any software item, library, or component not developed under the manufacturer's own IEC 62304 process, requires the same risk evaluation as internally written code, and IEC 62304 explicitly requires manufacturers to identify SOUP items, their versions, and the risks they introduce. This includes commercial libraries, open source components, operating systems, and third-party drivers, and the evaluation needs to consider known anomalies and vulnerabilities in the specific version being used, not just the component in general. A software bill of materials, or SBOM, is the practical mechanism for tracking this across the software's life, and it needs to be maintained continuously rather than generated once at submission and then left static. As new vulnerabilities are disclosed in a SOUP component after release, the SBOM is what lets a manufacturer quickly determine which of its products are affected and prioritize a response. ## How Does Software Development Interact With ISO 14971 Risk Management? Software development and ISO 14971 risk management are not separate workstreams, because software hazards identified during risk analysis become inputs to software requirements, and software architecture decisions in turn affect what hazards exist and how severe they are. A risk control implemented in software, such as an input validation check that prevents an out-of-range dose entry, needs to be traceable both to the risk analysis that identified the hazard and to the verification test that confirms the control works as intended. This bidirectional traceability, hazard to requirement to architecture to verification, and back again, is one of the most commonly cited gaps in FDA submissions, because it requires the software team and the risk management team to be working from the same documentation rather than reconciling two separate systems late in the project. ## Why Should Security Requirements Be a Design Input, Not an Afterthought? Security requirements belong in the design input phase because architecture decisions made without security in mind, such as how components authenticate to each other or how data is stored at rest, are expensive and sometimes impossible to fully correct after the architecture is locked. Secure coding practices, including input validation, memory-safe handling of external data, and least-privilege access between software items, need to be specified alongside functional requirements rather than treated as a separate security review that happens after functional development is complete. For SaMD and connected devices that meet the FDA's cyber device definition under Section 524B, security-related design inputs also need to map to the threat model and risk assessment that will appear in the eSTAR submission's Cybersecurity attachment area. Building this traceability from the start avoids the common scenario where a security team is asked to retrofit documentation onto an architecture that was never designed with those controls in mind. Our related article, **[Secure Software Development for Medical Devices: Ensuring Safety and Compliance](/blog/secure-software-development-for-medical-devices-ensuring-safety-and-compliance)**, covers how to build secure coding practices into each stage of the lifecycle. ## What Configuration Management Does the Project Need? Configuration management is what lets a manufacturer demonstrate, at any point after release, exactly which version of every requirement, design document, source file, SOUP component, and test result went into a specific released version of the software. This includes version control for source code, controlled change requests for requirements and design documents, and a defined process for evaluating whether a given change requires re-verification, re-validation, or a new risk assessment. Without disciplined configuration management, a manufacturer investigating a postmarket issue may not be able to reliably reconstruct what was actually shipped in the version a customer is using, which undermines both the postmarket vulnerability response process and any field investigation into a reported malfunction. ## What Documentation Does an FDA Submission Expect? An FDA submission expects a software description, the assigned IEC 62304 safety class with justification, the software requirements specification, architecture documentation, a summary of verification and validation activities and results, a SOUP list with associated risk evaluations, and, for devices meeting the Section 524B cyber device definition, cybersecurity documentation including a threat model, SBOM, and vulnerability management plan. The level of detail scales with safety class, with Class C software generally requiring the full documentation set described in the FDA's software guidance, while Class A software can be summarized more briefly. Reviewers are checking not just that each document exists, but that the documents are internally consistent: that the safety class matches the depth of the testing evidence, that the SOUP list matches what appears in the architecture, and that the cybersecurity documentation reflects the same architecture described elsewhere in the submission. Inconsistencies between these documents are one of the more common sources of review cycles and requests for additional information. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works alongside medical device software teams from early design input through submission, focusing on the traceability between requirements, risk controls, architecture, and test evidence that reviewers check most closely. We help teams determine IEC 62304 safety classification early, before architecture decisions lock in a level of process rigor the team was not planning for. Our threat modeling and secure architecture reviews are structured to fit into design input and design review activities rather than arriving as a separate, disconnected security exercise near the end of the project. We also help build and maintain the SBOM and SOUP risk documentation that submissions and postmarket monitoring both depend on. To see how this fits into a broader security engagement, visit our **[medical device threat modeling services](/services/medical-device-threat-modeling)** page. ## Frequently Asked Questions ### What is the difference between verification and validation in medical device software? Verification confirms that software was built correctly against its own specification at each lifecycle stage, while validation confirms that the finished software actually meets the user's clinical needs. A device can pass every verification test and still fail validation if the requirements themselves did not correctly capture what users needed. ### Does every software component need an IEC 62304 safety class? Yes, every software item within a medical device needs an assigned safety class of A, B, or C based on the potential harm from its failure. A single product can contain items at different classes as long as the manufacturer justifies the segmentation and shows lower-class items cannot compromise higher-class ones. ### What counts as SOUP in medical device software? SOUP includes any software component not developed under the manufacturer's own controlled process, such as open source libraries, commercial off-the-shelf software, operating systems, and third-party drivers. Each SOUP item needs a documented risk evaluation covering known anomalies and vulnerabilities in the specific version used. ### How does the QMSR change design controls for software? The QMSR incorporates ISO 13485 and reserves many of the previous Part 820 subparts, but the core design control expectations for traceability from user needs through verification and validation remain largely intact. 21 CFR 820.35's design history file records requirement stays in force under the QMSR. ### When should security requirements be defined in the development process? Security requirements should be defined during the design input phase, alongside functional requirements, rather than added after architecture and coding are complete. This is because foundational architecture decisions, such as authentication between components and data storage design, are difficult and costly to change later in the lifecycle. ### What documentation does a Class C software item need that a Class A item does not? Class C software items require rigorous unit-level test coverage, detailed design review records, and documented verification of risk control measures at the architecture level, none of which is mandated for Class A. Class A software still needs a development plan and requirements documentation, but without the same depth of unit and architecture-level testing evidence. ## CTA If your team needs help mapping IEC 62304 safety classification, building traceability between risk management and software requirements, or preparing the documentation an FDA submission expects, Blue Goat Cyber can help. **[Contact us today](/contact)** to talk through your software development lifecycle and what your next submission needs. ## About the Author Christian Espinosa is the CEO of Blue Goat Cyber, a veteran-owned medical device cybersecurity firm. He holds multiple advanced security certifications and has spent his career helping medical device manufacturers build secure, compliant software from design input through postmarket support. Learn more about his background on his **[author page](/christian-espinosa)**. --- ## Functional vs Non-Functional Device Requirements Source: https://bluegoatcyber.com/blog/medical-device-software-functional-and-non-functional-aspects-explained # Functional vs Non-Functional Requirements in Medical Device Software > **[DIRECT ANSWER]** Functional requirements define **what** medical device software does (calculate a dose, display an ECG, trigger an alarm). Non-functional requirements define **how well** it does it - performance, reliability, usability, and cybersecurity. Under the FDA's Feb 3, 2026 premarket cybersecurity guidance, cybersecurity is treated as a non-functional requirement that gates 510(k), De Novo, and PMA clearance: reviewers expect both requirement types documented, traced to hazards under ISO 14971, verified per IEC 62304, and evidenced in the submission's security architecture, SBOM, and testing package. _Reviewed July 24, 2026_ Medical device software is judged on two fronts: what it does and how well it does it. If either side is weak, patient safety, usability, and regulatory readiness suffer. ## Key Takeaways - Functional requirements define software's specific clinical actions. - Non-functional requirements describe performance qualities (e.g., speed, security). - Both requirement types are critical for device safety and effectiveness. - The FDA expects clear definition and validation of both functional and non-functional aspects. - Cybersecurity is a non-functional requirement impacting functional integrity. - Coordinating both types of requirements prevents safety gaps. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to medical device software functional and non-functional aspects explained the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Defining Medical Device Software Medical device software drives diagnosis, monitoring, therapy, and direct device control. It is the logic behind systems such as infusion pumps, imaging platforms, pacemakers, and clinical decision support tools. When that logic fails, the device may still power on, but it is no longer safe or trustworthy. Software may be embedded in hardware or operate independently on a desktop, server, or mobile platform. It can directly control a device, support clinical workflows, or inform treatment decisions. That range matters because the risks, validation approach, and cybersecurity expectations change based on intended use and system context. [Software can exist as part of a hardware device](/blog/what-is-software-as-a-medical-device) or as standalone software, but either way, manufacturers need to define the intended use with precision. ### The Role of Software in Medical Devices Software extends what a medical device can do. A pacemaker does not just monitor cardiac rhythm; its software interprets signals and adjusts therapy based on patient conditions. Remote monitoring platforms do not just collect data; they move that data, present it clearly, and support timely intervention. That is why software design cannot be treated as a supporting detail. It shapes clinical performance, operator trust, and postmarket risk. As capabilities expand into telemetry, predictive analytics, and connected care, the software becomes central to the safety case. ### Core Components of Medical Device Software Most medical device software includes a few foundational elements: user interfaces, data handling, communication mechanisms, and processing logic. Each one can introduce safety and security issues if poorly designed. [User interfaces](/blog) deserve special attention. They sit between the clinician and the system, often under time pressure. If the interface is confusing, cluttered, or inconsistent, users make mistakes. In a clinical environment, that is not a usability nuisance. It is a safety problem. Data management matters just as much. The software must collect, store, transmit, and present information accurately and consistently. Communication protocols also need scrutiny, especially in connected devices. If data integrity, timing, or authentication breaks down, the device may still appear functional while behaving unsafely. ## Functional Aspects of Medical Device Software Functional aspects describe what the software is supposed to do. These are the behaviors, actions, and outputs tied to intended use. If the software calculates a dose, displays an alarm, records a waveform, or triggers therapy, those are functional requirements. This is the part most teams recognize quickly. But writing functional requirements is not the same as writing useful ones. ### Understanding Functional Requirements Functional requirements define expected behavior in specific, testable terms. They should explain what the software does, what inputs it accepts, what outputs it produces, and how it responds to normal and abnormal conditions. For example, it is not enough to say a device "monitors vital signs." A meaningful requirement defines which vital signs, sampling rate, acceptable ranges, alarm thresholds, failure handling, and user notifications. Vague language creates validation gaps and weakens traceability. Good functional requirements also account for real clinical use. That means expected workflows, misuse scenarios, environmental constraints, and edge cases. Teams that skip this work usually pay for it later during verification, complaint handling, or submission review. ### Why Functional Requirements Matter for Patient Care If the software does the wrong thing, or fails to do the right thing at the right time, patient harm can follow. An incorrect calculation, missed alarm, corrupted reading, or silent failure can drive poor clinical decisions. Reliable functional behavior supports clinical trust. Physicians, nurses, and technicians rely on device output to make decisions quickly. If the software is inconsistent, the workflow slows down. If it is wrong, the result may be worse than delay. This is also where cybersecurity and safety start to overlap. If an attacker can alter logic, suppress alarms, or change data flows, a functional requirement has effectively failed. Manufacturers should stop treating cybersecurity as separate from product behavior. It affects product behavior directly. ## Non-Functional Aspects of Medical Device Software Non-functional aspects describe how the software performs. They cover qualities such as reliability, response time, availability, maintainability, usability, and security. These requirements do not define the clinical function itself, but they strongly influence whether that function is dependable in practice. ![Section Image](/imported-images/78dc88ce0189a194.png) A device can have the right features and still fail in the field if it is slow, unstable, confusing, or insecure. That is why non-functional requirements belong in the product definition early, not as cleanup work before release. ### Exploring Non-Functional Requirements Non-functional requirements should be measurable. Response times, uptime targets, memory limits, authentication controls, logging behavior, failover expectations, and recovery times all need explicit definition. Clinical context matters here. A two-second delay may be irrelevant for one workflow and unacceptable for another. The same goes for usability. A complicated interface in a low-risk consumer app is irritating. In a high-acuity care setting, it can contribute to use error. Security also belongs in this category, and it needs to be treated as an engineering requirement, not a policy statement. Access control, secure update mechanisms, encryption, logging, integrity checks, and resilience to misuse all affect whether the software can be trusted in real operating conditions. ### How Non-Functional Requirements Affect Device Performance Non-functional failures are often less obvious than functional failures, but they can be just as damaging. A system that freezes, lags, loses network state, drops data, or presents alerts inconsistently may technically meet its core feature list while still being unsafe to use. This is especially important for connected devices. As internet connectivity, cloud dependencies, and remote service functions increase, so do the chances of latency, interoperability problems, and cyber exposure. Manufacturers need to define acceptable performance under degraded conditions, not just ideal ones. ## How Functional and Non-Functional Requirements Work Together Functional and non-functional requirements are often written in separate documents or handled by different teams. That split causes problems. In practice, they shape the same product behavior and need to be engineered together. A feature that works only in a lab environment is not ready. A system that performs well but delivers the wrong output is not ready either. The goal is not feature volume. The goal is safe, repeatable operation in real clinical settings. Tradeoffs are unavoidable. More features can increase attack surface, complicate workflows, and strain processing resources. Tighter security controls can introduce friction if poorly implemented. That is why teams need disciplined system design, threat modeling, verification planning, and usability input from the start. Ongoing evaluation matters too. Software maintenance, defect correction, performance monitoring, and postmarket feedback all inform whether the balance still holds after release. Device software is not finished when it ships. ## Regulatory Considerations for Medical Device Software [Regulatory considerations](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) are not paperwork layered on top of product development. They are part of how manufacturers show the device is safe and effective, including how software behaves under expected and adverse conditions. ![Section Image](/imported-images/42cdb257ceded230.png) The FDA expects manufacturers to define software requirements clearly, validate them appropriately, and address cybersecurity as part of the overall safety and effectiveness case. That includes premarket evidence and postmarket processes. Checklist compliance will not carry a weak engineering record through review. ### Compliance with Health and Safety Standards Medical device software must align with applicable quality and safety expectations, often including standards such as [ISO 13485](/blog) and relevant [FDA guidance](/blog). That means requirements management, risk management, verification, validation, design controls, change control, and documentation all need to hold up under scrutiny. The FDA and other regulators are looking for consistency between intended use, system architecture, risk controls, test evidence, and labeling. If your functional requirements say one thing, your non-functional behavior shows another, and your documentation hand-waves the gap, reviewers will notice. ### Managing Regulatory Requirements Without Losing the Plot Regulatory work gets messy when teams treat it as a separate track. The better approach is to build requirements, risk controls, cybersecurity design, and verification into the development process from the beginning. That requires close coordination across software engineering, quality, regulatory, clinical, and security teams. It also requires plain language. If developers cannot understand the requirement set, they cannot implement it correctly. If quality teams cannot trace design decisions to evidence, the submission gets weaker. If cybersecurity is brought in late, the team usually ends up patching symptoms instead of fixing architecture. Patient safety depends on both function and performance. Manufacturers need software that does the right thing, does it reliably, and stands up to regulatory and cybersecurity scrutiny. That is the standard. Blue Goat Cyber helps medical device manufacturers build that standard into the product lifecycle, from FDA premarket preparation to postmarket security operations. If your team needs help with threat modeling, penetration testing, secure design review, or regulatory support, [contact us for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is a functional requirement for medical device software? A functional requirement specifies a distinct action or behavior the software must perform. Examples include calculating drug dosages, displaying patient data, or triggering an alarm under specific conditions. These requirements are directly tied to the device's intended clinical use. ### How do non-functional requirements affect medical device safety? Non-functional requirements, such as reliability, response time, and security, directly impact whether the software can consistently and safely deliver its intended function. A device might have correct features but be unsafe if it is unstable, too slow, or vulnerable to cyberattacks. Failing to meet non-functional requirements can lead to delayed care, data compromise, or device malfunction. ### Does the FDA distinguish between functional and non-functional requirements? The FDA expects manufacturers to define and validate both functional and non-functional requirements. While not always explicitly categorized this way in guidance, the agency reviews evidence that software performs its intended functions safely and effectively, and that it maintains qualities like cybersecurity and reliability, as outlined in the February 3, 2026 final guidance on premarket cybersecurity. ### Why is cybersecurity considered a non-functional requirement? Cybersecurity is a non-functional requirement because it defines how well the software protects its functions and data from unauthorized access or alteration. It ensures the software's integrity, availability, and confidentiality, which matter for the safe and effective operation of the medical device in a clinical environment. A lapse in cybersecurity can directly compromise the software's ability to perform its core functions reliably. ### How can manufacturers ensure both requirement types work together? Manufacturers should integrate functional and non-functional requirements from the initial design phase through a disciplined system engineering approach. This involves cross-functional collaboration among software, quality, regulatory, clinical, and security teams, using tools like threat modeling, strong verification and validation, and continuous postmarket monitoring to ensure a safe, effective, and secure device. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SQL Injection Prevention: MedTech Security | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/medical-device-sql-injection-parameterized-queries # SQL Injection Prevention for Medical Device Web Applications > **[DIRECT ANSWER]** SQL injection prevention in medical device software starts with parameterized queries that separate SQL code from user-controlled data, but a defensible web security posture also covers output encoding to stop cross-site scripting, deliberate HTTP method choice for APIs, and layered file upload validation. Each control needs a matching security requirement, an implementation standard, and verification evidence such as SAST results, penetration test findings, and traceability entries. Together these controls address the injection, scripting, request handling, and upload risks that reviewers evaluate under the FDA's premarket cybersecurity guidance. _Reviewed September 17, 2026_ Web-based interfaces sit at the center of most connected medical device ecosystems: clinician portals, cloud APIs, support consoles, and device provisioning tools all move patient data and device commands through the same handful of vulnerability classes. A single unparameterized query, an unencoded output field, a state-changing GET request, or an unvalidated file upload can expose patient health information or let an attacker manipulate device behavior. Reviewers treat these as design-controlled engineering gaps, not cosmetic bugs, because each one maps to a well-documented CWE with known exploitation paths. Manufacturers that cannot show how they identified these risks, implemented controls, and verified the results tend to draw Additional Information requests. This post consolidates the web application security controls that most often show up in medical device cybersecurity reviews: SQL injection prevention, cross-site scripting defense, GET versus POST API design, and secure file upload validation, along with the evidence each one needs to produce. ## Key Takeaways - Parameterized queries are the primary control for SQL injection (CWE-89) and must be applied to every database access point, not just login forms. - Output encoding and content security policies are the primary controls for cross-site scripting (CWE-79), and input validation alone is not sufficient. - HTTP method choice affects security: GET must stay side-effect-free, and POST needs authentication, authorization, and idempotency handling rather than an assumption of safety. - File upload endpoints require layered controls: allow-listed types, content-based verification, quarantine scanning, and storage isolation, addressing CWE-434. - Every one of these controls needs a documented requirement, implementation standard, and verification result that traces into the risk management file. - Testing generic OWASP checklists is not enough; verification has to target the device's actual endpoints, query surfaces, and upload paths. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (February 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers apply this guidance to web application security the same way they apply software lifecycle expectations from IEC 62304 and security risk management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Injection, scripting, API misuse, and unsafe file handling are among the most common vulnerability classes found in connected health software, largely because they appear in ordinary features like search boxes, report exports, and support portals rather than exotic attack surfaces. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA Additional Information letters, trailing only software documentation and clinical evidence. A missing SAST rule for injection or an undocumented rationale for a GET endpoint's method choice is exactly the kind of gap that generates a review cycle. Treating these controls as a checklist rather than a design-controlled engineering artifact is what creates the gap. Each control in this post needs to trace from a threat model entry through a security requirement to an implementation and a verification result, so a reviewer can follow the chain without asking for it separately. ## What Are Parameterized Queries and Why Do They Stop SQL Injection? Parameterized queries separate SQL code from user-controlled data so the database treats input as a value rather than an executable command. Instead of concatenating input into a query string, the application defines the SQL statement first and passes parameters separately, which prevents an attacker from changing the query's intent. **Risky pattern (avoid):** ``` query = "SELECT * FROM patients WHERE id = " + user_input ``` **Safer pattern:** ``` query = "SELECT * FROM patients WHERE id = ?" execute(query, [user_input]) ``` SQL injection shows up most often in the unglamorous parts of an application: search filters, sort options, report builders, export functions, admin tooling, and device provisioning workflows. Parameterization has to be a default requirement across every service that touches a database, not just the login screen. Two implementation details cause repeated problems. First, parameterization protects values, not dynamic SQL structure such as column names in an ORDER BY clause, so those cases need allowlists of known-safe options rather than user-supplied identifiers. Second, stored procedures are not automatically safe; a stored procedure that builds dynamic SQL internally from unvalidated input is just as vulnerable as inline application code. > **[KEY REQUIREMENT]** Every database access point must use parameterized queries or safe query builders, with no string-concatenated SQL anywhere in the codebase, verified through a code review checklist and SAST rule set targeting injection. Least-privilege database accounts add a second layer: separate read and write roles limit the blast radius if a parameterization gap slips through review. ## How Do You Stop Cross-Site Scripting in Medical Device Web Interfaces? Cross-site scripting is stopped by encoding output for the context it renders in, combined with a content security policy that restricts what scripts can execute. XSS (CWE-79) occurs when an application includes user-controlled data in a web page without neutralizing characters that browsers interpret as executable script, letting an attacker run code in another user's session. In a medical device ecosystem, XSS most often appears in clinician-facing portals: patient lists, alert messages, report viewers, and configuration screens that render device-supplied or user-supplied text. A successful attack can steal session tokens, exfiltrate patient data rendered on the page, or issue authenticated requests on the victim's behalf, including requests to connected devices if the portal has command capability. Input validation reduces the attack surface but does not replace output encoding, because legitimate input (names with apostrophes, clinical notes with symbols) can still be dangerous if rendered unescaped. Three controls work together: - **Context-aware output encoding**, escaping data differently depending on whether it lands in HTML, an attribute, JavaScript, or a URL. - **Content Security Policy (CSP)** headers that restrict script sources and block inline script execution as a second layer of defense. - **Framework defaults**, since most modern templating engines auto-escape output; disabling that auto-escaping for "convenience" is a recurring root cause. > **[KEY REQUIREMENT]** All user-controlled or device-controlled data rendered in a web interface must pass through context-appropriate output encoding, and a Content Security Policy must be deployed and verified through automated and manual testing, not left as a future enhancement. | Vulnerability Class | Control | Evidence the FDA Expects | |:---|:---|:---| | SQL injection (CWE-89) | Parameterized queries, allowlisted dynamic SQL, least-privilege DB accounts | Threat model entry, secure coding standard, SAST results, targeted DAST/pen test, risk file linkage | | Cross-site scripting (CWE-79) | Output encoding, Content Security Policy, framework auto-escaping | Threat model entry, code review checklist, DAST/pen test results, CSP configuration review | | Unsafe HTTP method use | GET restricted to safe reads, POST/PUT/PATCH for state changes with idempotency handling | API threat model, security requirements per endpoint, authorization test results, traceability to requirement | | Unrestricted file upload (CWE-434) | Allowlisted types, magic-byte verification, quarantine scanning, storage isolation | Upload threat model, secure design document, negative test results, malware scan logs | ## Why Does HTTP Method Choice Matter for Medical Device APIs? HTTP method choice matters because GET requests are expected to be safe and cacheable while POST and other write methods carry the responsibility for state changes, and mixing up that contract creates both security and reliability problems. Medical device APIs connect device telemetry, mobile apps, clinician dashboards, and service tooling, so the wrong method choice can expose data through logs and caches or let a state-changing action be triggered accidentally. **Use GET only for safe, read-only operations**, such as retrieving device status, historical telemetry, or SBOM documentation. Never place secrets or sensitive identifiers in a URL, because query strings routinely appear in logs, browser history, and proxy caches. **Use POST, PUT, PATCH, or DELETE for anything that creates, changes, or triggers an action.** A GET endpoint that reboots a device or changes a configuration violates the safe-method contract and can be triggered by prefetching, scanning, or caching infrastructure that assumes GET has no side effects. Neither method is secure by default. Broken object-level authorization, where an endpoint fails to verify the caller is allowed to access the specific object requested, causes more real-world API breaches than method misuse does. POST requests also need idempotency handling, since retries after a network timeout can duplicate a create or command action unless the API defines an idempotency key. > **[KEY REQUIREMENT]** Security requirements must define the allowed HTTP method for every endpoint and the object-level authorization check that runs on it, verified through negative testing that confirms unauthorized requests are denied. | Dimension | GET | POST/PUT/PATCH | |:---|:---|:---| | Intended use | Safe, cacheable reads | Create, update, or trigger actions | | Data location | URL query string | Request body | | Idempotency | Safe by definition | Not automatic; requires design | | Common failure | State changes triggered via GET | Missing object-level authorization | | FDA relevance | Must justify why PHI is not exposed via logged URLs | Must show authorization and validation on write paths | ## How Should File Upload Validation Work in a MedTech Web Application? File upload validation should combine an allowlist of accepted types, content-based verification, quarantine scanning, and storage isolation, because a file upload endpoint accepts binary content an attacker fully controls. Clinician portals, support consoles accepting device logs, and SaMD backends accepting patient documents all expose this surface, and CWE-434 (Unrestricted Upload of File with Dangerous Type) is the underlying weakness class. A resilient design assumes some validation step will eventually fail and layers controls so a single miss does not lead to compromise: - **Allowlist file types** rather than blocking known-bad ones, since "we accept anything" is how uploads become incidents. - **Verify content with multiple signals**: extension, server-side MIME detection, and file signature (magic byte) checks, since filenames and client-supplied MIME types are trivially spoofed. - **Rename files on upload** to a generated identifier and keep the original filename only as metadata, removing attacker-controlled naming from the storage path. - **Store outside the web root** with no execute permission, and serve downloads through a controlled endpoint with `Content-Disposition: attachment` headers. - **Quarantine and scan** every upload before it becomes available to other users or downstream processing. Archives deserve separate scrutiny: a ZIP or TAR file can hide a zip bomb or nested dangerous content, so uploads that accept archives need extracted-size limits, file-count limits, and content-type checks applied to everything inside. > **[KEY REQUIREMENT]** Every upload endpoint must enforce an allowlist, content-based type verification, and a quarantine-then-scan workflow before a file becomes accessible, with authorization checks enforced independently at upload and at retrieval. | Layer | Control | Failure Mode If Skipped | |:---|:---|:---| | Type validation | Allowlist plus magic-byte check | Renamed executable bypasses extension filter | | Storage | Outside web root, non-executable, generated filenames | Uploaded script executes on the server | | Processing | Quarantine bucket, async malware scan | Malicious file reaches users before detection | | Delivery | Controlled download endpoint, safe headers | Browser renders untrusted content inline | | Access control | Authorization at upload and retrieval | Users access other patients' uploaded files | ## How Do These Controls Map to a Premarket Submission? Each control maps to a submission the same way: a threat model entry, a documented security requirement, an implementation standard, and a verification result that a reviewer can trace end to end. A control described only in prose, without a corresponding test result, is the most common gap reviewers flag. A practical evidence set for this cluster of controls includes a threat model covering injection, scripting, API misuse, and upload abuse cases; a secure coding standard that states the requirement in testable language; SAST results with rules targeting the relevant CWEs; and DAST or penetration test results exercising the device's actual endpoints rather than a generic checklist. That evidence then needs a traceability entry linking each threat to its requirement, control, and verification result inside the risk management file. Manufacturers that build this evidence incrementally, as each feature is developed, avoid the scramble of reconstructing it after the fact when a submission deadline approaches. ## How Blue Goat Cyber Approaches This Blue Goat Cyber's medical device practice treats web application security controls as design-controlled engineering output, not a documentation exercise added at the end of development. Every control in this post (parameterized queries, output encoding, API method design, and upload validation) traces back to a threat model entry, a written requirement, and a verified test result before it goes into a submission package. Our [web application penetration testing services](/services/web-application-penetration-testing) target the device's real endpoints, query surfaces, and upload paths rather than a generic OWASP checklist, and findings cite the specific CWE and the FDA's February 3, 2026 premarket cybersecurity guidance so they translate directly into submission evidence. We integrate that testing with the existing IEC 62304 software lifecycle and ISO 14971 risk file so the resulting matrix holds up under review. ## Frequently Asked Questions ### Are parameterized queries enough to stop SQL injection? Parameterized queries are the most reliable primary control, but they work best paired with defense in depth: least-privilege database accounts, input validation for expected formats, logging of suspicious query patterns, and targeted security testing. Relying on a single control without verification evidence is what tends to draw reviewer questions. ### Does input validation prevent cross-site scripting on its own? No. Input validation reduces the attack surface, but output encoding at render time is the control that actually stops a browser from executing injected script. A Content Security Policy adds a second layer that limits damage if encoding is missed somewhere. ### Can GET requests ever be used for actions that change device state? They should not be. Standards define GET as a safe method with no side effects, and caches, proxies, and scanners are built on that assumption. Using GET for a state change like a reboot or configuration update creates risk from prefetching and unintended replay. ### Is checking a file's extension enough to validate an upload? No. Attackers can rename a file to any extension, so validation needs server-side MIME detection and magic-byte signature checks in addition to an extension allowlist. Content-based verification is what catches a renamed dangerous file. ### What evidence should a premarket submission include for these web security controls? At minimum: threat model coverage of injection, scripting, API misuse, and upload risks; documented secure coding and API design requirements; SAST and targeted DAST or penetration test results; and traceability linking each risk to its control and verification result in the risk management file. ### How do these controls fit together in a real device ecosystem? They typically apply to the same set of surfaces: clinician portals, cloud APIs, support consoles, and provisioning tools. A single portal might need parameterized queries for its search feature, output encoding for its patient list view, correct method choice for its command endpoints, and upload validation for its log-submission feature. ## CTA If your device ecosystem includes web portals, cloud APIs, or file upload features, we can help you turn these controls into submission-ready evidence through threat modeling, targeted penetration testing, and documentation that traces cleanly into your risk file. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## MedTech Cyber Standards Every Device Team Must Know Source: https://bluegoatcyber.com/blog/medtech-cyber-standards-every-device-team-must-know # MedTech Cyber Standards Every Device Team Must Know > **[DIRECT ANSWER]** MedTech device teams must map their cybersecurity program to seven interlocking standards: Section 524B of the FD&C Act as the statutory anchor, the FDA's February 2026 premarket guidance defining submission content, IEC 62304 and IEC 81001-5-1 for the software lifecycle and security activities, ISO 14971 and AAMI TIR57 / SW96 for risk management, and UL 2900 or IEC 62443 for engineering-level testing depth. Medical device manufacturers don't face one cybersecurity requirement. They face a layered ecosystem of overlapping MedTech cyber standards, each demanding something different from your design process, your documentation, and your submission package. Miss a layer and you're looking at an FDA deficiency letter, a delayed clearance, or a postmarket compliance gap that surfaces at the worst possible time. The seven frameworks covered in this article are FDA premarket cybersecurity guidance, IEC 62304, ISO 14971, AAMI TIR57 / ANSI/AAMI SW96:2023, UL 2900, IEC 62443, and IEC 81001-5-1. Each plays a distinct role. For connected devices, many are expected or strongly recommended by the FDA; some carry the force of law under Section 524B, while others are voluntary certifications that meaningfully reduce submission friction. Specialist firms like Blue Goat Cyber recommend simultaneous mapping across all applicable [MedTech Cybersecurity Standards](https://bluegoatcyber.com/topics/medtech-cybersecurity-standards) as a baseline practice for every engagement, rather than something to retrofit at the end of the project. By the time you finish reading, you'll know what each standard requires, how they interconnect, and what a compliance program built across all of them actually looks like in practice. ## Key Takeaways - Section 524B is statutory law, requiring cybersecurity documentation for cyber devices. - The FDA February 3, 2026 guidance defines submission package content. - IEC 62304 and IEC 81001-5-1 cover software lifecycle and security activities. - ISO 14971 integrates security risks into existing device risk management. - UL 2900 and IEC 62443 specify rigorous security testing and system security. - Map all applicable standards simultaneously to avoid compliance gaps. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to MedTech cyber standards every device team must know the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Why MedTech cyber standards form a layered compliance framework The medical device cybersecurity standard landscape isn't flat. It has at least four distinct layers: statutory law, regulatory guidance, consensus standards, and voluntary certification schemes. Section 524B of the FD&C Act sits at the statutory layer. FDA guidance sits at the regulatory layer. IEC and ISO standards sit at the consensus layer. UL and IEEE programs sit at the certification layer. These layers don't compete; they're designed to complement each other, and a manufacturer that addresses only one layer leaves visible gaps that FDA reviewers will find. The FDA's approach is explicitly risk-based, which means documentation requirements scale with the cybersecurity risk profile and complexity of the device. A low-risk, offline device has a lighter documentation burden than a networked infusion pump or a connected diagnostic system. Understanding the layers helps your team know exactly how much documentation your device's risk profile demands. It's also worth noting the broader international picture. IMDRF (the International Medical Device Regulators Forum) has published cybersecurity guidance that many global regulators, including the FDA, reference as a foundational framework. The [EU Cyber Resilience Act (CRA)](https://en.wikipedia.org/wiki/Cyber_Resilience_Act) is introducing additional obligations for connected medical devices sold in European markets, with requirements that overlap significantly with IEC 62443 and IEC 81001-5-1. If your device has international distribution, understanding how these regional obligations interact with the U.S. framework matters from day one. ### The statutory foundation: Section 524B of the FD&C Act Section 524B creates the legal obligation that anchors everything else. For devices that meet the definition of a "cyber device," manufacturers must include cybersecurity documentation and lifecycle controls in their premarket submissions as a condition of clearance. This statutory requirement is not guidance; it's law. Everything discussed in this article ultimately serves to satisfy Section 524B. ### Mandatory requirements vs. consensus standards FDA guidance is not law in the strict sense, but it functions as the interpretive standard for premarket submissions. FDA reviewers use it to evaluate your documentation. IEC and ISO standards are consensus-based, meaning industry and technical bodies developed them, but the FDA recognizes them formally. Demonstrating conformance with a recognized consensus standard is one of the most efficient ways to satisfy the FDA's expectations without reinventing the evidentiary wheel for each submission. ## The seven MedTech cyber standards your cybersecurity program must address Think of this section as a working reference, not a glossary. Each standard has a specific role in your compliance program, and understanding that role tells you what you need to produce to satisfy it. (See the [Guide to Medical Device Cybersecurity Standards (Premarket, Postmarket, & Lifecycle)](https://bluegoatcyber.com/blog/guide-to-medical-device-cybersecurity-standards-premarket-postmarket-lifecycle).) ### FDA premarket cybersecurity guidance and AAMI TIR57 The [FDA's final premarket cybersecurity guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket), aligned with Section 524B requirements, defines what your submission package must contain: a threat model, security architecture documentation, a software bill of materials (SBOM), penetration testing evidence, a vulnerability management plan, traceability linking risks to controls, and labeling or user information covering cybersecurity. These aren't optional supporting materials; they're the core of your cybersecurity submission. (The full checklist is covered in the documentation section below.) AAMI TIR57 / ANSI/AAMI SW96:2023 sits alongside FDA guidance as a principles-based cybersecurity risk assessment framework. Its contribution is specific: it shows manufacturers how to treat security risks using the same ISO 14971 risk management structure already used for patient safety risks. Instead of building a separate security risk file, TIR57 integrates threat identification, likelihood estimation, control implementation, and residual risk documentation directly into the risk management process reviewers already know how to evaluate. For submissions, this integration makes your risk file coherent rather than fragmented. ### IEC 62304 and IEC 81001-5-1: the software lifecycle pair [IEC 62304](https://www.iso.org/standard/38421.html) defines the software development lifecycle process for medical device software: development, maintenance, problem resolution, configuration management, and release control. It tells you when lifecycle controls should happen, covering requirements, design, implementation, verification, and maintenance. What IEC 62304 does not specify is what cybersecurity activities to perform at each stage. That's where IEC 81001-5-1 enters. [IEC 81001-5-1](https://www.iso.org/standard/76097.html) is the security overlay for the 62304 lifecycle. It specifies the cybersecurity activities to embed at each stage: threat modeling during requirements, security architecture during design, secure coding and static analysis during implementation, penetration testing and security verification during verification, and vulnerability monitoring with patch management postmarket. Read together, 62304 gives you the process scaffold and 81001-5-1 tells you what security work to place on it. ### ISO 14971: risk management depth ISO 14971 is the core medical device risk management standard. Cybersecurity risks belong in your ISO 14971 risk file when they can affect patient safety or device performance. For networked devices, evaluate case-by-case whether a cybersecurity issue can lead to hazardous situations - the answer is often yes, but the analysis should be explicit rather than assumed. Your security risk controls, residual risk rationale, and postmarket monitoring obligations all tie back to this standard. ### UL 2900 and IEC 62443: engineering depth UL 2900-2-1 addresses software vulnerability and weakness testing for network-connectable healthcare products. It specifies structured test categories including malware scanning, known vulnerability assessment, fuzz testing of exposed interfaces, and structured penetration testing. Where IEC 81001-5-1 tells you what security activities to perform, UL 2900 tells you how to test them rigorously. IEC 62443 brings the industrial and system-level security perspective, increasingly relevant for networked medical devices operating in clinical infrastructure. It addresses the security of systems and components, not just individual device software, and applies directly to manufacturers integrating devices into broader connected environments. It's also a key reference point for EU CRA compliance, making it doubly relevant for devices with international distribution. ## How these three standards form one integrated security framework Many reviewers and consultants observe that device teams approach IEC 62304, ISO 14971, and IEC 81001-5-1 as separate compliance checkboxes. That's a costly mental model. The three standards divide responsibilities in a way designed to work as a system, and understanding that system is what separates teams that achieve first-pass clearance from teams that receive deficiency letters. ### IEC 62304 provides the lifecycle scaffolding IEC 62304 defines when controls must be in place across the software lifecycle. Requirements, design, implementation, verification, release, and maintenance each have associated process obligations. This temporal structure is the skeleton of your compliance program. Without it, security activities are untethered from the development process and can't be demonstrated to a reviewer as systematic rather than ad hoc. ### ISO 14971 provides the risk management method Every security-related hazard your device faces gets analyzed and controlled through the ISO 14971 process: identify the hazard, estimate and evaluate the risk, implement controls, verify effectiveness, and monitor residual risk. Keeping safety and security risk management unified under one standard gives FDA reviewers a coherent risk file. It also prevents the common failure mode of building a separate "security risk" document that doesn't connect to the device's overall risk management record. ### IEC 81001-5-1 specifies the security activities IEC 81001-5-1 maps specific cybersecurity tasks to each lifecycle stage in a way that extends both 62304 and 14971. During requirements, it adds threat analysis and security objectives. During design, it adds security architecture and attack surface reduction. During implementation, it adds secure coding practices and configuration controls. During verification, it adds security testing and penetration testing. After release, it adds vulnerability monitoring, coordinated disclosure handling, and patch management. This is not a theoretical mapping - it's the activity list that produces the documentation your FDA submission needs. ## What FDA premarket submissions require across all these standards Understanding what the standards say is useful. Knowing what you must produce for the FDA is actionable. Every connected device submission needs a set of cybersecurity deliverables, and each deliverable maps to more than one standard simultaneously. ### Documentation that spans multiple standards simultaneously Your threat model satisfies both FDA guidance and IEC 81001-5-1's requirements for threat analysis during design and requirements phases. Your SBOM satisfies FDA guidance under Section 524B and IEC 62304's configuration management requirements. Your risk controls satisfy ISO 14971 and AAMI TIR57 / ANSI/AAMI SW96:2023. Your penetration testing results satisfy FDA guidance and UL 2900's structured testing categories. Manufacturers who build these deliverables standard-by-standard in silos end up with documentation that satisfies one framework while creating gaps in another, and those gaps are exactly what generate deficiency letters. Per the FDA's final premarket cybersecurity guidance and Section 524B implementation requirements, the full documentation set the FDA expects includes: - Threat model with identified risks and controls - Security architecture diagrams covering hardware, software, network, and cloud components - SBOM with commercial, open-source, and off-the-shelf components and version details - Penetration testing results mapped to the threat model - Vulnerability management and coordinated disclosure plan - Traceability matrix linking risks to controls and testing evidence - Cybersecurity labeling and user instructions ### Traceability as the connective tissue The traceability matrix is the single artifact that can demonstrate compliance across multiple standards at once, when built correctly. It links each identified cybersecurity risk to a specific control, the test evidence verifying that control, and the residual risk rationale supporting acceptance. FDA reviewers use this matrix to follow the thread from threat to mitigation to evidence. A well-constructed traceability matrix built to span FDA guidance, ISO 14971, and IEC 81001-5-1 simultaneously reduces reviewer questions and the likelihood of a deficiency hold. ## Third-party certification programs and when they matter Third-party certification isn't currently mandatory for FDA clearance, but it provides structured, independently verified evidence that can reduce reviewer questions and submission friction, particularly for higher-risk device classifications where the bar for demonstrating security engineering rigor is higher. ### IEEE 2621 and the UL Medical Cybersecurity Assurance Program The IEEE 2621 series defines a formal certification program for connected medical devices using third-party, IEEE-recognized labs. IEEE 2621.2, which covers security requirements and the device protection profile, is listed in the FDA's recognized consensus standards database. Certification testing under this program covers authentication, encryption, software integrity, and data protection, and the resulting test reports can be included directly in premarket submissions as evidence for the testing and validation section. This is one of the most direct paths to standardized, FDA-recognized security evidence for connected device submissions. UL's Medical Cybersecurity Assurance Program (Medical CAP) is built on the UL 2900-2-1 standard and aligned with IEC 81001-5-1 and IEC 62443-4-1. Its test scope includes: - Malware scanning - Known vulnerability assessment against the NIST NVD - Software weakness analysis - Fuzz testing of exposed interfaces - Security controls evaluation - Structured penetration testing UL lab reports from Medical CAP provide independently verified evidence accepted by regulatory stakeholders. Neither IEEE nor UL certification replaces your internal documentation, but both strengthen it in ways that matter most to reviewers evaluating complex or high-risk devices. ## Building a program that maps every MedTech cyber standard at once The complexity of the medical device cybersecurity standard landscape isn't incidental. It reflects the genuine depth of risk that connected devices introduce into clinical environments. That complexity is exactly why manufacturers need a compliance approach that spans all applicable standards from the start of development, not one standard at a time. ### Why siloed compliance creates expensive gaps Manufacturers who address each standard separately produce documentation that satisfies one framework while conflicting with or ignoring another. The result is a deficiency letter that traces back to an integration failure, not a knowledge failure. Your team may understand IEC 62304 thoroughly while producing a risk file that AAMI TIR57 / ANSI/AAMI SW96:2023 would find incomplete, or generating an SBOM that satisfies FDA guidance but isn't connected to the configuration management record IEC 62304 requires. These gaps are predictable when standards are treated as independent tasks rather than a coordinated system. ### How we map all applicable standards in a single program Our approach to every engagement starts with simultaneous mapping across all applicable MedTech cyber standards - FDA guidance, IEC 62304, ISO 14971, UL 2900, IEC 62443, AAMI TIR57 / ANSI/AAMI SW96:2023, and IEC 81001-5-1. Every deliverable, from the threat model to the traceability matrix to the penetration test report, is built to satisfy multiple frameworks in a single artifact rather than producing redundant or conflicting documentation across them. For teams navigating a first FDA submission, remediating a deficiency letter, or building a postmarket compliance program for an already-cleared device, that depth of integration is what separates a clean clearance from a multi-round deficiency cycle. ## The bottom line on MedTech cyber standards MedTech cyber standards aren't competing frameworks trying to occupy the same space. They're a layered system where each standard handles a specific piece of the compliance picture. Section 524B anchors the legal obligation. FDA guidance defines the submission requirements. ISO 14971 and IEC 62304 provide the process backbone. IEC 81001-5-1 adds the security activities. UL 2900 and IEC 62443 address engineering depth. AAMI TIR57 / ANSI/AAMI SW96:2023 ties security risk back to patient safety. IMDRF guidance and the EU CRA extend these obligations globally. Manufacturers who understand how these layers interact build better devices and have smoother, faster clearance paths. The manufacturers who struggle aren't the ones who lack effort - they're the ones who treat each standard as a separate task rather than part of a coordinated system. When one deliverable is built to satisfy multiple standards simultaneously, the documentation holds together, the traceability is clean, and reviewers can follow the thread from threat to control to evidence without gaps. If your team is mapping a cybersecurity program and needs to know exactly which MedTech cyber standards apply to your device and how to satisfy them in a single, submission-ready package, that's the work Blue Goat Cyber was built to do. Learn more in our [Mastering Cybersecurity in MedTech: The Key to Accelerating Innovation and Ensuring Patient Safety](https://bluegoatcyber.com/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). [Contact the team](https://bluegoatcyber.com/contact) to start with a standards gap assessment tailored to your device, your submission pathway, and your timeline. ## Which standard covers what Teams waste months treating these as separate projects. They overlap heavily. This is the shortest honest map of who covers what. | Standard | What it actually governs | What you produce for it | | --- | --- | --- | | ISO 14971 | Risk management for patient harm | Risk file, hazard analysis, residual risk rationale | | IEC 62304 | Software lifecycle processes | Development plan, architecture, unit and integration records | | ANSI/AAMI SW96:2023 | Security risk management for devices | Security risk analysis tied to the ISO 14971 file | | AAMI TIR57 | Bridging security risk to safety risk | Threat model and the mapping between the two risk views | | IEC 81001-5-1 | Secure development process maturity | Secure coding, verification, and release controls | | ISO 13485 and the QMSR | Quality system the rest sits inside | Procedures, training records, design controls | | UL 2900 series | Optional third-party security certification | Test evidence to a published criteria set | ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### Which cybersecurity standards does the FDA actually require for a medical device submission? The FDA does not certify against a single standard. Its premarket cybersecurity guidance expects evidence consistent with AAMI TIR57 / ANSI/AAMI SW96:2023, IEC 62304, ISO 14971, and the SPDF concepts now codified in Section 524B. AAMI TIR97 and IEC 81001-5-1 are increasingly cited for postmarket and lifecycle expectations. Reviewers want to see one coherent program that maps to these references, not seven parallel binders. ### Do I need IEC 62443 if I am building a medical device, not industrial control? IEC 62443 is not mandatory for medical devices, but the threat-modeling and zone/conduit concepts apply directly to connected infusion pumps, imaging systems, and clinical networks. Teams that pull selected requirements from IEC 62443 into their AAMI TIR57 / ANSI/AAMI SW96:2023 risk assessment usually produce a stronger architecture story than teams that ignore it. ### How do IEC 62304 and IEC 81001-5-1 fit together? IEC 62304 governs the software development lifecycle for the device itself. IEC 81001-5-1 extends those activities into security-specific lifecycle controls - threat modeling, secure coding, vulnerability handling, and postmarket monitoring. Most modern submissions cite both, with IEC 81001-5-1 used to evidence the security activities IEC 62304 does not explicitly require. ### Is UL 2900 still relevant after Section 524B? UL 2900 testing is no longer a prerequisite for FDA clearance, but the test methodology - fuzzing, known-vulnerability scanning, malformed input testing - remains a useful third-party validation of the testing evidence the FDA expects under 524B. Treat it as one tool, not the whole program. ### Can a small team realistically meet all seven standards? Yes, because the standards overlap significantly. A single threat model, a single SBOM, a single risk file, and a single set of test reports can satisfy clauses across IEC 62304, ISO 14971, AAMI TIR57 / ANSI/AAMI SW96:2023, and IEC 81001-5-1 if they are written with the cross-references in mind. The mistake is treating each standard as a separate workstream. ### Which standard should we adopt first if we are starting from scratch? Start with AAMI TIR57 / ANSI/AAMI SW96:2023 - it is the bridge between ISO 14971 risk management and security-specific threat modeling, and FDA reviewers expect to see it referenced. Add IEC 62304 once you have a software development plan, and layer IEC 81001-5-1 in as your secure development process matures. ## Related FDA & cybersecurity guides - [FDA Section 524B cybersecurity requirements explained](/guides/fda-524b-cybersecurity-requirements-explained) - [SBOM vulnerability management for medical devices](/guides/sbom-vulnerability-management-medical-devices) - [VEX document guide for FDA submissions](/guides/vex-document-medical-device-fda) - [FDA deficiency-letter response service](/fda-cybersecurity-deficiency-letters) - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Microkernel Architectures for Medical Devices Source: https://bluegoatcyber.com/blog/microkernels-medical-device-cybersecurity # Microkernel Architectures for Medical Devices: 2026 Best Practices > **[DIRECT ANSWER]** Microkernel architectures improve medical device cybersecurity by keeping only scheduling, memory management, and IPC in privileged kernel space, shrinking the trusted computing base and containing faults to isolated user-space services. The FDA does not require a microkernel, but reviewers expect evidence of real privilege boundaries, least privilege, secure boot, and verification testing that proves isolation and failure containment, not just the architecture label itself. ## Key Takeaways - Microkernels can improve isolation by keeping the kernel small and moving services to user space. - The security benefit comes from real privilege boundaries, not from the word “microkernel.” - Tradeoffs include IPC design complexity, performance considerations, and driver ecosystem constraints. - For FDA-facing evidence, focus on architecture clarity, risk traceability, and verification results that prove isolation and failure containment. ## What is a microkernel? A microkernel is a kernel design that keeps only a small set of core functions in privileged kernel space. Those core functions usually include scheduling, memory management, and inter-process communication (IPC). Other services that would typically live inside a monolithic kernel run in user space as separate processes. In a microkernel architecture, the OS looks more like a set of cooperating components than one large block of privileged code. The kernel coordinates, user-space services provide functionality, and IPC is the glue. ## Microkernel vs monolithic vs “hybrid” kernels ### Monolithic kernel (traditional) Most services run in kernel space. This can be fast and straightforward, but it also means a bug in a driver or subsystem can have a high impact because it runs with full kernel privileges. ### Microkernel Only essential mechanisms stay in the kernel. Many services run in user space with tighter privilege and stronger fault isolation. This can shrink the trusted computing base, but you also introduce IPC design complexity and performance considerations. ### Hybrid approaches Many real-world systems take a blended approach. What matters most is not the label, but where you draw privilege boundaries and how you enforce them. ## Why microkernel security matters In a connected medical device, “cybersecurity” is rarely a single control. It is how you limit the blast radius when something goes wrong. Microkernels can support that goal when you use them to create real isolation between: - **Safety-critical functions** (therapy delivery, alarms, essential performance) - **High-risk interfaces** (networking, file parsing, removable media, remote service channels) - **Support services** (logging, UI, telemetry, update clients) When the isolation is real, a bug in a non-safety service is less likely to become a full device compromise. That is the value proposition. FDA’s current premarket guidance emphasizes secure-by-design, architecture clarity, and verification evidence across the lifecycle. If your OS choice is part of your security argument, you should be ready to show how it supports isolation, least privilege, updateability, and vulnerability response. See the FDA guidance here: [FDA: Cybersecurity in Medical Devices (Premarket Guidance)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket). ## Where microkernels show up in safety-critical systems Microkernel ideas have a long history in safety-critical domains. A few commonly cited examples include seL4 (known for formal verification work) and QNX Neutrino (known for message-passing architecture in embedded systems). If you want to go deeper on these reference implementations: - ACM: seL4 formal verification overview - [QNX docs: Microkernel and message passing](https://www.qnx.com/developers/docs/8.0/com.qnx.doc.neutrino.getting_started/topic/s1_msg_Microkernel_and_messages.html) These are examples, not recommendations. The right OS for your device depends on your architecture, safety case, maintenance plan, and ability to produce evidence. ## The tradeoffs MedTech teams need to understand ### 1) Performance and latency Microkernels rely heavily on IPC. That can introduce overhead, especially if services are chatty or poorly partitioned. In many embedded systems the overhead is manageable, but you still need to measure it and make sure it does not affect essential performance. ### 2) Complexity moves, it does not disappear A microkernel reduces kernel complexity, but pushes more functionality into user-space services. That can be great for isolation, but it creates more components, more interfaces, and more integration testing. ### 3) Driver ecosystem and hardware support Device drivers are often where risk lives. Microkernels can help by running drivers in user space, but only if your platform and vendor ecosystem support that cleanly. ### 4) Security depends on policy, not architecture diagrams “We use a microkernel” is not a control. The controls are the actual enforcement mechanisms: capability or permission models, memory protection, IPC authorization, secure boot, signed updates, logging, and response procedures. ## A practical microkernel security checklist for medical devices ### Design - **Partition intentionally**: identify safety-critical functions and isolate them from networking and parsing surfaces. - **Define trust boundaries**: document which components are trusted, which are exposed, and what happens if each fails. - **Least privilege**: ensure each service runs with only the permissions it needs. - **Harden IPC**: treat IPC endpoints like APIs. Authenticate and authorize requests between components where applicable. ### Build and configure - **Secure boot and secure update**: make it hard to persist in the device even if a service is compromised. - **Memory protections**: turn on platform hardening (ASLR/DEP or equivalents) where supported. - **Logging that is usable**: log security-relevant events, privilege failures, and update events with enough fidelity to investigate issues. ### Test and prove it - **Negative tests**: prove components cannot access resources they should not access. - **Fault injection**: crash or degrade non-safety services and show the safety-critical path stays safe. - **Interface testing**: fuzz or stress parsers and IPC endpoints for robustness. - **Security testing**: validate exploitability assumptions, not just functional behavior. If you want support building this into your design process, [Secure MedTech Product Design Consulting](/services/secure-medtech-product-design-consulting) and [Medical Device Threat Modeling Services](/services/medical-device-threat-modeling) are designed for exactly this kind of architecture and evidence work. ## What to document for FDA-facing credibility FDA reviewers typically respond well to clear, testable architecture narratives. For a microkernel-based design, your documentation set should make these points obvious: - **Architecture views**: partitions, privilege boundaries, IPC flows, update paths, and trust boundaries. - **Risk management linkage**: threats tied to components and interfaces, plus mitigations and residual risk rationale. - **Third-party software story**: what you run, how you track it, and how you keep it updated, ideally supported by an SBOM. - **Verification evidence**: tests that prove isolation, least privilege, and failure containment. - **Postmarket plan**: monitoring, patch delivery, and vulnerability response over the lifecycle. Helpful internal resources: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA-Compliant SBOM Services for MedTech](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Cybersecurity Penetration Testing](/services/medical-device-penetration-testing) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance) ## Why microkernels matter for medical device cybersecurity Microkernel architectures are showing up in more safety-critical medical devices because reviewers increasingly want to see the smallest possible Trusted Computing Base behind every life-supporting function. The FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 calls out architecture choices that reduce attack surface as evidence of a mature Secure Product Development Framework, and AAMI TIR57:2016 explicitly recommends privilege separation and component isolation as risk-control measures. Formally verified microkernels like seL4 (the only OS kernel with a machine-checked proof of functional correctness, originally completed in 2009 by NICTA/Data61) and Common Criteria EAL 6+ kernels like INTEGRITY-178B carry submission weight a monolithic Linux kernel cannot match. For a Class III implantable or any device touching life-supporting therapy delivery, the choice between a microkernel and a general-purpose OS is increasingly a cybersecurity claim you will be asked to defend in deficiency review. ## How Blue Goat assesses microkernel-based medical devices Blue Goat Cyber tests microkernel-based medical devices the way reviewers expect them to be tested: per-component, against the IPC boundaries, with privilege escalation and supply-chain attacks modeled explicitly. We review the kernel configuration, IPC policies, capability assignments, and any user-space drivers; pen-test the device against the AAMI TIR57 and SW96 threat model; and trace findings back to specific Section 524B(b)(2) requirements in the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026. Our testers hold CISSP and OSCP credentials and include ex-military red team operators with embedded-systems backgrounds. Reports cite EAL-rated microkernels (seL4, PikeOS, INTEGRITY-178B) where applicable and document why the architecture reduces the attack surface a reviewer is going to ask about. See [medical device penetration testing](/services/medical-device-penetration-testing). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### Are microkernels “more secure” than monolithic kernels? They can be, because a smaller trusted computing base and stronger isolation can reduce blast radius. But the real outcome depends on how you partition services, enforce privilege, harden IPC, and maintain the system over time. ### Does the FDA require a microkernel for connected medical devices? No. The FDA expects reasonable assurance of cybersecurity based on risk. You can meet that expectation with different architectures if you can document and verify your controls. ### Do microkernels eliminate the need for secure coding? No. You still need secure coding, testing, and vulnerability management. A microkernel can limit impact of a bug, but it does not prevent bugs. ### How do we prove isolation in testing? Use negative tests for privilege boundaries, fault injection to show safety-critical paths remain safe, and targeted security testing for exposed interfaces and IPC flows. ### What is the biggest mistake teams make when adopting a microkernel? Assuming the architecture alone provides security. The hard work is in the permission model, IPC controls, update and logging design, and evidence that those controls work. ## Book a Discovery Session If you want help deciding whether a microkernel approach supports your device’s safety and cybersecurity goals, and you want documentation and test evidence that reviewers can follow, we can help. [**Book a Discovery Session**](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## Conclusion Microkernels are a useful tool for safety-critical systems because they can make isolation more practical. In MedTech, the smartest way to use that advantage is to design around trust boundaries, enforce least privilege, test failure containment, and document the results. That combination tends to stand up well in both engineering reality and regulatory review. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Mining FDA Databases for Cyber Precedent Source: https://bluegoatcyber.com/blog/mining-fda-databases-medical-device-cybersecurity-precedent # Mining FDA Databases for Medical Device Cybersecurity Precedent > **[DIRECT ANSWER]** Mining FDA databases for cybersecurity precedent means reading post-Section-524B 510(k) summaries, De Novo decision summaries, and PMA SSEDs in your product code to see what SBOM format, threat-model methodology, and pen-test scope reviewers are currently accepting. Cross-reference MAUDE and the FOIA reading room for postmarket signals, then use the findings to calibrate your submission before filing rather than guessing at the current bar. Cybersecurity precedent research is not a summary read. Done well, it is a structured pass through five FDA data sources that together tell you what the agency has actually accepted, redacted, or challenged in your product code. The February 3, 2026 final premarket cybersecurity guidance is the rulebook, but cleared submissions are the answer key. This guide is the workflow we run internally before we produce a Section 524B artifact for any new client device. It assumes you have already read the companion post on [navigating the 510(k), De Novo, and PMA databases](/blog/how-to-navigate-the-fda-510k-and-pma-databases) and want the operational sequence. ## Key Takeaways - Precedent research is a five-source workflow (Product Classification, 510(k), De Novo, PMA, MAUDE, FOIA), not a single database search. - Product code and regulation number scope the search; device name is unreliable. - De Novo Decision Summaries and PMA SSEDs carry the deepest FDA-authored cybersecurity reasoning in the public record. - FOIA exemption (b)(4) redactions still expose the structure of the submission, which is often what matters most. - MAUDE closes the postmarket loop by showing cybersecurity-adjacent failure modes for cleared devices in the same code. - The output of precedent research should be a written baseline: SBOM format, threat-model methodology, pen-test scope, and postmarket plan structure the FDA is currently accepting for your device category. ## Why Precedent Research Matters Under Section 524B Section 524B of the FD&C Act made cybersecurity a gating requirement for every "cyber device," and the FDA's February 2026 final premarket cybersecurity guidance defines the artifacts reviewers expect: SBOM, threat model, security risk assessment, security architecture views, penetration test, labeling, and postmarket vulnerability management plan. The guidance is uniform, but reviewer application is product-code specific. Precedent research tells you where the current bar sits for your code. Reviewers for infusion pumps, continuous glucose monitors, and radiation therapy planning software have different threat surfaces in mind even when they cite the same guidance sections. Reading three to five cleared post-524B submissions in your product code before you file is the fastest way to calibrate depth so the first-cycle review does not turn into an AI-letter exchange. Standards including AAMI TIR57, ANSI/AAMI SW96, and IEC 81001-5-1 are named in the guidance, but the way cleared summaries reference them (or do not) shows how strictly a specific review team is currently reading them. ## Step 1: Anchor the Search in the Product Classification Database Start at the [FDA Product Classification Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm). Search by device name or intended use to identify the three-letter product code and the 21 CFR regulation number for the device family. Note: - The device class (I, II, or III), which determines pathway and cybersecurity scrutiny - Any special controls listed against the regulation number - The submission type the code typically clears under (510(k), De Novo, PMA) - Whether the code was created by a De Novo grant, which the classification entry usually notes Everything downstream is keyed to this product code. Device-name searches miss synonyms and rebrands. ## Step 2: Read Post-524B 510(k) Clearances in Your Product Code Open the [510(k) Premarket Notification Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm), filter by product code, sort by decision date descending, and read the three to five most recent clearances issued after Section 524B took effect. For each Summary Statement: - Note whether the sponsor references the February 2026 final guidance, AAMI SW96, IEC 81001-5-1, or SPDX/CycloneDX SBOM format by name - Look for phrases like "cybersecurity risk assessment," "threat model," "penetration testing," and "coordinated vulnerability disclosure" - Flag redactions marked (b)(4) and note the section headings around them, structure is often more informative than the redacted content - Record the predicate K-number, so you can walk the predicate chain back to the original clearance > **[KEY REQUIREMENT]** Post-524B clearances are the only 510(k) precedent that reflects the current guidance. Pre-524B clearances are useful for predicate identification but are not a reliable model for cybersecurity documentation depth. ## Step 3: Read the De Novo Grant That Created Your Product Code If Step 1 showed your product code was created by a De Novo grant, pull the grant from the [De Novo Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm) and read the full **Decision Summary**. The Decision Summary is written by the FDA and is the single most valuable cybersecurity precedent document in the public record because it names: - The specific device risks the agency identified - The special controls the agency imposed (which become mandatory for every follow-on 510(k)) - The cybersecurity, software, and interoperability evidence the sponsor provided - The FDA's reasoning for accepting or rejecting specific mitigations De Novo cybersecurity special controls are precedent that outlives the grant. If your product code has them, your submission has to address them by name. ## Step 4: Read PMA SSEDs and Supplements for Change-Control Precedent If the device category clears under PMA, pull the most recent approvals in your product code from the [PMA Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm) and read the **Summary of Safety and Effectiveness Data (SSED)** for each. Then walk the supplement chain (S001, S002, and so on) to see how the FDA handled post-approval cybersecurity changes. Supplements are especially valuable if you plan to file a Predetermined Change Control Plan. They show which categories of cybersecurity change the FDA has previously accepted through PMA supplements, which is directly informative for scoping a PCCP under the December 2024 final PCCP guidance. See our [PCCP and cybersecurity guides collection](/collections/pccp-cybersecurity) for how to convert that precedent into a submission-ready PCCP. ## Step 5: Cross-Reference MAUDE and the FOIA Reading Room Premarket databases end at clearance. To see what happened after, use: - [MAUDE](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm), for adverse event reports in your product code. Filter by device problem codes related to software, connectivity, and unauthorized access to find cybersecurity-adjacent postmarket signals. - [FDA FOIA reading room](https://www.fda.gov/regulatory-information/freedom-information/electronic-reading-room), which occasionally releases redacted review memos, warning letters, and 483 observations with cybersecurity content. - [510(k) Third Party Review lists](https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/510k-third-party-review-program), to see which product codes have accelerated review paths. MAUDE will not name a "cybersecurity incident" as such, but device-problem code patterns (software issues, communication failures, unexpected behavior) in your product code often correlate to the postmarket cybersecurity risks the FDA now expects your submission to address. ## How to Turn Precedent Findings Into Submission-Ready Evidence Precedent research is only useful if it changes what you file. The deliverable should be a short written baseline that answers, for your product code: - What SBOM format has been accepted in recent post-524B clearances (SPDX, CycloneDX, both)? - What threat-model methodology appears (STRIDE, PASTA, TIR57-aligned custom)? - What penetration-test scope is treated as complete (RF, BLE, firmware, cloud APIs, mobile apps)? - Which standards are consistently cited by name (AAMI SW96, IEC 81001-5-1, ISO 14971)? - What postmarket cybersecurity plan structure appears in cleared submissions? That baseline becomes the calibration point for your artifacts. If your SBOM, threat model, or pen-test scope is materially thinner than the precedent baseline, you are filing below the current bar. Cross-check against the specific patterns in our [510(k) cybersecurity deficiencies that trigger FDA holds](/blog/510k-cybersecurity-deficiencies-that-trigger-fda-holds) analysis and our [FDA cybersecurity deficiency letter examples](/guides/fda-cybersecurity-deficiency-letter-examples) library before you submit. For AI/ML or firmware-updatable devices, feed the change-authority precedent you find into a [Predetermined Change Control Plan](/guides/fda-pccp-change-control-plans) so post-clearance updates stay inside the cleared envelope. Want the precedent baseline built for your product code before you file? [Schedule a scoping call](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will pull the post-524B clearances in your code and hand you the calibrated baseline. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. Precedent research is the first hour of every new engagement: we pull every post-Section-524B clearance in the client's product code, reconstruct the cybersecurity evidence pattern the FDA has been accepting, and set that as the floor for the artifacts we produce. The result is a submission calibrated to how reviewers in that product code are currently reading the February 2026 guidance, not to a generic template. See our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### How do I mine FDA databases for medical device cybersecurity precedent? Start at the Product Classification Database to lock in the product code, then read post-Section-524B 510(k) Summary Statements, the De Novo Decision Summary that created the code, and any recent PMA SSEDs and supplements in the same code. Close with MAUDE and the FOIA reading room for postmarket signals. Product code, not device name, is the correct search key throughout. ### What FDA cybersecurity content is public and what is redacted? Structural content, submission section headings, artifact types, standards references, and predicate chains, is almost always public. Specific technical detail (encryption implementation, exploitation findings, proprietary threat-model content) is typically redacted under FOIA exemption (b)(4). The structure that remains is usually enough to calibrate documentation depth. ### Are pre-Section-524B 510(k) clearances useful precedent? For predicate identification, yes. For cybersecurity documentation depth, no. Pre-524B clearances predate the current mandatory cybersecurity content requirements and do not reflect how the February 2026 guidance is being applied today. ### How do De Novo cybersecurity special controls apply to follow-on 510(k) submissions? When a De Novo grant creates a product code with cybersecurity special controls, every subsequent 510(k) in that code must demonstrate substantial equivalence to those controls. The Decision Summary is precedent that carries forward regardless of how much time has passed since the original grant. ### Can MAUDE show cybersecurity incidents in a product code? MAUDE does not tag reports as "cybersecurity," but device-problem code patterns tied to software, communications, and unexpected behavior in your product code often correlate to the postmarket cybersecurity risks the FDA now expects your submission to anticipate. Treat MAUDE as a signal source, not a definitive incident record. **Related:** [How to Navigate the FDA 510(k), De Novo, and PMA Databases for Cybersecurity](/blog/how-to-navigate-the-fda-510k-and-pma-databases) · [FDA Pathway Cybersecurity Differences](/guides/fda-pathway-cybersecurity-differences) · [FDA Cybersecurity Deficiency Letter Examples](/guides/fda-cybersecurity-deficiency-letter-examples) · [FDA PCCP Change-Control Plans](/guides/fda-pccp-change-control-plans) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [FDA Cybersecurity Documentation](/blog/a-guide-to-fdas-cybersecurity-documentation-requirements) --- ## MQTT Vulnerabilities in Connected Source: https://bluegoatcyber.com/blog/mqtt-vulnerabilities-connected-medical-devices-fda # MQTT Vulnerabilities in Connected Medical Devices: FDA Risks, Controls, and Deficiency Patterns > **[DIRECT ANSWER]** MQTT is common in connected medical devices and commonly misconfigured, with anonymous broker access, missing TLS, wildcard topic subscriptions, and shared client credentials leading the list. The FDA expects mutual TLS or equivalent authentication, per-device credentials, topic-level authorization, and test evidence showing those controls hold. MQTT shows up in roughly every connected device program we touch, patient monitors phoning home to a hospital gateway, wearable cardiac sensors streaming to a cloud broker, infusion-pump fleets reporting telemetry, and just about every cloud-companion architecture for a Class II SaMD. It is cheap on the wire, easy to implement, and as a result it is also the protocol we see misconfigured most often in cybersecurity deficiency letters. This post is the working brief we give clients before we threat-model an MQTT-based device for an FDA submission. It is not "what is MQTT." It is what goes wrong, what the FDA will ask about, and what evidence closes the loop. ## Key Takeaways - MQTT vulnerabilities in submissions are almost always design and configuration issues, not protocol bugs. - The big six: anonymous brokers, weak or absent TLS, broad topic ACLs, retained-message PHI leakage, QoS-2 denial of service, and broker exposure. - The FDA expects each MQTT-specific threat in your threat model with a mapped safety consequence and a verified control. - Mutual TLS with per-device certificates is the baseline. Username/password over TLS is no longer defensible for Class II/III. - Topic ACLs must be derived from the data flow diagram, not from convenience. - Retained messages and Last Will and Testament payloads are common PHI leakage paths reviewers now look for. ## Why MQTT matters for medical-device submissions MQTT is referenced explicitly in the FDA's February 3, 2026 final premarket cybersecurity guidance as an example of a communication protocol whose security properties must be documented in the security architecture views and security risk assessment. Reviewers do not want a paragraph saying "the device uses MQTT over TLS." They want a threat model entry per asset, the broker's configuration in evidence, and a penetration test that actually exercised the protocol, not a generic TLS scan. The bar moved with the 2026 guidance for one reason: MQTT brokers keep showing up in postmarket incidents. Shodan-indexed unauthenticated brokers exposing hospital telemetry have become a routine press story. The FDA reads the same news you do. ## The six MQTT vulnerabilities that actually generate deficiencies ### 1. Anonymous or shared-credential broker access `allow_anonymous true` is still the Mosquitto default in many container images, and we still find it in submission-ready firmware. The second-worst pattern is a single device-fleet username and password baked into firmware. If one device is extracted and reverse-engineered, the whole fleet is impersonable. **What reviewers cite:** lack of per-device authentication, inability to revoke a single compromised device, no binding between device identity and published topics. **Control:** mutual TLS with per-device X.509 certificates provisioned at manufacture, with a documented revocation path through your postmarket cybersecurity plan. ### 2. TLS that is present but not validated We see this constantly: TLS is on, but the client does not verify the broker's certificate, accepts self-signed certs in production, or pins to a CA that signs anything. The packet capture looks encrypted, the threat model says "TLS 1.2+," and the device is wide open to a man-in-the-middle on hospital Wi-Fi. **What reviewers cite:** insufficient evidence of certificate validation in the security testing report; no rationale for cipher suite selection; missing pinning strategy. **Control:** TLS 1.3 where the stack supports it, explicit server-certificate validation, certificate or public-key pinning where the operational model allows it, and a documented cipher allowlist tied to the cryptographic protections section of your [security risk assessment](/guides/security-risk-assessment-iec-81001-5-1). ### 3. Overly broad topic ACLs The convenient pattern, `device/#` for read, `device/#` for write, is the vulnerable pattern. A compromised or impersonated device can read every other device's telemetry and publish commands into other devices' topics. **What reviewers cite:** the security architecture view does not constrain which topics a given device identity may publish or subscribe to, and the broker configuration in evidence shows wildcards. **Control:** per-device topic ACLs derived from the data flow diagram. A device with identity `dev-{serial}` may only `PUBLISH` to `telemetry/{serial}/#` and `SUBSCRIBE` to `commands/{serial}/#`. Enforced at the broker, tested in pen test, and documented in the architecture view. ### 4. Retained messages and Last Will and Testament leaking PHI Retained messages persist on the broker until overwritten. Last Will and Testament payloads are delivered to subscribers when a device disconnects ungracefully. Both routinely contain device state, patient identifiers, or session tokens that the design team never intended to persist. **What reviewers cite:** insufficient analysis of data at rest on the broker; no PHI handling rule for retained payloads; LWT contents not enumerated in the data flow. **Control:** a written rule about what may and may not appear in retained or LWT payloads, enforced in code review and verified in test. PHI does not belong in either. ### 5. QoS-2 and unbounded queues as a denial-of-service path QoS-2 (exactly-once) is expensive. An attacker who can authenticate (or a misbehaving device) can publish high-volume QoS-2 traffic and force the broker to maintain large in-flight state per session. Combined with unbounded `max_queued_messages`, this is a clean DoS against the broker and every device depending on it. **What reviewers cite:** no availability analysis for the broker; no rate-limiting; QoS levels not justified in the design rationale. **Control:** per-client connection caps, message-rate limits, bounded queues, and a QoS-level rationale in the design, most medical telemetry is fine at QoS-1. ### 6. Broker exposed beyond its intended trust boundary The cloud broker is in a VPC. The on-premise gateway broker is on the clinical VLAN. Then someone opens 1883 (or worse, 8883 without client-cert auth) to the internet for a partner integration, and the asset inventory never reflects it. **What reviewers cite:** the security architecture view does not show the broker's network position or its exposure; the SBOM lists the broker but no attestation of its hardening. **Control:** broker network position documented in the [architecture views](/guides/fda-medical-device-threat-model-template), broker hardening checklist (disabled listeners, bind to specific interfaces, no anonymous, audit logging on) in evidence, and a postmarket monitoring entry for unexpected broker exposure. > **Shipping an MQTT-connected medical device?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Medical device penetration testing](/services/medical-device-penetration-testing) ## Mapping MQTT threats into the threat model For an FDA submission, every one of the issues above needs a row in your threat model with the following columns reviewers expect to see: - **Asset / data flow**, which MQTT topic, which direction, which device class. - **Threat (STRIDE)**, spoofing for shared-credential access, tampering for missing TLS validation, information disclosure for retained-message leakage, denial of service for QoS-2 abuse, elevation of privilege for broad ACLs. - **Safety consequence**, mapped through your ISO 14971 risk file. A spoofed infusion-pump command is not the same harm as a leaked battery-level telemetry. - **Control**, the specific cryptographic, ACL, or architectural mitigation. - **Verification**, the pen test case, unit test, or configuration audit that proves it. If you do not already have this structure, our [STRIDE threat modeling guide for medical devices](/guides/stride-threat-modeling-medical-devices) walks through it, and the [threat model template](/guides/fda-medical-device-threat-model-template) gives you the column layout reviewers accept. ## What the penetration test should actually do A TLS scanner against port 8883 is not a penetration test of MQTT. The test plan reviewers respect includes: - Connecting with no credentials, expired credentials, and another device's credentials, and confirming each is rejected. - Attempting to publish to and subscribe from topics outside the device's ACL scope. - Sending malformed CONNECT, PUBLISH, and SUBSCRIBE packets, there is a long history of broker memory-corruption CVEs (Mosquitto, EMQX, HiveMQ) and your version needs to be tested, not just listed in the SBOM. - Replaying captured packets to confirm packet-level anti-replay where the design claims it. - Stress testing QoS-2 and large retained payloads to validate the availability controls. - Capturing traffic on a hostile network to confirm certificate validation actually fails the handshake. The report should land in the [pen test section of your premarket package](/guides/fda-penetration-testing-scope-510k) with method, evidence, and a remediation status for every finding. ## Deficiency patterns we see in real letters Anonymized from cybersecurity deficiency letters we have responded to in the last 18 months: - *"The submission does not describe how the device authenticates to the cloud broker or how broker identity is validated by the device. Provide the authentication scheme, certificate management approach, and evidence of validation."* - *"The security architecture views do not enumerate the topics published or subscribed to by the device, nor the access control rules enforced by the broker."* - *"The risk analysis does not address denial-of-service against the broker as a hazard contributing to loss of essential clinical performance."* - *"Provide evidence that retained messages and Last Will and Testament payloads do not contain protected health information."* Every one of these is closeable inside the 180-day response clock if the underlying design is sound. They are not closeable if the broker really is `allow_anonymous true` and someone has to ship a firmware change first. That is the whole argument for getting MQTT right before submission, not after. ## What to put in your submission A short, opinionated checklist: 1. **Architecture view** showing the broker, its network position, the trust boundary it sits on, and every device that connects to it. 2. **Data flow** with one row per MQTT topic, direction, payload class, and PHI flag. 3. **Threat model rows** covering the six issues above, each mapped to a safety consequence and a verified control. 4. **Broker configuration in evidence**, actual configuration file or hardening attestation, not a screenshot. 5. **Per-device certificate provisioning and revocation procedure** in the postmarket plan. 6. **Pen test report** that exercised the protocol, not just TLS. 7. **SBOM entry** for the broker and client library, with VEX statements for any known CVEs. If those seven artifacts are present and consistent with each other, MQTT-specific deficiencies become rare. When they are not, MQTT is one of the easiest things for a reviewer to pick a thread on. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## Frequently Asked Questions ### What are the most common MQTT vulnerabilities in connected medical devices? The six that drive most FDA deficiencies: anonymous or default-credentialed brokers, unencrypted MQTT (port 1883) in production, weak or missing client-certificate validation, over-broad topic ACLs that let a compromised device read or write other devices' topics, retained-message abuse, and broker DoS via slow-loris-style CONNECT floods. Each of these maps to a STRIDE category and should appear explicitly in the threat model. ### Is MQTT acceptable for FDA-regulated devices, or do I need a different protocol? MQTT is acceptable. The FDA's February 3, 2026 premarket guidance is protocol-neutral - what matters is whether the implementation enforces authentication, encryption, authorization, and integrity. MQTT over TLS 1.2+ with mutual certificates, per-device topic scoping, and a hardened broker passes review routinely. Plaintext MQTT on port 1883 does not. ### Do I need to pen test the MQTT broker as well as the device? Yes. The broker is part of the device's trust boundary in any reasonable threat model, so a reviewer will expect the penetration test scope to cover broker authentication, ACL enforcement, TLS configuration, and topic-isolation between tenants. Testing only the device-side client misses the most common real-world MQTT attack paths. ### How does MQTT authentication interact with Section 524B postmarket obligations? Section 524B requires demonstrable patchability and ongoing vulnerability management for the full SBOM, which includes the MQTT client library and any embedded broker. CVEs in Mosquitto, EMQX, or paho-mqtt have to be tracked, triaged, and remediated through the same QMS-controlled process as any other component, with VEX statements where a CVE is not exploitable in your configuration. ### Isn't MQTT secure by default if I just turn on TLS? No - and this is the misconception that drives the most deficiencies. TLS encrypts the transport but does not authenticate the client unless you require client certificates, does not scope topic access unless you configure ACLs, and does not stop a compromised device from publishing to topics it should not see. TLS is necessary, not sufficient. ## Related reading - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) - [FDA-grade threat model template](/guides/fda-medical-device-threat-model-template) - [Penetration testing scope for FDA submissions](/guides/fda-penetration-testing-scope-510k) - [Security risk assessment under IEC 81001-5-1](/guides/security-risk-assessment-iec-81001-5-1) - [FDA cybersecurity deficiency letter response playbook](/guides/fda-cybersecurity-deficiency-letter-response-playbook) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA’s 18 Cybersecurity Deliverables Source: https://bluegoatcyber.com/blog/navigating-the-fdas-18-cybersecurity-deliverables-for-medical-device-submissions # Navigating the FDA’s 18 Cybersecurity Deliverables for Medical Device Cybersecurity Submissions > **[DIRECT ANSWER]** The FDA expects a set of roughly 18 cybersecurity deliverables in premarket submissions for connected devices, organized under a risk management report (threat model, risk assessment, SBOM), controls, security architecture views, testing evidence, cybersecurity labeling, an interoperability risk assessment, and a postmarket cybersecurity management plan. Depth scales with device complexity, but every category must trace risks to controls and verification evidence, or reviewers issue deficiencies. Developing a medical device is a complex, multi-disciplinary effort, and cybersecurity is no longer optional. If your device connects, communicates, or relies on software, the U.S. Food and Drug Administration (FDA) expects you to demonstrate that you’ve thought about cybersecurity across the entire product lifecycle. When you enter the premarket submission phase, this expectation becomes a substantial documentation burden. At Blue Goat Cyber, we categorize the FDA’s requirements into 18 key cybersecurity deliverables that appear, in some form, in nearly every modern submission for a device with cybersecurity risk. These aren’t an “official FDA checklist,” but they are a practical way to organize what the FDA’s [February 2026 final guidance](https://www.fda.gov/media/119933/download "") and the latest [eSTAR template (version 6)](https://www.fda.gov/medical-devices/how-study-and-market-your-device/estar-program "") actually require. ## Key Takeaways - FDA cybersecurity expectations scale by risk, not by general device type. - Documentation (e.g., SBOM, threat model) is required for most connected devices. - Traceability from risks to controls to testing is critical for submissions. - A postmarket plan demonstrates ongoing vulnerability management. - Early cybersecurity integration reduces documentation burden. - Complete documentation is essential for FDA submission success. ## Why this matters The FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 expanded the cybersecurity evidence reviewers expect to see in a premarket submission, and eSTAR v7.0 now has dedicated slots for those artifacts. Section 524B of the FD&C Act makes two of the eighteen deliverables, the SBOM and the postmarket Cybersecurity Management Plan, statutory requirements; the remaining sixteen are non-negotiable in practice because reviewers will issue a deficiency without them. The FDA's FY2024 Office of Product Evaluation and Quality cybersecurity data shows the majority of cyber-device submissions still receive at least one cybersecurity deficiency, and most deficiencies trace back to missing or misaligned artifacts in this exact set of eighteen. Treating the list as a checklist works only if every item maps cleanly to its eSTAR slot, traces back to the threat model, and is internally consistent, gaps and contradictions are what reviewers flag first. ## Cybersecurity expectations are consistent - but scale with risk A common misconception is that the FDA’s cybersecurity documentation requirements change significantly based on the device’s risk level or submission pathway. In reality, the categories of information the FDA expects are broadly consistent across “cyber devices” and other connected devices. What _does_ change is **depth and complexity**. - A relatively simple, minimally connected device (for example, an oxygen pump with limited network exposure) will have: - A simpler threat model - Fewer architecture views - Smaller SBOM and lighter test evidence - A complex, highly connected system (for example, a surgical robot with cloud connectivity and multiple interfaces) will need: - Detailed threat modeling across components - Extensive architecture views - A large SBOM and more rigorous testing (including deeper penetration testing and abuse-case testing) Yes, the same types of documents apply, but the level of rigor, detail, and page count increases with the level of cybersecurity risk. Christian Espinosa, founder of Blue Goat Cyber, sees this play out with clients every day. The biggest mistake? Treating cybersecurity as an afterthought instead of a structured, traceable part of the design from day one. ## How our 18 cybersecurity deliverables line up with the FDA’s eSTAR The FDA’s eSTAR (electronic Submission Template And Resource) organizes the Electrical, Software, and Cybersecurity content for electronic submissions. Within that structure, we consistently see 18 cybersecurity deliverables that together tell a complete story. Below is how we define them and how they align with FDA expectations. ### 1\. Risk Management Report This is the core of your cybersecurity story and typically includes three significant pieces: - **Threat Model** A structured analysis of how an attacker could compromise your device or ecosystem. We often use [STRIDE](/blog) and reference frameworks like MITRE ATT&CK for Medical Devices to ensure we’re covering realistic tactics and techniques. - **Cybersecurity Risk Assessment** For each threat/vulnerability pair, you evaluate likelihood and impact, then assign a risk level and define risk controls. This work should integrate with your overall ISO 14971 risk management process. - **Software Bill of Materials (SBOM)** A detailed inventory of all software components, including third-party and open-source libraries. This is now a hard expectation for cyber devices, and practically speaking, for most connected devices. - **SBOM Supporting Material** Information about support status, maintenance, and vulnerability monitoring for each component-plus how you’ll keep the SBOM current over the device’s life. ### 2\. Cybersecurity Assessment of Unresolved Anomalies No non-trivial software is perfect at release. This deliverable documents: - Known software anomalies or “acceptable” residual defects - How they were evaluated from a **security** perspective - Any mapping to frameworks such as CWE (Common Weakness Enumeration) - Why do you consider the remaining risk acceptable, and what controls or compensating measures exist The FDA wants to see that you didn’t ignore defects that _might_ have cybersecurity implications. ### 3\. Cybersecurity Metrics This document outlines **the methodology for measuring and monitoring** your cybersecurity posture over time. Examples include: - Percentage of identified vulnerabilities remediated within defined SLA windows - Average time from vulnerability discovery to patch release and deployment - Defect density over time by component or release - Results of recurring security tests (e.g., trend in pen test findings by severity) These metrics support the FDA’s emphasis on **total product lifecycle (TPLC)** risk management. ### 4\. Cybersecurity Controls Here, you translate the risk assessment into concrete controls and design decisions. This typically covers: - Access control and authentication (e.g., roles, multi-factor, local vs. remote access) - Encryption in transit and at rest - Logging, audit trails, and event detection - Network segmentation, firewalls, and secure network protocols - Hardening and configuration management - Safety-relevant behaviors in the presence of anomalous or malicious input The FDA will look for clear traceability between risks and controls, as well as between **controls** and **verification**. ### 5\. Security Architecture Views [Security architecture views](/blog) give reviewers a clear picture of: - **Global system architecture** (devices, cloud, apps, interfaces, networks) - **Data flows** and trust boundaries - **Multi-patient or multi-system harm scenarios** (e.g., what if this component is compromised?) - **Updatability and patchability**-how you deliver authenticated updates - Specific **security use cases** (e.g., secure provisioning, key management, credential rotation) These visuals and descriptions make your design choices understandable and reviewable. ### 6\. Cybersecurity Management Plan Often called the **postmarket cybersecurity management plan**, this deliverable describes how you will: - Monitor for new vulnerabilities (internal testing, external reports, threat intel) - Intake and triage vulnerability reports (coordinated disclosure process) - Assess risk, prioritize remediation, and issue patches or mitigations - Communicate with customers and regulators as appropriate The FDA wants to see a sustainable **process**, not just one-time design work. ### 7\. Cybersecurity Testing The FDA expects evidence that your controls were actually tested. We usually break this into several sub-deliverables: - **Static Application Security Testing (SAST)** Automated and manual review of source code for security-relevant issues. - **Penetration Test Plan** Scope, methodology, and environment setup for [security testing](/services/medical-device-penetration-testing)-including what is in scope (device, cloud, APIs, mobile apps) and what attack vectors will be exercised. - **Penetration Test Cases / Procedures** Representative test cases and abuse cases are mapped to your threat model and controls. - **Penetration Test Report** Findings by severity, exploitability, and impact, plus remediation status and residual risk justification. Depending on the device, we may also include DAST, fuzz testing, protocol testing, and network assessments. ### 8\. Cybersecurity Labeling The FDA’s guidance has a lot to say about what should appear in labeling and customer-facing security documentation. We typically organize this into three parts: - **Customer Security Documentation (often aligned to JSP2)** Many manufacturers use documentation aligned with the [Medical Device and Health IT Joint Security Plan (JSP2)](https://healthsectorcouncil.org/jsp2/ "") to describe responsibilities, supported configurations, and security features in a structured way. - **Manufacturer Disclosure Statement for Medical Device Security (MDS2)** A widely used form that provides healthcare delivery organizations (HDOs) and others with a detailed view of device security capabilities, dependencies, and expectations. - **Interoperability Labeling** If your device integrates with other systems or supports interfaces that influence clinical decisions, you’ll need specific labeling to describe safe and secure use of those connections. The FDA doesn’t “mandate” JSP2 or MDS2 by name, but they strongly align with the guidance’s requirements. ### 9\. Interoperability Risk Assessment If your device relies on external systems, services, or interfaces to perform critical functions, you’ll need a dedicated assessment that looks at: - Risks introduced by those dependencies - How you authenticate and authorize external connections - How you handle data integrity, timing, and failure conditions across systems - What happens if those external systems behave unexpectedly or maliciously The FDA wants to understand how your security and safety perform in a real-world **ecosystem**, not just in isolation. ## Why a structured, repeatable process matters Across all 18 deliverables, one theme consistently emerges: **structure and repeatability.** As Christian often says, “We have a very unique methodology that we follow… our risk is based on the actual worst-case scenario as opposed to hypotheticals around data, which is more traditional for cybersecurity risk assessments.” In practice, that means: - A consistent way to connect threats → risks → controls → tests - Reusable patterns across product lines and submissions - Transparency for both engineers and regulators - A strong foundation for postmarket vulnerability handling the team emphasizes the same point from a technical angle: “What can you do to get ready for it early? How can you maturely develop your software documentation to inform your security documentation? Make decisions like this early on and start with the end in mind.” ## The documentation burden is real-plan for it For most connected medical devices, cybersecurity documentation alone can easily run: - **~150 pages** for simpler, low-complexity devices - **600+ pages** for complex, multi-component systems with rich connectivity That level of effort is almost impossible to bolt on at the end. It must grow in tandem with your design and development process. Our advice: - **Start with the end in mind.** Use the 18 deliverables as a planning checklist early in development. - **Integrate security into your SDLC and QMS.** Let design documents, software requirements, and risk analysis inform your cybersecurity deliverables directly. - **Treat cybersecurity like any other safety-critical function.** Traceable, verified, and maintained over time. ## Partnering with medical device cybersecurity experts If all of this feels overwhelming, you’re not alone. Most teams don’t build multiple FDA-grade cybersecurity packages a year, but we do. At Blue Goat Cyber, we help medical device manufacturers: - Build and refine threat models and cybersecurity risk assessments - Create SBOMs and supporting processes that actually work - Develop security architecture views and controls that reviewers can follow - Plan and execute penetration testing that maps directly to FDA expectations - Assemble, organize, and polish the complete cybersecurity documentation package for eSTAR submissions “If you ever need help with this,” Christian likes to say, “this is what we do at Blue Goat Cyber. We can build these documents with you, take the learning curve off your shoulders, and help you get to an FDA-ready story faster.” **Need help with an FDA medical device submission or cybersecurity documentation?** Schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session "") with Blue Goat Cyber, and let’s map out your path to a secure, submission-ready device. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQs ### What is the FDA's current cybersecurity guidance? The FDA's current cybersecurity guidance is the February 3, 2026 final guidance. It outlines the agency's expectations for cybersecurity in medical device premarket submissions. ### Does the FDA cybersecurity guidance apply to all medical devices? The FDA cybersecurity guidance applies to devices that are connected, communicate, or rely on software. The specific documentation burden scales with the cybersecurity risk posed by the device. ### What is an SBOM and why does the FDA require it? An SBOM, or Software Bill of Materials is a detailed inventory of all software components in a device. The FDA requires it to help manufacturers and users identify, understand, and manage cybersecurity risks from third-party software. ### How does the FDA evaluate cybersecurity testing? The FDA expects evidence that cybersecurity controls were tested through methods like SAST, penetration testing, and other security assessments. Submissions should include test plans, procedures, and reports with findings and remediation status. ### What is a postmarket cybersecurity management plan? A postmarket cybersecurity management plan describes how a manufacturer will monitor for new vulnerabilities, triage reports, assess risk, and issue patches or mitigations after a device has been cleared or approved. ### How many pages of cybersecurity documentation does the FDA expect? The FDA documentation can range from approximately 150 pages for simpler devices to over 600 pages for complex, multi-component systems, depending on the device's complexity and connectivity. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [What are Medical Device De Novo Requests?](/blog/de-novo-requests-for-medical-devices-explained) - [What is a Modular PMA Submission?](/blog/what-is-a-modular-pma-submission) - [Premarket FDA Cybersecurity Checklist](/guides/fda-premarket-cybersecurity-submission-checklist) --- ## JTAG UART Debug Port Security: FDA Compliance | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/navigating-the-intersection-of-jtag-uart-debug-ports-and-fda-compliance-in-medical-device-cybersecurity # JTAG UART Debug Port Security for Medical Device Hardware > **[DIRECT ANSWER]** JTAG UART debug port security means disabling, fusing, or authenticating chip-level debug interfaces before a medical device ships, so an attacker with physical access cannot reach the same memory and registers a developer used during bring-up. Manufacturers should ship production firmware images with debug access removed or gated, keep engineering images internal, and document the threat model, chosen mitigation, and test evidence in the premarket cybersecurity submission. _Reviewed September 17, 2026_ A debug port left active on a production medical device hands an attacker with a screwdriver the same access a firmware engineer had on the bench. JTAG and UART headers are essential during development for flashing code, reading logs, and diagnosing failures, but they typically bypass every software-level protection on the device. Hardware penetration testers find these interfaces exposed on production units far more often than manufacturers expect, usually because a firmware configuration flag was toggled off rather than a physical or cryptographic lock applied. This creates real exposure and, since the February 3, 2026 final guidance, a documentation gap that reviewers flag directly. This article covers what testers find on exposed debug headers, how to properly disable or authenticate them, the difference between production and engineering firmware images, and how to write this up for submission. ## Key Takeaways - Exposed JTAG and UART headers give physical attackers developer-level access to memory and registers. - A firmware flag that disables debug access is not the same as a fused or cryptographically locked port. - Production firmware images should never ship with the same debug capability as engineering images. - Field service access to debug interfaces should require authentication, not just physical possession of the device. - Reviewers expect the threat model, mitigation, and test evidence for debug ports documented explicitly. - Hardware-focused penetration testing is the only reliable way to confirm a debug lockout actually holds. ## Why This Matters The FDA's February 3, 2026 premarket cybersecurity guidance, building on the September 2023 and June 27, 2025 final guidances, treats debug and test interfaces as external interfaces subject to the same threat modeling and risk management expectations as network ports or wireless radios. Cybersecurity documentation gaps, including missing coverage of hardware attack surfaces like JTAG and UART, are among the most common drivers of first-cycle additional information requests in 510(k) and PMA reviews. Debug ports get specific attention because of how much access they grant. Unlike a software vulnerability that might expose one function, a live JTAG interface can expose the entire memory space, halt the processor mid-execution, and bypass authentication that exists purely in software. An attacker who gains this level of access can extract firmware for reverse engineering, modify calibration data, or install persistent malicious code that survives a factory reset. AAMI SW96 (recognition number 13-131) and ISO 14971 both require that risk assessments account for physical access scenarios, not just network-based attacks, which puts JTAG and UART squarely inside the scope of the security risk management file. Manufacturers who treat debug port security as a manufacturing afterthought rather than a design requirement typically discover the gap only when a reviewer or penetration tester finds the header still live. ## What Do Testers Find on Exposed Debug Headers? Testers most often find fully functional JTAG or SWD debug access on production boards, sometimes broken out to a labeled header and sometimes reduced to bare test pads that still respond to a probe. Once connected, a debugger typically has read and write access to RAM and flash, the ability to halt the CPU, and often visibility into keys or credentials stored in memory. UART headers frequently expose a root or diagnostic shell with no login prompt, or a login prompt protected by a hardcoded credential documented in a service manual. In both cases, the access available through the debug port exceeds anything reachable through the device's normal user interface or network stack, which is exactly why it matters for a threat model built around patient safety. **[KEY REQUIREMENT]** Hardware penetration testing must attempt to connect to every identifiable header, test pad, and exposed trace on the production board, not rely on a schematic review alone, since physical probing regularly finds access that documentation did not anticipate. ## How Should Manufacturers Disable, Lock, or Authenticate Debug Ports? Manufacturers should disable, lock, or authenticate debug ports using hardware-enforced controls rather than firmware settings alone. Options include physically fusing the JTAG interface after production programming and test, removing or covering test pads, and requiring cryptographic authentication before a debugger can attach even to a port that remains physically present. | Approach | Strength | Trade-off | |---|---|---| | Firmware flag disables debug | Weak | Reversible via reflash or fault injection | | Physical fuse blows JTAG access | Strong | Permanent; complicates future field diagnostics | | Debug authentication challenge | Strong | Requires secure key management, adds complexity | | Remove headers/pads from board | Moderate | Test pads may still be probed by a skilled attacker | | UART console requires login | Moderate | Only as strong as the credential and lockout policy | Where field service genuinely requires ongoing debug access, an authentication challenge tied to a manufacturer-controlled key is preferable to leaving the port open, since it limits access to authorized personnel with the correct credential rather than anyone holding the device. ## What's the Difference Between Production and Engineering Firmware Images? Production firmware images should ship with debug capability removed or gated behind authentication, while engineering images used during development and verification testing can retain full debug access for the internal team. Many manufacturers build a single firmware image for both purposes, which means the debug capability engineers need on the bench ships unchanged to every unit in the field. Maintaining two build configurations, one hardened for production and one open for internal use, closes that gap without slowing development. Build pipelines should tag each image clearly and verification testing should specifically confirm that units programmed with the production image cannot be flashed back to the engineering configuration without going through the intended secure update process. ## How Should This Be Documented in the FDA Submission? This should be documented in the submission as a named entry in the threat model identifying JTAG and UART as external interfaces, paired with the specific mitigation chosen and the test evidence confirming it works. A statement that debug ports are "secured" without naming the mechanism, fuse, authentication, or removal, will not satisfy a reviewer looking for the same specificity expected of network-facing controls. **[KEY REQUIREMENT]** The eSTAR cybersecurity documentation should include penetration test results showing an attempted connection to the production board's debug interfaces and the outcome, not just a design statement that the ports are disabled. | Submission Element | Expected Content | |---|---| | Threat model | JTAG/UART listed as attack vectors with likelihood and impact | | Risk assessment | Mapped to ISO 14971, includes physical access scenarios | | Mitigation description | Named mechanism: fuse, authentication, removal | | Test evidence | Penetration test results confirming lockout holds | | Labeling/service docs | Field service procedure for authenticated debug access, if retained | ## How Blue Goat Cyber Approaches This Blue Goat Cyber's hardware testing engagements physically probe production boards for JTAG, SWD, and UART access rather than relying on a schematic or design review alone. Engineers with CISSP, OSCP, and prior red-team backgrounds attempt the same connections an attacker would, confirm whether debug lockout mechanisms hold under direct probing, and document the outcome in a form suitable for premarket submission. This testing integrates with the broader threat model and security risk assessment so that debug port findings feed directly into the documentation reviewers expect under the February 3, 2026 guidance. Manufacturers preparing a submission can scope this work through our [FDA premarket cybersecurity services](/services/fda-cybersecurity), which include hardware-focused penetration testing alongside SBOM and threat modeling support. ## Frequently Asked Questions ### What are JTAG and UART interfaces? JTAG is a standard for testing and debugging hardware at the chip level, giving direct access to memory and processor state. UART is a serial communication protocol commonly used for console access, logging, or data transfer between components on an embedded board. ### Why are these interfaces considered a security risk? They provide low-level, often privileged access that bypasses software-based authentication and other protections. If left exposed on a shipped device, an attacker with physical access can read memory, extract firmware, or alter device behavior directly. ### How are JTAG and UART typically exposed on a production device? They're usually accessible through headers, labeled test points, or bare solder pads on the circuit board. In many embedded medical devices, these access points remain physically present and functional after manufacturing unless deliberately fused or removed. ### Does the FDA require debug ports to be disabled? The February 3, 2026 guidance requires manufacturers to document how all external interfaces, including debug and test interfaces, are addressed in the threat model and risk assessment. It does not mandate one specific mitigation, but it does require a documented, tested control rather than an unaddressed gap. ## CTA Blue Goat Cyber's hardware penetration testers probe production boards for live JTAG, SWD, and UART access before it becomes an FDA deficiency. [Schedule a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to have your debug interfaces tested and documented correctly. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## NeuroTech Cybersecurity Risks Source: https://bluegoatcyber.com/blog/neurotech-cybersecurity-risks-neurostimulators-eeg-bci # NeuroTech Cybersecurity Risks: Neurostimulators, EEG, & BCI > **[DIRECT ANSWER]** NeuroTech cybersecurity risks arise because neurostimulators, EEG, and BCI devices are software-defined therapy systems where integrity and availability failures, not just data leaks, can directly harm patients. Key threats include unauthorized therapy modification, sensing manipulation, denial of therapy, and update compromise across the implant, controller, app, and cloud. Manufacturers should enforce mutual authentication, anti-replay protections, implant-enforced parameter bounds, signed updates, and full FDA-aligned threat modeling and SBOM documentation. ## Key Takeaways - **NeuroTech cybersecurity is therapy cybersecurity.** Integrity and availability failures can be safety failures. - **Model the entire ecosystem.** Apps, cloud services, and updates often dominate real-world risk. - **Authorization + secure updates are high use.** Get them right early. - **Enforce therapy bounds in the device.** Don’t rely on the phone or UI to keep therapy “in limits.” - **Evidence matters.** Trace threats → requirements/controls → tests → results for FDA-ready documentation. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to neurotech cybersecurity risks the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Quick glossary - **EEG (electroencephalography):** measures brain electrical activity via sensors (electrodes), often streaming data to a mobile app and/or cloud for analysis. - **BCI (brain-computer interface):** translates brain signals (often EEG) into commands or insights (e.g., cursor control, state detection, neurofeedback). - **Closed-loop neuromodulation:** adjusts therapy based on sensed signals/features rather than fixed settings alone. - **SPDF (Secure Product Development Framework):** secure-by-design lifecycle activities integrated into design controls. - **SBOM (Software Bill of Materials):** an inventory of software components and dependencies used to manage supply chain risk over time. - **CVD (Coordinated Vulnerability Disclosure):** a structured way to receive, triage, fix, and communicate vulnerabilities. ## Why NeuroTech is a special kind of cybersecurity problem - **Therapy is software-defined.** Stimulation parameters, modes, and closed-loop thresholds are controlled by software paths. - **Integrity and availability are first-class safety concerns.** “No data leaked” is not a win if therapy can be altered or disrupted. - **Your product is a system-of-systems.** Implant + external controller/programmer + patient app + cloud APIs + update infrastructure + third-party components. - **Neural data can be uniquely sensitive.** Raw signals and derived features can reveal conditions and states users may not expect to be inferable. FDA’s current premarket cybersecurity guidance emphasizes secure-by-design practices, appropriate testing evidence, and lifecycle readiness. See [FDA premarket cybersecurity guidance (final)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) and the [Federal Register notice](https://www.federalregister.gov/documents/2025/06/27/2025-11669/cybersecurity-in-medical-devices-quality-system-considerations-and-content-of-premarket-submissions). ## NeuroTech cybersecurity attack surface (neurostimulators, EEG, BCI) Start with a system view. These are the components that most often create practical risk: ### 1) Wireless links: implant ↔ controller ↔ programmer **Bluetooth Low Energy (BLE)**, proprietary telemetry, near-field communication (NFC), or Wi-Fi bridges can be attacked via spoofing, replay, **man-in-the-middle (MITM)**, or downgrade paths. In NeuroTech, the worst-case isn’t “stolen data”-it’s unauthorized commands or unsafe parameter changes. ### 2) Patient mobile app and accessories If the companion app is compromised (or the phone is rooted/jailbroken), attackers can pivot through authenticated sessions, tokens, cached sensitive data, or local control flows. Treat the app as part of your safety-relevant system boundary. ### 3) Cloud services and APIs Remote monitoring, analytics pipelines, clinician dashboards, and support tooling often become the largest exposure surface. Common failures include broken access control, weak tenant isolation, overly permissive tokens, and insufficient audit logging. ### 4) Update pipeline (firmware/software + keys) Update mechanisms are a favorite target: compromise signing, inject a malicious update, or exploit rollback. For NeuroTech, update security must also define safe interruption behavior and recovery that preserves therapy safety. ### 5) Third-party components and supply chain Connectivity stacks, real-time operating system (RTOS) components, mobile SDKs, and cloud dependencies increase vulnerability exposure over the product lifecycle. If you can’t quickly identify where a vulnerable component is used, response time and compliance suffer. **Threat modeling baseline:** The MITRE/MDIC playbook (funded by FDA) is a strong foundation for structuring medical device threat modeling workshops and outputs: [Playbook for Threat Modeling Medical Devices (MITRE/MDIC)](https://www.mitre.org/sites/default/files/2021-11/Playbook-for-Threat-Modeling-Medical-Devices.pdf). ## Threats that matter most in NeuroTech (and why) - **Unauthorized therapy modification:** attacker changes stimulation parameters, intensity, duty cycle, mode, or closed-loop thresholds. - **Sensing manipulation:** attacker injects/changes signals or derived features to mislead closed-loop control or clinical interpretation. - **Denial of therapy:** attacker drains battery, triggers repeated resets, jams telemetry, or forces lockout states. - **Update compromise:** attacker delivers malicious firmware/software or forces downgrade to a vulnerable version. - **Neural data exposure:** attacker exfiltrates raw neural signals, derived biomarkers, or longitudinal trends from phone/cloud. ## The failure patterns we see repeatedly - **Weak pairing / incomplete authentication.** Proximity or default BLE pairing without device identity and mutual authentication. - **No anti-replay for safety-relevant commands.** If commands can be replayed, therapy integrity can fail without “hacking” the implant directly. - **Authorization gaps.** Sessions are authenticated, but sensitive actions (therapy change, calibration, update) aren’t separately authorized and policy-checked. - **Update security bolted on late.** Key management, rollback protection, and compromise response are missing or undocumented. - **Safety and security documented separately.** Risk documentation doesn’t reflect cyber causes, creating traceability gaps. - **Minimal logging “because constrained.”** Without high-value security events, postmarket triage becomes slow and expensive. ## Controls that work for NeuroTech (secure-by-design, therapy-safe) ### Architecture and trust boundaries - **Define trust zones explicitly.** Implant, programmer, patient app, cloud, and update infrastructure should have clear trust relationships and least privilege. - **Separate roles.** Patient vs clinician vs manufacturing/service access should be distinct-with enforceable authorization in backends and devices. - **Assume the phone is hostile.** Design so a compromised app cannot directly violate therapy safety constraints. ### Identity, authentication, and authorization - **Mutual authentication.** Both endpoints prove identity; don’t rely on “the app knows the device.” - **Strong command authorization.** Therapy changes and updates require higher assurance and explicit policy checks. - **Session hardening.** Short-lived tokens, device-bound sessions where feasible, revocation and re-auth flows that are safe and usable. ### Protocol hygiene (anti-replay, integrity, safe failure) - **Anti-replay/freshness.** Nonces/counters/timestamps with clearly defined failure handling. - **Integrity first.** Encrypt in transit to resist MITM and command manipulation. - **Fail safely.** If integrity checks fail, default to a clinically justified safe mode rather than “continue as normal.” ### Therapy safety constraints enforced in the implant - **Hard parameter bounds.** Enforce safe ranges and rate-of-change limits in the implant, not only in the app/programmer UI. - **Independent safety checks.** Where feasible, decouple safety monitors from communications stacks and complex parsing. ### Secure updates for implantable neurostimulators - **Signed updates + rollback protection.** Verify authenticity before install; prevent downgrade to vulnerable versions. - **Resilient update behavior.** Defined recovery from interruption that preserves therapy safety and avoids bricking. - **Key lifecycle plan.** Rotation, revocation, incident response for compromised signing material-documented before launch. **Engineering baseline:** NISTIR 8259A defines practical baseline cybersecurity capabilities for connected devices (identity, secure update, data protection, logging). It’s not medical-device-specific, but it’s useful for checking coverage: [NISTIR 8259A (IoT device baseline capabilities)](https://csrc.nist.gov/pubs/ir/8259/a/final). **Lifecycle activities:** Many manufacturers map secure development lifecycle activities to IEC 81001-5-1 (health software/health IT security activities across the product life cycle): [IEC 81001-5-1 (publication page)](https://webstore.iec.ch/en/publication/108664). ## Neural data privacy: minimize collection and control secondary use Neural data can be sensitive even when it’s “not PHI” in a traditional clinical sense. Treat privacy as an engineering requirement, not a policy afterthought. - **Minimize collection.** Collect only what you need for clinical/functional intent, and document why. - **Encrypt at rest.** Protect data on device (where applicable), on the phone, and in cloud storage. - **Retention and deletion.** Define retention windows and deletion workflows; make enforcement auditable. - **Access control by design.** Strong tenant isolation, least privilege, and explicit consent boundaries for secondary use. ## FDA expectations: make NeuroTech cybersecurity “submission-ready” FDA’s guidance emphasizes an SPDF, security risk management and threat modeling, security architecture, appropriate cybersecurity testing, transparency, and postmarket readiness: [FDA premarket cybersecurity guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket). If your product meets FDA’s definition of a “cyber device,” be prepared to address FD&C Act Section 524B-related expectations (including postmarket monitoring and vulnerability handling). FDA’s FAQs summarize the statutory framing: [FDA Cybersecurity FAQs (Section 524B / “cyber device”)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs). **Standards alignment helps.** FDA recognizes AAMI TIR57 / ANSI/AAMI SW96:2023 for medical device security risk management-use it to support your risk management approach and vocabulary: [FDA recognized standard: AAMI TIR57](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=34082). Need help translating this into reviewer-friendly evidence (threat model, SBOM, testing, and documentation)? Blue Goat Cyber can help: - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Medical Device Threat Modeling Services](/services/medical-device-threat-modeling) - [FDA-Compliant SBOM Services](/services/fda-compliant-sbom-services-for-medtech) - [Medical Device Cybersecurity Penetration Testing](/services/medical-device-penetration-testing) - [FDA Postmarket Cybersecurity Management Services](/services/fda-postmarket-cybersecurity-services) - [Coordinated Vulnerability Disclosure (CVD)](/) ## NeuroTech cybersecurity checklist (fast self-assessment) - Mutual authentication between device, controller/app, and cloud - Explicit authorization for therapy changes and firmware/software updates - Anti-replay protections for safety-relevant commands - Implant-enforced parameter bounds and safe-state behavior - Signed updates with rollback protection and a key lifecycle plan - SBOM + vulnerability monitoring process (not a one-time export) - Security event logging that supports postmarket triage - CVD intake and response workflow ## Implementation checklist: a practical 30-60 day plan ### Days 1-10: establish the system view - Confirm architecture + data flows (implant, app, programmer, cloud, update infrastructure). - Define assets: therapy integrity/availability, credentials, update keys, neural data, clinical configuration. - Mark trust boundaries and entry points. ### Days 11-30: threat model + requirements that can be tested - Run threat modeling workshops with engineering, QA/RA, and product security. - Decide on mutual authentication, command authorization, anti-replay, secure update, logging, and safe-state behavior. - Write verifiable security requirements mapped to risks and hazards. ### Days 31-60: test, document, and operationalize postmarket - Execute cybersecurity testing (wireless/protocol, mobile, cloud/API, update abuse cases). - Produce an SBOM and implement ongoing monitoring/triage processes. - Stand up CVD: intake, triage, fix, validate, and communicate. - Prepare premarket artifacts: architecture, threat model summary, test evidence, and lifecycle plans. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### Is NeuroTech considered a “cyber device” under FDA rules? Many connected NeuroTech products can qualify if they include sponsor-validated software, can connect to the internet (directly or indirectly), and contain characteristics vulnerable to cybersecurity threats. FDA summarizes the statutory framing in its cybersecurity FAQs. ### What control is most often missing in NeuroTech systems? Strong authorization for sensitive actions (therapy changes, calibration, updates) enforced in the device and backends, not only in the app or programmer UI. ### Do we really need an SBOM for NeuroTech? If you’re in scope for “cyber device” expectations, you should be prepared to provide an SBOM-and show how you’ll maintain and monitor it across the lifecycle. ### How do we connect cybersecurity to medical device risk management? Treat cybersecurity threats as reasonably foreseeable sequences of events that can lead to hazardous situations (e.g., unauthorized parameter change → overstimulation). Then define and verify controls the same way you would for other safety risk controls. ### What should cybersecurity labeling include for NeuroTech devices? Secure configuration guidance, update expectations, supported environments, how to report vulnerabilities, and any cybersecurity-related limitations that affect safe use. ### What’s different about consumer NeuroTech vs medical NeuroTech? Technically, the risks are similar. Practically, the compliance expectations differ, and data practices often receive heavier scrutiny for consumer products, especially around consent and secondary use of sensitive signals. ## Conclusion NeuroTech rewards teams that treat cybersecurity as a design input, not a launch checkbox. Map the system, model realistic abuse cases, build high-use controls (authorization and secure updates), enforce therapy bounds in the device, and keep evidence traceable end-to-end. That’s how you protect patients, and keep regulators, clinical partners, and customers confident. ## Book a Discovery Session If you want an FDA-aligned NeuroTech cybersecurity plan-threat modeling, SBOM, testing, and submission-ready documentation-Blue Goat Cyber can help. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [GSM Cybersecurity Risks for Medical](/blog/gsm-cybersecurity-vulnerabilities-medical-devices) - [QNX Vulnerabilities in Medical Devices](/blog/understanding-qnx-operating-system-vulnerabilities-risks-and-mitigation-strategies) - [IPC Vulnerabilities in Medical Devices](/blog/ipc-vulnerabilities-medical-devices) --- ## NFC and Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/nfc-and-medical-device-cybersecurity # NFC and Medical Device Cybersecurity: What Manufacturers Need to Know > **[DIRECT ANSWER]** NFC secures medical device data transfer through its short physical range, typically a few centimeters, which limits the window for interception and supports encrypted, authenticated device pairing for patient monitoring and drug delivery systems. It reduces one category of risk but does not replace other required controls such as network security, access management, and vulnerability patching, and any NFC interface must still be threat-modeled and documented for FDA premarket review. _Updated October 26, 2024_ In today’s interconnected world, where data is king and cyber threats loom at every corner, the need for [cybersecurity measures](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) has never been greater. This is particularly true in the healthcare industry, where the stakes are high, and lives are on the line. One technology that has emerged as a game-changer in medical device cybersecurity is Near Field Communication or NFC. ## Key Takeaways - NFC secures medical data transfer through short-range communication. - Proximity is a built-in security feature of NFC technology. - NFC supports encrypted and authenticated connections for devices. - It streamlines secure patient monitoring and drug delivery. - NFC helps medical devices comply with security regulations. - The technology addresses medical device cybersecurity challenges. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to nfc and medical device cybersecurity the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding NFC Technology ![Section Image](/imported-images/2953b8e509ac485a.webp) [Near Field Communication (NFC)](https://developer.android.com/develop/connectivity/nfc#:~:text=Near%20Field%20Communication%20(NFC)%20is,between%20two%20Android%2Dpowered%20devices.) is a remarkable wireless communication technology that has revolutionized the way devices interact with each other. It enables the transfer of data between two devices by simply bringing them close together, typically within a few centimeters. This proximity requirement ensures secure data transfer and enhances user convenience in various applications. ### What is NFC? NFC operates on the principle of electromagnetic induction, allowing devices in close proximity to communicate and exchange information seamlessly. This technology is widely used in contactless payment systems, access control systems, and data sharing between smartphones, making it an integral part of our daily lives. ### How Does NFC Work? Unlike other wireless technologies like Bluetooth or Wi-Fi, NFC operates over shorter distances, typically within a range of a few centimeters. This close proximity requirement adds a layer of security, significantly reducing the risk of unauthorized access. At its core, NFC relies on two main components: an NFC initiator and an NFC target. The initiator actively generates an RF signal to establish a connection, while the target responds to this signal by transmitting data back to the initiator. This two-way communication enables and secure data transfer between devices. NFC technology has evolved to support various modes of operation, including card emulation mode, reader/writer mode, and peer-to-peer mode. Each mode serves specific purposes, such as enabling smartphones to act as contactless payment cards or facilitating data exchange between devices without complex pairing processes. ## The Role of NFC in Medical Devices ![Section Image](/imported-images/ea5ae8254713b327.webp) Near Field Communication (NFC) technology has been making significant strides in the healthcare industry, particularly in enhancing the security and efficiency of medical devices. By enabling short-range wireless communication between devices, NFC offers a secure method for transferring data, making it a valuable tool for safeguarding sensitive patient information. ### NFC in Patient Monitoring Systems Patient monitoring systems are critical in healthcare, providing real-time insights into patients’ conditions. By incorporating NFC technology, these devices can ensure the secure and accurate transmission of vital signs data to healthcare professionals. NFC-enabled devices can also streamline patient data collection, minimizing errors and enhancing patient care. NFC technology can facilitate integration with electronic health records (EHR) systems, allowing for efficient data sharing and analysis. This integration improves the overall quality of patient care and enhances the interoperability of medical devices within healthcare facilities. ### NFC in Drug Delivery Systems Another area where NFC shines in medical devices is in drug delivery systems. NFC-enabled packaging can provide valuable information about the medication, such as dosage instructions and expiration dates. Additionally, NFC can ensure the authenticity of medications, enabling healthcare providers to detect counterfeit drugs and protect patient safety. NFC technology can enable automatic medication adherence tracking, helping healthcare providers monitor patient compliance and intervene when necessary. This real-time data collection can lead to more personalized treatment plans and improved patient health outcomes. ## Cybersecurity Challenges in Medical Devices While the potential benefits of NFC in securing medical devices are undeniable, it’s crucial to acknowledge the cybersecurity challenges in this space. With the rapid advancement of technology in the healthcare industry, integrating medical devices with network connectivity has revolutionized patient care. However, this digital transformation has also opened new avenues for exploiting cyber threats and vulnerabilities. As medical devices become more interconnected and sophisticated, the need for cybersecurity measures becomes increasingly critical to safeguard patient information and ensure the integrity of healthcare services. ### Potential Threats and Vulnerabilities Medical devices are prime targets for cyberattacks, as they often house sensitive patient data and directly connect to hospital networks. From unauthorized access to patient records to manipulating device functionality, medical device cybersecurity threats are varied and ever-evolving. One key challenge in securing medical devices is the [diverse range of legacy systems](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) that may lack built-in security features or receive regular software updates. This creates vulnerabilities that malicious actors can exploit to gain unauthorized access to the devices and compromise patient data. Additionally, the proliferation of [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) devices in healthcare settings further complicates the cybersecurity landscape, as each connected device represents a potential entry point for cyber threats. ### The Consequences of Cybersecurity Breaches The consequences of cybersecurity breaches in medical devices can be dire. In addition to the potential compromise of patient data, breaches can lead to disruptions in medical procedures, compromise patient safety, and impact the reputation of healthcare organizations. The urgency to address these vulnerabilities cannot be overstated. The [interconnected nature of healthcare systems](/blog) means that a cybersecurity breach in one medical device can have cascading effects across an entire network, potentially affecting multiple facets of patient care. The financial implications of such breaches can also be significant, with healthcare organizations facing regulatory fines, lawsuits, and costly remediation efforts to restore trust and security in their systems. ## NFC as a Cybersecurity Solution Recognizing the immense cybersecurity challenges in medical devices, NFC technology emerges as a promising solution to safeguard patient data and ensure the integrity of healthcare operations. The need for cybersecurity measures becomes increasingly critical as the healthcare industry digitizes and incorporates IoT devices. NFC technology, known for its convenience and security, offers a viable solution to address these concerns. Integrating NFC into medical devices allows healthcare providers to enhance data protection, streamline operations, and improve patient care outcomes. ### Enhancing Data Protection with NFC NFC can significantly enhance data protection in medical devices by enabling [secure encryption and authentication protocols](/blog/securing-communication-protocols-in-medical-devices). By using NFC’s short-range capabilities, healthcare organizations can establish secure connections and protect sensitive data from unauthorized access. NFC technology provides an added layer of security by requiring physical proximity for data transmission. This proximity requirement ensures that data exchanges between devices are secure and minimizes the risk of interception by malicious actors. With NFC, healthcare providers can confidently transmit sensitive information, knowing that advanced encryption mechanisms protect it. ### NFC for Secure Device Pairing In addition to data protection, NFC can play a crucial role in secure device pairing. By using NFC technology, medical devices can establish secure connections with other devices, ensuring that only authorized devices can communicate with each other. This mitigates the risk of unauthorized access and reduces the potential for cyberattacks. NFC-enabled device pairing simplifies the integration of new medical devices into existing networks. Healthcare facilities can easily add new devices to their infrastructure without compromising security or causing disruptions to operations. This connectivity facilitated by NFC enhances the efficiency of healthcare workflows and promotes interoperability among various medical devices. ## Future Trends in NFC and Cybersecurity As technology evolves rapidly, staying informed about the emerging trends in NFC and cybersecurity in the healthcare industry is essential. ![Section Image](/imported-images/69f3f9ffeae0aebb.webp) In addition to the advancements in NFC technology, another area of interest is integrating blockchain technology with NFC for enhanced security. By combining blockchain’s tamper-resistant nature with NFC’s convenience, healthcare providers can ensure the integrity and confidentiality of patient data during transmission and storage. ### Emerging NFC Technologies for Medical Devices New advancements in NFC technology are paving the way for even more secure healthcare solutions. These emerging NFC technologies are promising to fortify medical device cybersecurity, from improved encryption algorithms to advanced authentication methods. Near Field Communication (NFC) use in medical devices is not limited to data transfer alone. NFC-enabled devices can also be leveraged for inventory management, asset tracking, and even patient monitoring, providing healthcare facilities with a solution for improving operational efficiency. ### The Evolving Landscape of Cybersecurity in Healthcare Cybersecurity in healthcare is a dynamic field that constantly evolves to keep up with the ever-growing threat landscape. Ongoing research and collaboration among industry experts drive innovation in cybersecurity practices, ensuring that medical devices remain protected against emerging threats. Implementing artificial intelligence and machine learning algorithms in cybersecurity systems revolutionizes how healthcare organizations detect and respond to security incidents. By analyzing vast amounts of data in real-time, AI-powered cybersecurity solutions can proactively identify anomalies and potential threats, strengthening the overall security posture of healthcare networks. ## Conclusion NFC is poised to revolutionize cybersecurity in medical devices, offering enhanced data protection, secure device pairing, and countless applications in patient care. As the healthcare industry continues embracing digital transformation, the importance of cybersecurity measures cannot be overstated. NFC provides a powerful tool to address medical devices’ cybersecurity challenges, ultimately ensuring patients’ safety and well-being. The urgency for advanced cybersecurity measures intensifies as the healthcare sector continues to integrate NFC technology into medical devices. Blue Goat Cyber stands at the forefront of this evolution, offering unparalleled expertise in safeguarding your medical devices against cyber threats. With our veteran-owned leadership and services, we ensure your operations meet the highest standards of HIPAA and FDA compliance. Don’t let the complexities of cybersecurity hinder your progress in the digital healthcare landscape. [Contact us today for cybersecurity help](/contact), and let us tailor a security strategy that fortifies your medical devices, protects patient data, and supports your mission to deliver exceptional care. Your security is our priority, and with Blue Goat Cyber, you can focus on what you do best-saving lives. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What is NFC in the context of medical devices? NFC in medical devices refers to Near Field Communication technology used for secure, short-range wireless data exchange between devices. It enhances security by requiring close proximity for communication, reducing the risk of unauthorized interception and Ensure data integrity. ### How does NFC improve medical device cybersecurity? NFC improves medical device cybersecurity by enabling secure data encryption, authentication protocols, and secure device pairing. Its short operational range minimizes the attack surface, protecting sensitive patient data and device functionality from cyber threats. ### Can NFC help with FDA compliance for medical devices? Yes, NFC can indirectly support FDA compliance by enhancing the security of medical devices, which is a key requirement of the FDA's February 3, 2026 final guidance. By facilitating secure communication and data protection, NFC contributes to the overall safety and effectiveness mandated by the FDA. ### What are the limitations of NFC for medical device security? While highly secure due to its short range, NFC's primary limitation is that very close physical access is needed for interaction. It is not suitable for long-range data transmission or remote monitoring applications that require continuous, distant connectivity. Other security measures are still necessary for a complete cybersecurity posture. ### Does NFC replace other cybersecurity measures in medical devices? No, NFC does not replace other cybersecurity measures but rather complements them. It provides an additional layer of security for specific short-range interactions. A complete cybersecurity strategy for medical devices integrates NFC with other controls like network security, access management, and vulnerability patching. ### How is NFC used in patient monitoring systems? In patient monitoring systems, NFC ensures the secure and accurate transmission of vital signs data to healthcare professionals. It can also streamline data collection, minimize errors, and facilitate integration with electronic health records, protecting patient information during transfers. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [RFID and Medical Device Cybersecurity](/blog/rfid-medical-devices-cybersecurity) - [Debunking 5 Med Device Cybersecurity Myths](/blog/debunking-the-top-5-medical-device-cybersecurity-myths-holding-back-innovation) - [Medical Device Cybersecurity Assessment](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist) - [Medical Device Inventory for Cybersecurity](/blog/conducting-a-comprehensive-medical-device-inventory-for-enhanced-cybersecurity) --- ## Medical Device OTA Update Vulnerabilities Source: https://bluegoatcyber.com/blog/ota-update-vulnerabilities # Medical Device OTA Update Vulnerabilities: What Manufacturers Need to Know > **[DIRECT ANSWER]** OTA update vulnerabilities in medical devices arise when packages aren't cryptographically signed, transport isn't encrypted, or a device installs updates without verifying their source, letting an attacker push malicious firmware or intercept sensitive data. The FDA's premarket cybersecurity guidance treats secure update mechanisms as a lifecycle requirement, so manufacturers need digital signatures, encrypted delivery over channels like HTTPS, tamper-evident update logs, and regular audits documented as verification evidence. _Reviewed July 24, 2026_ OTA updates are a core part of modern device management. They let manufacturers push software changes without physical access, keeping devices current and functionally sound. They also introduce a specific class of security risks that need to be engineered out from the start, not patched after the fact. ## Key Takeaways - OTA updates introduce vulnerabilities at each stage. - Spoofing and data theft are critical risks. - Weak verification leads to compromised updates. - Secure updates require authentication and encryption. - AI and blockchain enhance future OTA security. - Regulatory compliance is essential for medical devices. ## Why this matters Unaddressed OTA update vulnerabilities can directly compromise patient safety through device malfunction, exposure of sensitive patient data, and disruption of clinical operations. The FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 treats secure update mechanisms as a fundamental requirement throughout the total product lifecycle, not just at launch. Section 524B of the FD&C Act gives the FDA authority to reject premarket submissions that don't demonstrate adequate security controls for software updates. Standards including IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide the frameworks for identifying and controlling cybersecurity risks associated with software updates. Manufacturers who treat OTA security as optional will face regulatory non-compliance, adverse events, and serious reputational damage. The FDA expects evidence of systematic controls, and reviewers know what a well-engineered update process looks like. ## Understanding OTA Updates ### The Role of OTA Updates in Modern Technology OTA updates let manufacturers push software changes directly to deployed devices without physical contact. That convenience matters for medical devices, which may be distributed across many clinical sites and difficult to service in person. The convenience has limits, though. A poorly designed update process is an open door for attackers. An update that doesn't verify its own integrity can be replaced with something malicious in transit. A device that accepts unsigned updates is trusting the network, which is not a safe assumption in healthcare environments. Each stage of the OTA pipeline deserves the same scrutiny as the device software itself. ### The Process of OTA Updates An OTA update moves through three stages: package creation, delivery, and installation. Developers compile software changes into a package. That package travels to the device over Wi-Fi, cellular, or another network path. The device installs it, ideally without requiring manual intervention from clinical staff. Each of those stages is a potential [entry point for attack](/blog/cybersecurity-attack-entry-points-for-medical-devices). A package intercepted in transit can be modified before delivery. An installation process that doesn't validate the package signature before applying it will install whatever it receives. User permission prompts, if present, can be bypassed if users don't understand what they're authorizing. Security controls must address all three stages, not just one. ## Identifying the Vulnerabilities in OTA Updates ### Potential Security Risks Spoofing is among the most serious OTA attack vectors. An attacker who can impersonate a legitimate update server can push malicious firmware to any device that trusts that source. Devices that lack cryptographic verification of update packages are particularly exposed. ![Section Image](/imported-images/bd31c4ca1be33a49.png) Weak or missing verification is the root cause of most OTA compromises. If a device doesn't confirm that an update came from the expected source and hasn't been modified, it will install whatever arrives. For a medical device, that could mean running attacker-controlled code in a clinical setting. The data transmitted as part of an update can also be intercepted if the channel isn't encrypted, exposing configuration details or patient information that's bundled with the update payload. ### Impact on Device Performance Security failures in OTA updates don't always look like security failures. Sometimes they look like device bugs. A compromised update can cause sluggish operation, unexpected crashes, or partial loss of functionality. Clinical staff troubleshooting a device that "just started acting up" after an update may not immediately recognize it as a security event. Manufacturers who invest in update process security reduce both attack risk and the operational disruptions that compromise updates cause. The pressure to ship updates quickly is real, but skipping validation to meet a deadline is how bad code reaches production devices. For medical devices specifically, a faulty update is not just a software problem. It's a patient safety concern. ## The Real-World Consequences of OTA Update Vulnerabilities ### Breaches and Data Theft The most severe OTA incidents result in data breaches. Attackers who compromise an update server or intercept update traffic can potentially access patient records, device configuration data, or credentials. Once patient data is exposed, the consequences run in multiple directions simultaneously: regulatory penalties, legal liability, remediation costs, and lasting damage to patient trust. The psychological impact on patients shouldn't be underestimated. People who learn their medical device was compromised often lose confidence in the technology and the institution managing it. That lost confidence can affect future care-seeking behavior, which becomes a public health problem in its own right. ### Device Malfunction and User Experience OTA failures that affect device behavior put clinical staff in a difficult position. A [smart thermostat](https://www.foxnews.com/tech/another-home-thermostat-found-vulnerable-to-attack) that stops responding after an update is a nuisance. A patient monitoring system that fails the same way is an emergency. Clinicians who can't rely on device readings are forced to work around the technology, which adds time and cognitive load to already demanding workflows. User trust erodes quickly after device failures. When a device doesn't behave as expected, clinicians share those experiences. Negative word of mouth spreads across clinical networks and influences purchasing decisions. Manufacturers who cut corners on OTA security pay for it repeatedly, in returns, service calls, and lost contracts. ## Mitigating the Risks: Solutions for OTA Update Vulnerabilities ### Best Practices for Secure OTA Updates Secure OTA updates require authentication, integrity verification, and encrypted transport. Digital signatures on update packages confirm that the package came from a known source and hasn't been modified. Without verification, the device is trusting the network, which is not a sound security assumption. ![Section Image](/imported-images/3b2bb0f6fc1f767d.png) Delivery over [HTTPS](/blog) encrypts the update payload in transit, preventing interception and tampering. This is a baseline control, not an advanced one. Encrypting the update package itself adds an additional layer that protects the payload even if the transport channel is somehow compromised. Regular audits of the OTA process help manufacturers find weaknesses before attackers do, and they provide the documented evidence the FDA expects in premarket cybersecurity submissions. ### Advanced Security Measures for OTA Updates Machine learning algorithms that monitor update behavior can detect anomalies, flagging unusual traffic patterns or unexpected package characteristics before a malicious update reaches a device. Integrating real-time threat intelligence feeds keeps manufacturers aware of new attack techniques targeting OTA mechanisms. Building security literacy across the organization is just as important as the technical controls. Clinical staff, IT teams, and developers all interact with the OTA process at different points. When everyone understands why OTA security controls exist and what failure looks like, the organization responds faster and more effectively to incidents. Regular security training and clear incident reporting procedures support that readiness. ## The Future of OTA Updates ### Predicted Trends in OTA Update Security Demand for connected medical devices will keep growing, and so will the sophistication of attacks targeting them. The industry is moving toward standardized OTA security frameworks that provide consistent baseline protections across device categories. AI-assisted anomaly detection is becoming more accessible and will increasingly be a standard component of OTA security architectures. As [IoT](/blog) connectivity expands in healthcare, the sheer number of devices requiring secure updates makes manual oversight impractical. Automated security monitoring and self-healing update mechanisms will become necessary, not optional. ### Innovations in OTA Update Technology Blockchain-based update logs create tamper-evident records of every update applied to a device. If a device receives an unauthorized update, the log discrepancy is detectable. Manufacturers investing in this approach gain both a security control and an audit trail that supports regulatory compliance. Device interfaces are also improving. Clearer update notifications that explain what's changing and why give clinicians and patients the information they need to make informed decisions about accepting updates. Security and usability aren't in conflict here. Better communication builds the kind of trust that makes OTA updates an asset rather than a liability. ## Conclusion OTA update security is an engineering discipline, not a feature. Getting it right requires cryptographic verification, encrypted transport, regular auditing, and a development culture that treats security as a first-order concern. Blue Goat Cyber supports medical device manufacturers through exactly this kind of work, aligning with FDA, IEC 62304, and EU MDR requirements. Our team brings top-tier certifications and hands-on experience with premarket submissions and postmarket resilience. Don't let OTA vulnerabilities put your devices or your patients at risk. [Contact us today for cybersecurity help](/contact) and build a secure update foundation for your medical technology. ## How Blue Goat approaches this Blue Goat Cyber's approach to securing medical device OTA updates focuses on methodical risk identification and tailored mitigation strategies. We conduct in-depth analyses of update architectures, scrutinizing each stage from package generation and signing to secure delivery protocols and on-device installation validation. Our OSCP-certified penetration testers and ex-military red team experts simulate real-world attacks, uncovering weaknesses in authentication, encryption, and integrity verification. We provide actionable recommendations aligned with regulatory expectations and current threat landscapes. Our services include thorough documentation and remediation support, ensuring that medical device manufacturers meet and exceed security requirements. When partnering with us for FDA premarket cybersecurity services, if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We emphasize rigorous controls to protect sensitive health data and maintain device functionality. ## FAQ ### What are the primary security risks of medical device OTA updates? Primary security risks include spoofing attacks, where malicious updates are pushed, and data breaches due to inadequate verification mechanisms. Faulty updates can also compromise device functionality or expose sensitive patient information. ### How can medical device manufacturers secure their OTA update processes? Manufacturers should implement strong authentication, digital signatures for update package integrity, and encrypt transmissions using protocols like HTTPS. Regular security audits and threat intelligence integration also help identify and mitigate vulnerabilities. ### Does the FDA address OTA update security for medical devices? Yes, the FDA's February 3, 2026 final guidance on cybersecurity in medical devices emphasizes the importance of secure updates. It outlines expectations for managing postmarket vulnerabilities, including those related to OTA update mechanisms, to ensure continued device safety and effectiveness. ### What happens if a medical device receives a compromised OTA update? A compromised OTA update can lead to severe consequences, including device malfunction, operational disruption, unauthorized access to sensitive patient data, or even complete loss of device functionality. This significantly impacts patient safety and trust. ### What advanced technologies can enhance OTA update security? Advanced technologies for enhancing OTA update security include machine learning algorithms for anomaly detection in update patterns and blockchain for creating tamper-proof update logs. These innovations add layers of protection against evolving cyber threats. ### How do OTA update vulnerabilities affect medical device performance? Vulnerabilities in OTA updates can cause device performance degradation, leading to sluggish operation, crashes, or complete loss of functionality. Such issues directly impact clinical workflows and patient care. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## PACS Vulnerabilities in Medical Devices (2026) Source: https://bluegoatcyber.com/blog/pacs-medical-device-vulnerabilities # PACS Vulnerabilities in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** PACS vulnerabilities in medical imaging systems fall into three categories: software flaws like outdated components and weak authentication, hardware weaknesses such as default passwords and unpatched firmware, and network issues including unencrypted DICOM traffic and flat architectures. These gaps can expose protected health information, delay diagnoses, and disrupt clinical workflows. Mitigation requires regular audits, vulnerability assessments, encryption, network segmentation, patch management, and staff training aligned with the FDA's lifecycle cybersecurity expectations. Healthcare institutions depend on [Picture Archiving and Communication Systems (PACS)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1718393/) to manage medical imaging data. These systems let healthcare professionals store, access, and share patient images through a single digital infrastructure, improving diagnostic speed and patient care. Like any networked technology, though, PACS devices carry vulnerabilities that can compromise data security and patient privacy. This guide covers the major PACS vulnerability categories and lays out practical strategies to detect and reduce those risks. ## Key Takeaways - PACS vulnerabilities: software flaws, hardware weaknesses, network issues. - Mitigation: regular audits, vulnerability assessment tools. - Implement strong security protocols and encryption. - Keep systems updated with latest software and patches. - Train employees on cybersecurity best practices. - Protect patient data, maintain system integrity. ## Why this matters Unaddressed PACS vulnerabilities can cause data breaches, operational outages, and direct harm to patients. A breach of protected health information (PHI) stored in PACS triggers HIPAA penalties, reputational damage, and the slow erosion of patient trust. The FDA's *Cybersecurity in Medical Devices* Final Guidance, dated February 3, 2026, makes clear that manufacturers and healthcare providers share responsibility for managing cybersecurity risks across a device's full lifecycle. Proactive risk management is not optional; it's a prerequisite for demonstrating safety and effectiveness. Compliance with IEC 81001-5-1, ISO 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 establishes the baseline for a secure PACS environment. Failing to meet these standards exposes organizations to legal liability and puts patient care at risk. Good PACS cybersecurity isn't a checkbox exercise; it's an engineering discipline that protects both patient data and the continuity of clinical operations. ## Understanding PACS Medical Devices PACS, short for Picture Archiving and Communication Systems, is the digital backbone for medical images including X-rays, CT scans, and MRIs. These systems give healthcare professionals on-demand access to imaging studies, which speeds up diagnosis and supports better treatment planning. ![Section Image](/imported-images/2dc90404bea87f0a.webp) Beyond simple storage, PACS supports advanced functions such as image manipulation, annotation, and side-by-side comparison. Radiologists and other clinicians use these capabilities to analyze studies with a level of precision that film-based workflows never could have delivered. ### The Role of PACS in Healthcare PACS eliminated the delays and costs of physical film handling. Images are now available to authorized personnel within seconds, whether they're across the hall or across the country. That speed matters when a trauma patient needs an immediate read. Integration with Electronic Health Records (EHR) systems takes this further, giving providers a longitudinal view of a patient's imaging history alongside clinical notes and lab data. Decisions get better when clinicians see the full picture, not just the most recent scan. ### Components of PACS Systems A PACS has three interlocking parts: hardware, software, and network infrastructure. Hardware includes servers, workstations, archiving devices, and storage systems. Software covers the image viewer, database, and communication tools. The network ties all of it together, carrying image data between components and out to clinical endpoints. Modern PACS platforms increasingly incorporate AI-assisted image analysis, helping radiologists detect subtle findings that might otherwise be missed. These tools add diagnostic value but also widen the attack surface, since any software component can introduce new vulnerabilities. ## The Importance of PACS Cybersecurity PACS systems are not passive repositories. They drive time-sensitive diagnosis and treatment decisions. A compromise of PACS availability or data integrity translates directly into delayed or incorrect care, which makes security a clinical concern, not just an IT one. ### Potential Risks of PACS Vulnerabilities PACS vulnerabilities put [patient privacy](/blog) and data integrity at serious risk. Unauthorized access to patient images can expose confidential information, opening the door to identity theft. Attackers can also exploit PACS weaknesses to seize control of hardware or inject malicious software, disrupting operations at exactly the wrong moment. Healthcare organizations need layered defenses: regular security assessments, up-to-date software, and strict access controls. Getting these right reduces the window of opportunity attackers rely on and keeps patient information where it belongs. ### The Impact of Security Breaches on Patient Care A PACS breach cascades fast. Delayed diagnoses, misread images, and disrupted treatment workflows are the immediate clinical consequences. The financial damage follows close behind: regulatory fines, legal fees, and remediation costs can run into the millions, to say nothing of what a reputation hit does to patient volume over time. Investing in PACS cybersecurity is far cheaper than recovering from an incident. Prevention is the right frame here, not reaction. ## Identifying Common PACS Vulnerabilities Securing PACS in a healthcare setting means understanding where attackers actually find openings. There are three main categories. ### Software Weaknesses PACS software carries the same risks as any complex application: coding errors, outdated third-party components, and weak authentication mechanisms. Attackers actively look for unpatched dependencies and known CVEs in DICOM-related libraries. Delayed patching is one of the most common failure modes. Healthcare IT teams juggle many competing demands, and PACS update windows often get deferred. A disciplined patch management process with defined SLAs for critical patches is the practical fix. ### Hardware Vulnerabilities Hardware weaknesses include default or weak passwords on workstations and servers, outdated firmware on storage devices, and poorly secured physical infrastructure. Any of these can give an attacker a foothold. Hardening checklists, regular configuration reviews, and periodic penetration testing catch these issues before they're exploited. Physical access controls matter too; an unsecured server room is an invitation. ### Network Security Issues The network connecting PACS components is a frequent target. Weak or absent encryption, flat network architectures with no segmentation, and unsecured wireless access points all create exploitable paths. Enforcing TLS for all DICOM traffic, segmenting PACS onto a dedicated VLAN, and requiring multi-factor authentication for administrative access are the foundational controls. Continuous network monitoring adds the detection layer needed to catch anomalies when they appear. ## Strategies for Detecting PACS Vulnerabilities ![Section Image](/imported-images/535be394078ffe3a.webp) Proactive detection is what separates organizations that catch vulnerabilities from those that discover breaches through a news story. Two practices deliver the most value for [protecting patient data and maintaining the integrity of medical](/blog/medical-device-cybersecurity-best-practices) records. ### Regular System Audits System audits give you a structured look at hardware configurations, software versions, access control settings, and network infrastructure. Done well, they surface gaps before attackers find them. During an audit, cybersecurity engineers verify that encryption is actually in place, authentication mechanisms meet current standards, and access is limited to what each role actually needs. Quarterly audits are a reasonable baseline; post-incident or post-change audits are additional checkpoints worth building into change management. ### Vulnerability Assessment Tools Automated scanning tools identify known CVEs in PACS components and test whether security controls are working as designed. The output gives IT teams a prioritized remediation list. More sophisticated tools simulate attacker behavior to find vulnerabilities that signature-based scanners miss. Used together with manual penetration testing, they give a much more accurate picture of actual risk than either approach alone. ## Mitigating PACS Vulnerabilities Identifying vulnerabilities is step one. Acting on them is what actually reduces risk. Healthcare organizations need targeted mitigation strategies, not generic security policies copied from another industry. A solid risk assessment maps out which attack vectors pose the greatest threat given the specific PACS architecture, network topology, and clinical workflow. Penetration testing validates that assessment against real-world techniques. ### Implementing Security Protocols Access controls, encryption, and current software versions are the core controls. Enforcing role-based access ensures that a radiology tech can't see administrative functions, and an IT contractor can't pull patient studies. Multi-factor authentication for any privileged access adds a second barrier even when credentials are stolen. ### Regular System Updates and Patches Every unpatched vulnerability is an open invitation. PACS vendors issue security advisories; subscribing to those feeds and tracking them against your installed versions is a basic operational discipline that many organizations still skip. Beyond software patches, staying current on emerging threat intelligence lets teams address risks before CVEs are widely exploited. ### Employee Training and Awareness Human error drives a large share of security incidents. Phishing, misconfigured settings, and ignored security alerts all trace back to people making uninformed decisions. Regular training helps staff recognize social engineering attempts, understand why secure practices matter, and know exactly what to do when something looks wrong. Trained staff are a genuine defensive layer. ## Future Trends in PACS Security ![Section Image](/imported-images/de00f8d3e004cbab.webp) ### Advances in Encryption Technology Encryption protects patient data at rest and in transit. As quantum computing matures, traditional RSA and ECC algorithms face a credible long-term threat. Quantum-resistant algorithms, such as those based on lattice cryptography (now being standardized by NIST), are the right direction for organizations planning PACS infrastructure investments that will last a decade or more. ### The Role of Artificial Intelligence in Security AI-powered tools bring real value to PACS security through behavioral anomaly detection and predictive analysis. By establishing a baseline of normal user behavior, AI algorithms can flag account activity that deviates significantly from that baseline, such as a single user pulling thousands of studies at 2 a.m. That early signal is often the difference between catching a breach and missing it entirely. ### Regulatory Changes and Their Impact on PACS Security The FDA's February 3, 2026 guidance on premarket cybersecurity has already raised the bar for new devices. The EU's Medical Device Regulation (MDR) adds cybersecurity requirements for CE-marked devices. Staying current with these requirements and building security documentation as design-controlled artifacts, not afterthoughts, is how organizations stay ahead of the compliance curve rather than scrambling to catch up. ## Conclusion PACS vulnerabilities are a serious, specific threat to patient data and clinical operations. Understanding where the weaknesses sit, detecting them systematically, and applying targeted mitigations gives healthcare organizations real protection. Advances in encryption, AI-based detection, and an increasingly specific regulatory framework will continue shaping PACS security requirements. Getting ahead of those changes now is far better than responding to a breach later. Partnering with a cybersecurity team that knows medical device regulations is the most efficient path. Blue Goat Cyber specializes in PACS and medical device cybersecurity, including penetration testing, HIPAA compliance, and FDA submission support. [Contact us today for cybersecurity help](/contact) and put your vulnerabilities to rest with solutions built specifically for healthcare environments. ## How Blue Goat approaches this Blue Goat Cyber addresses PACS medical device vulnerabilities through a structured methodology focused on identifying and neutralizing threats. Our services begin with thorough threat modeling to pinpoint potential weaknesses at every stage of the PACS lifecycle. We then conduct targeted penetration testing, simulating real-world attacks to uncover exploitable vulnerabilities in software, hardware, and network configurations. Our team, composed of experts with CISSP and OSCP certifications and ex-military red team experience, provides actionable recommendations tailored to your specific PACS environment. For medical device manufacturers, we offer specialized FDA premarket cybersecurity services to ensure devices meet regulatory requirements before deployment. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Our postmarket cybersecurity services ensure ongoing protection through continuous monitoring and incident response planning, helping healthcare organizations maintain the integrity and security of their PACS systems against current and emerging threats. We deliver effective, hands-on security solutions. ## FAQ ### What are common PACS software vulnerabilities? Common PACS software vulnerabilities include coding errors, outdated components, and inadequate authentication mechanisms. These weaknesses can allow unauthorized access or compromise system integrity. ### How do hardware vulnerabilities affect PACS systems? Hardware vulnerabilities in PACS systems can involve weak passwords on devices, outdated firmware, and insecure physical infrastructure. These points create entryways for attackers to infiltrate the system and access sensitive data. ### What network security issues impact PACS? Network security issues impacting PACS include weak encryption protocols, unsecured wireless networks, and insufficient network segmentation. These can lead to unauthorized access and data breaches. ### How can healthcare organizations detect PACS vulnerabilities? Healthcare organizations can detect PACS vulnerabilities through regular system audits and by using vulnerability assessment tools. These methods help identify weaknesses and test security control effectiveness. ### What does the FDA say about medical device cybersecurity? The FDA's February 3, 2026 final guidance outlines cybersecurity requirements for medical devices, emphasizing the need for manufacturers to ensure devices are secure throughout their lifecycle. Manufacturers must demonstrate security control effectiveness and address identified vulnerabilities. ### Why is employee training important for PACS security? Employee training matters for PACS security because human error is a significant factor in security breaches. Training helps staff understand data security importance, recognize threats, and follow best practices to prevent incidents. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## PATCH Act: Legacy Device Cyber Gaps | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/patch-act-only-applies-to-new-medical-devices-leaves-legacy-systems-a-risk # PATCH Act Cybersecurity Rules for New Medical Devices > **[DIRECT ANSWER]** The PATCH Act became section 524B of the FD&C Act through the Consolidated Appropriations Act, 2023, and it applies only to cyber devices in premarket submissions filed after March 29, 2023, with refuse-to-accept enforcement starting October 1, 2023. Devices cleared before that date carry no comparable mandate for SBOMs, vulnerability handling, or patching plans. Millions of fielded legacy devices sit outside the law's reach even though they run for a decade or longer with weaker security controls than anything a current submission would allow. _Reviewed September 17, 2026_ Hospitals run infusion pumps, imaging systems, and patient monitors that were cleared long before Congress wrote a single word of cybersecurity law into the FD&C Act. Those devices keep functioning for years, sometimes decades, and none of them were ever required to include a software bill of materials or a documented vulnerability handling process. The PATCH Act closed that gap for new submissions, but it left the installed base of legacy devices exactly where it found them. Manufacturers and hospitals that assume the law protects everything on their network are wrong, and that assumption carries clinical and financial risk. ## Key Takeaways - The PATCH Act's requirements now live in section 524B of the FD&C Act, added by the Consolidated Appropriations Act, 2023. - Section 524B only reaches cyber devices in premarket submissions filed after March 29, 2023, with refuse-to-accept enforcement starting October 1, 2023. - Devices cleared before that window have no statutory cybersecurity mandate, regardless of how connected they are today. - Legacy devices commonly lack an SBOM, a coordinated disclosure process, and a documented patching capability that 524B requires of new submissions. - Manufacturers can voluntarily backfill SBOMs and compensating controls for fielded products even though the law does not compel it. - Hospitals need inventory and network segmentation programs because regulation will not retroactively secure equipment already in service. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* guidance, first issued in September 2023, updated June 27, 2025, and finalized again February 3, 2026, describes what section 524B requires of a premarket submission. None of those three guidance versions reach back to devices already cleared. That is a statutory limit, not a policy choice the FDA can waive, because section 524B itself defines its scope by submission date rather than by a device's current risk profile. The result is a two-tier fleet inside most health systems. Newer connected devices arrive with SBOMs, vulnerability disclosure commitments, and update mechanisms baked into their design controls. Older devices, some still under active service contracts, were built and cleared under premarket review that never asked those questions. A hospital's biomedical engineering team can be fully compliant with every purchase order it signs today and still operate a fleet where a majority of devices predate any cybersecurity submission requirement at all. This gap matters because attackers do not care when a device was cleared. A ventilator cleared in 2015 and a ventilator cleared in 2025 present the same attack surface to a threat actor scanning a hospital network, but only one of them has a documented vulnerability response path. Treating section 524B as a complete cybersecurity solution for a hospital fleet misreads what the law actually covers. ## What Was the PATCH Act and How Did It Become Section 524B? The PATCH Act, short for the Protecting and Transforming Cyber Healthcare Act, was proposed legislation that set out premarket cybersecurity requirements for medical devices. Its substantive language did not pass as a standalone bill. Congress instead folded that language into the Consolidated Appropriations Act, 2023, which added section 524B to the Federal Food, Drug, and Cosmetic Act. Section 524B requires manufacturers of "cyber devices" to submit a plan for identifying and addressing vulnerabilities, to maintain processes for providing reasonable assurance of device security throughout its lifecycle, and to provide an SBOM. A cyber device under the statute is one that can connect to the internet, contains software, and has technological characteristics that could be vulnerable to cybersecurity threats. That definition is broad enough to catch most connected devices going through premarket review today. **[KEY REQUIREMENT]** A submission for a cyber device must include a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities, a process that provides reasonable assurance the device and related systems are cybersecure, and a software bill of materials, or the FDA can refuse to accept the submission for review. | Section 524B origin | Detail | |---|---| | Source legislation | Consolidated Appropriations Act, 2023 (PATCH Act language) | | Codified as | Section 524B of the FD&C Act | | Applies to submissions filed | On or after March 29, 2023 | | Enforcement mechanism begins | October 1, 2023, via refuse-to-accept review | | Governing guidance chain | September 27, 2023 final, June 27, 2025 update, February 3, 2026 final | ## Which Devices Does Section 524B Actually Reach? Section 524B reaches only cyber devices included in premarket submissions filed on or after March 29, 2023. The FDA began enforcing this through refuse-to-accept checks on October 1, 2023, meaning submissions missing the required SBOM or vulnerability management plan can be bounced before substantive review even starts. Anything cleared, approved, or de novo granted before that date falls entirely outside the statute's reach, no matter how connected or clinically critical the device is. This creates a hard line rather than a gradient. A device cleared on March 28, 2023 has no statutory cybersecurity obligation under 524B. A device cleared one year later, built on the same platform with the same connectivity, must meet the full set of requirements. Manufacturers sometimes assume a "substantial equivalence" update to an older device pulls it into scope, and that can be true if the update itself constitutes a new premarket submission, but simply continuing to sell or support an already-cleared device does not trigger 524B on its own. For more detail on how the statute treats devices that fall right on that line, see [does section 524B apply to legacy medical devices](/blog/does-fda-section-524b-apply-to-legacy-medical-devices) and the breakdown of the statute's individual subsections in [FDA section 524B subsections explained](/blog/fda-section-524b-subsections-explained). ## What Gap Does This Leave for Legacy Devices? The gap is straightforward: legacy devices were never asked to produce the artifacts section 524B now requires, so most of them do not have them. Infusion pumps, imaging workstations, and monitors cleared years ago typically shipped without an SBOM, without a documented vulnerability disclosure process, and without a supported patching mechanism. Replacing that entire installed base is neither fast nor affordable for most health systems, so these devices stay in service well past the point their manufacturers stop actively supporting them. | What section 524B requires of new submissions | What legacy devices typically have | |---|---| | Software bill of materials | No SBOM, or an incomplete one assembled after the fact | | Documented vulnerability monitoring and disclosure plan | No formal process, vulnerabilities surface through ad hoc reports | | Postmarket patching capability | Limited or no remote update mechanism | | Security risk management aligned to premarket guidance | Risk analysis done under older, less specific frameworks | | Labeling describing cybersecurity controls | Labeling silent on cybersecurity | The 2022 FBI alert on networked medical devices and the Internet of Things found that over half of scanned devices carried at least one known vulnerability, a finding from before section 524B existed. Nothing in the statute retroactively patches those devices or forces a manufacturer to produce an SBOM for a product cleared a decade ago. ## What Should Manufacturers Do About Fielded Devices? Manufacturers should treat legacy SBOM and vulnerability management work as a voluntary but necessary extension of their premarket obligations, not as a compliance exercise the law demands. Building an SBOM for an already-cleared product, even informally, gives a manufacturer the ability to answer a hospital's vulnerability question quickly instead of scrambling through old engineering records. It also positions the company well if that product line is ever updated in a way that triggers a new submission. **[KEY REQUIREMENT]** Manufacturers should document, for every legacy product still in active service, whether a coordinated vulnerability disclosure path exists, whether patches can still be issued, and what compensating controls hospitals can apply if the answer to either question is no. Hospitals that assume their procurement policy alone satisfies cybersecurity obligations under section 524B are also mistaken, since procurement contracts cannot retroactively change what a manufacturer submitted to the FDA years earlier. The right frame is to treat section 524B compliance for new purchases and legacy device risk management as two separate programs that both need active attention, rather than assuming one solves the other. ## What Should Hospitals Do About Devices Outside 524B's Scope? Hospitals should build their own inventory and segmentation program because regulation will not retroactively secure equipment already purchased. Knowing which devices predate March 29, 2023 versus which were cleared under full 524B requirements lets a security team prioritize which parts of the fleet need network-level compensating controls, such as segmentation, monitoring, and restricted access, rather than relying on the device itself to enforce security. Procurement teams should also ask vendors directly whether a legacy product has any SBOM or vulnerability disclosure commitment, even an informal one, since the absence of a legal requirement does not mean the manufacturer has nothing to offer. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works with manufacturers on both sides of the March 29, 2023 line: new submissions that must satisfy section 524B in full, and legacy product lines where a manufacturer wants to build an SBOM and vulnerability management process voluntarily. Our engineers treat both efforts the same way, as design-controlled documentation tied to a verifiable engineering artifact rather than a paperwork exercise assembled after the fact. For submissions currently in progress, our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) build the SBOM, threat model, and vulnerability management plan section 524B requires, scoped to the device's actual architecture and risk profile. ## Frequently Asked Questions ### Does the PATCH Act apply to devices cleared before 2023? No. Section 524B, which carries the PATCH Act's requirements, applies only to premarket submissions filed on or after March 29, 2023. Devices cleared before that date have no statutory cybersecurity obligation under this specific law, regardless of their current connectivity or clinical use. ### What is the difference between the PATCH Act and section 524B? The PATCH Act was proposed legislation describing premarket cybersecurity requirements for medical devices. Its language was never enacted as a standalone bill; instead, Congress added it to the Consolidated Appropriations Act, 2023, which created section 524B of the FD&C Act. Section 524B is the enforceable statute; the PATCH Act name refers to its legislative origin. ### Can a legacy device become subject to section 524B later? Yes, if the manufacturer files a new premarket submission for that device, such as a significant design change requiring a new 510(k) or PMA supplement, that submission must meet section 524B requirements. Simply continuing to sell, service, or support an already-cleared device without a new submission does not trigger the statute. ### What should hospitals do with medical devices that predate the PATCH Act? Hospitals should inventory these devices, confirm whether the manufacturer offers any vulnerability disclosure or patching support, and apply network-level compensating controls such as segmentation and monitoring. Since these devices have no statutory cybersecurity mandate, the hospital's own security architecture becomes the primary defense. ## CTA Legacy devices and current submissions both need a documented cybersecurity story, even if only one of them is legally required to have one. [Contact Blue Goat Cyber](/contact) to talk through where your fleet or your submission pipeline stands against section 524B. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Patch and Update Mechanism Testing Source: https://bluegoatcyber.com/blog/patch-update-mechanism-fda-section-524b-testing # Patch and Update Mechanism Testing for FDA Section 524B(b)(1) > **[DIRECT ANSWER]** Section 524B(b)(1) makes the ability to patch a device a statutory requirement, so the update mechanism itself must be tested and documented. Expect to show signature verification, rollback and failure handling, interrupted-update recovery, and evidence that the tested mechanism matches the release process described in your postmarket plan. _Published June 11, 2026_ ## Key Takeaways - Patchability is statutory under Section 524B(b)(1). It is not optional for any cyber device. - The Feb 2026 guidance expects **test evidence** of the patch path, not just a description of it. - Reviewers expect specific test cases: signature bypass attempts, rollback to a vulnerable signed version, update channel spoofing, partial / interrupted updates, post-update integrity. - The patch mechanism lives in eSTAR v7.0 Slot 6 (Controls); the test evidence lives in Slot 7 (Testing). - The most common deficiency is "Provide evidence of patchability demonstrating compliance with Section 524B(b)(1)", issued when a submission describes the mechanism but shows no exercising tests. ## Why this matters The Feb 3, 2026 final guidance is the first FDA cybersecurity document to enforce **statutory** patchability requirements. Section 524B(b)(1) was added to the FD&C Act in 2023 and made effective in March 2023. The 2026 guidance operationalizes it. Reviewers are now actively flagging submissions where the patch mechanism is described but not tested. The clinical consequence is direct. A device that cannot be patched is a device that accumulates risk over its deployed lifetime. The agency's framing is that an unpatchable connected device should not reach market. ## What Section 524B(b)(1) actually requires The statute requires manufacturers to: 1. **Design** the device so it can be updated and patched. 2. **Demonstrate** the ability to update and patch in a reasonably and reliably timely manner. 3. **Maintain** the ability to do so across the deployed lifetime. The Feb 2026 guidance translates that into evidence the submission must contain: > **[FDA LANGUAGE]** "Submissions should include documentation and evidence demonstrating that the device can be updated and patched in a reasonably and reliably timely manner, including the design of the update mechanism, the test evidence supporting its operation, and the postmarket commitments for patch delivery." Two words carry the weight: **reasonably** (means there is an explicit SLA, not "best effort") and **reliably** (means the mechanism has been exercised under realistic and adverse conditions). Both require test evidence. ## The test cases reviewers look for A patchability evidence package that passes review on first read contains, at minimum, these test cases: ### Signature verification - Apply a valid signed update, expect success. - Apply an update with an invalid signature, expect rejection and logged event. - Apply an update signed by a different (untrusted) key, expect rejection. - Apply an update with a malformed signature block, expect rejection without crash. ### Anti-rollback / version monotonicity - Apply an older signed update than the currently installed version, expect rejection with logged event. - Attempt to flash a known-vulnerable signed historical version, expect rejection. - Verify that the rollback policy is enforced at the bootloader (not just the application). ### Update channel authentication - Spoof the update server (DNS / certificate manipulation), expect TLS validation failure and update abort. - Replay a captured-then-modified update, expect signature failure or replay protection. - Run the update over a network with on-path adversary tooling, confirm integrity is preserved. ### Partial / interrupted updates - Interrupt the update at multiple points (network drop, power loss, watchdog reset), expect either successful resumption or safe rollback to the prior known-good image. - Verify the device never boots into a partially-updated state. - Verify the device remains clinically safe during the update window (or documents the safe down-state). ### Post-update integrity - After a successful update, verify the bootloader chain still passes attestation. - Verify logs record the update with a tamper-resistant entry. - Verify any keys rotated as part of the update are usable and that the prior keys are revoked. ### Patch delivery SLA - Document the measured time from a representative CVE disclosure → patch availability → patch deployment. - Provide evidence (a CAPA record, a previous patch cycle log) that this SLA has been achieved in practice, not just promised. ## What an acceptable patchability evidence package looks like A Section 524B(b)(1) evidence package that reviewers accept on first read typically contains: - **Update mechanism design** description (filed in eSTAR Slot 6) with the cryptographic primitives, key management, channel design, and failure-mode handling - **Test plan** mapping each of the test categories above to specific test IDs - **Test report** with results for each test ID, including evidence (logs, screenshots, packet captures) for the negative cases - **SLA narrative** stating the time-from-CVE-disclosure-to-deployed-patch target and the prior-cycle evidence supporting it - **Postmarket commitment** referenced from the [Cybersecurity Management Plan](/guides/cybersecurity-management-plan-fda-medical-devices) and the Vulnerability Management Plan - **Operator-facing labeling** describing how the update reaches the deployed device This evidence sits across eSTAR v7.0 Slots 1 (Management Plan), 6 (Controls), and 7 (Testing), with cross-references that let a reviewer follow the thread. ## Common deficiency patterns The four deficiency patterns we see most often on patchability: 1. **Mechanism described, not tested.** The submission has an update-mechanism diagram but no Slot 7 test report exercising it. Most common pattern by a wide margin. 2. **No anti-rollback evidence.** Devices that prevent unsigned updates but happily accept older signed-and-vulnerable versions. Reviewers ask explicitly for rollback test cases now. 3. **No documented SLA.** A general statement that "patches will be delivered promptly" with no measurable time target. 4. **No partial-update safety analysis.** Reviewers ask "What happens if power is lost at byte N of the update?" If the answer is not in the submission, it becomes an AI request. ## How Blue Goat Cyber tests patch mechanisms Our pen testers run patch mechanisms through every test case above on a calibrated bench: signature manipulation, key substitution, rollback attempts to known-vulnerable signed versions, update-server impersonation with HackRF and rogue cert, repeated mid-update interruption with controlled power and network conditions, and post-update attestation. We deliver the Section 524B(b)(1) evidence package as part of the Slot 6 + Slot 7 attachments, with the traceability matrix back to the threat model. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** See our [penetration testing service](/services/penetration-testing) and the related [FDA Cybersecurity Testing Requirements Taxonomy](/guides/fda-cybersecurity-testing-requirements-taxonomy). ## FAQ ### Does Section 524B(b)(1) apply to my device? If the device meets the Section 524B definition of "cyber device", software validated by the sponsor, able to connect to the internet, and containing technological characteristics that could be vulnerable, then yes. That bar is intentionally low; almost every modern connected device qualifies. Use our [Cyber Device Applicability tool](/tools/cyber-device-applicability) to confirm. ### Is "reasonably and reliably timely" a defined SLA? The statute does not specify a number. Reviewers expect the **sponsor** to state the SLA and back it with evidence that the SLA has been met in practice. Typical SLAs we see accepted are "critical CVE → patch available within 30 days, deployed within 90 days" for non-life-sustaining devices and shorter for life-sustaining devices. ### Can patches be delivered manually (by a service technician)? Yes, with documented evidence the manual process meets the SLA. Pure-OTA is preferred but not required. The mechanism must be reliable and timely; the delivery mode is the sponsor's choice. ### What if the device has no field-update capability today? That is a design problem, not a documentation problem. Section 524B(b)(1) effectively requires field-updateable designs for new submissions. If the device cannot be updated, the path forward is design change before submission, not narrative-only justification. ### How is this different from change control after clearance? Change control (letter to file, special 510(k), PMA supplement) governs what regulatory submission a future change requires. Section 524B(b)(1) governs whether the device can deliver the change to the field at all. They are complementary, not substitutes. See our posts on [letter to file vs new 510(k)](/blog/letter-to-file-vs-new-510k-cybersecurity-changes) and [PMA supplement cybersecurity changes](/blog/pma-supplement-cybersecurity-changes). ### Where does the SBOM fit? The SBOM (Slot 5) drives the vulnerability management feed that triggers patch cycles. A patch mechanism without an SBOM-driven monitoring process is a patch mechanism with no input signal. See [SBOM vulnerability management](/guides/sbom-vulnerability-management-medical-devices). ## Ready to test your patch mechanism? If you are preparing a 510(k), De Novo, or PMA submission and have not yet exercised the patch mechanism under negative conditions, we will scope the testing to Section 524B(b)(1) and deliver an eSTAR-ready evidence package. [Request a scoping call](/contact). --- _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, ex-military red team. Has tested patch and update mechanisms across more than 275 FDA-submitted medical devices, including infusion pumps, implantables, and connected diagnostics. [More on the author](/team/christian-espinosa)._ ## Related reading - [The SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [eSTAR v7.0 Cybersecurity Attachments mapping](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) --- ## More on this topic - [FDA Cybersecurity Documentation](/blog/a-guide-to-fdas-cybersecurity-documentation-requirements) - [Q-Sub vs Pre-Sub: FDA Cybersecurity Feedback Guide](/blog/q-sub-vs-pre-sub-fda-cybersecurity) --- ## FDA PCCP Beyond AI: Cybersecurity & Firmware Uses Source: https://bluegoatcyber.com/blog/pccp-beyond-ai-cybersecurity-firmware-hardware # FDA PCCP Beyond AI: Predetermined Change Control Plans for Cybersecurity, Firmware, and Hardware > **[DIRECT ANSWER]** The FDA's December 2024 final PCCP guidance covers any pre-specifiable device modification, not just AI/ML models, so manufacturers can use a predetermined change control plan to pre-authorize recurring cybersecurity work such as cryptographic agility, SBOM component version refreshes, firmware OTA cadence, and bounded hardware substitutions. Each modification class needs its own bounded description, validation protocol, and rollback criteria, and the PCCP must reference the Section 524B postmarket cybersecurity plan by name. Most manufacturers still equate PCCP with AI/ML model updates. That was true of the April 2023 draft PCCP guidance. It is not true of the December 4, 2024 final guidance, *Predetermined Change Control Plans for Medical Devices*, which explicitly covers any modification type the manufacturer can specify in advance and control through a documented protocol. The mismatch matters for cybersecurity. Section 524B requires manufacturers to maintain a plan to monitor, identify, and address postmarket vulnerabilities. Patching cadence, cipher agility, and SBOM refresh are exactly the kind of recurring, pre-specifiable modifications a PCCP was designed for. This post explains where a non-AI PCCP fits, five modification classes reviewers are accepting, and how a cybersecurity PCCP interlocks with the FDA's February 3, 2026 final premarket cybersecurity guidance. ## Key Takeaways - The December 2024 final PCCP guidance applies to any pre-specifiable modification, not just AI/ML model updates. - A cybersecurity-scoped PCCP can pre-authorize crypto agility, SBOM component refresh, firmware OTA cadence, non-AI algorithm tuning, and select hardware substitutions. - Section 524B postmarket obligations map cleanly to a PCCP's Modification Protocol, this is the strongest current use case beyond AI. - Reviewers reject PCCPs that lack bounded modification specifications, validation protocols, and rollback criteria. - A cybersecurity PCCP does not replace the postmarket cybersecurity plan; it operationalizes it. ## Why This Matters The FDA's *Predetermined Change Control Plans for Medical Devices* final guidance (issued December 4, 2024) supersedes the 2023 AI/ML-only draft and applies broadly to 510(k), De Novo, and PMA devices. In parallel, the *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* final guidance issued February 3, 2026 codifies Section 524B expectations and explicitly encourages sponsors to plan for routine security updates. Together, they open a lane that most manufacturers are not yet using: pre-authorizing recurring cybersecurity modifications through a PCCP instead of processing every crypto library bump through change-control gymnastics. AAMI TIR57:2016/(R)2023 and IEC 81001-5-1:2021 back the underlying security risk management activities, and the January 2025 CDRH quarterly submission data showed cybersecurity as one of the top three deficiency categories on 510(k) submissions, a signal that reviewer attention to change control for security-relevant modifications is only rising. ## What the 2024 Final FDA PCCP Guidance Actually Covers The final guidance defines a PCCP as three linked elements: a **Description of Modifications** (what you plan to change), a **Modification Protocol** (how you will implement, verify, and validate each change), and an **Impact Assessment** (why the changes maintain safety and effectiveness within the authorized indications for use). Nothing in that structure is AI-specific. The guidance is explicit that any modification a manufacturer can specify with sufficient granularity and bound with an acceptable validation protocol is eligible. AI/ML model retraining is one example. Firmware feature rollout on a defined cadence, cipher-suite migration, and SBOM component version bumps are others. The gating question is not "is this AI" but "can you pre-specify the modification, its bounds, and how you will prove it is safe." For deeper background on the mechanics, see our [FDA PCCP change control plans guide](/guides/fda-pccp-change-control-plans). > **Read next →** [FDA PCCP change control plans guide](/guides/fda-pccp-change-control-plans) for the full anatomy of Description of Modifications, Modification Protocol, and Impact Assessment, with worked non-AI examples. ## Five Non-AI PCCP Modification Classes Worth Pre-Authorizing | Modification class | What the PCCP authorizes | Why it fits | | --- | --- | --- | | Cryptographic agility | Rotating cipher suites, key lengths, and TLS versions on a defined schedule as NIST deprecates algorithms | Bounded modification set, testable via known-answer + interoperability suites, aligns with 524B postmarket plan | | SBOM component refresh | Version bumps of pre-identified third-party components within specified semver ranges when triggered by CVE/VEX | Change is pre-specified per component; validation protocol is regression + security testing | | Firmware OTA cadence | Rolling out signed firmware releases on a stated frequency using an authenticated update channel | Update mechanism itself is validated once; per-release verification bounded by protocol | | Non-AI algorithm tuning | Parameter adjustments on deterministic algorithms (signal filters, thresholds, alarm logic) within pre-set ranges | Bounded parameter space, deterministic validation, no continuous learning | | Hardware component substitution | Pre-identified equivalent parts (sensors, radios, memory) with defined equivalence testing | Common in supply-chain resilience; substitution set is finite and each requires the same protocol | Each of these can be scoped narrowly enough to satisfy the guidance's requirement for a bounded, testable modification specification. > **Read next →** For the SBOM-refresh and cipher-agility rows, wire the Modification Protocol to the [SBOM vulnerability management workflow](/guides/sbom-vulnerability-management-medical-devices), [VEX document guide](/guides/vex-document-medical-device-fda), and the [SBOM for medical devices guide](/guides/sbom-for-medical-devices) so triage, exploitability, and evidence live in one loop. ## When a Cybersecurity PCCP Beats a Letter-to-File A letter-to-file works when the manufacturer decides, per modification, that it does not significantly affect safety or effectiveness. A PCCP works when the modification recurs and the *category* has been pre-authorized. For a Section 524B device that ships crypto library updates twice a year and SBOM component bumps monthly, the PCCP path avoids re-running the letter-to-file decision every time. > **[KEY REQUIREMENT]** A PCCP does not permit modifications the sponsor could not have made through a letter-to-file today. It permits pre-authorization of the same class of modifications on a documented, validated schedule. The efficiency gain is real when the modification is recurring, mechanically bounded, and validated by a stable protocol, which is exactly the profile of routine cybersecurity maintenance. [Talk to us about scoping a cybersecurity PCCP](https://bluegoatcyber.com/contact) if you are patching production devices faster than your change-control paperwork can keep up. > **Read next →** [FDA pathway cybersecurity differences guide](/guides/fda-pathway-cybersecurity-differences) to decide whether a given modification belongs in a PCCP, a letter-to-file, or a new submission. ## What FDA Reviewers Reject in a Non-AI PCCP Reviewer feedback on non-AI PCCPs in 2025 clustered around four defects: 1. **Unbounded modification descriptions.** "Update firmware as needed" is not a Description of Modifications; "signed firmware releases within features A/B/C, on the update channel validated in submission section X" is. 2. **Missing validation protocol per modification type.** Each modification class needs its own verification and validation approach, tied to the security risk file and the [security risk assessment under IEC 81001-5-1](/guides/security-risk-assessment-iec-81001-5-1). 3. **No rollback or abort criteria.** The Modification Protocol must state when a change is pulled back and what happens to fielded units. 4. **No linkage to the postmarket cybersecurity plan.** A cybersecurity PCCP that does not reference the Section 524B postmarket monitoring and vulnerability handling process reads as disconnected from the manufacturer's actual security operations. ## Common Reviewer Misconceptions About Non-AI PCCPs Sponsor teams, and, occasionally, reviewers themselves, carry over assumptions from the 2023 AI/ML draft that no longer apply. These are the misconceptions we see driving Additional Information (AI) requests and outright PCCP rejections on cybersecurity, firmware, and hardware scopes. | Misconception | What the 2024 final guidance actually says | | --- | --- | | "PCCPs are only for AI/ML models." | The final guidance applies to any modification a sponsor can pre-specify, bound, and validate. AI/ML is one worked example, not the scope limit. | | "A cybersecurity PCCP lets us skip 510(k) for anything security-related." | A PCCP only pre-authorizes changes that could otherwise be made through letter-to-file. Anything that would have required a new submission still does. | | "The Modification Protocol can point to our SOPs." | Reviewers want the protocol *in* the PCCP, with acceptance criteria and validation methods spelled out. Bare SOP references are a frequent rejection reason. | | "One PCCP can cover firmware, crypto, and hardware together with a shared protocol." | Each modification class needs its own Description of Modifications and its own Modification Protocol. A single generic protocol is treated as unbounded. | | "Impact Assessment is a paragraph of narrative." | It has to walk through safety, effectiveness, cybersecurity, and usability impacts *per modification class*, tied to the risk file and threat model. | | "PCCP means we can push updates without notifying the FDA." | Postmarket reporting obligations (including Section 524B(b)(2)(B) vulnerability handling and any applicable 21 CFR 806 corrections) still apply on top of the PCCP. | | "PCCPs remove the need for a postmarket cybersecurity plan." | The PCCP is the *authorization*; the postmarket plan is the *process*. Both are required, and reviewers expect them to cite each other by name. | | "We can add a PCCP after clearance without a submission." | Adding a PCCP to a cleared device requires a supplement or new submission, it is not a design history file update. | | "If the modification is in the PCCP, no documentation is needed at the time of change." | The Modification Protocol requires an executed record per modification, including verification/validation results and an updated PCCP change log. Inspectors ask for it. | ### The pattern behind the pattern Almost every rejection above traces to the same root cause: treating the PCCP as a *policy* rather than a *pre-executed regulatory decision*. The final guidance's structure, Description of Modifications, Modification Protocol, Impact Assessment, is a decision record the FDA is agreeing to in advance. Language that is fine in an internal SOP ("as needed", "per current best practice", "at the discretion of the security team") reads as unbounded delegation in a PCCP and gets sent back. > **[FDA LANGUAGE]** From the December 2024 final guidance: a PCCP must describe "the specific, planned device modifications" and "the associated methodology to develop, validate, and implement those modifications in a manner that ensures the continued safety and effectiveness of the device." Both halves must be present per modification class. If a draft PCCP cannot survive a red-team read against this list, it will not survive review. Fix the language before submission, not after the AI request. ## How a Cybersecurity PCCP Interlocks with the Section 524B Postmarket Plan Section 524B(b)(2)(B) of the FD&C Act obligates manufacturers to maintain "a plan to monitor, identify, and address, as appropriate, in a reasonable time, postmarket cybersecurity vulnerabilities and exploits." That plan is a *process* document. A PCCP is an *authorization* document. They answer different questions and are designed to be read together. - The **postmarket cybersecurity plan** answers: how do we detect vulnerabilities, triage them, communicate them, and close them? - The **PCCP** answers: which recurring fix categories are pre-authorized so that closure does not require a new submission or per-instance letter-to-file? ### The end-to-end loop ```text Postmarket monitoring (CVE feeds, CVD intake, telemetry) │ ▼ SBOM + VEX triage (exploitable in this device?) │ ├── Out of PCCP scope ──► CAPA ──► new submission or letter-to-file │ └── In PCCP scope ─────► Modification Protocol executes │ ▼ Verification + validation per protocol │ ▼ Signed release + fielded update │ ▼ Update SBOM/VEX, threat model, PCCP change log ``` Every step in this loop maps to a specific document. The postmarket plan governs detection, triage, and communication. The [SBOM vulnerability management workflow](/guides/sbom-vulnerability-management-medical-devices) governs exploitability determination. The PCCP's Modification Protocol governs execution and validation. The CAPA procedure (see [CAPA and medical device cybersecurity](/blog/capa-medical-device-cybersecurity)) governs anything that falls outside the pre-authorized scope. ### What the eSTAR package should show For eSTAR submissions, the PCCP is a distinct attachment cross-referenced from the cybersecurity content. Reviewers expect three explicit references: 1. The **postmarket cybersecurity plan** names the PCCP as the closure mechanism for in-scope modification categories. 2. The **PCCP's Impact Assessment** cites the threat model and the security risk file so that pre-authorized modifications are bounded by the analyzed attack surface. 3. The **cybersecurity management plan** ties both documents into the QMSR, see our [cybersecurity management plan guide](/guides/cybersecurity-management-plan-fda-medical-devices), the [eSTAR v7 cybersecurity mapping](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance), and the broader [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). Missing any one of those references is a common deficiency and the fastest way to turn a workable PCCP into an RTA or Additional Information request. > **[KEY REQUIREMENT]** The postmarket cybersecurity plan and the PCCP must reference each other by name in the submission. A PCCP that lists modifications with no link to the monitoring process, or a postmarket plan that names no pre-authorized fix path, reads as two disconnected workstreams and reviewers treat it that way. > **Read next →** [Postmarket cybersecurity monitoring program guide](/guides/postmarket-cybersecurity-monitoring-program) for the detection-to-closure process the PCCP plugs into, and the [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance) for the Section 524B expectations both documents must satisfy. --- **Not sure if your patching cadence justifies a PCCP?** [Book a 30-minute PCCP scoping call](https://bluegoatcyber.com/contact) and we will map your current change-control workflow against the postmarket plan and tell you where a PCCP would actually save time, and where it would not. ## How Blue Goat Cyber Approaches This We scope cybersecurity PCCPs against the device's threat model, SBOM, and postmarket plan so the Description of Modifications is bounded to what the security architecture actually supports. Our Modification Protocols reuse the security regression suites, SBOM/VEX workflow, and cryptographic validation harnesses we build during premarket, which means the PCCP inherits validated infrastructure rather than inventing new one. Our team holds CISSP and OSCP credentials with prior military red-team experience, and our work is grounded in the December 2024 final PCCP guidance, the February 3, 2026 final premarket cybersecurity guidance, Section 524B, AAMI TIR57 / SW96, and IEC 81001-5-1. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [FDA cybersecurity submission service](https://bluegoatcyber.com/services/fda-cybersecurity-submission) or our [postmarket SBOM and VEX monitoring service](https://bluegoatcyber.com/services/postmarket-sbom-vex-monitoring). ## Frequently Asked Questions These are the questions FDA reviewers actually raise on non-AI PCCP submissions, and how to answer them cleanly. Each answer links to the relevant Blue Goat Cyber guide for the underlying detail. ### Can a PCCP be used for something other than AI/ML? Yes. The FDA's December 4, 2024 final *Predetermined Change Control Plans for Medical Devices* guidance applies to any modification a sponsor can pre-specify, bound, and validate through a documented protocol. AI/ML model updates were the original driver, but firmware releases, cybersecurity patches, SBOM component refreshes, and bounded hardware substitutions are all in scope. See the mechanics in our [FDA PCCP change control plans guide](/guides/fda-pccp-change-control-plans). ### How does a cybersecurity PCCP satisfy Section 524B postmarket obligations? It does not satisfy them on its own. Section 524B(b)(2)(B) requires a plan to monitor, identify, and address vulnerabilities, that is the postmarket cybersecurity plan. The PCCP is the pre-authorized fix mechanism the plan routes to for in-scope modifications. Reviewers expect both, cross-referenced. Detail in our [postmarket cybersecurity monitoring program guide](/guides/postmarket-cybersecurity-monitoring-program) and the [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). ### What modifications must stay out of a cybersecurity PCCP? Anything the sponsor cannot bound in advance: novel architectural changes, new indications for use, new interfaces to previously unconnected subsystems, changes that alter the analyzed attack surface, or fixes to threat model gaps that were not disclosed in the original submission. Those still require a new submission or a traditional change-control decision, see our [FDA pathway cybersecurity differences guide](/guides/fda-pathway-cybersecurity-differences). ### Can a PCCP be added to a device that already has clearance? Yes, through a supplement or new submission that includes the PCCP. The sponsor still has to justify the Description of Modifications, Modification Protocol, and Impact Assessment against the cleared indications for use. Use our [FDA premarket cybersecurity submission checklist](/guides/fda-premarket-cybersecurity-submission-checklist) to confirm the surrounding package still lines up. ### What are the fastest ways a non-AI PCCP gets rejected? Unbounded modification language ("as needed"), a single generic Modification Protocol covering multiple classes, missing rollback criteria, and no cross-reference to the postmarket cybersecurity plan. See the full pattern in our [12 reasons the FDA rejects medical device cybersecurity submissions guide](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions) and the [FDA cybersecurity deficiency letter examples](/guides/fda-cybersecurity-deficiency-letter-examples). ### Is a PCCP required for cybersecurity patching? No. It is an option. Manufacturers can continue to handle security patches under existing change control. The PCCP is worth the investment when the patching cadence, cipher-agility program, or SBOM refresh workflow is frequent and bounded enough that pre-authorization saves meaningful engineering and regulatory time. ## Ready to scope a cybersecurity PCCP for your device? If your device ships crypto updates, firmware releases, or SBOM component bumps on a cadence and your change-control paperwork is the bottleneck, a cybersecurity-scoped PCCP is likely the right instrument. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. - **Download the checklist →** [PCCP Beyond AI: Reviewer Rejection & Corrective-Action Checklist (PDF)](/__l5e/assets-v1/b2ed8272-aaf8-4c21-b5fb-8915c2a0a85c/pccp-beyond-ai-reviewer-rejection-checklist.pdf), 20 items across Description of Modifications, Modification Protocol, Impact Assessment, 524B postmarket interlock, and eSTAR placement. - **Talk to an expert →** [Schedule a 30-minute discovery call](https://bluegoatcyber.com/contact) - **See the full service →** [FDA cybersecurity submission](https://bluegoatcyber.com/services/fda-cybersecurity-submission) - **Wire it to postmarket →** [Postmarket SBOM & VEX monitoring](https://bluegoatcyber.com/services/postmarket-sbom-vex-monitoring) --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led premarket and postmarket cybersecurity programs for connected medical devices across Class II and Class III submissions and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## PMA Supplement Cybersecurity Changes Source: https://bluegoatcyber.com/blog/pma-supplement-cybersecurity-changes # PMA Supplement vs Real-Time vs 30-Day Notice for Cybersecurity Changes > **[DIRECT ANSWER]** A cybersecurity change to a PMA device is reportable, and the only question is which supplement carries it. Security patches that do not alter the device's indications, design, or performance usually travel as a 30-Day Notice; changes to the trust boundary, cryptography, authentication design, or update mechanism need a Panel-Track or 180-Day Supplement. Document the risk analysis and verification evidence that justify the pathway you picked before you file. ## Key Takeaways - The 180-day PMA supplement is the default for any cybersecurity change that affects safety, effectiveness, or the cybersecurity risk profile. - Real-Time supplements compress review to a single meeting but are only available for narrow design changes. - Special PMA supplements (changes-being-effected) let you ship the change before the FDA finishes review - but only for changes that strengthen safety, never for new functionality. - 30-day notices are manufacturing-only. They are almost never the right path for substantive cybersecurity changes. - Annual reports are for administrative changes - typos, labeling cleanup. A cybersecurity change buried in an annual report is an enforcement risk. - Section 524B does not change which path applies, but it makes misclassification far more visible. ## Why this matters Selecting the incorrect regulatory pathway for cybersecurity changes to a Class III device can lead to significant postmarket enforcement actions, including recalls, consent decrees, and reputational damage. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the critical need for appropriate submission types for cybersecurity modifications to ensure continued safety and effectiveness. Misclassifying a change, such as submitting a substantive cybersecurity update via an annual report or a 30-day notice, signals to the FDA a lack of understanding of regulatory compliance and device risk management. This can trigger heightened scrutiny during inspections and impact future approvals. Compliance with relevant standards like IEC 60601-1-10:2020 for medical electrical equipment and ISO 14971:2019 for risk management is paramount, as these inform the FDA's expectations for design control and postmarket surveillance of cybersecurity risks. Correct classification ensures the FDA has adequate time and information to review changes that could impact patient safety or device functionality. ## The five PMA change paths at a glance | Path | What it's for | Review timeline | Cyber use case | |---|---|---|---| | 180-day PMA supplement | Changes affecting safety, effectiveness, design, performance, or labeling | 180 days | Default for substantive cyber changes | | Real-Time supplement | Narrow design or labeling changes appropriate for a single review meeting | ~90 days | Crypto algorithm bump, focused interface change | | Special PMA supplement (CBE) | Changes that strengthen safety; can ship before review completes | 30 days FDA acknowledgment, full review later | Adding MFA, adding signature verification, removing a vulnerable feature | | 30-day notice | Manufacturing process changes only | 30 days | Almost never appropriate for cyber | | Annual report | Changes not affecting safety, effectiveness, or cleared design | Annual filing | VEX status updates, documentation-only refreshes | ## 1. The 180-day PMA supplement - the default If a cybersecurity change affects safety, effectiveness, or the cybersecurity risk profile, the default path is a 180-day PMA supplement. This is the analog of filing a new 510(k) on a change. Cybersecurity changes that almost always require a 180-day supplement: - New cryptographic algorithms or key management infrastructure. - New authentication or authorization mechanisms. - New wireless or remote-access paths (BLE, Wi-Fi, cellular, cloud sync). - New third-party components that materially change the attack surface. - Replacing an end-of-support OS or runtime. - Any change that alters the threat model, trust boundaries, or intended use. - Adding cloud backend dependencies the device's security claims now rely on. The supplement must include a delta threat model, a delta security risk assessment, updated SBOM and VEX, and a focused security testing summary. The FDA reviewer expects the same depth of cybersecurity documentation as the original PMA, scoped to the change. ## 2. The Real-Time supplement A Real-Time supplement compresses review to a single meeting with the FDA. It is available for design and labeling changes the FDA judges appropriate for that format - typically narrow, well-bounded changes with clear test data. Cyber changes that can sometimes go Real-Time: - A single cryptographic algorithm upgrade with full test evidence and no other change. - A focused interface change that doesn't introduce new trust boundaries. - A labeling change reflecting a security postmarket commitment. The decision is the FDA's, not yours. Sponsors pre-coordinate via a Pre-Sub before committing. Getting a Real-Time supplement rejected mid-process forces you back to a 180-day supplement and resets the clock. ## 3. The Special PMA supplement (CBE - Changes Being Effected) Special PMA supplements are the most misunderstood path in PMA change management. They let you ship the change immediately on submission, with full FDA review happening afterward. The constraint: Special supplements are only for changes that **strengthen safety or effectiveness**. They are not a fast track for new functionality or new features. Cybersecurity changes that legitimately qualify: - Adding multi-factor authentication where none existed. - Adding signature verification to a previously unsigned update mechanism. - Removing or disabling a vulnerable feature without functional replacement. - Tightening cryptographic minimums (e.g., raising TLS minimum version, removing weak ciphers). - Pushing a patch that closes a specific known vulnerability with no functional change. What disqualifies a Special supplement: - Adding a new feature, even one with security in mind. - Migrating to a new component that introduces functional changes. - Any change that could plausibly reduce safety in some scenario. The trap: sponsors use Special supplements for "security improvements" that actually add features. The FDA notices, and the postmarket enforcement consequence is high. ## 4. The 30-day notice 30-day notices are limited to manufacturing process changes - moving production sites, changing suppliers, modifying manufacturing equipment. They are not a path for design or software changes. The only cyber-adjacent case for a 30-day notice is when the manufacturing change affects how cryptographic keys are provisioned at the factory (HSM swap, key ceremony change, certificate authority change). Even then, a Pre-Sub to confirm the path is cheaper than guessing wrong. If you are tempted to file a substantive cybersecurity change as a 30-day notice, the answer is almost certainly that it needs a 180-day or Special supplement instead. ## 5. The annual report Annual reports are for administrative changes that do not affect safety, effectiveness, or the cleared design. Cybersecurity changes that legitimately belong in an annual report: - VEX status updates that change `under_investigation` to `not_affected` with documented justification. - SBOM documentation refreshes that reflect no functional change. - Editorial labeling updates with no substantive change to security claims. - Postmarket cybersecurity monitoring summary as a yearly rollup. What does NOT belong in an annual report: - CVE patches that ship code changes. - Component version bumps that change behavior or interfaces. - Any change that touches crypto, auth, or attack surface. A cybersecurity change buried in an annual report when it should have been a supplement is the kind of finding that drives Warning Letters under Section 524B. ## The decision logic for a cyber change Ask these questions in order. The first "yes" determines the path. 1. **Does the change strengthen safety with no new functionality and no risk-reducing tradeoff?** → Special PMA supplement (CBE). 2. **Does the change affect the threat model, trust boundaries, crypto, auth, attack surface, or intended use?** → 180-day PMA supplement. Consider Real-Time only if the change is narrow and bounded enough to review in a single meeting. 3. **Is the change purely a manufacturing process modification with no design or software impact?** → 30-day notice. 4. **Is the change administrative or documentation-only with no impact on safety, effectiveness, or design?** → Annual report. Any time the path is unclear, a focused Pre-Sub is the cheapest insurance. The FDA can confirm the right path before you commit. ## How Section 524B changed the stakes Section 524B(b) did not move the change-classification thresholds. It did make the consequences of misclassification far more expensive: 1. **Postmarket cybersecurity monitoring is statutory.** A misclassified change is now visible to the FDA without an inspection - it shows up in postmarket data. 2. **The cybersecurity baseline expectation now follows the device.** A change that drifts the device away from the Feb 3, 2026 premarket guidance baseline is harder to justify as Special or as an annual report entry. 3. **Enforcement has a clear statutory hook.** A misclassified cyber change is not just a guidance violation - it is non-compliance with a specific provision of the FD&C Act. The practical effect: PMA sponsors who got away with aggressive change-path interpretations in 2022 are getting findings on the same patterns in 2026. ## Common gray zones - **TLS version bump on a connected Class III device.** Usually a 180-day supplement if labeling claims specific cipher support, Special supplement if it's pure tightening with no functional change. - **Adding a CVD program postmarket.** Process-only change, but if the original PMA didn't describe one, expect the FDA to ask for it as a supplement amendment rather than an annual report entry. - **SBOM component swap for an end-of-support library.** 180-day supplement if the replacement has different interfaces or trust context. Real-Time if it's a near-drop-in with full test evidence. - **Cloud backend changes the device doesn't ship but depends on.** If the device's security claims relied on the old backend, the change re-enters device scope and needs a supplement. For every gray-zone case, document the delta threat model and delta risk assessment regardless of the path chosen. The path you picked needs to be defensible. ## Reviewer and inspector red flags In a postmarket inspection or a Section 524B review, these patterns draw scrutiny: - A run of annual-report entries for cybersecurity changes that altered code. - Special supplements filed for changes that added functionality, not just safety. - 30-day notices used for software-touching changes. - No delta threat model accompanying any cybersecurity change, regardless of path. - Long gaps between known upstream CVEs in shipped components and any supplement or annual report acknowledging them. ## How Blue Goat scopes cybersecurity for PMA changes Blue Goat Cyber helps PMA holders pick the right change path *before* the change is implemented, so the cybersecurity evidence package matches the submission type. For a 180-day or Real-Time supplement we produce a full refreshed Section 524B package, updated SBOM with VEX, refreshed threat model, risk-tiered penetration test, and Cybersecurity Management Plan update, against the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026. For a 30-day notice or annual report we produce the lighter-weight evidence that reviewers expect: an SBOM delta, a VEX statement for any new CVEs, and a justification memo explaining why the change does not warrant a full supplement. Testers and reviewers hold CISSP and OSCP credentials and include ex-military red team operators. See [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### Is a CVE patch always a 180-day PMA supplement? No. A patch that strengthens safety with no new functionality can be a Special supplement (CBE). A patch that introduces interface changes, new dependencies, or trust boundary shifts is a 180-day supplement. A patch that is purely documentation/VEX with no code change can be an annual report entry. The intent of the change does not determine the path - the impact does. ### Can I use a Real-Time supplement for any cyber change? No. Real-Time is the FDA's choice, not yours. They use it when a change is narrow, bounded, and reviewable in a single meeting. Sponsors pre-coordinate via a Pre-Sub. A rejected Real-Time forces you to refile as a 180-day supplement. ### What's the difference between a Special PMA supplement and a 180-day supplement? A Special supplement (Changes Being Effected) can ship before the FDA finishes review and is limited to changes that strengthen safety with no new functionality. A 180-day supplement covers any change affecting safety, effectiveness, or the design, and requires FDA approval before shipping. Most substantive cyber changes are 180-day supplements. ### Can I bundle multiple cyber changes into one supplement? Yes, and it is often the right move. A consolidated 180-day supplement with five related cybersecurity changes is cheaper than five separate filings and produces a coherent threat model delta. The risk is that one weak change can drag the others. Bundle only what is logically related. ### Where do postmarket cybersecurity commitments live? Postmarket cybersecurity monitoring, vulnerability disclosure, and patch cadence commitments typically become Approval Order conditions at PMA approval. Updates to those commitments usually require a supplement, not an annual report - they are part of the cleared design's safety profile. ### How does this interact with the Feb 3, 2026 FDA premarket cybersecurity guidance? The 2026 guidance defines the cybersecurity baseline for cleared devices. A PMA change that drifts the device away from that baseline is harder to justify as Special or as an annual report entry, even if the change-classification flowchart would have allowed it before. Treat the 2026 guidance as a ceiling on what lighter paths can absorb. ## Picking the right PMA change path? The wrong PMA submission path on a cybersecurity change is the kind of mistake that turns into a Warning Letter under Section 524B. We help PMA sponsors choose the path, build the supplement, and ship the cyber package. - **Have a cyber change and not sure which path?** → [Book a discovery call](/contact) - **Need the standards mapping first?** → [FDA PMA Cybersecurity Requirements guide](/guides/fda-pma-cybersecurity-requirements) - **Already received a PMA deficiency?** → [FDA Cybersecurity Deficiency Response service](/services/fda-cybersecurity-deficiency-response) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [PMA Cybersecurity Deficiencies and Complete Response Letters](/blog/fda-cybersecurity-pma-deficiencies-complete-response-letters) --- ## Medical Device Penetration Testing Post Exploitation | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/post-exploitation-frameworks-medical-device-cybersecurity # Medical Device Penetration Testing Post Exploitation Explained > **[DIRECT ANSWER]** Medical device penetration testing post exploitation covers what a tester does after gaining an initial foothold on a device or its supporting infrastructure: pivoting into clinical network segments, establishing persistence on embedded targets, mapping data exfiltration paths, and documenting findings against safety and security risk requirements. It requires strict rules of engagement when a device could be patient connected, since safety takes priority over demonstrating further compromise. _Reviewed September 17, 2026_ Getting initial access to a medical device tells a manufacturer very little on its own; what matters is what an attacker could do next. A tester who stops at the first foothold leaves the highest-impact questions unanswered: can this access reach the hospital network, can it survive a reboot, and what patient data or clinical function is actually exposed. Skipping post-exploitation work produces a report that looks thorough but misses the findings a manufacturer's risk file actually needs. At the same time, post-exploitation testing on a device that may be connected to a patient carries real safety stakes that a typical IT penetration test does not. A pivot technique that is routine on a corporate laptop can crash an infusion pump or interrupt a monitor. This piece covers what post-exploitation testing looks like for medical devices: pivoting, persistence, exfiltration paths, the safety controls that bound the engagement, and how findings connect to security risk documentation reviewers expect to see. ## Key Takeaways - Post-exploitation testing answers what an attacker can reach and sustain after initial access, not just whether access was possible. - Pivoting from a device into clinical network segments is often the highest-impact finding in a medical device engagement. - Persistence on embedded targets is frequently limited by firmware immutability, which itself is a finding worth documenting. - Rules of engagement must define stop conditions before testing starts, especially for devices that may be patient connected. - Every post-exploitation finding should map to a specific entry in the security risk management file, not stand alone in a report appendix. ## Why This Matters A penetration test that stops at initial access misrepresents the actual risk a device carries. Attackers who gain a foothold rarely stop there; they look for a path to higher-value systems, a way to survive a restart, and a channel to move data out. If a test does not simulate that behavior under authorized, scoped conditions, the resulting report cannot tell a manufacturer whether its network segmentation, logging, or monitoring would catch a real intrusion in progress. For manufacturers, this connects directly to the FDA's expectation that cybersecurity risk be evaluated across the total product lifecycle, including how an exploited device could affect patient safety and the broader clinical environment. A post-exploitation finding, such as a successful pivot from a device's management interface into a hospital VLAN, is often the single piece of evidence that changes a risk score from acceptable to unacceptable. Without it, a risk file may understate the real exposure. The stakes are different from a typical IT penetration test because many medical devices interact directly with patients. A technique that is safe to run against a server can cause a device to freeze, reboot, or deliver an incorrect therapy. This is why post-exploitation testing on medical devices requires explicit safety controls and rules of engagement agreed before testing starts, not improvised in the moment when a tester finds a promising path. ## What Happens After Initial Access? Initial access is the starting point, not the finding. Once a tester has a foothold, whether through a compromised credential, an exposed debug interface, or a vulnerable service, the post-exploitation phase asks what that foothold actually enables: further access, persistence, or data exposure. This typically follows a structured sequence: situational awareness of the compromised system, privilege escalation if needed, then a decision about whether to pivot, persist, or move directly to data collection based on the scope agreed with the manufacturer. Each of these steps should be logged in real time, not reconstructed afterward from memory. **[KEY REQUIREMENT]** Every post-exploitation action taken during a test must be pre-authorized in the scope document, including which pivot targets, persistence techniques, and data types are in bounds. Testers should not improvise beyond that scope even when a promising path appears mid-engagement. ## How Does Pivoting Work from a Device into Clinical Networks? Pivoting from a device answers whether a compromised device can be used as a launch point into the broader clinical network, which is often the most consequential question in the engagement. A device that sits on the same VLAN as clinical workstations, or that trusts a shared authentication domain, can turn a single-device compromise into a hospital-wide exposure. Testers evaluate this by attempting authorized lateral movement from the device toward higher-value network segments, checking whether network segmentation, firewall rules, and access controls actually enforce the boundaries a manufacturer's architecture diagram claims exist. A finding here is not just "segmentation failed"; it needs to specify which segment was reached and by what path. | Pivot Scenario | What It Tests | Typical Root Cause | |---|---|---| | Device to hospital VLAN | Whether network segmentation is enforced in practice | Flat network design or misconfigured VLAN tagging | | Device to cloud backend | Whether device credentials grant broader cloud access | Shared service accounts, overly broad API scopes | | Device to another device of the same model | Whether compromise of one unit compromises the fleet | Shared hardcoded credentials or signing keys | ## What Does Persistence Look Like on Embedded Targets? Persistence on an embedded medical device is often more limited than on a general-purpose computer, and that limitation is itself worth documenting. Many embedded devices use read-only or signed firmware partitions that make traditional persistence techniques, such as planting a startup script, impossible without also compromising the update or signing process. Where persistence is possible, common paths include writable configuration partitions, unsigned auxiliary firmware components, or persistence at the cloud and account level rather than on the device itself. A tester should confirm whether a reboot or factory reset actually clears the compromise, since a manufacturer's incident response plan depends on knowing whether that is true. **[KEY REQUIREMENT]** A post-exploitation test must explicitly state whether persistence was achieved on the device, in supporting cloud infrastructure, or not at all, because this determines whether a field remediation can rely on a simple reboot or requires a full device recall and reflash. ## What Are the Common Data Exfiltration Paths? Data exfiltration testing maps how patient data, credentials, or device secrets could leave the environment once an attacker has access, not just whether the data exists. Common paths include unencrypted telemetry channels, cloud storage buckets with overly broad access, and local logs that capture more patient data than the device's stated data flow diagram accounts for. Testers also check whether large or unusual data transfers would actually be detected, since a manufacturer's monitoring plan is only as good as the paths it covers. A finding that data could leave through a channel the manufacturer had not documented is often a bigger risk factor than the exfiltration itself, because it means the risk assessment missed that data flow entirely. Checklist of paths to test: - Telemetry and diagnostic channels to cloud backends - Local log files and crash dumps that may retain patient identifiers - Removable media or service ports used by field technicians - API responses that return more data than the requesting role needs ## What Evidence Belongs in the Report? A post-exploitation report needs to document the path taken, the systems reached, the data or capability exposed, and whether the activity would have been detected, not just a list of techniques attempted. Each finding should reference the specific security requirement or risk item it affects, so the manufacturer can route it directly into their risk management file rather than treating it as a standalone narrative. Evidence should include timestamps, the exact commands or requests used within the agreed scope, and screenshots or logs proving the outcome, since a reviewer or auditor needs to be able to trace the claim back to something verifiable. Retest results after remediation belong in the same report structure so the full lifecycle of the finding is visible in one place. **[KEY REQUIREMENT]** A post-exploitation report must state explicitly that a passing test does not attest the manufacturer's design inputs were met; that verification remains the manufacturer's own responsibility, using the test findings as one input among several. ## What Safety Controls and Rules of Engagement Apply to Patient-Connected Devices? Safety controls take priority over demonstrating further compromise whenever a device may be connected to, or capable of affecting, a patient. Rules of engagement must define stop conditions in advance: what device states trigger an immediate halt, which techniques are excluded entirely, and who has authority to pause the test. Testing against live patient-connected devices is generally avoided; instead, testers work against bench units, clinical simulators, or isolated lab environments configured to match production as closely as possible. Where a live or clinical environment must be used, a clinical safety observer and a documented rollback plan should be part of the engagement, not an afterthought. | Control | Purpose | |---|---| | Pre-agreed stop conditions | Halt testing before a device state could affect patient safety | | Bench or simulated test targets | Remove patient risk while preserving realistic findings | | Documented rollback plan | Restore a device to a known-good state if testing causes disruption | | Named engagement authority | Single point of contact who can pause or stop testing immediately | ## How Blue Goat Cyber Approaches This Blue Goat Cyber scopes post-exploitation activity around the manufacturer's actual architecture and risk file, rather than running a generic playbook against every device. That means agreeing on pivot targets, persistence boundaries, and stop conditions before testing starts, and mapping every finding back to a specific security requirement so it can be verified against the manufacturer's own design inputs. Engagements that involve potential patient-connected states include documented safety controls and, where warranted, use bench or simulated environments instead of live devices. This work is typically scoped as part of [medical device penetration testing](/services/medical-device-penetration-testing) engagements. ## Frequently Asked Questions ### Is post-exploitation testing safe to run on a device that could be connected to a patient? Direct testing on a live patient-connected device is generally avoided. Testers instead use bench units or clinical simulators configured to match production, with pre-agreed stop conditions and a rollback plan in place if the environment must be closer to live conditions. ### What is the difference between initial access and post-exploitation in a device test? Initial access confirms a tester could get into the device or its supporting system, while post-exploitation determines what that access actually enables, such as reaching other network segments, surviving a reboot, or exposing data. Post-exploitation findings usually carry more weight in a risk assessment because they show real impact. ### Can persistence actually be achieved on a medical device? It depends on the device's firmware architecture. Devices with signed, read-only firmware partitions often resist traditional persistence, while writable configuration areas or supporting cloud accounts can retain a compromise; a test should state clearly which was true for the device under evaluation. ### How do exfiltration findings connect to a manufacturer's risk documentation? Each exfiltration path identified during testing should map to a specific data flow or asset entry in the manufacturer's security risk management file. If a path is found that was not documented, that gap itself becomes a finding, since it means the risk assessment did not account for that data flow. ### Does a clean post-exploitation test mean the device is fully secure? No test result should be read as a guarantee of security or of a specific FDA outcome. A clean result means the specific techniques and scope tested did not succeed; the manufacturer is still responsible for verifying that its full set of security requirements was met. ## CTA If your device testing program stops at initial access, you may be missing the findings that matter most for your risk file. [Book a discovery call](/contact) to scope a post-exploitation assessment that fits your device's safety profile. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian works with medical device manufacturers on FDA premarket submissions and postmarket cybersecurity compliance. [Read more about Christian](/christian-espinosa). --- ## FDA Postmarket Cybersecurity for Cleared Source: https://bluegoatcyber.com/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap # FDA Postmarket Cybersecurity Guidance: The 2026 Roadmap for Cleared Medical Devices > **[DIRECT ANSWER]** The FDA postmarket cybersecurity roadmap for cleared medical devices requires continuous vulnerability monitoring keyed to a current SBOM, validated patch testing with regression evidence, a published coordinated vulnerability disclosure policy, and 21 CFR Part 806 reporting within 10 working days when a correction could prevent death or serious injury. These obligations run under Section 524B for the device's full commercial life, not just at clearance, and every risk decision needs documented rationale. ## Key Takeaways - What the FDA Postmarket Cybersecurity Guidance Actually Requires. - Building a vulnerability monitoring program that holds up. - Postmarket patch management: validation, timing, and deployment. - Coordinated vulnerability disclosure and FDA incident reporting. - The documentation your compliance program needs on file. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this **fda postmarket cybersecurity guidance** the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## What the FDA Postmarket Cybersecurity Guidance Actually Requires ### Postmarket Management of Cybersecurity in Medical Devices: The 2016 Guidance and Section 524B The FDA finalized its [Postmarket Management of Cybersecurity in Medical Devices guidance](https://www.fda.gov/media/95862/download) on December 27, 2016. That document established a risk-based framework for managing cybersecurity vulnerabilities across the full device lifecycle, covering everything from monitoring and assessment through mitigation and disclosure. It wasn’t optional in practice: manufacturers who ignored it still needed to demonstrate device safety and effectiveness under existing law. The full FDA postmarket cybersecurity guidance is also available as an official downloadable PDF for reference: [FDA postmarket cybersecurity guidance PDF](https://www.fda.gov/media/102583/download). [Section 524B of the FD&C Act](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket), which took effect March 29, 2023, moved the needle further. Manufacturers of “cyber devices” must now include a postmarket cybersecurity plan in their premarket submission, covering how they will monitor, identify, and address vulnerabilities after clearance. The obligation doesn’t expire once the device ships. It’s a continuous requirement tied to the device’s commercial life, and the FDA’s February 2026 guidance updates reinforce that posture with enhanced SBOM requirements and stricter lifecycle documentation expectations. For a targeted breakdown of how recent regulatory updates affect device makers, see [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). ### Which devices fall under these obligations The framework applies to any device that uses software, including programmable logic, mobile medical apps, and software regulated as a device. The vast majority of connected devices on the market qualify as “cyber devices” under the statute’s definition. Ignoring these obligations isn’t a gray area: the FDA explicitly ties cybersecurity to device safety and effectiveness, which means a gap in your postmarket program is a gap in your safety case. ## Building a vulnerability monitoring program that holds up ### Where to monitor and how to filter signal from noise A monitoring program that doesn’t scale is one that gets abandoned. Manufacturers need to pull from specific, authoritative sources continuously: the [National Vulnerability Database](https://nvd.nist.gov/), ICS-CERT medical advisories, vendor security bulletins, and third-party component trackers. Without a structured intake mechanism, the volume of incoming advisories becomes unmanageable fast. The key is screening incoming data against the device’s actual software components, which is exactly what your Software Bill of Materials makes possible. A current, accurate SBOM for your device lets you eliminate irrelevant vulnerability reports immediately and focus engineering attention on components that are actually present in your build. Without a current SBOM, your team faces an impossible choice: drown in noise or miss something critical. For a deeper look at lifecycle practices that include SBOM management and related monitoring, see [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide). ### Scoring risk with clinical impact in mind The FDA recommends using the [Common Vulnerability Scoring System](https://www.first.org/cvss/) as a baseline, but manufacturers cannot stop there. CVSS scores reflect technical severity in a generic context. They don’t account for what happens when that vulnerability exists in a cardiac monitor or an infusion pump in a clinical setting. The FDA’s postmarket guidance recommends a two-factor assessment: exploitability of the vulnerability combined with the severity of patient harm if that vulnerability were exploited. A moderate CVSS score on a component that governs essential clinical performance carries a fundamentally different risk profile than the same score on a logging module. Clinical impact is the determining factor, and your risk documentation needs to reflect that reasoning explicitly. ## Postmarket patch management: validation, timing, and deployment ### The validated patch testing process Patches for cleared medical devices aren’t hotfixes. The FDA expects software updates to go through a design verification and validation process that includes regression testing against essential clinical performance, documentation of the testing rationale, and evidence that the update doesn’t introduce new risk. This is a meaningful departure from how most software teams handle security patches. One practical structure that works: a dedicated software-sustaining engineering group that handles third-party patch validation separately from new product development. This separation lets the team respond quickly to incoming advisories without disrupting active development cycles. It also creates a clear audit trail showing that patch work follows a defined, repeatable process rather than ad hoc remediation. ### When you must report versus when you can act quietly Under [21 CFR Part 806](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-806), manufacturers must report corrections to the FDA within 10 working days when a vulnerability correction could reasonably be expected to prevent death or serious injury. That’s the threshold that triggers mandatory reporting, and it’s specific. Proactive cybersecurity improvements that don’t meet that threshold do not require FDA reporting under the postmarket guidance, which gives manufacturers meaningful room to patch routinely without triggering a formal submission. What you do need is documented rationale for that determination. Every time your team assesses a vulnerability and concludes that a correction falls below the reporting threshold, that conclusion needs to be recorded in the risk management file with the reasoning that supports it. That record is what protects you during an inspection or audit. ## Coordinated vulnerability disclosure and FDA incident reporting ### CVD policy structure and realistic timelines Every cleared device manufacturer needs a published coordinated vulnerability disclosure policy. The core components are straightforward: a secure intake channel (a dedicated security email address or web form), a commitment to acknowledge reports within a defined timeframe, severity-based response timelines, and a process for coordinating with other affected vendors when a vulnerability spans multiple products. Standard timelines run 60 to 90 days for typical vulnerabilities, with expedited response when active exploitation is observed. [CERT/CC](https://www.sei.cmu.edu/about/divisions/cert/) and [FIRST](https://www.first.org/) set the norms here, and aligning your policy with their frameworks signals to researchers that you take disclosure seriously. For multi-party coordination specifics and accepted procedural norms, consult the [multiparty coordinated vulnerability disclosure guidelines](https://www.first.org/global/sigs/vulnerability-coordination/multiparty/guidelines-v1.1). Multi-party coordination is the hardest part operationally. Establishing those relationships upstream with component vendors before a vulnerability surfaces is far easier than trying to coordinate during a live incident. That groundwork is worth building now. ### Notifying customers, healthcare facilities, and the FDA When a vulnerability is confirmed and a patch is available, the notification sequence matters. Internal triage comes first, followed by healthcare facility notification with clear remediation instructions, then patient or provider notification where the clinical risk warrants it. FDA Medical Device Reporting under [21 CFR Part 803](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-803) applies when the cybersecurity risk meets the threshold for serious injury or death. The content of notifications carries real weight. Vague advisories that don’t identify affected product versions, don’t include a clinical risk assessment, and don’t provide specific remediation steps aren’t acceptable. Specificity is expected, and healthcare facilities need actionable information to protect patients. Notifications that bury the important details in boilerplate undermine the entire purpose of the disclosure process. ## The documentation your compliance program needs on file ### Maintaining and updating your SBOM The FDA’s updated guidance requires manufacturers to keep their SBOM current across the device’s commercial life. That means tracking all commercial, open-source, and off-the-shelf components with accurate version information, updated whenever the software changes. An SBOM that reflects a build from two years ago is functionally useless for vulnerability monitoring because you can’t match NVD advisories against components you haven’t tracked accurately. Traceability matters here too. The FDA expects a clear link between components in the SBOM and known vulnerabilities identified through monitoring. The cadence for SBOM review should tie directly to software updates and any discovery of new relevant vulnerabilities. For teams using CI/CD pipelines, automating [SBOM generation](/services/fda-compliant-sbom-services-for-medtech) at each release is the most reliable way to keep this current without adding manual overhead. ### Risk management records that demonstrate ongoing diligence A postmarket surveillance security program is only as defensible as its records. The FDA expects documentation of each vulnerability assessment, including the input data, the scoring rationale, the clinical impact determination, and the resulting decision. Patch validation test reports, CVD communications, MDR submissions, and updates to the cybersecurity risk management plan all belong in this file. These records serve a purpose beyond audit preparation. They form the chain of evidence that proves your program is active and functioning, not just documented on paper. An inspector who can trace a vulnerability from initial discovery through assessment, remediation, and notification is looking at a program that works. An inspector who finds gaps in that chain is looking at a liability. ## 30/60/90-Day Postmarket Cybersecurity Implementation Checklist Use this checklist to build and operationalize your postmarket cybersecurity program in the first 90 days after launch. ### First 30 Days: Build the Backbone - Assign ownership and escalation paths - Create and test a vulnerability intake channel - Define triage criteria and severity rules - Inventory products, versions, and deployment environments ### By 60 Days: Operationalize Monitoring and SBOM Use - Establish SBOM coverage for shipping products and major supported versions - Set up vulnerability monitoring tied to your SBOM - Define patch release steps (including verification expectations) - Create customer advisory templates (clear, actionable, non-alarmist) ### By 90 Days: Prove You Can Execute - Run a tabletop exercise: "New CVE impacts our device - what happens next?" - Measure response time from intake → triage → decision → guidance - Fix bottlenecks (ownership, testing, approvals, customer communications) - Start recurring reviews with basic metrics and continuous improvement ## Common Postmarket Mistakes to Avoid - No defined workflow (everything is ad hoc) - No coordinated vulnerability disclosure path (or an inbox nobody monitors) - Risk decisions not tied to device context or patient impact - SBOM created once and never updated - Patches released without adequate verification and validation - Customer communications that are vague, late, or overly technical - No evidence trail (which makes audits and future submissions harder) ## When to Use a Managed Postmarket Cybersecurity Program ### Why the ongoing burden catches manufacturers off guard Most device teams staff for the sprint to clearance. The premarket phase has a defined endpoint, and headcount decisions reflect that. Postmarket cybersecurity risk management has no endpoint: new vulnerabilities appear daily, SBOMs need updating after every software release, CVD responses require fast coordination, and documentation must stay current across the device's entire commercial life. Teams without a dedicated product security function find this is where programs quietly stop working. ### When a specialized partner changes the equation For device makers without the internal bandwidth to run this program reliably, specialized support keeps compliance active without pulling engineering resources away from product development. The alternative is a program that exists on paper but breaks down in practice, a risk that compounds over time as your device fleet ages and new vulnerabilities accumulate. ## How Blue Goat approaches this Blue Goat Cyber specializes exclusively in medical device cybersecurity, offering targeted services to meet postmarket requirements. Our approach focuses on developing and implementing practical, defensible vulnerability management programs tailored to the FDA's expectations. We assist manufacturers in establishing continuous SBOM monitoring, defining clear coordinated vulnerability disclosure policies, and executing validated patch management processes with careful documentation. Our team, featuring CISSP and OSCP certified experts, many from ex-military red teams, understands the nuances of both offensive security and regulatory compliance. We don't just identify gaps; we build the infrastructure required to maintain security over the entire product lifecycle. ## FAQ ### What does FDA's postmarket cybersecurity guidance actually require from cleared device manufacturers? The FDA postmarket cybersecurity guidance imposes five continuous obligations: vulnerability monitoring tied to a current SBOM, a published coordinated vulnerability disclosure (CVD) policy, validated patch management with documented rationale, FDA incident reporting under 21 CFR Part 806 when corrections could prevent death or serious injury, and ongoing risk management records. These flow from the 2016 Postmarket Management of Cybersecurity in Medical Devices guidance and Section 524B of the FD&C Act. ### When must a manufacturer report a cybersecurity vulnerability to the FDA? Under 21 CFR Part 806, manufacturers must report a correction within 10 working days when that correction could reasonably be expected to prevent death or serious injury. Proactive cybersecurity improvements below that threshold do not require FDA reporting - but your rationale for that determination must be documented in the risk management file. That documented reasoning is what protects the determination during an inspection. ### How often does the SBOM need to be updated after clearance? The SBOM must be updated with every software change - new components, version bumps, removed dependencies. For teams using CI/CD pipelines, automate SBOM generation at each release. The FDA expects the SBOM to reflect the current shipping build, not the submission-time snapshot. A stale SBOM makes vulnerability monitoring functionally impossible because incoming advisories cannot be reliably matched against components actually present in your device. ### What is a coordinated vulnerability disclosure policy and does our device need one? A CVD policy defines how you receive, acknowledge, assess, and respond to vulnerability reports from external researchers. If your device qualifies as a cyber device under Section 524B, this is an FDA expectation. Core elements: a secure intake channel, a defined acknowledgment timeframe, severity-based response windows (typically 60-90 days), and a multi-vendor coordination process for vulnerabilities that span multiple products or components. ### What happens if we don't have a functioning postmarket cybersecurity program and FDA asks about it? FDA ties cybersecurity directly to device safety and effectiveness, so a gap in your postmarket program is a gap in your safety case. During inspections, FDA can request vulnerability monitoring records, SBOM update history, patch validation reports, and CVD communications. Programs that exist on paper but not in practice are a documented liability. Blue Goat Cyber resolves all cybersecurity deficiencies at no additional cost for devices under our management. ## Audit Your Postmarket Program If FDA raises cybersecurity deficiencies on a device we manage, we resolve them at no additional cost. Book a free postmarket strategy call to audit your current program and identify what needs to be closed. [**Book a free postmarket strategy call**](/services/fda-postmarket-cybersecurity-services) *30 minutes · No cost · No commitment* --- ### About the Author **Christian Espinosa** | Founder & CEO, Blue Goat Cyber | CISSP Christian has built and managed postmarket cybersecurity programs for device manufacturers across 275+ FDA submissions. He founded Blue Goat Cyber to solve a problem he experienced personally: most MedTech teams clear their devices and then discover postmarket obligations with no infrastructure in place to meet them. --- ### Related Articles in This Series - [PATCH Act Only Applies to New Medical Devices, Leaves Legacy Systems a Risk](/blog/patch-act-only-applies-to-new-medical-devices-leaves-legacy-systems-a-risk) - [Ventilator Recalled for Cybersecurity Risk: Was a Lack of Secure by Design the Cause?](/blog/recalled-medical-devices-cybersecurity-failures) - [Securely Updating Medical Devices](/blog/patch-update-mechanism-fda-section-524b-testing) - [Medical Device OTA Update Vulnerabilities](/blog/ota-update-vulnerabilities) - [What is a Coordinated Vulnerability Disclosure Process?](/cvd) - [IMDRF: Harmonizing Med Device Regulations](/blog/imdrf-for-medical-devices-harmonizing-global-regulations) --- ## More on this topic - [FDA Cybersecurity Failure Consequences](/blog/fda-cybersecurity-failure-consequences-medical-devices) --- ## Premarket Cybersecurity in Your QMS: ISO 13485 & QMSR Source: https://bluegoatcyber.com/blog/premarket-cybersecurity-deliverables-qms-integration-iso-13485-qmsr # Integrating Premarket Cybersecurity Deliverables Into Your QMS (ISO 13485 / QMSR) > **[DIRECT ANSWER]** FDA premarket cybersecurity deliverables are quality-system outputs, not a parallel stack. Under the QMSR (effective Feb 2, 2026), each artifact lands in a specific ISO 13485 clause - design controls (7.3), risk management (7.1 + ISO 14971), or measurement/improvement (Clause 8) - so the same records that support your submission also run your Section 524B postmarket program. Quality and regulatory teams are right to scrutinize anything that touches the design history file. The concern usually takes one of two forms: outsourced deliverables will arrive as a separate stack of PDFs that live outside the quality system, or the method behind the submission will not be something the QMS can carry forward for the life of the device. Both worries rest on a premise the current FDA framework has retired. Cybersecurity is no longer a bolt-on to the submission - it is an output of the quality system itself. ## Key Takeaways - Cybersecurity artifacts are **QMS records first, submission attachments second**. - Under QMSR, ISO 13485:2016 Clause 7.3 replaces standalone 21 CFR 820.30 design controls. - The **Secure Product Development Framework (SPDF)** is designed to integrate with existing design, risk, and CAPA processes. - Every deliverable has a defined home in the **DHF, risk management file, or DMR/purchasing records**. - Section 524B postmarket obligations run on the same file, so integration is what makes a clearance sustainable. ## Why this matters On February 2, 2026, the FDA's final rule amending 21 CFR Part 820 took effect. The revised Part 820 - the **Quality Management System Regulation (QMSR)** - incorporates ISO 13485:2016 by reference. For US manufacturers, ISO 13485 and the QMSR are now effectively one framework. One day later, on February 3, 2026, the FDA issued the final guidance *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*. The title is not incidental: the guidance is explicit that documentation "related to the ongoing requirements of the QMSR may be one source of documentation to include as part of the premarket submission," and it describes "how the QMSR can be leveraged to demonstrate these performance outputs." Add Section 524B of the FD&C Act on top of that, and the picture is clear. Cybersecurity is a statutory requirement, its evidence lives in your quality system, and the same records you file at premarket are what carry your postmarket obligations. Recognized consensus standards - ISO 14971, ANSI/AAMI SW96, AAMI TIR57, IEC 81001-5-1, and IEC 62304 - are the language the artifacts are written in. ## What the framework actually says The QMSR keeps ISO 13485 as the core of the quality system and retains only a few FDA-specific sections on top of it, notably §820.35 (control of records) and §820.45 (device labeling and packaging). Three anchor points in that framework carry almost the entire cybersecurity file: - **Design and development, ISO 13485 Clause 7.3.** Design inputs, outputs, review, verification, validation, transfer, and change control. The home for security requirements, architecture, and testing evidence. - **Risk management, ISO 13485 Clause 7.1 with ISO 14971.** The home for the threat model, cybersecurity risk assessment, and residual-risk decisions. - **Measurement, analysis and improvement, Clause 8.** Complaints (8.2.2), CAPA (8.5), and servicing (7.5.4). The home for the postmarket cybersecurity management plan and coordinated disclosure. The FDA ties these together through the **Secure Product Development Framework (SPDF)** - a set of processes that reduce vulnerabilities across the lifecycle and that, in the FDA's words, "can be integrated with existing processes for product and software development, risk management, and the quality system at large." ## Where every deliverable lives The design history file and risk management file do most of the work, with the device master record and purchasing picking up the rest. The table below maps each premarket cybersecurity deliverable from the FDA's 2026 guidance to its home in an ISO 13485 / QMSR-aligned QMS. | Deliverable | ISO 13485 Clause | QMS Record Type | 524B / FDA Tie-in | | --- | --- | --- | --- | | Security Requirements & Control Coverage | 7.3.3 | Design input (DHF) | 524B(b)(1) secure design | | Security Architecture Views (global, multi-patient-harm, updateability, security-use-case) | 7.3.4 | Design output (DHF) | 524B(b)(1); guidance §V.A.3 | | Static Application Security Testing (SAST) | 7.3.6 | Design verification (DHF) | Guidance §V.B.2 | | Penetration Test Plan, Cases, Report | 7.3.2, 7.3.6 | Verification planning + record (DHF); findings → CAPA 8.5 | Guidance §V.B.4 | | Assessment of Unresolved Anomalies | 7.3.6 | Design verification record (DHF) | Guidance §V.B.5 | | Threat Model | 7.1 (with ISO 14971) | Hazard identification input (RMF) | Guidance §V.A.2 | | Cybersecurity Risk Assessment | 7.1 (with ISO 14971) | Security risk record bridged to safety (RMF) | Guidance §IV | | Interoperability Risk Assessment | 7.1 (with ISO 14971) | Connected-use risk record (RMF) | Guidance §V.A.4 | | Risk Management Report | 7.1 (with ISO 14971) | Residual-risk acceptability record (RMF) | Guidance §IV | | SBOM | 7.4, 7.5.1 | Controlled record (DMR) | 524B(b)(3); §820.35 | | Component Support & End-of-Support | 7.4 | Supplier-controlled information | 524B(b)(2) postmarket | | MDS2 | 7.5.1 | Labeling / communication record (DMR) | Guidance §VI | | Interoperability Labeling | 7.3.4, 7.5.1 | Labeling record (DMR) | Guidance §V.A.4 | | Cybersecurity Management Plan | 4.2, 8.2 | Process record | 524B(b)(2) postmarket | Reading the map: requirements, architecture, and controls are design inputs and outputs; SAST and penetration testing are design verification; the threat model and risk assessments populate the risk management file; labeling, MDS2, and SBOM belong to the device master record and purchasing. > **[KEY REQUIREMENT] How these records attach in eSTAR v7.0** > > eSTAR v7.0 (mandatory for 510(k) as of Oct 1, 2023, and required for most De Novo submissions from Oct 1, 2025) surfaces cybersecurity as a dedicated section that pulls directly from the QMS records above. At submission time, each deliverable is attached to a specific eSTAR node - the QMS record ID travels with it so the file stays traceable: > > - **Cybersecurity Management Plan** - eSTAR §Cybersecurity > *Security Risk Management Plan*. Source: QMS process record (Clause 4.2 / 8.2). > - **Threat Model + Cybersecurity Risk Assessment + Risk Management Report** - eSTAR §Cybersecurity > *Security Risk Assessment* and *Risk Management Report*. Source: risk management file (Clause 7.1 / ISO 14971). > - **Security Architecture Views** (global system, multi-patient harm, updateability, security-use-case) - eSTAR §Cybersecurity > *Architecture Views*. Source: DHF design outputs (Clause 7.3.4). Attach all four as separate PDFs. > - **SBOM + Vulnerability Assessment + Component Support/EOS** - eSTAR §Cybersecurity > *Software Bill of Materials*. Source: DMR / purchasing records (Clause 7.4, 7.5.1). SBOM in SPDX or CycloneDX; VEX as companion file. > - **SAST report + Penetration Test Plan/Report + Assessment of Unresolved Anomalies** - eSTAR §Cybersecurity > *Cybersecurity Testing*. Source: DHF verification records (Clause 7.3.6). > - **Security Requirements & Control Coverage** - eSTAR §Cybersecurity > *Security Controls*. Source: DHF design inputs (Clause 7.3.3). > - **Interoperability Risk Assessment + Interoperability Labeling** - eSTAR §Cybersecurity > *Interoperability* and §Labeling. Source: risk management file + DMR. > - **MDS2** - eSTAR §Labeling (customer-facing security disclosure). Source: DMR labeling record. > > Practical tip: name each PDF with its controlled document ID (e.g. `BGC-SRA-001-Rev-B_Security-Risk-Assessment.pdf`) so the eSTAR attachment and the QMS record are one lookup, not two. ## Ownership and control of the records A guidance artifact only integrates if the manufacturer owns it and can keep it controlled over the life of the device. Well-authored deliverables carry a stable document ID and revision indicator, are written to sit as a design input, design output, verification record, or risk file entry (not a free-form report), and are delivered with editable source so the manufacturer can maintain them. Approval routing runs through the sponsor's normal design review and risk review gates, not a separate track. ## How 21 CFR Part 11 applies to the DHF and RMF When the DHF and risk management file are maintained electronically (which they almost always are), the records and their approvals fall under **21 CFR Part 11 - Electronic Records; Electronic Signatures**. Part 11 does not change *what* the QMSR and ISO 14971 require; it governs *how* the electronic versions of those records must be trustworthy, reliable, and equivalent to paper. Four Part 11 controls carry the weight for cybersecurity deliverables: - **§11.10(a) Validation** - the eQMS, DHF/RMF repository, and any tool that generates a controlled record (SBOM generator, SAST platform, pen-test reporting tool) must be validated for intended use. Keep the validation record as an input to the design output that depends on the tool. - **§11.10(e) Audit trails** - secure, computer-generated, time-stamped audit trails on every create, modify, and delete of a DHF or RMF record. The threat model, cybersecurity risk assessment, and verification reports must show *who* changed *what* and *when*, retained for the life of the record. - **§11.10(c) Record protection and retention** - records are retained for the life of the device plus the retention period defined in the QMS. Backups, access controls, and integrity checks are Part 11 obligations, not just IT hygiene. - **§11.50 and §11.70 Electronic signatures** - design reviews, risk-acceptance decisions, and verification approvals signed electronically must include the printed name of the signer, date and time, and the meaning of the signature (author, reviewer, approver), and must be linked to the record so they cannot be excised or copied. Practical rule: if a cybersecurity deliverable is approved in the eQMS with an electronic signature, the eQMS's Part 11 validation package and audit trail are part of that record's defensibility. Author the deliverable, register it in the eQMS, route it through the same electronic signature workflow used for the rest of design controls, and the Part 11 posture is inherited rather than rebuilt. ### Example Part 11 audit trail entries Below is what a compliant audit trail should capture for a single cybersecurity deliverable (here, `THM-014 Threat Model v1.2`) as it moves from creation through modification to approval. Every row is computer-generated, time-stamped in UTC, tied to an authenticated user, and immutable. | Timestamp (UTC) | Record ID | Version | Action | User (role) | Signature meaning | Reason for change | Prior value / hash | New value / hash | |----------------------|-----------------|---------|---------------|--------------------------------|-------------------|--------------------------------------------|-----------------------------|-----------------------------| | 2026-03-04 14:02:11Z | THM-014 | 1.0 | CREATE | j.rivera (Security Engineer) | Author | Initial threat model for Device X rev B | (none) | sha256:9f2c...a41 | | 2026-03-11 09:47:33Z | THM-014 | 1.1 | MODIFY | j.rivera (Security Engineer) | Author | Added 3 STRIDE threats from DFD update | sha256:9f2c...a41 | sha256:b703...12e | | 2026-03-12 16:20:05Z | THM-014 | 1.1 | REVIEW | s.okafor (Cyber Lead) | Reviewer | Technical review complete, no findings | sha256:b703...12e | sha256:b703...12e | | 2026-03-14 11:08:52Z | THM-014 | 1.2 | MODIFY | j.rivera (Security Engineer) | Author | Incorporated reviewer comments on control mapping | sha256:b703...12e | sha256:c8d1...9f4 | | 2026-03-15 13:45:19Z | THM-014 | 1.2 | APPROVE | m.chen (Design Assurance Mgr) | Approver | Approved for DHF; released to design review | sha256:c8d1...9f4 | sha256:c8d1...9f4 (locked) | Notes on what makes this Part 11 defensible: - **Who / what / when** is captured on every row (§11.10(e)), including the *meaning* of each signature (Author, Reviewer, Approver) per §11.50. - **Reason for change** is required on modifications after initial approval and on any record-affecting override. - **Prior and new content hashes** demonstrate integrity (§11.10(c)) so any tampering is detectable. - Once APPROVE is signed, the record is locked; further changes require a new version and a new signature cycle, not an overwrite. - The same schema applies to the RMF (`RMF-*` risk assessments, `SR-*` cybersecurity risk items) and to verification and validation records supporting the cybersecurity deliverables. ## How this ties into postmarket Clearance is not the finish line. Section 524B and the QMSR both impose ongoing cybersecurity obligations, and the premarket file is what those obligations run on. Monitoring (vulnerability and KEV feeds, SBOM/VEX upkeep) feeds triage, which feeds coordinated disclosure and CAPA, which updates the same DHF and risk management file that supported the submission. That is why integration matters: a submission built on records the QMS can carry forward is one continuous file, not a fresh start every eighteen months. ## Common concerns **"Our QMS does not have a cybersecurity process. Do we need to write one?"** Not a parallel one. Cybersecurity activities attach to the procedures already in place: design controls (7.3), risk management (7.1), purchasing (7.4), and CAPA and complaints (8.x). Where a light procedural hook is useful - for example referencing the threat model as a design input or the management plan in the complaint-handling SOP - the change is a cross-reference, not a new quality system. **"Are these records subject to FDA inspection?"** Yes. Once filed in the DHF and risk management file, they are inspectable like any design or risk record under the QMSR. That is the point of authoring them as controlled records from day one. **"What happens when we make a design change after clearance?"** The same design change control (7.3.9) applies. The threat model, risk assessment, and verification evidence are updated as part of the change, and any submission consequence (letter to file, Special 510(k), or new submission) is a downstream determination the manufacturer makes against its already-updated file. ## How Blue Goat approaches this Blue Goat Cyber authors every premarket cybersecurity deliverable as a controlled record designed to drop into a specific ISO 13485 / QMSR clause - design input, design output, verification record, or risk management file entry - with a stable document ID and editable source. The methodology follows the FDA Secure Product Development Framework and the Feb 3, 2026 final premarket guidance, referencing ISO 14971, ANSI/AAMI SW96, IEC 81001-5-1, and IEC 62304 so the artifacts read in the same language as the rest of the technical file. Our team (CISSP, OSCP, ex-military red team) leads the technical authoring; the sponsor's quality and regulatory team registers, approves, and owns each record. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. See our [FDA premarket cybersecurity service](/services/fda-premarket-cybersecurity-services) for the full deliverable set. **Download the full guide:** [Integrating Premarket Cybersecurity Deliverables Into Your QMS (PDF)](/__l5e/assets-v1/3c00b75d-c3ad-459d-8a39-d5a0f4358962/qms-integration-guide.pdf) - the deliverable-to-clause table, ownership matrix, and postmarket tie-in. ## FAQ ### Are FDA premarket cybersecurity deliverables part of the quality management system? Yes. The Feb 3, 2026 FDA guidance is titled *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* and states that QMSR documentation is "one source of documentation to include as part of the premarket submission." The artifacts are QMS records first and submission attachments second. ### Where does the threat model live under ISO 13485? The threat model is a hazard-identification input to the risk management file under Clause 7.1, integrated with ISO 14971. It is not a standalone document - it feeds the cybersecurity risk assessment and the overall risk management report, and it is updated whenever design changes affect the attack surface. ### Does the QMSR replace 21 CFR 820.30 design controls for cybersecurity? Yes. Effective February 2, 2026, the QMSR incorporates ISO 13485:2016 by reference. The former standalone §820.30 design-controls section is satisfied through ISO 13485 Clause 7.3. Security requirements are design inputs (7.3.3), architecture is a design output (7.3.4), and SAST and penetration testing are design verification (7.3.6). ### Do I need a separate cybersecurity SOP? Usually no. Cybersecurity activities attach to existing procedures: design controls, risk management, purchasing, and CAPA. A light cross-reference in the existing SOPs - naming the threat model as a design input, or the cybersecurity management plan in complaint handling - is typically sufficient. ### How do the same records support Section 524B postmarket obligations? The premarket file becomes the postmarket file. Vulnerability monitoring, SBOM/VEX upkeep, and coordinated disclosure feed the complaint handling (8.2.2) and CAPA (8.5) processes, which update the same DHF and risk management file that supported the submission. That continuity is what makes 524B compliance operationally sustainable. ## Related reading - [FDA Section 524B Subsections Explained](/blog/fda-section-524b-subsections-explained) - [Types of 510(k): Traditional, Special, and Abbreviated Explained](/blog/types-of-510k-traditional-special-abbreviated-cybersecurity) - [Did AAMI SW96 Replace TIR57 for FDA Submissions?](/blog/did-aami-sw96-replace-tir57-fda-2026) - [The Impact of 524B(b)(2) on Medical Device Cybersecurity](/blog/the-impact-of-524bb2-on-medical-device-cybersecurity) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance under the QMSR. [Read more about Christian](/christian-espinosa). --- ## eSTAR 510(k) Cybersecurity Documentation Source: https://bluegoatcyber.com/blog/preparing-your-estar-510k-cybersecurity-documentation # Preparing Your eSTAR 510(k) Cybersecurity Documentation > **[DIRECT ANSWER]** An eSTAR 510(k) needs the full cybersecurity set: security risk assessment, threat model, SBOM with support and vulnerability status, architecture views, SPDF evidence, verification and penetration test reports, labeling, and the postmarket management plan. The fastest way to avoid deficiencies is a traceability matrix that maps each eSTAR cybersecurity prompt to the exact document and section that answers it. If you're asking how to prepare cybersecurity documentation for an FDA eSTAR 510(k) submission, the answer starts with understanding what reviewers are actually screening for, artifact by artifact. Cybersecurity documentation deficiencies are among the most frequently cited causes of Refuse to Accept (RTA) determinations and Additional Information (AI) requests in 510(k) reviews, according to FDA's premarket cybersecurity guidance. That's not a technicality; it means submissions get stopped before a substantive review even begins and timelines slip by months. The frustrating part is that most manufacturers arrive at the eSTAR template with a general idea of what cybersecurity documentation means, but no clear picture of what FDA reviewers actually want to see. The template itself doesn't explain it. This guide walks through every cybersecurity artifact the FDA expects for a new 510(k) submission, section by section, so you can build a complete package the first time. At Blue Goat Cyber, we've produced 275+ FDA submissions with zero cyber-related rejections, backed by a FDA cybersecurity deficiency commitment. What follows is exactly what goes inside one of those packages. ## Key Takeaways - Cyber device classification dictates required documentation tiers. - eSTAR v7.0 has one Cybersecurity attachment area, not per-deliverable slots. - Core artifacts: Threat Model, Risk Assessment, SBOM, SPDF evidence. - SBOMs must be complete, including open-source dependencies. - Testing reports require scope, methodology, findings, and re-test evidence. - Traceability matrix links risks, controls, and testing results. ## Why this matters Inadequate cybersecurity documentation is a primary reason for Refuse to Accept (RTA) determinations and additional information (AI) requests from the FDA for 510(k) submissions. Such delays can push product launches back by months, incurring significant financial penalties and lost market opportunities for medical device manufacturers. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly outlines the necessity for a structured approach to premarket cybersecurity documentation, emphasizing clear evidence of risk management throughout the device lifecycle. Failure to align with these guidelines and related standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023)/TIR97 not only risks regulatory delays but also exposes devices to potential vulnerabilities once deployed. An RTA or AI request signifies that the submission does not even meet the administrative requirements for review, indicating a fundamental mismatch between the submitted documentation and the FDA's expectations. This highlights the critical importance of a precise and complete cybersecurity package from the outset. ## Does Your Device Qualify as a "Cyber Device" Under Section 524B? [Section 524B of the FD&C Act](/guides/fda-524b-cybersecurity-requirements-explained) defines a cyber device as one that meets all three of the following criteria: it contains software (including firmware), it has the ability to connect to the internet, and it contains technological characteristics that could be vulnerable to cybersecurity threats. The FDA interprets "ability to connect" broadly. A device with unintentional wireless exposure, such as one that could be connected through a service port or a hospital network it wasn't designed for, still qualifies. This determination is the first decision point in your submission strategy. If your device qualifies as a cyber device, the documentation tier you need depends on whether you're submitting a new device or a modification. New submissions and security-impacting modifications require the full artifact set described throughout this guide. Non-security-impacting modifications require a lighter package focused on the SBOM, a Software Component Risk Management Report, and supporting risk documentation. **Misclassifying a modification as non-security-impacting is one of the most common deficiency triggers.** Reviewers will look for explicit justification, for example, a documented impact analysis tracing the change through your risk assessment, and "we didn't change any security features" is not sufficient without that supporting analysis. ## How the eSTAR Template Structures Cybersecurity Requirements eSTAR v7.0 (released June 1, 2026, and used for both the non-IVD and IVD templates) provides a single Cybersecurity attachment area, not one enforced slot per deliverable. The template checks that the area is populated before a human reviewer sees the submission, but it does not tell you how to organize what goes inside. That part is on the sponsor. The roughly 15 deliverables described in the FDA's February 3, 2026 final guidance all land in that one area, so the packaging we use groups them into clearly named attachments: management plan, security risk management, threat model with architecture views, risk assessment, SBOM, security controls, testing, and metrics. Labeling content stays in the separate Labeling section. See our [eSTAR v7.0 cybersecurity mapping guide](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) for the deliverable-by-deliverable breakdown. For new submissions and security-impacting modifications, the required artifacts are non-negotiable. Omissions from Appendix 1 of the FDA's cybersecurity guidance are flagged as deficiencies during technical screening. The core artifact set includes: - Security Risk Management Plan - Threat Modeling and Security Architecture Report - Cybersecurity Risk Assessment Report - Software Bill of Materials (SBOM) - SBOM Support Report Those five documents form the foundation. Each one must be device-specific, not adapted from a template without substantive modification, and not written to describe what you plan to do rather than what you did. Reviewers are trained to spot documentation that reads like a generic framework, and it frequently generates AI requests. ## Building Your Core Documentation: Threat Model, Risk Assessment, and SPDF Evidence The Threat Modeling and Security Architecture Report is the backbone document the rest of your package references. It must identify your device's attack surface, document threat scenarios using [STRIDE](/guides/stride-threat-modeling-medical-devices) or an equivalent methodology, map threats to device assets, and include architectural diagrams showing trust boundaries and data flows. FDA reviewers expect to see how the threat model drove design decisions. A threat model that exists as a standalone enumeration exercise, with no visible connection to the controls you implemented or the tests you ran, will generate an AI request. The Cybersecurity Risk Assessment Report must capture identified vulnerabilities, including any relevant entries from CISA's Known Exploited Vulnerabilities Catalog, with likelihood and impact scoring, applied mitigations, and residual risk justification aligned to ISO 14971. **The direct link between risks in this report and controls verified in your test reports is what reviewers look for first.** A risk assessment that doesn't trace forward to testing is treated as incomplete, regardless of how thorough the analysis itself is. [SPDF documentation](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) is where many submissions fall short. Reviewers aren't looking for a policy document that describes what your security process looks like in theory. They're looking for evidence that security was addressed throughout the development lifecycle: QMS procedures for security, design controls tied to cybersecurity requirements, and traceability showing that security was built in rather than added at submission time. Labeling is part of the SPDF record, not an afterthought. It must include a vulnerability reporting contact, expected software support duration, and connectivity disclosures, all consistent with the FDA's premarket cybersecurity guidance expectations for transparency and post-market support. ## SBOM Requirements: Format, Fields, and the Support Report ### SPDX vs. CycloneDX: Choosing Your Format Per the FDA's premarket cybersecurity guidance, the FDA accepts two machine-readable SBOM formats: [SPDX and CycloneDX](/guides/cyclonedx-vs-spdx-medical-devices) (JSON or XML). The agency doesn't mandate one over the other, but both must carry the minimum SBOM elements. Those elements originated in NTIA's July 2021 minimum elements document and are now defined by CISA's 2026 Minimum Elements for a Software Bill of Materials, published July 29, 2026, which replaced the 2021 version. They include supplier name, component name, version, unique identifiers (CPE or PURL preferred for vulnerability lookup), dependency relationships, SBOM author, and timestamp. ### Human-Readable Exports FDA reviewers frequently request a human-readable export alongside the machine-readable file. Include both a PDF or Excel version and the machine-readable artifact in your submission package. The [SBOM](/guides/sbom-vulnerability-management-medical-devices) does not stand alone. The SBOM Support Report documents how the SBOM was generated, what tooling was used, and how vulnerabilities within listed components were assessed for device-level impact. Known vulnerabilities in SBOM components must be evaluated with CVSS scoring, remediation timelines, and documented risk acceptance rationale where patches were not applied. **An SBOM that lists only first-party components and omits open-source dependencies is one of the most common deficiencies across 510(k) submissions.** Every component in your software stack, including transitive dependencies, needs to be accounted for. ## Cybersecurity Test Reports: What Reviewers Actually Examine The FDA expects a complete testing portfolio, not a single penetration test report. The portfolio should include penetration testing covering the full attack surface (network, firmware, APIs, wireless interfaces), fuzz testing for input handling and protocol robustness, and SAST/DAST for code-level and runtime vulnerabilities. Each report must include scope definition, methodology referencing frameworks like OWASP, MITRE ATT&CK for Healthcare, or NIST SP 800-115, CVSS-scored findings, and remediation verification with re-test evidence. Third-party penetration testing is preferred; reviewer scrutiny increases when the manufacturer's own team conducted the tests. For penetration testing specifically, reviewers look for a complete package of evidence: - Signed rules of engagement and tester credentials - A complete findings table mapping each finding to its severity, the affected SBOM component, exploit method, and threat model risk trace - Remediation status for every finding - Documented risk acceptance rationale and compensating controls for any unresolved high or critical findings Unresolved high or critical findings without that documentation will stop a review. The Cybersecurity Testing Summary serves as the master document in eSTAR, referencing all individual test reports as appendices. Vague summaries with no raw evidence attached are one of the most reliable ways to generate a late-cycle AI request, which resets your review timeline entirely. ## Assembling the Final Package: Traceability and Avoiding the Most Common Failures The traceability matrix is the document that ties the entire package together, and it's the one most manufacturers underinvest in. It should map Threat ID (from the threat model) to Security Control to Test Case to Verification Evidence to eSTAR Section. Bidirectional traceability is the strongest approach: every risk traces forward to a verified control, and every test case traces back to a risk. Without this document, reviewers must manually reconstruct relationships across separate artifacts, and the gaps they find become deficiency letters. The most common submission failures follow a predictable pattern: vague test report summaries without raw evidence, SBOMs that omit open-source dependencies, threat models that don't reflect the actual device architecture, and SPDF documentation that reads like an industry template with the device name swapped in. Each of these failures has a direct fix within the artifact structure above. Cybersecurity deficiencies often arrive late in the review cycle as AI requests rather than being caught at acceptance screening, which means manufacturers are weeks or months into the process before they learn there's a problem. At Blue Goat Cyber, we build submission-ready eSTAR cybersecurity packages that map to every artifact above, aligned with the FDA's current premarket cybersecurity guidance and verified against the eSTAR v7.0 Cybersecurity attachment area. Our FDA cybersecurity deficiency commitment means that if a submission is rejected for cybersecurity reasons, we fix it at no additional cost, removing the most expensive risk in the submission process for manufacturers who can't afford a cybersecurity-related delay at the end of a 510(k) review cycle. ## What a Complete eSTAR 510(k) Cybersecurity Submission Package Looks Like Preparing cybersecurity documentation for an FDA eSTAR 510(k) submission means assembling a specific set of artifacts and connecting them through a traceability structure that reviewers can follow end to end. The complete artifact set includes the Security Risk Management Plan, Threat Modeling and Security Architecture Report, Cybersecurity Risk Assessment, SBOM with Support Report, SPDF documentation, and a full testing portfolio, all tied together by a traceability matrix that maps every risk to a verified control. Get the traceability right. Keep the SBOM complete and current, covering every component including open-source dependencies. Make sure every test finding links back to your threat model. Those three things, done well, are what separates a clean clearance from a deficiency letter that resets your timeline. If you're building your first cybersecurity package or responding to a deficiency on an existing submission, the artifact list above is your starting point. Every item on it needs to be there before you submit. ## How Blue Goat approaches this Our methodology for eSTAR 510(k) cybersecurity documentation focuses on precision and alignment with FDA expectations. We integrate all required artifacts, including detailed threat models, risk assessments, and complete SBOMs, ensuring they are interlinked via a rigorous traceability matrix. Our team, including CISSP-certified professionals and ex-military red team operators, systematically addresses each cybersecurity deliverable in the eSTAR v7.0 Cybersecurity attachment area and the February 3, 2026 FDA guidance. We proactively identify potential gaps and ensure all controls are supported by verifiable testing evidence. This structured method minimizes the likelihood of deficiencies and accelerates time to market. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our approach at [Blue Goat Cyber's FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is a "cyber device" according to the FDA? A cyber device contains software, can connect to the internet, and has characteristics vulnerable to cybersecurity threats. The FDA interprets connectivity broadly, including unintentional network access. ### What core cybersecurity documents are needed for an eSTAR 510(k) submission? Key documents include the Security Risk Management Plan, Threat Modeling and Security Architecture Report, Cybersecurity Risk Assessment Report, Software Bill of Materials (SBOM), and SBOM Support Report. ### What is SPDF documentation? SPDF (Secure Product Development Framework) documentation provides evidence that security was addressed throughout the device's development lifecycle, including QMS procedures, design controls, and traceability, rather than just post-development patching. ### Does the FDA prefer SPDX or CycloneDX for SBOMs? The FDA accepts both SPDX and CycloneDX formats (JSON or XML), provided they carry the minimum SBOM elements defined in CISA's 2026 Minimum Elements for a Software Bill of Materials, which include supplier, component name, version, and unique identifiers like CPE or PURL. ### What kind of cybersecurity testing does the FDA expect for medical devices? The FDA expects a portfolio including penetration testing, fuzz testing, and SAST/DAST, with explicit scope, methodology, CVSS-scored findings, and remediation verification for each report. ### Why is a traceability matrix important for eSTAR cybersecurity submissions? A traceability matrix demonstrates that every identified cybersecurity risk is addressed by a specific control and verified through testing. It ensures reviewers can easily follow how security measures mitigate risks. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Unresolved Anomalies in FDA Cybersecurity](/blog/unresolved-anomalies-fda-cybersecurity-submission) --- ## Medical Device AI Evasion & Cybersecurity Source: https://bluegoatcyber.com/blog/protecting-medical-devices-ai-model-evasion-and-cybersecurity-threats # Medical Device AI Model Evasion and Cybersecurity Threats > **[DIRECT ANSWER]** AI model evasion is an attack where adversaries manipulate input data, such as imaging or sensor signals, to trick a medical device's machine learning model into misclassifying or malfunctioning. It threatens diagnostic accuracy and treatment safety in AI-powered devices. The FDA's February 3, 2026 guidance expects manufacturers to threat model these attacks, validate model robustness, apply strong authentication and encryption, and patch known weaknesses continuously. _Reviewed July 24, 2026_ Healthcare is increasingly reliant on technology. Medical devices such as MRI machines, pacemakers, and infusion pumps have become integral to effective patient care. However, what lurks beneath the surface? The answer lies in cybersecurity. Effective cybersecurity is paramount. With sensitive patient data on the line, a breach can lead to catastrophic consequences. These devices often connect to networks, making them susceptible to cyber-attacks. One must always ask: if cybercriminals can hack into a system, can they also manipulate machine functions? The thought is chilling. ## Key Takeaways - AI model evasion manipulates input data to trick medical devices. - Such attacks can lead to incorrect diagnoses or device malfunctions. - Vulnerabilities impact AI-powered diagnostic, treatment, and monitoring devices. - Strong security protocols are essential for protection. - Regular software updates and patching mitigate known weaknesses. - The FDA emphasizes cybersecurity in medical device development. ## Why this matters The stakes are high: AI model evasion in medical devices can directly jeopardize patient safety through misdiagnosis or device malfunction. Such attacks use vulnerabilities in AI/ML algorithms, leading to potentially life-threatening outcomes. The integrity of diagnostic tools and treatment delivery systems relies heavily on the trustworthiness of their underlying AI. The FDA, in its 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes that manufacturers must actively manage and mitigate cybersecurity risks throughout the device lifecycle, including those posed by AI-based components. This guidance underscores the necessity for premarket submissions to demonstrate effective security controls against evasion and other AI-specific threats. Relevant international standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide frameworks for risk management and cybersecurity in health IT and medical devices, all of which are increasingly challenged by sophisticated AI evasion techniques. Protecting these devices is not merely a technical challenge but a critical component of medical ethics and patient care. ## The Role of Medical Devices in Modern Healthcare Medical devices are the unsung heroes of modern healthcare. They aid in diagnosis, treatment, and patient monitoring and provide functionality and accessibility. Surgeons depend on advanced imaging technology, while patients benefit from wearable health monitors that track vitals. Yet, the complexity of these devices introduces vulnerabilities. When connected to a network, they may inadvertently become entry points for cyber threats. If you think these devices are only tools, think again- they are portals to valuable data. And where there’s data, there’s a risk of exposure. For instance, a compromised pacemaker could expose a patient’s health information and potentially alter its functioning, leading to dire health consequences. As such, integrating cybersecurity measures into the design and operation of these devices is not just a technical requirement; it is a moral imperative. ## The Growing Threat of Cyber Attacks in the Medical Field The medical field isn’t immune to cyber threats. In fact, attacks have been on the rise. Hospitals have reported [ransomware](/blog) incidents that have paralyzed operations. Imagine doctors being unable to access vital patient information due to a cyber attack- it’s a nightmare scenario. HHackers are sophisticated. They employ various techniques to breach systems. It’s no longer about simple firewalls; it’s about understanding the intricacies of medical devices. This sophistication amplifies the need for a proactive approach to cybersecurity. The healthcare industry must adopt a multi-layered security strategy that includes regular software updates, employee training, and incident response plans. Furthermore, collaboration between device manufacturers and healthcare providers is essential to ensure security measures are embedded from the ground up. As the landscape of cyber threats evolves, so too must the strategies to combat them, ensuring that [patient safety](/blog) and data integrity remain uncompromised. ## AI Model Evasion: A New Challenge in Cybersecurity As technology evolves, so do threats. Enter [AI model evasion](/blog), a buzzword capturing attention in cybersecurity circles. But what does it mean? It’s a technique where cybercriminals use adversarial inputs to deceive machine learning models. ![Section Image](/imported-images/a36fc393d4fa8ff0.png) This challenge is particularly relevant in the context of medical devices. A rogue input could produce an incorrect result if a device relies on AI for diagnosis. The consequences could be dire, ranging from erroneous treatment plans to patient harm. Thus, understanding AI model evasion isn’t just technical jargon; it’s a matter of life and death. ### Defining AI Model Evasion To grasp the essence of AI model evasion, one must look at the interaction between data and intelligence. It involves manipulating the data fed into an AI model. An attacker finds vulnerabilities in how the model processes input, leading to misclassification. For example, minor changes in the data can cause an AI system to output entirely different information. It’s like trying to outsmart a student who always reads the questions differently- at some point, the interpretation becomes distorted. That’s the crux of model evasion. ### The Impact of AI Model Evasion on Medical Devices The implications of AI model evasion for medical devices are staggering. Devices powered by AI risk being misled, leading to incorrect patient assessments. This not only jeopardizes individual treatment but also affects the broader healthcare ecosystem. Imagine a malfunctioning heart monitor due to an evasion attack. A false reading could lead to panic in a critical care situation. It’s a misplaced trust that must be addressed urgently. Therefore, employing layers of fail-safes is essential in mitigating such risks. The challenge extends beyond individual devices. As healthcare systems increasingly integrate AI across various platforms, from diagnostic imaging to robotic surgery, the potential for widespread disruption grows. A coordinated attack could exploit multiple entry points, creating a cascading effect that undermines the integrity of patient care. This highlights the necessity for cybersecurity measures and continuous monitoring to detect anomalies before they escalate into serious threats. In addition to the technical aspects, there is a pressing need for regulatory frameworks that can keep pace with these advancements. [Policymakers](https://www.fda.gov/media/184856/download) must collaborate with cybersecurity experts and healthcare professionals to establish guidelines ensuring the safety and reliability of AI-driven medical technologies. This proactive approach will protect patients and build trust in the evolving landscape of digital health solutions. ## Strategies for Protecting Medical Devices from Cyber Threats ![Section Image](/imported-images/01a47a1979764ad0.png) ### Implementing Resilient Security Protocols security protocols are the foundation of medical device security. This means establishing firewalls and employing advanced encryption methods and authentication processes. Devices should have secure default settings, and manufacturers must proactively patch vulnerabilities. The mantra here is: think like a [hacker](/blog). Regular assessments and penetration tests on the systems should be conducted to identify weaknesses. By doing so, healthcare providers can stay one step ahead and deter potential threats. Additionally, it’s essential to build a culture of security awareness among all staff members. Training sessions can equip employees with the knowledge to recognize phishing attempts or suspicious activity, which can be the first line of defense in thwarting cyber attacks. ### Regular Software Updates and Patches When was the last time you updated your phone? Medical devices need regular software updates and patches. Vulnerabilities will be discovered over time, and patching them before attackers exploit them is crucial. Establishing a schedule for these updates can turn a daunting task into a manageable routine. You wouldn’t want to hit the road with outdated software like maintaining a car. A well-maintained system is an ongoing shield against cyber threats. Moreover, it’s important to keep an inventory of all devices and their respective software versions. This inventory not only aids in tracking which devices require updates but also helps assess the overall security posture of the healthcare facility. By ensuring that all devices are accounted for and regularly updated, healthcare organizations can significantly reduce their vulnerability to cyber threats. ## The Future of Cybersecurity in Healthcare The landscape of cyber threats is ever-changing. Hence, the future of cybersecurity in healthcare demands a visionary approach. Stakeholders, including healthcare professionals and technology developers, must unite to fortify defenses. ### Predicted Cybersecurity Trends in Healthcare Expect the emergence of advanced protective measures in the coming years. Cybersecurity will increasingly integrate [machine learning](/blog) algorithms to identify threats dynamically. Predictive analytics will become paramount, monitoring data patterns for unusual behavior. Healthcare organizations must also embrace a culture of cybersecurity awareness. Training staff to recognize and report potential threats can significantly enhance security posture. Remember, courage isn’t the absence of fear; it’s acting despite it. Furthermore, building an environment where employees feel empowered to communicate about cybersecurity concerns can lead to a more vigilant workforce. Regular drills and simulations can prepare teams to respond effectively to potential breaches, ensuring everyone understands their role in maintaining security. ### The Role of AI in Enhancing Cybersecurity Measures AI isn’t just a threat in the context of evasion; it’s also a formidable ally in cybersecurity. By utilizing AI for anomaly detection, healthcare systems can identify and respond to potential threats in real-time. Automation in monitoring can reduce human error. Just as robots have transformed the industry, AI will redefine cybersecurity protocols. Embracing this technology can lead to more effective responses to emerging threats. Additionally, AI can assist in analyzing vast amounts of data generated by healthcare systems, pinpointing vulnerabilities that may not be immediately apparent. This proactive approach helps mitigate risks and develops a framework for future security measures. ## Conclusion Safeguarding medical devices against cyber threats is no small feat. However, understanding the risks and implementing proactive measures can create a safer environment for patient care. It’s a collaborative journey we must undertake to ward off threats lurking in the shadows. As we navigate the complexities of AI model evasion and the evolving cybersecurity threats to medical devices, the need for specialized expertise has never been more critical. Blue Goat Cyber stands at the forefront of medical device cybersecurity, offering services that meet and exceed FDA, IEC 62304, and EU MDR requirements. With a proven track record of guiding over 100 devices through FDA submissions and a commitment to tailored healthcare security, our expert team is equipped to ensure your devices are protected against the most sophisticated cyber threats. Don’t let your guard down- [Contact us today for cybersecurity help](/contact) and partner with a leader in the field to secure your medical devices for the safety of your patients and the longevity of your products. ## How Blue Goat approaches this Blue Goat Cyber addresses AI model evasion in medical devices through a focused methodology. Our engagements begin with detailed threat modeling to identify potential adversarial AI attack vectors relevant to your device's specific AI/ML algorithms. We then conduct targeted penetration testing, including adversarial machine learning techniques, to assess the resilience of your AI models against evasion attempts. Our team, composed of experts with certifications including CISSP and OSCP, and ex-military red team experience, provides specialized security assessments. We pinpoint vulnerabilities and recommend practical, implementable security controls to harden your AI-powered medical devices. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Our goal is to ensure compliance and enhance the security posture of your devices against emerging AI threats. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is AI model evasion in medical devices? AI model evasion occurs when attackers manipulate input data to deceive an AI-powered medical device into making incorrect predictions, diagnoses, or decisions. This can compromise patient safety and undermine trust in AI-driven healthcare systems. ### How do cybercriminals exploit AI models in medical devices? Cybercriminals use adversarial attacks by introducing subtle alterations to input data, such as modifying medical images or sensor readings. These changes are often undetectable to humans but can cause AI models to misinterpret data, leading to incorrect diagnoses or treatment recommendations. ### What types of medical devices are vulnerable to AI model evasion? Any medical device that relies on AI for decision-making, including AI-powered imaging systems, diagnostic software, robotic-assisted surgery tools, and remote patient monitoring devices is vulnerable to AI model evasion attacks. ### What are the potential consequences of AI model evasion in medical devices? AI model evasion can lead to incorrect diagnoses, improper medication dosing, failure to detect life-threatening conditions, and disruption of automated treatment systems. These consequences can severely impact patient outcomes and safety. ### How can medical device manufacturers protect against AI model evasion? Manufacturers should implement strong security protocols, integrate AI-specific cybersecurity measures, conduct adversarial testing, and ensure regular software updates. Adhering to the FDA's February 3, 2026 final guidance on premarket cybersecurity is also crucial. ### Does the FDA have guidance on AI in medical devices? Yes, the FDA has provided guidance on AI/ML-based medical devices, emphasizing the need for a "total product lifecycle" approach to managing risks. This includes Ensure cybersecurity measures account for AI model vulnerabilities like evasion. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Surgical Robot Cybersecurity: Protecting Source: https://bluegoatcyber.com/blog/protecting-surgical-robots-the-importance-of-cybersecurity # Protecting Surgical Robots: The Importance of Cybersecurity > **[DIRECT ANSWER]** Surgical robot cybersecurity means securing the console, patient-side cart, network communication, and embedded controller so a cyberattack cannot alter movement or disrupt a live procedure. The FDA's February 3, 2026 guidance treats robotic platforms as high-risk connected devices and expects a full SPDF package: a threat model, an SBOM with VEX, independent penetration testing, network segmentation, strong authentication, and a postmarket vulnerability management plan. Surgical robots have revolutionized the field of healthcare. These advanced machines assist surgeons in performing complex procedures with precision and accuracy. From delicate surgeries to intricate operations, surgical robots have become indispensable in saving lives. However, with increased reliance on technology comes the pressing need for cybersecurity measures to protect these valuable assets. ## Key Takeaways - Surgical robots are vulnerable to cyber attacks. - Breaches can harm patients and compromise data. - Implement strong authentication, updates, segmentation. - IT and healthcare collaboration is crucial. - The FDA February 3, 2026 guidance applies. - Proactive cybersecurity safeguards patient care. ## Why This Matters Surgical robots sit at the highest end of cyber-physical risk in MedTech: a successful compromise can directly affect patient safety during a live procedure. The FDA's February 3, 2026 final premarket cybersecurity guidance treats robotic systems as high-risk connected devices and expects a full SPDF evidence package - threat model, SBOM with VEX, secure architecture views, independent penetration testing, and a postmarket vulnerability management plan under Section 524B of the FD&C Act. Recent CISA ICS medical advisories on surgical and image-guided systems (including the 2024-2025 advisories on robotic platform control consoles and image-guided surgery navigation stacks) show the realistic threat: unauthenticated network services on the OR-side console, weak isolation between the surgeon console and the patient-side cart, and outdated third-party components in the embedded controller. Each is the kind of finding that turns into an Additional Information letter and a delayed clearance. The standards stack reviewers expect for robotic surgical platforms is IEC 60601-1 with the relevant particular standards, IEC 62304 (typically Class C software), ISO 14971 for the risk file, AAMI SW96 (FDA Recognized Consensus Standard 13-131) for security risk management, and IEC 81001-5-1 for the secure software lifecycle. Cybersecurity has to be traceable across that entire stack, not bolted on at the end. ## Understanding Surgical Robots and Their Functionality Surgical robots are sophisticated devices designed to assist surgeons in performing minimally invasive procedures. They are equipped with multiple arms that can hold various surgical instruments and a camera that provides a magnified view of the surgical site. By controlling these robots from a console, surgeons can perform intricate maneuvers with enhanced dexterity and precision. Over the years, surgical robots have evolved significantly. They have become smaller, more versatile, and incorporate technologies such as artificial intelligence and machine learning. These advancements have not only enhanced the capabilities of surgical robots but have also opened up new horizons for medical professionals. ### The Evolution of Surgical Robots In the early days, surgical robots were primarily used for procedures such as prostate surgeries and gynecological surgeries. However, technological advancements have expanded their applications to encompass various specialties. Nowadays, surgical robots assist in performing procedures ranging from cardiac surgeries to neurological interventions. For example, in cardiac surgery, surgical robots have revolutionized complex procedures. These robots can navigate through the intricate network of blood vessels with unparalleled precision, allowing surgeons to repair damaged heart valves or perform coronary artery bypass grafting with utmost accuracy. This level of precision minimizes the risk of complications and ensures better outcomes for patients. ### The Role of Surgical Robots in Modern Healthcare With their high precision and accuracy, surgical robots have proven to be a game-changer in healthcare. These robots enable surgeons to perform complex surgeries with minimal invasiveness, resulting in shorter recovery times and reduced patient risks. They also provide a training and skill development platform, allowing surgeons to enhance their expertise by simulating surgeries in a controlled environment. Surgical robots have the potential to bridge the gap between geographical distances and provide access to specialized healthcare. In remote areas with a scarcity of skilled surgeons, these robots can be remotely controlled by expert surgeons located in urban centers, allowing patients to receive high-quality care without needing to travel long distances. Surgical robots are not limited to assisting surgeons in the operating room. They also play a crucial role in medical research and innovation. By analyzing vast amounts of surgical data collected during procedures, these robots can contribute to developing new surgical techniques and improving existing ones. This continuous feedback loop between surgical robots and medical professionals builds a culture of innovation and drives advancements in the field of surgery. ## The Intersection of Cybersecurity and Healthcare In an era of increasingly prevalent cyber threats, the healthcare industry faces unique challenges in [safeguarding patient data and medical devices](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). The convergence of cybersecurity and healthcare has become a critical concern, and addressing the vulnerabilities that arise when surgical robots are interconnected with other systems is essential. ![Section Image](/imported-images/7959d9b7d186e656.webp) One key aspect of the intersection between cybersecurity and healthcare is data encryption. Encryption supports protecting sensitive patient information from unauthorized access. By encoding data so that only authorized parties can decipher it, healthcare organizations can mitigate the risks associated with data breaches and cyber attacks. Implementing [multi-factor authentication](/blog) is another vital component in enhancing cybersecurity within the healthcare sector. By requiring multiple forms of verification, such as passwords, biometric scans, or security tokens, healthcare providers can add an extra layer of protection to their systems, reducing the likelihood of unauthorized access. ### Why Cybersecurity Matters in Healthcare Cybersecurity is paramount in healthcare due to the sensitivity of patient data and the potential risks associated with compromised medical devices. Cybersecurity breaches can jeopardize patient privacy and safety, leading to severe consequences. Moreover, medical devices, including surgical robots, can be vulnerable to cyber attacks, putting surgeons and patients at risk. ### Potential Cyber Threats in Healthcare As technology advances, so do the tactics employed by cybercriminals. The healthcare industry has witnessed an alarming rise in cyber threats, ranging from ransomware attacks to data breaches. Surgical robots, with their interconnectivity and reliance on software, can be targeted by hackers seeking to exploit vulnerabilities in the system. These threats emphasize the need for cybersecurity measures to safeguard both patient data and medical devices. Another emerging concern in cybersecurity and healthcare is the proliferation of Internet of Things (IoT) devices. These connected devices, such as wearable health trackers and remote monitoring systems, introduce additional entry points for cyber attacks. Healthcare providers must stay vigilant in securing these IoT devices to prevent unauthorized access to sensitive medical information and ensure the integrity of patient care. ## The Vulnerability of Surgical Robots to Cyber Attacks While surgical robots offer numerous advantages, their intricate design and reliance on technology make them susceptible to cyber attacks. To develop effective countermeasures, it is crucial to identify the weak points in their security infrastructure. ![Section Image](/imported-images/70fb20715bcdf71a.webp) Surgical robots are a marvel of modern technology, revolutionizing the field of surgery with their precision and efficiency. However, this reliance on advanced technology also opens them up to [potential vulnerabilities that malicious actors can exploit](/blog). As these robots become more interconnected and integrated into healthcare systems, the need to address cybersecurity risks becomes increasingly urgent. ### Identifying the Weak Points Surgical robots rely on multiple components, such as control systems, communication networks, and software applications. Each of these components presents a potential vulnerability that hackers can exploit. Weak passwords, outdated software, and lack of encryption are some of the common weak points that cybercriminals target. The complexity of these robotic systems introduces challenges in ensuring security measures. Every aspect must be scrutinized for potential weaknesses, from the hardware components to the software algorithms that govern their operations. As the technology evolves, so too must the cybersecurity protocols to stay ahead of emerging threats. ### The Consequences of a Breach The consequences of a cyber attack on surgical robots can be catastrophic. If a hacker gains control over a robot during surgery, they could manipulate its movements, leading to serious harm to the patient. Additionally, a breach in the system’s security can compromise patient data, leading to identity theft or unauthorized access to medical records. The potential impact on patient safety and privacy cannot be underestimated. As the healthcare industry embraces digital transformation and the adoption of robotic technology, safeguarding these innovations against cyber threats is paramount. A successful cyber attack on surgical robots would have implications beyond individual patients to the trust and integrity of the entire healthcare system. Proactive measures and ongoing vigilance are essential to mitigate the risks posed by malicious actors seeking to exploit vulnerabilities in these medical devices. ## Implementing Cybersecurity Measures for Surgical Robots Safeguarding surgical robots against cyber threats requires a proactive approach and a cybersecurity strategy. The need for cybersecurity measures becomes increasingly critical as technology advances in the healthcare industry. Ensuring the safety and integrity of surgical robots is paramount to prevent potential cyber attacks that could compromise patient safety and sensitive medical information. ![Section Image](/imported-images/c3db14d504da5766.webp) A critical aspect of cybersecurity for surgical robots is the integration of encryption protocols to protect data transmission between devices and systems. Encryption helps to secure communication channels and prevent unauthorized access to sensitive information, adding an extra layer of defense against cyber threats. ### Essential Cybersecurity Protocols Implementing cybersecurity protocols is crucial to protect surgical robots and the interconnected systems. These protocols may include regular software updates, strong authentication measures, network segmentation, and continuous monitoring. Training healthcare professionals to identify and report potential cyber threats is vital to maintaining a secure environment. Regular security audits and penetration testing can also help identify vulnerabilities in the system and address them before malicious actors can exploit them. By staying proactive and vigilant, healthcare facilities can stay ahead of potential cybersecurity risks and ensure the safety and reliability of their surgical robots. ### The Role of IT in Healthcare Security Information technology (IT) is crucial in ensuring the security of surgical robots and other medical devices. Collaboration between IT professionals, healthcare providers, and manufacturers is essential to develop and implement effective cybersecurity measures. By working together, they can create a secure ecosystem that protects patient data and prevents unauthorized access to medical devices. Establishing incident response plans and protocols in a cyber attack is essential to minimize the impact and swiftly mitigate any potential damage. By having clear procedures, healthcare organizations can effectively respond to security incidents and safeguard the integrity of their systems and patient information. ## Future Perspectives: Strengthening Cybersecurity in Robotic Surgery As technology continues to advance, robotic surgery holds immense potential for further innovation and improvement. The future of surgical robots relies on cybersecurity measures to ensure patient safety and data integrity. ### Innovations in Cybersecurity for Healthcare Researchers and industry experts are continually developing new technologies and strategies to strengthen cybersecurity in healthcare. From blockchain-based solutions to artificial intelligence-powered threat detection systems, these innovations aim to mitigate the risks associated with cyber threats and protect the integrity of surgical robots. ### The Road Ahead for Secure Robotic Surgery As robotic surgery continues to evolve, it is crucial to prioritize and invest in cybersecurity measures. By staying vigilant, building collaboration, and implementing best practices, healthcare professionals can protect surgical robots from potential cyber attacks. As a result, patients can benefit from the tremendous advancements in surgical robotics, knowing that their safety and privacy are safeguarded. One area of focus in strengthening cybersecurity for robotic surgery is the development of advanced encryption techniques. These techniques ensure that the communication between robotic systems and the control center remains secure and protected from unauthorized access. By implementing encryption protocols, healthcare providers can prevent potential cyber attackers from intercepting and manipulating the data transmitted during surgical procedures. Additionally, integrating machine learning algorithms into cybersecurity systems has shown promising results in detecting and preventing cyber threats in real-time. These algorithms can analyze vast amounts of data, identify patterns, and quickly respond to potential security breaches. By continuously learning and adapting to new threats, machine learning-powered cybersecurity systems can provide extra protection for surgical robots, ensuring their uninterrupted and secure operation. ## Conclusion The increasing reliance on surgical robots in modern healthcare necessitates a proactive approach to cybersecurity. Protecting these valuable assets is not just a matter of safeguarding technology but also ensuring the safety and privacy of patients. By understanding surgical robots’ vulnerabilities, implementing cybersecurity measures, and embracing innovative solutions such as advanced encryption techniques and machine learning algorithms, we can strengthen their protection and shape a secure future for robotic surgery. As the reliance on surgical robots continues to grow, so does the importance of securing these critical technologies. Blue Goat Cyber stands at the forefront of cybersecurity excellence, ready to defend your healthcare innovations against the cyber threats. With our B2B services, including medical device cybersecurity, penetration testing, and HIPAA and FDA standards compliance, we are dedicated to protecting your operations. Our Veteran-Owned status reflects our commitment to service and security. Don’t let cyber vulnerabilities threaten your advancements in robotic surgery. [Contact us today for cybersecurity help](/contact), and partner with Blue Goat Cyber to ensure your surgical robots, and patients, are safeguarded with the highest level of expertise. ## How Blue Goat approaches this Blue Goat Cyber assists organizations in securing surgical robots by implementing a focused and adaptive cybersecurity strategy. Our team, comprised of certified professionals such as CISSP and OSCP holders, including ex-military red team members, applies a methodology that integrates security into the medical device lifecycle. We conduct thorough threat modeling, risk assessments, and vulnerability analyses specific to robotic surgery platforms. Our services include penetration testing and security architecture reviews to identify and mitigate potential weaknesses from design to deployment. Blue Goat Cyber also provides expert support for regulatory compliance, helping manufacturers meet the FDA's cybersecurity requirements for medical devices. We understand the nuances of medical device cybersecurity and offer clear pathways to strengthen your defenses. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [FDA Premarket Cybersecurity Services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What cybersecurity risks do surgical robots face? Surgical robots are susceptible to risks such as unauthorized control during surgery, data breaches compromising patient information, and operational disruptions from ransomware or malware attacks. These vulnerabilities stem from their complex software, connectivity, and reliance on electronic systems. ### How does the FDA regulate surgical robot cybersecurity? The FDA outlines cybersecurity expectations for medical devices, including surgical robots, in its February 3, 2026 final guidance. This guidance directs manufacturers to design and maintain secure devices throughout their lifecycle, addressing premarket submission requirements and postmarket responsibilities. ### What measures protect surgical robots from cyber attacks? Key protection measures include implementing strong access controls, regularly updating software, segmenting networks to isolate devices, and continuous security monitoring. Encryption of data and secure communication protocols are also vital for safeguarding sensitive information. ### Why is collaboration important for surgical robot security? Collaboration among manufacturers, healthcare IT teams, and clinicians is crucial because each party contributes unique expertise to identify and mitigate risks. Manufacturers design security features, IT manages network infrastructure, and clinicians understand operational workflows, ensuring a holistic security approach. ### What are the consequences of a cyber attack on a surgical robot? A cyber attack on a surgical robot can lead to severe patient harm if the robot's functionality is compromised. Additionally, it can result in exposure of sensitive patient data, significant operational downtime for hospitals, financial losses, and damage to institutional trust. **Related:** [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Cybersecurity Practices for Protecting](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist) - [Embedded Cybersecurity Challenges](/blog/embedded-cybersecurity-challenges) --- ## Q-Day: A Present-Day FDA Compliance Gap Source: https://bluegoatcyber.com/blog/q-day-medical-device-fda-compliance-gap # Q-Day Isn't a Future Problem for Medical Devices. It's a Present-Day FDA Compliance Gap > **[DIRECT ANSWER]** Q-Day, the point when quantum computers can break RSA and elliptic-curve cryptography, is already a present-day FDA compliance gap because the February 2026 premarket guidance requires cryptography that stays strong for a device's entire service life. Implants lasting 10 to 20 years cannot rely on classical crypto alone. Manufacturers should design for cryptographic agility, deploy hybrid classical plus post-quantum schemes, and document a PQC migration plan in the SPDF. _By Christian Espinosa, Founder & CEO, Blue Goat Cyber_ Last week I sat on a neurotech panel and made a point that landed harder than I expected: the implants we're putting in patients today are designed to last 10 to 20 years, but the cryptography protecting them won't. The CNN piece on Q-Day that's been making the rounds frames quantum computing as a looming cybersecurity crisis, and it is. But for medical devices, the framing is wrong. This isn't a future problem we have time to plan for. It's a present-day compliance gap the FDA has already written into guidance, and most manufacturers haven't read it that way yet. ## Key Takeaways - FDA guidance mandates crypto strong throughout device service life. - Long-lived implants (10-20 years) require post-quantum cryptography planning. - Classical crypto (RSA, ECC) will not suffice against quantum threats. - Design for cryptographic agility, enabling algorithm updates. - Implement hybrid classical+PQC schemes in new devices. - Document PQC migration plans in the SPDF for FDA submissions. ## Why this matters The stakes are high: patient safety and regulatory compliance. Medical devices, especially long-lived implants, face a unique threat from quantum computing. Cryptography considered secure today (e.g., RSA, ECC) will likely be vulnerable to cryptographically relevant quantum computers within the operational lifespan of many currently implanted devices. The potential for "harvest now, decrypt later" attacks, where encrypted patient data is exfiltrated today and decrypted years later with quantum computers, poses a severe risk to patient privacy and trust. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly states that manufacturers must use cryptography "expected to be considered cryptographically strong throughout the service life of the device." This guidance, alongside standards like IEC 81001-5-1 and AAMI SW96, creates an immediate compliance gap for devices with a 10-20 year service life that do not account for post-quantum cryptographic transitions. Failure to address this could lead to significant regulatory hurdles, market access delays, and post-market cybersecurity vulnerabilities. ## The FDA Already Wrote the Requirement Here's the language that matters. The [FDA's February 2026 Premarket Cybersecurity Guidance](/guides/fda-premarket-cybersecurity-submission-checklist) tells manufacturers to use cryptography "expected to be considered cryptographically strong throughout the service life of the device." Read that sentence with a pacemaker in mind. Or a neurostimulator. Or an implantable cardioverter-defibrillator. Or an insulin pump. These devices stay in patients for a decade or two. The crypto running on most of them today - RSA and elliptic curve - will not survive that window once a cryptographically relevant quantum computer arrives. The FDA already wrote the requirement. The industry just hasn't connected the dots. I review premarket submissions for a living, and I can tell you what I'm **not** seeing. I'm not seeing [threat models](/guides/stride-threat-modeling-medical-devices) that include a quantum adversary. I'm not seeing cryptographic agility designed into the device architecture. I'm not seeing migration plans for post-quantum cryptography in the [Secure Product Development Framework](/guides/medical-device-cybersecurity-spdf-playbook) documentation. The FDA guidance also says manufacturers should not implement deprecated algorithms, and that anything in "legacy use" status needs to be discussed with the agency at pre-submission. Once NIST formally deprecates RSA and ECC for the post-quantum era - and that timeline is shortening - every device shipping with classical-only crypto is going to be in that conversation whether the manufacturer wants to be or not. ## Harvest Now, Decrypt Later - But the Patient Is Still Wearing the Device The "harvest now, decrypt later" risk lands harder for medical devices than for almost any other sector. If an attacker captures biosignals from an implant today - cardiac rhythms, neural telemetry, continuous glucose data - that data stays sensitive for the patient's entire life. And the device transmitting it is still in their body when quantum decryption becomes practical. The data outlives the crypto. The hardware outlives the crypto. For a banking transaction, the exposure window closes when the account closes. For a neural implant, it doesn't close until the patient does. That's the asymmetry MedTech leaders need to internalize. ## The Tools to Fix This Already Exist The good news is the tools to fix this already exist. NIST finalized the first post-quantum cryptography standards in August 2024: **ML-KEM** for key encapsulation, **ML-DSA** and **SLH-DSA** for digital signatures. These are not research-grade. They're production-ready, and hybrid schemes that pair classical and post-quantum crypto are deployable today. For the algorithm-by-algorithm detail, the flash and bandwidth costs on constrained hardware, and the published migration deadlines, see our guide to [post-quantum cryptography for medical devices](/guides/post-quantum-cryptography-medical-devices). The path forward for medical device manufacturers is not "go build a quantum-proof device from scratch." It's three concrete steps that can be implemented now. ### 1. Design for cryptographic agility New devices entering premarket today should be architected so that cryptographic algorithms can be swapped without replacing the device. That means modular crypto libraries, sufficient compute and memory headroom, and a secure update mechanism enough to push a PQC migration over the air. The FDA's guidance on firmware and software updates already requires this kind of design thinking. Quantum just raises the stakes. ### 2. Deploy hybrid classical+PQC schemes on anything shipping in the next 24 months Hybrid approaches give you classical security against today's threats and post-quantum security against harvest-now-decrypt-later attacks. This is what cloud providers, browsers, and messaging platforms are already doing. There's no reason medical device manufacturers should be behind that curve. ### 3. Document a PQC migration plan in your SPDF When the FDA asks how your device will remain cryptographically strong over its service life - and they will ask - you need an answer that isn't "we'll figure it out." A documented migration plan, with milestones tied to NIST's deprecation timeline, is what a defensible submission looks like. ## This Isn't Theoretical Anymore None of this is theoretical. The standards are published. The FDA guidance is signed. The threat model is real, and for the devices we're putting in patients today, the timeline is shorter than the device's own warranty card. Q-Day isn't coming for MedTech. It's already here in the form of a requirement most manufacturers haven't satisfied. The work to close that gap starts now, in the next premarket submission, not in the next decade. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers navigate the evolving cybersecurity landscape, including the challenges posed by Q-Day. Our methodology centers on integrating forward-looking security directly into the product lifecycle. We specialize in developing Secure Product Development Frameworks (SPDFs) that incorporate cryptographic agility and PQC migration strategies, ensuring devices remain compliant and secure throughout their long service lives. Our team of experts, including CISSP and OSCP-certified professionals with ex-military red team experience, provides actionable guidance for threat modeling, architectural reviews, and secure code development. We assist in designing hybrid classical+PQC solutions and validating their implementation. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## Faq ### Does the FDA explicitly require post-quantum cryptography? Not by name. The February 2026 Premarket Cybersecurity Guidance requires cryptography "expected to be considered cryptographically strong throughout the service life of the device." For long-lived devices, that requirement cannot be satisfied with RSA or ECC alone - which makes PQC the practical answer. ### What is Q-Day? Q-Day is the point at which a cryptographically relevant quantum computer can break the public-key cryptography (RSA, ECC) that secures most digital communication today. Estimates vary, but credible forecasts place it inside the service life of implants being submitted right now. ### What is "harvest now, decrypt later"? An attacker captures encrypted traffic today and stores it until quantum computers can decrypt it. For medical telemetry - cardiac, neural, glucose - that captured data remains sensitive for the patient's lifetime. ### What should manufacturers do for devices already in the field? Postmarket devices need a documented [PQC migration plan](/guides/fda-524b-cybersecurity-requirements-explained) tied to the device's secure update mechanism. If the device has no field-updateable crypto stack, that's a [Section 524B](/guides/fda-524b-cybersecurity-requirements-explained) postmarket gap that needs an action plan. ### Which NIST PQC algorithms should I plan around? ML-KEM (FIPS 203) for key encapsulation, ML-DSA (FIPS 204) for digital signatures, and SLH-DSA (FIPS 205) as a hash-based signature alternative. Hybrid schemes pairing one of these with classical crypto are the current best practice for transition. --- ## Q-Sub vs Pre-Sub: FDA Cybersecurity Guide Source: https://bluegoatcyber.com/blog/q-sub-vs-pre-sub-fda-cybersecurity # Q-Sub vs Pre-Sub: What's the Difference for FDA Cybersecurity? > **[DIRECT ANSWER]** There is no meaningful difference, a Pre-Sub *is* a Q-Sub. Q-Submission (Q-Sub) is the FDA's umbrella program for all pre-market interactions with CDRH/CBER; every submission in the program gets a tracking number starting with "Q". Pre-Submission (Pre-Sub) is the most common *type* of Q-Sub: a formal written request for FDA feedback on a specific question before you file a 510(k), De Novo, or PMA. For medical device cybersecurity, a Pre-Sub is the right vehicle to de-risk threat model scope, SBOM format, penetration test methodology, or SW96 conformance approach before you burn a review cycle. People use "Q-Sub" and "Pre-Sub" interchangeably, and in casual conversation that is fine. Technically, **Pre-Sub ⊂ Q-Sub**, the Q-Sub program contains several submission types, and Pre-Sub is one of them. For cybersecurity teams, the distinction only matters when you are choosing the right vehicle. A Pre-Sub gets you written FDA feedback and a meeting. Other Q-Sub types (Informational Meeting, Study Risk Determination, Submission Issue Request) have different purposes, timelines, and expectations. This guide covers the Q-Sub umbrella, where Pre-Sub fits, when to use a Pre-Sub for cybersecurity questions, and what to include so the feedback is actually useful. ## Key Takeaways - Q-Sub is the umbrella program; Pre-Sub is the most common submission type inside it. - Every Q-Sub type gets a "Q" tracking number, which is why people conflate the terms. - Pre-Subs are the right vehicle for FDA feedback on cybersecurity strategy before filing. - FDA typically responds to a Pre-Sub within 70-75 days, often with a meeting. - Submission Issue Requests (SIRs) are also Q-Subs, but reviewer-initiated mid-review. - Cybersecurity Pre-Subs work best when scoped to 3-5 specific, answerable questions. ## Why this matters The FDA's Q-Submission program is governed by the guidance *Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program* (most recent revision June 2, 2023, still in force in 2026). Since the February 3, 2026 final premarket cybersecurity guidance took effect, cybersecurity Pre-Subs have become one of the highest-leverage tools MedTech teams have. A single well-scoped Pre-Sub can eliminate an entire deficiency cycle on a 510(k), saving 60-120 days of review time and avoiding the "restart the clock" penalty that a mid-review pivot triggers. Applicable standards for the substance of what you file include ANSI/AAMI SW96:2023, ANSI/AAMI/IEC 81001-5-1, and AAMI TIR97. ## What is the FDA Q-Submission (Q-Sub) program? The Q-Submission program is the FDA's structured mechanism for any pre-market interaction between a sponsor and CDRH or CBER. It covers written feedback requests, meetings, and reviewer-initiated communications during an active submission. Every item in the program is tracked with a number starting with "Q" (for example, Q240123). The program includes several distinct submission types: | Q-Sub Type | Purpose | Who Initiates | | --- | --- | --- | | Pre-Submission (Pre-Sub) | Formal request for FDA feedback on specific questions | Sponsor | | Informational Meeting | Share information with FDA; no feedback requested | Sponsor | | Study Risk Determination | Confirm whether a study is significant-risk | Sponsor | | Submission Issue Request (SIR) | Reviewer asks sponsor to fix a specific issue mid-review | FDA reviewer | | PMA Day 100 Meeting | Statutorily required meeting during PMA review | FDA / sponsor | | Agreement Meeting / Determination Meeting | PMA-specific pre-planning meetings | Sponsor | | Breakthrough Device Interactions | Structured feedback for Breakthrough-designated devices | Sponsor | All of these are Q-Subs. That is why "Q-Sub" alone is ambiguous unless you specify which type. ## What is a Pre-Submission (Pre-Sub)? A Pre-Submission is a formal written request for FDA feedback on specific questions about a device before you submit a marketing application. It is the workhorse of the Q-Sub program and the type most sponsors mean when they say "Q-Sub." A Pre-Sub typically includes device background, the regulatory pathway you are planning, the specific questions you want FDA to weigh in on, and any supporting artifacts (protocols, draft threat models, test plans). FDA responds in writing within roughly 70-75 calendar days and usually offers a teleconference or written-only response. The feedback is non-binding but carries substantial weight. If you follow FDA's Pre-Sub advice and document it, the review team will generally honor that position when your 510(k), De Novo, or PMA lands. If you ignore it, expect the same concerns to come back as deficiencies. ## Q-Sub vs Pre-Sub: side-by-side comparison | Dimension | Q-Sub (umbrella) | Pre-Sub (specific type) | | --- | --- | --- | | Scope | All pre-market FDA interactions | Written feedback on specific questions | | Tracking prefix | Q | Q (same, it is a Q-Sub) | | Who initiates | Sponsor or FDA (depending on type) | Sponsor | | FDA response format | Varies by type | Written feedback ± meeting | | Typical timeline | Varies (SIR is days, Breakthrough is ongoing) | ~70-75 calendar days | | Governing guidance | Q-Submission Program guidance (June 2023) | Same guidance, Section IV | | Cybersecurity use case | Any FDA cyber interaction | De-risk threat model, SBOM, pen test, SW96 scope | The one-line rule: **every Pre-Sub is a Q-Sub; not every Q-Sub is a Pre-Sub.** ## When should a cybersecurity team file a Pre-Sub? File a cybersecurity Pre-Sub when a wrong answer would cost you a review cycle. Good triggers: - Novel connectivity or architecture (mesh BLE, cellular fallback, cloud-controlled therapy) with no obvious precedent. - Uncertainty about whether the device falls under Section 524B (borderline "cyber device" definition). - Deciding between AAMI TIR57 and ANSI/AAMI SW96 as the primary threat model reference. - Penetration test scope questions on a modular platform where testing every configuration is impractical. - SBOM format or depth questions for a device with heavy third-party firmware. - Postmarket monitoring plan design where CVE triage cadence is unclear. - Predetermined Change Control Plan (PCCP) scope for cybersecurity patches or SBOM component swaps. Do *not* file a Pre-Sub for questions the [Feb 3, 2026 premarket guidance](/blog/fda-section-524b-subsections-explained) already answers clearly, or for questions you can resolve by [mining FDA databases for precedent](/blog/mining-fda-databases-medical-device-cybersecurity-precedent). Reviewers dislike Pre-Subs that ask them to re-explain published guidance. ## What to include in a cybersecurity Pre-Sub Keep it tight. A useful cybersecurity Pre-Sub is 15-30 pages, not 150. 1. **Device description**, one page. Intended use, architecture, connectivity, data flows. 2. **Regulatory strategy**, pathway (510(k) / De Novo / PMA), predicate if any, applicable product code. 3. **Cybersecurity posture summary**, standards you are aligning to (SW96, IEC 81001-5-1), SPDF stage. 4. **Draft artifacts**, threat model excerpt, SBOM sample, pen test scope document, postmarket plan outline. Excerpts, not full deliverables. 5. **Specific questions**, 3-5, numbered, each answerable in a paragraph. Avoid "do you have any concerns?" 6. **Your proposed answer**, for each question, state what you plan to do. FDA reviewers strongly prefer confirming or correcting a proposal to writing one from scratch. > **[KEY REQUIREMENT]** Every question in a cybersecurity Pre-Sub should include your proposed answer. Reviewers read "Question / Sponsor's proposed position / Question for FDA" formatting fastest, and it is the difference between a directive response and a hedge. ## How Blue Goat Cyber approaches cybersecurity Pre-Subs We draft cybersecurity Pre-Sub packages in the "Question / Proposed position / Ask" format the FDA reads fastest. Our team pairs an ex-military red team lead (OSCP) with a submission-side regulatory strategist to write the questions, build the supporting excerpts (threat model, SBOM, pen test scope), and rehearse the teleconference. See our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for scope and engagement models. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### Is a Q-Sub the same as a Pre-Sub? Not exactly, but close enough that most people use the terms interchangeably. Q-Sub is the umbrella program covering all pre-market FDA interactions. Pre-Sub is the most common *type* of Q-Sub, a written request for feedback on specific questions. Every Pre-Sub is a Q-Sub, but Q-Subs also include Informational Meetings, Study Risk Determinations, Submission Issue Requests, and Breakthrough interactions. ### How long does the FDA take to respond to a Pre-Sub? FDA targets 70-75 calendar days for a Pre-Sub response, either as written feedback only or as written feedback plus a teleconference. That target is met most of the time, but plan for 90 days when building your submission schedule. Complex cybersecurity questions rarely slip the timeline; scope-of-review disputes sometimes do. ### Do I need a Pre-Sub for Section 524B cybersecurity questions? No, and you should not file one for questions the Feb 3, 2026 premarket cybersecurity guidance already answers. File a Pre-Sub when your device architecture is genuinely novel, when precedent is ambiguous, or when a wrong methodological choice (threat model framework, pen test scope, SBOM depth) would cost you a review cycle. ### Is a Submission Issue Request (SIR) the same as a Pre-Sub? No. Both are Q-Subs, but a [SIR is reviewer-initiated mid-review](/blog/fda-sir-submission-issue-request-cybersecurity-response), the FDA reviewer asks you to fix or clarify something specific inside eSTAR before substantive review can continue. A Pre-Sub is sponsor-initiated, filed before the marketing application, and asks the FDA questions rather than answering them. ### Can I file a Pre-Sub after I have already submitted my 510(k)? Not for the same questions. Once a submission is under review, FDA's mechanism for reviewer-driven questions is the SIR, and the sponsor's mechanism for asking new questions is limited. If you need pre-market feedback, file the Pre-Sub before the 510(k). A Pre-Sub filed while a related 510(k) is open will usually be redirected or held. ## Ready to plan a cybersecurity Pre-Sub? If you are weighing a Pre-Sub for a Section 524B question, threat model framework, SBOM scope, pen test methodology, or PCCP design, [book a working session with Blue Goat Cyber](/schedule-expert). We will help you decide whether a Pre-Sub is the right vehicle and draft the questions if it is. --- *Christian Espinosa, Founder & CEO of Blue Goat Cyber, CISSP · OSCP. Christian has led cybersecurity submissions for connected medical devices across 510(k), De Novo, and PMA pathways, including Q-Sub strategy for novel connectivity and PCCP-scoped cybersecurity changes.* --- ## QIH Medical Device Vulnerabilities: What to Know (2026) Source: https://bluegoatcyber.com/blog/qih-medical-device-vulnerabilities-what-you-need-to-know # QIH Medical Device Vulnerabilities in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** QIH (Quantitative Imaging in Healthcare) medical device vulnerabilities stem from outdated software, weak encryption, and inadequate authentication in imaging and diagnostic systems, creating risk of misdiagnosis, data breaches, and service disruption. Addressing them requires regular updates, strong access controls, and encrypted data transmission. The FDA expects manufacturers to document these mitigations and maintain regulatory compliance and provider collaboration throughout the device lifecycle. _Updated October 26, 2024_ Device vulnerabilities in quantitative imaging have become a serious concern for healthcare providers and cybersecurity practitioners alike. This article covers the nature of QIH medical device vulnerabilities, the role of cybersecurity in protecting these devices, the regulatory measures in place, practical risk mitigation strategies, and where this field is headed. ## Key Takeaways - QIH device vulnerabilities pose risks to patient data and device function. - Common weaknesses include old software, encryption gaps, and weak authentication. - Exploits can cause misdiagnoses, data breaches, and service disruptions. - Cybersecurity measures matter for protecting QIH medical devices. - Regulatory compliance and manufacturer-provider collaboration are essential. - Proactive risk mitigation enhances device security and patient safety. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to QIH medical device vulnerabilities the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding QIH Medical Device Vulnerabilities ### Defining QIH Medical Device Vulnerabilities QIH, which stands for Quantitative Imaging in Healthcare, covers a range of advanced medical devices used for diagnostic and therapeutic purposes. These devices rely on advanced imaging techniques to produce accurate, reliable results. But like any technologically complex system, they carry vulnerabilities that must be understood and addressed. ![Section Image](/imported-images/a1e88e2d0147b2d3.webp) Think of a medical device as a structure with multiple entry points. Vulnerabilities can come from software weaknesses, absent or weak encryption, outdated operating systems, or inadequate authentication mechanisms. When attackers exploit these weaknesses, they can gain unauthorized access to patient data or manipulate device behavior directly, with severe consequences for patients and healthcare providers. Several specific vulnerability classes are worth calling out. First, lack of regular software updates: medical devices often run specialized software that doesn't receive frequent patches, leaving known vulnerabilities exposed for extended periods. Outdated operating systems compound this problem, since unpatched OS flaws are well-documented and widely exploited. Second, weak authentication: inadequate authentication mechanisms make it far easier for unauthorized users to access a device, putting patient data and device function at risk. Third, missing encryption: without encryption protocols, patient data in transit is readable to anyone on the same network. ### The Impact of QIH Medical Device Vulnerabilities The impact of QIH medical device vulnerabilities is direct and serious. They can compromise patient confidentiality and privacy, disrupt care delivery, and put patient safety at risk. A hacker who gains control of a QIH device in a radiology department could manipulate imaging results, triggering misdiagnoses or delayed treatment. That's not a hypothetical; it's a realistic attack path. The consequences extend well beyond individual patients. A successful attack on imaging devices across a facility could disrupt care for hundreds of patients at once, delaying diagnoses and interventions. And the financial fallout is real: legal liability, reputational damage, and remediation costs can be substantial for healthcare providers already operating with tight margins. ## The Role of Cybersecurity in Protecting QIH Medical Devices ### The Importance of Cybersecurity Measures With medical devices increasingly connected to hospital networks and the internet, effective cybersecurity is not optional. A sound cybersecurity program covers encryption, timely software updates and patches, thorough vulnerability assessments, and secure communication between devices and healthcare systems. It requires coordinated effort from manufacturers, healthcare providers, and regulatory bodies working from the same playbook. Attackers constantly develop new methods to [exploit vulnerabilities in medical devices](/blog), which means [proactive cybersecurity measures](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) must stay ahead of the threat. ### Strategies for Enhancing Cybersecurity Strengthening cybersecurity for QIH medical devices requires a multi-pronged strategy. Here are a few concrete approaches: 1. **Collaboration:** build collaboration between manufacturers, healthcare providers, and cybersecurity experts to exchange knowledge and best practices. By sharing insights and experiences, stakeholders can collectively improve their understanding of emerging threats and develop effective countermeasures. 2. **Education and Training:** Educate healthcare professionals about cybersecurity and provide training to identify and respond to potential threats. Equipping staff with the right knowledge makes them a genuine first line of defense. 3. **Secure Software Development Lifecycle:** Implement a [secure software development lifecycle](/blog) that includes rigorous testing, code review, and continuous monitoring for vulnerabilities. Integrating security practices throughout development minimizes the risk of shipping exploitable weaknesses. 4. **Regular Updates:** Update device firmware and software regularly to patch vulnerabilities and maintain optimal security. Promptly addressing known issues is one of the most effective risk reduction measures available. 5. **Secure Communication:** Ensure [secure communication protocols](/blog/securing-communication-protocols-in-medical-devices) between medical devices and healthcare systems, using encryption and authentication mechanisms to block unauthorized access. Protecting data in transit preserves patient confidentiality. Continuous monitoring, threat intelligence sharing, and scheduled risk assessments are essential to keeping a security program current. The threat environment doesn't stand still, and neither can the defenses protecting it. ## Regulatory Measures for QIH Medical Device Vulnerabilities ### Current Regulatory Standards Regulatory bodies worldwide have recognized the urgency of addressing QIH medical device vulnerabilities. Existing standards set a clear floor for device safety and security, though they must continue to adapt as attack techniques advance. ![Section Image]() Manufacturers must meet specific quality and safety standards to gain market access. Compliance with [ISO 13485](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity), IEC 62304, and [FDA guidelines](https://www.fda.gov/media/119933/download) is required. These standards address software development practices, risk management, and post-market surveillance. Meeting them involves thorough documentation, testing, and audits. Manufacturers that demonstrate consistent adherence to these standards build well-founded trust with healthcare providers and patients. ### Future Regulatory Trends Regulatory bodies are working with experts across disciplines to develop frameworks that address the shifting cybersecurity environment. These frameworks emphasize risk-based approaches, continuous monitoring, and greater transparency in device security. With the rise of [interconnected medical devices](/blog) and IoT in healthcare, future regulations will place greater weight on interoperability and data security. Manufacturers will need to think beyond individual device security and account for the broader system in which their products operate. Tighter collaboration between industry stakeholders, cybersecurity experts, and regulatory bodies will produce a more defensible healthcare infrastructure over time. ## Mitigating Risks Associated with QIH Medical Device Vulnerabilities ### Best Practices for Risk Mitigation Addressing QIH medical device vulnerabilities calls for a proactive approach to risk management. Some concrete best practices: - **Vulnerability Assessments:** Conduct regular vulnerability assessments to identify and address potential weaknesses before attackers do. - **Secure Supply Chain:** Work with trusted suppliers and implement mechanisms to verify the integrity of components used in QIH devices. - **User Training:** Educate healthcare professionals and end-users on device security, password hygiene, and safe usage practices. - **Incident Response:** Develop incident response plans to detect, contain, and recover from cybersecurity incidents. - **Continuous Monitoring:** Deploy real-time monitoring systems to detect anomalies and identify potential threats early. ### The Role of Healthcare Providers in Risk Mitigation Healthcare providers carry real responsibility for mitigating QIH medical device risks. They must treat cybersecurity as part of their overall risk management strategy, not a separate IT concern. Building strong partnerships with manufacturers, investing in staff training, and enforcing security policies creates a more defensible environment for patients. Providers should also communicate with patients about the potential risks associated with QIH medical devices. Patients who understand what to look for and feel comfortable raising concerns can provide an early warning signal when something seems wrong. Additionally, providers should stay current with developments in medical device security through industry conferences, working groups, and direct engagement with manufacturers. Staying informed is what keeps defenses current. ## The Future of QIH Medical Devices and Vulnerabilities ### Technological Advancements and Their Implications The future of QIH medical devices holds real potential for advances that will improve patient care. AI-powered diagnostics, tighter integration with electronic health records, and remote monitoring capabilities will continue to expand what these devices can do. But each new capability also expands the attack surface. ![Section Image]() Wireless connectivity is one specific area of concern. As QIH devices become more interconnected, the number of potential attack paths grows. Pacemakers, insulin pumps, and imaging systems that transmit data wirelessly offer genuine clinical value, but they also create opportunities for attackers to intercept or manipulate that data. Supply chain risk is another: with medical device manufacturing spread across a global supplier base, a single compromised component or malicious software update could affect an entire device population. Manufacturers need rigorous supply chain verification and a disciplined patch management process. ### Predicting Future Vulnerabilities and Solutions Predicting specific future vulnerabilities is difficult as attack techniques evolve. What's clear is that staying ahead requires sustained investment in research, threat intelligence sharing, and cross-sector collaboration. Encouraging cybersecurity research specific to medical devices and building a community of practitioners who share findings will make the whole field more resilient. Intrusion detection systems designed specifically for medical devices are one promising direction. These systems continuously monitor network traffic and device behavior, flagging anomalies before they escalate. Combining that with AI-assisted analysis, strong encryption, and rigorous adversarial testing gives manufacturers and providers a much stronger defensive posture. Shared information about threats, incident lessons learned, and emerging best practices can drive industry-wide standards that protect patients more consistently across all providers and device types. Blue Goat Cyber is ready to be that cybersecurity partner, bringing deep experience and a proactive approach to protecting critical healthcare technology. With specialized services in medical device cybersecurity, penetration testing, and compliance, we help ensure your operations stay ahead of threats. [Contact us today for cybersecurity help](/contact) and take the first step toward a secure digital environment for your healthcare technology. ## How Blue Goat approaches this Blue Goat Cyber addresses QIH medical device vulnerabilities by applying a structured methodology to identify, assess, and mitigate risks. Our team, composed of experts with CISSP and OSCP certifications including former military red team personnel, employs a proactive approach grounded in current threat intelligence and regulatory requirements. We conduct in-depth analyses of device architectures, review software integrity, and assess network communication security to uncover potential weaknesses. Our services focus on practical, actionable strategies that align with industry best practices and regulatory compliance. We provide evidence-based recommendations and support implementation to strengthen device defenses. Our commitment to securing QIH devices extends to post-market surveillance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our validation services: [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What are QIH medical device vulnerabilities? QIH medical device vulnerabilities are security weaknesses in Quantitative Imaging in Healthcare devices. These can include software bugs, lack of data encryption, or poor authentication that cyber attackers can exploit. ### How do QIH device vulnerabilities impact patients? Vulnerabilities can compromise patient confidentiality, lead to manipulation of imaging results causing misdiagnoses, undermine patient safety, and disrupt healthcare services. They can also expose sensitive patient data. ### What role do regulations play in QIH device security? Regulatory bodies like the FDA establish standards and guidelines to ensure the safety and security of medical devices. Manufacturers must comply with these, including the FDA's February 3, 2026 premarket guidance, to market their devices. ### What can manufacturers do to reduce QIH device risks? Manufacturers should implement secure software development lifecycles, provide regular software updates, ensure strong authentication and encryption, and collaborate with healthcare providers on security best practices. ### How can healthcare providers mitigate QIH medical device risks? Healthcare providers should conduct regular vulnerability assessments, ensure a secure supply chain, train staff on cybersecurity, develop incident response plans, and continuously monitor for threats to protect QIH devices. ### When should medical device software be updated? Medical device software and firmware should be updated regularly, and promptly when vulnerabilities are identified. Timely patching is one of the most effective steps in mitigating cyberattack risk and maintaining device integrity. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device MedRadio Vulnerabilities](/blog/examining-medradio-vulnerabilities-in-medical-devices-cybersecurity) --- ## QIH Medical Devices Explained Source: https://bluegoatcyber.com/blog/qih-medical-devices-explained # QIH Medical Devices Explained: What Manufacturers Need to Know > **[DIRECT ANSWER]** QIH (Quantitative Imaging in Healthcare) devices combine MRI, CT, or ultrasound imaging with software algorithms that extract objective numerical measurements, such as tumor size or blood flow, to guide diagnosis and treatment. Because outputs feed directly into clinical decisions, the FDA classifies most QIH devices as SaMD subject to Section 524B, requiring a threat model, SBOM with VEX, security architecture views, penetration testing, and a postmarket vulnerability plan. QIH (Quantitative Imaging Health) is an innovative technology that has revolutionized medical devices and how healthcare professionals diagnose and treat patients. By combining advanced imaging techniques with quantitative analysis, QIH devices provide accurate and objective measurements of various health parameters, enabling healthcare providers to make informed decisions regarding patient care. ## Key Takeaways - QIH devices combine imaging with quantitative analysis for objective health data. - They use MRI, CT, ultrasound to capture detailed images. - Software algorithms extract numerical data like size, density, and blood flow. - QIH devices support disease evaluation and treatment monitoring. - They enhance diagnostic accuracy and guide therapeutic interventions. - Cybersecurity for QIH devices is crucial due to sensitive data. ## Why This Matters Quantitative Imaging in Healthcare (QIH) devices are increasingly classified by the FDA as Software as a Medical Device (SaMD) or as the software component of an imaging system, which puts them squarely inside the cybersecurity scope of Section 524B of the FD&C Act and the FDA's February 3, 2026 final premarket cybersecurity guidance. That means a QIH submission today is expected to ship the full SPDF evidence package: threat model, SBOM with VEX, security architecture views, independent penetration testing, and a postmarket vulnerability management plan. The clinical consequence is what raises the stakes. QIH outputs - tumor volumes, perfusion parameters, automated measurements - feed directly into clinical decisions. A compromised algorithm or tampered DICOM input does not just leak data; it changes treatment. The FDA's *Guiding Principles for Good Machine Learning Practice* and the IMDRF *Principles and Practices for Medical Device Cybersecurity* both explicitly call out this risk class. The standards stack reviewers expect for QIH devices is IEC 62304 for the software lifecycle, ISO 14971 for the risk file, AAMI SW96 (FDA Recognized Consensus Standard 13-131) for security risk management, IEC 81001-5-1 for the secure software lifecycle, and the FDA's SaMD framework when the device is standalone software. Cybersecurity evidence has to be traceable across all of them. ## Understanding the Basics of QIH Devices ### Definition and Function of QIH Devices A [QIH device](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=5769) is a medical device that utilizes quantitative imaging techniques to generate precise measurements of specific health indicators. These devices employ advanced imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, to capture detailed body images. Unlike traditional medical imaging, which focuses on qualitative interpretation, QIH devices integrate software algorithms to analyze the images quantitatively. By extracting numerical data from the images, these devices provide objective measurements of parameters such as size, shape, density, and blood flow. This quantitative data can be used to evaluate disease progression, monitor treatment response, and aid in surgical planning, among other applications. ### History and Development of QIH Devices QIH devices have emerged due to advancements in imaging technology and the need for more precise and objective measurements in healthcare. The development and refinement of software algorithms have played a crucial role in enabling the quantitative analysis of medical images. Through dedicated research and collaborations between medical professionals, engineers, and software developers, QIH devices have evolved from experimental technology to valuable clinical tools. The field of QIH devices continues to evolve with ongoing research and development. Scientists and engineers are constantly exploring new imaging techniques and algorithms to enhance the capabilities of these devices. For example, researchers are investigating using artificial intelligence (AI) algorithms to improve the accuracy and efficiency of quantitative analysis. The integration of QIH devices with electronic health records (EHRs) has the potential to revolutionize healthcare. By transferring quantitative imaging data to patient records, healthcare providers can comprehensively view a patient’s health status. This integration can facilitate personalized and targeted treatment plans, improving patient outcomes. In addition to clinical applications, QIH devices also significantly impact medical research. The ability to obtain precise and objective measurements allows researchers to conduct studies with greater accuracy and reliability, which contributes to advancing medical knowledge and developing new treatments and therapies. ## Components and Design of QIH Devices ### Components of a QIH Device A Quantitative Image Analysis (QIH) device comprises various essential components that capture, process, and analyze medical images. These components include: ![Section Image](/imported-images/399338083eba794a.webp) - **Image acquisition hardware**: This component comprises the imaging modality, such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT), or ultrasound, which captures the detailed images of the body. The hardware must be carefully designed to ensure optimal image quality and minimize any potential artifacts that could affect the accuracy of the analysis. - **Software algorithms:** These algorithms play a crucial role in analyzing the acquired images. They extract quantitative measurements, such as tumor size or tissue density. These algorithms often involve complex mathematical models and machine-learning techniques to ensure accuracy and reliability. Developers continuously refine and improve these algorithms to enhance the precision and efficiency of the analysis. - **User interface:** The user interface is a vital component of a QIH device as it allows healthcare professionals to interact with it. It provides a platform for viewing the images and measurement results and can tailor the analysis parameters according to the patient’s specific needs. The user interface design must prioritize ease of use, intuitive navigation, and clear visualization of the analysis results. ### Design Principles and Considerations The design of a QIH device is driven by the need to ensure accuracy, reliability, and user-friendliness. To achieve these goals, developers must consider various factors, such as: - **Image quality:** The hardware of a QIH device should provide high-resolution images with minimal artifacts. This ensures the accuracy of the quantitative analysis and allows healthcare professionals to make informed decisions based on the image data. The hardware design must consider signal-to-noise ratio, spatial resolution, and contrast sensitivity to optimize image quality. - **Automated analysis:** QIH devices often employ algorithms to reduce user bias and increase efficiency. The design should prioritize the integration of such algorithms, allowing for automated measurements and analysis. This saves time and enhances the consistency and reproducibility of the results. - **Data security and privacy:** Given the sensitive nature of medical data, [QIH device design must ensure data security and privacy protection measures](/blog/qih-medical-device-vulnerabilities-what-you-need-to-know). This includes implementing encryption protocols, access controls, and secure data storage to comply with regulatory requirements and protect patient confidentiality. The design should facilitate easy integration with existing hospital information systems while maintaining data integrity and privacy. By carefully considering these components and design principles, QIH devices can provide healthcare professionals with powerful tools for accurate and efficient quantitative image analysis. Continuous advancements in hardware and software technologies further enhance these devices’ capabilities, improving patient care and clinical outcomes. The design of QIH devices is not limited to the technical aspects alone. Human factors engineering ensures these devices’ usability and user experience. Ergonomic considerations, such as the placement of buttons and controls, the arrangement of information on the user interface, and the overall device ergonomics, are taken into account to minimize user fatigue and maximize efficiency during prolonged use. Collaboration between engineers, clinicians, and usability experts is essential to creating a design that meets the needs of healthcare professionals and patients. ## Applications of QIH Devices in Healthcare ### QIH Devices in Diagnostic Procedures QIH devices have significantly impacted diagnostic procedures by providing precise and quantitative measurements that aid in identifying and characterizing various medical conditions. For example, in oncology, these devices can quantitatively evaluate tumor size, shape, and vascularity, assisting in cancer staging and treatment planning. QIH devices in neurology can assess brain volume changes and detect abnormalities in specific brain regions, facilitating the early detection and monitoring of neurodegenerative disorders such as Alzheimer’s. QIH devices in gastroenterology have revolutionized the field by enabling real-time assessment of gastrointestinal motility and function. These [devices can capture dynamic changes in the digestive system](/blog/top-10-embedded-operating-systems-for-medical-devices), aiding in the diagnosis of conditions like irritable bowel syndrome and gastroesophageal reflux disease. ### Therapeutic Uses of QIH Devices QIH devices also have therapeutic applications, particularly in image-guided interventions and minimally invasive procedures. For instance, QIH devices can provide precise blood flow and vessel diameter measurements during cardiac catheterization procedures, helping physicians navigate and deploy intravascular devices with greater accuracy. In addition, QIH devices are increasingly used in radiation therapy to optimize treatment planning and delivery. By quantitatively analyzing the patient’s anatomy and tumor characteristics, these devices contribute to personalized treatment approaches and minimize radiation dose to surrounding healthy tissues. In orthopedics, QIH devices are crucial in assessing joint function and biomechanics. By providing detailed quantitative data on joint movements and alignment, these devices assist orthopedic surgeons in planning and executing procedures such as joint replacement surgeries with enhanced precision. ## Advantages of Using QIH Devices ### Improving Patient Care with QIH Devices QIH devices offer several advantages that enhance patient care. These devices reduce interobserver variability and ensure consistency in diagnostic and treatment decisions by providing objective and quantitative measurements. This leads to improved accuracy in disease detection, staging, and monitoring. ![Section Image](/imported-images/17d39925bf1e5a4a.webp) QIH devices enable healthcare professionals to track treatment responses more effectively, allowing for timely adjustments if necessary. This improves patient outcomes and optimizes resource utilization in healthcare settings. Using QIH devices can enhance patient satisfaction by providing clear and measurable data regarding their health status. This transparency builds trust between patients and healthcare providers, leading to better communication and shared decision-making. ### Efficiency and Accuracy of QIH Devices QIH devices often streamline diagnostic workflows by automating the analysis process and reducing the time required for image interpretation. By providing precise and reproducible measurements, these devices improve efficiency and enable healthcare professionals to focus on other critical aspects of patient care. Additionally, the accuracy of QIH devices supports personalized medicine, where treatment plans are tailored to individual patients based on specific data points. The detailed information these devices provide allows for targeted interventions that can lead to better outcomes and improved quality of life for patients. ## Challenges and Limitations of QIH Devices ### Technical Challenges in QIH Device Usage Despite the numerous benefits, QIH devices also pose certain challenges. One significant challenge is the need for standardized imaging protocols and analysis methods. Variations in imaging techniques and analysis algorithms can introduce bias and affect the comparability of measurement results across different devices and institutions. Integrating QIH devices into existing healthcare systems can present technical hurdles, including interoperability issues, data integration, and compatibility with electronic medical records. For example, healthcare institutions may use different electronic medical record systems, making it difficult to transfer and integrate QIH device data into patient records seamlessly. Addressing these challenges requires collaboration between device manufacturers, healthcare providers, and regulatory authorities. Another technical challenge in QIH device usage is the need for quality control measures. Ensuring the accuracy and reliability of QIH device measurements is crucial for their successful implementation in clinical practice. This involves regular calibration of devices, validation of imaging protocols, and ongoing monitoring of performance metrics to detect any potential drift or degradation in measurement accuracy. ### Addressing Limitations and Concerns Efforts are underway to mitigate the limitations and concerns associated with QIH devices. Standardization initiatives, such as the Quantitative Imaging Biomarkers Alliance (QIBA), aim to establish standardized imaging acquisition and analysis guidelines, ensuring the consistency and reproducibility of quantitative measurements across devices. These guidelines encompass various aspects, including imaging protocols, data analysis algorithms, and quality control procedures. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), play a crucial role in evaluating and approving QIH devices, ensuring their safety and efficacy. Before granting market clearance or approval, they assess these devices’ technical performance, clinical utility, and potential risks. This regulatory oversight helps to instill confidence in the medical community and patients regarding the reliability and safety of QIH devices. Additionally, ongoing research and development aim to refine the algorithms and improve the accuracy and reliability of QIH device measurements. Researchers are exploring advanced machine learning techniques, such as deep learning and artificial intelligence, to enhance the automated analysis of imaging data and extract more meaningful quantitative information. These advancements can potentially revolutionize the field of quantitative imaging and further expand the clinical applications of QIH devices. ## The Future of QIH Devices in Medical Technology ### Emerging Trends in QIH Device Technology The future of QIH devices looks promising, with ongoing advancements and emerging trends shaping medical technology. One such trend is the integration of artificial intelligence [(AI) algorithms](/blog), which will enable QIH devices to learn from large datasets and improve their diagnostic capabilities. ![Section Image](/imported-images/0cc1f26724a80234.webp) Developing portable QIH devices can transform point-of-care diagnostics, bringing quantitative analysis to resource-limited settings and improving access to accurate healthcare assessments. ### Potential Impact of QIH Devices on Healthcare The impact of QIH devices on healthcare will continue to expand as their applications grow and their capabilities increase. These devices can revolutionize disease diagnosis, treatment planning, and monitoring across various medical disciplines. They hold the promise of personalized medicine, where treatment decisions are tailored based on quantitative data specific to each patient. As QIH devices become more widely adopted, healthcare providers, medical technology companies, and regulators must collaborate to ensure seamless, standardized integration that prioritizes patient safety and improved outcomes. One area where QIH devices are already making a significant impact is in the field of cancer detection. With their ability to provide precise and objective quantitative measurements, these devices enhance cancer diagnosis accuracy. By analyzing biomarkers and genetic markers, QIH devices can detect early signs of cancer, allowing for timely intervention and potentially saving lives. Integrating QIH devices with telemedicine platforms is another exciting development in the field. This combination allows for remote monitoring of patient’s health conditions, enabling healthcare professionals to provide real-time feedback and interventions. This is particularly beneficial for individuals living in rural or underserved areas, where access to specialized medical care may be limited. Additionally, the continuous advancements in QIH device technology pave the way for personalized treatment plans. By collecting and analyzing data on an individual’s unique physiological characteristics, QIH devices can assist healthcare providers in tailoring the most effective treatment options for each patient. This targeted approach improves patient outcomes and reduces the risk of adverse reactions to medications or treatments. ## QIH devices compared with conventional imaging | Aspect | Conventional imaging | QIH device | | --- | --- | --- | | Output | An image a clinician interprets | A number that feeds a clinical decision | | Failure mode | A poor image is visibly poor | A wrong measurement looks exactly like a right one | | Integrity requirement | The image must not be altered | The image, the algorithm, and the result must all be protected | | Regulatory framing | Often the imaging hardware itself | Usually software as a medical device under Section 524B | | Security evidence expected | Interface and network controls | Model integrity, input validation, output provenance, and the usual device controls | The difference that matters is silent failure. A corrupted measurement still renders cleanly, which is why integrity evidence carries so much weight here. ## Conclusion QIH devices are transforming the field of medical devices by providing precise and objective quantitative measurements. With their applications in diagnostics and therapeutics and the potential to revolutionize healthcare, these devices are shaping the future of medical technology. Standardization, collaboration, and ongoing research will pave the way for the widespread adoption of QIH devices, ultimately benefiting patients and healthcare providers. cybersecurity measures become paramount as QIH devices advance and integrate into the healthcare landscape. Blue Goat Cyber understands the critical nature of protecting medical devices and patient data. Specializing in medical device cybersecurity, HIPAA and FDA compliance, and a range of penetration testing services, we are dedicated to safeguarding your technology against cyber threats. Our veteran-owned business is committed to ensuring the security and integrity of your QIH devices. [Contact us today for cybersecurity help](/contact) and partner with a team as passionate about security as you are about healthcare. ## How Blue Goat approaches this Our approach to securing QIH medical devices focuses on proactive vulnerability identification and mitigation. We conduct in-depth security assessments, including penetration testing and threat modeling, tailored to the unique complexities of connected imaging systems and embedded software. Our team, comprised of certified experts like CISSPs and OSCPs, including ex-military red team members, understands both medical device functionality and attacker methodologies. We assist manufacturers in meeting regulatory requirements from the FDA, ensuring their QIH devices achieve proper authorization. Our services streamline the premarket submission process by integrating security from the design phase through postmarket surveillance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our security validation services for medical devices at [Blue Goat Cyber's Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is a QIH medical device? A QIH medical device uses advanced imaging (e.g., MRI, CT) and software to quantify health parameters. Unlike traditional imaging, it provides objective, numerical data to assist in diagnosis and treatment. ### How do QIH devices improve patient care? QIH devices improve patient care by providing objective and quantitative measurements, reducing variability in diagnostic and treatment decisions. This leads to more accurate disease detection, better treatment monitoring, and personalized care. ### What are the cybersecurity concerns for QIH devices? QIH devices handle sensitive patient data, making them targets for cyber threats. Data security and privacy, including encryption and access controls are critical design considerations to comply with regulations and protect patient confidentiality. ### Does the FDA regulate QIH medical devices? Yes, QIH medical devices are subject to regulation by the FDA, like other medical devices. Manufacturers must adhere to FDA guidelines and submission processes, including cybersecurity requirements outlined in the February 3, 2026 final guidance. ### How can QIH devices integrate with existing healthcare systems? Integrating QIH devices into existing healthcare systems requires addressing interoperability issues, data integration, and compatibility challenges with electronic medical records (EMRs). Strong design ensures data transfer while maintaining data integrity and privacy. **Related:** [Medical Device AI Performance Drift](/blog/understanding-ai-performance-drift-ensuring-medical-device-safety) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Recalled Medical Devices: Cyber Failures Source: https://bluegoatcyber.com/blog/recalled-medical-devices-cybersecurity-failures # Recalled Medical Devices: Cyber Failures. What Manufacturers Need to Know > **[DIRECT ANSWER]** Recalled medical devices most often fail because of weak or missing authentication, unpatched software and firmware vulnerabilities, unencrypted data transmission, and no secure update mechanism, as seen in the 2015 infusion pump alerts and the 2017 St. Jude defibrillator recall. The FDA's February 3, 2026 premarket guidance treats these as gating deficiencies under Section 524B, so manufacturers must build authentication, encryption, and patchability into design, not add them after a recall. _Updated November 16, 2024_ Medical device cybersecurity failures have become a growing concern in recent years. As devices have become more connected and more dependent on software, they have also become easier targets for cyber threats. This article covers the [importance of cybersecurity in medical devices](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry), the nature of cybersecurity failures, the recall process, and ways to reduce risk. ## Key Takeaways - Cybersecurity failures risk patient safety and data privacy. - Common issues: weak authentication, software vulnerabilities, no encryption. - Manufacturers must integrate security into device design. - Maintain secure update mechanisms for timely patching. - Proactive collaboration needed from all stakeholders. - Continuous monitoring and adaptation to new threats are essential. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to recalled medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Understanding the Importance of Cybersecurity in Medical Devices Medical devices, from pacemakers to insulin pumps, improve patient outcomes and make care more efficient. But internet connectivity and software dependence also make them targets. A cybersecurity breach in a medical device can compromise patient safety and, in some cases, lead to loss of life. ![Section Image](/imported-images/5d099a7cba3df1c4.png) ### The Role of Medical Devices in Healthcare Medical devices include a wide range of equipment, from diagnostic tools to implantable devices. They help clinicians diagnose conditions, monitor patients, and deliver treatment. Devices such as [MRI machines](/blog/what-is-a-radiology-information-system), infusion pumps, and defibrillators are standard parts of modern care. ### The Intersection of Cybersecurity and Medical Devices As medical devices become more connected and more integrated into healthcare systems, the risk of cybersecurity breaches rises. Attackers can exploit device vulnerabilities to gain unauthorized access, manipulate data, or disrupt device function. One example is remote hacking. If an attacker gets into a hospital network and takes control of a connected medical device, the result can be life-threatening. The attacker could change settings or cause the device to deliver the wrong dose. [Medical devices’ interconnectedness](/blog/medical-device-cybersecurity-interoperability-concerns) creates another problem. A breach in one device can spread risk across the network, exposing other connected devices and patient data. That is why security controls need to exist at the device, network, and system levels. ## The Nature of Cybersecurity Failures in Medical Devices Cybersecurity failures in medical devices come from several causes. Understanding them is the first step in fixing them. ![Section Image](/imported-images/2c82ff930fae6a9a.png) [Inadequate authentication mechanisms](/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization) are a common failure point. Weak passwords or no multi-factor authentication make it easier for unauthorized users to access devices and their networks. That can lead to tampering with critical medical equipment and put patient safety and privacy at risk. Software and firmware vulnerabilities are another major issue. Attackers can use them to bypass security controls and take control of devices. That can expose patient data, alter treatment protocols, or cause physical harm. The lack of [encryption](/blog) in data transmission between devices and healthcare networks is another serious weakness. Unencrypted data can be intercepted, exposing sensitive patient information. That creates privacy risk and opens the door to identity theft and other abuse. Another critical failure is the lack of secure update mechanisms. Even when manufacturers release patches, devices without secure update capability remain exposed. Attackers can keep exploiting known vulnerabilities that were never properly patched. ### The Impact of Cybersecurity Failures on Patient Safety The consequences of cybersecurity failures in medical devices are serious. A compromised device can create life-threatening conditions. For example, an attacker could change medication dosage in an infusion pump. That can cause severe complications or death. Real incidents show the risk is not theoretical. In 2015, the FDA issued a [safety alert regarding hospitals’ specific infusion pumps](https://www.aha.org/news/headline/2015-05-14-fda-alerts-health-care-facilities-infusion-pump-cybersecurity). Those pumps had vulnerabilities that could be exploited remotely to alter dosage. The incident made clear how badly medical devices need stronger security controls. Cybersecurity failures can also disable devices or make them unusable. That can delay treatment while providers find alternatives. In critical cases, those delays can directly affect outcomes. Cybersecurity failures in medical devices create significant [risks to patient safety](/blog) and privacy. Addressing them requires strong authentication, secure software and firmware, encryption, and reliable update mechanisms. Healthcare organizations that treat cybersecurity as part of device safety are in a better position to protect patients. ## The Process of Medical Device Recall Due to Cybersecurity Issues Identifying and fixing cybersecurity vulnerabilities in medical devices takes a structured process. When a device has cybersecurity flaws, manufacturers and [regulatory authorities must collaborate](/blog) to start a recall. ![Section Image](/imported-images/01c5f72bbafbdd93.png) ### Identifying Cybersecurity Vulnerabilities in Medical Devices Finding vulnerabilities in medical devices requires proactive testing and cybersecurity audits. Manufacturers should perform thorough assessments of software and hardware to identify weaknesses. Working with external cybersecurity experts can help surface issues internal teams miss. ### The Recall Procedure for Faulty Medical Devices When a cybersecurity vulnerability is found in a medical device, manufacturers need to act fast. That may mean notifying healthcare providers and recalling affected devices. The recall process usually includes coordination with regulatory authorities, notification of affected patients, and instructions for device replacement or software updates. Recalls tied to cybersecurity are difficult to execute. Manufacturers need clear communication with healthcare providers, patients, and regulators so everyone understands the issue and the required actions. The impact of a recall goes beyond inconvenience. It also exposes weaknesses in the broader healthcare cybersecurity posture and shows why continuous monitoring matters. One notable example came in 2017. St. Jude Medical recalled certain implantable defibrillators and cardiac resynchronization therapy devices after identifying vulnerabilities that could be exploited remotely and could compromise patient safety. The recall reinforced the need for regular cybersecurity assessments and fast remediation. ## Mitigating Cybersecurity Risks in Medical Devices To protect medical devices, organizations need practical strategies that reduce cybersecurity risk. ### Strategies for Enhancing Cybersecurity in Medical Devices Manufacturers should prioritize security throughout the product lifecycle. That includes implementing [secure coding practices](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist), performing thorough security testing, and running regular audits. Building security into design reduces the chance that attackers can exploit weaknesses later. Manufacturers should also make sure devices can receive and install security updates. That allows newly discovered vulnerabilities to be addressed quickly and reduces the window for attack. Regular patching is a basic requirement for protecting patient safety. Stakeholder collaboration matters too. Healthcare providers need ongoing training so they understand risks and know what good security practice looks like. Better awareness makes them more effective at spotting and responding to threats. Regulatory authorities also matter. They set cybersecurity standards and perform audits to check compliance. By enforcing stricter requirements and holding manufacturers accountable, they improve the overall security of medical devices. ### The Future of Cybersecurity in Medical Devices Cybersecurity in medical devices will keep changing as threats change. Machine learning and artificial intelligence may help detect and mitigate cyber threats by analyzing large volumes of data in real time and identifying abnormal behavior. Blockchain for secure data exchange and encryption is also getting attention in healthcare. Its decentralized, tamper-resistant design can help protect sensitive medical data. Used correctly, it can support confidentiality, integrity, and availability and reduce the risk of unauthorized access. ## A Secure-by-Design Failure: The 2025 Ventilator Recall A 2025 Class I recall of a ventilator shows what happens when secure-by-design principles are treated as optional rather than foundational. The manufacturer identified the weaknesses in November 2024 and, rather than remediate the installed fleet, exited the ventilator business entirely, ending production, distribution, and servicing of the affected units. The FDA classified the action [Class I](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=213249) because the flaws could directly threaten patient safety, even though no injuries or deaths were reported. The specific gaps were not exotic. They were the same basic controls that show up across most recalled devices: unencrypted passwords and sensitive data, physical ports exposed to anyone with hands-on access, and minimal authentication for the technicians who calibrate the device. | Vulnerability found | Basic control missing | | --- | --- | | Unencrypted passwords and stored data | Encryption of credentials and sensitive data at rest | | Physically exposed ports | Physical hardening or port lockdown | | Minimal calibration authentication | Role-based authentication for service and test functions | None of these require exotic engineering. They are the kind of controls a secure development lifecycle catches before a device ever reaches submission, which is why the recall reads less like a sophisticated attack and more like a design process that skipped basic steps. Legacy devices are the most exposed here, since the FDA's February 3, 2026 final premarket cybersecurity guidance sets clearer expectations for new submissions but does not retroactively harden equipment already in the field. The practical lesson for manufacturers is to audit existing product lines against these three failure categories specifically, not just wait for a new submission cycle to address them. Reviewing whether every device, new or legacy, has encrypted credential storage, controlled physical access, and authenticated service functions catches the pattern behind this recall before it becomes a Class I action rather than after. ## Conclusion Medical device cybersecurity failures put patient safety and healthcare system integrity at risk. Stakeholders involved in building, deploying, and using these devices need to understand why cybersecurity matters, how failures happen, how recalls work, and how to reduce risk. Prioritizing security and taking proactive steps helps support safe and effective use of medical devices in digital healthcare. The healthcare industry will keep moving toward connected systems, which means device cybersecurity will only matter more. Ongoing coordination among manufacturers, healthcare providers, and regulatory authorities is necessary to keep up with emerging threats. Regular review and improvement of cybersecurity strategy is part of that job. ## How Blue Goat approaches this Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result. Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our [medical device cybersecurity services](/services) for the full scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What specific cybersecurity failures affect medical devices? Common issues include weak authentication, unpatched software vulnerabilities, and a lack of encryption for data in transit. These can allow unauthorized access, data manipulation, or device malfunction. ### How do cybersecurity failures impact patient safety? Compromised devices can lead to life-threatening situations, such as altered medication dosages or device malfunction. Such failures can also delay treatment and cause severe complications, directly affecting patient outcomes. ### What is the process for recalling medical devices due to cybersecurity issues? The recall process involves identifying vulnerabilities through proactive testing, notifying healthcare providers, and coordinating with regulatory authorities. Manufacturers must issue instructions for device replacement or software updates to mitigate risks. ### How can manufacturers mitigate cybersecurity risks in medical devices? Manufacturers should prioritize security throughout the product lifecycle, using secure coding practices, thorough security testing, and regular audits. They must also ensure devices can receive and install security updates promptly. ### What are the FDA's cybersecurity requirements for medical devices? The FDA requires a secure product development lifecycle, threat modeling, post-market vulnerability management plans, and a Software Bill of Materials (SBOM). Manufacturers must also detail processes for releasing post-market updates and patches. ### How will future technologies impact medical device cybersecurity? Advanced technologies like machine learning, AI, and blockchain are expected to enhance cybersecurity by detecting and mitigating threats in real time. They can improve data integrity and support secure data exchange, reducing unauthorized access risks. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## RFID and Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/rfid-medical-devices-cybersecurity # RFID and Medical Device Cybersecurity: What Manufacturers Need to Know > **[DIRECT ANSWER]** RFID improves medical device cybersecurity by giving each device a unique identifier that supports authentication, real-time tracking of tampering or loss, and inventory management across implantables, drug delivery systems, and surgical instruments. It is not a standalone security control: RFID must be paired with encryption, access controls, and secure communication channels. The FDA's February 3, 2026 guidance still expects the full cybersecurity lifecycle, from design through postmarket updates, regardless of RFID use. _Updated November 16, 2024_ As electronic medical records, telemedicine, and connected devices spread across healthcare, [protecting patient data](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) and securing medical devices matter more than ever. One technology with a growing role in medical device security is [RFID (Radio Frequency Identification)](/blog/nfc-and-medical-device-cybersecurity). ## Key Takeaways - RFID ensures accurate identification and authentication of medical devices. - Real-time tracking with RFID prevents device loss and supports integrity. - Limitations include signal interference and initial infrastructure costs. - Emerging RFID trends offer enhanced security features and capabilities. - Integration with blockchain could provide tamper-resistant data management. - FDA guidance emphasizes secure product development and post-market updates. ## Why this matters The security of medical devices is critical, directly impacting patient safety, data privacy, and the operational integrity of healthcare systems. A compromised medical device can lead to patient harm, data breaches, and significant financial and reputational damage to healthcare providers and device manufacturers. RFID offers a vital layer of defense by enabling precise identification, authentication, and real-time tracking of devices, mitigating risks such as counterfeiting, unauthorized access, and supply chain vulnerabilities. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes the necessity for cybersecurity throughout the product lifecycle, from design to post-market surveillance. This guidance highlights the importance of capabilities like secure device identification and integrity checks, areas where RFID technology can play a significant role. Adherence to standards such as IEC 81001-5-1 (Health software, security activities in the product life cycle), ISO 27001 (Information security management systems), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management) is crucial. Effective cybersecurity measures, including those augmented by RFID, are not merely compliance requirements but fundamental components of safe and effective medical device deployment and operation. ## Understanding RFID Technology RFID is a wireless technology that uses radio waves to identify and track objects. It has three main parts: a tag, a reader, and a backend system. The tag, usually attached to an item, stores a unique identifier the reader can read. The reader uses an antenna to capture the tag’s information and send it to the backend system for processing. ![Section Image](/imported-images/78a583cbe8c5d18f.webp) RFID is used across retail, logistics, healthcare, and manufacturing. In retail, RFID tags improve inventory management with real-time data on stock levels and item locations. In healthcare, RFID systems track medical equipment, monitor patient flow, and help ensure medications are administered correctly. ### What is RFID? RFID stands for Radio Frequency Identification. It is an automatic identification technology that uses radio waves to identify and track objects. When RFID tags are attached to objects, they can wirelessly communicate identity and other relevant information. RFID technology includes passive, active, and semi-passive systems. Passive RFID tags do not have an internal power source and rely on the reader’s signal to transmit data. Active RFID tags have their own power source, which lets them broadcast over longer distances. Semi-passive tags combine elements of both and balance range with power use. ### How Does RFID Work? RFID works through electromagnetic coupling. When the reader emits a radio signal, the RFID tag receives it through its antenna. The tag uses energy from the reader’s signal to power its internal circuitry, then sends back a response containing its unique identifier and any additional stored data. A key advantage of RFID is real-time tracking and tracing. In supply chain management, RFID can improve visibility, reduce errors, and increase inventory accuracy. That helps organizations optimize processes and reduce losses. ## The Role of RFID in Medical Devices Medical devices support diagnosis, treatment, and monitoring. RFID can improve both their security and their operational use. ![Section Image](/imported-images/4313022ec132cc0e.webp) ### Types of Medical Devices Using RFID RFID is used in implantable devices, drug delivery systems, surgical instruments, and hospital beds. These devices use RFID tags for real-time tracking, inventory management, and authentication. [Implantable medical devices](/blog/implantable-device-cybersecurity-concerns), such as pacemakers and neurostimulators, often include RFID tags that store important patient information. That gives clinicians quick access to key data in an emergency. Drug delivery systems, such as insulin pumps, can also use RFID to support accurate dosing and track medication adherence. ### Benefits of RFID in Medical Devices Adding RFID to medical devices gives healthcare facilities several benefits. RFID supports fast, accurate device identification, which cuts down on human error. It also improves inventory management, so the right equipment is available when needed. RFID supports asset tracking as well, which helps reduce loss or theft of expensive devices. RFID can also improve patient safety. RFID-enabled surgical instruments can be tracked during procedures to help confirm the right tools are in use. Hospital beds with RFID tags can help staff monitor patient movement and improve bed utilization. ## Cybersecurity Threats in Healthcare As healthcare becomes more digital, cybersecurity threats keep growing. Attackers look for weaknesses in medical devices and networks that can put patient data and patient safety at risk. ![Section Image](/imported-images/32fab1d410c5328e.webp) Healthcare is a prime target because it stores large amounts of sensitive data. That includes patient records and intellectual property that can be [sold on the dark web](/blog). This makes healthcare organizations frequent ransomware targets, where attackers encrypt critical data and demand payment. ### Common Cybersecurity Vulnerabilities in Medical Devices Medical devices often have weak security controls, which makes them vulnerable to attack. Outdated software, weak or default passwords, and missing encryption can all let attackers gain unauthorized access, manipulate data, or disrupt device function. The [interconnected nature of healthcare systems](/blog/medical-device-cybersecurity-interoperability-concerns) adds another problem. As more devices connect to the internet for remote monitoring and data collection, the attack surface grows. One weakness can expose an entire network and lead to broad data breaches or system failures. ### The Impact of Cybersecurity Breaches in Healthcare Cybersecurity breaches in healthcare can have severe consequences. Beyond exposing patient data, they can lead to medical identity theft, inaccurate records, and direct patient harm. If attackers gain control of medical devices, they may alter dosages, change treatment plans, or create life-threatening conditions. A breach also damages trust. Patients may lose confidence in how their data is handled, and the organization may face legal consequences. Recovering from that takes more than fixing the immediate issue. It also requires stronger security measures and clear communication with patients and stakeholders. ## RFID as a Cybersecurity Solution RFID can help improve medical device security in healthcare. As healthcare keeps adding connected and IoT devices, security demands increase. RFID gives medical devices unique identifiers that can support stronger security controls. ### How RFID Enhances Medical Device Security By adding RFID tags to medical devices, healthcare providers can use authentication protocols to verify that devices are legitimate. RFID can also help create a secure communication channel between devices and support encrypted data transmission. It also allows real-time monitoring of device integrity to detect unauthorized tampering or modification. RFID can also improve inventory management, keep devices accounted for, and reduce theft or loss. That improves both security and day-to-day operations. ### Limitations and Challenges of RFID in Cybersecurity RFID has limits. One major issue is signal interference, which can reduce system accuracy and reliability. Cost is another barrier. Building RFID infrastructure across healthcare facilities can be expensive. Interoperability is also a challenge. RFID systems need to work with existing IT infrastructure, electronic health records, and other security controls. Without that, organizations will not get the full benefit. ## Future of RFID in Medical Device Cybersecurity The role of RFID in medical device cybersecurity will keep changing as technology advances and new threats appear. ### Emerging Trends in RFID Technology RFID technology is improving through smaller and more durable tags, better range and accuracy, and stronger data encryption. These advances should improve both security and effectiveness in medical device applications. ### Predictions for RFID and Cybersecurity in Healthcare Experts expect RFID to become more deeply integrated into medical device cybersecurity strategies. With continued research and development, RFID will keep adapting to changing cybersecurity threats in healthcare. One area to watch is real-time tracking and monitoring of medical devices. RFID tags paired with sensors can provide data such as temperature, location, and usage patterns. That can improve inventory management, patient care, and operational efficiency. Integrating [blockchain technology](/blog) with RFID in medical device cybersecurity could also improve data integrity and security. Blockchain’s decentralized, tamper-resistant model combined with RFID tracking can create a more transparent and secure way to manage medical device data. That could reduce the risk of data breaches and unauthorized access while helping protect patient information. ## Conclusion As healthcare organizations keep adopting RFID to improve medical device cybersecurity, they also need experienced security support. Blue Goat Cyber focuses on medical device cybersecurity and helps organizations address HIPAA and FDA compliance with a proactive security approach. [Contact us today for cybersecurity help](/contact) if you need help securing medical devices and patient data. Check out our [medical device cybersecurity FDA 510(k) submission package.](/) ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers and healthcare organizations in integrating and securing RFID technologies within their ecosystems. Our approach begins with a detailed assessment of existing infrastructure and potential vulnerabilities, followed by strategic recommendations tailored to specific needs. We develop protocols for secure RFID implementation, including encryption, access control, and anomaly detection to counter signal interference and data interception risks. Our team, comprised of CISSP and OSCP certified experts, including ex-military red team personnel, applies a careful methodology to identify and address weaknesses. We provide specialized services such as threat modeling and penetration testing to ensure RFID systems meet stringent security requirements. For FDA submissions, we focus on demonstrating security controls that align with regulatory expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We offer thorough support, from initial design consultation to post-market monitoring and incident response planning. Our objective is to enhance the security posture of medical devices, safeguarding patient safety and data confidentiality. Learn more about our specialized services at: [/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is RFID in the context of medical devices? RFID (Radio Frequency Identification) in medical devices uses radio waves to identify and track equipment. It involves tags attached to devices, readers, and a backend system to manage data, enhancing security and operational efficiency. ### How does RFID enhance medical device cybersecurity? RFID improves cybersecurity by providing unique device authentication, enabling secure communication channels, and supporting real-time monitoring for tampering detection. It also aids in inventory management, reducing theft and loss of critical devices. ### What are the limitations of using RFID for cybersecurity? Limitations include potential signal interference, which can affect accuracy, and the significant initial cost of implementing RFID infrastructure. Interoperability with existing IT systems and electronic health records also presents a challenge. ### Does the FDA require RFID in medical devices? The FDA does not mandate RFID use, but its February 3, 2026 final guidance on cybersecurity emphasizes secure product development, threat modeling, and post-market vulnerability management. RFID can support these requirements by enhancing device security and traceability. ### How can RFID technology evolve in medical device security? Future developments include smaller, more durable tags, improved range, and stronger encryption. Integrating RFID with blockchain technology could also create more transparent and secure data management for medical devices. ### What types of medical devices use RFID? RFID is used in various medical devices such as implantable devices, drug delivery systems, surgical instruments, and hospital beds. This enables real-time tracking, inventory management, and authentication for patient safety and operational efficiency. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Training Data Poisoning in Medical AI: Controls and Evidence Source: https://bluegoatcyber.com/blog/safeguarding-medical-device-ai-combating-data-poisoning-cybersecurity-threats # Training Data Poisoning in Medical AI: Controls and Evidence > **[DIRECT ANSWER]** Data poisoning corrupts an AI-enabled medical device by tampering with the data it learns from, either during initial training or during a later retraining cycle, so the deployed model produces wrong outputs that look plausible. Defending against it means controlling data provenance, verifying model integrity before and after every update, and keeping a rollback path. A Predetermined Change Control Plan and an AIBOM are how a manufacturer documents that control set for the FDA. An AI-enabled device that learns after clearance carries a risk that a fixed-function device does not: the thing being cleared can keep changing after it ships. If the data feeding that change is corrupted, the model drifts toward wrong answers without any code change to flag in a diff. A poisoned imaging classifier or dosing recommender does not crash. It keeps running and keeps producing confident, wrong output, which is worse for patient safety than an obvious failure. Reviewers now expect manufacturers to show exactly how they would catch that before it reaches a patient, not just describe the risk in prose. ## Key Takeaways - Poisoning can happen at initial training, at a vendor's dataset, or during a continuous learning cycle after clearance, and each path needs its own control. - A Predetermined Change Control Plan has to name what retraining is allowed to change and what triggers a stop before the changed model goes live. - An AIBOM extends the SBOM to cover the model, its weights, its training and evaluation datasets, and the third-party models it calls. - Model integrity verification and a working rollback path are the two controls reviewers ask about most often, and the two most often missing. - Good Machine Learning Practice guides how you build and evaluate the model; it does not replace the security controls around the pipeline that feeds it. ## Why This Matters The FDA's final guidance *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026, is the current end of a chain that ran through the September 27, 2023 final guidance and the June 27, 2025 update, and it treats AI-enabled devices as software that carries the same Section 524B cybersecurity obligations as any other cyber device. It does not use the word poisoning, but its expectations for data integrity, threat modeling, and change control apply directly to how a model learns. A device that retrains on field data has an attack surface that a static device does not: the data pipeline itself. AAMI CR515:2025 is the consensus report that names this attack surface explicitly, covering training data poisoning alongside adversarial evasion, model inversion, and pipeline compromise, and reviewers increasingly expect a threat model that reflects it rather than a generic STRIDE pass. Good Machine Learning Practice principles, jointly issued by the FDA and its counterparts, describe how to build and monitor a model responsibly, but they assume the data feeding it is trustworthy. Provenance and integrity controls are what make that assumption true. ## What actually counts as data poisoning in a medical device? Data poisoning is deliberate manipulation of the data a model learns from, so the model's behavior shifts in a way the attacker wants. It can happen at three points: in the original training set, in a vendor-supplied or licensed dataset, or in the stream of field data used for retraining after clearance. Each entry point needs a different control, because the trust boundary is different at each one. A mislabeled subset of training images, a small number of shifted labels, or fabricated samples blended into a real dataset are all forms of the same attack. The device keeps functioning and keeps producing plausible-looking outputs, so the corruption is not obvious in a demo. It shows up later as a pattern of wrong classifications that nobody connects to a specific batch of training data until someone goes looking. ## How does poisoning get in during retraining or continuous learning? Retraining is the highest-risk path because it happens after the device is already in clinical use and the data source is field data rather than a curated dataset. A device that adapts to hospital-specific patterns, or that periodically retrains on aggregated field data, is trusting every contributing site and every device instance that fed that pipeline. An attacker does not need to breach the device itself. Poisoning the data upstream, at a connected system, a labeling workflow, or a federated learning contributor, gets the same result with less effort. That is why the threat model for a continuously learning device has to extend past the device boundary to every system that touches the training data before it reaches the model. | Poisoning entry point | Trust boundary to control | Typical control | | --- | --- | --- | | Initial training set | Data vendor or internal curation team | Source attestation, sampling audit, label review | | Licensed or third-party dataset | Vendor contract and delivery pipeline | Cryptographic hash verification, provenance manifest | | Field data used for retraining | Every connected site or device instance | Anomaly detection on incoming samples, quarantine before use | | Federated learning contributor | Each participating node | Contribution bounding, outlier rejection before aggregation | > **[KEY REQUIREMENT]** If your device retrains on field data after clearance, the threat model has to name every contributing data source as a trust boundary, not just the device's own network interfaces. ## How does this interact with a Predetermined Change Control Plan and GMLP? A Predetermined Change Control Plan is the mechanism that lets a manufacturer make bounded changes to a cleared AI model without a new submission for every update. It has to state exactly what the retraining process is allowed to change, the data sources it is allowed to draw from, and the performance bounds that trigger a hold before a new model version goes live. A poisoning event that pushes the model outside those bounds should trip the same gate that a legitimate performance drift would trip. Good Machine Learning Practice guides model development, training methodology, and performance monitoring, but it assumes the underlying data is what it claims to be. A PCCP that only checks output accuracy against a validation set can still pass a poisoned model if the poisoning is subtle enough to stay inside the accuracy tolerance while shifting behavior on a specific input class. The PCCP's monitoring plan should include data-level checks, not only output-level accuracy checks, so a change in the input distribution gets flagged even when aggregate accuracy still looks fine. ## What does an AIBOM add that an SBOM does not cover? An SBOM inventories software components: libraries, frameworks, and their versions. It does not tell a reviewer what data trained the model, what version of the model is deployed, or which third-party or hosted models the device calls at inference time. An AIBOM, built in CycloneDX ML-BOM or the SPDX 3.0 AI profile, closes that gap by inventorying the model artifacts, their weights and versions, the training and evaluation datasets, and any external model dependencies. That inventory matters directly for poisoning response. If a poisoning event is discovered in a specific dataset version, the AIBOM is what tells you which model versions used that dataset and need to be pulled or retrained. Our [AIBOM guide](/guides/aibom-medical-devices) walks through the fields reviewers expect and how to generate one from an existing training pipeline. ## How do you verify model integrity and roll back a bad update? Model integrity verification means cryptographically confirming that the model running on the device matches the version that passed validation, every time it loads or updates. A signed model artifact with hash verification at load time catches both a poisoned retrain that slipped through validation and a tampered model pushed through a compromised update channel. Without this check, a device has no way to know that what it is running is what was actually validated. Rollback is the other half. If post-deployment monitoring flags a model version behaving outside its validated bounds, the device needs a tested path back to the last known-good version, not a manual patch process invented after the fact. That path should be exercised in verification testing before launch, the same way a firmware rollback would be, because the first time you need it should not be the first time you try it. ## What evidence does a reviewer expect to see? A reviewer expects to see the poisoning-relevant threat model, the data provenance controls for each training data source, the PCCP's monitoring and hold criteria, and a demonstrated rollback, not just a paragraph asserting that data governance exists. AAMI CR515:2025 is a consensus report rather than a certifiable standard, so you cannot claim conformity to it, but citing it as the method behind your ML threat model gives the reviewer a recognizable structure to evaluate against. Our [CR515 crosswalk tool](/tools/cr515-crosswalk) maps CR515's threat catalog against the controls a submission needs to show, which is useful for confirming nothing in the poisoning threat model got left out before you submit. ## How Blue Goat Cyber Approaches This We build the ML-specific threat model before we look at the rest of the security architecture, because a device that learns after clearance has an attack surface a static device does not, and generic threat modeling misses it. Our engineers map every data source that feeds training or retraining as a trust boundary, then verify that the PCCP's monitoring criteria would actually catch a poisoning event rather than only a benign performance drift. We build and validate the AIBOM alongside the SBOM, test the model integrity and rollback mechanisms as part of the same penetration test that covers the rest of the device, and document the result so the submission traces the threat to a control to a verified test outcome. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Frequently Asked Questions **Is data poisoning different from an adversarial evasion attack?** Yes. Poisoning corrupts the model during training so it learns the wrong thing permanently. Evasion attacks manipulate a single input at inference time to fool an already-trained model without changing what it learned. Both belong in an ML threat model, but they need different controls: provenance and integrity checks for poisoning, and input validation and robustness testing for evasion. **Does a device that never retrains still need these controls?** It needs the initial training data provenance controls and model integrity verification, but not the continuous monitoring and rollback infrastructure that a retraining device needs. A locked model still benefits from a signed artifact and hash verification at load, since a tampered update channel is a risk even without retraining. **Can a PCCP cover data provenance controls, or only model performance bounds?** A well-written PCCP should cover both. Performance bounds alone can miss a poisoning event that stays inside accuracy tolerance while shifting behavior on a narrow input class. Naming the allowed data sources and the checks applied to incoming retraining data closes that gap. **What is the difference between AAMI CR515 and Good Machine Learning Practice?** CR515 is a security-focused consensus report naming the threats specific to ML systems, including poisoning. GMLP is a set of practices for building, training, and evaluating a model well. They are complementary: GMLP tells you how to build a good model, CR515 tells you what can go wrong with the data and pipeline around it. **Do I need a separate AIBOM if I already maintain an SBOM?** Yes, if the device includes a model that learns from data. The SBOM covers software components; it does not capture model versions, weights, or training data provenance. Reviewers of AI-enabled devices increasingly ask for that information, and an AIBOM is the structured way to provide it. ## CTA If your device retrains after clearance, the poisoning threat model and the PCCP monitoring plan need to work together, not sit in separate documents. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to walk through your training pipeline and submission scope. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SaMD vs SiMD: What Manufacturers Need to Know Source: https://bluegoatcyber.com/blog/samd-vs-simd-what-medical-device-manufacturers-need-to-know # SaMD vs SiMD: What Medical Device Manufacturers Need to Know > **[DIRECT ANSWER]** SaMD (Software as a Medical Device) is standalone software running on general-purpose hardware, such as a diagnostic app or cloud AI service, while SiMD (Software in a Medical Device) is embedded firmware controlling a physical device like an infusion pump. Both are subject to Section 524B when they meet the cyber device definition, but SaMD emphasizes rapid cloud and OS-level updates while SiMD relies on hardware-level controls and slower, field-coordinated patch cycles. If you work in MedTech long enough, “SaMD vs SiMD” starts to blur into alphabet soup. But this distinction is not just academic. It drives how you architect your product, which standards apply, what your FDA strategy looks like, and how you structure cybersecurity across the total product life cycle. In this post, we break down SaMD vs SiMD in plain language, then connect it to modern medical device c [ybersecurity expectations and FDA submissions](https://www.fda.gov/media/119933/download ""). ## Key Takeaways - SaMD is standalone software; SiMD is embedded in hardware. - Classification impacts regulatory pathway and submission strategy. - Cybersecurity expectations vary for SaMD (cloud/app) and SiMD (firmware/device). - SaMD has rapid updates; SiMD updates are slower and controlled. - Many modern medical products include both SaMD and SiMD components. - The FDA February 3, 2026 guidance applies to both categories. ## At a glance | Dimension | SaMD (Software as a Medical Device) | SiMD (Software in a Medical Device) | |:--- |:--- |:--- | | **Definition** | Standalone software intended for medical purposes. | Software embedded within a physical medical device. | | **Typical Use Case** | Diagnostic apps, imaging analysis, cloud-based algorithms. | Pacemakers, infusion pumps, robotic surgical controllers. | | **Hardware** | General-purpose (smartphones, tablets, public cloud). | Proprietary, dedicated medical hardware or firmware. | | **Security Posture** | Rapid updates; relies on OS and cloud security. | Slower patch cycles; relies on hardware-level controls. | | **Common Attacks** | Data breaches, API vulnerabilities, unauthorized cloud access. | Physical tampering, side-channel attacks, signal interference. | | **FDA Relevance** | Subject to IMDRF frameworks and digital health guidance. | Evaluated as a component of the physical hardware system. | | **Key Tradeoff** | High accessibility and scale vs. platform volatility. | High reliability and control vs. difficult update logistics. | ## SaMD vs SiMD: Clearing Up the Acronyms **SaMD** stands for **Software as a Medical Device**. **SiMD** stands for **Software in a Medical Device**. They sound similar, but they describe very different realities. ## What Is SaMD (Software as a Medical Device)? Software as a Medical Device (SaMD) is standalone software that is itself considered a medical device. It has a medical intended use, but does not require being embedded in dedicated medical hardware. It usually runs on general-purpose hardware such as smartphones, tablets, laptops, workstations, or cloud infrastructure. Examples of SaMD include: - A mobile app that analyzes ECG data from a wearable to flag atrial fibrillation - A cloud-based AI service that reads radiology images and returns findings - A clinical decision support tool that recommends treatment pathways based on patient data - A web app that calculates risk scores for stroke, heart failure, or other conditions If you remove the software, the medical value disappears, even though the phone, laptop, or server still works as a generic device. ## What Is SiMD (Software in a Medical Device)? Software in a Medical Device is software that lives inside or directly controls a physical medical device. The hardware and software together form the regulated medical device. Examples of SiMD include: - Firmware that controls dose and timing in an infusion pump - Control software in a ventilator that manages pressure, volume, and alarms - Embedded code in an external defibrillator or implanted device programmer - Software inside an ultrasound system that drives acquisition and imaging modes If the software fails, the physical device may malfunction or behave in an unsafe manner. On its own, this software is not a device. It is part of the device. ## Why SaMD vs SiMD Classification Matters Getting the SaMD vs SiMD classification right is critical for several reasons. ### Regulatory Strategy and Classification SaMD is often cleared or approved as its own medical device with its own product code and risk classification. SiMD is typically treated as part of the physical device, and its risk and requirements are tied to the overall device classification. ### Standards and Guidance Both SaMD and SiMD are expected to align with key standards like: - IEC 62304 for software life cycle processes - ISO 14971 for risk management - [ISO 13485](/blog/iso-13485-and-its-relation-to-medical-device-cybersecurity) for quality management However, the emphasis differs. SaMD often focuses more on algorithms, data quality, and clinical performance. SiMD places a strong focus on safety interlocks, real-time behavior, and hardware integration. ### Cybersecurity Expectations Cybersecurity requirements now apply across the entire medical device ecosystem. Under current FDA cybersecurity guidance, both SaMD and SiMD that qualify as cyber devices are expected to show: - Secure by design architecture - Integrated cybersecurity risk management - A software bill of materials (SBOM) - Secure update and patching capabilities - Vulnerability monitoring and coordinated disclosure The implementation and documentation of these expectations differ significantly for embedded firmware in a pump versus a cloud-hosted AI system or mobile app. ### Postmarket Management SaMD is often updated frequently, with release cycles that resemble those of traditional software or SaaS. SiMD updates are slower and more controlled, usually requiring field service, planned downtime, and close coordination with hospitals and healthcare facilities. ## Cybersecurity for SiMD: Embedded But Exposed For SiMD, cybersecurity risk is closely tied to the physical device and its connection to the outside world. ### Common Attack Surfaces for SiMD Common attack surfaces for SiMD include: - Network interfaces such as Ethernet, Wi Fi, Bluetooth, or cellular - Local ports like USB, SD card, serial ports, and maintenance interfaces - Service and diagnostic modes - Supply chain components such as firmware, drivers, and libraries ### Modern Expectations for SiMD Cybersecurity Modern expectations for SiMD cybersecurity include: - Security risk management integrated with safety risk management - Threat modeling that links threats to hazards, harms, and controls - Secure by design architecture with defense in depth and least privilege - A complete SBOM for operating systems, real-time operating systems, communication stacks, and libraries - A secure and tested update mechanism for firmware and software - Defined processes for vulnerability intake, assessment, communication, and remediation ### Practical SiMD Cybersecurity Practices Practical SiMD cybersecurity practices often include: - Secure boot and signed firmware so that only trusted images can run - Hardened communication protocols with strong encryption and mutual authentication - Role-based access control for clinicians, administrators, and service technicians - Separation of safety-critical functions from non-critical components, such as the user interface - Fail-safe behavior so that the device moves to a safe state if integrity checks fail or anomalies are detected ## Cybersecurity for SaMD: Cloud, Web, and Mobile as Medical Devices For SaMD, the medical device is the software itself, and the attack surface resembles a modern application stack, with added safety and regulatory expectations. ### Typical Attack Surfaces for SaMD Typical attack surfaces for SaMD include: - Web applications and APIs - Cloud infrastructure and microservices - Mobile apps interacting with back-end services and occasionally with local devices - Integrations with EHRs, imaging systems, and third-party data sources ### Modern Expectations for SaMD Cybersecurity To satisfy regulators and protect patients, SaMD teams typically need to show: - A secure software development life cycle integrated with their quality system - Identity and access management, least privilege, and strong authentication - protection of patient data in transit and at rest - Logging, monitoring, and incident response tuned to clinical use - Dependency management backed by an accurate SBOM and vulnerability monitoring ### Practical SaMD Cybersecurity Practices Practical SaMD cybersecurity practices often include: - Secure coding standards and automated security testing in CI pipelines - Network segmentation and zero-trust principles in cloud architectures - Strong key management and secrets management - Continuous monitoring for anomalies, abuse, and unusual data access patterns - A release process that treats security fixes as first-class work, not as an afterthought ## Many Modern Products Are Both Real-world MedTech products often blend SaMD and SiMD. A typical ecosystem might include: - A wearable sensor with embedded firmware (SiMD) - A mobile app that configures the sensor and displays data (which may or may not be SaMD depending on claims) - A cloud-based AI system that analyzes aggregated data and produces risk scores (often SaMD) - A browser-based clinician dashboard From a regulatory and cybersecurity perspective, you may end up with: - A device submission that covers the hardware and SiMD - One or more SaMD submissions for analytics or decision support modules - Shared cybersecurity artifacts such as threat models, SBOMs, and test evidence are reused across components but tailored to each device’s risk profile Recognizing where SaMD ends, and SiMD begins helps you: - Set a realistic regulatory strategy - Define a clear cybersecurity scope and boundaries - Plan how vulnerabilities, updates, and patches will be managed across the ecosystem ## A Simple Way to Think About SaMD vs SiMD A helpful set of questions to quickly frame SaMD vs SiMD is: 1. **Does the software have a medical intended use,** such as diagnosing, treating, preventing, or informing decisions about a disease or condition? If not, it is unlikely to be a medical device, even if it supports healthcare. 2. **Can the software deliver that medical function without being part of dedicated medical hardware?** If so, it is likely to be SaMD. If not, it is likely SiMD, where the software is integrated into the physical device. 3. **Is the software only used for manufacturing, servicing, or quality management?** If so, it may not be considered a medical device, but you still have quality and cybersecurity responsibilities inside your quality system. This quick lens is not a substitute for formal regulatory analysis, but it helps teams avoid major missteps early in the design and planning process. ## SaMD vs SiMD: Key Differences at a Glance ### SaMD (Software as a Medical Device) - Standalone software that is a medical device - Runs on general-purpose hardware or in the cloud - Cybersecurity focuses on apps, API, data, cloud, and identity - Rapid release cycles and frequent updates ### SiMD (Software in a Medical Device) - Embedded software that is part of the medical device - Tightly integrated with dedicated hardware - Cybersecurity focuses on device hardening, secure boot, physical and network access, and safe failure modes - Conservative release cycles and tightly controlled updates Both must treat cybersecurity as a core element of safety and effectiveness, not as an afterthought. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Cyber Can Help At Blue Goat Cyber, we work with medical device manufacturers across the spectrum, from pure SaMD products to complex systems with multiple SiMD and SaMD components. We help teams: - Clarify whether their software falls under SaMD, SiMD, or both - Map their architecture to current FDA cybersecurity expectations - Build and document secure-by-design controls that regulators can follow - Develop SBOMs and vulnerability management processes that actually work in practice - Conduct penetration testing and security validation that is meaningful for both cloud and embedded environments - Integrate cybersecurity into premarket submissions and postmarket surveillance The bottom line: SaMD vs SiMD is more than a terminology exercise. It shapes how you design, secure, and support your product for years to come. Getting it right early can save you time, reduce regulatory friction, and most importantly, protect patients and providers who rely on your technology. Schedule a [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session "") today. ## FAQ ### What is the primary difference between SaMD and SiMD? SaMD is software that is itself a medical device and runs on general-purpose hardware. SiMD is software that is an integral part of a physical medical device. ### Does the FDA regulate SaMD and SiMD differently? Yes, while both must comply with the FDA's February 3, 2026 premarket cybersecurity guidance and other regulations, the classification influences the regulatory pathway, specific standards, and submission requirements. SaMD is often cleared as its own device, while SiMD is evaluated as part of the physical device. ### How does cybersecurity for SaMD differ from SiMD? SaMD cybersecurity typically focuses on application, API, cloud infrastructure, and data protection. SiMD cybersecurity emphasizes device hardening, secure boot, physical access controls, and safe failure modes within the embedded system. ### Can a medical product contain both SaMD and SiMD? Yes, many modern medical products are complex ecosystems that combine both SaMD and SiMD. For example, a wearable sensor with embedded firmware (SiMD) might connect to a mobile app (potentially SaMD) and a cloud-based AI for analysis (SaMD). ### What FDA cybersecurity guidance applies to SaMD and SiMD? Both SaMD and SiMD that qualify as cyber devices are expected to comply with the principles outlined in the FDA's February 3, 2026 final guidance on premarket cybersecurity. This includes secure by design architecture, cybersecurity risk management, and a Software Bill of Materials (SBOM). ### Why is the SaMD vs SiMD classification important for manufacturers? Accurate classification matters for setting an effective regulatory strategy, defining the scope of cybersecurity efforts, planning for vulnerability management and updates, and Ensure compliance with FDA expectations throughout the total product life cycle. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SBOM Diffing & CVE Correlation Postmarket Source: https://bluegoatcyber.com/blog/sbom-diffing-cve-correlation-postmarket-medical-devices # SBOM Diffing and CVE Correlation: The Postmarket Workflow the FDA Expects > **[DIRECT ANSWER]** SBOM diffing compares successive software bills of materials release over release to flag added, removed, upgraded, or re-pinned components, while CVE correlation checks each component against NVD, CISA's Known Exploited Vulnerabilities catalog, EPSS scores, and vendor advisories. Together they turn a static premarket SBOM into a living postmarket monitoring program. The FDA's February 3, 2026 guidance and Section 524B expect this workflow to run on a defined cadence with documented triage decisions and VEX statements. _Published June 3, 2026_ ## Key Takeaways - An SBOM submitted at clearance is a single frame. Postmarket cybersecurity is the film. Diffing turns the SBOM into a living artifact. - The Feb 3, 2026 premarket guidance and Section 524B require a documented postmarket plan for monitoring, identifying, and addressing cybersecurity vulnerabilities. SBOM diff + CVE correlation is the operational mechanism. - A defensible workflow has six steps: generate, diff, correlate, triage, decide (patch, mitigate, or VEX), and disclose. - Correlation must use multiple sources. NVD alone misses CISA KEV adds, EPSS exploitation likelihood, GHSA ecosystem advisories, and vendor-specific notices that often land first. - The most common failure mode is treating every new CVE as exploitable. The second-most-common is treating every old CVE as not exploitable. Both produce indefensible VEX statements. - Tooling helps, but the FDA expects a documented decision trail with a named owner - not just a dashboard. ## Why SBOM diffing and CVE correlation matters Section 524B(b)(1) of the FD&C Act and the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 both require a postmarket Cybersecurity Management Plan that actually identifies, evaluates, and responds to vulnerabilities as they emerge. SBOM diffing and CVE correlation are how that requirement gets operationalized, without them, the SBOM you filed with your premarket submission becomes a static snapshot of components and CVEs that drifted out of date the moment your next build shipped. The CISA Known Exploited Vulnerabilities catalog added 187 new entries in 2024 (CISA KEV catalog, January 2025), and an unknown but non-trivial fraction of them affect components inside fielded medical devices. The HSCC Joint Cybersecurity Working Group's SBOM guidance and AAMI TIR97:2019 both treat diff + correlate as the minimum viable postmarket loop, and reviewers will ask to see the cadence, the tooling, and the VEX outputs. ## What "SBOM diff" actually means A Software Bill of Materials (CycloneDX or SPDX) lists every component shipped in a medical device build: open-source libraries, third-party SDKs, OS packages, firmware blobs, container layers, and their versions, licenses, suppliers, and (ideally) cryptographic hashes. An **SBOM diff** is the structured comparison of two SBOMs - typically `release N` vs `release N+1`, or `today's production firmware` vs `last quarter's baseline`. A useful diff distinguishes: - **Added** components (new dependency, new transitive dependency, new container layer) - **Removed** components (deprecated module, library swap, refactor) - **Upgraded** components (semver bump, security patch, major version) - **Downgraded** components (rare, almost always a regression signal worth flagging) - **Re-pinned** components (same version string, different hash - supply chain alarm) - **Metadata-only changes** (license change, supplier change, PURL correction) What the diff is *not*: a list of vulnerabilities. The vulnerability picture only appears once you correlate the diff against CVE feeds. A diff with zero added components can still produce new CVEs - because the world publishes new CVEs against the components you already shipped, every day. ## What "CVE correlation" actually means CVE correlation is the process of taking each component-version pair in your SBOM (or in the SBOM diff) and asking, across multiple authoritative sources: - Is there a known CVE against this exact version, or against a version range that includes it? - Is it in CISA's Known Exploited Vulnerabilities (KEV) catalog? - What is the EPSS score (likelihood of exploitation in the wild within 30 days)? - Has the upstream vendor issued an advisory, security note, or fix? - Is the affected function or code path actually reachable from your device's attack surface? The output is not "list of CVEs." It is a **triaged, prioritized, decision-ready** view: which vulnerabilities require a VEX statement justifying non-exploitability, which require a coordinated disclosure, which require a patch, and which can be deferred with documented rationale. This is the moment most postmarket programs break. Either the team drowns in raw NVD output, or they suppress everything by hand without a defensible trail. Both fail FDA scrutiny. ## Why the FDA cares The Feb 3, 2026 premarket cybersecurity guidance is explicit that the cybersecurity story does not end at clearance. Submissions are expected to include: - A **plan to monitor, identify, and address postmarket cybersecurity vulnerabilities and exploits** - A **process for the timely identification and remediation** of new vulnerabilities affecting the device - **SBOM maintenance** with mechanisms to update it as the device evolves - **Coordinated vulnerability disclosure (CVD)** processes consistent with ISO/IEC 30111 and ISO/IEC 29147 Section 524B of the FD&C Act makes this binding for cyber devices. The guidance ties postmarket obligations back to the SBOM as the connective tissue. If your SBOM is not diffed and correlated on a defined cadence, you do not have a postmarket monitoring program; you have an artifact in a folder. For the broader postmarket context, see our companion piece on the [postmarket cybersecurity roadmap](/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap), and how EOL/EOS components specifically interact with Section 524B in [SBOM, End-of-Support, and Section 524B](/blog/sbom-end-of-support-eol-los-fda-section-524b). ## The six-step workflow A defensible postmarket SBOM monitoring program collapses to six repeatable steps. Each step has a deliverable, a named owner, and a documented decision trail.
Process flow

SBOM diff → CVE correlation → decision

  1. STEP 01 Automated
    Generate SBOM

    CycloneDX or SPDX from build pipeline. Same generator, every release. Hash-pinned components.

  2. STEP 02 Automated
    Diff against baseline

    Added, removed, upgraded, downgraded, re-pinned. Flag hash changes on same version.

  3. STEP 03 Automated
    Correlate against feeds

    NVD, CISA KEV, EPSS, GHSA, vendor advisories. Both the delta and the steady-state SBOM.

  4. STEP 04 Human
    Triage & reachability

    Is the vulnerable function reachable? Is the attack surface exposed? Patient-safety impact?

  5. STEP 05 Human
    Decide: patch, mitigate, VEX

    Issue VEX statement, schedule a patch, apply compensating control, or document deferral.

  6. STEP 06 Human
    Disclose & update SBOM

    CVD per ISO 30111/29147. Publish updated SBOM and VEX. Update postmarket record.

Automated · Human-owned
## Where teams go wrong: three failure patterns ### 1. Diffing without re-correlating the steady state Most pipelines correlate only the *added* components in a diff. That misses the most important class of postmarket vulnerability: a CVE published this week against a component you shipped last year. The components in your SBOM did not change; the threat landscape did. Correlation must run on the **full SBOM** on a fixed cadence (weekly is a defensible minimum), not just on the delta. ### 2. Treating NVD as the source of truth NVD is necessary and insufficient. CISA's KEV catalog is the FDA's clearest signal on exploitation; if a CVE in your SBOM lands on KEV, it is no longer a paper risk. EPSS gives a probability-weighted view that makes triage tractable when NVD throws hundreds of CVSS 7+ items at you in a release. GHSA catches ecosystem-specific issues (npm, PyPI, Maven, Go) that often appear before NVD. Vendor advisories - Microsoft, Red Hat, Wind River, NXP, ST, Nordic, Qualcomm - frequently land first and contain the exploit-context detail you need. A correlation pipeline that only hits NVD will miss and over-call simultaneously. ### 3. VEX statements without reachability evidence A VEX statement marking a CVE as `not_affected` with justification `vulnerable_code_not_in_execute_path` is a defensible answer - if you can show how you determined it. A pile of `not_affected` VEX entries with one-line justifications and no underlying call-graph, configuration, or threat-model reference is the exact pattern that triggers the FDA's most common SBOM deficiency: "Sponsor's VEX assertions are not substantiated." We've covered the specific patterns to avoid in [VEX Mistakes That Trigger FDA Deficiencies](/blog/vex-mistakes-fda-deficiencies). ## Diff-and-correlate cadences that hold up There is no single "right" cadence, but reviewers expect to see a defined one tied to risk class. A workable baseline:
Trigger SBOM diff? CVE re-correlation? Output
Every build Yes On delta Build-gate report; block if KEV hit
Every release Yes Full SBOM Release notes, updated SBOM + VEX
Weekly (steady state) Not applicable Full SBOM Monitoring digest; triage queue
CISA KEV add Not applicable Immediate, full SBOM Incident triage, CVD if applicable
Vendor advisory (high-impact) Not applicable Targeted re-correlation Patch decision, customer comms
Annual postmarket review Yes, year-over-year Full SBOM + EOL audit 524B postmarket evidence package
Pattern: diffs gate releases; correlation never stops. The FDA expects both, with a paper trail.
## What a defensible VEX decision looks like For each correlated CVE that lands in triage, a defensible decision record contains: - **Component and version** (with PURL or CPE) - **CVE ID and source** (NVD, KEV, EPSS score, vendor advisory) - **Reachability assessment**: is the vulnerable function called from the device's actual code paths and configurations? - **Attack-surface exposure**: is the affected interface exposed (network-reachable, user-facing, peripheral)? - **Patient-safety impact** referenced back to the device risk file - **Decision**: `affected`, `not_affected`, `fixed`, `under_investigation` - **Justification** using the standard VEX vocabulary (`component_not_present`, `vulnerable_code_not_in_execute_path`, `vulnerable_code_not_present`, `vulnerable_code_cannot_be_controlled_by_adversary`, `inline_mitigations_already_exist`) - **Named owner** and date - **Evidence link** - call-graph, threat-model artifact, test result, or compensating control reference When you can produce this record per CVE in your SBOM on demand, you have a postmarket monitoring program. When you can't, you have a list. For the deeper distinction between the SBOM artifact and the VEX layer, see [SBOM vs VEX: What's the Difference?](/blog/sbom-vs-vex-difference). ## Tooling: what to look for The market has converged on a few categories. None of them, by themselves, deliver a 524B-defensible workflow - but the right combination does. - **SBOM generators** built into the build pipeline (Syft, CycloneDX-CLI, language-native tools, container scanners). Same tool every time, hash-pinned outputs. - **SBOM diff tools** that understand semver, transitive vs direct dependencies, and PURL equivalence (CycloneDX `cyclonedx diff`, Anchore Grype/Syft, Snyk SBOM compare, in-house scripts on top of `spdx-tools`). - **Vulnerability correlation engines** that pull NVD, KEV, EPSS, GHSA, and vendor advisories (Grype, Trivy, OSV-Scanner, Dependency-Track, commercial platforms). Multi-source is non-negotiable. - **VEX authoring and publishing** (CycloneDX VEX, OpenVEX, CSAF). Whatever format you choose, publish it on a stable URL and version it. - **Workflow / decision tracking** - a ticket queue, a vulnerability management platform, or a structured spreadsheet with revision history. The reviewer cares about the trail, not the tool. Two practical notes. First, the FDA does not require any specific vendor. Second, "we use \[platform X\]" is not a postmarket program - the program is the documented cadence, the named owners, the decision records, and the disclosure path. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## Diffing vs correlation: two jobs, two outputs Teams collapse these into one task and then cannot explain their own evidence. They are separate, and they produce separate records. | | SBOM diffing | CVE correlation | | --- | --- | --- | | Question it answers | What changed between these two builds? | Which known flaws affect what we shipped? | | Input | Two SBOMs from two releases | One SBOM plus a vulnerability feed | | Output | Added, removed, and version-changed components | A ranked list of candidate vulnerabilities | | How often it runs | Every build | Continuously, because feeds change daily | | Main failure mode | Comparing different formats and calling it a diff | Matching on package name alone and drowning in false hits | | Record a reviewer wants | Change log tied to the release | Triage decision, with a VEX statement for anything not exploitable | ## How Blue Goat Cyber runs this Postmarket SBOM monitoring is one of the workstreams in our [postmarket retainer model](/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap). We run SBOM generation and diffing on the manufacturer's build pipeline (or instrument it if it isn't there), correlate weekly against NVD, CISA KEV, EPSS, GHSA, and the upstream advisories that matter for your stack, and produce a triaged decision queue with named owners and evidence links. VEX statements are authored against the device's actual reachability and threat model, not generic library metadata. The deliverable each quarter is an FDA-defensible postmarket cybersecurity record: SBOM, VEX, decision log, CVD activity, and an audit-ready trail back to Section 524B and the Feb 2026 guidance. If your SBOM stops at clearance and your postmarket program is "we'll respond if someone reports something," that's the gap to close before the next inspection or AI/NN letter. ## FAQ ### What is SBOM diffing? SBOM diffing is the structured comparison of two Software Bills of Materials for the same medical device - typically between releases, builds, or fixed time points - to identify which components have been added, removed, upgraded, downgraded, or re-pinned (same version, different hash). The diff is the foundation for postmarket vulnerability monitoring: it tells you what changed in your supply chain so you can ask what new exposures changed with it. ### What is CVE correlation? CVE correlation is the process of matching each component-version pair in your SBOM against vulnerability data sources - NVD, CISA KEV, EPSS, GHSA, and vendor advisories - to determine which Common Vulnerabilities and Exposures apply, how exploitable they are, and which require a VEX statement, patch, mitigation, or coordinated disclosure. Correlation must run on the full SBOM on a cadence, not just on what changed in the latest diff. ### How often should a medical device manufacturer diff its SBOM and correlate CVEs? A defensible cadence has multiple triggers. Diff on every build (gate releases on CISA KEV hits). Re-correlate the full SBOM on every release and weekly in steady state. Re-correlate immediately when a KEV entry or material vendor advisory lands. Run a full year-over-year diff and correlation as part of the annual postmarket cybersecurity review for the Section 524B evidence package. ### Why isn't NVD enough for CVE correlation? NVD is the canonical CVE catalog, but it lags upstream advisories, lacks exploitation context, and is missing many ecosystem-specific issues that GHSA captures. CISA KEV tells you what's actually being exploited. EPSS gives you a probability of near-term exploitation that makes large CVSS lists tractable. Vendor advisories from Microsoft, Red Hat, Wind River, Nordic, ST, NXP, Qualcomm, and others often land before NVD and contain the call-path detail you need. A pipeline that only consults NVD will both miss real risk and over-flag low-priority noise. ### Does the FDA require SBOM diffing specifically? The Feb 3, 2026 premarket cybersecurity guidance and Section 524B require a documented postmarket plan to monitor, identify, and address cybersecurity vulnerabilities over the supported life of the device, and they require the SBOM to be maintained. The guidance does not prescribe a particular tool or use the phrase "SBOM diffing." It does, in practice, require what SBOM diffing plus CVE correlation produces: a continuous, evidence-backed process that identifies new vulnerabilities and drives patch, mitigation, VEX, or disclosure decisions. A submission that says "we maintain the SBOM" without a documented diff-and-correlate cadence is the pattern that draws reviewer questions. ### What's the most common SBOM monitoring deficiency the FDA cites? Three patterns recur. First, VEX statements marked `not_affected` without underlying reachability evidence. Second, postmarket "plans" that describe the SBOM artifact but not the cadence, owners, or decision trail. Third, EOL or EOS components that were defensible at clearance but became indefensible when their support window closed, with no diff-driven review catching it. We've covered the EOL pattern in detail in [SBOM, End-of-Support, and Section 524B](/blog/sbom-end-of-support-eol-los-fda-section-524b). ## Related reading - [SBOM vs VEX: What's the Difference?](/blog/sbom-vs-vex-difference) - [SBOM, End-of-Support, and Section 524B](/blog/sbom-end-of-support-eol-los-fda-section-524b) - [VEX Mistakes That Trigger FDA Deficiencies](/blog/vex-mistakes-fda-deficiencies) - [Postmarket Cybersecurity for Medical Devices: The FDA Roadmap](/blog/postmarket-cybersecurity-for-medical-devices-the-fda-roadmap) - [Medical Device SBOM: FDA Requirements and Submission Guide](/blog/medical-device-sbom-fda-requirements-and-submission-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SBOM EOS, EOL & LoS for FDA 524B Source: https://bluegoatcyber.com/blog/sbom-end-of-support-eol-los-fda-section-524b # SBOM End-of-Support, EOL, and Level of Support: What the FDA Expects > **[DIRECT ANSWER]** End of Life marks when a vendor announces a product is being phased out, End of Support is when the vendor stops issuing security patches, and Level of Support describes the service tier (mainstream, extended, community) while a component remains supported. Section 524B(b)(3) requires manufacturers to track and disclose support status and end-of-support dates for each SBOM component, since EOS is the state that actually determines patchability. _Last updated: June 2026_ ## Key Takeaways - EOS (End of Support) is the regulatory anchor - no upstream patches, no clean remediation path. - LoS describes the tier of service (mainstream, extended, community) while a component is still supported. - Section 524B(b)(3) requires support status and end-of-support date in the SBOM, per component. - The Feb 2026 FDA guidance expects a Total Product Lifecycle plan covering components that will cross EOS during market life. - CycloneDX 1.5+ expresses this natively via `lifecycles` and `pedigree`; SPDX 2.3 requires custom annotations. - The defensible VEX status for an EOS component with no patch is typically `affected` + `will_not_fix` with a documented compensating control. ## Why this matters The distinction between End of Support (EOS), End of Life (EOL), and Level of Support (LoS) is critical for medical device manufacturers. Failure to track and proactively manage the EOS dates of SBOM components can lead to unpatchable vulnerabilities, rendering devices insecure and non-compliant with regulatory expectations. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly requires manufacturers to declare a support status and, where known, an end-of-support date for every SBOM component. Furthermore, this guidance mandates a Total Product Lifecycle plan outlining actions when components near or reach EOS during a device's market lifespan. Ignoring these distinctions undermines a manufacturer's ability to demonstrate a controlled and secure supply chain, potentially leading to significant delays in market authorization or adverse postmarket actions. Adherence to standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 also necessitates a clear understanding of component lifecycles to effectively manage cybersecurity risks throughout the product lifecycle. ## EOS vs EOL vs LoS ### End of Life (EOL) EOL is the **umbrella roadmap milestone**. The vendor has announced that the product is being wound down. EOL alone tells you nothing about whether the component is still patched, still sold, or still safe to ship. Microsoft, Cisco, and Red Hat all use EOL as a calendar event, not a technical state. Treat EOL as "we have been put on notice." ### End of Support / End of Sales (EOS) EOS is the term that matters for FDA submissions. Two flavors: - **End of Sales** - the component can no longer be licensed or purchased new. Existing deployments may still be supported. - **End of Support** - the vendor stops issuing security patches, bug fixes, and technical assistance. **End of Support is the cybersecurity-relevant one.** It is the date the patch pipeline closes. Once it passes, every new CVE against that component lands in your risk file with no upstream remediation path. Section 524B(b)(3) explicitly calls out *end-of-support date* as an SBOM field. If the column is blank, expect a question. ### Level of Support (LoS) LoS is the **tier of service** you are entitled to while a component is still supported. Common tiers: - **Mainstream / Full** - security patches, bug fixes, new features. - **Extended / Sustaining** - security patches only, often paid (Microsoft ESU, Red Hat ELS, Ubuntu Pro). - **Self-support / Community** - documentation only, no SLA, no committed patches. - **Custom paid extension** - negotiated past the public EOS date. LoS matters because two devices using the "same" component can have very different risk postures. A component on paid extended support is materially different from one on community best-effort, and the FDA expects the SBOM to reflect that. ### How vendors actually stage these A typical Microsoft, Cisco, or Red Hat lifecycle: ```text GA -> End of Sales -> End of Mainstream Support -> End of Extended Support -> EOL ``` Each transition changes the LoS tier. Your SBOM has to track which stage each component is in *today*, not when the device was cleared. ## What the Feb 3, 2026 FDA guidance requires The current premarket guidance is "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," issued February 3, 2026. It supersedes the June 27, 2025 and September 27, 2023 versions. Do not cite the older documents in new submissions. Four expectations are directly relevant to component lifecycle: **1. SBOM with support status and end-of-support date (statutory)** Section 524B(b)(3) requires the SBOM to capture, for each component, the support status from the developer or maintainer and the end-of-support date where known. Missing or "unknown" entries without justification are a documented deficiency-letter trigger. Our [Medical Device SBOM: FDA requirements and submission guide](/blog/medical-device-sbom-fda-requirements-and-submission-guide) walks through the exact fields FDA reviewers screen for at RTA. **2. Total Product Lifecycle (TPLC) plan** The 2026 guidance reinforces a QMS-integrated TPLC view. Components projected to cross EOS during the device's market life need a plan *before* submission: replace, upgrade, isolate, or document a risk-accept with compensating controls. "We will deal with it later" is not a TPLC plan. **3. The four required architecture views** EOS components show up explicitly in two of the four required views: - **Updateability and Patchability View** - if the upstream is EOS, the patch path is broken. Show the broken path and how the architecture compensates. - **Security Use Case View** - the compensating controls (network isolation, allowlisting, monitoring) for unpatchable components live here. The other two views (Global System, Multi-Patient Harm) inherit consequences from EOS components but are not the primary place to document them. **4. Risk management tie-in with AAMI TIR57 and ANSI/AAMI SW96** Every EOS component must be evaluated for patient-harm impact through your ISO 14971 risk file, using TIR57 principles premarket and SW96 across the lifecycle. "We cannot patch it" is not a risk treatment. The defensible position is *compensating controls plus a documented residual risk acceptance*, signed by the same risk authority that signs the rest of the file. ## How to express lifecycle data in the SBOM ### CycloneDX 1.5+ CycloneDX has native lifecycle support. The two relevant blocks: ```json { "component": { "name": "openssl", "version": "1.1.1w", "supplier": { "name": "OpenSSL Project" }, "pedigree": { "notes": "EOS 2023-09-11; no upstream patches. Compensating controls in Security Use Case View v3." }, "properties": [ { "name": "lifecycle:status", "value": "end-of-support" }, { "name": "lifecycle:eos-date", "value": "2023-09-11" }, { "name": "support:level", "value": "community-only" } ] } } ``` The `lifecycles` element at the BOM root captures the overall lifecycle phase; per-component status is best expressed via properties plus `pedigree` notes until tooling standardizes. ### SPDX 2.3 SPDX is weaker here. Use `annotations` with a structured comment convention so downstream consumers can parse: ```text Annotator: Tool: bgc-sbom-lifecycle AnnotationDate: 2026-06-01T00:00:00Z AnnotationType: OTHER AnnotationComment: lifecycle.status=end-of-support; eos.date=2023-09-11; support.level=community-only ``` If you have a choice, ship CycloneDX 1.5+ as the primary format for the FDA submission and SPDX as a secondary export. ## The EOS decision tree When a component is EOS (or will be during market life), there are four defensible branches. Pick one per component and document the choice in both the architecture views and the risk file. ```text Component going EOS | +-- Replace -> swap to a supported alternative, re-verify, file as material change if required | +-- Fork / fund -> in-house fork or paid extended-support contract (LoS = extended) | +-- Isolate -> compensating controls in the Security Use Case View; residual risk accepted under ISO 14971 | +-- Accept -> risk-accept with executive sign-off; allowed only when patient-harm impact is demonstrably low ``` Reviewers reject submissions where the branch is implicit. Make it explicit, per component, with traceability into the risk file. ## The canonical VEX statement for an EOS component When a new CVE lands against an EOS component you have chosen to isolate, the defensible VEX shape is: ```json { "vulnerability": { "id": "CVE-2026-XXXXX" }, "products": [{ "id": "device-model-x", "version": "3.2" }], "status": "affected", "justification": "vulnerable_code_not_in_execute_path", "response": ["will_not_fix"], "detail": "Component openssl 1.1.1w is end-of-support (2023-09-11). Compensating controls: network segmentation per Security Use Case View v3, allowlisted egress, signed firmware. Residual risk accepted in RMF-2026-014." } ``` Three things make this defensible: an explicit `will_not_fix` (not silence), a justification grounded in the architecture, and a pointer to the risk-management file entry that owns the residual risk. ## Reviewer red flags The Feb 2026 guidance has not changed *what* reviewers check on lifecycle - it has changed *how strict* they are about it. Common deficiency-letter triggers: - SBOM entries with no `support_status` field, or "unknown" without justification. - Known-EOS components (OpenSSL 1.1.1, CentOS 7, Python 2.7, older Linux kernels) shipped with no Updateability View commentary. - Patchability View that shows a patch channel for a component whose upstream is dead. - Risk file that scores an EOS component identically to a supported one with no compensating-control analysis. - VEX statements that mark EOS components as "under investigation" indefinitely. - TPLC plan that ends at clearance with no maintenance horizon. ## How this connects to the rest of the program EOS is a cross-cutting concern. It touches: - The **SBOM** (Section 524B(b)(3) fields) - The **threat model** (assets behind unpatchable components) - The **architecture views** (Updateability, Security Use Case) - The **risk file** (ISO 14971 + SW96 residual risk) - The **postmarket plan** (VEX, monitoring, CAPA triggers) - The **labeling** (customer security documentation for unsupported components) Treat it as a single thread that runs through every cybersecurity artifact in the submission, not as an SBOM-only field. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat approaches this Blue Goat Cyber's approach to SBOM End-of-Support management focuses on proactive risk mitigation and regulatory compliance. Our experts assist manufacturers in accurately delineating EOS, EOL, and LoS for all medical device software components, aligning with the FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026. We help integrate lifecycle data into SBOMs using formats like CycloneDX 1.5+ and develop thorough Total Product Lifecycle plans for managing components approaching EOS. Our team, comprised of CISSP and OSCP certified professionals, including ex-military red team personnel, specializes in identifying potential vulnerabilities arising from unsupported software and formulating defensible VEX statements for non-remediable issues. We ensure your premarket submissions meet FDA expectations, and if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized FDA premarket support at: [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services) --- ## FAQ ### Is End of Life the same as End of Support? No. End of Life is an umbrella roadmap announcement that a product is being wound down. End of Support is the specific date the vendor stops issuing security patches. EOL is calendar; EOS is technical. The FDA cares about EOS because that is when the patch path closes under Section 524B. ### Does the FDA require an EOS date in the SBOM? Yes, where known. Section 524B(b)(3) requires the SBOM to include the support status and end-of-support date for each component. Blank or "unknown" entries without justification are a documented deficiency trigger under the February 2026 premarket guidance. ### Can we ship a device with EOS components? Yes, but only with a defensible plan. The acceptable patterns are replace, fork or fund extended support, isolate with compensating controls, or risk-accept with executive sign-off and demonstrably low patient-harm impact. The choice must be reflected in the architecture views and the ISO 14971 risk file. ### How do we express EOS in CycloneDX vs SPDX? CycloneDX 1.5+ supports lifecycle natively via the `lifecycles` element, plus per-component `pedigree` notes and properties for status, EOS date, and support level. SPDX 2.3 requires structured `annotations` since the schema does not have first-class lifecycle fields. Prefer CycloneDX 1.5+ as the primary submission format. ### What is the right VEX status for an EOS component with no patch? Typically `affected` with `will_not_fix` and a justification tied to the architecture (e.g. `vulnerable_code_not_in_execute_path` or a documented compensating control). Avoid leaving EOS components in `under_investigation` long-term - reviewers read that as an unmanaged risk. ### Which FDA guidance should we cite? Cite **"Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," issued February 3, 2026**. It supersedes the June 2025 and September 2023 versions. Do not cite the older documents in new submissions. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). ## More on this topic - [Docker Containers in Medical Devices: FDA](/blog/docker-containers-medical-devices-fda-testing) - [Secure Update Infrastructure for Medical](/blog/secure-update-infrastructure-medical-devices) - [Medical Device Incident Response Plan](/blog/medical-device-incident-response-plan-fda) --- ## SBOM for Third-Party Chip Firmware Source: https://bluegoatcyber.com/blog/sbom-third-party-chip-firmware-medical-devices # SBOM for Third-Party Chip Firmware in Medical Devices > **[DIRECT ANSWER]** A chip vendor's SBOM is sufficient only while you ship their firmware unmodified and can document its provenance and support status. The moment you patch, configure, or rebuild modem, radio, or SoC firmware, you own that component in your SBOM and must provide your own vulnerability monitoring and update path for it. _Published June 11, 2026_ ## Key Takeaways - Most silicon-vendor "SBOMs" are release notes, not conformant SBOMs. Few meet the SBOM minimum elements, now set by CISA's 2026 list, out of the box. - Section 524B(b)(3) holds the **device manufacturer** accountable for the SBOM, supplier silence is not a defense. - A vendor SBOM only applies to the unmodified reference firmware. Any reflash, feature toggle, patch, or wrapper transfers SBOM authorship to the MedTech team. - Binary composition analysis (BCA) is the FDA-accepted fallback when source-derived SBOMs are unavailable for third-party firmware blobs. - VEX is the noise filter for chip firmware, most CVEs in a modem stack apply only to unused radio bands or disabled features. ## Why this matters The FDA's February 3, 2026 final premarket cybersecurity guidance restates the Section 524B(b)(3) requirement plainly: the SBOM submitted with a cyber device must include **commercial, open-source, and off-the-shelf software components**, including software embedded in third-party silicon. The agency does not distinguish between code your team wrote and firmware burned into a Quectel, u-blox, Nordic, Telit, or Qualcomm part. If it ships in the device, it belongs in the SBOM. Reviewers have started writing deficiencies that name this gap directly: *"The submitted SBOM does not appear to include the firmware of the cellular communications module. Provide the firmware SBOM and the associated vulnerability assessment."* That deficiency is increasingly common on connected Class II devices using off-the-shelf 4G/5G or BLE modules, and it adds an Additional Information cycle to the review timeline. ## When the chip vendor's SBOM is enough A vendor-supplied SBOM is acceptable as a drop-in component of your device SBOM when **all** of the following hold: - The file is **machine-readable** in CycloneDX 1.5+ JSON or SPDX 2.3+, not a PDF release note or vendor portal table. - It carries the **SBOM minimum elements** set by CISA's 2026 list (first published by NTIA in 2021): supplier, component name, version, unique identifier, dependency relationship, author, timestamp. - Components have **PURL and/or CPE** identifiers so they can be matched against NVD, GHSA, and OSV. - The SBOM version matches the **exact firmware binary** you flash and ship, same hash, same build ID. - You receive **updated SBOMs** within your patch SLA whenever the vendor releases new firmware. When all five conditions are met, you merge the vendor SBOM into your device SBOM, preserve the dependency relationship up to the chip module, and run the same vulnerability-management loop described in our [SBOM Vulnerability Management guide](/guides/sbom-vulnerability-management-medical-devices). ## When the vendor SBOM is not enough In practice, most chip vendors fail at least two of those five conditions. The recurring gaps: - **No machine-readable file.** A release note PDF listing "open-source components used" is not an SBOM. Reviewers reject it as such. - **Top-layer only.** The vendor lists their RTOS and TCP/IP stack but not the TLS library, the PPP stack, the audio codec, or the proprietary blobs from the underlying silicon supplier (Qualcomm, MediaTek, etc.). - **Stale.** The SBOM corresponds to a firmware release from 14 months ago; your latest flash is on a newer build. - **No identifiers.** Components are named but carry no PURL, CPE, or hash, so CVE matching is manual and unreliable. - **Reference-image-only.** The SBOM describes the vendor's reference firmware. The image you actually flash differs because of regional band configuration, feature toggles, or a vendor hotfix. When any of these apply, the vendor SBOM is an **input** to your SBOM, not a substitute. You either get a conformant SBOM from the vendor (the right ask) or generate one yourself via binary composition analysis. ## What changes when you modify a cellular modem or radio chip This is where the responsibility line moves. The FDA's definition of "manufacturer" for SBOM purposes follows the build artifact. If your team performs any of the following, you become the SBOM author for that firmware: - **Reflashing** a modem with custom AT-command firmware or a different vendor SKU image. - **Enabling, disabling, or reconfiguring** features, turning off unused radio bands, swapping the TCP/IP stack, changing TLS suites, disabling the audio path. - **Applying vendor hotfixes** that have not been published as a new official firmware release. - **Layering custom code** on programmable modems, Telit AppZone, Sequans Monarch GO, Nordic nRF SDK with custom application binaries, ESP32 with custom firmware. - **Statically linking** vendor SDKs into your own firmware image with selective inclusion. A practical example: a MedTech innovator using a Quectel BG95 module to provide 4G connectivity for a remote patient-monitoring device. Out of the box, the Quectel firmware ships with GSM, WCDMA, GNSS, and LTE-M support. The team disables GSM and WCDMA to reduce attack surface and applies a Quectel-supplied hotfix for a TLS issue. The shipping firmware is now neither the published Quectel reference nor an unmodified hotfix release. The Quectel SBOM (if one exists) describes neither of those configurations. The MedTech team is now the author of that derived firmware image for Section 524B purposes, and they owe the FDA an SBOM that reflects what actually ships. > **[KEY REQUIREMENT]** When the device manufacturer modifies third-party firmware in any way that changes the binary, the manufacturer owns the SBOM for the modified image. The vendor SBOM becomes an input artifact, not the deliverable. ## Binary composition analysis as the fallback When source-based SBOM generation is impossible, because the firmware is a vendor binary blob you do not have source for, the FDA-accepted fallback is **binary composition analysis (BCA)**. BCA tools unpack the firmware image, identify embedded components by signature, version, and dependency, and emit a CycloneDX or SPDX SBOM. The tooling landscape for medical device firmware: | Tool | Type | Strongest for | | --- | --- | --- | | `binwalk` + `cve-bin-tool` | Open source | Initial decomposition + CVE matching of common OSS libs | | Syft on extracted root filesystems | Open source | Embedded Linux modems (Yocto, Buildroot-based) | | Finite State, NetRise, CyberSwarm | Commercial | Full firmware BCA, VEX automation, MedTech-tuned matchers | | ONEKEY, JFrog Xray firmware mode | Commercial | Compliance reporting, supply-chain attestation | A BCA-generated SBOM is not as authoritative as a build-time SBOM, and the FDA knows that. Document the methodology, the tool and version used, the unidentified-byte percentage, and any components flagged with low confidence. Reviewers accept BCA output when the methodology is transparent. ## What the FDA evidence package looks like For each third-party chip whose firmware ships in the device, the submission should include: - **The chip module identified** in the device SBOM as a top-level component with supplier, model, and firmware version. - **A nested SBOM** for the chip firmware, either vendor-supplied (when conformant) or BCA-generated. - **The methodology note** for how that nested SBOM was obtained, including tool, version, and date. - **The vulnerability assessment** for the chip firmware components against NVD, KEV, GHSA, and OSV at submission date. - **VEX statements** for CVEs that do not apply because of disabled features or unreachable code paths (e.g. GSM-only CVEs on a modem with GSM disabled). - **The patch path** for the chip firmware, vendor cadence, your update mechanism, the SLA tying them together, traceable to your [Patch and Update Mechanism evidence](/blog/patch-update-mechanism-fda-section-524b-testing). This evidence sits in eSTAR v7.0 Slot 5 (SBOM) with cross-references to Slot 6 (Controls) and Slot 1 (Cybersecurity Management Plan). See our [eSTAR mapping guide](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) for placement detail. ## How Blue Goat Cyber handles third-party chip firmware We treat every third-party chip as a separate SBOM workstream. We start by asking the vendor for a conformant CycloneDX or SPDX file, and if one is not available, we run binary composition analysis on the exact firmware image flashing to the device, validate the result against the vendor's published component list, and generate VEX statements for the unused features so reviewers are not buried in irrelevant CVEs. For modified firmware (band reconfiguration, feature toggles, custom AppZone code), we rebuild the SBOM from the modified binary, not the reference image. The deliverable plugs into the Slot 5 attachment with the traceability matrix the FDA expects. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** See our [FDA-compliant SBOM services](/services/fda-compliant-sbom-services-for-medtech) and the [SBOM pillar guide](/guides/sbom-for-medical-devices). ## FAQ ### Does the FDA accept the chip vendor's PDF release note as an SBOM? No. Section 524B(b)(3) and the February 2026 guidance require the SBOM to be machine-readable in a widely-supported format. CycloneDX 1.5+ JSON and SPDX 2.3+ are the accepted formats. A PDF or HTML release note may be useful as an input but is not an SBOM and will be cited as a deficiency if submitted as one. ### What if the chip vendor refuses to provide an SBOM? That does not relieve the device manufacturer of the obligation. The fallback is binary composition analysis on the firmware image, documented with the tool, version, and methodology. Document the supplier ask and refusal in the supply-chain risk file, repeated refusal is itself a supplier-risk signal. ### Do I need an SBOM for a Bluetooth radio that has no internet path? If the device meets the Section 524B definition of "cyber device", software validated by the sponsor and able to connect to the internet through any path, even indirect, then every software component including the BLE radio firmware belongs in the SBOM. The BLE stack is a frequent CVE surface (e.g. BleedingTooth, SweynTooth, BrakTooth) and reviewers ask for it explicitly. ### How is this different from the main device SBOM? It is part of the main device SBOM, not a separate document. Best practice is a single top-level CycloneDX or SPDX file with nested dependency relationships that name the chip module as a component and link to or embed its firmware SBOM. One file, multiple layers, not two parallel SBOMs. ### What about programmable modems like Telit AppZone or Nordic nRF Connect SDK? These are the clearest cases of SBOM authorship transfer. The manufacturer is building and signing the firmware image; the chip vendor merely supplied the SDK. Generate the SBOM from your build pipeline using `cyclonedx-cli`, `syft`, or language-native generators, and merge any vendor-supplied component SBOMs underneath. ### Where do VEX statements fit for chip firmware? VEX is essential here. A 4G modem firmware will surface dozens of CVEs that do not apply because the device disables GSM, never enables voice, or runs in a constrained data-only mode. Publishing VEX statements for those CVEs is what keeps the postmarket vulnerability bulletin readable for hospital biomed teams. See our [VEX document guide](/guides/vex-document-medical-device-fda). ## Ready to close the chip-firmware SBOM gap? If your submission relies on a third-party cellular, Wi-Fi, BLE, or SoC module and you do not yet have a machine-readable SBOM for the firmware image that actually ships, we will run the BCA, validate vendor inputs, and deliver the Slot 5 evidence package before your next submission window closes. [Request a scoping call](/contact). --- _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, ex-military red team. Has built SBOMs for more than 275 FDA-submitted devices, including connected diagnostics with off-the-shelf 4G modems, programmable BLE implants, and Wi-Fi infusion pumps. [More on the author](/team/christian-espinosa)._ ## Related reading - [SBOM for Medical Devices: 2026 FDA Pillar Guide](/guides/sbom-for-medical-devices) - [SBOM Vulnerability Management for Medical Devices](/guides/sbom-vulnerability-management-medical-devices) - [CycloneDX vs SPDX for Medical Devices](/guides/cyclonedx-vs-spdx-medical-devices) - [VEX Documents for Medical Device FDA Submissions](/guides/vex-document-medical-device-fda) - [Medical Device SBOM: FDA Requirements & Submission Guide (2026)](/blog/medical-device-sbom-fda-requirements-and-submission-guide) - [Patch and Update Mechanism Testing for Section 524B(b)(1)](/blog/patch-update-mechanism-fda-section-524b-testing) - [eSTAR v7.0 Cybersecurity Attachments mapping](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) --- ## More on this topic - [Docker Containers in Medical Devices: FDA](/blog/docker-containers-medical-devices-fda-testing) - [Secure Update Infrastructure for Medical](/blog/secure-update-infrastructure-medical-devices) - [VxWorks Vulnerabilities in Medical Devices](/blog/identifying-vulnerabilities-with-vxworks) --- ## SBOM vs VEX: What's the Difference? Source: https://bluegoatcyber.com/blog/sbom-vs-vex-difference # SBOM vs VEX: What's the Difference? > **[DIRECT ANSWER]** An SBOM lists every software component in a medical device, while a VEX document assesses which known vulnerabilities against those components are actually exploitable, not affected, already fixed, or under investigation. The FDA expects both for a modern submission: the SBOM satisfies Section 524B's inventory requirement, and the VEX gives reviewers and hospitals the reasoning needed to act on that inventory without treating every listed CVE as an unresolved threat. **An SBOM lists what's in your software. A VEX explains which of those things actually matter from a security standpoint. Both are required for a modern FDA submission - but they answer different questions, and confusing them is the fastest way to a cybersecurity deficiency.** If you've spent any time reading the FDA's February 2026 premarket cybersecurity guidance, you've seen "SBOM" and "VEX" used together so often that they blur. They are not the same document and they don't serve the same purpose. This guide breaks down the difference in plain English, with the level of detail an FDA reviewer actually uses when reading your package. ## Key Takeaways - SBOM: Inventory of software components. - VEX: Assessment of component vulnerabilities. - The FDA mandates SBOMs; VEX is functionally required. - SBOMs are machine-readable (SPDX, CycloneDX). - VEX uses CSAF, CycloneDX VEX, or OpenVEX. - Reviewers cross-reference VEX with SBOM-derived CVEs. ## Why the SBOM vs VEX distinction matters Section 524B(b)(1) of the FD&C Act requires a Software Bill of Materials for every cyber device, and the FDA's *Cybersecurity in Medical Devices* final guidance dated February 3, 2026 expects the SBOM to be paired with a Vulnerability Exploitability eXchange (VEX) document that states, per CVE, whether the device is actually affected. Without VEX, every transitive CVE in your SBOM looks unpatched to a reviewer or hospital procurement team, even when the vulnerable function is not reachable in your build. VEX adoption still lags SBOM adoption across the industry, which is why HSCC procurement guidance and AAMI TIR97:2019 both treat VEX-with-SBOM as the minimum viable disclosure. NTIA's *The Minimum Elements for a Software Bill of Materials* (July 2021), replaced by CISA's 2026 Minimum Elements published July 29, 2026, defines what an SBOM is; CISA's VEX *Use Cases* (April 2022) defines what VEX adds. They are complements, not substitutes. ## TL;DR - at a glance | | **SBOM** | **VEX** | |---|---|---| | **Stands for** | Software Bill of Materials | Vulnerability Exploitability eXchange | | **Question it answers** | What components are in this device? | Which CVEs against those components actually affect us? | | **Format** | SPDX or CycloneDX | CSAF 2.0, CycloneDX VEX, or OpenVEX | | **Refresh cadence** | Per build / per release | Monthly minimum during FDA review | | **FDA expectation** | Required under Section 524B(b)(3) | Effectively required to answer SBOM-driven CVEs | | **Without it** | The reviewer can't see what's in your device | The reviewer sees unanswered CVEs and asks why | ## What an SBOM actually is An SBOM is an **inventory**. For every piece of software shipping on or with your medical device - firmware libraries, OS packages, application dependencies, container images - the SBOM records: - Component name and version (`openssl 3.0.7`) - A globally unique identifier (PURL or CPE) - License - Supplier - Cryptographic hash - Dependency relationships (what depends on what) That's it. An SBOM is a list. It does not say anything about whether any of those components have known vulnerabilities. That's the next step. For the four elements FDA reviewers actually verify on the SBOM itself, see our [Medical Device SBOM: FDA requirements and submission guide](/blog/medical-device-sbom-fda-requirements-and-submission-guide). The FDA expects the SBOM to be **machine-readable** - either SPDX or CycloneDX - so a reviewer can run automated tools against it. If you're choosing between the two, our [CycloneDX vs SPDX comparison](/guides/cyclonedx-vs-spdx-medical-devices) covers the tradeoffs. ## What a VEX actually is A VEX is an **assessment**. It takes the list of CVEs that fall out of running a vulnerability scanner against your SBOM and tells the reviewer, for each CVE: - Are we **affected** by this CVE? - Are we **not affected**? If so, why? (Vulnerable code not present? Not in the execute path? Mitigated by configuration?) - Has it been **fixed**? (In which version, by what means?) - Is it **under investigation**? (Who owns it, when's the close date?) A VEX is the document that turns a noisy CVE list into a reviewer-readable narrative. Without one, the FDA sees 47 open CVEs in your dependencies and has no way to know which ones you've already addressed. For the full mechanics - fields, formats, justification codes - read our [VEX document guide for medical devices](/guides/vex-document-medical-device-fda). ## How they work together Think of it as a two-step pipeline the FDA reviewer mentally runs: ``` SBOM ──▶ Vulnerability scan ──▶ CVE list ──▶ VEX ──▶ "Closed for review" ``` 1. Your SBOM lists every component. 2. A vulnerability scanner (NVD, OSV, Snyk, etc.) maps each component to known CVEs. 3. The VEX answers, for each CVE, whether your device is actually affected. 4. The reviewer marks the cybersecurity section as adequately addressed. If any step in that chain breaks, the reviewer writes a deficiency. The most common break point is step 3 - the VEX is missing, stale, or vague. We covered the failure modes in detail in [5 VEX mistakes that trigger FDA deficiencies](/blog/vex-mistakes-fda-deficiencies). ## Why you can't substitute one for the other The single most common misconception we see: "We have an SBOM, so we don't need a VEX." That is the same as saying "we have a parts list, so we don't need a safety analysis." The SBOM is raw material. The VEX is the reasoning the reviewer needs. A submission with only an SBOM forces the reviewer to do the VEX work themselves - and they won't. They'll issue a deficiency and hand it back. The reverse mistake - submitting a VEX without an SBOM - never happens because the VEX references SBOM components by PURL or CPE. Without the SBOM as ground truth, the VEX has nothing to reference. ## How the FDA actually reads your SBOM and VEX A reviewer's workflow is roughly this: 1. **Open the SBOM.** Confirm it's machine-readable, has the minimum SBOM elements defined in CISA's 2026 Minimum Elements for a Software Bill of Materials, published July 29, 2026 (supplier, component, version, unique identifier, dependency relationship, author, timestamp), and matches the device's stated software architecture. 2. **Run a CVE scan** against the SBOM's components. 3. **Open the VEX.** Cross-reference every CVE the scan produced against the VEX entries. Sort by CVSS, highest first. 4. **Read every `not_affected` justification** - especially on CVSS ≥ 7.0 entries. 5. **Check for SBOM/VEX drift** - component versions, generation dates, build hashes. Anywhere this workflow stalls (missing entry, stale timestamp, vague justification, format mismatch), you get a finding. Anywhere it flows cleanly, the reviewer moves on. ## Refresh cadence - the silent killer Sponsors often treat SBOM and VEX as deliverables they generate once at submission. Both should regenerate continuously: - **SBOM:** every build. Tie it into CI so it's never more than one commit out of date. - **VEX:** monthly minimum during active FDA review, plus immediately when a new high-CVSS CVE drops against any component in your SBOM. Why? Because the FDA reviewer reads the document **on the day they pick up the file**, not the day you submitted it. A VEX generated five months before review is almost certainly out of sync with the current CVE landscape, and reviewers know it. ## The three SBOM formats and the three VEX formats You'll see a lot of acronyms. Here's the practical map: | Document | Format options | When to choose which | |---|---|---| | SBOM | **CycloneDX** | Best when you also need VEX, SaaSBOM, or HBOM - broadest tool support in MedTech CI/CD | | SBOM | **SPDX** | Fine for OS/firmware-heavy devices; mandated in some non-FDA contexts | | VEX | **CycloneDX VEX** | Pair with CycloneDX SBOM. Embed inline plus ship standalone | | VEX | **CSAF 2.0 VEX** | Pair with SPDX SBOM. Best when coordinating with CISA / ICS-CERT | | VEX | **OpenVEX** | Lightweight, schema-simple, good for high-volume automation | The FDA accepts all combinations. The deciding factor is operational fit with your build pipeline, not the FDA's preference. ## Decision aid - which document fixes which problem? | Reviewer concern | Document that addresses it | |---|---| | "What's in this device?" | SBOM | | "Are you tracking your dependencies?" | SBOM | | "Why is this CVE in your software not addressed?" | VEX | | "Is this CVE actually exploitable on this device?" | VEX | | "How do you know your SBOM is current?" | SBOM regeneration policy + cover letter | | "How do you know your VEX is current?" | VEX regeneration policy + cover letter | If a reviewer's question maps to the wrong column in your response, that's a sign your team is still treating these two documents as one. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers navigate the complexities of FDA cybersecurity requirements, distinguishing between essential documentation like SBOMs and VEX. Our team, comprised of CISSP and OSCP certified experts, including ex-military red team personnel, specializes in generating precise, compliant documentation. We focus on creating actionable VEX files that accurately reflect the exploitability of vulnerabilities within your device's specific operational context. We don't just provide documents; we implement a structured methodology to analyze, assess, and articulate your device's security posture. This includes automating SBOM generation and linking it to a diligently prepared VEX to address potential cybersecurity deficiencies efficiently. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### Do I need both an SBOM and a VEX for the FDA? Effectively yes. Section 524B(b)(3) requires an SBOM. The February 2026 final premarket guidance requires you to assess every component for known vulnerabilities - and a VEX is the only practical way to deliver that assessment in machine-readable form. Submissions that include only an SBOM are routinely flagged with cybersecurity deficiencies. ### Can VEX statements live inside my SBOM? CycloneDX supports embedding VEX statements directly in the SBOM. That's allowed and convenient. But reviewers also want a **standalone, schema-valid VEX file** for independent parsing - so ship both. SPDX SBOMs cannot embed VEX statements; you pair them with a separate CSAF or OpenVEX file. ### Is a vulnerability scan report the same as a VEX? No. A scan report is the raw output - every CVE matched against your SBOM. A VEX is the curated assessment of those CVEs that tells the reviewer which ones matter and which ones don't, with justifications. The scan is input; the VEX is output. ### What happens if a new CVE lands after I submit? It depends on severity and timing. For a high-CVSS CVE landing during FDA review, the right move is to regenerate the VEX, add the new entry with `affected` or `not_affected` status and a justification, and send an unsolicited amendment to the reviewer. Doing nothing and hoping is how you end up with a hold letter - see our breakdown of [deficiency vs RTA vs hold letters](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter). ### Does this apply to non-FDA submissions like EU MDR? The same logic applies. EU MDR Annex I requires evidence of cybersecurity risk management, and a current SBOM + VEX is the cleanest way to provide it. The format expectations are similar - CycloneDX or SPDX for SBOM, any major VEX format for the assessment. ## Need help building this? If you're standing up SBOM and VEX from scratch - or your current pair just got flagged in an FDA deficiency letter - we can help. We've shipped clean SBOM + VEX pairs on 275+ FDA submissions and can triage your current package under NDA in 24 hours. - Read the **[VEX document guide](/guides/vex-document-medical-device-fda)** for the full format reference - Read **[5 VEX mistakes that trigger FDA deficiencies](/blog/vex-mistakes-fda-deficiencies)** for the failure modes to avoid - Choosing between SBOM formats? See **[CycloneDX vs SPDX for medical devices](/guides/cyclonedx-vs-spdx-medical-devices)** - Already received an FDA cybersecurity letter? Start with [which letter you got](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter), then [book a response call](/lp/fda-deficiency-letter) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Scoping a Medical Device Penetration Test: A Practical Guide Source: https://bluegoatcyber.com/blog/scoping-a-medical-device-penetration-test # How to Scope a Medical Device Penetration Test Correctly > **[DIRECT ANSWER]** Scope a medical device penetration test from your security architecture views, not from a price target. Every interface those views show crossing a trust boundary belongs in scope: the radios, the physical debug ports, the mobile app, the cloud APIs, and the update path. A scope narrower than your documented attack surface is the most common reason testing evidence generates an FDA deficiency question. _Reviewed September 17, 2026_ Most weak penetration tests are weak because of decisions made before anyone touched the device. The scope was set from a budget rather than from the architecture, the hardware arrived without a way to access it, or the testers were given a production unit locked down in ways that hid the interfaces they were supposed to examine. Scoping well is not complicated, but it requires knowing what your device actually exposes and being willing to include the parts that are inconvenient to test. This is how to do it so the resulting report supports your submission instead of raising questions about it. ## Key Takeaways - Your architecture views define the scope; anything crossing a trust boundary belongs in it. - Excluding an interface is defensible only if the exclusion is documented with a rationale. - Radio and hardware interfaces are the most commonly and most visibly omitted. - Testers need documentation, debug access, and spare units to produce useful depth. - Test late enough that the design is stable, early enough that findings can be fixed. - The report has to map to your threat model, or the reviewer cannot connect the two. ## Why Scope Is the Decision That Determines Report Quality The February 3, 2026 premarket cybersecurity guidance expects security testing to reflect the device's attack surface. That is a scoping statement, not a testing statement. A reviewer reading your report is comparing it against your architecture views and your threat model, and the comparison is quick: if the views show a Bluetooth radio and a debug header, and the report covers a web dashboard, the mismatch is obvious on the first pass. The cost of getting this wrong is measured in review cycles. A deficiency question about testing scope arrives months after the test, when the device has moved on, the lab availability has changed, and the schedule has no slack. Scoping correctly the first time is cheaper than any of the alternatives. There is also an engineering reason. A test scoped to the easy interfaces tells you your easy interfaces are fine. It does not tell you whether your firmware can be extracted through the debug header, which is what an attacker with the device in hand would try first. ## Start From the Architecture Views The four security architecture views the FDA describes are the natural starting point, because they already enumerate what your device connects to and what can affect multiple patients. Walk each view and list every arrow. | Interface category | Typical examples | Common excuse for omitting it | |---|---|---| | Wireless | BLE, Wi-Fi, cellular, NFC, proprietary radio | "The app testing covered it" | | Physical | JTAG, UART, SWD, USB, SD card, service port | "The enclosure is sealed" | | Network | Ethernet services, DICOM, HL7, proprietary TCP | "It sits on a hospital VLAN" | | Application | Mobile app, web UI, clinician portal | Usually included | | Cloud and API | Device telemetry endpoints, management APIs | "That is our cloud team's scope" | | Update path | Firmware delivery, signing, rollback | "Updates are internal" | | Supply chain interfaces | Manufacturing test modes, provisioning | "Only used in the factory" | The excuses in the third column are worth reading carefully because each one is an assumption. A sealed enclosure is a delay, not a barrier. A hospital VLAN is someone else's control that you do not administer. A factory test mode that ships enabled is a live interface regardless of its intended purpose. **[KEY REQUIREMENT]** If an interface is out of scope, record why in the test plan and carry that rationale into the submission. An interface that is simply absent from the report reads as an oversight; one that is excluded with a stated reason reads as a decision. ## What Testers Need From You The depth of a test is bounded by the access provided. Manufacturers frequently under-supply, then receive a report that is shallower than they wanted. | Provide | Why it changes the outcome | |---|---| | Architecture and data flow diagrams | Testers spend time on attack paths instead of on discovery | | Threat model | Testing targets the threats you care about, in your language | | Firmware images and source where possible | Enables review that black-box testing cannot reach | | Two or more test units | Hardware testing can be destructive; one unit ends the test | | Debug credentials and interface documentation | Distinguishes what is exposed from what is merely present | | Test accounts across every role | Authorization testing needs more than one privilege level | | Simulator or safe test mode | Allows realistic testing without clinical risk | Providing debug credentials sometimes feels like weakening the test. It does the opposite. A tester who spends three days bypassing a lock to reach a subsystem has spent three days proving the lock is slow, not evaluating the subsystem. Give the access, then test separately whether the lock holds. ## Black Box, Grey Box, or White Box The access model should follow from what you are trying to learn. | Model | What the tester gets | Best used for | |---|---|---| | Black box | No internal information | Simulating an outside attacker with no inside help | | Grey box | Documentation, some credentials | Most premarket submissions; balances realism and depth | | White box | Full source, design documents, credentials | Finding the most issues per hour; pairs with code review | Grey box is the usual right answer for a submission. Pure black box testing burns time on reconnaissance you could have supplied and produces less coverage for the same money, while white box testing finds the most issues but is harder to present as a simulation of a real attacker. Many programs do both: white box review during development, grey box testing to produce the submission evidence. ## Timing the Test Test when the design is stable enough that findings apply to the device you will ship, but early enough that fixing a finding does not mean re-opening a frozen design. In practice that means after design freeze and before verification and validation close, with enough calendar time for remediation and a retest of anything significant. Teams that test in the final weeks before filing usually end up submitting with findings open, which is a worse position than filing a little later with them closed. Hardware findings drive this more than software ones. A software fix is a firmware build; a finding that says the debug interface is accessible on the production board may require a board change, and board changes have lead times that no amount of urgency shortens. ## Scoping the Ecosystem, Not Just the Device For most modern devices, the device alone is an incomplete scope. The therapy or diagnostic chain includes a phone app, a gateway or hub, cloud services, and sometimes a clinician-facing portal. An attacker will target whichever link is weakest, and that link is frequently not the embedded device where the security effort was concentrated. A defensible scope covers the full chain, with the depth on each component proportional to its role. That does not mean equal effort everywhere. It means the cloud API that can push a configuration change to every device in the field gets attention proportional to that capability, because it is the clearest example of the multi-patient harm the architecture views are meant to surface. ## How Blue Goat Cyber Approaches This We scope from your architecture views and your threat model, then tell you plainly where the scope is thinner than the attack surface and what that will look like to a reviewer. Our engagements cover radio, hardware, firmware, application, and cloud layers, and the report is written so each finding maps back to the threat it exercises and the harm it could cause. Our [medical device penetration testing](/services/medical-device-penetration-testing) is built for submission evidence rather than for a generic scan report, and our [threat modeling](/services/threat-modeling) work produces the architecture views the scope should be derived from in the first place. ## Frequently Asked Questions ### What should be included in a medical device penetration test scope? Every interface that crosses a trust boundary in your security architecture views: wireless radios, physical debug and service ports, network services, the mobile or web application, cloud APIs, and the firmware update path. If your views show an interface and your test report does not mention it, a reviewer will notice the gap and ask about it. ### How long does a medical device penetration test take? It depends on the interface count and the depth required, but a connected device with a radio, an app, and cloud services typically takes several weeks of testing plus reporting time. Hardware-focused work can take longer because physical access, chip removal, and firmware extraction are slower than network testing and sometimes destroy the unit. ### Should we give the testers source code? For development-phase testing, yes, because source access finds more issues per hour than black-box work. For the submission evidence itself, a grey box model with documentation and credentials is usually the best balance. Many manufacturers do both, using white box review during design and grey box testing to produce the report they file. ### When in the development cycle should testing happen? After design freeze, so the findings apply to what you will ship, and before verification and validation close, so there is room to remediate and retest. Testing in the final weeks before filing tends to produce a submission with findings still open, which is a worse outcome than a slightly later filing with them resolved. ### Does the FDA require penetration testing? The February 3, 2026 premarket cybersecurity guidance identifies security testing, including penetration testing, as part of the expected submission content for cyber devices. What matters as much as performing the test is that its scope matches the attack surface you documented, and that the report is specific enough for a reviewer to connect findings to your threat model. ### What if we cannot test an interface for safety reasons? Document the constraint and the alternative you used, such as testing on a simulator, a non-clinical test article, or a bench setup that reproduces the interface. A stated constraint with a reasonable substitute is defensible. An interface that simply does not appear in the report, with no explanation, is the version that generates questions. ## Scope It Once, Properly Bring us your architecture views and we will tell you what a defensible test scope looks like for your device, including the interfaces that are inconvenient to include. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## Secure Software Dev for Medical Devices Source: https://bluegoatcyber.com/blog/secure-software-development-for-medical-devices-ensuring-safety-and-compliance # Secure Software Dev for Medical Devices > **[DIRECT ANSWER]** Secure development for medical devices means the security requirements come from a threat model, the code is written against a defined secure coding standard, third-party components are inventoried and monitored, and every control is verified with recorded evidence. Because the device can injure a patient, security defects are safety defects, which is why the work belongs inside design controls and the ISO 14971 risk file rather than beside them. _Updated October 27, 2024_ Patient safety comes first in healthcare. As software takes on more of the work inside medical devices, security matters more. Secure software development helps [protect patients’ lives and sensitive medical data](/blog). This article covers why secure software matters in medical devices and outlines the principles, regulations, and strategies used to build safe, compliant software. ## Key Takeaways - Software is central to modern medical devices, enabling advanced functions. - Insecure software can jeopardize patient safety and sensitive data. - Integrating security into development and testing lowers vulnerabilities. - Compliance with FDA and international standards is mandatory for market entry. - Risk assessment and quality assurance are core for software safety. - Emerging tech like AI and IoT demands evolving security strategies. ## Why this matters The stakes for secure software development in medical devices are patient lives and sensitive health information. Inadequate security can lead to device malfunction, data breaches, or even direct patient harm, as demonstrated by past vulnerabilities in critical medical equipment. The increasing connectivity of medical devices, while offering advanced functionalities, also expands their attack surface, making them attractive targets for cyber threats. Developing secure software is not merely a technical exercise but a regulatory imperative. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, mandates that manufacturers integrate security considerations throughout the device's total product lifecycle. Compliance with standards such as IEC 62304 for medical device software life cycle processes, ISO 14971 for risk management, and the AAMI TIR89 for premarket cybersecurity are critical. These standards and regulations aim to minimize vulnerabilities, manage risks, and ensure the continued safety and effectiveness of medical devices in a constantly evolving threat landscape. Prioritizing secure software development is essential for maintaining trust, patient safety, and market access. ## Understanding the Importance of Secure Software in Medical Devices Software is now central to modern medical devices. It enables advanced functions and improves care. From pacemakers to insulin pumps, software makes these devices more capable and more precise. ![Section Image](/imported-images/cfedea45faca8a60.png) But more connectivity also means more exposure. As medical devices connect to healthcare networks, they become targets for cyber threats. Insecure software can put patient safety and privacy at risk. For example, in 2017, the [U.S. Food and Drug Administration (FDA)](https://www.fda.gov/) issued a safety communication about vulnerabilities in certain pacemakers. Hackers could potentially exploit those flaws, affect device function, and put patients at risk. That incident made the need for secure software development in healthcare hard to ignore. ### The Role of Software in Modern Medical Devices Software in medical devices controls operations, processes data, and enables communication with other medical systems. Manufacturers need to understand how much device safety and reliability depend on software. Software also connects devices to electronic health record (EHR) systems, which improves data exchange and care coordination. But that connection also creates security risk if vulnerabilities are not addressed. Consider a wearable device that monitors a patient’s vital signs and sends the data to a provider’s EHR system. Clinicians may rely on that data to make treatment decisions. If the device software is insecure, an attacker could access it, alter the data, or inject false readings. That can lead to bad diagnoses and wrong interventions. ### The Risks of Insecure Software in Healthcare Insecure software in medical devices creates risks that range from patient harm to data breaches. Attackers can exploit vulnerabilities to disrupt device function, cause inaccurate diagnoses, alter dosage delivery, or disable the device entirely. Unauthorized access can also expose or alter patient data, putting privacy and confidentiality at risk. One example is the [ransomware](/blog) attack on [Hollywood Presbyterian Medical Center in 2016](https://www.latimes.com/business/technology/la-me-ln-hollywood-hospital-bitcoin-20160217-story.html), which disabled the hospital’s electronic health record system and demanded a ransom. Remote attack is another serious concern. Because many devices are connected, attackers can target them from anywhere. A device may be physically secure and still be vulnerable if its software is not. Given how critical these devices are, healthcare organizations and manufacturers need to treat secure software development as basic operational discipline. That means regular updates and patching, thorough testing and validation, and security controls that reduce cyber risk. ## Principles of Secure Software Development Developing secure software for medical devices requires following [specific principles](/guides/fda-cybersecurity-testing-requirements-taxonomy) and practices across the full development lifecycle. When security is built into each phase, manufacturers reduce vulnerabilities and lower risk. ![Section Image](/imported-images/f3d1bc8137eb9575.png) Developers need to know the basics of secure coding. That includes understanding common flaws such as buffer overflows and injection attacks and using techniques that prevent or limit them. One core practice is input validation. Software should treat incoming data as untrusted until proven otherwise. Validating and sanitizing input helps block exploitation. In medical devices, that matters because patient data integrity and confidentiality directly affect safety and privacy. ### Security Measures in the Development Process Secure coding is not enough by itself. Security controls need to be part of the development process. One example is threat modeling, which helps teams identify vulnerabilities and assess risk before release. Teams should also run regular security testing and code reviews. Those steps help find and fix weaknesses before deployment. Real-world failures show why this matters. The [Heartbleed vulnerability discovered in OpenSSL in 2014](https://www.cisa.gov/news-events/alerts/2014/04/08/openssl-heartbleed-vulnerability-cve-2014-0160) came from a simple coding error but exposed sensitive information across millions of systems. When manufacturers build these practices into development, they reduce risk, protect patient data, and support trust in the device. ## Regulatory Compliance in Medical Device Software Medical device software is subject to strict regulations and standards tied to patient safety and data privacy. Manufacturers need compliance to bring products to market and keep them there. ### Overview of Relevant Regulations and Standards The regulatory framework for medical device software includes international standards such as [ISO 13485](/blog) and [IEC 62304](/blog/iec-81001-5-1-vs-iec-62304-medical-device-standards), which define requirements for developing and maintaining medical device software. ISO 13485 is written for medical device manufacturers and provides a framework for implementing a [quality management system.](/blog/the-importance-of-implementing-a-medical-device-qms) It covers areas such as risk management, design and development, and post-market surveillance. Following ISO 13485 helps manufacturers show they can produce safe and effective medical device software. [IEC 62304](https://webstore.iec.ch/preview/info_iec62304%7Bed1.0%7Den_d.pdf) focuses on software life cycle processes. It covers development, verification, validation, and maintenance. Compliance with IEC 62304 helps manufacturers follow sound software engineering practices, reduce software failure risk, and improve product quality. Regulators such as the FDA in the United States and the European Medicines Agency (EMA) in Europe enforce guidance and requirements for medical device software development. The FDA’s framework includes premarket requirements such as a [510(k) clearance](/blog) submission or a pre-market approval (PMA) application. These processes involve close review of software safety, effectiveness, and compliance with applicable regulations. In Europe, the EMA oversees the regulatory approval process for medical device software. The agency requires manufacturers to obtain a [CE mark](/blog/what-is-a-ce-marking-in-med-devices), showing compliance with the European Union’s Medical Device Regulation (MDR). MDR sets requirements for product safety, performance, and clinical evaluation. ### Compliance as a Key Aspect of Software Security Compliance is not just a legal checkbox. It is part of software security. Regulatory standards push teams to build security into development early, which lowers the chance of vulnerabilities, patient harm, and data breaches. By following established regulations and standards, manufacturers can implement security practices such as encryption of patient data, secure authentication, and regular software updates to address emerging threats. These measures help protect sensitive information against unauthorized access and tampering. ## Strategies for Ensuring Safety in Medical Device Software [Secure software development](/blog) is ongoing. It takes a disciplined approach to identify and address risk and vulnerabilities. Safety strategies in medical device software protect both patients and sensitive medical data. ### Risk Assessment and Management in Software Development Thorough risk assessment during development helps teams identify threats and vulnerabilities early. Once risks are identified, developers can put the right controls and mitigation strategies in place. ### Quality Assurance and Testing for Software Safety [Quality assurance](/blog) and testing are core parts of software development. They confirm that the software works as intended and meets safety requirements. Rigorous testing helps uncover security flaws and functional issues before devices are deployed in clinical settings. ## Future Trends in Secure Software Development for Medical Devices As technology changes, so do the risks and opportunities in medical device software security. Teams need to keep up with new threats and technical shifts if they want to protect patients. ### The Impact of Emerging Technologies Emerging technologies such as [artificial intelligence (AI)](/blog) and the Internet of Things (IoT) create both benefits and risk in healthcare. AI-based software can improve diagnosis and treatment decisions, but it also introduces problems such as adversarial attacks against AI models. AI in medical devices could significantly change patient care. For example, AI algorithms can analyze patient data, detect patterns, and predict possible health issues. That can support earlier intervention and better outcomes. The growing use of IoT-connected medical devices also brings remote monitoring and better visibility. But it expands the attack surface and requires strong security controls. IoT also allows medical devices to connect with electronic health records (EHRs), giving healthcare professionals real-time patient information. That can improve workflow, diagnosis, and treatment planning. ### The Evolution of Security and Compliance Requirements Security and compliance requirements for medical devices continue to change as new threats emerge. Regulators keep updating guidance to address those threats and strengthen cybersecurity requirements. For example, the FDA’s premarket cybersecurity guidance issued in 2014 and expanded in 2018 reflects the growing focus on securing medical devices against cyber threats. Manufacturers need to adjust their development processes to meet these requirements. The [European Union’s Medical Device Regulation (MDR)](/blog) implemented in 2021 adds stricter cybersecurity requirements for medical device manufacturers. The regulation is intended to improve patient safety by requiring stronger security measures and ongoing monitoring of medical device software. Industry standards such as ISO 13485 and IEC 62304 also continue to guide secure software development for medical devices. Following those standards helps manufacturers apply best practices and include security throughout the software development lifecycle. ## SPDF activity by phase A secure product development framework becomes concrete when each phase produces an artifact someone else can review. | Phase | Security activity | Artifact it produces | Who reads it later | | --- | --- | --- | --- | | Concept and planning | Security requirements derived from intended use and environment | Security requirements traceable to design inputs | Reviewers checking traceability | | Architecture | Threat modeling against defined trust boundaries | Threat model with architecture views | The FDA reviewer, first | | Design | Control selection, cryptographic design decisions | Security design specification and cryptographic inventory | Your own team during a component change | | Implementation | Secure coding standards, static analysis, dependency management | Static analysis results, SBOM from the build | Vulnerability triage, for years | | Verification | Security requirement testing, fuzzing, penetration testing | Test reports mapped back to requirements | The submission package | | Release and postmarket | Vulnerability monitoring, patch cadence, disclosure process | Postmarket surveillance plan and patch records | Postmarket reviewers and customers | The test in every row is the same. If the activity happened but produced nothing reviewable, it will not count in a submission. ## Conclusion Secure software development is necessary for medical device safety and compliance. Manufacturers reduce risk by understanding the role of secure software, following secure coding principles, meeting regulatory requirements, and applying sound safety practices. As healthcare technology changes, teams need to keep up with new threats and changing security requirements to protect patients and maintain trust in medical devices. Blue Goat Cyber, a Veteran-Owned business, provides B2B cybersecurity services with expertise in medical device cybersecurity, penetration testing, and compliance with HIPAA, FDA, SOC 2, and PCI standards. [Contact us today for cybersecurity help](/contact). Check out our [medical device cybersecurity FDA compliance package.](/) ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers embed security into every phase of the software development lifecycle, from initial design to post-market surveillance. Our approach focuses on proactive identification and mitigation of threats, ensuring that security is a core component, not an afterthought. We assist with threat modeling, vulnerability assessments, and penetration testing, adhering to FDA guidelines and industry standards. Our team, comprising certified professionals (CISSP, OSCP) and former military red team members, brings a unique perspective to medical device cybersecurity. We provide actionable strategies to meet regulatory requirements and strengthen your product's security posture. We also offer tailored services, such as [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services), to streamline regulatory submissions. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### Why is secure software development crucial for medical devices? Secure software development is crucial to protect patients from harm, safeguard sensitive medical data from breaches, and ensure the reliable and intended function of medical devices. Vulnerabilities can be exploited, leading to device malfunction or unauthorized data access. ### What regulations govern medical device software security? Medical device software security is governed by regulations from bodies such as the FDA in the United States and the EU's Medical Device Regulation (MDR). International standards like IEC 62304 and ISO 13485 also provide frameworks for secure development and quality management. ### How does the FDA address medical device software security? The FDA addresses medical device software security through premarket requirements like 510(k) clearances and PMA applications, which review software safety and effectiveness. The February 3, 2026 final guidance also outlines cybersecurity requirements for medical devices. ### What are the common risks of insecure software in medical devices? Common risks include disruption of device function, inaccurate diagnoses, alteration of dosage delivery, exposure or alteration of patient data, and complete device disablement. Remote attacks can exploit connected devices, regardless of their physical security. ### What development practices ensure medical device software security? Ensure medical device software security involves practices such as threat modeling, secure coding, input validation, conducting regular security testing, and performing code reviews throughout the development lifecycle. These steps help identify and mitigate vulnerabilities early. ### How do emerging technologies impact medical device software security? Emerging technologies like AI and IoT introduce new benefits but also new security risks. AI models can be vulnerable to adversarial attacks, and the increased connectivity of IoT devices expands the attack surface, necessitating strong security controls and continuous monitoring. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Code Integrity with Secure Boot](/blog/code-integrity-with-secure-boot) - [RTOS in Medical Devices: A Complete Guide](/blog/rtos-a-comprehensive-guide) --- ## Secure Update Infrastructure for Medical Devices Source: https://bluegoatcyber.com/blog/secure-update-infrastructure-medical-devices # Secure Update Infrastructure for Medical Devices: A Safety-Critical Subsystem, Not IT Plumbing > **[DIRECT ANSWER]** Secure update infrastructure is the signed manifests, dual-bank A/B partitioning, rollback protection, hardware root of trust, and segmented update server that let a device receive patches without becoming an attack path. Section 524B(b)(2) requires devices be designed for updates, and the FDA's February 3, 2026 guidance expects an architecture view of the update path, threat model entries covering signing and distribution, and pen-test evidence against the real update infrastructure, not a generic web test. _Published June 5, 2026_ ## Key Takeaways - The update path is the single highest-leverage attack surface on a connected medical device - one compromise cascades to the entire fleet, persists across reboots, and bypasses every downstream control. - Section 524B(b)(2) requires the device to be designed to be updated and patched. "We'll figure out updates after launch" is not a postmarket problem - it is a premarket design-input failure. - The FDA's Feb 3, 2026 guidance expects an explicit architecture view of the update path, threat model entries that cover signing, distribution, install, and rollback, and pen-test evidence against the real update infrastructure (not a generic web pen test). - The reference architecture is signed manifests + dual-bank A/B + rollback protection + anti-downgrade counters + hardware root of trust + isolated update agent + segmented update server + mTLS to a dedicated endpoint. - Production signing keys belong in an HSM, generated and provisioned through an air-gapped ceremony, with separate signing identities per environment and per SKU. - Postmarket: coordinated disclosure → patch → VEX → deploy, with measurable SLAs that the postmarket plan in your submission already committed to. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to secure update infrastructure for medical devices the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Why the update path is the highest-leverage target Every other control on the device assumes the firmware it is running is the firmware you shipped. Break that assumption and the rest does not matter. - **One compromise, fleet-wide RCE.** A signed-but-malicious image, or an unsigned image accepted by a weak verifier, propagates to every device that polls the update server. The blast radius is the entire installed base, not one device. - **Persistence that survives every other control.** Antivirus, EDR, network segmentation, MFA on the clinical workstation - none of them touch the firmware loaded at boot. Compromise the update channel and you survive reboots, factory resets, and incident response. - **Bypasses every downstream control.** Secure boot, SBOM-based vulnerability monitoring, runtime integrity checks, and pen-test-derived hardening all assume the device boots the code you signed. If the update path delivers attacker code that is also signed (because the signing key leaked, or the verifier is wrong), those controls validate the wrong artifact. - **The patch path is the malware path.** The same channel you use to push security fixes is what an attacker uses to push their payload. If you have not isolated and hardened it, your defense and offense share infrastructure. This is why reviewers under Section 524B treat updates as a design-input topic rather than a postmarket nicety - and why the same posture should drive your internal engineering priorities. ## What the FDA expects in the submission The Feb 3, 2026 final guidance _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_ does not include a section titled "Update Infrastructure," but the requirements are spread across the package and reviewers ask for all of it. - **Architecture view of the update path.** Diagram the manifest source, signing infrastructure, distribution server, transport, update agent, storage banks, and verification points. The same architecture view requirement that covers the device's clinical data flow applies to its update flow. - **Threat model entries that cover the channel end-to-end.** Each step gets STRIDE entries: spoofing (fake update server), tampering (modified manifest), repudiation (no audit trail of who signed), information disclosure (leaking signing key, leaking installed-version telemetry), denial of service (force the device into a broken bank), elevation of privilege (update agent compromised → root). See our [threat modeling guide](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices). - **Controls traceability.** Every threat-model entry maps to a control (signed manifest, anti-downgrade counter, mTLS, HSM-backed signing) and every control maps back to a verification activity in the SPDF. - **Pen-test evidence against the real update infrastructure.** A pen test that scopes "the device" but ignores the update server, the signing infrastructure, and the on-device update agent is incomplete. Reviewers increasingly call this out as a deficiency - see [510(k) cybersecurity deficiencies that trigger FDA holds](/blog/510k-cybersecurity-deficiencies-that-trigger-fda-holds). - **Postmarket patch SLA.** The vulnerability management plan must state how fast critical vulnerabilities reach the field. "Within a reasonable time" does not survive review; "critical CVSS within 30 days, high within 60, with VEX published in parallel" does. See [SBOM vulnerability management](/guides/sbom-vulnerability-management-medical-devices) and [VEX mistakes that trigger FDA deficiencies](/blog/vex-mistakes-fda-deficiencies). ## Reference architecture The defensible pattern is the same whether you ship one SKU or a hundred. The pieces: - **Signed update manifests.** A manifest enumerates the artifact, version, target SKU, and hash. The manifest itself is signed; the artifact hash is in the signed payload, not alongside it. Verify the manifest signature, then verify the artifact matches the hash. - **Dual-bank A/B partitioning.** Two firmware banks. The device runs from one; updates land in the other. On successful boot and self-test, the new bank is marked active. On failure, the bootloader falls back to the previous bank. The therapy loop never sees a half-installed update. - **Rollback protection + anti-downgrade counter.** A monotonically increasing counter (stored in fused or write-once memory, or in a TPM/SE counter) is incremented on every accepted update. The bootloader refuses any image whose counter is lower than the current one. This blocks attackers from forcing the device back to a known-vulnerable version. - **Hardware root of trust.** The signing public key (or the hash of it) is anchored in immutable storage - eFuse, OTP, or a secure element. The boot ROM verifies the bootloader, which verifies the application, which verifies the update agent. No link in the chain trusts on first use. - **Isolated update agent.** A small, single-purpose process - no shell, no general-purpose network stack beyond what it needs, no write access to anything except the inactive bank. Ideally a separate UID, separate cgroup, separate seccomp/AppArmor profile. - **Segmented update server.** A dedicated host (or namespace) that serves only update artifacts. No shared credentials with telemetry, fleet management, or clinical data stores. Read-only artifact storage with a separate signing host that publishes into it. - **mTLS to a dedicated endpoint.** Each device has its own client certificate, provisioned at manufacture and rotated on a schedule. The update server validates the client cert; the device validates the server cert against a pinned issuer. Public-PKI-only or token-only auth is not enough on a device that will live in the field for a decade. ## Isolation patterns that hold up - **Separate VLAN or edge gateway.** The update endpoint reachable from the device sits on its own segment. The customer's IT can apply the same segmentation in their network using your published port/protocol list (which already lives in your cybersecurity labeling). - **No shared credentials with telemetry or clinical data.** Compromising the telemetry pipeline should never grant write access to the update channel. Different keys, different identities, different audit trails. - **Least-privilege service accounts.** The update agent owns its own bank and nothing else. The update server's signing host has no inbound network and no SSH from the production fleet network. - **HSM-backed signing.** Production signing keys live in a FIPS 140-2 Level 3 (or higher) HSM. The key never leaves the HSM. Signing is a brokered operation with audit logging and dual-control approval for new build promotion. - **Air-gapped signing ceremony.** Initial key generation is performed on a clean host with no network, with multiple-party attestation, recorded in a ceremony document the QMS retains. Key recovery, if applicable, uses Shamir splits held by separate custodians. - **Per-environment, per-SKU separation.** Development, staging, and production use different signing keys. SKUs that have meaningfully different threat models or service lives get separate roots. A single key for "everything we ever ship" is a single point of catastrophic failure. ## TUF and Uptane: when they fit, when they are overkill [TUF (The Update Framework)](https://theupdateframework.io/) defines roles (root, targets, snapshot, timestamp) that separate concerns and limit blast radius if any single key is compromised. [Uptane](https://uptane.org/) is the TUF adaptation for vehicles - and increasingly for any high-assurance embedded fleet. Both are appropriate for medical devices when: - **Heterogeneous fleet with multiple suppliers signing components.** TUF's role separation lets you delegate signing of an OS image to one party, an ML model to another, and a config bundle to a third without giving any of them root authority. - **Long device service life with foreseeable key rotation.** TUF's root key rotation flow is built for exactly this. - **Multi-tenant update server or shared infrastructure.** TUF's snapshot/timestamp roles defend against freeze and mix-and-match attacks that a hand-rolled server probably doesn't address. - **A regulatory environment that will eventually demand it.** Automotive went this way; MedTech is on the same trajectory for higher-risk classes. They are usually overkill when you ship a single product, sign every artifact yourself, control the update server end-to-end, and have a clear and short key-rotation playbook. In that case a careful custom implementation that delivers the same guarantees (signed manifests, anti-downgrade, root-of-trust, dual-bank, isolated agent) is defensible - but document why you chose it over TUF in the security risk file so the reviewer does not have to ask. ## Common pen-test findings in update infrastructure These are the findings that recur across [medical device penetration tests](/services/medical-device-penetration-testing) when the update channel is in scope: - **Unsigned images, or signature verification with a bypass.** A bootloader that "validates the signature" by checking only that a signature is present. A verifier that hashes the wrong bytes. A verifier called after the image has already been mapped executable. - **Trust on first use.** The device accepts whatever key the first update server presents and pins it. An attacker on the first power-on network controls the device for life. - **One signing key across every SKU and every environment.** A breach of any non-production system grants production signing authority. We have seen this pattern in firms that otherwise have strong AppSec posture. - **HTTP fallback.** TLS is required by config; falls back to HTTP on any TLS error. An on-path attacker forces the fallback by sending a TLS alert. - **No rollback protection.** The device accepts any signed image, including a signed older image with a known unpatched vulnerability. Anti-downgrade counter is missing or stored in writable flash. - **Update agent running as root with full network access.** A single bug in the parser becomes full device compromise plus arbitrary network egress. - **Update server with shared admin creds.** The on-call engineer who manages telemetry can also sign and push updates. No dual control, no audit trail. - **Signing host accessible from the build cluster.** A CI/CD compromise becomes a signing-key compromise becomes a fleet compromise. Each of these maps to a specific control in the reference architecture. The fixes are not exotic - they are operational discipline applied to a system most teams treat as plumbing. ## Postmarket: disclose, patch, VEX, deploy - with SLAs The postmarket cybersecurity management plan in your submission already committed you to specific timelines. The update infrastructure is what lets you keep that commitment. 1. **Disclose.** A researcher (or internal monitoring) reports a vulnerability. The CVD program triages within the SLA committed in the plan. See our [VDP/CVD workflows guide](/guides/medical-device-vdp-cvd-workflows-guide). 2. **Patch.** Engineering produces a fix, regression tests it, and re-runs the relevant security tests. The fix lands in the next build, signed in the HSM, with an incremented anti-downgrade counter. 3. **VEX.** Publish a [VEX statement](/guides/vex-document-medical-device-fda) describing the affected components (linked to the SBOM), the status (fixed in version X), and any compensating controls customers should apply in the meantime. 4. **Deploy.** Push through the update infrastructure with the committed SLA - critical within 30 days, high within 60, communicated to operating organizations as required by Section 524B(b)(1). The same infrastructure that lets you deploy a feature lets you deploy a security fix. The teams that treat updates as plumbing miss every SLA in their own postmarket plan; the teams that treat updates as a safety subsystem hit them. ## How Blue Goat Cyber helps We design and pen-test secure update infrastructure as part of [medical device penetration testing](/services/medical-device-penetration-testing) and [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services), including signing infrastructure review, update-agent code review, and end-to-end fleet-side attack scenarios. The deliverable is an architecture view, threat model entries, and pen-test evidence reviewers can read straight into an eSTAR Section 14 - and a postmarket patch SLA you can actually hit. ## FAQ ### Does Section 524B require dual-bank A/B updates specifically? No. The statute requires the device to be designed so updates and patches can be made available. Dual-bank A/B is the most common architecture that satisfies that requirement reliably without taking the device offline for the install window. Other architectures (in-place updates with bootloader recovery, package-based updates on a Linux device with snapshot rollback) are acceptable if they deliver the same safety guarantees - documented in the threat model and verified in pen testing. ### Where does the postmarket patch SLA live in the submission? In the postmarket cybersecurity management plan, which Section 524B(b)(1) requires explicitly. The plan should state monitoring sources, triage cadence, severity thresholds, patch-availability SLAs by severity, and customer-notification mechanism. Vague SLAs ("as soon as practicable") are flagged in deficiency letters. ### How do we pen-test the update infrastructure without disrupting the production fleet? A representative staging environment with the same signing keys (lower-privilege equivalents), update server, and a small fleet of test devices. The pen test exercises the manifest signing, transport, agent behavior, rollback, and downgrade defenses against that environment. Findings are remediated and verified before any change to production. ### What if our update server is operated by the customer (on-prem hospital deployment)? Then the device-side defenses carry the entire weight: client-side certificate validation, signed-manifest verification independent of transport, anti-downgrade counter enforced in the bootloader, and a pinned trust anchor that the customer's IT cannot relax. Document the deployment model explicitly so reviewers see that the on-prem variant is not a hole in the trust model. ### Should signing keys be rotated on a schedule, or only on compromise? Both. Plan for routine rotation that exercises the recovery path (typically every 1-3 years for intermediate keys, longer for root) and have an out-of-cycle rotation playbook for compromise. The first time you rotate a key should not be in the middle of an incident. ## Related reading - [FDA Section 524B Cybersecurity Requirements Explained](/guides/fda-524b-cybersecurity-requirements-explained) - [SBOM Vulnerability Management for Medical Devices](/guides/sbom-vulnerability-management-medical-devices) - [VEX Mistakes That Trigger FDA Deficiencies](/blog/vex-mistakes-fda-deficiencies) - [FDA Cybersecurity Deficiency Response Checklist](/guides/fda-cybersecurity-deficiency-response-checklist) - [A Step-by-Step Guide to Threat Modeling Connected and Implantable Medical Devices](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) - [Postmarket Cybersecurity Readiness Plan](/guides/postmarket-cybersecurity-readiness-plan) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Section 524B(b)(2): Medical Device](/blog/the-impact-of-524bb2-on-medical-device-cybersecurity) --- ## Medical Device Protocol Cybersecurity Source: https://bluegoatcyber.com/blog/securing-communication-protocols-in-medical-devices # Medical Device Protocol Cybersecurity: What Manufacturers Need to Know > **[DIRECT ANSWER]** Securing communication protocols in medical devices means applying protocol-specific controls, such as DTLS for CoAP, TLS with correct cipher suites for other transports, mutual authentication, and encrypted key management, rather than relying on generic 'use TLS' guidance. The FDA's February 3, 2026 guidance expects manufacturers to document these controls per protocol in the threat model and submission, aligned with IEC 81001-5-1, ISO 27001, and AAMI SW96, and verify them through regular audits and penetration testing. _Reviewed July 24, 2026_ In an era where healthcare is increasingly intertwined with technology, the security of communication protocols in medical devices has emerged as a critical facet of medical device manufacturing. These devices, which often handle sensitive patient data and are integral to patient care, are becoming targets for sophisticated cyber-attacks. The consequences of compromised device communications range from patient privacy breaches to life-threatening malfunctions. Establishing security measures for communication protocols is not just a technical necessity but a fundamental aspect of ensuring patient safety and maintaining public trust in healthcare technologies. ## Key Takeaways - Secure protocols prevent data breaches and device manipulation. - The FDA mandates security by design for medical devices. - Encryption and authentication are foundational security layers. - Protocol-specific controls address unique attack surfaces. - Regular audits and penetration testing identify vulnerabilities. - Compliance with FDA guidance and standards is essential. ## Why this matters The security of communication protocols in medical devices is paramount because compromised devices can lead to grave consequences, including patient harm, data breaches, and operational disruptions within healthcare systems. The increasing integration of medical devices into networked environments, often handling sensitive personal health information, makes them attractive targets for cyber attackers. Unauthorized access or manipulation of these devices or their communications can alter therapy, disable critical functions, or expose confidential patient data. Regulatory bodies, particularly the FDA, emphasize the necessity of strong cybersecurity throughout the medical device lifecycle. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly outlines expectations for manufacturers to ensure device security, including securing communication channels. This guidance highlights the importance of adhering to recognized standards like IEC 81001-5-1 for risk management in IT networks incorporating medical devices, ISO 27001 for information security management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles for medical device security, risk management. Neglecting these areas not only puts patients at risk but also exposes manufacturers to significant regulatory penalties and reputational damage. Therefore, proactive and diligent security measures for medical device communication protocols are not merely good practice but a regulatory and ethical imperative. ## Understanding the Need for Secure Communication Protocols in Medical Devices The imperative for secure communication protocols in medical devices cannot be overstated in the digital health landscape. The interconnectedness of these devices with broader healthcare ecosystems exposes them to many cyber threats, making secure communications a paramount concern. ### The Rising Tide of Connectivity in Healthcare - **Expanding Digital Infrastructure**: The healthcare sector rapidly integrates digital solutions, from electronic health records (EHR) to telehealth services. Medical devices are increasingly becoming a part of this digital fabric, often transmitting critical health data across various platforms and networks. - **The Internet of Medical Things (IoMT)**: [IoMT devices](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) are revolutionizing healthcare delivery but also increasing the vulnerability to cyberattacks due to the vast number of connected devices and the diversity of their deployment environments. ### The Diversity of Cyber Threats The spectrum of cyber threats facing medical devices is vast, and each threat type brings its unique challenges: - **Data Breaches and Privacy Concerns**: Insecure communication channels can expose sensitive patient data, violating privacy laws and eroding patient trust. - **Device Manipulation Risks**: Cybercriminals could potentially alter the functionality of a medical device, posing direct risks to patient health and safety. - **Service Disruption Threats**: Attacks like [Distributed Denial of Service (DDoS)](/blog) can incapacitate a device’s communication capabilities, leading to critical lapses in patient monitoring and care. - **Supply Chain Attacks**: Insecure protocols can be exploited to introduce vulnerabilities during the manufacturing or software update processes. ### Regulatory and Compliance Imperatives - **Evolving Regulatory Landscape**: Organizations like the [FDA](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity), EMA, and others have been updating their guidelines to include specific requirements for cybersecurity, focusing heavily on secure communication protocols. - **Global Standards and Frameworks**: Compliance with international standards such as [ISO/IEC 27001](/blog) and adherence to frameworks like NIST’s cybersecurity guidelines are becoming increasingly crucial. ### The Complexity of Medical Device Ecosystems - **Heterogeneous Networks**: Medical devices often operate within complex networks that include legacy systems, modern applications, and cloud-based services, each with its unique security needs. - **Interoperability Challenges**: As devices from different manufacturers need to communicate with each other, establishing common, secure communication standards is a significant challenge. ### The Convergence of Advanced Technologies - **Emerging Technologies**: The integration of AI, machine learning, and big data analytics in medical devices adds layers of complexity to communication protocols, necessitating advanced security measures. - **Remote Monitoring and Telemedicine**: These technologies require secure, real-time data transmission channels to ensure accurate and safe patient care. ### Key Risks in Communication Protocols - **Data Interception:** Without encryption and proper authentication, communication protocols are vulnerable to eavesdropping, allowing unauthorized actors to capture sensitive patient data and intellectual property. - **Device Tampering:** Weak or poorly implemented protocols may be exploited to alter device behavior, potentially leading to patient harm or regulatory noncompliance. - **Denial of Service (DoS) Attacks:** Malicious actors can disrupt or flood communication channels, rendering connected medical devices unresponsive or inoperable at critical moments. ## Establishing Resilient Cybersecurity Measures Fortifying communication protocols in medical devices involves several layers of security, each addressing different aspects of cybersecurity. ### Advanced Encryption Techniques - **Implementation of Dynamic Encryption**: Utilizing encryption methods that evolve dynamically to counteract emerging decryption strategies employed by cyber attackers. - **Encryption Key Management**: Ensuring secure encryption key generation, storage, and disposal. ### Complete Authentication Mechanisms - **Biometric Authentication**: Implementing advanced biometric authentication methods, such as fingerprint or retina scans, for devices that require user interaction. - **Continuous Authentication**: Establishing a system that continuously monitors and authenticates the user to prevent unauthorized access after initial login. ### Resilient Network Security Protocols - **Intrusion Detection Systems (IDS)**: Deploying [IDS](/blog) to monitor network traffic for suspicious activities and potential breaches. - **Virtual Private Networks (VPN)**: Utilizing VPNs for remote access to ensure secure communication channels over public networks. ### Regular Security Auditing and Penetration Testing - **Ongoing Vulnerability Assessments**: Conducting regular security assessments to identify and rectify vulnerabilities in the communication protocols. - **[Penetration Testing](/services/medical-device-penetration-testing)**: Employing ethical hackers to simulate cyber-attacks and test the resilience of the communication protocols. ### Security by Design - **Incorporating Security in the Development Lifecycle:** Cybersecurity should be integrated from the earliest stages of product development, including threat modeling, secure coding practices, and vulnerability assessments throughout the lifecycle. - **Proactive Risk Mitigation:** By addressing potential threats early, manufacturers can reduce remediation costs, enhance device safety, and meet evolving regulatory expectations for secure-by-default medical devices. ### Compliance with Security Standards and Protocols - **Adhering to HIPAA and HITECH**: For U.S.-based devices, ensuring compliance with Health Insurance Portability and Accountability Act (HIPAA) and Health Information Technology for Economic and Clinical Health Act ( [HITECH](/blog)) standards regarding patient data security. - **Following International Standards**: Complying with global standards like ISO/IEC 27001 for information security management. ## Protocol-specific risks and controls Generic "use TLS" guidance only goes so far. The wireless and IoT protocols MedTech teams actually ship with each have distinct attack surfaces, footgun defaults, and FDA review expectations. The sections below distil what reviewers and pen testers look for on the four protocols we see most often. ### CoAP (Constrained Application Protocol) CoAP is a UDP-based REST protocol designed for resource-constrained devices - common in implantables, wearables, and battery-powered home-monitoring hubs that can't afford a full TCP/TLS stack. - **Default risk:** CoAP itself is plaintext. Confidentiality, integrity, and authentication all depend on **DTLS (Datagram TLS)** being correctly enabled. We routinely see devices ship with `coap://` endpoints exposed instead of `coaps://`. - **What the FDA expects to see:** DTLS 1.2 minimum (1.3 preferred), mutual authentication via pre-shared keys or raw public keys, and key rotation documented in the SBOM/SPDF package. - **Common pen-test findings:** amplification-attack exposure on multicast endpoints, no replay protection on observed-resource notifications, and resource-discovery endpoints (`/.well-known/core`) leaking device topology. ### MQTT (Message Queuing Telemetry Transport) MQTT is the most common pub/sub broker pattern for IoMT - telemetry from a CGM, infusion pump, or remote-monitoring patch to a cloud aggregator. - **Default risk:** Anonymous access is on by default in most brokers. Authentication via username/password is plaintext unless wrapped in TLS. Topic ACLs are often missing entirely - any authenticated device can subscribe to any topic, including other patients' streams. - **What the FDA expects to see:** TLS 1.2+ for all broker connections, per-device X.509 client certificates (not shared credentials), topic-level ACLs scoped to a single device or patient, and broker logs retained for incident response. - **Common pen-test findings:** wildcard topic subscriptions (`#`) returning other patients' data, retained-message replay exposing historical readings, and self-signed broker certificates that clients accept without validation. ### Narrowband IoT (NB-IoT) and cellular LPWAN NB-IoT (and LTE-M) is the backbone for long-range, low-power patient-monitoring devices that ship directly to homes without relying on the patient's Wi-Fi. - **Default risk:** Carrier-level encryption protects the radio link but **terminates at the carrier's core**. Anything between the carrier APN and your cloud is your problem. Many teams assume "the carrier handles it" and ship without application-layer encryption. - **What the FDA expects to see:** application-layer encryption (TLS or DTLS) on top of the carrier link, certificate pinning to the cloud endpoint, and a documented threat model that acknowledges the carrier as a trust boundary. - **Common pen-test findings:** unencrypted HTTP POSTs to the cloud endpoint, hardcoded APN credentials in firmware, and no fallback when the SIM is cloned or swapped. ### ANT/ANT+ and BLE peripherals ANT/ANT+ shows up in fitness/wellness-adjacent devices (heart-rate straps, pedal sensors) that increasingly cross into regulated MedTech via SaMD apps. BLE has similar pitfalls. - **Default risk:** ANT+ public profiles broadcast in cleartext by design - the assumption was "non-sensitive fitness data." That assumption breaks the moment a SaMD app uses the stream for clinical decisions. - **What the FDA expects to see:** if the data drives a regulated function, either move to the encrypted **ANT-FS** profile or wrap the stream in application-layer authentication. Document the decision in your risk analysis. - **Common pen-test findings:** pairing without numeric comparison or passkey entry (Just Works mode), no protection against rogue peripherals impersonating a known device, and firmware update channels reachable over the same unauthenticated pairing. For a deeper inventory of every protocol we see in MedTech submissions - including HL7, DICOM, Modbus, and proprietary RF stacks - see [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples). ## Protocol by Protocol: Risk and Control Generic advice to use TLS does not answer the question a reviewer is asking, because several of these protocols do not run over TCP at all. | Protocol | Where it shows up | Main weakness | Control to document | |---|---|---|---| | CoAP | Constrained sensors and wearables | Runs over UDP, so TLS does not apply | DTLS with mutual authentication and managed keys | | MQTT | Telemetry to a cloud broker | Broker level authorization often too broad | TLS, per device credentials, topic scoped permissions | | NB-IoT and cellular | Home monitors and mobile devices | Carrier encryption ends at the carrier | Application layer encryption end to end | | BLE and ANT+ | Phone paired peripherals | Unauthenticated pairing modes | LE Secure Connections plus application authentication | | HL7 v2 | Hospital integration | No authentication in the protocol itself | Transport security, peer authentication, input validation | | DICOM | Imaging workflows | Open association acceptance | DICOM TLS, restricted peers, audit logging | ## Case Studies - Successes and Failures in Securing Communication Protocols Notable successes and cautionary tales mark the medical device cybersecurity landscape. Examining these cases provides invaluable insights into the best practices and pitfalls in securing communication protocols. ### Successful Implementation: The Case of Advanced Insulin Pumps **Background**: Modern insulin pumps are designed for remote management, enabling patients and healthcare providers to monitor and adjust insulin levels via wireless connections. **Challenge**: The primary challenge was ensuring the secure transmission of sensitive data between the pump, the patient’s monitoring devices, and healthcare providers’ systems. **Solution**: Manufacturers implemented a multi-layered security approach: - **End-to-End Encryption**: Utilizing strong encryption standards like AES-256 to secure data transmission. - **Secure Pairing Protocols**: Establishing a secure and authenticated connection between the pump and remote devices. - **Continuous Security Updates**: Regular firmware updates to address emerging vulnerabilities and threats. **Outcome**: These measures led to a system capable of safeguarding patient data and device functionality, setting a standard in medical device cybersecurity. ### Learning from Failures: The 2017 Pacemaker Recall **Background**: In 2017, a major manufacturer recalled hundreds of thousands of pacemakers due to cybersecurity vulnerabilities. **Challenge**: The pacemakers were found to be susceptible to hacking, potentially allowing malicious actors to deplete the batteries or alter the pacing. **Solution and Pitfalls**: - **Lack of Encryption**: The communication protocols used in these devices lacked strong encryption, making them susceptible to interception and manipulation. - **Inadequate Authentication Mechanisms**: There was a failure to implement authentication protocols, leaving the devices open to unauthorized access. - **Delayed Response**: The manufacturer’s response to these vulnerabilities was reactive rather than proactive, highlighting the need for ongoing security assessments. **Outcome**: The recall led to logistical and financial challenges and highlighted the critical need for medical device design and development security strategies. ### Broader Implications and Lessons Learned These case studies underscore several key lessons for manufacturers: - **Proactive Security Measures**: It is crucial to incorporate security features during the design phase rather than as an afterthought. - **Regular Security Audits and Updates**: Monitor and update devices to address new vulnerabilities. - **Regulatory Compliance**: Ensuring that all devices meet the stringent security standards set by regulatory bodies. - **Stakeholder Education**: Educating patients and healthcare providers on the proper use and maintenance of devices to prevent security breaches. These real-world examples provide a roadmap for manufacturers, emphasizing that securing communication protocols is a dynamic and ongoing process critical to the integrity and trustworthiness of medical devices in our increasingly connected world. ## Navigating Regulatory Compliance Ensuring secure communication protocols in medical devices is not just a technological imperative but also a regulatory one. Navigating the complex regulatory compliance landscape is essential for manufacturers, as it involves adhering to stringent standards that govern the cybersecurity measures of medical devices. ### FDA Guidelines and Recommendations - **Pre-Market Approval Process**: The FDA requires that manufacturers demonstrate the security of their devices’ communication protocols as part of the pre-market approval process. This involves detailed documentation of the security measures and their effectiveness. - [**Post-Market Surveillance**](/services/fda-postmarket-cybersecurity-services): The FDA also monitors the cybersecurity of medical devices after entering the market, requiring manufacturers to continuously update and patch their devices in response to new threats. ### Global Regulations - **European Union (EU) Regulations**: In the EU, regulations like the Medical Device Regulation (MDR) and General Data Protection Regulation (GDPR) place strict requirements on data security and patient privacy, impacting how communication protocols are secured. - **Other International Standards**: Manufacturers must also know of standards such as ISO 13485 for medical devices and ISO/IEC 27001 for information security management. ### Compliance Best Practices #### Risk Management Approach - **Risk Analysis**: It is crucial to conduct thorough risk assessments of communication protocols as part of the device’s overall risk management plan. This involves identifying potential vulnerabilities and the likelihood of their exploitation. - **Mitigation Strategies**: Developing and implementing strategies to mitigate identified risks, including secure design, encryption, and access controls. #### Documentation and Reporting - **Detailed Documentation**: Maintaining records of all cybersecurity measures, including how communication protocols are secured, is essential for demonstrating compliance. - **Incident Reporting Protocols**: Establishing clear procedures for reporting cybersecurity incidents to regulatory bodies is mandatory in many jurisdictions. ### Challenges and Considerations #### Keeping Pace with Technology - **Keeping Pace with Technology:** Rapid advancements in connectivity, software, and AI continuously reshape the threat landscape, requiring proactive adaptation in cybersecurity design and risk management. - **Evolving Standards:** Regulatory bodies update cybersecurity expectations to reflect emerging threats and technologies. Manufacturers must regularly monitor and integrate these changes to maintain compliance and market readiness. #### Harmonization of Standards - **Harmonization of Standards:** Aligning with multiple international cybersecurity frameworks-such as FDA, EU MDR, and ISO/IEC standards, is essential for ensuring consistent device security across regions. - **Global Market Access:** Achieving harmonized compliance enables manufacturers to streamline regulatory submissions and expand into global markets with greater efficiency and confidence. #### Data Protection and Privacy - **Data Protection and Privacy:** Communication protocols must safeguard sensitive patient information and operational data from interception, tampering, and unauthorized access, aligning with HIPAA and FDA cybersecurity expectations. - **Balancing Security and Usability:** Security controls must be yet thoughtfully implemented to maintain device performance and ease of use, ensuring clinicians and authorized users can access necessary data without friction. ## Conclusion As the integration of digital technology in healthcare continues to grow, the security of medical device communication protocols becomes increasingly paramount. This is not just a matter of protecting data but is intrinsically linked to safeguarding human lives. Manufacturers must adopt a multi-faceted, proactive approach encompassing advanced encryption, authentication, stringent network security, and continuous compliance monitoring. By doing so, they ensure that their medical devices are functional, innovative, secure, and trustworthy. The future of healthcare technology depends on the ability to provide secure, reliable medical devices, and securing communication protocols is a critical step in this journey. Let’s embrace this challenge and commit to a future where medical technology and cybersecurity go hand in hand, ensuring safe and effective care for all. [Contact us](/contact) if you need help securing your medical device. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers secure communication protocols. Our team, comprised of CISSP and OSCP certified experts, including ex-military red team personnel, conducts thorough security assessments tailored to specific communication technologies like CoAP, MQTT, NB-IoT, and BLE. We perform threat modeling to identify potential attack vectors and validate existing security controls. Our methodology includes penetration testing and vulnerability assessments focused on protocol-level weaknesses. We assist with pre-market and post-market cybersecurity compliance, aligning with the FDA's guidance. Our services include designing and implementing security features such as encryption, authentication, and secure boot mechanisms. We provide actionable recommendations to harden device communications against exploitation. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is medical device protocol cybersecurity? Medical device protocol cybersecurity refers to the practices and technologies used to protect the communication channels of medical devices from unauthorized access, use, disclosure, disruption, modification, or destruction. This ensures the integrity, confidentiality, and availability of patient data and device functionality. ### Why is securing communication protocols important for medical devices? Securing these protocols is crucial to prevent cyberattacks that could lead to patient harm, data breaches, and operational disruptions. Compromised communication can alter device functions, expose sensitive patient information, or render devices inoperable during critical care. ### What does the FDA expect for medical device communication security? The FDA expects medical device manufacturers to implement security by design principles, use strong encryption and authentication, and address protocol-specific risks. The February 3, 2026 final guidance outlines requirements for premarket submissions, emphasizing threat modeling and vulnerability management. ### How can manufacturers secure CoAP in medical devices? For CoAP, manufacturers should always use DTLS 1.2 or higher for confidentiality and integrity. The FDA expects mutual authentication via pre-shared keys or raw public keys and documented key rotation. Avoid exposing plaintext CoAP endpoints. ### What are common security risks in MQTT for medical devices? Common risks include anonymous access being enabled by default, plaintext authentication, and missing topic ACLs. This can expose patient data or allow unauthorized topic subscriptions. Shared credentials are also a prevalent issue. ### Does carrier-level encryption provide sufficient security for NB-IoT devices? No, carrier-level encryption only protects the radio link and terminates at the carrier's core network. The FDA expects application-layer encryption (TLS or DTLS) on top of the carrier link, with certificate pinning, because the carrier is considered a trust boundary. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Securing a Fleet of Connected Devices in Hospitals Source: https://bluegoatcyber.com/blog/securing-iot-devices-in-healthcare-the-frontline-of-patient-safety # Securing a Fleet of Connected Devices in Hospitals > **[DIRECT ANSWER]** Securing a hospital fleet of connected devices is a scale problem, not a single-device problem: provisioning thousands of units with unique identities, managing certificates and keys across their lifespan, and delivering patches without a truck roll to every hospital. The manufacturer owns device-resident security controls, certificate lifecycle, and patch packaging; the hospital owns network segmentation, physical access, and account administration. MDS2 disclosure and a documented end-of-support plan are what let both sides do their part. A single connected infusion pump or vital-signs monitor is a small security problem. Three thousand of them, deployed across forty hospitals, provisioned over six years by different staff with different network configurations, is a different problem entirely. The devices that get compromised in real incidents are rarely the ones with a design flaw; they are the ones onboarded with a default certificate nobody rotated, or left on a flat network because segmentation was assumed rather than verified. Fleet-scale security fails at the seams between manufacturer and hospital responsibility, not usually inside either party's own controls. ## Key Takeaways - Provisioning at scale needs unique device identity from manufacturing, not a shared default credential assigned at install. - Certificate and key management across a multi-year fleet lifespan is an operational program, not a one-time PKI setup. - Network segmentation is a joint responsibility: the manufacturer documents what the device needs, the hospital implements the VLAN and firewall rules. - MDS2 is the disclosure mechanism hospitals use to evaluate fleet risk before and after purchase, and it needs to be accurate, not just complete. - Patch delivery has to work across devices with intermittent connectivity and hospital-controlled maintenance windows. - Shared clinical logins are a workflow reality, not a policy failure, and device design has to account for them rather than assume individual authentication will happen. ## Why This Matters The FDA's final guidance *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026, continues the chain that began with the September 2023 premarket guidance and the June 2025 update, and it treats fleet-scale postmarket management as part of the total product lifecycle, not an afterthought. For connected accessory and monitoring devices sold in the hundreds or thousands of units, that means your submission has to describe how you provision, patch, and eventually decommission the fleet, not just how the individual device resists attack on a bench. CISA's 2026 Minimum Elements for a Software Bill of Materials now supersede the NTIA's 2021 framework, and hospital procurement teams increasingly cross-reference your SBOM against MDS2 disclosures during purchasing review, not just at initial evaluation. AAMI SW96 (recognized as 13-131) and TIR97 (13-112) both expect postmarket controls scaled to actual deployment size. A device that is secure in isolation but has no realistic plan for certificate rotation or patch delivery across a real fleet does not meet that expectation, regardless of how clean its individual threat model looks. ## How do you provision and onboard thousands of devices securely? Secure provisioning means every device gets a unique cryptographic identity at manufacturing time, not a shared default that gets "personalized" during hospital install. Manufacturers who leave identity assignment to the field almost always end up with some devices still carrying the factory default, because on-site provisioning gets rushed and skipped under deployment pressure. Identity, including a device certificate or equivalent credential, needs to be injected during manufacturing and verifiable during onboarding, so a hospital can confirm the device is genuine before it ever joins the network. | Provisioning stage | Manufacturer-side control | What fails without it | | --- | --- | --- | | Manufacturing | Unique key or certificate injected per unit | Shared credentials across an entire product line | | Shipping and staging | Signed configuration package, tamper-evident state | Devices arrive in an unverifiable trust state | | Hospital onboarding | Automated registration against a defined identity | Manual entry errors, default credentials left active | | Ongoing fleet inventory | Central device management console with real-time status | Hospital has no accurate count of what is actually deployed | > **[KEY REQUIREMENT]** Zero-touch provisioning should be the default design goal for any device shipped in fleet quantities; every manual step in onboarding is a step that gets skipped somewhere in a large deployment. ## How do you manage certificates and keys across a device fleet? Certificate and key management has to be treated as an ongoing operational program with a defined rotation schedule, not a one-time PKI decision made at product launch. Devices that ship with certificates valid for the device's entire expected service life avoid one problem and create another: a compromised key stays valid for years with no path to revoke and reissue it. The realistic middle ground is certificates with a defined validity window and an automated renewal mechanism that does not require a service visit. Manufacturers need a certificate authority strategy that survives their own organizational changes: what happens to device trust if the manufacturer changes its signing infrastructure, gets acquired, or discontinues a product line. A fleet with no answer to that question is a fleet that eventually loses the ability to trust its own devices. ## Who owns network segmentation, the hospital or the manufacturer? Network segmentation is implemented by the hospital, but the manufacturer owns telling the hospital exactly what the device needs to reach and nothing more. A device manufacturer cannot configure a hospital's VLANs or firewall rules, but a device that ships without a clear network requirements document forces IT staff to guess, and guessing usually produces an overly permissive rule set. The manufacturer's job is a documented, minimal set of required ports, protocols, and destinations that the hospital's network team can implement as a segmentation policy with confidence. | Responsibility | Manufacturer owns | Hospital owns | | --- | --- | --- | | Device network requirements | Documented minimal port/protocol list | Implementing the VLAN and firewall rules | | Device-resident controls | Authentication, encryption, secure boot | Physical placement and access control | | Credential lifecycle | Certificate issuance and renewal mechanism | Local account administration, badge access | | Vulnerability disclosure | Coordinated disclosure process, patches | Applying patches within maintenance windows | | Risk visibility | Accurate MDS2 and SBOM | Asset inventory and risk assessment across vendors | The hospital's IT and biomed teams cannot segment what they do not know exists on the network, which is why an accurate device inventory feeding into the hospital's asset management is as important as the segmentation rule itself. ## What does MDS2 actually need to say? MDS2 is the disclosure document hospitals use to assess a device's risk profile during procurement and renewal, and it only works if the answers are specific rather than defensively vague. A form that answers "encryption used: yes" without specifying algorithm, key length, or scope gives a hospital security team nothing to evaluate. Hospitals increasingly cross-check MDS2 answers against the SBOM and against what the pentest report actually found, so inconsistency between those documents raises more questions than an honest gap would. Our [MDS2 and JSP2 post](/blog/the-role-of-mds2-in-medical-device-cybersecurity) and [role of MDS2 post](/blog/the-role-of-mds2-in-medical-device-cybersecurity) go deeper on filling the form out in a way that actually holds up under a hospital security review. ## How do you deliver patches across a fleet without disrupting care? Patch delivery at fleet scale has to account for intermittent device connectivity and hospital-controlled maintenance windows, not assume every unit is reachable on demand. A device that requires a physical visit to apply a security patch will realistically go unpatched for a large share of the fleet, since biomed staff cannot service every unit on release day. The design goal is a signed, staged update mechanism that a device can pull and apply during a hospital-defined window, with rollback if the update fails. > **[KEY REQUIREMENT]** Your postmarket plan needs a documented patch delivery mechanism, not just a patch development process; reviewers and hospital security teams both want to know how the fix actually reaches a device that may be offline for weeks. Reporting matters as much as delivery. Hospitals need a way to see which devices in their fleet are on which firmware version, so a security team can answer "are we exposed to this CVE" without manually inventorying every unit. ## How should end-of-support be communicated to hospitals? End-of-support communication has to reach the hospital's security and procurement teams directly and early, not rely on a notice buried in a support portal. Hospitals plan capital budgets years in advance, and a device reaching end of support with no advance notice forces an unplanned replacement or, more commonly, continued use of an unsupported device with no compensating controls in place. Manufacturers should give hospitals a firm end-of-support date at launch when possible, and update it proactively rather than waiting for a customer to ask. A realistic end-of-support communication includes what stops (security patches, vulnerability monitoring) and what a hospital should do in the interim, such as additional network isolation, since simply telling a hospital to "upgrade" ignores capital budget cycles that can run several years. ## What do shared clinical accounts mean for device design? Shared clinical logins are a workflow reality on hospital units, and device authentication design has to account for them rather than assume individual login will happen. A nurse moving between patients every few minutes will not log out and back in for each interaction, no matter what policy says, and a device that only supports a single shared credential loses all ability to attribute an action to a person. The practical fix is designing for fast, low-friction identity, such as badge tap or proximity authentication layered on top of a device-level credential, rather than insisting on password-based individual login that clinical workflow will simply route around. Audit logging should be designed assuming shared accounts exist, capturing device and session context even when individual attribution is imperfect, rather than treating incomplete attribution as a reason to skip logging altogether. ## How Blue Goat Cyber Approaches This We evaluate fleet devices differently from single-unit devices, because the failure modes are different: provisioning gaps, certificate lifecycle blind spots, and patch delivery mechanisms that look fine in a lab and fail against real hospital connectivity. Our team tests the full deployment lifecycle, from manufacturing-time identity injection through onboarding, patch delivery, and decommissioning, not just the device's static attack surface. For MDS2 and SBOM work, we help manufacturers write disclosures that will hold up when a hospital security team cross-references them against pentest findings, because inconsistency there damages trust faster than an honest limitation does. We also help manufacturers document the network requirements hospitals need to segment correctly, since a device that ships without that documentation puts the burden of guessing on hospital IT. If the FDA raises cybersecurity deficiencies after our submission work, we resolve them at no additional cost. ## Frequently Asked Questions **How many devices need to be compromised before a fleet-wide problem becomes a hospital-wide one?** Sometimes just one. A single device with weak segmentation or a shared credential can be a pivot point into the broader hospital network, regardless of fleet size. The risk scales with how uniformly devices are configured, since a shared vulnerability across thousands of identically provisioned units is a single fix for an attacker to reuse everywhere. **Whose job is it to segment our device from the rest of the hospital network?** The hospital implements the segmentation, but the manufacturer has to make that possible by documenting exactly what network access the device needs. A device that requires broad, undocumented connectivity forces the hospital to either over-permission it or risk breaking functionality, and both outcomes create risk the manufacturer could have prevented with clear documentation. **Do we need individual logins on every device to be secure?** Not necessarily, but you do need a way to attribute actions and protect access that survives real clinical workflow, where shared or fast-switch accounts are common. Layering a fast authentication method like badge tap on top of device-level credentials, combined with logging that captures device and session context, is usually more effective than mandating individual password logins clinicians will bypass. **What happens if we can't patch every device in a fleet on the same schedule?** That is normal, not a failure, as long as you can report which devices are on which version and prioritize outreach for units that fall furthest behind. The bigger risk is not knowing which devices are unpatched, so version reporting and fleet visibility matter as much as the patch itself. **How far in advance should we tell hospitals about end of support?** As early as possible, ideally at launch with a stated date, and updated proactively as the date approaches rather than left to a support ticket. Hospitals plan capital replacement on multi-year cycles, so late notice often forces them to keep running an unsupported device with no compensating controls in place. **Does MDS2 replace the need for a penetration test?** No. MDS2 is a disclosure document describing what security capabilities the device has; a penetration test verifies whether those capabilities actually work as claimed. Hospitals increasingly compare the two, and gaps between what MDS2 states and what testing finds are a fast way to lose a hospital's trust. ## CTA If your fleet's provisioning, certificate management, or patch delivery plan only works on paper, a hospital security review or a real incident will find the gap before we do unless we find it first. [Contact us](/contact) to have your fleet security architecture and MDS2 disclosure reviewed together. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Securing IoT-Enabled Medical Devices: 5 Source: https://bluegoatcyber.com/blog/securing-iot-enabled-medical-devices-5-essential-tips # Securing IoT-Enabled Medical Devices: 5 Essential Tips > **[DIRECT ANSWER]** Securing IoT-enabled medical devices comes down to five practical steps: build a security framework aligned with recognized standards, apply software updates and patches promptly, require strong multi-factor authentication, encrypt patient data in transit and at rest, and run regular security audits and vulnerability assessments. The FDA's February 3, 2026 guidance ties these practices to a device's total product lifecycle, consistent with IEC 81001-5-1, ISO 27001, and AAMI SW96 risk management requirements. _Updated November 16, 2024_ Rapid advances in technology have changed healthcare. The Internet of Things (IoT) helps [improve patient care and streamline medical processes](/blog). But as IoT-enabled medical devices spread, so does the need for stronger security. This article covers the value of IoT in healthcare, the [risks and challenges tied to IoT devices](/blog/securing-iot-devices-in-healthcare-the-frontline-of-patient-safety), and five practical ways to secure them. ## Key Takeaways - Implement security frameworks aligned with industry standards. - Apply software updates and patches promptly. - Use strong multi-factor authentication for access control. - Ensure all patient data is encrypted in transit and at rest. - Conduct frequent security audits and vulnerability assessments. - use AI/ML for real-time threat detection and response. ## Why this matters The security of IoT-enabled medical devices directly impacts patient safety, data privacy, and the operational integrity of healthcare systems. A compromised device can lead to unauthorized access to sensitive patient health information (PHI), device malfunction, or even cessation of critical care, posing severe risks to patient well-being. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the necessity of cybersecurity practices throughout a device's total product lifecycle. This guidance highlights the imperative for manufacturers and healthcare providers to implement controls aligned with recognized standards. Relevant standards include IEC 81001-5-1 (Health software, security activities in the product life cycle), ISO 27001 (Information security management systems), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management). Failure to adequately secure these devices not only jeopardizes patient outcomes but also exposes organizations to significant financial penalties, legal liabilities, and reputational damage. Proactive cybersecurity protects against evolving threats and ensures the continuity of care. ## Understanding the Importance of IoT in Healthcare The integration of Internet of Things (IoT) technology in healthcare has changed patient monitoring, diagnostics, and treatment. IoT devices, such as wearable sensors and remote monitoring systems, let healthcare professionals gather real-time patient data, track vital signs, and even deliver personalized care from a distance. This technology has been especially useful for managing chronic conditions and enabling rapid response to emergencies. One example is the development of [IoT-enabled devices by Philips Healthcare](https://www.usa.philips.com/healthcare/medical-specialties/healthcare-informatics/integrated-diagnostics). These devices monitor patients with chronic illnesses and send data to healthcare providers for remote analysis. That allows doctors to intervene quickly when needed, saving lives and reducing hospital readmissions. IoT in modern medicine goes beyond patient care. IoT-enabled medical devices also change how medical systems operate. They can automate inventory management, streamline workflows, and track equipment maintenance. That improves efficiency, reduces costs, and improves patient experience. A good example is the [smart infusion pumps produced by companies like Becton Dickinson and Company (BD)](https://www.bd.com/en-us/products-and-solutions/products/product-brands/alaris). These devices monitor medication administration to ensure accurate dosing and use IoT functions to help staff track and manage drug inventory. That helps prevent shortages and improves patient safety. ### The Future Possibilities of IoT in Healthcare As IoT keeps advancing, its healthcare use cases will grow. One promising area is telemedicine. Remote monitoring and personalized care can help close the gap between patients and providers, especially in rural or underserved areas. IoT can also support preventive healthcare. By continuously monitoring vital signs and collecting lifestyle data, IoT devices can help people make better health decisions and help clinicians spot early warning signs of potential problems. ### Risks and Challenges of IoT in Healthcare The benefits of IoT in healthcare are clear, but the rapid growth of connected devices also creates serious risks. These devices are attractive targets for cybercriminals looking to exploit weaknesses. A successful attack can compromise patient privacy, disrupt critical medical services, and put lives at risk. Recent incidents have exposed these weaknesses. I [n 2015, hackers gained access to a prominent hospital’s network](https://www.wired.com/2015/06/hackers-can-send-fatal-doses-hospital-drug-pumps/), taking control of its IoT-enabled drug infusion pumps. That incident made the need for stronger security impossible to ignore. Integrating IoT devices into existing healthcare systems is also difficult. Interoperability, data privacy, and regulatory compliance remain ongoing concerns that must be addressed if healthcare is going to get the full value from IoT. ## The Need for Security in IoT-Enabled Medical Devices Securing IoT-enabled medical devices is necessary to protect patient data, preserve the integrity of medical procedures, and keep care running. These devices need protection from unauthorized access, malware, and data breaches. They also need protection against physical tampering, because compromised functionality can have serious consequences. ![Section Image]() Securing these devices takes more than one control. It requires strong encryption, [secure communication protocols](/blog/securing-communication-protocols-in-medical-devices), strict access controls, continuous monitoring, and timely software updates to address new threats. ### The Vulnerability of IoT Medical Devices IoT medical devices are vulnerable for several reasons. First, many run outdated or unpatched software, which exposes known weaknesses. Manufacturers need to prioritize regular updates to reduce that risk. Second, the number of devices and the complexity of their interconnected networks create many entry points for attackers. Each device can become the weak link. One compromised device can have broad impact. Network segmentation and access controls are essential to reduce unauthorized access. For example, in 2017, the United States Food and Drug Administration (FDA) issued a cybersecurity alert concerning a specific type of implantable cardiac pacemaker due to cybersecurity vulnerabilities. If exploited, those vulnerabilities could let an attacker manipulate the device’s functionality and endanger the patient’s life. To address these risks, manufacturers and healthcare providers need to work closely with cybersecurity experts to identify threats, assess risk, and [implement effective security measures](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples). That helps ensure devices are designed with security in mind and that healthcare teams know how to reduce risk in practice. ### Potential Consequences of Unsecured Devices The consequences of unsecured IoT medical devices go beyond immediate patient safety risks. Data breaches can expose sensitive patient information and lead to identity theft and fraud. Unauthorized access to medical devices can disrupt critical healthcare services, delay treatment, and affect medical research. For instance, in 2019, a large-scale data breach affected Quest Diagnostics, a prominent medical laboratory company. The breach exposed the personal information of nearly 12 million patients, showing how large the impact can be on patients and healthcare organizations. It led to financial losses, damaged trust, and harmed the company’s reputation. Unsecured IoT medical devices can also become part of botnets, networks of compromised devices controlled by malicious actors. Those botnets can launch large-scale [distributed denial-of-service (DDoS) attacks](/blog), overwhelming critical healthcare infrastructure and disrupting essential services. Healthcare organizations need to reduce these risks with regular security audits, employee training, incident response plans, and continuous monitoring and updates. ## Essential Tips for Securing IoT-Enabled Medical Devices ### 1\. Establishing a Resilient Security Framework Healthcare organizations need security frameworks that cover all aspects of IoT device security. That includes access controls, network segmentation, regular vulnerability assessments, and incident response plans. These frameworks should align with industry best practices and regulatory requirements. Healthcare organizations can also consider advanced threat detection systems that use machine learning to identify and respond to threats in real time. These systems can analyze network traffic patterns, device behavior, and user activity to detect anomalies that may indicate a breach. ### 2\. Regular Software Updates and Patches Manufacturers need to build secure software and release updates quickly when vulnerabilities are found. Healthcare organizations need to make sure deployed devices receive those updates and patches on time. Regular updates fix newly discovered flaws and improve the overall security posture of IoT devices. One example of proactive updates is [Apple’s iOS](https://developer.apple.com/ios/), which powers the Apple Watch, among other devices. Apple regularly releases software updates, including security patches, to address emerging threats and keep devices resistant to cyberattacks. Healthcare organizations can also build partnerships with software vendors and device manufacturers to receive timely notice of security updates and patches. That helps providers stay aware of new vulnerabilities and respond quickly. ### 3\. Implementing Strong Authentication Measures Only authorized personnel should be able to access and interact with IoT medical devices. Strong [multi-factor authentication](/blog) measures, such as biometric verification and cryptography, should be used to prevent unauthorized access. Each user should have an individual account with unique credentials for accountability and tighter access control. Healthcare organizations can also use advanced [user behavior analytics (UBA)](/blog) systems. These systems analyze user activity patterns and detect suspicious behavior that may indicate a compromised account. Continuous monitoring helps identify threats and stop unauthorized access quickly. ### 4\. Ensuring Data Encryption Encrypting data at rest and in transit is essential to protect sensitive patient information from unauthorized disclosure and tampering. Strong encryption algorithms and protocols should be used to secure data generated, transmitted, and stored by IoT medical devices. That includes data stored on device memory, sent across networks, and exchanged with backend systems. Healthcare organizations can also use [data loss prevention (DLP)](/blog) systems. These systems monitor data flows and help prevent leaks or unauthorized access. With clear policies and rules for data use and access, DLP systems help providers maintain control over IoT-enabled medical device data. ### 5\. Conducting Regular Security Audits Healthcare organizations should [conduct regular security audits](/services) of their IoT medical devices to maintain security and catch new vulnerabilities. These audits should review device configurations, network infrastructure, and security controls to identify weaknesses. The results should drive security improvements and support compliance with relevant regulations and industry standards. Healthcare organizations can also establish bug bounty programs. These programs reward ethical hackers for finding and reporting vulnerabilities in IoT medical devices. That gives providers access to outside expertise and helps them address threats before attackers do. ## Future of IoT Security in Healthcare ### Emerging Trends in IoT Security Advances in artificial intelligence (AI) and machine learning (ML) are changing IoT security. These technologies can detect unusual behavior in IoT networks, identify threats, and respond in real time. AI-powered systems support proactive monitoring and better threat intelligence. [Blockchain technology](/blog) is also gaining traction as a secure and decentralized approach to IoT security. Healthcare organizations can use blockchain’s immutable and transparent structure to improve IoT data integrity, secure device communication, and strengthen access controls. For example, a blockchain-based healthcare network can verify medical devices’ authenticity and secure patient data exchange. ### The Role of AI and Machine Learning in IoT Security AI and ML algorithms are increasingly used to detect and mitigate cybersecurity threats in IoT devices. These algorithms can analyze large volumes of data in real time and identify patterns that suggest a security breach. That helps healthcare organizations detect and respond to threats faster, reduce the chance of successful attacks, and protect the integrity of IoT-enabled medical devices. ### Regulatory Measures for IoT Security in Healthcare Regulators are paying closer attention to IoT security in healthcare. Governments and industry groups around the world are issuing guidelines and standards for medical device security to protect patients and data. Compliance is becoming a baseline requirement for manufacturers and healthcare providers. The EU has taken a major step with the [Medical Device Regulation (MDR).](https://eumdr.com/) The MDR sets strict criteria for cybersecurity and data protection in medical devices, raising the security bar across the EU healthcare system. ## Control and the evidence a reviewer expects Implementing a control is half the job. The other half is producing something that shows it works. | Control | What implementation looks like | Evidence the FDA expects to see | | --- | --- | --- | | Authentication on every interface | Unique credentials, no shared service accounts, lockout behavior | Design documentation plus test results showing failed and successful paths | | Encryption in transit and at rest | TLS with current cipher suites, encrypted storage of sensitive data | Cryptographic inventory naming algorithms, key lengths, and key storage | | Signed firmware updates | Signature verification anchored in hardware where possible | Description of the root of trust and evidence that unsigned images are rejected | | Component inventory | A machine readable SBOM produced by the build | The SBOM itself plus your support and vulnerability handling process | | Logging and detection | Security relevant events exported to the customer environment | The event list and how customers are expected to consume it | | Secure default configuration | Debug interfaces disabled, no default passwords in production | Production configuration documentation and test evidence against the shipped image | A control described in prose and never tested is the single most common cause of a cybersecurity deficiency letter. ## Conclusion IoT devices bring real benefits to healthcare, but they also introduce real security risks. To secure IoT-enabled medical devices, healthcare organizations and manufacturers need to build strong security frameworks, keep software updated, use strong authentication, encrypt data, and run regular security audits. AI, ML, and blockchain may improve IoT security further. Regulations such as the MDR will also keep shaping how patient safety and data privacy are protected. Blue Goat Cyber provides B2B cybersecurity services focused on medical device security. The team handles penetration testing, HIPAA and FDA compliance, SOC 2 Penetration testing, and PCI penetration testing, among other services. [Contact us today for cybersecurity help](/contact). Check out our [full-service FDA cybersecurity submission package.](/) ## How Blue Goat approaches this Blue Goat Cyber applies a methodical approach to securing IoT devices, integrating security into every phase of the device lifecycle. Our method includes thorough threat modeling, risk assessments, and vulnerability testing specific to IoT medical devices. We help organizations meet regulatory expectations by aligning security measures with FDA guidance and industry standards. Our team, comprising certified professionals (CISSP, OSCP) with ex-military red team experience, delivers practical security solutions. We conduct penetration testing and design security architectures that address the unique challenges of connected medical technology. Learn more about our services, including [medical device penetration testing](/services/medical-device-penetration-testing), which helps uncover vulnerabilities before they can be exploited. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What are the primary risks of unsecured IoT medical devices? Unsecured IoT medical devices pose risks such as patient data breaches, disruption of critical medical services, and potential harm to patients through manipulated device functionality. They can also become part of botnets used for larger cyberattacks. ### How does the FDA address cybersecurity for medical devices? The FDA provides guidance, such as the February 3, 2026 final guidance, which outlines cybersecurity requirements for medical device manufacturers. This guidance emphasizes secure design, risk management, and postmarket activities to maintain device security. ### Why are regular software updates important for IoT medical devices? Regular software updates and patches are crucial because they address newly discovered vulnerabilities and security flaws. Prompt application of these updates helps protect devices from exploitation by cybercriminals and improves overall security. ### Can AI and machine learning improve IoT medical device security? Yes, AI and machine learning can significantly enhance IoT medical device security. They enable real-time threat detection by analyzing network traffic and user behavior, identifying anomalies that may indicate a security breach before it escalates. ### What is multi-factor authentication and why is it needed for medical devices? Multi-factor authentication requires users to provide two or more verification factors to gain access, such as a password and a fingerprint scan. It is essential for medical devices to prevent unauthorized access and protect sensitive patient information. ### How often should healthcare organizations audit IoT medical devices? Healthcare organizations should conduct regular and frequent security audits of their IoT medical devices. These audits help to identify configuration weaknesses, enforce compliance with security policies, and ensure controls remain effective against evolving threats. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Securing the Total Product Lifecycle](/blog/securing-the-total-product-lifecycle-protecting-medical-devices-from-concept-to-disposal) --- ## Cybersecurity for Faster FDA Clearance (2026) Source: https://bluegoatcyber.com/blog/securing-medical-devices-the-key-to-faster-fda-approval-and-investor-confidence # Cybersecurity for Faster FDA Approval: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Cybersecurity investment speeds FDA clearance when it starts at the beginning of device development rather than in the final weeks before submission, when teams often discover thousands of unaddressed vulnerabilities. Under the FDA's February 3, 2026 guidance, manufacturers should build threat modeling, secure coding, and penetration testing into every phase of the total product lifecycle. That reduces late-stage remediation, strengthens investor confidence, and helps devices gain acceptance on hospital networks. ## Key Takeaways - Integrate cybersecurity early in device development. - Avoid delays by prioritizing security from the start. - Proactive security streamlines FDA clearance. - Secure devices boost investor and provider confidence. - Cybersecurity provides a competitive market advantage. - Address security throughout the device lifecycle. ## Why this matters The stakes are high for medical device manufacturers. The timely integration of a security program directly impacts market entry, regulatory compliance, and patient safety. Under the FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, manufacturers are expected to address cybersecurity throughout the total product lifecycle. Neglecting security until late in development can lead to substantial delays and increased costs. Many manufacturers face thousands of vulnerabilities identified just weeks before their FDA submission, necessitating extensive, time-consuming remediation. This reactive approach impacts investor confidence, delays market access, and can strain relationships with healthcare providers increasingly concerned about network security. Proactive security, aligned with standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023, streamlines the regulatory process. By baking cybersecurity into the design, development, and testing phases, device manufacturers can demonstrate adherence to FDA guidelines and significantly accelerate their path to market. This not only avoids costly setbacks but also positions the manufacturer as a leader committed to patient trust and data integrity. ## The Importance of Proactive Cybersecurity in Medical Device Development In the world of medical technology, cybersecurity has become a critical concern for device manufacturers. As Christian Espinosa, the founder and CEO of Blue Goat Cyber, points out, many organizations wait until the last minute to address cybersecurity, leading to costly delays, frustrated investors, and potential risks to patient safety. However, by embracing a proactive approach to cybersecurity, medical device companies can meet FDA requirements more efficiently, position themselves as industry leaders, and gain a competitive edge. ## The Consequences of Neglecting Cybersecurity Espinosa’s experience with his own medical scare has given him a unique perspective on the importance of secure medical devices. After suffering from a life-threatening condition, he realized the critical role that technology played in his recovery. However, he also recognized the potential risks associated with vulnerabilities in medical devices, and the devastating impact they can have on patient outcomes. As Espinosa explains, many medical device manufacturers wait until the last minute, typically 60 days before their device is due for FDA clearance, to address cybersecurity concerns. This reactive approach often results in the discovery of thousands of vulnerabilities that must be fixed before the device can be cleared for use. The time and resources required to address these issues can lead to significant delays, frustrating both the manufacturer and their investors. The increasing scrutiny from healthcare organizations regarding the cybersecurity of medical devices has become a significant concern. Hospitals are now more vigilant than ever in evaluating the security measures implemented in the devices they allow on their networks. Manufacturers who can demonstrate that their devices were developed with a strong focus on cybersecurity will have a distinct advantage in gaining acceptance from these healthcare providers. ## The Benefits of Proactive Cybersecurity Espinosa advocates for a proactive approach to cybersecurity, where it is considered as a competitive advantage rather than a necessary evil. By integrating cybersecurity into the product development process from the very beginning, medical device manufacturers can avoid the costly and time-consuming delays that often plague those who wait until the last minute. Embracing proactive cybersecurity offers several key benefits: - **Faster FDA Clearance:** By addressing cybersecurity concerns early on, manufacturers can streamline the approval process and avoid the frustration of having to fix numerous vulnerabilities at the eleventh hour. - **Increased Investor Confidence:** Investors are often wary of companies that wait until the end to address cybersecurity, as it can lead to costly overruns and delays. By demonstrating a commitment to security, manufacturers can instill confidence in their investors and secure the necessary funding to bring their products to market. - **Competitive Advantage:** Manufacturers who prioritize cybersecurity can differentiate themselves from their competitors, positioning their devices as more secure and trustworthy in the eyes of healthcare providers and patients. - **Improved Patient Outcomes:** Secure medical devices not only protect against cyber threats, but also ensure that patients receive accurate diagnoses and effective treatments, ultimately improving their overall health and well-being. ## Implementing a Complete Cybersecurity Strategy Espinosa’s company, Blue Goat Cyber, offers a range of services to help medical device manufacturers implement a cybersecurity strategy. From secure product design to [pre-market submission support](/), Blue Goat Cyber can assist manufacturers in every step of the process, ensuring that their devices meet or exceed FDA requirements. One of the key services offered by Blue Goat Cyber is the ability to conduct thorough [penetration testing](/services/medical-device-penetration-testing) and vulnerability assessments. By identifying and addressing potential weaknesses in the device’s security, manufacturers can proactively mitigate risks and demonstrate their commitment to patient safety. Additionally, Blue Goat Cyber can provide support with the pre-market submission process, handling all the necessary deliverables, testing, analysis, and risk assessment required by the FDA. This approach allows manufacturers to focus on their core competencies while ensuring that their devices are approved in a timely and efficient manner. ## The Iterative Nature of Cybersecurity Espinosa emphasizes that cybersecurity is not a one-and-done process, but rather an iterative journey that must be considered throughout the entire product lifecycle. As technology evolves and new threats emerge, medical device manufacturers must remain vigilant and continuously update their security measures to protect their products and the patients who rely on them. By adopting this mindset, manufacturers can stay ahead of the curve, anticipating and addressing cybersecurity challenges before they become critical issues. This proactive approach not only enhances the security of the device, but also demonstrates to the FDA, healthcare providers, and investors that the manufacturer is committed to patient safety and the long-term reliability of their products. ## Conclusion: Embracing Cybersecurity as a Competitive Advantage In the landscape of medical technology, cybersecurity has become a crucial factor in the success and acceptance of medical devices. As Christian Espinosa has eloquently articulated, by embracing a proactive approach to cybersecurity, medical device manufacturers can not only meet FDA requirements more efficiently, but also position themselves as industry leaders and gain a distinct competitive advantage. By integrating cybersecurity into the product development process from the very beginning, manufacturers can avoid the costly and time-consuming delays that often plague those who wait until the last minute. This proactive approach not only instills confidence in investors, but also demonstrates to healthcare providers and patients that the manufacturer is committed to the security and reliability of their devices. As the medical industry continues to grapple with the growing threat of cyber attacks, the importance of secure medical devices cannot be overstated. By partnering with experts like Blue Goat Cyber, medical device manufacturers can develop a cybersecurity strategy that not only protects their products, but also sets them apart in the highly competitive market. Embracing cybersecurity as a competitive advantage is not only a smart business decision, but also a crucial step in ensuring the safety and well-being of patients worldwide. ## How Blue Goat approaches this Blue Goat Cyber’s approach focuses on embedding security from the initial concept phase of medical device development, aligning with the FDA's expectations for a Secure Product Development Framework (SPDF). Our team, comprised of experts with certifications like CISSP and OSCP, and ex-military red team experience, works alongside your engineers to identify and mitigate vulnerabilities before they become costly deficiencies. We provide essential services such as threat modeling, penetration testing, and security architecture reviews. Our commitment to your success: If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. This proactive partnership is designed to accelerate your path to market via efficient premarket cybersecurity services, minimize risks, and build stakeholder confidence. Learn more at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is proactive cybersecurity for medical devices? Proactive cybersecurity involves integrating security measures and considerations into the medical device development process from its initial stages. This approach ensures security is a foundational element, not an afterthought, helping to prevent vulnerabilities. ### How does proactive cybersecurity help FDA clearance? By addressing cybersecurity early, manufacturers can identify and mitigate vulnerabilities throughout the development cycle, significantly reducing issues prior to submission. This leads to a smoother review process and faster clearance from the FDA, avoiding late-stage remediation. ### Why is investor confidence improved with early cybersecurity? Investors view early cybersecurity integration as a risk mitigation strategy. It reduces the likelihood of costly delays, regulatory hurdles, and potential security breaches that could devalue the product or company, thus increasing their confidence in the investment. ### Does the FDA require cybersecurity for medical devices? Yes, the FDA requires medical device manufacturers to address cybersecurity. The February 3, 2026 final guidance outlines the agency's expectations for cybersecurity in premarket submissions, emphasizing a secure product development framework. ### What are the risks of neglecting medical device cybersecurity? Neglecting cybersecurity can lead to significant delays in FDA clearance, increased development costs due to late-stage vulnerability fixes, and potential patient safety risks. It can also damage a manufacturer's reputation and lead to reduced acceptance by healthcare organizations. ### How can manufacturers implement an effective cybersecurity strategy? Manufacturers should integrate cybersecurity into every phase of the device lifecycle, from design to post-market surveillance. This includes conducting threat modeling, risk assessments, penetration testing, and adhering to the FDA's cybersecurity guidance. --- ## Total Product Lifecycle Security for Devices Source: https://bluegoatcyber.com/blog/securing-the-total-product-lifecycle-protecting-medical-devices-from-concept-to-disposal # Total Product Lifecycle Security: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Total Product Lifecycle security means treating cybersecurity as a continuous requirement from concept through decommissioning, not just during development. It requires a Secure Product Development Framework covering secure coding, threat modeling, and vulnerability management, plus attention to often-overlooked risks like unencrypted hard drives left in decommissioned devices and weak keys in update channels. The FDA's February 3, 2026 guidance mandates SPDF as part of the quality system across the entire lifecycle. In the world of medical technology, the security of medical devices has become a critical concern. As devices become increasingly connected and data-driven, the potential for cyber threats to compromise patient safety and sensitive information has never been higher. To address this challenge, a holistic approach to security is essential - one that considers the entire lifecycle of a medical device, from the initial concept to its eventual decommissioning. This approach is known as the Total Product Lifecycle (TPLC) security, and it is a crucial component of the Secure Product Development Framework (SPDF). In this in-depth blog post, we’ll explore the importance of TPLC and SPDF, covers real-world case studies, and uncover best practices to ensure your medical devices are secure from start to finish. ## Key Takeaways - TPLC secures medical devices end-to-end. - SPDF integrates security into development. - Decommissioning risks require planning. - Update processes must be secure. - Threat modeling guides complete security. - FDA guidance mandates lifecycle security. ## Why this matters The stakes for inadequate medical device cybersecurity are high, impacting patient safety, data privacy, and regulatory standing. A single vulnerability can lead to device malfunction, data breaches, and severe patient harm. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly mandates that manufacturers implement a Secure Product Development Framework (SPDF) as part of their quality system, ensuring security considerations are addressed throughout the entire product lifecycle. This aligns with international standards such as IEC 81001-5-1 (Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product lifecycle) and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management), which provide guidance for managing security risks across the medical device lifecycle. Addressing cybersecurity from concept through disposal is not merely a compliance checkbox; it is a fundamental requirement to build trust, prevent operational disruptions, and protect vulnerable patients from evolving cyber threats. ## Understanding the Total Product Lifecycle (TPLC) and Secure Product Development Framework (SPDF) TPLC security encompasses the entire journey of a medical device, from its initial conception to its eventual decommissioning. This includes the design, development, manufacturing, deployment, maintenance, and disposal stages. The SPDF, on the other hand, is a more focused approach that specifically addresses the security considerations during the product development process. As Christian Espinosa, the CEO and founder of Blue Goat Cyber, explains, “The SPDF is part of the total product life cycle. It’s a framework that ensures you are managing security at every step of the way. You aren’t missing any big considerations. You’re designing it with security at the front of mind.” The SPDF is often synonymous with the Secure Software Development Lifecycle (SSDLC), which focuses on the cyclical process of making changes, reviewing them, implementing them, and testing them - all with security at the forefront. ## The Importance of Considering the Entire Product Lifecycle One of the key reasons why the TPLC is so crucial is that it helps address the often-overlooked security risks that can arise during the decommissioning and disposal stages of a medical device’s lifecycle. As the Blue Goat Cyber team explains: > “I know in the past I’ve worked with a medical device manufacturer that had the assumption, which is a true assumption, that the device would be in a secure room in a hospital. But what they did not consider is when the device is decommissioned and the hospital no longer wants it, what were they going to do with the device? And these devices did not have encrypted hard drives. So the hospitals were getting rid of these devices. People were able to purchase them off of eBay and other sources and grab all the PHI off the hard drive.” This scenario underscores the importance of considering the entire product lifecycle, encompassing both the decommissioning and disposal stages. Failing to do so can lead to the unintended release of sensitive patient data, putting individuals at risk of identity theft and other privacy breaches. The same issue has been observed in other industries as well. the team recounts a similar situation from his time working for the government, where classified printers were sold off without properly wiping the hard drives, potentially exposing sensitive information. ## Vulnerabilities in the Update Process Another critical aspect of the TPLC is the update process for medical devices. As devices become more connected and software-driven, the ability to push out updates and patches is essential for addressing vulnerabilities and maintaining security. However, this process can also introduce new risks if not adequately secured. Espinosa shares a real-world example of a client’s device that was highly secure in its core functionality, but had a vulnerability in the update process: > “What it was doing, it was taking in some information and then it was receiving updates. It was performing analysis on a local machine receiving updates from the cloud anytime there was a change and you can see you can capture that update process. It’s encrypted of course because it’s going over the open internet under HTTPS. You even look at the cipher suites. That’s a common problem. So what type of encryption are you using on that transfer? Everything was secure. And then we looked at the sort of the password for that transfer and it was pulled straight out of [Stack Overflow](https://stackoverflow.com/questions "") with a publicly disclosed vulnerability in the uh key itself for the encryption for the data transfer. So the encryption was secure, but the key was something that could be easily guessed and had been easily guessed before.” This example highlights the importance of considering the entire update process, from the security of the communication channels to the integrity of the update packages themselves. Even if the core device is highly secure, vulnerabilities in the update infrastructure can provide a backdoor for attackers to compromise the entire system. ## Threat Modeling and the Wider Development Environment Effective TPLC security also requires a thorough understanding of the broader development environment and potential threats. This is where [threat modeling](/services/medical-device-threat-modeling) comes into play, as it helps identify and mitigate risks throughout the product’s lifecycle. the team emphasizes the importance of looking beyond just the device itself and considering the broader systems and processes involved: > “Threat modeling covers that whole total product life cycle outside of just looking at the device. And you know, I’m sure we’ve talked about threat modeling a lot and we’ve talked about all the common pitfalls, but that’s a really big one with threat modeling is keeping the lens too narrow, focusing on the device instead of widening it and looking at the product and the systems involved.” This includes factors such as the security of the development environment, the integrity of the supply chain, and the potential risks posed by natural disasters or geopolitical events that could impact the availability and security of the device’s infrastructure. For example, the team mentions the importance of considering where the device’s data is hosted, as storing it in a region prone to natural disasters or political instability could compromise the device’s security and availability. ## Challenges in Implementing a Secure Product Development Framework Despite the clear importance of TPLC and SPDF, many medical device manufacturers struggle to implement these frameworks effectively. the Blue Goat Cyber team have encountered a range of challenges in their work with clients, including: - **Lack of Expertise and Resources:** Many startups and smaller medical device companies lack the expertise and resources to develop a [SPDF](/services/secure-medtech-product-design-consulting), as it requires specialized skills and a significant investment of time and money. - **Prioritizing Speed to Market:** With the pressure to get products to market quickly, security considerations can often take a backseat to other development priorities, especially for companies that are still establishing themselves. - **Outsourcing Development:** When medical device manufacturers outsource their software development to third-party contractors, they may lack complete visibility or control over the security practices being followed, which can lead to potential vulnerabilities. - **Resistance to Change:** Implementing a TPLC security approach can be a significant shift for many organizations, and there is often resistance to the additional time and cost required to do it properly. Espinosa estimates that only around 10% of their clients have a secure product development framework in place before engaging with Blue Goat Cyber. The remaining 90% often struggle to prioritize and implement these critical security measures. ## Building a Secure Product Development Framework that Works Despite the challenges, there are proven strategies and best practices that medical device manufacturers can adopt to build a SPDF and ensure the security of their products throughout the TPLC: - **Adhere to Secure Coding Standards:** Ensure that your engineering team follows well-established secure coding practices, such as the CERT Secure Coding Standards, to minimize the introduction of vulnerabilities. - **Implement Multi-Layer Verification:** Require multiple layers of review and approval before any code changes can be made, ensuring that mistakes or malicious actions are caught early in the process. - **Automate Security Testing:** Integrate automated security testing, including [static code analysis](/services/static-application-security-testing-sast) and [software bill of materials (SBOM) checks](/services), into your continuous integration and continuous deployment (CI/CD) pipeline to catch issues before they reach production. - **Secure the Development Environment:** Ensure that the development environment itself is secure, with measures such as multi-factor authentication, secure remote access, and strict access controls to prevent unauthorized access or tampering. - **Establish a Secure Update Process:** Carefully design the update process for your medical devices, ensuring that the communication channels are secure, the update packages are digitally signed, and the overall process is resilient to potential attacks. - **Plan for Decommissioning and Disposal:** Develop a plan for the secure decommissioning and disposal of your medical devices, including the proper sanitization of any sensitive data or components. Implementing these best practices requires a significant investment of time and resources, but as the Blue Goat Cyber team emphasize, it is a necessary step to ensure the long-term security and compliance of your medical devices. ## Conclusion: Embracing the Total Product Lifecycle Approach In the landscape of medical technology, the security of medical devices has become a critical concern. By embracing the Total Product Lifecycle (TPLC) security approach and the Secure Product Development Framework (SPDF), medical device manufacturers can ensure that their products are secure from concept to disposal. This approach requires a shift in mindset, as it goes beyond just securing the device itself and considers the wider systems, processes, and environments involved throughout the product’s lifecycle. By addressing vulnerabilities in the update process, conducting thorough threat modeling, and planning for secure decommissioning, medical device manufacturers can better protect their products and the sensitive data they handle. While implementing a TPLC and SPDF can be challenging, especially for startups and smaller companies, the long-term benefits in terms of patient safety, regulatory compliance, and brand reputation make it a critical investment. By partnering with cybersecurity experts like those at Blue Goat Cyber, medical device manufacturers can navigate these complexities and develop a security strategy that effectively safeguards their products from end to end. Remember, in the world of medical device security, the journey doesn’t end when the product is delivered - it’s a lifelong commitment to protecting patients, data, and your organization’s reputation. By embracing the Total Product Lifecycle approach, you can ensure that your medical devices remain secure throughout their entire lifecycle, from concept to disposal. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers integrate security into every phase of their device's Total Product Lifecycle (TPLC). Our approach focuses on embedding security early and continuously, from initial design to decommissioning. We assist with threat modeling to identify potential vulnerabilities, support the creation of a Secure Product Development Framework (SPDF), and ensure that security controls are properly implemented and validated. Our experts, including CISSP and OSCP certified professionals with ex-military red team experience, provide actionable guidance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We offer services like medical device penetration testing to validate your security posture, helping you meet regulatory requirements and protect patients. Learn more about our TPLC support here: [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is Total Product Lifecycle (TPLC) security? TPLC security for medical devices ensures security is considered from a device's inception, through its design, development, manufacturing, use, and eventual disposal. It's a continuous process to manage risks throughout the device's entire lifespan. ### How does the SPDF relate to TPLC security? The Secure Product Development Framework (SPDF) is a core component within TPLC security. It specifically focuses on integrating security practices and considerations into the product development phase, ensuring security is built into the device from the earliest stages. ### Why is secure decommissioning important for medical devices? Secure decommissioning is critical to prevent sensitive patient data from being exposed when a device is retired or disposed of. Failing to properly wipe data can lead to privacy breaches and regulatory violations. ### Does the FDA require TPLC security for medical devices? Yes, the FDA expects medical device manufacturers to implement cybersecurity measures across the total product lifecycle. The February 3, 2026 final guidance emphasizes the importance of managing cybersecurity risks throughout a device's entire existence. ### What are common challenges in implementing SPDF? Common challenges include a lack of specialized expertise, pressure to accelerate time to market, complexities with outsourced development, and organizational resistance to adopting new security-focused processes. ### How can manufacturers build an effective SPDF? Manufacturers can build an effective SPDF by adhering to secure coding standards, implementing multi-layer verification for code changes, automating security testing, securing the development environment, and planning for secure updates and decommissioning. --- ## Security Architecture Views: The FDA's Four Required Diagrams Source: https://bluegoatcyber.com/blog/security-architecture-diagrams-medical-device-cybersecurity # Security Architecture Views the FDA Expects in Submissions > **[DIRECT ANSWER]** The FDA's premarket cybersecurity guidance asks for security architecture views rather than a single system diagram, because each view answers a different question. The four are the global system view, the multi-patient harm view, the updateability and patchability view, and the security use case views. A submission that supplies one block diagram and labels it "architecture" has answered one question out of four. _Reviewed September 17, 2026_ Architecture views are one of the few submission elements where a reviewer can see, in a few seconds, whether the manufacturer understands their own attack surface. A diagram either shows trust boundaries and what crosses them, or it shows boxes connected by unlabeled lines. The second kind is common, and it generates questions. These views also do work for you internally. The scope of your penetration test, the completeness of your threat model, and the coherence of your risk file all depend on having an accurate picture of what connects to what. Drawing them properly once makes several later documents easier. ## Key Takeaways - Four distinct views are expected, each answering a different question. - A view is about trust boundaries and data flows, not about physical layout. - The multi-patient harm view is the one most often missing entirely. - Updateability must show how an update is authenticated, not just that updates happen. - Security use case views walk through specific interactions end to end. - Views must agree with the threat model, the testing scope, and the labeling. ## Why Four Views Instead of One Diagram The February 3, 2026 premarket cybersecurity guidance frames architecture documentation as a set of views because a single diagram cannot carry the information a reviewer needs. A picture that shows every component at once becomes unreadable, and a picture simplified enough to read leaves out the detail that matters. Separating the views also separates the questions. One asks what the system is and where its boundaries lie. One asks what happens when the failure is not confined to a single patient. One asks how the device changes after it is deployed. One asks how a specific security-relevant interaction actually works, step by step. Reviewers use these views as an index into the rest of the submission. When a threat model references an interface, the reviewer looks for it in the views. When a penetration test report covers a component, the reviewer checks whether the views show it. Inconsistency between them is one of the fastest ways to draw a deficiency question, because it suggests the documents were produced by different people who did not reconcile them. ## The Four Views and What Each Must Show | View | Question it answers | Must include | |---|---|---| | Global system | What is the whole system and where are its boundaries? | Every component, interface, external system, and trust boundary | | Multi-patient harm | What happens if this fails for more than one patient at once? | Shared infrastructure, fleet management paths, aggregation points | | Updateability and patchability | How does the device change after deployment? | Update origin, authentication, delivery, verification, rollback | | Security use cases | How does a specific security-relevant interaction work? | Step-by-step flow for authentication, pairing, update, or data transfer | The global system view is the one most manufacturers already have in some form, usually as an engineering block diagram. Converting it into a security view means adding what the engineering diagram leaves out: where trust changes, what protocol carries each connection, what authenticates at each hop, and which side of each boundary you control. The multi-patient harm view is the one most often absent. It exists because a compromise of a single device harms one patient, while a compromise of the cloud service that configures every device harms all of them. The view should identify every place where one action affects many patients: management APIs, configuration servers, shared credentials, drug libraries, model update pipelines, and hospital-side aggregation points. The updateability view has to show authentication, not just delivery. A diagram with an arrow labeled "firmware update" tells a reviewer nothing. The view should show where the update originates, how it is signed, where the verification key lives, what verifies the signature before installation, what happens if verification fails, and whether the device can roll back. Security use case views are narrative diagrams for individual interactions. Pick the interactions that carry security weight, typically initial pairing, user authentication, firmware update, remote access, and data export, and show each one as a sequence with what is exchanged at each step. **[KEY REQUIREMENT]** Every boundary in every view should be labeled with what crosses it, what protects it, and what authenticates at it. An unlabeled arrow is an unanswered question. ## Mistakes That Draw Deficiency Questions | Mistake | Why it is a problem | Fix | |---|---|---| | Reusing the marketing system diagram | Shows product features, not trust boundaries | Redraw with boundaries and protocols labeled | | Only one view provided | Three of the four questions are unanswered | Produce all four, even if some are short | | Cloud drawn as a single cloud icon | Hides the highest-value multi-patient target | Break out services, APIs, data stores, and access paths | | No trust boundaries marked | Reviewer cannot see where trust changes | Draw and label every boundary explicitly | | Update path shown as one arrow | Signature verification is invisible | Show signing, verification, failure handling, and rollback | | Views contradict the threat model | Suggests documents were not reconciled | Cross-check interface by interface before filing | | Third-party components omitted | Supply chain risk appears unconsidered | Show them and mark which are yours to control | The cloud icon problem is worth dwelling on. For a connected device, the back end usually holds the capability with the broadest reach: it can push configuration, deliver firmware, and read data from the whole fleet. Compressing all of that into one icon removes precisely the detail the multi-patient harm view exists to expose. ## Keeping the Views Consistent With Everything Else Views are cross-referenced, so consistency is a submission-level property rather than a diagram-level one. A short reconciliation pass before filing catches most of what reviewers would otherwise find. | Check | What to compare | |---|---| | Views against the threat model | Every interface in the views has threats; every threat names an interface in the views | | Views against the test scope | Every interface is tested or explicitly excluded with a rationale | | Views against the SBOM | Third-party components shown in the views appear in the SBOM | | Views against labeling | Environmental assumptions in the views appear in customer-facing documentation | | Views against the risk file | Multi-patient paths appear in the ISO 14971 analysis with appropriate severity | That last row is the one with the most leverage. If the multi-patient harm view identifies a cloud path that can affect every deployed device, the risk file should rate the harm accordingly. When the two documents disagree about how bad something is, the submission tells two different stories. ## Practical Advice on Drawing Them Use whatever tool your team already uses. The FDA does not prescribe a notation, and a clear diagram in a common format beats a formal notation nobody on your team can maintain. What matters is legibility at submission resolution, consistent labeling, and a legend that explains your symbols. Keep the views under version control alongside the design documentation, because they will change and a stale view is worse than a simple one. When an interface is added late in development, the views are the first thing that should be updated, since everything downstream references them. Finally, write a short paragraph alongside each view explaining what it shows and what conclusions to draw. A reviewer who has to interpret a diagram unaided may interpret it differently than you intended. ## How Blue Goat Cyber Approaches This We build architecture views as the foundation of the submission rather than as an illustration added at the end, because the views determine what the threat model must cover and what the testing must include. That means working from your actual interfaces, marking trust boundaries you may not have drawn before, and making the multi-patient paths visible. Our [threat modeling](/services/threat-modeling) engagements produce all four views alongside the threat analysis, and our [medical device penetration testing](/services/medical-device-penetration-testing) scopes directly from them so the two documents agree. ## Frequently Asked Questions ### What are the FDA's security architecture views? They are the architecture documentation the premarket cybersecurity guidance expects: a global system view showing the whole system and its boundaries, a multi-patient harm view showing where one failure affects many patients, an updateability and patchability view showing how the device changes after deployment, and security use case views showing specific security-relevant interactions step by step. ### Can we submit one diagram instead of four views? You can submit whatever you like, but a single diagram answers one of the four questions the views exist to answer. Reviewers use the views to cross-check the threat model, testing scope, and risk file, and a submission that provides only a general system diagram commonly receives a request for the missing views. ### What is the multi-patient harm view for? It identifies the paths through which a single compromise can affect more than one patient, such as cloud management APIs, configuration servers, firmware distribution, shared credentials, and hospital-side aggregation. It exists because the severity of a multi-patient event is categorically different from a single-device event, and the risk file should reflect that difference. ### Does the FDA require a specific diagram format? No. The guidance describes what the views must communicate, not which notation to use. Clarity matters more than formality: label every boundary and connection, include a legend, keep the diagrams readable at submission resolution, and add a short explanation of what each view shows. ### How detailed should the updateability view be? Detailed enough to show how an update is authenticated. That means the origin of the update, the signing process, where the verification key resides, what performs verification before installation, what happens when verification fails, and whether rollback is possible. An arrow labeled "OTA update" does not answer any of those questions. ### How often should the views be updated? Whenever an interface changes. The views sit upstream of the threat model, the test scope, and the labeling, so a stale view propagates errors into all three. Keeping them under version control with the design documentation is the practical way to avoid filing a submission whose diagrams describe an earlier revision of the device. ## Need Views a Reviewer Can Follow? We can turn your engineering diagrams into the four views the FDA expects, with trust boundaries labeled and the multi-patient paths made visible. [Book a strategy session](/contact). --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## Security Requirements Testing vs Penetration Testing Source: https://bluegoatcyber.com/blog/security-requirements-testing-vs-penetration-testing # Security Requirements Testing vs Penetration Testing > **[DIRECT ANSWER]** Security requirements testing is documented evidence that each security design input requirement was implemented successfully, including boundary analysis and the rationale behind the boundary assumptions. It is verification inside your own quality system, so the manufacturer owns it. Penetration testing is adversarial validation of the built device by independent testers who never see those design inputs. The FDA's February 3, 2026 final guidance expects both as separate evidence, and one never substitutes for the other. _Published September 4, 2026_ Teams routinely treat "security testing" as a single line item on the submission plan, commission a penetration test, and file that report everywhere testing evidence is requested. The February 3, 2026 final premarket cybersecurity guidance does not accept that. It expects separate evidence streams, and the first of them is one no outside firm can produce for you. ## Why this matters Section 524B(b)(2) of the FD&C Act requires processes that provide a reasonable assurance the device is cybersecure, and the FDA's February 3, 2026 final guidance, _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_, is the interpretation reviewers apply. It treats security testing as quality system output produced inside a Secure Product Development Framework, not as an external assessment bolted on before filing. That distinction has teeth. Testing evidence is expected to trace to design inputs under design controls, now ISO 13485 clause 7.3 as incorporated into 21 CFR Part 820 by the QMSR. A submission holding only an outside report gives the reviewer an assessment with no anchor in the design history file, and the deficiency writes itself: show the requirements, show they were implemented, show how the boundaries were tested and why those boundaries are right. ## The two activities answer different questions Security requirements testing asks: **did we build what we specified?** It is verification. You wrote security requirements as design inputs. You built the device. Now you demonstrate, requirement by requirement, that the built device implements each one as specified, with test cases written against pass criteria defined in advance and results traceable to requirement identifiers. Penetration testing asks: **what can someone do to what we built?** It is validation, and it is deliberately not bounded by your requirements. The best findings from a penetration test are the ones no requirement ever contemplated: a chained path combining two individually acceptable behaviors, an undocumented debug interface, a maintenance credential in the field image. Requirements verification cannot surface those, because it only proves the specified thing works. | | Security requirements testing | Penetration testing | | --- | --- | --- | | Type | Verification | Validation | | Driven by | Design inputs and the traceability matrix | Threat model and adversary behavior | | Scope | Everything specified | Everything reachable, specified or not | | Independence | Internal, under design controls | Testers organizationally separate from the design team | | Output | Verification records per requirement | Findings report with scope, duration, methods, results | | Owner | The manufacturer | An independent testing partner | ## Boundary analysis is the part reviewers read The guidance does not just ask whether the requirement passed. It asks for boundary analysis and, critically, for **the rationale behind the boundary assumptions used**. Every security requirement carries implicit limits. A session timeout has a minimum and a maximum. A rate limit has a threshold separating normal clinical use from abuse. An input handler has a maximum legitimate payload size. Requirements testing exercises values at the boundary, one step inside, one step outside, and at the invalid extremes. The rationale is a claim about your device's intended use, not about your code. This is the longest a clinician can be away from the console mid-procedure, so this is the timeout. This is the largest legitimate message the hospital system sends this interface, so this is the size ceiling. A reviewer reading that rationale is checking whether the boundaries came from the clinical workflow and the threat model, or from the framework defaults. Defaults draw questions. ## Why requirements testing cannot be outsourced There is a structural reason a security firm cannot sign this deliverable. Security requirements testing verifies the device against your design inputs, held in your quality system, under your design controls. An external tester has no visibility into any of that. They do not hold your requirement identifiers, your traceability matrix, your design history file, or the clinical justification behind your boundary assumptions. Being handed a requirements document is not the same as attesting that the design inputs were correct, complete, and correctly implemented under a quality system you do not operate. The honest division: - **You own** the security requirements, the traceability matrix, the boundary assumptions and their rationale, the verification protocols, and the signed verification records. - **A testing partner owns** its own scope, methodology, independence statement, and results. It can build harnesses and execute tests against nominated boundaries, feeding results into your records. - **Nobody outside your quality system** should attest that your design inputs were satisfied. An attestation like that will not survive the first reviewer question about where the requirements came from. That is the point of the deliverable. The FDA wants evidence that security was engineered into design controls, not inspected in at the end. ## The two categories in the middle Requirements testing and penetration testing are the ends of the spectrum. The guidance names two more categories between them. **Threat mitigation testing** proves that each risk control identified in the threat model is effective on the built device. Not "the requirement was implemented," and not "an adversary tried everything," but: this control was meant to mitigate this threat, and here is the evidence that it does. **Vulnerability testing** covers SAST, DAST, software composition analysis against the SBOM, protocol fuzzing, and scanning. These find defect patterns and known weaknesses. None of them knows what your requirements say, so none can stand in for requirements testing. The chain reviewers trace runs threat, to risk control, to design input requirement, to verification evidence, to mitigation effectiveness evidence, to adversarial validation. A break anywhere is a deficiency. ## The deficiency pattern The recurring version looks like this. The submission contains one well-produced penetration test report. The cybersecurity testing attachment points to it for everything. The Additional Information request comes back asking for security requirements verification with boundary analysis, and for evidence that the risk controls in the threat model were tested for effectiveness. Now the team is generating design-controlled verification records under review-clock pressure, which is the worst possible time to be writing boundary rationale. The fix is structural, not last-minute. Separate the four categories in your testing summary, name them explicitly, and point to where each one is filed. Reviewers who cannot find something record it as missing. ## How Blue Goat approaches this We scope third-party work to what a third party can legitimately attest to: penetration testing, vulnerability testing, protocol fuzzing, and control-effectiveness testing, each signed with our own scope, methodology, independence statement, and results. Security requirements testing stays with the manufacturer, because it verifies design inputs inside a quality system we do not operate. Where teams want support, we work upstream: checking that the requirements set covers the threat model, pressure-testing boundary assumptions against the clinical workflow, and building harnesses your engineering team executes and records under its own design controls. ## FAQ ### Can a penetration test report satisfy the security requirements testing expectation? No. A penetration test evaluates the built device against adversary behavior. Security requirements testing verifies the device against documented design inputs, requirement by requirement, with boundary analysis. Reviewers look for requirement identifiers and a traceability matrix, and a penetration test report contains neither. Filing one against both expectations is a common deficiency trigger. ### Who signs the requirements testing records? Whoever your quality system designates for design verification records, typically engineering with quality assurance approval. External partners sign only their own scope and results. No third party should attest that your design inputs were satisfied, because no third party operates the quality system those inputs live in. ### What counts as boundary analysis? Testing at, inside, and outside each requirement's limits: minimum and maximum values, thresholds, timeouts, key lengths, input sizes, rate limits. The guidance also expects the rationale for those boundary assumptions, grounded in intended use and the threat model rather than in framework defaults. ### Do SAST and DAST cover requirements testing? No. Both are vulnerability testing. They find defect patterns and runtime weaknesses without any knowledge of what your requirements specify, so neither can demonstrate that a given requirement was implemented as written. They are complementary evidence in a different category. ### What happens if a requirement fails verification? Fix it and retest, or document it as an accepted residual risk justified against the security risk assessment. Omitting it is the one option that does not work. A requirement sitting in the traceability matrix with no corresponding result reads as unresolved, which is worse than a documented and justified gap. ## CTA Not sure whether your testing evidence covers all four categories the guidance expects? [Book a submission review](/contact) and we will map what you have against what reviewers look for. Full detail lives in the [security requirements testing guide](/guides/fda-security-requirements-testing-guide). --- ## SPDF Cybersecurity Documentation Source: https://bluegoatcyber.com/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect # SPDF Cybersecurity Documentation: What FDA Reviewers Expect > **[DIRECT ANSWER]** Reviewers read the Secure Product Development Framework section as proof that security was engineered in, not documented afterward. They expect design inputs that name specific security requirements, a threat model that generated those requirements, verification records that close each one, a change-control process covering security-relevant updates, and evidence the framework runs inside your quality system. A generic policy PDF with no device-specific artifacts is the most common reason this section fails. Device teams consistently make the same mistake with SPDF (Secure Product Development Framework) cybersecurity documentation: they treat it as a paperwork exercise and assemble artifacts at the end of development instead of generating them as engineering work happens. The result is a submission that looks complete on the surface but falls apart under FDA review because the documents don’t connect to each other. A threat model that doesn’t trace to test results, an SBOM that can’t be read by a machine, a postmarket plan with no patching timeline, these aren’t rare edge cases. They’re the pattern Blue Goat Cyber sees across submissions that come back with deficiency letters. Blue Goat Cyber has worked through hundreds of FDA submissions, and one finding holds consistently. FDA reviewers often cite lack of traceability rather than single missing artifacts. Deficiency letters come from documents that exist in isolation, never wired together into a coherent story that a reviewer can follow from risk identification through mitigation, testing, and ongoing management. The FDA isn’t looking for a folder of files; it’s looking for evidence that cybersecurity is genuinely built into your product, a standard rooted in the agency’s own framing of cybersecurity as a safety issue. This article maps every SPDF cybersecurity documentation artifact the FDA expects, shows where each one belongs inside the eSTAR template, identifies the deficiencies reviewers flag most often, and outlines a workflow for keeping documentation current after clearance. ## Key Takeaways - Traceability is critical: link risks to mitigations and test results. - Embed SPDF processes within your Quality Management System. - Provide a machine-readable SBOM with all NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026). - Use design decisions to generate live threat models and risk assessment. - Conduct security testing as part of development, not after. - Ensure postmarket plans specify patching timelines and incident response. ## Why this matters Disconnected cybersecurity documentation isn't merely a paperwork error; it reflects a fundamental gap in a medical device’s security posture that can lead to significant delays in FDA clearance, market access, and ultimately, patient safety risks. The FDA's February 3, 2026, 'Cybersecurity in Medical Devices' Final Guidance explicitly frames cybersecurity as a safety issue, demanding rigorous documentation proving security is 'designed-in' from concept through postmarket. Without clear traceability from identified threats to implemented controls and verified testing, manufacturers fail to demonstrate due diligence against evolving cyber threats, which can exploit vulnerabilities and compromise device function or patient data. Reviews frequently cite a lack of integrated thought, where threat models don't align with risk assessments, and test results fail to validate specific controls. These issues directly contradict the principles laid out in standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023, which emphasize iterative risk management and lifecycle integration. Device manufacturers risk deficiency letters, product recalls, or even adverse event reporting if security isn't demonstrably continuous. ## What the Secure Product Development Framework actually demands from documentation The FDA organizes SPDF evidence into four buckets: Security Risk Management, Security Architecture, Cybersecurity Testing, and Cybersecurity Transparency and Postmarket Management. These aren’t just organizational labels for filing purposes. They tell reviewers a coherent story about how cybersecurity is integrated across the total product lifecycle, from initial design decisions through years of postmarket operation. The critical requirement is traceability. Every identified risk must link to a mitigation control. Every mitigation must link to a test result. Every test result must link to an ongoing management commitment. When that chain breaks anywhere, reviewers stop and issue an additional information request. The four-bucket structure is the framework you use to verify the chain is intact before you submit. The FDA also expects SPDF processes to be embedded in your Quality Management System, not maintained as a separate cybersecurity silo sitting outside the QMS. Under the Quality Management System Regulation aligned with 21 CFR Part 820, cybersecurity documentation must appear in design history files, SOPs, and quality manuals. Submissions that treat cybersecurity as a standalone deliverable rather than a QMS-integrated process flag immediately. Missing QMS integration evidence is one of the earliest red flags a reviewer encounters. ## The complete SPDF cybersecurity documentation artifacts FDA reviewers look for The Security Risk Management bucket requires a threat modeling analysis that includes attack surfaces, threat actors, risk scenarios, data flow diagrams, and full system context. The DFDs need to show security boundaries between components, trusted and untrusted networks, and external entities like cloud services. A threat model without complete DFDs is one of the most common triggers for additional information requests. The cybersecurity risk assessment and management plan must integrate patient safety risks and cover third-party and off-the-shelf components, not just internally developed software. The Security Architecture bucket requires documentation of design decisions, architecture views, data flows, security boundaries, and control rationale. Security requirements must be traceable to specific identified threats and specific design controls, not written as general security objectives. Reviewers look for the direct line from a threat scenario to the engineering decision that addresses it. The Cybersecurity Testing bucket requires a specific set of interconnected deliverables: - Test plans linked to security requirements and the threat model - Vulnerability testing results with disposition and remediation tracking - Penetration testing reports including retest evidence after fixes are applied - Software testing evidence covering SAST, DAST, fuzzing, and code review results The Cybersecurity Transparency bucket is where many teams underinvest. **The SBOM must be machine-readable in SPDX or CycloneDX format and include the seven SBOM minimum elements** for every component, as set by CISA's 2026 Minimum Elements, published July 29, 2026, which replaced the 2021 NTIA list: supplier name, component name, version, unique identifier, dependency relationship, SBOM author, and timestamp. A Word document listing components does not satisfy the SBOM obligation in Section 524B(b)(1) of the FD&C Act. The vulnerability monitoring and management plan must specify patching timelines and coordinated disclosure procedures with documented channels and CVSS scoring. The postmarket cybersecurity plan must cover updates, incident response, and lifecycle monitoring. User security information must appear in device labeling. ## Mapping SPDF artifacts to your eSTAR submission The eSTAR cybersecurity section became mandatory for 510(k) submissions on October 1, 2023, and for De Novo submissions on October 1, 2025. The template uses color-coding to flag incomplete sections: reviewers see the same gaps you see when you open the file. Unresolved red fields translate directly into additional information requests, which means a pre-submission review of your eSTAR file is not optional. The FDA’s premarket cybersecurity guidance further details these expectations: [FDA premarket cybersecurity guidance](https://www.fda.gov/media/119933/download). For a practical checklist aligned to 524B and eSTAR, refer to our [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance). The Security Risk Management Report and threat model go into the Threat/Risk Management section. The SBOM and vulnerability management plan attach in the Cybersecurity section. Open anomalies and residual risk documentation feed the Risk Analysis section. For each artifact you attach, the document title in eSTAR must match the title in the document itself exactly, reviewers cross-reference them by name, and inconsistent naming creates unnecessary confusion that invites follow-up questions. **Build a traceability matrix that links every identified risk to a mitigation control, a test result, and a postmarket monitoring commitment.** This matrix is the single most useful tool for catching broken chains before submission. Reuse validated artifacts across sections rather than creating duplicate documents that can drift out of sync as the project evolves. A threat model that appears in two places with slightly different content raises questions you don’t want to answer under reviewer scrutiny. For an in-depth checklist of required artifacts and where they belong, see our [SPDF and FDA Cybersecurity Requirements](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect). Before you submit, run an internal mock review focused specifically on SBOM completeness and threat-to-control mappings. Assign someone outside the core documentation team to conduct it, the gaps invisible to the team building the artifacts are obvious to someone reviewing them with fresh eyes. ### eSTAR naming conventions Use a consistent filename convention that mirrors eSTAR section labels. For example: _CYB-ThreatModel-v1.2.pdf_, _CYB-SBOM-v2.0.spdx_, _CYB-PenTest-Report-v1.0.pdf_. When the document title, the filename, and the eSTAR attachment label all match, reviewers can cross-reference without ambiguity. Inconsistencies, even minor ones, slow the review and can generate information requests that have nothing to do with the substance of your cybersecurity program. ## Artifact, Reviewer Question, Usual Gap | Artifact | What the reviewer is checking | Where teams fall short | |---|---|---| | Threat model | Derived from this device's architecture | Reused from a template or an earlier product | | Security risk assessment | Threats traced to patient harm | Scored on CVSS alone with no clinical link | | Architecture views | Trust boundaries labeled | One block diagram standing in for four views | | SBOM | Machine readable and complete | Missing the radio stack or the operating system | | Testing evidence | Scope matches the attack surface | Application tested, radio and hardware skipped | | Vulnerability management plan | Timelines and a disclosure path | Generic policy with no named process owner | | Labeling | Security assumptions stated for the customer | Assumptions left implicit | | Update capability | Signing, verification, and rollback described | A single arrow labeled update | ## Common SPDF documentation deficiencies that delay clearance Incomplete SPDF-QMS integration is the most persistent problem. It shows up as cybersecurity documentation that exists entirely outside the design history file. FDA reviewers check for evidence that cybersecurity processes are embedded in design controls and lifecycle documentation from the start. When the design history file doesn’t reference cybersecurity activities, the submission signals that security was added after development rather than built in. Superficial threat models follow closely. Missing data flow diagrams, no end-to-end connection analysis, and no treatment of known vulnerabilities as design hazards all generate deficiency findings. Because the threat model is the foundation document for the entire SPDF submission package, a thin one undermines every downstream artifact built from it. Non-compliant SBOMs generate deficiencies at a high rate because the SBOM minimum element requirement is specific and unambiguous. Absent elements, outdated component lists, and non-machine-readable formats all fall short of Section 524B(b)(1). Per FDA communications on FD&C Act Section 524B implementation, since October 1, 2023, incomplete SBOMs can trigger refuse-to-accept notifications, pushing the entire submission back before it reaches substantive review. Testing documentation that isn’t traced to risk mitigations is a surprisingly common problem. A penetration testing report sitting in a submission without explicit connection to the specific risk mitigations it validates provides limited value to a reviewer. **Every test result needs a clear path back to the risk it addresses and forward to the postmarket management commitment that maintains the control.** Finally, weak postmarket plans consistently draw findings. A plan with no defined patching schedule, no coordinated disclosure process, and no incident response criteria fails the requirement. The FDA’s expectation is that critical vulnerabilities get addressed as soon as possible, with documented plans and justifications. Describing intentions without specifying processes and timelines doesn’t satisfy the standard. ## Building your SPDF documentation package with a phased workflow The design and architecture phase is when you produce the threat model, risk assessment, security requirements, and security architecture documentation. These must be live working documents, not post-hoc reconstructions written after the design is already finalized. Documentation written to describe decisions already made is harder to keep accurate and harder to defend when a reviewer asks how specific design choices were informed by specific threat scenarios. The implementation and verification phase generates test plans, SAST and DAST results, penetration testing reports, and traceability matrices as direct outputs of development activities. The testing evidence should be a byproduct of engineering work, not a separate effort launched after development closes. When testing is integrated into the development cycle, the documentation captures actual results rather than retrospective summaries. The release and maintenance phase finalizes the SBOM, completes the vulnerability management plan, and locks the postmarket cybersecurity plan before submission. Use Word or searchable PDF formats aligned to eSTAR terminology and match document titles exactly to what the submission template references. Standardize templates across submissions so reviewers encounter a consistent documentation structure. Familiarity with your format builds reviewer confidence and reduces questions about organizational decisions unrelated to the substance of the submission. Store all SPDF cybersecurity documentation artifacts in a shared system with version control tied to design history file milestones, consistent with FDA QMS guidance under 21 CFR Part 820 and IEC 81001-5-1. Integrate document generation into phase gate reviews so documentation status is visible at every development checkpoint, not just at submission time. ## Maintaining SPDF documentation after market clearance Clearance is not the end of the SPDF documentation obligation. Threat models, SBOMs, security architecture views, and vulnerability management plans must be version-controlled to reflect new attack vectors, software updates, and emerging threats throughout the device’s commercial life. For Class III devices and 510(k) changes, all cybersecurity modifications must be documented annually, even those not formally reported to the FDA. Every versioning event must trace back to the original design history file and forward to updated QMS records. Active vulnerability monitoring requires tracking CISA’s Known Exploited Vulnerabilities Catalog, ICS-CERT advisories, and [H-ISAC](https://health-isac.org/ "") threat feeds. Regular patches should deploy on a justified schedule. Critical vulnerabilities require out-of-cycle patches addressed as soon as possible, with documentation supporting the timeline decision. Maintain a formal coordinated vulnerability disclosure process with documented channels, CVSS scoring, and communication timelines for external researchers. The process needs to be written down, not improvised when a researcher makes contact. Report cybersecurity incidents under MDR rules and 21 CFR Part 806 when they contribute to death, serious injury, or device malfunction with safety implications. Routine patches applied before harm occurs are generally exempt, but the threshold analysis must be documented. The postmarket phase is where many manufacturers lose the documentation discipline they applied during premarket development, and FDA inspections under Compliance Program 7382.850 are designed to surface exactly that gap. ## Get the SPDF cybersecurity documentation right the first time SPDF cybersecurity documentation isn’t paperwork. It’s structured evidence that proves cybersecurity is built into your product and maintained throughout its lifecycle. A submission with complete, traceable, interconnected artifacts tells a reviewer a coherent story. A submission with disconnected documents signals gaps in the program, not just the paperwork. The actionable path is clear: organize artifacts into the four FDA buckets, map them to eSTAR using consistent IDs and traceability matrices, address the common deficiency patterns before submission, and maintain version-controlled documentation through the product’s full lifecycle. None of those steps are optional, and none are quick if you start them at the end of development. If you’d rather not learn through rejection, Blue Goat Cyber builds this documentation as part of your submission package. The team has guided hundreds of FDA submissions, responded to cybersecurity deficiency letters, and developed the templates, workflows, and traceability practices described in this article. Schedule a no-cost [Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session "") with us today. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat approaches this Blue Goat Cyber's methodology prioritizes the integration of cybersecurity into your device's design and Quality Management System (QMS) from the outset. We don't just generate documents; we help you create a **living security posture** that evolves with your product. Our consultants, including CISSP and OSCP certified engineers and ex-military red team personnel, work with your engineering teams to embed security activities like threat modeling and security testing directly into your development sprints. This continuous approach ensures documentation, such as machine-readable SBOMs and traceability matrices, is generated as a byproduct of development, not an afterthought. We validate every control and verify every mitigation, ensuring that your submission tells a coherent, traceable story to the FDA. Our goal is to achieve 'submission-ready' documentation long before your deadline. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our approach to premarket support: [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services) ## FAQ ### What is SPDF cybersecurity documentation? SPDF cybersecurity documentation provides evidence that a medical device manufacturer has followed a Secure Product Development Framework. It demonstrates how cybersecurity is incorporated throughout the device's entire lifecycle, from design to postmarket management. ### Why is traceability important in FDA cybersecurity submissions? Traceability is crucial because it allows the FDA to verify that all identified cybersecurity risks have corresponding mitigation controls, that these controls have been tested, and that there are plans for ongoing postmarket management. Broken traceability chains lead to deficiency letters. ### Does the FDA require SBOMs to be machine-readable? Yes, the FDA explicitly requires SBOMs to be machine-readable, ideally in SPDX or CycloneDX format, and include all seven SBOM minimum elements from CISA's 2026 list. Non-machine-readable SBOMs or those lacking elements can lead to submission rejection. ### How does the FDA evaluate QMS integration of cybersecurity? The FDA expects cybersecurity processes to be embedded within the manufacturer's Quality Management System, not treated as a separate silo. Reviewers look for evidence in design history files, SOPs, and quality manuals to ensure cybersecurity is integral to design controls and lifecycle documentation. ### What are common deficiencies in SPDF documentation? Common deficiencies include incomplete QMS integration, superficial threat models lacking detailed data flow diagrams, non-compliant machine-readable SBOMs, testing documentation not traced to risk mitigations, and weak postmarket plans without specific patching schedules or incident response criteria. ### When is the eSTAR cybersecurity section mandatory for submissions? The eSTAR cybersecurity section became mandatory for 510(k) submissions on October 1, 2023, and will become mandatory for De Novo submissions on October 1, 2025. Unresolved sections in eSTAR can lead to additional information requests. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## Related SPDF reading - **Pillar guide:** [Medical Device Cybersecurity SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [CI/CD Security Gates for Medical Devices: SPDF in Practice](/blog/cicd-security-gates-medical-devices-spdf) - [SPDF and IEC 62304 Mapping for Medical Device Cybersecurity](/blog/spdf-iec-62304-mapping-medical-device-cybersecurity) - [SPDF vs SSDLC: What Medtech Teams Get Wrong](/blog/spdf-vs-ssdlc-medical-device-cybersecurity) - [SPDF vs TPLC in Medical Device Cybersecurity](/blog/spdf-vs-tplc-in-medical-device-cybersecurity) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## SPDF and IEC 62304 Mapping: FDA Cyber Source: https://bluegoatcyber.com/blog/spdf-iec-62304-mapping-medical-device-cybersecurity # How SPDF Maps to IEC 62304 for FDA Cybersecurity > **[DIRECT ANSWER]** SPDF activities map directly onto IEC 62304's software lifecycle processes: planning, requirements, architecture, detailed design, implementation, integration testing, system testing, release, maintenance, risk management, configuration management, and problem resolution each get a corresponding SPDF artifact, such as threat models, SBOMs, or postmarket monitoring plans. The FDA expects these to trace bidirectionally within one design history file, since IEC 62304 alone leaves gaps in threat modeling, SBOM, and coordinated vulnerability disclosure. Reviewers at the FDA do not treat your SPDF and your IEC 62304 file as separate documents. They expect to open one design history file and trace a single security requirement from the planning record, through architecture and threat model, into code and unit tests, and out to a postmarket monitoring plan. When that trace breaks, you get an Additional Information letter and an 8 to 12 week clearance delay. This post is the crosswalk. It walks IEC 62304 process by process, shows the SPDF activity that belongs in each one, and flags the three places where 62304 alone is not enough to satisfy the [February 3, 2026 premarket cybersecurity guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) or Section 524B. ## Key Takeaways - IEC 62304 defines software lifecycle processes; SPDF adds the cybersecurity layer that reviewers expect inside each one. - The mapping is concrete: every 62304 clause has a named SPDF artifact that should live in the same design history file. - IEC 62304 is silent on threat modeling, SBOM, and Coordinated Vulnerability Disclosure - SPDF fills those gaps. - 62304 software safety classification (A, B, C) does not replace security risk classification under [AAMI SW96](/blog/aami-tir57-vs-tir97-vs-sw96-medical-device-cybersecurity) and ISO 14971. - Reviewers want bidirectional traceability between 62304 software items and SPDF threats, controls, and security tests. - Building the crosswalk once, in your QMS, is faster than rebuilding it for every submission. ## Why this matters The FDA's February 3, 2026 final premarket cybersecurity guidance is explicit that cybersecurity must be integrated into the software lifecycle, not bolted on. [IEC 62304](https://www.iso.org/standard/38421.html) is the lifecycle standard the FDA recognizes; the [Secure Product Development Framework](/services/fda-premarket-cybersecurity-services) is how Section 524B's "reasonable assurance of cybersecurity" gets operationalized inside it. When a submission shows SPDF and 62304 as two parallel documents that never reference each other, reviewers read that as a process problem, not a documentation problem. [AAMI SW96](/guides/aami-tir57-vs-tir97-comparison) and [IEC 81001-5-1](https://www.iso.org/standard/72704.html) both reinforce the same point: security activities belong inside the controlled software lifecycle, traceable to design inputs and verified against design outputs. Across 275+ submissions, the strongest packages we've produced share one trait - a single integrated lifecycle file where the 62304 process step and the SPDF artifact for that step live side by side. ## How does IEC 62304 actually relate to SPDF? IEC 62304 is process scaffolding. It tells you what software lifecycle activities must exist, who owns them, and what records they produce. It is intentionally silent on cybersecurity content because it predates Section 524B and the 2026 guidance. SPDF is the cybersecurity content that fills that scaffolding. It does not replace 62304 planning records, requirements, or unit testing - it specifies the security flavor of each. The result is one lifecycle, not two. > **[KEY REQUIREMENT]** The FDA expects bidirectional traceability between 62304 software items and SPDF threats, security requirements, controls, and security tests. A standalone SPDF document that does not reference 62304 software items, or vice versa, is a structural deficiency. ## Process-by-process crosswalk: 62304 to SPDF The mapping below covers the eight IEC 62304 processes most submissions touch. Use it as a checklist when you build the design history file. | IEC 62304 process | SPDF activity that lives inside it | Artifact reviewers look for | | --- | --- | --- | | 5.1 Software development planning | SPDF policy + security gates per phase | Plan referencing SPDF policy, security exit criteria per phase | | 5.2 Software requirements analysis | Security requirements derivation from threats and standards | Security requirements specification, traced to threats and tests | | 5.3 Software architectural design | Threat modeling, trust boundaries, FDA architecture views | Data flow diagrams, [STRIDE](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) register, four FDA architecture views | | 5.4 Software detailed design | Security design decisions, crypto choices, key handling | Design records identifying security-relevant modules and rationale | | 5.5 Software unit implementation | Secure coding standard, SAST/SCA in CI, SBOM generation | Coding standard, [SAST](/services/static-application-security-testing-sast) results, [CycloneDX or SPDX SBOM](/blog/medical-device-sbom-fda-requirements-and-submission-guide) | | 5.6 Software integration and testing | Integration-level security tests, fuzzing on untrusted inputs | Integration test reports including negative and abuse cases | | 5.7 Software system testing | [Penetration testing](/services/medical-device-penetration-testing) across all interfaces | Pen test report scoped to threat model, written for FDA audience | | 5.8 Software release | Release record including security verification status | Signed release record, residual security risk acceptance | | 6 Software maintenance | Postmarket monitoring, vulnerability triage, validated patching | [Postmarket plan](/services/fda-postmarket-cybersecurity-services), monitoring sources, patch SLAs | | 7 Risk management | Security risk integrated with [ISO 14971](https://www.iso.org/standard/72704.html) hazard file | Security Risk Assessment with exploitability-to-harm mapping | | 8 Configuration management | SBOM as a configuration item, component lifecycle tracking | SBOM regenerated per build, SOUP analysis with CVE evaluation | | 9 Problem resolution | Coordinated Vulnerability Disclosure intake feeding problem records | Published [CVD policy](/guides/coordinated-vulnerability-disclosure-medical-devices), triage workflow with SLAs | Read every row left to right: the 62304 process is the container, the SPDF activity is the cybersecurity content, and the artifact is what ends up in the design history file. Reviewers should not have to ask where any of these live. > **Mapping SPDF work into IEC 62304 deliverables?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## Where IEC 62304 stops and SPDF takes over Three areas are not covered by IEC 62304 at all. If your only software process standard is 62304, you have known gaps the FDA will flag. **Threat modeling.** 62304 requires architectural design records but does not require threat enumeration, trust boundaries, or the four [FDA architecture views](/services/medical-device-threat-modeling) (global system, multi-patient harm, updateability, security use case). SPDF supplies all four. **SBOM and SOUP cybersecurity evaluation.** 62304 requires SOUP identification and anomaly tracking, but not a machine-readable [SBOM](/services/fda-compliant-sbom-services-for-medtech), supplier metadata, transitive dependencies, or CVE-level vulnerability evaluation. Section 524B and the 2026 guidance require all of it. **Coordinated Vulnerability Disclosure.** 62304 problem resolution assumes problems come from internal testing and customer complaints. It does not anticipate external security researchers, [ISO/IEC 29147](https://www.iso.org/standard/72311.html) intake, or risk-based response SLAs. SPDF adds a published CVD program tied into problem resolution. ## How do safety class and security risk class interact? IEC 62304 software safety classes (A, B, C) measure the harm a software failure can cause. They do not measure the harm a cybersecurity exploit can cause. A Class A device with a connected interface can still have a Class C-equivalent security risk if exploitation could affect multiple patients. > **[FDA LANGUAGE]** Cybersecurity risk is evaluated through exploitability and patient harm, not through software safety class. A submission that uses 62304 safety class as a proxy for security risk class will be cited for inadequate security risk analysis. Use [AAMI SW96](/blog/aami-tir57-vs-tir97-vs-sw96-medical-device-cybersecurity) and ISO 14971 to classify security risk independently, then trace each security risk back to the affected 62304 software item. The two classifications can differ for the same component, and that is the point. ## How Blue Goat Cyber approaches the crosswalk We build the SPDF-to-62304 crosswalk once, inside the client's QMS, so every future submission inherits it. Our team brings CISSP, OSCP, and ex-military red team experience to the threat modeling and penetration testing layers, and we sit alongside your software quality lead so the 62304 records and SPDF artifacts are produced together, not reconciled afterwards. Across 275+ FDA submissions we have not had a cybersecurity rejection. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Most engagements start with a fixed-fee gap analysis against the crosswalk above; you get a scored readiness view and a remediation plan within days, not weeks. See our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for scope and timelines. [Book a 30-minute strategy session →](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## Frequently Asked Questions ### Does SPDF replace IEC 62304? No. SPDF is a cybersecurity layer that sits inside the IEC 62304 software lifecycle. 62304 tells you what software processes must exist; SPDF tells you what cybersecurity content goes into each process. You need both, integrated in the same design history file, to satisfy the FDA's February 3, 2026 premarket cybersecurity guidance. ### Can I use my existing 62304 documentation as my SPDF documentation? Partially. Your 62304 plans, requirements, architecture, and test records become the containers, but they need security-specific content added: threat model, security requirements, SBOM, security tests, and CVD. The FDA will flag a submission that submits 62304 records alone without the SPDF artifacts the 2026 guidance requires. ### How does the IEC 62304 software safety class affect SPDF scope? Safety class affects the depth of software lifecycle records 62304 requires, but it does not scale SPDF scope. Security risk classification under [AAMI SW96](/blog/aami-tir57-vs-tir97-vs-sw96-medical-device-cybersecurity) is independent. A Class A device with a wireless interface can still require full SPDF depth because exploitability and patient harm, not safety class, drive security scope. ### Where does the SBOM live - in 62304 configuration management or in SPDF? Both. The SBOM is a configuration item under 62304 Clause 8, and it is also an SPDF postmarket monitoring input. The crosswalk handles this by treating the SBOM as one artifact with two roles - regenerated per build by configuration management, and consumed by the postmarket vulnerability monitoring workflow defined in SPDF. ### Is IEC 81001-5-1 a replacement for the SPDF-62304 crosswalk? [IEC 81001-5-1](https://www.iso.org/standard/72704.html) is closer to a security-specific lifecycle standard and overlaps significantly with SPDF. Many manufacturers adopt 81001-5-1 as the security lifecycle and keep 62304 as the general software lifecycle, then map both into one design history file. The crosswalk principle is the same: one integrated lifecycle, traceable end to end. ### What is the fastest way to build the crosswalk if we are mid-development? Start with the table above and audit each 62304 process for the matching SPDF artifact. Gaps usually cluster in three places: threat model depth, SBOM completeness, and CVD program. Fix those first, then backfill traceability. Most teams need two to four weeks of focused work to retrofit a credible crosswalk on a project already in 62304 execution. ## Build the crosswalk before your next submission If you are preparing a 510(k), De Novo, or PMA and your SPDF and 62304 records currently live in separate files, that gap is fixable in weeks, not months. Book a free 30-minute strategy session and we will walk the crosswalk against your current design history file, flag the gaps the FDA is most likely to hit, and give you a fixed-fee quote within 24 hours. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Book your strategy session →](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) --- *Albert Konik, Director of Medical Device Cybersecurity, CISSP, OSCP. Albert has led SPDF and IEC 62304 integration work across 275+ FDA submissions, with a focus on building one design history file that satisfies both software lifecycle and cybersecurity reviewers in a single pass.* ## Related SPDF reading - **Pillar guide:** [Medical Device Cybersecurity SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [CI/CD Security Gates for Medical Devices: SPDF in Practice](/blog/cicd-security-gates-medical-devices-spdf) - [SPDF Cybersecurity Documentation: What FDA Reviewers Expect](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) - [SPDF vs SSDLC: What Medtech Teams Get Wrong](/blog/spdf-vs-ssdlc-medical-device-cybersecurity) - [SPDF vs TPLC in Medical Device Cybersecurity](/blog/spdf-vs-tplc-in-medical-device-cybersecurity) ## About the author **Christian Espinosa, CISSP - Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device Incident Response Plan](/blog/medical-device-incident-response-plan-fda) - [HHS 405(d) HICP Practice #9 for 524B](/blog/hhs-405d-medical-device-cybersecurity) - [IEC 62304 Classes vs FDA Device Classes](/blog/iec-62304-classes-vs-fda-device-classes-cybersecurity) - [How SPDF Maps to IEC 81001-5-1 Activities](/blog/how-spdf-maps-to-iec-81001-5-1-activities) --- ## SPDF vs SSDLC: What Medtech Teams Get Source: https://bluegoatcyber.com/blog/spdf-vs-ssdlc-medical-device-cybersecurity # SPDF vs SSDLC for Medical Device Cybersecurity > **[DIRECT ANSWER]** SPDF is the FDA's expected Secure Product Development Framework, and it inherits standard Secure SDLC practices like threat modeling and secure coding while adding four medtech-specific requirements: ISO 14971 patient-harm traceability, AAMI SW96 security risk management, a postmarket vulnerability monitoring plan, and a coordinated vulnerability disclosure process. A team with a mature SSDLC is roughly 60 percent of the way to SPDF; the missing 40 percent is what deficiency letters cite. A common assumption inside medtech engineering teams is that an existing Secure SDLC ports cleanly to FDA submissions. It does not. The FDA's February 3, 2026 final premarket cybersecurity guidance names the Secure Product Development Framework (SPDF) as the expected lifecycle model, and Section 524B of the FD&C Act gives the agency authority to refuse submissions that do not meet it. This post draws the line between the two frameworks for medtech teams currently running an SSDLC and trying to figure out the delta before their next 510(k), De Novo, or PMA submission. ## Key Takeaways - SSDLC is a software-engineering practice; SPDF is a regulatory framework built on top of it. - SPDF requires every SSDLC activity plus four medtech-specific additions: ISO 14971 harm mapping, AAMI SW96 security risk management, postmarket monitoring, and a coordinated vulnerability disclosure process. - The biggest gap is traceability: SSDLC traces threats to controls; SPDF traces threats to patient harm. - A team running a mature SSDLC is roughly 60% of the way to SPDF, the missing 40% is what gets cited in deficiency letters. - The FDA's 2026 final guidance treats SPDF as the default expectation, not one of several acceptable options. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* final guidance (February 3, 2026) is explicit that manufacturers are expected to implement an SPDF and to document it in the submission. Section 524B of the FD&C Act, in effect since March 29, 2023, makes that an enforcement matter: a cyber device submission lacking SPDF-equivalent evidence can be refused. Reviewers do not grade your SSDLC. They grade your SPDF artifacts: the security risk file under AAMI SW96, the threat model with four architecture views, the SBOM with VEX, the postmarket cybersecurity plan, and the coordinated vulnerability disclosure (CVD) process. Each one has an SSDLC analogue and a medtech-specific extension. The most-cited 2025-2026 cybersecurity deficiencies (per FDA's own published data on AI request rates for cyber devices) cluster around four themes: missing patient-harm traceability, incomplete postmarket plans, SBOMs without exploitability context, and threat models that read like IT threat models. All four are SPDF gaps, not SSDLC gaps, a team can have a working SSDLC and still trigger every one of them. ## What SSDLC actually covers SSDLC, as practiced across general enterprise software (Microsoft SDL, OWASP SAMM, NIST SSDF SP 800-218), covers: - Security requirements gathering during design. - Threat modeling, typically STRIDE. - Secure coding standards and developer training. - Static and dynamic application security testing (SAST/DAST). - Code review with a security lens. - Vulnerability remediation before release. - Some form of dependency scanning. What it does **not** require: linking each threat to a patient-harm scenario under ISO 14971, planning postmarket monitoring of vulnerabilities for the operational life of the device, or running a public coordinated vulnerability disclosure program. Those are not failures of SSDLC. They are simply outside its scope. ## What SPDF adds on top of SSDLC SPDF inherits SSDLC and adds five medtech-specific obligations. Each maps to a discrete artifact reviewers look for in the submission. ### 1. ISO 14971 patient-harm traceability Every cybersecurity threat must trace to a clinical harm scenario. A spoofed sensor reading is not a CIA-triad incident; it is a wrong-therapy scenario with a severity grade under your ISO 14971 risk file. SSDLC has no concept of this. ### 2. AAMI TIR57 / SW96 security risk management ANSI/AAMI SW96:2023 governs security risk management for medical-device software. It defines how the security risk file integrates with the ISO 14971 safety risk file. Reviewers expect this integration explicitly, not a parallel risk register. ### 3. Postmarket cybersecurity management plan SPDF requires a documented plan for vulnerability monitoring, patch deployment, and end-of-support communication for the operational life of the device. SSDLC does not extend past release. ### 4. SBOM with VEX A Software Bill of Materials in CycloneDX or SPDX format, paired with VEX (Vulnerability Exploitability eXchange) to communicate which listed CVEs actually apply to the device. SSDLC dependency scanning produces inputs to this; it is not a substitute. ### 5. Coordinated Vulnerability Disclosure (CVD) process A published, externally reachable path for researchers and operators to report vulnerabilities, plus an internal triage and response process. Required under Section 524B and the 2026 guidance. SSDLC does not address this at all. ## Side-by-side: SPDF vs SSDLC | Dimension | SSDLC | SPDF | | --- | --- | --- | | **Origin** | Software engineering practice (Microsoft SDL, NIST SSDF, OWASP SAMM) | FDA premarket cybersecurity expectation (Feb 3, 2026 guidance) | | **Scope** | Design through release | Concept through end-of-support (total product lifecycle) | | **Risk basis** | CIA-triad impact | Patient-harm scenarios under ISO 14971 | | **Risk management standard** | None mandated | AAMI TIR57 / ANSI/AAMI SW96 | | **Threat model output** | Threat list with controls | Threat list + four architecture views + harm traceability matrix | | **SBOM** | Optional, often dependency-scan output | Required, CycloneDX or SPDX, paired with VEX | | **Postmarket obligations** | None | Documented monitoring plan, patch cadence, end-of-support comms | | **Vulnerability disclosure** | Internal | Externally published CVD process | | **Regulatory consequence of gaps** | Internal risk acceptance | Refuse-to-accept, deficiency letter, or hold | [Talk to a MedTech cybersecurity expert about your SPDF gap analysis](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) > **Moving from a general SSDLC to the SPDF?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## Where SSDLC teams most often fall short Across recent FDA cybersecurity deficiency letters our team has resolved, the same four SPDF-vs-SSDLC gaps recur: 1. **Threat model without architecture views.** STRIDE spreadsheets are common SSDLC output. SPDF wants global, multi-patient harm, updateability, and security use-case views. See the [step-by-step threat modeling guide](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) for the structure reviewers expect. 2. **Risk register that lives separately from ISO 14971.** Security and safety risks tracked in different files with no cross-reference. SW96 requires integration. 3. **SBOM with no VEX.** Reviewers see hundreds of "open" CVEs in third-party components with no exploitability statement. See [SBOM third-party chip firmware for medical devices](/blog/sbom-third-party-chip-firmware-medical-devices) for the SBOM/VEX pattern. 4. **No CVD process or a CVD process buried in a customer-support page.** Reviewers look for a discoverable, dedicated security.txt or `/security` page with a real intake. ## How to upgrade an existing SSDLC into an SPDF The fastest path is additive, not a rewrite: 1. Adopt AAMI SW96 as your security risk management standard and integrate the security risk file into the existing ISO 14971 file. 2. Extend the existing threat model with the four architecture views and add a harm-traceability column linking each threat to a clinical scenario. 3. Produce a CycloneDX or SPDX SBOM from the existing dependency scanner and add a VEX feed. 4. Write a postmarket cybersecurity management plan covering monitoring sources, patch cadence, and end-of-support communication. 5. Publish a CVD policy and security contact at a stable URL. These five steps close the typical SSDLC-to-SPDF gap without disrupting the working SSDLC underneath. ## How Blue Goat Cyber Approaches This Blue Goat Cyber runs SPDF gap assessments for medtech teams who already have an SSDLC and need to know exactly what reviewers will flag. The engagement maps your existing artifacts to the 2026 final guidance line-by-line and produces a remediation backlog ordered by deficiency-letter likelihood. Christian Espinosa, our founder, has led cybersecurity submissions on more than 275 FDA-cleared devices, including connected implantables, infusion pumps, and IVD analyzers. For teams further along, our [SPDF implementation service](/services/fda-premarket-cybersecurity-services) builds the missing artifacts directly: SW96 risk files, architecture views, SBOM/VEX pipelines, postmarket plans, and CVD process. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## Frequently Asked Questions ### What is the difference between SPDF and SSDLC for medical devices? SSDLC is a software-engineering practice that builds security into design, coding, and testing. SPDF is the FDA's medical-device-specific lifecycle framework that includes every SSDLC activity plus ISO 14971 patient-harm traceability, AAMI SW96 security risk management, an SBOM with VEX, a postmarket cybersecurity management plan, and a coordinated vulnerability disclosure process. SSDLC ends at release; SPDF runs through end-of-support. ### Does a mature SSDLC satisfy the FDA's SPDF expectation? No. A mature SSDLC covers roughly 60% of SPDF: the design, coding, testing, and vulnerability remediation activities. The remaining 40%, patient-harm traceability, SW96 integration, postmarket plan, SBOM/VEX, and CVD, is medtech-specific and must be added explicitly. Submissions that present an SSDLC alone routinely receive cybersecurity deficiency letters. ### Is SPDF required by law or only by FDA guidance? Both. Section 524B of the FD&C Act, in effect since March 29, 2023, gives the FDA authority to refuse cyber-device submissions that lack adequate cybersecurity evidence. The February 3, 2026 final premarket cybersecurity guidance names SPDF as the expected framework. The guidance is non-binding in form but is the operational standard reviewers apply. ### Can we keep using NIST SSDF or Microsoft SDL terminology in the submission? Yes, as long as you map it to SPDF artifacts. Reviewers do not require a specific vendor framework, but they do require the SPDF outputs: security risk file under SW96, threat model with the four architecture views, SBOM with VEX, postmarket plan, and CVD process. Use whatever upstream framework you prefer; produce the SPDF artifacts on top. ### How long does it take to upgrade an SSDLC into an SPDF? For a team with a mature SSDLC and a single connected Class II device in scope, the typical timeline is 8-12 weeks of focused work. The pacing items are SW96 risk-file integration and producing the four architecture views; the SBOM/VEX pipeline and CVD policy are usually faster. ### Does SPDF apply to SaMD as well as connected hardware devices? Yes. SPDF applies to any cyber device under Section 524B, which includes Software as a Medical Device (SaMD) that contains software, the ability to connect to the internet, or any technological characteristic that could be vulnerable to a cybersecurity threat. The artifacts are the same; only the architecture views shift in shape. ## CTA Run an SPDF gap assessment against your existing SSDLC before the next submission window. We deliver a reviewer-readable gap report and a remediation backlog in two weeks. If we miss something the FDA later cites, we resolve it at no additional cost. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session). _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, CCISO, ex-military red team. Has led SPDF implementations and FDA cybersecurity submissions for more than 275 medical devices, including connected implantables, infusion pumps, IVD analyzers, and SaMD platforms. [More on the author](/team/christian-espinosa)._ ## Related SPDF reading - **Pillar guide:** [Medical Device Cybersecurity SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [CI/CD Security Gates for Medical Devices: SPDF in Practice](/blog/cicd-security-gates-medical-devices-spdf) - [SPDF Cybersecurity Documentation: What FDA Reviewers Expect](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) - [SPDF and IEC 62304 Mapping for Medical Device Cybersecurity](/blog/spdf-iec-62304-mapping-medical-device-cybersecurity) - [SPDF vs TPLC in Medical Device Cybersecurity](/blog/spdf-vs-tplc-in-medical-device-cybersecurity) --- ## More on this topic - [GET vs POST: When to Use Each HTTP Method](/blog/medical-device-sql-injection-parameterized-queries) --- ## Medical Device Cybersecurity SPDF vs TPLC Source: https://bluegoatcyber.com/blog/spdf-vs-tplc-in-medical-device-cybersecurity # Medical Device Cybersecurity SPDF vs TPLC > **[DIRECT ANSWER]** SPDF is a focused set of secure coding, threat modeling, and vulnerability management practices for building security into a device during development, while TPLC is the broader framework covering the device's entire existence, from concept and manufacturing through post-market surveillance and disposal. SPDF satisfies FDA premarket cybersecurity documentation expectations, and TPLC aligns with quality management system and post-market surveillance requirements under the FDA's February 3, 2026 guidance. _Updated November 10, 2024_ [Safeguarding sensitive patient data](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) and ensuring the integrity of medical devices is of utmost importance. Two frameworks that have emerged to address these concerns are SPDF (Secure Product Development Framework) and TPLC (Total Product Development Lifecycle). This article will covers the intricacies of SPDF and TPLC, exploring their roles, features, benefits, and limitations in medical device cybersecurity. ## Key Takeaways - SPDF builds security into device development through secure coding and testing. - TPLC manages the device from concept through disposal, including security. - SPDF ensures "security by design" and proactive threat prevention. - TPLC ensures cybersecurity remains viable across the device's entire lifespan. - Both frameworks are critical for complying with the FDA's cybersecurity guidance. - SPDF addresses specific technical exploits; TPLC addresses broader lifecycle risks. ## Why this matters The security of medical devices directly impacts patient welfare and data privacy. Substandard cybersecurity can lead to device malfunction, data breaches, and harm to patients, incurring severe financial and reputational damage to manufacturers. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, mandates that manufacturers demonstrate a commitment to security throughout the device's lifecycle. SPDF and TPLC are essential for meeting these regulatory expectations. SPDF, by integrating security measures early in the development process, helps prevent vulnerabilities that are costly to fix later. TPLC, on the other hand, extends this vigilance across the device's entire operational period, addressing evolving threats, post-market surveillance, and incident response. Adherence to standards like IEC 60601-1-10 (Medical electrical equipment, Part 1-10: General requirements for basic safety and essential performance, Collateral Standard: Requirements for the development of physiologic closed-loop controllers), ISO 14971 (Medical devices, Application of risk management to medical devices), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management) further supports the implementation of these frameworks, creating a resilient cybersecurity posture for medical devices. ## At a glance | Dimension | Secure Product Development Framework (SPDF) | Total Product Life Cycle (TPLC) | |:--- |:--- |:--- | | **Definition** | A subset of processes focused specifically on building security into software/hardware. | A holistic management framework covering a device from concept to decommissioning. | | **Typical Use Case** | Guiding engineering teams through secure coding, testing, and vulnerability remediation. | Managing business, regulatory, and safety milestones across the entire product lifespan. | | **Range/Scope** | Concentrated on technical security controls and threat modeling during development. | Broad scope including clinical trials, manufacturing, marketing, and end-of-life disposal. | | **Security Posture** | Proactive "Security by Design"; focuses on hardening the technical architecture. | Operational continuity; ensures security remains viable during field use and updates. | | **Common Attacks** | Focuses on preventing exploits like buffer overflows or credential stuffing. | Focuses on mitigating supply chain risks and long-term legacy system vulnerabilities. | | **Regulatory Relevance** | Directly satisfies FDA premarket expectations for cybersecurity documentation and rigorous testing. | Aligns with Quality Management System (QMS) and post-market surveillance requirements. | | **Key Tradeoff** | Requires deep technical expertise but creates highly resilient, defensible products. | and simplifies compliance but can be resource-intensive to maintain long-term. | ## Understanding SPDF and TPLC ### Defining SPDF [SPDF](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) is a approach encompassing secure coding practices, risk assessment, vulnerability management, and continuous monitoring. It provides a structured framework for developing and maintaining secure medical devices throughout their lifecycle. On the other hand, Total Product Development Lifecycle (TPLC) takes a broader perspective, considering all stages of a product’s existence. From the initial concept to the final disposal, TPLC encapsulates the entire journey of a medical device. This holistic methodology emphasizes integrating [risk management](/blog/cybersecurity-measures-and-metrics-for-medical-devices-navigating-fda-compliance), including cybersecurity measures, to ensure medical devices’ safety, efficacy, and quality. By incorporating cybersecurity practices at every phase of development, TPLC aims to mitigate potential threats and vulnerabilities that could compromise the integrity of the medical device. ### Defining TPLC [TPLC](/blog/cybersecurity-measures-and-metrics-for-medical-devices-navigating-fda-compliance) is a holistic methodology encompassing all stages of a product’s development, from conceptualization to disposal. It emphasizes the need for integrated risk management, including cybersecurity, to ensure medical devices’ safety, efficacy, and quality. ## The Role of SPDF in Medical Device Cybersecurity ![Section Image](/imported-images/0acaa6e72bbcc2cd.webp) Given the increasing connectivity and digitization of medical devices, cybersecurity is critical to healthcare technology. SPDF supports ensuring the security and integrity of these devices throughout their lifecycle. ### Key Features of SPDF SPDF incorporates a range of essential features to enhance the security posture of medical devices. These include: - [Secure coding practices](/blog) - [Threat modeling and risk assessment](/blog/a-step-by-step-guide-to-threat-modeling-connected-and-implantable-medical-devices) - Vulnerability management - Incident response planning - Continuous monitoring and updates By integrating these features into the development process, SPDF helps mitigate potential security risks associated with medical devices. SPDF promotes a proactive approach to cybersecurity by emphasizing the importance of security considerations at every stage of the medical device development lifecycle. This approach ensures that security measures are not just an afterthought but are integrated from the initial design phase onwards. ### Benefits and Limitations of SPDF SPDF offers several advantages, such as: - Enhanced security and protection against cyber threats - Improved compliance with regulatory requirements - Early detection and mitigation of vulnerabilities However, it is important to acknowledge the limitations of SPDF. These may include: - The need for skilled personnel to implement and maintain the framework - Potential impact on development timelines and costs - The dynamic nature of cybersecurity threats requires continuous updates and adaptations to the framework Despite these challenges, the benefits of implementing SPDF in medical device cybersecurity far outweigh the limitations. Organizations that prioritize security by adopting SPDF can enhance patient safety, protect sensitive data, and [maintain the trust of healthcare providers and patients alike](/blog). ## The Role of TPLC in Medical Device Cybersecurity ![Section Image](/imported-images/aecb47dcaa588723.webp) Medical device cybersecurity is a critical aspect of healthcare technology, especially with the increasing connectivity and digitization of medical devices. TPLC ensures that [cybersecurity is integrated into every medical device’s](/blog/integrating-cybersecurity-assessments-into-the-medical-device-lifecycle) development and deployment stage. ### Key Features of TPLC TPLC emphasizes integrated risk management and incorporates various features, such as: - Market analysis and user needs assessment - Design and development - Manufacturing - Distribution and installation - Maintenance and post-market surveillance TPLC aims to ensure that medical devices are secure and reliable by integrating cybersecurity considerations throughout these stages. TPLC also focuses on regulatory compliance, ensuring that medical devices meet the cybersecurity standards set forth by regulatory bodies such as the [FDA](https://www.fda.gov/media/119933/download) and ISO. This compliance not only enhances the security of the devices but also instills trust in healthcare providers and patients regarding the safety and efficacy of the technology. ### Benefits and Limitations of TPLC TPLC offers several benefits for medical device cybersecurity, including: - risk management throughout the entire lifecycle - Integration of cybersecurity from the inception of product development - Improved product quality and reliability However, TPLC also has its limitations, such as: - Potential complexity and resource requirements, particularly for smaller organizations - Possible challenges in adapting to evolving cybersecurity threats - The need for collaboration and coordination across various stakeholders Despite these limitations, adopting TPLC in medical device cybersecurity is crucial for safeguarding patient data, ensuring the integrity of medical procedures, and maintaining overall trust in healthcare technology. ## Comparing SPDF and TPLC in Cybersecurity When delving deeper into the comparison between SPDF and TPLC in medical device cybersecurity, it is essential to consider these frameworks’ practical implications and real-world applications. By examining how these frameworks are implemented in healthcare settings, we can better understand their effectiveness and suitability for different scenarios. ### Similarities Between SPDF and TPLC SPDF and TPLC share similarities in addressing cybersecurity concerns in medical devices. These include: - Recognition of the importance of cybersecurity in the healthcare industry - Integration of risk management principles - Emphasis on continuous monitoring and updates These shared elements underscore the collective goal of ensuring the security and integrity of medical devices. The alignment of SPDF and TPLC with regulatory standards and guidelines specific to medical device cybersecurity further solidifies their significance in enhancing healthcare technologies’ overall safety and reliability. ### Differences Between SPDF and TPLC Despite the overlaps, SPDF and TPLC also have distinct characteristics that set them apart: - SPDF primarily focuses on cybersecurity, whereas TPLC takes a broader approach encompassing the entire product development lifecycle. - SPDF emphasizes secure coding practices, vulnerability management, and continuous monitoring, while TPLC addresses cybersecurity concerns in conjunction with other stages of product development. - SPDF may require specialized skills and resources for implementation, whereas TPLC may involve greater stakeholder coordination. Understanding these differences is crucial when deciding which framework to adopt for medical device cybersecurity. Exploring case studies and success stories of organizations implementing either SPDF or TPLC can offer valuable insights into each framework’s practical outcomes and challenges, aiding stakeholders in making informed decisions regarding their cybersecurity strategies. ## Future Trends in Medical Device Cybersecurity ### The Evolving Threat Landscape The threat landscape for medical device cybersecurity is continually evolving, with hackers becoming more sophisticated in their methods. Ongoing vigilance and proactive measures are necessary to combat these emerging threats. ### Innovations in Secure Product Development and Lifecycle Management The field of secure product development and lifecycle management is constantly innovating to stay ahead of emerging cybersecurity challenges. These advancements include enhanced encryption protocols, machine learning algorithms for threat detection, and secure communication frameworks. One notable innovation in secure product development is the implementation of blockchain technology. Initially designed for secure financial transactions, blockchain is now being explored as a potential solution for medical device cybersecurity. Utilizing blockchain allows medical devices to maintain a decentralized and tamper-proof record of their operations, making it difficult for hackers to manipulate or compromise the device’s functionality. Another area of innovation is integrating artificial intelligence (AI) into medical device cybersecurity. AI-powered systems can continuously monitor and analyze device behavior, detecting abnormal patterns or suspicious activities. This proactive approach enables early detection of potential threats, allowing healthcare providers to take immediate action and prevent security breaches. Advancements in secure communication frameworks enhance the protection of sensitive patient data. Secure communication protocols, such as Transport Layer Security (TLS), are being implemented to encrypt data transmission between medical devices and healthcare systems. This ensures that patient information remains confidential and inaccessible to unauthorized individuals. By using these innovations, organizations can bolster their cybersecurity practices and ensure the safety and integrity of medical devices. ## Conclusion As the medical device industry continues to confront the challenges of an evolving cyber threat landscape, the need for a trusted cybersecurity partner becomes paramount. Blue Goat Cyber stands at the vanguard of cybersecurity excellence, offering bespoke B2B services encompassing the full medical device cybersecurity spectrum. Our veteran-owned company is committed to ensuring your compliance with HIPAA, FDA regulations, and beyond, providing the expertise necessary to navigate these complex requirements with confidence. With Blue Goat Cyber, you gain more than just a service provider; you gain a partner whose proactive approach and solutions are tailored to your unique needs. Whether you’re a startup or an established enterprise, our team of certified experts is ready to help you integrate SPDF and TPLC principles into your product development lifecycle, ensuring that your medical devices are not only secure but also resilient against the threats of tomorrow. Don’t let cybersecurity concerns hinder your innovation in the healthcare sector. [Contact us today](/contact) for cybersecurity help and take the first step towards a secure and successful digital future with Blue Goat Cyber. Embrace security, embrace success. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in navigating the complexities of SPDF and TPLC implementation. Our team, comprised of certified professionals such as CISSP and OSCP holders, including ex-military red team specialists, applies practical methodologies to integrate security into every phase of device development and management. We focus on identifying critical vulnerabilities early in the SPDF, transitioning to continuous risk assessment and mitigation strategies throughout the TPLC. Our services include threat modeling, penetration testing, and compliance readiness, ensuring alignment with regulatory bodies. We help establish repeatable processes for secure coding, vulnerability management, and incident response tailored to your product^{\text{'s}} lifecycle needs. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our post-market support at [FDA postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services). ## FAQ ### What is the primary difference between SPDF and TPLC in medical device cybersecurity? SPDF focuses specifically on integrating security into the product development process through secure coding, testing, and vulnerability management. TPLC is a broader framework that manages the medical device from its initial concept to its final decommissioning, incorporating cybersecurity as one component of overall risk management across its entire lifespan. ### How does the FDA view SPDF and TPLC? The FDA's February 3, 2026 final guidance on cybersecurity emphasizes the importance of both Secure Product Development Framework (SPDF) principles and lifecycle management (TPLC concepts). SPDF directly aligns with premarket expectations for rigorous testing and documentation, while TPLC aligns with quality management system and post-market surveillance requirements. ### Can a medical device manufacturer use both SPDF and TPLC? Yes, medical device manufacturers should use both. SPDF provides the essential technical foundation for building secure products, while TPLC provides the overarching management structure to ensure security is maintained and evolved throughout the device's operational life. ### What are the key benefits of implementing SPDF? Implementing SPDF enhances security against cyber threats, improves compliance with regulatory requirements, and supports early detection and mitigation of vulnerabilities. It leads to more resilient and defensible medical devices by embedding security from the start. ### What are the key benefits of implementing TPLC? Implementing TPLC provides complete risk management throughout the device's entire lifecycle and ensures cybersecurity is integrated from inception. It improves product quality and reliability by maintaining security posture through all phases, including post-market surveillance and updates. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## Related SPDF reading - **Pillar guide:** [Medical Device Cybersecurity SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [CI/CD Security Gates for Medical Devices: SPDF in Practice](/blog/cicd-security-gates-medical-devices-spdf) - [SPDF Cybersecurity Documentation: What FDA Reviewers Expect](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) - [SPDF and IEC 62304 Mapping for Medical Device Cybersecurity](/blog/spdf-iec-62304-mapping-medical-device-cybersecurity) - [SPDF vs SSDLC: What Medtech Teams Get Wrong](/blog/spdf-vs-ssdlc-medical-device-cybersecurity) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Special vs Traditional 510(k) Source: https://bluegoatcyber.com/blog/special-vs-traditional-510k-cybersecurity-changes # Special vs Traditional 510(k) for Cybersecurity Changes > **[DIRECT ANSWER]** The FDA generally accepts a Special 510(k) for cybersecurity changes to your own cleared device, such as firmware signing updates, BLE hardening, Secure Boot, or SBOM swaps, when the change uses well-established evaluation methods and does not alter intended use. Changes that expand attack surface, add wireless paths, or shift the risk profile typically require a Traditional 510(k) instead. A Pre-Sub can confirm the pathway. If you are modifying a cleared device for cybersecurity reasons - replacing an end-of-support library, hardening BLE, enabling Secure Boot, rotating a signing key infrastructure, or refreshing TLS - the first regulatory question is not *what* you are changing. It is *which 510(k) type* the change belongs in. Pick wrong and you eat a 60-day delay, or worse, an RTA after you have already filed. ## Key Takeaways - Three 510(k) types: Traditional (90-day goal), Special (30-day goal), Abbreviated (90-day, uses consensus standards). - Special 510(k) is for *your own* cleared device, with well-established evaluation methods, and a summary-level review. - Cybersecurity changes are a gray zone - the FDA looks at impact on the security risk profile and threat model, not just code diff size. - Changes that expand attack surface, add wireless paths, or alter intended use almost always get bumped to Traditional. - A Pre-Sub (Q-Sub) is the cheapest way to confirm the pathway before you build the submission package. - Aligned with the Feb 3, 2026 the FDA premarket cybersecurity guidance and Section 524B(b) obligations. ## Why this matters Choosing the correct 510(k) pathway for cybersecurity changes impacts your time to market and regulatory burden. Missteps can lead to significant delays, including RTA (Refuse to Accept) decisions, costing manufacturers valuable resources and delaying patient access to improved medical devices. The FDA's February 3, 2026 final guidance, "Cybersecurity in Medical Devices," clarifies expectations, emphasizing the need for a thorough understanding of how cybersecurity modifications affect a device's safety and effectiveness. Navigating the Special vs. Traditional 510(k) distinction, especially for changes involving software bill of materials (SBOM) updates, threat model revisions, or expanded attack surfaces, is critical. Adhering to standards like IEC 81001-5-1, AAMI SW96, and AAMI TIR57 can facilitate the Abbreviated pathway, but the material impact of a change often dictates a longer review. Early engagement with the FDA via a Pre-Submission is essential to confirm the appropriate regulatory path, preventing costly rework and accelerating clearance. ## The Three 510(k) Types in One Table | Type | Review Goal | When to Use | Cybersecurity Implication | | --- | --- | --- | --- | | **Traditional** | 90 days | New device, new predicate, or substantive change to your own device | Full Section 524B(b) package: SBOM, threat model, SPDF evidence, pen test, architecture views | | **Special** | 30 days | Modification to *your own* cleared device, evaluable with well-established methods, summary-level review | Delta package: scoped threat model update, SBOM diff + VEX delta, regression test summary | | **Abbreviated** | 90 days | Submission uses FDA-recognized consensus standards or special controls | Useful when relying on IEC 81001-5-1, AAMI SW96, or AAMI TIR57 declarations | The Special pathway exists because the FDA does not want to re-review the entire device every time you swap a connector or refresh a component. It leans on your **design controls** and **change-management** records under 21 CFR 820.30. ## When Cybersecurity Changes Fit the Special Pathway These are the changes the FDA *usually* accepts as Special, assuming your design history file backs them up: - **Cryptographic library version bumps** with no algorithm change (e.g., OpenSSL 3.0.x to 3.0.y) where the API contract and threat model are unchanged. - **SBOM component refresh** driven by end-of-support, where the replacement is a drop-in with equivalent or stronger security posture and no new network behavior. - **TLS minimum version raise** (e.g., disabling TLS 1.1) that *reduces* attack surface without introducing new protocols. - **Signing key infrastructure rotation** with no change to the signing algorithm, verification chain, or boot flow. - **Patch deployment** for known vulnerabilities where the patch is vendor-supplied and the change is bounded. The common thread: the change is **defensive, bounded, and does not alter the device's security risk profile** as documented in your threat model and security risk assessment. ## When the FDA Will Push You to Traditional These changes almost always force a Traditional submission, even if the code diff looks small: - **Enabling or disabling a wireless interface** (BLE, Wi-Fi, NFC, cellular). Adding a radio expands attack surface; removing one changes intended use. - **Adding a remote-access path** - cloud telemetry, remote service portal, OTA update channel where none existed. - **First-time Secure Boot enablement** on a device that previously had none. This changes the trust boundary and the recovery model. - **Firmware signing algorithm change** (e.g., RSA-2048 to ECDSA-P256, or SHA-1 to SHA-256 in the verification chain). Different cryptographic primitives mean a different threat model. - **New third-party SBOM components** with material function (not a drop-in replacement) - especially open-source components with unknown provenance or weak maintainer signals. - **Intended-use changes** that bring the device into a new clinical context, new patient population, or new network environment. - **Architecture changes** that affect any of the four architecture views the FDA expects: Global System, Multi-Patient Harm, Updateability/Patchability, or Security Use Case. If any of the above describe your change, do not file Special. You will get an RTA or a deficiency letter that costs more than the time you tried to save. ## The Decision Tree ```text Is this a modification to YOUR OWN cleared device? No --> Traditional (or new 510(k) entirely) Yes --> continue Does the change alter the device's security risk profile, threat model, attack surface, or intended use? Yes --> Traditional No --> continue Can the change be evaluated using well-established methods (known test protocols, recognized standards, summary analysis)? No --> Traditional Yes --> continue Does the change introduce a new wireless path, remote-access channel, or third-party component with material function? Yes --> Traditional No --> Special 510(k) candidate - confirm via Pre-Sub ``` The last step is not optional. Cybersecurity changes are exactly the category where reviewers' opinions vary, and a 15-page Pre-Sub is cheaper than a 60-day delay. ## The Pre-Sub (Q-Sub) Move A [Pre-Submission](/services/fda-premarket-cybersecurity-services) for a Special vs Traditional pathway question should include: 1. **Change description** - what is being modified, scoped tightly. One paragraph. 2. **Threat model delta** - the specific STRIDE entries, attack trees, or asset/threat pairs that change. If none change, say so explicitly and show the diff. 3. **Security risk assessment delta** - updated rows in your ISO 14971 / AAMI TIR57 / ANSI/AAMI SW96:2023 risk table. Include residual risk before and after. 4. **SBOM diff** - components added, removed, version-bumped. Reference your CycloneDX or SPDX baseline. 5. **VEX delta** - any new affected/not_affected/fixed/under_investigation statuses driven by the change. 6. **Proposed verification** - what regression testing, pen test scoping, and labeling updates you intend. 7. **Specific question to the FDA** - "Does the FDA agree that the proposed change qualifies for the Special 510(k) pathway under [criteria]?" Get a written answer before you build the submission. ## What a Special 510(k) Cybersecurity Package Actually Contains When the Special pathway *is* accepted, the FDA still expects Section 524B(b) artifacts - just scoped to the change: - **Threat model update** - delta only, with traceability to the baseline model on file. - **SBOM** - full current SBOM, plus a diff document highlighting changes since the cleared baseline. CycloneDX 1.5+ or SPDX 2.3 with lifecycle fields. - **VEX** - updated VEX document covering any vulnerabilities introduced or resolved by the change. - **Security risk assessment update** - updated rows, not a full rewrite. - **Regression pen test summary** - scoped to the changed interfaces and components. Full re-test is not required, but the scope rationale must be explicit. - **Updated labeling** - if the change affects user-facing security behavior (e.g., new pairing flow, changed update mechanism). - **Updated SPDF evidence** - which Secure Product Development Framework controls were exercised for the change. The package is smaller than a Traditional, but every artifact still needs to defend itself in isolation. ## Reviewer Red Flags If a reviewer sees any of these in a Special 510(k) cybersecurity package, expect a deficiency letter or a pathway bump: - Threat model update with no traceability to the on-file baseline. - SBOM with no diff document - reviewer has to compute it themselves. - VEX with new vulnerabilities marked `under_investigation` and no remediation timeline. - Regression pen test scope that excludes the changed interface ("we tested everything except the thing that changed"). - Labeling unchanged when user-facing security behavior changed. - Security risk assessment with residual risk *increased* but no benefit-risk justification. Any of these signal that the change is bigger than the submission admits, and the reviewer will ask for the Traditional package. ## How This Aligns with the Feb 3, 2026 the FDA Guidance The Feb 3, 2026 the FDA premarket cybersecurity guidance does not redefine 510(k) pathways - it defines the *artifacts* every premarket cybersecurity submission must contain. Special 510(k)s are not exempt. The guidance's expectation is that the **depth** of each artifact scales with the change, but the **set** of artifacts does not shrink. Section 524B(b)(1)-(3) obligations - plan to monitor/identify/address vulnerabilities, processes to provide reasonable assurance the device and related systems are cybersecure, and the SBOM - apply to every cyber device submission regardless of 510(k) type. ## Related Reading - [Preparing Your eSTAR 510(k) Cybersecurity Documentation](/blog/preparing-your-estar-510k-cybersecurity-documentation) - [SBOM End-of-Support, EOL, and Level of Support: What the FDA Expects](/blog/sbom-end-of-support-eol-los-fda-section-524b) - [How Long Does FDA Cybersecurity Review Take?](/blog/how-long-does-fda-cybersecurity-review-take) - [Medical Device Cybersecurity Risk Analysis: The FDA Playbook](/blog/medical-device-cybersecurity-risk-analysis-the-fda-playbook) ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in strategically navigating the FDA's 510(k) pathways for cybersecurity-driven changes. Our methodology focuses on a careful analysis of the proposed device modifications and their potential impact on security risk. We prepare Pre-Submission (Q-Sub) packages, framing your cybersecurity changes effectively to secure FDA agreement on the appropriate pathway and prevent costly rejections. Our team, composed of OSCP-certified penetration testers, CISSP-credentialed security architects, and former military red team members, understands the nuances of the FDA's expectations. We produce detailed documentation, including updated threat models, SBOM deltas, and verification test results, tailored for the chosen pathway. We are experienced in Section 524B(b) obligations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### Can I use a Special 510(k) for a cybersecurity patch? Sometimes. If the patch is vendor-supplied, bounded, does not alter the threat model, and can be evaluated with well-established methods, the Special pathway is a candidate. Confirm with a Pre-Sub before filing. ### Does enabling Secure Boot require a Traditional 510(k)? If it is the first time Secure Boot is enabled on the device, almost always yes. It changes the trust boundary, the recovery model, and the update flow - all of which materially shift the security risk profile. ### What if I am swapping an end-of-support SBOM component? If the replacement is a functional drop-in with equivalent or stronger security posture and no new network behavior, the Special pathway is plausible. If the replacement adds new dependencies, changes the API contract, or has different cryptographic behavior, expect to file Traditional. ### Do I still need an SBOM for a Special 510(k)? Yes. Section 524B(b)(3) requires an SBOM for every cyber device regardless of 510(k) type. For a Special, submit the full current SBOM plus a diff document against the cleared baseline. ### How long does a Pre-Sub take? The FDA's goal is a written response within 70 days of acceptance, with a meeting if requested. For a pathway-selection question, 70 days is faster than discovering mid-review that you filed wrong. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Infusion Pump Cybersecurity: FDA](/blog/infusion-pump-cybersecurity-fda) - [HHS 405(d) HICP Practice #9 for 524B](/blog/hhs-405d-medical-device-cybersecurity) - [AAMI SW96 vs TIR57: Did SW96 Replace It?](/blog/did-aami-sw96-replace-tir57-fda-2026) --- ## SweynTooth BLE Vulnerability in Medical Devices Source: https://bluegoatcyber.com/blog/sweyntooth-exploring-the-bluetooth-vulnerability # SweynTooth BLE Vulnerability in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** SweynTooth is a family of Bluetooth Low Energy stack vulnerabilities that can crash, hang, or destabilize connected medical devices such as pacemakers and glucose monitors, since many products inherited the flaw from third-party chipsets or SDKs. It matters for 2026 submissions because the FDA expects manufacturers to show component-level SBOM visibility, a clear VEX position, and test evidence tying the vulnerability to realistic patient-safety impact. [SweynTooth](https://www.cisa.gov/news-events/ics-alerts/ics-alert-20-063-01) is a family of BLE stack vulnerabilities that drew unusual joint attention from CISA and the FDA because pacemakers, glucose monitors, and other patient-connected devices were affected. For MedTech teams preparing a 510(k), De Novo, or PMA in 2026, it remains a useful case study for what the FDA now expects under **Section 524B**: SBOM-based component triage, clear VEX positions, and test evidence tied to realistic threat scenarios. ## Key Takeaways - SweynTooth exposed hidden risks in third-party BLE components. - FDA expects detailed SBOMs and VEX for premarket submissions. - Show how vulnerabilities impact device operation and patient safety. - Test evidence must validate claims about component security. - Implement practical mitigations for BLE, like secure pairing. - Wireless stack failures necessitate both cybersecurity and safety plans. ## Why this matters The stakes involved with vulnerabilities like SweynTooth are exceptionally high for medical devices; a seemingly minor wireless communication flaw can translate directly into patient harm or death. A software or hardware component failure, induced by an exploit in a third-party BLE stack, can render devices inoperable, compromise patient data, or disrupt critical therapy delivery. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes this risk. It requires manufacturers to submit detailed Bill of Materials (SBOMs) and Vulnerability Exploitability eXchange (VEX) statements for premarket submissions. This guidance aligns with existing standards such as IEC 81001-5-1 for health software and devices, ISO 14971 for risk management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles for medical device security. Such documentation must clearly articulate how potential vulnerabilities, even within third-party components, are addressed. Manufacturers must demonstrate, through testing and analysis, that their devices maintain safety and essential performance despite the presence of known vulnerabilities, and that their mitigations are effective in all realistic attack scenarios. This moves beyond simple patch verification to a deeper analysis of impact and exploitability. ## What SweynTooth Actually Is SweynTooth is not a single bug. It is a set of vulnerabilities found in Bluetooth Low Energy implementations used by multiple chipset vendors and device manufacturers. Most of the issues sit in the BLE link layer, where malformed or unexpected packets can trigger crashes, deadlocks, denial of service, or other unsafe behavior. ![Section Image](/imported-images/c9f8429b57fcc2bc.png) That matters in medical devices because BLE is often treated as a convenience feature when it is really part of the device’s operational attack surface. If the wireless stack can be knocked over, patient monitoring, alarms, data transfer, pairing, or therapy support functions may also fail. ### Why the Name Stuck “SweynTooth” came from the researchers’ naming convention, referencing Sweyn Forkbeard. The name is memorable, but the practical lesson is supply-chain exposure. Many affected products inherited vulnerable BLE behavior from third-party SDKs and SoCs rather than from custom application code. ### The Medical Device Problem For consumer gadgets, a BLE crash is annoying. For a medical device, the same failure can become a safety issue. A radio stack failure can interrupt telemetry, block clinician access, delay data synchronization, or force the device into a degraded state that was never fully analyzed for security and safety impact. That is exactly why SweynTooth still matters in premarket work. The FDA is not just looking for confirmation that a CVE was patched. Reviewers want to see that the manufacturer understood where the vulnerable component existed, whether the product was actually affected, what exploit conditions were realistic, and how residual risk was handled. ## How SweynTooth Attacks Work SweynTooth attacks generally rely on sending crafted BLE packets to a target running a vulnerable stack. Depending on the flaw, the device may crash, hang, stop responding, or enter an unintended state. In some cases, the result is denial of service; in others, the behavior can create a path to broader compromise. ![Section Image](/imported-images/aca4e91ed2997793.png) BLE was designed for low-power, intermittent communication, which makes it a good fit for wearables, implanted devices, and home-use medical products. It also means many implementations were optimized for efficiency first. When vendors cut corners in packet handling, state management, or error recovery, security faults show up in exactly the places manufacturers assumed were handled safely by the chipset or SDK provider. For medical device teams, the key point is simple: if your product includes BLE, the attack path does not end at “wireless present.” You need to map how malformed radio traffic affects device state, safety controls, logging, alarms, recovery behavior, and any downstream trust assumptions. ## What SweynTooth Teaches §524B Submitters SweynTooth is a good example of why checklist security fails. Saying “Bluetooth is encrypted” or “we use a reputable module” does not answer the questions the FDA is asking under §524B. You need evidence. ### Start with Component-Level Visibility If your device includes a BLE chipset, module, SDK, or third-party stack, it belongs in the SBOM at the right level of detail. That means enough specificity to support vulnerability correlation later. “Bluetooth library” is not useful. Vendor, component name, version, and dependency context are. Once a SweynTooth-related CVE is identified, triage should answer four questions: 1. Is the affected component present in the shipped or supported configuration? 2. Is the vulnerable code path reachable in this product? 3. What is the clinical and operational impact if exploited? 4. What compensating controls, patches, or design constraints change exploitability? That is where a VEX statement earns its keep. Not as paperwork, but as a concise technical position backed by traceable facts. ### Show Your Threat Model, Not Just the CVE List A premarket submission should connect the vulnerability to real system behavior. For SweynTooth, that usually means evaluating threats such as nearby unauthorized radio interaction, malformed packet injection during pairing or established sessions, disruption of telemetry, and forced device restart or lockup. If the device can fail safely, say how. If it cannot, explain what controls prevent the exploit or reduce likelihood. The FDA will not be impressed by a vulnerability table that stops at severity scores. Reviewers want to see whether the issue changes the device’s security and safety profile in a meaningful way. ### Test the Claim You Are Making If your position is “not affected,” support it with architecture and version evidence. If your position is “affected but mitigated,” support it with test data. If your position is “patched,” show what changed and how you verified the fix. That often includes: - BLE fuzzing or malformed packet testing against exposed interfaces - Verification of crash resistance, watchdog recovery, and safe-state behavior - Confirmation that security logging captures the event where appropriate - Regression testing to show the patch did not break pairing, telemetry, or therapy-supporting workflows - Evidence that exploit preconditions are blocked by design, not assumed away This is the difference between vulnerability management and submission-ready evidence. ## Protecting Devices from SweynTooth-Class Issues The first control is obvious but often incomplete: apply the vendor patch if one exists. The harder part is proving that the patch reached the actual fielded configuration and that it closed the problem without creating a new one. ![Section Image](/imported-images/488e7950c1d9d085.png) Medical device manufacturers also need to resist the temptation to push all responsibility onto the chipset supplier. If the BLE stack is inside your product, it is your risk to assess, document, and validate. ### Practical Mitigations Several defensive steps help reduce exposure to SweynTooth-style flaws: - Keep firmware, BLE stacks, and module SDKs current - Remove unused Bluetooth features and services - Require secure pairing and sane authentication flows - Constrain radio behavior to the minimum necessary operating modes - Monitor vendor advisories and maintain traceability from advisory to shipped product versions - Verify recovery behavior after malformed traffic, not just confidentiality controls For medical devices, add one more requirement: evaluate whether a wireless stack failure can create a hazardous situation. If so, the mitigation plan has to cover both cybersecurity and safety engineering. ## Where Bluetooth Security Is Headed SweynTooth was not the last BLE implementation problem, and it will not be the last inherited vulnerability from a third-party software component. What is changing is the level of scrutiny. The FDA, customers, and procurement teams increasingly expect manufacturers to show software transparency, faster vulnerability triage, and evidence that exploitability was evaluated in the context of the actual device. That means stronger secure development practices for wireless features, tighter supplier management, and more disciplined validation of third-party components. It also means fewer hand-wavy claims about “industry-standard Bluetooth security” and more product-specific proof. SweynTooth still earns attention because it exposed a pattern that shows up again and again in medical devices: hidden dependency risk, weak component traceability, and too little testing at the protocol boundary. Teams that fix those three problems are in much better shape for §524B submissions and for real-world security. If your team needs help turning BLE vulnerability triage into submission-ready evidence, Blue Goat Cyber works with medical device manufacturers on penetration testing, product security assessments, and FDA-aligned cybersecurity documentation. [Contact us for cybersecurity help](/contact). ## SweynTooth issue classes compared | Issue class | What the attacker sends | Effect on the device | Why it matters clinically | | --- | --- | --- | --- | | Link layer length overflow | An oversized or malformed length field | Crash or memory corruption in the stack | A therapy device that reboots mid-use is a safety event | | Truncated or invalid packets | A deliberately incomplete exchange | Deadlock in the connection state machine | The device stops responding until power cycled | | Public key crash | A malformed pairing key | Crash during pairing | Denial of service before any session exists | | Security bypass | A skipped or reordered pairing step | Connection without the intended authentication | Commands accepted from an unpaired peer | | Stack-specific memory bugs | Vendor-specific malformed input | Arbitrary behavior in the controller | The fix depends on a chip vendor you do not control | SweynTooth was not one bug. It was a demonstration that the Bluetooth stack you bought is software you are accountable for. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in navigating complex cybersecurity requirements, including preparing for the FDA’s stringent premarket submissions. Our work in threat modeling, penetration testing, and gap analysis helps identify and remediate vulnerabilities stemming from third-party components, such as those exposed by SweynTooth. We develop precise SBOMs and actionable VEX statements and provide tailored test evidence to comply with the FDA's February 3, 2026 final guidance. Our team, comprised of CISSP and OSCP-certified experts, including ex-military red team personnel, brings practical, security-first methodologies to every engagement. We prioritize identifying exploitability and its impact on essential performance and safety. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is SweynTooth? SweynTooth is a collection of vulnerabilities found in Bluetooth Low Energy (BLE) implementations across various chipset vendors. These flaws primarily affect the BLE link layer, potentially causing device crashes, denial of service, or other unsafe behaviors. ### Why does SweynTooth matter for medical devices? A BLE vulnerability like SweynTooth in a medical device can lead to safety issues, such as interrupted patient monitoring, delayed data synchronization, or critical device function failures. The FDA expects manufacturers to understand and mitigate these risks thoroughly in premarket submissions. ### What does the FDA expect regarding SweynTooth-like vulnerabilities? Under its February 3, 2026 final guidance, the FDA expects manufacturers to provide a software bill of materials (SBOM) with component details, a Vulnerability Exploitability eXchange (VEX) statement explaining exploitability, and test evidence. This demonstrates how vulnerabilities are identified, assessed, and mitigated within medical devices. ### How can manufacturers protect devices from SweynTooth-type issues? Manufacturers should keep firmware and BLE stacks updated, remove unused Bluetooth features, require secure pairing, and constrain radio behavior. They must also monitor vendor advisories, trace components, and verify recovery behavior after malformed traffic. ### Does patching a SweynTooth vulnerability fulfill FDA requirements? Simply patching a vulnerability is not enough for the FDA. Manufacturers must provide evidence that the patch was correctly implemented, verify its effectiveness, and demonstrate that it did not introduce new problems. Testing should confirm crash resistance, watchdog recovery, and safe-state behavior. **Related:** [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [What are Medical Device De Novo Requests?](/blog/de-novo-requests-for-medical-devices-explained) - [What is a Modular PMA Submission?](/blog/what-is-a-modular-pma-submission) - [Windows LAPS for Medical Devices](/blog/windows-laps-for-medical-devices-manage-local-admin-passwords-safely-not-gpp) - [Password Security for Medical Devices](/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization) --- ## TARA Threat Analysis and Risk Assessment | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/tara-medical-device-cybersecurity # TARA Threat Analysis and Risk Assessment for Medical Devices > **[DIRECT ANSWER]** TARA, threat analysis and risk assessment, is a structured method that identifies assets, builds damage and threat scenarios, analyzes attack paths, scores attack feasibility, and determines risk treatment decisions. It originated in automotive cybersecurity through ISO/SAE 21434 and maps onto medical device security risk management through AAMI SW96 and ISO 14971. TARA is most useful when a manufacturer needs a feasibility-driven, asset-centric risk picture rather than a purely categorical threat sweep like STRIDE. _Reviewed September 17, 2026_ Medical device manufacturers increasingly hear "TARA" from consultants and standards bodies without a clear explanation of where it came from or how it differs from the STRIDE-based threat modeling many teams already use. That confusion has a cost: choosing the wrong framing, or applying TARA terminology without its actual attack feasibility and risk treatment steps, can produce a security risk assessment that looks complete but leaves gaps a reviewer will find. TARA did not originate in medical devices. It came from automotive cybersecurity, where ISO/SAE 21434 formalized it as the method for assessing cyber risk to connected vehicle systems. Medical device teams have since adapted the same structure because it forces a disciplined path from asset to attack path to risk decision, which aligns well with how AAMI SW96 and ISO 14971 expect security risk to be documented. This guide explains the method's origin, its steps, how it maps onto medical device standards, and when it makes more sense than a STRIDE-only approach. ## Key Takeaways - TARA originated in automotive cybersecurity under ISO/SAE 21434 and was adapted for medical devices because both domains need feasibility-driven, asset-centric risk scoring. - AAMI SW96 and ISO 14971 give medical device manufacturers the structure to connect TARA's attack feasibility and risk determination steps to formal patient harm categories. - TARA's core steps are asset identification, damage scenarios, threat scenarios, attack path analysis, attack feasibility rating, risk determination, and treatment decisions. - TARA is strongest when a team needs to justify why a risk was accepted, transferred, or mitigated with a defensible feasibility rationale, not just a category label. - STRIDE and TARA are complementary rather than competing; many manufacturers use STRIDE to enumerate threats and TARA's feasibility and treatment steps to finish the risk assessment. ## Why This Matters The FDA's premarket cybersecurity guidance, finalized February 3, 2026, requires every cyber device submission under Section 524B of the FD&C Act to include a documented threat model and a security risk assessment connected to patient harm. The guidance does not name TARA specifically, but its requirements, asset and threat identification, risk scoring tied to clinical consequence, and documented treatment decisions, map directly onto TARA's structure. Manufacturers coming from automotive, industrial, or aerospace backgrounds often bring TARA with them because it is the risk assessment method their engineers already know from ISO/SAE 21434. The challenge is that automotive TARA scores risk against vehicle safety and financial impact, while medical device risk management under ISO 14971 requires scoring against patient harm categories, so the method needs adaptation, not a direct copy. AAMI SW96, the software cybersecurity standard for medical devices, describes a risk management process compatible with TARA's steps: identify assets, characterize threats, assess feasibility, determine risk, and decide on treatment. Used correctly, TARA gives manufacturers a defensible, repeatable way to justify why a given vulnerability was mitigated, accepted, or transferred, which is exactly the kind of documented decision-making the FDA's reviewers expect to see in a security risk assessment rather than an unexplained risk rating. ## Where Did TARA Come From? TARA originated in automotive cybersecurity, formalized as a required process under ISO/SAE 21434 for assessing cyber risk across a vehicle's electronic systems. The automotive industry needed a method that could rate the feasibility of an attack, not just its theoretical existence, because vehicle systems face a wide range of attackers with very different capabilities. That feasibility focus is TARA's defining trait compared to a pure threat enumeration method. Rather than just listing that a threat exists, TARA asks how feasible it actually is for a realistic attacker to execute, given the elapsed time, expertise, knowledge of the system, window of opportunity, and equipment required. **[KEY REQUIREMENT]** Any TARA adapted for medical devices must replace automotive-specific feasibility factors and damage categories with equivalents grounded in clinical environments and patient safety impact, not a direct copy-paste of the ISO/SAE 21434 scoring tables. ## How Does TARA Map Onto Medical Device Risk Management? TARA maps onto medical device risk management by substituting ISO 14971 patient harm severity for automotive safety and financial impact categories, while keeping the same asset-to-treatment structure. AAMI SW96 describes a compatible process, so a manufacturer using TARA is not inventing a new risk management approach, but adapting an established one to a standard the FDA already recognizes. The practical mapping happens at the damage scenario and risk determination steps. A damage scenario in automotive TARA might describe unintended braking; in a medical device, the equivalent describes a clinical consequence, such as unintended therapy delivery or delayed treatment. The risk determination step then uses the same ISO 14971 severity and probability matrix a manufacturer's broader risk management file already relies on. | TARA step | Automotive framing (ISO/SAE 21434) | Medical device framing | |---|---|---| | Asset identification | Vehicle ECUs, communication buses, external interfaces | Implant firmware, programmer, mobile app, cloud services | | Damage scenario | Unintended acceleration or braking | Unintended or withheld therapy delivery | | Risk determination basis | Safety, financial, operational, privacy impact | ISO 14971 severity and probability of patient harm | | Governing standard | ISO/SAE 21434 | AAMI SW96 and ISO 14971 | ## What Are the Steps in a TARA Process? A TARA process runs through seven steps: asset identification, damage scenario definition, threat scenario development, attack path analysis, attack feasibility rating, risk determination, and treatment decision. Each step builds on the last, so skipping one, such as attack path analysis, weakens the feasibility rating that follows it. Asset identification lists every component and data element with security relevance, similar to the scoping step in STRIDE-based threat modeling. Damage scenarios describe what happens if an asset's security property is compromised, expressed in terms of clinical consequence for a medical device rather than a generic technical impact statement. Threat scenarios describe how an attacker could cause that damage, and attack path analysis breaks the threat scenario into the specific steps and preconditions an attacker would need. Attack feasibility rating then scores how realistic that path actually is, considering the elapsed time, specialist expertise, knowledge of the device, window of opportunity, and equipment an attacker would need. **[KEY REQUIREMENT]** Attack feasibility ratings must be documented with the specific factors that produced the score, not just a final number, so a reviewer can evaluate whether the rating is defensible. Risk determination combines the feasibility rating with the damage scenario's severity, typically using ISO 14971's severity and probability matrix for medical devices. Treatment decisions then record whether the manufacturer will mitigate, accept, transfer, or avoid the risk, along with the rationale. ## When Is TARA the Right Framing Instead of STRIDE? TARA is the right framing when a manufacturer needs a defensible, feasibility-driven justification for a risk treatment decision, particularly for regulatory bodies or standards that expect ISO/SAE 21434-style rigor. STRIDE, by contrast, is better suited to systematically enumerating threats across every trust boundary in a data flow diagram, which is why many teams use both rather than choosing one exclusively. A manufacturer building a connected infusion pump might use STRIDE to walk every trust boundary and generate a full threat register, then apply TARA's attack feasibility and risk determination steps to the highest-priority threats to produce a documented, defensible treatment decision. Using TARA alone, without a systematic enumeration step like STRIDE, risks missing threats that a category-based sweep would have caught, since TARA's structure assumes threats have already been identified before feasibility scoring begins. | Dimension | TARA | STRIDE | FMEA | |---|---|---|---| | Primary strength | Feasibility-driven risk scoring and treatment justification | Systematic threat enumeration across trust boundaries | Failure mode analysis tied to functional safety | | Origin | Automotive cybersecurity, ISO/SAE 21434 | Microsoft security engineering | Reliability engineering | | Best used for | Prioritizing and justifying treatment of identified threats | Finding threats you have not thought of yet | Analyzing how component failures propagate to hazards | | Medical device mapping | AAMI SW96, ISO 14971 severity and probability | AAMI SW96 categories layered with ISO 14971 harm | ISO 14971 hazard and harm analysis | | Typical gap if used alone | May miss threats without a prior enumeration step | Can under-weight attacker feasibility and realistic effort | Not designed to capture intentional adversarial behavior | For a closer comparison of category-based threat modeling methods, see [Comparing DREAD, STRIDE, and PASTA Threat Models](/blog/comparing-dread-stride-and-pasta-threat-models-which-is-most-effective), and for how failure-mode analysis compares to threat modeling generally, see [FMEA vs Threat Modeling for Medical Devices](/blog/fmea-vs-threat-modeling-medical-devices). ## What Attack Feasibility Factors Should a Medical Device TARA Use? A medical device TARA should score attack feasibility using elapsed time, specialist expertise required, knowledge of the specific device, window of opportunity, and equipment needed, adapted from the automotive model but applied to clinical and home-use environments. A device used unsupervised in a patient's home, for example, has a different window-of-opportunity profile than one used only in a monitored clinical setting. Feasibility scoring should also account for whether an attacker needs physical access to the device, since implantables and home-use devices often have different physical exposure than devices confined to a hospital network. A threat that requires extended physical possession of an implant is far less feasible for a remote attacker than one exploitable over a hospital Wi-Fi network. ## How Should Risk Determination and Treatment Decisions Be Documented? Risk determination should combine the attack feasibility rating with the ISO 14971 severity of the associated damage scenario, using the same risk matrix already defined in the manufacturer's risk management file. This keeps the TARA output consistent with the broader risk management documentation the FDA reviews, rather than introducing a second, incompatible risk scale. Treatment decisions need to record which of four options was chosen, mitigate, accept, transfer, or avoid, along with the rationale and any residual risk. A decision to accept a risk without mitigation needs a documented justification tied to the feasibility and severity ratings, since reviewers commonly ask why a given risk was left unaddressed. ## How Blue Goat Cyber Approaches This Blue Goat Cyber builds threat analysis and risk assessments for medical device manufacturers that combine STRIDE-based threat enumeration with TARA-style feasibility scoring and ISO 14971 risk determination, producing documentation structured for AAMI SW96 alignment and FDA premarket review. The work maps damage scenarios to clinical consequences and documents attack feasibility factors specific to the device's use environment, whether that is a hospital network or unsupervised home use. For manufacturers who want this work scoped as part of an ongoing program, see [Threat Modeling Services](/services/medical-device-threat-modeling), which covers both threat enumeration and risk assessment documentation. ## Frequently Asked Questions ### Does the FDA require TARA by name? No. The FDA's February 3, 2026 premarket cybersecurity guidance does not name TARA specifically, but it requires a documented threat model and a security risk assessment tied to patient harm, requirements that TARA's structure satisfies when adapted to ISO 14971 severity categories. ### Can TARA replace STRIDE entirely? TARA can replace STRIDE for the risk scoring and treatment portion of the process, but it assumes threats have already been identified. Most manufacturers use STRIDE, or a similar enumeration method, to find threats systematically and TARA's feasibility and treatment steps to finish the risk assessment. ### What is the biggest difference between automotive and medical device TARA? The biggest difference is the risk determination basis: automotive TARA scores against vehicle safety, financial, operational, and privacy impact, while medical device TARA scores against ISO 14971 patient harm severity and probability. The steps and structure carry over, but the scoring categories need to be rebuilt around clinical consequence. ### Is TARA suitable for a low-risk connected accessory? Yes, though the depth of the analysis can scale with the device's risk classification. A low-risk accessory still needs asset identification and a documented rationale for any threats rated as low feasibility or low severity, even if the full attack path analysis is lighter than it would be for an implantable device. ### How does AAMI SW96 relate to TARA? AAMI SW96 describes a software cybersecurity risk management process for medical devices that is structurally compatible with TARA's steps, including asset identification, threat characterization, and risk-based treatment decisions. It gives manufacturers a recognized standard to reference when documenting a TARA-based security risk assessment for the FDA. ## CTA If your team needs help scoping a threat analysis and risk assessment for a premarket submission or aligning an existing TARA with AAMI SW96 and ISO 14971, [talk to Blue Goat Cyber](/contact) about how the work fits your submission timeline. Christian Espinosa is the founder of Blue Goat Cyber and writes on medical device cybersecurity, threat modeling, and FDA premarket strategy. Read more from him at [his author page](/christian-espinosa). --- ## TGA Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/tga-australia-medical-device-cybersecurity # TGA Medical Device Cybersecurity: Australia Requirements in 2026 > **[DIRECT ANSWER]** The TGA regulates medical device cybersecurity through Essential Principles 12 and 12A rather than a dedicated submission section, supported by its Medical device cyber security guidance for industry (v1.2, November 2022). Most of an FDA Section 524B package is reusable for an ARTG inclusion, but it must be mapped to the Essential Principles and paired with Australian labeling, an Australian Declaration of Conformity, and a postmarket plan that reflects URPTG and TGA reporting. The TGA aligns with IMDRF principles and recognizes much of the content that satisfies the FDA's February 3, 2026 final premarket cybersecurity guidance. The mechanism is different: instead of a single submission section, cybersecurity evidence is mapped to the Essential Principles 12 and 12A and to the conformity assessment route appropriate for the device class. This post explains what the TGA expects in 2026, where Australian sponsors and overseas manufacturers most commonly fall short, and how to convert an existing FDA package into ARTG-ready content. ## Key Takeaways - The TGA classifies devices as Class I, IIa, IIb, III, and AIMD, broadly aligned with the EU MDR system. - Cybersecurity is regulated through Essential Principles 12 (software) and 12A (programmable medical devices). - The TGA's Medical device cyber security guidance for industry (v1.2, November 2022) lists six pre-market expectations that mirror the FDA and Health Canada model. - Postmarket vigilance under the Uniform Recall Procedure for Therapeutic Goods (URPTG) applies to cybersecurity incidents. - An FDA Section 524B package is reusable but must be mapped to the Essential Principles and Australian labeling rules. ## Why this matters The Australian Register of Therapeutic Goods (ARTG) is the gateway for medical device commercialization in Australia. Cybersecurity expectations are written into the Essential Principles in the Therapeutic Goods (Medical Devices) Regulations 2002 and elaborated in the TGA's industry guidance. The guidance aligns with IMDRF N60 ("Principles and Practices for Medical Device Cybersecurity") and references IEC 81001-5-1, AAMI TIR57 / ANSI/AAMI SW96:2023, and ISO 14971. Sponsors that operate from an FDA Section 524B baseline can reuse most technical content, but the conformity assessment evidence, labeling, and postmarket plan need to map to Australian rules. Skipping that mapping is the most common reason TGA reviewers raise cybersecurity questions on otherwise complete applications. ## How the TGA Classifies Medical Devices ### EU-Aligned Classification The TGA uses classes broadly aligned with the EU MDR: Class I, Class IIa, Class IIb, Class III, and Active Implantable Medical Devices (AIMD). The classification rules under Schedule 2 of the Regulations determine the conformity assessment route. Connected diagnostic and therapeutic software devices commonly fall in Class IIa or IIb; implantables and life-sustaining devices fall in Class III or AIMD. ### The Software Classification Rule The TGA's software-as-a-medical-device classification rules, in force since February 2021 with transition arrangements that closed in November 2024, elevated many SaMD products to Class IIa or higher. This rule is significant for cybersecurity because the rule shifts the bar for evidence and conformity assessment. Sponsors must check current classification rules for software products at the time of application. ## How the TGA Classifies IVD Medical Devices In vitro diagnostic devices sit in a separate classification scheme in Australia. IVDs are classified Class 1, 2, 3, or 4 IVD under Schedule 2A of the Therapeutic Goods (Medical Devices) Regulations 2002, based on the public health risk and the risk to the individual if the result is wrong. That is a different ladder from the Class I to III and AIMD scheme used for other devices, and it changes both the conformity assessment route and the depth of cybersecurity evidence the TGA expects. ### Decision Criteria Work through these questions in order to place an IVD: 1. **Is the product an IVD at all?** If it is a reagent, calibrator, control material, instrument, or software intended to examine a specimen taken from the body to provide information about a physiological state, disease, or compatibility, it is an IVD. Software that only stores or transmits results without interpreting them may fall outside the IVD scheme and be regulated as SaMD instead. 2. **Is it for self-testing or point of care?** Self-test IVDs carry a higher classification than the same assay used in a laboratory, because there is no professional interpreting the result. 3. **What happens if the result is wrong for the individual?** A wrong result that leads to a life-threatening treatment decision, a missed cancer diagnosis, or a transfusion error pushes the device up the ladder. 4. **What happens if the result is wrong at population scale?** Transmissible-agent screening, blood and tissue donor screening, and detection of agents with a high risk of propagation sit at the top of the scheme. 5. **Is it an in-house IVD?** Laboratories manufacturing IVDs for their own use fall under a separate TGA framework with its own notification and compliance obligations rather than standard ARTG inclusion. The practical result: | IVD class | Risk framing | Typical examples | Conformity assessment | | --- | --- | --- | --- | | Class 1 IVD | No public health risk, low personal risk | Specimen receptacles, general culture media | Sponsor self-assessment, ARTG inclusion | | Class 2 IVD | Low public health risk, moderate personal risk | Vitamin D assays, pregnancy self-tests, urinalysis analyzers | TGA or notified body evidence, application audit possible | | Class 3 IVD | Moderate public health risk, high personal risk | HIV and hepatitis staging assays, companion diagnostics, cancer markers | Conformity assessment evidence required, mandatory application audit | | Class 4 IVD | High public health risk | Blood and tissue donor screening, HIV and HCV detection, blood grouping (ABO, Rh) | TGA conformity assessment certification, mandatory audit | ### How IVD Class Changes Cybersecurity Obligations The six pre-market expectations in the TGA cyber security guidance apply to every connected IVD, but the evidence bar scales with class: - **Class 1 and 2 IVD.** A documented security risk assessment tied to ISO 14971, an SBOM for any bundled software, secure configuration labeling, and a postmarket monitoring plan. Penetration testing is expected where the analyzer or middleware is network connected. - **Class 3 IVD.** Everything above plus a formal threat model that treats result integrity, quality-control bypass, and LIS or middleware interoperability as first-class harm scenarios, security architecture views, and verification evidence proportionate to the mandatory application audit. - **Class 4 IVD.** The Class 3 content plus population-scale harm analysis in the risk file (for example, a manipulated donor-screening result propagating into the blood supply), documented controls over result transmission integrity, and a postmarket plan with defined timelines for vulnerability triage across long installed lifetimes. Two class-driven consequences catch sponsors out. First, Class 3 and Class 4 IVDs attract a mandatory application audit, so cybersecurity evidence that would never be read for a Class 1 device is read line by line. Second, the harm analysis has to be about diagnostic error, not device malfunction. A threat model that only reasons about availability and device uptime will draw questions, because the patient harm from an IVD flows through the wrong result reaching a clinician. Connectivity does not change the class, but it does change the evidence. A Class 2 IVD analyzer with an HL7 or ASTM interface into a networked LIS needs the same interface-level analysis as a higher-class device, because that interface is the path an attacker uses to alter results. ## Essential Principles 12 and 12A ### What the Essential Principles Require Essential Principle 12 covers medical devices that incorporate software or are themselves software, requiring that they be developed with regard to the state of the art and to the principles of development lifecycle, risk management, validation, and verification. Essential Principle 12A explicitly covers programmable medical devices and requires repeatability, reliability, and performance consistent with the intended use. Cybersecurity sits inside both principles. > **[KEY REQUIREMENT]** The TGA expects sponsors to demonstrate compliance with EPs 12 and 12A through documented evidence, not by reference to compliance with other jurisdictions alone. ### How the TGA Reads the Evidence The TGA accepts evidence from EU notified body conformity assessments, MDSAP audits, and FDA submissions in many cases, but the sponsor's Australian Declaration of Conformity must explicitly map evidence to the relevant Essential Principles. A US-cleared device with an FDA Section 524B package still needs the EP mapping for the ARTG inclusion. ## The TGA Cybersecurity Guidance Content Areas The TGA's "Medical device cyber security guidance for industry" (v1.2, November 2022, still the current version as of 2026) lists six pre-market expectations: | TGA expectation | What it covers | | --- | --- | | Risk management | Security risk management process per AAMI TIR57 / ANSI/AAMI SW96:2023 or equivalent, integrated with ISO 14971 | | Secure design | Architectural decisions, trust boundaries, defense in depth | | Verification | Security testing including penetration testing where appropriate | | SBOM | Inventory of software components, including third-party libraries | | Labeling | Information for users on secure deployment and operation | | Postmarket plan | Vulnerability monitoring, response, and update strategy | The structure mirrors the FDA Feb 3, 2026 guidance and the Health Canada 2019 guidance, which is why the technical content is largely portable. ## ARTG Conformity Assessment Evidence Routes by Class Classification tells you the risk tier. The conformity assessment route tells you who has to certify the evidence, which certificate the TGA will accept, and how much of your cybersecurity documentation a reviewer will actually read before inclusion. Sponsors who get the classification right and the route wrong still end up in a request for information. ### Who Can Certify the Evidence Australia recognizes three broad sources of conformity assessment evidence: - **TGA Conformity Assessment Certificate.** Issued by the TGA itself after a direct assessment of the manufacturer's quality management system and technical documentation. Mandatory for Class 4 IVDs and for Australian-manufactured Class III and AIMD devices, and available by choice to any manufacturer. - **Comparable overseas regulator evidence.** The TGA accepts EU MDR and IVDR notified body certificates, and in defined circumstances certificates and approvals from other comparable regulators, as the basis for an abridged assessment. This is the route most overseas manufacturers use. - **Manufacturer's own declaration.** For the lowest risk tiers, the manufacturer holds the technical file and the sponsor makes an Australian Declaration of Conformity without third-party certification. The evidence still has to exist and be produceable on request. Whichever route applies, the sponsor lodges an Australian Declaration of Conformity that maps the evidence to the Essential Principles. Cybersecurity evidence is mapped to Essential Principles 12 and 12A, and that mapping is the sponsor's obligation regardless of who issued the underlying certificate. ### Routes and Cybersecurity Evidence Depth | Class | Typical conformity assessment route | Application audit | Cybersecurity evidence a reviewer expects to see | | --- | --- | --- | --- | | Class I (non-sterile, non-measuring) | Manufacturer declaration, sponsor holds evidence | Rarely selected | Security risk assessment, SBOM if software is present, secure use labeling | | Class I sterile, measuring, reusable surgical | Third-party certificate covering the specific aspect | Possible | As above plus verification evidence for the certified aspect | | Class IIa | EU notified body certificate or TGA certificate | Random selection | Risk assessment, secure design rationale, SBOM, security testing summary, postmarket plan | | Class IIb | EU notified body certificate or TGA certificate | Higher likelihood, mandatory for some device types | Full six-expectation set with a documented threat model and penetration testing evidence | | Class III | TGA certificate or accepted overseas certificate | Mandatory | Threat model, security architecture views, SBOM with VEX, verification and penetration testing reports, postmarket cybersecurity management plan | | AIMD | TGA conformity assessment certificate | Mandatory | Class III content plus elevated verification of security controls and an explicit patient-harm linkage in the ISO 14971 file | | Class 1 and 2 IVD | Manufacturer declaration or overseas certificate | Class 2 may be selected | Risk assessment, SBOM, labeling, postmarket monitoring plan | | Class 3 IVD | Conformity assessment evidence required | Mandatory | Threat model covering result integrity and LIS interfaces, architecture views, testing evidence | | Class 4 IVD | TGA conformity assessment certificate | Mandatory | Class 3 IVD content plus population-scale harm analysis and result transmission integrity controls | ### What This Means in Practice Three route-driven behaviors are worth planning for. Mandatory audit classes get a real technical review. For Class III, AIMD, and Class 3 and 4 IVDs, the TGA reads the technical documentation rather than accepting the certificate at face value. Cybersecurity gaps that survived a notified body review can surface here, most often as a threat model that is not traceable to the risk management file. Abridged routes still need the Essential Principles mapping. An EU MDR certificate demonstrates conformity with the EU General Safety and Performance Requirements, not with the Australian Essential Principles. The crosswalk from GSPR 17 and Annex I security content to EPs 12 and 12A has to be written out, and it is the single most common piece of missing paperwork in cybersecurity-related requests for information. Changes to security controls can be certificate-affecting. Adding an update mechanism, changing authentication architecture, or altering the network interface can constitute a substantial change requiring notification to the certifying body and to the TGA before the change reaches the Australian market. Build that trigger into the change control procedure rather than discovering it during a postmarket update. ## Relying on Comparable Overseas Regulator Reports The TGA runs a comparable overseas regulator (COR) framework that lets sponsors use assessment reports and approvals from other trusted regulators instead of repeating the full assessment in Australia. For cybersecurity, this is the mechanism that makes a Section 524B package or an EU notified body file worth reusing. It is a reliance pathway, not a mutual recognition pathway: the TGA still makes its own decision, and it still expects the evidence to be mapped to the Australian Essential Principles. ### Which Regulators the TGA Treats as Comparable The TGA's comparable overseas regulator arrangements cover, among others, the US FDA, the EU notified body system under MDR and IVDR, Health Canada, Japan's PMDA, and Singapore's HSA, with the accepted scope varying by device type and by the specific program the approval came from. Two points matter more than the list itself. First, the scope is device-specific: a regulator can be comparable for one class or device type and not for another. Second, the report has to cover the same device, same intended purpose, and same manufacturing sites as the Australian application. Confirm current scope on the TGA's comparable overseas regulator pages before you build an application around a given report, because the arrangements are updated over time. ### What a COR Report Can and Cannot Do for Cybersecurity A COR report can shorten the TGA's assessment of technical documentation you have already had reviewed elsewhere. It cannot replace the sponsor's Australian obligations. - **Can support:** the security risk assessment, threat model, secure design rationale, SBOM, verification and penetration testing evidence, and the software lifecycle process evidence under IEC 81001-5-1. - **Cannot replace:** the Australian Declaration of Conformity, the EP 12 and 12A mapping, Australian-specific labeling and instructions for use, and the postmarket plan aligned to URPTG and TGA adverse event reporting. - **Does not transfer automatically:** conditions, restrictions, or postmarket commitments imposed by the overseas regulator. Disclose them; the TGA will decide whether equivalent conditions apply in Australia. > **[KEY REQUIREMENT]** Reliance on a comparable overseas regulator report does not remove the sponsor's obligation to demonstrate compliance with Essential Principles 12 and 12A. The mapping document is always the sponsor's to produce. ### Practical Guidance for Citing Overseas Reports Treat the citation as a traceable evidence package rather than a reference in a cover letter. 1. **Cite the report precisely.** Name the regulator, the decision or certificate number (510(k) number, De Novo number, PMA number, notified body certificate number), the decision date, the device name as approved, and the intended purpose as approved. A reference to "FDA cleared" with no number will draw a request for information. 2. **Include the report itself, not a summary.** Provide the assessment report or certificate plus the relevant technical documentation. Where the FDA decision summary is thin on cybersecurity, which is common, include the submitted cybersecurity documentation directly rather than relying on the public summary to carry it. 3. **Prove device identity.** Add a short statement of equivalence covering device name and model, intended purpose, software version, hardware configuration, and manufacturing sites, with an explicit note on any difference between the overseas-approved device and the Australian device. Software version drift is the difference sponsors most often forget to declare. 4. **Provide the crosswalk table.** One row per Essential Principle clause relevant to software and cybersecurity, with the specific overseas document, section, and page number that satisfies it. Reviewers follow this table; if it is missing, they ask for it. 5. **Reconcile the standards.** State which standards the overseas evidence was built against (ANSI/AAMI SW96:2023, AAMI TIR57, IEC 81001-5-1, ISO 14971, IMDRF N60) and confirm they are the versions the TGA guidance points to. Where an older version was used, explain the gap and how it was closed. 6. **Declare deficiencies and their resolution.** If the overseas regulator raised cybersecurity deficiencies, include the deficiency letter and your response. Omitting them and having the TGA find them later is materially worse than disclosing them. 7. **Bridge the postmarket plan.** The overseas plan usually maps to the overseas reporting regime. Add an Australian annex covering URPTG obligations, TGA adverse event reporting timelines, and the Australian sponsor contact who owns vulnerability disclosure intake. 8. **Keep the file current.** If the overseas approval is amended, supplemented, or subject to a safety action after you lodge, update the Australian application. Reliance on a superseded decision is a live compliance risk, not just an administrative one. ### A Worked Example A Class IIb connected infusion pump cleared by the FDA under a 510(k) in 2026 would cite the 510(k) number and decision date, attach the cybersecurity documentation submitted with that 510(k) (threat model, SBOM with VEX, architecture views, penetration testing report, postmarket cybersecurity management plan), add a statement confirming the Australian device is the same model at the same software version from the same manufacturing site, and provide a crosswalk table mapping each artifact to EP 12 and EP 12A. The postmarket cybersecurity management plan would carry an Australian annex for URPTG and TGA reporting. That package is normally enough for the TGA to rely on the FDA assessment rather than re-reviewing the technical file from scratch. ## Mapping an FDA Section 524B Package to ARTG Content ### What Maps Directly The threat model, SBOM with VEX, security architecture views, verification and penetration testing evidence, and postmarket cybersecurity management plan from a Section 524B package map directly into the TGA's six expectations. Sponsors should bundle the evidence with an explicit EP 12 and EP 12A mapping document so reviewers can trace each expectation to a piece of evidence. ### What Needs Adaptation The Australian labeling content must satisfy local language and regulatory requirements. The postmarket plan must reference Uniform Recall Procedure for Therapeutic Goods (URPTG) obligations and the TGA's adverse event reporting expectations, not the FDA's 21 CFR Part 803 pathway alone. The Declaration of Conformity must be Australian-specific. ## Postmarket Obligations and Recall Reporting ### URPTG and Hazard Alerts The Uniform Recall Procedure for Therapeutic Goods governs how sponsors handle product recalls, hazard alerts, and safety advisories in Australia. Cybersecurity incidents that meet the threshold for a hazard alert or recall trigger URPTG obligations, including notifications to the TGA and to healthcare providers. ### Adverse Event Reporting Sponsors must report serious adverse events and near-incidents to the TGA. Cybersecurity incidents that result in or could result in serious injury, illness, or death are reportable. The IR plan and CVD policy referenced in the application package should make the Australian reporting pathway explicit. > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat Approaches TGA Submissions We treat TGA submissions as an Essential Principles mapping exercise for sponsors who already have an FDA Section 524B package. The technical content set carries over largely intact; the work is in the Declaration of Conformity, the EP 12/12A mapping, the Australian-specific labeling, and the postmarket plan adaptation for URPTG and TGA adverse event reporting. Our team holds CISSP, OSCP, and prior military red-team credentials, and our submission work is grounded in IEC 81001-5-1, AAMI TIR57 / ANSI/AAMI SW96:2023, ISO 14971, IMDRF N60, and the FDA February 3, 2026 final premarket cybersecurity guidance. If the regulator raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Start with our [international medical device cybersecurity services](https://bluegoatcyber.com/services/medical-device-cybersecurity) or compare regimes on the [EU MDR vs FDA cybersecurity guide](https://bluegoatcyber.com/guides/eu-mdr-vs-fda-cybersecurity). ## FAQ ### Does the TGA require an SBOM? Yes. The TGA's medical device cybersecurity guidance lists an SBOM as one of the six pre-market expectations. CycloneDX and SPDX are the common formats, consistent with FDA and Health Canada practice. The SBOM must be current at the time of application. ### Can the TGA accept an FDA Section 524B submission as-is? The technical content is largely accepted, but the sponsor still must produce an Australian Declaration of Conformity, an Essential Principles 12 and 12A mapping, and labeling and postmarket content that fit Australian requirements. The TGA does not waive the EP mapping based on FDA clearance alone. ### What is Essential Principle 12A? EP 12A is the Australian Essential Principle that explicitly covers programmable medical devices. It requires that programmable medical devices perform with repeatability, reliability, and consistency appropriate for the intended use. Cybersecurity evidence supports EP 12A by demonstrating that security controls do not undermine that performance. ### How does TGA classification differ from FDA classification? The TGA uses an EU-aligned classification system (I, IIa, IIb, III, AIMD), while the FDA uses three classes (I, II, III) under 21 CFR Part 860. The classification rules are different, and a device that is FDA Class II may be TGA Class IIa, IIb, or III depending on the rules that apply. ### What postmarket reporting applies to cybersecurity incidents? Sponsors must report serious adverse events and near-incidents to the TGA, and incidents that meet the threshold for a hazard alert or recall trigger URPTG obligations. The postmarket cybersecurity plan should describe the decision criteria, the timeline, and the owner for each pathway. ## Ready to bring your device to the Australian market? If you have an FDA-cleared device and need a TGA ARTG inclusion with cybersecurity content that maps cleanly to Essential Principles 12 and 12A, we can help. If the regulator raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. [Schedule a discovery call](https://bluegoatcyber.com/contact). --- *Christian Espinosa, Founder, Blue Goat Cyber, CISSP, OSCP. Christian has led international medical device cybersecurity programs across FDA, EU MDR, and APAC pathways and previously commanded military red-team operations. Read more at [christian-espinosa](https://bluegoatcyber.com/christian-espinosa).* --- ## The Dangers of Pacemaker Hacks Source: https://bluegoatcyber.com/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know # The Dangers of Pacemaker Hacks: for Medical Device Manufacturers > **[DIRECT ANSWER]** Pacemaker hacks are attacks that exploit wireless programming interfaces or unsecured monitoring links to alter heart rhythm, drain the battery, or cause device malfunction, sometimes through proximity-based signal manipulation. The FDA's February 3, 2026 premarket cybersecurity guidance expects manufacturers to design encryption, authentication, and secure pairing into pacemakers and to maintain those controls across the device lifecycle. Patients and providers should keep software updated and monitor for unusual device behavior. _Updated October 26, 2024_ In our increasingly connected world, the threat of cyber attacks extends beyond computers and smartphones. With the advent of [Internet of Things (IoT) devices](/blog/securing-iot-enabled-medical-devices-5-essential-tips), even life-saving medical devices are potential targets. One such device is the pacemaker, a small implantable device that helps regulate a person’s heartbeat. While pacemakers have undoubtedly improved the quality of life for millions of individuals, they are not immune to hacking. Understanding the risks and taking preventive measures is crucial to ensuring the safety and well-being of patients who rely on these devices. ## Key Takeaways - Modern pacemakers have wireless vulnerabilities. - Hacks can alter heart rhythm or cause malfunction. - Patients need regular software updates. - Secure wireless communication is critical. - Healthcare providers must ensure device security. - Regulatory bodies set cybersecurity standards. ## Why this matters The stakes involved when medical devices like pacemakers are compromised are profoundly high; patient safety and lives depend on their uninterrupted, secure function. The FDA, in its Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, emphasizes that manufacturers are responsible for designing, developing, and maintaining devices with appropriate cybersecurity controls throughout their lifecycle. Failure to do so can lead to device malfunction, data breaches, and severe patient harm. This guidance highlights the necessity for proactive cybersecurity measures to protect patients from potential exploitation of device vulnerabilities. Adherence to standards like IEC 81001-5-1, ISO 27001, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is crucial for establishing a baseline for risk management and ensuring medical device security. These standards provide frameworks for managing information security risks in healthcare environments and specifically for medical devices, reinforcing the need for continuous vigilance against evolving cyber threats. The integrity of pacemakers directly impacts patient well-being, making cybersecurity an integral component of medical device safety. ## Understanding Pacemaker Hacks ![Section Image](/imported-images/63d80f97168d96df.png) ### The Basics of Pacemakers and Digital Security Pacemakers are small devices that monitor and regulate the electrical impulses in the heart to maintain a steady heartbeat. They are implanted surgically and typically programmed by healthcare professionals to suit the individual patient’s needs. Modern pacemakers are equipped with wireless capabilities, allowing healthcare providers to monitor and adjust their settings remotely without the need for invasive procedures. However, this convenience comes with a potential downside - the [vulnerability to hacking](/blog). Several high-profile incidents have highlighted the threat posed by pacemaker hacks in recent years. ### How Pacemaker Hacks Occur Like any other IoT device, Pacemakers communicate wirelessly using radio frequency (RF) signals. Hackers exploit vulnerabilities in the pacemaker system to gain unauthorized access and tamper with the device’s functionality. This can include altering the heartbeat rhythm, draining the battery, or even causing the device to malfunction, which poses a serious threat to the patient’s life. One common method of pacemaker hacking is unauthorized access to the pacemaker’s programming interface. By gaining access to this interface, hackers can modify the device’s settings and override the controls put in place by healthcare professionals. Another avenue for pacemaker hacks is wireless communication between the pacemaker and external monitoring devices. If these communication channels are not properly secured, hackers can intercept and manipulate the data to their advantage. Researchers have discovered that pacemakers can be vulnerable to attacks through proximity-based techniques. This means that a hacker could potentially gain control of a pacemaker by being physically close to the patient. By using specialized equipment, hackers can exploit the wireless signals emitted by the pacemaker, allowing them to manipulate the device’s functionality without even needing to access the programming interface. The increasing connectivity of pacemakers to other medical devices and systems opens up additional avenues for potential hacks. For example, if a pacemaker is connected to a hospital’s network, it becomes susceptible to attacks from external sources. Hackers could potentially infiltrate the hospital’s network and gain access to the pacemaker, compromising its security and putting the patient’s life at risk. manufacturers and healthcare providers are aware of these vulnerabilities and are continuously working to improve the security measures in pacemakers. They are implementing encryption protocols, authentication mechanisms, and regular software updates to mitigate the risk of hacking. Regulatory bodies are also taking steps to enforce stricter [cybersecurity standards for medical devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity), ensuring that patient safety remains a top priority. ## The Risks Associated with Pacemaker Hacks ![Section Image]() ### Potential Health Consequences The potential health consequences of pacemaker hacks are dire. By manipulating the pacemaker’s programming, hackers can disrupt the patient’s heartbeat, leading to irregular rhythms or complete cardiac arrest. In some cases, patients may experience dizziness, fainting, or shortness of breath due to the altered pacing of their heart. ### Emotional and Psychological Impact Aside from the physical risks, pacemaker hacks can have severe emotional and psychological impacts on individuals who rely on these devices. The loss of trust in a life-saving device and the fear of being vulnerable to cyber attacks can lead to heightened anxiety, depression, and a decreased quality of life. The emotional toll of feeling violated and invaded by a malicious external force can be overwhelming for pacemaker patients. The sense of personal security and autonomy is shattered when one’s own body, which is supposed to be a source of strength and reliability, becomes a target for potential harm through cyber means. The constant fear and paranoia that come with the knowledge that a pacemaker can be remotely tampered with can lead to social withdrawal and a reluctance to engage in normal daily activities. The once mundane tasks of going for a walk or attending social gatherings may now be fraught with anxiety and fear, as the individual grapples with the uncertainty of their own safety. ## Preventing Pacemaker Hacks ![Section Image]() ### Steps to Secure Your Pacemaker While pacemaker hacks are a concerning reality, there are steps patients can take to minimize the risk: 1. Regularly update the pacemaker’s software: Manufacturers often release updates to address security vulnerabilities. Patients should stay informed about such updates and work closely with their healthcare providers to ensure their pacemakers are up-to-date. 2. Secure wireless communication: Patients should ensure that their pacemakers are connected only to trusted and secure monitoring devices. Implementing encryption protocols can help protect against unauthorized access. ### Role of Healthcare Providers in Pacemaker Security Healthcare providers also play a pivotal role in pacemaker security. They should stay abreast of the latest cybersecurity threats and work closely with manufacturers to implement security measures in pacemaker systems. Regular monitoring, timely software updates, and patient education are essential to ensure pacemaker security. Patients with pacemakers should be cautious about sharing their personal information online, as hackers can potentially use this information to access their medical devices. It is important for individuals to be mindful of the information they disclose on social media platforms and to use privacy settings to limit access to personal details. In addition to software updates and secure communication, patients can benefit from physical security measures. For instance, keeping the pacemaker identification card with them at all times can help healthcare providers quickly identify the device in an emergency. Moreover, patients should be vigilant about suspicious activity around their pacemakers and immediately report any concerns to their healthcare providers. ## Legal and Ethical Aspects of Pacemaker Hacks ### Current Laws Regarding Digital Health Device Hacking As technology progresses, legislation is evolving to address the growing threat of cyber attacks on medical devices. Regulatory bodies in various countries have implemented guidelines and regulations regarding the security of IoT medical devices, including pacemakers. For example, in the United States, the [Food and Drug Administration (FDA) released guidelines for managing cybersecurity risks in medical devices](https://www.fda.gov/media/119933/download). With healthcare systems becoming increasingly interconnected and telemedicine rising, the vulnerability of digital health devices to cyber threats has become a major concern. The [European Union’s Medical Device Regulation (MDR)](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745) and the General Data Protection Regulation (GDPR) also play crucial roles in setting standards for the security and privacy of medical devices and patient data. ### Ethical Considerations and Discussions Pacemaker hacks raise important ethical questions about patient safety, privacy, and consent. The medical community is engaged in ongoing discussions to strike the right balance between innovation and patient security. Healthcare professionals and researchers are exploring the ethical implications of potential scenarios where pacemakers could be hacked, such as unauthorized patient data access or malicious device functionality tampering. Ensuring patient autonomy and informed consent in the context of digital health interventions is paramount, requiring a delicate balance between protecting patient privacy and enabling technological advancements in healthcare. ## Future of Pacemaker Security ### Technological Advances in Pacemaker Security Researchers and manufacturers are developing innovative solutions to address the growing concerns related to pacemaker hacks. Advances in encryption techniques and secure communication protocols can significantly enhance pacemaker security. Integrating [artificial intelligence (AI)](/blog) and machine learning algorithms into pacemaker systems is being explored to detect and prevent potential cyber threats in real-time. By continuously analyzing data patterns and anomalies, AI-powered pacemakers can adapt their security measures to evolving risks, ensuring a proactive defense against hacking attempts. ### The Role of Policy in Ensuring Pacemaker Security In addition to technological advancements, policy-level interventions are crucial in safeguarding pacemaker users. Governments and regulatory bodies must continue collaborating with healthcare providers and manufacturers to establish cybersecurity regulations and standards for medical devices. International cooperation and information sharing among regulatory agencies are essential to address global cybersecurity challenges in the medical device industry. A unified front can be presented against cyber threats targeting pacemakers and other critical healthcare technologies by harmonizing standards and best practices across borders. ## Conclusion Pacemaker hacks pose a real and potentially life-threatening risk to users. It is imperative that patients, healthcare providers, and policymakers actively work together to enhance the security of these devices. By understanding the risks, taking preventive measures, and using technological advancements, we can ensure the safety and well-being of individuals relying on pacemakers for healthier and happier lives. As you consider the importance of pacemaker security and the broader implications for medical device cybersecurity, remember that proactive measures are vital to protecting against cyber threats. Blue Goat Cyber, a Veteran-Owned business specializing in medical device cybersecurity and compliance, is here to help secure your devices and systems. With expertise in HIPAA and FDA compliance, SOC 2, and PCI penetration testing, we are dedicated to safeguarding your business against attackers. [Contact us today for cybersecurity help](/contact) and ensure your patients’ and products’ safety and well-being. > **Related reading:** The same wireless-programmer threat model that drives pacemaker risk applies to neurostimulators - where the harm shifts from arrhythmia to altered motor function, mood, or seizure control. See [brainjacking: the cyber-physical threat to NeuroTech](/blog/brainjacking-cyber-physical-threat-neurotech). ## How Blue Goat approaches this Our approach to securing medical devices like pacemakers involves a systematic evaluation of potential vulnerabilities and the implementation of tailored safeguards. We perform thorough threat modeling and penetration testing to identify weaknesses before they can be exploited. Our team, composed of professionals with CISSP, OSCP, and ex-military red team backgrounds, brings direct experience in uncovering sophisticated cyber threats. We work to ensure devices meet regulatory requirements, including those specified by the FDA. Should the FDA raise cybersecurity deficiencies after our submission, we resolve them at no additional cost. We focus on enhancing device resilience, ensuring secure firmware, and establishing incident response plans. For more details on protecting medical devices, explore our services at: /services/medical-device-penetration-testing. ## FAQ ### What are the risks of a pacemaker hack? Pacemaker hacks can lead to serious health consequences, including altered heart rhythms, cardiac arrest, dizziness, fainting, and shortness of breath. There are also significant emotional and psychological impacts on patients. ### How do pacemaker hacks occur? Pacemaker hacks can occur by exploiting vulnerabilities in the device's wireless communication or programming interface. Hackers can gain unauthorized access through proximity-based techniques or by infiltrating connected hospital networks. ### What can patients do to prevent pacemaker hacks? Patients should ensure their pacemaker's software is regularly updated and that it connects only to trusted, secure monitoring devices. They should also be cautious about sharing personal information online. ### What is the FDA's role in pacemaker security? The FDA provides guidance for managing cybersecurity risks in medical devices, including pacemakers. The FDA Feb 3, 2026 final premarket cybersecurity guidance (which supersedes the September 2023 and June 2025 versions) outlines cybersecurity requirements for premarket submissions of medical devices. ### Are pacemaker manufacturers addressing these vulnerabilities? Yes, manufacturers are continuously working to improve security by implementing encryption protocols, authentication mechanisms, and regular software updates. They also collaborate with regulatory bodies to meet cybersecurity standards. ### What are the legal implications of pacemaker hacks? Legislation is evolving to address cyberattacks on medical devices, with regulations like the EU's MDR and GDPR setting standards for security and privacy. The FDA also plays a key role through its complete cybersecurity guidance. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FHIR Protocol Security in Medical Devices (2026) Source: https://bluegoatcyber.com/blog/the-fhir-medical-device-protocol # FHIR Protocol Security in Medical Devices: A 2026 Guide > **[DIRECT ANSWER]** FHIR is a standard for exchanging healthcare data that improves interoperability but does not make a device secure on its own. Security depends on how manufacturers implement authenticated API access, role-based authorization, encryption in transit, audit logging, and integrity checks around the protocol. The FDA's February 3, 2026 guidance expects these controls documented and tested as part of the total product lifecycle, not treated as a separate interoperability feature. FHIR can improve how medical devices exchange data, but it does not make a product secure by itself. For device manufacturers, the real question is whether a FHIR implementation supports safe interoperability without creating new attack paths, new privacy failures, or new regulatory problems. ## Key Takeaways - FHIR standardizes medical device data exchange. - It requires secure system design, not just protocol use. - Integrity and confidentiality are paramount for devices. - Authenticate access, authorize usage, encrypt data. - Validate data paths and manage dependencies. - Document security controls for FDA submission. ## Why this matters The security implications of the FHIR medical device protocol are substantial because connected devices are integral to modern healthcare, moving critical data that directly impacts patient care. Weak security within these systems can lead to compromised therapy delivery, alarm failures, and clinical decision-making errors. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the necessity of secure device design, authenticated communications, patching strategies, and access controls to mitigate these risks. Device manufacturers must ensure that FHIR adoption enhances interoperability without introducing new attack surfaces or compromising data integrity and confidentiality. Adherence to standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is crucial for managing cybersecurity risks in the context of integrating devices into IT networks. The integrity and authenticity of medical device data are paramount, necessitating careful validation of data paths, dependency management, and documentation of security controls for regulatory submissions. For healthcare delivery organizations, this translates to demanding secure by design devices and implementing rigorous monitoring and incident response protocols. ## Why Cybersecurity Still Sits at the Center of Device Interoperability Connected medical devices are now part of routine care. Infusion pumps, cardiac implants, bedside monitors, imaging systems, and remote monitoring platforms all depend on moving data between devices, applications, cloud services, and clinical systems. That connectivity improves care. It also expands the attack surface. When a device is exposed to hospital networks, mobile applications, APIs, or third-party integrations, the consequences of weak security are no longer limited to data loss. A compromise can affect therapy delivery, alarm integrity, device availability, and clinical decision-making. That is why cybersecurity for medical devices cannot be treated as an IT afterthought or a documentation exercise. Manufacturers and healthcare delivery organizations both have work to do. Devices need secure design, authenticated communications, patching strategies, and access controls that hold up in real environments. Organizations using those devices need segmentation, monitoring, incident response, and procurement standards that go beyond checkbox language. The threat picture is not theoretical. Healthcare continues to see ransomware, credential attacks, vulnerable remote access paths, third-party software risk, and exploitation of unpatched systems. If a device communicates through modern APIs, those APIs need the same level of scrutiny as any other externally reachable interface. ## What FHIR Actually Is [FHIR (Fast Healthcare Interoperability Resources)](https://ecqi.healthit.gov/fhir) is a standard for exchanging healthcare information electronically. It defines data structures, workflows, and API patterns so systems can share clinical information in a more consistent way. That matters for medical devices because device data often needs to move into EHRs, dashboards, analytics platforms, remote monitoring systems, and clinician workflows. FHIR gives manufacturers a common model for representing and exchanging that information instead of relying on brittle custom integrations. ![Section Image]() FHIR is widely adopted because it aligns with modern web technologies. It supports formats such as JSON and XML and commonly uses RESTful APIs. That makes implementation more practical than older interface approaches in many settings. It also means security has to be handled with the same seriousness you would apply to any internet-connected API ecosystem. ## Why FHIR Fits Medical Device Communications FHIR is attractive for device interoperability for a few simple reasons. First, it is modular. Data is organized into resources, which makes it easier to expose or consume only what is needed for a given workflow. Second, it is easier to integrate with current software stacks than many legacy healthcare protocols. That lowers friction for connecting devices to hospital applications, cloud services, and patient-facing tools. Third, it can be extended. That flexibility helps when manufacturers need to represent device-specific data elements or workflows. But it also creates a governance issue: extensions that are poorly designed, weakly documented, or inconsistently implemented can break interoperability and complicate security review. FHIR is useful. It is not magic. A bad architecture built on FHIR is still a bad architecture. ## Where FHIR Helps Security FHIR can support better security outcomes when it is implemented correctly. It gives teams a more standardized way to handle data exchange, which reduces some of the guesswork and inconsistency that often show up in one-off integrations. For medical device manufacturers, the security value comes from how FHIR-based interfaces can be paired with strong controls such as: - authenticated access to APIs - role-based or context-based authorization - encryption in transit - audit logging - integrity checks on exchanged data - constrained exposure of only necessary resources and operations Used well, those controls can reduce the chance of unauthorized access, silent data manipulation, and poorly governed data sharing. ![Section Image]() FHIR can also improve traceability. Standardized APIs and data models make it easier to understand what data is moving, who should have access to it, and where logging needs to occur. That helps with security operations, postmarket monitoring, and regulatory documentation. Still, none of this is automatic. FHIR does not guarantee secure authentication. It does not guarantee least privilege. It does not guarantee safe implementation of tokens, sessions, gateways, mobile apps, or cloud connectors. Security depends on the system design around the protocol. ## Data Integrity and Confidentiality Matter More Than API Convenience Too many interoperability discussions focus on ease of integration and skip the harder question: can clinicians trust the data, and can the manufacturer defend the system under attack? For medical devices, data integrity is often more important than convenience. If transmitted values are altered, delayed, replayed, mismatched to the wrong patient or device, or pulled from an untrusted source, the issue is not just privacy. It can become a patient safety problem. FHIR can help support integrity and confidentiality because it standardizes data exchange and makes interface behavior more predictable. That predictability is useful for validation, monitoring, and access control design. It also helps reduce the messy translation layers that often introduce errors or undocumented behavior. This is where manufacturers need discipline. If your device or companion system exposes FHIR endpoints, you need to know: - what data is exposed - who can request it - how identities are verified - how authorization is enforced - how requests and responses are logged - how integrity issues are detected - what happens when dependent services fail or degrade Those are product security questions, not just interoperability questions. ## Implementing FHIR in Medical Devices Without Creating New Risk Implementing FHIR in a device ecosystem takes planning. The protocol itself is not the hard part. The hard part is integrating it into a safe and defensible product architecture. Manufacturers should start by designing with cybersecurity in mind from the beginning. That means secure coding, threat modeling, dependency management, authentication design, secrets handling, software bill of materials visibility, and validation of data flows between device components and external systems. It also means understanding how the interface could be misused, not just how it is supposed to work. A practical FHIR integration effort usually includes: - defining the minimum necessary data exchange - mapping device data to appropriate FHIR resources - identifying trust boundaries and external dependencies - securing API access and identity flows - testing failure modes, malformed requests, and abuse cases - validating logs, alerts, and recovery behavior - documenting security controls for internal review and regulatory use Healthcare organizations deploying FHIR-enabled devices also need operating procedures for configuration, credential management, updates, network placement, and incident response. A secure product can still be deployed badly. ### Common implementation problems The biggest problems are usually not the standard itself. They are the shortcuts around it. Legacy systems can create compatibility headaches. Cloud-connected architectures can increase exposure if interfaces are opened without proper segmentation or monitoring. Extensions can become a mess if they are not governed. Privacy obligations can be missed when teams expose more data than a workflow actually requires. There is also a recurring mistake in device development: treating interoperability as a feature and cybersecurity as a separate compliance workstream. That approach fails under scrutiny. The FDA expects cybersecurity to be built into device design, risk management, and lifecycle maintenance. If your FHIR interface changes the risk profile of the device, that needs to show up in your analysis, your testing, and your documentation. ## What This Means for the FDA and Device Manufacturers For manufacturers, FHIR adoption should be tied to product security evidence, not marketing language. If a device uses FHIR-based communications, you should be ready to explain how that interface is authenticated, how misuse is constrained, how updates are managed, and how security risk was assessed across the device system. That matters during design reviews, customer security assessments, and FDA submission preparation. It also matters after release. Postmarket issues often show up in integrations, remote services, third-party components, and configuration drift, not just in the embedded device itself. FHIR can support safer interoperability. But if it increases connectivity without a matching investment in architecture, monitoring, and lifecycle controls, it simply gives attackers another route in. ## The Long View: Better Interoperability, Better Security Discipline FHIR will remain part of the healthcare technology stack because the need for cleaner data exchange is not going away. For medical devices, that is a good thing. Better standards can reduce custom integrations, improve consistency, and make security review more manageable. ![Section Image]() The long-term benefit is not just easier connectivity. It is the chance to build device ecosystems that are easier to understand, test, secure, and maintain. That only happens when manufacturers treat interoperability as a security-relevant design choice from day one. If you are adopting FHIR, do it with discipline. Define the use case. Limit exposure. Validate the data path. Test abuse cases. Document the controls. And make sure your security story would stand up to both customers and the FDA. Blue Goat Cyber helps medical device manufacturers assess connected product risk, strengthen security design, and prepare for real regulatory scrutiny. If your team is building or deploying FHIR-enabled capabilities, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers implement FHIR securely and meet regulatory requirements. Our team, comprised of CISSPs, OSCPs, and ex-military red team members, focuses on identifying and mitigating risks introduced by new communication protocols. We conduct in-depth threat modeling specific to FHIR-enabled devices, perform penetration testing, and validate security controls for data integrity, confidentiality, and availability. Our approach involves evaluating authentication, authorization, encryption, and audit logging mechanisms to ensure they align with the FDA's expectations. We work to integrate security into every stage of the product lifecycle, from design to postmarket oversight. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is FHIR? FHIR (Fast Healthcare Interoperability Resources) is a standard for exchanging healthcare information electronically. It defines data structures, workflows, and API patterns for consistent clinical data sharing among systems. ### How does FHIR improve medical device cybersecurity? FHIR can improve cybersecurity by standardizing interfaces, which facilitates the implementation of strong controls like authenticated access, role-based authorization, encryption, and audit logging. This makes it easier to track and secure data flows. ### Does FHIR make medical devices secure by default? No, FHIR does not inherently make medical devices secure. Security depends on how FHIR is implemented within a product's architecture, including secure coding practices, threat modeling, and strong access controls. ### What should manufacturers consider when implementing FHIR? Manufacturers should define minimum necessary data exchange, map device data to FHIR resources, secure API access, test failure modes, and rigorously document security controls for FDA submission and postmarket monitoring. ### How does the FDA view FHIR implementation in medical devices? The FDA expects cybersecurity to be built into device design, risk management, and lifecycle maintenance. Manufacturers using FHIR must demonstrate how the interface is authenticated, how misuse is constrained, and how security risk was assessed across the device system, as outlined in the February 3, 2026 final guidance. ### What are common pitfalls when using FHIR for medical devices? Common pitfalls include treating interoperability as only a feature, neglecting secure architecture around the protocol, poorly governed extensions, and failing to manage cloud or legacy system compatibility challenges. ## Related FDA & cybersecurity guides - [FDA Section 524B cybersecurity requirements explained](/guides/fda-524b-cybersecurity-requirements-explained) - [SBOM vulnerability management for medical devices](/guides/sbom-vulnerability-management-medical-devices) - [VEX document guide for FDA submissions](/guides/vex-document-medical-device-fda) - [FDA deficiency-letter response service](/fda-cybersecurity-deficiency-letters) - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [EHR/EMR Medical Device Integration](/blog/ehr-emr-medical-device-integration-cybersecurity-risks) - [GET vs POST: When to Use Each HTTP Method](/blog/medical-device-sql-injection-parameterized-queries) --- ## Section 524B(b)(2): Medical Device Cyber Duties Source: https://bluegoatcyber.com/blog/the-impact-of-524bb2-on-medical-device-cybersecurity # The Impact of 524B(b)(2) on Medical Device Cybersecurity > **[DIRECT ANSWER]** Section 524B(b)(2) turns secure development from best practice into statute. Sponsors of a cyber device must design, develop, and maintain processes that reasonably assure the device and connected systems are cybersecure, make postmarket updates and patches available on a regular cycle, and ship out-of-cycle fixes for critical vulnerabilities. Failing to evidence those processes gives the FDA statutory grounds to refuse the submission. Section 524B(b)(2) changed medical device cybersecurity from guidance-driven good practice into a statutory requirement. If a product meets the definition of a cyber device, manufacturers now need to show the FDA that cybersecurity is built into design, maintenance, and update processes across the device lifecycle. ## Key Takeaways - What 524B(b)(2) Requires. - What It Means for Device Manufacturers. - What It Means for Healthcare Providers. - Where This Is Headed. ## What 524B(b)(2) Requires 524B(b)(2) sits within the FD&C Act’s cyber device requirements and focuses on process, not checkbox paperwork. The law expects manufacturers to design, develop, and maintain processes that provide reasonable assurance that a device and related systems are cybersecure. ![Section Image](/imported-images/ffd4666417c771e9.webp) At a practical level, that means manufacturers need to do more than claim they take security seriously. They need evidence. They need risk-based design controls. They need a plan to identify vulnerabilities, reduce exploitability, and make patches and updates available on an ongoing basis. The statutory language in [524B(b)(2)](https://www.fda.gov/media/119933/download?attachment) also lines up with what the FDA has been signaling for years: cybersecurity belongs in product development, validation, release management, and postmarket support. It is not something to bolt on at the end of a submission. ### Core expectations for manufacturers For most device manufacturers, 524B(b)(2) translates into a few non-negotiable expectations: - Security requirements must be defined during design and development. - Risk analysis must address cybersecurity threats, not just safety hazards in isolation. - Manufacturers need repeatable processes for vulnerability intake, triage, remediation, and disclosure. - Devices must be supportable in the field, including the ability to deliver patches and updates as appropriate. - Submission materials need to show how these processes work in practice, not just that a policy exists. That last point matters. The FDA is not asking for checklist theater. Reviewers want to see how security decisions were made, how risks were evaluated, and how the manufacturer will maintain the device after it ships. That is a much higher bar than a generic statement about “industry best practices” or a [risk assessments to identify vulnerabilities](/blog) claim with no operational backing. ## Why 524B(b)(2) Matters for Medical Device Cybersecurity Connected devices create a larger attack surface. They also create a direct path from technical weakness to patient harm, operational disruption, privacy exposure, or all three at once. 524B(b)(2) matters because it forces sponsors to treat those risks as product risks. That shift has consequences. Security architecture, authentication, logging, update mechanisms, software bill of materials management, and vulnerability handling are no longer side issues for an engineering team to address later. They affect whether a submission is ready and whether a device can be sustained in the market. The requirement also raises the floor for the industry. Manufacturers that already built security into their quality system and development lifecycle are in a stronger position. Those that relied on minimal documentation or outsourced security thinking to a late-stage test report now have to close real gaps. ## What It Means for Device Manufacturers For manufacturers, 524B(b)(2) changes both premarket preparation and postmarket obligations. On the premarket side, teams need better alignment between engineering, quality, regulatory, and security. Threat modeling, security requirements, architecture decisions, testing evidence, and update planning all need to connect. If they do not, the submission will show the seams. On the postmarket side, the device must remain supportable. A manufacturer needs a credible way to monitor for vulnerabilities, assess impact, develop remediations, and communicate changes. Security does not end at clearance or approval. The law makes that explicit. There is also a business reality here. Manufacturers that can demonstrate mature cybersecurity processes are easier for health systems to trust. Procurement teams, security teams, and clinical engineering groups increasingly ask hard questions about supportability, patching, third-party software, and coordinated vulnerability disclosure. 524B(b)(2) pushes manufacturers toward answers that stand up under scrutiny. ## What It Means for Healthcare Providers The statute is directed at manufacturers, but providers feel the impact immediately. Hospitals and health systems depend on vendors to deliver devices that can be deployed, monitored, and maintained without creating unmanaged cyber risk. That means providers should expect clearer security documentation, better-defined patching processes, and more realistic conversations about asset inventory, network segmentation, update timing, and end-of-support planning. If a manufacturer cannot explain how the device is maintained securely, providers inherit the operational risk. Providers still have work to do on their side. They need to validate device inventories, understand which assets are cyber devices, coordinate patch windows, and build incident response procedures that account for clinical operations. But 524B(b)(2) shifts more accountability back where it belongs: onto the manufacturer to deliver and support a cybersecure product. ## Where This Is Headed 524B(b)(2) is not the end state. It is the baseline. The FDA will continue refining how it evaluates cybersecurity evidence through guidance, review practice, and feedback to sponsors. Expectations around secure update capability, coordinated vulnerability disclosure, SBOM quality, and postmarket monitoring will keep maturing. Manufacturers should plan accordingly. The winning approach is not to produce prettier documentation right before submission. It is to build a development and maintenance system that generates defensible evidence as a byproduct of doing the work correctly. That is the real impact of 524B(b)(2). It forces cybersecurity into the operating model of medical device companies. The organizations that adapt will move faster, defend their design choices more effectively, and ship products that are safer to connect and easier to maintain. As medical device cybersecurity expectations tighten, manufacturers need partners who understand both the technical work and the FDA implications. Blue Goat Cyber helps device companies test products, strengthen secure development practices, and prepare evidence that holds up under regulatory review. [Contact us today for cybersecurity help](/contact) if you need to close gaps before submission or improve postmarket readiness. Check out our [medical device cybersecurity premarket submission FDA compliance package](/). ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in navigating the complexities of 524B(b)(2) and establishing defensible cybersecurity programs. Our approach focuses on developing tailored security architectures, implementing practical risk management frameworks, and operationalizing secure development lifecycles. We guide clients through premarket submissions, ensuring their devices meet statutory requirements and the expectations set forth in the FDA Cybersecurity in Medical Devices Final Guidance dated February 3, 2026. Our team, comprised of certified professionals (CISSP, OSCP, ex-military red team), brings deep technical expertise and regulatory understanding to each engagement. We help embed essential security principles from design conception through postmarket support. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more at [bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the primary impact of 524B(b)(2) on medical device manufacturers? The primary impact is that cybersecurity is now a statutory requirement for cyber devices, demanding manufacturers provide evidence of integrated security processes throughout the device lifecycle to the FDA. It shifts the focus from voluntary guidelines to mandatory compliance. ### How does 524B(b)(2) affect medical device design and development? Manufacturers must define security requirements early in design, conduct risk analyses that include cybersecurity threats, and implement repeatable processes for vulnerability handling. Security architecture, authentication, and update mechanisms are no longer secondary considerations but integral to product development. ### Does 524B(b)(2) change postmarket obligations for medical devices? Yes, 524B(b)(2) explicitly mandates that devices remain supportable postmarket. Manufacturers need credible processes for monitoring vulnerabilities, assessing their impact, developing remediations, and communicating changes to ensure long-term device security and functionality. ### What evidence does the FDA expect under 524B(b)(2)? The FDA expects evidence demonstrating how security decisions were made, how risks were evaluated, and how the manufacturer will maintain the device throughout its lifecycle. This goes beyond generic policy statements, requiring proof of operationalized security aspects. ### How does this regulation benefit healthcare providers? Healthcare providers can expect clearer security documentation, better-defined patching processes, and more realistic conversations about device supportability. This shifts more accountability to manufacturers for delivering and supporting cybersecure products, reducing operational risk for providers. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity Abuse & Source: https://bluegoatcyber.com/blog/the-impact-of-cybersecurity-abuse-and-misuse-in-medical-devices # The Impact of Cybersecurity Abuse and Misuse in Medical Devices > **[DIRECT ANSWER]** Cybersecurity abuse and misuse in medical devices means intentional exploitation or careless mishandling of device access that disrupts therapy, exposes patient data, or damages hospital operations. Abuse typically involves malicious exploitation, while misuse can stem from weak training or poor configuration, but both create the same risk: unsafe devices and costly incident response. The FDA's February 3, 2026 guidance expects manufacturers to build lifecycle controls, and providers to maintain asset visibility and access restrictions. _Updated November 2, 2024_ Connected medical devices improve care, but they also create real attack paths into clinical operations and patient therapy. When cybersecurity is abused or misused-whether by an external attacker, an insider, or simple operational negligence, the result is not just an IT problem. It can become a patient safety event, a regulatory problem, and a business crisis at the same time. ## Key Takeaways - Abuse and misuse jeopardize patient safety and data integrity. - Incidents incur significant financial and operational costs for providers. - FDA expects cybersecurity throughout the device lifecycle. - Providers must ensure asset visibility and secure configurations. - Legacy systems and human factors increase risk exposure. - Strong access controls and vigilant monitoring are essential. ## Why this matters The stakes are profoundly high when medical device cybersecurity is compromised. Patient safety, data privacy, and operational continuity in healthcare delivery organizations (HDOs) depend on securing these critical technologies. Abuse or misuse, whether malicious or accidental, directly threatens device functionality, potentially leading to incorrect diagnoses, therapy interruptions, or even direct patient harm. Beyond immediate clinical impact, such incidents incur substantial financial penalties, reputational damage, and legal liabilities for manufacturers and HDOs. The FDA, in its "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, explicitly mandates that manufacturers integrate cybersecurity throughout the total product lifecycle. This includes adherence to standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR97. Failure to meet these requirements not only endangers patients but also places manufacturers at risk of regulatory non-compliance, market restrictions, and recalls, underscoring the critical need for vigilant cybersecurity practices. ## Understanding Cybersecurity in Medical Devices Healthcare depends on medical devices to monitor patients, deliver therapy, and support diagnosis. From infusion pumps to implantable devices, these technologies are now part of networked environments that include hospital systems, cloud services, mobile apps, and third-party components. That connectivity increases capability, but it also increases exposure. Cybersecurity in medical devices is about more than keeping data private. It is about maintaining device availability, preserving integrity of therapy and clinical data, and preventing unauthorized access that could change how a device behaves. If a connected device can be interrupted, altered, or taken offline, patient care can suffer fast. Cyberattacks against healthcare providers continue to show how disruptive these failures can be. The [WannaCry ransomware attack](https://en.wikipedia.org/wiki/WannaCry_ransomware_attack) is still one of the clearest examples: hospitals lost access to systems, appointments were delayed, and surgeries were postponed. Once devices are tied into that same ecosystem, the blast radius gets larger. Common threats include malware infections, unauthorized access, denial-of-service conditions, credential abuse, insecure remote access, and exploitation of unpatched software. Attackers may target the device directly, or they may move through the surrounding environment first and reach the device through a trusted connection. Medical devices also present a hard engineering problem. They often rely on legacy operating systems, constrained hardware, third-party software, and long service lives. Security cannot be bolted on at the end. It has to be designed, tested, monitored, and maintained throughout the product lifecycle. ## How Abuse and Misuse Cause Harm The line between abuse and misuse matters. Abuse usually means intentional exploitation or manipulation. Misuse may be accidental, careless, or deliberate. Both create risk, and both can lead to the same outcome: unsafe devices, disrupted care, and expensive fallout. ### Patient Safety Risks The most serious consequence is patient harm. If an attacker changes device settings, interrupts communications, or blocks intended operation, therapy can become unsafe. That is why device cybersecurity is a safety issue first and a compliance issue second. The FDA has repeatedly made this point. In 2015, the FDA issued a safety communication about vulnerabilities in certain infusion pumps because exploitation could affect dosage delivery. That is not hypothetical. If an infusion pump’s configuration is altered, a patient may receive too much medication, too little, or none at all. The same concern applies to pacemakers, insulin pumps, patient monitors, and other connected systems. A [cyberattack that targets implantable pacemakers](/blog/implantable-device-cybersecurity-concerns) is not just unauthorized access. It is unauthorized influence over therapy. That changes the risk conversation entirely. ### Financial and Operational Impact on Healthcare Institutions Hospitals and health systems also absorb major financial damage when medical device cybersecurity fails. Costs can include incident response, forensics, legal fees, downtime, emergency device replacement, network segmentation projects, and remediation across thousands of assets. Those direct costs are only part of the problem. Clinical disruption can reduce patient volume, delay procedures, and force manual workarounds that are slower and less reliable. A provider dealing with a breach or device-related outage may also face regulatory scrutiny, contract disputes, and reputational damage that lasts long after systems are restored. The 2016 breach of a major healthcare organization that exposed patient records showed how expensive these events become. Settlements, investigations, and system improvements can easily run into the millions. When medical devices are involved, the complexity goes up because restoration is tied to safety validation, not just IT recovery. ### Unintentional Misuse Not every incident starts with a malicious actor. Some start with poor process. Staff may reuse credentials, connect unauthorized media, skip updates, disable security controls for convenience, or misunderstand how a device should be segmented and maintained. A 2019 healthcare data breach tied to accidental disclosure of sensitive patient information is a reminder that human error still opens major security gaps. In the device context, weak training and weak procedures can expose clinical systems, service accounts, and connected devices to unnecessary risk. This is where checklist theater fails. A policy on paper does not help if staff do not understand how device connectivity works, which systems are safety-relevant, or what to do when a device behaves unexpectedly. ### Deliberate Misuse Deliberate misuse can come from insiders, contractors, service personnel, or outside actors using valid credentials. Motives vary: sabotage, fraud, espionage, retaliation, or simple opportunism. There have been cases where individuals tampered with devices in care environments and caused patient harm. Incidents like that show why access control cannot be treated as an administrative detail. If too many people can change device settings, connect support tools, or bypass authentication, the organization has already accepted unnecessary risk. Strong controls matter here: least-privilege access, audit logging, session accountability, and technical restrictions on who can modify configurations and when. ## Reducing Risk in Medical Devices ![Section Image](/imported-images/16e3aa1f62eaa4a3.webp) Reducing cybersecurity risk in medical devices takes coordinated work across manufacturers, healthcare delivery organizations, security teams, and regulators. No single control fixes the problem. ### What the FDA Expects The FDA has made device cybersecurity a lifecycle expectation, not a one-time submission artifact. Through premarket expectations and [postmarket guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices), the FDA has been clear: manufacturers need to identify cybersecurity risks, design controls into the product, document those controls, and maintain the device after release. That means threat modeling, secure design decisions, testing that reflects realistic abuse cases, coordinated vulnerability disclosure processes, patching plans, SBOM awareness, and postmarket monitoring. If a manufacturer treats cybersecurity as a document package for FDA reviewers instead of a real engineering discipline, the gaps usually show up later in validation, deployment, or incident response. ### What Healthcare Providers Should Be Doing Healthcare providers also carry operational responsibility. They need asset visibility, network segmentation, secure configuration management, disciplined patching where feasible, and a clear process for evaluating manufacturer advisories and compensating controls. Training matters, but it has to be practical. Clinicians and biomedical teams need to know what suspicious behavior looks like, how devices connect to the network, what remote access paths exist, and when to escalate. Security teams need to understand that medical devices are not standard endpoints and cannot always be patched or scanned the same way. Basic controls still matter: - restrict access to device interfaces and admin functions - encrypt sensitive data where appropriate - remove or disable unnecessary services - maintain accurate inventories and software component records - monitor for abnormal traffic and unauthorized changes - coordinate closely with manufacturers before applying updates or mitigations ## What’s Next for Medical Device Cybersecurity ![Section Image](/imported-images/ef8aa76cff89a966.webp) New technologies will help, but they will not replace sound engineering and disciplined postmarket practice. Machine learning and AI-based detection can improve visibility into device behavior, network anomalies, and signs of compromise. Used well, these tools may help security teams identify unusual communications, unauthorized configuration changes, or early indicators of exploitation before patient care is affected. AI can also support authentication workflows, anomaly detection, and predictive analysis of likely weaknesses across a fleet of connected devices. But AI is not a substitute for secure architecture, validated controls, and tested incident response. If the underlying product is insecure, smarter monitoring just tells you that faster. Blockchain gets attention as a way to protect integrity of records and transactions, but it is not a default answer for device security. In some use cases, it may support data integrity or traceability. In many others, it adds complexity without addressing the core issues: authentication, authorization, secure updates, software quality, and safe fail states. The future will belong to manufacturers and providers that treat cybersecurity as part of safety, quality, and operational resilience, not as a marketing line and not as a compliance checklist. Cybersecurity abuse and misuse in medical devices can affect therapy, expose patient data, disrupt care, and trigger lasting financial damage. The organizations handling this well are the ones that build security into design, maintain it after deployment, and make decisions based on real risk rather than paperwork. Blue Goat Cyber helps medical device manufacturers and healthcare organizations address those risks with technically grounded assessments, penetration testing, and advisory support aligned to HIPAA and the FDA’s expectations. If you need help finding exploitable gaps before attackers or regulators do, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers and healthcare providers proactively address potential cybersecurity abuse and misuse. Our methodology focuses on integrating security into every stage of the medical device lifecycle, from initial concept through postmarket support. We perform in-depth threat modeling, penetration testing, and vulnerability assessments to identify potential attack vectors and weaknesses before they can be exploited. Our consultants, including CISSP and OSCP certified experts and former military red team members, deliver actionable insights and implement practical security controls tailored to medical device environments. We assist with regulatory compliance, ensuring devices meet or exceed the FDA's cybersecurity requirements. For manufacturers seeking premarket approval, we offer specialized regulatory support. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized regulatory support services at [bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the primary difference between cybersecurity abuse and misuse in medical devices? Abuse typically refers to intentional, malicious exploitation of vulnerabilities. Misuse, while also risky, can be accidental, negligent, or deliberate, often stemming from improper operation or configuration rather than direct malicious intent. ### How does the FDA view cybersecurity in medical devices? The FDA considers cybersecurity a critical component of medical device safety and effectiveness throughout the entire product lifecycle. Manufacturers must design in controls, manage risks, and maintain devices postmarket, aligning with the February 3, 2026 final guidance. ### Can unintentional misuse of a medical device lead to patient harm? Yes, unintentional misuse, such as incorrect configuration, disabled security features, or inadequate staff training, can expose devices to vulnerabilities that lead to patient harm, operational disruptions, or data breaches. ### What are common consequences for healthcare providers when medical device cybersecurity fails? Healthcare providers face substantial financial impacts, including incident response costs, legal fees, decreased patient volume, and regulatory fines. They also suffer clinical disruption, reputational damage, and potential patient safety incidents. ### Does AI or blockchain completely solve medical device cybersecurity challenges? No, while AI and blockchain can enhance certain aspects of medical device security, they do not offer complete solutions. AI may improve anomaly detection, and blockchain could support data integrity in some cases, but neither replaces foundational secure architecture, verified controls, and disciplined postmarket practices. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) [YouTube](https://www.youtube.com/@BlueGoatCyber) [Instagram](https://www.instagram.com/bluegoatcyber/) [Twitter](https://twitter.com/bluegoatcyber) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## BLE Security in Medical Devices: What to Get Right Source: https://bluegoatcyber.com/blog/the-importance-of-ble-in-medical-devices-cybersecurity # BLE Security in Medical Devices: Risks and Requirements > **[DIRECT ANSWER]** BLE security in medical devices depends entirely on how pairing, bonding, and access control are configured, not on BLE itself. The protocol supports LE Secure Connections with authenticated pairing and per-device keys, but a device shipped with Just Works pairing, static long-term keys, or unauthenticated GATT characteristics is exposed to spoofing, MITM, and unauthorized read or write of therapy-relevant data. Manufacturers must threat model BLE-specific attack paths and document mitigations for the FDA's premarket cybersecurity review. _Reviewed September 17, 2026_ BLE shows up in continuous glucose monitors, insulin pumps, hearing aids, patient monitors, and clinician programmers because it is low power and widely supported, not because it is inherently secure. That distinction matters because the same protocol that lets a device run for months on a coin cell can also expose therapy settings, telemetry, or firmware update channels if pairing and access control are left at default settings. A CGM broadcasting glucose values without link-layer encryption, or a programmer that accepts any device advertising a matching name, are configuration failures, not protocol failures. Manufacturers preparing an FDA submission need to show they evaluated BLE's specific pairing, bonding, and GATT permission model against realistic attacker capability, not assert that using BLE satisfies a security requirement on its own. ## Key Takeaways - BLE security outcomes are determined by pairing method, key management, and GATT permissions, not by the fact that a device uses BLE. - Legacy pairing and Just Works remain exploitable in the field even though LE Secure Connections has existed since Bluetooth 4.2. - Unauthenticated GATT characteristics are one of the most common findings in medical device BLE assessments, exposing telemetry or configuration without any pairing at all. - Resolvable private addresses defeat casual tracking, but only if the device actually rotates them and the companion app does not defeat the purpose by logging static identifiers elsewhere. - Application-layer authentication and encryption, independent of the BLE link layer, is what limits damage when a link-layer pairing weakness is found later. - The FDA expects BLE-specific attack scenarios in the threat model, not a generic statement that encryption is used. ## Why This Matters The FDA's "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" final guidance, dated February 3, 2026, expects manufacturers to identify the specific communication interfaces on a device and analyze the attack surface each one introduces. BLE is treated as a distinct interface with its own pairing, bonding, and characteristic-level access control model, and a generic wireless security narrative does not satisfy that expectation. Reviewers look for evidence that the manufacturer considered how an attacker within radio range, not just an attacker with network access, could interact with the device. This matters because BLE's convenience, no cables, long battery life, broad phone compatibility, creates an attack surface that classic wired interfaces do not have. A device with a vulnerable BLE implementation can be attacked without ever touching the patient's network, simply by being physically nearby. AAMI SW96, FDA Recognized Consensus Standard 13-131, and IEC 81001-5-1 both expect wireless-specific risk analysis as part of the broader security risk management process, and BLE pairing and GATT design decisions are exactly the kind of detail that analysis has to cover. ## What Is BLE and How Does It Differ From Bluetooth Classic? BLE, or Bluetooth Low Energy, is a wireless protocol that shares the 2.4 GHz ISM band with Bluetooth Classic but uses a different stack designed for intermittent, low-power communication rather than continuous streaming. Bluetooth Classic maintains a persistent connection suited to audio and file transfer, which draws significantly more power. BLE instead uses short connection events and a client-server data model, which is why it dominates in battery-powered medical devices that need to report periodically rather than stream continuously. The two protocols are not interoperable at the radio or stack level, despite sharing a brand and frequency band. A device supporting BLE will not connect to a Bluetooth Classic-only peer, and security mechanisms, including pairing methods and key exchange, are defined separately for each. ## What Is the BLE Stack and GATT Model? The BLE stack organizes communication into layers, with the Generic Attribute Profile, GATT, defining how data is structured and exchanged between a central device, such as a phone or programmer, and a peripheral, such as a sensor or pump. GATT organizes data into services and characteristics, each with its own read, write, and notify permissions. A characteristic can be configured to require no security, unauthenticated pairing, or authenticated pairing with encryption before it can be accessed. **[KEY REQUIREMENT]** Every GATT characteristic that exposes therapy settings, calibration data, or firmware control must require authenticated encryption at the attribute permission level, not rely solely on the fact that the device paired successfully at connection time. ## Why Do Medical Devices Use BLE? Medical devices use BLE because it delivers months or years of battery life while still supporting periodic data exchange with a phone, gateway, or clinician programmer. Continuous glucose monitors and patient wearables use it to push readings to a companion app without daily charging. Insulin pumps and hearing aids use it for configuration and firmware updates from a paired device, and patient monitors and programmers use it to pull telemetry or push therapy adjustments in clinical settings. These use cases share a common risk profile: the data or commands passing over BLE often have direct clinical consequence if intercepted or forged. ## How Do BLE Pairing and Bonding Methods Compare? BLE pairing methods differ in how they establish a shared key and how resistant they are to interception or impersonation, and the difference between Legacy pairing and LE Secure Connections is the most consequential choice a manufacturer makes. | Method | How It Works | MITM Resistance | Typical Use | |---|---|---|---| | Just Works | Devices agree on a key with no user verification step | None | Devices with no display or input, high risk if used for sensitive characteristics | | Passkey Entry | User enters or compares a six-digit code on one or both devices | Moderate, depends on entropy and side channel | Devices with a keypad or simple display | | Numeric Comparison | Both devices display a code the user confirms matches | Strong, when using LE Secure Connections | Devices with a screen, such as programmers | | Out of Band (OOB) | Key material exchanged over a separate channel, such as NFC | Strong, tied to physical proximity | Devices with NFC or another secondary interface | Legacy pairing, used before Bluetooth 4.2's LE Secure Connections, derives keys using a method vulnerable to passive eavesdropping if an attacker captures the pairing exchange. LE Secure Connections uses Elliptic Curve Diffie-Hellman, ECDH, key exchange instead, so a passive observer of the pairing process cannot derive the resulting long-term key even if they capture every packet. This is the single most important upgrade a legacy BLE implementation can make. ## What Are the Concrete BLE Attack Classes? BLE attacks target specific weaknesses in pairing, addressing, and the GATT access model, and most fall into a small number of well-documented classes. Passive sniffing of Legacy pairing exchanges lets an attacker with commodity sniffer hardware recover the long-term key without ever interacting with either device. A man-in-the-middle attack against Just Works pairing succeeds because Just Works provides no way for either party to confirm they are talking to the intended peer, so an attacker can relay or alter traffic during the pairing exchange itself. Spoofing and impersonation attacks exploit devices that authenticate only by advertised name or service UUID, letting an attacker's device masquerade as a legitimate sensor or programmer. KNOB and BLURtooth-class attacks manipulate key negotiation or cross-transport key derivation to force weaker encryption or reuse keys across Bluetooth Classic and BLE. GATT characteristic enumeration lets an attacker discover every exposed service on a device, and unauthenticated read or write access on any of those characteristics can leak telemetry or alter configuration without ever completing a real pairing. Replay attacks resend previously captured legitimate commands when a device does not track sequence numbers or freshness. Denial of service and battery drain attacks repeatedly trigger connection attempts or advertising responses to exhaust a battery-powered device faster than intended. Finally, tracking risk differs sharply between devices that broadcast a static MAC address, which lets an observer log a patient's device location over time, and devices using resolvable private addresses that rotate on a schedule known only to bonded peers. ## What Does Good BLE Security Look Like? Good BLE security combines LE Secure Connections with the strongest pairing method the device's I/O supports, Numeric Comparison or OOB where a display or secondary channel exists, and treats the link layer as one layer of defense rather than the only one. Application-layer authentication and encryption, independent of the BLE link, should protect any command or data that has clinical consequence, so that a link-layer pairing weakness discovered later does not expose the therapy path directly. **[KEY REQUIREMENT]** Devices should use per-device keys rather than a shared key baked into firmware across a product line, since a single extracted key from one compromised unit should never grant access to every other unit in the field. Additional practices that separate a defensible implementation from a vulnerable one include enforcing attribute permissions that require authenticated encryption on any sensitive characteristic, managing bonding records so a lost or decommissioned device's keys can be revoked, authenticating firmware updates delivered over BLE so a bonded connection alone is not sufficient to push new code, and limiting the pairing window so a device only accepts new bonds during a deliberate, physically proximate action rather than indefinitely. ## How Should BLE Security Be Tested? BLE security should be tested with a combination of radio-level sniffing, protocol-level enumeration, and active manipulation, not just a code review of the stack configuration. Sniffer hardware captures the pairing exchange and connection traffic to verify whether Legacy pairing or LE Secure Connections is actually in use in the field, since firmware documentation and field behavior do not always match. GATT enumeration tools map every service and characteristic to confirm which ones require authentication and which do not. Fuzzing the BLE stack, sending malformed or out-of-sequence packets, tests whether the implementation handles unexpected input without crashing or entering an insecure state, and replay testing confirms whether previously captured commands can be resent successfully. ## What Should the Threat Model and FDA Submission Document? The threat model and FDA submission should document the specific BLE pairing method used, the rationale for that choice given the device's I/O capabilities, and the mitigations in place for each attack class relevant to the device's GATT design. Under the FDA's February 3, 2026 premarket cybersecurity guidance, reviewers expect this analysis to name BLE explicitly rather than fold it into a general wireless security statement. The submission should show which characteristics carry sensitive data or commands, what permission level protects each one, and how bonding and key management are handled across the device's lifecycle, including decommissioning. ## How Blue Goat Cyber Approaches This Blue Goat Cyber evaluates BLE implementations through architecture review, protocol-level testing, and penetration testing rather than a documentation-only assessment. We capture and analyze the actual pairing exchange in the field, enumerate GATT services and characteristics for unauthenticated access, and test companion mobile applications for the same trust assumptions that show up in firmware. In BLE engagements we most commonly find Just Works pairing left enabled in production, static keys reused across units, and GATT characteristics that expose configuration without authentication, each of which we map to a specific threat and mitigation in the submission package. Our team includes CISSP and OSCP-certified engineers with backgrounds in red team operations. Manufacturers preparing a BLE-enabled device for submission can start with our [medical device penetration testing](/services/medical-device-penetration-testing) services. ## Frequently Asked Questions ### Is BLE inherently secure for medical devices? No, BLE is a transport protocol whose security depends entirely on how pairing, bonding, and GATT permissions are configured. A device using BLE with Just Works pairing and unauthenticated characteristics is not secure simply because it uses BLE. Manufacturers have to make explicit configuration choices and document why they are appropriate for the device's risk profile. ### What is the difference between Legacy pairing and LE Secure Connections? Legacy pairing, used in earlier Bluetooth versions, derives its shared key in a way that a passive eavesdropper can recover if they capture the pairing exchange. LE Secure Connections, introduced in Bluetooth 4.2, uses Elliptic Curve Diffie-Hellman key exchange, so a passive observer cannot derive the resulting key even with a full capture of the exchange. Devices should use LE Secure Connections wherever the hardware supports it. ### Why is Just Works pairing considered risky? Just Works pairing provides no mechanism for either device to verify the identity of the other during the pairing exchange, which means it offers no resistance to a man-in-the-middle attack. It remains common because it requires no display or input on the peripheral device. Where a device has no I/O capability at all, application-layer authentication should compensate for what link-layer pairing cannot provide. ### What is GATT characteristic enumeration and why does it matter? GATT characteristic enumeration is the process of discovering every service and characteristic a BLE device exposes, along with the permission level protecting each one. It matters because unauthenticated read or write access on a single overlooked characteristic can expose telemetry or allow configuration changes without ever completing a real pairing. It is one of the most consistently productive tests in a BLE security assessment. ### Do resolvable private addresses solve BLE tracking risk? Resolvable private addresses reduce tracking risk by rotating the address a device broadcasts on a schedule known only to bonded peers, rather than exposing a static MAC address indefinitely. They do not eliminate tracking risk on their own if a companion app logs a persistent identifier elsewhere or if the rotation interval is too long. The address scheme has to be evaluated alongside the rest of the device's identifier handling. ### What does the FDA expect documented about BLE specifically? The FDA's February 3, 2026 premarket cybersecurity guidance expects the threat model to name BLE explicitly, describe the pairing method chosen and why, and map specific attack classes relevant to the device's GATT design to documented mitigations. A generic statement that the device uses encrypted wireless communication does not meet this expectation. ## CTA If your BLE implementation has not been tested at the protocol level, radio-based attacks against pairing and GATT access can be missed by a code review alone. Blue Goat Cyber can assess your BLE stack, pairing configuration, and companion app before your next FDA submission. [Contact us](/contact) to scope a wireless security assessment. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Cybersecurity: A 2026 Executive Playbook Source: https://bluegoatcyber.com/blog/the-importance-of-cybersecurity-in-the-medical-device-industry # Medical Device Cybersecurity: A 2026 Executive Playbook > **[DIRECT ANSWER]** For MedTech executives, medical device cybersecurity is a budget and timeline decision, not a technical afterthought: threat modeling before architecture freeze costs weeks, threat modeling after freeze costs a redesign. Section 524B makes the postmarket vulnerability plan you file a legal commitment the FDA can enforce after clearance. Fund it like a product requirement, on the same timeline as design, and it stops adding review cycles to your submission. The cost of medical device cybersecurity is not the line item in the engineering budget. It is the review cycle added when a reviewer sends an Additional Information request, the redesign forced when a threat model is bolted on after architecture freeze, and the postmarket obligation that stays enforceable for the life of the device after clearance. Most executives budget for the first cost and get blindsided by the other two. This playbook is written for the decisions that sit above engineering: when to fund cybersecurity, what Section 524B actually exposes the company to, and what it costs the business when a postmarket program exists on paper but not in practice. ## Key Takeaways - Cybersecurity funded before architecture freeze is a design cost. Funded after, it is a redesign cost, and the difference shows up in submission timelines. - Section 524B turns your filed postmarket vulnerability plan into an enforceable commitment, not a one-time premarket document. - A missed or unstaffed postmarket program is a common trigger for Warning Letters and recalls, not just a compliance gap. - The FDA's cybersecurity review is not a separate track from your 510(k) or PMA timeline. Cybersecurity deficiencies delay the entire submission. - Treating an SBOM as a submission artifact rather than a monitored asset removes your ability to answer "are we affected" when a new CVE lands. - The business exposure from cybersecurity failure extends past the FDA to hospital procurement reviews and contractual liability with health systems. ## Why This Matters The FDA's premarket cybersecurity expectations were finalized in September 2023, revised in draft form in June 2025, and finalized again as *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* on February 3, 2026. Section 524B of the FD&C Act sits alongside that guidance and applies to any "cyber device," meaning software that connects to the internet with the potential for a cybersecurity vulnerability. For an executive, the guidance and the statute together mean cybersecurity is no longer a one-time gate before clearance. It is a lifecycle obligation that the company has to staff and fund after the device ships, and the FDA has enforcement tools, including Refuse to Accept determinations and Warning Letters, for companies that treat the filed plan as paperwork rather than an operating program. ## When should cybersecurity get funded in the product timeline? Cybersecurity should be funded before the system architecture is locked, because the cost of adding it afterward is a redesign, not an addition. A threat model built while interfaces are still being decided shapes those decisions. A threat model built after the architecture is frozen has to work around decisions already made, and the mismatches that creates are what reviewers flag. | When cybersecurity work starts | Typical impact on timeline | Typical impact on submission risk | | --- | --- | --- | | Before architecture freeze | Runs in parallel with design, absorbed into the normal schedule | Lower: threat model and architecture describe the same system | | After architecture freeze, before submission | Requires revisiting design decisions already made | Higher: rework often surfaces new interfaces late | | At submission, in response to a deficiency | Adds one or more Additional Information review cycles | Highest: risk of Refuse to Accept or repeated deficiency rounds | > **[KEY REQUIREMENT]** Fund threat modeling and security architecture review as a design-phase activity with its own line item, not as a subtask absorbed into general engineering. A program with no dedicated cybersecurity budget line before architecture freeze is the pattern behind almost every late-stage cybersecurity delay we see. ## What does Section 524B actually expose the business to? Section 524B requires cyber device sponsors to submit a postmarket vulnerability monitoring plan, maintain processes to identify and patch vulnerabilities, and provide a software bill of materials, and once filed, that plan is treated as a commitment the company has to operate, not a document it can leave unstaffed. It applies across 510(k), De Novo, PMA, PDP, and HDE submissions, so there is no pathway that avoids it for a connected device. The exposure does not stop at the FDA. Hospital procurement teams increasingly request the same evidence (MDS2 forms, SBOM, vulnerability response commitments) during purchasing review, so a weak postmarket program can cost sales cycles even for a device that already cleared. A mismatch between the device as marketed and the device as cleared, caused by an unstaffed postmarket plan, is also one of the more direct paths to a Warning Letter. > **Making a cybersecurity investment decision for a cyber device?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team scopes the threat modeling, testing, and postmarket program budget against your actual submission timeline. [Medical device penetration testing](/services/medical-device-penetration-testing) ## What happens to a submission when cybersecurity is treated as a checkbox? Treating cybersecurity as a checkbox produces documents that do not agree with each other, and reviewers respond to that with Additional Information requests, which is the direct cause of longer review timelines. A threat model written to satisfy a template, disconnected from the actual architecture, is the most common version of this failure. The cybersecurity review is not a side track from the rest of your 510(k), De Novo, or PMA review. Cybersecurity deficiencies delay the whole submission, because reviewers will not clear the device while an open question about vulnerability management remains. Budgeting cybersecurity as a genuine workstream, with its own milestones inside the submission timeline, is what keeps it from becoming the reason the whole submission slips. ## What does a postmarket cybersecurity failure cost after clearance? A postmarket cybersecurity failure costs more than the incident response itself, because it also exposes the gap between the plan filed with the FDA and the program actually running. When a widely used software component gets a new CVE and there is no SBOM monitoring to catch it, no triage process to assess patient impact, and no coordinated disclosure workflow to manage the response, the company is improvising in front of a regulator, customers, and potentially the press at the same time. That improvisation is what turns a routine vulnerability disclosure into a Warning Letter, a field action, or a lost hospital contract. The fix is operational, not technical: assign an owner for vulnerability intake, fund SBOM monitoring as an ongoing service rather than a one-time deliverable, and rehearse the coordinated disclosure process before you need it under pressure. ## Why the FDA's Rules Function as Protection, Not Red Tape The FDA's cybersecurity requirements read like a compliance burden until you trace what they are actually built to prevent: a device compromise that reaches a patient, a data breach that triggers notification obligations, or a recall that damages both revenue and reputation. The February 3, 2026 final guidance is the second major revision in three years, which can look like regulatory churn, but it reflects how fast the threat landscape connected devices face is actually moving. Framed as a cost, the guidance is a submission requirement. Framed as a business decision, it is closer to insurance against three specific failure modes: - A Refuse to Accept determination that stalls market entry before review even begins. - A postmarket vulnerability that surfaces after clearance with no coordinated disclosure process ready to respond. - A recall triggered by a security gap that a threat model would have caught before the device shipped. Manufacturers following a secure-by-design approach, building an SBOM early, running a documented risk assessment, and testing the update mechanism before submission, spend that effort once during development instead of paying for it twice through remediation after a deficiency letter or a field action. Standards like ANSI/AAMI SW96 (FDA Recognized Consensus Standard 13-131) and IEC 81001-5-1 exist precisely to give manufacturers a repeatable way to produce that evidence rather than reinventing the process for every submission. The collaboration point matters here too. Software, hardware, and regulatory teams that coordinate from the start produce documentation that actually matches the shipped device, which is what a reviewer is checking for regardless of how the requirement is framed internally. Manufacturers that treat these rules as a shared engineering requirement, rather than a regulatory afterthought handed to compliance at the end, are the ones who see the least submission friction and the fewest costly surprises after clearance. ## How Blue Goat Cyber Approaches This We work with MedTech leadership to place cybersecurity spend where it changes the outcome, which is before architecture freeze, not after a deficiency letter arrives. Our team, including CISSP and OSCP-certified engineers with prior red-team backgrounds, builds the threat modeling, testing, and SBOM program as a scoped workstream against your actual submission timeline, aligned to the FDA's February 3, 2026 final premarket cybersecurity guidance and Section 524B. For companies further along, we review what has already been filed and give a prioritized list of what is missing, what is weak, and what to fix first, so leadership can make an informed call on timeline and spend before the next deficiency letter rather than after. **Our commitment:** if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our [postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services). ## Frequently Asked Questions **Why does cybersecurity timing matter more than cybersecurity spend?** Timing determines whether cybersecurity work is a design cost or a redesign cost. A threat model built before architecture freeze shapes design decisions in parallel with normal engineering, while the same work done after freeze forces the team to revisit decisions already locked in, which costs more time and money for the same outcome. **Does Section 524B apply to every medical device?** No, it applies to devices that meet the definition of a "cyber device": software that connects to the internet and has the potential for a cybersecurity vulnerability. It applies across submission types, including 510(k), De Novo, PMA, PDP, and HDE, so most connected, software-driven devices are in scope. **What is the real business risk if we skip a dedicated postmarket cybersecurity program?** The immediate risk is a mismatch between your filed plan and your actual operations, which the FDA can act on through mechanisms including Warning Letters. The broader risk is losing hospital procurement reviews and contractual standing with health systems that now request the same vulnerability response evidence during purchasing. **How much does a cybersecurity deficiency typically delay a submission?** There is no fixed number, because it depends on how many Additional Information cycles the deficiency triggers. What is consistent is that cybersecurity deficiencies delay the entire submission rather than running on a separate track, because reviewers will not clear a device with an open cybersecurity question. **Should cybersecurity be a line item in the product budget or absorbed into engineering?** It should be a visible line item, especially for threat modeling and security architecture review before architecture freeze. Absorbing it into general engineering budget is the pattern behind most late-discovered cybersecurity work, because there is no forcing function to start it early. **What does the FDA expect us to maintain after clearance, not just submit?** The FDA expects an operating postmarket vulnerability monitoring program: a way to receive vulnerability reports, triage them for patient safety impact, issue patches in a reasonable timeframe, and communicate with customers. Under Section 524B, this is a commitment tied to the cleared device, not a document that can sit unused after submission. ## CTA If your cybersecurity plan lives in a submission binder and nowhere else in the organization, that gap is a business risk before it is a technical one. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will help you size the investment against your actual timeline and exposure. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical device cybersecurity abuse and misuse](/blog/the-impact-of-cybersecurity-abuse-and-misuse-in-medical-devices) - [Why medical device cybersecurity is nothing like enterprise IT](/blog/why-medical-device-cybersecurity-is-nothing-like-enterprise-it) - [IVD medical device cybersecurity risks](/blog/cybersecurity-risk-with-ivd-medical-devices) - [CBER and medical device cybersecurity](/blog/who-is-center-for-biologics-evaluation-and-research-cber) --- ## The Importance of a Medical Device QMS Source: https://bluegoatcyber.com/blog/the-importance-of-implementing-a-medical-device-qms # The Importance of a Medical Device QMS > **[DIRECT ANSWER]** A Medical Device QMS is the documented set of policies, procedures, and controls, covering risk management, document control, training, and internal audits, that governs a device's design, manufacturing, and postmarket surveillance. It matters because it enforces consistent quality and catches defects before they reach patients, and the FDA expects cybersecurity considerations such as threat modeling and software validation to be built into these QMS processes under standards like ISO 13485 and IEC 62304. With technological advancements and an increasing focus on patient safety, the need for an efficient and well-implemented Medical Device Quality Management System (QMS) cannot be overstated. In this article, we will covers the importance of implementing a QMS, understand its basics, explore its role in the medical device industry, and uncover its benefits. We will also discuss the steps to implement a QMS, address the challenges that may arise, and look toward the future of QMS in the medical device industry. ## Key Takeaways - QMS defines procedures for device quality and safety. - Ensures compliance with FDA and ISO regulations. - Components include policies, risk management, documentation. - Promotes consistent manufacturing processes. - Reduces product risks and minimizes errors. - Enhances overall patient safety and product reliability. ## Why this matters The criticality of a Medical Device Quality Management System (QMS) in safeguarding patient lives cannot be overstated. Without a managed QMS, medical devices risk design flaws, manufacturing errors, and post-market vulnerabilities that directly endanger users. The FDA, in its 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes that QMS processes must explicitly integrate cybersecurity considerations, including threat modeling, risk management, and software validation. This directive underscores that quality extends beyond traditional performance metrics to encompass digital security. Deviations from established QMS protocols, such as those outlined in ISO 13485 (Medical devices, Quality management systems, Requirements for regulatory purposes), IEC 62304 (Medical device software, Software life cycle processes), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management), can lead to product recalls, regulatory penalties, and, most critically, patient harm. A properly implemented QMS acts as a systematic defense against these preventable risks, building product reliability and maintaining public trust in medical technology. ## Understanding the Basics of a Medical Device QMS Before fully comprehending the importance of implementing a Medical Device QMS, we must have a solid understanding of its fundamentals. A Medical Device QMS can be defined as a set of procedures, processes, and resources to ensure the quality, safety, and effectiveness of medical devices throughout their life cycle. The primary function of a Medical Device QMS is to establish a systematic approach that enables organizations to meet regulatory requirements, maintain consistency in production, and continuously improve their processes. Now, let’s explore the key components that form the foundation of a Medical Device QMS. ### Definition and Function of a Medical Device QMS At its core, a Medical Device QMS serves as a framework to manage all aspects of the medical device manufacturing process. It encompasses various activities, including design and development, manufacturing, storage, distribution, installation, servicing, and post-market surveillance. Organizations can implement a Medical Device QMS to ensure that each step of the production cycle adheres to predefined quality standards and meets regulatory requirements. This helps achieve consistent and reliable product performance and instills confidence in healthcare professionals and patients. ### Components of a Medical Device QMS A well-designed and implemented Medical Device QMS comprises several important components that harmonize to establish a quality management system. These components include: 1. Policies and Procedures: Clearly defined policies and procedures provide a roadmap for organizations to follow, ensuring consistent adherence to quality standards and regulatory requirements. 2. Risk Management: Identifying and mitigating risks associated with the entire product life cycle is crucial to a Medical Device QMS, ensuring patient safety and product effectiveness. 3. Document Control: Maintaining proper documentation of processes, specifications, and changes is essential for traceability, accountability, and effective communication within the organization. 4. Training and Competence: Ensuring that personnel are adequately trained and possess the necessary skills and knowledge is vital for maintaining product quality and compliance. 5. Internal Audits: Regular internal audits provide organizations with valuable insights into their QMS’s effectiveness, helping identify improvement areas and ensuring ongoing compliance. These components and other essential elements form the backbone of a Medical Device QMS, working together to create a quality management system. However, it is essential to note that a Medical Device QMS is not a static entity. It is a dynamic system that requires continuous monitoring and improvement. Organizations must regularly review and update their QMS to adapt to changes in regulations, technology advancements, and customer needs. A successful Medical Device QMS goes beyond mere compliance with regulations. It builds a quality culture throughout the organization, encouraging employees to take ownership of their work and strive for excellence. This quality culture permeates every aspect of the organization, from the top management to the production floor, ensuring that quality is not just a checkbox but a mindset. ## The Role of a QMS in the Medical Device Industry A well-implemented QMS is pivotal in ensuring [compliance with regulatory standards](/blog), promoting efficiency and consistency in production, and ultimately enhancing patient safety and product quality. ### Ensuring Compliance with Regulatory Standards The medical device industry is highly regulated, with strict guidelines and standards that manufacturers must adhere to. By implementing a Medical Device QMS, organizations can ensure that all necessary regulations, such as those set by the [Food and Drug Administration (FDA)](/blog/21-cfr-part-820-and-its-role-in-medical-device-cybersecurity) and the [International Organization for Standardization (ISO)](https://www.iso.org/home.html), are followed meticulously. A QMS helps establish documented processes and procedures that conform to these standards, enabling organizations to streamline their operations while staying compliant with regulatory requirements. This, in turn, instills trust in regulatory bodies, healthcare professionals, and patients, assuring them that the products they are using are safe and reliable. For example, the FDA has specific regulations regarding the manufacturing of implantable medical devices to ensure their safety and efficacy. A well-implemented QMS ensures that every step of the manufacturing process, from design and development to production and distribution, is closely monitored and documented. This level of compliance meets regulatory requirements and gives manufacturers a competitive edge in the market. ### Promoting Efficiency and Consistency in Production Efficiency and consistency are integral aspects of any successful organization. Implementing a Medical Device QMS allows organizations to standardize their processes and procedures, ensuring consistent quality across their product lines. By establishing clear guidelines and workflows, organizations can minimize errors, reduce the risk of product recalls, and optimize their production processes. This enhances overall efficiency, leads to cost savings, and improves customer satisfaction. Take, for example, the production of diagnostic medical devices. These devices require precise calibration and testing to ensure accurate results. With a well-implemented QMS, organizations can establish standardized protocols for calibration and testing, ensuring that every device meets the required specifications. This reduces the likelihood of errors and improves the reliability of the diagnostic results, ultimately benefiting healthcare professionals and patients alike. In addition, a QMS enables organizations to identify and address any bottlenecks or inefficiencies in their production processes. By continuously monitoring key performance indicators and conducting regular audits, organizations can identify areas for improvement and implement corrective actions. This proactive approach to quality management leads to streamlined operations, reduced waste, and increased productivity. ## Where Each Requirement Now Lives Since the QMSR compliance date of February 2, 2026, the regulation incorporates ISO 13485:2016, so procedures that cite the older structure need remapping. | Activity | Where it sits now | What it must contain for a connected device | |---|---|---| | Design planning | ISO 13485 clause 7.3.2 | Security activities scheduled with design milestones | | Design inputs | Clause 7.3.3 | Security requirements from the threat model | | Design verification | Clause 7.3.6 | Evidence each security requirement was met | | Design changes | Clause 7.3.9 | Security impact assessed before approval | | Risk management | ISO 14971, referenced throughout | Security risk integrated with safety risk | | Supplier controls | Clause 7.4 | Third party components tracked through the SBOM | | CAPA | Clause 8.5.2 | Vulnerabilities handled as nonconformities | | Records | 21 CFR 820.35 and clause 4.2.5 | Retained and retrievable during inspection | ## Benefits of Implementing a Medical Device QMS ### Enhancing Product Quality and Safety Product quality and safety are paramount in the medical device industry, directly impacting patient outcomes. Implementing a Medical Device QMS ensures that quality is ingrained in every stage of the product life cycle, from design and manufacturing to distribution and post-market surveillance. By adhering to stringent quality control measures and continuously monitoring product performance, organizations can identify and rectify any issues on time, preventing potential patient harm. This enhances patient safety and safeguards the reputation of the organization and its products. ### Reducing Risks and Errors The medical device industry operates in a high-stakes environment where even minor errors can have severe consequences. By implementing a QMS, organizations can systematically identify and mitigate risks associated with their products. Organizations can apply risk management principles to assess and prioritize potential risks, implement preventive measures, and proactively address any issues. This helps reduce the likelihood of errors, minimize product recalls, and enhance overall patient safety. ### Improving Customer Satisfaction In today’s consumer-centric landscape, customer satisfaction is the key to success. Implementing a Medical Device QMS enables organizations to deliver products that consistently meet or exceed customer expectations. Organizations can build trust with healthcare professionals and patients by ensuring product quality, safety, and reliability, building loyalty and satisfaction. A satisfied customer becomes a repeat customer and acts as a brand ambassador, positively impacting the organization’s reputation. An effective QMS also streamlines communication and collaboration within the organization. Establishing clear processes and responsibilities ensures everyone is on the same page and working towards the same goals. This improves efficiency and reduces the chances of miscommunication or misunderstandings that can lead to errors or delays. Implementing a QMS provides organizations with a competitive edge in the market. With regulatory bodies increasingly emphasizing quality and safety, having a QMS demonstrates a commitment to excellence and compliance. This can give organizations a significant advantage when securing contracts or partnerships, as potential clients or collaborators will have confidence in the organization’s ability to deliver high-quality products. ## Steps to Implement a Medical Device QMS Now that we have explored the benefits of implementing a Medical Device QMS let’s discuss the steps involved in the implementation process. Implementing a QMS requires careful planning, system design and development, practical training and deployment, and ongoing monitoring and improvement. Let’s break down these steps further. ![Section Image](/imported-images/04099d5be93c1883.webp) ### Planning and Preparation Before embarking on the implementation journey, organizations must develop a plan that outlines their objectives, timeline, and resource allocation. This involves conducting a thorough gap analysis to identify areas that need improvement and establishing measurable goals. During this phase, organizations must also gain buy-in from stakeholders and build a culture of quality within the organization. Engaging employees and creating a shared vision for quality will be crucial in successfully implementing the QMS. Organizations should consider assessing risks to identify risks and develop mitigation strategies. This proactive approach ensures that potential challenges are addressed early on, minimizing disruptions during implementation. ### System Design and Development The next step in implementing a Medical Device QMS is designing and developing the system itself. This involves creating a framework that aligns with regulatory requirements and industry best practices. During this phase, organizations must establish standard operating procedures, document control processes, and risk management methodologies. It is crucial to consider the organization’s unique needs and processes while designing the system, ensuring it is tailored to its specific requirements. Additionally, organizations should consider using technology solutions to streamline and automate processes within the QMS. This can include implementing electronic document management systems, automated quality control tools, and real-time data analytics platforms. Embracing technology can enhance efficiency, accuracy, and transparency within the QMS, ultimately improving product quality and compliance. ### Training and System Deployment Once the system has been designed and developed, it is time to train employees and deploy the QMS across the organization. Training is vital in ensuring employees understand their roles and responsibilities and the procedures they must follow to maintain product quality and compliance. Organizations should consider a multi-faceted approach during the training phase, including classroom training, hands-on workshops, and online modules. This allows employees to learn in various formats and ensures the training is accessible to all organization members. Organizations should establish a communication plan to inform employees about the implementation progress, address any concerns or questions, and celebrate milestones achieved. Open and transparent communication builds a sense of ownership and commitment to the QMS, driving its successful adoption and integration within the organization. This phase also involves assessing the effectiveness of the QMS through internal audits and conducting regular performance reviews. Continuous monitoring and feedback allow organizations to identify areas for improvement and make necessary adjustments to optimize the system’s performance. Establishing [key performance indicators (KPIs)](/blog) and metrics to track the success of the QMS and ensure that it delivers the desired outcomes is important. By following these steps, organizations can successfully implement a Medical Device QMS and reap the benefits of improved product quality, regulatory compliance, and customer satisfaction. The journey towards a QMS may require time, effort, and resources, but the long-term rewards are worth the investment. ## Overcoming Challenges in QMS Implementation Implementing a new system within an organization can be challenging. It is important to anticipate and address these challenges proactively to ensure a smooth transition and successful implementation of the QMS. Let’s discuss some common challenges and strategies for overcoming them. ![Section Image](/imported-images/1e57911fbc46f7fd.webp) ### Addressing Resistance to Change Resistance to change is a common challenge when implementing a new system. Employees may be apprehensive about the QMS’s changes, fearing job redundancies or increased workload. Organizations should build open communication, involve employees in the planning and implementation, and provide training and support to overcome this challenge. Emphasizing the benefits of the QMS and addressing any concerns can help alleviate resistance and create a sense of ownership among employees. ### Managing Implementation Costs Implementing a QMS requires financial investments in system development, training, and infrastructure upgrades. Managing implementation costs can be challenging, especially for smaller organizations with limited resources. Organizations can overcome this challenge by conducting a thorough cost-benefit analysis and prioritizing investments based on their impact on product quality and compliance. It is essential to balance cost-effectiveness and the organization’s long-term goals. ### Ensuring Continuous Improvement and Maintenance Implementing a QMS is not a one-time activity but an ongoing process. Continuous improvement and maintenance are essential to keeping the system effective and up to date. By conducting regular internal audits, using feedback from stakeholders, and staying informed about regulatory changes, organizations can identify areas for improvement and proactively address any issues that arise. This creates a culture of continuous improvement and ensures the long-term success of the QMS. ## The Future of QMS in the Medical Device Industry ### Technological Advancements and QMS Integrating advanced technologies, such as artificial intelligence, the Internet of Things (IoT), and data analytics, is revolutionizing the medical device industry. These technologies offer great potential for improving product quality, enhancing traceability, and enabling predictive maintenance. By using these advancements, organizations can enhance their QMS, enabling real-time monitoring of product performance, proactive identification of potential issues, and targeted improvements in product design and manufacturing processes. ### Evolving Regulatory Standards and QMS Regulatory standards in the medical device industry constantly evolve to keep pace with technological advancements and ensure patient safety. These evolving standards will shape the future of QMS, pushing organizations to improve their processes and systems continually. Organizations that embrace these changes and proactively adapt their QMS will have a competitive advantage in the market. By staying ahead of regulatory requirements, organizations can deliver products that meet the highest quality standards while complying with the necessary regulations. ## Conclusion The importance of implementing a Medical Device QMS cannot be overstated. Organizations can proactively enhance product quality, reduce risks, and improve customer satisfaction by understanding the basics of a QMS, recognizing its role in the medical device industry, and acknowledging its benefits. Though implementing a QMS may pose certain challenges, such as resistance to change and managing implementation costs, addressing these challenges proactively ensures a smooth transition and successful implementation. Looking toward the future, technological advancements and evolving regulatory standards will continue to shape the QMS landscape, enabling organizations to stay at the forefront of innovation and ensure patient safety. As you consider the critical role of a Medical Device QMS in enhancing product quality, reducing risks, and ensuring regulatory compliance, remember that cybersecurity is an integral part of this equation. With its veteran-owned pride and cybersecurity expertise, Blue Goat Cyber stands ready to protect your medical devices against cyber threats. Our tailored B2B services, including medical device cybersecurity, penetration testing, and HIPAA and FDA standards compliance, are designed to integrate into your quality management strategy. [Contact us today for cybersecurity help](/contact), and take a proactive step towards safeguarding your digital assets and securing your peace of mind in the healthcare industry. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers integrate cybersecurity into their Medical Device QMS. Our approach focuses on developing and implementing processes that satisfy regulatory requirements and enhance device security posture. We work with clients to embed cybersecurity controls and risk management throughout the device lifecycle, from initial design to post-market activities. Our team of experts, including CISSP and OSCP certified professionals, many with ex-military red team experience, provides targeted support for QMS development regarding cybersecurity. We assist with gap analysis, policy and procedure creation, and validation of security measures within the QMS framework. Our services include thorough documentation and evidence generation to support regulatory submissions. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support for regulatory submissions at [/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the primary goal of a Medical Device QMS? The primary goal of a Medical Device QMS is to ensure medical devices consistently meet defined quality, safety, and performance criteria, aligning with regulatory mandates and industry standards. ### How does a QMS help with FDA compliance? A QMS helps with FDA compliance by establishing documented processes and procedures that align with the agency's regulations, such as those related to manufacturing controls and post-market surveillance. This systematic approach ensures all required guidelines are consistently met. ### What are the key components of a Medical Device QMS? Key components of a Medical Device QMS typically include defined policies and procedures, risk management processes, stringent document control, personnel training and competence frameworks, and regular internal audits. ### Does a QMS improve product safety? Yes, a QMS significantly improves product safety by integrating risk management throughout the product lifecycle. It enables organizations to proactively identify, assess, and mitigate potential hazards before they can impact patients. ### When is a QMS implemented? A QMS should be implemented early in the medical device development process and maintained throughout the product's entire lifecycle, from initial design concepts through manufacturing, distribution, and post-market activities. ### Why is document control important in a QMS? Document control is important in a QMS to maintain traceability, accountability, and effective communication. It ensures that all processes, specifications, and changes are properly recorded and managed. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Conducting a Medical Device Security Audit](/blog/a-guide-to-conducting-a-medical-device-security-audit-for-manufacturers) --- ## Medical Device Vulnerability Testing Source: https://bluegoatcyber.com/blog/the-importance-of-medical-device-vulnerability-testing # The Importance of Medical Device Vulnerability Testing > **[DIRECT ANSWER]** Vulnerability testing is how you prove security controls work rather than merely exist. A submission-grade program combines authenticated and unauthenticated scanning, SBOM-driven CVE analysis, protocol fuzzing on every external interface, firmware and binary analysis, and manual penetration testing against the threat model. Document scope, methodology, tooling, and findings disposition, because the FDA evaluates the rigor of the test as closely as the result. Medical devices improve care, extend lives, and increasingly connect to hospital networks, cloud platforms, and mobile apps. That connectivity creates risk. Vulnerability testing helps manufacturers find and fix exploitable weaknesses before they turn into patient safety events, data exposure, or regulatory problems. ## Key Takeaways - Vulnerability testing identifies exploitable weaknesses in medical devices. - Unchecked vulnerabilities risk patient harm, data exposure, and operational disruption. - Testing evaluates device software, hardware, networks, and third-party components. - The FDA expects risk-based testing and postmarket vulnerability management. - Effective testing supports ongoing safety, essential performance, and data security. - Testing must adapt to evolving threats and increased device connectivity. ## Why this matters The security of medical devices directly impacts patient safety and the integrity of healthcare operations. Unidentified or unaddressed vulnerabilities can lead to device malfunction, data breaches encompassing sensitive protected health information (PHI), and even physical harm to patients. Beyond the immediate clinical risks, compromised devices can disrupt hospital networks, degrade trust in medical technology, and result in significant financial penalties and reputational damage for manufacturers. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, explicitly states the agency's expectation that manufacturers actively manage and mitigate cybersecurity risks throughout the device lifecycle, beginning with premarket testing. This guidance emphasizes the necessity of vulnerability testing as part of a broader security assurance program. Adherence to standards such as IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023 further underscores the industry's commitment to securing these critical technologies. Effective vulnerability testing is not merely a compliance task; it is fundamental to upholding the essential performance and safety of medical devices in an increasingly connected and threat-laden healthcare landscape. ## What Medical Device Vulnerability Means A vulnerability is a weakness that can be exploited to gain unauthorized access, alter device behavior, interrupt availability, or expose sensitive data. In medical devices, those weaknesses may come from software defects, insecure communications, poor authentication, unsafe update mechanisms, third-party components, or design decisions made early in development. This is not just an IT issue. A vulnerability in a medical device can affect clinical performance, safety functions, and trust in the product. ### Where Vulnerabilities Show Up Medical device vulnerabilities take different forms. An attacker might exploit an insecure wireless protocol to intercept patient data. A software flaw could cause a device to freeze, misread inputs, or deliver therapy incorrectly. Weak access controls might allow unauthorized configuration changes. In more serious cases, a remotely exploitable issue could let an attacker take control of device functions, [jeopardizing patient safety](/blog). ### Why This Matters in Clinical Use Medical devices support diagnosis, monitoring, and treatment across every care setting. That includes simple products like blood pressure cuffs and thermometers, as well as complex systems such as infusion pumps, imaging platforms, implantables, and network-connected bedside devices. As device connectivity increases, so does the attack surface. Testing for vulnerabilities is how manufacturers move from assumptions to evidence. It shows whether security controls actually work under realistic conditions and whether risks have been reduced to an acceptable level. ## The Risks of Unchecked Vulnerabilities When vulnerabilities are not identified and remediated, the consequences are rarely limited to a failed audit item. They can affect safety, operations, privacy, and market access. ![Section Image](/imported-images/5760220e36f57259.png) Manufacturers and healthcare delivery organizations both have a role here, but the primary burden sits with the manufacturer. Security testing cannot be treated as a one-time exercise or a document package assembled right before submission. Devices need to be evaluated as they are built, updated, integrated, and maintained. ### Device Failure and Patient Harm Unchecked vulnerabilities can lead to device malfunction, loss of availability, or unauthorized changes to therapy and settings. In a connected insulin pump, infusion system, or pacemaker ecosystem, that is not hypothetical risk. It is a direct patient safety concern. Security weaknesses can also trigger cascading failures. A compromised support system, update server, mobile app, or network connection may affect how the device performs in the field. The result can be delayed care, incorrect readings, or interruption of therapy. ### Data Exposure and Operational Impact Many medical devices collect, store, or transmit protected health information and other sensitive data. If those pathways are insecure, attackers may be able to intercept or extract that information. The 2015 [Anthem breach exposed the records of nearly 78.8 million individuals](https://www.insurance.ca.gov/0400-news/0100-press-releases/anthemcyberattack.cfm#:~:text=Anthem%20Blue%20Cross%20Blue%20Shield,of%20the%20company's%20IT%20system.), a reminder that healthcare data remains a high-value target. For device manufacturers, data security failures also create downstream business problems: incident response costs, customer notifications, recalls, patch pressure, and hard questions from regulators and procurement teams. Security debt has a way of surfacing at the worst possible time. ## How Vulnerability Testing Works Medical device vulnerability testing is a structured process for identifying, validating, and prioritizing weaknesses in the product and its ecosystem. Done well, it supports both risk management and design improvement. ![Section Image](/imported-images/6d2190722c506dd2.png) Testing should reflect how the device is actually used and attacked. That means looking beyond the firmware binary or application code and examining interfaces, dependencies, cloud connections, mobile apps, update workflows, and manufacturing or service pathways where relevant. ### Core Testing Activities A typical engagement starts with scoping: what the device is, how it communicates, where trust boundaries exist, and which assets matter most. From there, testers identify likely attack paths and review the architecture, software, interfaces, and known component risks. Next comes hands-on validation. The goal is to determine whether weaknesses are real, how exploitable they are, and what impact they could have on safety, essential performance, and data confidentiality, integrity, and availability. Findings are then prioritized based on actual risk, not just severity labels. That last point matters. A theoretical issue with no practical exploit path is not the same as a remotely reachable flaw affecting therapy delivery. Good testing distinguishes between the two. ### Common Tools and Techniques Effective testing usually combines several methods: - Static analysis to review source code or binaries for insecure patterns - Dynamic analysis to observe runtime behavior - Penetration testing to simulate attacker actions against exposed interfaces - Fuzz testing to uncover unexpected crashes, hangs, or unsafe states - Software composition analysis to identify vulnerable third-party components - Protocol and wireless testing for Bluetooth, Wi-Fi, BLE, Zigbee, proprietary RF, and similar interfaces No single tool is enough. Automated scanners can help, but they do not understand clinical context, safety implications, or chained exploits. Medical device testing requires human judgment, especially when a finding could affect essential performance or patient harm scenarios. ## Regulatory Standards for Medical Device Testing Regulators expect cybersecurity work to be tied to product risk, design controls, and lifecycle maintenance. That expectation has become much clearer in recent years, especially for connected devices. ![Section Image](/imported-images/529625b94e8dfe38.png) Testing is not just about finding bugs. It is part of showing that the device is reasonably secure, that risks have been assessed appropriately, and that security controls are verified and maintained over time. ### FDA Expectations The FDA has issued cybersecurity guidance that makes manufacturers’ responsibilities hard to ignore. The FDA expects security to be built into design and supported with evidence, including threat modeling, risk-based testing, SBOM considerations, secure update capabilities, and plans for vulnerability handling after release. For submissions, the FDA wants more than broad claims that a device was “tested.” Reviewers look for traceability between identified risks, implemented controls, verification activities, and residual risk decisions. If vulnerability testing is shallow or disconnected from the actual architecture, it shows. The FDA also expects postmarket discipline. Vulnerability intake, assessment, remediation, coordinated disclosure, and communication planning are all part of maintaining a device that remains safe and effective after launch. ### International Standards and Compliance Outside the United States, standards from IEC, ISO, and related frameworks shape how manufacturers approach security engineering and testing. These standards help establish repeatable practices for risk management, software lifecycle controls, and system security. Compliance matters, but checkbox compliance is not enough. A device can align neatly with a standard on paper and still be exposed in practice. The right question is not “Do we have the artifact?” It is “Does this evidence show the device can withstand realistic attacks without creating unacceptable risk?” ## The Future of Medical Device Security Medical device security is not getting simpler. Connectivity is expanding, software supply chains are getting messier, and adversaries have more tooling than ever. Manufacturers need testing programs that keep pace with how devices are actually deployed and targeted. ### Emerging Threats and Challenges The growth of the [Internet of Medical Things (IoMT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) has increased device interdependence across hospitals, homes, and cloud-connected care models. That creates more entry points and more ways for a single weakness to affect multiple systems. Telemedicine and remote monitoring add convenience and clinical value, but they also introduce new attack paths through apps, APIs, clinician portals, and remote update channels. Third-party software and open-source components add another layer of exposure. If manufacturers are not continuously tracking and testing those dependencies, they are operating with blind spots. ### What Better Security Testing Looks Like The industry is improving. Manufacturers are adopting stronger encryption, better authentication, signed updates, and more disciplined vulnerability management processes. Testing is also becoming more realistic, with greater emphasis on exploitability, attack chains, and the interaction between cybersecurity and safety. Machine learning may help analysts sort findings faster, but it does not replace hands-on validation or engineering judgment. What works is a mature security program: threat modeling early, testing throughout development, retesting after changes, and postmarket processes that do not collapse the first time a researcher reports an issue. Medical device vulnerability testing matters because unsafe software and unsafe connectivity can become unsafe care. Manufacturers that treat testing as an engineering function, not a submission chore, are in a much stronger position to protect patients, satisfy the FDA, and avoid preventable failures in the field. As the medical device industry continues to change, the need for serious cybersecurity work only grows. Blue Goat Cyber, a Veteran-Owned business, provides specialized B2B cybersecurity services to help manufacturers address these risks. Our expertise in medical device cybersecurity, penetration testing, HIPAA, the FDA compliance, and other security services helps protect devices and patient data against real-world threats. [Contact us today for cybersecurity help](/contact) and work with a team focused on protecting your business and products from attackers. ## How Blue Goat approaches this Blue Goat Cyber's methodology for medical device vulnerability testing focuses on identifying real-world attack vectors and exploit chains. Our team, comprised of professionals holding certifications like CISSP and OSCP, including ex-military red team personnel, applies a threat-informed approach to uncover weaknesses across device software, hardware, and network interfaces. We conduct thorough penetration testing, fuzz testing, and configuration reviews, aligned with FDA guidance such as the "Cybersecurity in Medical Devices" Final Guidance (February 3, 2026). We provide actionable remediation guidance and support for both premarket and postmarket device security. Our engagements aim for clear, repeatable results, demonstrating compliance and enhancing device resilience. Explore our specialized services at: [Medical Device Penetration Testing](/services/medical-device-penetration-testing). When we handle your FDA premarket submission cybersecurity documentation, if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is medical device vulnerability testing? It is a systematic process to find security weaknesses in medical devices and their connected systems. This includes examining software, hardware, network interfaces, and integrated components to identify potential attack vectors. ### Why is vulnerability testing important for medical devices? Testing is crucial to prevent device malfunctions, protect patient data, and maintain clinical operational integrity. It helps manufacturers identify and remediate risks before they can be exploited to cause harm or compromise privacy. ### What types of vulnerabilities are common in medical devices? Common vulnerabilities include software defects, insecure communication protocols, weak authentication, poor access controls, and risks from outdated or vulnerable third-party components. These can affect device function, data security, and patient safety. ### Does the FDA require medical device vulnerability testing? Yes, the FDA expects manufacturers to incorporate cybersecurity into device design and provide evidence of risk-based testing. The February 3, 2026 final guidance emphasizes lifecycle security, including strong premarket testing and postmarket vulnerability management. ### How does vulnerability testing protect patient safety? By identifying and mitigating security flaws, testing prevents unauthorized access, alteration of device behavior, or interruption of availability that could directly impact therapy delivery, monitoring accuracy, or diagnostic results, thereby safeguarding patient care. ### What methods are used in medical device vulnerability testing? Testing employs methods such as static and dynamic analysis, penetration testing, fuzz testing, and software composition analysis. These techniques evaluate code, observe runtime behavior, simulate attacks, and identify supply chain risks. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Software Verification and Validation: What FDA Expects Source: https://bluegoatcyber.com/blog/the-importance-of-verification-and-validation-in-medical-device-software # Medical Device Software Verification and Validation Explained > **[DIRECT ANSWER]** Medical device software verification and validation are two distinct, required activities. Verification confirms you built the software right by testing it against documented requirements and specifications. Validation confirms you built the right software by demonstrating it meets user needs and intended use. The FDA requires evidence of both under 21 CFR 820.30(f) and (g), and IEC 62304 maps each to specific lifecycle phases with rigor scaled by software safety classification. _Reviewed September 17, 2026_ Every FDA submission for a software-containing device lives or dies on whether the manufacturer can prove two separate claims: that the software matches what was specified, and that what was specified actually solves the user's problem safely. Conflating these two questions is one of the most common reasons reviewers issue deficiency letters. A device can pass every unit test against its requirements and still fail validation if the requirements themselves missed a use error, a workflow gap, or an unanticipated clinical environment. Getting the distinction right, and documenting it with traceable evidence, is what separates a submission that moves forward from one that stalls in additional-information cycles. ## Key Takeaways - Verification and validation answer different questions: built it right versus built the right thing, and a submission needs objective evidence for both. - Design controls require separate, documented verification and validation records, now under ISO 13485 clause 7.3.6 and 7.3.7 as incorporated by the QMSR (formerly 21 CFR 820.30(f) and (g)). - IEC 62304 assigns V&V activities to specific lifecycle phases, and the depth of evidence scales with software safety classification A, B, or C. - Traceability from user need through requirement, design, code, test, and result is the backbone reviewers check first. - Security requirements verify the same way any functional requirement does, and penetration testing supplements but never replaces that verification. - A third party can report test results, but it cannot attest that the manufacturer's own design inputs were satisfied. ## Why This Matters Weak or incomplete verification and validation is a recurring root cause behind recalls, warning letters, and refuse-to-accept holds. The FDA's "Cybersecurity in Medical Devices" final guidance, dated February 3, 2026, reinforces that cybersecurity controls are design inputs like any other, and that manufacturers must verify those controls were implemented correctly and validate that they do not degrade safety, effectiveness, or usability. IEC 62304 and the design control requirements at 21 CFR 820.30 already required this discipline for functional requirements. The February 2026 guidance closes the gap for security-specific requirements, making clear that a security control with no verification record is treated by reviewers as an unimplemented control. Under the quality management system regulation (QMSR), design control expectations carry forward largely unchanged even though several legacy Part 820 subparts are now reserved. Manufacturers still need a documented design history file showing verification and validation were planned, executed, and reviewed. Reviewers use that traceability to decide whether a device is ready for market, and gaps here are one of the most common reasons for additional-information requests during premarket review. ## What Is the Difference Between Verification and Validation? Verification asks whether the software was built correctly against its documented requirements, and validation asks whether the software is the right solution for the user's actual needs. Verification is an internal, objective comparison: does the output match the specification. Validation is an external, use-context comparison: does the finished device work correctly for real users in the real intended use environment. A classic example is a dosing calculation that verifies perfectly against its requirement but fails validation because the requirement itself omitted a rounding rule that matters clinically. **[KEY REQUIREMENT]** Every requirement in the design input document needs at least one verification test, and every user need needs at least one validation activity tracing back to it. A requirement with no test, or a user need with no validation evidence, is a gap a reviewer will find. ## Where Do V&V Sit in the IEC 62304 Lifecycle? IEC 62304 places verification inside each development phase and validation at the system level once integration is complete. Unit implementation is verified against unit-level requirements, software integration is verified against architecture, and system testing verifies the complete software system against the software requirements specification. Validation happens against user needs and intended use, typically as part of the broader device-level validation required under design controls, and it often includes usability evaluation under IEC 62366-1. Traceability matrices required by IEC 62304 tie each verification and validation record back to a specific requirement or user need. ## How Do Design Verification and Validation Requirements Apply Under the QMSR? ISO 13485 clause 7.3.6, incorporated by the QMSR, requires design verification, and clause 7.3.7 requires design validation (formerly 21 CFR 820.30(f) and (g)), including software validation, and both must be documented in the design history file. Design verification under (f) confirms that design outputs meet design input requirements, using methods like analysis, inspection, or test. Design validation under (g) confirms the device conforms to defined user needs and intended uses under actual or simulated use conditions, and it explicitly calls out software validation and risk analysis as part of that activity. Records for both must identify the design, method, date, and the individuals performing the activity. ## Verification vs Validation vs Testing vs QA: What Is the Difference? Testing is a technique used inside both verification and validation, and quality assurance is the broader system that ensures both happen consistently and are documented. | Activity | Question Answered | Typical Method | Owner | |---|---|---|---| | Verification | Did we build it to spec | Unit, integration, code review, static analysis | Engineering | | Validation | Did we build the right thing | System-level, usability, clinical evaluation | Engineering plus clinical/human factors | | Testing | Does this specific case behave as expected | Test execution against a defined case | QA/test engineers | | Quality Assurance | Is the whole process controlled and repeatable | Process audits, procedure review, record checks | Quality | ## What Activities Make Up a Complete V&V Program? A complete program layers unit, integration, system, regression, usability, and, where applicable, clinical evaluation. Unit testing checks individual functions or modules against their specifications, and integration testing checks that modules work together correctly. System testing exercises the complete software against the full software requirements specification, and regression testing reruns prior tests after any change to confirm nothing broke. Usability testing under IEC 62366-1 validates that intended users can operate the device safely and effectively, and clinical evaluation, where the intended use warrants it, provides evidence the device performs as intended in the clinical population. ## How Does Software Safety Classification Change the Evidence Needed? IEC 62304 assigns each software system a safety classification of A, B, or C based on the severity of harm a failure could cause, and that classification scales how much verification and validation evidence is expected. Class A software, where failure cannot cause injury, needs the least rigorous documentation. Class B, where failure could cause non-serious injury, requires more detailed unit and integration verification records. Class C, where failure could cause death or serious injury, requires the most rigorous verification, including detailed traceability, more extensive testing, and often independent review of test results. ## What About Tool Validation and SOUP? Any automated tool used to build, test, or verify the software needs its own validation record showing it performs its intended function reliably. Software of unknown provenance (SOUP), including open source libraries and third-party components, must be identified, and the manufacturer must assess and document the risk it introduces, even though the manufacturer did not write it. Verification activities for SOUP typically include confirming the version in use, checking known vulnerabilities, and testing the integration points where SOUP interfaces with manufacturer-written code. ## Why Does Traceability From User Need to Test Result Matter? Traceability is the mechanism that lets a reviewer confirm nothing was verified in isolation from an actual need. The chain runs from user need, to design input requirement, to design output, to verification or validation test, to a documented result. A break anywhere in that chain, a requirement with no test, or a test with no traceable requirement, is treated as unaddressed risk by both internal quality reviewers and the FDA. ## What Does an FDA Reviewer Look for in a Submission? A reviewer looks for a complete, traceable record showing every requirement was verified and every user need was validated with objective evidence. That means test protocols with pass/fail criteria defined before execution, signed and dated test results, a traceability matrix connecting requirements to tests, and a rationale for the software safety classification assigned. Reviewers also expect the design history file to show that failures found during testing were investigated, corrected, and retested, not simply logged and left open. ## How Does Cybersecurity Fit Into V&V? Security requirements must be verified the same way any other design input is verified, with documented test protocols, pass/fail criteria, and traceable results. The February 3, 2026 FDA premarket cybersecurity guidance is explicit that cybersecurity risk controls are design inputs, and a control that was never verified is functionally the same as a control that was never implemented. Penetration testing is independent adversarial evidence that a security control holds up under attack, but it is not a substitute for the manufacturer's own verification that its design inputs were satisfied. **[KEY REQUIREMENT]** A third party performing penetration testing or independent assessment should never attest that a manufacturer's design inputs were satisfied. That attestation belongs to the manufacturer, based on its own verification and validation records; the third party's role is to report findings against the scope it tested, not to certify design input closure. ## What an Outside Firm Can and Cannot Do for Your V&V Record Buyers often ask whether an external security firm can simply own verification and validation. It cannot, and any vendor who says otherwise is selling something that will not hold up. Your design inputs, your requirements, and your sign-off belong to your quality system. What an outside firm adds is independent testing evidence against those requirements, which is exactly the part reviewers question when it comes only from the team that wrote the code. | Activity | Manufacturer owns | Independent firm contributes | |---|---|---| | Defining software requirements and design inputs | Yes, always | Review for testability and security gaps | | Software safety classification under IEC 62304 | Yes | Input on security-relevant failure modes | | Verification that requirements were met | Yes, in the design history file | Test execution and reported results | | Security testing against the threat model | Shared | Execution, tooling, and findings | | Validation that the device meets user needs | Yes | Not applicable | | Final release sign-off | Yes | Never | Budget accordingly. The external line item is testing and evidence, usually scoped by interface count and report depth rather than by document page count, and the [penetration testing cost guide](/blog/cost-of-medical-device-penetration-testing) sets out those drivers. The internal line item, which is usually the larger of the two, is the requirements and traceability work that only your team can do. ## How Blue Goat Cyber Approaches This Blue Goat Cyber supports manufacturers in closing the specific gap between security requirements and verifiable evidence, without ever standing in for the manufacturer's own design control sign-off. Our [medical device penetration testing](/services/medical-device-penetration-testing) engagements are scoped against the manufacturer's documented security requirements, so findings map directly to the requirements a design history file needs to show were tested. We also support [threat modeling](/services/medical-device-threat-modeling) earlier in the lifecycle, so security requirements exist before verification testing starts, rather than being retrofitted after the fact. Throughout, we produce reports that document what we tested and found, so the manufacturer's own quality team can complete the verification and validation record with defensible, traceable evidence. ## Frequently Asked Questions ### What is the difference between verification and validation in simple terms? Verification checks that the software matches its written specification, answering "did we build it right." Validation checks that the finished software meets the actual needs of its users in its intended use environment, answering "did we build the right thing." Both require documented, objective evidence. ### Does IEC 62304 require validation, or only verification? IEC 62304 focuses primarily on verification activities within the software development lifecycle, while validation is typically addressed through the broader design control process required by regulations such as 21 CFR 820.30(g). In practice, manufacturers run both under a single integrated V&V plan so evidence stays traceable. ### What is software safety classification and why does it matter for V&V? Software safety classification under IEC 62304 sorts software into Class A, B, or C based on the potential severity of harm from a failure. Class C software, tied to death or serious injury, requires the most rigorous verification and validation evidence, while Class A requires the least. ### Can penetration testing substitute for security verification? No. Penetration testing provides independent adversarial evidence that a control holds up under attack, but the manufacturer must still verify, through its own documented process, that each security design input was implemented and functions as specified. A third party should never attest that the manufacturer's design inputs were satisfied. ### What records does the FDA expect to see for software V&V? The FDA expects test protocols with predefined pass/fail criteria, signed and dated results, a traceability matrix linking user needs, requirements, and tests, and documentation of how any failures were investigated and resolved. This evidence typically lives in the design history file. ### How does SOUP or open source software get verified? Software of unknown provenance must be identified, version-controlled, and risk-assessed, even though the manufacturer did not write it. Verification typically confirms the specific version in use, checks it against known vulnerabilities, and tests the integration points where it connects to manufacturer-written code. ## CTA Incomplete verification and validation records are one of the most common reasons FDA submissions stall. If your team needs independent testing evidence that maps cleanly to your documented security requirements, [contact us](/contact) to scope an engagement built around your traceability matrix, not a generic test plan. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Founder Guide to MedTech Cyber Risk (2026) Source: https://bluegoatcyber.com/blog/the-overlooked-threat-in-medtech-innovation-cybersecurity-risks-every-founder-must-address # Founder Guide to MedTech Cyber Risk: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Cybersecurity is frequently overlooked by MedTech founders who focus on device innovation and regulatory milestones until late in development, when retrofitting security becomes costly and delays FDA submissions. Addressing firmware, software, and hardware vulnerabilities early, along with risks from interconnected devices and hostile hospital networks, protects patients, satisfies the FDA's February 3, 2026 guidance, and builds investor and market trust. In the fast-paced medical technology (MedTech) innovation world, founders are often laser-focused on developing groundbreaking devices, perfecting their software, and navigating the complex regulatory landscape. However, one critical area that is frequently overlooked is cybersecurity - a threat that can derail even the most promising MedTech startups. In a recent interview at the [LSI USA 2025 - The Emerging MedTech Summit](https://www.lsiusasummit.com/), Omar Khateeb, host of the [State of MedTech Podcast](https://podcasts.apple.com/us/podcast/state-of-medtech/id1597688404), sat down with Christian Espinosa, CEO and Founder of [Blue Goat Cyber](/), to uncover the often-overlooked cybersecurity threats facing the MedTech industry. ## Key Takeaways - MedTech founders often overlook cybersecurity risks. - Early integration of cybersecurity prevents costly delays. - Specialized expertise is critical for MedTech cybersecurity. - Interconnected devices and hostile hospital environments increase risk. - Cybersecurity is a strategic advantage, not just a compliance hurdle. - The FDA's February 3, 2026, guidance mandates strong cybersecurity. ## Why this matters The stakes for overlooking MedTech cybersecurity are profound, impacting patient safety, market access, and financial viability. Devices with inadequate security pose direct risks to patient health through data breaches or device malfunction from cyberattacks. Beyond safety, founders face substantial regulatory hurdles; the FDA's February 3, 2026, final guidance mandates stringent cybersecurity controls, and non-compliance can lead to costly delays, rejection of submissions, and significant reputational damage. Ignoring security during development often results in retrofitting, which is far more expensive and time-consuming than integrating it from inception. Early consideration of standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023)/TIR97 is vital. Furthermore, investors are increasingly scrutinizing cybersecurity posture, as it directly correlates with a device's market readiness and long-term success. A breach can erode trust, halt product rollout, and necessitate expensive remediation, making cybersecurity a non-negotiable component of modern MedTech innovation. ## The Cybersecurity Blind Spot in MedTech Innovation Espinosa explains that many MedTech founders simply don’t realize the gravity of their devices’ cybersecurity risks. “Most people don’t know what they don’t know about cybersecurity,” he says. “They don’t think about it until the very end, right before they’re trying to get their device cleared by the FDA or MDR (Medical Device Regulation), and then their regulatory affairs person’s like, ‘Oh, cybersecurity is on the checklist of documents we have to submit.'” By that point, it’s often too late. Espinosa recounts a real-world example where his team discovered over 4,000 vulnerabilities in a client’s device just 60 days before their FDA submission. “They cannot fix it in two months,” he explains. “It delays their time to market, it causes frustration with the innovator, the investors, and everyone else, and it’s really costly.” ## The Complexity of MedTech Cybersecurity MedTech cybersecurity is a far more complex challenge than many founders realize. It’s not just about protecting against external attacks; it’s about understanding the unique vulnerabilities inherent in the various components of a medical device. ### Firmware, Software, and Hardware Vulnerabilities - **Firmware:** Espinosa cites the example of a client developing a bronchial decongestion system that used a microcontroller with firmware that didn’t support [secure boot](/blog) - a requirement of the FDA. “They had to basically make their device stand-alone because it was too risky to have it connected to anything,” he explains. - **Software:** “Traditionally, we see vulnerabilities in software,” Espinosa says. “My team is very good at breaking things. We look at every angle an attacker would take to break into the device - every interface into the device.” - **Hardware:** Hardware vulnerabilities can be just as dangerous. Espinosa emphasizes the importance of considering what interfaces are exposed on a device and whether they’re necessary for its operation. “If we don’t need access to these ports on the device, maybe we should create an enclosure to cover them up,” he suggests. ### The Threat of Interconnected Devices MedTech devices don’t exist in a vacuum; they’re often interconnected with other systems, creating a complex web of potential vulnerabilities. “If I have a system that’s imaging and it connects to a PACS (Picture Archiving and Communication System) server, now we have to consider: Is the data we’re getting from that PACS server trustworthy?” Espinosa explains. “How do we know it hasn’t been altered? And then the data we’re sending back, how does that device know that the data hasn’t been altered?” This interoperability challenge is a significant concern, as malicious actors can exploit vulnerabilities in one device to gain access to the broader ecosystem. ### The Threat of Hostile Environments Espinosa describes Medical devices often deployed in healthcare environments as “hostile.” He explains, “Hospitals are notorious for not securing their networks. I mean, how if you just look at the news, pretty much every hospital’s been compromised. Just when you think that can’t be a bigger data breach of a hospital, the next day you read in the news there’s been a bigger one.” When a MedTech device is installed on a hospital’s network, it becomes vulnerable to the same threats that have plagued the healthcare industry. “That environment is not friendly,” Espinosa warns. “You can expect that device to be attacked over and over and over as soon as it’s plugged into the environment.” ## The Consequences of Overlooking Cybersecurity The consequences of overlooking cybersecurity in MedTech innovation can be severe, ranging from regulatory delays to patient safety risks. ### Regulatory Delays and Investor Frustration As Espinosa’s example illustrates, discovering critical vulnerabilities late in the development process can lead to significant delays in getting a device approved by the [FDA](https://www.fda.gov/media/119933/download) or other regulatory bodies. “It delays their time to market, it causes frustration with the innovator, the investors, and everyone else, and it’s really costly,” he says. These delays can be devastating for startups, eroding investor confidence and jeopardizing funding opportunities. Founders who fail to prioritize cybersecurity early on may find themselves struggling to secure the resources they need to bring their innovations to market. ### Patient Safety Risks Perhaps the most concerning consequence of overlooking cybersecurity is the potential impact on patient safety. Espinosa emphasizes that MedTech cybersecurity is not just about protecting data; it’s about safeguarding human lives. “If I can affect the device in a manner that translates to affecting patient health or causing harm to a patient or a misdiagnosis or delayed diagnosis, then that needs to be fixed,” he says. “The bottom line is, if we can affect the device in a manner that translates to affecting patient health or causing harm to a patient, then that needs to be fixed.” ## Cybersecurity as a Competitive Advantage While many founders view cybersecurity as a necessary evil, Espinosa believes it can be a strategic advantage for MedTech startups. “If I can help in that regard as part of our cybersecurity service, if there’s a way for me to help with the entrepreneur journey because I’ve been doing entrepreneurship for a while, I like to do that too,” he says. By proactively addressing cybersecurity concerns, founders can not only mitigate risks but also differentiate their offerings in a crowded market. Espinosa suggests that “if you can show that your device is more secure than your competitor’s, that’s a competitive advantage.” ## Taking Action: Cybersecurity Strategies for MedTech Founders So, what should MedTech founders do to address their cybersecurity challenges? Espinosa offers the following advice: ### 1\. Integrate Cybersecurity into the Product Roadmap Cybersecurity should be a core consideration from the very beginning of the product development process, not an afterthought. “At the requirements phase is where they should be looking at cybersecurity,” Espinosa says. “And then if it’s design, the requirements phase is done properly, then it enters the design phase, and the controls are designed into the device.” ### 2\. Engage Specialized Cybersecurity Expertise MedTech cybersecurity is a highly specialized field, and founders should not attempt to handle it in-house or as an add-on to their existing regulatory or quality management efforts. “You really need to hire someone that knows what they’re doing, not somebody that just, you know, took a cybersecurity course and is trying to help you with cybersecurity,” Espinosa advises. Founders can explore resources like Blue Goat Cyber to find specialized MedTech cybersecurity expertise that can guide them through the process. ### 3\. Raise Awareness and Educate the Team One of the key initiatives at Blue Goat Cyber is to “raise the awareness about the importance of cybersecurity early on in a product’s life cycle,” Espinosa says. Founders should ensure that their entire team, from engineering to regulatory affairs, understands the gravity of cybersecurity risks and the importance of addressing them proactively. ### 4\. Incorporate Cybersecurity into the Funding Roadmap Securing the necessary resources to address cybersecurity concerns should be a critical part of a MedTech startup’s funding strategy. Founders should allocate budget and resources for cybersecurity assessments, penetration testing, and ongoing monitoring and maintenance. ## Conclusion: Embracing Cybersecurity for MedTech Innovation In the world of medical technology, cybersecurity is no longer an optional consideration - it’s a critical component of successful innovation. By proactively addressing cybersecurity risks, MedTech founders can protect their patients and their businesses and position their companies for long-term success. As Espinosa eloquently states, “If it wasn’t for a medical device, I wouldn’t be here.” The stakes are simply too high to overlook the cybersecurity threats facing the MedTech industry. By embracing cybersecurity as a strategic priority, founders can unlock new opportunities, drive innovation, and ultimately, save lives. To learn more about the importance of cybersecurity in MedTech innovation, be sure to check out the [State of MedTech Podcast](https://podcasts.apple.com/us/podcast/state-of-medtech/id1597688404) and explore the resources available at [Blue Goat Cyber](/). Together, we can build a future where medical technology is not only groundbreaking but also secure. ## How Blue Goat approaches this Blue Goat Cyber assists MedTech founders in navigating the intricate cybersecurity landscape, transforming potential liabilities into market strengths. Our approach focuses on embedding security throughout the product lifecycle, from concept to post-market surveillance. We offer specialized services including threat modeling, penetration testing, and premarket cybersecurity services tailored to meet regulatory requirements. Our team brings deep expertise, holding certifications like CISSP and OSCP, and using insights from ex-military red team personnel. We work alongside your team to identify and mitigate risks proactively, ensuring your devices meet the stringent requirements of the FDA's February 3, 2026, guidance. Should the FDA raise cybersecurity deficiencies after our submission, we resolve them at no additional cost. We emphasize practical, effective security solutions that align with innovation, avoiding last-minute, budget-consuming fixes. Learn more about our thorough support at [Blue Goat Cyber FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### Why is cybersecurity often overlooked in MedTech development? Founders frequently prioritize innovation and regulatory navigation, postponing cybersecurity considerations until late in the development process. This often stems from a lack of awareness regarding the complexity and criticality of medical device security. ### What are the consequences of neglecting MedTech cybersecurity? Neglecting cybersecurity can lead to severe issues, including significant regulatory delays, increased development costs, investor frustration, and serious patient safety risks from compromised devices. It can also harm market reputation. ### How does the FDA view cybersecurity in medical devices? The FDA considers cybersecurity a critical element of medical device safety and effectiveness. Their February 3, 2026, final guidance outlines stringent expectations for cybersecurity throughout the total product lifecycle, requiring strong security measures for all submissions. ### When should cybersecurity be integrated into MedTech product development? Cybersecurity should be integrated at the earliest stages of product development, ideally during the requirements phase. This ensures that security controls are designed into the device rather than being retrofitted, which is more effective and less costly. ### Can strong cybersecurity be a competitive advantage for MedTech companies? Yes, demonstrating a commitment to strong cybersecurity can be a significant competitive advantage. It builds trust with healthcare providers and patients, reduces market entry barriers, and differentiates a company's products from less secure alternatives. ### What specific vulnerabilities are common in MedTech devices? MedTech devices commonly exhibit vulnerabilities in firmware, software, and hardware. Interconnectedness with other systems and deployment in potentially 'hostile' hospital network environments further amplify these risks, creating multiple points of attack. --- ## IEC 81001-5-1 & Medical Device Security Source: https://bluegoatcyber.com/blog/the-relationship-of-iec-81001-5-1-2021-with-medical-device-security # IEC 81001-5-1: 2021 and Medical Device Security > **[DIRECT ANSWER]** IEC 81001-5-1 is the health-software secure-development lifecycle standard, and it is the process backbone the FDA's Secure Product Development Framework expectations are usually satisfied with. It specifies activities across requirements, design, implementation, verification, release, and maintenance, including SBOM management and vulnerability handling. Aligning with it gives you documented, auditable process evidence, which is exactly what reviewers ask for when a submission looks like a one-off effort. _Updated October 26, 2024_ [IEC 81001-5-1:2021](https://www.iso.org/standard/76097.html) matters because medical device cybersecurity cannot be bolted on after design freeze. The standard sets expectations for secure product development of health software and software used in medical devices, pushing manufacturers to build security into the lifecycle instead of treating it like a documentation exercise. ## Key Takeaways - Integrates security into the entire product lifecycle. - Requires documented, repeatable secure development processes. - Emphasizes active risk management for software security. - Covers requirements, architecture, verification, and maintenance. - Helps prepare for FDA cybersecurity expectations. - Prioritizes evidence from actual development work. ## Why this matters IEC 81001-5-1:2021 matters because medical device cybersecurity is critical and cannot be merely an afterthought. This standard sets clear expectations for secure product development, pushing manufacturers to embed security throughout the entire lifecycle rather than treating it solely as a documentation requirement. Adherence to IEC 81001-5-1 directly supports compliance with the FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, which emphasizes a **Security by Design** approach and premarket submission requirements for cybersecurity. The FDA expects manufacturers to demonstrate that cybersecurity is an integral part of their quality management system, aligning with principles found in ISO 13485 and risk management per ISO 14971. Furthermore, following IEC 81001-5-1 helps manufacturers prepare for evolving regulatory landscapes and industry best practices such as those outlined by AAMI TIR97. It provides a structured framework for proving that security is a continuous part of design, implementation, verification, release, and ongoing maintenance activities, thereby enhancing patient safety and device trustworthiness. ## What IEC 81001-5-1:2021 Covers IEC 81001-5-1:2021 is part of the IEC 81001 family and focuses on secure product development for health software and software contained in medical devices. For manufacturers, that means the standard is not just about whether a device works as intended. It is about whether the organization developing that device has defined, repeatable processes for building software that is safer and more secure. That distinction matters. Too many teams treat cybersecurity as a penetration test near the end of development or as a set of artifacts assembled for regulators. IEC 81001-5-1 pushes against that mindset by tying security work to the product lifecycle. The standard aligns well with broader expectations around [managing risks associated with the development and production of medical devices](/blog/iso-14971-risk-management-in-medical-device-security). It gives manufacturers a structure for showing that security is part of design, implementation, verification, release, and maintenance. ## Core Elements Manufacturers Need to Address ### General requirements IEC 81001-5-1 expects manufacturers to establish and maintain a secure development process. That includes documented procedures, assigned responsibilities, and evidence that the process is actually followed. This is where many organizations stumble. A policy library is not the same as a functioning secure development lifecycle. If engineering, quality, and regulatory teams are not working from the same set of requirements, gaps will show up in verification, traceability, and postmarket response. ### Risk management throughout the lifecycle Risk management is central to the standard. Security hazards need to be identified, evaluated, controlled, and revisited as the device changes over time. That should sound familiar to any manufacturer already working under ISO 14971, but IEC 81001-5-1 makes clear that software security risks need disciplined treatment, not hand-waving. That means threat-informed analysis, documented control decisions, and evidence that mitigations were implemented and tested. It also means looking beyond safety-only thinking. A cybersecurity weakness may not look like a traditional safety issue at first, but in connected medical devices, that separation often collapses quickly. Manufacturers that already perform [potential hazards](/blog/medical-device-hazard-analysis-and-critical-control-points) analysis should make sure cybersecurity hazards are not being forced into a purely operational or IT bucket. For regulated devices, that is a mistake. ### Software lifecycle controls Because software drives device behavior, the standard puts real weight on lifecycle controls. Requirements management, architecture, verification, validation, configuration management, issue handling, and maintenance all matter. Security failures usually come from ordinary engineering breakdowns: unclear requirements, untracked changes, inherited third-party code, weak verification, or poor patch planning. IEC 81001-5-1 addresses those realities by expecting manufacturers to treat secure software development as an engineering discipline, not a side task for one security specialist. ## What Changed in the 2021 Edition The 2021 edition sharpened the focus on secure product development and made the expectations more usable for modern medical software environments. ![Section Image]() As devices become more connected, more distributed, and more dependent on software, manufacturers need standards that reflect how products are actually built and maintained. One important shift is the stronger emphasis on process maturity across the full product lifecycle. Security is not limited to initial release. It extends into maintenance, updates, vulnerability handling, and coordination across suppliers and integrated systems. That matters for manufacturers building products with network connectivity, cloud dependencies, mobile components, diagnostic platforms, and monitoring systems. These are not edge cases anymore. They are standard product architectures. ## What This Means for Device Manufacturers If your team designs or produces software-enabled medical devices, IEC 81001-5-1 should affect how you work day to day. It may require changes to development procedures, design reviews, supplier controls, verification planning, and defect handling. It may also expose uncomfortable truths. For example: - security requirements are missing or too vague - architecture decisions are not linked to threat considerations - third-party software is poorly tracked - vulnerability handling starts after release instead of during development - evidence for security claims is scattered across teams Those are not minor process issues. They turn into regulatory issues, product risk, and expensive remediation. For manufacturers preparing FDA submissions, this standard is also useful because it supports the kind of disciplined security process the FDA increasingly expects to see. While conformity to IEC 81001-5-1 is not a shortcut to clearance or approval, it can strengthen the story you tell FDA reviewers about how cybersecurity is built into your quality system and product lifecycle. ## Achieving Compliance Without Checklist Theater Compliance with IEC 81001-5-1:2021 should not be reduced to a gap assessment spreadsheet and a few updated SOPs. If the process is not changing engineering behavior, it is probably not doing much. ![Section Image]() A practical path usually includes: - defining a secure development lifecycle that maps to actual engineering work - integrating security requirements into product and software requirements - performing repeatable risk analysis tied to system design - establishing verification activities for security controls - documenting configuration, change, and release controls - planning for vulnerability intake, triage, remediation, and disclosure after release - ensuring suppliers and software components are governed, not assumed safe Documentation still matters. So do testing and traceability. But evidence should come from real work performed during development, not from retroactive cleanup before an audit or submission. ## Why Compliance Is Worth the Effort Done well, alignment with IEC 81001-5-1 improves more than audit readiness. It helps manufacturers build devices that are easier to defend, easier to maintain, and less likely to generate avoidable postmarket problems. There are business benefits too. Stronger development discipline reduces rework. Clearer evidence supports regulatory submissions. Better vulnerability handling improves trust with customers, partners, and internal stakeholders. And yes, it can help with market credibility. But that should be the byproduct, not the goal. The real value is fewer preventable security failures in deployed devices. ## Where the Standard Is Headed IEC 81001-5-1 will keep moving in the same direction the industry is moving: more connected systems, more software dependencies, more postmarket security expectations, and less tolerance for shallow security claims. ![Section Image]() Future revisions will likely continue to pressure manufacturers to handle cybersecurity as a lifecycle responsibility tied to interoperability, remote access, data flows, software updates, and coordinated vulnerability management. That is especially relevant as devices increasingly incorporate [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) capabilities, cloud services, and AI-enabled functions. The manufacturers that will handle those changes best are the ones building repeatable security practices now. Not just policies. Not just templates. Actual operational discipline across engineering, quality, regulatory, and postmarket teams. IEC 81001-5-1:2021 is a useful standard because it forces the right question: can you show that security was engineered into the device lifecycle? If the answer is shaky, that is the work to fix. Blue Goat Cyber helps medical device manufacturers build that evidence the right way, through penetration testing, HIPAA compliance support, FDA compliance support, and medical device cybersecurity services grounded in how products are designed, tested, and reviewed. [Contact us today for cybersecurity help](/contact). ## Which standard covers what | Standard | Scope | What it gives you | What it does not cover | | --- | --- | --- | --- | | IEC 62304 | Software lifecycle processes | Development, maintenance, and problem resolution structure | Security activities in any depth | | IEC 81001-5-1 | Security activities layered onto that lifecycle | Secure design, implementation, verification, and maintenance requirements | Risk acceptability decisions | | ISO 14971 | Risk management for the device | The framework that ties hazards to patient harm | Security-specific analysis methods | | AAMI SW96 | Security risk management for devices | How to run security risk inside the 14971 framework | Detailed lifecycle process requirements | | AAMI TIR57 | Security risk management method | Practical guidance you cite as method | Anything you certify to | They are layers, not alternatives. 81001-5-1 is where the FDA's secure product development expectations meet a lifecycle a reviewer recognizes. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers implement and demonstrate compliance with IEC 81001-5-1:2021. Our team, comprised of cybersecurity experts with certifications like CISSP and OSCP, including ex-military red team members, focuses on practical, evidence-based approaches. We assist in establishing a repeatable secure development lifecycle (SDLC) tailored to your specific product and organizational needs, ensuring security is integrated from conception to post-market. Rather than simply checking boxes, we prioritize actionable processes that genuinely improve security posture and provide the necessary objective evidence for regulatory submissions. We support the creation of required documentation, conduct thorough security testing, and facilitate the adoption of secure coding practices. Our services are designed to streamline your regulatory journey. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Discover how we can assist with your premarket needs: [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the purpose of IEC 81001-5-1:2021? The purpose of IEC 81001-5-1:2021 is to provide a framework for medical device manufacturers to integrate cybersecurity into the secure product development lifecycle of health software and software in medical devices. It aims to ensure that security is built in from the start, rather than added later. ### Does IEC 81001-5-1:2021 apply to all medical devices? This standard specifically applies to health software and software components used within medical devices. It is especially relevant for connected devices, those using cloud services, or those with significant software-driven functionality. ### How does IEC 81001-5-1:2021 relate to FDA requirements? While not directly an FDA regulation, conformity to IEC 81001-5-1:2021 can strengthen a manufacturer's FDA submission by demonstrating a disciplined approach to cybersecurity within their quality system. The FDA's February 3, 2026 premarket cybersecurity guidance aligns with many principles found in this standard. ### What are the core elements of IEC 81001-5-1:2021? Key elements include establishing a secure development process, implementing risk management across the entire product lifecycle for security hazards, and applying specific software lifecycle controls like secure requirements management, architecture, verification, and maintenance. ### Is compliance with IEC 81001-5-1:2021 mandatory? Compliance with IEC 81001-5-1:2021 is not universally mandatory but is widely recognized as a critical benchmark for secure medical device development. Regulators, including the FDA, consider such standards as evidence of a manufacturer's commitment to cybersecurity. ### How does compliance benefit manufacturers beyond regulatory checks? Beyond regulatory compliance, IEC 81001-5-1:2021 alignment leads to more defensible and maintainable devices, reduces rework, improves trust with customers, and mitigates postmarket security problems, ultimately lowering overall product risk. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) LinkedIn [Youtube](https://www.youtube.com/@BlueGoatCyber) [Instagram](https://www.instagram.com/bluegoatcyber/) [Twitter](https://twitter.com/bluegoatcyber) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Conducting a Medical Device Security Audit](/blog/a-guide-to-conducting-a-medical-device-security-audit-for-manufacturers) - [How SPDF Maps to IEC 81001-5-1 Activities](/blog/how-spdf-maps-to-iec-81001-5-1-activities) - [Medical Device Cybersecurity](/blog/medical-device-sql-injection-parameterized-queries) - [MedTech Cyber Standards Every Device](/blog/medtech-cyber-standards-every-device-team-must-know) --- ## Rising Medical Device Cyber Threats: Risks and Mitigations Source: https://bluegoatcyber.com/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks # Rising Medical Device Cyber Threats in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** Cyber threats against medical devices, from pacemakers to insulin pumps, can directly endanger patients by enabling unauthorized reprogramming, altered dosing, or disrupted therapy, not just data theft. Risks stem from legacy software, inconsistent standards, growing connectivity, and insecure supply chains. The FDA's February 3, 2026 guidance addresses this by requiring lifecycle risk management, threat modeling, and secure-by-design controls throughout premarket and postmarket phases. _Updated April 15, 2015_ In today’s digital landscape, one growing threat continues to receive far too little attention: the cybersecurity risks facing medical devices. These aren’t just technical glitches-we’re talking about the potential compromise of devices designed to sustain and save lives. From pacemakers to infusion pumps, the very tools that support modern healthcare are becoming prime targets for cyberattacks. In this post, Blue Goat Cyber breaks down the scope of the problem, clarifies the stakes, and offers practical, actionable insights to help you stay ahead of the threat. ## Key Takeaways - Medical devices are targets due to valuable data and vulnerabilities. - Cyberattacks can directly endanger patient lives through device malfunction. - Legacy software and inconsistent standards increase device risk. - FDA guidance emphasizes cybersecurity in premarket submissions. - Proactive measures include updates, penetration testing, and staff training. - Emerging tech like AI and Zero Trust will enhance future defense. ## Why this matters The stakes are critically high in medical device cybersecurity; compromised devices can directly endanger patient lives through malfunction, data manipulation, or unauthorized control. Beyond immediate patient harm, cyberattacks can lead to extensive data breaches of protected health information (PHI), resulting in severe financial penalties and irreparable reputational damage for healthcare providers and device manufacturers. The increasing connectivity of medical devices, often combined with legacy software and inconsistent security standards, broadens the attack surface. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, mandates that manufacturers integrate security throughout the total product lifecycle, emphasizing risk management, including threat modeling and vulnerability assessments, in premarket submissions. Adherence to standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is not merely regulatory compliance; it's fundamental to ensuring the safety, efficacy, and trustworthiness of medical technology in an interconnected healthcare ecosystem. Ignoring these risks jeopardizes patient well-being and the integrity of healthcare delivery. ## A New Frontier for Hackers: Medical Devices Gone are the days when hackers only aimed for computers or smartphones. The new frontier? Medical devices. From pacemakers to insulin pumps, these lifesaving gadgets are now potential targets. But why are they so attractive to cybercriminals? The reasons are as varied as the devices themselves: - **Valuable Data**: Medical devices store heaps of personal health information, a goldmine for identity thieves. - **Vulnerability**: Many devices weren’t built with cybersecurity in mind, making them easier targets. - **High Stakes**: Tampering with a medical device can have dire consequences, giving hackers use for ransom demands. ### Understanding the Risks To grasp the issue, let’s zoom in on a couple of examples: - **Pacemakers**: Imagine a device that keeps a heart beating remotely controlled by a hacker. Scary, right? Such devices can be reprogrammed to deliver irregular shocks or even shut down. - **Insulin Pumps**: These devices automatically administer insulin to diabetics. A cyberattack could alter dosages, leading to life-threatening situations. ### Statistics Speak Volumes A recent study highlighted a worrying trend: over 70% of medical devices are vulnerable to cyberattacks. This isn’t just a number; it’s a loud alarm bell. ## Why Medical Devices Are Vulnerable to Cyber Threats ### Legacy Software Still in Use Many medical devices operate on outdated or unsupported software platforms-leaving them defenseless against modern cyber threats. It’s like securing your home with a skeleton key in a neighborhood full of digital lockpickers. ### Inconsistent Cybersecurity Standards The medical device industry is still aligning on cybersecurity standards. This regulatory gap results in a patchwork of protections-where some devices are well-guarded, and others are dangerously exposed. ### Increased Connectivity, Greater Exposure The [Internet of Medical Things (IoMT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) has revolutionized healthcare by improving efficiency and patient outcomes. But every new connection creates a new potential attack vector-turning life-saving tools into possible entry points for hackers. ### Insecure Supply Chains Many devices rely on third-party components, legacy code, or open-source libraries that aren’t always fully vetted for security. A vulnerability in any one piece of that chain can compromise the entire system-making supply chain risk a growing concern for regulators and manufacturers alike. ### Lack of Secure-by-Design Architecture Historically, many medical devices were built for functionality and compliance, not for resilience against cyber threats. Without security embedded from the ground up, retrofitting protection into these devices is often difficult, costly, and incomplete. ## The Real-World Impact Cyberattacks on medical devices go far beyond stolen data; they can directly endanger patient lives. A compromised device could deliver inaccurate readings, disrupt critical therapies, or delay urgent treatments. In high-stakes clinical environments, even seconds matter. This isn’t a futuristic scenario; it’s happening now, and the consequences are real, immediate, and potentially fatal. ## Protecting Against the Rising Tide: Practical Steps to Secure Medical Devices Now that we understand the scope of the threat, it’s time to focus on solutions. Securing medical devices isn’t just a technical necessity; it’s a clinical imperative. Here are key strategies to fortify these critical systems against cyber threats: ### Regular Software Updates Think of software updates as routine checkups for your devices. Timely patches and firmware updates fix known vulnerabilities and ensure systems are resilient against newly discovered threats. Manufacturers should streamline update mechanisms, while healthcare providers must prioritize deployment. ### Implementing Resilient Cybersecurity Controls Security must be built into every layer of the medical device lifecycle. This includes: - **Strong encryption** for data in transit and at rest - **Secure authentication protocols** to prevent unauthorized access - **Routine vulnerability scans and assessments** to identify and remediate risks proactively Manufacturers and hospitals must collaborate to ensure these controls are implemented and maintained. ### Training Healthcare Professionals Human error remains one of the top causes of security breaches. Educating healthcare professionals on cybersecurity best practices-such as recognizing phishing attempts, securing login credentials, and reporting anomalies, is crucial for creating a security-aware culture. ### Conducting Penetration Testing [Penetration testing](/services/medical-device-penetration-testing) simulates real-world attacks to uncover weaknesses before malicious actors can exploit them. Incorporating medical device penetration testing into the development and postmarket processes helps ensure vulnerabilities are identified early and addressed comprehensively. ## The Role of Regulatory Bodies Regulatory bodies, like the FDA in the United States, play a critical role. They’re increasingly mandating stricter cybersecurity standards for medical devices. The FDA’s latest guidance, “ [Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions](https://www.fda.gov/media/119933/download "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions"),” provides detailed guidance on cybersecurity requirements for medical device manufacturers. ## Looking Ahead: The Future of Medical Device Cybersecurity As cyber threats grow more sophisticated, so must the technologies designed to counter them. The future of medical device cybersecurity will be driven by powerful innovations that offer smarter, faster, and more resilient protection. Here are five technologies poised to lead the charge: ### 1\. Artificial Intelligence (AI) and Machine Learning (ML) [AI and ML](/blog) are set to become frontline defenders in medical device security. These technologies can analyze vast amounts of data to detect anomalies in real-time, allowing healthcare organizations to identify and respond to threats before damage occurs. From predictive risk modeling to adaptive threat response, AI-driven systems will enable a more proactive, intelligent approach to cybersecurity. _Use Case Example:_ Continuous monitoring of infusion pumps for behavioral anomalies that may indicate tampering or malware activity. ### 2\. Blockchain Technology [Blockchain](/blog) introduces decentralized, immutable records-ideal for safeguarding medical device data and communications integrity. Its transparency and resistance to tampering make it a promising tool for tracking device updates, validating access, and ensuring end-to-end trust. _Use Case Example:_ Verifying the authenticity and integrity of software updates across a fleet of deployed devices in hospitals. ### 3\. Advanced Encryption Techniques As devices become more interconnected, the need for strong, adaptive encryption is more critical than ever. Emerging technologies such as [quantum-resistant algorithms](/blog) and lightweight cryptography tailored for resource-constrained devices will help ensure secure data transmission without compromising performance. _Use Case Example:_ Securing telemetry data from wearable cardiac monitors to cloud-based analysis platforms. ### 4\. Zero Trust Architecture The traditional “trust but verify” model is being replaced by [Zero Trust](/blog), where no device or user is trusted by default-whether inside or outside the network. Zero Trust enforces strict identity verification, continuous authentication, and access control in a healthcare setting, significantly reducing the risk of lateral movement in the event of a breach. _Use Case Example:_ Limiting device communication only to verified, authorized endpoints using dynamic segmentation. ### 5\. Regulatory Tech & Compliance Automation Future regulatory frameworks must rely heavily on automated tools that simplify compliance and enforce best practices. Technologies such as [Software Bill of Materials (SBOM) management](/services) platforms, automated vulnerability scanners, and risk-scoring engines will help manufacturers and healthcare providers stay ahead of compliance requirements while minimizing manual oversight. _Use Case Example:_ Automated generation and updating of SBOMs as part of the CI/CD pipeline, feeding directly into FDA cybersecurity submissions. ## Threats ranked by patient impact, not by headline Not every threat deserves equal attention. The ones that change clinical care outrank the ones that only touch data. | Threat | Immediate clinical impact | Regulatory consequence | First control that actually helps | | --- | --- | --- | --- | | Ransomware on connected hospital systems | Devices unusable, procedures delayed | Postmarket reporting and customer escalation | Segmentation and a documented offline mode for the device | | Unauthorized command to a therapy device | Direct patient harm | Potential recall, mandatory reporting | Authenticated command channel with replay protection | | Firmware tampering or unsigned update | Persistent compromise across a fleet | Design control finding, submission deficiency | Signed updates with a verified root of trust | | Credential reuse on service accounts | Fleet wide access from a single leak | Finding against access control requirements | Unique credentials per device and per service | | Unpatched third party component | Varies from none to critical | SBOM and vulnerability handling scrutiny | Component inventory plus a triage process with a stated cadence | | Exposure of patient data | No immediate clinical impact | HIPAA and breach notification exposure | Encryption at rest and in transit, minimal data retention | The order matters because remediation budgets are finite. Anything that can change therapy comes before anything that only exposes a record. ## A Call to Action At Blue Goat Cyber, we’re committed to securing the future of healthcare by collaborating with every stakeholder in the medical device ecosystem-manufacturers, healthcare providers, regulatory bodies, and even patients. Cybersecurity isn’t a siloed responsibility; it’s a shared mission that demands coordinated effort and unwavering vigilance. The devices we rely on for diagnosis, treatment, and life-sustaining care must be protected against evolving cyber threats compromising patient safety and trust. Whether it’s guiding a product through [FDA premarket submission](/services/fda-premarket-cybersecurity-services) or supporting postmarket vulnerability management, we bring deep expertise and proven strategies to the table. Together, we can build a safer, more resilient healthcare environment, because when we secure medical devices, we don’t just protect data; we protect lives. ## Conclusion: Vigilance and Collaboration The growing wave of cyber threats targeting medical devices is not just a technical issue; it’s a matter of patient safety. Ignoring it is not an option. We can strengthen our defenses by maintaining vigilance, embracing proactive security measures, and building cross-industry collaboration. At the end of the day, cybersecurity in healthcare isn’t just about protecting systems; it’s about protecting lives. ## How Blue Goat approaches this Blue Goat Cyber's approach is grounded in deep technical expertise, including CISSP and OSCP certifications, and practical experience from former military red team operations. We apply a focused methodology to identify and mitigate medical device cybersecurity risks, aligning with regulatory requirements like the FDA's February 3, 2026 final guidance. Our services include in-depth threat modeling, penetration testing, and security architecture reviews tailored to the unique challenges of medical technology. We don't just find vulnerabilities; we provide actionable remediation strategies and support manufacturers through the complex regulatory landscape. For instance, in premarket submissions, we offer targeted assistance to meet FDA cybersecurity requirements. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. This focused, results-oriented approach helps secure medical devices and streamline market entry. Learn more about our services at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### Why are medical devices susceptible to cyber threats? Medical devices become susceptible to cyber threats due to increased connectivity, reliance on potentially outdated software, and design priorities that historically favored functionality over cybersecurity. Their integration into healthcare networks also expands their exposure to attacks. ### How can cyber threats to medical devices impact patients? Cyber threats can directly impact patients by causing device malfunctions, delivering inaccurate readings, or disrupting critical therapies. This can lead to misdiagnoses, inappropriate treatments, or even life-threatening situations, compromising patient safety and trust. ### What is the FDA's role in securing medical devices? The FDA plays a critical role by issuing guidance and mandating cybersecurity requirements for medical devices. Their February 3, 2026 final guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," outlines detailed expectations for manufacturers regarding cybersecurity. ### What measures improve medical device cybersecurity? Improving medical device cybersecurity involves regular software updates, implementing strong encryption and authentication, conducting routine vulnerability scans and penetration testing, and educating healthcare professionals on cybersecurity best practices. ### What emerging technologies enhance medical device security? Emerging technologies such as Artificial Intelligence (AI) for threat detection, Blockchain for data integrity, advanced encryption techniques, and Zero Trust Architecture are poised to significantly enhance the security posture of medical devices against evolving cyber threats. ### Who is responsible for medical device cybersecurity? Securing medical devices is a shared responsibility among manufacturers, healthcare providers, regulatory bodies like the FDA, and even patients. A coordinated effort and unwavering vigilance across these stakeholders are necessary for effective protection. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [GSM Cybersecurity Risks for Medical](/blog/gsm-cybersecurity-vulnerabilities-medical-devices) - [QNX Vulnerabilities in Medical Devices](/blog/understanding-qnx-operating-system-vulnerabilities-risks-and-mitigation-strategies) - [IPC Vulnerabilities in Medical Devices](/blog/ipc-vulnerabilities-medical-devices) - [Bluetooth in Medical Devices: Risks](/blog/bluetooth-in-medical-devices-understanding-the-risks-and-protecting-patient-safety) --- ## MDS2 Form: Hospital Guide to Disclosures | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/the-role-of-mds2-in-medical-device-cybersecurity # MDS2 Form: What It Covers and How Hospitals Use It > **[DIRECT ANSWER]** The MDS2 form (Manufacturer Disclosure Statement for Medical Device Security, HIMSS/NEMA HN 1-2019) is a standardized questionnaire manufacturers complete to disclose a device's security features: encryption, authentication, patching, data storage, and remote access. Hospital procurement and clinical engineering teams use it to assess risk before purchase. It is not a substitute for a security architecture document, threat model, or SBOM, and it does not fulfill the FDA's premarket cybersecurity documentation requirements on its own. _Reviewed September 17, 2026_ A poorly completed MDS2 form can stall a hospital purchasing decision for months or trigger a security exception review that manufacturers never see coming. Hospital value analysis committees increasingly require the form before they will even evaluate a device, and many manufacturers treat it as an afterthought filled out by whoever is available. That approach creates inconsistent answers across a product line, contradicts other regulatory submissions, and signals to buyers that security was not built into the product. Understanding what the form actually asks, who inside an organization should own it, and how it fits alongside SBOM and the FDA's current premarket guidance turns the MDS2 from a procurement hurdle into a credible sales asset. This guide walks through the form section by section, flags the mistakes reviewers see most often, and clarifies where the MDS2 stops and other documentation must start. ## Key Takeaways - The MDS2 form standardizes how manufacturers disclose device cybersecurity capabilities to healthcare providers. - Hospitals use it during procurement and risk assessment, not as a compliance filing with the FDA. - Sections on authentication, encryption, and remote access are where reviewers find the most inconsistencies. - An MDS2 is a summary disclosure; it cannot replace an SBOM, threat model, or security risk management file. - The February 3, 2026 final guidance expects lifecycle security documentation the MDS2 only partially represents. - Update the MDS2 whenever a software or security-relevant change occurs, not just at initial launch. ## Why This Matters Hospitals cannot inspect source code or run their own penetration tests on every device before purchase, so they rely on manufacturer disclosures to gauge risk. The MDS2 form is the closest thing the industry has to a common language for that disclosure, and its consistent, accurate use directly affects patient safety decisions. A device with unpatched authentication weaknesses that goes undisclosed can end up on a clinical network without the compensating controls a hospital would otherwise put in place. Manufacturers also have a commercial stake. Many health systems now require a completed MDS2 as a gating document in their procurement workflow, meaning an incomplete or inconsistent form can delay or block a sale entirely. Cybersecurity and clinical engineering teams cross-reference MDS2 answers against network segmentation plans, vulnerability management contracts, and incident response expectations. Finally, the form intersects with regulatory expectations. While the MDS2 itself is not an FDA-mandated document, its content overlaps with disclosures manufacturers must also make in premarket submissions and labeling under the FDA's current guidance. Treating the MDS2 as a one-time checkbox exercise, rather than a living document tied to the same underlying security data used elsewhere, creates conflicting records that both hospitals and reviewers can catch. ## What Is the MDS2 Form? The MDS2 is a standardized disclosure form published under HIMSS/NEMA HN 1-2019 that manufacturers use to communicate a medical device's cybersecurity-relevant characteristics. It was developed jointly by HIMSS and NEMA to give healthcare delivery organizations a consistent format instead of dozens of vendor-specific security questionnaires. The current version covers categories such as authentication controls, data encryption in transit and at rest, audit logging, remote access capability, malware protection, and the manufacturer's patching and vulnerability disclosure process. Each section asks the manufacturer to answer yes, no, or "see notes," with a free-text field to add context. **[KEY REQUIREMENT]** Every "yes" or "no" answer should be verifiable against the device's actual architecture and current software version, not an aspirational answer based on a future release. ## Who Fills Out the MDS2 and When The manufacturer's quality, regulatory, or product security team typically owns the MDS2, drawing on input from engineering. It is not something a sales or marketing team should complete independently, since inaccurate technical claims create liability and damage trust once discovered. The form should be completed before a device is offered for sale to healthcare providers, and updated at defined trigger points rather than left static for years. | Trigger event | MDS2 update needed? | |---|---| | New software version with security-relevant changes | Yes | | Newly disclosed vulnerability affecting the device | Yes | | Minor UI change with no security impact | No | | Change in supported operating system | Yes | | Annual review cycle even with no changes | Recommended | ## How Hospitals Use the MDS2 in Procurement Hospitals use the MDS2 as an early screening tool during vendor evaluation, often before a purchase order is issued. Clinical engineering and information security teams read the form to decide whether a device needs network isolation, additional monitoring, or contractual security commitments before it connects to the network. Larger health systems frequently require the MDS2 as a mandatory attachment in their value analysis or capital equipment approval process. A missing or vague MDS2 can push a device evaluation back to the vendor for clarification, adding weeks to a sales cycle that manufacturers rarely anticipate. ## Section-by-Section Walkthrough Each MDS2 section maps to a specific operational concern for the buyer. - **Management of Private Data:** what patient data types the device stores, transmits, or processes. - **Automatic Logoff and Access Controls:** whether sessions time out and how user roles are enforced. - **Audit Controls:** whether the device logs security-relevant events and how those logs are accessed. - **Node Authentication and Encryption:** how the device authenticates to a network and protects data in transit. - **Remote Service and Support:** whether the manufacturer or a third party can access the device remotely, and under what controls. - **System and Application Hardening:** malware protection, patching cadence, and third-party component management. Buyers most closely scrutinize the remote access and patching sections, since those answers determine ongoing operational risk rather than a one-time design decision. Some procurement teams also compare the MDS2 answers against publicly known vulnerability disclosures for similar device classes before approving a purchase. A device with strong MDS2 answers but no visible history of security patches for known component vulnerabilities can still raise flags during this cross-check. ## Common Mistakes Manufacturers Make The most frequent MDS2 errors are inconsistency and vagueness rather than outright dishonesty. Below are patterns reviewers flag repeatedly. | Common mistake | Why it causes problems | |---|---| | Answering "N/A" for sections that clearly apply | Signals the form was rushed or delegated to someone unfamiliar with the device | | Claiming encryption without specifying algorithm or scope | Leaves security teams unable to verify the claim during risk assessment | | Listing remote access as disabled when a support backdoor exists | Creates a compliance and trust gap once discovered during testing | | Never updating the form after a software release | Produces answers that no longer match the shipped device | | Copying answers from a similar product without verification | Introduces claims that do not apply to the actual device architecture | ## MDS2, SBOM, and the FDA's February 2026 Guidance The MDS2 and a software bill of materials serve different but complementary purposes. The MDS2 gives a narrative, checkbox-style summary of security features, while an SBOM is a structured, machine-readable inventory of every software component and its version. Hospitals increasingly ask for both: the MDS2 to understand the security posture at a glance, and the SBOM to run vulnerability correlation against components like OpenSSL or embedded operating systems. The FDA's February 3, 2026 final guidance on premarket cybersecurity (following the September 2023 final guidance and the June 27, 2025 update) expects manufacturers to provide SBOM, a documented security risk management process aligned to ISO 14971, and evidence of a secure product development lifecycle referencing AAMI SW96 (recognition number 13-131). **[KEY REQUIREMENT]** None of these premarket submission artifacts can be satisfied by pointing the FDA to an MDS2 form; the agency expects the underlying technical documentation, not the summary disclosure built for hospital buyers. ## Where the MDS2 Is Not a Substitute for Security Documentation The MDS2 was never designed to serve as a threat model, risk management file, or premarket submission artifact, and treating it that way creates gaps in both regulatory and procurement contexts. It summarizes features at a point in time; it does not document the manufacturer's process for identifying vulnerabilities, assessing their severity, or tracking remediation. Hospitals that rely solely on the MDS2 for vendor risk assessment, without requesting an SBOM or asking about the manufacturer's vulnerability disclosure program, are working from an incomplete picture. Manufacturers should maintain the MDS2 as one output of a broader security documentation set, not as the whole set. ## How Blue Goat Cyber Approaches This Blue Goat Cyber helps manufacturers complete MDS2 forms that are accurate, consistent with their premarket submissions, and defensible under hospital procurement scrutiny. This starts with a technical review of the device's architecture, authentication design, encryption implementation, and patching process, so every MDS2 answer is grounded in verified fact rather than assumption. The same underlying documentation is then cross-checked against the manufacturer's SBOM and security risk management file to eliminate contradictions between what hospitals see and what regulators see. Manufacturers preparing a submission under the FDA's current framework can review our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for how MDS2 completion fits into a broader submission strategy, including SBOM generation and risk documentation aligned to ISO 14971. ## Frequently Asked Questions ### What is the MDS2 form used for? The MDS2 form discloses a medical device's cybersecurity features, such as authentication, encryption, and patching practices, to healthcare providers. Hospitals use it during procurement and risk assessment to decide what network controls or contractual protections a device needs before deployment. ### Is the MDS2 form required by the FDA? No. The MDS2 is a HIMSS/NEMA industry standard used primarily for hospital procurement, not a document the FDA requires in premarket submissions. Manufacturers still need separate documentation such as an SBOM and a security risk management file to meet the FDA's current premarket cybersecurity guidance. ### Who should complete the MDS2 form at a manufacturer? Quality, regulatory affairs, or product security staff with direct knowledge of the device's architecture should complete the MDS2, with technical input from engineering. Sales or marketing teams should not complete it independently, since inaccurate answers create liability. ### How often should a manufacturer update the MDS2? Update the MDS2 whenever a software release changes security-relevant functionality, when a new vulnerability affecting the device is disclosed, or at least annually as part of routine review. Static, years-old MDS2 forms are a common red flag for hospital security reviewers. ### Does an MDS2 form replace an SBOM? No. The MDS2 is a summary disclosure of security features, while an SBOM is a structured inventory of software components used for vulnerability tracking. Hospitals and regulators increasingly expect both documents, and each serves a distinct purpose. ## CTA Need an MDS2 form that holds up under hospital scrutiny and aligns with your FDA submission? Blue Goat Cyber can review your device architecture, complete accurate disclosures, and connect that work to your SBOM and risk documentation. [Schedule a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to get started. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## UL 2900 and Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/the-role-of-ul-2900-in-medical-device-security # UL 2900 and Medical Device Cybersecurity > **[DIRECT ANSWER]** UL 2900 is an FDA-recognized cybersecurity standard that certifies medical devices through structured assessment of hardware and software components, including vulnerability analysis, penetration testing, and remediation verification by an independent evaluator. It gives manufacturers a documented framework for secure software development and ongoing vulnerability monitoring, and certification requires continuous compliance as new threats emerge, not a one-time evaluation before launch. _Updated October 26, 2024_ The field of healthcare has undergone significant transformation with the advent of technology. From electronic health records to wearable devices, technology has revolutionized the way medical care is delivered. However, with these advancements come new challenges, particularly in cybersecurity. The rise of connected medical devices has opened up vulnerabilities that malicious actors can exploit. To address this issue, various [cybersecurity standards have been developed](/blog), one of which is UL 2900. The US FDA has officially recognized the [UL 2900 Cybersecurity standard for medical devices](https://www.ul.com/news/us-fda-has-officially-recognized-ul-2900-cybersecurity-standard-medical-devices). ## Key Takeaways - UL 2900 certifies medical device cybersecurity. - It covers hardware and software components. - The standard helps protect patient data. - FDA recognizes UL 2900 for device security. - Certification enhances manufacturer reputation. - Ongoing compliance is essential for security. ## Why this matters The criticality of medical device security cannot be overstated; vulnerabilities endanger patient safety and privacy. Cyberattacks can lead to device malfunction, data breaches, and compromise sensitive patient health information. Adhering to standards like UL 2900 significantly mitigates these risks, demonstrating a commitment to secure product development and lifecycle management. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes the necessity of premarket and postmarket cybersecurity considerations, including the adoption of recognized standards. UL 2900 aligns with the FDA's expectations, providing a structured approach to identifying and addressing security flaws. Compliance with similar standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 further strengthens a device's security posture. For medical device manufacturers, integrating UL 2900 into their design and development processes is not just about regulatory compliance; it's about building trust, protecting patients, and minimizing financial and reputational damage from security incidents. ## Understanding the Basics of UL 2900 UL 2900 is a set of standards created by Underwriters Laboratories (UL), a global safety science company. These standards are specifically designed to assess and certify the cybersecurity of medical devices. UL 2900 provides manufacturers with guidelines to ensure their devices are secure and protected against cyber threats. ![Section Image](/imported-images/ace084b0dfe15d6f.webp) The stakes are incredibly high regarding cybersecurity in the healthcare industry. Medical devices are crucial for patient care and store sensitive information that must be kept confidential. UL 2900 supports addressing these concerns by offering a framework that comprehensively evaluates these devices’ security posture. ### Definition of UL 2900 UL 2900 is a cybersecurity standard that focuses on medical devices. It establishes criteria for evaluating the security of connected healthcare systems, including hardware and software components. The standard covers many devices, including implantable devices, hospital equipment, and wearable sensors. UL 2900 is designed to be adaptable to the evolving landscape of cybersecurity threats. It considers the dynamic nature of cyber risks and provides a flexible approach for manufacturers to improve their products’ security continuously. ### Importance of UL 2900 in Medical Devices The significance of UL 2900 in terms of medical devices cannot be overstated. The need for cybersecurity measures has become paramount with the increasing use of connected devices in healthcare settings. By adhering to UL 2900 standards, manufacturers can ensure their devices are secure and safeguard patient data from unauthorized access. UL 2900 certification can also enhance the reputation of medical device manufacturers in the industry. It serves as a testament to their commitment to cybersecurity best practices. It can instill confidence in healthcare providers and patients regarding the safety and integrity of their devices. ## The Role of UL 2900 in Cybersecurity In an interconnected world where cyber threats are becoming more sophisticated and prevalent, UL 2900 is crucial in enhancing cybersecurity for medical devices. ![Section Image](/imported-images/a15aa7f256f1b16a.webp) With the increasing digitization of healthcare systems and the rise of Internet of Things (IoT) devices in medical settings, the need for cybersecurity measures has never been more pressing. UL 2900 sets the standard for ensuring that medical devices are developed, deployed, and maintained with security in mind, protecting patient data and healthcare operations’ integrity. ### Ensuring Software Security with UL 2900 One key aspect of UL 2900 is its focus on software security. The standard provides guidelines for developing secure software resistant to cyber attacks. By utilizing secure coding practices and rigorous testing, manufacturers can mitigate the risk of software vulnerabilities that hackers can exploit. UL 2900 emphasizes the importance of ongoing monitoring and updates to software systems to address emerging threats and vulnerabilities. This proactive approach to software security ensures that medical devices remain resilient in the face of evolving cyber risks, safeguarding both patients and healthcare providers. ### Addressing Cybersecurity Threats in Medical Devices The cybersecurity threats faced by medical devices are diverse and constantly evolving. From ransomware attacks to unauthorized access to patient data, the consequences of a security breach can be severe. UL 2900 assists manufacturers in identifying and mitigating these threats by providing guidelines for risk assessment, vulnerability management, and incident response. By incorporating the principles outlined in UL 2900 into their cybersecurity practices, medical device manufacturers can enhance the trustworthiness of their products and contribute to a more secure healthcare ecosystem. This proactive approach protects sensitive patient information and ensures the reliability and safety of medical devices in critical healthcare settings. ## The Certification Process of UL 2900 Obtaining UL 2900 certification is a rigorous process that involves multiple steps to ensure compliance with the standards. ![Section Image](/imported-images/9cd57dd167ef2753.webp) UL 2900 certification is highly sought in the cybersecurity industry due to its evaluation of devices to ensure they meet stringent security standards. This certification assures consumers and businesses that the certified products have undergone thorough testing and meet the necessary cybersecurity requirements. ### Steps to Achieve UL 2900 Certification The certification process begins with an assessment of the device’s cybersecurity posture. This includes evaluating the hardware and software components, analyzing potential vulnerabilities, and conducting penetration testing to identify weaknesses. Once the assessment is complete, remediation measures are implemented to address any identified issues. Finally, an independent third-party evaluation is carried out to determine if the device meets the requirements for UL 2900 certification. During the assessment phase, cybersecurity experts review the device’s design and functionality to identify potential entry points for cyber threats. This in-depth analysis helps to uncover vulnerabilities that could be exploited by malicious actors, allowing manufacturers to strengthen their products’ security measures. ### Maintaining Compliance with UL 2900 Obtaining certification is just the beginning. To ensure ongoing compliance with UL 2900, manufacturers must establish cybersecurity practices and continually monitor their devices for any new vulnerabilities or threats. Regular updates and patches must be implemented to address emerging cyber risks. Continuous improvement is key to maintaining UL 2900 certification. Manufacturers must stay abreast of the latest cybersecurity trends and best practices to enhance the security of their products. By investing in cybersecurity awareness and education for their teams, companies can proactively address potential threats and ensure their devices comply with UL 2900 standards. ## The Impact of UL 2900 on the Medical Device Industry The adoption of UL 2900 has significantly impacted the medical device industry, benefiting both manufacturers and patients. UL 2900 is a set of cybersecurity standards tailored explicitly for medical devices. These standards are designed to address healthcare technology’s unique vulnerabilities and risks, ensuring that medical devices are secure and reliable. The certification process involves rigorous testing and evaluation to verify compliance with these standards, providing manufacturers with a framework for cybersecurity best practices. ### Benefits of UL 2900 for Manufacturers UL 2900 certification provides manufacturers with a competitive edge in the market. They can instill confidence in their customers by demonstrating compliance with stringent cybersecurity standards. This, in turn, can lead to increased sales and improved brand reputation. Moreover, UL 2900 certification ensures manufacturers have implemented cybersecurity measures, reducing the risk of costly data breaches and potential legal liabilities. UL 2900 certification is not just a one-time achievement; it requires ongoing monitoring and updates to maintain compliance with evolving cybersecurity threats. This continuous improvement process helps manufacturers avoid emerging risks and demonstrates their commitment to prioritizing cybersecurity. ### How UL 2900 Improves Patient Safety Patient safety is a primary concern in healthcare, and UL 2900 supports enhancing it. By ensuring the cybersecurity of medical devices, UL 2900 helps prevent unauthorized access to patient data, protects against malicious attacks that could compromise patient care, and maintains the integrity and privacy of medical information. Ultimately, UL 2900 helps create a safer healthcare environment for patients. Implementing UL 2900 standards can lead to greater interoperability among medical devices, improving the efficiency and effectiveness of healthcare delivery. When medical devices adhere to consistent cybersecurity protocols, healthcare providers can integrate different technologies, leading to better care coordination and more personalized patient treatment options. ## Future Trends in UL 2900 and Medical Device Security As technology advances, the medical device security field will undergo further evolution. UL 2900 is expected to adapt to these changes and address emerging cybersecurity challenges. ### Evolving Cybersecurity Standards UL 2900 will likely continue to evolve to keep pace with the rapidly changing cybersecurity landscape. As new threats arise, the standard will be updated to provide manufacturers with the necessary guidelines to mitigate these risks effectively. This will ensure that medical devices remain secure in the face of increasingly sophisticated cyber attacks. ### The Role of UL 2900 in the Future of Medical Devices As the use of connected medical devices proliferates, the importance of UL 2900 will only increase. Manufacturers must stay abreast of the evolving standards to ensure their devices remain secure and compliant. By doing so, they can contribute to the future of medical devices by providing safe and reliable healthcare solutions. In addition to the evolving cybersecurity standards, several other factors will shape the future of UL 2900 and medical device security. One such factor is the increasing reliance on artificial intelligence (AI) and machine learning (ML) in healthcare. AI and ML have the potential to revolutionize medical devices, enabling them to analyze vast amounts of data and make accurate predictions. However, with this increased connectivity and reliance on AI, the risk of cyber threats also grows. UL 2900 will be crucial in ensuring that AI-powered medical devices are secure and protected from potential attacks. As the Internet of Things (IoT) expands, connected medical devices will skyrocket. From wearable health trackers to implantable devices, the IoT has the potential to revolutionize healthcare delivery. However, this interconnectedness also presents significant security challenges. UL 2900 must adapt to address the unique vulnerabilities and risks associated with IoT-enabled medical devices. This will involve developing guidelines and best practices tailored to the IoT ecosystem, ensuring these devices are secure and protected from cyber threats. ## UL 2900 against the other benchmarks | Benchmark | What it is | How it is used | Standing with the FDA | | --- | --- | --- | --- | | UL 2900-2-1 | A testable security requirements standard for healthcare devices | Third-party evaluation and certification | Useful supporting evidence, not a substitute for your own file | | IEC 81001-5-1 | Lifecycle security process requirements | Built into your development process | Widely cited in submissions as process evidence | | AAMI SW96 | Security risk management method | Ties security findings to patient harm | Recognized method for the risk argument | | FDA premarket guidance | The agency's own expectations | Defines what the submission must contain | The thing you are actually judged against | A UL 2900 evaluation is evidence you can hand a reviewer. It does not answer the questions the guidance asks about your specific device. ## Conclusion UL 2900 supports medical device cybersecurity. The standard provides manufacturers with guidelines to ensure the security of their devices and protect against cyber threats. By adhering to UL 2900, manufacturers can bolster patient safety, enhance their brand reputation, and stay ahead of evolving cybersecurity risks. As technology advances, the medical device industry must prioritize cybersecurity and embrace standards like UL 2900 to create a secure healthcare environment. As the landscape of medical device cybersecurity continues to evolve, it’s crucial to partner with experts who can navigate these complex waters. Blue Goat Cyber, a veteran-owned business, specializes in medical device cybersecurity and offers various services, including penetration testing, HIPAA compliance, and FDA compliance. Our team is dedicated to securing your business and products against cyber threats. [Contact us today for cybersecurity help](/contact) and ensure your medical devices meet the rigorous standards of UL 2900, safeguarding your technology and patients alike. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in navigating UL 2900 and achieving and maintaining compliance. Our team, comprised of certified professionals such as CISSP and OSCP holders, including former military red team specialists, applies a methodology to uncover vulnerabilities and ensure device integrity. We provide services including threat modeling, penetration testing, and security architecture reviews tailored to UL 2900 requirements. Our experience in pre-market and post-market cybersecurity allows us to develop practical security controls for hardware, software, and network components. We streamline the path to regulatory submission by focusing on the specific needs of medical devices. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Cybersecurity Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is UL 2900? UL 2900 is a series of cybersecurity standards from Underwriters Laboratories for medical devices. It provides criteria for assessing the security of connected healthcare systems, including software and hardware. ### Why is UL 2900 important for medical devices? UL 2900 is important because it establishes guidelines to secure medical devices against cyber threats. This helps protect patient data, maintain device functionality, and prevent security breaches that could compromise patient care. ### Does the FDA recognize UL 2900? Yes, the FDA officially recognizes the UL 2900 series of standards as an appropriate method for assessing the cybersecurity of medical devices. ### What does UL 2900 certification involve? UL 2900 certification involves assessing a device's cybersecurity posture, including vulnerability analysis and penetration testing. It requires implementing remediation measures and undergoing independent third-party evaluation to meet standard requirements. ### How does UL 2900 address software security? UL 2900 provides guidelines for developing secure software, emphasizing secure coding practices and rigorous testing. It also stresses continuous monitoring and updates to address emerging threats and vulnerabilities in software systems. ### How often do UL 2900 standards change? UL 2900 standards are dynamic and evolve to keep pace with the changing cybersecurity landscape. Manufacturers must continuously monitor and update their devices to maintain compliance with emerging threats and revised guidelines. **Related:** [ISO 27001 and Medical Device Cybersecurity](/blog/why-iso-27001-and-soc-2-are-not-enough-for-fda-medical-device-cybersecurity) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Therac-25: The Root Cause Behind Six Radiation Overdoses Source: https://bluegoatcyber.com/blog/the-therac-25-incident-a-critical-analysis-of-medical-device-failures # Therac-25: What Happened and Why It Still Matters > **[DIRECT ANSWER]** The Therac-25 was a computer-controlled radiation therapy machine built by Atomic Energy of Canada Limited (AECL) that caused six documented radiation overdoses between June 1985 and January 1987, resulting in three deaths. The root cause was a race condition in the control software, inherited from earlier Therac-6 and Therac-20 models, combined with the removal of the hardware safety interlocks those older machines relied on. A fast-typing operator could edit the treatment setup within about eight seconds and trigger a concurrency flaw that let the electron beam fire in high-energy mode without the beam-flattening target in place. The case, documented in detail by Nancy Leveson and Clark Turner's 1993 IEEE Computer investigation, became the founding example behind modern software safety standards including IEC 62304 and ISO 14971. _Reviewed September 17, 2026_ Six patients received radiation doses tens to hundreds of times higher than prescribed from a single machine model over an 18-month period, and it took the fourth accident before AECL and hospital physicists correctly identified software as the cause. The Therac-25 incident is taught in nearly every software engineering and safety curriculum because it shows, with unusual clarity, how a latent software defect combined with removed hardware safeguards can kill people through a machine that had operated safely thousands of times before. Understanding exactly what failed, and why the failure took so long to diagnose, is directly relevant to how medical device makers build, verify, and secure software today. ## Key Takeaways - Six confirmed Therac-25 overdose accidents occurred between 1985 and 1987, resulting in three deaths. - The core defect was a race condition in the data entry editing path, not a single "bug" in the radiation calculation itself. - AECL removed hardware interlocks present on the Therac-6 and Therac-20 and relied on software alone to prevent overdose conditions. - A one-byte counter overflow in the Set-Up Test routine caused a related but distinct failure mode. - Vague error messages like "Malfunction 54" gave operators no way to know an overdose had occurred, and frequent minor errors desensitized them to real ones. - Modern practice addresses every one of these root causes through IEC 62304 software safety classification, ISO 14971 risk management, and independent verification. ## Why This Matters The Therac-25 is the case study that established why software cannot be treated as a black box in a safety-critical device. Before Therac-25, many manufacturers assumed that software, unlike a mechanical part, either worked or it did not, and that removing a hardware interlock was acceptable if the software "already" checked for the same condition. Leveson and Turner's investigation showed that assumption was false: the software passed years of field use before a specific timing sequence exposed the defect, and no amount of ordinary testing had caught it. That gap between "worked in the field for years" and "safe" is exactly what the FDA's February 3, 2026 final premarket cybersecurity guidance and standards like IEC 62304 and ISO 14971 now require manufacturers to close through documented risk analysis, software safety classification, and independent verification rather than field experience alone. The guidance also reflects a point Therac-25 makes concrete: safety and security failures share the same root cause pattern, an unverified assumption about how software will behave under conditions nobody tested for. Regulators and standards bodies did not treat Therac-25 as a one-time engineering mistake. It shaped the expectation, still in force today, that safety-critical software needs a documented hazard analysis, traceable requirements, and verification independent of the original developer, before it ever reaches a patient. ## What Was the Therac-25? The Therac-25 was a dual-mode linear accelerator built by Atomic Energy of Canada Limited (AECL) that could deliver either low-energy electron beam therapy or high-energy X-ray photon therapy, selected by software rather than a separate physical configuration for each mode. It was the successor to AECL's Therac-6 and Therac-20 machines, both of which had used the same PDP-11-based control software architecture but retained independent hardware interlocks that physically prevented the beam from firing in the wrong configuration. AECL's key design change in the Therac-25 was to remove those redundant hardware interlocks and rely on the software to enforce the same safety checks, on the theory that the software had already been proven reliable on the earlier machines. That assumption did not hold, because the earlier machines' hardware interlocks had been silently catching the same software defect for years without anyone noticing it existed. ## What Was the Timeline of the Therac-25 Accidents? Six accidents are documented between June 1985 and January 1987, spread across cancer treatment centers in the United States and Canada. The first occurred in Marietta, Georgia in June 1985, followed by a second in Hamilton, Ontario in July 1985, both producing severe tissue injuries that were not immediately connected to a machine malfunction. A third accident occurred in Yakima, Washington in December 1985. The fourth and fifth accidents, in Tyler, Texas in March and April 1987, produced overdoses severe enough that a hospital physicist, Fritz Hager, was able to reproduce the fault by rapidly re-entering treatment parameters, which finally pointed investigators toward the software. A sixth accident occurred in Yakima in January 1987. Three of the six patients died from their injuries; the others suffered severe radiation burns and lasting tissue damage. ## What Were the Technical Root Causes? The Therac-25's failures trace to a small number of specific, well-documented software and process defects, not a vague "bug" or single line of bad code. ### Reused software without hardware interlocks AECL carried forward control software from the Therac-6 and Therac-20 into the Therac-25 but removed the hardware interlocks that had backstopped that software on the earlier machines. The software had latent defects the whole time; the hardware had simply been catching them. ### The race condition in the data entry editing path The core defect was a race condition triggered when an operator used the keyboard to edit treatment parameters after they had already been entered, and did so quickly, typically within about eight seconds. If the edit occurred during a specific window in the software's mode-setting sequence, the machine could apply the high-energy X-ray beam current setting while the physical turntable was still in the low-energy electron configuration, delivering an unfiltered, unflattened high-energy beam directly to the patient. ### The one-byte overflow in the Set-Up Test counter A separate defect involved a counter used in the Set-Up Test routine that incremented past its maximum representable value and overflowed to zero. When that overflow occurred at the wrong moment, a safety check that was supposed to run before treatment could be silently skipped, allowing treatment to proceed without the verification it depended on. ### Misleading error messages When the software detected an anomaly, it displayed generic codes such as "Malfunction 54" with no explanation of severity or cause. Operators had no way to distinguish a serious overdose condition from a minor, harmless glitch, so many simply pressed a key to bypass the message and continue treatment. ### No independent safety analysis AECL had not commissioned an independent hazard analysis or code review of the control software before deployment, and the company's own safety analysis relied heavily on the assumption that software, once fielded successfully, was reliable. No process existed to systematically ask what could go wrong in the software's timing behavior specifically. ### Operator desensitization to frequent errors The Therac-25 generated dozens of minor error messages during routine operation that required nothing more than pressing a key to continue. That volume of routine, harmless errors trained operators to treat every error message, including the rare serious one, as routine. **[KEY REQUIREMENT]** A safety-critical device should never rely on software alone to enforce a condition that was previously enforced in hardware, unless that software has undergone independent verification specifically targeting timing and concurrency behavior, not just functional correctness. ## What Was the Regulatory and Industry Aftermath? The Therac-25 accidents led the FDA to recall and require corrective action on the remaining machines, and AECL redesigned the software and reinstated hardware interlocks. More significantly, the case became a reference point cited in the development of subsequent software safety standards, because it demonstrated a concrete, documented failure chain rather than a hypothetical risk. Leveson and Turner's 1993 IEEE Computer paper, based on AECL's own incident records and interviews, remains the standard sourced account of the incident and is still assigned in software engineering and biomedical engineering coursework today. The paper's central finding, that the accidents resulted from a systemic development and safety-culture failure rather than a single coding mistake, directly shaped how later standards frame software safety as a lifecycle discipline rather than a testing checkbox. ## How Do Modern Standards Address Each Therac-25 Root Cause? Every root cause identified in the Therac-25 investigation maps to a specific control that is now standard practice, or explicitly required, in medical device software development. | Therac-25 root cause | Modern control that addresses it | | --- | --- | | Reused software with hardware interlocks removed | IEC 62304 software safety classification, which requires risk-based rigor scaled to the harm a software failure could cause | | Race condition in the editing path | Independent verification and testing targeting concurrency and timing behavior, not only functional test cases | | One-byte counter overflow | Static analysis and code review practices required under IEC 62304, plus defense in depth so no single check failure allows unsafe operation | | Misleading "Malfunction 54" messages | Usability and human factors engineering requirements (IEC 62366) that mandate clear, actionable error information | | No independent safety analysis | ISO 14971 risk management, which requires a documented hazard analysis before and after design changes | | Operator desensitization to frequent errors | Human factors validation and alarm/alert design practices that limit nuisance alerts and preserve operator response to real hazards | ## Why Do Safety and Security Share the Same Failure Modes? Therac-25 was a safety failure, not a security failure, but the pattern is identical to one seen repeatedly in medical device security incidents: an unverified assumption about how software behaves under conditions nobody explicitly tested. A race condition that an attacker could trigger deliberately is a security vulnerability; the same race condition triggered by an operator's typing speed was a safety defect. Both come from the same source, insufficient verification of the software's actual behavior under untested conditions. This is why the FDA's February 3, 2026 final premarket cybersecurity guidance asks manufacturers to build security into the same secure product development framework used for safety, rather than treating cybersecurity as a separate bolt-on activity. Defense in depth, the principle that no single control failure should lead directly to patient harm, applies equally to a missing hardware interlock and a missing network segmentation boundary. > **Designing safety-critical software?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## What This Means If You Are Commissioning Software Safety and Security Testing Most teams read the Therac-25 case as history. If you are the person who has to buy verification work for a device whose software enforces a safety condition, it is a specification. Every root cause below is still something an independent test program either looks for or misses, and the difference usually shows up in how the engagement was scoped rather than in the final report's length. | Therac-25 root cause | What to require in a testing scope today | Evidence a reviewer expects | |---|---|---| | Race condition in the operator input path | Timing and concurrency abuse cases, not just functional test steps | Test cases traced to hazards in the ISO 14971 risk file | | Software as the only barrier after interlocks were removed | Explicit review of every safety control that has no hardware backstop | Architecture views showing where each control lives | | Reused code assumed safe from prior models | Legacy and third-party component review, including the SBOM | Component inventory with a rationale for reused code | | Counter overflow in a setup routine | Boundary and fault injection testing on embedded code paths | Findings mapped to software safety classification | | Vague error messages that hid the overdose | Review of alarms and error handling as a safety function | Human factors and alarm behavior documented | | No independent hazard analysis | Testing performed by a party independent of the developers | Named independent test firm and scope statement | Two practical notes for budgeting. Concurrency and fault injection work on embedded code costs more analyst time than interface scanning, so a quote that does not mention either is probably not scoped for this class of problem. And the independence requirement is why in-house verification alone tends to draw follow-up questions: the team that wrote the assumption is rarely the team that finds it. Our [medical device penetration testing cost guide](/blog/cost-of-medical-device-penetration-testing) breaks down what each layer of that scope adds to a number. ## How Blue Goat Cyber Approaches This Blue Goat Cyber applies the same lesson the Therac-25 investigation taught the industry: software behavior needs to be independently verified against realistic failure conditions, not just functional requirements. Our [medical device threat modeling](/services/medical-device-threat-modeling) work identifies race conditions, timing dependencies, and single points of failure in device software and architecture before they reach a patient or a submission reviewer. We pair that with [medical device penetration testing](/services/medical-device-penetration-testing) to validate that safety-relevant logic cannot be bypassed or manipulated through an exposed interface, and we help manufacturers build the ISO 14971 risk management file and IEC 62304 safety classification documentation the FDA's February 3, 2026 premarket cybersecurity guidance expects. If the FDA raises cybersecurity deficiencies after our submission support, we resolve them at no additional cost. ## Frequently Asked Questions ### What was the Therac-25? The Therac-25 was a computer-controlled radiation therapy machine built by Atomic Energy of Canada Limited (AECL) in the early 1980s, designed to deliver both electron beam and high-energy X-ray cancer treatment from a single unit. It replaced the hardware safety interlocks used in AECL's earlier Therac-6 and Therac-20 with software-only controls. ### How many people were harmed by the Therac-25? Six documented accidents occurred between June 1985 and January 1987, and three of the affected patients died from their radiation injuries. The others suffered severe radiation burns and permanent tissue damage. ### What caused the Therac-25 overdoses? The primary cause was a race condition in the software's data entry editing path, which could let the beam fire in high-energy mode without the correct physical configuration in place if an operator edited treatment parameters quickly. A separate counter overflow defect and the removal of hardware interlocks compounded the risk. ### Why did it take so long to identify the cause? Early incidents were attributed to operator error or unrelated equipment problems because the software had operated without incident for years and the error messages the machine displayed gave no indication of an overdose. It took a hospital physicist reproducing the exact keystroke timing during the fourth accident to demonstrate the software defect directly. ### Who documented the Therac-25 investigation? Nancy Leveson and Clark Turner published the standard account, "An Investigation of the Therac-25 Accidents," in IEEE Computer in 1993, based on AECL incident records, FDA correspondence, and interviews. It remains the most cited and most rigorously sourced account of the incident. ### What is the main lesson for medical device manufacturers today? The main lesson is that software cannot be assumed safe because it has run successfully in the field; it needs independent verification against a documented hazard analysis, and no single software check should be the only barrier preventing patient harm. Standards like IEC 62304 and ISO 14971, and the FDA's current cybersecurity guidance, exist specifically to enforce that discipline. ## CTA If your device relies on software to enforce a safety condition that used to sit in hardware, that is exactly the pattern that caused the Therac-25 accidents. [Contact Blue Goat Cyber](/contact) to threat model your device's failure modes before an independent reviewer, or a real-world incident, finds them first. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Top 50 Medical Device Cybersecurity Issues Source: https://bluegoatcyber.com/blog/the-top-50-cybersecurity-issues-with-medical-devices # Top 50 Medical Device Cybersecurity Issues > **[DIRECT ANSWER]** The most common medical device cybersecurity issues include hardcoded credentials, unencrypted data transmission, outdated software, weak access controls, unsecured wireless communication, and unpatched third-party components, each capable of enabling unauthorized access or device malfunction that harms patients. Penetration testing catches these before an FDA submission by simulating real attacks against device interfaces, firmware, and network connections, producing the evidence needed for premarket cybersecurity documentation. _Reviewed July 24, 2026_ Medical devices need strong cybersecurity. Healthcare now depends on connected systems, software, and wireless communication. When device security fails, patient safety and sensitive medical data are both at risk. [Medical device cybersecurity](/services/fda-premarket-cybersecurity-services) covers encryption, authentication, software updates, network security, and protection against direct attacks. As devices become more connected, attackers get more ways in. That puts pressure on manufacturers, healthcare providers, and regulators to keep those devices secure and reliable. This post lists 50 common cybersecurity issues in medical devices. For each one, we explain the threat, the likely impact, and a real-world style example. It covers everything from IoT-connected devices to regulatory compliance problems in digital healthcare. ## Key Takeaways - FDA guidance requires cybersecurity throughout the total product lifecycle. - Manufacturers must provide a Software Bill of Materials (SBOM). - Postmarket vulnerability management plans are mandated. - Secure design and clear documentation are essential for compliance. - Proactive cybersecurity mitigates common medical device risks. ## Why this matters The security of medical devices directly impacts patient safety and privacy. Flaws like unencrypted data or weak authentication can lead to device malfunction, data breaches, and even direct harm to patients through unauthorized control or manipulation of life-sustaining equipment. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes that manufacturers must integrate cybersecurity throughout the total product lifecycle, from design to postmarket surveillance. Failure to adhere to these foundational cybersecurity principles not only jeopardizes patient well-being but also exposes healthcare providers and manufacturers to significant regulatory penalties, legal liabilities, and reputational damage. Compliance with standards such as IEC 81001-5-1, ISO 27001, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is no longer optional; it's a necessity for ensuring the trustworthiness and continued operation of medical technology in an increasingly connected healthcare ecosystem. Unaddressed vulnerabilities can disrupt healthcare operations, compromise sensitive protected health information (PHI), and erode public trust in medical technology. ## Top 50 cybersecurity issues facing medical devices ### 1\. Lack of Encryption - **Description:** Unencrypted data transmission in medical devices can lead to unauthorized access and interception of sensitive health information. - **Example:** A heart rate monitor transmitting unencrypted data could be intercepted by unauthorized entities, compromising patient privacy. ### 2\. Inadequate User Authentication - **Description:** Weak or insufficient authentication mechanisms allow unauthorized users to access and manipulate medical device functions. - **Example:** An unauthorized staff member accessed a medication dispensing system with weak password protection, leading to incorrect medication dosage. ### 3\. Outdated Software - **Description:** Medical devices running on outdated software are vulnerable to known exploits and security breaches. - **Example:** A known vulnerability exploited an MRI machine running on outdated software, causing system malfunction and data loss. ### 4\. Vulnerable Wireless Communication - **Description:** Wireless communication channels in medical devices, like Wi-Fi or [Bluetooth](/blog/top-ble-cybersecurity-vulnerabilities), can be exploited if not properly secured. - **Example:** A wireless insulin pump was hacked through its Bluetooth connection, leading to unauthorized changes in insulin delivery. ### 5\. Insufficient Data Integrity Checks - **Description:** Without proper verification, data integrity issues in medical devices can lead to incorrect patient treatment. - **Example:** A blood analysis machine with compromised data integrity provided inaccurate results, leading to a misdiagnosis. ### 6\. Lack of Physical Security - **Description:** Physical access to medical devices can result in tampering, data theft, or unauthorized use. - **Example:** A portable ultrasound machine left unsecured was physically tampered with, resulting in altered diagnostic capabilities. ### 7\. Insecure APIs - **Description:** Application Programming Interfaces (APIs) that lack security measures can be entry points for cyberattacks. - **Example:** An [insecure API](/blog) in a patient monitoring system was exploited, leading to unauthorized data access. ### 8\. Unpatched Security Vulnerabilities - **Description:** Medical devices without regular updates are at risk of exploitation through known vulnerabilities. - **Example:** A networked patient monitoring system was compromised using an unpatched security flaw, affecting patient data confidentiality. ### 9\. Poor Network Segmentation - **Description:** Inadequate network segmentation can lead to widespread impact in case of a cyber breach. - **Example:** A [ransomware attack](https://en.wikipedia.org/wiki/WannaCry_ransomware_attack "ransomware attack") spread across a hospital’s network due to poor segmentation, affecting multiple medical devices. ### 10\. Legacy Systems - **Description:** [Older medical devices](/services/legacy-medical-device-cybersecurity-services) no longer supported pose significant security risks. - **Example:** An outdated patient records system, no longer receiving security updates, was breached, leading to a significant data leak. ### 11\. Insufficient Staff Training - **Description:** Lack of adequate cybersecurity training for healthcare staff can lead to inadvertent security breaches. - **Example:** A staff member unknowingly installed malware on a hospital computer, compromising connected medical devices. ### 12\. Lack of Emergency Response Plans - **Description:** The absence of a proper plan for responding to cybersecurity incidents can exacerbate the impact of an attack. - **Example:** A hospital was slow to respond to a cyberattack due to a lack of a predefined response plan, resulting in prolonged system downtime. ### 13\. Third-Party Risk - **Description:** Dependencies on [third-party vendors for software](/services) or hardware can introduce security vulnerabilities. - **Example:** A third-party service provider’s compromised system led to a data breach in a hospital’s networked medical devices. ### 14\. Supply Chain Vulnerabilities - **Description:** Weaknesses in the [supply chain](/blog) can lead to compromised components being used in medical devices. - **Example:** A batch of diagnostic devices contained a hardware vulnerability due to a compromised supply chain. ### 15\. Lack of Transparency from Manufacturers - **Description:** Manufacturers not providing detailed security information can hinder proper risk assessment. - **Example:** A healthcare provider could not assess the security risk of an infusion pump because the manufacturer did not provide enough information. ### 16\. Overlooking End-of-Life Devices - **Description:** Continuing to use devices that are no longer supported by manufacturers can pose serious security risks. - **Example:** An end-of-life patient monitoring system was exploited due to outdated security protocols. ### 17\. Remote Access Vulnerabilities - **Description:** Insecure remote access to medical devices can lead to unauthorized control and data breaches. - **Example:** Hackers gained remote access to a [telemedicine system](/blog/telemedicine-cybersecurity-risks), compromising patient consultations. ### 18\. Inadequate Incident Detection - **Description:** Poor detection mechanisms can delay the response to a cyberattack, increasing its impact. - **Example:** A slow response to a data breach in a radiology system caused extended exposure of sensitive patient data. ### 19\. Poor Data Backup and Recovery - **Description:** Inadequate backup and recovery plans can lead to significant data loss during cybersecurity incidents. - **Example:** A ransomware attack resulted in the loss of critical patient data due to inadequate backup systems. ### 20\. Compliance with Regulations - **Description:** Failure to comply with cybersecurity regulations can lead to legal and financial penalties. - **Example:** A medical device company faced heavy fines for violating HIPAA security standards. ### 21\. Risk Management Failures - **Description:** Ineffective risk management strategies can expose devices and data to cyber threats. - **Example:** Inadequate risk assessment led to a data leak in a hospital’s networked device infrastructure. ### 22\. IoT Integration Challenges - **Description:** Integrating [IoT devices](/blog) into healthcare environments increases the complexity of cybersecurity. - **Example:** An IoT-enabled patient monitoring system was compromised, leading to false health alerts. ### 23\. Mobile Device Vulnerabilities - **Description:** [Mobile devices](/services/mobile-application-penetration-testing) used in healthcare can be a weak link in cybersecurity if not properly managed. - **Example:** A doctor’s compromised smartphone led to unauthorized access to a patient management app. ### 24\. Weak Default Settings - **Description:** Devices shipped with weak default settings can be easily exploited if not properly configured. - **Example:** A default admin password for a medical storage refrigerator was exploited, leading to temperature manipulation. ### 25\. Lack of Regular Security Audits - **Description:** Without regular security audits, vulnerabilities in medical devices can remain undetected. - **Example:** A periodic audit revealed critical vulnerabilities in a patient data management system that had gone unnoticed. ### 26\. Insecure Data Storage - **Description:** Storing patient data insecurely on medical devices can lead to unauthorized access and data breaches. - **Example:** A compromised server in a hospital leaked sensitive patient records due to inadequate data encryption. ### 27\. Cross-Site Scripting (XSS) Attacks - **Description:** Medical device web interfaces are vulnerable to [XSS attacks](/blog), allowing attackers to inject malicious scripts. - **Example:** An XSS vulnerability in a patient management system’s web portal stole login credentials. ### 28\. SQL Injection Threats - **Description:** SQL injection vulnerabilities in database-driven medical applications can lead to unauthorized data access. - **Example:** An attacker exploited a [SQL injection](/blog/medical-device-sql-injection-parameterized-queries) flaw in a medical record system, altering patient data. ### 29\. Insufficient Error Handling - **Description:** Poor [error handling](/blog) in medical software can lead to information leaks and system crashes. - **Example:** Improperly handled system errors in a diagnostic tool exposed sensitive debug information. ### 30\. Misconfigured Cloud Services - **Description:** Incorrectly configured cloud services used by medical devices can expose data and systems to risks. - **Example:** A misconfiguration in a cloud-based medical imaging service led to public exposure of patient images. ### 31\. Inadequate Access Controls - **Description:** Weak access controls can allow unauthorized personnel to access sensitive medical device functions. - **Example:** Lack of proper access controls enabled an unauthorized employee to access a drug dispensing system. ### 32\. Phishing Attacks - **Description:** Healthcare professionals can be targeted by phishing attacks, leading to compromised medical devices and data. - **Example:** A phishing email tricked a healthcare worker into revealing login credentials for a patient monitoring system. ### 33\. Social Engineering Tactics - **Description:** Social engineering can manipulate healthcare staff into compromising device security. - **Example:** A social engineering attack convinced a staff member to install unauthorized software on a medical device. ### 34\. Ransomware Threats - **Description:** Ransomware can cripple healthcare operations by locking access to crucial medical devices and data. - **Example:** A hospital’s critical systems were locked down by ransomware, disrupting patient care and access to electronic health records. ### 35\. DDoS Attacks - **Description:** Distributed Denial of Service (DDoS) attacks can overwhelm healthcare networks, disrupting medical device functionality. - **Example:** A DDoS attack on a hospital network rendered several networked medical devices inoperable. ### 36\. Insider Threats - **Description:** Malicious actions by insiders can lead to significant security breaches in medical devices. - **Example:** An employee with malicious intent uploaded a virus to a networked medical device, causing system failures. ### 37\. Lack of Security in the Design Phase - **Description:** Failing to incorporate security features during the design phase of medical devices can lead to inherent vulnerabilities. - **Example:** A newly developed ECG machine was found to have critical security flaws due to neglect in the design phase. ### 38\. Firmware Vulnerabilities - **Description:** Vulnerabilities in the firmware of medical devices can be exploited for unauthorized access or control. - **Example:** A firmware flaw in a ventilator system was exploited to alter its functionality. ### 39\. Inconsistent Patching Across Devices - **Description:** Variations in patching across different devices can lead to security inconsistencies. - **Example:** Inconsistent patching made some infusion pumps vulnerable to a known exploit. ### 40\. AI and Machine Learning Risks - **Description:** [AI and ML](/blog) components in medical devices can introduce unique vulnerabilities and biases. - **Example:** An AI-driven diagnostic tool exhibited biased outcomes due to flawed training data, affecting patient treatment. ### 41\. Biometric Data Security - **Description:** Inadequate protection of biometric data gathered by medical devices can lead to privacy breaches. - **Example:** A biometric patient identification system was compromised, resulting in unauthorized access to personal health records. ### 42\. Malware Infections - **Description:** Medical devices can be infected with malware, disrupting their functionality and compromising patient data. - **Example:** A malware infection in a hospital’s imaging devices caused delays in diagnostic procedures and corrupted data. ### 43\. Unsecured Device Interfaces - **Description:** Interfaces on medical devices that are not securely designed can be exploited for unauthorized access or control. - **Example:** An unsecured USB port on a medical device was used to upload malicious software, altering its operation. ### 44\. Lack of Device Authentication - **Description:** Failure to authenticate communications between medical devices can lead to data interception and manipulation. - **Example:** Non-authenticated communication between a blood glucose monitor and an insulin pump was exploited to deliver incorrect insulin dosages. ### 45\. Eavesdropping and Interception - **Description:** Eavesdropping on data transmissions from medical devices can lead to unauthorized access to sensitive information. - **Example:** Cybercriminals intercept unencrypted patient data from a wireless medical device, leading to identity theft. ### 46\. Cross-Site Request Forgery (CSRF) Attacks - **Description:** [CSRF attacks](/blog) can exploit web-based interfaces of medical devices to perform unauthorized actions. - **Example:** A CSRF attack on a web-based medication administration system resulted in the unauthorized modification of drug dosages. ### 47\. Data Tampering - **Description:** Altering data within medical devices can lead to incorrect diagnoses or treatments. - **Example:** Data tampering in a digital health record system caused incorrect patient information to be recorded, leading to inappropriate treatment. ### 48\. Unauthorized Data Sharing - **Description:** Inappropriate or unauthorized data sharing from medical devices can compromise patient confidentiality. - **Example:** A connected patient monitoring device inadvertently shared sensitive health data with unauthorized third-party applications. ### 49\. Compliance Audits and Penalties - **Description:** Failure to comply with industry standards and regulations can result in audits and penalties for healthcare providers. - **Example:** A healthcare facility faced significant fines for non-compliance with data protection regulations after a routine audit revealed lapses in medical device security. ### 50\. Evolving Cyber Threat Landscape - **Description:** The continuously changing nature of cyber threats poses a persistent challenge to the security of medical devices. - **Example:** A healthcare provider struggled to keep pace with ransomware tactics, resulting in repeated breaches of their medical devices. ## Penetration Testing: A Proactive Approach to Preventing Cybersecurity Issues in Medical Devices [Penetration testing](/services/medical-device-penetration-testing), often called pen testing, helps prevent and reduce many of the 50 issues listed above. It simulates real attacks so teams can find and fix weaknesses before an attacker does. ### 1\. Identifying Vulnerabilities Penetration testing helps find weaknesses in medical devices and connected systems. By simulating real attacks, testers can uncover hidden flaws, from inadequate encryption (Issue 1) to insecure data storage (Issue 26). That gives manufacturers and healthcare providers a chance to fix them before they are exploited. ### 2\. Testing Defense Mechanisms Regular pen testing measures how well existing security controls actually work. It shows whether medical devices can withstand attacks such as SQL injection (Issue 28) or Cross-Site Scripting (XSS) attacks (Issue 27). This confirms whether the controls in place are effective. ### 3\. Compliance with Regulations Regular penetration testing supports compliance with regulatory standards (Issue 20). Regulations like HIPAA, [FDA](https://www.fda.gov/media/119933/download), and GDPR often require strict data security measures. Pen testing helps verify compliance and find gaps before they turn into fines or penalties (Issue 49). ### 4\. Training and Awareness Penetration testing also helps train healthcare staff and raise awareness of likely threats (Issue 11). When staff see how breaches happen, they are better prepared to spot and stop phishing (Issue 32) or social engineering attacks (Issue 33). ### 5\. Preparing for the Unknown As threats change (Issue 50), pen testing helps teams stay ahead of new attack paths. It shows how emerging threats could affect medical devices so defenses can keep up. ### 6\. Emergency Response Planning Pen testing can improve emergency response plans (Issue 12). If you know how an attack is likely to unfold, you can build a better incident response process around it. ### 7\. Enhancing Data Integrity and Patient Safety Regular penetration testing helps protect patient data integrity (Issue 5) and patient safety overall. That matters most for devices that directly affect care, such as drug infusion pumps (Issue 2) or remote monitoring systems (Issue 17). ### 8\. Securing IoT and Mobile Devices As medical devices become more interconnected (Issue 22) and more dependent on mobile technology (Issue 23), penetration testing becomes essential for securing those systems against multi-part cyber threats. ## Conclusion The top 50 cybersecurity issues in medical devices show a simple reality: as healthcare technology advances, so do the risks. Weak authentication, outdated software, insecure APIs, and AI-related risks all create threats to data and patient safety. Cybersecurity in medical devices is not optional. It takes ongoing work from manufacturers, healthcare providers, regulators, and security teams. Penetration testing is one important part of that work. It helps find and fix vulnerabilities before attackers exploit them. It is not the only control, but it is a practical one. Use secure-by-design principles, improve security awareness, and keep pace with new threats. That is how you build safer digital healthcare systems. Check out our [medical device penetration testing services](/services/medical-device-penetration-testing). ## Which of these issues actually block a submission Not every issue on this list carries the same regulatory weight. This is how they sort in practice. | Issue category | Typical submission impact | Typical fix window | | --- | --- | --- | | Hardcoded or shared credentials | Deficiency letter almost every time | Firmware change before release | | No SBOM, or an incomplete one | Refuse to accept at the front door | Days, once the build system produces it | | Unauthenticated update path | Deficiency letter, and a recall risk later | Significant, often a bootloader change | | Exposed debug port with no lockout | Frequent reviewer question | Board revision or fuse setting | | Unencrypted data in transit | Deficiency letter when patient data is involved | Firmware and server change | | Weak logging and no event records | Follow-up question rather than a block | Firmware change | | Legacy operating system past support | Depends on documented compensating controls | Long, and sometimes a redesign | ## How Blue Goat approaches this Blue Goat Cyber addresses medical device cybersecurity issues by focusing on established methodologies and deep technical expertise. Our process starts with a thorough review of device architecture and intended use, aligning with regulatory requirements like those outlined in the FDA's 'Cybersecurity in Medical Devices' Final Guidance. We implement detailed threat modeling and risk assessments to identify potential vulnerabilities before they become critical issues. Our team, comprising professionals with CISSP and OSCP certifications, including former military red team members, employs focused penetration testing and vulnerability analysis to pinpoint weaknesses. We then provide actionable recommendations for remediation and work with manufacturers to develop strong Software Bill of Materials (SBOMs) and postmarket vulnerability management plans. Our commitment: If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is the FDA's current guidance on medical device cybersecurity? The FDA's current guidance is the final guidance titled "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions" issued on February 3, 2026. This guidance outlines the cybersecurity information required in premarket submissions. ### Does the FDA require a Software Bill of Materials (SBOM) for medical devices? Yes, the FDA requires manufacturers to include a Software Bill of Materials (SBOM) in their premarket submissions. The SBOM helps identify and manage known vulnerabilities in device software components. ### What does the FDA expect for postmarket cybersecurity management? The FDA expects manufacturers to have a plan for identifying, assessing, and remediating postmarket cybersecurity vulnerabilities. This ensures ongoing safety and effectiveness throughout the device's lifecycle. ### When did the FDA release its critical guidance on medical device premarket cybersecurity? The FDA released its final guidance, "Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions," on February 3, 2026. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Top 10 Embedded OS for Medical Devices (2026) Source: https://bluegoatcyber.com/blog/top-10-embedded-operating-systems-for-medical-devices # Top 10 Embedded Operating Systems for Medical Devices (2026 Comparison) > **[DIRECT ANSWER]** The top 10 embedded operating systems used in FDA-cleared medical devices in 2026 include Embedded Linux, VxWorks, QNX Neutrino, INTEGRITY-178 tuMP, Windows IoT Enterprise LTSC, Zephyr RTOS, FreeRTOS, Eclipse ThreadX, RTEMS, and Apache NuttX. Selection should weigh long-term support horizon, real-time determinism, safety and security certifications like IEC 62304, and update architecture with signed images and secure boot, since Class II and III devices typically favor Linux or VxWorks while low-power sensors favor FreeRTOS or Zephyr. > > 1. **Embedded Linux (Yocto / Buildroot)** - imaging, infusion pumps, patient monitors > 2. **Wind River VxWorks** - hard real-time, DO-178C / IEC 62304 pedigree > 3. **QNX Neutrino (BlackBerry)** - microkernel isolation for surgical robotics > 4. **Green Hills INTEGRITY-178 tuMP** - EAL 6+ separation kernel > 5. **Windows IoT Enterprise LTSC** - imaging consoles and workstation-class devices > 6. **Zephyr RTOS (LTS)** - connected MCU wearables and sensors > 7. **FreeRTOS (AWS)** - low-power wearables and disposables > 8. **Eclipse ThreadX (formerly Azure RTOS)** - Class II devices at scale > 9. **RTEMS** - open-source deterministic RTOS with full-source IEC 62304 auditability > 10. **Apache NuttX** - POSIX-like RTOS for wearables and connected sensors > > Select on four FDA-relevant criteria: (1) long-term support horizon matching 7-15 year device life, (2) real-time determinism, (3) safety and security certifications (IEC 62304, IEC 61508, DO-178C, Common Criteria), and (4) update architecture with A/B partitions, signed images, and secure boot. Yocto and VxWorks dominate high-risk Class II/III devices; FreeRTOS and Zephyr dominate low-power sensors. Choosing an embedded operating system for a medical device is not just a performance decision; it’s a lifecycle decision. Your OS choice affects how you ship security updates, how you isolate critical functions, how you manage third-party components, and how confidently you can respond when the next vulnerability hits. This guide breaks down the most common embedded operating systems used in medical devices today and compares them through a medical-device lens: long-term support, real-time behavior, safety considerations, and practical cybersecurity features like secure boot, isolation, and update readiness. ## Key Takeaways - OS choice affects security updates and postmarket risk management. - Long-term support and patchability are critical for device lifecycles. - Secure boot and isolation capabilities reduce attack surface. - An effective update architecture matters for ongoing security. - Maintaining an SBOM for OS components is essential for vulnerability response. - Align OS selection with FDA premarket cybersecurity guidance. ## Why this matters The choice of an embedded operating system is a foundational cybersecurity decision for any medical device. A poorly chosen OS can introduce significant technical debt, lead to unmanageable security vulnerabilities, and jeopardize patient safety. Medical device manufacturers must consider the OS's support lifecycle, patchability, and inherent security features like secure boot and isolation when making this critical decision. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly states that manufacturers must address OS selection within their premarket submissions, emphasizing characteristics that facilitate postmarket security updates and vulnerability management. Failure to prioritize these OS considerations can result in costly postmarket remediation, regulatory non-compliance, and damage to patient trust. This also directly impacts standards adherence, including elements of IEC 60601-1-10, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023, which demand careful attention to the software components influencing device safety and effectiveness throughout its lifecycle. An OS that supports a defensible security architecture from day one significantly reduces these risks. ## What Is an Embedded Operating System? An embedded operating system is specialized software designed to control a dedicated hardware device. Unlike general-purpose desktops, embedded OSes are built for predictable behavior, constrained resources, and long lifecycles. In medical devices, they’re the foundation for everything from data acquisition and control loops to networking, UI, logging, and update mechanisms. ## Cybersecurity Criteria That Matter in Medical Devices If you only evaluate the OS on “does it run my app,” you’ll regret it later. Here are the criteria that usually make or break medical device OS decisions: - **Support lifetime:** Can you get security updates for the length of your product life (often 7-15+ years)? - **Patchability:** Can you update the OS safely in the field (and prove what changed)? - **Secure boot + measured boot options:** Can you protect startup integrity and reduce persistent compromise? - **Isolation and least privilege:** Memory protection, process separation, and permissions that let you contain failures. - **Update security:** Signed updates, rollback protections, and a realistic story for key management. - **Supply chain visibility:** Can you build/maintain an [SBOM](/services/fda-compliant-sbom-services-for-medtech) for OS components and respond to CVEs? - **Vendor security posture:** PSIRT/vuln disclosure process, advisories, and responsiveness. - **Regulated development reality:** Tooling, traceability, testing support, and documentation maturity. ## Quick Comparison Table This table is intentionally practical. It’s not “best/worst”-it’s “where it tends to fit” in medical device product lines. | OS | Current version (2026) | Best fit | Security strengths | FDA / medical track record | Lifecycle note | | --- | --- | --- | --- | --- | --- | | Embedded Linux (Yocto / Buildroot) | Kernel 6.6+ LTS, Yocto 5.x "Scarthgap" | UI, networking, complex apps | Broad hardening options (SELinux, dm-verity, secure boot) | Widely used in imaging, infusion pumps, patient monitors | Own kernel + userland CVE patching cadence | | QNX Neutrino RTOS | QNX 8.0 (2024) | Safety-critical real-time | Microkernel isolation, IEC 62304 evidence pack available | Deployed across Class II/III devices; common in surgical robotics | BlackBerry commercial support, 10+ yr LTS | | Wind River VxWorks | VxWorks 24.03 | Hard real-time, safety-critical | Mature RTOS, DO-178C/IEC 62304 pedigree | Long history in imaging, radiation therapy, lab analyzers | Commercial LTS, priced per-seat | | Green Hills INTEGRITY-178 tuMP | INTEGRITY-178 tuMP | High-assurance partitioning | EAL 6+ evaluated; strong separation kernel | Used where multi-partition isolation is a design requirement | Commercial, safety-cert artifacts available | | Windows IoT Enterprise LTSC | Win 11 IoT Ent. LTSC 2024 | Rich UI / Windows-app devices | Enterprise security stack (BitLocker, WDAC, VBS) | Common in workstation-class devices, imaging consoles | 10 yrs mainstream + extended support | | Zephyr RTOS (LTS) | Zephyr 3.7 LTS (LTS v3, 2024) | Connected MCU-class devices | Modern MCUboot, PSA Crypto, TF-M integration | Growing use in wearables, connected sensors, Bluetooth devices | LTS maintained ~2.5 yrs; plan LTS→LTS jumps | | FreeRTOS | FreeRTOS 11.x (2024) | Small footprint MCU | Widely audited kernel; pairs with AWS IoT / OTA | Long history in low-power wearables and disposables | AWS-stewarded LTS releases (2+ yrs) | | Eclipse ThreadX (ex-Azure RTOS) | ThreadX 6.4+ (Eclipse, 2024) | MCU + full middleware stack | RTOS + FileX/NetX/USBX under one SBOM | Deployed at massive scale in Class II devices | Now vendor-neutral (Eclipse Foundation) | | RTEMS | RTEMS 6 (2024) | Deterministic RTOS, open source | Full source access simplifies IEC 62304 audit | Niche but growing in research-grade and Class II devices | Community + commercial support (OAR, embedded brains) | | Apache NuttX | NuttX 12.x (2024) | POSIX-like RTOS environments | POSIX API + small footprint, permissive license | Emerging in wearables and connected sensors | Apache-governed; commercial support via vendors | > **Picking an OS for a new device?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Secure MedTech product design consulting](/services/secure-medtech-product-design-consulting) ## The Top 10 Embedded Operating Systems for Medical Devices ### 1) Embedded Linux (Yocto-based Linux, etc.) **Why it’s used:** [Embedded Linux](https://www.yoctoproject.org/) is the default choice when you need a rich networking stack, complex application logic, modern UI frameworks, and broad hardware support. It’s common in imaging, gateways, bedside systems, and connected platforms. **Security considerations:** Linux can be extremely secure, but you have to earn it: hardening, least privilege, configuration control, and disciplined patching. Your update architecture matters as much as your distro choice. **Lifecycle tip:** Pick an LTS approach early and define who owns kernel/userland CVEs, rebuild cadence, and validation scope. ### 2) QNX Neutrino RTOS **Why it’s used:** QNX is common in safety-critical environments where determinism and stability matter. Its microkernel architecture is often attractive for systems that benefit from strong component separation. **Security considerations:** The isolation story is a real advantage when designed correctly (contain faults, reduce blast radius). Still, you need a clear patch and vulnerability response process. **Lifecycle tip:** Align commercial support terms with device lifecycle and field update expectations. ### 3) Wind River VxWorks **Why it’s used:** VxWorks has a long track record in mission-critical real-time systems. Teams use it when they need deterministic behavior, mature tooling, and strong vendor support. **Security considerations:** Focus on segmentation, least privilege, secure services exposure, and update strategy. RTOS devices still get CVEs-treat postmarket response as a core requirement. **Lifecycle tip:** Confirm how security advisories, patches, and long-term support align to your product roadmap. ### 4) Green Hills INTEGRITY **Why it’s used:** INTEGRITY is frequently selected for safety and high-assurance designs. The separation/partitioning model is appealing in devices where isolation is a design requirement, not a nice-to-have. **Security considerations:** Strong separation can simplify your risk story if you use it intentionally (e.g., separating safety functions from networking/UI components). **Lifecycle tip:** Ensure your architecture supports secure updates and that your verification plan covers security-relevant changes. ### 5) Windows IoT Enterprise LTSC (e.g., Windows 11 IoT Enterprise LTSC 2024) **Why it’s used:** When a medical device needs a Windows ecosystem (UI, peripherals, enterprise integration, familiar toolchains), Windows IoT Enterprise LTSC is the “long-lived device” option rather than consumer Windows. **Security considerations:** Treat it like a managed endpoint: harden the build, lock down services, control application allow-listing, and define update/validation processes. **Lifecycle tip:** LTSC is designed for fixed-purpose devices with long support lifecycles-plan your patch validation and deployment workflow accordingly. ### 6) Zephyr RTOS (prefer LTS releases for products) **Why it’s used:** Zephyr has become a major choice for connected, MCU-class devices, especially where you want a modern open-source RTOS and community momentum. **Security considerations:** Treat dependencies seriously: networking stacks, libraries, and configuration can be your biggest exposure. Use LTS releases where stability and long-term maintenance matter. **Lifecycle tip:** Favor Zephyr LTS for product baselines, and define how you’ll consume security fixes without breaking verification scope. ### 7) FreeRTOS **Why it’s used:** FreeRTOS is a classic choice for small, resource-constrained devices. It’s lightweight, fast, and widely adopted, which makes it attractive in wearable and portable designs. **Security considerations:** FreeRTOS gives you the scheduling foundation. Security posture often depends on the surrounding architecture: secure boot, secure storage, communications security, and how you expose services. **Lifecycle tip:** Define how you will update firmware safely at scale (signing, rollback, key handling, verification). ### 8) Eclipse ThreadX (formerly Azure RTOS) **Why it’s used:** ThreadX has been deployed at massive scale and is often paired with a broader embedded middleware suite (file system, networking, USB, etc.). **Security considerations:** Middleware is where risk often hides. Treat the OS plus middleware as “the platform,” and SBOM it accordingly. **Lifecycle tip:** ThreadX’s transition to the Eclipse Foundation makes it more vendor-neutral and open-source-friendly-still plan governance and update intake like you would any platform component. ### 9) RTEMS **Why it’s used:** RTEMS is a mature open-source RTOS used in systems that need deterministic behavior and transparency. It can be a good fit for teams that prefer open ecosystems but still need serious real-time performance. **Security considerations:** Like other RTOS platforms, your exposure is often driven by networking, update paths, and any externally reachable interfaces. **Lifecycle tip:** Define a repeatable process for monitoring fixes and integrating updates with verification testing. ### 10) Apache NuttX **Why it’s used:** NuttX is a real-time OS with an emphasis on standards (POSIX/ANSI) and a small footprint. Teams like it when they want RTOS determinism but with a more familiar programming model than some classic RTOS environments. **Security considerations:** Same story: reduce attack surface, harden interfaces, and treat networking + update mechanisms as first-class security features. **Lifecycle tip:** Make sure your build system and dependency strategy can produce repeatable SBOMs and patch evidence. ## What Changed From Older “Top 10” Lists? Embedded OS landscapes change. Two practical updates worth calling out: - **Windows 10 IoT Core is retired**, so for long-lived device builds you generally look at Windows IoT Enterprise LTSC options instead. If your shortlist has narrowed to those two families, see our head-to-head [Linux vs. Windows security comparison for medical device OS selection](/blog/linux-vs-windows-a-security-comparison). - **Some legacy RTOS products have been discontinued** by vendors over time, which makes lifecycle and support terms a first-order decision, not a footnote. ## How Blue Goat Cyber Helps If you’re selecting an OS, inheriting an existing platform, or trying to make a legacy choice survivable postmarket, we can help you build a defensible cybersecurity story and the evidence to support it-without turning your development team into full-time compliance writers. - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [Medical Device Threat Modeling](/services/medical-device-threat-modeling) - [Medical Device Penetration Testing](/services/medical-device-penetration-testing) - [FDA-Compliant SBOM Services for MedTech](/services/fda-compliant-sbom-services-for-medtech) - [FDA Postmarket Cybersecurity Management](/services/fda-postmarket-cybersecurity-services) - [Contact Blue Goat Cyber](/contact) **Bottom line:** pick the OS that supports your clinical requirements _and_ your long-term security reality. The best device in the world doesn’t survive the field if it can’t be patched, monitored, and maintained. ## FAQ ### Which embedded OS is “best” for medical devices? There isn’t one best OS. The right choice depends on your architecture: UI-heavy vs MCU, real-time constraints, safety needs, connectivity, and how you plan to patch and support the device for years. ### Linux vs RTOS: which is easier to secure? Linux offers mature security tooling and broad ecosystem support, but it also expands your dependency surface. RTOS platforms can be simpler and smaller, but security posture often depends heavily on your architecture (interfaces, update paths, crypto, and service exposure). Both can be secured well-both can be secured poorly. ### How do OS CVEs affect postmarket medical device cybersecurity? Your OS and its components are part of your attack surface. A strong postmarket program tracks relevant vulnerabilities, assesses exposure in your architecture, and deploys updates or mitigations with verification evidence. ### Do we need an SBOM for the operating system? Practically, yes-because vulnerabilities often land in OS components and bundled libraries. You want the ability to quickly answer: “Are we affected?” and “What do we do next?” ### What matters more: OS choice or update architecture? In real life, update architecture is often the deciding factor. A “secure OS” without a secure and maintainable update path becomes a long-term risk. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Microkernels for Medical Devices](/blog/microkernels-medical-device-cybersecurity) - [Examples of Hacked Medical Devices](/blog/examples-of-hacked-medical-devices) - [Understanding Threats to Medical Devices](/blog/understanding-relevant-threats-for-medical-devices) - [Recalled Medical Devices: Cyber Failures](/blog/recalled-medical-devices-cybersecurity-failures) --- ## Top 10 Medical Device Vulnerabilities Source: https://bluegoatcyber.com/blog/top-10-medical-device-vulnerabilities-revealed-protecting-patient-safety # Top 10 Medical Device Vulnerabilities: What Manufacturers Need to Know > **[DIRECT ANSWER]** Real-world medical device penetration testing most often finds hardcoded or default credentials, unsecured or unencrypted communication channels, outdated third-party components, weak access controls, and firmware lacking integrity checks, each of which can let an attacker alter therapy or expose patient data. Manufacturers should follow secure coding standards like IEC 62304, maintain an SBOM, and adopt a secure product development framework rather than relying only on late-stage penetration testing to catch these flaws. In the world of healthcare technology, medical devices have become increasingly interconnected and sophisticated. While these advancements have revolutionized patient care, they have also introduced new cybersecurity risks that cannot be ignored. This blog post will examine the top 10 most common and dangerous vulnerabilities discovered during real-world medical device penetration testing, providing practical insights and actionable advice for manufacturers, healthcare providers, and cybersecurity professionals. ## Key Takeaways - Hardcoded credentials enable unauthorized device access. - Unsecured communication jeopardizes patient data privacy. - Outdated components introduce exploitable weaknesses. - Poor access control allows privilege escalation. - Disabled debug interfaces prevent deep system access. - Weak firmware integrity checks risk malicious modification. ## Why this matters The stakes for medical device cybersecurity are uniquely high, directly impacting patient safety and clinical outcomes. A compromised device can lead to serious patient harm or even death, far exceeding the impact of a typical data breach. The FDA, in its final guidance “Cybersecurity in Medical Devices” dated February 3, 2026, emphasizes the critical need for manufacturers to integrate cybersecurity throughout the total product lifecycle, from design to post-market surveillance. This guidance mandates rigorous pre-market evaluations and continuous post-market monitoring to mitigate risks. Key industry standards like IEC 62304 for medical device software life cycle processes, ISO 14971 for risk management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles for medical device security are vital for identifying and mitigating vulnerabilities. Manufacturers must proactively address issues such as weak authentication, insecure data transmission, and vulnerabilities in third-party components. Failure to do so not only risks patient well-being but also regulatory penalties, reputational damage, and significant financial liabilities. Prioritizing cybersecurity is not merely a compliance issue; it is a fundamental pillar of responsible medical device manufacturing. ## The Importance of Penetration Testing in MedTech Penetration testing, or “pen testing,” is a critical process in medical device cybersecurity. It involves simulating the tactics and techniques of malicious actors to identify vulnerabilities before they can be exploited. As the [Blue Goat Cyber](/) team explains: > _“Penetration testing is in its essence trying to simulate what a bad hacker is doing before they can do it. If a good guy hacks into a device, they responsibly and ethically tell the manufacturer of the device how they did it so that they can go and fix these problems before it’s in the market. It’s going to lead to a safer product as opposed to waiting for someone with maybe more malicious intentions to find these vulnerabilities first.”_ Unlike traditional cybersecurity, which often focuses on data breaches and information disclosure, the stakes are much higher in the medical device industry. As Myles Kellerman, the Director of MedTech Cybersecurity at Blue Goat Cyber, explains: > _“If somebody hacks into a defibrillator and shocks you to death, it’s a little bit more severe than your credit card information being stolen. You can recover from your credit card information being stolen, but you can’t recover if you die from being shocked to death, obviously. So, the risk is much greater.”_ This unique risk profile requires a specialized approach to cybersecurity, one that blends traditional information security principles with a deep understanding of patient safety and the regulatory landscape of the medical device industry. ## The Top 10 Medical Device Vulnerabilities Based on their extensive experience conducting penetration tests on real-world medical devices, the team at Blue Goat Cyber has identified the top 10 most common and dangerous vulnerabilities. Let’s dive into each one and explore practical examples, industry standards, and mitigation strategies. ### 1\. Hardcoded or Default Credentials One of the most prevalent vulnerabilities discovered during pen testing is the presence of hardcoded or default credentials in medical devices. As Myles Kellerman explains, this issue is all too common: > _“We’ve seen many examples of this. A lot of times where I see it is in static code analysis, we will see these passwords hardcoded in, and then with device access as well when we’re physically testing medical devices, we’ll find that certain menus are using default passwords that can clearly be looked up on the internet or just best guess passwords either using the company name or just as simple as admin admin or password one two three.”_ Beyond just default passwords, the team has also encountered issues with BIOS passwords that are either hardcoded or not enabled at all, which can lead to devastating consequences if exploited. To address this vulnerability, manufacturers should follow industry standards such as [IEC 62304](/blog) for secure software development and [IEC 81001-5-1](/blog/the-relationship-of-iec-81001-5-1-2021-with-medical-device-security) for the total product life cycle. These standards emphasize the importance of proper password management, secure coding practices, and continuous monitoring to identify and mitigate emerging threats. ### 2\. Unsecured Communication Channels Another common vulnerability found in medical devices is the lack of secure communication channels, particularly regarding data encryption. As Myles Kellerman explains: > _“We’re looking at data flows that are encrypted. So encryption in transit to protect the patient data if there is any part of that data flow. And so some of the things we see are no encryption at all for the data in transit, and that includes PHI or PII being part of those data flows, or maybe they’re using encryption but it’s maybe a standard that’s no longer supported or has been sunsetted.”_ Beyond just the type of encryption used, the team has also encountered issues with poor key management, where the encryption keys are easily discoverable, rendering the encryption useless. To mitigate this vulnerability, manufacturers should follow the guidance provided by the [FDA’s Cybersecurity for Medical Devices](https://www.fda.gov/media/119933/download "") initiative, which recommends the use of the latest encryption standards, such as those outlined in [FIPS 140-3](/blog). Additionally, they should implement key management practices to ensure the confidentiality and integrity of sensitive data. ### 3\. Outdated or Vulnerable Third-Party Components Medical devices often rely on a complex ecosystem of third-party software components, and the failure to properly manage and maintain these components can lead to significant vulnerabilities. As the Blue Goat Cyber team explains: > _“We’ve already talked about the fact that medical systems have higher risk than other systems just because we’re dealing with patient safety. But moving through regulated industries is much harder than say, you know, I know in the past we’ve talked about the Silicon Valley mindset, move fast and break things. \[…\] But in a regulated industry such as healthcare, there are processes that need to be followed, standards you need to adhere to, documentation requirements and traceability that is just far too commonly missing.”_ To address this vulnerability, manufacturers should implement a [Software Bill of Materials (SBOM)](/services) process, which involves continuously monitoring and updating their devices’ third-party components to identify and mitigate emerging threats. ### 4\. Improper Access Control Weak or improper access control is another common vulnerability found in medical devices, both at the logical and physical levels. As the Blue Goat Cyber team explains: > _“When we’re looking at access control, that’s the FDA terminology would be authentication. So, how are we determining who is authenticated into different levels of permission, different amounts of information, different levels of access? \[…\] We see this all too often where one user is able to read another user’s information. This can be very dangerous especially if they have PHI involved or one user can say like a general user can access an admin role.”_ Myles Kellerman has also encountered issues with web applications, where low-privilege users can access admin functions or bypass authentication mechanisms altogether: > _“A lot of times I’ll find that the low-privilege user can use an admin function that it’s not intended to be able to use or even see and then that goes into like information disclosure of patient data even. So it can really get nasty with not having a proper pen test that checks the access controls.”_ To address this vulnerability, manufacturers should implement authentication and authorization mechanisms, following industry standards such as [IEC 81001-5-1](/blog/iec-80001-1-enhancing-medical-device-cybersecurity) for risk management in IT networks incorporating medical devices. ### 5\. Debug Interfaces Left Enabled Medical devices often include debug interfaces, such as UART and JTAG ports, which can be exploited if enabled in production devices. As the Blue Goat Cyber team explains: > _“JTAG and UART will be a little bit different from say a USB port which is intended to be exposed on the outside. But if we have a JTAG port, UART port, usually that’s going to be on a printed circuit board itself. So that’s deeper in the system. If you need to shred apart the plastic on a device, tear it open to access that port, that’s going to be evidence enough of compromise.”_ While these debug interfaces can be useful for maintenance and updates, they must be properly secured or disabled in production devices to prevent unauthorized access and potential exploitation. Manufacturers should implement controls such as JTAG and UART authentication, as well as tamper-evident seals, to mitigate this vulnerability and ensure the integrity of their medical devices. ### 6\. Missing or Weak Firmware Integrity Checks Ensuring the integrity of a medical device’s firmware is crucial, as any unauthorized modifications can have severe consequences. As the Blue Goat Cyber team explains: > _“If someone can flash on their own firmware or modify the existing firmware, it can be extremely dangerous because they can change it to do pretty much anything they want. And this is why we do white box penetration testing to cover these things which would reveal even the type of microcontroller and chipset that a manufacturers’s chosen because certain microcontrollers don’t support secure boot.”_ To address this vulnerability, manufacturers should implement secure boot processes and code signing mechanisms, as recommended by the [FDA’s Cybersecurity for Medical Devices](https://www.fda.gov/media/119933/download "") guidance. ### 7\. Poor Session Management Weak session management can leave medical devices vulnerable to [session hijacking](/blog/understanding-relevant-threats-for-medical-devices) and other attacks. As Myles Kellerman explains: > _“Poor session management, the top form that I see a lot would be if the session does not have a timeout period. So for example, if I can I log in, a session’s created for me while I’m logged in and then what happens next is I hit the log off button and then better security would be to have that session invalidated as soon as I hit the logoff button.”_ To mitigate this vulnerability, manufacturers should implement session management controls, such as session timeouts, session invalidation upon logout, and session activity logging to detect potential session hijacking attempts. ### 8\. Fuzzing Vulnerabilities (Buffer Overflows) Fuzzing, the process of sending unexpected or malformed inputs to a system, can often reveal vulnerabilities such as buffer overflows. As the Blue Goat Cyber team explains: > _“Fuzzing is pretty much just taking tons of different bits of input and putting it at a certain field or connection that is meant to receive input. \[…\] And often times there will be a problem where the system does not handle it properly on the back end and this can lead to most commonly a denial of service which is when the system can no longer operate due to receiving unexpected input that causes it to crash and this is often through a buffer overflow.”_ While buffer overflow vulnerabilities are becoming less common in modern software, they are still a concern, especially in legacy medical devices that may be using older, memory-unsafe programming languages. Manufacturers should ensure that their devices are designed and implemented with modern, memory-safe coding practices to mitigate this risk. ### 9\. Lack of Tamper Detection Ensuring the physical and logical integrity of a medical device is crucial, as any unauthorized modifications can have severe consequences. As the Blue Goat Cyber team explains: > _“If we look at a device where you’re able to just pop it apart, it has, you know, maybe one or two screws and the whole thing falls apart and you can put it back together without anyone noticing. That wouldn’t be great control. But we often recommend that you can put like tamper evidence stickers that need to be signed by a service technician over these panels. So if there the panel is open that sticker would need to be torn or cut and then you have a labeling control saying hey you know before using the device check these stickers make sure they’re intact and if you see that one is broken you assume the device has been compromised and tampered with and you shouldn’t use it.”_ In addition to physical tamper detection, manufacturers should also implement audit trails and logging mechanisms to detect any unauthorized logical modifications to the device. ### 10\. No Rate Limiting or Automation Controls The lack of rate limiting or automation controls can leave medical devices vulnerable to brute-force attacks and other automated exploitation attempts. As the Blue Goat Cyber team explains: > _“Brute forcing attacks are a low-hanging fruit for a lot of hackers. And brute forcing is trying to just use a ton of different passwords against a single login or a single password against a whole bunch of login and trying to see if they can get a match. \[…\] If we see that we can try our phone password 10,000 times and nothing happens, then we can set up an automation, which is what we’re doing in these cases, which does these 10,000 attempts in a matter of seconds.”_ To mitigate this vulnerability, manufacturers should implement rate limiting and automation controls to prevent brute-force attacks and other automated exploitation attempts. ## Secure Product Development Frameworks and DevSecOps While penetration testing is a valuable tool for identifying vulnerabilities, it is a reactive approach. To truly address the cybersecurity challenges facing the medical device industry, manufacturers should adopt a proactive, holistic approach to secure product development. This includes implementing secure product development frameworks, such as those outlined in IEC 62304 and IEC 81001-5-1, and embracing [DevSecOps practices](/blog) to integrate security throughout the entire product life cycle. As Christian Espinosa, the CEO and founder of Blue Goat Cyber, emphasizes: > _“Penetration testing is more reactive. And unfortunately when we’re called into to do penetration testing, we find a lot of vulnerabilities that often result in a lot of extra effort on the manufacturer to fix them versus if they would have enabled a secure product development framework early on.”_ ## Regulatory Perspective and the Importance of Patient Safety The medical device industry is heavily regulated, and for good reason. As the Blue Goat Cyber team explains: > _“The FDA and other regulatory authorities, they don’t want your device to be safe most of the time. They want it to be safe all of the time because the risk is super high. \[…\] There’s very little room for error in a lot of these medical devices and we need to make sure that that’s considered when we’re handling security there.”_ Manufacturers must prioritize patient safety above all else, and this requires a approach to cybersecurity that goes far beyond checkbox compliance. Every vulnerability uncovered during penetration testing is a reminder that patient lives depend on secure devices, not just functional ones. At Blue Goat Cyber, we’ve seen firsthand how even small oversights-default passwords, outdated components, weak encryption-can lead to significant risks if left unaddressed. But we’ve also seen the power of proactive security: organizations that embrace penetration testing, implement Secure Product Development Frameworks (SPDFs), and align with global regulatory expectations consistently bring safer, more trusted devices to market. The path forward is clear: cybersecurity must be woven into the DNA of medical device development, from design through postmarket management. By doing so, manufacturers reduce risk and avoid regulatory delays and strengthen their competitive position in a MedTech landscape. The bottom line? Cybersecurity isn’t just about protecting systems; it’s about protecting patients. And when patients can trust the devices that support their care, the entire healthcare ecosystem becomes stronger. Ready to strengthen your medical device cybersecurity? [Contact Blue Goat Cyber today](/contact) to schedule a penetration test or learn how our experts can help you achieve FDA and global regulatory compliance with confidence. ## The ten vulnerabilities by patient impact and fix cost Ranking by severity score alone misleads. What matters is what a patient experiences and what it costs you to close. | Vulnerability | Realistic patient impact | Cost to fix late | | --- | --- | --- | | Hardcoded credentials | Full device control by anyone with the firmware | Low in code, high in fielded units | | Unsigned firmware updates | Attacker-supplied firmware on a treating device | High, usually a bootloader change | | Open debug interfaces | Key extraction and code modification on the bench | High if it needs a board change | | Unencrypted wireless traffic | Exposure of readings and command injection | Moderate | | Weak or absent authentication | Unauthorized therapy or setting changes | Moderate | | Outdated third-party components | Public exploits available on day one | Ongoing, not one time | | No integrity checking at boot | Persistent compromise that survives reset | High | | Excessive network services | More ways in than the design ever needed | Low | | Poor key management | One compromised unit exposes the fleet | High | | No security logging | You cannot prove what happened after an incident | Low to moderate | ## How Blue Goat approaches this Our approach to identifying medical device vulnerabilities utilizes a rigorous, multi-faceted methodology. We perform detailed threat modeling and penetration testing, simulating real-world attack scenarios to uncover weaknesses before malicious actors can exploit them. Our team comprises industry experts, including CISSP and OSCP certified professionals, with backgrounds in ex-military red team operations, ensuring a deep understanding of attacker tactics. We assess devices against relevant standards such as IEC 62304 and the FDA's "Cybersecurity in Medical Devices" guidance. Our testing includes scrutinizing hardcoded credentials, communication protocols, software integrity, and access controls. This allows us to provide actionable insights for manufacturers to remediate vulnerabilities and enhance device security. We also offer thorough support for regulatory submissions; if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our capabilities at [https://bluegoatcyber.com/services/medical-device-penetration-testing](https://bluegoatcyber.com/services/medical-device-penetration-testing). ## FAQ ### What is penetration testing for medical devices? Penetration testing for medical devices involves simulating cyberattacks to identify vulnerabilities before malicious actors can exploit them. This proactive approach helps manufacturers strengthen device security and protect patient safety. ### Why are hardcoded credentials a significant risk? Hardcoded or default credentials allow unauthorized users, including attackers, to gain access to device functions and sensitive data without proper authentication. These are often easy to discover or widely known. ### How does the FDA guidance address medical device cybersecurity? The FDA's February 3, 2026 final guidance recommends strong cybersecurity measures, including secure design, vulnerability management, and Ensure the confidentiality and integrity of data. It emphasizes a total product lifecycle approach to security. ### What risks do unsecured communication channels pose? Unsecured communication channels can expose sensitive patient data (PHI/PII) to interception and tampering. Lack of proper encryption or use of outdated encryption standards makes devices vulnerable during data transmission. ### What is an SBOM and why is it important? A Software Bill of Materials (SBOM) is a formal record listing the components in a software product. It helps manufacturers identify, track, and manage third-party components, which matters for addressing vulnerabilities in the supply chain. ### Can debug interfaces be a security risk? Yes, if debug interfaces like UART or JTAG ports are left enabled or unsecured in production devices, they can provide deep access to the system for unauthorized users. These must be properly secured or disabled. --- ## More on this topic - [LoRaWan Vulnerabilities on Medical](/blog/lorawan-vulnerabilities-on-medical-device-cybersecurity) - [Medical Device MedRadio Vulnerabilities](/blog/examining-medradio-vulnerabilities-in-medical-devices-cybersecurity) - [Enhancing Medical Device Security: Tamper](/blog/enhancing-medical-device-security-tamper-proof-seals-and-cybersecurity-labeling) --- ## BLE Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/top-ble-cybersecurity-vulnerabilities # BLE Vulnerabilities in Medical Devices: What Manufacturers Need to Know > **[DIRECT ANSWER]** The BLE vulnerabilities that matter most for FDA-regulated devices are device spoofing, man-in-the-middle interception, and replay attacks, each exploiting weak pairing, missing encryption, or unauthenticated command channels to manipulate therapy or steal data. Manufacturers should mitigate these with AES encryption, certificate-based authentication, and regular firmware updates, then document the threat model and test results to satisfy Section 524B premarket requirements under the FDA's February 3, 2026 guidance. Bluetooth Low Energy (BLE) is now embedded in nearly every connected medical device class - continuous glucose monitors, insulin pumps, cardiac wearables, hearing aids, surgical tools, and clinician programmers. For FDA-regulated manufacturers, BLE is also one of the most aggressively scrutinized attack surfaces in 2026 premarket reviews under **Section 524B** and the **Feb 3, 2026 final FDA premarket cybersecurity guidance** (which supersedes the September 2023 and June 2025 versions). This guide walks through the BLE vulnerabilities medical device teams must threat-model, test, and document - and how each maps to a defensible §524B submission package. ## Key Takeaways - BLE is critical for connected medical devices. - Address device spoofing in risk management. - Mitigate man-in-the-middle attacks. - Prevent replay attacks on device functions. - Implement encryption and authentication. - Follow FDA cybersecurity guidance (2026). ## Why this matters BLE vulnerabilities in medical devices pose significant risks to patient safety, data confidentiality, and device functionality. Exploiting these weaknesses can lead to unauthorized access, alteration of therapy, or exposure of protected health information. The FDA, in its final guidance dated February 3, 2026, emphasizes the critical need for medical device manufacturers to proactively identify and mitigate cybersecurity risks, particularly those associated with wireless technologies like BLE, throughout the entire product lifecycle. Compliance with this guidance is essential for regulatory clearance and demonstrates a commitment to patient welfare. Failing to address BLE cybersecurity in premarket submissions, such as 510(k)s, can result in delays, additional review cycles, or outright refusal of market authorization. Relevant standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide frameworks for risk management and security by design, which are crucial for developing defensible mitigation strategies for BLE-enabled devices. Manufacturers must not only identify potential threats but also demonstrate effective testing and validation of their security controls to ensure the device's trustworthiness and resilience against cyberattacks. ## Understanding BLE Cybersecurity Before we discuss the vulnerabilities, let’s understand BLE cybersecurity. BLE is a wireless communication protocol that allows devices to exchange data over short distances. It is designed for low power consumption and is commonly used in Internet of Things (IoT) devices. ![Section Image](/imported-images/862562c06918d28c.webp) So, what does BLE cybersecurity entail? Simply put, it involves safeguarding these BLE devices against unauthorized access, data breaches, and malicious attacks. This is crucial because compromised BLE devices can disrupt their intended functionality and become potential entry points for hackers to infiltrate larger systems. ### What is BLE Cybersecurity? BLE cybersecurity focuses on protecting the confidentiality, integrity, and availability of data exchanged between BLE devices. It involves implementing encryption, authentication, and authorization mechanisms to prevent unauthorized access and ensure that data remains secure. ### Importance of BLE Cybersecurity The significance of BLE cybersecurity cannot be overstated. With the proliferation of BLE devices, ranging from smartwatches to industrial sensors, our lives have become highly interconnected. Imagine the consequences if these devices were compromised. Personal information could be exposed, critical infrastructure could be disrupted, and even lives could be at stake. Thus, addressing the vulnerabilities in BLE cybersecurity and adopting security measures is imperative. One of the challenges in BLE cybersecurity is the limited range of the protocol. While this low power consumption feature is advantageous in terms of energy efficiency, it also means that the signal strength is weaker, making it susceptible to eavesdropping attacks. Hackers can potentially intercept the communication between BLE devices by using specialized equipment within close proximity. Another vulnerability lies in the encryption algorithms used in BLE. While encryption is essential to BLE cybersecurity, it is not foolproof. Weak encryption algorithms or improper implementation can leave the data vulnerable to brute force attacks or cryptographic vulnerabilities. Developers and manufacturers must stay updated with the latest encryption standards and best practices to ensure the highest level of security. ## Common BLE Cybersecurity Vulnerabilities ![Section Image]() ### Device Spoofing One of the prominent vulnerabilities in BLE cybersecurity is device spoofing. Hackers can impersonate legitimate BLE devices, tricking users into connecting to malicious devices. This allows attackers to access sensitive data or execute malicious actions. Device spoofing can be particularly dangerous when BLE devices are used for critical functions, such as in healthcare or industrial settings. Malicious actors could disrupt [operations or compromise patient safety by spoofing essential devices](/blog/top-10-embedded-operating-systems-for-medical-devices). ### Man-in-the-Middle Attacks Another concerning vulnerability is the man-in-the-middle attack. In this scenario, an attacker can intercept communication between two BLE devices and manipulate the sent data. This enables them to eavesdrop on confidential information or even inject malicious commands into the communication. [Man-in-the-middle](/blog) attacks are a serious threat to the integrity and confidentiality of data exchanged between BLE devices. By exploiting this vulnerability, attackers can potentially steal sensitive information, such as login credentials or personal data, leading to serious privacy breaches. ### Replay Attacks Replay attacks involve recording and replaying data packets exchanged between BLE devices. This allows attackers to mimic legitimate devices and replay captured commands or actions. As a result, they can gain unauthorized access or manipulate the device’s behavior. Replay attacks pose a significant risk to the security of BLE devices. Attackers can use captured data to impersonate authorized users or devices. By replaying commands or actions, malicious actors can disrupt normal device operations or perform unauthorized actions without detection. ## Impact of BLE Cybersecurity Vulnerabilities ![Section Image]() ### Potential Risks and Threats Compromised BLE devices can expose users’ personal information, financial data, and physical safety. For instance, an attacker could gain unauthorized access to a smart lock’s authentication mechanism, allowing them to enter a person’s home undetected. Additionally, unauthorized access to medical devices could threaten patient safety and privacy. The interconnected nature of BLE devices means that a single vulnerability could have far-reaching consequences. A security breach in one device could potentially compromise an entire network of connected devices, amplifying the impact of the initial attack. ### Consequences of Ignoring BLE Cybersecurity If the cybersecurity vulnerabilities in BLE devices are ignored, the consequences can be dire. Organizations may face legal and financial repercussions due to data breaches and privacy violations. Users could suffer from identity theft, financial loss, or physical harm. Moreover, the trust in BLE technology could erode, hindering its growth and potential. Stakeholders in the BLE ecosystem must collaborate on improving cybersecurity measures, from implementing encryption protocols to regularly updating firmware to patch known vulnerabilities. By prioritizing cybersecurity, we can continue enjoying BLE technology’s benefits while minimizing the associated risks. > **Shipping a BLE-enabled device?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Medical device penetration testing](/services/medical-device-penetration-testing) ## Mitigating BLE Cybersecurity Vulnerabilities Fortunately, measures can be taken to mitigate the cybersecurity vulnerabilities inherent in BLE devices. Let’s explore some security measures and best practices to protect against threats. When securing BLE devices, it’s also crucial to consider the physical layer. Physical security measures, such as tamper-evident packaging and secure boot processes, can prevent unauthorized access to the device itself. Additionally, implementing secure coding practices during the development phase can help reduce the likelihood of introducing vulnerabilities into the device’s software. ### Security Measures for BLE Devices Implementing encryption algorithms, such as [AES (Advanced Encryption Standard)](/blog), can protect the data transmitted between BLE devices. Additionally, using digital signatures and certificate-based authentication can ensure the integrity and authenticity of the exchanged data. Another important aspect of securing BLE devices is properly configuring device permissions. Limiting the permissions granted to different device functionalities and services can minimize the attack surface for potential exploits. Regularly monitoring and auditing these permissions can help detect unauthorized changes that could compromise the device’s security. ### Best Practices for BLE Cybersecurity Adopting good cybersecurity practices can significantly enhance the security of BLE devices. This includes regularly updating device firmware, validating the integrity of devices and applications, and educating users about potential risks and how to mitigate them. Furthermore, conducting thorough security assessments and penetration testing can help identify vulnerabilities and proactively address them. One often overlooked aspect of BLE cybersecurity is the secure disposal of devices. Properly decommissioning BLE devices by wiping sensitive data and ensuring they are securely erased before disposal or recycling can prevent data leakage and unauthorized access to confidential information. By incorporating secure disposal practices into the device lifecycle, organizations can further safeguard their data and protect against potential security breaches. ## Future of BLE Cybersecurity ### Emerging Trends in BLE Cybersecurity With the increasing adoption of BLE technology, we can expect advancements in security measures and protocols specifically tailored for BLE devices. Machine learning algorithms and artificial intelligence can be leveraged to detect anomalies and potential threats in real-time, enhancing the overall security posture. One emerging trend in BLE cybersecurity is the use of blockchain technology. Blockchain, known for its decentralized and tamper-proof nature, can provide additional security for BLE devices. By storing transactional data in a distributed ledger, it becomes extremely difficult for hackers to manipulate or tamper with the information, ensuring the integrity and confidentiality of BLE communications. ### Predicted Challenges and Solutions However, along with these advancements, new challenges may arise. The rapid proliferation of BLE devices may strain security resources and expertise. Therefore, organizations must invest in continuous research and development to keep up with evolving threats. Collaboration between industry experts, researchers, and policymakers is crucial to address [BLE cybersecurity’s legal and ethical implications](/blog/the-importance-of-ble-in-medical-devices-cybersecurity). Another challenge is the potential for quantum computing to break current encryption algorithms. As quantum computers become more powerful, they could threaten the security of BLE devices. To combat this, researchers are already exploring post-quantum cryptography, which utilizes mathematical problems resistant to quantum attacks. BLE devices can maintain their security despite quantum computing advancements by implementing post-quantum cryptographic algorithms. ## Conclusion The vulnerabilities in BLE cybersecurity pose significant risks to our interconnected world. Understanding these vulnerabilities, their impact and the measures to mitigate them is paramount. By implementing security measures, adopting best practices, and staying vigilant, we can ensure the safety and privacy of BLE devices. Let’s create a secure and resilient future for BLE technology. As you navigate the complexities of BLE cybersecurity, remember that the right expertise can make all the difference. Blue Goat Cyber, a Veteran-Owned leader in cybersecurity, stands ready to guide you through the evolving threats in the digital landscape. Our specialized services in medical device cybersecurity, penetration testing, and compliance are designed to integrate into your business operations, offering protection and a strategic advantage. Don’t let cybersecurity vulnerabilities leave you exposed. [Contact us today for cybersecurity help](/contact), and partner with Blue Goat Cyber to transform your cybersecurity challenges into opportunities for growth and resilience. ## How Blue Goat approaches this Blue Goat Cyber's approach to BLE cybersecurity in medical devices focuses on identifying and remediating vulnerabilities efficiently for FDA submissions. Our methodology includes detailed threat modeling specific to BLE implementations, penetration testing to uncover exploitable flaws, and thorough documentation of mitigation strategies. We assess device spoofing, man-in-the-middle attacks, and replay attacks, ensuring all findings are aligned with the FDA's cybersecurity guidance dated February 3, 2026. Our team, comprised of professionals with certifications like CISSP and OSCP, including former military red team members, provides actionable insights and supports manufacturers in preparing their 510(k) cybersecurity documentation. We streamline the testing and validation process, aiming for a smooth regulatory review. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What are common BLE vulnerabilities in medical devices? Common BLE vulnerabilities include device spoofing, where an attacker impersonates a legitimate device; man-in-the-middle attacks, where communication is intercepted; and replay attacks, where recorded data packets are replayed to gain unauthorized access. ### How can device spoofing impact medical devices? Device spoofing can allow unauthorized devices to connect to a medical device, potentially leading to data exfiltration, manipulation of device settings, or disruption of critical functions, impacting patient care and safety. ### How does the FDA evaluate BLE cybersecurity in medical devices? The FDA evaluates BLE cybersecurity based on the February 3, 2026, guidance, requiring manufacturers to identify, assess, and mitigate cybersecurity risks. This includes demonstrating strong controls against common vulnerabilities in premarket submissions. ### What mitigation strategies should be used for BLE vulnerabilities? Effective mitigation strategies include implementing strong encryption (e.g., AES), secure authentication, authorization mechanisms, regular firmware updates, secure coding practices, and complete security testing. ### Why is BLE cybersecurity important for patient safety? Compromised BLE in medical devices can directly jeopardize patient safety by allowing unauthorized access to devices that deliver therapy, monitor vital signs, or manage critical health data, leading to incorrect treatment or privacy breaches. **Related:** [20 Medical Device Protocols: Security Flaws, FDA Guidance, and Examples](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [AJAX Vulnerabilities in Medical Devices](/blog/medical-device-sql-injection-parameterized-queries) - [JTAG and UART Vulnerabilities in Medical](/blog/navigating-the-intersection-of-jtag-uart-debug-ports-and-fda-compliance-in-medical-device-cybersecurity) - [NFC & BLE Security in Medical Devices](/blog/nfc-and-medical-device-cybersecurity) - [Secure Software Dev for Medical Devices](/blog/secure-software-development-for-medical-devices-ensuring-safety-and-compliance) --- ## Traditional vs Medical Device Cybersecurity (2026) Source: https://bluegoatcyber.com/blog/traditional-cybersecurity-vs-medical-device-cybersecurity # Traditional vs Medical Device Cybersecurity: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Traditional IT cybersecurity protects data confidentiality and business continuity using fast patch cycles, while medical device cybersecurity protects patient safety and clinical function across devices that often stay in service for 10 to 20 years and require rigorous clinical validation before any update. The FDA's February 3, 2026 guidance requires manufacturers to manage this longer, higher-stakes lifecycle with specialized risk management, incident response, and regulatory documentation that general IT frameworks like ISO 27001 do not cover. _Reviewed July 24, 2026_ Cybersecurity is a pressing concern across various sectors in today’s digital age. While many know traditional cybersecurity, medical device cybersecurity remains less understood. This article aims to untangle these complex subjects, highlighting key differences. ## Key Takeaways - Medical device cybersecurity prioritizes patient harm prevention. - Traditional cybersecurity protects data and business operations. - Medical devices have longer lifecycles than IT assets. - FDA regulations uniquely govern medical device security. - Patching medical devices requires rigorous clinical validation. - Incident response differs due to patient care implications. ## Why this matters The distinction between traditional and medical device cybersecurity is profoundly significant because the stakes involve human life. An attack on a medical device can lead to physical harm, delayed treatment, or even death, a far more severe outcome than typical data breaches or financial losses in traditional IT. This necessitates specialized approaches to security architecture, risk management, and incident response. The FDA, in its "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, emphasizes that manufacturers must proactively integrate cybersecurity throughout the total product lifecycle, from design to post-market surveillance. This guidance underscores the unique regulatory landscape for medical devices, which contrasts sharply with the general data protection regulations governing traditional IT. Furthermore, medical device cybersecurity often involves compliance with specific standards such as IEC 81001-5-1 (Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product lifecycle) and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management), focusing on factors like usability in clinical settings and the challenge of patching legacy systems still in use decades after their release. The implications for patient care, privacy, and the operational integrity of healthcare systems make this area a critical concern for manufacturers, providers, and regulatory bodies alike. ## At a glance | Dimension | Traditional IT Cybersecurity | Medical Device Cybersecurity | |:--- |:--- |:--- | | **Primary Goal** | Protect data confidentiality and business continuity. | Ensure patient safety and device clinical functionality. | | **Typical Asset** | Laptops, servers, cloud databases, and mobile apps. | Infusion pumps, MRI machines, and implantable pacemakers. | | **Lifecycle** | Fast-paced; hardware replaced every 3-5 years. | Long-term; devices often remain in service 10-20 years. | | **Patching Process** | Automated, frequent updates with minimal testing required. | Slow; requires rigorous validation to ensure clinical safety. | | **Security Risk** | Financial loss, identity theft, and reputational damage. | Physical harm, treatment delays, or loss of life. | | **Regulatory Focus** | GDPR, HIPAA, and industry-specific frameworks like PCI-DSS. | FDA pre-market/post-market guidance and ISO/IEC 81001-5-1. | | **Common Attacks** | Phishing, ransomware, and credential harvesting. | DoS on critical functions, unauthorized telemetry, and malware. | | **Key Tradeoff** | Productivity versus access controls. | Security hardening versus emergency access for clinicians. | ## Understanding Traditional Cybersecurity Traditional cybersecurity refers to the mechanisms and strategies to protect networks, devices, and data from unauthorized access or attacks. It safeguards information systems across diverse industries, ensuring confidentiality, integrity, and availability. ### Definition and Importance of Traditional Cybersecurity Cybersecurity is the defense of computers, servers, mobile devices, electronic systems, networks, and data from malicious threats. Its importance cannot be overstated. With the growing dependence on technology, the threats lurking in the digital shadows have become increasingly sophisticated. Organizations must prioritize cybersecurity to prevent data breaches, identity theft, and financial loss. The infamous [Equifax breach of 2017](https://www.fbi.gov/news/stories/chinese-hackers-charged-in-equifax-breach-021020) serves as a stark reminder; it exposed the personal information of 147 million people. This colossal breach stressed the need for cybersecurity practices. The repercussions of such incidents extend beyond immediate financial losses; they can erode customer trust and tarnish an organization’s reputation for years to come, highlighting the critical need for ongoing vigilance and investment in cybersecurity measures. ### Core Principles of Traditional Cybersecurity At its core, traditional cybersecurity is built on several [fundamental principles](/blog): - **Confidentiality:** Ensuring that sensitive information is accessed only by authorized individuals. - **Integrity:** Protecting information from being altered or destroyed in an unauthorized manner. - **Availability:** Ensuring that systems and data are accessible to authorized users when needed. These principles guide organizations in establishing effective cybersecurity strategies. Each element plays a role in fortifying the digital fortresses against potential attackers. For instance, implementing encryption protocols can enhance confidentiality, while regular audits and checks can help maintain data integrity. Furthermore, backup solutions are essential to ensure availability, allowing organizations to recover quickly from incidents that might compromise their systems. ### Common Threats in Traditional Cybersecurity Traditional cybersecurity faces an array of threats. Cybercriminals continuously innovate, devising new methods to exploit vulnerabilities. Some common threats include: 1. **Malware**: Malicious software, such as viruses and ransomware, that disrupts operations. 2. **Phishing**: Deceptive emails aimed at tricking individuals into revealing sensitive information. 3. **DDoS Attacks**: Distributed Denial of Service attacks overwhelm systems, making them inaccessible. These threats can cause significant financial and reputational damage. Organizations must remain vigilant and proactive to mitigate risks. Additionally, insider threats pose another layer of complexity; employees with malicious intent or those who inadvertently compromise security can lead to devastating breaches. Therefore, building a culture of cybersecurity awareness through training and education is vital, empowering employees to recognize potential threats and respond appropriately. ## Delving into Medical Device Cybersecurity Integrating [connected medical devices](/blog) into healthcare systems amplifies the need for specialized cybersecurity as technology advances. Medical device cybersecurity focuses on protecting these devices from cyber threats. ![Section Image](/imported-images/5124e404fd07b922.png) ### Defining Medical Device Cybersecurity Medical device cybersecurity involves safeguarding devices that monitor or treat patients. These devices range from simple heart monitors to complex surgical robots. As they increasingly connect to the internet, they become viable targets for cyber attacks. Healthcare organizations must implement stringent cybersecurity measures to ensure the safety and effectiveness of these devices. A cyber incident affecting a life-saving device can have dire consequences. ### Unique Aspects of Medical Device Cybersecurity Medical device cybersecurity presents unique challenges not typically found in traditional cybersecurity. - **Regulatory Scrutiny:** Medical devices are heavily regulated by entities like the [FDA](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity). Compliance is paramount. - **Real-time Security:** Healthcare providers often need to balance security with the need for immediate patient care. - **Device Lifecycle Management:** Devices have long lifecycles, necessitating ongoing updates and patches. These factors complicate the implementation of security protocols. They require collaboration among manufacturers, healthcare providers, and regulatory bodies. Moreover, the rapid pace of technological advancements means that security measures must evolve continuously. Manufacturers are increasingly being called upon to [incorporate security features during the design phase](/blog) rather than as an afterthought to mitigate potential vulnerabilities immediately. ### Potential Risks in Medical Device Cybersecurity The risks associated with inadequate medical device cybersecurity are alarming. A compromised device could deliver incorrect dosages, misreport patient data, or even be remotely controlled by malicious actors. In 2019, the FDA issued warnings about vulnerabilities in insulin pumps, urging patients to secure their devices. Such incidents highlight the urgent need for attention in this niche. Additionally, the interconnected nature of healthcare systems means that a breach in one device can potentially lead to a cascading effect, compromising other devices and systems. This interconnectedness underscores the importance of risk assessments and the implementation of multi-layered security strategies encompassing individual devices and the entire healthcare infrastructure. ## Comparing Traditional Cybersecurity and Medical Device Cybersecurity While traditional and medical device cybersecurity share common goals, they diverge significantly. ![Section Image](/imported-images/4f0411cf57139c71.png) ### Similarities Between the Two Domains Both fields aim to protect sensitive information and maintain operational integrity. They utilize many of the same tools and techniques, such as firewalls, encryption, and multi-factor authentication. Both areas also emphasize the importance of regular software updates. Ultimately, both seek to minimize risks that could harm individuals or organizations. However, the context and nuances of each present unique challenges. ### Key Differences Highlighted The distinction between the two realms becomes clearer when we examine key differences: - **Stakeholders:** Traditional cybersecurity generally involves IT departments, while medical device cybersecurity necessitates collaboration between IT, clinical engineering, and healthcare practitioners. - **Risk Tolerance:** Traditional organizations may have different risk thresholds than healthcare organizations, where patients’ lives are at stake. - **Incident Response:** Medical device cybersecurity requires a more agile and specialized response plan due to real-time implications. In short, while both domains aim to mitigate cybersecurity threats, their application, urgency, and methodologies often differ significantly. ### Regulatory Frameworks and Compliance Another critical difference lies in the regulatory frameworks governing each field. Traditional cybersecurity is often guided by industry standards such as [ISO/IEC 27001](/blog) or NIST guidelines, which provide a broad data protection and risk management framework. In contrast, medical device cybersecurity is subject to stringent regulations from bodies such as the FDA in the United States and the [European Medicines Agency in Europe.](https://www.ema.europa.eu/en/homepage) These regulations dictate how devices should be secured and impose rigorous testing and validation processes to ensure that security measures do not interfere with the device’s primary function. This added layer of scrutiny reflects the high stakes involved in healthcare, where compromised devices can directly impact patient safety. ### Impact of Emerging Technologies The rapid advancement of technology further complicates the cybersecurity landscape in both domains. In traditional cybersecurity, the rise of cloud computing and the [Internet of Things (IoT)](/blog) has introduced new vulnerabilities, necessitating updated security protocols and strategies. Meanwhile, innovations in medical devices such as telemedicine and connected health devices have transformed patient care and expanded the attack surface for cyber threats. As these devices become increasingly interconnected, the potential for cyberattacks grows, prompting a need for more sophisticated security measures to adapt to evolving threats while ensuring compliance with regulatory standards. This dynamic environment requires continuous education and adaptation from all stakeholders, emphasizing the importance of staying informed about technological advancements and emerging cyber risks. ## Implications of Differences in Cybersecurity Practices Understanding these differences impacts organizations by informing their cybersecurity practices. ### Impact on Risk Management Strategies Organizations need tailored risk management strategies. Traditional strategies may not suffice for patient safety. The healthcare sector must formulate a unique paradigm, emphasizing rapid response and proactive risk mitigation. Incorporating direct feedback from medical professionals can enhance these strategies significantly. They bring a firsthand perspective on what threats could impact patient care. Furthermore, integrating advanced data analytics into risk management can help identify emerging threats and vulnerabilities, allowing organizations to avoid potential cyber incidents. By using predictive modeling, healthcare organizations can anticipate risks based on historical data, thus refining their strategies to address specific challenges unique to their operational environment. ### Influence on Regulatory Compliance Regulatory requirements differ considerably. Healthcare organizations must comply not only with general cybersecurity standards but also with specific medical device regulations. The FDA, for instance, mandates stringent security guidelines for new devices. This [regulatory complexity](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) amplifies the need for compliance frameworks explicitly tailored for medical devices. Additionally, organizations must remain vigilant about evolving regulations, as governmental bodies frequently update guidelines in response to new threats. This necessitates ongoing training and education for staff to ensure compliance is maintained across all levels of the organization. Regular audits and assessments can also help identify compliance gaps, allowing for timely adjustments to policies and practices. ### Effect on Incident Response Planning Incident response plans must be agile. In healthcare, every second counts. An effective incident response plan should involve IT professionals and clinical staff. This collaborative approach ensures swift action to secure devices and protect patient welfare. Regular simulations and [tabletop exercises](/blog) can prepare teams for real-world scenarios, enhancing their ability to respond effectively under pressure. These drills improve coordination among various departments and help identify weaknesses in the response plan. By building a culture of preparedness, healthcare organizations can significantly reduce the impact of cyber incidents on patient care and operational continuity. Understanding the nuances between traditional cybersecurity and medical device cybersecurity equips organizations to address threats effectively. ## Conclusion While both areas fall under the cybersecurity umbrella, the key differences demand tailored approaches. Recognizing these distinctions is vital for safeguarding sensitive data and, more importantly, ensuring patient safety in the expanded digital healthcare landscape. The need for specialized cybersecurity strategies becomes more critical as the digital healthcare landscape evolves. Blue Goat Cyber stands at the forefront of medical device cybersecurity, offering unparalleled expertise and services that align with FDA, IEC 62304, and EU MDR requirements. With a proven track record of guiding over 100 devices through FDA submissions and a commitment to secure development and early threat mitigation, our expert team is equipped to ensure your medical devices are compliant and resilient against cyber threats. Don’t let cybersecurity challenges hinder your mission to enhance patient safety. [Contact us today for cybersecurity help](/contact) and partner with a leader in healthcare security to build a secure future for your medical technology. ## How Blue Goat approaches this Blue Goat Cyber approaches medical device cybersecurity with a specialized understanding of healthcare environments and regulatory demands. Our methodology integrates threat modeling, penetration testing, and security architecture reviews tailored to medical device lifecycles and clinical contexts. We ensure alignment with the FDA's "Cybersecurity in Medical Devices" Final Guidance, bringing deep expertise to pre-market and post-market compliance. Our professionals, including CISSP and OSCP certified experts, many with ex-military red team experience, identify vulnerabilities and propose practical, effective safeguards. Blue Goat Cyber does not just identify risks; we offer actionable strategies for mitigation. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to protect innovation while prioritizing patient safety and regulatory adherence. Visit our services at: /services/fda-premarket-cybersecurity-services. ## FAQ ### What is the primary goal of medical device cybersecurity? The primary goal of medical device cybersecurity is to ensure patient safety and maintain the clinical functionality of medical devices. This focus distinguishes it from traditional cybersecurity, which often prioritizes data confidentiality and business continuity. ### How does the FDA influence medical device cybersecurity? The FDA significantly influences medical device cybersecurity by establishing rigorous pre-market and post-market guidance. Manufacturers must adhere to these regulations, such as the February 3, 2026 final guidance, to ensure devices are designed and maintained securely throughout their lifecycle. ### Why do medical devices have such long lifecycles? Medical devices often have long lifecycles, sometimes remaining in service for 10-20 years, due to their high cost, complexity, and critical role in patient care. This extended lifespan poses unique challenges for cybersecurity, as devices must remain secure against evolving threats for many years. ### What unique challenges does patching present in medical device cybersecurity? Patching medical devices is uniquely challenging because updates require rigorous validation to ensure they do not compromise clinical safety or device functionality. This contrasts with traditional IT environments, where automated and frequent updates are common. The patching process is often slower and more deliberate. ### Does medical device cybersecurity handle the same threats as traditional IT? While there is some overlap, medical device cybersecurity faces unique threats such as denial-of-service attacks on critical device functions and unauthorized telemetry, which could directly impact patient treatment. Traditional IT more commonly experiences phishing, ransomware, and credential harvesting. ### Can a cyberattack on a medical device cause physical harm? Yes, a cyberattack on a medical device can cause physical harm or even death. Compromised devices could deliver incorrect dosages, misreport vital patient data, or be remotely controlled by malicious actors, leading to severe consequences for patients. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Why Hooded Hackers Hurt Medical Device](/blog/medical-device-cybersecurity-the-real-threat-isnt-genius-hackers-its-neglect) - [Ephemeral Ports in Medical Device](/blog/understanding-relevant-threats-for-medical-devices) - [Enhancing Medical Device Security: Tamper](/blog/enhancing-medical-device-security-tamper-proof-seals-and-cybersecurity-labeling) --- ## Types of 510(k): Traditional, Special, Abbreviated Source: https://bluegoatcyber.com/blog/types-of-510k-traditional-special-abbreviated-cybersecurity # Types of 510(k): Traditional, Special, and Abbreviated Explained > **[DIRECT ANSWER]** The FDA recognizes three types of 510(k): Traditional, Special, and Abbreviated. Traditional is the default 90-day pathway for most Class II devices. Special is a 30-day pathway for a manufacturer's own modification to its cleared device using well-established evaluation methods. Abbreviated is a 90-day pathway that leans on FDA-recognized consensus standards. All three must satisfy FD&C Act Section 524B for cyber devices. Picking the wrong 510(k) type is one of the fastest ways to burn a quarter of your regulatory calendar. A Special 510(k) filed for a change that expands the attack surface will get bumped to Traditional at Acceptance Review. An Abbreviated 510(k) filed without a matching declaration of conformity to a recognized standard will get the same treatment. Cybersecurity makes the choice harder, not easier. Since the Feb 3, 2026 the FDA final guidance took effect, reviewers scrutinize the security risk profile of the change - not just the code diff. This guide compares the three 510(k) types on eligibility, review clock, format, and the cybersecurity package each one actually needs. ## Key Takeaways - Three 510(k) types exist: Traditional (90-day goal), Special (30-day goal), and Abbreviated (90-day goal using consensus standards). - Every 510(k) type is subject to Section 524B and the Feb 3, 2026 the FDA premarket cybersecurity guidance - the pathway does not shrink the artifact list. - Special 510(k) requires *your own* cleared predicate and well-established evaluation methods; cybersecurity changes that expand attack surface get pushed to Traditional. - Abbreviated 510(k) trades narrative testing for declarations of conformity to FDA-recognized standards like ANSI/AAMI SW96:2023 and IEC 62304. - eSTAR is mandatory for all three types since Oct 2023; the cybersecurity section is the most-cited driver of Refuse-To-Accept (RTA) holds. - A Pre-Sub is the cheapest way to confirm the pathway before you assemble the package. ## Why This Matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) applies to every 510(k) - Traditional, Special, and Abbreviated - because Section 524B of the FD&C Act does not distinguish among the three. Reviewers expect the same seven-section cybersecurity package: SPDF documentation, threat model, SBOM, security architecture views, security risk assessment, penetration test evidence, and a postmarket monitoring plan. The FY2024 CDRH performance report shows cybersecurity remains among the top three deficiency categories cited in 510(k) Acceptance Review holds, behind only software documentation and clinical evidence. That statistic is pathway-agnostic - a Special 510(k) does not get a lighter cybersecurity review, only a faster clock. Applicable standards include IEC 62304 (software lifecycle), ISO 14971 (risk management), and ANSI/AAMI SW96:2023 (medical device security risk management, which replaced AAMI TIR57 as the primary reference in the 2026 guidance). ## What Are the Three Types of 510(k)? The three 510(k) types are defined in the FDA's guidance *The Special 510(k) Program* (Sept 2019) and *The Abbreviated 510(k) Program* (Sept 2019), both of which remain current. They are not different regulatory outcomes - all three result in a "substantially equivalent" clearance decision under 21 USC 360(k). They differ in *how* you build the case for substantial equivalence and *how fast* the FDA promises to review it. ## Traditional vs Special vs Abbreviated: Side-by-Side | Dimension | Traditional 510(k) | Special 510(k) | Abbreviated 510(k) | |---|---|---|---| | Review clock (MDUFA goal) | 90 FDA days | 30 FDA days | 90 FDA days | | Predicate | Any legally marketed predicate | Your own cleared device only | Any legally marketed predicate | | Basis for substantial equivalence | Direct performance comparison | Design controls + risk analysis on your own change | Declaration of conformity to FDA-recognized consensus standard(s) | | When to use | Default; new device or predicate not yours | Modification to your own device using well-established evaluation methods | Change or new device where a recognized standard fully addresses performance | | Cybersecurity package | Full seven-section package | Full seven-section package scoped to the change | Full seven-section package + declarations of conformity | | eSTAR mandatory | Yes (since Oct 2023) | Yes | Yes | | Common rejection trigger | Missing/weak pen test, incomplete SBOM | Change expands attack surface or alters intended use | Declaration cites a non-recognized version of the standard | ## When Do You Use a Traditional 510(k)? Use a Traditional 510(k) as the default. It applies when you are a first-time submitter for the device, when the predicate belongs to another manufacturer, when your change to a cleared device is significant enough to affect safety or effectiveness, or when no consensus standard fully covers the performance claims you need to make. Traditional is also the fallback when a Special or Abbreviated submission gets converted by the FDA during Acceptance Review - which happens roughly 20% of the time for Special submissions per the FDA's public 510(k) statistics. ## When Does a Special 510(k) Actually Apply? A Special 510(k) applies when *all* of the following are true: the modification is to your own legally marketed device, the modification does not alter the intended use, the modification does not alter the fundamental scientific technology, and the performance data needed to evaluate the change comes from *well-established evaluation methods* whose results can be sufficiently reviewed in a summary or risk-analysis format. For cybersecurity changes, "well-established evaluation methods" is the sticking point. Rotating a signing certificate under an existing PKI usually qualifies. Adding a new BLE advertising service does not - it expands the attack surface and triggers a new threat-modeling cycle. See our companion post on [Special vs Traditional 510(k) for cybersecurity changes](/blog/special-vs-traditional-510k-cybersecurity-changes) for the decision tree. ## When Is an Abbreviated 510(k) the Right Move? An Abbreviated 510(k) is the right move when performance can be demonstrated through conformity to one or more FDA-recognized consensus standards, an FDA-issued guidance document, or a special control. You submit summary reports and declarations of conformity instead of full test reports. For a connected medical device, the standards that most often carry the Abbreviated pathway are IEC 62304 for software lifecycle, IEC 81001-5-1 for health-software security, and ANSI/AAMI SW96:2023 for security risk management. Verify the exact recognition number and version on the FDA's Recognized Consensus Standards database before filing - a declaration to an outdated edition is a common RTA trigger. ## How Cybersecurity Requirements Differ by 510(k) Type They do not differ in *scope* - Section 524B is pathway-agnostic. They differ in *format and framing*. **Traditional:** Full narrative for every artifact. Threat model, SBOM with VEX, security architecture views (global, multi-patient harm, updateability, security use case), security risk assessment, pen test report, and postmarket plan - each with its own detailed evidence. **Special:** Same seven artifacts, but scoped to the delta. The threat model updates the sections touched by the change. The SBOM shows before/after. The pen test focuses on the changed surface. Reviewers still expect a complete, standalone cybersecurity section in eSTAR. **Abbreviated:** Same seven artifacts, but performance claims can reference a declaration of conformity. The SBOM and pen test still need to be filed as evidence - the standard does not replace them, it just lets you point to it for methodology. > **[KEY REQUIREMENT]** Regardless of type, every 510(k) for a "cyber device" (as defined in Section 524B(c)) must include: a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities; a process for CVD; and an SBOM. Omit any of the three and the submission is rejected at Acceptance Review. ## How Blue Goat Approaches This Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We start every engagement with a pathway assessment - Traditional, Special, or Abbreviated - because the cybersecurity package needs to be scoped to the clock and the format the FDA expects, not built generically and reshaped later. For clients unsure of the right pathway, we prepare a targeted Pre-Sub to confirm it with the FDA before assembling the full submission. Every artifact - threat model, SBOM, security risk assessment, penetration test, labeling - traces back to a controlled requirement and a verified result, aligned with the Feb 3, 2026 guidance. See our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) for scope. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** ## FAQ ### What are the three types of 510(k) submissions? The FDA recognizes Traditional, Special, and Abbreviated 510(k) submissions. Traditional is the default 90-day pathway. Special is a 30-day pathway limited to a manufacturer's own modification to its cleared device using well-established evaluation methods. Abbreviated is a 90-day pathway that relies on declarations of conformity to FDA-recognized consensus standards, guidance documents, or special controls. ### Does the cybersecurity package change with 510(k) type? No. Section 524B applies to every 510(k) type, so the seven-section cybersecurity package - SPDF documentation, threat model, SBOM, architecture views, security risk assessment, penetration test, and postmarket plan - is required in all three. Only the *depth of narrative* changes: Special scopes to the delta, Abbreviated can reference consensus standards, Traditional requires full narrative. ### Is a Special 510(k) always faster than a Traditional? Only if the FDA accepts it as a Special. Roughly one in five Special 510(k) submissions is converted to Traditional at Acceptance Review, restarting the clock at 90 days. For cybersecurity changes, submitting a Pre-Sub before filing is the reliable way to confirm the pathway. ### Can I file an Abbreviated 510(k) for a connected medical device? Yes, if FDA-recognized consensus standards cover the performance you need to demonstrate. For connected devices, IEC 62304, IEC 81001-5-1, and ANSI/AAMI SW96:2023 are the standards most commonly used. Verify the recognition number and edition on the FDA's Recognized Consensus Standards database before submitting. ### Is eSTAR required for all three 510(k) types? Yes. Since Oct 1, 2023, eSTAR has been mandatory for all 510(k) submissions - Traditional, Special, and Abbreviated. The cybersecurity section within eSTAR is identical across the three types and is the most-cited driver of Refuse-To-Accept holds. ## Ready to Confirm the Right 510(k) Type? If you are weighing Traditional, Special, or Abbreviated for an upcoming submission, we will map your change to the right pathway and build the cybersecurity package to match. [Schedule a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - and if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. **Related:** - [Special vs Traditional 510(k) for cybersecurity changes](/blog/special-vs-traditional-510k-cybersecurity-changes) - [Letter to File vs new 510(k) for cybersecurity changes](/blog/letter-to-file-vs-new-510k-cybersecurity-changes) - [Preparing your eSTAR 510(k) cybersecurity documentation](/blog/preparing-your-estar-510k-cybersecurity-documentation) - [510(k) cybersecurity deficiencies that trigger the FDA holds](/blog/510k-cybersecurity-deficiencies-that-trigger-fda-holds) - [Q-Sub vs Pre-Sub: FDA cybersecurity guide](/blog/q-sub-vs-pre-sub-fda-cybersecurity) ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance across Traditional, Special, and Abbreviated 510(k) pathways. [Read more about Christian](/christian-espinosa). --- ## Medical Device AI Performance Drift Source: https://bluegoatcyber.com/blog/understanding-ai-performance-drift-ensuring-medical-device-safety # Medical Device AI Performance Drift: What Manufacturers Need to Know > **[DIRECT ANSWER]** AI performance drift is the gradual decline in an AI-enabled medical device's accuracy as real-world data patterns diverge from its training data, which can cause misdiagnosis or inappropriate treatment recommendations over time. Manufacturers should mitigate it through continuous model retraining on diverse datasets, real-time anomaly monitoring, and feedback loops, since the FDA's February 3, 2026 guidance expects postmarket mechanisms to detect and respond to this kind of performance degradation. _Reviewed July 24, 2026_ AI performance drift refers to changes in artificial intelligence systems’ performance over time. This can occur for various reasons, including shifts in data patterns, evolving user needs, or changes in the AI’s environment. Understanding this phenomenon is crucial for stakeholders in the medical device industry, especially as reliance on AI becomes increasingly prevalent. ## Key Takeaways - AI drift alters model performance over time. - Monitor AI regularly to detect performance shifts. - Drift can compromise device accuracy and patient safety. - Continuous retraining and diverse data mitigate drift. - Strong monitoring enhances trust and ensures reliability. - Proactive strategies are vital for long-term safety. ## Why this matters The stakes surrounding AI performance drift in medical devices are exceptionally high, directly impacting patient safety and treatment efficacy. A diagnostic AI tool that degrades over time could misclassify diseases, leading to incorrect diagnoses, delayed interventions, or even unnecessary treatments. Such failures undermine trust in AI-powered medical technologies and can result in severe adverse events for patients. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes the necessity for postmarket cybersecurity management, which inherently includes monitoring for and addressing AI drift. This guidance calls for mechanisms to detect and respond to changes in a device's risk posture or performance due to evolving threats or operational shifts. Relevant standards like IEC 81001-5-1, ISO 13485, and AAMI TIR57 / ANSI/AAMI SW96:2023 also highlight the importance of risk management, quality systems, and secure product development lifecycles that anticipate and manage performance degradation. Proactive management of AI drift is not merely a technical challenge but a regulatory and ethical imperative to ensure the long-term reliability and safety of medical devices using artificial intelligence. ## The Basics of AI Performance Drift At its core, AI performance drift can be likened to a ship slowly veering off course. Initially, the journey may seem smooth, but over time, minor deviations can lead to significant misalignments. Even slight variations in AI predictions can have substantial implications for patient safety and treatment efficacy in healthcare. Performance drift can manifest in several ways, including **_declining accuracy and increased error rates_**. It often raises alarms among healthcare professionals and technology developers alike. Recognizing and addressing drift is imperative to ensure that AI-driven medical devices continue to perform optimally. Furthermore, the underlying algorithms may require periodic retraining with fresh data to adapt to new trends and patterns, underscoring the importance of continuous monitoring and evaluation in AI systems. ## How AI Performance Drift Impacts Medical Devices The implications of AI performance drift in medical devices can be dire. Imagine a diagnostic tool that begins misclassifying diseases due to out-of-date training data. The consequences could range from misdiagnosis to unnecessary treatments, endangering lives. The impact is not just direct. A single malfunction can erode trust in the technology itself. Patients and healthcare providers may hesitate to use AI-assisted devices, fearing unreliable results. This erosion of trust can significantly slow down advancements in AI technology, which in turn hampers potential innovations in patient care. Additionally, the financial repercussions for healthcare institutions can be substantial, as they may face increased liability and costs associated with corrective measures, retraining staff, and potentially compensating affected patients. Proactive strategies such as implementing monitoring systems and establishing feedback loops are essential to combat AI performance drift. These systems can help identify performance issues in real-time, allowing for timely interventions. Furthermore, building collaboration between data scientists, clinicians, and [regulatory bodies](https://www.fda.gov/media/184856/download) can lead to more effective strategies for maintaining AI performance, ensuring that these technologies meet current standards and evolve with the changing landscape of healthcare needs. ## The Role of AI in Medical Device Safety ![Section Image](/imported-images/643234970dcdb6da.png) ### AI’s Contribution to Medical Device Functionality AI has many benefits for medical devices. For instance, AI algorithms can analyze vast amounts of patient data in mere seconds, uncovering patterns that would otherwise go unnoticed. This ability enhances diagnostic accuracy and enables personalized treatment plans. Additionally, AI can facilitate real-time monitoring. Wearable devices can track patients’ vital signs and alert doctors to anomalies instantaneously. These capabilities can lead to quicker responses in emergencies, ultimately saving lives. AI can assist in predictive analytics, forecasting [potential health issues](/blog) before they arise. By identifying at-risk patients through historical data trends, healthcare providers can implement preventive measures, thereby reducing hospital admissions and improving overall patient outcomes. ### Potential Risks of AI in Medical Devices However, with great power comes great responsibility-or, in this case, significant risk. AI-driven medical devices can face vulnerabilities, from data breaches to algorithmic biases. A biased AI model could draw faulty conclusions, leading to inappropriate treatments, a risk that cannot be taken lightly. If an AI’s training data does not represent the diversity of the population it serves, there could be a significant risk of health disparities. These unintended consequences highlight the importance of continuous monitoring and improvement of AI systems. In addition to these concerns, the lack of transparency in how AI algorithms make decisions poses a challenge for healthcare professionals. Clinicians may struggle to trust AI-generated recommendations if they cannot understand the underlying rationale, which could hinder the adoption of these technologies in clinical settings. Thus, building a collaborative environment where AI tools complement human expertise is essential for maximizing the benefits while minimizing the risks associated with AI in medical devices. ## Monitoring AI Performance Drift in Medical Devices Effective monitoring techniques are essential in mitigating the risks posed by AI performance drift. [Regular assessments](/services/medical-device-penetration-testing) ensure that AI systems remain aligned with current medical standards and patient needs. After all, keeping an eye on the ship’s compass is just as important as steering the wheel. ### Importance of Regular Monitoring Regular monitoring acts as an early warning system, signaling when an AI system begins to drift. This proactive approach allows for timely interventions, ensuring patient safety remains paramount. Just as a mechanic regularly checks an engine to prevent breakdowns, healthcare professionals must consistently evaluate AI performances. Ongoing monitoring builds trust among users. When healthcare providers know that AI systems are actively supervised, they are more likely to embrace these technologies. This collaboration can lead to improved patient outcomes. Trust is particularly crucial in healthcare settings, where the stakes are high and the margin for error is minimal. Healthcare organizations can cultivate a safety and accountability culture by demonstrating a commitment to rigorous monitoring and reassuring practitioners and patients alike. ### Techniques for Tracking AI Performance Drift Several techniques can be employed to track AI performance drift. One standard method is to establish benchmarks based on historical data. Deviations can be quickly identified and addressed by comparing ongoing AI performance against these benchmarks. Another effective strategy involves feedback loops. Collecting data from user interactions with AI systems helps confirm accuracy levels and identify emerging trends or concerns. By implementing such practices, healthcare providers can significantly enhance the reliability of their AI-driven medical devices. Additionally, integrating real-time analytics can provide deeper insights into AI performance, enabling healthcare teams to respond swiftly to any anomalies. This dynamic approach enhances the adaptability of AI systems and ensures that they evolve alongside advancements in medical knowledge and technology. Involving interdisciplinary teams in the monitoring process can enrich the evaluation of AI performance. By bringing together data scientists, clinicians, and regulatory experts, healthcare organizations can create a more monitoring framework. This collaboration helps ensure that various perspectives are considered, leading to more assessments and informed decision-making. Integrating diverse expertise is essential in navigating the complexities of AI in healthcare, particularly as regulations and ethical considerations continue to evolve. ## Mitigating the Effects of AI Performance Drift A proactive, multi-faceted approach is essential to mitigate the effects of AI performance drift. Strategies must be in place to reduce drift and ensure safety. A penny saved is a penny earned, but in healthcare, prevention is the name of the game. ### Strategies for Reducing AI Performance Drift One effective strategy is continuous model retraining. Regularly updating AI models with new data can minimize the likelihood of drift. Think of it as feeding the AI system fresh fruits, keeping it nourished and equipped to handle new challenges. Additionally, diverse datasets should be utilized in training models. Incorporating varied patient demographics ensures that the AI system can respond appropriately to a wide range of scenarios. This diversity strengthens the AI’s applicability, leading to better health outcomes. ### Ensuring Safety Despite AI Performance Drift Ensuring safety in the face of potential AI performance drift requires vigilance and resilience. Companies must be prepared to intervene swiftly if drift is detected. protocols for emergency interventions must be instituted, enabling rapid responses to avert risks. building a culture of safety within organizations enhances readiness. Every team member should be educated about the potential implications of performance drift, empowering them to be part of the solution. Remember, it takes a village to raise a child and a committed team to uphold patient safety. ## Future Perspectives on AI Performance Drift and Medical Device Safety As technology evolves, so too will our understanding of AI performance drift and its impact on medical device safety. The horizon is not just about challenges; it also shines with promising developments that could redefine patient care. ### Predicted Developments in AI for Medical Devices We can expect AI systems to become increasingly with advancements in [machine learning algorithms](/blog) and data collection practices. Future AI models may employ adaptive learning techniques, allowing them to adjust in real-time based on fresh data inputs. Additionally, we may see the emergence of more intuitive interfaces that enable healthcare professionals to interact with AI systems more effectively, reducing the chances of human error. This progressive trajectory holds the promise of enhanced efficiency in healthcare delivery. ### The Long-Term Impact of AI Performance Drift on Medical Device Safety The long-term effects of AI performance drift on medical device safety will depend mainly on how proactively stakeholders address these issues. If left unmonitored, drift could lead to significant healthcare challenges in the future. Yet, by embracing continual learning and adaptation, we can cultivate an environment where AI augments, rather than undermines, patient safety. Together, we can ensure that technology and healthcare partnerships flourish, ultimately creating a safer, healthier world. ## Conclusion As we navigate the complexities of AI performance drift and its implications for medical device safety, the need for expert guidance and cybersecurity measures has never been more critical. Blue Goat Cyber, with its deep expertise in medical device cybersecurity and a proven track record of FDA compliance support, stands ready to assist manufacturers in ensuring that their devices are compliant and resilient against evolving cyber threats. Our tailored healthcare security services provide the technical rigor and human-focused strategies essential for safeguarding patient safety. Don’t let AI performance drift compromise your medical device’s integrity. [Contact us today for cybersecurity help](/contact) and partner with a team prioritizing your device’s security throughout its lifecycle. ## How Blue Goat approaches this Blue Goat Cyber addresses AI performance drift through structured methodologies focused on continuous monitoring and risk adaptation. Our approach begins with establishing baselines and implementing real-time anomaly detection systems tailored to device-specific AI models. We integrate these systems into a cyclical feedback loop, ensuring that insights from deployed devices inform future training and model updates. Our team, with its background including CISSP and OSCP certifications, along with ex-military red team experience, brings a pragmatic and security-first perspective to AI lifecycle management. We emphasize proactive identification of drift indicators, enabling timely intervention before patient safety is compromised. Our services, which can include threat modeling, help anticipate potential failure points and data integrity issues that contribute to drift. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [FDA postmarket cybersecurity services](/services/fda-postmarket-cybersecurity-services). ## FAQ ### What is AI performance drift in medical devices? AI performance drift in medical devices is the decline in an AI model's accuracy and reliability over time, often due to changes in real-world data or operating environments. This can lead to incorrect diagnostic or treatment recommendations. ### How does AI performance drift impact patient safety? AI performance drift directly impacts patient safety by increasing the risk of misdiagnosis, inappropriate treatment, or faulty interpretation of critical health data. Unaddressed drift can lead to adverse health outcomes. ### What causes AI models to drift in medical devices? AI models drift due to several factors, including shifts in patient demographics, changes in disease prevalence, updates to clinical protocols, or environmental alterations that affect data input. Evolving data patterns are a primary cause. ### How can medical device manufacturers prevent AI performance drift? Manufacturers can prevent AI performance drift through continuous model retraining with fresh, diverse datasets, implementing strong monitoring systems, and establishing feedback loops. Proactive detection and intervention are key. ### Does the FDA address AI performance drift in medical devices? Yes, the FDA addresses the challenges of AI performance drift. The February 3, 2026 final guidance emphasizes the need for medical device manufacturers to implement postmarket surveillance and maintenance for AI-enabled devices to manage AI drift effectively. ### What techniques can track AI performance changes? Techniques for tracking AI performance changes include establishing benchmarks for expected behavior, using real-time analytics to detect anomalies, and implementing feedback loops from clinical use to identify discrepancies. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Interoperable Medical Device Risk Source: https://bluegoatcyber.com/blog/understanding-and-mitigating-the-risks-of-interoperable-medical-devices # Interoperable Medical Device Risk: What Manufacturers Need to Know > **[DIRECT ANSWER]** Interoperable medical devices exchange data across manufacturers and systems, which improves care coordination but creates cybersecurity risk through unauthorized access, data breaches, and incorrect data exchange between devices like glucose monitors and insulin pumps. Mitigating that risk requires strong authentication and encryption, accurate data validation protocols, and staff training, all aligned with the FDA's February 3, 2026 guidance on lifecycle risk management for interoperable systems. _Updated Novermber 16, 2024_ Modern healthcare relies heavily on interconnected systems and devices for efficient and effective patient care. One area that has gained significant attention in recent years is interoperable medical devices. These devices are designed to exchange data and communicate with each other, enhancing healthcare delivery and patient outcomes. However, with the benefits come potential risks that must be understood and mitigated for such devices’ safe and secure use. ## Key Takeaways - Interoperable devices enhance patient care through data exchange. - Cybersecurity threats and data privacy issues are key risks. - The FDA regulates device safety and cybersecurity. - Risk mitigation requires strong technical and organizational controls. - Healthcare staff training is vital for safe device use. - Patient education promotes informed decision-making. ## Why this matters The increasing reliance on interoperable medical devices presents significant stakes for patient safety and data integrity. While these devices enhance care coordination and efficiency, their interconnected nature can introduce vulnerabilities that malicious actors might exploit. A breach could compromise patient data, disrupt device function, and directly impact patient health outcomes. The FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, explicitly outlines the need for manufacturers to consider cybersecurity throughout the total product lifecycle. This guidance, alongside standards like IEC 81001-5-1 (Health software, security activities in the product life cycle), ISO 14971 (Medical devices, Application of risk management to medical devices), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management), emphasizes a proactive, risk-based approach to securing these complex systems. Failure to address these risks can lead to regulatory non-compliance, financial penalties, and a loss of public trust in medical technology. Protecting these systems is not just a regulatory obligation but a moral imperative. ## Defining Interoperable Medical Devices Interoperable medical devices can exchange and use information with other devices, systems, or software applications from different manufacturers and vendors. This facilitates the integration and sharing of data, promoting interoperability and streamlining workflow in healthcare settings. ![Section Image](/imported-images/afc62027e3d58fa6.png) ### The Role of Interoperable Devices in Modern Healthcare [Interoperable devices](/blog/medical-device-cybersecurity-interoperability-concerns) play a crucial role in modern healthcare by improving the efficiency, accuracy, and accessibility of patient care. For example, interoperability allows different devices, such as glucose monitors and insulin pumps, to communicate, enabling real-time monitoring and adjustment of insulin dosages for patients with diabetes. This integration eliminates the need for manual data entry and reduces the risk of errors. The use of interoperable devices extends beyond diabetes management. In emergencies, interoperability allows for communication between various medical devices, such as defibrillators, vital sign monitors, and electronic health records (EHR) systems. This enables healthcare professionals to quickly access critical patient information and make informed decisions, ultimately saving lives. ### Key Features of Interoperable Medical Devices Interoperable medical devices possess key features that enable data exchange and integration. These include standardized data formats, [common communication protocols,](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) and secure authentication mechanisms. By adhering to these standards, interoperable devices can communicate effectively, ensuring the accuracy and integrity of the exchanged data. Interoperable devices often incorporate advanced data encryption techniques to protect patient privacy and maintain data security. This ensures that sensitive medical information remains confidential and is only accessible to authorized healthcare professionals. Additionally, interoperable devices are designed with user-friendly interfaces, allowing healthcare providers to easily navigate and interpret the exchanged data, enhancing overall usability and efficiency. ## The Potential Risks of Interoperable Medical Devices Despite the numerous benefits of interoperable medical devices, there are inherent risks associated with their use. Identifying and addressing these risks is important to safeguard patient safety and maintain data privacy. ### Security Concerns in Interoperability Interoperable medical devices are vulnerable to cybersecurity threats, such as unauthorized access, data breaches, and malware attacks. These risks can compromise patient privacy and the integrity of healthcare data. Several high-profile incidents have highlighted the need for security measures to design, implement, and use interoperable devices in recent years. One example of a cybersecurity threat in interoperable medical devices is the possibility of a hacker gaining unauthorized access to a patient’s implanted device, such as a [pacemaker](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know) or insulin pump. This could have severe consequences, as the hacker could potentially manipulate the device’s settings, leading to life-threatening situations for the patient. To mitigate this risk, manufacturers and healthcare providers must ensure strong authentication protocols and encryption mechanisms to protect device communication and prevent unauthorized access. ### Patient Safety and Data Privacy Issues Interoperability introduces new challenges regarding patient safety and data privacy. For instance, if an interoperable device receives incorrect data from another device, it could lead to wrong diagnoses or inappropriate treatments. This emphasizes the importance of accurate and reliable data exchange protocols between devices, as any errors or discrepancies can have serious implications for patient care. The sharing of patient data among multiple devices and systems raises concerns about data privacy and consent. Patients must be confident that their personal information is adequately protected and only accessible to authorized individuals. To address this issue, healthcare organizations must implement stringent data privacy policies and ensure that patients have full control over their data, including the ability to grant or revoke consent for its sharing. Additionally, healthcare professionals must receive proper training on using interoperable devices to minimize the risk of errors or misuse. This includes understanding the limitations and potential risks associated with these devices and knowing how to interpret and validate the data they provide. ## Regulatory Landscape for Interoperable Devices The healthcare industry is regulated to ensure the safety, effectiveness, and proper use of medical devices. Similarly, the [regulatory landscape](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) for interoperable devices is constantly evolving to address the unique challenges associated with their use. Interoperable medical devices are designed to communicate and exchange information with other devices and systems, enabling healthcare providers to access and share critical patient data. This interoperability has the potential to revolutionize healthcare delivery, improving patient outcomes and streamlining workflows. However, it also introduces new complexities and risks that regulators must address. ### Current Regulations and Standards The Food and Drug Administration (FDA) has developed guidelines and policies for regulating interoperable medical devices in the United States. These guidelines emphasize the importance of cybersecurity, risk management, and human factors engineering in designing, developing, and using such devices. For instance, the FDA recognizes the need for cybersecurity measures to protect against potential threats and vulnerabilities. They require manufacturers to implement safeguards to prevent unauthorized access, ensure data integrity, and maintain the confidentiality of patient information. Additionally, the FDA emphasizes the importance of human factors engineering, which involves designing devices with the end-user in mind to minimize the risk of user error and enhance usability. Similarly, international organizations, such as the International Electrotechnical Commission (IEC) and the International Organization for Standardization (ISO), have established standards for interoperable medical devices to ensure global compatibility and safety. These standards address various aspects, including data exchange protocols, device interoperability, and safety requirements. ### Future Regulatory Trends As technology advances, regulators are working to adapt and enhance regulations for interoperable devices. For example, the FDA is actively exploring approaches to regulating [software as a medical device](/blog), including some interoperable applications. Regulators are also keen on addressing the evolving risks associated with interoperable devices. They recognize that the potential for cybersecurity threats increases as more devices become interconnected. To mitigate these risks, regulators are collaborating with industry stakeholders to develop frameworks that ensure the safe and secure use of interoperable devices. These frameworks aim to establish best practices for cybersecurity, risk management, and data privacy. They encourage manufacturers to implement security measures, conduct thorough risk assessments, and prioritize patient privacy. By doing so, regulators aim to build an environment where healthcare providers and patients can confidently embrace the benefits of interoperable devices without compromising safety or privacy. ## Strategies for Mitigating Risks Mitigating the risks associated with interoperable medical devices requires a multifaceted approach encompassing technical, organizational, and educational measures. ![Section Image](/imported-images/aa7a5c1483dd7a16.png) When implementing security measures, manufacturers and healthcare organizations must go above and beyond to ensure the safety of interoperable devices. They must prioritize security in designing, implementing, and maintaining these devices. This includes adopting encryption and authentication techniques to protect sensitive data from unauthorized access. Regularly updating software and firmware is also essential to stay ahead of potential vulnerabilities that may arise. To ensure the highest level of security, rigorous testing should be conducted to identify and address any potential weaknesses in the devices. Enhancing data privacy protocols is of utmost importance in addition to implementing security measures. Patient data privacy should always be a top priority when dealing with interoperable medical devices. Organizations must take proactive steps to implement strict access controls, encryption, and consent management protocols to protect patient information from unauthorized disclosure. Regular audits and risk assessments should be conducted to identify and address potential privacy risks. By implementing these strategies, manufacturers and healthcare organizations can mitigate the risks associated with interoperable medical devices. This ensures the safety and privacy of patient data and builds trust among healthcare professionals and patients alike. All stakeholders in the healthcare industry must work together to create a secure and interoperable ecosystem that prioritizes patient safety and privacy at every step. ## The Role of Healthcare Professionals in Risk Mitigation Healthcare professionals are critical in mitigating the risks associated with interoperable medical devices through training, education, and patient engagement. ![Section Image](/imported-images/b35b5223143c46b9.png) ### Training and Education for Healthcare Staff Healthcare providers should receive training on the safe and effective use of interoperable devices. This includes understanding the risks associated with interoperability, recognizing signs of cybersecurity threats, and implementing best practices to protect patient privacy. Organizations like the [Association for the Advancement of Medical Instrumentation (AAMI)](/guides/aami-tir57-vs-tir97-comparison) offer training programs and resources for healthcare professionals to enhance their knowledge and skills. ### Promoting Patient Awareness and Education Patients should be educated about the benefits and risks of interoperable medical devices and their role in safeguarding their data privacy. For instance, patients should be encouraged to ask about security measures and how their data will be used and protected. Healthcare organizations can provide educational materials and resources to empower patients to make informed decisions about using interoperable devices. Healthcare professionals can play a crucial role in promoting patient awareness by engaging in open and transparent conversations about the potential risks and benefits of interoperable medical devices. Healthcare professionals can help patients feel more confident and empowered in their healthcare journey by explaining the importance of data privacy and security. Additionally, healthcare professionals can further educate patients on the steps to protect their data privacy. This can include providing guidance on password management, encouraging patients to update their device’s software regularly, and advising them to recognize and report any suspicious activities related to their medical devices. By actively involving patients in the conversation and providing them with the necessary knowledge and tools, healthcare professionals can build a sense of shared responsibility in mitigating the risks associated with interoperable medical devices. ## Interoperability risks at a glance | Interface | The assumption teams make | What actually happens | The control that holds | | --- | --- | --- | --- | | HL7 v2 messaging | The sending system is trusted because it is inside the hospital | Any host on the segment can craft a message | Authenticate the connection, validate the message, log rejections | | DICOM associations | The imaging network is closed | Association requests arrive from unexpected hosts | Called and calling AE title checks plus TLS where the peer supports it | | Middleware and gateways | A pass-through adds no risk | The gateway becomes the highest-value target on the segment | Treat it as a device in its own right in the threat model | | Vendor remote support | Access is temporary | Persistent tunnels outlive the engineer who opened them | Time-bound, per-session credentials with an audit trail | | Shared clinical workstations | One user, one session | Sessions stay open across shifts | Session timeouts and per-user identity, not a shared login | Interoperability failures are rarely exotic. They come from trusting a peer nobody ever authenticated. ## Conclusion Interoperable medical devices have the potential to revolutionize healthcare delivery by enabling data exchange and integration. However, understanding and mitigating the associated risks are crucial to protect patient safety and data privacy. By implementing security measures, enhancing data privacy protocols, and promoting training and education, the healthcare industry can use the benefits of interoperability while ensuring the highest standards of safety and privacy for patients. As healthcare continues to evolve with the integration of interoperable medical devices, the importance of cybersecurity measures has never been more critical. Blue Goat Cyber, a Veteran-Owned business, specializes in medical device cybersecurity and compliance, offering a suite of services to protect your organization from cyber threats. Our expertise in HIPAA and FDA compliance and penetration testing ensures that your medical devices and patient data remain secure. Don’t let cybersecurity concerns hold back the potential of your healthcare technology. [Contact us today for cybersecurity help](/contact) and partner with a team passionate about safeguarding your business and products from attackers. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers and healthcare providers in managing the challenges of interoperable medical device security. Our methodology focuses on identifying and reducing vulnerabilities across the product lifecycle. We employ a skilled team, including CISSP and OSCP certified professionals, with experience from ex-military red teams, to conduct detailed security assessments and penetration testing. Our services include threat modeling, risk assessments, and incident response planning, specifically tailored to the unique demands of medical device ecosystems. We help navigate the regulatory landscape, ensuring compliance with the FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We provide focused solutions to protect patient data and device functionality. Learn more about our offerings at [bluegoatcyber.com/services/medical-device-penetration-testing](https://bluegoatcyber.com/services/medical-device-penetration-testing). ## FAQ ### What are interoperable medical devices? Interoperable medical devices are designed to exchange and utilize information with other devices, systems, or software applications from various manufacturers, facilitating integrated healthcare and streamlined workflows. ### How do interoperable devices benefit healthcare? These devices improve healthcare by increasing efficiency, accuracy, and accessibility of patient care through real-time data exchange, reducing manual efforts, and enabling quicker, more informed medical decisions. ### What are the main risks of interoperable medical devices? The primary risks include cybersecurity vulnerabilities, such as unauthorized access and data breaches, and patient safety concerns arising from incorrect data exchange or privacy breaches. ### How does the FDA regulate interoperable medical devices? The FDA provides guidance and policies, including the February 3, 2026 final guidance on premarket cybersecurity, emphasizing cybersecurity, risk management, and human factors in device design and deployment. ### What strategies mitigate interoperable device risks? Mitigation strategies involve implementing strong security measures, enhancing data privacy protocols, conducting regular risk assessments, and providing complete training for healthcare professionals on safe device use. ### Does Blue Goat Cyber help with interoperable device cybersecurity? Yes, Blue Goat Cyber specializes in medical device cybersecurity consultation, helping manufacturers and healthcare organizations handle interoperable device security and regulatory compliance. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Top 50 Medical Device Cybersecurity Issues](/blog/the-top-50-cybersecurity-issues-with-medical-devices) --- ## Med Device Software Composition Analysis Source: https://bluegoatcyber.com/blog/understanding-binary-software-composition-analysis-with-medical-device-testing # Med Device Software Composition Analysis: What Manufacturers Need to Know > **[DIRECT ANSWER]** Binary Software Composition Analysis (BSCA) examines a medical device's compiled software binaries to identify the third-party and open-source components inside them, revealing security vulnerabilities and licensing risks that source-level reviews can miss. It matters because the FDA's February 3, 2026 final guidance calls for detailed software bills of materials in premarket submissions, and BSCA is a practical way to generate that component-level evidence. _Updated October 26, 2024_ In the fast-paced world of technology, software supports our daily lives. From smartphones to medical devices, software is central to innovation. However, ensuring the security and reliability of software is of utmost importance, especially for critical applications like medical devices. This is where Binary Software Composition Analysis (BSCA) and Medical Device Testing (MDT) come into play. ## Key Takeaways - BSCA analyzes software binaries for third-party components. - Medical devices heavily rely on integrated software. - BSCA helps identify security vulnerabilities in medical devices. - It ensures compliance with software licensing requirements. - Strict FDA regulations necessitate thorough BSCA in MDT. - Proactive risk mitigation enhances patient safety. ## Why this matters The security of medical devices is paramount, directly impacting patient safety and data privacy. Critical patient care infrastructure relies on software, making vulnerabilities in these systems a significant concern. The FDA's February 3, 2026, "Cybersecurity in Medical Devices" final guidance emphasizes the necessity of thorough premarket and postmarket cybersecurity measures, explicitly calling for detailed software bills of materials (SBOMs) derived from processes like Binary Software Composition Analysis (BSCA). Non-compliance with these regulations can lead to enforcement actions, recalls, and reputational damage. Furthermore, industry standards such as IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023 underscore the need for effective risk management and security controls during medical device development and deployment. BSCA directly supports these requirements by providing granular visibility into software components, enabling proactive identification and mitigation of security flaws, license compliance issues, and supply chain risks before they compromise device integrity or patient well-being. ## The Basics of Binary Software Composition Analysis Binary Software Composition Analysis, often abbreviated as BSCA or [SCA (Software Composition Analysis)](/blog), is a process that involves examining the composition of software binaries. But what exactly does this mean? ![Section Image](/imported-images/eedc6164c723a088.webp) Simply put, software binaries are the executable code that drives applications. BSCA aims to analyze these binaries to identify any third-party and open-source components used in the software. By examining the composition of software binaries, organizations can gain insights into potential security vulnerabilities and licensing risks. ### Defining Binary Software Composition Analysis Binary Software Composition Analysis analyzes software binaries to identify third-party and open-source components. These components may include libraries, frameworks, or other pre-built software modules developers utilize to build their applications. By understanding the composition of these components, organizations can better manage security risks and maintain compliance with licensing obligations. ### Importance of Binary Software Composition Analysis The importance of BSCA cannot be overstated, especially in the context of software security. Many modern software applications heavily rely on third-party and open-source components, as they provide time and cost benefits. However, this heavy reliance also introduces potential security vulnerabilities. Take, for example, the [Equifax data breach in 2017](https://www.ftc.gov/enforcement/refunds/equifax-data-breach-settlement). The breach exposed the personal information of millions of people and was caused by a vulnerability in an open-source component used by Equifax’s software. This incident illustrates the significance of thoroughly analyzing software composition to identify and address potential security risks. Another example of the importance of BSCA can be seen in the healthcare industry. With the increasing use of electronic health records and telemedicine platforms, the reliance on software binaries has become crucial. Healthcare organizations must ensure their software is secure and compliant with privacy regulations. By conducting thorough BSCA, they can identify any vulnerabilities or outdated components that may pose a risk to patient data. BSCA also supports managing licensing risks. Many open-source components have specific licensing requirements that organizations must adhere to. Failure to comply with these obligations can result in legal consequences and reputational damage. Organizations can identify licensing issues by conducting a analysis of software binaries and taking appropriate actions to ensure compliance. ## Medical Device Testing Rigorous testing is paramount when it comes to medical devices. These devices often directly impact patients’ health and well-being, making their reliability and safety paramount. [Medical device testing](/services) is a multifaceted process involving physical, chemical, biological, and software testing. Each aspect is crucial in ensuring that the device functions as intended and poses no harm to the end user. This approach helps identify potential issues early in development, ultimately leading to safer and more effective medical devices. ### The Role of Software in Medical Devices Software supports modern medical devices. From pacemakers to imaging systems, software controls and monitors various functionalities. As technology advances, medical devices become increasingly complex, relying heavily on computer software to deliver accurate and timely healthcare services. The software used in medical devices must adhere to strict regulatory requirements to ensure patient safety and data security. Any bugs or malfunctions in the software could have serious consequences, underscoring the importance of thorough testing and validation procedures. ### Aspects of Medical Device Testing Medical Device Testing (MDT) encompasses a wide range of activities to ensure medical devices’ safety, effectiveness, and quality. This includes testing the hardware components, software functionality, user interfaces, and interoperability. One company that emphasizes the importance of thorough testing is Johnson & Johnson. The company’s dedicated software testing team conducts extensive tests on medical devices to ensure their reliability and compliance with regulatory standards. By conducting rigorous testing, Johnson & Johnson can confidently deliver safe and effective medical devices. Medical device testing also involves conducting usability studies to evaluate how easily and effectively users can interact with the device. This human factors testing is essential in identifying design flaws or user interface issues that could potentially impact the device’s performance in real-world scenarios. By incorporating user feedback into the testing process, manufacturers can enhance their medical devices’ overall usability and safety. ## The Intersection of Binary Software Composition Analysis and Medical Device Testing Binary Software Composition Analysis (BSCA) and Medical Device Testing (MDT) share a common goal: to ensure the security and reliability of software-driven applications. Their intersection becomes even more crucial in medical devices. Medical devices play a vital role in healthcare, assisting in diagnosis, treatment, and patient monitoring. These devices often incorporate third-party and open-source software components to enhance functionality and reduce development time. However, these external components can introduce potential security vulnerabilities and licensing risks, which may have severe consequences in healthcare. Organizations can identify and mitigate these risks by incorporating BSCA into the medical device testing process. This proactive approach allows for better security management and ensures compliance with regulatory requirements. ### Why Binary Software Composition Analysis is Essential for Medical Device Testing Medical devices are subject to strict regulations and standards to ensure patient safety. [Regulatory bodies, such as the U.S. Food and Drug Administration (FDA)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity), require documentation and evidence of software security and reliability. Binary Software Composition Analysis supports meeting these requirements. With BSCA, organizations can analyze the composition of the software used in medical devices, identifying any vulnerable or outdated components. This analysis helps assess the potential risks associated with the software and enables organizations to make informed decisions regarding its use in medical devices. BSCA allows organizations to track and manage the licenses of third-party and open-source software components. This helps avoid legal issues and ensures compliance with licensing agreements, protecting the organization and the end-users. ### Challenges in Integrating Binary Software Composition Analysis with Medical Device Testing Although integrating BSCA with MDT offers significant benefits, it also presents challenges. One such challenge is the extensive documentation and traceability required to satisfy regulatory standards. Performing BSCA and MDT separately can be complex, and integrating them adds another layer of complexity. ## Future Trends in Binary Software Composition Analysis and Medical Device Testing The world of technology is ever-evolving, and both Binary Software Composition Analysis and Medical Device Testing must adapt to keep pace with advancements. ![Section Image](/imported-images/2b9750caf024fdda.webp) ### Technological Advancements Impacting the Field As technology advances, so does the complexity of software-driven applications. This complexity poses new challenges in ensuring their security and reliability. Fortunately, advancements in artificial intelligence and machine learning are revolutionizing the field. These technologies can assist in automating the BSCA and MDT processes, detecting potential vulnerabilities, and predicting future risks. The integration of blockchain technology in software composition analysis is gaining traction. Blockchain’s decentralized and secure nature provides a promising solution for tracking and verifying software components’ origins and dependencies. By using blockchain, organizations can enhance the transparency and traceability of their software supply chain, reducing the risk of malicious code injections and ensuring compliance with licensing requirements. ### Predicted Changes in Regulatory Frameworks Regulatory frameworks play a vital role in shaping the practices and standards for BSCA and MDT. As technology evolves, regulatory bodies must adapt and update their guidelines to address emerging challenges. For instance, the U.S. Food and Drug Administration (FDA) has been actively working on enhancing its regulatory oversight of medical device software. By closely monitoring changes in regulatory frameworks, organizations can ensure that their BSCA and MDT practices align with the latest industry standards and compliance requirements. The European Union’s Medical Device Regulation (MDR) is set to change the medical device testing landscape significantly. The MDR aims to strengthen post-market surveillance, enhance traceability of medical devices, and improve transparency for patients and healthcare professionals. Compliance with the MDR will require organizations to adapt their testing processes to meet the new regulatory requirements, ensuring the safety and effectiveness of medical devices in the market. ## Source SCA, binary SCA, and build-generated SBOM | Method | What it sees | What it misses | Best use | | --- | --- | --- | --- | | Source-level SCA | Declared dependencies in your manifests | Anything vendored, statically linked, or shipped by a supplier | Your own repositories, early and often | | Build-generated SBOM | What the build actually pulled in | Components added after the build, and supplier binaries | The authoritative SBOM for software you compile | | Binary SCA | Components inside a shipped image, including supplier code | Exact versions when the binary is stripped | Third-party firmware, legacy devices, acquisitions | | Firmware extraction plus binary SCA | The filesystem, services, and libraries on the device as sold | Nothing added by a field update afterward | Verifying that the SBOM matches the device | The useful test is simple. Run binary analysis on the shipped image and see whether it matches the SBOM you were about to submit. ## Conclusion Understanding Binary Software Composition Analysis (BSCA) and Medical Device Testing (MDT) is crucial for developing and deploying secure and reliable software-driven applications, particularly in medical devices. Companies can proactively address potential security vulnerabilities and licensing risks by embracing BSCA and integrating it into the MDT process. With advancements in technology and regulatory frameworks, the future of BSCA and MDT holds promising opportunities to enhance software security and ensure patient safety. ![Section Image](/imported-images/9c9f95d0f5655400.webp) As you navigate the complexities of Binary Software Composition Analysis and Medical Device Testing, remember that security is not just a feature; it’s a necessity. Blue Goat Cyber, a Veteran-Owned business, is at the forefront of providing B2B cybersecurity services tailored to the medical device industry. Our expertise in medical device cybersecurity, penetration testing, and compliance with HIPAA, FDA, SOC 2, and PCI standards ensures your products are safeguarded against threats. [Contact us today](/contact) for cybersecurity help and partner with a team dedicated to protecting your devices as you are to improve patient care. Check out our [medical device cybersecurity FDA compliance package.](/) ## How Blue Goat approaches this Our approach to Binary Software Composition Analysis for medical devices focuses on precision and regulatory alignment. We use established methodologies to scrutinize software binaries, uncovering dependencies, known vulnerabilities (CVEs), and license compliance issues. Our team, comprised of certified experts with CISSP and OSCP credentials, including former military red team members, applies practical insights gained from years of specialized experience. This ensures that every analysis is accurate and actionable. We work closely with manufacturers to interpret findings, prioritize remediation efforts, and generate the detailed SBOMs required by the FDA. Our services are tailored to support regulatory submissions, minimizing friction in the approval process. We aim to integrate into your development lifecycle, elevating device security. Learn more about our postmarket services: [https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services). If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## FAQ ### What is Binary Software Composition Analysis (BSCA)? BSCA is the process of examining executable software code (binaries) to identify all third-party and open-source components it contains. This analysis helps detect potential security vulnerabilities and understand licensing obligations associated with those components. ### Why is BSCA important for medical devices? BSCA matters for medical devices because it helps identify security flaws and licensing issues in integrated software components that could compromise patient safety or data. The FDA requires medical devices to meet strict cybersecurity and reliability standards, which BSCA supports. ### How does the FDA view software components in medical devices? The FDA considers the security and integrity of all software components within medical devices critical for patient safety. The February 3, 2026 final guidance on premarket cybersecurity emphasizes the need for manufacturers to manage and document risks associated with third-party software as part of their submissions. ### What challenges exist in integrating BSCA with Medical Device Testing (MDT)? Integrating BSCA with MDT presents challenges due to the extensive documentation and traceability required by regulatory bodies like the FDA. Ensure consistent analysis across various development stages and maintaining compliance for complex software supply chains adds layers of complexity. ### Can BSCA help with FDA regulatory compliance? Yes, BSCA significantly aids in FDA regulatory compliance by providing a clear inventory of software components and their associated vulnerabilities and licenses. This information is critical for demonstrating that a medical device meets the FDA's cybersecurity requirements and Ensure safe premarket authorization. ### What trends are impacting BSCA and MDT for medical devices? Technological advancements like AI and machine learning are enhancing BSCA and MDT by automating analysis and improving vulnerability detection. Regulatory frameworks, such as the FDA's evolving cybersecurity guidance and the EU's MDR, are also shaping practices, demanding greater transparency and traceability. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Debunking 5 Med Device Cybersecurity Myths](/blog/debunking-the-top-5-medical-device-cybersecurity-myths-holding-back-innovation) --- ## AI Model Inversion Attacks on Medical Devices Source: https://bluegoatcyber.com/blog/understanding-medical-device-ai-model-inversion-cybersecurity-threats-and-solutions # AI Model Inversion Attacks on Medical Devices: How They Work and How to Defend (2026) > **[DIRECT ANSWER]** Model inversion is an attack that extracts sensitive training data from an AI-enabled medical device by probing its outputs, threatening patient privacy and clinical trust. Manufacturers can defend against it through architecture controls, restricted model access, adversarial testing, and monitoring. The FDA's February 3, 2026 cybersecurity guidance expects these AI-specific risks to be addressed throughout the device's total product lifecycle, alongside standards like IEC 81001-5-1 and AAMI TIR107. _Reviewed July 24, 2026_ AI-enabled medical devices create a new class of security and privacy problems. One of the most overlooked is model inversion: an attack that pulls sensitive information out of a trained model by probing its outputs. For device manufacturers, this is not an academic issue. It affects patient privacy, design controls, and what the FDA expects to see in a credible cybersecurity story. ## Key Takeaways - Model inversion extracts sensitive data from trained medical AI models. - Such attacks compromise patient privacy and device integrity. - Attack surfaces include model interfaces, training pipelines, and data. - Defense requires architecture controls, access limits, and adversarial testing. - The FDA expects strong risk management for AI-enabled devices. - Proactive security design reduces risk and aids regulatory compliance. ## Why this matters The stakes are high. Medical device AI model inversion directly compromises patient privacy, potentially exposing highly sensitive health information, and undermines clinical trust. It represents a significant patient safety risk if inferences from compromised models lead to incorrect diagnoses or treatments. Compliance is also key; the FDA, in its "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026, explicitly expects manufacturers to address cybersecurity risks, including those unique to AI/ML, throughout the device's lifecycle. Failing to address model inversion can lead to significant financial penalties, reputational damage, and even product recalls. Manufacturers must integrate security controls aligned with standards such as IEC 81001-5-1 for health software and IT network security, ISO 13485 for quality management systems, and AAMI TIR107 for adoption of AI in medical devices, specifically addressing AI model vulnerabilities. Proactive risk management isn't just about avoiding penalties; it's about safeguarding patient data and maintaining the integrity of medical technology. ## Why AI in Medical Devices Changes the Risk Picture AI now sits inside or alongside many device functions, from radiology image analysis to patient monitoring and clinical decision support. That can improve speed and performance. It also changes what has to be protected. Traditional software risks still matter: authentication failures, insecure updates, exposed interfaces, weak logging, and poor access control. AI adds another layer. Models can expose training data, behave unpredictably under unusual inputs, or fail in ways that are hard to trace if the development team cannot explain model behavior clearly. In devices such as insulin pumps, implantables, imaging platforms, and remote monitoring systems, those failures are not abstract. They can affect patient safety and clinical trust. ## What Model Inversion Actually Means Model inversion is an attack in which an adversary interacts with a trained AI model and uses its responses to infer sensitive information about the data used to train it. In healthcare, that could mean reconstructing attributes tied to a patient, inferring whether a person’s data was included in training, or extracting proprietary characteristics of the model itself. This matters because the model can become a side channel for protected information. An attacker may never access the original dataset directly, yet still recover details that should have remained private. In a medical context, that could expose medical history, imaging characteristics, biometric data, or genetic indicators. The result is not just a [patient privacy](https://www.hhs.gov/hipaa/index.html) problem. It is also a product security problem, a trust problem, and potentially a regulatory problem. There is a second-order effect too. If manufacturers and clinical partners believe AI models cannot be deployed or shared safely, collaboration slows down. Security failures do not just create breaches. They also chill adoption and weaken confidence in the systems meant to improve care. ## Where AI Security Breaks Down in Healthcare Healthcare environments are already difficult to secure. Add AI, remote connectivity, cloud services, and third-party software, and the attack surface expands fast. ### AI Models Are Exposed in Different Ways Than Traditional Code AI models can be attacked through their interfaces, their training pipelines, and the data they consume. A model may be overly sensitive to query patterns. It may reveal too much confidence information. It may inherit weaknesses from tainted or low-quality training data. If external users, researchers, integrators, or even internal teams can query the model without limits, they may be able to extract more than intended. Opacity makes this worse. Many teams trust model outputs without enough visibility into how those outputs were produced. That lack of [transparency](/blog) makes it harder to spot abuse, validate performance, or explain security controls to regulators and customers. ### Model Inversion Is Not the Only Threat Model inversion sits alongside several other AI-specific attack types. Data poisoning changes training data so the model learns the wrong thing. Evasion attacks manipulate inputs to trigger incorrect predictions. Membership inference tries to determine whether a specific record was used in training. Each attack path creates different failure modes, but all can undermine device performance and safety. The spread of AI into connected care also raises the stakes. [Telemedicine](/blog/telemedicine-cybersecurity-risks) platforms, cloud-based analytics, and remote monitoring workflows create more opportunities for unauthorized access and more ways for data to move outside controlled environments. If manufacturers do not define where models run, who can query them, how outputs are constrained, and how activity is monitored, they are leaving obvious gaps. ## The Impact on Medical Devices The damage from model inversion is practical, not theoretical. It affects privacy, device operation, and postmarket risk. ![Section Image](/imported-images/ff5fd73404ffcb5f.png) ### Risks to Patient Privacy A successful inversion attack can expose patient-related information even when the attacker never touches the original record set. That is serious on its own. In healthcare, it also undermines the trust patients and providers place in connected devices and AI-supported systems. Once privacy concerns become visible, behavior changes. Patients may be less willing to share data. Clinical partners may limit adoption. Research collaborations may narrow. Security failures ripple outward. ### Threats to Device Safety and Function If attackers can manipulate access to a model, abuse its interfaces, or exploit associated infrastructure, device behavior can degrade. A [pacemaker](/blog/the-dangers-of-pacemaker-hacks-what-you-need-to-know), imaging system, or monitoring platform that relies on corrupted outputs or compromised supporting software can misclassify conditions, delay care, or trigger unsafe workflows. For manufacturers, this is where AI security has to be treated like product security, not just data governance. If the model supports a clinical function, attacks against that model can become safety issues. That has implications for risk management, architecture, verification, labeling, and postmarket monitoring. ## How to Reduce Model Inversion Risk There is no single control that fixes this. Teams need architecture decisions, access controls, testing, and documentation that hold up under scrutiny. ### Limit What the Model Can Reveal Start with the interface. Restrict who can query the model, how often, and through which pathways. Minimize unnecessary output detail, especially confidence scores, intermediate values, or verbose responses that help attackers learn the model’s internal behavior. Rate limiting, segmentation, API hardening, and strong authorization matter here. Privacy-preserving techniques can also help. Differential privacy, output perturbation, and carefully designed training approaches can reduce leakage. Federated learning may be appropriate in some settings, but only when the implementation and threat model actually support it. These are engineering choices, not marketing terms. ### Secure the Surrounding System Many AI failures are really system failures. Protect the model storage location, the update mechanism, the training pipeline, and the monitoring stack. Use encryption where it makes sense, but do not treat encryption as a substitute for access control or architecture review. [Multi-factor authentication](/blog) should be standard for administrative access. Logging should be detailed enough to detect unusual query behavior and support investigation. Regular software updates still matter. Vulnerabilities in operating systems, libraries, inference services, or cloud components can create the opening an attacker needs. A disciplined patch process is basic cyber hygiene, but in medical devices it also supports a stronger safety case. ### Test Like an Attacker, Not a Compliance Checklist Manufacturers should perform adversarial testing against the model and the full device ecosystem. That means testing for inversion, membership inference, abuse of APIs, privilege escalation, update tampering, and data path weaknesses. If your security validation only proves that a checklist was completed, it is not enough. The FDA has been clear that cybersecurity is part of device quality and risk management, not a bolt-on. Security claims need evidence. Threat models need to reflect how the device is actually used, updated, connected, and maintained. ## What Comes Next for Medical Device AI Security AI security in medical devices is moving from a niche concern to a standard expectation. Manufacturers that treat it early will be in a much stronger position than teams trying to patch the issue during submission prep or after release. ![Section Image](/imported-images/2b24695986e85b78.png) ### The FDA and Other Regulators Will Keep Raising the Bar The FDA expects manufacturers to show credible cybersecurity risk management across the product lifecycle. For AI-enabled devices, that includes understanding how the model can be attacked, what the clinical impact would be, and what controls are in place to reduce risk to acceptable levels. [Regulations](https://www.fda.gov/media/184856/download) and guidance are pushing manufacturers toward better security documentation, better software practices, and clearer postmarket planning. That is a good shift. Reactive security is expensive, slow, and hard to defend. Proactive security design is easier to explain to the FDA, easier to maintain, and safer for patients. ### Defensive AI Has a Place, but It Is Not Magic AI can help defenders spot anomalous traffic, unusual usage patterns, and emerging abuse. That is useful. So are behavioral analytics and automated monitoring. But none of that replaces sound architecture, threat modeling, secure development, and disciplined change control. Some teams also look to [blockchain technology](/blog) for integrity and audit use cases. In a narrow set of scenarios, that may help. Most of the time, though, the bigger gains come from simpler controls done well: authenticated updates, controlled interfaces, segmented networks, reproducible builds, and strong logging tied to real response procedures. ## Build Security Into the Device, Not Around It Model inversion is one more reminder that AI features do not sit outside product security. They are product security. If your device depends on AI, then model exposure, data leakage, and adversarial abuse belong in your design inputs, your risk files, your verification plan, and your postmarket process. Blue Goat Cyber helps medical device manufacturers build security programs that match how products are actually designed, submitted, and maintained. Our team supports secure development, threat modeling, vulnerability assessment, and regulatory-ready cybersecurity work aligned to the FDA, IEC 62304, and EU MDR. [Contact us today for cybersecurity help](/contact) if you need to tighten your AI security posture before it becomes a submission issue or a field problem. ## How Blue Goat approaches this Blue Goat Cyber addresses medical device AI model inversion through a risk-based methodology focused on prevention and detection. Our approach integrates security from the earliest stages of device design, considering the unique attack surfaces of AI models within medical devices. We conduct expert-level threat modeling to identify potential inversion vectors and develop tailored mitigation strategies, including data anonymization, differential privacy techniques, and secure model deployment. Our team, including CISSP and OSCP certified engineers and ex-military red team personnel, specializes in adversarial machine learning testing to validate model defenses against inversion attacks. We help manufacturers navigate the evolving regulatory landscape, ensuring compliance with guidance such as the FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026. For premarket submissions, if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized services at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What is AI model inversion in medical devices? AI model inversion is an attack where an adversary interacts with a trained AI model to deduce sensitive information about its training data. In medical devices, this can lead to the exposure of patient data or proprietary model characteristics. ### How does AI model inversion pose a risk to healthcare data? Attackers can infer medical images, biometric traits, health status, or determine if a specific patient's record was used in model training. This compromises patient privacy, potentially leading to identity fraud or a loss of trust in connected medical devices. ### Which medical devices are vulnerable to AI model inversion? Any AI-enabled medical device or connected software function processing sensitive health data can be vulnerable. This includes AI-powered diagnostic imaging tools, predictive analytics software, and wearable medical devices. ### How can manufacturers reduce the risk of AI model inversion? Manufacturers should limit model output details, restrict query access, and employ privacy-preserving techniques like differential privacy. Securing the surrounding system, including storage and update mechanisms is also essential. ### What are the FDA's expectations regarding AI model inversion risk? The FDA expects manufacturers to incorporate cybersecurity risk management for AI-enabled devices across the product lifecycle. This includes understanding potential model attacks, assessing clinical impact, and implementing controls, consistent with the February 3, 2026 final guidance. ### Does adversarial testing help prevent model inversion? Yes, adversarial testing is crucial. Manufacturers should test for inversion, membership inference, API abuse, and other vulnerabilities against the model and the device ecosystem to validate security claims. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Attack Surface Analysis: A Practitioner Method Source: https://bluegoatcyber.com/blog/understanding-medical-device-attack-surface-analysis # Medical Device Attack Surface Analysis: A Practitioner Method > **[DIRECT ANSWER]** Attack surface analysis for a medical device means enumerating every interface an attacker or a legitimate user could touch, physical ports, wireless radios, network services, the mobile app, the cloud API, the update channel, service mode, and removable media, then tying each one to evidence and to a line in the threat model. The February 3, 2026 premarket guidance expects this enumeration to be traceable into your security risk assessment and your test protocol, not just described in prose. A reviewer does not accept "we considered the attack surface" as a claim. They expect a list of interfaces, evidence that each one was found through a method rather than memory, and a line from each interface to a threat and a test case. Teams that skip this rigor tend to discover the missing interface during a deficiency letter or, worse, during an incident. This post gives you the enumeration method: the interface classes to work through, what evidence documents each one, how the list feeds the threat model in the [relevant threats post](/blog/understanding-relevant-threats-for-medical-devices), and which interfaces get missed most often. ## Key Takeaways - Attack surface analysis is an enumeration method, not a paragraph in the risk file, and it needs to produce a list a reviewer can check against the architecture. - Interfaces fall into classes: physical and debug ports, wireless radios, network services, mobile app, cloud API, update channel, service and maintenance mode, and removable media. - Every interface needs an evidence source, a schematic, a port scan, a firmware manifest entry, or a protocol capture, not just a claim that it exists. - The interface list has to map one to one into the threat model and into the penetration test scope, or the two documents will not reconcile under review. - Debug headers, service mode, and third party SDK network calls are the interfaces manufacturers most often leave off the list. - AAMI SW96 (FDA recognition number 13-131) expects the attack surface to be revisited whenever the architecture changes, not fixed once at design freeze. ## Why This Matters The FDA's final guidance, *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026 and following the September 2023 and June 2025 versions in that chain, asks for a security risk assessment built on the device's architecture and interfaces. You cannot produce that assessment from memory once a device has more than a handful of components. An incomplete attack surface produces two failure modes. The threat model omits a class of attack the interface enables, so the risk assessment understates residual risk. The penetration test scope then mirrors that same gap, so testing confirms a false sense of security instead of finding the real one. eSTAR v7.0, effective June 1, 2026, collapses the cybersecurity content into one attachment area rather than the eight separate slots some older guidance implied. That consolidation makes the attack surface inventory more important, not less, because the reviewer is now reading one coherent narrative and expects the interface list, the threat model, and the test report to visibly agree with each other. ## What counts as an interface for attack surface purposes? An interface is any point where data, power, or physical access crosses the boundary of the device. Group them into eight classes so nothing gets lost in an undifferentiated list. | Class | Examples | Typical risk | | --- | --- | --- | | Physical and debug ports | JTAG, UART, SWD, USB, exposed test pads | Firmware extraction, credential recovery, bypassing boot protections | | Wireless radios | Bluetooth Low Energy, Wi-Fi, cellular, NFC, proprietary RF | Pairing abuse, replay, jamming, unauthenticated command injection | | Network services | Open TCP or UDP ports, embedded web servers, DICOM, HL7 listeners | Unauthenticated access, protocol exploitation, lateral movement | | Mobile app | Companion app, local storage, app to device pairing | Credential leakage, insecure storage, reverse engineered protocols | | Cloud API | REST or MQTT endpoints, third party SDKs, telemetry ingestion | Broken authorization, tenant data crossover, exposed keys | | Update channel | OTA firmware delivery, signed package verification | Malicious firmware installation, downgrade attacks | | Service and maintenance mode | Factory reset, calibration mode, biomed diagnostic tools | Privilege escalation, hidden functionality left enabled in the field | | Removable media | SD cards, USB drives, exported logs, patient data cards | Malware introduction, data exfiltration on a lost card | > **[KEY REQUIREMENT]** Every interface in this list needs a named owner on the engineering team who can state whether it is present, active, and reachable in the shipping configuration. An interface without an owner is the one that gets missed. ## How do you find every interface instead of the obvious ones? You find the full surface by combining four independent methods, because any single method misses classes of interface the others catch. Schematic and bill of materials review catches physical and debug interfaces that software documentation never mentions. Firmware and binary analysis catches network listeners, hardcoded services, and third party libraries that open their own connections without engineering's knowledge. Dynamic discovery, port scanning, protocol fuzzing, and RF spectrum analysis, catches what actually runs at power on versus what the design intended. Interviews with firmware, mobile, and cloud engineers catch service modes and debug backdoors that exist for manufacturing or support and never made it into a requirements document. Cross-check the four lists against each other; disagreements between them are usually where the real gaps sit. ## What evidence documents each interface? Each interface needs a specific artifact, not a checkbox, because the reviewer is evaluating whether the claim is verifiable. The table below maps interface class to the evidence a submission should be able to produce on request. | Interface class | Evidence artifact | | --- | --- | | Physical and debug ports | Schematic annotation or photo showing port location and lockout status | | Wireless radios | RF protocol specification, pairing flow diagram, radio configuration file | | Network services | Port scan output, service banner capture, firewall or ACL configuration | | Mobile app | App architecture diagram, static analysis report, API call inventory | | Cloud API | API specification (OpenAPI or similar), authentication scheme, access control matrix | | Update channel | Signing and verification design, update sequence diagram, rollback protection description | | Service and maintenance mode | Mode activation procedure, authentication requirement, field enablement status | | Removable media | Data classification of what the media can hold, encryption at rest status | ## How does the interface list become a threat model and a test scope? The interface list becomes a threat model by running STRIDE against each interface rather than against the device as a single black box. Each interface, or the data flow crossing it, gets evaluated for spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege, and the full method for deciding which resulting threats are actually relevant to your device lives in the [relevant threats post](/blog/understanding-relevant-threats-for-medical-devices). The same list becomes the penetration test scope directly. Every interface class with a nontrivial risk rating in the threat model should appear as a line item in the test plan, with a stated method, hardware access for physical interfaces, protocol tooling for wireless, credentialed and uncredentialed testing for network services, and static plus dynamic analysis for the app and cloud layers. > **[KEY REQUIREMENT]** If an interface is in the architecture diagram but absent from the test report, the submission has an unexplained gap. Reviewers increasingly reconcile these two documents side by side. ## Which interfaces do teams forget? Debug headers left populated on production boards are the most common miss, because engineering assumes they will be removed before manufacturing and nobody verifies it on the shipping unit. Service and maintenance mode is a close second; it is authenticated in the design document and unauthenticated in the field build because the credential got hardcoded during bring up and never rotated. Third party SDKs embedded in the mobile app or the cloud backend open their own network connections for analytics, crash reporting, or licensing, and those connections are rarely inventoried as part of the device's attack surface even though they carry device or patient data. Removable media is frequently treated as a convenience feature rather than a data exfiltration path, especially when the card holds calibration data alongside clinical logs. Legacy interfaces from a prior hardware revision, an old cellular modem's AT command interface, or a diagnostic port kept for backward compatibility with older service tools, also get left off current documentation because nobody updates the interface list when a component is deprecated rather than removed. ## How Blue Goat Cyber Approaches This We start every engagement with a structured interface enumeration across the four discovery methods, schematic review, firmware analysis, dynamic discovery, and engineering interviews, before we open a threat modeling session. That order matters, because a threat model built on an incomplete interface list produces a test plan with the same blind spots. Our team, made up of CISSP and OSCP certified engineers including former military red team members, treats the interface list as a living artifact that gets revisited whenever the architecture changes, in line with what AAMI SW96 expects from an ongoing security risk management process. We hand back a reconciled set: the interface inventory, the threat model built from it, and the test scope that covers every interface with material risk. If the FDA raises cybersecurity deficiencies tied to our submission work, we resolve them at no additional cost. Our [medical device penetration testing](/services/medical-device-penetration-testing) and [medical device threat modeling](/services/medical-device-threat-modeling) services both start from this same interface inventory. ## Frequently Asked Questions **What is the difference between attack surface analysis and threat modeling?** Attack surface analysis enumerates the interfaces where an attacker could interact with the device. Threat modeling takes that enumeration and applies a method, typically STRIDE, to decide which attacks are plausible against each interface and how severe they would be. You need the enumeration first, or the threat model has nothing concrete to evaluate. **Does attack surface analysis apply to legacy devices already on the market?** Yes. A legacy device without a current interface inventory cannot support a credible postmarket security risk assessment, and the FDA's guidance treats cybersecurity as a total product lifecycle obligation. Legacy devices often need a fresh enumeration because field modifications and component substitutions accumulate undocumented interfaces over time. **How often should the interface list be updated?** Update it whenever the architecture changes: a new radio, a firmware revision that opens a service, a new cloud integration, or a hardware respin. AAMI SW96 treats security risk management as continuous, so a static list produced once at design freeze will not hold up under postmarket review. **Can a penetration test substitute for attack surface analysis?** No. A penetration test verifies whether interfaces you already identified are exploitable; it does not reliably discover interfaces nobody told the tester about. Schematic and firmware review has to happen first so the test plan has a complete list to work against. **Do we need to attack-surface-map third party components we did not build?** Yes, if they run on the device or communicate on its behalf. A purchased wireless module, an embedded RTOS network stack, or a mobile SDK all add interfaces to your device's surface even though your team did not write that code, and the FDA's cybersecurity bill of materials expectations extend to those components. **Where does removable media fit if the device never leaves the clinical setting?** It still counts. SD cards and USB exports move data outside the device's control regardless of where the device sits, and a lost or discarded card is a realistic loss scenario even in a hospital environment. ## CTA If your current attack surface documentation is a paragraph rather than a list with evidence, that gap will surface as a reviewer question or a missed finding in testing. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will walk your architecture against this enumeration method before it becomes a deficiency letter. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## QNX Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/understanding-qnx-operating-system-vulnerabilities-risks-and-mitigation-strategies # QNX Vulnerabilities in Medical Devices: What Manufacturers Need to Know > **[DIRECT ANSWER]** QNX is a real-time microkernel operating system used in many medical devices for its fault isolation and deterministic performance, but that architecture does not eliminate risk from buffer overflows, insecure interprocess communication, misconfigured permissions, or exposed debug interfaces added during integration. Manufacturers should maintain disciplined patching, harden network services, enforce least privilege, and validate the platform through threat modeling and penetration testing to meet the FDA's lifecycle risk management expectations. _Updated November 10, 2024_ ## Key Takeaways - QNX is an RTOS foundational to many medical devices. - Vulnerabilities can arise from the OS, third-party code, or configuration. - Exploits can impact data, system stability, and patient safety. - Mitigation requires strong architecture and disciplined patching. - FDA expects complete cybersecurity risk management. - User awareness and secure practices matter for deployed devices. ## Why this matters The security of QNX operating systems in medical devices directly impacts patient welfare and device functionality. Exploitable vulnerabilities can lead to data breaches, unauthorized device control, and severe operational disruptions, potentially causing patient harm or death. The FDA, in its 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes the manufacturer's responsibility to manage cybersecurity risks throughout the device lifecycle, from design to postmarket surveillance. Failure to adequately address QNX vulnerabilities can result in regulatory non-compliance, costly recalls, and significant reputational damage. Manufacturers must integrate security by design, adhering to standards like IEC 81001-5-1, ISO 14971 (risk management), and AAMI TIR57 / ANSI/AAMI SW96:2023 and TIR97 (postmarket cybersecurity). These frameworks guide the identification, assessment, and mitigation of risks associated with QNX and other embedded systems. Proactive security measures, including threat modeling, penetration testing, and continuous monitoring, are indispensable. The stakes are profoundly high, demanding careful attention to detail and a proactive stance against evolving cyber threats to ensure both regulatory adherence and, most critically, patient safety. ## Introduction to the QNX Operating System QNX shows up in systems that cannot tolerate timing drift, unstable behavior, or sloppy failure handling. That includes automotive platforms, industrial controls, and many [medical devices](/blog/top-10-embedded-operating-systems-for-medical-devices) where predictable operation matters as much as feature count. QNX is a [real-time operating system](/blog) (RTOS) built around a microkernel design. That architecture gives manufacturers useful fault isolation, but it does not eliminate security risk. If a device team treats the OS choice as the security strategy, they are already behind. ### History and Development of QNX Originally developed in the early [1980s by Quantum Software Systems, QNX](https://en.wikipedia.org/wiki/QNX) built its reputation on stability and deterministic performance in embedded environments. Over time, it expanded from a niche RTOS into a widely adopted platform for connected and safety-conscious systems. In 2010, QNX was acquired by [BlackBerry](https://blackberry.qnx.com/en), which pushed the platform further into embedded and mobile-adjacent use cases. Since then, QNX has added networking capabilities, multicore support, and broader tooling for modern software development. Those improvements made adoption easier, but they also increased attack surface in the same way they do on any mature platform. ### Key Features of the QNX Operating System The defining feature of QNX is its [microkernel architecture](/blog). Core services are kept separate rather than packed into a monolithic kernel, which helps contain faults and keep other services running when one component fails. That matters in medical devices. Fault isolation can support availability and safer degradation modes, especially in systems that must keep operating during partial failures. QNX also supports POSIX-aligned development, multiple programming languages, and a mature set of tools and libraries. For manufacturers, that means easier integration and faster development. It also means more code paths, more interfaces, and more opportunities to introduce weaknesses if secure design is not part of the engineering process from the start. ## QNX Vulnerabilities: What Goes Wrong QNX has a strong reputation, but reputation is not a control. Like any operating system, it can contain implementation flaws, insecure configurations, exposed services, and supply chain dependencies that create real risk in deployed devices. ![Section Image](/imported-images/831218cd80bd9653.png) ### Common Types of Vulnerabilities The most common issues look familiar: [buffer overflows](/blog), improper input validation, [race conditions](/blog), insecure interprocess communication, misconfigured permissions, and outdated third-party components. In connected devices, weak network service hardening and poor authentication handling also show up often. Some of these flaws come from the OS itself. Many come from how manufacturers integrate QNX into the product. Custom services, legacy libraries, debug interfaces left enabled, and poorly segmented network functions can turn a manageable platform into an exposed one very quickly. ### Why These Vulnerabilities Matter in Real Systems When attackers find these weaknesses, they do not stop at a crash. They look for persistence, privilege escalation, unauthorized access, data manipulation, and disruption of device functionality. That is where medical device risk becomes concrete. A vulnerability in a QNX-based infusion pump, imaging system, bedside monitor, or lab platform is not just an IT issue. It can affect device availability, integrity of clinical data, maintenance workflows, and in some cases patient safety. Real-time systems are especially sensitive because even small delays, reboots, or control failures can create outsized operational consequences. ## Risks Associated with QNX Vulnerabilities For device manufacturers, the risk is broader than technical exploitation. QNX vulnerabilities can trigger safety concerns, service interruptions, privacy incidents, compliance problems, and expensive remediation after release. If the product is already on the market, the cost goes up fast. ![Section Image](/imported-images/9841fd86c2932c85.png) ### Potential Threats to Data Security Compromised QNX systems can expose sensitive data, including patient information, device logs, credentials, configuration files, and service records. In healthcare environments, that creates immediate privacy and operational concerns. For manufacturers, data exposure also has regulatory consequences. The FDA expects cybersecurity risk management to account for confidentiality, integrity, and availability across the device lifecycle. If a vulnerability can alter data, suppress alarms, change configuration, or enable unauthorized access, the issue is bigger than breach notification. It can affect the device’s intended use and its risk profile. ### Risks to System Stability and Performance Stability failures are not hypothetical. If an attacker can crash a service, exhaust resources, interfere with scheduling, or trigger repeated restarts, a real-time platform can miss deadlines or enter unsafe states. That is a serious problem in connected medical devices. Systems that depend on QNX often sit inside larger clinical workflows, so one unstable device can create delays, force manual workarounds, or disrupt treatment. Interconnected environments amplify the impact. A compromise in one component can spread operational pain well beyond the original target. ## Mitigation Strategies for QNX Vulnerabilities Security work on QNX-based devices should be practical and evidence-driven. Not checklist theater. Manufacturers need to know what is running, what is exposed, which threats matter for the intended use, and how those findings connect to safety and regulatory obligations. ### Regular System Updates and Patches Patch discipline still matters. Keeping QNX components, BSPs, middleware, and third-party packages current closes known issues and reduces exploitability. But “apply updates” is not enough by itself, especially for regulated products. Medical device manufacturers need a process for vulnerability intake, impact analysis, testing, release planning, and field deployment. That includes understanding which components are present in the software bill of materials, how patches affect device functionality, and whether compensating controls are needed when immediate patching is not possible. The FDA will expect that level of traceability and decision-making, not just a claim that updates are handled. ### Security Controls That Actually Reduce Risk Strong mitigation starts with architecture. Reduce exposed services. Disable debug functionality in production. Enforce least privilege. Segment networks. Lock down remote access. Use secure boot where supported. Protect credentials properly. Validate inputs across trust boundaries. Log security-relevant events in ways that support investigation. Regular security testing matters too. That includes threat modeling, code review, SBOM analysis, vulnerability assessment, and penetration testing against the real device architecture. The goal is not to produce a binder full of generic controls. The goal is to show that the device resists realistic attack paths and that the remaining risk is understood and managed. Training also matters, but it should be role-specific. Developers need secure coding guidance. Service teams need field-hardening procedures. Product security and regulatory teams need a shared view of exploitability, safety impact, and submission implications. ## The Future of QNX Security QNX security will keep moving in the same direction as the rest of embedded security: better isolation, better visibility, and faster detection of misuse. That is useful, but no platform feature will rescue a weak product security program. ![Section Image](/imported-images/e36debb062aa7272.png) ### Anticipated Developments in QNX Security We can expect continued investment in stronger platform security features, better update mechanisms, and tighter support for secure-by-design development. More vendors are also pushing runtime monitoring and anomaly detection into embedded environments, including systems that need deterministic performance. Those advances help. They do not replace disciplined engineering. A manufacturer still has to define the security architecture, evaluate exploit paths, validate controls, and make sure the final device behaves safely under adverse conditions. That is the standard the FDA is moving toward, and it is the right one. ### Role of User Awareness in Enhancing Security User awareness still counts, especially for administrators, service personnel, and hospital engineering teams interacting with QNX-based systems. Poor password handling, exposed maintenance interfaces, and weak network practices can undo good engineering work. Training should focus on the situations people actually face: recognizing suspicious behavior, managing remote access safely, handling updates correctly, and escalating anomalies before they become incidents. Frontline users often spot operational issues first. Give them a clear way to report concerns, and security gets better faster. ## QNX Security Requires Product-Level Discipline QNX can be a strong foundation for medical devices, but it is still just a foundation. Vulnerabilities can emerge from the OS, third-party components, custom integrations, insecure defaults, or weak deployment practices. The real question is whether the manufacturer can identify those risks early, test them realistically, and manage them across the product lifecycle. That is the work. Know your attack surface. Maintain your SBOM. Test the device the way an attacker would. Tie cybersecurity decisions back to safety and intended use. If your team does that well, QNX can support reliable and secure products. If not, the microkernel will not save you. If you are still choosing a platform rather than defending one, compare the general-purpose alternatives in our [Linux vs. Windows security comparison for medical devices](/blog/linux-vs-windows-a-security-comparison). Blue Goat Cyber helps medical device manufacturers assess embedded platforms, validate security controls, and prepare for FDA scrutiny with evidence that holds up. If you need help evaluating a QNX-based device, hardening its architecture, or testing its real attack paths, [contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in understanding and mitigating QNX vulnerabilities through a focused, risk-based methodology. Our approach integrates security from the design phase, emphasizing threat modeling tailored to the unique aspects of QNX microkernel architectures. We conduct thorough penetration testing and vulnerability assessments, scrutinizing both the QNX OS layer and integrated third-party components. Our team, comprised of cybersecurity experts with certifications like CISSP and OSCP, including former military red team personnel, specializes in identifying subtle weaknesses that could impact safety and efficacy. We align our services with current regulatory expectations, ensuring that your medical devices meet the stringent cybersecurity requirements from bodies like the FDA. Should the FDA raise cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at Blue Goat Cyber's [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is QNX and why is it used in medical devices? QNX is a real-time operating system (RTOS) known for its stability and deterministic performance. Its microkernel architecture provides fault isolation, making it suitable for medical devices where predictable operation and safety are paramount. ### What types of vulnerabilities are common in QNX-based medical devices? Common vulnerabilities include buffer overflows, improper input validation, race conditions, insecure interprocess communication, and misconfigurations. Many issues stem from how manufacturers integrate QNX into the product, including custom services and third-party libraries. ### How do QNX vulnerabilities impact patient safety? In medical devices, QNX vulnerabilities can lead to device malfunction, disruption of clinical data integrity, or unauthorized access. Such incidents can affect device availability, compromise patient data, or directly endanger patient safety depending on the device's function. ### What mitigation strategies should manufacturers implement for QNX devices? Manufacturers should implement regular system updates and patches, enforce least privilege, segment networks, secure remote access, and use secure boot. Threat modeling, code review, SBOM analysis, and penetration testing are also essential. ### Does the FDA address QNX security in its guidance? The FDA expects medical device manufacturers to manage cybersecurity risks across the device lifecycle, including those related to underlying operating systems like QNX. The February 3, 2026 final guidance outlines expectations for secure design, vulnerability management, and postmarket activities. ### Why is user awareness important for QNX medical device security? User awareness is vital because human factors like poor password handling, exposed maintenance interfaces, and weak network practices can compromise even well-engineered systems. Training for administrators and clinical staff helps prevent operational issues and facilitates prompt incident reporting. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Bluetooth in Medical Devices: Risks](/blog/bluetooth-in-medical-devices-understanding-the-risks-and-protecting-patient-safety) - [AJAX Vulnerabilities in Medical Devices](/blog/medical-device-sql-injection-parameterized-queries) - [LoRaWan Vulnerabilities on Medical](/blog/lorawan-vulnerabilities-on-medical-device-cybersecurity) - [MQTT Vulnerabilities in Connected](/blog/mqtt-vulnerabilities-connected-medical-devices-fda) --- ## Deciding Which Threats Are Relevant to Your Medical Device Source: https://bluegoatcyber.com/blog/understanding-relevant-threats-for-medical-devices # Deciding Which Threats Are Relevant to Your Medical Device > **[DIRECT ANSWER]** A threat is relevant to your medical device when a realistic threat source can exploit a specific interface or data flow in your architecture, given your device's intended use and use environment, to cause a patient safety or data harm you can describe concretely. Relevance is not read off a generic threat catalog; it is derived per element with STRIDE, scored for patient safety impact separately from data impact, and documented so a reviewer can trace the decision back to your architecture. Most threat catalogs list the same forty items regardless of what the device does, and a reviewer can tell within a page whether your threat model was copied from one or actually derived from your architecture. The February 3, 2026 premarket guidance expects you to show your reasoning, not just your conclusions, because Section 524B puts the burden of a credible cybersecurity risk analysis on the manufacturer. This post is about the decision process: how intended use and use environment drive relevance, how to run STRIDE per element instead of per device, how to separate patient safety impact from data impact, and how to write the relevance decision so it survives a reviewer's questions. For the separate question of what interfaces exist to threat model in the first place, see the [attack surface analysis post](/blog/understanding-medical-device-attack-surface-analysis). ## Key Takeaways - A threat is relevant only in relation to a specific device's architecture, intended use, and use environment, not by appearing on a general list. - Run STRIDE per element of your data flow diagram, not once for the whole device, or you will miss threats specific to individual interfaces. - Rank threat sources by capability and motive for your specific device rather than assuming every actor targets every device equally. - Score patient safety impact and data impact as separate axes, because a data-only breach and a harm-causing malfunction get different mitigation priorities. - Document why excluded threats were excluded, not just which threats were kept, because reviewers ask about the exclusions. - AAMI TIR57 (FDA recognition number 13-83) and TIR97 (13-112) both expect this relevance reasoning to be traceable in the security risk management file. ## Why This Matters The FDA's final guidance, *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions*, issued February 3, 2026 after the September 2023 and June 2025 versions in that chain, asks manufacturers to identify threats specific to their device under Section 524B rather than submit a generic threat inventory. A reviewer reading a threat model that lists every MITRE ATT&CK technique with no connection to the device's own interfaces cannot conclude the risk analysis is complete. CISA's 2026 Minimum Elements for a software bill of materials, which supersede the NTIA 2021 framework, also assume the manufacturer has already reasoned about which components carry exploitable exposure, since a component inventory without a relevance judgment does not tell a reviewer anything about actual risk. AAMI TIR57 and TIR97 both frame threat identification as an exercise tied to your specific architecture and clinical context, not a literature review. Getting relevance wrong in either direction causes real cost. Too broad, and the risk file drowns in low value entries that dilute attention from the threats that matter. Too narrow, and a plausible attack path goes unaddressed until postmarket surveillance or an incident surfaces it. ## What makes a threat relevant instead of generic? A threat is relevant when three things are all true for your device: a threat source with real capability and motive exists, that source can reach a specific interface or data flow in your architecture, and the resulting harm is one you can describe in concrete clinical or data terms. Drop any one of the three and the threat belongs in an exclusion log with a reason, not in the active risk register. Generic catalogs fail this test because they list attack techniques without connecting them to your interfaces. "SQL injection" is not relevant to a device with no database exposed to untrusted input; it is highly relevant to a cloud API backend that stores patient records. The enumeration method in the [attack surface analysis post](/blog/understanding-medical-device-attack-surface-analysis) is the input this exercise needs, because you cannot judge whether a threat source can reach an interface you have not identified. ## How does intended use and use environment change relevance? Intended use and use environment determine which threat sources have realistic access and which harms actually matter, so they are the first filter, not an afterthought. A device indicated for a monitored intensive care unit faces a different attacker population than one indicated for unsupervised home use, and the [home use versus hospital cybersecurity post](/blog/home-use-vs-hospital-device-cybersecurity) covers how that environment shift changes the assumptions your model can make. | Intended use factor | Effect on relevant threats | | --- | --- | | Clinical function (diagnostic, therapeutic, monitoring) | Sets whether a compromise can directly cause physical harm or only misinform a decision | | Connectivity (standalone, networked, wireless, cellular) | Determines which remote threat sources have any path to the device at all | | Use environment (hospital, home, ambulatory, implanted) | Changes which compensating controls exist and which physical access threats are realistic | | Patient population | Affects consequence severity, since a vulnerable population raises the harm rating for the same technical failure | | Data handled | Determines whether a breach is a privacy event, a safety event, or both | > **[KEY REQUIREMENT]** State the assumed intended use and use environment explicitly in the threat model document itself, not only in the Indications for Use statement. A reviewer should not have to cross-reference two documents to see which threats you excluded and why. ## How do you run STRIDE without turning it into a checklist? Run STRIDE against each element of your data flow diagram, processes, data stores, and trust boundary crossings, rather than asking once whether the device as a whole is vulnerable to each category. A single device typically has ten to thirty elements once you break it into components and interfaces, and each one has its own plausible subset of the six STRIDE categories. | STRIDE category | Example relevant to a networked infusion pump | | --- | --- | | Spoofing | A rogue device impersonates the pump on the hospital network to intercept commands | | Tampering | Firmware update package modified in transit due to weak signature verification | | Repudiation | Dosage change made without an audit trail that identifies the operator | | Information disclosure | Patient dosage history exposed through an unauthenticated diagnostic port | | Denial of service | Wireless jamming prevents the pump from receiving a stop command | | Elevation of privilege | Service mode credential reused as the clinical operator credential | Elements that have no realistic exposure to a category get marked not applicable with a one-line reason, which is what separates a real STRIDE analysis from a checklist filled in on autopilot. A data store that never leaves the device and has no write interface does not need a tampering entry beyond physical access controls, and saying so explicitly is more useful to a reviewer than silence. ## How do you separate patient safety impact from data impact? Score patient safety impact and data impact on two separate axes, because the same threat can rate low on one and high on the other, and merging them into a single severity number hides that distinction from the people who need to act on it. ISO 14971 already asks for harm severity tied to the patient, and privacy impact under HIPAA or GDPR runs on a different scale entirely. A threat that exposes patient names and device serial numbers without any effect on device function is a real data impact and a near-zero patient safety impact. A threat that could cause an incorrect therapy delivery is a severe patient safety impact even if no data is exposed at all. Keeping the two axes separate lets you prioritize the safety-relevant threats for design mitigation first, without deprioritizing the data-only threats that still need addressing under your privacy and security program. ## How do you document a relevance decision a reviewer will accept? Document three things for every threat: the reasoning that made it relevant or not, the element of the architecture it maps to, and the mitigation or the accepted risk decision tied to it. A reviewer checking your work wants to trace a line from architecture to threat to mitigation to test evidence, and a gap anywhere in that chain reads as an unresolved question. Keep an explicit exclusion log alongside the active threat register. A threat you considered and excluded, with a stated reason such as "no network exposure" or "requires physical access already excluded by the enclosure's tamper design," is far more defensible than a threat that simply never appears anywhere in the documentation. Reviewers who ask "did you consider X" are almost always looking for that log, not looking to catch you skipping X entirely. > **[KEY REQUIREMENT]** Every excluded threat needs a one-sentence documented reason tied to your architecture or use environment, not a blanket statement that the risk was judged acceptable. ## Are Ephemeral Ports a Relevant Threat for Your Device? Ephemeral ports become relevant to a threat model only when your architecture actually uses outbound connections, and for most connected devices, telemetry, cloud sync, update checks, that condition is almost always true. Ephemeral ports are the temporary, automatically assigned client-side ports, in IANA's 49152-65535 dynamic and private range, that a device's operating system hands out for each outbound connection so many sessions can run at once. They are not a vulnerability by themselves, but running the relevance test from this article against them shows exactly where they do and do not matter. Applying the three-part relevance test: a threat source (a network attacker or a misconfigured hospital firewall) can reach the interface (the device's outbound connection behavior), and the harm (a missed vulnerability indicator or a failed clinical connection) is concrete. That clears the bar for inclusion, but the specific STRIDE categories that apply are narrower than a generic port-scanning entry would suggest. | STRIDE category | Relevant to ephemeral ports? | Why | | --- | --- | --- | | Spoofing | Rarely, for the port itself | Ephemeral ports are not typically listening services | | Information disclosure | Yes | Unlogged outbound connections can hide indicators of compromise | | Denial of service | Yes | Port exhaustion under load can block outbound connectivity | | Tampering | Indirectly | Depends on the protocol carried, not the port assignment | The documentation a reviewer expects is not a claim that ephemeral ports are "secured." It is a data flow description: destination IP or FQDN, destination port, protocol, and the logging that would surface an unusual outbound connection or a repeated failure. Excluding ephemeral port ranges themselves from the active threat register, with a one-line reason that they are client-side and not exposed listeners, is a legitimate exclusion under the documentation standard this article describes, as long as egress logging and destination allow-listing are addressed as the actual relevant controls. ## Does Steganography Belong in Your Threat Model? Steganography, hiding data or executable payloads inside legitimate-looking files or traffic, clears the relevance bar for any device with an imaging interface, a firmware update channel, or a telemetry stream, because the threat source, capability, and harm are all documented in the wild rather than theoretical. CISA and the HHS Health Sector Cybersecurity Coordination Center have both published advisories on payloads embedded in DICOM headers and on update-channel abuse where a firmware image passes a naive signature check while carrying smuggled code. That is exactly the kind of sourced, real-world threat source this article's relevance test asks you to look for before adding an entry to the active register. Running STRIDE at the element level, rather than treating "steganography" as one generic line item, surfaces where it actually attaches to your architecture: | Interface or element | Relevant covert-channel risk | STRIDE category | | --- | --- | --- | | DICOM or imaging transfer | Payload hidden in image metadata or pixel data | Information disclosure, tampering | | Firmware update channel | Code smuggled inside a validly signed but bloated image | Tampering | | Telemetry stream | Data or command signals hidden in timing or header fields | Information disclosure | | Configuration or log files | Hidden instructions in unused fields | Elevation of privilege | A device with no imaging interface, no update channel accepting external files, and no telemetry stream leaving the device has a legitimate basis to exclude covert-channel threats, with that reasoning stated in the exclusion log rather than left implicit. Most connected devices do not meet that bar, since firmware updates alone are close to universal. The mitigations trace back to the same integrity controls this site covers elsewhere: signed and verified updates, egress filtering against a known destination list, entropy or size anomaly monitoring on outbound data, and payload validation for DICOM or HL7 interfaces. Documenting the relevance decision, and the specific interface it maps to, is what turns "we considered steganography" from a narrative claim into evidence a reviewer can trace. ## How Blue Goat Cyber Approaches This We start relevance decisions from your intended use statement and your interface inventory, not from a generic threat list, because those two inputs are what actually change which threats apply to your device. Our team, which includes CISSP and OSCP certified engineers and former military red team members, runs STRIDE at the element level and documents both the included and excluded threats so the reasoning survives a reviewer's questions. We keep patient safety impact and data impact on separate tracks throughout the analysis, which lets us hand engineering a prioritized list for design mitigation rather than a single blended severity score that obscures which threats need physical redesign versus which need an encryption fix. If the FDA raises cybersecurity deficiencies tied to our submission work, we resolve them at no additional cost. Our [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) build this relevance analysis as a documented, traceable deliverable rather than a narrative summary. ## Frequently Asked Questions **Is a generic threat catalog ever useful?** Yes, as a starting checklist to make sure you have not overlooked a category, but it cannot be the final artifact. Every entry from a generic catalog needs to be tested against your specific architecture and intended use before it earns a place in your active threat register. **How many threats should a typical device's threat model contain?** There is no fixed number, and a reviewer is not counting entries. What matters is that every interface from your attack surface inventory has been evaluated with STRIDE and that the relevant threats trace to real elements of your architecture, with exclusions documented rather than omitted. **Do we need separate threat models for different use environments?** If a device is indicated for more than one use environment, the threat model should account for the weaker environment's assumptions, as covered in the [home use versus hospital cybersecurity post](/blog/home-use-vs-hospital-device-cybersecurity). A single model can cover both if it is built against the more permissive attacker access. **How does STRIDE differ from a DREAD or CVSS scoring approach?** STRIDE is a categorization method that helps you find and name threats systematically across a data flow diagram. DREAD and CVSS are scoring methods applied afterward to rank the threats STRIDE surfaced by severity and likelihood. You typically need both: STRIDE to find relevant threats, then a scoring method to prioritize them. **What happens if a reviewer disagrees with a relevance exclusion?** They will ask for the reasoning behind the exclusion, which is exactly why the exclusion log needs to state a specific, architecture-grounded reason rather than a general risk acceptance statement. A well-documented exclusion is usually resolved with a clarifying response; an undocumented one often becomes a formal deficiency. **Does threat relevance change after the device ships?** Yes. New attack techniques, newly disclosed component vulnerabilities, and field data on actual use environments can all shift which threats are relevant, which is why AAMI TIR97 ties this analysis to postmarket surveillance rather than treating it as a one-time premarket exercise. ## CTA If your threat model reads like a catalog rather than an argument built from your own architecture, that is what a reviewer will notice first. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) and we will walk your device's interfaces into a threat model that holds up to that scrutiny. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Unresolved Anomalies in FDA Cybersecurity Filings Source: https://bluegoatcyber.com/blog/unresolved-anomalies-fda-cybersecurity-submission # Unresolved Anomalies in FDA Cybersecurity Submissions: What Reviewers Expect > **[DIRECT ANSWER]** The unresolved anomalies assessment lists security-relevant defects and vulnerabilities you are shipping with, along with the safety impact, compensating controls, and the plan and timeline to fix them. The deficiency pattern is an empty or silent list, because reviewers assume a real device has known open items and expect the residual risk argument instead. _Published June 11, 2026_ ## Key Takeaways - The Feb 2026 final guidance expects an explicit unresolved-anomalies assessment, not silence. - "None known" is acceptable, if the assessment process behind it is documented. - Each unresolved anomaly must include: identifier, description, cybersecurity impact, compensating controls, residual-risk justification, planned resolution. - Common sources: third-party CVEs with `under_investigation` VEX status, pen test findings deferred to next release, known suppression of static analysis findings. - The assessment lives in eSTAR v7.0 Slot 7 (Testing), referenced from Slot 4 (Risk Assessment) and Slot 5 (SBOM). ## Why this matters Reviewers know that no real device ships with zero open findings. A clean submission acknowledges what is open, characterizes the risk, and shows that the residual is acceptable. The Feb 2026 guidance is explicit: > **[FDA LANGUAGE]** "The submission should include an assessment of the cybersecurity impact of any unresolved anomalies, identified by the manufacturer or known from third-party sources, that remain in the device at the time of submission." Submissions that omit the section, or include a one-liner saying "no unresolved anomalies," draw the same deficiency pattern: "Provide the manufacturer's assessment process and the results, including any items identified and the rationale for leaving them unresolved." That request stops the review clock on PMA / De Novo and triggers an AI request on 510(k). ## What counts as an unresolved anomaly Reviewers treat the following as in-scope for the anomaly assessment: - **Known CVEs in third-party components** that are present in the SBOM but not yet patched, including those VEX-marked `under_investigation` or `affected` with a deferred fix - **Static analysis findings** that have been triaged and suppressed (with rationale) but remain in the codebase - **Dynamic analysis / DAST findings** that were accepted as low-risk or deferred to a future release - **Penetration test findings** that were not remediated before submission - **Fuzz testing crashes** that have been triaged but not yet fixed - **Architectural decisions** that introduce known residual risk (e.g. legacy protocol support required for interoperability) - **Configuration items** that are not at the cybersecurity ideal (e.g. a logging level that is reduced for performance) This is not a list of failures. It is a list of decisions. Reviewers credit explicit decisions and penalize silence. ## What every anomaly entry must contain A compliant entry has six elements: 1. **Identifier**, internal tracking ID, plus CVE / CWE where applicable. 2. **Description**, what the anomaly is, in language a reviewer can understand without internal context. 3. **Cybersecurity impact**, the threat(s) it relates to (referenced by Slot 3 threat model ID), the patient-harm pathway it could enable, and the CVSS or equivalent severity. 4. **Compensating controls**, what is in place that reduces the practical risk (network isolation, authentication requirement, off-by-default configuration, monitoring detection). 5. **Residual-risk justification**, why the remaining risk is acceptable, tied to the Slot 4 risk assessment thresholds. 6. **Planned resolution**, when and how the anomaly will be addressed (next minor release, next major release, monitored indefinitely with rationale). For VEX-driven CVE entries, the VEX statement and the entry above must agree. Reviewers cross-check. ## How to present a clean assessment The cleanest format we have seen accepted is a single appendix to the Slot 7 Testing attachment with two tables and a narrative: **Table 1, Anomaly process.** How does the manufacturer surface anomalies? What feeds are watched (NVD, GitHub Advisory DB, CISA KEV, EPSS, vendor advisories, internal bug tracker, pen test reports, fuzz use output)? Who triages? On what cadence? **Table 2, Open anomalies at submission.** One row per anomaly with the six required elements above. **Narrative.** A one- to two-page summary that explains the patterns reviewers should expect to see, calls out the highest-residual items, and links each one back to the Slot 4 residual-risk argument and the postmarket monitoring plan. ## Common deficiency patterns 1. **No assessment at all.** "Submission does not contain an assessment of unresolved cybersecurity anomalies. Provide." 2. **"None" without process.** "Manufacturer states no unresolved anomalies. Provide the process by which anomalies are identified and triaged, and the evidence supporting the 'none' conclusion." 3. **CVE list without VEX agreement.** SBOM shows an applicable CVE; anomaly assessment does not list it; no VEX statement disposes of it. Reviewers flag the inconsistency. 4. **Pen test findings deferred without rationale.** Pen test report shows a Medium finding; anomaly list shows the same finding "deferred"; no compensating control listed and no residual-risk argument. Reviewers ask why. 5. **Suppressed SAST findings with stub rationale.** "False positive" with no detail. Reviewers want the analysis that supports the suppression. ## How Blue Goat Cyber prepares anomaly assessments We treat the anomaly assessment as a synthesis deliverable that draws from the SBOM, the SAST/DAST reports, the pen test report, and the fuzz use output. Every entry is checked against its source artifact and against the Slot 4 residual-risk thresholds. VEX statements are reconciled with the assessment entries. The assessment goes into the Slot 7 attachment with cross-references that let a reviewer trace any item back to its source in one hop. Where decisions favor deferral, we write the compensating-control narrative before submission, not in response to a deficiency. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** See our [cybersecurity submission services](/services/medical-device-cybersecurity). ## FAQ ### Is "no unresolved anomalies" an acceptable answer? Yes, if the **process** behind that answer is documented. Reviewers accept "no unresolved anomalies at the time of submission" when the assessment process is described and the inputs (SBOM scan, SAST, DAST, pen test, fuzz use output) are summarized. They reject the same sentence when it stands alone. ### How is this different from the SBOM vulnerability analysis? The SBOM vulnerability analysis identifies which CVEs in third-party components apply to your device and assigns VEX status. The anomaly assessment is the broader synthesis that also includes first-party findings (SAST, DAST, pen test, fuzz) and architectural decisions. The SBOM analysis feeds the anomaly assessment. ### Do we have to fix every Medium or higher pen test finding before submission? No, but every Medium-or-higher finding that remains open at submission belongs in the anomaly assessment with a compensating control and a residual-risk argument. Reviewers credit transparency. They penalize silence. ### Where does the anomaly assessment live in eSTAR? Slot 7 (Testing), with cross-references to Slot 4 (Risk Assessment) for the residual-risk thresholds and Slot 5 (SBOM) for the third-party CVE entries. ### How often should the anomaly assessment be updated? Before every submission and at every major release postmarket. Many manufacturers maintain a live anomaly register and snapshot it at submission time. ## Need help preparing your anomaly assessment? If you are within 4-8 weeks of a 510(k), De Novo, or PMA submission and have not yet built the unresolved anomalies appendix, we will synthesize it from your existing artifacts and write the residual-risk argument. [Request a scoping call](/contact). --- _Christian Espinosa, Founder, Blue Goat Cyber. CISSP, ex-military red team. Has prepared anomaly assessments for more than 275 FDA-submitted medical devices. [More on the author](/team/christian-espinosa)._ ## Related reading - [FDA Cybersecurity Testing Requirements Taxonomy](/guides/fda-cybersecurity-testing-requirements-taxonomy) - [The SPDF Playbook](/guides/medical-device-cybersecurity-spdf-playbook) - [eSTAR v7.0 Cybersecurity Attachments mapping](/guides/estar-v7-cybersecurity-mapping-fda-2026-guidance) - [Cybersecurity Management Plan for FDA Submissions](/guides/cybersecurity-management-plan-fda-medical-devices) - [Security Control Categories the FDA Expects](/guides/fda-security-control-categories-medical-devices) - [STRIDE Threat Modeling for Medical Devices](/guides/stride-threat-modeling-medical-devices) --- ## More on this topic - [Mastering Cybersecurity in MedTech](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) --- ## 5 VEX Mistakes That Trigger FDA Findings Source: https://bluegoatcyber.com/blog/vex-mistakes-fda-deficiencies # 5 VEX Mistakes That Trigger FDA Cybersecurity Deficiencies > **[DIRECT ANSWER]** Five VEX mistakes generate FDA findings: publishing status values with no technical justification, marking components not affected without naming the code path that makes them unreachable, letting the VEX drift out of sync with the shipped SBOM version, omitting CISA KEV entries entirely, and delivering VEX as prose instead of machine-readable CycloneDX or CSAF. Fix all five before submission, because reviewers cross-check the VEX against your SBOM line by line. **A VEX document is supposed to make your SBOM easier for FDA reviewers to read. Done wrong, it does the opposite - it gives the reviewer a stack of unanswered CVEs and a reason to issue a deficiency letter. Here are the five mistakes we see most often, and exactly how to avoid each one.** If you're preparing a 510(k), De Novo, or PMA submission under the February 2026 final FDA premarket cybersecurity guidance, your SBOM will travel with a Vulnerability Exploitability eXchange (VEX) document. The VEX is what tells the reviewer "we know about CVE X - here's why it doesn't affect this device." Get it right and the reviewer moves on. Get it wrong and you'll be answering questions for the next 180 days. Across 275+ FDA submissions, the same five VEX mistakes account for the majority of cybersecurity deficiency findings tied to vulnerability management. Fix these before you submit. > New to VEX? Read the [VEX document guide for medical devices](/guides/vex-document-medical-device-fda) first, then come back here for the failure modes. ## Key Takeaways - Update VEX frequently during FDA review. - Justify 'not affected' with specific evidence. - Ensure SBOM and VEX components match exactly. - Address all CVEs with CVSS ≥ 7.0 explicitly. - Use correct VEX format for your SBOM. - Validate VEX against a complete checklist. ## Why this matters VEX (Vulnerability Exploitability eXchange) documents are critical for demonstrating software transparency and safety to the FDA. Mishandling your VEX can lead to significant delays in product approval, as the FDA requires thorough cybersecurity documentation in premarket submissions. Without an accurate and well-maintained VEX, reviewers may interpret unaddressed vulnerabilities as potential risks to device safety and effectiveness. This often results in a deficiency letter, requiring device manufacturers to expend additional time and resources to revise and resubmit documentation. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly outlines expectations for SBOMs and associated vulnerability information, including the need to explain the exploitability status of identified CVEs. Failing to meet these requirements can stall market access and impact revenue projections. Adhering to standards like IEC 81001-5-1, ISO/IEC 27034, and AAMI TIR107 is crucial for developing VEX documents that satisfy regulatory scrutiny and ensure patient safety. A flawed VEX not only delays approval but also reflects poorly on a manufacturer’s commitment to cybersecurity hygiene, potentially inviting greater scrutiny on future submissions. ## Mistake 1: Treating VEX as a one-time deliverable The single biggest mistake is generating a VEX once - at submission - and never updating it. A VEX is a **living artifact**. Between the day you generate it and the day a reviewer reads it, new CVEs in your dependencies will land. If your SBOM lists `openssl 3.0.7` and three CVEs were published against that version after you submitted, the reviewer sees three unanswered vulnerabilities. That's a deficiency every time. **How to fix it:** - Regenerate the VEX **on the same cadence as your SBOM** - minimum monthly during active review. - Include a "VEX generation date" and "SBOM correlation hash" in the cover letter so the reviewer can confirm they're paired. - Build VEX regeneration into your secure development framework (SPDF) as a documented process, not an ad-hoc task. The fix is operational, not technical. Teams that automate VEX generation in CI never see this finding. ## Mistake 2: "Not affected" with no justification Every VEX statement carries a status: `not_affected`, `affected`, `fixed`, or `under_investigation`. The trap is `not_affected` - it requires a `justification` field, and reviewers read every one. Common bad justifications: - "Not exploitable in our use case." *(why?)* - "Code is not executed in production." *(prove it)* - "Mitigated by network controls." *(which controls? where documented?)* Vague justifications don't close the loop. The CISA-defined justification codes (`component_not_present`, `vulnerable_code_not_present`, `vulnerable_code_not_in_execute_path`, `vulnerable_code_cannot_be_controlled_by_adversary`, `inline_mitigations_already_exist`) exist for a reason - **use them by name** and include an `impact_statement` field that points to the specific design control, configuration, or test result that backs the claim. **Good example:** ```json { "status": "not_affected", "justification": "vulnerable_code_not_in_execute_path", "impact_statement": "The vulnerable parser in libxml2 is only invoked by the optional config-import feature, which is disabled at compile time in the production firmware build (see build flag CONFIG_NO_IMPORT in /firmware/build.config, line 142). Verified by static analysis report DEV-SAST-2026-04-12, finding ID SAST-114." } ``` That kind of specificity is what closes a deficiency. "Not exploitable" alone does not. ## Mistake 3: Mismatch between SBOM and VEX components A VEX statement references components by PURL (`pkg:npm/lodash@4.17.21`) or CPE. Reviewers cross-check every reference against your SBOM. Common mismatches that trigger findings: - VEX references `pkg:npm/lodash@4.17.21` but your SBOM lists `pkg:npm/lodash@4.17.20`. - VEX uses CPE format; your SBOM uses PURL. - VEX names a component the SBOM doesn't include at all (often a transitive dependency that was filtered out). - Version strings don't match because one document was generated against the dev build and the other against the release build. Reviewers don't reconcile these for you. They flag the mismatch and ask which document is authoritative. **How to fix it:** - Generate the SBOM and VEX from the **same build artifact in the same CI run**. - Standardize on **PURL** for both documents (PURL is the FDA-friendly default for software; CPE is fine for OS and firmware components). - Validate the SBOM ↔ VEX pairing programmatically before submission - every component referenced in the VEX must exist in the SBOM at the same version. ## Mistake 4: Missing VEX for high-CVSS CVEs Reviewers don't read every VEX entry. They sort the CVEs by CVSS score and read the high ones first. If a CVE in your SBOM has a CVSS of 9.8 and your VEX is silent on it, that's the first thing the reviewer sees - and the first thing they'll ask about. The fix is procedural: **never submit a package where any CVE with a CVSS ≥ 7.0 lacks a VEX entry**. Status can be `under_investigation` if you genuinely don't know yet, but silence is not an option. **Pre-submission checklist:** 1. Pull every CVE from the SBOM-driven vulnerability scan. 2. Filter to CVSS ≥ 7.0. 3. Confirm a VEX statement exists for every one. 4. For any `under_investigation`, document the investigation owner and target close date in the cover letter. A single missing high-CVSS VEX entry is enough to trigger a deficiency. This is a 30-minute check that prevents weeks of back-and-forth. ## Mistake 5: Wrong VEX format for the FDA pathway The FDA accepts VEX in three formats: **CSAF 2.0 VEX**, **CycloneDX VEX**, and **OpenVEX**. They are not interchangeable for every reviewer. Common errors: - Submitting a CycloneDX VEX with a SPDX SBOM and no mapping document. - Embedding VEX statements inline in a CycloneDX SBOM and not providing a standalone VEX file. Reviewers want both - the embedded statements *and* a separate, machine-readable VEX document the reviewer can parse independently. - Using OpenVEX without including the JSON Schema reference, so the reviewer's tooling can't validate it. **The rule of thumb:** match your VEX format to your SBOM format (CycloneDX VEX with CycloneDX SBOM, CSAF VEX with SPDX SBOM), and always ship a **standalone, schema-validated VEX file** alongside any embedded statements. If you're choosing between SBOM formats, our [CycloneDX vs SPDX guide for medical devices](/guides/cyclonedx-vs-spdx-medical-devices) covers the tradeoffs the FDA cares about. ## A pre-submission VEX checklist Before you ship a submission package, walk through this list: - [ ] VEX generation date is within 30 days of submission - [ ] VEX and SBOM share the same build artifact and hash - [ ] Every `not_affected` entry uses a CISA-defined justification code - [ ] Every `not_affected` entry has an `impact_statement` with a specific evidence reference - [ ] Every CVE with CVSS ≥ 7.0 has an explicit VEX entry - [ ] Component references (PURL/CPE) match exactly between SBOM and VEX - [ ] VEX file is schema-valid and standalone (not only embedded) - [ ] Cover letter explains the SBOM ↔ VEX correlation and the regeneration cadence Teams that complete this checklist before submission don't get VEX-driven deficiencies. Teams that skip it usually find out which step they missed when the FDA letter arrives. ## How Blue Goat approaches this Our approach to VEX documentation focuses on accuracy and regulatory alignment, avoiding common pitfalls that lead to FDA deficiencies. We assist medical device manufacturers in generating, validating, and maintaining VEX documents that meet the specific requirements of the FDA's “Cybersecurity in Medical Devices” Final Guidance dated February 3, 2026. Our team, comprised of certified experts (CISSP, OSCP, ex-military red team), ensures each VEX clearly articulates the exploitability status of vulnerabilities for your device. We specialize in careful review and alignment of SBOMs and VEX documents, ensuring consistency and proper justification for all vulnerability statuses. Our process identifies and rectifies common errors, such as outdated VEX information or insufficient 'not affected' justifications, *before* submission. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our validation processes for submissions: [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### Does the FDA require a VEX document? The FDA's February 2026 final premarket cybersecurity guidance expects a vulnerability assessment that addresses every component in the SBOM. A VEX document is the most practical way to deliver that assessment in a machine-readable, reviewer-friendly format. While the guidance does not name VEX by name as mandatory, every modern submission ships one. ### Can I use OpenVEX instead of CSAF or CycloneDX VEX? Yes. OpenVEX is acceptable. Include the schema reference in the document header so the reviewer's validation tooling can parse it. The deciding factor is consistency with your SBOM format, not the VEX format itself. ### How often should I regenerate VEX during FDA review? Monthly at minimum during active review, and immediately if a high-CVSS CVE lands against a component in your SBOM. The FDA reviewer's lookup happens at read-time, not at submission-time - out-of-date VEX is the most common VEX-related deficiency. ### What's the difference between VEX and a vulnerability scan report? A vulnerability scan report tells you which CVEs were detected against your SBOM. A VEX document tells the reviewer **what you did about each one** - affected, not affected (and why), fixed, or under investigation. The scan is input, the VEX is output. ### If a CVE is fixed in a later version, do I still need a VEX entry? If your SBOM ships the patched version, no VEX entry is needed for that CVE - your SBOM already shows the fix. If your SBOM still ships an older version and the CVE is fixed upstream, mark it `fixed` in the VEX and explain why you can't yet upgrade, or `not_affected` if the vulnerable code path is not reachable in your build. ## Want a second pair of eyes on your VEX? If you're about to ship a 510(k), De Novo, or PMA package and want a senior reviewer to walk your SBOM and VEX before the FDA does, we triage submission packages under NDA in 24 hours. We've shipped clean VEX-backed responses on 275+ FDA submissions. - See the full [VEX document reference guide](/guides/vex-document-medical-device-fda) - Read **[SBOM vs VEX: What's the difference?](/blog/sbom-vs-vex-difference)** if your team is still unclear on the split - If you already have an FDA letter in hand, see [which letter you got](/blog/fda-deficiency-letter-vs-rta-vs-hold-letter) and [book a deficiency response call](/lp/fda-deficiency-letter) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## VM Escape Attacks: How They Work Source: https://bluegoatcyber.com/blog/vm-escape-medical-device-cybersecurity # VM Escape in Medical Device Cybersecurity: Risk and Mitigations > **[DIRECT ANSWER]** VM escape is a failure of the virtualization boundary that lets a process running inside a guest virtual machine break out and reach the host or hypervisor, turning one compromised workload into a platform-wide compromise. In MedTech it threatens cloud services, customer-hosted virtual appliances, remote support systems, and build pipelines that touch device data or signing keys. Teams should isolate the management plane, patch hypervisors aggressively, segment workloads, and monitor at the host level to reduce exposure. ## Key Takeaways - **VM escape** is a boundary failure where a guest VM reaches the host or hypervisor, turning a contained compromise into a platform compromise. - In MedTech, VM escape is often an **ecosystem risk**: cloud services, customer-hosted virtual appliances, remote support, and build/signing infrastructure. - Best defenses are layered: management plane isolation, aggressive patching, reduced host-guest attack surface, workload segregation, egress controls, and host-level monitoring. - For FDA-aligned evidence, document virtualization trust boundaries, risk controls, and verification artifacts that demonstrate secure-by-design and lifecycle readiness. ## Why this matters VM escape poses a severe risk to medical device ecosystems, potentially compromising sensitive patient data, device functionality, and the integrity of supporting infrastructure. An attacker exploiting a VM escape vulnerability could move from a compromised virtual machine to the underlying host, gaining unauthorized access to other patient data, control systems, or even the ability to manipulate medical device operations. This type of breach can lead to HIPAA violations, severe patient harm, loss of trust, and significant financial penalties. The FDA, in its Cybersecurity in Medical Devices Final Guidance dated February 3, 2026, explicitly expects manufacturers to address security risks across the entire product lifecycle, including those within virtualized environments. This guidance emphasizes adopting a secure-by-design approach and implementing risk management strategies for all components of the medical device ecosystem. Manufacturers must demonstrate that virtualized components meet industry standards for security and isolation, aligning with principles found in IEC 81001-5-1 for health software and AAMI TIR57 / ANSI/AAMI SW96:2023 for medical device security risk management, to protect against sophisticated threats like VM escape. ## What is VM escape? A **virtual machine (VM)** is a software-based system that behaves like a dedicated computer while sharing physical resources with other VMs on a host. Virtualization relies on a **hypervisor** (or host virtualization layer) to provide isolation between guests. **VM escape** refers to vulnerabilities or exploit chains that allow a process in the guest VM to **break out** of the guest boundary and interact with or compromise the host/hypervisor. In other words: the isolation boundary fails. Why this matters: NIST notes that virtualized environments can be dynamic and complex, and security boundaries can become harder to maintain. NIST SP 800-125 provides guidance on security concerns and recommendations for full virtualization technologies. [NIST SP 800-125](https://csrc.nist.gov/pubs/sp/800/125/final) ## VM escape vs. related concepts (don’t mix these up) Teams often use “escape” as a catch-all. For threat modeling and response, these distinctions help: ### VM escape vs. management plane compromise - **VM escape**: guest workload breaks isolation through a hypervisor/host boundary weakness. - **Management plane compromise**: attacker gets access to vCenter/Hyper-V management, cloud console, orchestration APIs, etc. This can be just as catastrophic, but it’s not technically “escape.” ### VM escape vs. container escape - **VM escape** crosses a hypervisor boundary. - **Container escape** crosses a container runtime boundary (often into the host OS kernel). The mitigations overlap (least privilege, patching, hardening), but your control points differ. ### VM escape vs. sandbox/virtualization evasion - **Sandbox/virtualization evasion** is when malware detects it’s running in a VM/sandbox and changes behavior to avoid analysis. MITRE ATT&CK tracks this as Virtualization/Sandbox Evasion (T1497). [MITRE ATT&CK T1497](https://attack.mitre.org/techniques/T1497/) - **VM escape** is about breaking out of the VM to reach the host/hypervisor. ## Where VM escape risk shows up in medical device ecosystems If your first reaction is “we don’t use VMs in our device,” you’re probably thinking too narrowly. VM escape is an **ecosystem risk**. Here are the MedTech scenarios where it becomes real: ### 1) Cloud workloads that process telemetry, clinical workflow data, or support artifacts Even when PHI/PII is not your primary data type, cloud services may process sensitive operational data: device IDs, customer site metadata, logs, remote support artifacts, keys/tokens, and update distribution metadata. A single compromised workload that escalates to the host can expose more than you expected. ### 2) Customer-hosted “virtual appliances” (hospital DMZ gateways, integration brokers) Many manufacturers ship on-prem virtual appliances to simplify integration or to isolate device communications. If that appliance runs on a shared virtualization platform, the risk includes both: - the appliance being compromised, and - the compromise affecting other workloads on the host (or vice versa). ### 3) Remote support environments and jump infrastructure Remote support often concentrates privileged access: customer connectivity, admin tools, credentials, and “break glass” procedures. If those systems are virtualized (often they are), protect them like high-value assets, because they are. ### 4) Build, signing, and release pipelines CI/CD runners, build VMs, artifact repositories, and signing infrastructure are frequent targets. A hypervisor-level compromise here can become a supply chain problem fast: modified build outputs, stolen signing keys, or tampered update packages. ## Why FDA-aligned teams should care (beyond “it’s scary”) FDA’s current guidance emphasizes secure-by-design development, cybersecurity risk management, and evidence that you can maintain cybersecurity across the total product lifecycle. The guidance is intended to promote consistency and efficient premarket review, and it also addresses expectations for “cyber devices” under section 524B of the FD&C Act. [FDA Cybersecurity in Medical Devices guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) VM escape is not something you “document away,” but it is something you can show you’ve **designed down** through: - clear architecture and trust boundaries (where virtualization sits and what it protects), - hardening baselines and patch hygiene, - least privilege and secrets management, - monitoring and incident readiness, - and verification artifacts that tie controls to risk. ## How VM escape attacks typically happen VM escape usually requires one of two things: (1) a vulnerability in the hypervisor/host boundary, or (2) an overly-permissive configuration that makes exploitation easier or increases impact. ### Common technical pathways - **Hypervisor vulnerabilities** in emulated/paravirtual devices, VM tools, or boundary services. - **Exposed management interfaces** and weak admin controls (a different but equally dangerous pathway). - **Risky integrations** such as shared folders, clipboard sharing, copy/paste, or host-guest channels that expand the boundary surface. - **Device passthrough** (USB/GPU/PCI) and broad access to host resources. - **Weak tenant/workload isolation** when multiple critical workloads share a host without strong segmentation and policy. NIST SP 800-125 and SP 800-125A Rev.1 provide practical recommendations for securing virtualization and server-based hypervisor platforms, including the need to secure baseline hypervisor functions and the surrounding environment. [NIST SP 800-125](https://csrc.nist.gov/pubs/sp/800/125/final) [NIST SP 800-125A Rev.1](https://csrc.nist.gov/pubs/sp/800/125/a/r1/final) ## Risk assessment: when VM escape is “high” vs. “manageable” Not every virtualized environment has the same exposure. Use a simple risk lens during threat modeling and architecture reviews: ### Higher risk conditions - Workloads handle **regulated data** or high-value secrets (tokens, keys, signing certs). - Multiple workloads share hosts across different trust levels (e.g., support tooling + analytics + general IT). - Management plane is reachable from broad networks or lacks strong MFA/RBAC. - Slow patch cadence or unmanaged hypervisor versions. - Customer-hosted deployments where you cannot enforce hardening/patching. ### Lower risk conditions - Single-purpose hosts with limited workload mix and strong segmentation. - Strict management plane isolation and tight administrative access controls. - Fast patch SLAs for hypervisor/host vulnerabilities. - Minimal host-guest integrations and reduced attack surface. ## Controls that actually reduce VM escape risk (and produce good evidence) There is no single control that “stops VM escape.” The goal is to reduce likelihood and blast radius with layered protections that you can verify and document. ### 1) Treat the hypervisor management plane as a Tier-1 asset - **Isolate management networks** from production and user networks. - **Strong admin authentication** (MFA) and strict role-based access control. - **Limit admin pathways**: bastion/jump hosts, conditional access, and audit trails. - **Monitor management actions** (new VM creation, snapshot/export, network changes, role changes). ### 2) Patch aggressively with explicit SLAs Hypervisor boundary vulnerabilities deserve “drop everything” attention. Define patch SLAs by severity and prove adherence: - Critical hypervisor/host vulnerabilities: patch within a defined short window. - High severity: patch quickly or document compensating controls. - Anything end-of-life: explicitly accept risk or migrate-don’t drift. NIST’s virtualization guidance emphasizes the complexity of maintaining security boundaries in virtual environments and provides recommendations for addressing those concerns. Patch discipline is part of that boundary maintenance. [NIST SP 800-125](https://csrc.nist.gov/pubs/sp/800/125/final) ### 3) Reduce attack surface at the guest-host boundary - Disable unnecessary host-guest integrations (shared clipboard/folders, unused virtual devices). - Restrict passthrough features unless justified by requirements and controlled by policy. - Keep VM tools/integration services to the minimum required and patched. ### 4) Strong workload isolation and blast-radius control - **Separate high-value workloads** (signing, update distribution, remote support) onto dedicated hosts or tightly controlled clusters. - **Segment networks** so a compromised workload cannot freely pivot laterally. - **Egress allowlisting** for sensitive workloads: restrict outbound to known destinations/ports. Internal link opportunity: [Network segmentation as a security strategy](/blog) ### 5) Least privilege everywhere (including inside guests) - Run services as non-root/non-admin where feasible. - Use short-lived credentials and scoped tokens. - Centralize secrets management and avoid static secrets baked into images. ### 6) Monitoring and detection for virtualized environments Traditional network monitoring is helpful, but incomplete. Add host-level and management-plane visibility: - Hypervisor and host OS logs (auth events, service changes, kernel alerts where available). - Management-plane audit logs (role changes, network reconfig, VM exports). - Alerts for anomalous VM behavior (unexpected admin tools, unusual process trees, new persistence). - Baseline expected outbound destinations; alert on new domains/IPs and unusual traffic rates. ### 7) Recovery readiness (because “assume breach” is practical here) - Test backups and restore procedures for management plane components. - Define “clean rebuild” playbooks for hosts and clusters. - Practice isolating a compromised host without taking down safety-critical services. ## How to test VM escape risk without “trying to exploit the hypervisor” Most manufacturers (and many security consultancies) do not attempt full hypervisor exploit development-nor should that be the default expectation. Practical verification is still possible: - **Configuration verification**: confirm hardening baselines, disabled features, and management plane isolation. - **Patch verification**: prove version hygiene and time-to-remediation for hypervisor advisories. - **Privilege validation**: confirm least privilege for admins and service accounts. - **Attack path reviews**: simulate “guest compromise” and validate containment (segmentation, egress control, detection, response playbooks). - **Tabletop + technical drills**: validate your ability to collect evidence and recover. NIST SP 800-125A Rev.1 focuses on recommendations to ensure secure execution of baseline hypervisor functions and provides a useful framework for what to validate as part of deployment and operations. [NIST SP 800-125A Rev.1](https://csrc.nist.gov/pubs/sp/800/125/a/r1/final) ## FDA-aligned documentation: what to include in your “evidence pack” If VM escape is relevant to your device ecosystem, your documentation should make it easy to see the boundary, the risk, and the controls. Aim for clarity and verifiability: ### Architecture and boundary artifacts - Architecture diagrams showing virtualization layers and trust boundaries. - Data flow diagrams for regulated data, secrets, update distribution, and remote access paths. - An inventory of virtualization platforms used in the ecosystem (not just “cloud”). ### Control evidence - Hardening standards/baselines for hypervisors and management planes. - Patch SLAs and records demonstrating remediation performance. - RBAC model and admin access control evidence (MFA, role separation, audit trails). - Segmentation and egress control documentation for high-value workloads. - Monitoring and incident response procedures specific to virtualized environments. FDA’s guidance is focused on secure-by-design practices and the information to include in premarket submissions for devices with cybersecurity risk, supporting consistent review and lifecycle readiness. [FDA guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers identify and mitigate VM escape risks across their entire ecosystem. Our approach begins with a detailed assessment of your virtualized infrastructure, including cloud deployments, customer-hosted appliances, and CI/CD pipelines, employing methodologies aligned with NIST SP 800-125 recommendations. We conduct targeted penetration testing, perform architecture reviews, and implement threat modeling to uncover potential VM escape vectors. Our team, comprising OSCP-certified and ex-military red team experts, advises on hardening hypervisors, implementing least privilege principles, and establishing strong isolation controls. We integrate these security practices into your existing development and postmarket processes, ensuring compliance with the FDA's Cybersecurity in Medical Devices Final Guidance dated February 3, 2026. For premarket submissions, we offer targeted assistance. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is VM escape in simple terms? VM escape is when code inside a virtual machine breaks the isolation boundary and gains access to the host system or hypervisor. That can expose other VMs and the underlying platform. ### Do medical device manufacturers need to worry if the device itself isn’t virtualized? Often, yes. Your supporting ecosystem may be virtualized (cloud backends, virtual appliances, CI/CD, remote support). A compromise there can affect device security, data protection, update integrity, or service availability. ### What’s the most effective mitigation for VM escape risk? There’s no single fix. The highest ROI combination is usually: (1) isolate and harden the management plane, (2) patch hypervisors/hosts quickly with clear SLAs, and (3) minimize host-guest integrations and risky passthrough features. NIST provides detailed recommendations for hypervisor deployment security. [NIST SP 800-125A Rev.1](https://csrc.nist.gov/pubs/sp/800/125/a/r1/final) ### How should we handle VM escape risk in customer-hosted virtual appliances? Assume you cannot enforce perfect patching and hardening. Design for resilience: limit privileges, restrict outbound connections, minimize required integrations, provide clear hardening guides, and consider deployment patterns that separate your appliance from unrelated tenant workloads when feasible. ### How does VM escape relate to FDA cybersecurity expectations? FDA emphasizes secure-by-design development and lifecycle risk management. If virtualization supports your device ecosystem in ways that could affect confidentiality, integrity, availability, or safety, you should include it in threat modeling and provide evidence of controls and verification. [FDA guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) ### What should we log to improve detection of virtualization-layer incidents? At minimum: management-plane audit logs, hypervisor/host authentication logs, configuration change logs, and baselined outbound network destinations for high-value workloads. The goal is to detect unexpected administrative actions and unusual workload behavior early. ## Isolation approaches compared | Approach | Strength of the boundary | Where it fits in MedTech | What breaks it | | --- | --- | --- | --- | | Shared-kernel containers | Weakest, one kernel for all workloads | Internal tooling and stateless services | A kernel vulnerability reaches every workload on the host | | Type 2 hypervisor on a general OS | Moderate, the host OS is also attack surface | Developer and test environments | Host OS compromise, not the hypervisor itself | | Type 1 hypervisor | Strong, a thin layer with a smaller attack surface | Production virtual appliances and cloud services | Unpatched hypervisor bugs and over-permissive device passthrough | | Separate physical hosts | Strongest, no shared execution boundary | Signing keys, build systems, regulated data stores | Shared management network or shared credentials | | Separate accounts or tenants | Strong for blast radius, not for execution | Production versus development cloud estates | Cross-account roles nobody reviews | Most real incidents do not begin with a hypervisor exploit. They begin with a management plane that shares credentials with everything it manages. ## Conclusion VM escape is a reminder that “isolation” is an engineering claim that must be maintained-through hardening, patching, monitoring, and recovery readiness. For medical device manufacturers, the risk is often in the ecosystem more than the device. If you treat the hypervisor and management plane as tier-1 assets, design down the boundary surface, and build verifiable evidence, you’ll reduce real-world exposure and strengthen your FDA-aligned cybersecurity story. ## Book a Discovery Session If you need help threat modeling virtualized architectures (cloud and customer-hosted), building an FDA-aligned evidence pack, or validating controls with practical testing, let’s talk. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## DICOM Protocol Vulnerabilities in Medical Devices Source: https://bluegoatcyber.com/blog/vulnerabilities-with-dicom-in-medtech # DICOM Protocol Vulnerabilities in Medical Devices: Risks, Mitigations & FDA Expectations (2026) > **[DIRECT ANSWER]** DICOM protocol vulnerabilities in medical devices typically come from weak authentication that trusts IP addresses or Application Entity Titles, software flaws in viewers and PACS servers, and complex integrations across imaging systems that widen the attack surface. Exploitation can expose patient metadata, alter images, or disrupt clinical workflows. The FDA expects manufacturers to secure DICOM implementations through strong authentication, encryption, input validation, network segmentation, and postmarket vulnerability handling, not rely on the standard alone. DICOM is the format and transport layer that keeps medical imaging moving between modalities, viewers, PACS, and clinical systems. That makes it operationally indispensable, and a frequent source of security exposure when manufacturers and providers treat interoperability as separate from cybersecurity. DICOM itself is not the problem. Weak implementations, insecure configurations, outdated software, and flat hospital networks are. ## Key Takeaways - DICOM vulnerabilities stem from weak authentication and software flaws. - Complex integrations increase the attack surface for imaging systems. - Risks include patient data exposure and compromised image integrity. - Operational disruptions and financial losses are significant consequences. - Secure implementation and FDA alignment are critical for mitigation. - Basic security hygiene prevents most DICOM-related issues. ## Why this matters DICOM vulnerabilities are not merely theoretical concerns; they represent tangible threats to patient safety, data privacy, and operational continuity within healthcare. Unauthorized access to DICOM data can expose sensitive patient health information (PHI), leading to severe privacy breaches and non-compliance with regulations such as HIPAA. Beyond privacy, compromised DICOM images can be altered, potentially leading to misdiagnoses, delayed treatments, or even adverse patient outcomes. The integrity of medical imaging is paramount for effective clinical decision-making. The FDA's Cybersecurity in Medical Devices Final Guidance, dated February 3, 2026, explicitly mandates that manufacturers address cybersecurity risks throughout the total product lifecycle, including those associated with communication protocols like DICOM. Failure to adequately secure DICOM implementations can result in regulatory actions, significant financial penalties, and reputational damage. Adherence to standards such as IEC 81001-5-1, ISO 27001, and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) is crucial for establishing a resilient security posture. These vulnerabilities underscore the critical need for proactive security measures to safeguard both patient well-being and organizational stability. ## Understanding DICOM in MedTech DICOM is the [common language for sharing and exchanging medical imaging data](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples). It allows devices and software from different vendors to create, store, transmit, and display images in a consistent way. Without it, cross-system imaging workflows would break down fast. A DICOM object is more than an image file. It also carries metadata: patient identifiers, study details, modality settings, timestamps, measurements, annotations, and other clinical context. That metadata is exactly why DICOM is so useful, and exactly why it creates privacy and security risk when it is mishandled. [DICOM standards](https://www.dicomstandard.org/) support traditional modalities such as X-ray, CT, MRI, and ultrasound, along with newer workflows including 3D rendering, digital pathology, and advanced visualization. The standard’s reach across so many systems means a DICOM weakness rarely stays contained to one device. [DICOM compliance is not limited to image storage and transmission](/blog/securing-communication-protocols-in-medical-devices). It also affects how systems authenticate peers, protect data, log activity, and preserve integrity across clinical workflows. For device manufacturers, that matters not just for security engineering but for FDA submissions, risk management files, and postmarket response. ## Where DICOM Vulnerabilities Show Up ### Weak authentication and access control Many DICOM environments still rely on trust assumptions that do not hold up in modern healthcare networks. Systems may accept connections based on IP address, Application Entity Title, or network location without strong identity verification. That is not enough. When authentication is weak, attackers or unauthorized insiders may gain access to imaging studies, move laterally across connected systems, or push malicious data into clinical workflows. In practice, that can expose protected health information and undermine confidence in image integrity. ### Software flaws in viewers, servers, and gateways The bigger issue is usually not the DICOM standard on paper. It is the code that implements it. DICOM viewers, archives, modality worklist services, converters, and interface engines can all contain memory corruption bugs, parsing errors, insecure deserialization paths, or poor input validation. An attacker who can exploit those flaws may be able to execute arbitrary code, crash systems, alter image presentation, or tamper with associated metadata. That is not just an IT outage. In the wrong context, it can affect diagnosis, treatment planning, or surgical workflows. ### Complex integrations increase the attack surface DICOM rarely operates alone. It connects to [Picture Archiving and Communication Systems (PACS)](/blog/what-is-pacs-in-medical-devices), vendor-neutral archives, radiology viewers, modality worklists, and often EHR platforms. Every interface is another dependency. Every dependency is another place for bad assumptions to hide. That is why checklist security fails here. A device can claim DICOM support, use encryption somewhere in the workflow, and still be insecure because of poor certificate handling, weak segmentation, default accounts, unsupported legacy services, or unpatched third-party components. ## The Impact of DICOM Vulnerabilities on MedTech ![Section Image](/imported-images/d12ac7666ae7a1ad.webp) The most obvious risk is exposure of patient data. DICOM files can include names, dates of birth, medical record numbers, accession numbers, physician details, and embedded annotations. Unauthorized access can trigger privacy violations, breach notification requirements, and loss of patient trust. But confidentiality is only part of the problem. Integrity matters just as much. If an attacker modifies an image, changes metadata, swaps studies, or interferes with transmission, clinicians may make decisions based on inaccurate information. That risk deserves more attention than it usually gets. Healthcare providers also face operational fallout. A successful attack against imaging infrastructure can delay reads, interrupt scheduling, block image retrieval, and force downtime procedures. That affects revenue, patient throughput, and safety at the same time. For manufacturers, the consequences extend into regulatory and contractual territory. Security weaknesses tied to device software, interfaces, or maintenance practices can create problems during customer security reviews, procurement, incident response, and interactions with the FDA. If a product handles DICOM traffic but cannot support reasonable security controls, the market will notice. Exploiting [DICOM vulnerabilities can lead to significant financial losses](/blog) as well. Investigations, forensics, remediation, field updates, legal review, and customer communications are expensive. The cost climbs further when the issue touches shipped devices that cannot be patched easily or safely. ## Mitigating DICOM Vulnerabilities in MedTech ### Secure the implementation, not just the protocol The first step is simple: stop assuming DICOM interoperability equals secure design. It does not. Manufacturers should require strong authentication where feasible, encrypt data in transit, validate inputs aggressively, harden parsing logic, remove unnecessary services, and maintain a software bill of materials that includes DICOM libraries and supporting components. Patch discipline matters. So does secure configuration at deployment. Network architecture matters too. Imaging systems should not sit exposed on flat internal networks with broad trust relationships. Segmentation, monitored interfaces, least-privilege access, and controlled remote support reduce the blast radius when something goes wrong. ### Build for FDA scrutiny and postmarket reality Security claims around DICOM should be backed by evidence. That means threat modeling, abuse-case analysis, verification of security controls, and testing that reflects realistic hospital environments rather than ideal lab conditions. For medical device manufacturers, this lines up with what the FDA expects: secure product development, risk-based design controls, documented cybersecurity requirements, and a plan for vulnerability handling after release. If your DICOM workflow depends on assumptions customers cannot enforce, that is a product problem, not something to hand-wave into the user manual. ### Be careful with “future” fixes New ideas get a lot of attention here, especially blockchain and AI-based monitoring. They may have narrow use cases, but they are not substitutes for secure coding, segmentation, patching, logging, and incident response. Most DICOM security failures are still basic engineering failures. If you want better protection, start with fundamentals: authenticated connections, encrypted transport, hardening, visibility, tested update mechanisms, and a coordinated vulnerability disclosure process. ## The State of DICOM Security in MedTech ![Section Image](/imported-images/8ba6df40edae0eb8.webp) DICOM remains essential to modern care delivery. That will not change. What needs to change is the habit of treating imaging workflows as special-purpose clinical infrastructure that sits outside normal cybersecurity expectations. The real risks are clear: weak authentication, exploitable software, exposed metadata, fragile integrations, and poor operational controls. Left alone, those weaknesses can compromise privacy, disrupt care, and create serious regulatory and business consequences. Manufacturers that take DICOM security seriously will stand out. They design for hostile environments, validate their assumptions, support secure deployment, and prepare for postmarket vulnerability response before customers force the issue. Blue Goat Cyber helps medical device companies do exactly that. We support device manufacturers with medical device cybersecurity, penetration testing, threat modeling, and alignment with HIPAA and the FDA’s cybersecurity expectations. If DICOM is part of your product or ecosystem, [contact us today for cybersecurity help](/contact). Check out our [medical device cybersecurity FDA compliance package.](/) ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers identify and mitigate DICOM-related vulnerabilities. Our methodology begins with threat modeling, specifically analyzing how DICOM implementations introduce risk within varied clinical workflows. We then conduct targeted penetration testing of devices and integrated systems to uncover weaknesses in authentication, access control, and data handling within the DICOM standard. Our team, comprised of CISSP and OSCP certified professionals, including ex-military red team members, focuses on actionable remediation strategies. We provide detailed reports and work with your engineering teams to improve the security posture of your DICOM-enabled devices. Our services extend to premarket submissions, ensuring your cybersecurity documentation aligns with FDA expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support for FDA premarket submissions at [https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services). ## FAQ ### What are common DICOM vulnerabilities? Common DICOM vulnerabilities include weak authentication mechanisms, software defects in imaging viewers and servers, and insecure configurations arising from complex system integrations. These issues can allow unauthorized access or data manipulation. ### How does DICOM metadata create security risks? DICOM objects contain extensive metadata, such as patient identifiers, study details, and clinical context. If mishandled or inadequately protected, this metadata can lead to privacy breaches, unauthorized disclosure of protected health information, and regulatory non-compliance. ### Does the FDA address DICOM cybersecurity in its guidance? The FDA's February 3, 2026 final guidance on premarket cybersecurity expects medical device manufacturers to address cybersecurity risks across all device functions, including those involving DICOM. This includes secure design, risk management, and postmarket vulnerability handling. ### How can manufacturers mitigate DICOM vulnerabilities? Manufacturers should implement strong authentication, encrypt data in transit, validate inputs, harden parsing logic, and maintain a software bill of materials. Network segmentation and adherence to the FDA's secure product development principles are also essential. ### Can exploiting DICOM flaws impact patient safety? Yes, if an attacker modifies an image, alters metadata, or interferes with transmission, clinicians may make medical decisions based on inaccurate information. This can directly affect diagnosis, treatment planning, and surgical workflows, jeopardizing patient safety. **Related:** [What is a Coordinated Vulnerability Disclosure Process?](/cvd) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [MQTT Vulnerabilities in Connected](/blog/mqtt-vulnerabilities-connected-medical-devices-fda) --- ## V&V and Regression Testing for Medical Devices Source: https://bluegoatcyber.com/blog/vv-regression-testing-medical-device-cybersecurity # V&V and Regression Testing for Medical Device Cybersecurity (FDA §524B) > **[DIRECT ANSWER]** Verification proves each security control works, validation confirms the secured device still performs clinically, and regression testing proves a patch or model update did not break either. Together they generate the evidence chain Section 524B expects for premarket filing and for every postmarket update. Define the regression suite before you ship, because it is what lets you release a critical security patch quickly without reopening the whole verification effort. Verification, validation, and regression testing are three of the most overloaded words in MedTech engineering - and three of the most consistently misapplied in FDA cybersecurity submissions. Reviewers in 2026, working under **Section 524B of the FD&C Act**, the **Feb 3, 2026 final FDA premarket cybersecurity guidance** (which supersedes the September 2023 and June 2025 versions), **IEC 62304**, and **IEC 81001-5-1**, expect every cybersecurity claim in your premarket submission to trace back to a verification activity, a validation activity, *and* a regression-testing strategy that survives the device's full lifecycle. This guide consolidates how those three activities relate, where they sit inside your SPDF, and what evidence belongs in your 510(k), De Novo, or PMA package. ## Key Takeaways - Verification: Confirm security controls are built correctly. - Validation: Confirm the right security controls are built. - Regression testing: Ensure updates do not break controls. - The FDA expects traceability across these activities. - Evidence maps to Section 524B and IEC 81001-5-1. - Inadequate traceability is a common submission deficiency. ## Why this matters The security of medical devices directly impacts patient safety, making verification, validation, and regression testing fundamental requirements. Without these activities, devices risk vulnerabilities that could lead to data breaches, device malfunction, or unauthorized access, directly endangering patients. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly mandates these rigorous testing protocols for premarket submissions. Device manufacturers must demonstrate traceability between cybersecurity requirements, design, implementation verification (e.g., against IEC 62443 standards), validation of their effectiveness (aligned with ISO 14971 risk management), and continuous regression testing throughout the product lifecycle. This ongoing assurance is critical, especially as devices connect to complex network environments. Inadequate testing or a lack of clear traceability often leads to significant delays in regulatory approval and can result in costly postmarket remediation efforts. ## The Three Activities, Defined for Cybersecurity | Activity | Question Answered | §524B / SPDF Role | | --- | --- | --- | | **Verification** | "Did we build the security control correctly?" | Each security requirement traced to a test that proves the implementation matches the design | | **Validation** | "Did we build the right security controls?" | Evidence the controls actually mitigate the threats in your threat model and the patient harms in your ISO 14971 risk file | | **Regression Testing** | "Did our last change quietly break a control?" | Continuous evidence - premarket and postmarket - that updates do not weaken the security posture | Most deficiency letters in 2026 are not about missing controls. They are about **missing traceability between these three layers**. ## Verification: Proving the Control Was Built Correctly For cybersecurity, verification typically includes: - **SAST** (static analysis) - every flagged finding triaged with disposition and CAPA linkage - **SCA** (software composition analysis) - reconciled against the SBOM, with VEX statements for non-exploitable CVEs - **Unit tests** for security-relevant code paths (auth, crypto, input validation, audit logging) - **Configuration verification** - secure boot enabled, debug interfaces disabled in production, default credentials removed - **Cryptographic verification** - algorithm/key-size checks against your cryptographic inventory Each of these maps to a **security requirement → test case → result** row in your traceability matrix. Reviewers literally read this matrix. ## Validation: Proving the Right Controls Were Built Validation is where most submissions are weakest. Validation evidence for cybersecurity comes from: - **Penetration testing** by an independent team, scoped to the full system - **DAST** and protocol fuzzing against external interfaces - **Threat-model-driven test cases** - every STRIDE element produces at least one test - **Patient-safety scenario testing** - explicit attempts to trigger the harms enumerated in your ISO 14971 file - **Negative-path testing** - what happens when an authentication failure is repeated 10,000 times? Does the audit log fill the disk? Validation evidence is what proves your controls actually *work* against a thinking adversary, not just that they exist. ## Regression Testing: The Activity Most Submissions Skip Regression testing for cybersecurity is mandatory but rarely documented well. The 2026 FDA expectation is that every release - premarket and postmarket - runs an automated regression suite that re-executes: 1. **Authentication and authorization tests** - privilege boundaries don't quietly drift 2. **Cryptographic conformance tests** - algorithms haven't been swapped or weakened 3. **SBOM diff + VEX re-evaluation** - new components are triaged before release 4. **Known-finding re-tests** - every closed pen-test finding is re-run after each significant change 5. **Update-mechanism integrity tests** - signed update verification, rollback protection, and recovery paths Regression evidence is what reviewers ask for in postmarket Section 524B(b)(1) plans. Without it, a vulnerability disclosure 18 months after clearance becomes a recall trigger instead of a routine patch. ## Where These Sit Inside the SPDF Mapped to **IEC 81001-5-1**: | SPDF Activity | Verification | Validation | Regression | | --- | --- | --- | --- | | Security requirements | Requirements → test traceability | Threat-model → requirement linkage | Re-validation of requirement coverage after change | | Secure design | Design review | Architecture validation | Architecture diff review | | Secure implementation | SAST, SCA, unit tests | Code review against threat model | Automated re-run of SAST/SCA in CI | | Verification | Per-requirement test results | - | Regression suite execution | | Validation | - | Pen test, fuzz, scenario tests | Re-run on each release | | Defect management | CAPA evidence | Root-cause linkage to threat model | Re-test of every closed defect | | Update management | Update integrity unit tests | Update integrity scenario tests | Update mechanism regression after every firmware release | The single deliverable that ties this together is the **traceability matrix**: requirement → design → implementation → verification test → validation test → regression coverage → CAPA disposition. ## What Belongs in Your Premarket Submission For each cybersecurity control: - The requirement (with §524B subsection mapping where applicable) - The threat-model element it addresses - The verification test result - The validation test result (typically the pen-test report citation) - The regression-suite identifier and last-run date - The residual risk acceptance, signed by the named risk owner Submissions that present this consistently across every control clear the first round. Submissions that present pen-test results without verification traceability - or verification results without validation - almost always draw an AI request or hold letter. ## How Blue Goat Cyber Helps Our pen-test engagements deliver verification, validation, and regression-suite evidence in a single coherent package, mapped to §524B subsections, SPDF activities, and your ISO 14971 risk file. Findings come with CAPA-ready dispositions and regression test cases your team can run on every subsequent release. [Schedule a discovery session →](/contact) to scope the V&V coverage for your device. ## FAQ ### What is verification in medical device cybersecurity? Verification ensures that security controls are implemented precisely as designed. Activities include static analysis, software composition analysis, unit tests for security features, and configuration checks to confirm correct building of controls. ### How does validation differ from verification for device cybersecurity? Validation demonstrates that the implemented security controls are effective against real threats and prevent identified patient harms. This differs from verification, which only confirms correct implementation. Validation often involves penetration testing and threat-model-driven test cases. ### Why is regression testing critical for FDA cybersecurity submissions? Regression testing is critical because it provides continuous evidence that new software versions or updates do not negatively impact the device's existing security controls. The FDA requires this to ensure cybersecurity posture is maintained across the device's entire lifecycle. ### What evidence should be included for FDA premarket cybersecurity submissions? Submissions should include the security requirement, its associated threat-model element, verification test results, validation test results (e.g., pen-test report citation), the regression-suite identifier, and residual risk acceptance for each control. ### Does the FDA accept third-party testing for V&V activities? Yes, third-party testing, such as independent penetration tests, provides crucial validation evidence. Such tests demonstrate external verification of control effectiveness against a thinking adversary, which is often a challenge for internal teams. ### How does the traceability matrix support V&V and regression testing? The traceability matrix links requirements to design, implementation, verification tests, validation tests, regression coverage, and CAPA. This document helps the FDA reviewers understand the complete lifecycle of each security control. ## Related FDA & cybersecurity guides - [FDA Section 524B cybersecurity requirements explained](/guides/fda-524b-cybersecurity-requirements-explained) - [SBOM vulnerability management for medical devices](/guides/sbom-vulnerability-management-medical-devices) - [VEX document guide for FDA submissions](/guides/vex-document-medical-device-fda) - [FDA deficiency-letter response service](/fda-cybersecurity-deficiency-letters) - [STRIDE threat modeling for medical devices](/guides/stride-threat-modeling-medical-devices) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Hardware Hacking Tools for Medical](/blog/hardware-hacking-tools-medical-device-cybersecurity) - [Secure File Upload Validation: Best](/blog/medical-device-sql-injection-parameterized-queries) --- ## What Are IRT Medical Devices? Explained Source: https://bluegoatcyber.com/blog/what-are-irt-medical-devices # What Are IRT Medical Devices? Explained > **[DIRECT ANSWER]** IRT medical devices use infrared thermography to capture the body's surface temperature and convert it into thermal images that reveal inflammation, circulatory problems, and other physiological changes without radiation or physical contact. Core components include an infrared camera, thermal sensor, analysis software, and a user interface, and the devices support diagnosis in dermatology and rheumatology as well as treatment monitoring in physical therapy and surgery. Connected IRT systems still need encryption, access control, and postmarket vulnerability management. Many devices help diagnose and treat medical conditions. One that has drawn attention is the IRT medical device. This guide explains what IRT medical devices are, how they work, their types, their benefits, their risks and limits, and where the technology is headed. ## Key Takeaways - IRT devices use infrared to map body temperature. - They help detect inflammation and circulatory issues. - Key components: infrared camera, software, sensors. - Non-invasive for patient comfort, no radiation. - Aid healthcare providers with accurate, efficient data. - Future enhancements include AI, portability, and IoT integration. ## Why this matters IRT medical devices offer significant diagnostic potential, utilizing infrared technology for non-invasive temperature mapping. However, like all connected medical devices, they present cybersecurity risks that demand rigorous attention. Breaches can compromise patient data, disrupt device functionality, and lead to misdiagnosis or treatment delays, directly impacting patient safety. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the critical need for secure design and postmarket management throughout a device's lifecycle. Manufacturers and healthcare providers must address cybersecurity proactively, adhering to standards such as IEC 81001-5-1 for the manufacturer secure software lifecycle (with IEC 81001-5-1 governing hospital/HDO network integration), ISO 27001 for information security management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for principles for medical device security, risk management. Neglecting these aspects can result in regulatory non-compliance, financial penalties, reputational damage, and, most critically, harm to patients. Effective cybersecurity measures ensure the integrity, availability, and confidentiality of the data IRT devices collect, safeguarding both patient trust and clinical efficacy. ## Understanding IRT Medical Devices ### Definition and Function of IRT Devices IRT stands for Infrared Thermography. IRT medical devices use this technology to measure and map the body’s surface temperature. By capturing thermal patterns, these devices can show physiological changes and abnormalities. ![Section Image](/imported-images/8c2902cc7f811de8.webp) This is a non-invasive, radiation-free technique. It offers a safe alternative to methods such as X-rays or invasive procedures. IRT medical devices help with early detection of several health conditions. Their ability to detect subtle temperature changes can aid in [diagnosing conditions like inflammation](/services), circulatory issues, and some types of cancer. Earlier detection can support faster intervention and better outcomes. ### Key Components of IRT Medical Devices IRT medical devices include several core components: - **Infrared Camera:** Captures thermal images of the patient’s body. - **Software:** Software analyzes and interprets the thermal images and gives healthcare professionals useful information. - **User Interface:** IRT devices usually include a user interface that lets healthcare professionals operate the device efficiently. Another key component is the thermal sensor, which detects and measures the infrared radiation emitted by the body. This sensor is central to accurate temperature measurement, which directly affects diagnostic performance. The device’s cooling system also helps maintain a stable temperature for consistent performance during prolonged use. ## The Science Behind IRT Medical Devices ### The Role of Infrared Technology in Medicine Infrared technology is used in many medical applications because it can reveal physiological changes that are not otherwise visible. IRT medical devices use infrared radiation and convert it into visual maps of body temperature distribution. That information can help identify irregularities, inflammation, and other abnormalities. ![Section Image](/imported-images/02eff2f4d5f37d9b.webp) One advantage of IRT medical devices is that they are noninvasive. Traditional methods may require physical contact or invasive procedures. Infrared technology allows quick, painless monitoring. That makes it useful when patients need continuous monitoring without added discomfort. ### How IRT Devices Interact with the Human Body When an IRT medical device is used, it detects and measures the infrared radiation emitted by the human body. Blood circulation, metabolic activity, and other biological processes influence that radiation. By analyzing the thermal images, healthcare professionals can identify patterns that may point to health concerns. Data from IRT devices can also support preventive healthcare. By tracking temperature distribution over time, medical professionals may detect early signs of some conditions before they appear clinically. That can lead to earlier intervention and better outcomes. ## Types of IRT Medical Devices ### IRT Devices for Diagnosis A key use of IRT medical devices is diagnosis. In dermatology, for example, IRT devices can help with early detection of skin cancers or vascular abnormalities. These devices provide precise temperature measurements, which helps healthcare professionals identify abnormal areas quickly. IRT devices are also used in specialties such as rheumatology and [neurology](https://www.urmc.rochester.edu/highland/departments-centers/neurology/what-is-a-neurologist.aspx#:~:text=Neurology%20is%20the%20branch%20of,the%20brain%20and%20spinal%20cord). In rheumatology, they can help assess joint inflammation and monitor disease progression. In neurology, IRT technology is used to study brain activity patterns and detect abnormalities that may indicate neurological disorders. ### IRT Devices for Treatment IRT medical devices are not limited to diagnosis. They are also used in treatment for some conditions. In physical therapy, for example, IRT devices can help therapists assess muscle activity or identify inflammation. That information helps tailor treatment plans for better recovery. IRT devices are also being incorporated into surgical procedures for intraoperative imaging and tissue perfusion assessment. Surgeons can use them to support precise tissue ablation or monitor blood flow in real time during complex surgeries, improving outcomes and patient safety. > **Securing a connected IRT system?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ Medical device penetration testing](/services/medical-device-penetration-testing) ## Benefits of Using IRT Medical Devices ### Advantages for Patients One major advantage of IRT medical devices is that they are non-invasive. Patients can undergo diagnosis or treatment without discomfort or exposure to harmful radiation. That improves comfort, reduces anxiety, and often improves patient satisfaction. IRT medical devices can also provide faster results than traditional methods. Real-time analysis of thermal images speeds up diagnosis, which helps healthcare professionals make treatment decisions sooner and may save lives. Their non-invasive nature also makes them useful for pediatric patients and people with sensory sensitivities. Children and patients who avoid traditional procedures may find IRT devices less intimidating, which can improve compliance. Another patient benefit is their usefulness in monitoring chronic conditions. Patients with arthritis or circulatory issues, for example, can use regular thermal imaging to track inflammation or blood flow changes, supporting early intervention and more personalized treatment. ### Advantages for Healthcare Providers IRT medical devices give healthcare providers better accuracy and efficiency in diagnosis. High-resolution thermal images and [sophisticated software algorithms](/blog/a-comprehensive-guide-to-software-testing-for-medical-devices) provide precise information that helps clinicians diagnose more accurately. IRT devices also let healthcare providers monitor treatment progress in real time. By comparing thermal images over time, they can assess whether treatment is working and adjust as needed. Some IRT devices are portable, which allows quick assessments in different care settings. Emergency responders, sports medicine practitioners, and remote healthcare providers can use IRT devices to assess injuries, monitor healing, and make decisions without bulky equipment. ## Potential Risks and Limitations of IRT Medical Devices ### Understanding the Risks IRT medical devices have clear benefits, but they also have limits. They may not detect deep-seated abnormalities or conditions that do not affect surface temperature. ![Section Image](/imported-images/da9dc6670ea7ddec.webp) Healthcare professionals need to interpret thermal images correctly and should not rely on IRT devices alone. Clinical judgment is still required for accurate diagnosis and treatment planning. Environmental factors can also affect IRT accuracy. Ambient temperature, humidity, and patient movement can all affect thermal imaging results. Healthcare providers need to account for those variables to avoid misreading the data. ### Overcoming the Limitations Medical technology companies are working to address these limits. Ongoing research and development aims to improve temperature depth and accuracy and strengthen the interpretive capabilities of IRT software. Collaboration between medical professionals and technology companies matters here. Clinical input plus technical improvement can make IRT devices more useful for early detection, accurate diagnosis, and personalized treatment. ## Future of IRT Medical Devices ### Emerging Trends in IRT Technology The future of IRT medical devices looks strong. Advances in artificial intelligence and machine learning are helping IRT devices deliver more accurate, automated analysis and reduce reliance on manual interpretation. Miniaturization and portability are also getting more attention. That makes it easier for healthcare professionals to use IRT devices in ambulatory care, home healthcare, and remote consultations. The [integration of Internet of Things](/blog) (IoT) technology with IRT devices is changing how healthcare data is collected and analyzed. IoT connectivity supports real-time monitoring of patients’ vital signs and health parameters, giving healthcare providers useful data for timely intervention and personalized treatment. This [interconnected ecosystem](/blog/understanding-and-mitigating-the-risks-of-interoperable-medical-devices) improves healthcare delivery and gives patients a more active role in managing their health. ### Predictions for Future IRT Applications in Healthcare The possible uses of IRT medical devices in healthcare are broad. Future systems will likely integrate IRT with wearable devices, telemedicine platforms, and electronic health records. These advances will support data sharing, remote monitoring, and personalized healthcare, with the goal of improving patient outcomes and changing how care is delivered. Augmented reality (AR) and virtual reality (VR) used with IRT devices may also change medical training and surgical procedures. Surgeons could use immersive simulations and real-time guidance during complex operations to improve precision and reduce patient risk. IRT medical devices are part of a broader shift in healthcare technology. They support diagnosis, treatment, and patient care, and ongoing improvements between medical professionals and technology companies will keep expanding their use. As the healthcare industry continues to embrace the innovative capabilities of IRT medical devices, ensuring the cybersecurity of these technologies becomes paramount. Blue Goat Cyber, a Veteran-Owned business, specializes in medical device cybersecurity, offering services that include penetration testing, HIPAA compliance, FDA Compliance, and more. Protect your medical devices and patient data from cyber threats with our expert services. [Contact us today for cybersecurity help](/contact) and partner with a team passionate about securing your business and products. ## IRT compared with other imaging modalities | Modality | What it measures | Radiation | Contact | Security-relevant output | | --- | --- | --- | --- | --- | | Infrared thermography | Surface temperature distribution | None | None | Thermal images plus patient metadata | | X-ray and CT | Density and structure | Yes | None | Large DICOM studies on the imaging network | | Ultrasound | Reflected sound, structure and flow | None | Yes, probe contact | Images and measurements, often cart based | | MRI | Tissue composition | None | None | High-volume DICOM studies | | Contact thermometry | Temperature at one point | None | Yes | A single value, often over a wireless link | Thermography avoids radiation, not cybersecurity. Once the images and the patient record travel together, the obligations are the same as any imaging device. ## How Blue Goat approaches this Blue Goat Cyber helps manufacturers secure IRT medical devices with a focused approach on vulnerability identification and mitigation. Our team, comprised of CISSP and OSCP-certified experts, including former military red team members, evaluates device architectures and software for exploitable weaknesses. We conduct in-depth penetration testing and threat modeling tailored to the unique physiological data IRT devices handle. We understand the specific cybersecurity requirements for medical devices and provide actionable solutions that align with regulatory expectations. Our **[FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services)** ensure that cybersecurity is integrated from the earliest stages of device development. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. We aim to help manufacturers achieve regulatory compliance while building genuinely secure devices that protect patient data and well-being. ## FAQ ### What is an IRT medical device? An IRT medical device uses infrared thermography to measure and visualize temperature patterns on the body's surface. These patterns can indicate physiological changes, aiding in the diagnosis and monitoring of various medical conditions. ### How does an IRT medical device work? IRT devices detect the natural infrared radiation emitted by the human body. An infrared camera captures this radiation, and specialized software converts it into a visual thermal map, which healthcare professionals analyze for abnormalities. ### Are IRT medical devices safe? Yes, IRT medical devices are non-invasive and do not use radiation, making them a safe alternative to some other diagnostic methods. They are painless and do not require physical contact with the patient. ### What are the main benefits of IRT medical devices? Benefits include non-invasive diagnosis, radiation-free operation, faster results, and real-time monitoring capabilities. They offer improved comfort for patients and enhanced accuracy and efficiency for healthcare providers in various settings. ### What are the limitations of IRT medical devices? Limitations include potential inability to detect deep-seated abnormalities and susceptibility to environmental factors like ambient temperature, which can affect accuracy. Proper interpretation by skilled professionals is crucial. ### Does the FDA regulate IRT medical devices? Yes, IRT medical devices are subject to regulation by the FDA, like other medical devices. Manufacturers must ensure their devices meet FDA requirements for safety, effectiveness, and cybersecurity, as detailed in agency guidance documents, including the February 3, 2026 final guidance. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## CE Marking Medical Devices: What EU MDR Actually Requires Source: https://bluegoatcyber.com/blog/what-is-a-ce-marking-in-med-devices # CE Marking Medical Devices: What EU MDR Actually Requires > **[DIRECT ANSWER]** CE marking medical devices means the manufacturer has completed a conformity assessment demonstrating the device meets the EU Medical Device Regulation 2017/745 (or IVDR 2017/746 for in vitro diagnostics) and has signed a Declaration of Conformity. It is not an approval issued by a regulator, a quality award, or a one-time test result. Depending on device classification, it requires a quality management system, technical documentation under Annex II and III, and, for anything above Class I, review by a Notified Body before the device can legally be placed on the EU market. _Reviewed September 17, 2026_ A device without a valid CE mark cannot legally be sold or distributed anywhere in the European Economic Area, which makes CE marking medical devices a gating requirement rather than a marketing checkbox. Manufacturers frequently misunderstand what the mark actually certifies: it is the manufacturer's own declaration, backed by evidence and, in most cases, third-party review, that the device meets EU legal requirements at the moment of assessment. It does not mean a regulator tested the device, and it does not mean the device is risk-free. For connected and software-driven devices, the evidence a Notified Body now expects includes cybersecurity risk management under MDR Annex I Section 17.2, which is where CE marking and premarket security testing intersect directly. ## Key Takeaways - CE marking medical devices is a manufacturer declaration of conformity to EU MDR or IVDR, not a government approval or a quality endorsement. - Device classification (I, IIa, IIb, III under the MDR; A through D under the IVDR) determines whether a Notified Body must review the technical file before the mark can be affixed. - Technical documentation under Annex II and III must include risk management, verification and validation evidence, and, for software, documented IT security measures under Annex I Section 17.2. - MDCG 2019-16 sets the cybersecurity expectations Notified Bodies use to evaluate that Annex I Section 17.2 evidence, and it now sits alongside the incoming EU Cyber Resilience Act's requirements for products with digital elements. - CE marking and FDA 510(k) clearance both demand evidence of safety and performance, but they run on different legal instruments, different reviewer models, and different post-market obligations. ## Why This Matters CE marking is the legal precondition for market access across the EEA, and its absence stops a device at the border regardless of how well it performs clinically. The MDR 2017/745 and the IVDR 2017/746 replaced the older directives with tighter classification rules, mandatory clinical evidence, and, through Annex I Section 17.2 and MDCG 2019-16, explicit cybersecurity expectations for software and connected devices. A parallel obligation is arriving through the EU Cyber Resilience Act, which adds product-wide cybersecurity requirements that overlap with, but do not replace, MDR obligations for devices with digital elements. The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions final guidance, issued February 3, 2026, sets a comparable expectation in the United States: security evidence has to be built into the design history file, not bolted on before submission. Manufacturers selling in both markets increasingly build one threat model and one set of security testing evidence, then map it to each jurisdiction's specific documentation format, because the underlying engineering work, secure development, risk management, and vulnerability testing, is largely the same regardless of which mark or clearance letter it eventually supports. ## What Does the CE Mark Legally Mean? The CE mark is a legal declaration by the manufacturer, not a certificate issued by a government agency, and no EU body "approves" a device the way the FDA clears or approves one. Affixing the mark means the manufacturer has completed the applicable conformity assessment route, holds the technical documentation to prove it, and has signed a Declaration of Conformity taking legal responsibility for the claim. For Class I devices with no measuring function and no sterile requirement, the manufacturer can self-certify. For every other class, a Notified Body must review the file first and issue a certificate before the manufacturer can affix the mark. The mark is also not permanent: it depends on the manufacturer maintaining the quality system and technical file for as long as the device stays on the market. **[KEY REQUIREMENT]** The CE mark is a legal declaration of conformity to MDR or IVDR requirements, evidenced by a technical file and, above Class I, a Notified Body certificate. It is not a safety guarantee and not equivalent to a regulatory approval. ## How Are Devices Classified Under MDR and IVDR? Classification determines the conformity assessment route, and it is based on intended use, invasiveness, and duration of contact with the body rather than on the manufacturer's own risk judgment. The MDR sets four classes: Class I (lowest risk, largely self-certified), Class IIa, Class IIb, and Class III (highest risk, implants and life-sustaining devices, always requiring full Notified Body involvement). The IVDR uses a separate letter scale, Class A through D, running from low individual and public health risk (A) to high public health risk and high individual risk (D), reflecting the different risk logic of diagnostic tests versus therapeutic devices. Software that drives or influences clinical decisions is classified according to MDR Rule 11 (or the equivalent IVDR rule), which frequently pushes standalone diagnostic and clinical decision software into Class IIa or higher, triggering Notified Body review that manufacturers sometimes do not anticipate. ## What Conformity Assessment Route Applies, and When Is a Notified Body Required? The applicable route depends on device class, and a Notified Body is required for every class above Class I (non-measuring, non-sterile). Manufacturers choose among several MDR Annex routes: full quality assurance (Annex IX), type-examination combined with production quality assurance (Annex X and XI), or, for Class I devices without special conditions, self-certification with no external review at all. A Notified Body's role is to audit the manufacturer's quality management system, review the technical documentation, and, for higher-risk classes, examine the device's own design dossier before issuing an EU certificate. That certificate, not the CE mark itself, is the artifact a competent authority or customer can request as proof the assessment happened. | Device Class | Typical Examples | Notified Body Required | Assessment Depth | | --- | --- | --- | --- | | MDR Class I | Bandages, non-sterile exam tools | No (self-certification) | Manufacturer declaration only | | MDR Class IIa | Diagnostic ultrasound, infusion sets | Yes | QMS audit plus technical file sampling | | MDR Class IIb | Ventilators, infusion pumps | Yes | Full technical file review | | MDR Class III | Implants, life-sustaining devices | Yes | Full technical file plus design dossier examination | | IVDR Class A | General lab equipment | No (self-certification) | Manufacturer declaration only | | IVDR Class D | HIV, blood-borne pathogen tests | Yes, plus EU reference laboratory | Full technical file plus batch verification | ## What Goes Into the Technical Documentation? Annex II and Annex III of the MDR define the technical documentation a manufacturer must hold and, for non-Class I devices, submit for Notified Body review. Annex II covers device description, design and manufacturing information, general safety and performance requirements, benefit-risk analysis, verification and validation data, and, for software, a description of the software's architecture and security measures. Annex III covers post-market surveillance documentation, including the post-market surveillance plan and periodic safety update reports for higher-risk classes. For software-containing devices, this file has to demonstrate compliance with MDR Annex I Section 17, which requires manufacturers to develop and manufacture software according to the state of the art, considering the principles of the development lifecycle, risk management, verification, and validation, and to set minimum requirements for IT security including protection against unauthorized access. **[KEY REQUIREMENT]** MDR Annex I Section 17.2 requires manufacturers to design software with IT security measures appropriate to intended use, including protection against unauthorized access, and to define minimum hardware and network characteristics needed to run it safely. ## Which Standards Do Notified Bodies Actually Check? Notified Bodies evaluate the technical file against a set of harmonized and recognized standards rather than inventing their own criteria case by case. ISO 13485 governs the quality management system the manufacturer runs the whole design and production process under, and a current ISO 13485 certificate is close to a precondition for any Notified Body engagement. ISO 14971 governs risk management and is the backbone document that every safety and security claim in the technical file has to trace back to. IEC 62304 governs the software development lifecycle for medical device software, covering software safety classification, architecture, verification, and problem resolution. IEC 81001-5-1 extends that lifecycle model specifically to health software security, covering secure design, security risk management, and security verification activities that MDCG 2019-16 references directly when describing acceptable cybersecurity evidence. ## What Does MDCG 2019-16 Require for Cybersecurity? MDCG 2019-16 is the Medical Device Coordination Group's guidance on cybersecurity for medical devices, and it is what Notified Bodies use to interpret Annex I Section 17.2 in practice. It expects manufacturers to run a documented security risk management process alongside the standard ISO 14971 safety risk process, covering secure design, a defined secure development lifecycle, vulnerability and patch management, and evidence of security testing, including penetration testing where the device's connectivity and risk profile warrant it. The guidance does not name a specific test methodology, but reviewers increasingly expect testing evidence that traces to a documented threat model rather than a generic vulnerability scan. Manufacturers preparing a CE technical file alongside an FDA submission commonly build this evidence once and format it for both audiences, since the underlying security engineering the two frameworks expect is closely aligned. ## How Does the EU Cyber Resilience Act Interact With MDR? The EU Cyber Resilience Act introduces horizontal cybersecurity requirements for products with digital elements sold in the EU, and medical devices already regulated under the MDR or IVDR are largely carved out from duplicating requirements the MDR already covers, but the interaction is not a full exemption. Where the MDR's own cybersecurity requirements (Annex I Section 17.2, as interpreted by MDCG 2019-16) are judged equivalent to a Cyber Resilience Act obligation, that MDR pathway satisfies it; where a gap exists, for example around vulnerability disclosure and incident reporting timelines for connected components, the Cyber Resilience Act's own obligations apply on top of MDR compliance. Manufacturers of connected devices should treat the two frameworks as complementary evidence sets rather than assume MDR compliance alone closes every Cyber Resilience Act obligation. ## What Are the Declaration of Conformity, UDI, and EUDAMED Requirements? The Declaration of Conformity is the manufacturer's signed legal statement that the device meets all applicable MDR or IVDR requirements, and it must be kept current and available to competent authorities for as long as the device is on the market. Every device also needs a Unique Device Identifier (UDI), assigned by the manufacturer and registered in the EUDAMED database, which links the device to its technical documentation, certificates, and post-market data in a single EU-wide record. Manufacturers based outside the EU must also appoint an Authorized Representative established within the EU, who acts as the manufacturer's legal contact for competent authorities and holds a copy of the technical documentation and Declaration of Conformity on file. ## What Post-Market Obligations Come After the CE Mark Is Affixed? CE marking is not a one-time event; it carries ongoing post-market surveillance (PMS) obligations for the life of the device on the market. Manufacturers must run a documented PMS plan, collecting field data, complaints, and incident reports, and feed that data back into the risk management file. Higher-risk devices additionally require Periodic Safety Update Reports (PSURs), submitted to the Notified Body or competent authority on a defined schedule, and any serious incident triggers vigilance reporting obligations with strict timelines. For connected and software devices, this is also where post-market vulnerability monitoring and patch deployment evidence belongs, feeding the same risk file that supported the original CE mark. ## How Does CE Marking Compare to FDA 510(k) Clearance? CE marking and FDA 510(k) clearance both require documented evidence of safety and performance, but they differ in who reviews the evidence, what legal instrument grants market access, and what happens after the device ships. | What Each Requires | CE Marking (MDR) | FDA 510(k) | | --- | --- | --- | | Reviewing body | Notified Body (above Class I) or self-certification | The FDA reviews the submission directly | | Legal basis | Manufacturer's Declaration of Conformity | FDA clearance letter | | Classification basis | Risk class I to III (MDR) or A to D (IVDR) | Device class I to III plus predicate comparison | | Core comparison standard | Conformity with harmonized standards and GSPRs | Substantial equivalence to a predicate device | | Cybersecurity evidence | Annex I Section 17.2, MDCG 2019-16, IEC 81001-5-1 | Section 524B, February 3, 2026 premarket guidance, ANSI/AAMI SW96 | | Post-market obligation | PMS plan, PSUR, vigilance reporting | Postmarket surveillance, Section 524B vulnerability monitoring | | Market covered | European Economic Area | United States | ## How Blue Goat Cyber Approaches This Blue Goat Cyber supports manufacturers building the cybersecurity evidence that CE marking and FDA submissions both depend on, without displacing the regulatory or quality work a Notified Body or the FDA actually reviews. In dual-market submissions we see the same threat model and SBOM reused across both jurisdictions, with a short crosswalk annex mapping SW96 controls to MDR Annex I Section 17.2, which tends to shorten the Notified Body question cycle. Our [medical device penetration testing](/services/medical-device-penetration-testing) work is scoped against the device's own threat model so the resulting evidence supports Annex I Section 17.2 and MDCG 2019-16 review, not a generic vulnerability scan. Manufacturers preparing an EU technical file alongside a Cyber Resilience Act assessment can also review our [EU Cyber Resilience Act support](/services/eu-cyber-resilience-act-medical-devices) for how the two evidence sets map together. ## Frequently Asked Questions ### Does CE marking mean a medical device is FDA approved? No. CE marking and FDA clearance are entirely separate legal processes tied to different markets. A CE-marked device has no standing in the United States until it goes through its own FDA pathway, and an FDA-cleared device needs a separate MDR or IVDR conformity assessment before it can be sold in the EEA. ### Who is legally responsible for CE marking a medical device? The manufacturer is legally responsible for CE marking, even when a Notified Body reviews the technical file. The manufacturer signs the Declaration of Conformity and carries ongoing liability for the accuracy of that declaration for as long as the device remains on the market. ### Can a manufacturer self-certify a CE mark without a Notified Body? Only for MDR Class I devices with no measuring function and no sterile packaging requirement, or IVDR Class A devices. Every higher class requires a Notified Body to review the technical documentation and issue a certificate before the mark can be affixed. ### What is the difference between the CE mark and a Notified Body certificate? The CE mark is the visible symbol affixed to the device; the Notified Body certificate is the underlying evidence that a third party reviewed the technical file and found it compliant. The certificate has an identification number that must appear alongside the CE mark for any device that required Notified Body review. ### How long does it take to get CE marking for a medical device? Timelines vary widely with device class and Notified Body workload, and vary enough by device and Notified Body that manufacturers should scope timing directly with their chosen body rather than assume a fixed figure. Higher-risk classes and devices with significant software or cybersecurity documentation gaps generally take longer because of the additional review cycles. ### Do software-only medical devices need CE marking? Yes, standalone software that meets the MDR's definition of a medical device (intended for a medical purpose such as diagnosis, monitoring, or treatment) needs its own CE marking under the same classification and conformity assessment rules as hardware devices, frequently landing in Class IIa or higher under MDR Rule 11. ## CTA If your device needs cybersecurity evidence that will hold up under Notified Body review or an FDA submission, or both, [talk to Blue Goat Cyber](/contact) about scoping threat modeling and penetration testing against your specific technical file requirements. We build the evidence once and map it to the jurisdictions you are actually shipping into. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA and EU MDR submissions. [Read more about Christian](/christian-espinosa). --- ## What Is a Medical Cyber Device? FDA Definition Source: https://bluegoatcyber.com/blog/what-is-a-medical-cyber-device-unraveling-the-fdas-cyber-device-definition # What Is a Medical Cyber Device? FDA Cyber-Device Definition Explained > **[DIRECT ANSWER]** A cyber device, under Section 524B(c), is a device that includes software validated, installed, or authorized by the sponsor, has the ability to connect to the internet, and contains technological characteristics that could be vulnerable to cybersecurity threats. All three conditions must hold. A USB port, Bluetooth radio, or cloud dashboard is usually enough to pull the device in, which means the full premarket cybersecurity package applies. As medical technology continues to advance, the line between traditional medical devices and "cyber devices" has become increasingly blurred. Many medical device manufacturers are surprised to learn that their products may qualify as cyber-enabled under the [FDA's regulatory framework](https://www.fda.gov/media/119933/download "") - even if they don't have obvious internet connectivity. In this in-depth blog post, we'll unpack the FDA's definition of a "cyber device" and explore the common misconceptions that lead many MedTech innovators astray. We'll dive into specific examples of hardware interfaces that can unexpectedly classify a device as cyber-enabled, and discuss practical strategies for avoiding this classification or properly securing your product. ## Key Takeaways - Defining a Medical Cyber Device: Software and Connectivity. - The Challenge of Proving “Zero Vulnerabilities”. - Unexpected Cyber Enablers: Hardware Interfaces. - The 3D Printing Software Surprise. - Strategies for Avoiding Cyber Device Classification. ## Why this matters Misinterpreting the FDA's definition of a medical cyber device carries significant regulatory and reputational stakes for manufacturers. Devices incorrectly assumed to be non-cyber can face premarket submission denials or costly delays if found to be out of compliance with cybersecurity requirements outlined in the FDA's Cybersecurity in Medical Devices Final Guidance dated February 3, 2026. This oversight can expose patients to increased risks from cyber threats, damage brand trust, and incur substantial remediation expenses. Adhering to these guidelines, along with relevant standards like IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023, is not merely a formality; it is essential for ensuring device safety, effectiveness, and market access. Understanding this nuanced definition early in the product lifecycle allows for proactive design choices, preventing costly retrospective changes and ensuring patient safety. ## Defining a Medical Cyber Device: Software and Connectivity According to Christian Espinosa, CEO of Blue Goat Cyber, the FDA’s definition of a cyber device boils down to two key criteria: - **Does the device contain software?** - **Does the device have any possible way to connect to the internet?** If a medical device meets both of these conditions, then it is considered a cyber device - regardless of whether that internet connectivity is actively used or not. As the Blue Goat Cyber team explains, the second criteria around connectivity is where a lot of the confusion arises: > “The fact that there’s a USB port means it’s a cyber device. But I that’s a misconception I hear all the time still.” Many manufacturers assume that only obvious internet-enabled interfaces like Wi-Fi or Ethernet would qualify a device as cyber-enabled. However, the FDA takes a much broader view - considering any potential pathway for data exchange or remote access as a cyber risk, including: - Wi-Fi - Cellular - Bluetooth (including Bluetooth Low Energy) - USB ports - Serial ports - Magnetic coils (e.g. RFID, NFC) - HDMI Even if these interfaces are not actively used for internet connectivity, the mere presence of a potential attack vector is enough to classify the device as cyber-enabled in the eyes of the FDA. ## The Challenge of Proving “Zero Vulnerabilities” One common misconception that the Blue Goat Cyber team often encounter is the idea that a device can avoid cyber device classification if it can be proven to have “zero vulnerabilities”. > “It’s a very hard argument to make and it’s a very risky approach to take. And so typically we recommend saying if your device has software, there’s likely going to be a way to exploit it.” As the team explains, the burden of proof required to demonstrate a complete absence of vulnerabilities, even in a small piece of software, is immense: > “One team member that we have for part of his M’s program had to prove a piece of software was vulnerability free. It was like three lines of code and something around 50 pages of proof to prove that three lines of code was free of any vulnerabilities whatsoever. Now imagine when you’re moving into a medical device which can have thousands, tens of thousands, hundreds of thousands lines of code. The proof that it’s going to be free of vulnerabilities would be so much more effort than complying to the cyber security guidelines.” Rather than attempting to prove the impossible, the Blue Goat Cyber team recommend that manufacturers simply accept that any device with software is likely to have some form of exploitable vulnerability - and focus their efforts on properly securing and mitigating those risks. ## Unexpected Cyber Enablers: Hardware Interfaces While the presence of software is a clear indicator of a cyber device, the connectivity criteria is where many manufacturers get tripped up. As the team explains, even seemingly innocuous hardware interfaces can open the door to cyber risks: > “USB port is the perfect example. You would not inherently think a USB port can introduce a network scenario into the device and it’s just a little bit of a misconception with a what the interface can do and b what the FDA defines as internet connectivity.” One particularly surprising example is the case of HDMI ports. While most people think of HDMI as simply a display output, the protocol actually includes capabilities that can enable cyber attacks: > “HDMI, exactly like you said, you’re normally thinking about it connecting into your TV or into a second monitor, just providing display output, but those cables and those connections can actually provide control over systems over the CEC, the consumer electronics communications.” the team goes on to explain how the [HDMI Ethernet Channel (HEC) feature](https://en.wikipedia.org/wiki/HDMI "") can even allow Ethernet communications to be passed through the HDMI interface - effectively turning it into a network connection point. Similarly, Bluetooth - including Bluetooth Low Energy (BLE) - is another interface that is often overlooked as a cyber risk. As Espinosa notes, even the relatively short range of BLE can be extended through the use of specialized equipment: > “Often times you can see some examples that have been done by security researchers in the past at events like Black Hat where they have [Bluetooth sniper rifles](/blog) for an example which sounds like a ridiculous concept but they look like sniper rifles that I believe have a range of around a kilometer to send and receive Bluetooth signals with super super targeted precise antennas.” This type of long-range Bluetooth attack has even been a concern for high-profile individuals like former Vice President Dick Cheney, who had the wireless capabilities of his pacemaker disabled out of fear of remote exploitation. ## The 3D Printing Software Surprise One real-world case that the Blue Goat Cyber team encountered highlights just how broad the FDA’s definition of a cyber device can be. In this instance, a client who manufactured a 3D printing system for medical implants was surprised to learn that their device was classified as cyber-enabled - not because of the 3D printer itself, but because of the software used to model the implants: > “The FDA determined that the software they were using to plan treatments for their patients was a pivotal component of the device. So it was included in the boundary of the device. And this is what manufacturers need to be extra aware of is where are they drawing the lines with those boundaries.” Even though the 3D printing software was a third-party tool, not developed by the client, the FDA still considered it an integral part of the overall medical device. This meant the client had to comply with the same cybersecurity requirements as if they had developed the software themselves. As the team explains, the key lesson here is that manufacturers must carefully define the boundaries of their “device” - including any third-party components or software that are essential to its functionality. Anything that falls within that defined scope is subject to the FDA’s cyber device regulations. ## Strategies for Avoiding Cyber Device Classification If a medical device does meet the criteria of a cyber device, the path forward can seem daunting. However, the Blue Goat Cyber team outline several practical strategies that manufacturers can employ to either avoid this classification or properly secure their cyber-enabled products: ### Removing Unnecessary Connectivity One of the simplest approaches is to eliminate any unnecessary hardware interfaces that could potentially enable cyber attacks. As Espinosa explains: > “The way to remove that from being classified as a cyber device is to enclose that USB port and put tamperproof seals on the device. So, now it’s purely self-contained. it doesn’t there’s no way to connect to the software which is a simple fix uh if you relatively simple to avoid the whole cyber security path with the FDA.” By physically securing or removing unused ports and connectivity, manufacturers can potentially reclassify their device as non-cyber, avoiding the need to comply with the full set of cybersecurity requirements. ### Isolating Functionality In some cases, it may not be feasible to remove connectivity completely. However, the team notes that manufacturers can sometimes restructure their device’s functionality to limit the cyber attack surface: > “If you’re able to, you know, remove this entirely, you’re flashing it on at the board level, um you’re doing it, you know, as kind of a oneanddone process, or you’re changing the way that your device works so that you don’t require as much of these updates, and you strip out any of that connectivity. You just try to isolate it from being a cyber device.” By minimizing the need for remote updates, cloud connectivity, or other cyber-enabled features, manufacturers can potentially reclassify their device or at least reduce the scope of cybersecurity requirements. ### Consulting Experts and the FDA Ultimately, the Blue Goat Cyber team emphasize that there is no one-size-fits-all approach to navigating the FDA’s cyber device regulations. They recommend that manufacturers reach out to experts like the team at Blue Goat Cyber for guidance, as well as directly engage with the FDA to understand the specific classification and compliance requirements for their product: > “Reaching out to experts like our team at Blue Goat to say hey are we a cyber device? How can we not become a cyber device? How can we secure us being a cyber device? We can help you with all of these answers and make sure that we’re guiding you around. We’re guiding you on a secure path forward.” By proactively addressing cyber device classification and security, manufacturers can save themselves significant time, effort, and frustration down the road - ensuring their innovative medical technologies can reach patients safely and securely. ## Bottom line on cyber-device classification The line between traditional medical devices and cyber-enabled products has become increasingly blurred. As the FDA continues to expand its definition of what constitutes a "cyber device," medical device manufacturers must be vigilant in understanding the regulatory landscape and taking proactive steps to secure their innovations. Whether it's unexpected hardware interfaces, third-party software dependencies, or the challenge of proving "zero vulnerabilities," the cybersecurity requirements for medical devices can be complex and ever-evolving. By partnering with experts like the team at Blue Goat Cyber, manufacturers can navigate these waters with confidence, ensuring their products meet the FDA's stringent cybersecurity standards while bringing life-saving technologies to market. ## Get a cyber-device determination on your product If you're unsure whether your device crosses the FDA's cyber-device line, we'll walk the interfaces, software boundary, and third-party components with you and tell you in one call. **If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.** [**Book a free premarket strategy call**](/services/fda-premarket-cybersecurity-services) *30 minutes · No cost · No commitment* ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in understanding and addressing the FDA's cybersecurity requirements for cyber devices. Our team, comprised of CISSP-certified professionals, OSCP-holders, and ex-military red team experts, applies a practical, threat-informed approach to secure your devices. We identify potential connectivity points, assess software vulnerabilities, and develop strategies to meet premarket submission standards. This includes threat modeling, penetration testing, and security architecture reviews tailored to your specific device. Our process helps manufacturers navigate the complexities of the FDA's definition, ensuring devices are both compliant and resilient against cyber threats. We stand by our work: if the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support for FDA premarket submissions: [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What makes a medical device a "cyber device" according to the FDA? A medical device is classified as a "cyber device" by the FDA if it contains software and has any potential capability to connect to the internet. This includes various hardware interfaces that could facilitate data exchange, even if not actively used for internet access. ### Does a medical device need Wi-Fi or Bluetooth to be a cyber device? No, a medical device does not exclusively need Wi-Fi or Bluetooth. Any interface such as a USB port, HDMI port, or even magnetic coil (RFID/NFC) that allows for potential data transfer or communication can lead to the FDA classifying it as a cyber device. ### Can I avoid cyber device classification by proving my software has no vulnerabilities? No, attempting to prove a device's software has "zero vulnerabilities" is an impractical and difficult approach. The FDA recommends assuming vulnerabilities exist in any software-driven device and focusing on risk mitigation as per the February 3, 2026 final guidance. ### How does the FDA view third-party software used with a medical device? The FDA may consider third-party software as an integral part of the overall medical device if it is essential to the device's functionality, even if not developed by the manufacturer. This means the third-party software falls within the scope of the FDA's cyber device regulations. ### What can manufacturers do to avoid cyber device classification? Manufacturers can try to avoid cyber device classification by physically removing or enclosing unnecessary connectivity ports, or by isolating device functionality to reduce the cyber attack surface. Engaging with experts and the FDA early matters for specific guidance. ### When did the FDA release its final guidance on cybersecurity in medical devices? The FDA released its final guidance on cybersecurity in medical devices on February 3, 2026. This guidance outlines the agency's expectations for premarket submissions of cyber devices. --- ## About the author **Christian Espinosa** | Founder & CEO, Blue Goat Cyber | CISSP Christian has led cybersecurity submissions for 275+ medical devices across 510(k), De Novo, and PMA pathways, including many that hinged on whether a product met the FDA's "cyber device" threshold. He founded Blue Goat Cyber around a single focus: turning FDA cybersecurity requirements into submission-ready evidence that clears without deficiency letters. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [EHR/EMR Medical Device Integration](/blog/ehr-emr-medical-device-integration-cybersecurity-risks) - [HIPAA and Medical Device Manufacturers](/blog/hipaa-medical-device-manufacturers-cybersecurity) - [The FDA’s New Medical Device](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) - [Nonrepudiation in Medical Device Security](/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization) --- ## Modular PMA Submission: What MedTech Teams Need to Know (2026) Source: https://bluegoatcyber.com/blog/what-is-a-modular-pma-submission # Modular PMA Submission: What MedTech Teams Need to Know in 2026 > **[DIRECT ANSWER]** A modular PMA submission lets a manufacturer submit a Premarket Approval application in separate sections, such as preclinical, manufacturing, and clinical modules, rather than as one complete package, so the FDA can review and provide feedback on each module as it becomes available. This phased approach helps teams address issues earlier, manage complex or software-driven devices, and maintain ongoing dialogue with FDA reviewers throughout the process. The Modular Premarket Approval (PMA) Submission is essential for medical device manufacturers seeking FDA clearance. This method breaks down the traditional submission process into manageable parts, promotes efficiency, and encourages a more interactive approach with the [FDA](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity). But what exactly does it entail? Let’s dive in. ## Key Takeaways - Divided into distinct sections for submission. - Enables continuous dialogue with the FDA. - Offers flexibility in the submission timeline. - Enhances risk management for complex devices. - Can improve efficiency and resource allocation. - Aims for quicker approval for new technologies. ## Why this matters The modular PMA submission method is crucial for efficiently introducing innovative, yet secure, medical devices to market. For manufacturers, it streamlines the regulatory pathway by allowing iterative feedback from the FDA, reducing the risk of a complete submission rejection. This approach is particularly relevant for devices with integrated software and connectivity, where cybersecurity is a critical component. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes the need for well-documented cybersecurity controls throughout the device lifecycle. A Modular PMA can facilitate demonstrating adherence to standards such as IEC 81001-5-1 for health IT security and ISO 14971 for risk management, by allowing manufacturers to address these complex sections in dedicated modules. By tackling cybersecurity and other multifaceted requirements in phases, manufacturers can ensure that device safety and efficacy are reviewed, reducing potential post-market issues and recalls. This phased approach builds earlier identification and mitigation of risks, ultimately benefiting patient safety and healthcare system integrity. ## Understanding the Basics of a Modular PMA Submission A [Modular PMA Submission](https://www.fda.gov/medical-devices/premarket-approval-pma/pma-application-methods#modular) allows developers to submit their application in discrete sections or modules. This method offers flexibility. Instead of submitting a complete package at once, companies can provide data progressively, improving the chances of successful approval for complex devices. ![Section Image](/imported-images/7f5d8adbad3643d8.png) ### Definition of a Modular PMA Submission A Modular PMA Submission is a structured way to present a medical device for FDA clearance. The submission is divided into distinct components, allowing smaller data portions to be submitted as they become available. This isn’t just a linear journey; it’s more like climbing a mountain, module by module. Each module can cover different aspects of the device, such as design, manufacturing processes, or clinical data, allowing for a more thorough and organized review process. This modular approach streamlines the submission and helps maintain clear communication with the FDA, as feedback can be incorporated into subsequent modules. ### Importance of a Modular PMA Submission Why is this approach significant? Think of it as a safety use for manufacturers. It mitigates risks associated with the lengthy approval process. Manufacturers can address potential issues in earlier modules rather than facing an all-or-nothing scenario. This method is a game-changer in navigating the often turbulent waters of medical device regulations. Additionally, it allows companies to adapt to evolving [regulatory requirements](/blog/510k-cybersecurity-requirements-every-maker-must-meet) and incorporate new findings or technological changes without restarting the entire submission process. By breaking down the submission into manageable parts, companies can allocate resources more effectively, ensuring that each module receives the attention it deserves, ultimately leading to a more and compliant product. ## Components of a Modular PMA Submission A Modular PMA Submission consists of several key components, each critical in the approval process. Let’s explore these modules in depth. ![Section Image](/imported-images/cfbab35cc99fdc37.png) ### Preclinical Module The Preclinical Module is the foundation of the submission. It includes all non-clinical data regarding the device’s safety and effectiveness. This may involve animal studies, [testing protocols](/blog/abuse-and-misuse-cases-testing-medical-devices-with-malformed-and-unexpected-inputs), and results demonstrating the device’s behavior before it’s tested on humans. The data gathered here must be and well-documented, as it sets the stage for subsequent modules. The preclinical phase often includes a thorough [risk assessment](/blog/510k-cybersecurity-requirements-every-maker-must-meet), identifying potential hazards associated with the device, and outlining mitigation strategies. This proactive approach strengthens the submission and demonstrates a commitment to patient safety from the outset. ### Manufacturing Module Next is the Manufacturing Module. This section details how the device is produced. Manufacturers must provide information about their facilities, [quality control processes](/blog/the-importance-of-implementing-a-medical-device-qms), and equipment used in production. The FDA wants to see that you can consistently produce your device and meet all safety standards. A recipe without proper ingredients isn’t going to yield a cake! This module may also require a description of the supply chain management practices in place, ensuring that all materials sourced are of high quality and that contingency plans are in place for potential disruptions. Transparency in manufacturing processes not only builds trust with regulatory bodies but also enhances the overall credibility of the device. ### Clinical Module Finally, the Clinical Module spotlights human data. This is where the rubber meets the road; clinical trial data illustrates how the device performs in real-world settings. Details such as study design, statistical analysis, and patient outcomes are scrutinized here. It’s akin to sharing your final exam results; you better be prepared for questions! This module often includes post-market surveillance plans, outlining how the manufacturer intends to monitor the device’s performance once it is on the market. This ongoing commitment to safety and efficacy can significantly influence the FDA’s perception of the device’s overall risk-benefit profile, making it a vital aspect of the submission process. ## Modular Versus Traditional PMA The choice affects when cybersecurity evidence has to be ready, not whether it is required. | | Traditional PMA | Modular PMA | |---|---|---| | How it is filed | One complete submission | Sections submitted as they are finished | | Feedback timing | After the full package is reviewed | Per module, as each is reviewed | | Effect on schedule | Long single review | Earlier feedback, longer total engagement | | Cybersecurity evidence | Assembled once, near the end | Must be planned so modules stay consistent | | Main risk | A late finding affects everything | A change in one module invalidates another | | Suits | Devices with a settled design | Long development programs with staged data | ## The Process of a Modular PMA Submission The journey through a Modular PMA Submission is both structured and critical. Following a systematic process can save time and resources. Let’s navigate through each step. ### Preparing for a Modular PMA Submission Preparation is everything. It’s not just about gathering data; it’s about strategic planning. Manufacturers must outline their submission roadmap and gather all necessary materials. Engaging with regulatory experts during this phase can provide insights and help avoid pitfalls. It’s like having a compass before setting off on a journey! Manufacturers should conduct a thorough risk assessment to identify potential challenges that may arise during the submission process. This proactive approach enables teams to devise contingency plans, ensuring they are well-equipped to address unforeseen issues. Assembling a cross-functional team that includes members from regulatory affairs, clinical, and quality assurance can build a collaborative environment, enhance the quality of the submission, and ensure that all perspectives are considered. This foundational work sets the stage for a smoother submission process, ultimately increasing the likelihood of a successful outcome. ### Submitting the Modules Once prepared, it’s time to submit those modules. Each submission is subject to review. Companies can submit each module as completed, remaining engaged with the FDA throughout the process. This is essential for maintaining [regulatory momentum](/blog/fda-medical-device-submission-costs-explained-510k-pma-and-more-2025-guide). Consider it a relay race, where passing the baton at the right time can lead to success. Effective communication with the FDA during this phase is crucial. Manufacturers should be prepared to provide additional context or clarification regarding their submissions, which can expedite the review process. Utilizing tools such as submission tracking systems can help keep all stakeholders informed about the status of each module, ensuring that everyone is aligned and aware of any upcoming deadlines or required actions. This level of diligence demonstrates a commitment to regulatory compliance and builds a positive relationship with the FDA, which can be beneficial for future submissions. ### Review and Approval Process After submission, the review process begins. The FDA assesses each module’s merits and looks at how they connect. This stage may involve back-and-forth communication. It’s an opportunity for clarification and further data requests. The process can feel like a tug of war; patience and perseverance are crucial. During this review phase, manufacturers need to remain responsive and organized. Keeping detailed records of all communications with the FDA can help streamline the process and ensure no critical information is overlooked. Additionally, manufacturers should be prepared for potential advisory committee meetings, where they may need to present their data and address questions from experts in the field. This engagement not only provides an opportunity to clarify any concerns but also allows manufacturers to showcase the robustness of their data and the safety and efficacy of their products. By approaching this stage with transparency and readiness, companies can significantly enhance their chances of a favorable review outcome. ## Benefits of a Modular PMA Submission The Modular PMA Submission isn’t just another piece of paperwork; it offers several advantages that can’t be overlooked. Companies often reap substantial rewards from this approach. ### Flexibility and Efficiency One of the most significant benefits is flexibility. This method allows manufacturers to work at their own pace. They are not tethered to the rigid timeline of traditional submissions. As a result, risks are lowered, and workflows become more efficient. It’s like driving a car with cruise control; you can relax while keeping your eyes on the road. This flexibility also extends to the ability to prioritize different components of the submission, allowing companies to focus on the most critical aspects first, which can lead to quicker approvals for essential technologies. ### Continuous Interaction with the FDA Another major perk is the ongoing dialogue with the FDA. Continuous interaction ensures that any uncertainties are addressed early on. It builds collaboration rather than competition. This back-and-forth can lead to more thorough submissions, ultimately benefiting patient safety. Think of it as a trusted partnership aiming for the same goal. Additionally, this interaction can provide invaluable insights into regulatory expectations, enabling companies to tailor their submissions more effectively and reduce the likelihood of delays caused by misunderstandings or miscommunications. ### Enhanced Risk Management Moreover, the Modular PMA Submission approach allows for enhanced risk management. By breaking down the submission into manageable modules, companies can identify and mitigate potential risks at each process stage. This proactive approach not only safeguards the integrity of the product but also instills confidence among stakeholders, including investors and healthcare providers. It’s akin to building a house one brick at a time, ensuring that each layer is solid before moving on to the next. ### Cost-Effectiveness Finally, the Modular PMA Submission can be more cost-effective in the long run. By streamlining the submission process and reducing the time to market, companies can save on development costs and allocate resources more efficiently. This financial advantage can be particularly crucial for smaller companies or startups that may not have the same level of funding as larger corporations. With the ability to bring innovations to market more quickly, these companies can also gain a competitive edge, positioning themselves as leaders in their respective fields. ## Challenges in a Modular PMA Submission Of course, it’s not all roses. This modular approach is not without its challenges, and companies must be keenly aware of potential pitfalls. ![Section Image](/imported-images/2eac87456db5e8c3.png) ### Managing the Modular Process One challenge involves managing multiple modules. Keeping track of each component can be a juggling act. It requires a diligent approach to documentation and data management. If one module falls behind, progress on the entire submission can be delayed. It’s essential to stay organized and focused. This often means implementing project management tools and strategies to monitor timelines and responsibilities effectively. Regular team meetings can also help ensure that everyone is on the same page and that any issues are addressed promptly. The complexity of coordinating various teams-research and development, regulatory affairs, and quality assurance-adds another layer of difficulty, necessitating clear communication and collaboration. ### Ensuring Module Completeness Additionally, ensuring the completeness of each module is paramount. Submitting an incomplete module can lead to delays or even denials. It’s crucial to revisit and double-check every detail. Having a checklist can be invaluable in this regard. A stitch in time saves nine! The regulatory landscape continually evolves, so what was considered complete a year ago may no longer meet current standards. Companies must stay updated on the latest guidelines and incorporate any changes into their submissions. Engaging with regulatory consultants or attending industry workshops can provide valuable insights and help navigate these complexities. Furthermore, the review process can be lengthy, and any oversight may result in significant setbacks, emphasizing the importance of thoroughness in every module submitted. ## Tips for a Successful Modular PMA Submission So, how can manufacturers ensure the success of their Modular PMA Submission? By following a few key strategies, businesses can avoid common mistakes and streamline their approval process. ### Planning and Organization First and foremost, planning and organization are essential. Having a clear outline for each module helps tremendously. Set realistic deadlines and allocate resources wisely. A well-organized submission process makes reviewing far less daunting. Consider creating a project management timeline with milestones for each submission phase. This keeps the team on track and allows for adjustments as needed, ensuring that no critical elements are overlooked. Regular team meetings can enhance collaboration and ensure everyone is aligned on goals and responsibilities. ### Communication with FDA Effective communication is also crucial. Establishing rapport with FDA reviewers can facilitate smoother interactions and build understanding. Regular check-ins can keep the process transparent. After all, communication is the lifeblood of any relationship. Preparing for these interactions is beneficial by having a list of questions or concerns ready, which can help clarify any uncertainties early on. Furthermore, utilizing the FDA’s pre-submission process can provide invaluable feedback on your proposed submission strategy, allowing you to address potential issues before they arise. ### Quality Control and Assurance Lastly, quality control and assurance processes cannot be overlooked. It’s crucial to ensure that all data submitted is accurate and reliable. Conduct internal audits and gather feedback before submission to catch any discrepancies early. Remember, an ounce of prevention is worth a pound of cure. A standardized checklist for each module can help maintain consistency and ensure all necessary documentation is included. Additionally, training team members on best practices for data management and submission protocols can further enhance the quality of the submission, reducing the likelihood of delays due to incomplete or incorrect information. Consider using technology to support your quality assurance efforts. Software tools that specialize in regulatory compliance can streamline data collection and reporting, making it easier to track changes and maintain version control. This not only enhances the submission’s accuracy but also provides a clear audit trail that can be beneficial during the review process. ## Conclusion A Modular PMA Submission offers a unique and efficient pathway for medical device manufacturers. By understanding its components, benefits, and challenges, companies can confidently navigate the regulatory landscape. With a little planning and organization, success is within reach-like a finish line waiting to be crossed. As you approach the finish line of your Modular PMA Submission, remember that cybersecurity is a critical component that cannot be overlooked. Blue Goat Cyber specializes in medical device cybersecurity, ensuring that your submission meets the highest standards for FDA clearance. Our expert team, with top certifications and Veteran-Owned business status, is committed to integrating security throughout your device’s lifecycle. From advanced penetration testing to ongoing support, we tailor our services to your needs, offering fixed-fee pricing and unlimited retesting for full transparency and assurance. Don’t let cybersecurity challenges slow down your progress. [Contact us today for cybersecurity help](/contact). Let us secure your devices, ensure compliance, and provide the peace of mind you need to succeed in the digital healthcare landscape. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in preparing and navigating each module of a Modular PMA Submission, with a particular focus on the cybersecurity aspects. Our team, composed of cybersecurity experts with CISSP and OSCP certifications and ex-military red team experience, helps structure cybersecurity documentation to meet current FDA expectations. We provide targeted guidance on risk management, threat modeling, and control implementation, aligning with the iterative nature of modular submissions. Our methodology ensures that each cybersecurity module is defensible and aligns with regulatory requirements. We collaborate closely with your team to integrate security across development phases, addressing potential deficiencies proactively. Our service offerings, such as [Medical Device Penetration Testing](/services/medical-device-penetration-testing), bolster the evidence presented in cybersecurity modules. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. This focused approach ensures efficient progress towards market approval. ## FAQ ### What is a Modular PMA Submission? A Modular PMA Submission is an FDA application method where manufacturers submit medical device approval information in discrete, structured modules like preclinical, manufacturing, and clinical data, rather than one large document. ### What are the benefits of a Modular PMA? Key benefits include increased flexibility, continuous communication and feedback from the FDA, enhanced risk management by addressing issues early, and improved efficiency in resource allocation. ### Does a Modular PMA replace traditional PMA submissions? No, a Modular PMA is an alternative method for submitting a Premarket Approval application. It offers a different structural approach but serves the same purpose of seeking FDA clearance for high-risk medical devices. ### What components are in a Modular PMA Submission? Typical components include a Preclinical Module with non-clinical data, a Manufacturing Module detailing production and quality control, and a Clinical Module presenting human study data and patient outcomes. ### How does the FDA review Modular PMA submissions? The FDA reviews each module as it is submitted, allowing for back-and-forth communication and potential adjustments before the entire application is complete. This iterative process allows for early identification and resolution of potential issues. ### Is a Modular PMA suitable for all medical devices? The suitability of a Modular PMA depends on the device's complexity and the manufacturer's development and data generation timeline. It is particularly advantageous for complex devices requiring extensive data that become available incrementally. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [PMA Cybersecurity Deficiencies and Complete Response Letters](/blog/fda-cybersecurity-pma-deficiencies-complete-response-letters) --- ## Radiology Information System: What It Is and How It Works Source: https://bluegoatcyber.com/blog/what-is-a-radiology-information-system # What Is a Radiology Information System? RIS Explained > **[DIRECT ANSWER]** A radiology information system (RIS) is software that manages the business and clinical workflow of an imaging department: scheduling, order entry, patient tracking, reporting, film/image tracking, and billing. It is distinct from PACS, which stores and distributes the actual images, and from the EHR, which holds the full patient record. A RIS integrates with PACS, modalities, and the EHR through HL7 v2, FHIR, and DICOM interfaces, and because it carries electronic protected health information across those interfaces, it needs role-based access control, MFA, segmentation, and audit logging. _Reviewed September 17, 2026_ Radiology departments run on scheduling accuracy, order accuracy, and report turnaround, and the software that holds those three things together is the radiology information system. When a RIS goes down, exams cannot be scheduled, technologists cannot confirm what was ordered, and reports stop moving to referring physicians. Hospitals evaluating a new RIS, or trying to understand why an existing one keeps generating wrong-patient or wrong-study errors, need to know exactly which module does what and where the system's integration points create risk. This guide walks through every RIS module, how a study flows from order to report, the integration standards involved, on-prem versus cloud deployment, buyer evaluation criteria, and the security controls that protect the ePHI a RIS handles. ## Key Takeaways - A RIS manages radiology workflow and administrative data; PACS stores images; the EHR holds the enterprise patient record. - A RIS is organized into distinct modules: scheduling, patient tracking, order entry/worklist, reporting and dictation, film/image tracking, billing and coding, and analytics. - HL7 v2 carries orders and results, FHIR is the modern API layer, and DICOM modality worklist synchronizes acquisition with the order. - Cloud RIS shifts patching and uptime to the vendor but expands the network trust boundary that must be secured. - Buyers should evaluate interoperability, workflow fit, uptime guarantees, and the vendor's security posture, not just price per seat. - Because a RIS touches ePHI at every interface, it needs the same access control, segmentation, and monitoring rigor as any other critical clinical system. ## Why This Matters A RIS sits at the center of imaging operations, brokering data between modalities, PACS, the EHR, and reporting tools. That position makes it one of the highest-impact systems in a health system: a compromise or outage here can corrupt orders, misroute images, or expose every imaging study the department has touched. The HHS Office for Civil Rights breach portal and the Health Sector Coordinating Council's *Health Industry Cybersecurity Practices* both list imaging-adjacent systems among the most frequently breached clinical environments. When a RIS is part of a regulated medical device product, such as a modality-bundled workstation or a vendor-managed cloud RIS, the FDA's February 3, 2026 final premarket cybersecurity guidance and Section 524B of the FD&C Act apply to it directly. That means a threat model, an SBOM, security architecture views, independent penetration testing, and a postmarket vulnerability management plan are expected deliverables, not optional documentation. The standards stack that reviewers and hospital security teams expect around RIS environments includes HL7 and DICOM for the integration interfaces, IEC 81001-5-1 for the secure software lifecycle on regulated RIS products, ANSI/AAMI SW96 (FDA Recognized Consensus Standard 13-131) for security risk management, and NIST SP 800-66 for HIPAA Security Rule implementation in the operating environment. ## What Does a Radiology Information System Do? A radiology information system is the software of record for everything that happens to an imaging exam except the image data itself. It tracks a study from the moment it is ordered through scheduling, acquisition, interpretation, and billing. Every RIS is organized into a set of functional modules, and most vendors implement all of them even when their marketing names differ. ### Scheduling The scheduling module books exams against modality time slots, room availability, and technologist staffing. It manages cancellations, no-shows, and rescheduling, and it coordinates across multiple sites so that a shared modality (for example, a single MRI scanner serving two clinics) is not double-booked. Scheduling rules also encode prep requirements, such as contrast fasting windows, so the front desk gives patients the correct instructions. ### Patient tracking Patient tracking maintains status as a patient moves through the department: checked in, in the waiting room, in the exam room, in acquisition, and discharged. This module gives front-desk and clinical staff a live view of where every patient is, which matters for throughput and for flagging patients who have been waiting too long. ### Order entry and worklist management Order entry captures the referring physician's request, including the study type, clinical indication, and priority. The RIS then generates a worklist, the list of exams a technologist needs to perform on a given modality, and pushes the matching patient demographics and order details to the modality through DICOM Modality Worklist. This step is what prevents a technologist from manually retyping patient information at the scanner console. ### Reporting and dictation Once images are acquired, the reporting module supports the radiologist's dictation, structured reporting templates, and report distribution. Voice recognition dictation, addenda, and critical-result flagging typically live here, and the finalized report is pushed back to the EHR and to the referring physician. ### Film and image tracking Even in a fully digital department, a RIS tracks the chain of custody for images and any physical media (CDs, historical film) that still circulate. This module logs who accessed a study, whether it was copied to external media, and whether outside images were imported for comparison. ### Billing and coding The billing module captures CPT and ICD-10 codes tied to each completed exam and feeds them into the revenue cycle system. Some RIS platforms include full billing; others hand off coded encounter data to a separate billing system or the hospital's HIS. ### Analytics and operational reporting Analytics modules turn workflow data into operational metrics: turnaround time from order to final report, modality utilization, no-show rates, and referring-physician volume. These reports are what department leadership uses to justify staffing and equipment decisions. ## RIS vs PACS vs EHR vs VNA: What Is the Difference? These four systems are frequently confused because they sit next to each other in the same workflow, but each holds a different type of data and serves a different purpose. | System | Primary purpose | Typical data held | | --- | --- | --- | | Radiology Information System (RIS) | Radiology workflow and departmental operations | Orders, scheduling, exam status, reports, billing codes | | Picture Archiving and Communication System (PACS) | Imaging storage, retrieval, and distribution | Image pixel data, study/series metadata, viewer access logs | | Electronic Health Record (EHR) | Enterprise patient record and clinical operations | Demographics, clinical documentation, orders, results, billing context | | Vendor Neutral Archive (VNA) | Long-term, vendor-independent image and object storage | Archived images and documents from multiple PACS or departments, often with a DICOM/XDS interface | **[KEY REQUIREMENT]** A RIS should never be the sole system of record for image pixel data; that responsibility belongs to PACS or a VNA, and any RIS deployment that stores diagnostic images directly needs an explicit data retention and disaster recovery plan for that image store. ## How Does a Study Flow From Order to Report? A study moves through a fixed sequence regardless of which vendor's RIS is running it. First, a referring physician or ordering system creates the order, which the RIS receives as an HL7 order message. Second, the RIS schedules the exam and, at the time of acquisition, publishes the matching entry to the modality worklist so the technologist selects the correct patient instead of retyping demographics. Third, the modality acquires the images and sends them to PACS using DICOM store operations, while the RIS updates the exam status to completed. Fourth, the radiologist reads the study in a viewer connected to PACS, dictates a report through the RIS reporting module, and finalizes it. Fifth, the RIS transmits the finished report back to the EHR and to the referring physician, typically as an HL7 ORU message, and closes the loop by generating the billing codes for the encounter. ## How Does a RIS Integrate With Other Systems? Interoperability is what makes a RIS valuable, and it runs on three standards. HL7 v2 is the workhorse messaging standard for orders, results, and admission/discharge/transfer (ADT) feeds between the RIS, the EHR, and the HIS. FHIR is the newer, REST-based API standard that many vendors now expose alongside or instead of HL7 v2, particularly for mobile and web-based integrations. DICOM Modality Worklist is the mechanism that pushes scheduled order and patient data from the RIS to imaging modalities, and it is what keeps a scanned patient's demographics matched to the correct order. IHE (Integrating the Healthcare Enterprise) profiles, especially Scheduled Workflow, standardize how RIS, PACS, and modalities coordinate these exchanges so that systems from different vendors interoperate predictably. **[KEY REQUIREMENT]** Every HL7, FHIR, and DICOM interface a RIS exposes should require authentication and be reachable only from a defined, segmented network path, because none of these protocols authenticate by default at the message level. ## On-Prem vs Cloud RIS: Which Deployment Model Fits? An on-premises RIS runs on hospital-owned servers, giving the organization full control over data location and network configuration but placing the full burden of patching, uptime, and hardware refresh on internal IT. A cloud or vendor-hosted RIS shifts patching, backup, and infrastructure uptime to the vendor, which usually improves baseline security hygiene for organizations without a dedicated infrastructure team. Cloud deployment does not remove security responsibility; it relocates part of it. The hospital still owns access control, network segmentation on its side of the connection, and vendor risk management, while the vendor owns the infrastructure and application security of the hosted environment. Buyers should get a written breakdown of which controls the vendor owns and which the hospital owns before signing a cloud RIS contract. ## What Should Buyers Evaluate When Selecting a RIS? Buyers should weigh interoperability, workflow fit, uptime, and vendor security posture as a single evaluation, not as separate checkboxes. Interoperability means confirming the vendor supports HL7 v2 and FHIR out of the box and has a track record of successful integrations with the buyer's existing EHR and PACS. Workflow fit means the scheduling, worklist, and reporting modules match how the department actually operates, since a mismatch here creates manual workarounds that erode the value of the system. Uptime and support terms matter because a RIS outage stops scheduling and reporting across the department, so buyers should confirm the vendor's service-level agreement and disaster recovery commitments in writing. Vendor security posture includes the vendor's patching cadence, its willingness to provide a software bill of materials, its incident notification timeline, and whether it will support the hospital's segmentation and access control requirements rather than requiring broad flat-network access. ## What Are the Main RIS Security Risks? RIS environments handle ePHI at every interface, so the risk surface tracks the integration points described above. The main failure modes are interface exposure, weak identity controls, legacy dependencies, flat networks, and unmanaged vendor connectivity. - **Interface exposure**: HL7, FHIR, and DICOM interfaces are unauthenticated by default at the protocol level, so any exposed or misconfigured interface engine is a direct path to ePHI or to injecting false orders. - **Identity and access weaknesses**: shared logins, weak passwords, and over-permissioned roles let one compromised credential reach scheduling, reporting, and billing data alike. - **Legacy dependencies**: older operating systems and unpatched third-party components are common in long-lived RIS deployments and rarely get replaced on a security timeline. - **Flat networks**: without segmentation between RIS, PACS, modalities, and general IT, a single compromised workstation can reach the entire imaging chain. - **Vendor and connected-device risk**: remote support access and third-party integrations expand the trust boundary beyond what the hospital directly controls. ### Access control, segmentation, and audit logging Because none of the core integration protocols authenticate by default, the controls that actually protect a RIS live around it: role-based access control with unique user IDs, multi-factor authentication on admin and remote access, network segmentation between RIS, PACS, and modality networks, and audit logging on user administration, interface configuration changes, and report edits. These controls do not require replacing the RIS itself; they require the hospital and vendor to jointly enforce them at every interface. > **Securing a RIS/PACS integration?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [Medical device penetration testing](/services/medical-device-penetration-testing) ## What to Budget For If You Build or Buy RIS Software RIS security work gets bought by two different groups, and they need different scopes. A vendor building a RIS product that forms part of a regulated submission needs premarket evidence. A health system deploying or migrating a RIS needs assurance about the integration points it now owns. Scoping the wrong one is the most common reason a security engagement produces a report nobody can use. | If you are | Your scope centers on | What the work produces | Who signs off | |---|---|---|---| | A RIS or imaging software vendor in a submission | Threat model, SBOM, interface and API testing, architecture views | Premarket cybersecurity documentation package | Your regulatory team, with our evidence attached | | A vendor updating a shipped RIS | Change impact review, postmarket vulnerability handling | Updated risk file and patch process evidence | Your quality system | | A health system deploying a RIS | HL7, FHIR, and DICOM interface exposure, identity, segmentation | Prioritized findings and remediation plan | Your security and imaging leadership | | A health system inheriting a legacy RIS | Unsupported components, shared logins, remote support paths | Risk register with compensating controls | Your risk committee | The cost driver in every case is interface count, not user count. A RIS with four live integrations and a vendor remote support tunnel takes substantially more testing effort than a larger deployment with two. The same logic that prices device testing applies here, and the [penetration testing cost breakdown](/blog/cost-of-medical-device-penetration-testing) walks through how interface count moves the number. ## How Blue Goat Cyber Approaches This RIS environments sit inside larger connected ecosystems where imaging devices, hospital networks, and vendor cloud platforms all touch the same patient data. Blue Goat Cyber helps medical device manufacturers and healthcare organizations map that ecosystem through [medical device threat modeling](/services/medical-device-threat-modeling), identifying which interfaces (HL7, FHIR, DICOM, remote support) create real exposure rather than treating every connection as equal risk. For RIS products that are part of a regulated device submission, we build the security architecture views, SBOM, and independent penetration test evidence the FDA's February 3, 2026 premarket cybersecurity guidance expects, and we support the postmarket monitoring program once the product ships. If the FDA raises cybersecurity deficiencies after our work, we resolve them at no additional cost. ## Frequently Asked Questions ### What does RIS stand for in radiology? RIS stands for radiology information system, software that manages radiology department workflow, including scheduling, order entry, exam tracking, reporting, and billing. It is distinct from PACS, which handles image storage and distribution. ### What is the difference between RIS and PACS? A RIS manages workflow and administrative data such as orders, scheduling, and reports, while PACS stores, retrieves, and distributes the actual diagnostic images. Most radiology departments run both systems together, integrated through HL7 and DICOM. ### Does a RIS store images? Generally no. A RIS tracks that a study exists and its workflow status, but the diagnostic image data itself is stored in PACS or a vendor-neutral archive, which is built for large binary image storage and long-term retention. ### How does a RIS connect to the EHR? A RIS typically connects to the EHR through HL7 v2 messages for orders, ADT feeds, and results, or through FHIR APIs in newer implementations. This lets the EHR display up-to-date order status and finalized radiology reports without duplicate data entry. ### Is a cloud-based RIS secure enough for a hospital? A cloud RIS can meet hospital security requirements if the vendor documents its patching cadence, access controls, and breach notification process, and if the hospital enforces segmentation and MFA on its side of the connection. Security responsibility splits between vendor and hospital rather than disappearing with cloud deployment. ### What causes most RIS-related security incidents? Most incidents trace back to unauthenticated or poorly monitored interface engines, weak identity controls like shared logins, or unpatched legacy components that sit in the RIS environment for years. Segmentation, MFA, and interface monitoring address the majority of this exposure. ## CTA If your organization is deploying, migrating, or securing a RIS as part of a regulated medical device, Blue Goat Cyber can threat model the integration points, test the interfaces, and build the documentation your FDA submission needs. [Contact us](/contact) to talk through your RIS security posture before your next audit or submission deadline. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## What Is DICOM in Medical Devices? Source: https://bluegoatcyber.com/blog/what-is-dicom-in-medical-devices # What Is DICOM in Medical Devices? > **[DIRECT ANSWER]** DICOM is the standard format and communication protocol that lets imaging systems such as X-ray, MRI, CT, and ultrasound devices exchange images and associated patient metadata consistently across vendors. It enables interoperability with PACS, RIS, and EHR platforms, but the standard itself does not guarantee security, since encryption, authentication, and access control depend on how a manufacturer implements it. Under the FDA's February 3, 2026 premarket cybersecurity guidance, manufacturers must validate and document those DICOM implementation choices. Updated November 16, 2024 DICOM, short for Digital Imaging and Communications in Medicine, is the standard that lets medical imaging systems exchange images and related data in a usable format. If your device creates, stores, transmits, or displays diagnostic images, DICOM is usually part of the architecture, and part of the risk surface. ## Key Takeaways - DICOM is the medical imaging standard. - It defines image formats and communication protocols. - Enables interoperability across diverse systems. - Critical for X-ray, MRI, CT, and ultrasound. - Impacts data integrity and cybersecurity. - Requires careful implementation and validation. ## Why this matters The stakes for DICOM implementation are high: improper handling can lead to significant cybersecurity risks, including unauthorized access to patient data, data tampering, and disruption of clinical operations. DICOM-enabled devices, by their nature, transmit and store sensitive patient information, making them prime targets for cyberattacks if not adequately secured. The FDA, in its "Cybersecurity in Medical Devices" final guidance dated February 3, 2026, emphasizes that manufacturers must account for the security of medical device data during all phases of the product lifecycle, including adherence to established standards like DICOM for data exchange. This guidance mandates that manufacturers identify and mitigate cybersecurity vulnerabilities that could arise from standard protocols. Relevant standards include IEC 81001-5-1 for risk management of IT networks incorporating medical devices, and elements of IEC 62304 for medical device software lifecycle processes, which indirectly apply to secure DICOM implementation. AAMI TIR57 / ANSI/AAMI SW96:2023 also provides valuable guidance on the principles of medical device security, which are directly applicable to securing DICOM communications and data storage. ## Understanding the Basics of DICOM [DICOM](https://www.dicomstandard.org/) defines both a file format and communication rules for exchanging medical images and associated information. The goal is interoperability: imaging systems, workstations, archives, and clinical platforms should be able to move data without custom one-off integrations for every vendor pairing. ![Section Image](/imported-images/5654ae4a3ec0dbe1.webp) DICOM is not just about pixels. It also carries metadata such as patient identifiers, study details, acquisition parameters, measurements, annotations, and reports. That context is what makes an image clinically useful and operationally traceable. ### Defining DICOM in Medical Devices DICOM is most closely associated with imaging devices such as X-ray systems, MRI scanners, CT scanners, ultrasound machines, and mammography platforms. These systems generate images in a standardized structure so downstream systems can store, retrieve, display, and analyze them consistently. The standard supports more than simple 2D images. Depending on the modality and use case, DICOM can represent 3D reconstructions, multi-frame studies, waveforms, structured reports, and other data objects used across radiology, cardiology, oncology, orthopedics, and related specialties. ### Why DICOM Matters in Healthcare Without a shared standard, imaging data gets trapped in vendor silos. DICOM gives healthcare organizations a common format and protocol set so clinicians can access studies across devices and systems with less friction. That matters for patient care, but it also matters for compliance and security. A DICOM implementation affects data integrity, traceability, authentication, encryption choices, workflow design, and how a device interacts with PACS, RIS, EHR platforms, and remote systems. For manufacturers, this is not just an interoperability feature. It is a design control and cybersecurity concern. ## How DICOM Works DICOM uses a [network communication protocol known as TCP/IP](/blog/securing-communication-protocols-in-medical-devices) for transport and defines its own application-layer services for moving and managing medical data. Devices and software exchange information using standardized commands and service classes, while the DICOM file structure stores image data and metadata in a predictable format. A few technical concepts matter in practice: - **Objects and metadata:** DICOM packages images and related information together so the receiving system has clinical context, not just a bitmap. - **UIDs (Unique Identifiers):** Studies, series, and individual instances get unique identifiers so systems can track and reference data accurately. - **Services and workflows:** Systems can store, query, retrieve, print, and exchange worklists using defined DICOM services. - **Modality worklists:** Imaging devices can pull scheduled exam and patient information from systems such as [Radiology Information Systems (RIS)](/blog/what-is-a-radiology-information-system), reducing manual entry and the errors that come with it. ### Key Features of DICOM Several features explain why DICOM remains foundational in medical imaging: - **Standardized formatting:** It gives vendors a common structure for many image and data types. - **Interoperability:** It allows devices and software from different manufacturers to exchange data with less custom integration work. - **Compression support:** It can reduce storage and bandwidth demands, though compression choices must be validated for the intended clinical use. - **Structured reporting:** It supports standardized representation of findings and measurements. - **Display conventions:** Hanging protocols help define how images are presented for review. Security is often discussed here, but manufacturers should be careful not to overstate what DICOM itself provides. Encryption, authentication, authorization, and secure deployment depend heavily on implementation choices, surrounding infrastructure, and system configuration, not just the presence of the standard. ## The Role of DICOM in Different Medical Devices ![Section Image](/imported-images/2a842b45d9ef93d5.webp) ### DICOM in Imaging Devices For imaging devices, DICOM is the backbone of image acquisition, storage, export, and review workflows. It helps ensure that a CT, MRI, ultrasound, or X-ray study can be sent to PACS, opened on a workstation, and interpreted without format translation chaos. That interoperability supports clinical collaboration, but it also introduces attack paths. A networked imaging device that accepts inbound associations, exports studies, or queries archives is not operating in isolation. Manufacturers need to assess those interfaces the same way they assess any other external-facing functionality. ### DICOM in Monitoring and Other Clinical Devices DICOM is not limited to traditional imaging. Some monitoring and specialty devices use DICOM objects to transmit waveforms, measurements, and related patient data to enterprise systems or other compatible platforms. That can improve visibility and continuity of care, especially when data needs to move across departments or facilities. It also expands the integration footprint. Once devices begin exchanging near-real-time clinical data across interconnected environments, interoperability and cybersecurity stop being separate conversations. They are the same design problem. ## Benefits of Using DICOM in Medical Devices ### Better Clinical Access to Data DICOM makes it easier for clinicians to access studies across systems and compare imaging over time. That supports diagnosis, treatment planning, and follow-up, especially when multiple modalities or specialists are involved. ### Smoother Operations and Integration DICOM-compatible devices can integrate with [Picture Archiving and Communication Systems (PACS)](/blog/pacs-medical-device-vulnerabilities), EHR systems, and departmental platforms with less manual handling. That reduces duplicate entry, cuts avoidable workflow errors, and makes imaging operations more scalable. Interoperability also improves care continuity. When data can move cleanly between facilities and systems, clinicians spend less time chasing images and more time using them. ### Better Support for Security and Privacy Controls DICOM-based workflows can support strong security and privacy controls, but only when the implementation is engineered correctly. Transport encryption, access control, auditability, data minimization, and secure configuration all matter. So does lifecycle maintenance. For device manufacturers, this is where checklist thinking causes problems. Saying a device “supports DICOM” or “uses encryption” is not enough for the FDA, hospital security teams, or procurement reviewers. You need to show how the implementation protects confidentiality, integrity, and availability in the real deployment context. ## Challenges and Solutions in Implementing DICOM ![Section Image](/imported-images/0d295c41461237cf.webp) DICOM implementation gets messy fast. Different vendors interpret optional elements differently. Legacy systems linger. Hospitals run mixed environments. And devices often need to interoperate with systems the manufacturer does not control. ### Common DICOM Integration Problems A few problems show up repeatedly: - **Version and implementation differences:** Two products may both claim DICOM support and still fail to interoperate cleanly. - **Data mapping issues:** Patient, study, and workflow fields do not always align across systems. - **Legacy dependencies:** Older archives, modalities, and viewers may support outdated behaviors that still need accommodation. - **Scale and storage burdens:** Imaging datasets are large, and retrieval performance matters in clinical environments. - **Security gaps:** Unencrypted transport, weak trust configuration, exposed services, and poor segmentation can turn interoperability into exposure. ### How Manufacturers and Healthcare Organizations Can Address Them The fix is not “buy a library and hope for the best.” It takes engineering discipline. Use proven DICOM toolkits where appropriate, but validate behavior across the systems your customers actually use. Test normal workflows and failure conditions. Verify data integrity, authentication, encryption, error handling, logging, and timeout behavior. Document the security assumptions your device makes about the environment. Manufacturers should also align DICOM design decisions with FDA expectations for secure product development. If a DICOM service is network-accessible, it belongs in your threat model. If it affects essential clinical performance, it belongs in your safety analysis. If it depends on configuration by the customer, that configuration needs clear, defensible guidance. ## The Future of DICOM in Medical Devices DICOM continues to adapt as healthcare infrastructure changes. Cloud-hosted workflows, remote collaboration, enterprise imaging, and connected device ecosystems all increase pressure for data to move cleanly across environments. ### Emerging Trends in DICOM Technology One notable shift is the growing use of web-based services and APIs alongside traditional DICOM networking. As cloud adoption increases and the [Internet of Things (IoT)](/blog/iot-vs-iomt-understanding-the-differences-in-the-internet-of-things-and-internet-of-medical-things) expands into healthcare, manufacturers will need architectures that support secure exchange across hybrid environments, not just inside a hospital network. That raises the bar. Connectivity is useful, but every new interface adds trust decisions, authentication requirements, and monitoring needs. ### The Impact of AI and Machine Learning on DICOM [AI and machine learning](/blog) systems depend on well-structured, well-labeled data. DICOM provides much of that foundation by pairing images with metadata, measurements, and workflow context. That makes it useful for training, inference, triage, image analysis, and decision support applications. But AI adds its own risks. Data provenance, model drift, preprocessing consistency, and integration security all matter. If your device uses DICOM to feed an AI feature-or receives AI-generated results through a DICOM-based workflow; you need to validate more than connectivity. You need to validate clinical and cybersecurity behavior together. ## DICOM security options compared | Mechanism | What it protects | What it does not do | When to use it | | --- | --- | --- | --- | | AE title checking | Rejects associations from unexpected peers | Nothing an attacker cannot spoof on its own | Always, as a baseline, never as the only control | | TLS on the DICOM association | Confidentiality and integrity in transit | Authorization of what the peer may request | Any link that crosses a segment or leaves the facility | | User identity negotiation | Ties an operation to a user or system identity | Protection of data at rest | Where audit trails have to name a person | | De-identification profiles | Removes identifiers before secondary use | Protection of the original study | Research exports, vendor support copies, test data sets | | Storage encryption on the PACS | Data at rest on disks and backups | Anything once the application is running | Always, and state the key management in the submission | DICOM gives you the option of each of these. None of them is on by default, and that gap is what a reviewer looks for. ## Conclusion DICOM is the standard that makes modern medical imaging ecosystems work. It enables interoperability, supports clinical workflows, and creates the structure that downstream systems depend on. It also introduces meaningful security, integration, and compliance challenges that manufacturers cannot afford to treat as box-checking exercises. If your device uses DICOM, you need to understand the protocol, the workflow, and the threat model. That is how you build something hospitals can trust, and something the FDA will not view as an afterthought. As DICOM-connected products grow more integrated with enterprise systems, cloud platforms, and AI-driven workflows, the cybersecurity burden grows with them. Blue Goat Cyber helps medical device manufacturers assess those risks, test real-world exposures, and build evidence that stands up to customers and the FDA. [Contact us today for cybersecurity help](/contact). ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in understanding and mitigating the cybersecurity risks associated with DICOM implementation. Our methodology includes detailed threat modeling specific to DICOM workflows, vulnerability assessments of DICOM-enabled devices, and secure configuration guidance. We help our clients identify potential attack vectors in data transmission and storage, ensuring adherence to regulatory requirements and industry best practices. Our team, comprised of CISSP-certified professionals, OSCP-holders, and ex-military red team experts, possesses a deep understanding of medical device security challenges. We provide actionable recommendations to harden DICOM interfaces and integrate security controls into the device's architecture. Our services extend to assisting with premarket submissions, ensuring that cybersecurity documentation for DICOM is accurate and complete. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What medical devices use DICOM? Many medical devices use DICOM, including imaging modalities like X-ray, MRI, CT, and ultrasound systems. It is also used by Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and some electronic health record (EHR) platforms or specialized clinical devices that exchange images or waveforms. ### How does DICOM ensure data privacy? DICOM itself defines how image data and metadata are structured and exchanged, but it does not inherently guarantee data privacy or security. Implementation choices, such as transport encryption, access controls, secure configurations, and proper network segmentation are necessary to protect patient information exchanged via DICOM. ### Does the FDA regulate DICOM-enabled devices? Yes, the FDA regulates medical devices that use DICOM. Manufacturers must demonstrate that their DICOM implementation supports safety and essential clinical performance, addressing cybersecurity risks as outlined in the February 3, 2026 final guidance on premarket cybersecurity for medical devices. This includes validating data integrity, interoperability, and secure operation. ### What are DICOM's cybersecurity risks? DICOM's cybersecurity risks stem from open network services, potential for unencrypted data transmission, and vulnerabilities in parsing or handling DICOM objects. Poorly secured DICOM implementations can lead to unauthorized access, data manipulation, or denial of service, impacting patient safety and data privacy if not properly mitigated through secure design and configuration. ### Can DICOM be used with AI applications? Yes, DICOM is foundational for AI and machine learning in healthcare because it provides structured image data and rich metadata. This standardized data is essential for training AI models, performing inference, and supporting AI-driven diagnostic or analytical tools. Secure integration and validation of AI workflows are crucial. ### What is a DICOM Conformance Statement? A DICOM Conformance Statement is a document provided by a medical device manufacturer that details how its product implements the DICOM standard. It specifies the DICOM service classes, information objects, transfer syntaxes, and other capabilities supported by the device, helping users understand its interoperability with other DICOM-compliant systems. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) YouTube ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [What Are IRT Medical Devices? Explained](/blog/what-are-irt-medical-devices) - [CVSS 3.1 vs 4.0 for Medical Devices](/blog/cvss-3-1-vs-4-0-medical-devices) - [What is the IVD Regulation in Medical](/blog/what-is-the-ivd-regulation-in-medical-device-cybersecurity) - [Return-to-libc Attacks in Medical Devices](/blog/understanding-relevant-threats-for-medical-devices) --- ## Joint Security Plan (JSP): What MedTech Teams Need to Know (2026) Source: https://bluegoatcyber.com/blog/what-is-medical-device-and-health-it-joint-security-plan-jsp # Joint Security Plan (JSP): What MedTech Teams Need to Know in 2026 > **[DIRECT ANSWER]** A Joint Security Plan (JSP) is a collaborative framework, developed jointly by medical device manufacturers, health IT developers, and healthcare providers, that integrates risk management, security controls, and compliance measures across interconnected medical devices and health IT systems. It standardizes security practices, supports alignment with standards like IEC 81001-5-1 and ISO 27001, and helps organizations document a consistent, defensible cybersecurity posture ahead of FDA submissions. _Updated October 26, 2024_ Medical Device and Health IT Joint Security Plan (JSP) is a crucial framework that ensures the security and protection of medical devices and health IT systems within healthcare organizations. A security plan has become paramount as the healthcare industry increasingly relies on technology. ## Key Takeaways - JSP integrates security for medical devices and health IT systems. - It covers risk management, security controls, and compliance. - Collaboration among stakeholders matters for JSP success. - JSP mitigates cybersecurity risks and protects patient data. - Technological and organizational hurdles exist in JSP implementation. - New technologies and evolving threats require adaptable JSP measures. ## Why this matters The criticality of a Joint Security Plan (JSP) in healthcare cannot be overstated, as the integrity and safety of patient care hinge on securing interconnected medical devices and health IT systems. Escalating cyber threats, including ransomware and data breaches, directly impact patient safety and privacy. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly emphasizes the necessity of a structured approach to cybersecurity throughout the medical device lifecycle, aligning directly with JSP principles. A well-executed JSP ensures adherence to crucial standards such as IEC 81001-5-1 for the manufacturer secure software lifecycle (with IEC 81001-5-1 governing hospital/HDO network integration), ISO 27001 for information security management, and AAMI TIR57 / ANSI/AAMI SW96:2023 for medical device security risk management. These standards, when incorporated into a JSP, form a strong defense against vulnerabilities. Without a cohesive JSP, organizations face fragmented security efforts, increased compliance burdens, and heightened exposure to cyber incidents that can disrupt clinical operations, compromise sensitive patient data, and erode public trust in healthcare systems. Proactive JSP implementation is essential for maintaining operational continuity and safeguarding patient well-being. ## Understanding the Concept of Medical Device and Health IT Joint Security Plan ### Definition of Medical Device and Health IT Joint Security Plan The Medical Device and Health IT Joint Security Plan, commonly called JSP, is a strategic initiative to integrate the security of medical devices and health IT systems. It incorporates risk management, security controls, and compliance measures to safeguard patient data and ensure the integrity of healthcare systems. ![Section Image](/imported-images/305e88b0d38d5d36.png) One key aspect of the JSP is its focus on collaboration between medical device manufacturers, health IT developers, healthcare providers, and regulatory bodies. This collaborative approach ensures that all stakeholders work together to address security challenges and develop effective solutions that meet industry standards and regulatory requirements. ### The Importance of JSP in Healthcare The need for a unified security plan has become critical with the growing interconnectivity of medical devices and health IT systems. JSP provides a approach to addressing the increasing cybersecurity threats faced by healthcare organizations. By implementing JSP, healthcare providers can mitigate potential risks, safeguard patient information, and maintain patients’ trust. The JSP helps healthcare organizations streamline their security efforts by providing a framework for consistent security practices across different types of medical devices and health IT systems. This standardization enhances security posture and simplifies compliance with regulatory requirements such as HIPAA and GDPR, reducing the burden on healthcare providers and improving overall system efficiency. ## Components of a Joint Security Plan ### Risk Management in JSP Effective risk management is a core component of JSP. Healthcare organizations must identify potential risks and vulnerabilities associated with their medical devices and health IT infrastructure. By conducting thorough risk assessments, they can develop strategies and protocols to minimize the impact of potential security breaches. ![Section Image](/imported-images/a481f8c87a554f76.png) One crucial aspect of risk management in a Joint Security Plan (JSP) is [continuously monitoring](/) and updating risk assessments. As the healthcare landscape evolves and new threats emerge, organizations must stay vigilant in reassessing and adapting their risk management strategies. This proactive approach ensures that security measures remain effective and aligned with the ever-changing cybersecurity landscape. ### Security Controls in JSP JSP relies on various security controls to protect medical devices and health IT systems. These controls encompass various measures such as access controls, encryption, firewalls, and intrusion detection systems. By implementing these security controls, healthcare organizations can ensure the confidentiality, integrity, and availability of patient information. An essential aspect of security controls within a JSP is the concept of defense-in-depth. This strategy involves layering multiple security measures throughout the IT infrastructure to create overlapping layers of protection. By employing defense-in-depth, organizations can significantly enhance their security posture and mitigate the risks of sophisticated cyber threats. ## Challenges in Implementing a Joint Security Plan ### Technological Hurdles Implementing JSP can be challenging due to the complex and diverse nature of medical devices and health IT systems. Updating or securing legacy devices, integrating new technologies, and ensuring interoperability across different systems pose significant challenges for healthcare organizations. Overcoming these technological hurdles requires careful planning, investment, and collaboration with vendors and stakeholders. The rapid pace of technological advancements in the healthcare industry adds another layer of complexity to implementing a Joint Security Plan. To avoid potential vulnerabilities, healthcare organizations must constantly adapt to new software updates, security patches, and emerging threats. This dynamic environment requires ongoing monitoring and proactive measures to safeguard patient data and ensure the integrity of medical systems. ### Organizational Challenges The successful implementation of JSP also requires a cultural shift within healthcare organizations. It involves educating staff about the importance of cybersecurity, promoting security-conscious behavior, and building a culture of continuous improvement. Resistance to change and lack of awareness about cybersecurity risks can hinder the effective implementation of JSP. Organizational challenges may arise from the complex hierarchy and diverse roles within healthcare institutions. Coordinating efforts between different departments, such as IT, clinical staff, and administrative personnel, can be daunting. Effective communication, clear role definitions, and cross-departmental collaboration are essential to ensure a cohesive approach to implementing and maintaining a Joint Security Plan across the organization. ## Future Trends in Medical Device and Health IT Joint Security Plan ### Impact of Emerging Technologies The rapid evolution of technologies such as artificial intelligence (AI), the Internet of Things (IoT), and telemedicine presents both opportunities and challenges for JSP. While these technologies improve patient care and operational efficiency, they also introduce new security risks. Healthcare organizations must stay updated on emerging threats and adapt their JSP accordingly to ensure the security of future technologies. ### Evolving Security Threats and Solutions As technology evolves, so do security threats. Cybercriminals constantly develop new techniques to exploit vulnerabilities in medical devices and health IT systems. Healthcare organizations must continuously enhance their security measures, conduct regular security assessments, and collaborate with industry partners to stay one step ahead of potential threats. By staying proactive, JSP can effectively address healthcare organizations’ evolving security challenges. One emerging technology that has the potential to revolutionize healthcare is AI. With its ability to analyze vast amounts of data and identify patterns, AI can greatly enhance diagnostic accuracy and treatment outcomes. However, integrating AI into medical devices and health IT systems introduces new security concerns. As AI algorithms become more complex and sophisticated, they may become vulnerable to attacks from malicious actors seeking to manipulate the algorithms or gain unauthorized access to patient data. Therefore, healthcare organizations must develop security protocols to protect AI-powered systems and ensure the integrity and confidentiality of patient information. In addition to AI, the Internet of Things (IoT) is another technology transforming the healthcare industry. IoT devices like wearable health trackers and remote patient monitoring systems enable real-time data collection and analysis, leading to more personalized and efficient healthcare delivery. However, the proliferation of IoT devices also expands the attack surface for cybercriminals. If not properly secured, these devices can become entry points for hackers to infiltrate health IT systems and compromise patient data. To mitigate this risk, healthcare organizations must implement authentication mechanisms, encryption protocols, and regular firmware updates to ensure the [security of IoT devices](/blog) and protect patient privacy. The increasing adoption of telemedicine has brought about significant benefits regarding remote patient care and accessibility. Patients can now consult with healthcare professionals from the comfort of their homes, reducing the need for in-person visits and improving overall healthcare outcomes. However, telemedicine platforms and applications are not immune to security threats. Unauthorized individuals can intercept the transmission of sensitive patient data over the internet if proper security measures are not in place. Healthcare organizations must prioritize implementing secure communication channels, encryption protocols, and user authentication mechanisms to safeguard patient information during telemedicine consultations. ## Conclusion The landscape of healthcare technology demands a and adaptable approach to security. The Medical Device and Health IT Joint Security Plan (JSP) is a crucial framework to ensure the security and integrity of medical devices and health IT systems within the healthcare industry. By implementing JSP, healthcare organizations can protect patient data, ensure compliance with regulations, and mitigate potential security risks. However, the successful implementation of JSP requires overcoming technological and organizational challenges. Organizations must embrace emerging technologies to stay ahead in this dynamic environment and adapt their security measures accordingly. By doing so, they can proactively address the [security threats](/blog) and maintain patients’ trust. As the healthcare sector continues to navigate the complexities of cybersecurity, the need for expert guidance and security solutions becomes increasingly critical. Blue Goat Cyber, a Veteran-Owned business, stands at the forefront of medical device cybersecurity, offering a suite of B2B services tailored to your needs. From penetration testing to HIPAA and FDA compliance, our team is dedicated to securing your operations against the latest threats. [Contact us today for cybersecurity help](/contact) and partner with a team passionate about protecting your business and products from cyber attackers. ## How Blue Goat approaches this Our approach to Medical Device and Health IT JSPs focuses on identifying and mitigating specific threats relevant to your ecosystem. We begin with a detailed assessment of your existing infrastructure, identifying vulnerabilities and potential compliance gaps. Our team, comprised of CISSP and OSCP certified experts, including ex-military red team personnel, develops a tailored JSP that aligns with your operational realities and regulatory obligations. We prioritize practical, implementable security controls and provide actionable recommendations for enhancing your security posture. Our services, including threat modeling and penetration testing, ensure your JSP is effective against evolving cyber threats. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support at [Medical Device Penetration Testing](/services/medical-device-penetration-testing). ## FAQ ### What is a Medical Device and Health IT Joint Security Plan? A Joint Security Plan (JSP) is a strategic initiative that integrates security measures for medical devices and health IT systems. It ensures the protection of patient data and the integrity of healthcare systems through focused risk management and security controls. ### Why is JSP important in healthcare? JSP is critical in healthcare due to the increasing interconnectivity of medical devices and IT systems. It provides a framework to address cybersecurity threats, protect patient information, and streamline compliance with regulations such as HIPAA. ### What are the main components of a JSP? The main components of a JSP include effective risk management, which identifies and mitigates potential vulnerabilities, and the implementation of various security controls like access controls, encryption, and intrusion detection systems to protect data. ### What challenges exist in implementing a JSP? Challenges in implementing a JSP include technological hurdles, such as securing legacy devices and integrating new technologies, and organizational challenges like building a cybersecurity-aware culture and coordinating efforts across different departments. ### How do emerging technologies impact JSP? Emerging technologies like AI, IoT, and telemedicine introduce new security risks and opportunities for JSP. Healthcare organizations must adapt their JSP to account for these technologies, ensuring ongoing security against new threats. ### Does the FDA require a JSP? The FDA emphasizes cybersecurity for medical devices, particularly in its February 3, 2026 final guidance. While not explicitly mandating a "Joint Security Plan" by name, the guidance requires manufacturers to consider many elements described in a JSP. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Health Canada Medical Device](/blog/health-canada-medical-device-cybersecurity) - [PowerShell in Medical Device](/blog/understanding-relevant-threats-for-medical-devices) - [Nonrepudiation in Medical Device Security](/blog/fda-medical-device-cybersecurity-requirements-security-controls-for-authentication-and-authorization) - [OpenSSF’s Impact on Medical Device](/blog/medical-device-cybersecurity-best-practices) --- ## PACS in Medical Devices: What It Is and How to Secure It Source: https://bluegoatcyber.com/blog/what-is-pacs-in-medical-devices # What Is PACS in Medical Devices and Why It Matters > **[DIRECT ANSWER]** PACS stands for Picture Archiving and Communication System. It is the software and storage infrastructure that receives, archives, retrieves, and distributes medical images from modalities such as CT, MRI, ultrasound, and X-ray, almost always using the DICOM standard. In the United States, PACS is a regulated medical device, generally Class II under 21 CFR 892.2050, which means the cybersecurity expectations that apply to imaging hardware apply to the archive as well. _Reviewed September 17, 2026_ A hospital can lose access to every prior study in its archive without a single imaging machine being touched. That is what makes PACS worth understanding as a device rather than as IT plumbing. It sits between the modalities that create images and the clinicians who read them, it holds years of patient studies, and it speaks a protocol that was designed for a trusted network in an era when hospital networks were assumed to be closed. Manufacturers building imaging systems, viewers, AI triage tools, or cloud archives inherit that history. If your product sends, receives, or stores DICOM, your submission has to explain how the interface behaves when the network is not friendly. This page covers what PACS actually is, where it is exposed, and what regulators expect you to document. ## Key Takeaways - PACS is a regulated medical device in the United States, not general-purpose hospital IT. - Its core protocol, DICOM, supports security features but does not require them by default. - Exposed DICOM ports have been repeatedly found on the public internet, exposing studies with patient identifiers. - The archive is a multi-patient asset, so a single compromise carries broader harm than one device. - Your submission must describe the PACS interface as an attack surface, with authentication and encryption stated explicitly. - Interoperability with third-party viewers and AI tools expands your threat model rather than reducing your responsibility. ## Why PACS Security Matters More Than Most Imaging Components PACS matters because it concentrates risk. A single modality produces studies for the patients scanned on it; the archive holds the studies for everyone. When the FDA's premarket cybersecurity guidance, issued February 3, 2026, asks manufacturers to consider multi-patient harm in their security architecture views, the archive is the clearest example of what that means in practice. The exposure is not theoretical. Security researchers scanning for open DICOM services have repeatedly found unauthenticated systems reachable from the public internet, returning studies complete with patient names, dates of birth, and identifiers. Reporting on these scans, including work published by ProPublica in 2019 based on research by Greenbone Networks, documented millions of exposed images across multiple countries. The underlying cause is consistent: a protocol that permits open association requests, deployed on a network that was assumed to be private. For a manufacturer, the regulatory consequence is straightforward. Section 524B of the FD&C Act applies to cyber devices, and a PACS product that connects to the internet and contains software falls squarely inside that definition. The archive is also a place where the availability half of security maps directly to clinical impact: when priors cannot be retrieved, diagnosis is delayed, and delayed diagnosis is patient harm under ISO 14971, not merely an IT outage. ## What PACS Actually Does in a Clinical Workflow PACS performs four functions: acquisition, archiving, retrieval, and distribution. A modality completes a study and pushes it to the archive. The archive stores it, indexes it against the patient record, and serves it back when a radiologist opens a worklist. That worklist usually arrives from a separate system, the RIS, and the order that created it usually originated in the EHR. Understanding those boundaries matters because each one is an interface you must document. | Component | What it does | Typical protocol | Security question to answer | |---|---|---|---| | Modality | Acquires the image | DICOM C-STORE | Can an unauthorized host send studies in? | | PACS archive | Stores and indexes studies | DICOM, SQL | Is data encrypted at rest and access logged? | | Viewer or workstation | Displays studies to clinicians | DICOMweb, WADO, proprietary | Is the session authenticated and encrypted? | | RIS | Manages orders and worklists | HL7, DICOM MWL | Can worklist data be altered in transit? | | VNA or cloud archive | Long-term vendor-neutral storage | DICOMweb, object storage | Who holds the keys and who can read the bucket? | **[KEY REQUIREMENT]** Every one of those arrows is an interface in your security architecture views. A submission that draws PACS as a single box labeled "archive" has not described its attack surface. ## Is PACS Regulated as a Medical Device? Yes. In the United States, a PACS is generally classified under 21 CFR 892.2050 as a medical image management and processing system, a Class II device that typically reaches market through the 510(k) pathway. That classification is why PACS vendors submit to the FDA at all, and why the cybersecurity documentation expectations in the February 3, 2026 premarket guidance apply to them. The classification has practical consequences beyond paperwork. It means the software is subject to the Quality Management System Regulation, it means changes may require a new submission depending on their significance, and it means postmarket obligations under Section 524B, including vulnerability disclosure and the ability to deploy updates, apply to the archive just as they do to the scanner. Cloud-hosted archives do not escape this. Hosting changes where the risk lives, not whether the product is a device. A cloud PACS adds tenancy isolation, key management, and provider shared-responsibility questions on top of everything an on-premises archive already had to answer. ## Where DICOM Leaves the Door Open DICOM is not an insecure protocol; it is a permissive one. The standard defines security mechanisms, including TLS transport and user identity negotiation, but it does not force a product to use them, and interoperability pressure has historically pushed vendors toward the most permissive configuration that works with the most equipment. The practical failure modes follow from that. | Weakness | What goes wrong | Control that closes it | |---|---|---| | Open association acceptance | Any host that knows the AE title can query or store | Restrict by calling AE title, host, and port; require authentication | | Unencrypted transport | Studies and identifiers readable on the wire | DICOM TLS, or DICOMweb over HTTPS | | Weak or shared credentials | Service accounts reused across installs | Unique credentials per deployment, no default passwords | | No audit logging | Access to studies cannot be reconstructed | DICOM audit trail events sent to a syslog collector | | Unbounded C-FIND queries | Bulk extraction of the patient index | Query limits, rate limiting, and result scoping by role | | Legacy SOP class support | Old code paths kept alive for compatibility | Explicit decision to disable, documented in the threat model | The last row is the one most often skipped. Backward compatibility is a business requirement, not a security exemption, and a submission reads better when it says plainly that a legacy path was kept, why, and what compensating control surrounds it. ## What the FDA Expects in a PACS Submission The expectations are the same as for any cyber device, but the emphasis shifts toward data handling and multi-patient impact. Your threat model should show what an attacker gains from reaching the archive rather than a single endpoint, and your architecture views should show the archive's position relative to every system that reads from or writes to it. Practically, a reviewer is looking for these elements to be present and consistent with each other: | Deliverable | What it must show for PACS specifically | |---|---| | Threat model | Scenarios involving bulk study access, study alteration, and archive unavailability | | SBOM | Every third-party imaging library, database, and web framework in the product | | Security architecture views | The archive shown with its modality, viewer, RIS, and cloud interfaces | | Authentication design | How DICOM peers and human users are each authenticated, separately | | Cryptography inventory | What protects data in transit, at rest, and in backups, with key handling described | | Testing evidence | Penetration testing that exercised the DICOM interface, not only the web viewer | | Update capability | How the archive is patched without losing access to prior studies | Testing scope is where products most often come up short. A web-based viewer gets tested because it looks like a web application, while the DICOM listener, which is the interface an attacker on the network would actually reach first, goes untested. If your evidence package covers only the browser-facing component, expect a question about it. ## How Interoperability Changes the Risk Picture Modern imaging environments rarely stop at one vendor. A hospital may run an archive from one supplier, viewers from another, an AI triage tool from a third, and a vendor-neutral archive underneath all of it. Each integration adds a party that can read studies, and each one is a place where your product's security assumptions meet someone else's defaults. Two principles keep this manageable. First, state your assumptions rather than relying on them silently. If your archive assumes the network segment it sits on is controlled, say so in the labeling and in the threat model, because an unstated assumption is an unverifiable one. Second, treat every third-party integration as an authenticated relationship with defined scope, not as a trusted peer with full access. An AI tool that needs to read chest CTs does not need the ability to delete studies. Interoperability also affects your postmarket posture. When a vulnerability appears in a shared imaging library, your customers will ask whether your product is affected, and they will ask quickly. The SBOM you produced for the submission is what lets you answer in hours rather than weeks. ## How Blue Goat Cyber Approaches This We test PACS and imaging products the way an attacker on a hospital network would reach them: at the DICOM listener, at the web services, and at the trust relationships between the archive and everything connected to it. That means association handling, query behavior, authentication paths, transport protection, and the interfaces your viewer exposes, with findings written in terms a reviewer can map to your threat model. If you are preparing an imaging submission, our [medical device penetration testing](/services/medical-device-penetration-testing) work produces the testing evidence that supports it, and our [threat modeling](/services/threat-modeling) engagements make sure the archive appears in your architecture views as the multi-patient asset it is. ## Frequently Asked Questions ### Is PACS considered a medical device by the FDA? Yes. PACS is generally regulated under 21 CFR 892.2050 as a medical image management and processing system, typically Class II, reaching market through the 510(k) pathway. Because it contains software and connects to networks, a PACS product also falls within the definition of a cyber device under Section 524B, which brings premarket cybersecurity documentation and postmarket update obligations with it. ### What is the difference between PACS, RIS, and DICOM? PACS stores and distributes images. RIS, the radiology information system, manages orders, scheduling, and reporting workflow. DICOM is the standard that defines both the image file format and the network protocol they use to exchange studies. They are commonly discussed together because a working imaging department needs all three, but they are distinct systems with distinct interfaces to secure. ### Can DICOM traffic be encrypted? Yes. The DICOM standard supports TLS for transport security, and DICOMweb services run over HTTPS. The obstacle is rarely technical capability and usually deployment practice, because encryption has historically been optional and disabling it removes interoperability friction with older equipment. A submission should state whether encryption is on by default and what happens when a peer does not support it. ### Why do exposed PACS systems keep appearing on the internet? Because DICOM services can accept connections without authentication, and because archives are sometimes placed on networks with more reachability than their owners realize. Research scans have repeatedly identified unauthenticated DICOM endpoints returning studies with patient identifiers. The fix is a combination of network placement, mandatory authentication, and configurations that do not accept associations from unknown peers. ### Does a cloud-hosted archive reduce a manufacturer's responsibility? No. Hosting shifts some controls to the cloud provider but leaves the manufacturer responsible for tenancy isolation, key management, access control, logging, and the security of the application itself. The FDA will expect the shared-responsibility boundary to be described explicitly, including which controls the customer must configure and which are yours. ### What testing should a PACS product undergo before submission? At minimum, penetration testing that exercises the DICOM interface directly, testing of any web viewer or API, authentication and authorization testing across user roles, and verification that the security requirements you wrote were actually implemented. Testing that covers only the browser-facing portion leaves the interface most reachable from the hospital network unexamined. ## Get Your Imaging Product Reviewed Before the FDA Does If your product stores, moves, or displays DICOM studies, the archive interface belongs in your threat model and your testing scope. We can tell you what a reviewer will ask and what an attacker would find. [Book a strategy session](/contact) and bring your architecture diagram. --- _Blue Goat Cyber specializes in medical device cybersecurity, from threat modeling and penetration testing through premarket submission support. Our team works exclusively with device manufacturers preparing FDA submissions. Learn more about [Christian Espinosa](/christian-espinosa), our founder and CEO._ --- ## Software as a Medical Device: Definition, Risk, and Rules Source: https://bluegoatcyber.com/blog/what-is-software-as-a-medical-device # Software as a Medical Device: What It Is and How It Is Regulated > **[DIRECT ANSWER]** Software as a medical device (SaMD) is software intended to be used for one or more medical purposes, such as diagnosis, treatment, or monitoring, that performs that purpose without being part of a hardware medical device. The definition comes from the International Medical Device Regulators Forum (IMDRF) and is applied by the FDA, the EMA, and other regulators. SaMD is classified into IMDRF risk categories I through IV, must meet software lifecycle requirements under IEC 62304, and, when it processes or transmits data over a network, is typically a cyber device under FDA Section 524B. _Reviewed September 17, 2026_ A diagnostic algorithm running on a hospital server, a mobile app that calculates insulin dosing, and a cloud platform that flags arrhythmias in ECG data all raise the same question for the people building them: is this a medical device, and if so, what rules apply? Getting the answer wrong has real consequences. Manufacturers who misclassify their software risk marketing an unapproved device, missing the cybersecurity documentation the FDA now expects in every submission, or over-building compliance for a product that actually falls outside the regulated category altogether. This article works through the IMDRF definition, how SaMD differs from software in a medical device and from exempt clinical decision support, the four IMDRF risk categories, the FDA pathways that apply, the IEC 62304 safety classification that governs the build process, and the cybersecurity obligations that attach once the software qualifies as a cyber device. ## Key Takeaways - SaMD is software with a medical purpose that functions on its own, separate from any specific hardware medical device. - The IMDRF risk framework sorts SaMD into four categories, I through IV, based on the significance of the information it provides and the seriousness of the healthcare situation. - Most networked or data-exchanging SaMD meets the FDA's cyber device definition under Section 524B and requires a cybersecurity management plan, SBOM, and vulnerability handling process at submission. - IEC 62304 governs the software development lifecycle for SaMD and assigns a safety class, A, B, or C, that determines how much process rigor is required. - Not all clinical software is SaMD. Wellness apps and certain clinical decision support tools are excluded if they meet specific criteria in the 21st Century Cures Act. - Cloud and mobile deployment does not remove the manufacturer's security obligations. The manufacturer remains accountable even when execution is shared with a platform provider. ## Why This Matters Misclassifying SaMD, or treating it as a lower-risk product than the IMDRF category and FDA pathway actually require, creates downstream problems that are expensive to fix after development is underway. A device built assuming IEC 62304 Class A rigor, then found during review to function at Class C risk, faces a redo of unit and integration testing that a correct classification at the design stage would have avoided. The FDA's Cybersecurity in Medical Devices final guidance, dated February 3, 2026, makes cybersecurity documentation a Refuse to Accept criterion for devices that meet the Section 524B cyber device definition, and most connected SaMD does. Manufacturers who treat cybersecurity as an afterthought risk a stalled submission rather than a straightforward review. Getting the classification and the security posture right from the start of development is far less costly than retrofitting them after a submission comes back with deficiencies. ## What Is the IMDRF Definition of SaMD? The International Medical Device Regulators Forum defines SaMD as software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device. This definition, published in IMDRF's 2013 framework document and still the reference point used by the FDA, the EMA, and other national regulators, hinges on two things: the software's intended medical purpose and its independence from a specific piece of hardware. A blood glucose meter's onboard firmware is not SaMD because it is embedded in and inseparable from the hardware. A mobile app that receives glucose readings from that meter and calculates an insulin dose recommendation is SaMD, because the calculation function stands on its own regardless of which meter or phone runs it. The medical purpose element matters as much as the independence element. Software only qualifies as SaMD if its intended use, as described by the manufacturer, is to treat, diagnose, cure, mitigate, or prevent disease, or to inform clinical management. General wellness software, scheduling tools, and administrative systems fall outside SaMD even when they run in a healthcare setting, because they lack that intended medical purpose. ## SaMD vs SiMD vs Wellness Software vs Exempt Clinical Decision Support These four categories look similar from the outside but are treated very differently under FDA regulation, and confusing them is one of the most common classification mistakes manufacturers make. **Software in a Medical Device (SiMD)** is embedded software that is part of a hardware device and cannot function independently of it. An infusion pump's dosing firmware, a pacemaker's programming logic, and an imaging system's acquisition software are all SiMD. SiMD is regulated as part of the hardware device under the same 510(k) or PMA submission, and it does not carry its own separate SaMD classification. **General wellness software** is excluded from FDA device regulation under the agency's general wellness policy when it only relates to maintaining or encouraging a general state of health, such as fitness trackers or sleep coaching apps, and does not make disease-specific claims. The moment a wellness app claims to diagnose, treat, or mitigate a specific disease, it moves out of the wellness exemption and into SaMD territory. **Clinical decision support (CDS) software** occupies its own carved-out space created by the 21st Century Cures Act. CDS software is exempt from FDA regulation as a device if it meets all four criteria in Section 520(o)(1)(E): it does not acquire, process, or analyze a medical image or signal; it displays, analyzes, or prints medical information; it is intended to support a healthcare professional in making a recommendation; and it allows that professional to independently review the basis for the recommendation rather than relying on it exclusively. CDS that fails any one of these four criteria, most often because it processes an image or signal directly, or because it does not let the clinician see the underlying basis for its output, is regulated as SaMD. **[KEY REQUIREMENT]** Document the intended use statement precisely before development begins. The exact wording of the intended use, not the underlying technology, is what determines whether software is SaMD, exempt CDS, or general wellness software, and it drives every downstream classification and submission decision. For a deeper comparison of SaMD and SiMD specifically, including how the two are documented differently in a submission, see our companion article, **[SaMD vs SiMD: What Medical Device Manufacturers Need to Know](/blog/samd-vs-simd-what-medical-device-manufacturers-need-to-know)**. ## How Does the IMDRF Risk Categorization Work? IMDRF sorts SaMD into four risk categories based on two factors: the significance of the information the software provides to a healthcare decision, and the state of the healthcare situation or condition it addresses. The framework treats these as a matrix rather than a single scale, and the resulting category informs how much clinical evidence and quality rigor a regulator expects. | Category | Healthcare Situation | Significance of Information | Example | |---|---|---|---| | I | Non-serious | Informs clinical management | App that logs symptoms for a minor condition | | II | Serious | Informs clinical management, or non-serious and drives clinical management | Software that flags an abnormal lab trend for physician review | | III | Critical | Informs clinical management, or serious and drives clinical management | Software that recommends a treatment change for a chronic disease | | IV | Critical | Drives clinical management or diagnoses/treats directly | Software that provides a primary diagnosis for a life-threatening condition | Category I represents the lowest combined risk and Category IV the highest. A single piece of software is not locked into one category forever. If a manufacturer expands the same software's intended use from informing a non-serious condition to diagnosing a critical one, the IMDRF category and the corresponding regulatory expectations move with it. ## What FDA Pathways Apply to SaMD? Most SaMD reaches the market through the 510(k) pathway by demonstrating substantial equivalence to a legally marketed predicate device, but a growing share of novel SaMD, particularly software using adaptive machine learning or addressing a use case with no existing predicate, goes through De Novo classification instead. The FDA does not have a pathway called "SaMD clearance." Instead, SaMD is evaluated using the same device classification framework, Class I, II, or III, applied to any other medical device, with the IMDRF risk category informing but not directly dictating the FDA class. De Novo requests are common for first-of-kind SaMD because no predicate exists to compare against, and a successful De Novo grant then becomes the predicate that later 510(k) submissions in the same category can reference. Class III SaMD, which is rare but does occur for software making life-sustaining or life-supporting claims, requires a Premarket Approval (PMA) application with full clinical evidence rather than a substantial equivalence argument. Regardless of pathway, the eSTAR submission template's single Cybersecurity attachment area is where the manufacturer's Section 524B documentation, threat model, and SBOM are expected to live. ## What Software Safety Classification Does IEC 62304 Require? IEC 62304 assigns every software system, including SaMD, one of three safety classes, A, B, or C, based on the severity of harm that could result if the software fails, and that classification determines how much documentation and testing rigor the development process must produce. Class A applies where no injury or damage to health is possible. Class B applies where non-serious injury is possible. Class C applies where death or serious injury is possible. Unlike the IMDRF risk category, which is about the clinical significance of the information the software provides, the IEC 62304 class is about engineering process rigor: what level of unit testing, architecture documentation, and risk control verification the development team must demonstrate. A SaMD product's IMDRF category and its IEC 62304 class are related but not identical, since IEC 62304 looks specifically at software failure modes rather than at the overall clinical use case. A Category III SaMD product, for example, will typically carry an IEC 62304 Class C classification for the components whose failure could directly cause serious harm, while lower-risk supporting modules within the same product might be classified separately at Class A or B. ## When Is SaMD a Cyber Device Under Section 524B? SaMD is a cyber device under FDA Section 524B when it includes software validated, installed, or authorized by the sponsor, has the ability to connect to the internet, and contains technological characteristics that could be vulnerable to cybersecurity threats, and the vast majority of networked or cloud-hosted SaMD meets all three conditions. Because Section 524B applies at the point of premarket submission, meeting the cyber device definition means the manufacturer must submit a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities, a process to provide reasonable assurance the device is cybersecure, an SBOM, and documentation of coordinated vulnerability disclosure processes. The FDA's Cybersecurity in Medical Devices final guidance, dated February 3, 2026, describes what reviewers expect within each of these elements, including threat modeling, security risk assessment tied to ISO 14971, and evidence of a documented CISA 2026 SBOM Minimum Elements compliant SBOM. Since Section 524B refuse-to-accept enforcement began on October 1, 2023, submissions lacking this documentation for a qualifying cyber device have been returned rather than reviewed, so the classification question of whether SaMD meets the cyber device definition needs to be answered early in development, not at submission time. ## Who Is Responsible for Cloud and Mobile Platform Security? The SaMD manufacturer remains responsible for the security of its software regardless of whether it runs on a cloud platform, a mobile operating system, or a hospital-managed server, because the FDA's expectations attach to the manufacturer of record, not to the infrastructure provider. This means the manufacturer must document a clear division of responsibility with each platform: which party patches the operating system, which party manages identity and access controls, which party owns tenant isolation in a multi-tenant cloud deployment, and which party is responsible for monitoring and responding to a vulnerability once it is disclosed. Cloud and mobile deployment does not create a gap in accountability, but it does create a gap in visibility if the manufacturer does not actively track the shared responsibility model. A manufacturer that assumes a cloud provider's general security certifications cover its own SaMD's specific threat model is likely to find that assumption tested during an FDA review or, worse, during an actual security incident. ## What Postmarket Obligations Apply After Launch? Once SaMD is on the market, the manufacturer must maintain the postmarket cybersecurity processes described in its premarket submission, including monitoring for new vulnerabilities in the software and its third-party components, issuing patches within the timelines the manufacturer committed to, and updating the SBOM as components change. Section 524B requires manufacturers to have a way to make patches and updates available on a reasonably justified regular cycle, and to have a coordinated vulnerability disclosure process that allows outside researchers to report issues. For SaMD specifically, postmarket obligations extend to the deployment environment as well. If the software's intended use changes, if a new operating system version breaks compatibility, or if a cloud platform migration introduces a new attack surface, the manufacturer needs a documented change control process, tied back to its IEC 62304 lifecycle records, to evaluate whether the change requires a new risk assessment or a new regulatory submission. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works with SaMD manufacturers from early architecture decisions through FDA submission and into postmarket monitoring. We help teams determine the correct IMDRF risk category and IEC 62304 safety class before development locks in an architecture that is expensive to change later. Our threat modeling work maps the manufacturer-versus-platform responsibility split for cloud and mobile deployments so that Section 524B documentation reflects how the software actually runs in production, not a generic template. We also build and maintain SBOMs aligned to the CISA 2026 SBOM Minimum Elements and support the vulnerability disclosure processes the FDA expects to see referenced in a submission. To see how this fits into a full premarket cybersecurity engagement, visit our **[medical device penetration testing services](/services/medical-device-penetration-testing)** page. ## Frequently Asked Questions ### Is a mobile health app always SaMD? No. A mobile health app is SaMD only if its intended use is a medical purpose, such as diagnosis or treatment, and it functions independently of specific hardware. An app that only tracks steps or sleep for general wellness purposes, without disease-specific claims, typically falls outside the SaMD definition and FDA jurisdiction. ### Does SaMD need a 510(k)? Most SaMD needs either a 510(k) or a De Novo submission, depending on whether a predicate device already exists. Class I SaMD is sometimes exempt from premarket submission, but the majority of Class II SaMD requires a 510(k), and novel Class II or III software without a predicate typically goes through De Novo or PMA. ### What is the difference between SaMD and a medical device with embedded software? SaMD functions independently of any specific hardware and is itself the regulated product. Embedded software, referred to as SiMD, is part of a hardware device and is regulated together with that hardware under a single submission rather than separately. ### Do wellness apps need FDA clearance? General wellness apps that only support a general state of health, without making disease-specific diagnostic or treatment claims, are excluded from FDA device regulation under the agency's general wellness policy. Once an app claims to diagnose or treat a specific disease, it typically needs to be evaluated as SaMD. ### How does IEC 62304 relate to SaMD cybersecurity? IEC 62304 governs the software development lifecycle and assigns a safety class based on potential harm from failure, which shapes engineering rigor but does not by itself cover cybersecurity. Cybersecurity requirements come from Section 524B and the FDA's February 3, 2026 final guidance, and are typically implemented alongside IEC 62304 controls rather than as a substitute for them. ### What documentation does a SaMD cybersecurity submission need? A SaMD cybersecurity submission typically needs a cybersecurity management plan, a threat model, a security risk assessment tied to ISO 14971, an SBOM, and evidence of a coordinated vulnerability disclosure process. Our companion guide, **[SaMD Cybersecurity Requirements: FDA, IEC 82304-1 and EU MDR](/guides/samd-cybersecurity-requirements)**, walks through each element in detail. ## CTA If you are developing SaMD and need help determining its IMDRF risk category, IEC 62304 safety class, or Section 524B cyber device status before you submit, Blue Goat Cyber can help you build the right documentation the first time. **[Contact us today](/contact)** to talk through your product's classification and cybersecurity requirements with our team. ## About the Author Christian Espinosa is the CEO of Blue Goat Cyber, a veteran-owned medical device cybersecurity firm. He holds multiple advanced security certifications and has spent his career helping medical device manufacturers navigate FDA cybersecurity requirements and build secure products. Learn more about his background on his **[author page](/christian-espinosa)**. --- ## What is CDRH? FDA's Device Center Explained Source: https://bluegoatcyber.com/blog/what-is-the-center-for-devices-and-radiological-health-cdrh # What is the Center for Devices and Radiological Health (CDRH)? > **[DIRECT ANSWER]** The Center for Devices and Radiological Health, or CDRH, is the branch of the FDA that regulates medical devices and radiation-emitting products across their entire lifecycle, not just at clearance. It reviews premarket submissions such as 510(k), De Novo, and PMA applications, conducts postmarket surveillance, enforces compliance, and increasingly treats cybersecurity as a core safety and effectiveness issue for connected devices. Manufacturers should expect CDRH oversight to shape design, documentation, labeling, and incident response, not just the initial submission. The [Center for Devices and Radiological Health (CDRH)](https://www.fda.gov/about-fda/fda-organization/center-devices-and-radiological-health) is the branch of the U.S. Food and Drug Administration responsible for regulating medical devices and radiation-emitting products. If you build, test, market, or maintain medical technology in the United States, CDRH is the part of the FDA that shapes the rules you live under. ## Key Takeaways - CDRH regulates medical devices and radiation-emitting products. - Oversight spans premarket review to postmarket surveillance. - CDRH policy shapes device design, testing, and lifecycle management. - Cybersecurity is a key safety component for connected devices. - Regulation balances patient access with safety and effectiveness. - CDRH influences global medical device standards. ## What CDRH Does CDRH exists to help ensure patients get access to devices that are safe, effective, and appropriately controlled across the product lifecycle. That means far more than reviewing submissions. CDRH writes and interprets policy, evaluates evidence before devices reach the market, monitors performance after launch, and takes action when risk outweighs benefit. For manufacturers, that translates into a very practical reality. CDRH influences how you design your device, document risk, validate claims, label the product, manage quality, and respond to postmarket issues. It is not just a gatekeeper at the submission stage. It is a regulator with lifecycle authority. ### CDRH’s Mission and Scope CDRH regulates medical devices from low-risk products to high-risk implantables, along with in vitro diagnostics and many radiation-emitting products. Its work spans premarket review, postmarket surveillance, compliance, enforcement, standards participation, and policy development. That scope matters because device safety is not settled at clearance or approval. A device can look acceptable in a submission package and still create problems in the field due to usability failures, manufacturing drift, software defects, cybersecurity weaknesses, or poor servicing controls. CDRH’s oversight is built around that reality. ### How CDRH Is Organized CDRH sits within the FDA and operates through multiple offices with specialized functions. Those offices cover areas such as premarket review, in vitro diagnostics, radiological health, compliance, product quality, and center leadership. That structure is not just bureaucratic plumbing. It reflects how device regulation actually works. Scientific review, quality system oversight, compliance action, and postmarket monitoring are interconnected. Manufacturers that treat them as separate workstreams usually end up with gaps, delays, or both. ## How CDRH Regulates Medical Devices and Radiological Health CDRH’s core job is oversight. In practice, that means reviewing products before marketing when required, enforcing applicable requirements, and monitoring how products perform in the real world. ![Section Image](/imported-images/0493d4846553079f.png) ### Medical Device Oversight For medical devices, CDRH reviews premarket submissions such as [510(k) notifications, PMA applications, and De Novo requests](/services/fda-premarket-cybersecurity-services). The depth of review depends on the device type, risk profile, intended use, technological characteristics, and the evidence needed to support safety and effectiveness. This is where many teams get tripped up. They think the submission is the product. It isn’t. The submission is evidence about the product. CDRH reviewers assess whether the design, testing, labeling, and supporting data justify market access under the relevant pathway. Take an implantable cardiac device as an example. CDRH may review bench testing, software documentation, biocompatibility, electrical safety, clinical data, human factors, labeling, and manufacturing controls. If the device includes connectivity, cybersecurity is also part of the discussion. Not as an afterthought, but as a safety and effectiveness issue. ### Radiological Health Oversight CDRH also regulates radiation-emitting products such as X-ray systems, CT scanners, mammography equipment, lasers, and certain radioactive product categories. The goal is straightforward: limit unnecessary exposure and make sure these products meet applicable radiation safety standards. That oversight includes guidance, inspections, reporting requirements, and action when manufacturers fail to meet requirements. For companies working in imaging or other radiation-related technologies, CDRH is not simply reviewing performance claims. It is also examining whether the product can be used safely in clinical settings without creating avoidable exposure risks. ## Why CDRH Matters to Public Health CDRH affects public health in two ways at once. It helps keep unsafe or ineffective products off the market, and it helps move useful technology to patients faster when the evidence supports it. ### Safety and Effectiveness Are the Baseline A central part of CDRH’s mission is evaluating whether medical devices perform as intended without creating unacceptable risk. That includes premarket review, postmarket signal detection, adverse event analysis, recalls, safety communications, and corrective actions. Reusable devices are a good example. Cleaning and disinfection failures can turn an otherwise useful device into an infection vector. CDRH has repeatedly addressed these issues through guidance, review expectations, and postmarket action. That is the agency doing what it is supposed to do: connecting real-world use to regulatory control. For manufacturers, the lesson is simple. Safety is not what your design team intended. Safety is what can be demonstrated, maintained, and monitored in actual use. ### CDRH Also Pushes Innovation Good regulation should not reward paperwork theater. It should reward evidence, clear claims, and disciplined engineering. CDRH has programs intended to support that, including the Breakthrough Devices Program for technologies that may offer more effective treatment or diagnosis for serious conditions. The point is not speed for its own sake. The point is getting clinically meaningful technology to patients without dropping the standard. That balance matters, especially in software-enabled and connected devices where iteration is common but risk does not disappear just because the release cycle is fast. > **Preparing a 510(k), De Novo, or PMA?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) ## CDRH’s Influence Beyond the United States CDRH regulates products for the U.S. market, but its influence reaches much further. Many of its policies, review approaches, and standards work shape how manufacturers build products for global distribution. ![Section Image](/imported-images/2dab644f44452cc9.png) CDRH works with regulators and standards bodies outside the United States to improve alignment and reduce unnecessary duplication. That does not mean every market is the same. It means there is value in shared approaches to evidence, safety expectations, and technical standards. One important piece of that work is participation in international standards development. For example, standards in the IEC 60601 family help define safety expectations for medical electrical equipment used across markets. When CDRH contributes to that work, manufacturers benefit from clearer design targets and more consistent expectations across jurisdictions. International collaboration also matters for emerging technologies. Software, AI-enabled functions, wireless communications, and cybersecurity risks do not stop at borders. Regulators know that. Manufacturers should act like they know it too. ## Where CDRH Is Headed CDRH is dealing with a device market that looks very different from the one many legacy regulations were written for. Software updates are frequent. Connectivity is standard. Clinical functionality increasingly depends on data pipelines, third-party components, cloud services, and machine learning. ![Section Image](/imported-images/844112be71b27865.png) ### Emerging Challenges Several issues continue to pressure both industry and regulators: - digital health expansion - AI and machine learning in device functions - software validation and change management - [medical device cybersecurity](/blog) - postmarket visibility into real-world performance - data integrity, privacy, and interoperability Cybersecurity deserves special attention. Connected devices create real attack surface, and the FDA has made clear that cybersecurity is part of device safety. That means manufacturers need more than a vague risk statement and a few security claims in a design document. They need secure architecture, threat modeling, verification, SBOM discipline where applicable, vulnerability handling processes, and evidence they can defend in an FDA submission and after launch. ### Strategic Priorities CDRH’s priorities continue to center on patient access, product quality, regulatory science, and modern review approaches for newer technologies. Programs related to digital health and software oversight reflect an effort to adapt regulatory tools to how products are actually built and maintained. The direction of travel is clear. The FDA expects manufacturers to understand their devices as systems, not static widgets. That includes software behavior, update mechanisms, interfaces, supply chain dependencies, and postmarket risk management. Teams that still treat compliance as a last-minute submission exercise will keep running into avoidable problems. CDRH is one of the most important parts of the FDA for device manufacturers because it sits at the intersection of safety, innovation, and enforcement. If you make medical technology, understanding how CDRH thinks is not optional. It is part of building products that can survive review, perform in the field, and stay on the market. As CDRH pushes harder on connected technology, manufacturers need cybersecurity work that stands up to scrutiny. Blue Goat Cyber, a Veteran-Owned business, helps medical device companies assess and strengthen security through penetration testing, HIPAA support, and FDA compliance services. If your device has software, connectivity, or patient risk tied to cyber failure, [contact us today for cybersecurity help](/contact). ## Which FDA center reviews what | Center | Products it regulates | Typical submission | Cybersecurity relevance | | --- | --- | --- | --- | | CDRH | Medical devices, radiation-emitting products, most SaMD | 510(k), De Novo, PMA | Owns the premarket cybersecurity expectations most manufacturers face | | CBER | Biologics, and devices used with them | BLA, and device submissions for associated products | Applies device cybersecurity expectations to those products | | CDER | Drugs, including many combination products | NDA, ANDA | The device constituent still carries device security obligations | | Office of Combination Products | Assigns the lead center | Request for Designation | Determines whose review your security file lands in | Knowing your lead center matters because it sets who reviews the cybersecurity file and which precedents they have in mind. ## How Blue Goat approaches this The Blue Goat Cyber methodology aligns with the FDA's expectations for medical device cybersecurity, preventing issues before they become costly problems. Our team identifies and mitigates vulnerabilities across the entire product lifecycle, from initial design to postmarket support. We perform thorough threat modeling, risk assessments, and penetration testing, applying specialized knowledge in medical device contexts. Our experts, including CISSP and OSCP certified professionals with ex-military red team experience, prepare and review documentation for FDA submissions, ensuring compliance. We focus on practical, actionable security measures that satisfy regulatory requirements and enhance device safety. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our [premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is the primary role of CDRH? CDRH assures that medical devices and radiation-emitting products are safe and effective for patients. This involves premarket evaluation, postmarket monitoring, and enforcement of regulatory requirements. ### How does CDRH handle cybersecurity for medical devices? CDRH views cybersecurity as integral to device safety and effectiveness. The February 3, 2026 final guidance outlines expectations for secure product design, threat modeling, and postmarket vulnerability management for FDA submissions. ### Does CDRH regulate all medical devices? Yes, CDRH regulates all medical devices, from low-risk general wellness products to high-risk implantable devices, based on their classification and intended use. ### How does CDRH support innovation in medical technology? CDRH supports innovation through programs like the Breakthrough Devices Program, which aims to expedite market access for technologies offering more effective treatment or diagnosis for serious conditions, provided evidence supports safety and effectiveness. ### Why is CDRH's influence global? CDRH's policies and review approaches often shape global manufacturing practices. It also collaborates with international regulators and standards bodies to build alignment and consistency in medical device oversight. ### What emerging challenges is CDRH addressing? CDRH is adapting to challenges posed by digital health, AI/ML integration, software as a medical device, and the increasing complexity of medical device cybersecurity and interoperability. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## IVD Regulation and Device Cybersecurity (2026) Source: https://bluegoatcyber.com/blog/what-is-the-ivd-regulation-in-medical-device-cybersecurity # IVD Regulation Cybersecurity: A 2026 Medical Device Compliance Guide > **[DIRECT ANSWER]** The EU's In Vitro Diagnostic Regulation (IVDR) requires manufacturers of diagnostic devices to build cybersecurity into design, premarket testing, and ongoing post-market surveillance so that connected devices resist unauthorized access, data breaches, and result manipulation. It matters alongside the FDA's February 3, 2026 final guidance, since both frameworks expect documented risk management and security controls before a device reaches patients. In our increasingly digital world, cybersecurity is a paramount concern. This is especially true in the healthcare industry, where we rely on medical devices to save lives and improve patient outcomes. To ensure the safety and security of these devices, the European Union (EU) has implemented the [In Vitro Diagnostic (IVD) Regulation](https://ec.europa.eu/commission/presscorner/detail/en/ip_21_5209). ## Key Takeaways - IVDR mandates cybersecurity for in vitro diagnostic devices in the EU. - It covers pre-market scrutiny and post-market surveillance. - Manufacturers must manage risks and assure quality in device cybersecurity. - The regulation impacts device design, testing, and documentation. - Future IVDR updates will address emerging tech, like IoT and AI. - Compliance protects patient data and diagnostics integrity. ## Why this matters The criticality of medical device cybersecurity, particularly for In Vitro Diagnostic (IVD) devices, stems from the direct impact on patient health and data integrity. Cyber vulnerabilities in IVDs can lead to misdiagnoses, delayed treatments, or compromise sensitive patient information, carrying severe consequences. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes the need for manufacturers to integrate cybersecurity throughout the total product lifecycle, from design to post-market surveillance. Compliance with regulations like the IVDR, alongside standards such as IEC 81001-5-1 (Health software and health IT systems safety, effectiveness and security, Part 5-1: Security, Activities in the product lifecycle), ISO 27001 (Information security management systems), and AAMI TIR57 (now supplemented by ANSI/AAMI SW96:2023) (Principles for medical device security, Risk management), is not merely a regulatory hurdle; it is fundamental to patient safety. These frameworks guide manufacturers in identifying, assessing, and mitigating cybersecurity risks, ensuring that IVD devices function as intended without introducing new avenues for harm. Protecting these devices safeguards patient care and maintains trust in the healthcare ecosystem. ## Understanding the IVD Regulation Before we covers the specifics of the IVD Regulation, let’s first understand what it is and why it is necessary. The IVD Regulation is a framework put in place by the EU to [regulate the cybersecurity of in vitro diagnostic devices](/blog). These devices analyze samples from the human body to provide information for diagnostic, monitoring, and treatment decisions. ![Section Image](/imported-images/a3f502258e071d13.webp) ### Definition and Purpose of IVD Regulation At its core, the IVD Regulation aims to ensure that medical devices in the EU are safe, effective, and reliable in their cybersecurity measures. It sets out requirements for manufacturers regarding the design, production, and post-market surveillance of these devices. Doing so helps protect patient privacy and safeguards against potential cyber threats. But what does it mean for a medical device to be safe, effective, and reliable regarding cybersecurity? These devices should have security features to prevent unauthorized access, data breaches, and other cyber attacks. This includes encryption of patient data, secure communication protocols, and regular software updates to patch potential vulnerabilities. The IVD Regulation also emphasizes the [importance of post-market surveillance](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry). This means that manufacturers are required to monitor the performance of their devices even after they have been placed on the market. By doing so, they can identify and address any potential cybersecurity issues that may arise over time, ensuring the devices’ ongoing safety and security. ### The Role of IVD in Medical Device Cybersecurity You may be wondering why the IVD Regulation specifically focused on medical device cybersecurity. The answer is that in vitro diagnostic devices often connect to other devices, networks, and systems within and outside healthcare facilities. This connectivity opens up possibilities for cyber attacks, which can compromise patient data and pose severe risks to patient safety. Imagine a hacker gaining unauthorized access to a hospital’s network through a vulnerable in vitro diagnostic device. They could potentially manipulate test results, leading to misdiagnoses and improper treatment. This highlights the critical importance of ensuring the cybersecurity of these devices. By regulating the cybersecurity of these devices, the IVD Regulation aims to mitigate these risks and ensure that healthcare professionals and patients can trust in the security of their medical devices. It provides a clear framework for manufacturers to follow, ensuring they implement the necessary security measures to protect patient data and maintain the integrity of diagnostic results. ## Key Components of the IVD Regulation The IVD Regulation is a framework that aims to ensure the safety and effectiveness of in vitro diagnostic devices. It covers a wide range of aspects, including pre-market scrutiny, post-market surveillance, risk management, and quality assurance, to safeguard public health and promote innovation in the healthcare industry. ### Pre-market Scrutiny One important aspect of the IVD Regulation is the pre-market scrutiny process. This involves a assessment of the device’s cybersecurity measures before it can be placed on the market. Manufacturers must demonstrate that their devices meet security requirements and are adequately protected against cyber threats. The pre-market scrutiny process also evaluates the device’s analytical and clinical performance to ensure its accuracy and reliability. This rigorous assessment helps prevent the introduction of substandard or unsafe devices into the market, ultimately enhancing patient safety and confidence in diagnostic results. ### Post-market Surveillance Once a device is on the market, the IVD Regulation also requires ongoing post-market surveillance. This entails monitoring the device’s performance and cybersecurity over its lifecycle, including identifying and addressing potential vulnerabilities or incidents. By doing so, the regulatory authorities can take prompt action to mitigate risks and ensure the continued safety and security of the devices. Continuous post-market surveillance is essential for detecting emerging issues or trends related to the device’s cybersecurity and performance. It enables regulatory authorities to respond swiftly to any concerns, such as cybersecurity breaches or adverse events, and take appropriate measures to protect public health and maintain the integrity of diagnostic testing. ### Risk Management and Quality Assurance Risk management and quality assurance are integral parts of the IVD Regulation. Manufacturers must implement a systematic approach to identifying, assessing, and managing the cybersecurity risks associated with their devices. This includes developing quality management systems and processes to ensure devices meet the highest cybersecurity standards. Effective risk management practices enhance the cybersecurity of IVD devices and contribute to overall product quality and reliability. By proactively addressing potential risks and implementing quality assurance measures, manufacturers can improve their devices’ performance, safety, and cybersecurity, ultimately benefiting patients, healthcare providers, and regulatory authorities alike. ## The Impact of IVD Regulation on Medical Device Manufacturers ![Section Image](/imported-images/2e178a1a5e6ebbc7.webp) The In Vitro Diagnostic (IVD) Regulation not only sets out compliance requirements but also significantly influences the landscape for medical device manufacturers. It necessitates a paradigm shift in how manufacturers approach cybersecurity and security measures for their devices, emphasizing the critical need for protection against cyber threats. ### Compliance Requirements The IVD Regulation imposes strict compliance requirements on manufacturers. They must adhere to the established cybersecurity standards and ensure their devices meet security measures. This may involve investing in cybersecurity expertise, conducting thorough risk assessments, and implementing appropriate security controls throughout the device’s lifecycle. Manufacturers are required to maintain documentation demonstrating their compliance with the regulation. This includes detailed records of cybersecurity measures implemented, risk assessment reports, and evidence of ongoing monitoring and updates to ensure the device’s security remains effective. ### Potential Challenges and Solutions While complying with the IVD Regulation may pose challenges for manufacturers, it also presents opportunities for innovation and collaboration. Manufacturers can use cybersecurity best practices and technologies to enhance the security of their devices. Collaborating with cybersecurity experts and regulatory authorities can also help address challenges and ensure compliance with the regulations while continuing to deliver safe and effective devices. The emphasis on cybersecurity and data protection under the IVD Regulation encourages manufacturers to adopt a proactive approach to security. This includes integrating security features into the device’s design phase, conducting regular security assessments, and staying abreast of emerging cyber threats to mitigate risks proactively. ## Future of IVD Regulation in Cybersecurity As technology continues to evolve, so too will IVD Regulation in cybersecurity. Let’s take a glimpse into the future and explore emerging trends and predicted changes in the regulation. The landscape of medical device cybersecurity is constantly shifting, driven by rapid technological advancements and the increasing interconnectedness of devices. As the healthcare industry embraces digital transformation, the security of medical devices becomes paramount. The future of IVD Regulation will likely focus on addressing the complex challenges posed by the Internet of Things (IoT) and the potential vulnerabilities they introduce. Stakeholders will need to collaborate closely to develop cybersecurity measures that safeguard patient data and ensure the integrity of medical devices. ### Emerging Trends in Medical Device Cybersecurity Advancements in technology bring both opportunities and challenges in medical device cybersecurity. With the rise of interconnected devices and the Internet of Things (IoT), ensuring the security and privacy of patient data becomes even more crucial. As such, future iterations of the IVD Regulation may need to address these emerging trends and provide guidance on securing connected medical devices. The emergence of artificial intelligence and machine learning in healthcare introduces new considerations for cybersecurity. These technologies can revolutionize patient care and raise concerns about data privacy and security. The future of IVD Regulation may involve incorporating guidelines for the safe and ethical use of AI in medical devices, ensuring that patient information is protected while using the benefits of these innovative technologies. ### Predicted Changes in IVD Regulation With the growing awareness of cybersecurity risks and the need to protect patient safety, the IVD Regulation is likely to continue evolving. This may include updates to the pre-market scrutiny process, enhanced post-market surveillance requirements, and enforcement of stricter compliance measures. Manufacturers should stay informed about these predicted changes to ensure they remain compliant and prioritize their devices’ cybersecurity. As global cybersecurity threats evolve, international collaboration and harmonization of regulations will be crucial. The future of IVD Regulation may involve closer alignment with international standards and frameworks to create a unified approach to cybersecurity in the healthcare sector. By building cooperation among regulatory bodies worldwide, stakeholders can work together to establish cybersecurity practices that protect patients and uphold the integrity of medical devices on a global scale. ## Conclusion: The Importance of IVD Regulation in Ensuring Cybersecurity The IVD Regulation is critical in ensuring the cybersecurity of in vitro diagnostic devices. By setting out clear requirements and guidelines, it helps protect patient data, maintain the integrity of medical devices, and safeguard against potential cyber threats. In an increasingly digital healthcare landscape, the IVD Regulation ensures patient safety and maintains trust in medical devices. ![Section Image](/imported-images/2acd268b000b8a72.webp) As the IVD Regulation underscores the critical importance of cybersecurity in the medical device sector, it’s clear that compliance is not just a regulatory requirement but a strategic imperative. Blue Goat Cyber stands ready to assist you in navigating the complexities of medical device cybersecurity. Our veteran-owned business specializes in providing B2B cybersecurity services, including adherence to stringent HIPAA and FDA regulations. With our team’s high-level certifications and proactive approach, we ensure that your medical devices are compliant and secured against the evolving landscape of cyber threats. [Contact us today for cybersecurity help](/contact), and let us be your partner in protecting patient data and maintaining trust in your medical devices. Embrace security and embrace success with Blue Goat Cyber. ## How Blue Goat approaches this Our approach to IVDR-related cybersecurity for medical devices centers on a proactive and adaptive strategy. We identify potential cybersecurity risks early in the development lifecycle, aligning with regulatory expectations and recognized security frameworks. Our team, comprised of CISSP and OSCP-certified experts, including former military red team members, applies practical security methodologies to device design and implementation. We focus on actionable recommendations for secure architecture, vulnerability management, and incident response planning. For instance, our premarket cybersecurity services, viewable at [bluegoatcyber.com/services/fda-premarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-premarket-cybersecurity-services), streamline submissions and address potential issues before they become roadblocks. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. This commitment ensures that your IVD devices meet regulatory requirements and maintain a strong security posture against evolving threats. ## FAQ ### What is the primary goal of the IVD Regulation? The IVD Regulation's primary goal is to ensure that in vitro diagnostic medical devices in the EU are safe, effective, and reliable, specifically concerning their cybersecurity measures. This helps protect patient data and safeguards against potential cyber threats. ### Does the IVD Regulation apply to all medical devices? No, the IVD Regulation specifically applies to in vitro diagnostic (IVD) medical devices. These are devices used to analyze samples from the human body for diagnostic, monitoring, or treatment purposes. ### What is pre-market scrutiny under the IVDR? Pre-market scrutiny under the IVDR involves a thorough assessment of a device's cybersecurity measures before it can be introduced to the market. Manufacturers must demonstrate that their devices meet all security requirements. ### How does the IVD Regulation address post-market cybersecurity? The IVD Regulation requires ongoing post-market surveillance, where device performance and cybersecurity are continuously monitored throughout their lifecycle. Manufacturers must identify and address potential vulnerabilities or incidents promptly after the device is on the market. ### Why is cybersecurity important for in vitro diagnostic devices? Cybersecurity matters for in vitro diagnostic devices because they often connect to networks and systems, creating potential entry points for cyberattacks. Such attacks could compromise sensitive patient data or manipulate diagnostic results, posing significant patient safety risks. ### Will the IVD Regulation adapt to new technologies like AI? Yes, as technology evolves, future iterations of the IVD Regulation are likely to address emerging trends such as the Internet of Things (IoT) and artificial intelligence (AI) in medical devices. This ensures that guidelines are continuously updated for securing connected devices and protecting patient information. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## FDA Cybersecurity Deficiencies Triggers Source: https://bluegoatcyber.com/blog/what-triggers-fda-cybersecurity-deficiencies-for-devices # What Triggers FDA Cybersecurity Deficiencies for Devices > **[DIRECT ANSWER]** Most FDA cybersecurity deficiencies come from incomplete documentation rather than an insecure device, since reviewers judge the submission's evidence, not the hardware itself. Common triggers include an SBOM missing machine-readable formatting or CVE traceability, a threat model not linked to risk assessments and testing, missing architecture views, penetration testing on the wrong build, unresolved findings, weak authentication documentation, and vague postmarket patching plans. A pre-submission self-audit against these gaps catches most deficiencies before the FDA does. Understanding what causes the FDA to issue a cybersecurity deficiency for medical devices starts with one uncomfortable truth: most deficiencies have nothing to do with a bad device. The device might be perfectly secure. The submission just didn’t prove it. FDA reviewers work from documentation, not hardware they test themselves. If your submission doesn’t tell a complete, traceable security story, from identified threats to implemented controls to verified outcomes, the deficiency letter follows. That’s how this works. The stakes are real. A cybersecurity deficiency can delay clearance by months, cost hundreds of thousands in rework, and in serious cases, force a complete resubmission. Section 524B of the FD&C Act, which took effect in March 2023, moved cybersecurity from guidance recommendations to enforceable mandates. Deficiency rates climbed after that shift. eSTAR submissions now face Technical Screening holds when cybersecurity documentation is missing. What used to be best practice is now a Refuse to Accept risk. The sections below break down the specific triggers that generate deficiency letters, what FDA reviewers flag, why they flag it, and what you can do about each one before the letter arrives. ## Key Takeaways - Most FDA deficiencies relate to documentation, not device insecurity. - Section 524B mandates strong cybersecurity documentation for devices. - Common gaps: incomplete SBOMs, threat modeling, architecture views. - Technical issues: pen test on wrong builds, weak authentication, encryption. - Post-market: missing vulnerability policies, unrealistic patch plans. - Pre-submission audits prevent costly delays and deficiency letters. ## Why this matters Understanding the triggers for FDA cybersecurity deficiencies is critical because these can significantly delay market clearance, increase development costs, and harm a manufacturer's reputation. Since March 2023, Section 524B of the FD&C Act has mandated cybersecurity documentation as an enforceable requirement, shifting it from recommended guidance to a 'Refuse to Accept' risk if documentation is missing or inadequate. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, explicitly outlines expectations for securing devices throughout their lifecycle. Manufacturers must demonstrate adherence to security best practices through detailed documentation, aligning with standards like IEC 81001-5-1, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023. Failure to do so, even if the device itself is secure, results in deficiencies because reviewers evaluate submissions based on the evidence provided. This situation underscores the importance of a prepared submission that anticipates FDA scrutiny, ensuring all cybersecurity aspects, from design to post-market surveillance, are clearly articulated and supported. ## Why FDA Cybersecurity Deficiencies Are Mostly a Documentation Failure Reviewers work from your documentation package. If that package doesn’t connect threats to controls to testing results in a traceable, coherent way, they have no choice but to ask for more. The burden of proof sits entirely with the manufacturer. That’s not a criticism of the process; it’s how regulatory review works, and device makers who treat cybersecurity documentation as secondary pay for it later. Section 524B changed the enforcement landscape in a meaningful way. Before 2023, FDA cybersecurity guidance carried significant weight but wasn’t directly tied to submission acceptance. Now it is. Submissions for cyber devices, defined as devices that include software validated by the sponsor, can connect to the internet, and have characteristics vulnerable to cybersecurity threats, must demonstrate compliance with Section 524B requirements or face RTA action. The October 2023 eSTAR enforcement rollout made this concrete. Missing cybersecurity documentation now stops submissions at Technical Screening, not just during substantive review. ## What Causes the FDA to Issue a Cybersecurity Deficiency: Common Documentation Triggers [Software Bill of Materials](/blog/medical-device-sbom-fda-requirements-and-submission-guide) are among the most consistent deficiency triggers in current submissions. The Software Bill of Materials is mandatory under Section 524B, and FDA expectations go well beyond a component list. Reviewers cross-reference SBOMs against vulnerability databases like the NVD. Your SBOM must be machine-readable, formatted in SPDX or CycloneDX, and include all NTIA minimum elements (superseded by CISA's 2026 Minimum Elements for an SBOM, published July 29, 2026): supplier name, component name, version, unique identifier, dependency relationship, SBOM author, and timestamp. It also needs support lifecycle metadata, including end-of-support dates, and traceable vulnerability assessments for known CVEs. A high-level spreadsheet won’t clear this bar. ### Threat Modeling Gaps [Threat modeling](/services/medical-device-threat-modeling) is another major documentation failure that draws deficiencies. Reviewers expect defined assets, specific attack surfaces, concrete threat scenarios, and direct traceability from each threat to mitigations and testing results. Submissions that include a data flow diagram without connecting it to the risk assessment consistently draw additional information requests. The threat model isn’t decorative. It’s supposed to function as the backbone of your cybersecurity risk management file, not a one-time deliverable that gets filed and forgotten. ### Architecture Documentation Shortfalls Architecture documentation is a third consistent gap in 510(k) cybersecurity requirements. The FDA expects multiple views, including a Multi-Patient Harm View and an Updateability and Patchability View. These aren’t optional formatting preferences. If your architecture documentation doesn’t show how security controls are implemented at the design level, the submission signals that cybersecurity was retrofitted rather than built in. That signal tends to generate scrutiny across the entire cybersecurity section of the submission. ## Technical Testing Failures That Stall Clearance Penetration testing deficiencies come down to one persistent mistake: testing on the wrong build. [FDA guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket) is clear that pen testing must be conducted on a final, production-equivalent device, not a prototype, not a pre-release version. Every finding must be addressed. If a low or medium risk is accepted rather than remediated, the submission needs explicit acceptance criteria and documented justification. Submitting a pen test report with open findings and no disposition is one of the fastest ways to generate a deficiency letter. Reviewers aren’t looking for a clean bill of health; they’re looking for evidence that findings were taken seriously and handled systematically. ### Authentication and Access Control Authentication and access control documentation is another consistent source of deficiencies. Per FDA guidance, reviewers look for layered authentication models that differentiate user roles: caregiver, administrator, service technician. Single-layer authentication with no role-based access controls, or submissions that fail to document how the device handles unauthorized access attempts, draw additional information requests. The documentation needs to be specific, not descriptive. “The device uses strong authentication” is not a sufficient answer. ### Encryption and Key Management Encryption gaps complete the technical testing picture. Inadequate key management documentation, unprotected data transfers, and failure to demonstrate that sensitive data, including commands, credentials, and patient information, is protected both in transit and at rest are all flagged. High-level statements about encryption without implementation details and verification evidence don’t satisfy reviewers. They need to see what was implemented and how it was confirmed to work. ## Post-Market Planning Failures the FDA Consistently Catches A cybersecurity deficiency isn’t always about the device at launch. The FDA expects lifecycle proof. Submissions that lack a credible [vulnerability disclosure policy](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs) are flagged consistently. The policy needs to include a contact point for reporting vulnerabilities, a defined response process, and integration with the manufacturer’s MDR obligations. Labeling must also disclose the expected security update support lifetime and connectivity details. Referencing a policy without providing specifics doesn’t satisfy this requirement. ### Patching and Update Plans Patching and update plans are another common failure point. Reviewers evaluate whether the device can actually be updated in the field and whether the manufacturer has a realistic plan for doing so. Plans that don’t specify update timelines, don’t differentiate between routine and emergency patches, or fail to address devices in remote or resource-limited environments don’t hold up. The plan needs to be specific and operationally credible, not aspirational. Post-market surveillance processes must show active monitoring, not reactive response. The FDA wants evidence that manufacturers will continuously monitor for new vulnerabilities in deployed devices. Submissions that lack defined processes for monitoring, assessing, and communicating post-market risks leave reviewers without confidence that device safety will be maintained through the product lifecycle. This is where many submissions fall short: premarket documentation is solid, but the forward-looking plan is thin. ## A Pre-Submission Self-Audit to Catch These Gaps First Before you submit, run through this documentation audit. Is the SBOM complete, machine-readable, and current? Does the threat model trace directly to the risk assessment and to testing results? Are all required architecture views included? Is the cybersecurity risk management file traceable end-to-end from identified threats through implemented controls to verified outcomes? Are all labeling requirements met, including support lifetime and vulnerability reporting contact information? These are the same questions an FDA reviewer will ask. Answering them before submission is cheaper than answering them after. On the technical side, verify that penetration testing was performed on a production-equivalent build, that all findings are resolved or explicitly accepted with documented justification, and that authentication, encryption, and access control documentation is specific rather than descriptive. Confirm that no known vulnerabilities in your SBOM components are unaddressed, even low-severity ones. Unaddressed CVEs in a submitted SBOM are a direct deficiency trigger. For most device makers, especially those navigating a first 510(k) or working with a new FDA reviewer, an independent pre-submission cybersecurity review is the most reliable way to surface these gaps before the FDA does. That’s exactly the work Blue Goat Cyber does: reviewing submissions against current FDA guidance to identify the specific documentation and testing gaps that generate deficiency letters. Companies that complete this step consistently avoid the costly delays that come from reactive fixes after a letter arrives. ## How to Respond Effectively When a Deficiency Letter Has Already Arrived FDA Additional Information letters give manufacturers 180 calendar days to respond via resubmission. Use that window carefully. If any of the deficiency language is unclear or seems misaligned with prior FDA feedback, file a Submission Issue Request through the Q-Submission process before reworking your documentation. FDA responds to SIRs within 21 days. Clarifying the scope of a deficiency before you respond saves significant time compared to submitting a response that misses the point. A complete deficiency response package includes: revised and traceable risk documentation, an updated SBOM with current CVE assessments, a revised threat model if the original was deficient, complete penetration testing results on a current production-equivalent device, and documented post-market plans that address the specific gaps the reviewer identified. Reference the [FDA cybersecurity guidance](/guides/fda-cybersecurity-guidance) throughout your response to anchor every element to current standards. Partial fixes that address one section without resolving root cause across the full submission typically generate another round of deficiencies, which extends your timeline by another 180-day cycle. When manufacturers are already in the review cycle and need to build a complete evidence package quickly, having a team with deep FDA submission experience makes the difference between a clean response and a second deficiency letter. [Blue Goat Cyber’s deficiency response support](/services/fda-cybersecurity-deficiency-response) is built for exactly this scenario, with a track record across hundreds of medical device submissions. ## Start with the Audit, Not the Fix Knowing what causes the FDA to issue a cybersecurity deficiency for medical devices makes the solution straightforward: audit before you submit. The same gaps appear across submissions, incomplete SBOMs, disconnected threat models, unresolved testing findings, and post-market plans that don’t hold up to scrutiny. None of these are unavoidable. They’re all catchable in a pre-submission review, and they’re all fixable with the right documentation and evidence. The manufacturers who clear fastest treat their submission the way an FDA reviewer would before it reaches one. That means tracing every claim back to evidence, resolving every finding, and building a post-market plan that’s operationally credible. The device might be genuinely secure. The goal is to prove it on paper with the same rigor used to build it. ## How Blue Goat approaches this Blue Goat Cyber's methodology for FDA pre-market submissions centers on proactive identification and remediation of potential cybersecurity deficiencies. Our team, comprised of certified experts (CISSP, OSCP) with ex-military red team experience, conducts thorough audits of your documentation and proposed security controls against the FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, and other relevant standards. We specialize in constructing clear, traceable security narratives that address every facet of the FDA's requirements, from detailed SBOMs and threat modeling to architecture views, technical testing results, and post-market plans. Our goal is to ensure your submission is complete and compliant the first time. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services at [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is Section 524B and why is it important for medical devices? Section 524B of the FD&C Act, effective March 2023, now legally mandates cybersecurity requirements for medical devices. This means compliance is no longer just guidance; it's enforceable, and non-compliance can lead to Refuse to Accept actions during submission reviews. ### Does the FDA test my medical device hardware for cybersecurity? No, the FDA reviewers primarily work from your submitted documentation package, not the physical device. Your submission must provide a complete, traceable security narrative from identified threats to implemented controls and verified outcomes. ### What elements are critical for a compliant Software Bill of Materials (SBOM)? A compliant SBOM must be machine-readable (SPDX or CycloneDX), include all the SBOM minimum elements (supplier, component, version, and so on) now set by CISA's 2026 Minimum Elements, published July 29, 2026, which replaced the 2021 NTIA list, and provide support lifecycle metadata. It must also link to traceable vulnerability assessments for known CVEs. ### Why does the FDA flag threat modeling documentation? The FDA flags threat modeling when it lacks defined assets, specific attack surfaces, concrete threat scenarios, and direct traceability from each threat to demonstrated mitigations and testing results. It should be the backbone of your risk management, not a standalone document. ### How can I avoid penetration testing deficiencies? Ensure penetration testing is conducted on a final, production-equivalent device. Address every finding; if a risk is accepted, provide explicit acceptance criteria and documented justification in your submission. Do not submit a report with open, undiscussed findings. ### What post-market plans does the FDA expect for cybersecurity? The FDA expects a credible vulnerability disclosure policy, realistic and specific patching and update plans, and defined processes for continuous post-market surveillance. These demonstrate ongoing security management throughout the device's lifecycle. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Reports](/blog/fda-section-524b-subsections-explained) - [Former Cybersecurity Employees Indicted](/blog/when-cybersecurity-becomes-a-crime-what-the-illumina-case-signals-for-medical-device-makers) - [Hire Cybersecurity Consultant vs. In-House](/blog/when-to-hire-device-security-consultant-vs-build-in-house) --- ## Illumina FDA Cybersecurity Case: What It Signals Source: https://bluegoatcyber.com/blog/when-cybersecurity-becomes-a-crime-what-the-illumina-case-signals-for-medical-device-makers # Illumina FDA Cybersecurity Case: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** The Illumina case shows that overstating cybersecurity capabilities in federal sales or contracts can trigger False Claims Act liability even without a breach, since the DOJ's $9.8 million settlement rested on misrepresented claims about secure design and compliance with standards like ISO 27001. Meeting FDA premarket requirements is not enough on its own; manufacturers selling to government or federally funded healthcare buyers must ensure every cybersecurity claim in submissions, contracts, and marketing matches what was actually built and tested. ## Key Takeaways - False cybersecurity claims trigger legal action, not just breaches. - The DOJ uses the False Claims Act for cybersecurity misrepresentations. - Regulatory compliance alone does not prevent legal liability. - Cybersecurity is a patient safety issue, increasing scrutiny. - Manufacturers must validate all cybersecurity claims internally. - Integrated legal, engineering, and quality teams are crucial. ## A New Era of Accountability for Medical Device Cybersecurity In the past, cybersecurity issues in medical devices were considered technical oversights-correctable, internal, and largely shielded from public scrutiny. But in 2025, the U.S. Department of Justice (DOJ) issued a stark warning to the healthcare technology sector: **_cybersecurity failures can now lead to legal action._** ![illumina medical device cybersecurity](/imported-images/3388972b93e45aec.png) That warning came in the form of a [$9.8 million False Claims Act settlement with genomic sequencing giant Illumina](https://www.justice.gov/opa/media/1409561/dl "$9.8 million False Claims Act settlement with genomic sequencing giant Illumina"). The enforcement wasn’t triggered by a breach, ransomware, or a data leak. It was based on allegations that the company misrepresented its cybersecurity capabilities when selling sequencing platforms to federally funded institutions. This case represents a seismic shift in how the U.S. government views cybersecurity, not as an IT problem, but as a contract enforcement issue and a public safety concern. ## What the DOJ Alleged The DOJ’s complaint alleged that [Illumina](https://www.illumina.com/ "") knowingly sold diagnostic platforms to federal agencies with undisclosed cybersecurity vulnerabilities, including the MiSeq Dx and NextSeq 550Dx systems. Specifically, the government alleged that: - Illumina did not incorporate secure design or lifecycle management practices into its software. - It lacked an adequate product cybersecurity program and quality system. - The company falsely certified compliance with industry cybersecurity standards such as [ISO 27001](/blog) and the NIST Cybersecurity Framework, which were required under certain procurement terms. These claims were enough to trigger an investigation and ultimately a settlement-despite the fact that no actual data breach occurred. > “ _The United States contends that the claims to the Agencies were false, regardless of whether any actual cybersecurity breaches occurred…_” - DOJ Settlement Agreement Illumina denied the allegations and did not admit liability in the settlement, but agreed to pay $9.8 million, with $4.3 million designated as restitution. ## Why This Case Matters This case is one of the clearest examples yet of the DOJ using the [Civil Cyber-Fraud Initiative (CCFI)](https://www.justice.gov/archives/opa/pr/deputy-attorney-general-lisa-o-monaco-announces-new-civil-cyber-fraud-initiative "") to target vendors who allegedly fail to meet cybersecurity requirements tied to government contracts. The initiative was launched to ensure that organizations receiving federal funds, including healthcare providers, diagnostics vendors, and device manufacturers, are truthful in their cybersecurity representations. It’s a shift from reactive enforcement (after a breach) to proactive prosecution of false claims, inadequate cybersecurity programs, and negligent system design. ## From Regulatory Compliance to Legal Liability In the FDA world, cybersecurity has become tightly integrated into regulatory guidance. The agency’s [2025 final guidance on premarket submissions](https://www.fda.gov/media/119933/download "") requires manufacturers to: - Implement a Secure Product Development Framework (SPDF) - Provide threat modeling - Validate security controls - Maintain [postmarket surveillance](/services/fda-postmarket-cybersecurity-services) But what the Illumina case shows is that regulatory compliance is no longer the end of the road. A manufacturer may clear the FDA’s bar and still find itself in legal jeopardy if its cybersecurity documentation, certifications, or marketing claims don’t match reality. This risk is especially acute for companies doing business with: - The Department of Veterans Affairs (VA) - The Department of Defense (DoD) - National Institutes of Health (NIH) - Hospitals or labs receiving CMS or federal grant funding ## Patient Safety at the Core Why is this happening? Because cybersecurity lapses aren’t just technical. They increasingly represent a **threat to patient safety**. Imagine a sequencing platform that receives a malicious update because secure boot is missing. Or a diagnostic device that can be remotely tampered with due to hardcoded credentials. These scenarios can lead to: - Incorrect diagnoses - Treatment delays - Data corruption in clinical workflows Healthcare cybersecurity is now recognized as **clinical risk**, not just compliance risk. The DOJ has picked up on that, and they’re acting accordingly. ## What Medical Device Makers Must Do If your company develops, sells, or services connected medical devices or diagnostic platforms, especially into government or research healthcare settings-here’s how to respond: ### 1\. Review All Cybersecurity Claims Go back through your FDA submissions, procurement documents, and commercial contracts. Ensure that your cybersecurity claims are not overstated or outdated. ### 2\. Build a True SPDF Don’t just document a secure product development lifecycle-live it. Integrate secure coding, SBOM tracking, code signing, and secure update mechanisms from day one. ### 3\. Conduct Penetration Testing Real testing, by third-party experts, not just vulnerability scans. These findings should feed into your risk assessment and mitigation strategy. ### 4\. Align Legal, Engineering, and Quality Teams The biggest risk in most companies? Departments working in silos. Sales signs off on cybersecurity promises that engineering can’t fulfill. This is how False Claims exposure begins. ### 5\. Prepare for Oversight Whether from FDA, OIG, or DOJ, enforcement is rising. Show that you’ve taken meaningful steps to protect patient data, system integrity, and contractual obligations. ## Blue Goat Cyber’s Perspective We’ve worked with device makers across diagnostics, wearables, and implantables. We’ve helped clients navigate FDA guidance, develop SPDF-aligned security processes, and uncover vulnerabilities in systems already in production. The Illumina case is a clear sign: You need provable, documented, and functional cybersecurity programs, not just language in a slide deck or SOP. If your device is being used in a hospital, research lab, or any federally funded setting, you are accountable, even without a breach. ## Final Thoughts The DOJ has changed the rules. Cybersecurity missteps can now cost millions in penalties and damage your brand reputation beyond repair. Illumina may be the first, but it won’t be the last. ### Ready to Take Control of Your Cyber Risk? Blue Goat Cyber offers penetration testing, SBOM validation, SPDF alignment, and cybersecurity gap assessments tailored for FDA- and government-facing medical device firms. Let’s secure your device-before someone else investigates it. Schedule a [free consultation](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session "") with us today. ## How Blue Goat approaches this Blue Goat Cyber's methodology for medical device cybersecurity is centered on verifiable security and regulatory alignment. We help manufacturers establish and validate their security posture, preventing the pitfalls seen in the Illumina case. Our team, comprised of CISSP-certified professionals, OSCP holders, and ex-military red team specialists, conducts careful assessments and provides actionable insights. We focus on integrating security into every phase of the device lifecycle, from design to postmarket activities, ensuring that claims of compliance and security are fully substantiated. Our services include gap analysis against FDA guidance and relevant standards (e.g., IEC 81001-5-1), penetration testing, and software bill of materials (SBOM) generation. We work to ensure your cybersecurity documentation and implementation withstand scrutiny, reflecting true security maturity. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What was the Illumina False Claims Act settlement about? Illumina settled allegations that it knowingly sold diagnostic platforms with undisclosed cybersecurity vulnerabilities to federally funded institutions, misrepresenting its security capabilities and compliance with standards like ISO 27001. ### Does the Illumina case mean a data breach must occur for legal action? No, the Illumina case demonstrates that legal action can occur based on false or misleading cybersecurity claims, even if no actual data breach or security incident takes place. ### How does the FDA premarket guidance relate to this case? While the FDA premarket cybersecurity guidance provides regulatory requirements, the Illumina case shows that meeting these alone may not prevent legal liability if a manufacturer's cybersecurity claims or practices are found to be false under federal contracts. ### What should medical device makers do differently now? Medical device makers must scrupulously review all cybersecurity claims, implement a true Secure Product Development Framework (SPDF), conduct thorough penetration testing, and ensure legal, engineering, and quality teams are aligned on cybersecurity representations. ### Why is the DOJ focused on medical device cybersecurity? The DOJ views medical device cybersecurity as a critical patient safety issue and a matter of contract enforcement. Failures can lead to incorrect diagnoses, treatment delays, and other clinical risks, making it a public safety concern. ### What is the Civil Cyber-Fraud Initiative? The Civil Cyber-Fraud Initiative is a DOJ program launched to pursue parties that knowingly provide deficient cybersecurity products or services, misrepresent their cybersecurity practices, or fail to report cybersecurity incidents when required by government contracts. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Former Cybersecurity Employees Indicted](/blog/when-cybersecurity-becomes-a-crime-what-the-illumina-case-signals-for-medical-device-makers) - [Hire Cybersecurity Consultant vs. In-House](/blog/when-to-hire-device-security-consultant-vs-build-in-house) --- ## Hire Cybersecurity Consultant vs. In-House Source: https://bluegoatcyber.com/blog/when-to-hire-device-security-consultant-vs-build-in-house # When to Hire a Device Security Consultant vs. Build In-House > **[DIRECT ANSWER]** Hire a specialized device security consultant when you are approaching an FDA 510(k), De Novo, or PMA submission and need SPDF documentation, a threat model mapped to FDA-accepted frameworks, an SBOM in SPDX or CycloneDX, and penetration test evidence on a fixed timeline. Build in-house only when you have six to twelve months of runway, a complex ongoing device portfolio, and budget for a full security toolchain plus the regulatory ramp-up time most engineers need to learn FDA-specific requirements. Most medical device manufacturers assume they can solve their cybersecurity problem by hiring a device security consultant or adding a security engineer to the team. Both instincts can be right, but the gap between "we have someone who handles security" and "we have FDA-ready cybersecurity documentation" is wider than most product teams expect - until they're staring at a deficiency letter with a clearance deadline looming. This article is a decision guide. It covers the real cost of building device security expertise in-house, what a qualified external consultant actually delivers, why FDA submission speed depends on regulatory specialization, how to evaluate and shortlist candidates, and how to scope an engagement with measurable outcomes. ## Key Takeaways - In-house security hires face significant ramp-up for FDA specific knowledge. - First-year cost for a single in-house expert can exceed $300,000. - FDA premarket guidance requires specialized documentation expertise. - Specialized consultants provide submission-ready artifacts immediately. - A single FDA cyber deficiency can cost more than specialist fees. - Evaluate consultants on technical depth and FDA regulatory alignment. ## Why this matters The stakes for medical device cybersecurity are higher than ever, driven by the FDA's "Cybersecurity in Medical Devices" Final Guidance dated February 3, 2026. This guidance mandates rigorous premarket and postmarket cybersecurity controls, making the decision between internal expertise and external consultation critical. A single FDA deficiency related to cybersecurity can halt product clearance, incurring significant delays and financial penalties that often far exceed the cost of proactive specialist engagement. Building an in-house team capable of meeting these evolving requirements demands substantial investment not only in salaries and benefits but also in continuous training on standards such as IEC 60601-1-10, ISO 14971, and AAMI TIR57 / ANSI/AAMI SW96:2023. Achieving the necessary depth of understanding for device architecture, threat modeling, vulnerability management, and regulatory documentation is a sustained effort. External consultants, however, provide immediate access to this specialized knowledge, expediting premarket submissions and ensuring alignment with the FDA's stringent expectations. Their expertise can significantly reduce time to market and mitigate regulatory risks. ## The real cost of building in-house device security expertise The assumption most MedTech teams make is that one strong security hire solves the problem. In practice, securing a connected medical device across hardware, firmware, BLE, cloud integrations, and FDA documentation simultaneously requires a team, a toolchain, and a significant runway of regulatory learning. A single engineer rarely covers all of it, and the costs stack up faster than most budgets anticipate. ### Hidden costs beyond a single security salary In 2026, a senior embedded or firmware security engineer with FDA medical device experience typically commands $150,000 to $200,000 in base salary, with principal-level specialists reaching $200,000 to $250,000. Total employer cost, including benefits, payroll taxes, and overhead, runs roughly 1.2 to 1.4 times that figure. Add specialized tooling: Ghidra for firmware reverse engineering, hardware lab equipment for JTAG and UART interface testing, fuzzing infrastructure, and SBOM management tooling. These investments are not optional for a credible device security program. **When you factor in tooling, onboarding time, and ramp costs, the first-year cost of a single qualified hire can easily reach or exceed $300,000 depending on role level and device complexity.** ### The competency gap that surprises most MedTech teams Even experienced cybersecurity engineers don't arrive knowing FDA premarket requirements. SPDF documentation, threat modeling mapped to FDA-accepted frameworks, SBOM development in SPDX or CycloneDX format, and eSTAR Section 524B deliverables represent a specialized regulatory language. In practice, engineers from general cybersecurity backgrounds typically need 3 to 6 months of focused effort to reach working independence on standard FDA submissions, and closer to 6 to 12 months for first-time engineers without external regulatory support or a complex device architecture. For most product launch timelines, that ramp period is simply not available. A delayed clearance costs far more than the consulting fees it was meant to avoid. ## What a specialized device security consultant actually delivers A qualified external consultant brings assessment depth and documentation capability that most in-house teams can't match on day one. The scope of a proper engagement goes well beyond a vulnerability scan and a report. It covers the full device attack surface and produces the specific artifacts that move a program forward. ### The full assessment scope across the device stack A thorough device security assessment covers hardware interfaces including JTAG, UART, and SPI; firmware extraction and static analysis; BLE, RF, and wireless protocol testing; cloud and API review; mobile app assessment; and boot chain validation. A quality consultant doesn't stop at findings. They produce a risk register, a threat model with attack scenarios mapped to real evidence, a prioritized remediation roadmap with owner assignments, and an executive summary with severity ratings. The deliverable set should be specific enough that your engineering team can act on it immediately rather than interpret it. Some deliverables, such as retest cycles and source code review, may require separate contracting depending on the engagement scope. For a broader reference on IoT and embedded device testing principles, see the [OWASP IoT Security Testing Guide](https://owasp.org/www-project-iot-security-testing-guide/). ### Typical engagement timelines and pricing benchmarks Before contacting vendors, it helps to have realistic budget anchors. Standard firmware and hardware security consultant engagements run $15,000 to $40,000 for focused assessments, with lightweight scoping packages available from $5,000 to $15,000 for early-stage teams. Deep technical assessments with full threat modeling for a regulated device range from $50,000 to $150,000 or more. Monthly advisory retainers for ongoing support sit between $8,000 and $20,000. For commercial launch prep on a connected device, budget $25,000 to $60,000 as a working planning number. These ranges reflect the complexity of the work and the regulatory experience required, not just hours billed. Actual costs vary by region, device complexity, and the depth of FDA documentation required. ## FDA submission speed and the premarket cybersecurity bottleneck [The FDA's February 2026 Final Premarket Cybersecurity Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket), combined with FD&C Act Section 524B, makes cybersecurity documentation a hard submission gate. Missing or weak artifacts don't just draw comments - they generate deficiency letters that delay clearance by months and sometimes require complete rework of the submission package. For legal analysis of the guidance and its implications for premarket submissions, see this [DLA Piper briefing on the revised premarket submission guidance](https://www.dlapiper.com/insights/publications/2026/02/fda-issues-revised-cybersecurity-premarket-submission-guidance). ### Why generalist consultants create submission risk An IoT security consulting firm without FDA experience can produce technically sound testing work and still generate documentation that FDA reviewers reject. Typical gaps include threat models not mapped to FDA-accepted frameworks, SBOMs missing machine-readable format requirements, SPDF documentation that doesn't align with QMSR language, and postmarket plans that don't address coordinated vulnerability disclosure requirements. Each of these gaps can trigger a deficiency letter on its own. The [NIST SP 800-213 series on IoT device cybersecurity](https://csrc.nist.gov/publications/detail/sp/800-213/final) is a useful reference for mapping device controls across the lifecycle. **The cost of a single FDA cybersecurity deficiency letter response, in consulting fees, internal time, and delayed revenue, can outweigh the price difference between a generalist and a specialist engagement.** That math should drive the sourcing decision more than hourly rates. ### How a device security consultant with FDA specialization compresses timelines What separates a medical device cybersecurity consultant from a generalist IoT security firm is the ability to deliver a complete, submission-ready package under the February 2026 FDA guidance without requiring extensive back-and-forth. A qualified firm at this level produces SPDF documentation, a threat model tied to FDA-accepted methodology, SBOM development in SPDX or CycloneDX, security architecture views, and eSTAR-ready Section 524B documentation as standard deliverables, not add-ons. Blue Goat Cyber is built specifically for this work. With a track record spanning 275+ FDA submissions and no cyber-related deficiency letters across that portfolio, our premarket packages are scoped to fit regulated device timelines and structured to meet current FDA documentation standards. That kind of documented, submission-specific experience is what you should be evaluating when comparing firms, not generic security credentials. See [Securing Medical Devices: The Key to Faster FDA Approval and Investor Confidence](/blog/securing-medical-devices-the-key-to-faster-fda-approval-and-investor-confidence) for practical examples of how security work accelerates approvals and supports investor conversations. ## How to evaluate and shortlist a medical device cybersecurity consultant Once you've decided external consulting is the right move, the next challenge is separating strong candidates from firms that look credible on a website but lack the specific experience your submission requires. The evaluation criteria that matter most are technical depth and FDA regulatory alignment, in that order. ### Technical skills and certifications worth requiring Prioritize demonstrated experience over paper credentials. The skills that matter are hands-on firmware reverse engineering with tools like Ghidra or IDA, hardware interface testing across JTAG, UART, and SWD, wireless protocol security covering BLE, Zigbee, and MQTT, and cryptography and key management in constrained environments. A device cybersecurity consultant's value shows in their portfolio, not their certifications list. Certifications like CISSP or GIAC are useful signals but secondary to a verifiable portfolio of completed embedded device assessments. Ask directly: "Show me a real finding from an embedded medical device engagement and walk me through how it was remediated." Firms that answer specifically are worth continuing with. Firms that pivot to slide decks and methodology overviews probably aren't. ### FDA regulatory alignment: the questions that separate specialists from generalists Use these five questions to run a fast filter on any candidate: - "How do you map threat modeling outputs to the FDA's premarket guidance, and which framework do you use?" - "How do you structure SPDF documentation for eSTAR submissions?" - "Have you responded to an FDA cybersecurity deficiency letter, and what was the outcome?" - "What SBOM format do you deliver, and does it meet machine-readable requirements under Section 524B?" - "How do you align postmarket vulnerability handling plans with FDA coordinated disclosure expectations?" A generalist IoT security consulting firm will hesitate, give vague answers, or ask follow-up questions about what the FDA requires. A medical device cybersecurity specialist will answer immediately and specifically. That response quality tells you more than any credentials document. ## Scoping the engagement and building your RFP A well-scoped engagement protects your budget, gives you measurable outcomes, and forces the vendor to commit to specifics before the work begins. Vague scope documents produce vague deliverables, and vague deliverables don't support FDA submissions. ### Defining deliverables and measurable outcomes A solid scope document should require a named vulnerability report with severity ratings and proof-of-concept evidence, a prioritized remediation roadmap with owner assignments, a threat model tied to FDA-accepted methodology, an SBOM in SPDX or CycloneDX format, and a defined retest cycle after remediation is complete. When requesting SBOMs, specify the format explicitly - SPDX and CycloneDX are the machine-readable standards FDA reviewers expect under Section 524B. **If the consultant won't commit to deliverable format and depth in writing, that's a red flag worth acting on before you sign anything.** "Security assessment" as a line item in a contract is not a deliverable. It's a description of effort with no accountability attached. ### Choosing the right engagement model for your stage Match the model to your lifecycle position. Early-stage companies preparing a first FDA submission benefit most from a fixed-fee premarket package with a defined deliverable set and a timeline that fits your regulatory calendar. Teams in active development need a monthly advisory retainer with defined hours and clear escalation protocols. Companies managing a cleared device fleet need ongoing SBOM maintenance, vulnerability monitoring, patch validation, and postmarket coordination. Budget planning benchmarks: $25,000 to $60,000 for commercial launch prep; $50,000 to $150,000 or more for a complex regulated device with full FDA documentation; $8,000 to $20,000 per month for ongoing postmarket support. Whether you're engaging a firmware security consultant for a focused assessment or a full-service medical device cybersecurity consultant for a complete premarket package, matching scope to stage keeps costs predictable and outcomes measurable. The difference between a delayed launch and a first-pass FDA clearance often comes down to whether your device security consultant has completed this exact submission type before, on a device like yours, under current guidance. That specificity is what you're actually buying. ## Make the decision with the right criteria Building in-house device security expertise rarely covers FDA submission requirements at the depth and speed a product launch demands. Generalist IoT security consultants miss the premarket documentation specifics that drive clearance. Specialized medical device cybersecurity consultants pay for themselves when they prevent a single deficiency letter, and they pay for themselves several times over when they compress your clearance timeline by months. The checklist is straightforward. Define deliverables before you sign. Verify FDA regulatory experience with direct questions. Require a portfolio of real findings from similar devices. Choose an engagement model that matches your current stage. Don't accept "we've done medical device work" as a qualifier - ask for the submission pathway, the device class, and the outcome. If you're preparing an FDA premarket submission and need a device security consultant with a documented track record spanning 275+ FDA submissions and no cyber-related deficiency letters, Blue Goat Cyber is built specifically for that engagement. Our premarket packages are structured to meet current FDA documentation standards, with turnaround timelines scoped to regulated device schedules. For practical planning and launch guidance, see [Why Your Medical Device Go-to-Market Strategy Should Include Cybersecurity](/blog/cybersecurity-before-mvp-vs-after-market-fit-cost-of-waiting), and for a list of common submission pitfalls review [12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions](/guides/12-reasons-the-fda-rejects-medical-device-cybersecurity-submissions). ## Hire vs build, on the factors that actually decide it The honest comparison is not cost per hour. It is time to a defensible submission and what happens when one person leaves. | Factor | Building in-house | Specialist consultant | | --- | --- | --- | | Time to first submission-ready evidence | Nine to eighteen months, including hiring | Weeks, on an existing process | | Breadth of skills needed | Firmware, radio, cloud, regulatory writing, rarely in one person | Covered by a team | | Cost shape | Fixed salaries and equipment, paid year-round | Project-based, matched to submission timing | | Independence for reviewers | Internal testers reviewing their own product | Independent party, which reviewers read differently | | Knowledge retention | Stays with you if the person stays | Stays with the firm, so ask for documented handover | | Best fit | Steady multi-product pipeline and a mature quality system | First submissions, deficiency responses, and peak load | ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers navigate the complexities of FDA cybersecurity mandates. Our approach focuses on delivering actionable, FDA-ready documentation and technical assessments without the overhead of building a specialized internal team from scratch. Our consultants, many with CISSP and OSCP certifications and backgrounds in ex-military red teams, apply deep technical knowledge to threat modeling, penetration testing, and security architecture reviews. We accelerate your premarket submission process by providing immediate access to expertise in regulatory compliance, translating technical findings into the specific artifacts required by the FDA. This direct engagement avoids lengthy hiring cycles and training programs. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support for /services/fda-premarket-cybersecurity-services. ## FAQ ### What signals that we should hire a consultant instead of building in-house? An imminent 510(k), De Novo, or PMA submission; no in-house FDA cybersecurity submission experience; a device portfolio of one or two products rather than ten; and a need for clearance on a quarterly milestone rather than an open-ended timeline. In all four cases, a specialized consultant is usually faster and cheaper than a 6-12 month internal ramp. ### What does a fully loaded in-house device security hire actually cost? Salary is only one line. Add benefits, the toolchain (SAST, SCA, DAST, threat-modeling, SBOM, fuzz), training, conference and certification budgets, and the regulatory ramp - someone new to MedTech typically needs 6-12 months before they are productive against an FDA submission. Most teams underestimate the loaded cost by 2-3x. ### How is a specialized MedTech consultant different from a generalist IoT or AppSec consultant? A specialist writes deliverables in the FDA's expected shape: threat models referencing AAMI TIR57 / ANSI/AAMI SW96:2023, SBOMs in SPDX or CycloneDX, pen test reports mapped to Section 524B, and SPDF evidence packages reviewers recognize. Generalist IoT or AppSec consultants often produce technically sound work that still gets rejected because the format and references do not match what the FDA expects. ### How should we structure the RFP for a MedTech security consulting engagement? Define the device class and pathway (510(k), De Novo, PMA), the submission date, the testing scope (interfaces, protocols, cloud), the required deliverables (threat model, SBOM, VEX, pen test report, SPDF evidence), and the standards to reference. Ask for two prior anonymized FDA deliverables as work samples. Avoid hourly engagements for submissions - fixed-scope is what compresses timelines. ### What questions separate qualified consultants from unqualified ones? Ask how many FDA cybersecurity deficiency letters they have responded to, which standards they cite by default in threat models, whether they produce SBOMs in SPDX or CycloneDX (and why), how they handle VEX, and what their typical timeline is from kickoff to submission-ready package. Vague answers are a signal. ### Can we hybrid - keep some work in-house and outsource the rest? Often the strongest model. Keep secure coding, SAST, SCA, and fuzz testing in engineering. Outsource the threat model, the external pen test, the SBOM/VEX production, and the SPDF evidence package for the submission itself. That keeps internal cost manageable while still getting clearance-grade deliverables. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## When to Start Medical Device Cybersecurity Source: https://bluegoatcyber.com/blog/when-to-start-medical-device-cybersecurity # When to Start Medical Device Cybersecurity in Product Development > **[DIRECT ANSWER]** Start cybersecurity at concept, not at submission. The threat model should exist before the architecture freezes, because it generates security requirements that become design inputs, and design inputs are cheap to add and expensive to retrofit. Teams that begin after verification usually discover an unsigned update path or an unauthenticated interface they cannot change without reopening design controls and repeating testing. If your team is two years into product development and still says "we're not ready for cybersecurity yet," you are not early. You are late, and the cost has already been paid, you just haven't seen the invoice. That invoice arrives in one of three ways: a Refuse to Accept (RTA) hold on your 510(k), an Additional Information (AI) letter listing cybersecurity deficiencies that force architectural changes, or a postmarket vulnerability that pulls the device off shelves. Each one resets your timeline by quarters, not weeks. The good news: the fix is not "spend more." It is "sequence correctly." Cybersecurity done at the right phase of design controls is cheaper than the same work done later, because the artifacts you produce (threat model, security requirements, SBOM, architecture views) double as design inputs the FDA already requires under 21 CFR 820.30. ## Key Takeaways - The correct start point is concept phase, before design freeze, when threat modeling and security requirements become design inputs under 21 CFR 820.30. - Teams two years into development without a threat model are not "not ready", they have unresolved architectural risk that will surface in an FDA Additional Information letter. - The February 3, 2026 FDA premarket cybersecurity guidance made SPDF a gating criterion for 510(k) and PMA acceptance under Section 524B, so backfilling security late means backfilling a design history file. - Six specific activities have to happen before design freeze: threat model, security risk assessment, security architecture views, authentication and update mechanism decisions, SBOM baseline, and vulnerability handling plan. - Retrofit cost for a connected Class II device runs 4-10x the cost of doing the same work at concept, plus deferred revenue from missed submission windows. - If you are already late, the recovery play is a focused 6-8 week security architecture sprint that produces the FDA-required artifacts against your current design. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions* (final, February 3, 2026) made the Secure Product Development Framework a gating criterion for premarket acceptance under Section 524B of the FD&C Act. Reviewers now expect cybersecurity artifacts to be traceable to design inputs, not appended as a submission-time attachment. Two standards codify what "traceable" means. AAMI TIR57 / ANSI/AAMI SW96:2023 defines security risk management as a parallel process to safety risk management under ISO 14971, executed across the design lifecycle. IEC 81001-5-1 (adopted by the FDA in 2024 as a recognized consensus standard) defines security activities per lifecycle phase, mapping cleanly onto IEC 62304's software lifecycle. The practical effect: the FDA reviewer opens your Design History File and expects to see security requirements alongside functional requirements, a threat model referenced in your design inputs, and verification evidence (pen test, SBOM scans) traceable to those inputs. A submission that pastes cybersecurity in as a standalone section, with no design-control trail, is the pattern the FDA's FY2024 CDRH performance report flags as a top cybersecurity deficiency category in AI letters. ## When should you actually start medical device cybersecurity? **Concept phase, before the first architecture review.** That is the honest answer, and it is not a marketing answer, it is what 21 CFR 820.30 and IEC 81001-5-1 require when read together. Three decisions get locked in during concept and early design that determine 80% of your cybersecurity submission risk: 1. **Authentication model.** How does a user, service, or peer device prove identity? Changing this after design freeze means changing every interface. 2. **Update mechanism.** How does the device receive verified software updates in the field? Bolt this on late and you get a postmarket vulnerability management plan the FDA will not accept. 3. **Trust boundary.** What crosses the network, what stays local, what touches PHI? Move a trust boundary after V&V and you re-run the whole risk file. These are not "cybersecurity features." They are architecture decisions the security team either informs early or discovers late. Discovery-late is the two-year-in scenario. ## What does "not ready for cybersecurity" actually mean? When a MedTech founder says "we're not ready for cybersecurity," they usually mean one of four things. Each has a different real answer. | What they say | What it usually means | The real answer | |---|---|---| | "We don't have a threat model yet" | Nobody has looked at attack surface | You are ready, this IS the starting activity | | "The device isn't final" | Architecture is still moving | You are the most ready, freeze security decisions with the architecture | | "We can't afford a pen test" | Budget is thin | Pen testing is the last step, not the first, don't do it yet | | "We'll do it before submission" | Deferring to Q4 | You will miss submission window; SPDF artifacts take 3-6 months to produce cleanly | The pattern: teams conflate "cybersecurity" with the single most expensive activity (penetration testing) and defer the whole discipline. Threat modeling and security requirements, the activities that actually need to happen early, cost engineering time, not tooling budget. ## Which cybersecurity activities happen in which design phase? Mapped to IEC 62304 software lifecycle phases, extended with IEC 81001-5-1 security activities: | Phase | Cybersecurity activities | Deferable? | |---|---|---| | Concept / planning | Security posture, applicable regulations, framework choice (SPDF, JSP2, 81001-5-1) | No | | Requirements | Threat model v1, security requirements, security risk assessment | No | | Architecture / design | Architecture views (global, multi-patient harm, updateability, security use case), auth + update + trust decisions, SBOM baseline | No | | Implementation | Secure coding standards, SAST, dependency scanning, SBOM maintenance | Partial | | Integration & verification | Security testing, fuzz testing, threat model v2, vulnerability scanning | No | | Release | Penetration test, final SBOM, VEX, labeling, CVD process | Yes, this is the correct time | | Postmarket | Vulnerability monitoring, patch cadence, incident response, SBOM refresh | Ongoing | > **[KEY REQUIREMENT]** The February 3, 2026 FDA guidance requires four architecture views in the premarket submission: global system view, multi-patient harm view, updateability view, and security use case view. All four are architecture-phase artifacts. If your architecture is done and these views do not exist, they cannot be produced accurately, they will be reverse-engineered, and reviewers can tell. ## What does it cost to start late? For a connected Class II device, order-of-magnitude estimates from Blue Goat engagements: | Timing | Full SPDF artifact set cost | Timeline impact | |---|---|---| | Concept phase | $30-60K, absorbed into design work | Zero, runs in parallel | | Post design freeze | $80-150K | 2-4 months added | | Pre-submission scramble | $150-300K | 4-8 months added (miss submission window) | | Post-AI letter response | $200-500K + resubmission | 6-18 months added | | Postmarket vulnerability recall | $500K-$5M + revenue loss | Unbounded | The retrofit multiplier is not because security work is inherently more expensive later. It is because late security work triggers cascading rework: architecture change → re-verification → re-validation → new threat model → new pen test → updated submission. ## You are two years in with nothing, what now? The recovery play is not "start over." It is a focused 6-8 week security architecture sprint that produces the FDA-required artifacts against your current design, identifies which existing decisions have to change, and separates "fix before submission" from "document as accepted residual risk." The sequence: 1. **Week 1-2:** Threat model against as-built architecture. Identify assets, entry points, trust boundaries, adversary profiles. 2. **Week 2-4:** Security risk assessment tied to AAMI TIR57 / ISO 14971 harm outcomes. This produces your security risk file. 3. **Week 3-5:** Four FDA architecture views produced against current design. Gaps become findings. 4. **Week 5-7:** Security requirements traced to design inputs. Gap remediation plan for anything that cannot be documented as-is. 5. **Week 6-8:** SBOM baseline, VEX, CVD policy, postmarket monitoring plan. Penetration testing comes after, once the artifacts are in place, the pen test is the verification activity, not the discovery activity. ## How Blue Goat approaches this Blue Goat Cyber runs this exact 6-8 week sprint for MedTech teams who realize late that cybersecurity has to be a design-control artifact, not a submission attachment. Our team, CISSP-, OSCP-, and ex-military-red-team-credentialed engineers who work only on medical device cybersecurity, produces the threat model, security risk file, four architecture views, SBOM baseline, and postmarket plan the FDA expects under the February 3, 2026 guidance. We also handle [FDA premarket cybersecurity submissions](/services/fda-premarket-cybersecurity-services) end-to-end. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Related reading: [Cybersecurity Before MVP vs After Market Fit](/blog/cybersecurity-before-mvp-vs-after-market-fit-cost-of-waiting) covers the pre-MVP decisions, and [FDA Pen Test Timing for Submission](/blog/fda-pen-test-timing-submission) covers when penetration testing actually belongs in the sequence. ## FAQ ### When should medical device cybersecurity start in product development? It should start at concept phase, before the first architecture review is signed off. Threat modeling, security requirements, and framework selection are design inputs under 21 CFR 820.30 and IEC 81001-5-1. Waiting until verification or submission prep means backfilling design-control artifacts, which is what the FDA flags most often in Additional Information letters. ### Is it ever too late to start medical device cybersecurity? No, but the recovery cost grows quickly. A team two years into development can still produce a compliant Secure Product Development Framework artifact set in 6-8 weeks against the as-built design. What is not recoverable is the low cost of doing it at concept: retrofit engagements run 4-10x the concept-phase cost. ### Can we just do a penetration test and call it cybersecurity? No. Penetration testing is a verification activity that comes near release. Without a threat model, security requirements, and architecture views in place first, a pen test has nothing to verify against, and the FDA does not accept a pen test report as a substitute for SPDF artifacts under the February 3, 2026 guidance. ### What if our device is "not final" yet? That is the ideal state to start cybersecurity, not a reason to defer. Security decisions made while architecture is still moving are cheap; security decisions imposed after freeze are expensive. The three decisions to lock down early are authentication model, update mechanism, and trust boundary. ### Does Section 524B apply if we haven't submitted yet? Yes. Section 524B of the FD&C Act applies to any device that meets the definition of a "cyber device" at the time of submission. If your device includes software, has the ability to connect to the internet, and could be vulnerable to cybersecurity threats, 524B applies to your 510(k), De Novo, or PMA, regardless of when you started thinking about it. ### How long does it take to produce the FDA-required cybersecurity artifacts? Cleanly, from a standing start, 3-6 months for a Class II connected device when done in parallel with normal design work. Compressed under submission pressure, 6-8 weeks with a focused sprint. Both are cheaper and faster than an Additional Information letter response, which adds 6-18 months. ## Ready to stop deferring? If your team is deep into product development without a threat model, security risk file, or architecture views, you are one FDA letter away from a resubmission. Book a [medical device cybersecurity consultation](/contact) and we will scope a 6-8 week sprint that produces the SPDF artifact set your submission needs. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance, and has run the concept-phase-to-submission sequence for dozens of Class II and Class III connected devices. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [Medical Device URL Encoding for Web](/blog/medical-device-sql-injection-parameterized-queries) - [Medical Device Cybersecurity](/blog/medical-device-cybersecurity-with-interconnected-devices) - [Fuzz Harness Generation for Medical](/blog/fuzz-harness-generation-medical-device-protocols) - [TGA Medical Device Cybersecurity](/blog/tga-australia-medical-device-cybersecurity) --- ## CBER: What MedTech Teams Need to Know About FDA Biologics (2026) Source: https://bluegoatcyber.com/blog/who-is-center-for-biologics-evaluation-and-research-cber # CBER (Center for Biologics Evaluation and Research): What MedTech Teams Need to Know in 2026 > **[DIRECT ANSWER]** CBER (Center for Biologics Evaluation and Research) is the FDA center that regulates biologic products such as vaccines, blood components, tissues, and cell and gene therapies for safety, purity, potency, and effectiveness. MedTech teams need to understand CBER when their device stores, delivers, monitors, or integrates with biologic products, since cybersecurity controls must protect the data integrity and safe administration of those products. _Updated October 26, 2024_ The [Center for Biologics Evaluation and Research (CBER)](https://www.fda.gov/about-fda/fda-organization/center-biologics-evaluation-and-research-cber) is the part of the U.S. Food and Drug Administration that regulates many biologic products, including vaccines, blood and blood components, tissues, and cell and gene therapies. Its job is straightforward: make sure these products meet standards for safety, purity, potency, and effectiveness before and after they reach the market. For MedTech companies, CBER matters when your product sits at the intersection of device, biologic, software, and connected systems. If your technology supports, delivers, stores, monitors, or integrates with biologic products, you need to understand how CBER thinks about quality, evidence, manufacturing, and postmarket oversight. ## Key Takeaways - CBER regulates biologics for safety, purity, potency, and effectiveness. - Oversight includes product review, facility inspections, and postmarket monitoring. - Biologics' complexity demands stringent process controls and evidence. - Cybersecurity is crucial if software affects biologic product quality or safety. - CBER evaluates data integrity and controls for advanced technologies. - Innovation is supported, but with expectations for evidence and control. ## Why this matters For medical device manufacturers, understanding CBER's role is critical when devices interact with biologic products. The stakes are high: compromised device cybersecurity can directly impact the safety, purity, and potency of biologics, leading to patient harm or ineffective treatments. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, explicitly mandates that medical devices, regardless of their primary regulatory center, demonstrate adequate cybersecurity measures throughout their total product lifecycle. This includes ensuring the integrity of data related to biologic products, securing software that controls their administration, and protecting networked systems involved in their storage or monitoring. Compliance extends beyond simply preventing breaches; it involves proactive threat modeling, vulnerability management, and maintaining data integrity, particularly for sensitive biologic information. Relevant standards like ISO 81001-5-1, IEC 62443, and AAMI TIR57 / ANSI/AAMI SW96:2023 provide frameworks for establishing and maintaining secure environments for medical devices, which are equally applicable when those devices interface with CBER-regulated biologics. ## What CBER Does CBER evaluates biologic products and the systems used to develop and manufacture them. That includes reviewing preclinical and clinical data, assessing manufacturing consistency, setting policy, and monitoring safety after approval. Biologics are different from small-molecule drugs. They are often derived from living sources and can include proteins, nucleic acids, blood products, tissues, and engineered cells. That complexity creates variability, and variability creates regulatory risk. CBER exists to reduce that risk with scientific review and regulatory controls. CBER also conducts and supports research. That work helps the FDA update its thinking as new technologies move from the lab into clinical use. Areas like gene editing, personalized therapies, and emerging infectious disease response all push CBER to refine policy in real time. ## Why Biologics Require a Different Level of Oversight Biologics are often used in high-risk settings: oncology, autoimmune disease, rare disease, transplantation, and genetic disorders. The margin for error is small. Product quality, sterility, chain of custody, manufacturing controls, and postmarket surveillance all matter. Unlike conventional pharmaceuticals, biologics can be highly sensitive to process changes. A manufacturing deviation, storage issue, or handling problem can affect safety or performance in ways that are not always obvious. That is why CBER spends so much attention on process controls and evidence, not just end-product claims. For companies building connected platforms around biologics, this should sound familiar. Cybersecurity failures can also become quality failures. If software affects manufacturing data, product traceability, environmental monitoring, access control, or clinical decision support, regulators will not treat that as an IT side issue. ## How CBER Is Organized CBER includes multiple offices with different responsibilities, from product review to inspections, compliance, epidemiology, and policy. The structure matters because sponsors are rarely dealing with just one regulatory function. ![Section Image](/imported-images/9332439aaf1a39e1.png) Two offices are especially worth noting: - The Office of Biostatistics and Epidemiology supports data analysis, statistical review, and evidence interpretation. - The [Office of Compliance and Biologics Quality (OCBQ)](https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/office-compliance-and-biologics-quality-ocbq) focuses on compliance, inspections, and biologics quality systems. That combination tells you a lot about how CBER operates. The center is not only asking whether a product works. It is also asking whether the evidence is sound, the process is controlled, and the manufacturer can keep it that way. Leadership inside CBER also works across industry, academia, and other regulators. That collaboration shapes policy and can influence how quickly new technologies move into workable regulatory pathways. ## The Scope of CBER’s Work CBER’s responsibilities go well beyond initial review. The center oversees biologic products across the full lifecycle, from development through postmarket monitoring. ![Section Image](/imported-images/c16b6d75689bd7df.png) ### Regulatory Responsibilities CBER reviews applications, inspects facilities, evaluates manufacturing controls, and monitors safety signals after products are marketed. It also works with international regulators to support consistent standards and broader access to safe biologics. That lifecycle view should be familiar to medical device manufacturers. The FDA does not want static documentation built for a submission and forgotten after clearance or approval. It expects systems that remain effective as products, threats, suppliers, and clinical use change over time. That is one reason [the FDA’s 18 cybersecurity deliverables for medical device submissions](/blog/navigating-the-fdas-18-cybersecurity-deliverables-for-medical-device-submissions) matter so much. The same principle applies in biologics oversight: evidence has to connect to actual controls, and controls have to hold up in practice. ### Public Health Contributions CBER also supports public health during outbreaks, supply disruptions, and safety events involving biologic products. Its scientific and regulatory work helps inform policy, labeling, guidance, and risk communication. The center’s research function matters here too. CBER does not only review sponsor-generated data. It builds internal expertise so the FDA can evaluate new product categories without relying solely on industry’s framing of the science. > **Preparing an FDA submission?** > > Blue Goat Cyber is a medical-device-only cybersecurity firm. Our team runs the threat modeling, penetration testing, and FDA-facing documentation MedTech submissions live or die on. [→ FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services) ## CBER’s Impact on Industry CBER sets the terms for how biologics move from concept to market. That affects timelines, development strategy, manufacturing design, clinical evidence plans, and postmarket obligations. ![Section Image](/imported-images/4c27af9f4e976ec5.png) ### Safety, Effectiveness, and Trust When CBER applies rigorous review standards, it increases confidence in approved biologics. That trust matters to patients, clinicians, payers, and investors. It also matters to manufacturers trying to build durable market access instead of chasing a one-time approval milestone. The impact is easy to see in areas like monoclonal antibodies and advanced therapies. Products such as rituximab and trastuzumab changed cancer treatment, but they only became viable at scale because regulators established clear expectations around evidence, manufacturing quality, and ongoing surveillance. CBER’s postmarket oversight is just as important. Safety monitoring does not stop once a product is approved. If new risks emerge, the FDA expects companies to detect them, assess them, and respond with discipline. ### Innovation, With Guardrails CBER has also helped open paths for newer treatment models, including cell and gene therapies. A good example is [CAR-T therapy](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells), which created new treatment options for certain leukemias and lymphomas. But innovation is not a free pass. CBER supports new approaches while still demanding evidence, control, and reproducibility. That is the right model for cybersecurity, too. Novel software, AI-enabled tooling, cloud infrastructure, and connected workflows are fine if you can show they are secure, validated where needed, and governed across the lifecycle. ## What’s Next for CBER CBER is dealing with the same pressure every modern regulator faces: more technical products, more software dependence, more data, and less tolerance for failure. ### Emerging Challenges Personalized medicine is one pressure point. Individualized therapies do not fit neatly into older regulatory models, which means CBER has to keep adapting its review approaches without lowering standards. AI is another. [Artificial intelligence in healthcare and medical device cybersecurity](/blog/emerging-technologies-and-their-impact-on-medical-device-cybersecurity) is already influencing research, development, manufacturing, and surveillance. The opportunity is real. So is the risk. If AI affects product quality, patient safety, or regulated decision-making, companies should expect close scrutiny. CBER is also paying attention to data integrity and information flow. Whether the enabling technology is advanced analytics, modern cloud architecture, or distributed records systems, the underlying issue stays the same: can the FDA trust the data and the controls around it? ### Strategic Priorities CBER’s stated priorities include improving regulatory efficiency, supporting scientific innovation, strengthening international coordination, and maintaining a workforce that can evaluate complex technologies. For industry, the takeaway is practical. Do not treat regulation as a documentation exercise. Build systems that can withstand inspection, change control, postmarket scrutiny, and security testing. If your platform touches biologics operations or patient-facing workflows, cybersecurity belongs inside quality and regulatory planning from the start. CBER is not just a biologics reviewer. It is part of the larger FDA framework that expects manufacturers to understand how product safety, software risk, data integrity, and operational control fit together. If your organization is building connected medical technologies that intersect with biologics, that expectation is not theoretical. It will show up in your design controls, your supplier oversight, your submission strategy, and your postmarket obligations. [Contact us today for cybersecurity help](/contact). ## CBER, CDRH, and CDER compared | Center | Primary products | What it means for a connected product | Who you talk to about security | | --- | --- | --- | --- | | CBER | Vaccines, blood products, cell and gene therapies | Devices used with these products are reviewed here | CBER, applying the same device cybersecurity expectations | | CDRH | Devices and most software as a medical device | The default home for connected device review | CDRH reviewers and their cybersecurity specialists | | CDER | Drugs and many drug-led combination products | The device constituent still needs a security file | CDER, with device expertise consulted | | Lead center assignment | Determined by primary mode of action | Decides which queue and which reviewers | Established before you submit, not after | The center changes who reads the file. It does not change what the file has to contain. ## How Blue Goat approaches this Blue Goat Cyber assists medical device manufacturers in navigating the cybersecurity requirements for devices interacting with CBER-regulated biologics. Our focused methodology helps integrate cybersecurity into device design and development, ensuring compliance with FDA expectations. We provide detailed guidance on risk management, vulnerability assessments, and secure software development, tailored to the unique challenges of biologic-adjacent technologies. Our team, composed of experts with CISSP and OSCP certifications, including ex-military red team personnel, brings practical defensive and offensive security experience. We specialize in preparing accurate and complete cybersecurity documentation for premarket submissions, helping to prevent deficiencies. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Explore our services at [Medical Device Penetration Testing](/services/medical-device-penetration-testing) to learn how we can secure your innovations. ## FAQ ### What is CBER? CBER is the Center for Biologics Evaluation and Research, a part of the FDA. It regulates biologic products including vaccines, blood products, and cell and gene therapies to ensure their safety, purity, potency, and effectiveness. ### How does CBER impact medical device cybersecurity? If a medical device or connected system supports, delivers, or interacts with biologic products, CBER's regulatory focus on quality and control extends to its cybersecurity. Cybersecurity failures impacting manufacturing data, traceability, or decision support are quality issues. ### Why is CBER's oversight of biologics so strict? Biologics are often used in high-risk medical settings and are highly sensitive to process changes. CBER's strict oversight ensures product quality, sterility, and performance are maintained, mitigating risks to patients. ### Does CBER only review new biologic products? No, CBER oversees biologic products across their entire lifecycle. This includes initial review, facility inspections, manufacturing control evaluation, and ongoing postmarket safety monitoring and surveillance. ### What role does CBER play in emerging technologies like AI? CBER scrutinizes emerging technologies like AI when they impact product quality, patient safety, or regulated decision-making for biologics. It focuses on data integrity and the controls surrounding these advanced systems. ### What are CBER's strategic priorities? CBER prioritizes improving regulatory efficiency, supporting scientific innovation, strengthening international coordination, and maintaining a workforce capable of evaluating complex, modern biologic technologies. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Why IDS/IPS Agents Fail on Medical Devices Source: https://bluegoatcyber.com/blog/why-ids-ips-agents-dont-work-for-medical-devices # IDS/IPS Agents on Medical Devices: A 2026 Playbook for MedTech Leaders > **[DIRECT ANSWER]** Traditional IDS and IPS agents generally do not work on medical devices because constrained embedded systems and legacy Windows builds lack the CPU and memory to run them, and installing one can void FDA clearance, break vendor warranties, or crash the device mid-treatment. Effective alternatives include network-based IDS and IPS at the gateway, micro-segmentation with least-privilege access lists, clinical security gateways that validate DICOM and HL7 traffic, and passive asset discovery paired with SBOM-driven vulnerability prioritization instead of on-device scanning. When most industries think about intrusion detection (IDS) or intrusion prevention (IPS), they imagine installing agents directly on endpoints. But in the world of medical devices, that approach rarely works - and can even create risks for patient safety. Devices like infusion pumps, ventilators, imaging systems, and surgical robots don’t operate like corporate laptops or servers. They have strict performance constraints, regulatory requirements, and clinical safety considerations that make traditional endpoint security impractical. In this blog, we’ll explain why agents don’t fit medical devices, the strategies that work, and how these align with [FDA expectations for medical device cybersecurity](https://www.fda.gov/media/119933/download). ## Key Takeaways - Medical devices lack resources for agents. - Agents risk patient safety and void warranties. - Network-based IDS/IPS protects devices without agents. - Micro-segmentation isolates devices for security. - Clinical security gateways validate device traffic. - FDA guidance supports layered, risk-based controls. ## Why this matters The security of medical devices significantly impacts patient care delivery and patient safety outcomes. Deploying unsuitable agent-based security solutions can introduce critical vulnerabilities, degrade device performance, or even cause device failures, directly jeopardizing patient well-being. Furthermore, such actions can invalidate manufacturer warranties and compliance certifications, leading to costly regulatory penalties and operational disruptions for healthcare delivery organizations. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes a risk-based approach to medical device cybersecurity, advocating for controls that do not interfere with device function or patient safety. The guidance aligns with international standards such as IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR97, which call for appropriate, non-intrusive security measures tailored to the unique constraints of medical technology. Understanding these limitations and adopting alternative, agent-less security strategies is crucial for maintaining device functionality, ensuring patient safety, and achieving regulatory compliance in the medical device ecosystem. ## Why Agents Aren’t Feasible on Medical Devices Medical devices often run on constrained embedded operating systems (RTOS, embedded Linux) or legacy Windows builds. These systems are designed for reliability and performance, not for handling resource-heavy agents. Here’s why agents aren’t viable: - Resource constraints: CPU, memory, and storage are limited; an agent could cause performance degradation. - Regulatory and vendor support: Adding an agent may void FDA clearance or vendor warranties. - Patient safety risks: An agent crash or false positive could disrupt care delivery in real time. - Legacy designs: Many devices weren’t built with the ability to support third-party applications. For these reasons, installing IDS/IPS or EDR-style agents directly on medical devices is generally not an option. ## Practical Alternatives for Medical Devices Since on-device agents aren’t feasible, healthcare organizations and manufacturers rely on network- and system-level protections that work around device limitations. ### 1\. Network-Based IDS/IPS - Passive IDS sensors monitor traffic from devices without touching the device itself. - Inline IPS gateways enforce rules at the network edge, blocking malicious activity like command injection or ransomware traffic. - Works well for protecting infusion pumps, imaging modalities, and monitoring systems without altering their configuration. ### 2\. Micro-Segmentation and Allowlists - Devices are grouped into role-based VLANs (e.g., imaging, monitoring, therapy). - Least-privilege ACLs ensure devices only talk to PACS, EMR, or update servers. - Prevents lateral movement and blocks Internet exposure by default. ### 3\. Clinical Security Gateways and Proxies - Gateways sit between devices and hospital networks, providing: - Protocol validation (e.g., DICOM, HL7). - Malware filtering and virtual patching. - TLS termination and inspection when appropriate. ### 4\. Using Device-Native Capabilities - Secure logging: Forward syslog or export logs to SIEM if supported. - Signed updates and secure boot: Ensure authenticity of firmware and updates. - Audit trails: Use built-in logging to monitor clinical use and detect anomalies. ### 5\. Passive Asset Discovery + SBOM Use - Passive tools discover devices without active scanning. - [SBOMs (Software Bill of Materials)](/services) map known vulnerabilities to deployed assets. - Risk-prioritized controls (segmentation, IPS rules) are applied when patching isn’t possible. ### 6\. Network Access Control (NAC) - Enforces that only approved medical devices connect to clinical VLANs. - Rogue or noncompliant devices are quarantined automatically. ### 7\. Change Control and Safety Testing - Every segmentation or IPS rule change is validated in a clinical safety lab. - Ensures new rules don’t disrupt patient care or critical device functionality. ## When a Lightweight Agent Might Work In rare cases, newer Windows-based devices may support vendor-approved lightweight monitoring agents. Even then, these should be used for visibility only (e.g., log forwarding, asset inventory), not prevention or enforcement. Safety and vendor approval must always come first. ## Decision Guide for IDS/IPS in Medical Devices **Is the device vendor-supported for agents?** - No → Use network-based IDS/IPS + segmentation. - Yes (documented) → Consider visibility-only agents, with network IPS for enforcement. **Can the device tolerate inline inspection?** - Yes → Place inline IPS at gateways; latency-test and allowlist. - No/Unknown → Rely on passive IDS + ACLs/micro-segmentation. **Is patching unavailable?** - Apply virtual patching at IPS, restrict egress, monitor via passive IDS. ## Alignment with FDA Guidance The FDA emphasizes that cybersecurity is part of medical device safety throughout the Total Product Lifecycle (TPLC). While FDA does not require agents on devices, it does expect: - Risk-based controls (threat modeling, secure updates, validated logging). - Compensating controls when patching isn’t feasible (e.g., segmentation, IDS/IPS). - Postmarket monitoring via secure logs and network visibility. Healthcare providers and manufacturers can meet regulatory expectations while protecting patients by adopting layered network protections and using existing device features. ## Final Thoughts Traditional endpoint security agents don’t fit the medical device environment. Instead, manufacturers and healthcare providers must rely on network-based defenses, segmentation, and secure processes to detect and prevent intrusions without compromising patient safety. At Blue Goat Cyber, we help manufacturers and healthcare systems design practical, [FDA-aligned cybersecurity strategies](/services/fda-premarket-cybersecurity-services) that integrate IDS and IPS effectively - without introducing unnecessary risk. The goal is always the same: protect patients, maintain trust, and ensure safe, reliable care. ## Agent based and network based monitoring compared The argument against agents on medical devices is not ideological. It is that an agent changes the validated configuration of a regulated product. | Consideration | Endpoint agent on the device | Network based monitoring | | --- | --- | --- | | Effect on validated state | Changes the software configuration, which can trigger revalidation | None, the device is untouched | | Resource demand | Competes with real time clinical tasks on constrained hardware | None on the device | | Manufacturer support | Usually voids support or violates the terms of the service agreement | Compatible with almost every support agreement | | Visibility gained | Process, file, and memory level detail | Traffic patterns, protocol anomalies, and unexpected peers | | Update burden | Agent signatures need their own change control path | Updated outside the device entirely | | Failure mode | An agent fault can affect device behavior | A monitoring fault loses visibility, not therapy | | Where it fits | General purpose workstations and servers the manufacturer controls | Embedded, unpatchable, or clinically critical devices | The compromise most hospitals land on is network monitoring for the device fleet and agents only on the general purpose computers that support it. ## How Blue Goat approaches this The Blue Goat Cyber approach acknowledges that medical devices require security tailored to their unique operational and regulatory landscapes. We specialize in identifying security vulnerabilities without disrupting clinical workflows or device functionality. Our methodology includes thorough threat modeling, penetration testing (by OSCP and ex-military red team experts), and thorough risk assessments that consider the entire medical device ecosystem. We focus on network-level controls, secure configurations, and clinical security gateway strategies that protect devices without requiring burdensome on-device agents. For manufacturers, our team, including CISSP-certified professionals, assists with pre-market and post-market cybersecurity submissions, ensuring alignment with the FDA's rigorous expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our services: [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) ## FAQ ### Why can't I install IDS/IPS agents on medical devices? Medical devices have strict performance and reliability requirements. Traditional agents can consume too many resources (CPU, memory), disrupt device function, or invalidate the device's FDA clearance or vendor warranty, posing risks to patient safety. ### What are the alternatives to agents for medical device security? Effective alternatives include network-based intrusion detection/prevention systems, micro-segmentation, clinical security gateways, passive asset discovery, and using native device security features like secure boot and audit trails. ### How does this align with the FDA's cybersecurity guidance? The FDA's February 3, 2026 final guidance on premarket cybersecurity emphasizes risk-based controls and compensating controls for unpatchable vulnerabilities, such as network segmentation and IDS/IPS. It supports layered defenses that do not compromise device safety. ### Does the FDA mandate specific cybersecurity technologies for medical devices? No, the FDA does not mandate specific technologies. Instead, it expects manufacturers to implement risk-based cybersecurity controls throughout the Total Product Lifecycle (TPLC) to ensure device safety and effectiveness. This often requires adopting a combination of controls tailored to device specifics. ### Can lightweight agents ever be used on medical devices? In rare instances, newer Windows-based medical devices might support vendor-approved lightweight agents for visibility (e.g., logging, asset inventory). However, these should not be for prevention or enforcement, and patient safety and vendor approval remain paramount. ### What risks do agents pose to patient safety if installed on medical devices? An agent could cause performance degradation, system crashes, or false positives that disrupt device operation, potentially delaying or interfering with critical care delivery. This direct impact on device functionality creates unacceptable patient safety risks. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [QIH Medical Devices Explained](/blog/qih-medical-devices-explained) - [Why Is “Insecure” Used Instead](/blog) - [CVSS 3.1 vs 4.0 for Medical Devices](/blog/cvss-3-1-vs-4-0-medical-devices) - [Write Blocker: Forensic Use, Types](/blog/write-blocker-medical-device-cybersecurity) --- ## ISO 27001 & SOC 2 vs FDA Medical Device Rules Source: https://bluegoatcyber.com/blog/why-iso-27001-and-soc-2-are-not-enough-for-fda-medical-device-cybersecurity # Why ISO 27001 and SOC 2 Are Not Enough for FDA Medical Device Cybersecurity > **[DIRECT ANSWER]** ISO 27001 and SOC 2 certify how your organization manages information security. The FDA reviews whether a specific device is safe, so it asks for device-level artifacts those frameworks never produce: a system threat model, a machine-readable SBOM, security architecture views, verification records per control, and a postmarket vulnerability plan. Certification helps your process story, but it does not satisfy Section 524B. Here’s a pattern Blue Goat Cyber sees regularly: a medical device manufacturer arrives at premarket submission with an ISO 27001 certificate in hand, convinced their cybersecurity story is complete. Weeks later, a deficiency letter arrives. The FDA isn’t questioning their information security posture. It’s asking for a Secure Product Development Framework, a threat model tied to multi-patient harm scenarios, and a Software Bill of Materials. None of those exist in ISO 27001. This is one of the most predictable failure modes in the FDA submission process, and it stems from a structural mismatch that’s easy to miss until it’s costly. Based on Blue Goat Cyber’s experience across 510(k), De Novo, and PMA submissions, this gap between enterprise IT certification and FDA cybersecurity compliance isn’t a documentation formatting issue. It’s a fundamental difference in what problem each framework was built to solve. Understanding why standard IT security frameworks fall short for FDA medical devices is the first step toward building a submission that actually clears review. ## Key Takeaways - Enterprise IT security frameworks do not meet FDA device cybersecurity requirements. - FDA mandates device-specific cybersecurity evidence linked to patient safety. - Required documents include SPDF, threat models, and SBOMs. - AAMI TIR57 / ANSI/AAMI SW96:2023, IEC 62443-4-1, and UL 2900 are recognized by the FDA. - Misaligned frameworks cause submission delays and postmarket liabilities. - Cybersecurity for medical devices focuses on clinical harm, not just data. ## Why this matters The stakes are high: medical device manufacturers relying solely on enterprise IT security frameworks like ISO 27001 or SOC 2 face significant delays, deficiency letters, and potential recalls from the FDA. The FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026, emphasizes a distinct focus on **device-specific cybersecurity** directly linked to patient safety, clinical impact, and the entire device lifecycle. Unlike general IT security, which prioritizes data confidentiality, integrity, and availability, medical device cybersecurity centers on preventing clinical harm, ensuring device functionality, and protecting patient health. The guidance explicitly requires elements such as a Secure Product Development Framework (SPDF), detailed threat models that address multi-patient harm scenarios, and Software Bills of Materials (SBOMs) specific to the device architecture. Frameworks like AAMI TIR57 / ANSI/AAMI SW96:2023, IEC 62443-4-1, and UL 2900 are recognized by the FDA precisely because they address these device-specific requirements. Ignoring this distinction leads to submissions that fail to meet regulatory scrutiny, risking market access and incurring substantial financial and reputational costs. ## What ISO 27001 and SOC 2 Were Actually Built to Do ISO 27001 was designed to protect organizational information assets: servers, databases, customer data, and business processes. It gives organizations a structured Information Security Management System built around 93 controls, risk treatment plans, and annual certification audits. SOC 2 gives service organizations a way to demonstrate trustworthiness to enterprise clients through five trust service criteria, security, availability, confidentiality, processing integrity, and privacy. Both frameworks treat security as an organizational posture question. They ask: does this company manage risk responsibly? The FDA asks an entirely different question: does this specific device protect patients from harm caused by a cybersecurity failure? The unit of analysis is the device, not the organization. The risk frame is patient safety, not data confidentiality or business continuity. That distinction changes everything about what documentation is required. Holding an ISO 27001 certificate tells the FDA nothing about whether a device’s firmware handles authentication securely, whether the SBOM has been catalogued, or whether a vulnerability disclosure process exists for cleared products. The certificate proves the company has a well-managed information security program. It says nothing about the clinical risks embedded in the device itself. That’s the core limitation of ISO 27001 for FDA medical devices, and it cannot be papered over with addenda or mapping exercises. ## What the FDA’s Cybersecurity Submission Actually Requires Under section 524B of the FD&C Act, sponsors of 510(k), PMA, De Novo, and other premarket submissions for “cyber devices” must include documented evidence of secure-by-design architecture, lifecycle vulnerability management plans, and postmarket monitoring processes. The [FDA’s 2026 final guidance on premarket cybersecurity, _Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions_](https://www.fda.gov/media/119933/download ""), supersedes earlier versions and raises the evidentiary bar significantly, specifying approximately 12 standardized documents submitted through the eSTAR format. The specific documentation FDA reviewers look for includes a Security Product Development Framework integrated into the Quality Management System, a threat model addressing multi-patient harm scenarios and supply chain vulnerabilities, an SBOM covering all software components with version information and End of Support dates, and labeling disclosures about connectivity and device support lifetime. These are not checkbox items. FDA reviewers evaluate whether the threat model reflects the actual device architecture and whether mitigations trace back to identified risks. A detailed narrative without a traceability matrix fails to meet FDA standards, even if it covers the right topics. Every cybersecurity control must connect back to patient safety impact, a vulnerability that could cause an infusion pump to deliver the wrong dose is categorically different from a data breach risk. FDA submissions must reflect that distinction, with hazard analysis tied to clinical outcomes rather than generic security control language borrowed from enterprise frameworks. ## Why Standard IT Security Frameworks Fail for FDA Medical Devices ISO 27001 risk assessments evaluate threats to information assets. They don’t evaluate threats to a patient whose infusion pump communicates over an unencrypted channel. The FDA’s risk framework, aligned with ISO 14971, requires harm analysis tied to clinical outcomes. Enterprise frameworks have no equivalent construct, which means even a thorough ISO 27001 risk assessment produces documentation that FDA reviewers cannot use to evaluate patient safety risk. The lifecycle evidence problem is equally significant. FDA submissions require documented evidence across the entire device lifecycle, from initial design through postmarket surveillance. ISO 27001’s ISMS covers ongoing organizational operations, not the structured premarket-to-postmarket regulatory lifecycle evidence the FDA expects. SOC 2 reports are point-in-time attestations, not living development lifecycle records with traceability to design controls. Device-specific technical constraints make the mismatch even more pronounced. Real-time operation requirements, limited CPU and memory in embedded systems, legacy firmware without update mechanisms, and constrained connectivity patterns make many standard IT security controls technically unworkable on medical devices. Controls like real-time antivirus scanning, SIEM logging, and continuous patching assume abundant computing resources and flexible architectures, assumptions that don’t hold for a cardiac monitor running safety-critical firmware on a constrained embedded processor. An ISO 27001 control set designed for enterprise servers cannot be applied without substantial adaptation to that kind of environment. For software-based medical devices, the limitations of standard IT frameworks are equally acute. SaMD security requirements under FDA guidance demand software lifecycle documentation, including IEC 62304-aligned development processes, that neither ISO 27001 nor SOC 2 was structured to produce. The clinical context of software execution changes what “secure” means in ways enterprise frameworks simply don’t account for. ## The Specialized Frameworks the FDA Actually Recognizes AAMI TIR57 provides principles for medical device security risk management that directly align with ISO 14971. It bridges clinical safety risk management with cybersecurity risk analysis in a way ISO 27001 cannot. The FDA recognizes AAMI TIR57 as an accepted approach to security risk management in premarket submissions, and the 2026 final guidance names it as a core standard alongside ANSI/AAMI SW96. Manufacturers should build their security risk management processes on this foundation, not on enterprise risk frameworks that lack any clinical harm analysis component. IEC 62443-4-1 defines a secure product development lifecycle for industrial and embedded systems. Its focus on security requirements for product developers maps directly to what the FDA expects in an SPDF. The standard addresses security requirements definition, secure design, secure implementation, verification and validation, defect management, patch management, and end-of-life, a scope that aligns tightly with FDA premarket expectations. For health software, IEC 81001-5-1 builds on IEC 62443-4-1 with lifecycle requirements tailored to clinical context. Together, these two standards give manufacturers a defensible, internationally recognized basis for their development process documentation. UL 2900-1 and UL 2900-2-1 establish testable cybersecurity requirements for network-connectable products, including medical devices. UL 2900-2-1 adds healthcare-specific requirements covering PHI and PII protection, threat modeling by intended use, defense-in-depth architecture, and incident response for healthcare contexts. The FDA recognized both standards in 2017 and 2018 as consensus standards, meaning manufacturers can reference UL 2900 compliance directly in premarket submissions as objective evidence of cybersecurity risk management. That kind of testable, device-specific evidence is something ISO 27001 was never designed to provide. For details on the FDA recognition of these consensus standards, see the FDA standards database entries for [UL 2900‑1](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=42309) and UL 2900‑2‑1. ## Real Consequences of Using the Wrong Framework When a submission arrives with ISO 27001 documentation as the primary cybersecurity basis, FDA reviewers issue Additional Information requests. These deficiency letters require manufacturers to produce the SPDF, threat model, and risk assessment evidence that should have been in the original package. The most commonly cited deficiencies involve incomplete threat modeling, absent traceability between identified risks and mitigations, missing cybersecurity views of device architecture, and weak postmarket vulnerability management plans. Each round of responses adds months to the review timeline, delays that carry real cost in delayed market entry and diverted engineering resources. Device recalls demonstrate what happens when device-specific cybersecurity is treated as an afterthought. The [2025 recall of the Abiomed Automated Impella Controller](https://www.aha.org/news/headline/2025-10-13-most-serious-fda-recall-issued-abiomed-heart-pump-controllers "") was triggered by network and physical access vulnerabilities in the operating system, creating risk of device control loss in a cardiac support device. The FDA classified it as the most serious recall category, indicating potential for serious injury or death. Abbott pacemaker vulnerabilities led to recalls involving hundreds of thousands of units. These cases reflect what happens when connected devices ship without rigorous, device-specific security architecture, not inadequate organizational security programs. Cleared devices with weak security become compounding postmarket liabilities. FDA’s postmarket guidance expects ongoing vulnerability monitoring, patch procedures, and exploit response plans, all of which require device-specific infrastructure that enterprise frameworks were never designed to create. For additional context on what the FDA expects for postmarket cybersecurity activities, see the agency’s [cybersecurity FAQs for medical devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity-medical-devices-frequently-asked-questions-faqs). A company that relied on ISO 27001 documentation to support a cleared submission may find itself structurally unprepared for postmarket surveillance obligations, creating ongoing regulatory exposure long after the device reaches market. ## Building a Submission-Ready Security Posture from the Right Foundation The practical path forward starts with choosing the right framework stack rather than retrofitting enterprise controls. Build on AAMI TIR57 / ANSI/AAMI SW96:2023 for security risk management, IEC 62443-4-1 for the development process and SPDF foundation, and UL 2900 for testable security requirements. Layer ISO 14971-aligned hazard analysis on top to connect cybersecurity risks to clinical harm. These frameworks were designed for the problem the FDA is trying to solve. Mapping ISO 27001 controls onto this structure produces documentation with a structural gap, the clinical harm linkage that FDA reviewers look for simply isn’t there. For the full list of the FDA’s expectations in premarket submissions, consult the agency’s final premarket cybersecurity guidance. Complete submissions require a full [SPDF cybersecurity documentation](/blog/spdf-cybersecurity-documentation-what-fda-reviewers-expect) aligned with FDA expectations, a threat model built from the device’s actual architecture using a recognized methodology like STRIDE, an SBOM cataloging every software component with version and support lifecycle data, penetration testing and vulnerability scanning results with documented mitigation traceability, and a vulnerability management plan covering both premarket and postmarket phases. Each element must trace back to patient safety mitigations. Based on current reviewer patterns, incomplete SBOMs, particularly those missing End of Support dates, and unresolved penetration testing findings without documented acceptance criteria are among the most frequently flagged issues. This is the documentation stack Blue Goat Cyber builds for medical device manufacturers preparing premarket submissions. The team’s experience spans 510(k), De Novo, and PMA pathways, with deep familiarity with what FDA reviewers scrutinize most closely at each stage. For manufacturers who need to get it right the first time, working with a team that understands FDA device cybersecurity requirements, such as described in [Securing Medical Devices: The Key to Faster FDA Clearance and Investor Confidence](/blog/securing-medical-devices-the-key-to-faster-fda-approval-and-investor-confidence), is the clearest path to clearance. ## The Right Framework from the Start ISO 27001 and SOC 2 are rigorous, valuable frameworks for what they were designed to do. They were not designed for FDA medical device cybersecurity submissions. Understanding why standard IT security frameworks fail for FDA medical devices isn’t a criticism of those frameworks, it’s a recognition that regulated devices require a different evidentiary foundation entirely. The FDA is looking for SPDF documentation, AAMI TIR57 / ANSI/AAMI SW96:2023-aligned risk management, threat models tied to clinical harm, SBOMs, and testable security evidence from frameworks like UL 2900. Using enterprise IT frameworks as a substitute creates gaps that generate deficiency letters, extend timelines, and in the worst cases, contribute to device vulnerabilities that reach patients. The fix is to build on the right foundation before the submission package is assembled, and ideally before design freeze. Every month spent correcting framework mismatches during submission review is a month that could have been spent getting the device to patients who need it. Blue Goat Cyber works with medical device manufacturers at every stage of the FDA submission lifecycle, from early design consulting through postmarket compliance. If your next submission is approaching and your cybersecurity documentation isn’t built on the frameworks FDA reviewers actually expect, [navigating the cybersecurity landscape for MedTech innovators](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) with experienced advisors can close the gap. [Contact our team for a consultation](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session ""). We’ll identify exactly what’s missing and build the complete package to close the gap. ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers navigate the complex landscape of FDA cybersecurity compliance. Our tailored approach focuses on building a submission-ready security posture from the ground up, prioritizing patient safety and clinical impact. We go beyond general IT certifications, developing device-specific documentation like SPDF, detailed threat models, and accurate SBOMs aligned with FDA expectations. Our team, comprised of experts with certifications like CISSP and OSCP, and ex-military red team experience, understands the specialized requirements for medical devices, including constrained environments and unique risk profiles. We prepare all necessary premarket documentation. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Partner with us to build an enduring cybersecurity framework tailored to medical device regulations. Learn more about our services at [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### Why are ISO 27001 and SOC 2 insufficient for FDA medical device submissions? ISO 27001 and SOC 2 focus on organizational information security and data protection. The FDA requires device-specific cybersecurity evidence, including secure design, lifecycle management, and risk analysis tied directly to patient safety and clinical harm scenarios, which these frameworks do not cover. ### What specific documents does the FDA require that ISO 27001 does not provide? The FDA requires a Secure Product Development Framework (SPDF), threat models addressing multi-patient harm, a Software Bill of Materials (SBOM) with version and end-of-support data, and traceable cybersecurity controls directly linked to clinical outcomes. These are beyond the scope of ISO 27001. ### What frameworks does the FDA recognize for medical device cybersecurity? The FDA recognizes AAMI TIR57 / ANSI/AAMI SW96:2023 for security risk management, IEC 62443-4-1 (and IEC 81001-5-1 for health software) for secure product development, and UL 2900 series for testable cybersecurity requirements. These standards align with the agency's focus on device-specific protections. ### How does the FDA's cybersecurity focus differ from enterprise information security? The FDA's focus is on protecting patients from harm caused by a cybersecurity failure in the medical device itself. Enterprise information security focuses on protecting organizational data and IT assets. This difference in risk context (patient harm vs. Data confidentiality) dictates distinct documentation and analysis requirements. ### What are the consequences of using the wrong cybersecurity framework for an FDA submission? Using inappropriate frameworks leads to deficiency letters, significant delays in market entry, and increased costs due to additional information requests. It can also result in postmarket liabilities, including recalls, if devices have inadequate security for patient-facing scenarios. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [AAMI SW96 vs TIR57: Did SW96 Replace It?](/blog/did-aami-sw96-replace-tir57-fda-2026) - [Why Is “Insecure” Used Instead](/blog) - [De-Identification vs Anonymization](/blog/de-identification-vs-anonymization-medical-devices-hipaa-gdpr) - [Reports](/blog/fda-section-524b-subsections-explained) --- ## Why Medical Device Cybersecurity Is Not Enterprise IT Source: https://bluegoatcyber.com/blog/why-medical-device-cybersecurity-is-nothing-like-enterprise-it # Why Medical Device Cybersecurity Is Nothing Like Enterprise IT > **[DIRECT ANSWER]** Enterprise IT optimizes for confidentiality and patches on a monthly cadence. A medical device cannot reboot mid-therapy, may run a fifteen-year-old embedded OS, and needs a regulatory pathway before a patch can ship. Risk is measured in patient harm rather than data loss, controls must be verified as design outputs, and every change carries change-control obligations. Applying an enterprise playbook unchanged is how device programs fail review. Picture a seasoned enterprise CISO handed responsibility for a fleet of connected infusion pumps and networked imaging systems. They reach for familiar tools: EDR agents, patch managers, a NIST-aligned risk framework, and an annual compliance audit cycle. Within weeks, the tools don’t install. The patches won’t deploy without clinical validation cycles that take months. The FDA documentation requirements look nothing like any compliance program they’ve run before. The playbook doesn’t work here. Medical device security versus enterprise security isn’t just a difference in tools or frameworks, it’s a difference in fundamental operating rules, risk consequences, and regulatory obligations. Both disciplines share some vocabulary: vulnerabilities, threat models, access controls. But applying enterprise methodology to medical devices doesn’t just fall short; it creates real gaps in safety, documentation, and regulatory compliance. This is precisely why firms like Blue Goat Cyber exist, built exclusively around medical device cybersecurity, because general IT security expertise doesn’t transfer cleanly into this space. Read more on the topic of [Traditional vs Medical Device Cybersecurity](/blog/traditional-cybersecurity-vs-medical-device-cybersecurity) to understand why a different playbook is required. The sections below break down the principal technical, regulatory, and operational differences between medical device security and enterprise security so security leaders can make better decisions about how they approach device security, and understand what kind of expertise that actually requires. ## Key Takeaways - Patient safety reframes risk; availability/integrity are critical. - FDA regulations like premarket submissions are mandatory for market access. - Medical devices have unique OS, hardware, and patching constraints. - Long device lifecycles complicate vulnerability management. - Enterprise IT tools are inadequate for medical device security. - Specialized expertise is essential for regulatory compliance. ## Why this matters The FDA's *Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions* (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers now apply this guidance to why medical device cybersecurity is nothing like enterprise it the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023. Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap. ## Patient Safety Changes the Entire Risk Calculus in Medical Device Security vs Enterprise Security Enterprise security failures cost money, reputation, and data. Medical device security failures can cost lives. A compromised infusion pump doesn’t just expose records; it can alter drug dosing. A ransomware infection that locks imaging systems delays diagnosis for patients who can’t afford that delay. These aren’t theoretical edge cases. They’re the reason cybersecurity is treated as a safety function in medical devices, not just an IT function. For a deeper look at how safety and security interact in medical devices, see [Medical Device Safety vs Security Risks](/blog/medical-device-safety-vs-security-risks). This reframes availability as a clinical obligation. In enterprise IT, availability is an SLA concern. On a ventilator or cardiac monitor, downtime is a patient harm event. The standard CIA triad still applies, but the weighting shifts sharply: availability and integrity dominate because they map directly to patient outcomes, while confidentiality takes a secondary role to keeping devices operational and accurate. The FDA ties cybersecurity explicitly to device safety and effectiveness under the FD&C Act, not to data protection alone. Every security decision, authentication tradeoffs, update timing, network segmentation strategy, gets evaluated against potential clinical impact. That constraint doesn’t exist anywhere in enterprise security architecture, and it changes nearly everything downstream. ## FDA Regulatory Obligations That Enterprise Compliance Doesn’t Touch Enterprise IT frameworks like NIST CSF and ISO 27001 are advisory. They represent best practices organizations choose to adopt for certification or operational maturity. FDA cybersecurity requirements for cyber devices are binding for market access. Without compliant documentation, a device doesn’t reach patients. Premarket submissions, whether 510(k), PMA, or De Novo, must include threat models, penetration testing evidence, vulnerability assessments, a Cybersecurity Management Plan, and a Software Bill of Materials. The SBOM requirement stands out: it must enumerate every software component in the device, commercial, open-source, and off-the-shelf, with version and supplier metadata for vulnerability tracking. Enterprise IT has no equivalent hard requirement tied to market entry. The [Feb 2026 updated FDA guidance](https://www.fda.gov/media/119933/download "") expands this scope further, covering servers, cloud infrastructure, and third-party integrations that affect patient safety, while requiring standardized documentation sets submitted through eSTAR. Postmarket obligations are equally demanding. Manufacturers must maintain continuous vulnerability monitoring, operate coordinated vulnerability disclosure programs, and issue patches for critical vulnerabilities within 60 days. The FDA requires cybersecurity testing and reevaluation every six months until end-of-support. Compare that to the annual audit cycles of SOC 2 or ISO 27001, which are certification-oriented and not tied to patient safety obligations. EU MDR imposes parallel requirements under Annex I GSPR, creating a second compliance layer for manufacturers seeking CE marking. None of this maps to anything enterprise security teams typically operate. ## Hardware and OS Constraints: Where Device Security vs Enterprise Security Diverges Most Sharply Most enterprise endpoint security tools make three core assumptions: a general-purpose OS, available compute resources, and the ability to install agents. Medical devices invalidate all three. They run lightweight real-time embedded operating systems or proprietary firmware, prioritize stability over updates, and carry MCUs with limited CPU headroom, minimal memory, and, in implantable or portable devices, strict battery constraints. There’s no standard API surface for agents. There’s no supported patch channel. Active monitoring processes would compete for resources the device needs for clinical function. ### Unpatched Vulnerabilities and Legacy Exposure Standard network inventory scanners miss devices running proprietary operating systems entirely. According to Claroty’s 2023 research, 53% of networked medical devices carry known unpatched vulnerabilities precisely because standard patch management can’t reach them, and 60% of hospital-connected devices are end-of-life and unpatchable by any conventional method. For enterprise security teams trained on active endpoint management, passive network-based monitoring is often the only viable detection posture, and that’s a fundamentally different security model. ### Cryptographic Constraints in Embedded Devices Cryptography faces the same resource limitations. Enterprise endpoints support full PKI, large key sizes, and frequent certificate rotations. Medical devices with low-power MCUs and battery-dependent designs need lighter approaches: AES symmetric encryption, elliptic curve cryptography for its efficiency at smaller key sizes, hardware security modules to offload crypto from the main processor, and Cryptographic Key Management Services to enforce policy across software components. Key management must be designed into device architecture from the start. The FDA requires manufacturers to justify cryptographic tradeoffs in submissions, which means ad hoc retrofits don’t satisfy regulatory scrutiny even if they work technically. Many embedded systems constraints are also documented in clinical- and engineering-focused studies of [embedded device security challenges](https://pmc.ncbi.nlm.nih.gov/articles/PMC4156282/). ## Lifecycle Management and the Patching Trap Enterprise IT hardware refreshes on 3, 5 year cycles. Software patches deploy quarterly or monthly. Medical devices run for 10, 20 years on the same firmware, sometimes longer. That gap alone creates a structural problem with no clean enterprise analog. Patching a medical device isn’t like pushing a Windows update. Every patch requires engineering analysis, bench testing, clinical validation, and in many cases, FDA notification or recertification, depending on the change’s scope. By the time a vulnerability patch clears that process, months have passed. In enterprise IT, that lag is a risk management failure. In medical devices, it’s the expected operating condition, and security strategy has to account for it from the beginning. Practical approaches to medical device patch management emphasize compensating controls, staged validation, and coordinated disclosure to minimize clinical disruption. According to the Cynerio 2022 State of IoMT Cybersecurity Report, 73% of hospital-connected devices are classified as legacy systems with limited or no vendor support for security updates. Enterprise security teams often treat a legacy device as a manageable edge case. In healthcare environments, it’s the majority of the fleet. Securing legacy devices requires network segmentation to limit exposure, compensating controls at the network layer, and postmarket monitoring programs built around the reality that endpoint-centric tools won’t reach these devices. Blue Goat Cyber’s legacy device security work addresses exactly this scenario for cleared devices, applying controls that don’t require firmware access or disrupt clinical operation. ## Why Generalist Firms Create Risk: Medical Device Security vs Enterprise Security Expertise Most enterprise cybersecurity firms know how to secure infrastructure, applications, and endpoints. Very few have navigated an FDA premarket submission, structured an SBOM to FDA standards, or run penetration testing against embedded device firmware. These are specialized skills that don’t develop from general IT security work. A generalist firm applying enterprise methodology to medical device security doesn’t merely fall short, it produces documentation gaps, misaligned risk models, and regulatory deficiencies that delay or block clearance. FDA cybersecurity deficiencies are among the most common reasons 510(k) submissions stall. The firms that consistently avoid them are those who work exclusively in this space and understand where reviewers look, what documentation needs to demonstrate, and how to structure submissions that don’t invite additional information requests. Blue Goat Cyber is built around exactly this model. The firm works exclusively with medical device manufacturers and MedTech companies, navigating FDA cybersecurity requirements, from SPDF development and threat modeling through penetration testing and eSTAR-ready submission documentation. The team has handled hundreds of FDA submissions, which means they recognize deficiency patterns before documentation is filed, not after a rejection lands. Their full-lifecycle approach integrates security at design, carries it through premarket documentation, tests it against FDA expectations, and maintains it postmarket through ongoing vulnerability monitoring and patching programs. For additional background on premarket considerations and developer-focused guidance, see [Medical Device Cybersecurity Insights](/blog/cracking-the-code-insider-cybersecurity-insights-for-medical-device-premarket-success). Organizations that recognize the distinction between medical device security and enterprise IT security need a partner who has operated within that difference for years. Learning on the engagement, in a domain where documentation errors cost months and security failures cost lives, isn’t an acceptable option. ## The Distinction That Matters in Medical Device Security vs Enterprise Security Patient safety stakes, FDA premarket and postmarket obligations, hardware and OS constraints, and lifecycle complexity aren’t variations on enterprise IT security. They’re a separate discipline with its own frameworks, standards, tooling, and expertise requirements. The tools and processes that protect enterprise environments don’t map onto medical devices without significant adaptation, and in many cases they fail entirely. Whether you’re a CISO at a health system, a regulatory affairs lead at a device manufacturer, or a VP of IT at a MedTech company, understanding the difference between medical device security and enterprise security is the first step to making better decisions. The second step is building a program, or finding a partner, with the right kind of expertise for this specific domain. If you recognize the gap and need a partner who works exclusively in medical device cybersecurity, reach out to Blue Goat Cyber. Medical device security demands specialized expertise, not an enterprise security playbook with a healthcare header on it. ## How Blue Goat approaches this Blue Goat Cyber's approach to medical device cybersecurity recognizes the unique landscape of patient safety, regulatory mandates, and technical limitations. Our methodology is purpose-built for medical devices, avoiding the pitfalls of generic enterprise IT security. We prioritize practical, implementable security measures that align with the specific operational realities and long lifecycles of medical technology. Our team comprises industry experts with credentials such as CISSP and OSCP, including former military red team specialists, who bring an adversarial but compliance-focused perspective to device security. We provide tailored services from threat modeling to FDA premarket submissions. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized approach to [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services). ## FAQ ### Why is medical device cybersecurity different from enterprise IT security? Medical device cybersecurity is distinct due to direct patient safety implications, stringent FDA regulatory mandates, and inherent technical limitations of medical device hardware and software platforms. These factors create a unique risk landscape and compliance burden not present in traditional enterprise IT. ### Does the FDA regulate medical device cybersecurity? Yes, the FDA heavily regulates medical device cybersecurity, treating it as a critical component of device safety and effectiveness. Manufacturers must meet premarket submission requirements, including threat models and SBOMs, and postmarket obligations like continuous vulnerability monitoring. ### How do medical device hardware limitations affect cybersecurity? Medical devices often run on resource-constrained embedded systems with proprietary OS or real-time operating systems, limited compute power, and strict power budgets. These limitations restrict the use of standard enterprise security agents, complex cryptography, and frequent patching, demanding specialized security approaches. ### What is an SBOM in the context of medical devices? An SBOM (Software Bill of Materials) for medical devices is a detailed list of all software components, commercial and open-source, used in a device, including versions and suppliers. The FDA requires this to enable manufacturers and users to track and manage vulnerabilities effectively throughout the device lifecycle. ### Can general IT security teams secure medical devices? General IT security teams typically lack the specialized expertise for medical devices, which includes navigating FDA regulatory requirements, understanding embedded system constraints, and addressing patient safety-driven risk models. Applying enterprise methodologies often leads to compliance gaps and ineffective security for medical devices. ### What are the postmarket cybersecurity requirements for medical devices? Postmarket requirements include continuous vulnerability monitoring, managing coordinated vulnerability disclosure programs, and issuing timely patches for critical vulnerabilities. The FDA requires periodic cybersecurity testing and reevaluation for the device's entire lifecycle. **Related:** [The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks](/blog/the-rising-tide-of-cyber-threats-in-medical-devices-understanding-the-risks) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Windows LAPS for Medical Devices Source: https://bluegoatcyber.com/blog/windows-laps-for-medical-devices-manage-local-admin-passwords-safely-not-gpp # Windows LAPS for Medical Devices: Manage Local Admin Passwords Safely (Not GPP) > **[DIRECT ANSWER]** Windows LAPS is Microsoft's tool for giving each Windows-based medical device a unique, automatically rotating local administrator password instead of the shared password many teams distribute through Group Policy Preferences, a method with a well-documented history of exposing stored credentials to attackers. LAPS backs passwords up to Active Directory or Entra ID, restricts who can retrieve them, and logs access for audit evidence. Devices that cannot be domain-joined still need a controlled break-glass process, rotation cadence, and access logging. ## Key Takeaways - Avoid distributing local admin passwords via GPO Preferences. - Use Windows LAPS for unique, rotating local admin passwords. - Control and audit who can retrieve local admin passwords. - Address both domain-joined and non-domain-joined systems. - Factor in serviceability and customer network constraints. - Generate audit evidence for premarket/postmarket needs. ## Why this matters Managing local administrator passwords safely on medical devices is more critical than ever, directly impacting patient safety, data integrity, and operational continuity. The widespread reuse of default or easily discoverable passwords across a fleet of devices creates a single point of failure, making an organization vulnerable to broad cyberattacks. Such vulnerabilities can lead to unauthorized access, data breaches, and disruption of device functionality, escalating risks for clinical operations. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes the critical need for manufacturers to implement processes to manage and protect credentials, specifically calling out the importance of unique, difficult-to-guess passwords and mechanisms for their secure storage and rotation. Effective credential management, like that offered by Windows LAPS, aligns with the security principles outlined in standards such as IEC 80001-2-2, ISO/IEC 27001, and AAMI TIR57 / ANSI/AAMI SW96:2023, all of which prioritize secure access controls and system hardening to mitigate cybersecurity risks in healthcare environments. ## Windows LAPS for Medical Devices: The Safe Way to Manage Local Admin Passwords (Not “Set It via GPO”) If your medical device ecosystem includes Windows-device-side gateways, imaging workstations, lab PCs, service laptops, kiosk-mode systems, or embedded Windows variants-you’ve probably run into the same question: **How do we manage local administrator passwords safely at scale?** Many teams still stumble into the old idea of “just set the local admin password with a Group Policy (GPO).” It sounds simple. In practice, it can create the exact problem attackers love: the same privileged password spread across many endpoints. ![Windows LAPS for Medical Devices: Manage Local Admin Passwords Safely (Not GPP)](/imported-images/389a44bce0d6e573.png) This post explains what to do instead-using **Windows LAPS**-and how to think about it in a **medical device cybersecurity** context where lifecycle, serviceability, and auditability matter. Quick takeaways - **Don’t distribute local admin passwords via GPO Preferences.** It’s risky and widely discouraged. - **Use Windows LAPS** to generate _unique_, rotating local admin passwords per device and control who can retrieve them. - **MedTech reality:** not every system can be domain-joined, so you need a “Plan B” that’s still controlled and auditable. ## Why “setting local admin passwords via GPO” is a bad idea There are two core issues with “push a local admin password everywhere” approaches: ### 1) Password reuse becomes lateral movement fuel If multiple endpoints share the same local admin password, one compromise can cascade into many. In healthcare environments-where devices and workstations often share network space, this is exactly how small footholds become big incidents. ### 2) GPO Preferences password storage has an ugly history Historically, Group Policy Preferences (GPP) could embed credentials in ways that were recoverable by attackers. Even if your environment has been “patched,” the lesson remains: **don’t build your privileged access model on password distribution mechanisms that weren’t designed for strong credential protection.** **Better approach:** don’t distribute a single password. Instead, give each device a unique password and rotate it automatically. ## What is Windows LAPS? **Windows LAPS (Local Administrator Password Solution)** is Microsoft’s modern solution for managing local administrator passwords at scale. In plain English, Windows LAPS: - sets a unique local admin password per device - automatically rotates the password on a schedule (or on demand) - backs up the password to a protected directory target (commonly Active Directory or [Microsoft Entra ID](https://www.microsoft.com/en-us/security/business/identity-access/microsoft-entra-id)) - lets you control who can retrieve the password and logs/audits access For medical device companies, this is the difference between “we hope our local admin passwords are under control” and “we can prove they’re under control.” ## Which LAPS option fits your MedTech environment? Most medical device ecosystems fall into one of these buckets: ### A) Domain-joined / AD-managed environments If your device-side Windows systems are domain-joined (common for internal labs, manufacturing, corporate environments, or some customer deployments), Windows LAPS can back up passwords to [Active Directory](/blog) and enforce rotation with policy. ### B) Cloud-managed (Entra ID / Intune-managed) environments If your endpoints are Entra ID-joined and managed through Intune, Windows LAPS can be configured via Intune policy and store passwords in Entra ID for authorized retrieval. ### C) Not domain-joined (very common in fielded medical device deployments) Many fielded systems can’t be reliably domain-joined due to hospital IT constraints, offline operation, or product architecture. In these cases, you still need a secure approach: - avoid shared passwords - use a controlled “break-glass” process - store credentials in an approved vault - rotate on a defined cadence and after service events - log who accessed what and why This isn’t as elegant as LAPS-but it’s far better than password reuse or ad hoc spreadsheets. ## How to implement Windows LAPS (high-level, practical) This is the “what to do” checklist without turning your blog into an admin manual. ### Step 1: Decide which local admin account you’ll manage - Use a dedicated managed local admin account (preferred), or - Manage the built-in Administrator (only if your environment requires it and you can control it tightly) ### Step 2: Set a rotation policy you can defend - Choose a rotation interval that fits operational reality (common ranges: weekly to monthly) - Rotate **immediately after** a password is retrieved for service access (strongly recommended) ### Step 3: Pick the backup target (AD vs Entra ID) - **AD DS** if you’re domain-joined and on-prem directory is the control plane - **Entra ID** if your endpoints are cloud-joined and managed via Intune ### Step 4: Lock down retrieval permissions (this is where teams win or lose) - Limit retrieval to a small, named group (not “everyone in IT”) - Require MFA for admins - Use role-based access and ticket-based processes (where possible) - Make retrieval auditable and reviewed ### Step 5: Operationalize it - Create a short runbook: “How to retrieve a password,” “When to rotate,” “What to log” - Test the workflow with the teams who actually service devices - Include it in onboarding for support and field service ## Medical device cybersecurity considerations (the stuff generic IT posts miss) ### 1) Serviceability is a real constraint-design for it Medical devices need servicing. The goal isn’t “no one ever uses local admin.” The goal is **controlled use**: least privilege, traceability, and fast recovery. ### 2) Your ecosystem likely includes customer-managed networks When your device sits inside a hospital network, you can’t assume perfect segmentation or perfect admin hygiene around it. Password reuse and weak privileged access controls become especially risky. ### 3) Evidence matters (premarket/postmarket) If you can show that local admin passwords are unique, rotated, and access-controlled, and you can produce audit evidence-you’re in a much stronger position than “we set it once and hope it stayed secret.” ### 4) Platform choice sets the baseline Privileged access management looks very different on Windows IoT Enterprise LTSC than on a hardened embedded Linux build. See our [Linux vs. Windows security comparison for medical device OS selection](/blog/linux-vs-windows-a-security-comparison) for how the two platforms differ on attack surface, update architecture, and support windows. ## Comparison table: GPP vs Windows LAPS vs Vaulted Break-Glass | Approach | What it is | Pros | Cons | Best for | | --- | --- | --- | --- | --- | | **GPO “set local admin password” (GPP-style)** | Distribute/set a password via policy | Easy to deploy (on paper) | Encourages password reuse; weak credential distribution patterns; hard to defend | Honestly: avoid | | **Windows LAPS (AD DS)** | Unique, rotated password per device backed up to AD | Strong control, scalable, auditable | Requires domain join + directory configuration | Enterprise / lab / internal fleets | | **Windows LAPS (Entra ID / Intune)** | Unique, rotated password per device managed via Intune | Cloud-friendly, scalable, good admin UX | Requires cloud-managed endpoints | Modern managed fleets | | **Vaulted “break-glass” (non-domain)** | Password stored in approved vault + strict access workflow | Works when you can’t domain-join | More process-heavy; must be disciplined | Fielded devices with constraints | > **Need help?** Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our [medical device cybersecurity services](/services) or [book a discovery call](/contact). ## How Blue Goat approaches this Blue Goat Cyber helps medical device manufacturers and healthcare organizations implement secure privileged access management for Windows-based medical devices. Our approach addresses the unique operational constraints of healthcare environments while meeting regulatory demands. We provide practical guidance for deploying Windows LAPS, considering factors such as devices that cannot be domain-joined, serviceability requirements, and existing network architectures. Our methodology, informed by our team's experience as CISSP, OSCP, and ex-military red team members, focuses on enabling maintainable security. We work with clients to design and implement LAPS solutions that improve overall security posture and generate auditable evidence for regulatory submissions. Our services include designing LAPS deployments, supporting custom integration for non-standard environments, and helping develop supporting documentation for regulatory submissions. We ensure your LAPS implementation aligns with established security frameworks while minimizing disruption to clinical workflows. Learn more about our specialized support for post-market needs at [https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services](https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services). ## FAQ ### What is Windows LAPS? Windows LAPS is Microsoft’s solution for generating unique local admin passwords per device, rotating them automatically, and controlling who can retrieve them. ### Can we use LAPS on medical devices? Often, yes-especially for Windows-based systems in your ecosystem (gateways, workstations, service laptops). Whether it fits depends on your deployment model, customer constraints, and device architecture. ### What if our device can’t be domain-joined? Use a controlled alternative: vault the credential, restrict access, require approvals/MFA, rotate regularly and after use, and keep an audit trail. ### How often should we rotate local admin passwords? Choose an interval you can operationalize (weekly/monthly are common), and rotate immediately after any retrieval used for service access. ### Does LAPS help with ransomware and lateral movement? Yes. Unique local admin passwords reduce the “one password unlocks everything” problem that attackers exploit for lateral movement. ### What’s the most common mistake teams make? They implement password rotation but leave retrieval permissions too broad. Control who can retrieve passwords, and treat retrieval like a privileged action that should be reviewed. ## Need help hardening privileged access in your medical device ecosystem? Blue Goat Cyber helps medical device teams reduce real-world risk in Windows-based ecosystems, including identity hardening, service access workflows, and postmarket-ready evidence. - [Medical Device Penetration Testing Services](/services/medical-device-penetration-testing) - [FDA Premarket Cybersecurity Services](/services/fda-premarket-cybersecurity-services) - [FDA Postmarket Cybersecurity Services](/services/fda-postmarket-cybersecurity-services) - [Contact Blue Goat Cyber](/contact) YouTube ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Medical Device Wi-Fi Security Guide | Blue Goat Cyber Source: https://bluegoatcyber.com/blog/wpa2-4-way-handshake-vulnerabilities-what-medical-device-teams-need-to-know-about-wi-fi-risk # Medical Device Wi-Fi Security: WPA2, WPA3, and the Handshake > **[DIRECT ANSWER]** Medical device Wi-Fi security depends on the WPA2/WPA3 handshake that derives session keys, the authentication model chosen (802.1X/EAP-TLS versus a shared passphrase), and how the device behaves once it joins an untrusted hospital or home network. The main risks are weak pre-shared keys, KRACK-style key reinstallation flaws, and manufacturers assuming clinical networks are safe. Mitigations include supporting WPA3-SAE or WPA2/WPA3 transition mode, preferring EAP-TLS with certificate rotation for enterprise deployments, enabling Protected Management Frames, and documenting wireless trust boundaries for the FDA. _Reviewed September 17, 2026_ A hospital biomedical engineering team cannot assume the Wi-Fi network their infusion pumps, patient monitors, or imaging gateways join is trustworthy. Guest networks, misconfigured VLANs, legacy access points, and shared passphrases are common in clinical environments, and a device that treats "connected" as "safe" inherits every weakness of that network. When a connected device's therapy delivery, alarms, or telemetry depend on Wi-Fi, a handshake flaw or a weak authentication choice is not a theoretical IT problem, it is a patient safety and regulatory problem. Manufacturers that get this wrong face rework late in development, FDA additional information requests, and postmarket incident response that could have been avoided with better upfront architecture decisions and documented evidence. ## Key Takeaways - Medical device Wi-Fi security starts with the WPA2/WPA3 4-way handshake, which derives session keys but does not make the local network trustworthy. - KRACK-style key reinstallation flaws and weak pre-shared keys are the two most common WPA2 failure modes in fielded devices. - Enterprise authentication (802.1X with EAP-TLS) is stronger than PSK for hospital deployments because it avoids shared secrets and supports per-device certificates. - Certificate provisioning and rotation must be planned as a lifecycle process, not a one-time manufacturing step. - Manufacturers should never assume hospital networks are segmented, patched, or monitored; design as if the Wi-Fi network is hostile. - The FDA expects wireless interfaces, trust boundaries, and mitigations documented in the premarket submission, not just implemented in firmware. ## Why This Matters Wi-Fi is the default connectivity path for infusion pumps, patient monitors, imaging workstations, remote monitoring hubs, and home-use devices. Unlike a wired connection, Wi-Fi extends the device's attack surface to anyone within radio range, and clinical environments are dense with overlapping networks, guest access, and legacy equipment that IT teams cannot always segment or patch quickly. A device that authenticates weakly, reuses static keys, or blindly trusts the local subnet can be intercepted, spoofed, or used as a pivot point into a broader clinical network. This matters for three reasons. First, availability: a disrupted Wi-Fi session can delay alarms, therapy delivery, or monitoring data, with direct clinical consequences. Second, confidentiality and integrity: poorly authenticated Wi-Fi links can expose patient data or allow manipulation of device commands. Third, regulatory exposure: the FDA's current premarket cybersecurity guidance treats wireless interfaces as part of the required threat model, security architecture, and verification evidence. Manufacturers who treat Wi-Fi as "solved by the chipset vendor" typically discover the gap during FDA review or, worse, after a field incident, when the cost of remediation is far higher than it would have been at the design stage. ## How Does the WPA2/WPA3 Handshake Secure Medical Device Wi-Fi? The WPA2 4-way handshake exchanges four EAPOL-Key messages between a device and an access point to confirm both sides hold the same key material and to derive fresh session keys. It does not transmit the passphrase itself, and it is what actually encrypts traffic after a device associates with a network. WPA3 replaces the PSK exchange with Simultaneous Authentication of Equals (SAE), which resists offline dictionary attacks even against weak passphrases. For medical devices, the practical difference is resilience under real-world conditions. WPA2-Personal security depends almost entirely on passphrase strength, something the manufacturer usually does not control in the field. WPA3 raises the floor by making brute-force attacks against captured handshakes much harder, and it requires Protected Management Frames (PMF), which reduces disruption from spoofed deauthentication frames. | Capability | WPA2-Personal (PSK) | WPA2-Enterprise | WPA3-Personal (SAE) | WPA3-Enterprise | |---|---|---|---|---| | Key exchange | 4-way handshake with shared PSK | 4-way handshake with 802.1X-derived MSK | SAE (resistant to offline cracking) | SAE or 802.1X, with stronger cipher requirements | | Shared secret exposure | High (one passphrase for all devices) | Low (per-user/device credentials) | Lower than PSK | Lowest | | PMF requirement | Optional | Optional | Required | Required | | Typical fit | Home-use devices, small clinics | Hospital enterprise networks | Newer home-use deployments | Newer hospital deployments | **[KEY REQUIREMENT]** New Wi-Fi enabled device designs should support WPA3 or WPA2/WPA3 transition mode, and should never depend on a hardcoded or default passphrase as the sole protection for network access. ## What Is KRACK and Does It Still Matter for Medical Devices? KRACK (Key Reinstallation Attack) exploited a flaw in how some WPA2 implementations handled retransmitted handshake messages, allowing an attacker to force key reuse and decrypt or forge traffic. Vendor patches addressed the specific CVEs starting in 2017, but the underlying lesson still applies to long-lived medical devices: protocol implementations can have bugs, and a device that cannot receive validated firmware updates carries that risk for its entire service life. KRACK matters today less as an active threat and more as a test case for patchability. A device fielded in 2026 running an unpatched 2016-era Wi-Fi stack is still vulnerable in principle, even though the industry-wide patching cycle finished years ago. Reviewers and integrators increasingly ask what a manufacturer's process is for responding to a newly disclosed wireless vulnerability, not just whether the device shipped clean. Three questions determine whether a device is defensible against the next KRACK-class finding: can the Wi-Fi stack be updated in the field, does the manufacturer track the chipset vendor's security advisories, and is there a documented process for validating and deploying an emergency patch without disrupting clinical use. A device that cannot answer yes to all three carries open-ended postmarket risk regardless of its day-one configuration. ## 802.1X and EAP-TLS vs. Pre-Shared Keys: Which Should Your Device Support? Enterprise authentication using 802.1X with EAP-TLS is generally preferable to a pre-shared key for any device deployed in a hospital, because it replaces one shared secret for the whole network with a unique certificate per device. Under 802.1X, the device authenticates to a RADIUS server using a client certificate, and the resulting session keys are unique to that session and that device, so compromise of one device's credential does not expose the entire fleet. PSK-based WPA2 or WPA3-Personal remains appropriate for home-use devices, where hospital-grade infrastructure (RADIUS, certificate authorities) is not available and the user manages a household router. In that case, the design should compensate at the application layer, using [TLS](/blog/securing-communication-protocols-in-medical-devices) with certificate pinning or mutual authentication so that Wi-Fi access alone never grants device control. | Factor | PSK (WPA2/WPA3-Personal) | 802.1X / EAP-TLS | |---|---|---| | Best fit | Home-use, small clinic | Hospital enterprise network | | Credential model | One shared passphrase | Per-device certificate | | Revocation | Requires changing the passphrase network-wide | Revoke a single certificate | | IT integration | Minimal | Requires RADIUS/PKI integration with hospital IT | | Manufacturer burden | Lower upfront, higher long-term risk | Higher upfront (PKI, provisioning), lower long-term risk | **[KEY REQUIREMENT]** Devices intended for hospital deployment should support 802.1X/EAP-TLS as a configuration option, even if PSK is retained as a fallback for smaller sites, and the fallback path must be documented and risk-assessed. ## How Should Manufacturers Handle Certificate Provisioning and Rotation? Certificate provisioning must be planned as a manufacturing and lifecycle process, not a one-time engineering task. Each device needs a unique identity certificate issued during manufacturing or first commissioning, tied to a private key generated or injected securely, and a defined expiration and renewal path that does not require returning the device to the factory. Rotation is where most programs struggle. A certificate with no renewal plan either expires and disconnects the device from the network, or is issued with an unrealistically long validity period that undermines the security benefit of using certificates at all. A practical approach uses a device-initiated renewal request well before expiration, backed by a hospital-integrated or manufacturer-hosted certificate authority, with a documented fallback for devices that miss the renewal window. Manufacturers also need a revocation path. If a device is decommissioned, lost, or found to be compromised, its certificate should be revocable without disrupting the rest of the fleet, which is one of the structural advantages of certificate-based authentication over a shared PSK. ## What Hospital Network Assumptions Should Manufacturers Avoid? Manufacturers should never assume the hospital network is segmented, monitored, fully patched, or free of legacy Wi-Fi equipment. Biomedical and IT teams manage large, heterogeneous environments, and a device that only works correctly on an idealized, well-managed network will behave unpredictably in the field. Common bad assumptions include: that the local subnet is trusted and any device on it can be treated as authorized, that the hospital's access points are all running current firmware and support WPA3, that guest and clinical traffic are always separated, and that IT staff will proactively update device-facing network configuration. None of these hold universally across hospital systems, and a device architecture that depends on any of them will eventually fail somewhere in the field. The safer design principle is to treat the Wi-Fi network purely as transport and to enforce authentication, authorization, and integrity checks at the application and device level regardless of network configuration. This also gives manufacturers a stronger answer when hospital IT asks what happens if the device ends up on a flat, unsegmented network by mistake. ## What Does the FDA Expect Documented About Wireless Interfaces? The FDA expects wireless interfaces to appear explicitly in the system architecture, threat model, and verification evidence submitted as part of a premarket cybersecurity submission. This traces to the current final guidance chain (September 2023, updated June 27, 2025, and finalized February 3, 2026) on cybersecurity in medical devices, which frames connectivity, including Wi-Fi, as a required element of the security risk assessment under Section 524B of the FD&C Act. In practice, reviewers look for a data flow diagram showing where Wi-Fi enters and exits the trust boundary, a threat model that addresses handshake weaknesses, rogue access points, and weak authentication, documented security requirements for supported Wi-Fi modes (WPA2-Personal, WPA2-Enterprise, WPA3), and verification evidence showing those requirements were tested, including negative testing against misconfiguration. Manufacturers can also reference AAMI SW96 (recognition number 13-131) for structuring the underlying security risk management process that ties these pieces together. ## How Blue Goat Cyber Approaches This Blue Goat Cyber works with manufacturers to threat model wireless interfaces early, before architecture decisions are locked in, so that Wi-Fi authentication choices, certificate lifecycle plans, and network trust assumptions are traceable to documented requirements and verification results. This includes evaluating whether a device needs 802.1X support for hospital deployment, reviewing certificate provisioning and rotation design, and validating handshake and configuration behavior through hands-on testing. For teams preparing a submission, our [medical device penetration testing services](/services/medical-device-penetration-testing) validate wireless configurations against real attack techniques, while our [medical device threat modeling](/services/medical-device-threat-modeling) work builds the documented trust boundary analysis reviewers expect to see. The goal is a wireless security story that holds up under FDA review and under real hospital network conditions, not just a chipset vendor's default configuration. ## Frequently Asked Questions ### Is WPA2 still acceptable for medical devices? WPA2 remains acceptable when configured correctly, meaning current firmware, strong passphrases or 802.1X authentication, and Protected Management Frames enabled where supported. New designs should plan a path to WPA3 or transition mode, since WPA3 raises the baseline against offline password attacks and requires PMF by default. ### Do all medical devices need to support 802.1X? Not all devices need 802.1X, but any device intended for hospital enterprise networks should support it as an option. Home-use devices typically rely on WPA2/WPA3-Personal because hospital-grade RADIUS and certificate infrastructure is not available in a home setting. ### What happens if a device's Wi-Fi certificate expires in the field? Without a renewal plan, an expired certificate disconnects the device from the network until it is manually reprovisioned. Manufacturers should design automated, pre-expiration renewal requests and a documented fallback procedure so a missed renewal window does not take a clinical device offline unexpectedly. ### How is this different from the site's Bluetooth and NFC/RFID coverage? This article focuses specifically on Wi-Fi authentication and the WPA2/WPA3 handshake. For short-range wireless risks, see our coverage of [Bluetooth in medical devices](/blog/bluetooth-in-medical-devices-understanding-the-risks-and-protecting-patient-safety) and [NFC and RFID security in medical devices](/blog/nfc-and-medical-device-cybersecurity). ## CTA If your device connects over Wi-Fi and you need a defensible security architecture, from authentication model to certificate lifecycle to FDA-ready documentation, Blue Goat Cyber can help you build and test it. [Book a discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) to scope the work for your device. ## About the Author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian focuses on medical device cybersecurity for FDA premarket submissions and postmarket compliance, including wireless architecture review and penetration testing. [Read more about Christian](/christian-espinosa). --- ## What Is a Write Blocker? Hardware vs Software Source: https://bluegoatcyber.com/blog/write-blocker-medical-device-cybersecurity # Write Blockers for Medical Device Cybersecurity Investigations > **[DIRECT ANSWER]** A write blocker is hardware or software placed between a storage device and an investigator's workstation that prevents write commands from reaching the media, keeping it effectively read-only during forensic imaging so evidence integrity is preserved. MedTech teams use write blockers for returned-device investigations, postmarket incident response, and vulnerability root-cause analysis. Hardware blockers are preferred for high-assurance chain-of-custody work, while software blockers can support faster triage if their configuration and limitations are clearly documented. ## Key Takeaways - A write blocker helps preserve evidence by preventing writes to storage media during acquisition and examination. - MedTech teams use write blockers for incident response, returned device investigations, and defensible root-cause analysis. - Hardware write blockers are typically preferred for high-assurance workflows; software can be useful with documented limitations. - A repeatable workflow (imaging + hashing + chain of custody) turns “we looked at it” into credible evidence. ## Why this matters The integrity of data collected during medical device cybersecurity investigations is paramount. Without proper evidence preservation, an incident response could be compromised, root-cause analysis skewed, and compliance with regulatory bodies like the FDA jeopardized. Write blockers ensure that original data on devices, returned products, or compromised systems remains unaltered during forensic acquisition, providing a forensically sound basis for any subsequent analysis. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, emphasizes the importance of postmarket activities, including incident response and vulnerability management, which necessitate reliable data collection. Failure to adhere to rigorous evidence collection practices can lead to significant regulatory scrutiny and potential enforcement actions. Device manufacturers are also expected to align with industry standards such as ISO/IEC 80001 (Application of risk management for IT networks incorporating medical devices) and AAMI TIR97 (Principles for medical device security, security risk management for medical devices and health delivery organizations), which implicitly demand credible evidence handling. Write blockers are a foundational tool for meeting these expectations, supporting defensible incident investigation, accurate vulnerability assessment, and consistent quality system processes. ## What is a write blocker? A **write blocker** is hardware or software that prevents a computer from sending write commands to a storage device during access or acquisition. Its job is simple: make the target media effectively **read-only** while you collect forensic images or examine files. Write blockers are commonly used in digital forensics, and NIST’s Computer Forensics Tool Testing (CFTT) program publishes test information for hardware write block tools. [NIST CFTT: Hardware Write Block](https://www.nist.gov/itl/ssd/software-quality-group/computer-forensics-tool-testing-program-cftt/cftt-technical/hardware) ## Why write blockers matter in medical device cybersecurity Most device manufacturers don’t run “criminal forensics” day-to-day-but you still face high expectations for disciplined investigations and documentation when something goes wrong. A write blocker helps you preserve evidence in situations like: - **Returned product investigations (RMA/field returns):** you want to examine logs, configs, binaries, or suspicious artifacts without contaminating the device’s storage. - **Postmarket incident response:** malware on a service laptop, compromised update path, unexpected outbound connections, or a suspected breach involving device data. - **Vulnerability investigations:** reproducing an issue while preserving original images for later comparison and root-cause analysis. - **Supplier or third-party component concerns:** validating what was actually deployed in the field (versions, configs, unexpected executables). FDA emphasizes readiness and response activities across the medical device lifecycle, and evidence-quality matters during real incident response and postmarket actions. [FDA medical device cybersecurity resources (includes incident response materials)](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) ## Hardware vs. software write blockers ### Hardware write blockers **Hardware write blockers** are physical devices you place between the evidence drive and your workstation (e.g., SATA/USB/NVMe bridges). They intercept write commands at the hardware layer. **When hardware is the safer choice:** - You need strong assurance that no writes occur (best for “gold standard” evidence handling). - You’re acquiring images from removable media (drives pulled from gateways, logs on USB, SD cards). - You need consistent, repeatable acquisition across different workstations. NIST CFTT maintains test information for specific hardware write-block solutions and configurations, which is useful when selecting tools for a defensible process. [NIST CFTT: Hardware Write Block](https://www.nist.gov/itl/ssd/software-quality-group/computer-forensics-tool-testing-program-cftt/cftt-technical/hardware) ### Software write blockers **Software write blockers** are OS-level controls or applications that prevent writes to attached media. They can be useful in field work, labs, or constrained environments, but they come with more dependency on correct configuration and operator discipline. **When software can be appropriate:** - You’re doing preliminary triage and need speed (with clear documentation of limitations). - You can’t physically insert a hardware blocker due to form factor or access constraints. - You’re working with virtual disks/images rather than raw physical drives. **Reality check:** for high-stakes investigations, many teams prefer hardware write blocking where feasible, then document any exceptions. ## How a write blocker works (simple explanation) When your workstation tries to write-updating timestamps, indexing, creating hidden files, mounting volumes, the write blocker blocks or redirects those write commands so they never reach the target media. Reads still work normally, so you can: - Capture a bit-for-bit forensic image - Hash the evidence (e.g., SHA-256) to prove integrity - Analyze copies without touching the original ## Common pitfalls in MedTech investigations ### Pitfall 1: “We plugged it in just to look” Modern operating systems can write to a drive the moment it’s mounted, sometimes without obvious prompts. That can change timestamps, metadata, or system areas. If you need defensible evidence, don’t attach suspect media without a write-blocking approach and a documented procedure. ### Pitfall 2: SSDs, TRIM, and modern storage behavior Solid-state drives behave differently than spinning disks. Wear leveling and TRIM can complicate “what changed when.” A write blocker helps reduce unintentional writes, but you still need a careful acquisition plan and clear documentation of device state and handling. ### Pitfall 3: NVMe and interface mismatch Medical devices and gateways increasingly use NVMe storage. Make sure your tooling supports the interface you’ll see in the real world (SATA vs NVMe vs USB-C enclosures), and validate your process before you need it. ### Pitfall 4: Confusing “live response” with “dead box” forensics If the device must remain powered on to preserve volatile data (RAM, network connections), you may do **live response** first (documented commands, captures, logs), then do offline imaging later. Write blockers are primarily for offline acquisition of storage media, not a replacement for a full incident response plan. ## A practical, defensible write-blocking workflow If you’re building a repeatable MedTech-ready process, this is a solid baseline: 1. **Decide the goal:** triage vs full forensic acquisition. 2. **Document the evidence source:** device ID/serial, media type, where/when collected, who handled it. 3. **Use write blocking:** hardware preferred when possible; if software, document configuration and verification steps. 4. **Acquire an image:** capture a forensic image to controlled storage. 5. **Hash and verify:** record hashes for the source (when possible) and image, and verify integrity. 6. **Maintain chain of custody:** log transfers, access, storage conditions, and analysis actions. 7. **Analyze only copies:** keep the original image and media preserved as your “known good” baseline. SWGDE’s computer forensic best practices are a helpful reference point for evidence handling discipline and integrity-focused workflows. [SWGDE Best Practices for Computer Forensic Examination](https://www.swgde.org/wp-content/uploads/2024/05/2018-07-11-SWGDE-Best-Practices-for-Computer-Fo.pdf) ## Choosing the right write blocker (MedTech-oriented criteria) - **Interface coverage:** SATA + USB is common; NVMe support is increasingly important. - **Proven behavior:** prefer tools with published test information or rigorous internal validation (NIST CFTT is a strong reference for hardware tools). - **Operational fit:** lab acquisitions vs field triage; portability; power requirements; adapter ecosystem. - **Repeatability:** can your team run the same procedure every time and produce consistent documentation? ## Where this connects to FDA-ready cybersecurity programs Evidence integrity isn’t just a “forensics” issue; it supports mature postmarket response. If you’re aligning to FDA expectations for lifecycle cybersecurity, write-blocking procedures commonly sit alongside: - Incident response and escalation playbooks - Vulnerability intake, triage, and root-cause analysis - Logging requirements and log retention strategies - Secure update and patch processes For broader program structure, see our related guidance on [postmarket cybersecurity management](/blog) and building a submission-ready [Secure Product Development Framework (SPDF)](/blog). ## How Blue Goat approaches this Our approach to medical device cybersecurity investigations starts with the principle of evidence preservation. We use appropriate write-blocking technologies, both hardware and software, to ensure that all data collected during incident response, vulnerability assessments, or postmarket analysis remains untainted. This careful care supports accurate root-cause analysis and strengthens defensibility. Our team, including CISSP and OSCP certified experts, many with ex-military red team experience, applies this methodology to various scenarios, from returned product investigations to supply chain assessments. We partner with MedTech innovators to build rigorous cybersecurity programs from the ground up, emphasizing readiness and response capabilities that align with FDA expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our support for premarket compliance: [FDA premarket cybersecurity services](/services/fda-premarket-cybersecurity-services). ## FAQ ### What does a write blocker do? A write blocker prevents a workstation from writing to connected storage media while still allowing reads. That reduces the risk of altering evidence during forensic acquisition and analysis. ### Do medical device manufacturers really need write blockers? If you investigate cybersecurity incidents, analyze returned devices, or need defensible evidence for root-cause analysis, write blockers are a practical control. They’re especially useful when storage media can be removed and imaged offline. ### Is a software write blocker good enough? Sometimes-especially for triage. But software approaches depend on correct OS configuration and operator discipline. For higher assurance workflows, hardware write blocking is commonly preferred, supported by testing references such as NIST CFTT for hardware write block tools. [NIST CFTT: Hardware Write Block](https://www.nist.gov/itl/ssd/software-quality-group/computer-forensics-tool-testing-program-cftt/cftt-technical/hardware) ### Can connecting a drive without a write blocker change evidence? Yes. Many systems write metadata automatically when media is mounted (indexing, hidden files, timestamps). If evidence integrity matters, don’t attach suspect media without a write-blocking approach and a documented procedure. ### Do write blockers work for SSDs and NVMe drives? Many do, but you must confirm interface support (SATA vs NVMe) and validate your process. SSD behaviors like wear leveling and TRIM can complicate forensic interpretation, so strong documentation and repeatable acquisition steps matter. ### How does this relate to FDA cybersecurity expectations? FDA emphasizes lifecycle cybersecurity and incident readiness. Strong evidence handling supports postmarket investigations and response activities, especially when you need to demonstrate what happened and how you validated mitigations. [FDA medical device cybersecurity resources](https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity) ## Write blocker types compared | Type | How it works | Strength for chain of custody | Best use | | --- | --- | --- | --- | | Hardware write blocker | A physical bridge that drops write commands on the interface | Highest, the protection is independent of the examiner's machine | Returned-device investigations and anything that could be disputed | | Software write blocker | The operating system is configured to mount media read only | Moderate, depends on correct configuration every time | Fast triage where the finding will be confirmed later | | Forensic imaging to a verified copy | Acquire once, then work only on the copy | High, if the hash is recorded and checked | Any analysis that takes more than one sitting | | Chip-off or direct flash read | Removes the storage from the board | High for the read, destructive to the device | Devices whose interfaces are locked or damaged | | Live acquisition | Collect while the device runs | Lowest, the state changes as you work | Volatile data you cannot recover after power down | Pick the method before you touch the device, and write down which one you used. The method is the part somebody challenges later. ## Conclusion Write blockers aren’t flashy, but they’re one of the simplest ways to avoid self-inflicted damage during an investigation. If your team touches returned devices, collects logs from removable media, or needs defensible incident evidence, a write-blocking workflow is a practical step toward mature medical device cybersecurity operations. ## Book a Discovery Session If you need help building an FDA-aligned cybersecurity program, including incident response workflows, threat modeling, testing, SBOMs, and postmarket management-let’s talk. [Book a Discovery Session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## Zigbee in Medical Devices Cybersecurity Source: https://bluegoatcyber.com/blog/zigbee-in-medical-devices-cybersecurity-a-comprehensive-guide # Zigbee in Medical Devices Cybersecurity: What Manufacturers Need to Know > **[DIRECT ANSWER]** Zigbee is a low-power, mesh-network wireless protocol used in medical devices such as wearables and remote monitors because it extends battery life and supports many interconnected devices exchanging patient data. It provides built-in encryption, secure key management, and device authentication, but these features must be implemented and validated correctly to satisfy FDA reviewers. Manufacturers should run risk assessments before deployment, restrict network joining to authenticated devices, keep firmware patched, and document Zigbee-specific threat modeling in premarket submissions. In an era where interconnectedness and digitization dominate the healthcare landscape, the importance of [cybersecurity measures](/blog/the-importance-of-cybersecurity-in-the-medical-device-industry) cannot be overstated. One technology that has emerged as a powerful ally in safeguarding medical devices against malicious attacks is Zigbee. In this guide, we will covers the world of Zigbee and explore its role in ensuring the cybersecurity of medical devices. ## Key Takeaways - Zigbee uses a mesh network for reliable device communication. - Encryption and authentication protect sensitive patient data. - Low power consumption supports continuous device operation. - Interference avoidance ensures stable data transmission. - Adherence to FDA guidance is necessary for medical device cybersecurity. - Regular risk assessments matter for secure implementation. ## Why this matters The stakes for medical device cybersecurity are critically high: patient safety, data privacy, and operational continuity depend on secure systems. Failure to properly implement and maintain cybersecurity can lead to compromised devices, unauthorized data access, and ultimately, harm to patients. The FDA's 'Cybersecurity in Medical Devices' Final Guidance, dated February 3, 2026, mandates that manufacturers integrate security throughout the total product lifecycle, including for wireless protocols like Zigbee. Medical device manufacturers must adhere to internationally recognized standards such as IEC 81001-5-1 for the manufacturer secure software lifecycle (with IEC 81001-5-1 governing hospital/HDO network integration), ISO 27001 for information security management, and AAMI TIR57 / ANSI/AAMI SW96:2023 regarding the principles for medical device security, risk management. These frameworks guide the secure design, development, and deployment of devices utilizing Zigbee, ensuring that encryption, authentication, and network resilience meet necessary regulatory and safety requirements. Ignoring these guidelines and standards exposes manufacturers to significant regulatory scrutiny, reputational damage, and potential legal liabilities. ## Understanding Zigbee Technology Before we dive into the specifics of [Zigbee’s application in medical devices cybersecurity](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples), it is crucial to gain a solid understanding of the technology itself. Zigbee is a low-power wireless communication protocol that allows devices to connect, communicate, and share data seamlessly. Its design prioritizes energy efficiency and simplicity, making it an ideal choice for battery-operated devices. ![Section Image](/imported-images/f489a68d4f3352bf.webp) Through Zigbee, medical devices can form a wireless network, enabling them to exchange information in real-time, facilitate remote monitoring, and build integration with other healthcare systems. ### The Basics of Zigbee At its core, Zigbee operates using a mesh network topology, wherein each device serves as a node that can both send and receive data. This decentralized network structure ensures robustness and redundancy, as any device within the network can act as a relay, transmitting data to its intended destination. Zigbee operates in the 2.4 GHz ISM band, offering excellent range and overcoming obstacles that may impede communication between devices. This versatility makes Zigbee an attractive option for medical devices, where reliable and continuous data transmission is paramount. ### Zigbee’s Role in Medical Devices With the increasing integration of medical devices into the [Internet of Medical Things (IoMT)](/blog), a secure and reliable communication protocol has become paramount. Zigbee rises to the occasion, providing a platform for medical devices to exchange critical patient data while ensuring data integrity and confidentiality. One of the key advantages of Zigbee is its ability to handle a large number of interconnected medical devices simultaneously. This scalability enables healthcare providers to monitor multiple patients simultaneously, facilitating efficient and informed decision-making. [Zigbee’s low-power consumption](/blog/20-medical-device-protocols-descriptions-purposes-security-flaws-fda-guidance-and-examples) ensures prolonged battery life for medical devices, reducing the need for frequent battery replacement or recharging. This is especially crucial when medical devices are implanted or attached to patients, allowing for continuous monitoring without causing discomfort or inconvenience. Zigbee’s compatibility with various healthcare systems and electronic medical records (EMR) platforms further enhances its utility in the medical field. By integrating with existing infrastructure, Zigbee enables healthcare providers to access and analyze patient data in real-time, leading to improved diagnostics, personalized treatment plans, and better patient outcomes. In addition, Zigbee’s security features, such as encryption and authentication mechanisms, ensure the confidentiality and privacy of sensitive patient information. This is particularly important in medical devices, where the unauthorized access or manipulation of data can severely affect patient safety and privacy. Overall, Zigbee technology is vital in advancing medical devices and healthcare systems. Its energy efficiency, scalability, and security features make it an ideal choice for enabling communication, remote monitoring, and integration of medical devices, ultimately leading to improved patient care and outcomes. ## The Importance of Cybersecurity in Medical Devices As the use of medical devices proliferates, so does the potential for cybersecurity breaches. These breaches can have dire consequences, compromising patient safety, data privacy, and even the integrity of medical procedures. Therefore, it is imperative for healthcare organizations to prioritize cybersecurity measures to protect both patients and their valuable data. ![Section Image]() ### Risks Associated with Medical Devices Despite their life-saving capabilities, medical devices are not immune to cyber threats. They can be susceptible to unauthorized access, data breaches, and even remote manipulation, putting patient safety at risk. One startling example is the potential for hackers to tamper with medical device settings, leading to incorrect dosages or erroneous treatment. Additionally, compromised medical devices can become a gateway for attackers to infiltrate the broader healthcare network, facilitating the unauthorized access of sensitive patient data or even holding healthcare organizations hostage through ransomware attacks. ### The Need for Resilient Cybersecurity Measures In light of the aforementioned risks, it is evident that medical devices necessitate cybersecurity measures. Such measures encompass a multi-faceted approach, including but not limited to secure communication protocols, data encryption, device authentication, and regular software updates. Healthcare organizations must cultivate a cybersecurity awareness and education culture among their staff. Organizations can establish a strong line of defense against cyber attacks by training employees to recognize and respond to potential threats. The rapid advancement of technology in the medical field has brought about a new wave of innovative medical devices. These devices have revolutionized patient care and monitoring, from smart implants to wearable health trackers. However, with this innovation comes an increased need for cybersecurity. Imagine a scenario where a patient’s pacemaker, connected to the internet for remote monitoring, becomes compromised by a cybercriminal. The consequences could be catastrophic, with the hacker gaining control over the pacemaker’s functionality. This could result in life-threatening situations for the patient, highlighting the urgency for cybersecurity measures. Medical devices often store and transmit sensitive patient data, including personal information and medical records. If this data falls into the wrong hands, it can be used for identity theft, blackmail, or even sold on the [dark web](/blog). The potential harm caused by such breaches cannot be understated. To address these risks, healthcare organizations must invest in cybersecurity solutions beyond basic protection. This includes [implementing intrusion detection systems](/blog), conducting regular vulnerability assessments, and establishing incident response plans to mitigate potential breaches swiftly. Collaboration between healthcare providers, device manufacturers, and cybersecurity experts is crucial. By working together, they can develop industry-wide standards and best practices to ensure the highest level of security for medical devices. ## Zigbee and Cybersecurity: A Powerful Combination Recognizing the need for enhanced cybersecurity in medical devices, Zigbee has emerged as a powerful ally in safeguarding healthcare systems. By using Zigbee’s unique features and capabilities, healthcare organizations can bolster their defense against cyber threats. ![Section Image]() ### How Zigbee Enhances Cybersecurity Zigbee incorporates multiple layers of security to ensure transmitted data’s [confidentiality, integrity, and availability](/blog). These security measures include encryption algorithms, secure key management protocols, and authentication mechanisms. But let’s dive deeper into Zigbee’s security features. Zigbee’s [encryption algorithms](/blog/understanding-relevant-threats-for-medical-devices) are designed to protect data from unauthorized access or tampering. These algorithms use complex mathematical calculations to convert plain text into ciphertext, making it virtually impossible for hackers to decipher the information. Zigbee’s [secure key management protocols](/blog/medical-device-key-exchange-cybersecurity) are crucial in maintaining the system’s integrity. These protocols ensure that only authorized devices can join the network, preventing any unauthorized access attempts. Additionally, they facilitate the secure exchange of encryption keys between devices, further strengthening the overall security posture. Another noteworthy security feature of Zigbee is its authentication mechanisms. These mechanisms verify the identity of devices before allowing them to connect to the network. By implementing strong authentication protocols, Zigbee ensures that only trusted devices can communicate with the healthcare system, minimizing the risk of malicious actors infiltrating the network. Additionally, Zigbee utilizes [frequency hopping spread spectrum (FHSS)](/blog) techniques, where devices continuously switch frequencies during transmission. This dynamic frequency hopping enhances data transmission security, making it difficult for attackers to intercept or decipher sensitive information. ### The Benefits of Using Zigbee for Cybersecurity Besides its inherent security features, Zigbee brings several other benefits when deployed in medical devices for cybersecurity purposes. Firstly, Zigbee’s low-power consumption and energy-efficient design ensure minimal impact on device battery life, facilitating continuous monitoring and surveillance. Imagine a scenario where a medical device’s battery drains quickly due to constant communication with the healthcare system. This could lead to critical data being lost or delayed, potentially compromising patient care. However, with Zigbee’s low-power consumption, medical devices can operate for extended periods without requiring frequent battery replacements, ensuring uninterrupted monitoring and timely data transmission. Zigbee’s ability to establish reliable and connections, even in the presence of interference, contributes to the overall stability and integrity of the healthcare system. In a busy hospital environment with numerous wireless devices operating simultaneously, interference can disrupt communication and compromise patient safety. However, Zigbee’s advanced interference avoidance mechanisms enable communication, ensuring that critical healthcare data is transmitted without interruptions. ## Zigbee Compared With the Other Radios Choosing a radio is a security decision as much as a power and range decision. | | Zigbee | Bluetooth Low Energy | Wi-Fi | |---|---|---|---| | Typical use | Mesh of many sensors | One device paired to a phone | High bandwidth to hospital network | | Power draw | Low | Very low | High | | Range pattern | Extended through mesh hops | Short, point to point | Access point dependent | | Built in security | AES-128 network and link keys | Pairing dependent | WPA2 or WPA3 | | Main weakness in practice | Key distribution during joining | Unauthenticated pairing modes | Depends on hospital configuration | | Who controls the security posture | You, through commissioning design | You, through pairing choice | Largely the hospital | ## Implementing Zigbee in Medical Devices for Enhanced Cybersecurity While the potential benefits of Zigbee in medical devices cybersecurity are undoubtedly compelling, the implementation process requires careful consideration and planning. Healthcare organizations must follow a systematic approach to use Zigbee’s capabilities effectively. ### Steps to Implement Zigbee 1. **Conduct a risk assessment:** Before embarking on the implementation journey, healthcare organizations must assess the potential risks and vulnerabilities associated with their existing medical devices infrastructure. 2. **Select Zigbee-enabled medical devices:** Identify medical devices that can be integrated with Zigbee technology. Consider factors such as compatibility, ease of integration, and vendor support. 3. **Develop a communication infrastructure:** Establish an infrastructure that supports Zigbee’s requirements, including appropriate network design, topology, and signal coverage. 4. **Implement encryption and authentication mechanisms:** Ensure that all communications between Zigbee-enabled devices are encrypted and authenticated, safeguarding the integrity and confidentiality of transmitted data. 5. **Regularly update and patch software:** Stay vigilant by promptly applying software updates and patches provided by both the [Zigbee Alliance](https://csa-iot.org/) and individual device manufacturers. These updates often include security enhancements and address any known vulnerabilities. ### Challenges and Solutions in Implementation While Zigbee’s benefits in medical device cybersecurity are immense, implementation is not without its challenges. One common obstacle is interoperability, as different medical devices may have varying degrees of Zigbee support or compatibility. Healthcare organizations can overcome this challenge by working closely with device manufacturers and meeting compatibility requirements before making procurement decisions. Collaboration between manufacturers can also lead to the development of standardized protocols, easing the integration process. Additionally, healthcare organizations should prioritize employee training to ensure that staff members are well-versed in operating Zigbee-enabled medical devices and are equipped to respond effectively to any cybersecurity incidents that may arise. It is crucial to consider the physical security of Zigbee-enabled medical devices. While the focus is often on cybersecurity, physical access to these devices can pose significant risks. Healthcare organizations should implement restricted access areas, surveillance cameras, and tamper-evident seals to prevent unauthorized physical access to the devices. Healthcare organizations should establish incident response plans specifically tailored to Zigbee-enabled medical devices. These plans should outline the steps during a cybersecurity incident, including isolating affected devices, forensic analysis, and communication protocols with relevant stakeholders. ## Future of Zigbee in Medical Devices Cybersecurity As technology continues to evolve, so does the role of Zigbee in ensuring the cybersecurity of medical devices. Several emerging trends and developments indicate a promising future for Zigbee’s integration into healthcare systems. ### Emerging Trends in Zigbee Technology One notable trend is the increasing adoption of Zigbee in wearable medical devices. Wearables, such as smartwatches and fitness trackers, are rapidly gaining popularity in the healthcare sector due to their ability to monitor vital signs and facilitate early detection of health issues. Zigbee’s low-power consumption and integration capabilities make it a natural fit for wearable medical devices, enabling continuous monitoring without burdening users with frequent battery replacements. But what sets Zigbee apart from other wireless communication protocols is its ability to create a mesh network. This means that each device within the network can act as a repeater, extending the network’s range and coverage. This feature is particularly beneficial in healthcare settings, where medical devices may be scattered throughout a facility. ### Predictions for Zigbee’s Role in Cybersecurity Looking to the future, Zigbee is poised to play an even more significant role in the cybersecurity landscape of medical devices. As the healthcare industry continues to grapple with cybersecurity challenges, Zigbee’s security features, scalability, and compatibility will position it as a preferred choice for safeguarding sensitive patient data and ensuring the integrity of medical procedures. Ongoing advancements in Zigbee technology, such as developing Zigbee 3.0 and improved device interoperability, will further expand its potential applications and benefits in healthcare settings. Imagine a future where Zigbee-enabled medical devices communicate with each other, sharing vital information in real-time. This interconnectedness would enhance patient care and enable healthcare professionals to make more informed decisions based on data analysis. With the concerted efforts of healthcare organizations, device manufacturers, and industry bodies, Zigbee’s future hails a new era of enhanced cybersecurity in medical devices, paving the way for safer, more connected healthcare systems. But the potential of Zigbee doesn’t stop there. As the Internet of Things (IoT) expands, Zigbee’s compatibility with other IoT devices opens up possibilities. Imagine a smart hospital where medical devices, from infusion pumps to patient monitors, communicate with each other, optimizing workflows and improving patient outcomes. ## Conclusion As medical devices continue to embrace the era of interconnectedness, cybersecurity remains a critical element in maintaining patient safety and data integrity. Zigbee technology offers a solution, enabling communication while ensuring the confidentiality and integrity of sensitive patient information. By implementing Zigbee in medical devices, healthcare organizations can fortify their cybersecurity defenses, safeguarding patients and healthcare systems. As the future unfolds, Zigbee’s role in medical device cybersecurity is set to become even more prominent, building a secure and interconnected healthcare environment for all. As the medical device landscape continues to integrate with the Internet of Things, ensuring the cybersecurity of these devices is not just an option; it’s a necessity. Blue Goat Cyber stands at the vanguard of cybersecurity excellence, offering bespoke solutions catering to medical device cybersecurity’s unique challenges. Our veteran-owned business is committed to protecting your operations with rigorous HIPAA and FDA compliance, thorough penetration testing, and cybersecurity strategies. Don’t let cyber threats compromise your patient care and data integrity. [Contact us today for cybersecurity help](/contact), and let Blue Goat Cyber be your ally in navigating the complexities of digital security. Together, we can transform your vulnerabilities into fortified assets, ensuring a secure and successful future in the digital healthcare space. ## How Blue Goat approaches this Blue Goat Cyber's methodology prioritizes the integrity and functionality of medical devices. We assess Zigbee implementations through a focused lens, evaluating network architecture, encryption protocols, and authentication mechanisms to identify potential vulnerabilities. Our team, comprised of experts with CISSP and OSCP certifications, including ex-military red team personnel, specializes in uncovering weaknesses before they can be exploited. We then provide actionable recommendations tailored to mitigate risks and enhance digital defenses. For manufacturers navigating premarket submissions, our experts guide the integration of cybersecurity controls into Zigbee-enabled devices. We ensure alignment with the FDA's expectations, helping to secure regulatory clearance efficiently. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our [premarket cybersecurity services here](/services/fda-premarket-cybersecurity-services). ## FAQ ### What is Zigbee in medical devices? Zigbee is a low-power wireless communication protocol used in medical devices to enable secure and efficient data exchange. It supports mesh networking, allowing devices to connect and share data while prioritizing energy efficiency. ### How does Zigbee secure medical device data? Zigbee secures medical device data through encryption algorithms, secure key management, and authentication mechanisms. These features protect data from unauthorized access, ensure only trusted devices communicate, and verify device identities. ### Why is low power consumption important for medical devices? Low power consumption is important for medical devices because it extends battery life, allowing for continuous monitoring and data transmission without frequent recharging or battery replacement. This is especially critical for implanted or patient-attached devices. ### Does the FDA have guidance on Zigbee security? The FDA's February 3, 2026 premarket cybersecurity guidance outlines general principles for securing medical devices, including those using wireless protocols like Zigbee. Manufacturers must demonstrate that their devices mitigate cybersecurity risks effectively throughout the product lifecycle. ### What risks do medical devices face without proper cybersecurity? Without proper cybersecurity, medical devices face risks such as unauthorized access, data breaches, and remote manipulation. These threats can compromise patient safety, expose sensitive personal health information, and disrupt healthcare operations. ### How can healthcare organizations implement Zigbee securely? Healthcare organizations should conduct thorough risk assessments, select Zigbee-enabled devices compatible with their infrastructure, develop a strong communication infrastructure, and implement strong encryption and authentication. Regular updates and staff training are also essential. **Related:** [Medical Device Cybersecurity: A Complete Lifecycle Guide](/blog/medical-device-cybersecurity-a-complete-lifecycle-guide) ## About the author **Christian Espinosa, CISSP, Founder, Blue Goat Cyber.** Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. [Read more about Christian](/christian-espinosa). --- ## More on this topic - [QIH Medical Devices Explained](/blog/qih-medical-devices-explained) - [Managing Interconnected Medical Devices](/blog/managing-connected-medical-devices-a-strategic-approach) - [Cybersecurity Practices for Protecting](/blog/cybersecurity-practices-for-protecting-medical-devices-manufacturers-checklist) - [CoAP Cybersecurity in Medical Devices](/blog/cybersecurity-in-the-coap-medical-device-protocol)